ENTRY       H00001                      Disease
NAME        B lymphoblastic leukemia/lymphoma
DESCRIPTION Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). In the case of B-ALL, numerous reports have demonstrated that recurring genetic abnormalities are associated with sufficiently unique clinical, immunophenotypic, and/or prognostic features so that they can be considered as distinct entities. The most common rearrangements observed in B-ALL are the t(12;21) (p13;q22) rearrangement resulting in expression of the ETV6-RUNX1 fusion (TEL-AML1); the t(1;19) (q23;p13) translocation that results in expression of the TCF3 (E2A) fusion partner, (also known as TCF3) TFPT-PBX1 fusion (E2A-PBX); the t(9;22) (q34;q11.2) "Philadelphia" chromosome resulting in expression of the BCR-ABL1 fusion; and rearrangements of MLL (also known as KMT2A) at 11q23 to a diverse array of fusion partners. If none of these specific genetic abnormalities are found, the designation of "B lymphoblastic leukemia/lymphoma, not otherwise specified," is appropriate.
CATEGORY    Cancer
GENE        BCR-ABL (translocation) [HSA:613 25] [KO:K08878 K06619]
            MLL-AF4 (translocation) [HSA:4297 4299] [KO:K09186 K15184]
            E2A-PBX1 (translocation) [HSA:6929 5087] [KO:K09063 K09355]
            TEL-AML1 (translocation) [HSA:2120 861] [KO:K03211 K08367]
            c-MYC (rearrangement) [HSA:4609] [KO:K04377]
            CRLF2 (rearrangement) [HSA:64109] [KO:K05078]
            PAX5 (rearrangement) [HSA:5079] [KO:K09383]
CARCINOGEN  *Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium232 dioxide
            *: Although this is a risk factor for ALL in general, the strength of association with different histological tumor types is not well understood.
MARKER      BCR-ABL fusion gene [HSA:613 25] [KO:K08878 K06619]
DRUG        Vincristine [DG:DG00690]
            Prednisone [DG:DG00094]
            Daunorubicin [DG:DG00697]
            Asparaginase [DR:D02997]
            Methotrexate [DG:DG00681]
            Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Doxorubicin [DG:DG00696]
            Dexamethasone [DG:DG00011]
            Cytarabine [DG:DG00686]
            6-mercaptopurine [DG:DG00683]
COMMENT     ICD-O-3.1: 9811/3 B lymphoblastic leukemia/lymphoma, NOS
            ICD-O-3.1: 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1
            ICD-O-3.1: 9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged
            ICD-O-3.1: 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)
            ICD-O-3.1: 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy
            ICD-O-3.1: 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)
            ICD-O-3.1: 9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH
            ICD-O-3.1: 9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
DBLINKS     ICD-10: C83.5 C91.0
            MeSH: D054198
REFERENCE   PMID:25781572 (gene)
  AUTHORS   Roberts KG, Mullighan CG
  TITLE     Genomics in acute lymphoblastic leukaemia: insights and treatment implications.
  JOURNAL   Nat Rev Clin Oncol 12:344-57 (2015)
REFERENCE   PMID:23023711 (gene)
  AUTHORS   Mullighan CG
  TITLE     Molecular genetics of B-precursor acute lymphoblastic leukemia.
  JOURNAL   J Clin Invest 122:3407-15 (2012)
REFERENCE   PMID:18783329 (gene)
  AUTHORS   Teitell MA, Pandolfi PP
  TITLE     Molecular genetics of acute lymphoblastic leukemia.
  JOURNAL   Annu Rev Pathol 4:175-98 (2009)
REFERENCE   PMID:19357394 (gene)
  AUTHORS   Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD
  TITLE     The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
  JOURNAL   Blood 114:937-51 (2009)
REFERENCE   PMID:22449370
  AUTHORS   Cornell RF, Palmer J
  TITLE     Adult acute leukemia.
  JOURNAL   Dis Mon 58:219-38 (2012)
REFERENCE   PMID:27069254 (tumor type)
  AUTHORS   Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW
  TITLE     The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
  JOURNAL   Blood 127:2391-405 (2016)
REFERENCE   PMID:12556326 (carcinogen)
  AUTHORS   Harrison JD, Muirhead CR.
  TITLE     Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
  JOURNAL   Int J Radiat Biol 79:1-13 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00002                      Disease
NAME        T lymphoblastic leukemia/lymphoma
DESCRIPTION Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). T-ALL comprises 15% of paediatric and 25% of adult ALL cases. T cell transformation is a multi-step process in which different genetic alterations cooperate to alter the normal mechanisms that control cell growth, proliferation, survival, and differentiation during thymocyte development. In this context, constitutive activation of NOTCH1 signaling is the most prominent oncogenic pathway in T cell transformation. In addition, T-ALLs characteristically show the translocation and aberrant expression of transcription factor oncogenes. These oncogenic transcription factors include T-cell leukaemia homeobox protein 1 (TLX1 also known as HOX11), TLX3 (HOX11L2), LYL1, TAL1 and MLL.
CATEGORY    Cancer
GENE        NOTCH1 (mutation) [HSA:4851] [KO:K02599]
            TAL1 (overexpression) [HSA:6886] [KO:K09068]
            LYL1 (expression) [HSA:4066] [KO:K15604]
            MLL-ENL (translocation) [HSA:4297 4298] [KO:K09186 K15187]
            HOX11 (translocation) [HSA:3195] [KO:K09340]
            MYC (translocation) [HSA:4609] [KO:K04377]
            LMO2 (translocation) [HSA:4005] [KO:K15612]
            HOX11L2 (translocation) [HSA:30012] [KO:K15607]
            PCALM-MLLT10 (translocation) [HSA:8301 8028] [KO:K20044]
CARCINOGEN  *Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium232 dioxide
            *: Although this is a risk factor for ALL in general, the strength of association with different histological tumor types is not well understood.
MARKER      BCR-ABL fusion gene [HSA:613 25] [KO:K08878 K06619]
DRUG        Vincristine [DG:DG00690]
            Prednisone [DG:DG00094]
            Daunorubicin [DG:DG00697]
            Asparaginase [DR:D02997]
            Methotrexate [DG:DG00681]
            Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Doxorubicin [DG:DG00696]
            Dexamethasone [DG:DG00011]
            Cytarabine [DG:DG00686]
            6-mercaptopurine [DG:DG00683]
COMMENT     ICD-O-3.1: 9837/3 T lymphoblastic leukemia/lymphoma
DBLINKS     ICD-10: C83.5 C91.0
            MeSH: D054218
REFERENCE   PMID:25781572 (gene)
  AUTHORS   Roberts KG, Mullighan CG
  TITLE     Genomics in acute lymphoblastic leukaemia: insights and treatment implications.
  JOURNAL   Nat Rev Clin Oncol 12:344-57 (2015)
REFERENCE   PMID:18783329 (gene)
  AUTHORS   Teitell MA, Pandolfi PP
  TITLE     Molecular genetics of acute lymphoblastic leukemia.
  JOURNAL   Annu Rev Pathol 4:175-98 (2009)
REFERENCE   PMID:23023710 (gene)
  AUTHORS   Van Vlierberghe P, Ferrando A
  TITLE     The molecular basis of T cell acute lymphoblastic leukemia.
  JOURNAL   J Clin Invest 122:3398-406 (2012)
REFERENCE   PMID:22449370
  AUTHORS   Cornell RF, Palmer J
  TITLE     Adult acute leukemia.
  JOURNAL   Dis Mon 58:219-38 (2012)
REFERENCE   PMID:22145858
  AUTHORS   Kraszewska MD, Dawidowska M, Szczepanski T, Witt M
  TITLE     T-cell acute lymphoblastic leukaemia: recent molecular biology findings.
  JOURNAL   Br J Haematol 156:303-15 (2012)
REFERENCE   PMID:27069254 (tumor type)
  AUTHORS   Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW
  TITLE     The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
  JOURNAL   Blood 127:2391-405 (2016)
REFERENCE   PMID:12556326 (carcinogen)
  AUTHORS   Harrison JD, Muirhead CR.
  TITLE     Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
  JOURNAL   Int J Radiat Biol 79:1-13 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00003                      Disease
NAME        Acute myeloid leukemia (AML)
DESCRIPTION Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program. AML accounts for approximately 80% of all adult leukemias and remains the most common cause of leukemia death. Two major types of genetic events have been described that are crucial for leukemic transformation. A proposed necessary first event is disordered cell growth and upregulation of cell survival genes. The most common of these activating events were observed in the RTK Flt3, in N-Ras and K-Ras, in Kit, and sporadically in other RTKs. Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for leukemogenesis. Transcription factor fusion proteins such as PML-RARalpha (in Acute promyelocytic leukemia, a subtype of AML), AML-ETO or PLZF-RARalpha block myeloid cell differentiation by repressing target genes. In other cases,  the transcription factors themselves are mutated.
CATEGORY    Cancer
GENE        FLT3 (mutation) [HSA:2322] [KO:K05092]
            c-KIT (mutation) [HSA:3815] [KO:K05091]
            N-ras (mutation) [HSA:4893] [KO:K07828]
            K-ras (mutation) [HSA:3845] [KO:K07827]
            PML-RARalpha (translocation) [HSA:5371 5914] [KO:K10054 K08527]
            AML1-ETO (translocation) [HSA:861 862] [KO:K08367 K10053]
            PLZF-RARalpha (translocation) [HSA:7704 5914] [KO:K10055 K08527]
            AML1 (mutation) [HSA:861] [KO:K08367]
            C/EBPalpha (mutation) [HSA:1050] [KO:K09055]
            PU.1 (mutation) [HSA:6688] [KO:K09438]
CARCINOGEN  Benzene [CPD:C01407]
            1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [DR:D00248]
            Chlorambucil [DR:D00266]
            Cyclophosphamide [DG:DG00675]
            Ethylene oxide [CPD:C06548]
            Melphalan [DG:DG00676]
            Thiotepa [CPD:C07641]
MARKER      BCR-ABL fusion gene [HSA:613 25] [KO:K08878 K06619]
DRUG        Cytarabine [DG:DG00686]
            Daunorubicin [DG:DG00697]
            Idarubicin [DG:DG00700]
            Tretinoin [DR:D00094]
COMMENT     ICD-O: 9896/3, Tumor type: AML with t(8;21)(q22;q22), (AML1/ETO)
            ICD-O: 9871/3, Tumor type: AML with inv(16)(p13q22) or t(16; 16)(p13, q22), (CBF-beta/MYH11)
            ICD-O: 9866/3, Tumor type: Acute promyelocytic leukaemia (AML with t(15;17)(q22;q12), (PML/RAR-alpha) and variants)
            ICD-O: 9897/3, Tumor type: AML with 11q23 (MLL) abnormalities
DBLINKS     ICD-10: C92.0
            MeSH: D015470
REFERENCE   PMID:10502596 (tumor type)
  AUTHORS   Lowenberg B, Downing JR, Burnett A.
  TITLE     Acute myeloid leukemia.
  JOURNAL   N Engl J Med 341:1051-62 (1999)
REFERENCE   PMID:16236521 (gene)
  AUTHORS   Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H.
  TITLE     The molecular pathogenesis of acute myeloid leukemia.
  JOURNAL   Crit Rev Oncol Hematol 56:195-221 (2005)
REFERENCE   PMID:12194988 (gene)
  AUTHORS   Kelly LM, Gilliland DG.
  TITLE     Genetics of myeloid leukemias.
  JOURNAL   Annu Rev Genomics Hum Genet 3:179-98 (2002)
REFERENCE   PMID:16757428 (gene)
  AUTHORS   Kiyoi H, Naoe T.
  TITLE     Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
  JOURNAL   Int J Hematol 83:301-8 (2006)
REFERENCE   PMID:6786872 (carcinogen)
  AUTHORS   Adamson RH, Seiber SM.
  TITLE     Chemically induced leukemia in humans.
  JOURNAL   Environ Health Perspect 39:93-103 (1981)
REFERENCE   PMID:9055951 (carcinogen)
  AUTHORS   Savitz DA, Andrews KW.
  TITLE     Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers.
  JOURNAL   Am J Ind Med 31:287-95 (1997)
REFERENCE   PMID:3713721 (carcinogen)
  AUTHORS   Bishop JB, Wassom JS.
  TITLE     Toxicological review of busulfan (Myleran).
  JOURNAL   Mutat Res 168:15-45 (1986)
REFERENCE   PMID:3865372 (carcinogen)
  AUTHORS   Cannon GW, Jackson CG, Samuelson CO Jr, Ward JR, Williams HJ, Clegg DO.
  TITLE     Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review.
  JOURNAL   Semin Arthritis Rheum 15:106-18 (1985)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:12464351 (carcinogen)
  AUTHORS   Kolman A, Chovanec M, Osterman-Golkar S.
  TITLE     Genotoxic effects of ethylene oxide, propylene oxide and epichlorohydrin in humans: update review (1990-2001).
  JOURNAL   Mutat Res 512:173-94 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:25885425 (drug)
  AUTHORS   Coombs CC, Tavakkoli M, Tallman MS
  TITLE     Acute promyelocytic leukemia: where did we start, where are we now, and the future.
  JOURNAL   Blood Cancer J 5:e304 (2015)
///
ENTRY       H00004                      Disease
NAME        Chronic myeloid leukemia (CML)
DESCRIPTION Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22.  The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.
CATEGORY    Cancer
GENE        BCR-ABL (translocation) [HSA:613 25] [KO:K08878 K06619]
            EVI1 (overexpression) [HSA:2122] [KO:K04462]
            AML1 (translocation) [HSA:861] [KO:K08367]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            p53 (mutation) [HSA:7157] [KO:K04451]
            RB1 (mutation) [HSA:5925] [KO:K06618]
CARCINOGEN  1,3-Butadiene [CPD:C16450]
            Rubber industry
MARKER      BCR-ABL (translocation) [HSA:613 25]
            WT1 [HSA:7490]
DRUG        Imatinib mesylate (Gleevec) [DG:DG00710]
            Nilotinib [DG:DG00716]
            Dasatinib [DG:DG00714]
COMMENT     ICD-O: 9875/3, Tumor type: Chronic myelogenous leukaemia
DBLINKS     ICD-10: C92.1
            MeSH: D015464
REFERENCE   PMID:15719031 (gene, tumor type)
  AUTHORS   Ren R.
  TITLE     Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
  JOURNAL   Nat Rev Cancer 5:172-83 (2005)
REFERENCE   PMID:10403855 (gene)
  AUTHORS   Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
  TITLE     The biology of chronic myeloid leukemia.
  JOURNAL   N Engl J Med 341:164-72 (1999)
REFERENCE   PMID:14982876 (gene)
  AUTHORS   Calabretta B, Perrotti D.
  TITLE     The biology of CML blast crisis.
  JOURNAL   Blood 103:4010-22 (2004)
REFERENCE   PMID:16155477 (carcinogen)
  AUTHORS   Graff JJ, Sathiakumar N, Macaluso M, Maldonado G, Matthews R, Delzell E.
  TITLE     Chemical exposures in the synthetic rubber industry and lymphohematopoietic cancer mortality.
  JOURNAL   J Occup Environ Med 47:916-32 (2005)
REFERENCE   PMID:9498905 (carcinogen)
  AUTHORS   Blair A, Kazerouni N.
  TITLE     Reactive chemicals and cancer.
  JOURNAL   Cancer Causes Control 8:473-90 (1997)
REFERENCE   PMID:16873420 (carcinogen)
  AUTHORS   Alder N, Fenty J, Warren F, Sutton AJ, Rushton L, Jones DR, Abrams KR.
  TITLE     Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry.
  JOURNAL   Am J Epidemiol 164:405-20 (2006)
REFERENCE   PMID:16299089 (carcinogen)
  AUTHORS   Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R, Delzell E.
  TITLE     An updated study of mortality among North American synthetic rubber industry workers.
  JOURNAL   Occup Environ Med 62:822-9 (2005)
REFERENCE   PMID:15265366 (marker)
  AUTHORS   Chen ZX, Kaeda J, Saunders S, Goldman JM.
  TITLE     Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
  JOURNAL   Chin Med J (Engl) 117:968-71 (2004)
REFERENCE   PMID:15661271 (marker)
  AUTHORS   Na IK, Kreuzer KA, Lupberger J, Dorken B, le Coutre P.
  TITLE     Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
  JOURNAL   Leuk Res 29:343-5 (2005)
REFERENCE   PMID:11529849 (marker)
  AUTHORS   Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P, Schmidt CA.
  TITLE     Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.
  JOURNAL   Br J Haematol 114:313-8 (2001)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00005                      Disease
NAME        Chronic lymphocytic leukemia (CLL)
DESCRIPTION B-cell chronic lymphocytic leukemia (CLL) is caused by the abnormal progressive accumulation of functionally incompetent monoclonal B-lymphocytes in blood, bone marrow, lymph nodes and spleen. It is the most common adult leukemia in Western countries, accounting for about 30% of total leukaemias. Worldwide there are approximately 180,000 new cases every year. A main focus in CLL research involved the evaluation of genetic features related to somatic gene mutation or deletions that disrupt apoptosis and enhance tumor cell proliferation. The best characterized genes are TP53 (also known as p53) and ATM, for which mutations and/or deletions have been described that predict rapid disease progression, resistance to conventional therapies and poor survival.
CATEGORY    Cancer
GENE        Bcl-2 (overexpression) [HSA:596] [KO:K02161]
            p53 (mutation) [HSA:7157] [KO:K04451]
            ATM (germline and somatic mutation) [HSA:472] [KO:K04728]
            Fas (absent) [HSA:355] [KO:K04390]
CARCINOGEN  1,3-Butadiene [CPD:C16450]
            Ethylene oxide [CPD:C06548]
            Rubber industry
MARKER      Beta-2-microglobulin (B2M) [HSA:567] [KO:K08055]
            BCR-ABL fusion gene [HSA:613 25] [KO:K08878 K06619]
            Lactate dehydrogenase [HSA:3939 3945 3948] [KO:K00016]
DRUG        Fludarabine [DG:DG00685]
            Cyclophosphamide [DG:DG00675]
            Rituximab [DR:D02994]
            Bendamustine [DG:DG00678]
            Chlorambucil [DR:D00266]
COMMENT     ICD-O: 9823/3, Tumor type: Chronic lymphocytic leukemia
DBLINKS     ICD-10: C91.1
            MeSH: D015451
REFERENCE   PMID:18059180 (description, gene, marker)
  AUTHORS   Chen J, McMillan NA
  TITLE     Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.
  JOURNAL   Cancer Biol Ther 7:174-9 (2008)
REFERENCE   PMID:17961188 (description, gene)
  AUTHORS   Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A
  TITLE     Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics  to identify predisposing genes.
  JOURNAL   Br J Haematol 139:744-52 (2007)
REFERENCE   PMID:10687725 (gene, tumor type)
  AUTHORS   Bannerji R, Byrd JC.
  TITLE     Update on the biology of chronic lymphocytic leukemia.
  JOURNAL   Curr Opin Oncol 12:22-9 (2000)
REFERENCE   PMID:11491097 (gene, tumor type)
  AUTHORS   Caligaris-Cappio F.
  TITLE     Biology of chronic lymphocytic leukemia.
  JOURNAL   Rev Clin Exp Hematol 4:5-21 (2000)
REFERENCE   PMID:9498905 (carcinogen)
  AUTHORS   Blair A, Kazerouni N.
  TITLE     Reactive chemicals and cancer.
  JOURNAL   Cancer Causes Control 8:473-90 (1997)
REFERENCE   PMID:16155477 (carcinogen)
  AUTHORS   Graff JJ, Sathiakumar N, Macaluso M, Maldonado G, Matthews R, Delzell E.
  TITLE     Chemical exposures in the synthetic rubber industry and lymphohematopoietic cancer mortality.
  JOURNAL   J Occup Environ Med 47:916-32 (2005)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:12464351 (carcinogen)
  AUTHORS   Kolman A, Chovanec M, Osterman-Golkar S.
  TITLE     Genotoxic effects of ethylene oxide, propylene oxide and epichlorohydrin in humans: update review (1990-2001).
  JOURNAL   Mutat Res 512:173-94 (2002)
REFERENCE   PMID:16873420 (carcinogen)
  AUTHORS   Alder N, Fenty J, Warren F, Sutton AJ, Rushton L, Jones DR, Abrams KR.
  TITLE     Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry.
  JOURNAL   Am J Epidemiol 164:405-20 (2006)
REFERENCE   PMID:16299089 (carcinogen)
  AUTHORS   Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R, Delzell E.
  TITLE     An updated study of mortality among North American synthetic rubber industry workers.
  JOURNAL   Occup Environ Med 62:822-9 (2005)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00006                      Disease
NAME        Hairy-cell leukemia
DESCRIPTION Hairy cell Leukemia (HCL) is a chronic lymphoproliferative disorder that is defined, according to the WHO classification, as a mature (peripheral) B-cell neoplasm. HCL accounts for between 2-3% of all leukemia cases, with about 600 new cases diagnosed in the U.S. each year. With regard to genetic abnormalities of potential pathogenetic importance in HCL, only a few have been described. Mutations of p53 and Bcl-6 have been reported in about one-third of cases, but their functional significance is unclear. Over-expression of cyclin D1, an important cell cycle regulator, has been reported in cases of HCL as well as mantle cell lymphoma (MCL) and in a few cases of chronic lymphocytic leukemia among lymphoid malignancies.
CATEGORY    Cancer
GENE        p53 (mutation) [HSA:7157] [KO:K04451]
            Bcl-6 (mutation) [HSA:604] [KO:K15618]
            Cyclin D1 (overexpression) [HSA:595] [KO:K04503]
MARKER      CD20 [HSA:931] [KO:K06466]
DRUG        Cladribine (2-chlorodeoxyadeosine; CdA) [DR:D01370]
COMMENT     ICD-O: 9940/3, Tumor type: Hairy cell leukemia
DBLINKS     ICD-10: C91.4
            MeSH: D007943
REFERENCE   PMID:12670461 (gene, tumor type)
  AUTHORS   Zuzel M, Cawley JC.
  TITLE     The biology of hairy cells.
  JOURNAL   Best Pract Res Clin Haematol 16:1-13 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00007                      Disease
NAME        Hodgkin lymphoma
DESCRIPTION Hodgkin's lymphoma (HL) is one of the most frequent lymphomas in the Western world and often affects young adults. HL is subdivided into classical and nodular lymphocyte-predominant forms. About 95% of cases are classical HL, and 5% are nodular lymphocyte-predominant HL (NLPHL). A characteristic feature of HL is the rareness of the tumor cells, which are called Hodgkin's and Reed/Sternberg (HRS) cells in classical HL and lymphocytic and histiocytic (L&H) cells in NLPHL. These cells represent only about 1% of the cellular infiltrate, while the vast majority of infiltrating cells are T lymphocytes, histiocytes, eosinophilic granulocytes and plasma cells. HRS cells show constitutive activity of both the classical and alternative NF-{kappa}B signalling pathways, which is probably a major pathogenetic mechanism in Hodgkin's lymphoma. The NF-{kappa}B activity in HRS cells is probably mediated by diverse mechanisms: receptor signalling through CD40, RANK, BCMA, and TACI, genomic REL amplification, destructive mutations in IKBA and IKBE. In HL pathogenesis associated with Epstein-Barr virus infection, the activation of NF-{kappa}B is induced by viral latent membrane protein 1 (LMP1).
CATEGORY    Cancer
GENE        IKBA (mutation) [HSA:4792] [KO:K04734]
            IKBE (mutation) [HSA:4794] [KO:K05872]
            c-rel (amplification) [HSA:5966] [KO:K09254]
            CD95 (mutation) [HSA:355] [KO:K04390]
PATHOGEN    Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
MARKER      CD30 [HSA:943]
            IL-10 [HSA:3586]
DRUG        Doxorubicin (Adriamycin) [DG:DG00696]
            Bleomycin [DG:DG00705]
            Vinblastine [DG:DG00689]
            Dacarbazine (ABVD) [DG:DG00680]
            Mechlorethamine [DR:D07671]
            Etoposide [DG:DG00693]
            Vincristine [DG:DG00690]
            Prednisone [DG:DG00094]
            Cyclophosphamide [DG:DG00675]
            Procarbazine [DG:DG00706]
            Prednisone [DG:DG00094]
COMMENT     ICD-O: 9650/3, Tumor type: Classical Hodgkin lymphoma
            ICD-O: 9663/3, Tumor type: Nodular sclerosis classical Hodgkin lymphoma
            ICD-O: 9651/3, Tumor type: Lymphocyte-rich classical Hodgkin lymphoma
            ICD-O: 9652/3, Tumor type: Mixed cellularity classical Hodgkin lymphoma
            ICD-O: 9653/3, Tumor type: Lymphocyte-depleted classical Hodgkin lymphoma
DBLINKS     ICD-10: C81
            MeSH: D006689
REFERENCE   PMID:15618006 (tumor type)
  AUTHORS   Kuppers R, Hansmann ML.
  TITLE     The Hodgkin and Reed/Sternberg cell.
  JOURNAL   Int J Biochem Cell Biol 37:511-7 (2005)
REFERENCE   PMID:15803153 (gene, carcinogen, tumor type)
  AUTHORS   Kuppers R.
  TITLE     Mechanisms of B-cell lymphoma pathogenesis.
  JOURNAL   Nat Rev Cancer 5:251-62 (2005)
REFERENCE   PMID:16385563 (gene, carcinogen)
  AUTHORS   Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R.
  TITLE     Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.
  JOURNAL   Int J Cancer 118:1853-61 (2006)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:12078906 (marker)
  AUTHORS   Zander T, Wiedenmann S, Wolf J.
  TITLE     Prognostic factors in Hodgkin's lymphoma.
  JOURNAL   Ann Oncol 13 Suppl 1:67-74 (2002)
REFERENCE   PMID:11142480 (marker)
  AUTHORS   Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M.
  TITLE     Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
  JOURNAL   Ann Oncol 11:1405-11 (2000)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00008                      Disease
NAME        Burkitt lymphoma
DESCRIPTION Burkitt lymphoma (BL) is a highly aggressive mature B-cell non-Hodgkin's lymphoma consisting of endemic, sporadic, and immunodeficiency-associated variants. Endemic BL (eBL) affects children and young adults in Africa and some other geographical areas and carries Epstein-Barr virus (EBV) in more than 95% of cases. In contrast, sporadic BL (sBL) among adolescents in Europe and North America are mostly EBV-negative. A third type of BL is associated with HIV-infection in adults. All of these subtypes possess chromosomal rearrangements of the c-myc oncogene, the genetic hallmark of BL that contributes to lymphomagenesis through alterations in cell cycle regulation, cellular differentiation, apoptosis, cellular adhesion, and metabolism. Many BL carry point mutation in the p53 tumor suppressor gene or other defects in the p14ARF-MDM2-p53 pathway, and inactivation of the p16INK4a gene by promoter methylation or homozygous deletion. This indicates that disruption of both the pRb and p53 tumor suppressor pathways is critical for BL development.
CATEGORY    Cancer
GENE        MYC-IgH (translocation) [HSA:4609] [KO:K04377]
            p53 (mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (promoter methylation) [HSA:1029] [KO:K06621]
CARCINOGEN  Azathioprine [DG:DG00743]
            Ethylene oxide [CPD:C06548]
            2,3,7,8-Tetrachlorodibenzo-para-dioxin [CPD:C07557]
PATHOGEN    Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
            Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
MARKER      CD20 [HSA:931] [KO:K06466]
DRUG        Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Doxorubicin [DG:DG00696]
            Prednisone (CHOP) [DG:DG00094]
            Rituximab [DR:D02994]
COMMENT     ICD-O: 9687/3, Tumor type: Burkitt lymphoma
            Although the carcinogens listed and infection with HIV-1 are risk factors for non-Hodgkin lymphoma in general, the strength of association with different histological tumor types is not well understood.
DBLINKS     ICD-10: C83.7
            MeSH: D002051
REFERENCE   PMID:12191637 (gene, carcinogen, tumor type)
  AUTHORS   Lindstrom MS, Wiman KG.
  TITLE     Role of genetic and epigenetic changes in Burkitt lymphoma.
  JOURNAL   Semin Cancer Biol 12:381-7 (2002)
REFERENCE   PMID:15803153 (gene, carcinogen)
  AUTHORS   Kuppers R.
  TITLE     Mechanisms of B-cell lymphoma pathogenesis.
  JOURNAL   Nat Rev Cancer 5:251-62 (2005)
REFERENCE   PMID:16062089 (carcinogen)
  AUTHORS   Patel P, Moazzam N, Potti A, Mehdi SA.
  TITLE     Azathioprine induced hodgkin lymphoma: a case report and review of literature.
  JOURNAL   Am J Clin Oncol 28:427-8 (2005)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:12464351 (carcinogen)
  AUTHORS   Kolman A, Chovanec M, Osterman-Golkar S.
  TITLE     Genotoxic effects of ethylene oxide, propylene oxide and epichlorohydrin in humans: update review (1990-2001).
  JOURNAL   Mutat Res 512:173-94 (2002)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00009                      Disease
NAME        Adult T-cell leukemia
DESCRIPTION Adult T-cell leukemia (ATL) is one of the most aggressive hematologic malignancies and is caused by human T-cell leukemia virus type I (HTLV-I). The HTLV-I Tax protein has been demonstrated to be the oncogenic protein of the virus. Tax may contribute to the process of carcinogenesis by a variety of mechanisms, including upregulating the expression of cellular genes involved in T cell growth and proliferation, including IL-2, IL-2R-alpha, and IL-15. However, ATL cells do not always need Tax expression in the later stage of leukemogenesis. Genetic and epigenetic changes should be implicated in such multistep leukemogenesis. Regarding genetic changes, mutation of p53, and deletion of p16 have been reported in ATL. Mutations of Fas gene are also reported in patients with ATL cells. However, such genetic changes were not frequently detected. In this regard, epigenetic change of p16/INK4A gene was more frequent in ATL cells, and accumulated according to the disease progression. This finding suggests that epigenetic change, including DNA methylation, plays an important role in the leukemogenesis of ATL.
CATEGORY    Cancer
GENE        p53 (mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (deletion, promoter methylation) [HSA:1029] [KO:K06621]
            Fas (mutation) [HSA:355] [KO:K04390]
PATHOGEN    Human T-lymphotropic virus 1 [GN:T40003]
MARKER      Lactate dehydrogenase [HSA:3939 3945 3948] [KO:K00016]
DRUG        Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Doxorubicin [DG:DG00696]
            Prednisone (CHOP) [DG:DG00094]
            Rituximab [DR:D02994]
COMMENT     ICD-O: 9827/3, Tumor type: Adult T-cell leukaemia
DBLINKS     ICD-10: C91.5
            MeSH: D015459
REFERENCE   PMID:12910250 (description, gene)
  AUTHORS   Matsuoka M
  TITLE     Human T-cell leukemia virus type I and adult T-cell leukemia.
  JOURNAL   Oncogene 22:5131-40 (2003)
REFERENCE   PMID:14686488 (gene)
  AUTHORS   Yasunaga J, Matsuoka M
  TITLE     Leukemogenesis of adult T-cell leukemia.
  JOURNAL   Int J Hematol 78:312-20 (2003)
REFERENCE   PMID:10190897 (gene, tumor type)
  AUTHORS   Maeda T, Yamada Y, Moriuchi R, Sugahara K, Tsuruda K, Joh T, Atogami S, Tsukasaki K, Tomonaga M, Kamihira S.
  TITLE     Fas gene mutation in the progression of adult T cell leukemia.
  JOURNAL   J Exp Med 189:1063-71 (1999)
REFERENCE   PMID:17387298 (carcinogen)
  AUTHORS   Yasunaga J, Matsuoka M.
  TITLE     Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms.
  JOURNAL   Cancer Control 14:133-40 (2007)
REFERENCE   PMID:16362996 (carcinogen)
  AUTHORS   Jarrett RF.
  TITLE     Viruses and lymphoma/leukaemia.
  JOURNAL   J Pathol 208:176-86 (2006)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:26626770
  AUTHORS   Chung CG, Poligone B
  TITLE     Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
  JOURNAL   Curr Hematol Malig Rep 10:468-76 (2015)
///
ENTRY       H00010                      Disease
NAME        Multiple myeloma
DESCRIPTION Multiple myeloma is a disorder in which malignant plasma cells accumulate, generally derived from one clone in the bone marrow. Intricate interactions occur between the bone-marrow microenvironment and the myeloma cells, frequently causing bone destruction, which in turn stimulates tumor growth. Often it is preceded by a premalignant tumor called monoclonal gammopathy of undetermined significance (MGUS). Multiple oncogenic events have been identified that have contributed to the pathogenesis of myeloma. Among the earliest genetic events are translocations of the immunoglobulin heavy-chain gene locus, which leads to dysregulation of oncogenes at translocation partner regions (cyclin D1 at 11q13, FGFR3/MMSET at 4p16.3, c-MAF at 16q23, and cyclin D3 at 6p21), and deletions of 13q14, the site of a putative tumor suppressor gene. Additional molecular events include epigenetic changes and activation of oncogenes (mutations of N-RAS and K-RAS, and changes in c-MYC), which are usually associated with disease progression.
CATEGORY    Cancer
GENE        CCND1-IgH (translocation) [HSA:595] [KO:K04503 K06856]
            CCND3-IgH (translocation) [HSA:896] [KO:K10152 K06856]
            IgH-FGFR3 (translocation) [HSA:2261] [KO:K06856 K05094]
            IgH-MMSET (translocation) [HSA:7468] [KO:K06856 K11424]
            IgH-MAF (translocation) [HSA:4094] [KO:K06856 K09035]
            N-ras (activating mutation) [HSA:4893] [KO:K07828]
            K-ras (activating mutation) [HSA:3845] [KO:K07827]
            c-MYC (dysregulation) [HSA:4609] [KO:K04377]
            p53 (mutation) [HSA:7157] [KO:K04451]
MARKER      Beta-2-microglobulin (B2M) [HSA:567] [KO:K08055]
            Immunoglobulins
DRUG        Bortezomib [DR:D03150]
            Dexamethasone [DG:DG00011]
            Thalidomide [DR:D00754]
            Lenalidomide [DG:DG00744]
            Melphalan [DG:DG00676]
            Prednisone [DG:DG00094]
COMMENT     ICD-O: 9732/3, Tumor type: Plasma cell myeloma
DBLINKS     ICD-10: C90.0
            MeSH: D009101
REFERENCE   PMID:15031034 (description)
  AUTHORS   Sirohi B, Powles R
  TITLE     Multiple myeloma.
  JOURNAL   Lancet 363:875-87 (2004)
REFERENCE   PMID:12965277 (description, gene)
  AUTHORS   Seidl S, Kaufmann H, Drach J
  TITLE     New insights into the pathophysiology of multiple myeloma.
  JOURNAL   Lancet Oncol 4:557-64 (2003)
REFERENCE   PMID:12358886 (gene)
  AUTHORS   Joy Ho P
  TITLE     Chromosomal and genetic abnormalities in myeloma.
  JOURNAL   Clin Lab Haematol 24:259-69 (2002)
REFERENCE   PMID:16155016 (gene, tumor type)
  AUTHORS   Bergsagel PL, Kuehl WM.
  TITLE     Molecular pathogenesis and a consequent classification of multiple myeloma.
  JOURNAL   J Clin Oncol 23:6333-8 (2005)
REFERENCE   PMID:12370633 (gene)
  AUTHORS   Podczaski E, Cain J.
  TITLE     Multiple myeloma.
  JOURNAL   Clin Obstet Gynecol 45:928-38 (2002)
REFERENCE   PMID:9414264 (gene)
  AUTHORS   Hallek M, Bergsagel PL, Anderson KC.
  TITLE     Multiple myeloma: increasing evidence for a multistep transformation process.
  JOURNAL   Blood 91:3-21 (1998)
REFERENCE   PMID:11607813 (gene)
  AUTHORS   Bergsagel PL, Kuehl WM
  TITLE     Chromosome translocations in multiple myeloma.
  JOURNAL   Oncogene 20:5611-22 (2001)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00011                      Disease
NAME        Lymphoplasmacytic lymphoma
DESCRIPTION Lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL) subtype characterized by small B-lymphocytes, plasmacytoid lymphocytes, and plasma cells, usually involving bone marrow, lymph nodes, and the spleen. WM can be distinguished clinically from LPL on the basis of a detectable monoclonal (IgM) immunoglobulin spike in serum. In the general population, LPL/WM is a very rare disease, accounting for only 1%-2% of all hematologic malignancies, reflected in an incidence rate of 3-4 cases per million people per year. The t(9;14)(p13;q32) is present in near 50% of cases of LPL. This chromosomal translocation involves a junction between 9p13 and the switch micro region of the Ig heavy chain locus on 14q32. The 9p13 breakpoint contains the PAX-5 gene which encodes a B-cell specific transcription factor involved in the control of B-cell proliferation and differentiation. The translocation causes the juxtaposition of the PAX-5 gene to the IgH locus in the opposite direction of transcription, resulting in an 11-fold over-expression of PAX-5 mRNA.
CATEGORY    Cancer
GENE        Pax5-IgH (translocation) [HSA:5079] [KO:K09383 K06856]
CARCINOGEN  Azathioprine [DG:DG00743]
            Ethylene oxide [CPD:C06548]
            2,3,7,8-Tetrachlorodibenzo-para-dioxin [CPD:C07557]
PATHOGEN    Hepatitis C virus [GN:T40066]
            Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
MARKER      Beta-2-microglobulin (B2M) [HSA:567] [KO:K08055]
            CD20 [HSA:931] [KO:K06466]
            Immunoglobulins
DRUG        Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Doxorubicin [DG:DG00696]
            Prednisone (CHOP) [DG:DG00094]
            Rituximab [DR:D02994]
COMMENT     ICD-O: 9671/3, Tumor type: Lymphoplasmacytic lymphoma
            Although the carcinogens listed and infection with HIV-1 are risk factors for non-Hodgkin lymphoma in general, the strength of association with different histological tumor types is not well understood.
DBLINKS     ICD-10: C83.8 C88.0
REFERENCE   PMID:19362964 (description)
  AUTHORS   Kristinsson SY, Koshiol J, Goldin LR, Bjorkholm M, Turesson I, Gridley G, McMaster ML, Landgren O
  TITLE     Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenstrom's macroglobulinemia.
  JOURNAL   Clin Lymphoma Myeloma 9:23-6 (2009)
REFERENCE   PMID:18499469 (description, gene, carcinogen)
  AUTHORS   Vitolo U, Ferreri AJ, Montoto S
  TITLE     Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
  JOURNAL   Crit Rev Oncol Hematol 67:172-85 (2008)
REFERENCE   PMID:11232108 (gene, tumor type)
  AUTHORS   Arber DA.
  TITLE     Molecular diagnostic approach to non-Hodgkin's lymphoma.
  JOURNAL   J Mol Diagn 2:178-90 (2000)
REFERENCE   PMID:15803153 (gene)
  AUTHORS   Kuppers R.
  TITLE     Mechanisms of B-cell lymphoma pathogenesis.
  JOURNAL   Nat Rev Cancer 5:251-62 (2005)
REFERENCE   PMID:10350329
  AUTHORS   Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera R
  TITLE     Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32).
  JOURNAL   Leuk Lymphoma 34:25-33 (1999)
REFERENCE   PMID:10784387
  AUTHORS   Ohno H, Ueda C, Akasaka T
  TITLE     The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
  JOURNAL   Leuk Lymphoma 36:435-45 (2000)
REFERENCE   PMID:16062089 (carcinogen)
  AUTHORS   Patel P, Moazzam N, Potti A, Mehdi SA.
  TITLE     Azathioprine induced hodgkin lymphoma: a case report and review of literature.
  JOURNAL   Am J Clin Oncol 28:427-8 (2005)
REFERENCE   PMID:12464351 (carcinogen)
  AUTHORS   Kolman A, Chovanec M, Osterman-Golkar S.
  TITLE     Genotoxic effects of ethylene oxide, propylene oxide and epichlorohydrin in humans: update review (1990-2001).
  JOURNAL   Mutat Res 512:173-94 (2002)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00012                      Disease
NAME        Polycythemia vera
DESCRIPTION Polycythemia vera (PV) is a clonal myeloproliferative disease characterized by an erythroid dominant trilineage proliferation of hematopoietic precursor cells. PV belongs to the family of chronic myeloproliferative disorders (MPD), which includes hematological diseases that share clinical and biological similarities, such as a hematopoietic stem cell origin: PV, essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), some types of hypereosinophilic syndrome (HES), systemic mast cell disease (SMD) and other rare disorders. Recently, a specific point mutation in the Janus kinase 2 (JAK2) gene was described in a majority of PV patients and thus constitutes a sensitive diagnostic marker for the disease.
CATEGORY    Cancer
GENE        JAK2 (mutation) [HSA:3717] [KO:K04447]
MARKER      JAK2 (mutation) [HSA:3717]
            PRV-1 [HSA:57126]
            EPO [HSA:2056]
DRUG        Hydroxyurea [DR:D00341]
COMMENT     ICD-O: 9950/3, Tumor type: Polycythemia vera
DBLINKS     ICD-10: D45
            MeSH: D011087
REFERENCE   PMID:16879013 (gene, tumor type)
  AUTHORS   Cao M, Olsen RJ, Zu Y.
  TITLE     Polycythemia vera: new clinicopathologic perspectives.
  JOURNAL   Arch Pathol Lab Med 130:1126-32 (2006)
REFERENCE   PMID:16781479 (gene)
  AUTHORS   Chen G, Prchal JT.
  TITLE     Polycythemia vera and its molecular basis: an update.
  JOURNAL   Best Pract Res Clin Haematol 19:387-97 (2006)
REFERENCE   PMID:17131059 (gene)
  AUTHORS   Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W.
  TITLE     Oncogenic mechanisms in myeloproliferative disorders.
  JOURNAL   Cell Mol Life Sci 63:2939-53 (2006)
REFERENCE   PMID:16919893 (marker)
  AUTHORS   Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
  TITLE     Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
  JOURNAL   Pathol Biol (Paris) 55:92-104 (2007)
REFERENCE   PMID:15217712 (marker)
  AUTHORS   Klippel S, Pahl HL.
  TITLE     Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders.
  JOURNAL   Pathol Biol (Paris) 52:267-74 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00013                      Disease
NAME        Small cell lung cancer
DESCRIPTION Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases.  Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control.
CATEGORY    Cancer
GENE        c-MYC (amplification) [HSA:4609] [KO:K04377]
            RAR-beta (promoter hypermethylation) [HSA:5915] [KO:K08528]
            FHIT (mutation) [HSA:2272] [KO:K01522]
            p53 (LOH, mutation) [HSA:7157] [KO:K04451]
            RB1 (LOH, mutation) [HSA:5925] [KO:K06618]
            PTEN (mutation, deletion) [HSA:5728] [KO:K01110]
            Bcl-2 (overexpression) [HSA:596] [KO:K02161]
CARCINOGEN  Arsenic and arsenic compounds [CPD:C06269]
            Asbestos [CPD:C16442]
            Beryllium and beryllium compounds [CPD:C16460]
            Bis(chloromethyl)ether and chloromethyl methyl ether (technical-grade)
            N'-Nitrosonornicotine (NNN) and 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone(NNK) [CPD:C16452 C16453]
            Radon-222 and its decay products
            Silica, crystalline (inhaled in the form of quartz orcristobalite from occupational sources) [CPD:C16459]
            Tobacco smoking and tobacco smoke
            *Aluminium production
            *Benzo[a]pyrene [CPD:C07535]
            *Cadmium and cadmium compounds
            *Chimney sweeping
            *Coal gasification
            *Coal-tar pitches
            *Coal-tars [DR:D03573]
            *Coke production
            *Furniture and cabinet making
            *Haematite mining (underground) with exposure to radon
            *Household combustion of coal, indoor emissions from
            *Involuntary smoking (exposure to secondhand or environmental tobacco smoke)
            *Iron and steel founding
            *Mineral oils, untreated and mildly treated
            *Painter (occupational exposure as a)
            *Paving and roofing with coal-tar pitch
            *Shale-oils [CPD:C16458]
            *Soots
            *Strong-inorganic-acid mists containing sulfuric acid
            *Talc containing asbestiform fibres
            *2,3,7,8-Tetrachlorodibenzo-para-dioxin
            *X- and gamma-radiation
            *: Although this is a risk factor for lung cancer in general, the strength of association with different histological tumor types is not well understood.
MARKER      Cytokeratin fragments 21-1 (Cyfra 21-1) [HSA:3880] [KO:K04604]
            Neuron-specific enolase (NSE) [HSA:2026] [KO:K01689]
DRUG        Cisplatin [DR:D00275]
            Etoposide [DG:DG00693]
            Carboplatin [DR:D01363]
COMMENT     ICD-O: 8041/3, Tumor type: Small cell carcinoma
DBLINKS     ICD-10: C34
            MeSH: D055752
REFERENCE   PMID:12741677 (gene, tumor type)
  AUTHORS   Yokota J, Nishioka M, Tani M, Kohno T.
  TITLE     Genetic alterations responsible for metastatic phenotypes of lung cancer cells.
  JOURNAL   Clin Exp Metastasis 20:189-93 (2003)
REFERENCE   PMID:12711111 (tumor type)
  AUTHORS   Sanchez-Cespedes M.
  TITLE     Dissecting the genetic alterations involved in lung carcinogenesis.
  JOURNAL   Lung Cancer 40:111-21 (2003)
REFERENCE   PMID:12407699 (gene)
  AUTHORS   Mitsuuchi Y, Testa JR.
  TITLE     Cytogenetics and molecular genetics of lung cancer.
  JOURNAL   Am J Med Genet 115:183-8 (2002)
REFERENCE   PMID:16112428 (gene)
  AUTHORS   Panani AD, Roussos C.
  TITLE     Cytogenetic and molecular aspects of lung cancer.
  JOURNAL   Cancer Lett 239:1-9 (2006)
REFERENCE   PMID:15322513 (carcinogen)
  AUTHORS   Boffetta P.
  TITLE     Epidemiology of environmental and occupational cancer.
  JOURNAL   Oncogene 23:6392-403 (2004)
REFERENCE   PMID:2831418 (carcinogen)
  AUTHORS   Adachi S, Takemoto K.
  TITLE     [Occupational lung cancer. A comparison between humans and experimental animals]
  JOURNAL   Sangyo Igaku 29:345-57 (1987)
REFERENCE   PMID:17375514 (carcinogen)
  AUTHORS   O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ.
  TITLE     Asbestos-related lung disease.
  JOURNAL   Am Fam Physician 75:683-8 (2007)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:12082370 (carcinogen)
  AUTHORS   Gottschall EB.
  TITLE     Occupational and environmental thoracic malignancies.
  JOURNAL   J Thorac Imaging 17:189-97 (2002)
REFERENCE   PMID:17630920 (carcinogen)
  AUTHORS   Grozio A, Catassi A, Cavalieri Z, Paleari L, Cesario A, Russo P.
  TITLE     Nicotine, lung and cancer.
  JOURNAL   Anticancer Agents Med Chem 7:461-6 (2007)
REFERENCE   PMID:10076528 (carcinogen)
  AUTHORS   Schuller HM, Orloff M.
  TITLE     Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells.
  JOURNAL   Biochem Pharmacol 55:1377-84 (1998)
REFERENCE   PMID:16155477 (carcinogen)
  AUTHORS   Graff JJ, Sathiakumar N, Macaluso M, Maldonado G, Matthews R, Delzell E.
  TITLE     Chemical exposures in the synthetic rubber industry and lymphohematopoietic cancer mortality.
  JOURNAL   J Occup Environ Med 47:916-32 (2005)
REFERENCE   PMID:16299089 (carcinogen)
  AUTHORS   Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R, Delzell E.
  TITLE     An updated study of mortality among North American synthetic rubber industry workers.
  JOURNAL   Occup Environ Med 62:822-9 (2005)
REFERENCE   PMID:11886955 (carcinogen)
  AUTHORS   Verma DK, Purdham JT, Roels HA.
  TITLE     Translating evidence about occupational conditions into strategies for prevention.
  JOURNAL   Occup Environ Med 59:205-13; quiz 214 (2002)
REFERENCE   PMID:9358915 (carcinogen)
  AUTHORS   Honma K, Chiyotani K, Kimura K.
  TITLE     Silicosis, mixed dust pneumoconiosis, and lung cancer.
  JOURNAL   Am J Ind Med 32:595-9 (1997)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:17589590 (carcinogen)
  AUTHORS   Zhang JJ, Smith KR.
  TITLE     Household air pollution from coal and biomass fuels in china: measurements, health impacts, and interventions.
  JOURNAL   Environ Health Perspect 115:848-55 (2007)
REFERENCE   PMID:17882278 (carcinogen)
  AUTHORS   Sun S, Schiller JH, Gazdar AF.
  TITLE     Lung cancer in never smokers--a different disease.
  JOURNAL   Nat Rev Cancer 7:778-90 (2007)
REFERENCE   PMID:10723042 (carcinogen)
  AUTHORS   Stern FB, Ruder AM, Chen G.
  TITLE     Proportionate mortality among unionized roofers and waterproofers.
  JOURNAL   Am J Ind Med 37:478-92 (2000)
REFERENCE   PMID:17032693 (carcinogen)
  AUTHORS   Hsu YM, Wu CY, Lundgren DA, Birky BK.
  TITLE     Size-resolved sulfuric acid mist concentrations at phosphate fertilizer manufacturing facilities in Florida.
  JOURNAL   Ann Occup Hyg 51:81-9 (2007)
REFERENCE   PMID:9498905 (carcinogen)
  AUTHORS   Blair A, Kazerouni N.
  TITLE     Reactive chemicals and cancer.
  JOURNAL   Cancer Causes Control 8:473-90 (1997)
REFERENCE   PMID:15070562 (carcinogen)
  AUTHORS   Berrington de Gonzalez A, Darby S.
  TITLE     Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.
  JOURNAL   Lancet 363:345-51 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00014                      Disease
NAME        Non-small cell lung cancer
DESCRIPTION Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a  inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.
CATEGORY    Cancer
GENE        K-ras (mutation) [HSA:3845] [KO:K07827]
            EGFR (mutation) [HSA:1956] [KO:K04361]
            RAR-beta (promoter hypermethylation) [HSA:5915] [KO:K08528]
            FHIT (mutation) [HSA:2272] [KO:K01522]
            RASSF1 (promoter hypermethylation) [HSA:11186] [KO:K09850]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            p53 (mutation/deletion) [HSA:7157] [KO:K04451]
            EML4-ALK (translocation) [HSA:27436 238] [KO:K15420 K05119]
            TFG-ALK (translocation) [HSA:10342 238] [KO:K09292 K05119]
            SLC34A2-ROS1 (translocation) [HSA:10568 6098] [KO:K14683 K05088]
CARCINOGEN  Arsenic and arsenic compounds [CPD:C06269]
            Arsenic in drinking-water
            Asbestos [CPD:C16442]
            Chromium[VI]
            Mustard gas (Sulfur mustard)
            Nickel compounds
            Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols
            Radon-222 and its decay products
            Silica, crystalline (inhaled in the form of quartz orcristobalite from occupational sources) [CPD:C16459]
            Tobacco smoking and tobacco smoke
            *Aluminium production
            *Benzo[a]pyrene [CPD:C07535]
            *Cadmium and cadmium compounds
            *Chimney sweeping
            *Coal gasification
            *Coal-tar pitches [CPD:C16451]
            *Coal-tars [DR:D03573]
            *Coke production
            *Furniture and cabinet making
            *Haematite mining (underground) with exposure to radon
            *Household combustion of coal, indoor emissions from
            *Involuntary smoking (exposure to secondhand or environmental tobacco smoke)
            *Iron and steel founding
            *Mineral oils, untreated and mildly treated
            *Painter (occupational exposure as a)
            *Paving and roofing with coal-tar pitch
            *Shale-oils [CPD:C16458]
            *Soots
            *Strong-inorganic-acid mists containing sulfuric acid
            *Talc containing asbestiform fibres
            *2,3,7,8-Tetrachlorodibenzo-para-dioxin
            *X- and gamma-radiation
            *: Although this is a risk factor for lung cancer in general, the strength of association with different histological tumor types is not well understood.
MARKER      EML4-ALK (translocation) [HSA:27436 238] [KO:K15420 K05119]
            TFG-ALK (translocation) [HSA:10342 238] [KO:K09292 K05119]
            Carcinoembryonic antigen (CEA) [HSA:634] [KO:K06499]
            Cytokeratin fragments 21-1 (Cyfra 21-1) [HSA:3880] [KO:K04604]
            EGFR mutation analysis [HSA:1956] [KO:K04361]
            KRAS mutation analysis [HSA:3845] [KO:K07827]
            Programmed death ligand 1 (PD-L1) [HSA:29126] [KO:K06745]
DRUG        Cisplatin [DR:D00275]
            Vinorelbine [DG:DG00692]
            Etoposide [DG:DG00693]
            Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
            Gemcitabine [DG:DG00688]
            Pemetrexed [DR:D07472]
            Bevacizumab [DR:D06409]
COMMENT     ICD-O: 8140/3, Tumor type: Adenocarcinoma
            ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
DBLINKS     ICD-10: C34
            MeSH: D002289
REFERENCE   PMID:12741677 (tumor type)
  AUTHORS   Yokota J, Nishioka M, Tani M, Kohno T.
  TITLE     Genetic alterations responsible for metastatic phenotypes of lung cancer cells.
  JOURNAL   Clin Exp Metastasis 20:189-93 (2003)
REFERENCE   PMID:12711111 (tumor type)
  AUTHORS   Sanchez-Cespedes M.
  TITLE     Dissecting the genetic alterations involved in lung carcinogenesis.
  JOURNAL   Lung Cancer 40:111-21 (2003)
REFERENCE   PMID:12407699 (gene)
  AUTHORS   Mitsuuchi Y, Testa JR.
  TITLE     Cytogenetics and molecular genetics of lung cancer.
  JOURNAL   Am J Med Genet 115:183-8 (2002)
REFERENCE   PMID:16112428 (gene)
  AUTHORS   Panani AD, Roussos C.
  TITLE     Cytogenetic and molecular aspects of lung cancer.
  JOURNAL   Cancer Lett 239:1-9 (2006)
REFERENCE   PMID:15769940 (gene)
  AUTHORS   Meuwissen R, Berns A.
  TITLE     Mouse models for human lung cancer.
  JOURNAL   Genes Dev 19:643-64 (2005)
REFERENCE   PMID:17625570 (gene)
  AUTHORS   Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H
  TITLE     Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
  JOURNAL   Nature 448:561-6 (2007)
REFERENCE   PMID:19406209 (gene)
  AUTHORS   Brenner JC, Chinnaiyan AM
  TITLE     Translocations in epithelial cancers.
  JOURNAL   Biochim Biophys Acta 1796:201-15 (2009)
REFERENCE   PMID:21850578 (gene)
  AUTHORS   Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S
  TITLE     Molecular oncology of lung cancer.
  JOURNAL   Gen Thorac Cardiovasc Surg 59:527-37 (2011)
REFERENCE   PMID:23733083 (gene)
  AUTHORS   Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M
  TITLE     Non-small cell lung cancer--genetic predictors.
  JOURNAL   Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157:125-36 (2013)
REFERENCE   PMID:15322513 (carcinogen)
  AUTHORS   Boffetta P.
  TITLE     Epidemiology of environmental and occupational cancer.
  JOURNAL   Oncogene 23:6392-403 (2004)
REFERENCE   PMID:2831418 (carcinogen)
  AUTHORS   Adachi S, Takemoto K.
  TITLE     [Occupational lung cancer. A comparison between humans and experimental animals]
  JOURNAL   Sangyo Igaku 29:345-57 (1987)
REFERENCE   PMID:14643412 (carcinogen)
  AUTHORS   Rossman TG.
  TITLE     Mechanism of arsenic carcinogenesis: an integrated approach.
  JOURNAL   Mutat Res 533:37-65 (2003)
REFERENCE   PMID:17244035 (carcinogen)
  AUTHORS   Walvekar RR, Kane SV, Nadkarni MS, Bagwan IN, Chaukar DA, D'Cruz AK.
  TITLE     Chronic arsenic poisoning: a global health issue -- a report of multiple primary cancers.
  JOURNAL   J Cutan Pathol 34:203-6 (2007)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:17375514 (carcinogen)
  AUTHORS   O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ.
  TITLE     Asbestos-related lung disease.
  JOURNAL   Am Fam Physician 75:683-8 (2007)
REFERENCE   PMID:12082370 (carcinogen)
  AUTHORS   Gottschall EB.
  TITLE     Occupational and environmental thoracic malignancies.
  JOURNAL   J Thorac Imaging 17:189-97 (2002)
REFERENCE   PMID:12556326 (carcinogen)
  AUTHORS   Harrison JD, Muirhead CR.
  TITLE     Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
  JOURNAL   Int J Radiat Biol 79:1-13 (2003)
REFERENCE   PMID:16411224 (carcinogen)
  AUTHORS   Taeger D, Fritsch A, Wiethege T, Johnen G, Eisenmenger A, Wesch H, Ko Y, Stier S, Michael Muller K, Bruning T, Pesch B.
  TITLE     Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium miners.
  JOURNAL   Cancer 106:881-9 (2006)
REFERENCE   PMID:11135223 (carcinogen)
  AUTHORS   Kreuzer M, Muller KM, Brachner A, Gerken M, Grosche B, Wiethege T, Wichmann HE.
  TITLE     Histopathologic findings of lung carcinoma in German uranium miners.
  JOURNAL   Cancer 89:2613-21 (2000)
REFERENCE   PMID:11886955 (carcinogen)
  AUTHORS   Verma DK, Purdham JT, Roels HA.
  TITLE     Translating evidence about occupational conditions into strategies for prevention.
  JOURNAL   Occup Environ Med 59:205-13; quiz 214 (2002)
REFERENCE   PMID:9358915 (carcinogen)
  AUTHORS   Honma K, Chiyotani K, Kimura K.
  TITLE     Silicosis, mixed dust pneumoconiosis, and lung cancer.
  JOURNAL   Am J Ind Med 32:595-9 (1997)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:17589590 (carcinogen)
  AUTHORS   Zhang JJ, Smith KR.
  TITLE     Household air pollution from coal and biomass fuels in china: measurements, health impacts, and interventions.
  JOURNAL   Environ Health Perspect 115:848-55 (2007)
REFERENCE   PMID:17882278 (carcinogen)
  AUTHORS   Sun S, Schiller JH, Gazdar AF.
  TITLE     Lung cancer in never smokers--a different disease.
  JOURNAL   Nat Rev Cancer 7:778-90 (2007)
REFERENCE   PMID:10723042 (carcinogen)
  AUTHORS   Stern FB, Ruder AM, Chen G.
  TITLE     Proportionate mortality among unionized roofers and waterproofers.
  JOURNAL   Am J Ind Med 37:478-92 (2000)
REFERENCE   PMID:17032693 (carcinogen)
  AUTHORS   Hsu YM, Wu CY, Lundgren DA, Birky BK.
  TITLE     Size-resolved sulfuric acid mist concentrations at phosphate fertilizer manufacturing facilities in Florida.
  JOURNAL   Ann Occup Hyg 51:81-9 (2007)
REFERENCE   PMID:9498905 (carcinogen)
  AUTHORS   Blair A, Kazerouni N.
  TITLE     Reactive chemicals and cancer.
  JOURNAL   Cancer Causes Control 8:473-90 (1997)
REFERENCE   PMID:15070562 (carcinogen)
  AUTHORS   Berrington de Gonzalez A, Darby S.
  TITLE     Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.
  JOURNAL   Lancet 363:345-51 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00015                      Disease
NAME        Malignant pleural mesothelioma
DESCRIPTION Malignant mesothelioma (MM) is a rare but very aggressive tumor that arises from mesothelial cells lining the pleural, peritoneal and pericardial cavities. Malignant pleural mesothelioma (MPM) is the most common type, accounting for about 70% of all MM cases. Past asbestos exposure represents the major risk factor for MPM, as the link between asbestos fibres and MPM has been largely proved by epidemiological and experimental studies. Recently, simian virus 40 (SV40) has been implicated in the aetiology of MPM. The accumulation of numerous clonal chromosomal deletions in most MMs suggests a multistep process of tumorigenesis, characterized by the loss and/or inactivation of multiple tumor suppressor genes (TSGs). Cytogenetic and loss of heterozygosity (LOH) analyses of MMs have demonstrated frequent deletions of specific sites within chromosome arms 1p, 3p, 6q, 9p, 13q, 15q, and 22q. Furthermore, TSGs within two of these regions, i.e., p16/CDKN2A-p14ARF at 9p21 and NF2 at 22q12, are frequently altered in MMs. Mutations of the p53 gene (TP53) are occasionally observed in MMs.
CATEGORY    Cancer
GENE        p53 (inactivation) [HSA:7157] [KO:K04451]
            p16/CDKN2A (deletion) [HSA:1029] [KO:K06621]
            p15/CDKN2B (deletion) [HSA:1030] [KO:K04685]
            NF2 (mutation) [HSA:4771] [KO:K16684]
            PDGF-A (overexpression) [HSA:5154] [KO:K04359]
            PDGF-B (overexpression) [HSA:5155] [KO:K17386]
            IGF-1 (expression) [HSA:3479] [KO:K05459]
            IGF-R1 (expression) [HSA:3480] [KO:K05087]
CARCINOGEN  Asbestos [CPD:C16442]
PATHOGEN    Simian virus 40 (SV40) [GN:T40086]
MARKER      Calretinin [HSA:794]
            WT-1 [HSA:7490]
            Cytokeratin 5 [HSA:3852]
            Cytokeratin 6 [HSA:3853 3854 286887]
DRUG        Cisplatin [DR:D00275]
            Pemetrexed [DG:DG00682]
            Carboplatin [DR:D01363]
            Gemcitabine [DG:DG00688]
COMMENT     ICD-O: 9050/3, Tumor type: Diffuse malignant mesothelioma
            ICD-O: 9050/3, Tumor type: Localized malignant mesothelioma
DBLINKS     ICD-10: C45
            MeSH: D008654
REFERENCE   PMID:16216411 (gene, tumor type, carcinogen)
  AUTHORS   Whitson BA, Kratzke RA.
  TITLE     Molecular pathways in malignant pleural mesothelioma.
  JOURNAL   Cancer Lett 239:183-9 (2006)
REFERENCE   PMID:15691231 (gene, carcinogen)
  AUTHORS   Jaurand MC, Fleury-Feith J.
  TITLE     Pathogenesis of malignant pleural mesothelioma.
  JOURNAL   Respirology 10:2-8 (2005)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:17375514 (carcinogen)
  AUTHORS   O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ.
  TITLE     Asbestos-related lung disease.
  JOURNAL   Am Fam Physician 75:683-8 (2007)
REFERENCE   PMID:15955137 (marker)
  AUTHORS   Sterman DH, Albelda SM.
  TITLE     Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
  JOURNAL   Respirology 10:266-83 (2005)
REFERENCE   PMID:12883236 (marker)
  AUTHORS   Ordonez NG.
  TITLE     The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
  JOURNAL   Am J Surg Pathol 27:1031-51 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00016                      Disease
NAME        Oral cancer
DESCRIPTION Oral cancer refers to a subgroup of head and neck malignancies that develop at the lips, tongue, salivary glands, gingiva, floor of the mouth, oropharynx, buccal surfaces and other intra-oral locations, according to the International Classification of Diseases. Nevertheless, the term is synonymous to squamous cell carcinoma (SCC) of oral mucosal origin that accounts for more than 90% of all malignant presentations at the aforementioned anatomical sites. Worldwide, oral SCC (OSCC) is the sixth most common cancer; more than 300,000 new cases are diagnosed each year. The development of OSCC is a multistep process requiring the accumulation of multiple genetic alterations, influenced by a patient's genetic predisposition as well as by environmental influences, including tobacco, alcohol, chronic inflammation, and viral infection. The genetic changes include activation of the epidermal growth factor receptor (EGFR), alterations of tumor suppressors p53 and p16, and cyclin D1 overexpression.
CATEGORY    Cancer
GENE        p53 (mutation, deletion) [HSA:7157] [KO:K04451]
            p16/INK4A (mutation, loss of expression) [HSA:1029] [KO:K06621]
            EGFR (overexpression) [HSA:1956] [KO:K04361]
            c-myc/N-myc (amplification, overexpression) [HSA:4609] [KO:K04377]
            N-ras (amplification) [HSA:4893] [KO:K07828]
            K-ras (amplification) [HSA:3845] [KO:K07827]
            Cyclin D1 (amplification) [HSA:595] [KO:K04503]
            STAT-3 (expression) [HSA:6774] [KO:K04692]
CARCINOGEN  Alcoholic beverages
            Areca nut
            Betel quid with tobacco
            Betel quid without tobacco
            Radionuclides, alpha-particle-emitting, internally deposited
            Tobacco, smokeless
            Tobacco smoking and tobacco smoke
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
            Human papillomavirus type 18 [GN:T40088]
            Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
MARKER      EGFR [HSA:1956]
            Cyclin D1 [HSA:595]
            Ki67 [HSA:4288]
            AgNOR
            RB1 [HSA:5925]
            p53 [HSA:7157]
            Zeta-chain
DRUG        Cisplatin [DR:D00275]
            Fluorouracil [DG:DG00687]
            Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
            Docetaxel [DG:DG00694]
            Cetuximab [DR:D03455]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
DBLINKS     ICD-10: C00 C01 C02 C03 C04 C05 C06
            MeSH: D009062
REFERENCE   PMID:17258495 (description, tumor type)
  AUTHORS   Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG
  TITLE     Advances in the biology of oral cancer.
  JOURNAL   Oral Oncol 43:523-34 (2007)
REFERENCE   PMID:18096889 (description, gene)
  AUTHORS   Choi S, Myers JN
  TITLE     Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy.
  JOURNAL   J Dent Res 87:14-32 (2008)
REFERENCE   PMID:12444391 (gene, tumor type, carcinogen)
  AUTHORS   Das BR, Nagpal JK.
  TITLE     Understanding the biology of oral cancer.
  JOURNAL   Med Sci Monit 8:RA258-67 (2002)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:17646865 (carcinogen)
  AUTHORS   Seitz HK, Stickel F.
  TITLE     Molecular mechanisms of alcohol-mediated carcinogenesis.
  JOURNAL   Nat Rev Cancer 7:599-612 (2007)
REFERENCE   PMID:9448210 (carcinogen)
  AUTHORS   Norton SA.
  TITLE     Betel: consumption and consequences.
  JOURNAL   J Am Acad Dermatol 38:81-8 (1998)
REFERENCE   PMID:17163423 (carcinogen)
  AUTHORS   Thomas SJ, Bain CJ, Battistutta D, Ness AR, Paissat D, Maclennan R.
  TITLE     Betel quid not containing tobacco and oral cancer: a report on a case-control study in Papua New Guinea and a meta-analysis of current evidence.
  JOURNAL   Int J Cancer 120:1318-23 (2007)
REFERENCE   PMID:14996286 (carcinogen)
  AUTHORS   Warnakulasuriya S.
  TITLE     Smokeless tobacco and oral cancer.
  JOURNAL   Oral Dis 10:1-4 (2004)
REFERENCE   PMID:9524432 (carcinogen)
  AUTHORS   Hoffmann D, Djordjevic MV.
  TITLE     Chemical composition and carcinogenicity of smokeless tobacco.
  JOURNAL   Adv Dent Res 11:322-9 (1997)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:12767868 (marker)
  AUTHORS   Schliephake H.
  TITLE     Prognostic relevance of molecular markers of oral cancer--a review.
  JOURNAL   Int J Oral Maxillofac Surg 32:233-45 (2003)
REFERENCE   PMID:14693233 (marker)
  AUTHORS   Bettendorf O, Piffko J, Bankfalvi A.
  TITLE     Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy?
  JOURNAL   Oral Oncol 40:110-9 (2004)
REFERENCE   PMID:15580114 (marker)
  AUTHORS   Chimenos-Kustner E, Font-Costa I, Lopez-Lopez J.
  TITLE     Oral cancer risk and molecular markers.
  JOURNAL   Med Oral Patol Oral Cir Bucal 9:381-4; 377-80 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00017                      Disease
NAME        Esophageal cancer
DESCRIPTION Esophageal cancer represents the 9th leading cancer in the world and is associated with a 5-year survival rate under 25%. The two main forms are squamous-cell carcinoma (ECSC) and adenocarcinoma (EAC). ECSC is the most frequent histological subtype in esophageal cancer, although the incidence of EAC is increasing faster than any other malignancy in the western world. Whereas ESCC can be attributed to alcohol and tobacco consumption, the most important risk factor for the development of EAC is duodenal-gastric-esophageal reflux. In the process of tumorigenesis at the cellular level, multiple genetic alterations are involved, including mutation of the p53 gene, amplification of cyclin D1 gene, among others.
CATEGORY    Cancer
GENE        EGFR (overexpression) [HSA:1956] [KO:K04361]
            p53 (mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (homozygous deletion, LOH) [HSA:1029] [KO:K06621]
            RB1 (LOH) [HSA:5925] [KO:K06618]
            iNOS (increased expression) [HSA:4843] [KO:K13241]
            COX2 (overexpression) [HSA:5743] [KO:K11987]
            APC (LOH) [HSA:324] [KO:K02085]
            Cyclin D1 (amplification) [HSA:595] [KO:K04503]
            FAS (increased expression) [HSA:355] [KO:K04390]
CARCINOGEN  Betel quid with tobacco
            Betel quid without tobacco
            Ethanol in alcoholic beverages [CPD:C00469]
MARKER      p53 [HSA:7157]
            TGF-alpha [HSA:7039]
DRUG        Cisplatin [DR:D00275]
            Fluorouracil [DG:DG00687]
            Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
            ICD-O: 8140/3, Tumor type: Adenocarcinoma
DBLINKS     ICD-10: C15
            MeSH: D004938
REFERENCE   PMID:15622457 (gene, tumor type)
  AUTHORS   Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, Fukai Y, Sohda M, Kimura H, Faried A.
  TITLE     Genetic alterations in esophageal cancer.
  JOURNAL   Surg Today 35:7-18 (2005)
REFERENCE   PMID:12951586 (gene, tumor type)
  AUTHORS   Wild CP, Hardie LJ.
  TITLE     Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.
  JOURNAL   Nat Rev Cancer 3:676-84 (2003)
REFERENCE   PMID:15914317 (gene)
  AUTHORS   McCabe ML, Dlamini Z.
  TITLE     The molecular mechanisms of oesophageal cancer.
  JOURNAL   Int Immunopharmacol 5:1113-30 (2005)
REFERENCE   PMID:15455377 (carcinogen)
  AUTHORS   Lee CH, Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, Wang TN, Huang MC, Wu MT.
  TITLE     Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan.
  JOURNAL   Int J Cancer 113:475-82 (2005)
REFERENCE   PMID:17431955 (carcinogen)
  AUTHORS   Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Cogliano V.
  TITLE     Carcinogenicity of alcoholic beverages.
  JOURNAL   Lancet Oncol 8:292-3 (2007)
REFERENCE   PMID:17383866 (carcinogen)
  AUTHORS   Lee CH, Wu DC, Lee JM, Wu IC, Goan YG, Kao EL, Huang HL, Chan TF, Chou SH, Chou YP, Lee CY, Chen PS, Ho CK, He J, Wu MT.
  TITLE     Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking.
  JOURNAL   Eur J Cancer 43:1188-99 (2007)
REFERENCE   PMID:11565671 (marker)
  AUTHORS   Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE 2nd, D'Amico TA.
  TITLE     Tumor marker expression is predictive of survival in patients with esophageal cancer.
  JOURNAL   Ann Thorac Surg 72:859-66 (2001)
REFERENCE   PMID:17069584 (marker)
  AUTHORS   Vallbohmer D, Lenz HJ.
  TITLE     Predictive and prognostic molecular markers in outcome of esophageal cancer.
  JOURNAL   Dis Esophagus 19:425-32 (2006)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00018                      Disease
NAME        Gastric cancer
DESCRIPTION Gastric cancer is the second most common cause of cancer-related death worldwide. There is substantial international variation in gastric cancer incidence with the highest rates reported from Korea, Japan and eastern Asia. The global burden of gastric cancer is shifting rapidly from the developed world to the developing world. Despite the worldwide decline in incidence and the major improvements in diagnosis and treatment, less than 20% of patients survive to 5 years. Phenotypically, gastric cancer is divided into two histomorphological entities denominated 'intestinal' (IGCA) and 'diffuse' (DGCA), which differ in epidemiology, pathogenesis, clinical outcome and genetic profile. The risk of both IGCA and DGCA is increased in the presence of Helicobacter pylori infection, and the risk rises with increases in grade and extent of atrophic gastritis and intestinal metaplasia. Mutations and/or amplification/overexpression of the oncogenes c-K-ras, c-erbB-2, K-sam and c-met, inactivation of tumor suppressor genes p53, APC and DCC, and abnormal transcription of CD44 are believed to play a role in gastric carcinogenesis but seem to vary in frequency between IGCA and DGCA. E-cadherin/CDH1 gene germline mutations have been recognized in families with an inherited predisposition to DGCA.
CATEGORY    Cancer
GENE        K-ras (mutation) [HSA:3845] [KO:K07827]
            c-met (amplification) [HSA:4233] [KO:K05099]
            K-sam (amplification) [HSA:2263] [KO:K05093]
            ERBB2 (amplification) [HSA:2064] [KO:K05083]
            EGFR (overexpression) [HSA:1956] [KO:K04361]
            EGF (overexpression) [HSA:1950] [KO:K04357]
            TGF-alpha (overexpression) [HSA:7039] [KO:K08774]
            VEGF (overexpression) [HSA:7422 7423 7424 2277] [KO:K05448 K16858 K05449]
            p53 (mutation, LOH) [HSA:7157] [KO:K04451]
            APC (mutation, LOH) [HSA:324] [KO:K02085]
            DCC (LOH) [HSA:1630] [KO:K06765]
            E-Cadherin (mutation) [HSA:999] [KO:K05689]
            beta-Catenin (mutation) [HSA:1499] [KO:K02105]
            CD44 (abnormal splice variants) [HSA:960] [KO:K06256]
            Bcl-2 (LOH) [HSA:596] [KO:K02161]
            Cyclin E (amplification) [HSA:898 9134] [KO:K06626]
CARCINOGEN  Benzo[a]pyrene [CPD:C07535]
PATHOGEN    Helicobacter pylori (infection with)
MARKER      CA19-9 [GL:G12794]
            Carcinoembryonic antigen (CEA) [HSA:634] [KO:K06499]
            HER2/neu gene amplification or protein overexpression [HSA:2064] [KO:K05083]
DRUG        Epirubicin [DG:DG00698]
            Cisplatin [DR:D00275]
            Fluorouracil [DG:DG00687]
            Docetaxel [DG:DG00694]
            Leucovorin [DR:D01211]
            Oxaliplatin [DR:D01790]
            Trastuzumab [DG:DG01358]
COMMENT     ICD-O: 8140/3, Tumor type: Adenocarcinoma
            ICD-O: 8144/3, Tumor type: intestinal type
            ICD-O: 8145/3, Tumor type: diffuse type
DBLINKS     ICD-10: C16
            MeSH: D013274
REFERENCE   PMID:11315254 (gene, tumor type)
  AUTHORS   Werner M, Becker KF, Keller G, Hofler H.
  TITLE     Gastric adenocarcinoma: pathomorphology and molecular pathology.
  JOURNAL   J Cancer Res Clin Oncol 127:207-16 (2001)
REFERENCE   PMID:15224192 (gene, tumor type)
  AUTHORS   Zheng L, Wang L, Ajani J, Xie K.
  TITLE     Molecular basis of gastric cancer development and progression.
  JOURNAL   Gastric Cancer 7:61-77 (2004)
REFERENCE   PMID:16718776 (gene)
  AUTHORS   Smith MG, Hold GL, Tahara E, El-Omar EM.
  TITLE     Cellular and molecular aspects of gastric cancer.
  JOURNAL   World J Gastroenterol 12:2979-90 (2006)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00019                      Disease
NAME        Pancreatic cancer
DESCRIPTION Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways.  Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.
CATEGORY    Cancer
GENE        K-ras (mutation) [HSA:3845] [KO:K07827]
            ERBB2 (overexpression) [HSA:2064] [KO:K05083]
            p16/INK4A (mutation, deletion, promoter methylation) [HSA:1029] [KO:K06621]
            p53 (mutation) [HSA:7157] [KO:K04451]
            SMAD4 (mutation) [HSA:4089] [KO:K04501]
            BRCA2 (germline mutation) [HSA:675] [KO:K08775]
            STK11 (germline mutation) [HSA:6794] [KO:K07298]
CARCINOGEN  Tobacco smoking and tobacco smoke
MARKER      CA19-9 [GL:G12794]
            Carcinoembryonic antigen (CEA) [HSA:634] [KO:K06499]
DRUG        Gemcitabine [DG:DG00688]
            Cisplatin [DR:D00275]
            Paclitaxel [DG:DG01430]
            Erlotinib [DG:DG00711]
            Fluorouracil [DG:DG00687]
            Leucovorin (FOLFOX4) [DR:D01211 D04715]
            Irinotecan [DG:DG00726]
            Oxaliplatin [DR:D01790]
COMMENT     ICD-O: 8500/3, Tumor type: Ductal adenocarcinoma
DBLINKS     ICD-10: C25
            MeSH: D010190
REFERENCE   PMID:12459728 (gene, tumor type)
  AUTHORS   Bardeesy N, DePinho RA.
  TITLE     Pancreatic cancer biology and genetics.
  JOURNAL   Nat Rev Cancer 2:897-909 (2002)
REFERENCE   PMID:16702400 (tumor type)
  AUTHORS   Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.
  TITLE     Genetics and biology of pancreatic ductal adenocarcinoma.
  JOURNAL   Genes Dev 20:1218-49 (2006)
REFERENCE   PMID:11407945 (gene)
  AUTHORS   Bardeesy N, Sharpless NE, DePinho RA, Merlino G.
  TITLE     The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.
  JOURNAL   Semin Cancer Biol 11:201-18 (2001)
REFERENCE   PMID:10955772 (gene)
  AUTHORS   Hruban RH, Goggins M, Parsons J, Kern SE.
  TITLE     Progression model for pancreatic cancer.
  JOURNAL   Clin Cancer Res 6:2969-72 (2000)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00020                      Disease
NAME        Colorectal cancer
DESCRIPTION Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as  microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).
CATEGORY    Cancer
GENE        beta-Catenin (mutation) [HSA:1499] [KO:K02105]
            K-ras (mutation) [HSA:3845] [KO:K07827]
            APC (germline mutation (FAP), somatic mutation) [HSA:10297] [KO:K02085]
            DCC (deletion) [HSA:1630] [KO:K06765]
            TGF-betaRII (mutation) [HSA:7048] [KO:K04388]
            Smad2 (mutation) [HSA:4087] [KO:K04500]
            Smad4 (deletion) [HSA:4089] [KO:K04501]
            BAX (mutation) [HSA:581] [KO:K02159]
            p53 (deletion) [HSA:7157] [KO:K04451]
            MLH1 (germline mutation (HNPCC), LOH, promoter hypermethylation) [HSA:4292] [KO:K08734]
            MSH2 (germline mutation (HNPCC), LOH, somatic mutation) [HSA:4436] [KO:K08735]
            MSH3 (somatic frameshift mutation) [HSA:4437] [KO:K08736]
            MSH6 (germline mutation (HNPCC), LOH, somatic frameshift mutation) [HSA:2956] [KO:K08737]
            GALNT12 (germline mutation, somatic mutation) [HSA:79695] [KO:K00710]
CARCINOGEN  Mineral oils, untreated and mildly treated
            X- and gamma-radiation
MARKER      BRAF mutation V600E [HSA:673] [KO:K04365]
            Carcinoembryonic antigen (CEA) [HSA:634] [KO:K06499]
            Circulating tumor cells of epithelial origin
            KRAS mutation analysis [HSA:3845] [KO:K07827]
DRUG        5-Fluorouracil (5-FU) [DG:DG00687]
            Leucovorin (FOLFOX4) [DR:D01211 D04715]
            Oxaliplatin [DR:D01790]
            Capecitabine [DR:D01223]
            Irinotecan [DG:DG00726]
            Bevacizumab [DR:D06409]
COMMENT     ICD-O: 8140/3, Tumor type: Adenocarcinoma
DBLINKS     ICD-10: C18 C19 C20
            MeSH: D015179
REFERENCE   PMID:15000146 (gene, tumor type)
  AUTHORS   Grady WM.
  TITLE     Genomic instability and colon cancer.
  JOURNAL   Cancer Metastasis Rev 23:11-27 (2004)
REFERENCE   PMID:11477132 (tumor type)
  AUTHORS   Houlston RS.
  TITLE     What we could do now: molecular pathology of colorectal cancer.
  JOURNAL   Mol Pathol 54:206-14 (2001)
REFERENCE   PMID:16555243 (gene)
  AUTHORS   Soreide K, Janssen EA, Soiland H, Korner H, Baak JP.
  TITLE     Microsatellite instability in colorectal cancer.
  JOURNAL   Br J Surg 93:395-406 (2006)
REFERENCE   PMID:12621137 (gene)
  AUTHORS   Lynch HT, de la Chapelle A.
  TITLE     Hereditary colorectal cancer.
  JOURNAL   N Engl J Med 348:919-32 (2003)
REFERENCE   PMID:15310786 (gene)
  AUTHORS   Mehlen P, Fearon ER.
  TITLE     Role of the dependence receptor DCC in colorectal cancer pathogenesis.
  JOURNAL   J Clin Oncol 22:3420-8 (2004)
REFERENCE   PMID:9498901 (carcinogen)
  AUTHORS   Tolbert PE.
  TITLE     Oils and cancer.
  JOURNAL   Cancer Causes Control 8:386-405 (1997)
REFERENCE   PMID:15070562 (carcinogen)
  AUTHORS   Berrington de Gonzalez A, Darby S.
  TITLE     Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.
  JOURNAL   Lancet 363:345-51 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:19617566 (gene)
  AUTHORS   Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, Velculescu VE, Kinzler KW, Papadopoulos N, Vogelstein B, Willis J, Gerken TA, Markowitz SD
  TITLE     Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
  JOURNAL   Proc Natl Acad Sci U S A 106:12921-5 (2009)
///
ENTRY       H00021                      Disease
NAME        Renal cell carcinoma
DESCRIPTION Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.
CATEGORY    Cancer
GENE        VHL (germline mutation (VHL disease), somatic mutation) [HSA:7428] [KO:K03871]
            Met (germline activating mutation (HPRC), somatic activating mutation) [HSA:4233] [KO:K05099]
            FH (germline loss-of-function mutation (HLPCC), LOH, somatic mutation) [HSA:2271] [KO:K01679]
            BHD (germline mutation (Birt-Hogg-Dube syndrome)) [HSA:201163] [KO:K09594]
            PRCC-TFE3 (translocation) [HSA:5546 7030] [KO:K13105 K09105]
CARCINOGEN  Aluminium production
            Cadmium and cadmium compounds
            Chimney sweeping
            Radium-224 and its decay products
            Shale-oils
            Tobacco smoking and tobacco smoke
MARKER      CA9 [HSA:768]
            p53 [HSA:7157]
            Gelsolin [HSA:2934]
            Ki67 [HSA:4288]
            CA12 [HSA:771]
            Vimentin [HSA:7431]
            CD44 [HSA:960]
            VEGF [HSA:7422 7423 7424 2277]
DRUG        Sunitinib [DG:DG00712]
            Temsirolimus [DR:D06068]
            Bevacizumab [DR:D06409]
            Sorafenib [DG:DG00713]
            Pazopanib [DR:D05380]
            Interleukin-2 [DR:D00748]
            Interferon-alpha [DR:D02745]
            Axitinib [DR:D03218]
COMMENT     ICD-O: 8310/3, Tumor type: Clear cell carcinoma
            ICD-O: 8260/3, Tumor type: Papillary renal cell carcinoma
            ICD-O: 8317/3, Tumor type: Chromophobe renal cell carcinoma
            ICD-O: 8290/0, Tumor type: Oncocytoma
            ICD-O: 8319/3, Tumor type: Carcinoma of the collecting ducts of Bellini
DBLINKS     ICD-10: C64
            MeSH: D002292
REFERENCE   PMID:15122209 (gene, tumor type)
  AUTHORS   Pavlovich CP, Schmidt LS.
  TITLE     Searching for the hereditary causes of renal-cell carcinoma.
  JOURNAL   Nat Rev Cancer 4:381-93 (2004)
REFERENCE   PMID:16339096 (gene)
  AUTHORS   Cohen HT, McGovern FJ.
  TITLE     Renal-cell carcinoma.
  JOURNAL   N Engl J Med 353:2477-90 (2005)
REFERENCE   PMID:15380513 (gene)
  AUTHORS   Linehan WM, Zbar B.
  TITLE     Focus on kidney cancer.
  JOURNAL   Cancer Cell 6:223-8 (2004)
REFERENCE   PMID:19406209
  AUTHORS   Brenner JC, Chinnaiyan AM
  TITLE     Translocations in epithelial cancers.
  JOURNAL   Biochim Biophys Acta 1796:201-15 (2009)
REFERENCE   PMID:19233641
  AUTHORS   Prensner JR, Chinnaiyan AM
  TITLE     Oncogenic gene fusions in epithelial carcinomas.
  JOURNAL   Curr Opin Genet Dev 19:82-91 (2009)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:16102569 (carcinogen)
  AUTHORS   Il'yasova D, Schwartz GG.
  TITLE     Cadmium and renal cancer.
  JOURNAL   Toxicol Appl Pharmacol 207:179-86 (2005)
REFERENCE   PMID:10564925 (carcinogen)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:15821467 (marker)
  AUTHORS   Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA.
  TITLE     Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
  JOURNAL   J Urol 173:1496-501 (2005)
REFERENCE   PMID:16194700 (marker)
  AUTHORS   Lam JS, Leppert JT, Figlin RA, Belldegrun AS.
  TITLE     Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.
  JOURNAL   Urology 66:1-9 (2005)
REFERENCE   PMID:12681265 (marker)
  AUTHORS   Michael A, Pandha HS.
  TITLE     Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies.
  JOURNAL   Lancet Oncol 4:215-23 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00022                      Disease
NAME        Bladder cancer
DESCRIPTION The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of  E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).
CATEGORY    Cancer
GENE        H-ras (activating mutation) [HSA:3265] [KO:K02833]
            FGFR3 (activating mutation) [HSA:2261] [KO:K05094]
            p16/INK4A (homozygous deletion or hypermethylation) [HSA:1029] [KO:K06621]
            p53 (inactivating mutation or deletion) [HSA:7157] [KO:K04451]
            RB1 (deletion or hyperphosphorylation) [HSA:5925] [KO:K06618]
            EGFR (overexpression) [HSA:1956] [KO:K04361]
            ERBB2 (overexpression) [HSA:2064] [KO:K05083]
            RASSF1 (hypermethylation) [HSA:11186] [KO:K09850]
            DAPK1 (hypermethylation) [HSA:1612] [KO:K08803]
CARCINOGEN  Aluminium production
            4-Aminobiphenyl [CPD:C10998]
            Arsenic in drinking-water
            Auramine, manufacture of
            Benzidine [CPD:C16444]
            Benzo[a]pyrene [CPD:C07535]
            N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine)
            Coal gasification
            Coal-tar pitches [CPD:C16451]
            Coal-tars [DR:D03573]
            Herbal remedies containing plant species of the genus Aristolochia
            Magenta, manufacture of
            2-Naphthylamine [CPD:C02227]
            Paving and roofing with coal-tar pitch
            Radium-224 and its decay products [CPD:C16455]
            Schistosoma haematobium (infection with)
            Shale-oils [CPD:C16458]
            Tobacco smoking and tobacco smoke
            X- and gamma-radiation
MARKER      Chromosomes 3, 7, 17 and, 9p21
            Fibrin/fibrinogen [HSA:2243 2244 2266] [KO:K03903 K03904 K03905]
            Nuclear matrix protein 22 [HSA:4926] [KO:K16808]
DRUG        Gemcitabine [DG:DG00688]
            Cisplatin (M-VAC) [DR:D00275]
            Methotrexate [DG:DG00681]
            Vinblastine [DG:DG00689]
            Doxorubicin (adriamycin) [DG:DG00696]
COMMENT     ICD-O: 8120/3, Tumor type: Infiltrating urothelial carcinoma
            ICD-O: 8120/2, Tumor type: Urothelial carcinoma in situ
            ICD-O: 8130/23, Tumor type: Non-invasive papillary urothelial carcinoma, high grade
            ICD-O: 8130/21, Tumor type: Non-invasive papillary urothelial carcinoma, low grade
DBLINKS     ICD-10: C67
            MeSH: D001749
REFERENCE   PMID:16110317 (tumor type)
  AUTHORS   Wu XR.
  TITLE     Urothelial tumorigenesis: a tale of divergent pathways.
  JOURNAL   Nat Rev Cancer 5:713-25 (2005)
REFERENCE   PMID:17149381 (gene)
  AUTHORS   Sugano K, Kakizoe T.
  TITLE     Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
  JOURNAL   Nat Clin Pract Urol 3:642-52 (2006)
REFERENCE   PMID:16474624 (gene)
  AUTHORS   Wolff EM, Liang G, Jones PA.
  TITLE     Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
  JOURNAL   Nat Clin Pract Urol 2:502-10 (2005)
REFERENCE   PMID:17158541 (gene)
  AUTHORS   Mitra AP, Datar RH, Cote RJ.
  TITLE     Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
  JOURNAL   J Clin Oncol 24:5552-64 (2006)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:11473382 (carcinogen)
  AUTHORS   Burger MS, Torino JL, Swaminathan S.
  TITLE     DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl.
  JOURNAL   Environ Mol Mutagen 38:1-11 (2001)
REFERENCE   PMID:14643412 (carcinogen)
  AUTHORS   Rossman TG.
  TITLE     Mechanism of arsenic carcinogenesis: an integrated approach.
  JOURNAL   Mutat Res 533:37-65 (2003)
REFERENCE   PMID:9498898 (carcinogen)
  AUTHORS   Vineis P, Pirastu R.
  TITLE     Aromatic amines and cancer.
  JOURNAL   Cancer Causes Control 8:346-55 (1997)
REFERENCE   PMID:14648102 (carcinogen)
  AUTHORS   Golka K, Wiese A, Assennato G, Bolt HM.
  TITLE     Occupational exposure and urological cancer.
  JOURNAL   World J Urol 21:382-91 (2004)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:17195421 (carcinogen)
  AUTHORS   Olfert SM, Felknor SA, Delclos GL.
  TITLE     An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures.
  JOURNAL   South Med J 99:1256-63 (2006)
REFERENCE   PMID:11886955 (carcinogen)
  AUTHORS   Verma DK, Purdham JT, Roels HA.
  TITLE     Translating evidence about occupational conditions into strategies for prevention.
  JOURNAL   Occup Environ Med 59:205-13; quiz 214 (2002)
REFERENCE   PMID:12505369 (carcinogen)
  AUTHORS   Nortier JL, Vanherweghem JL.
  TITLE     Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).
  JOURNAL   Toxicology 181-182:577-80 (2002)
REFERENCE   PMID:14672753 (carcinogen)
  AUTHORS   Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ.
  TITLE     Herbal bioactivation: the good, the bad and the ugly.
  JOURNAL   Life Sci 74:935-68 (2004)
REFERENCE   PMID:10723042 (carcinogen)
  AUTHORS   Stern FB, Ruder AM, Chen G.
  TITLE     Proportionate mortality among unionized roofers and waterproofers.
  JOURNAL   Am J Ind Med 37:478-92 (2000)
REFERENCE   PMID:10564925 (carcinogen)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:15070562 (carcinogen)
  AUTHORS   Berrington de Gonzalez A, Darby S.
  TITLE     Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.
  JOURNAL   Lancet 363:345-51 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00023                      Disease
NAME        Testicular cancer
DESCRIPTION Testicular germ cell tumor (TGCT) comprises about 98% of all testicular neoplasms and is thereby the most common malignancy among young males. Overall, three different entities of TGCT can be distinguished: teratomas and yolk sac tumors of newborns and infants, seminomatous and nonseminomatous germ cell tumors of adolescents and young adults, and spermatocytic seminoma of elderly men. Recent studies of TGCTs have suggested that overexpression of cyclin D2 is a very early, possibly the oncogenic, event in GC tumorigenesis.
CATEGORY    Cancer
GENE        Cyclin D2 (amplification) [HSA:894] [KO:K10151]
MARKER      Alpha-fetoprotein (AFP) [HSA:174] [KO:K16144]
            Beta-human chorionic gonadotropin (Beta-hCG) [HSA:1082] [KO:K10045]
            Lactate dehydrogenase [HSA:3939 3945 3948] [KO:K00016]
DRUG        Cisplatin [DR:D00275]
            Etoposide [DG:DG00693]
            Bleomycin [DG:DG00705]
            Mesna [DR:D01459]
            Ifosfamide [DR:D00343]
COMMENT     ICD-O: 9064/2, Tumor type: Intratubular germ cell neoplasia, unclassified
            ICD-O: 9061/3, Tumor type: Seminoma
            ICD-O: 9063/3, Tumor type: Spermatocytic seminoma
            ICD-O: 9100/3, Tumor type: Choriocarcinoma
            ICD-O: 9070/3, Tumor type: Embryonal carcinooma
            ICD-O: 9071/3, Tumor type: Yolk sac tumor
            ICD-O: 9080/3, Tumor type: Teratoma
DBLINKS     ICD-10: C62
            MeSH: D013736
REFERENCE   PMID:18042148 (description, tumor type)
  AUTHORS   Lind GE, Skotheim RI, Lothe RA
  TITLE     The epigenome of testicular germ cell tumors.
  JOURNAL   APMIS 115:1147-60 (2007)
REFERENCE   PMID:10749107 (gene, tumor type)
  AUTHORS   Chaganti RS, Houldsworth J.
  TITLE     Genetics and biology of adult human male germ cell tumors.
  JOURNAL   Cancer Res 60:1475-82 (2000)
REFERENCE   PMID:9791864 (gene, tumor type)
  AUTHORS   Lutzker SG, Barnard NJ.
  TITLE     Testicular germ cell tumors: molecular understanding and clinical implications.
  JOURNAL   Mol Med Today 4:404-11 (1998)
REFERENCE   PMID:16095047 (tumor type)
  AUTHORS   Stenman UH.
  TITLE     Testicular cancer: the perfect paradigm for marker combinations.
  JOURNAL   Scand J Clin Lab Invest 65:181-8 (2005)
REFERENCE   PMID:9820318 (tumor type)
  AUTHORS   Horwich A, Huddart R, Dearnaley D.
  TITLE     Markers and management of germ-cell tumours of the testes.
  JOURNAL   Lancet 352:1535-8 (1998)
REFERENCE   PMID:17683189 (tumor type)
  AUTHORS   Bahrami A, Ro JY, Ayala AG.
  TITLE     An overview of testicular germ cell tumors.
  JOURNAL   Arch Pathol Lab Med 131:1267-80 (2007)
REFERENCE   PMID:17414640 (tumor type)
  AUTHORS   Bridges B, Hussain A.
  TITLE     Testicular germ cell tumors.
  JOURNAL   Curr Opin Oncol 19:222-8 (2007)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00024                      Disease
NAME        Prostate cancer
DESCRIPTION Prostate cancer constitutes a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. The identification of key molecular alterations in prostate-cancer cells implicates carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27), and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells. Glutathione S-transferases (GSTP1) are detoxifying enzymes. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1, undergo genomic damage mediated by carcinogens. NKX3.1, PTEN, and p27 regulate the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased apoptosis. Androgen receptor (AR) is a transcription factor that is normally activated by its androgen ligand. During androgen withdrawal therapy, the AR signal transduction pathway also could be activated by amplification of the AR gene, by AR gene mutations, or by altered activity of AR coactivators. Through these mechanisms, tumor cells lead to the emergence of androgen-independent prostate cancer.
CATEGORY    Cancer
GENE        AR (amplification, mutation) [HSA:367] [KO:K08557]
            CDKN1B (allelic loss) [HSA:1027] [KO:K06624]
            NKX3.1 (allelic loss) (decreased expression) [HSA:4824] [KO:K09348]
            PTEN (allelic loss) [HSA:5728] [KO:K01110]
            GSTP1 (hypermethylation) [HSA:2950] [KO:K00799]
            TMPRSS2-ERG (translocation) [HSA:7113 2078] [KO:K09633 K09435]
            TMPRSS2-ETV1 (translocation) [HSA:7113 2115] [KO:K09633 K09431]
            TMPRSS2-ETV4 (translocation) [HSA:7113 2118] [KO:K09633 K15592]
            TMPRSS2-ETV5 (translocation) [HSA:7113 2119] [KO:K09633 K15593]
            SLC45A3-ETV1 (translocation) [HSA:85414 2115] [KO:K15379 K09431]
            SLC45A3-ELK4 (translocation) [HSA:85414 2005] [KO:K15379 K04376]
            DDX5-ETV4 (translocation) [HSA:1655 2118] [KO:K12823 K15592]
CARCINOGEN  Cadmium and cadmium compounds [CPD:C01413]
            Chimney sweeping
MARKER      Circulating tumor cells of epithelial origin
            Prostate-specific antigen (PSA) [HSA:354] [KO:K01351]
DRUG        Leuprolide [DR:D00989]
            Goserelin [DG:DG00731]
            Triptorelin [DG:DG00732]
            Degarelix [DG:DG00736]
            Flutamide [DR:D00586]
            Bicalutamide [DR:D00961]
            Nilutamide [DR:D00965]
COMMENT     ICD-O: 8140/3, Tumor type: Adenocarcinoma (acinar)
            ICD-O: 8148/2, Tumor type: Prostatic intraepithelial neoplasia, glade III (PIN III)
DBLINKS     ICD-10: C61
REFERENCE   PMID:12878745 (gene, tumor type)
  AUTHORS   Nelson WG, De Marzo AM, Isaacs WB.
  TITLE     Prostate cancer.
  JOURNAL   N Engl J Med 349:366-81 (2003)
REFERENCE   PMID:17384581 (gene, tumor type)
  AUTHORS   De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG.
  TITLE     Inflammation in prostate carcinogenesis.
  JOURNAL   Nat Rev Cancer 7:256-69 (2007)
REFERENCE   PMID:11018010 (tumor type)
  AUTHORS   Abate-Shen C, Shen MM.
  TITLE     Molecular genetics of prostate cancer.
  JOURNAL   Genes Dev 14:2410-34 (2000)
REFERENCE   PMID:15149739 (gene)
  AUTHORS   Porkka KP, Visakorpi T.
  TITLE     Molecular mechanisms of prostate cancer.
  JOURNAL   Eur Urol 45:683-91 (2004)
REFERENCE   PMID:19406209 (gene)
  AUTHORS   Brenner JC, Chinnaiyan AM
  TITLE     Translocations in epithelial cancers.
  JOURNAL   Biochim Biophys Acta 1796:201-15 (2009)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00025                      Disease
NAME        Penile cancer
DESCRIPTION Penile cancer is a disease with a high morbidity and mortality. Its prevalence is relatively rare in developed countries but more common in South America and East Africa. Squamous cell carcinoma (SCC) is the predominant tumor type in penile cancer, accounting for 95% of cases. Penile cancers are thought to arise from the progression of precursor lesions and can be subdivided into human papilloma virus (HPV) positive and HPV negative cases. Most common disrupted pathways, both in HPV-mediated and HPV-independent penile carcinogenesis, involve the p14ARF/MDM2/p53 and/or p16INK4a/cyclin D/Rb pathways. HPVs exert their oncogenic effect by expressing the oncoproteins E6 and E7, which bind to and inactivate the p53 and Rb tumor suppressor gene products, respectively. HPV independent mechanisms of pathway inactivation include silencing of the p16INK4a gene by promoter hypermethylation, somatic mutations of the p53 gene, over-expression of MDM2 and mutation of p14ARF. Several other molecular events include alterations in the activity and/or expression of ras and myc genes, cyclo-oxygenase-2 (COX) pathway and prostaglandin E2 synthase. These alterations have been described in both HPV-positive and -negative penile cancers.
CATEGORY    Cancer
GENE        p16/INK4a (promoter hypermethylation) [HSA:1029] [KO:K06621]
            BMI1 (overexpression) [HSA:648] [KO:K11459]
            p53 (mutation) [HSA:7157] [KO:K04451]
            MDM2 (overexpression) [HSA:4193] [KO:K06643]
            H-ras (mutation) [HSA:3265] [KO:K02833]
            c-MYC (mutation) [HSA:4609] [KO:K04377]
            E-Cadherin (expression) [HSA:999] [KO:K05689]
            MMP-2 (expression) [HSA:4313] [KO:K01398]
            MMP-9 (expression) [HSA:4318] [KO:K01403]
            COX-2 (expression) [HSA:5743] [KO:K11987]
            PTGES2 (expression) [HSA:80142] [KO:K05309]
CARCINOGEN  Tobacco smoking and tobacco smoke
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
            Human papillomavirus type 18 [GN:T40088]
MARKER      Human papillomavirus types 16, 18
            Ki-67 [HSA:4288]
            p53 [HSA:7157]
            E-Cadherin [HSA:999]
DRUG        Bleomycin [DG:DG00705]
            Cisplatin [DR:D00275]
            Methotrexate [DG:DG00681]
            Fluorouracil [DG:DG00687]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
DBLINKS     ICD-10: C60
            MeSH: D010412
REFERENCE   PMID:18607597 (description, gene, carcinogen, tumor type)
  AUTHORS   Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ
  TITLE     Penile cancer: epidemiology, pathogenesis and prevention.
  JOURNAL   World J Urol 27:141-50 (2009)
REFERENCE   PMID:17466899 (gene, carcinogen, tumor type)
  AUTHORS   Kayes O, Ahmed HU, Arya M, Minhas S.
  TITLE     Molecular and genetic pathways in penile cancer.
  JOURNAL   Lancet Oncol 8:420-9 (2007)
REFERENCE   PMID:18548255 (carcinogen, marker, tumor type)
  AUTHORS   Muneer A, Kayes O, Ahmed HU, Arya M, Minhas S
  TITLE     Molecular prognostic factors in penile cancer.
  JOURNAL   World J Urol 27:161-7 (2009)
REFERENCE   PMID:11281434 (carcinogen)
  AUTHORS   Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK.
  TITLE     Human papillomavirus infections: epidemiology, pathogenesis, and therapy.
  JOURNAL   J Cutan Med Surg 5:43-60 (2001)
REFERENCE   PMID:1311142 (carcinogen)
  AUTHORS   Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, Weiss NS.
  TITLE     Cigarette smoking and the risk of anogenital cancer.
  JOURNAL   Am J Epidemiol 135:180-9 (1992)
REFERENCE   PMID:16569359 (marker)
  AUTHORS   Gentile V, Vicini P, Giacomelli L, Cardillo MR, Pierangeli A, Degener AM.
  TITLE     Detection of human papillomavirus DNA, p53 and ki67 expression in penile carcinomas.
  JOURNAL   Int J Immunopathol Pharmacol 19:209-15 (2006)
REFERENCE   ((fifth Japanese edition) drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00026                      Disease
NAME        Endometrial Cancer
DESCRIPTION Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.
CATEGORY    Cancer
GENE        K-ras (mutational activation) [HSA:3845] [KO:K07827]
            beta-Catenin (mutation) [HSA:1499] [KO:K02105]
            ERBB2 (amplification) [HSA:2064] [KO:K05083]
            PTEN (mutation, deletions, methylation) [HSA:5728] [KO:K01110]
            p53 (mutation) [HSA:7157] [KO:K04451]
            MLH1 (mutation, methylation) [HSA:4292] [KO:K08734]
CARCINOGEN  Estrogen therapy, postmenopausal
            Tamoxifen [CPD:C07108]
MARKER      ER [HSA:2099 2100]
            PR [HSA:5241]
            CEA [HSA:1048]
            CA125 [HSA:94025]
DRUG        Progestin
            Tamoxifen [DG:DG00734]
            Aromatase inhibitors
            Cisplatin [DR:D00275]
            Doxorubicin [DR:D03899]
            Carboplatin [DR:D01363]
            Paclitaxel [DG:DG01430]
COMMENT     ICD-O: 9380/3, Tumor type: Endometrioid adenocarcinoma
            ICD-O: 8441/3, Tumor type: Serous adenocarcinoma
DBLINKS     ICD-10: C54
            MeSH: D016889
REFERENCE   PMID:17028294 (gene, tumor type)
  AUTHORS   Hecht JL, Mutter GL.
  TITLE     Molecular and pathologic aspects of endometrial carcinogenesis.
  JOURNAL   J Clin Oncol 24:4783-91 (2006)
REFERENCE   PMID:15947972 (tumor type)
  AUTHORS   Ryan AJ, Susil B, Jobling TW, Oehler MK.
  TITLE     Endometrial cancer.
  JOURNAL   Cell Tissue Res 322:53-61 (2005)
REFERENCE   PMID:12583434 (gene)
  AUTHORS   Salvesen HB, Akslen LA.
  TITLE     Molecular pathogenesis and prognostic factors in endometrial carcinoma.
  JOURNAL   APMIS 110:673-89 (2002)
REFERENCE   PMID:16508724 (gene)
  AUTHORS   Shiozawa T, Konishi I.
  TITLE     Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
  JOURNAL   Int J Clin Oncol 11:13-21 (2006)
REFERENCE   PMID:17464097 (carcinogen)
  AUTHORS   Ito K.
  TITLE     Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
  JOURNAL   Tohoku J Exp Med 212:1-12 (2007)
REFERENCE   PMID:17198307 (carcinogen)
  AUTHORS   Yeh IT.
  TITLE     Postmenopausal hormone replacement therapy: endometrial and breast effects.
  JOURNAL   Adv Anat Pathol 14:17-24 (2007)
REFERENCE   PMID:10383884 (carcinogen)
  AUTHORS   White IN.
  TITLE     The tamoxifen dilemma.
  JOURNAL   Carcinogenesis 20:1153-60 (1999)
REFERENCE   PMID:15203746 (marker)
  AUTHORS   Marjoniemi VM.
  TITLE     Immunohistochemistry in gynaecological pathology: a review.
  JOURNAL   Pathology 36:109-19 (2004)
REFERENCE   PMID:15188130 (marker)
  AUTHORS   Prat J.
  TITLE     Prognostic parameters of endometrial carcinoma.
  JOURNAL   Hum Pathol 35:649-62 (2004)
REFERENCE   PMID:14739059 (marker)
  AUTHORS   Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR.
  TITLE     Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
  JOURNAL   Biomed Pharmacother 58:24-38 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00027                      Disease
NAME        Ovarian cancer
DESCRIPTION Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.
CATEGORY    Cancer
GENE        BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605]
            BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775]
            MSH2 (germline mutation) [HSA:4436] [KO:K08735]
            MLH1 (germline mutation) [HSA:4292] [KO:K08734]
            ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083]
            K-ras (mutation) [HSA:3845] [KO:K07827]
            AKT2 (amplification) [HSA:208] [KO:K04456]
            PIK3CA (amplification) [HSA:5290] [KO:K00922]
            c-MYC (overexpression) [HSA:4609] [KO:K04377]
            p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451]
MARKER      BRCA1 and BRCA2 gene mutations [HSA:672 675] [KO:K10605 K08775]
            CA125 [HSA:94025] [KO:K16145]
            HE4 [HSA:10406]
            5-Protein signature (Ova1) [HSA:335 567 94025 7276 7018] [KO:K08757 K08055 K16145 K14736]
DRUG        Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
            Docetaxel [DG:DG00694]
            Cisplatin [DR:D00275]
            Gemcitabine [DR:D02368]
            Doxorubicin [DR:D01275]
            Topotecan [DR:D08618]
            Cyclophosphamide [DR:D07760]
            Etoposide [DR:D00125]
            Bevacizumab [DR:D06409]
COMMENT     ICD-O: 8441/3, Tumor type: Adenocarcinoma
            ICD-O: 8480/3, Tumor type: Adenocarcinoma
            ICD-O: 8380/3, Tumor type: Adenocarcinoma, not otherwise specified
            ICD-O: 8310/3, Tumor type: Adenocarcinoma
            ICD-O: 9000/3, Tumor type: Malignant Brenner tumor
DBLINKS     ICD-10: C56
            MeSH: D010051
REFERENCE   PMID:15111296 (tumor type)
  AUTHORS   Shih IeM, Kurman RJ.
  TITLE     Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
  JOURNAL   Am J Pathol 164:1511-8 (2004)
REFERENCE   PMID:12886939 (gene, tumor type)
  AUTHORS   Katabuchi H, Okamura H.
  TITLE     Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis.
  JOURNAL   Med Electron Microsc 36:74-86 (2003)
REFERENCE   PMID:12413930 (gene)
  AUTHORS   Wenham RM, Lancaster JM, Berchuck A.
  TITLE     Molecular aspects of ovarian cancer.
  JOURNAL   Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00028                      Disease
NAME        Choriocarcinoma
DESCRIPTION Gestational choriocarcinoma is a highly malignant epithelial tumor that can be associated with any type of gestational event, most often a complete hydatidiform mole (CM). CM occur in about one per 1000 pregnancies, and about 5-20% of CM progress to invasive moles or choriocarcinoma. Several molecular studies have been done to establish the expression of tumor-associated proteins in choriocarcinoma. In the p53 pathway, overexpression of the p53 protein and the p53-associated protein, MDM2, have been detected. Synergistic upregulation of c-MYC, c-ERB-2, c-FMS, and BCL-2 oncoproteins have also been suggested to have an important role in the pathogenesis of choriocarcinoma. Moreover, choriocarcinomas have been shown to express increased concentrations of MMP and decreased concentrations of TIMP to help with tumor invasion and metastasis.
CATEGORY    Cancer
GENE        p53 (overexpression) [HSA:7157] [KO:K04451]
            MdM2 (overexpression) [HSA:4193] [KO:K06643]
            EGFR (overexpression) [HSA:1956] [KO:K04361]
            c-MYC (overexpression) [HSA:4609] [KO:K04377]
            ERBB2 (overexpression) [HSA:2064] [KO:K05083]
            c-FMS (overexpression) [HSA:1436] [KO:K05090]
            Bcl-2 (overexpression) [HSA:596] [KO:K02161]
            MMP-1 (overexpression) [HSA:4312] [KO:K01388]
            MMP-2 (overexpression) [HSA:4313] [KO:K01398]
MARKER      Beta-human chorionic gonadotropin (Beta-hCG) [HSA:1082] [KO:K10045]
DRUG        Methotrexate [DG:DG00681]
            Dactinomycin [DR:D00214]
            Etoposide [DG:DG00693]
            Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
COMMENT     ICD-O: 9100/3, Tumor type: Choriocarcinoma
DBLINKS     ICD-10: C58
            MeSH: D002822
REFERENCE   PMID:17613426 (description, gene, tumor type)
  AUTHORS   Shih IeM.
  TITLE     Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets.
  JOURNAL   Lancet Oncol 8:642-50 (2007)
REFERENCE   PMID:11869089 (description, gene)
  AUTHORS   Li HW, Tsao SW, Cheung AN
  TITLE     Current understandings of the molecular genetics of gestational trophoblastic diseases.
  JOURNAL   Placenta 23:20-31 (2002)
REFERENCE   PMID:17304028 (gene, tumor type)
  AUTHORS   Garner EI, Goldstein DP, Feltmate CM, Berkowitz RS.
  TITLE     Gestational trophoblastic disease.
  JOURNAL   Clin Obstet Gynecol 50:112-22 (2007)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00029                      Disease
NAME        Vulvar cancer
DESCRIPTION Vulvar cancer is a relatively uncommon malignancy, occurring at a rate of 2.2 per 100,000 women per year. Squamous cell carcinoma (SCC) is the most common type of vulvar cancer and is observed in 80% to 90% of cases. There are at least two quite different types of SCC of the vulva. The less common, accounting for about one-third of cases, occurs in relatively young women, is usually preceded by the undifferentiated form of vulvar squamous intraepithelial neoplasia (VIN) and is associated with high-risk human papillomavirus (HPV) infection; the more frequent form develops in elderly patients, is not commonly associated with undifferentiated VIN but is frequently associated with differentiated VIN, lichen sclerosus or squamous hyperplasia, and is generally not linked to HPV infection. Relatively little is known about molecular changes in the genesis of vulvar cancer. Some studies suggest that early p53 mutation may be a defining step only in HPV-negative tumors. A rather small study suggests that mutation in phosphatase and tensin homologue (PTEN) is an early change in a substantial subset of vulvar carcinomas.
CATEGORY    Cancer
GENE        PTEN (mutation) [HSA:5728] [KO:K01110]
            p53 (mutation) [HSA:7157] [KO:K04451]
CARCINOGEN  Azathioprine [DG:DG00743]
            Tobacco smoking and tobacco smoke
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
            Human papillomavirus type 18 [GN:T40088]
MARKER      Ki-67 [HSA:4288]
DRUG        Cisplatin [DR:D00275]
            Bleomycin [DG:DG00705]
            Fluorouracil [DG:DG00687]
            Methotrexate [DG:DG00681]
            Mitomycin [DR:D00208]
            Doxorubicin [DG:DG00696]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
DBLINKS     ICD-10: C51
            MeSH: D014846
REFERENCE   PMID:12605639 (description, gene, carcinogen, tumor type)
  AUTHORS   Fox H, Wells M
  TITLE     Recent advances in the pathology of the vulva.
  JOURNAL   Histopathology 42:209-16 (2003)
REFERENCE   PMID:19286150 (description, carcinogen)
  AUTHORS   Lanneau GS, Argenta PA, Lanneau MS, Riffenburgh RH, Gold MA, McMeekin DS, Webster N, Judson PL
  TITLE     Vulvar cancer in young women: demographic features and outcome evaluation.
  JOURNAL   Am J Obstet Gynecol 200:645.e1-5 (2009)
REFERENCE   PMID:10955808 (gene, tumor type)
  AUTHORS   Holway AH, Rieger-Christ KM, Miner WR, Cain JW, Dugan JM, Pezza JA, Silverman ML, Shapter A, McLellan R, Summerhayes IC.
  TITLE     Somatic mutation of PTEN in vulvar cancer.
  JOURNAL   Clin Cancer Res 6:3228-35 (2000)
REFERENCE   PMID:11156383 (gene, tumor type)
  AUTHORS   Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin WG Jr, Crook T.
  TITLE     Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus.
  JOURNAL   Cancer Res 60:6875-7 (2000)
REFERENCE   PMID:15203746 (marker, tumor type)
  AUTHORS   Marjoniemi VM.
  TITLE     Immunohistochemistry in gynaecological pathology: a review.
  JOURNAL   Pathology 36:109-19 (2004)
REFERENCE   PMID:11281434 (carcinogen)
  AUTHORS   Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK.
  TITLE     Human papillomavirus infections: epidemiology, pathogenesis, and therapy.
  JOURNAL   J Cutan Med Surg 5:43-60 (2001)
REFERENCE   PMID:1311142 (carcinogen)
  AUTHORS   Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, Weiss NS.
  TITLE     Cigarette smoking and the risk of anogenital cancer.
  JOURNAL   Am J Epidemiol 135:180-9 (1992)
REFERENCE   PMID:16062089 (carcinogen)
  AUTHORS   Patel P, Moazzam N, Potti A, Mehdi SA.
  TITLE     Azathioprine induced hodgkin lymphoma: a case report and review of literature.
  JOURNAL   Am J Clin Oncol 28:427-8 (2005)
REFERENCE   PMID:12605088 (marker)
  AUTHORS   Nucci MR, Castrillon DH, Bai H, Quade BJ, Ince TA, Genest DR, Lee KR, Mutter GL, Crum CP.
  TITLE     Biomarkers in diagnostic obstetric and gynecologic pathology: a review.
  JOURNAL   Adv Anat Pathol 10:55-68 (2003)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00030                      Disease
NAME        Cervical cancer
DESCRIPTION Cervical cancer is the second largest cause of cancer-related death in women worldwide, and it occurs following persistent infection, sometimes for decades, with a specific subset of human papillomavirus (HPV) types, particularly types 16, 18, 33 and 42. Experimental studies show that the E6 and E7 genes of these high risk HPVs are oncogenes that deregulate key cell cycle controls. The E6 and E7 oncoproteins bind respectively to the p53 and Retinoblastoma (Rb) tumor suppressor proteins, which are involved in the regulation of growth control. The abnormalities in other cellular genes found in cervical cancer, including mutations in ras family of genes, and amplification in EGFR and ERBB2, may also play an important role in carcinogenesis and the aggressiveness of cervical tumors, although to date the role of most of these genetic abnormalities does not appear to be as important as the role of HPV.
CATEGORY    Cancer
GENE        K-ras (mutation) [HSA:3845] [KO:K07827]
            H-ras (mutation) [HSA:3265] [KO:K02833]
            EGFR (amplification) [HSA:1956] [KO:K04361]
            ERBB2 (amplification) [HSA:2064] [KO:K05083]
            p21 (overexpression) [HSA:1026] [KO:K06625]
            CDK4 (overexpression) [HSA:1019] [KO:K02089]
            Bcl-2 (overexpression) [HSA:596] [KO:K02161]
CARCINOGEN  Azathioprine [DG:DG00743]
            Diethylstilboestrol [CPD:C07620] [DR:D00577]
            Estrogens, nonsteroidal
            Tobacco smoking and tobacco smoke
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
            Human papillomavirus type 18 [GN:T40088]
            Human papillomavirus type 45
MARKER      HPV (Human papillomavirus) DNA (L1) [VG:1489082]
            SCC antigen [HSA:6317]
            CYFRA [HSA:3880]
DRUG        Cisplatin [DR:D00275]
            Paclitaxel [DG:DG01430]
            Topotecan [DG:DG00725]
            Carboplatin [DR:D01363]
            Gemcitabine [DG:DG00688]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma, not otherwise specified
            ICD-O: 8140/3, Tumor type: Adenocarcinoma
DBLINKS     ICD-10: C53
            MeSH: D002583
REFERENCE   PMID:11486705 (gene, carcinogen)
  AUTHORS   Wolf JK, Ramirez PT.
  TITLE     The molecular biology of cervical cancer.
  JOURNAL   Cancer Invest 19:621-9 (2001)
REFERENCE   PMID:10471054 (gene, carcinogen)
  AUTHORS   Lazo PA.
  TITLE     The molecular genetics of cervical carcinoma.
  JOURNAL   Br J Cancer 80:2008-18 (1999)
REFERENCE   PMID:16062089 (carcinogen)
  AUTHORS   Patel P, Moazzam N, Potti A, Mehdi SA.
  TITLE     Azathioprine induced hodgkin lymphoma: a case report and review of literature.
  JOURNAL   Am J Clin Oncol 28:427-8 (2005)
REFERENCE   PMID:15168959 (carcinogen)
  AUTHORS   Schrager S, Potter BE.
  TITLE     Diethylstilbestrol exposure.
  JOURNAL   Am Fam Physician 69:2395-400 (2004)
REFERENCE   PMID:17390375 (carcinogen)
  AUTHORS   Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN.
  TITLE     Cancer risk in women prenatally exposed to diethylstilbestrol.
  JOURNAL   Int J Cancer 121:356-60 (2007)
REFERENCE   PMID:11281434 (carcinogen)
  AUTHORS   Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK.
  TITLE     Human papillomavirus infections: epidemiology, pathogenesis, and therapy.
  JOURNAL   J Cutan Med Surg 5:43-60 (2001)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:12612656 (marker)
  AUTHORS   Baldwin P, Laskey R, Coleman N.
  TITLE     Translational approaches to improving cervical screening.
  JOURNAL   Nat Rev Cancer 3:217-26 (2003)
REFERENCE   PMID:12797857 (marker)
  AUTHORS   Garland SM.
  TITLE     Can we really beat cervical cancer?
  JOURNAL   Med J Aust 178:647-9 (2003)
REFERENCE   PMID:14739059 (marker)
  AUTHORS   Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR.
  TITLE     Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
  JOURNAL   Biomed Pharmacother 58:24-38 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00031                      Disease
NAME        Breast cancer
DESCRIPTION Breast cancer remains the most common malignancy in women worldwide and is the leading cause of cancer-related mortality. More than 1-2 million cases are diagnosed every year, affecting 10-12% of the female population and accounting for 500 000 deaths per year worldwide. Approximately 5-10% are thought to be inherited. The hereditary breast cancer syndrome includes genetic alterations in various susceptibility genes such as p53, PTEN, BRCA1, and BRCA2. Sporadic breast cancers result from a serial stepwise accumulation of acquired and uncorrected mutations in somatic genes, without any germline mutation playing a role. Oncogenes that have been reported to play an early role in sporadic breast cancer are MYC, CCND1 (Cyclin D1) and ERBB2 (HER2/neu). In sporadic breast cancer, mutational inactivation of BRCA1/2 is rare. However, non-mutational functional suppression could result from various mechanisms, such as hypermethylation of the BRCA1 promoter.
CATEGORY    Cancer
GENE        BRCA1 (germline mutation, hypermethylation) [HSA:672] [KO:K10605]
            BRCA2 (germline mutation) [HSA:675] [KO:K08775]
            p53 (mutation) [HSA:7157] [KO:K04451]
            RB1 (underexpression) [HSA:5925] [KO:K06618]
            PTEN (germline mutation) [HSA:5728] [KO:K01110]
            c-MYC (overexpression) [HSA:4609] [KO:K04377]
            ERBB2 (overexpression) [HSA:2064] [KO:K05083]
            CDH1 (mutation) [HSA:999] [KO:K05689]
            CCND1 (overexpression) [HSA:595] [KO:K04503]
CARCINOGEN  Estrogen-progestogen menopausal therapy (combined)
            Estrogen-progestogen oral contraceptives (combined)
            Estrogen therapy, postmenopausal
            Oral contraceptives, sequential
            Radium-224 and its decay products
            X- and gamma-radiation
MARKER      CA15-3/CA27.29 [HSA:4582] [KO:K06568] [GL:G00242]
            Carcinoembryonic antigen (CEA) [HSA:634] [KO:K06499]
            Circulating tumor cells of epithelial origin
            Estrogen receptor (ER) / progesterone receptor (PR) [HSA:2099 2100] [KO:K08550 K08551] [HSA:5241] [KO:K08556]
            HER2/neu gene amplification or protein overexpression [HSA:2064] [KO:K05083]
            Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) [HSA:5328 5054] [KO:K01348 K03982]
DRUG        Tamoxifen [DG:DG00734]
            Anastrozole [DR:D00960]
            Letrozole [DR:D00964]
            Exemestane [DR:D00963]
            Doxorubicin [DG:DG00696]
            Cyclophosphamide [DG:DG00675]
            Docetaxel [DG:DG00694]
            Paclitaxel [DG:DG01430]
            Trastuzumab [DG:DG01358]
            Carboplatin [DR:D01363]
COMMENT     ICD-O: 8500/3, Tumor type: Invasive ductal carcinoma, not otherwise specified
            ICD-O: 8520/3, Tumor type: Invasive lobular carcinoma
DBLINKS     ICD-10: C50
            MeSH: D001943
REFERENCE   PMID:10448115 (gene, tumor type)
  AUTHORS   Ingvarsson S.
  TITLE     Molecular genetics of breast cancer progression.
  JOURNAL   Semin Cancer Biol 9:277-88 (1999)
REFERENCE   PMID:15351094 (gene)
  AUTHORS   Kenemans P, Verstraeten RA, Verheijen RH.
  TITLE     Oncogenic pathways in hereditary and sporadic breast cancer.
  JOURNAL   Maturitas 49:34-43 (2004)
REFERENCE   PMID:17464097 (carcinogen)
  AUTHORS   Ito K.
  TITLE     Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
  JOURNAL   Tohoku J Exp Med 212:1-12 (2007)
REFERENCE   PMID:17135036 (carcinogen)
  AUTHORS   Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS.
  TITLE     Hormone replacement therapy in menopausal women: Past problems and future possibilities.
  JOURNAL   Gynecol Endocrinol 22:564-77 (2006)
REFERENCE   PMID:15192054 (carcinogen)
  AUTHORS   .
  TITLE     Hormones and breast cancer.
  JOURNAL   Hum Reprod Update 10:281-93 (2004)
REFERENCE   PMID:14534338 (carcinogen)
  AUTHORS   Petitti DB.
  TITLE     Clinical practice. Combination estrogen-progestin oral contraceptives.
  JOURNAL   N Engl J Med 349:1443-50 (2003)
REFERENCE   PMID:16278609 (carcinogen)
  AUTHORS   Shah NR, Borenstein J, Dubois RW.
  TITLE     Postmenopausal hormone therapy and breast cancer: a systematic review  and meta-analysis.
  JOURNAL   Menopause 12:668-78 (2005)
REFERENCE   PMID:10564925 (carcinogen)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:15070562 (carcinogen)
  AUTHORS   Berrington de Gonzalez A, Darby S.
  TITLE     Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.
  JOURNAL   Lancet 363:345-51 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00032                      Disease
NAME        Thyroid cancer
DESCRIPTION Thyroid cancer is the most common endocrine malignancy and accounts for the majority of endocrine cancer- related deaths each year. More than 95% of thyroid carcinomas are derived from follicular cells.  Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC, respectively) to the extremely aggressive undifferentiated carcinoma (UC). Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages. The most distinctive molecular features of FTC are the prominence of aneuploidy and the high prevalence of RAS mutations and PAX8-PPAR{gamma} rearrangements. p53 seems to play a crucial role in the dedifferentiation process of thyroid carcinoma.
CATEGORY    Cancer
GENE        RET/PTC1 (rearrangement) [HSA:5979 8030] [KO:K05126 K09288]
            RET/PTC3 (rearrangement) [HSA:5979 8031] [KO:K05126 K09289]
            TPM3/NTRK1 (rearrangement) [HSA:4914 7170] [KO:K03176 K09290]
            TPR/NTRK1 (rearrangement) [HSA:7175 10342] [KO:K09291 K09292]
            H-ras (mutation) [HSA:3265] [KO:K02833]
            K-ras (mutation) [HSA:3845] [KO:K07827]
            N-ras (mutation) [HSA:4893] [KO:K07828]
            BRAF (mutation) [HSA:673] [KO:K04365]
            PAX8/PPARgamma (rearrangement) [HSA:7849 5468] [KO:K09293 K08530]
            beta-Catenin (mutation) [HSA:1499] [KO:K02105]
            p53 (mutation) [HSA:7157] [KO:K04451]
            E-cadherin (downregulation) [HSA:999] [KO:K05689]
CARCINOGEN  Radium-224 and its decay products [CPD:C16455]
            Radioiodines, short-lived isotopes, including iodine131, from atomic reactor accidents and nuclear
MARKER      Thyroglobulin [HSA:7038] [KO:K10809]
DRUG        Sodium iodide I 131 [DR:D02259]
            Sorafenib [DG:DG00713]
            Sunitinib [DG:DG00712]
            Pazopanib [DR:D05380]
            Vandetanib [DR:D06407]
COMMENT     ICD-O: 8260/3, Tumor type: Papillary carcinoma
            ICD-O: 8330/3, Tumor type: Follicular carcinoma
            ICD-O: 8020/3, Tumor type: Undifferentiated (anaplastic) carcinoma
DBLINKS     ICD-10: C73
            MeSH: D013964
REFERENCE   PMID:16557281 (gene, tumor type)
  AUTHORS   Kondo T, Ezzat S, Asa SL.
  TITLE     Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
  JOURNAL   Nat Rev Cancer 6:292-306 (2006)
REFERENCE   PMID:16831036 (tumor type)
  AUTHORS   Al-Brahim N, Asa SL.
  TITLE     Papillary thyroid carcinoma: an overview.
  JOURNAL   Arch Pathol Lab Med 130:1057-62 (2006)
REFERENCE   PMID:16807500 (tumor type)
  AUTHORS   Lin JD, Chao TC.
  TITLE     Follicular thyroid carcinoma: From diagnosis to treatment.
  JOURNAL   Endocr J 53:441-8 (2006)
REFERENCE   PMID:15521953 (tumor type)
  AUTHORS   Bojunga J, Zeuzem S.
  TITLE     Molecular detection of thyroid cancer: an update.
  JOURNAL   Clin Endocrinol (Oxf) 61:523-30 (2004)
REFERENCE   PMID:11165748 (gene)
  AUTHORS   Gimm O.
  TITLE     Thyroid cancer.
  JOURNAL   Cancer Lett 163:143-56 (2001)
REFERENCE   PMID:16189702 (gene)
  AUTHORS   Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P.
  TITLE     Molecular pathology of well-differentiated thyroid carcinomas.
  JOURNAL   Virchows Arch 447:787-93 (2005)
REFERENCE   PMID:10564925 (carcinogen)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:11340615 (carcinogen)
  AUTHORS   Rabes HM.
  TITLE     Gene rearrangements in radiation-induced thyroid carcinogenesis.
  JOURNAL   Med Pediatr Oncol 36:574-82 (2001)
REFERENCE   PMID:9743453 (carcinogen)
  AUTHORS   Hall P, Holm LE.
  TITLE     Radiation-associated thyroid cancer--facts and fiction.
  JOURNAL   Acta Oncol 37:325-30 (1998)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00033                      Disease
NAME        Adrenal carcinoma
DESCRIPTION Adrenocortical carcinoma (ACC) is a rare endocrine malignancy defined by a heterogeneous clinical presentation, dismal prognosis, and lack of effective therapeutic regimens. The incidence of ACC ranges from 0.5 to 2 cases per million people per year, accounting for 0.02% of all reported cancers. Unfortunately, most patients present with metastatic disease which reduces the 5 year survival rate to less than 10%. Oncogenes and tumor-suppressor genes involved in adrenal carcinomas include mutations in the p53 tumor-suppressor gene and rearrangements of the chromosomal locus 11p15.5 associated with IGF II hyperexpression. Deletions of the ACTH receptor gene have recently been found in undifferentiated adenomas and in aggressive ACCs.
CATEGORY    Cancer
GENE        ACTH-R (deletion) [HSA:4158] [KO:K04200]
            GNAI2 (mutation) [HSA:2771] [KO:K04630]
            N-ras (mutation) [HSA:4893] [KO:K07828]
            IGF II (overexpression) [HSA:3481] [KO:K13769]
            p53 (LOH, mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (LOH, low expression) [HSA:1028] [KO:K09993]
            MEN1 (LOH, mutation) [HSA:4221] [KO:K14970]
MARKER      Ki-67 [HSA:4288]
            p21 [HSA:1026]
            p27 [HSA:1027]
DRUG        Mitotane [DR:D00420]
COMMENT     ICD-O: 8370/3, Tumor type: Adrenal cortical carcinoma
DBLINKS     ICD-10: C74
            MeSH: D000306
REFERENCE   PMID:17934868 (description, tumor type)
  AUTHORS   Barlaskar FM, Hammer GD
  TITLE     The molecular genetics of adrenocortical carcinoma.
  JOURNAL   Rev Endocr Metab Disord 8:343-8 (2007)
REFERENCE   PMID:11281372 (description, gene, tumor type)
  AUTHORS   Reincke M, Beuschlein F, Slawik M, Borm K.
  TITLE     Molecular adrenocortical tumourigenesis.
  JOURNAL   Eur J Clin Invest 30 Suppl 3:63-8 (2000)
REFERENCE   PMID:12920217 (marker, tumor type)
  AUTHORS   Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, Nissan A, Cordon-Cardo C, Ghossein RA.
  TITLE     Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis.
  JOURNAL   Mod Pathol 16:742-51 (2003)
REFERENCE   PMID:12466322 (gene)
  AUTHORS   Koch CA, Pacak K, Chrousos GP.
  TITLE     The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors.
  JOURNAL   J Clin Endocrinol Metab 87:5367-84 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00034                      Disease
NAME        Carcinoid
DESCRIPTION Carcinoid tumors are relatively uncommon neoplasms that nonetheless comprise up to 85% of neuroendocrine gastrointestinal neoplasms. They most frequently occur in the midgut and develop from neuroendocrine cells that are normally and diffusely present in this location. Most carcinoids are sporadic but epidemiological studies report a familial risk. Moreover, carcinoids can occur within the multiple endocrine neoplasia (MEN) syndrome, a rare familiar tumor syndrome in which mutations in the MEN1 gene are manifested. Recently, it has been shown that a majority (78%) of sporadic carcinoids display loss of heterozygosity for markers around the MEN 1 region, thus suggesting involvement of this gene in the pathogenesis of both familial and sporadic carcinoids.
CATEGORY    Cancer
GENE        MEN1 (mutation, LOH) [HSA:4221] [KO:K14970]
            SDHD (germline mutation, LOH) [HSA:6392] [KO:K00237]
MARKER      Chromogranin A (CgA) [HSA:1113] [KO:K19990]
DRUG        Streptozocin [DR:D05932]
            Fluorouracil [DG:DG00687]
            Bevacizumab [DR:D06409]
            Sorafenib [DG:DG00713]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 8240/3, Tumor type: Carcinoid (well differentiated endocrine neoplasm)
DBLINKS     ICD-10: C17
            MeSH: D002276
REFERENCE   PMID:15887161 (gene, tumor type)
  AUTHORS   Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD.
  TITLE     Current status of gastrointestinal carcinoids.
  JOURNAL   Gastroenterology 128:1717-51 (2005)
REFERENCE   PMID:14713256 (gene)
  AUTHORS   Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV.
  TITLE     Genetics of neuroendocrine and carcinoid tumours.
  JOURNAL   Endocr Relat Cancer 10:437-50 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00035                      Disease
NAME        Ewing's sarcoma
DESCRIPTION Ewing's sarcoma is the second most common malignant bone tumor occurring in children and young adults, and accounts for 10-15% of all primary bone tumors. The annual incidence is approximately 0.6/million total population, and it usually occurs between the ages of 10 and 20 years. Ewing's sarcoma is in 85% of cases associated with the translocation t(11;22)(q24;q12), which leads to the formation of the EWSR1-FLI1 fusion gene. In another 10-15% of cases the translocation t(21;12)(22;12) generates the EWSR1-ERG fusion, whereas the remaining 1-5% of cases may harbor one of several possible translocations, each resulting in a fusion gene containing a portion of the EWSR1 gene and a member of the ETS family of transcription factors.
CATEGORY    Cancer
GENE        EWSR1-FLI1 (translocation) [HSA:2130 2313] [KO:K13209 K09436]
            EWSR1-ERG (translocation) [HSA:2130 2078] [KO:K13209 K09435]
            EWSR1-ETV1 (translocation) [HSA:2130 2115] [KO:K13209 K09431]
            EWSR1-ETV4 (translocation) [HSA:2130 2118] [KO:K13209 K15592]
            EWSR1-FEV (translocation) [HSA:2130 54738] [KO:K13209 K09437]
MARKER      EWS-FLI1 (translocation) [HSA:2130 2313]
            LDH [HSA:3939 3945 3948 197257]
            S-100 [HSA:6271]
            CD99 [HSA:4267]
            Vimentin [HSA:7431]
            CD57 [HSA:27087]
DRUG        Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Dactinomycin [DR:D00214]
            Ifosfamide [DR:D00343]
            Etoposide [DG:DG00693]
COMMENT     ICD-O: 9260/3, Tumor type: Ewing sarcoma
DBLINKS     ICD-10: C41
            MeSH: D012512
REFERENCE   PMID:12560386 (description, gene, tumor type)
  AUTHORS   Burchill SA.
  TITLE     Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities.
  JOURNAL   J Clin Pathol 56:96-102 (2003)
REFERENCE   PMID:11607824 (gene)
  AUTHORS   Arvand A, Denny CT.
  TITLE     Biology of EWS/ETS fusions in Ewing's family tumors.
  JOURNAL   Oncogene 20:5747-54 (2001)
REFERENCE   PMID:17250957 (description, gene)
  AUTHORS   Riggi N, Stamenkovic I.
  TITLE     The Biology of Ewing sarcoma.
  JOURNAL   Cancer Lett 254:1-10 (2007)
REFERENCE   PMID:16096383 (marker)
  AUTHORS   Khoury JD.
  TITLE     Ewing sarcoma family of tumors.
  JOURNAL   Adv Anat Pathol 12:212-20 (2005)
REFERENCE   PMID:12633526 (marker)
  AUTHORS   Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ, Lewis IJ.
  TITLE     A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.
  JOURNAL   Health Technol Assess 7:1-162 (2003)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00036                      Disease
NAME        Osteosarcoma
DESCRIPTION Osteosarcoma is the most common type of primary bone cancer. Approximately 900 new cases of osteosarcoma are diagnosed each year in the United States. The presentation of this disease is bimodal, with peaks in adolescence and after the age of 50 years. The tumors typically arise in the metaphyseal regions of long bones, with the distal femur, proximal tibia, and proximal humerus representing the three most common sites. Genomic amplification, especially of both the p53-binding MDM2 gene and the flanking SAS gene, plays an important role in the biology of these tumors. Alterations of Rb1 and c-myc are also common, and mutations have been reported in p53, p16INK4A, and CDKN2B.
CATEGORY    Cancer
GENE        MDM2 (amplification) [HSA:4193] [KO:K06643]
            SAS (amplification) [HSA:6302] [KO:K17356]
            p53 (losses, rearrangements, point mutation) [HSA:7157] [KO:K04451]
            RB1 (losses, rearrangements, point mutation) [HSA:5925] [KO:K06618]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            CDKN2B (mutation) [HSA:1030] [KO:K04685]
            c-MYC (amplification) [HSA:4609] [KO:K04377]
CARCINOGEN  Radium-224 and its decay products [CPD:C16455]
            Radium-226 and its decay products [CPD:C16456]
            Radium-228 and its decay products [CPD:C16457]
MARKER      CYP3A4 [HSA:1576]
            CYP3A5 [HSA:1577]
            Ezrin [HSA:7430]
            Alpha-smooth muscle actin [HSA:59]
            Survivin [HSA:332]
DRUG        Doxorubicin [DG:DG00696]
            Cisplatin [DR:D00275]
            Ifosfamide [DR:D00343]
            Methotrexate [DG:DG00681]
COMMENT     ICD-O: 9180/3, Tumor type: Osteosarcoma
DBLINKS     ICD-10: C41
            MeSH: D012516
REFERENCE   PMID:11378650 (description, gene)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:11950895 (description)
  AUTHORS   Ragland BD, Bell WC, Lopez RR, Siegal GP
  TITLE     Cytogenetics and molecular biology of osteosarcoma.
  JOURNAL   Lab Invest 82:365-73 (2002)
REFERENCE   PMID:17263592 (description, gene, tumor type)
  AUTHORS   Kansara M, Thomas DM.
  TITLE     Molecular pathogenesis of osteosarcoma.
  JOURNAL   DNA Cell Biol 26:1-18 (2007)
REFERENCE   PMID:17241811 (gene)
  AUTHORS   Papachristou DJ, Papavassiliou AG.
  TITLE     Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions.
  JOURNAL   Int J Biochem Cell Biol 39:857-62 (2007)
REFERENCE   PMID:10564927 (carcinogen)
  AUTHORS   Gossner W.
  TITLE     Pathology of radium-induced bone tumors: new aspects of histopathology and histogenesis.
  JOURNAL   Radiat Res 152:S12-5 (1999)
REFERENCE   PMID:10564925 (carcinogen)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:12829666 (marker)
  AUTHORS   Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH.
  TITLE     Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.
  JOURNAL   J Clin Oncol 21:2481-5 (2003)
REFERENCE   PMID:17786474 (marker)
  AUTHORS   Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, Bollini G, Curvale G, Gentet JC, Duffaud F, Figarella-Branger D, Bouvier C.
  TITLE     Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.
  JOURNAL   Virchows Arch 451:999-1007 (2007)
REFERENCE   PMID:17327929 (marker)
  AUTHORS   Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J.
  TITLE     Survivin as a prognostic factor for osteosarcoma patients.
  JOURNAL   Acta Histochem Cytochem 39:95-100 (2006)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00037                      Disease
NAME        Alveolar rhabdomyosarcoma
DESCRIPTION Rhabdomyosarcomas (RMSs) are soft tissue sarcomas that are one of the most common neoplasms in children and adolescents. RMSs are presumed to be associated with the skeletal muscle lineage, although those tumors can be present in organs histologically lacking skeletal muscle, like prostate, urinary bladder or gallbladder. RMS comprises a heterogeneous into two major histologic subtypes, embryonal (ERMS) and alveolar (ARMS). Alveolar rhabdomyosarcoma (ARMS) is a pediatric sarcoma that typically occurs in older children predominantly arising in the trunk and extremities, and exhibits a worse prognosis than other types of RMSs. ARMS is associated with 2;13 or 1;13 chromosomal translocations, which generate PAX3-FOXO1A and PAX7-FOXO1A fusion products, respectively. These translocations result in altered expression, function, and subcellular localization of the fusion products relative to the wild-type proteins, and ultimately contribute to oncogenic behavior by modifying growth, differentiation, and apoptosis pathways.
CATEGORY    Cancer
GENE        PAX3-FOXO1A (translocation) [HSA:5077 2308] [KO:K09381 K07201]
            PAX7-FOXO1A (translocation) [HSA:5081 2308] [KO:K09381 K07201]
            MDM2 (amplification) [HSA:4193] [KO:K06643]
            ATR (amplification) [HSA:545] [KO:K06640]
MARKER      PAX3-FOXO1A (translocation) [HSA:5077 2308]
            PAX7-FOXO1A (translocation) [HSA:5081 2308]
            MyoD1 [HSA:4654]
            Myogenin [HSA:4656]
DRUG        Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Ifosfamide [DR:D00343]
            Mesna [DR:D01459]
            Imatinib [DG:DG00710]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 8920/3, Tumor type: Alveolar rhabdomyosarcoma
DBLINKS     ICD-10: C49
            MeSH: D018232
REFERENCE   PMID:19008039 (desciption, gene)
  AUTHORS   Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M
  TITLE     Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?
  JOURNAL   Cancer Lett 279:126-36 (2009)
REFERENCE   PMID:12170781 (description, gene)
  AUTHORS   Xia SJ, Pressey JG, Barr FG
  TITLE     Molecular pathogenesis of rhabdomyosarcoma.
  JOURNAL   Cancer Biol Ther 1:97-104 (2002)
REFERENCE   PMID:11378650 (gene, tumor type)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:12951587 (gene)
  AUTHORS   Helman LJ, Meltzer P.
  TITLE     Mechanisms of sarcoma development.
  JOURNAL   Nat Rev Cancer 3:685-94 (2003)
REFERENCE   PMID:10516379 (gene)
  AUTHORS   Fisher C.
  TITLE     Current aspects of the pathology of soft tissue sarcomas.
  JOURNAL   Semin Radiat Oncol 9:315-27 (1999)
REFERENCE   PMID:16365729 (marker)
  AUTHORS   Krskova L, Mrhalova M, Sumerauer D, Kodet R.
  TITLE     Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
  JOURNAL   Virchows Arch 448:449-58 (2006)
REFERENCE   PMID:11007039 (marker)
  AUTHORS   Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M.
  TITLE     Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues.
  JOURNAL   Mod Pathol 13:988-93 (2000)
REFERENCE   PMID:12039929 (marker)
  AUTHORS   Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG.
  TITLE     PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
  JOURNAL   J Clin Oncol 20:2672-9 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00038                      Disease
NAME        Malignant melanoma
DESCRIPTION Melanoma is a form of skin cancer that has a poor prognosis and which is on the rise in Western populations.  Melanoma arises from the malignant transformation of pigment-producing cells, melanocytes. The only known environmental risk factor is exposure to ultraviolet (UV) light and in people with fair skin the risk is greatly increased. Melanoma pathogenesis is also driven by genetic factors. Oncogenic NRAS mutations activate both effector pathways Raf-MEK-ERK and PI3K-Akt. The Raf-MEK-ERK pathway may also be activated via mutations in the BRAF gene. The PI3K-Akt pathway may be activated through loss or mutation of the inhibitory tumor suppressor gene PTEN. These mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Melanoma development has been shown to be strongly associated with inactivation of the p16INK4a/cyclin dependent kinases 4 and 6/retinoblastoma protein (p16INK4a/CDK4,6/pRb) and p14ARF/human double minute 2/p53 (p14ARF/HMD2/p53) tumor suppressor pathways. MITF and TP53 are implicated in further melanoma progression.
CATEGORY    Cancer
GENE        BRAF (mutation) [HSA:673] [KO:K04365]
            NRAS (mutation) [HSA:4893] [KO:K07828]
            CDK4 (mutation) [HSA:1019] [KO:K02089]
            MITF (amplification) [HSA:4286] [KO:K09455]
            PTEN (deletion, germline mutation, somatic mutation, LOH) [HSA:5728] [KO:K01110]
            p16/INK4A (loss/mutation) [HSA:1029] [KO:K06621]
            p53 (loss/mutation) [HSA:7157] [KO:K04451]
CARCINOGEN  8-Methoxypsoralen (Methoxsalen) plus ultraviolet A radiation [CPD:C01864] [DR:D00139]
            Solar radiation
            *Benzo[a]pyrene [CPD:C07535]
            *Chimney sweeping
            *Mineral oils, untreated and mildly treated
            *: Although this is a risk factor for skin cancer in general, the strength of association with different histological tumor types is not well understood.
MARKER      BRAF mutation V600E [HSA:673] [KO:K04365]
            Lactate dehydrogenase [HSA:3939 3945 3948] [KO:K00016]
DRUG        Ipilimumab [DR:D04603]
            Vemurafenib [DR:D09996]
            Interleukin-2
COMMENT     ICD-O: 8720/3, Tumor type: Malignant melanoma
DBLINKS     ICD-10: C43
            MeSH: D008545
REFERENCE   PMID:16822996 (gene, tumor type)
  AUTHORS   Miller AJ, Mihm MC Jr.
  TITLE     Melanoma.
  JOURNAL   N Engl J Med 355:51-65 (2006)
REFERENCE   PMID:15468170 (gene)
  AUTHORS   Tsai KY, Tsao H.
  TITLE     The genetics of skin cancer.
  JOURNAL   Am J Med Genet C Semin Med Genet 131C:82-92 (2004)
REFERENCE   PMID:15785879 (gene)
  AUTHORS   Gray-Schopfer VC, da Rocha Dias S, Marais R.
  TITLE     The role of B-RAF in melanoma.
  JOURNAL   Cancer Metastasis Rev 24:165-83 (2005)
REFERENCE   PMID:9091799 (carcinogen)
  AUTHORS   Stern RS, Nichols KT, Vakeva LH.
  TITLE     Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.
  JOURNAL   N Engl J Med 336:1041-5 (1997)
REFERENCE   PMID:15701081 (carcinogen)
  AUTHORS   Hussein MR.
  TITLE     Ultraviolet radiation and skin cancer: molecular mechanisms.
  JOURNAL   J Cutan Pathol 32:191-205 (2005)
REFERENCE   PMID:14643412 (carcinogen)
  AUTHORS   Rossman TG.
  TITLE     Mechanism of arsenic carcinogenesis: an integrated approach.
  JOURNAL   Mutat Res 533:37-65 (2003)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:9498901 (carcinogen)
  AUTHORS   Tolbert PE.
  TITLE     Oils and cancer.
  JOURNAL   Cancer Causes Control 8:386-405 (1997)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00039                      Disease
NAME        Basal cell carcinoma
DESCRIPTION Cancer of the skin is the most common cancer in Caucasians and basal cell carcinomas (BCC) account for 90% of all skin cancers. The vast majority of BCC cases are sporadic, though there is a rare familial syndrome basal cell nevus syndrome (BCNS, or Gorlin syndrome) that predisposes to development of BCC. In addition, there is strong epidemiological and genetic evidence that demonstrates UV exposure as a risk factor of prime importance. The development of basal cell carcinoma is associated with constitutive activation of sonic hedgehog signaling. The mutations in SMOH, PTCH1, and SHH in BCCs result in continuous activation of target genes. At a cellular level, sonic hedgehog signaling promotes cell proliferation. Mutations in TP53 are also found with high frequency (>50%) in sporadic BCC.
CATEGORY    Cancer
GENE        SHH (germline, somatic mutation) [HSA:6469] [KO:K11988]
            SMO (somatic mutation) [HSA:6608] [KO:K06226]
            p53 (mutation) [HSA:7157] [KO:K04451]
            PTCH (germline, somatic mutation) [HSA:5727] [KO:K06225]
CARCINOGEN  Arsenic in drinking-water
            Solar radiation
            *Benzo[a]pyrene [CPD:C07535]
            *Chimney sweeping
            *Mineral oils, untreated and mildly treated
            *: Although this is a risk factor for skin cancer in general, the strength of association with different histological tumor types is not well understood.
MARKER      p63 [HSA:8626]
DRUG        Cisplatin [DR:D00275]
            Doxorubicin [DG:DG00696]
COMMENT     ICD-O: 8090/3, Tumor type: Basal cell carcinoma
DBLINKS     ICD-10: C44
            MeSH: D002280
REFERENCE   PMID:15978322 (gene, tumor type)
  AUTHORS   Daya-Grosjean L, Couve-Privat S.
  TITLE     Sonic hedgehog signaling in basal cell carcinomas.
  JOURNAL   Cancer Lett 225:181-92 (2005)
REFERENCE   PMID:16541145 (gene)
  AUTHORS   Khavari PA.
  TITLE     Modelling cancer in human skin tissue.
  JOURNAL   Nat Rev Cancer 6:270-80 (2006)
REFERENCE   PMID:15468170 (gene)
  AUTHORS   Tsai KY, Tsao H.
  TITLE     The genetics of skin cancer.
  JOURNAL   Am J Med Genet C Semin Med Genet 131C:82-92 (2004)
REFERENCE   PMID:14643412 (carcinogen)
  AUTHORS   Rossman TG.
  TITLE     Mechanism of arsenic carcinogenesis: an integrated approach.
  JOURNAL   Mutat Res 533:37-65 (2003)
REFERENCE   PMID:17244035 (carcinogen)
  AUTHORS   Walvekar RR, Kane SV, Nadkarni MS, Bagwan IN, Chaukar DA, D'Cruz AK.
  TITLE     Chronic arsenic poisoning: a global health issue -- a report of multiple primary cancers.
  JOURNAL   J Cutan Pathol 34:203-6 (2007)
REFERENCE   PMID:15701081 (carcinogen)
  AUTHORS   Hussein MR.
  TITLE     Ultraviolet radiation and skin cancer: molecular mechanisms.
  JOURNAL   J Cutan Pathol 32:191-205 (2005)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:9498901 (carcinogen)
  AUTHORS   Tolbert PE.
  TITLE     Oils and cancer.
  JOURNAL   Cancer Causes Control 8:386-405 (1997)
REFERENCE   PMID:16307669 (marker)
  AUTHORS   Takeuchi Y, Tamura A, Kamiya M, Fukuda T, Ishikawa O.
  TITLE     Immunohistochemical analyses of p63 expression in cutaneous tumours.
  JOURNAL   Br J Dermatol 153:1230-2 (2005)
REFERENCE   PMID:15268709 (marker)
  AUTHORS   Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE.
  TITLE     Expression profiles of p63, p53, survivin, and hTERT in skin tumors.
  JOURNAL   J Cutan Pathol 31:544-9 (2004)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00040                      Disease
NAME        Squamous cell carcinoma
DESCRIPTION Non-melanoma skin cancer, i.e. basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most frequent tumors and their number is still increasing world- wide. Approximately 200000 cases of SCC develop per year, causing about 2000 deaths. Unlike BCCs, which have no known precursor lesions, SCCs can emerge from actinic keratoses. SCC in anogenital regions can be caused by oncogenic human papillomavirus (HPV) strains. As with BCC, risk for development of SCC is strongly influenced by the nature and dose of UV radiation and genetic backgrounds that regulate that interaction. Mutations in TP53 have been described in actinic keratoses, in situ SCC, and invasive SCC with UV signature lesions common, and a reported mutation rate as high as 45%. As with TP53, UV-induced mutations in HRAS and KRAS have also been characterized in both actinic keratoses and SCC. The reported frequency of RAS mutations in SCCs ranges from approximately 10% to almost 50%. Several recent studies have also reported mutations of p16 in up to 24% of SCCs.
CATEGORY    Cancer
GENE        p53 (mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            H-ras (mutation) [HSA:3265] [KO:K02833]
            K-ras (mutation) [HSA:3845] [KO:K07827]
CARCINOGEN  Solar radiation
            Ciclosporin [DR:D00184]
            *Benzo[a]pyrene [CPD:C07535]
            *Chimney sweeping
            *Mineral oils, untreated and mildly treated
            *: Although this is a risk factor for skin cancer in general, the strength of association with different histological tumor types is not well understood.
PATHOGEN    Human papillomavirus types 8, 18, 5 [GN:T40089]
MARKER      p63 [HSA:8626]
DRUG        Cisplatin [DR:D00275]
            Doxorubicin [DG:DG00696]
COMMENT     ICD-O: 8070/3, Tumor type: squamous cell carcinoma
DBLINKS     ICD-10: C44
            MeSH: D002294
REFERENCE   PMID:15468170 (description, gene, carcinogen, tumor type)
  AUTHORS   Tsai KY, Tsao H.
  TITLE     The genetics of skin cancer.
  JOURNAL   Am J Med Genet C Semin Med Genet 131C:82-92 (2004)
REFERENCE   PMID:11708952 (description, gene)
  AUTHORS   Tsao H.
  TITLE     Genetics of nonmelanoma skin cancer.
  JOURNAL   Arch Dermatol 137:1486-92 (2001)
REFERENCE   PMID:11078916 (carcinogen)
  AUTHORS   Biliris KA, Koumantakis E, Dokianakis DN, Sourvinos G, Spandidos DA
  TITLE     Human papillomavirus infection of non-melanoma skin cancers in immunocompetent hosts.
  JOURNAL   Cancer Lett 161:83-8 (2000)
REFERENCE   PMID:16652084 (carcinogen)
  AUTHORS   Tiu J, Li H, Rassekh C, van der Sloot P, Kovach R, Zhang P.
  TITLE     Molecular basis of posttransplant squamous cell carcinoma: the potential role of cyclosporine a in carcinogenesis.
  JOURNAL   Laryngoscope 116:762-9 (2006)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:9498901 (carcinogen)
  AUTHORS   Tolbert PE.
  TITLE     Oils and cancer.
  JOURNAL   Cancer Causes Control 8:386-405 (1997)
REFERENCE   PMID:16307669 (marker)
  AUTHORS   Takeuchi Y, Tamura A, Kamiya M, Fukuda T, Ishikawa O.
  TITLE     Immunohistochemical analyses of p63 expression in cutaneous tumours.
  JOURNAL   Br J Dermatol 153:1230-2 (2005)
REFERENCE   PMID:15268709 (marker)
  AUTHORS   Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE.
  TITLE     Expression profiles of p63, p53, survivin, and hTERT in skin tumors.
  JOURNAL   J Cutan Pathol 31:544-9 (2004)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00041                      Disease
NAME        Kaposi's sarcoma
DESCRIPTION Kaposi's sarcoma (KS) is an angioproliferative disease occurring in several different clinical-epidemiological forms that, however, share the same histological traits and are all associated with infection by the human herpesvirus 8 (HHV8; also known as KSHV). Evidence indicates that KS progression occurs upon the deregulated expression of anti-apoptotic genes (Bcl-2), oncogenes (c-myc, c-int, ras) and oncosuppressor genes (TP53), and is associated with the long-lasting expression of HHV8 latency genes (LANA, v-cyc D, v-FLIP, Kaposin). All these genes are, in fact, expressed or altered in most KS spindle cells in the nodular-late stage of KS. Bcl-2 acts as a major KS progression factor, and TP53 and c-myc may also have a role in disease progression. HHV8 latency gene products may be involved in KS progression due to their capability of promoting cell growth by direct effects or antiapoptotic effects.
CATEGORY    Cancer
GENE        Bcl-2 (overexpression) [HSA:596] [KO:K02161]
            c-MYC (overexpression) [HSA:4609] [KO:K04377]
            c-INT (overexpression, mutation) [HSA:2248] [KO:K04358]
            K-ras (overexpression, mutation) [HSA:3845] [KO:K07827]
            p53 (mutation) [HSA:7157] [KO:K04451]
CARCINOGEN  Azathioprine [DG:DG00743]
PATHOGEN    Human herpesvirus 8 (KSHV) [GN:T40081]
            Human immunodeficiency virus 1 [GN:T40001] (infection with)
MARKER      HHV-8 (cellular viremia and viral load)
DRUG        Doxorubicin [DG:DG00696]
            Daunorubicin [DG:DG00697]
COMMENT     ICD-O: 9140/3, Tumor type: Kaposi sarcoma
DBLINKS     ICD-10: C46
            MeSH: D012514
REFERENCE   PMID:11423257 (description, gene, carcinogen)
  AUTHORS   Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P
  TITLE     Biology of Kaposi's sarcoma.
  JOURNAL   Eur J Cancer 37:1251-69 (2001)
REFERENCE   PMID:15334644 (carcinogen, tumor type)
  AUTHORS   Schwartz RA.
  TITLE     Kaposi's sarcoma: an update.
  JOURNAL   J Surg Oncol 87:146-51 (2004)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:16062089 (carcinogen)
  AUTHORS   Patel P, Moazzam N, Potti A, Mehdi SA.
  TITLE     Azathioprine induced hodgkin lymphoma: a case report and review of literature.
  JOURNAL   Am J Clin Oncol 28:427-8 (2005)
REFERENCE   PMID:17630560 (marker)
  AUTHORS   Anderson LA, Goedert JJ.
  TITLE     Tumor markers and treatments for Kaposi sarcoma.
  JOURNAL   AIDS 21:1637-9 (2007)
REFERENCE   PMID:15578080 (marker)
  AUTHORS   Hammock L, Reisenauer A, Wang W, Cohen C, Birdsong G, Folpe AL.
  TITLE     Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients.
  JOURNAL   Mod Pathol 18:463-8 (2005)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00042                      Disease
NAME        Glioma
DESCRIPTION Gliomas are the most common of the primary brain tumors and account for more than 40% of all central nervous system neoplasms. Gliomas include tumours that are composed predominantly of astrocytes (astrocytomas), oligodendrocytes (oligodendrogliomas), mixtures of various glial cells (for example,oligoastrocytomas) and ependymal cells (ependymomas). The most malignant form of infiltrating astrocytoma - glioblastoma multiforme (GBM) - is one of the most aggressive human cancers. GBM may develop de novo (primary glioblastoma) or by progression from low-grade or anaplastic astrocytoma (secondary glioblastoma).  Primary glioblastomas develop in older patients and typically show genetic alterations (EGFR amplification, p16/INK4a deletion, and PTEN mutations) at frequencies of 24-34%. Secondary glioblastomas develop in younger patients and frequently show overexpression of PDGF and CDK4 as well as p53 mutations (65%) and loss of Rb playing major roles in such transformations. Loss of PTEN has been implicated in both pathways, although it is much more common in the pathogenesis of primary GBM.
CATEGORY    Cancer
GENE        EGFR (amplification, overexpression) [HSA:1956] [KO:K04361]
            MDM2 (amplification, overexpression) [HSA:4193] [KO:K06643]
            PTEN (mutation) [HSA:5728] [KO:K01110]
            p16/INK4A (deletion) [HSA:1029] [KO:K06621]
            PDGF-A (overexpression) [HSA:5154] [KO:K04359]
            PDGF-B (overexpression) [HSA:5155] [KO:K17386]
            PDGFR-alpha (overexpression, amplification) [HSA:5156] [KO:K04363]
            PDGFR-beta (overexpression, amplification) [HSA:5159] [KO:K05089]
            CDK4 (amplification) [HSA:1019] [KO:K02089]
            p53 (mutation) [HSA:7157] [KO:K04451]
            RB1 (loss) [HSA:5925] [KO:K06618]
CARCINOGEN  X- and gamma-radiation
MARKER      p53 (mutation) [HSA:7157]
            PTEN (mutation) [HSA:5728]
            EGFR (amplification) [HSA:1956]
DRUG        Carmustine [DR:D00254]
            Lomustine [DR:D00363]
            Procarbazine [DG:DG00706]
            Vincristine [DG:DG00690]
            Temozolomide [DR:D06067]
COMMENT     ICD-O: 9401/3, Tumor type: Anaplastic astrocytoma
            ICD-O: 9440/3, Tumor type: Glioblastoma
DBLINKS     ICD-10: C71
            MeSH: D005910
REFERENCE   PMID:15639402 (gene, tumor type)
  AUTHORS   Soni D, King JA, Kaye AH, Hovens CM.
  TITLE     Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge.
  JOURNAL   J Clin Neurosci 12:1-5 (2005)
REFERENCE   PMID:11253051 (gene)
  AUTHORS   Holland EC.
  TITLE     Gliomagenesis: genetic alterations and mouse models.
  JOURNAL   Nat Rev Genet 2:120-9 (2001)
REFERENCE   PMID:12154354 (gene)
  AUTHORS   Zhu Y, Parada LF.
  TITLE     The molecular and genetic basis of neurological tumours.
  JOURNAL   Nat Rev Cancer 2:616-26 (2002)
REFERENCE   PMID:11604478 (carcinogen)
  AUTHORS   Bondy ML, Wang LE, El-Zein R, de Andrade M, Selvan MS, Bruner JM, Levin VA, Alfred Yung WK, Adatto P, Wei Q.
  TITLE     Gamma-radiation sensitivity and risk of glioma.
  JOURNAL   J Natl Cancer Inst 93:1553-7 (2001)
REFERENCE   PMID:2790826 (carcinogen)
  AUTHORS   Preston-Martin S, Mack W, Henderson BE.
  TITLE     Risk factors for gliomas and meningiomas in males in Los Angeles County.
  JOURNAL   Cancer Res 49:6137-43 (1989)
REFERENCE   PMID:12826827 (marker)
  AUTHORS   Hill C, Hunter SB, Brat DJ.
  TITLE     Genetic markers in glioblastoma: prognostic significance and future therapeutic implications.
  JOURNAL   Adv Anat Pathol 10:212-7 (2003)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00043                      Disease
NAME        Neuroblastoma
DESCRIPTION Neuroblastoma is a tumor derived from primitive cells of the sympathetic nervous system and is the most common solid tumor in childhood. Approximately one-half of children have localized tumors that can be cured with surgery alone. These favorable tumors are characterized by near-triploid karyotypes with whole chromosome gains. These tumors rarely have structural rearrangements, and they usually express the TrkA neurotrophin receptor. Patients with these tumors are more likely to be less than 1 year of age. The remaining children have widespread metastatic disease or quite large, aggressive, localized tumors. These unfavorable tumors are characterized by structural changes, including deletions of 1p or 11q, unbalanced gain of 17q and/or amplification of the MYCN protooncogene. They might also express the TrkB neurotrophin receptor and its ligand, brain-derived neurotrophic factor (BDNF). These patients are usually older than 1 year of age, and have a poor long-term survival rate of approximately 30%.
CATEGORY    Cancer
GENE        MYCN (normal/amplified) [HSA:4613] [KO:K09109]
            TrkA (high/low expression) [HSA:4914] [KO:K03176]
            TrkB (low/high expression) [HSA:4915] [KO:K04360]
            TrkC (high/low expression) [HSA:4916] [KO:K05101]
MARKER      Lactate dehydrogenase [HSA:3939 3945 3948] [KO:K00016]
            Neuron-specific enolase (NSE) [HSA:2026] [KO:K01689]
DRUG        Cyclophosphamide [DG:DG00675]
            Doxorubicin [DG:DG00696]
            Cisplatin [DR:D00275]
            Etoposide [DG:DG00693]
COMMENT     ICD-O: 9500/3, Tumor type: Neuroblastoma
DBLINKS     ICD-10: C38 C47 C48 C72 C74 C76
            MeSH: D009447
REFERENCE   PMID:12612655 (gene, tumor type)
  AUTHORS   Brodeur GM.
  TITLE     Neuroblastoma: biological insights into a clinical enigma.
  JOURNAL   Nat Rev Cancer 3:203-16 (2003)
REFERENCE   PMID:14697505 (gene)
  AUTHORS   van Noesel MM, Versteeg R.
  TITLE     Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.
  JOURNAL   Gene 325:1-15 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00044                      Disease
NAME        Cancer of the anal canal
DESCRIPTION Squamous cell carcinoma of the anal canal accounts for 1.5 per cent of all digestive system cancers in the USA, with an estimated 4,660 new cases and 660 deaths in 2006. Epidemiological and molecular-biology studies have now shown that sexually transmitted infection with human papillomavirus (HPV) is the most important aetiological agent. Human immunodeficiency virus (HIV) infection is also associated with anal cancer. HPV infection is transient in most immunocompetent individuals, but HIV-positive patients have evidence of persistent HPV infection within the anal canal. Current data suggest that mutations in p53, DCC and APC tumor suppressor genes contribute to the stepwise progression of anal squamous cell carcinoma in immunocompetent individuals.
CATEGORY    Cancer
GENE        p53 (mutation) [HSA:7157] [KO:K04451]
            DCC (mutation) [HSA:1630] [KO:K06765]
            APC (mutation) [HSA:324] [KO:K02085]
CARCINOGEN  Tobacco smoking and tobacco smoke
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
            Human papillomavirus type 18 [GN:T40088]
            Human immunodeficiency virus 1 [GN:T40001]
MARKER      p63 [HSA:8626]
            SCC [HSA:6317]
            TPA [HSA:3856 3875 3880]
DRUG        Fluorouracil [DG:DG00687]
            Mitomycin [DR:D00208]
            Cisplatin [DR:D00275]
            Doxorubicin [DG:DG00696]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
DBLINKS     ICD-10: C21
            MeSH: D001005
REFERENCE   PMID:16607677 (gene, carcinogen, tumor type)
  AUTHORS   Gervaz P, Hirschel B, Morel P.
  TITLE     Molecular biology of squamous cell carcinoma of the anus.
  JOURNAL   Br J Surg 93:531-8 (2006)
REFERENCE   PMID:12947531 (gene, carcinogen)
  AUTHORS   Gervaz P, Allal AS, Villiger P, Buhler L, Morel P.
  TITLE     Squamous cell carcinoma of the anus: another sexually transmitted disease.
  JOURNAL   Swiss Med Wkly 133:353-9 (2003)
REFERENCE   PMID:11281434 (carcinogen)
  AUTHORS   Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK.
  TITLE     Human papillomavirus infections: epidemiology, pathogenesis, and therapy.
  JOURNAL   J Cutan Med Surg 5:43-60 (2001)
REFERENCE   PMID:1311142 (carcinogen)
  AUTHORS   Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, Weiss NS.
  TITLE     Cigarette smoking and the risk of anogenital cancer.
  JOURNAL   Am J Epidemiol 135:180-9 (1992)
REFERENCE   PMID:17255774 (marker)
  AUTHORS   Owens SR, Greenson JK.
  TITLE     Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas.
  JOURNAL   Am J Surg Pathol 31:285-90 (2007)
REFERENCE   PMID:9372374 (marker)
  AUTHORS   Indinnimeo M, Reale MG, Cicchini C, Stazi A, Fiori E, Izzo P.
  TITLE     CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
  JOURNAL   Int Surg 82:275-9 (1997)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00045                      Disease
NAME        Pancreatic neuroendocrine tumor
DESCRIPTION Pancreatic neuroendocrine tumors (PNETs), also known as islet cell tumors, are rare neoplasms that arise in the endocrine tissues of the pancreas. They may occur sporadically or in association with a genetic syndrome, such as multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Landau (VHL) syndrome, neurofibromatosis type 1, or tuberous sclerosis. The most frequent genetic alterations in PNET occur in MEN1 (Multiple Endocrine Neoplasia-1 Gene), DAXX/ATRX (Death-Domain Associated Protein/Mental Retardation Syndrome X-Linked Genes) and the mTOR pathway (Mammalian Target of Rapamycin). A germline mutation in the MEN1 tumor suppressor gene causes MEN1, the above-mentioned autosomal dominant hereditary syndrome. Mutations of DAXX and ATRX are common and related to altered telomeres but not to prognosis.
CATEGORY    Cancer
GENE        MEN1 (mutation) [HSA:4221] [KO:K14970]
            DAXX (mutation) [HSA:1616] [KO:K02308]
            ATRX (mutation) [HSA:546] [KO:K10779]
MARKER      Chromogranin A (CgA) [HSA:1113] [KO:K19990]
DRUG        Everolimus [DR:D02714]
            Bevacizumab [DR:D06409]
            Temsirolimus [DR:D06068]
            Sunitinib [DR:D08552]
            Streptozotocin [DR:D05932]
            Temozolomide [DR:D06067]
COMMENT     ICD-O-3: 8151/3 Insulinoma, malignant (C25._)
            ICD-O-3: 8153/3 Gastrinoma, malignant
            ICD-O-3: 8155/3 Vipoma, malignant
            ICD-O-3: 8152/3 Glucagonoma, malignant (C25._)
            ICD-O-3: 8156/3 Somatostatinoma, malignant
DBLINKS     ICD-10: C25.4
            MeSH: D018273
REFERENCE   PMID:27021395 (description, gene, drug)
  AUTHORS   Viudez A, De Jesus-Acosta A, Carvalho FL, Vera R, Martin-Algarra S, Ramirez N
  TITLE     Pancreatic neuroendocrine tumors: Challenges in an underestimated disease.
  JOURNAL   Crit Rev Oncol Hematol 101:193-206 (2016)
REFERENCE   PMID:25619712 (gene, drug)
  AUTHORS   Capurso G, Archibugi L, Delle Fave G
  TITLE     Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
  JOURNAL   J Hepatobiliary Pancreat Sci 22:594-601 (2015)
REFERENCE   PMID:25341008 (gene, drug)
  AUTHORS   Halperin DM, Kulke MH, Yao JC
  TITLE     A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
  JOURNAL   Annu Rev Med 66:1-16 (2015)
REFERENCE   PMID:24828360 (description)
  AUTHORS   Rustagi T, Farrell JJ
  TITLE     Endoscopic diagnosis and treatment of pancreatic neuroendocrine tumors.
  JOURNAL   J Clin Gastroenterol 48:837-44 (2014)
REFERENCE   PMID:24987821 (gene, ICD-O-3)
  AUTHORS   Karakaxas D, Gazouli M, Liakakos T, Vaiopoulou A, Apessou D, Papaparaskeva K, Patapis P, Dervenis C
  TITLE     Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm.
  JOURNAL   Eur J Gastroenterol Hepatol 26:826-35 (2014)
REFERENCE   PMID:23237225 (ICD-O-3)
  AUTHORS   Ro C, Chai W, Yu VE, Yu R
  TITLE     Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.
  JOURNAL   Chin J Cancer 32:312-24 (2013)
REFERENCE   PMID:22586144 (description, gene)
  AUTHORS   Capurso G, Festa S, Valente R, Piciucchi M, Panzuto F, Jensen RT, Delle Fave G
  TITLE     Molecular pathology and genetics of pancreatic endocrine tumours.
  JOURNAL   J Mol Endocrinol 49:R37-50 (2012)
REFERENCE   PMID:25689919 (description)
  AUTHORS   Grozinsky-Glasberg S, Mazeh H, Gross DJ
  TITLE     Clinical features of pancreatic neuroendocrine tumors.
  JOURNAL   J Hepatobiliary Pancreat Sci 22:578-85 (2015)
///
ENTRY       H00046                      Disease
NAME        Cholangiocarcinoma
DESCRIPTION Cholangiocarcinoma is a highly malignant neoplasm that carries a poor prognosis and lacks effective therapy. It is the second most common primary hepatic tumor, and it is increasing in incidence and carries a high mortality. The tumor arises from the ductular epithelium of the biliary tree, either within the liver (intrahepatic cholangiocarcinoma: ICC) or more commonly from the extrahepatic bile ducts (extrahepatic cholangiocarcinoma). Several studies have demonstrated mutations resulting in overexpression of K-ras and p53 genes. These genetic alterations are associated with a more aggressive phenotype in this cancer. Many reports have implicated overexpression of the tyrosine kinase proto-oncogenes c-erbB-2 (HER-2/neu) and c-Met, as well as cyclo-oxygenase-2 (COX-2) activity in intrahepatic cholangiocarcinoma.
CATEGORY    Cancer
GENE        K-ras (mutation) [HSA:3845] [KO:K07827]
            p53 (mutation) [HSA:7157] [KO:K04451]
            c-Met (overexpression) [HSA:4233] [KO:K05099]
            ERBB2 (overexpression, amplification) [HSA:2064] [KO:K05083]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            COX2 (overexpression) [HSA:5743] [KO:K11987]
CARCINOGEN  Opisthorchis viverrini (infection with)
            Radium-224 and its decay products [CPD:C16455]
            *Chimney sweeping
            *2,3,7,8-Tetrachlorodibenzo-para-dioxin [CPD:C07557]
            *Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium232 dioxide
            *Tobacco smoking and tobacco smoke
            *: Although this is a risk factor for liver cancer in general, the strength of association with different histological tumor types is not well understood.
MARKER      CA19-9 [GL:G12794]
DRUG        Fluorouracil [DG:DG00687]
            Streptozocin [DR:D05932]
            Gemcitabine [DG:DG00688]
            Leucovorin [DR:D01211]
COMMENT     ICD-O: 8160/3, Tumor type: Intrahepatic cholangiocarcinoma
DBLINKS     ICD-10: C22
            MeSH: D018281
REFERENCE   PMID:15218306 (gene, tumor type)
  AUTHORS   Olnes MJ, Erlich R.
  TITLE     A review and update on cholangiocarcinoma.
  JOURNAL   Oncology 66:167-79 (2004)
REFERENCE   PMID:17069969 (gene)
  AUTHORS   Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H, Alpini G.
  TITLE     Molecular pathology of biliary tract cancers.
  JOURNAL   Cancer Lett 250:155-67 (2007)
REFERENCE   PMID:15887157 (gene)
  AUTHORS   Lazaridis KN, Gores GJ.
  TITLE     Cholangiocarcinoma.
  JOURNAL   Gastroenterology 128:1655-67 (2005)
REFERENCE   PMID:15928434 (carcinogen)
  AUTHORS   Khurana S, Dubey ML, Malla N.
  TITLE     Association of parasitic infections and cancers.
  JOURNAL   Indian J Med Microbiol 23:74-9 (2005)
REFERENCE   PMID:15744742 (carcinogen)
  AUTHORS   Herrera LA, Benitez-Bribiesca L, Mohar A, Ostrosky-Wegman P.
  TITLE     Role of infectious diseases in human carcinogenesis.
  JOURNAL   Environ Mol Mutagen 45:284-303 (2005)
REFERENCE   PMID:10564925 (carcinogene)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:12556326 (carcinogen)
  AUTHORS   Harrison JD, Muirhead CR.
  TITLE     Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
  JOURNAL   Int J Radiat Biol 79:1-13 (2003)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00047                      Disease
NAME        Gallbladder cancer
DESCRIPTION Gallbladder cancer (GBC) is a relatively uncommon neoplasm, however its prognosis is poor with less than a 5% 5-year survival rate. There are considerable geographic differences in its incidence and etiology. Two main pathways of GBC pathogenesis have been identified. The most common is associated with gallstones and chronic inflammation of the gallbladder, whereas a second, less frequent pathway is associated with a congenital abnormality of the pancreatic bile-duct junction, which is particularly common in Japan. TP53 inactivation has an important and early role in GBC associated with gallstones and chronic inflammation. Although KRAS mutations are rarely detected in GBC associated with gallstones, they are frequent and early events in tumors associated with congenital abnormality of the pancreatic bile-duct junction.
CATEGORY    Cancer
GENE        p53 (mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            K-ras (mutation) [HSA:3845] [KO:K07827]
            APC (mutation) [HSA:324] [KO:K02085]
MARKER      CA19-9 [GL:G12794]
DRUG        Fluorouracil [DG:DG00687]
            Mitomycin [DR:D00208]
            Doxorubicin [DG:DG00696]
            Gemcitabine [DG:DG00688]
            Leucovorin [DR:D01211]
COMMENT     ICD-O: 8140/3, Tumor type: Adenocarcinoma
DBLINKS     ICD-10: C23
            MeSH: D005706
REFERENCE   PMID:15343276 (description, gene, tumor type)
  AUTHORS   Wistuba II, Gazdar AF.
  TITLE     Gallbladder cancer: lessons from a rare tumour.
  JOURNAL   Nat Rev Cancer 4:695-706 (2004)
REFERENCE   (gene)
  AUTHORS   Hansel DE, Argani P.
  TITLE     Pathology of the gallbladder: a concise review.
  JOURNAL   Current Diagnostic Pathology 10:304-317 (2004)
REFERENCE   PMID:10526058 (gene)
  AUTHORS   Wistuba II, Albores-Saavedra J.
  TITLE     Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma.
  JOURNAL   J Hepatobiliary Pancreat Surg 6:237-44 (1999)
REFERENCE   PMID:11410326 (gene)
  AUTHORS   Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, Kim SW, Kim WH, Yoon YB, Kim CY.
  TITLE     Genetic alterations in gallbladder adenoma, dysplasia and carcinoma.
  JOURNAL   Cancer Lett 169:59-68 (2001)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00048                      Disease
NAME        Hepatocellular carcinoma
DESCRIPTION Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. Chronic infections with the hepatitis B virus (HBV) and the hepatitis C virus (HCV) have been implicated in about 80% of cases worldwide, and other known environmental risk factors, including alcohol abuse and dietary intake of aflatoxin B1, might synergize with viral infections. Recent studies have discovered genetic and epigenetic changes involved in the molecular pathogenesis of HCC, including mutations in Rb1, AXIN1, p53, IGFR-II/M6PR, p16, E-Cadherin, and PTEN. The most frequently mutated genes in HCC include p53 and beta-catenin, although mutation prevalence varies greatly depending on etiology.
CATEGORY    Cancer
GENE        PTEN (mutation) [HSA:5728] [KO:K01110]
            H-ras (mutation) [HSA:3265] [KO:K02833]
            K-ras (mutation) [HSA:3845] [KO:K07827]
            N-ras (mutation) [HSA:4893] [KO:K07828]
            AXIN1 (mutation) [HSA:8312] [KO:K02157]
            beta-Catenin (mutation) [HSA:1499] [KO:K02105]
            p53 (mutation) [HSA:7157] [KO:K04451]
            p73 (mutation) [HSA:7161] [KO:K10148]
            RB1 (mutation) [HSA:5925] [KO:K06618]
            p16/INK4A (mutation) [HSA:1029] [KO:K06621]
            E-Cadherin (mutation) [HSA:999] [KO:K05689]
            IGF2R (mutation) [HSA:3482] [KO:K06564]
CARCINOGEN  Aflatoxins (naturally occurring mixtures of) [CPD:C06800]
            Alcoholic beverages
            Opisthorchis viverrini (infection with)
            Radium-224 and its decay products [CPD:C16455]
            *Chimney sweeping
            *2,3,7,8-Tetrachlorodibenzo-para-dioxin [CPD:C07557]
            *Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium232 dioxide
            *Tobacco smoking and tobacco smoke
            *: Although this is a risk factor for liver cancer in general, the strength of association with different histological tumor types is not well understood.
PATHOGEN    Hepatitis B virus [GN:T40004] (chronic infection with)
            Hepatitis C virus [GN:T40066] (chronic infection with)
MARKER      Alpha-fetoprotein (AFP) [HSA:174] [KO:K16144]
DRUG        Doxorubicin [DG:DG00696]
COMMENT     ICD-O: 8170/3, Tumor type: Hepatocellular carcinoma (liver cell carcinoma)
DBLINKS     ICD-10: C22
            MeSH: D006528
REFERENCE   PMID:17295177 (gene, tumor type)
  AUTHORS   Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM.
  TITLE     Genomics and signaling pathways in hepatocellular carcinoma.
  JOURNAL   Semin Liver Dis 27:55-76 (2007)
REFERENCE   PMID:11935086 (gene, tumor type)
  AUTHORS   Rocken C, Carl-McGrath S.
  TITLE     Pathology and pathogenesis of hepatocellular carcinoma.
  JOURNAL   Dig Dis 19:269-78 (2001)
REFERENCE   PMID:17051452 (tumor type)
  AUTHORS   Spangenberg HC, Thimme R, Blum HE.
  TITLE     Serum markers of hepatocellular carcinoma.
  JOURNAL   Semin Liver Dis 26:385-90 (2006)
REFERENCE   PMID:12149612 (gene)
  AUTHORS   Thorgeirsson SS, Grisham JW.
  TITLE     Molecular pathogenesis of human hepatocellular carcinoma.
  JOURNAL   Nat Genet 31:339-46 (2002)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:15757802 (carcinogen)
  AUTHORS   McGlynn KA, London WT.
  TITLE     Epidemiology and natural history of hepatocellular carcinoma.
  JOURNAL   Best Pract Res Clin Gastroenterol 19:3-23 (2005)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:11285186 (carcinogen)
  AUTHORS   Smela ME, Currier SS, Bailey EA, Essigmann JM.
  TITLE     The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis.
  JOURNAL   Carcinogenesis 22:535-45 (2001)
REFERENCE   PMID:15928434 (carcinogen)
  AUTHORS   Khurana S, Dubey ML, Malla N.
  TITLE     Association of parasitic infections and cancers.
  JOURNAL   Indian J Med Microbiol 23:74-9 (2005)
REFERENCE   PMID:10564925 (carcinogen)
  AUTHORS   Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  TITLE     Malignancies in patients treated with high doses of radium-224.
  JOURNAL   Radiat Res 152:S3-7 (1999)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:15660110 (carcinogen)
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
REFERENCE   PMID:12556326 (carcinogen)
  AUTHORS   Harrison JD, Muirhead CR.
  TITLE     Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
  JOURNAL   Int J Radiat Biol 79:1-13 (2003)
REFERENCE   (drug)
  AUTHORS   Skeel RT (ed).
  TITLE     Handbook of Cancer Chemotherapy, Sixth Edition
  JOURNAL   Lippincott Williams & Wilkins (2003)
///
ENTRY       H00049                      Disease
NAME        Myxoid liposarcoma
DESCRIPTION Liposarcoma(LS) represents the most common soft-tissue sarcoma of adults and occurs most often in the thigh and retroperitoneum. LSs are subclassified into well-differentiated, myxoid, round cell, and pleomorphic types. The myxoid type, the most common subtype, accounts for approximately 40% to 54% of all liposarcomas. The karyotypic hallmark of myxoid LS is the t(12;16)(q13;p11), present cytogenetically in >90% of the cases. The translocation leads to the fusion of the DDIT3(CHOP) and FUS(TLS) genes at 12q13 and 16p11, respectively, and the generation of a FUS-DDIT3 hybrid protein. In 4 cases of myxoid LS, a variant chromosomal translocation has been described, t(12;22), in which DDIT3 fuses instead with EWSR1(EWS), a gene highly related to TLS.
CATEGORY    Cancer
GENE        FUS-DDIT3 (translocation) [HSA:2521 1649] [KO:K13098 K04452]
            EWSR1-DDIT3 (translocation) [HSA:2130 1649] [KO:K13209 K04452]
MARKER      Ki67 [HSA:4288]
            FUS-DDIT3 (translocation) [HSA:2521 1649]
            Vimentin [HSA:7431]
            S-100 [HSA:6271]
DRUG        Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Ifosfamide [DR:D00343]
            Mesna [DR:D01459]
            Imatinib [DG:DG00710]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 8852/3, Tumor type: Myxoid liposarcoma
DBLINKS     ICD-10: C49
            MeSH: D018208
REFERENCE   PMID:11229517 (description, gene)
  AUTHORS   Antonescu CR, Elahi A, Humphrey M, Lui MY, Healey JH, Brennan MF, Woodruff JM, Jhanwar SC, Ladanyi M
  TITLE     Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas.
  JOURNAL   J Mol Diagn 2:132-8 (2000)
REFERENCE   PMID:11378650 (gene, tumor type)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:12951587 (gene)
  AUTHORS   Helman LJ, Meltzer P.
  TITLE     Mechanisms of sarcoma development.
  JOURNAL   Nat Rev Cancer 3:685-94 (2003)
REFERENCE   PMID:12890805 (marker)
  AUTHORS   Tateishi U, Hasegawa T, Beppu Y, Kawai A, Moriyama N.
  TITLE     Prognostic significance of grading (MIB-1 system) in patients with myxoid liposarcoma.
  JOURNAL   J Clin Pathol 56:579-82 (2003)
REFERENCE   PMID:7817937 (marker)
  AUTHORS   Gibas Z, Miettinen M, Limon J, Nedoszytko B, Mrozek K, Roszkiewicz A, Rys J, Niezabitowski A, Debiec-Rychter M.
  TITLE     Cytogenetic and immunohistochemical profile of myxoid liposarcoma.
  JOURNAL   Am J Clin Pathol 103:20-6 (1995)
REFERENCE   PMID:7805034 (marker)
  AUTHORS   Knight JC, Renwick PJ, Cin PD, Van den Berghe H, Fletcher CD.
  TITLE     Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis.
  JOURNAL   Cancer Res 55:24-7 (1995)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00050                      Disease
NAME        Synovial sarcoma
DESCRIPTION Synovial sarcomas account for 7% to 10% of all human soft-tissue sarcomas. The tumors arise at any age, but affect mainly young adults and more commonly males. Clinically, they appear as deep-seated slowly growing masses. In more than half of the cases, metastases develop, primarily to the lungs but also to the lymph nodes and bone marrow. A specific translocation, t(X; 18)(p11.2; q11.2), is found in more than 90% of reported synovial sarcoma, including biphasic, monophasic, and poorly differentiated tumors. The breakpoints of the t(X; 18) have been cloned and shown to involve the fusion of the SYT gene at 18q11 to either of two highly homologous genes at Xp11 called SSX1 and SSX2. The SYT-SSX1 fusion is associated with biphasic morphology and a worse prognosis, whereas the SYT-SSX2 fusion tends to show monophasic morphology and better outcome.
CATEGORY    Cancer
GENE        SYT-SSX1 (translocation) [HSA:6760 6756] [KO:K15623 K15624]
            SYT-SSX2 (translocation) [HSA:6760 6757] [KO:K15623 K15625]
            IGF-IR (overexpression) [HSA:3480] [KO:K05087]
MARKER      SYT-SSX1 (translocation) [HSA:6760 6756]
            SYT-SSX2 (translocation) [HSA:6760 6757]
            Ki-67 [HSA:4288]
DRUG        Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Ifosfamide [DR:D00343]
            Mesna [DR:D01459]
            Imatinib [DG:DG00710]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 9040/3, Tumor type: Synovial sarcoma
DBLINKS     ICD-10: C49
            MeSH: D013584
REFERENCE   PMID:11107170 (description, gene)
  AUTHORS   dos Santos NR, de Bruijn DR, van Kessel AG
  TITLE     Molecular mechanisms underlying human synovial sarcoma development.
  JOURNAL   Genes Chromosomes Cancer 30:1-14 (2001)
REFERENCE   PMID:11378650 (gene, tumor type)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:12951587 (gene)
  AUTHORS   Helman LJ, Meltzer P.
  TITLE     Mechanisms of sarcoma development.
  JOURNAL   Nat Rev Cancer 3:685-94 (2003)
REFERENCE   PMID:10516379 (gene)
  AUTHORS   Fisher C.
  TITLE     Current aspects of the pathology of soft tissue sarcomas.
  JOURNAL   Semin Radiat Oncol 9:315-27 (1999)
REFERENCE   PMID:10824918 (marker)
  AUTHORS   Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N, Eimoto T.
  TITLE     Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma.
  JOURNAL   Mod Pathol 13:482-8 (2000)
REFERENCE   PMID:11826189 (marker)
  AUTHORS   Bijwaard KE, Fetsch JF, Przygodzki R, Taubenberger JK, Lichy JH.
  TITLE     Detection of SYT-SSX fusion transcripts in archival synovial sarcomas by real-time reverse transcriptase-polymerase chain reaction.
  JOURNAL   J Mol Diagn 4:59-64 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00051                      Disease
NAME        Alveolar soft part sarcoma
DESCRIPTION Alveolar soft part sarcoma (ASPS) is a rare, histologically distinctive soft-tissue sarcoma typically occurring in children and young adults. Although it displays a relatively indolent clinical course, the ultimate prognosis is poor and is often characterised by late metastases. ASPS is characterised by an unbalanced translocation: der(17)t(X:17)(p11;q25). This translocation causes the fusion of the TEF3 (transcription factor binding to IGHM enhancer 3) with a novel gene at 17q25, named ASPL. Translocation between chromosomes X and 17 is seen in all the tested cases, implicating transcriptional deregulation in the pathogenesis of this tumor.
CATEGORY    Cancer
GENE        ASPL-TFE3 (translocation) [HSA:79058 7030] [KO:K15627 K09105]
MARKER      ASPL-TFE3 (translocation) [HSA:79058 7030]
DRUG        Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Ifosfamide [DR:D00343]
            Mesna [DR:D01459]
            Imatinib [DG:DG00710]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 9581/3, Tumor type: Alveolar soft part sarcoma
DBLINKS     ICD-10: C49
            MeSH: D018234
REFERENCE   PMID:17516754 (description, gene)
  AUTHORS   Zarrin-Khameh N, Kaye KS
  TITLE     Alveolar soft part sarcoma.
  JOURNAL   Arch Pathol Lab Med 131:488-91 (2007)
REFERENCE   PMID:12951587 (gene, tumor type)
  AUTHORS   Helman LJ, Meltzer P.
  TITLE     Mechanisms of sarcoma development.
  JOURNAL   Nat Rev Cancer 3:685-94 (2003)
REFERENCE   PMID:11378650 (gene)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:17071801 (gene, marker)
  AUTHORS   Folpe AL, Deyrup AT.
  TITLE     Alveolar soft-part sarcoma: a review and update.
  JOURNAL   J Clin Pathol 59:1127-32 (2006)
REFERENCE   PMID:12766578 (marker)
  AUTHORS   Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M.
  TITLE     Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
  JOURNAL   Am J Surg Pathol 27:750-61 (2003)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00052                      Disease
NAME        Clear cell sarcoma of soft tissue
DESCRIPTION Soft tissue sarcomas account for only about 1% of all malignant diseases and there are less than 8,700 new cases per year in the United States. Clear cell sarcoma (CCS), a highly malignant tumor of deep soft tissues is perhaps the rarest of these. CCS is characterized by the translocation t(12;22)(q13;q12). This translocation rearranges the ATF1 gene at 12q13 and the EWSR1 gene at 22q12, originating an EWSR1/ATF1 fusion gene. Given its specificity, this genetic aberration is considered pathognomonic for CCS and can be used as a diagnostic marker of this neoplasia.
CATEGORY    Cancer
GENE        EWSR1-ATF1 (translocation) [HSA:2130 466] [KO:K13209 K09053]
MARKER      EWSR1-ATF1 (translocation) [HSA:2130 466]
            S-100 [HSA:6271]
            HMB-45 (antibody)
            MART-1 [HSA:2315]
DRUG        Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Ifosfamide [DR:D00343]
            Mesna [DR:D01459]
            Imatinib [DG:DG00710]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 9044/3, Tumor type: Clear cell sarcoma of soft tissue
DBLINKS     ICD-10: C49
            MeSH: D018227
REFERENCE   PMID:17192915 (description)
  AUTHORS   Malchau SS, Hayden J, Hornicek F, Mankin HJ
  TITLE     Clear cell sarcoma of soft tissues.
  JOURNAL   J Surg Oncol 95:519-22 (2007)
REFERENCE   PMID:12935923 (description, gene, marker)
  AUTHORS   Teixeira MR, Ribeiro FR, Cerveira N, Torres L, Amaro T, Henrique R, Lopes C
  TITLE     Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) and type 1 EWS/ATF1.
  JOURNAL   Cancer Genet Cytogenet 145:121-5 (2003)
REFERENCE   PMID:11378650 (gene, tumor type)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:12951587 (gene)
  AUTHORS   Helman LJ, Meltzer P.
  TITLE     Mechanisms of sarcoma development.
  JOURNAL   Nat Rev Cancer 3:685-94 (2003)
REFERENCE   PMID:10516379 (gene)
  AUTHORS   Fisher C.
  TITLE     Current aspects of the pathology of soft tissue sarcomas.
  JOURNAL   Semin Radiat Oncol 9:315-27 (1999)
REFERENCE   PMID:15677980 (marker)
  AUTHORS   Kim YC, Vandersteen DP, Jung HG.
  TITLE     Myxoid clear cell sarcoma.
  JOURNAL   Am J Dermatopathol 27:51-5 (2005)
REFERENCE   PMID:11892024 (marker)
  AUTHORS   Tong TR, Chow TC, Chan OW, Lee KC, Yeung SH, Lam A, Yu CK.
  TITLE     Clear-cell sarcoma diagnosis by fine-needle aspiration: cytologic, histologic, and ultrastructural features; potential pitfalls; and literature review.
  JOURNAL   Diagn Cytopathol 26:174-80 (2002)
REFERENCE   PMID:11863218 (marker)
  AUTHORS   Creager AJ, Pitman MB, Geisinger KR.
  TITLE     Cytologic features of clear cell sarcoma (malignant melanoma) of soft parts: a study of fine-needle aspirates and exfoliative specimens.
  JOURNAL   Am J Clin Pathol 117:217-24 (2002)
REFERENCE
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00053                      Disease
NAME        Extraskeletal myxoid chondrosarcoma
DESCRIPTION Extraskeletal myxoid chondrosarcoma (EMC) is a unique, rare soft-tissue tumor with prominent myxoid morphology. The tumor most commonly develops in deep parts of the proximal extremities and limb girdles in middle-aged adults, and there is a predilection for male patients. Currently, a chromosomal translocation t(9;22)(q22;q12) and the resultant fusion gene, EWSR1-NR4A3, has been defined in approximately 75% of EMC. More recently, another fusion gene, TAF15-NR4A3, resulting from t(9;17)(q22;q11.2), has been identified. The abnormal proteins resulting from these fusion genes aberrantly affect gene transcription and cellular signaling pathways thought to be responsible for initiating sarcoma formation.
CATEGORY    Cancer
GENE        EWSR1-NR4A3 (translocation) [HSA:2130 8013] [KO:K13209 K08559]
            TAF15-NR4A3 (translocation) [HSA:8148 8013] [KO:K14651 K08559]
MARKER      S-100 [HSA:6271]
            Synaptophysin [HSA:6855]
            Vimentin [HSA:7431]
            EWSR1-NR4A3 (translocation) [HSA:2130 8013]
DRUG        Doxorubicin [DG:DG00696]
            Dacarbazine [DG:DG00680]
            Ifosfamide [DR:D00343]
            Mesna [DR:D01459]
            Imatinib [DG:DG00710]
            Sunitinib [DG:DG00712]
COMMENT     ICD-O: 9231/3, Tumor type: Extraskeletal myxoid chondrosarcoma
DBLINKS     ICD-10: C41
            MeSH: D002813
REFERENCE   PMID:12599237 (gene, description)
  AUTHORS   Kawaguchi S, Wada T, Nagoya S, Ikeda T, Isu K, Yamashiro K, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Umeda T, Yoshikawa H, Hasegawa T
  TITLE     Extraskeletal myxoid chondrosarcoma: a Multi-Institutional Study of 42 Cases in Japan.
  JOURNAL   Cancer 97:1285-92 (2003)
REFERENCE   PMID:11378650 (gene, tumor type)
  AUTHORS   Letson GD, Muro-Cacho CA.
  TITLE     Genetic and molecular abnormalities in tumors of the bone and soft tissues.
  JOURNAL   Cancer Control 8:239-51 (2001)
REFERENCE   PMID:12951587 (gene)
  AUTHORS   Helman LJ, Meltzer P.
  TITLE     Mechanisms of sarcoma development.
  JOURNAL   Nat Rev Cancer 3:685-94 (2003)
REFERENCE   PMID:10516379 (gene)
  AUTHORS   Fisher C.
  TITLE     Current aspects of the pathology of soft tissue sarcomas.
  JOURNAL   Semin Radiat Oncol 9:315-27 (1999)
REFERENCE   PMID:11679947 (marker)
  AUTHORS   Okamoto S, Hisaoka M, Ishida T, Imamura T, Kanda H, Shimajiri S, Hashimoto H.
  TITLE     Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases.
  JOURNAL   Hum Pathol 32:1116-24 (2001)
REFERENCE   PMID:10955458 (marker)
  AUTHORS   Oliveira AM, Sebo TJ, McGrory JE, Gaffey TA, Rock MG, Nascimento AG.
  TITLE     Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases.
  JOURNAL   Mod Pathol 13:900-8 (2000)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00054                      Disease
NAME        Nasopharyngeal cancer
DESCRIPTION Nasopharyngeal carcinoma (NPC) is a rare disease in most parts of the world, with an age-standardised annual incidence of less than 1 per 100000. However, in Southern China, parts of Southeast Asia and the Mediterranean basin, NPC is an endemic disease with an incidence of 10-30 per 100000. Genome-wide studies have unravelled multiple chromosomal abnormalities with involvement of specific oncogenes and tumor suppressor genes. Alterations of genes such as Ras association domain family 1A (RASSF1A), p16/INK4A, p14/ARF suggest that multiple cellular pathways were dysregulated in the NPC cells. Studies on the precancerous lesions revealed early genetic changes and a critical role of Epstein- Barr virus (EBV) latent infection in the development of this cancer.
CATEGORY    Cancer
GENE        RASSF1 (promoter hypermethylation) [HSA:11186] [KO:K09850]
            p16/INK4A (promoter hypermethylation) [HSA:1029] [KO:K06621]
            Bcl-2 (overexpression) [HSA:596] [KO:K02161]
            EDNRB (promoter hypermethylation) [HSA:1910] [KO:K04198]
            TSLC1 (promoter hypermethylation) [HSA:23705] [KO:K06781]
            E-cadherin (decreased expression) [HSA:999] [KO:K05689]
CARCINOGEN  Formaldehyde [CPD:C00067]
            Salted fish (Chinese-style)
            Tobacco smoking and tobacco smoke
            Wood dust
PATHOGEN    Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
MARKER      EBV-DNA
DRUG        Cisplatin [DR:D00275]
            Fluorouracil [DG:DG00687]
            Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
            Docetaxel[DG:DG00694]
            Cetuximab [DR:D03455]
COMMENT     ICD-O: 8072/3, Tumor type: Non-keratinizing carcinoma
            ICD-O: 8071/3, Tumor type: Keratinizing squamous cell carcinoma
            ICD-O: 8083/3, Tumor type: Basaloid squamous cell carcinoma
DBLINKS     ICD-10: C11
            MeSH: D009303
REFERENCE   PMID:15958470 (description, carcinogen)
  AUTHORS   Chan AT
  TITLE     Head and neck cancer: treatment of nasopharyngeal cancer.
  JOURNAL   Ann Oncol 16 Suppl 2:ii265-8 (2005)
REFERENCE   PMID:12450731 (description, gene, carcinogen)
  AUTHORS   Lo KW, Huang DP.
  TITLE     Genetic and epigenetic changes in nasopharyngeal carcinoma.
  JOURNAL   Semin Cancer Biol 12:451-62 (2002)
REFERENCE   PMID:15510157 (gene, tumor type)
  AUTHORS   Young LS, Rickinson AB.
  TITLE     Epstein-Barr virus: 40 years on.
  JOURNAL   Nat Rev Cancer 4:757-68 (2004)
REFERENCE   PMID:15760280 (carcinogen)
  AUTHORS   Schottenfeld D, Beebe-Dimmer JL.
  TITLE     Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  JOURNAL   Annu Rev Public Health 26:37-60 (2005)
REFERENCE   PMID:17033133 (carcinogen)
  AUTHORS   Binetti R, Costamagna FM, Marcello I.
  TITLE     Development of carcinogenicity classifications and evaluations: the case of formaldehyde.
  JOURNAL   Ann Ist Super Sanita 42:132-43 (2006)
REFERENCE   PMID:16140628 (carcinogen)
  AUTHORS   Cogliano VJ, Grosse Y, Baan RA, Straif K, Secretan MB, El Ghissassi F.
  TITLE     Meeting report: summary of IARC monographs on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol.
  JOURNAL   Environ Health Perspect 113:1205-8 (2005)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:12176778 (marker)
  AUTHORS   Chan AT, Teo PM, Johnson PJ.
  TITLE     Nasopharyngeal carcinoma.
  JOURNAL   Ann Oncol 13:1007-15 (2002)
REFERENCE   PMID:12450734 (marker)
  AUTHORS   Chan KC, Lo YM.
  TITLE     Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma.
  JOURNAL   Semin Cancer Biol 12:489-96 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00055                      Disease
NAME        Laryngeal cancer
DESCRIPTION Laryngeal cancer is one of the most common malignancies in Europe, with about 52,000 new cases per year, 90% of them occurring in men. Smoke and alcohol represent the major behavioral risk factors. Of all laryngeal cancers, some 95% are squamous cell carcinomas. Some molecular events have been described in laryngeal squamous cell carcinoma (LSCC). Although tumor suppressor inactivation of p53 and p16 is common in these tumors (about 50% each), oncogenic activation is less well characterized. Cyclin D1 and epidermal growth factor receptor amplification have been reported in one-third and one-quarter of LSCCs, respectively, both related to advanced stages, whereas c-myc could be amplified in 13% of cases although without associated overexpression.
CATEGORY    Cancer
GENE        p53 (mutation) [HSA:7157] [KO:K04451]
            p16/INK4A (mutation, LOH, hypermethylation) [HSA:1029] [KO:K06621]
            Cyclin D1 (amplification) [HSA:595] [KO:K04503]
            EGFR (amplification) [HSA:1956] [KO:K04361]
            c-MYC (amplification) [HSA:4609] [KO:K04377]
            Cyclin E (amplification) [HSA:898 9134] [KO:K06626]
CARCINOGEN  Alcoholic beverages
            Betel quid with tobacco
            Coal-tar pitches [CPD:C16451]
            Isopropyl alcohol manufacture (strong-acid process)
            Mineral oils, untreated and mildly treated
            Paving and roofing with coal-tar pitch
            Strong-inorganic-acid mists containing sulfuric acid
            Tobacco smoking and tobacco smoke
MARKER      p53 [HSA:7157]
            Cyclin D1 [HSA:595]
            EGFR [HSA:1956]
DRUG        Cisplatin [DR:D00275]
            Fluorouracil [DG:DG00687]
            Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
            Docetaxel[DG:DG00694]
            Cetuximab [DR:D03455]
COMMENT     ICD-O: 8070/3, Tumor type: Squamous cell carcinoma
DBLINKS     ICD-10: C32
            MeSH: D007822
REFERENCE   PMID:12853099 (description, gene, tumor type)
  AUTHORS   Licitra L, Bernier J, Grandi C, Locati L, Merlano M, Gatta G, Lefebvre JL
  TITLE     Cancer of the larynx.
  JOURNAL   Crit Rev Oncol Hematol 47:65-80 (2003)
REFERENCE   PMID:12536308 (description, gene, tumor type)
  AUTHORS   Nadal A, Cardesa A.
  TITLE     Molecular biology of laryngeal squamous cell carcinoma.
  JOURNAL   Virchows Arch 442:1-7 (2003)
REFERENCE   PMID:17530489 (carcinogen)
  AUTHORS   Abnet CC.
  TITLE     Carcinogenic food contaminants.
  JOURNAL   Cancer Invest 25:189-96 (2007)
REFERENCE   PMID:17646865 (carcinogen)
  AUTHORS   Seitz HK, Stickel F.
  TITLE     Molecular mechanisms of alcohol-mediated carcinogenesis.
  JOURNAL   Nat Rev Cancer 7:599-612 (2007)
REFERENCE   PMID:15957167 (carcinogen)
  AUTHORS   Lee KW, Kuo WR, Tsai SM, Wu DC, Wang WM, Fang FM, Chiang FY, Ho KY, Wang LF, Tai CF, Kao EL, Chou SH, Lee CH, Chai CY, Ko YC.
  TITLE     Different impact from betel quid, alcohol and cigarette: risk factors for pharyngeal and laryngeal cancer.
  JOURNAL   Int J Cancer 117:831-6 (2005)
REFERENCE   PMID:9498904 (carcinogen)
  AUTHORS   Boffetta P, Jourenkova N, Gustavsson P.
  TITLE     Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
  JOURNAL   Cancer Causes Control 8:444-72 (1997)
REFERENCE   PMID:8189372 (carcinogen)
  AUTHORS   Wong O, Foliart DE.
  TITLE     Epidemiological factors of cancer in Louisiana.
  JOURNAL   J Environ Pathol Toxicol Oncol 12:171-83 (1993)
REFERENCE   PMID:9498901 (carcinogen)
  AUTHORS   Tolbert PE.
  TITLE     Oils and cancer.
  JOURNAL   Cancer Causes Control 8:386-405 (1997)
REFERENCE   PMID:10723042 (carcinogen)
  AUTHORS   Stern FB, Ruder AM, Chen G.
  TITLE     Proportionate mortality among unionized roofers and waterproofers.
  JOURNAL   Am J Ind Med 37:478-92 (2000)
REFERENCE   PMID:17032693 (carcinogen)
  AUTHORS   Hsu YM, Wu CY, Lundgren DA, Birky BK.
  TITLE     Size-resolved sulfuric acid mist concentrations at phosphate fertilizer manufacturing facilities in Florida.
  JOURNAL   Ann Occup Hyg 51:81-9 (2007)
REFERENCE   PMID:9498905 (carcinogen)
  AUTHORS   Blair A, Kazerouni N.
  TITLE     Reactive chemicals and cancer.
  JOURNAL   Cancer Causes Control 8:473-90 (1997)
REFERENCE   PMID:15489140 (carcinogen)
  AUTHORS   Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
  TITLE     Environmental and chemical carcinogenesis.
  JOURNAL   Semin Cancer Biol 14:473-86 (2004)
REFERENCE   PMID:15552776 (carcinogen)
  AUTHORS   Sasco AJ, Secretan MB, Straif K.
  TITLE     Tobacco smoking and cancer: a brief review of recent epidemiological evidence.
  JOURNAL   Lung Cancer 45 Suppl 2:S3-9 (2004)
REFERENCE   PMID:10764231 (marker)
  AUTHORS   Greenman J, Homer JJ, Stafford ND.
  TITLE     Markers in cancer of the larynx and pharynx.
  JOURNAL   Clin Otolaryngol Allied Sci 25:9-18 (2000)
REFERENCE   PMID:15763643 (marker)
  AUTHORS   Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M.
  TITLE     Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach.
  JOURNAL   Eur J Cancer 41:683-93 (2005)
REFERENCE   PMID:11016683 (marker)
  AUTHORS   Nylander K, Dabelsteen E, Hall PA.
  TITLE     The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
  JOURNAL   J Oral Pathol Med 29:413-25 (2000)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H00056                      Disease
NAME        Alzheimer's disease (AD)
DESCRIPTION Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.
CATEGORY    Neurodegenerative disease
GENE        (AD1) APP; amyloid beta (A4) protein (mutation) [HSA:351] [KO:K04520]
            (AD2) APOE; apolipoprotein E (mutation) [HSA:348] [KO:K04524]
            (AD3) PSEN1; presenilin 1 (mutation) [HSA:5663] [KO:K04505]
            (AD4) PSEN2; presenilin 2 (mutation) [HSA:5664] [KO:K04522]
MARKER      N-acetylaspartate (reduction)
DRUG        Donepezil [DG:DG00983] acetylcholinesterase (AChE) inhibitor
            Galantamine [DG:DG00985] acetylcholinesterase (AChE) inhibitor
            Rivastigmine [DG:DG00984] acetylcholinesterase (AChE) inhibitor
            Memantine [DG:DG00986] NMDA receptor antagonist
COMMENT     Disease class: tauopathy
            Affected region: hippocampus, cerebral cortex
            Microscopic lesion: amyloid plaques, neurofibrillary tangles, Lewy bodies (seen in Lewy body variant)
DBLINKS     ICD-10: G30
            MeSH: D000544
            OMIM: 104300 104310 607822 606889
REFERENCE   PMID:19679070 (AD2)
  AUTHORS   Kim J, Basak JM, Holtzman DM
  TITLE     The role of apolipoprotein E in Alzheimer's disease.
  JOURNAL   Neuron 63:287-303 (2009)
REFERENCE   PMID:19524503
  AUTHORS   Kim D, Tsai LH
  TITLE     Bridging physiology and pathology in AD.
  JOURNAL   Cell 137:997-1000 (2009)
REFERENCE   PMID:18802446
  AUTHORS   Bertram L, Tanzi RE
  TITLE     Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.
  JOURNAL   Nat Rev Neurosci 9:768-78 (2008)
REFERENCE   PMID:18414205
  AUTHORS   Bird TD
  TITLE     Genetic aspects of Alzheimer disease.
  JOURNAL   Genet Med 10:231-9 (2008)
REFERENCE   PMID:18370236 (drug)
  AUTHORS   Cacabelos R
  TITLE     Pharmacogenomics in Alzheimer's disease.
  JOURNAL   Methods Mol Biol 448:213-357 (2008)
REFERENCE   PMID:17158517
  AUTHORS   Thomas P, Fenech M
  TITLE     A review of genome mutation and Alzheimer's disease.
  JOURNAL   Mutagenesis 22:15-33 (2007)
REFERENCE   PMID:17082447
  AUTHORS   Goedert M, Spillantini MG
  TITLE     A century of Alzheimer's disease.
  JOURNAL   Science 314:777-81 (2006)
REFERENCE   PMID:16631796 (AD2)
  AUTHORS   Fazekas F, Enzinger C, Ropele S, Schmidt H, Schmidt R, Strasser-Fuchs S
  TITLE     The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis.
  JOURNAL   J Neurol Sci 245:35-9 (2006)
REFERENCE   PMID:12788204
  AUTHORS   Rocchi A, Pellegrini S, Siciliano G, Murri L.
  TITLE     Causative and susceptibility genes for Alzheimer's disease: a review.
  JOURNAL   Brain Res Bull 61:1-24 (2003)
REFERENCE   PMID:1303291 (AD3)
  AUTHORS   Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Diaz P, Rossor M, Crook R, Hardy J, Duff K, et al.
  TITLE     A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene.
  JOURNAL   Nat Genet 2:340-2 (1992)
REFERENCE   PMID:7651536 (AD4)
  AUTHORS   Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al.
  TITLE     Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.
  JOURNAL   Nature 376:775-8 (1995)
///
ENTRY       H00057                      Disease
NAME        Parkinson's disease (PD)
DESCRIPTION Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that results primarily from the death of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc). Mutations in alpha-synuclein, UCHL1 (a ubiquitin carboxy-terminal hydrolase L1), parkin, DJ1 (a parkin-associated protein involved with oxidative stress), and PINK1 (a putative serine threonine kinase) are known to cause early-onset PD. Mutations or altered expression of these proteins contributes to the damage and subsequent loss of DA neurons through common mechanisms that result in proteasome dysfunction, mitochondrial impairment, and oxidative stress. The demise of DA neurons located in the SNc leads to a drop in the dopaminergic input to the striatum. This results in a reduced activation of the direct pathway and in a disinhibition of the indirect pathway, which is associated with the elevation of adenosine A2A receptor transmission. Such unbalanced activity of the striatal output pathway is at the basis of the motor impairment observed in PD.
CATEGORY    Neurodegenerative disease
GENE        (PARK1/PARK4) SNCA (mutation/duplication, triplication) [HSA:6622] [KO:K04528]
            (PARK2) Parkin (mutation, genomic rearrangement) [HSA:5071] [KO:K04556]
            (PARK5) UCHL1 (mutation) [HSA:7345] [KO:K05611]
            (PARK6) PINK1 (mutation) [HSA:65018] [KO:K05688]
            (PARK7) DJ1 (mutation) [HSA:11315] [KO:K05687]
            (PARK8) LRRK2 (mutation) [HSA:120892] [KO:K08844]
            (PARK9) ATP13A2 (mutation) [HSA:23400] [KO:K13526]
            (PARK11) GIGYF2 (mutation) [HSA:26058] [KO:K18730]
            (PARK13) HTRA2 (mutation) [HSA:27429] [KO:K08669]
            (PARK14) PLA2G6 (mutation) [HSA:8398] [KO:K16343]
            (PARK15) FBXO7 (mutation) [HSA:25793] [KO:K10293]
            (PARK17) VPS35 (mutation) [HSA:55737] [KO:K18468]
            (PARK18) EIF4G1 (mutation) [HSA:1981] [KO:K03260]
            (PARK19) DNAJC16 (mutation) [HSA:23341] [KO:K09536]
            (PARK22) CHCHD2 (mutation) [HSA:51142]
            NR4A2 (mutation) [HSA:4929] [KO:K08558]
ENV_FACTOR  MPTP [CPD:C04599]
            Rotenone [CPD:C07593]
            Maneb [CPD:C15231]
            Paraquat [CPD:C14701]
MARKER      Dopamine [CPD:C03758]
            Homovanillic acid [CPD:C05582]
            Tyrosine hydroxylase [HSA:7054]
            DOPA decarboxylase [HSA:1644]
DRUG        Carbidopa [DR:D00558] DOPA decarboxylase inhibitor
            Levodopa [DR:D00059] dopamine precursor
            Biperiden [DG:DG00852]
            Amantadine hydrochloride [DG:DG00860]
            Istradefylline [DR:D04641] adenosine A2a receptor antagonist
COMMENT     Disease class: synucleinopathy
            Affected region: substantia nigra, putamen, caudate nucleus, hypothalamus
            Microscopic lesion: Lewy bodies
DBLINKS     ICD-10: G20
            MeSH: D010300
            OMIM: 168600 168601 605543 600116 605909 606324 607060 606693 607688 610297 612953 260300 614203 614251 615528 616710
REFERENCE   PMID:19729209 (Env_factor)
  AUTHORS   Cicchetti F, Drouin-Ouellet J, Gross RE
  TITLE     Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?
  JOURNAL   Trends Pharmacol Sci 30:475-83 (2009)
REFERENCE   PMID:19419854
  AUTHORS   Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C
  TITLE     The genetics of Parkinson's syndromes: a critical review.
  JOURNAL   Curr Opin Genet Dev 19:254-65 (2009)
REFERENCE   PMID:19297401
  AUTHORS   Lesage S, Brice A
  TITLE     Parkinson's disease: from monogenic forms to genetic susceptibility factors.
  JOURNAL   Hum Mol Genet 18:R48-59 (2009)
REFERENCE   PMID:19182805 (PARK9)
  AUTHORS   Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S
  TITLE     Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.
  JOURNAL   Nat Genet 41:308-15 (2009)
REFERENCE   PMID:17582365 (PARK2, PARK6, PARK8)
  AUTHORS   Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE
  TITLE     Deciphering the role of heterozygous mutations in genes associated with parkinsonism.
  JOURNAL   Lancet Neurol 6:652-62 (2007)
REFERENCE   PMID:17499497 (PARK2, PARK6, PARK7)
  AUTHORS   Dodson MW, Guo M
  TITLE     Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.
  JOURNAL   Curr Opin Neurobiol 17:331-7 (2007)
REFERENCE   PMID:16024878
  AUTHORS   Hague SM, Klaffke S, Bandmann O.
  TITLE     Neurodegenerative disorders: Parkinson's disease and Huntington's disease.
  JOURNAL   J Neurol Neurosurg Psychiatry 76:1058-63 (2005)
REFERENCE   PMID:16009383
  AUTHORS   Pardo LM, van Duijn CM.
  TITLE     In search of genes involved in neurodegenerative disorders.
  JOURNAL   Mutat Res 592:89-101 (2005)
REFERENCE   PMID:15760766
  AUTHORS   Eriksen JL, Przedborski S, Petrucelli L
  TITLE     Gene dosage and pathogenesis of Parkinson's disease.
  JOURNAL   Trends Mol Med 11:91-6 (2005)
REFERENCE   PMID:15390068 (PARK2)
  AUTHORS   Hedrich K, Eskelson C, Wilmot B, Marder K, Harris J, Garrels J, Meija-Santana H, Vieregge P, Jacobs H, Bressman SB, Lang AE, Kann M, Abbruzzese G, Martinelli P, Schwinger E, Ozelius LJ, Pramstaller PP, Klein C, Kramer P
  TITLE     Distribution, type, and origin of Parkin mutations: review and case studies.
  JOURNAL   Mov Disord 19:1146-57 (2004)
REFERENCE   PMID:12953260
  AUTHORS   Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW
  TITLE     The role of pathogenic DJ-1 mutations in Parkinson's disease.
  JOURNAL   Ann Neurol 54:283-6 (2003)
REFERENCE   PMID:12496759 (NR4A2)
  AUTHORS   Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK
  TITLE     Mutations in NR4A2 associated with familial Parkinson disease.
  JOURNAL   Nat Genet 33:85-9 (2003)
REFERENCE   PMID:27090875 (PARK17, PARK18, PARK19)
  AUTHORS   Hernandez DG, Reed X, Singleton AB
  TITLE     Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.
  JOURNAL   J Neurochem 139 Suppl 1:59-74 (2016)
REFERENCE   PMID:25662902 (PARK22)
  AUTHORS   Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S, Li Y, Ogaki K, Ando M, Yoshino H, Tomiyama H, Nishioka K, Hasegawa K, Saiki H, Satake W, Mogushi K, Sasaki R, Kokubo Y, Kuzuhara S, Toda T, Mizuno Y, Uchiyama Y, Ohno K, Hattori N
  TITLE     CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study.
  JOURNAL   Lancet Neurol 14:274-82 (2015)
///
ENTRY       H00058                      Disease
NAME        Amyotrophic lateral sclerosis (ALS);
            Lou Gehrig's disease
DESCRIPTION Amyotrophic lateral sclerosis (ALS) is a progressive, lethal, degenerative disorder of motor neurons. The hallmark of this disease is the selective death of motor neurons in the brain and spinal cord, leading to paralysis of voluntary muscles. Mutant superoxide dismutase 1 (SOD1), as seen in some familial ALS (FALS) cases, is unstable, forming aggregates in the motor neuron cytoplasm, axoplasm and mitochondria. Within mitochondria, mutant SOD1 may interfere with the anti-apoptotic function of Bcl-2, affect mitochondrial import by interfering with the translocation machinery (TOM/TIM), and generate toxic free radicals (ROS). Reactive oxygen species (ROS), produced within mitochondria, inhibit the function of EAAT2, the main glial glutamate transporter protein, responsible for most of the reuptake of synaptically released glutamate. Glutamate excess increases intracellular calcium, which enhances oxidative stress and mitochondrial damage. Mutant SOD1 can also trigger oxidative reactions , which can then cause damage through the formation of hydroxyl radicals or via nitration of tyrosine residues on proteins. Nitration may target neurofilament proteins, affecting axonal transport. Collectively, these mechanisms are predicted to disturb cellular homeostasis, ultimately triggering motor neuron death.
CATEGORY    Neurodegenerative disease
GENE        (ALS1) SOD1; superoxide dismutase (mutation) [HSA:6647] [KO:K04565]
            (ALS1) NEFH; neurofilament (deletion/insertion) [HSA:4744] [KO:K04574]
            (ALS1) PRPH; peripherin (deletion) [HSA:5630] [KO:K07607]
            (ALS1) DCTN1; dynactin 1 (mutation) [HSA:1639] [KO:K04648]
            (ALS2) ALS2; alsin (mutation) [HSA:57679] [KO:K04575]
            (ALS4) SETX; senataxin (mutation) [HSA:23064] [KO:K10706]
            (ALS6) FUS; fusion (mutation) [HSA:2521] [KO:K13098]
            (ALS8) VAPB; VAMP-associated protein (mutation) [HSA:9217] [KO:K10707]
            (ALS9) ANG; angiogenin (mutation) [HSA:283] [KO:K16631]
            (ALS10) TARDBP; TAR DNA binding protein (mutation) [HSA:23435]
            (ALS11) FIG4; FIG4 homolog (mutation) [HSA:9896]
            (ALS12) OPTN; optineurin (mutation) [HSA:10133] [KO:K19946]
            (ALS14) VCP [HSA:7415] [KO:K13525]
            (ALS15) UBQLN2 [HSA:29978] [KO:K04523]
            (ALS16) SIGMAR1 [HSA:10280] [KO:K20719]
            (ALS17) CHMP2B [HSA:25978] [KO:K12192]
            (ALS18) PFN1 [HSA:5216] [KO:K05759]
            (ALS19) ERBB4 [HSA:2066] [KO:K05085]
            (ALS20) HNRNPA1 [HSA:3178] [KO:K12741]
            (ALS21) MATR3 [HSA:9782] [KO:K13213]
            (ALS22) TUBA4A [HSA:7277] [KO:K07374]
            MAPT; microtubule-associated protein tau [HSA:4137] [KO:K04380]
            (ALSFTD1) ALSFTD [HSA:203228]
            (ALSFTD2) CHCHD10 [HSA:400916]
            (ALS/PDC) TRPM7 [HSA:54822] [KO:K04982]
DRUG        Riluzole [DR:D00775] glutamate release inhibitor
COMMENT     Affected region: motor cortex, brain stem, spinal cord
            Microscopic lesion: hyaline inclusions
DBLINKS     ICD-10: G12.2
            MeSH: D000690
            OMIM: 105400 205100 602433 608030 608627 611895 612069 612577 613435 613954 300857 614373 614696 614808 615515 615426 606070 616208 615911 105500
REFERENCE   PMID:19251628 (ALS6)
  AUTHORS   Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE
  TITLE     Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.
  JOURNAL   Science 323:1208-11 (2009)
REFERENCE   PMID:19251627 (ALS6)
  AUTHORS   Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr
  TITLE     Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.
  JOURNAL   Science 323:1205-8 (2009)
REFERENCE   PMID:19118816 (ALS11)
  AUTHORS   Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, Everett L, Lenk GM, McKenna-Yasek DM, Weisman LS, Figlewicz D, Brown RH, Meisler MH
  TITLE     Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS.
  JOURNAL   Am J Hum Genet 84:85-8 (2009)
REFERENCE   PMID:19081518 (drug)
  AUTHORS   Turner MR, Kiernan MC, Leigh PN, Talbot K
  TITLE     Biomarkers in amyotrophic lateral sclerosis.
  JOURNAL   Lancet Neurol 8:94-109 (2009)
REFERENCE   PMID:18802454 (ALS10)
  AUTHORS   Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R
  TITLE     Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral  sclerosis.
  JOURNAL   PLoS Genet 4:e1000193 (2008)
REFERENCE   PMID:16924260
  AUTHORS   Pasinelli P, Brown RH
  TITLE     Molecular biology of amyotrophic lateral sclerosis: insights from genetics.
  JOURNAL   Nat Rev Neurosci 7:710-23 (2006)
REFERENCE   PMID:16503123
  AUTHORS   Gros-Louis F, Gaspar C, Rouleau GA
  TITLE     Genetics of familial and sporadic amyotrophic lateral sclerosis.
  JOURNAL   Biochim Biophys Acta 1762:956-72 (2006)
REFERENCE   PMID:16501576 (ALS9)
  AUTHORS   Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Patterson V, Swingler R, Kieran D, Prehn J, Morrison KE, Green A, Acharya KR, Brown RH Jr, Hardiman O
  TITLE     ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis.
  JOURNAL   Nat Genet 38:411-3 (2006)
REFERENCE   PMID:15952898 (ALS1)
  AUTHORS   Valentine JS, Doucette PA, Zittin Potter S
  TITLE     Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis.
  JOURNAL   Annu Rev Biochem 74:563-93 (2005)
REFERENCE   PMID:15478096 (ALS4)
  AUTHORS   Kunst CB
  TITLE     Complex genetics of amyotrophic lateral sclerosis.
  JOURNAL   Am J Hum Genet 75:933-47 (2004)
REFERENCE   PMID:15106121
  AUTHORS   Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, Nicholson GA, Auer-Grumbach M, Wagner K, De Jonghe P, Griffin JW, Fischbeck KH, Timmerman V, Cornblath DR, Chance PF
  TITLE     DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4).
  JOURNAL   Am J Hum Genet 74:1128-35 (2004)
REFERENCE   PMID:11239414
  AUTHORS   Julien JP.
  TITLE     Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded.
  JOURNAL   Cell 104:581-91 (2001)
REFERENCE   PMID:20428114 (ALS12)
  AUTHORS   Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H
  TITLE     Mutations of optineurin in amyotrophic lateral sclerosis.
  JOURNAL   Nature 465:223-6 (2010)
REFERENCE   PMID:26213621 (gene)
  AUTHORS   Yamashita S, Ando Y
  TITLE     Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis.
  JOURNAL   Transl Neurodegener 4:13 (2015)
REFERENCE   PMID:19567404 (gene)
  AUTHORS   Sieh W, Choi Y, Chapman NH, Craig UK, Steinbart EJ, Rothstein JH, Oyanagi K, Garruto RM, Bird TD, Galasko DR, Schellenberg GD, Wijsman EM
  TITLE     Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates.
  JOURNAL   Hum Mol Genet 18:3725-38 (2009)
///
ENTRY       H00059                      Disease
NAME        Huntington's disease (HD)
DESCRIPTION Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15gene, which results in a long stretch of polyglutamine close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. In the cytoplasm, full-length mHtt can interfere with BDNF vesicular transport on microtubules. This mutant protein also may lead to abnormal endocytosis and secretion in neurons, because normal Htt form a complex with the proteins Hip1, clathrin and AP2 that are involved in endocytosis. In addition, mHtt affects Ca2+ signaling by sensitizing InsP3R1 to activation by InsP3, stimulating NMDAR activity, and destabilizing mitochondrial Ca2+ handling. The mHtt translocates to the nucleus, where it forms intranuclear inclusions. Nuclear toxicity is believed to be caused by interference with gene transcription, leading to loss of transcription of neuroprotective molecules such as BDNF. While mHtt binds to p53 and upregulates levels of nuclear p53 as well as p53 transcriptional activity. Augmented p53 mediates mitochondrial dysfunction.
CATEGORY    Neurodegenerative disease
GENE        HTT; huntingtin (CAG repeat expansion) [HSA:3064] [KO:K04533]
DRUG        Tiagabine [DG:DG00850]
COMMENT     Disease class: polyglutamine disease
            Affected region: caudate nucleus, globus pallidus, thalamus, hippocampus
            Microscopic lesion: neuronal intranuclear inclusions
DBLINKS     ICD-10: G10
            MeSH: D000690
            OMIM: 143100
REFERENCE   PMID:18466116
  AUTHORS   Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, Krishna G, Davies JE, Ttofi E, Underwood BR, Rubinsztein DC
  TITLE     Huntington's disease: from pathology and genetics to potential therapies.
  JOURNAL   Biochem J 412:191-209 (2008)
REFERENCE   PMID:17217424
  AUTHORS   Spires TL, Hannan AJ
  TITLE     Molecular mechanisms mediating pathological plasticity in Huntington's disease and Alzheimer's disease.
  JOURNAL   J Neurochem 100:874-82 (2007)
REFERENCE   PMID:16829072
  AUTHORS   Gusella JF, Macdonald ME
  TITLE     Huntington's disease: seeing the pathogenic process through a genetic lens.
  JOURNAL   Trends Biochem Sci 31:533-40 (2006)
REFERENCE   PMID:15480847
  AUTHORS   Gardian G, Vecsei L.
  TITLE     Huntington's disease: pathomechanism and therapeutic perspectives.
  JOURNAL   J Neural Transm 111:1485-94 (2004)
///
ENTRY       H00060                      Disease
NAME        Dentatorubropallidoluysian atrophy (DRPLA)
DESCRIPTION Dentatorubropallidoluysian atrophy (DRPLA) is one of the CAG repeat diseases like Huntington's disease. It is caused by expansion of a CAG repeat in the atrophin 1 gene and shows various combinations of clinical symptoms depending on the age of onset. The clinical features of DRPLA include progressive myoclonus, seizure, and mental retardation in patients with an earlier onset (generally < 20 years) and cerebellar ataxia, choreoathetosis, and dementia in patients with a later onset (> 40 years).
CATEGORY    Neurodegenerative disease
GENE        ATN1; atrophin 1 (CAG repeat expansion) [HSA:1822] [KO:K05626]
COMMENT     Disease class: polyglutamine disease
            Affected region: cerebellum, cerebral cortex, basal ganglia, Luys body
            Microscopic lesion: neuronal and glial intranuclear inclusions
DBLINKS     ICD-10: G11.2
            OMIM: 125370
REFERENCE   PMID:18473821
  AUTHORS   Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, Adachi H, Sobue G
  TITLE     Molecular genetics and biomarkers of polyglutamine diseases.
  JOURNAL   Curr Mol Med 8:221-34 (2008)
REFERENCE   PMID:14585172
  AUTHORS   Rudnicki DD, Margolis RL.
  TITLE     Repeat expansion and autosomal dominant neurodegenerative disorders: consensus and controversy.
  JOURNAL   Expert Rev Mol Med 5:1-24 (2003)
REFERENCE   PMID:12464607
  AUTHORS   Nucifora FC Jr, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, Hayden MR, Dawson VL, Dawson TM, Ross CA
  TITLE     Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity.
  JOURNAL   J Biol Chem 278:13047-55 (2003)
REFERENCE   PMID:10677044
  AUTHORS   Schilling G, Wood JD, Duan K, Slunt HH, Gonzales V, Yamada M, Cooper JK, Margolis RL, Jenkins NA, Copeland NG, Takahashi H, Tsuji S, Price DL, Borchelt DR, Ross CA
  TITLE     Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA.
  JOURNAL   Neuron 24:275-86 (1999)
REFERENCE   PMID:10434307
  AUTHORS   Kanazawa I
  TITLE     Molecular pathology of dentatorubral-pallidoluysian atrophy.
  JOURNAL   Philos Trans R Soc Lond B Biol Sci 354:1069-74 (1999)
REFERENCE   PMID:10434299
  AUTHORS   Ross CA, Wood JD, Schilling G, Peters MF, Nucifora FC Jr, Cooper JK, Sharp AH, Margolis RL, Borchelt DR
  TITLE     Polyglutamine pathogenesis.
  JOURNAL   Philos Trans R Soc Lond B Biol Sci 354:1005-11 (1999)
REFERENCE   PMID:9933295
  AUTHORS   Kanazawa I
  TITLE     Dentatorubral-pallidoluysian atrophy or Naito-Oyanagi disease.
  JOURNAL   Neurogenetics 2:1-17 (1998)
///
ENTRY       H00061                      Disease
NAME        Prion diseases;
            Creutzfeldt-Jacob disease (CJD);
            Gerstmann-Straussler disease (GSD);
            Gerstmann-Straussler-Scheinker disease (GSSD);
            Fatal familial insomnia (FFI)
DESCRIPTION Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.
CATEGORY    Neurodegenerative disease
GENE        PRNP (mutation) [HSA:5621] [KO:K05634]
COMMENT     Affected region: cerebral cortex, thalamus, brain stem, cerebellum, etc.
            Microscopic lesion: prion plaques
DBLINKS     ICD-10: A81.0
            MeSH: D017096
            OMIM: 123400 137440 600072 606688
REFERENCE   PMID:14744440
  AUTHORS   Aguzzi A, Polymenidou M.
  TITLE     Mammalian prion biology: one century of evolving concepts.
  JOURNAL   Cell 116:313-27 (2004)
///
ENTRY       H00062                      Disease
NAME        Spinal and bulbar muscular atrophy (SBMA);
            Kennedy's disease
DESCRIPTION Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy disease, is a motor neuron disease characterized by progressive weakening of the limb and bulbar muscles. It is an X-linked recessive disease that only affects males. SBMA is caused by expansion of CAG trinucleotide repeats in the first exon of the androgen receptor gene. The expansion of encoded polyglutamine tracts results in protein aggregation and is associated with neuronal cell death.
CATEGORY    Neurodegenerative disease
GENE        AR; androgen receptor (CAG repeat expansion) [HSA:367] [KO:K08557]
DRUG        Leuprorelin acetate [DR:D00989] (clinical trials)
COMMENT     Disease class: polyglutamine disease
            Affected region: anterior horn, bulbar region (cerebellum, medulla oblongata, pons), dorsal root ganglia
            Microscopic lesion: neuronal and cytoplasmic inclusions
DBLINKS     ICD-10: G12.1
            MeSH: D020966
            OMIM: 313200
REFERENCE   PMID:19405197
  AUTHORS   Finsterer J
  TITLE     Bulbar and spinal muscular atrophy (Kennedy's disease): a review.
  JOURNAL   Eur J Neurol 16:556-61 (2009)
REFERENCE   PMID:19066230
  AUTHORS   Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H, Tanaka K, Hamazaki J, Murata S, Tanaka F, Sobue G
  TITLE     17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.
  JOURNAL   Hum Mol Genet 18:898-910 (2009)
REFERENCE   PMID:18775514
  AUTHORS   Jordan CL, Lieberman AP
  TITLE     Spinal and bulbar muscular atrophy: a motoneuron or muscle disease?
  JOURNAL   Curr Opin Pharmacol 8:752-8 (2008)
REFERENCE   PMID:18473821
  AUTHORS   Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, Adachi H, Sobue G
  TITLE     Molecular genetics and biomarkers of polyglutamine diseases.
  JOURNAL   Curr Mol Med 8:221-34 (2008)
REFERENCE   PMID:17984063
  AUTHORS   Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, Yu Z, Lieberman AP, Breedlove SM, Jordan CL
  TITLE     Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease.
  JOURNAL   Proc Natl Acad Sci U S A 104:18259-64 (2007)
REFERENCE   PMID:17359355
  AUTHORS   Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G
  TITLE     Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
  JOURNAL   Neuropathol Appl Neurobiol 33:135-51 (2007)
REFERENCE   PMID:17334372
  AUTHORS   Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, Merry DE, Sobue G, Chen LM, Chang SS, Chang C
  TITLE     ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.
  JOURNAL   Nat Med 13:348-53 (2007)
REFERENCE   PMID:15133611
  AUTHORS   Katsuno M, Adachi H, Tanaka F, Sobue G
  TITLE     Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.
  JOURNAL   J Mol Med 82:298-307 (2004)
REFERENCE   PMID:14585172
  AUTHORS   Rudnicki DD, Margolis RL.
  TITLE     Repeat expansion and autosomal dominant neurodegenerative disorders: consensus and controversy.
  JOURNAL   Expert Rev Mol Med 5:1-24 (2003)
REFERENCE   PMID:12470181
  AUTHORS   Sperfeld AD, Karitzky J, Brummer D, Schreiber H, Haussler J, Ludolph AC, Hanemann CO
  TITLE     X-linked bulbospinal neuronopathy: Kennedy disease.
  JOURNAL   Arch Neurol 59:1921-6 (2002)
REFERENCE   PMID:12189162
  AUTHORS   McManamny P, Chy HS, Finkelstein DI, Craythorn RG, Crack PJ, Kola I, Cheema SS, Horne MK, Wreford NG, O'Bryan MK, De Kretser DM, Morrison JR
  TITLE     A mouse model of spinal and bulbar muscular atrophy.
  JOURNAL   Hum Mol Genet 11:2103-11 (2002)
REFERENCE   PMID:12161529
  AUTHORS   Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, Tardieu S, Chadarevian R, Giral P, Turpin G
  TITLE     A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length.
  JOURNAL   J Clin Endocrinol Metab 87:3893-901 (2002)
REFERENCE   PMID:2062380
  AUTHORS   La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH
  TITLE     Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.
  JOURNAL   Nature 352:77-9 (1991)
REFERENCE   PMID:1449253
  AUTHORS   Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A
  TITLE     Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene.
  JOURNAL   Ann Neurol 32:707-10 (1992)
REFERENCE   PMID:1303283
  AUTHORS   La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee WC, Fischbeck KH
  TITLE     Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat  in X-linked spinal and bulbar muscular atrophy.
  JOURNAL   Nat Genet 2:301-4 (1992)
///
ENTRY       H00063                      Disease
NAME        Spinocerebellar ataxia (SCA)
DESCRIPTION The dominantly inherited ataxias or spinocerebellar ataxias (SCAs) are a clinically heterogeneous group of progressive disorders which characteraized by cerebellar ataxia, seizures, eyes/oculomotor deficits, gait ataxia and dysarthria ataxia.The prevalence of SCAs is estimated to be 1-4/100.000. At least 28 genetic loci for SCAs had been discovered. SCA1, 2, 3, 6, 7 and 17 are caused by CAG repeat expansions that encode a pure repeat of the amino acid glutamine in the disease protein. SCA8, 10 and 12 are due to repeat expansions outside of the protein-coding region of the respective disease genes. SCA5, 13, 14 and 27 are caused by conventional mutations in specific genes: deletion, missense, nonsense and splice site mutations.
CATEGORY    Neurodegenerative disease
GENE        (SCA1) ATXN1 (CAG repeat expansion) [HSA:6310]
            (SCA2) ATXN2 (CAG repeat expansion) [HSA:6311]
            (SCA3) ATXN3 (CAG repeat expansion) [HSA:4287] [KO:K11863]
            (SCA5/ SCAR14) SPTBN2; spectrin, beta, non-erythrocytic 2 (mutation) [HSA:6712] [KO:K06115]
            (SCA6) CACNA1A; calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (CAG repeat expansion) [HSA:773] [KO:K04344]
            (SCA7) ATXN7 (CAG repeat expansion) [HSA:6314] [KO:K11318]
            (SCA8) ATXN8 opposite strand (CTG/CAG repeat expansion)
            (SCA10) ATXN10 (ATTCT repeat expansion) [HSA:25814] [KO:K19323]
            (SCA11) TTBK2; tau tubulin kinase 2 (mutation) [HSA:146057] [KO:K08815]
            (SCA12) PPP2R2B; protein phosphatase 2 (CAG repeat expansion) [HSA:5521] [KO:K04354]
            (SCA13) KCNC3; potassium voltage-gated channel, Shaw-related subfamily, member 3 (mutation) [HSA:3748] [KO:K04889]
            (SCA14) PRKCG; protein kinase C, gamma (mutation) [HSA:5582] [KO:K19663]
            (SCA15) ITPR1; inositol 1,4,5-triphosphate receptor, type 1 (deletion) [HSA:3708] [KO:K04958]
            (SCA17) TBP; TATA box binding protein (CAG repeat expansion) [HSA:6908] [KO:K03120]
            (SCA23) PDYN; prodynorphin [HSA:5173] [KO:K15840]
            (SCA27) FGF14; fibroblast growth factor 14 (mutation) [HSA:2259] [KO:K04358]
            (SCA28) AFG3L2; AFG3 ATPase family gene 3-like 2 [HSA:10939] [KO:K08956]
            (SCA31) BEAN1; brain expressed, associated with NEDD4, 1 [HSA:146227] [KO:K19324]
            (SCA36) NOP56 [HSA:10528] [KO:K14564]
            (SCAR5) ZNF592 [HSA:9640] [KO:K19325]
            (SCAR8) SYNE1 [HSA:23345] [KO:K19326]
            (SCAR9) ADCK3 [HSA:56997] [KO:K08869]
            (SCAR10) ANO10 [HSA:55129] [KO:K19327]
            (SCAR11) SYT14 [HSA:255928] [KO:K19328]
            (SCAR12) WWOX [HSA:51741] [KO:K19329]
            (SCAR13) GRM1 [HSA:2911] [KO:K04603]
            (SCAR15) KIAA0226 [HSA:9711] [KO:K19330]
            (SCAR16) STUB1 [HSA:10273] [KO:K09561]
            (SCAN1) TDP1 [HSA:55775] [KO:K10862]
DRUG        (SCA3/SCA14) Chantix [DR:D06282]
            (SCA3) Lamictal [DR:D00354]
COMMENT     Disease class: polyglutamine disease
            Affected region: cerebellum, dentate nucleus, brain stem (SCA1); cerebellum, brain stem, frontotemporal lobes (frontal lobe and temporal lobe) (SCA2); cerebellum, basal ganglia, brain stem, spinal cord (SCA3); cerebellum (SCA5); cerebellum, dentate nucleus, inferior olive (SCA6); cerebellum, inferior olive, dentate nucleus, pontine nuclei (also the retina) (SCA7); cerebral cortex, cerebellum (SCA12); cerebellum, inferior olive (SCA17)
            Microscopic lesion: neuronal inclusions (SCA1, SCA2, SCA3, SCA7, SCA17); cytoplasmic inclusions (SCA6)
            See also H01478 Machado-Joseph disease.
DBLINKS     ICD-10: G31.9
            MeSH: D020754
            OMIM: 164400 183090 109150 183086 600224 164500 608768 604326 605259 603516 604432 605361 609307 607136 606658 610245 610246 117210 606937 610743 612016 613728 607250 614153 614229 614322 614831 615386 615705 615768
REFERENCE   PMID:19050414 (drug)
  AUTHORS   Zesiewicz TA, Sullivan KL
  TITLE     Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14).
  JOURNAL   Clin Neuropharmacol 31:363-5 (2008)
REFERENCE   PMID:18317266 (SCA3)
  AUTHORS   Rub U, Brunt ER, Deller T
  TITLE     New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease).
  JOURNAL   Curr Opin Neurol 21:111-6 (2008)
REFERENCE   PMID:17620880
  AUTHORS   Soong BW, Paulson HL
  TITLE     Spinocerebellar ataxias: an update.
  JOURNAL   Curr Opin Neurol 20:438-46 (2007)
REFERENCE   PMID:17590087 (SCA15)
  AUTHORS   van de Leemput J, Chandran J, Knight MA, Holtzclaw LA, Scholz S, Cookson MR, Houlden H, Gwinn-Hardy K, Fung HC, Lin X, Hernandez D, Simon-Sanchez J, Wood NW, Giunti P, Rafferty I, Hardy J, Storey E, Gardner RJ, Forrest SM, Fisher EM, Russell JT, Cai H, Singleton AB
  TITLE     Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans.
  JOURNAL   PLoS Genet 3:e108 (2007)
REFERENCE   PMID:17390258 (SCA3)
  AUTHORS   Paulson HL
  TITLE     Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3.
  JOURNAL   Semin Neurol 27:133-42 (2007)
REFERENCE   PMID:16927298 (SCA5)
  AUTHORS   Bauer P, Schols L, Riess O
  TITLE     Spectrin mutations in spinocerebellar ataxia (SCA).
  JOURNAL   Bioessays 28:785-7 (2006)
REFERENCE   PMID:15876340 (Drug)
  AUTHORS   Liu CS, Hsu HM, Cheng WL, Hsieh M
  TITLE     Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy.
  JOURNAL   Acta Neurol Scand 111:385-90 (2005)
REFERENCE   PMID:14585172
  AUTHORS   Rudnicki DD, Margolis RL.
  TITLE     Repeat expansion and autosomal dominant neurodegenerative disorders: consensus and controversy.
  JOURNAL   Expert Rev Mol Med 5:1-24 (2003)
REFERENCE   PMID:12869811
  AUTHORS   Albin RL
  TITLE     Dominant ataxias and Friedreich ataxia: an update.
  JOURNAL   Curr Opin Neurol 16:507-14 (2003)
REFERENCE   PMID:10525976 (SCA1, SCA2, SCA3)
  AUTHORS   Burk K, Fetter M, Abele M, Laccone F, Brice A, Dichgans J, Klockgether T
  TITLE     Autosomal dominant cerebellar ataxia type I: oculomotor abnormalities in families with SCA1, SCA2, and SCA3.
  JOURNAL   J Neurol 246:789-97 (1999)
REFERENCE   PMID:20531441
  AUTHORS   Nicolas E, Poitelon Y, Chouery E, Salem N, Levy N, Megarbane A, Delague V
  TITLE     CAMOS, a nonprogressive, autosomal recessive, congenital cerebellar ataxia, is caused by a mutant zinc-finger protein, ZNF592.
  JOURNAL   Eur J Hum Genet 18:1107-13 (2010)
REFERENCE   PMID:17159980
  AUTHORS   Gros-Louis F, Dupre N, Dion P, Fox MA, Laurent S, Verreault S, Sanes JR, Bouchard JP, Rouleau GA
  TITLE     Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia.
  JOURNAL   Nat Genet 39:80-5 (2007)
REFERENCE   PMID:18319074
  AUTHORS   Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, Drouot N, Busso C, Makri S, Ali-Pacha L, Benhassine T, Anheim M, Lynch DR, Thibault C, Plewniak F, Bianchetti L, Tranchant C, Poch O, DiMauro S, Mandel JL, Barros MH, Hirano M, Koenig M
  TITLE     ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency.
  JOURNAL   Am J Hum Genet 82:661-72 (2008)
REFERENCE   PMID:21092923
  AUTHORS   Vermeer S, Hoischen A, Meijer RP, Gilissen C, Neveling K, Wieskamp N, de Brouwer A, Koenig M, Anheim M, Assoum M, Drouot N, Todorovic S, Milic-Rasic V, Lochmuller H, Stevanin G, Goizet C, David A, Durr A, Brice A, Kremer B, van de Warrenburg BP, Schijvenaars MM, Heister A, Kwint M, Arts P, van der Wijst J, Veltman J, Kamsteeg EJ, Scheffer H, Knoers N
  TITLE     Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10  mutations in patients with autosomal-recessive cerebellar ataxia.
  JOURNAL   Am J Hum Genet 87:813-9 (2010)
REFERENCE   PMID:17948061
  AUTHORS   Hirano R, Interthal H, Huang C, Nakamura T, Deguchi K, Choi K, Bhattacharjee MB, Arimura K, Umehara F, Izumo S, Northrop JL, Salih MA, Inoue K, Armstrong DL, Champoux JJ, Takashima H, Boerkoel CF
  TITLE     Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
  JOURNAL   EMBO J 26:4732-43 (2007)
REFERENCE   PMID:22901947 (SCAR13)
  AUTHORS   Guergueltcheva V, Azmanov DN, Angelicheva D, Smith KR, Chamova T, Florez L, Bynevelt M, Nguyen T, Cherninkova S, Bojinova V, Kaprelyan A, Angelova L, Morar B, Chandler D, Kaneva R, Bahlo M, Tournev I, Kalaydjieva L
  TITLE     Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1.
  JOURNAL   Am J Hum Genet 91:553-64 (2012)
REFERENCE   PMID:21683323
  AUTHORS   Kobayashi H, Abe K, Matsuura T, Ikeda Y, Hitomi T, Akechi Y, Habu T, Liu W, Okuda H, Koizumi A
  TITLE     Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type  of spinocerebellar ataxia accompanied by motor neuron involvement.
  JOURNAL   Am J Hum Genet 89:121-30 (2011)
REFERENCE   PMID:21835308
  AUTHORS   Doi H, Yoshida K, Yasuda T, Fukuda M, Fukuda Y, Morita H, Ikeda S, Kato R, Tsurusaki Y, Miyake N, Saitsu H, Sakai H, Miyatake S, Shiina M, Nukina N, Koyano S, Tsuji S, Kuroiwa Y, Matsumoto N
  TITLE     Exome sequencing reveals a homozygous SYT14 mutation in adult-onset, autosomal-recessive spinocerebellar ataxia with psychomotor retardation.
  JOURNAL   Am J Hum Genet 89:320-7 (2011)
REFERENCE   PMID:20826435 (SCAR15)
  AUTHORS   Assoum M, Salih MA, Drouot N, H'Mida-Ben Brahim D, Lagier-Tourenne C, AlDrees A, Elmalik SA, Ahmed TS, Seidahmed MZ, Kabiraj MM, Koenig M
  TITLE     Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia.
  JOURNAL   Brain 133:2439-47 (2010)
REFERENCE   PMID:24312598
  AUTHORS   Shi Y, Wang J, Li JD, Ren H, Guan W, He M, Yan W, Zhou Y, Hu Z, Zhang J, Xiao J, Su Z, Dai M, Wang J, Jiang H, Guo J, Zhou Y, Zhang F, Li N, Du J, Xu Q, Hu Y, Pan Q, Shen L, Wang G, Xia K, Zhang Z, Tang B
  TITLE     Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia.
  JOURNAL   PLoS One 8:e81884 (2013)
REFERENCE   PMID:24369382
  AUTHORS   Mallaret M, Synofzik M, Lee J, Sagum CA, Mahajnah M, Sharkia R, Drouot N, Renaud M, Klein FA, Anheim M, Tranchant C, Mignot C, Mandel JL, Bedford M, Bauer P, Salih MA, Schule R, Schols L, Aldaz CM, Koenig M
  TITLE     The tumour suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation.
  JOURNAL   Brain 137:411-9 (2014)
///
ENTRY       H00064                      Disease
NAME        Ataxia telangiectasia (AT);
            Louis-Bar syndrome;
            Boder-Sedgwick syndrome
DESCRIPTION Ataxia-telangiectasia is an autosomal recessive disorder with a birth frequency of about 1 in 300 000. It is a progressive neurodegenerative disease associated with abnormal eye movements and cutaneous telangiectasia, immunodeficiency, and premature aging. The product of the causative gene ATM is a 350 kDa protein of the phosphatidylinositol 3-kinase family that is involved in mitogenic signal transduction, intracellular protein transport, and cell cycle control.
CATEGORY    Neurodegenerative disease; Primary immunodeficiency
GENE        ATM (mutation) [HSA:472] [KO:K04728]
COMMENT     Affected region: cerebellum
            Microscopic lesion: neuronal degeneration, particularly the loss of cerebellar granule and Purkinje cells
DBLINKS     ICD-10: G11.3
            MeSH: D001260
            OMIM: 208900
REFERENCE   PMID:17889645
  AUTHORS   Rass U, Ahel I, West SC.
  TITLE     Defective DNA repair and neurodegenerative disease.
  JOURNAL   Cell 130:991-1004 (2007)
REFERENCE   PMID:15175861
  AUTHORS   Ristow M.
  TITLE     Neurodegenerative disorders associated with diabetes mellitus.
  JOURNAL   J Mol Med 82:510-29 (2004)
///
ENTRY       H00065                      Disease
NAME        Alexander disease
DESCRIPTION Alexander disease is a rare, but often fatal neurological disorder that has been divided into three subtypes based on the age of onset: the infantile, juvenile and adult forms. The characteristic neuropathological feature of all forms of Alexander's disease is the presence of Rosenthal fibers which include protein aggregates that contain glial fibrillary acidic protein (GFAP) and small stress proteins in astrocytes.
CATEGORY    Neurodegenerative disease
GENE        GFAP; glial fibrillary acidic protein (mutation) [HSA:2670] [KO:K05640]
DRUG        thyrotropin releasing hormone [DR:D00176]
COMMENT     Disease class: leukodystrophy
            Affected regtion: midbrain, cerebellum
            Microscopic lesion: Rosenthal fibers
DBLINKS     MeSH: D038261
            OMIM: 203450
REFERENCE   PMID:17498694
  AUTHORS   Quinlan RA, Brenner M, Goldman JE, Messing A.
  TITLE     GFAP and its role in Alexander disease.
  JOURNAL   Exp Cell Res 313:2077-87 (2007)
REFERENCE   PMID:16826512
  AUTHORS   Der Perng M, Su M, Wen SF, Li R, Gibbon T, Prescott AR, Brenner M, Quinlan RA
  TITLE     The Alexander disease-causing glial fibrillary acidic protein mutant, R416W, accumulates into Rosenthal fibers by a pathway that involves filament aggregation and the association of alpha B-crystallin and HSP27.
  JOURNAL   Am J Hum Genet 79:197-213 (2006)
REFERENCE   PMID:16774812 (drug)
  AUTHORS   Ishigaki K, Ito Y, Sawaishi Y, Kodaira K, Funatsuka M, Hattori N, Nakano K, Saito K, Osawa M
  TITLE     TRH therapy in a patient with juvenile Alexander disease.
  JOURNAL   Brain Dev 28:663-7 (2006)
REFERENCE   PMID:12175861
  AUTHORS   Li R, Messing A, Goldman JE, Brenner M
  TITLE     GFAP mutations in Alexander disease.
  JOURNAL   Int J Dev Neurosci 20:259-68 (2002)
REFERENCE   PMID:11138011
  AUTHORS   Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A
  TITLE     Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with  Alexander disease.
  JOURNAL   Nat Genet 27:117-20 (2001)
///
ENTRY       H00066                      Disease
NAME        Lewy body dementia (LBD);
            Dementia with Lewy bodies (DLB)
DESCRIPTION Lewy Body dementia (LDB) is neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. It is the second most-common degenerative dementia after Alzheimer's disease. Progressive accumulation of alpha-synuclein- and ubiquitin-positive Lewy Bodies is seen in the brainstem, the limbic system or cortical and subcortical regions, depending on disease subtype. The genetic risk factors include alpha-synuclein mutations and SNCA locus triplicationslocus triplications. Mutations of leucine-rich repeat kinase 2 (LRRK2) and the glucocerebrosidase (GBA) gene have also been implicated in familial DLB.
CATEGORY    Neurodegenerative disease
GENE        SNCA; synuclein, alpha (mutation, triplications) [HSA:6622] [KO:K04528]
            SNCB; synuclein, beta (mutation) [HSA:6620]
            LRRK2; leucine-rich repeat kinase 2 (mutation) [HSA:120892] [KO:K08844]
            GBA; glucosidase, beta; acid (mutation) [HSA:2629] [KO:K01201]
COMMENT     Disease class: synucleinopathy
            Affected region: basal ganglia
            Microscopic lesion: Lewy bodies
DBLINKS     ICD-10: G31.8
            MeSH: D020961
            OMIM: 127750
REFERENCE   PMID:18541113
  AUTHORS   Bonifati V
  TITLE     Recent advances in the genetics of dementia with lewy bodies.
  JOURNAL   Curr Neurol Neurosci Rep 8:187-9 (2008)
REFERENCE   PMID:18413475
  AUTHORS   Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan CF, Idezuka J, Wakabayashi K, Onodera O, Iwatsubo T, Nishizawa M, Takahashi H, Ishikawa A
  TITLE     Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia.
  JOURNAL   Arch Neurol 65:514-9 (2008)
REFERENCE   PMID:18332251
  AUTHORS   Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, Schellenberg GD, Sidransky E, Bird TD, Leverenz JB, Tsuang D, Zabetian CP
  TITLE     Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.
  JOURNAL   Arch Neurol 65:379-82 (2008)
REFERENCE   PMID:18195271
  AUTHORS   Obi T, Nishioka K, Ross OA, Terada T, Yamazaki K, Sugiura A, Takanashi M, Mizoguchi K, Mori H, Mizuno Y, Hattori N
  TITLE     Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia.
  JOURNAL   Neurology 70:238-41 (2008)
REFERENCE   PMID:16437559
  AUTHORS   Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW
  TITLE     Lrrk2 and Lewy body disease.
  JOURNAL   Ann Neurol 59:388-93 (2006)
REFERENCE   PMID:16131416
  AUTHORS   Burn DJ
  TITLE     Update on dementia with Lewy bodies.
  JOURNAL   Curr Neurol Neurosci Rep 5:339-44 (2005)
REFERENCE   PMID:15655259
  AUTHORS   Hashimoto M, Kawahara K, Bar-On P, Rockenstein E, Crews L, Masliah E
  TITLE     The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.
  JOURNAL   J Mol Neurosci 24:343-52 (2004)
REFERENCE   PMID:15312277
  AUTHORS   Aarsland D, Ballard CG, Halliday G
  TITLE     Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?
  JOURNAL   J Geriatr Psychiatry Neurol 17:137-45 (2004)
REFERENCE   PMID:12898286
  AUTHORS   Graeber MB, Muller U
  TITLE     Dementia with Lewy bodies: disease concept and genetics.
  JOURNAL   Neurogenetics 4:157-62 (2003)
REFERENCE   PMID:11890854
  AUTHORS   Brett FM, Henson C, Staunton H
  TITLE     Familial diffuse Lewy body disease, eye movement abnormalities, and distribution  of pathology.
  JOURNAL   Arch Neurol 59:464-7 (2002)
REFERENCE   PMID:11470957
  AUTHORS   Dickson DW
  TITLE     Alpha-synuclein and the Lewy body disorders.
  JOURNAL   Curr Opin Neurol 14:423-32 (2001)
///
ENTRY       H00067                      Disease
NAME        Friedreich ataxia
DESCRIPTION Friedreich ataxia is one of the most common forms of autosomal recessive ataxia caused by severely reduced levels of frataxin as a result of a large GAA triplet-repeat expansion within the first intron of the frataxin gene. Frataxin deficiency is thought to cause generation of reactive oxygen species, reactive nitrogen species and mitochondrial dysfunction.
CATEGORY    Neurodegenerative disease
GENE        FXN; frataxin (GAA repeat expansion) [HSA:2395] [KO:K19054]
COMMENT     Disease class: mitochondrial disorder
            Affected region: spinal cord, peripheral nerves
            Microscopic lesion: brain iron accumulation
DBLINKS     ICD-10: G11.1
            MeSH: D005621
            OMIM: 229300
REFERENCE   PMID:18852343
  AUTHORS   Pandolfo M
  TITLE     Friedreich ataxia.
  JOURNAL   Arch Neurol 65:1296-303 (2008)
REFERENCE   PMID:17596984
  AUTHORS   Babady NE, Carelle N, Wells RD, Rouault TA, Hirano M, Lynch DR, Delatycki MB, Wilson RB, Isaya G, Puccio H
  TITLE     Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for  treatments.
  JOURNAL   Mol Genet Metab 92:23-35 (2007)
REFERENCE   PMID:16942541
  AUTHORS   Finsterer J.
  TITLE     Central nervous system manifestations of mitochondrial disorders.
  JOURNAL   Acta Neurol Scand 114:217-38 (2006)
REFERENCE   PMID:16805775
  AUTHORS   Kwong JQ, Beal MF, Manfredi G.
  TITLE     The role of mitochondria in inherited neurodegenerative diseases.
  JOURNAL   J Neurochem 97:1659-75 (2006)
REFERENCE   PMID:15896810
  AUTHORS   Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA
  TITLE     Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
  JOURNAL   J Neurol Sci 233:145-62 (2005)
///
ENTRY       H00068                      Disease
NAME        Leber hereditary optic atrophy (LHON);
            Leber optic atrophy
DESCRIPTION Leber hereditary optic neuropathy (LHON) is a maternally transmitted inherited genetic disease underlying mutation of mitochondrial DNA (mtDNA). It is primarily an ophthalmological disorder, presenting predominantly in young adult males and characterized by acute or subacute bilateral optic atrophy that results in the loss of central vision. In most of the patients with LHON, visual dysfunction is the only manifestation of the disease. The incidence of LHON in Western Europe is 1/30000-1/50000; at least 1 in 14000 males is affected.
CATEGORY    Neurodegenerative disease
GENE        ND1; NADH dehydrogenase I, subunit 1 (mutation) [HSA:4535] [KO:K03878]
            ND2; NADH dehydrogenase I, subunit 2 (mutation) [HSA:4536] [KO:K03879]
            ND4; NADH dehydrogenase I, subunit 4 (mutation) [HSA:4538] [KO:K03881]
            ND4L; NADH dehydrogenase I, subunit 4L (mutation) [HSA:4539] [KO:K03882]
            ND5; NADH dehydrogenase I, subunit 5 (mutation) [HSA:4540] [KO:K03883]
            ND6; NADH dehydrogenase I, subunit 6 (mutation) [HSA:4541] [KO:K03884]
            CYTB; cytochrome b (mutation) [HSA:4519] [KO:K00412]
            COX1; cytochrome c oxidase subunit I (mutation) [HSA:4512] [KO:K02256]
            COX3; cytochrome c oxidase III (mutation) [HSA:4514] [KO:K02262]
            ATP6; ATP synthase F0 subunit 6 (mutation) [HSA:4508] [KO:K02126]
DRUG        Antioxidants (vitamins A, C and E, selenium and zinc)
COMMENT     Disease class: mitochondrial disorder
            Affected region: optic nerves
            Microscopic lesion: degeneration of retinal ganglion cells
DBLINKS     ICD-10: H47.2
            MeSH: D029242
            OMIM: 535000
REFERENCE   PMID:19001017
  AUTHORS   Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF
  TITLE     Inherited mitochondrial optic neuropathies.
  JOURNAL   J Med Genet 46:145-58 (2009)
REFERENCE   PMID:16829155
  AUTHORS   Yen MY, Wang AG, Wei YH
  TITLE     Leber's hereditary optic neuropathy: a multifactorial disease.
  JOURNAL   Prog Retin Eye Res 25:381-96 (2006)
REFERENCE   PMID:16942541
  AUTHORS   Finsterer J.
  TITLE     Central nervous system manifestations of mitochondrial disorders.
  JOURNAL   Acta Neurol Scand 114:217-38 (2006)
REFERENCE   PMID:15513454
  AUTHORS   Johns DR, Colby KA
  TITLE     Treatment of Leber's hereditary optic neuropathy: theory to practice.
  JOURNAL   Semin Ophthalmol 17:33-8 (2002)
REFERENCE   PMID:12464728
  AUTHORS   Newman NJ
  TITLE     From genotype to phenotype in Leber hereditary optic neuropathy: still more questions than answers.
  JOURNAL   J Neuroophthalmol 22:257-61 (2002)
REFERENCE   PMID:8755941
  AUTHORS   Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S
  TITLE     Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy.
  JOURNAL   Am J Hum Genet 59:481-5 (1996)
REFERENCE   PMID:8240102
  AUTHORS   Smith KH, Johns DR, Heher KL, Miller NR
  TITLE     Heteroplasmy in Leber's hereditary optic neuropathy.
  JOURNAL   Arch Ophthalmol 111:1486-90 (1993)
REFERENCE   PMID:7760326
  AUTHORS   Riordan-Eva P, Harding AE
  TITLE     Leber's hereditary optic neuropathy: the clinical relevance of different mitochondrial DNA mutations.
  JOURNAL   J Med Genet 32:81-7 (1995)
REFERENCE   PMID:3201231
  AUTHORS   Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK
  TITLE     Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
  JOURNAL   Science 242:1427-30 (1988)
REFERENCE   PMID:1634041
  AUTHORS   Brown MD, Voljavec AS, Lott MT, MacDonald I, Wallace DC.
  TITLE     Leber's hereditary optic neuropathy: a model for mitochondrial neurodegenerative diseases.
  JOURNAL   FASEB J 6:2791-9 (1992)
///
ENTRY       H00069                      Disease
NAME        Glycogen storage diseases (GSD), including:
            von Gierke disease (GSD type Ia);
            Pompe disease (GSD type II);
            Cori disease, Forbe disease (GSD type III);
            Andersen disease (GSD type IV);
            McArdle disease (GSD type V);
            Hers disease (GSD type VI);
            Tarui disease (GSD type VII);
            Phosphorylase kinase deficiency (GSD type IX);
            Fanconi-Bickel syndrome (GSD type XI);
            Glycogen synthase deficiency (GSD type 0)
DESCRIPTION Glycogen storage disease (GSD) is an autosomal recessive (all types except IXa and IXd) or X-linked (types IXa and IXd) disorder with symptoms ranging from weakness to growth abnormalities. GSD is caused by a defect in an enzyme gene or a transporter gene involved in glycogen metabolism; types I, VII, and XI for processing of glucose, types II-VI and IX for processing of glycogen, and type 0 for glycogen synthesis. Pompe disease (type II) is a lysosomal storage disease.
CATEGORY    Inherited metabolic disease
GENE        (GSD Ia) G6PC; glucose-6-phosphatase [HSA:2538] [KO:K01084]
            (GSD Ib/Ic) SLC37A4; glucose-6P transporter [HSA:2542] [KO:K08171]
            (GSD II) GAA; alpha-glucosidase [HSA:2548] [KO:K12316]
            (GSD III) AGL; amylo-1,6-glucosidase [HSA:178] [KO:K01196]
            (GSD IV) GBE1; 1,4-alpha-glucan branching enzyme [HSA:2632] [KO:K00700]
            (GSD V) PYGM; glycogen phosphorylase, muscle [HSA:5837] [KO:K00688]
            (GSD VI) PYGL; glycogen phosphorylase, liver [HSA:5836] [KO:K00688]
            (GSD VII) PFKM; phosphofructokinase, muscle [HSA:5213] [KO:K00850]
            (GSD IXa) PHKA2; phosphorylase kinase alpha subunit, liver [HSA:5256] [KO:K07190]
            (GSD IXb) PHKB; phosphorylase kinase beta subunit [HSA:5257] [KO:K07190]
            (GSD IXc) PHKG2; phosphorylase kinase gamma subunit, liver [HSA:5261] [KO:K00871]
            (GSD IXd) PHKA1; phosphorylase kinase alpha subunit, muscle [HSA:5255] [KO:K07190]
            (GSD X) PGAM2; 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase [HSA:5224] [KO:K01834]
            (GSD XI/FBS) SLC2A2; glucose transporter [HSA:6514] [KO:K07593]
            (GSD XI) LDHA; lactate dehydrogenase A [HSA:3939] [KO:K00016]
            (GSD XII) ALDOA; fructose-bisphosphate aldolase A [HSA:226] [KO:K01623]
            (GSD XIII) ENO3; beta-enolase [HSA:2027] [KO:K01689]
            (GSD XIV) PGM1; phosphoglucomutase-1 [HSA:5236] [KO:K01835]
            (GSD XV) GYG1; glycogenin-1 [HSA:2992] [KO:K00750]
            (GSDH) PRKAG2; 5'-AMP-activated protein kinase subunit gamma-2 [HSA:51422] [KO:K07200]
            (GSD 0a) GYS2; glycogen synthase, liver [HSA:2998] [KO:K00693]
            (GSD 0b) GYS1; glycogen synthase, muscle [HSA:2997] [KO:K00693]
MARKER      Creatine kinase (GSD II)
            Glycogen [CPD:C00182]
DRUG        Myozyme [DR:D03207] (GSD II)
COMMENT     Additional genes for phosphorylase kinase, which activates glycogen phosphorylase, may also be involved.
DBLINKS     ICD-10: E74.0
            MeSH: D006008
            OMIM: 232200 232220 232240 232300 232400 232500 232600 232700 232800 306000 261750 613027 300559 261670 227810 612933 611881 612932 612934 613507 261740 240600 611556
REFERENCE   PMID:17552001
  AUTHORS   Ozen H
  TITLE     Glycogen storage diseases: new perspectives.
  JOURNAL   World J Gastroenterol 13:2541-53 (2007)
REFERENCE   PMID:17027861
  AUTHORS   Shin YS
  TITLE     Glycogen storage disease: clinical, biochemical, and molecular heterogeneity.
  JOURNAL   Semin Pediatr Neurol 13:115-20 (2006)
REFERENCE   PMID:11949931 (GSD type I)
  AUTHORS   Chou JY, Matern D, Mansfield BC, Chen YT
  TITLE     Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.
  JOURNAL   Curr Mol Med 2:121-43 (2002)
REFERENCE   PMID:11949932 (GSD type II)
  AUTHORS   Raben N, Plotz P, Byrne BJ
  TITLE     Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
  JOURNAL   Curr Mol Med 2:145-66 (2002)
REFERENCE   PMID:11949933 (GSD type III)
  AUTHORS   Shen JJ, Chen YT
  TITLE     Molecular characterization of glycogen storage disease type III.
  JOURNAL   Curr Mol Med 2:167-75 (2002)
REFERENCE   PMID:11949934 (GSD type IV)
  AUTHORS   Moses SW, Parvari R
  TITLE     The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies.
  JOURNAL   Curr Mol Med 2:177-88 (2002)
REFERENCE   PMID:11949935 (GSD type V)
  AUTHORS   Dimaur S, Andreu AL, Bruno C, Hadjigeorgiou GM
  TITLE     Myophosphorylase deficiency (glycogenosis type V; McArdle disease).
  JOURNAL   Curr Mol Med 2:189-96 (2002)
REFERENCE   PMID:8655128 (GSD type IX)
  AUTHORS   Hendrickx J, Willems PJ
  TITLE     Genetic deficiencies of the glycogen phosphorylase system.
  JOURNAL   Hum Genet 97:551-6 (1996)
REFERENCE   PMID:11949937 (GSD type XI)
  AUTHORS   Santer R, Steinmann B, Schaub J
  TITLE     Fanconi-Bickel syndrome--a congenital defect of facilitative glucose transport.
  JOURNAL   Curr Mol Med 2:213-27 (2002)
REFERENCE   PMID:16337419 (GSD type 0)
  AUTHORS   Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI
  TITLE     Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia.
  JOURNAL   Mol Genet Metab 87:284-8 (2006)
REFERENCE   PMID:8447317 (GSD type X)
  AUTHORS   Tsujino S, Shanske S, Sakoda S, Fenichel G, DiMauro S
  TITLE     The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency.
  JOURNAL   Am J Hum Genet 52:472-7 (1993)
REFERENCE   PMID:2334430 (GSD type XI)
  AUTHORS   Maekawa M, Sudo K, Kanno T, Li SS
  TITLE     Molecular characterization of genetic mutation in human lactate dehydrogenase-A (M) deficiency.
  JOURNAL   Biochem Biophys Res Commun 168:677-82 (1990)
REFERENCE   PMID:8598869 (GSD type XII)
  AUTHORS   Kreuder J, Borkhardt A, Repp R, Pekrun A, Gottsche B, Gottschalk U, Reichmann H, Schachenmayr W, Schlegel K, Lampert F
  TITLE     Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A.
  JOURNAL   N Engl J Med 334:1100-4 (1996)
REFERENCE   PMID:11506403 (GSD type XIII)
  AUTHORS   Comi GP, Fortunato F, Lucchiari S, Bordoni A, Prelle A, Jann S, Keller A, Ciscato P, Galbiati S, Chiveri L, Torrente Y, Scarlato G, Bresolin N
  TITLE     Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis.
  JOURNAL   Ann Neurol 50:202-7 (2001)
REFERENCE   PMID:19625727 (GSD type XIV)
  AUTHORS   Stojkovic T, Vissing J, Petit F, Piraud M, Orngreen MC, Andersen G, Claeys KG, Wary C, Hogrel JY, Laforet P
  TITLE     Muscle glycogenosis due to phosphoglucomutase 1 deficiency.
  JOURNAL   N Engl J Med 361:425-7 (2009)
REFERENCE   PMID:20357282 (GSD type XV)
  AUTHORS   Moslemi AR, Lindberg C, Nilsson J, Tajsharghi H, Andersson B, Oldfors A
  TITLE     Glycogenin-1 deficiency and inactivated priming of glycogen synthesis.
  JOURNAL   N Engl J Med 362:1203-10 (2010)
REFERENCE   PMID:15877279 (GSD of Heart)
  AUTHORS   Burwinkel B, Scott JW, Buhrer C, van Landeghem FK, Cox GF, Wilson CJ, Grahame Hardie D, Kilimann MW
  TITLE     Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by  phosphorylase kinase deficiency.
  JOURNAL   Am J Hum Genet 76:1034-49 (2005)
///
ENTRY       H00070                      Disease
NAME        Galactosemia, including:
            Galactose-1P uridylyltransferase deficiency;
            Galactokinase deficiency;
            Galactose epimerase deficiency
DESCRIPTION Galactosemia is an autosomal recessive disorder caused by a defect in one of the three enzyme genes for galactose metabolism. Newborns with the enzyme deficiency cannot properly metabolize milk sugar. Without treatment, toxic metabolites can cause severe growth problems including cataracts.
CATEGORY    Inherited metabolic disease
GENE        (Type 1) GALT; galactose-1P uridylyltransferase [HSA:2592] [KO:K00965]
            (Type 2) GALK1; galactokinase 1 [HSA:2584] [KO:K00849]
            (Type 3) GALE; UDP-galactose-4-epimerase [HSA:2582] [KO:K01784]
MARKER      GALT [HSA:2592]
            galactose [CPD:C00124]
COMMENT     Galactosemia is routinely detected by a newborn screening test.
DBLINKS     ICD-10: E74.2
            MeSH: D005693
            OMIM: 230400 230200 230350
REFERENCE   PMID:17001680
  AUTHORS   Fridovich-Keil JL
  TITLE     Galactosemia: the good, the bad, and the unknown.
  JOURNAL   J Cell Physiol 209:701-5 (2006)
REFERENCE   PMID:16838075
  AUTHORS   Bosch AM
  TITLE     Classical galactosaemia revisited.
  JOURNAL   J Inherit Metab Dis 29:516-25 (2006)
REFERENCE   PMID:9012409
  AUTHORS   Langley SD, Lai K, Dembure PP, Hjelm LN, Elsas LJ
  TITLE     Molecular basis for Duarte and Los Angeles variant galactosemia.
  JOURNAL   Am J Hum Genet 60:366-72 (1997)
REFERENCE   PMID:7670469
  AUTHORS   Stambolian D, Ai Y, Sidjanin D, Nesburn K, Sathe G, Rosenberg M, Bergsma DJ
  TITLE     Cloning of the galactokinase cDNA and identification of mutations in two families with cataracts.
  JOURNAL   Nat Genet 10:307-12 (1995)
REFERENCE   PMID:9973283
  AUTHORS   Wohlers TM, Christacos NC, Harreman MT, Fridovich-Keil JL
  TITLE     Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia.
  JOURNAL   Am J Hum Genet 64:462-70 (1999)
///
ENTRY       H00071                      Disease
NAME        Hereditary fructose intolerance;
            Fructosemia
DESCRIPTION Hereditary fructose intolerance or fructosemia (fructose in the blood) is an autosomal recessive disorder caused by a defect in an aldolase gene (aldolase B), which is normally expressed in liver and kidney. Aldolase is the enzyme that converts fructose 6P (a six-carbon compound) to glycerone-P and glyceraldehyde-3P (two three-carbon compounds).
CATEGORY    Inherited metabolic disease
GENE        ALDOB; aldolase B [HSA:229] [KO:K01623]
DBLINKS     ICD-10: E74.1
            MeSH: D005633
            OMIM: 229600
REFERENCE   PMID:16086449
  AUTHORS   Wong D
  TITLE     Hereditary fructose intolerance.
  JOURNAL   Mol Genet Metab 85:165-7 (2005)
REFERENCE   PMID:9610797
  AUTHORS   Ali M, Rellos P, Cox TM
  TITLE     Hereditary fructose intolerance.
  JOURNAL   J Med Genet 35:353-65 (1998)
///
ENTRY       H00072                      Disease
NAME        Pyruvate dehydrogenase complex deficiency, including:
            Leigh syndrome [DS:H01354];
            Pyruvate dehydrogenase phosphatase deficiency;
            Pyruvate dehydrogenase E3-binding protein deficiency (PDHXD)
DESCRIPTION Pyruvate dehydrogenase complex deficiency is an autosomal or X-linked recessive disorder caused by deficient enzyme activity in the pyruvate dehydrogenase complex, resulting in deficiency of acetyl CoA and reduced synthesis of acetylcholine. This deficiency in newborns may lead to brain malformations. Pyruvate dehydrogenase phosphatase (PDP) is an enzyme which regulates the activity of the pyruvate dehydrogenase complex. It has been reported that the mutations in PDP1 result in severe exercise intolerance and mild developmental delay.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease
GENE        PDHA1; pyruvate dehydrogenase E1 component subunit alpha 1 [HSA:5160] [KO:K00161]
            PDHB; pyruvate dehydrogenase E1 component subunit beta [HSA:5162] [KO:K00162]
            DLAT; pyruvate dehydrogenase E2 component, dihydrolipoamide acetyltransferase [HSA:1737] [KO:K00627]
            DLD; dihydrolipoamide dehydrogenase [HSA:1738] [KO:K00382]
            PDHX; pyruvate dehydrogenase complex component X [HSA:8050] [KO:K13997]
            PPM2C; pyruvate dehyrogenase phosphatase catalytic subunit 1 [HSA:54704] [KO:K01102]
            LRPPRC; Leucine-rich PPR motif-containing protein, mitochondrial [HSA:10128] [KO:K17964]
DBLINKS     ICD-10: E74.4 G31.8
            MeSH: D015325
            OMIM: 256000 614111 245348 245349 308930 312170 608782 220111
REFERENCE   PMID:16854608
  AUTHORS   Robinson BH
  TITLE     Lactic acidemia and mitochondrial disease.
  JOURNAL   Mol Genet Metab 89:3-13 (2006)
REFERENCE   PMID:16843025
  AUTHORS   Mine M, Brivet M, Schiff M, de Baulny HO, Chuzhanova N, Marsac C
  TITLE     A novel gross deletion caused by non-homologous recombination of the PDHX gene in a patient with pyruvate dehydrogenase deficiency.
  JOURNAL   Mol Genet Metab 89:106-10 (2006)
REFERENCE   PMID:16156009
  AUTHORS   Pithukpakorn M
  TITLE     Disorders of pyruvate metabolism and the tricarboxylic acid cycle.
  JOURNAL   Mol Genet Metab 85:243-6 (2005)
REFERENCE   PMID:12925875
  AUTHORS   Grafakou O, Oexle K, van den Heuvel L, Smeets R, Trijbels F, Goebel HH, Bosshard N, Superti-Furga A, Steinmann B, Smeitink J
  TITLE     Leigh syndrome due to compound heterozygosity of dihydrolipoamide dehydrogenase gene mutations. Description of the first E3 splice site mutation.
  JOURNAL   Eur J Pediatr 162:714-8 (2003)
REFERENCE   PMID:10679936
  AUTHORS   Lissens W, De Meirleir L, Seneca S, Liebaers I, Brown GK, Brown RM, Ito M, Naito E, Kuroda Y, Kerr DS, Wexler ID, Patel MS, Robinson BH, Seyda A
  TITLE     Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency.
  JOURNAL   Hum Mutat 15:209-19 (2000)
REFERENCE   PMID:7853374
  AUTHORS   Brown GK, Otero LJ, LeGris M, Brown RM
  TITLE     Pyruvate dehydrogenase deficiency.
  JOURNAL   J Med Genet 31:875-9 (1994)
REFERENCE   PMID:16574315
  AUTHORS   Maj MC, Cameron JM, Robinson BH
  TITLE     Pyruvate dehydrogenase phosphatase deficiency: orphan disease or an under-diagnosed condition?
  JOURNAL   Mol Cell Endocrinol 249:1-9 (2006)
REFERENCE   PMID:12529507
  AUTHORS   Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, Sladek R, Xu F, Mitchell GA, Morin C, Mann M, Hudson TJ, Robinson B, Rioux JD, Lander ES
  TITLE     Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics.
  JOURNAL   Proc Natl Acad Sci U S A 100:605-10 (2003)
REFERENCE   PMID:9399911
  AUTHORS   Aral B, Benelli C, Ait-Ghezala G, Amessou M, Fouque F, Maunoury C, Creau N, Kamoun P, Marsac C
  TITLE     Mutations in PDX1, the human lipoyl-containing component X of the pyruvate dehydrogenase-complex gene on chromosome 11p1, in congenital lactic acidosis.
  JOURNAL   Am J Hum Genet 61:1318-26 (1997)
///
ENTRY       H00073                      Disease
NAME        Pyruvate carboxylase deficiency
DESCRIPTION Pyruvate carboxylase deficiency is an autosomal recessive disorder caused by deficient activity of pyruvate carboxylase, an enzyme that catalyzes conversion from pyruvate to oxaloacetate.
CATEGORY    Inherited metabolic disease
GENE        PC; pyruvate carboxylase [HSA:5091] [KO:K01958]
DBLINKS     ICD-10: E74.4
            MeSH: D015324
            OMIM: 266150
REFERENCE   PMID:18676167
  AUTHORS   Wang D, Yang H, De Braganca KC, Lu J, Yu Shih L, Briones P, Lang T, De Vivo DC
  TITLE     The molecular basis of pyruvate carboxylase deficiency: mosaicism correlates with prolonged survival.
  JOURNAL   Mol Genet Metab 95:31-8 (2008)
REFERENCE   PMID:16156009
  AUTHORS   Pithukpakorn M
  TITLE     Disorders of pyruvate metabolism and the tricarboxylic acid cycle.
  JOURNAL   Mol Genet Metab 85:243-6 (2005)
REFERENCE   PMID:12597053
  AUTHORS   De Meirleir L
  TITLE     Defects of pyruvate metabolism and the Krebs cycle.
  JOURNAL   J Child Neurol 17 Suppl 3:3S26-33; discussion 3S33-4 (2002)
///
ENTRY       H00074                      Disease
NAME        Canavan disease (CD)
DESCRIPTION Canavan disease (CD) is an autosomal recessive neurodegenerative disorder associated with mutations of the gene encoding aspartoacylase (ASPA). In humans, the CD syndrome is marked by early onset, hydrocephalus, macroencephaly, psychomotor retardation, and spongiform myelin sheath vacuolization with progressive leukodystrophy. The disease is caused by aspartoacylase deficiency resulting in accumulation of N-acetylaspartic acid (NAA) in the brain. The increased levels of NAA in CD lead to swelling or sponginess of the brain. Two mutations account for about 98% of the alleles of Ashkenazi Jewish patients, in which population the disease is highly prevalent(E285A and Y231X in ASPA protein). Mutations in the ASPA gene in non-Jewish patients are different and more diverse.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease
GENE        ASPA; aspartoacylase [HSA:443] [KO:K01437]
MARKER      N-acetylaspartate [CPD:C01042]
            N-acetylaspartylglutamate [CPD:C12270]
COMMENT     Disease class: leukodystrophy
            Affected region: cerebral white matter
            Microscopic lesion: accumulation of a chemical called N-acetyl-aspartic acid (NAA) and degeneration of myelin
DBLINKS     ICD-10: E75.2
            MeSH: D017825
            OMIM: 271900
REFERENCE   PMID:19319678
  AUTHORS   Baslow MH, Guilfoyle DN
  TITLE     Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
  JOURNAL   Neurochem Res 34:1523-34 (2009)
REFERENCE   PMID:17391648
  AUTHORS   Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA
  TITLE     Mutational analysis of aspartoacylase: implications for Canavan disease.
  JOURNAL   Brain Res 1148:1-14 (2007)
REFERENCE   PMID:16807907
  AUTHORS   Kumar S, Mattan NS, de Vellis J.
  TITLE     Canavan disease: a white matter disorder.
  JOURNAL   Ment Retard Dev Disabil Res Rev 12:157-65 (2006)
REFERENCE   PMID:16647192
  AUTHORS   Namboodiri AM, Peethambaran A, Mathew R, Sambhu PA, Hershfield J, Moffett JR, Madhavarao CN
  TITLE     Canavan disease and the role of N-acetylaspartate in myelin synthesis.
  JOURNAL   Mol Cell Endocrinol 252:216-23 (2006)
REFERENCE   PMID:14567959
  AUTHORS   Surendran S, Michals-Matalon K, Quast MJ, Tyring SK, Wei J, Ezell EL, Matalon R
  TITLE     Canavan disease: a monogenic trait with complex genomic interaction.
  JOURNAL   Mol Genet Metab 80:74-80 (2003)
REFERENCE   PMID:12638939
  AUTHORS   Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ, Raghavan S, Ong E, Pastores GM, Kolodny EH
  TITLE     Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.
  JOURNAL   J Inherit Metab Dis 25:557-70 (2002)
REFERENCE   PMID:8252036
  AUTHORS   Kaul R, Gao GP, Balamurugan K, Matalon R
  TITLE     Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
  JOURNAL   Nat Genet 5:118-23 (1993)
///
ENTRY       H00075                      Disease
NAME        Refsum disease;
            Heredopathia atactica polyneuritiformis
DESCRIPTION Refsum disease (RD) is an autosomal recessive sensory motor neuropathy charactarized by retinitis pigmentosa, peripheral neuropathy, anosmia, deafness, cerebellar ataxia and elevated protein concentrations in the cerebrospinal fluid in the absence of an increased number of cells. The age at which symptoms first present in RD can be variable although most cases present in adolescence. Because the patients are unable to metabolize phytanic acid derived from exogenous sources, highly raised plasma phytanic acid (PA) level in tissues and body fluids is the hallmark of RD. Mutant forms of phytanoyl-CoA 2-hydroxylase (PHYH) which plays a key role of phytanic acid alpha-oxidation in peroxisomes have been shown to be responsible for some, but not all, cases of Refsum's disease. Peroxisomal PHYH import occurs via PEX7 which is the peroxisomal matrix protein receptor. Though PEX7 has been identified another responsible gene, there still remain a small number of patients in whom no mutations in either of these two genes can be found.
CATEGORY    Neurodegenerative disease; Inherited metabolic disease; Peroxisomal disease
GENE        PHYH; phytanoyl-CoA 2-hydroxylase [HSA:5264] [KO:K00477]
            PEX7; peroxisomal biogenesis factor 7 [HSA:5191] [KO:K13341]
ENV_FACTOR  Phytanic acid from diet
MARKER      Phytanic acid [CPD:C01607]
COMMENT     Disease class: leukodystrophy; phytanic acid storage disease
            Affected region: cerebellum
            Microscopic lesion: accumulation of phytanic acid
DBLINKS     ICD-10: G60.1
            MeSH: D012035
            OMIM: 266500
REFERENCE   PMID:17956237
  AUTHORS   Wierzbicki AS
  TITLE     Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
  JOURNAL   Biochem Soc Trans 35:881-6 (2007)
REFERENCE   PMID:17956234
  AUTHORS   Wanders RJ, Komen JC
  TITLE     Peroxisomes, Refsum's disease and the alpha- and omega-oxidation of phytanic acid.
  JOURNAL   Biochem Soc Trans 35:865-9 (2007)
REFERENCE   PMID:16799769
  AUTHORS   van den Brink DM, Wanders RJ
  TITLE     Phytanic acid: production from phytol, its breakdown and role in human disease.
  JOURNAL   Cell Mol Life Sci 63:1752-65 (2006)
REFERENCE   PMID:14974078 (PEX7)
  AUTHORS   Jansen GA, Waterham HR, Wanders RJ.
  TITLE     Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7).
  JOURNAL   Hum Mutat 23:209-18 (2004)
REFERENCE   PMID:12700346
  AUTHORS   Wierzbicki AS, Mayne PD, Lloyd MD, Burston D, Mei G, Sidey MC, Feher MD, Gibberd FB
  TITLE     Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease.
  JOURNAL   J Lipid Res 44:1481-8 (2003)
REFERENCE   PMID:12633678
  AUTHORS   Wanders RJ, Jansen GA, Lloyd MD
  TITLE     Phytanic acid alpha-oxidation, new insights into an old problem: a review.
  JOURNAL   Biochim Biophys Acta 1631:119-35 (2003)
///
ENTRY       H00076                      Disease
NAME        Cockayne syndrome
DESCRIPTION Cockayne syndrome (CS) is a rare recessive disorder characterized by progressive multisystem abnormalities such as postnatal growth deficiency, progressive pigmentary retinopathy, sensorineural hearing loss, dental caries and neurological degeneration. CS has thus been classified as a segmental premature-aging syndrome. CSA caused by mutation in the gene encoding the group 8 excision-repair cross-complementing protein (ERCC8) is early childhood onset in the second year of life, CSB caused by mutation in the ERCC6 gene is late childhood onset with mild symptoms. ERCC8 encodes a Walker domain (WD)-repeat protein involved in the transcription-coupled repair system of the actively transcribed DNA. ERCC6 protein is at the interface of transcription and DNA repair and is involved in transcription-coupled and global genome-DNA repair, as well as in general transcription.
CATEGORY    Neurodegenerative disease
GENE        (CSA) ERCC8; Excision repair cross complementing, group 8 (mutation) [HSA:1161] [KO:K10570]
            (CSB) ERCC6; Excision repair cross complementing, group 6 (mutation) [HSA:2074] [KO:K10841]
DRUG        Prodarsan (Phase I)
COMMENT     Affected region: cerebral cortex, cerebellum, basal ganglia
            Microscopic lesion: accumulate of DNA lesions, tigroid-type demyelination, multifocal calcium deposition
DBLINKS     ICD-10: Q87.1
            MeSH: D003057
            OMIM: 216400 133540
REFERENCE   PMID:17603927
  AUTHORS   Frosina G.
  TITLE     The current evidence for defective repair of oxidatively damaged DNA in Cockayne syndrome.
  JOURNAL   Free Radic Biol Med 43:165-77 (2007)
REFERENCE   PMID:17084038
  AUTHORS   Kleppa L, Kanavin OJ, Klungland A, Stromme P
  TITLE     A novel splice site mutation in the Cockayne syndrome group A gene in two siblings with Cockayne syndrome.
  JOURNAL   Neuroscience 145:1397-406 (2007)
REFERENCE   PMID:14639525 (CSB)
  AUTHORS   Licht CL, Stevnsner T, Bohr VA
  TITLE     Cockayne syndrome group B cellular and biochemical functions.
  JOURNAL   Am J Hum Genet 73:1217-39 (2003)
REFERENCE   PMID:9443879 (CSB)
  AUTHORS   Mallery DL, Tanganelli B, Colella S, Steingrimsdottir H, van Gool AJ, Troelstra C, Stefanini M, Lehmann AR
  TITLE     Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome.
  JOURNAL   Am J Hum Genet 62:77-85 (1998)
REFERENCE   PMID:7664335 (CSA)
  AUTHORS   Henning KA, Li L, Iyer N, McDaniel LD, Reagan MS, Legerski R, Schultz RA, Stefanini M, Lehmann AR, Mayne LV, Friedberg EC
  TITLE     The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH.
  JOURNAL   Cell 82:555-64 (1995)
///
ENTRY       H00077                      Disease
NAME        Progressive supranuclear palsy (PSP);
            Steele-Richardson-Olszewski syndrome
DESCRIPTION Progressive supranuclear palsy (PSP) is a progressing degenerative disease belonging to the family of tauophaties caused by abnormalities in the microtubule-associated protein, tau. PSP presents with an atypical parkinsonism characterized by progressive axial rigidity, vertical gaze palsy, dysarthria and dysphagia. Although the majority of cases of progressive supranuclear palsy appear to be sporadic, the scarcity of familial cases may lack of recognition of the variable phenotypic expression of PSP. One in every 100,000 Americans over the age of 60 have PSP and patients are usually middle-aged or elderly, and men are affected more often than women.
CATEGORY    Neurodegenerative disease
GENE        MAPT; microtubule-associated protein tau (mutation) [HSA:4137] [KO:K04380]
COMMENT     Disease class: tauopathy
            Affected region: basal ganglia, brain stem, cerebellum
            Microscopic lesion: tau positive inclusions
DBLINKS     ICD-10: G23.1
            MeSH: D013494
            OMIM: 601104 260540
REFERENCE   PMID:19233037
  AUTHORS   Williams DR, Lees AJ
  TITLE     Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.
  JOURNAL   Lancet Neurol 8:270-9 (2009)
REFERENCE   PMID:18267262
  AUTHORS   Houghton DJ, Litvan I
  TITLE     Unraveling progressive supranuclear palsy: from the bedside back to the bench.
  JOURNAL   Parkinsonism Relat Disord 13 Suppl 3:S341-6 (2007)
REFERENCE   PMID:17493041
  AUTHORS   Dickson DW, Rademakers R, Hutton ML.
  TITLE     Progressive supranuclear palsy: pathology and genetics.
  JOURNAL   Brain Pathol 17:74-82 (2007)
REFERENCE   PMID:12151839
  AUTHORS   Pastor P, Tolosa E
  TITLE     Progressive supranuclear palsy: clinical and genetic aspects.
  JOURNAL   Curr Opin Neurol 15:429-37 (2002)
///
ENTRY       H00078                      Disease
NAME        Frontotemporal lobar degeneration (FTLD), including:
            Pick disease of brain;
            Frontotemporal dementia (FTD);
            Ubiquitin-positive frontotemporal dementia (UP-FTD);
            Progressive supranuclear palsy type 1 (PSNP1);
            Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD);
            Frontotemporal dementia, chromosome 3-linked (FTD3)
DESCRIPTION Frontotemporal lobar degeneration (FTLD) is a heterogeneous syndrome with the common feature being a relatively selective degeneration of the frontal and temporal lobes. Multiple genes have been implicated in FTLD including microtubule associate protein tau (MAPT), progranulin (PGRN),Valosin-containing protein (VCP) and chromatin modifying protein 2B (CHMP2B). MAPT mutations are associated with tau pathology. Mutations in progranulin and valosin are associated with TDP-43 inclusions. The CHMP2B mutations are associated with ubiquitin-positive pathology.
CATEGORY    Neurodegenerative disease
GENE        (Pick disease/ FTD/ PSNP1) MAPT [HSA:4137] [KO:K04380]
            (Pick disease/ FTD) PSEN1 [HSA:5663] [KO:K04505]
            (UP-FTD) GRN [HSA:2896]
            (IBMPFD) VCP [HSA:7415] [KO:K13525]
            (FTD3) CHMP2B [HSA:25978] [KO:K12192]
COMMENT     Disease class: tauopathy
            Affected region: frontal lobe, temporal lobe
            Microscopic lesion: Pick bodies
DBLINKS     ICD-10: G31.0
            MeSH: D057174
            OMIM: 172700 600274 607485 601104 167320 600795
REFERENCE   PMID:19638255
  AUTHORS   Neumann M, Tolnay M, Mackenzie IR
  TITLE     The molecular basis of frontotemporal dementia.
  JOURNAL   Expert Rev Mol Med 11:e23 (2009)
REFERENCE   PMID:18631953
  AUTHORS   Trojanowski JQ, Duff K, Fillit H, Koroshetz W, Kuret J, Murphy D, Refolo L
  TITLE     New directions for frontotemporal dementia drug discovery.
  JOURNAL   Alzheimers Dement 4:89-93 (2008)
REFERENCE   PMID:18596549
  AUTHORS   Bigio EH
  TITLE     Update on recent molecular and genetic advances in frontotemporal lobar degeneration.
  JOURNAL   J Neuropathol Exp Neurol 67:635-48 (2008)
REFERENCE   PMID:18090424
  AUTHORS   Kertesz A
  TITLE     Pick complex--historical introduction.
  JOURNAL   Alzheimer Dis Assoc Disord 21:S5-7 (2007)
REFERENCE   PMID:17805587
  AUTHORS   Mackenzie IR, Rademakers R
  TITLE     The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments.
  JOURNAL   Neurogenetics 8:237-48 (2007)
REFERENCE   PMID:17764635
  AUTHORS   Rademakers R, Hutton M
  TITLE     The genetics of frontotemporal lobar degeneration.
  JOURNAL   Curr Neurol Neurosci Rep 7:434-42 (2007)
REFERENCE   PMID:17596717
  AUTHORS   van der Zee J, Gijselinck I, Pirici D, Kumar-Singh S, Cruts M, Van Broeckhoven C.
  TITLE     Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update.
  JOURNAL   Neurodegener Dis 4:227-35 (2007)
REFERENCE   PMID:14593167
  AUTHORS   Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hyslop P.
  TITLE     The genetics of adult-onset neuropsychiatric disease: complexities and conundra?
  JOURNAL   Science 302:822-6 (2003)
REFERENCE   PMID:19924424
  AUTHORS   Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM
  TITLE     Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update.
  JOURNAL   Acta Neuropathol 119:1-4 (2010)
///
ENTRY       H00079                      Disease
NAME        Asthma
DESCRIPTION Asthma is a complex syndrome with many clinical phenotypes in both adults and children. Its major characteristics include a variable degree of airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Inhaled allergens encounter antigen presenting cells (APC) that line the airway. Upon recognition of the antigen and activation by APC, naive T cells differentiate into TH2 cells. Activated TH2 stimulate the formation of IgE by B cells. IgE molecules bind to IgE receptors located on mast cells. The crosslinking of mast-cell-bound IgE by allergens leads to the release of biologically active mediators (histamine, leukotrienes) by means of degranulation and, so, to the immediate symptoms of allergy. Mast cells also release chemotactic factors that contribute to the recruitment of inflammatory cells, particularly eosinophils, whose proliferation and differentiation from bone marrow progenitors is promoted by IL-5. The activation of eosinophils leads to release of toxic granules and oxygen free radicals that lead to tissue damage and promote the development of chronic inflammation.
CATEGORY    Immune system disease
GENE        IL4 (polymorphism) [HSA:3565] [KO:K05430]
            IL4RA (polymorphism) [HSA:3566] [KO:K05071]
            IL13 (polymorphism) [HSA:3596] [KO:K05435]
            FCER1B (polymorphism) [HSA:2206] [KO:K08090]
            TNFA (polymorphism) [HSA:7124] [KO:K03156]
            ADAM33 (polymorphism) [HSA:80332] [KO:K08616]
            CD14 (polymorphism) [HSA:929] [KO:K04391]
            HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
            ADRB2 (polymorphism) [HSA:154] [KO:K04142]
ENV_FACTOR  Particulate matter
            Diesel exhaust
            NO2 (nitrogen dioxide)
            Passive smoking/environmental tobacco smoke (ETS)
            Ozone
            Sulfur dioxide [CPD:C09306]
MARKER      NO (exhaled gas) [CPD:C00533]
DRUG        Methylprednisolone [DR:D00407]
            Prednisolone [DR:D00472]
            Prednisone [DR:D00473]
            Salmeterol [DR:D00687]
            Formoterol [DR:D07990]
            Fluticasone [DR:D07981]
            Salmeterol [DR:D05792]
            Budesonide [DR:D00246]
            Cromolyn [DR:D00526]
            Nedocromil [DR:D05129]
            Tiotropium [DR:D01929]
            Montelukast [DR:D08229]
            Zafirlukast [DR:D00411]
            Zileuton [DR:D00414]
            Theophylline [DR:D00371]
            Omalizumab [DR:D05251]
            Beclomethasone [DR:D00689]
            Flunisolide [DR:D00324]
            Fluticasone [DR:D07981]
            Mometasone [DR:D08227]
            Triamcinolone acetonide [DR:D00983]
            Albuterol [DR:D00683]
            Pirbuterol [DR:D08387]
            Levalbuterol [DR:D02281]
            Ipratropium [DR:D02212]
COMMENT     Allergen:
            Furred pet (cat, dog)
            Dust mite
            Cockroach
            Rodent (rat, mouse)
            Mold
            Pollen (tree, grass, weed)
DBLINKS     ICD-10: J45
            MeSH: D001249
REFERENCE   PMID:18446588 (description, gene)
  AUTHORS   Warrier MR, Hershey GK.
  TITLE     Asthma genetics: personalizing medicine.
  JOURNAL   J Asthma 45:257-64 (2008)
REFERENCE   PMID:11172168 (description)
  AUTHORS   Busse WW, Lemanske RF Jr.
  TITLE     Asthma.
  JOURNAL   N Engl J Med 344:350-62 (2001)
REFERENCE   PMID:18301422 (gene)
  AUTHORS   Vercelli D.
  TITLE     Discovering susceptibility genes for asthma and allergy.
  JOURNAL   Nat Rev Immunol 8:169-82 (2008)
REFERENCE   PMID:16395390 (gene)
  AUTHORS   Ober C, Hoffjan S.
  TITLE     Asthma genetics 2006: the long and winding road to gene discovery.
  JOURNAL   Genes Immun 7:95-100 (2006)
REFERENCE   PMID:17050746 (env_factor)
  AUTHORS   Castro-Giner F, Kauffmann F, de Cid R, Kogevinas M.
  TITLE     Gene-environment interactions in asthma.
  JOURNAL   Occup Environ Med 63:776-86, 761 (2006)
REFERENCE   PMID:18426614 (env_factor, allergen)
  AUTHORS   Diette GB, McCormack MC, Hansel NN, Breysse PN, Matsui EC.
  TITLE     Environmental issues in managing asthma.
  JOURNAL   Respir Care 53:602-15; discussion 616-7 (2008)
REFERENCE   PMID:16164436 (env_factor)
  AUTHORS   D'Amato G, Liccardi G, D'Amato M, Holgate S.
  TITLE     Environmental risk factors and allergic bronchial asthma.
  JOURNAL   Clin Exp Allergy 35:1113-24 (2005)
REFERENCE   PMID:17099035 (marker)
  AUTHORS   Kharitonov SA, Barnes PJ.
  TITLE     Exhaled biomarkers.
  JOURNAL   Chest 130:1541-6 (2006)
REFERENCE   PMID:9624291 (marker)
  AUTHORS   Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ.
  TITLE     Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma.
  JOURNAL   Thorax 53:91-5 (1998)
REFERENCE   PMID:12101782 (marker)
  AUTHORS   Kharitonov SA, Barnes PJ.
  TITLE     Biomarkers of some pulmonary diseases in exhaled breath.
  JOURNAL   Biomarkers 7:1-32 (2002)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:16581556 (allergen)
  AUTHORS   Zeldin DC, Eggleston P, Chapman M, Piedimonte G, Renz H, Peden D.
  TITLE     How exposures to biologics influence the induction and incidence of asthma.
  JOURNAL   Environ Health Perspect 114:620-6 (2006)
///
ENTRY       H00080                      Disease
NAME        Systemic lupus erythematosus
DESCRIPTION Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.
CATEGORY    Immune system disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DQA1 (polymorphism) [HSA:3117] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
            C2 (deletion) [HSA:717] [KO:K01332]
            C4 (null alleles) [HSA:720] [KO:K03989]
            TNF-alpha (polymorphism) [HSA:7124] [KO:K03156]
            Fc gamma RIIA (polymorphism) [HSA:2212] [KO:K06472]
            Fc gamma RIIB (polymorphism) [HSA:2213] [KO:K12560]
            Fc gamma RIIIA (polymorphism) [HSA:2214] [KO:K06463]
            Fc gamma RIIIB (polymorphism) [HSA:2215] [KO:K06463]
            PARP (polymorphism)
            CRP (polymorphism) [HSA:1401] [KO:K16143]
            TLR5 (polymorphism) [HSA:7100] [KO:K10168]
            PDCD1 (polymorphism) [HSA:5133] [KO:K06744]
            OAZ (polymorphism) [HSA:23090]
ENV_FACTOR  Hydrazines
            Procainamide [DR:D00477]
            Chlorpromazine [DR:D00270 D00789]
            Isoniazid [DR:D00346 ]
            Phenytoin [DR:D00512 ]
            Penicillamine [DR:D00496]
            Tobacco smoke
            Hair dyes
            Ultraviolet light
            Epstein-Barr virus
MARKER      Anti-C1q
            Anti-dsDNA
            C3 [HSA:718]
            C4d
            CR1/E [HSA:1378]
            CRP [HSA:1401]
            CD27 [HSA:939]
            IL-6 [HSA:3569]
            IL-10 [HSA:3586]
            IL-12 [HSA:3594 3565]
            IL-13 [HSA:3596]
            IL-16 [HSA:3603]
            IL-18 [HSA:3606]
            INF-alpha
            TNF-alpha [HSA:7124]
            Urine MCP-1
            IL2R [HSA:3559 3560 3561]
            TNFR
            IL1Ra (IL-1R antagonist) [HSA:3557]
            CD27 [HSA:939]
            CD154 [HSA:959]
            ICAM-1 [HSA:3383]
            sVCAM-1 [HSA:7412]
            Thrombomodulin [HSA:7056]
DRUG        NSAID
            Hydroxychloroquine [DG:DG01015]
            Methylprednisolone [DG:DG00410]
            Prednisone [DR:D00473]
            Cyclophosphamide [DG:DG00675]
            Mycophenolate mofetil [DR:D00752 D05094]
            Azathioprine [DG:DG00743]
            Rituximab [DR:D02994]
            Epatuzumab
            Abetimus sodium [DR:D03204]
            CTLA-4-Ig
COMMENT     Autoantigen:
            Double-stranded DNA [CPD:C00434]
            H2A [HSA:474382]
            H2B [HSA:8346]
            H3 [HSA:3020]
            H4 [HSA:8359]
            Ro/SS-A [HSA:6737]
            La/SS-B [HSA:6741]
            Sm-B [HSA:6628]
            Sm-D [HSA:6632]
            NR2A [HSA:2903]
            NR2B [HSA:2904]
            Phosphatidyl-serine [CPD:C02737]
            C1q [HSA:712]
DBLINKS     ICD-10: M32
            MeSH: D008180
            OMIM: 152700 601744 605218
REFERENCE   PMID:12835292 (description, gene, env_factor, autoantigen)
  AUTHORS   Mok CC, Lau CS.
  TITLE     Pathogenesis of systemic lupus erythematosus.
  JOURNAL   J Clin Pathol 56:481-90 (2003)
REFERENCE   PMID:18305268 (gene, autoantigen)
  AUTHORS   Rahman A, Isenberg DA.
  TITLE     Systemic lupus erythematosus.
  JOURNAL   N Engl J Med 358:929-39 (2008)
REFERENCE   PMID:18075789 (gene)
  AUTHORS   Rhodes B, Vyse TJ.
  TITLE     General aspects of the genetics of SLE.
  JOURNAL   Autoimmunity 40:550-9 (2007)
REFERENCE   PMID:16941108 (gene)
  AUTHORS   Wong M, Tsao BP.
  TITLE     Current topics in human SLE genetics.
  JOURNAL   Springer Semin Immunopathol 28:97-107 (2006)
REFERENCE   PMID:18028758 (env_factor)
  AUTHORS   Albilia JB, Lam DK, Clokie CM, Sandor GK.
  TITLE     Systemic lupus erythematosus: a review for dentists.
  JOURNAL   J Can Dent Assoc 73:823-8 (2007)
REFERENCE   PMID:16373251 (env_factor)
  AUTHORS   Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A.
  TITLE     Environment and systemic lupus erythematosus: an overview.
  JOURNAL   Autoimmunity 38:465-72 (2005)
REFERENCE   PMID:17307106 (env_factor)
  AUTHORS   D'Cruz DP, Khamashta MA, Hughes GR.
  TITLE     Systemic lupus erythematosus.
  JOURNAL   Lancet 369:587-96 (2007)
REFERENCE   PMID:16168709 (marker)
  AUTHORS   Croker JA, Kimberly RP.
  TITLE     SLE: challenges and candidates in human disease.
  JOURNAL   Trends Immunol 26:580-6 (2005)
REFERENCE   PMID:16093831 (marker)
  AUTHORS   Liu CC, Manzi S, Ahearn JM.
  TITLE     Biomarkers for systemic lupus erythematosus: a review and perspective.
  JOURNAL   Curr Opin Rheumatol 17:543-9 (2005)
REFERENCE   PMID:15248202 (marker)
  AUTHORS   Illei GG, Tackey E, Lapteva L, Lipsky PE.
  TITLE     Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.
  JOURNAL   Arthritis Rheum 50:2048-65 (2004)
REFERENCE   PMID:15355751 (marker)
  AUTHORS   Illei GG, Lipsky PE.
  TITLE     Biomarkers in systemic lupus erythematosus.
  JOURNAL   Curr Rheumatol Rep 6:382-90 (2004)
REFERENCE   (drug)
REFERENCE   PMID:18068856 (drug)
  AUTHORS   King JK, Hahn BH.
  TITLE     Systemic lupus erythematosus: modern strategies for management: a moving target.
  JOURNAL   Best Pract Res Clin Rheumatol 21:971-87 (2007)
REFERENCE   PMID:17699298 (drug)
  AUTHORS   Ponticelli C.
  TITLE     New therapies for lupus nephritis.
  JOURNAL   Clin J Am Soc Nephrol 1:863-8 (2006)
REFERENCE   PMID:15380523 (autoantigen)
  AUTHORS   Hoffman RW.
  TITLE     T cells in the pathogenesis of systemic lupus erythematosus.
  JOURNAL   Clin Immunol 113:4-13 (2004)
REFERENCE   PMID:16932712 (autoantigen)
  AUTHORS   Cook HT, Botto M.
  TITLE     Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus.
  JOURNAL   Nat Clin Pract Rheumatol 2:330-7 (2006)
///
ENTRY       H00081                      Disease
NAME        Hashimoto's thyroiditis
DESCRIPTION Hashimoto's thyroiditis (HT) is a common form of chronic autoimmune thyroid disease (AITD), and is characterized by an inflammatory infiltrate of immunocytes that replace the parenchyma and induce thyroid enlargement, which eventually leads to gland fibrosis. Progressive thyrocyte depletion results in impaired thyroid hormone production and clinical hypothyroidism, a condition that involves a marked reduction of metabolic activity in various cells and tissues. AITDs are regarded as polygenic disorders resulting from the combination of a genetic predisposition in conjunction with an environmental trigger. Two main approaches have been employed to locate susceptibility loci for AITD, namely case control candidate gene studies and genome-wide linkage screens. Case control candidate gene studies have been employed to investigate numerous genes for association with AITD, but to date, only the human leucocyte region (HLA) on chromosome 6p21 and the cytotoxic T lymphocyte associated 4 (CTLA-4) gene on chromosome 2q33 have been consistently shown to be associated with disease.
CATEGORY    Immune system disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DQA1 (polymorphism) [HSA:3117] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
            CTLA-4 (polymorphism) [HSA:1493] [KO:K06538]
ENV_FACTOR  Iodine [CPD:C01382]
            Amiodarone [DR:D00636 D02910]
            IFN-alpha [DR:D00745 D02745 D03305 D04552 D04553]
            Infectious organisms
            IL-2 [HSA:3558]
MARKER      TSH (thyrotropin) [HSA:1081 7252]
            Thyroxine (T4) [CPD:C01829]
            Triiodothyronine (T3) [CPD:C02465]
            Anti-Tg
            Anti-TPO
DRUG        Levothyroxine [DG:DG00510]
            Thyroxine (T4) [DR:D08125]
            Simvastatin [DR:D00434]
            Selenium selenite
COMMENT     Autoantigens:
            Thyroidperoxidase (TPO) [HSA:7173]
            Thyroglobulin (Tg) [HSA:7038]
            Na+/ I- symporter (NIS) [HSA:6528]
DBLINKS     ICD-10: E06.3
            MeSH: D050031
REFERENCE   PMID:11913070 (description)
  AUTHORS   Stassi G, De Maria R.
  TITLE     Autoimmune thyroid disease: new models of cell death in autoimmunity.
  JOURNAL   Nat Rev Immunol 2:195-204 (2002)
REFERENCE   PMID:15049952 (gene, env_factor)
  AUTHORS   Fountoulakis S, Tsatsoulis A.
  TITLE     On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis.
  JOURNAL   Clin Endocrinol (Oxf) 60:397-409 (2004)
REFERENCE   PMID:15030506 (description, gene)
  AUTHORS   Simmonds MJ, Gough SC.
  TITLE     Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond.
  JOURNAL   Clin Exp Immunol 136:1-10 (2004)
REFERENCE   PMID:15762980 (gene, env_factor, marker)
  AUTHORS   Chistiakov DA.
  TITLE     Immunogenetics of Hashimoto's thyroiditis.
  JOURNAL   J Autoimmune Dis 2:1 (2005)
REFERENCE   PMID:12734493 (gene, env_factor, marker, autoantigen)
  AUTHORS   Ai J, Leonhardt JM, Heymann WR.
  TITLE     Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations.
  JOURNAL   J Am Acad Dermatol 48:641-59; quiz 660-2 (2003)
REFERENCE   PMID:15132715 (env_factor)
  AUTHORS   Prummel MF, Strieder T, Wiersinga WM.
  TITLE     The environment and autoimmune thyroid diseases.
  JOURNAL   Eur J Endocrinol 150:605-18 (2004)
REFERENCE   (drug)
REFERENCE   PMID:16127951 (drug)
  AUTHORS   Reid JR, Wheeler SF.
  TITLE     Hyperthyroidism: diagnosis and treatment.
  JOURNAL   Am Fam Physician 72:623-30 (2005)
REFERENCE   PMID:11396701 (autoantigen)
  AUTHORS   Ruwhof C, Drexhage HA.
  TITLE     Iodine and thyroid autoimmune disease in animal models.
  JOURNAL   Thyroid 11:427-36 (2001)
REFERENCE   PMID:15135604 (autoantigen)
  AUTHORS   Scofield RH.
  TITLE     Autoantibodies as predictors of disease.
  JOURNAL   Lancet 363:1544-6 (2004)
///
ENTRY       H00082                      Disease
NAME        Graves' disease
DESCRIPTION Grave's disease is a common form of chronic autoimmune thyroid disease (AITD), and is characterized by overstimulation of the thyroid gland with agonistic anti-thyrotropin (TSH) receptor autoantibodies. This overstimulation leads to follicular hypertrophy and hyperplasia, causing thyroid enlargement, as well as increases in thyroid hormone production and the fraction of triiodothyronine (T3) relative to thyroxine (T4) in thyroid secretion. Thyroid autoimmune diseases are regarded as polygenic disorders resulting from the combination of a genetic predisposition in conjunction with an environmental trigger. Two main approaches have been employed to locate susceptibility loci for AITD, namely case control candidate gene studies and genome-wide linkage screens. Case control candidate gene studies have been employed to investigate numerous genes for association with AITD, but to date, only the human leucocyte region (HLA) on chromosome 6p21 and the cytotoxic T lymphocyte associated 4 (CTLA-4) gene on chromosome 2q33 have been consistently shown to be associated with disease.
CATEGORY    Immune system disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DQA1 (polymorphism) [HSA:3117] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
            CTLA-4 (polymorphism) [HSA:1493] [KO:K06538]
ENV_FACTOR  Iodine [CPD:C01382]
            IFN-alpha [DR:D00745 D02745 D03305 D04552 D04553]
            Infectious organisms
            Smoking
MARKER      TSH (thyrotropin) [HSA:1081 7252]
            Thyroxine (T4) [CPD:C01829]
            Triiodothyronine (T3) [CPD:C02465]
            Anti-TSHR
DRUG        Propranolol [DG:DG00305]
            Methimazole [DR:D00401 ]
            Propylthiouracil [DR:D00562]
            Iopanoic acid (Telepaque) [DR:D01014]
            Ipodate sodium (Bilivist, Oragrafin) [DR:D01015]
            Radioactive iodine (131I)
COMMENT     Autoantigen:
            TSH-R [HSA:7253]
DBLINKS     ICD-10: E05.0
            MeSH: D006111
REFERENCE   PMID:15049952 (gene, env_factor)
  AUTHORS   Fountoulakis S, Tsatsoulis A.
  TITLE     On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis.
  JOURNAL   Clin Endocrinol (Oxf) 60:397-409 (2004)
REFERENCE   PMID:15030506 (description, gene)
  AUTHORS   Simmonds MJ, Gough SC.
  TITLE     Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond.
  JOURNAL   Clin Exp Immunol 136:1-10 (2004)
REFERENCE   PMID:12734493 (gene, env_factor, marker, autoantigen)
  AUTHORS   Ai J, Leonhardt JM, Heymann WR.
  TITLE     Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations.
  JOURNAL   J Am Acad Dermatol 48:641-59; quiz 660-2 (2003)
REFERENCE   PMID:15132715 (env_factor)
  AUTHORS   Prummel MF, Strieder T, Wiersinga WM.
  TITLE     The environment and autoimmune thyroid diseases.
  JOURNAL   Eur J Endocrinol 150:605-18 (2004)
REFERENCE   (marker, drug)
REFERENCE   PMID:18550875 (description, marker, drug)
  AUTHORS   Brent GA.
  TITLE     Clinical practice. Graves' disease.
  JOURNAL   N Engl J Med 358:2594-605 (2008)
REFERENCE   PMID:16127951 (drug)
  AUTHORS   Reid JR, Wheeler SF.
  TITLE     Hyperthyroidism: diagnosis and treatment.
  JOURNAL   Am Fam Physician 72:623-30 (2005)
REFERENCE   PMID:11396701 (autoantigen)
  AUTHORS   Ruwhof C, Drexhage HA.
  TITLE     Iodine and thyroid autoimmune disease in animal models.
  JOURNAL   Thyroid 11:427-36 (2001)
REFERENCE   PMID:15135604 (autoantigen)
  AUTHORS   Scofield RH.
  TITLE     Autoantibodies as predictors of disease.
  JOURNAL   Lancet 363:1544-6 (2004)
///
ENTRY       H00083                      Disease
NAME        Allograft rejection
DESCRIPTION Allograft rejection is the consequence of the recipient's alloimmune response to nonself antigens expressed by donor tissues. After transplantation of organ allografts, there are two pathways of antigen presentation. In the direct pathway, recipient T cells react to intact allogeneic MHC molecules expressed on the surface of donor cells. This pathway would activate host CD4 or CD8 T cells. In contrast, donor MHC molecules (and all other proteins) shed from the graft can be taken up by host APCs and presented to recipient T cells in the context of self-MHC molecules - the indirect pathway. Such presentation activates predominantly CD4 T cells. A direct cytotoxic T-cell attack on graft cells can be made only by T cells that recognize the graft MHC molecules directly. Nontheless, T cells with indirect allospecificity can contribute to graft rejection by activating macrophages, which cause tissue injury and fibrosis, and are also likely to be important in the development of an alloantibody response to graft.
CATEGORY    Immune system disease
GENE        TNF-alpha (polymorphism) [HSA:7124] [KO:K03156]
            IL-10 (polymorphism) [HSA:3586] [KO:K05443]
            TGF-beta (polymorphism) [HSA:7040 7042 7043] [KO:K13375 K13376 K13377]
            IFN-gamma (polymorphism) [HSA:3458] [KO:K04687]
            HLA-DMA (polymorphism) [HSA:3108] [KO:K06752]
            ICAM-1 (polymorphism) [HSA:3383] [KO:K06490]
            CTLA4 (polymorphism) [HSA:1493] [KO:K06538]
            ACE (polymorphism) [HSA:1636] [KO:K01283]
            GPIIIA (polymorphism) [HSA:3690] [KO:K06493]
ENV_FACTOR  HLA mismatch
DRUG        Cyclosporine A (CsA) [DR:D00184]
            Tacrolimus (FK506) [DG:DG00439]
            Azathioprine (AZA) [DG:DG00743]
            Mycophenolate mofetil (MMF) [DR:D00752 D05094]
            Sirolimus (Rapamycin) [DR:D00753]
            OKT3 (anti-CD3 antibody) [DR:D05092]
            RATG
            Methylprednisolone [DG:DG00410]
            Prednisone [DG:DG00094]
            Daclizumab [DR:D03639]
            Basiliximab [DR:D03058]
DBLINKS     ICD-10: T86
REFERENCE   PMID:11544006 (description, gene)
  AUTHORS   Akalin E, Murphy B.
  TITLE     Gene polymorphisms and transplantation.
  JOURNAL   Curr Opin Immunol 13:572-6 (2001)
REFERENCE   PMID:15690532 (gene)
  AUTHORS   Warle MC, Metselaar HJ, Hop WC, Tilanus HW.
  TITLE     Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis.
  JOURNAL   Liver transpl 11(1):19-26 (2005)
REFERENCE   PMID:12089714 (gene)
  AUTHORS   Warle MC, Farhan A, Metselaar HJ, Hop WC, Perrey C, Zondervan PE, Kap M, de Rave S, Kwekkeboom J, Ijzermans JN, Tilanus HW, Pravica V, Hutchinson IV, Bouma GJ.
  TITLE     Cytokine gene polymorphisms and acute human liver graft rejection.
  JOURNAL   Liver Transpl 8:603-11 (2002)
REFERENCE   PMID:15848524 (gene)
  AUTHORS   Lacha J, Hribova P, Kotsch K, Brabcova I, Bartosova K, Volk HD, Vitko S.
  TITLE     Effect of cytokines and chemokines (TGF-beta, TNF-alpha, IL-6, IL-10, MCP-1, RANTES) gene polymorphisms in kidney recipients on posttransplantation outcome: influence of donor-recipient match.
  JOURNAL   Transplant Proc 37:764-6 (2005)
REFERENCE   PMID:15249346 (drug)
  AUTHORS   Magee CC, Pascual M.
  TITLE     Update in renal transplantation.
  JOURNAL   Arch Intern Med 164:1373-88 (2004)
REFERENCE   PMID:15635544 (drug)
  AUTHORS   Patel JK, Kobashigawa JA.
  TITLE     Immunosuppression, diagnosis, and treatment of cardiac allograft rejection.
  JOURNAL   Semin Thorac Cardiovasc Surg 16:378-85 (2004)
REFERENCE   PMID:15635537 (drug)
  AUTHORS   Allan JS.
  TITLE     Immunosuppression for lung transplantation.
  JOURNAL   Semin Thorac Cardiovasc Surg 16:333-41 (2004)
REFERENCE   PMID:15240845 (drug)
  AUTHORS   Encke J, Uhl W, Stremmel W, Sauer P.
  TITLE     Immunosuppression and modulation in liver transplantation.
  JOURNAL   Nephrol Dial Transplant 19 Suppl 4:iv22-5 (2004)
REFERENCE   PMID:11583484 (env_factor)
  AUTHORS   Paul LC.
  TITLE     Immunologic risk factors for chronic renal allograft dysfunction.
  JOURNAL   Transplantation 71:SS17-23 (2001)
///
ENTRY       H00084                      Disease
NAME        Graft-versus-host disease
DESCRIPTION Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.
CATEGORY    Immune system disease
GENE        TNF-alpha (polymorphism) [HSA:7124] [KO:K03156]
            IL-10 (polymorphism) [HSA:3586] [KO:K05443]
            IL1A (polymorphism) [HSA:3552] [KO:K04383]
            IL-1-RA (polymorphism) [HSA:3557] [KO:K05481]
            IFN-gamma (polymorphism) [HSA:3458] [KO:K04687]
            IL-6 (polymorphism) [HSA:3569] [KO:K05405]
            TGF-beta (polymorphism) [HSA:7040 7042 7043] [KO:K13375 K13376 K13377]
            IL13 (polymorphism) [HSA:3596] [KO:K05435]
            TNFRSF1B (polymorphism) [HSA:7133] [KO:K05141]
            IL2 (polymorphism) [HSA:3558] [KO:K05429]
ENV_FACTOR  Donor-recipient gender mismatch
            Histocompatibility antigen mismatch (major and minor)
            Host exposure to previous blood product transfusion
            Low concentrations of immunosuppressants in recipient
            Older age of both recipient and donor
            Intensity of preparative regimen
MARKER      TNF-alpha [HSA:7124]
            TNF receptor
DRUG        Cyclosporine A (CSA) [DR:D00184]
            Tacrolimus (FK506) [DG:DG00439]
            Methotrexate [DG:DG00681]
            Corticosteroid
            Mycophenolate mofetil (MMF) [DR:D00752 D05094]
            Antithymocyte globulin (ATG)
            Alemtuzumab [DR:D02802]
            Methylprednisolone [DG:DG00410]
            Daclizumab [DR:D03639]
            Infliximab [DR:D02598 ]
            Prednison [DG:DG00094]
            Azathioprine [DG:DG00743]
DBLINKS     ICD-10: T86
            MeSH: D006086
REFERENCE   PMID:19000150 (description, gene)
  AUTHORS   Markey KA, MacDonald KP, Hill GR
  TITLE     Impact of cytokine gene polymorphisms on graft-vs-host disease.
  JOURNAL   Tissue Antigens 72:507-16 (2008)
REFERENCE   PMID:12394168 (gene)
  AUTHORS   Holler E.
  TITLE     Cytokines, viruses, and graft-versus-host disease.
  JOURNAL   Curr Opin Hematol 9:479-84 (2002)
REFERENCE   PMID:18503983 (gene)
  AUTHORS   Dickinson AM, Holler E.
  TITLE     Polymorphisms of cytokine and innate immunity genes and GVHD.
  JOURNAL   Best Pract Res Clin Haematol 21:149-64 (2008)
REFERENCE   PMID:17976248 (gene)
  AUTHORS   Dickinson AM, Harrold JL, Cullup H.
  TITLE     Haematopoietic stem cell transplantation: can our genes predict clinical outcome?
  JOURNAL   Expert Rev Mol Med 9:1-19 (2007)
REFERENCE   PMID:15245422 (env_factor)
  AUTHORS   Gilliam AC.
  TITLE     Update on graft versus host disease.
  JOURNAL   J Invest Dermatol 123:251-7 (2004)
REFERENCE   PMID:17784964 (env_factor, drug)
  AUTHORS   Jacobsohn DA, Vogelsang GB.
  TITLE     Acute graft versus host disease.
  JOURNAL   Orphanet J Rare Dis 2:35 (2007)
REFERENCE   PMID:17336259 (marker)
  AUTHORS   Ferrara JL.
  TITLE     Novel strategies for the treatment and diagnosis of graft-versus-host-disease.
  JOURNAL   Best Pract Res Clin Haematol 20:91-7 (2007)
REFERENCE   PMID:12359826 (drug)
  AUTHORS   Vogelsang GB, Lee L, Bensen-Kennedy DM.
  TITLE     Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant.
  JOURNAL   Annu Rev Med 54:29-52 (2003)
REFERENCE   PMID:15931364 (drug)
  AUTHORS   Iwasaki T.
  TITLE     Recent advances in the treatment of graft-versus-host disease.
  JOURNAL   Clin Med Res 2:243-52 (2004)
///
ENTRY       H00085                      Disease
NAME        Agammaglobulinemias, including the following six diseases:
            X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA);
            IgM heavy chain gene deletions;
            Ig-alpha defect;
            Autosomal recessive agammaglobulinaemia;
            B cell-linker protein (BLNK) deficiency;
            Leucine-rich repeat-containing 8
DESCRIPTION There are three major categories of antibody deficiencies: (a) defects in early B cell development, (b) hyper-IgM syndromes (also called class switch recombination defects), and (c) common variable immunodeficiency (CVID). Category (a) consists of agammaglobulinaemias. Defects in early B cell development are characterized by the onset of recurrent bacterial infections in the first 5 years of life, profound hypogammaglobulinemia, markedly reduced or absent B cells in the peripheral circulation, and (in the bone marrow) a severe block in B cell differentiation before the production of surface immunoglobulin-positive B cells. Mutations in Btk, the gene responsible for X-linked agammaglobulinemia (XLA), account for approximately 85% of affected patients. Approximately half of the remaining patients have mutations in genes encoding components of the pre-B cell receptor (pre-BCR) or BCR, including mu heavy chain (IGHM); the signal transduction molecules Ig-alpha (CD79A) and Ig-beta (CD79B); and lambda 5 (IGLL1), which forms the surrogate light chain with Vpre-B. A small number of patients with defects in BLNK, a scaffold protein that assembles signal transduction molecules activated by cross-linking of the BCR, have been reported.
CATEGORY    Primary immunodeficiency
GENE        Btk [HSA:695] [KO:K07370]
            CD79a [HSA:973] [KO:K06506]
            mu (IGHM)
            lamda 5(CD179B) [HSA:3543] [KO:K06554]
            BLNK [HSA:29760] [KO:K07371]
            LRRC8 [HSA:56262 23507 84230 55144 80131]
            CD79B [HSA:974] [KO:K06507]
DBLINKS     ICD-10: D80
            MeSH: D000361
            OMIM: 601495 613500 613501 613502 613506 612692 300755
REFERENCE   PMID:19302039 (description, gene)
  AUTHORS   Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, Howard V, Campana D
  TITLE     Primary B cell immunodeficiencies: comparisons and contrasts.
  JOURNAL   Annu Rev Immunol 27:199-227 (2009)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561 (gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00086                      Disease
NAME        Hyper IgM syndromes, autosomal recessive type, including the following three diseases:
            Activation-induced cytidine deaminase (AICD) defect;
            Uracil nucleotide glycoside glycosylase (UNG) defect;
            Immunodeficiency with hyper-IgM type 3
DESCRIPTION There are three major categories of antibody deficiencies: (a) defects in early B cell development, (b) hyper-IgM syndromes (also called class switch recombination defects), and (c) common variable immunodeficiency (CVID). Category (b), hyper-IgM syndrome (HIM), represents a group of distinct entities characterized by defective normal or elevated IgM in the presence of diminished IgG and IgA levels. Seventy per cent of the cases are X-linked in inheritance, and others are autosomal recessive. In the autosomal recessive hyper IgM syndromes, the problem lies in the nucleotide-editing enzymes AICD or UNG. These enzymes are only present in the germinal center B cells, and defects in either disrupt B-cell development and antibody production. Patients with these syndromes typically have recurrent bacterial infections and often have lymphoid hyperplasia.
CATEGORY    Primary immunodeficiency
GENE        AID [HSA:57379] [KO:K10989]
            UNG [HSA:7374] [KO:K03648]
            CD40 [HSA:958] [KO:K03160]
DBLINKS     ICD-10: D80
            MeSH: D053306
            OMIM: 608106 605258 606843
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00087                      Disease
NAME        Other humoral immunodeficiencies, including the following three diseases:
            Immunodeficiency, centromeric instability, facial anomalies (ICF)-syndrome;
            kappa light-chain deficiency;
            Ig heavy chain gene deletions
DESCRIPTION Immunodeficiency, centromeric instability, facial anomaly syndrome (ICF syndrome) is a rare autosomal recessive syndrome associated with mutations in the DNA methyltransferase 3B gene (DNMT3B) in 75% of cases. Patients have variable hypogammaglobulinemia but typically have profound reduction or absence of two or more Ig isotypes. This leads to severe immunodeficiency and death due to infection often before adulthood. Deficiencies of B-cell receptors are caused by mutations in the genes that encode immunoglobulin heavy or light chains or their associated signaling molecules, leading to agammaglobulinemia or hypogammaglobulinemia. Mutations in immunoglobulin heavy-chain genes (such as gamma1, 2, 3, or 4; alpha1 or 2; and epsilon) cause deficiencies of individual classes or subclasses of immunoglobulins, but circulating B cells are present and overall antibody function is usually normal. Mutations in the kappa light-chain gene result in a population of immunoglobulin molecules with only lambda light chains instead of the usual mixture of kappa and lambda types.
CATEGORY    Primary immunodeficiency
GENE        DNMT3B [HSA:1789] [KO:K17399]
            IGKC
            Ig heavy chain
DBLINKS     ICD-10: D80
            MeSH: C537362
REFERENCE   PMID:11058677 (description, gene)
  AUTHORS   Buckley RH.
  TITLE     Primary immunodeficiency diseases due to defects in lymphocytes.
  JOURNAL   N Engl J Med 343:1313-24 (2000)
REFERENCE   PMID:17162365 (description, gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:15096561 (gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00088                      Disease
NAME        Common variable immunodeficiency (CVID), including the following four diseases:
            Inducible T Cell costimulator (ICOS) defect;
            TACI defect;
            CD19 defect;
            BAFFR defect;
            CD20 defect;
            CD81 defect
DESCRIPTION There are three major categories of antibody deficiencies: (a) defects in early B cell development, (b) hyper-IgM syndromes (also called class switch recombination defects), and (c) common variable immunodeficiency (CVID). Category (c) CVID, also called acquired hypogammaglobulinemia, adult-onset hypogammaglobulinemia, or dysgammaglobulinemia, is a heterogeneous group of disorders involving both B-cell and T-cell immune function, the predominant manifestation of which is hypogammaglobulinemia. CVID is characterized by recurrent bacterial infections, decreased serum Ig levels, and abnormal antibody responses. The mutated genes that produce the CVID phenotype are known only for a minority of patients, and they are diverse in their influence on immune function. Homozygous mutations in ICOS are clearly the cause of disease. Heterozygous mutations in the TNF receptor family member TACI (transmembrane activator and calcium-modulating cyclophilin ligand interactor) can be found in up to 10% of patients with CVID.
CATEGORY    Primary immunodeficiency
GENE        ICOS [HSA:29851] [KO:K06713]
            TACI [HSA:23495] [KO:K05150]
            CD19 [HSA:930] [KO:K06465]
            TNFRSF13C [HSA:115650] [KO:K05151]
            MS4A1 [HSA:931] [KO:K06466]
            CD81 [HSA:975] [KO:K06508]
DBLINKS     ICD-10: D80
            MeSH: D017074
            OMIM: 607594 240500 609529 613493 613494 613495 613496
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
REFERENCE   PMID:22236429 (gene)
  AUTHORS   Park JH, Resnick ES, Cunningham-Rundles C
  TITLE     Perspectives on common variable immune deficiency.
  JOURNAL   Ann N Y Acad Sci 1246:41-9 (2011)
///
ENTRY       H00089                      Disease
NAME        IFN-gamma/IL-12 axis, including the following five diseases:
            IL-12 p40 subunit deficiency;
            IL-12 receptor (IL-12R) beta1 chain deficiency;
            IFN-gamma receptor (IFN gamma R) alpha chain deficiency;
            IFN-gamma receptor (IFN gamma R) beta chain deficiency;
            STAT-1 deficiency
DESCRIPTION The interferon-gamma-interleukin-12 axis is critical for defense against intracellular microbes such as mycobacteria, salmonella, and listeria. Mutations in either chain of the IFN-gammaR lead to severe susceptibility to mycobacteria and are very difficult to treat. Mutations in IL-12p40 or IL-12R beta 1 are milder clinically and can be treated with IFN-gamma because that receptor is still intact. Complete recessive mutations in STAT1 are more severe than any of the others because they affect both IFN-gamma and IFN-alpha signaling.
CATEGORY    Primary immunodeficiency
GENE        IL12B [HSA:3593] [KO:K05425]
            IL12RB1 [HSA:3594] [KO:K05063]
            IFNGR1 [HSA:3459] [KO:K05132]
            IFNGR2 [HSA:3460] [KO:K05133]
            STAT1 [HSA:6772] [KO:K11220]
REFERENCE   PMID:15100664 (description)
  AUTHORS   Rosenzweig SD, Holland SM
  TITLE     Phagocyte immunodeficiencies and their infections.
  JOURNAL   J Allergy Clin Immunol 113:620-6 (2004)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00090                      Disease
NAME        NK cell defects, including the following disease:
            CD16 deficiency
DESCRIPTION A patient with a mutation in CD16, also known as FcgRIIIa, has been identified. He was a 3-year-old boy, and suffered from recurrent viral respiratory tract infections since birth. CD16 is part of the FcgRIII found on NK cells as well as macrophages and some T cells. The receptor allows NK cells to phagocytose organisms or cells coated with IgG in the absence of MHC (antibody-dependent cellular cytotoxicity). The mutation disrupts NK cell function and is associated with NK cytopenia. The patient also had severe clinical problems after BCG vaccination.
CATEGORY    Primary immunodeficiency
GENE        FCGR3A [HSA:2214] [KO:K06463]
REFERENCE   PMID:17162365 (description, gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:8874200 (description, gene)
  AUTHORS   de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne AE, Waaijer JL, Haraldsson A, de Haas M, van Tol MJ
  TITLE     Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections.
  JOURNAL   Blood 88:3022-7 (1996)
///
ENTRY       H00091                      Disease
NAME        T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases:
            X-linked SCID;
            Janus kinase-3 (Jak3) deficiency;
            IL-7 receptor alpha (IL7R alpha) deficiency;
            IL-2 receptor alpha (IL2R alpha) deficiency;
            CD45 deficiency;
            CD3 deficiency;
            Winged Helix Nude (WHN) deficiency;
            Immunodeficiency with thynoma
DESCRIPTION Severe combined immunodeficiency (SCID) comprises a heterogeneous group of monogenic disorders that result in early-onset severe infections by a range of pathogens (such as bacteria, viruses and fungi). Typically, patients with SCID have a severe defect in T-cell differentiation, along with direct or indirect impairment of B-cell development and function. SCIDs with lack of circulating T cells but a normal number of B cells accounts for 30 to 50% of all cases of human SCIDs. The most frequent form of SCID, X-linked SCID (SCID-X1), is caused by mutations in the gamma-chain-encoding gene. Gamma-chain is a common subunit shared by several cytokine receptors. It results in an absence of both mature T lymphocytes and NK lymphocytes. The second most common variant is autosomal recessive and due to mutations of the JAK3 gene. IL-7R alpha gene mutations result in a pure T-cell deficiency. Rare cases of SCID consisting of pure T-cell deficiencies have been attributed to defects in key proteins involved in pre-TCR/TCR signaling. Deficiency in the CD45 phosphatase has been reported in two cases of SCID, while defects in CD3 delta, CD3 epsilon and CD zeta have also been described.
CATEGORY    Primary immunodeficiency
GENE        IL2RG [HSA:3561] [KO:K05070]
            JAK3 [HSA:3718] [KO:K11218]
            IL7R [HSA:3575] [KO:K05072]
            IL2RA [HSA:3559] [KO:K05068]
            PTPRC (CD45) [HSA:5788] [KO:K06478]
            delta CD3 [HSA:915] [KO:K06450]
            epsilon CD3 [HSA:916] [KO:K06451]
            zeta CD3 [HSA:919] [KO:K06453]
            FOXN1 [HSA:8456] [KO:K09407]
DBLINKS     ICD-10: D81
            MeSH: D053632
            OMIM: 608971 300400 606367 610163
REFERENCE   PMID:15661024 (description, gene)
  AUTHORS   Fischer A, Le Deist F, Hacein-Bey-Abina S, Andre-Schmutz I, Basile Gde S, de Villartay JP, Cavazzana-Calvo M.
  TITLE     Severe combined immunodeficiency. A model disease for molecular immunology and therapy.
  JOURNAL   Immunol Rev 203:98-109 (2005)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561 (gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00092                      Disease
NAME        T-B-Severe combined immunodeficiencies (SCIDs), including the following four diseases:
            Adenosine deaminase (ADA) deficiency;
            Recombinase activating gene (RAG) deficiencies;
            Artemis deficiency;
            Reticular dysgenesis
DESCRIPTION Severe combined immunodeficiency (SCID) comprises a heterogeneous group of monogenic disorders that result in early-onset severe infections by a range of pathogens (such as bacteria, viruses and fungi). Typically, patients with SCID have a severe defect in T-cell differentiation, along with direct or indirect impairment of B-cell development and function. Adenosine deaminase (ADA) deficiency accounts for about half of the autosomal recessive forms of SCIDs. It is one of the most severe immunodeficiencies and is associated with severe depletion of B cells, T cells, and NK cells. V(D)J- recombination deficiency caused by defects in recombinase-activating gene 1 (RAG1), RAG2 and Artemis (DCLRE1C) leads to a T-B-SCID phenotype that is characterized by an arrest of B- and T-cell maturation at the stage of pro-B and pre-T cells, respectively, whereas natural killer (NK)-cell maturation is not affected. V(D)J recombination generates the diversity of B- and T-cell primary immune repertoires.
CATEGORY    Primary immunodeficiency
GENE        ADA [HSA:100] [KO:K01488]
            RAG-1 [HSA:5896] [KO:K10628]
            RAG-2 [HSA:5897] [KO:K10988]
            DCLRE1C [HSA:64421] [KO:K10887]
            AK2 [HSA:204] [KO:K00939]
DBLINKS     ICD-10: D81
            MeSH: C563440
            OMIM: 102700 601457 602450 267500
REFERENCE   PMID:14647478 (description, gene)
  AUTHORS   de Villartay JP, Fischer A, Durandy A.
  TITLE     The mechanisms of immune diversification and their disorders.
  JOURNAL   Nat Rev Immunol 3:962-72 (2003)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561 (gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
REFERENCE   PMID:19043417 (gene)
  AUTHORS   Pannicke U, Honig M, Hess I, Friesen C, Holzmann K, Rump EM, Barth TF, Rojewski MT, Schulz A, Boehm T, Friedrich W, Schwarz K
  TITLE     Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding  mitochondrial adenylate kinase 2.
  JOURNAL   Nat Genet 41:101-5 (2009)
REFERENCE   PMID:19895994 (gene)
  AUTHORS   Patel NC, Chinen J, Rosenblatt HM, Hanson IC, Krance RA, Paul ME, Abramson SL, Noroski LM, Davis CM, Seeborg FO, Foster SB, Leung KS, Brown BS, Ritz J, Shearer WT
  TITLE     Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.
  JOURNAL   J Allergy Clin Immunol 124:1062-9.e1-4 (2009)
///
ENTRY       H00093                      Disease
NAME        Combined immunodeficiencies (CIDs), including the following nine diseases:
            X-linked hyper IgM syndrome;
            X-linked, moderate;
            CD40 deficiency hyper IgM syndrome;
            Purine nucleoside phosphorylase (PNP) deficiency;
            RAG deficiency with granulomas;
            Omenn syndrome;
            MHC deficiency (HLA-class I);
            MHC deficiency (HLA-class II);
            Zap-70 deficiency;
            Ca2+ channel deficiency;
            p56 Lck deficiency;
            CD8 deficiency
DESCRIPTION The term combined immunodeficiency (CID) is used to distinguish patients with low, but not absent, T-cell function from those with severe CID (SCID) characterized by profound deficiencies of T- and B-cell (and sometimes NK- cell) function. Hyper-IgM syndrome (HIM) represents a group of distinct entities characterized by defective normal or elevated IgM in the presence of diminished IgG and IgA levels. The genetic anomaly in X-linked hyper-IgM syndrome has been mapped to Xq26, and resides in mutations of the CD40 ligand gene. Missense mutation in exon 7 of the common gamma chain (IL2RG) causes a moderate form of X-linked CID. This point mutation in IL2RG leads to a less severe degree of deficiency in cellular and humoral immunity than that seen in XSCID. Two related deficiencies of recombination activating genes, RAG1 and RAG2 result in a spectrum of SCID called RAG1/RAG2 deficiency and Omenn syndrome. Mutations that lead to total absence of RAG1 or RAG2 gene product (null mutations) are known to lead to SCID without mature lymphoid cells, whereas mutations that result in partial V(D)J recombinase activity due to missense mutation on at least one allele lead to Omenn syndrome. Mutations of both TAP1 and TAP2 genes result in deficient expression of class I HLA proteins on the cell surface with defects in natural killer cell cytotoxicity. Defective expression of major histocompatibility complex (MHC) class II molecules account for 5% of SCID. The genetic lesions responsible for this syndrome do not lie within the MHC-II locus itself, but reside instead in genes encoding transcription factors, RFX5, RFXAP, RFXANK(B), and CIITA, controlling MHC-II expression. ZAP-70 deficiency is inherited in an autosomal recessive manner. Recurrent and opportunistic infections occur within the first year of life. The mutations in genes responsible for CRAC channel function, ORAI1 and STIM1, cause the defect in Ca2+ influx.
CATEGORY    Primary immunodeficiency
GENE        CD40L (TNFSF5) [HSA:959] [KO:K03161]
            CD40 [HSA:958] [KO:K03160]
            IL2RG [HSA:3561] [KO:K05070]
            PNP [HSA:4860] [KO:K03783]
            RAG1 [HSA:5896] [KO:K10628]
            RAG2 [HSA:5897] [KO:K10988]
            TAP1 [HSA:6890] [KO:K05653]
            TAP2 [HSA:6891] [KO:K05654]
            CIITA [HSA:4261] [KO:K08060]
            RFX5 [HSA:5993] [KO:K08061]
            RFXAP [HSA:5994] [KO:K08063]
            RFXANK [HSA:8625] [KO:K08062]
            Zap-70 [HSA:7535] [KO:K07360]
            ORAI1 [HSA:84876] [KO:K16056]
            STIM1 [HSA:6786] [KO:K16059]
            LCK [HSA:3932] [KO:K05856]
            CD8A [HSA:925] [KO:K06458]
DBLINKS     ICD-10: D81
            MeSH: D053632
            OMIM: 308230 312863 613179 603554 233650 612782 612783
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561 (description, gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
REFERENCE   PMID:20004777 (gene)
  AUTHORS   Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Hammartrom L, Nonoyama S, Ochs HD, Puck J, Roifman C, Seger R, Wedgwood J
  TITLE     Primary immunodeficiencies: 2009 update.
  JOURNAL   J Allergy Clin Immunol 124:1161-78 (2009)
REFERENCE   PMID:7883965 (description, gene)
  AUTHORS   Schmalstieg FC, Leonard WJ, Noguchi M, Berg M, Rudloff HE, Denney RM, Dave SK, Brooks EG, Goldman AS
  TITLE     Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency.
  JOURNAL   J Clin Invest 95:1169-73 (1995)
REFERENCE   PMID:21831415 (gene)
  AUTHORS   Kuijpers TW, Baars PA, Aan de Kerk DJ, Jansen MH, Derks IA, Bredius RG, Sanders EA, van der Burg M, Alders M, van Lier RA
  TITLE     A novel mutation in CD132 causes X-CID with defective T-cell activation and impaired humoral reactivity.
  JOURNAL   J Allergy Clin Immunol 128:1360-1363.e4 (2011)
REFERENCE   PMID:20172764 (description, gene)
  AUTHORS   Niehues T, Perez-Becker R, Schuetz C
  TITLE     More than just SCID--the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2.
  JOURNAL   Clin Immunol 135:183-92 (2010)
REFERENCE   PMID:18463379 (gene)
  AUTHORS   Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, Schneider DT, Manfras B, Pannicke U, Willemze R, Knuchel R, Gobel U, Schulz A, Borkhardt A, Friedrich W, Schwarz K, Niehues T
  TITLE     An immunodeficiency disease with RAG mutations and granulomas.
  JOURNAL   N Engl J Med 358:2030-8 (2008)
REFERENCE   PMID:20189884 (gene)
  AUTHORS   Feske S, Picard C, Fischer A
  TITLE     Immunodeficiency due to mutations in ORAI1 and STIM1.
  JOURNAL   Clin Immunol 135:169-82 (2010)
REFERENCE   PMID:21986549 (gene)
  AUTHORS   Verbsky JW, Chatila TA
  TITLE     T-regulatory cells in primary immune deficiencies.
  JOURNAL   Curr Opin Allergy Clin Immunol 11:539-44 (2011)
///
ENTRY       H00094                      Disease
NAME        Immunodeficiency associated with DNA repair defects, including the following six diseases:
            Ataxia telangiectasia (AT) [DS:H00064];
            Ataxia-talangiectasia-like syndrome;
            Nijmegen syndrome [DS:H01344];
            DNA ligase I deficiency;
            DNA ligase IV deficiency;
            Bloom syndrome [DS:H01346]
DESCRIPTION A number of genetically determined disorders collectively called as the chromosome breakage syndromes or DNA-repair disorders have a characteristic cytogenetic feature, chromosome instability. They are all autosomal recessive, show an increased tendency for chromosomal aberrations and to develop malignancies. Ataxia telangiectasia (AT), Nijmegen breakage syndrome (NBS), and an ataxia-like disorder (ATLD), are chromosome instability disorders that are defective in the ataxia telangiectasia mutated (ATM), NBS, and Mre11 genes, respectively. These genes are critical in maintaining cellular resistance to ionizing radiation (IR), which kills largely by the production of double-strand breaks (DSBs). Bloom syndrome involves a defect in the BLM helicase, which seems to play a role in restarting DNA replication forks that are blocked at lesions, thereby promoting chromosome stability. A point mutational change in DNA ligase I was identified in a unique immunodeficient individual who suffered recurrent sinopulmonary infection leading to bronchiectasis. A non-inactivating mutational change in DNA ligase IV has also been identified in a leukaemia patient, who was dramatically over-sensitive to radiotherapy.
CATEGORY    Primary immunodeficiency
GENE        ATM [HSA:472] [KO:K04728]
            MRE11A [HSA:4361] [KO:K10865]
            NBS1(Nibrin) [HSA:4683] [KO:K10867]
            LIG1 [HSA:3978] [KO:K10747]
            LIG4 [HSA:3981] [KO:K10777]
            BLM [HSA:641] [KO:K10901]
DBLINKS     ICD-10: D82.8 G11.3
            MeSH: D001260 D049932 C564694 D001816 
            OMIM: 208900 604391 251260 210900 606593
REFERENCE   PMID:12427531 (gene)
  AUTHORS   Thompson LH, Schild D
  TITLE     Recombinational DNA repair and human disease.
  JOURNAL   Mutat Res 509:49-78 (2002)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561 (gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00095                      Disease
NAME        Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases:
            NF-kappa-B essential modulator (NEMO) defect;
            Inhibitor of kappa-B (I-kappa-B) defect
DESCRIPTION Ectodermal dysplasia (ED) refers to a group of inherited disorders involving absence or dysplasia of the ectodermal appendages. Clinically, it is characterized by absence, abnormality, or deficient function of ectodermal derivatives, including skin, teeth, hair, eccrine glands, or nails. In the hypohidrotic/ anhidrotic form of ED (HED/EDA) the patient has no sweat glands, sparse scalp hair and rare conical teeth. Patients with EDA and immunodeficiency (EDA-ID) present some or all of these features, together with severe infectious diseases. EDA-ID principally affects boys, suggesting X-linked recessive inheritance (XL-EDA-ID). This was confirmed in 2000 and beyond with the identification of disease-causing hypomorphic mutations in NEMO, which is located on the X chromosome and encodes IKK-gamma. A novel autosomal dominant of EDA-ID, recently identified in one child, was found to be caused by a hypermorphic mutation of the gene encoding I{kappa}B{alpha}. Similar to XL-EDA-ID patients, from the age of two months he suffered from multiple and severe infections with several Gram-positive and Gram-negative bacteria, leading to chronic bronchopneumonitis and gastroenteritis, with failure to thrive.
CATEGORY    Primary immunodeficiency
GENE        IKBKG [HSA:8517] [KO:K07210]
            IKBA [HSA:4792] [KO:K04734]
DBLINKS     MeSH: C567411 C536181
            OMIM: 612132 300291
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:18424339
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00096                      Disease
NAME        Defects of toll-like receptor signaling, including the following disease:
            Il-1 receptor-associated kinase 4 (IRAK-4) deficiency
DESCRIPTION Human interleukin (IL) 1 receptor-associated kinase 4 (IRAK-4) deficiency is a recently discovered primary immunodeficiency that impairs Toll/IL-1R immunity, except for the Toll-like receptor (TLR) 3- and TLR4-interferon (IFN)-a/b pathways. IRAK-4 is a kinase that plays a crucial role downstream of individual TLR and IL-1R receptors and upstream of TNF receptor-associated factor-6 (TRAF-6). Patients with IRAK-4 deficiency thus fail to produce TNF-alpha, IL-6, and IFN-gamma in response to IL-1beta and IL-18, respectively. Their blood cells also fail to produce IL-1beta, IL-6, IL-8, IL-12, and TNF-alpha upon stimulation with known TLR agonists. Despite the broad impairment at the two subsequent levels of onset (TLR) and propagation (IL-1R) of inflammation, the clinical phenotype of IRAK-4 deficiency is relatively mild. Patients present no developmental defect and a restricted spectrum of infectious diseases, mostly caused by pyogenic encapsulated bacteria, principally, but not exclusively Gram-positive.
CATEGORY    Primary immunodeficiency
GENE        IRAK4 [HSA:51135] [KO:K04733]
DBLINKS     OMIM: 607676
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00097                      Disease
NAME        Chemokine receptor defect, including the following disease:
            WHIM syndrome
DESCRIPTION WHIM (an acronym for warts, hypogammaglobulinemia, infections and myelokathexis, a form of neutropenia) syndrome is a congenital immunodeficiency disease characterized by neutropenia, hypogammaglobulinemia and susceptibility to human papillomavirus (HPV) infection. Affected individuals have mutations that variably truncate the cytoplasmic tail domain of CXC chemokine receptor 4 (CXCR4). Leukocytes expressing truncated CXCR4 display enhanced responses to the receptor ligand CXCL12, including chemotaxis, which likely impair their trafficking and contribute to the immunohematologic clinical manifestations of the syndrome.
CATEGORY    Primary immunodeficiency
GENE        CXCR4 [HSA:7852] [KO:K04189]
DBLINKS     OMIM: 193670
REFERENCE   PMID:18436740 (description, gene)
  AUTHORS   Lagane B, Chow KY, Balabanian K, Levoye A, Harriague J, Planchenault T, Baleux F, Gunera-Saad N, Arenzana-Seisdedos F, Bachelerie F
  TITLE     CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced  chemotaxis to CXCL12 in WHIM syndrome.
  JOURNAL   Blood 112:34-44 (2008)
REFERENCE   PMID:19057201 (description, gene)
  AUTHORS   Kawai T, Malech HL
  TITLE     WHIM syndrome: congenital immune deficiency disease.
  JOURNAL   Curr Opin Hematol 16:20-6 (2009)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00098                      Disease
NAME        Chronic granulomatous disease, including the following four diseases:
            X-linked CGD (gp91 phox CGD);
            p22phox deficiency (p22phox CGD);
            p47phox deficiency (p47phox CGD);
            p67phox deficiency (p67phox CGD)
DESCRIPTION Chronic granulomatous disease (CGD) is characterized by impaired activation of the NADPH oxidase activity in phagocytic cells, resulting in the inability of these cells to generate toxic oxygen radicals and hence to kill catalase-positive bacteria. The NADPH oxidase is composed of four polypeptide subunits and mutations in the corresponding genes (gp91phox, p22phox, p47phox, and p67phox) are responsible for the four different genetic subgroups of CGD. Most cases (65%) involve mutations in gp91phox and are inherited in an X-linked recessive manner. The remainder are autosomal recessive (AR).
CATEGORY    Primary immunodeficiency
GENE        CYBB [HSA:1536] [KO:K21421]
            CYBA [HSA:1535] [KO:K08009]
            NCF1 [HSA:653361] [KO:K08011]
            NCF2 [HSA:4688] [KO:K08010]
PATHOGEN    Granulobacter bethesdensis [GN:gbe]
DRUG        Trimethoprim-sulfamethoxazole (TMP-SMZ) [DG:DG00595]
            Itraconazole [DR:D00350]
            Linezolid [DR:D00947]
            Voriconazole [DR:D00578]
            Posaconazole [DR:D02555]
COMMENT     X-linked CGD (gp91 phox CGD)
            p22phox deficiency (p22phox CGD)
            p47phox deficiency (p47phox CGD)
            p67phox deficiency (p67phox CGD)
DBLINKS     ICD-10: D71
            MeSH: D006105
            OMIM: 306400 233690 233700 233710
REFERENCE   PMID:17162365
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
REFERENCE   PMID:18217895
  AUTHORS   Seger RA
  TITLE     Modern management of chronic granulomatous disease.
  JOURNAL   Br J Haematol 140:255-66 (2008)
///
ENTRY       H00099                      Disease
NAME        Leukocyte adhesion deficiency (LAD), including the following four diseases:
            Leukocyte adhesion deficiency (I);
            Leukocyte adhesion deficiency (II);
            Leukocyte adhesion deficiency (III);
            LAD with Rac2 deficiency
DESCRIPTION Leukocyte adhesion deficiency (LAD) is a rare, autosomal recessive genetic disorder in which neutrophils fail to mobilize and migrate to sites of injury. At least three genetically distinct forms of this group of disorders have been described: LAD I, II, and III. Defects in the expression of beta2-integrins and fucose- containing proteins account for LAD-I and LAD-II, respectively. In LAD-III integrin expression by leukocytes is normal, but the integrins fail to generate high avidity for their cognate endothelial-cell ligands. Mutations in the KINDLIN3 (official symbol FERMT3), a gene that encodes an intracellular protein that interacts with cytoplasmic tails of beta-integrins in hematopoietic cells, is the cause of LAD-III. Dominant-negative mutations resulting in deficiency of ras-related C3 botulinum toxin substrate (Rac2), the predominant hematopoeitic-specific Rho GTPase in neutrophils also leads to leukocyte adhesion deficiency.
CATEGORY    Primary immunodeficiency
GENE        ITGB2 [HSA:3689] [KO:K06464]
            SLC35C1 [HSA:55343] [KO:K15279]
            FERMT3 [HSA:83706] [KO:K17084]
            RAC2 [HSA:5880] [KO:K07860]
DBLINKS     MeSH: C535887 C535755 C567555
            OMIM: 116920 266265 612840 608203
REFERENCE   PMID:17960151 (description, gene)
  AUTHORS   Marodi L, Notarangelo LD.
  TITLE     Immunological and genetic bases of new primary immunodeficiencies.
  JOURNAL   Nat Rev Immunol 7:851-61 (2007)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
REFERENCE   PMID:19423742 (gene)
  AUTHORS   Zimmerman GA
  TITLE     LAD syndromes: FERMT3 kindles the signal.
  JOURNAL   Blood 113:4485-6 (2009)
REFERENCE   PMID:10758162
  AUTHORS   Ambruso DR, Knall C, Abell AN, Panepinto J, Kurkchubasche A, Thurman G, Gonzalez-Aller C, Hiester A, deBoer M, Harbeck RJ, Oyer R, Johnson GL, Roos D
  TITLE     Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2  mutation.
  JOURNAL   Proc Natl Acad Sci U S A 97:4654-9 (2000)
///
ENTRY       H00100                      Disease
NAME        Neutropenic disorders, including the following three diseases:
            Kostmann syndrome;
            Cyclic neutropenia;
            X-linked neutropenia/myelodysplasia
DESCRIPTION Neutropenias represent a series of potentially life-threatening disorders characterised by a reduction in circulating neutrophils. Since neutrophils play a major role in host defense against bacteria, neutropenia patients suffer from frequent episodes of opportunistic bacterial infections. Severe congenital neutropenia (SCN) is a rare neutropenia with a bone marrow maturation arrest of granulocytic differentiation. Kostmann syndrome is an autosomal recessive SCN. The characteristic maturation arrest and the lack of mature neutrophils in peripheral blood of patients with Kostmann syndrome can be explained by the deletion of an anti-apoptotic factor (HAX-1) in myeloid cells of these patients. Heterozygous mutations in the protooncogene growth factor-independent 1 (GFI1) gene are also associated with SCN. In patients with autosomal dominant cyclic neutropenia (CyN), a condition with oscillating neutrophil counts but less severe clinical symptoms, heterozygous mutations in ELA-2/ELANE were discovered. Patients with X-linked severe congenital neutropenia (SCN) have been reported with activating mutations in WASp leading to a constitutively-active form of the protein, and unregulated actin polymerization.
CATEGORY    Primary immunodeficiency
GENE        HAX1 [HSA:10456] [KO:K16220]
            GFI1 [HSA:2672] [KO:K09223]
            ELA2 [HSA:1991] [KO:K01327]
            WAS [HSA:7454] [KO:K05747]
DRUG        Filgrastim [DR:D03235]
            Lenograstim [DR:D03247]
            Nartograstim [DR:D03245]
DBLINKS     ICD-10: D70
            OMIM: 610738 613107 202700 300299
REFERENCE   PMID:17162365
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:15096561
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
REFERENCE   PMID:19811314
  AUTHORS   Rezaei N, Moazzami K, Aghamohammadi A, Klein C
  TITLE     Neutropenia and primary immunodeficiency diseases.
  JOURNAL   Int Rev Immunol 28:335-66 (2009)
///
ENTRY       H00101                      Disease
NAME        Other phagocyte defects, including the following eight diseases:
            Chediak-Higashi syndrome;
            Griscelli syndrome, type 1 (GS1);
            Griscelli syndrome, type 2 (GS2);
            Griscelli syndrome, type 3 (GS3);
            beta-actin deficiency;
            Neutrophil-specific granule deficiency;
            Myeloperoxidase deficiency;
            Glucose 6-phosphate dehydrogenase deficiency;
            Shwachman syndrome
DESCRIPTION Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by partial skin and ocular albinism, increased susceptibility to infections, and progressive neuropathy. Clinical reports of CHS have identified mutations throughout the CHS1/LYST gene. Griscelli syndrome (GS) is a rare autosomal recessive disorder caused by mutations in either the myosin VA (GS1), RAB27A (GS2) or melanophilin (GS3) genes. GS is characterized by partial albinism, hepatosplenomegaly, progressive neurological deterioration, hypogammaglobulinemia and pancytopenia. Abnormal-beta-actin disease accompanies neutrophil chemotactic dysfunction. Neutrophil specific granule deficiency is a rare disorder of neutrophil function characterized by a lack of neutrophil secondary granule proteins and associated with recurrent bacterial infections. It has been linked to a defect in the transcription factor CCAAT/enhancer binding protein (C/EBP) epsilon. Myeloperoxidase deficiency is the most common inherited disorder of neutrophils. Heterogeneous mutations in the gene encoding myeloperoxidase have been described. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a X-chromosomally transmitted disorder. The most frequent clinical manifestations of G6PD deficiency are neonatal jaundice, and acute haemolytic anaemia, which is usually triggered by an exogenous agent. Shwachman-Diamond syndrome (SDS) is a rare autosomal-recessive, multisystem disease characterized by exocrine pancreatic insufficiency, impaired hematopoiesis, and leukemia predisposition. The only gene known to be associated with SDS is SBDS, which encodes a ribosome maturation protein.
CATEGORY    Primary immunodeficiency
GENE        CHS1 [HSA:1130]
            MYO5A [HSA:4644] [KO:K10357]
            RAB27A [HSA:5873] [KO:K07885]
            MLPH [HSA:79083]
            ACTB [HSA:60] [KO:K05692]
            CEBPE [HSA:1053] [KO:K10051]
            MPO [HSA:4353] [KO:K10789]
            G6PD [HSA:2539] [KO:K00036]
            SBDS [HSA:51119] [KO:K14574]
COMMENT     For Glucose 6-phosphate dehydrogenase deficiency, see H01375.
DBLINKS     OMIM: 214500 214450 607624 245480 254600 260400
REFERENCE   PMID:15096561 (description, gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:17498436 (description, gene)
  AUTHORS   Kharkar V, Pande S, Mahajan S, Dwiwedi R, Khopkar U
  TITLE     Griscelli syndrome: a new phenotype with circumscribed pigment loss?
  JOURNAL   Dermatol Online J 13:17 (2007)
REFERENCE   PMID:11594510 (description, gene)
  AUTHORS   Nunoi H, Yamazaki T, Kanegasaki S
  TITLE     Neutrophil cytoskeletal disease.
  JOURNAL   Int J Hematol 74:119-24 (2001)
REFERENCE   PMID:11701548 (description, gene)
  AUTHORS   Dinauer MC, Lekstrom-Himes JA, Dale DC
  TITLE     Inherited Neutrophil Disorders: Molecular Basis and New Therapies.
  JOURNAL   Hematology Am Soc Hematol Educ Program 303-318 (2000)
REFERENCE   PMID:11964737 (description, gene)
  AUTHORS   Etzioni A
  TITLE     Novel aspects of phagocytic cell disorders.
  JOURNAL   Curr Opin Allergy Clin Immunol 1:535-40 (2001)
REFERENCE   PMID:18177777 (description, gene)
  AUTHORS   Cappellini MD, Fiorelli G
  TITLE     Glucose-6-phosphate dehydrogenase deficiency.
  JOURNAL   Lancet 371:64-74 (2008)
REFERENCE   PMID:19102804 (description, gene)
  AUTHORS   Dror Y
  TITLE     Shwachman-Diamond syndrome: implications for understanding the molecular basis of leukaemia.
  JOURNAL   Expert Rev Mol Med 10:e38 (2008)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00102                      Disease
NAME        Classic complement pathway component defects, including the following eight diseases:
            C1q alpha-chain deficiency;
            C1q beta-chain deficiency;
            C1q gamma-chain deficiency;
            C1r deficiency;
            C1s deficiency;
            C2 deficiency;
            C3 deficiency;
            C4 deficiency
DESCRIPTION Complement disorders account for only 2 percent of all primary immunodeficiency disorders. They result from the disruption of one of the proteins involved in the classic or nonclassic activation pathways of the complement response. Defects in the classic pathway account for the more common type of complement deficiency, and are associated with increased risk to develop systemic lupus erythematosus (SLE) and SLE-like diseases. Homozygous C2 deficiency, which is the most frequent hereditary deficiency in complement classical pathway components, is associated with SLE in 10% of the cases. Complete C1q and C4 deficiencies are less frequent but associated with a higher prevalence of SLE.
CATEGORY    Primary immunodeficiency
GENE        C1QA [HSA:712] [KO:K03986]
            C1QB [HSA:713] [KO:K03987]
            C1QG [HSA:714] [KO:K03988]
            C1R [HSA:715] [KO:K01330]
            C1S [HSA:716] [KO:K01331]
            C2 [HSA:717] [KO:K01332]
            C3 [HSA:718] [KO:K03990]
            C4A [HSA:720] [KO:K03989]
            C4B [HSA:421]
DBLINKS     OMIM: 613652 613783 217000 613779 614380 614379 120790
REFERENCE   PMID:19028607 (description, gene)
  AUTHORS   Bussone G, Mouthon L
  TITLE     Autoimmune manifestations in primary immune deficiencies.
  JOURNAL   Autoimmun Rev 8:332-6 (2009)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00103                      Disease
NAME        Late complement pathway defects, including the following seven diseases:
            C5 deficiency;
            C6 deficiency;
            C7 deficiency;
            C8 alpha-chain deficiency;
            C8 beta-chain deficiency;
            C8 gamma-chain deficiency;
            C9 deficiency
DESCRIPTION Late complement component (the final common pathway C5b-C9 components) deficiencies are all inherited in an autosomal recessive manner. In all cases, homozygous recessive patients have greatly reduced levels of the respective complement component. Generally, patients with deficiencies of C5, C6, C7, or C8 are particularly susceptible to systemic infections with Neisseria meningitidies and N. gonorrhoeae. Infections are rarely fulminant but are often recurrent and frequently involve unusual serotypes of the organism.
CATEGORY    Primary immunodeficiency
GENE        C5 [HSA:727] [KO:K03994]
            C6 [HSA:729] [KO:K03995]
            C7 [HSA:730] [KO:K03996]
            C8 alpha [HSA:731] [KO:K03997]
            C8 beta [HSA:732] [KO:K03998]
            C8 gamma [HSA:733] [KO:K03999]
            C9 [HSA:735] [KO:K04000]
DBLINKS     OMIM: 609536 612446 610102 608957 613790 613789 613825
REFERENCE   PMID:19758139 (description, gene)
  AUTHORS   Pettigrew HD, Teuber SS, Gershwin ME
  TITLE     Clinical significance of complement deficiencies.
  JOURNAL   Ann N Y Acad Sci 1173:108-23 (2009)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00104                      Disease
NAME        Alternative complement pathway component defects, including the following four diseases:
            Factor B deficiency;
            Factor D deficiency;
            Factor H deficiency;
            Properdin deficiency
DESCRIPTION The alternative pathway is antibody independent and relies on native C3 undergoing minimal spontaneous hydrolysis. Hydrolyzed C3 binds factor B. Factor B, when bound to hydrolyzed C3, is cleaved by factor D into Ba and Bb. Hydrolyzed C3Bb is responsible for a constant low level of C3 cleavage into C3b. If C3b binds to an appropriate surface, factor B will bind with C3b to form C3bBb, a highly efficient C3-cleaving enzyme. This overall series of successive proteolytic steps is enhanced by the serum protein properdin, which stabilizes protein:protein interactions during the process. Factor H is essential in controlling the function of the alternative pathway by inhibiting the formation of and degrading C3bBb. Deficiencies of alternative pathway-specific components are rare, and usually lead to an increased frequency of Neisseria infections.
CATEGORY    Primary immunodeficiency
GENE        BF [HSA:629] [KO:K01335]
            DF [HSA:1675] [KO:K01334]
            HF1 [HSA:3075] [KO:K04004]
            PFC [HSA:5199] [KO:K15412]
DBLINKS     OMIM: 613912 609814 312060
REFERENCE   PMID:19758139 (description, gene)
  AUTHORS   Pettigrew HD, Teuber SS, Gershwin ME
  TITLE     Clinical significance of complement deficiencies.
  JOURNAL   Ann N Y Acad Sci 1173:108-23 (2009)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00105                      Disease
NAME        Mannose-binding lectin pathway component defects, including the following two diseases:
            Mannose-binding lectin deficiency;
            Mannose-binding lectin-associated serine protease (MASP) 2 deficiency
DESCRIPTION There is an increasing number of clinical studies indicating that deficiency of the lectin pathway has been associated with an increased risk, severity, and frequency of infections but also autoimmune disorders. MBL deficiency is one of the most common human immunodeficiencies and arises primarily from three single point mutations in exon 1 of the MBL-2 gene. These mutations result in a failure to assemble fully functional multimeric protein. Inherited MASP-2 deficiency has been described as the result of a mutation causing the exchange of aspartic acid with a glycine at position 105, a position in the first domain, CUB1, involved in calcium binding. This mutation abolishes the binding to MBL and ficolins, and deprives MASP-2 of functional activity.
CATEGORY    Primary immunodeficiency
GENE        MBL2 [HSA:4153] [KO:K03991]
            MASP2 [HSA:10747] [KO:K03993]
DBLINKS     OMIM: 614372 613791
REFERENCE   PMID:19481265 (description, gene)
  AUTHORS   Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F
  TITLE     Complement in human diseases: Lessons from complement deficiencies.
  JOURNAL   Mol Immunol 46:2774-83 (2009)
REFERENCE   PMID:14568388 (description, gene)
  AUTHORS   Turner MW
  TITLE     The role of mannose-binding lectin in health and disease.
  JOURNAL   Mol Immunol 40:423-9 (2003)
REFERENCE   PMID:16189649 (description, gene)
  AUTHORS   Sorensen R, Thiel S, Jensenius JC
  TITLE     Mannan-binding-lectin-associated serine proteases, characteristics and disease associations.
  JOURNAL   Springer Semin Immunopathol 27:299-319 (2005)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00106                      Disease
NAME        Complement regulatory protein defects, including the following six diseases:
            C1 inhibitor deficiency (hereditary angioedema);
            C4 binding protein alpha deficiency;
            C4 binding protein beta deficiency;
            Factor I deficiency;
            Decay-accelerating factor (CD55) deficiency;
            CD59 deficiency
DESCRIPTION To prevent undesirable complement activation, host tissues express a number of complement regulatory proteins. They include C1 inhibitor (C1-INH, also termed SERPING1), C4 binding protein (C4BP), Factor I, decay accelerating factor (DAF), CD59, and so on. C1-INH (SERPING1) deficiency can be genetic or acquired, and this causes an episodic, local increase in vascular permeability in the subcutaneous and submucosal layers, identified as angioedema (hereditary or acquired). Genetic deficiency of C4BP has only been reported in one individual who developed an illness with similarities to Behcet's syndrome. Heterozygous mutations within the Factor I gene have been recently identified in individuals with atypical hemolytic uremic syndrome (aHUS), while homozygous deficiency of Factor I is an unusual feature. Factor I-deficient patients present high susceptibility to respiratory tract infections and meningitis. Kidney impairment and autoimmune disorders have also been observed. Only a single case of CD59 deficiency has been reported and this individual developed a paroxysmal nocturnal haemoglobinuria(PNH)-like illness. In contrast, deficiency of DAF is not associated with haemolytic anaemia.
CATEGORY    Primary immunodeficiency
GENE        SERPING1 [HSA:710] [KO:K04001]
            C4BPA [HSA:722] [KO:K04002]
            C4BPB [HSA:725] [KO:K04003]
            IF [HSA:3426] [KO:K01333]
            DAF [HSA:1604] [KO:K04006]
            CD59 [HSA:966] [KO:K04008]
DBLINKS     OMIM: 106100 610984 612300
REFERENCE   PMID:19481265 (description, gene)
  AUTHORS   Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F
  TITLE     Complement in human diseases: Lessons from complement deficiencies.
  JOURNAL   Mol Immunol 46:2774-83 (2009)
REFERENCE   PMID:19162547 (description, gene)
  AUTHORS   Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M
  TITLE     C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
  JOURNAL   Trends Mol Med 15:69-78 (2009)
REFERENCE   PMID:18374984 (description, gene)
  AUTHORS   Ponce-Castro IM, Gonzalez-Rubio C, Delgado-Cervino EM, Abarrategui-Garrido C, Fontan G, Sanchez-Corral P, Lopez-Trascasa M
  TITLE     Molecular characterization of Complement Factor I deficiency in two Spanish families.
  JOURNAL   Mol Immunol 45:2764-71 (2008)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00107                      Disease
NAME        Other well-defined immunodeficiency syndromes, including the following eight diseases:
            Wiskott-Aldrich syndrome;
            DiGeorge syndrome;
            Hyper-IgE syndrome;
            X-linked lymphoproliferative syndrome;
            Lymphoproliferative syndrome, EBV-associated, autosomal, 1;
            Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX);
            Cartilage-Hair Hypoplasia;
            Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
DESCRIPTION Wiskott-Aldrich syndrome (WAS) is an X-linked recessive disease and characterized by immune dysregulation and microthrombocytopenia. Several nonsense and missense mutations as well as deletions and insertions of the WAS gene have been identified in WAS patients. DiGeorge/velocardiofacial syndrome (DGS) is a congenital immune disorder characterized by lack of embryonic development or underdevelopment of the thymus and surrounding organs. The DGS is a member of a group of disorders that have in common a chromosome deletion involving 22q11.2 (the DiGeorge syndrome chromosome region, or DGCR). Hyper-IgE syndrome (HIES) is characterized by atopic dermatitis associated with extremely high serum IgE levels and susceptibility to infections with extracellular bacteria. Dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT3) gene result in the classical multisystem form of HIES, whereas a null mutation in the tyrosine kinase 2 (TYK2) gene causes an autosomal recessive HIES associated with viral and mycobacterial infections. X-linked lymphoproliferative syndrome (XLP) is a rare primary immunodeficiency, with manifestations ranging from fatal infectious mononucleosis to B cell lymphomas and hypogammaglobulinemia. Mutations in the X-linked inhibitor of apoptosis (XIAP) as well as in a distinct gene, SLAM-associated protein (SAP/DSP1/SH2D1A) have been identified in patients with XLP. Recently, it has been shown that a homozygous mutation in the SH2 domain of the IL-2-inducible T-cell kinase (ITK) gene is associated with fatal Epstein Barr virus associated lymphoproliferation, with a clinical picture similar to that seen in XLP. Immune dysregulation, polyendocrinopathy, enteropathy and X-linked (IPEX) syndrome and autoimmune polyendocrinopathy, candidiasis, ectodermal dysplasia (APECED) are examples of dysregulated immunity resulting in a disturbed tolerance and multiple autoimmune phenomena. IPEX is caused by mutations in the FOXP3 gene, and APECED results from mutations in the autoimmune regulator (AIRE) gene. Cartilage hair hypoplasia (CHH) is due to either the homozygous or compound heterozygous mutations in the nuclear encoded, non-coding RNA gene RMRP.
CATEGORY    Primary immunodeficiency
GENE        WAS [HSA:7454] [KO:K05747]
            TBX1 [HSA:6899] [KO:K10175]
            STAT3 [HSA:6774] [KO:K04692]
            TYK2 [HSA:7297] [KO:K11219]
            SH2D1A [HSA:4068] [KO:K07990]
            XIAP [HSA:331] [KO:K04725]
            ITK [HSA:3702] [KO:K07363]
            AIRE [HSA:326] [KO:K10603]
            FOXP3 [HSA:50943] [KO:K10163]
            RMRP [HSA:6023] [KO:K14576]
DBLINKS     OMIM: 301000 188400 147060 243700 308240 300635 613011 304790 250250 240300 611521
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:9737224 (gene)
  AUTHORS   Ten RM.
  TITLE     Primary immunodeficiencies.
  JOURNAL   Mayo Clin Proc 73:865-72 (1998)
REFERENCE   PMID:15096561 (description, gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:19425169 (gene)
  AUTHORS   Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A
  TITLE     Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation.
  JOURNAL   J Clin Invest 119:1350-8 (2009)
REFERENCE   PMID:21109689 (description, gene)
  AUTHORS   Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A, Resnick IB
  TITLE     IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
  JOURNAL   Haematologica 96:472-6 (2011)
REFERENCE   PMID:18264745 (description, gene)
  AUTHORS   Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD
  TITLE     Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED.
  JOURNAL   J Clin Immunol 28 Suppl 1:S11-9 (2008)
REFERENCE   PMID:19717292 (description, gene)
  AUTHORS   Minegishi Y
  TITLE     Hyper-IgE syndrome.
  JOURNAL   Curr Opin Immunol 21:487-92 (2009)
REFERENCE   PMID:16838329 (description, gene)
  AUTHORS   Hermanns P, Tran A, Munivez E, Carter S, Zabel B, Lee B, Leroy JG
  TITLE     RMRP mutations in cartilage-hair hypoplasia.
  JOURNAL   Am J Med Genet A 140:2121-30 (2006)
REFERENCE   PMID:19595300 (description, gene)
  AUTHORS   Rumble JM, Oetjen KA, Stein PL, Schwartzberg PL, Moore BB, Duckett CS
  TITLE     Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP).
  JOURNAL   Cell Immunol 259:82-9 (2009)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00108                      Disease
NAME        Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases:
            CD95 (Fas) defect, ALPS type 1a;
            CD95L (Fas ligand) defect, ALPS type 1b;
            Caspase 10 defect, ALPS type 2a;
            Caspase 8 defext, ALPS type 2b;
            Activaing N-Ras defect, N-Ras ALPS
DESCRIPTION Autoimmune lymphoproliferative syndrome (ALPS) is an autosomal dominant disorder with clinical features of various autoimmune manifestations that predominantly involve polyclonal accumulation of lymphocytes in the spleen and lymph nodes with lymphadenopathy and/or splenomegaly, and expansion of double-negative (DN) T cells in the peripheral blood. Central to the cellular pathogenesis is defective FAS-induced apoptosis, which in turn leads to dysregulation of lymphocyte homeostasis. ALPS caused by heterozygous mutations in the Fas gene (ALPS Type Ia) make up the majority of identified cases. However, other mutations, namely of the FasL gene (ALPS Type Ib) and the caspase 8 and 10 gene (ALPS Type II) are occasionally detected, whereas some patients do not present any known mutations (ALPS-III). Recently, mutations of the NRAS gene have been suggested to cause ALPS Type IV.
CATEGORY    Primary immunodeficiency
GENE        TNFRSF6 (Fas) [HSA:8771] [KO:K05143]
            TNFSF6 (Fas ligand) [HSA:356] [KO:K04389]
            Caspase 10 [HSA:843] [KO:K04400]
            Caspase 8 [HSA:841] [KO:K04398]
            N-Ras [HSA:4893] [KO:K07828]
DBLINKS     OMIM: 601859 603909 614470 607271
REFERENCE   PMID:17999750 (description, gene)
  AUTHORS   Cerutti E, Campagnoli MF, Ferretti M, Garelli E, Crescenzio N, Rosolen A, Chiocchetti A, Lenardo MJ, Ramenghi U, Dianzani U
  TITLE     Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome.
  JOURNAL   BMC Immunol 8:28 (2007)
REFERENCE   PMID:16611303 (gene)
  AUTHORS   Worth A, Thrasher AJ, Gaspar HB
  TITLE     Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical  phenotype.
  JOURNAL   Br J Haematol 133:124-40 (2006)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00109                      Disease
NAME        Familial hemophagocytic lymphohistiocytosis (FHPL), including the following three diseases:
            Perforin deficiency;
            Munc deficiency;
            STX11 deficiency
DESCRIPTION Familial hemophagocytic lymphohistiocytosis is an autosomal recessive disorder with uncontrolled activation of T cells and macrophages (hemophagocytic activation) that infiltrate into liver, spleen, bone marrow, and CNS. The symptoms include fever, hepatosplenomegaly, and cytopenia. Homozygous and heterozygous gene mutations of perforin, the major immune cytotoxic protein, were detected with frequency between 15% and 50% of all FHPL patients. UNC13D is the second gene associated with FHPL. The encoded protein (Munc13-4) is important for cytolytic granule exocytosis. Recently a third FHPL associated gene on chromosome 6q24 with mutations in STX11 was identified. The encoded protein, t-SNARE syntaxin 11, also plays a role in intracellular trafficking, but its precise role is not known.
CATEGORY    Primary immunodeficiency
GENE        PRF1 [HSA:5551] [KO:K07818]
            UNC13D [HSA:201294] [KO:K19728]
            STX11 [HSA:8676] [KO:K08487]
DBLINKS     ICD-10: D76.1
            MeSH: D056735
            OMIM: 603553 608898 603552
REFERENCE   PMID:16304363 (description, gene)
  AUTHORS   Janka G, zur Stadt U
  TITLE     Familial and acquired hemophagocytic lymphohistiocytosis.
  JOURNAL   Hematology Am Soc Hematol Educ Program 82-8 (2005)
REFERENCE   PMID:17162365 (gene)
  AUTHORS   Kumar A, Teuber SS, Gershwin ME.
  TITLE     Current perspectives on primary immunodeficiency diseases.
  JOURNAL   Clin Dev Immunol 13:223-59 (2006)
REFERENCE   PMID:15096561 (gene)
  AUTHORS   Lim MS, Elenitoba-Johnson KS.
  TITLE     The molecular pathology of primary immunodeficiencies.
  JOURNAL   J Mol Diagn 6:59-83 (2004)
REFERENCE   PMID:18424339 (gene)
  AUTHORS   Morra M, Geigenmuller U, Curran J, Rainville IR, Brennan T, Curtis J, Reichert V, Hovhannisyan H, Majzoub J, Miller DT.
  TITLE     Genetic diagnosis of primary immune deficiencies.
  JOURNAL   Immunol Allergy Clin North Am 28:387-412, x (2008)
REFERENCE   PMID:17952897 (gene)
  AUTHORS   Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarstrom L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J.
  TITLE     Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.
  JOURNAL   J Allergy Clin Immunol 120:776-94 (2007)
///
ENTRY       H00110                      Disease
NAME        Cholera
DESCRIPTION Cholera is a clinical-epidemiologic syndrome caused by the infection of O1 and O139 serogroups of Vibrio cholerae, a Gram-negative bacillus with the ability to produce a potent enterotoxin (cholera toxin) responsible for the lethal symptoms of the disease. Serogroup O1 causes over 98% of cases worldwide. In its severe form, it is characterized by profuse watery diarrhea and can quickly lead to severe dehydration and death if treatment is not promptly given. Case-fatality rates as high as 50% can be reduced to less than 1% with proper rehydration. Fluid and electrolyte replacement is the mainstay of treatment of cholera patients; the severe cases require antibiotic treatment to reduce the duration of illness and replacement of fluid intake. The antibiotic therapy currently has faced difficulties due to the rapid emergence and spread of multidrug resistant V. cholerae causing several outbreaks in the globe.
CATEGORY    Infectious disease
PATHOGEN    Vibrio cholerae serotype O1 [GN:vch vcm vcj vci vce vcs]
            Vibrio cholerae serotype O395 [GN:vco vcr]
            cholera enterotoxin [KO:K10928 K10929]
            zona occludens toxin [KO:K10954]
            accessory cholera enterotoxin [KO:K10952]
            pore-forming toxin [KO:K10948 K10953]
            membrane-damaging toxin [KO:K11018]
DBLINKS     ICD-10: A00
            MeSH: D002771
            MedlinePlus: 000303
REFERENCE   PMID:7704895
  AUTHORS   Kaper JB, Morris JG Jr, Levine MM
  TITLE     Cholera.
  JOURNAL   Clin Microbiol Rev 8:48-86 (1995)
REFERENCE   PMID:21803312
  AUTHORS   Mandal S, Mandal MD, Pal NK
  TITLE     Cholera: a great global concern.
  JOURNAL   Asian Pac J Trop Med 4:573-80 (2011)
///
ENTRY       H00111                      Disease
NAME        Typhoid fever
DESCRIPTION Typhoid fever, or enteric fever, caused by Salmonella enterica serovar Typhi is a systemic febrile disease and endemic disease in many areas of the world, mainly in developing countries. Typhoid is transmitted through ingestion of contaminated water or food and characterized by a variable incubation period ranging from three days to one month. The symptoms include fever, rash, headache, abdominal complaints, nausea, vomiting and anorexia.
CATEGORY    Infectious disease
PATHOGEN    Salmonella enterica subsp. enterica serovar Typhi [GN:sty stt sex]
DRUG        Chloramphenicol [DG:DG00399]
            Norfloxacin [DG:DG00620]
            Sparfloxacin [DR:D00590]
            Tosufloxacin [DG:DG01217]
            Trimethoprim-sulfamethoxazole [DR:D00285]
DBLINKS     ICD-10: A01.0
            MeSH: D014435
            MedlinePlus: 001332
REFERENCE   PMID:19397806
  AUTHORS   Bhunia R, Hutin Y, Ramakrishnan R, Pal N, Sen T, Murhekar M
  TITLE     A typhoid fever outbreak in a slum of South Dumdum municipality, West Bengal, India, 2007: evidence for foodborne and waterborne transmission.
  JOURNAL   BMC Public Health 9:115 (2009)
///
ENTRY       H00112                      Disease
NAME        Paratyphoid fever
DESCRIPTION Paratyphoid fever is a systemic febrile illness endemic in developing countries that is a similar to typhoid fever but gives a milder infection. The disease mainly affects those living in developing countries where sanitation is lacking and the access to clean water is reduced.
CATEGORY    Infectious disease
PATHOGEN    Salmonella enterica serovar Paratyphi A [GN:spt sek]
            Salmonella enterica serovar Paratyphi B [GN:spq]
            Salmonella enterica serovar Paratyphi C [GN:sei]
DRUG        Fluoroquinolones [ATC:J01MA]
            Ciprofloxacin [DG:DG00617]
            Ceftriaxone [DG:DG00573]
DBLINKS     ICD-10: A01.1 A01.2 A01.3 A01.4
            MeSH: D010284
REFERENCE   PMID:21301658 (description, env_factor, drug)
  AUTHORS   Mayer CA, Neilson AA
  TITLE     Typhoid and paratyphoid fever - prevention in travellers.
  JOURNAL   Aust Fam Physician 39:847-51 (2010)
REFERENCE   PMID:16700236 (description, env_factor)
  AUTHORS   Xavier G
  TITLE     Management of typhoid and paratyphoid fevers.
  JOURNAL   Nurs Times 102:49-51 (2006)
REFERENCE   PMID:20014951 (description)
  AUTHORS   Crump JA, Mintz ED
  TITLE     Global trends in typhoid and paratyphoid Fever.
  JOURNAL   Clin Infect Dis 50:241-6 (2010)
///
ENTRY       H00113                      Disease
NAME        Salmonellosis
DESCRIPTION Salmonellosis (non-typhoid) is an infectious disease caused by any serotype of bacteria in the genus Salmonella, other than Salmonella that causes typhoid and paratyphoid fever. Salmonellosis is one of the most frequently occurring food-borne diseases worldwide, usually acquired via the food chain. Foods prepared with contaminated raw eggs, egg products, and insufficiently heated poultry meat and pork have been identified as the primary sources of human Salmonella infections. Salmonellosis is characterized by the acute onset of fever, abdominal pain, nausea, diarrhoea, and sometimes vomiting. The disease is usually self-limiting, lasting a few days. However, in some cases, more serious complications follow, especially in immunocompromised people, pregnant women, the elderly and children.
CATEGORY    Infectious disease
PATHOGEN    Salmonella enterica subsp. enterica serovar Typhimurium [GN:stm seo sev sem setc send seni]
            Salmonella enterica subsp. enterica serovar Choleraesuis [GN:sec]
            Salmonella enterica subsp. enterica serovar Heidelberg [GN:seh shb seeh senh]
            Salmonella enterica subsp. enterica serovar Newport [GN:see]
            Salmonella enterica subsp. enterica serovar Schwarzengrund [GN:sew]
            Salmonella enterica subsp. enterica serovar Agona [GN:sea sens]
            Salmonella enterica subsp. enterica serovar Dublin [GN:sed]
            Salmonella enterica subsp. enterica serovar Enteritidis [GN:set]
            Salmonella enterica subsp. enterica Serovar Cubana [GN:seec]
            Salmonella enterica subsp. arizonae serovar 62:z4,z23:- RSK2980 [GN:ses]
DBLINKS     ICD-10: A02
            MeSH: D012478
REFERENCE   PMID:22016569 (description)
  AUTHORS   Alvarez-Ordonez A, Begley M, Prieto M, Messens W, Lopez M, Bernardo A, Hill C
  TITLE     Salmonella spp. survival strategies within the host gastrointestinal tract.
  JOURNAL   Microbiology 157:3268-81 (2011)
REFERENCE   PMID:21856826 (description)
  AUTHORS   Wattiau P, Boland C, Bertrand S
  TITLE     Methodologies for Salmonella enterica subsp. enterica subtyping: gold standards and alternatives.
  JOURNAL   Appl Environ Microbiol 77:7877-85 (2011)
REFERENCE   PMID:18577459 (description)
  AUTHORS   Dunkley KD, Callaway TR, Chalova VI, McReynolds JL, Hume ME, Dunkley CS, Kubena LF, Nisbet DJ, Ricke SC
  TITLE     Foodborne Salmonella ecology in the avian gastrointestinal tract.
  JOURNAL   Anaerobe 15:26-35 (2009)
///
ENTRY       H00114                      Disease
NAME        Fructose-1,6-bisphosphatase deficiency
DESCRIPTION Fructose-1,6-bisphosphatase deficiency is an autosomal recessive disorder caused by a defect in FBP1 gene and characterized by impaired gluconeogenesis.
CATEGORY    Inherited metabolic disease
GENE        FBP1; fructose-1,6-bisphosphatase 1 [HSA:2203] [KO:K03841]
DBLINKS     ICD-10: E74.1
            OMIM: 229700
REFERENCE   PMID:8884571
  AUTHORS   van den Berghe G
  TITLE     Disorders of gluconeogenesis.
  JOURNAL   J Inherit Metab Dis 19:470-7 (1996)
///
ENTRY       H00115                      Disease
NAME        Congenital sucrase-isomaltase deficiency;
            Disaccharide intolerance I
DESCRIPTION Congenital sucrase-isomaltase deficiency an autosomal recessive disorder caused by enzyme deficiency for metabolizing sucrose and starch.
CATEGORY    Inherited metabolic disease
GENE        SI; sucrase-isomaltase / oligo-1,6-glucosidase [HSA:6476] [KO:K01203]
DRUG        Sucraid [DR:D05782]
DBLINKS     ICD-10: E74.3
            MeSH: C538139
            OMIM: 222900
REFERENCE   PMID:16329100
  AUTHORS   Sander P, Alfalah M, Keiser M, Korponay-Szabo I, Kovacs JB, Leeb T, Naim HY
  TITLE     Novel mutations in the human sucrase-isomaltase gene (SI) that cause congenital carbohydrate malabsorption.
  JOURNAL   Hum Mutat 27:119 (2006)
///
ENTRY       H00116                      Disease
NAME        Congenital lactase deficiency;
            Disaccharide intolerance II
DESCRIPTION Congenital lactase deficiency is an autosomal recessive disorder caused by enzyme deficiency for metabolizing lactose.
CATEGORY    Inherited metabolic disease
GENE        LCT; lactase [HSA:3938] [KO:K01229]
DBLINKS     ICD-10: E73.0
            MeSH: C562600
            OMIM: 223000 223100
REFERENCE   PMID:16400612
  AUTHORS   Kuokkanen M, Kokkonen J, Enattah NS, Ylisaukko-Oja T, Komu H, Varilo T, Peltonen L, Savilahti E, Jarvela I
  TITLE     Mutations in the translated region of the lactase gene (LCT) underlie congenital lactase deficiency.
  JOURNAL   Am J Hum Genet 78:339-44 (2006)
REFERENCE   PMID:14616060
  AUTHORS   Swallow DM
  TITLE     Genetics of lactase persistence and lactose intolerance.
  JOURNAL   Annu Rev Genet 37:197-219 (2003)
///
ENTRY       H00117                      Disease
NAME        Primary hyperoxaluria (HP)
DESCRIPTION Primary hyperoxaluria is an autosomal recessive disorder characterized by the overproduction of oxalate.
CATEGORY    Inherited metabolic disease
GENE        (HP1) AGXT; alanine-glyoxylate aminotransferase [HSA:189] [KO:K00830]
            (HP2) GRHPR; glyoxylate reductase/hydroxypyruvate reductase [HSA:9380] [KO:K00049]
DBLINKS     ICD-10: E74.8
            MeSH: D006960
            OMIM: 259900 260000
REFERENCE   PMID:17027096
  AUTHORS   Danpure CJ
  TITLE     Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways.
  JOURNAL   Biochim Biophys Acta 1763:1776-84 (2006)
REFERENCE   PMID:11518794
  AUTHORS   Leumann E, Hoppe B
  TITLE     The primary hyperoxalurias.
  JOURNAL   J Am Soc Nephrol 12:1986-93 (2001)
REFERENCE   PMID:9243228
  AUTHORS   Kemper MJ, Conrad S, Muller-Wiefel DE
  TITLE     Primary hyperoxaluria type 2.
  JOURNAL   Eur J Pediatr 156:509-12 (1997)
///
ENTRY       H00118                      Disease
NAME        Congenital disorders of glycosylation (CDG) type I
DESCRIPTION Congenital disorders of glycosylation (CDGs) are a group of disorders caused by defects in various genes for N-glycan biosynthesis. CDG type I is defined by mutations in genes encoding enzymes which involves disrupted synthesis of the lipid linked oligosaccharide precursor and its transfer to polypeptide chain of protein, affecting N-glycan assembly in cytosol and endoplasmic reticulum. An increasing number of disorders have been discovered, with many subtypes identified. PMM2-CDG is the most common form, with over 800 patients diagnosed mostly in Europe. Almost all type present in infancy. These diseases demonstrate a broad range of clinical manifestation, associated with developmental delay, psychomotor retardation, hypotonia, seizures, hepatomegaly, microcephaly, and pericardial effusion.
CATEGORY    Inherited metabolic disease
GENE        (CDG-Ia) PMM2 [HSA:5373] [KO:K17497]
            (CDG-Ib) MPI [HSA:4351] [KO:K01809]
            (CDG-Ic) ALG6 [HSA:29929] [KO:K03848]
            (CDG-Id) ALG3 [HSA:10195] [KO:K03845]
            (CDG-Ie) DPM1 [HSA:8813] [KO:K00721]
            (CDG-If) MPDU1 [HSA:9526] [KO:K09660]
            (CDG-Ig) ALG12 [HSA:79087] [KO:K03847]
            (CDG-Ih) ALG8 [HSA:79053] [KO:K03849]
            (CDG-Ii) ALG2 [HSA:85365] [KO:K03843]
            (CDG-Ij) DPAGT1, ALG7 [HSA:1798] [KO:K01001]
            (CDG-Ik) ALG1 [HSA:56052] [KO:K03842]
            (CDG-IL) ALG9 [HSA:79796] [KO:K03846]
            (CDG-Im) DOLK [HSA:22845] [KO:K00902]
            (CDG-In) RFT1 [HSA:91869] [KO:K06316]
            (CDG-Io) DPM3 [HSA:54344] [KO:K09659]
            (CDG-Ip) ALG11 [HSA:440138] [KO:K03844]
            (CDG-Iq) SRD5A3 [HSA:79644] [KO:K12345]
            (CDG-Ir) DDOST [HSA:1650] [KO:K12670]
            (CDG-Is) ALG13 [HSA:79868] [KO:K07432]
            (CDG-Iu) DPM2 [HSA:8818] [KO:K09658]
            (CDG-Iw) STT3A [HSA:3703] [KO:K07151]
            (CDG-Ix) STT3B [HSA:201595] [KO:K07151]
            (CDG-Iy) SSR4 [HSA:6748] [KO:K04571]
            (CDG-Iz) CAD [HSA:790] [KO:K11540]
MARKER      Transferrin [HSA:7018] (The glycosylation profile shows increased amounts of disialo- and asialotransferrin.)
DBLINKS     ICD-10: E77.8
            MeSH: D018981
            OMIM: 212065 602579 603147 601110 608799 609180 607143 608104 607906 608093 608540 608776 610768 612015 612937 613661 612379 614507 300884 615042 615596 615597 300934 616457
REFERENCE   PMID:16511948
  AUTHORS   Sparks SE
  TITLE     Inherited disorders of glycosylation.
  JOURNAL   Mol Genet Metab 87:1-7 (2006)
REFERENCE   PMID:12756558
  AUTHORS   Marquardt T, Denecke J
  TITLE     Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.
  JOURNAL   Eur J Pediatr 162:359-79 (2003)
REFERENCE   PMID:12905014 (CDG type Ia)
  AUTHORS   Neumann LM, von Moers A, Kunze J, Blankenstein O, Marquardt T
  TITLE     Congenital disorder of glycosylation type 1a in a macrosomic 16-month-old boy with an atypical phenotype and homozygosity of the N216I mutation.
  JOURNAL   Eur J Pediatr 162:710-3 (2003)
REFERENCE   PMID:12414827 (CDG type Ib)
  AUTHORS   Vuillaumier-Barrot S, Le Bizec C, de Lonlay P, Barnier A, Mitchell G, Pelletier V, Prevost C, Saudubray JM, Durand G, Seta N
  TITLE     Protein losing enteropathy-hepatic fibrosis syndrome in Saguenay-Lac St-Jean, Quebec is a congenital disorder of glycosylation type Ib.
  JOURNAL   J Med Genet 39:849-51 (2002)
REFERENCE   PMID:10359825 (CDG type Ic)
  AUTHORS   Imbach T, Burda P, Kuhnert P, Wevers RA, Aebi M, Berger EG, Hennet T
  TITLE     A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic.
  JOURNAL   Proc Natl Acad Sci U S A 96:6982-7 (1999)
REFERENCE   PMID:15108280 (CDG type Id)
  AUTHORS   Denecke J, Kranz C, Kemming D, Koch HG, Marquardt T
  TITLE     An activated 5' cryptic splice site in the human ALG3 gene generates a premature termination codon insensitive to nonsense-mediated mRNA decay in a new case of congenital disorder of glycosylation type Id (CDG-Id).
  JOURNAL   Hum Mutat 23:477-86 (2004)
REFERENCE   PMID:12736397 (CDG type Ig)
  AUTHORS   Zdebska E, Bader-Meunier B, Schischmanoff PO, Dupre T, Seta N, Tchernia G, Koscielak J, Delaunay J
  TITLE     Abnormal glycosylation of red cell membrane band 3 in the congenital disorder of glycosylation Ig.
  JOURNAL   Pediatr Res 54:224-9 (2003)
REFERENCE   PMID:15235028 (CDG type Ih)
  AUTHORS   Schollen E, Frank CG, Keldermans L, Reyntjens R, Grubenmann CE, Clayton PT, Winchester BG, Smeitink J, Wevers RA, Aebi M, Hennet T, Matthijs G
  TITLE     Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 deficiency).
  JOURNAL   J Med Genet 41:550-6 (2004)
REFERENCE   PMID:12684507 (CDG type Ii)
  AUTHORS   Thiel C, Schwarz M, Peng J, Grzmil M, Hasilik M, Braulke T, Kohlschutter A, von Figura K, Lehle L, Korner C.
  TITLE     A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis.
  JOURNAL   J Biol Chem 278:22498-505 (2003)
REFERENCE   PMID:12872255 (CDG type Ij)
  AUTHORS   Wu X, Rush JS, Karaoglu D, Krasnewich D, Lubinsky MS, Waechter CJ, Gilmore R, Freeze HH
  TITLE     Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of Glycosylation Type Ij.
  JOURNAL   Hum Mutat 22:144-50 (2003)
REFERENCE   PMID:17273964 (CDG type Im)
  AUTHORS   Kranz C, Jungeblut C, Denecke J, Erlekotte A, Sohlbach C, Debus V, Kehl HG, Harms E, Reith A, Reichel S, Grobe H, Hammersen G, Schwarzer U, Marquardt T
  TITLE     A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy.
  JOURNAL   Am J Hum Genet 80:433-40 (2007)
REFERENCE   PMID:18313027 (CDG type In)
  AUTHORS   Haeuptle MA, Pujol FM, Neupert C, Winchester B, Kastaniotis AJ, Aebi M, Hennet T
  TITLE     Human RFT1 deficiency leads to a disorder of N-linked glycosylation.
  JOURNAL   Am J Hum Genet 82:600-6 (2008)
REFERENCE   PMID:19576565 (CDG type Io)
  AUTHORS   Lefeber DJ, Schonberger J, Morava E, Guillard M, Huyben KM, Verrijp K, Grafakou O, Evangeliou A, Preijers FW, Manta P, Yildiz J, Grunewald S, Spilioti M, van den Elzen C, Klein D, Hess D, Ashida H, Hofsteenge J, Maeda Y, van den Heuvel L, Lammens M, Lehle L, Wevers RA
  TITLE     Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies.
  JOURNAL   Am J Hum Genet 85:76-86 (2009)
REFERENCE   PMID:20080937 (CDG type Ip)
  AUTHORS   Rind N, Schmeiser V, Thiel C, Absmanner B, Lubbehusen J, Hocks J, Apeshiotis N, Wilichowski E, Lehle L, Korner C
  TITLE     A severe human metabolic disease caused by deficiency of the endoplasmatic mannosyltransferase hALG11 leads to congenital disorder of glycosylation-Ip.
  JOURNAL   Hum Mol Genet 19:1413-24 (2010)
REFERENCE   PMID:20637498 (CDG type Iq)
  AUTHORS   Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blumel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CR, Freeze HH, Morava E, Al-Gazali L, Gleeson JG
  TITLE     SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder.
  JOURNAL   Cell 142:203-17 (2010)
REFERENCE   PMID:22305527 (CDG type Ir)
  AUTHORS   Jones MA, Ng BG, Bhide S, Chin E, Rhodenizer D, He P, Losfeld ME, He M, Raymond K, Berry G, Freeze HH, Hegde MR
  TITLE     DDOST mutations identified by whole-exome sequencing are implicated in congenital disorders of glycosylation.
  JOURNAL   Am J Hum Genet 90:363-8 (2012)
REFERENCE   PMID:22492991 (CDG type Is)
  AUTHORS   Timal S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, Paprocka J, Jamroz E, van Spronsen FJ, Korner C, Gilissen C, Rodenburg RJ, Eidhof I, Van den Heuvel L, Thiel C, Wevers RA, Morava E, Veltman J, Lefeber DJ
  TITLE     Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing.
  JOURNAL   Hum Mol Genet 21:4151-61 (2012)
REFERENCE   PMID:23109149 (CDG type Iu)
  AUTHORS   Barone R, Aiello C, Race V, Morava E, Foulquier F, Riemersma M, Passarelli C, Concolino D, Carella M, Santorelli F, Vleugels W, Mercuri E, Garozzo D, Sturiale L, Messina S, Jaeken J, Fiumara A, Wevers RA, Bertini E, Matthijs G, Lefeber DJ
  TITLE     DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy.
  JOURNAL   Ann Neurol 72:550-8 (2012)
REFERENCE   PMID:23842455 (CDG type Iw, Ix)
  AUTHORS   Shrimal S, Ng BG, Losfeld ME, Gilmore R, Freeze HH
  TITLE     Mutations in STT3A and STT3B cause two congenital disorders of glycosylation.
  JOURNAL   Hum Mol Genet 22:4638-45 (2013)
REFERENCE   PMID:17716641 (marker)
  AUTHORS   Marklova E, Albahri Z
  TITLE     Screening and diagnosis of congenital disorders of glycosylation.
  JOURNAL   Clin Chim Acta 385:6-20 (2007)
REFERENCE   PMID:17523137 (marker)
  AUTHORS   Sanz-Nebot V, Balaguer E, Benavente F, Neususs C, Barbosa J
  TITLE     Characterization of transferrin glycoforms in human serum by CE-UV and CE-ESI-MS.
  JOURNAL   Electrophoresis 28:1949-57 (2007)
REFERENCE   PMID:19862844
  AUTHORS   Haeuptle MA, Hennet T
  TITLE     Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides.
  JOURNAL   Hum Mutat 30:1628-41 (2009)
REFERENCE   PMID:24218363 (CDG type Iy)
  AUTHORS   Losfeld ME, Ng BG, Kircher M, Buckingham KJ, Turner EH, Eroshkin A, Smith JD, Shendure J, Nickerson DA, Bamshad MJ, Freeze HH
  TITLE     A new congenital disorder of glycosylation caused by a mutation in SSR4, the signal sequence receptor 4 protein of the TRAP complex.
  JOURNAL   Hum Mol Genet 23:1602-5 (2014)
REFERENCE   PMID:28007989 (CDG type Iz)
  AUTHORS   Koch J, Mayr JA, Alhaddad B, Rauscher C, Bierau J, Kovacs-Nagy R, Coene KL, Bader I, Holzhacker M, Prokisch H, Venselaar H, Wevers RA, Distelmaier F, Polster T, Leiz S, Betzler C, Strom TM, Sperl W, Meitinger T, Wortmann SB, Haack TB
  TITLE     CAD mutations and uridine-responsive epileptic encephalopathy.
  JOURNAL   Brain 140:279-286 (2017)
///
ENTRY       H00119                      Disease
NAME        Congenital disorders of glycosylation (CDG) type II
DESCRIPTION Congenital disorders of glycosylation (CDGs) are a group of disorders caused by defects in various genes for N-glycan biosynthesis. CDG-II is defined by mutations in genes encoding enzymes in the processing of N-glycans on the glycosylated proteins either late in the endoplasmic reticulum or the Golgi compartments. Multiple subtypes have been identified although the numbers and forms of affected individuals with CDG-I are still much more. In contrast to type I, the type II patients show a more severe psychomotor retardation, no peripheral neuropathy and a cerebellar hypoplasia. According to the serum transferrin glycoform, a portion of CDG-II can be diagnosed. Distinct from CDG-I,  the serum trisialo- and asialotransferrin are increased in CDG-II.
CATEGORY    Inherited metabolic disease
GENE        (CDG-IIa) MGAT2 [HSA:4247] [KO:K00736]
            (CDG-IIb) GCS1 [HSA:7841] [KO:K01228]
            (CDG-IIc) SLC35C1 [HSA:55343] [KO:K15279]
            (CDG-IId) B4GALT1 [HSA:2683] [KO:K07966]
            (CDG-IIe) COG7 [HSA:91949] [KO:K20294]
            (CDG-IIf) SLC35A1 [HSA:10559] [KO:K15272]
            (CDG-IIg) COG1 [HSA:9382] [KO:K20288]
            (CDG-IIh) COG8 [HSA:84342] [KO:K20295]
            (CDG-IIi) COG5 [HSA:10466] [KO:K20292]
            (CDG-IIj) COG4 [HSA:25839] [KO:K20291]
            (CDG-IIk) TMEM165 [HSA:55858]
            (CDG-IIl) COG6 [HSA:57511] [KO:K20293]
            (CDG-IIm) SLC35A2 [HSA:7355] [KO:K15272]
            (CDG-IIn) SLC39A8 [HSA:64116] [KO:K14714]
            (CDG-IIo) CCDC115 [HSA:84317]
            (CDG-IIp) TMEM199 [HSA:147007]
MARKER      Transferrin [HSA:7018] (The glycosylation profile shows increased amounts of trisialo- and asialo-transferrin.)
DBLINKS     ICD-10: E77.8
            MeSH: D018981
            OMIM: 212066 606056 266265 607091 603585 608779 611209 611182 613612 613489 614727 614576 300896 616721 616828 616829
REFERENCE   PMID:11228641 (CDG type IIa)
  AUTHORS   Cormier-Daire V, Amiel J, Vuillaumier-Barrot S, Tan J, Durand G, Munnich A, Le Merrer M, Seta N
  TITLE     Congenital disorders of glycosylation IIa cause growth retardation, mental retardation, and facial dysmorphism.
  JOURNAL   J Med Genet 37:875-7 (2000)
REFERENCE   PMID:10788335 (CDG type IIb)
  AUTHORS   De Praeter CM, Gerwig GJ, Bause E, Nuytinck LK, Vliegenthart JF, Breuer W, Kamerling JP, Espeel MF, Martin JJ, De Paepe AM, Chan NW, Dacremont GA, Van Coster RN
  TITLE     A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency.
  JOURNAL   Am J Hum Genet 66:1744-56 (2000)
REFERENCE   PMID:11326280 (CDG type IIc)
  AUTHORS   Lubke T, Marquardt T, Etzioni A, Hartmann E, von Figura K, Korner C
  TITLE     Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency.
  JOURNAL   Nat Genet 28:73-6 (2001)
REFERENCE   PMID:11901181 (CDG type IId)
  AUTHORS   Hansske B, Thiel C, Lubke T, Hasilik M, Honing S, Peters V, Heidemann PH, Hoffmann GF, Berger EG, von Figura K, Korner C
  TITLE     Deficiency of UDP-galactose:N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IId.
  JOURNAL   J Clin Invest 109:725-33 (2002)
REFERENCE   PMID:17356545 (CDG type IIe)
  AUTHORS   Morava E, Zeevaert R, Korsch E, Huijben K, Wopereis S, Matthijs G, Keymolen K, Lefeber DJ, De Meirleir L, Wevers RA
  TITLE     A common mutation in the COG7 gene with a consistent phenotype including microcephaly, adducted thumbs, growth retardation, VSD and episodes of hyperthermia.
  JOURNAL   Eur J Hum Genet 15:638-45 (2007)
REFERENCE   PMID:15576474 (CDG type IIf)
  AUTHORS   Martinez-Duncker I, Dupre T, Piller V, Piller F, Candelier JJ, Trichet C, Tchernia G, Oriol R, Mollicone R
  TITLE     Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter.
  JOURNAL   Blood 105:2671-6 (2005)
REFERENCE   PMID:16537452 (CDG type IIg)
  AUTHORS   Foulquier F, Vasile E, Schollen E, Callewaert N, Raemaekers T, Quelhas D, Jaeken J, Mills P, Winchester B, Krieger M, Annaert W, Matthijs G
  TITLE     Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II.
  JOURNAL   Proc Natl Acad Sci U S A 103:3764-9 (2006)
REFERENCE   PMID:17331980 (CDG type IIh)
  AUTHORS   Kranz C, Ng BG, Sun L, Sharma V, Eklund EA, Miura Y, Ungar D, Lupashin V, Winkel RD, Cipollo JF, Costello CE, Loh E, Hong W, Freeze HH
  TITLE     COG8 deficiency causes new congenital disorder of glycosylation type IIh.
  JOURNAL   Hum Mol Genet 16:731-41 (2007)
REFERENCE   PMID:17220172 (CDG type IIh)
  AUTHORS   Foulquier F, Ungar D, Reynders E, Zeevaert R, Mills P, Garcia-Silva MT, Briones P, Winchester B, Morelle W, Krieger M, Annaert W, Matthijs G
  TITLE     A new inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for the Cog1-Cog8 interaction in COG complex formation.
  JOURNAL   Hum Mol Genet 16:717-30 (2007)
REFERENCE   PMID:19690088 (CDG type IIi)
  AUTHORS   Paesold-Burda P, Maag C, Troxler H, Foulquier F, Kleinert P, Schnabel S, Baumgartner M, Hennet T
  TITLE     Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation.
  JOURNAL   Hum Mol Genet 18:4350-6 (2009)
REFERENCE   PMID:19494034 (CDG type IIj)
  AUTHORS   Reynders E, Foulquier F, Leao Teles E, Quelhas D, Morelle W, Rabouille C, Annaert W, Matthijs G
  TITLE     Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
  JOURNAL   Hum Mol Genet 18:3244-56 (2009)
REFERENCE   PMID:22683087 (CDG type IIk)
  AUTHORS   Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, Bammens R, Morelle W, Rosnoblet C, Legrand D, Demaegd D, Buist N, Cheillan D, Guffon N, Morsomme P, Annaert W, Freeze HH, Van Schaftingen E, Vikkula M, Matthijs G
  TITLE     TMEM165 deficiency causes a congenital disorder of glycosylation.
  JOURNAL   Am J Hum Genet 91:15-26 (2012)
REFERENCE   PMID:23430903 (CDG type IIl)
  AUTHORS   Huybrechts S, De Laet C, Bontems P, Rooze S, Souayah H, Sznajer Y, Sturiale L, Garozzo D, Matthijs G, Ferster A, Jaeken J, Goyens P
  TITLE     Deficiency of Subunit 6 of the Conserved Oligomeric Golgi Complex (COG6-CDG): Second Patient, Different Phenotype.
  JOURNAL   JIMD Rep 4:103-8 (2012)
REFERENCE   PMID:23561849 (CDG type IIm)
  AUTHORS   Ng BG, Buckingham KJ, Raymond K, Kircher M, Turner EH, He M, Smith JD, Eroshkin A, Szybowska M, Losfeld ME, Chong JX, Kozenko M, Li C, Patterson MC, Gilbert RD, Nickerson DA, Shendure J, Bamshad MJ, Freeze HH
  TITLE     Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation.
  JOURNAL   Am J Hum Genet 92:632-6 (2013)
REFERENCE   PMID:26637979 (CDG type IIn)
  AUTHORS   Park JH, Hogrebe M, Gruneberg M, DuChesne I, von der Heiden AL, Reunert J, Schlingmann KP, Boycott KM, Beaulieu CL, Mhanni AA, Innes AM, Hortnagel K, Biskup S, Gleixner EM, Kurlemann G, Fiedler B, Omran H, Rutsch F, Wada Y, Tsiakas K, Santer R, Nebert DW, Rust S, Marquardt T
  TITLE     SLC39A8 Deficiency: A Disorder of Manganese Transport and Glycosylation.
  JOURNAL   Am J Hum Genet 97:894-903 (2015)
REFERENCE   PMID:26833332 (CDG type IIo)
  AUTHORS   Jansen JC, Cirak S, van Scherpenzeel M, Timal S, Reunert J, Rust S, Perez B, Vicogne D, Krawitz P, Wada Y, Ashikov A, Perez-Cerda C, Medrano C, Arnoldy A, Hoischen A, Huijben K, Steenbergen G, Quelhas D, Diogo L, Rymen D, Jaeken J, Guffon N, Cheillan D, van den Heuvel LP, Maeda Y, Kaiser O, Schara U, Gerner P, van den Boogert MA, Holleboom AG, Nassogne MC, Sokal E, Salomon J, van den Bogaart G, Drenth JP, Huynen MA, Veltman JA, Wevers RA, Morava E, Matthijs G, Foulquier F, Marquardt T, Lefeber DJ
  TITLE     CCDC115 Deficiency Causes a Disorder of Golgi Homeostasis with Abnormal Protein Glycosylation.
  JOURNAL   Am J Hum Genet 98:310-21 (2016)
REFERENCE   PMID:26833330 (CDG type IIp)
  AUTHORS   Jansen JC, Timal S, van Scherpenzeel M, Michelakakis H, Vicogne D, Ashikov A, Moraitou M, Hoischen A, Huijben K, Steenbergen G, van den Boogert MA, Porta F, Calvo PL, Mavrikou M, Cenacchi G, van den Bogaart G, Salomon J, Holleboom AG, Rodenburg RJ, Drenth JP, Huynen MA, Wevers RA, Morava E, Foulquier F, Veltman JA, Lefeber DJ
  TITLE     TMEM199 Deficiency Is a Disorder of Golgi Homeostasis Characterized by Elevated Aminotransferases, Alkaline Phosphatase, and Cholesterol and Abnormal Glycosylation.
  JOURNAL   Am J Hum Genet 98:322-30 (2016)
REFERENCE   PMID:10571011 (description)
  AUTHORS   Schachter H, Jaeken J
  TITLE     Carbohydrate-deficient glycoprotein syndrome type II.
  JOURNAL   Biochim Biophys Acta 1455:179-92 (1999)
REFERENCE   PMID:7944531 (description)
  AUTHORS   Jaeken J, Schachter H, Carchon H, De Cock P, Coddeville B, Spik G
  TITLE     Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II.
  JOURNAL   Arch Dis Child 71:123-7 (1994)
REFERENCE   PMID:11701646 (marker)
  AUTHORS   Jaeken J, Matthijs G
  TITLE     Congenital disorders of glycosylation.
  JOURNAL   Annu Rev Genomics Hum Genet 2:129-51 (2001)
///
ENTRY       H00120                      Disease
NAME        Dystroglycanopathy;
            Walker-Warburg syndrome (WWS);
            Muscle-eye-brain disease (MEB);
            Fukuyama congenital muscular dystrophy (FCMD);
            Congenital muscular dystrophy with muscle hypertrophy (MDC1C);
            Congenital muscular dystrophy with severe intellectual impairment and abnormal glycosylation (MDC1D)
DESCRIPTION Muscular dystrophies due to reduced glycosylation of alpha-dystroglycan have emerged as a common group of conditions, now referred to as dystroglycanopathies.
CATEGORY    Inherited metabolic disease; Muscular disease
GENE        POMT1; protein-O-mannosyltransferase 1 [HSA:10585] [KO:K00728]
            POMT2; protein-O-mannosyltransferase 2 [HSA:29954] [KO:K00728]
            POMGNT1; protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase [HSA:55624] [KO:K09666]
            GTDC2; protein O-mannose beta-1,4-N-acetylglucosaminyltransferase [HSA:84892] [KO:K18207]
            FKTN; fukutin [HSA:2218] [KO:K19872]
            FKRP; fukutin related protein [HSA:79147] [KO:K19873]
            LARGE [HSA:9215] [KO:K09668]
DBLINKS     ICD-10: G71.2 Q04.3
            MeSH: D058494
            OMIM: 236670 613150 253280 614830 253800 606612 608840
REFERENCE   PMID:19019316
  AUTHORS   Muntoni F, Torelli S, Brockington M
  TITLE     Muscular dystrophies due to glycosylation defects.
  JOURNAL   Neurotherapeutics 5:627-32 (2008)
REFERENCE   PMID:17030669
  AUTHORS   Biancheri R, Bertini E, Falace A, Pedemonte M, Rossi A, D'Amico A, Scapolan S, Bergamino L, Petrini S, Cassandrini D, Broda P, Manfredi M, Zara F, Santorelli FM, Minetti C, Bruno C
  TITLE     POMGnT1 mutations in congenital muscular dystrophy: genotype-phenotype correlation and expanded clinical spectrum.
  JOURNAL   Arch Neurol 63:1491-5 (2006)
REFERENCE   PMID:15121789
  AUTHORS   Beltran-Valero de Bernabe D, Voit T, Longman C, Steinbrecher A, Straub V, Yuva Y, Herrmann R, Sperner J, Korenke C, Diesen C, Dobyns WB, Brunner HG, van Bokhoven H, Brockington M, Muntoni F
  TITLE     Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome.
  JOURNAL   J Med Genet 41:e61 (2004)
REFERENCE   PMID:15894594
  AUTHORS   van Reeuwijk J, Janssen M, van den Elzen C, Beltran-Valero de Bernabe D, Sabatelli P, Merlini L, Boon M, Scheffer H, Brockington M, Muntoni F, Huynen MA, Verrips A, Walsh CA, Barth PG, Brunner HG, van Bokhoven H
  TITLE     POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome.
  JOURNAL   J Med Genet 42:907-12 (2005)
REFERENCE   PMID:21496624 (gene)
  AUTHORS   Sparks SE, Escolar DM
  TITLE     Congenital muscular dystrophies.
  JOURNAL   Handb Clin Neurol 101:47-79 (2011)
REFERENCE   PMID:18769252 (gene)
  AUTHORS   Guglieri M, Straub V, Bushby K, Lochmuller H
  TITLE     Limb-girdle muscular dystrophies.
  JOURNAL   Curr Opin Neurol 21:576-84 (2008)
REFERENCE   PMID:22958903
  AUTHORS   Manzini MC, Tambunan DE, Hill RS, Yu TW, Maynard TM, Heinzen EL, Shianna KV, Stevens CR, Partlow JN, Barry BJ, Rodriguez J, Gupta VA, Al-Qudah AK, Eyaid WM, Friedman JM, Salih MA, Clark R, Moroni I, Mora M, Beggs AH, Gabriel SB, Walsh CA
  TITLE     Exome sequencing and functional validation in zebrafish identify GTDC2 mutations  as a cause of Walker-Warburg syndrome.
  JOURNAL   Am J Hum Genet 91:541-7 (2012)
///
ENTRY       H00122                      Disease
NAME        Multiple exostoses
DESCRIPTION Hereditary multiple exostoses syndrome is the most frequent glycosylation defect, which is characterized by benign osteochondromas on the ends of long bones.
CATEGORY    Inherited metabolic disease; Connective tissue disease
GENE        EXT1; glucuronyl/N-acetylglucosaminyl transferase EXT1 [HSA:2131] [KO:K02366]
            EXT2; glucuronyl/N-acetylglucosaminyl transferase EXT2 [HSA:2132] [KO:K02367]
DBLINKS     ICD-10: Q78.6
            MeSH: D005097
            OMIM: 133700 133701
REFERENCE   PMID:18367479
  AUTHORS   Nadanaka S, Kitagawa H
  TITLE     Heparan sulphate biosynthesis and disease.
  JOURNAL   J Biochem 144:7-14 (2008)
REFERENCE   PMID:10679937
  AUTHORS   Wuyts W, Van Hul W
  TITLE     Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes.
  JOURNAL   Hum Mutat 15:220-7 (2000)
///
ENTRY       H00123                      Disease
NAME        Mucopolysaccharidosis type IV (MPS4), including:
            Morquio syndrome A (MPS4A);
            Morquio syndrome B (MPS4B)
DESCRIPTION Mucopolysaccharidosis type IV is an autosomal recessive lysosomal storage disorder caused by a defect in one of the enzyme genes involved in glycosaminoglycan degradation. The defect results in the accumulation of keratan sulfate and chondroitin sulfate in many organs, as well as elevated metabolite levels in urine. Common signs and symptoms include normal cognition, coarse faces, and dysostosis multiplex.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS4A) GALNS; N-acetylgalactosamine-6-sulfatase [HSA:2588] [KO:K01132]
            (MPS4B) GLB1; beta-galactosidase [HSA:2720] [KO:K12309]
MARKER      keratan sulfate [CPD:C00573]
            Chondroitin sulfate [CPD:C00607]
            Urine oligosaccharides
DRUG        Hematopoietic stem cell transplantation
            Chemical chaperone therapy; N-octyl-4-epi-beta-valienamine (NOEV)
            (limited experience)
COMMENT     Morquio syndrome B is allelic to the various forms of GM1-gangliosidosis (see, H00281). The latter disorders show central nervous system involvement.
DBLINKS     ICD-10: E76.2
            MeSH: D009085
            OMIM: 253000 253010
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:16854371
  AUTHORS   Kolter T, Sandhoff K
  TITLE     Sphingolipid metabolism diseases.
  JOURNAL   Biochim Biophys Acta 1758:2057-79 (2006)
REFERENCE   PMID:19472408
  AUTHORS   Hofer D, Paul K, Fantur K, Beck M, Burger F, Caillaud C, Fumic K, Ledvinova J, Lugowska A, Michelakakis H, Radeva B, Ramaswami U, Plecko B, Paschke E
  TITLE     GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
  JOURNAL   Hum Mutat 30:1214-21 (2009)
REFERENCE   PMID:18202827
  AUTHORS   Suzuki Y
  TITLE     Chemical chaperone therapy for GM1-gangliosidosis.
  JOURNAL   Cell Mol Life Sci 65:351-3 (2008)
///
ENTRY       H00124                      Disease
NAME        GM2 gangliosidoses, including:
            Tay-Sachs disease (type I);
            Sandhoff disease (type II);
            Tay-Sachs disease AB variant
DESCRIPTION GM2 gangliosidoses are a group of autosomal recessive lysosomal storage disorders caused by deficiency of beta-hexosaminiase or the noncatalytic GM2 activator in glycosphingolipid catabolism. The enzymatic defect results in the accumulation of GM2 ganglioside in neurons that mainly affects motor and spinocerebellar function. Mutations of the HEXA gene cause deficiency of the beta-hexosaminidase A and result in Tay-Sachs disease. Mutations of the HEXB gene, encoding the beta-subunit, cause deficiency of both enzymes (beta-hexosaminidase A and B), leading to Sandhoff disease. Deficiency of the GM2 activator protein, which mediates the interaction between the water-soluble beta-hexosaminidase A and GM2 ganglioside, causes the AB variant of GM2 gangliosidosis.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        (Type I) HEXA; beta-hexosaminidase A [HSA:3073] [KO:K12373]
            (Type II) HEXB; beta-hexosaminidase B [HSA:3074] [KO:K12373]
            (AB variant) GM2A; ganglioside GM2 activator [HSA:2760] [KO:K12383]
MARKER      Urine oligosaccharides
            GM2 ganglioside [GL:G00109] [CPD:C04884]
            keratan sulfate [CPD:C00573]
DRUG        Substrate reduction therapy
DBLINKS     ICD-10: E75.0
            MeSH: D020143
            OMIM: 268800 272800 272750
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:16854371
  AUTHORS   Kolter T, Sandhoff K
  TITLE     Sphingolipid metabolism diseases.
  JOURNAL   Biochim Biophys Acta 1758:2057-79 (2006)
REFERENCE   PMID:15647514
  AUTHORS   Winchester B
  TITLE     Lysosomal metabolism of glycoproteins.
  JOURNAL   Glycobiology 15:1R-15R (2005)
REFERENCE   PMID:12019216
  AUTHORS   Myerowitz R, Lawson D, Mizukami H, Mi Y, Tifft CJ, Proia RL
  TITLE     Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.
  JOURNAL   Hum Mol Genet 11:1343-50 (2002)
REFERENCE   PMID:19595619 (therapy)
  AUTHORS   Maegawa GH, Banwell BL, Blaser S, Sorge G, Toplak M, Ackerley C, Hawkins C, Hayes J, Clarke JT
  TITLE     Substrate reduction therapy in juvenile GM2 gangliosidosis.
  JOURNAL   Mol Genet Metab 98:215-24 (2009)
///
ENTRY       H00125                      Disease
NAME        Fabry disease
DESCRIPTION Fabry disease is an X-linked lysosomal storage disorder caused by deficient alpha-galactosidase A activity. Symptoms arise because of accumulation of glycosphingolipids -mainly globotriaosylceramide- in multiple organs. Fabry disease affects almost all organs. The most serious complications involve the kidneys, heart, and central nervous system. In contrast to many X-linked diseases, female heterozygotes cannot be considered merely carriers of the mutation. All of the signs and symptoms found in males with Fabry disease also have been reported in females.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease; Cardiovascular disease
GENE        GLA; alpha-galactosidase [HSA:2717] [KO:K01189]
MARKER      Ceramidetrihexoside [GL:G00036] [CPD:C04845]
DRUG        Enzyme-replacement therapy
            Carbamazepine [DR:D00252]
            Agalsidase alfa [DR:D02784]
            Agalsidase beta [DR:D03228]
DBLINKS     ICD-10: E75.2
            MeSH: D000795
            OMIM: 301500
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:18940466
  AUTHORS   Zarate YA, Hopkin RJ
  TITLE     Fabry's disease.
  JOURNAL   Lancet 372:1427-35 (2008)
REFERENCE   PMID:16854371
  AUTHORS   Kolter T, Sandhoff K
  TITLE     Sphingolipid metabolism diseases.
  JOURNAL   Biochim Biophys Acta 1758:2057-79 (2006)
REFERENCE   PMID:12633142
  AUTHORS   Wenger DA, Coppola S, Liu SL
  TITLE     Insights into the diagnosis and treatment of lysosomal storage diseases.
  JOURNAL   Arch Neurol 60:322-8 (2003)
REFERENCE   PMID:19318041
  AUTHORS   Schiffmann R
  TITLE     Fabry disease.
  JOURNAL   Pharmacol Ther 122:65-77 (2009)
REFERENCE   PMID:17279083
  AUTHORS   Moller AT, Jensen TS
  TITLE     Neurological manifestations in Fabry's disease.
  JOURNAL   Nat Clin Pract Neurol 3:95-106 (2007)
///
ENTRY       H00126                      Disease
NAME        Gaucher disease
DESCRIPTION Gaucher disease is an autosomal recessive lysosomal storage disorder caused by deficient beta-glucocerebrosidase (glucosylceramidase) activity or saposin C which is an activator of beta-glucocerebrosidase in sphingolipid metabolism. The enzymatic defects lead to the accumulation of glucosylceramide (GC) in lysosomes of affected cells. Despite the fact that Gaucher Disease consists of a phenotype, with varying degrees of severity, it has been sub-divided in three subtypes according to the presence or absence of neurological involvement. The sub-types are Type 1, 2 and 3.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        GBA; glucosylceramidase [HSA:2629] [KO:K01201]
            PSAP; prosaposin [HSA:5660] [KO:K12382]
MARKER      Glucocerebroside [GL:G10238] [CPD:C01190]
DRUG        Enzyme-replacement therapy
            Hematopoietic stem cell transplantation
            Alglucerase [DR:D02810]
            Imiglucerase [DR:D03020]
            Miglustat [DR:D05032]
            Velaglucerase alfa [DR:D09029]
COMMENT     The most common mutations: N370S, L444P, 84GG, IVS2+1G>A, V394L, del55bp, D409H, R496H, and RecNciI.
DBLINKS     ICD-10: E75.2
            MeSH: D005776
            OMIM: 230800 230900 231000 231005 608013 610539
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:17644022
  AUTHORS   Butters TD
  TITLE     Gaucher disease.
  JOURNAL   Curr Opin Chem Biol 11:412-8 (2007)
REFERENCE   PMID:15464415
  AUTHORS   Sidransky E
  TITLE     Gaucher disease: complexity in a "simple" disorder.
  JOURNAL   Mol Genet Metab 83:6-15 (2004)
REFERENCE   PMID:12633142
  AUTHORS   Wenger DA, Coppola S, Liu SL
  TITLE     Insights into the diagnosis and treatment of lysosomal storage diseases.
  JOURNAL   Arch Neurol 60:322-8 (2003)
REFERENCE   PMID:23400823 (mutations)
  AUTHORS   Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A
  TITLE     Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
  JOURNAL   Am J Hematol 88:179-84 (2013)
///
ENTRY       H00127                      Disease
NAME        Metachromatic leukodystrophy (MLD)
DESCRIPTION Metachromatic leukodystrophy (MLD) is an autosomal recessive demyelinating lysosomal storage disease caused by deficiency of lysosomal arylsulfatase A (ARSA). The enzyme defect results in the accumulation of sulfatide in the central and peripheral nervous systems and extensive white matter damage and loss of both cognitive and motor functions. Mutated PSAP gene resulting in sphingolipid activator protein B deficiency is known to cause MLD variant in which ARSA is normal.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        ARSA; arylsulfatase A [HSA:410] [KO:K01134]
            PSAP; saposin [HSA:5660] [KO:K12382]
MARKER      Urine sulfatides [GL:G11122] [CPD:C06125]
DRUG        Enzyme-replacement therapy
            Hematopoietic stem cell transplantation
DBLINKS     ICD-10: E75.2
            MeSH: D007966
            OMIM: 250100 249900
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:18465098
  AUTHORS   Eckhardt M
  TITLE     The role and metabolism of sulfatide in the nervous system.
  JOURNAL   Mol Neurobiol 37:93-103 (2008)
REFERENCE   PMID:16854371
  AUTHORS   Kolter T, Sandhoff K
  TITLE     Sphingolipid metabolism diseases.
  JOURNAL   Biochim Biophys Acta 1758:2057-79 (2006)
REFERENCE   PMID:17347913
  AUTHORS   Sevin C, Aubourg P, Cartier N
  TITLE     Enzyme, cell and gene-based therapies for metachromatic leukodystrophy.
  JOURNAL   J Inherit Metab Dis 30:175-83 (2007)
REFERENCE   PMID:19267410 (MLD variant)
  AUTHORS   Kuchar L, Ledvinova J, Hrebicek M, Myskova H, Dvorakova L, Berna L, Chrastina P, Asfaw B, Elleder M, Petermoller M, Mayrhofer H, Staudt M, Krageloh-Mann I, Paton BC, Harzer K
  TITLE     Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations.
  JOURNAL   Am J Med Genet A 149A:613-21 (2009)
///
ENTRY       H00128                      Disease
NAME        Mucopolysaccharidosis type I (MPS1);
            Hurler-Scheie syndrome (MPS1HS);
            Hurler syndrome (MPS1H);
            Scheie syndrome (MPS1S)
DESCRIPTION Mucopolysaccharidosis type I is an autosomal recessive lysosomal storage disorder caused by deficient activity of alpha-L-iduronidase in glycosaminoglycan degradation. The enzyme defect results in the accumulation of heparan sulfate and dermatan sulfate in many organs, as well as elevated metabolite levels in urine. Hurler syndrome is characterized by coarse faces, hydrocephalus, dysostosis multiplex, cardiac valve disease, airway obstruction, and mental retardation. Scheie syndrome is a milder form.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS1) IDUA; alpha-L-iduronidase [HSA:3425] [KO:K01217]
MARKER      Urine glycosaminoglycans
            Heparan sulfate [CPD:C00925]
            Dermatan sulfate [CPD:C00426]
DRUG        Hematopoietic stem cell transplantation
            Enzyme-replacement therapy
            Aldurazyme [DR:D04670]
DBLINKS     ICD-10: E76.0
            MeSH: D008059
            OMIM: 607014 607015 607016
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:16124866
  AUTHORS   Diez-Roux G, Ballabio A
  TITLE     Sulfatases and human disease.
  JOURNAL   Annu Rev Genomics Hum Genet 6:355-79 (2005)
REFERENCE   PMID:18050087
  AUTHORS   El Dib RP, Pastores GM
  TITLE     Laronidase for treating mucopolysaccharidosis type I.
  JOURNAL   Genet Mol Res 6:667-74 (2007)
///
ENTRY       H00129                      Disease
NAME        Mucopolysaccharidosis type II (MPS2);
            Hunter syndrome
DESCRIPTION Mucopolysaccharidosis type II is an X-linked lysosomal storage disorder caused by deficient activity of iduronate-2-sulfatase in glycosaminoglycan degradation. The enzyme defect results in the accumulation of heparan sulfate and dermatan sulfate in many organs, as well as elevated metabolite levels in urine. The heterogeneity of clinical phenotypes, ranging from mild-to-severe forms, is a result of different mutations in the IDS gene. This disorder is characterized by mental retardation, coarse faces, short stature, hearing loss, hydrocephalus, hepatosplenomegaly, dysostosis multiplex, airway obstruction, and cardiac valve disease.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS2) IDS; iduronate 2-sulfatase [HSA:3423] [KO:K01136]
MARKER      Urine glycosaminoglycans
            Heparan sulfate [CPD:C00925]
            Dermatan sulfate [CPD:C00426]
DRUG        Enzyme-replacement therapy
            Elaprase [DR:D04499]
DBLINKS     ICD-10: E76.1
            MeSH: D016532
            OMIM: 309900
REFERENCE   PMID:18618289
  AUTHORS   Al Sawaf S, Mayatepek E, Hoffmann B
  TITLE     Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.
  JOURNAL   J Inherit Metab Dis 31:473-80 (2008)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
///
ENTRY       H00130                      Disease
NAME        Mucopolysaccharidosis type III (MPS3), including:
            Sanfilippo A syndrome (MPS3A);
            Sanfilippo B syndrome (MPS3B);
            Sanfilippo C syndrome (MPS3C);
            Sanfilippo D syndrome (MPS3D)
DESCRIPTION Mucopolysaccharidosis type III is an autosomal recessive lysosomal storage disorder caused by a defect in one of the four enzyme genes involved in glycosaminoglycan degradation. The defect results in the accumulation of heparan sulfate in many organs, as well as elevated metabolite levels in urine. Common signs and symptoms include mental retardation, behavior and aggression problems, and seizures.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        (MPS3A) SGSH; N-sulfoglucosamine sulfohydrolase [HSA:6448] [KO:K01565]
            (MPS3B) NAGLU; alpha-N-acetylglucosaminidase [HSA:4669] [KO:K01205]
            (MPS3C) HGSNAT; heparan-alpha-glucosaminide N-acetyltransferase [HSA:138050] [KO:K10532]
            (MPS3D) GNS; N-acetylglucosamine-6-sulfatase [HSA:2799] [KO:K01137]
MARKER      Urine glycosaminoglycans
            Heparan sulfate [CPD:C00925]
DBLINKS     ICD-10: E76.2
            MeSH: D009084
            OMIM: 252900 252920 252930 252940
REFERENCE   PMID:18392742
  AUTHORS   Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA
  TITLE     Sanfilippo syndrome: A mini-review.
  JOURNAL   J Inherit Metab Dis (2008)
REFERENCE   PMID:16124866
  AUTHORS   Diez-Roux G, Ballabio A
  TITLE     Sulfatases and human disease.
  JOURNAL   Annu Rev Genomics Hum Genet 6:355-79 (2005)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
///
ENTRY       H00131                      Disease
NAME        Mucopolysaccharidosis type VI (MPS6);
            Maroteaux-Lamy syndrome
DESCRIPTION Mucopolysaccharidosis type VI is an autosomal recessive lysosomal storage disorder caused by deficient activity of arylsulfatase B in glycosaminoglycan degradation. The enzyme defect results in the accumulation of dermatan sulfate and chondroitin 4-sulfate in many organs, as well as elevated metabolite levels in urine. This disorder is characterized by normal cognition, coarse faces and dysostosis multiplex, hepatosplenomegaly, and cardiac valve disease.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS6) ARSB; arylsulfatase B [HSA:411] [KO:K01135]
MARKER      Urine glycosaminoglycans
            Heparan sulfate [CPD:C00925]
            Chondroitin 4-sulfate [CPD:C00634]
DRUG        Hematopoietic stem cell transplantation
            Enzyme-replacement therapy
            Aryplase [DR:D06565]
DBLINKS     ICD-10: E76.2
            MeSH: D009087
            OMIM: 253200
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:16124866
  AUTHORS   Diez-Roux G, Ballabio A
  TITLE     Sulfatases and human disease.
  JOURNAL   Annu Rev Genomics Hum Genet 6:355-79 (2005)
REFERENCE   PMID:20385007
  AUTHORS   Valayannopoulos V, Nicely H, Harmatz P, Turbeville S
  TITLE     Mucopolysaccharidosis VI.
  JOURNAL   Orphanet J Rare Dis 5:5 (2010)
///
ENTRY       H00132                      Disease
NAME        Mucopolysaccharidosis type VII (MPS7);
            Sly syndrome
DESCRIPTION Mucopolysaccharidosis type VII is an autosomal recessive lysosomal storage disorder caused by deficient activity of beta-glucuronidase in glycosaminoglycan degradation. The enzyme defect results in the accumulation of heparan sulfate, dermatan sulfate, and chondroitin-4,6-sulfate occurs in many organs, as well as elevated metabolite levels in urine. This disorder is characterized by mental retardation, coarse faces, dysostosis multiplex, hepatosplenomegaly, and hydrops fetails.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS7) GUSB; beta-glucuronidase [HSA:2990] [KO:K01195]
MARKER      Urine glycosaminoglycans
            Heparan sulfate [CPD:C00925]
            Dermatan sulfate [CPD:C00426]
            Chondroitin sulfate [CPD:C00607]
COMMENT     Hematopoietic stem cell transplantation (limited experience)
DBLINKS     ICD-10: E76.2
            MeSH: D016538
            OMIM: 253220
REFERENCE   PMID:16601332
  AUTHORS   Venkat-Raman N, Sebire NJ, Murphy KW
  TITLE     Recurrent fetal hydrops due to mucopolysaccharidoses type VII.
  JOURNAL   Fetal Diagn Ther 21:250-4 (2006)
REFERENCE   PMID:19224584
  AUTHORS   Tomatsu S, Montano AM, Dung VC, Grubb JH, Sly WS
  TITLE     Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome).
  JOURNAL   Hum Mutat 30:511-9 (2009)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
///
ENTRY       H00133                      Disease
NAME        Mucopolysaccharidosis type IX (MPS9);
            Hyaluronidase deficiency
DESCRIPTION Mucopolysaccharidosis type IX is a very rare autosomal recessive lysosomal storage disorder caused by deficient activity of lysosomal hyaluronidase.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS9) HYAL1; hyaluronoglucosaminidase [HSA:3373] [KO:K01197]
DBLINKS     ICD-10: E76.3
            MeSH: C563209
            OMIM: 601492
REFERENCE   PMID:18344557
  AUTHORS   Martin DC, Atmuri V, Hemming RJ, Farley J, Mort JS, Byers S, Hombach-Klonisch S, Csoka AB, Stern R, Triggs-Raine BL
  TITLE     A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis.
  JOURNAL   Hum Mol Genet 17:1904-15 (2008)
REFERENCE   PMID:10339581
  AUTHORS   Triggs-Raine B, Salo TJ, Zhang H, Wicklow BA, Natowicz MR
  TITLE     Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.
  JOURNAL   Proc Natl Acad Sci U S A 96:6296-300 (1999)
///
ENTRY       H00134                      Disease
NAME        X-linked ichthyosis (XLI)
DESCRIPTION X-linked ichthyosis is caused by deficient activity of steroid sulfatase. It is often associated with further clinical problems, including cryptorchidism or social communication deficits, such as attention deficit hyperactivity syndrome or autism.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease
GENE        STS [HSA:412] [KO:K01131]
DBLINKS     ICD-10: Q80.1
            MeSH: D016114
            OMIM: 308100
REFERENCE   PMID:15561802
  AUTHORS   Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV
  TITLE     Steroid sulfatase: molecular biology, regulation, and inhibition.
  JOURNAL   Endocr Rev 26:171-202 (2005)
REFERENCE   PMID:9252398 (gene)
  AUTHORS   Alperin ES, Shapiro LJ
  TITLE     Characterization of point mutations in patients with X-linked ichthyosis. Effects on the structure and function of the steroid sulfatase protein.
  JOURNAL   J Biol Chem 272:20756-63 (1997)
REFERENCE   PMID:18413370
  AUTHORS   Kent L, Emerton J, Bhadravathi V, Weisblatt E, Pasco G, Willatt LR, McMahon R, Yates JR
  TITLE     X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits.
  JOURNAL   J Med Genet 45:519-24 (2008)
///
ENTRY       H00135                      Disease
NAME        Krabbe disease;
            Globoid cell leukodystrophy
DESCRIPTION Krabbe disease is an autosomal recessive disorder caused by deficient activity of galactosylceramidase.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        GALC; galactosylceramidase [HSA:2581] [KO:K01202]
            PSAP; prosaposin [HSA:5660] [KO:K12382]
MARKER      Galactocerebroside [GL:G11121] [CPD:C02686]
            Psychosine [CPD:C01747]
DRUG        Hematopoietic stem cell transplantation
            Enzyme-replacement therapy
DBLINKS     ICD-10: E75.2
            MeSH: D007965
            OMIM: 245200 611722
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:16854371
  AUTHORS   Kolter T, Sandhoff K
  TITLE     Sphingolipid metabolism diseases.
  JOURNAL   Biochim Biophys Acta 1758:2057-79 (2006)
REFERENCE   PMID:10833326
  AUTHORS   Wenger DA, Rafi MA, Luzi P, Datto J, Costantino-Ceccarini E
  TITLE     Krabbe disease: genetic aspects and progress toward therapy.
  JOURNAL   Mol Genet Metab 70:1-9 (2000)
REFERENCE   PMID:15773042
  AUTHORS   Spiegel R, Bach G, Sury V, Mengistu G, Meidan B, Shalev S, Shneor Y, Mandel H, Zeigler M
  TITLE     A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans.
  JOURNAL   Mol Genet Metab 84:160-6 (2005)
///
ENTRY       H00136                      Disease
NAME        Niemann-Pick disease type C (NPC), including:
            Niemann-Pick disease type C1;
            Niemann-Pick disease type C2
DESCRIPTION Niemann-Pick disease type C is an autosomal recessive lysosomal lipid storage disorder caused by a defect of NPC1 or NPC2 involved in cholesterol trafficking. The disease is characterized by neurodegeneration starting from early life. While NPC1 is a lysosomal transmembrane protein involved in shuttling of substrates to the Golgi and possibly elsewhere in cells, NPC2 is a soluble lysosomal protein known to bind cholesterol.
CATEGORY    Inherited metabolic disease; Nervous system disease; Lysosomal storage disease
GENE        (NPC1/ D) NPC1 [HSA:4864] [KO:K12385]
            (NPC2) NPC2 [HSA:10577] [KO:K13443]
MARKER      Cholesterol [CPD:C00187]
DRUG        Miglustat [DR:D05032]
COMMENT     Niemann-Pick disease, type D is now thought to be a variant of type C. TypeD has only been found in the French Canadian population of Yarmouth County, Nova Scotia.
DBLINKS     ICD-10: E75.2
            MeSH: D052556
            OMIM: 257220 607625
REFERENCE   PMID:18782459
  AUTHORS   Pacheco CD, Lieberman AP
  TITLE     The pathogenesis of Niemann-Pick type C disease: a role for autophagy?
  JOURNAL   Expert Rev Mol Med 10:e26 (2008)
REFERENCE   PMID:16797010
  AUTHORS   Vance JE
  TITLE     Lipid imbalance in the neurological disorder, Niemann-Pick C disease.
  JOURNAL   FEBS Lett 580:5518-24 (2006)
REFERENCE   PMID:15207834
  AUTHORS   Ikonen E, Holtta-Vuori M
  TITLE     Cellular pathology of Niemann-Pick type C disease.
  JOURNAL   Semin Cell Dev Biol 15:445-54 (2004)
REFERENCE   PMID:15465424
  AUTHORS   Mukherjee S, Maxfield FR
  TITLE     Lipid and cholesterol trafficking in NPC.
  JOURNAL   Biochim Biophys Acta 1685:28-37 (2004)
REFERENCE   PMID:15465426
  AUTHORS   Walkley SU, Suzuki K
  TITLE     Consequences of NPC1 and NPC2 loss of function in mammalian neurons.
  JOURNAL   Biochim Biophys Acta 1685:48-62 (2004)
REFERENCE   PMID:17689147 (drug)
  AUTHORS   Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE
  TITLE     Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.
  JOURNAL   Lancet Neurol 6:765-72 (2007)
///
ENTRY       H00137                      Disease
NAME        Niemann-Pick disease (NPD) typeA and B, including:
            Niemann-Pick disease, type A;
            Niemann-Pick disease, type B
DESCRIPTION Niemann-Pick disease (NPD) is an autosomal recessive lysosomal storage disorder caused by deficient acid sphingomyelinase (ASM) activity, resulting in accumulation of sphingomyelin and cholesterol in many organs. ASM plays an important role in normal membrane turnover and is one of the key enzymes responsible for the production of ceramide. Type A NPD is the infantile form characterized by a rapidly progressive neurodegenerative course that leads to early death. Type B NPD is the later-onset form in which patients exhibit little or no neurological symptoms, but may have severe and progressive visceral organ abnormalities, including hepatosplenomegaly and cardiovascular disease. The different clinical presentations of Types A and B NPD are likely due to small differences in the amount of residual, functional ASM activity.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        SMPD1; sphingomyelin phosphodiesterase [HSA:6609] [KO:K12350]
MARKER      Niemann-Pick cell: marrow film containing characteristic foamy macrophage of Niemann-Pick disease
DRUG        Enzyme-replacement therapy
            Hematopoietic stem cell transplantation (type B)
COMMENT     Descriptions of type E and type F have been published, but they are not well characterized, and are currently classified under type B.
DBLINKS     ICD-10: E75.2
            MeSH: D052536 D052537
            OMIM: 257200 607616
REFERENCE   PMID:18567738
  AUTHORS   Smith EL, Schuchman EH
  TITLE     The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.
  JOURNAL   FASEB J 22:3419-31 (2008)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:17632693
  AUTHORS   Schuchman EH
  TITLE     The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.
  JOURNAL   J Inherit Metab Dis 30:654-63 (2007)
REFERENCE   PMID:10760463
  AUTHORS   Ridgway ND
  TITLE     Interactions between metabolism and intracellular distribution of cholesterol and sphingomyelin.
  JOURNAL   Biochim Biophys Acta 1484:129-41 (2000)
REFERENCE   PMID:19944693
  AUTHORS   Schuchman EH
  TITLE     Acid sphingomyelinase, cell membranes and human disease: Lessons from Niemann-Pick disease.
  JOURNAL   FEBS Lett (2009)
///
ENTRY       H00138                      Disease
NAME        Farber lipogranulomatosis;
            Farber disease
DESCRIPTION Farber lipogranulomatosis is an autosomal recessive disorder caused by acid ceramidase deficiency.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        ASAH1; acid ceramidase [HSA:427] [KO:K12348]
MARKER      Ceramide [CPD:C00195]
DRUG        Hematopoietic stem cell transplantation
DBLINKS     ICD-10: E75.2
            MeSH: D055577
            OMIM: 228000
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:17064658
  AUTHORS   Park JH, Schuchman EH
  TITLE     Acid ceramidase and human disease.
  JOURNAL   Biochim Biophys Acta 1758:2133-8 (2006)
REFERENCE   PMID:12633142
  AUTHORS   Wenger DA, Coppola S, Liu SL
  TITLE     Insights into the diagnosis and treatment of lysosomal storage diseases.
  JOURNAL   Arch Neurol 60:322-8 (2003)
REFERENCE   PMID:11241842
  AUTHORS   Bar J, Linke T, Ferlinz K, Neumann U, Schuchman EH, Sandhoff K
  TITLE     Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
  JOURNAL   Hum Mutat 17:199-209 (2001)
///
ENTRY       H00139                      Disease
NAME        alpha-Mannosidosis
DESCRIPTION Alpha-mannosidosis is an autosomal recessive lysosomal storage disorder caused by deficient activity of alpha-mannosidase in glycoprotein catabolism. The enzymatic defect results in the accumulation of mannose-rich oligosaccharides in many organs. Alpha-mannosidosis is characterized by immune deficiency, facial and skeletal abnormalities, hearing impairment, and mental retardation. The disorder has been described as two distinct phenotypes: a severe form with hepatomegaly and early death following severe infections (type 1) and a mild form with hearing loss and mental retardation (type 2).
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        MAN2B1; lysosomal alpha-mannosidase [HSA:4125] [KO:K12311]
MARKER      Urine oligosaccharides
            Vacuolated lymphocytes
DRUG        Hematopoietic stem cell transplantation
DBLINKS     ICD-10: E77.1
            MeSH: D008363
            OMIM: 248500
REFERENCE   PMID:18651971
  AUTHORS   Malm D, Nilssen O
  TITLE     Alpha-mannosidosis.
  JOURNAL   Orphanet J Rare Dis 3:21 (2008)
REFERENCE   PMID:11322479
  AUTHORS   Sun H, Wolfe JH
  TITLE     Recent progress in lysosomal alpha-mannosidase and its deficiency.
  JOURNAL   Exp Mol Med 33:1-7 (2001)
REFERENCE   PMID:10571005
  AUTHORS   Michalski JC, Klein A
  TITLE     Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
  JOURNAL   Biochim Biophys Acta 1455:69-84 (1999)
///
ENTRY       H00140                      Disease
NAME        beta-Mannosidosis
DESCRIPTION Beta-Mannosidosis is an autosomal recessive lysosomal storage disorder caused by deficient activity of beta-mannosidase. This disorder is characterized by mental retardation, behavioural problems, hearing loss, recurrent respiratory infections, angiokeratoma, facial dysmorphism, skeletal deformation, seizures, hypotonia, demyelinating polyneuropathy, and hepatosplenomegaly.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        MANBA; lysosomal beta-mannosidase [HSA:4126] [KO:K01192]
MARKER      Urine oligosaccharides
DBLINKS     ICD-10: E77.1
            MeSH: D044905
            OMIM: 248510
REFERENCE   PMID:15647514
  AUTHORS   Winchester B
  TITLE     Lysosomal metabolism of glycoproteins.
  JOURNAL   Glycobiology 15:1R-15R (2005)
REFERENCE   PMID:10571005
  AUTHORS   Michalski JC, Klein A
  TITLE     Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
  JOURNAL   Biochim Biophys Acta 1455:69-84 (1999)
REFERENCE   PMID:18980795
  AUTHORS   Labauge P, Renard D, Castelnovo G, Sabourdy F, de Champfleur N, Levade T
  TITLE     Beta-mannosidosis: a new cause of spinocerebellar ataxia.
  JOURNAL   Clin Neurol Neurosurg 111:109-10 (2009)
///
ENTRY       H00141                      Disease
NAME        Fucosidosis
DESCRIPTION Fucosidosis is an autosomal recessive lysosomal storage disease caused by deficient activity of alpha fucosidase. The enzymatic defect results in the accumulation of a variety of fucose-rich storage products of glycoproteins and glycolipids in many organs. The disease is classified into two types: type 1 for severe phenotypes and type 2 for milder phenotypes.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        FUCA1; alpha-L-fucosidase [HSA:2517] [KO:K01206]
MARKER      Urine oligosaccharides
DRUG        Hematopoietic stem cell transplantation
DBLINKS     ICD-10: E77.1
            MeSH: D005645
            OMIM: 230000
REFERENCE   PMID:15647514
  AUTHORS   Winchester B
  TITLE     Lysosomal metabolism of glycoproteins.
  JOURNAL   Glycobiology 15:1R-15R (2005)
REFERENCE   PMID:10571005
  AUTHORS   Michalski JC, Klein A
  TITLE     Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
  JOURNAL   Biochim Biophys Acta 1455:69-84 (1999)
REFERENCE   PMID:10094192
  AUTHORS   Willems PJ, Seo HC, Coucke P, Tonlorenzi R, O'Brien JS
  TITLE     Spectrum of mutations in fucosidosis.
  JOURNAL   Eur J Hum Genet 7:60-7 (1999)
REFERENCE   PMID:11290499
  AUTHORS   Galluzzi P, Rufa A, Balestri P, Cerase A, Federico A
  TITLE     MR brain imaging of fucosidosis type I.
  JOURNAL   AJNR Am J Neuroradiol 22:777-80 (2001)
REFERENCE   PMID:17767638
  AUTHORS   Abdallah C, Hannallah R, McGill W
  TITLE     Anesthesia for fucosidosis.
  JOURNAL   Paediatr Anaesth 17:994-7 (2007)
///
ENTRY       H00142                      Disease
NAME        Sialidosis;
            Mucolipidosis I
DESCRIPTION Sialidosis is an autosomal recessive lysosomal storage disorder caused by deficient activity of sialidase (neuraminidase). The enzymatic defect results in the accumulation of sialidated glycopeptides and oligosaccharides in many organs. The disease is classified into two types: type 1 for the mild form with late-onset and type 2 for the severe form with infantile onset.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        NEU1; lysosomal sialidase [HSA:4758] [KO:K01186]
MARKER      N-Acetylneuraminic acid (Sialic acid) [CPD:C00270]
DBLINKS     ICD-10: E77.1
            MeSH: D009081
            OMIM: 256550
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:14517945
  AUTHORS   Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV
  TITLE     Molecular pathology of NEU1 gene in sialidosis.
  JOURNAL   Hum Mutat 22:343-52 (2003)
REFERENCE   PMID:8985184
  AUTHORS   Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A
  TITLE     Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.
  JOURNAL   Genes Dev 10:3156-69 (1996)
REFERENCE   PMID:16712870
  AUTHORS   Chen CM, Lai SC, Chen IC, Hsu KC, Lyu RK, Ro LS, Chang HS
  TITLE     First report of two Taiwanese siblings with sialidosis type I: a 10-year follow-up study.
  JOURNAL   J Neurol Sci 247:65-9 (2006)
REFERENCE   PMID:19568825
  AUTHORS   Caciotti A, Di Rocco M, Filocamo M, Grossi S, Traverso F, d'Azzo A, Cavicchi C, Messeri A, Guerrini R, Zammarchi E, Donati MA, Morrone A
  TITLE     Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients.
  JOURNAL   J Neurol 256:1911-5 (2009)
///
ENTRY       H00143                      Disease
NAME        Mucolipidosis II and III, including:
            Mucolipidosis II / I-cell disease;
            Mucolipidosis III A / Pseudo-Hurler polydystrophy;
            Mucolipidosis III C
DESCRIPTION Mucolipidosis type II (ML II) and mucolipidosis type III (ML III) are autosomal recessive lysosomal storage disorders caused by the deficiency of N-acetylglucosamine-1-phosphate transferase which is multimeric enzyme involved in phosphotransfer of UDP-N-acetylglucosamine to lysosomal enzymes (glycoproteins). It is the necessary process for the transport of newly synthesized lysosomal proteins to the lysosomes.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (ML II and ML IIIA) GNPTAB; N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits [HSA:79158] [KO:K08239]
            (ML IIIC) GNPTAG; N-acetylglucosamine-1-phosphate transferase, gamma subunit [HSA:84572] [KO:K10087]
DBLINKS     ICD-10: E77.0
            MeSH: D009081
            OMIM: 252500 252600 252605
REFERENCE   PMID:16465621
  AUTHORS   Kudo M, Brem MS, Canfield WM
  TITLE     Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta -subunits precursor gene.
  JOURNAL   Am J Hum Genet 78:451-63 (2006)
REFERENCE   PMID:16630736
  AUTHORS   Bargal R, Zeigler M, Abu-Libdeh B, Zuri V, Mandel H, Ben Neriah Z, Stewart F, Elcioglu N, Hindi T, Le Merrer M, Bach G, Raas-Rothschild A
  TITLE     When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients.
  JOURNAL   Mol Genet Metab 88:359-63 (2006)
REFERENCE   PMID:19124046
  AUTHORS   Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B
  TITLE     Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins.
  JOURNAL   Biochim Biophys Acta 1793:710-25 (2009)
///
ENTRY       H00144                      Disease
NAME        Mucolipidosis IV
DESCRIPTION Mucolipidosis IV (ML IV) is an autosomal recessive neurodegenerative lysosomal storage disorder characterized by psychomotor retardation and ophthalmologic abnormalities. ML IV is caused by mutations in mucolipin 1 (MCOLN1), a late endosomal/lysosomal ion channel. Cells from patients with MLIV accumulate enlarged vacuolar structures containing phospholipids, sphingolipids, mucopolysaccharides, and gangliosides. Accumulation of lipids results from defects in membrane transport along the late endocytic pathway. It was found that MCOLN1 is required for efficient fusion of both late endosomes and autophagosomes with lysosomes.
CATEGORY    Inherited metabolic disease; Nervous system disease; Lysosomal storage disease
GENE        MCOLN1; mucolipin 1 [HSA:57192] [KO:K04992]
MARKER      Plasma gastrin
DBLINKS     ICD-10: E75.1
            MeSH: D009081
            OMIM: 252650
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:15570434
  AUTHORS   Bach G
  TITLE     Mucolipin 1: endocytosis and cation channel--a review.
  JOURNAL   Pflugers Arch 451:313-7 (2005)
REFERENCE   PMID:11461186
  AUTHORS   Bach G
  TITLE     Mucolipidosis type IV.
  JOURNAL   Mol Genet Metab 73:197-203 (2001)
REFERENCE   PMID:10973263
  AUTHORS   Bargal R, Avidan N, Ben-Asher E, Olender Z, Zeigler M, Frumkin A, Raas-Rothschild A, Glusman G, Lancet D, Bach G
  TITLE     Identification of the gene causing mucolipidosis type IV.
  JOURNAL   Nat Genet 26:118-23 (2000)
///
ENTRY       H00145                      Disease
NAME        Aspartylglucosaminuria (AGU)
DESCRIPTION Aspartylglucosaminuria (AGU) is an autosomal recessive lysosomal storage disorder caused by deficiency of aspartylglucosaminidase, which is a key enzyme in the catabolism of N-linked oligosaccharides of glycoproteins. The enzymatic defect results in inappropriate accumulation of aspartylglucosamines in various organ systems as well as elevated metabolite levels in urine. The main symptoms of aspartylglucosaminuria are progressive mental retardation, coarce faces, behavioral, and hepatosplenomegaly.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        AGA; aspartylglucosaminidase [HSA:175] [KO:K01444]
MARKER      Urine oligosaccharides, Vacuolated lymphocytes
DRUG        Hematopoietic stem cell transplantation
DBLINKS     ICD-10: E77.1
            MeSH: D054880
            OMIM: 208400
REFERENCE   PMID:10571008
  AUTHORS   Aronson NN Jr
  TITLE     Aspartylglycosaminuria: biochemistry and molecular biology.
  JOURNAL   Biochim Biophys Acta 1455:139-54 (1999)
REFERENCE   PMID:16944277
  AUTHORS   Lindblom N, Kivinen S, Heiskala H, Laakso ML, Kaski M
  TITLE     Sleep disturbances in aspartylglucosaminuria (AGU): a questionnaire study.
  JOURNAL   J Inherit Metab Dis 29:637-46 (2006)
REFERENCE   PMID:10571005
  AUTHORS   Michalski JC, Klein A
  TITLE     Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
  JOURNAL   Biochim Biophys Acta 1455:69-84 (1999)
REFERENCE   PMID:8405810
  AUTHORS   Mononen I, Fisher KJ, Kaartinen V, Aronson NN Jr
  TITLE     Aspartylglycosaminuria: protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation.
  JOURNAL   FASEB J 7:1247-56 (1993)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
///
ENTRY       H00146                      Disease
NAME        Alpha-N-acetylgalactosaminidase deficiency, including:
            Schindler disease;
            Kanzaki disease
DESCRIPTION Alpha-N-acetylgalactosaminidase (NAGA) deficiency is an autosomal recessive lysosomal storage disorder caused by deficiency of alpha-N-acetylgalactosaminidase, which removes terminal alpha-GalNAc monosaccharides from glycolipids and glycoproteins (primarily O-linked). The enzymatic defect results in inappropriate accumulation of substrates in various organ systems. NAGA deficiency is divided into three types. Type 1 is Schindler disease, characterized by mental retardation, spasticity ,and myoclonus. Type 2, known as Kanzaki disease, is an adult-onset disorder characterized by angiokeratoma corporis diffusum and mild intellectual impairment. Type 3 is an intermediate disorder with mild-to-moderate neurologic manifestations.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        NAGA; alpha-N-acetylgalactosaminidase [HSA:4668] [KO:K01204]
MARKER      Urine oligosaccharides
DBLINKS     ICD-10: E77.9
            MeSH: C536631
            OMIM: 609241 609242
REFERENCE   PMID:14685826
  AUTHORS   Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T
  TITLE     Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).
  JOURNAL   J Hum Genet 49:1-8 (2004)
REFERENCE   PMID:10571005
  AUTHORS   Michalski JC, Klein A
  TITLE     Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
  JOURNAL   Biochim Biophys Acta 1455:69-84 (1999)
REFERENCE   PMID:19683538
  AUTHORS   Clark NE, Garman SC
  TITLE     The 1.9 a structure of human alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and Kanzaki diseases.
  JOURNAL   J Mol Biol 393:435-47 (2009)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:8782044
  AUTHORS   Keulemans JL, Reuser AJ, Kroos MA, Willemsen R, Hermans MM, van den Ouweland AM, de Jong JG, Wevers RA, Renier WO, Schindler D, Coll MJ, Chabas A, Sakuraba H, Suzuki Y, van Diggelen OP
  TITLE     Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype.
  JOURNAL   J Med Genet 33:458-64 (1996)
///
ENTRY       H00147                      Disease
NAME        Sialuria/ Sialic acid storage disease, including:
            Infantile sialic acid storage disease (ISSD);
            Sialuria, Finnish type / Salla disease (SD);
            Sialuria, French type
DESCRIPTION Salla disease (SD) and infantile sialic acid storage disorder (ISSD) is a rare autosomal recessive lysosomal storage disease caused by mutations in SLC17A5 gene which codes for the protein sialin. Sialin is lysosomal membrane transporter that exports free sialic acid from lysosomes and deficient of sialin results in excessive lysosomal storage of free sialic acid. ISSD has a severe phenotype with infantile onset, while the SD has a milder phenotype with later onset. Both disorders cause developmental delay, and ISSD is generally fatal in early childhood. The differential diagnosis of free sialic acid storage also includes French type sialuria, a disorder due to mutations in the UDP-GlcNAc 2-epimerase (GNE), the key enzyme for the biosynthesis of sialic acid.
CATEGORY    Inherited metabolic disease
GENE        (SD, ISSD) SLC17A5; sodium/sialic acid cotransporter [HSA:26503] [KO:K12301]
            (French type) GNE; UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase [HSA:10020] [KO:K12409]
MARKER      Sialic acid in urine
            N-Acetylneuraminic acid (Sialic acid) [CPD:C00270]
DBLINKS     ICD-10: E88.8
            MeSH: D029461
            OMIM: 269920 604369 269921
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:10863944
  AUTHORS   Mancini GM, Havelaar AC, Verheijen FW
  TITLE     Lysosomal transport disorders.
  JOURNAL   J Inherit Metab Dis 23:278-92 (2000)
REFERENCE   PMID:12885332
  AUTHORS   Strehle EM
  TITLE     Sialic acid storage disease and related disorders.
  JOURNAL   Genet Test 7:113-21 (2003)
REFERENCE   PMID:15172001
  AUTHORS   Kleta R, Morse RP, Orvisky E, Krasnewich D, Alroy J, Ucci AA, Bernardini I, Wenger DA, Gahl WA
  TITLE     Clinical, biochemical, and molecular diagnosis of a free sialic acid storage disease patient of moderate severity.
  JOURNAL   Mol Genet Metab 82:137-43 (2004)
REFERENCE   PMID:17706199 (French type)
  AUTHORS   Bork K, Reutter W, Weidemann W, Horstkorte R
  TITLE     Enhanced sialylation of EPO by overexpression of UDP-GlcNAc 2-epimerase/ManAc kinase containing a sialuria mutation in CHO cells.
  JOURNAL   FEBS Lett 581:4195-8 (2007)
///
ENTRY       H00148                      Disease
NAME        Lysosomal acid lipase deficiency, including:
            Wolman disease;
            Cholesterol ester storage disease (CESD)
DESCRIPTION Lysosomal acid lipase (LAL) deficiency is autosomal recessive lysosomal storage disorders including Wolman disease and Cholesteryl ester storage disease (CESD). This disease is characterized by massive accumulation of cholesteryl ester and triglycerides. Wolman disease is the infantile form presenting in early infancy with diarrhea, massive hepatosplenomegaly, failure to thrive, and calcification of adrenal glands. Without treatment, hepatic failure and death occur within the first year of life. In CESD, hepatomegaly may be the only clinical abnormality, although lipid deposition is widespread. Although hematopoietic cell transplantation (HCT) was the only therapy, in 2015 sebelipase alfa was approved in the US and EU for the treatment of LAL deficiency.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        LIPA [HSA:3988] [KO:K01052]
MARKER      Serum cholesterol
DRUG        Sebelipase alfa [DR:D10377]
DBLINKS     ICD-10: E75.5
            MeSH: D015223
            OMIM: 278000
REFERENCE   PMID:9705237
  AUTHORS   Du H, Sheriff S, Bezerra J, Leonova T, Grabowski GA
  TITLE     Molecular and enzymatic analyses of lysosomal acid lipase in cholesteryl ester storage disease.
  JOURNAL   Mol Genet Metab 64:126-34 (1998)
REFERENCE   PMID:9367797
  AUTHORS   Redonnet-Vernhet I, Chatelut M, Basile JP, Salvayre R, Levade T
  TITLE     Cholesteryl ester storage disease: relationship between molecular defects and in situ activity of lysosomal acid lipase.
  JOURNAL   Biochem Mol Med 62:42-9 (1997)
REFERENCE   PMID:18776925 (treatment)
  AUTHORS   Tolar J, Petryk A, Khan K, Bjoraker KJ, Jessurun J, Dolan M, Kivisto T, Charnas L, Shapiro EG, Orchard PJ
  TITLE     Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease.
  JOURNAL   Bone Marrow Transplant 43:21-7 (2009)
REFERENCE   PMID:11347090 (Japanese)
  AUTHORS   Tanaka A
  TITLE     [Wolman disease and cholesteryl ester storage disease]
  JOURNAL   Nippon Rinsho 59 Suppl 3:337-40 (2001)
REFERENCE   PMID:26352813 (drug)
  AUTHORS   Burton BK, Balwani M, Feillet F, Baric I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sanchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG
  TITLE     A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.
  JOURNAL   N Engl J Med 373:1010-20 (2015)
///
ENTRY       H00149                      Disease
NAME        Neuronal ceroid lipofuscinosis, including:
            Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1);
            Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2);
            Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3);
            Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4);
            LINCL variant (CLN5, CLN6, CLN7, CLN8);
            Batten Disease variant (CLN9);
            Congenital NCL (CLN10)
DESCRIPTION Neuronal ceroid lipofuscinosis (NCL) is a group of severe neurodegenerative lysosomal storage diseases characterized by intracellular accumulation of ceroid lipofuscin in neurons. NCLs share similar symptoms and signs such as retinopathy, epilepsy, and dementia. Previously, the NCLs were classified into different forms on the basis of age of onset as well as clinical and electron microscopic findings. The presently used nomenclature is based on the genetic findings and divides the NCLs into ten forms, CLN1-CLN10.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease; Lysosomal storage disease
GENE        (INCL) PPT1, CLN1; palmitoyl-protein thioesterase 1 [HSA:5538] [KO:K01074]
            (LINCL) TPP1, CLN2; tripeptidyl peptidase I [HSA:1200] [KO:K01279]
            (JNCL) BTS, CLN3; battenin [HSA:1201] [KO:K12389]
            (LINCL) CLN5; ceroid-lipofuscinosis neuronal protein 5 [HSA:1203] [KO:K12390]
            (LINCL) CLN6; ceroid-lipofuscinosis neuronal protein 6 [HSA:54982] [KO:K12359]
            (LINCL) MSFD8, CLN7; MFS transporter [HSA:256471] [KO:K12307]
            (LINCL) CLN8; ceroid-lipofuscinosis neuronal protein 8 [HSA:2055] [KO:K12360]
            (Congenital NCL) CTSD, CLN10; cathepsin D [HSA:1509] [KO:K01379]
MARKER      Sphingolipid activator proteins (SAPs): CLN1, CLN10
            Subunit c of mitochondrial ATP synthase (SCMAS): CLN2, CLN3, CLN4, CLN5, CLN6, CLN7, CLN8, CLN9
DRUG        (INCL) Cysteamine [DR:D03634] (experimental stage)
COMMENT     Genetic variants with mild mutations can have a significantly later onset than their classical forms.
            CLN4 is a term reserved for an adult form of NCL (Kufs disease) that is still defined by clinical and neuropathological findings alone. A juvenile NCL clinically not distinguishable from CLN3 was termed CLN9 but has resisted genetic clarification until now.
DBLINKS     ICD-10: E75.4
            MeSH: D009472
            OMIM: 256730 204500 204200 204300 256731 601780 610951 600143 610003 609055 610127
REFERENCE   PMID:15965709
  AUTHORS   Mole SE, Williams RE, Goebel HH
  TITLE     Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.
  JOURNAL   Neurogenetics 6:107-26 (2005)
REFERENCE   PMID:14997938
  AUTHORS   Goebel HH, Wisniewski KE
  TITLE     Current state of clinical and morphological features in human NCL.
  JOURNAL   Brain Pathol 14:61-9 (2004)
REFERENCE   PMID:11548735
  AUTHORS   Wisniewski KE, Zhong N, Philippart M
  TITLE     Pheno/genotypic correlations of neuronal ceroid lipofuscinoses.
  JOURNAL   Neurology 57:576-81 (2001)
REFERENCE   PMID:19195801
  AUTHORS   Kohlschutter A, Schulz A
  TITLE     Towards understanding the neuronal ceroid lipofuscinoses.
  JOURNAL   Brain Dev 31:499-502 (2009)
REFERENCE   PMID:18668166 (treatment/ drug)
  AUTHORS   Pierret C, Morrison JA, Kirk MD
  TITLE     Treatment of lysosomal storage disorders: focus on the neuronal ceroid-lipofuscinoses.
  JOURNAL   Acta Neurobiol Exp (Wars) 68:429-42 (2008)
///
ENTRY       H00150                      Disease
NAME        Danon disease;
            X-linked vacuolar cardiomyopathy and myopathy
DESCRIPTION Danon disease is an X-linked disorder caused by deficiency of lysosomal-associated membrane protein Lamp2 and resulting in cardiomyopathy, myopathy, and mental retardation. Originally Danon disease was classificatied as a variant of glycogen storage disease II (Pompe disease). However, at present, it is considered that Danon disease is not a glycogen storage disease because the disease is caused by the primary deficiency of a lysosomal membrane protein instead of a glycolytic enzyme and detailed pathological features are different from those of Pompe disease.
CATEGORY    Inherited metabolic disease; Nervous system disease; Lysosomal storage disease
GENE        LAMP2; lysosomal-associated membrane protein 2 [HSA:3920] [KO:K06528]
DBLINKS     ICD-10: E74.0
            MeSH: D052120
            OMIM: 300257
REFERENCE   PMID:17027858
  AUTHORS   Nishino I
  TITLE     Autophagic vacuolar myopathy.
  JOURNAL   Semin Pediatr Neurol 13:90-5 (2006)
REFERENCE   PMID:18377432
  AUTHORS   Yang Z, Vatta M
  TITLE     Danon disease as a cause of autophagic vacuolar myopathy.
  JOURNAL   Congenit Heart Dis 2:404-9 (2007)
REFERENCE   PMID:15673802
  AUTHORS   Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG
  TITLE     Glycogen storage diseases presenting as hypertrophic cardiomyopathy.
  JOURNAL   N Engl J Med 352:362-72 (2005)
///
ENTRY       H00151                      Disease
NAME        Cerebrotendinous xanthomatosis;
            Van Bogaert-Scherer-Epstein Disease
DESCRIPTION Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid-storage disorder caused by deficient activity of CYP27A1 and characterized by formation of xanthomatous lesions in many tissues, particularly the brain, the lens of the eye, and tendons.
CATEGORY    Inherited metabolic disease; Connective tissue disease
GENE        CYP27A1 [HSA:1593] [KO:K00488]
DRUG        Chenix [DR:D00163]
            Cholic acid [CPD:C00695]
DBLINKS     ICD-10: E75.5
            MeSH: D019294
            OMIM: 213700
REFERENCE   PMID:16816916
  AUTHORS   Gallus GN, Dotti MT, Federico A
  TITLE     Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene.
  JOURNAL   Neurol Sci 27:143-9 (2006)
REFERENCE   PMID:15061585
  AUTHORS   Moghadasian MH
  TITLE     Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds.
  JOURNAL   Clin Invest Med 27:42-50 (2004)
///
ENTRY       H00152                      Disease
NAME        Sitosterolemia
DESCRIPTION Sitosterolemia is an autosomal recessive lipid disorder caused by mutation in the ABC transporter gene and characterized by elevated plasma levels of plant sterols due to increased intestinal absorption and reduced biliary secretion of neutral sterols.
CATEGORY    Inherited metabolic disease; Cardiovascular disease
GENE        ABCG5 [HSA:64240] [KO:K05683]
            ABCG8 [HSA:64241] [KO:K05684]
DRUG        Colestyramine [DR:D02690]
DBLINKS     ICD-10: E78.5
            MeSH: C537345
            OMIM: 210250
REFERENCE   PMID:15599566
  AUTHORS   Sudhop T, von Bergmann K
  TITLE     Sitosterolemia--a rare disease. Are elevated plant sterols an additional risk factor?
  JOURNAL   Z Kardiol 93:921-8 (2004)
REFERENCE   PMID:11264985
  AUTHORS   Lee MH, Lu K, Patel SB
  TITLE     Genetic basis of sitosterolemia.
  JOURNAL   Curr Opin Lipidol 12:141-9 (2001)
///
ENTRY       H00153                      Disease
NAME        Familial combined hyperlipidemia (FCHL)
DESCRIPTION Familial combined hyperlipidemia is linked and associated with the gene encoding upstream transcription factor 1 (USF1) and characterized by elevated levels of serum total cholesterol, triglycerides, or both.
CATEGORY    Inherited metabolic disease
GENE        USF1 [HSA:7391] [KO:K09106]
DRUG        Bezafibrate [DR:D01366]
            Pravachol [DR:D00893]
            Colestyramine [DR:D02690]
            Probucol [DR:D00476]
            Ezetimibe [DR:D01966]
DBLINKS     ICD-10: E78.4
            MeSH: D006950
            OMIM: 144250 602491
REFERENCE   PMID:16680034
  AUTHORS   Naukkarinen J, Ehnholm C, Peltonen L
  TITLE     Genetics of familial combined hyperlipidemia.
  JOURNAL   Curr Opin Lipidol 17:285-90 (2006)
REFERENCE   PMID:16531745
  AUTHORS   Lee JC, Lusis AJ, Pajukanta P
  TITLE     Familial combined hyperlipidemia: upstream transcription factor 1 and beyond.
  JOURNAL   Curr Opin Lipidol 17:101-9 (2006)
REFERENCE   PMID:14991056
  AUTHORS   Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, Laakso M, Ehnholm C, Taskinen MR, Peltonen L
  TITLE     Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1).
  JOURNAL   Nat Genet 36:371-6 (2004)
///
ENTRY       H00154                      Disease
NAME        Hyperlipoproteinemia, type I
DESCRIPTION Type I hyperlipoproteinemia is an autosomal recessive disorder caused by deficiency of lipoprotein lipase or its activator apolipoprotein C-II. The defects result in a massive increase in chylomicron and triglyceride levels in plasma.
CATEGORY    Inherited metabolic disease; Cardiovascular disease
GENE        LPL; lipoprotein lipase [HSA:4023] [KO:K01059]
            APOC2; apolipoprotein C-II [HSA:344]
            GPIHBP1 [HSA:338328] [KO:K20001]
DRUG        Bezafibrate [DR:D01366]
            Fenofibrate [DR:D00565]
DBLINKS     ICD-10: E78.3
            MeSH: D008072
            OMIM: 238600 207750 615947
REFERENCE   PMID:15719847
  AUTHORS   Nierman MC, Rip J, Twisk J, Meulenberg JJ, Kastelein JJ, Stroes ES, Kuivenhoven JA
  TITLE     Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.
  JOURNAL   Neth J Med 63:14-9 (2005)
REFERENCE   PMID:8843465
  AUTHORS   Murthy V, Julien P, Gagne C
  TITLE     Molecular pathobiology of the human lipoprotein lipase gene.
  JOURNAL   Pharmacol Ther 70:101-35 (1996)
REFERENCE   PMID:3630977
  AUTHORS   Berger GM
  TITLE     An incomplete form of familial lipoprotein lipase deficiency presenting with type I hyperlipoproteinemia.
  JOURNAL   Am J Clin Pathol 88:369-73 (1987)
REFERENCE   PMID:2010533
  AUTHORS   Ameis D, Kobayashi J, Davis RC, Ben-Zeev O, Malloy MJ, Kane JP, Lee G, Wong H, Havel RJ, Schotz MC
  TITLE     Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene.
  JOURNAL   J Clin Invest 87:1165-70 (1991)
///
ENTRY       H00155                      Disease
NAME        Familial hypercholesterolaemia
DESCRIPTION Familial hypercholesterolaemia is an autosomal dominant disorder caused by deficiency of low density lipoprotein receptor. Other forms of this disorder include hypercholesterolemia caused by mutation of APOB or PCSK9 gene. This disorder is characterized by severely elevated plasma LDL cholesterol, tuberous and tendon xanthomata, and premature atherosclerosis. Patients have a significantly elevated risk of early coronary heart disease.
CATEGORY    Inherited metabolic disease; Cardiovascular disease
GENE        LDLR [HSA:3949] [KO:K12473]
            APOB [HSA:338] [KO:K14462]
            PCSK9 [HSA:255738] [KO:K13050]
MARKER      plasma LDL cholesterol
DRUG        Atorvastatin [DR:D00887 D02258]
            Colestimide [DR:D01934]
            Ezetimibe [DR:D01966]
            Pravachol [DR:D00893]
            Simvastatin [DR:D00434]
            Mipomersen [DR:D08946]
            Lomitapide [DR:D09638]
            Alirocumab [DR:D10335]
DBLINKS     ICD-10: E78.0
            MeSH: D006937
            OMIM: 143890 144010 603776
REFERENCE   PMID:18607183
  AUTHORS   Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D
  TITLE     What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia?
  JOURNAL   Curr Opin Lipidol 19:362-8 (2008)
REFERENCE   PMID:15657617
  AUTHORS   Newson AJ, Humphries SE
  TITLE     Cascade testing in familial hypercholesterolaemia: how should family members be contacted?
  JOURNAL   Eur J Hum Genet 13:401-8 (2005)
REFERENCE   PMID:15990592
  AUTHORS   Hadfield SG, Humphries SE
  TITLE     Implementation of cascade testing for the detection of familial hypercholesterolaemia.
  JOURNAL   Curr Opin Lipidol 16:428-33 (2005)
REFERENCE   PMID:24589695 (Drug)
  AUTHORS   Rader DJ, Kastelein JJ
  TITLE     Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
  JOURNAL   Circulation 129:1022-32 (2014)
REFERENCE   PMID:24373748 (Drug)
  AUTHORS   Farnier M
  TITLE     PCSK9: From discovery to therapeutic applications.
  JOURNAL   Arch Cardiovasc Dis 107:58-66 (2014)
///
ENTRY       H00156                      Disease
NAME        Hyperlipoproteinemia, type III;
            Dysbetalipoproteinemia
DESCRIPTION Hyperlipoproteinemia type III is an autosomal recessively disorder characterized by the accumulation of intermediate-density lipoprotein due to mutation of apolipoprotein E.
CATEGORY    Inherited metabolic disease; Cardiovascular disease
GENE        APOE; apolipoprotein E [HSA:348] [KO:K04524]
MARKER      IDL cholesterol
DRUG        Bezafibrate [DR:D01366]
            Fenofibrate [DR:D00565]
            Pravator [DR:D08410]
DBLINKS     ICD-10: E78.2
            MeSH: D006952
REFERENCE   PMID:17593519
  AUTHORS   Karube M, Nakabayashi K, Fujioka Y, Yoshihara K, Yamada A, Matsunaga A, Saito T
  TITLE     Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.
  JOURNAL   Clin Exp Nephrol 11:174-9 (2007)
REFERENCE   PMID:15630634
  AUTHORS   Smelt AH, de Beer F
  TITLE     Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
  JOURNAL   Semin Vasc Med 4:249-57 (2004)
///
ENTRY       H00157                      Disease
NAME        Hyperlipoproteinemia, type V
DESCRIPTION Type V hyperlipoproteinemia is an autosomal recessive disorder caused by deficiency of apolipoprotein A-V and characterized by an increase of chylomicrons and VLDL and a decrease of LDL and HDL in the plasma after a fast.
CATEGORY    Inherited metabolic disease
GENE        APOA5; apolipoprotein A-V [HSA:116519] [KO:K09025]
MARKER      chylomicron
            VLDL
DRUG        Bezafibrate [DR:D01366]
            Fenofibrate [DR:D00565]
DBLINKS     ICD-10: E78.3
            MeSH: D006954
            OMIM: 144650
REFERENCE   PMID:16531747
  AUTHORS   Calandra S, Priore Oliva C, Tarugi P, Bertolini S
  TITLE     APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency.
  JOURNAL   Curr Opin Lipidol 17:122-7 (2006)
REFERENCE   PMID:16306435
  AUTHORS   Rensen PC, van Dijk KW, Havekes LM
  TITLE     Apolipoprotein AV: low concentration, high impact.
  JOURNAL   Arterioscler Thromb Vasc Biol 25:2445-7 (2005)
///
ENTRY       H00158                      Disease
NAME        Lecithin:cholesterol acyltransferase deficiency;
            Norum disease;
            Fish-eye disease
DESCRIPTION Lecithin:cholesterol acyltransferase (LCAT) deficiency is an autosomal recessive disorder of HDL metabolism characterized by low HDL-cholesterol level in blood and accumulation of free cholesterol in tissue leading to a triad of corneal dystrophy, hemolytic anemia, and proteinuria.
CATEGORY    Inherited metabolic disease
GENE        LCAT; lecithin-cholesterol acyltransferase [HSA:3931] [KO:K00650]
DBLINKS     ICD-10: E78.6
            MeSH: D007863
            OMIM: 245900 136120
REFERENCE   PMID:16709953
  AUTHORS   Berglund L
  TITLE     Lipoprotein metabolism: a well-tried tool to characterize dyslipidemic mechanisms.
  JOURNAL   Arterioscler Thromb Vasc Biol 26:1201-3 (2006)
REFERENCE   PMID:16543491
  AUTHORS   Nishiwaki M, Ikewaki K, Bader G, Nazih H, Hannuksela M, Remaley AT, Shamburek RD, Brewer HB Jr
  TITLE     Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X.
  JOURNAL   Arterioscler Thromb Vasc Biol 26:1370-5 (2006)
REFERENCE   PMID:9162740
  AUTHORS   Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J
  TITLE     The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.
  JOURNAL   J Lipid Res 38:191-205 (1997)
///
ENTRY       H00159                      Disease
NAME        Tangier disease
DESCRIPTION Tangier disease is an autosomal recessive disorder caused by mutation of ABCA1 gene leading to the accumulation of cholesterol in tissue macrophages and prevalent atherosclerosis.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        ABCA1 [HSA:19] [KO:K05641]
DBLINKS     ICD-10: E78.6
            MeSH: D013631
            OMIM: 205400
REFERENCE   PMID:16235041
  AUTHORS   Nofer JR, Remaley AT
  TITLE     Tangier disease: still more questions than answers.
  JOURNAL   Cell Mol Life Sci 62:2150-60 (2005)
REFERENCE   PMID:11927274
  AUTHORS   Oram JF
  TITLE     Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1.
  JOURNAL   Trends Mol Med 8:168-73 (2002)
REFERENCE   PMID:11111099
  AUTHORS   Oram JF
  TITLE     Tangier disease and ABCA1.
  JOURNAL   Biochim Biophys Acta 1529:321-30 (2000)
///
ENTRY       H00160                      Disease
NAME        Abetalipoproteinemia;
            Bassen-Kornzweig Disease
DESCRIPTION Abetalipoproteinemia is an autosomal recessive disorder of lipid metabolism caused by mutation of MTTP gene involved in the transport of lipids and required in the secretion of beta-lipoproteins.
CATEGORY    Inherited metabolic disease
GENE        MTTP; microsomal triglyceride transfer protein [HSA:4547] [KO:K14463]
DBLINKS     ICD-10: E78.6
            MeSH: D000012
            OMIM: 200100
REFERENCE   PMID:18611256
  AUTHORS   Zamel R, Khan R, Pollex RL, Hegele RA
  TITLE     Abetalipoproteinemia: two case reports and literature review.
  JOURNAL   Orphanet J Rare Dis 3:19 (2008)
REFERENCE   PMID:10940349
  AUTHORS   Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR
  TITLE     The role of the microsomal triglygeride transfer protein in abetalipoproteinemia.
  JOURNAL   Annu Rev Nutr 20:663-97 (2000)
///
ENTRY       H00161                      Disease
NAME        Smith-Lemli-Opitz syndrome
DESCRIPTION Smith-Lemli-Opitz syndrome is an autosomal recessive disorder caused by deficiency of 7-dehydrocholesterol reductase in cholesterol biosynthesis.
CATEGORY    Inherited metabolic disease
GENE        DHCR7; 7-dehydrocholesterol reductase [HSA:1717] [KO:K00213]
MARKER      Dehydrocholesterol [CPD:C01164]
DRUG        dietary cholesterol
DBLINKS     ICD-10: Q87.1
            MeSH: D019082
            OMIM: 270400
REFERENCE   PMID:18285838
  AUTHORS   Porter FD
  TITLE     Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management.
  JOURNAL   Eur J Hum Genet 16:535-41 (2008)
REFERENCE   PMID:16207203
  AUTHORS   Yu H, Patel SB
  TITLE     Recent insights into the Smith-Lemli-Opitz syndrome.
  JOURNAL   Clin Genet 68:383-91 (2005)
REFERENCE   PMID:15670717
  AUTHORS   Correa-Cerro LS, Porter FD
  TITLE     3beta-hydroxysterol Delta7-reductase and the Smith-Lemli-Opitz syndrome.
  JOURNAL   Mol Genet Metab 84:112-26 (2005)
///
ENTRY       H00162                      Disease
NAME        Sjogren-Larsson syndrome
DESCRIPTION Sjogren-Larsson syndrome is an autosomal recessive neurocutaneous disorder caused by deficiency of microsomal fatty aldehyde dehydrogenase in fatty alcohol metabolism and characterized by congenital ichthyosis.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease
GENE        ALDH3A2; aldehyde dehydrogenase [HSA:224] [KO:K00128]
DBLINKS     ICD-10: E71.3
            MeSH: D016111
            OMIM: 270200
REFERENCE   PMID:17254005
  AUTHORS   Gordon N
  TITLE     Sjogren-Larsson syndrome.
  JOURNAL   Dev Med Child Neurol 49:152-4 (2007)
REFERENCE   PMID:16996289
  AUTHORS   Rizzo WB
  TITLE     Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency.
  JOURNAL   Mol Genet Metab 90:1-9 (2007)
REFERENCE   PMID:15931689
  AUTHORS   Rizzo WB, Carney G
  TITLE     Sjogren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2).
  JOURNAL   Hum Mutat 26:1-10 (2005)
///
ENTRY       H00163                      Disease
NAME        Alkaptonuria
DESCRIPTION Alkaptonuria is a rare, inherited defect of homogentisic acid 1,2-dioxygenase that leads to the widespread deposition of polymeric homogentisic acid, and clinical symptoms from degeneration of joints and the aortic valve.
CATEGORY    Inherited metabolic disease
GENE        HGD; homogentisate 1,2-dioxygenase [HSA:3081] [KO:K00451]
MARKER      Homogentisate [CPD:C00544]
DRUG        Ascorbic acid [DG:DG00126]
DBLINKS     ICD-10: E70.2
            MeSH: D000474
            OMIM: 203500
REFERENCE   PMID:18336562
  AUTHORS   Helliwell TR, Gallagher JA, Ranganath L
  TITLE     Alkaptonuria--a review of surgical and autopsy pathology.
  JOURNAL   Histopathology 53:503-12 (2008)
REFERENCE   PMID:9529368
  AUTHORS   La Du BN Jr
  TITLE     Are we ready to try to cure alkaptonuria?
  JOURNAL   Am J Hum Genet 62:765-7 (1998)
REFERENCE   PMID:8782815
  AUTHORS   Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, Renedo M, Fernandez-Ruiz E, Penalva MA, Rodriguez de Cordoba S
  TITLE     The molecular basis of alkaptonuria.
  JOURNAL   Nat Genet 14:19-24 (1996)
REFERENCE   PMID:23430917 (treatment)
  AUTHORS   Cox TM
  TITLE     Alkaptonuria: leading to the treasure in exceptions.
  JOURNAL   JIMD Rep 5:49-57 (2012)
///
ENTRY       H00164                      Disease
NAME        Carbamoyl phosphate synthetase I deficiency
DESCRIPTION Carbamoylphosphate synthetase I deficiency is a urea-cycle disorder characterized by hyperammonemia.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        CPS1; carbamoyl-phosphate synthase [HSA:1373] [KO:K01948]
DRUG        Sodium phenylacetate [DR:D05867]
            Sodium benzoate [DR:D02277]
DBLINKS     ICD-10: E72.2
            MeSH: D020165
            OMIM: 237300
REFERENCE   PMID:17310273
  AUTHORS   Kurokawa K, Yorifuji T, Kawai M, Momoi T, Nagasaka H, Takayanagi M, Kobayashi K, Yoshino M, Kosho T, Adachi M, Otsuka H, Yamamoto S, Murata T, Suenaga A, Ishii T, Terada K, Shimura N, Kiwaki K, Shintaku H, Yamakawa M, Nakabayashi H, Wakutani Y, Nakahata T
  TITLE     Molecular and clinical analyses of Japanese patients with carbamoylphosphate synthetase 1 (CPS1) deficiency.
  JOURNAL   J Hum Genet 52:349-54 (2007)
REFERENCE   PMID:9711878
  AUTHORS   Finckh U, Kohlschutter A, Schafer H, Sperhake K, Colombo JP, Gal A
  TITLE     Prenatal diagnosis of carbamoyl phosphate synthetase I deficiency by identification of a missense mutation in CPS1.
  JOURNAL   Hum Mutat 12:206-11 (1998)
///
ENTRY       H00165                      Disease
NAME        Tyrosinemia;
            Tyrosinemia, type I;
            Tyrosinemia, type II;
            Tyrosinemia, type III;
            Hawkinsinuria
DESCRIPTION The tyrosinemias are characterized by the accumulation of tyrosine in body fluids and tissues. Type I is the most severe form of tyrosinemia, is caused by a deficiency of fumarylacetoacetate hydrolase (FAH). This disorder is associated with liver failure, painful neurologic crises, rickets, and hepatocarcinoma. Type II is caused by a deficiency of tyrosine aminotransferase (TAT), and clinically presents with hyperkeratotic plaques on the hands and soles of the feet and photophobia due to deposition of tyrosine crystals within the cornea. Type III is a rare disorder caused by a deficiency of 4-hydroxyphenylpyruvate dioxygenase, that is associated with ataxia and mild mental retardation.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        (Type I) FAH; fumarylacetoacetate hydrolase [HSA:2184] [KO:K01555]
            (Type II) TAT; tyrosine aminotransferase [HSA:6898] [KO:K00815]
            (Type III) HPD; 4-hydroxyphenylpyruvate dioxygenase [HSA:3242] [KO:K00457]
MARKER      (Type I) Increased fumarylacetoacetic acid [CPD:C01061] and succinylacetone
            (Type II) Increased tyrosine [CPD:C00082]
            (Type III) Increased 4-hydroxyphenylpyruvate [CPD:C01179]
DRUG        (Type I) Nitisinone [DR:D05177]
DBLINKS     ICD-10: E70.2
            MeSH: D020176
            OMIM: 276700 276600 276710 140350
REFERENCE   PMID:16602095
  AUTHORS   Scott CR
  TITLE     The genetic tyrosinemias.
  JOURNAL   Am J Med Genet C Semin Med Genet 142C:121-6 (2006)
REFERENCE   PMID:15531838
  AUTHORS   Karnik D, Thomas N, Eapen CE, Jana AK, Oommen A
  TITLE     Tyrosinemia type I: a clinico-laboratory case report.
  JOURNAL   Indian J Pediatr 71:929-32 (2004)
REFERENCE   PMID:18422479 (drug)
  AUTHORS   Santra S, Baumann U
  TITLE     Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
  JOURNAL   Expert Opin Pharmacother 9:1229-36 (2008)
///
ENTRY       H00166                      Disease
NAME        Hermansky-Pudlak syndrome (HPS)
DESCRIPTION Hermansky-Pudlak syndrome (HPS) is a group of autosomal recessive disorders caused by defects in lysosome-related organelles and characterized by albinism and prolonged bleeding.
CATEGORY    Inherited metabolic disease; Hematologic disease; Eye disease
GENE        (HPS1) HPS1 [HSA:3257] [KO:K20193]
            (HPS2) AP3B1 [HSA:8546] [KO:K12397]
            (HPS3) HPS3 [HSA:84343] [KO:K20190]
            (HPS4) HPS4 [HSA:89781] [KO:K20194]
            (HPS5) HPS5 [HSA:11234] [KO:K20191]
            (HPS6) HPS6 [HSA:79803] [KO:K20192]
            (HPS7) DTNBP1 [HSA:84062] [KO:K20189]
            (HPS8) BLOC1S3 [HSA:388552] [KO:K20186]
DBLINKS     ICD-10: E70.3
            MeSH: D022861
            OMIM: 203300 608233
REFERENCE   PMID:16420244
  AUTHORS   Wei ML
  TITLE     Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function.
  JOURNAL   Pigment Cell Res 19:19-42 (2006)
REFERENCE   PMID:15941404
  AUTHORS   Di Pietro SM, Dell'Angelica EC
  TITLE     The cell biology of Hermansky-Pudlak syndrome: recent advances.
  JOURNAL   Traffic 6:525-33 (2005)
REFERENCE   PMID:12243726
  AUTHORS   Starcevic M, Nazarian R, Dell'Angelica EC
  TITLE     The molecular machinery for the biogenesis of lysosome-related organelles: lessons from Hermansky-Pudlak syndrome.
  JOURNAL   Semin Cell Dev Biol 13:271-8 (2002)
///
ENTRY       H00167                      Disease
NAME        Phenylketonuria (PKU);
            Hyperphenylalaninemia, BH4-deficient
DESCRIPTION Phenylketonuria is one of the most common inborn errors of metabolism marked by a deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH), leading to a toxic accumulation of phenylalanine in the blood and multiple tissues and potentially to intellectual disability, delayed speech, seizures, and behavior abnormalities. Deficiency of tetrahydrobiopterin (BH4), the cofactor of PAH, is caused by defects of the enzymes in pterin biosynthesis. Because BH4 is also a cofactor of tyrosine hydroxylase and tryptophan hydroxylase in neurotransmitter synthesis, BH4-deficient hyperphenylalaninemia is characterized by neurotransmitter deficiencies.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        PAH; phenylalanine hydroxylase [HSA:5053] [KO:K00500]
            (BH4-deficient, A) QDPR; quinoid dihydropteridine reductase [HSA:5860] [KO:K00357]
            (BH4-deficient, B) GCH1; GTP cyclohydrolase 1 [HSA:2643] [KO:K01495]
            (BH4-deficient, C) PTS; 6-pyruvoyltetrahydropterin synthase [HSA:5805] [KO:K01737]
            (BH4-deficient, D) PCBD1; pterin-4 alpha-carbinolamine dehydratase [HSA:5092] [KO:K01724]
MARKER      Phenylalanine [CPD:C00079]
DRUG        Low phenylalanine diet
            (BH4-deficient) Sapropterin [DG:DG00147]
DBLINKS     ICD-10: E70.0
            MeSH: D010661
            OMIM: 261600 261630 233910 261640 264070
REFERENCE   PMID:23430527
  AUTHORS   Lindegren ML, Krishnaswami S, Reimschisel T, Fonnesbeck C, Sathe NA, McPheeters ML
  TITLE     A Systematic Review of BH4 (Sapropterin) for the Adjuvant Treatment of Phenylketonuria.
  JOURNAL   JIMD Rep 8:109-19 (2013)
///
ENTRY       H00168                      Disease
NAME        Oculocutaneous albinism (OCA)
DESCRIPTION Oculocutaneous albinism is a genetically heterogeneous congenital disorder of melanin biosynthesis characterized by decreased or absent pigmentation in the hair, skin, and eyes.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease; Eye disease
GENE        (OCA1) TYR [HSA:7299] [KO:K00505]
            (OCA2) OCA2 [HSA:4948]
                        MC1R [HSA:4157] [KO:K04199]
            (OCA3) TYRP1 [HSA:7306] [KO:K00506]
            (OCA4) SLC45A2 [HSA:51151] [KO:K15378]
            (OCA6) SLC24A5 [HSA:283652] [KO:K13753]
            (OCA7) C10orf11 [HSA:83938]
COMMENT     See also ocular albinism [DS:H00169], which is restricted phenotypically to ocular involvement only.
DBLINKS     ICD-10: E70.3
            MeSH: D016115
            OMIM: 203100 606952 203200 203290 606574 113750 615179
REFERENCE   PMID:17980020
  AUTHORS   Gronskov K, Ek J, Brondum-Nielsen K
  TITLE     Oculocutaneous albinism.
  JOURNAL   Orphanet J Rare Dis 2:43 (2007)
REFERENCE   PMID:10094567
  AUTHORS   Oetting WS, King RA
  TITLE     Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism.
  JOURNAL   Hum Mutat 13:99-115 (1999)
REFERENCE   PMID:23395477 (gene)
  AUTHORS   Gronskov K, Dooley CM, Ostergaard E, Kelsh RN, Hansen L, Levesque MP, Vilhelmsen K, Mollgard K, Stemple DL, Rosenberg T
  TITLE     Mutations in c10orf11, a melanocyte-differentiation gene, cause autosomal-recessive albinism.
  JOURNAL   Am J Hum Genet 92:415-21 (2013)
REFERENCE   PMID:18680187 (gene)
  AUTHORS   Chiang PW, Fulton AB, Spector E, Hisama FM
  TITLE     Synergistic interaction of the OCA2 and OCA3 genes in a family.
  JOURNAL   Am J Med Genet A 146A:2427-30 (2008)
///
ENTRY       H00169                      Disease
NAME        Ocular albinism;
            Ocular albinism, type I (OA1);
            Waardenburg syndrome, type II (WS2-OA)
DESCRIPTION Ocular albinism type I is an X-linked disorder characterized by reduced visual acuity, photophobia, nystagmus, translucent irides, strabismus, hypermetropic refractive errors. Waardenburg syndrome type II is an autosomal recessive ocular albinism.
CATEGORY    Inherited metabolic disease; Eye disease
GENE        (OA1) GPR143 [HSA:4935] [KO:K08470]
            (WS2-OA) MITF [HSA:4286] [KO:K09455]
DBLINKS     ICD-10: E70.3
            MeSH: D016117
            OMIM: 300500 103470
REFERENCE   PMID:15254223
  AUTHORS   Vetrini F, Auricchio A, Du J, Angeletti B, Fisher DE, Ballabio A, Marigo V
  TITLE     The microphthalmia transcription factor (Mitf) controls expression of the ocular  albinism type 1 gene: link between melanin synthesis and melanosome biogenesis.
  JOURNAL   Mol Cell Biol 24:6550-9 (2004)
///
ENTRY       H00170                      Disease
NAME        Piebaldism
DESCRIPTION Piebaldism is caused by mutation of kit proto-oncogene, or snail 2 transcription factor, implicated in the differentiation and migration of melanoblasts. The disease is characterized by the congenital absence of melanocytes in affected areas of the skin and hair.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease
GENE        KIT [HSA:3815] [KO:K05091]
            SNAI2 [HSA:6591] [KO:K05706]
DBLINKS     ICD-10: E70.3
            MeSH: D016116
            OMIM: 172800
REFERENCE   PMID:15485525
  AUTHORS   Thomas I, Kihiczak GG, Fox MD, Janniger CK, Schwartz RA
  TITLE     Piebaldism: an update.
  JOURNAL   Int J Dermatol 43:716-9 (2004)
///
ENTRY       H00171                      Disease
NAME        Histidinemia
DESCRIPTION Histidinemia is an autosomal recessive disorder resulting from histidase deficiency.
CATEGORY    Inherited metabolic disease
GENE        HAL; histidine ammonia-lyase [HSA:3034] [KO:K01745]
DBLINKS     ICD-10: E70.8
            MeSH: C538320
            OMIM: 235800
REFERENCE   PMID:15806399
  AUTHORS   Kawai Y, Moriyama A, Asai K, Coleman-Campbell CM, Sumi S, Morishita H, Suchi M
  TITLE     Molecular characterization of histidinemia: identification of four missense mutations in the histidase gene.
  JOURNAL   Hum Genet 116:340-6 (2005)
REFERENCE   PMID:8463510
  AUTHORS   Virmani K, Widhalm K
  TITLE     Histidinemia: a biochemical variant or a disease?
  JOURNAL   J Am Coll Nutr 12:115-24 (1993)
REFERENCE   PMID:1943682
  AUTHORS   Taylor RG, Levy HL, McInnes RR
  TITLE     Histidase and histidinemia. Clinical and molecular considerations.
  JOURNAL   Mol Biol Med 8:101-16 (1991)
///
ENTRY       H00172                      Disease
NAME        Maple syrup urine disease (MSUD)
DESCRIPTION Maple syrup urine disease (MSUD) is an autosomal recessive inherited disorder caused by a defect in the oxidative decarboxylation of branched-chain amino acids (BCAA) leading to mental and physical retardation, feeding problems, and a maple syrup odor to the urine. Currently, there are effective therapies that are in use for MSUD; the dietary therapy and thiamin supplementation. The dietary therapy, which involves feeding patients with a synthetic diet containing reduced BCAA contents.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        BCKDHA; branched chain keto acid dehydrogenase E1, alpha subunit [HSA:593] [KO:K00166]
            BCKDHB; branched chain keto acid dehydrogenase E1, beta subunit [HSA:594] [KO:K00167]
            DBT; dihydrolipoamide branched chain transacylase E2 [HSA:1629] [KO:K09699]
            DLD; dihydrolipoamide dehydrogenase [HSA:1738] [KO:K00382]
MARKER      Leucine [CPD:C00123]
DRUG        Thiamine [DG:DG00125]
DBLINKS     ICD-10: E71.0
            MeSH: D008375
            OMIM: 248600
REFERENCE   PMID:16365091 (therapy)
  AUTHORS   Chuang DT, Chuang JL, Wynn RM
  TITLE     Lessons from genetic disorders of branched-chain amino acid metabolism.
  JOURNAL   J Nutr 136:243S-9S (2006)
REFERENCE   PMID:9546032
  AUTHORS   Chuang DT
  TITLE     Maple syrup urine disease: it has come a long way.
  JOURNAL   J Pediatr 132:S17-23 (1998)
REFERENCE   PMID:9266218
  AUTHORS   Schadewaldt P, Wendel U
  TITLE     Metabolism of branched-chain amino acids in maple syrup urine disease.
  JOURNAL   Eur J Pediatr 156 Suppl 1:S62-6 (1997)
///
ENTRY       H00173                      Disease
NAME        Isovaleric acidemia (IVA)
DESCRIPTION Isovaleric acidemia is an autosomal recessive inborn error of leucine metabolism caused by a deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase resulting in the accumulation of derivatives of isovaleryl-CoA.
CATEGORY    Inherited metabolic disease
GENE        IVD; isovaleryl-CoA dehydrogenase [HSA:3712] [KO:K00253]
MARKER      Isovalerylcarnitine [CPD:C20826]
            acylcarnitine profile
DRUG        Levocarnitine [DG:DG00143]
DBLINKS     ICD-10: E71.1
            MeSH: C538167
            OMIM: 243500
REFERENCE   PMID:16602101
  AUTHORS   Vockley J, Ensenauer R
  TITLE     Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity.
  JOURNAL   Am J Med Genet C Semin Med Genet 142C:95-103 (2006)
REFERENCE   PMID:15486829
  AUTHORS   Ensenauer R, Vockley J, Willard JM, Huey JC, Sass JO, Edland SD, Burton BK, Berry SA, Santer R, Grunert S, Koch HG, Marquardt I, Rinaldo P, Hahn S, Matern D
  TITLE     A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening.
  JOURNAL   Am J Hum Genet 75:1136-42 (2004)
///
ENTRY       H00174                      Disease
NAME        Methylmalonic aciduria (MMA);
            Methylmalonic acidemia
DESCRIPTION Methylmalonic aciduria (MMA) is caused by a deficiency of methylmalonyl-CoA mutase, which is a vitamin B12-dependent enzyme. Defects of adenosylcobalamin metabolism lead to variant forms of MMA.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        MUT; methylmalonyl-CoA mutase [HSA:4594] [KO:K01847]
            MMAA [HSA:166785] [KO:K07588]
            MMAB [HSA:326625] [KO:K00798]
            LMBRD1 [HSA:55788] [KO:K14617]
            MMACHC [HSA:25974] [KO:K14618]
            MMADHC [HSA:27249]
            MCEE [HSA:84693] [KO:K05606]
            ABCD4 [HSA:5826] [KO:K05678]
MARKER      (blood and urine) Methylmalonic acid [CPD:C02170]
            (urine) Propanoic acid [CPD:C00163], 3-Hydroxypropionic acid [CPD:C01013]
            (blood) Propionylcarnitine [CPD:C03017]
            Acylcarnitine [CPD:C02301]
DRUG        Vitamin B12 [DR:D00191]
DBLINKS     ICD-10: E71.1
            MeSH: C537358 C537359 C564743 C564747
            OMIM: 251000 251100 251110 277380 277400 277410 251120 614857
REFERENCE   PMID:16602092
  AUTHORS   Deodato F, Boenzi S, Santorelli FM, Dionisi-Vici C
  TITLE     Methylmalonic and propionic aciduria.
  JOURNAL   Am J Med Genet C Semin Med Genet 142C:104-12 (2006)
REFERENCE   PMID:12069539
  AUTHORS   Ogier de Baulny H, Saudubray JM
  TITLE     Branched-chain organic acidurias.
  JOURNAL   Semin Neonatol 7:65-74 (2002)
REFERENCE   PMID:16752391
  AUTHORS   Bikker H, Bakker HD, Abeling NG, Poll-The BT, Kleijer WJ, Rosenblatt DS, Waterham HR, Wanders RJ, Duran M
  TITLE     A homozygous nonsense mutation in the methylmalonyl-CoA epimerase gene (MCEE) results in mild methylmalonic aciduria.
  JOURNAL   Hum Mutat 27:640-3 (2006)
REFERENCE   PMID:22922874
  AUTHORS   Coelho D, Kim JC, Miousse IR, Fung S, du Moulin M, Buers I, Suormala T, Burda P, Frapolli M, Stucki M, Nurnberg P, Thiele H, Robenek H, Hohne W, Longo N, Pasquali M, Mengel E, Watkins D, Shoubridge EA, Majewski J, Rosenblatt DS, Fowler B, Rutsch F, Baumgartner MR
  TITLE     Mutations in ABCD4 cause a new inborn error of vitamin B12 metabolism.
  JOURNAL   Nat Genet 44:1152-5 (2012)
///
ENTRY       H00175                      Disease
NAME        Propionic acidemia
DESCRIPTION Propionic acidaemia is caused by a deficiency of propionyl-CoA carboxylase which accumulates toxic compounds affecting brain metabolism.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        PCCA; propionyl-CoA carboxylase alpha chain [HSA:5095] [KO:K01965]
            PCCB; propionyl-CoA carboxylase beta chain [HSA:5096] [KO:K01966]
MARKER      Methylcitric acid [CPD:C02225]
            3-Hydroxypropanoate [CPD:C01013]
DRUG        Carglumic acid [DR:D07130]
            Carnitine [DR:D02176]
DBLINKS     ICD-10: E71.1
            MeSH: D056693
            OMIM: 606054
REFERENCE   PMID:17951291
  AUTHORS   Wikoff WR, Gangoiti JA, Barshop BA, Siuzdak G
  TITLE     Metabolomics identifies perturbations in human disorders of propionate metabolism.
  JOURNAL   Clin Chem 53:2169-76 (2007)
REFERENCE   PMID:16602092
  AUTHORS   Deodato F, Boenzi S, Santorelli FM, Dionisi-Vici C
  TITLE     Methylmalonic and propionic aciduria.
  JOURNAL   Am J Med Genet C Semin Med Genet 142C:104-12 (2006)
REFERENCE   PMID:12069539
  AUTHORS   Ogier de Baulny H, Saudubray JM
  TITLE     Branched-chain organic acidurias.
  JOURNAL   Semin Neonatol 7:65-74 (2002)
///
ENTRY       H00176                      Disease
NAME        Adrenoleukodystrophy (ALD), including:
            Schilder-Addison Complex;
            Childhood cerebral adrenoleukodystrophy (CCER);
            adrenomyeloneuropathy (AMN)
DESCRIPTION Adrenoleukodystrophy (ALD) is an X-linked disorder caused by mutation in the ABCD1 gene that encodes ABCD1/ALDP, a peroxisomal ABC transporter. ALD is biochemically characterized by the accumulation of saturated very long chain fatty acids (VLCFA) in tissues such as adrenal cortex and white matter of central nervous system. The phenotypes can be subdivided into four main categories: Childhood cerebral adrenoleukodystrophy (CCER), adrenomyeloneuropathy (AMN), Addison-only, and asymptomatic. This disorder is characterized by progressive behavioral, cognitive and neurologic deficit.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease; Peroxisomal disease
GENE        ABCD1 [HSA:215] [KO:K05675]
MARKER      VLCFA
DRUG        Hematopoietic stem cell transplantation
            Lorenzo's oil
            Fenofibrate [DR:D00565]
            Lovastatin [DR:D00359]
            Sodium phenylbutyrate [DR:D05868] (in the experimental stage)
COMMENT     Childhood CER: Onset at 3-10 years of age.
            AMN: Onset 11-21 years of age.
            Addison-only: Onset common before 7.5 years.
DBLINKS     ICD-10: E71.3
            MeSH: D000326
            OMIM: 300100
REFERENCE   PMID:17342190
  AUTHORS   Moser HW, Mahmood A, Raymond GV
  TITLE     X-linked adrenoleukodystrophy.
  JOURNAL   Nat Clin Pract Neurol 3:140-51 (2007)
REFERENCE   PMID:15167059
  AUTHORS   Moser H, Dubey P, Fatemi A
  TITLE     Progress in X-linked adrenoleukodystrophy.
  JOURNAL   Curr Opin Neurol 17:263-9 (2004)
REFERENCE   PMID:17092750
  AUTHORS   Kemp S, Wanders RJ
  TITLE     X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment.
  JOURNAL   Mol Genet Metab 90:268-76 (2007)
REFERENCE   PMID:19801636 (marker)
  AUTHORS   Pillai BK, Jasuja R, Simard JR, Hamilton JA
  TITLE     Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins: implications for adrenoleukodystrophy.
  JOURNAL   J Biol Chem 284:33296-304 (2009)
REFERENCE   PMID:17603264 (drug)
  AUTHORS   Morita M
  TITLE     [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents] Japanese
  JOURNAL   Yakugaku Zasshi 127:1059-64 (2007)
///
ENTRY       H00177                      Disease
NAME        Adrenoleukodystrophy, neonatal (NALD)
DESCRIPTION The neonatal form of adrenoleukodystrophy is a peroxisomal disorder caused by mutation of one of the peroxisomal biogenesis factor genes.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease
GENE        PEX1 [HSA:5189] [KO:K13338]
            PEX5 [HSA:5830] [KO:K13342]
            PEX10 [HSA:5192] [KO:K13346]
            PEX13 [HSA:5194] [KO:K13344]
            PEX26 [HSA:55670] [KO:K13340]
DBLINKS     ICD-10: E71.3
            MeSH: D018901
            OMIM: 202370
REFERENCE   PMID:15679822
  AUTHORS   Wanders RJ, Waterham HR
  TITLE     Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders.
  JOURNAL   Clin Genet 67:107-33 (2005)
REFERENCE   PMID:12740827
  AUTHORS   Depreter M, Espeel M, Roels F
  TITLE     Human peroxisomal disorders.
  JOURNAL   Microsc Res Tech 61:203-23 (2003)
///
ENTRY       H00178                      Disease
NAME        Glutaric acidemia, including:
            Glutaric acidemia, type I (GA1);
            Glutaric acidemia, type II (GA2);
            Multiple acyl coenzyme A dehydrogenase deficiency
DESCRIPTION Glutaric aciduria type I is an autosomal recessive disorder resulting from a deficiency of glutaryl-CoA dehydrogenase leading to an accumulation of glutaric and 3-hydroxyglutaric acids and secondary carnitine deficiency. Glutaric aciduria type II is caused by a deficiency of either electron transport flavoprotein or of electron transport flavoprotein oxoreductase.
CATEGORY    Inherited metabolic disease
GENE        (GA1) GCDH; glutaryl-CoA dehydrogenase [HSA:2639] [KO:K00252]
            (GA2) ETFA; electron transfer flavoprotein alpha subunit [HSA:2108] [KO:K03522]
            (GA2) ETFB; electron transfer flavoprotein beta subunit [HSA:2109] [KO:K03521]
            (GA2) ETFDH; electron-transferring-flavoprotein dehydrogenase [HSA:2110] [KO:K00311]
            (GA3) SUGCT; succinate--hydroxymethylglutarate CoA-transferase [HSA:79783] [KO:K18703]
MARKER      (GA1) 3-hydroxyglutarate
            (GA2) 2-hydroxyglutarate [CPD:C02630]
            (GA2) Methylmalonate [CPD:C02170]
            (GA2) Hippurate [CPD:C01586]
            (GA2) adipic acid
DRUG        Baclofen [DR:D00241]
            Riboflavin [DG:DG00130]
            Carnitine [DR:D02030]
            Sodium-D,L-3-hydroxybutyrate
DBLINKS     ICD-10: E71.3 E72.3
            MeSH: D054069 C536833
            OMIM: 231670 231680 231690
REFERENCE   PMID:16368216
  AUTHORS   Gordon N
  TITLE     Glutaric aciduria types I and II.
  JOURNAL   Brain Dev 28:136-40 (2006)
REFERENCE   PMID:23893049
  AUTHORS   Marlaire S, Van Schaftingen E, Veiga-da-Cunha M
  TITLE     C7orf10 encodes succinate-hydroxymethylglutarate CoA-transferase, the enzyme that converts glutarate to glutaryl-CoA.
  JOURNAL   J Inherit Metab Dis 37:13-9 (2014)
///
ENTRY       H00179                      Disease
NAME        3-Hydroxy-3-methylglutaryl-CoA lyase deficiency
DESCRIPTION 3-Hydroxy-3-methylglutaryl-CoA lyase (HL) deficiency is a rare autosomal recessive genetic disorder characterized by recurrent episodes of metabolic acidosis, hyperammonemia without ketosis, hypoglycemia, lethargy, hepatomegaly, and seizures.
CATEGORY    Inherited metabolic disease
GENE        HMGCL; hydroxymethylglutaryl-CoA lyase [HSA:3155] [KO:K01640]
DRUG        Carnitine [DR:D02030]
DBLINKS     ICD-10: E71.1
            MeSH: C538324
            OMIM: 246450
REFERENCE   PMID:17692550
  AUTHORS   Pie J, Lopez-Vinas E, Puisac B, Menao S, Pie A, Casale C, Ramos FJ, Hegardt FG, Gomez-Puertas P, Casals N
  TITLE     Molecular genetics of HMG-CoA lyase deficiency.
  JOURNAL   Mol Genet Metab 92:198-209 (2007)
REFERENCE   PMID:10371384
  AUTHORS   Yalcinkaya C, Dincer A, Gunduz E, Ficicioglu C, Kocer N, Aydin A
  TITLE     MRI and MRS in HMG-CoA lyase deficiency.
  JOURNAL   Pediatr Neurol 20:375-80 (1999)
///
ENTRY       H00180                      Disease
NAME        Holocarboxylase synthetase deficiency;
            Multiple carboxylase deficiency
DESCRIPTION Holocarboxylase synthetase (HLCS) deficiency is an autosomal recessive disorder of biotin metabolism that results from holocarboxylase synthetase activity disruption. HLCS deficiency is also called multiple carboxylase deficiency, because deficient HLCS activity results in reduced activity of multiple carboxylases. In humans, four carboxylases are known to be biotinylated by HLCS. They are pyruvate carboxylase, propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and acetyl-CoA carboxylase. Symptoms of HLCS deficiency include metabolic acidosis, a characteristic organic aciduria, lethargy, hypotonia, convulsions, and dermatitis.
CATEGORY    Inherited metabolic disease
GENE        HLCS; holocarboxylase synthetase [HSA:3141] [KO:K01942]
DRUG        Biotin [DG:DG00131]
DBLINKS     ICD-10: E53.8
            MeSH: D028922
            OMIM: 253270
REFERENCE   PMID:16134170
  AUTHORS   Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y
  TITLE     Mutations in the holocarboxylase synthetase gene HLCS.
  JOURNAL   Hum Mutat 26:285-90 (2005)
REFERENCE   PMID:12459313
  AUTHORS   Pacheco-Alvarez D, Solorzano-Vargas RS, Del Rio AL
  TITLE     Biotin in metabolism and its relationship to human disease.
  JOURNAL   Arch Med Res 33:439-47 (2002)
///
ENTRY       H00181                      Disease
NAME        3-Methylcrotonylglycinuria;
            3-Methylcrotonyl-CoA carboxylase deficiency
DESCRIPTION 3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine catabolism with a variable phenotype.
CATEGORY    Inherited metabolic disease
GENE        MCCC1; 3-methylcrotonyl-CoA carboxylase alpha subunit [HSA:56922] [KO:K01968]
            MCCC2; 3-methylcrotonyl-CoA carboxylase beta subunit [HSA:64087] [KO:K01969]
MARKER      3-Methylcrotonylglycine [CPD:C20828]
            3-Hydroxyisovaleric acid [CPD:C20827]
DBLINKS     ICD-10: E71.1
            MeSH: C535308 C535309
            OMIM: 210200 210210
REFERENCE   PMID:16010683
  AUTHORS   Dantas MF, Suormala T, Randolph A, Coelho D, Fowler B, Valle D, Baumgartner MR
  TITLE     3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28 probands, 9 symptomatic and 19 detected by newborn screening.
  JOURNAL   Hum Mutat 26:164 (2005)
REFERENCE   PMID:15868465
  AUTHORS   Baumgartner MR
  TITLE     Molecular mechanism of dominant expression in 3-methylcrotonyl-CoA carboxylase deficiency.
  JOURNAL   J Inherit Metab Dis 28:301-9 (2005)
REFERENCE   PMID:11181649
  AUTHORS   Baumgartner MR, Almashanu S, Suormala T, Obie C, Cole RN, Packman S, Baumgartner ER, Valle D
  TITLE     The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency.
  JOURNAL   J Clin Invest 107:495-504 (2001)
///
ENTRY       H00182                      Disease
NAME        Cystathioninuria
DESCRIPTION Hereditary cystathioninuria is caused by deficiency of the activity of cystathionine gamma-lyase, which is normally required for the conversion of methionine into cysteine. Patients with cystathioninuria may have mild to moderate hyperhomocysteinemia.
CATEGORY    Inherited metabolic disease
GENE        CTH; cystathionine gamma-lyase [HSA:1491] [KO:K01758]
DBLINKS     ICD-10: E72.1
            MeSH: C535408
            OMIM: 219500
REFERENCE   PMID:16702350
  AUTHORS   Finkelstein JD
  TITLE     Inborn errors of sulfur-containing amino acid metabolism.
  JOURNAL   J Nutr 136:1750S-1754S (2006)
REFERENCE   PMID:12574942
  AUTHORS   Wang J, Hegele RA
  TITLE     Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH).
  JOURNAL   Hum Genet 112:404-8 (2003)
///
ENTRY       H00183                      Disease
NAME        Homocystinuria
DESCRIPTION Homocystinuria is a metabolic disorder due to cystathionine beta-synthase deficiency leading to various malfunctions in the eyes and the central nervous, skeletal, and vascular systems.
CATEGORY    Inherited metabolic disease; Nervous system disease; Cardiovascular disease
GENE        CBS; cystathionine beta-synthase [HSA:875] [KO:K01697]
            MTRR [HSA:4552] [KO:K00597]
            MTHFR [HSA:4524] [KO:K00297]
MARKER      Methionine [CPD:C00073]
            Homocysteine [CPD:C00155]
DRUG        Betaine [DR:D07523]
            Pyridoxine [DR:D08454]
DBLINKS     ICD-10: E72.1
            MeSH: D006712
            OMIM: 236200 236270 236250
REFERENCE   PMID:10338090
  AUTHORS   Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP, Sebastio G, de Franchis R, Andria G, Kluijtmans LA, Blom H, Boers GH, Gordon RB, Kamoun P, Tsai MY, Kruger WD, Koch HG, Ohura T, Gaustadnes M
  TITLE     Cystathionine beta-synthase mutations in homocystinuria.
  JOURNAL   Hum Mutat 13:362-75 (1999)
REFERENCE   PMID:14739681
  AUTHORS   Orendac M, Zeman J, Stabler SP, Allen RH, Kraus JP, Bodamer O, Stockler-Ipsiroglu S, Kvasnicka J, Kozich V
  TITLE     Homocystinuria due to cystathionine beta-synthase deficiency: novel biochemical findings and treatment efficacy.
  JOURNAL   J Inherit Metab Dis 26:761-73 (2003)
REFERENCE   PMID:9587026
  AUTHORS   Kraus JP
  TITLE     Biochemistry and molecular genetics of cystathionine beta-synthase deficiency.
  JOURNAL   Eur J Pediatr 157 Suppl 2:S50-3 (1998)
REFERENCE   PMID:9587033
  AUTHORS   Fowler B, Jakobs C
  TITLE     Post- and prenatal diagnostic methods for the homocystinurias.
  JOURNAL   Eur J Pediatr 157 Suppl 2:S88-93 (1998)
///
ENTRY       H00184                      Disease
NAME        Hypermethioninemia;
            Methionine adenosyltransferase deficiency;
            S-adenosylhomocysteine hydrolase deficiency
DESCRIPTION Hypermethioninemia is an inborn error of methionine metabolism.
CATEGORY    Inherited metabolic disease
GENE        MAT1A [HSA:4143] [KO:K00789]
            AHCY [HSA:191] [KO:K01251]
            GNMT [HSA:27232] [KO:K00552]
DBLINKS     ICD-10: E72.1
            MeSH: C564683
            OMIM: 250850 180960 606664
REFERENCE   PMID:15024124
  AUTHORS   Baric I, Fumic K, Glenn B, Cuk M, Schulze A, Finkelstein JD, James SJ, Mejaski-Bosnjak V, Pazanin L, Pogribny IP, Rados M, Sarnavka V, Scukanec-Spoljar M, Allen RH, Stabler S, Uzelac L, Vugrek O, Wagner C, Zeisel S, Mudd SH
  TITLE     S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism.
  JOURNAL   Proc Natl Acad Sci U S A 101:4234-9 (2004)
REFERENCE   PMID:11145114
  AUTHORS   Mudd SH, Jenden DJ, Capdevila A, Roch M, Levy HL, Wagner C
  TITLE     Isolated hypermethioninemia: measurements of S-adenosylmethionine and choline.
  JOURNAL   Metabolism 49:1542-7 (2000)
REFERENCE   PMID:21308989
  AUTHORS   Mudd SH
  TITLE     Hypermethioninemias of genetic and non-genetic origin: A review.
  JOURNAL   Am J Med Genet C Semin Med Genet 157:3-32 (2011)
REFERENCE   PMID:9612070 (Japanese)
  AUTHORS   Nagao M
  TITLE     [Molecular pathology and DNA diagnosis of phenylketonuria and hypermethioninemia].
  JOURNAL   Tanpakushitsu Kakusan Koso 43:762-9 (1998)
///
ENTRY       H00185                      Disease
NAME        Citrullinemia (CTLN)
DESCRIPTION Citrullinemia is an autosomal recessive disease caused by a deficiency of argininosuccinate synthetase/citrin and characterized primarily by elevated serum and urine citrulline levels.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        (CTLN1) ASS1; argininosuccinate synthetase 1 [HSA:445] [KO:K01940]
            (CTLN2) SLC25A13 [HSA:10165] [KO:K15105]
MARKER      Citrulline [CPD:C00327]
DBLINKS     ICD-10: E72.2
            MeSH: D020159
            OMIM: 215700 603471 605814
REFERENCE   PMID:18473344
  AUTHORS   Berning C, Bieger I, Pauli S, Vermeulen T, Vogl T, Rummel T, Hohne W, Koch HG, Rolinski B, Gempel K, Haberle J
  TITLE     Investigation of citrullinemia type I variants by in vitro expression studies.
  JOURNAL   Hum Mutat 29:1222-7 (2008)
REFERENCE   PMID:15050970
  AUTHORS   Saheki T, Kobayashi K, Iijima M, Horiuchi M, Begum L, Jalil MA, Li MX, Lu YB, Ushikai M, Tabata A, Moriyama M, Hsiao KJ, Yang Y
  TITLE     Adult-onset type II citrullinemia and idiopathic neonatal hepatitis caused by citrin deficiency: involvement of the aspartate glutamate carrier for urea synthesis and maintenance of the urea cycle.
  JOURNAL   Mol Genet Metab 81 Suppl 1:S20-6 (2004)
///
ENTRY       H00186                      Disease
NAME        Hyperargininemia
DESCRIPTION Hyperargininemia is an autosomal recessive disorder caused by a defect in the arginase I enzyme resulting in high plasma arginine and ammonia levels, that develops encephalopathy.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        ARG1; arginase [HSA:383] [KO:K01476]
DBLINKS     ICD-10: E72.2
            MeSH: D020162
            OMIM: 207800
REFERENCE   PMID:16602094
  AUTHORS   Scaglia F, Lee B
  TITLE     Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency.
  JOURNAL   Am J Med Genet C Semin Med Genet 142C:113-20 (2006)
REFERENCE   PMID:15694174
  AUTHORS   Crombez EA, Cederbaum SD
  TITLE     Hyperargininemia due to liver arginase deficiency.
  JOURNAL   Mol Genet Metab 84:243-51 (2005)
///
ENTRY       H00187                      Disease
NAME        Ornithine transcarbamylase deficiency
DESCRIPTION Ornithine transcarbamylase deficiency, the most common urea cycle defect, results in failure to thrive, hypotonia, seizures and mental retardation.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        OTC; ornithine carbamoyltransferase [HSA:5009] [KO:K00611]
MARKER      Orotic acid [CPD:C00295]
DRUG        Sodium benzoate [DR:D02277]
            Phenylbutyrate [DR:D05868]
DBLINKS     ICD-10: E72.4
            MeSH: D020163
            OMIM: 311250
REFERENCE   PMID:18038189
  AUTHORS   Gropman AL, Summar M, Leonard JV
  TITLE     Neurological implications of urea cycle disorders.
  JOURNAL   J Inherit Metab Dis 30:865-79 (2007)
REFERENCE   PMID:12788037
  AUTHORS   Gordon N
  TITLE     Ornithine transcarbamylase deficiency: a urea cycle defect.
  JOURNAL   Eur J Paediatr Neurol 7:115-21 (2003)
REFERENCE   PMID:10885542
  AUTHORS   Butterworth RF
  TITLE     Evidence for forebrain cholinergic neuronal loss in congenital ornithine transcarbamylase deficiency.
  JOURNAL   Metab Brain Dis 15:83-91 (2000)
///
ENTRY       H00188                      Disease
NAME        Hyperlysinemia
DESCRIPTION Hyperlysinemia is an autosomal recessive metabolic disorder caused by aminoadipate-semialdehyde synthase deficiency and characterized by an abnormal increase of lysine in the blood.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        AASS; aminoadipate-semialdehyde synthase [HSA:10157] [KO:K14157]
MARKER      Lysine [CPD:C00047]
DBLINKS     ICD-10: E72.3
            MeSH: D020167
            OMIM: 238700
REFERENCE   PMID:10775527
  AUTHORS   Sacksteder KA, Biery BJ, Morrell JC, Goodman BK, Geisbrecht BV, Cox RP, Gould SJ, Geraghty MT
  TITLE     Identification of the alpha-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia.
  JOURNAL   Am J Hum Genet 66:1736-43 (2000)
///
ENTRY       H00189                      Disease
NAME        Ornithinaemia;
            Gyrate Atrophy
DESCRIPTION Ornithinemia due to deficiency of ornithine ketoacid aminotransferase induces hyperornithinemia and gyrate atrophy.
CATEGORY    Inherited metabolic disease; Eye disease
GENE        OAT; ornithine aminotransferase [HSA:4942] [KO:K00819]
DBLINKS     ICD-10: E72.4
            MeSH: D015799
            OMIM: 258870
REFERENCE   PMID:11465067
  AUTHORS   Seiler N
  TITLE     Ornithine aminotransferase, a potential target for the treatment of hyperammonemias.
  JOURNAL   Curr Drug Targets 1:119-53 (2000)
REFERENCE   PMID:24429551
  AUTHORS   Katagiri S, Gekka T, Hayashi T, Ida H, Ohashi T, Eto Y, Tsuneoka H
  TITLE     OAT mutations and clinical features in two Japanese brothers with gyrate atrophy  of the choroid and retina.
  JOURNAL   Doc Ophthalmol 128:137-48 (2014)
///
ENTRY       H00190                      Disease
NAME        Hyperprolinemia (HP)
DESCRIPTION Hyperprolinemia is a phenotype present in two distinct, autosomal recessive metabolic disorders caused by defects in the l-proline catabolic pathway. Hyperprolinemia type I (HPI) and type II (HPII) are caused by deficiencies in proline dehydrogenase (PRODH) and P5C dehydrogenase (P5CDH; also known as ALDH4A1), respectively. Patients with HPI may exhibit an increase in plasma proline level in absence of urinary pyrroline-5-carboxylate (P5C) while those with HPII have elevated levels of P5C and proline in plasma, urine, and cerebrospinal fluid. Some patients have neurological, renal, and/or auditory defects.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        (HP1) PRODH; proline dehydrogenase [HSA:5625] [KO:K00318]
            (HP2) ALDH4A1; 1-pyrroline-5-carboxylate dehydrogenase [HSA:8659] [KO:K00294]
MARKER      Proline [CPD:C00148]
DBLINKS     ICD-10: E72.5
            MeSH: C538384 C538385
            OMIM: 239500 239510
REFERENCE   PMID:18806117
  AUTHORS   Mitsubuchi H, Nakamura K, Matsumoto S, Endo F
  TITLE     Inborn errors of proline metabolism.
  JOURNAL   J Nutr 138:2016S-2020S (2008)
REFERENCE   PMID:15214748 (gene)
  AUTHORS   Onenli-Mungan N, Yuksel B, Elkay M, Topaloglu AK, Baykal T, Ozer G
  TITLE     Type II hyperprolinemia: a case report.
  JOURNAL   Turk J Pediatr 46:167-9 (2004)
REFERENCE   PMID:12217952 (gene)
  AUTHORS   Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, Haouzir S, Allio G, Fouldrin G, Drouin V, Bou J, Petit M, Campion D, Frebourg T
  TITLE     PRODH mutations and hyperprolinemia in a subset of schizophrenic patients.
  JOURNAL   Hum Mol Genet 11:2243-9 (2002)
REFERENCE   PMID:20524212 (description, gene)
  AUTHORS   Guilmatre A, Legallic S, Steel G, Willis A, Di Rosa G, Goldenberg A, Drouin-Garraud V, Guet A, Mignot C, Des Portes V, Valayannopoulos V, Van Maldergem L, Hoffman JD, Izzi C, Espil-Taris C, Orcesi S, Bonafe L, Le Galloudec E, Maurey H, Ioos C, Afenjar A, Blanchet P, Echenne B, Roubertie A, Frebourg T, Valle D, Campion D
  TITLE     Type I hyperprolinemia: genotype/phenotype correlations.
  JOURNAL   Hum Mutat 31:961-5 (2010)
REFERENCE   PMID:22516612 (description, gene)
  AUTHORS   Srivastava D, Singh RK, Moxley MA, Henzl MT, Becker DF, Tanner JJ
  TITLE     The Three-Dimensional Structural Basis of Type II Hyperprolinemia.
  JOURNAL   J Mol Biol 420:176-89 (2012)
REFERENCE   PMID:21882227 (description, gene)
  AUTHORS   Ferreira AG, da Cunha AA, Machado FR, Pederzolli CD, Dalazen GR, de Assis AM, Lamers ML, dos Santos MF, Dutra-Filho CS, Wyse AT
  TITLE     Experimental hyperprolinemia induces mild oxidative stress, metabolic changes, and tissue adaptation in rat liver.
  JOURNAL   J Cell Biochem 113:174-83 (2012)
///
ENTRY       H00191                      Disease
NAME        Nonketotic hyperglycinemia;
            Glycine encephalopathy (GCE)
DESCRIPTION Nonketotic hyperglycinemia is an inborn error of glycine metabolism caused by a deficiency of the glycine cleavage system, which is composed of four proteins in the mitochondria and results in severe neurologic dysfunctions.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        GLDC; glycine dehydrogenase [HSA:2731] [KO:K00281]
            AMT; aminomethyltransferase [HSA:275] [KO:K00605]
            GCSH [HSA:2653] [KO:K02437]
DBLINKS     ICD-10: E72.5
            OMIM: 605899
REFERENCE   PMID:15864413
  AUTHORS   Boneh A, Korman SH, Sato K, Kanno J, Matsubara Y, Lerer I, Ben-Neriah Z, Kure S
  TITLE     A single nucleotide substitution that abolishes the initiator methionine codon of the GLDC gene is prevalent among patients with glycine encephalopathy in Jerusalem.
  JOURNAL   J Hum Genet 50:230-4 (2005)
REFERENCE   PMID:11592811
  AUTHORS   Applegarth DA, Toone JR
  TITLE     Nonketotic hyperglycinemia (glycine encephalopathy): laboratory diagnosis.
  JOURNAL   Mol Genet Metab 74:139-46 (2001)
REFERENCE   PMID:8412015
  AUTHORS   Tada K, Kure S
  TITLE     Non-ketotic hyperglycinaemia: molecular lesion, diagnosis and pathophysiology.
  JOURNAL   J Inherit Metab Dis 16:691-703 (1993)
///
ENTRY       H00192                      Disease
NAME        Xanthinuria
DESCRIPTION Xanthinuria is characterized by excretion of large amounts of xanthine in the urine and caused by deficiency of xanthine dehydrogenase and molybdenum cofactors, which are essential to the function of xanthine dehydrogenase.
CATEGORY    Inherited metabolic disease; Urologic disease
GENE        XDH; xanthine dehydrogenase [HSA:7498] [KO:K00106]
            AOX1 [HSA:316] [KO:K00157]
            MOCS1 [HSA:4337] [KO:K20967]
            MOCS2 [HSA:4338] [KO:K03635]
            GEPH [HSA:10243] [KO:K15376]
            MOCOS [HSA:55034] [KO:K15631]
DBLINKS     ICD-10: E79.9
            MeSH: C562584 C566358
            OMIM: 278300 252150 603592
REFERENCE   PMID:14624414
  AUTHORS   Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Tuneyoshi K, Matsui K, Cheng J, Hada T
  TITLE     Identification of a new point mutation in the human molybdenum cofactor sulferase gene that is responsible for xanthinuria type II.
  JOURNAL   Metabolism 52:1501-4 (2003)
REFERENCE   PMID:11379872
  AUTHORS   Sakamoto N, Yamamoto T, Moriwaki Y, Teranishi T, Toyoda M, Onishi Y, Kuroda S, Sakaguchi K, Fujisawa T, Maeda M, Hada T
  TITLE     Identification of a new point mutation in the human xanthine dehydrogenase gene responsible for a case of classical type I xanthinuria.
  JOURNAL   Hum Genet 108:279-83 (2001)
REFERENCE   PMID:11302742 (gene)
  AUTHORS   Ichida K, Matsumura T, Sakuma R, Hosoya T, Nishino T
  TITLE     Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II.
  JOURNAL   Biochem Biophys Res Commun 282:1194-200 (2001)
REFERENCE   PMID:10844591
  AUTHORS   Levartovsky D, Lagziel A, Sperling O, Liberman U, Yaron M, Hosoya T, Ichida K, Peretz H
  TITLE     XDH gene mutation is the underlying cause of classical xanthinuria: a second report.
  JOURNAL   Kidney Int 57:2215-20 (2000)
REFERENCE   PMID:9153281
  AUTHORS   Ichida K, Amaya Y, Kamatani N, Nishino T, Hosoya T, Sakai O
  TITLE     Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria.
  JOURNAL   J Clin Invest 99:2391-7 (1997)
REFERENCE   PMID:12754701
  AUTHORS   Reiss J, Johnson JL
  TITLE     Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH.
  JOURNAL   Hum Mutat 21:569-76 (2003)
///
ENTRY       H00193                      Disease
NAME        Dihydropyrimidine dehydrogenase deficiency
DESCRIPTION Dihydropyrimidine dehydrogenase enzyme deficiency is a pharmacogenetic syndrome leading to severe side-effects in patients receiving therapies containing the anticancer drug 5-fluorouracil.
CATEGORY    Inherited metabolic disease
GENE        DPYD; dihydropyrimidine dehydrogenase [HSA:1806] [KO:K00207]
ENV_FACTOR  Fluorouracil [DR:D00584]
DBLINKS     ICD-10: E79.8
            MeSH: D054067
            OMIM: 274270
REFERENCE   PMID:17905396
  AUTHORS   Ben Fredj R, Gross E, Chouchen L, B'Chir F, Ben Ahmed S, Neubauer S, Kiechle M, Saguem S
  TITLE     Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.
  JOURNAL   C R Biol 330:764-9 (2007)
REFERENCE   PMID:17876700
  AUTHORS   Okamoto Y, Ueta A, Sumi S, Ito T, Okubo Y, Jose Y, Ninomiya A, Togari H, Nishida M
  TITLE     SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit.
  JOURNAL   Biochem Genet 45:713-24 (2007)
///
ENTRY       H00194                      Disease
NAME        Lesch-Nyhan syndrome;
            Hypoxanthine-guanine phosophoribosyltransferase deficiency
DESCRIPTION Deficiency of hypoxanthine-guanine phosphoribosyltransferase activity is an inborn error of purine metabolism characterized by hyperuricemia with hyperuricosuria and a continuum spectrum of neurological manifestations.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        HPRT1; hypoxanthine phosphoribosyltransferase [HSA:3251] [KO:K00760]
MARKER      Uric acid [CPD:C00366]
DRUG        Allopurinol [DG:DG00779]
DBLINKS     ICD-10: E79.1
            MeSH: D007926
            OMIM: 300322 300323
REFERENCE   PMID:18067674
  AUTHORS   Torres RJ, Puig JG
  TITLE     Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome.
  JOURNAL   Orphanet J Rare Dis 2:48 (2007)
REFERENCE   PMID:15711436
  AUTHORS   Deutsch SI, Long KD, Rosse RB, Mastropaolo J, Eller J
  TITLE     Hypothesized deficiency of guanine-based purines may contribute to abnormalities of neurodevelopment, neuromodulation, and neurotransmission in Lesch-Nyhan syndrome.
  JOURNAL   Clin Neuropharmacol 28:28-37 (2005)
REFERENCE   PMID:15571219
  AUTHORS   McCarthy G
  TITLE     Medical diagnosis, management and treatment of Lesch Nyhan disease.
  JOURNAL   Nucleosides Nucleotides Nucleic Acids 23:1147-52 (2004)
///
ENTRY       H00195                      Disease
NAME        Adenine phosphoribosyltransferase deficiency;
            2,8-Dihydroxyadenine urolithiasis
DESCRIPTION Adenine phosphoribosyltransferase deficiency is an autosomal recessive disorder of purine metabolism and causes urolithiasis due to accumulation of the insoluble purine 2,8-dihydroxyadenine.
CATEGORY    Inherited metabolic disease; Urologic disease
GENE        APRT; adenine phosphoribosyltransferase [HSA:353] [KO:K00759]
MARKER      2,8-dihydroxyadenine
DRUG        Allopurinol [DG:DG00779]
DBLINKS     ICD-10: N20.2
            MeSH: C538228
            OMIM: 102600
REFERENCE   PMID:15571218
  AUTHORS   Taniguchi A, Tsuchida S, Kuno S, Mita M, Machida T, Ioritani N, Terai C, Yamanaka H, Kamatani N
  TITLE     Identification of two novel mutations in adenine phosphoribosyltransferase gene in patients with 2,8-dihydroxyadenine urolithiasis.
  JOURNAL   Nucleosides Nucleotides Nucleic Acids 23:1141-5 (2004)
REFERENCE   PMID:15196008
  AUTHORS   Silva M, Silva CH, Iulek J, Thiemann OH
  TITLE     Three-dimensional structure of human adenine phosphoribosyltransferase and its relation to DHA-urolithiasis.
  JOURNAL   Biochemistry 43:7663-71 (2004)
REFERENCE   PMID:11243733
  AUTHORS   Deng L, Yang M, Frund S, Wessel T, De Abreu RA, Tischfield JA, Sahota A
  TITLE     2,8-Dihydroxyadenine urolithiasis in a patient with considerable residual adenine phosphoribosyltransferase activity in cell extracts but with mutations in both copies of APRT.
  JOURNAL   Mol Genet Metab 72:260-4 (2001)
///
ENTRY       H00196                      Disease
NAME        Phosphoribosylpyrophosphate synthetase I superactivity
DESCRIPTION Phosphoribosylpyrophosphate synthetase I superactivity is an X-linked inborn error of metabolism in which increased enzyme activity is associated with hyperuricemia and gout.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        PRPS1; phosphoribosylpyrophosphate synthetase [HSA:5631] [KO:K00948]
DBLINKS     MeSH: C567064
            OMIM: 300661
REFERENCE   PMID:16176880
  AUTHORS   Nyhan WL
  TITLE     Disorders of purine and pyrimidine metabolism.
  JOURNAL   Mol Genet Metab 86:25-33 (2005)
REFERENCE   PMID:10066814
  AUTHORS   Ahmed M, Taylor W, Smith PR, Becker MA
  TITLE     Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase.
  JOURNAL   J Biol Chem 274:7482-8 (1999)
REFERENCE   PMID:8702702
  AUTHORS   Becker MA, Taylor W, Smith PR, Ahmed M
  TITLE     Overexpression of the normal phosphoribosylpyrophosphate synthetase 1 isoform underlies catalytic superactivity of human phosphoribosylpyrophosphate synthetase.
  JOURNAL   J Biol Chem 271:19894-9 (1996)
///
ENTRY       H00197                      Disease
NAME        Adenylosuccinate lyase deficiency
DESCRIPTION Adenylosuccinate lyase deficiency is an autosomal-recessive disorder of the purine de novo synthesis pathway. Mental retardation is a major manifestation and most patients have seizures.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        ADSL; adenylosuccinate lyase [HSA:158] [KO:K01756]
MARKER      Succinyladenosine [CPD:C03794]
            Succinylaminoimidazole carboxamide ribotide (SAICAR) [CPD:C04823]
DRUG        Allopurinol [DG:DG00779]
DBLINKS     ICD-10: E79.9
            MeSH: C538235
            OMIM: 103050
REFERENCE   PMID:16839792
  AUTHORS   Spiegel EK, Colman RF, Patterson D
  TITLE     Adenylosuccinate lyase deficiency.
  JOURNAL   Mol Genet Metab 89:19-31 (2006)
REFERENCE   PMID:11392513
  AUTHORS   Ciardo F, Salerno C, Curatolo P
  TITLE     Neurologic aspects of adenylosuccinate lyase deficiency.
  JOURNAL   J Child Neurol 16:301-8 (2001)
REFERENCE   PMID:11042421
  AUTHORS   Nassogne M, Henrot B, Aubert G, Bonnier C, Marie S, Saint-Martin C, Van den Berghe G, Sebire G, Vincent M
  TITLE     Adenylosuccinase deficiency: an unusual cause of early-onset epilepsy associated with acquired microcephaly.
  JOURNAL   Brain Dev 22:383-6 (2000)
///
ENTRY       H00198                      Disease
NAME        Orotic aciduria
DESCRIPTION Orotic aciduria is characterized by megaloblastic anemia that is unresponsive to vitamin B12 and folic acid.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        UMPS; uridine monophosphate synthetase [HSA:7372] [KO:K13421]
MARKER      Orotic acid [CPD:C00295]
DRUG        Uridine [CPD:C00299]
DBLINKS     ICD-10: D53.0
            MeSH: C537136 C562589
            OMIM: 258900
REFERENCE   PMID:16176880
  AUTHORS   Nyhan WL
  TITLE     Disorders of purine and pyrimidine metabolism.
  JOURNAL   Mol Genet Metab 86:25-33 (2005)
REFERENCE   PMID:9042911
  AUTHORS   Suchi M, Mizuno H, Kawai Y, Tsuboi T, Sumi S, Okajima K, Hodgson ME, Ogawa H, Wada Y
  TITLE     Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families.
  JOURNAL   Am J Hum Genet 60:525-39 (1997)
///
ENTRY       H00199                      Disease
NAME        Dihydropyrimidinase deficiency;
            Dihydropyrimidinuria
DESCRIPTION Dihydropyrimidinase deficiency is characterized by dihydropyrimidinuria and is associated with seizures and mental retardation.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        DPYS; dihydropyrimidinase [HSA:1807] [KO:K01464]
MARKER      Dihydrouracil [CPD:C00429]
            Dihydrothymine [CPD:C00906]
DBLINKS     MeSH: C562815
            OMIM: 222748
REFERENCE   PMID:16176880
  AUTHORS   Nyhan WL
  TITLE     Disorders of purine and pyrimidine metabolism.
  JOURNAL   Mol Genet Metab 86:25-33 (2005)
REFERENCE   PMID:9718352
  AUTHORS   Hamajima N, Kouwaki M, Vreken P, Matsuda K, Sumi S, Imaeda M, Ohba S, Kidouchi K, Nonaka M, Sasaki M, Tamaki N, Endo Y, De Abreu R, Rotteveel J, van Kuilenburg A, van Gennip A, Togari H, Wada Y
  TITLE     Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene.
  JOURNAL   Am J Hum Genet 63:717-26 (1998)
REFERENCE   PMID:9266350
  AUTHORS   van Gennip AH, de Abreu RA, van Lenthe H, Bakkeren J, Rotteveel J, Vreken P, van Kuilenburg AB
  TITLE     Dihydropyrimidinase deficiency: confirmation of the enzyme defect in dihydropyrimidinuria.
  JOURNAL   J Inherit Metab Dis 20:339-42 (1997)
///
ENTRY       H00200                      Disease
NAME        Beta-ureidopropionase deficiency
DESCRIPTION Deficiency of beta-ureidopropionase which catalyzes the biosynthesis of beta-alanine and the last step in pyrimidine degradation is an autosomal recessive condition associated with neurological and developmental problems.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        UPB1; beta-ureidopropionase [HSA:51733] [KO:K01431]
DRUG        Beta-Alanine [DR:D07561]
DBLINKS     ICD-10: E72.8
            MeSH: C563210
            OMIM: 606673
REFERENCE   PMID:17964839
  AUTHORS   Yaplito-Lee J, Pitt J, Meijer J, Zoetekouw L, Meinsma R, van Kuilenburg AB
  TITLE     Beta-ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems.
  JOURNAL   Mol Genet Metab 93:190-4 (2008)
REFERENCE   PMID:16541364
  AUTHORS   Assmann B, Gohlich G, Baethmann M, Wevers RA, Van Gennip AH, Van Kuilenburg AB, Dietrich C, Wagner L, Rotteveel JJ, Schaper J, Mayatepek E, Hoffmann GF, Voit T
  TITLE     Clinical findings and a therapeutic trial in the first patient with beta-ureidopropionase deficiency.
  JOURNAL   Neuropediatrics 37:20-5 (2006)
REFERENCE   PMID:16176880
  AUTHORS   Nyhan WL
  TITLE     Disorders of purine and pyrimidine metabolism.
  JOURNAL   Mol Genet Metab 86:25-33 (2005)
///
ENTRY       H00201                      Disease
NAME        Erythropoietic porphyria (EP), including:
            Erythropoietic protoporphyria (EPP);
            Congenital erythropoietic porphyria (CEP);
            Gunther Disease;
            Hepatoerythropoietic porphyria (HEP)
DESCRIPTION Erythropoietic protoporphyria is an inborn error of heme biosynthesis porphyrin metabolism caused by deficiency of enzymes of porphyrin metabolism. Porphyrias are divided into erythropoietic and hepatic according to the predominant porphyrin-accumulating tissue. Three different erythropoietic porphyrias (EP) have been described: erythropoietic protoporphyria (EPP) the most frequent, congenital erythropoietic porphyria (CEP) /Gunther Disease, and the very rare hepatoerythropoietic porphyria (HEP). The symptoms include photosensitivity and hemolytic anemia. ALAS deficiency is responsible for X-linked sideroblastic anemia.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        (EPP) FECH [HSA:2235] [KO:K01772]
            (CEP) UROS [HSA:7390] [KO:K01719]
            (HEP) UROD [HSA:7389] [KO:K01599]
DRUG        Bone marrow transplantation
DBLINKS     ICD-10: E80.0
            MeSH: D017092
            OMIM: 177000 263700 176100
REFERENCE   PMID:18537592
  AUTHORS   Richard E, Robert-Richard E, Ged C, Moreau-Gaudry F, de Verneuil H
  TITLE     Erythropoietic porphyrias: animal models and update in gene-based therapies.
  JOURNAL   Curr Gene Ther 8:176-86 (2008)
REFERENCE   PMID:16385445
  AUTHORS   Gouya L, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V, Brun P, Simonin S, Lyoumi S, Grandchamp B, Beaumont C, Puy H, Deybach JC
  TITLE     Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria.
  JOURNAL   Am J Hum Genet 78:2-14 (2006)
REFERENCE   PMID:15574461
  AUTHORS   Ohgari Y, Sawamoto M, Yamamoto M, Kohno H, Taketani S
  TITLE     Ferrochelatase consisting of wild-type and mutated subunits from patients with a dominant-inherited disease, erythropoietic protoporphyria, is an active but unstable dimer.
  JOURNAL   Hum Mol Genet 14:327-34 (2005)
REFERENCE   PMID:11117426
  AUTHORS   Gross U, Hoffmann GF, Doss MO
  TITLE     Erythropoietic and hepatic porphyrias.
  JOURNAL   J Inherit Metab Dis 23:641-61 (2000)
REFERENCE   PMID:8829650
  AUTHORS   Xu W, Astrin KH, Desnick RJ
  TITLE     Molecular basis of congenital erythropoietic porphyria: mutations in the human uroporphyrinogen III synthase gene.
  JOURNAL   Hum Mutat 7:187-92 (1996)
REFERENCE   PMID:21653323
  AUTHORS   To-Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, Lyoumi S, Gouya L, de Verneuil H, Beaumont C, Ferreira GC, Deybach JC, Herrero C, Puy H
  TITLE     ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
  JOURNAL   Blood 118:1443-51 (2011)
///
ENTRY       H00202                      Disease
NAME        Hepatic porphyria, including:
            Porphyria Cutanea Tarda (PCT);
            VHepatoerythropoietic porphyria;
            Acute Intermittent Porphyria (AIP);
            Variegate porphyria (VP);
            ALA-dehydratase deficiency porphyria (ALADP);
            Hereditary Coproporphyria (HCP)
DESCRIPTION Hepatic porphyrias are diseases due to marked deficiencies of enzymes in the heme biosynthetic pathway. Clinical manifestations in porphyria are neurovisceral or cutaneous as well as hematic or hepatic.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease; Liver disease
GENE        (PCT) UROD; uroporphyrinogen decarboxylase [HSA:7389] [KO:K01599]
            (AIP) HMBS; hydroxymethylbilane synthase [HSA:3145] [KO:K01749]
            (VP) PPOX; protoporphyrinogen oxidase [HSA:5498] [KO:K00231]
            (ALADP) ALAD; porphobilinogen synthase [HSA:210] [KO:K01698]
            (HCP) CPOX; coproporphyrinogen III oxidase [HSA:1371] [KO:K00228]
MARKER      Coproporphyrins
DRUG        Hemin [DR:D10003]
DBLINKS     ICD-10: E80.1 E80.2
            MeSH: D017094
            OMIM: 176100 176000 176200 121300 125270
REFERENCE   PMID:14995910
  AUTHORS   Kauppinen R
  TITLE     Molecular diagnostics of acute intermittent porphyria.
  JOURNAL   Expert Rev Mol Diagn 4:243-9 (2004)
REFERENCE   PMID:12919129
  AUTHORS   Lecha M, Herrero C, Ozalla D
  TITLE     Diagnosis and treatment of the hepatic porphyrias.
  JOURNAL   Dermatol Ther 16:65-72 (2003)
REFERENCE   PMID:12367763
  AUTHORS   Nordmann Y, Puy H
  TITLE     Human hereditary hepatic porphyrias.
  JOURNAL   Clin Chim Acta 325:17-37 (2002)
REFERENCE   PMID:9199558
  AUTHORS   Puy H, Deybach JC, Lamoril J, Robreau AM, Da Silva V, Gouya L, Grandchamp B, Nordmann Y
  TITLE     Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.
  JOURNAL   Am J Hum Genet 60:1373-83 (1997)
REFERENCE   PMID:8852667
  AUTHORS   Deybach JC, Puy H, Robreau AM, Lamoril J, Da Silva V, Grandchamp B, Nordmann Y
  TITLE     Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria.
  JOURNAL   Hum Mol Genet 5:407-10 (1996)
REFERENCE   PMID:16945618 (drug)
  AUTHORS   Anderson KE, Collins S
  TITLE     Open-label study of hemin for acute porphyria: clinical practice implications.
  JOURNAL   Am J Med 119:801.e19-24 (2006)
///
ENTRY       H00203                      Disease
NAME        Acatalasia, including:
            Acatalasemia;
            Takahara's disease;
            Hypocatalasemia
DESCRIPTION Acatalasia is an autosomal recessive peroxisomal disorder caused by deficiency of erythrocyte catalase that metabolizes both hydrogen peroxide and a variety of substrates such as ethanol, methanol, phenol and nitrites. Catalase has an important protective function against the toxic effects of peroxides generated in peroxisomes and removes them with high efficiency. The Japanese, Swiss, and Hungarian types of acatalasemia display differences in biochemical and genetic aspects. Takahara's disease shows progressive oral gangrene and formerly occurred in about half of Japanese acatalasemia patients.
CATEGORY    Inherited metabolic disease; Peroxisomal disease
GENE        CAT; catalase [HSA:847] [KO:K03781]
DBLINKS     ICD-10: E80.3
            MeSH: D020642
            OMIM: 614097
REFERENCE   PMID:19122680
  AUTHORS   Ogata M, Wang DH, Ogino K
  TITLE     Mammalian acatalasemia: the perspectives of bioinformatics and genetic toxicology.
  JOURNAL   Acta Med Okayama 62:345-61 (2008)
REFERENCE   PMID:15771551
  AUTHORS   Goth L, Rass P, Pay A
  TITLE     Catalase enzyme mutations and their association with diseases.
  JOURNAL   Mol Diagn 8:141-9 (2004)
REFERENCE   PMID:11500062
  AUTHORS   Goth L
  TITLE     A new type of inherited catalase deficiencies: its characterization and comparison to the Japanese and Swiss type of acatalasemia.
  JOURNAL   Blood Cells Mol Dis 27:512-7 (2001)
REFERENCE   PMID:17034877
  AUTHORS   Schrader M, Fahimi HD
  TITLE     Peroxisomes and oxidative stress.
  JOURNAL   Biochim Biophys Acta 1763:1755-66 (2006)
///
ENTRY       H00204                      Disease
NAME        Infantile Refsum disease (IRD);
            Infantile phytanic acid storage disease
DESCRIPTION Infantile Refsum disease (IRD) is an autosomal recessive peroxisome biogenesis disorder, whose clinical and biochemical features are different from the adult form of Refsum disease. IRD is characterized by delayed development, mental retardation, hepatomegaly, and skeletal changes.
CATEGORY    Inherited metabolic disease
GENE        PEX1; peroxisomal biogenesis factor 1 [HSA:5189] [KO:K13338]
            PEX2; peroxisomal biogenesis factor 2 [HSA:5828] [KO:K06664]
            PEX26; peroxisomal biogenesis factor 26 [HSA:55670] [KO:K13340]
MARKER      Phytanic acid [CPD:C01607]
COMMENT     For Refsum disease, see H00075.
DBLINKS     ICD-10: G60.1
            MeSH: D052919
            OMIM: 266510
REFERENCE   PMID:17055079
  AUTHORS   Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW
  TITLE     Peroxisome biogenesis disorders.
  JOURNAL   Biochim Biophys Acta 1763:1733-48 (2006)
REFERENCE   PMID:15679822
  AUTHORS   Wanders RJ, Waterham HR
  TITLE     Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders.
  JOURNAL   Clin Genet 67:107-33 (2005)
REFERENCE   PMID:10904262
  AUTHORS   Gould SJ, Valle D
  TITLE     Peroxisome biogenesis disorders: genetics and cell biology.
  JOURNAL   Trends Genet 16:340-5 (2000)
REFERENCE   PMID:10528859
  AUTHORS   Shimozawa N, Imamura A, Zhang Z, Suzuki Y, Orii T, Tsukamoto T, Osumi T, Fujiki Y, Wanders RJ, Besley G, Kondo N
  TITLE     Defective PEX gene products correlate with the protein import, biochemical abnormalities, and phenotypic heterogeneity in peroxisome biogenesis disorders.
  JOURNAL   J Med Genet 36:779-81 (1999)
///
ENTRY       H00205                      Disease
NAME        Peroxisome biogenesis disorder, including:
            Zellweger syndrome (ZS) [DS:H01342];
            Adrenoleukodystrophy, neonatal (NALD) [DS:H00177];
            Infantile Refsum disease (IRD) [DS:H00204];
            Rhizomelic chondrodysplasia punctata (RCDP1) [DS:H00207]
DESCRIPTION Peroxisome biogenesis disorder (PBD) is a group of lethal disorders caused by mutation of peroxisomal biogenesis factor (PEX) genes. PBDs fall into 4 main phenotypic classes; Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), Infantile Refsum disease (IRD), and rhizomelic chondrodysplasia punctata (RCDP1). Zellweger syndrome is the most severe form and results in neurological dysfunction, craniofacial abnormalities, eye abnormalities, hepatomegaly, and chondrodysplasia punctata. The patients of NALD and IRD have similar symptoms, but they survive considerably longer than ZS. NALD is the intermediate form and IRD is the mildest form.
CATEGORY    Inherited metabolic disease; Nervous system disease; Liver disease; Peroxisomal disease
GENE        (PBD1A/1B) PEX1 [HSA:5189] [KO:K13338]
            (PBD2A/2B) PEX5 [HSA:5830] [KO:K13342]
            (PBD3A/3B) PEX12 [HSA:5193] [KO:K13345]
            (PBD4A/4B) PEX6 [HSA:5190] [KO:K13339]
            (PBD5A/5B) PEX2 [HSA:5828] [KO:K06664]
            (PBD6A/6B) PEX10 [HSA:5192] [KO:K13346]
            (PBD7A/7B) PEX26 [HSA:55670] [KO:K13340]
            (PBD8A/8B) PEX16 [HSA:9409] [KO:K13335]
            (PBD10A) PEX3 [HSA:8504] [KO:K13336]
            (PBD11A/11B) PEX13 [HSA:5194] [KO:K13344]
            (PBD12A) PEX19 [HSA:5824] [KO:K13337]
            (PBD13A) PEX14 [HSA:5195] [KO:K13343]
            (PBD9B) PEX7 [HSA:5191] [KO:K13341]
MARKER      increased VLCFA
            increased Phytanic acid [CPD:C01607] and Pristanic acid
DBLINKS     ICD-10: Q87.8
            MeSH: D018901
            OMIM: 214100 214110 614859 614862 614866 614870 614872 614876 614882 614883 614886 614887 601539 202370 266510 614863 614867 614871 614873 614877 614879 614885
REFERENCE   PMID:17055079
  AUTHORS   Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW
  TITLE     Peroxisome biogenesis disorders.
  JOURNAL   Biochim Biophys Acta 1763:1733-48 (2006)
REFERENCE   PMID:15868469
  AUTHORS   Faust PL, Banka D, Siriratsivawong R, Ng VG, Wikander TM
  TITLE     Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain.
  JOURNAL   J Inherit Metab Dis 28:369-83 (2005)
REFERENCE   PMID:15679822
  AUTHORS   Wanders RJ, Waterham HR
  TITLE     Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders.
  JOURNAL   Clin Genet 67:107-33 (2005)
REFERENCE   PMID:12169017
  AUTHORS   Brosius U, Gartner J
  TITLE     Cellular and molecular aspects of Zellweger syndrome and other peroxisome biogenesis disorders.
  JOURNAL   Cell Mol Life Sci 59:1058-69 (2002)
REFERENCE   PMID:10904262
  AUTHORS   Gould SJ, Valle D
  TITLE     Peroxisome biogenesis disorders: genetics and cell biology.
  JOURNAL   Trends Genet 16:340-5 (2000)
REFERENCE   PMID:17347916
  AUTHORS   Shimozawa N
  TITLE     Molecular and clinical aspects of peroxisomal diseases.
  JOURNAL   J Inherit Metab Dis 30:193-7 (2007)
///
ENTRY       H00206                      Disease
NAME        Mevalonate kinase deficiency;
            Hyperimmunoglobulinemia D;
            Mevalonic aciduria
DESCRIPTION Mevalonate kinase deficiency is an autosomal recessive disorder, which is identified as the cause of two inherited human autoinflammatory disorders: mevalonic aciduria (MVA) and hyperimmunoglobulinemia D syndrome (HIDS). Mevalonate kinase is located at the beginning of the cholesterol biosynthesis pathway compromising the biosynthesis of nonsterol isoprenes in addition to cholesterol. Patients of MVA show the symptoms, including dysmorphic features, cataracts, neurologic symptoms. The majority of patients with HIDS experience only recurrent febrile crises, without any neurologic abnormalities or dysmorphic features. Mevalonic kinase activity in HIDS patients is generally in the range of 5-15% of normal as compared to 0-4% in MVA.
CATEGORY    Inherited metabolic disease; Immune system disease
GENE        MVK; mevalonate kinase [HSA:4598] [KO:K00869]
MARKER      Mevalonic acid [CPD:C00418]
DRUG        Anakinra [DR:D02934] (HIDS)
            Simvastatin [DR:D00434] (HIDS)
DBLINKS     ICD-10: D89.2
            MeSH: D054078
            OMIM: 260920 610377
REFERENCE   PMID:17467679
  AUTHORS   Buhaescu I, Izzedine H
  TITLE     Mevalonate pathway: a review of clinical and therapeutical implications.
  JOURNAL   Clin Biochem 40:575-84 (2007)
REFERENCE   PMID:16835861
  AUTHORS   Mandey SH, Schneiders MS, Koster J, Waterham HR
  TITLE     Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency.
  JOURNAL   Hum Mutat 27:796-802 (2006)
REFERENCE   PMID:16722536
  AUTHORS   Haas D, Hoffmann GF
  TITLE     Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome.
  JOURNAL   Orphanet J Rare Dis 1:13 (2006)
REFERENCE   PMID:12861380
  AUTHORS   Houten SM, Frenkel J, Waterham HR
  TITLE     Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation.
  JOURNAL   Cell Mol Life Sci 60:1118-34 (2003)
REFERENCE   PMID:11111075
  AUTHORS   Houten SM, Wanders RJ, Waterham HR
  TITLE     Biochemical and genetic aspects of mevalonate kinase and its deficiency.
  JOURNAL   Biochim Biophys Acta 1529:19-32 (2000)
REFERENCE   PMID:11792727
  AUTHORS   Hogenboom S, Romeijn GJ, Houten SM, Baes M, Wanders RJ, Waterham HR
  TITLE     Absence of functional peroxisomes does not lead to deficiency of enzymes involved in cholesterol biosynthesis.
  JOURNAL   J Lipid Res 43:90-8 (2002)
REFERENCE   PMID:19768193 (HIDS)
  AUTHORS   Goldfinger S
  TITLE     The inherited autoinflammatory syndrome: a decade of discovery.
  JOURNAL   Trans Am Clin Climatol Assoc 120:413-8 (2009)
REFERENCE   PMID:17473510 (drug)
  AUTHORS   Naruto T
  TITLE     [MVK gene abnormality and new approach to treatment of hyper IgD syndrome and periodic fever syndrome]
  JOURNAL   Nihon Rinsho Meneki Gakkai Kaishi 30:86-9 (2007)
REFERENCE   PMID:20020131 (drug)
  AUTHORS   Shendi HM, Walsh D, Edgar JD
  TITLE     Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome.
  JOURNAL   Rheumatol Int (2009)
///
ENTRY       H00207                      Disease
NAME        Rhizomelic chondrodysplasia punctata, including:
            Rhizomelic chondrodysplasia punctata, type I (RCDP1);
            Rhizomelic chondrodysplasia punctata, type II (RCDP2);
            Rhizomelic chondrodysplasia punctata, type III (RCDP3)
DESCRIPTION Rhizomelic chondrodysplasia punctata (RCDP) is a lethal autosomal recessive disease associated with impaired peroxisomes characterized by proximal limb shortening, severely disturbed endochondrial bone formation, and mental retardation. RCDP1 is peroxisome biogenesis disorder caused by mutation of peroxisomal biogenesis factor 7(PEX7) genes. RCDP2 and RCDP3 are single peroxisomal enzyme deficiencies caused by mutation of GNPAT and AGPS. Both of them are key enzymes in the biosynthesis of ether phospholipids localized in peroxisomes.
CATEGORY    Inherited metabolic disease; Musculoskeletal disease; Peroxisomal disease
GENE        (RCDP1) PEX7; peroxisomal biogenesis factor 7 [HSA:5191] [KO:K13341]
            (RCDP2) GNPAT; glyceronephosphate O-acyltransferase [HSA:8443] [KO:K00649]
            (RCDP3) AGPS; alkyldihydroxyacetonephosphate synthase [HSA:8540] [KO:K00803]
MARKER      low plasmalogen levels
DBLINKS     ICD-10: Q77.3
            MeSH: D018902
            OMIM: 215100 222765 600121
REFERENCE   PMID:17055079
  AUTHORS   Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW
  TITLE     Peroxisome biogenesis disorders.
  JOURNAL   Biochim Biophys Acta 1763:1733-48 (2006)
REFERENCE   PMID:15679822
  AUTHORS   Wanders RJ, Waterham HR
  TITLE     Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders.
  JOURNAL   Clin Genet 67:107-33 (2005)
REFERENCE   PMID:11478383
  AUTHORS   Powers JM
  TITLE     Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders.
  JOURNAL   J Mol Neurosci 16:285-7; discussion 317-21 (2001)
REFERENCE   PMID:10904262
  AUTHORS   Gould SJ, Valle D
  TITLE     Peroxisome biogenesis disorders: genetics and cell biology.
  JOURNAL   Trends Genet 16:340-5 (2000)
REFERENCE   PMID:10553003
  AUTHORS   de Vet EC, Ijlst L, Oostheim W, Dekker C, Moser HW, van Den Bosch H, Wanders RJ
  TITLE     Ether lipid biosynthesis: alkyl-dihydroxyacetonephosphate synthase protein deficiency leads to reduced dihydroxyacetonephosphate acyltransferase activities.
  JOURNAL   J Lipid Res 40:1998-2003 (1999)
REFERENCE   PMID:10227689
  AUTHORS   Purdue PE, Skoneczny M, Yang X, Zhang JW, Lazarow PB
  TITLE     Rhizomelic chondrodysplasia punctata, a peroxisomal biogenesis disorder caused by defects in Pex7p, a peroxisomal protein import receptor: a minireview.
  JOURNAL   Neurochem Res 24:581-6 (1999)
///
ENTRY       H00208                      Disease
NAME        Hyperbilirubinemia, including:
            Crigler-Najjar syndrome, type I (CN1);
            Crigler-Najjar syndrome, type II (CN2);
            Gilbert Syndrome;
            Dubin-Johnson syndrome (DJS);
            Roter syndrome (RS)
DESCRIPTION Gilbert disease and Crigler-Najjar syndromes result in unconjugated hyperbilirubinemia caused by deficiency of bilirubin-UDP-glucuronosyltransferase which is involved in the detoxification of bilirubin by conjugation with glucuronic acid. Gilbert disease is a benign familial disorder characterized by low-grade chronic hyperbilirubinemia, while Crigler-Najjar syndromes are more severe by kernicterus and jaundice. Dubin-Johnson syndrome (DJS) is caused by mutations in ABCC2, a canalicular bilirubin glucuronide and xenobiotic export pump. Roter syndrome (RS) is caused by mutations in the SLCO1B1 and SLCO1B3 genes that encode organic anion transporters. In both DJS and RS, mild jaundice begins shortly after birth or in childhood. There are no signs of hemolysis, and routine hematologic and clinical-biochemistry test results are normal, aside from the primarily conjugated hyperbilirubinemia. The hepatocyte pigment deposits is typical of DJS. Total urinary excretion of coproporphyrins is greatly increased in RS.
CATEGORY    Inherited metabolic disease; Liver disease
GENE        UGT1A1; UDP glucuronosyltransferase [HSA:54658] [KO:K00699]
            (DJS) ABCC2 [HSA:1244] [KO:K05666]
            (RS) SLCO1B1 [HSA:10599] [KO:K05043]
            (RS) SLCO1B3 [HSA:28234] [KO:K05043]
MARKER      Bilirubin [CPD:C00486]
            Coproporphyrin [CPD:C05769]
DRUG        (CN2) Phenobarbital [DG:DG00845]
DBLINKS     ICD-10: E80.4 E80.5 E80.6
            MeSH: D006932
            OMIM: 218800 606785 143500 237900 237500 237450
REFERENCE   PMID:16386929
  AUTHORS   Costa E
  TITLE     Hematologically important mutations: bilirubin UDP-glucuronosyltransferase gene mutations in Gilbert and Crigler-Najjar syndromes.
  JOURNAL   Blood Cells Mol Dis 36:77-80 (2006)
REFERENCE   PMID:12480568
  AUTHORS   Bosma PJ
  TITLE     Inherited disorders of bilirubin metabolism.
  JOURNAL   J Hepatol 38:107-17 (2003)
REFERENCE   PMID:11013440
  AUTHORS   Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR
  TITLE     Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.
  JOURNAL   Hum Mutat 16:297-306 (2000)
REFERENCE   PMID:10091414
  AUTHORS   Sampietro M, Iolascon A
  TITLE     Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes.
  JOURNAL   Haematologica 84:150-7 (1999)
REFERENCE   PMID:12388192
  AUTHORS   Keitel V, Nies AT, Brom M, Hummel-Eisenbeiss J, Spring H, Keppler D
  TITLE     A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2).
  JOURNAL   Am J Physiol Gastrointest Liver Physiol 284:G165-74 (2003)
REFERENCE   PMID:22232210
  AUTHORS   van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticova E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH
  TITLE     Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
  JOURNAL   J Clin Invest 122:519-28 (2012)
///
ENTRY       H00209                      Disease
NAME        Menkes disease (MD);
            Menkes kinky hair syndrome
DESCRIPTION Menkes disease (MD) is an X-linked recessive disorder of copper deficiency caused by mutation of a copper-transporting P-type ATPase, resulting in dysfunction of copper-dependent enzymes.
CATEGORY    Inherited metabolic disease; Nervous system disease; Skin and connective tissue disease
GENE        ATP7A; Cu2+-exporting ATPase [HSA:538] [KO:K17686]
MARKER      Ceruloplasmin [HSA:1356]
            Copper [CPD:C00070]
DBLINKS     ICD-10: E83.0
            MeSH: D007706
            OMIM: 309400
REFERENCE   PMID:17989919
  AUTHORS   Bertini I, Rosato A
  TITLE     Menkes disease.
  JOURNAL   Cell Mol Life Sci 65:89-91 (2008)
REFERENCE   PMID:17717039
  AUTHORS   de Bie P, Muller P, Wijmenga C, Klomp LW
  TITLE     Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes.
  JOURNAL   J Med Genet 44:673-88 (2007)
REFERENCE   PMID:12539963
  AUTHORS   Voskoboinik I, Camakaris J
  TITLE     Menkes copper-translocating P-type ATPase (ATP7A): biochemical and cell biology properties, and role in Menkes disease.
  JOURNAL   J Bioenerg Biomembr 34:363-71 (2002)
///
ENTRY       H00210                      Disease
NAME        Wilson disease;
            Hepatolenticular degeneration
DESCRIPTION Wilson disease is an autosomal recessive disorder caused by mutation of a P-type ATPase important for copper excretion into bile, leading to copper accumulation in the liver. Toxic concentration of copper affects brain and kidney as well as liver.
CATEGORY    Inherited metabolic disease; Nervous system disease; Liver disease
GENE        ATP7B; Cu2+-exporting ATPase [HSA:540] [KO:K17686]
MARKER      Ceruloplasmin [HSA:1356]
DRUG        Penicillamine [DR:D00496]
            Galzin [DR:D06408]
DBLINKS     ICD-10: E83.0
            MeSH: D006527
            OMIM: 277900
REFERENCE   PMID:17717039
  AUTHORS   de Bie P, Muller P, Wijmenga C, Klomp LW
  TITLE     Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes.
  JOURNAL   J Med Genet 44:673-88 (2007)
REFERENCE   PMID:17382611
  AUTHORS   Medici V, Rossaro L, Sturniolo GC
  TITLE     Wilson disease--a practical approach to diagnosis, treatment and follow-up.
  JOURNAL   Dig Liver Dis 39:601-9 (2007)
REFERENCE   PMID:17276780
  AUTHORS   Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML
  TITLE     Wilson's disease.
  JOURNAL   Lancet 369:397-408 (2007)
REFERENCE   PMID:17272992
  AUTHORS   Durand F
  TITLE     Wilson's disease: an old disease keeps its old secrets.
  JOURNAL   Eur J Gastroenterol Hepatol 19:97-9 (2007)
///
ENTRY       H00211                      Disease
NAME        Hemochromatosis (HFE);
            Juvenile hemochromatosis (JH)
DESCRIPTION Hereditary hemochromatosis is an autosomal recessive iron metabolism disorder characterized by increased intestinal iron absorption, which leads to progressive accumulation of iron in the body.
CATEGORY    Inherited metabolic disease
GENE        (HFE) HFE [HSA:3077]
            (JH) HFE2 [HSA:148738] [KO:K06847]
            (JH) HAMP [HSA:57817]
            (HFE3) TFR2 [HSA:7036]
            (HFE4) SLC40A1 [HSA:30061] [KO:K14685]
            (HFE5) FTH1 [HSA:2495] [KO:K00522]
MARKER      Transferrin [HSA:7018]
DRUG        Deferoxamine mesilate [DR:D01186]
DBLINKS     ICD-10: E83.1
            MeSH: D006432
            OMIM: 235200 602390 613313 604250 606069 615517
REFERENCE   PMID:18061062
  AUTHORS   Adams PC, Barton JC.
  TITLE     Haemochromatosis.
  JOURNAL   Lancet 370:1855-60 (2007)
REFERENCE   PMID:16019461
  AUTHORS   Franchini M, Veneri D.
  TITLE     Hereditary hemochromatosis.
  JOURNAL   Hematology 10:145-9 (2005)
REFERENCE   PMID:15747119
  AUTHORS   Franchini M, Veneri D.
  TITLE     Recent advances in hereditary hemochromatosis.
  JOURNAL   Ann Hematol. 84:347-52 (2005)
REFERENCE   PMID:11389486 (gene)
  AUTHORS   Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, Kobune M, Takada K, Takimoto R, Hamada H, Ikeda T, Niitsu Y
  TITLE     A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal  dominant iron overload.
  JOURNAL   Am J Hum Genet 69:191-7 (2001)
///
ENTRY       H00212                      Disease
NAME        Acrodermatitis enteropathica (AEZ)
DESCRIPTION Acrodermatitis enteropathica is an autosomal recessive disorder of zinc deficiency caused by defects of a zinc transporter gene. The disorder is characterized by intermittent simultaneous occurrence of diarrhea and dermatitis with failure to thrive.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease; Gastrointestinal disease
GENE        SLC39A4 [HSA:55630] [KO:K14710]
DRUG        Zinc sulfate [DR:D06371]
DBLINKS     ICD-10: E83.2
            MeSH: C538178
            OMIM: 201100
REFERENCE   PMID:17190629
  AUTHORS   Maverakis E, Fung MA, Lynch PJ, Draznin M, Michael DJ, Ruben B, Fazel N
  TITLE     Acrodermatitis enteropathica and an overview of zinc metabolism.
  JOURNAL   J Am Acad Dermatol 56:116-24 (2007)
REFERENCE   PMID:11173209
  AUTHORS   Sehgal VN, Jain S
  TITLE     Acrodermatitis enteropathica.
  JOURNAL   Clin Dermatol 18:745-8 (2000)
///
ENTRY       H00213                      Disease
NAME        Hypophosphatasia
DESCRIPTION Hypophosphatasia is an autosomal recessive disorder caused by deficiency of alkaline phosphatase activity and characterized by defective bone and teeth mineralization.
CATEGORY    Inherited metabolic disease
GENE        ALPL; alkaline phosphatase [HSA:249] [KO:K01077]
MARKER      reduced serum ALP activity
DBLINKS     ICD-10: E83.3
            MeSH: D007014
            OMIM: 146300 241500 241510
REFERENCE   PMID:17916236
  AUTHORS   Mornet E
  TITLE     Hypophosphatasia.
  JOURNAL   Orphanet J Rare Dis 2:40 (2007)
REFERENCE   PMID:10737975 (description, gene, marker)
  AUTHORS   Mornet E
  TITLE     Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene.
  JOURNAL   Hum Mutat 15:309-15 (2000)
REFERENCE   PMID:18328985 (description, gene, marker)
  AUTHORS   Mornet E
  TITLE     Hypophosphatasia.
  JOURNAL   Best Pract Res Clin Rheumatol 22:113-27 (2008)
///
ENTRY       H00214                      Disease
NAME        Hypophosphatemic rickets, including:
            X-Linked dominant hypophosphatemia (XLH);
            X-Linked recessive hypophosphatemia (XLRH);
            Autosomal dominant hypophosphatemic rickets (ADHR);
            Autosomal recessive hypophosphatemic rickets (ARHR);
            Hereditary hypophophatemic rickets with hypercalciuria (HHRH)
DESCRIPTION Hypophosphataemic rickets, also known as vitamin D resistant rickets, is a group of genetic disorders characterized by defective reabsorption of inorganic phosphorus by the renal tubules resulting in hypophosphatemia and rickets associated with mineralization defect. Fibroblast growth factor-23 (FGF23) regulates phos- phate reabsorption in the kidney and therefore plays an essential role in phosphate balance in humans. There is a host of defects that ultimately lead to excess FGF23 levels and thereby cause renal phosphate wasting and hypophosphatemic rickets.
CATEGORY    Inherited metabolic disease; Connective tissue disease; Urologic disease
GENE        (XLH) PHEX [HSA:5251] [KO:K08636]
            (XLRH) CLCN5 [HSA:1184] [KO:K05012]
            (ADHR) FGF23 [HSA:8074] [KO:K04358]
            (ARHR1) DMP1 [HSA:1758]
            (ARHR2) ENPP1 [HSA:5167] [KO:K01513]
            (HHRH) SLC34A3 [HSA:142680] [KO:K14683]
MARKER      Hypophosphatemia
            Elevated FGF23 level
DRUG        Calcitriol [DR:D00129]
            Sodium phosphate [DR:D08815]
DBLINKS     ICD-10: E83.3
            MeSH: D063730 D053098
            OMIM: 307800 300554 193100 241520 613312 241530
REFERENCE   PMID:18214537
  AUTHORS   Pettifor JM
  TITLE     What's new in hypophosphataemic rickets?
  JOURNAL   Eur J Pediatr 167:493-9 (2008)
REFERENCE   PMID:17117305
  AUTHORS   de Menezes Filho H, de Castro LC, Damiani D
  TITLE     Hypophosphatemic rickets and osteomalacia.
  JOURNAL   Arq Bras Endocrinol Metabol 50:802-13 (2006)
REFERENCE   PMID:15470265
  AUTHORS   Rowe PS
  TITLE     The wrickkened pathways of FGF23, MEPE and PHEX.
  JOURNAL   Crit Rev Oral Biol Med 15:264-81 (2004)
REFERENCE   PMID:20137772
  AUTHORS   Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R
  TITLE     Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene.
  JOURNAL   Am J Hum Genet 86:273-8 (2010)
REFERENCE   PMID:25620749 (marker)
  AUTHORS   Goldsweig BK, Carpenter TO
  TITLE     Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
  JOURNAL   Curr Osteoporos Rep 13:88-97 (2015)
///
ENTRY       H00215                      Disease
NAME        Periodic paralysis, including: ;
            Hyperkalemic periodic paralysis (HyperPP) [DS:H00745];
            Hypokalemic periodic paralysis (HypoPP) [DS:H00746];
            Andersen-Tawil syndrome (ATS) [DS:H00748]
DESCRIPTION The periodic paralyses are characterized by episodic muscle weakness often related to potassium levels. They include hyperkalaemic periodic paralysis (HyperPP), hypokalaemic periodic paralysis (HypoPP) and Andersen-Tawil syndrome (ATS) caused by mutations in the calcium-channel, sodium-channel, and potassium-channel genes, respectively.
CATEGORY    Inherited metabolic disease; Nervous system disease; Muscular disease
GENE        (HyperPP HypoPP) SCN4A; voltage-gated sodium channel [HSA:6329] [KO:K04837]
            (HypoPP) CACNA1S; voltage-dependent calcium channel [HSA:779] [KO:K04857]
            (HypoPP) KCNE3; voltage-gated potassium channel [HSA:10008] [KO:K04897]
            (ATS) KCNJ2; potassium inwardly-rectifying channel [HSA:3759] [KO:K04996]
DRUG        Acetazolamide [DG:DG01134]
            Diclofenamide [DR:D00518]
DBLINKS     ICD-10: G72.3
            MeSH: D020513 D020514 D050030
            OMIM: 170500 170400 170390
REFERENCE   PMID:18254068
  AUTHORS   Sansone V, Meola G, Links TP, Panzeri M, Rose MR
  TITLE     Treatment for periodic paralysis.
  JOURNAL   Cochrane Database Syst Rev CD005045 (2008)
REFERENCE   PMID:18031562
  AUTHORS   Finsterer J
  TITLE     Primary periodic paralyses.
  JOURNAL   Acta Neurol Scand 117:145-58 (2008)
REFERENCE   PMID:16195244
  AUTHORS   Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, Tristani-Firouzi M, Tawil R, Griggs RC
  TITLE     The primary periodic paralyses: diagnosis, pathogenesis and treatment.
  JOURNAL   Brain 129:8-17 (2006)
REFERENCE   PMID:20634695
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
///
ENTRY       H00216                      Disease
NAME        Congenital adrenal hyperplasia (CAH)
DESCRIPTION Congenital adrenal hyperplasia is a group of monogenic autosomal recessive disorders due to an enzyme deficiency in steroid biosynthesis. All the adrenal hyperplasia syndromes are examples of mixed hypo- and hyperadrenocorticism.
CATEGORY    Inherited metabolic disease; Endocrine disease
GENE        (Type1) STAR; steroidogenic acute regulatory protein [HSA:6770] [KO:K16931]
            (Type1) CYP11A; cholesterol monooxygenase [HSA:1583] [KO:K00498]
            (Type2) HSD3B2; 3beta-hydroxy-delta5-steroid dehydrogenase / steroid delta-isomerase [HSA:3284] [KO:K00070]
            (Type3) CYP21A2; steroid 21-monooxygenase [HSA:1589] [KO:K00513]
            (Type4) CYP11B1; steroid 11beta-monooxygenase [HSA:1584] [KO:K00497]
            (Type5) CYP17A1; steroid 17alpha-monooxygenase [HSA:1586] [KO:K00512]
            POR; cytochrome p450 oxidoreductase [HSA:5447] [KO:K00327]
DRUG        Hydrocortisone [DG:DG00012]
            Dexamethasone [DG:DG00011]
            Prednisolone [DG:DG00093]
            Fludrocortisone [DG:DG00506]
DBLINKS     ICD-10: E25.0
            MeSH: D000312
            OMIM: 201710 201810 201910 202010 613571
REFERENCE   PMID:18844712
  AUTHORS   Demirci C, Witchel SF
  TITLE     Congenital adrenal hyperplasia.
  JOURNAL   Dermatol Ther 21:340-53 (2008)
REFERENCE   PMID:18574213
  AUTHORS   Lin-Su K, Nimkarn S, New MI
  TITLE     Congenital adrenal hyperplasia in adolescents: diagnosis and management.
  JOURNAL   Ann N Y Acad Sci 1135:95-8 (2008)
REFERENCE   PMID:15554890
  AUTHORS   Charmandari E, Brook CG, Hindmarsh PC
  TITLE     Classic congenital adrenal hyperplasia and puberty.
  JOURNAL   Eur J Endocrinol 151 Suppl 3:U77-82 (2004)
REFERENCE   PMID:12930931
  AUTHORS   Speiser PW, White PC
  TITLE     Congenital adrenal hyperplasia.
  JOURNAL   N Engl J Med 349:776-88 (2003)
REFERENCE   PMID:16906539
  AUTHORS   Williamson L, Arlt W, Shackleton C, Kelley RI, Braddock SR
  TITLE     Linking Antley-Bixler syndrome and congenital adrenal hyperplasia: a novel case of P450 oxidoreductase deficiency.
  JOURNAL   Am J Med Genet A 140A:1797-803 (2006)
///
ENTRY       H00217                      Disease
NAME        Pulmonary surfactant metabolism dysfunction (SMDP)
DESCRIPTION Pulmonary surfactant is required for the reduction of surface tension at the air-liquid interface in the alveoli of the lung. Pulmonary surfactant metabolism dysfunction (SMDP) is caused by one of the three different genes associated with surfactant metabolism in type II epithelial cells and characterized by respiratory distress after birth.
CATEGORY    Inherited metabolic disease; Respiratory disease
GENE        (SMDP1) SFTPB [HSA:6439]
            (SMDP2) SFTPC [HSA:6440]
            (SMDP3) ABCA3 [HSA:21] [KO:K05643]
DRUG        Surfacten [DR:D04289]
DBLINKS     ICD-10: P28.0
            MeSH: C580477
            OMIM: 265120 610913 610921
REFERENCE   PMID:17575475
  AUTHORS   Hamvas A, Cole FS, Nogee LM
  TITLE     Genetic disorders of surfactant proteins.
  JOURNAL   Neonatology 91:311-7 (2007)
REFERENCE   PMID:16798578
  AUTHORS   Whitsett JA
  TITLE     Genetic disorders of surfactant homeostasis.
  JOURNAL   Paediatr Respir Rev 7 Suppl 1:S240-2 (2006)
REFERENCE   PMID:15218289
  AUTHORS   Nogee LM
  TITLE     Genetic mechanisms of surfactant deficiency.
  JOURNAL   Biol Neonate 85:314-8 (2004)
///
ENTRY       H00218                      Disease
NAME        Cystic fibrosis (CF)
DESCRIPTION Cystic fibrosis (CF) is an autosomal recessive disorder of the exocrine glands caused by mutation of CFTR gene which encodes an ABC transporter for salt homeostasis. CF is a common lethal single-gene disorder in Caucasians with an incidence of 1 in 1500 to 1 in 6500, whereas it is rare among Orientals (1:90000). The common clinical features are chronic lung infections, respiratory distress, and pancreatic insufficiency.
CATEGORY    Inherited metabolic disease; Digestive disease; Respiratory disease
GENE        CFTR [HSA:1080] [KO:K05031]
DRUG        Mucolytics
            Antibiotics
            Antifungals
            Ursodeoxycholic acid [DR:D00734]
DBLINKS     ICD-10: E84
            MeSH: D003550
            OMIM: 219700
REFERENCE   PMID:18304008
  AUTHORS   Riordan JR
  TITLE     CFTR function and prospects for therapy.
  JOURNAL   Annu Rev Biochem 77:701-26 (2008)
REFERENCE   PMID:18193900
  AUTHORS   Cheung JC, Deber CM
  TITLE     Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
  JOURNAL   Biochemistry 47:1465-73 (2008)
REFERENCE   PMID:17573123
  AUTHORS   Amaral MD, Kunzelmann K
  TITLE     Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.
  JOURNAL   Trends Pharmacol Sci 28:334-41 (2007)
REFERENCE   PMID:16554808
  AUTHORS   Gadsby DC, Vergani P, Csanady L
  TITLE     The ABC protein turned chloride channel whose failure causes cystic fibrosis.
  JOURNAL   Nature 440:477-83 (2006)
///
ENTRY       H00219                      Disease
NAME        Hemophilia, including:
            Hemophilia A (HEMA);
            Hemophilia B (HEMB);
            von Willebrand disease (VWD);
            von Willebrand disease, platelet-type
DESCRIPTION Hemophilia A and B are X-linked recessive disorders which are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of blood coagulation factor VIII (FVIII) and factor IX (FIX), respectively. Von Willebrand disease is caused by quantitative and/or qualitative defects of von Willebrand factor and inherited in both autosomal dominant and recessive manner.
CATEGORY    Hematologic disease
GENE        (HEMA) F8; coagulation factor VIII [HSA:2157] [KO:K03899]
            (HEMB) F9; coagulation factor IX (Christmas factor) [HSA:2158] [KO:K01321]
            (VWD) VWF; von Willebrand factor [HSA:7450] [KO:K03900]
            (Platelet-type) GP1BA [HSA:2811] [KO:K06261]
DRUG        Blood-coagulation factor VIII [DR:D08798 D08793]
            Blood-coagulation factor IX [DR:D08797 D08794]
DBLINKS     ICD-10: D66 D67 D68.0
            OMIM: 306700 306900 193400 613554 277480 177820
REFERENCE   PMID:17178659
  AUTHORS   Franchini M
  TITLE     Advances in the diagnosis and management of von Willebrand disease.
  JOURNAL   Hematology 11:219-25 (2006)
REFERENCE   PMID:16684001
  AUTHORS   Peyvandi F, Jayandharan G, Chandy M, Srivastava A, Nakaya SM, Johnson MJ, Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM
  TITLE     Genetic diagnosis of haemophilia and other inherited bleeding disorders.
  JOURNAL   Haemophilia 12 Suppl 3:82-9 (2006)
REFERENCE   PMID:16470522
  AUTHORS   Haberichter SL, Shi Q, Montgomery RR
  TITLE     Regulated release of VWF and FVIII and the biologic implications.
  JOURNAL   Pediatr Blood Cancer 46:547-53 (2006)
REFERENCE   PMID:15205640
  AUTHORS   Lee JW
  TITLE     Von Willebrand disease, hemophilia A and B, and other factor deficiencies.
  JOURNAL   Int Anesthesiol Clin 42:59-76 (2004)
REFERENCE   PMID:756222
  AUTHORS   Marzullo A, Masci P, Rovacchi G, Toti G, Dompe G
  TITLE     [Gastric leiomyoblastoma]
  JOURNAL   Arch De Vecchi Anat Patol 62:279-90 (1977)
REFERENCE   PMID:21497427
  AUTHORS   Othman M
  TITLE     Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder.
  JOURNAL   Blood Rev 25:147-53 (2011)
///
ENTRY       H00220                      Disease
NAME        Factor V deficiency;
            Owren disease
DESCRIPTION Factor V deficiency is an autosomal recessive hemorrhagic disorder, which is identified as an inherited resistance to the anticoagulant function of activated protein C.
CATEGORY    Hematologic disease
GENE        F5; coagulation factor V (labile factor) [HSA:2153] [KO:K03902]
DBLINKS     ICD-10: D68.2
            OMIM: 227400
REFERENCE   PMID:16476093
  AUTHORS   Yamakage N, Ikejiri M, Okumura K, Takagi A, Murate T, Matushita T, Naoe T, Yamamoto K, Takamatsu J, Yamazaki T, Hamaguchi M, Kojima T
  TITLE     A case of coagulation factor V deficiency caused by compound heterozygous mutations in the factor V gene.
  JOURNAL   Haemophilia 12:172-8 (2006)
REFERENCE   PMID:9576178
  AUTHORS   Guasch JF, Cannegieter S, Reitsma PH, van't Veer-Korthof ET, Bertina RM
  TITLE     Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene.
  JOURNAL   Br J Haematol 101:32-9 (1998)
REFERENCE   PMID:7590506
  AUTHORS   De Stefano V, Leone G
  TITLE     Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
  JOURNAL   Haematologica 80:344-56 (1995)
///
ENTRY       H00221                      Disease
NAME        Combined deficiency of factors V and VIII (F5F8D)
DESCRIPTION Combined deficiency of factors V and VIII is caused by mutations in LMAN1 or MCFD2, which form a complex working as an cargo receptor for transport of coagulation factors V and VIII from ER to Golgi.
CATEGORY    Hematologic disease
GENE        LMAN1; mannose-binding lectin 1 [HSA:3998] [KO:K10080]
            MCFD2 [HSA:90411] [KO:K20364]
DRUG        Desmopressin [DG:DG00497]
            Coagulation factor VIII [DR:D08798]
DBLINKS     OMIM: 227300 613625
REFERENCE   PMID:19141160
  AUTHORS   Spreafico M, Peyvandi F
  TITLE     Combined FV and FVIII deficiency.
  JOURNAL   Haemophilia 14:1201-8 (2008)
REFERENCE   PMID:18391077
  AUTHORS   Zhang B, Spreafico M, Zheng C, Yang A, Platzer P, Callaghan MU, Avci Z, Ozbek N, Mahlangu J, Haw T, Kaufman RJ, Marchant K, Tuddenham EG, Seligsohn U, Peyvandi F, Ginsburg D
  TITLE     Genotype-phenotype correlation in combined deficiency of factor V and factor VIII.
  JOURNAL   Blood 111:5592-600 (2008)
REFERENCE   PMID:16304051
  AUTHORS   Zhang B, McGee B, Yamaoka JS, Guglielmone H, Downes KA, Minoldo S, Jarchum G, Peyvandi F, de Bosch NB, Ruiz-Saez A, Chatelain B, Olpinski M, Bockenstedt P, Sperl W, Kaufman RJ, Nichols WC, Tuddenham EG, Ginsburg D
  TITLE     Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2.
  JOURNAL   Blood 107:1903-7 (2006)
REFERENCE   PMID:12717434
  AUTHORS   Zhang B, Cunningham MA, Nichols WC, Bernat JA, Seligsohn U, Pipe SW, McVey JH, Schulte-Overberg U, de Bosch NB, Ruiz-Saez A, White GC, Tuddenham EG, Kaufman RJ, Ginsburg D
  TITLE     Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex.
  JOURNAL   Nat Genet 34:220-5 (2003)
///
ENTRY       H00222                      Disease
NAME        Afibrinogenemia;
            Dysfibrinogenemia
DESCRIPTION Congenital fibrinogen defects caused by mutation of any of fibrinogen genes (FGA, FGB, and FGG) include both quantitative defects (type I deficiencies or afibrinogenemia) and qualitative defects (type II deficiencies or dysfibrinogenemia). Fibrinogen deficiency and dysfunction are associated with bleeding or thrombosis.
CATEGORY    Hematologic disease
GENE        FGA; fibrinogen alpha chain [HSA:2243] [KO:K03903]
            FGB; fibrinogen beta chain [HSA:2244] [KO:K03904]
            FGG; fibrinogen gamma chain [HSA:2266] [KO:K03905]
DRUG        Fibrinogen [DG:DG00167]
DBLINKS     ICD-10: D68.2
            OMIM: 202400
REFERENCE   PMID:18564189
  AUTHORS   Hill M, Dolan G
  TITLE     Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias.
  JOURNAL   Haemophilia 14:889-97 (2008)
REFERENCE   PMID:16999847
  AUTHORS   Asselta R, Duga S, Tenchini ML
  TITLE     The molecular basis of quantitative fibrinogen disorders.
  JOURNAL   J Thromb Haemost 4:2115-29 (2006)
REFERENCE   PMID:16855369
  AUTHORS   Neerman-Arbez M
  TITLE     Molecular basis of fibrinogen deficiency.
  JOURNAL   Pathophysiol Haemost Thromb 35:187-98 (2006)
///
ENTRY       H00223                      Disease
NAME        Inherited thrombophilia
DESCRIPTION Congenital thrombophilias are inherited disorders associated with an increased tendency to venous thromboembolism caused by mutation of genes affecting the anticoagulant pathways of blood coagulation.
CATEGORY    Hematologic disease
GENE        SERPINC1; antithrombin III [HSA:462] [KO:K03911]
            PROC; protein C [HSA:5624] [KO:K01344]
            PROS1; protein S [HSA:5627] [KO:K03908]
            F2; coagulation factor II (thrombin) [HSA:2147] [KO:K01313]
            F5; coagulation factor V (labile factor) [HSA:2153] [KO:K03902]
            HRG; histidine-rich glycoprotein [HSA:3273]
            PLG; plasminogen [HSA:5340] [KO:K01315]
            SERPINE1; plasminogen activator inhibitor 1 [HSA:5054] [KO:K03982]
            FGA; fibrinogen alpha chain [HSA:2243] [KO:K03903]
            FGB; fibrinogen beta chain [HSA:2244] [KO:K03904]
            FGG; fibrinogen gamma chain [HSA:2266] [KO:K03905]
            SERPIND1; heparin cofactor II [HSA:3053] [KO:K03912]
            THBD; thrombomodulin [HSA:7056] [KO:K03907]
            F9; coagulation factor IX [HSA:2158] [KO:K01321]
DRUG        Warfarin [DG:DG00149]
            Heparin [DG:DG00150 DG00151 DG00152 DG00153]
DBLINKS     ICD-10: D68.2
            OMIM: 188050 188055 612336 107300 176860 188040 176860 612304 612356 300807 613116
REFERENCE   PMID:18574041
  AUTHORS   Dahlback B
  TITLE     Advances in understanding pathogenic mechanisms of thrombophilic disorders.
  JOURNAL   Blood 112:19-27 (2008)
REFERENCE   PMID:17024597
  AUTHORS   Simioni P, Tormene D, Spiezia L, Tognin G, Rossetto V, Radu C, Prandoni P
  TITLE     Inherited thrombophilia and venous thromboembolism.
  JOURNAL   Semin Thromb Hemost 32:700-8 (2006)
REFERENCE   PMID:16962914
  AUTHORS   Coppens M, Kaandorp SP, Middeldorp S
  TITLE     Inherited thrombophilias.
  JOURNAL   Obstet Gynecol Clin North Am 33:357-74 (2006)
REFERENCE   PMID:15331254
  AUTHORS   Feero WG
  TITLE     Genetic thrombophilia.
  JOURNAL   Prim Care 31:685-709, xi (2004)
REFERENCE   PMID:12787534
  AUTHORS   Buchanan GS, Rodgers GM, Ware Branch D
  TITLE     The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation.
  JOURNAL   Best Pract Res Clin Obstet Gynaecol 17:397-411 (2003)
REFERENCE   PMID:19846852
  AUTHORS   Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, Finn JD, Spiezia L, Radu C, Arruda VR
  TITLE     X-linked thrombophilia with a mutant factor IX (factor IX Padua).
  JOURNAL   N Engl J Med 361:1671-5 (2009)
///
ENTRY       H00224                      Disease
NAME        Bernard-Soulier syndrome;
            Giant platelet syndrome
DESCRIPTION Bernard-Soulier syndrome is a bleeding disorder caused by a defect in or deficiency of the platelet membrane von Willebrand factor receptor which is composed of 4 proteins, GP1BA, GP1BB, GP9 and GP5. The clinical feature is characterized by variable thrombocytopenia and large defective platelets.
CATEGORY    Hematologic disease
GENE        GP1BA [HSA:2811] [KO:K06261]
            GP1BB [HSA:2812] [KO:K06262]
            GP9 [HSA:2815] [KO:K06263]
DBLINKS     ICD-10: D69.1
            OMIM: 153670 231200
REFERENCE   PMID:18081445
  AUTHORS   Pham A, Wang J
  TITLE     Bernard-Soulier syndrome: an inherited platelet disorder.
  JOURNAL   Arch Pathol Lab Med 131:1834-6 (2007)
REFERENCE   PMID:17109744
  AUTHORS   Lanza F
  TITLE     Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
  JOURNAL   Orphanet J Rare Dis 1:46 (2006)
///
ENTRY       H00225                      Disease
NAME        Thrombotic thrombocytopenic purpura;
            Moschcowitz disease;
            Schulman-Upshaw syndrome
DESCRIPTION Thrombotic thrombocytopenic purpura is caused by mutation in the ADAMTS13 gene and characterized by microangiopathic hemolytic anemia and thrombocytopenia. The idiopathic forms were found to have acquired autoantibody inhibitors of the ADAMTS13 metalloprotease.
CATEGORY    Hematologic disease; Cardiovascular disease; Immune system disease
GENE        ADAMTS13 [HSA:11093] [KO:K08627]
DBLINKS     ICD-10: D69.2
            OMIM: 274150
REFERENCE   PMID:18574040
  AUTHORS   Sadler JE
  TITLE     Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
  JOURNAL   Blood 112:11-8 (2008)
REFERENCE   PMID:17666281
  AUTHORS   Tsai HM
  TITLE     Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.
  JOURNAL   Hematol Oncol Clin North Am 21:609-32, v (2007)
REFERENCE   PMID:17124092
  AUTHORS   Sadler JE
  TITLE     Thrombotic thrombocytopenic purpura: a moving target.
  JOURNAL   Hematology Am Soc Hematol Educ Program 415-20 (2006)
///
ENTRY       H00226                      Disease
NAME        Glanzmann thrombasthenia
DESCRIPTION Glanzmann thrombasthenia is a rare autosomal recessive bleeding syndrome affecting the megakaryocyte lineage and characterized by lack of platelet aggregation. This disease is caused by mutation in the integrin family receptor genes encoding platelet glycoprotein alpha-IIb or platelet glycoprotein IIIa.
CATEGORY    Hematologic disease
GENE        ITGA2B [HSA:3674] [KO:K06476]
            ITGB3 [HSA:3690] [KO:K06493]
DRUG        Coagulation factor VIIa [DR:D00172]
DBLINKS     ICD-10: D69.1
            OMIM: 273800 273800
REFERENCE   PMID:16722529
  AUTHORS   Nurden AT
  TITLE     Glanzmann thrombasthenia.
  JOURNAL   Orphanet J Rare Dis 1:10 (2006)
REFERENCE   PMID:16427383
  AUTHORS   Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y
  TITLE     Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
  JOURNAL   Semin Hematol 43:S33-6 (2006)
REFERENCE   PMID:12487785
  AUTHORS   Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D
  TITLE     Glanzmann's thrombasthenia: updated.
  JOURNAL   Platelets 13:387-93 (2002)
///
ENTRY       H00227                      Disease
NAME        Congenital amegakaryocytic thrombocytopenia (CAMT)
DESCRIPTION Congenital amegakaryocytic thrombocytopenia (CAMT) is an autosomal recessive bone marrow failure syndrome, characterized by thrombocytopenia due to defective megakaryocytopoiesis. The disorder is induced by defective expression or function of the thrombopoietin (THPO) receptor caused by mutations in the MPL gene.
CATEGORY    Hematologic disease
GENE        MPL [HSA:4352] [KO:K05082]
MARKER      THPO [HSA:7066]
DBLINKS     ICD-10: D69.4
            OMIM: 604498
REFERENCE   PMID:19388932
  AUTHORS   Ballmaier M, Germeshausen M
  TITLE     Advances in the understanding of congenital amegakaryocytic thrombocytopenia.
  JOURNAL   Br J Haematol 146:3-16 (2009)
REFERENCE   PMID:19327586
  AUTHORS   Geddis AE
  TITLE     Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.
  JOURNAL   Hematol Oncol Clin North Am 23:321-31 (2009)
REFERENCE   PMID:17666371
  AUTHORS   Savoia A, Dufour C, Locatelli F, Noris P, Ambaglio C, Rosti V, Zecca M, Ferrari S, di Bari F, Corcione A, Di Stazio M, Seri M, Balduini CL
  TITLE     Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations.
  JOURNAL   Haematologica 92:1186-93 (2007)
REFERENCE   PMID:16822462
  AUTHORS   Geddis AE
  TITLE     Inherited thrombocytopenia: Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.
  JOURNAL   Semin Hematol 43:196-203 (2006)
///
ENTRY       H00228                      Disease
NAME        Thalassemia;
            Alpha thalassemia;
            Beta thalassemia;
            Alpha thalassemia, X-linked (ATRX)
DESCRIPTION Thalassemia is the most common hereditary blood disease caused by mutation of genes encoding hemoglobin alpha and beta chains. The anemia that is associated with thalassemia is caused by ineffective erythropoiesis which results from apoptosis of erythroid precursors or hemolysis due to the chain imbalances.
CATEGORY    Hematologic disease
GENE        (Alpha) HBA1 [HSA:3039] [KO:K13822]
            (Alpha) HBA2 [HSA:3040] [KO:K13822]
            (Beta) HBB [HSA:3043] [KO:K13823]
            (Beta) HBG1 [HSA:3047] [KO:K13824]
            (Beta) HBG2 [HSA:3048] [KO:K13824]
            (ATRX) ATRX [HSA:546] [KO:K10779]
DRUG        Deferoxamine [DR:D03670]
            Deferasirox [DR:D03669]
            Deferiprone [DR:D07416]
COMMENT     The X-linked mental retardation-hypotonic facies syndrome is also caused by mutation in the ATRX gene.
            See also H01752 ATR-X syndrome.
DBLINKS     ICD-10: D56.0 D56.1 D56.2 D56.4
            OMIM: 141750 604131 603902 141800 141900 300448 301040 309580 141749
REFERENCE   PMID:18406222
  AUTHORS   Leung WC, Leung KY, Lau ET, Tang MH, Chan V
  TITLE     Alpha-thalassaemia.
  JOURNAL   Semin Fetal Neonatal Med 13:215-22 (2008)
REFERENCE   PMID:16162884
  AUTHORS   Rund D, Rachmilewitz E
  TITLE     Beta-thalassemia.
  JOURNAL   N Engl J Med 353:1135-46 (2005)
REFERENCE   PMID:15660507
  AUTHORS   Schrier SL, Angelucci E
  TITLE     New strategies in the treatment of the thalassemias.
  JOURNAL   Annu Rev Med 56:157-71 (2005)
REFERENCE   PMID:15561674
  AUTHORS   Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E
  TITLE     Thalassemia.
  JOURNAL   Hematology Am Soc Hematol Educ Program 14-34 (2004)
REFERENCE   PMID:20439494
  AUTHORS   Miccio A, Blobel GA
  TITLE     Role of the GATA-1/FOG-1/NuRD pathway in the expression of human beta-like globin genes.
  JOURNAL   Mol Cell Biol 30:3460-70 (2010)
///
ENTRY       H00229                      Disease
NAME        Sickle cell anemia (SCA)
DESCRIPTION Sickle cell anaemia is a recessive genetic disease caused by a single-point mutation in the beta globin gene in codon 6 (Glu6Val) that specifies one of the chains of haemoglobin. The disease is characterized by a chronic haemolytic anaemia with the sickle cells which show abnormal morphology due to the damage of the membrane skeletons and agglutinate under deoxygenated conditions.
CATEGORY    Hematologic disease
GENE        HBB [HSA:3043] [KO:K13823]
DRUG        Hydroxyurea [DR:D00341]
DBLINKS     ICD-10: D57
            OMIM: 603903
REFERENCE   PMID:16530854
  AUTHORS   Steinberg MH
  TITLE     Pathophysiologically based drug treatment of sickle cell disease.
  JOURNAL   Trends Pharmacol Sci 27:204-10 (2006)
REFERENCE   PMID:15020275
  AUTHORS   De Franceschi L, Corrocher R
  TITLE     Established and experimental treatments for sickle cell disease.
  JOURNAL   Haematologica 89:348-56 (2004)
REFERENCE   PMID:10068648
  AUTHORS   Bunn HF
  TITLE     Induction of fetal hemoglobin in sickle cell disease.
  JOURNAL   Blood 93:1787-9 (1999)
REFERENCE   PMID:9287233
  AUTHORS   Bunn HF
  TITLE     Pathogenesis and treatment of sickle cell disease.
  JOURNAL   N Engl J Med 337:762-9 (1997)
///
ENTRY       H00230                      Disease
NAME        Hereditary spherocytosis (SPH)
DESCRIPTION Hereditary spherocytosis is a heterogeneous group of disorders characterized by rounded red cells and chronic hemolysis.
CATEGORY    Hematologic disease
GENE        (SPH1) ANK1 [HSA:286] [KO:K10380]
            (SPH2) SPTB [HSA:6710] [KO:K06115]
            (SPH3) SPTA1 [HSA:6708] [KO:K06114]
            (SPH4) SLC4A1 [HSA:6521] [KO:K06573]
            (SPH5) EPB42 [HSA:2038]
DRUG        Folic acid [DG:DG00176]
DBLINKS     ICD-10: D58.0
            OMIM: 182900 182870 270970 109270 612690
REFERENCE   PMID:15287938
  AUTHORS   Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ
  TITLE     Guidelines for the diagnosis and management of hereditary spherocytosis.
  JOURNAL   Br J Haematol 126:455-74 (2004)
REFERENCE   PMID:15121908
  AUTHORS   Shah S, Vega R
  TITLE     Hereditary spherocytosis.
  JOURNAL   Pediatr Rev 25:168-72 (2004)
REFERENCE   PMID:15071790
  AUTHORS   Eber S, Lux SE
  TITLE     Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer.
  JOURNAL   Semin Hematol 41:118-41 (2004)
///
ENTRY       H00231                      Disease
NAME        Hereditary elliptocytosis (HE)
DESCRIPTION Elliptocytosis is an autosomal dominant hematologic disorder characterized by elliptically shaped erythrocytes and a variable degree of hemolytic anemia caused by fragility of the erythrocyte membrane skeleton due to defects in alpha-spectrin, beta-spectrin, or protein 4.1.
CATEGORY    Hematologic disease
GENE        (HE1) EPB41 [HSA:2035] [KO:K06107]
            (HE2) SPTA1 [HSA:6708] [KO:K06114]
            (HE3) SPTB [HSA:6710] [KO:K06115]
            (HE4) SLC4A1 [HSA:6521] [KO:K06573]
DBLINKS     ICD-10: D58.1
            OMIM: 611804 130600 182870 166900
REFERENCE   PMID:18341630
  AUTHORS   An X, Mohandas N
  TITLE     Disorders of red cell membrane.
  JOURNAL   Br J Haematol 141:367-75 (2008)
REFERENCE   PMID:16730867
  AUTHORS   Delaunay J
  TITLE     The molecular basis of hereditary red cell membrane disorders.
  JOURNAL   Blood Rev 21:1-20 (2007)
REFERENCE   PMID:15071791
  AUTHORS   Gallagher PG
  TITLE     Hereditary elliptocytosis: spectrin and protein 4.1R.
  JOURNAL   Semin Hematol 41:142-64 (2004)
///
ENTRY       H00232                      Disease
NAME        Hereditary stomatocytosis (HSt), including:
            Dehydrated hereditary stomatocytosis (DHS);
            Overhydrated hereditary stomatocytosis (OHS);
            Familial pseudohyperkalemia (FP);
            Cryohydrocytosis (CHC)
DESCRIPTION Hereditary stomatocytosis describes a group of hemolytic anemias with mouth-shaped red blood cells which fail to transport monovalent cations, such as sodium and potassium.
CATEGORY    Hematologic disease
GENE        (OHS) RHAG [HSA:6005] [KO:K06580]
            (DHS1) PIEZO1 [HSA:9780]
            (DHS2) KCNN4 [HSA:3783] [KO:K04945]
            (FP) ABCB6 [HSA:10058] [KO:K05661]
            (CHC) SLC4A1 [HSA:6521] [KO:K06573]
DBLINKS     ICD-10: D58.8
            OMIM: 185000 194380 616689 609153 185020
REFERENCE   PMID:19261491
  AUTHORS   Bruce LJ
  TITLE     Hereditary stomatocytosis and cation leaky red cells--recent developments.
  JOURNAL   Blood Cells Mol Dis 42:216-22 (2009)
REFERENCE   PMID:15071792
  AUTHORS   Delaunay J
  TITLE     The hereditary stomatocytoses: genetic disorders of the red cell membrane permeability to monovalent cations.
  JOURNAL   Semin Hematol 41:165-72 (2004)
REFERENCE   PMID:10088641
  AUTHORS   Delaunay J, Stewart G, Iolascon A
  TITLE     Hereditary dehydrated and overhydrated stomatocytosis: recent advances.
  JOURNAL   Curr Opin Hematol 6:110-4 (1999)
REFERENCE   PMID:27756835
  AUTHORS   Andolfo I, Russo R, Gambale A, Iolascon A
  TITLE     New insights on hereditary erythrocyte membrane defects.
  JOURNAL   Haematologica 101:1284-1294 (2016)
///
ENTRY       H00233                      Disease
NAME        MYH9-related disease, including:
            May-Hegglin anomaly;
            Sebastian syndrome;
            Fechtner syndrome;
            Epstein syndrome
DESCRIPTION The autosomal dominant disorders, which are caused by mutation of gene encoding nonmuscle myosin heavy chain 9, May-Hegglin anomaly , Fechtner syndrome(FTNS), and Sebastian syndrome , share the triad of thrombocytopenia, large platelets and characteristic leukocyte inclusions (Dohle-like bodies). Epstein syndrome is clinically identical to FTNS, except Dohle-like bodies have not been described.
CATEGORY    Hematologic disease
GENE        MYH9 [HSA:4627] [KO:K10352]
DRUG        Activated factor VII [DR:D00172]
COMMENT     See also H00578 Epstein syndrome.
DBLINKS     ICD-10: D72.0
            MeSH: C535507
            OMIM: 155100 605249 153640 600208
REFERENCE   PMID:19408192
  AUTHORS   Althaus K, Greinacher A
  TITLE     MYH9-related platelet disorders.
  JOURNAL   Semin Thromb Hemost 35:189-203 (2009)
REFERENCE   PMID:17655694
  AUTHORS   Selleng K, Lubenow LE, Greinacher A, Warkentin TE
  TITLE     Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome).
  JOURNAL   Eur J Haematol 79:263-8 (2007)
REFERENCE   PMID:16162639
  AUTHORS   Pecci A, Canobbio I, Balduini A, Stefanini L, Cisterna B, Marseglia C, Noris P, Savoia A, Balduini CL, Torti M
  TITLE     Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
  JOURNAL   Hum Mol Genet 14:3169-78 (2005)
REFERENCE   PMID:16098078
  AUTHORS   Dong F, Li S, Pujol-Moix N, Luban NL, Shin SW, Seo JH, Ruiz-Saez A, Demeter J, Langdon S, Kelley MJ
  TITLE     Genotype-phenotype correlation in MYH9-related thrombocytopenia.
  JOURNAL   Br J Haematol 130:620-7 (2005)
REFERENCE   PMID:12161364
  AUTHORS   Balduini CL, Iolascon A, Savoia A
  TITLE     Inherited thrombocytopenias: from genes to therapy.
  JOURNAL   Haematologica 87:860-80 (2002)
REFERENCE   PMID:10973259
  AUTHORS   Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA
  TITLE     Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.
  JOURNAL   Nat Genet 26:103-5 (2000)
REFERENCE   PMID:1449176
  AUTHORS   Brodie HA, Chole RA, Griffin GC, White JG
  TITLE     Macrothrombocytopenia and progressive deafness: a new genetic syndrome.
  JOURNAL   Am J Otol 13:507-11 (1992)
///
ENTRY       H00234                      Disease
NAME        Pelger-Huet anomaly
DESCRIPTION Pelger-Huet anomaly is an autosomal dominant disorder characterized by abnormal nuclear shape and chromatin organization in blood granulocytes with skeletal abnormalities.
CATEGORY    Hematologic disease
GENE        LBR [HSA:3930] [KO:K19532]
DBLINKS     ICD-10: D72.0
            OMIM: 169400
REFERENCE   PMID:17467691
  AUTHORS   Worman HJ, Bonne G
  TITLE     "Laminopathies": a wide spectrum of human diseases.
  JOURNAL   Exp Cell Res 313:2121-33 (2007)
REFERENCE   PMID:17245605
  AUTHORS   Hoffmann K, Sperling K, Olins AL, Olins DE
  TITLE     The granulocyte nucleus and lamin B receptor: avoiding the ovoid.
  JOURNAL   Chromosoma 116:227-35 (2007)
REFERENCE   PMID:14684694
  AUTHORS   Oosterwijk JC, Mansour S, van Noort G, Waterham HR, Hall CM, Hennekam RC
  TITLE     Congenital abnormalities reported in Pelger-Huet homozygosity as compared to Greenberg/HEM dysplasia: highly variable expression of allelic phenotypes.
  JOURNAL   J Med Genet 40:937-41 (2003)
///
ENTRY       H00235                      Disease
NAME        Methemoglobinemia
DESCRIPTION Hereditary methemoglobinemia is an autosomal recessive disorder characterized by NADH-cytochrome b5 reductase deficiency.
CATEGORY    Hematologic disease
GENE        CYB5R3 [HSA:1727] [KO:K00326]
            CYB5A [HSA:1528]
DBLINKS     ICD-10: D74.0
            OMIM: 250800 250790
REFERENCE   PMID:18318771
  AUTHORS   Percy MJ, Lappin TR
  TITLE     Recessive congenital methaemoglobinaemia: cytochrome b(5) reductase deficiency.
  JOURNAL   Br J Haematol 141:298-308 (2008)
REFERENCE   PMID:18202104
  AUTHORS   Ewenczyk C, Leroux A, Roubergue A, Laugel V, Afenjar A, Saudubray JM, Beauvais P, Billette de Villemeur T, Vidailhet M, Roze E
  TITLE     Recessive hereditary methaemoglobinaemia, type II: delineation of the clinical spectrum.
  JOURNAL   Brain 131:760-1 (2008)
REFERENCE   PMID:2107882
  AUTHORS   Kobayashi Y, Fukumaki Y, Yubisui T, Inoue J, Sakaki Y
  TITLE     Serine-proline replacement at residue 127 of NADH-cytochrome b5 reductase causes hereditary methemoglobinemia, generalized type.
  JOURNAL   Blood 75:1408-13 (1990)
REFERENCE   PMID:8168836
  AUTHORS   Giordano SJ, Kaftory A, Steggles AW
  TITLE     A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism.
  JOURNAL   Hum Genet 93:568-70 (1994)
///
ENTRY       H00236                      Disease
NAME        Congenital polycythemia;
            Familial erythrocytosis (ECYT)
DESCRIPTION Familial and congenital polycythemia/erythrocytosis includes a heterogeneous group of disorders with the common characteristic of an absolute increased red cell mass caused by inherited defects in hypoxia sensing. In primary polycythemias there is an innate defect in the hematopoietic progenitors which allows constitutive overproduction whereas in secondary polycythemias normal progenitors are acted on by serum erythropoietin.
CATEGORY    Hematologic disease
GENE        (ECYT1) EPOR [HSA:2057] [KO:K05079]
            (ECYT2) VHL [HSA:7428] [KO:K03871]
            (ECYT3) EGLN1 [HSA:54583] [KO:K09592]
            (ECYT4) EPAS1 [HSA:2034] [KO:K09095]
DBLINKS     ICD-10: D75.0
            OMIM: 133100 263400 609820 611783
REFERENCE   PMID:18538455
  AUTHORS   Lee FS
  TITLE     Genetic causes of erythrocytosis and the oxygen-sensing pathway.
  JOURNAL   Blood Rev 22:321-32 (2008)
REFERENCE   PMID:17454194
  AUTHORS   Percy MJ
  TITLE     Genetically heterogeneous origins of idiopathic erythrocytosis.
  JOURNAL   Hematology 12:131-9 (2007)
REFERENCE   PMID:15642677
  AUTHORS   Gordeuk VR, Stockton DW, Prchal JT
  TITLE     Congenital polycythemias/erythrocytoses.
  JOURNAL   Haematologica 90:109-16 (2005)
///
ENTRY       H00237                      Disease
NAME        Diamond-Blackfan anemia (DBA)
DESCRIPTION Diamond-Blackfan anemia (DBA) is a genetically and clinically heterogeneous congenital erythroid aplasia that develops within the first year of life. Faulty ribosome biogenesis is hypothesized to be the underlying defect, leading to erythroid failure due to accelerated apoptosis in affected erythroid progenitors/precursors.
CATEGORY    Hematologic disease
GENE        (DBA) RPS19 [HSA:6223] [KO:K02966]
            (DBA3) RPS24 [HSA:6229] [KO:K02974]
            (DBA4) RPS17 [HSA:6218] [KO:K02962]
            (DBA5) RPL35A [HSA:6165] [KO:K02917]
            (DBA6) RPL5 [HSA:6125] [KO:K02932]
            (DBA7) RPL11 [HSA:6135] [KO:K02868]
            (DBA8) RPS7 [HSA:6201] [KO:K02993]
            (DBA9) RPS10 [HSA:6204] [KO:K02947]
            (DBA10) RPS26 [HSA:6231] [KO:K02976]
DBLINKS     ICD-10: D61.0
            MeSH: D029503
            OMIM: 105650 610629 612527 612528 612561 612562 612563 613308 613309
REFERENCE   PMID:18671700
  AUTHORS   Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, Meerpohl J, Karlsson S, Liu JM, Leblanc T, Paley C, Kang EM, Leder EJ, Atsidaftos E, Shimamura A, Bessler M, Glader B, Lipton JM
  TITLE     Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.
  JOURNAL   Br J Haematol 142:859-76 (2008)
REFERENCE   PMID:17164339
  AUTHORS   Flygare J, Karlsson S
  TITLE     Diamond-Blackfan anemia: erythropoiesis lost in translation.
  JOURNAL   Blood 109:3152-4 (2007)
REFERENCE   PMID:16942586
  AUTHORS   Gazda HT, Sieff CA
  TITLE     Recent insights into the pathogenesis of Diamond-Blackfan anaemia.
  JOURNAL   Br J Haematol 135:149-57 (2006)
///
ENTRY       H00238                      Disease
NAME        Fanconi anemia
DESCRIPTION Fanconi anemia (FA), a recessive syndrome with both autosomal and X-linked inheritance, features diverse clinical symptoms, such as progressive bone marrow failures, chromosomal instability and susceptibility to cancer. To date, 13 FA gene products have been identified, which cooperate in a common DNA damage-activated signaling pathway regulating DNA repair (the FA pathway).
CATEGORY    Hematologic disease
GENE        FANCA [HSA:2175] [KO:K10888]
            FANCB [HSA:2187] [KO:K10889]
            FANCC [HSA:2176] [KO:K10890]
            BRCA2 [HSA:675] [KO:K08775]
            FANCD2 [HSA:2177] [KO:K10891]
            FANCE [HSA:2178] [KO:K10892]
            FANCF [HSA:2188] [KO:K10893]
            FANCG [HSA:2189] [KO:K10894]
            FANCI [HSA:55215] [KO:K10895]
            BRIP1 [HSA:83990] [KO:K15362]
            FANCL [HSA:55120] [KO:K10606]
            FANCM [HSA:57697] [KO:K10896]
            FANCN [HSA:79728] [KO:K10897]
            RAD51C [HSA:5889] [KO:K10870]
DBLINKS     ICD-10: D61.0
            OMIM: 227650 300514 227645 605724 227646 600901 603467 609053 609054 608111 609644 610832 614082 613390
REFERENCE   PMID:18995829
  AUTHORS   Cohn MA, D'Andrea AD
  TITLE     Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways.
  JOURNAL   Mol Cell 32:306-12 (2008)
REFERENCE   PMID:18047734
  AUTHORS   Jacquemont C, Taniguchi T
  TITLE     The Fanconi anemia pathway and ubiquitin.
  JOURNAL   BMC Biochem 8 Suppl 1:S10 (2007)
REFERENCE   PMID:19101576
  AUTHORS   Rego MA, Kolling FW 4th, Howlett NG
  TITLE     The Fanconi anemia protein interaction network: casting a wide net.
  JOURNAL   Mutat Res 668:27-41 (2009)
REFERENCE   PMID:16493006
  AUTHORS   Taniguchi T, D'Andrea AD
  TITLE     Molecular pathogenesis of Fanconi anemia: recent progress.
  JOURNAL   Blood 107:4223-33 (2006)
///
ENTRY       H00239                      Disease
NAME        Bartter syndrome
DESCRIPTION Bartter syndrome(BS) is a heterogeneous rare disease unified by autosomal recessive transmission. BS is characterized by impaired salt reabsorption in the thick ascending loop of Henle with elevated aldosterone excretion resulting in salt wasting, hypokalemic metabolic alkalosis, and hypercalciuria. Type 1 and 2 are the neonatal type but genetically, clinically, and biochemically different. Type 4A shows Bartter syndrome with sensorineural deafness. Type 3 is classic Bartter syndrome. Type 5 is characterized by hypocalcemic hypercalciuria with parathyroid hormone suppression.
CATEGORY    Endocrine disease; Urinary system disease
GENE        (Type 1) SLC12A1 [HSA:6557] [KO:K14425]
            (Type 2) KCNJ1 [HSA:3758] [KO:K04995]
            (Type 3) CLCNKB [HSA:1188] [KO:K05018]
            (Type 4A) BSND [HSA:7809] [KO:K19331]
            (Type 4B) CLCNKA,CLCNKB (double mutation) [HSA:1187 1188] [KO:K05017 K05018]
            (Type 5) CASR [HSA:846] [KO:K04612]
DRUG        Spironolactone [DR:D00443]
            Soldactone [DR:D01943]
            Triamterene [DR:D00386]
            Indometacin [DG:DG00241]
DBLINKS     ICD-10: E26.8
            MeSH: D001477
            OMIM: 601678 241200 607364 602522 613090
REFERENCE   PMID:16785747
  AUTHORS   Kleta R, Bockenhauer D
  TITLE     Bartter syndromes and other salt-losing tubulopathies.
  JOURNAL   Nephron Physiol 104:p73-80 (2006)
REFERENCE   PMID:15056980
  AUTHORS   Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D
  TITLE     Bartter's and Gitelman's syndromes: from gene to clinic.
  JOURNAL   Nephron Physiol 96:p65-78 (2004)
REFERENCE   PMID:15044642 (Type 4B)
  AUTHORS   Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, Waldegger S
  TITLE     Salt wasting and deafness resulting from mutations in two chloride channels.
  JOURNAL   N Engl J Med 350:1314-9 (2004)
REFERENCE   PMID:12920401
  AUTHORS   Hebert SC
  TITLE     Bartter syndrome.
  JOURNAL   Curr Opin Nephrol Hypertens 12:527-32 (2003)
REFERENCE   PMID:10787448
  AUTHORS   Amirlak I, Dawson KP
  TITLE     Bartter syndrome: an overview.
  JOURNAL   QJM 93:207-15 (2000)
///
ENTRY       H00240                      Disease
NAME        Gitelman syndrome
DESCRIPTION Gitelman syndrome is an autosomal recessive renal tubular disorder characterized by hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria and is caused by mutations in the thiazide-sensitive sodium chloride transporter.
CATEGORY    Endocrine disease; Urinary system disease
GENE        SLC12A3 [HSA:6559] [KO:K14426]
DRUG        Spironolactone [DR:D00443]
            Triamterene [DR:D00386]
            Eplerenone [DR:D01115]
DBLINKS     ICD-10: E26.8
            MeSH: D053579
            OMIM: 263800
REFERENCE   PMID:18667063
  AUTHORS   Knoers NV, Levtchenko EN
  TITLE     Gitelman syndrome.
  JOURNAL   Orphanet J Rare Dis 3:22 (2008)
REFERENCE   PMID:17918133
  AUTHORS   Wagner CA
  TITLE     Disorders of renal magnesium handling explain renal magnesium transport.
  JOURNAL   J Nephrol 20:507-10 (2007)
REFERENCE   PMID:17061123
  AUTHORS   Riveira-Munoz E, Chang Q, Bindels RJ, Devuyst O
  TITLE     Gitelman's syndrome: towards genotype-phenotype correlations?
  JOURNAL   Pediatr Nephrol 22:326-32 (2007)
///
ENTRY       H00241                      Disease
NAME        Combined proximal and distal renal tubular acidosis (RTA type 3)
DESCRIPTION Renal tubular acidosis (RTA) is characterized by metabolic acidosis, a severe disturbance of extracellular pH homeostasis, due to renal impaired acid excretion. Type 3 RTA is a mixed type that shares the features of both proximal and distal lesions, with impaired proximal bicarbonate reabsorption coupled with an inability to acidify the urine maximally despite severe degrees of systemic acidemia. The condition is due to an inherited deficiency of carbonic anhydrase II (CAII) caused by a recessive mutation in the CA2 gene on chromosome 8q22.
CATEGORY    Urinary system disease
GENE        CA2 [HSA:760] [KO:K18245]
ENV_FACTOR  High salt intake
MARKER      Plasma K+ [CPD:C00238]
            Urinary anion gap [CPD:C01330 C00238 C00698]
            Urine pH
            Urinary NH4+
DRUG        Intravenous potassium supplement
            Sodium bicarbonate [DR:D01203]
DBLINKS     ICD-10: N25.8
            MeSH: D000141
            OMIM: 259730
REFERENCE   PMID:11045400 (gene)
  AUTHORS   Rodriguez-Soriano J
  TITLE     New insights into the pathogenesis of renal tubular acidosis--from functional to  molecular studies.
  JOURNAL   Pediatr Nephrol 14:1121-36 (2000)
REFERENCE   PMID:17557941 (gene)
  AUTHORS   Fry AC, Karet FE
  TITLE     Inherited renal acidoses.
  JOURNAL   Physiology (Bethesda) 22:202-11 (2007)
REFERENCE   PMID:12138150 (gene, env_factor, marker)
  AUTHORS   Rodriguez Soriano J
  TITLE     Renal tubular acidosis: the clinical entity.
  JOURNAL   J Am Soc Nephrol 13:2160-70 (2002)
REFERENCE   (marker)
  AUTHORS   McPhee SJ, Papadakis MA (ed).
  TITLE     Current Medical Diagnosis & Treatment 2010, Forty-Ninth Edition
  JOURNAL   The McGraw-Hill Companies, Inc. (2010)
REFERENCE   PMID:17657093 (drug)
  AUTHORS   Al-Ibrahim A, Al-Harbi M, Al-Musallam S
  TITLE     Paralysis Episodes in Carbonic Anhydrase II Deficiency.
  JOURNAL   Saudi J Kidney Dis Transpl 14:70-4 (2003)
///
ENTRY       H00242                      Disease
NAME        Liddle syndrome
DESCRIPTION Liddle syndrome (LS) is a rare form of autosomal dominant hypertension characterized by hypokalemic metabolic alkalosis, low-renin activity, and suppressed aldosterone secretion. The mutations in the epithelial Na+ channel gene cause failure of the protein endocytosis and accumulation of active channels at the cell surface, leading persistent absorption of Na+ and resulting in large blood volume and high blood pressure.
CATEGORY    Endocrine disease; Urinary system disease
GENE        SCNN1B [HSA:6338] [KO:K04825]
            SCNN1G [HSA:6340] [KO:K04827]
DRUG        Triamterene [DR:D00386]
DBLINKS     ICD-10: I15.2
            OMIM: 177200
REFERENCE   PMID:19007435
  AUTHORS   Rotin D
  TITLE     Role of the UPS in Liddle syndrome.
  JOURNAL   BMC Biochem 9 Suppl 1:S5 (2008)
REFERENCE   PMID:15980941
  AUTHORS   Lang F, Capasso G, Schwab M, Waldegger S
  TITLE     Renal tubular transport and the genetic basis of hypertensive disease.
  JOURNAL   Clin Exp Nephrol 9:91-9 (2005)
REFERENCE   PMID:11780687
  AUTHORS   Warnock DG
  TITLE     Liddle syndrome: genetics and mechanisms of Na+ channel defects.
  JOURNAL   Am J Med Sci 322:302-7 (2001)
///
ENTRY       H00243                      Disease
NAME        Hyperkalemic distal renal tubular acidosis (RTA type 4), including:
            Pseudohypoaldosteronism type I  (PHA1);
            Pseudohypoaldosteronism type II (Gordon's syndrome)
DESCRIPTION Renal tubular acidosis (RTA) is characterized by metabolic acidosis, a severe disturbance of extracellular pH homeostasis, due to renal impaired acid excretion. Type 4 RTA is a heterogeneous group of disorders associated with hyperkalemia due to aldosterone deficiency or impairment in aldosterone molecular signaling. Primary pseudohypoaldosteronism type 1 (PHA1) is characterized by salt-wasting, hyperkalemia, and metabolic acidosis in the presence of markedly elevated plasma renin activity and aldosterone concentration. In the autosomal dominant form, aldosterone resistance is due to heterozygous mutations in the mineralocorticoid receptor gene. In the autosomal recessive form, aldosterone resistance is caused by loss-of-function homozygous mutations in the genes encoding one of the three constitutive subunits (alpha, beta, and gamma) of the epithelial Na+ channel (SCNN1A, SCNN1B, and SCNN1G). Other inherited cause of type 4 RTA includes hyperkalaemia associated with hypertension and low or normal levels of plasma aldosterone. This syndrome is called pseudohypoaldosteronism type 2 (PHA2), or Gordon's syndrome, which results in a renal aldosterone resistance. Mutations in the genes encoding WNK1 and WNK4 kinases (WNK1 and WNK4), which regulate ion-transportors on renal tubules, were identified in patients with PHA2. Acquired hyperkalemic RTA is observed in the context of mineralocorticoid deficiency, systemic lupus erythematosus, and AIDS nephropathy. It is also often seen in a number of tubulointerstitial renal diseases. Finally, a great number of drugs may induce hyperkalemic RTA.
CATEGORY    Endocrine disease; Urinary system disease
GENE        SCNN1A [HSA:6337] [KO:K04824]
            SCNN1B [HSA:6338] [KO:K04825]
            SCNN1G [HSA:6340] [KO:K04827]
            NR3C2 [HSA:4306] [KO:K08555]
            WNK1 [HSA:65125] [KO:K08867]
            WNK4 [HSA:65266] [KO:K08867]
ENV_FACTOR  Cyclo-oxygenase inhibitors
            Converting enzyme inhibitors
            Heparin [DR:D07510]
            Potassium-retaining diuretics
            Trimethoprim [DR:D00145]
            Pentamidine [DR:D08333]
            Cyclosporin A [DR:D00184]
            Insulin antagonists
            Beta-adrenergic antagonists
            Alpha-adrenergic agonists
            Digitalis [DR:D03819]
            Succinylcholine [DR:D00766]
MARKER      Plasma K+ [CPD:C00238]
            Urinary anion gap [CPD:C01330 C00238 C00698]
            Urine pH
            Urinary NH4+
DRUG        Fludrocortisone [DG:DG00506]
            Furosemide [DG:DG00272]
            Sodium bicarbonate [DR:D01203]
DBLINKS     ICD-10: N25.8
            MeSH: D011546
            OMIM: 264350 177735 145260
REFERENCE   PMID:19721811 (gene)
  AUTHORS   Pereira PC, Miranda DM, Oliveira EA, Silva AC
  TITLE     Molecular pathophysiology of renal tubular acidosis.
  JOURNAL   Curr Genomics 10:51-9 (2009)
REFERENCE   PMID:11045400 (gene)
  AUTHORS   Rodriguez-Soriano J
  TITLE     New insights into the pathogenesis of renal tubular acidosis--from functional to  molecular studies.
  JOURNAL   Pediatr Nephrol 14:1121-36 (2000)
REFERENCE   PMID:12138150 (gene, env_factor, marker, drug)
  AUTHORS   Rodriguez Soriano J
  TITLE     Renal tubular acidosis: the clinical entity.
  JOURNAL   J Am Soc Nephrol 13:2160-70 (2002)
REFERENCE   (marker, drug)
  AUTHORS   McPhee SJ, Papadakis MA (ed).
  TITLE     Current Medical Diagnosis & Treatment 2010, Forty-Ninth Edition
  JOURNAL   The McGraw-Hill Companies, Inc. (2010)
///
ENTRY       H00244                      Disease
NAME        Pseudohypoparathyroidism
DESCRIPTION Pseudohypoparathyroidism refers to a heterogeneous group of autosomal dominant disorders characterized by hypocalcemia and hyperphosphatemia due to resistance to parathyroid hormone. The disease phenotype of type Ia is characterized by Albright hereditary osteodystrophy (AHO) and resistance PTH and many other hormones, while that of type Ib shows hypothyroidism due to resistance to TSH restricted to renal tubule cells.
CATEGORY    Endocrine disease; Musculoskeletal disease
GENE        (Type Ia) GNAS (maternal inheritance) [HSA:2778] [KO:K04632]
            (Type Ib) GNAS (loss of imprinting) [HSA:2778] [KO:K04632]
            (Type Ib) STX16 (deletion) [HSA:8675] [KO:K08489]
DRUG        Secalciferol [DR:D00628]
DBLINKS     ICD-10: E20.1
            MeSH: D011547
            OMIM: 103580 603233 612462 612463
REFERENCE   PMID:17595244
  AUTHORS   Mantovani G, Bondioni S, Linglart A, Maghnie M, Cisternino M, Corbetta S, Lania AG, Beck-Peccoz P, Spada A
  TITLE     Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib.
  JOURNAL   J Clin Endocrinol Metab 92:3738-42 (2007)
REFERENCE   PMID:16789629
  AUTHORS   Juppner H, Bastepe M
  TITLE     Different mutations within or upstream of the GNAS locus cause distinct forms of pseudohypoparathyroidism.
  JOURNAL   J Pediatr Endocrinol Metab 19 Suppl 2:641-6 (2006)
REFERENCE   PMID:15711092
  AUTHORS   Bastepe M, Juppner H
  TITLE     GNAS locus and pseudohypoparathyroidism.
  JOURNAL   Horm Res 63:65-74 (2005)
REFERENCE   PMID:11588148
  AUTHORS   Weinstein LS, Yu S, Warner DR, Liu J
  TITLE     Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting.
  JOURNAL   Endocr Rev 22:675-705 (2001)
///
ENTRY       H00245                      Disease
NAME        Familial hypocalciuric hypercalcemia (FHH1);
            Neonatal severe hyperparathyroidism (NSHPT);
            Autosomal dominant hypocalcemia (ADH);
            Familial hypercalciuric hypocalcemia
DESCRIPTION The mutations in the CASR gene which expresses in the parathyroid hormone producing chief cells of the parathyroid gland and the cells lining the kidney tubule affect calcium homeostasis. Loss-of-function mutations in the CASR gene are responsible for familial hypocalciuric hypercalcemia (FHH1) and for neonatal severe hyperparathyroidism (NSHPT). FHH1 is caused by homozygous mutations and characterized by benign symptoms with mild hypercalcaemia, whereas NSHPT is caused by homozygous mutations and characterized by more severe ones with severe hypercalcaemia and hyperparathyroid bone disease. Gain-of-function mutations are responsible for autosomal dominant hypocalcemia (ADH) that characterized by seizures in infancy, moderate hypocalcaemia and, absolute hypercalciuria.
CATEGORY    Endocrine disease; Urinary system disease
GENE        CASR [HSA:846] [KO:K04612]
DBLINKS     ICD-10: E83.5
            MeSH: C537145 C563375 C562783
            OMIM: 145980 239200 146200
REFERENCE   PMID:18328986
  AUTHORS   Egbuna OI, Brown EM
  TITLE     Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.
  JOURNAL   Best Pract Res Clin Rheumatol 22:129-48 (2008)
REFERENCE   PMID:11706743
  AUTHORS   Heath DA
  TITLE     Familial hypocalciuric hypercalcemia.
  JOURNAL   Rev Endocr Metab Disord 1:291-6 (2000)
REFERENCE   PMID:11033758
  AUTHORS   Brown EM
  TITLE     Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium.
  JOURNAL   Endocrinol Metab Clin North Am 29:503-22 (2000)
REFERENCE   PMID:11013439
  AUTHORS   Hendy GN, D'Souza-Li L, Yang B, Canaff L, Cole DE
  TITLE     Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia.
  JOURNAL   Hum Mutat 16:281-96 (2000)
///
ENTRY       H00246                      Disease
NAME        Primary hyperparathyroidism;
            Familial hyperparathyroidism (HRPT)
DESCRIPTION Familial hyperparathyroidism is characterized by parathyroid adenoma and hyperplasia with hypersecretion of parathyroid hormone and hypercalcaemia. It is caused by mutation in the HRPT2 (CDC73 or Parafibromin) gene that also causes the hyperparathyroidism-jaw tumor syndrome. Sporadic cases are also known to occur with somatic mutations within the MEN1 gene.
CATEGORY    Endocrine disease; Urinary system disease
GENE        CDC73 [HSA:79577] [KO:K15175]
            MEN1 [HSA:4221] [KO:K14970]
            CASR [HSA:846] [KO:K04612]
            GCM2 [HSA:9247]
MARKER      parathyroid hormone (PTH) [HSA:5741]
DBLINKS     ICD-10: E21.0
            MeSH: D049950
            OMIM: 145000 145001 239200 617343
REFERENCE   PMID:19092296
  AUTHORS   Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S, Bilezikian JP, Pinchera A, Marcocci C
  TITLE     Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
  JOURNAL   J Endocrinol Invest 31:900-4 (2008)
REFERENCE   PMID:18684024
  AUTHORS   DeLellis RA, Mazzaglia P, Mangray S
  TITLE     Primary hyperparathyroidism: a current perspective.
  JOURNAL   Arch Pathol Lab Med 132:1251-62 (2008)
REFERENCE   PMID:16001331
  AUTHORS   Wang PF, Tan MH, Zhang C, Morreau H, Teh BT
  TITLE     HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome.
  JOURNAL   Horm Metab Res 37:380-3 (2005)
REFERENCE   PMID:27745835 (gene)
  AUTHORS   Guan B, Welch JM, Sapp JC, Ling H, Li Y, Johnston JJ, Kebebew E, Biesecker LG, Simonds WF, Marx SJ, Agarwal SK
  TITLE     GCM2-Activating Mutations in Familial Isolated Hyperparathyroidism.
  JOURNAL   Am J Hum Genet 99:1034-1044 (2016)
///
ENTRY       H00247                      Disease
NAME        Multiple endocrine neoplasia syndrome (MEN);
            Wermer syndrome;
            Sipple's syndrome
DESCRIPTION Multiple endocrine neoplasias (MEN) are autosomal dominant syndrome which is characterized by the occurrence of tumors involving two or more endocrine glands. Four major forms of MEN are recognized, namely MEN1, MEN2A, MEN2B and MEN4. MEN1, which is also referred as Wermer's syndrome, is characterized by parathyroid adenoma, gastrinoma, and pituitary adenoma. Gastrinomas are the most common type, leading to the Zollinger-Ellison Syndrome (see H01522). MEN2 are characterized by medullary thyroid cancer (MTC) and includes three subtypes: MEN2A (Sipple's syndrome), MEN2B (MEN3) and familial MTC. MEN2A develop MTC in association with phaeochromocytoma and parathyroid tumors. MEN2B develop MTC in association with marfanoid habitus, mucosal neuromas, medullated corneal fibers and intestinal autonomic ganglion dysfunction, leading to megacolon. MEN4, also referred to as MENX, appears to have signs and symptoms similar to those of type 1. However MEN4 patients have mutations in other genes. The mutations in their responsible genes are found in Each MEN syndrome.
CATEGORY    Endocrine disease; Cancer
GENE        (MEN1) MEN1 [HSA:4221] [KO:K14970]
            (MEN2A MEN2B) RET [HSA:5979] [KO:K05126]
            (MEN4) CDKN1B [HSA:1027] [KO:K06624]
DBLINKS     ICD-10: D44.8
            MeSH: D009377
            OMIM: 131100 162300 171400 610755
REFERENCE   PMID:18328987
  AUTHORS   Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML
  TITLE     Multiple endocrine neoplasms.
  JOURNAL   Best Pract Res Clin Rheumatol 22:149-63 (2008)
REFERENCE   PMID:17030811
  AUTHORS   Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ
  TITLE     Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.
  JOURNAL   Proc Natl Acad Sci U S A 103:15558-63 (2006)
REFERENCE   PMID:17037976
  AUTHORS   Lakhani VT, You YN, Wells SA
  TITLE     The multiple endocrine neoplasia syndromes.
  JOURNAL   Annu Rev Med 58:253-65 (2007)
REFERENCE   PMID:17024155
  AUTHORS   Dreijerink KM, Hoppener JW, Timmers HM, Lips CJ
  TITLE     Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation.
  JOURNAL   Nat Clin Pract Endocrinol Metab 2:562-70 (2006)
REFERENCE   PMID:15864278
  AUTHORS   Marx SJ
  TITLE     Molecular genetics of multiple endocrine neoplasia types 1 and 2.
  JOURNAL   Nat Rev Cancer 5:367-75 (2005)
REFERENCE   PMID:15608505
  AUTHORS   Carling T
  TITLE     Multiple endocrine neoplasia syndrome: genetic basis for clinical management.
  JOURNAL   Curr Opin Oncol 17:7-12 (2005)
REFERENCE   PMID:23933118
  AUTHORS   Thakker RV
  TITLE     Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).
  JOURNAL   Mol Cell Endocrinol 386:2-15 (2014)
REFERENCE   PMID:24931355
  AUTHORS   Walls GV
  TITLE     Multiple endocrine neoplasia (MEN) syndromes.
  JOURNAL   Semin Pediatr Surg 23:96-101 (2014)
///
ENTRY       H00249                      Disease
NAME        Thyroid hormone resistance syndrome, including:
            Generalized thyroid hormone resistance;
            Refetoff Syndrome;
            Selective pituitary thyroid hormone resistance
DESCRIPTION Thyroid hormone resistance syndrome, which inherits in either autosomal dominant or recessive manner, is characterized by reduced end-organ responsiveness to thyroid hormone. It is caused by mutations in the gene of thyroid hormone receptor and the locations of the mutations in the gene are associated with the phenotypes, such as generalized resistance, pituitary selective resistance.
CATEGORY    Endocrine disease
GENE        THRB [HSA:7068] [KO:K08362]
MARKER      thyroid hormone [HSA:5741] [KO:K05261]
DBLINKS     ICD-10: E07.8
            MeSH: D018382 C564154
            OMIM: 188570 274300 145650
REFERENCE   PMID:17132274
  AUTHORS   Olateju TO, Vanderpump MP
  TITLE     Thyroid hormone resistance.
  JOURNAL   Ann Clin Biochem 43:431-40 (2006)
REFERENCE   PMID:15860414
  AUTHORS   Cheng SY
  TITLE     Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance.
  JOURNAL   Trends Endocrinol Metab 16:176-82 (2005)
///
ENTRY       H00250                      Disease
NAME        Congenital nongoitrous hypothyroidism (CHNG)
DESCRIPTION Congenital nongoitrous hypothyroidism is characterized as resistance to thyroid-stimulating hormone (TSH) causing increased levels of plasma TSH and low levels of thyroid hormone which is essential for early brain development. The neonatal screening can avoid the poor prognosis of hypothyroidism.
CATEGORY    Endocrine disease
GENE        (CHNG1) TSHR [HSA:7253] [KO:K04249]
            (CHNG2) PAX8 [HSA:7849] [KO:K09293]
            (CHNG4) TSHB [HSA:7252] [KO:K05251]
            (CHNG5) NKX2-5 [HSA:1482] [KO:K09345]
MARKER      TSH [HSA:1081 7252] [KO:K08522 K05251]
            T4 [CPD:C01829]
DRUG        Thyroid [DR:D06482]
            Levothroid [DR:D01010]
DBLINKS     ICD-10: E03.1
            MeSH: D003409
            OMIM: 275200 218700 275100 225250
REFERENCE   PMID:18174723
  AUTHORS   Gruters A, Krude H
  TITLE     Update on the management of congenital hypothyroidism.
  JOURNAL   Horm Res 68 Suppl 5:107-11 (2007)
REFERENCE   PMID:16740880
  AUTHORS   Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK
  TITLE     Update of newborn screening and therapy for congenital hypothyroidism.
  JOURNAL   Pediatrics 117:2290-303 (2006)
REFERENCE   PMID:15863666
  AUTHORS   Park SM, Chatterjee VK
  TITLE     Genetics of congenital hypothyroidism.
  JOURNAL   J Med Genet 42:379-89 (2005)
REFERENCE   PMID:15554885
  AUTHORS   Gruters A, Krude H, Biebermann H
  TITLE     Molecular genetic defects in congenital hypothyroidism.
  JOURNAL   Eur J Endocrinol 151 Suppl 3:U39-44 (2004)
///
ENTRY       H00251                      Disease
NAME        Thyroid dyshormonogenesis;
            Dyshormogenetic goiter
DESCRIPTION Thyroid dyshormonogenesis is a genetically heterogeneous group of inherited disorders in the enzymatic cascade of thyroid hormone synthesis that result in congenital hypothyroidism due to genetic defects in the synthesis of thyroid hormones.
CATEGORY    Endocrine disease
GENE        (Type 1) SLC5A5 [HSA:6528] [KO:K14385]
            (Type 2A) TPO [HSA:7173] [KO:K00431]
            (Type 2B) SLC26A4 [HSA:5172] [KO:K14702]
            (Type 2B) FOXI1 [HSA:2299] [KO:K09401]
            (Type 4) IYD [HSA:389434] [KO:K17231]
            (Type 5) DUOXA2 [HSA:405753] [KO:K17232]
            TG [HSA:7038] [KO:K10809]
            (Type 6) DUOX2 [HSA:50506] [KO:K13411]
MARKER      Thyroglobulin [HSA:7038] [KO:K10809]
DRUG        Thyroid [DR:D06482]
            Levothroid [DG:DG00510]
DBLINKS     ICD-10: E07.1
            MeSH: C564766 C563206 C536648 C562769 C562770 C562771 C564608
            OMIM: 274400 274500 274600 274800 274900 607200 188450
REFERENCE   PMID:17551472
  AUTHORS   Topaloglu AK
  TITLE     Athyreosis, dysgenesis, and dyshormonogenesis in congenital hypothyroidism.
  JOURNAL   Pediatr Endocrinol Rev 3  Suppl 3:498-502 (2006)
REFERENCE   PMID:17684392
  AUTHORS   Moreno JC, Visser TJ
  TITLE     New phenotypes in thyroid dyshormonogenesis: hypothyroidism due to DUOX2 mutations.
  JOURNAL   Endocr Dev 10:99-117 (2007)
REFERENCE   PMID:17468186
  AUTHORS   Avbelj M, Tahirovic H, Debeljak M, Kusekova M, Toromanovic A, Krzisnik C, Battelino T
  TITLE     High prevalence of thyroid peroxidase gene mutations in patients with thyroid dyshormonogenesis.
  JOURNAL   Eur J Endocrinol 156:511-9 (2007)
REFERENCE   PMID:16424561
  AUTHORS   Kumar PG, Anand SS, Sood V, Kotwal N
  TITLE     Thyroid dyshormonogenesis.
  JOURNAL   Indian Pediatr 42:1233-5 (2005)
REFERENCE   PMID:15863666
  AUTHORS   Park SM, Chatterjee VK
  TITLE     Genetics of congenital hypothyroidism.
  JOURNAL   J Med Genet 42:379-89 (2005)
REFERENCE   PMID:18042646
  AUTHORS   Zamproni I, Grasberger H, Cortinovis F, Vigone MC, Chiumello G, Mora S, Onigata K, Fugazzola L, Refetoff S, Persani L, Weber G
  TITLE     Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism.
  JOURNAL   J Clin Endocrinol Metab 93:605-10 (2008)
///
ENTRY       H00252                      Disease
NAME        Congenital nephrogenic diabetes insipidus (NDI)
DESCRIPTION Nephrogenic diabetes insipidus is characterized by renal insensitivity to the antidiuretic effect of arginine vasopressin.
CATEGORY    Endocrine disease; Kidney disease
GENE        (NDI1) AVPR2 [HSA:554] [KO:K04228]
            (NDI2) AQP2 [HSA:359] [KO:K09865]
DRUG        Desmopressin [DG:DG00497]
DBLINKS     ICD-10: N25.1
            MeSH: D018500
            OMIM: 304800 125800
REFERENCE   PMID:17908859
  AUTHORS   Linshaw MA
  TITLE     Back to basics: congenital nephrogenic diabetes insipidus.
  JOURNAL   Pediatr Rev 28:372-80 (2007)
REFERENCE   PMID:16580609
  AUTHORS   Bichet DG
  TITLE     Nephrogenic diabetes insipidus.
  JOURNAL   Adv Chronic Kidney Dis 13:96-104 (2006)
REFERENCE   PMID:11793119
  AUTHORS   Knoers NV, Deen PM
  TITLE     Molecular and cellular defects in nephrogenic diabetes insipidus.
  JOURNAL   Pediatr Nephrol 16:1146-52 (2001)
///
ENTRY       H00253                      Disease
NAME        Neurohypophyseal diabetes insipidus (NPDI);
            Central Diabetes Insipidus
DESCRIPTION Central Diabetes Insipidus is a heterogeneous condition characterized by polyuria and polydipsia caused by defect of antidiuretic hormone secreted from the pituitary gland.
CATEGORY    Endocrine disease; Kidney disease
GENE        AVP [HSA:551] [KO:K05242]
DRUG        Desmopressin [DG:DG00497]
DBLINKS     ICD-10: E23.2
            MeSH: D020790
            OMIM: 125700
REFERENCE   PMID:16713494
  AUTHORS   Christensen JH, Rittig S
  TITLE     Familial neurohypophyseal diabetes insipidus--an update.
  JOURNAL   Semin Nephrol 26:209-23 (2006)
REFERENCE   PMID:12874957
  AUTHORS   Christensen JH, Siggaard C, Rittig S
  TITLE     Autosomal dominant familial neurohypophyseal diabetes insipidus.
  JOURNAL   APMIS Suppl 92-5 (2003)
///
ENTRY       H00254                      Disease
NAME        Pituitary Dwarfism (PD);
            Laron Syndrome (PD2);
            Isolated growth hormone deficiency (IGHD);
            Short Stature and Pituitary Defects (SSPD);
            Insulin-like growth factor 1 deficiency (IGFD);
            Combined pituitary hormone deficiency (CPHD)
DESCRIPTION Pituitary dwarfism is a heterogeneous condition characterized by growth retardation with short statue and normal body proportions caused by growth hormone deficiency.
CATEGORY    Endocrine disease; Musculoskeletal disease
GENE        (IGHD1A PD1) GH1 [HSA:2688] [KO:K05438]
            (IGHD1B) GHRH [HSA:2691] [KO:K05260]
            (IGHD1B) GHRHR [HSA:2692] [KO:K04584]
            (IGHD3) BTK [HSA:695] [KO:K07370]
            (PD2) GHR [HSA:2690] [KO:K05080]
            (PD3 CPHD1) POU1F1 [HSA:5449] [KO:K09363]
            (PD3 CPHD2) PROP1 [HSA:5626] [KO:K09327]
            (PD3) HESX1 [HSA:8820] [KO:K09354]
            (PD3 CPHD3) LHX3 [HSA:8022] [KO:K09374]
            (PD4) SOX3 [HSA:6658] [KO:K09267]
            (SSPD CPHD4) LHX4 [HSA:89884] [KO:K09374]
            (IGFD) IGF1 [HSA:3479] [KO:K05459]
DRUG        Protropin [DR:D05884]
            Somatropin [DR:D02691]
DBLINKS     ICD-10: E23.0
            MeSH: D004393 D046150
            OMIM: 262400 612781 173100 262650 262500  262600  262700 307200 312000 608747 612781 613038 221750
REFERENCE   PMID:17965963
  AUTHORS   Hernandez LM, Lee PD, Camacho-Hubner C
  TITLE     Isolated growth hormone deficiency.
  JOURNAL   Pituitary 10:351-7 (2007)
REFERENCE   PMID:17336732
  AUTHORS   Mullis PE
  TITLE     Genetics of growth hormone deficiency.
  JOURNAL   Endocrinol Metab Clin North Am 36:17-36 (2007)
REFERENCE   PMID:12201208
  AUTHORS   Hayashi Y, Kamijo T, Ogawa M, Seo H
  TITLE     Familial isolated growth hormone deficiency: genetics and pathophysiology.
  JOURNAL   Endocr J 49:265-72 (2002)
REFERENCE   PMID:9799079
  AUTHORS   Procter AM, Phillips JA 3rd, Cooper DN
  TITLE     The molecular genetics of growth hormone deficiency.
  JOURNAL   Hum Genet 103:255-72 (1998)
REFERENCE   PMID:7868072
  AUTHORS   Perez Jurado LA, Argente J
  TITLE     Molecular basis of familial growth hormone deficiency.
  JOURNAL   Horm Res 42:189-97 (1994)
REFERENCE   PMID:21292919
  AUTHORS   Steuerman R, Shevah O, Laron Z
  TITLE     Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies.
  JOURNAL   Eur J Endocrinol 164:485-9 (2011)
REFERENCE   PMID:15928241
  AUTHORS   Turton JP, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, Tiulpakov A, Zdravkovic V, Hamilton J, Attard-Montalto S, Parascandalo R, Vella C, Clayton PE, Shalet S, Barton J, Brue T, Dattani MT
  TITLE     Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency.
  JOURNAL   J Clin Endocrinol Metab 90:4762-70 (2005)
///
ENTRY       H00255                      Disease
NAME        Hypogonadotropic hypogonadism, including:
            Kallmann syndrome (KAL);
            Fertile eunuch syndrome (FEUNS)
DESCRIPTION Kallmann Syndrome is a clinically and genetically heterogeneous disorder, characterized by isolated hypogonadotropic hypogonadism and anosmia.
CATEGORY    Endocrine disease
GENE        (HH1/KAL1) KAL1 [HSA:3730]
            (HH2/KAL2) FGFR1 [HSA:2260] [KO:K04362]
            (HH3/KAL3) PROKR2 [HSA:128674] [KO:K08380]
            (HH4/KAL4) PROK2 [HSA:60675]
            (HH5/KAL5) CHD7 [HSA:55636] [KO:K14437]
            (HH6/KAL6) FGF8 [HSA:2253] [KO:K04358]
            (HH7/FEUNS) GNRHR [HSA:2798] [KO:K04280]
            (HH8) KISS1R [HSA:84634] [KO:K08374]
            (HH9) NSMF [HSA:26012]
            (HH10) TAC3 [HSA:6866] [KO:K05240]
            (HH11) TACR3 [HSA:6870] [KO:K04224]
            (HH12) GNRH1 [HSA:2796] [KO:K05252]
            (HH13) KISS1 [HSA:3814]
            (HH14) WDR11 [HSA:55717]
            (HH15) HS6ST1 [HSA:9394] [KO:K02514]
            (HH16) SEMA3A [HSA:10371] [KO:K06840]
            (HH17) SPRY4 [HSA:81848] [KO:K17385]
            (HH18) IL17RD [HSA:54756] [KO:K05167]
            (HH19) DUSP6 [HSA:1848] [KO:K04459]
            (HH20) FGF17 [HSA:8822] [KO:K04358]
            (HH21) FLRT3 [HSA:23767] [KO:K16362]
            (HH22) FEZF1 [HSA:389549]
DRUG        Progesterone [DR:D00066]
            Testosterone [DG:DG00460]
            Estradiol [DG:DG00462]
DBLINKS     ICD-10: E23.0
            MeSH: D007006 D017436 C537919
            OMIM: 308700 147950 244200 610628 612370 612702 146110 614837 614838 614839 614840 614841 614842 228300 614858 614880 614897 615266 615267 615269 615270 615271 616030
REFERENCE   PMID:18987492
  AUTHORS   Hardelin JP, Dode C
  TITLE     The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al.
  JOURNAL   Sex Dev 2:181-93 (2008)
REFERENCE   PMID:18985070
  AUTHORS   Dode C, Hardelin JP
  TITLE     Kallmann syndrome.
  JOURNAL   Eur J Hum Genet 17:139-46 (2009)
REFERENCE   PMID:17624596
  AUTHORS   Trarbach EB, Silveira LG, Latronico AC
  TITLE     Genetic insights into human isolated gonadotropin deficiency.
  JOURNAL   Pituitary 10:381-91 (2007)
REFERENCE   PMID:15722618
  AUTHORS   Karges B, de Roux N
  TITLE     Molecular genetics of isolated hypogonadotropic hypogonadism and Kallmann syndrome.
  JOURNAL   Endocr Dev 8:67-80 (2005)
REFERENCE   PMID:11397842 (FEUNS)
  AUTHORS   Pitteloud N, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF Jr, Hayes FJ
  TITLE     The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor.
  JOURNAL   J Clin Endocrinol Metab 86:2470-5 (2001)
REFERENCE   PMID:22229029
  AUTHORS   Beate K, Joseph N, Nicolas de R, Wolfram K
  TITLE     Genetics of isolated hypogonadotropic hypogonadism: role of GnRH receptor and other genes.
  JOURNAL   Int J Endocrinol 2012:147893 (2012)
REFERENCE   PMID:22335740
  AUTHORS   Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, Erdogan S, Gurbuz F, Temiz F, Millar RP, Yuksel B
  TITLE     Inactivating KISS1 mutation and hypogonadotropic hypogonadism.
  JOURNAL   N Engl J Med 366:629-35 (2012)
REFERENCE   PMID:20887964
  AUTHORS   Kim HG, Ahn JW, Kurth I, Ullmann R, Kim HT, Kulharya A, Ha KS, Itokawa Y, Meliciani I, Wenzel W, Lee D, Rosenberger G, Ozata M, Bick DP, Sherins RJ, Nagase T, Tekin M, Kim SH, Kim CH, Ropers HH, Gusella JF, Kalscheuer V, Choi CY, Layman LC
  TITLE     WDR11, a WD protein that interacts with transcription factor EMX1, is mutated in  idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.
  JOURNAL   Am J Hum Genet 87:465-79 (2010)
REFERENCE   PMID:22927827
  AUTHORS   Hanchate NK, Giacobini P, Lhuillier P, Parkash J, Espy C, Fouveaut C, Leroy C, Baron S, Campagne C, Vanacker C, Collier F, Cruaud C, Meyer V, Garcia-Pinero A, Dewailly D, Cortet-Rudelli C, Gersak K, Metz C, Chabrier G, Pugeat M, Young J, Hardelin JP, Prevot V, Dode C
  TITLE     SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.
  JOURNAL   PLoS Genet 8:e1002896 (2012)
REFERENCE   PMID:23643382
  AUTHORS   Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, Beenken A, Clarke J, Pers TH, Dworzynski P, Keefe K, Niedziela M, Raivio T, Crowley WF Jr, Seminara SB, Quinton R, Hughes VA, Kumanov P, Young J, Yialamas MA, Hall JE, Van Vliet G, Chanoine JP, Rubenstein J, Mohammadi M, Tsai PS, Sidis Y, Lage K, Pitteloud N
  TITLE     Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.
  JOURNAL   Am J Hum Genet 92:725-43 (2013)
REFERENCE   PMID:25192046 (gene)
  AUTHORS   Kotan LD, Hutchins BI, Ozkan Y, Demirel F, Stoner H, Cheng PJ, Esen I, Gurbuz F, Bicakci YK, Mengen E, Yuksel B, Wray S, Topaloglu AK
  TITLE     Mutations in FEZF1 cause Kallmann syndrome.
  JOURNAL   Am J Hum Genet 95:326-31 (2014)
///
ENTRY       H00256                      Disease
NAME        Familial glucocorticoid deficiency (FGD)
DESCRIPTION Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disease characterized by glucocorticoid deficiency despite high levels of plasma ACTH. Affected individuals typically present within the first few months of life with symptoms related to cortisol deficiency, including recurrent illnesses or infections, hypoglycemia, convulsions, failure to thrive and shock. The disease is life threatening if untreated. Glucocorticoid replacement is the recommended treatment. It has been reported that FGD is caused by mutation of the ACTH receptor (MC2R) and the accessory protein (MRAP).
CATEGORY    Endocrine disease
GENE        (FGD1) MC2R [HSA:4158] [KO:K04200]
            (FGD2) MRAP [HSA:56246]
            (FGD4) NNT [HSA:23530] [KO:K00323]
MARKER      Low levels of serum cortisol [CPD:C00735], plasma androstenedione [CPD:C00280], dehydroepiandrosterone (DHEA)[CPD:C01227], and DHEA sulfate (DHEA-S) [CPD:C04555].
DRUG        Hydrocortisone [DR:D00088]
            Dexamethasone [DR:D00292]
COMMENT     See also H00257 Achalasia-Addisonianism-Alacrima syndrome.
DBLINKS     ICD-10: E27
            MeSH: C565974 C564577
            OMIM: 202200 607398 609197 614736
REFERENCE   PMID:18059087
  AUTHORS   Chan LF, Clark AJ, Metherell LA
  TITLE     Familial glucocorticoid deficiency: advances in the molecular understanding of ACTH action.
  JOURNAL   Horm Res 69:75-82 (2008)
REFERENCE   PMID:18493136
  AUTHORS   Cooray SN, Chan L, Metherell L, Storr H, Clark AJ
  TITLE     Adrenocorticotropin resistance syndromes.
  JOURNAL   Endocr Dev 13:99-116 (2008)
REFERENCE   PMID:17161331
  AUTHORS   Metherell LA, Chan LF, Clark AJ
  TITLE     The genetics of ACTH resistance syndromes.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 20:547-60 (2006)
REFERENCE   PMID:22634753 (gene)
  AUTHORS   Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, Nurnberg P, Mann NP, Banerjee R, Saka HN, Chapple JP, King PJ, Clark AJ, Metherell LA
  TITLE     Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency.
  JOURNAL   Nat Genet 44:740-2 (2012)
REFERENCE   PMID:17893271 (drug , marker)
  AUTHORS   Rumie H, Metherell LA, Clark AJ, Beauloye V, Maes M
  TITLE     Clinical and biological phenotype of a patient with familial glucocorticoid deficiency type 2 caused by a mutation of melanocortin 2 receptor accessory protein.
  JOURNAL   Eur J Endocrinol 157:539-42 (2007)
REFERENCE   PMID:9196605 (marker)
  AUTHORS   Weber A, Clark AJ, Perry LA, Honour JW, Savage MO
  TITLE     Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche.
  JOURNAL   Clin Endocrinol (Oxf) 46:431-7 (1997)
///
ENTRY       H00257                      Disease
NAME        Achalasia-Addisonianism-Alacrima syndrome;
            Triple A syndrome;
            Allogrove syndrome
DESCRIPTION Allgrove syndrome (or triple-A syndrome) is a rare autosomal recessive disorder characterized by alacrima, achalasia, adrenal insufficiency and autonomic instability caused by mutation in the AAAS gene on 12q13.
CATEGORY    Endocrine disease
GENE        AAAS [HSA:8086] [KO:K14320]
DBLINKS     ICD-10: E27.4
            MeSH: C536008
            OMIM: 231550
REFERENCE   PMID:18426811
  AUTHORS   Collares CV, Antunes-Rodrigues J, Moreira AC, Franca SN, Pereira LA, Soares MM, Elias Junior J, Clark AJ, de Castro M, Elias LL
  TITLE     Heterogeneity in the molecular basis of ACTH resistance syndrome.
  JOURNAL   Eur J Endocrinol 159:61-8 (2008)
REFERENCE   PMID:16938764
  AUTHORS   Ismail EA, Tulliot-Pelet A, Mohsen AM, Al-Saleh Q
  TITLE     Allgrove syndrome with features of familial dysautonomia: a novel mutation in the AAAS gene.
  JOURNAL   Acta Paediatr 95:1140-3 (2006)
REFERENCE   PMID:15217518
  AUTHORS   Brooks BP, Kleta R, Caruso RC, Stuart C, Ludlow J, Stratakis CA
  TITLE     Triple-A syndrome with prominent ophthalmic features and a novel mutation in the AAAS gene: a case report.
  JOURNAL   BMC Ophthalmol 4:7 (2004)
REFERENCE   PMID:14621049
  AUTHORS   Bhargavan PV, Kumar KM, Rajendran VR, Fassaludeen AS
  TITLE     Allgrove syndrome--a syndrome of primary adrenocortical insufficiency with achalasia of the cardia and deficient tear production.
  JOURNAL   J Assoc Physicians India 51:726-8 (2003)
///
ENTRY       H00258                      Disease
NAME        Aldosterone synthase deficiency;
            Corticosterone methyloxidase type I deficiency;
            Corticosterone methyloxidase type II deficiency
DESCRIPTION Aldosterone synthase deficiency is an autosomal recessive disorder caused by a defect in the final biochemical step of aldosterone biosynthesis, the 18-hydroxylation of 18-hydroxycorticosterone to aldosterone. This disease is characterized by life-threatening salt-loss, failure to thrive, hyponatraemia and hyperkalaemia in early infancy. In type I deficiency, aldosterone is undetectable, whereas in type II aldosterone can be low or normal.
CATEGORY    Endocrine disease
GENE        CYP11B2 [HSA:1585] [KO:K07433]
MARKER      Corticosterone [CPD:C02140]
            11-deoxycorticosterone [CPD:C03205 ]
DRUG        9alpha-fluorocortisol
            Fludrocortisone acetate [DG:DG00506]
DBLINKS     ICD-10: E27.4 I15.2
            OMIM: 203400 610600
REFERENCE   PMID:15134805
  AUTHORS   White PC
  TITLE     Aldosterone synthase deficiency and related disorders.
  JOURNAL   Mol Cell Endocrinol 217:81-7 (2004)
REFERENCE   PMID:11174838
  AUTHORS   Wasniewska M, De Luca F, Valenzise M, Lombardo F, De Luca F
  TITLE     Aldosterone synthase deficiency type I with no documented homozygous mutations in the CYP11B2 gene.
  JOURNAL   Eur J Endocrinol 144:59-62 (2001)
REFERENCE   PMID:10559665
  AUTHORS   Peter M, Dubuis JM, Sippell WG
  TITLE     Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
  JOURNAL   Horm Res 51:211-22 (1999)
///
ENTRY       H00259                      Disease
NAME        Apparent mineralocorticoid excess syndrome;
            11-beta-ketoreductase deficiency
DESCRIPTION Apparent mineralocorticoid excess (AME) syndrome is characterized by hypertension, low plasma renin and aldosterone and hypokalaemia caused by deficiency of 11b-hydroxysteroid dehydrogenase type 2 which is a microsomal enzyme complex responsible for the interconversion of cortisol and cortisone.
CATEGORY    Endocrine disease; Metabolic disease
GENE        HSD11B2 [HSA:3291] [KO:K00071]
DRUG        Dexamethasone [DG:DG00011]
DBLINKS     ICD-10: E27.4 I15.2
            OMIM: 218030 207765
REFERENCE   PMID:16980198
  AUTHORS   Hammer F, Stewart PM
  TITLE     Cortisol metabolism in hypertension.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 20:337-53 (2006)
REFERENCE   PMID:15761540
  AUTHORS   Palermo M, Quinkler M, Stewart PM
  TITLE     Apparent mineralocorticoid excess syndrome: an overview.
  JOURNAL   Arq Bras Endocrinol Metabol 48:687-96 (2004)
///
ENTRY       H00260                      Disease
NAME        Pigmented micronodular adrenocortical disease (PPNAD)
DESCRIPTION Primary pigmented micronodular adrenocortical disease is a form of ACTH-independent adrenal hyperplasia resulting in endogenous Cushing's syndrome.
CATEGORY    Endocrine disease
GENE        (PPNAD1) PRKAR1A [HSA:5573] [KO:K04739]
            (PPNAD2) PDE11A [HSA:50940] [KO:K13298]
            (PPNAD3) PDE8B [HSA:8622] [KO:K18437]
DBLINKS     ICD-10: E27.5
            MeSH: C566469 C566472
            OMIM: 610489 610475 603390
REFERENCE   PMID:18549891
  AUTHORS   Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR, Pingpank JF, Keil M, Bartlett DL, Libutti SK
  TITLE     Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia.
  JOURNAL   Surgery 143:750-8 (2008)
REFERENCE   PMID:18493137
  AUTHORS   Stratakis CA
  TITLE     Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome).
  JOURNAL   Endocr Dev 13:117-32 (2008)
REFERENCE   PMID:12119280
  AUTHORS   Bourdeau I, Stratakis CA
  TITLE     Cyclic AMP-dependent signaling aberrations in macronodular adrenal disease.
  JOURNAL   Ann N Y Acad Sci 968:240-55 (2002)
///
ENTRY       H00261                      Disease
NAME        Meckel syndrome (MKS);
            Meckel-Gruber syndrome
DESCRIPTION Meckel syndrome (MKS) is a lethal, autosomal recessive disorder characterized by anomalies of the central nervous system, cystic dysplasia of the kidneys, and malformations of the hands and feet.
CATEGORY    Nervous system disease; Kidney disease
GENE        (MKS1) MKS1 [HSA:54903] [KO:K19332]
            (MKS3) TMEM67 [HSA:91147] [KO:K19348]
            (MKS4) CEP290 [HSA:80184] [KO:K16533]
            (MKS5) RPGRIP1L [HSA:23322] [KO:K16550]
            (MKS6) CC2D2A [HSA:57545] [KO:K19352]
            (MKS7) NPHP3 [HSA:27031] [KO:K19360]
            (MKS8) TCTN2 [HSA:79867] [KO:K19361]
            (MKS9) B9D1 [HSA:27077] [KO:K16744]
            (MKS10) B9D2 [HSA:80776] [KO:K16745]
            (MKS11) TMEM231 [HSA:79583] [KO:K19362]
DBLINKS     ICD-10: Q61.9
            MeSH: C536133 C536131 C536132
            OMIM: 249000 603194 607361 611134 611561 612284 267010 613885 614209 614175 615397
REFERENCE   PMID:17389183
  AUTHORS   Chen CP
  TITLE     Meckel syndrome: genetics, perinatal findings, and differential diagnosis.
  JOURNAL   Taiwan J Obstet Gynecol 46:9-14 (2007)
REFERENCE   PMID:16879033
  AUTHORS   Alexiev BA, Lin X, Sun CC, Brenner DS
  TITLE     Meckel-Gruber syndrome: pathologic manifestations, minimal diagnostic criteria, and differential diagnosis.
  JOURNAL   Arch Pathol Lab Med 130:1236-8 (2006)
REFERENCE   PMID:9643292
  AUTHORS   Salonen R, Paavola P
  TITLE     Meckel syndrome.
  JOURNAL   J Med Genet 35:497-501 (1998)
REFERENCE   PMID:21898032
  AUTHORS   Bergmann C
  TITLE     Educational paper : Ciliopathies.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:18371931
  AUTHORS   Bergmann C, Fliegauf M, Bruchle NO, Frank V, Olbrich H, Kirschner J, Schermer B, Schmedding I, Kispert A, Kranzlin B, Nurnberg G, Becker C, Grimm T, Girschick G, Lynch SA, Kelehan P, Senderek J, Neuhaus TJ, Stallmach T, Zentgraf H, Nurnberg P, Gretz N, Lo C, Lienkamp S, Schafer T, Walz G, Benzing T, Zerres K, Omran H
  TITLE     Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia.
  JOURNAL   Am J Hum Genet 82:959-70 (2008)
REFERENCE   PMID:21462283
  AUTHORS   Shaheen R, Faqeih E, Seidahmed MZ, Sunker A, Alali FE, AlQahtani K, Alkuraya FS
  TITLE     A TCTN2 mutation defines a novel Meckel Gruber syndrome locus.
  JOURNAL   Hum Mutat 32:573-8 (2011)
REFERENCE   PMID:21763481
  AUTHORS   Dowdle WE, Robinson JF, Kneist A, Sirerol-Piquer MS, Frints SG, Corbit KC, Zaghloul NA, van Lijnschoten G, Mulders L, Verver DE, Zerres K, Reed RR, Attie-Bitach T, Johnson CA, Garcia-Verdugo JM, Katsanis N, Bergmann C, Reiter JF
  TITLE     Disruption of a ciliary B9 protein complex causes Meckel syndrome.
  JOURNAL   Am J Hum Genet 89:94-110 (2011)
REFERENCE   PMID:23349226
  AUTHORS   Shaheen R, Ansari S, Mardawi EA, Alshammari MJ, Alkuraya FS
  TITLE     Mutations in TMEM231 cause Meckel-Gruber syndrome.
  JOURNAL   J Med Genet 50:160-2 (2013)
///
ENTRY       H00262                      Disease
NAME        Spina bifida
DESCRIPTION Spina bifida is a group of congenital defects of closure of one or more vertebral arches. The genetic studies have shown the relationships of folate-related genes.
CATEGORY    Developmental disorder; Nervous system disease
GENE        MTHFR [HSA:4524] [KO:K00297]
            VANGL1 [HSA:81839] [KO:K04510]
            MTR [HSA:4548] [KO:K00548]
            MTRR [HSA:4552] [KO:K00597]
            MTHFD1 [HSA:4522] [KO:K00288]
DRUG        Folic acid [DG:DG00176]
DBLINKS     ICD-10: Q05
            MeSH: D016135
            OMIM: 182940 601634
REFERENCE   PMID:19120526
  AUTHORS   Kondo A, Kamihira O, Ozawa H
  TITLE     Neural tube defects: prevalence, etiology and prevention.
  JOURNAL   Int J Urol 16:49-57 (2009)
REFERENCE   PMID:17963270
  AUTHORS   Beaudin AE, Stover PJ
  TITLE     Folate-mediated one-carbon metabolism and neural tube defects: balancing genome synthesis and gene expression.
  JOURNAL   Birth Defects Res C Embryo Today 81:183-203 (2007)
REFERENCE   PMID:17470131
  AUTHORS   Kibar Z, Capra V, Gros P
  TITLE     Toward understanding the genetic basis of neural tube defects.
  JOURNAL   Clin Genet 71:295-310 (2007)
///
ENTRY       H00263                      Disease
NAME        Acrocallosal syndrome;
            Greig cephalopolysyndactyly syndrome
DESCRIPTION Acrocallosal syndrome is an autosomal recessive condition, characterized by agenesis of the corpus callosum, polydactyly, minor craniofacial anomalies and psychomotor retardation.
CATEGORY    Nervous system disease; Skeletal dysplasia
GENE        GLI3 [HSA:2737] [KO:K06230]
DBLINKS     ICD-10: Q04.0
            MeSH: D055673 C537300
            OMIM: 200990 175700
REFERENCE   PMID:18435847
  AUTHORS   Biesecker LG
  TITLE     The Greig cephalopolysyndactyly syndrome.
  JOURNAL   Orphanet J Rare Dis 3:10 (2008)
REFERENCE   PMID:12414818
  AUTHORS   Elson E, Perveen R, Donnai D, Wall S, Black GC
  TITLE     De novo GLI3 mutation in acrocallosal syndrome: broadening the phenotypic spectrum of GLI3 defects and overlap with murine models.
  JOURNAL   J Med Genet 39:804-6 (2002)
REFERENCE   PMID:11857542
  AUTHORS   Koenig R, Bach A, Woelki U, Grzeschik KH, Fuchs S
  TITLE     Spectrum of the acrocallosal syndrome.
  JOURNAL   Am J Med Genet 108:7-11 (2002)
REFERENCE   PMID:15739154
  AUTHORS   Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylsworth AS, Bamshad MJ, Booth C, Curry CJ, David A, Dinulos MB, Flannery DB, Fox MA, Graham JM, Grange DK, Guttmacher AE, Hannibal MC, Henn W, Hennekam RC, Holmes LB, Hoyme HE, Leppig KA, Lin AE, Macleod P, Manchester DK, Marcelis C, Mazzanti L, McCann E, McDonald MT, Mendelsohn NJ, Moeschler JB, Moghaddam B, Neri G, Newbury-Ecob R, Pagon RA, Phillips JA, Sadler LS, Stoler JM, Tilstra D, Walsh Vockley CM, Zackai EH, Zadeh TM, Brueton L, Black GC, Biesecker LG
  TITLE     Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations.
  JOURNAL   Am J Hum Genet 76:609-22 (2005)
///
ENTRY       H00264                      Disease
NAME        Charcot-Marie-Tooth disease (CMT);
            Hereditary motor and sensory neuropathy;
            Peroneal muscular atrophy
DESCRIPTION Charcot-Marie-Tooth disease is a genetically heterogeneous group of inherited peripheral neuropathies characterized by progressive distal wasting and loss of reflexes in the muscles of the legs.
CATEGORY    Neurodegenerative disease
GENE        (CMT1A/1E) PMP22 [HSA:5376] [KO:K19289]
            (CMT1B/2I/2J/4E) MPZ [HSA:4359] [KO:K06770]
            (CMT1C) LITAF [HSA:9516] [KO:K19363]
            (CMT1D/4E) EGR2 [HSA:1959] [KO:K12496]
            (CMT1F/2E) NEFL [HSA:4747] [KO:K04572]
            (CMT2A1) KIF1B [HSA:23095] [KO:K10392]
            (CMT2A2/6) MFN2 [HSA:9927] [KO:K06030]
            (CMT2B) RAB7A [HSA:7879] [KO:K07897]
            (CMT2B1) LMNA [HSA:4000] [KO:K12641]
            (CMT2B2) MED25 [HSA:81857] [KO:K15168]
            (CMT2D) GARS [HSA:2617] [KO:K01880]
            (CMT2F) HSPB1 [HSA:51668] [KO:K19369]
            (CMT2K/4A/RIA) GDAP1 [HSA:54332]
            (CMT2L) HSPB8 [HSA:26353] [KO:K08879]
            (CMT2M/DIB) DNM2 [HSA:1785] [KO:K01528]
            (CMT2N) AARS [HSA:16] [KO:K01872]
            (CMT2O) DYNC1H1 [HSA:1778] [KO:K10413]
            (CMT2P) LRSAM1 [HSA:90678] [KO:K10641]
            (CMT2Q) DHTKD1 [HSA:55526] [KO:K15791]
            (CMT2R) TRIM2 [HSA:23321] [KO:K11997]
            (CMT2S) IGHMBP2 [HSA:3508] [KO:K19036]
            (CMT2T) MME [HSA:4311] [KO:K01389]
            (CMT2U) MARS [HSA:4141] [KO:K01874]
            (CMT2W) HARS [HSA:3035] [KO:K01892]
            (CMT2Y) VCP [HSA:7415] [KO:K13525]
            (CMT2Z) MORC2 [HSA:22880]
            (CMT4B1) MTMR2 [HSA:8898] [KO:K18081]
            (CMT4B2) SBF2 [HSA:81846] [KO:K18061]
            (CMT4B3) SBF1 [HSA:6305] [KO:K18061]
            (CMT4C/MNMN) SH3TC2 [HSA:79628]
            (CMT4D) NDRG1 [HSA:10397] [KO:K18266]
            (CMT4F) PRX [HSA:57716]
            (CMT4H) FGD4 [HSA:121512] [KO:K05723]
            (CMT4J) FIG4 [HSA:9896]
            (CMT4K) SURF1 [HSA:6834] [KO:K14998]
            (CMTX1) GJB1 [HSA:2705] [KO:K07620]
            (CMTX5) PRPS1 [HSA:5631] [KO:K00948]
            (CMTDIC) YARS [HSA:8565] [KO:K01866]
            (CMTDIE) INF2 [HSA:64423]
            (CMTDIF) GNB4 [HSA:59345] [KO:K04538]
            (CMTRIB) KARS [HSA:3735] [KO:K04567]
            (CMTRIC) PLEKHG5 [HSA:57449] [KO:K19464]
            (CMTRID) COX6A1 [HSA:1337] [KO:K02266]
COMMENT     CMT1: Abnormal myelin, autosomal dominant
            CMT2: Axonopathy, autosomal dominant
            Intermediate form: Combination of myelinopathy and axonopathy in individual, autosomal dominant
            CMT4: Either myelinopathy or axonopathy, autosomal recessive
            CMTX: Axonopathy with secondary myelin changes, X-linked dominant
            MNMN: Mononeuropathy of the median nerve mild
DBLINKS     ICD-10: G60.0
            MeSH: D002607
            OMIM: 118200 118210 118220 118300 145900 214400 302800 311070 607678 607734 600882 601098 601382 601472 601455 605253 601596 603623 604563 605588 605589 606482 606595 607677 607684 607706 607734 607736 607791 607831 608323 608340 608673 609260 609311 611228 613287 614228 614436 615025 615490 613641 601152 613353 616155 617017 616280 616625 616687 616688 607706 614455 615185 615376 616039 615284 616684
REFERENCE   PMID:18215208
  AUTHORS   Barisic N, Claeys KG, Sirotkovic-Skerlev M, Lofgren A, Nelis E, De Jonghe P, Timmerman V
  TITLE     Charcot-Marie-Tooth disease: a clinico-genetic confrontation.
  JOURNAL   Ann Hum Genet 72:416-41 (2008)
REFERENCE   PMID:16775378
  AUTHORS   Niemann A, Berger P, Suter U
  TITLE     Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.
  JOURNAL   Neuromolecular Med 8:217-42 (2006)
REFERENCE   PMID:15518599
  AUTHORS   Bertorini T, Narayanaswami P, Rashed H
  TITLE     Charcot-Marie-Tooth disease (hereditary motor sensory neuropathies) and hereditary sensory and autonomic neuropathies.
  JOURNAL   Neurologist 10:327-37 (2004)
REFERENCE   PMID:14685682
  AUTHORS   Young P, Suter U
  TITLE     The causes of Charcot-Marie-Tooth disease.
  JOURNAL   Cell Mol Life Sci 60:2547-60 (2003)
REFERENCE   PMID:12030326
  AUTHORS   Berger P, Young P, Suter U
  TITLE     Molecular cell biology of Charcot-Marie-Tooth disease.
  JOURNAL   Neurogenetics 4:1-15 (2002)
REFERENCE   PMID:17595294
  AUTHORS   Nangle LA, Zhang W, Xie W, Yang XL, Schimmel P
  TITLE     Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered  dimer interface and neurite distribution defect.
  JOURNAL   Proc Natl Acad Sci U S A 104:11239-44 (2007)
REFERENCE   PMID:20301532
  AUTHORS   Bird TD
  TITLE     Charcot-Marie-Tooth Hereditary Neuropathy Overview
  JOURNAL   (1993)
REFERENCE   PMID:20220177 (MNMN)
  AUTHORS   Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, Bainbridge M, Dinh H, Jing C, Wheeler DA, McGuire AL, Zhang F, Stankiewicz P, Halperin JJ, Yang C, Gehman C, Guo D, Irikat RK, Tom W, Fantin NJ, Muzny DM, Gibbs RA
  TITLE     Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy.
  JOURNAL   N Engl J Med 362:1181-91 (2010)
REFERENCE   PMID:21820100
  AUTHORS   Weedon MN, Hastings R, Caswell R, Xie W, Paszkiewicz K, Antoniadi T, Williams M, King C, Greenhalgh L, Newbury-Ecob R, Ellard S
  TITLE     Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant  axonal Charcot-Marie-Tooth disease.
  JOURNAL   Am J Hum Genet 89:308-12 (2011)
REFERENCE   PMID:20865121
  AUTHORS   Guernsey DL, Jiang H, Bedard K, Evans SC, Ferguson M, Matsuoka M, Macgillivray C, Nightingale M, Perry S, Rideout AL, Orr A, Ludman M, Skidmore DL, Benstead T, Samuels ME
  TITLE     Mutation in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-Marie-Tooth disease.
  JOURNAL   PLoS Genet 6 (2010)
REFERENCE   PMID:23141294
  AUTHORS   Xu WY, Gu MM, Sun LH, Guo WT, Zhu HB, Ma JF, Yuan WT, Kuang Y, Ji BJ, Wu XL, Chen Y, Zhang HX, Sun FT, Huang W, Huang L, Chen SD, Wang ZG
  TITLE     A nonsense mutation in DHTKD1 causes Charcot-Marie-Tooth disease type 2 in a large Chinese pedigree.
  JOURNAL   Am J Hum Genet 91:1088-94 (2012)
REFERENCE   PMID:23562820
  AUTHORS   Ylikallio E, Poyhonen R, Zimon M, De Vriendt E, Hilander T, Paetau A, Jordanova A, Lonnqvist T, Tyynismaa H
  TITLE     Deficiency of the E3 ubiquitin ligase TRIM2 in early-onset axonal neuropathy.
  JOURNAL   Hum Mol Genet 22:2975-83 (2013)
REFERENCE   PMID:25439726 (gene)
  AUTHORS   Cottenie E, Kochanski A, Jordanova A, Bansagi B, Zimon M, Horga A, Jaunmuktane Z, Saveri P, Rasic VM, Baets J, Bartsakoulia M, Ploski R, Teterycz P, Nikolic M, Quinlivan R, Laura M, Sweeney MG, Taroni F, Lunn MP, Moroni I, Gonzalez M, Hanna MG, Bettencourt C, Chabrol E, Franke A, von Au K, Schilhabel M, Kabzinska D, Hausmanowa-Petrusewicz I, Brandner S, Lim SC, Song H, Choi BO, Horvath R, Chung KW, Zuchner S, Pareyson D, Harms M, Reilly MM, Houlden H
  TITLE     Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.
  JOURNAL   Am J Hum Genet 95:590-601 (2014)
REFERENCE   PMID:26991897 (gene)
  AUTHORS   Higuchi Y, Hashiguchi A, Yuan J, Yoshimura A, Mitsui J, Ishiura H, Tanaka M, Ishihara S, Tanabe H, Nozuma S, Okamoto Y, Matsuura E, Ohkubo R, Inamizu S, Shiraishi W, Yamasaki R, Ohyagi Y, Kira J, Oya Y, Yabe H, Nishikawa N, Tobisawa S, Matsuda N, Masuda M, Kugimoto C, Fukushima K, Yano S, Yoshimura J, Doi K, Nakagawa M, Morishita S, Tsuji S, Takashima H
  TITLE     Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2.
  JOURNAL   Ann Neurol 79:659-72 (2016)
REFERENCE   PMID:23729695 (gene)
  AUTHORS   Gonzalez M, McLaughlin H, Houlden H, Guo M, Yo-Tsen L, Hadjivassilious M, Speziani F, Yang XL, Antonellis A, Reilly MM, Zuchner S
  TITLE     Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2.
  JOURNAL   J Neurol Neurosurg Psychiatry 84:1247-9 (2013)
REFERENCE   PMID:26072516 (gene)
  AUTHORS   Safka Brozkova D, Deconinck T, Griffin LB, Ferbert A, Haberlova J, Mazanec R, Lassuthova P, Roth C, Pilunthanakul T, Rautenstrauss B, Janecke AR, Zavadakova P, Chrast R, Rivolta C, Zuchner S, Antonellis A, Beg AA, De Jonghe P, Senderek J, Seeman P, Baets J
  TITLE     Loss of function mutations in HARS cause a spectrum of inherited peripheral neuropathies.
  JOURNAL   Brain 138:2161-72 (2015)
REFERENCE   PMID:25125609 (gene)
  AUTHORS   Gonzalez MA, Feely SM, Speziani F, Strickland AV, Danzi M, Bacon C, Lee Y, Chou TF, Blanton SH, Weihl CC, Zuchner S, Shy ME
  TITLE     A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease.
  JOURNAL   Brain 137:2897-902 (2014)
REFERENCE   PMID:26659848 (gene)
  AUTHORS   Albulym OM, Kennerson ML, Harms MB, Drew AP, Siddell AH, Auer-Grumbach M, Pestronk A, Connolly A, Baloh RH, Zuchner S, Reddel SW, Nicholson GA
  TITLE     MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs.
  JOURNAL   Ann Neurol 79:419-27 (2016)
REFERENCE   PMID:22187985 (gene)
  AUTHORS   Boyer O, Nevo F, Plaisier E, Funalot B, Gribouval O, Benoit G, Huynh Cong E, Arrondel C, Tete MJ, Montjean R, Richard L, Karras A, Pouteil-Noble C, Balafrej L, Bonnardeaux A, Canaud G, Charasse C, Dantal J, Deschenes G, Deteix P, Dubourg O, Petiot P, Pouthier D, Leguern E, Guiochon-Mantel A, Broutin I, Gubler MC, Saunier S, Ronco P, Vallat JM, Alonso MA, Antignac C, Mollet G
  TITLE     INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy.
  JOURNAL   N Engl J Med 365:2377-88 (2011)
REFERENCE   PMID:23434117 (gene)
  AUTHORS   Soong BW, Huang YH, Tsai PC, Huang CC, Pan HC, Lu YC, Chien HJ, Liu TT, Chang MH, Lin KP, Tu PH, Kao LS, Lee YC
  TITLE     Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-Tooth disease.
  JOURNAL   Am J Hum Genet 92:422-30 (2013)
REFERENCE   PMID:23777631 (gene)
  AUTHORS   Azzedine H, Zavadakova P, Plante-Bordeneuve V, Vaz Pato M, Pinto N, Bartesaghi L, Zenker J, Poirot O, Bernard-Marissal N, Arnaud Gouttenoire E, Cartoni R, Title A, Venturini G, Medard JJ, Makowski E, Schols L, Claeys KG, Stendel C, Roos A, Weis J, Dubourg O, Leal Loureiro J, Stevanin G, Said G, Amato A, Baraban J, LeGuern E, Senderek J, Rivolta C, Chrast R
  TITLE     PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease.
  JOURNAL   Hum Mol Genet 22:4224-32 (2013)
REFERENCE   PMID:25152455 (gene)
  AUTHORS   Tamiya G, Makino S, Hayashi M, Abe A, Numakura C, Ueki M, Tanaka A, Ito C, Toshimori K, Ogawa N, Terashima T, Maegawa H, Yanagisawa D, Tooyama I, Tada M, Onodera O, Hayasaka K
  TITLE     A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth disease.
  JOURNAL   Am J Hum Genet 95:294-300 (2014)
REFERENCE   PMID:24799518 (gene)
  AUTHORS   Alazami AM, Alzahrani F, Bohlega S, Alkuraya FS
  TITLE     SET binding factor 1 (SBF1) mutation causes Charcot-Marie-tooth disease type 4B3.
  JOURNAL   Neurology 82:1665-6 (2014)
REFERENCE   PMID:24027061 (gene)
  AUTHORS   Echaniz-Laguna A, Ghezzi D, Chassagne M, Mayencon M, Padet S, Melchionda L, Rouvet I, Lannes B, Bozon D, Latour P, Zeviani M, Mousson de Camaret B
  TITLE     SURF1 deficiency causes demyelinating Charcot-Marie-Tooth disease.
  JOURNAL   Neurology 81:1523-30 (2013)
///
ENTRY       H00265                      Disease
NAME        Hereditary sensory and autonomic neuropathy (HSAN), including:
            Familial dysautonomia (FD/HSAN3);
            Riley-Day syndrome (HSAN3);
            Congenital pain insensitivity with anhidrosis (CIPA/HSAN4)
DESCRIPTION Hereditary sensory and autonomic neuropathies (HSAN), also known as hereditary sensory neuropathies (HSN), are a clinically and genetically heterogeneous group of disorders of low prevalence. They are caused by neuronal atrophy and degeneration, predominantly affecting peripheral sensory and autonomic neurons. Hallmark features are progressive sensory loss, chronic skin ulcers, and other skin abnormalities. Autonomic features vary between different subgroups. Distal muscle weakness and wasting may be present and is sometimes so prominent that it becomes difficult to distinguish HSAN from Charcot-Marie-Tooth (CMT) syndrome [DS:H00264].  Many of the causing genes for autosomal-dominant and autosomal-recessive HSAN  have been identified. These genes have been shown to play roles in lipid metabolism and the regulation of intracellular vesicular transport, but also a presumptive transcriptional regulator, a nerve growth factor receptor, and a nerve growth factor have been described among the causative genes in HSAN. HSAN1 and CMT2B are clinically identical despite being caused by mutations in different genes.
CATEGORY    Nervous system disease
GENE        (HSAN1) SPTLC1 [HSA:10558] [KO:K00654]
            (HSAN1C) SPTLC2 [HSA:9517] [KO:K00654]
            (CMT2B/HMSN2B) RAB7 [HSA:7879] [KO:K07897]
            (HSAN2) HSN2 [HSA:65125] [KO:K08867]
            (HSAN2B) FAM134B [HSA:54463]
            (HSAN2C) KIF1A [HSA:547] [KO:K10392]
            (HSAN3/FD) IKBKAP [HSA:8518] [KO:K11373]
            (HSAN4/CIPA) NTRK1 [HSA:4914] [KO:K03176]
            (HSAN5) NGFB [HSA:4803] [KO:K02582]
            (HSNSP) CCT5 [HSA:22948] [KO:K09497]
            (Channelopathy associated insensitivity to pain) SCN9A [HSA:6335] [KO:K04841]
            (HSAN6) DST [HSA:667] [KO:K10382]
            (HSAN7) SCN11A [HSA:11280] [KO:K04843]
            (HSAN8) PRDM12 [HSA:59335]
DBLINKS     ICD-10: G90.1 G60.8
            MeSH: D009477
            OMIM: 162400 613640 600882 201300 613115 614213 223900 256800 608654 256840 243000 614653 615548 616488
REFERENCE   PMID:16775373 (description, gene)
  AUTHORS   Auer-Grumbach M, Mauko B, Auer-Grumbach P, Pieber TR
  TITLE     Molecular genetics of hereditary sensory neuropathies.
  JOURNAL   Neuromolecular Med 8:147-58 (2006)
REFERENCE   PMID:19917815 (description, gene)
  AUTHORS   Reilly MM, Shy ME
  TITLE     Diagnosis and new treatments in genetic neuropathies.
  JOURNAL   J Neurol Neurosurg Psychiatry 80:1304-14 (2009)
REFERENCE   PMID:19838196 (gene)
  AUTHORS   Kurth I, Pamminger T, Hennings JC, Soehendra D, Huebner AK, Rotthier A, Baets J, Senderek J, Topaloglu H, Farrell SA, Nurnberg G, Nurnberg P, De Jonghe P, Gal A, Kaether C, Timmerman V, Hubner CA
  TITLE     Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and autonomic neuropathy.
  JOURNAL   Nat Genet 41:1179-81 (2009)
REFERENCE   PMID:21820098 (gene)
  AUTHORS   Riviere JB, Ramalingam S, Lavastre V, Shekarabi M, Holbert S, Lafontaine J, Srour M, Merner N, Rochefort D, Hince P, Gaudet R, Mes-Masson AM, Baets J, Houlden H, Brais B, Nicholson GA, Van Esch H, Nafissi S, De Jonghe P, Reilly MM, Timmerman V, Dion PA, Rouleau GA
  TITLE     KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2.
  JOURNAL   Am J Hum Genet 89:219-30 (2011)
REFERENCE   PMID:17915006
  AUTHORS   Axelrod FB, Gold-von Simson G
  TITLE     Hereditary sensory and autonomic neuropathies: types II, III, and IV.
  JOURNAL   Orphanet J Rare Dis 2:39 (2007)
REFERENCE   PMID:16969157
  AUTHORS   Verhoeven K, Timmerman V, Mauko B, Pieber TR, De Jonghe P, Auer-Grumbach M
  TITLE     Recent advances in hereditary sensory and autonomic neuropathies.
  JOURNAL   Curr Opin Neurol 19:474-80 (2006)
REFERENCE   PMID:16183296
  AUTHORS   Verpoorten N, De Jonghe P, Timmerman V
  TITLE     Disease mechanisms in hereditary sensory and autonomic neuropathies.
  JOURNAL   Neurobiol Dis 21:247-55 (2006)
REFERENCE   PMID:20920666
  AUTHORS   Rotthier A, Auer-Grumbach M, Janssens K, Baets J, Penno A, Almeida-Souza L, Van Hoof K, Jacobs A, De Vriendt E, Schlotter-Weigel B, Loscher W, Vondracek P, Seeman P, De Jonghe P, Van Dijck P, Jordanova A, Hornemann T, Timmerman V
  TITLE     Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I.
  JOURNAL   Am J Hum Genet 87:513-22 (2010)
REFERENCE   PMID:16399879
  AUTHORS   Bouhouche A, Benomar A, Bouslam N, Chkili T, Yahyaoui M
  TITLE     Mutation in the epsilon subunit of the cytosolic chaperonin-containing t-complex  peptide-1 (Cct5) gene causes autosomal recessive mutilating sensory neuropathy with spastic paraplegia.
  JOURNAL   J Med Genet 43:441-3 (2006)
REFERENCE   PMID:22522446 (gene)
  AUTHORS   Edvardson S, Cinnamon Y, Jalas C, Shaag A, Maayan C, Axelrod FB, Elpeleg O
  TITLE     Hereditary sensory autonomic neuropathy caused by a mutation in dystonin.
  JOURNAL   Ann Neurol 71:569-72 (2012)
REFERENCE   PMID:25118027 (gene)
  AUTHORS   Woods CG, Babiker MO, Horrocks I, Tolmie J, Kurth I
  TITLE     The phenotype of congenital insensitivity to pain due to the NaV1.9 variant p.L811P.
  JOURNAL   Eur J Hum Genet 23:561-3 (2015)
REFERENCE   PMID:16360608 (gene)
  AUTHORS   Butler J, Fleming P, Webb D
  TITLE     Congenital insensitivity to pain--review and report of a case with dental implications.
  JOURNAL   Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:58-62 (2006)
///
ENTRY       H00266                      Disease
NAME        Hereditary spastic paraplegia (SPG)
DESCRIPTION Hereditary spastic paraplegias are a group of clinically and genetically diverse disorders characterized by progressive distal limb weakness and lower extremity spasticity.
CATEGORY    Nervous system disease; Muscular disease
GENE        (SPG1) L1CAM [HSA:3897] [KO:K06550]
            (SPG2) PLP1 [HSA:5354] [KO:K17271]
            (SPG3) ATL1 [HSA:51062] [KO:K17339]
            (SPG4) SPAST [HSA:6683] [KO:K13254]
            (SPG5) CYP7B1 [HSA:9420] [KO:K07430]
            (SPG6) NIPA1 [HSA:123606] [KO:K19364]
            (SPG7) SPG7 [HSA:6687] [KO:K09552]
            (SPG8) KIAA0196 [HSA:9897] [KO:K18464]
            (SPG10) KIF5A [HSA:3798] [KO:K10396]
            (SPG11) SPG11 [HSA:80208] [KO:K19026]
            (SPG13) HSPD1 [HSA:3329] [KO:K04077]
            (SPG15) ZFYVE26 [HSA:23503] [KO:K19027]
            (SPG17) BSCL2 [HSA:26580] [KO:K19365]
            (SPG20) SPG20 [HSA:23111] [KO:K19366]
            (SPG21) SPG21 [HSA:51324] [KO:K19367]
            (SPG31) REEP1 [HSA:65055] [KO:K17338]
            (SPG33) ZFYVE27 [HSA:118813] [KO:K19368]
            (SPG39) PNPLA6 [HSA:10908] [KO:K14676]
            (SPG42) SLC33A1 [HSA:9197] [KO:K03372]
            (SPG44) GJC2 [HSA:57165] [KO:K07619]
            (SPG48) AP5Z1 [HSA:9907] [KO:K19025]
DRUG        Baclofen [DR:D00241]
            Dantrolene [DG:DG00778]
            Tizanidine [DG:DG00773]
DBLINKS     ICD-10: G11.4
            MeSH: D015419
            OMIM: 303350 312920 182600 182601 270800 600363 607259 603563 604187 604360 605280 270700 270685 275900 248900 607584 608220 609195 609041 609340 609727 610357 610250 611252 610244 300750 612319 611945 612335 612020 612539 613206 613647
REFERENCE   PMID:19007737
  AUTHORS   Salinas S, Proukakis C, Crosby A, Warner TT
  TITLE     Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms.
  JOURNAL   Lancet Neurol 7:1127-38 (2008)
REFERENCE   PMID:16469273
  AUTHORS   Fink JK
  TITLE     Hereditary spastic paraplegia.
  JOURNAL   Curr Neurol Neurosci Rep 6:65-76 (2006)
REFERENCE   PMID:14597333
  AUTHORS   Fink JK
  TITLE     Advances in the hereditary spastic paraplegias.
  JOURNAL   Exp Neurol 184 Suppl 1:S106-10 (2003)
REFERENCE   PMID:19056803
  AUTHORS   Orthmann-Murphy JL, Salsano E, Abrams CK, Bizzi A, Uziel G, Freidin MM, Lamantea E, Zeviani M, Scherer SS, Pareyson D
  TITLE     Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations.
  JOURNAL   Brain 132:426-38 (2009)
REFERENCE   PMID:20613862
  AUTHORS   Slabicki M, Theis M, Krastev DB, Samsonov S, Mundwiller E, Junqueira M, Paszkowski-Rogacz M, Teyra J, Heninger AK, Poser I, Prieur F, Truchetto J, Confavreux C, Marelli C, Durr A, Camdessanche JP, Brice A, Shevchenko A, Pisabarro MT, Stevanin G, Buchholz F
  TITLE     A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia.
  JOURNAL   PLoS Biol 8:e1000408 (2010)
REFERENCE   PMID:14564668
  AUTHORS   Simpson MA, Cross H, Proukakis C, Pryde A, Hershberger R, Chatonnet A, Patton MA, Crosby AH
  TITLE     Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia.
  JOURNAL   Am J Hum Genet 73:1147-56 (2003)
///
ENTRY       H00267                      Disease
NAME        Holoprosencephaly (HPE)
DESCRIPTION Holoprosencephaly is characterized by incomplete separation of forebrain and facial components into left and right sides.
CATEGORY    Developmental disorder; Nervous system disease
GENE        (HPE2) SIX3 [HSA:6496] [KO:K19473]
            (HPE3) SHH [HSA:6469] [KO:K11988]
            (HPE4) TGIF1 [HSA:7050] [KO:K19383]
            (HPE5) ZIC2 [HSA:7546] [KO:K06235]
            (HPE7) PTCH1 [HSA:5727] [KO:K06225]
            (HPE9) GLI2 [HSA:2736] [KO:K16798]
DBLINKS     ICD-10: Q04.2
            MeSH: D016142
            OMIM: 236100 157170 142945 142946 609637 605934 610828 609408 610829
REFERENCE   PMID:18695774
  AUTHORS   Lim AS, Lim TH, Kee SK, Chia P, Raman S, Eu EL, Lim JY, Tien SL
  TITLE     Holoprosencephaly: an antenatally-diagnosed case series and subject review.
  JOURNAL   Ann Acad Med Singapore 37:594-7 (2008)
REFERENCE   PMID:18394003
  AUTHORS   Fernandes M, Hebert JM
  TITLE     The ups and downs of holoprosencephaly: dorsal versus ventral patterning forces.
  JOURNAL   Clin Genet 73:413-23 (2008)
REFERENCE   PMID:17274816
  AUTHORS   Dubourg C, Bendavid C, Pasquier L, Henry C, Odent S, David V
  TITLE     Holoprosencephaly.
  JOURNAL   Orphanet J Rare Dis 2:8 (2007)
REFERENCE   PMID:17001700
  AUTHORS   Cohen MM Jr
  TITLE     Holoprosencephaly: clinical, anatomic, and molecular dimensions.
  JOURNAL   Birth Defects Res A Clin Mol Teratol 76:658-73 (2006)
REFERENCE   PMID:10923031
  AUTHORS   Wallis D, Muenke M
  TITLE     Mutations in holoprosencephaly.
  JOURNAL   Hum Mutat 16:99-108 (2000)
///
ENTRY       H00268                      Disease
NAME        Lissencephaly (LIS);
            Miller-Dieker syndrome (MDLS)
DESCRIPTION Lissencephaly, literally meaning smooth brain, is a severe neuronal migration disorder that ranges from agyria/pachygyria to subcortical band heterotopia.
CATEGORY    Developmental disorder; Nervous system disease
GENE        (LIS1/MDLS) PAFAH1B1 [HSA:5048] [KO:K16794]
            (LIS2) RELN [HSA:5649] [KO:K06249]
            (LIS3) TUBA1A [HSA:7846] [KO:K07374]
            (LISX1) DCX [HSA:1641] [KO:K16579]
            (LISX2) ARX [HSA:170302] [KO:K09452]
            (MDLS) YWHAE [HSA:7531] [KO:K06630]
DBLINKS     ICD-10: Q04.3
            MeSH: D054082
            OMIM: 607432 257320 611603 300067 300215
REFERENCE   PMID:19136950
  AUTHORS   Bi W, Sapir T, Shchelochkov OA, Zhang F, Withers MA, Hunter JV, Levy T, Shinder V, Peiffer DA, Gunderson KL, Nezarati MM, Shotts VA, Amato SS, Savage SK, Harris DJ, Day-Salvatore DL, Horner M, Lu XY, Sahoo T, Yanagawa Y, Beaudet AL, Cheung SW, Martinez S, Lupski JR, Reiner O
  TITLE     Increased LIS1 expression affects human and mouse brain development.
  JOURNAL   Nat Genet 41:168-77 (2009)
REFERENCE   PMID:19120042
  AUTHORS   Spalice A, Parisi P, Nicita F, Pizzardi G, Del Balzo F, Iannetti P
  TITLE     Neuronal migration disorders: clinical, neuroradiologic and genetics aspects.
  JOURNAL   Acta Paediatr 98:421-33 (2009)
REFERENCE   PMID:18685874
  AUTHORS   Leger PL, Souville I, Boddaert N, Elie C, Pinard JM, Plouin P, Moutard ML, des Portes V, Van Esch H, Joriot S, Renard JL, Chelly J, Francis F, Beldjord C, Bahi-Buisson N
  TITLE     The location of DCX mutations predicts malformation severity in X-linked lissencephaly.
  JOURNAL   Neurogenetics. 9:277-85 (2008)
REFERENCE   PMID:18379572
  AUTHORS   Herman TE, Siegel MJ
  TITLE     Miller--Dieker syndrome, type 1 lissencephaly.
  JOURNAL   J Perinatol 28:313-5 (2008)
REFERENCE   PMID:18201775
  AUTHORS   Sarkisian MR, Bartley CM, Rakic P
  TITLE     Trouble making the first move: interpreting arrested neuronal migration in the cerebral cortex.
  JOURNAL   Trends Neurosci 31:54-61 (2008)
REFERENCE   PMID:17997185
  AUTHORS   Kerjan G, Gleeson JG
  TITLE     Genetic mechanisms underlying abnormal neuronal migration in classical lissencephaly.
  JOURNAL   Trends Genet 23:623-30 (2007)
REFERENCE   PMID:16724181
  AUTHORS   Guerrini R, Marini C
  TITLE     Genetic malformations of cortical development.
  JOURNAL   Exp Brain Res 173:322-33 (2006)
///
ENTRY       H00269                      Disease
NAME        Primary microcephaly (MCPH)
DESCRIPTION Autosomal recessive primary microcephaly (MCPH) is a neurodevelopmental disorder characterized by reduced skull circumference and brain volume.
CATEGORY    Developmental disorder; Nervous system disease
GENE        (MCPH1) MCPH1 [HSA:79648] [KO:K19403]
            (MCPH2) WDR62 [HSA:284403]
            (MCPH3) CDK5RAP2 [HSA:55755] [KO:K16542]
            (MCPH4) CASC5 [HSA:57082] [KO:K11542]
            (MCPH5) ASPM [HSA:259266] [KO:K16743]
            (MCPH6) CENPJ [HSA:55835] [KO:K11502]
            (MCPH7) STIL [HSA:6491] [KO:K16724]
            (MCPH8) CEP135 [HSA:9662] [KO:K16461]
            (MCPH9) CEP152 [HSA:22995] [KO:K16728]
            (MCPH10) ZNF335 [HSA:63925]
            (MCPH11) PHC1 [HSA:1911] [KO:K11456]
            (MCPHSBA) MED17 [HSA:9440] [KO:K15133]
            (MSCCA) QARS [HSA:5859] [KO:K01886]
COMMENT     MCPHSBA: Microcephaly postnatal progressive with seizures and brain atrophy
            MSCCA: Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy
DBLINKS     ICD-10: Q02
            MeSH: D008831
            OMIM: 607117 604317 604804 604321 608716 608393 612703 614673 614852 615095 615414 613668 615760
REFERENCE   PMID:17980308
  AUTHORS   Abuelo D
  TITLE     Microcephaly syndromes.
  JOURNAL   Semin Pediatr Neurol 14:118-27 (2007)
REFERENCE   PMID:16829198
  AUTHORS   Cox J, Jackson AP, Bond J, Woods CG
  TITLE     What primary microcephaly can tell us about brain growth.
  JOURNAL   Trends Mol Med 12:358-66 (2006)
REFERENCE   PMID:15806441
  AUTHORS   Woods CG, Bond J, Enard W
  TITLE     Autosomal recessive primary microcephaly (MCPH): a review of clinical, molecular, and evolutionary findings.
  JOURNAL   Am J Hum Genet 76:717-28 (2005)
REFERENCE   PMID:20950787
  AUTHORS   Kaufmann R, Straussberg R, Mandel H, Fattal-Valevski A, Ben-Zeev B, Naamati A, Shaag A, Zenvirt S, Konen O, Mimouni-Bloch A, Dobyns WB, Edvardson S, Pines O, Elpeleg O
  TITLE     Infantile cerebral and cerebellar atrophy is associated with a mutation in the MED17 subunit of the transcription preinitiation mediator complex.
  JOURNAL   Am J Hum Genet 87:667-70 (2010)
REFERENCE   PMID:24656866
  AUTHORS   Zhang X, Ling J, Barcia G, Jing L, Wu J, Barry BJ, Mochida GH, Hill RS, Weimer JM, Stein Q, Poduri A, Partlow JN, Ville D, Dulac O, Yu TW, Lam AT, Servattalab S, Rodriguez J, Boddaert N, Munnich A, Colleaux L, Zon LI, Soll D, Walsh CA, Nabbout R
  TITLE     Mutations in QARS, encoding glutaminyl-tRNA synthetase, cause progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures.
  JOURNAL   Am J Hum Genet 94:547-58 (2014)
REFERENCE   PMID:21496009
  AUTHORS   Bhat V, Girimaji SC, Mohan G, Arvinda HR, Singhmar P, Duvvari MR, Kumar A
  TITLE     Mutations in WDR62, encoding a centrosomal and nuclear protein, in Indian primary microcephaly families with cortical malformations.
  JOURNAL   Clin Genet 80:532-40 (2011)
REFERENCE   PMID:22983954
  AUTHORS   Genin A, Desir J, Lambert N, Biervliet M, Van Der Aa N, Pierquin G, Killian A, Tosi M, Urbina M, Lefort A, Libert F, Pirson I, Abramowicz M
  TITLE     Kinetochore KMN network gene CASC5 mutated in primary microcephaly.
  JOURNAL   Hum Mol Genet 21:5306-17 (2012)
REFERENCE   PMID:22521416
  AUTHORS   Hussain MS, Baig SM, Neumann S, Nurnberg G, Farooq M, Ahmad I, Alef T, Hennies HC, Technau M, Altmuller J, Frommolt P, Thiele H, Noegel AA, Nurnberg P
  TITLE     A truncating mutation of CEP135 causes primary microcephaly and disturbed centrosomal function.
  JOURNAL   Am J Hum Genet 90:871-8 (2012)
REFERENCE   PMID:23178126 (MCPH10)
  AUTHORS   Yang YJ, Baltus AE, Mathew RS, Murphy EA, Evrony GD, Gonzalez DM, Wang EP, Marshall-Walker CA, Barry BJ, Murn J, Tatarakis A, Mahajan MA, Samuels HH, Shi Y, Golden JA, Mahajnah M, Shenhav R, Walsh CA
  TITLE     Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation.
  JOURNAL   Cell 151:1097-112 (2012)
REFERENCE   PMID:23418308
  AUTHORS   Awad S, Al-Dosari MS, Al-Yacoub N, Colak D, Salih MA, Alkuraya FS, Poizat C
  TITLE     Mutation in PHC1 implicates chromatin remodeling in primary microcephaly pathogenesis.
  JOURNAL   Hum Mol Genet 22:2200-13 (2013)
///
ENTRY       H00270                      Disease
NAME        Periventricular nodular heterotopia (PVNH)
DESCRIPTION Periventricular nodular heterotopia (PNH) is a malformation of neuronal migration in which a subset of neurons fails to migrate into the developing cerebral cortex and composes heterotopic nodules along the lateral ventricles.
CATEGORY    Developmental disorder; Nervous system disease
GENE        (PVNH1/3) FLNA [HSA:2316] [KO:K04437]
            (PVNH2) ARFGEF2 [HSA:10564] [KO:K18442]
DBLINKS     ICD-10: Q04.8
            MeSH: D054091
            OMIM: 300049 300537 608097
REFERENCE   PMID:19120042
  AUTHORS   Spalice A, Parisi P, Nicita F, Pizzardi G, Del Balzo F, Iannetti P
  TITLE     Neuronal migration disorders: clinical, neuroradiologic and genetics aspects.
  JOURNAL   Acta Paediatr 98:421-33 (2009)
REFERENCE   PMID:18201775
  AUTHORS   Sarkisian MR, Bartley CM, Rakic P
  TITLE     Trouble making the first move: interpreting arrested neuronal migration in the cerebral cortex.
  JOURNAL   Trends Neurosci 31:54-61 (2008)
REFERENCE   PMID:16724181
  AUTHORS   Guerrini R, Marini C
  TITLE     Genetic malformations of cortical development.
  JOURNAL   Exp Brain Res 173:322-33 (2006)
REFERENCE   PMID:15996530
  AUTHORS   Lu J, Sheen V
  TITLE     Periventricular heterotopia.
  JOURNAL   Epilepsy Behav 7:143-9 (2005)
///
ENTRY       H00271                      Disease
NAME        Polymicrogyria, including:
            Bilateral frontal polymicrogyria (BFP);
            Bilateral frontoparietal polymicrogyria (BFPP);
            Bilateral perisylvian polymicrogyria (BPP);
            Bilateral parasagittal parieto-occipital polymicrogyria (BPOP);
            Bilateral generalised polymicrogyria (BGP);
            Unilateral Polymicrogyria (ULP);
            Polymicrogyria with optic nerve hypoplasia;
            Polymicrogyria, symmetric or asymmetric (PMGYSA);
            Polymicrogyria with seizures (PMGYS)
DESCRIPTION Polymicrogyria (PMG) is a malformation of cortical development characterized by an excessive number of small gyri with abnormal lamination.
CATEGORY    Developmental disorder; Nervous system disease
GENE        (BFPP/ BPP) GPR56 [HSA:9289] [KO:K08450]
            (BPP) SRPX2 [HSA:27286] [KO:K19408]
            (ULP) PAX6 [HSA:5080] [KO:K08031]
            (BGP) KIAA1279 [HSA:26128]
            EOMES [HSA:8320] [KO:K10173]
            RAB3GAP1 [HSA:22930] [KO:K18270]
            COL18A1 [HSA:80781] [KO:K06823]
            TUBA8 [HSA:51807] [KO:K07374]
            (PMGYSA) TUBB2B [HSA:347733] [KO:K07375]
            (PMGYS) RTTN [HSA:25914] [KO:K16484]
DBLINKS     ICD-10: Q04.8
            MeSH: D054220
            OMIM: 606854 615752 300388 610031 613180 614833
REFERENCE   PMID:18262290
  AUTHORS   Guerrini R, Dobyns WB, Barkovich AJ
  TITLE     Abnormal development of the human cerebral cortex: genetics, functional consequences and treatment options.
  JOURNAL   Trends Neurosci 31:154-62 (2008)
REFERENCE   PMID:15863665
  AUTHORS   Jansen A, Andermann E
  TITLE     Genetics of the polymicrogyria syndromes.
  JOURNAL   J Med Genet 42:369-78 (2005)
REFERENCE   PMID:19896110
  AUTHORS   Abdollahi MR, Morrison E, Sirey T, Molnar Z, Hayward BE, Carr IM, Springell K, Woods CG, Ahmed M, Hattingh L, Corry P, Pilz DT, Stoodley N, Crow Y, Taylor GR, Bonthron DT, Sheridan E
  TITLE     Mutation of the variant alpha-tubulin TUBA8 results in polymicrogyria with optic  nerve hypoplasia.
  JOURNAL   Am J Hum Genet 85:737-44 (2009)
REFERENCE   PMID:22333901
  AUTHORS   Guerrini R, Mei D, Cordelli DM, Pucatti D, Franzoni E, Parrini E
  TITLE     Symmetric polymicrogyria and pachygyria associated with TUBB2B gene mutations.
  JOURNAL   Eur J Hum Genet 20:995-8 (2012)
REFERENCE   PMID:22939636
  AUTHORS   Kheradmand Kia S, Verbeek E, Engelen E, Schot R, Poot RA, de Coo IF, Lequin MH, Poulton CJ, Pourfarzad F, Grosveld FG, Brehm A, de Wit MC, Oegema R, Dobyns WB, Verheijen FW, Mancini GM
  TITLE     RTTN mutations link primary cilia function to organization of the human cerebral  cortex.
  JOURNAL   Am J Hum Genet 91:533-40 (2012)
///
ENTRY       H00272                      Disease
NAME        Multiple sulfatase deficiency (MSD)
DESCRIPTION Multiple sulfatase deficiency (MSD) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of sulfatase modifying factor 1 (SUMF1), which posttranslationally activates lysosomal sulfatases by generating formylglycine in their catalytic sites. MSD is known to combine sulfatase deficiency and clinical features of metachromatic leukodystrophy [DS:H00127]. The clinical course ranges from neonatal severe to mild juvenile cases.
CATEGORY    Inherited metabolic disease; Nervous system disease; Lysosomal storage disease
GENE        SUMF1; sulfatase modifying factor [HSA:285362] [KO:K13444]
DBLINKS     ICD-10: E75.2
            MeSH: D052517
            OMIM: 272200
REFERENCE   PMID:18157819
  AUTHORS   Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J
  TITLE     Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency.
  JOURNAL   Hum Mutat 29:205 (2008)
REFERENCE   PMID:12757705
  AUTHORS   Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figura K
  TITLE     Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme.
  JOURNAL   Cell 113:435-44 (2003)
REFERENCE   PMID:1883197
  AUTHORS   Neufeld EF
  TITLE     Lysosomal storage diseases.
  JOURNAL   Annu Rev Biochem 60:257-80 (1991)
REFERENCE   PMID:19124046
  AUTHORS   Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B
  TITLE     Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins.
  JOURNAL   Biochim Biophys Acta 1793:710-25 (2009)
///
ENTRY       H00273                      Disease
NAME        Pycnodysostosis
DESCRIPTION Pycnodysostosis is an autosomal recessive skeletal disorder caused by deficiency of cathepsin K in the metabolism of the skeletal system, causing defects in bone resorption and bone remodeling. Pycnodysostosis is characterized by short stature, osteosclerosis, acroosteolysis, separated cranial sutures with open fontanelles, bone fragility, and loss of mandibular angle.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        CTSK; cathepsin K [HSA:1513] [KO:K01371]
COMMENT     It is suggested that cathepsin K plays an important role in the immune system.
DBLINKS     ICD-10: E88.9
            MeSH: D058631
            OMIM: 265800
REFERENCE   PMID:8703060
  AUTHORS   Gelb BD, Shi GP, Chapman HA, Desnick RJ
  TITLE     Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
  JOURNAL   Science 273:1236-8 (1996)
REFERENCE   PMID:14756243
  AUTHORS   Goto T, Yamaza T, Tanaka T
  TITLE     Cathepsins in the osteoclast.
  JOURNAL   J Electron Microsc (Tokyo) 52:551-8 (2003)
REFERENCE   PMID:19338743
  AUTHORS   Zhao Q, Jia Y, Xiao Y
  TITLE     Cathepsin K: a therapeutic target for bone diseases.
  JOURNAL   Biochem Biophys Res Commun 380:721-3 (2009)
REFERENCE   PMID:1883197
  AUTHORS   Neufeld EF
  TITLE     Lysosomal storage diseases.
  JOURNAL   Annu Rev Biochem 60:257-80 (1991)
REFERENCE   PMID:18239127 (immune system)
  AUTHORS   Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H
  TITLE     Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
  JOURNAL   Science 319:624-7 (2008)
///
ENTRY       H00274                      Disease
NAME        Papillon-Lefevre syndrome
DESCRIPTION Papillon-Lefevre syndrome (PLS) is an autosomal recessive disorder caused by deficiency of cathepsin C, a lysosomal cysteine proteinase that functions by removing dipeptides from the amino termini of its substrates. The disease is characterized by palmoplantar keratoderma and juvenile periodontitis.
CATEGORY    Inherited metabolic disease
GENE        CTSC; cathepsin C [HSA:1075] [KO:K01275]
DBLINKS     ICD-10: Q82.8
            MeSH: D010214
            OMIM: 245000
REFERENCE   PMID:12509601
  AUTHORS   Almuneef M, Al Khenaizan S, Al Ajaji S, Al-Anazi A
  TITLE     Pyogenic liver abscess and Papillon-Lefevre syndrome: not a rare association.
  JOURNAL   Pediatrics 111:e85-8 (2003)
REFERENCE   PMID:18401176
  AUTHORS   Nakajima K, Nakano H, Takiyoshi N, Rokunohe A, Ikenaga S, Aizu T, Kaneko T, Mitsuhashi Y, Sawamura D
  TITLE     Papillon-Lefevre syndrome and malignant melanoma. A high incidence of melanoma development in Japanese palmoplantar keratoderma patients.
  JOURNAL   Dermatology 217:58-62 (2008)
REFERENCE   PMID:1883197
  AUTHORS   Neufeld EF
  TITLE     Lysosomal storage diseases.
  JOURNAL   Annu Rev Biochem 60:257-80 (1991)
///
ENTRY       H00275                      Disease
NAME        Cystinosis
DESCRIPTION Cystinosis is an autosomal recessive lysosomal storage disorder caused by deficiency of lysosomal cystine transporter, which leads to intracellular cystine crystals, widespread cellular destruction, renal Fanconi syndrome in infancy, renal glomerular failure in later childhood, and other systemic complications. Since the introduction of cysteamine into the pharmacological management of cystinosis, well-treated adolescent and young adult patients have experienced normal growth and maintenance of renal glomerular function.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        CTNS; cystinosin [HSA:1497] [KO:K12386]
MARKER      Cystine [CPD:C00491]
DRUG        Cysteamine [DR:D03634]
            Tiopronin [DR:D01430]
DBLINKS     ICD-10: E72.0
            MeSH: D003554
            OMIM: 219800 219900 219750
REFERENCE   PMID:932205
  AUTHORS   Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA
  TITLE     Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo.
  JOURNAL   J Clin Invest 58:180-9 (1976)
REFERENCE   PMID:15500372 (drug)
  AUTHORS   Kleta R, Gahl WA
  TITLE     Pharmacological treatment of nephropathic cystinosis with cysteamine.
  JOURNAL   Expert Opin Pharmacother 5:2255-62 (2004)
REFERENCE   PMID:1883197
  AUTHORS   Neufeld EF
  TITLE     Lysosomal storage diseases.
  JOURNAL   Annu Rev Biochem 60:257-80 (1991)
///
ENTRY       H00276                      Disease
NAME        Galactosialidosis
DESCRIPTION Galactosialidosis is an autosomal recessive lysosomal storage disorder caused by cathepsin A deficiency and accompanied by combined deficiency of beta-galactosidase and alpha-neuraminidase.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        CTSA; cathepsin A [HSA:5476] [KO:K13289]
            GLB1; beta-galactosidase [HSA:2720] [KO:K12309]
            NEU1; lysosomal sialidase [HSA:4758] [KO:K01186]
MARKER      urinary sialic acid-rich oligosaccharides
DBLINKS     ICD-10: E75.1
            MeSH: C536411
            OMIM: 256540
REFERENCE   PMID:19097920
  AUTHORS   Darin N, Kyllerman M, Hard AL, Nordborg C, Mansson JE
  TITLE     Juvenile galactosialidosis with attacks of neuropathic pain and absence of sialyloligosacchariduria.
  JOURNAL   Eur J Paediatr Neurol (2008)
REFERENCE   PMID:1883197
  AUTHORS   Neufeld EF
  TITLE     Lysosomal storage diseases.
  JOURNAL   Annu Rev Biochem 60:257-80 (1991)
///
ENTRY       H00277                      Disease
NAME        Enterohemorrhagic Escherichia coli (EHEC) infection
DESCRIPTION Enterohaemorrhagic Escherichia coli (EHEC) infection is typically contracted through consumption of contaminated food or contact with contaminated water, animal feces or infected animals. EHEC is also referred to as verocytotoxin producing E. coli (VTEC) or Shiga toxin producing E. coli (STEC). The serotype O157:H7 is first associated with human disease after a multistate outbreak in the United States in 1982 involving contaminated hamburgers. The symptoms of EHEC infection range from mild diarrhea to hemorrhagic colitis and can progress to a severe cases called hemolytic uremic syndrome (HUS).
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli O157:H7 [GN:ece ecs ecf etw elx]
            Escherichia coli O26:H11 [GN:eoj]
            Escherichia coli O111:H- [GN:eoi]
            Escherichia coli O103:H2 [GN:eoh]
            Escherichia coli O104:H4 [GN:eso esm esl]
            Escherichia coli O145:H28 [GN:ecoo ecoh]
            shiga toxin [KO:K11006 K11007]
            pore-forming toxin [KO:K11003 K11004 K11005]
DBLINKS     ICD-10: A04.3
            MeSH: D004927
REFERENCE   PMID:17890332
  AUTHORS   Baker DR, Moxley RA, Steele MB, Lejeune JT, Christopher-Hennings J, Chen DG, Hardwidge PR, Francis DH
  TITLE     Differences in virulence among Escherichia coli O157:H7 strains isolated from humans during disease outbreaks and from healthy cattle.
  JOURNAL   Appl Environ Microbiol 73:7338-46 (2007)
REFERENCE   PMID:23133618
  AUTHORS   Ahmed SA, Awosika J, Baldwin C, Bishop-Lilly KA, Biswas B, Broomall S, Chain PS, Chertkov O, Chokoshvili O, Coyne S, Davenport K, Detter JC, Dorman W, Erkkila TH, Folster JP, Frey KG, George M, Gleasner C, Henry M, Hill KK, Hubbard K, Insalaco J, Johnson S, Kitzmiller A, Krepps M, Lo CC, Luu T, McNew LA, Minogue T, Munk CA, Osborne B, Patel M, Reitenga KG, Rosenzweig CN, Shea A, Shen X, Strockbine N, Tarr C, Teshima H, van Gieson E, Verratti K, Wolcott M, Xie G, Sozhamannan S, Gibbons HS
  TITLE     Genomic comparison of Escherichia coli O104:H4 isolates from 2009 and 2011 reveals plasmid, and prophage heterogeneity, including shiga toxin encoding phage stx2.
  JOURNAL   PLoS One 7:e48228 (2012)
///
ENTRY       H00278                      Disease
NAME        Enteropathogenic Escherichia coli (EPEC) infection
DESCRIPTION Enteropathogenic Escherichia coli (EPEC) infection is a common cause of watery diarrhea in developing countries. EPEC is a gram-negative bacterial pathogen that mediates infection in the human intestine, often causing life-threatening diarrhea. Each year EPEC is responsible for thousands of deaths worldwide, mostly in infants and young children.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli O127:H6 [GN:ecg]
            Escherichia coli O55:H7 [GN:eok elr]
DBLINKS     ICD-10: A04.0
            MeSH: D004927
REFERENCE   PMID:18455741
  AUTHORS   Ochoa TJ, Barletta F, Contreras C, Mercado E
  TITLE     New insights into the epidemiology of enteropathogenic Escherichia coli infection.
  JOURNAL   Trans R Soc Trop Med Hyg 102:852-6 (2008)
///
ENTRY       H00279                      Disease
NAME        Uropathogenic Escherichia coli (UPEC) infection
DESCRIPTION Uropathogenic Escherichia coli (UPEC) infection is a prevalent infectious disease with potentially severe complications. UPEC, the most common etiological agent of community-acquired urinary tract infections (UTIs), accounts for >80% of UTI infections worldwide. Once inside the urinary tract, UPEC preferentially colonizes the bladder and causes cystitis, but can also ascend through the ureters into the kidneys, causing pyelonephritis.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli (UPEC) [GN:ecc eci ecp ect eum ena ecoj]
            pore-forming toxin [KO:K11003 K11004 K11005]
DBLINKS     ICD-10: N39
            MeSH: D004927
REFERENCE   PMID:9551528
  AUTHORS   Matsumoto T
  TITLE     [Virulence factors and host responses in urinary tract infections].
  JOURNAL   J UOEH 20:45-60 (1998)
REFERENCE   PMID:16100859 (drug)
  AUTHORS   Mehnert-Kay SA
  TITLE     Diagnosis and management of uncomplicated urinary tract infections.
  JOURNAL   Am Fam Physician 72:451-6 (2005)
REFERENCE   PMID:16406777
  AUTHORS   Svanborg C, Bergsten G, Fischer H, Godaly G, Gustafsson M, Karpman D, Lundstedt AC, Ragnarsdottir B, Svensson M, Wullt B
  TITLE     Uropathogenic Escherichia coli as a model of host-parasite interaction.
  JOURNAL   Curr Opin Microbiol 9:33-9 (2006)
REFERENCE   PMID:17458672
  AUTHORS   Yamamoto S
  TITLE     Molecular epidemiology of uropathogenic Escherichia coli.
  JOURNAL   J Infect Chemother 13:68-73 (2007)
REFERENCE   PMID:18482721
  AUTHORS   Wiles TJ, Kulesus RR, Mulvey MA
  TITLE     Origins and virulence mechanisms of uropathogenic Escherichia coli.
  JOURNAL   Exp Mol Pathol 85:11-9 (2008)
REFERENCE   PMID:18616559
  AUTHORS   Dhakal BK, Kulesus RR, Mulvey MA
  TITLE     Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli.
  JOURNAL   Eur J Clin Invest 38 Suppl 2:2-11 (2008)
///
ENTRY       H00280                      Disease
NAME        Enterotoxigenic Escherichia coli (ETEC) infection
DESCRIPTION Enterotoxigenic Escherichia coli (ETEC) infection is one of the main causes of infantile diarrhea in developing countries and an important etiologic agent for travelers' diarrhea. ETEC strains colonize the small intestine, secrete enterotoxins, and cause watery diarrhea. The clinical symptoms of ETEC infection can range from mild diarrhea to a severe cholera-like syndrome.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli O139:H28 [GN:ecw]
            Escherichia coli O78:H11 [GN:elh]
            heat-labile enterotoxin [KO:K10928 K10929]
            heat-stable enterotoxin STa [KO:K16883]
            heat-stable enterotoxin STb [KO:K16884]
            serine protease autotransporter EatA [KO:K12684]
            pore-forming cytotoxin [KO:K11139]
DBLINKS     ICD-10: A04.1
            MeSH: D004927
REFERENCE   PMID:16020685
  AUTHORS   Qadri F, Svennerholm AM, Faruque AS, Sack RB
  TITLE     Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention.
  JOURNAL   Clin Microbiol Rev 18:465-83 (2005)
REFERENCE   PMID:16958845
  AUTHORS   Turner SM, Scott-Tucker A, Cooper LM, Henderson IR
  TITLE     Weapons of mass destruction: virulence factors of the global killer enterotoxigenic Escherichia coli.
  JOURNAL   FEMS Microbiol Lett 263:10-20 (2006)
///
ENTRY       H00281                      Disease
NAME        GM1 gangliosidosis
DESCRIPTION GM1-gangliosidosis is an autosomal recessive lysosomal storage disorder caused by deficient beta-galactosidase activity. The enzymatic defect results in the accumulation of GM1 ganglioside in nervous tissues and a highly variable storage of keratan sulfate and glycopeptides in visceral and skeletal tissues. There are three main clinical variants, infantile (type I), juvenile (type II), and adult (type III), categorized by severity of symptoms and variable residual enzymatic activity of beta-galactosidase.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        GLB1; beta-galactosidase [HSA:2720] [KO:K12309]
MARKER      GM1 ganglioside [GL:G00110] [CPD:C04911]
            keratan sulfate [CPD:C00573]
            Chondroitin sulfate [CPD:C00607]
            Urine oligosaccharides
DRUG        Hematopoietic stem cell transplantation
            Chemical chaperone therapy; N-octyl-4-epi-beta-valienamine (NOEV)
            (limited experience)
COMMENT     Morquio syndrome B is allelic to the various forms of GM1-gangliosidosis (see, H00123). Morquio syndrome B is characterized by skeletal dysplasia and corneal clouding. There is no central nervous system involvement and intelligence is normal.
DBLINKS     ICD-10: E75.1
            MeSH: D016537
            OMIM: 230500 230600 230650
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:19472408
  AUTHORS   Hofer D, Paul K, Fantur K, Beck M, Burger F, Caillaud C, Fumic K, Ledvinova J, Lugowska A, Michelakakis H, Radeva B, Ramaswami U, Plecko B, Paschke E
  TITLE     GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
  JOURNAL   Hum Mutat 30:1214-21 (2009)
REFERENCE   PMID:18202827
  AUTHORS   Suzuki Y
  TITLE     Chemical chaperone therapy for GM1-gangliosidosis.
  JOURNAL   Cell Mol Life Sci 65:351-3 (2008)
///
ENTRY       H00282                      Disease
NAME        Cryopyrin associated periodic syndrome (CAPS), including:
            Muckle-Wells syndrome (MWS);
            Familial cold autoinflammatory syndrome (FCAS);
            Chronic infantile neurologic, cutaneous, articular (CINCA) syndrome
DESCRIPTION Cryopyrin associated periodic syndromes (CAPS) all arise from a missense mutation in the CIAS1 gene that encodes NALP3. These are autosomal dominant inherited disease characterized by recurrent inflammatory episodes. The pathogenic mechanism of these syndromes is attributed to increased activation of the NALP3 inflammasome, resulting in aberrantly high production of IL-1beta.
CATEGORY    Immune system disease
GENE        NALP3 [HSA:114548] [KO:K12800]
            (FCAS) NALP12 [HSA:91662] [KO:K20865]
ENV_FACTOR  Exposure to cold (FCAS)
DRUG        Anakinra [DR:D02934]
            Rilonacept [DR:D06635] (FCAS)
            Canakinumab [DR:D09315]
DBLINKS     ICD-10: E85.0 E85.2 L50.8 L50.2 G03.1 G44.8 M08.9
            MeSH: D056587
            OMIM: 191900 120100 607115 611762
REFERENCE   PMID:14476827
  AUTHORS   MUCKLE TJ, WELLSM
  TITLE     Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome.
  JOURNAL   Q J Med 31:235-48 (1962)
REFERENCE   PMID:11687797 (gene)
  AUTHORS   Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD
  TITLE     Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.
  JOURNAL   Nat Genet 29:301-5 (2001)
REFERENCE   PMID:14872505 (drug)
  AUTHORS   Hawkins PN, Lachmann HJ, Aganna E, McDermott MF
  TITLE     Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.
  JOURNAL   Arthritis Rheum 50:607-12 (2004)
REFERENCE   PMID:12483741
  AUTHORS   Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron K, O'Shea JJ, Kastner DL, Goldbach-Mansky R
  TITLE     De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.
  JOURNAL   Arthritis Rheum 46:3340-8 (2002)
REFERENCE   PMID:14630794
  AUTHORS   Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, Derfalvi B, Benjaponpitak S, Vesely R, Sauvain MJ, Oertle S, Allen R, Morgan G, Borkhardt A, Hill C, Gardner-Medwin J, Fischer A, de Saint Basile G
  TITLE     Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU.
  JOURNAL   Blood 103:2809-15 (2004)
REFERENCE   PMID:18665151
  AUTHORS   Neven B, Prieur AM, Quartier dit Maire P
  TITLE     Cryopyrinopathies: update on pathogenesis and treatment.
  JOURNAL   Nat Clin Pract Rheumatol 4:481-9 (2008)
REFERENCE   PMID:11590390 (gene)
  AUTHORS   Hoffman HM, Wanderer AA, Broide DH
  TITLE     Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever.
  JOURNAL   J Allergy Clin Immunol 108:615-20 (2001)
REFERENCE   PMID:25438464 (drug)
  AUTHORS   Giat E, Lidar M
  TITLE     Cryopyrin-associated periodic syndrome.
  JOURNAL   Isr Med Assoc J 16:659-61 (2014)
///
ENTRY       H00283                      Disease
NAME        Ebola haemorrhagic fever
DESCRIPTION Ebola virus causes a severe form of viral haemorrhagic fever infection in man, designated Ebola haemorrhagic fever that was discovered in 1976. The mortality rate is as high as 90% and there is no prophylaxis or cure. It is endemic in Central Africa.
CATEGORY    Infectious disease
PATHOGEN    Zaire ebolavirus [GN:T40012]
            Reston ebolavirus [GN:T40013]
            Sudan ebolavirus [GN:T40014]
            Bundibugyo virus [GN:T40121]
            Tai Forest ebolavirus [GN:T40125]
DBLINKS     ICD-10: A98.4
            MeSH: D019142
            MedlinePlus: 001339
REFERENCE   PMID:21084112 (description)
  AUTHORS   Feldmann H, Geisbert TW
  TITLE     Ebola haemorrhagic fever.
  JOURNAL   Lancet 377:849-62 (2011)
REFERENCE   PMID:12000905 (description)
  AUTHORS   Bruce J, Brysiewicz P
  TITLE     Ebola fever: the African emergency.
  JOURNAL   Int J Trauma Nurs 8:36-41 (2002)
///
ENTRY       H00284                      Disease
NAME        Crimean-Congo hemorrhagic fever
DESCRIPTION Crimean-Congo haemorrhagic fever is a fatal viral infection that occurs sporadically in Africa, Asia, eastern and southern Europe, and the Middle East. Patients may develop subclinical symptoms to severe hemorrhagic disease.
CATEGORY    Infectious disease
PATHOGEN    Crimean-Congo hemorrhagic fever virus [GN:T40011]
DRUG        Ribavirin [DR:D00423]
COMMENT     Vectors: Hyalomma spp ticks
DBLINKS     ICD-10: A98.0
            MeSH: D006479
REFERENCE   PMID:16554245 (description, env_factor, comment)
  AUTHORS   Ergonul O
  TITLE     Crimean-Congo haemorrhagic fever.
  JOURNAL   Lancet Infect Dis 6:203-14 (2006)
REFERENCE   PMID:21362441 (drug)
  AUTHORS   Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S
  TITLE     Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies.
  JOURNAL   Antiviral Res 90:85-92 (2011)
///
ENTRY       H00285                      Disease
NAME        Blau syndrome
DESCRIPTION Blau syndrome is an autosomal dominantly-inherited disease which is presented with triad of juvenile-onset granulomatous arthritis, uveitis, and skin rashes. Inflammation of the eyes, camptodactyly and lymphaedenopathy are additional feature of the disease. Missense mutations in the NOD region of NOD2 underlie Blau syndrome, augmenting NOD2 activity even in the absence of pathogenic stimuli. Inflammation seen in patients with Blau syndrome might be due to an aberrant activation of NOD2 and constitutive NF-kappaB activation. Blau syndrome usually occurs in children younger than age 4 years.
CATEGORY    Immune system disease
GENE        NOD2 [HSA:64127] [KO:K10165]
PATHOGEN    Propionobacterium acnes [GN:pac]
            Atypical mycobacterium [GN:mav mpa mmi msm mul mgi]
DRUG        Infliximab [DR:D02598]
            Anakinra [DR:D02934]
DBLINKS     MeSH: C538157
            OMIM: 186580
REFERENCE   PMID:4056967
  AUTHORS   Blau EB
  TITLE     Familial granulomatous arthritis, iritis, and rash.
  JOURNAL   J Pediatr 107:689-93 (1985)
REFERENCE   PMID:11528384 (gene)
  AUTHORS   Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, Chamaillard M, Zouali H, Thomas G, Hugot JP
  TITLE     CARD15 mutations in Blau syndrome.
  JOURNAL   Nat Genet 29:19-20 (2001)
REFERENCE   PMID:18718560 (gene, drug)
  AUTHORS   Punzi L, Furlan A, Podswiadek M, Gava A, Valente M, De Marchi M, Peserico A
  TITLE     Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review.
  JOURNAL   Autoimmun Rev 8:228-32 (2009)
///
ENTRY       H00286                      Disease
NAME        Crohn's disease
DESCRIPTION Crohn's disease is a chronic, relapsing inflammatory bowel disease characterized by granulomatous inflammation, primarily localized to the terminal ileum. Most patients have involvement of the small intestine, but the other area of gastrointestinal tract may also be affected. In Western populations, over 50% of patients possess NOD2 mutations. Evidence exists that the NOD2 polymorphysms impair NF-kappaB activation and cytokine secretion in response to its ligand. The pathogenesis of Crohn's disease is also attributed to intestinal bacteria that may initiate mucosal inflammation in genetically susceptible individuals. Additional genes associated with the disease are recently being identified.
CATEGORY    Immune system disease
GENE        NOD2 [HSA:64127] [KO:K10165]
            SLC22A4 (polymorphism) [HSA:6583] [KO:K08202]
            SLC22A5 (polymorphism) [HSA:6584] [KO:K08202]
            TNFSF15 (polymorphism) [HSA:9966] [KO:K05478]
            IL23R (polymorphism) [HSA:149233] [KO:K05065]
            ATG16L1 (polymorphism) [HSA:55054] [KO:K17890]
            IRGM (polymorphism) [HSA:345611] [KO:K14139]
            IL10RB [HSA:3588] [KO:K05135]
            IL10RA [HSA:3587] [KO:K05134]
ENV_FACTOR  Infectious diseases
            Food preferences
PATHOGEN    Mycobacterium avium subsp. [GN:mav mpa mao]
            Escherichia coli (AIEC) [GN:eln elu]
DRUG        Infliximab [DR:D02598] Adalimuab [DR:D02597] Certolizumab pegol [DR:D03441] (anti-TNF-alpha agents)
            Natalizumab [DR:D06886] (anti-integrin agent)
            Budesonide [DR:D00246]
COMMENT     The polymorphysm in the TNFSF15 gene contribute to the susceptibility to Crohn's disease in the Japanese.
DBLINKS     ICD-10: K50
            MeSH: D003424
            OMIM: 266600 612261 611081 612567 613148 612278
REFERENCE   PMID:11385577 (gene)
  AUTHORS   Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH
  TITLE     A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.
  JOURNAL   Nature 411:603-6 (2001)
REFERENCE   PMID:15107849 (gene)
  AUTHORS   Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH, Siminovitch KA
  TITLE     Functional variants of OCTN cation transporter genes are associated with Crohn disease.
  JOURNAL   Nat Genet 36:471-5 (2004)
REFERENCE   PMID:16221758 (gene)
  AUTHORS   Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y
  TITLE     Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease.
  JOURNAL   Hum Mol Genet 14:3499-506 (2005)
REFERENCE   PMID:17068223 (gene)
  AUTHORS   Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH
  TITLE     A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
  JOURNAL   Science 314:1461-3 (2006)
REFERENCE   PMID:17200669 (gene)
  AUTHORS   Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Gunther S, Prescott NJ, Onnie CM, Hasler R, Sipos B, Folsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S
  TITLE     A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1.
  JOURNAL   Nat Genet 39:207-11 (2007)
REFERENCE   PMID:12843021 (env_factor)
  AUTHORS   Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G, Pickup R, Hermon-Taylor J
  TITLE     Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease.
  JOURNAL   J Clin Microbiol 41:2915-23 (2003)
REFERENCE   PMID:19923578 (drug)
  AUTHORS   Abraham C, Cho JH
  TITLE     Inflammatory bowel disease.
  JOURNAL   N Engl J Med 361:2066-78 (2009)
///
ENTRY       H00287                      Disease
NAME        Pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome
DESCRIPTION Pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome is a rare autoimflammatory disease with early onset, developing erosive arthritis. It is inherited in an autosomal dominant fashion. Patients typically develop cystic acne, abscesses and cutaneous ulcers, including pyoderma gangrenosum-like lesions. PAPA syndrome is caused by gain-of function mutations in PSTPIP1, a protein capable of associating with pyrin. Mutated PSTPIP1 reduces the inhibitory role of pyrin on inflammasome activation and therefore, potenciates the IL-1beta pathway. Elevated TNFalpha levels are also described.
CATEGORY    Immune system disease
GENE        PSTPIP1 [HSA:9051] [KO:K12804]
DRUG        Etanercept [DR:D00742]
            Infliximab [DR:D02598]
            Anakinra [DR:D02934]
DBLINKS     MeSH: C536253
            OMIM: 604416
REFERENCE   PMID:9212761
  AUTHORS   Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT
  TITLE     A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome.
  JOURNAL   Mayo Clin Proc 72:611-5 (1997)
REFERENCE   PMID:18347298 (drug)
  AUTHORS   Farasat S, Aksentijevich I, Toro JR
  TITLE     Autoinflammatory diseases: clinical and genetic advances.
  JOURNAL   Arch Dermatol 144:392-402 (2008)
REFERENCE   PMID:19290936 (gene)
  AUTHORS   Veillette A, Rhee I, Souza CM, Davidson D
  TITLE     PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders.
  JOURNAL   Immunol Rev 228:312-24 (2009)
REFERENCE   PMID:11971877 (gene)
  AUTHORS   Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M
  TITLE     Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder.
  JOURNAL   Hum Mol Genet 11:961-9 (2002)
///
ENTRY       H00288                      Disease
NAME        Familial Mediterranean fever (FMF);
            Familial hereditary periodic fever syndromes
DESCRIPTION Familial Mediterranean fever (FMF) is the most prevalent hereditary periodic fever, affecting 0.1% in people of Mediterranean descent. It is also reported throughout the world's populations. FMF is an autosomal recessive disorder caused by missense mutations in the MEFV gene, which encodes the pyrin protein. Mutations in pyrin may lead to uncontrolled inflammation due to IL-1beta hyperactivation. FMF is characterized by recurrent inflammatory fevers with sterile peritonitis, pleuritis, arthritis, myalgia and erysipelas-like skin lesions. Renal amyloidosis is the most severe complication, leads to renal failure. These symptoms start before 20 years of age in about 90% of cases.
CATEGORY    Immune system disease
GENE        MEFV [HSA:4210] [KO:K12803]
            MICA (polymorphism) [HSA:100507436] [KO:K07985]
DRUG        Etanercept [DR:D00742]
            Infliximab [DR:D02598]
            Anakinra [DR:D02934]
COMMENT     {Alpha}/{alpha} genotype of SAA1 [HSA:6288] is a risk factor for amyloidosis.
DBLINKS     ICD-10: E85.0
            MeSH: D010505
            OMIM: 249100 134610
REFERENCE   PMID:19339884 (gene, drug)
  AUTHORS   Guz G, Kanbay M, Ozturk MA
  TITLE     Current perspectives on familial Mediterranean fever.
  JOURNAL   Curr Opin Infect Dis 22:309-15 (2009)
REFERENCE   PMID:11464238 (gene)
  AUTHORS   Touitou I
  TITLE     The spectrum of Familial Mediterranean Fever (FMF) mutations.
  JOURNAL   Eur J Hum Genet 9:473-83 (2001)
REFERENCE   PMID:17911435 (gene, drug)
  AUTHORS   Bhat A, Naguwa SM, Gershwin ME
  TITLE     Genetics and new treatment modalities for familial Mediterranean fever.
  JOURNAL   Ann N Y Acad Sci 1110:201-8 (2007)
///
ENTRY       H00289                      Disease
NAME        Recurrent hydatidiform moles (RHM);
            Familial biparental hydatidiform
DESCRIPTION Hydatidiform mole is an abnormal human pregnancy composed of hyperproliferative trophoblast occuring in approximately 1 in every 1500 pregnancies in Europe and North America. This incidence is higher in other areas in the world. Recurrent hydatidiform mole (RHM), the familial cases of the disease, is an autosomal recessive disorder in which molar tissues are diploid and have a biparental contribution to their genome. The molar tissues show abnormal epigenetic marking of maternal imprinted genes. Affected women have biallelic mutations in the NLRP7 gene (NALP7), a gene thought to be involved in inflammatory and apoptotic pathways.
CATEGORY    Pregnancy, childbirth and the puerperium
GENE        NALP7 [HSA:199713] [KO:K20864]
DBLINKS     ICD-10: O01
            MeSH: D006828
            OMIM: 231090
REFERENCE   PMID:17204043 (gene)
  AUTHORS   Slim R, Mehio A
  TITLE     The genetics of hydatidiform moles: new lights on an ancient disease.
  JOURNAL   Clin Genet 71:25-34 (2007)
REFERENCE   PMID:16462743 (gene)
  AUTHORS   Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, Bagga R, Kircheisen R, Ao A, Ratti B, Hanash S, Rouleau GA, Slim R
  TITLE     Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans.
  JOURNAL   Nat Genet 38:300-2 (2006)
REFERENCE   PMID:16501554 (gene)
  AUTHORS   Bestor TH, Bourc'his D
  TITLE     Genetics and epigenetics of hydatidiform moles.
  JOURNAL   Nat Genet 38:274-6 (2006)
REFERENCE   PMID:19309689 (gene)
  AUTHORS   Hayward BE, De Vos M, Talati N, Abdollahi MR, Taylor GR, Meyer E, Williams D, Maher ER, Setna F, Nazir K, Hussaini S, Jafri H, Rashid Y, Sheridan E, Bonthron DT
  TITLE     Genetic and epigenetic analysis of recurrent hydatidiform mole.
  JOURNAL   Hum Mutat 30:E629-39 (2009)
REFERENCE   PMID:16540529
  AUTHORS   Van den Veyver IB, Al-Hussaini TK
  TITLE     Biparental hydatidiform moles: a maternal effect mutation affecting imprinting in the offspring.
  JOURNAL   Hum Reprod Update 12:233-42 (2006)
///
ENTRY       H00290                      Disease
NAME        Aicardi-Goutieres Syndrome (AGS)
DESCRIPTION Aicardi-Goutieres Syndrome (AGS) is an autosomal recessive encephalopathy characterized by basal ganglia and white matter calcification in the presence of chronic cerebrospinal fluid lymphocytosis, and a raised level of cerebrospinal fluid IFNalpha. There is progressive neurological dysfunction resulting in a failure of development of expected physical and social skills. AGS presents in infancy and is lethal in ~40% of cases. It can be caused by mutations in the following genes, TREX1, RNaseH2 and SAMHD1 that lead to excessive intracellular accumulation of DNA and abnormal type I IFN metabolism.
CATEGORY    Immune system disease
GENE        TREX1 [HSA:11277] [KO:K10790]
            RNaseH2 [HSA:10535 79621 84153] [KO:K10743 K10744 K10745]
            SAMHD1 [HSA:25939]
DBLINKS     ICD-10: G31.8
            MeSH: C535607
            OMIM: 225750 610181 610329 610333 606754
REFERENCE   PMID:19442247
  AUTHORS   Lindahl T, Barnes DE, Yang YG, Robins P
  TITLE     Biochemical properties of mammalian TREX1 and its association with DNA replication and inherited inflammatory disease.
  JOURNAL   Biochem Soc Trans 37:535-8 (2009)
REFERENCE   PMID:19525956 (gene)
  AUTHORS   Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, Ali M, Gornall H, Couthard LR, Aeby A, Attard-Montalto SP, Bertini E, Bodemer C, Brockmann K, Brueton LA, Corry PC, Desguerre I, Fazzi E, Cazorla AG, Gener B, Hamel BC, Heiberg A, Hunter M, van der Knaap MS, Kumar R, Lagae L, Landrieu PG, Lourenco CM, Marom D, McDermott MF, van der Merwe W, Orcesi S, Prendiville JS, Rasmussen M, Shalev SA, Soler DM, Shinawi M, Spiegel R, Tan TY, Vanderver A, Wakeling EL, Wassmer E, Whittaker E, Lebon P, Stetson DB, Bonthron DT, Crow YJ
  TITLE     Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response.
  JOURNAL   Nat Genet 41:829-32 (2009)
REFERENCE   PMID:18583934 (gene)
  AUTHORS   Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, Atkinson JP
  TITLE     New roles for the major human 3'-5' exonuclease TREX1 in human disease.
  JOURNAL   Cell Cycle 7:1718-25 (2008)
REFERENCE   PMID:18406216 (gene)
  AUTHORS   O'Driscoll M
  TITLE     TREX1 DNA exonuclease deficiency, accumulation of single stranded DNA and complex human genetic disorders.
  JOURNAL   DNA Repair (Amst) 7:997-1003 (2008)
REFERENCE   PMID:18693262
  AUTHORS   Rigby RE, Leitch A, Jackson AP
  TITLE     Nucleic acid-mediated inflammatory diseases.
  JOURNAL   Bioessays 30:833-42 (2008)
REFERENCE   PMID:18724932 (gene)
  AUTHORS   Stetson DB, Ko JS, Heidmann T, Medzhitov R
  TITLE     Trex1 prevents cell-intrinsic initiation of autoimmunity.
  JOURNAL   Cell 134:587-98 (2008)
REFERENCE   PMID:19808788 (description, gene)
  AUTHORS   Crow YJ, Rehwinkel J
  TITLE     Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity.
  JOURNAL   Hum Mol Genet 18:R130-6 (2009)
REFERENCE   PMID:18343173 (description, gene)
  AUTHORS   Stephenson JB
  TITLE     Aicardi-Goutieres syndrome (AGS).
  JOURNAL   Eur J Paediatr Neurol 12:355-8 (2008)
REFERENCE   PMID:18422679 (description, gene)
  AUTHORS   Crow YJ, Livingston JH
  TITLE     Aicardi-Goutieres syndrome: an important Mendelian mimic of congenital infection.
  JOURNAL   Dev Med Child Neurol 50:410-6 (2008)
///
ENTRY       H00291                      Disease
NAME        Familial chilblain lupus (FCL);
            Chilblain lupus erythematosus (CHLE)
DESCRIPTION Familial chilblain lupus (FCL) is a rare, inherited form of cutaneous lupus with prominent skin manifestations in acral parts of the body. Two families with autosomal dominant-inherited chilblain lupus have been reported. First symptoms manifest in early childhood, developing hypergammaglobulinemia and rheumatoid factor antibody production. In FCL, missense mutations in TREX1 that decrease its exonuclease activity were described. The failure of DNA degradation can result in aberrant immune response.
CATEGORY    Immune system disease
GENE        TREX1 [HSA:11277] [KO:K10790]
ENV_FACTOR  cold and wet exposure
MARKER      Antinuclear antibodies
            Anti-Ro/SSA antibodies
            Rheumatoid factor
DBLINKS     MeSH: C535924
            OMIM: 610448
REFERENCE   PMID:18543054
  AUTHORS   Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, Heubner G, Lee-Kirsch MA, Gahr M
  TITLE     Chilblain lupus erythematosus--a review of literature.
  JOURNAL   Clin Rheumatol 27:949-54 (2008)
REFERENCE   PMID:18583934 (gene)
  AUTHORS   Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, Atkinson JP
  TITLE     New roles for the major human 3'-5' exonuclease TREX1 in human disease.
  JOURNAL   Cell Cycle 7:1718-25 (2008)
REFERENCE   PMID:17357087 (gene)
  AUTHORS   Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, Robins P, Harvey S, Hollis T, O'Hara A, Herrick AL, Bowden AP, Perrino FW, Lindahl T, Barnes DE, Crow YJ
  TITLE     Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome.
  JOURNAL   Am J Hum Genet 80:811-5 (2007)
REFERENCE   PMID:17440703 (gene, description)
  AUTHORS   Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K, Pfeiffer C, Hollis T, Gahr M, Perrino FW, Lieberman J, Hubner N
  TITLE     A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus.
  JOURNAL   J Mol Med 85:531-7 (2007)
REFERENCE   PMID:19478477 (gene)
  AUTHORS   Gunther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA
  TITLE     Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.
  JOURNAL   Dermatology 219:162-6 (2009)
///
ENTRY       H00292                      Disease
NAME        Hypertrophic cardiomyopathy (HCM)
DESCRIPTION Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.
CATEGORY    Cardiovascular disease
GENE        MYH7 (mutation) [HSA:4625] [KO:K17751]
            TNNT2 (mutation) [HSA:7139] [KO:K12045]
            MYBPC3 (mutation) [HSA:4607] [KO:K12568]
            TPM1 (mutation) [HSA:7168] [KO:K10373]
            TNNI3 (mutation) [HSA:7137] [KO:K12044]
            MYL2 (mutation) [HSA:4633] [KO:K10351]
            MYL3 (mutation) [HSA:4634] [KO:K12749]
            ACTC1 (mutation) [HSA:70] [KO:K12314]
            TTN (mutation) [HSA:7273] [KO:K12567]
            MYH6 (mutation) [HSA:4624] [KO:K17751]
            PRKAG2 (mutation) [HSA:51422] [KO:K07200]
            CSRP3 (mutation) [HSA:8048] [KO:K09377]
            TNNC1 (mutation) [HSA:7134] [KO:K05865]
            VCL (mutation) [HSA:7414] [KO:K05700]
ENV_FACTOR  Athletic training
DRUG        Beta-blockers
            Disopyramide [DG:DG00194]
            Verapamil [DG:DG00329]
            Diltiazem [DG00331]
DBLINKS     ICD-10: I42
            OMIM: 192600 115195 115197 115196 613690 608758 608751 612098 188840 613251 612098 600858 612124 613243 613255
REFERENCE   PMID:12270949 (gene)
  AUTHORS   Fatkin D, Graham RM
  TITLE     Molecular mechanisms of inherited cardiomyopathies.
  JOURNAL   Physiol Rev 82:945-80 (2002)
REFERENCE   PMID:12844200 (gene)
  AUTHORS   Moolman-Smook JC, Mayosi BM, Brink PA, Corfield VA
  TITLE     Molecular genetics of cardiomyopathy: changing times, shifting paradigms.
  JOURNAL   Cardiovasc J S Afr 14:145-55 (2003)
REFERENCE   PMID:11716909 (gene)
  AUTHORS   Franz WM, Muller OJ, Katus HA
  TITLE     Cardiomyopathies: from genetics to the prospect of treatment.
  JOURNAL   Lancet 358:1627-37 (2001)
REFERENCE   PMID:11273720 (gene)
  AUTHORS   Marian AJ, Roberts R
  TITLE     The molecular genetic basis for hypertrophic cardiomyopathy.
  JOURNAL   J Mol Cell Cardiol 33:655-70 (2001)
REFERENCE   PMID:18572189 (gene)
  AUTHORS   Landstrom AP, Parvatiyar MS, Pinto JR, Marquardt ML, Bos JM, Tester DJ, Ommen SR, Potter JD, Ackerman MJ
  TITLE     Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C.
  JOURNAL   J Mol Cell Cardiol 45:281-8 (2008)
REFERENCE   PMID:16712796 (gene)
  AUTHORS   Vasile VC, Ommen SR, Edwards WD, Ackerman MJ
  TITLE     A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy.
  JOURNAL   Biochem Biophys Res Commun 345:998-1003 (2006)
REFERENCE   PMID:15183628 (env_factor ,drug)
  AUTHORS   Elliott P, McKenna WJ
  TITLE     Hypertrophic cardiomyopathy.
  JOURNAL   Lancet 363:1881-91 (2004)
REFERENCE   PMID:18930982 (drug)
  AUTHORS   Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, Butany J
  TITLE     Hypertrophic cardiomyopathy: current understanding and treatment objectives.
  JOURNAL   J Clin Pathol 62:226-35 (2009)
REFERENCE   PMID:19568388 (drug)
  AUTHORS   Marian AJ
  TITLE     Contemporary treatment of hypertrophic cardiomyopathy.
  JOURNAL   Tex Heart Inst J 36:194-204 (2009)
REFERENCE   PMID:15123994 (drug)
  AUTHORS   Ommen SR, Nishimura RA
  TITLE     Hypertrophic cardiomyopathy.
  JOURNAL   Curr Probl Cardiol 29:239-91 (2004)
///
ENTRY       H00293                      Disease
NAME        Arrhythmogenic right ventricular cardiomyopathy (ARVC)
DESCRIPTION Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.
CATEGORY    Cardiovascular disease
GENE        JUP (mutation) [HSA:3728] [KO:K10056]
            RYR2 (mutation) [HSA:6262] [KO:K04962]
            DSP (mutation) [HSA:1832] [KO:K10381]
            PKP2 (mutation) [HSA:5318] [KO:K12642]
            TGF-beta 3 (mutation) [HSA:7043] [KO:K13377]
            DSG2 (mutation) [HSA:1829] [KO:K07597]
            DSC2 (mutation) [HSA:1824] [KO:K07601]
            TMEM43 (mutation) [HSA:79188]
DRUG        Beta-blockers [ATC:C07A]
            Sotalol [DG:DG00307]
            Amiodarone [DG:DG00204]
DBLINKS     ICD-10: I42
            OMIM: 611528 600996 607450 609040 107970 610193 610476 604400
REFERENCE   PMID:18001465 (gene, drug)
  AUTHORS   Thiene G, Corrado D, Basso C
  TITLE     Arrhythmogenic right ventricular cardiomyopathy/dysplasia.
  JOURNAL   Orphanet J Rare Dis 2:45 (2007)
REFERENCE   PMID:17413274 (gene)
  AUTHORS   van Tintelen JP, Hofstra RM, Wiesfeld AC, van den Berg MP, Hauer RN, Jongbloed JD
  TITLE     Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon?
  JOURNAL   Curr Opin Cardiol 22:185-92 (2007)
REFERENCE   PMID:18382419 (gene)
  AUTHORS   Awad MM, Calkins H, Judge DP
  TITLE     Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy.
  JOURNAL   Nat Clin Pract Cardiovasc Med 5:258-67 (2008)
REFERENCE   PMID:22426942 (gene)
  AUTHORS   Murray B
  TITLE     Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C): A Review of Molecular and Clinical Literature.
  JOURNAL   J Genet Couns 21:494-504 (2012)
REFERENCE   PMID:19362677 (drug)
  AUTHORS   Basso C, Corrado D, Marcus FI, Nava A, Thiene G
  TITLE     Arrhythmogenic right ventricular cardiomyopathy.
  JOURNAL   Lancet 373:1289-300 (2009)
REFERENCE   PMID:19205777 (drug)
  AUTHORS   Herren T, Gerber PA, Duru F
  TITLE     Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a not so rare "disease of the desmosome" with multiple clinical presentations.
  JOURNAL   Clin Res Cardiol 98:141-58 (2009)
///
ENTRY       H00294                      Disease
NAME        Dilated cardiomyopathy (DCM)
DESCRIPTION Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM ("familial" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of "familial" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an "idiopathic" DCM. Current hypotheses regarding causes of "idiopathic" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with "idiopathic" DCM,  may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.
CATEGORY    Cardiovascular disease
GENE        TNNT2 (mutation) [HSA:7139] [KO:K12045]
            TTN (mutation) [HSA:7273] [KO:K12567]
            DES (mutation) [HSA:1674] [KO:K07610]
            SGCD (mutation) [HSA:6444] [KO:K12563]
            MYBPC3 (mutation) [HSA:4607] [KO:K12568]
            MYH7 (mutation) [HSA:4625] [KO:K17751]
            ACTC1 (mutation) [HSA:70] [KO:K12314]
            TPM1 (mutation) [HSA:7168] [KO:K10373]
            LMNA (mutation) [HSA:4000] [KO:K12641]
            DMD (mutation) [HSA:1756] [KO:K10366]
            Tafazzin (mutation) [HSA:6901] [KO:K13511]
            LDB3 (mutation) [HSA:11155] [KO:K19867]
            ACTN2 (mutation) [HSA:88] [KO:K21073]
            NEXN (mutation) [HSA:91624]
            RBM20 (mutation) [HSA:282996]
            SCN5A (mutation) [HSA:6331] [KO:K04838]
            MYH6 (mutation) [HSA:4624] [KO:K17751]
            TNNI3 (mutation) [HSA:7137] [KO:K12044]
            SDHA (mutation) [HSA:6389] [KO:K00234]
            EYA4 (mutation) [HSA:2070] [KO:K17622]
            CSRP3 (mutation) [HSA:8048] [KO:K09377]
            TCAP (mutation) [HSA:8557] [KO:K19879]
            ABCC9 (mutation) [HSA:10060] [KO:K05033]
            PLN (mutation) [HSA:5350] [KO:K05852]
            TMPO (mutation) [HSA:7112]
            PSEN1 (mutation) [HSA:5663] [KO:K04505]
            PSEN2 (mutation) [HSA:5664] [KO:K04522]
            VCL (mutation) [HSA:7414] [KO:K05700]
            FKTN (mutation) [HSA:2218] [KO:K19872]
            TNNC1 (mutation) [HSA:7134] [KO:K05865]
            TNNI3 (mutation) [HSA:7137] [KO:K12044]
            TAZ (mutation) [HSA:6901] [KO:K13511]
            HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DPA1 (polymorphism) [HSA:3113] [KO:K06752]
            HLA-DPB1 (polymorphism) [HSA:3115] [KO:K06752]
            HLA-DQA1 (polymorphism) [HSA:3117] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
ENV_FACTOR  LPS [CPD:C00338]
            Ethanol [CPD:C00469]
            Anthracycline
            Low oxygen [CPD:C00007]
PATHOGEN    Coxsackievirus B3
            Adenovirus
            Cytomegalovirus
            Parvovirus B19
            Hepatitis C virus [GN:T40066]
            Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
            Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
            Human herpesvirus 6B [GN:T40075]
            Human herpes virus-6 (HHV6) [RS:NC_001664]
            Trypanosoma cruzi [GN:tcr]
            Chlamydia pneumoniae
            Borrelia burgdorferi
MARKER      Virus-specific IgM class antibodies
DBLINKS     ICD-10: I42
            OMIM: 601494 604145 604765 606685 115200 613426 613424 611878 302045 601493 612158 613122 613172 601154 613252 613642 605362 607482 607487 608569 609909 613740 613694 613697 611407 611615 611879 611880 613286 300069
REFERENCE   PMID:12270949 (gene)
  AUTHORS   Fatkin D, Graham RM
  TITLE     Molecular mechanisms of inherited cardiomyopathies.
  JOURNAL   Physiol Rev 82:945-80 (2002)
REFERENCE   PMID:12844200 (gene)
  AUTHORS   Moolman-Smook JC, Mayosi BM, Brink PA, Corfield VA
  TITLE     Molecular genetics of cardiomyopathy: changing times, shifting paradigms.
  JOURNAL   Cardiovasc J S Afr 14:145-55 (2003)
REFERENCE   PMID:20864896 (gene)
  AUTHORS   Hershberger RE, Morales A, Siegfried JD
  TITLE     Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals.
  JOURNAL   Genet Med 12:655-67 (2010)
REFERENCE   PMID:20236114 (gene)
  AUTHORS   Franciosi S
  TITLE     Nexilin: a potential novel factor contributing to dilated cardiomyopathy.
  JOURNAL   Clin Genet 77:535-6 (2010)
REFERENCE   PMID:20551992 (gene)
  AUTHORS   Levitas A, Muhammad E, Harel G, Saada A, Caspi VC, Manor E, Beck JC, Sheffield V, Parvari R
  TITLE     Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase.
  JOURNAL   Eur J Hum Genet 18:1160-5 (2010)
REFERENCE   PMID:19015585 (gene)
  AUTHORS   Arimura T, Hayashi YK, Murakami T, Oya Y, Funabe S, Arikawa-Hirasawa E, Hattori N, Nishino I, Kimura A
  TITLE     Mutational analysis of fukutin gene in dilated cardiomyopathy and hypertrophic cardiomyopathy.
  JOURNAL   Circ J 73:158-61 (2009)
REFERENCE   (gene)
  AUTHORS   Richard P, Villard E, Charron P, Isnard R
  TITLE     The Genetic Bases of Cardiomyopathies
  JOURNAL   J Am Coll Cardiol 48:79-89 (2006)
REFERENCE   PMID:19017683 (env_factor, marker, drug)
  AUTHORS   Luk A, Ahn E, Soor GS, Butany J
  TITLE     Dilated cardiomyopathy: a review.
  JOURNAL   J Clin Pathol 62:219-25 (2009)
REFERENCE   PMID:15246023 (env_factor, drug)
  AUTHORS   Mobini R, Maschke H, Waagstein F
  TITLE     New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy.
  JOURNAL   Autoimmun Rev 3:277-84 (2004)
REFERENCE   PMID:15931504 (env_factor)
  AUTHORS   Poller W, Kuhl U, Tschoepe C, Pauschinger M, Fechner H, Schultheiss HP
  TITLE     Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy.
  JOURNAL   J Mol Med 83:579-86 (2005)
REFERENCE   PMID:11716909 (drug)
  AUTHORS   Franz WM, Muller OJ, Katus HA
  TITLE     Cardiomyopathies: from genetics to the prospect of treatment.
  JOURNAL   Lancet 358:1627-37 (2001)
///
ENTRY       H00295                      Disease
NAME        Viral myocarditis
DESCRIPTION Myocarditis is clinically defined as cardiac disease associated with inflammation of the myocardium and necrosis and/or degeneration of adjacent myocytes in the absence of an ischemic event. Most often, myocarditis results from common viral infections; less commonly, specific forms of myocarditis may result from other pathogens, toxic or hypersensitivity drug reactions, giant-cell myocarditis, or sarcoidosis. More than 20 common viruses, including coxsackieviruses, adenoviruses, influenza viruses, cytomegaloviruses, and human immunodeficiency virus, have been associated with myocarditis in humans. However, coxsackieviruses are considered the dominant cause of myocarditis, particularly in neonates and young children. After the acute phase caused by direct cytopathic effects of the virus, a small proportion of patients subsequently develop autoimmune- mediated, chronic myocarditis [4], accompanied by circulating autoantibodies to cardiac myosin and other heart antigens, which can sometimes lead to heart failure and death associated with dilated cardiomyopathy (DCM). Genetic linkage between susceptibility to myocarditis/DCM and the major histocompatibility complex (MHC) genes has been reported in both humans and experimentally induced mouse models.
CATEGORY    Cardiovascular disease
GENE        HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
PATHOGEN    Coxsackievirus B3
            Adenovirus
            Cytomegalovirus
            Parvovirus B19
            Hepatitis C virus [GN:T40066]
            Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
            Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
            Influenza virus
            Human herpesvirus 6B [GN:T40075]
            Human Herpes Virus 6 (HHV6) [RS:NC_001664]
            Echovirus
MARKER      Viral genome
            Creatinine kinase-MB fraction
            troponin I [HSA:7137]
            troponin T [HSA:7139]
            C-reactive protein [HSA:1401]
DRUG        Interferon-beta [DR:D00746 D03304 D04554]
            Prednisone [DG:DG00094]
            Azathioprine [DG:DG00743]
            Cyclosporine [DR:D00184]
            Corticosteroid
            Intravenous immune globulin [DR:D04516]
DBLINKS     ICD-10: I40
REFERENCE   PMID:19127454 (gene)
  AUTHORS   Portig I, Sandmoeller A, Kreilinger S, Maisch B
  TITLE     HLA-DQB1* polymorphism and associations with dilated cardiomyopathy, inflammatory dilated cardiomyopathy and myocarditis.
  JOURNAL   Autoimmunity 42:33-40 (2009)
REFERENCE   PMID:18190873 (gene)
  AUTHORS   Li HS, Ligons DL, Rose NR
  TITLE     Genetic complexity of autoimmune myocarditis.
  JOURNAL   Autoimmun Rev 7:168-73 (2008)
REFERENCE   PMID:8793712 (env_factor, marker, drug)
  AUTHORS   Fairley CK, Ryan M, Wall PG, Weinberg J
  TITLE     The organisms reported to cause infective myocarditis and pericarditis in England and Wales.
  JOURNAL   J Infect 32:223-5 (1996)
REFERENCE   PMID:18617482 (env_factor)
  AUTHORS   Dennert R, Crijns HJ, Heymans S
  TITLE     Acute viral myocarditis.
  JOURNAL   Eur Heart J (2008)
REFERENCE   PMID:17575480 (env_factor, marker)
  AUTHORS   Ellis CR, Di Salvo T
  TITLE     Myocarditis: basic and clinical aspects.
  JOURNAL   Cardiol Rev 15:170-7 (2007)
REFERENCE   PMID:19357408 (marker,drug)
  AUTHORS   Cooper LT Jr
  TITLE     Myocarditis.
  JOURNAL   N Engl J Med 360:1526-38 (2009)
REFERENCE   PMID:11524405 (marker,drug)
  AUTHORS   Liu PP, Mason JW
  TITLE     Advances in the understanding of myocarditis.
  JOURNAL   Circulation 104:1076-82 (2001)
REFERENCE   PMID:16106325 (marker,drug)
  AUTHORS   Burian J, Buser P, Eriksson U
  TITLE     Myocarditis: the immunologist's view on pathogenesis and treatment.
  JOURNAL   Swiss Med Wkly 135:359-64 (2005)
REFERENCE   PMID:16476862 (marker,drug)
  AUTHORS   Magnani JW, Dec GW
  TITLE     Myocarditis: current trends in diagnosis and treatment.
  JOURNAL   Circulation 113:876-90 (2006)
///
ENTRY       H00296                      Disease
NAME        Defects in RecQ helicases, including:
            Bloom's syndrome [DS:H01346];
            Werner's syndrome [DS:H01733];
            Rothmund-Thomson syndrome [DS:H01734];
            RAPADILINO syndrome [DS:H00965];
            Baller-Gerold syndrome
DESCRIPTION RecQ helicases have crucial roles in the maintenance of genome stability. In humans, it is known that deficiencies in three of the five human RecQ helicases cause genetic disorders characterized by cancer predisposition, premature aging and developmental abnormalities. These disorders are Bloom's syndrome (BS), Werner's syndrome (WS), and Rothmund-Thomson syndrome (RTS), which are caused by mutations in BLM, WRN and RECQ4, respectively. Despite the apparent structural and biochemical similarities between the BLM, WRN and RECQ4 proteins, the phenotypes of BS, WS and RTS are different, suggesting that each disease pathway is functionally distinct to some extent. BS is characterized by most prominently, a predisposition to all types of cancers. WS is characterized by the premature development of features that resemble aging. RTS is characterized by skin and skeletal abnormalities, signs of premature aging, and cancer predisposition, especially to osteosarcomas. Recent research has shown many connections between all three proteins and the regulation of excess HR (Homologous recombination). It was also indicated that BLM is involved in repair of stalled DNA replication forks, and that WRN is required for telomere maintenance. Mutations in RECQL4 also associate with 2 additional syndromes, Rapadilino and Baller-Gerold syndrome.
CATEGORY    Congenital disorder of DNA repair systems
GENE        BLM [HSA:641] [KO:K10901]
            WRN [HSA:7486] [KO:K10900]
            RECQL4 [HSA:9401] [KO:K10730]
COMMENT     DNA replication proteins [BR:ko03032]
            DNA repair and recombination proteins [BR:ko03400]
DBLINKS     ICD-10: Q82.8 E34.8
            MeSH: D001816 D014898 D011038 C535288
            OMIM: 210900 277700 268400 266280 218600
REFERENCE   PMID:12200042
  AUTHORS   Mohaghegh P, Hickson ID
  TITLE     Premature aging in RecQ helicase-deficient human syndromes.
  JOURNAL   Int J Biochem Cell Biol 34:1496-501 (2002)
REFERENCE   PMID:18430459
  AUTHORS   Ouyang KJ, Woo LL, Ellis NA.
  TITLE     Homologous recombination and maintenance of genome integrity: Cancer and aging through the prism of human RecQ helicases.
  JOURNAL   Mech Ageing Dev 129:425-40 (2008)
REFERENCE   PMID:17571213
  AUTHORS   Hanada K, Hickson ID
  TITLE     Molecular genetics of RecQ helicase disorders.
  JOURNAL   Cell Mol Life Sci 64:2306-22 (2007)
REFERENCE   PMID:19661064
  AUTHORS   Kikuchi K, Abdel-Aziz HI, Taniguchi Y, Yamazoe M, Takeda S, Hirota K
  TITLE     Bloom DNA helicase facilitates homologous recombination between diverged homologous sequences.
  JOURNAL   J Biol Chem 284:26360-7 (2009)
///
ENTRY       H00297                      Disease
NAME        Plague
DESCRIPTION Plague is a deadly infectious disease caused by Yersinia pestis. The pathogen has rodent reservoirs and is transmitted to humans usually by fleas as vectors. There are three major manifestations: bubonic, septicemic, and pneumonic plagues. Severe epidemics in the past include the Plague of Justinian in the sixth century, the Black Death in the fourteenth century, and the Third Pandemic that began in Central Asia in the nineteenth century. The genome sequences have been determined for the strains responsible for these epidemics.
CATEGORY    Infectious disease
PATHOGEN    Yersinia pestis CO92 (biovar Orientalis) [GN:ype] (Third Pandemic)
            Yersinia pestis KIM (biovar Mediaevalis) [GN:ypk] (Black Death)
            Yersinia pestis Antiqua,Nepal516 (biovar Antiqua) [GN:ypa ypn] (Plague of Justinian)
            Yersinia pestis Pestoides F [GN:ypp]
            Yersinia pestis Angola [GN:ypg]
            Yersinia pestis D106004 [GN:ypd]
            Yersinia pestis D182038 [GN:ypx]
COMMENT     Vector: Xenopsylla cheopis (rat flea)
            murine toxin [KO:K11009]
DBLINKS     ICD-10: A20
            MeSH: D010930
            MedlinePlus: 000596
///
ENTRY       H00298                      Disease
NAME        Yersiniosis
DESCRIPTION Yersiniosis (non-plague) is an infectious disease caused by two species, Yersinia enterocolitica and Y. pseudotuberculosis, which is zoonotic, capable of being transmitted from infected animals to man. Major clinical forms include acute gastroenteritis and mesenteric lymphadenitis, which are often accompanied by fever and abdominal pain. Routes of transmission include fecal-oral spread via ingestion of contaminated food as the most common route and consumption of contaminated water supplies. Yersiniosis occurs more commonly in regions with temperate rather than tropical or subtropical climates.
CATEGORY    Infectious disease
PATHOGEN    Yersinia pseudotuberculosis [GN:yps ypi ypy ypb]
            Yersinia enterocolitica [GN:yen yep yey]
            superantigen [KO:K11010]
DBLINKS     ICD-10: A04.6 A28.2
            MeSH: D015009
REFERENCE   PMID:10192708 (description)
  AUTHORS   Smego RA, Frean J, Koornhof HJ
  TITLE     Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections.
  JOURNAL   Eur J Clin Microbiol Infect Dis 18:1-15 (1999)
REFERENCE   PMID:15721832 (description)
  AUTHORS   Pujol C, Bliska JB
  TITLE     Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae.
  JOURNAL   Clin Immunol 114:216-26 (2005)
///
ENTRY       H00299                      Disease
NAME        Shigellosis;
            Bacillary dysentery
DESCRIPTION Shigellosis (bacillary dysentery) is a foodborne enterobacterial infection caused by Shigella species. There are four subgroups of Shigella: S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. Of these, S. flexneri is the most frequently observed worldwide, and S. dysenteriae causes severe disease with the highest fatality rate. Clinical symptoms include an acute rectocolitis associated with fever, nausea, anorexia, dehydration, mucopurulent and bloody diarrhea, and tenesmus. Transmission usually occurs via contaminated food and water or through person-to-person contact. In humans, shigellosis can be provoked by an extremely small number of organisms (10-100).
CATEGORY    Infectious disease
PATHOGEN    Shigella flexneri [GN:sfl sfx sfv sfe]
            Shigella sonnei [GN:ssn ssj]
            Shigella boydii [GN:sbo sbc]
            Shigella dysenteriae [GN:sdy]
            shiga toxin [KO:K11006 K11007]
            enterotoxin ShET-1 [KO:K11011 K11012]
COMMENT     Due to the global emergence of drug resistance, the choice of antimicrobial agents for treating shigellosis is limited.
DBLINKS     ICD-10: A03
            MeSH: D004405
            MedlinePlus: 000295
REFERENCE   PMID:18448978 (description)
  AUTHORS   Kweon MN
  TITLE     Shigellosis: the current status of vaccine development.
  JOURNAL   Curr Opin Infect Dis 21:313-8 (2008)
REFERENCE   PMID:16954064 (description)
  AUTHORS   Warren BR, Parish ME, Schneider KR
  TITLE     Shigella as a foodborne pathogen and current methods for detection in food.
  JOURNAL   Crit Rev Food Sci Nutr 46:551-67 (2006)
REFERENCE   PMID:15880088 (description, comment)
  AUTHORS   Niyogi SK
  TITLE     Shigellosis.
  JOURNAL   J Microbiol 43:133-43 (2005)
///
ENTRY       H00300                      Disease
NAME        Enterobacter infection
DESCRIPTION Enterobacter infections are commonly found in nosocomial settings. They have been recognized as increasingly important pathogens because of their resistance to older antimicrobial agents. Enterobacter are recovered from the respiratory tract, surgical wounds, urinary tract, and blood and are implicated in a broad range of clinical syndromes.
CATEGORY    Infectious disease
PATHOGEN    Enterobacter sakazakii [GN:esa csk]
            Enterobacter cloacae [GN:enc eec]
            Cronobacter turicensis z3032 [GN:ctu]
            Enterobacter agglomerans
COMMENT     Approximately 31% of Enterobacter spp. infections in intensive care units in the United States involve strains not susceptible to third-generation cephalosporins.
DBLINKS     ICD-10: A04.8
REFERENCE   PMID:9105752 (description, env_factor)
  AUTHORS   Sanders WE Jr, Sanders CC
  TITLE     Enterobacter spp.: pathogens poised to flourish at the turn of the century.
  JOURNAL   Clin Microbiol Rev 10:220-41 (1997)
REFERENCE   PMID:16813978 (description, comment)
  AUTHORS   Paterson DL
  TITLE     Resistance in gram-negative bacteria: Enterobacteriaceae.
  JOURNAL   Am J Infect Control 34:S20-8; discussion S64-73 (2006)
///
ENTRY       H00301                      Disease
NAME        Klebsiella infection
DESCRIPTION Klebsiella is a gram-negative bacterium of Enterobacteriaceae with multidrug-resistance. They produce extended-spectrum beta-lactamase (ESBL) enzymes, making themselves resistant to antibiotic drugs. Klebsiella pneumoniae can cause sepsis, conjunctivitis, urinary tract infections, and surgical site infections. Bloodstream infections with Klebsiella markedly increase the rates of treatment failure and death.
CATEGORY    Infectious disease
PATHOGEN    Klebsiella pneumoniae [GN:kpn kpu kpm kpp kpt kpa kps kpc]
            Klebsiella oxytoca E718 [GN:koe]
            Klebsiella quasipneumoniae [GN:kqu]
DBLINKS     ICD-10: A49.8 B96.1 J15.0
            MeSH: D007710
REFERENCE   PMID:21653305 (description)
  AUTHORS   Gupta N, Limbago BM, Patel JB, Kallen AJ
  TITLE     Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.
  JOURNAL   Clin Infect Dis 53:60-7 (2011)
REFERENCE   PMID:13679928 (descrioption)
  AUTHORS   Gupta A, Ampofo K, Rubenstein D, Saiman L
  TITLE     Extended spectrum beta lactamase-producing Klebsiella pneumoniae infections: a review of the literature.
  JOURNAL   J Perinatol 23:439-43 (2003)
REFERENCE   PMID:16436702 (description)
  AUTHORS   Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, Fadda G, Cauda R
  TITLE     Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.
  JOURNAL   Antimicrob Agents Chemother 50:498-504 (2006)
REFERENCE   PMID:15711657 (description)
  AUTHORS   Panhotra BR, Saxena AK, Al-Ghamdi AM
  TITLE     Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome.
  JOURNAL   Saudi Med J 25:1871-6 (2004)
///
ENTRY       H00302                      Disease
NAME        Citrobacter infection
DESCRIPTION Citrobacter species may cause infections in neonates and immunocompromised hosts. Among them, C. koseri is an important cause of neonatal meningitis and brain abscess formation. Neonates may acquire C. koseri horizontally in hospital settings or vertically from the mother at delivery.
CATEGORY    Infectious disease
PATHOGEN    Citrobacter koseri (infants and immunocompromised) [GN:cko]
            Citrobacter freundii (immunocompromised)
DRUG        Gentamicin [DG:DG00401]
            Aminoglycosides [ATC:J01G]
            Third-generation cephalosporins [ATC:J01DD]
            Chloramphenicol [DG:DG00399]
            Imipenim/cilastatin [DR:D00344]
            Trimethoprim [DG:DG00595]
            Penicillin [DG:DG00534]
DBLINKS     ICD-10: A49.8
REFERENCE   PMID:10064257 (description, env_factor, drug)
  AUTHORS   Doran TI
  TITLE     The role of Citrobacter in clinical disease of children: review.
  JOURNAL   Clin Infect Dis 28:384-94 (1999)
REFERENCE   PMID:12751719
  AUTHORS   Prais D, Nussinovitch M, Harel L, Amir J
  TITLE     Citrobacter koseri (diversus) meningitis in an otherwise healthy adolescent.
  JOURNAL   Scand J Infect Dis 35:202-4 (2003)
///
ENTRY       H00303                      Disease
NAME        Serratia infection
DESCRIPTION Serratia species are gram-negative bacilli of the Enterobacteriaceae that cause hospital-acquired infection. Numerous outbreaks have been reported in association with medical devices and neonatal intensive care unit.
CATEGORY    Infectious disease
PATHOGEN    Serratia marcescens [GN:smar]
            Serratia proteamaculans [GN:spe]
            Serratia liquefaciens
COMMENT     Infections caused by S. marcescens may be difficult to treat because of resistance to a variety of antibiotics, including ampicillin and first and second generation cephalosporins.
DBLINKS     ICD-10: A49.8
            MeSH: D016868
REFERENCE   PMID:21976608 (description, env_factor)
  AUTHORS   Mahlen SD
  TITLE     Serratia infections: from military experiments to current practice.
  JOURNAL   Clin Microbiol Rev 24:755-91 (2011)
REFERENCE   PMID:9368530 (description, comment)
  AUTHORS   Hejazi A, Falkiner FR
  TITLE     Serratia marcescens.
  JOURNAL   J Med Microbiol 46:903-12 (1997)
REFERENCE   PMID:9211156 (description)
  AUTHORS   van Ogtrop ML, van Zoeren-Grobben D, Verbakel-Salomons EM, van Boven CP
  TITLE     Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature.
  JOURNAL   J Hosp Infect 36:95-103 (1997)
///
ENTRY       H00304                      Disease
NAME        Haemophilus influenzae infection
DESCRIPTION Haemophilus influenzae type b (Hib) infections are a major cause of severe infections in children between 2 months and 5 years of age worldwide. It affects approximately 25000 patients each year. Severity of the symptoms of Hib infection depends on the patient's age, and infants between 4 months and 1 year of age are at highest risk for meningitis. Invasive disease due to Hib may produce various clinical syndromes including meningitis, arthritis, pneumonia,	 cellulitis, osteomyelitis, and epiglottitis. Mucosal infections, such as bronchitis, sinusitis and conjunctivitis, and otitis media, can also be caused by Hib, but they are considered to be noninvasive disease.
CATEGORY    Infectious disease
PATHOGEN    Haemophilus influenzae [GN:hin hit hip hiq hiu hik]
DRUG        Third-generation cephalosporins [DG:DG00570 DG00573]
            Comination of ampicillin and chloramphenicol [DG:DG00517 DG00399]
            Rifampicin (prophylaxis) [DG:DG00639]
            Hib conjugate vaccine [DR:D09189]
COMMENT     American Indians and Alaskan Eskimos are at increased risk specifically for meningitis caused by Hib.
DBLINKS     ICD-10: A41.3 A49.2 G00.0 J14 J20.1
            MeSH: D006192
REFERENCE   PMID:2194406 (description, drug, comment)
  AUTHORS   Janai H, Stutman HR, Marks MI
  TITLE     Invasive Haemophilus influenzae type B infections: a continuing challenge.
  JOURNAL   Am J Infect Control 18:160-6 (1990)
REFERENCE   PMID:22244051 (drug)
  AUTHORS   Ladhani SN
  TITLE     Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom.
  JOURNAL   Clin Ther 34:385-99 (2012)
REFERENCE   PMID:20980793 (drug)
  AUTHORS   Fitzwater SP, Watt JP, Levine OS, Santosham M
  TITLE     Haemophilus influenzae type b conjugate vaccines: considerations for vaccination  schedules and implications for developing countries.
  JOURNAL   Hum Vaccin 6:810-8 (2010)
REFERENCE   PMID:3325012 (drug)
  AUTHORS   Gilbert GL
  TITLE     Epidemiology and prevention of invasive Haemophilus influenzae type b infection.
  JOURNAL   Aust Paediatr J 23:323-7 (1987)
///
ENTRY       H00305                      Disease
NAME        Chancroid
DESCRIPTION Chancroid is a sexually transmitted disease (STD) caused by the gram negative, short, slender bacterium Haemophilus ducreyi. It is a classical genito-ulcerative disease accompanied by inguinal lymphadenitis that is endemic in sub-Saharan Africa. It has generated considerable interest because it is associated as a co-factor for HIV transmission.
CATEGORY    Infectious disease
PATHOGEN    Haemophilus ducreyi [GN:hdu]
            cytolethal distending toxin [KO:K11013 K11014 K11015]
MARKER      16S rRNA (multiplex PCR) [HDU:16SrRNA_1 16SrRNA_2 16SrRNA_3 16SrRNA_4 16SrRNA_5 16SrRNA_6] [KO:K01977]
DRUG        Ciprofloxacin [DG:DG00617]
            Erythromycin [DG:DG00436]
            Ceftriaxone [DG:DG00573]
            Azithromycin [DG:DG00606]
            Spectinomycin [DG:DG00634]
COMMENT     Pregnant women should be treated with either erythromycin or ceftriaxone regimens.
DBLINKS     ICD-10: A57
            MeSH: D002602
            MedlinePlus: 000635
REFERENCE   PMID:12576620 (description, env_factor, drug)
  AUTHORS   Lewis DA
  TITLE     Chancroid: clinical manifestations, diagnosis, and management.
  JOURNAL   Sex Transm Infect 79:68-71 (2003)
REFERENCE   PMID:12653911 (description)
  AUTHORS   Sehgal VN, Srivastava G
  TITLE     Chancroid: contemporary appraisal.
  JOURNAL   Int J Dermatol 42:182-90 (2003)
REFERENCE   PMID:15918786 (description)
  AUTHORS   Annan NT, Lewis DA
  TITLE     Treatment of chancroid in resource-poor countries.
  JOURNAL   Expert Rev Anti Infect Ther 3:295-306 (2005)
REFERENCE   PMID:8748271 (marker)
  AUTHORS   Orle KA, Gates CA, Martin DH, Body BA, Weiss JB
  TITLE     Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers.
  JOURNAL   J Clin Microbiol 34:49-54 (1996)
///
ENTRY       H00306                      Disease
NAME        Pasteurellosis
DESCRIPTION Pasteurella are gram-positive, facultative anaerobic bacilli found in the animal's oral cavity. Disseminated Pasteurella infections can lead to serious diseases including septic shock and meningitis mostly in infants and pregnant women. Many patients with P. multocida-related bacteraemia have evidence of liver disease.
CATEGORY    Infectious disease
PATHOGEN    Pasteurella multocida [GN:pmu pmv pmul]
            Pasteurella canis
            Pasteurella multocida subsp septica
            Pasteurella stomatis
            Pasteurella dagmatis
            Capsular lipopolysaccharide
            Iron acquisition proteins
DRUG        Betalactam antibiotics [ATC:J01C]
            Second-generation and third-generation cephalosporins [ATC:J01DC J01DD]
COMMENT     Pasteurella are usually not susceptible to dicloxacillin, cephalexin, clindamycin, or erythromycin.
DBLINKS     ICD-10: A28.0
            MeSH: D010326 D012766
REFERENCE   PMID:6371440 (drug)
  AUTHORS   Weber DJ, Wolfson JS, Swartz MN, Hooper DC
  TITLE     Pasteurella multocida infections. Report of 34 cases and review of the literature.
  JOURNAL   Medicine (Baltimore) 63:133-54 (1984)
REFERENCE   PMID:19555903 (env_factor)
  AUTHORS   Oehler RL, Velez AP, Mizrachi M, Lamarche J, Gompf S
  TITLE     Bite-related and septic syndromes caused by cats and dogs.
  JOURNAL   Lancet Infect Dis 9:439-47 (2009)
///
ENTRY       H00307                      Disease
NAME        Vibrio parahaemolyticus infection
DESCRIPTION Vibrio parahaemolyticus is a Gram-negative halophilic bacterium that naturally inhabits marine and estuarine environments. It is a well-recognized pathogen of both aquatic animals and humans. In the case of humans, it is often acquired through the consumption of raw or undercooked seafood, causing gastroenteritis with watery diarrhea. Clinical symptoms of V. parahaemolyticus infections include watery diarrhea, abdominal cramps, nausea, vomiting, headaches, fever, and chills.
CATEGORY    Infectious disease
PATHOGEN    Vibrio parahaemolyticus [GN:vpa vpk]
            pore-forming toxin [KO:K11019]
            membrane-damaging toxin [KO:K11018]
DBLINKS     ICD-10: A05.3
            MeSH: D014735
REFERENCE   PMID:19342185 (description)
  AUTHORS   Austin B
  TITLE     Vibrios as causal agents of zoonoses.
  JOURNAL   Vet Microbiol 140:310-7 (2010)
REFERENCE   PMID:20847516 (description)
  AUTHORS   Shimohata T, Takahashi A
  TITLE     Diarrhea induced by infection of Vibrio parahaemolyticus.
  JOURNAL   J Med Invest 57:179-82 (2010)
///
ENTRY       H00308                      Disease
NAME        Vibrio vulnificus infection
DESCRIPTION Vibrio vulnificus is a gram-negative bacillus found in warm coastal waters. It causes two distinct syndromes: a primary septicemia related to seafood consumption and a necrotizing wound infection acquired by exposing open wounds to contaminated seawater.
CATEGORY    Infectious disease
PATHOGEN    Vibrio vulnificus [GN:vvu vvy vvm]
            pore-forming toxin [KO:K10948 K10953]
            membrane-damaging toxin [KO:K11018]
DRUG        Cefotaxime [DG:DG00570]
            Ceftriaxone [DG:DG00573]
            Ceftazidime [DG:DG00571]
            Piperacillin-tazobactam [DR:D02505]
            Imipenem-cilastatin [DR:D00344]
            Minocycline [DG:DG00009]
            Doxycycline [DG:DG00008]
            Gentamicin [DG:DG00401]
            Amikacin [DG:DG00403]
            Ciprofloxacin [DG:DG00617]
            Moxifloxacin [DG:DG00626]
            Levofloxacin [DG:DG00624]
            Trimethoprim-sulfamethoxazole [DR:D00285]
            Chloramphenicol [DG:DG00399]
DBLINKS     ICD-10: A05.9
            MeSH: C536348
REFERENCE   (drug)
REFERENCE   PMID:21177133 (description, env_factor, drug)
  AUTHORS   Horseman MA, Surani S
  TITLE     A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis  and skin and soft-tissue infection.
  JOURNAL   Int J Infect Dis 15:e157-66 (2011)
REFERENCE   PMID:17853628 (description, env_factor)
  AUTHORS   Bross MH, Soch K, Morales R, Mitchell RB
  TITLE     Vibrio vulnificus infection: diagnosis and treatment.
  JOURNAL   Am Fam Physician 76:539-44 (2007)
///
ENTRY       H00309                      Disease
NAME        Multidrug-resistant Acinetobacter infection
DESCRIPTION Acinetobacter baumannii has emerged as a worldwide problem as a nosocomial pathogen in hospitalized patients. It can cause bacteremia, pneumonia, meningitis, urinary tract infection, wound infection, and nosocomial infections with mortality rates of 20 to 60%. Isolates resistant to almost all commercially available antimicrobials have been identified.
CATEGORY    Infectious disease
PATHOGEN    Acinetobacter baumannii [GN:aby abc abn abx abz abr abd abh abad abau abaa abk]
DRUG        Colistin [DG:DG00087]
DBLINKS     ICD-10: A49.9
            MeSH: D000151
REFERENCE   PMID:18444865 (drug)
  AUTHORS   Maragakis LL, Perl TM
  TITLE     Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.
  JOURNAL   Clin Infect Dis 46:1254-63 (2008)
REFERENCE   PMID:16008625 (drug)
  AUTHORS   Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E
  TITLE     Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.
  JOURNAL   Clin Microbiol Infect 11:682-3 (2005)
REFERENCE   PMID:16048915 (drug)
  AUTHORS   Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME
  TITLE     Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
  JOURNAL   Antimicrob Agents Chemother 49:3136-46 (2005)
REFERENCE   PMID:21502736 (desciption)
  AUTHORS   Doughari HJ, Ndakidemi PA, Human IS, Benade S
  TITLE     The ecology, biology and pathogenesis of Acinetobacter spp.: an overview.
  JOURNAL   Microbes Environ 26:101-12 (2011)
REFERENCE   PMID:15280512 (description)
  AUTHORS   Jain R, Danziger LH
  TITLE     Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
  JOURNAL   Ann Pharmacother 38:1449-59 (2004)
REFERENCE   PMID:18588496 (description)
  AUTHORS   Gootz TD, Marra A
  TITLE     Acinetobacter baumannii: an emerging multidrug-resistant threat.
  JOURNAL   Expert Rev Anti Infect Ther 6:309-25 (2008)
REFERENCE   PMID:16238638 (drug)
  AUTHORS   Hanlon GW
  TITLE     The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting.
  JOURNAL   Lett Appl Microbiol 41:375-8 (2005)
///
ENTRY       H00310                      Disease
NAME        Q fever
DESCRIPTION Q fever is a worldwide zoonosis caused by Coxiella burnetii, a gram-negative obligate intracellular bacterium. This infection has many different reservoirs that mainly consist of dairy cattle. Infection in humans is often asymptomatic, but may appear either in an acute form accompanied mainly by fever (self-limited flu-like disease, pneumonia, or hepatitis) or in a chronic form (mainly endocarditis).
CATEGORY    Infectious disease
PATHOGEN    Coxiella burnetii [GN:cbu cbs cbg cbc]
MARKER      htpAB-associated element (PCR detection)
DRUG        Levofloxacin [DG:DG00624]
            Sparfloxacin [DR:D00590]
            Doxycycline [DG:DG00008]
            Hydroxychloroquine [DG:DG01015]
            Ofloxacin [DG:DG00616]
            Pefloxacin [DG:DG00618]
            Rifampin [DR:D00211]
            Chloroquine [DG:DG01014]
COMMENT     Vector: Rhipicephalus sanguineus (brown dog tick)
DBLINKS     ICD-10: A78
            MeSH: D011778
            MedlinePlus: 000611 001337
REFERENCE   PMID:22125041 (description, env_factor, drug)
  AUTHORS   Delsing CE, Warris A, Bleeker-Rovers CP
  TITLE     Q fever: still more queries than answers.
  JOURNAL   Adv Exp Med Biol 719:133-43 (2011)
REFERENCE   PMID:12693856 (description)
  AUTHORS   Kovacova E, Kazar J
  TITLE     Q fever--still a query and underestimated infectious disease.
  JOURNAL   Acta Virol 46:193-210 (2002)
REFERENCE   PMID:16481501 (drug)
  AUTHORS   Kazar J
  TITLE     Coxiella burnetii infection.
  JOURNAL   Ann N Y Acad Sci 1063:105-14 (2005)
REFERENCE   PMID:15196898 (description, drug)
  AUTHORS   Woldehiwet Z
  TITLE     Q fever (coxiellosis): epidemiology and pathogenesis.
  JOURNAL   Res Vet Sci 77:93-100 (2004)
REFERENCE   PMID:2378478 (marker)
  AUTHORS   Mallavia LP, Whiting LL, Minnick MF, Heinzen R, Reschke D, Foreman M, Baca OG, Frazier ME
  TITLE     Strategy for detection and differentiation of Coxiella burnetii strains using the polymerase chain reaction.
  JOURNAL   Ann N Y Acad Sci 590:572-81 (1990)
REFERENCE   PMID:14605144 (marker)
  AUTHORS   Fournier PE, Raoult D
  TITLE     Comparison of PCR and serology assays for early diagnosis of acute Q fever.
  JOURNAL   J Clin Microbiol 41:5094-8 (2003)
///
ENTRY       H00311                      Disease
NAME        Legionellosis;
            Legionnaires disease
DESCRIPTION Legionnaires disease (LD), caused by Gram-negative Legionella spp., can be nosocomial, community acquired or travel related. L. pneumophila is the most common cause of LD. The source of LD is potable water systems that become colonized by the microorganism, transmitted by inhalation of contaminated aerosols and aspiration. Classically, it can cause two different forms of disease in humans: LD, with an incubation period of 2-10 days, which is a multisystem illness that involves the lungs, causing pneumonia, and can cause neurological symptoms, diarrhea and high mortality (up to 50%), and Pontiac fever, with a shorter incubation period of 1-2 days, which is an acute, self-limited, influenza-like disease that does not cause pneumonia. Patients who are at risk for infection include the immunosuppressed, especially those submitted to transplantation (mainly of solid organs), those with chronic lung disease, smokers, and the elderly.
CATEGORY    Infectious disease
PATHOGEN    Legionella pneumophila [GN:lpf lpp lpn lpc lpa lpe]
            Legionella longbeachae [GN:llo]
            pore-forming toxin [KO:K11022]
DBLINKS     ICD-10: A48.1 A48.2
            MeSH: D007876 D007877
            MedlinePlus: 000616
REFERENCE   PMID:12734447
  AUTHORS   Roig J, Sabria M, Pedro-Botet ML
  TITLE     Legionella spp.: community acquired and nosocomial infections.
  JOURNAL   Curr Opin Infect Dis 16:145-51 (2003)
REFERENCE   PMID:20051846
  AUTHORS   Carratala J, Garcia-Vidal C
  TITLE     An update on Legionella.
  JOURNAL   Curr Opin Infect Dis 23:152-7 (2010)
REFERENCE   PMID:19917208
  AUTHORS   Blyth CC, Adams DN, Chen SC
  TITLE     Diagnostic and typing methods for investigating Legionella infection.
  JOURNAL   N S W Public Health Bull 20:157-61 (2009)
REFERENCE   PMID:19622057 (description)
  AUTHORS   Levin AS
  TITLE     Nosocomial legionellosis: prevention and management.
  JOURNAL   Expert Rev Anti Infect Ther 7:57-68 (2009)
///
ENTRY       H00312                      Disease
NAME        Tularemia
DESCRIPTION Tularemia is a rare zoonotic infection caused by the bacterium Francisella tularensis. It occurs in North America, Europe and Asia. The most common clinical presentation is ulceroglandular tularemia with chills, fever, head and muscle pain, and prostration. Some people may develop pneumonia or septicemia. Rabbits serve as an important reservoir host for F. tularensis.
CATEGORY    Infectious disease
PATHOGEN    Francisella tularensis [GN:ftu ftw ftl fth fta ftr fts]
            Francisella holarctica [GN:ftl fth fta]
COMMENT     Vector: Dermacentor reticulatus and Ixodes ricinus (tick)
DBLINKS     ICD-10: A21
            MeSH: D014406
            MedlinePlus: 000856
REFERENCE   PMID:19713053 (description, env_factor)
  AUTHORS   Foley JE, Nieto NC
  TITLE     Tularemia.
  JOURNAL   Vet Microbiol 140:332-8 (2010)
REFERENCE   PMID:18755386 (description)
  AUTHORS   Nigrovic LE, Wingerter SL
  TITLE     Tularemia.
  JOURNAL   Infect Dis Clin North Am 22:489-504, ix (2008)
REFERENCE   PMID:17435120 (description)
  AUTHORS   Keim P, Johansson A, Wagner DM
  TITLE     Molecular epidemiology, evolution, and ecology of Francisella.
  JOURNAL   Ann N Y Acad Sci 1105:30-66 (2007)
///
ENTRY       H00313                      Disease
NAME        Multidrug-resistant Pseudomonas aeruginosa infection
DESCRIPTION Pseudomonas aeruginosa is an opportunistic pathogen that may cause severe invasive diseases in critically ill patients. In the 21st century, when the life expectancy of highly susceptible immunocompromised groups has been extended in most countries, P. aeruginosa plays an increasingly prominent role in hospital infections. This organism shows a remarkable capacity to resist antibiotics, either intrinsically (because of constitutive expression of beta-lactamases and efflux pumps, combined with low permeability of the outer-membrane) or following acquisition of resistance genes (e.g., genes for beta-lactamases, or enzymes inactivating aminoglycosides or modifying their target), over-expression of efflux pumps, decreased expression of porins, or mutations in quinolone targets. These mechanisms mediate the multidrug-resistant (MDR) phenotype in P. aeruginosa.
CATEGORY    Infectious disease
PATHOGEN    Pseudomonas aeruginosa [GN:pap pnc prp]
DRUG        Colistin [DG:DG00087]
            Aztreonam [DG:DG00589]
            Meropenem [DG:DG00591]
            Polymyxin B [DG:DG00083]
COMMENT     P. aeruginosa genes containing mutations:
            nalC [KO:K18130]
            nalD [KO:K18135]
DBLINKS     ICD-10: A49.8 J15.1
            MeSH: D011552
REFERENCE   PMID:20715920
  AUTHORS   Hirsch EB, Tam VH
  TITLE     Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.
  JOURNAL   Expert Rev Pharmacoecon Outcomes Res 10:441-51 (2010)
REFERENCE   PMID:17266725 (description)
  AUTHORS   Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F
  TITLE     Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.
  JOURNAL   Clin Microbiol Infect 13:560-78 (2007)
REFERENCE   PMID:24409175 (description)
  AUTHORS   Morita Y, Tomida J, Kawamura Y
  TITLE     Responses of Pseudomonas aeruginosa to antimicrobials.
  JOURNAL   Front Microbiol 4:422 (2014)
REFERENCE   PMID:20107499 (pathogen)
  AUTHORS   Roy PH, Tetu SG, Larouche A, Elbourne L, Tremblay S, Ren Q, Dodson R, Harkins D, Shay R, Watkins K, Mahamoud Y, Paulsen IT
  TITLE     Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7.
  JOURNAL   PLoS One 5:e8842 (2010)
REFERENCE   PMID:22123763 (pathogen)
  AUTHORS   Miyoshi-Akiyama T, Kuwahara T, Tada T, Kitao T, Kirikae T
  TITLE     Complete genome sequence of highly multidrug-resistant Pseudomonas aeruginosa NCGM2.S1, a representative strain of a cluster endemic to Japan.
  JOURNAL   J Bacteriol 193:7010 (2011)
REFERENCE   PMID:23908295 (pathogen)
  AUTHORS   Jeukens J, Boyle B, Bianconi I, Kukavica-Ibrulj I, Tummler B, Bragonzi A, Levesque RC
  TITLE     Complete Genome Sequence of Persistent Cystic Fibrosis Isolate Pseudomonas aeruginosa Strain RP73.
  JOURNAL   Genome Announc 1 (2013)
REFERENCE   PMID:25070493 (drug)
  AUTHORS   Nakamura I, Yamaguchi T, Tsukimori A, Sato A, Fukushima S, Matsumoto T
  TITLE     New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.
  JOURNAL   Eur J Clin Microbiol Infect Dis 34:83-7 (2015)
REFERENCE   PMID:16641429 (comment)
  AUTHORS   Quale J, Bratu S, Gupta J, Landman D
  TITLE     Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.
  JOURNAL   Antimicrob Agents Chemother 50:1633-41 (2006)
///
ENTRY       H00314                      Disease
NAME        Meningococcal infections
DESCRIPTION Neisseria meningitidis is a gram-negative bacterial pathogen that specifically infects humans. It colonizes in the human upper respiratory tract and in susceptible individuals, it causes meningococcal meningitis and severe septicaemia.
CATEGORY    Infectious disease
PATHOGEN    Neisseria meningitidis serogroup A [GN:nma nmw nmx]
            Neisseria meningitidis serogroup B [GN:nme nmh nmd nmm nms nmq nmz]
            Neisseria meningitidis serogroup C [GN:nmc nmn nmt]
COMMENT     Antibiotic resistance in N. meningitidis ash been reported.
DBLINKS     ICD-10: A39
            MeSH: D008589
REFERENCE   PMID:19287450 (description)
  AUTHORS   Virji M
  TITLE     Pathogenic neisseriae: surface modulation, pathogenesis and infection control.
  JOURNAL   Nat Rev Microbiol 7:274-86 (2009)
REFERENCE   PMID:12150701 (drug)
  AUTHORS   Foster C, Nadel S
  TITLE     New therapies and vaccines for bacterial meningitis.
  JOURNAL   Expert Opin Investig Drugs 11:1051-60 (2002)
REFERENCE   PMID:22085175 (description)
  AUTHORS   Safadi MA, McIntosh ED
  TITLE     Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
  JOURNAL   Expert Rev Vaccines 10:1717-30 (2011)
REFERENCE   PMID:21832882 (description)
  AUTHORS   Yogev R, Tan T
  TITLE     Meningococcal disease: the advances and challenges of meningococcal disease prevention.
  JOURNAL   Hum Vaccin 7:828-37 (2011)
///
ENTRY       H00315                      Disease
NAME        Gonococcal infections;
            Gonorrhea
DESCRIPTION Gonorrhea is an ancient disease caused by the strict human pathogen Neisseria gonorrhoeae. It remains a major public health concern and multidrug-resistant forms of gonorrhea have been discovered.
CATEGORY    Infectious disease
PATHOGEN    Neisseria gonorrhoeae [GN:ngo ngk]
DRUG        Azithromycin [DG:DG00606]
            Ceftriaxone [DG:DG00573]
            Cephalosporins [ATC:J01DB J01DC J01DD J01DE]
            Cefixime [DG:DG00577]
DBLINKS     ICD-10: A54
            MeSH: D006069
            MedlinePlus: 007267
REFERENCE   PMID:22163356 (drug)
  AUTHORS   Campos-Outcalt D
  TITLE     CDC update on gonorrhea: expand treatment to limit resistance.
  JOURNAL   J Fam Pract 60:736-40 (2011)
REFERENCE   PMID:22239555 (description)
  AUTHORS   Unemo M, Shafer WM
  TITLE     Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future.
  JOURNAL   Ann N Y Acad Sci 1230:E19-28 (2011)
///
ENTRY       H00316                      Disease
NAME        Glanders
DESCRIPTION Glanders is an infectious disease of equines that can be transmitted to humans by direct contact with infected animals as veterinarians, grooms, and farmers. The causative agent of glanders is Burkholderia mallei, a gram-negative aerobic bacterium. In equines and humans, B. mallei infection can present as either nasal-pulmonary infections (glanders) or cutaneous infections (farcy).
CATEGORY    Infectious disease
PATHOGEN    Burkholderia mallei [GN:bma bml bmn]
DRUG        Imipenem [DG:DG01212]
            Doxycycline [DG:DG00008]
            Azithromycin [DG:DG00606]
DBLINKS     ICD-10: A24.0
            MeSH: D005896
REFERENCE   PMID:19585782 (description, env_factor)
  AUTHORS   Larsen JC, Johnson NH
  TITLE     Pathogenesis of Burkholderia pseudomallei and Burkholderia mallei.
  JOURNAL   Mil Med 174:647-51 (2009)
REFERENCE   PMID:18221181 (description)
  AUTHORS   Gilad J
  TITLE     Burkholderia mallei and Burkholderia pseudomallei: the causative micro-organisms  of glanders and melioidosis.
  JOURNAL   Recent Pat Antiinfect Drug Discov 2:233-41 (2007)
REFERENCE   PMID:20528691 (description)
  AUTHORS   Galyov EE, Brett PJ, DeShazer D
  TITLE     Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis.
  JOURNAL   Annu Rev Microbiol 64:495-517 (2010)
REFERENCE   PMID:22398248 (description)
  AUTHORS   Waag DM, England MJ, DeShazer D
  TITLE     Humoral immune responses in a human case of glanders.
  JOURNAL   Clin Vaccine Immunol 19:814-6 (2012)
REFERENCE   PMID:20192686 (drug)
  AUTHORS   Estes DM, Dow SW, Schweizer HP, Torres AG
  TITLE     Present and future therapeutic strategies for melioidosis and glanders.
  JOURNAL   Expert Rev Anti Infect Ther 8:325-38 (2010)
///
ENTRY       H00317                      Disease
NAME        Melioidosis
DESCRIPTION Melioidosis is an infection caused by the gram-negative soil-dwelling bacillus Burkholderia pseudomallei. It predominantly affects people in regular contact with soil and water and is endemic in areas of Southeast Asia and Northern Australia. There are many possible disease manifestations including melioidosis septic shock, pneumonia, and hepatic and splenic abscesses. Mortality from melioidosis septic shock remains high.
CATEGORY    Infectious disease
PATHOGEN    Burkholderia pseudomallei [GN:bps bpm bpl bpd bpr bpse bpz bpq]
DRUG        Trimethoprim-sulfamethoxazole (TMP-SMZ) [DR:D00285]
            Ceftazidime [DG:DG00571]
            Meropenem [DG:DG00591]
            Doxycycline [DG:DG00008]
            Chloramphenicol [DG:DG00399]
            Imipenem [DG:DG01212]
            Ciprofloxacin [DG:DG00617]
            Ofloxacin [DG:DG00616]
DBLINKS     ICD-10: A24.1 A24.2 A24.3 A24.4
            MeSH: D008554
REFERENCE   PMID:21558159 (description, env_factor, drug)
  AUTHORS   Limmathurotsakul D, Peacock SJ
  TITLE     Melioidosis: a clinical overview.
  JOURNAL   Br Med Bull 99:125-39 (2011)
REFERENCE   PMID:16541135 (description, env_factor)
  AUTHORS   Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ
  TITLE     Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei.
  JOURNAL   Nat Rev Microbiol 4:272-82 (2006)
REFERENCE   PMID:15831829 (env_factor)
  AUTHORS   Cheng AC, Currie BJ
  TITLE     Melioidosis: epidemiology, pathophysiology, and management.
  JOURNAL   Clin Microbiol Rev 18:383-416 (2005)
REFERENCE   PMID:20192686 (drug)
  AUTHORS   Estes DM, Dow SW, Schweizer HP, Torres AG
  TITLE     Present and future therapeutic strategies for melioidosis and glanders.
  JOURNAL   Expert Rev Anti Infect Ther 8:325-38 (2010)
///
ENTRY       H00319                      Disease
NAME        Pertussis;
            Whooping cough
DESCRIPTION Pertussis, or whooping cough, caused by the gram-negative bacillus Bordetella pertussis, is a highly contagious, acute respiratory disease of humans. Despite high vaccination rates, this illness has re-emerged worldwide, causing approximately 300 000 deaths each year. Waning immunity after childhood immunization has resulted in a growing pool of susceptible adolescents and adults who are capable of transmitting pertussis to vulnerable unvaccinated or incompletely vaccinated infants. The hallmark symptoms of pertussis are paroxysmal coughing with whooping and post-tussive vomiting. Persistent coughing may last for weeks to months with a gradual decrease in frequency and severity. However, it should be noted that B. pertussis infections, particularly in hosts with partial immunity to the bacterium, may also follow a much milder or subclinical course. Complications that are frequently associated with classical pertussis include pneumonia, otitis media, seizures, encephalopathy, and (brain) hemorrhages.
CATEGORY    Infectious disease
PATHOGEN    Bordetella pertussis [GN:bpe bpc bpet]
            Bordetella parapertussis [GN:bpa]
            pertussis toxin [KO:K11023 K11024 K11025 K11026 K11027]
            adenylate cyclase toxin (ACT) [KO:K11029]
            dermonecrotic toxin (DNT) [KO:K11008]
DBLINKS     ICD-10: A37
            MeSH: D014917
            MedlinePlus: 001561
REFERENCE   PMID:21204863 (description)
  AUTHORS   de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR
  TITLE     Pertussis: a matter of immune modulation.
  JOURNAL   FEMS Microbiol Rev 35:441-74 (2011)
REFERENCE   PMID:19879977
  AUTHORS   Mooi FR
  TITLE     Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen.
  JOURNAL   Infect Genet Evol 10:36-49 (2010)
REFERENCE   PMID:10943406
  AUTHORS   Locht C
  TITLE     Molecular aspects of Bordetella pertussis pathogenesis.
  JOURNAL   Int Microbiol 2:137-44 (1999)
REFERENCE   PMID:20109046 (description)
  AUTHORS   Heininger U
  TITLE     Update on pertussis in children.
  JOURNAL   Expert Rev Anti Infect Ther 8:163-73 (2010)
REFERENCE   PMID:16522501 (description)
  AUTHORS   Munoz FM
  TITLE     Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention.
  JOURNAL   Semin Pediatr Infect Dis 17:14-9 (2006)
///
ENTRY       H00320                      Disease
NAME        Helicobacter pylori infection
DESCRIPTION Helicobacter pylori (HP) is a gram-negative pathogenic bacterium that specifically colonizes in the gastric epithelium and causes chronic gastritis, peptic ulcer disease, and/or gastric malignancies. Persistent infection can cause inflammation and gastritis that may lead to carcinogenesis. Transmission is still not entirely clarified, but human-to-human spread through oral-oral or fecal-oral route is thought to be the most plausible. The prevalence of HP infection varies between different geographical regions; generally, the prevalence is about 30% in developed and up to 80% in developing countries. Although HP may sometimes be eradicated by antibiotics given for other infections, infection usually persists life-long unless specific combination antibiotic therapy is taken.
CATEGORY    Infectious disease
PATHOGEN    Helicobacter pylori [GN:hpy hpj hpa hps hpg hpp hpb hpl hpi hpq hpw hef hpf heq hex hpv hey hpyb heb hez]  
            vacuolating cytotoxin [KO:K11028]
DRUG        proton pump inhibitors [DG:DG00020 DG00021 DG00022 DG00023] [ATC:A02BC]
            Amoxicillin [DG:DG00520]
            Bismuth subsalicylate [DG:DG00027]
            Clarithromycin [DG:DG00605]
DBLINKS     ICD-10: A49.8
            MeSH: D016481
REFERENCE
  AUTHORS   Papadakis MA, Tierney LM (ed).
  TITLE     [Current Medical Diagnosis & Treatment 2004, Forty-Third Edition] (In Japanese)
  JOURNAL   Nikkei Business Publications, Inc. (2004)
REFERENCE   PMID:21546717
  AUTHORS   Albaker WI
  TITLE     Helicobacter pylori infection and its relationship to metabolic syndrome: is it a myth or fact?
  JOURNAL   Saudi J Gastroenterol 17:165-9 (2011)
REFERENCE   PMID:21896079
  AUTHORS   Goh KL, Chan WK, Shiota S, Yamaoka Y
  TITLE     Epidemiology of Helicobacter pylori infection and public health implications.
  JOURNAL   Helicobacter 16 Suppl 1:1-9 (2011)
REFERENCE   PMID:17309745
  AUTHORS   Kabir S
  TITLE     The current status of Helicobacter pylori vaccines: a review.
  JOURNAL   Helicobacter 12:89-102 (2007)
REFERENCE   PMID:14501997
  AUTHORS   Moss SF, Sood S
  TITLE     Helicobacter pylori.
  JOURNAL   Curr Opin Infect Dis 16:445-51 (2003)
///
ENTRY       H00321                      Disease
NAME        Campylobacter infection;
            Campylobacteriosis
DESCRIPTION Campylobacter infection is a diarrhoeal disease that is most commonly caused by Campylobacter jejuni. It rarely affects the bloodstream. Serious sequelae of Campylobacter infection are reported, including Guillian-Barre and Reiter syndromes.
CATEGORY    Infectious disease
PATHOGEN    Campylobacter jejuni [GN:cje cjr cjj cju cjd cjm cjy cjn]
            Campylobacter fetus [GN:cff]
            Campylobacter curvus [GN:ccv]
            Campylobacter concisus 13826 [GN:cco]
            Campylobacter lari [GN:cla]
            Campylobacter coli [GN:ccc ccq]
            cytolethal distending toxin [KO:K11013 K11014 K11015]
COMMENT     Reservoirs: wild birds
DBLINKS     ICD-10: A04.5
            MeSH: D002169
REFERENCE   PMID:10081669 (description)
  AUTHORS   Altekruse SF, Stern NJ, Fields PI, Swerdlow DL
  TITLE     Campylobacter jejuni--an emerging foodborne pathogen.
  JOURNAL   Emerg Infect Dis 5:28-35 (1999)
REFERENCE   PMID:7267960 (description)
  AUTHORS   Schmidt U, Chmel H, Kaminski Z, Sen P
  TITLE     The clinical spectrum of Campylobacter fetus infections: report of five cases and review of the literature.
  JOURNAL   Q J Med 49:431-42 (1980)
REFERENCE   PMID:9310640
  AUTHORS   Jousimies-Somer H
  TITLE     Recently described clinically important anaerobic bacteria: taxonomic aspects and update.
  JOURNAL   Clin Infect Dis 25 Suppl 2:S78-87 (1997)
///
ENTRY       H00322                      Disease
NAME        Typhus fever
DESCRIPTION Typhus fever is caused by gram-negative rickettsia species in the typhus biogroup that are transmitted by infective louse and flea. The disease is widely distributed in tropical and subtropical areas. Most patients present with an acute febrile disease with constitutional symptom and maculopapular exanthema.
CATEGORY    Infectious disease
PATHOGEN    Rickettsia prowazekii [GN:rpr rpq rpn rpl] (epidemic louse-borne typhus)
            Rickettsia typhi [GN:rty] (murine flea-borne typhus)
            Rickettsia felis [GN:rfe] (feline flea-borne typhus)
DRUG        Tetracyclines [DG:DG01197]
COMMENT     Vectors: Prediculus humanus (human body louse); Xenopsylla cheopis (rat flea) and Polyplax spinulos (rat louse)
DBLINKS     ICD-10: A75
            MeSH: D014437 D014438
            MedlinePlus: 001363
REFERENCE   PMID:15353963 (env_factor, comment)
  AUTHORS   Rolain JM, Jensenius M, Raoult D
  TITLE     Rickettsial infections--a threat to travellers?
  JOURNAL   Curr Opin Infect Dis 17:433-7 (2004)
REFERENCE   PMID:15546086
  AUTHORS   Jensenius M, Fournier PE, Raoult D
  TITLE     Rickettsioses and the international traveler.
  JOURNAL   Clin Infect Dis 39:1493-9 (2004)
REFERENCE   PMID:15845235 (description)
  AUTHORS   Parola P, Davoust B, Raoult D
  TITLE     Tick- and flea-borne rickettsial emerging zoonoses.
  JOURNAL   Vet Res 36:469-92 (2005)
///
ENTRY       H00323                      Disease
NAME        Spotted fever;
            Tick-borne rickettsioses
DESCRIPTION Tick-borne rickettsioses are caused by gram-negative obligate intracellular bacteria belonging to the spotted fever group (SFG) of the genus Rickettsia within the family Rickettsiaceae in the order Rickettsiales. The diseases present with high fever, a inoculation eschar, and a maculopapular rash.
CATEGORY    Infectious disease
PATHOGEN    Rickettsia rickettsii [GN:rri] (Rocky Mountain spotted fever)
            Rickettsia conorii [GN:rco] (African tick typhus / Boutonneuse fever)
            Rickettsia sibirica (North Asian tick fever / Siberian tick typhus)
            Rickettsia massiliae [GN:rms]
            Rickettsia africae [GN:raf]
            Rickettsia japonica [GN:rja] (Japanese spotted fever)
            Rickettsia heilongjiangensis [GN:rhe] (Far-Eastern spotted fever)
MARKER      ompA (PCR detection) [KO:K03162]
            gltA(PCR detection) [rrj:RrIowa_1533 rri:A1G_07170] [KO:K01647]
DRUG        Tetracyclines [DG:DG01197]
            Doxycycline [DG:DG00008]
            Chloramphenicol [DG:DG00399]
            Josamycin [DG:DG00604]
COMMENT     Vectors: Rhipicephalus sanguineus (brown dog tick) for Rickettsia conorii
DBLINKS     ICD-10: A77
            MeSH: D012373 D001907
            MedlinePlus: 000654
REFERENCE   PMID:16223955 (marker, drug)
  AUTHORS   Parola P, Paddock CD, Raoult D
  TITLE     Tick-borne rickettsioses around the world: emerging diseases challenging old concepts.
  JOURNAL   Clin Microbiol Rev 18:719-56 (2005)
REFERENCE   PMID:19358804 (env_factor, vector)
  AUTHORS   Socolovschi C, Mediannikov O, Raoult D, Parola P
  TITLE     The relationship between spotted fever group Rickettsiae and ixodid ticks.
  JOURNAL   Vet Res 40:34 (2009)
REFERENCE   PMID:15225980 (description)
  AUTHORS   Parola P
  TITLE     Tick-borne rickettsial diseases: emerging risks in Europe.
  JOURNAL   Comp Immunol Microbiol Infect Dis 27:297-304 (2004)
REFERENCE   PMID:18755389 (description)
  AUTHORS   Cazorla C, Socolovschi C, Jensenius M, Parola P
  TITLE     Tick-borne diseases: tick-borne spotted fever rickettsioses in Africa.
  JOURNAL   Infect Dis Clin North Am 22:531-44, ix-x (2008)
///
ENTRY       H00324                      Disease
NAME        Scrub typhus
DESCRIPTION Scrub typhus, also known as tsutsugamushi disease, is a zoonosis caused by Orientia tsutsugamushi, an obligate intracellular bacterium that is transmitted by the Leptotrombidium species mite. The disease is confined to East Asia and characterized by fever, rash, eschar, pneumonitis, meningitis, and disseminated intravascular coagulation. If left untreated, the mortality rates can reach up to 50% of cases.
CATEGORY    Infectious disease
PATHOGEN    Orientia tsutsugamushi [GN:ots ott] (mite-borne typhus)
DRUG        Chloramphenicol [DG:DG00399]
            Demeclocycline [DG:DG00396]
            Minocycline [DG:DG00009]
            Tetracycline [DG:DG00005]
COMMENT     Vector: Leptotrombidium deliense, L. fletcheri and L. arenicola
DBLINKS     ICD-10: A75.3
            MeSH: D012612
REFERENCE   PMID:11226850 (description, env_factor)
  AUTHORS   Seong SY, Choi MS, Kim IS
  TITLE     Orientia tsutsugamushi infection: overview and immune responses.
  JOURNAL   Microbes Infect 3:11-21 (2001)
REFERENCE   PMID:21458586 (description, env_factor, drug)
  AUTHORS   Ge Y, Rikihisa Y
  TITLE     Subversion of host cell signaling by Orientia tsutsugamushi.
  JOURNAL   Microbes Infect 13:638-48 (2011)
REFERENCE   PMID:10796680 (drug)
  AUTHORS   Panpanich R, Garner P
  TITLE     Antibiotics for treating scrub typhus.
  JOURNAL   Cochrane Database Syst Rev CD002150 (2000)
///
ENTRY       H00325                      Disease
NAME        Brucellosis
DESCRIPTION Brucellosis is a zoonotic disease of worldwide distribution that mainly affects persons working with domestic animals. Although many countries have eradicated Brucella abortus from cattle, Brucella melitensis remains a major cause of infection in cattle and human in Latin America, the Middle East, Spain, parts of Africa, and western Asia. Consumption of contaminated foods is the sources of infection. The clinical presentation can vary from asymptomatic infection to a fever, night sweats and joint manifestations.
CATEGORY    Infectious disease
PATHOGEN    Brucella melitensis [GN:bme bmf bmi bmz]
            Brucella abortus [GN:bmb bmc]
            Brucella suis [GN:bms bmt]
            Brucella canis [GN:bcs]
            Brucella ovis [GN:bov]
DRUG        Rifampicin [DG:DG00639]
            Doxycycline [DG:DG00008]
            Levofloxacin [DG:DG00624]
            Sparfloxacin [DR:D00590]
            Tetracycline [DG:DG00005]
DBLINKS     ICD-10: A23
            MeSH: D002006
            MedlinePlus: 000597
REFERENCE   PMID:9204307 (description, env_factor, drug)
  AUTHORS   Corbel MJ
  TITLE     Brucellosis: an overview.
  JOURNAL   Emerg Infect Dis 3:213-21 (1997)
REFERENCE   PMID:14769288 (description)
  AUTHORS   Memish ZA, Balkhy HH
  TITLE     Brucellosis and international travel.
  JOURNAL   J Travel Med 11:49-55 (2004)
REFERENCE   PMID:17901634 (description, env_factor)
  AUTHORS   Mantur BG, Amarnath SK, Shinde RS
  TITLE     Review of clinical and laboratory features of human brucellosis.
  JOURNAL   Indian J Med Microbiol 25:188-202 (2007)
///
ENTRY       H00326                      Disease
NAME        Bartonellosis, including:
            Cat-scratch disease;
            Bacillary Angiomatosis;
            Oroya Fever;
            Carrion Disease;
            Trench Fever
DESCRIPTION Bartonella species are fastidious gram-negative bacilli. They are usually transmitted by hematophagous insects, such as sandflies, fleas, and lice but can also be transmitted by animal scratches and bites. Human bartonellosis is a group of diseases with a rapidly increasing clinical spectrum. At least six Bartonella species are responsible for human diseases as well as zoonotic diseases.
CATEGORY    Infectious disease
PATHOGEN    Bartonella henselae (Cat-scratch disease) [GN:bhe]
            Bartonella bacilliformis (Oroya fever and bacillary angiomatosis) [GN:bbk]
            Bartonella quintana (Trench fever and bacillary angiomatosis) [GN:bqu]
            Bartonella grahami (Neuroretinitis) [GN:bgr]
            Bartonella elizabethae
            Candidatus Bartonella ancashi [GN: banc]
DRUG        Chloramphenicol [DG:DG00399]
            Erythromycin [DG:DG00436]
            Ciprofloxacin [DG:DG00617]
            Doxycycline [DG:DG00008]
            Rifampin [DR:D00211]
COMMENT     For trench fever, see also H00327.
DBLINKS     ICD-10: A28.1 A44
            MeSH: D001474
            MedlinePlus: 001614
REFERENCE   PMID:11176245 (drug)
  AUTHORS   Conrad DA
  TITLE     Treatment of cat-scratch disease.
  JOURNAL   Curr Opin Pediatr 13:56-9 (2001)
REFERENCE   PMID:19362689 (description, env_factor, drug)
  AUTHORS   Maguina C, Guerra H, Ventosilla P
  TITLE     Bartonellosis.
  JOURNAL   Clin Dermatol 27:271-80 (2009)
REFERENCE   PMID:12807686 (description, drug)
  AUTHORS   Velho PE, Cintra ML, Uthida-Tanaka AM, de Moraes AM, Mariotto A
  TITLE     What do we (not) know about the human bartonelloses?
  JOURNAL   Braz J Infect Dis 7:1-6 (2003)
///
ENTRY       H00327                      Disease
NAME        Trench fever
DESCRIPTION Trench fever is a disease caused by the facultative intracellular gram-negative bacterium Bartonella quintana. It affected several million people worldwide during the two world wars. The incidence of trench fever dramatically decreased after World War II, but recently it reemerged in urban homeless populations of developed countries. The most frequent presentation of trench fever includes repeated cycles of high fever, headache, and dizziness.
CATEGORY    Infectious disease
PATHOGEN    Bartonella quintana [GN:bqu]
COMMENT     Vector: Pediculus humanus (human body louse)
DBLINKS     ICD-10: A79.0
            MeSH: D014205
REFERENCE   PMID:22360386 (description, env_factor)
  AUTHORS   Badiaga S, Brouqui P
  TITLE     Human louse-transmitted infectious diseases.
  JOURNAL   Clin Microbiol Infect 18:332-7 (2012)
///
ENTRY       H00328                      Disease
NAME        Anthrax
DESCRIPTION Bacillus anthracis is a gram-positive, rod-shaped bacteria that exists in the environment as a spore. Infection with the bacteria is rare in developed countries, but the potential use of the bacteria for bioterrorism has focused interest on it. B. anthracis causes symptoms ranging from cutaneous anthrax that resolves spontaneously to gastrointestinal and inhalational anthrax associated with shock and subsequent mortality.
CATEGORY    Infectious disease
PATHOGEN    Bacillus anthracis [GN:ban bar bat bai bax bans]
            Bacillus cereus [GN:bal]
            anthrax toxin [KO:K11029 K11030 K08645]
            pore-forming toxin [KO:K11031 K11068 K11033 K11034]
MARKER      Gram stain and culture from blood or surgical specimens
            B. anthracis chromosome and virulence plasmids (PCR detection)
            Cell surface protein (immunohistochemistry)
DRUG        Ciprofloxacin [DG:DG00617]
            Doxycycline [DG:DG00008]
            Clindamycin [DG:DG00435]
            Penicillin G [DG:DG00534]
DBLINKS     ICD-10: A22
            MeSH: D000881
            MedlinePlus: 001325
REFERENCE   PMID:21852539 (description, env_factor, drug)
  AUTHORS   Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ
  TITLE     Anthrax infection.
  JOURNAL   Am J Respir Crit Care Med 184:1333-41 (2011)
REFERENCE   PMID:21777993 (description)
  AUTHORS   Aquino LL, Wu JJ
  TITLE     Cutaneous manifestations of category A bioweapons.
  JOURNAL   J Am Acad Dermatol 65:1213.e1-1213.e15 (2011)
///
ENTRY       H00329                      Disease
NAME        Foodborne Bacillus cereus intoxication
DESCRIPTION Bacillus cereus is a gram-positive aerobic-to-facultatively anaerobic bacterium that causes gastrointestinal infections. The organism produces an emetic or diarrheal syndrome induced by an emetic toxin and enterotoxin, respectively. These infections are frequently associated with the consumption of rice-based dishes. B. cereus is also recognized as an infrequent cause of non-gastrointestinal infections such as ocular infections, septicemia, meningitis, endocarditis, osteomyelitis, and surgical and traumatic wound infections.
CATEGORY    Infectious disease
PATHOGEN    Bacillus cereus [GN:bce bca bcz bcr bcb bcu bcg bcx bnc]
            Bacillus cytotoxicus [GN:bcy]
            pore-forming toxin [KO:K11031 K11032 K11068 K11035 K11036 K11037 K11033 K11034]
DRUG        Vancomycin [DG:DG00086]
            Ciprofloxacin [DG:DG00617]
            Clindamycin [DG:DG00435]
            Gentamicin [DG:DG00401]
            Chloramphenicol [DG:DG00399]
            Erythromycin [DG:DG00436]
DBLINKS     ICD-10: A05.4
            MeSH: D016863
REFERENCE   PMID:8269390 (env_factor, drug)
  AUTHORS   Drobniewski FA
  TITLE     Bacillus cereus and related species.
  JOURNAL   Clin Microbiol Rev 6:324-38 (1993)
REFERENCE   PMID:20375358 (description)
  AUTHORS   Bottone EJ
  TITLE     Bacillus cereus, a volatile human pathogen.
  JOURNAL   Clin Microbiol Rev 23:382-98 (2010)
REFERENCE   PMID:10742691 (description)
  AUTHORS   Kotiranta A, Lounatmaa K, Haapasalo M
  TITLE     Epidemiology and pathogenesis of Bacillus cereus infections.
  JOURNAL   Microbes Infect 2:189-98 (2000)
REFERENCE   PMID:15771198 (description)
  AUTHORS   Schoeni JL, Wong AC
  TITLE     Bacillus cereus food poisoning and its toxins.
  JOURNAL   J Food Prot 68:636-48 (2005)
///
ENTRY       H00330                      Disease
NAME        Methicillin-resistant Staphylococcal aureus (MRSA) infection
DESCRIPTION Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major multidrug-resistant bacteria which have become endemic in the hospital environment, particularly in intensive care units (ICUs). Originally limited to the hospital setting, MRSA is a growing cause of infections in the community. Community-associated MRSA (CA-MRSA) strains are genetically different from MRSA strains originating in the hospital. Its increase in the community is of concern because CA-MRSA strains appear to be highly virulent, and colonization with CA-MRSA is often undetected in hospitalized patients, which can facilitate its potential for becoming resistant to multiple antibiotics. Health care-associated MRSA (HA-MRSA) is usually associated with pneumonia, urinary tract, blood stream, and surgical wound infections. In contrast, CA-MRSA strains are overwhelmingly associated with skin and soft tissue infections.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus aureus [GN:sau sar sac sah suw sug sut sauz sauy saux sauw sauv sauq sauk sauj saut] (hospital-acquired MRSA)
            Staphylococcus aureus [GN:sam saa suj suz suu saun saus sauu saug] (community-acquired MRSA)
DBLINKS     ICD-10: U82.1
            MeSH: D013203
            MedlinePlus: 007261
REFERENCE   PMID:20825344 (definition)
  AUTHORS   Otto M
  TITLE     Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus.
  JOURNAL   Annu Rev Microbiol 64:143-62 (2010)
REFERENCE   PMID:18996277 (definition)
  AUTHORS   Chavez TT, Decker CF
  TITLE     Health care-associated MRSA versus community-associated MRSA.
  JOURNAL   Dis Mon 54:763-8 (2008)
REFERENCE   PMID:16813982 (definition)
  AUTHORS   Henderson DK
  TITLE     Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms.
  JOURNAL   Am J Infect Control 34:S46-54: discussion S64-73 (2006)
///
ENTRY       H00331                      Disease
NAME        Vancomycin-resistant Staphylococcal aureus (VRSA) infection
DESCRIPTION Vancomycin-resistant Staphylococcus aureus (VRSA) represents strains of S. aureus that have ability of resistance to the glycopeptide antibiotic vancomycin. S. aureus is the most common cause of nosocomial infections. The glycopeptides-notably vancomycin-have traditionally been the mainstay of treatment of methicillin-resistant S. aureus (MRSA) but overuse has led to the emergence of vancomycin-intermediate and vancomycin-resistant S. aureus (VISA and VRSA, respectively). Limited treatment options make resistant S. aureus infections particularly difficult and costly to treat, especially in areas of poor antibiotic penetration, such as joint spaces and the central nervous system. A gene known as vanA is a major determinant, which is transferable and can be acquired by sensitive bacteria from resistant organisms.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus aureus [GN:sav saw saj suv suk]
DRUG        Linezolid [DR:D00947]
            Ampicillin sodium - sulbactam [DR:D02065]
            Arbekacin [DG:DG00614]
DBLINKS     ICD-10: U83.0
            MeSH: D013203
REFERENCE   PMID:11871491 (drug)
  AUTHORS   Hiramatsu K
  TITLE     Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.
  JOURNAL   Lancet Infect Dis 1:147-55 (2001)
REFERENCE   PMID:16575232 (description)
  AUTHORS   Todd B
  TITLE     Beyond MRSA: VISA and VRSA: what will ward off these pathogens in health care facilities?
  JOURNAL   Am J Nurs 106:28-30 (2006)
REFERENCE   PMID:16445720 (description)
  AUTHORS   Appelbaum PC
  TITLE     The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus  aureus.
  JOURNAL   Clin Microbiol Infect 12 Suppl 1:16-23 (2006)
///
ENTRY       H00332                      Disease
NAME        Listeriosis
DESCRIPTION Listeriosis is a severe foodborne infection with high case fatality rate caused by Listeria monocytogenes. High-risk groups for listeriosis include elderly and immunocompromised patients, pregnant women, newborns, and infants.
CATEGORY    Infectious disease
PATHOGEN    Listeria monocytogenes [GN:lmo lmf lmc lmn lmy lmp lmoj lmz lmoa lmoc lmon lmol lmoz lmom]
            pore-forming toxin [KO:K11031]
DRUG        Ampicillin [DG:DG00517]
            Sulfamethoxazole [DR:D00447]
            Gentamicin [DG:DG00401]
DBLINKS     ICD-10: A32
            MeSH: D008088
            MedlinePlus: 001380
REFERENCE   PMID:22037557 (description, drug)
  AUTHORS   Munoz P, Rojas L, Bunsow E, Saez E, Sanchez-Cambronero L, Alcala L, Rodriguez-Creixems M, Bouza E
  TITLE     Listeriosis: An emerging public health problem especially among the elderly.
  JOURNAL   J Infect 64:19-33 (2012)
REFERENCE   PMID:19332898 (description)
  AUTHORS   Rebagliati V, Philippi R, Rossi M, Troncoso A
  TITLE     Prevention of foodborne listeriosis.
  JOURNAL   Indian J Pathol Microbiol 52:145-9 (2009)
REFERENCE   PMID:17094698 (description)
  AUTHORS   Jemmi T, Stephan R
  TITLE     Listeria monocytogenes: food-borne pathogen and hygiene indicator.
  JOURNAL   Rev Sci Tech 25:571-80 (2006)
REFERENCE   PMID:16161698 (description)
  AUTHORS   ILSI Research Foundation; Risk Science Institute.
  TITLE     Achieving continuous improvement in reductions in foodborne listeriosis--a risk-based approach.
  JOURNAL   J Food Prot 68:1932-94 (2005)
REFERENCE   PMID:12648845 (description)
  AUTHORS   Rocourt J, BenEmbarek P, Toyofuku H, Schlundt J
  TITLE     Quantitative risk assessment of Listeria monocytogenes in ready-to-eat foods: the FAO/WHO approach.
  JOURNAL   FEMS Immunol Med Microbiol 35:263-7 (2003)
///
ENTRY       H00333                      Disease
NAME        Streptococcal infection
DESCRIPTION Streptococci are gram-positive bacteria. The beta-hemolytic streptococci are divided into two groups: group A Streptococcus (GAS) that causes over 600 million cases of infections each year, ranging from mild pharyngitis to severe streptococcal toxic shock-like syndrome (STSS), and group B Streptococcus (GBS) that causes neonatal invasive infections including sepsis, pneumonia, and meningitis.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spa spb stg soz spyo] (Severe invasive streptococcal infection / Streptococcal toxic shock-like syndrome, Group A Streptococcus infection)
            Streptococcus agalactiae [GN:sag sak san sagn] (Group B Streptococcus infection)
            pore-forming toxin [KO:K11031 K11045 K11046]
            pore-forming toxin [KO:K11052]
            superantigen [KO:K11040]
            ADP-ribosyltransferase SpyA [KO:K11044]
DRUG        Penicillin G [DG:DG00534]
            Clindamycin [DG:DG00435]
            Erythromycin [DG:DG00436]
            Cephalosporins
            Vancomycin [DG:DG00086]
            Azithromycin [DG:DG00606]
            Clarithromycin [DG:DG00605]
DBLINKS     ICD-10: A40 A49.1 G00.2 J02.0 J03.0 J15.3 J15.4 M60.0A P36.0 P36.1
            MeSH: D013290
REFERENCE   (drug)
REFERENCE   PMID:21921933 (description)
  AUTHORS   Cole JN, Barnett TC, Nizet V, Walker MJ
  TITLE     Molecular insight into invasive group A streptococcal disease.
  JOURNAL   Nat Rev Microbiol 9:724-36 (2011)
REFERENCE   PMID:21415743 (description)
  AUTHORS   Lynskey NN, Lawrenson RA, Sriskandan S
  TITLE     New understandings in Streptococcus pyogenes.
  JOURNAL   Curr Opin Infect Dis 24:196-202 (2011)
REFERENCE   PMID:21672083 (description)
  AUTHORS   Melin P
  TITLE     Neonatal group B streptococcal disease: from pathogenesis to preventive strategies.
  JOURNAL   Clin Microbiol Infect 17:1294-303 (2011)
///
ENTRY       H00334                      Disease
NAME        Bacterial endocarditis;
            Infective endocarditis
DESCRIPTION Infective endocarditis is a microbial infection of the endocardial surface of the heart. The characteristic lesion, a vegetation, is composed of a collection of platelets, fibrin, microorganisms, and inflammatory cells. It most commonly involves heart valves but may also occur at the site of a septal defect, on the chordae tendineae, or on the mural endocardium. Staphylococci and streptococci account for 80% of cases of infective endocarditis, with staphylococci currently the most common pathogens. Cerebral complications are the most frequent and most severe extracardiac complications.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus viridans
            Streptococcus sanguinis [GN:ssa]
            Streptococcus suis [GN:ssu ssv]
            Streptococcus gordonii [GN:sgo]
            Staphylococcus aureus [GN:sau sav saw sam sar sas sac sab saa sax sao saj sah sae]
            Enterococcus
            Aggregatibacter aphrophilus [GN:aap]
            Aggregatibacter actinomycetemcomitans [GN:aat aao aan]
            Cardiobacterium hominis
            Eikenella corrodens
            Kingella kingae
            superantigen [KO:K11040 K11041 K11042 K11043]
            pore-forming toxin [KO:K11031 K11032 K11038 K11039]
            membrane-damaging toxin [KO:K01114]
DRUG        Vancomycin [DG:DG00086]
            Ceftriaxone [DG:DG00573]
            Penicillin G [DG:DG00534]
            Gentamicin [DG:DG00401]
            Streptomycin [DG:DG00082]
            Ampicillin [DG:DG00517]
            Nafcillin [DG:DG00544]
            Oxacillin [DG:DG00542]
            Cefazolin [DG:DG00550]
            Ceftriaxone [DG:DG00573
COMMENT     Monotherapy
            Vancomycin [DR:D00212]
            Ceftriaxone sodium [DR:D00924]
            Penicillin G potassium [DR:D01053]
            Gentamicin sulfate [DR:D01063]
            Ampicillin [DR:D00204]
            Nafcillin sodium [DR:D00928]
            Oxacillin sodium [DR:D00929]
            Cefazolin [DR:D02299]
            Ceftriaxone sodium [DR:D00924]
            Combination therapy
            Penicillin G potassium [DR:D01053] + Streptomycin sulfate [DR:D01350]
            Penicillin G potassium [DR:D01053] + Gentamicin sulfate [DR:D01063]
DBLINKS     ICD-10: I39.8
            MeSH: D004697
            MedlinePlus: 000681
REFERENCE   (drug)
REFERENCE   PMID:16902214 (description)
  AUTHORS   Beynon RP, Bahl VK, Prendergast BD
  TITLE     Infective endocarditis.
  JOURNAL   BMJ 333:334-9 (2006)
REFERENCE   PMID:23574121 (description)
  AUTHORS   Hoen B, Duval X
  TITLE     Clinical practice. Infective endocarditis.
  JOURNAL   N Engl J Med 368:1425-33 (2013)
REFERENCE   PMID:11794152 (description)
  AUTHORS   Mylonakis E, Calderwood SB
  TITLE     Infective endocarditis in adults.
  JOURNAL   N Engl J Med 345:1318-30 (2001)
///
ENTRY       H00335                      Disease
NAME        Foodborne Clostridium perfringens intoxication
DESCRIPTION Clostridium perfringens is a spore-forming, gram-positive, anaerobic bacterium consisting of five types (A-E), according to the major toxins they produce. It causes two different foodborne diseases: Type A food poisoning and Type C food poisoning. Type A is a relatively mild diarrhea common in the industrialized countries whereas Type C is a rare but very serious necrotic enteritis.
CATEGORY    Infectious disease
PATHOGEN    Clostridium perfringens [GN:cpe cpf cpr]
            hyaluronidase/collagenase [KO:K01186 K01197 K01387 K08587]
            pore-forming toxin [KO:K03699 K06442 K11031 K11068]
            membrane-damaging toxin [KO:K16619]
            enterotoxin [KO:K11059 K11060 K11061 K11062]
            enterotoxin Cpe [KO:K11058]
            beta2 toxin [KO:K11057]
DBLINKS     ICD-10: A05.2 B96.7
            MeSH: D003015
REFERENCE   PMID:11981970 (description, env_factor)
  AUTHORS   Brynestad S, Granum PE
  TITLE     Clostridium perfringens and foodborne infections.
  JOURNAL   Int J Food Microbiol 74:195-202 (2002)
REFERENCE   PMID:21315973 (description)
  AUTHORS   Lindstrom M, Heikinheimo A, Lahti P, Korkeala H
  TITLE     Novel insights into the epidemiology of Clostridium perfringens type A food poisoning.
  JOURNAL   Food Microbiol 28:192-8 (2011)
///
ENTRY       H00336                      Disease
NAME        Gas gangrene;
            Clostridial myonecrosis
DESCRIPTION Gas gangrene is a rare and devastating wound infection by toxin-producing bacteria of the genus Clostridium. It is characterized by the presence of gas in the affected tissue and is associated with trauma.
CATEGORY    Infectious disease
PATHOGEN    Clostridium perfringens [GN:cpe cpf cpr]
            hyaluronidase/collagenase [KO:K01186 K01197 K01387 K08587]
            pore-forming toxin [KO:K03699 K06442 K11031 K11058 K11068]
            membrane-damaging toxin [KO:K16619]
            enterotoxin [KO:K11059 K11060 K11061 K11062]
            beta2 toxin [KO:K11057]
DRUG        Penicillin G [DG:DG00534]
            Polyvalent antitoxin
DBLINKS     ICD-10: A48.0
            MeSH: D005738
            MedlinePlus: 000620
REFERENCE   PMID:14468017 (description, env_factor, drug)
  AUTHORS   MACLENNAN JD
  TITLE     The histotoxic clostridial infections of man.
  JOURNAL   Bacteriol Rev 26:177-276 (1962)
REFERENCE   PMID:10832675 (description)
  AUTHORS   Sasaki T, Nanjo H, Takahashi M, Sugiyama T, Ono I, Masuda H
  TITLE     Non-traumatic gas gangrene in the abdomen: report of six autopsy cases.
  JOURNAL   J Gastroenterol 35:382-90 (2000)
///
ENTRY       H00337                      Disease
NAME        Tetanus
DESCRIPTION Tetanus is a serious, often fatal intoxication caused by infection of Clostridium tetani, a gram-positive bacterium, through cuts or wounds. Mortality rates among untreated patients is high (40%). Tetanus affects the muscles and nerves and manifests as muscle spasms in the jaw (lockjaw). Tetanus can be prevented by getting the tetanus vaccine.
CATEGORY    Infectious disease
PATHOGEN    Clostridium tetani [GN:ctc]
            tetanus toxin (TeTx) [KO:K08644]
            pore-forming toxin [KO:K06442 K11031 K11068]
DRUG        Human tetanus immune globulin
            Metronidazole [DG:DG00006]
            Midazolam [DG:DG00920]
DBLINKS     ICD-10: A33 A34 A35
            MeSH: D013742
            MedlinePlus: 000615
REFERENCE   PMID:22111470 (description, drug)
  AUTHORS   Otero-Maldonado M, Bosques-Rosado M, Soto-Malave R, Deliz-Roldan B, Bertran-Pasarell J, Vargas Otero P
  TITLE     Tetanus is still present in the 21st century: case report and review of literature.
  JOURNAL   Bol Asoc Med P R 103:41-7 (2011)
REFERENCE   PMID:9416389 (description, drug)
  AUTHORS   Ernst ME, Klepser ME, Fouts M, Marangos MN
  TITLE     Tetanus: pathophysiology and management.
  JOURNAL   Ann Pharmacother 31:1507-13 (1997)
REFERENCE   PMID:18588497 (env_factor)
  AUTHORS   Brook I
  TITLE     Current concepts in the management of Clostridium tetani infection.
  JOURNAL   Expert Rev Anti Infect Ther 6:327-36 (2008)
///
ENTRY       H00338                      Disease
NAME        Pseudomembranous colitis
DESCRIPTION Clostridium difficile is a gram-positive anaerobic bacillus that causes a broad spectrum of clinical symptoms ranging from mild diarrhea to severe pseudomembranous colitis. C. difficile can be acquired by the fecal-oral route and in hospitals, from instrument to patient.
CATEGORY    Infectious disease
PATHOGEN    Peptoclostridium difficile [GN:cdf pdc cdc cdl cdg]
            toxin A/B [KO:K11063]
            pore-forming toxin [KO:K06442 K11068]
MARKER      toxin A/B (ELISA detection)
            tcdA (PCR detection) [CDF:CD0663] [KO:K11063]
            tcdB (PCR detection) [CDF:CD0660] [KO:K11063]
DRUG        Hospitalization
            Advanced age
            Metronidazole [DG:DG00006]
            Vancomycin [DG:DG00086]
DBLINKS     ICD-10: A04.7
            MeSH: D004761
            MedlinePlus: 000259
REFERENCE   (drug)
REFERENCE   PMID:21609252 (description, env_factor, drug)
  AUTHORS   Kachrimanidou M, Malisiovas N
  TITLE     Clostridium difficile infection: a comprehensive review.
  JOURNAL   Crit Rev Microbiol 37:178-87 (2011)
REFERENCE   PMID:17640189 (description, drug)
  AUTHORS   Elliott B, Chang BJ, Golledge CL, Riley TV
  TITLE     Clostridium difficile-associated diarrhoea.
  JOURNAL   Intern Med J 37:561-8 (2007)
REFERENCE   PMID:15997485 (description)
  AUTHORS   Bouza E, Munoz P, Alonso R
  TITLE     Clinical manifestations, treatment and control of infections caused by Clostridium difficile.
  JOURNAL   Clin Microbiol Infect 11 Suppl 4:57-64 (2005)
///
ENTRY       H00339                      Disease
NAME        Botulism
DESCRIPTION Botulism is an acute neuroparalytic illness caused by a botulinum toxin produced by Clostridium botulinum, an anaerobic, gram-positive bacterium. Botulism occurs in four forms: foodborne, wound, infant botulism, and adult intestinal toxemia. Botulinum toxin blocks acetylcholine release in a dose-dependent fashion, resulting in symmetrical, descending, and progressive muscle weakness. Delay in treatment may allow progression of paralysis.
CATEGORY    Infectious disease
PATHOGEN    Clostridium botulinum [GN:cbo cba cbh cby cbl cbk cbb cbi cbt cbf]
            Clostridium butyricum
            Clostridium baratii
            botulinum neurotoxin (BoNT) [KO:K06011]
            hyaluronidase/collagenase [KO:K01387 K08587]
            pore-forming toxin [KO:K06442 K11068]
DRUG        Botulism antitoxin [DR:D03151]
            Botulism immune globulin intravenous
DBLINKS     ICD-10: A05.1
            MeSH: D001906
            MedlinePlus: 000598
REFERENCE   PMID:21171845 (description, env_factor, drug)
  AUTHORS   Zhang JC, Sun L, Nie QH
  TITLE     Botulism, where are we now?
  JOURNAL   Clin Toxicol (Phila) 48:867-79 (2010)
REFERENCE   PMID:18388640 (description, drug)
  AUTHORS   Dembek ZF, Smith LA, Rusnak JM
  TITLE     Botulism: cause, effects, diagnosis, clinical and laboratory identification, and  treatment modalities.
  JOURNAL   Disaster Med Public Health Prep 1:122-34 (2007)
REFERENCE   PMID:17224901 (env_factor)
  AUTHORS   Brook I
  TITLE     Botulism: the challenge of diagnosis and treatment.
  JOURNAL   Rev Neurol Dis 3:182-9 (2006)
REFERENCE   PMID:21412916 (description)
  AUTHORS   Chalk C, Benstead TJ, Keezer M
  TITLE     Medical treatment for botulism.
  JOURNAL   Cochrane Database Syst Rev CD008123 (2011)
REFERENCE   PMID:12503947 (description)
  AUTHORS   Robinson RF, Nahata MC
  TITLE     Management of botulism.
  JOURNAL   Ann Pharmacother 37:127-31 (2003)
///
ENTRY       H00340                      Disease
NAME        Vancomycin-resistant enterococci infection
DESCRIPTION Enterococci are gram-positive, facultative bacteria with low intrinsic virulence that constitute the normal colonizing flora of the human gastrointestinal tract. Vancomycin-resistant enterococci (VRE) have emerged as major hospital-acquired antimicrobial-resistant pathogens globally, causing bacteremia with or without endocarditis, and intra-abdominal, wound, and genitourinary infection in immunocompromised patients. The mortality rate is high.
CATEGORY    Infectious disease
PATHOGEN    Enterococcus faecalis [GN:efa]
            Enterococcus faecium [GN:efc]
            Enterococcus gallinarum
DRUG        Ampicillin [DG:DG00517]
            Ampicillin sodium-sulbactam sodium mixt [DR:D02065]
            Teicoplanin [DR:D02142]
            Doxycycline [DG:DG00008]
            Novobiocin sodium [DR:D01209]
            Bacitracin [DG:DG00400]
            Nitrofurantoin [DR:D00439] (UTI)
            Quinupristin-dalfopristin mixt [DR:D00854]
            Linezolid [DR:D00947]
DBLINKS     ICD-10: A41.4A A49.8A J15.8A
REFERENCE   PMID:11827558 (drug)
  AUTHORS   Linden PK
  TITLE     Treatment options for vancomycin-resistant enterococcal infections.
  JOURNAL   Drugs 62:425-41 (2002)
///
ENTRY       H00341                      Disease
NAME        Mycoplasma pneumonia
DESCRIPTION Mycoplasmas represent the smallest self-replicating organisms that are most closely related to the gram-positive bacterial group that includes streptococci, bacilli, and lactobacilli. Mycoplasma pneumoniae is a member of the family Mycoplasmataceae that causes lower respiratory tract infection endemically in most areas of the world. Most infections are mild, but small proportion of infected individuals may develop serious pneumonia due to an enhanced host cellular immune response.
CATEGORY    Infectious disease
PATHOGEN    Mycoplasma pneumoniae [GN:mpn mpm mpj]
            Mycoplasma penetrans [GN:mpe]
MARKER      16S rRNA (PCR detection) [KO:K01977]
DRUG        Clarithromycin [DG:DG00605]
            Azithromycin [DG:DG00606]
            Roxithromycin [DR:D01710]
            Erythromycin [DG:DG00436]
DBLINKS     ICD-10: J15.7 J20.0
            MeSH: D011019
            MedlinePlus: 000082
REFERENCE   PMID:11548186 (description, env_factor, drug)
  AUTHORS   Ferwerda A, Moll HA, de Groot R
  TITLE     Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures.
  JOURNAL   Eur J Pediatr 160:483-91 (2001)
REFERENCE   PMID:18754792 (description)
  AUTHORS   Atkinson TP, Balish MF, Waites KB
  TITLE     Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections.
  JOURNAL   FEMS Microbiol Rev 32:956-73 (2008)
REFERENCE   PMID:15489344 (description, drug)
  AUTHORS   Waites KB, Talkington DF
  TITLE     Mycoplasma pneumoniae and its role as a human pathogen.
  JOURNAL   Clin Microbiol Rev 17:697-728, table of contents (2004)
///
ENTRY       H00342                      Disease
NAME        Tuberculosis
DESCRIPTION Tuberculosis is a infectious disease caused by strains of mycobacteria, mainly Mycobacterium tuberculosis, resulting in an estimated two million deaths each year worldwide, more than from any other single bacterial pathogen. Inhalation is the predominant pathway of infection, making pulmonary tuberculosis the most common form of tuberculosis. Tuberculosis may arise either from a recent infection with M. tuberculosis, or from the reactivation of dormant bacilli, years or decades after initial infection. Extrapulmonary tuberculosis mainly results from reactivation of a tuberculous focus after hematogenous dissemination or lymphogenous spread from a primary, usually pulmonary focus.
CATEGORY    Infectious disease
GENE        IFNGR1 [HSA:3459] [KO:K05132]
            IFNGR2 [HSA:3460] [KO:K05133]
            HLA-DRB1 [HSA:3123] [KO:K06752]
            HLA-DQB1 [HSA:3119] [KO:K06752]
            SLC11A1 [HSA:6556] [KO:K12347]
            VDR [HSA:7421] [KO:K08539]
            MBL [HSA:4153] [KO:K03991]
PATHOGEN    Mycobacterium tuberculosis [GN:mtu mtc mra mtf mtb mtg mti mte mtl mtj mtuh mtuc mtue]
DRUG        Isoniazid [DG:DG00642]
            Rifampicin [DG:DG00639]
            Pyrazinamide [DR:D00144]
            Ethambutol [DG:DG00643]
DBLINKS     ICD-10: A15 A16 A17 A18 A19
            MeSH: D014376
            MedlinePlus: 000077
REFERENCE   (drug)
REFERENCE   PMID:20206579 (gene)
  AUTHORS   Moller M, Hoal EG
  TITLE     Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis.
  JOURNAL   Tuberculosis (Edinb) 90:71-83 (2010)
REFERENCE   PMID:16519730 (gene)
  AUTHORS   Fernando SL, Britton WJ
  TITLE     Genetic susceptibility to mycobacterial disease in humans.
  JOURNAL   Immunol Cell Biol 84:125-37 (2006)
REFERENCE   PMID:12121000 (gene)
  AUTHORS   Hoal EG
  TITLE     Human genetic susceptibility to tuberculosis and other mycobacterial diseases.
  JOURNAL   IUBMB Life 53:225-9 (2002)
REFERENCE   PMID:17147011 (description)
  AUTHORS   De Backer AI, Mortele KJ, De Keulenaer BL, Parizel PM
  TITLE     Tuberculosis: epidemiology, manifestations, and the value of medical imaging in diagnosis.
  JOURNAL   JBR-BTR 89:243-50 (2006)
REFERENCE   PMID:15482144 (description)
  AUTHORS   Smith KC, Armitige L, Wanger A
  TITLE     A review of tuberculosis: reflections on the past, present and future of a global epidemic disease.
  JOURNAL   Expert Rev Anti Infect Ther 1:483-91 (2003)
REFERENCE   PMID:21420161 (description)
  AUTHORS   Lawn SD, Zumla AI
  TITLE     Tuberculosis.
  JOURNAL   Lancet 378:57-72 (2011)
///
ENTRY       H00343                      Disease
NAME        Diphtheria
DESCRIPTION Diphtheria is a contagious and potentially life-threatening childhood disease caused by Corynebacterium diphtheriae. In industrialized countries, immunization against diphtheria became widespread in the 1940s and the incidence of the disease markedly decreased. However, diphtheria still remains endemic in several regions including Africa, India, Bangladesh, Vietnam, the tropics, and South America. Moreover, a large proportion of adults in industrialized countries are now susceptible to diphtheria because the protection by vaccine does not last for long time unless periodic booster is given.
CATEGORY    Infectious disease
PATHOGEN    Corynebacterium diphtheriae [GN:cdi cdd cdw cdz]
            diphtheria toxin [KO:K00776]
DRUG        Benzylpenicillin [DG:DG00534]
            Erythromycin [DG:DG00436]
DBLINKS     ICD-10: A36
            MeSH: D004165
            MedlinePlus: 001608
REFERENCE   (drug)
  AUTHORS   Papadakis MA, Tierney LM (ed).
  TITLE     [Current Medical Diagnosis & Treatment 2004, Forty-Third Edition] (In Japanese)
  JOURNAL   Nikkei Business Publications, Inc. (2004)
REFERENCE   PMID:15049077 (description)
  AUTHORS   Mattos-Guaraldi AL, Moreira LO, Damasco PV, Hirata Junior R
  TITLE     Diphtheria remains a threat to health in the developing world--an overview.
  JOURNAL   Mem Inst Oswaldo Cruz 98:987-93 (2003)
REFERENCE   PMID:7489768 (description)
  AUTHORS   Galazka AM, Robertson SE
  TITLE     Diphtheria: changing patterns in the developing world and the industrialized world.
  JOURNAL   Eur J Epidemiol 11:107-17 (1995)
REFERENCE   PMID:7489783 (description)
  AUTHORS   Galazka AM, Robertson SE, Oblapenko GP
  TITLE     Resurgence of diphtheria.
  JOURNAL   Eur J Epidemiol 11:95-105 (1995)
///
ENTRY       H00344                      Disease
NAME        Leprosy;
            Hansen disease
DESCRIPTION Leprosy, caused by Mycobacterium leprae, is still one of the main causes of physical disability worldwide. The new case detection rate remains high, with about 250 000 new cases being registered each year. Infection leads to chronic granulomatous inflammation in skin and peripheral nerves and resulting disability brings about social disadvantage for patients and their family members.
CATEGORY    Infectious disease
GENE        HLA; human leucocyte antigens [HSA:3105 3106 3107 3133 3134 3135] [KO:K06751]
            TLR1 (polymorphism) [HSA:7096] [KO:K05398]
            TLR2 (polymorphism) [HSA:7097] [KO:K10159]
            LTA; lymphotoxin alpha (polymorphism) [HSA:4049] [KO:K05468]
            PRKN (polymorphism) [HSA:5071] [KO:K04556]
PATHOGEN    Mycobacterium leprae [GN:mle] (from India)
            Mycobacterium leprae [GN:mlb] (from Brazil)
MARKER      M. leprae phenolic glycolipid-I (PGL-1) (dipstick, ELISA, ML Flow test)
DRUG        Dapsone [DR:D00592]
            Rifampicin [DG:DG00639]
            Clofazimine [DR:D00278]
DBLINKS     ICD-10: A30
            MeSH: D007918
            OMIM: 613223 246300 610988 607572
            MedlinePlus: 001347
REFERENCE   PMID:21616456 (description, drug, marker)
  AUTHORS   Rodrigues LC, Lockwood DNj
  TITLE     Leprosy now: epidemiology, progress, challenges, and research gaps.
  JOURNAL   Lancet Infect Dis 11:464-70 (2011)
REFERENCE   PMID:15337986 (description, marker)
  AUTHORS   Moschella SL
  TITLE     An update on the diagnosis and treatment of leprosy.
  JOURNAL   J Am Acad Dermatol 51:417-26 (2004)
REFERENCE   PMID:21585261 (description)
  AUTHORS   Cardoso CC, Pereira AC, de Sales Marques C, Moraes MO
  TITLE     Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome.
  JOURNAL   Future Microbiol 6:533-49 (2011)
REFERENCE   PMID:16728267 (gene)
  AUTHORS   Geluk A, Ottenhoff TH
  TITLE     HLA and leprosy in the pre and postgenomic eras.
  JOURNAL   Hum Immunol 67:439-45 (2006)
REFERENCE   PMID:17548585 (gene)
  AUTHORS   Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E, Hamann L, Schumann RR, Tapping RI
  TITLE     Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy.
  JOURNAL   J Immunol 178:7520-4 (2007)
REFERENCE   PMID:15726416 (gene)
  AUTHORS   Malhotra D, Relhan V, Reddy BS, Bamezai R
  TITLE     TLR2 Arg677Trp polymorphism in leprosy: revisited.
  JOURNAL   Hum Genet 116:413-5 (2005)
REFERENCE   PMID:17353895 (gene)
  AUTHORS   Alcais A, Alter A, Antoni G, Orlova M, Nguyen VT, Singh M, Vanderborght PR, Katoch K, Mira MT, Vu HT, Ngyuen TH, Nguyen NB, Moraes M, Mehra N, Schurr E, Abel L
  TITLE     Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy.
  JOURNAL   Nat Genet 39:517-22 (2007)
REFERENCE   PMID:14737177 (gene)
  AUTHORS   Mira MT, Alcais A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, Mai CP, Nguyen TH, Nguyen NB, Pham XK, Sarno EN, Alter A, Montpetit A, Moraes ME, Moraes JR, Dore C, Gallant CJ, Lepage P, Verner A, Van De Vosse E, Hudson TJ, Abel L, Schurr E
  TITLE     Susceptibility to leprosy is associated with PARK2 and PACRG.
  JOURNAL   Nature 427:636-40 (2004)
///
ENTRY       H00345                      Disease
NAME        Nocardiosis
DESCRIPTION Nocardiosis is an uncommon gram-positive bacterial infection that affects mainly patients with deficient cell-mediated immunity. It has been reported worldwide in all ages and ethnic groups. Pulmonary disease is the most common clinical presentation especially in immunocompromised patients, accounting for more than 40% of reported cases. Nocardiosis also occurs in disseminated form, affecting lungs, central nervous system, skin, and the soft tissues. Primary cutaneous nocardiosis typically affects immunocompetent individuals with traumatic inoculation at the infected site.
CATEGORY    Infectious disease
PATHOGEN    Nocardia farcinica [GN:nfa]
            Nocardia brasiliensis
            Nocardia asteroides sensu stricto
            Nocardia nova
            Nocardia cyriacigeorgica [GN:ncy]
MARKER      16S rRNA (PCR detection) [KO:K01977]
DRUG        Trimethoprim-sulfamethoxazole (TMP-SMZ) [DR:D00285]
            Fluoroquinolone
            Ceftriaxone [DG:DG00573]
            Moxifloxacine
            Imipenem [DG:DG01212]
            Amikacin [DG:DG00403]
DBLINKS     ICD-10: A43
            MeSH: D009617
            MedlinePlus: 000679
REFERENCE   PMID:20306281 (description, env_factor, drug)
  AUTHORS   Ambrosioni J, Lew D, Garbino J
  TITLE     Nocardiosis: updated clinical review and experience at a tertiary center.
  JOURNAL   Infection 38:89-97 (2010)
REFERENCE   PMID:20463251 (decription, env_factor, drug)
  AUTHORS   Sullivan DC, Chapman SW
  TITLE     Bacteria that masquerade as fungi: actinomycosis/nocardia.
  JOURNAL   Proc Am Thorac Soc 7:216-21 (2010)
REFERENCE   PMID:16614249 (description)
  AUTHORS   Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr
  TITLE     Clinical and laboratory features of the Nocardia spp. based on current molecular  taxonomy.
  JOURNAL   Clin Microbiol Rev 19:259-82 (2006)
REFERENCE   PMID:18427245 (description, env_factor)
  AUTHORS   Martinez R, Reyes S, Menendez R
  TITLE     Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis.
  JOURNAL   Curr Opin Pulm Med 14:219-27 (2008)
REFERENCE   PMID:19387343 (description)
  AUTHORS   Lalitha P
  TITLE     Nocardia keratitis.
  JOURNAL   Curr Opin Ophthalmol 20:318-23 (2009)
///
ENTRY       H00346                      Disease
NAME        Extrinsic allergic alveolitis (EAA);
            Hypersensitivity pneumonitis
DESCRIPTION Extrinsic allergic alveolitis (EAA), also known as hypersensitivity pneumonitis, is caused by repeated inhalation of mainly organic antigens by sensitized subjects. This induces a hypersensitivity response in the distal bronchioles and alveoli and subjects may present clinically with a variety of symptoms. EAA is caused by a wide variety of antigens including bacteria, organic materials, fungal spores, and chemicals. Of the various EAA syndromes, Farmer's lung and Bird fancier's disease are the commonest forms that have been studied. EEA is a complex dynamic clinical syndrome where clinical expression depends on the frequency and amount of contact with antigen and host susceptibility. The manifestations and symptoms can be complicated by self-regulatory measures performed by those affected individuals to reduce antigen exposure. There are many individuals with a positive antibody reaction who remain asymptomatic. EEA traditionally has been described as occurring in a state of acute, subacute, and chronic form.
CATEGORY    Immune system disease; Respiratory disease; Infectious disease
ENV_FACTOR  Thermophilic actinomycetes (Farmer's lung)
            Saccharopolyspora rectivirgula (Micropolyspora faeni) (Farmer's lung)
            Thermoactinomyces vulgaris (Farmer's lung)
            Thermoactinomyces sacchari (Bagassosis)
            Thermoactinomycete sp. (Mushroom-worker's lung)
            Agarieus hortensis spores (Mushroom-worker's lung)
            Micropolyspora faeni (Humidifier lung)
            Penicillium frequentans (Suberosis)
            Aspergillus clavatus [GN:act] (Malt-worker's lung)
            Penicillium chrysogenum [GN:pcs] (Woodworker's lung)
            Penicillium casei (Cheese-washer's lung)
            Cryptostroma corticale (Maple-bark stripper's lung)
            Mucor stolanifer (Paprika slicer's lung)
            Mycobacterium avium [GN:mpa mao mav] (Hot-tub lung)
            Mycobacterium intracellulare [GN:mit mir mia] (Hot-tub lung)
            Trichosporon cutaneum (Summer-type hypersensitivity pneumonitis)
            Candida albicans [GN:cal] (Sax lung)
            Avian proteins (Bird fanciers disease)
            Laboratory animals (Animal handlers lung)
            Fish meal extract (Fish meal workers lung)
            Rat serum proteins (Rat handlers lung)
            Paints, plastics (Isocyanates)
            Plastics (Anhydrides)
DRUG        Prednisone [DG:DG00094]
DBLINKS     ICD-10: J67
            MeSH: D000542
            MedlinePlus: 000109
REFERENCE   (drug)
REFERENCE   PMID:16635083 (description, env_factor)
  AUTHORS   Ismail T, McSharry C, Boyd G
  TITLE     Extrinsic allergic alveolitis.
  JOURNAL   Respirology 11:262-8 (2006)
///
ENTRY       H00347                      Disease
NAME        Chlamydia infection, including the following disease:
            Chlamydial urethritis
DESCRIPTION Chlamydia trachomatis is a gram-negative, obligate intracellular bacterium that causes the most common sexually transmissible diseases in the world. Most of these infections are asymptomatic but, if not treated, can lead to non-gonococcal urethritis and post-gonococcal urethritis in men. Urethritis can be complicated by acute epididymitis.
CATEGORY    Infectious disease
PATHOGEN    Chlamydia trachomatis [GN:ctr cta ctb ctl ctj]
DRUG        Doxycycline [DG:DG00008]
            Azithromycin [DG:DG00606]
            Ofloxacin [DG:DG00616]
            Rifampicin [DG:DG00639]
            Macrolides [ATC:J01FA]
DBLINKS     ICD-10: A56.0 N37.0
            MeSH: D002690
            MedlinePlus: 000659 000439
REFERENCE   PMID:20358033 (description, env_factor)
  AUTHORS   Rohde G, Straube E, Essig A, Reinhold P, Sachse K
  TITLE     Chlamydial zoonoses.
  JOURNAL   Dtsch Arztebl Int 107:174-80 (2010)
REFERENCE   PMID:19220334 (description, drug)
  AUTHORS   Bebear C, de Barbeyrac B
  TITLE     Genital Chlamydia trachomatis infections.
  JOURNAL   Clin Microbiol Infect 15:4-10 (2009)
REFERENCE   PMID:8993862 (description)
  AUTHORS   Black CM
  TITLE     Current methods of laboratory diagnosis of Chlamydia trachomatis infections.
  JOURNAL   Clin Microbiol Rev 10:160-84 (1997)
///
ENTRY       H00348                      Disease
NAME        Lymphogranuloma venereum
DESCRIPTION Chlamydia trachomatis is a gram-negative, obligate intracellular bacterium that causes the most common sexually transmissible diseases in the world. Serovars L1, L2, L2a and L3 of C. trachomatis are the agents of lymphogranuloma venereum, a disease found in isolated groups of men who have sex with men (MSM) across western Europe, North America, and Australia.
CATEGORY    Infectious disease
PATHOGEN    Chlamydia trachomatis [GN:ctr cta ctb ctl ctj]
DRUG        Doxycycline [DG:DG00008]
            Erythromycin [DG:DG00436]
            Rifampicin [DG:DG00639]
            Macrolides [ATC:J01FA]
DBLINKS     ICD-10: A55
            MeSH: D008219
            MedlinePlus: 000634
REFERENCE   PMID:20358033 (description, env_factor)
  AUTHORS   Rohde G, Straube E, Essig A, Reinhold P, Sachse K
  TITLE     Chlamydial zoonoses.
  JOURNAL   Dtsch Arztebl Int 107:174-80 (2010)
REFERENCE   PMID:19220334 (description, drug)
  AUTHORS   Bebear C, de Barbeyrac B
  TITLE     Genital Chlamydia trachomatis infections.
  JOURNAL   Clin Microbiol Infect 15:4-10 (2009)
REFERENCE   PMID:8993862 (description)
  AUTHORS   Black CM
  TITLE     Current methods of laboratory diagnosis of Chlamydia trachomatis infections.
  JOURNAL   Clin Microbiol Rev 10:160-84 (1997)
///
ENTRY       H00349                      Disease
NAME        Trachoma
DESCRIPTION Trachoma is the leading infectious cause of blindness worldwide. Infections with serovars A, B, Ba and C of Chlamydia trachomatis cause chronic keratoconjunctivitis in children with subsequent scarring and blindness in adults. At least 1.3 million people in poor, rural communities in low-income countries, particularly in sub-Saharan Africa were blind from trachoma in 2002.
CATEGORY    Infectious disease
PATHOGEN    Chlamydia trachomatis [GN:ctr cta ctb ctl ctj ctct]
DRUG        Tetracycline [DG:DG00005]
            Azithromycin [DG:DG00606]
DBLINKS     ICD-10: A71
            MeSH: D014141
            MedlinePlus: 001486
REFERENCE   PMID:20374566 (description, drug, comment)
  AUTHORS   Hu VH, Harding-Esch EM, Burton MJ, Bailey RL, Kadimpeul J, Mabey DC
  TITLE     Epidemiology and control of trachoma: systematic review.
  JOURNAL   Trop Med Int Health 15:673-91 (2010)
REFERENCE   PMID:21738814 (description)
  AUTHORS   Smith JL, Haddad D, Polack S, Harding-Esch EM, Hooper PJ, Mabey DC, Solomon AW, Brooker S
  TITLE     Mapping the global distribution of trachoma: why an updated atlas is needed.
  JOURNAL   PLoS Negl Trop Dis 5:e973 (2011)
REFERENCE   PMID:21412875 (drug)
  AUTHORS   Evans JR, Solomon AW
  TITLE     Antibiotics for trachoma.
  JOURNAL   Cochrane Database Syst Rev CD001860 (2011)
///
ENTRY       H00350                      Disease
NAME        Psittacosis;
            Parrot fever
DESCRIPTION Psittacosis, also known as parrot disease, is an infectious disease caused by Chlamydophila (Cp.) psittaci that is usually transmitted to humans from birds. Although pneumonia is the most common manifestation of this disease, all organ systems can be involved.
CATEGORY    Infectious disease
PATHOGEN    Chlamydophila psittaci [GN:chp chb cht]
            Working with domestic poultry
DRUG        Minocycline [DG:DG00009]
            Doxycycline [DG:DG00008]
DBLINKS     ICD-10: A70
            MeSH: D009956
            MedlinePlus: 000088
REFERENCE   PMID:20358033 (description)
  AUTHORS   Rohde G, Straube E, Essig A, Reinhold P, Sachse K
  TITLE     Chlamydial zoonoses.
  JOURNAL   Dtsch Arztebl Int 107:174-80 (2010)
REFERENCE   PMID:20171542 (drug)
  AUTHORS   Stewardson AJ, Grayson ML
  TITLE     Psittacosis.
  JOURNAL   Infect Dis Clin North Am 24:7-25 (2010)
REFERENCE   PMID:11681143 (description)
  AUTHORS   Elliott JH
  TITLE     Psittacosis. A flu like syndrome.
  JOURNAL   Aust Fam Physician 30:739-41 (2001)
///
ENTRY       H00351                      Disease
NAME        Chlamydial pneumonia
DESCRIPTION Chlamydophila pneumoniae is an obligate intracellular bacteria that causes human respiratory infections. Repeated or prolonged exposure to Cp. pneumoniae is associated with asthmatic bronchitis and asthma, and chronic infection can contribute to the development of adult-onset asthma.
CATEGORY    Infectious disease
PATHOGEN    Chlamydophila pneumoniae [GN:cpa cpn cpj cpt]
DBLINKS     ICD-10: J16
            MeSH: D061387
REFERENCE   PMID:20358033 (description)
  AUTHORS   Rohde G, Straube E, Essig A, Reinhold P, Sachse K
  TITLE     Chlamydial zoonoses.
  JOURNAL   Dtsch Arztebl Int 107:174-80 (2010)
REFERENCE   PMID:2056624 (description)
  AUTHORS   Hahn DL, Dodge RW, Golubjatnikov R
  TITLE     Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.
  JOURNAL   JAMA 266:225-30 (1991)
///
ENTRY       H00352                      Disease
NAME        Whipple's disease
DESCRIPTION Whipple's disease (WD) is a rare chronic multi-system disease associated with the bacterium Tropheryma whipplei that is ubiquitously present in the environment. The clinical features of WD are non-specific and histological lesions in gastrointestinal system can be the major manifestations. Patients without symptoms of gastrointestinal disease might be insufficiently treated, resulting in a potentially fatal outcome such as endocarditis, neurological infection, osteoarticular infection, or uveitis.
CATEGORY    Infectious disease
PATHOGEN    Tropheryma whipplei [GN:twh tws]
MARKER      16S rRNA (PCR detection) [TWH:TWTRNA11] [TWS:TWr03] [KO:K01977]
            PAS-staining
DRUG        Tetracycline [DG:DG00005]
            Trimethoprim-sulfamethoxazole (TMP-SMZ) [DR:D00285]
            Streptomycin [DG:DG00082]
            Penicillin G [DG:DG00534]
            Ceftriaxone [DG:DG00573]
            Doxycycline [DG:DG00008]
            Hydroxychloroquine [DG:DG01015]
            Co-trimoxazole [DR:D00285]
DBLINKS     ICD-10: K90.8
            MeSH: D008061
            MedlinePlus: 000209
REFERENCE   PMID:21461659 (description, drug)
  AUTHORS   Moos V, Schneider T
  TITLE     Changing paradigms in Whipple's disease and infection with Tropheryma whipplei.
  JOURNAL   Eur J Clin Microbiol Infect Dis 30:1151-8 (2011)
REFERENCE   PMID:20708091 (description, drug)
  AUTHORS   Desnues B, Al Moussawi K, Fenollar F
  TITLE     New insights into Whipple's disease and Tropheryma whipplei infections.
  JOURNAL   Microbes Infect 12:1102-10 (2010)
REFERENCE   PMID:18291339 (description, drug)
  AUTHORS   Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D
  TITLE     Whipple's disease: new aspects of pathogenesis and treatment.
  JOURNAL   Lancet Infect Dis 8:179-90 (2008)
///
ENTRY       H00353                      Disease
NAME        Borreliosis, including:
            Lyme disease;
            Neuroborreliosis;
            Acrodermatitis chronica atrophicans
DESCRIPTION Borreliosis is the multisystem infectious disease caused by the tick-borne spirochetes Borrelia. Localized infection is manifested by erythema migrans skin lesions and this is known as acrodermatitis chronica atrophicans in late Lyme borreliosis. Broad variety of peripheral nerve disorders (Lyme neuroborreliosis) can occur as well.
CATEGORY    Infectious disease
PATHOGEN    Borrelia burgdorferi (Lyme disease) [GN:bbu bbn bbj]
            Borrelia garinii [GN:bga bgb]
            Borrelia afzelii [GN:baf bafz bafh bafe]
            Borrelia bissettii [GN:bbs]
DRUG        Doxycycline [DG:DG00008]
            Amoxicillin [DG:DG00520]
            Phenoxymethylpenicillin [DG:DG00535]
            Cefuroxime [DG:DG00558]
            Penicillin G [DG:DG00534]
COMMENT     Vector: Ixodes sp. (tick)
DBLINKS     ICD-10: A69.2
            MeSH: D001899
            MedlinePlus: 001319
REFERENCE   PMID:21903253 (description, drug, comment)
  AUTHORS   Stanek G, Wormser GP, Gray J, Strle F
  TITLE     Lyme borreliosis.
  JOURNAL   Lancet 379:461-73 (2012)
REFERENCE   PMID:12872317 (description, env_factor, drug)
  AUTHORS   Halperin JJ
  TITLE     Lyme disease and the peripheral nervous system.
  JOURNAL   Muscle Nerve 28:133-43 (2003)
REFERENCE   PMID:21958583 (description)
  AUTHORS   Zajkowska J, Czupryna P, Pancewicz SA, Kondrusik M, Moniuszko A
  TITLE     Acrodermatitis chronica atrophicans.
  JOURNAL   Lancet Infect Dis 11:800 (2011)
REFERENCE   PMID:15547252 (description)
  AUTHORS   Glockner G, Lehmann R, Romualdi A, Pradella S, Schulte-Spechtel U, Schilhabel M, Wilske B, Suhnel J, Platzer M.
  TITLE     Comparative analysis of the Borrelia garinii genome.
  JOURNAL   Nucleic Acids Res 32:6038-46 (2004)
///
ENTRY       H00354                      Disease
NAME        Syphilis
DESCRIPTION Syphilis is one of the oldest recognized venereal infection caused by the spirochete Treponema pallidum subsp. pallidum. It is characterized by genital ulceration, skin rash, and development of serious systemic disease. Syphilis may also alter the course of HIV disease. Effective therapy is available but the incidence is increasing in many parts of the world.
CATEGORY    Infectious disease
PATHOGEN    Treponema pallidum [GN:tpa tpp tpu tph tpo tpas]
DRUG        Penicillin G [DG:DG00534]
            Tetracycline [DG:DG00005]
            Doxycycline [DG:DG00008]
            Erythromycin [DG:DG00436]
            Azithromycin [DG:DG00606]
DBLINKS     ICD-10: A50 A51 A52 A53
            MeSH: D013587
            MedlinePlus: 001327
REFERENCE   PMID:11825779 (description, env_factor, drug)
  AUTHORS   Antal GM, Lukehart SA, Meheus AZ
  TITLE     The endemic treponematoses.
  JOURNAL   Microbes Infect 4:83-94 (2002)
REFERENCE   PMID:22133883 (drug)
  AUTHORS   Ho EL, Lukehart SA
  TITLE     Syphilis: using modern approaches to understand an old disease.
  JOURNAL   J Clin Invest 121:4584-92 (2011)
REFERENCE   PMID:18510892 (description)
  AUTHORS   Daskalakis D
  TITLE     Syphilis: continuing public health and diagnostic challenges.
  JOURNAL   Curr HIV/AIDS Rep 5:72-7 (2008)
///
ENTRY       H00355                      Disease
NAME        Leptospirosis
DESCRIPTION Leptospirosis is an emerging zoonotic infection caused by spirochetes belonging to the genus Leptospira. Leptospira infects a variety of animals, being secreted into the environment. Leptospirosis often presents as a self-limiting non-specific febrile event. Asymptomatic infections are common in endemic areas. However, small proportion of the patients may have febrile illness with icterus, splenomegaly and nephritis, febrile illness with pulmonary haemorrhages, or ocular manifestations.
CATEGORY    Infectious disease
PATHOGEN    Leptospira interrogans [GN:lil lic lis]
            Leptospira borgpetersenii [GN:lbj lbl]
            Leptospira santarosai [GN:lst]
DRUG        Penicillin G [DG:DG00534]
            Doxycycline [DG:DG00008]
            Azithromycin [DG:DG00606]
DBLINKS     ICD-10: A27
            MeSH: D007922
            MedlinePlus: 001376
REFERENCE   PMID:21874744 (description, drug)
  AUTHORS   Lim VK
  TITLE     Leptospirosis: a re-emerging infection.
  JOURNAL   Malays J Pathol 33:1-5 (2011)
REFERENCE   PMID:19208981 (description)
  AUTHORS   Vijayachari P, Sugunan AP, Shriram AN
  TITLE     Leptospirosis: an emerging global public health problem.
  JOURNAL   J Biosci 33:557-69 (2008)
REFERENCE   PMID:21788890 (description)
  AUTHORS   Leshem E, Meltzer E, Schwartz E
  TITLE     Travel-associated zoonotic bacterial diseases.
  JOURNAL   Curr Opin Infect Dis 24:457-63 (2011)
///
ENTRY       H00356                      Disease
NAME        Cryptosporidiosis
DESCRIPTION Human cryptosporidiosis is a self-limited diarrheal disease characterized by acute, persistent, or chronic diarrhea and biliary/pulmonary disease. Transmission of the causative agent, Cryptosporidium, occurs by fecal-oral route. Water-borne transmission often occurs. The disease can be potentially serious in immunocompromised patients.
CATEGORY    Infectious disease
PATHOGEN    Cryptosporidium parvum [GN:cpv]
            Cryptosporidium hominis [GN:cho]
COMMENT     The most important therapy is hydroelectrolytic resuscitation. Antiretroviral therapy appears to play a critical role in resolution of AIDS-associated cryptosporidiosis.
DBLINKS     ICD-10: A07.2
            MeSH: D003457
            MedlinePlus: 000617
REFERENCE   PMID:20521158 (description, env_factor, comment)
  AUTHORS   Collinet-Adler S, Ward HD
  TITLE     Cryptosporidiosis: environmental, therapeutic, and preventive challenges.
  JOURNAL   Eur J Clin Microbiol Infect Dis 29:927-35 (2010)
REFERENCE   PMID:12686887 (description, env_factor)
  AUTHORS   Chappell CL, Okhuysen PC
  TITLE     Cryptosporidiosis.
  JOURNAL   Curr Opin Infect Dis 15:523-7 (2002)
REFERENCE   PMID:20689422 (comment)
  AUTHORS   Cabada MM, White AC Jr
  TITLE     Treatment of cryptosporidiosis: do we know what we think we know?
  JOURNAL   Curr Opin Infect Dis 23:494-9 (2010)
REFERENCE   PMID:22029525 (description)
  AUTHORS   McDonald V
  TITLE     Cryptosporidiosis: host immune responses and the prospects for effective immunotherapies.
  JOURNAL   Expert Rev Anti Infect Ther 9:1077-86 (2011)
///
ENTRY       H00357                      Disease
NAME        African trypanosomiasis;
            Sleeping sickness
DESCRIPTION African trypanosomiasis is a parasitic condition affecting both humans and livestocks. It is endemic to remote rural populations in sub-Saharan Africa with 300 000 to 500 000 new cases annually. Its causative agent is Trypanosoma brucei, whose protein has been shown to induce apoptosis in human brain.
CATEGORY    Infectious disease
PATHOGEN    Trypanosoma brucei [GN:tbr]
COMMENT     Vector: Glossina pallidipes (tsetse fly)
DBLINKS     ICD-10: B56
            MeSH: D014353
            MedlinePlus: 001362
///
ENTRY       H00358                      Disease
NAME        Chagas disease;
            American trypanosomiasis
DESCRIPTION Chagas disease, also known as American trypanosomiasis, affects 20 million people in Latin America and is caused by infection with protozoan parasite Trypanosoma cruzi. The infection is transmitted by hematophagous reduviid insect vectors through fecal contamination. Chagas disease is characterized by an acute phase followed by a chronic phase, with sustained inflammation that causes cardiomyopathy, digestive disorders, and neuropathies.
CATEGORY    Infectious disease
PATHOGEN    Trypanosoma cruzi [GN:tcr]
COMMENT     Vector: Rhodnius prolixus (Reduviid bug)
DBLINKS     ICD-10: B57
            MeSH: D014355
            MedlinePlus: 001372
///
ENTRY       H00359                      Disease
NAME        Leishmaniasis
DESCRIPTION Leishmaniasis is a vector-borne disease that affects more than 10 million people especially in developing countries of Africa, the Americas, and Asia. Leishmaniasis is caused by a protozoan parasite of the genus Leishmania transmitted by phlebotomine sandflies. In humans, leishmanial infections cause self-healing, cutaneous lesions or lethal mucosal and visceral infection (kala azar). There is no defined vaccine available against the disease.
CATEGORY    Infectious disease
PATHOGEN    Leishmania major [GN:lma] (Cutaneous leishmaniasis)
            Leishmania infantum [GN:lif] (Kala-azar / Visceral leishmaniasis)
            Leishmania mexicana MHOM/GT/2001/U1103 [GN:lmi] 
            Leishmania donovani [GN:ldo]
COMMENT     Vector: Phlebotomus papatasi (sand fly)
DBLINKS     ICD-10: B55
            MeSH: D007896
            MedlinePlus: 001386
///
ENTRY       H00360                      Disease
NAME        Amoebiasis
DESCRIPTION Amoebiasis is the infection of gastrointestinal tract that affects approximately 50 million people each year and is responsible for 40 to 100 thousand deaths. People living in Central and South America and Africa are at highest risk of infection. Ingestion of water and food contaminated with Entamoeba histolytica, an extracellular parasitic amoeba causes amoebic colitis and amoebic liver abscess. Amoebic colitis is characterized by devastating dysentery that usually contains blood. Entamoeba histolytica is a human-specific pathogen.
CATEGORY    Infectious disease
PATHOGEN    Entamoeba histolytica [GN:ehi]
DRUG        Erythromycin [DG:DG00436]
DBLINKS     ICD-10: A06
            MeSH: D000562
            MedlinePlus: 000298
///
ENTRY       H00361                      Disease
NAME        Malaria
DESCRIPTION Malaria is the most important threatening infectious disease, infecting approximately 300 million people and causing more than one million deaths in each year. Most severe cases occur in sub-Saharan Africa. Malaria is caused by Plasmodium parasites that are transmitted through the bite of female Anopheline mosquitos. In severe malaria, complications such as anaemia, respiratory distress, renal failure, and cerebral malaria are observed in addition to cyclical fevers. There are four species which infect humans; Plasmodium malariae (quartian malaria), Plasmodium vivax (benign tertian malaria), Plasmodium falciparum (malignant tertian malaria) and Plasmodium ovale (ovale tertian malaria).
CATEGORY    Infectious disease
PATHOGEN    Plasmodium falciparum [GN:pfa pfd pfh] (Falciparum malaria)
            Plasmodium vivax [GN:pvx] (Vivax malaria)
            Plasmodium knowlesi H [GN:pkn]
            Plasmodium malariae
            Plasmodium ovale
DRUG        Chloroquine [DG:DG01014] (aminoquinolines)
            Primaquine [DG:DG01016] (aminoquinolines)
            Quinine [DG:DG01019] (methanolquinolines)
            Mefloquine [DG:DG01020] (methanolquinolines)
            Artesunate [DR:D02482] (artemisinin derivatives)
COMMENT     Vector: Anopheles gambiae (African malaria mosquito) [GN:aga]
DBLINKS     ICD-10: B50 B51 B52 B53
            MeSH: D008288
            MedlinePlus: 000621
REFERENCE   PMID:23088834
  AUTHORS   Antinori S, Galimberti L, Milazzo L, Corbellino M
  TITLE     Plasmodium knowlesi: the emerging zoonotic malaria parasite.
  JOURNAL   Acta Trop 125:191-201 (2013)
///
ENTRY       H00362                      Disease
NAME        Giardiasis;
            Lambliasis
DESCRIPTION Giardiasis is one of the most common parasite-induced diarrhoea caused by the protozoan parasite Giardia lamblia. It is a waterborne infection and is responsible for 280 million infections per year, affecting children, pregnant women, the immunocompromised individuals, and people living with poor sanitation facilities.
CATEGORY    Infectious disease
PATHOGEN    Giardia lamblia [GN:gla]
DRUG        Metronidazole [DG:DG00006]
            Tinidazole [DR:D01426]
            Ornidazole [DR:D05274]
            Secnidazole[DR:D07353]
            Nitrofuran [DR:D00439]
            Furazolidone [DR:D00830]
            Quinacrine [DG:DG01012]
            Albendazole [DG:DG01022]
            Chloroquine [DG:DG01014]
            Paromomycin [DG:DG00084]
DBLINKS     ICD-10: A07.1
            MeSH: D005873
            MedlinePlus: 000288
REFERENCE   PMID:20701575 (description)
  AUTHORS   Escobedo AA, Almirall P, Robertson LJ, Franco RM, Hanevik K, Morch K, Cimerman S
  TITLE     Giardiasis: the ever-present threat of a neglected disease.
  JOURNAL   Infect Disord Drug Targets 10:329-48 (2010)
REFERENCE   PMID:21857510 (drug)
  AUTHORS   Tejman-Yarden N, Eckmann L
  TITLE     New approaches to the treatment of giardiasis.
  JOURNAL   Curr Opin Infect Dis 24:451-6 (2011)
REFERENCE   PMID:19285075 (description)
  AUTHORS   Geurden T, Vercruysse J, Claerebout E
  TITLE     Is Giardia a significant pathogen in production animals?
  JOURNAL   Exp Parasitol 124:98-106 (2010)
///
ENTRY       H00363                      Disease
NAME        Candidiasis
DESCRIPTION Candidiasis is a fungal infection with Candida species, predominantly with Candida albicans. Invasive candidiasis is a major cause of morbidity and mortality in the intensive care unit (ICU) setting, causing bloodstream infections. Recently, various non-C. albicans species have emerged as infecting agents. In patients with impaired IL-17 immunity, recurrent or persistent infections are observed (chronic mucocutaneous candidiasis disease).
CATEGORY    Infectious disease
GENE        IL17RA [HSA:23765] [KO:K05164]
            IL17F [HSA:112744] [KO:K05494]
            STAT1 [HSA:6772] [KO:K11220]
PATHOGEN    Candida albicans [GN:cal]
            Candida dubliniensis [GN:cdu]
            Candida tropicalis [GN:ctp]
            Candida glabrata [GN:cgr]
DRUG        Clotrimazole [DR:D00282]
            Fluconazole [DG:DG00371]
            Isoconazole [DG:DG00365]
            Itraconazole [DR:D00350]
            Ketoconazole [DR:D00351]
            Miconazole [DG:DG00004]
            Nystatin [DR:D00202]
DBLINKS     ICD-10: B37
            MeSH: D002177
REFERENCE
  AUTHORS   Papadakis MA, Tierney LM (ed).
  TITLE     [Current Medical Diagnosis & Treatment 2004, Forty-Third Edition] (In Japanese)
  JOURNAL   Nikkei Business Publications, Inc. (2004)
REFERENCE   PMID:21486733 (description)
  AUTHORS   Rodloff C, Koch D, Schaumann R
  TITLE     Epidemiology and antifungal resistance in invasive candidiasis.
  JOURNAL   Eur J Med Res 16:187-95 (2011)
REFERENCE   PMID:18279532 (description)
  AUTHORS   Mean M, Marchetti O, Calandra T
  TITLE     Bench-to-bedside review: Candida infections in the intensive care unit.
  JOURNAL   Crit Care 12:204 (2008)
REFERENCE   PMID:21350122 (gene)
  AUTHORS   Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL
  TITLE     Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17  immunity.
  JOURNAL   Science 332:65-8 (2011)
REFERENCE   PMID:21727188 (gene)
  AUTHORS   Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B, Flatot J, Migaud M, Chrabieh M, Kochetkov T, Bolze A, Borghesi A, Toulon A, Hiller J, Eyerich S, Eyerich K, Gulacsy V, Chernyshova L, Chernyshov V, Bondarenko A, Maria Cortes Grimaldo R, Blancas-Galicia L, Madrigal Beas IM, Roesler J, Magdorf K, Engelhard D, Thumerelle C, Burgel PR, Hoernes M, Drexel B, Seger R, Kusuma T, Jansson AF, Sawalle-Belohradsky J, Belohradsky B, Jouanguy E, Bustamante J, Bue M, Karin N, Wildbaum G, Bodemer C, Lortholary O, Fischer A, Blanche S, Al-Muhsen S, Reichenbach J, Kobayashi M, Rosales FE, Lozano CT, Kilic SS, Oleastro M, Etzioni A, Traidl-Hoffmann C, Renner ED, Abel L, Picard C, Marodi L, Boisson-Dupuis S, Puel A, Casanova JL
  TITLE     Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
  JOURNAL   J Exp Med 208:1635-48 (2011)
///
ENTRY       H00364                      Disease
NAME        Cryptococcosis
DESCRIPTION Cryptococcus is a pathogenic yeast that causes opportunistic infection especially in the immunocompromised patient. It mainly infects the central nervous system and causes meningitis. Cryptococcal meningitis is responsible for over 600 000 deaths worldwide annually, especially in developing countries. Mortality rate reaches 70% in sub-Saharan Africa. Cryptococcal lung disease is also an important clinical outcome, leading to severe pneumonia with respiratory failure.
CATEGORY    Infectious disease
PATHOGEN    Cryptococcus neoformans [GN:cne cnb]
            Cryptococcus gattii [GN:cgi]
DRUG        Fluconazole [DG:DG00371]
            Amphotericin B [DR:D00203]
            Flucytosine [DR:D00323]
DBLINKS     ICD-10: B45
            MeSH: D003453
            MedlinePlus: 001328
REFERENCE   PMID:22424297 (description, env_factor, drug)
  AUTHORS   Desalermos A, Kourkoumpetis TK, Mylonakis E
  TITLE     Update on the epidemiology and management of cryptococcal meningitis.
  JOURNAL   Expert Opin Pharmacother 13:783-9 (2012)
REFERENCE   PMID:19352182 (description)
  AUTHORS   Shirley RM, Baddley JW
  TITLE     Cryptococcal lung disease.
  JOURNAL   Curr Opin Pulm Med 15:254-60 (2009)
///
ENTRY       H00365                      Disease
NAME        Herpes simplex infection;
            HSV infection
DESCRIPTION Herpes simplex viruses (HSV-1 and HSV-2) are responsible for long-term latent infections causing recurrent painful blisters on an erythematous base. HSV-1 and HSV-2 are the usual cause of herpes labialis and herpes genitalis, respectively. However  It is now widely accepted that HSV-1 is an important cause for genital herpes. Infection can also occur in other parts of the body such as the brain (called herpes encephalitis), spinal cord (called herpes meningitis), cornea of the eye (called herpes simplex keratitis) and skin (called eczema herpeticum) if the immune system is severely defective or compromised. HSV spreads through direct contact. Most HSV infection are asymptomatic. However when symptoms do occur, they tend to be more severe with primary compared with recurrent infections. An initial episode of herpes may produce a systemic prodrome of fever and malaise.
CATEGORY    Infectious disease
PATHOGEN    Human herpesvirus 1 [GN:T40073]
            Human herpesvirus 2 [GN:T40074]
DRUG        Aciclovir [DG:DG00406]
            Valaciclovir [DG:DG00647]
            Vidarabine [DG:DG00645]
DBLINKS     ICD-10: B00 A60 O26.4 P35.2
            MeSH: D006561
            MedlinePlus: 001324
REFERENCE   PMID:21970493 (description, env_factor)
  AUTHORS   Chisholm C, Lopez L
  TITLE     Cutaneous infections caused by Herpesviridae: a review.
  JOURNAL   Arch Pathol Lab Med 135:1357-62 (2011)
REFERENCE   PMID:18541820 (drug)
  AUTHORS   Cernik C, Gallina K, Brodell RT
  TITLE     The treatment of herpes simplex infections: an evidence-based review.
  JOURNAL   Arch Intern Med 168:1137-44 (2008)
REFERENCE   PMID:24906668
  AUTHORS   Hill GM, Ku ES, Dwarakanathan S
  TITLE     Herpes simplex keratitis.
  JOURNAL   Dis Mon 60:239-46 (2014)
REFERENCE   PMID:24142852
  AUTHORS   Steiner I, Benninger F
  TITLE     Update on herpes virus infections of the nervous system.
  JOURNAL   Curr Neurol Neurosci Rep 13:414 (2013)
REFERENCE   PMID:21483260
  AUTHORS   Steiner I
  TITLE     Herpes simplex virus encephalitis: new infection or reactivation?
  JOURNAL   Curr Opin Neurol 24:268-74 (2011)
REFERENCE   PMID:4361958
  AUTHORS   Morrison RE, Miller MH, Lyon LW, Griffiss JM, Artenstein MS
  TITLE     Adult meningoencephalitis caused by herpesvirus hominis type 2.
  JOURNAL   Am J Med 56:540-4 (1974)
REFERENCE   PMID:23242894
  AUTHORS   Liaw FY, Huang CF, Hsueh JT, Chiang CP
  TITLE     Eczema herpeticum: a medical emergency.
  JOURNAL   Can Fam Physician 58:1358-61 (2012)
REFERENCE   PMID:22944008
  AUTHORS   Rowe AM, St Leger AJ, Jeon S, Dhaliwal DK, Knickelbein JE, Hendricks RL
  TITLE     Herpes keratitis.
  JOURNAL   Prog Retin Eye Res 32:88-101 (2013)
REFERENCE   PMID:21942600
  AUTHORS   Berardi A, Lugli L, Rossi C, Maria CL, Guidotti I, Gallo C, Ferrari F
  TITLE     Neonatal herpes simplex virus.
  JOURNAL   J Matern Fetal Neonatal Med 24 Suppl 1:88-90 (2011)
REFERENCE   PMID:10213894
  AUTHORS   Desselberger U
  TITLE     Herpes simplex virus infection in pregnancy: diagnosis and significance.
  JOURNAL   Intervirology 41:185-90 (1998)
///
ENTRY       H00366                      Disease
NAME        Varicella;
            Chickenpox;
            Herpes zoster;
            Shingles
DESCRIPTION Varicella-zoster virus (human herpesvirus 3) is an almost inevitable human pathogen that has a double-stranded linear DNA genome. Primary infection usually causes varicella (chickenpox) in children, after which the virus establishes latency in sensory neurons. Subsequent reactivation causes herpes zoster (shingles) in adults. Infiltration of the viral vesicles with inflammatory cells leads to pustule formation, which is followed by ulceration and encrustation in both diseases.
CATEGORY    Infectious disease
PATHOGEN    Human herpesvirus 3 [GN:T40078]
DRUG        Valacyclovir [DG:DG00647]
            Acyclovir [DG:DG00406]
            Penciclovir [DG:DG00408]
            Famciclovir [DR:D00317]
            Ganciclovir [DG:DG00646]
            Cidofovir [DR:D00273]
            Foscarnet [DG:DG00651]
            Freeze-dried live attenuated varicella vaccine [DR:D08777]
DBLINKS     ICD-10: B01 B02
            MeSH: D002644 D006562
            MedlinePlus: 001592
REFERENCE   PMID:21970493 (description, env_factor)
  AUTHORS   Chisholm C, Lopez L
  TITLE     Cutaneous infections caused by Herpesviridae: a review.
  JOURNAL   Arch Pathol Lab Med 135:1357-62 (2011)
REFERENCE   PMID:16098235 (description, drug)
  AUTHORS   Quinlivan M, Breuer J
  TITLE     Molecular and therapeutic aspects of varicella-zoster virus infection.
  JOURNAL   Expert Rev Mol Med 7:1-24 (2005)
REFERENCE   PMID:9514102 (description, drug)
  AUTHORS   Harper DR, Gilbert RL, Jeffries DJ
  TITLE     Molecular biology of varicella-zoster virus. A review prepared for the UK Advisory Group on Chickenpox.
  JOURNAL   J Infect 36 Suppl 1:1-10 (1998)
REFERENCE   PMID:21342215 (description)
  AUTHORS   Gilden D, Mahalingam R, Nagel MA, Pugazhenthi S, Cohrs RJ
  TITLE     Review: The neurobiology of varicella zoster virus infection.
  JOURNAL   Neuropathol Appl Neurobiol 37:441-63 (2011)
///
ENTRY       H00367                      Disease
NAME        Infectious mononucleosis;
            Epstein-Barr virus (EBV) infection
DESCRIPTION Epstein-Barr virus (EBV) is a common gammaherpesvirus whose initial infection manifests as infectious mononucleosis that is defined as a clinical triad of fever, pharyngitis, and adenopathy. EBV establishes a life-long asymptomatic infection in B cells and can contribute to oncogenesis including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant B cell lymphomas.
CATEGORY    Infectious disease
PATHOGEN    Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
DBLINKS     ICD-10: B27.0
            MeSH: D020031 D002051 D007244
            MedlinePlus: 000591
REFERENCE   PMID:8380053
  AUTHORS   Straus SE, Cohen JI, Tosato G, Meier J
  TITLE     NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management.
  JOURNAL   Ann Intern Med 118:45-58 (1993)
///
ENTRY       H00368                      Disease
NAME        Cytomegalovirus infection;
            CMV infection
DESCRIPTION Cytomegalovirus (CMV) is a double-stranded DNA virus of the Herpesviridae family acquired by late childhood in the majority of individuals. Primary infection is nonspecific but after that the virus becomes latent in multiple organs and can later be reactivated. CMV is an important and common cause of mortality and morbidity in immunocompromised patients such as those with HIV/AIDS or transplant recipients on immunosuppressive therapy.
CATEGORY    Infectious disease
PATHOGEN    Human herpesvirus 5 (Human cytomegalovirus) [GN:T40080]
MARKER      Serological test (detection of CMV IgG antibodies)
            Antigenemia assay (detection of CMV pp65 antigen)
            CMV DNA/mRNA (PCR/RT-PCR)
            Nucleic acid sequence-based amplification of unspliced viral mRNAs (pp67 mRNA)
DRUG        Ganciclovir [DR:D00333 D04301]
            Valganciclovir [DR:D03256]
            Foscarnet [DR:D00579 D02267]
            Acyclovir [DR:D00222 D02764]
            Cidofovir [DR:D00273]
DBLINKS     ICD-10: B20.2 B25 B27.1 P35.1
            MeSH: D003586
REFERENCE   PMID:21970493 (env_factor, marker)
  AUTHORS   Chisholm C, Lopez L
  TITLE     Cutaneous infections caused by Herpesviridae: a review.
  JOURNAL   Arch Pathol Lab Med 135:1357-62 (2011)
REFERENCE   PMID:21748845 (description)
  AUTHORS   Fishman JA
  TITLE     Infections in immunocompromised hosts and organ transplant recipients: essentials.
  JOURNAL   Liver Transpl 17 Suppl 3:S34-7 (2011)
REFERENCE   PMID:21056604 (description)
  AUTHORS   Jackson SE, Mason GM, Wills MR
  TITLE     Human cytomegalovirus immunity and immune evasion.
  JOURNAL   Virus Res 157:151-60 (2011)
REFERENCE   PMID:21841300 (drug)
  AUTHORS   Jain M, Duggal S, Chugh TD
  TITLE     Cytomegalovirus infection in non-immunosuppressed critically ill patients.
  JOURNAL   J Infect Dev Ctries 5:571-9 (2011)
REFERENCE   PMID:21827433 (marker)
  AUTHORS   Ross SA, Novak Z, Pati S, Boppana SB
  TITLE     Overview of the diagnosis of cytomegalovirus infection.
  JOURNAL   Infect Disord Drug Targets 11:466-74 (2011)
///
ENTRY       H00369                      Disease
NAME        Exanthema subitum;
            Roseolovirus infection;
            Roseola;
            Pityriasis rosea
DESCRIPTION Human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7) are members of beta-herpesvirus that are prevalent in the human population. Like all herpesviruses, HHV-6 and HHV-7 establish latency in the host following primary infection. Primary infection with HHV-6 can either be asymptomatic, cause roseola with high fever and rash, or be associated with an undifferentiated short febrile illness without rash. Primary infection with HHV-7 is milder and most often asymptomatic, although some cases of roseola-like illness have been linked to it.
CATEGORY    Infectious disease
PATHOGEN    Human herpesvirus 6B [GN:T40075]
            Human herpesvirus 7 [GN:T40076]
DRUG        Patients with active HHV-6 replication and roseola should not be treated with antiherpesviral therapy because the drugs have little antiherpesviral activity against HHV-6 and HHV-7.
DBLINKS     ICD-10: B08.2
            MeSH: D019349 D005077
            MedlinePlus: 000968
REFERENCE   PMID:21120721 (description)
  AUTHORS   Prober CG
  TITLE     Human herpesvirus 6.
  JOURNAL   Adv Exp Med Biol 697:87-90 (2011)
REFERENCE   PMID:17802896 (description, env_factor)
  AUTHORS   Caselli E, Di Luca D
  TITLE     Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7.
  JOURNAL   New Microbiol 30:173-87 (2007)
REFERENCE   PMID:10698157 (description, env_factor)
  AUTHORS   Kosuge H
  TITLE     HHV-6, 7 and their related diseases.
  JOURNAL   J Dermatol Sci 22:205-12 (2000)
REFERENCE   PMID:11924827 (description, drug)
  AUTHORS   Blauvelt A
  TITLE     Skin diseases associated with human herpesvirus 6, 7, and 8 infection.
  JOURNAL   J Investig Dermatol Symp Proc 6:197-202 (2001)
///
ENTRY       H00370                      Disease
NAME        Progressive multifocal leukoencephalopathy (PML)
DESCRIPTION Progressive multifocal leukoencephalopathy (PML) is a fatal neurological disorder characterized by destruction of oligodendrocytes by the JC polyomavirus that occurs in immunosuppressed individuals such as patients with AIDS. Patients with PML show white matter lesions on head computed tomography scan or magnetic resonance imaging.
CATEGORY    Infectious disease
PATHOGEN    JC polyomavirus [GN:T40072]
COMMENT     Combination therapy
            AIDS-associated: Highly active antiretroviral therapy (HAART) + Cidofovir
            Immunodepressed patient: Discontinuation of immunosuppressive agent + Cidofovir [DR:D00273]
DBLINKS     ICD-10: A81.2
            MeSH: D007968
            MedlinePlus: 000674
REFERENCE   PMID:15167073 (description)
  AUTHORS   Koralnik IJ
  TITLE     New insights into progressive multifocal leukoencephalopathy.
  JOURNAL   Curr Opin Neurol 17:365-70 (2004)
REFERENCE   PMID:7551117
  AUTHORS   Major EO, Ault GS
  TITLE     Progressive multifocal leukoencephalopathy: clinical and laboratory observations  on a viral induced demyelinating disease in the immunodeficient patient.
  JOURNAL   Curr Opin Neurol 8:184-90 (1995)
///
ENTRY       H00371                      Disease
NAME        Adenovirus infection, including:
            Viral conjunctivitis [DS:H01320]
DESCRIPTION Adenoviruses (Ads) are recognized as etiologic agents of the respiratory and gastrointestinal tracts, eye, kidney, and, more recently, of other organs as a consequence of solid organ and bone marrow transplantations with their associated immunosuppression. Ads are rarely associated with severe clinical symptoms in healthy individuals. In contrast, in the pediatric population, military recruits, and immunocompromised individuals, Ad infections often result in disseminated and potentially life-threatening disease. Ocular Ad infections are among the leading causes of viral conjunctivitis. There is currently no formally approved antiviral therapy for the treatment of severe Ad keratoconjunctivitis and life-threatening Ad infections in immunocompromised patients.
CATEGORY    Infectious disease
PATHOGEN    Human mastadenovirus A
            Human mastadenovirus B [GN:T40100]
            Human mastadenovirus C
            Human mastadenovirus D [GN:T40102]
            Human mastadenovirus E [GN:T40101]
            Human mastadenovirus F
DBLINKS     ICD-10: B97.0
            MeSH: D000258
REFERENCE   PMID:17446135 (description)
  AUTHORS   Hayashi S, Hogg JC
  TITLE     Adenovirus infections and lung disease.
  JOURNAL   Curr Opin Pharmacol 7:237-43 (2007)
REFERENCE   PMID:18655013 (description)
  AUTHORS   Lenaerts L, De Clercq E, Naesens L
  TITLE     Clinical features and treatment of adenovirus infections.
  JOURNAL   Rev Med Virol 18:357-74 (2008)
///
ENTRY       H00372                      Disease
NAME        Smallpox;
            Variola
DESCRIPTION Smallpox is a contagious disease caused by the variola virus, one of the Orthopoxviruses that causes skin eruption and marked toxemia. There were two distinct clinical varieties of smallpox: variola major with a case fatality rate of 30% and variola minor with milder severity. Smallpox is an old disease that spread throughout the world causing death in millions of people.
CATEGORY    Infectious disease
PATHOGEN    Variola virus [GN:T40082]
DRUG        Smallpox vaccine [DR:D05295]
DBLINKS     ICD-10: B03
            MeSH: D012899
            MedlinePlus: 001356
REFERENCE   PMID:10616173 (description)
  AUTHORS   Arita I
  TITLE     Standardization of smallpox vaccines and the eradication programme--a WHO perspective.
  JOURNAL   Dev Biol Stand 100:31-7 (1999)
REFERENCE   PMID:3319266 (description, drug)
  AUTHORS   Jezek Z, Khodakevich LN, Wickett JF
  TITLE     Smallpox and its post-eradication surveillance.
  JOURNAL   Bull World Health Organ 65:425-34 (1987)
REFERENCE   PMID:9795781 (description, env_factor)
  AUTHORS   Ellner PD
  TITLE     Smallpox: gone but not forgotten.
  JOURNAL   Infection 26:263-9 (1998)
///
ENTRY       H00373                      Disease
NAME        Monkeypox
DESCRIPTION Human monkeypox is a rare viral zoonotic disease caused by Monkeypox virus of the genus Orthopoxvirus. It occurs mostly in the rain forests of central and western Africa. Human monkeypox has a clinical presentation similar to that of smallpox, including characteristic rash. 90% of patients develop lymphadenopathy. By contrast with smallpox, human monkeypox has low transmissibility between human beings.
CATEGORY    Infectious disease
PATHOGEN    Monkeypox virus [GN:T40083]
DRUG        Smallpox vaccine [DR:D05295]
            Cidofovir [DR:D00273]
COMMENT     Many animals are infected with monkeypox virus under natural conditions, including squirrels, non-human primates, and rats. However, the primary reservoir for human infection remains unknown.
DBLINKS     ICD-10: B04
            MeSH: D045908
REFERENCE   PMID:6304185 (description, comment. drug)
  AUTHORS   Jezek Z, Gromyko AI, Szczeniowski MV
  TITLE     Human monkeypox.
  JOURNAL   J Hyg Epidemiol Microbiol Immunol 27:13-28 (1983)
REFERENCE   PMID:16288402 (description, drug)
  AUTHORS   Nalca A, Rimoin AW, Bavari S, Whitehouse CA
  TITLE     Reemergence of monkeypox: prevalence, diagnostics, and countermeasures.
  JOURNAL   Clin Infect Dis 41:1765-71 (2005)
REFERENCE   PMID:17661673 (description)
  AUTHORS   Parker S, Nuara A, Buller RM, Schultz DA
  TITLE     Human monkeypox: an emerging zoonotic disease.
  JOURNAL   Future Microbiol 2:17-34 (2007)
///
ENTRY       H00374                      Disease
NAME        Viral wart
DESCRIPTION Human papillomaviruses (HPVs) are small DNA viruses of the papovavirus family that can be associated with various skin warts including common warts, plantar warts, plane warts, condyloma acuminatum, Bowenoid papulosis, epidermodysplasia verruciformis, and laryngeal papillomas. Other lesions reported to be HPV-associated are squamous papilloma, verruca vulgaris, warty lip lesions, and conjunctival papillomas.
CATEGORY    Infectious disease
PATHOGEN    Alphapapillomavirus [GN:T40098 T40109]
            Betapapillomavirus [GN:T40089 T40110 T40111]
            Gammapapillomavirus [GN:T40113 T40114]
            Mupapillomavirus [GN:T40108 T40115]
DRUG        Imiquimod [DR:D02500] (Condyloma acuminatum, Myrmecia, Pigmented wart, Punctate wart, Verrucous papule, Flat wart)
            Cimetidine [DG:DG00017] (Epidermodysplasia verruciformis)
            Interferon alfa [DR:D00745 D02745 D04552 D04553] (Epidermodysplasia verruciformis)
DBLINKS     ICD-10: B07
            MeSH: D014860
            MedlinePlus: 000885 000886
REFERENCE   PMID:19374195 (pathogen)
  AUTHORS   Kiyofumi E
  TITLE     [HPV-associated cutaneous lesions]
  JOURNAL   Uirusu 58:173-82 (2008)
REFERENCE   PMID:22131115 (description)
  AUTHORS   Cardoso JC, Calonje E
  TITLE     Cutaneous manifestations of human papillomaviruses: a review.
  JOURNAL   Acta Dermatovenerol Alp Panonica Adriat 20:145-54 (2011)
REFERENCE   PMID:17668552 (drug)
  AUTHORS   Fradet-Turcotte A, Archambault J
  TITLE     Recent advances in the search for antiviral agents against human papillomaviruses.
  JOURNAL   Antivir Ther 12:431-51 (2007)
REFERENCE   PMID:9675641 (drug)
  AUTHORS   Gross G
  TITLE     Therapy of human papillomavirus infection and associated epithelial tumors.
  JOURNAL   Intervirology 40:368-77 (1997)
///
ENTRY       H00376                      Disease
NAME        Acute poliomyelitis;
            Polio
DESCRIPTION Polioviruses are members of the Enterovirus genus that are transmitted via the hand-to-hand-to-mouth contact. Small proportion of poliovirus infections results in paralytic poliomyelitis due to the viral invasion to central nervous system. The virus destroys lower motor neurons, causing an asymmetric paralysis. The loss of motor neurons is permanent.
CATEGORY    Infectious disease
PATHOGEN    Poliovirus [TAX:12080 12083 12086]
DRUG        Poliovirus vaccine [DR:D05544 D05543]
DBLINKS     ICD-10: A80
            MeSH: D011051
            MedlinePlus: 001402
REFERENCE   PMID:20978089 (description)
  AUTHORS   Nathanson N, Kew OM
  TITLE     From emergence to eradication: the epidemiology of poliomyelitis deconstructed.
  JOURNAL   Am J Epidemiol 172:1213-29 (2010)
///
ENTRY       H00377                      Disease
NAME        Rabies
DESCRIPTION Rabies is an old zoonotic disease which has been known for more than 4300 years. The common mode of transmission of rabies in man is by bite of the animals already suffering from it. Dogs are the major vectors. Rabies affects the central nervous system and causes fatal encephalomyelitis. WHO estimates that over 30 000 people in Asia and at least 24 000 people in Africa die every year due to rabies.
CATEGORY    Infectious disease
PATHOGEN    Rabies virus (RABV) [GN:T40022]
DRUG        Rabies vaccine [DR:D06504]
            Rabies immune globulin [DR:D05686]
COMMENT     Preexposure vaccination with modern cell culture vaccine is recommended for people at high risk of exposure. Postexposure prophylaxis consists of wound cleansing and immunization with modern cell culture vaccine, together with administration of rabies immune globulin. There is no certain cure for rabies except supportive care.
DBLINKS     ICD-10: A82
            MeSH: D011818
            MedlinePlus: 001334
REFERENCE   PMID:22348291 (description, env_factor, comment)
  AUTHORS   Yousaf MZ, Qasim M, Zia S, Khan Mu, Ashfaq UA, Khan S
  TITLE     Rabies molecular virology, diagnosis, prevention and treatment.
  JOURNAL   Virol J 9:50 (2012)
REFERENCE   PMID:18297443 (description, env_factor, drug)
  AUTHORS   Takayama N
  TITLE     Rabies: a preventable but incurable disease.
  JOURNAL   J Infect Chemother 14:8-14 (2008)
REFERENCE   PMID:18165217
  AUTHORS   Leung AK, Davies HD, Hon KL
  TITLE     Rabies: epidemiology, pathogenesis, and prophylaxis.
  JOURNAL   Adv Ther 24:1340-7 (2007)
///
ENTRY       H00378                      Disease
NAME        Lyssavirus infection;
            Rabies-related virus infection
DESCRIPTION Lyssaviruses are a group of viruses that includes rabies virus and other rabies-related bat lyssaviruses. Rabies-related lyssaviruses can cause acute, fatal encephalitis similar to that seen with rabies virus infection of humans. There is no effective treatment.
CATEGORY    Infectious disease
PATHOGEN    Australian bat lyssavirus [GN:T40023]
            European bat lyssavirus 1 [GN:T40024]
            European bat lyssavirus 2 [GN:T40025]
DRUG        Rabies vaccine [DR:D06504]
            Rabies immune globulin [DR:D05686]
COMMENT     Hosts: Chiroptera
DBLINKS     ICD-10: A82
REFERENCE   PMID:22440925 (description, env_factor)
  AUTHORS   Rupprecht CE, Turmelle A, Kuzmin IV
  TITLE     A perspective on lyssavirus emergence and perpetuation.
  JOURNAL   Curr Opin Virol 1:662-70 (2011)
REFERENCE   PMID:21601050 (description, env_factor)
  AUTHORS   Banyard AC, Hayman D, Johnson N, McElhinney L, Fooks AR
  TITLE     Bats and lyssaviruses.
  JOURNAL   Adv Virus Res 79:239-89 (2011)
REFERENCE   PMID:14959767 (description)
  AUTHORS   Fooks AR, Brookes SM, Johnson N, McElhinney LM, Hutson AM
  TITLE     European bat lyssaviruses: an emerging zoonosis.
  JOURNAL   Epidemiol Infect 131:1029-39 (2003)
///
ENTRY       H00379                      Disease
NAME        Mosquito-borne viral encephalitis, including:
            Japanese encephalitis [DS:H01533];
            Western equine encephalitis [DS:H01534];
            Eastern equine encephalitis [DS:H01535];
            Australian encephalitis [DS:H01536];
            California encephalitis [DS:H01537]
DESCRIPTION Mosquito-borne viral encephalitis are infections of the central nervous system with brain involvement that are caused by several members of arboviruses. Japanese encephalitis virus, maintained in pigs, causes severe encephalitis in Asia with an estimated 50 000 cases each year. Its case fatality rate reaches 30%. Other viruses whose reservoirs are mainly birds cause encephalitis only a very low proportion of infected people and there is high proportion of asymptomatic infections.
CATEGORY    Infectious disease
PATHOGEN    Japanese encephalitis virus [GN:T40052] (Japanese encephalitis)
            Western equine encephalitis virus [GN:T40053] (Western equine encephalitis)
            Eastern equine encephalitis virus [GN:T40054] (Eastern equine encephalitis)
            Murray Valley encephalitis virus [GN:T40055] (Murray Valley encephalitis / Australian encephalitis)
            La Crosse virus [GN:T40056] (La Crosse encephalitis / California encephalitis)
DRUG        Japanese encephalitis vaccine [DR:D05313]
COMMENT     Vector: Culex spp. (mosquito)
DBLINKS     ICD-10: A83
            MeSH: D004670 D004672 D020242 D020241
REFERENCE   PMID:21802875 (description, comment)
  AUTHORS   Stahl JP, Mailles A, Dacheux L, Morand P
  TITLE     Epidemiology of viral encephalitis in 2011.
  JOURNAL   Med Mal Infect 41:453-64 (2011)
REFERENCE   PMID:22084515 (description)
  AUTHORS   Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS
  TITLE     Estimated global incidence of Japanese encephalitis: a systematic review.
  JOURNAL   Bull World Health Organ 89:766-74, 774A-774E (2011)
REFERENCE   PMID:22432670 (description)
  AUTHORS   Knox J, Cowan RU, Doyle JS, Ligtermoet MK, Archer JS, Burrow JN, Tong SY, Currie BJ, Mackenzie JS, Smith DW, Catton M, Moran RJ, Aboltins CA, Richards JS
  TITLE     Murray Valley encephalitis: a review of clinical features, diagnosis and treatment.
  JOURNAL   Med J Aust 196:322-6 (2012)
///
ENTRY       H00380                      Disease
NAME        Tick-borne viral encephalitis
DESCRIPTION Tick-borne viral encephalitis is a group of diseases caused by arboviruses closely related to yellow fever, dengue, Japanese encephalitis, and West Nile viruses. It is the most important viral tick-borne disease in Europe and is also important in the Far East and in other parts of Asia.
CATEGORY    Infectious disease
PATHOGEN    Langat virus [GN:T40059] (Langat encephalitis)
            Powassan virus [GN:T40060] (Powassan encephalitis)
            Tick-borne encephalitis virus [GN:T40061]
MARKER      TBEV-specific IgM and IgG (ELISA detection)
DRUG        Tick-borne encephalitis can be prevented by vaccination.
COMMENT     Vector: Ixodes spp. (tick) and Culex spp. (mosquito)
DBLINKS     ICD-10: A84
            MeSH: D004675
REFERENCE   PMID:18514730 (description, comment)
  AUTHORS   Lindquist L, Vapalahti O
  TITLE     Tick-borne encephalitis.
  JOURNAL   Lancet 371:1861-71 (2008)
REFERENCE   PMID:21771531 (description)
  AUTHORS   Suss J
  TITLE     Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview.
  JOURNAL   Ticks Tick Borne Dis 2:2-15 (2011)
REFERENCE   PMID:19420159 (description, marker)
  AUTHORS   Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T
  TITLE     Tick-borne encephalitis virus - a review of an emerging zoonosis.
  JOURNAL   J Gen Virol 90:1781-94 (2009)
///
ENTRY       H00381                      Disease
NAME        Dengue
DESCRIPTION Dengue is a globally important infection that endangers 2.5 billion people in over 100 countries, especially in Southeast and South Asia and Central and South America. Dengue virus infection can cause two forms of illness, dengue fever (DF) and dengue haemorrhagic fever (DHF), depending on host and viral factors. DHF is a life-threatening syndrome characterized by plasma leakage into interstitial spaces, haemorrhagic manifestation, and circulatory shock.
CATEGORY    Infectious disease
PATHOGEN    Dengue virus [GN:T40048]
COMMENT     Vectors: Aedes mosquitoes
DBLINKS     ICD-10: A97
            MeSH: D003715
            MedlinePlus: 001374 001373
REFERENCE   PMID:21781999 (description, env_factor)
  AUTHORS   Whitehorn J, Simmons CP
  TITLE     The pathogenesis of dengue.
  JOURNAL   Vaccine 29:7221-8 (2011)
REFERENCE   PMID:11590668 (deacription)
  AUTHORS   Kurane I, Takasaki T
  TITLE     Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large.
  JOURNAL   Rev Med Virol 11:301-11 (2001)
REFERENCE   PMID:21514129
  AUTHORS   Coller BA, Clements DE
  TITLE     Dengue vaccines: progress and challenges.
  JOURNAL   Curr Opin Immunol 23:391-8 (2011)
REFERENCE   PMID:21831182
  AUTHORS   Tomashek KM, Margolis HS
  TITLE     Dengue: a potential transfusion-transmitted disease.
  JOURNAL   Transfusion 51:1654-60 (2011)
///
ENTRY       H00382                      Disease
NAME        Mosquito-borne viral fevers, including:
            Chikungunya fever;
            O'nyong-nyong fever;
            Venezuelan equine fever;
            West Nile fever;
            Rift Valley fever
DESCRIPTION Mosquito-borne viral fevers are a group of disorders caused by several members of arboviruses, most of them being maintained in an enzootic cycle between mosquitoes and birds. Humans are infected incidentally when bitten by mosquitoes. These viruses infect the central nervous system and can cause severe disease.
CATEGORY    Infectious disease
PATHOGEN    Chikungunya virus [GN:T40026] (Chikungunya fever)
            O'nyong-nyong virus [GN:T40027] (O'nyong-nyong fever)
            Venezuelan equine encephalitis virus [GN:T40028] (Venezuelan equine fever)
            West Nile virus [GN:T40029] (West Nile fever)
            Rift Valley fever virus [GN:T40030] (Rift Valley fever)
            Bunyamwera virus [GN:T40031] (Bunyamwera virus fever)
            Mayaro virus [GN:T40032] (Mayaro fever)
DBLINKS     ICD-10: A92
            MeSH: C535923 D004685 D014901 D012295
            MedlinePlus: 007186
REFERENCE   PMID:10436876 (description)
  AUTHORS   Lundstrom JO
  TITLE     Mosquito-borne viruses in western Europe: a review.
  JOURNAL   J Vector Ecol 24:1-39 (1999)
REFERENCE   PMID:19857523 (description)
  AUTHORS   Weaver SC, Reisen WK
  TITLE     Present and future arboviral threats.
  JOURNAL   Antiviral Res 85:328-45 (2010)
REFERENCE   PMID:19663604 (description)
  AUTHORS   Staples JE, Breiman RF, Powers AM
  TITLE     Chikungunya fever: an epidemiological review of a re-emerging infectious disease.
  JOURNAL   Clin Infect Dis 49:942-8 (2009)
REFERENCE   PMID:14651460 (description)
  AUTHORS   Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC
  TITLE     Venezuelan equine encephalitis.
  JOURNAL   Annu Rev Entomol 49:141-74 (2004)
REFERENCE   PMID:21994755 (description)
  AUTHORS   Lim SM, Koraka P, Osterhaus AD, Martina BE
  TITLE     West Nile virus: immunity and pathogenesis.
  JOURNAL   Viruses 3:811-28 (2011)
REFERENCE   PMID:21450816
  AUTHORS   Boshra H, Lorenzo G, Busquets N, Brun A
  TITLE     Rift valley fever: recent insights into pathogenesis and prevention.
  JOURNAL   J Virol 85:6098-105 (2011)
///
ENTRY       H00383                      Disease
NAME        Arthropod-borne viral fevers, including:
            Oropouche fever;
            Sandfly fever;
            Colorado tick fever
DESCRIPTION Arthropod-borne viral fevers are emerging zoonotic viral diseases that cause febrile illness with abrupt onset of fever, headache, myalgia, anorexia, and photophobia.
CATEGORY    Infectious disease
PATHOGEN    Oropouche virus [GN:T40062] (Oropouche fever)
            Colorado tick fever virus [GN:T40063] (Colorado tick fever)
            Sandfly fever Naples virus [GN:T40064] (Sandfly fever)
            Apoi virus [GN:T40065]
DBLINKS     ICD-10: A93
            MeSH: D010217 D003121
            MedlinePlus: 000675
REFERENCE   PMID:9230800 (description)
  AUTHORS   Watts DM, Lavera V, Callahan J, Rossi C, Oberste MS, Roehrig JT, Cropp CB, Karabatsos N, Smith JF, Gubler DJ, Wooster MT, Nelson WM, Hayes CG
  TITLE     Venezuelan equine encephalitis and Oropouche virus infections among Peruvian army troops in the Amazon region of Peru.
  JOURNAL   Am J Trop Med Hyg 56:661-7 (1997)
REFERENCE   PMID:7840443 (description)
  AUTHORS   Tesh RB
  TITLE     The emerging epidemiology of Venezuelan hemorrhagic fever and Oropouche fever in  tropical South America.
  JOURNAL   Ann N Y Acad Sci 740:129-37 (1994)
REFERENCE   PMID:19485115 (description)
  AUTHORS   Brett-Major DM, Claborn DM
  TITLE     Sand fly fever: what have we learned in one hundred years?
  JOURNAL   Mil Med 174:426-31 (2009)
REFERENCE   PMID:14501989 (description)
  AUTHORS   Dionisio D, Esperti F, Vivarelli A, Valassina M
  TITLE     Epidemiological, clinical and laboratory aspects of sandfly fever.
  JOURNAL   Curr Opin Infect Dis 16:383-8 (2003)
REFERENCE   PMID:11982311 (description)
  AUTHORS   Klasco R
  TITLE     Colorado tick fever.
  JOURNAL   Med Clin North Am 86:435-40, ix (2002)
///
ENTRY       H00384                      Disease
NAME        Yellow fever
DESCRIPTION Yellow fever is an acute hemorrhagic fever with high mortality caused by the yellow fever virus of Flaviviridae. It is transmitted by mosquitoes and occurs only in Africa and Central and South America. Immunization is the most important method of prevention of yellow fever but vaccine-associated adverse events have been reported, including hypersensitivity reactions, neurotropic disease, and viscerotropic disease.
CATEGORY    Infectious disease
PATHOGEN    Yellow fever virus [GN:T40057]
DRUG        Yellow fever vaccine [DR:D06347]
COMMENT     Vector: Aedes aegypti (Africa), Haemagogus spp. (South America)
DBLINKS     ICD-10: A95
            MeSH: D015004
            MedlinePlus: 001365
REFERENCE   PMID:17304460 (description, drug)
  AUTHORS   Barnett ED
  TITLE     Yellow fever: epidemiology and prevention.
  JOURNAL   Clin Infect Dis 44:850-6 (2007)
REFERENCE   PMID:21798462 (description)
  AUTHORS   Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP
  TITLE     The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.
  JOURNAL   Lancet Infect Dis 11:622-32 (2011)
///
ENTRY       H00385                      Disease
NAME        South American (new world arenaviral) hemorrhagic fevers, including:
            Argentine hemorrhagic fever;
            Bolivian haemorrhagic fever;
            Venezuelan hemorrhagic fever;
            Brazilian hemorrhagic fever
DESCRIPTION Several New World arenaviruses including Junin virus, Machupo virus, Guanarito virus, Sabia virus, and Tacaribe virus are known to cause severe multisystemic illnesses endemic in various regions of South America. The disease is characterized by fever, malaise, bleeding, and refractory shock. These viruses can also result in central nervous system disease.
CATEGORY    Infectious disease
PATHOGEN    New world arenaviruses including:
            Junin mammarenavirus [GN:T40005] (Argentine hemorrhagic fever)
            Machupo mammarenavirus [GN:T40006] (Bolivian hemorrhagic fever)
            Guanarito mammarenavirus [GN:T40007] (Venezuelan hemorrhagic fever)
            Sabia mammarenavirus [GN:T40008] (Brazilian hemorrhagic fever)
            Tacaribe mammarenavirus [GN:T40009]
DBLINKS     ICD-10: A96
REFERENCE   PMID:18036672 (description, env_factor)
  AUTHORS   Gowen BB, Holbrook MR
  TITLE     Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses.
  JOURNAL   Antiviral Res 78:79-90 (2008)
REFERENCE   PMID:16815457 (description)
  AUTHORS   Marty AM, Jahrling PB, Geisbert TW
  TITLE     Viral hemorrhagic fevers.
  JOURNAL   Clin Lab Med 26:345-86, viii (2006)
REFERENCE   PMID:15955687 (description)
  AUTHORS   Bray M
  TITLE     Pathogenesis of viral hemorrhagic fever.
  JOURNAL   Curr Opin Immunol 17:399-403 (2005)
///
ENTRY       H00386                      Disease
NAME        Lassa fever
DESCRIPTION Lassa fever (LF) is an acute viral hemorrhagic illness caused by Lassa virus, an RNA virus of the family Arenaviridae. LF is endemic in parts of West Africa, where 100 000 to 300 000 cases and 5000 deaths occur each year. LF is characterized by fever, muscle aches, sore throat, nausea, vomiting and, chest and abdominal pain.
CATEGORY    Infectious disease
PATHOGEN    Lassa mammarenavirus [GN:T40010] (Old world arenavirus)
MARKER      S RNA (PCR detection)
            NP protein (ELISA and immunoblot detection) [VG:956584] 
            GPC protein (ELISA and immunoblot detection) [VG:3197498]
            Z protein (ELISA and immunoblot detection) [VG:956586]
DRUG        Ribavirin [DR:D00423]
COMMENT     Natural hosts: Mastomys
DBLINKS     ICD-10: A96.2
            MeSH: D007835
REFERENCE   PMID:15487592 (description, marker)
  AUTHORS   Gunther S, Lenz O
  TITLE     Lassa virus.
  JOURNAL   Crit Rev Clin Lab Sci 41:339-90 (2004)
REFERENCE   PMID:18241935 (drug)
  AUTHORS   Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A, Fair J, Guttieri MC, Ferro P, Imes T, Monagin C, Garry RF, Bausch DG
  TITLE     New opportunities for field research on the pathogenesis and treatment of Lassa fever.
  JOURNAL   Antiviral Res 78:103-15 (2008)
REFERENCE   PMID:17378212 (description)
  AUTHORS   Ogbu O, Ajuluchukwu E, Uneke CJ
  TITLE     Lassa fever in West African sub-region: an overview.
  JOURNAL   J Vector Borne Dis 44:1-11 (2007)
REFERENCE   PMID:16802617 (description)
  AUTHORS   Curtis N
  TITLE     Viral haemorrhagic fevers caused by Lassa, Ebola and Marburg viruses.
  JOURNAL   Adv Exp Med Biol 582:35-44 (2006)
///
ENTRY       H00387                      Disease
NAME        B virus infection
DESCRIPTION Macacine herpesvirus 1, also known as B virus, is an alpha-herpesvirus that naturally infects Asiatic macaques. It is transmitted by exposure to contaminated bodily fluids. In macaques, the infection is similar to that of HSV-1 and HSV-2 in humans and serious disease is rare. However, in humans, it invades the central nervous system and causes serious encephalitis with a fatality rate greater than 70%.
CATEGORY    Infectious disease
PATHOGEN    Macacine herpesvirus 1 [GN:T40077]
DBLINKS     ICD-10: B00.4A
REFERENCE   PMID:20510749 (description, env_factor)
  AUTHORS   Estep RD, Messaoudi I, Wong SW
  TITLE     Simian herpesviruses and their risk to humans.
  JOURNAL   Vaccine 28 Suppl 2:B78-84 (2010)
REFERENCE   PMID:19793452 (description)
  AUTHORS   Elmore D, Eberle R
  TITLE     Monkey B virus (Cercopithecine herpesvirus 1).
  JOURNAL   Comp Med 58:11-21 (2008)
REFERENCE   PMID:1313312 (description)
  AUTHORS   Weigler BJ
  TITLE     Biology of B virus in macaque and human hosts: a review.
  JOURNAL   Clin Infect Dis 14:555-67 (1992)
///
ENTRY       H00388                      Disease
NAME        Non-chlamydial non-gonococcal urethritis
DESCRIPTION Urethritis in men is one of the most common sexually transmitted diseases. Mycoplasma genitalium, that shares several features with M. pneumoniae, has been implicated in non-chlamydial non-gonococcal urethritis. Moreover, it is linked to several inflammatory reproductive tract syndromes in women including cervicitis, pelvic inflammatory disease, adverse pregnancy outcome, and infertility.
CATEGORY    Infectious disease
PATHOGEN    Mycoplasma genitalium [GN:mge mgu mgc mgq mgx]
            Mycoplasma penetrans [GN:mpe]
            Mycoplasma hominis [GN:mho]
            Ureaplasma urealyticum [GN:uue]
            Ureaplasma parvum [GN:uur upa]
DRUG        Doxycycline [DG:DG00008]
            Azithromycin [DG:DG00606]
DBLINKS     ICD-10: A49.3 N34.2
            MeSH: D045704
            MedlinePlus: 000439
REFERENCE   PMID:19177768 (drug)
  AUTHORS   Deguchi T, Yasuda M, Maeda S
  TITLE     [Non-chlamydial non-gonococcal urethritis]
  JOURNAL   Nippon Rinsho 67:167-71 (2009)
REFERENCE   PMID:14678525 (description)
  AUTHORS   Jensen JS
  TITLE     Mycoplasma genitalium: the aetiological agent of urethritis and other sexually transmitted diseases.
  JOURNAL   J Eur Acad Dermatol Venereol 18:1-11 (2004)
REFERENCE   PMID:15364301 (description)
  AUTHORS   Ishihara S, Yasuda M, Ito S, Maeda S, Deguchi T
  TITLE     Mycoplasma genitalium urethritis in men.
  JOURNAL   Int J Antimicrob Agents 24 Suppl 1:S23-7 (2004)
REFERENCE   PMID:20706675
  AUTHORS   Larsen B, Hwang J
  TITLE     Mycoplasma, Ureaplasma, and adverse pregnancy outcomes: a fresh look.
  JOURNAL   Infect Dis Obstet Gynecol 2010 (2010)
///
ENTRY       H00389                      Disease
NAME        Hemorrhagic fever with renal syndrome (HFRS)
DESCRIPTION Hemorrhagic fever with renal syndrome (HFRS) is a group of diseases caused by hantaviruses which are members of family Bunyaviridae. HFRS is characterized by renal failure, hemorrhages, and shock and is caused by the serotypes Hantaan, Seoul, Puumala, and Dobrava-Belgrade viruses. The serotype Puumala virus also causes nephropathia epidemica, a milder variant of HFRS.
CATEGORY    Infectious disease
PATHOGEN    Hantaan virus [GN:T40016]
            Seoul virus [GN:T40017]
            Dobrava-Belgrade virus [GN:T40018]
            Puumala virus [GN:T40019]
DBLINKS     ICD-10: A98.5
            MeSH: D006480
REFERENCE   PMID:15744574 (description, env_factor)
  AUTHORS   Zeier M, Handermann M, Bahr U, Rensch B, Muller S, Kehm R, Muranyi W, Darai G
  TITLE     New ecological aspects of hantavirus infection: a change of a paradigm and a challenge of prevention--a review.
  JOURNAL   Virus Genes 30:157-80 (2005)
REFERENCE   PMID:22403334 (description)
  AUTHORS   Kariwa H, Yoshikawa K, Tanikawa Y, Seto T, Sanada T, Saasa N, Ivanov LI, Slonova R, Zakharycheva TA, Nakamura I, Yoshimatsu K, Arikawa J, Yoshii K, Takashima I
  TITLE     Isolation and characterization of hantaviruses in Far East Russia and etiology of hemorrhagic fever with renal syndrome in the region.
  JOURNAL   Am J Trop Med Hyg 86:545-53 (2012)
///
ENTRY       H00390                      Disease
NAME        Hantavirus pulmonary syndrome (HPS)
DESCRIPTION Hantavirus pulmonary syndrome (HPS) is a severe hantaviral disease in Americas with high case fatality (40%). HPS-associated hantaviruses are transmitted by the inhalation of virus particles aerosolized from the excrement or body fluids of rodents. The disease presents as a flu-like illness. Microvascular leakage is responsible for the clinical manifestations such as pulmonary edema and cardiac depression.
CATEGORY    Infectious disease
PATHOGEN    Sin Nombre virus [GN:T40020]
            Andes virus [GN:T40021]
COMMENT     At present there are no efficacious vaccines, immunotherapeutics, or antivirals licensed for HPS.
DBLINKS     ICD-10: B33.4
            MeSH: D018804
REFERENCE   PMID:21945215 (description, env_factor, comment)
  AUTHORS   Macneil A, Nichol ST, Spiropoulou CF
  TITLE     Hantavirus pulmonary syndrome.
  JOURNAL   Virus Res 162:138-47 (2011)
REFERENCE   PMID:19434035 (deacription, env_factor)
  AUTHORS   Vinh DC, Embil JM
  TITLE     Hantavirus pulmonary syndrome: a concise clinical review.
  JOURNAL   South Med J 102:620-5 (2009)
REFERENCE   PMID:12521363 (description)
  AUTHORS   Lednicky JA
  TITLE     Hantaviruses. a short review.
  JOURNAL   Arch Pathol Lab Med 127:30-5 (2003)
///
ENTRY       H00391                      Disease
NAME        Henipavirus infection, including:
            Hendra virus infection;
            Nipah virus infection
DESCRIPTION Hendra virus and Nipah virus are members of a new genus, Henipavirus, in the emerging family Paramyxoviridae. They are bat-borne paramyxoviruses which are responsible for severe disease with high mortality rates (50-100%).
CATEGORY    Infectious disease
PATHOGEN    Hendra virus [GN:T40046]
            Nipah virus [GN:T40047]
COMMENT     Vector: Pteropus bats (flying foxex)
DBLINKS     MeSH: D045464
REFERENCE   PMID:22483665 (description)
  AUTHORS   Marsh GA, Wang LF
  TITLE     Hendra and Nipah viruses: why are they so deadly?
  JOURNAL   Curr Opin Virol 2:242-7 (2012)
REFERENCE   PMID:21488828 (description)
  AUTHORS   Vigant F, Lee B
  TITLE     Hendra and nipah infection: pathology, models and potential therapies.
  JOURNAL   Infect Disord Drug Targets 11:315-36 (2011)
REFERENCE   PMID:22482714 (drug)
  AUTHORS   Broder CC
  TITLE     Henipavirus outbreaks to antivirals: the current status of potential therapeutics.
  JOURNAL   Curr Opin Virol 2:176-87 (2012)
///
ENTRY       H00393                      Disease
NAME        Enterovirus infection
DESCRIPTION Enteroviruses (EVs) are single-stranded, positive-sense RNA viruses from the enterovirus genus in the family Picornaviridae. They are major public health issues of children across Asia, causing hand, foot and mouth disease (HFMD), herpangina, and acute epidemic haemorrhagic conjunctivitis.
CATEGORY    Infectious disease
PATHOGEN    Enterovirus A [GN:T40103] (Herpangina)
            Enterovirus B [GN:T40104]
            Enterovirus C [GN:T40105]
            Enterovirus D [GN:T40106]
            Human echovirus 1
            Human enterovirus 71 (Hand, foot and mouth disease)
            Human coxsackievirus A16 (Hand, foot and mouth disease)
MARKER      5' untranslated or VP1 region of the viral genome (PCR detection)
            IgM antibodies (ELISA test)
DRUG        Intravenous immunoglobulin
DBLINKS     ICD-10: B34.1 A85.0 A87.0 B08.4 B08.5 B30.3
            MeSH: D004769
            MedlinePlus: 000965 000969 001340
REFERENCE   PMID:21251690 (description, env_factor)
  AUTHORS   Rhoades RE, Tabor-Godwin JM, Tsueng G, Feuer R
  TITLE     Enterovirus infections of the central nervous system.
  JOURNAL   Virology 411:288-305 (2011)
REFERENCE   PMID:20056019 (marker, drug)
  AUTHORS   Wong SS, Yip CC, Lau SK, Yuen KY
  TITLE     Human enterovirus 71 and hand, foot and mouth disease.
  JOURNAL   Epidemiol Infect 138:1071-89 (2010)
REFERENCE   PMID:20965438 (drug)
  AUTHORS   Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T
  TITLE     Clinical features, diagnosis, and management of enterovirus 71.
  JOURNAL   Lancet Neurol 9:1097-105 (2010)
REFERENCE   PMID:20961813 (description)
  AUTHORS   Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH
  TITLE     Virology, epidemiology, pathogenesis, and control of enterovirus 71.
  JOURNAL   Lancet Infect Dis 10:778-90 (2010)
REFERENCE   PMID:17671037 (description)
  AUTHORS   Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY
  TITLE     Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005.
  JOURNAL   Pediatrics 120:e244-52 (2007)
///
ENTRY       H00394                      Disease
NAME        Measles
DESCRIPTION Measles is a highly contagious respiratory disease caused by measles virus that belongs to genus Morbillivirus. Measles is a leading cause of mortality in children worldwide. An estimated 30-40 million people are affected, resulting in 777 000 deaths in 2002. Measles infection is characterized by immunosuppression and lymphopenia.
CATEGORY    Infectious disease
PATHOGEN    Measles virus [GN:T40033]
DRUG        Measles vaccine [DR:D04866 D06806 D08804]
DBLINKS     ICD-10: B05
            MeSH: D008457
            MedlinePlus: 001569
///
ENTRY       H00395                      Disease
NAME        Rubella, including:
            Congenital rubella syndrome
DESCRIPTION Rubella is a viral infection caused by the rubella virus of the togaviridae, genus rubivirus. It is a disease with minor morbidity, however, when contracted by a pregnant woman, fetal death or severe congenital defects (congenital rubella syndrome) such as blindness and deafness can occur due to the virus-induced cellular damage.
CATEGORY    Infectious disease
PATHOGEN    Rubella virus [GN:T40070]
DRUG        Rubella vaccine [DR:D05362 D06512 D08804]
DBLINKS     ICD-10: B06 P35.0
            MeSH: D012409 D012410
            MedlinePlus: 001574 001658
REFERENCE   PMID:15064032 (description)
  AUTHORS   Banatvala JE, Brown DW
  TITLE     Rubella.
  JOURNAL   Lancet 363:1127-37 (2004)
REFERENCE   PMID:9796387 (description)
  AUTHORS   Hinman AR, Hersh BS, de Quadros CA
  TITLE     Rational use of rubella vaccine for prevention of congenital rubella syndrome in  the Americas.
  JOURNAL   Rev Panam Salud Publica 4:156-60 (1998)
REFERENCE   PMID:16580940 (description)
  AUTHORS   De Santis M, Cavaliere AF, Straface G, Caruso A
  TITLE     Rubella infection in pregnancy.
  JOURNAL   Reprod Toxicol 21:390-8 (2006)
///
ENTRY       H00396                      Disease
NAME        Mumps
DESCRIPTION Mumps is an acute systemic viral infection classically manifested by inflammation of parotid glands and fever. Mortality is rare, but it often accompanied by more serious complications such as aseptic meningitis, pediatric deafness, and orchitis.
CATEGORY    Infectious disease
PATHOGEN    Mumps virus [GN:T40034]
DRUG        Mumps vaccine [DR:D05089 D06486]
DBLINKS     ICD-10: B26
            MeSH: D009107
            MedlinePlus: 001557
REFERENCE   PMID:16750064
  AUTHORS   Campos-Outcalt D
  TITLE     Mumps epidemic in 2006: are you prepared to detect and prevent it?
  JOURNAL   J Fam Pract 55:500-2 (2006)
REFERENCE   PMID:21120728
  AUTHORS   MacDonald N, Hatchette T, Elkout L, Sarwal S
  TITLE     Mumps is back: why is mumps eradication not working?
  JOURNAL   Adv Exp Med Biol 697:197-220 (2011)
REFERENCE   PMID:19815120 (descirption)
  AUTHORS   Barskey AE, Glasser JW, LeBaron CW
  TITLE     Mumps resurgences in the United States: A historical perspective on unexpected elements.
  JOURNAL   Vaccine 27:6186-95 (2009)
///
ENTRY       H00397                      Disease
NAME        Ross River fever
DESCRIPTION Ross River fever is a mosquito-borne alphavirus infection that is endemic and enzootic in Australia and the Western Pacific region. Approximately 5000 human cases are reported annually. The infection is not fatal, but rheumatic symptoms in addition to fever and rash can persist for months to years.
CATEGORY    Infectious disease
PATHOGEN    Ross River virus [GN:T40071]
COMMENT     Vectors: Aedes vigilax, A. camptorhynchus, and Culex annulirostris
DBLINKS     ICD-10: B33.1
REFERENCE   PMID:15923040 (description, env_factor)
  AUTHORS   Rulli NE, Suhrbier A, Hueston L, Heise MT, Tupanceska D, Zaid A, Wilmes A, Gilmore K, Lidbury BA, Mahalingam S
  TITLE     Ross River virus: molecular and cellular aspects of disease pathogenesis.
  JOURNAL   Pharmacol Ther 107:329-42 (2005)
REFERENCE   PMID:11585790 (description, comment)
  AUTHORS   Harley D, Sleigh A, Ritchie S
  TITLE     Ross River virus transmission, infection, and disease: a cross-disciplinary review.
  JOURNAL   Clin Microbiol Rev 14:909-32, table of contents (2001)
REFERENCE   PMID:11729067 (description)
  AUTHORS   Russell RC
  TITLE     Ross River virus: ecology and distribution.
  JOURNAL   Annu Rev Entomol 47:1-31 (2002)
///
ENTRY       H00398                      Disease
NAME        Influenza
DESCRIPTION Influenza is typically a self-limiting upper respiratory disease caused by three types of influenza viruses: influenza A, B, and C. Influenza A and B viruses cause highly contagious diseases whereas influenza C virus causes only mild upper respiratory tract illness. Influenza A virus is responsible for annual epidemics in humans with high mortality rates.
CATEGORY    Infectious disease
PATHOGEN    Influenza A virus (A/Puerto Rico/8/1934(H1N1)) [GN:T40035]
            Influenza A virus (A/Korea/426/1968(H2N2)) [GN:T40036]
            Influenza A virus (A/New York/392/2004(H3N2)) [GN:T40037]
            Influenza A virus (A/Hong Kong/1073/99(H9N2)) [GN:T40038]
            Influenza B virus [GN:T40039]
            Influenza C virus (C/Ann Arbor/1/50) [GN:T40040]
DRUG        Amantadine [DG:DG00860]
            Rimantadine [DG:DG00650]
            Ribavirin [DR:D00423]
            Zanamivir [DG:DG00664]
            Oseltamivir [DG:DG00665]
            Influenza vaccine [DG:DG00674]
DBLINKS     ICD-10: J10
            MeSH: D007251
            MedlinePlus: 000080
///
ENTRY       H00399                      Disease
NAME        Avian influenza;
            Bird flu;
            H5N1 flu
DESCRIPTION Influenza A virus exhibits the broad host spectrum (birds, humans, other mammals) and viruses that have been isolated from birds are termed avian influenza viruses. Avian influenza viruses can cross the species barrier into humans via direct contact with infected birds. Subtype H5N1 is a highly pathogenic avian influenza virus that causes a severe viral pneumonia. The infection is highly fatal (60% mortality).
CATEGORY    Infectious disease
PATHOGEN    Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) [GN:T40041]
DBLINKS     ICD-10: J09
            MeSH: D005585
            MedlinePlus: 007263
REFERENCE   PMID:22129374 (description)
  AUTHORS   Chmielewski R, Swayne DE
  TITLE     Avian influenza: public health and food safety concerns.
  JOURNAL   Annu Rev Food Sci Technol 2:37-57 (2011)
REFERENCE   PMID:17126960 (description)
  AUTHORS   Alexander DJ
  TITLE     An overview of the epidemiology of avian influenza.
  JOURNAL   Vaccine 25:5637-44 (2007)
///
ENTRY       H00400                      Disease
NAME        Parainfluenza infections
DESCRIPTION Human parainfluenza viruses (HPIV) are single-stranded RNA viruses belonging to the paramyxovirus family. They are the second most common causes of pediatric lower respiratory tract diseaseleading to hospitalization after respiratory syncytial virus. It can cause repeated infections throughout life, causing flu-like illness.
CATEGORY    Infectious disease
PATHOGEN    Human parainfluenza virus 1 [GN:T40043]
            Human parainfluenza virus 2 [GN:T40042]
            Human parainfluenza virus 3 [GN:T40044]
            Human parainfluenza virus 4 [GN:T40122]
DBLINKS     ICD-10: J12.2 J20.4
            MeSH: D018184
REFERENCE   PMID:21859271 (description, env_factor)
  AUTHORS   Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, Collins PL
  TITLE     Progress in the development of human parainfluenza virus vaccines.
  JOURNAL   Expert Rev Respir Med 5:515-26 (2011)
REFERENCE   PMID:18820572 (description)
  AUTHORS   Sato M, Wright PF
  TITLE     Current status of vaccines for parainfluenza virus infections.
  JOURNAL   Pediatr Infect Dis J 27:S123-5 (2008)
///
ENTRY       H00401                      Disease
NAME        Respiratory syncytial virus infection;
            RSV infection
DESCRIPTION Respiratory syncytial virus (RSV) of the Paramyxoviridae family is a major cause of acute lower respiratory tract illness in infants and young children. It affects the elderly and immunocompromised individuals as well. Although RSV was discovered half a century ago, no effective treatment for the infection exists.
CATEGORY    Infectious disease
PATHOGEN    Human respiratory syncytial virus [GN:T40045]
DRUG        Palivizumab (genetical recombination) [DR:D02737]
DBLINKS     ICD-10: J12.1 J20.5 J21.0
            MeSH: D018357
            MedlinePlus: 001564
REFERENCE   PMID:21171875 (description)
  AUTHORS   Krilov LR
  TITLE     Respiratory syncytial virus disease: update on treatment and prevention.
  JOURNAL   Expert Rev Anti Infect Ther 9:27-32 (2011)
REFERENCE   PMID:21963675 (description)
  AUTHORS   Collins PL, Melero JA
  TITLE     Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.
  JOURNAL   Virus Res 162:80-99 (2011)
REFERENCE   PMID:21524347 (description)
  AUTHORS   Chang J
  TITLE     Current progress on development of respiratory syncytial virus vaccine.
  JOURNAL   BMB Rep 44:232-7 (2011)
///
ENTRY       H00402                      Disease
NAME        Severe acute respiratory syndrome;
            SARS
DESCRIPTION Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by SARS coronavirus. SARS is a serious form of pneumonia and its rapid global spread has come to the public attention.
CATEGORY    Infectious disease
PATHOGEN    SARS coronavirus [GN:T40069]
DBLINKS     ICD-10: U04
            MeSH: D045169
            MedlinePlus: 007192
REFERENCE   PMID:20801001 (description)
  AUTHORS   Anderson LJ, Tong S
  TITLE     Update on SARS research and other possibly zoonotic coronaviruses.
  JOURNAL   Int J Antimicrob Agents 36 Suppl 1:S21-5 (2010)
REFERENCE   PMID:22094080 (description)
  AUTHORS   Weiss SR, Leibowitz JL
  TITLE     Coronavirus pathogenesis.
  JOURNAL   Adv Virus Res 81:85-164 (2011)
REFERENCE   PMID:14733734 (description)
  AUTHORS   Navas-Martin S, Weiss SR
  TITLE     SARS: lessons learned from other coronaviruses.
  JOURNAL   Viral Immunol 16:461-74 (2003)
REFERENCE   PMID:20674795 (description)
  AUTHORS   Hui DS, Chan PK
  TITLE     Severe acute respiratory syndrome and coronavirus.
  JOURNAL   Infect Dis Clin North Am 24:619-38 (2010)
///
ENTRY       H00403                      Disease
NAME        Disorders of nucleotide excision repair, including:
            Xeroderma pigmentosum (XP);
            Cockayne syndrome (CS);
            UV-sensitive syndrome (UVS);
            Trichothiodystrophy (TTD);
            Cerebro-oculo-facio-skeletal syndrome (COFS);
            XFE progeroid syndrome
DESCRIPTION Mutations in genes on the nucleotide excision repair pathway are associated with diseases, such as xeroderma pigmentosum (XP), Cockayne syndrome (CS) and trichothiodystrophy (TTD). XP is caused by mutations in XPA, ERCC3/XPB, XPC, ERCC2/XPD, DDB2/XPE, ERCC4/XPF, ERCC5/XPG and POLH. XP is classified into eight genetic complementation groups by the present. In this inside, 7groups from the XP-A group to the G group show the abnormality in NER. The symptoms of XP begin in early life. Severe sunburn and blistering occurs in a half of patients, and all show early extensive freckling. Cancer incidence for individuals with XP under 20 years of age is 2,000 times as high as incidence in the general population. Neurodegeneration can be correlated with mutations in specific XP genes (XPA, ERCC3, ERCC2 and ERCC5). Some patients of XP- A develop neurologic symptoms or a more severe clinical phenotype known as de Sanctis-Cacchione syndrome, associated with mutations in the ERCC6 gene. CS is caused by mutations in ERCC8/CSA, ERCC6/CSB. CS is predominantly a developmental and neurological disorder. It results in a severely reduced lifespan but is not linked to an increased incidence of cancer. The three of the XP genes (ERCC2, ERCC3, and ERCC5) are also found to be mutated XP/CS patients (exhibiting both XP and Cockayne's symptoms). ERCC6 is a cause of UV-sensitive syndrome (UVS) which is characterized by photosensitivity and mild freckling but without neurological abnormalities or skin tumors. TTD is a premature aging syndrome, with the hallmark feature of brittle hair and nails, ichthyosis, and progressive mental and physical retardation. Within photo-sensitive TTD, three TFIIH coding genes (ERCC2, ERCC3, and TTDA/GTF2H5) are implicated. Cerebro-oculo-facio-skeletal (COFS) syndrome is rare autosomal recessive disorder with microcephaly, severe mental retardation, and death in childhood. COFS can result from mutations in ERCC1, ERCC2, ERCC5 and ERCC6.
CATEGORY    Congenital disorder of DNA repair systems
GENE        (XPA) XPA; xeroderma pigmentosum, complementation group A [HSA:7507] [KO:K10847]
            (XPB, XP/CS, TTD) ERCC3; DNA excision repair protein ERCC-3 [HSA:2071] [KO:K10843]
            (XPC) XPC; xeroderma pigmentosum, complementation group C [HSA:7508] [KO:K10838]
            (XPD, XP/CS, TTD) ERCC2; DNA excision repair protein ERCC-2 [HSA:2068] [KO:K10844]
            (XPE) DDB2; damage-specific DNA binding protein 2 [HSA:1643] [KO:K10140]
            (XPE-2) DDB1; damage-specific DNA binding protein 1 [HSA:1642] [KO:K10610] 
            (XPF) ERCC4; DNA excision repair protein ERCC-4 [HSA:2072] [KO:K10848]
            (XPG, XP/CS, COFS3) ERCC5; DNA excision repair protein ERCC-5 [HSA:2073] [KO:K10846]
            (XPV) POLH; DNA polymerase eta [HSA:5429] [KO:K03509]
            (CSA) ERCC8; DNA excision repair protein ERCC-8 [HSA:1161] [KO:K10570]
            (CSB, DSC, UVS, COFS1) ERCC6; DNA excision repair protein ERCC-6 [HSA:2074] [KO:K10841]
            (TTD) GTF2H5; general transcription factor IIH, polypeptide 5 [HSA:404672] [KO:K10845]
            (COFS4) ERCC1; DNA excision repair protein ERCC-1 [HSA:2067] [KO:K10849]
DBLINKS     ICD-10: Q82.1 Q87.1
            MeSH: D014983 D003057 C563466 D054463
            OMIM: 278700 610651 278720 278730 278740 278760 278780 278750 216400 133540 278800 600630 601675 214150 610756 610758 610965
REFERENCE   PMID:19809470
  AUTHORS   Cleaver JE, Lam ET, Revet I
  TITLE     Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity.
  JOURNAL   Nat Rev Genet 10:756-68 (2009)
REFERENCE   PMID:11710928 (XP and TTD)
  AUTHORS   Queille S, Drougard C, Sarasin A, Daya-Grosjean L
  TITLE     Effects of XPD mutations on ultraviolet-induced apoptosis in relation to skin cancer-proneness in repair-deficient syndromes.
  JOURNAL   J Invest Dermatol 117:1162-70 (2001)
REFERENCE   PMID:11443545 (COFS)
  AUTHORS   Graham JM Jr, Anyane-Yeboa K, Raams A, Appeldoorn E, Kleijer WJ, Garritsen VH, Busch D, Edersheim TG, Jaspers NG
  TITLE     Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy.
  JOURNAL   Am J Hum Genet 69:291-300 (2001)
REFERENCE   PMID:15220921 (TTD)
  AUTHORS   Giglia-Mari G, Coin F, Ranish JA, Hoogstraten D, Theil A, Wijgers N, Jaspers NG, Raams A, Argentini M, van der Spek PJ, Botta E, Stefanini M, Egly JM, Aebersold R, Hoeijmakers JH, Vermeulen W
  TITLE     A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A.
  JOURNAL   Nat Genet 36:714-9 (2004)
REFERENCE   PMID:18339586 (TTD and CS)
  AUTHORS   Brooks PJ, Cheng TF, Cooper L
  TITLE     Do all of the neurologic diseases in patients with DNA repair gene mutations result from the accumulation of DNA damage?
  JOURNAL   DNA Repair (Amst) 7:834-48 (2008)
REFERENCE   PMID:20221251 (XFE progeroid syndrome)
  AUTHORS   Ahmad A, Enzlin JH, Bhagwat NR, Wijgers N, Raams A, Appledoorn E, Theil AF, J Hoeijmakers JH, Vermeulen W, J Jaspers NG, Scharer OD, Niedernhofer LJ
  TITLE     Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.
  JOURNAL   PLoS Genet 6:e1000871 (2010)
///
ENTRY       H00404                      Disease
NAME        Erythema infectiosum;
            Fifth disease
DESCRIPTION Erythema infectiosum, or fifth disease, is a benign pediatric condition caused by B19 parvovirus. It is a mild, self-limiting 'slapped-cheek' facial rash with low-grade fever and malaise in immunocompetent children. However, B19 parvovirus is associated with a wide clinical spectrum ranging from thrombocytopenia and neurological manifestations in immunocompromised patients and intrauterine fetal death in primary infected pregnant women.
CATEGORY    Infectious disease
PATHOGEN    Human parvovirus B19 [GN:T40084]
MARKER      IgM against B19 (radioimmunoassay, ELISA)
DBLINKS     ICD-10: B08.3
            MeSH: D016731
            MedlinePlus: 000977
REFERENCE   PMID:16502203 (description, env_factor, marker)
  AUTHORS   Vafaie J, Schwartz RA
  TITLE     Erythema infectiosum.
  JOURNAL   J Cutan Med Surg 9:159-61 (2005)
REFERENCE   PMID:16961667 (description)
  AUTHORS   Broliden K, Tolfvenstam T, Norbeck O
  TITLE     Clinical aspects of parvovirus B19 infection.
  JOURNAL   J Intern Med 260:285-304 (2006)
REFERENCE   PMID:21351281 (description)
  AUTHORS   de Jong EP, Walther FJ, Kroes AC, Oepkes D
  TITLE     Parvovirus B19 infection in pregnancy: new insights and management.
  JOURNAL   Prenat Diagn 31:419-25 (2011)
///
ENTRY       H00405                      Disease
NAME        Marburg disease
DESCRIPTION Marburg disease is a severe, haemorrhagic, febrile illness caused by the Marburg viruse, a member of the Filoviridae family that includes Ebola virus. It can spread person-to-person and manifests as abrupt fever, headache, nausea and muscle pain followed by diarrhoea.
CATEGORY    Infectious disease
PATHOGEN    Marburg marburgvirus [GN:T40015]
DBLINKS     ICD-10: A98.3
            MeSH: D008379
REFERENCE   PMID:21722250 (description)
  AUTHORS   Leroy EM, Gonzalez JP, Baize S
  TITLE     Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa.
  JOURNAL   Clin Microbiol Infect 17:964-76 (2011)
///
ENTRY       H00406                      Disease
NAME        Acquired immunodeficiency syndrome (AIDS)
DESCRIPTION Since the discovery in 1980s, HIV/AIDS has become the most important infectious disease globally. Many of the clinical features of HIV/AIDS can be ascribed to the profound immune deficiency in patients. HIV infection also increases the risk of autoimmune diseases and malignancies such as non-Hodgkin's lymphoma and Kaposi's sarcoma.
CATEGORY    Infectious disease; Immune system disease
PATHOGEN    Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
DBLINKS     ICD-10: B20 B21 B22 B23 B24
REFERENCE   PMID:22303636
  AUTHORS   Duesberg PH, Mandrioli D, McCormack A, Nicholson JM, Rasnick D, Fiala C, Koehnlein C, Bauer HH, Ruggiero M
  TITLE     AIDS since 1984: no evidence for a new, viral epidemic--not even in Africa.
  JOURNAL   Ital J Anat Embryol 116:73-92 (2011)
///
ENTRY       H00407                      Disease
NAME        Peroxisomal beta-oxidation enzyme deficiency, including:
            Acyl-CoA oxidase (ACOX) deficiency;
            D-bifunctional protein (DBP) deficiency;
            Perrault syndrome;
            Sterol carrier protein X (SCPx) deficiency;
            2-Methylacyl-CoA racemase (AMCR) deficiency;
            Hypercholanemia
DESCRIPTION Peroxisomal beta-oxidation enzyme deficiency is a group of inherited peroxisomal diseases caused by mutation of one of genes that encode peroxisomal fatty acid beta-oxidation system enzymes. The system includes straight-chain acyl-CoA oxidase (ACOX1), 2-methylacyl CoA racemase (AMACR), D-bifunctional protein (DBP) and sterol carrier protein X (SCPx). It is known that some types of fatty acids including very-long-chain fatty acids (VLCFA), branched-chain fatty acid, and the bile acid synthesis intermediates, rely fully on peroxisomes for beta-oxidation. The enzyme defects result in the accumulation of these fatty acids in many organs. The clinical manifestations mimic those of the Zellweger syndrome spectrum. [DS:H00205]
CATEGORY    Inherited metabolic disease; Peroxisomal disease
GENE        ACOX1; acyl-CoA oxidase 1 [HSA:51] [KO:K00232]
            AMACR; alpha-methylacyl-CoA racemase [HSA:23600] [KO:K01796]
            SCL2; sterol carrier protein 2 [HSA:6342] [KO:K08764]
            HSD17B4; D-bifunctional protein [HSA:3295] [KO:K12405]
            BAAT; bile acid-CoA:amino acid N-acyltransferase [HSA:570] [KO:K00659]
MARKER      (ACOX1, DBP) increased VLCFA
            (SCPx, AMACR) increased phytanic acid [CPD:C01607] and pristanic acid
DBLINKS     ICD-10: E71.3
            MeSH: C536662 C537286 C565768 C535444 C564336
            OMIM: 264470 261515 614307 214950 607748 233400
REFERENCE   PMID:17347916
  AUTHORS   Shimozawa N
  TITLE     Molecular and clinical aspects of peroxisomal diseases.
  JOURNAL   J Inherit Metab Dis 30:193-7 (2007)
REFERENCE   PMID:16376506
  AUTHORS   Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T, Kojidani T, Osumi T, Fukao T, Kondo N
  TITLE     Aberrant peroxisome morphology in peroxisomal beta-oxidation enzyme deficiencies.
  JOURNAL   Brain Dev 28:287-92 (2006)
REFERENCE   PMID:20064629
  AUTHORS   Wanders RJ, Ferdinandusse S, Brites P, Kemp S
  TITLE     Peroxisomes, lipid metabolism and lipotoxicity.
  JOURNAL   Biochim Biophys Acta (2010)
///
ENTRY       H00408                      Disease
NAME        Type I diabetes mellitus
DESCRIPTION The majority of type 1 diabetes mellitus (T1DM) cases are believed to arise from an inflammatory, autoimmune attack against the beta cells in the pancreas, which consequently leads to the failure of insulin-mediated blood glucose regulation in the body. T1DM signs and symptoms can come on quickly and may include increased thirst and frequent urination, fatigue, weight loss and so on. It is recognized that both genetic and environmental determinants are important in defining disease risk. The HLA class II genes are most strongly associated with T1DM. Another plausible candidate genes are INS, CTLA4 and PTPN22. The disease may be a result of variations in several susceptibility genes, with the majority only contributing weak effects.
CATEGORY    Metabolic disease; Immune system disease; Endocrine disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
            HLA-DQA1 (polymorphism) [HSA:3117] [KO:K06752]
            INS (polymorphism) [HSA:3630] [KO:K04526]
            CTLA-4 (polymorphism) [HSA:1493] [KO:K06538]
            PTPN22 (polymorphism) [HSA:26191] [KO:K18024]
            IL-2RA (polymorphism) [HSA:3559] [KO:K05068]
            PTPN2 (polymorphism) [HSA:5771] [KO:K18026]
            ERBB3 (polymorphism) [HSA:2065] [KO:K05084]
            IL2 - IL21 (intergenic region polymorphism) [HSA:3558 59067] [KO:K05429 K05434]
            IFIH1 (polymorphism) [HSA:64135] [KO:K12647]
            CLEC16A (polymorphism) [HSA:23274] [KO:K19513]
            BACH2 (polymorphism) [HSA:60468] [KO:K09042]
            PRKCQ (polymorphism) [HSA:5588] [KO:K18052]
            CTSH (polymorphism) [HSA:1512] [KO:K01366]
            C1QTNF6 (polymorphism) [HSA:114904] [KO:K19470]
            SH2B3 (polymorphism) [HSA:10019] [KO:K12459]
            C12orf30 (polymorphism) [HSA:80018] [KO:K17973]
            CD226 (polymorphism) [HSA:10666] [KO:K06567]
            ITPR3 (polymorphism) [HSA:3710] [KO:K04960]
            CYP27B1 (polymorphism) [HSA:1594] [KO:K07438]
ENV_FACTOR  Congenital rubella infection
            Cow's milk proteins
            Deficiency of vitamin D
            N-Nitroso compounds
PATHOGEN    Enterovirus (polioviruses, coxsackievirus B serotypes)
MARKER      GAD65
            IA2-Ab
            IAA
            ICA
DRUG        Insulin [DR:D00085]
DBLINKS     ICD-10: E10
            MeSH: D003922
            OMIM: 601942 601388 125852 612520
REFERENCE   PMID:19369670 (gene)
  AUTHORS   Concannon P, Rich SS, Nepom GT
  TITLE     Genetics of type 1A diabetes.
  JOURNAL   N Engl J Med 360:1646-54 (2009)
REFERENCE   PMID:18482868 (gene)
  AUTHORS   Ounissi-Benkalha H, Polychronakos C
  TITLE     The molecular genetics of type 1 diabetes: new genes and emerging mechanisms.
  JOURNAL   Trends Mol Med 14:268-75 (2008)
REFERENCE   PMID:19232167 (gene)
  AUTHORS   Bergholdt R
  TITLE     Understanding type 1 diabetes genetics - approaches for identification of susceptibility genes in multi-factorial diseases.
  JOURNAL   Dan Med Bull 56:1-39 (2009)
REFERENCE   PMID:19884899 (gene)
  AUTHORS   Handel AE, Handunnetthi L, Ebers GC, Ramagopalan SV
  TITLE     Type 1 diabetes mellitus and multiple sclerosis: common etiological features.
  JOURNAL   Nat Rev Endocrinol 5:655-64 (2009)
REFERENCE   PMID:17554260
  AUTHORS   Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tirgoviste C, Simmonds MJ, Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG
  TITLE     Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.
  JOURNAL   Nat Genet 39:857-64 (2007)
REFERENCE   PMID:18978792 (gene)
  AUTHORS   Cooper JD, Smyth DJ, Smiles AM, Plagnol V, Walker NM, Allen JE, Downes K, Barrett JC, Healy BC, Mychaleckyj JC, Warram JH, Todd JA
  TITLE     Meta-analysis of genome-wide association study data identifies additional type 1  diabetes risk loci.
  JOURNAL   Nat Genet 40:1399-401 (2008)
REFERENCE   PMID:16475896 (marker)
  AUTHORS   Seissler J, Scherbaum WA
  TITLE     Autoimmune diagnostics in diabetes mellitus.
  JOURNAL   Clin Chem Lab Med 44:133-7 (2006)
REFERENCE   PMID:12116173 (environmental factor)
  AUTHORS   Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M
  TITLE     Environmental factors in the etiology of type 1 diabetes.
  JOURNAL   Am J Med Genet 115:18-29 (2002)
REFERENCE   PMID:17203405 (environmental factor)
  AUTHORS   Peng H, Hagopian W
  TITLE     Environmental factors in the development of Type 1 diabetes.
  JOURNAL   Rev Endocr Metab Disord 7:149-62 (2006)
///
ENTRY       H00409                      Disease
NAME        Type II diabetes mellitus
DESCRIPTION Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia due to insulin resistance of peripheral tissues (skeletal muscle, liver, adipose tissue) and insufficient compensatory insulin secretion by pancreatic beta cells. Both insulin resistance and beta cell dysfunction are thought to result from the complex interplay of many different pathways under the combined control of environmental and genetic factors. It is accepted that T2DM results from population aging and adverse environmental factors of the modern world which favor the development of obesity.
CATEGORY    Metabolic disease; Endocrine disease
GENE        CDKN2A (polymorphism) [HSA:1029] [KO:K06621]
            CDKN2B (polymorphism) [HSA:1030] [KO:K04685]
            IGF2BP2 (polymorphism) [HSA:10644] [KO:K17392]
            CAPN10 (polymorphism) [HSA:11132] [KO:K08579]
            SLC30A8 (polymorphism) [HSA:169026] [KO:K14695]
            JAZF1 (polymorphism) [HSA:221895] [KO:K19495]
            HHEX (polymorphism) [HSA:3087] [KO:K08024]
            KCNJ11 (polymorphism) [HSA:3767] [KO:K05004]
            KCNQ1 (polymorphism) [HSA:3784] [KO:K04926]
            MTNR1B (polymorphism) [HSA:4544] [KO:K04286]
            NOTCH2 (polymorphism) [HSA:4853] [KO:K20994]
            ENPP1 (polymorphism) [HSA:5167] [KO:K01513]
            PPARG (polymorphism) [HSA:5468] [KO:K08530]
            CDKAL1 (polymorphism) [HSA:54901] [KO:K15865]
            ADAMTS9 (polymorphism) [HSA:56999] [KO:K08624]
            HNF1B (polymorphism) [HSA:6928] [KO:K08034]
            TCF7L2 (polymorphism) [HSA:6934] [KO:K04491]
            WFS1 (polymorphism) [HSA:7466] [KO:K14020]
            FTO (polymorphism) [HSA:79068] [KO:K19469]
DRUG        Glibenclamide [DR:D00336] (sulfonylureas)
            Metformin [DR:D00944] (biguanides)
            Acarbose [DR:D00216] (alpha-glucosidase inhibitors)
            Pioglitazone [DR:D00945] (thiazolidinediones)
            Nateglinide [DR:D01111] (glinides)
            Glybuzole [DR:D01210] (sulfonamides)
DBLINKS     ICD-10: E11
            MeSH: D003924
            OMIM: 125853 601283
REFERENCE   PMID:19749172 (gene)
  AUTHORS   Staiger H, Machicao F, Fritsche A, Haring HU
  TITLE     Pathomechanisms of type 2 diabetes genes.
  JOURNAL   Endocr Rev 30:557-85 (2009)
REFERENCE   PMID:18782870 (gene)
  AUTHORS   Florez JC
  TITLE     Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008.
  JOURNAL   J Clin Endocrinol Metab 93:4633-42 (2008)
REFERENCE   PMID:18762020 (gene)
  AUTHORS   Doria A, Patti ME, Kahn CR
  TITLE     The emerging genetic architecture of type 2 diabetes.
  JOURNAL   Cell Metab 8:186-200 (2008)
///
ENTRY       H00410                      Disease
NAME        Maturity onset diabetes of the young (MODY)
DESCRIPTION Maturity-onset diabetes of the young (MODY) is a genetically and clinically heterogeneous subtype of familial diabetes mellitus characterized by autosomal dominant inheritance, early onset before 25 years of age and primary insulin secretion defects. Mutations in six genes, encoding the glucose sensor enzyme glucokinase and five transcription factors that participate in a regulatory network essential for adult beta cell function, cause most of the MODY cases.
CATEGORY    Metabolic disease; Endocrine disease
GENE        (MODY1) HNF4A [HSA:3172] [KO:K07292]
            (MODY2) GCK [HSA:2645] [KO:K12407]
            (MODY3) TCF1 [HSA:6927] [KO:K08036]
            (MODY4) PDX1 [HSA:3651] [KO:K07594]
            (MODY5) TCF2 [HSA:6928] [KO:K08034]
            (MODY6) NEUROD1 [HSA:4760] [KO:K08033]
            (MODY7) KLF11 [HSA:8462] [KO:K09209]
            (MODY8) CEL [HSA:1056] [KO:K12298]
            (MODY9) PAX4 [HSA:5078] [KO:K08032]
            (MODY10) INS [HSA:3630] [KO:K04526]
            (MODY11) BLK [HSA:640] [KO:K08890]
DRUG        Insulin [DR:D00085]
DBLINKS     ICD-10: E13
            MeSH: C565101 C564219 C563933 C563451 C535520 C565231 C566466 C565225 C567393
            OMIM: 606391 125850 138079 600496 606392 137920 606394 610508 609812 612225 613370 613375
REFERENCE   PMID:18436708 (gene)
  AUTHORS   Vaxillaire M, Froguel P
  TITLE     Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes.
  JOURNAL   Endocr Rev 29:254-64 (2008)
REFERENCE   PMID:11979019 (gene)
  AUTHORS   Velho G, Robert JJ
  TITLE     Maturity-onset diabetes of the young (MODY): genetic and clinical characteristics.
  JOURNAL   Horm Res 57 Suppl 1:29-33 (2002)
REFERENCE   PMID:15774581 (MODY7)
  AUTHORS   Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly E, Vaillant E, Benmezroua Y, Durand E, Bakaher N, Delannoy V, Vaxillaire M, Cook T, Dallinga-Thie GM, Jansen H, Charles MA, Clement K, Galan P, Hercberg S, Helbecque N, Charpentier G, Prentki M, Hansen T, Pedersen O, Urrutia R, Melloul D, Froguel P
  TITLE     Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function.
  JOURNAL   Proc Natl Acad Sci U S A 102:4807-12 (2005)
REFERENCE   PMID:16369531 (MODY8)
  AUTHORS   Raeder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, Nermoen I, Eide SA, Grevle L, Bjorkhaug L, Sagen JV, Aksnes L, Sovik O, Lombardo D, Molven A, Njolstad PR
  TITLE     Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction.
  JOURNAL   Nat Genet 38:54-62 (2006)
REFERENCE   PMID:17426099 (MODY9)
  AUTHORS   Plengvidhya N, Kooptiwut S, Songtawee N, Doi A, Furuta H, Nishi M, Nanjo K, Tantibhedhyangkul W, Boonyasrisawat W, Yenchitsomanus PT, Doria A, Banchuin N
  TITLE     PAX4 mutations in Thais with maturity onset diabetes of the young.
  JOURNAL   J Clin Endocrinol Metab 92:2821-6 (2007)
REFERENCE   PMID:20226046 (MODY10)
  AUTHORS   Boesgaard TW, Pruhova S, Andersson EA, Cinek O, Obermannova B, Lauenborg J, Damm P, Bergholdt R, Pociot F, Pisinger C, Barbetti F, Lebl J, Pedersen O, Hansen T
  TITLE     Further evidence that mutations in INS can be a rare cause of Maturity-Onset Diabetes of the Young (MODY).
  JOURNAL   BMC Med Genet 11:42 (2010)
REFERENCE   PMID:19667185 (MODY11)
  AUTHORS   Borowiec M, Liew CW, Thompson R, Boonyasrisawat W, Hu J, Mlynarski WM, El Khattabi I, Kim SH, Marselli L, Rich SS, Krolewski AS, Bonner-Weir S, Sharma A, Sale M, Mychaleckyj JC, Kulkarni RN, Doria A
  TITLE     Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction.
  JOURNAL   Proc Natl Acad Sci U S A 106:14460-5 (2009)
///
ENTRY       H00411                      Disease
NAME        Hepatitis A;
            Hepatitis A virus (HAV) infection
DESCRIPTION Hepatitis A accounts for 20 to 25% of clinically apparent hepatitis cases worldwide. It is transmitted by the fecal-oral route and in countries with poor sanitary conditions, the population acquires infection in childhood. In these cases, infection causes only minimal illness. In developed countries with good sanitation, people sometimes acquire hepatitis A by travelling to endemic areas, and infection in adults causes severe icteric hepatitis.
CATEGORY    Infectious disease
PATHOGEN    Hepatovirus A [GN:T40068]
DBLINKS     ICD-10: B15
            MeSH: D006506
            MedlinePlus: 000278
REFERENCE   PMID:8182265 (description)
  AUTHORS   Shapiro CN, Margolis HS
  TITLE     Worldwide epidemiology of hepatitis A virus infection.
  JOURNAL   J Hepatol 18 Suppl 2:S11-4 (1993)
REFERENCE   PMID:22008459 (description)
  AUTHORS   Mohd Hanafiah K, Jacobsen KH, Wiersma ST
  TITLE     Challenges to mapping the health risk of hepatitis A virus infection.
  JOURNAL   Int J Health Geogr 10:57 (2011)
REFERENCE   PMID:8882375 (description)
  AUTHORS   Strader DB, Seeff LB
  TITLE     New hepatitis A vaccines and their role in prevention.
  JOURNAL   Drugs 51:359-66 (1996)
///
ENTRY       H00412                      Disease
NAME        Hepatitis B;
            Hepatitis B virus (HBV) infection
DESCRIPTION Hepatitis B is a global health problem, estimated to affect more than 350 million people. The carrier rate is high in sub-Saharan Africa and parts of Asia (8-20%). Chronic infection can lead to significant irreversible liver damage, such as end stage cirrhosis. The infection is also linked to the incidence of hepatocellular carcinoma.
CATEGORY    Infectious disease
PATHOGEN    Hepatitis B virus (HBV) [GN:T40004]
DRUG        PEG-IFN-alpha [DR:D02747]
            Entecavir [DG:DG00661]
            Tenofovir [DG:DG01223]
            Lamivudine [DR:D00353]
            Ganciclovir [DG:DG00646]
DBLINKS     ICD-10: B16
            MeSH: D006509
            MedlinePlus: 000279
REFERENCE   PMID:22252919 (description, drug)
  AUTHORS   Nebbia G, Peppa D, Maini MK
  TITLE     Hepatitis B infection: current concepts and future challenges.
  JOURNAL   QJM 105:109-13 (2012)
REFERENCE   PMID:12000599 (description, drug)
  AUTHORS   Pramoolsinsup C
  TITLE     Management of viral hepatitis B.
  JOURNAL   J Gastroenterol Hepatol 17 Suppl:S125-45 (2002)
REFERENCE   PMID:22171125 (description)
  AUTHORS   Tan YJ
  TITLE     Hepatitis B virus infection and the risk of hepatocellular carcinoma.
  JOURNAL   World J Gastroenterol 17:4853-7 (2011)
///
ENTRY       H00413                      Disease
NAME        Hepatitis C;
            Hepatitis C virus (HCV) infection
DESCRIPTION Hepatitis C is a blood-borne viral disease caused by Hepatitis C virus (HCV) belonging to the Flaviviridae family. HCV is a major cause of persistent liver disease, with approximately 170 million individuals infected worldwide. Up to 80% of patients will have chronic infection, 30-40 percent of these patients develop into degenerative liver disease including fibrosis and cirrhosis over 20 years after infection. Some of these patients will develop hepatocellular carcinoma. Treatment of chronic hepatitis C virus infections has undergone a huge transformation in recent years. Although interferon-based therapies have been the mainstay of treatment for HCV infection, new interferon-free therapies have recently been approved.
CATEGORY    Infectious disease
PATHOGEN    Hepatitis C virus (HCV) [GN:T40066]
DRUG        Ribavirin [DR:D00423]
            Telaprevir [DR:D09012]
            Boceprevir [DR:D08876]
            Simeprevir sodium [DR:D10469]
            Vaniprevir [DR:D09987]
            Asunaprevir [DR:D10093]
            Daclatasvir dihydrochloride [DR:D10105]
            Sofosbuvir [DR:D10366]
            Ledipasvir - sofosbuvir mixt [DR:D10578]
            Ombitasvir - paritaprevir -ritonavir mixt [DR:D10745]
            Dasabuvir - ombitasvir - paritaprevir -ritonavir mixt [DR:D10582]
            Elbasvir - grazoprevir mixt [DR:D10778]
            Interferon alfa [DR:D03305]
            Interferon beta [DR:D03304]
            Interferon alfa-2b [DR:D02745]
            Peginterferon alfa-2b [DR:D02748]
            Peginterferon alfa-2a [DR:D02747]
DBLINKS     ICD-10: B17.1
            MeSH: D006526
            MedlinePlus: 000284
///
ENTRY       H00414                      Disease
NAME        Hepatitis D;
            Hepatitis delta virus (HDV) infection
DESCRIPTION Hepatitis D virus (HDV) infection is only found in a subgroup of individuals simultaneously infected with the hepatitis B virus (HBV), because HDV is a defective RNA agent needing the presence of HBV to produce its own coat. HDV may worsen an existing chronic hepatitis B.
CATEGORY    Infectious disease
PATHOGEN    Hepatitis delta virus [GN:T40085]
DRUG        PEG-IFN-alpha [DR:D02747]
DBLINKS     ICD-10: B18
            MeSH: D003699
            MedlinePlus: 000216
REFERENCE   PMID:20880077 (description)
  AUTHORS   Pascarella S, Negro F
  TITLE     Hepatitis D virus: an update.
  JOURNAL   Liver Int 31:7-21 (2011)
REFERENCE   PMID:17098688 (description, drug)
  AUTHORS   Hsieh TH, Liu CJ, Chen DS, Chen PJ
  TITLE     Natural course and treatment of hepatitis D virus infection.
  JOURNAL   J Formos Med Assoc 105:869-81 (2006)
///
ENTRY       H00415                      Disease
NAME        Hepatitis E;
            Hepatitis E virus (HEV) infection
DESCRIPTION Hepatitis E is an infection with hepatitis E virus (HEV) that is transmitted through fecal-oral route. The disease is highly endemic in developing countries with poor sanitation and contamination of drinking water. Its case-fatality rates are in the range of 0.5% to 4%. Hepatitis E manifests as acute icteric hepatitis in high-endemicity areas. However, in recent years, cases of hepatitis E have been observed in low-endemicity areas as well, including chronic hepatitis E with higher mortality rate.
CATEGORY    Infectious disease
PATHOGEN    Hepatitis E virus (HEV) [GN:T40067]
            Pregnancy
DBLINKS     ICD-10: B17.2
            MeSH: D016751
REFERENCE   PMID:19686410 (description, env_factor)
  AUTHORS   Aggarwal R, Naik S
  TITLE     Epidemiology of hepatitis E: current status.
  JOURNAL   J Gastroenterol Hepatol 24:1484-93 (2009)
REFERENCE   PMID:21458513 (description, env_factor)
  AUTHORS   Aggarwal R
  TITLE     Clinical presentation of hepatitis E.
  JOURNAL   Virus Res 161:15-22 (2011)
REFERENCE   PMID:21932388 (description)
  AUTHORS   Aggarwal R, Jameel S
  TITLE     Hepatitis E.
  JOURNAL   Hepatology 54:2218-26 (2011)
///
ENTRY       H00416                      Disease
NAME        Omsk hemorrhagic fever
DESCRIPTION Omsk hemorrhagic fever is an acute viral disease that was found in Omsk, west Siberia in Russia. It causes severe disease and death in farmers hunting muskrats. The disease presents with fever, headache, nausea, severe muscle pain, cough, and moderately severe hemorrhagic manifestations.
CATEGORY    Infectious disease
PATHOGEN    Omsk hemorrhagic fever virus [GN:T40058]
COMMENT     Vector: Dermacentor reticulatus (tick)
DBLINKS     ICD-10: A98.1
            MeSH: D006481
REFERENCE   PMID:20850178 (description, comment)
  AUTHORS   Ruzek D, Yakimenko VV, Karan LS, Tkachev SE
  TITLE     Omsk haemorrhagic fever.
  JOURNAL   Lancet 376:2104-13 (2010)
REFERENCE   PMID:18262042 (description)
  AUTHORS   Gould EA, Solomon T
  TITLE     Pathogenic flaviviruses.
  JOURNAL   Lancet 371:500-9 (2008)
///
ENTRY       H00417                      Disease
NAME        Alstrom syndrome (AS)
DESCRIPTION Alstrom syndrome (AS) is a rare autosomal recessive inherited disorder characterized by multiorgan dysfunction. AS shares several features with the common metabolic syndrome, namely obesity, hyperinsulinemia, and hypertriglyceridemia. A wide range of clinical variability is observed among individuals with AS, including among sibs. ALMS1 is the only gene currently known to be associated with AS. However, it is not yet known how this gene causes the disorder.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        ALMS1 [HSA:7840] [KO:K16741]
DBLINKS     ICD-10: E66.0 H35.5
            MeSH: D056769
            OMIM: 203800
REFERENCE   PMID:18154657
  AUTHORS   Joy T, Cao H, Black G, Malik R, Charlton-Menys V, Hegele RA, Durrington PN
  TITLE     Alstrom syndrome (OMIM 203800): a case report and literature review.
  JOURNAL   Orphanet J Rare Dis 2:49 (2007)
REFERENCE   PMID:17940554
  AUTHORS   Marshall JD, Beck S, Maffei P, Naggert JK
  TITLE     Alstrom syndrome.
  JOURNAL   Eur J Hum Genet 15:1193-202 (2007)
///
ENTRY       H00418                      Disease
NAME        Bardet-Biedl syndrome (BBS)
DESCRIPTION Bardet-Biedl syndrome (BBS) is a rare autosomal recessive disorder with genetic heterogeneity characterized by defects in multiple organ systems. The main features are retinal degeneration, obesity, hypogonadism, polydactyly, renal dysfunction, and mental retardation. BBS is typified by clinical variability observed both within and between families, which can be explained in part by the presence of second-site modifiers. Recent findings in genetic research have suggested that the BBS phenotype is largely associated with ciliary dysfunction.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        (BBS1) BBS1 [HSA:582] [KO:K16746]
            (BBS2) BBS2 [HSA:583] [KO:K16747]
            (BBS3) ARL6 [HSA:84100] [KO:K07951]
            (BBS4) BBS4 [HSA:585] [KO:K16531]
            (BBS5) BBS5 [HSA:129880] [KO:K16748]
            (BBS6) MKKS [HSA:8195] [KO:K09492]
            (BBS7) BBS7 [HSA:55212] [KO:K16749]
            (BBS8) TTC8 [HSA:123016] [KO:K16781]
            (BBS9) BBS9 [HSA:27241] [KO:K19398]
            (BBS10) BBS10 [HSA:79738] [KO:K19401]
            (BBS11) TRIM32 [HSA:22954] [KO:K10607]
            (BBS12) BBS12 [HSA:166379] [KO:K19402]
            (BBS13) MKS1 [HSA:54903] [KO:K19332]
            (BBS14) CEP290 [HSA:80184] [KO:K16533]
            (BBS15) WDPCP [HSA:51057]
            (BBS16) SDCCAG8 [HSA:10806] [KO:K16488]
            (BBS17) LZTFL1 [HSA:54585] [KO:K19400]
            (BBS18) BBIP1 [HSA:92482] [KO:K19399]
            (BBS19) IFT27 [HSA:11020] [KO:K07934]
DBLINKS     ICD-10: Q87.8
            MeSH: D020788
            OMIM: 209900
REFERENCE   PMID:14976158
  AUTHORS   Katsanis N
  TITLE     The oligogenic properties of Bardet-Biedl syndrome.
  JOURNAL   Hum Mol Genet 13 Spec No 1:R65-71 (2004)
REFERENCE   PMID:19252258
  AUTHORS   Zaghloul NA, Katsanis N
  TITLE     Mechanistic insights into Bardet-Biedl syndrome, a model ciliopathy.
  JOURNAL   J Clin Invest 119:428-37 (2009)
REFERENCE   PMID:20142850
  AUTHORS   Pereiro I, Valverde D, Pineiro-Gallego T, Baiget M, Borrego S, Ayuso C, Searby C, Nishimura D
  TITLE     New mutations in BBS genes in small consanguineous families with Bardet-Biedl syndrome: detection of candidate regions by homozygosity mapping.
  JOURNAL   Mol Vis 16:137-43 (2010)
REFERENCE   PMID:18327255
  AUTHORS   Leitch CC, Zaghloul NA, Davis EE, Stoetzel C, Diaz-Font A, Rix S, Alfadhel M, Lewis RA, Eyaid W, Banin E, Dollfus H, Beales PL, Badano JL, Katsanis N
  TITLE     Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome.
  JOURNAL   Nat Genet 40:443-8 (2008)
REFERENCE   PMID:20671153 (BBS15)
  AUTHORS   Kim SK, Shindo A, Park TJ, Oh EC, Ghosh S, Gray RS, Lewis RA, Johnson CA, Attie-Bittach T, Katsanis N, Wallingford JB
  TITLE     Planar cell polarity acts through septins to control collective cell movement and ciliogenesis.
  JOURNAL   Science 329:1337-40 (2010)
REFERENCE   PMID:22626039
  AUTHORS   Billingsley G, Vincent A, Deveault C, Heon E
  TITLE     Mutational analysis of SDCCAG8 in Bardet-Biedl syndrome patients with renal involvement and absent polydactyly.
  JOURNAL   Ophthalmic Genet 33:150-4 (2012)
REFERENCE   PMID:22510444
  AUTHORS   Marion V, Stutzmann F, Gerard M, De Melo C, Schaefer E, Claussmann A, Helle S, Delague V, Souied E, Barrey C, Verloes A, Stoetzel C, Dollfus H
  TITLE     Exome sequencing identifies mutations in LZTFL1, a BBSome and smoothened trafficking regulator, in a family with Bardet--Biedl syndrome with situs inversus and insertional polydactyly.
  JOURNAL   J Med Genet 49:317-21 (2012)
REFERENCE   PMID:24026985
  AUTHORS   Scheidecker S, Etard C, Pierce NW, Geoffroy V, Schaefer E, Muller J, Chennen K, Flori E, Pelletier V, Poch O, Marion V, Stoetzel C, Strahle U, Nachury MV, Dollfus H
  TITLE     Exome sequencing of Bardet-Biedl syndrome patient identifies a null mutation in the BBSome subunit BBIP1 (BBS18).
  JOURNAL   J Med Genet 51:132-6 (2014)
REFERENCE   PMID:24488770
  AUTHORS   Aldahmesh MA, Li Y, Alhashem A, Anazi S, Alkuraya H, Hashem M, Awaji AA, Sogaty S, Alkharashi A, Alzahrani S, Al Hazzaa SA, Xiong Y, Kong S, Sun Z, Alkuraya FS
  TITLE     IFT27, encoding a small GTPase component of IFT particles, is mutated in a consanguineous family with Bardet-Biedl syndrome.
  JOURNAL   Hum Mol Genet 23:3307-15 (2014)
///
ENTRY       H00419                      Disease
NAME        Congenital generalized lipodystrophy (CGL)
DESCRIPTION Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disease characterized by near total absence of adipose tissue from birth. Several metabolic alterations in carbohydrate (diabetes mellitus) and lipid metabolism and involvement of heart, bone and ovaries are also observed in this disease. Patients typically have low serum levels of leptin and adiponectin. Several genes were studied to identify the molecular alteration responsible for CGL, which have been found to contribute to lipid droplet formation in adipocytes.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease
GENE        (CGL1) AGPAT2 [HSA:10555] [KO:K13509]
            (CGL2) BSCL2 [HSA:26580] [KO:K19365]
            (CGL3) CAV1 [HSA:857] [KO:K06278]
            (CGL4) PTRF [HSA:284119] [KO:K19387]
DBLINKS     ICD-10: E88.1
            MeSH: D052497
            OMIM: 269700 608594 612526 613327
REFERENCE   PMID:19494770
  AUTHORS   Simha V, Garg A
  TITLE     Inherited lipodystrophies and hypertriglyceridemia.
  JOURNAL   Curr Opin Lipidol 20:300-8 (2009)
REFERENCE   PMID:19167372
  AUTHORS   Gomes KB, Pardini VC, Fernandes AP
  TITLE     Clinical and molecular aspects of Berardinelli-Seip Congenital Lipodystrophy (BSCL).
  JOURNAL   Clin Chim Acta 402:1-6 (2009)
REFERENCE   PMID:19162222
  AUTHORS   Garg A, Agarwal AK
  TITLE     Lipodystrophies: disorders of adipose tissue biology.
  JOURNAL   Biochim Biophys Acta 1791:507-13 (2009)
REFERENCE   PMID:19726876
  AUTHORS   Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, Park YE, Nonaka I, Hino-Fukuyo N, Haginoya K, Sugano H, Nishino I
  TITLE     Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy.
  JOURNAL   J Clin Invest 119:2623-33 (2009)
///
ENTRY       H00420                      Disease
NAME        Familial partial lipodystrophy (FPL), including the following four diseases:
            Kobberling-type lipodystrophy (FPLD1);
            Dunnigan-type lipodystrophy (FPLD2);
            Dunnigan-like lipodystrophy (FPLD3);
            AKT2 associated lipodystrophy
DESCRIPTION Familial partial lipodystrophy (FPL) is a rare autosomal dominant disorder characterized by variable loss of body fat from the extremities as well as from the truncal region. LMNA, PPARG and AKT2 have been identified in association with FPL. However, it is not yet known how these genes cause the disorder. Besides them, additional loci are likely as many FPL patients do not reveal any mutations in these genes. LMNA mutations may affect nuclear function, and may be involved in apoptosis and premature cell death of adipocytes, thus causing lipodystrophy. PPARG and AKT2 are regulators of adipocyte differentiation. AKT2 is also involved in postreceptor insulin signaling. Thus, mutations in these two genes could result in lipodystrophy. The reason why loss of fat is restricted to partial areas remains unknown.
CATEGORY    Metabolic disease; Skin and connective tissue disease
GENE        LMNA [HSA:4000] [KO:K12641]
            PPARG [HSA:5468] [KO:K08530]
            AKT2 [HSA:208] [KO:K04456]
            LMNB2 [HSA:84823] [KO:K07611]
DBLINKS     ICD-10: E88.1
            MeSH: D052496
            OMIM: 608600 151660 604367 164731 608709
REFERENCE   PMID:19494770
  AUTHORS   Simha V, Garg A
  TITLE     Inherited lipodystrophies and hypertriglyceridemia.
  JOURNAL   Curr Opin Lipidol 20:300-8 (2009)
REFERENCE   PMID:19162222
  AUTHORS   Garg A, Agarwal AK
  TITLE     Lipodystrophies: disorders of adipose tissue biology.
  JOURNAL   Biochim Biophys Acta 1791:507-13 (2009)
REFERENCE   PMID:12074822
  AUTHORS   Bhayana S, Hegele RA
  TITLE     The molecular basis of genetic lipodystrophies.
  JOURNAL   Clin Biochem 35:171-7 (2002)
REFERENCE   PMID:16826530
  AUTHORS   Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW, Durrington PN
  TITLE     Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy.
  JOURNAL   Am J Hum Genet 79:383-9 (2006)
///
ENTRY       H00421                      Disease
NAME        Mucopolysaccharidosis (MPS), including:
            Hurler-Scheie syndrome (type1) [DS:H00128];
            Hunter syndrome (type2) [DS:H00129];
            Sanfilippo syndrome (type3) [DS:H00130];
            Morquio syndrome (type4) [DS:H00123];
            Maroteaux-Lamy syndrome (type6) [DS:H00131];
            Sly syndrome (type7) [DS:H00132];
            Hyaluronidase deficiency (type9) [DS:H00133]
DESCRIPTION Mucopolysaccharidosis (MPS) is a group of lysosomal storage diseases caused by deficient activity of enzymes that play important roles in the degradation of glycosaminoglycans. MPS2/ Hunter syndrome is an X-linked disease and the others are autosomal recessive diseases. The enzyme defects result in the accumulation of glycosaminoglycans such as heparan sulfate, dermatan sulfate, and keratan sulfate in many organs, as well as elevated metabolite levels in urine. The MPS diseases share many clinical features that include organomegaly, dysostosis multiplex, decreased growth, and recurrent infections. Most of MPS diseases do not affect the nervous system, and are considered as potentially amenable to enzyme replacement therapy.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (MPS1) IDUA; alpha-L-iduronidase [HSA:3425] [KO:K01217]
            (MPS2) IDS; iduronate 2-sulfatase [HSA:3423] [KO:K01136]
            (MPS3A) SGSH; N-sulfoglucosamine sulfohydrolase [HSA:6448] [KO:K01565]
            (MPS3B) NAGLU; alpha-N-acetylglucosaminidase [HSA:4669] [KO:K01205]
            (MPS3C) HGSNAT; heparan-alpha-glucosaminide N-acetyltransferase [HSA:138050] [KO:K10532]
            (MPS3D) GNS; N-acetylglucosamine-6-sulfatase [HSA:2799] [KO:K01137]
            (MPS4A) GALNS; N-acetylgalactosamine-6-sulfatase [HSA:2588] [KO:K01132]
            (MPS4B) GLB1; beta-galactosidase [HSA:2720] [KO:K12309]
            (MPS6) ARSB; arylsulfatase B [HSA:411] [KO:K01135]
            (MPS7) GUSB; beta-glucuronidase [HSA:2990] [KO:K01195]
            (MPS9) HYAL1; hyaluronoglucosaminidase [HSA:3373] [KO:K01197]
MARKER      Urine glycosaminoglycans
            (MPS1, MPS2, MPS3, MPS6, MPS7) Heparan sulfate [CPD:C00925]
            (MPS1, MPS2, MPS7) Dermatan sulfate [CPD:C00426]
            (MPS4A) keratan sulfate [CPD:C00573]
            (MPS6) Chondroitin 4-sulfate [CPD:C00634]
            (MPS4B, MPS7) Chondroitin sulfate [CPD:C00607]
DRUG        Hematopoietic stem cell transplantation (MPS1, MPS4, MPS6, MPS7)
            Enzyme-replacement therapy (MPS1, MPS2, MPS6)
            (MPS1) Aldurazyme [DR:D04670]
            (MPS2) Elaprase [DR:D04499]
            (MPS6) Aryplase [DR:D06565]
            Chemical chaperone therapy (MPS4, limited experience)
            (MPS4) N-octyl-4-epi-beta-valienamine (NOEV)
COMMENT     The diagnosis is confirmed by measuring IDS activity in leukocytes or fibroblasts.
            Morquio syndrome B (MPS4B) is allelic to the various forms of GM1-gangliosidosis (see, H00281). The latter disorders show central nervous system involvement.
DBLINKS     ICD-10: E76.0 E76.1 E76.2
            OMIM: 607015 607016 309900 252900 252920 252930 252940 253000 253010 253200 253220 601492
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:16124866
  AUTHORS   Diez-Roux G, Ballabio A
  TITLE     Sulfatases and human disease.
  JOURNAL   Annu Rev Genomics Hum Genet 6:355-79 (2005)
REFERENCE   PMID:15691212
  AUTHORS   Wraith EJ, Hopwood JJ, Fuller M, Meikle PJ, Brooks DA
  TITLE     Laronidase treatment of mucopolysaccharidosis I.
  JOURNAL   BioDrugs 19:1-7 (2005)
REFERENCE   PMID:8680403 (MPS1)
  AUTHORS   Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ
  TITLE     Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.
  JOURNAL   Hum Mutat 6:288-302 (1995)
REFERENCE   PMID:18618289 (MPS2)
  AUTHORS   Al Sawaf S, Mayatepek E, Hoffmann B
  TITLE     Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.
  JOURNAL   J Inherit Metab Dis 31:473-80 (2008)
REFERENCE   PMID:18392742 (MPS3)
  AUTHORS   Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA
  TITLE     Sanfilippo syndrome: A mini-review.
  JOURNAL   J Inherit Metab Dis (2008)
REFERENCE   PMID:19472408 (MPS4B)
  AUTHORS   Hofer D, Paul K, Fantur K, Beck M, Burger F, Caillaud C, Fumic K, Ledvinova J, Lugowska A, Michelakakis H, Radeva B, Ramaswami U, Plecko B, Paschke E
  TITLE     GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
  JOURNAL   Hum Mutat 30:1214-21 (2009)
REFERENCE   PMID:17671068 (MPS6)
  AUTHORS   Giugliani R, Harmatz P, Wraith JE
  TITLE     Management guidelines for mucopolysaccharidosis VI.
  JOURNAL   Pediatrics 120:405-18 (2007)
REFERENCE   PMID:19224584 (MPS7)
  AUTHORS   Tomatsu S, Montano AM, Dung VC, Grubb JH, Sly WS
  TITLE     Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome).
  JOURNAL   Hum Mutat 30:511-9 (2009)
REFERENCE   PMID:10339581 (MPS9)
  AUTHORS   Triggs-Raine B, Salo TJ, Zhang H, Wicklow BA, Natowicz MR
  TITLE     Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.
  JOURNAL   Proc Natl Acad Sci U S A 96:6296-300 (1999)
///
ENTRY       H00422                      Disease
NAME        Glycoproteinoses, including:
            Sialidosis/ Mucolipidosis I [DS:H00142];
            Galactosialidosis [DS:H00276];
            alpha-Mannosidosis [DS:H00139];
            beta-Mannosidosis [DS:H00140];
            Aspartylglucosaminuria (AGU) [DS:H00145];
            Fucosidosis [DS:H00141];
            Schindler/ Kanzaki disease [DS:H00146]
DESCRIPTION Glycoproteinoses is a group of autosomal recessive lysosomal storage diseases caused by deficient activty of enzymes that play important roles in the degradation of glycoproteins such as N-linked or O-linked oligosaccharides. The lack of a single enzyme leads to the complete blockage of the catabolic chain and results in the accumulation of undegraded oligosaccharides in lysosomes. Glycoproteinoses share many clinical features such as mental retardation, coarse facies, and dysostosis multiplex. Cathepsin A-deficiency causes combined sialidase and beta-galactosidase deficiency (Sialidosis and Galactosialidosis) due to its function in stabilising these two hydrolases.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        (Sialidosis, Galactosialidosis) NEU1; lysosomal sialidase [HSA:4758] [KO:K01186]
            (Galactosialidosis) CTSA; cathepsin A [HSA:5476] [KO:K13289]
            (Galactosialidosis) GLB1; beta-galactosidase [HSA:2720] [KO:K12309]
            (alpha-Mannosidosis) MAN2B1; lysosomal alpha-mannosidase [HSA:4125] [KO:K12311]
            (beta-Mannosidosis) MANBA; lysosomal beta-mannosidase [HSA:4126] [KO:K01192]
            (AGU) AGA; aspartylglucosaminidase [HSA:175] [KO:K01444]
            (Fucosidosis) FUCA1; alpha-L-fucosidase [HSA:2517] [KO:K01206]
            (Schindler/ Kanzaki) NAGA; alpha-N-acetylgalactosaminidase [HSA:4668] [KO:K01204]
MARKER      (Sialidosis, Galactosialidosis) N-Acetylneuraminic acid (Sialic acid) [CPD:C00270]
            (alpha, beta-Mannosidosis, AGU, Fucosidosis, Schindler/ Kanzaki) Urine oligosaccharides, Vacuolated lymphocytes
            (Fucosidosis type 1) Increased sodium chloride content of sweat
DRUG        (alpha-Mannosidosis, AGU, Fucosidosis) Hematopoietic stem cell transplantation
COMMENT     The diagnosis is confirmed by measuring enzyme activity in leukocytes or fibroblasts.
            Some diseases are described as some phenotypes.
            (Sialidosis) Type 1: the mild form with late-onset. Type 2: the severe form with infantile onset.
            (Galactosialidosis) The early infantile type. The late infantile type. The juvenile/adult type.
            (alpha-Mannosidosis) Type 1: a severe form with hepatomegaly and early death. Type2: a mild form with hearing loss and mental retardation.
            (Fucosidosis) Type 1: a severe form. Type2: a mild form.
            (Schindler/ Kanzaki) Type1 (Schindler disease): a severe form. Type2 (Kanzaki disease): an adult-onset disorder. Type3: an intermediate disorder with mild-to-moderate neurologic manifestations.
DBLINKS     ICD-10: E77.1
            OMIM: 256550 256540 248500 248510 208400 230000 609241 609242
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:14517945
  AUTHORS   Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV
  TITLE     Molecular pathology of NEU1 gene in sialidosis.
  JOURNAL   Hum Mutat 22:343-52 (2003)
REFERENCE   PMID:8985184 (Sialidosis, Galactosialidosis)
  AUTHORS   Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A
  TITLE     Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.
  JOURNAL   Genes Dev 10:3156-69 (1996)
REFERENCE   PMID:10571005
  AUTHORS   Michalski JC, Klein A
  TITLE     Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
  JOURNAL   Biochim Biophys Acta 1455:69-84 (1999)
REFERENCE   PMID:16712870 (Sialidosis)
  AUTHORS   Chen CM, Lai SC, Chen IC, Hsu KC, Lyu RK, Ro LS, Chang HS
  TITLE     First report of two Taiwanese siblings with sialidosis type I: a 10-year follow-up study.
  JOURNAL   J Neurol Sci 247:65-9 (2006)
REFERENCE   PMID:18651971 (alpha-Mannosidosis)
  AUTHORS   Malm D, Nilssen O
  TITLE     Alpha-mannosidosis.
  JOURNAL   Orphanet J Rare Dis 3:21 (2008)
REFERENCE   PMID:18980795 (beta-Mannosidosis)
  AUTHORS   Labauge P, Renard D, Castelnovo G, Sabourdy F, de Champfleur N, Levade T
  TITLE     Beta-mannosidosis: a new cause of spinocerebellar ataxia.
  JOURNAL   Clin Neurol Neurosurg 111:109-10 (2009)
REFERENCE   PMID:8405810 (AGU)
  AUTHORS   Mononen I, Fisher KJ, Kaartinen V, Aronson NN Jr
  TITLE     Aspartylglycosaminuria: protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation.
  JOURNAL   FASEB J 7:1247-56 (1993)
REFERENCE   PMID:10094192 (Fucosidosis)
  AUTHORS   Willems PJ, Seo HC, Coucke P, Tonlorenzi R, O'Brien JS
  TITLE     Spectrum of mutations in fucosidosis.
  JOURNAL   Eur J Hum Genet 7:60-7 (1999)
REFERENCE   PMID:17767638 (Fucosidosis)
  AUTHORS   Abdallah C, Hannallah R, McGill W
  TITLE     Anesthesia for fucosidosis.
  JOURNAL   Paediatr Anaesth 17:994-7 (2007)
REFERENCE   PMID:14685826
  AUTHORS   Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T
  TITLE     Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).
  JOURNAL   J Hum Genet 49:1-8 (2004)
REFERENCE   PMID:19683538 (Schindler/ Kanzaki)
  AUTHORS   Clark NE, Garman SC
  TITLE     The 1.9 a structure of human alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and Kanzaki diseases.
  JOURNAL   J Mol Biol 393:435-47 (2009)
///
ENTRY       H00423                      Disease
NAME        Defects in the degradation of sulfatide, including:
            Metachromatic leukodystrophy (MLD) [DS:H00127];
            Krabbe disease/ Globoid cell leukodystrophy [DS:H00135]
DESCRIPTION Defects in the degradation of sulfatide is a group of autosomal recessive demyelinating lysosomal storage diseases including Metachromatic leukodystrophy (MLD) and Krabbe disease. MLD caused by deficiency of lysosomal arylsulfatase A (ARSA) and Krabbe disease caused by deficiency of galactosylceramidase. The enzyme defects result in the accumulation of sulfatide and galactocerebroside in the central and peripheral nervous systems and extensive white matter damage and loss of both cognitive and motor functions. Mutated PSAP gene resulting in sphingolipid activator proteins (saposin) Saposin B deficiency is known to cause MLD variant in which ARSA is normal. It is also known that saposin A and saposin C are able to stimulate the step of galactocerebroside degradation.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        (MLD)ARSA; arylsulfatase A [HSA:410] [KO:K01134]
            (Krabbe) GALC; galactosylceramidase [HSA:2581] [KO:K01202]
            (MLD, Krabbe) PSAP; saposin [HSA:5660] [KO:K12382]
MARKER      (MLD) sulfatides [GL:G11122] [CPD:C06125]
            (Krabbe) Galactocerebroside [GL:G11121] [CPD:C02686]
            (Krabbe) Psychosine [CPD:C01747]
DRUG        Enzyme-replacement therapy
            Hematopoietic stem cell transplantation
DBLINKS     ICD-10: E75.2
            OMIM: 250100 249900 245200
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:18465098
  AUTHORS   Eckhardt M
  TITLE     The role and metabolism of sulfatide in the nervous system.
  JOURNAL   Mol Neurobiol 37:93-103 (2008)
REFERENCE   PMID:16854371
  AUTHORS   Kolter T, Sandhoff K
  TITLE     Sphingolipid metabolism diseases.
  JOURNAL   Biochim Biophys Acta 1758:2057-79 (2006)
REFERENCE   PMID:17347913 (MLD)
  AUTHORS   Sevin C, Aubourg P, Cartier N
  TITLE     Enzyme, cell and gene-based therapies for metachromatic leukodystrophy.
  JOURNAL   J Inherit Metab Dis 30:175-83 (2007)
REFERENCE   PMID:19267410 (MLD variant)
  AUTHORS   Kuchar L, Ledvinova J, Hrebicek M, Myskova H, Dvorakova L, Berna L, Chrastina P, Asfaw B, Elleder M, Petermoller M, Mayrhofer H, Staudt M, Krageloh-Mann I, Paton BC, Harzer K
  TITLE     Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations.
  JOURNAL   Am J Med Genet A 149A:613-21 (2009)
REFERENCE   PMID:10833326 (Krabbe)
  AUTHORS   Wenger DA, Rafi MA, Luzi P, Datto J, Costantino-Ceccarini E
  TITLE     Krabbe disease: genetic aspects and progress toward therapy.
  JOURNAL   Mol Genet Metab 70:1-9 (2000)
REFERENCE   PMID:18157819 (MSD)
  AUTHORS   Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J
  TITLE     Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency.
  JOURNAL   Hum Mutat 29:205 (2008)
///
ENTRY       H00424                      Disease
NAME        Defects in the degradation of sphingomyelin, including:
            Niemann-Pick disease (NPD), type A/ B [DS:H00137];
            Farber lipogranulomatosis [DS:H00138]
DESCRIPTION Defects in the degradation of sphingomyelin is a group of autosomal recessive lysosomal storage diseases including Niemann-Pick disease (NPD), type A/B and Farber lipogranulomatosis. NPD caused by deficient acid sphingomyelinase (ASM) activity, and Farber lipogranulomatosis is caused by acid ceramidase deficiency, resulting in accumulation of sphingomyelin, ceramide and cholesterol in many organs. ASM and acid ceramidase are key enzymes of the two steps degradation of sphingomyelin and play important roles in normal membrane turnover.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        (NPD) SMPD1, ASM; sphingomyelin phosphodiesterase [HSA:6609] [KO:K12350]
            (Farber) ASAH1; acid ceramidase [HSA:427] [KO:K12348]
MARKER      (NPD) Niemann-Pick cell: A rounded or polygonal mononuclear cell with indistinctly or palely staining, foamlike cytoplasm that contains numerous droplets of sphingomyelin. [CPD:C00550]
            (Farber) Ceramide [CPD:C00195]
DRUG        (NPD type B)
            Enzyme-replacement therapy
COMMENT     NPD typeA is the infantile form characterized by a rapidly progressive neurodegenerative course that leads to early death. NPD typeB is the later-onset form in which patients exhibit little or no neurological symptoms, but may have severe and progressive visceral organ abnormalities, including hepatosplenomegaly and cardiovascular disease. The different clinical presentations of Types A and B NPD are likely due to small differences in the amount of residual, functional ASM activity.
DBLINKS     ICD-10: E75.2
            OMIM: 257200 607616 228000
REFERENCE   PMID:18567738
  AUTHORS   Smith EL, Schuchman EH
  TITLE     The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.
  JOURNAL   FASEB J 22:3419-31 (2008)
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:17632693
  AUTHORS   Schuchman EH
  TITLE     The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.
  JOURNAL   J Inherit Metab Dis 30:654-63 (2007)
REFERENCE   PMID:10760463
  AUTHORS   Ridgway ND
  TITLE     Interactions between metabolism and intracellular distribution of cholesterol and sphingomyelin.
  JOURNAL   Biochim Biophys Acta 1484:129-41 (2000)
REFERENCE   PMID:19944693 (NPC)
  AUTHORS   Schuchman EH
  TITLE     Acid sphingomyelinase, cell membranes and human disease: Lessons from Niemann-Pick disease.
  JOURNAL   FEBS Lett (2009)
REFERENCE   PMID:17064658 (Farber)
  AUTHORS   Park JH, Schuchman EH
  TITLE     Acid ceramidase and human disease.
  JOURNAL   Biochim Biophys Acta 1758:2133-8 (2006)
REFERENCE   PMID:11241842 (Farber)
  AUTHORS   Bar J, Linke T, Ferlinz K, Neumann U, Schuchman EH, Sandhoff K
  TITLE     Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
  JOURNAL   Hum Mutat 17:199-209 (2001)
///
ENTRY       H00425                      Disease
NAME        Lysosomal cysteine protease deficiencies, including:
            Papillon-Lefevre syndrome (PLS) [DS:H00274];
            Pycnodysostosis [DS:H00273]
DESCRIPTION Defects in lysosomal cysteine proteases (Cathepsins) are autosomal recessive lysosomal storage diseases. To date only following two human diseases cathepsin deficiencies have been described, though there are eleven lysosomal cystein proteases. Deficiency of cathepsin C leads to Papillon-Lefevre syndrome characterized by palmoplantar hyperkeratosis and severe early onset periodontitis. Deficiency of cathepsin K leads to pycnodysostosis characterized by osteosclerosis and short stature. Recent findings suggest a more expanded role for cathepsins in human biology.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        (PLS) CTSC; cathepsin C [HSA:1075] [KO:K01275]
            (Pycnodysostosis) CTSK; cathepsin K [HSA:1513] [KO:K01371]
COMMENT     In mice, other Cathepsin deficiencies have also been generated. Deficiency of cathepsin F causes lysosomal storage defects and late-onset neurological disease. Lacking cathepsin L develop periodic hair loss. Recent findings suggest a more expanded role for cathepsins in human biology. These roles include apoptosis, MHC class II immune responses, prohormone processing, and extracellular matrix (ECM) remodeling important to cardiovascular or bone development. Cathepsins may also lead to accelerated collagen and elastin degradation and cause the diseases such as atherosclerosis.
DBLINKS     ICD-10: Q82.8
            OMIM: 245000 265800
REFERENCE   PMID:1883197
  AUTHORS   Neufeld EF
  TITLE     Lysosomal storage diseases.
  JOURNAL   Annu Rev Biochem 60:257-80 (1991)
REFERENCE   PMID:15647514 (Description)
  AUTHORS   Winchester B
  TITLE     Lysosomal metabolism of glycoproteins.
  JOURNAL   Glycobiology 15:1R-15R (2005)
REFERENCE   PMID:9074757
  AUTHORS   Chapman HA, Riese RJ, Shi GP
  TITLE     Emerging roles for cysteine proteases in human biology.
  JOURNAL   Annu Rev Physiol 59:63-88 (1997)
REFERENCE   PMID:18401176 (PLS)
  AUTHORS   Nakajima K, Nakano H, Takiyoshi N, Rokunohe A, Ikenaga S, Aizu T, Kaneko T, Mitsuhashi Y, Sawamura D
  TITLE     Papillon-Lefevre syndrome and malignant melanoma. A high incidence of melanoma development in Japanese palmoplantar keratoderma patients.
  JOURNAL   Dermatology 217:58-62 (2008)
REFERENCE   PMID:19338743 (Pycnodysostosis)
  AUTHORS   Zhao Q, Jia Y, Xiao Y
  TITLE     Cathepsin K: a therapeutic target for bone diseases.
  JOURNAL   Biochem Biophys Res Commun 380:721-3 (2009)
REFERENCE   PMID:14756243 (Pycnodysostosis)
  AUTHORS   Goto T, Yamaza T, Tanaka T
  TITLE     Cathepsins in the osteoclast.
  JOURNAL   J Electron Microsc (Tokyo) 52:551-8 (2003)
///
ENTRY       H00426                      Disease
NAME        Defects in the degradation of ganglioside, including:
            GM1 gangliosidosis [DS:H00281];
            Tay-Sachs disease (GM2 gangliosidoses type 1) [DS:H00124];
            Sandhoff disease (GM2 gangliosidoses type 2) [DS:H00124];
            Gaucher disease [DS:H00126]
DESCRIPTION Defects in the degradation of ganglioside is a group of autosomal recessive lysosomal storage diseases caused by deficient activty of enzymes or their activators that play important roles in the degradation of ganglioside. The lack of a single enzyme leads to the complete blockage of the catabolic chain and results in the accumulation of undegraded substrates such as keratan sulfate, gangliosides, glucosylceramide and glycopeptides in neurons and skeletal tissues. Deficiency of the GM2 activator protein causes the AB variant of GM2 gangliosidosis. And saposin C is an activator of beta-glucocerebrosidase.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease; Nervous system disease
GENE        (GM1) GLB1; beta-galactosidase [HSA:2720] [KO:K12309]
            (GM2 type1) HEXA; beta-hexosaminidase A [HSA:3073] [KO:K12373]
            (GM2 type2) HEXB; beta-hexosaminidase B [HSA:3074] [KO:K12373]
            (GM2 AB variant) GM2A; ganglioside GM2 activator [HSA:2760] [KO:K12383]
            (Gaucher) GBA; glucosylceramidase [HSA:2629] [KO:K01201]
            (Gaucher) PSAP; prosaposin [HSA:5660] [KO:K12382]
MARKER      Urine oligosaccharides
            (GM1) GM1 ganglioside [GL:G00110] [CPD:C04911]
            (GM2) GM2 ganglioside [GL:G00109] [CPD:C04884]
            (GM1, GM2) keratan sulfate [CPD:C00573]
            (GM1) Chondroitin sulfate [CPD:C00607]
            (Gaucher) Glucocerebroside [GL:G10238] [CPD:C01190]
DRUG        (GM1)
            Hematopoietic stem cell transplantation
            Chemical chaperone therapy; N-octyl-4-epi-beta-valienamine (NOEV) (limited experience)
            (GM2)
            Enzyme replacement therapy, Gene therapy, Substrate reduction therapy (limited experience)
            (Gaucher)
            Hematopoietic stem cell transplantation
            Enzyme-replacement therapy: Cerezyme [DR:D03020] Alglucerase [DR:D02810] Imiglucerase [DR:D03020]
            Substrate reduction therapy: Miglustat, Zavesca [DR:D05032]
COMMENT     Morquio syndrome B is non-neuronopathic form of GM1-gangliosidosis (see, H00123).
            Some diseases are described as some phenotypes.
            (GM1) Type 1: the severe infantile form. Type 2: the juvenile form. Type 3 the mild adult form
            (Gaucher) Type 1: non-neuronopathic form. Type2: acute infantile neuropathic form. Type3: the chronic neuropathic form.
DBLINKS     ICD-10: E75.1 E75.2
            OMIM: 230500 230600 230650 268800 272800 272750 230800 230900 231000 231005 608013
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE   PMID:19472408 (GM1)
  AUTHORS   Hofer D, Paul K, Fantur K, Beck M, Burger F, Caillaud C, Fumic K, Ledvinova J, Lugowska A, Michelakakis H, Radeva B, Ramaswami U, Plecko B, Paschke E
  TITLE     GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
  JOURNAL   Hum Mutat 30:1214-21 (2009)
REFERENCE   PMID:18202827 (GM1/ therapy)
  AUTHORS   Suzuki Y
  TITLE     Chemical chaperone therapy for GM1-gangliosidosis.
  JOURNAL   Cell Mol Life Sci 65:351-3 (2008)
REFERENCE   PMID:12019216 (GM2)
  AUTHORS   Myerowitz R, Lawson D, Mizukami H, Mi Y, Tifft CJ, Proia RL
  TITLE     Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.
  JOURNAL   Hum Mol Genet 11:1343-50 (2002)
REFERENCE   PMID:16801539 (GM2)
  AUTHORS   Cachon-Gonzalez MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, Cox TM
  TITLE     Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
  JOURNAL   Proc Natl Acad Sci U S A 103:10373-8 (2006)
REFERENCE   PMID:19595619
  AUTHORS   Maegawa GH, Banwell BL, Blaser S, Sorge G, Toplak M, Ackerley C, Hawkins C, Hayes J, Clarke JT
  TITLE     Substrate reduction therapy in juvenile GM2 gangliosidosis.
  JOURNAL   Mol Genet Metab 98:215-24 (2009)
REFERENCE   PMID:18339196 (Gaucher)
  AUTHORS   Platt FM, Jeyakumar M
  TITLE     Substrate reduction therapy.
  JOURNAL   Acta Paediatr Suppl 97:88-93 (2008)
///
ENTRY       H00427                      Disease
NAME        Relapsing fever
DESCRIPTION Relapsing fever was once a major global epidemic disease. Louseborne relapsing fever is now geographically limited, but tickborne relapsing fever still causes major health problems in Africa. The symptoms are variable. Relapsing fever spirochaetes persist in the brain, which can be reactivated on immunosuppression.
CATEGORY    Infectious disease
PATHOGEN    Borrelia recurrentis [GN:bre] (Louse-borne relapsing fever)
            Borrelia duttonii [GN:bdu] (Tick-borne relapsing fever)
            Borrelia hermsii [GN:bhr] (Tick-borne relapsing fever)
            Borrelia turicatae [GN:btu] (Tick-borne relapsing fever)
            Borrelia crocidurae [GN:bcw] (Tick-borne relapsing fever)
DRUG        Tetracycline [DG:DG00005]
            Benzylpenicillin [DG:DG00534]
            Amoxicillin[DG:DG00520]
            Doxycycline [DG:DG00008]
            Ceftriaxone [DG:DG00573]
            Cefotaxime [DG:DG00570]
COMMENT     Vectors: Pediculus humanus (body louse), Ornithodoros moubata (African tick)
DBLINKS     ICD-10: A68
            MeSH: D012061
            MedlinePlus: 001350
REFERENCE   PMID:19886891 (description)
  AUTHORS   Cutler SJ
  TITLE     Relapsing fever--a forgotten disease revealed.
  JOURNAL   J Appl Microbiol 108:1115-22 (2010)
REFERENCE   PMID:19623064 (drug)
  AUTHORS   Larsson C, Andersson M, Bergstrom S
  TITLE     Current issues in relapsing fever.
  JOURNAL   Curr Opin Infect Dis 22:443-9 (2009)
REFERENCE   PMID:16704771 (description)
  AUTHORS   Cutler SJ
  TITLE     Possibilities for relapsing fever reemergence.
  JOURNAL   Emerg Infect Dis 12:369-74 (2006)
///
ENTRY       H00428                      Disease
NAME        Distal renal tubular acidosis (RTA type 1)
DESCRIPTION Renal tubular acidosis (RTA) is characterized by metabolic acidosis, a severe disturbance of extracellular pH homeostasis, due to renal impaired acid excretion. The distal type of RTA (dRTA) arises when the collecting duct fails to remove excess acid into the urine and is characterized by the inability to lower urine pH maximally (below 5.5) in the face of spontaneous acidemia or after acid loading. Autosomal-dominant and -recessive forms of dRTA are caused by mutations in ion transporters of the acid-secreting Type A intercalated cell of the renal collecting duct. These include the AE1 Cl-/HCO3- exchanger of the basolateral membrane and at least two subunits of the apical membrane vacuolar (v)H+-ATPase, the V1 subunit B1 (associated with deafness) and the V0 subunit a4.
CATEGORY    Urinary system disease
GENE        SCL4A1 [HSA:6521] [KO:K06573]
            ATP6V1B1 [HSA:525] [KO:K02147]
            ATP6V0A4 [HSA:50617] [KO:K02154]
ENV_FACTOR  Amphotericin B [DR:D00203]
            Lithium [DR:D08133]
            Analgesic abuse
            Toluene [CPD:C01455]
            Cyclamate
            Amiloride [DR:D07447]
            Trimethoprim [DR:D00145]
            Pentamidine [DR:D08333]
            Vanadium [CPD:C06267]
MARKER      Plasma K+ [CPD:C00238]
            Urinary anion gap [CPD:C01330 C00238 C00698]
            Urine pH
            Urinary NH4+
DRUG        A mixture of Na+ and K+ salts [CPD:C01330 C00238]
            Potassium citrate [DR:D05578]
            Sodium bicarbonate [DR:D01203]
DBLINKS     ICD-10: N25.8
            MeSH: D000141
            OMIM: 179800 267300 602722
REFERENCE   PMID:19721811 (gene)
  AUTHORS   Pereira PC, Miranda DM, Oliveira EA, Silva AC
  TITLE     Molecular pathophysiology of renal tubular acidosis.
  JOURNAL   Curr Genomics 10:51-9 (2009)
REFERENCE   PMID:11045400 (gene)
  AUTHORS   Rodriguez-Soriano J
  TITLE     New insights into the pathogenesis of renal tubular acidosis--from functional to  molecular studies.
  JOURNAL   Pediatr Nephrol 14:1121-36 (2000)
REFERENCE   PMID:17557941 (gene)
  AUTHORS   Fry AC, Karet FE
  TITLE     Inherited renal acidoses.
  JOURNAL   Physiology (Bethesda) 22:202-11 (2007)
REFERENCE   PMID:12138150 (gene, env_factor, marker)
  AUTHORS   Rodriguez Soriano J
  TITLE     Renal tubular acidosis: the clinical entity.
  JOURNAL   J Am Soc Nephrol 13:2160-70 (2002)
REFERENCE   PMID:11095551 (env_factor)
  AUTHORS   Kurtzman NA
  TITLE     Renal tubular acidosis syndromes.
  JOURNAL   South Med J 93:1042-52 (2000)
REFERENCE   (marker, drug)
  AUTHORS   McPhee SJ, Papadakis MA (ed).
  TITLE     Current Medical Diagnosis & Treatment 2010, Forty-Ninth Edition
  JOURNAL   The McGraw-Hill Companies, Inc. (2010)
///
ENTRY       H00429                      Disease
NAME        Proximal renal tubular acidosis (RTA type 2)
DESCRIPTION Renal tubular acidosis (RTA) is characterized by metabolic acidosis, a severe disturbance of extracellular pH homeostasis, due to renal impaired acid excretion. Proximal RTA (type 2) is caused by an impairment of bicarbonate reabsorption in the proximal tubules, resulting in low renal bicarbonate threshold. Mutations in the gene SLC4A4, encoding Na+-HCO3- cotransporter (NBC-1), have been found in proximal RTA.
CATEGORY    Urinary system disease
GENE        SLC4A4 [HSA:8671] [KO:K13575]
ENV_FACTOR  Acetazolamide [DR:D00218]
            Outdated tetracycline
            Aminoglycoside antibiotics
            Valproate
            6-Mercaptopurine [DR:D00161 D04931]
            Streptozotocin [DR:D05932]
            Iphosphamide
            Lead
            Cadmium [CPD:C01413]
            Mercury [DR:D04934]
            Arginine [DR:D02982]
            Gentamicin [DR:D08013]
            Glue(toluene) [CPD:C01455]
            Maleic acid [CPD:C01384]
            Methyl-3-chromone
MARKER      Plasma K+ [CPD:C00238]
            Urinary anion gap [CPD:C01330 C00238 C00698]
            Urine pH
DRUG        Sodium bicarbonate [DR:D01203]
            Potassium bicarbonate [DR:D02077]
            Thiazide
DBLINKS     ICD-10: N25.8
            MeSH: D000141
            OMIM: 604278
REFERENCE   PMID:11045400 (gene)
  AUTHORS   Rodriguez-Soriano J
  TITLE     New insights into the pathogenesis of renal tubular acidosis--from functional to  molecular studies.
  JOURNAL   Pediatr Nephrol 14:1121-36 (2000)
REFERENCE   PMID:17557941 (gene)
  AUTHORS   Fry AC, Karet FE
  TITLE     Inherited renal acidoses.
  JOURNAL   Physiology (Bethesda) 22:202-11 (2007)
REFERENCE   PMID:12138150 (gene, env_factor, marker)
  AUTHORS   Rodriguez Soriano J
  TITLE     Renal tubular acidosis: the clinical entity.
  JOURNAL   J Am Soc Nephrol 13:2160-70 (2002)
REFERENCE   PMID:11095551 (env_factor, drug)
  AUTHORS   Kurtzman NA
  TITLE     Renal tubular acidosis syndromes.
  JOURNAL   South Med J 93:1042-52 (2000)
REFERENCE   (marker, drug)
  AUTHORS   McPhee SJ, Papadakis MA (ed).
  TITLE     Current Medical Diagnosis & Treatment 2010, Forty-Ninth Edition
  JOURNAL   The McGraw-Hill Companies, Inc. (2010)
///
ENTRY       H00430                      Disease
NAME        Fibrodysplasia ossificans progressiva (FOP)
DESCRIPTION Fibrodysplasia ossificans progressiva (FOP) is a very rare disorder that leads to progressive ossification of muscle tissue and connective tissue. This process becomes noticeable in early childhood. Affected individuals harbor missense mutations in the ACVR1A gene that brings about constitutive activation of BMP type I receptor. FOP can be inherited in an autosomal dominant pattern.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        ACVR1 (polymorphism) [HSA:90] [KO:K04675]
ENV_FACTOR  trauma
MARKER      ACVR1 [HSA:90]
DBLINKS     ICD-10: M61.1
            MeSH: D009221
            OMIM: 135100
REFERENCE   PMID:18328989 (gene, description)
  AUTHORS   Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM
  TITLE     Fibrodysplasia ossificans progressiva.
  JOURNAL   Best Pract Res Clin Rheumatol 22:191-205 (2008)
REFERENCE   PMID:18590993 (gene, description)
  AUTHORS   Shore EM, Kaplan FS
  TITLE     Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).
  JOURNAL   Bone 43:427-33 (2008)
REFERENCE   PMID:16642017 (gene, description)
  AUTHORS   Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS
  TITLE     A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.
  JOURNAL   Nat Genet 38:525-7 (2006)
///
ENTRY       H00431                      Disease
NAME        Ossification of the posterior longitudinal ligament of spine (OPLL)
DESCRIPTION Ossification of the posterior longitudinal ligament of spine (OPLL) is an osteogenetic disorder of the spine found among Japanese and other East Asian populations. Ectopic bone formation in the posterior longitudinal ligaments causes myelopathy in patients with OPLL. Genetic linkage studies revealed genes encoding collagens, nucleotide pyrophosphatase, and TGF-beta3 in association with susceptibility to the disease.
CATEGORY    Skeletal dysplasia
GENE        COL11A2 (polymorphism) [HSA:1302] [KO:K19721]
            NPPS [HSA:5167] [KO:K01513]
            COL6A1 (polymorphism) [HSA:1291] [KO:K06238]
            TGFB3 (polymorphism) [HSA:7043] [KO:K13377]
ENV_FACTOR  machanical stress
            nutrition
            glucose intolerance
            high body mass index
DBLINKS     ICD-10: M48.8
            MeSH: D017887
            OMIM: 602475
REFERENCE   PMID:9585596 (gene, description)
  AUTHORS   Koga H, Sakou T, Taketomi E, Hayashi K, Numasawa T, Harata S, Yone K, Matsunaga S, Otterud B, Inoue I, Leppert M
  TITLE     Genetic mapping of ossification of the posterior longitudinal ligament of the spine.
  JOURNAL   Am J Hum Genet 62:1460-7 (1998)
REFERENCE   PMID:10453738 (gene, description)
  AUTHORS   Nakamura I, Ikegawa S, Okawa A, Okuda S, Koshizuka Y, Kawaguchi H, Nakamura K, Koyama T, Goto S, Toguchida J, Matsushita M, Ochi T, Takaoka K, Nakamura Y
  TITLE     Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL).
  JOURNAL   Hum Genet 104:492-7 (1999)
REFERENCE   PMID:12958705 (gene, description)
  AUTHORS   Tanaka T, Ikari K, Furushima K, Okada A, Tanaka H, Furukawa K, Yoshida K, Ikeda T, Ikegawa S, Hunt SC, Takeda J, Toh S, Harata S, Nakajima T, Inoue I
  TITLE     Genomewide linkage and linkage disequilibrium analyses identify COL6A1, on chromosome 21, as the locus for ossification of the posterior longitudinal ligament of the spine.
  JOURNAL   Am J Hum Genet 73:812-22 (2003)
REFERENCE   PMID:16609882 (gene, env_factor)
  AUTHORS   Horikoshi T, Maeda K, Kawaguchi Y, Chiba K, Mori K, Koshizuka Y, Hirabayashi S, Sugimori K, Matsumoto M, Kawaguchi H, Takahashi M, Inoue H, Kimura T, Matsusue Y, Inoue I, Baba H, Nakamura K, Ikegawa S
  TITLE     A large-scale genetic association study of ossification of the posterior longitudinal ligament of the spine.
  JOURNAL   Hum Genet 119:611-6 (2006)
///
ENTRY       H00432                      Disease
NAME        Hereditary dentine disorders, including the following three diseases:
            Dentine dysplasia, type II;
            Dentinogenesis imperfecta, types II and III
DESCRIPTION These three disorders comprise a group of autosomal dominant diseases characterized by opalescent teeth caused by abnormal dentine structure. The phenotype varies from mild and severe, affecting either deciduous or both deciduous and permanent dentition. These diseases arise from mutations of the dentine sialophosphoprotein gene (DSPP) that is involved in dentin matrix formation.
CATEGORY    Mouth and dental disease
GENE        DSPP [HSA:1834]
DBLINKS     ICD-10: K00.5
            OMIM: 125490 125500 125420
REFERENCE   PMID:19021896
  AUTHORS   Barron MJ, McDonnell ST, Mackie I, Dixon MJ
  TITLE     Hereditary dentine disorders: dentinogenesis imperfecta and dentine dysplasia.
  JOURNAL   Orphanet J Rare Dis 3:31 (2008)
REFERENCE   PMID:17452557
  AUTHORS   Kim JW, Simmer JP
  TITLE     Hereditary dentin defects.
  JOURNAL   J Dent Res 86:392-9 (2007)
REFERENCE   PMID:16955410
  AUTHORS   MacDougall M, Dong J, Acevedo AC
  TITLE     Molecular basis of human dentin diseases.
  JOURNAL   Am J Med Genet A 140:2536-46 (2006)
///
ENTRY       H00433                      Disease
NAME        Holt-Oram syndrome
DESCRIPTION Holt-Oram syndrome (HOS) is an autosomal-dominant disorder characterized by bilateral forelimb anomalies and congenital heart diseases. All patients with HOS have abnormal carpal bones and about 85% to 95% develop cardiac malformation including atrial septal defect and ventricular septal defect. The disease is caused by mutations of the T-box transcription factor TBX5.
CATEGORY    Skeletal dysplasia; Cardiovascular disease
GENE        TBX5 [HSA:6910] [KO:K10179]
MARKER      TBX5 [HSA:6910]
DBLINKS     ICD-10: Q87.2
            MeSH: C535326
            OMIM: 142900
REFERENCE   PMID:12436037 (gene, description)
  AUTHORS   Huang T
  TITLE     Current advances in Holt-Oram syndrome.
  JOURNAL   Curr Opin Pediatr 14:691-5 (2002)
REFERENCE   PMID:15096952 (gene, description)
  AUTHORS   Mori AD, Bruneau BG
  TITLE     TBX5 mutations and congenital heart disease: Holt-Oram syndrome revealed.
  JOURNAL   Curr Opin Cardiol 19:211-5 (2004)
REFERENCE   PMID:12668595 (gene, description)
  AUTHORS   Packham EA, Brook JD
  TITLE     T-box genes in human disorders.
  JOURNAL   Hum Mol Genet 12 Spec No 1:R37-44 (2003)
///
ENTRY       H00434                      Disease
NAME        Camurati-Engelmann disease;
            Progressive diaphyseal dysplasia
DESCRIPTION Camurati-Engelmann disease (CED) is an autosomal dominant disorder characterized by hyperostosis of the diaphysis of long bones and the skull. The onset of CED is during early childhood with muscle weakness and limb pain. The mutations in TGF-beta 1 LAP domain modulate TGF-beta 1 activity and leads to increased proliferation of osteoblasts in CED.
CATEGORY    Skeletal dysplasia
GENE        TGFB1 [HSA:7040] [KO:K13375]
MARKER      TGFB1 [HSA:7040]
DBLINKS     ICD-10: Q78.3
            MeSH: D003966
            OMIM: 131300
REFERENCE   PMID:10973241 (genedescription)
  AUTHORS   Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K
  TITLE     Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.
  JOURNAL   Nat Genet 26:19-20 (2000)
REFERENCE   PMID:15103729 (genedescription)
  AUTHORS   Kinoshita A, Fukumaki Y, Shirahama S, Miyahara A, Nishimura G, Haga N, Namba A, Ueda H, Hayashi H, Ikegawa S, Seidel J, Niikawa N, Yoshiura K
  TITLE     TGFB1 mutations in four new families with Camurati-Engelmann disease: confirmation of independently arising LAP-domain-specific mutations.
  JOURNAL   Am J Med Genet A 127A:104-7 (2004)
REFERENCE   PMID:11278244 (genedescription)
  AUTHORS   Saito T, Kinoshita A, Yoshiura Ki, Makita Y, Wakui K, Honke K, Niikawa N, Taniguchi N
  TITLE     Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1.
  JOURNAL   J Biol Chem 276:11469-72 (2001)
REFERENCE   PMID:20301335 (marker)
  AUTHORS   Wallace SE, Wilcox WR
  TITLE     Camurati-Engelmann Disease
  JOURNAL   (1993)
///
ENTRY       H00435                      Disease
NAME        Toxoplasmosis
DESCRIPTION The intracellular protozoan parasite Toxoplasma gondii is distributed worldwide among warm-blood animals. In humans, the infection rate is estimated at 10-30 %. Infection is acquired by ingestion of the parasite released by parasitized cats or contained in undercooked meat. The parasite usually causes asymptomatic infection but in immunocompromised indivisuals, it can result in fatal disease with encephalitis. Transmission can also occur vertically. Congenital infection causes spontaneous abortion or serious defects such as hydrocephalus, chorioretinitis, and intracranial calcification in infants.
CATEGORY    Infectious disease
PATHOGEN    Toxoplasma gondii [GN:tgo]
COMMENT     Definitive host: Felis silvestris catus
DBLINKS     ICD-10: B58
            MeSH: D014123
///
ENTRY       H00436                      Disease
NAME        Osteopetrosis, including:
            Osteopetrosis, severe neonatal or infantile forms;
            Osteopetrosis, intermediate forms;
            Osteopetrosis with renal tubular acidosis;
            Osteopetrosis, late-onset form type 1;
            Osteopetrosis, late-onset form type 2;
            Osteopetrosis, osteoclast poor
DESCRIPTION The osteopetroses are a heterogeneous group of disorders characterized by increased bone density and the replacement of trabecular bone with compact bone due to reduced osteoclastic bone resorption. Some osteopetrotic conditions exhibit additional clinical features including renal tubular acidosis and secondary neurological impairment. In forms of osteopetrosis with normal osteoclast counts, most of the mutated genes encode proteins that regulate the intra- and extracellular pH of osteoclasts, such as TCIRG1 gene encoding for the a3 subunit of the V-ATPase and ClCN7 gene. In cases with decreased osteoclast counts, osteoclast differentiation is impaired by mutations in RANKL or RANK. These RANK-deficient patients could be rescued by hematopoietic stem cell transplantation.
CATEGORY    Skeletal dysplasia
GENE        (neonatal) TCIRG1 [HSA:10312] [KO:K02154]
            (neonatal) OSTM1 [HSA:28962]
            (neonatal, intermedite, late-onset 2) CLCN7 [HSA:1186] [KO:K05016]
            (renal) CA2 [HSA:760] [KO:K18245]
            (late-onset 1) LRP5 [HSA:4041] [KO:K03068]
            PLEKHM1 [HSA:440456]
            (osteoclast poor) RANKL [HSA:8600] [KO:K05473]
            (osteoclast poor) RANK [HSA:8792] [KO:K05147]
DBLINKS     ICD-10: Q78.2
            MeSH: D010022
            OMIM: 259700 611490 259720 259730 607634 166600 611497 259710 612301
REFERENCE   PMID:20855225 (gene)
  AUTHORS   Michou L, Brown JP
  TITLE     Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta.
  JOURNAL   Joint Bone Spine 78:252-8 (2011)
REFERENCE   PMID:16307387 (gene, description)
  AUTHORS   Balemans W, Van Wesenbeeck L, Van Hul W
  TITLE     A clinical and molecular overview of the human osteopetroses.
  JOURNAL   Calcif Tissue Int 77:263-74 (2005)
REFERENCE   PMID:17936098 (gene, description)
  AUTHORS   Del Fattore A, Cappariello A, Teti A
  TITLE     Genetics, pathogenesis and complications of osteopetrosis.
  JOURNAL   Bone 42:19-29 (2008)
REFERENCE   PMID:20301306 (gene)
  AUTHORS   Schulz A, Kornak U
  TITLE     CLCN7-Related Osteopetrosis
  JOURNAL   (1993)
REFERENCE   PMID:17997709 (gene)
  AUTHORS   Del Fattore A, Fornari R, Van Wesenbeeck L, de Freitas F, Timmermans JP, Peruzzi B, Cappariello A, Rucci N, Spera G, Helfrich MH, Van Hul W, Migliaccio S, Teti A
  TITLE     A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts.
  JOURNAL   J Bone Miner Res 23:380-91 (2008)
REFERENCE   PMID:17632511 (gene)
  AUTHORS   Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH
  TITLE     Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.
  JOURNAL   Nat Genet 39:960-2 (2007)
REFERENCE   PMID:18606301 (gene)
  AUTHORS   Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A
  TITLE     Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
  JOURNAL   Am J Hum Genet 83:64-76 (2008)
REFERENCE   PMID:6702897 (description)
  AUTHORS   Kahler SG, Burns JA, Aylsworth AS
  TITLE     A mild autosomal recessive form of osteopetrosis.
  JOURNAL   Am J Med Genet 17:451-64 (1984)
///
ENTRY       H00437                      Disease
NAME        Paget's disease of bone and related disorders, including: ;
            Paget's disease of bone (PDB);
            Familial expansile osteolysis (FEO);
            Early-onset Paget's disease of bone (PDB2);
            Expansile skeletal hyperphosphatasia (ESH);
            Juvenile Paget's disease (JPD)
DESCRIPTION Paget's disease of bone and related disorders are rare inherited osteolytic disorders that show phenotypic overlap. Patients with these diseases carry mutations in RANK, OPG or SQSTM1, resulting in activation of RANKL-RANK signaling axis with increases in bone resorption. Hearing impairment and tooth loss is common. Apart from JPD, the condition is inherited as an autosomal dominant trait.
CATEGORY    Skeletal dysplasia
GENE        (PDB FEO PDB2 ESH) RANK (mutation) [HSA:8792] [KO:K05147]
            (PDB) SQSTM1 (mutation) [HSA:8878] [KO:K14381]
            (JPD) OPG (mutation) [HSA:4982] [KO:K05148]
PATHOGEN    Paramyxovirus (chronic infection with) [RS:NC_002199]
            Measles virus [GN:T40033]
            Canine distemper virus [RS:NC_001921]
DRUG        Alendronate [DR:D00939]
            Etidronic acid [DG:DG00780]
DBLINKS     ICD-10: M89.8 M88.9
            MeSH: D010001
            OMIM: 602080 174810 239000
REFERENCE   PMID:16831914 (gene)
  AUTHORS   Whyte MP
  TITLE     Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
  JOURNAL   Ann N Y Acad Sci 1068:143-64 (2006)
REFERENCE   PMID:20392234 (gene, env_factor)
  AUTHORS   Roodman GD
  TITLE     Insights into the pathogenesis of Paget's disease.
  JOURNAL   Ann N Y Acad Sci 1192:176-80 (2010)
REFERENCE   PMID:12929927 (gene)
  AUTHORS   Nakatsuka K, Nishizawa Y, Ralston SH
  TITLE     Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene.
  JOURNAL   J Bone Miner Res 18:1381-5 (2003)
REFERENCE   PMID:10615125 (gene)
  AUTHORS   Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM
  TITLE     Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
  JOURNAL   Nat Genet 24:45-8 (2000)
REFERENCE   PMID:12362049 (gene)
  AUTHORS   Palenzuela L, Vives-Bauza C, Fernandez-Cadenas I, Meseguer A, Font N, Sarret E, Schwartz S, Andreu AL
  TITLE     Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene.
  JOURNAL   J Med Genet 39:E67 (2002)
REFERENCE   PMID:11771666 (gene)
  AUTHORS   Whyte MP, Hughes AE
  TITLE     Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis.
  JOURNAL   J Bone Miner Res 17:26-9 (2002)
REFERENCE   PMID:12124406 (gene)
  AUTHORS   Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S
  TITLE     Osteoprotegerin deficiency and juvenile Paget's disease.
  JOURNAL   N Engl J Med 347:175-84 (2002)
REFERENCE   PMID:18328984
  AUTHORS   Ralston SH
  TITLE     Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders.
  JOURNAL   Best Pract Res Clin Rheumatol 22:101-11 (2008)
REFERENCE   PMID:20875342 (drug)
  AUTHORS   Brandi ML
  TITLE     Current treatment approaches for Paget's Disease of Bone.
  JOURNAL   Discov Med 10:209-12 (2010)
REFERENCE   PMID:2460988
  AUTHORS   Carey PO, Lippert MC
  TITLE     Treatment of painful prostatic bone metastases with oral etidronate disodium.
  JOURNAL   Urology 32:403-7 (1988)
///
ENTRY       H00438                      Disease
NAME        Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL);
            Nasu-Hakola disease
DESCRIPTION Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), or Nasu-hakola disease is an autosomal recessive inherited disorder. It is characterized by repeated fractures occurring during adolescence and progressive presenile dementia in the fourth decade. The disease is caused by a mutation in the TREM2 or DAP12 gene that regulates osteoclast differentiation. TREM2-DAP12 is also expressed by microglia, thus neurological impairments seen in this disease are considered to be directly caused by microglial dysfunstion.
CATEGORY    Skeletal dysplasia; Neurodegenerative disease
GENE        TREM2 [HSA:54209] [KO:K14378]
            DAP12 [HSA:7305] [KO:K07992]
DBLINKS     ICD-10: E75.2
            MeSH: C536329
            OMIM: 221770
REFERENCE   PMID:20500450 (gene, description)
  AUTHORS   Kaneko M, Sano K, Nakayama J, Amano N
  TITLE     Nasu-Hakola disease: The first case reported by Nasu and review.
  JOURNAL   Neuropathology (2010)
REFERENCE   PMID:20836191 (gene, description)
  AUTHORS   Bianchin MM, Martin KC, de Souza AC, de Oliveira MA, Rieder CR
  TITLE     Nasu-Hakola disease and primary microglial dysfunction.
  JOURNAL   Nat Rev Neurol 6:2 p following 523 (2010)
REFERENCE   PMID:20301376 (description)
  AUTHORS   Paloneva J, Autti T, Hakola P, Haltia MJ
  TITLE     Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)
  JOURNAL   (1993)
///
ENTRY       H00439                      Disease
NAME        Shwachman-Diamond syndrome (SDS)
DESCRIPTION Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive disease, mainly characterized by exocrine pancreatic insufficiency, hematological dysfunction and skeletal abnormalities. In most cases, SDS is associated with mutations in SBDS,a protein involved in maturation and export of the ribosomal 60S subunit.
CATEGORY    Congenital disorder of development; Ribosomopathy
GENE        SBDS [HSA:51119] [KO:K14574]
DBLINKS     ICD-10: D61.0
            MeSH: C537330
            OMIM: 260400
REFERENCE   PMID:19327581
  AUTHORS   Burroughs L, Woolfrey A, Shimamura A
  TITLE     Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment.
  JOURNAL   Hematol Oncol Clin North Am 23:233-48 (2009)
REFERENCE   PMID:20174677
  AUTHORS   Freed EF, Bleichert F, Dutca LM, Baserga SJ
  TITLE     When ribosomes go bad: diseases of ribosome biogenesis.
  JOURNAL   Mol Biosyst 6:481-93 (2010)
///
ENTRY       H00440                      Disease
NAME        Rett syndrome
DESCRIPTION Rett Syndrome is a severe neurological disorder found almost exclusively in girls. It is characterized by acquired microcephaly, communication dysfunction, psychomotor regression, seizures and stereotypical hand movements. Mutations in MECP2 are identified in most patients with classic Rett syndrome. Recently, mutations in FOXG1 gene have been shown to cause congenital variant of Rett syndrome.
CATEGORY    Neurodegenerative disease
GENE        MECP2 [HSA:4204] [KO:K11588]
            FOXG1B [HSA:2290] [KO:K09385]
DBLINKS     ICD-10: F84.2
            MeSH: D015518
            OMIM: 312750 613454
REFERENCE   PMID:12928486
  AUTHORS   Kriaucionis S, Bird A
  TITLE     DNA methylation and Rett syndrome.
  JOURNAL   Hum Mol Genet 12 Spec No 2:R221-7 (2003)
REFERENCE   PMID:19623215
  AUTHORS   Jacob FD, Ramaswamy V, Andersen J, Bolduc FV
  TITLE     Atypical Rett syndrome with selective FOXG1 deletion detected by comparative genomic hybridization: case report and review of literature.
  JOURNAL   Eur J Hum Genet 17:1577-81 (2009)
///
ENTRY       H00441                      Disease
NAME        Progressive osseous heteroplasia (POH)
DESCRIPTION Progressive osseous heteroplasia (POH) is a genetic disorder where heterozygous inactivating mutations in the GNAS gene have been identified. Patients with POH characteristically develop extensive bone formation within the superficial dermal layer of the skin.
CATEGORY    Skeletal dysplasia
GENE        GNAS [HSA:2778] [KO:K04632]
DBLINKS     MeSH: C562735
            OMIM: 166350
REFERENCE   PMID:8126048 (description)
  AUTHORS   Kaplan FS, Craver R, MacEwen GD, Gannon FH, Finkel G, Hahn G, Tabas J, Gardner RJ, Zasloff MA
  TITLE     Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification. Two new case reports and follow-up of three previously  reported cases.
  JOURNAL   J Bone Joint Surg Am 76:425-36 (1994)
REFERENCE   PMID:11784876 (gene)
  AUTHORS   Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, Gardner RJ, Zasloff MA, Whyte MP, Levine MA, Kaplan FS
  TITLE     Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia.
  JOURNAL   N Engl J Med 346:99-106 (2002)
///
ENTRY       H00442                      Disease
NAME        Campomelic dysplasia (CD)
DESCRIPTION Campomelic dysplasia (CD) is a rare congenital skeletal dysplasia characterized by bowing of the long bones (campomelia). It is often associated with male-to-female autosomal sex reversal. Haploinsufficiency of SOX9 gene has been reported.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        SOX9 [HSA:6662] [KO:K18435]
DBLINKS     ICD-10: Q87.1
            MeSH: D055036
            OMIM: 114290
REFERENCE   PMID:21309066 (description, gene)
  AUTHORS   Lee YH, Saint-Jeannet JP
  TITLE     Sox9 function in craniofacial development and disease.
  JOURNAL   Genesis 49:200-8 (2011)
///
ENTRY       H00443                      Disease
NAME        Osteoglophonic dysplasia (OD);
            Osteoglophonic dwarfism (OGD)
DESCRIPTION Osteoglophonic dysplasia (OD) or osteoglophonic dwarfism (OGD) is an autosomal dominant disorder that has skeletal phenotypes of craniosynostosis. Missense mutation of FGFR1 has been reported.
CATEGORY    Skeletal dysplasia
GENE        FGFR1 [HSA:2260] [KO:K04362]
DBLINKS     ICD-10: Q87.1
            MeSH: C536050
            OMIM: 166250
REFERENCE   PMID:20339250 (description)
  AUTHORS   Shankar VN, Ajila V, Kumar G
  TITLE     Osteoglophonic dysplasia: a case report.
  JOURNAL   J Oral Sci 52:167-71 (2010)
REFERENCE   PMID:20236123 (gene)
  AUTHORS   Sow AJ, Ramli R, Latiff ZA, Ichikawa S, Gray AK, Nordin R, Abd Jabar MN, Primuharsa Putra SH, Siar CH, Econs MJ
  TITLE     Osteoglophonic dysplasia: A 'common' mutation in a rare disease.
  JOURNAL   Clin Genet 78:197-8 (2010)
REFERENCE   PMID:15625620 (gene)
  AUTHORS   White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ
  TITLE     Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.
  JOURNAL   Am J Hum Genet 76:361-7 (2005)
///
ENTRY       H00444                      Disease
NAME        Osteopathia striata with cranial sclerosis
DESCRIPTION Osteopathia striata with cranial sclerosis (OSCS) is a bone dysplasia characterized by longitudinal striations in the metaphyseal region of the long bones and sclerosis of the craniofacial bones. The condition is X-linked dominant. Germline mutations in WTX gene cause OSCS through increased osteoblast activity.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FAM123B [HSA:139285] [KO:K19407]
DBLINKS     ICD-10: Q78.8
            MeSH: C536053
            OMIM: 300373
REFERENCE   PMID:20209645 (description, gene)
  AUTHORS   Perdu B, de Freitas F, Frints SG, Schouten M, Schrander-Stumpel C, Barbosa M, Pinto-Basto J, Reis-Lima M, de Vernejoul MC, Becker K, Freckmann ML, Keymolen K, Haan E, Savarirayan R, Koenig R, Zabel B, Vanhoenacker FM, Van Hul W
  TITLE     Osteopathia striata with cranial sclerosis owing to WTX gene defect.
  JOURNAL   J Bone Miner Res 25:82-90 (2010)
REFERENCE   PMID:9842992 (description)
  AUTHORS   Bueno AL, Ramos FJ, Bueno O, Olivares JL, Bello ML, Bueno M
  TITLE     Severe malformations in males from families with osteopathia striata with cranial sclerosis.
  JOURNAL   Clin Genet 54:400-5 (1998)
REFERENCE   PMID:19079258 (gene)
  AUTHORS   Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Minaur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Ades LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, Robertson SP
  TITLE     Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis.
  JOURNAL   Nat Genet 41:95-100 (2009)
///
ENTRY       H00445                      Disease
NAME        Osteoarthritis with mild chondrodysplasia
DESCRIPTION The disease is characterized by a progressive degeneration of the articular cartilages of joints with mild spinal chondrodysplasia due to the mutation of type II procollagen (COL2A1).
CATEGORY    Skeletal dysplasia
GENE        COL2A1 [HSA:1280] [KO:K19719]
DBLINKS     MeSH: C565740
            OMIM: 604864
REFERENCE   PMID:11708863 (description, gene)
  AUTHORS   Mier RJ, Holderbaum D, Ferguson R, Moskowitz R
  TITLE     Osteoarthritis in children associated with a mutation in the type II procollagen  gene (COL2A1).
  JOURNAL   Mol Genet Metab 74:338-41 (2001)
REFERENCE   PMID:2300123 (description, gene)
  AUTHORS   Knowlton RG, Katzenstein PL, Moskowitz RW, Weaver EJ, Malemud CJ, Pathria MN, Jimenez SA, Prockop DJ
  TITLE     Genetic linkage of a polymorphism in the type II procollagen gene (COL2A1) to primary osteoarthritis associated with mild chondrodysplasia.
  JOURNAL   N Engl J Med 322:526-30 (1990)
///
ENTRY       H00446                      Disease
NAME        Craniofacial-deafness-hand syndrome
DESCRIPTION Craniofacial-deafness-hand syndrome is inherited as an autosomal dominant or X-linked mutation characterized by a flat facial profile, hypoplastic nose, and a sensorineural hearing loss. A missense mutation in the PAX3 has been detected in patients with the disease.
CATEGORY    Developmental disorder
GENE        PAX3 [HSA:5077] [KO:K09381]
DBLINKS     MeSH: C536453
            OMIM: 122880
REFERENCE   PMID:14556253 (gene, description)
  AUTHORS   Sommer A, Bartholomew DW
  TITLE     Craniofacial-deafness-hand syndrome revisited.
  JOURNAL   Am J Med Genet A 123A:91-4 (2003)
REFERENCE   PMID:8664898 (gene)
  AUTHORS   Asher JH Jr, Sommer A, Morell R, Friedman TB
  TITLE     Missense mutation in the paired domain of PAX3 causes craniofacial-deafness-hand  syndrome.
  JOURNAL   Hum Mutat 7:30-5 (1996)
REFERENCE   PMID:6859126 (description)
  AUTHORS   Sommer A, Young-Wee T, Frye T
  TITLE     Previously undescribed syndrome of craniofacial, hand anomalies, and sensorineural deafness.
  JOURNAL   Am J Med Genet 15:71-7 (1983)
///
ENTRY       H00447                      Disease
NAME        HEM skeletal dysplasia;
            Greenberg dysplasia
DESCRIPTION Hydrops ectopic calcification-moth-eaten (HEM) or Greenberg skeletal dysplasia is a lethal chondrodystrophy characterized by fetal hydrops, short limbs, and abnormal chondro-osseous calcification. It is inherited as an autosomal recessive trait. Homozygous mutation in LBR is the cause of HEM/Greenberg skeletal dysplasia.
CATEGORY    Skeletal dysplasia
GENE        LBR [HSA:3930] [KO:K19532]
DBLINKS     ICD-10: Q78.8
            MeSH: C535858
            OMIM: 215140
REFERENCE   PMID:12618959 (description, gene)
  AUTHORS   Waterham HR, Koster J, Mooyer P, Noort Gv G, Kelley RI, Wilcox WR, Wanders RJ, Hennekam RC, Oosterwijk JC
  TITLE     Autosomal recessive HEM/Greenberg skeletal dysplasia is caused by 3 beta-hydroxysterol delta 14-reductase deficiency due to mutations in the lamin B  receptor gene.
  JOURNAL   Am J Hum Genet 72:1013-7 (2003)
REFERENCE   PMID:17467691 (description, gene)
  AUTHORS   Worman HJ, Bonne G
  TITLE     "Laminopathies": a wide spectrum of human diseases.
  JOURNAL   Exp Cell Res 313:2121-33 (2007)
///
ENTRY       H00448                      Disease
NAME        Familial osteochondritis dissecans;
            Osteochondritis dissecans, short stature, and early-onset osteoarthritis
DESCRIPTION Osteochondritis dissecans is defined as a separation of articular cartilage and subchondral bone from the joint surface, affecting the knee, ankle and elbow joints. The disease is caused by heterozygous missense mutation in Aggrecan (ACAN) which is a major cartilage component.
CATEGORY    Skeletal dysplasia
GENE        ACAN [HSA:176] [KO:K06792]
DBLINKS     MeSH: D010008
            OMIM: 165800
REFERENCE   PMID:18226555 (description)
  AUTHORS   Stattin EL, Tegner Y, Domellof M, Dahl N
  TITLE     Familial osteochondritis dissecans associated with early osteoarthritis and disproportionate short stature.
  JOURNAL   Osteoarthritis Cartilage 16:890-6 (2008)
REFERENCE   PMID:20137779 (gene)
  AUTHORS   Stattin EL, Wiklund F, Lindblom K, Onnerfjord P, Jonsson BA, Tegner Y, Sasaki T, Struglics A, Lohmander S, Dahl N, Heinegard D, Aspberg A
  TITLE     A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans.
  JOURNAL   Am J Hum Genet 86:126-37 (2010)
///
ENTRY       H00449                      Disease
NAME        Oculodentodigital dysplasia
DESCRIPTION Oculodentodigital dysplasia (ODDD) is an inherited disorder involving characteristic facial appearance and abnormalities of eyes, teeth, and limbs. The disease is inherited in both an autosomal dominant and recessive fasion. ODDD is caused by mutations in the gap junction alpha 1 gene.
CATEGORY    Skeletal dysplasia
GENE        GJA1 [HSA:2697] [KO:K07372]
DBLINKS     ICD-10: Q87.8
            MeSH: C563160
            OMIM: 164200 257850
REFERENCE   PMID:15512999 (description)
  AUTHORS   Frasson M, Calixto N, Cronemberger S, de Aguiar RA, Leao LL, de Aguiar MJ
  TITLE     Oculodentodigital dysplasia: study of ophthalmological and clinical manifestations in three boys with probably autosomal recessive inheritance.
  JOURNAL   Ophthalmic Genet 25:227-36 (2004)
REFERENCE   PMID:19338053 (gene)
  AUTHORS   Paznekas WA, Karczeski B, Vermeer S, Lowry RB, Delatycki M, Laurence F, Koivisto PA, Van Maldergem L, Boyadjiev SA, Bodurtha JN, Jabs EW
  TITLE     GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype.
  JOURNAL   Hum Mutat 30:724-33 (2009)
///
ENTRY       H00450                      Disease
NAME        Sclerosing bone dysplasias, including:
            Endosteal hyperostosis;
            Van Buchem disease, type 2;
            Osteopetrosis, autosomal dominant 1 (OPTA1)
DESCRIPTION These are a heterogeneous group of genetic disorders characterized by high bone density. These diseases are caused by missense mutations in the LRP5, a co-receptor for Wnt.
CATEGORY    Skeletal dysplasia
GENE        LRP5 [HSA:4041] [KO:K03068]
DBLINKS     ICD-10: Q78.8 Q78.2
            MeSH: C536748 C536527
            OMIM: 144750 607634 607636
REFERENCE   PMID:12579474
  AUTHORS   Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W
  TITLE     Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.
  JOURNAL   Am J Hum Genet 72:763-71 (2003)
///
ENTRY       H00451                      Disease
NAME        Osteoporosis-pseudoglioma syndrome (OPPG)
DESCRIPTION Osteoporosis-pseudoglioma syndrome (OPPG) is inherited as an autosomal recessive condition and is characterized by severe congenital osteoporosis with blindness. Mutations in LRP5 causes OPPG.
CATEGORY    Skeletal dysplasia
GENE        LRP5 [HSA:4041] [KO:K03068]
DBLINKS     MeSH: C536063
            OMIM: 259770
REFERENCE   PMID:16252235 (description, gene)
  AUTHORS   Ai M, Heeger S, Bartels CF, Schelling DK
  TITLE     Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.
  JOURNAL   Am J Hum Genet 77:741-53 (2005)
REFERENCE   PMID:15850991 (description, gene)
  AUTHORS   Levasseur R, Lacombe D, de Vernejoul MC
  TITLE     LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
  JOURNAL   Joint Bone Spine 72:207-14 (2005)
///
ENTRY       H00452                      Disease
NAME        Disorders caused by loss-of-function of LEMD3, including:
            Osteopoikilosis;
            Buschke-Ollendorff syndrome (BOS);
            Melorheostosis
DESCRIPTION Osteopoikilosis, Buschke-Ollendorff syndrome (BOS) and melorheostosis are disorders characterized by increased bone density. Loss-of-function mutations in LEMD3, which encodes an inner nuclear membrane protein can result in these conditions. LEMD3 is thought to be involved in Smad signaling.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        LEMD3 [HSA:23592] [KO:K19410]
DBLINKS     ICD-10: Q78.8 Q77.4
            MeSH: D008557 D010023
            OMIM: 166700 155950
REFERENCE   PMID:15489854 (description, gene)
  AUTHORS   Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk PC, Costa T, Janssens K, Menten B, Van Roy N, Vermeulen SJ, Savarirayan R, Van Hul W, Vanhoenacker F, Huylebroeck D, De Paepe A, Naeyaert JM, Vandesompele J, Speleman F, Verschueren K, Coucke PJ, Mortier GR
  TITLE     Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis.
  JOURNAL   Nat Genet 36:1213-8 (2004)
REFERENCE   PMID:18313966 (description, gene)
  AUTHORS   Hassikou H, Tabache F, Safi S, Baaj M, Hadri L
  TITLE     Buschke-Ollendorff syndrome.
  JOURNAL   Joint Bone Spine 75:212-4 (2008)
REFERENCE   PMID:18986450 (description, gene)
  AUTHORS   Schena D, Germi L, Zamperetti MR, Colato C, Girolomoni G
  TITLE     Buschke-Ollendorff syndrome.
  JOURNAL   Int J Dermatol 47:1159-61 (2008)
REFERENCE   PMID:19634844 (description, gene)
  AUTHORS   Jain VK, Arya RK, Bharadwaj M, Kumar S
  TITLE     Melorheostosis: clinicopathological features, diagnosis, and management.
  JOURNAL   Orthopedics 32:512 (2009)
///
ENTRY       H00453                      Disease
NAME        Contiguous gene deletion syndrome involving EYA1, including:
            Oto-facio-cervical syndrome (OFC);
            Branchiootic syndrome 1 (BOS1);
            Branchio-oto-renal syndrome (BOR)
DESCRIPTION These conditions show overlapping phenotypes of bilateral conductive hearing loss, branchial defects, and facial abnormalities. Indivisuals with BOR syndrome have renal anomalies as well. Mutations in the EYA1 or its transcription cofactor SIX1 and SIX5 are responsible for the diseases.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        (OFC, BOS1, BOR) EYA1 [HSA:2138] [KO:K15616]
            (BOS1, BOR) SIX1 [HSA:6495] [KO:K15614]
            (BOR) SIX5 [HSA:147912] [KO:K19474]
DBLINKS     ICD-10: Q87.0 Q87.8
            MeSH: D019280
            OMIM: 166780 602588 113650 610896 608389
REFERENCE   PMID:8558563 (description, gene)
  AUTHORS   Dallapiccola B, Mingarelli R
  TITLE     Otofaciocervical syndrome: a sporadic patient supports splitting from the branchio-oto-renal syndrome.
  JOURNAL   J Med Genet 32:816-8 (1995)
REFERENCE   PMID:11409867 (description, gene)
  AUTHORS   Rickard S, Parker M, van't Hoff W, Barnicoat A, Russell-Eggitt I, Winter RM, Bitner-Glindzicz M
  TITLE     Oto-facio-cervical (OFC) syndrome is a contiguous gene deletion syndrome involving EYA1: molecular analysis confirms allelism with BOR syndrome and further narrows the Duane syndrome critical region to 1 cM.
  JOURNAL   Hum Genet 108:398-403 (2001)
REFERENCE   PMID:17637804 (gene)
  AUTHORS   Sanggaard KM, Rendtorff ND, Kjaer KW, Eiberg H, Johnsen T, Gimsing S, Dyrmose J, Nielsen KO, Lage K, Tranebjaerg L
  TITLE     Branchio-oto-renal syndrome: detection of EYA1 and SIX1 mutations in five out of  six Danish families by combining linkage, MLPA and sequencing analyses.
  JOURNAL   Eur J Hum Genet 15:1121-31 (2007)
REFERENCE   PMID:15141091 (gene)
  AUTHORS   Ruf RG, Xu PX, Silvius D, Otto EA, Beekmann F, Muerb UT, Kumar S, Neuhaus TJ, Kemper MJ, Raymond RM Jr, Brophy PD, Berkman J, Gattas M, Hyland V, Ruf EM, Schwartz C, Chang EH, Smith RJ, Stratakis CA, Weil D, Petit C, Hildebrandt F
  TITLE     SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes.
  JOURNAL   Proc Natl Acad Sci U S A 101:8090-5 (2004)
///
ENTRY       H00454                      Disease
NAME        Oral-facial-digital syndrome
DESCRIPTION Oral-facial-digital syndrome is a group of heterogeneous disorders characterized by malformations of the face, oral cavity and digits. OFD type I is a male lethal disorder and due to mutations in the OFD1 gene on the X chromosome. OFD type IV is due to mutations in the TCTN3 gene and patients have tibial dysplasia. OFD type V is due to mutations in the DDX59 gene and patients show the core features of cleft palate, lobulated tongue, and polydactyly.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        (OFD1) OFD1 [HSA:8481] [KO:K16480]
            (OFD4) TCTN3 [HSA:26123] [KO:K19382]
            (OFD5) DDX59 [HSA:83479] [KO:K19466]
DBLINKS     ICD-10: Q87.0
            MeSH: D009958
            OMIM: 311200 258860 174300
REFERENCE   PMID:19876934 (description, gene)
  AUTHORS   Macca M, Franco B
  TITLE     The molecular basis of oral-facial-digital syndrome, type 1.
  JOURNAL   Am J Med Genet C Semin Med Genet 151C:318-25 (2009)
REFERENCE   PMID:20920500 (gene)
  AUTHORS   Bimonte S, De Angelis A, Quagliata L, Giusti F, Tammaro R, Dallai R, Ascenzi MG, Diez-Roux G, Franco B
  TITLE     Ofd1 is required in limb bud patterning and endochondral bone development.
  JOURNAL   Dev Biol 349:179-91 (2011)
REFERENCE   PMID:22883145
  AUTHORS   Thomas S, Legendre M, Saunier S, Bessieres B, Alby C, Bonniere M, Toutain A, Loeuillet L, Szymanska K, Jossic F, Gaillard D, Yacoubi MT, Mougou-Zerelli S, David A, Barthez MA, Ville Y, Bole-Feysot C, Nitschke P, Lyonnet S, Munnich A, Johnson CA, Encha-Razavi F, Cormier-Daire V, Thauvin-Robinet C, Vekemans M, Attie-Bitach T
  TITLE     TCTN3 mutations cause Mohr-Majewski syndrome.
  JOURNAL   Am J Hum Genet 91:372-8 (2012)
REFERENCE   PMID:23972372
  AUTHORS   Shamseldin HE, Rajab A, Alhashem A, Shaheen R, Al-Shidi T, Alamro R, Al Harassi S, Alkuraya FS
  TITLE     Mutations in DDX59 implicate RNA helicase in the pathogenesis of orofaciodigital  syndrome.
  JOURNAL   Am J Hum Genet 93:555-60 (2013)
///
ENTRY       H00455                      Disease
NAME        Spinal muscular atrophy (SMA), including:
            SMA type I (SMA1) / Werdning-Hoffman disease;
            SMA type II (SMA2);
            SMA type III (SMA3) / Kugeleberg-Welander disease;
            SMA type IV (SMA4);
            X-linked SMA (SMAX);
            Distal SMA autosomal recessive (DSMA);
            Congenital distal spinal muscular atrophy (SMAL);
            SMA proximal adult autosomal dominant (SMAPAD)
DESCRIPTION Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by degeneration of motor neurons, resulting in progressive muscle atrophy and paralysis. The most common form of SMA is caused by mutations of the SMN gene, that encodes the SMN protein, which regulates snRNP assembly. Four types of SMA are recognized depending on the age of onset and the severity of the disease: type I (Werdning-Hoffman), type II (intermediate), type III (Kugeleberg-Welander) and type IV (adult form). Other forms of spinal muscular atrophy are caused by mutation of other genes, some known and others not yet defined.
CATEGORY    Neurodegenerative disease
GENE        (SMA1,2,3,4) SMN1 [HSA:6606] [KO:K13129]
            (SMA3) SMN2 [HSA:6607] [KO:K13129]
            (SMAX1) AR [HSA:367] [KO:K08557]
            (SMAX2) UBE1 [HSA:7317] [KO:K03178]
            (SMAX3/DSMAX) ATP7A [HSA:538] [KO:K17686]
            (DSMA1) IGHMBP2 [HSA:3508] [KO:K19036]
            (DSMA4) PLEKHG5 [HSA:57449] [KO:K19464]
            (DSMA5) DNAJB2 [HSA:3300] [KO:K09508]
            (SMAL) TRPV4 [HSA:59341] [KO:K04973]
            (SMAPAD) VAPB [HSA:9217] [KO:K10707]
COMMENT     About SMAX1, please refer to H00062, for detail.
DBLINKS     ICD-10: G12.0 G12.1
            MeSH: D009134
            OMIM: 253300 253550 253400 271150 313200 301830 300489 604320 611067 614881 600175 182980
REFERENCE   PMID:20302191
  AUTHORS   Stavarachi M, Apostol P, Toma M, Cimponeriu D, Gavrila L
  TITLE     Spinal muscular atrophy disease: a literature review for therapeutic strategies.
  JOURNAL   J Med Life 3:3-9 (2010)
REFERENCE   PMID:18179898
  AUTHORS   Ramser J, Ahearn ME, Lenski C, Yariz KO, Hellebrand H, von Rhein M, Clark RD, Schmutzler RK, Lichtner P, Hoffman EP, Meindl A, Baumbach-Reardon L
  TITLE     Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy.
  JOURNAL   Am J Hum Genet 82:188-93 (2008)
REFERENCE   PMID:20170900
  AUTHORS   Kennerson ML, Nicholson GA, Kaler SG, Kowalski B, Mercer JF, Tang J, Llanos RM, Chu S, Takata RI, Speck-Martins CE, Baets J, Almeida-Souza L, Fischer D, Timmerman V, Taylor PE, Scherer SS, Ferguson TA, Bird TD, De Jonghe P, Feely SM, Shy ME, Garbern JY
  TITLE     Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy.
  JOURNAL   Am J Hum Genet 86:343-52 (2010)
REFERENCE   PMID:20037588
  AUTHORS   Auer-Grumbach M, Olschewski A, Papic L, Kremer H, McEntagart ME, Uhrig S, Fischer C, Frohlich E, Balint Z, Tang B, Strohmaier H, Lochmuller H, Schlotter-Weigel B, Senderek J, Krebs A, Dick KJ, Petty R, Longman C, Anderson NE, Padberg GW, Schelhaas HJ, van Ravenswaaij-Arts CM, Pieber TR, Crosby AH, Guelly C
  TITLE     Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C.
  JOURNAL   Nat Genet 42:160-4 (2010)
REFERENCE   PMID:21821450
  AUTHORS   Amara A, Adala L, Ben Charfeddine I, Mamai O, Mili A, Lazreg TB, H'mida D, Amri F, Salem N, Boughammura L, Saad A, Gribaa M
  TITLE     Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients.
  JOURNAL   Eur J Paediatr Neurol (2011)
REFERENCE   PMID:17564964
  AUTHORS   Maystadt I, Rezsohazy R, Barkats M, Duque S, Vannuffel P, Remacle S, Lambert B, Najimi M, Sokal E, Munnich A, Viollet L, Verellen-Dumoulin C
  TITLE     The nuclear factor kappaB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset.
  JOURNAL   Am J Hum Genet 81:67-76 (2007)
REFERENCE   PMID:19158098
  AUTHORS   Guenther UP, Handoko L, Laggerbauer B, Jablonka S, Chari A, Alzheimer M, Ohmer J, Plottner O, Gehring N, Sickmann A, von Au K, Schuelke M, Fischer U
  TITLE     IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder  distal SMA type 1 (DSMA1).
  JOURNAL   Hum Mol Genet 18:1288-300 (2009)
REFERENCE   PMID:22522442
  AUTHORS   Blumen SC, Astord S, Robin V, Vignaud L, Toumi N, Cieslik A, Achiron A, Carasso RL, Gurevich M, Braverman I, Blumen N, Munich A, Barkats M, Viollet L
  TITLE     A rare recessive distal hereditary motor neuropathy with HSJ1 chaperone mutation.
  JOURNAL   Ann Neurol 71:509-19 (2012)
///
ENTRY       H00456                      Disease
NAME        Fronto-Otopalatodigital Osteodysplasia, including:
            Otopalatodigital syndrome, type I;
            Otopalatodigital syndrome, type II;
            Melnick-Needles syndrome;
            Frontometaphyseal dysplasia
DESCRIPTION Fronto-Otopalatodigital Osteodysplasia comprises four disorders that arise from missense mutations in FLNA encoding the actin-binding cytoskeletal protein filamin A. The disorders are inherited in X-linked fashion and characterized by a typical facial appearance and generalized osteodysplasia.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        FLNA [HSA:2316] [KO:K04437]
DBLINKS     ICD-10: Q77.8 Q78.5
            MeSH: C538064 C536065 C538089
            OMIM: 311300 304120 309350 305620
REFERENCE   PMID:10706363 (description)
  AUTHORS   Verloes A, Lesenfants S, Barr M, Grange DK, Journel H, Lombet J, Mortier G, Roeder E
  TITLE     Fronto-otopalatodigital osteodysplasia: clinical evidence for a single entity encompassing Melnick-Needles syndrome, otopalatodigital syndrome types 1 and 2, and frontometaphyseal dysplasia.
  JOURNAL   Am J Med Genet 90:407-22 (2000)
REFERENCE   PMID:21031081 (gene)
  AUTHORS   Foley C, Roberts K, Tchrakian N, Morgan T, Fryer A, Robertson SP, Tubridy N
  TITLE     Expansion of the Spectrum of FLNA Mutations Associated with Melnick-Needles Syndrome.
  JOURNAL   Mol Syndromol 1:121-126 (2010)
///
ENTRY       H00457                      Disease
NAME        Primary hypertrophic osteoarthropathy (PHO)
DESCRIPTION Primary hypertrophic osteoarthropathy (PHO) is a familial disorder with delayed cranial suture closure, digital clubbing, arthropathy, and acro-osteolysis. Homozygous mutations in HPGD gene, which encodes 15-hydroxyprostaglandin dehydrogenase, were reported.
CATEGORY    Skeletal dysplasia
GENE        HPGD [HSA:3248] [KO:K00069]
DBLINKS     MeSH: D010004
            OMIM: 259100
REFERENCE   PMID:19568269 (description, gene)
  AUTHORS   Seifert W, Beninde J, Hoffmann K, Lindner TH, Bassir C, Aksu F, Hubner C, Verbeek NE, Mundlos S, Horn D
  TITLE     HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing.
  JOURNAL   Eur J Hum Genet 17:1570-6 (2009)
REFERENCE   PMID:18500342 (description, gene)
  AUTHORS   Uppal S, Diggle CP, Carr IM, Fishwick CW, Ahmed M, Ibrahim GH, Helliwell PS, Latos-Bielenska A, Phillips SE, Markham AF, Bennett CP, Bonthron DT
  TITLE     Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy.
  JOURNAL   Nat Genet 40:789-93 (2008)
///
ENTRY       H00458                      Disease
NAME        Craniosynostosis, including:
            Pfeiffer syndrome;
            Apert syndrome;
            Crouzon syndrome;
            Jackson-Weiss syndrome;
            Beare-Stevenson syndrome;
            Muenke craniosynostosis;
            Saethre-Chotzen syndrome;
            Craniosynostosis Boston type;
            Antley-Bixler syndrome;
            Carpenter syndrome;
            Craniofrontonasal dysplasia;
            Noonan syndrome;
            Baller-Gerold syndrome
DESCRIPTION Craniosynostosis is the premature fusion of the cranial sutures and secondary distortion of skull shape. The genes most frequently mutated are FGFRs.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        (Pfeiffer) FGFR1 [HSA:2260] [KO:K04362]
            (Apert, Pfeiffer, Crouzon, Jackson-Weiss, Beare-Stevenson, Antley-Bixler) FGFR2 [HSA:2263] [KO:K05093]
            (Muenke) FGFR3 [HSA:2261] [KO:K05094]
            (Saethre-Chotzen) TWIST1 [HSA:7291] [KO:K09069]
            (Boston) MSX2 [HSA:4488] [KO:K09341]
            (Antley-Bixler) POR [HSA:5447] [KO:K00327]
            (Carpenter) RAB23 [HSA:51715] [KO:K06234]
            (Craniofrontonasal) EFNB1 [HSA:1947] [KO:K05463]
            (Noonan) KRAS [HSA:3845] [KO:K07827]
            (Baller-Gerold) RECQL4 [HSA:9401] [KO:K10730]
            (CRS3) TCF12 [HSA:6938] [KO:K15603]
            (CRS4) ERF [HSA:2077] [KO:K09434]
            (CRS6) ZIC1 [HSA:7545] [KO:K09224]
COMMENT     See also H01753  Antley-Bixler syndrome, H01754  Crouzon syndrome, H01755  Apert syndrome, H01756  Pfeiffer syndrome, and  H00523  Noonan syndrome.
DBLINKS     ICD-10: Q75 Q87
            MeSH: D000168 D003398 D054882
            OMIM: 101600 101200 123500 123150 123790 602849 612247 101400 604757 207410 201750 201000 304110 609942 218600 123100 123150 207410 615314 600775 616602
REFERENCE   PMID:21248745
  AUTHORS   Johnson D, Wilkie AO
  TITLE     Craniosynostosis.
  JOURNAL   Eur J Hum Genet 19:369-76 (2011)
REFERENCE   PMID:15828709
  AUTHORS   Aleck K
  TITLE     Craniosynostosis syndromes in the genomic era.
  JOURNAL   Semin Pediatr Neurol 11:256-61 (2004)
REFERENCE   PMID:23438589 (gene)
  AUTHORS   Fitzpatrick DR
  TITLE     Filling in the gaps in cranial suture biology.
  JOURNAL   Nat Genet 45:231-2 (2013)
REFERENCE   PMID:26340333 (gene)
  AUTHORS   Twigg SR, Forecki J, Goos JA, Richardson IC, Hoogeboom AJ, van den Ouweland AM, Swagemakers SM, Lequin MH, Van Antwerp D, McGowan SJ, Westbury I, Miller KA, Wall SA, van der Spek PJ, Mathijssen IM, Pauws E, Merzdorf CS, Wilkie AO
  TITLE     Gain-of-Function Mutations in ZIC1 Are Associated with Coronal Craniosynostosis and Learning Disability.
  JOURNAL   Am J Hum Genet 97:378-88 (2015)
///
ENTRY       H00459                      Disease
NAME        Synpolydactyly
DESCRIPTION Synpolydactyly is a dominantly inherited congenital limb malformation showing digit duplication and webbing of third and fourth fingers. Mutation in HOXD13 induces synpolydactyly.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        HOXD13 [HSA:3239] [KO:K09298]
DBLINKS     ICD-10: Q70.0 Q70.2
            MeSH: C538153
            OMIM: 186000
REFERENCE   PMID:12357469 (description, gene)
  AUTHORS   Goodman FR
  TITLE     Limb malformations and the human HOX genes.
  JOURNAL   Am J Med Genet 112:256-65 (2002)
REFERENCE   PMID:21782042 (description, gene)
  AUTHORS   Brison N, Tylzanowski P, Debeer P
  TITLE     Limb skeletal malformations - What the HOX is going on?
  JOURNAL   Eur J Med Genet (2011)
///
ENTRY       H00460                      Disease
NAME        Hand-foot-genital syndrome
DESCRIPTION Hand-foot-genital syndrome is very rare dominantly inherited condition affecting the development of the limbs and genitourinary tract.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        HOXA13 [HSA:3209] [KO:K09298]
DBLINKS     ICD-10: Q51.5
            MeSH: C535627
            OMIM: 140000
REFERENCE   PMID:21782042 (description, gene)
  AUTHORS   Brison N, Tylzanowski P, Debeer P
  TITLE     Limb skeletal malformations - What the HOX is going on?
  JOURNAL   Eur J Med Genet (2011)
REFERENCE   PMID:10839976 (description, gene)
  AUTHORS   Goodman FR, Bacchelli C, Brady AF, Brueton LA, Fryns JP, Mortlock DP, Innis JW, Holmes LB, Donnenfeld AE, Feingold M, Beemer FA, Hennekam RC, Scambler PJ
  TITLE     Novel HOXA13 mutations and the phenotypic spectrum of hand-foot-genital syndrome.
  JOURNAL   Am J Hum Genet 67:197-202 (2000)
///
ENTRY       H00461                      Disease
NAME        FLNB-related disorders, including: ;
            Atelostogenesis, type I;
            Boomerang dysplasia;
            Atelosteogenesis, type III;
            Larsen syndrome
DESCRIPTION The FLNB-related disorders include mild to severe osteochondrodysplasias with congenital joint dislocation. AOI and AOIII are lethal or semilethal disorders. Mutations in the gene encoding filamin B (FLNB) are associated with these disorders.
CATEGORY    Skeletal dysplasia
GENE        FLNB [HSA:2317] [KO:K04437]
DBLINKS     ICD-10: Q78.8 Q87.1 Q68.8
            MeSH: C536573
            OMIM: 108720 112310 108721 150250
REFERENCE   PMID:20301736 (description, gene)
  AUTHORS   Robertson S
  TITLE     FLNB-Related Disorders
  JOURNAL   (1993)
REFERENCE   PMID:16752402 (description, gene)
  AUTHORS   Farrington-Rock C, Firestein MH, Bicknell LS, Superti-Furga A, Bacino CA, Cormier-Daire V, Le Merrer M, Baumann C, Roume J, Rump P, Verheij JB, Sweeney E, Rimoin DL, Lachman RS, Robertson SP, Cohn DH, Krakow D
  TITLE     Mutations in two regions of FLNB result in atelosteogenesis I and III.
  JOURNAL   Hum Mutat. 27:705-10 (2006)
REFERENCE   PMID:9409862 (description)
  AUTHORS   Nishimura G, Horiuchi T, Kim OH, Sasamoto Y
  TITLE     Atypical skeletal changes in otopalatodigital syndrome type II: phenotypic overlap among otopalatodigital syndrome type II, boomerang dysplasia, atelosteogenesis type I and type III, and lethal male phenotype of Melnick-Needles syndrome.
  JOURNAL   Am J Med Genet 73:132-8 (1997)
///
ENTRY       H00462                      Disease
NAME        Stuve-Wiedemann syndrome
DESCRIPTION Stuve-Wiedemann syndrome is an autosomal recessively inherited disorder characterized by congenital bone dysplasia like bowing of the long bones. Mutations in LIFR result in this disease.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        LIFR [HSA:3977] [KO:K05058]
DBLINKS     MeSH: C537502
            OMIM: 601559
REFERENCE   PMID:8723080 (description)
  AUTHORS   Wiedemann HR, Stuve A.
  TITLE     Stuve-Wiedemann syndrome: update and historical footnote.
  JOURNAL   Am J Med Genet. 63:12-6 (1996)
REFERENCE   PMID:18546280 (description, gene)
  AUTHORS   Gaspar IM, Saldanha T, Cabral P, Vilhena MM, Tuna M, Costa C, Dagoneau N, Daire VC, Hennekam RC
  TITLE     Long-term follow-up in Stuve-Wiedemann syndrome: a clinical report.
  JOURNAL   Am J Med Genet A 146A:1748-53 (2008)
REFERENCE   PMID:14740318 (gene)
  AUTHORS   Dagoneau N, Scheffer D, Huber C, Al-Gazali LI, Di Rocco M, Godard A, Martinovic J, Raas-Rothschild A, Sigaudy S, Unger S, Nicole S, Fontaine B, Taupin JL, Moreau JF, Superti-Furga A, Le Merrer M, Bonaventure J, Munnich A, Legeai-Mallet L, Cormier-Daire V
  TITLE     Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome.
  JOURNAL   Am J Hum Genet 74:298-305 (2004)
///
ENTRY       H00463                      Disease
NAME        Currarino syndrome
DESCRIPTION Currarino syndrome is a condition characterized by the combination of sacral malformation, hindgut anomaly, and presacral mass. The HLXB9 gene is responsible for the symdrome.
CATEGORY    Skeletal dysplasia
GENE        HLXB9 [HSA:3110] [KO:K08025]
DBLINKS     ICD-10: Q42
            MeSH: C536221
            OMIM: 176450
REFERENCE   PMID:6789651 (description)
  AUTHORS   Currarino G, Coln D, Votteler T
  TITLE     Triad of anorectal, sacral, and presacral anomalies.
  JOURNAL   AJR Am J Roentgenol 137:395-8 (1981)
REFERENCE   PMID:8740138 (description)
  AUTHORS   Kochling J, Pistor G, Marzhauser Brands S, Nasir R, Lanksch WR
  TITLE     The Currarino syndrome--hereditary transmitted syndrome of anorectal, sacral and  presacral anomalies. Case report and review of the literature.
  JOURNAL   Eur J Pediatr Surg 6:114-9 (1996)
REFERENCE   PMID:18449898 (gene)
  AUTHORS   Cretolle C, Pelet A, Sanlaville D, Zerah M, Amiel J, Jaubert F, Revillon Y, Baala L, Munnich A, Nihoul-Fekete C, Lyonnet S
  TITLE     Spectrum of HLXB9 gene mutations in Currarino syndrome and genotype-phenotype correlation.
  JOURNAL   Hum Mutat 29:903-10 (2008)
REFERENCE   PMID:10749657 (gene)
  AUTHORS   Hagan DM, Ross AJ, Strachan T, Lynch SA, Ruiz-Perez V, Wang YM, Scambler P, Custard E, Reardon W, Hassan S, Nixon P, Papapetrou C, Winter RM, Edwards Y, Morrison K, Barrow M, Cordier-Alex MP, Correia P, Galvin-Parton PA, Gaskill S, Gaskin KJ, Garcia-Minaur S, Gereige R, Hayward R, Homfray T
  TITLE     Mutation analysis and embryonic expression of the HLXB9 Currarino syndrome gene.
  JOURNAL   Am J Hum Genet 66:1504-15 (2000)
///
ENTRY       H00464                      Disease
NAME        Patella dysplasias, including:
            Small patella syndrome (SPS);
            Nail-patella syndrome;
            Ear-patella-short statute syndrome
DESCRIPTION Patella dysplasias are a group of disorders that include aplasia/hypoplasia of patellar. Small patella syndrome is a skeletal dysplasia with anomalies of the pelvis. Ossification of the ischia and inferior pubic rami is also disrupted in patients with small patella syndrome. Nail-patella syndrome is a condition caused by mutation in LMX1B that regulates COL4A4 and COL4A3 expression. The most common associated abnormality is nail dysplasia. Ear-patella-short statute syndrome is characterized by microtia and growth retardation due to delayed skeletal development.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        (small) TBX4 [HSA:9496] [KO:K10178]
            (nail) LMX1B [HSA:4010] [KO:K09371]
            (ear) ORC1 [HSA:4998] [KO:K02603]
            (ear) ORC4 [HSA:5000] [KO:K02606]
            (ear) CDT1 [HSA:81620] [KO:K10727]
DBLINKS     ICD-10: Q74.1 Q87.2
            MeSH: C535540 D009261 C538012
            OMIM: 147891 161200 224690
REFERENCE   PMID:15106123 (gene)
  AUTHORS   Bongers EM, Duijf PH, van Beersum SE, Schoots J, Van Kampen A, Burckhardt A, Hamel BC, Losan F, Hoefsloot LH, Yntema HG, Knoers NV, van Bokhoven H
  TITLE     Mutations in the human TBX4 gene cause small patella syndrome.
  JOURNAL   Am J Hum Genet 74:1239-48 (2004)
REFERENCE   PMID:9133358 (description)
  AUTHORS   Azouz EM, Kozlowski K.
  TITLE     Small patella syndrome: a bone dysplasia to recognize and differentiate from the nail-patella syndrome.
  JOURNAL   Pediatr Radiol. 27:432-5 (1997)
REFERENCE   PMID:12666288 (description)
  AUTHORS   Sferopoulos NK, Tsitouridis I
  TITLE     Ischiopubic hypoplasia: a rare constituent of congenital syndromes.
  JOURNAL   Acta Orthop Belg 69:29-34 (2003)
REFERENCE   PMID:12215822 (description, gene)
  AUTHORS   Bongers EM, Gubler MC, Knoers NV
  TITLE     Nail-patella syndrome. Overview on clinical and molecular findings.
  JOURNAL   Pediatr Nephrol 17:703-12 (2002)
REFERENCE   PMID:11175791 (description, gene)
  AUTHORS   Morello R, Zhou G, Dreyer SD, Harvey SJ, Ninomiya Y, Thorner PS, Miner JH, Cole W, Winterpacht A, Zabel B, Oberg KC, Lee B
  TITLE     Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome.
  JOURNAL   Nat Genet 27:205-8 (2001)
REFERENCE   PMID:10213048 (description)
  AUTHORS   Loeys BL, Lemmerling MM, Van Mol CE, Leroy JG
  TITLE     The Meier-Gorlin syndrome, or ear-patella-short stature syndrome, in sibs.
  JOURNAL   Am J Med Genet 84:61-7 (1999)
REFERENCE   PMID:11807867 (description)
  AUTHORS   Cohen A, Mulas R, Seri M, Gaiero A, Fichera G, Marini M, Baffico M, Camera G
  TITLE     Meier-Gorlin syndrome (ear-patella-short stature syndrome) in an Italian patient: clinical evaluation and analysis of possible candidate genes.
  JOURNAL   Am J Med Genet 107:48-51 (2002)
REFERENCE   PMID:11477602 (description)
  AUTHORS   Bongers EM, Opitz JM, Fryer A, Sarda P, Hennekam RC, Hall BD, Superneau DW, Harbison M, Poss A, van Bokhoven H, Hamel BC, Knoers NV
  TITLE     Meier-Gorlin syndrome: report of eight additional cases and review.
  JOURNAL   Am J Med Genet 102:115-24 (2001)
REFERENCE   PMID:21358632 (gene)
  AUTHORS   Bicknell LS, Bongers EM, Leitch A, Brown S, Schoots J, Harley ME, Aftimos S, Al-Aama JY, Bober M, Brown PA, van Bokhoven H, Dean J, Edrees AY, Feingold M, Fryer A, Hoefsloot LH, Kau N, Knoers NV, Mackenzie J, Opitz JM, Sarda P, Ross A, Temple IK, Toutain A, Wise CA, Wright M, Jackson AP
  TITLE     Mutations in the pre-replication complex cause Meier-Gorlin syndrome.
  JOURNAL   Nat Genet 43:356-9 (2011)
REFERENCE   PMID:21358631 (gene)
  AUTHORS   Guernsey DL, Matsuoka M, Jiang H, Evans S, Macgillivray C, Nightingale M, Perry S, Ferguson M, LeBlanc M, Paquette J, Patry L, Rideout AL, Thomas A, Orr A, McMaster CR, Michaud JL, Deal C, Langlois S, Superneau DW, Parkash S, Ludman M, Skidmore DL, Samuels ME
  TITLE     Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome.
  JOURNAL   Nat Genet 43:360-4 (2011)
///
ENTRY       H00465                      Disease
NAME        Fragile X syndrome (FXS)
DESCRIPTION Fragile X syndrome (FXS) is a cognitive disorder caused by silencing of the fragile X mental retardation 1 gene (FMR1). Absence of the associated protein FMRP leads to the dysregulation of many genes creating a phenotype of ADHD, anxiety, epilepsy and autism.There are also several physical features commonly associated with FXS, including elongated faces, prominent ears, and macroorchidism. The most prevalent genetic aberration at the FMR1 locus arises from a noncoding CGG repeat in the 5'untranslated region.
CATEGORY    Chromosomal abnormality
GENE        FMR1 [HSA:2332] [KO:K15516]
COMMENT     See also H01731 Fragile X tremor/ataxia syndrome (FXTAS).
            (FXR) Full mutation expansions (>200 CGG repeats)
            (FXTAS) Smaller expansions in the premutation range (55-200 CGG repeats)
DBLINKS     ICD-10: Q99.2
            MeSH: D005600
            OMIM: 300624
REFERENCE   PMID:18805096
  AUTHORS   Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, Witke W, Costa-Mattioli M, Sonenberg N, Achsel T, Bagni C
  TITLE     The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.
  JOURNAL   Cell 134:1042-54 (2008)
REFERENCE   PMID:19325170
  AUTHORS   Pfeiffer BE, Huber KM
  TITLE     The state of synapses in fragile X syndrome.
  JOURNAL   Neuroscientist 15:549-67 (2009)
REFERENCE   PMID:20682752
  AUTHORS   Bhogal B, Jongens TA
  TITLE     Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention.
  JOURNAL   Dis Model Mech 3:693-700 (2010)
///
ENTRY       H00466                      Disease
NAME        Grebe dysplasia;
            Acromesomelic dysplasia Hunter-Thompson type
DESCRIPTION Acromesomelic dysplasia is a rare form of severe acromesomelic limb shortening inherited in autosomal recessive fashion. Lower limbs are more affected than the upper limbs, showing nonfunctional fingers. Homozygous mutations in GDF5 are the cause of the disease.
CATEGORY    Skeletal dysplasia
GENE        GDF5 [HSA:8200] [KO:K04664]
DBLINKS     ICD-10: Q77.8
            MeSH: C537915 C535658
            OMIM: 200700 201250
REFERENCE   PMID:9288098 (description, gene)
  AUTHORS   Thomas JT, Kilpatrick MW, Lin K, Erlacher L, Lembessis P, Costa T, Tsipouras P, Luyten FP
  TITLE     Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1.
  JOURNAL   Nat Genet 17:58-64 (1997)
REFERENCE   PMID:12124730 (description, gene)
  AUTHORS   Faiyaz-Ul-Haque M, Ahmad W, Wahab A, Haque S, Azim AC, Zaidi SH, Teebi AS, Ahmad M, Cohn DH, Siddique T, Tsui LC
  TITLE     Frameshift mutation in the cartilage-derived morphogenetic protein 1 (CDMP1) gene and severe acromesomelic chondrodysplasia resembling Grebe-type chondrodysplasia.
  JOURNAL   Am J Med Genet 111:31-7 (2002)
REFERENCE   PMID:12567410 (description, gene)
  AUTHORS   Savarirayan R, White SM, Goodman FR, Graham JM Jr, Delatycki MB, Lachman RS, Rimoin DL, Everman DB, Warman ML
  TITLE     Broad phenotypic spectrum caused by an identical heterozygous CDMP-1 mutation in  three unrelated families.
  JOURNAL   Am J Med Genet A 117A:136-42 (2003)
///
ENTRY       H00467                      Disease
NAME        Fibular hypoplasia and complex brachydactyly;
            Du Pan syndrome
DESCRIPTION Fibular hypoplasia and complex brachydactyly (DuPan syndrome), inherited as an autosomal recessive trait, is characterized by fibula aplasia and severe limb shortening. Affected individuals were reported to be homozygous for a GDF5 missense mutation.
CATEGORY    Skeletal dysplasia
GENE        GDF5 [HSA:8200] [KO:K04664]
DBLINKS     MeSH: C537931
            OMIM: 228900
REFERENCE   PMID:12567410 (description, gene)
  AUTHORS   Savarirayan R, White SM, Goodman FR, Graham JM Jr, Delatycki MB, Lachman RS, Rimoin DL, Everman DB, Warman ML
  TITLE     Broad phenotypic spectrum caused by an identical heterozygous CDMP-1 mutation in  three unrelated families.
  JOURNAL   Am J Med Genet A 117A:136-42 (2003)
REFERENCE   PMID:12121354 (description, gene)
  AUTHORS   Faiyaz-Ul-Haque M, Ahmad W, Zaidi SH, Haque S, Teebi AS, Ahmad M, Cohn DH, Tsui LC
  TITLE     Mutation in the cartilage-derived morphogenetic protein-1 (CDMP1) gene in a kindred affected with fibular hypoplasia and complex brachydactyly (DuPan syndrome).
  JOURNAL   Clin Genet 61:454-8 (2002)
///
ENTRY       H00468                      Disease
NAME        Acromesomelic dysplasia with genital anomalies
DESCRIPTION Acromesomelic dysplasia with genital anomalies is a condition that shows severe limb malformation with brachydactyly. Hypogonadism is also present. It is caused by homozygous mutation of BMPR1B.
CATEGORY    Skeletal dysplasia
GENE        BMPR1B [HSA:658] [KO:K13578]
DBLINKS     MeSH: C537913
            OMIM: 609441
REFERENCE   PMID:15805157 (description, gene)
  AUTHORS   Demirhan O, Turkmen S, Schwabe GC, Soyupak S, Akgul E, Tastemir D, Karahan D, Mundlos S, Lehmann K
  TITLE     A homozygous BMPR1B mutation causes a new subtype of acromesomelic chondrodysplasia with genital anomalies.
  JOURNAL   J Med Genet 42:314-7 (2005)
REFERENCE   PMID:19790289 (description, gene)
  AUTHORS   Mundlos S
  TITLE     The brachydactylies: a molecular disease family.
  JOURNAL   Clin Genet 76:123-36 (2009)
///
ENTRY       H00469                      Disease
NAME        Mitochondrial DNA depletion syndrome (MDS)
DESCRIPTION Mitochondrial DNA depletion syndromes (MDSs) are a group of heterogeneous autosomal recessive disorders associated with a severe reduction in mitochondrial DNA in the affected tissues. The manifestations vary from tissue-specific mtDNA depletion to wide-spread multisystemic disorders. Some genes are known to underlie this group of disorders, and many disease genes are still unidentified. However, the disease mechanisms seem to be intimately associated with mtDNA replication and nucleotide pool regulation.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        (MTDPS1) TYMP [HSA:1890] [KO:K00758]
            (MTDPS2) TK2 [HSA:7084] [KO:K00857]
            (MTDPS3) DGUOK [HSA:1716] [KO:K00904]
            (MTDPS4A/4B) POLG [HSA:5428] [KO:K02332]
            (MTDPS5) SUCLA2 [HSA:8803] [KO:K01900]
            (MTDPS6) MPV17 [HSA:4358] [KO:K13348]
            (MTDPS7) PEO1 [HSA:56652] [KO:K17680]
            (MTDPS8A/8B) RRM2B [HSA:50484] [KO:K10808]
            (MTDPS9) SUCLG1 [HSA:8802] [KO:K01899]
            (MTDPS10) AGK [HSA:55750] [KO:K09881]
            (MTDPS11) MGME1 [HSA:92667] [KO:K19465]
            (MTDPS12) SLC25A4 [HSA:291] [KO:K05863]
            (MTDPS13) FBXL4 [HSA:26235] [KO:K10270]
DRUG        Pyruvate [CPD:C00022]
COMMENT     MNGIE type: MTDPS1, MTDPS4B, MTDPS8B
            Myopathic type: MTDPS2, MTDPS11
            Hepatocerebral type: MTDPS3, MTDPS6, MTDPS7 
            Encephalomyopathic: MTDPS5, MTDPS8A, MTDPS9, MTDP12, MTDP13
            Alpers type: MTDPS4A
DBLINKS     ICD-10: E88.8
            MeSH: D017237
            OMIM: 603041 609560 251880 203700 613662 612073 256810 271245 612075 245400 221350 615084 615418 615471
REFERENCE   PMID:20444604
  AUTHORS   Suomalainen A, Isohanni P
  TITLE     Mitochondrial DNA depletion syndromes--many genes, common mechanisms.
  JOURNAL   Neuromuscul Disord 20:429-37 (2010)
REFERENCE   PMID:21855607
  AUTHORS   Saito K, Kimura N, Oda N, Shimomura H, Kumada T, Miyajima T, Murayama K, Tanaka M, Fujii T
  TITLE     Pyruvate therapy for mitochondrial DNA depletion syndrome.
  JOURNAL   Biochim Biophys Acta (2011)
REFERENCE   PMID:22284826
  AUTHORS   Mayr JA, Haack TB, Graf E, Zimmermann FA, Wieland T, Haberberger B, Superti-Furga A, Kirschner J, Steinmann B, Baumgartner MR, Moroni I, Lamantea E, Zeviani M, Rodenburg RJ, Smeitink J, Strom TM, Meitinger T, Sperl W, Prokisch H
  TITLE     Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome.
  JOURNAL   Am J Hum Genet 90:314-20 (2012)
REFERENCE   PMID:23313956
  AUTHORS   Kornblum C, Nicholls TJ, Haack TB, Scholer S, Peeva V, Danhauser K, Hallmann K, Zsurka G, Rorbach J, Iuso A, Wieland T, Sciacco M, Ronchi D, Comi GP, Moggio M, Quinzii CM, DiMauro S, Calvo SE, Mootha VK, Klopstock T, Strom TM, Meitinger T, Minczuk M, Kunz WS, Prokisch H
  TITLE     Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease.
  JOURNAL   Nat Genet 45:214-9 (2013)
REFERENCE   PMID:16155110
  AUTHORS   Palmieri L, Alberio S, Pisano I, Lodi T, Meznaric-Petrusa M, Zidar J, Santoro A, Scarcia P, Fontanesi F, Lamantea E, Ferrero I, Zeviani M
  TITLE     Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy.
  JOURNAL   Hum Mol Genet 14:3079-88 (2005)
REFERENCE   PMID:23993193
  AUTHORS   Bonnen PE, Yarham JW, Besse A, Wu P, Faqeih EA, Al-Asmari AM, Saleh MA, Eyaid W, Hadeel A, He L, Smith F, Yau S, Simcox EM, Miwa S, Donti T, Abu-Amero KK, Wong LJ, Craigen WJ, Graham BH, Scott KL, McFarland R, Taylor RW
  TITLE     Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance.
  JOURNAL   Am J Hum Genet 93:471-81 (2013)
///
ENTRY       H00470                      Disease
NAME        Acromesomelic dysplasia, Maroteaux type
DESCRIPTION Acromesomelic dysplasia, Maroteaux type is an autosomal recessive skeletal dysplasia that affects postnatal skeletal growth. Affected indivisials show marked short stature and limb shortening. Homozygous loss-of-function mutations in NPR2 have been identified.
CATEGORY    Skeletal dysplasia
GENE        NPR2 [HSA:4882] [KO:K12324]
DBLINKS     ICD-10: Q77.8
            MeSH: C535661
            OMIM: 602875
REFERENCE   PMID:18945719 (gene)
  AUTHORS   Hume AN, Buttgereit J, Al-Awadhi AM, Al-Suwaidi SS, John A, Bader M, Seabra MC, Al-Gazali L, Ali BR
  TITLE     Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux.
  JOURNAL   Hum Mol Genet 18:267-77 (2009)
REFERENCE   PMID:15146390 (description, gene)
  AUTHORS   Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI, Kant S, Cole T, Morton J, Cormier-Daire V, Faivre L, Lees M, Kirk J, Mortier GR, Leroy J, Zabel B, Kim CA, Crow Y, Braverman NE, van den Akker F, Warman ML
  TITLE     Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux.
  JOURNAL   Am J Hum Genet 75:27-34 (2004)
REFERENCE   PMID:17652215 (description, gene)
  AUTHORS   Hachiya R, Ohashi Y, Kamei Y, Suganami T, Mochizuki H, Mitsui N, Saitoh M, Sakuragi M, Nishimura G, Ohashi H, Hasegawa T, Ogawa Y
  TITLE     Intact kinase homology domain of natriuretic peptide receptor-B is essential for  skeletal development.
  JOURNAL   J Clin Endocrinol Metab 92:4009-14 (2007)
///
ENTRY       H00471                      Disease
NAME        Split-hand/foot malformation (SHFM)
DESCRIPTION Split hand/foot malformation (SHFM) is a congenital limb malformation characterized by median clefts of hands and foot. Disrupted formation of the apical ectodermal ridge during development results in central ray deficiency in SHFM patients.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        (SHFM4) TP63 [HSA:8626] [KO:K10149]
            (SHFM6) WNT10B [HSA:7480] [KO:K01357]
DBLINKS     MeSH: C567893 C564056 C565437 C565344 C564674 C567616
            OMIM: 605289 225300
REFERENCE   PMID:16283879 (description, gene)
  AUTHORS   Elliott AM, Evans JA, Chudley AE
  TITLE     Split hand foot malformation (SHFM).
  JOURNAL   Clin Genet 68:501-5 (2005)
REFERENCE   PMID:16763964 (description, gene)
  AUTHORS   Basel D, Kilpatrick MW, Tsipouras P
  TITLE     The expanding panorama of split hand foot malformation.
  JOURNAL   Am J Med Genet A 140:1359-65 (2006)
REFERENCE   PMID:12668597 (description, gene)
  AUTHORS   Duijf PH, van Bokhoven H, Brunner HG
  TITLE     Pathogenesis of split-hand/split-foot malformation.
  JOURNAL   Hum Mol Genet 12 Spec No 1:R51-60 (2003)
REFERENCE   PMID:21554266 (gene)
  AUTHORS   Khan S, Basit S, Zimri F, Ali N, Ali G, Ansar M, Ahmad W
  TITLE     A novel homozygous missense mutation in WNT10B in familial split-hand/foot malformation.
  JOURNAL   Clin Genet (2011)
///
ENTRY       H00472                      Disease
NAME        Torg-Winchester syndrome
DESCRIPTION Torg-Winchester syndrome is a multicentric osteolysis syndrome characterized by progressive bone loss in hands and feet. MMP2 mutations are reported in patients with Torg-Winchester syndrome.
CATEGORY    Skeletal dysplasia
GENE        MMP2 [HSA:4313] [KO:K01398]
DBLINKS     MeSH: C536051
            OMIM: 259600
REFERENCE   PMID:10861676 (description)
  AUTHORS   Al Aqeel A, Al Sewairi W, Edress B, Gorlin RJ, Desnick RJ, Martignetti JA
  TITLE     Inherited multicentric osteolysis with arthritis: a variant resembling Torg syndrome in a Saudi family.
  JOURNAL   Am J Med Genet 93:11-8 (2000)
REFERENCE   PMID:17059372 (description, gene)
  AUTHORS   Zankl A, Pachman L, Poznanski A, Bonafe L, Wang F, Shusterman Y, Fishman DA, Superti-Furga A
  TITLE     Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome.
  JOURNAL   J Bone Miner Res 22:329-33 (2007)
REFERENCE   PMID:20720557 (description, gene)
  AUTHORS   Jeong SY, Kim BY, Kim HJ, Yang JA, Kim OH
  TITLE     A novel homozygous MMP2 mutation in a patient with Torg-Winchester syndrome.
  JOURNAL   J Hum Genet 55:764-6 (2010)
///
ENTRY       H00473                      Disease
NAME        Mitochondrial respiratory chain deficiencies (MRCD), including:
            Mitochondrial complex I deficiency (MT-C1D);
            Complex II deficiency (MT-C2D);
            Complex III deficiency (MT-C3D);
            Leigh syndrome (LS) [DS:H01354];
            Leber Hereditary Optic Neuropathy (LHON) [DS:H00068];
            Leber Optic Atrophy and Dystonia (LDYT) [DS:H01365];
            MELAS Syndrome [DS:H01347];
            Kearns-Sayre Syndrome (KSS) [DS:H01355];
            GRACILE Syndrome
DESCRIPTION Mitochondrial respiratory chain deficiencies (MRCD) are a group of disorders of adults and children, with highly variable phenotypes that include macrocephaly with progressive leukodystrophy, encephalopathy (including MELAS), cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease and Alzheimer's disease.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        (MT-C1D) NDUFS1 [HSA:4719] [KO:K03934]
            (MT-C1D) NDUFS2 [HSA:4720] [KO:K03935]
            (MT-C1D/LS) NDUFS3 [HSA:4722] [KO:K03936]
            (MT-C1D/LS) NDUFS4 [HSA:4724] [KO:K03937]
            (MT-C1D) NDUFS6 [HSA:4726] [KO:K03939]
            (MT-C1D/LS) NDUFS7 [HSA:374291] [KO:K03940]
            (MT-C1D/LS) NDUFS8 [HSA:4728] [KO:K03941]
            (MT-C1D) NDUFA1 [HSA:4694] [KO:K03945]
            (MT-C1D) NDUFA11 [HSA:126328] [KO:K03956]
            (MT-C1D/LS) NDUFAF2 [HSA:91942] [KO:K18160]
            (MT-C1D) NDUFAF3 [HSA:25915] [KO:K09008]
            (MT-C1D) NDUFAF4 [HSA:29078] [KO:K18161]	
            (MT-C1D/LS) NDUFV1 [HSA:4723] [KO:K03942]
            (MT-C1D) NDUFV2 [HSA:4729] [KO:K03943]
            (MT-C1D) NUBPL [HSA:80224] [KO:K03593]
            (MT-C1D/LS) FOXRED1 [HSA:55572] [KO:K18166]
            (MT-C1D) NDUFAF5 [HSA:79133] [KO:K18162]
            (MT-C1D/LS) NDUFAF6 [HSA:137682] [KO:K18163]
            (MT-C1D) ACAD9 [HSA:28976] [KO:K15980]
            (MT-C1D/LHON/LDYT/MELAS) MT-ND1 [HSA:4535] [KO:K03878]
            (MT-C1D/LHON) MT-ND2 [HSA:4536] [KO:K03879]
            (MT-C1D/LS/LDYT/KSS) MT-ND3 [HSA:4537] [KO:K03880]
            (MT-C1D/LHON/LDYT/KSS) MT-ND4 [HSA:4538] [KO:K03881]
            (MT-C1D/LHON) MT-ND4L [HSA:4539] [KO:K03882]
            (MT-C1D/LHON/LS/MELAS/KSS) MT-ND5 [HSA:4540] [KO:K03883]
            (MT-C1D/LHON/LDYT/KSS) MT-ND6 [HSA:4541] [KO:K03884]
            (MT-C2D) SDHAF1 [HSA:644096] [KO:K18167]
            (MT-C2D/LS) SDHA [HSA:6389] [KO:K00234]
            (MT-C3D/LS/GRACILE) BCS1L [HSA:617] [KO:K08900]
            (MT-C3D) UQCRQ [HSA:27089] [KO:K00418]
            (MT-C3D) UQCRB [HSA:7381] [KO:K00417]
            (MT-C3D/LHON/KSS) MT-CYB [HSA:4519] [KO:K00412]
            (MT-C3D) TTC19 [HSA:54902] [KO:K18169]
DRUG        (MELAS) L-arginin [DR:D02982]
            (MELAS) Coenzyme Q10 [DR:D01065]
COMMENT     KSS, LHON, MELAS, and MERRF can be caused by mutation in multiple genes encoded by the mitochondrial genome mtDNA.
DBLINKS     ICD-10: E88.8
            MeSH: C537475 C565375 C565128
            OMIM: 252010 252011 124000 611126 256000 220111 535000 500001 540000 530000 603358
REFERENCE   PMID:19336460
  AUTHORS   Distelmaier F, Koopman WJ, van den Heuvel LP, Rodenburg RJ, Mayatepek E, Willems PH, Smeitink JA
  TITLE     Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease.
  JOURNAL   Brain 132:833-42 (2009)
REFERENCE   PMID:16288654
  AUTHORS   Bayley JP, Devilee P, Taschner PE
  TITLE     The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency.
  JOURNAL   BMC Med Genet 6:39 (2005)
REFERENCE   PMID:18601960
  AUTHORS   Benit P, Lebon S, Rustin P
  TITLE     Respiratory-chain diseases related to complex III deficiency.
  JOURNAL   Biochim Biophys Acta 1793:181-5 (2009)
REFERENCE   PMID:18590986
  AUTHORS   Saneto RP, Friedman SD, Shaw DW
  TITLE     Neuroimaging of mitochondrial disease.
  JOURNAL   Mitochondrion 8:396-413 (2008)
REFERENCE   PMID:21412973
  AUTHORS   Alfadhel M, Lillquist YP, Waters PJ, Sinclair G, Struys E, McFadden D, Hendson G, Hyams L, Shoffner J, Vallance HD
  TITLE     Infantile cardioencephalopathy due to a COX15 gene defect: report and review.
  JOURNAL   Am J Med Genet A 155A:840-4 (2011)
REFERENCE   PMID:20973690
  AUTHORS   Santa KM
  TITLE     Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome.
  JOURNAL   Pharmacotherapy 30:1179-96 (2010)
REFERENCE   PMID:20649546
  AUTHORS   Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T
  TITLE     MELAS and L-arginine therapy: pathophysiology of stroke-like episodes.
  JOURNAL   Ann N Y Acad Sci 1201:104-10 (2010)
REFERENCE   PMID:21871538
  AUTHORS   Coskun P, Wyrembak J, Schriner S, Chen HW, Marciniack C, Laferla F, Wallace DC
  TITLE     A mitochondrial etiology of Alzheimer and Parkinson disease.
  JOURNAL   Biochim Biophys Acta (2011)
REFERENCE   PMID:17564966
  AUTHORS   He M, Rutledge SL, Kelly DR, Palmer CA, Murdoch G, Majumder N, Nicholls RD, Pei Z, Watkins PA, Vockley J
  TITLE     A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency.
  JOURNAL   Am J Hum Genet 81:87-103 (2007)
REFERENCE   PMID:19162478
  AUTHORS   Blazquez A, Gil-Borlado MC, Moran M, Verdu A, Cazorla-Calleja MR, Martin MA, Arenas J, Ugalde C
  TITLE     Infantile mitochondrial encephalomyopathy with unusual phenotype caused by a novel BCS1L mutation in an isolated complex III-deficient patient.
  JOURNAL   Neuromuscul Disord 19:143-6 (2009)
///
ENTRY       H00474                      Disease
NAME        Schneckenbecken dysplasia
DESCRIPTION Schneckenbecken dysplasia is a severe skeletal dysplasia that leads to perinatal death. The characteristic is the snail-like configuration of the hypoplastic iliac bones. Patients also have limbs with extremely short long bones and flat vertebratal bodies. Loss-of-function mutations in SLC35D1 gene impair the transporter activity of nucleotide sugars in Schneckenbecken dysplasia. The disease is inherited as an autosomal recessive trait.
CATEGORY    Skeletal dysplasia
GENE        SLC35D1 [HSA:23169] [KO:K15281]
DBLINKS     MeSH: C536637
            OMIM: 269250
REFERENCE   PMID:3799723 (description)
  AUTHORS   Borochowitz Z, Jones KL, Silbey R, Adomian G, Lachman R, Rimoin DL
  TITLE     A distinct lethal neonatal chondrodysplasia with snail-like pelvis: Schneckenbecken dysplasia.
  JOURNAL   Am J Med Genet 25:47-59 (1986)
REFERENCE   PMID:15386610 (description)
  AUTHORS   Varkey JJ, Jones RA
  TITLE     Perinatally lethal, short-limbed dwarfism with distinct features -- Schneckenbecken dysplasia.
  JOURNAL   Ultrasound Obstet Gynecol 24:575-7 (2004)
REFERENCE   PMID:11200994 (description)
  AUTHORS   Nikkels PG, Stigter RH, Knol IE, van der Harten HJ
  TITLE     Schneckenbecken dysplasia, radiology, and histology.
  JOURNAL   Pediatr Radiol 31:27-30 (2001)
REFERENCE   PMID:19508970 (gene)
  AUTHORS   Furuichi T, Kayserili H, Hiraoka S, Nishimura G, Ohashi H, Alanay Y, Lerena JC, Aslanger AD, Koseki H, Cohn DH, Superti-Furga A, Unger S, Ikegawa S
  TITLE     Identification of loss-of-function mutations of SLC35D1 in patients with Schneckenbecken dysplasia, but not with other severe spondylodysplastic dysplasias group diseases.
  JOURNAL   J Med Genet 46:562-8 (2009)
REFERENCE   PMID:17952091 (gene)
  AUTHORS   Hiraoka S, Furuichi T, Nishimura G, Shibata S, Yanagishita M, Rimoin DL, Superti-Furga A, Nikkels PG, Ogawa M, Katsuyama K, Toyoda H, Kinoshita-Toyoda A, Ishida N, Isono K, Sanai Y, Cohn DH, Koseki H, Ikegawa S
  TITLE     Nucleotide-sugar transporter SLC35D1 is critical to chondroitin sulfate synthesis in cartilage and skeletal development in mouse and human.
  JOURNAL   Nat Med 13:1363-7 (2007)
///
ENTRY       H00475                      Disease
NAME        Enlarged parietal foramina/cranium bifidum
DESCRIPTION Enlarged parietal foramina/cranium bifidum is characterised by oval defects in the parietal bones. It results from incomplete ossification of the parietal bones during development and is caused by ALX4 or MSX2 gene mutations.
CATEGORY    Skeletal dysplasia
GENE        (parietal foramina 1, parietal foramina with cleidocranial dysplasia) MSX2 [HSA:4488] [KO:K09341]
            (parietal foramina 2) ALX4 [HSA:60529] [KO:K09451]
DBLINKS     ICD-10: Q75.8
            MeSH: C566826
            OMIM: 168500 609597 168550
REFERENCE   PMID:20301307 (description, gene)
  AUTHORS   Wilkie AOM, Mavrogiannis LA
  TITLE     Enlarged Parietal Foramina/Cranium Bifidum
  JOURNAL   (1993)
REFERENCE   PMID:11106354 (gene)
  AUTHORS   Wuyts W, Cleiren E, Homfray T, Rasore-Quartino A, Vanhoenacker F, Van Hul W
  TITLE     The ALX4 homeobox gene is mutated in patients with ossification defects of the skull (foramina parietalia permagna, OMIM 168500).
  JOURNAL   J Med Genet 37:916-20 (2000)
REFERENCE   PMID:20306736 (description)
  AUTHORS   Bello TO, Bajomo AA, Adeniyi TO
  TITLE     Foramina parietalia permagna in a Nigerian family.
  JOURNAL   West Afr J Med 28:182-4 (2009)
///
ENTRY       H00476                      Disease
NAME        Multiple epiphyseal dysplasia (MED)
DESCRIPTION Multiple epiphyseal dysplasia (MED) is a genetically heterogeneous condition where ossification of epiphyses is delayed. Mutations causing MED have been identified in COMP, DTDST, MATN3, COL9A1, COL9A2, and COL9A3.
CATEGORY    Skeletal dysplasia
GENE        (EDM1) COMP [HSA:1311] [KO:K04659]
            (EDM2) COL9A2 [HSA:1298] [KO:K08131]
            (EDM3) COL9A3 [HSA:1299] [KO:K08131]
            (EDM4) DTDST [HSA:1836] [KO:K14701]
            (EDM5) MATN3 [HSA:4148] [KO:K19467]
DBLINKS     MeSH: C535501 C535502 C535503 C535504 C535505
            OMIM: 132400 600204 600969 226900 607078
REFERENCE   PMID:18328978 (description, gene)
  AUTHORS   Unger S, Bonafe L, Superti-Furga A
  TITLE     Multiple epiphyseal dysplasia: clinical and radiographic features, differential diagnosis and molecular basis.
  JOURNAL   Best Pract Res Clin Rheumatol 22:19-32 (2008)
REFERENCE   PMID:12687890 (description, gene)
  AUTHORS   Chapman KL, Briggs MD, Mortier GR
  TITLE     Review: clinical variability and genetic heterogeneity in multiple epiphyseal dysplasia.
  JOURNAL   Pediatr Pathol Mol Med 22:53-75 (2003)
REFERENCE   PMID:11891674 (description, gene)
  AUTHORS   Unger S, Hecht JT
  TITLE     Pseudoachondroplasia and multiple epiphyseal dysplasia: New etiologic developments.
  JOURNAL   Am J Med Genet 106:244-50 (2001)
///
ENTRY       H00477                      Disease
NAME        Pseudoachondroplasia (PSACH)
DESCRIPTION Pseudoachondroplasia (PSACH) is a condition with short-limb, short stature, joint pain, and early-onset osteoarthrosis caused by epiphyseal ossifcation delay. PSACH is caused by mutations in COMP.
CATEGORY    Skeletal dysplasia
GENE        COMP [HSA:1311] [KO:K04659]
DBLINKS     MeSH: C535819
            OMIM: 177170
REFERENCE   PMID:11891674 (description, gene)
  AUTHORS   Unger S, Hecht JT
  TITLE     Pseudoachondroplasia and multiple epiphyseal dysplasia: New etiologic developments.
  JOURNAL   Am J Med Genet 106:244-50 (2001)
REFERENCE   PMID:15094116 (description, gene)
  AUTHORS   Posey KL, Hayes E, Haynes R, Hecht JT
  TITLE     Role of TSP-5/COMP in pseudoachondroplasia.
  JOURNAL   Int J Biochem Cell Biol 36:1005-12 (2004)
///
ENTRY       H00478                      Disease
NAME        Prader-Willi syndrome (PWS)
DESCRIPTION Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are the most studied genomic-imprinting disorders mapped to chromosome 15q11-q13. Lack of a functional paternal copy of 15q11-q13 causes PWS. Additionally, it has been reported that MECP2 deficiency leads to decreased expression of UBE3A. PWS and AS have characteristic neurologic, developmental, and behavioral phenotypes plus other structural and functional abnormalities. The behavioral and endocrine disorders are more severe in PWS, including obsessive-compulsive symptoms and hypothalamic insufficiency.
CATEGORY    Developmental disorder
GENE        NDN [HSA:4692] [KO:K19482]
            SNRPN [HSA:6638] [KO:K11100]
COMMENT     See also H01732 Angelman syndrome (AS).
DBLINKS     ICD-10: Q87.1
            MeSH: D011218
            OMIM: 176270
REFERENCE   PMID:11180221
  AUTHORS   Cassidy SB, Dykens E, Williams CA
  TITLE     Prader-Willi and Angelman syndromes: sister imprinted disorders.
  JOURNAL   Am J Med Genet 97:136-46 (2000)
REFERENCE   PMID:18627066
  AUTHORS   Horsthemke B, Wagstaff J
  TITLE     Mechanisms of imprinting of the Prader-Willi/Angelman region.
  JOURNAL   Am J Med Genet A 146A:2041-52 (2008)
REFERENCE   PMID:15757975
  AUTHORS   Makedonski K, Abuhatzira L, Kaufman Y, Razin A, Shemer R
  TITLE     MeCP2 deficiency in Rett syndrome causes epigenetic aberrations at the PWS/AS imprinting center that affects UBE3A expression.
  JOURNAL   Hum Mol Genet 14:1049-58 (2005)
///
ENTRY       H00479                      Disease
NAME        Metaphyseal dysplasias, including:
            Metaphyseal dysplasia, Schmid type;
            Metaphyseal dysplasia, McKusik type;
            Metaphyseal dysplasia, Jansen type;
            Shwachman-Bodian-Diamond syndrome (SBDS);
            Metaphyseal anadysplasia (MAD)
DESCRIPTION Metaphyseal dysplasias are very rare skeletal disorders with short limb/short stature phenotypes. Defects in metaphyseal development leads to enlarged metaphyses of long bones that tend to fracture in these diseases.
CATEGORY    Skeletal dysplasia
GENE        (Schmid) COL10A1 [HSA:1300] [KO:K19479]
            (McKusik) RMRP [HSA:6023] [KO:K14576]
            (Jansen) PTHR1 [HSA:5745] [KO:K04585]
            (SBDS) SBDS [HSA:51119] [KO:K14574]
            (MAD) MMP9 [HSA:4318] [KO:K01403]
            (MAD) MMP13 [HSA:4322] [KO:K07994]
DBLINKS     ICD-10: Q78.5 Q78.8 D61.0
            MeSH: C536252
            OMIM: 156500 250250 156400 260400 602111 613073
REFERENCE   PMID:21447328 (description, gene)
  AUTHORS   Zhu Y, Li L, Zhou L, Mei H, Jin K, Liu K, Xu W, Tang J, Yang Y, Zhao R, He X
  TITLE     A novel mutation leading to elongation of the deduced alpha1(X) chain results in  Metaphyseal Chondrodysplasia type Schmid.
  JOURNAL   Clin Chim Acta 412:1266-9 (2011)
REFERENCE   PMID:10721676 (description, gene)
  AUTHORS   Matsui Y, Yasui N, Kawabata H, Ozono K, Nakata K, Mizushima T, Tsumaki N, Kataoka E, Fujita Y, Ochi T
  TITLE     A novel type X collagen gene mutation (G595R) associated with Schmid-type metaphyseal chondrodysplasia.
  JOURNAL   J Hum Genet 45:105-8 (2000)
REFERENCE   PMID:8579897 (description)
  AUTHORS   Olsen BR
  TITLE     Mutations in collagen genes resulting in metaphyseal and epiphyseal dysplasias.
  JOURNAL   Bone 17:45S-49S (1995)
REFERENCE   PMID:16832578 (gene)
  AUTHORS   Hirose Y, Nakashima E, Ohashi H, Mochizuki H, Bando Y, Ogata T, Adachi M, Toba E, Nishimura G, Ikegawa S
  TITLE     Identification of novel RMRP mutations and specific founder haplotypes in Japanese patients with cartilage-hair hypoplasia.
  JOURNAL   J Hum Genet 51:706-10 (2006)
REFERENCE   PMID:10901979 (description)
  AUTHORS   Kozlowski K, Campbell JB, Azouz ME, Sprague P
  TITLE     Metaphyseal chondrodysplasia, type Jansen.
  JOURNAL   Australas Radiol 43:544-7 (1999)
REFERENCE   PMID:12357475 (gene)
  AUTHORS   Cohen MM Jr
  TITLE     Some chondrodysplasias with short limbs: molecular perspectives.
  JOURNAL   Am J Med Genet 112:304-13 (2002)
REFERENCE   PMID:7701349 (gene)
  AUTHORS   Schipani E, Kruse K, Juppner H
  TITLE     A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia.
  JOURNAL   Science 268:98-100 (1995)
REFERENCE   PMID:17400792 (gene)
  AUTHORS   Nishimura G, Nakashima E, Hirose Y, Cole T, Cox P, Cohn DH, Rimoin DL, Lachman RS, Miyamoto Y, Kerr B, Unger S, Ohashi H, Superti-Furga A, Ikegawa S
  TITLE     The Shwachman-Bodian-Diamond syndrome gene mutations cause a neonatal form of spondylometaphysial dysplasia (SMD) resembling SMD Sedaghatian type.
  JOURNAL   J Med Genet 44:e73 (2007)
REFERENCE   PMID:9916842 (description, gene)
  AUTHORS   Nishimura G, Ikegawa S, Saga T, Nagai T, Aya M, Kawano T
  TITLE     Metaphyseal anadysplasia: evidence of genetic heterogeneity.
  JOURNAL   Am J Med Genet 82:43-8 (1999)
REFERENCE   PMID:19615667 (description, gene)
  AUTHORS   Lausch E, Keppler R, Hilbert K, Cormier-Daire V, Nikkel S, Nishimura G, Unger S, Spranger J, Superti-Furga A, Zabel B
  TITLE     Mutations in MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum of metaphyseal anadysplasia.
  JOURNAL   Am J Hum Genet 85:168-78 (2009)
REFERENCE   PMID:1867263 (description)
  AUTHORS   Maroteaux P, Verloes A, Stanescu V, Stanescu R
  TITLE     Metaphyseal anadysplasia: a metaphyseal dysplasia of early onset with radiological regression and benign course.
  JOURNAL   Am J Med Genet 39:4-10 (1991)
///
ENTRY       H00480                      Disease
NAME        Non-syndromic X-linked mental retardation
DESCRIPTION X-linked mental retardation (XLMR) is an inherited condition that causes failure to develop cognitive abilities because of mutations in several genes on the X chromosome. XLMR is subdivided into syndromic and non-syndromic forms (NS-XLMR), depending on whether further abnormalities are found on physical examination, laboratory investigation and brain imaging. The majority of genes that are mutated in NS-XLMR encode proteins are involved in three distinct pathways: Rho GTPases pathway modulating neuronal differentiation and synaptic plasticity; Rab GTPases pathway regulating synaptic vesicle cycling; gene expression regulation.
CATEGORY    Congenital disorder; Mental retardation
GENE        FMR2 [HSA:2334] [KO:K15194]
            GDI1 [HSA:2664] [KO:K17255]
            PAK3 [HSA:5063] [KO:K05733]
            IL1RAPL1 [HSA:11141] [KO:K05170]
            RPS6KA3 [HSA:6197] [KO:K04373]
            MECP2 [HSA:4204] [KO:K11588]
            ARHGEF6 [HSA:9459] [KO:K05729]
            TM4SF2 [HSA:7102] [KO:K06571]
            SLC6A8 [HSA:6535] [KO:K05039]
            ARX [HSA:170302] [KO:K09452]
            ATRX [HSA:546] [KO:K10779]
            ACSL4 [HSA:2182] [KO:K01897]
            AGTR2 [HSA:186] [KO:K04167]
            PQBP1 [HSA:10084] [KO:K12865]
            ZNF41 [HSA:7592] [KO:K09228]
            NLGN4 [HSA:57502] [KO:K07378]
            FTSJ1 [HSA:24140] [KO:K14864]
            DLG3 [HSA:1741] [KO:K21098]
            HSD17B10 [HSA:3028] [KO:K08683]
            MAGT1 [HSA:84061] [KO:K19478]
            ZNF81 [HSA:347344] [KO:K09228]
            IQSEC2 [HSA:23096] [KO:K12495]
COMMENT     RPS6KA3, MECP2, SLC6A8, ARX, ATRX, PQBP1, and NLGL4 are also mutated in syndromic X-linked mental retardation
DBLINKS     ICD-10: F78.9
            MeSH: C564490
            OMIM: 309548 300849 300558 300143 300844 300055 300260 300436 300210 300419 300387 300852 300848 300495 309549 300850 300705 300716 300498 309530
REFERENCE   PMID:15690397
  AUTHORS   Renieri A, Pescucci C, Longo I, Ariani F, Mari F, Meloni I
  TITLE     Non-syndromic X-linked mental retardation: from a molecular to a clinical point of view.
  JOURNAL   J Cell Physiol 204:8-20 (2005)
REFERENCE   PMID:16118346
  AUTHORS   Raymond FL
  TITLE     X linked mental retardation: a clinical guide.
  JOURNAL   J Med Genet 43:193-200 (2006)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
REFERENCE   PMID:18455129
  AUTHORS   Molinari F, Foulquier F, Tarpey PS, Morelle W, Boissel S, Teague J, Edkins S, Futreal PA, Stratton MR, Turner G, Matthijs G, Gecz J, Munnich A, Colleaux L
  TITLE     Oligosaccharyltransferase-subunit mutations in nonsyndromic mental retardation.
  JOURNAL   Am J Hum Genet 82:1150-7 (2008)
REFERENCE   PMID:15121780
  AUTHORS   Kleefstra T, Yntema HG, Oudakker AR, Banning MJ, Kalscheuer VM, Chelly J, Moraine C, Ropers HH, Fryns JP, Janssen IM, Sistermans EA, Nillesen WN, de Vries LB, Hamel BC, van Bokhoven H
  TITLE     Zinc finger 81 (ZNF81) mutations associated with X-linked mental retardation.
  JOURNAL   J Med Genet 41:394-9 (2004)
REFERENCE   PMID:20473311
  AUTHORS   Shoubridge C, Tarpey PS, Abidi F, Ramsden SL, Rujirabanjerd S, Murphy JA, Boyle J, Shaw M, Gardner A, Proos A, Puusepp H, Raymond FL, Schwartz CE, Stevenson RE, Turner G, Field M, Walikonis RS, Harvey RJ, Hackett A, Futreal PA, Stratton MR, Gecz J
  TITLE     Mutations in the guanine nucleotide exchange factor gene IQSEC2 cause nonsyndromic intellectual disability.
  JOURNAL   Nat Genet 42:486-8 (2010)
///
ENTRY       H00481                      Disease
NAME        Cone-rod dystrophy and cone dystrophy, including:
            Cone-rod dystrophy (CORD);
            Cone dystrophy (COD);
            Retinal cone dystrophy (RCD)
DESCRIPTION Cone-rod dystrophy (CORD) and cone dystrophy (COD) are a subgroup of inherited retinal dystrophies characterized by progressive loss of photoreceptor function. In contrast to retinitis pigmentosa (RP), deterioration of the cone cells is more severe than the rod cells. In CORD, there is a progressive loss of cone photoreceptor function followed by gradual loss of rod photoreceptor function and retinal degeneration. In COD, cone function decreases progressively from its onset, though rod function is well preserved until the late stages of the disease.
CATEGORY    Inherited metabolic disease; Nervous system disease; Eye disease
GENE        (CORD2) CRX [HSA:1406] [KO:K09337]
            (CORD3) ABCA4 [HSA:24] [KO:K05644]
            (CORD5) PITPNM3 [HSA:83394]
            (CORD6/RCD2) GUCY2D [HSA:3000] [KO:K12321]
            (CORD7) RIMS1 [HSA:22999] [KO:K15291]
            (CORD9) ADAM9 [HSA:8754] [KO:K06834]
            (CORD10) SEMA4A [HSA:64218] [KO:K06521]
            (CORD11) RAX2 [HSA:84839] [KO:K09333]
            (CORD12) PROM1 [HSA:8842] [KO:K06532]
            (CORD13) RPGRIP1 [HSA:57096] [KO:K16512]
            (CORD14/ COD3) GUCA1A [HSA:2978] [KO:K08328]
            (CORD15) CDHR1 [HSA:92211] [KO:K16501]
            (CORDX1/COD1) RPGR [HSA:6103] [KO:K19607]
            (CORDX3) CACNA1F [HSA:778] [KO:K04853]
            (COD4) PDE6C [HSA:5146] [KO:K13757]
            (RCD3A) PDE6H [HSA:5149] [KO:K13760]
            (RCD3B) KCNV2 [HSA:169522] [KO:K04935]
            (RCD4) CACNA2D4 [HSA:93589] [KO:K04861]
COMMENT     Other mapped loci for autosomal CORD include CORD1 on chromosome 18q21.1-q21.3 and CORD8 on chromosome 1q12-q24.
DBLINKS     ICD-10: H35.5
            MeSH: D000071700
            OMIM: 120970 604116 600977 601777 603649 612775 610283 610381 612657 608194 602093 613660 304020 300476 613093 610024 180020 610356 610478
REFERENCE   PMID:17270046
  AUTHORS   Hamel CP
  TITLE     Cone rod dystrophies.
  JOURNAL   Orphanet J Rare Dis 2:7 (2007)
REFERENCE   PMID:17896309
  AUTHORS   Adams NA, Awadein A, Toma HS
  TITLE     The retinal ciliopathies.
  JOURNAL   Ophthalmic Genet 28:113-25 (2007)
REFERENCE   PMID:21552474
  AUTHORS   Garcia-Hoyos M, Auz-Alexandre CL, Almoguera B, Cantalapiedra D, Riveiro-Alvarez R, Lopez-Martinez MA, Gimenez A, Blanco-Kelly F, Avila-Fernandez A, Trujillo-Tiebas MJ, Garcia-Sandoval B, Ramos C, Ayuso C
  TITLE     Mutation analysis at codon 838 of the Guanylate Cyclase 2D gene in Spanish families with autosomal dominant cone, cone-rod, and macular dystrophies.
  JOURNAL   Mol Vis 17:1103-9 (2011)
REFERENCE   PMID:21882291
  AUTHORS   Wissinger B, Schaich S, Baumann B, Bonin M, Jagle H, Friedburg C, Varsanyi B, Hoyng CB, Dollfus H, Heckenlively JR, Rosenberg T, Rudolph G, Kellner U, Salati R, Plomp A, De Baere E, Andrassi-Darida M, Sauer A, Wolf C, Zobor D, Bernd A, Leroy BP, Enyedi P, Cremers FP, Lorenz B, Zrenner E, Kohl S
  TITLE     Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response.
  JOURNAL   Hum Mutat 32:1398-406 (2011)
///
ENTRY       H00482                      Disease
NAME        Brachydactyly, including:
            type A;
            type B;
            type D;
            type E
DESCRIPTION Brachydactyly comprises hereditary limb malformations characterized by apparent shortening of digits. Bone dysostosis is seen in middle phalanges in type A; distal phalanges in type B; distal phalanx of the thumb in type D; metacarpals in type E. Brachydactyly is caused by improper development of the bones.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        (BDA1) IHH [HSA:3549] [KO:K11989]
            (BDA2) BMPR1B [HSA:658] [KO:K13578]
            (BDA2) BMP2 [HSA:650] [KO:K21283]
            (BDB1) ROR2 [HSA:4920] [KO:K05123]
            (BDB2) NOG [HSA:9241] [KO:K04658]
            (BDD, BDE1) HOXD13 [HSA:3239] [KO:K09298]
            (BDE2) PTHLH [HSA:5744]
            (with hypertension) PDE3A [HSA:5139] [KO:K19021]
DBLINKS     MeSH: D059327
            OMIM: 112500 112600 112700 113000 611377 113200 113300 613382 112410
REFERENCE   PMID:19790289 (description, gene)
  AUTHORS   Mundlos S
  TITLE     The brachydactylies: a molecular disease family.
  JOURNAL   Clin Genet 76:123-36 (2009)
REFERENCE   PMID:18554391 (description, gene)
  AUTHORS   Temtamy SA, Aglan MS
  TITLE     Brachydactyly.
  JOURNAL   Orphanet J Rare Dis 3:15 (2008)
REFERENCE   PMID:19327734
  AUTHORS   Dathe K, Kjaer KW, Brehm A, Meinecke P, Nurnberg P, Neto JC, Brunoni D, Tommerup N, Ott CE, Klopocki E, Seemann P, Mundlos S
  TITLE     Duplications involving a conserved regulatory element downstream of BMP2 are associated with brachydactyly type A2.
  JOURNAL   Am J Hum Genet 84:483-92 (2009)
REFERENCE   PMID:20170896
  AUTHORS   Klopocki E, Hennig BP, Dathe K, Koll R, de Ravel T, Baten E, Blom E, Gillerot Y, Weigel JF, Kruger G, Hiort O, Seemann P, Mundlos S
  TITLE     Deletion and point mutations of PTHLH cause brachydactyly type E.
  JOURNAL   Am J Hum Genet 86:434-9 (2010)
REFERENCE   PMID:9696728
  AUTHORS   Toka HR, Bahring S, Chitayat D, Melby JC, Whitehead R, Jeschke E, Wienker TF, Toka O, Schuster H, Luft FC
  TITLE     Families with autosomal dominant brachydactyly type E, short stature, and severe  hypertension.
  JOURNAL   Ann Intern Med 129:204-8 (1998)
///
ENTRY       H00483                      Disease
NAME        Brachydactyly, including:
            Brachydactyly type C;
            Angel shaped phalangoepiphyseal dysplasia (ASPED)
DESCRIPTION Brachydactyly represents hereditary limb malformation characterised by apparent shortening of digits. Type C characterized by shortening of multiple phalanges and hyperphalangy. Digit 4 is relatively normal in brachydactyly type C. Transformed middle phalanges with angel-like shape have been observed.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        GDF5 [HSA:8200] [KO:K04664]
DBLINKS     MeSH: C537093 C536361
            OMIM: 113100 105835
REFERENCE   PMID:19790289 (description, gene)
  AUTHORS   Mundlos S
  TITLE     The brachydactylies: a molecular disease family.
  JOURNAL   Clin Genet 76:123-36 (2009)
REFERENCE   PMID:18554391 (description, gene)
  AUTHORS   Temtamy SA, Aglan MS
  TITLE     Brachydactyly.
  JOURNAL   Orphanet J Rare Dis 3:15 (2008)
REFERENCE   PMID:15173244 (description)
  AUTHORS   Holder-Espinasse M, Escande F, Mayrargue E, Dieux-Coeslier A, Fron D, Doual-Bisser A, Boute-Benejean O, Robert Y, Porchet N, Manouvrier-Hanu S
  TITLE     Angel shaped phalangeal dysplasia, hip dysplasia, and positional teeth abnormalities are part of the brachydactyly C spectrum associated with CDMP-1 mutations.
  JOURNAL   J Med Genet 41:e78 (2004)
REFERENCE   PMID:15565340 (description)
  AUTHORS   Castriota-Scanderbeg A, Garaci FG, Beluffi G
  TITLE     Angel-shaped phalanges in brachydactyly C: a case report, and speculation on pathogenesis.
  JOURNAL   Pediatr Radiol 35:535-8 (2005)
REFERENCE   PMID:12580536 (description)
  AUTHORS   Warashina H, Sakano S, Kitamura S, Yamauchi K, Kito H, Hasegawa Y
  TITLE     Total hip arthroplasty for a patient with angel-shaped phalango-epiphyseal dysplasia (ASPED). A case report.
  JOURNAL   Nagoya J Med Sci 65:103-7 (2002)
REFERENCE   PMID:8267010 (description)
  AUTHORS   Giedion A, Prader A, Fliegel C, Krasikov N, Langer L, Poznanski A
  TITLE     Angel-shaped phalango-epiphyseal dysplasia (ASPED): identification of a new genetic bone marker.
  JOURNAL   Am J Med Genet 47:765-71 (1993)
///
ENTRY       H00484                      Disease
NAME        Other brachydactylies, including:
            Proximal symphalangism;
            Multiple synostosis syndrome
DESCRIPTION Proximal symphalangism is an autosomal-dominant condition characterized by variable fusion of the proximal interphalangeal joints. Multiple synostosis syndrome is a more severe form of proximal symphalangism with additional bone fusions involving carpal, tarsal, and other joints.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        GDF5 [HSA:8200] [KO:K04664]
            NOG [HSA:9241] [KO:K04658]
            FGF9 [HSA:2254] [KO:K04358]
DBLINKS     ICD-10: Q70.9 Q87.8
            MeSH: C536223 C536943 C537380 C567839
            OMIM: 185800 186500 610017 612961
REFERENCE   PMID:19790289 (description, gene)
  AUTHORS   Mundlos S
  TITLE     The brachydactylies: a molecular disease family.
  JOURNAL   Clin Genet 76:123-36 (2009)
REFERENCE   PMID:18283415 (description, gene)
  AUTHORS   Yang W, Cao L, Liu W, Jiang L, Sun M, Zhang D, Wang S, Lo WH, Luo Y, Zhang X
  TITLE     Novel point mutations in GDF5 associated with two distinct limb malformations in  Chinese: brachydactyly type C and proximal symphalangism.
  JOURNAL   J Hum Genet 53:368-74 (2008)
REFERENCE   PMID:17994231 (description, gene)
  AUTHORS   Plett SK, Berdon WE, Cowles RA, Oklu R, Campbell JB
  TITLE     Cushing proximal symphalangism and the NOG and GDF5 genes.
  JOURNAL   Pediatr Radiol 38:209-15 (2008)
REFERENCE   PMID:7428777 (description)
  AUTHORS   Pedersen JC, Fryns JP, Carpentier G, Heremans G, Van den Berghe H
  TITLE     Multiple synostosis syndrome.
  JOURNAL   Eur J Pediatr 134:273-5 (1980)
REFERENCE   PMID:16532400
  AUTHORS   Dawson K, Seeman P, Sebald E, King L, Edwards M, Williams J 3rd, Mundlos S, Krakow D
  TITLE     GDF5 is a second locus for multiple-synostosis syndrome.
  JOURNAL   Am J Hum Genet 78:708-12 (2006)
REFERENCE   PMID:19589401
  AUTHORS   Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ, Cui B, Wang L, Lu SY, Chen XY, Zhang HG, Huang W, Yuan WT, Yang JM, Gu Q, Fei J, Chen Z, Yuan ZM, Wang ZG
  TITLE     Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene.
  JOURNAL   Am J Hum Genet 85:53-63 (2009)
///
ENTRY       H00485                      Disease
NAME        Robinow syndrome
DESCRIPTION Robinow syndrome is characterized by distinctive craniofacial features, mesomelic limb shorting, and other anomalies. ROR2, a receptor tyrosine kinase, is responsible for the disease.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        ROR2 [HSA:4920] [KO:K05123]
DBLINKS     MeSH: C562492
            OMIM: 268310
REFERENCE   PMID:19790289 (description, gene)
  AUTHORS   Mundlos S
  TITLE     The brachydactylies: a molecular disease family.
  JOURNAL   Clin Genet 76:123-36 (2009)
REFERENCE   PMID:12011143 (description, gene)
  AUTHORS   Patton MA, Afzal AR
  TITLE     Robinow syndrome.
  JOURNAL   J Med Genet 39:305-10 (2002)
REFERENCE   PMID:20301418 (description, gene)
  AUTHORS   Bacino C
  TITLE     ROR2-Related Robinow Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:21496006 (description)
  AUTHORS   Beiraghi S, Leon-Salazar V, Larson BE, John MT, Cunningham ML, Petryk A, Lohr JL
  TITLE     Craniofacial and intraoral phenotype of Robinow syndrome forms.
  JOURNAL   Clin Genet 80:15-24 (2011)
///
ENTRY       H00486                      Disease
NAME        Sclerosteosis
DESCRIPTION Sclerosteosis is a rare sclerosing bone dysplasias inherited in autosomal recessive manner. The main clinical features are enlargement of the jaw and facial bones, which can lead to secondary findings such as facial distortion, increased intracranial pressure often resulting in headaches, and entrapment of the cranial nerves. Other findings include syndactyly and tall stature. This disease is due to loss-of-function mutations in the SOST gene, a protein that bind to LRP5/6 and antagonize Wnt signaling. Recently, mutations in the LRP4 gene, coding for a Wnt signaling coreceptor, have been found in patients with sclerosteosis.
CATEGORY    Skeletal dysplasia
GENE        SOST [HSA:50964] [KO:K16834]
            LRP4 [HSA:4038] [KO:K20051]
DBLINKS     ICD-10: Q78.8
            MeSH: C537525
            OMIM: 269500 614305
REFERENCE   PMID:20948575 (description, gene)
  AUTHORS   Mason JJ, Williams BO
  TITLE     SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease.
  JOURNAL   J Osteoporos 2010 (2010)
REFERENCE   PMID:20473488 (description, gene)
  AUTHORS   Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL
  TITLE     Sclerostin: current knowledge and future perspectives.
  JOURNAL   Calcif Tissue Int 87:99-107 (2010)
REFERENCE   PMID:21339215 (description)
  AUTHORS   Papapoulos SE
  TITLE     Targeting sclerostin as potential treatment of osteoporosis.
  JOURNAL   Ann Rheum Dis 70 Suppl 1:i119-22 (2011)
REFERENCE   PMID:26751728 (gene)
  AUTHORS   Fijalkowski I, Geets E, Steenackers E, Van Hoof V, Ramos FJ, Mortier G, Fortuna AM, Van Hul W, Boudin E
  TITLE     A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
  JOURNAL   J Bone Miner Res 31:874-81 (2016)
///
ENTRY       H00487                      Disease
NAME        Trichodentoosseous dysplasia
DESCRIPTION Trichodentoosseous syndrome (TDO) is a dysplasia with an autosomal dominant mode of inheritance. Mutation in DLX3 leads to the defects in hair, teeth, and bone.
CATEGORY    Skeletal dysplasia
GENE        DLX3 [HSA:1747] [KO:K09315]
DBLINKS     MeSH: C536549
            OMIM: 190320
REFERENCE   PMID:15454107 (description, gene)
  AUTHORS   Haldeman RJ, Cooper LF, Hart TC, Phillips C, Boyd C, Lester GE, Wright JT
  TITLE     Increased bone density associated with DLX3 mutation in the tricho-dento-osseous  syndrome.
  JOURNAL   Bone 35:988-97 (2004)
REFERENCE   PMID:18203197 (description, gene)
  AUTHORS   Wright JT, Hong SP, Simmons D, Daly B, Uebelhart D, Luder HU
  TITLE     DLX3 c.561_562delCT mutation causes attenuated phenotype of tricho-dento-osseous  syndrome.
  JOURNAL   Am J Med Genet A 146:343-9 (2008)
REFERENCE   PMID:18492670 (description, gene)
  AUTHORS   Duverger O, Lee D, Hassan MQ, Chen SX, Jaisser F, Lian JB, Morasso MI
  TITLE     Molecular consequences of a frameshifted DLX3 mutant leading to Tricho-Dento-Osseous syndrome.
  JOURNAL   J Biol Chem 283:20198-208 (2008)
///
ENTRY       H00490                      Disease
NAME        Diaphyseal dysplasia with anemia (Ghosal)
DESCRIPTION Diaphyseal dysplasia with anemia (Ghosal) is characterized by increased bone density associated with myelophthisic anemia. Mutation in TBXAS1, which encodes thromboxane synthase, has been reported.
CATEGORY    Skeletal dysplasia
GENE        TBXAS1 [HSA:6916] [KO:K01832]
DBLINKS     MeSH: C565551
            OMIM: 231095
REFERENCE   PMID:18264100 (description, gene)
  AUTHORS   Genevieve D, Proulle V, Isidor B, Bellais S, Serre V, Djouadi F, Picard C, Vignon-Savoye C, Bader-Meunier B, Blanche S, de Vernejoul MC, Legeai-Mallet L, Fischer AM, Le Merrer M, Dreyfus M, Gaussem P, Munnich A, Cormier-Daire V
  TITLE     Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).
  JOURNAL   Nat Genet 40:284-6 (2008)
REFERENCE   PMID:20672367 (description, gene)
  AUTHORS   Mazaheri P, Nadkarni G, Lowe E, Hines P, Vuica M, Griffin M, Resar LM
  TITLE     Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia.
  JOURNAL   Pediatr Blood Cancer 55:1187-90 (2010)
REFERENCE   PMID:17401271 (description)
  AUTHORS   Mondal RK, Karmakar B, Chandra PK, Mukherjee K
  TITLE     Ghosal type hemato-diaphyseal dysplasia: a rare variety of Engelmann's disease.
  JOURNAL   Indian J Pediatr 74:291-3 (2007)
///
ENTRY       H00491                      Disease
NAME        Craniometaphyseal dysplasia
DESCRIPTION Craniometaphyseal dysplasia, caused by mutations in ANKH, is a very rare condition characterized by progressive hyperostosis of cranial bones and malformations of metaphyseal long bones.
CATEGORY    Skeletal dysplasia
GENE        ANKH [HSA:56172]
DBLINKS     ICD-10: Q75.1 Q78.8
            MeSH: C537519
            OMIM: 123000
REFERENCE   PMID:20301634 (description, gene)
  AUTHORS   Reichenberger E, Chen IP
  TITLE     Craniometaphyseal Dysplasia, Autosomal Dominant
  JOURNAL   (1993)
REFERENCE   PMID:20186813 (gene)
  AUTHORS   Zajac A, Baek SH, Salhab I, Radecki MA, Kim S, Hakonarson H, Nah HD
  TITLE     Novel ANKH mutation in a patient with sporadic craniometaphyseal dysplasia.
  JOURNAL   Am J Med Genet A 152A:770-6 (2010)
///
ENTRY       H00492                      Disease
NAME        SHOX-related haploinsufficiency disorders, including:
            Isolated short stature;
            Langer syndrome;
            Leri-Weill syndrome
DESCRIPTION Isolated short stature, Leri-Weill and Langer syndromes are conditions with growth retardation. Patients also exhibit mesomelic shortening in Leri-Weill and Langer syndromes. These conditions are due to mutations in SHOX gene within the pseudoautosomal regions of sex chromosomes.
CATEGORY    Skeletal dysplasia
GENE        SHOX [HSA:6473] [KO:K09331]
DBLINKS     ICD-10: E34.3 Q87.1 Q77.8
            MeSH: C564479 C537267 C537119
            OMIM: 300582 249700 127300
REFERENCE   PMID:16650979 (gene)
  AUTHORS   Blaschke RJ, Rappold G
  TITLE     The pseudoautosomal regions, SHOX and disease.
  JOURNAL   Curr Opin Genet Dev 16:233-9 (2006)
REFERENCE   PMID:16807223 (description, gene)
  AUTHORS   Leka SK, Kitsiou-Tzeli S, Kalpini-Mavrou A, Kanavakis E
  TITLE     Short stature and dysmorphology associated with defects in the SHOX gene.
  JOURNAL   Hormones (Athens) 5:107-18 (2006)
REFERENCE   PMID:11408757 (description, gene)
  AUTHORS   Blaschke RJ, Rappold GA
  TITLE     SHOX in short stature syndromes.
  JOURNAL   Horm Res 55 Suppl 1:21-3 (2001)
///
ENTRY       H00493                      Disease
NAME        Heparan sulfate proteoglycan gene defects, including:
            Dyssegmental dysplasia, Silverman-Handmaker type;
            Schwartz-Jampel syndrome;
            Simpson-Golabi-Behmel syndrome, type 1;
            Omodysplasia 1;
            Multiple exostoses
DESCRIPTION Defects in heparan sulfate proteoglycans (HSPGs), which present in cartilage, are associated with skeletal growth disorders. Mutations in either HS biosynthetic enzymes or HS proteoglycan core proteins have been reported so far.
CATEGORY    Skeletal dysplasia
GENE        (Silverman-Handmaker, Schwartz-Jampel) HSPG2 [HSA:3339] [KO:K06255]
            (Simpson-Golabi-Behmel) GPC3 [HSA:2719] [KO:K08109]
            (Omodysplasia 1) GPC6 [HSA:10082] [KO:K08112]
            (Multiple exostoses) EXT1 [HSA:2131] [KO:K02366]
            (Multiple exostoses) EXT2 [HSA:2132] [KO:K02367]
DBLINKS     ICD-10: Q87.1 G71.1 Q87.8 Q78.6
            MeSH: C537998 C537340 C537746 D005097
            OMIM: 224410 255800 312870 258315 133700 133701
REFERENCE   PMID:12042245 (description, gene)
  AUTHORS   Schwartz NB, Domowicz M
  TITLE     Chondrodysplasias due to proteoglycan defects.
  JOURNAL   Glycobiology 12:57R-68R (2002)
REFERENCE   PMID:12975604 (description, gene)
  AUTHORS   Hassell J, Yamada Y, Arikawa-Hirasawa E
  TITLE     Role of perlecan in skeletal development and diseases.
  JOURNAL   Glycoconj J 19:263-7 (2002)
REFERENCE   PMID:15831077 (description)
  AUTHORS   Farach-Carson MC, Hecht JT, Carson DD
  TITLE     Heparan sulfate proteoglycans: key players in cartilage biology.
  JOURNAL   Crit Rev Eukaryot Gene Expr 15:29-48 (2005)
REFERENCE   PMID:14566439 (description)
  AUTHORS   Elcioglu NH, Gustavson KH, Wilkie AO, Yuksel-Apak M, Spranger JW
  TITLE     Recessive omodysplasia: five new cases and review of the literature.
  JOURNAL   Pediatr Radiol 34:75-82 (2004)
REFERENCE   PMID:19481194 (gene)
  AUTHORS   Campos-Xavier AB, Martinet D, Bateman J, Belluoccio D, Rowley L, Tan TY, Baxova A, Gustavson KH, Borochowitz ZU, Innes AM, Unger S, Beckmann JS, Mittaz L, Ballhausen D, Superti-Furga A, Savarirayan R, Bonafe L
  TITLE     Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia.
  JOURNAL   Am J Hum Genet 84:760-70 (2009)
///
ENTRY       H00494                      Disease
NAME        Desbuquois syndrome;
            Desbuquois dysplasia (DBQD)
DESCRIPTION Desbuquois syndrome is an autosomal recessive chondrodysplasia. Highly characteristic appearance of proximal femur, called 'Swedish key', is reported in the disease. Mutations in the calcium-activated nucleotidase 1 gene (CANT1) and xylosyltransferase 1 (XYLT1) have been identified.
CATEGORY    Skeletal dysplasia
GENE        (DBQD1) CANT1 [HSA:124583] [KO:K12304]
            (DBQD2) XYLT1 [HSA:64131] [KO:K00771]
DBLINKS     ICD-10: Q78.8
            MeSH: C535943
            OMIM: 251450 615777
REFERENCE   PMID:7977470 (description)
  AUTHORS   Shohat M, Lachman R, Gruber HE, Hsia YE, Golbus MS, Witt DR, Bodell A, Bryke CR, Hogge WA, Rimoin DL
  TITLE     Desbuquois syndrome: clinical, radiographic, and morphologic characterization.
  JOURNAL   Am J Med Genet 52:9-18 (1994)
REFERENCE   PMID:20425819 (gene)
  AUTHORS   Faden M, Al-Zahrani F, Arafah D, Alkuraya FS
  TITLE     Mutation of CANT1 causes Desbuquois dysplasia.
  JOURNAL   Am J Med Genet A 152A:1157-60 (2010)
REFERENCE   PMID:19853239 (gene)
  AUTHORS   Huber C, Oules B, Bertoli M, Chami M, Fradin M, Alanay Y, Al-Gazali LI, Ausems MG, Bitoun P, Cavalcanti DP, Krebs A, Le Merrer M, Mortier G, Shafeghati Y, Superti-Furga A, Robertson SP, Le Goff C, Muda AO, Paterlini-Brechot P, Munnich A, Cormier-Daire V
  TITLE     Identification of CANT1 mutations in Desbuquois dysplasia.
  JOURNAL   Am J Hum Genet 85:706-10 (2009)
REFERENCE   PMID:24581741 (gene)
  AUTHORS   Bui C, Huber C, Tuysuz B, Alanay Y, Bole-Feysot C, Leroy JG, Mortier G, Nitschke P, Munnich A, Cormier-Daire V
  TITLE     XYLT1 mutations in Desbuquois dysplasia type 2.
  JOURNAL   Am J Hum Genet 94:405-14 (2014)
///
ENTRY       H00495                      Disease
NAME        Eiken dysplasia
DESCRIPTION Eiken dysplasia is an extremely rare form of epiphyseal dysplasia. It is caused by a homozygous nonsense mutation in the PTHR1 gene.
CATEGORY    Skeletal dysplasia
GENE        PTHR1 [HSA:5745] [KO:K04585]
DBLINKS     MeSH: C564010
            OMIM: 600002
REFERENCE   PMID:15525660
  AUTHORS   Duchatelet S, Ostergaard E, Cortes D, Lemainque A, Julier C
  TITLE     Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes.
  JOURNAL   Hum Mol Genet 14:1-5 (2005)
///
ENTRY       H00496                      Disease
NAME        Congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD)
DESCRIPTION Congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) is an X-linked dominant, male-lethal trait with a lateralized inflammatory nevus and body hypoplasia. Loss of function of NSDHL, an enzyme involved in cholesterol biosynthesis leads to the condition.
CATEGORY    Skeletal dysplasia; Skin and connective tissue disease
GENE        NSDHL [HSA:50814] [KO:K07748]
DBLINKS     ICD-10: Q87.8
            MeSH: C562515
            OMIM: 308050
REFERENCE   PMID:16088165 (description, gene)
  AUTHORS   Kim CA, Konig A, Bertola DR, Albano LM, Gattas GJ, Bornholdt D, Leveleki L, Happle R, Grzeschik KH
  TITLE     CHILD syndrome caused by a deletion of exons 6-8 of the NSDHL gene.
  JOURNAL   Dermatology 211:155-8 (2005)
REFERENCE   PMID:10710235 (description, gene)
  AUTHORS   Konig A, Happle R, Bornholdt D, Engel H, Grzeschik KH
  TITLE     Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome.
  JOURNAL   Am J Med Genet 90:339-46 (2000)
///
ENTRY       H00497                      Disease
NAME        Cherubism
DESCRIPTION Cherubism is an uncommon disorder of the jaws in childhood. The maxillary bones are replaced with pseudocystic osteolytic lesions, affecting dentition. Mutated SH3BP2, which can enhance BCR signaling, is involved in the pathogenesis of cherubism.
CATEGORY    Skeletal dysplasia
GENE        SH3BP2 [HSA:6452] [KO:K07984]
DBLINKS     ICD-10: K10.8
            MeSH: D002636
            OMIM: 118400
REFERENCE   PMID:20301316 (description, gene)
  AUTHORS   Baskin B, Bowdin S, Ray PN
  TITLE     Cherubism
  JOURNAL   (1993)
REFERENCE   PMID:19165006 (description, gene)
  AUTHORS   Mortellaro C, Bello L, Lucchina AG, Pucci A
  TITLE     Diagnosis and treatment of familial cherubism characterized by early onset and rapid development.
  JOURNAL   J Craniofac Surg 20:116-20 (2009)
REFERENCE   PMID:21794028 (gene)
  AUTHORS   Ogi K, Nakashima K, Chihara K, Takeuchi K, Horiguchi T, Fujieda S, Sada K
  TITLE     Enhancement of B-cell receptor signaling by a point mutation of adaptor protein 3BP2 identified in human inherited disease cherubism.
  JOURNAL   Genes Cells 16:951-60 (2011)
///
ENTRY       H00498                      Disease
NAME        Gnathodiaphyseal dysplasia
DESCRIPTION Gnathodiaphyseal dysplasia is a rare skeletal syndrome with autosomal dominant inheritance. It is characterized by cemento-osseous lesions of the jawbone, bone fragility, and sclerosis of tubular bones. Missense mutations of GDD1, which shows homology to TMEM16E, were identified.
CATEGORY    Skeletal dysplasia
GENE        GDD1/TMEM16E [HSA:203859] [KO:K19480]
DBLINKS     MeSH: C536039
            OMIM: 166260
REFERENCE   PMID:11547842 (description)
  AUTHORS   Riminucci M, Collins MT, Corsi A, Boyde A, Murphey MD, Wientroub S, Kuznetsov SA, Cherman N, Robey PG, Bianco P
  TITLE     Gnathodiaphyseal dysplasia: a syndrome of fibro-osseous lesions of jawbones, bone fragility, and long bone bowing.
  JOURNAL   J Bone Miner Res 16:1710-8 (2001)
REFERENCE   PMID:15124103 (gene)
  AUTHORS   Tsutsumi S, Kamata N, Vokes TJ, Maruoka Y, Nakakuki K, Enomoto S, Omura K, Amagasa T, Nagayama M, Saito-Ohara F, Inazawa J, Moritani M, Yamaoka T, Inoue H, Itakura M
  TITLE     The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD).
  JOURNAL   Am J Hum Genet 74:1255-61 (2004)
REFERENCE   PMID:17418107 (gene)
  AUTHORS   Mizuta K, Tsutsumi S, Inoue H, Sakamoto Y, Miyatake K, Miyawaki K, Noji S, Kamata N, Itakura M
  TITLE     Molecular characterization of GDD1/TMEM16E, the gene product responsible for autosomal dominant gnathodiaphyseal dysplasia.
  JOURNAL   Biochem Biophys Res Commun 357:126-32 (2007)
///
ENTRY       H00499                      Disease
NAME        Spondylocarpotarsal synostosis syndrome
DESCRIPTION Spondylocarpotarsal synostosis syndrome is an autosomal recessive disease characterized by the malsegmentation of vertebrae and the fusion of carpal and tarsal bones. Retinal anomalies and hearing loss are also observed. Spondylocarpotarsal synostosis syndrome is due to FLNB mutations.
CATEGORY    Skeletal dysplasia
GENE        FLNB (nonsense mutation) [HSA:2317] [KO:K04437]
DBLINKS     MeSH: C535780
            OMIM: 272460
REFERENCE   PMID:18386804 (description, gene)
  AUTHORS   Brunetti-Pierri N, Esposito V, De Brasi D, Mattiacci DM, Krakow D, Lee B, Salerno M
  TITLE     Spondylocarpotarsal synostosis: long-term follow-up of a case due to FLNB mutations.
  JOURNAL   Am J Med Genet A 146A:1230-3 (2008)
REFERENCE   PMID:9557886 (description)
  AUTHORS   Coelho KE, Ramos ES, Felix TM, Martelli L, de Pina-Neto JM, Niikawa N
  TITLE     Three new cases of spondylocarpotarsal synostosis syndrome: clinical and radiographic studies.
  JOURNAL   Am J Med Genet 77:12-5 (1998)
///
ENTRY       H00500                      Disease
NAME        Keutel syndrome
DESCRIPTION Keutel syndrome is a rare autosomal recessive condition characterized by diffuse cartilage calcification. Mutations in the matrix Gla protein gene (MGP) have been reported.
CATEGORY    Skeletal dysplasia
GENE        MGP [HSA:4256] [KO:K19481]
DBLINKS     MeSH: C536167
            OMIM: 245150
REFERENCE   PMID:9674914 (description)
  AUTHORS   Teebi AS, Lambert DM, Kaye GM, Al-Fifi S, Tewfik TL, Azouz EM
  TITLE     Keutel syndrome: further characterization and review.
  JOURNAL   Am J Med Genet 78:182-7 (1998)
REFERENCE   PMID:15810001 (gene)
  AUTHORS   Hur DJ, Raymond GV, Kahler SG, Riegert-Johnson DL, Cohen BA, Boyadjiev SA
  TITLE     A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome.
  JOURNAL   Am J Med Genet A 135:36-40 (2005)
///
ENTRY       H00501                      Disease
NAME        Fibrous dysplasia, polyostotic;
            Albright hereditary osteodystrophy
DESCRIPTION Polyostotic fibrous dysplasia is a condition of subcutaneous ossification associated with short stature, round face and brachydactyly. Mosaic GNAS mutations that results in abnormal differentiation of osteoblastic cells are responsible for the condition.
CATEGORY    Skeletal dysplasia
GENE        GNAS [HSA:2778] [KO:K04632]
DBLINKS     MeSH: D005359
            OMIM: 174800
REFERENCE   PMID:18328981 (description, gene)
  AUTHORS   Chapurlat RD, Orcel P
  TITLE     Fibrous dysplasia of bone and McCune-Albright syndrome.
  JOURNAL   Best Pract Res Clin Rheumatol 22:55-69 (2008)
REFERENCE   PMID:20703219 (description, gene)
  AUTHORS   Shore EM, Kaplan FS
  TITLE     Inherited human diseases of heterotopic bone formation.
  JOURNAL   Nat Rev Rheumatol 6:518-27 (2010)
REFERENCE   PMID:15116703 (description, gene)
  AUTHORS   Job-Deslandre C
  TITLE     Inherited ossifying diseases.
  JOURNAL   Joint Bone Spine 71:98-101 (2004)
///
ENTRY       H00502                      Disease
NAME        Pallister-Hall syndrome
DESCRIPTION Pallister-Hall syndrome is characterized by polydactyly, hypothalamic hamartoma, and malformations of other parts of the body. Cases with severe malformations are neonatally lethal. Pallister-Hall syndrome is caused by GLI3 mutations.
CATEGORY    Skeletal dysplasia
GENE        GLI3 [HSA:2737] [KO:K06230]
DBLINKS     ICD-10: D33.0
            MeSH: D054975
            OMIM: 146510
REFERENCE   PMID:20301638 (description, gene)
  AUTHORS   Biesecker LG
  TITLE     Pallister-Hall Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:15739154 (gene)
  AUTHORS   Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylsworth AS, Bamshad MJ, Booth C, Curry CJ, David A, Dinulos MB, Flannery DB, Fox MA, Graham JM, Grange DK, Guttmacher AE, Hannibal MC, Henn W, Hennekam RC, Holmes LB, Hoyme HE, Leppig KA, Lin AE, Macleod P, Manchester DK, Marcelis C, Mazzanti L, McCann E, McDonald MT, Mendelsohn NJ, Moeschler JB, Moghaddam B, Neri G, Newbury-Ecob R, Pagon RA, Phillips JA, Sadler LS, Stoler JM, Tilstra D, Walsh Vockley CM, Zackai EH, Zadeh TM, Brueton L, Black GC, Biesecker LG
  TITLE     Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations.
  JOURNAL   Am J Hum Genet 76:609-22 (2005)
///
ENTRY       H00503                      Disease
NAME        EVC-related disorders, including:
            Ellis-van Creveld syndrome;
            Weyers acrodental dysostosis
DESCRIPTION Ellis-van Creveld syndrome is a recessive disorder of bone growth. Indivisuals with this condition have short ribs, postaxial polydactyly, and dysplastic teeth and nails. Congenital cardiovascular malformations are seen in 60% of the cases. Loss-of-function mutations in EVC or EVC2 genes and resulting hedgehog signaling defects are causative of this disease. Weyers acrodental dysostosis is an allelic dominant disorder with milder phenotype.
CATEGORY    Skeletal dysplasia
GENE        (Ellis-van Creveld) EVC1 [HSA:2121] [KO:K19605]
            (Ellis-van Creveld, Weyers) EVC2 [HSA:132884] [KO:K19608]
DBLINKS     ICD-10: Q77.6 Q75.4
            MeSH: D004613
            OMIM: 225500 193530
REFERENCE   PMID:17547743 (description, gene)
  AUTHORS   Baujat G, Le Merrer M
  TITLE     Ellis-van Creveld syndrome.
  JOURNAL   Orphanet J Rare Dis 2:27 (2007)
REFERENCE   PMID:19876929 (description, gene)
  AUTHORS   Ruiz-Perez VL, Goodship JA
  TITLE     Ellis-van Creveld syndrome and Weyers acrodental dysostosis are caused by cilia-mediated diminished response to hedgehog ligands.
  JOURNAL   Am J Med Genet C Semin Med Genet 151C:341-51 (2009)
REFERENCE   PMID:10700184
  AUTHORS   Ruiz-Perez VL, Ide SE, Strom TM, Lorenz B, Wilson D, Woods K, King L, Francomano C, Freisinger P, Spranger S, Marino B, Dallapiccola B, Wright M, Meitinger T, Polymeropoulos MH, Goodship J
  TITLE     Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrodental dysostosis.
  JOURNAL   Nat Genet 24:283-6 (2000)
///
ENTRY       H00504                      Disease
NAME        Rubinstein-Taybi syndrome
DESCRIPTION Rubinstein-Taybi syndrome is an autosomal dominant disorder with distinctive facial features, broad thumbs and toes, and mental retardation. Mutations in CREBBP and EP300 have been reported in the syndrome.
CATEGORY    Skeletal dysplasia
GENE        CREBBP [HSA:1387] [KO:K04498]
            EP300 [HSA:2033] [KO:K04498]
DBLINKS     ICD-10: Q87.2
            MeSH: D012415
            OMIM: 180849 613684
REFERENCE   PMID:7630403 (description, gene)
  AUTHORS   Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al.
  TITLE     Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.
  JOURNAL   Nature 376:348-51 (1995)
REFERENCE   PMID:16021471 (description)
  AUTHORS   Bartsch O, Schmidt S, Richter M, Morlot S, Seemanova E, Wiebe G, Rasi S
  TITLE     DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.
  JOURNAL   Hum Genet 117:485-93 (2005)
REFERENCE   PMID:17942008 (gene)
  AUTHORS   Roelfsema JH, Peters DJ
  TITLE     Rubinstein-Taybi syndrome: clinical and molecular overview.
  JOURNAL   Expert Rev Mol Med 9:1-16 (2007)
///
ENTRY       H00505                      Disease
NAME        FGFR3-related short limb skeletal dysplasias, including:
            Achondroplasia;
            Hypochondroplasia;
            Thanatophoric dysplasia, type 1;
            Thanatophoric dysplasia, type 2;
            Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
DESCRIPTION FGFR3-related short limb skeletal dysplasias are a group of dwarfisms ranging from mild to lethal at the severe end. FGFR3 mutations cause these conditions by disrupting endochondral bone growth.
CATEGORY    Skeletal dysplasia
GENE        FGFR3 [HSA:2261] [KO:K05094]
COMMENT     See also H01749 Achondroplasia and H01750 Thanatophoric dysplasia.
DBLINKS     ICD-10: Q77.4
            MeSH: D000130 D013796
            OMIM: 100800 146000 187600 187601
REFERENCE   PMID:12357475 (description, gene)
  AUTHORS   Cohen MM Jr
  TITLE     Some chondrodysplasias with short limbs: molecular perspectives.
  JOURNAL   Am J Med Genet 112:304-13 (2002)
REFERENCE   PMID:10885578 (description, gene)
  AUTHORS   McIntosh I, Bellus GA, Jab EW
  TITLE     The pleiotropic effects of fibroblast growth factor receptors in mammalian development.
  JOURNAL   Cell Struct Funct 25:85-96 (2000)
///
ENTRY       H00506                      Disease
NAME        Osteogenesis imperfecta
DESCRIPTION Osteogenesis imperfecta is characterized by an inherited bone fragility mainly caused by mutations in type I collagen. Poor teeth development, blue sclerae and hearing impairment also manifest in individuals with osteogenesis imperfecta. Mutations in the other genes have been recently identified.
CATEGORY    Skeletal dysplasia
GENE        (type I, II, III, IV) COL1A1 [HSA:1277] [KO:K06236]
            (type I, II, III, IV) COL1A2 [HSA:1278] [KO:K06236]
            (type V) IFITM5 [HSA:387733] [KO:K06566]
            (type VI) SERPINF1 [HSA:5176] [KO:K19614]
            (type VII) CRTAP [HSA:10491] [KO:K19606]
            (type VIII) LEPRE1 [HSA:64175] [KO:K08134]
            (type IX) PPIB [HSA:5479] [KO:K03768]
            (typeX) SERPINH1 [HSA:871] [KO:K09501]
            (type XI) FKBP10 [HSA:60681] [KO:K09575]
            (type XII) SP7 [HSA:121340] [KO:K09197]
            (type XIII) BMP1 [HSA:649] [KO:K05502]
DBLINKS     ICD-10: Q78.0
            MeSH: D010013
            OMIM: 166200 166210 259420 166220 610967 613982 610682 610915 613982 259440 613848 610968 613849 614856
REFERENCE   PMID:20855225 (description, gene)
  AUTHORS   Michou L, Brown JP
  TITLE     Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta.
  JOURNAL   Joint Bone Spine 78:252-8 (2011)
REFERENCE   PMID:19878741 (description, gene)
  AUTHORS   Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM
  TITLE     Classification of Osteogenesis Imperfecta revisited.
  JOURNAL   Eur J Med Genet 53:1-5 (2010)
REFERENCE   PMID:10885578 (gene)
  AUTHORS   McIntosh I, Bellus GA, Jab EW
  TITLE     The pleiotropic effects of fibroblast growth factor receptors in mammalian development.
  JOURNAL   Cell Struct Funct 25:85-96 (2000)
REFERENCE   PMID:22863190
  AUTHORS   Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegawa S, Yoo WJ, Choi IH, Kim JW
  TITLE     A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V.
  JOURNAL   Am J Hum Genet 91:343-8 (2012)
REFERENCE   PMID:21353196
  AUTHORS   Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, de Vries P, Wirth B, Schoenau E, Wollnik B, Veltman JA, Hoischen A, Netzer C
  TITLE     Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta.
  JOURNAL   Am J Hum Genet 88:362-71 (2011)
REFERENCE   PMID:20188343
  AUTHORS   Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH
  TITLE     Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta.
  JOURNAL   Am J Hum Genet 86:389-98 (2010)
REFERENCE   PMID:22718341
  AUTHORS   Barnes AM, Cabral WA, Weis M, Makareeva E, Mertz EL, Leikin S, Eyre D, Trujillo C, Marini JC
  TITLE     Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix.
  JOURNAL   Hum Mutat 33:1589-98 (2012)
REFERENCE   PMID:20579626
  AUTHORS   Lapunzina P, Aglan M, Temtamy S, Caparros-Martin JA, Valencia M, Leton R, Martinez-Glez V, Elhossini R, Amr K, Vilaboa N, Ruiz-Perez VL
  TITLE     Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.
  JOURNAL   Am J Hum Genet 87:110-4 (2010)
REFERENCE   PMID:22482805
  AUTHORS   Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, Yigit G, Pohl E, Becker J, Frommolt P, Sonntag C, Altmuller J, Zimmermann K, Greenspan DS, Akarsu NA, Netzer C, Schonau E, Wirth R, Hammerschmidt M, Nurnberg P, Wollnik B, Carney TJ
  TITLE     Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish.
  JOURNAL   Am J Hum Genet 90:661-74 (2012)
///
ENTRY       H00507                      Disease
NAME        Dyskeratosis congenita (DC), including:
            X-linked dyskeratosis congenita (DKCX);
            Autosomal dominant dyskeratosis congenita (DKCA1);
            Autosomal recessive dyskeratosis congenita (DKCB1)
DESCRIPTION Dyskeratosis congenita (DC) is a severe inherited bone marrow failure syndrome with associated cutaneous and noncutaneous abnormalities. In most cases, the inheritance pattern is X-linked recessive, while autosomal dominant and autosomal recessive forms have been reported. Remarkably, all causative gene mutations identified to date share a link to telomere/telomerase biology. Moreover, dyskeratosis congenita is linked to defective ribosome biogenesis.
CATEGORY    Congenital disorder of development; Ribosomopathy
GENE        (DKCX) DKC1 [HSA:1736] [KO:K11131]
            (DKCA1) TERC [HSA:7012]
            (DKCA2/B4) TERT [HSA:7015] [KO:K11126]
            (DKCB1) NOP10 [HSA:55505] [KO:K11130] 
            (DKCB1) NHP2 [HSA:55651] [KO:K11129]
COMMENT     Two variants of dyskeratosis congenita has been reported  in which additional findings including cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome, H00788) and bilateral exudative retinopathy and intracranial calcifications (Revesz syndrome, H00921) exist.
DBLINKS     ICD-10: Q82.8
            MeSH: D019871
            OMIM: 305000 127550 224230 613989
REFERENCE   PMID:18005359
  AUTHORS   Kirwan M, Dokal I
  TITLE     Dyskeratosis congenita: a genetic disorder of many faces.
  JOURNAL   Clin Genet 73:103-12 (2008)
REFERENCE   PMID:20008900
  AUTHORS   Trahan C, Martel C, Dragon F
  TITLE     Effects of dyskeratosis congenita mutations in dyskerin, NHP2 and NOP10 on assembly of H/ACA pre-RNPs.
  JOURNAL   Hum Mol Genet 19:825-36 (2010)
REFERENCE   PMID:18460650
  AUTHORS   Basel-Vanagaite L, Dokal I, Tamary H, Avigdor A, Garty BZ, Volkov A, Vulliamy T
  TITLE     Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations.
  JOURNAL   Haematologica 93:943-4 (2008)
REFERENCE   PMID:17785587
  AUTHORS   Marrone A, Walne A, Tamary H, Masunari Y, Kirwan M, Beswick R, Vulliamy T, Dokal I
  TITLE     Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.
  JOURNAL   Blood 110:4198-205 (2007)
///
ENTRY       H00508                      Disease
NAME        Blomstrand syndrome;
            Blomstrand chondrodysplasia
DESCRIPTION Blomstrand syndrome is a lethal osteochondrodysplasia due to nonfunctioning PTHrP receptors. Patients show increased bone density and advanced endochondral bone maturation.
CATEGORY    Skeletal dysplasia
GENE        PTHR1 [HSA:5745] [KO:K04585]
DBLINKS     ICD-10: Q78.8
            MeSH: C537914
            OMIM: 215045
REFERENCE   PMID:15525660 (gene)
  AUTHORS   Duchatelet S, Ostergaard E, Cortes D, Lemainque A, Julier C
  TITLE     Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes.
  JOURNAL   Hum Mol Genet 14:1-5 (2005)
///
ENTRY       H00509                      Disease
NAME        3M syndrome
DESCRIPTION The 3M syndrome is an autosomal recessive disorder characterized by pre- and postnatal growth retardation. It is caused by mutations in CUL7 and OBSL1.
CATEGORY    Skeletal dysplasia
GENE        CUL7 [HSA:9820] [KO:K10613]
            OBSL1 [HSA:23363] [KO:K19574]
            CCDC8 [HSA:83987] [KO:K17561]
DBLINKS     ICD-10: Q87.1
            MeSH: C535314
            OMIM: 273750 612921 614205
REFERENCE   PMID:19225462 (gene, description)
  AUTHORS   Huber C, Delezoide AL, Guimiot F, Baumann C, Malan V, Le Merrer M, Da Silva DB, Bonneau D, Chatelain P, Chu C, Clark R, Cox H, Edery P, Edouard T, Fano V, Gibson K, Gillessen-Kaesbach G, Giovannucci-Uzielli ML, Graul-Neumann LM, van Hagen JM, van Hest L, Horovitz D, Melki J, Partsch CJ, Plauchu H, Rajab A, Rossi M, Sillence D, Steichen-Gersdorf E, Stewart H, Unger S, Zenker M, Munnich A, Cormier-Daire V
  TITLE     A large-scale mutation search reveals genetic heterogeneity in 3M syndrome.
  JOURNAL   Eur J Hum Genet 17:395-400 (2009)
REFERENCE   PMID:21396581 (gene, description)
  AUTHORS   Huber C, Munnich A, Cormier-Daire V
  TITLE     The 3M syndrome.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 25:143-51 (2011)
REFERENCE   PMID:19877176 (gene, description)
  AUTHORS   Huber C, Fradin M, Edouard T, Le Merrer M, Alanay Y, Da Silva DB, David A, Hamamy H, van Hest L, Lund AM, Michaud J, Oley C, Patel C, Rajab A, Skidmore DL, Stewart H, Tauber M, Munnich A, Cormier-Daire V
  TITLE     OBSL1 mutations in 3-M syndrome are associated with a modulation of IGFBP2 and IGFBP5 expression levels.
  JOURNAL   Hum Mutat 31:20-6 (2010)
REFERENCE   PMID:21737058 (gene)
  AUTHORS   Hanson D, Murray PG, O'Sullivan J, Urquhart J, Daly S, Bhaskar SS, Biesecker LG, Skae M, Smith C, Cole T, Kirk J, Chandler K, Kingston H, Donnai D, Clayton PE, Black GC
  TITLE     Exome sequencing identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth.
  JOURNAL   Am J Hum Genet 89:148-53 (2011)
///
ENTRY       H00510                      Disease
NAME        Feingold syndrome
DESCRIPTION Feingold syndrome is characterized by limb malformations, microcephaly, esophageal/duodenal atresias, and learning disability. Feingold syndrome is caused by mutations in NMYC and inherited as an autosomal dominant trait.
CATEGORY    Skeletal dysplasia
GENE        NMYC [HSA:4613] [KO:K09109]
DBLINKS     ICD-10: Q87.8
            MeSH: C537734
            OMIM: 164280
REFERENCE   PMID:19790289 (description, gene)
  AUTHORS   Mundlos S
  TITLE     The brachydactylies: a molecular disease family.
  JOURNAL   Clin Genet 76:123-36 (2009)
REFERENCE   PMID:16906565 (description, gene)
  AUTHORS   Teszas A, Meijer R, Scheffer H, Gyuris P, Kosztolanyi G, van Bokhoven H, Kellermayer R
  TITLE     Expanding the clinical spectrum of MYCN-related Feingold syndrome.
  JOURNAL   Am J Med Genet A 140:2254-6 (2006)
REFERENCE   PMID:20301770 (description, gene)
  AUTHORS   Marcelis CLM, de Brouwer APM
  TITLE     Feingold Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:9096751
  AUTHORS   Kawame H, Pagon RA, Hudgins L
  TITLE     Digital anomalies, microcephaly, and normal intelligence: new syndrome or Feingold syndrome?
  JOURNAL   Am J Med Genet 69:240-4 (1997)
///
ENTRY       H00511                      Disease
NAME        Short rib-polydactyly syndrome
DESCRIPTION Short-rib polydactyly (SRP) syndromes are most frequent autosomal recessive osteochondrodysplasias ascribed to mutations in DYNC2H1, a cytoplasmic dynein. The fetus with SRP develops polydactyly, shortened tubular bones, and other malformations such as cleft lip/palate.
CATEGORY    Skeletal dysplasia
GENE        (type II/III) DYNC2H1 [HSA:79659] [KO:K10414]
            (type II) NEK1 [HSA:4750] [KO:K08857]
DBLINKS     MeSH: D012779
            OMIM: 263510 263520
REFERENCE   PMID:19361615 (description, gene)
  AUTHORS   Merrill AE, Merriman B, Farrington-Rock C, Camacho N, Sebald ET, Funari VA, Schibler MJ, Firestein MH, Cohn ZA, Priore MA, Thompson AK, Rimoin DL, Nelson SF, Cohn DH, Krakow D
  TITLE     Ciliary abnormalities due to defects in the retrograde transport protein DYNC2H1  in short-rib polydactyly syndrome.
  JOURNAL   Am J Hum Genet 84:542-9 (2009)
REFERENCE   PMID:19442771 (gene)
  AUTHORS   Dagoneau N, Goulet M, Genevieve D, Sznajer Y, Martinovic J, Smithson S, Huber C, Baujat G, Flori E, Tecco L, Cavalcanti D, Delezoide AL, Serre V, Le Merrer M, Munnich A, Cormier-Daire V
  TITLE     DYNC2H1 mutations cause asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III.
  JOURNAL   Am J Hum Genet 84:706-11 (2009)
REFERENCE   PMID:21211617 (gene)
  AUTHORS   Thiel C, Kessler K, Giessl A, Dimmler A, Shalev SA, von der Haar S, Zenker M, Zahnleiter D, Stoss H, Beinder E, Abou Jamra R, Ekici AB, Schroder-Kress N, Aigner T, Kirchner T, Reis A, Brandstatter JH, Rauch A
  TITLE     NEK1 mutations cause short-rib polydactyly syndrome type majewski.
  JOURNAL   Am J Hum Genet 88:106-14 (2011)
///
ENTRY       H00512                      Disease
NAME        Permanent neonatal diabetes mellitus (PNDM)
DESCRIPTION Neonatal diabetes mellitus (NDM), which is a monogenic form of diabetes, is a heterogeneous group of disorders characterized by hyperglycemia in the first 6 months of life. NDM is categorized into transient (TNDM) and permanent (PNDM). In the case of PNDM, the condition does not resolve over time. The most frequent causes of PNDM are heterozygous mutations in the KCNJ11, INS and ABCC8 genes that play a critical role in insulin secretion from pancreatic beta-cells. The responsible genes remain unknown in up to 40% of patients.
CATEGORY    Metabolic disease; Endocrine disease
GENE        KCNJ11 [HSA:3767] [KO:K05004]
            ABCC8 [HSA:6833] [KO:K05032]
            GCK [HSA:2645] [KO:K12407]
            INS [HSA:3630] [KO:K04526]
            IPF1 [HSA:3651] [KO:K07594]
            PTF1A [HSA:256297] [KO:K09073]
            FOXP3 [HSA:50943] [KO:K10163]
            EIF2AK3 [HSA:9451] [KO:K08860]
            GLIS3 [HSA:169792] [KO:K09232]
DRUG        Insulin [DR:D00085]
DBLINKS     ICD-10: P70.2
            MeSH: C563424 C563425 C563796
            OMIM: 606176 609069 610199
REFERENCE   PMID:17349054 (gene)
  AUTHORS   Polak M, Cave H
  TITLE     Neonatal diabetes mellitus: a disease linked to multiple mechanisms.
  JOURNAL   Orphanet J Rare Dis 2:12 (2007)
REFERENCE   PMID:21054355 (gene)
  AUTHORS   Rubio-Cabezas O, Klupa T, Malecki MT
  TITLE     Permanent neonatal diabetes mellitus--the importance of diabetes differential diagnosis in neonates and infants.
  JOURNAL   Eur J Clin Invest 41:323-33 (2011)
///
ENTRY       H00513                      Disease
NAME        Transient neonatal diabetes mellitus (TNDM)
DESCRIPTION Neonatal diabetes mellitus (NDM), which is a monogenic form of diabetes, is a heterogeneous group of disorders characterized by hyperglycemia in the first 6 months of life. NDM is categorized into transient (TNDM) and permanent (PNDM). TNDM is a developmental disorder of insulin production that resolves by age 18 months but can reappear later in life. TNDM is different from type 1 diabetes since no islet cell antibodies or autoimmune phenomenon were found in these patients. 6q24-related TNDM is an imprinting disorder resulting from overexpression of at least two imprinted genes, PLAGL1 and HYMAI, on chromosome 6q24. Hypomethylation of multiple imprinted loci is associated with mutations in ZFP57. Mutations in ABCC8 and KCNJ11 encoding Kir6.2 and SUR1 are other genetic causes of TNDM.
CATEGORY    Metabolic disease; Endocrine disease
GENE        ZFP57 [HSA:346171] [KO:K09228]
            PLAGL1 [HSA:5325] [KO:K19485]
            HYMAI [HSA:57061]
            ABCC8 [HSA:6833] [KO:K05032]
            KCNJ11 [HSA:3767] [KO:K05004]
DRUG        Insulin [DR:D00085]
DBLINKS     ICD-10: P70.2
            MeSH: C563322 C563672 C566432
            OMIM: 601410 610374 610582
REFERENCE   PMID:21034612 (gene)
  AUTHORS   Xu XF, Du LZ
  TITLE     Epigenetics in neonatal diseases.
  JOURNAL   Chin Med J (Engl) 123:2948-54 (2010)
REFERENCE   PMID:20922569 (gene)
  AUTHORS   Temple IK, Shield JP
  TITLE     6q24 transient neonatal diabetes.
  JOURNAL   Rev Endocr Metab Disord 11:199-204 (2010)
REFERENCE   PMID:17349054 (gene)
  AUTHORS   Polak M, Cave H
  TITLE     Neonatal diabetes mellitus: a disease linked to multiple mechanisms.
  JOURNAL   Orphanet J Rare Dis 2:12 (2007)
///
ENTRY       H00514                      Disease
NAME        Bruck syndrome
DESCRIPTION Bruck syndrome is a recessively-inherited form of osteogenesis imperfecta in combination with pterygium formation across large joints. In Bruck syndrome, joint mobility is significantly reduced, showing arthrogryposis multiplex congenita.
CATEGORY    Skeletal dysplasia
GENE        PLOD2 [HSA:5352] [KO:K13645]
            FKBP10 [HSA:60681] [KO:K09575]
DBLINKS     ICD-10: Q78.0
            MeSH: C537406 C537407
            OMIM: 609220
REFERENCE   PMID:15523624 (description, gene)
  AUTHORS   Ha-Vinh R, Alanay Y, Bank RA, Campos-Xavier AB, Zankl A, Superti-Furga A, Bonafe L
  TITLE     Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation  in PLOD2.
  JOURNAL   Am J Med Genet A 131:115-20 (2004)
REFERENCE   PMID:21567934 (description, gene)
  AUTHORS   Shaheen R, Al-Owain M, Faqeih E, Al-Hashmi N, Awaji A, Al-Zayed Z, Alkuraya FS
  TITLE     Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans.
  JOURNAL   Am J Med Genet A 155A:1448-52 (2011)
///
ENTRY       H00515                      Disease
NAME        The DTDST-related disorders, including:
            Achondrogenesis IB (ACG IB);
            Atelosteogenesis II (AO II);
            Diastrophic dysplasia (DTD)
DESCRIPTION The DTDST-related disorders are severe recessive chondrodysplasias including two lethal disorders ACG IB and AO II; and a non-lethal disorder DTD. Patients with these disorders suffer from impaired proteoglycan sulfation due to mutations in DTDST.
CATEGORY    Skeletal dysplasia
GENE        DTDST [HSA:1836] [KO:K14701]
DBLINKS     ICD-10: Q77.0 Q77.5
            MeSH: C536016 C536017 C536170
            OMIM: 600972 256050 222600
REFERENCE   PMID:11448940 (description, gene)
  AUTHORS   Karniski LP
  TITLE     Mutations in the diastrophic dysplasia sulfate transporter (DTDST) gene: correlation between sulfate transport activity and chondrodysplasia phenotype.
  JOURNAL   Hum Mol Genet 10:1485-90 (2001)
REFERENCE   PMID:8791509 (description, gene)
  AUTHORS   Francomano CA, McIntosh I, Wilkin DJ
  TITLE     Bone dysplasias in man: molecular insights.
  JOURNAL   Curr Opin Genet Dev 6:301-8 (1996)
///
ENTRY       H00516                      Disease
NAME        Isolated orofacial clefts, including:
            Cleft lip with or without cleft palate;
            Cleft palate
DESCRIPTION Cleft lip and/or cleft palate represents a spectrum of craniofacial anomalies. These clefts are one of the most common congenital malformations that can arise as part of a syndrome or in the absence of other defects. A large fraction of clefts occurs without other defects and is termed isolated orofacial clefts.
CATEGORY    Developmental disorder
GENE        IRF6 [HSA:3664] [KO:K10154]
            MSX1 [HSA:4487] [KO:K09341]
            FGFR1 [HSA:2260] [KO:K04362]
            PVRL1 [HSA:5818] [KO:K06081]
            TP63 [HSA:8626] [KO:K10149]
            TBX22 [HSA:50945] [KO:K10186]
            TGFA [HSA:7039] [KO:K08774]
            TGFB3 [HSA:7043] [KO:K13377]
            MTHFR [HSA:4524] [KO:K00297] 
            RARA [HSA:5914] [KO:K08527]
            GSTT1 [HSA:2952] [KO:K00799]
            EPHX1 [HSA:2052] [KO:K01253]
            SUMO1 [HSA:7341] [KO:K12160]
            BMP4 [HSA:652] [KO:K04662]
ENV_FACTOR  Phenytoin [CPD:C07443] 
            Valproic acid [CPD:C07185]
            Alcohol [CPD:C00469]
            Cigarette smoke
            Altitude
            Folic acid [CPD:C00504]
            Retinoic acid [CPD:C00777]
            Corticosteroids
DBLINKS     ICD-10: Q36 Q37 Q87.8
            MeSH: D002972
            OMIM: 608874 608864 225060 129400 119540 613705 600625
REFERENCE   PMID:11753106 (gene)
  AUTHORS   Spritz RA
  TITLE     The genetics and epigenetics of orofacial clefts.
  JOURNAL   Curr Opin Pediatr 13:556-60 (2001)
REFERENCE   PMID:19583827 (gene)
  AUTHORS   Jugessur A, Farlie PG, Kilpatrick N
  TITLE     The genetics of isolated orofacial clefts: from genotypes to subphenotypes.
  JOURNAL   Oral Dis 15:437-53 (2009)
REFERENCE   PMID:19186243 (gene)
  AUTHORS   Gritli-Linde A
  TITLE     The etiopathogenesis of cleft lip and cleft palate: usefulness and caveats of mouse models.
  JOURNAL   Curr Top Dev Biol 84:37-138 (2008)
REFERENCE   PMID:15917202 (gene, env_factor)
  AUTHORS   Jugessur A, Murray JC
  TITLE     Orofacial clefting: recent insights into a complex trait.
  JOURNAL   Curr Opin Genet Dev 15:270-8 (2005)
REFERENCE   PMID:12030886 (gene, env_factor)
  AUTHORS   Murray JC
  TITLE     Gene/environment causes of cleft lip and/or palate.
  JOURNAL   Clin Genet 61:248-56 (2002)
REFERENCE   PMID:15923821 (env_factor)
  AUTHORS   Eppley BL, van Aalst JA, Robey A, Havlik RJ, Sadove AM
  TITLE     The spectrum of orofacial clefting.
  JOURNAL   Plast Reconstr Surg 115:101e-114e (2005)
REFERENCE   PMID:16990542
  AUTHORS   Alkuraya FS, Saadi I, Lund JJ, Turbe-Doan A, Morton CC, Maas RL
  TITLE     SUMO1 haploinsufficiency leads to cleft lip and palate.
  JOURNAL   Science 313:1751 (2006)
REFERENCE   PMID:19249007
  AUTHORS   Suzuki S, Marazita ML, Cooper ME, Miwa N, Hing A, Jugessur A, Natsume N, Shimozato K, Ohbayashi N, Suzuki Y, Niimi T, Minami K, Yamamoto M, Altannamar TJ, Erkhembaatar T, Furukawa H, Daack-Hirsch S, L'heureux J, Brandon CA, Weinberg SM, Neiswanger K, Deleyiannis FW, de Salamanca JE, Vieira AR, Lidral AC, Martin JF, Murray JC
  TITLE     Mutations in BMP4 are associated with subepithelial, microform, and overt cleft lip.
  JOURNAL   Am J Hum Genet 84:406-11 (2009)
///
ENTRY       H00517                      Disease
NAME        Spondylocostal dysostosis (SCD)
DESCRIPTION Spondylocostal dysostosis (SCD) is a group of disorders characterized by vertebral defects along the entire spinal column with rib fusions and deletions. SCD arises from disturbed somite segmentation during embryonic development due to mutations in Notch pathway genes.
CATEGORY    Skeletal dysplasia
GENE        (SCD1) DLL3 [HSA:10683] [KO:K06051]
            (SCD2) MESP2 [HSA:145873] [KO:K09076]
            (SCD3) LNFG [HSA:3955] [KO:K05948]
            (SCD4) HES7 [HSA:84667] [KO:K09087]
DBLINKS     ICD-10: Q76.8
            MeSH: C537565
            OMIM: 277300 608681 609813 613686
REFERENCE   PMID:19995916 (description, gene)
  AUTHORS   Zanotti S, Canalis E
  TITLE     Notch and the skeleton.
  JOURNAL   Mol Cell Biol 30:886-96 (2010)
REFERENCE   PMID:17600784 (description, gene)
  AUTHORS   Shifley ET, Cole SE
  TITLE     The vertebrate segmentation clock and its role in skeletal birth defects.
  JOURNAL   Birth Defects Res C Embryo Today 81:121-33 (2007)
REFERENCE   PMID:20087400 (description, gene)
  AUTHORS   Sparrow DB, Sillence D, Wouters MA, Turnpenny PD, Dunwoodie SL
  TITLE     Two novel missense mutations in HAIRY-AND-ENHANCER-OF-SPLIT-7 in a family with spondylocostal dysostosis.
  JOURNAL   Eur J Hum Genet 18:674-9 (2010)
///
ENTRY       H00518                      Disease
NAME        RMRP related disorders, including:
            Anauxetic dysplasia (AD);
            Cartilage-hair hypoplasia (CHH);
            Metaphyseal dysplasia without hypotrichosis (MDWH)
DESCRIPTION RNase MRP RNA is the RNA subunit of the RNase mitochondrial RNA processing (MRP) enzyme complex. In addition to its mitochondrial function, mutations on RNase MRP RNA gene (RMRP) cause a recessively inherited developmental disorder, cartilage-hair hypoplasia (CHH). CHH is a skeletal dysplasia inherited as an autosomal recessive trait. Beyond CHH, RNase MRP RNA mutations have been implicated in a variety of other inherited skeletal dysplasias, including anauxetic dysplasia (AD) and metaphyseal dysplasia without hypotrichosis (MDWH).
CATEGORY    Congenital disorder of development; Ribosomopathy
GENE        RMRP [HSA:6023] [KO:K14576]
DBLINKS     ICD-10: Q78.8 Q78.5
            MeSH: C538256 C535916 C563574
            OMIM: 607095 250250 250460
REFERENCE   PMID:17189938
  AUTHORS   Martin AN, Li Y
  TITLE     RNase MRP RNA and human genetic diseases.
  JOURNAL   Cell Res 17:219-26 (2007)
///
ENTRY       H00519                      Disease
NAME        Type XI collagenopathies, including:
            Stickler syndrome type 2;
            Stickler syndrome type 3;
            Otospondylomegaepiphyseal dysplasia (OSMED);
            Marshall syndrome;
            Weissenbacher-Zweymuller syndrome
DESCRIPTION Type XI collagenopathies are a group of osteochondrodysplasias that arise from mutations in the COL11A1 and COL11A2 genes. These diseases are characterized by midfacial hypoplasia, early-onset arthropathy, and sensorineuronal hearing loss.
CATEGORY    Skeletal dysplasia
GENE        (Stickler 2, Marshall) COL11A1 [HSA:1301] [KO:K19721]
            (Stickler 3, OSMED, Weissenbacher-Zweymuller) COL11A2 [HSA:1302] [KO:K19721]
DBLINKS     ICD-10: Q87.8 Q77.7 Q87.0 Q87.2
            MeSH: C537493 C537494 C536025
            OMIM: 604841 184840 215150 154780 277610
REFERENCE   PMID:9799295 (description, gene)
  AUTHORS   Spranger J
  TITLE     The type XI collagenopathies.
  JOURNAL   Pediatr Radiol 28:745-50 (1998)
REFERENCE   PMID:12453309 (description, gene)
  AUTHORS   Reginato AM, Olsen BR
  TITLE     The role of structural genes in the pathogenesis of osteoarthritic disorders.
  JOURNAL   Arthritis Res 4:337-45 (2002)
///
ENTRY       H00520                      Disease
NAME        Type II collagenopathies, including:
            Achondrogenesis II;
            Hypochondrogenesis;
            SED congenita;
            SMED Strudwick type;
            Kniest dysplasia;
            Spondyloperipheral dysplasia;
            Osteoarthritis with mild chondrodysplasia;
            Stickler syndrome 1;
            Platyspondylic skeletal dysplasia, Torrance type;
            Epiphyseal dysplasia, multiple, with myopia and deafness;
            Czech dysplasia
DESCRIPTION Type II collagenopathies are a spectrum of phenotypes which affect the skeletal and visual systems. The severity ranges from perinatal lethality (achondrogenesis II, hypochondrogenesis) to the milder conditions caused by reduced collagen content in cartilage (Kniest dysplasia).
CATEGORY    Skeletal dysplasia
GENE        COL2A1 [HSA:1280] [KO:K19719]
DBLINKS     ICD-10: Q77.8 Q87.8
            OMIM: 200610 183900 184250 156550 271700 604864 108300 151210 132450 609162
REFERENCE   PMID:12453309 (description)
  AUTHORS   Reginato AM, Olsen BR
  TITLE     The role of structural genes in the pathogenesis of osteoarthritic disorders.
  JOURNAL   Arthritis Res 4:337-45 (2002)
REFERENCE   PMID:8791509 (description, gene)
  AUTHORS   Francomano CA, McIntosh I, Wilkin DJ
  TITLE     Bone dysplasias in man: molecular insights.
  JOURNAL   Curr Opin Genet Dev 6:301-8 (1996)
REFERENCE   PMID:21332586 (description, gene)
  AUTHORS   Kannu P, Bateman J, Savarirayan R
  TITLE     Clinical phenotypes associated with type II collagen mutations.
  JOURNAL   J Paediatr Child Health (2011)
REFERENCE   PMID:15643621 (description, gene)
  AUTHORS   Zankl A, Neumann L, Ignatius J, Nikkels P, Schrander-Stumpel C, Mortier G, Omran H, Wright M, Hilbert K, Bonafe L, Spranger J, Zabel B, Superti-Furga A
  TITLE     Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, torrance type, and define a novel subfamily within the type 2 collagenopathies.
  JOURNAL   Am J Med Genet A 133A:61-7 (2005)
///
ENTRY       H00521                      Disease
NAME        Cleidocranial dysplasia
DESCRIPTION Cleidocranial dysplasia is an autosomal dominant skeletal dysplasia characterized by hypoplastic clavicles, delayed closure of the cranial sutures, and dental abnormalities resulted from defective intramembranous ossification. Mutations in RUNX2, which is involved in osteoblast differentiation, is the cause of the disease.
CATEGORY    Skeletal dysplasia
GENE        RUNX2 [HSA:860] [KO:K09278]
DBLINKS     ICD-10: Q74.0
            MeSH: D002973
            OMIM: 119600
REFERENCE   PMID:8782054 (description)
  AUTHORS   Ramesar RS, Greenberg J, Martin R, Goliath R, Bardien S, Mundlos S, Beighton P
  TITLE     Mapping of the gene for cleidocranial dysplasia in the historical Cape Town (Arnold) kindred and evidence for locus homogeneity.
  JOURNAL   J Med Genet 33:511-4 (1996)
REFERENCE   PMID:20648631 (gene)
  AUTHORS   Ott CE, Leschik G, Trotier F, Brueton L, Brunner HG, Brussel W, Guillen-Navarro E, Haase C, Kohlhase J, Kotzot D, Lane A, Lee-Kirsch MA, Morlot S, Simon ME, Steichen-Gersdorf E, Tegay DH, Peters H, Mundlos S, Klopocki E
  TITLE     Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasia.
  JOURNAL   Hum Mutat 31:E1587-93 (2010)
REFERENCE   PMID:15952089 (gene)
  AUTHORS   Zheng Q, Sebald E, Zhou G, Chen Y, Wilcox W, Lee B, Krakow D
  TITLE     Dysregulation of chondrogenesis in human cleidocranial dysplasia.
  JOURNAL   Am J Hum Genet 77:305-12 (2005)
///
ENTRY       H00522                      Disease
NAME        TRPV4-related skeletal dysplasias, including:
            Autosomal dominant brachyolmia;
            Spondylometaphyseal dysplasia, Kozlowski type (SMDK);
            Metatropic dysplasia;
            Spondyloepiphyseal dysplasia, Maroteaux type ;
            Parastremmatic dysplasia
DESCRIPTION TRPV4-related skeletal dysplasias are a spectrum of disorders that share some clinical features. Mutations in the TRPV4, a calcium-permeable nonselective cation channel expressed in osteoblasts and ostoclasts, cause these bone dysplasias.
CATEGORY    Skeletal dysplasia
GENE        TRPV4 [HSA:59341] [KO:K04973]
DBLINKS     ICD-10: Q77.8 Q87.1
            MeSH: C537098 C535797
            OMIM: 113500 184252 156530 184095 168400
REFERENCE   PMID:21658220 (description, gene)
  AUTHORS   Andreucci E, Aftimos S, Alcausin M, Haan E, Hunter W, Kannu P, Kerr B, McGillivray G, McKinlay Gardner RJ, Patricelli MG, Sillence D, Thompson E, Zacharin M, Zankl A, Lamande SR, Savarirayan R
  TITLE     TRPV4 related skeletal dysplasias: a phenotypic spectrum highlighted byclinical,  radiographic, and molecular studies in 21 new families.
  JOURNAL   Orphanet J Rare Dis 6:37 (2011)
REFERENCE   PMID:20505684 (description, gene)
  AUTHORS   Dai J, Cho TJ, Unger S, Lausch E, Nishimura G, Kim OH, Superti-Furga A, Ikegawa S
  TITLE     TRPV4-pathy, a novel channelopathy affecting diverse systems.
  JOURNAL   J Hum Genet 55:400-2 (2010)
REFERENCE   PMID:20503319 (gene)
  AUTHORS   Nishimura G, Dai J, Lausch E, Unger S, Megarbane A, Kitoh H, Kim OH, Cho TJ, Bedeschi F, Benedicenti F, Mendoza-Londono R, Silengo M, Schmidt-Rimpler M, Spranger J, Zabel B, Ikegawa S, Superti-Furga A
  TITLE     Spondylo-epiphyseal dysplasia, Maroteaux type (pseudo-Morquio syndrome type 2), and parastremmatic dysplasia are caused by TRPV4 mutations.
  JOURNAL   Am J Med Genet A 152A:1443-9 (2010)
///
ENTRY       H00523                      Disease
NAME        Noonan syndrome and related disorders, including:
            Noonan syndrome (NS);
            Leopard syndrome (LS);
            Noonan syndrome-like with loose anagen hair (NS/LAH);
            CBL-mutation associated syndrome (CBL);
            Neurofibromatosis type 1 (NF1);
            Neurofibromatosis-Noonan syndrome (NFNS);
            Legius syndrome;
            Cardiofaciocutaneous syndrome (CFCS);
            Costello syndrome (CS);
            Watson syndrome
DESCRIPTION Noonan syndrome comprises genetically heterogeneous disorders that usually include postnatally reduced growth, distinctive facial dysmorphic features, and congenital heart defects and related disorders show considerable overlapping phenotypes with Noonan syndrome. These disorders are caused by germline mutations in genes that encode components or regulators of the Ras/MAPK pathway, and are called RASopathies.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        (NS, LS) PTPN11 [HSA:5781] [KO:K07293]
            (NS, CFCS) KRAS [HSA:3845] [KO:K07827]
            (NS) SOS1 [HSA:6654] [KO:K03099]
            (NS, LS) RAF1 [HSA:369] [KO:K08845]
            (NS) NRAS [HSA:4893] [KO:K07828]
            (NS, LS, CFCS) BRAF [HSA:673] [KO:K04365]
            (NS) RIT1 [HSA:6016] [KO:K07832]
            (CBL) CBL [HSA:867] [KO:K04707]
            (NS/LAH) SHOC2 [HSA:8036] [KO:K19613]
            (CFCS) MEK1 [HSA:5604] [KO:K04368]
            (CFCS) MEK2 [HSA:5605] [KO:K04369]
            (NF1, NFNS) NF1 [HSA:4763] [KO:K08052]
            (Legius) SPRED1 [HSA:161742] [KO:K04703]
            (CS) HRAS [HSA:3265] [KO:K02833]
COMMENT     See also H01738 Noonan syndrome, H01745 Cardiofaciocutaneous syndrome, and H01747 Costello syndrome.
DBLINKS     ICD-10: Q87.1 Q87.8 Q85.0
            MeSH: D009634 D044542 D056685
            OMIM: 163950 609942 610733 611553 613224 613706 151100 611554 613707 607721 613563 162200 101000 601321 611431 115150 218040 193520 162210 615355
REFERENCE   PMID:21396583 (gene, description)
  AUTHORS   Tartaglia M, Gelb BD, Zenker M
  TITLE     Noonan syndrome and clinically related disorders.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 25:161-79 (2011)
REFERENCE   PMID:19545378 (gene)
  AUTHORS   Evans DG
  TITLE     Neurofibromatosis type 2 (NF2): a clinical and molecular review.
  JOURNAL   Orphanet J Rare Dis 4:16 (2009)
REFERENCE   PMID:8317503
  AUTHORS   Tassabehji M, Strachan T, Sharland M, Colley A, Donnai D, Harris R, Thakker N
  TITLE     Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family  with features of Watson syndrome and Noonan syndrome.
  JOURNAL   Am J Hum Genet 53:90-5 (1993)
REFERENCE   PMID:23791108
  AUTHORS   Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, Hoshika T, Barnett C, Ohashi H, Kawame H, Hasegawa T, Okutani T, Nagashima T, Hasegawa S, Funayama R, Nagashima T, Nakayama K, Inoue S, Watanabe Y, Ogura T, Matsubara Y
  TITLE     Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
  JOURNAL   Am J Hum Genet 93:173-80 (2013)
REFERENCE   PMID:23875798
  AUTHORS   Rauen KA
  TITLE     The RASopathies.
  JOURNAL   Annu Rev Genomics Hum Genet 14:355-69 (2013)
///
ENTRY       H00524                      Disease
NAME        TRPV4-related peripheral neuropathies, including:
            Congenital distal spinal muscular atrophy (CDSMA);
            Scapuloperoneal spinal muscle atrophy (SPSMA);
            Hereditary motor and sensory neuropathy type IIC (HMSN IIC)
DESCRIPTION These are a heterogeneous group of dominantly inherited disorders with muscle weakness. Mutations in TRPV4 have been linked to these disorders.
CATEGORY    Nervous system disease
GENE        TRPV4 [HSA:59341] [KO:K04973]
DBLINKS     ICD-10: G12.2 G12.1 G60.0
            MeSH: C563981 C537992
            OMIM: 600175 181405 606071
REFERENCE   PMID:20505684 (gene)
  AUTHORS   Dai J, Cho TJ, Unger S, Lausch E, Nishimura G, Kim OH, Superti-Furga A, Ikegawa S
  TITLE     TRPV4-pathy, a novel channelopathy affecting diverse systems.
  JOURNAL   J Hum Genet 55:400-2 (2010)
REFERENCE   PMID:21454511 (gene)
  AUTHORS   Fecto F, Shi Y, Huda R, Martina M, Siddique T, Deng HX
  TITLE     Mutant TRPV4-mediated toxicity is linked to increased constitutive function in axonal neuropathies.
  JOURNAL   J Biol Chem 286:17281-91 (2011)
REFERENCE   PMID:20460441 (gene, description)
  AUTHORS   Zimon M, Baets J, Auer-Grumbach M, Berciano J, Garcia A, Lopez-Laso E, Merlini L, Hilton-Jones D, McEntagart M, Crosby AH, Barisic N, Boltshauser E, Shaw CE, Landoure G, Ludlow CL, Gaudet R, Houlden H, Reilly MM, Fischbeck KH, Sumner CJ, Timmerman V, Jordanova A, Jonghe PD
  TITLE     Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies.
  JOURNAL   Brain 133:1798-809 (2010)
///
ENTRY       H00525                      Disease
NAME        Disorders of fatty-acid oxidation, including:
            Medium-chain (MC) acyl-CoA dehydrogenase (AD) deficiency (MCADD);
            Short-chain AD deficiency (SCADD) ;
            Short-branched-chain AD deficiency (SBCADD) ;
            Very long-chain AD deficiency  (VLCADD) ;
            Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHADD) ;
            Trifunctional protein deficiency (TFP);
            Carnitine palmitoyltransferase deficiency (CPT);
            Carnitine-acylcarnitine translocase deficiency (CACT);
            Systemic primary carnitine deficiency (CDSP)
DESCRIPTION Fatty acid oxidation disorders (FAODs) are a group of rare inherited conditions that lead to accumulation of fatty acids and decreases in cell energy metabolism due to enzyme defects in the fatty acid metabolic pathway. The symptoms and treatment vary between different FAODs.
CATEGORY    Inherited metabolic disease
GENE        (MCADD) ACADM [HSA:34] [KO:K00249]
            (SCADD) ACADS [HSA:35] [KO:K00248]
            (SBCADD) ACADSB [HSA:36] [KO:K09478]
            (VLCADD) ACADVL [HSA:37] [KO:K09479]
            (LCHADD/TFP) HADHA [HSA:3030] [KO:K07515]
            (TFP) HADHB [HSA:3032] [KO:K07509]
            (CPT I) CPT1A [HSA:1374] [KO:K08765]
            (CPT II) CPT2 [HSA:1376] [KO:K08766]
            (CACT) SLC25A20 [HSA:788] [KO:K15109]
            (CDSP) SLC22A5 [HSA:6584] [KO:K08202]
MARKER      Tandem mass spectrometry
DRUG        (MCAD) L-carnitine [DR:D02176]
DBLINKS     ICD-10: E71.3
            MeSH: D008052
            OMIM: 201450 201470 610006 201475 609016 609015 608836 600649 255110 255120 212138 212140
REFERENCE   PMID:20049534
  AUTHORS   Wilcken B
  TITLE     Fatty acid oxidation disorders: outcome and long-term prognosis.
  JOURNAL   J Inherit Metab Dis 33:501-6 (2010)
REFERENCE   PMID:20066495
  AUTHORS   Lund AM, Skovby F, Vestergaard H, Christensen M, Christensen E
  TITLE     Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.
  JOURNAL   J Inherit Metab Dis 33:495-500 (2010)
REFERENCE   PMID:17347912 (Marker)
  AUTHORS   Han LS, Ye J, Qiu WJ, Gao XL, Wang Y, Gu XF
  TITLE     Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a four-year report.
  JOURNAL   J Inherit Metab Dis 30:507-14 (2007)
REFERENCE   PMID:15877203 (drug)
  AUTHORS   Lee PJ, Harrison EL, Jones MG, Jones S, Leonard JV, Chalmers RA
  TITLE     L-carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase  (MCAD) deficiency: a pilot study.
  JOURNAL   J Inherit Metab Dis 28:141-52 (2005)
///
ENTRY       H00526                      Disease
NAME        Camptodactyly-arthropathy-coxa vara-pericarditis syndrome;
            Jacobs syndrome
DESCRIPTION The camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) is an autosomal recessive disorder caused by mutations in the Proteoglycan 4 (PRG4), a chondroitin sulfate proteoglycan that acts as a lubricant for the cartilage surface. Affected individuals present with arthropathy associated with camptodactyly. Some patients have pericarditis with effusions.
CATEGORY    Developmental disorder
GENE        PRG4 [HSA:10216]
DBLINKS     MeSH: C537560
            OMIM: 208250
REFERENCE   PMID:12453309 (description, gene)
  AUTHORS   Reginato AM, Olsen BR
  TITLE     The role of structural genes in the pathogenesis of osteoarthritic disorders.
  JOURNAL   Arthritis Res 4:337-45 (2002)
REFERENCE   PMID:15702367 (description, gene)
  AUTHORS   Shayan K, Ho M, Edwards V, Laxer R, Thorner PS
  TITLE     Synovial pathology in camptodactyly-arthropathy-coxa vara-pericarditis syndrome.
  JOURNAL   Pediatr Dev Pathol 8:26-33 (2005)
REFERENCE   PMID:16429407 (description, gene)
  AUTHORS   Alazami AM, Al-Mayouf SM, Wyngaard CA, Meyer B
  TITLE     Novel PRG4 mutations underlie CACP in Saudi families.
  JOURNAL   Hum Mutat 27:213 (2006)
REFERENCE   PMID:16037531 (description)
  AUTHORS   Offiah AC, Woo P, Prieur AM, Hasson N, Hall CM
  TITLE     Camptodactyly-arthropathy-coxa vara-pericarditis syndrome versus juvenile idiopathic arthropathy.
  JOURNAL   AJR Am J Roentgenol 185:522-9 (2005)
///
ENTRY       H00527                      Disease
NAME        Retinitis pigmentosa (RP)
DESCRIPTION Retinitis pigmentosa (RP) is a group of inherited progressive retinal diseases characterized by progressive peripheral vision loss and night vision difficulties. RP can be divided into syndromic (40 %) and non-syndromic (60 %) forms. The most frequent forms of syndromic RP are Usher syndrome and Bardet-Biedl syndrome. Mutations in more than 50 genes are known to cause non-syndromic RP. Non-syndromic RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner.
CATEGORY    Inherited metabolic disease; Nervous system disease; Eye disease
GENE        (RP1) RP1 [HSA:6101] [KO:K19538]
            (RP2) RP2 [HSA:6102] [KO:K18272]
            (RP3/RP15) RPGR [HSA:6103] [KO:K19607]
            (RP4) RHO [HSA:6010] [KO:K04250]
            (RP7) PRPH2 [HSA:5961] [KO:K17343]
            (RP9) RP9 [HSA:6100] [KO:K19604]
            (RP10) IMPDH1 [HSA:3614] [KO:K00088]
            (RP11) PRPF31 [HSA:26121] [KO:K12844]
            (RP12) CRB1 [HSA:23418] [KO:K16681]
            (RP13) PRPF8 [HSA:10594] [KO:K12856]
            (RP14) TULP1 [HSA:7287] [KO:K19600]
            (RP17) CA4 [HSA:762] [KO:K18246]
            (RP18) PRPF3 [HSA:9129] [KO:K12843]
            (RP19) ABCA4 [HSA:24] [KO:K05644]
            (RP20) RPE65 [HSA:6121] [KO:K11158]
            (RP25) EYS [HSA:346007] [KO:K19601]
            (RP26) CERKL [HSA:375298] [KO:K19602]
            (RP27) NRL [HSA:4901] [KO:K09038]
            (RP28) FAM161A [HSA:84140] [KO:K16772]
            (RP30) FSCN2 [HSA:25794] [KO:K17455]
            (RP31) TOPORS [HSA:10210] [KO:K10631]
            (RP33) SNRNP200 [HSA:23020] [KO:K12854]
            (RP35) SEMA4A [HSA:64218] [KO:K06521]
            (RP36) PRCD [HSA:768206] [KO:K19637]
            (RP37) NR2E3 [HSA:10002] [KO:K08546]
            (RP38) MERTK [HSA:10461] [KO:K05117]
            (RP39) USH2A [HSA:7399] [KO:K19636]
            (RP40) PDE6B [HSA:5158] [KO:K13756]
            (RP41) PROM1 [HSA:8842] [KO:K06532]
            (RP42) KLHL7 [HSA:55975] [KO:K10445]
            (RP43) PDE6A [HSA:5145] [KO:K08718]
            (RP44) RGR [HSA:5995] [KO:K04254]
            (RP45) CNGB1 [HSA:1258] [KO:K04952]
            (RP46) IDH3B [HSA:3420] [KO:K00030]
            (RP47) SAG [HSA:6295] [KO:K19627]
            (RP48) GUCA1B [HSA:2979] [KO:K08328]
            (RP49) CNGA1 [HSA:1259] [KO:K04948]
            (RP50) BEST1 [HSA:7439] [KO:K13878]
            (RP54) C2orf71 [HSA:388939]
            (RP55) ARL6 [HSA:84100] [KO:K07951]
            (RP56) IMPG2 [HSA:50939] [KO:K19017]
            (RP57) PDE6G [HSA:5148] [KO:K13759]
            (RP58) ZNF513 [HSA:130557]
            (RP59) DHDDS [HSA:79947] [KO:K11778]
            (ARRP) SPATA7 [HSA:55812] [KO:K19655]
            (Juvenile) LRAT [HSA:9227] [KO:K00678]
            (Bothnia retinal dystrophy) RLBP1 [HSA:6017] [KO:K19625]
DRUG        Vitamin A [DG:DG00123]
            Diltiazem [DG:DG00331]
            Nilvadipine [DR:D01908]
            Apocynin [CPD:C11380]
            Retinal cell transplantation
            Administration of growth factor, particularly ciliary neurotrophic factor (CNTF)
            Gene therapy
DBLINKS     ICD-10: H35.5
            MeSH: D012174
            OMIM: 180100 312600 300029 300455 613731 608133 180104 180105 600138 600105 600059 600132 600852 601414 601718 613794 602772 608380 613750 606068 607921 609923 610359 610282 610599 611131 613862 613809 613801 612095 612943 613810 613769 613767 612572 613758 613827 613756 613194 613464 613428 613575 613581 613582 613617 613341 268000 607475 613861
REFERENCE   PMID:17296890
  AUTHORS   Daiger SP, Bowne SJ, Sullivan LS
  TITLE     Perspective on genes and mutations causing retinitis pigmentosa.
  JOURNAL   Arch Ophthalmol 125:151-8 (2007)
REFERENCE   PMID:10889272
  AUTHORS   Phelan JK, Bok D
  TITLE     A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes.
  JOURNAL   Mol Vis 6:116-24 (2000)
REFERENCE   PMID:15563868
  AUTHORS   Wang DY, Chan WM, Tam PO, Baum L, Lam DS, Chong KK, Fan BJ, Pang CP
  TITLE     Gene mutations in retinitis pigmentosa and their clinical implications.
  JOURNAL   Clin Chim Acta 351:5-16 (2005)
REFERENCE   PMID:21233585 (RP4, RP7, RP20, RP38, RP40, RP43)
  AUTHORS   Sakamoto K, Mori A, Nakahara T, Ishii K
  TITLE     [Cause of retinitis pigmentosa and new therapeutics under development] Japanese
  JOURNAL   Nihon Yakurigaku Zasshi 137:22-6 (2011)
REFERENCE   PMID:9751768
  AUTHORS   Li T, Sandberg MA, Pawlyk BS, Rosner B, Hayes KC, Dryja TP, Berson EL
  TITLE     Effect of vitamin A supplementation on rhodopsin mutants threonine-17 --&gt; methionine and proline-347 --&gt; serine in transgenic mice and in cell cultures.
  JOURNAL   Proc Natl Acad Sci U S A 95:11933-8 (1998)
REFERENCE   PMID:11239245
  AUTHORS   Pearce-Kelling SE, Aleman TS, Nickle A, Laties AM, Aguirre GD, Jacobson SG, Acland GM
  TITLE     Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.
  JOURNAL   Mol Vis 7:42-7 (2001)
REFERENCE   PMID:12356837
  AUTHORS   Tao W, Wen R, Goddard MB, Sherman SD, O'Rourke PJ, Stabila PF, Bell WJ, Dean BJ, Kauper KA, Budz VA, Tsiaras WG, Acland GM, Pearce-Kelling S, Laties AM, Aguirre GD
  TITLE     Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa.
  JOURNAL   Invest Ophthalmol Vis Sci 43:3292-8 (2002)
REFERENCE   PMID:17896309
  AUTHORS   Adams NA, Awadein A, Toma HS
  TITLE     The retinal ciliopathies.
  JOURNAL   Ophthalmic Genet 28:113-25 (2007)
REFERENCE   PMID:11176989
  AUTHORS   Burstedt MS, Forsman-Semb K, Golovleva I, Janunger T, Wachtmeister L, Sandgren O
  TITLE     Ocular phenotype of bothnia dystrophy, an autosomal recessive retinitis pigmentosa associated with an R234W mutation in the RLBP1 gene.
  JOURNAL   Arch Ophthalmol 119:260-7 (2001)
REFERENCE   PMID:21295282
  AUTHORS   Zelinger L, Banin E, Obolensky A, Mizrahi-Meissonnier L, Beryozkin A, Bandah-Rozenfeld D, Frenkel S, Ben-Yosef T, Merin S, Schwartz SB, Cideciyan AV, Jacobson SG, Sharon D
  TITLE     A missense mutation in DHDDS, encoding dehydrodolichyl diphosphate synthase, is associated with autosomal-recessive retinitis pigmentosa in Ashkenazi Jews.
  JOURNAL   Am J Hum Genet 88:207-15 (2011)
///
ENTRY       H00528                      Disease
NAME        Frontonasal dysplasia
DESCRIPTION Frontonasal dysplasia is a rare developmental field defect with separation or clefting of the central portion of the face. Its basic characteristics include hypertelorism, a broad nose, or complete midline splitting of the nose.
CATEGORY    Developmental disorder
GENE        ALX1 [HSA:8092] [KO:K09334]
            ALX3 [HSA:257] [KO:K09323]
            ALX4 [HSA:60529] [KO:K09451]
DBLINKS     MeSH: C538065
            OMIM: 613456 613451
REFERENCE   PMID:21108387 (description)
  AUTHORS   Brugmann SA, Cordero DR, Helms JA
  TITLE     Craniofacial ciliopathies: A new classification for craniofacial disorders.
  JOURNAL   Am J Med Genet A 152A:2995-3006 (2010)
REFERENCE   PMID:21285785 (description)
  AUTHORS   Allam KA, Wan DC, Kawamoto HK, Bradley JP, Sedano HO, Saied S
  TITLE     The spectrum of median craniofacial dysplasia.
  JOURNAL   Plast Reconstr Surg 127:812-21 (2011)
REFERENCE   PMID:20451171 (gene)
  AUTHORS   Uz E, Alanay Y, Aktas D, Vargel I, Gucer S, Tuncbilek G, von Eggeling F, Yilmaz E, Deren O, Posorski N, Ozdag H, Liehr T, Balci S, Alikasifoglu M, Wollnik B, Akarsu NA
  TITLE     Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia.
  JOURNAL   Am J Hum Genet 86:789-96 (2010)
REFERENCE   PMID:19409524 (gene)
  AUTHORS   Twigg SR, Versnel SL, Nurnberg G, Lees MM, Bhat M, Hammond P, Hennekam RC, Hoogeboom AJ, Hurst JA, Johnson D, Robinson AA, Scambler PJ, Gerrelli D, Nurnberg P, Mathijssen IM, Wilkie AO
  TITLE     Frontorhiny, a distinctive presentation of frontonasal dysplasia caused by recessive mutations in the ALX3 homeobox gene.
  JOURNAL   Am J Hum Genet 84:698-705 (2009)
REFERENCE   PMID:19692347 (gene)
  AUTHORS   Kayserili H, Uz E, Niessen C, Vargel I, Alanay Y, Tuncbilek G, Yigit G, Uyguner O, Candan S, Okur H, Kaygin S, Balci S, Mavili E, Alikasifoglu M, Haase I, Wollnik B, Akarsu NA
  TITLE     ALX4 dysfunction disrupts craniofacial and epidermal development.
  JOURNAL   Hum Mol Genet 18:4357-66 (2009)
///
ENTRY       H00529                      Disease
NAME        Cranioectodermal dysplasia
DESCRIPTION Cranioectodermal dysplasia is a rare disorder characterized by defects of ectoderm-derived structures with typical craniofacial appearances, skeletal deformities and tubulointerstitial nephritis. The craniofacial features include dolichocephaly, sagittal craniosynostosis, and hypoodontia.
CATEGORY    Developmental disorder
GENE        WDR35 [HSA:57539] [KO:K19674]
            IFT122 [HSA:55764] [KO:K19656]
            IFT43 [HSA:112752] [KO:K19675]
            WDR19 [HSA:57728] [KO:K19671]
DBLINKS     ICD-10: Q87.5
            MeSH: C562966
            OMIM: 218330 613610 614099 614378
REFERENCE   PMID:21108387 (description)
  AUTHORS   Brugmann SA, Cordero DR, Helms JA
  TITLE     Craniofacial ciliopathies: A new classification for craniofacial disorders.
  JOURNAL   Am J Med Genet A 152A:2995-3006 (2010)
REFERENCE   PMID:19760621 (description)
  AUTHORS   Konstantinidou AE, Fryssira H, Sifakis S, Karadimas C, Kaminopetros P, Agrogiannis G, Velonis S, Nikkels PG, Patsouris E
  TITLE     Cranioectodermal dysplasia: a probable ciliopathy.
  JOURNAL   Am J Med Genet A 149A:2206-11 (2009)
REFERENCE   PMID:20817137 (gene)
  AUTHORS   Gilissen C, Arts HH, Hoischen A, Spruijt L, Mans DA, Arts P, van Lier B, Steehouwer M, van Reeuwijk J, Kant SG, Roepman R, Knoers NV, Veltman JA, Brunner HG
  TITLE     Exome sequencing identifies WDR35 variants involved in Sensenbrenner syndrome.
  JOURNAL   Am J Hum Genet 87:418-23 (2010)
REFERENCE   PMID:20493458 (gene)
  AUTHORS   Walczak-Sztulpa J, Eggenschwiler J, Osborn D, Brown DA, Emma F, Klingenberg C, Hennekam RC, Torre G, Garshasbi M, Tzschach A, Szczepanska M, Krawczynski M, Zachwieja J, Zwolinska D, Beales PL, Ropers HH, Latos-Bielenska A, Kuss AW
  TITLE     Cranioectodermal Dysplasia, Sensenbrenner syndrome, is a ciliopathy caused by mutations in the IFT122 gene.
  JOURNAL   Am J Hum Genet 86:949-56 (2010)
REFERENCE   PMID:21378380 (gene)
  AUTHORS   Arts HH, Bongers EM, Mans DA, van Beersum SE, Oud MM, Bolat E, Spruijt L, Cornelissen EA, Schuurs-Hoeijmakers JH, de Leeuw N, Cormier-Daire V, Brunner HG, Knoers NV, Roepman R
  TITLE     C14ORF179 encoding IFT43 is mutated in Sensenbrenner syndrome.
  JOURNAL   J Med Genet 48:390-5 (2011)
REFERENCE   PMID:22019273 (gene)
  AUTHORS   Bredrup C, Saunier S, Oud MM, Fiskerstrand T, Hoischen A, Brackman D, Leh SM, Midtbo M, Filhol E, Bole-Feysot C, Nitschke P, Gilissen C, Haugen OH, Sanders JS, Stolte-Dijkstra I, Mans DA, Steenbergen EJ, Hamel BC, Matignon M, Pfundt R, Jeanpierre C, Boman H, Rodahl E, Veltman JA, Knappskog PM, Knoers NV, Roepman R, Arts HH
  TITLE     Ciliopathies with Skeletal Anomalies and Renal Insufficiency due to Mutations in  the IFT-A Gene WDR19.
  JOURNAL   Am J Hum Genet 89:634-43 (2011)
///
ENTRY       H00530                      Disease
NAME        Joubert syndrome
DESCRIPTION Joubert syndrome and related disorders are a group of multiple congenital anomaly syndromes characterized by 'molar tooth sign', a specific midbrain-hindbrain malformation seen in brain images. Joubert syndrome is associated with retinal dystrophy, nephronophthisis, liver fibrosis and polydactyly. Most of the causative genes encode cilium-related proteins.
CATEGORY    Developmental disorder
GENE        (JBTS1) INPP5E [HSA:56623] [KO:K20278]
            (JBTS2) TMEM216 [HSA:51259] [KO:K19385]
            (JBTS3) AHI1 [HSA:54806] [KO:K16740]
            (JBTS4) NPHP1 (deletion) [HSA:4867] [KO:K19657]
            (JBTS5) CEP290 [HSA:80184] [KO:K16533]
            (JBTS6) TMEM67 [HSA:91147] [KO:K19348]
            (JBTS7) RPGRIP1L [HSA:23322] [KO:K16550]
            (JBTS8) ARL13B [HSA:200894] [KO:K07962]
            (JBTS9) CC2D2A [HSA:57545] [KO:K19352]
            (JBTS10) OFD1 [HSA:8481] [KO:K16480]
            (JBTS11) TTC21B [HSA:79809] [KO:K19673]
            (JBTS12) KIF7 [HSA:374654] [KO:K18806]
            (JBTS13) TECT1 [HSA:79600] [KO:K19382]
            (JBTS14) TMEM237 [HSA:65062]
            (JBTS15) CEP41 [HSA:95681] [KO:K16455]
            (JBTS16) TMEM138 [HSA:51524]
            (JBTS17) C5orf42 [HSA:65250]
            (JBTS18) TCTN3 [HSA:26123] [KO:K19382]
            (JBTS19) ZNF423 [HSA:23090]
            (JBTS20) TMEM231 [HSA:79583] [KO:K19362]
            (JBTS21) CSPP1 [HSA:79848] [KO:K16771]
            (JBTS22) PDE6D [HSA:5147] [KO:K13758]
            (JBTS23) JBTS23 [HSA:9786]
            (JBTS24) TCTN2 [HSA:79867] [KO:K19361]
            (JBTS25) CEP104 [HSA:9731] [KO:K16458]
            (JBTS26) JBTS26 [HSA:23247]
DBLINKS     ICD-10: Q04.3 Q87.8 Q87.0
            MeSH: C536293 C536294 C536295 C536296 C537688 C537689 C566916 C567358 C567364 C567582
            OMIM: 213300 608091 608629 609583 610188 610688 611560 612291 612285 300804 613820 200990 614173 614424 614464 614465 614615 614815 614844 614970 615636 615665 616490 616654 616781 616784
REFERENCE   PMID:21108387 (description, gene)
  AUTHORS   Brugmann SA, Cordero DR, Helms JA
  TITLE     Craniofacial ciliopathies: A new classification for craniofacial disorders.
  JOURNAL   Am J Med Genet A 152A:2995-3006 (2010)
REFERENCE   PMID:20615230 (description, gene)
  AUTHORS   Brancati F, Dallapiccola B, Valente EM
  TITLE     Joubert Syndrome and related disorders.
  JOURNAL   Orphanet J Rare Dis 5:20 (2010)
REFERENCE   PMID:19668216 (gene)
  AUTHORS   Bielas SL, Silhavy JL, Brancati F, Kisseleva MV, Al-Gazali L, Sztriha L, Bayoumi RA, Zaki MS, Abdel-Aleem A, Rosti RO, Kayserili H, Swistun D, Scott LC, Bertini E, Boltshauser E, Fazzi E, Travaglini L, Field SJ, Gayral S, Jacoby M, Schurmans S, Dallapiccola B, Majerus PW, Valente EM, Gleeson JG
  TITLE     Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies.
  JOURNAL   Nat Genet 41:1032-6 (2009)
REFERENCE   PMID:21258341
  AUTHORS   Davis EE, Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV, Muzny DM, Young AC, Wheeler DA, Cruz P, Morgan M, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG, Gyapay G, Rieger S, Tonshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG, Maher ER, Attie-Bitach T, Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N
  TITLE     TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum.
  JOURNAL   Nat Genet 43:189-96 (2011)
REFERENCE   PMID:21633164
  AUTHORS   Dafinger C, Liebau MC, Elsayed SM, Hellenbroich Y, Boltshauser E, Korenke GC, Fabretti F, Janecke AR, Ebermann I, Nurnberg G, Nurnberg P, Zentgraf H, Koerber F, Addicks K, Elsobky E, Benzing T, Schermer B, Bolz HJ
  TITLE     Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics.
  JOURNAL   J Clin Invest 121:2662-7 (2011)
REFERENCE   PMID:21725307
  AUTHORS   Garcia-Gonzalo FR, Corbit KC, Sirerol-Piquer MS, Ramaswami G, Otto EA, Noriega TR, Seol AD, Robinson JF, Bennett CL, Josifova DJ, Garcia-Verdugo JM, Katsanis N, Hildebrandt F, Reiter JF
  TITLE     A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition.
  JOURNAL   Nat Genet 43:776-84 (2011)
REFERENCE   PMID:22152675
  AUTHORS   Huang L, Szymanska K, Jensen VL, Janecke AR, Innes AM, Davis EE, Frosk P, Li C, Willer JR, Chodirker BN, Greenberg CR, McLeod DR, Bernier FP, Chudley AE, Muller T, Shboul M, Logan CV, Loucks CM, Beaulieu CL, Bowie RV, Bell SM, Adkins J, Zuniga FI, Ross KD, Wang J, Ban MR, Becker C, Nurnberg P, Douglas S, Craft CM, Akimenko MA, Hegele RA, Ober C, Utermann G, Bolz HJ, Bulman DE, Katsanis N, Blacque OE, Doherty D, Parboosingh JS, Leroux MR, Johnson CA, Boycott KM
  TITLE     TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone.
  JOURNAL   Am J Hum Genet 89:713-30 (2011)
REFERENCE   PMID:22246503
  AUTHORS   Lee JE, Silhavy JL, Zaki MS, Schroth J, Bielas SL, Marsh SE, Olvera J, Brancati F, Iannicelli M, Ikegami K, Schlossman AM, Merriman B, Attie-Bitach T, Logan CV, Glass IA, Cluckey A, Louie CM, Lee JH, Raynes HR, Rapin I, Castroviejo IP, Setou M, Barbot C, Boltshauser E, Nelson SF, Hildebrandt F, Johnson CA, Doherty DA, Valente EM, Gleeson JG
  TITLE     CEP41 is mutated in Joubert syndrome and is required for tubulin glutamylation at the cilium.
  JOURNAL   Nat Genet 44:193-9 (2012)
REFERENCE   PMID:22282472
  AUTHORS   Lee JH, Silhavy JL, Lee JE, Al-Gazali L, Thomas S, Davis EE, Bielas SL, Hill KJ, Iannicelli M, Brancati F, Gabriel SB, Russ C, Logan CV, Sharif SM, Bennett CP, Abe M, Hildebrandt F, Diplas BH, Attie-Bitach T, Katsanis N, Rajab A, Koul R, Sztriha L, Waters ER, Ferro-Novick S, Woods CG, Johnson CA, Valente EM, Zaki MS, Gleeson JG
  TITLE     Evolutionarily assembled cis-regulatory module at a human ciliopathy locus.
  JOURNAL   Science 335:966-9 (2012)
REFERENCE   PMID:22425360
  AUTHORS   Srour M, Schwartzentruber J, Hamdan FF, Ospina LH, Patry L, Labuda D, Massicotte C, Dobrzeniecka S, Capo-Chichi JM, Papillon-Cavanagh S, Samuels ME, Boycott KM, Shevell MI, Laframboise R, Desilets V, Maranda B, Rouleau GA, Majewski J, Michaud JL
  TITLE     Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population.
  JOURNAL   Am J Hum Genet 90:693-700 (2012)
REFERENCE   PMID:22883145
  AUTHORS   Thomas S, Legendre M, Saunier S, Bessieres B, Alby C, Bonniere M, Toutain A, Loeuillet L, Szymanska K, Jossic F, Gaillard D, Yacoubi MT, Mougou-Zerelli S, David A, Barthez MA, Ville Y, Bole-Feysot C, Nitschke P, Lyonnet S, Munnich A, Johnson CA, Encha-Razavi F, Cormier-Daire V, Thauvin-Robinet C, Vekemans M, Attie-Bitach T
  TITLE     TCTN3 mutations cause Mohr-Majewski syndrome.
  JOURNAL   Am J Hum Genet 91:372-8 (2012)
REFERENCE   PMID:22863007
  AUTHORS   Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, Gee HY, Ramaswami G, Hong CJ, Hamilton BA, Cervenka I, Ganji RS, Bryja V, Arts HH, van Reeuwijk J, Oud MM, Letteboer SJ, Roepman R, Husson H, Ibraghimov-Beskrovnaya O, Yasunaga T, Walz G, Eley L, Sayer JA, Schermer B, Liebau MC, Benzing T, Le Corre S, Drummond I, Janssen S, Allen SJ, Natarajan S, O'Toole JF, Attanasio M, Saunier S, Antignac C, Koenekoop RK, Ren H, Lopez I, Nayir A, Stoetzel C, Dollfus H, Massoudi R, Gleeson JG, Andreoli SP, Doherty DG, Lindstrad A, Golzio C, Katsanis N, Pape L, Abboud EB, Al-Rajhi AA, Lewis RA, Omran H, Lee EY, Wang S, Sekiguchi JM, Saunders R, Johnson CA, Garner E, Vanselow K, Andersen JS, Shlomai J, Nurnberg G, Nurnberg P, Levy S, Smogorzewska A, Otto EA, Hildebrandt F
  TITLE     Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to  DNA damage response signaling.
  JOURNAL   Cell 150:533-48 (2012)
REFERENCE   PMID:23012439
  AUTHORS   Srour M, Hamdan FF, Schwartzentruber JA, Patry L, Ospina LH, Shevell MI, Desilets V, Dobrzeniecka S, Mathonnet G, Lemyre E, Massicotte C, Labuda D, Amrom D, Andermann E, Sebire G, Maranda B, Rouleau GA, Majewski J, Michaud JL
  TITLE     Mutations in TMEM231 cause Joubert syndrome in French Canadians.
  JOURNAL   J Med Genet 49:636-41 (2012)
REFERENCE   PMID:24360807
  AUTHORS   Akizu N, Silhavy JL, Rosti RO, Scott E, Fenstermaker AG, Schroth J, Zaki MS, Sanchez H, Gupta N, Kabra M, Kara M, Ben-Omran T, Rosti B, Guemez-Gamboa A, Spencer E, Pan R, Cai N, Abdellateef M, Gabriel S, Halbritter J, Hildebrandt F, van Bokhoven H, Gunel M, Gleeson JG
  TITLE     Mutations in CSPP1 lead to classical Joubert syndrome.
  JOURNAL   Am J Hum Genet 94:80-6 (2014)
REFERENCE   PMID:24166846
  AUTHORS   Thomas S, Wright KJ, Le Corre S, Micalizzi A, Romani M, Abhyankar A, Saada J, Perrault I, Amiel J, Litzler J, Filhol E, Elkhartoufi N, Kwong M, Casanova JL, Boddaert N, Baehr W, Lyonnet S, Munnich A, Burglen L, Chassaing N, Encha-Ravazi F, Vekemans M, Gleeson JG, Valente EM, Jackson PK, Drummond IA, Saunier S, Attie-Bitach T
  TITLE     A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
  JOURNAL   Hum Mutat 35:137-46 (2014)
REFERENCE   PMID:26096313 (gene)
  AUTHORS   Bachmann-Gagescu R, Phelps IG, Dempsey JC, Sharma VA, Ishak GE, Boyle EA, Wilson M, Marques Lourenco C, Arslan M, Shendure J, Doherty D
  TITLE     KIAA0586 is Mutated in Joubert Syndrome.
  JOURNAL   Hum Mutat 36:831-5 (2015)
REFERENCE   PMID:25118024 (gene)
  AUTHORS   Huppke P, Wegener E, Bohrer-Rabel H, Bolz HJ, Zoll B, Gartner J, Bergmann C
  TITLE     Tectonic gene mutations in patients with Joubert syndrome.
  JOURNAL   Eur J Hum Genet 23:616-20 (2015)
REFERENCE   PMID:26477546 (gene)
  AUTHORS   Srour M, Hamdan FF, McKnight D, Davis E, Mandel H, Schwartzentruber J, Martin B, Patry L, Nassif C, Dionne-Laporte A, Ospina LH, Lemyre E, Massicotte C, Laframboise R, Maranda B, Labuda D, Decarie JC, Rypens F, Goldsher D, Fallet-Bianco C, Soucy JF, Laberge AM, Maftei C, Boycott K, Brais B, Boucher RM, Rouleau GA, Katsanis N, Majewski J, Elpeleg O, Kukolich MK, Shalev S, Michaud JL
  TITLE     Joubert Syndrome in French Canadians and Identification of Mutations in CEP104.
  JOURNAL   Am J Hum Genet 97:744-53 (2015)
REFERENCE   PMID:26714646 (gene)
  AUTHORS   Sanders AA, de Vrieze E, Alazami AM, Alzahrani F, Malarkey EB, Sorusch N, Tebbe L, Kuhns S, van Dam TJ, Alhashem A, Tabarki B, Lu Q, Lambacher NJ, Kennedy JE, Bowie RV, Hetterschijt L, van Beersum S, van Reeuwijk J, Boldt K, Kremer H, Kesterson RA, Monies D, Abouelhoda M, Roepman R, Huynen MH, Ueffing M, Russell RB, Wolfrum U, Yoder BK, van Wijk E, Alkuraya FS, Blacque OE
  TITLE     KIAA0556 is a novel ciliary basal body component mutated in Joubert syndrome.
  JOURNAL   Genome Biol 16:293 (2015)
///
ENTRY       H00531                      Disease
NAME        Venous malformations, including:
            Sporadic venous malformation;
            Cutaneomucosal venous malformation;
            Glomuvenous malformation
DESCRIPTION Venous malformations are vascular anomalies that present with congenital blue-colored birthmarks resulted from dilated veins. Birthmarks in cutaneomucosal venous malformation appear mainly on skin and mucosa, whereas plaques in glomuvenous malformation are located on the extremities, usually nodular and associated with abnormal smooth muscle-like 'glomus cells'. The disease-causing genes are glomulin and TIE2, a receptor for angiogenic factors.
CATEGORY    Developmental disorder; Vascular disease
GENE        (sporadic, cutaneomucosal) TIE2 [HSA:7010] [KO:K05121]
            (glomuvenous) GLMN [HSA:11146]
DBLINKS     ICD-10: Q27.9 Q27.8
            OMIM: 600195 138000
REFERENCE   PMID:17670762 (description, gene)
  AUTHORS   Brouillard P, Vikkula M
  TITLE     Genetic causes of vascular malformations.
  JOURNAL   Hum Mol Genet 16 Spec No. 2:R140-9 (2007)
REFERENCE   PMID:16379592 (description, gene)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
REFERENCE   PMID:19079259 (gene)
  AUTHORS   Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M
  TITLE     Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.
  JOURNAL   Nat Genet 41:118-24 (2009)
///
ENTRY       H00532                      Disease
NAME        RASA1-related disorders, including:
            Parkes-Weber slndrome;
            Capillary malformation-arteriovenous malformation (CM-AVM);
            Arteriovenous fistula (AVF)
DESCRIPTION These RASA1-related disorders are conditions with atypical cutaneous capillary malformations localized on the face and limbs. Some patients have fast-flow vascular lesion with directly connected arteries and veins.
CATEGORY    Developmental disorder; Vascular disease
GENE        RASA1 [HSA:5921] [KO:K04352]
DBLINKS     OMIM: 608355 608354
REFERENCE   PMID:17670762 (description, gene)
  AUTHORS   Brouillard P, Vikkula M
  TITLE     Genetic causes of vascular malformations.
  JOURNAL   Hum Mol Genet 16 Spec No. 2:R140-9 (2007)
REFERENCE   PMID:21348050 (description, gene)
  AUTHORS   Bayrak-Toydemir P, Stevenson D
  TITLE     RASA1-Related Disorders
  JOURNAL   (1993)
///
ENTRY       H00533                      Disease
NAME        Hereditary hemorrhagic telangiectasia (HHT);
            Osler's disease
DESCRIPTION Hereditary hemorrhagic telangiectasia (HHT), also known as Osler's disease, is an autosomal dominant vascular dysplasia characterized by severe recurrent nasal and gastrointestinal bleeding and cutaneomucosal telangiectases. HHT is often associated with arteriovenous malformations in the pulmonary, hepatic, cerebral, and spinal circulations. The disease arises from defects in TGF-beta signaling.
CATEGORY    Developmental disorder; Vascular disease
GENE        ENG [HSA:2022] [KO:K06526]
            ACVRL1 [HSA:94] [KO:K13594]
            SMAD4 [HSA:4089] [KO:K04501]
            GDF2 [HSA:2658] [KO:K05503]
DBLINKS     ICD-10: I78.0
            MeSH: D013683
            OMIM: 187300 600376 175050 615506
REFERENCE   PMID:17670762 (description)
  AUTHORS   Brouillard P, Vikkula M
  TITLE     Genetic causes of vascular malformations.
  JOURNAL   Hum Mol Genet 16 Spec No. 2:R140-9 (2007)
REFERENCE   PMID:16379592 (description)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
REFERENCE   PMID:20870325 (gene)
  AUTHORS   Shovlin CL
  TITLE     Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.
  JOURNAL   Blood Rev 24:203-19 (2010)
REFERENCE   PMID:20345718 (gene)
  AUTHORS   Dupuis-Girod S, Bailly S, Plauchu H
  TITLE     Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.
  JOURNAL   J Thromb Haemost 8:1447-56 (2010)
REFERENCE   PMID:23972370 (gene)
  AUTHORS   Wooderchak-Donahue WL, McDonald J, O'Fallon B, Upton PD, Li W, Roman BL, Young S, Plant P, Fulop GT, Langa C, Morrell NW, Botella LM, Bernabeu C, Stevenson DA, Runo JR, Bayrak-Toydemir P
  TITLE     BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia.
  JOURNAL   Am J Hum Genet 93:530-7 (2013)
///
ENTRY       H00534                      Disease
NAME        Cerebral cavernous malformation
DESCRIPTION Cerebral cavernous malformations are vascular malformations of the central nervous system comprising enlarged caverns with a single layer of endothelium, which easily lead to cerebral hemorrhages. The disease present as either sporadic or autosomal dominant conditions and is linked to three genes KRIT1, MGC4607, and PDCD10. Mutations in KRIT1 impair its interaction with ICAP-1 alpha, a beta 1 integrin binding protein, and influence beta 1 integrin-dependent angiogenesis.
CATEGORY    Developmental disorder; Vascular disease
GENE        CCM1 [HSA:889] [KO:K17705]
            MGC4607 [HSA:83605]
            PDCD10 [HSA:11235] [KO:K18269]
DBLINKS     OMIM: 116860 603284 603285
REFERENCE   PMID:17670762 (description, gene)
  AUTHORS   Brouillard P, Vikkula M
  TITLE     Genetic causes of vascular malformations.
  JOURNAL   Hum Mol Genet 16 Spec No. 2:R140-9 (2007)
REFERENCE   PMID:16379592 (description, gene)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
///
ENTRY       H00535                      Disease
NAME        Lymphedemas, including:
            Lymphedema, hereditary I;
            Lymphedema-distichiasis syndrome (LD);
            Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS);
            Hennekam lymphangiectasia-lymphedema syndrome (HLLS)
DESCRIPTION Lymphoedemas are developmental disorders characterized by chronic lesions of the extremities due to insufficient lymphatic drainage. The dilated lymphatic channels that are not connected to the lymphatic vessels cause these edemas. LD patients develop extra eyelashes, HLTS is associated with sparse hair and cutaneous telangiectasias, and HLLS patients have unusual facies and severe mental retardation, in addition to the lymphoedemas.
CATEGORY    Developmental disorder
GENE        (hereditary I) FLT4 [HSA:2324] [KO:K05097]
            (LD) FOXC2 [HSA:2303] [KO:K09396] 
            (HLTS) SOX18 [HSA:54345] [KO:K09270]
            (HLLS) CCBE1 [HSA:147372] [KO:K19638]
DBLINKS     ICD-10: Q82.0
            OMIM: 153100 153400 607823 235510
REFERENCE   PMID:17670762 (description, gene)
  AUTHORS   Brouillard P, Vikkula M
  TITLE     Genetic causes of vascular malformations.
  JOURNAL   Hum Mol Genet 16 Spec No. 2:R140-9 (2007)
REFERENCE   PMID:16379592 (description, gene)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
REFERENCE   PMID:11371511 (gene)
  AUTHORS   Finegold DN, Kimak MA, Lawrence EC, Levinson KL, Cherniske EM, Pober BR, Dunlap JW, Ferrell RE
  TITLE     Truncating mutations in FOXC2 cause multiple lymphedema syndromes.
  JOURNAL   Hum Mol Genet 10:1185-9 (2001)
REFERENCE   PMID:19935664
  AUTHORS   Alders M, Hogan BM, Gjini E, Salehi F, Al-Gazali L, Hennekam EA, Holmberg EE, Mannens MM, Mulder MF, Offerhaus GJ, Prescott TE, Schroor EJ, Verheij JB, Witte M, Zwijnenburg PJ, Vikkula M, Schulte-Merker S, Hennekam RC
  TITLE     Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans.
  JOURNAL   Nat Genet 41:1272-4 (2009)
///
ENTRY       H00536                      Disease
NAME        Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL)
DESCRIPTION CADASIL is a chronic cerebrovascular disorder characterized by recurrent ischemic attacks and frequent migraines associated with diffuse white-matter abnormalities. CADASIL is caused by mutations in the NOTCH3 gene.
CATEGORY    Developmental disorder; Vascular disease
GENE        NOTCH3 [HSA:4854] [KO:K20995]
DBLINKS     ICD-10: F01.1 I67.3
            OMIM: 125310
REFERENCE   PMID:16379592 (description, gene)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
REFERENCE   PMID:20967782 (description, gene)
  AUTHORS   Joutel A
  TITLE     Pathogenesis of CADASIL: transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature.
  JOURNAL   Bioessays 33:73-80 (2011)
///
ENTRY       H00537                      Disease
NAME        Nephronophthisis-medullary cystic kidney disease, including:
            Nephronophthisis (NPH) ;
            Nephronophthisis-like nephropathy 1;
            Medullary cystic kidney disease 1;
            Medullary cystic kidney disease 2 (MSKD2)
DESCRIPTION Nephronophthisis and medullary cystic kidney disease are inherited disorders that share many features including irregular tubular basement membrane, tubular cyst formation, and interstitial cell infiltration with fibrosis. The outcome of these diseases is end-stage renal disease. Multiple signaling pathways are altered because of mutated cilia genes.
CATEGORY    Developmental disorder; Kidney disease
GENE        (NPH) NPHP1 [HSA:4867] [KO:K19657]
            (NPH) INVS [HSA:27130] [KO:K19626]
            (NPH) NPHP3 [HSA:27031] [KO:K19360]
            (NPH) NPHP4 [HSA:261734] [KO:K16478]
            (NPH) IQCB1 [HSA:9657] [KO:K16774]
            (NPH) CEP290 [HSA:80184] [KO:K16533]
            (NPH) GLIS2 [HSA:84662] [KO:K09233]
            (NPH) NEK8 [HSA:284086] [KO:K20877]
            (NPH) SDCCAG8 [HSA:10806] [KO:K16488]
            (NPH) TMEM67 [HSA:91147] [KO:K19348]
            (NPH) TTC21B [HSA:79809] [KO:K19673]
            (NPH) WDR19 [HSA:57728] [KO:K19671]
            (NPH) ZNF423 [HSA:23090]
            (NPH) CEP164 [HSA:22897] [KO:K16462]
            (NPH) ANKS6 [HSA:203286] [KO:K21415]
            (NPH-like) XPNPEP3 [HSA:63929] [KO:K01262]
            (MSKD2) UMOD [HSA:7369] [KO:K18274]
COMMENT     For Senior-Loken syndrome, see H00538.
DBLINKS     ICD-10: N11.8 Q61.5
            MeSH: D052177
            OMIM: 256100 602088 604387 606966 611498 613824 613550 613820 614377 614844 614845 615382 613159 603860
REFERENCE   PMID:21898032 (description, gene)
  AUTHORS   Bergmann C
  TITLE     Educational paper : Ciliopathies.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:11261687 (description)
  AUTHORS   Hildebrandt F, Omram H
  TITLE     New insights: nephronophthisis-medullary cystic kidney disease.
  JOURNAL   Pediatr Nephrol 16:168-76 (2001)
REFERENCE   PMID:20652329 (gene)
  AUTHORS   Wolf MT, Hildebrandt F
  TITLE     Nephronophthisis.
  JOURNAL   Pediatr Nephrol 26:181-94 (2011)
REFERENCE   PMID:23559409
  AUTHORS   Halbritter J, Porath JD, Diaz KA, Braun DA, Kohl S, Chaki M, Allen SJ, Soliman NA, Hildebrandt F, Otto EA
  TITLE     Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy.
  JOURNAL   Hum Genet 132:865-84 (2013)
REFERENCE   PMID:22863007
  AUTHORS   Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, Gee HY, Ramaswami G, Hong CJ, Hamilton BA, Cervenka I, Ganji RS, Bryja V, Arts HH, van Reeuwijk J, Oud MM, Letteboer SJ, Roepman R, Husson H, Ibraghimov-Beskrovnaya O, Yasunaga T, Walz G, Eley L, Sayer JA, Schermer B, Liebau MC, Benzing T, Le Corre S, Drummond I, Janssen S, Allen SJ, Natarajan S, O'Toole JF, Attanasio M, Saunier S, Antignac C, Koenekoop RK, Ren H, Lopez I, Nayir A, Stoetzel C, Dollfus H, Massoudi R, Gleeson JG, Andreoli SP, Doherty DG, Lindstrad A, Golzio C, Katsanis N, Pape L, Abboud EB, Al-Rajhi AA, Lewis RA, Omran H, Lee EY, Wang S, Sekiguchi JM, Saunders R, Johnson CA, Garner E, Vanselow K, Andersen JS, Shlomai J, Nurnberg G, Nurnberg P, Levy S, Smogorzewska A, Otto EA, Hildebrandt F
  TITLE     Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to  DNA damage response signaling.
  JOURNAL   Cell 150:533-48 (2012)
REFERENCE   PMID:23793029
  AUTHORS   Hoff S, Halbritter J, Epting D, Frank V, Nguyen TM, van Reeuwijk J, Boehlke C, Schell C, Yasunaga T, Helmstadter M, Mergen M, Filhol E, Boldt K, Horn N, Ueffing M, Otto EA, Eisenberger T, Elting MW, van Wijk JA, Bockenhauer D, Sebire NJ, Rittig S, Vyberg M, Ring T, Pohl M, Pape L, Neuhaus TJ, Elshakhs NA, Koon SJ, Harris PC, Grahammer F, Huber TB, Kuehn EW, Kramer-Zucker A, Bolz HJ, Roepman R, Saunier S, Walz G, Hildebrandt F, Bergmann C, Lienkamp SS
  TITLE     ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3.
  JOURNAL   Nat Genet 45:951-6 (2013)
///
ENTRY       H00538                      Disease
NAME        Senior-Loken syndrome
DESCRIPTION Senior-Loken syndrome is a rare disorder that combines nephronophthisis and retinitis pigmentosa.
CATEGORY    Developmental disorder; Kidney disease; Nervous system disease
GENE        NPHP1 [HSA:4867] [KO:K19657]
            NPHP3 [HSA:27031] [KO:K19360]
            NPHP4 [HSA:261734] [KO:K16478]
            IQCB1 [HSA:9657] [KO:K16774]
            CEP290 [HSA:80184] [KO:K16533]
            SDCCAG8 [HSA:10806] [KO:K16488]
COMMENT     For nephronophthisis and related disorders, see H00537.
DBLINKS     ICD-10: Q74.8
            MeSH: C537580
            OMIM: 266900 606996 609254 610189 613615
REFERENCE   PMID:21898032 (gene)
  AUTHORS   Bergmann C
  TITLE     Educational paper : Ciliopathies.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:17896309 (description)
  AUTHORS   Adams NA, Awadein A, Toma HS
  TITLE     The retinal ciliopathies.
  JOURNAL   Ophthalmic Genet 28:113-25 (2007)
REFERENCE   PMID:15723066 (gene)
  AUTHORS   Otto EA, Loeys B, Khanna H, Hellemans J, Sudbrak R, Fan S, Muerb U, O'Toole JF, Helou J, Attanasio M, Utsch B, Sayer JA, Lillo C, Jimeno D, Coucke P, De Paepe A, Reinhardt R, Klages S, Tsuda M, Kawakami I, Kusakabe T, Omran H, Imm A, Tippens M, Raymond PA, Hill J, Beales P, He S, Kispert A, Margolis B, Williams DS, Swaroop A, Hildebrandt F
  TITLE     Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome  and interacts with RPGR and calmodulin.
  JOURNAL   Nat Genet 37:282-8 (2005)
REFERENCE   PMID:17617513 (gene)
  AUTHORS   Helou J, Otto EA, Attanasio M, Allen SJ, Parisi MA, Glass I, Utsch B, Hashmi S, Fazzi E, Omran H, O'Toole JF, Sayer JA, Hildebrandt F
  TITLE     Mutation analysis of NPHP6/CEP290 in patients with Joubert syndrome and Senior-Loken syndrome.
  JOURNAL   J Med Genet 44:657-63 (2007)
REFERENCE   PMID:11920287 (gene)
  AUTHORS   Schuermann MJ, Otto E, Becker A, Saar K, Ruschendorf F, Polak BC, Ala-Mello S, Hoefele J, Wiedensohler A, Haller M, Omran H, Nurnberg P, Hildebrandt F
  TITLE     Mapping of gene loci for nephronophthisis type 4 and Senior-Loken syndrome, to chromosome 1p36.
  JOURNAL   Am J Hum Genet 70:1240-6 (2002)
REFERENCE   PMID:11752023
  AUTHORS   Omran H, Sasmaz G, Haffner K, Volz A, Olbrich H, Melkaoui R, Otto E, Wienker TF, Korinthenberg R, Brandis M, Antignac C, Hildebrandt F
  TITLE     Identification of a gene locus for Senior-Loken syndrome in the region of the nephronophthisis type 3 gene.
  JOURNAL   J Am Soc Nephrol 13:75-9 (2002)
REFERENCE   PMID:20835237
  AUTHORS   Otto EA, Hurd TW, Airik R, Chaki M, Zhou W, Stoetzel C, Patil SB, Levy S, Ghosh AK, Murga-Zamalloa CA, van Reeuwijk J, Letteboer SJ, Sang L, Giles RH, Liu Q, Coene KL, Estrada-Cuzcano A, Collin RW, McLaughlin HM, Held S, Kasanuki JM, Ramaswami G, Conte J, Lopez I, Washburn J, Macdonald J, Hu J, Yamashita Y, Maher ER, Guay-Woodford LM, Neumann HP, Obermuller N, Koenekoop RK, Bergmann C, Bei X, Lewis RA, Katsanis N, Lopes V, Williams DS, Lyons RH, Dang CV, Brito DA, Dias MB, Zhang X, Cavalcoli JD, Nurnberg G, Nurnberg P, Pierce EA, Jackson PK, Antignac C, Saunier S, Roepman R, Dollfus H, Khanna H, Hildebrandt F
  TITLE     Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy.
  JOURNAL   Nat Genet 42:840-50 (2010)
///
ENTRY       H00539                      Disease
NAME        PTEN hamartoma tumor syndrome (PHTS), including:
            Cowden syndrome;
            Bannayan-Riley-Ruvalcaba syndrome;
            Proteus syndrome;
            Proteus-like syndrome
DESCRIPTION PTEN hamartoma tumor syndrome (PHTS) is a spectrum of disorders associated with the formation of hamartomas caused by mutations of the tumor suppressor PTEN. The hamartomas tend to be both benign and malignant tumors, especially in Cowden syndrome.
CATEGORY    Developmental disorder; Cancer
GENE        PTEN [HSA:207] [KO:K04456]
DBLINKS     ICD-10: Q85.8 Q87.8 Q87.3
            MeSH: D016715 C566636 C567337
            OMIM: 158350 153480 176920
REFERENCE   PMID:19668082 (description, gene)
  AUTHORS   Hobert JA, Eng C
  TITLE     PTEN hamartoma tumor syndrome: an overview.
  JOURNAL   Genet Med 11:687-94 (2009)
REFERENCE   PMID:12938083 (description, gene)
  AUTHORS   Eng C
  TITLE     PTEN: one gene, many syndromes.
  JOURNAL   Hum Mutat 22:183-98 (2003)
REFERENCE   PMID:16379592 (description, gene)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
///
ENTRY       H00540                      Disease
NAME        Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID);
            Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
DESCRIPTION A rare X-linked recessive syndrome 'Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency', abbreviated as OLEDAID, is caused by termination codon mutations in the NEMO gene which encodes the essential modulator of NF-kappa B.
CATEGORY    Primary immunodeficiency; Skeletal dysplasia
GENE        IKBKG [HSA:8517] [KO:K07210]
DBLINKS     MeSH: C536181
            OMIM: 300301
REFERENCE   PMID:21622647 (description, gene)
  AUTHORS   Hubeau M, Ngadjeua F, Puel A, Israel L, Feinberg J, Chrabieh M, Belani K, Bodemer C, Fabre I, Plebani A, Boisson-Dupuis S, Picard C, Fischer A, Israel A, Abel L, Veron M, Casanova JL, Agou F, Bustamante J
  TITLE     New mechanism of X-linked anhidrotic ectodermal dysplasia with immunodeficiency:  impairment of ubiquitin binding despite normal folding of NEMO protein.
  JOURNAL   Blood 118:926-35 (2011)
REFERENCE   PMID:17670762 (description, gene)
  AUTHORS   Brouillard P, Vikkula M
  TITLE     Genetic causes of vascular malformations.
  JOURNAL   Hum Mol Genet 16 Spec No. 2:R140-9 (2007)
REFERENCE   PMID:16379592 (description, gene)
  AUTHORS   Wang QK
  TITLE     Update on the molecular genetics of vascular anomalies.
  JOURNAL   Lymphat Res Biol 3:226-33 (2005)
REFERENCE   PMID:16307387 (description, gene)
  AUTHORS   Balemans W, Van Wesenbeeck L, Van Hul W
  TITLE     A clinical and molecular overview of the human osteopetroses.
  JOURNAL   Calcif Tissue Int 77:263-74 (2005)
REFERENCE   PMID:17936098 (description, gene)
  AUTHORS   Del Fattore A, Cappariello A, Teti A
  TITLE     Genetics, pathogenesis and complications of osteopetrosis.
  JOURNAL   Bone 42:19-29 (2008)
REFERENCE   PMID:20301306 (description, gene)
  AUTHORS   Schulz A, Kornak U
  TITLE     CLCN7-Related Osteopetrosis
  JOURNAL   (1993)
///
ENTRY       H00541                      Disease
NAME        Uromodulin-associated kidney diseases, including:
            Medullary cystic kidney disease 2;
            Familial juvenile hyperuremic nephropathy (HNFJ);
            Glomerulocystic kidney disease
DESCRIPTION Uromodulin-associated kidney diseases are autosomal dominant tubulointerstitial kidney diseases caused by mutations in the ciliary protein uromodulin (Tamm-Horsfall protein), which is exclusively produced in the kidney.
CATEGORY    Kidney disease
GENE        UMOD [HSA:7369] [KO:K18274]
            TCF2 [HSA:6928] [KO:K08034]
            REN [HSA:5972] [KO:K01380]
DBLINKS     ICD-10: Q61.5
            MeSH: C537696
            OMIM: 603860 162000 609886 613092
REFERENCE   PMID:21898032 (description, gene)
  AUTHORS   Bergmann C
  TITLE     Educational paper : Ciliopathies.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:21654721 (description, gene)
  AUTHORS   Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O
  TITLE     The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease.
  JOURNAL   Kidney Int 80:338-47 (2011)
REFERENCE   PMID:11261687 (description, gene)
  AUTHORS   Hildebrandt F, Omram H
  TITLE     New insights: nephronophthisis-medullary cystic kidney disease.
  JOURNAL   Pediatr Nephrol 16:168-76 (2001)
REFERENCE   PMID:19664745 (HNFJ2)
  AUTHORS   Zivna M, Hulkova H, Matignon M, Hodanova K, Vylet'al P, Kalbacova M, Baresova V, Sikora J, Blazkova H, Zivny J, Ivanek R, Stranecky V, Sovova J, Claes K, Lerut E, Fryns JP, Hart PS, Hart TC, Adams JN, Pawtowski A, Clemessy M, Gasc JM, Gubler MC, Antignac C, Elleder M, Kapp K, Grimbert P, Bleyer AJ, Kmoch S
  TITLE     Dominant renin gene mutations associated with early-onset hyperuricemia, anemia,  and chronic kidney failure.
  JOURNAL   Am J Hum Genet 85:204-13 (2009)
///
ENTRY       H00542                      Disease
NAME        Polycystic kidney disease
DESCRIPTION Polycystic kidney disease is the most common life-threatening genetic disease characterized by bilateral cyst formation on the kidneys. It is often associated with liver cysts. Autosomal dominant form of polycystic kidney disease carries mutations in the PKD1 and PKD2 genes whereas recessive form is caused by mutations in PKHD1.
CATEGORY    Developmental disorder; Kidney disease; Liver disease
GENE        PKD1 [HSA:5310] [KO:K04985]
            PKD2 [HSA:5311] [KO:K04986]
            PKHD1 [HSA:5314] [KO:K19865]
DRUG        Tolvaptan [DR:D01213]
DBLINKS     ICD-10: Q61.2 Q61.1
            MeSH: D007690
            OMIM: 613095 173900 263200
REFERENCE   PMID:21898032 (description, gene)
  AUTHORS   Bergmann C
  TITLE     Educational paper : Ciliopathies.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:21079243 (description, gene)
  AUTHORS   Chapin HC, Caplan MJ
  TITLE     The cell biology of polycystic kidney disease.
  JOURNAL   J Cell Biol 191:701-10 (2010)
REFERENCE   PMID:21515270 (description, gene)
  AUTHORS   Strazzabosco M, Somlo S
  TITLE     Polycystic liver diseases: congenital disorders of cholangiocyte signaling.
  JOURNAL   Gastroenterology 140:1855-9, 1859.e1 (2011)
REFERENCE   PMID:24706579 (drug)
  AUTHORS   Baur BP, Meaney CJ
  TITLE     Review of tolvaptan for autosomal dominant polycystic kidney disease.
  JOURNAL   Pharmacotherapy 34:605-16 (2014)
///
ENTRY       H00543                      Disease
NAME        Renal-hepatic-pancreatic dysplasia
DESCRIPTION Renal-hepatic-pancreatic dysplasia is a rare lethal disorder characterized by pancreatic cyst formation in addition to the combination of renal dysplasia and hepatic fibrosis. NPHP3-null mutations cause the disorder.
CATEGORY    Developmental disorder; Pancreas disease; Kidney disease; Liver disease
GENE        NPHP3 [HSA:27031] [KO:K19360]
COMMENT     See also H01435 Congenital asplenia
DBLINKS     MeSH: C567142
            OMIM: 208540
REFERENCE   PMID:17605805 (description)
  AUTHORS   Vankalakunti M, Gupta K, Kakkar N, Das A
  TITLE     Renal-hepatic-pancreatic dysplasia syndrome (Ivemark's syndrome).
  JOURNAL   Diagn Pathol 2:24 (2007)
REFERENCE   PMID:20007846 (gene)
  AUTHORS   Fiskerstrand T, Houge G, Sund S, Scheie D, Leh S, Boman H, Knappskog PM
  TITLE     Identification of a gene for renal-hepatic-pancreatic dysplasia by microarray-based homozygosity mapping.
  JOURNAL   J Mol Diagn 12:125-31 (2010)
REFERENCE   PMID:18371931 (gene)
  AUTHORS   Bergmann C, Fliegauf M, Bruchle NO, Frank V, Olbrich H, Kirschner J, Schermer B, Schmedding I, Kispert A, Kranzlin B, Nurnberg G, Becker C, Grimm T, Girschick G, Lynch SA, Kelehan P, Senderek J, Neuhaus TJ, Stallmach T, Zentgraf H, Nurnberg P, Gretz N, Lo C, Lienkamp S, Schafer T, Walz G, Benzing T, Zerres K, Omran H
  TITLE     Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia.
  JOURNAL   Am J Hum Genet 82:959-70 (2008)
REFERENCE   PMID:23686967
  AUTHORS   Copelovitch L, O'Brien MM, Guttenberg M, Otto EA, Kaplan BS
  TITLE     Renal-hepatic-pancreatic dysplasia: a sibship with skeletal and central nervous system anomalies and NPHP3 mutation.
  JOURNAL   Am J Med Genet A 161A:1743-9 (2013)
///
ENTRY       H00544                      Disease
NAME        Septo-optic dysplasia
DESCRIPTION Septo-optic dysplasia is a heterogeneous condition with optic nerve hypoplasia, dysgenesis of the septum pellucidum, and pituitary hypofunction.
CATEGORY    Developmental disorder; Nervous system disease
GENE        HESX1 [HSA:8820] [KO:K09354]
            SOX2 [HSA:6657] [KO:K16796] 
            SOX3 [HSA:6658] [KO:K09267] 
            OTX2 [HSA:5015] [KO:K18490]
ENV_FACTOR  drug and alcohol abuse during pregnancy
DBLINKS     ICD-10: Q04.8
            MeSH: D025962
            OMIM: 182230
REFERENCE   PMID:10762523 (description)
  AUTHORS   Miller SP, Shevell MI, Patenaude Y, Poulin C, O'Gorman AM
  TITLE     Septo-optic dysplasia plus: a spectrum of malformations of cortical development.
  JOURNAL   Neurology 54:1701-3 (2000)
REFERENCE   PMID:17587179 (gene)
  AUTHORS   Kelberman D, Dattani MT
  TITLE     Genetics of septo-optic dysplasia.
  JOURNAL   Pituitary 10:393-407 (2007)
REFERENCE   PMID:21396578 (gene)
  AUTHORS   McCabe MJ, Alatzoglou KS, Dattani MT
  TITLE     Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 25:115-24 (2011)
///
ENTRY       H00545                      Disease
NAME        Polycystic liver disease
DESCRIPTION Isolated polycystic liver disease is an inherited disorder in which cysts occur only in the liver without renal involvement. The two genes, PRKCSH, encoding hepatocystin, and SEC63, are found in patients with isolated polycystic liver disease.
CATEGORY    Developmental disorder; Liver disease
GENE        PRKCSH [HSA:5589] [KO:K08288]
            SEC63 [HSA:11231] [KO:K09540]
COMMENT     For disorders in which liver cysts occur together with kidney cysts, see polycystic kidney disease (H00542).
DBLINKS     ICD-10: Q44.6
            MeSH: C536330
            OMIM: 174050
REFERENCE   PMID:21515270 (description, gene)
  AUTHORS   Strazzabosco M, Somlo S
  TITLE     Polycystic liver diseases: congenital disorders of cholangiocyte signaling.
  JOURNAL   Gastroenterology 140:1855-9, 1859.e1 (2011)
REFERENCE   PMID:21790682 (description, gene)
  AUTHORS   Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, van Pelt J, Nevens F
  TITLE     Systematic review: the pathophysiology and management of polycystic liver disease.
  JOURNAL   Aliment Pharmacol Ther 34:702-13 (2011)
///
ENTRY       H00546                      Disease
NAME        Atrial septal defect
DESCRIPTION Atrial septal defect is an abnormal hole in the interatrial septum between right and left atria. Atrial septal defect is one of the most frequent types of malformations in congenital heart defect that arise from perturbations of cardiac development during embryogenesis. Multiple transcriptions factors that regulate cardiac development as well as various chemicals and maternal diseases have been implicated in the disease.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        NKX2.5 [HSA:1482] [KO:K09345]
            GATA4 [HSA:2626] [KO:K09183]
            TBX20 [HSA:57057] [KO:K10185]
            ACTC1 [HSA:70] [KO:K12314]
            MYH6 [HSA:4624] [KO:K17751]
ENV_FACTOR  Organic solvents
            Anticonvulsants
            Ibuprofen [CPD:C01588] 
            Sulfasalazine [CPD:C07316]
            Thalidomide [CPD:C07910]
            Trimethoprim-sulfonamide [DR:D00285]
            Retinoic acid [CPD:C00777]
            Maternal phenylketonuria
            Maternal progestational diabetes
            Maternal febrile illness
            Maternal influenza
            Maternal rubella
            Maternal epilepsy
DBLINKS     ICD-10: Q21.1
            OMIM: 108900 607941 611363 612794 613087
REFERENCE   PMID:20012542 (gene)
  AUTHORS   Posch MG, Perrot A, Berger F, Ozcelik C
  TITLE     Molecular genetics of congenital atrial septal defects.
  JOURNAL   Clin Res Cardiol 99:137-47 (2010)
REFERENCE   PMID:11376442 (gene)
  AUTHORS   Vaughan CJ, Basson CT
  TITLE     Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.
  JOURNAL   Am J Med Genet 97:304-9 (2000)
REFERENCE   PMID:17519397 (env_factor)
  AUTHORS   Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL
  TITLE     Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on  Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.
  JOURNAL   Circulation 115:2995-3014 (2007)
REFERENCE   PMID:1397217 (env_factor)
  AUTHORS   Tikkanen J, Heinonen OP
  TITLE     Risk factors for atrial septal defect.
  JOURNAL   Eur J Epidemiol 8:509-15 (1992)
///
ENTRY       H00547                      Disease
NAME        Atrioventricular septal defect;
            Atrioventricular canal defect
DESCRIPTION Atrioventricular septal defect, also known as atrioventricular canal defect or endocardial cushion defect, is a congenital heart malformation involving the interatrial septum, interventricular septum, and atrioventricular valves. The defect is often associated with Down syndrome (trisomy 21).
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        CRELD1 [HSA:78987]
            GJA1 [HSA:2697] [KO:K07372]
            GATA4 [HSA:2626] [KO:K09183]
            GATA6 [HSA:2627] [KO:K17897]
ENV_FACTOR  Organic solvents
            Anticonvulsants
            Ibuprofen [CPD:C01588] 
            Sulfasalazine [CPD:C07316]
            Thalidomide [CPD:C07910]
            Trimethoprim-sulfonamide [DR:D00285]
            Retinoic acid [CPD:C00777]
            Maternal phenylketonuria
            Maternal progestational diabetes
            Maternal febrile illness
            Maternal influenza
            Maternal rubella
            Maternal epilepsy
DBLINKS     ICD-10: Q21.2
            OMIM: 606217 600309 614430 614474
REFERENCE   PMID:15096951 (gene)
  AUTHORS   Maslen CL
  TITLE     Molecular genetics of atrioventricular septal defects.
  JOURNAL   Curr Opin Cardiol 19:205-10 (2004)
REFERENCE   PMID:11376442 (description)
  AUTHORS   Vaughan CJ, Basson CT
  TITLE     Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.
  JOURNAL   Am J Med Genet 97:304-9 (2000)
REFERENCE   PMID:17519397 (env_factor)
  AUTHORS   Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL
  TITLE     Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on  Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.
  JOURNAL   Circulation 115:2995-3014 (2007)
REFERENCE   PMID:7805255 (description)
  AUTHORS   Payne RM, Johnson MC, Grant JW, Strauss AW
  TITLE     Toward a molecular understanding of congenital heart disease.
  JOURNAL   Circulation 91:494-504 (1995)
REFERENCE   PMID:11470490 (gene)
  AUTHORS   Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH
  TITLE     Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE).
  JOURNAL   Mutat Res 479:173-86 (2001)
REFERENCE   PMID:17643447 (gene)
  AUTHORS   Rajagopal SK, Ma Q, Obler D, Shen J, Manichaikul A, Tomita-Mitchell A, Boardman K, Briggs C, Garg V, Srivastava D, Goldmuntz E, Broman KW, Benson DW, Smoot LB, Pu WT
  TITLE     Spectrum of heart disease associated with murine and human GATA4 mutation.
  JOURNAL   J Mol Cell Cardiol 43:677-85 (2007)
REFERENCE   PMID:20581743 (gene)
  AUTHORS   Maitra M, Koenig SN, Srivastava D, Garg V
  TITLE     Identification of GATA6 sequence variants in patients with congenital heart defects.
  JOURNAL   Pediatr Res 68:281-5 (2010)
///
ENTRY       H00548                      Disease
NAME        Brunner syndrome;
            MAOA deficiency
DESCRIPTION Brunner syndrome is a form of X-linked non-dysmorphic mild mental retardation. It is caused by a monoamine oxidase A (MAOA) deficiency, which leads to an excess of monoamines in the brain, such as serotonin, dopamine, and epinephrine.
CATEGORY    Inherited metabolic disease; Mental retardation
GENE        MAOA [HSA:4128] [KO:K00274]
MARKER      Serotonin [CPD:C00780]
            Dopamine [CPD:C03758]
            Norepinephrine [CPD:C00547]
DBLINKS     ICD-10: F54 E70.8
            MeSH: C563156
            OMIM: 300615
REFERENCE   PMID:8211186
  AUTHORS   Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA
  TITLE     Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A.
  JOURNAL   Science 262:578-80 (1993)
REFERENCE   PMID:17295220
  AUTHORS   Craig IW
  TITLE     The importance of stress and genetic variation in human aggression.
  JOURNAL   Bioessays 29:227-36 (2007)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
REFERENCE   PMID:8862875
  AUTHORS   Brunner HG
  TITLE     MAOA deficiency and abnormal behaviour: perspectives on an association.
  JOURNAL   Ciba Found Symp 194:155-64; discussion 164-7 (1996)
///
ENTRY       H00549                      Disease
NAME        Tetralogy of Fallot
DESCRIPTION The four classic features of tetralogy of Fallot are ventricular septal defect, pulmonary stenosis, right ventricular hypertrophy, and overrinding aorta. These cardiac abnormalities are resulted from altered neural crest migration during embryogenesis.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        NKX2.5 [HSA:1482] [KO:K09345]
            JAG1 [HSA:182] [KO:K06052]
            ZFPM2 [HSA:23414] [KO:K17442]
            GDF1 [HSA:2657] [KO:K05495]
            GATA4 [HSA:2626] [KO:K09183]
            GATA6 [HSA:2627] [KO:K17897]
            TBX1 [HSA:6899] [KO:K10175]
ENV_FACTOR  Organic solvents
DBLINKS     ICD-10: Q21.3
            MeSH: D013771
            OMIM: 187500
REFERENCE   PMID:19818949 (gene)
  AUTHORS   Di Felice V, Zummo G
  TITLE     Tetralogy of fallot as a model to study cardiac progenitor cell migration and differentiation during heart development.
  JOURNAL   Trends Cardiovasc Med 19:130-5 (2009)
REFERENCE   PMID:17924340 (gene)
  AUTHORS   Karkera JD, Lee JS, Roessler E, Banerjee-Basu S, Ouspenskaia MV, Mez J, Goldmuntz E, Bowers P, Towbin J, Belmont JW, Baxevanis AD, Schier AF, Muenke M
  TITLE     Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans.
  JOURNAL   Am J Hum Genet 81:987-94 (2007)
REFERENCE   PMID:17519397 (env_factor)
  AUTHORS   Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL
  TITLE     Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on  Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.
  JOURNAL   Circulation 115:2995-3014 (2007)
REFERENCE   PMID:20631719 (gene)
  AUTHORS   Lin X, Huo Z, Liu X, Zhang Y, Li L, Zhao H, Yan B, Liu Y, Yang Y, Chen YH
  TITLE     A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defect.
  JOURNAL   J Hum Genet 55:662-7 (2010)
REFERENCE   PMID:19948535 (gene)
  AUTHORS   Rauch R, Hofbeck M, Zweier C, Koch A, Zink S, Trautmann U, Hoyer J, Kaulitz R, Singer H, Rauch A
  TITLE     Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot.
  JOURNAL   J Med Genet 47:321-31 (2010)
///
ENTRY       H00550                      Disease
NAME        Complete transposition of the great arteries
DESCRIPTION Complete transposition of the great arteries is a congenital heart defect with atrioventricular concordance and ventriculoarterial discordance in which the aorta arises from the morphologic right ventricle and the pulmonary artery arises from the morphologic left ventricle, resulting in severe cyanosis. Transposition of the great arteries (TGA) is frequently associated with other cardiac malformations such as ventricular septal defect. TGA is divided into three groups. Group I is TGA with intact ventricular septum. Group II is TGA with ventricular septal defect. Group III is TGA/VSD with pulmonary stenosis.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        MED13L [HSA:23389] [KO:K15164]
            CFC1 [HSA:55997]
            GDF1 [HSA:2657] [KO:K05495]
ENV_FACTOR  Organic solvents
            Maternal progestational diabetes
            Maternal influenza
            Ibuprofen [CPD:C01588]
DRUG        Prostaglandin E1 [DR:D00180]
DBLINKS     ICD-10: Q20.3
            MeSH:D014188
            OMIM: 608808 613853 613854
REFERENCE   PMID:18851735 (description)
  AUTHORS   Martins P, Castela E
  TITLE     Transposition of the great arteries.
  JOURNAL   Orphanet J Rare Dis 3:27 (2008)
REFERENCE   PMID:17159076 (description)
  AUTHORS   Warnes CA
  TITLE     Transposition of the great arteries.
  JOURNAL   Circulation 114:2699-709 (2006)
REFERENCE   PMID:21532774 (gene)
  AUTHORS   Richards AA, Garg V
  TITLE     Genetics of congenital heart disease.
  JOURNAL   Curr Cardiol Rev 6:91-7 (2010)
REFERENCE   PMID:17519397 (env_factor)
  AUTHORS   Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL
  TITLE     Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on  Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.
  JOURNAL   Circulation 115:2995-3014 (2007)
REFERENCE   PMID:23403903
  AUTHORS   Asadollahi R, Oneda B, Sheth F, Azzarello-Burri S, Baldinger R, Joset P, Latal B, Knirsch W, Desai S, Baumer A, Houge G, Andrieux J, Rauch A
  TITLE     Dosage changes of MED13L further delineate its role in congenital heart defects and intellectual disability.
  JOURNAL   Eur J Hum Genet 21:1100-4 (2013)
REFERENCE   PMID:11799476
  AUTHORS   Goldmuntz E, Bamford R, Karkera JD, dela Cruz J, Roessler E, Muenke M
  TITLE     CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.
  JOURNAL   Am J Hum Genet 70:776-80 (2002)
REFERENCE   PMID:17924340
  AUTHORS   Karkera JD, Lee JS, Roessler E, Banerjee-Basu S, Ouspenskaia MV, Mez J, Goldmuntz E, Bowers P, Towbin J, Belmont JW, Baxevanis AD, Schier AF, Muenke M
  TITLE     Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans.
  JOURNAL   Am J Hum Genet 81:987-94 (2007)
REFERENCE   PMID:23133484 (drug)
  AUTHORS   Hong SJ, Choi HJ, Kim YH, Hyun MC, Lee SB, Cho JY
  TITLE     Clinical features and surgical outcomes of complete transposition of the great arteries.
  JOURNAL   Korean J Pediatr 55:377-82 (2012)
///
ENTRY       H00551                      Disease
NAME        Alagille syndrome
DESCRIPTION Alagille syndrome is a multi-system hereditary disorder characterized by hepatic bile duct paucity and cardiovascular malformations including pulmonic stenosis/ peripheral pulmonary stenosis and tetralogy of Fallot. Affected individuals show typical facies and abnormal butterfly vertebrae as well. Mutations in the Notch pathway cause Alagille syndrome.
CATEGORY    Developmental disorder; Cardiovascular disease; Liver disease
GENE        JAG1 [HSA:182] [KO:K06052]
            NOTCH2 [HSA:4853] [KO:K20994]
DBLINKS     ICD-10: Q44.7
            MeSH: D016738
            OMIM: 118450 610205
REFERENCE   PMID:21532774 (gene)
  AUTHORS   Richards AA, Garg V
  TITLE     Genetics of congenital heart disease.
  JOURNAL   Curr Cardiol Rev 6:91-7 (2010)
REFERENCE   PMID:16773578 (description, gene)
  AUTHORS   McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB
  TITLE     NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway.
  JOURNAL   Am J Hum Genet 79:169-73 (2006)
REFERENCE   PMID:17600784 (description)
  AUTHORS   Shifley ET, Cole SE
  TITLE     The vertebrate segmentation clock and its role in skeletal birth defects.
  JOURNAL   Birth Defects Res C Embryo Today 81:121-33 (2007)
///
ENTRY       H00552                      Disease
NAME        Glycerol kinase deficiency (GKD), including:
            Hyperglycerolemia;
            Chromosome Xp21 deletion syndrome;
            X-linked Addison disease (AHX);
            Duchenne muscular dystrophy (DMD)
DESCRIPTION Glycerol kinase deficiency (GKD) is an X-linked recessive enzyme defect characterized biochemically by hyperglycerolemia and glyceroluria. There are two types, an isolated form and a complex form. The complex GKD is an Xp21 contiguous gene syndrome involving the glycerol kinase locus together with X-linked Addison disease (AHX) or Duchenne muscular dystrophy (DMD) loci or both.
CATEGORY    Inherited metabolic disease
GENE        (GKD) GK [HSA:2710] [KO:K00864]
            (AHX) NR0B1 [HSA:190] [KO:K08562]
            (DMD) DMD [HSA:1756] [KO:K10366]
MARKER      Glycerol concentration in urine
DBLINKS     ICD-10: E74.8
            MeSH: C538138
            OMIM: 307030 300679 300200 310200
REFERENCE   PMID:11032329
  AUTHORS   Sjarif DR, Ploos van Amstel JK, Duran M, Beemer FA, Poll-The BT
  TITLE     Isolated and contiguous glycerol kinase gene disorders: a review.
  JOURNAL   J Inherit Metab Dis 23:529-47 (2000)
REFERENCE   PMID:16887896
  AUTHORS   Klein RD, Thorland EC, Gonzales PR, Beck PA, Dykas DJ, McGrath JM, Bale AE
  TITLE     A multiplex assay for the detection and mapping of complex glycerol kinase deficiency.
  JOURNAL   Clin Chem 52:1864-70 (2006)
REFERENCE   PMID:17406644
  AUTHORS   Rahib L, MacLennan NK, Horvath S, Liao JC, Dipple KM
  TITLE     Glycerol kinase deficiency alters expression of genes involved in lipid metabolism, carbohydrate metabolism, and insulin signaling.
  JOURNAL   Eur J Hum Genet 15:646-57 (2007)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
///
ENTRY       H00553                      Disease
NAME        Congenital supravalvar aortic stenosis
DESCRIPTION Congenital supravalvar aortic stenosis is a rare stenotic lesion of the left ventricular out flow tract. The malformation consists a supravalvar narrowing at the aortic sinotubular junction. The underlying cause of the disease is a loss-of function mutation of the elastin gene.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        ELN [HSA:2006] [KO:K14211]
DBLINKS     ICD-10: Q25.3
            OMIM: 185500
REFERENCE   PMID:19022009 (gene)
  AUTHORS   Hickey EJ, Jung G, Williams WG, Manlhiot C, Van Arsdell GS, Caldarone CA, Coles J, McCrindle BW
  TITLE     Congenital supravalvular aortic stenosis: defining surgical and nonsurgical outcomes.
  JOURNAL   Ann Thorac Surg 86:1919-27; discussion 1927 (2008)
REFERENCE   PMID:11167112 (gene)
  AUTHORS   Stamm C, Friehs I, Ho SY, Moran AM, Jonas RA, del Nido PJ
  TITLE     Congenital supravalvar aortic stenosis: a simple lesion?
  JOURNAL   Eur J Cardiothorac Surg 19:195-202 (2001)
///
ENTRY       H00554                      Disease
NAME        Bicuspid aortic valve
DESCRIPTION Bicuspid aortic valve is the most common congenital heart defect with strong male predominance. It may arise in isolation or in association with other congenital heart lesions. The bicuspid aortic valve is typically made of two unequal-sized leaflets, whereas the normal valve is known to have three leaflets.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        NOTCH1 [HSA:4851] [KO:K02599]
DBLINKS     ICD-10: Q23.1
            OMIM: 109730
REFERENCE   PMID:21532774 (gene)
  AUTHORS   Richards AA, Garg V
  TITLE     Genetics of congenital heart disease.
  JOURNAL   Curr Cardiol Rev 6:91-7 (2010)
REFERENCE   PMID:21181071 (description)
  AUTHORS   Yuan SM, Jing H
  TITLE     The bicuspid aortic valve and related disorders.
  JOURNAL   Sao Paulo Med J 128:296-301 (2010)
REFERENCE   PMID:20579534 (description)
  AUTHORS   Siu SC, Silversides CK
  TITLE     Bicuspid aortic valve disease.
  JOURNAL   J Am Coll Cardiol 55:2789-800 (2010)
///
ENTRY       H00555                      Disease
NAME        Char syndrome
DESCRIPTION Char syndrome is a rare autosomal dominant disorder characterized by a combination of three major features: typical facial features, patent ductus arteriosus, and hypoplasia of the middle phalanges of the fifth digits.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        TFAP2B [HSA:7021] [KO:K09176]
DBLINKS     MeSH: C566815
            OMIM: 169100
REFERENCE   PMID:21532774 (gene)
  AUTHORS   Richards AA, Garg V
  TITLE     Genetics of congenital heart disease.
  JOURNAL   Curr Cardiol Rev 6:91-7 (2010)
REFERENCE   PMID:10802654 (gene)
  AUTHORS   Satoda M, Zhao F, Diaz GA, Burn J, Goodship J, Davidson HR, Pierpont ME, Gelb BD
  TITLE     Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus.
  JOURNAL   Nat Genet 25:42-6 (2000)
REFERENCE   PMID:20301285 (description, gene)
  AUTHORS   Gelb BD
  TITLE     Char Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:1342853 (description)
  AUTHORS   Temple IK
  TITLE     Char syndrome (unusual mouth, patent ductus arteriosus, phalangeal anomalies).
  JOURNAL   Clin Dysmorphol 1:17-21 (1992)
///
ENTRY       H00556                      Disease
NAME        CHARGE syndrome
DESCRIPTION CHARGE syndrome is a rare, usually sporadic disorder with multiple congenital anomalies. CHARGE is an acronym for the six prevalent clinical features of the disease, namely, coloboma, heart defect, atresia of choanae, retardation of growth and development, genital hypoplasia, and ear anomalies/deafness. Abnormal semicircular canals, arhinencephaly, and rhombencephalic dysfunctions are also considered as important features. Nearly 2/3 of cases harbor mutations within the CHD7 gene.
CATEGORY    Developmental disorder
GENE        CHD7 [HSA:55636] [KO:K14437]
            SEMA3E [HSA:9723] [KO:K06840]
DBLINKS     ICD-10: Q87.8
            MeSH: D058747
            OMIM: 214800
REFERENCE   PMID:20363513 (description, gene)
  AUTHORS   Pampal A
  TITLE     CHARGE: an association or a syndrome?
  JOURNAL   Int J Pediatr Otorhinolaryngol 74:719-22 (2010)
REFERENCE   PMID:17299439 (description, gene)
  AUTHORS   Sanlaville D, Verloes A
  TITLE     CHARGE syndrome: an update.
  JOURNAL   Eur J Hum Genet 15:389-99 (2007)
REFERENCE   PMID:15235037 (gene)
  AUTHORS   Lalani SR, Safiullah AM, Molinari LM, Fernbach SD, Martin DM, Belmont JW
  TITLE     SEMA3E mutation in a patient with CHARGE syndrome.
  JOURNAL   J Med Genet 41:e94 (2004)
///
ENTRY       H00557                      Disease
NAME        Cutis laxa, including:
            Autosomal dominant cutis laxa (ADCL);
            Autosomal recessive cutis laxa I (ARCL1);
            Autosomal recessive cutis laxa II (ARCL2);
            Autosomal recessive cutis laxa III (ARCL3);
            X-linked recessive cutis laxa (XRCL);
            Wrinkly skin syndrome
DESCRIPTION Cutis laxa is a heterogeneous group of connective tissue disorders with variable organ involvement. The most obvious symptom of cutis laxa is loose and sagging skin due to reduced elastic fibers in the dermis. The phenotype of autosomal recessive cutis laxa II includes abnormal growth, developmental delay, and associated skeletal abnormalities. Autosomal recessive cutis laxa III, also known as De Barsy syndrome, is characterized by an aged appearance with distinctive facial features, sparse hair, ophthalmologic abnormalities, and intrauterine growth retardation.
CATEGORY    Developmental disorder; Skin and connective tissue disease
GENE        (ADCL) ELN [HSA:2006] [KO:K14211]
            (ARCL1) FBLN4 [HSA:30008] [KO:K19866]
            (ARCL1) FBLN5 [HSA:10516] [KO:K17340]
            (ARCL2, wrinkly) ATP6V0A2 [HSA:23545] [KO:K02154]
            (ARCL3A) ALDH18A1 [HSA:5832] [KO:K12657]
            (ARCL2B/ 3B) PYCR1 [HSA:5831] [KO:K00286]
            (XRCL) ATP7A [HSA:538] [KO:K17686]
DBLINKS     ICD-10: E83.0 M35.9
            MeSH: D003483
            OMIM: 123700 219100 219150 612940 614438 219200 304150 219200 278250
REFERENCE   PMID:19401719 (gene)
  AUTHORS   Morava E, Guillard M, Lefeber DJ, Wevers RA
  TITLE     Autosomal recessive cutis laxa syndrome revisited.
  JOURNAL   Eur J Hum Genet 17:1099-110 (2009)
REFERENCE   PMID:16780467 (description)
  AUTHORS   Gupta N, Phadke SR
  TITLE     Cutis laxa type II and wrinkly skin syndrome: distinct phenotypes.
  JOURNAL   Pediatr Dermatol 23:225-30 (2006)
REFERENCE   PMID:21309044 (gene, description)
  AUTHORS   Callewaert B, Renard M, Hucthagowder V, Albrecht B, Hausser I, Blair E, Dias C, Albino A, Wachi H, Sato F, Mecham RP, Loeys B, Coucke PJ, De Paepe A, Urban Z
  TITLE     New insights into the pathogenesis of autosomal-dominant cutis laxa with report of five ELN mutations.
  JOURNAL   Hum Mutat 32:445-55 (2011)
REFERENCE   PMID:21739576
  AUTHORS   Skidmore DL, Chitayat D, Morgan T, Hinek A, Fischer B, Dimopoulou A, Somers G, Halliday W, Blaser S, Diambomba Y, Lemire EG, Kornak U, Robertson SP
  TITLE     Further expansion of the phenotypic spectrum associated with mutations in ALDH18A1, encoding Delta(1)-pyrroline-5-carboxylate synthase (P5CS).
  JOURNAL   Am J Med Genet A 155A:1848-56 (2011)
REFERENCE   PMID:19648921
  AUTHORS   Reversade B, Escande-Beillard N, Dimopoulou A, Fischer B, Chng SC, Li Y, Shboul M, Tham PY, Kayserili H, Al-Gazali L, Shahwan M, Brancati F, Lee H, O'Connor BD, Schmidt-von Kegler M, Merriman B, Nelson SF, Masri A, Alkazaleh F, Guerra D, Ferrari P, Nanda A, Rajab A, Markie D, Gray M, Nelson J, Grix A, Sommer A, Savarirayan R, Janecke AR, Steichen E, Sillence D, Hausser I, Budde B, Nurnberg G, Nurnberg P, Seemann P, Kunkel D, Zambruno G, Dallapiccola B, Schuelke M, Robertson S, Hamamy H, Wollnik B, Van Maldergem L, Mundlos S, Kornak U
  TITLE     Mutations in PYCR1 cause cutis laxa with progeroid features.
  JOURNAL   Nat Genet 41:1016-21 (2009)
///
ENTRY       H00558                      Disease
NAME        Geroderma osteodysplasticum
DESCRIPTION Geroderma osteodysplasticum is a rare autosomal recessive disorder characterized by wrinkled skin and severe osteopenia with spontaneous fractures and the lack of large open fontanels. Mutations have been discovered in SCYL1BP1, which localizes to the Golgi apparatus and is expressed in skin and osteoblasts.
CATEGORY    Developmental disorder; Skin and connective tissue disease; Skeletal dysplasia
GENE        SCYL1BP1 [HSA:92344] [KO:K19748]
            PYCR1 [HSA:5831] [KO:K00286]
DBLINKS     ICD-10: Q82.9
            MeSH: C537799
            OMIM: 231070 612940
REFERENCE   PMID:19401719 (gene, description)
  AUTHORS   Morava E, Guillard M, Lefeber DJ, Wevers RA
  TITLE     Autosomal recessive cutis laxa syndrome revisited.
  JOURNAL   Eur J Hum Genet 17:1099-110 (2009)
REFERENCE   PMID:18348262 (gene, description)
  AUTHORS   Rajab A, Kornak U, Budde BS, Hoffmann K, Jaeken J, Nurnberg P, Mundlos S
  TITLE     Geroderma osteodysplasticum hereditaria and wrinkly skin syndrome in 22 patients  from Oman.
  JOURNAL   Am J Med Genet A 146A:965-76 (2008)
REFERENCE   PMID:18997784 (gene, description)
  AUTHORS   Hennies HC, Kornak U, Zhang H, Egerer J, Zhang X, Seifert W, Kuhnisch J, Budde B, Natebus M, Brancati F, Wilcox WR, Muller D, Kaplan PB, Rajab A, Zampino G, Fodale V, Dallapiccola B, Newman W, Metcalfe K, Clayton-Smith J, Tassabehji M, Steinmann B, Barr FA, Nurnberg P, Wieacker P, Mundlos S
  TITLE     Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin.
  JOURNAL   Nat Genet 40:1410-2 (2008)
REFERENCE   PMID:21204221 (gene, description)
  AUTHORS   Yildirim Y, Tolun A, Tuysuz B
  TITLE     The phenotype caused by PYCR1 mutations corresponds to geroderma osteodysplasticum rather than autosomal recessive cutis laxa type 2.
  JOURNAL   Am J Med Genet A 155A:134-40 (2011)
///
ENTRY       H00559                      Disease
NAME        von Hippel-Lindau syndrome
DESCRIPTION von Hippel-Lindau syndrome is an autosomal dominant disorder associated with tumors in the central nervous system and other organs. The most frequent tumors are cerebellar and retinal haemangioblastomas, pancreatic neuroendocrine tumors, renal cell carcinoma, phaeochromocytoma in the adrenal gland, epididymal cystadenoma, and endolymphatic sac tumours. Germline inactivation of VHL tumor suppressor protein leads to the upregulation of HIF and promotes to carcinogenesis.
CATEGORY    Developmental disorder; Cancer
GENE        VHL [HSA:7428] [KO:K03871]
            CCND1 (polymorphism) [HSA:595] [KO:K04503]
DBLINKS     ICD-10: Q85.8
            MeSH: D006623
            OMIM: 193300
REFERENCE   PMID:21386872 (description, gene)
  AUTHORS   Maher ER, Neumann HP, Richard S
  TITLE     von Hippel-Lindau disease: a clinical and scientific review.
  JOURNAL   Eur J Hum Genet 19:617-23 (2011)
REFERENCE   PMID:16818478 (description, gene)
  AUTHORS   Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S
  TITLE     Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment.
  JOURNAL   Jpn J Clin Oncol 36:337-43 (2006)
REFERENCE   PMID:15611513 (gene)
  AUTHORS   Kim WY, Kaelin WG.
  TITLE     Role of VHL gene mutation in human cancer.
  JOURNAL   J Clin Oncol 22:4991-5004 (2004)
REFERENCE   PMID:12097293 (gene)
  AUTHORS   Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER
  TITLE     Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
  JOURNAL   Cancer Res 62:3803-11 (2002)
///
ENTRY       H00560                      Disease
NAME        Pseudoxanthoma elasticum, including:
            Pseudoxanthoma elasticum (PXE);
            Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency
DESCRIPTION Pseudoxanthoma elasticum (PXE) is a multisystem genetic disorder characterized by aberrant mineralization of elastic fibers in connective tissue affecting the skin, eyes and the arterial blood vessels. The mutated gene is identified as ABCC6, an ATP-binding cassette transporter. Recently, mutations in the GGCX gene in a family with PXE-like phenotypes has been reported.
CATEGORY    Developmental disorder; Skin and connective tissue disease
GENE        (PXE) ABCC6 [HSA:368] [KO:K05669]
            (PXE-like) GGCX [HSA:2677] [KO:K10106]
DBLINKS     ICD-10: Q82.8 D68.4
            MeSH: D011561
            OMIM: 264800 177850 610842
REFERENCE   PMID:19054062 (gene. description)
  AUTHORS   Li Q, Jiang Q, Pfendner E, Varadi A, Uitto J
  TITLE     Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms.
  JOURNAL   Exp Dermatol 18:1-11 (2009)
REFERENCE   PMID:19298904 (gene. description)
  AUTHORS   Finger RP, Charbel Issa P, Ladewig MS, Gotting C, Szliska C, Scholl HP, Holz FG
  TITLE     Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches.
  JOURNAL   Surv Ophthalmol 54:272-85 (2009)
REFERENCE   PMID:16604369 (gene)
  AUTHORS   Bergen AA, Plomp AS, Hu X, de Jong PT, Gorgels TG
  TITLE     ABCC6 and pseudoxanthoma elasticum.
  JOURNAL   Pflugers Arch 453:685-91 (2007)
REFERENCE   PMID:19116367 (gene)
  AUTHORS   Li Q, Schurgers LJ, Smith AC, Tsokos M, Uitto J, Cowen EW
  TITLE     Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene.
  JOURNAL   Am J Pathol 174:534-40 (2009)
REFERENCE   PMID:18800149 (gene)
  AUTHORS   Li Q, Grange DK, Armstrong NL, Whelan AJ, Hurley MY, Rishavy MA, Hallgren KW, Berkner KL, Schurgers LJ, Jiang Q, Uitto J
  TITLE     Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes.
  JOURNAL   J Invest Dermatol 129:553-63 (2009)
///
ENTRY       H00561                      Disease
NAME        Brachydactyly-mental retardation syndrome;
            Chromosome 2q37 deletion syndrome
DESCRIPTION Brachydactyly mental retardation syndrome (BDMR), also known as Albright hereditary osteodystrophy-like syndrome, is a complex disorder characterized by brachydactyly and mental retardation including autism spectrum disorder. It has been confirmed that this disease is associated with some deletions of 2q37. Individuals with BDMR and Smith-Magenis syndrome (SMS) have very similar features. Mutation of the BDMR-causative gene HDAC4 results in reduced expression of RAI1, whose haploinsufficiency leads to SMS.
CATEGORY    Skeletal dysplasia
GENE        HDAC4 [HSA:9759] [KO:K11406]
COMMENT     See also H1791 Smith-Magenis syndrome.
            For Albright hereditary osteodystrophy, see H00501.
DBLINKS     ICD-10: Q93.5
            MeSH: C538317
            OMIM: 600430
REFERENCE   PMID:20691407 (description, gene)
  AUTHORS   Williams SR, Aldred MA, Der Kaloustian VM, Halal F, Gowans G, McLeod DR, Zondag S, Toriello HV, Magenis RE, Elsea SH
  TITLE     Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
  JOURNAL   Am J Hum Genet 87:219-28 (2010)
REFERENCE   PMID:7847374 (description, gene)
  AUTHORS   Wilson LC, Leverton K, Oude Luttikhuis ME, Oley CA, Flint J, Wolstenholme J, Duckett DP, Barrow MA, Leonard JV, Read AP, et al.
  TITLE     Brachydactyly and mental retardation: an Albright hereditary osteodystrophy-like  syndrome localized to 2q37.
  JOURNAL   Am J Hum Genet 56:400-7 (1995)
///
ENTRY       H00562                      Disease
NAME        Dystrophinopathies, including:
            Duchenne muscular dystrophy (DMD);
            Becker muscular dystrophy (BMD);
            X-linked dilated cardiomyopathy (XLCM)
DESCRIPTION Duchenne muscular dystrophy (DMD) is characterized by weakness of leg, pelvic and shoulder girdle muscles starting in early childhood. Becker muscular dystrophy (BMD) is a milder variant of DMD with a better prognosis, with a mean age of onset at 11 years. X-linked dilated cardiomyopathy (XLCM) is a rare disorder with rapidly progressive cardiomyopathy but almost no skeletal muscle impairment. Absence of the dystrophin protein (DMD) and reduced levels or abnormal configuration of dystrophin (BMD) leads to membrane fragility making muscle cells susceptible to damage from contraction. Secondary increase in free radicals and activation of calcium-dependent proteases are thought to further contribute to muscle degeneration. Recently, heterozygous MYF6 mutation is reported to be associated with BMD.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        DMD [HSA:1756] [KO:K10366]
            MYF6 [HSA:4618] [KO:K18485]
DBLINKS     ICD-10: G71.0
            MeSH: D020388
            OMIM: 310200 300376 302045
REFERENCE   PMID:20627570 (description, gene)
  AUTHORS   Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG
  TITLE     Hereditary muscular dystrophies and the heart.
  JOURNAL   Neuromuscul Disord 20:479-92 (2010)
REFERENCE   PMID:11879882 (gene)
  AUTHORS   Emery AE
  TITLE     The muscular dystrophies.
  JOURNAL   Lancet 359:687-95 (2002)
REFERENCE   PMID:11053684 (gene)
  AUTHORS   Kerst B, Mennerich D, Schuelke M, Stoltenburg-Didinger G, von Moers A, Gossrau R, van Landeghem FK, Speer A, Braun T, Hubner C
  TITLE     Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy.
  JOURNAL   Neuromuscul Disord 10:572-7 (2000)
///
ENTRY       H00563                      Disease
NAME        Emery-Dreifuss muscular dystrophy
DESCRIPTION Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of joint contractures that begin in early childhood, slowly progressive muscle weakness and wasting initially in a humeroperoneal distribution that later extends to the scapular and pelvic girdle muscles, and cardiac involvement that usually occurs after the second decade of life. So far, five genes, EMD (emerin), LMNA, SYNE (nesprin)1, SYNE2 and FHL1, have been associated to EDMD phenotypes, that can be inherited following an X-linked, autosomal dominant or autosomal recessive pattern of inheritance. Most of genes known to be associated with EDMD are critical for nuclear envelope integrity.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (EDMD1) EMD [HSA:2010] [KO:K12569]
            (EDMD2 EDMD3) LMNA [HSA:4000] [KO:K12641]
            (EDMD4) SYNE1 [HSA:23345] [KO:K19326]
            (EDMD5) SYNE2 [HSA:23224] [KO:K19346]
            (EDMD6) FHL1 [HSA:2273] [KO:K14365]
DBLINKS     ICD-10: G71.0
            MeSH: C535734
            OMIM: 310300 181350 612998 612999 300696
REFERENCE   PMID:20301609 (description, gene)
  AUTHORS   Bonne G, Leturcq F, Ben Yaou R
  TITLE     Emery-Dreifuss Muscular Dystrophy
  JOURNAL   (1993)
REFERENCE   PMID:11879882 (gene)
  AUTHORS   Emery AE
  TITLE     The muscular dystrophies.
  JOURNAL   Lancet 359:687-95 (2002)
REFERENCE   PMID:17761684 (gene)
  AUTHORS   Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, Mellad JA, Warren DT, Wheeler MA, Ellis JA, Skepper JN, Vorgerd M, Schlotter-Weigel B, Weissberg PL, Roberts RG, Wehnert M, Shanahan CM
  TITLE     Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity.
  JOURNAL   Hum Mol Genet 16:2816-33 (2007)
REFERENCE   PMID:20108321 (description)
  AUTHORS   Randles KN, Lam le T, Sewry CA, Puckelwartz M, Furling D, Wehnert M, McNally EM, Morris GE
  TITLE     Nesprins, but not sun proteins, switch isoforms at the nuclear envelope during muscle development.
  JOURNAL   Dev Dyn 239:998-1009 (2010)
REFERENCE   PMID:21496632 (description)
  AUTHORS   Puckelwartz M, McNally EM
  TITLE     Emery-Dreifuss muscular dystrophy.
  JOURNAL   Handb Clin Neurol 101:155-66 (2011)
///
ENTRY       H00564                      Disease
NAME        Primary ciliary dyskinesia, including:
            Primary ciliary dyskinesia;
            Kartagener syndrome
DESCRIPTION Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder with recurrent oto-sinopulmonary infections, bronchiectasis, and infertility owing to impaired motile ciliary function. Alterations in the left-right organization of the internal organ positioning, which is caused by dysfunctional nodal cilia in early developmental stage, occur in approximately 50% of PCD patients and this combination is referred as Kartagener syndrome.
CATEGORY    Developmental disorder
GENE        DNAI1 [HSA:27019] [KO:K10409]
            DNAAF3 [HSA:352909] [KO:K19752]
            DNAH5 [HSA:1767] [KO:K10408]
            HYDIN [HSA:54768] [KO:K17570]
            TXNDC3 [HSA:51314] [KO:K19868]
            DNAH11 [HSA:8701] [KO:K10408]
            DNAI2 [HSA:64446] [KO:K11143]
            KTU [HSA:55172] [KO:K19751]
            RSPH4A [HSA:345895] [KO:K19756]
            RSPH9 [HSA:221421] [KO:K19757]
            LRRC50 [HSA:123872] [KO:K19750]
            CCDC39 [HSA:339829]
            CCDC40 [HSA:55036]
            DNAL1 [HSA:83544] [KO:K10411]
            CCDC103 [HSA:388389]
            HEATR2 [HSA:54919] [KO:K19759]
            LRRC6 [HSA:23639] [KO:K19753]
            CCDC114 [HSA:93233]
            DRC1 [HSA:92749] [KO:K19754]
            ZMYND10 [HSA:51364]
            ARMC4 [HSA:55130]
            RSPH1 [HSA:89765] [KO:K19755]
            DYX1C1 [HSA:161582] [KO:K19758]
            C21ORF59 [HSA:56683]
            CCDC65 [HSA:85478]
            SPAG1 [HSA:6674] [KO:K19870]
            CCNO [HSA:10309] [KO:K10861]
            CCDC151 [HSA:115948]
            RSPH3 [HSA:83861]
            GAS8 [HSA:2622] [KO:K19942]
DBLINKS     ICD-10: J98.0
            MeSH: D007619
            OMIM: 244400 606763 608644 608647 610852 611884 612444 612518 612649 612650 613193 613807 613808 614017 614679 614874 614935 615067 615294 615444 615451 615481 615482 615500 615504 615505 615872 616037 616481 616726
REFERENCE   PMID:21898032 (gene)
  AUTHORS   Bergmann C
  TITLE     Educational paper : Ciliopathies.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:19606528 (gene)
  AUTHORS   Leigh MW, Pittman JE, Carson JL, Ferkol TW, Dell SD, Davis SD, Knowles MR, Zariwala MA
  TITLE     Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome.
  JOURNAL   Genet Med 11:473-87 (2009)
REFERENCE   PMID:21926394 (gene)
  AUTHORS   Zariwala MA, Omran H, Ferkol TW
  TITLE     The emerging genetics of primary ciliary dyskinesia.
  JOURNAL   Proc Am Thorac Soc 8:430-3 (2011)
REFERENCE   PMID:17059358 (description)
  AUTHORS   Zariwala MA, Knowles MR, Omran H
  TITLE     Genetic defects in ciliary structure and function.
  JOURNAL   Annu Rev Physiol 69:423-50 (2007)
REFERENCE   PMID:22387996
  AUTHORS   Mitchison HM, Schmidts M, Loges NT, Freshour J, Dritsoula A, Hirst RA, O'Callaghan C, Blau H, Al Dabbagh M, Olbrich H, Beales PL, Yagi T, Mussaffi H, Chung EM, Omran H, Mitchell DR
  TITLE     Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia.
  JOURNAL   Nat Genet 44:381-9, S1-2 (2012)
REFERENCE   PMID:23022101
  AUTHORS   Olbrich H, Schmidts M, Werner C, Onoufriadis A, Loges NT, Raidt J, Banki NF, Shoemark A, Burgoyne T, Al Turki S, Hurles ME, Kohler G, Schroeder J, Nurnberg G, Nurnberg P, Chung EM, Reinhardt R, Marthin JK, Nielsen KG, Mitchison HM, Omran H
  TITLE     Recessive HYDIN mutations cause primary ciliary dyskinesia without randomization  of left-right body asymmetry.
  JOURNAL   Am J Hum Genet 91:672-84 (2012)
REFERENCE   PMID:23255504
  AUTHORS   Antony D, Becker-Heck A, Zariwala MA, Schmidts M, Onoufriadis A, Forouhan M, Wilson R, Taylor-Cox T, Dewar A, Jackson C, Goggin P, Loges NT, Olbrich H, Jaspers M, Jorissen M, Leigh MW, Wolf WE, Daniels ML, Noone PG, Ferkol TW, Sagel SD, Rosenfeld M, Rutman A, Dixit A, O'Callaghan C, Lucas JS, Hogg C, Scambler PJ, Emes RD, Chung EM, Shoemark A, Knowles MR, Omran H, Mitchison HM
  TITLE     Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia  with axonemal disorganization and absent inner dynein arms.
  JOURNAL   Hum Mutat 34:462-72 (2013)
REFERENCE   PMID:21496787
  AUTHORS   Mazor M, Alkrinawi S, Chalifa-Caspi V, Manor E, Sheffield VC, Aviram M, Parvari R
  TITLE     Primary ciliary dyskinesia caused by homozygous mutation in DNAL1, encoding dynein light chain 1.
  JOURNAL   Am J Hum Genet 88:599-607 (2011)
REFERENCE   PMID:22581229
  AUTHORS   Panizzi JR, Becker-Heck A, Castleman VH, Al-Mutairi DA, Liu Y, Loges NT, Pathak N, Austin-Tse C, Sheridan E, Schmidts M, Olbrich H, Werner C, Haffner K, Hellman N, Chodhari R, Gupta A, Kramer-Zucker A, Olale F, Burdine RD, Schier AF, O'Callaghan C, Chung EM, Reinhardt R, Mitchison HM, King SM, Omran H, Drummond IA
  TITLE     CCDC103 mutations cause primary ciliary dyskinesia by disrupting assembly of ciliary dynein arms.
  JOURNAL   Nat Genet 44:714-9 (2012)
REFERENCE   PMID:23040496
  AUTHORS   Horani A, Druley TE, Zariwala MA, Patel AC, Levinson BT, Van Arendonk LG, Thornton KC, Giacalone JC, Albee AJ, Wilson KS, Turner EH, Nickerson DA, Shendure J, Bayly PV, Leigh MW, Knowles MR, Brody SL, Dutcher SK, Ferkol TW
  TITLE     Whole-exome capture and sequencing identifies HEATR2 mutation as a cause of primary ciliary dyskinesia.
  JOURNAL   Am J Hum Genet 91:685-93 (2012)
REFERENCE   PMID:23122589
  AUTHORS   Kott E, Duquesnoy P, Copin B, Legendre M, Dastot-Le Moal F, Montantin G, Jeanson L, Tamalet A, Papon JF, Siffroi JP, Rives N, Mitchell V, de Blic J, Coste A, Clement A, Escalier D, Toure A, Escudier E, Amselem S
  TITLE     Loss-of-function mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia.
  JOURNAL   Am J Hum Genet 91:958-64 (2012)
REFERENCE   PMID:23261302
  AUTHORS   Knowles MR, Leigh MW, Ostrowski LE, Huang L, Carson JL, Hazucha MJ, Yin W, Berg JS, Davis SD, Dell SD, Ferkol TW, Rosenfeld M, Sagel SD, Milla CE, Olivier KN, Turner EH, Lewis AP, Bamshad MJ, Nickerson DA, Shendure J, Zariwala MA
  TITLE     Exome sequencing identifies mutations in CCDC114 as a cause of primary ciliary dyskinesia.
  JOURNAL   Am J Hum Genet 92:99-106 (2013)
REFERENCE   PMID:23354437
  AUTHORS   Wirschell M, Olbrich H, Werner C, Tritschler D, Bower R, Sale WS, Loges NT, Pennekamp P, Lindberg S, Stenram U, Carlen B, Horak E, Kohler G, Nurnberg P, Nurnberg G, Porter ME, Omran H
  TITLE     The nexin-dynein regulatory complex subunit DRC1 is essential for motile cilia function in algae and humans.
  JOURNAL   Nat Genet 45:262-8 (2013)
REFERENCE   PMID:23891471
  AUTHORS   Moore DJ, Onoufriadis A, Shoemark A, Simpson MA, zur Lage PI, de Castro SC, Bartoloni L, Gallone G, Petridi S, Woollard WJ, Antony D, Schmidts M, Didonna T, Makrythanasis P, Bevillard J, Mongan NP, Djakow J, Pals G, Lucas JS, Marthin JK, Nielsen KG, Santoni F, Guipponi M, Hogg C, Antonarakis SE, Emes RD, Chung EM, Greene ND, Blouin JL, Jarman AP, Mitchison HM
  TITLE     Mutations in ZMYND10, a gene essential for proper axonemal assembly of inner and  outer dynein arms in humans and flies, cause primary ciliary dyskinesia.
  JOURNAL   Am J Hum Genet 93:346-56 (2013)
REFERENCE   PMID:23849778
  AUTHORS   Hjeij R, Lindstrand A, Francis R, Zariwala MA, Liu X, Li Y, Damerla R, Dougherty GW, Abouhamed M, Olbrich H, Loges NT, Pennekamp P, Davis EE, Carvalho CM, Pehlivan D, Werner C, Raidt J, Kohler G, Haffner K, Reyes-Mugica M, Lupski JR, Leigh MW, Rosenfeld M, Morgan LC, Knowles MR, Lo CW, Katsanis N, Omran H
  TITLE     ARMC4 mutations cause primary ciliary dyskinesia with randomization of left/right body asymmetry.
  JOURNAL   Am J Hum Genet 93:357-67 (2013)
REFERENCE   PMID:23993197
  AUTHORS   Kott E, Legendre M, Copin B, Papon JF, Dastot-Le Moal F, Montantin G, Duquesnoy P, Piterboth W, Amram D, Bassinet L, Beucher J, Beydon N, Deneuville E, Houdouin V, Journel H, Just J, Nathan N, Tamalet A, Collot N, Jeanson L, Le Gouez M, Vallette B, Vojtek AM, Epaud R, Coste A, Clement A, Housset B, Louis B, Escudier E, Amselem S
  TITLE     Loss-of-function mutations in RSPH1 cause primary ciliary dyskinesia with central-complex and radial-spoke defects.
  JOURNAL   Am J Hum Genet 93:561-70 (2013)
REFERENCE   PMID:23872636
  AUTHORS   Tarkar A, Loges NT, Slagle CE, Francis R, Dougherty GW, Tamayo JV, Shook B, Cantino M, Schwartz D, Jahnke C, Olbrich H, Werner C, Raidt J, Pennekamp P, Abouhamed M, Hjeij R, Kohler G, Griese M, Li Y, Lemke K, Klena N, Liu X, Gabriel G, Tobita K, Jaspers M, Morgan LC, Shapiro AJ, Letteboer SJ, Mans DA, Carson JL, Leigh MW, Wolf WE, Chen S, Lucas JS, Onoufriadis A, Plagnol V, Schmidts M, Boldt K, Roepman R, Zariwala MA, Lo CW, Mitchison HM, Knowles MR, Burdine RD, Loturco JJ, Omran H
  TITLE     DYX1C1 is required for axonemal dynein assembly and ciliary motility.
  JOURNAL   Nat Genet 45:995-1003 (2013)
REFERENCE   PMID:24094744
  AUTHORS   Austin-Tse C, Halbritter J, Zariwala MA, Gilberti RM, Gee HY, Hellman N, Pathak N, Liu Y, Panizzi JR, Patel-King RS, Tritschler D, Bower R, O'Toole E, Porath JD, Hurd TW, Chaki M, Diaz KA, Kohl S, Lovric S, Hwang DY, Braun DA, Schueler M, Airik R, Otto EA, Leigh MW, Noone PG, Carson JL, Davis SD, Pittman JE, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Dell SD, Rosenfeld M, Milla CE, Loges NT, Omran H, Porter ME, King SM, Knowles MR, Drummond IA, Hildebrandt F
  TITLE     Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia.
  JOURNAL   Am J Hum Genet 93:672-86 (2013)
REFERENCE   PMID:24055112
  AUTHORS   Knowles MR, Ostrowski LE, Loges NT, Hurd T, Leigh MW, Huang L, Wolf WE, Carson JL, Hazucha MJ, Yin W, Davis SD, Dell SD, Ferkol TW, Sagel SD, Olivier KN, Jahnke C, Olbrich H, Werner C, Raidt J, Wallmeier J, Pennekamp P, Dougherty GW, Hjeij R, Gee HY, Otto EA, Halbritter J, Chaki M, Diaz KA, Braun DA, Porath JD, Schueler M, Baktai G, Griese M, Turner EH, Lewis AP, Bamshad MJ, Nickerson DA, Hildebrandt F, Shendure J, Omran H, Zariwala MA
  TITLE     Mutations in SPAG1 cause primary ciliary dyskinesia associated with defective outer and inner dynein arms.
  JOURNAL   Am J Hum Genet 93:711-20 (2013)
REFERENCE   PMID:24747639
  AUTHORS   Wallmeier J, Al-Mutairi DA, Chen CT, Loges NT, Pennekamp P, Menchen T, Ma L, Shamseldin HE, Olbrich H, Dougherty GW, Werner C, Alsabah BH, Kohler G, Jaspers M, Boon M, Griese M, Schmitt-Grohe S, Zimmermann T, Koerner-Rettberg C, Horak E, Kintner C, Alkuraya FS, Omran H
  TITLE     Mutations in CCNO result in congenital mucociliary clearance disorder with reduced generation of multiple motile cilia.
  JOURNAL   Nat Genet 46:646-51 (2014)
REFERENCE   PMID:24067530
  AUTHORS   Jerber J, Baas D, Soulavie F, Chhin B, Cortier E, Vesque C, Thomas J, Durand B
  TITLE     The coiled-coil domain containing protein CCDC151 is required for the function of IFT-dependent motile cilia in animals.
  JOURNAL   Hum Mol Genet 23:563-77 (2014)
REFERENCE   PMID:26073779 (gene)
  AUTHORS   Jeanson L, Copin B, Papon JF, Dastot-Le Moal F, Duquesnoy P, Montantin G, Cadranel J, Corvol H, Coste A, Desir J, Souayah A, Kott E, Collot N, Tissier S, Louis B, Tamalet A, de Blic J, Clement A, Escudier E, Amselem S, Legendre M
  TITLE     RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial Spokes.
  JOURNAL   Am J Hum Genet 97:153-62 (2015)
REFERENCE   PMID:26387594 (gene)
  AUTHORS   Olbrich H, Cremers C, Loges NT, Werner C, Nielsen KG, Marthin JK, Philipsen M, Wallmeier J, Pennekamp P, Menchen T, Edelbusch C, Dougherty GW, Schwartz O, Thiele H, Altmuller J, Rommelmann F, Omran H
  TITLE     Loss-of-Function GAS8 Mutations Cause Primary Ciliary Dyskinesia and Disrupt the  Nexin-Dynein Regulatory Complex.
  JOURNAL   Am J Hum Genet 97:546-54 (2015)
///
ENTRY       H00565                      Disease
NAME        Sarcoglycanopathies, including:
            Limb-girdle muscular dystrophy (LGMD) 2C;
            Limb-girdle muscular dystrophy (LGMD) 2D;
            Limb-girdle muscular dystrophy (LGMD) 2E;
            Limb-girdle muscular dystrophy (LGMD) 2F
DESCRIPTION Sarcoglycanopathies are a group of a four genetically closely related muscular dystrophies with a phenotype often similar to the X-linked Duchenne muscular dystrophy [DS:H00562]. It has been demonstrated that pathological mutations of the alpha-sarcoglycan (SG), beta-SG, gamma-SG, and delta-SG genes cause autosomal recessive muscular dystrophies. Clinical presentation of sarcoglycanopathies is characterized by a slowly progressive proximal muscle weakness, leading to loss of ambulation during adolescence in most patients.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (LGMD2C) SGCG [HSA:6445] [KO:K12564]
            (LGMD2D) SGCA [HSA:6442] [KO:K12565]
            (LGMD2E) SGCB [HSA:6443] [KO:K12566]
            (LGMD2F) SGCD [HSA:6444] [KO:K12563]
DBLINKS     ICD-10: G71.0
            MeSH: D058088
            OMIM: 253700 608099 604286 601287
REFERENCE   PMID:21496623 (description, gene)
  AUTHORS   Kirschner J, Lochmuller H
  TITLE     Sarcoglycanopathies.
  JOURNAL   Handb Clin Neurol 101:41-6 (2011)
REFERENCE   PMID:19781108 (gene)
  AUTHORS   Sandona D, Betto R
  TITLE     Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects.
  JOURNAL   Expert Rev Mol Med 11:e28 (2009)
///
ENTRY       H00566                      Disease
NAME        Dysferlinopathies, including:
            Miyoshi myopathy (MM);
            Limb-girdle muscular dystrophy (LGMD) 2B;
            Distal myopathy with anterior tibial onset (DMAT)
DESCRIPTION Dysferlinopathies encompass a large variety of neuromuscular diseases characterized by the absence of dysferlin in skeletal muscle and an autosomal recessive mode of inheritance. Dysferlin is a sarcolemmal protein involved in an important role in repairing defects in skeletal membrane. The clinical phenotype is quite variable. Affected individuals usually present with early involvement of the posterior calf muscles, but can present with proximal greater than distal weakness, and less commonly with anterior tibial weakness.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        DYSF [HSA:8291] [KO:K18261]
DBLINKS     ICD-10: G71.0
            MeSH: C537480 C535899
            OMIM: 254130 253601 606768
REFERENCE   PMID:21496627 (description, gene)
  AUTHORS   Amato AA, Brown RH Jr
  TITLE     Dysferlinopathies.
  JOURNAL   Handb Clin Neurol 101:111-8 (2011)
REFERENCE   PMID:18974555 (description, gene)
  AUTHORS   Urtizberea JA, Bassez G, Leturcq F, Nguyen K, Krahn M, Levy N
  TITLE     Dysferlinopathies.
  JOURNAL   Neurol India 56:289-97 (2008)
///
ENTRY       H00567                      Disease
NAME        Caveolinopathies, including:
            Limb-girdle muscular dystrophy (LGMD) 1C;
            Rippling muscle disease (RMD);
            Idiopathic hyperCKemia;
            Distal myopathy with decreased caveolin 3;
            Hypertrophic cardiomyopathy (HCM)
DESCRIPTION Caveolinopathies are a group of muscle diseases and can lead to a broad spectrum of clinical phenotypes. The same mutation could lead to heterogeneous clinical phenotypes and muscle histopathological changes. They are usually inherited in an autosomal dominant pattern. Recently, an autosomal recessive inheritance was considered. The clinical findings that may suggest the diagnosis of a caveolinopathy are: onset usually in the first two decades, progressive, proximal, symmetrical muscle weakness, positive Gowers sign, calf hypertrophy, myalgia, cramps, and/or stiffness after exercise, muscle hyperirritability, etc.
CATEGORY    Musculoskeletal disease; Nervous system disease; Cardiovascular disease
GENE        CAV3 [HSA:859] [KO:K12959]
DBLINKS     ICD-10: G71.0 G71.1 I42.2
            MeSH: C563362 C535686 D024741
            OMIM: 607801 606072 123320 192600
REFERENCE   PMID:21496630 (description, gene)
  AUTHORS   Gazzerro E, Bonetto A, Minetti C
  TITLE     Caveolinopathies: translational implications of caveolin-3 in skeletal and cardiac muscle disorders.
  JOURNAL   Handb Clin Neurol 101:135-42 (2011)
REFERENCE   PMID:18583131 (description, gene)
  AUTHORS   Aboumousa A, Hoogendijk J, Charlton R, Barresi R, Herrmann R, Voit T, Hudson J, Roberts M, Hilton-Jones D, Eagle M, Bushby K, Straub V
  TITLE     Caveolinopathy--new mutations and additional symptoms.
  JOURNAL   Neuromuscul Disord 18:572-8 (2008)
REFERENCE   PMID:15580566 (description, gene)
  AUTHORS   Fulizio L, Nascimbeni AC, Fanin M, Piluso G, Politano L, Nigro V, Angelini C
  TITLE     Molecular and muscle pathology in a series of caveolinopathy patients.
  JOURNAL   Hum Mutat 25:82-9 (2005)
///
ENTRY       H00568                      Disease
NAME        Myotonic dystrophy (DM)
DESCRIPTION Myotonic dystrophy (DM) is a complex multisystemic disorder linked to two different genetic loci. DM1 is caused by an expansion of a CTG repeat located in the 3' untranslated region (UTR) of DMPK. DM2 is caused by an unstable CCTG repeat in intron 1 of ZNF9. Therefore, both DMs are caused by a repeat expansion in a region transcribed into RNA but not translated into protein. The mutant RNA transcripts aberrantly affect the splicing of the same target RNAs, such as chloride channel 1 (ClC-1) and insulin receptor (INSR), resulting in their shared myotonia and insulin resistance. Affected individuals express highly heterogeneous, multisystemic symptoms including myotonia (muscle hyperexcitability), progressive muscle weakness and wasting, cataract development, testicular atrophy, and cardiac conduction defects. It has an autosomal dominant mode of inheritance and disease severity generally correlates with repeat length.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (DM1) DMPK [HSA:1760] [KO:K08788]
            (DM2) ZNF9 [HSA:7555] [KO:K09250]
DBLINKS     ICD-10: G71.1
            MeSH: D009223
            OMIM: 160900 602668
REFERENCE   PMID:16876389 (description, gene)
  AUTHORS   Cho DH, Tapscott SJ
  TITLE     Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
  JOURNAL   Biochim Biophys Acta 1772:195-204 (2007)
REFERENCE   PMID:21496635 (gene)
  AUTHORS   Ashizawa T, Sarkar PS
  TITLE     Myotonic dystrophy types 1 and 2.
  JOURNAL   Handb Clin Neurol 101:193-237 (2011)
///
ENTRY       H00569                      Disease
NAME        Aarskog-Scott syndrome;
            Faciogenital dysplasia
DESCRIPTION Aarskog-Scott syndrome (AAS) is an X-linked disorder characterized by craniofacial, skeletal, and urogenital malformations and short stature. Mutations in the only known causative gene FGD1 are found in about one-fifth of the cases with the clinical diagnosis of AAS.
CATEGORY    Developmental disorder
GENE        FGD1 [HSA:2245] [KO:K05720]
DBLINKS     ICD-10: Q87.1
            MeSH: C535331
            OMIM: 305400
REFERENCE   PMID:14560308
  AUTHORS   Orrico A, Galli L, Cavaliere ML, Garavelli L, Fryns JP, Crushell E, Rinaldi MM, Medeira A, Sorrentino V
  TITLE     Phenotypic and molecular characterisation of the Aarskog-Scott syndrome: a survey of the clinical variability in light of FGD1 mutation analysis in 46 patients.
  JOURNAL   Eur J Hum Genet 12:16-23 (2004)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
///
ENTRY       H00570                      Disease
NAME        Kabuki syndrome
DESCRIPTION Kabuki syndrome, or Kabuki make-up syndrome, is a multiple malformation/mental retardation syndrome that is inherited in an autosomal dominant manner. Patients often have long palpebral fissures with eversion of the lateral one-third of the lower eyelids and arched and broad eyebrows that resemble the make-up of actors in Kabuki, the traditional Japanese play. Other features include postnatal growth delay during the first year of life, persistent fetal fingertip pads, congenital heart defects, and skeletal anomalies such as the absence of digital triradius c and/or d.
CATEGORY    Developmental disorder
GENE        MLL2 [HSA:8085] [KO:K09187]
DBLINKS     ICD-10: Q89.8
            MeSH: C537705
            OMIM: 147920
REFERENCE   PMID:15691356 (description)
  AUTHORS   Adam MP, Hudgins L
  TITLE     Kabuki syndrome: a review.
  JOURNAL   Clin Genet 67:209-19 (2005)
REFERENCE   PMID:12002156 (description)
  AUTHORS   Wessels MW, Brooks AS, Hoogeboom J, Niermeijer MF, Willems PJ
  TITLE     Kabuki syndrome: a review study of three hundred patients.
  JOURNAL   Clin Dysmorphol 11:95-102 (2002)
REFERENCE   PMID:21882399 (gene)
  AUTHORS   Adam MP, Hudgins L, Hannibal M
  TITLE     Kabuki Syndrome
  JOURNAL   (1993)
///
ENTRY       H00571                      Disease
NAME        Johanson-Blizzard syndrome
DESCRIPTION Johanson-Blizzard syndrome is a rare, sometimes fatal disorder that is inherited in autosomal recessive pattern. Exocrine pancreatic insufficiency including decreased secretion of lipases and trypsinogen is the most consistent feature. Nasal wing hypoplasia, scalp defects, and sensorineural hearing loss are additional clinical features of the disease. The causative gene, ubiquitin-protein ligase E3 component N-recognin 1 (UBR1), is involved in protein destabilization.
CATEGORY    Developmental disorder; Pancreas disease
GENE        UBR1 [HSA:197131] [KO:K10625]
DBLINKS     ICD-10: Q45.0 Q87.8
            MeSH: C535880
            OMIM: 243800
REFERENCE   PMID:20556422 (description)
  AUTHORS   Rezaei N, Sabbaghian M, Liu Z, Zenker M
  TITLE     Eponym: Johanson-Blizzard syndrome.
  JOURNAL   Eur J Pediatr 170:179-83 (2011)
REFERENCE   PMID:16311597 (gene)
  AUTHORS   Zenker M, Mayerle J, Lerch MM, Tagariello A, Zerres K, Durie PR, Beier M, Hulskamp G, Guzman C, Rehder H, Beemer FA, Hamel B, Vanlieferinghen P, Gershoni-Baruch R, Vieira MW, Dumic M, Auslender R, Gil-da-Silva-Lopes VL, Steinlicht S, Rauh M, Shalev SA, Thiel C, Ekici AB, Winterpacht A, Kwon YT, Varshavsky A, Reis A
  TITLE     Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome).
  JOURNAL   Nat Genet 37:1345-50 (2005)
REFERENCE   PMID:21931868 (gene)
  AUTHORS   Hwang CS, Sukalo M, Batygin O, Addor MC, Brunner H, Aytes AP, Mayerle J, Song HK, Varshavsky A, Zenker M
  TITLE     Ubiquitin ligases of the N-end rule pathway: assessment of mutations in UBR1 that cause the Johanson-Blizzard syndrome.
  JOURNAL   PLoS One 6:e24925 (2011)
///
ENTRY       H00572                      Disease
NAME        ESCO2-related disorders, including:
            Roberts syndrome;
            SC phocomelia syndrome
DESCRIPTION Roberts syndrome is a autosomal recessive disorder featuring severe pre- and postnatal growth retardation, craniofacial anomalies, and tetraphocomelia that is caused by mesomelic shortening. SC phocomelia is milder with less marked limb reduction. Mutations in the ESCO2 gene have been detected in both disorders.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        ESCO2 [HSA:157570] [KO:K11268]
DBLINKS     ICD-10: Q73.8
            MeSH: C535687
            OMIM: 268300 269000
REFERENCE   PMID:8291532 (description)
  AUTHORS   Van Den Berg DJ, Francke U
  TITLE     Roberts syndrome: a review of 100 cases and a new rating system for severity.
  JOURNAL   Am J Med Genet 47:1104-23 (1993)
REFERENCE   PMID:20301332 (description, gene)
  AUTHORS   Gordillo M, Vega H, Jabs EW
  TITLE     Roberts Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:20101700 (description, gene)
  AUTHORS   Goh ES, Li C, Horsburgh S, Kasai Y, Kolomietz E, Morel CF
  TITLE     The Roberts syndrome/SC phocomelia spectrum--a case report of an adult with review of the literature.
  JOURNAL   Am J Med Genet A 152A:472-8 (2010)
REFERENCE   PMID:16380922 (description, gene)
  AUTHORS   Schule B, Oviedo A, Johnston K, Pai S, Francke U
  TITLE     Inactivating mutations in ESCO2 cause SC phocomelia and Roberts syndrome: no phenotype-genotype correlation.
  JOURNAL   Am J Hum Genet 77:1117-28 (2005)
///
ENTRY       H00573                      Disease
NAME        Townes-Brocks syndrome
DESCRIPTION Townes-Brocks syndrome is an autosomal dominant disorder. Characteristic features of the disease include external ear anomalies called microtia, hearing loss, hand anomalies like preaxial polydactyly/triphalangeal thumbs, imperforate anus and renal malformations.
CATEGORY    Developmental disorder
GENE        SALL1 [HSA:6299] [KO:K19871]
DBLINKS     ICD-10: Q87.8
            MeSH: C536974
            OMIM: 107480
REFERENCE   PMID:10051003 (description, gene)
  AUTHORS   Powell CM, Michaelis RC
  TITLE     Townes-Brocks syndrome.
  JOURNAL   J Med Genet 36:89-93 (1999)
REFERENCE   PMID:11102974 (description, gene)
  AUTHORS   Kohlhase J
  TITLE     SALL1 mutations in Townes-Brocks syndrome and related disorders.
  JOURNAL   Hum Mutat 16:460-6 (2000)
REFERENCE   PMID:11478532 (description, gene)
  AUTHORS   Keegan CE, Mulliken JB, Wu BL, Korf BR
  TITLE     Townes-Brocks syndrome versus expanded spectrum hemifacial microsomia: review of  eight patients and further evidence of a "hot spot" for mutation in the SALL1 gene.
  JOURNAL   Genet Med 3:310-3 (2001)
///
ENTRY       H00574                      Disease
NAME        Coffin-Lowry syndrome (CLS)
DESCRIPTION Coffin-Lowry syndrome (CLS) is a syndromic form of X-linked mental retardation, which is characterized in male patients by psychomotor and growth retardation and various skeletal anomalies. Typical facial changes and specific clinical and radiological signs in the hand are useful aids in the diagnosis. Mutations in the RSK2 (RPS6KA3) gene cause CLS. The RPS6KA3 gene encodes RSK2 that is involved with signaling within cells.
CATEGORY    Congenital disorder; Mental retardation
GENE        RPS6KA3 [HSA:6197] [KO:K04373]
COMMENT     Mutation in the RPS6KA3 gene can also cause nonsyndromic X-linked mental retardation-19.
DBLINKS     ICD-10: F78.8 Q89.8
            MeSH: D038921
            OMIM: 303600
REFERENCE   PMID:19888300
  AUTHORS   Pereira PM, Schneider A, Pannetier S, Heron D, Hanauer A
  TITLE     Coffin-Lowry syndrome.
  JOURNAL   Eur J Hum Genet 18:627-33 (2010)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
///
ENTRY       H00575                      Disease
NAME        Renal tubular dysgenesis
DESCRIPTION Autosomal recessive renal tubular dysgenesis (RTD) is a rare lethal disorder characterized by the absence or incomplete differentiation of proximal tubules. Patients present persistent fetal anuria leading to oligohydramnios sequence. Homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, angiotensin converting enzyme or angiotensin II receptor type 1 may cause RTD. These genes are renin-angiotensin system components which regulate renal growth during embryogenesis.
CATEGORY    Developmental disorder; Kidney disease
GENE        REN [HSA:5972] [KO:K01380]
            AGT [HSA:183] [KO:K09821]
            ACE [HSA:1636] [KO:K01283]
            AGTR1 [HSA:185] [KO:K04166]
DBLINKS     MeSH: C537048
            OMIM: 267430
REFERENCE   PMID:20969579 (description, gene)
  AUTHORS   Benoit G, Machuca E, Heidet L, Antignac C
  TITLE     Hereditary kidney diseases: highlighting the importance of classical Mendelian phenotypes.
  JOURNAL   Ann N Y Acad Sci 1214:83-98 (2010)
REFERENCE   PMID:19924102 (description, gene)
  AUTHORS   Gubler MC, Antignac C
  TITLE     Renin-angiotensin system in kidney development: renal tubular dysgenesis.
  JOURNAL   Kidney Int 77:400-6 (2010)
REFERENCE   PMID:16116425 (gene)
  AUTHORS   Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, Laurent N, Bouton JM, Feuillet F, Makni S, Ben Amar H, Laube G, Delezoide AL, Bouvier R, Dijoud F, Ollagnon-Roman E, Roume J, Joubert M, Antignac C, Gubler MC
  TITLE     Mutations in genes in the renin-angiotensin system are associated with autosomal  recessive renal tubular dysgenesis.
  JOURNAL   Nat Genet 37:964-8 (2005)
REFERENCE   PMID:8023970 (description)
  AUTHORS   Tufro-McReddie A, Johns DW, Geary KM, Dagli H, Everett AD, Chevalier RL, Carey RM, Gomez RA
  TITLE     Angiotensin II type 1 receptor: role in renal growth and gene expression during normal development.
  JOURNAL   Am J Physiol 266:F911-8 (1994)
///
ENTRY       H00576                      Disease
NAME        Pierson syndrome
DESCRIPTION Pierson syndrome is an autosomal recessive disease characterized by congenital nephrotic syndrome, bilateral microcoria, and neurological abnormalities. The nephrotic syndrome progresses to end-stage renal disease during the first year of life. Pierson syndrome is caused by a deficiency of 2-laminin in the basement membrane.
CATEGORY    Developmental disorder; Kidney disease
GENE        LAMB2 [HSA:3913] [KO:K06243]
DBLINKS     ICD-10: N04.9
            MeSH: C537185
            OMIM: 609049 614199
REFERENCE   PMID:20969579 (gene, description)
  AUTHORS   Benoit G, Machuca E, Heidet L, Antignac C
  TITLE     Hereditary kidney diseases: highlighting the importance of classical Mendelian phenotypes.
  JOURNAL   Ann N Y Acad Sci 1214:83-98 (2010)
REFERENCE   PMID:16864643 (description)
  AUTHORS   VanDeVoorde R, Witte D, Kogan J, Goebel J
  TITLE     Pierson syndrome: a novel cause of congenital nephrotic syndrome.
  JOURNAL   Pediatrics 118:e501-5 (2006)
REFERENCE   PMID:18094725 (gene, description)
  AUTHORS   Gubler MC
  TITLE     Inherited diseases of the glomerular basement membrane.
  JOURNAL   Nat Clin Pract Nephrol 4:24-37 (2008)
REFERENCE   PMID:21071975 (gene, description)
  AUTHORS   Kashtan CE, Segal Y
  TITLE     Genetic disorders of glomerular basement membranes.
  JOURNAL   Nephron Clin Pract 118:c9-c18 (2011)
///
ENTRY       H00577                      Disease
NAME        Syndromic X-linked mental retardation with epilepsy or seizures, including:
            West syndrome (WS);
            Partington syndrome (PRTS);
            Proud syndrome (ACCAG);
            XMRE;
            MRXHF1;
            XMR OPHN1-related (MRXSO) ;
            XELBD;
            XMR, Christianson type (MRXSC);
            Creatine deficiency syndrome (XL-CDS);
            Renpenning syndrome (RENS1);
            Epilepsy and mental retardation limited to females (EFMR);
            Periventricular nodular heterotopia (PVNH);
            Hydrocephalus (XLH);
            XMR, JARID1C related (MRXSJ);
            BFLS;
            CK syndrome (CKS);
            MICPCH;
            Rolandic epilepsy
DESCRIPTION X-linked mental retardation (XMR) is an inherited condition that causes failure to develop cognitive abilities because of mutations in several genes on the X chromosome. XLMR is subdivided into syndromic and non-syndromic forms (NS-XLMR), depending on whether further abnormalities are found on physical examination, laboratory investigation and brain imaging. Epilepsy is often associated with MR. Although this does not always indicate that the two conditions share the same genetic defects, a genetic correlation between MR and epilepsy has been suggested in some diseases.
CATEGORY    Congenital disorder; Mental retardation; Epilepsy
GENE        (WS/PRTS/ACCAG) ARX [HSA:170302] [KO:K09452]
            (XMRE) ATP6AP2 [HSA:10159] [KO:K19514]
            (MRXHF1) ATRX [HSA:546] [KO:K10779]
            (MRXSO) OPHN1 [HSA:4983] [KO:K20650]
            (XELBD) SYN1 [HSA:6853] [KO:K19941]
            (MRXSC) SLC9A6 [HSA:10479] [KO:K12041]
            (XL-CDS) SLC6A8 [HSA:6535] [KO:K05039]
            (RENS1) PQBP1 [HSA:10084] [KO:K12865]
            (EFMR) PCDH19 [HSA:57526] [KO:K16499]
            (PVNH) FLNA [HSA:2316] [KO:K04437]
            (XLH) L1CAM [HSA:3897] [KO:K06550]
            (MRXSJ) SMCX [HSA:8242] [KO:K11446]
            (BFLS) PHF6 [HSA:84295]
            (MRX72) RAB39B [HSA:116442] [KO:K07925]
            (MRXSYP) SYP [HSA:6855]
            (MRX91) ZDHHC15 [HSA:158866] [KO:K20028]
            (MRXSW) GRIA3 [HSA:2892] [KO:K05199]
            (Stocco dos Santos) SHROOM4 [HSA:57477] [KO:K18625]
            (CKS) NSDHL [HSA:50814] [KO:K07748]
            (MRXHF1) CASK [HSA:8573] [KO:K06103]
            (Rolandic epilepsy) SRPX2 [HSA:27286] [KO:K19408]
COMMENT     XMR-hypotonic facies syndrome (MRXHF1) includes Juberg-Marsidi, Carpenter-Waziri, Holmes-Gang, and Smith-Fineman-Myers syndromes.
            XELBD: X-linked epilepsy with variable learning disabilities and behavior disorders
            XMRE: XMR and epilepsy
            MRXHF1: Mental retardation and microcephaly with pontine and cerebellar hypoplasia
            BFLS: Boerjeson-Forssman syndrome
DBLINKS     ICD-10: G40.4 F78.9
            MeSH: D013036
            OMIM: 308350 309510 300004 300423 309580 300486 300491 300243 300352 309500 300088 300049 307000 300534 301900 300271 300802 300577 300699 300434 300831 300749 300643
REFERENCE   PMID:12689693
  AUTHORS   Hirose S, Mitsudome A
  TITLE     X-linked mental retardation and epilepsy: pathogenetic significance of ARX mutations.
  JOURNAL   Brain Dev 25:161-5 (2003)
REFERENCE   PMID:20506206
  AUTHORS   Shoubridge C, Fullston T, Gecz J
  TITLE     ARX spectrum disorders: making inroads into the molecular pathology.
  JOURNAL   Hum Mutat 31:889-900 (2010)
REFERENCE   PMID:15746149 (XMRE)
  AUTHORS   Ramser J, Abidi FE, Burckle CA, Lenski C, Toriello H, Wen G, Lubs HA, Engert S, Stevenson RE, Meindl A, Schwartz CE, Nguyen G
  TITLE     A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor.
  JOURNAL   Hum Mol Genet 14:1019-27 (2005)
REFERENCE   PMID:21666679
  AUTHORS   Iwase S, Xiang B, Ghosh S, Ren T, Lewis PW, Cochrane JC, Allis CD, Picketts DJ, Patel DJ, Li H, Shi Y
  TITLE     ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome.
  JOURNAL   Nat Struct Mol Biol 18:769-76 (2011)
REFERENCE   PMID:12805098 (MRXSO)
  AUTHORS   Bergmann C, Zerres K, Senderek J, Rudnik-Schoneborn S, Eggermann T, Hausler M, Mull M, Ramaekers VT
  TITLE     Oligophrenin 1 (OPHN1) gene mutation causes syndromic X-linked mental retardation with epilepsy, rostral ventricular enlargement and cerebellar hypoplasia.
  JOURNAL   Brain 126:1537-44 (2003)
REFERENCE   PMID:14985377 (XELBD)
  AUTHORS   Garcia CC, Blair HJ, Seager M, Coulthard A, Tennant S, Buddles M, Curtis A, Goodship JA
  TITLE     Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy.
  JOURNAL   J Med Genet 41:183-6 (2004)
REFERENCE   PMID:18342287 (MRXSC)
  AUTHORS   Gilfillan GD, Selmer KK, Roxrud I, Smith R, Kyllerman M, Eiklid K, Kroken M, Mattingsdal M, Egeland T, Stenmark H, Sjoholm H, Server A, Samuelsson L, Christianson A, Tarpey P, Whibley A, Stratton MR, Futreal PA, Teague J, Edkins S, Gecz J, Turner G, Raymond FL, Schwartz C, Stevenson RE, Undlien DE, Stromme P
  TITLE     SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome.
  JOURNAL   Am J Hum Genet 82:1003-10 (2008)
REFERENCE   PMID:12701824
  AUTHORS   Schulze A
  TITLE     Creatine deficiency syndromes.
  JOURNAL   Mol Cell Biochem 244:143-50 (2003)
REFERENCE   PMID:20950397
  AUTHORS   Germanaud D, Rossi M, Bussy G, Gerard D, Hertz-Pannier L, Blanchet P, Dollfus H, Giuliano F, Bennouna-Greene V, Sarda P, Sigaudy S, Curie A, Vincent MC, Touraine R, des Portes V
  TITLE     The Renpenning syndrome spectrum: new clinical insights supported by 13 new PQBP1-mutated males.
  JOURNAL   Clin Genet 79:225-35 (2011)
REFERENCE   PMID:21519002
  AUTHORS   Dibbens LM, Kneen R, Bayly MA, Heron SE, Arsov T, Damiano JA, Desai T, Gibbs J, McKenzie F, Mulley JC, Ronan A, Scheffer IE
  TITLE     Recurrence risk of epilepsy and mental retardation in females due to parental mosaicism of PCDH19 mutations.
  JOURNAL   Neurology 76:1514-9 (2011)
REFERENCE   PMID:20888935
  AUTHORS   Masurel-Paulet A, Haan E, Thompson EM, Goizet C, Thauvin-Robinet C, Tai A, Kennedy D, Smith G, Khong TY, Sole G, Guerineau E, Coupry I, Huet F, Robertson S, Faivre L
  TITLE     Lung disease associated with periventricular nodular heterotopia and an FLNA mutation.
  JOURNAL   Eur J Med Genet 54:25-8 (2011)
REFERENCE   PMID:19641926
  AUTHORS   Jackson SR, Guner YS, Woo R, Randolph LM, Ford H, Shin CE
  TITLE     L1CAM mutation in association with X-linked hydrocephalus and Hirschsprung's disease.
  JOURNAL   Pediatr Surg Int 25:823-5 (2009)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
REFERENCE   PMID:16912705
  AUTHORS   Gecz J, Turner G, Nelson J, Partington M
  TITLE     The Borjeson-Forssman-Lehman syndrome (BFLS, MIM #301900).
  JOURNAL   Eur J Hum Genet 14:1233-7 (2006)
REFERENCE   PMID:20159109
  AUTHORS   Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, Vecellio M, Russo S, Cogliati F, Larizza L, Ropers HH, Tzschach A, Kalscheuer V, Oehl-Jaschkowitz B, Skinner C, Schwartz CE, Gecz J, Van Esch H, Raynaud M, Chelly J, de Brouwer AP, Toniolo D, D'Adamo P
  TITLE     Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.
  JOURNAL   Am J Hum Genet 86:185-95 (2010)
REFERENCE   PMID:19377476 (SYP, ZNF711 and CASK)
  AUTHORS   Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, O'Meara S, Latimer C, Dicks E, Menzies A, Stephens P, Blow M, Greenman C, Xue Y, Tyler-Smith C, Thompson D, Gray K, Andrews J, Barthorpe S, Buck G, Cole J, Dunmore R, Jones D, Maddison M, Mironenko T, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Teague J, Butler A, Jenkinson A, Jia M, Richardson D, Shepherd R, Wooster R, Tejada MI, Martinez F, Carvill G, Goliath R, de Brouwer AP, van Bokhoven H, Van Esch H, Chelly J, Raynaud M, Ropers HH, Abidi FE, Srivastava AK, Cox J, Luo Y, Mallya U, Moon J, Parnau J, Mohammed S, Tolmie JL, Shoubridge C, Corbett M, Gardner A, Haan E, Rujirabanjerd S, Shaw M, Vandeleur L, Fullston T, Easton DF, Boyle J, Partington M, Hackett A, Field M, Skinner C, Stevenson RE, Bobrow M, Turner G, Schwartz CE, Gecz J, Raymond FL, Futreal PA, Stratton MR
  TITLE     A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation.
  JOURNAL   Nat Genet 41:535-43 (2009)
REFERENCE   PMID:15915161
  AUTHORS   Mansouri MR, Marklund L, Gustavsson P, Davey E, Carlsson B, Larsson C, White I, Gustavson KH, Dahl N
  TITLE     Loss of ZDHHC15 expression in a woman with a balanced translocation t(X;15)(q13.3;cen) and severe mental retardation.
  JOURNAL   Eur J Hum Genet 13:970-7 (2005)
REFERENCE   PMID:12673656
  AUTHORS   Stocco dos Santos RC, Castro NH, Lillia Holmes A, Becak W, Tackels-Horne D, Lindsey CJ, Lubs HA, Stevenson RE, Schwartz CE
  TITLE     Stocco dos Santos X-linked mental retardation syndrome: clinical elucidation and  localization to Xp11.3-Xq21.3.
  JOURNAL   Am J Med Genet A 118A:255-9 (2003)
REFERENCE   PMID:21129721
  AUTHORS   McLarren KW, Severson TM, du Souich C, Stockton DW, Kratz LE, Cunningham D, Hendson G, Morin RD, Wu D, Paul JE, An J, Nelson TN, Chou A, DeBarber AE, Merkens LS, Michaud JL, Waters PJ, Yin J, McGillivray B, Demos M, Rouleau GA, Grzeschik KH, Smith R, Tarpey PS, Shears D, Schwartz CE, Gecz J, Stratton MR, Arbour L, Hurlburt J, Van Allen MI, Herman GE, Zhao Y, Moore R, Kelley RI, Jones SJ, Steiner RD, Raymond FL, Marra MA, Boerkoel CF
  TITLE     Hypomorphic temperature-sensitive alleles of NSDHL cause CK syndrome.
  JOURNAL   Am J Hum Genet 87:905-14 (2010)
REFERENCE   PMID:16497722
  AUTHORS   Roll P, Rudolf G, Pereira S, Royer B, Scheffer IE, Massacrier A, Valenti MP, Roeckel-Trevisiol N, Jamali S, Beclin C, Seegmuller C, Metz-Lutz MN, Lemainque A, Delepine M, Caloustian C, de Saint Martin A, Bruneau N, Depetris D, Mattei MG, Flori E, Robaglia-Schlupp A, Levy N, Neubauer BA, Ravid R, Marescaux C, Berkovic SF, Hirsch E, Lathrop M, Cau P, Szepetowski P
  TITLE     SRPX2 mutations in disorders of language cortex and cognition.
  JOURNAL   Hum Mol Genet 15:1195-207 (2006)
///
ENTRY       H00578                      Disease
NAME        Epstein syndrome;
            Fechtner syndrome
DESCRIPTION Epstein and Fechtner syndromes are rare autosomal dominant progressive nephropathies associated with macrothrombocytopenia. Sensorineural hearing loss can also occur. Fechtner syndrome shows the additional features of cataracts and blue leukocyte inclusion bodies (Doehle-like bodies). Both disorders are linked to mutations in MYH9, the nonmuscle myosin heavy chain. It has been suggested that renoprotective treatment by renin-angiotensin system blockade is effective in reducing proteinuria in patients with MYH9 nephropathy.
CATEGORY    Kidney disease; Hematologic disease; Nervous system disease
GENE        MYH9 [HSA:4627] [KO:K10352]
DRUG        Ramipril [DR:D00421]
            Telmisartan [DR:D00627]
            Losartan [DR:D00357]
COMMENT     See also H00233 MYH9-related disease.
DBLINKS     ICD-10: D69.4
            MeSH: C535507
            OMIM: 153650 153640
REFERENCE   PMID:18094725 (gene, description)
  AUTHORS   Gubler MC
  TITLE     Inherited diseases of the glomerular basement membrane.
  JOURNAL   Nat Clin Pract Nephrol 4:24-37 (2008)
REFERENCE   PMID:21071975 (gene, description)
  AUTHORS   Kashtan CE, Segal Y
  TITLE     Genetic disorders of glomerular basement membranes.
  JOURNAL   Nephron Clin Pract 118:c9-c18 (2011)
REFERENCE   PMID:21210153 (gene, description)
  AUTHORS   Han KH, Lee H, Kang HG, Moon KC, Lee JH, Park YS, Ha IS, Ahn HS, Choi Y, Cheong HI
  TITLE     Renal manifestations of patients with MYH9-related disorders.
  JOURNAL   Pediatr Nephrol 26:549-55 (2011)
REFERENCE   PMID:18503011 (drug)
  AUTHORS   Pecci A, Granata A, Fiore CE, Balduini CL
  TITLE     Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein  syndrome).
  JOURNAL   Nephrol Dial Transplant 23:2690-2 (2008)
///
ENTRY       H00579                      Disease
NAME        Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC)
DESCRIPTION Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC) is a syndrome that is linked to the missense mutations in the COL4A1 in basement membranes. The renal manifestations include hematuria and bilateral renal cysts. In affected individuals, retinal arteriolar tortuosity and intracranial aneurysms are commonly observed.
CATEGORY    Kidney disease
GENE        COL4A1 [HSA:1282] [KO:K06237]
DBLINKS     ICD-10: R31 H35.0
            MeSH: C567088
            OMIM: 611773
REFERENCE   PMID:18094725 (description, gene)
  AUTHORS   Gubler MC
  TITLE     Inherited diseases of the glomerular basement membrane.
  JOURNAL   Nat Clin Pract Nephrol 4:24-37 (2008)
REFERENCE   PMID:21071975 (description, gene)
  AUTHORS   Kashtan CE, Segal Y
  TITLE     Genetic disorders of glomerular basement membranes.
  JOURNAL   Nephron Clin Pract 118:c9-c18 (2011)
REFERENCE   PMID:18160688 (gene)
  AUTHORS   Plaisier E, Gribouval O, Alamowitch S, Mougenot B, Prost C, Verpont MC, Marro B, Desmettre T, Cohen SY, Roullet E, Dracon M, Fardeau M, Van Agtmael T, Kerjaschki D, Antignac C, Ronco P
  TITLE     COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps.
  JOURNAL   N Engl J Med 357:2687-95 (2007)
REFERENCE   PMID:20818663 (gene)
  AUTHORS   Plaisier E, Chen Z, Gekeler F, Benhassine S, Dahan K, Marro B, Alamowitch S, Paques M, Ronco P
  TITLE     Novel COL4A1 mutations associated with HANAC syndrome: a role for the triple helical CB3[IV] domain.
  JOURNAL   Am J Med Genet A 152A:2550-5 (2010)
///
ENTRY       H00580                      Disease
NAME        Schimke immunoosseous dysplasia
DESCRIPTION Schimke immunoosseous dysplasia is an autosomal recessive disorder characterized by spondyloepiphyseal dysplasia resulting in a short-trunk disproportionate dwarfism, T cell immunodeficiency, and progressive nephropathy with focal segmental glomerulosclerosis.
CATEGORY    Skeletal dysplasia; Primary immunodeficiency; Kidney disease
GENE        SMARCAL1 [HSA:50485] [KO:K14440]
DBLINKS     MeSH: C536629
            OMIM: 242900
REFERENCE   PMID:20301550 (gene, description)
  AUTHORS   Baradaran-Heravi A, Morimoto M, Lucke T, Boerkoel CF
  TITLE     Schimke Immunoosseous Dysplasia
  JOURNAL   (1993)
REFERENCE   PMID:20013129 (gene, description)
  AUTHORS   Hunter KB, Lucke T, Spranger J, Smithson SF, Alpay H, Andre JL, Asakura Y, Bogdanovic R, Bonneau D, Cairns R, Cransberg K, Frund S, Fryssira H, Goodman D, Helmke K, Hinkelmann B, Lama G, Lamfers P, Loirat C, Majore S, Mayfield C, Pontz BF, Rusu C, Saraiva JM, Schmidt B, Shoemaker L, Sigaudy S, Stajic N, Taha D, Boerkoel CF
  TITLE     Schimke immunoosseous dysplasia: defining skeletal features.
  JOURNAL   Eur J Pediatr 169:801-11 (2010)
///
ENTRY       H00581                      Disease
NAME        Alport syndrome
DESCRIPTION Alport syndrome is a hereditary hematuric nephropathy with frequent hearing loss and ocular anomalies. Defects of basement membranes arise from mutations in alpha 3, alpha 4, and alpha 5 type IV collagen chains. The mode of inheritance is either X-linked or autosomal recessive, although autosomal dominant form has been observed in a few families. Male patients with X-linked Alport syndrome suffer from severe renal symptoms that progress to end-stage renal disease associated with deafness which starts during the first decade of life, and ocular lesions including anterior lenticonus. Autosomal recessive Alport syndrome is usually severe, showing progressive nephritis and hearing impairment.
CATEGORY    Kidney disease
GENE        (autosomal) COL4A3 [HSA:1285] [KO:K06237]
            (autosomal) COL4A4 [HSA:1286] [KO:K06237]
            (X-linked) COL4A5 [HSA:1287] [KO:K06237]
DBLINKS     ICD-10: Q87.8
            MeSH: D009394
            OMIM: 301050 203780 104200
REFERENCE   PMID:18094725 (gene, description)
  AUTHORS   Gubler MC
  TITLE     Inherited diseases of the glomerular basement membrane.
  JOURNAL   Nat Clin Pract Nephrol 4:24-37 (2008)
REFERENCE   PMID:21071975 (gene, description)
  AUTHORS   Kashtan CE, Segal Y
  TITLE     Genetic disorders of glomerular basement membranes.
  JOURNAL   Nephron Clin Pract 118:c9-c18 (2011)
REFERENCE   PMID:19470679 (gene, description)
  AUTHORS   Heidet L, Gubler MC
  TITLE     The renal lesions of Alport syndrome.
  JOURNAL   J Am Soc Nephrol 20:1210-5 (2009)
///
ENTRY       H00582                      Disease
NAME        Benign familial hematuria;
            Thin basement membrane nephropathy
DESCRIPTION Benign familial hematuria is an autosomal dominant disorder characterized by recurrent dysmorphic hematuria detected in childhood. The glomerular basement membrane is uniformly thin, but renal function is normal. Heterozygous mutations in COL4A3 or COL4A4 lead to reduced collagen network levels in the basement membrane.
CATEGORY    Kidney disease
GENE        COL4A3 [HSA:1285] [KO:K06237]
            COL4A4 [HSA:1286] [KO:K06237]
DBLINKS     MeSH: C562476
            OMIM: 141200
REFERENCE   PMID:18094725 (gene, description)
  AUTHORS   Gubler MC
  TITLE     Inherited diseases of the glomerular basement membrane.
  JOURNAL   Nat Clin Pract Nephrol 4:24-37 (2008)
REFERENCE   PMID:21071975 (gene, description)
  AUTHORS   Kashtan CE, Segal Y
  TITLE     Genetic disorders of glomerular basement membranes.
  JOURNAL   Nephron Clin Pract 118:c9-c18 (2011)
REFERENCE   PMID:12969134 (description)
  AUTHORS   Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY
  TITLE     Thin basement membrane nephropathy.
  JOURNAL   Kidney Int 64:1169-78 (2003)
///
ENTRY       H00583                      Disease
NAME        Opitz-GBBB syndrome
DESCRIPTION Opitz GBBB syndrome is a pleiotropic genetic disorder characterized by hypertelorism, hypospadias, and additional midline defects. This syndrome was originally described as two distinct entities, the BBB syndrome with cleft lip, palate and mental retardation, and the G-syndrome characterized by gastrointestinal anomalies. Subsequently, both syndromes were merged and reclassified as Opitz GBBB syndrome. There are two forms of Opitz GBBB syndrome, which are distinguished by their genetic causes and patterns of inheritance. The X-linked form is caused by a mutation in the gene MID1 that encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Autosomal dominant form results from a deletion at chromosome 22q11.2.
CATEGORY    Congenital disorder of development
GENE        MID1 [HSA:4281] [KO:K08285]
DBLINKS     MeSH: C567932 C538387
            OMIM: 300000 145410
REFERENCE   PMID:12655643
  AUTHORS   Schweiger S, Schneider R
  TITLE     The MID1/PP2A complex: a key to the pathogenesis of Opitz BBB/G syndrome.
  JOURNAL   Bioessays 25:356-66 (2003)
REFERENCE   PMID:12833403
  AUTHORS   De Falco F, Cainarca S, Andolfi G, Ferrentino R, Berti C, Rodriguez Criado G, Rittinger O, Dennis N, Odent S, Rastogi A, Liebelt J, Chitayat D, Winter R, Jawanda H, Ballabio A, Franco B, Meroni G
  TITLE     X-linked Opitz syndrome: novel mutations in the MID1 gene and redefinition of the clinical spectrum.
  JOURNAL   Am J Med Genet A 120A:222-8 (2003)
REFERENCE   PMID:18197188
  AUTHORS   Chiurazzi P, Schwartz CE, Gecz J, Neri G
  TITLE     XLMR genes: update 2007.
  JOURNAL   Eur J Hum Genet 16:422-34 (2008)
///
ENTRY       H00584                      Disease
NAME        Epidermolysis bullosa simplex, including:
            Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM);
            Epidermolysis bullosa simplex, Koebner type (EBS-K);
            Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC);
            Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP);
            Epidermolysis bullosa simplex with migratory circinate erythema;
            Epidermolysis bullosa simplex, recessive;
            Epidermolysis bullosa, lethal acantholytic
DESCRIPTION Inherited epidermolysis bullosa is a diverse group of disorders that encompass dozens of clinically and genotypically distinct diseases. It is characterized by mechanically fragile skin that readily blister. The simplex forms of epidermolysis bullosa demonstrate blister formation within the basal keratinocytes due to the mutations in the basal keratin genes, KRT5 and KRT14.
CATEGORY    Skin and connective tissue disease
GENE        (EBS-DM, EBS-K, EBS-WC, recessive) KRT14 [HSA:3861] [KO:K07604]
            (EBS-DM, EBS-K, EBS-WC, EBS-MP, migratory circinate erythema) KRT5 [HSA:3852] [KO:K07605]
            (lethal acantholytic) DSP [HSA:1832] [KO:K10381]
DBLINKS     ICD-10: Q81.0
            MeSH: D016110
            OMIM: 131760 131900 131800 131960 609352 601001 609638
REFERENCE   PMID:20616732 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: recent basic and clinical advances.
  JOURNAL   Curr Opin Pediatr 22:453-8 (2010)
REFERENCE   PMID:20536471 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: past, present, and future.
  JOURNAL   Ann N Y Acad Sci 1194:213-22 (2010)
REFERENCE   PMID:15708287 (gene)
  AUTHORS   Uitto J, Richard G
  TITLE     Progress in epidermolysis bullosa: from eponyms to molecular genetic classification.
  JOURNAL   Clin Dermatol 23:33-40 (2005)
REFERENCE   PMID:20507384 (gene)
  AUTHORS   Sawamura D, Nakano H, Matsuzaki Y
  TITLE     Overview of epidermolysis bullosa.
  JOURNAL   J Dermatol 37:214-9 (2010)
REFERENCE   PMID:20507631 (gene)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa.
  JOURNAL   Orphanet J Rare Dis 5:12 (2010)
///
ENTRY       H00585                      Disease
NAME        Epidermolysis bullosa, hemidesmosomal, including:
            Epidermolysis bullosa, generalized atrophic benign (GABEB);
            Epidermolysis bullosa simplex with pyloric atresia (EBS-PA);
            Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD);
            Epidermolysis bullosa simplex, Ogna type (EBS-Ogna)
DESCRIPTION Inherited epidermolysis bullosa is a diverse group of disorders characterized by mechanically fragile skin that readily blister. The conditions in which the blister formation occurs at the level of hemidesmosome are classified as hemidesmosomal variants, that is subtype of epidermolysis bullosa simplex.
CATEGORY    Skin and connective tissue disease
GENE        (GABEB) LAMA3 [HSA:3909] [KO:K06240]
            (EBS-PA, EBS-MD, EBS-Ogna) PLEC1 [HSA:5339] [KO:K10388]
DBLINKS     ICD-10: G71.0 Q81.0
            MeSH: D016109 C567408
            OMIM: 226650 612138 226670 131950
REFERENCE   PMID:20616732 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: recent basic and clinical advances.
  JOURNAL   Curr Opin Pediatr 22:453-8 (2010)
REFERENCE   PMID:20536471 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: past, present, and future.
  JOURNAL   Ann N Y Acad Sci 1194:213-22 (2010)
REFERENCE   PMID:15708287 (gene)
  AUTHORS   Uitto J, Richard G
  TITLE     Progress in epidermolysis bullosa: from eponyms to molecular genetic classification.
  JOURNAL   Clin Dermatol 23:33-40 (2005)
REFERENCE   PMID:20507384 (gene)
  AUTHORS   Sawamura D, Nakano H, Matsuzaki Y
  TITLE     Overview of epidermolysis bullosa.
  JOURNAL   J Dermatol 37:214-9 (2010)
REFERENCE   PMID:20507631 (gene)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa.
  JOURNAL   Orphanet J Rare Dis 5:12 (2010)
///
ENTRY       H00586                      Disease
NAME        Epidermolysis bullosa, junctional, including:
            Epidermolysis bullosa, junctional, Herlitz type (JEB-H);
            Epidermolysis bullosa, junctional, non-Herlitz type (JEB-nH);
            Epidermolysis bullosa, junctional, with pyloric atresia (JEB-PA)
DESCRIPTION Inherited epidermolysis bullosa is a diverse group of disorders characterized by mechanically fragile skin that readily blister. The junctional forms of epidermolysis bullosa are characterized by blister formation within the lamina lucida of the dermal-epidermal basement membrane. Herlitz subtype, the classic form of the disease, shows a severe phenotype that may lead to death during infancy or early childhood owing to infection.
CATEGORY    Skin and connective tissue disease
GENE        (JEB-H, JEB-nH) LAMA3 [HSA:3909] [KO:K06240]
            (JEB-H, JEB-nH) LAMB3 [HSA:3914] [KO:K06244]
            (JEB-H, JEB-nH) LAMC2 [HSA:3918] [KO:K06246]
            (JEB-nH) COL17A1 [HSA:1308] [KO:K07603]
            (JEB-PA) ITGB4 [HSA:3691] [KO:K06525]
            (JEB-PA) ITGA6 [HSA:3655] [KO:K06485]
DBLINKS     ICD-10: Q81
            MeSH: D016109
            OMIM: 226700 226650 226730 226730
REFERENCE   PMID:20616732 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: recent basic and clinical advances.
  JOURNAL   Curr Opin Pediatr 22:453-8 (2010)
REFERENCE   PMID:20536471 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: past, present, and future.
  JOURNAL   Ann N Y Acad Sci 1194:213-22 (2010)
REFERENCE   PMID:15708287 (gene)
  AUTHORS   Uitto J, Richard G
  TITLE     Progress in epidermolysis bullosa: from eponyms to molecular genetic classification.
  JOURNAL   Clin Dermatol 23:33-40 (2005)
REFERENCE   PMID:20507384 (gene)
  AUTHORS   Sawamura D, Nakano H, Matsuzaki Y
  TITLE     Overview of epidermolysis bullosa.
  JOURNAL   J Dermatol 37:214-9 (2010)
REFERENCE   PMID:20507631 (gene)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa.
  JOURNAL   Orphanet J Rare Dis 5:12 (2010)
///
ENTRY       H00587                      Disease
NAME        Epidermolysis bullosa, dysprophica, including: ;
            Epidermolysis bullosa dystrophica, AD;
            Epidermolysis bullosa dystrophica, AR;
            Epidermolysis bullosa pruriginosa;
            Epidermolysis bullosa, pretibial
DESCRIPTION Inherited epidermolysis bullosa is a diverse group of disorders characterized by mechanically fragile skin that readily blister. The dystrophic forms of epidermolysis bullosa, in which tissue separation occurs in the dermis, are inherited in either autosomal dominant or autosomal recessive pattern. In the most severe subtype of recessive dystrophic epidermolysis bullosa,  there is esophageal stenosis and pseudosyndactyly.
CATEGORY    Skin and connective tissue disease
GENE        COL7A1 [HSA:1294] [KO:K16628]
DBLINKS     ICD-10: Q81.2
            MeSH: D016108
            OMIM: 131750 226600 604129 131850 132000
REFERENCE   PMID:20616732 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: recent basic and clinical advances.
  JOURNAL   Curr Opin Pediatr 22:453-8 (2010)
REFERENCE   PMID:20536471 (desciption)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: past, present, and future.
  JOURNAL   Ann N Y Acad Sci 1194:213-22 (2010)
REFERENCE   PMID:15708287 (gene)
  AUTHORS   Uitto J, Richard G
  TITLE     Progress in epidermolysis bullosa: from eponyms to molecular genetic classification.
  JOURNAL   Clin Dermatol 23:33-40 (2005)
REFERENCE   PMID:20507384 (gene)
  AUTHORS   Sawamura D, Nakano H, Matsuzaki Y
  TITLE     Overview of epidermolysis bullosa.
  JOURNAL   J Dermatol 37:214-9 (2010)
REFERENCE   PMID:20507631 (gene)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa.
  JOURNAL   Orphanet J Rare Dis 5:12 (2010)
///
ENTRY       H00588                      Disease
NAME        Kindler syndrome
DESCRIPTION Kinder syndrome is a rare autosomal recessive disease characterized by blister, poikiloderma, skin atrophy, and photosensitivity.
CATEGORY    Skin and connective tissue disease
GENE        KIND1 [HSA:55612] [KO:K17082]
COMMENT     For epidermolysis bullosa, see H00584-H00587.
DBLINKS     MeSH: C536321
            OMIM: 173650
REFERENCE   PMID:20507384 (gene)
  AUTHORS   Sawamura D, Nakano H, Matsuzaki Y
  TITLE     Overview of epidermolysis bullosa.
  JOURNAL   J Dermatol 37:214-9 (2010)
REFERENCE   PMID:20507631 (description)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa.
  JOURNAL   Orphanet J Rare Dis 5:12 (2010)
REFERENCE   PMID:20536471 (desciption, gene)
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: past, present, and future.
  JOURNAL   Ann N Y Acad Sci 1194:213-22 (2010)
REFERENCE   PMID:12668616 (desciption, gene)
  AUTHORS   Jobard F, Bouadjar B, Caux F, Hadj-Rabia S, Has C, Matsuda F, Weissenbach J, Lathrop M, Prud'homme JF, Fischer J
  TITLE     Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome.
  JOURNAL   Hum Mol Genet 12:925-35 (2003)
///
ENTRY       H00589                      Disease
NAME        Familial exudative vitreoretinopathy (FEVR), including:
            Exudative vitreoretinopathy 1 (EVR1);
            Exudative vitreoretinopathy2, X-linked  (EVR2);
            Exudative vitreoretinopathy 4 (EVR4);
            Exudative vitreoretinopathy 5 (EVR5);
            Norrie disease (ND)
DESCRIPTION Familial exudative vitreoretinopathy (FEVR) and Norrie disease (ND) are two inherited retinal disorders with highly overlapping ocular manifestations that are caused by alterations in the Wnt signaling network. FEVR and ND share an abnormal vascularization of the peripheral retina with the formation of retinal folds, retinal detachment, and in many cases the creation of a fibrovascular membrane located behind the lens. ND is a severe X-linked recessive form of congenital blindness, which in about one-third of the cases is accompanied by mental retardation and deafness. Mutations in NDP, FZD4, and LRP5 have been reported to be responsible for ophthalmic diseases including ND, FEVR, and osteoporosis pseudoglioma syndrome. The proteins encoded by these genes have all been shown to participate in the Wnt/Norrin signaling pathway. Recently, heterozygous mutations in TSPAN12, which is a component of the Norrin-FZD4-LRP5 signaling complex, have been found to be responsible for autosomal dominant FEVR.
CATEGORY    Inherited disease; Nervous system disease; Eye disease
GENE        (EVR1) FZD4 [HSA:8322] [KO:K02354]
            (EVR2/ND) NDP [HSA:4693]
            (EVR4) LRP5 [HSA:4041] [KO:K03068]
            (EVR5) TSPAN12 [HSA:23554] [KO:K17355]
COMMENT     Exudative vitreoretinopathy 3 (EVR3)  results from a deletion at chromosome 11p13-p12.
DBLINKS     ICD-10: Q15.8 H35.0
            MeSH: C580083
            OMIM: 133780 305390 601813 613310 310600
REFERENCE   PMID:20340138
  AUTHORS   Nikopoulos K, Venselaar H, Collin RW, Riveiro-Alvarez R, Boonstra FN, Hooymans JM, Mukhopadhyay A, Shears D, van Bers M, de Wijs IJ, van Essen AJ, Sijmons RH, Tilanus MA, van Nouhuys CE, Ayuso C, Hoefsloot LH, Cremers FP
  TITLE     Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP.
  JOURNAL   Hum Mutat 31:656-66 (2010)
REFERENCE   PMID:20427659
  AUTHORS   Seitz R, Hackl S, Seibuchner T, Tamm ER, Ohlmann A
  TITLE     Norrin mediates neuroprotective effects on retinal ganglion cells via activation  of the Wnt/beta-catenin signaling pathway and the induction of neuroprotective growth factors in Muller cells.
  JOURNAL   J Neurosci 30:5998-6010 (2010)
REFERENCE   PMID:19837026
  AUTHORS   Clevers H
  TITLE     Eyeing up new Wnt pathway players.
  JOURNAL   Cell 139:227-9 (2009)
REFERENCE   PMID:19837033
  AUTHORS   Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, Costa M, Rice DS, Ye W
  TITLE     TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling.
  JOURNAL   Cell 139:299-311 (2009)
REFERENCE   PMID:18197188
  AUTHORS   Chiurazzi P, Schwartz CE, Gecz J, Neri G
  TITLE     XLMR genes: update 2007.
  JOURNAL   Eur J Hum Genet 16:422-34 (2008)
///
ENTRY       H00590                      Disease
NAME        Congenital muscular dystrophies (CMD/MDC), including:
            Merosin-deficient CMD (MDC1A);
            Ullrich CMD (UCMD);
            Integrin alpha7-deficient CMD;
            CMD with joint hyperlaxity (CMDH);
            CMD with epidermolysis bullosa;
            Walker-Warburg syndrome (WWS);
            Muscle-eye-brain disease (MEB);
            Fukuyama CMD (FCMD);
            CMD with muscle hypertrophy (MDC1C);
            CMD with severe intellectual impairment and abnormal glycosylation (MDC1D);
            Rigid spine syndrome (RSS);
            LMNA-deficient CMD;
            CMD with respiratory failure and muscle hypertrophy (MDC1B)
DESCRIPTION Congenital muscular dystrophies (CMDs) are a heterogeneous group of inherited disorders characterized by muscle weakness from birth and variable clinical manifestations of the eye and central nervous system. According to the disease mechanisms, the CMDs may be grouped as follows: defects in genes encoding for structural proteins of the basal membrane or extracellular matrix of the skeletal muscle fibers, which include collagen 6 genes, laminin alpha2 chain and integrin alpha7; defects in genes encoding for putative or demonstrated glycosyltransferases, which include POMT1, POMT2, POMGnT1, fukutin, fukutin-related protein (FKRP) and Large; defects in ER and nuclear proteins, which are selenoprotein 1 and lamin A/C.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (MDC1A) LAMA2 [HSA:3908] [KO:K05637]
            (UCMD) COL6A [HSA:1291 1292 1293] [KO:K06238]
            (ITGA7-deficient CMD) ITGA7 [HSA:3679] [KO:K06583]
            (CMDH) ITGA9 [HSA:3680] [KO:K06585]
            (CMD with epidermolysis bullosa) PLEC [HSA:5339] [KO:K10388]
            (WWS) POMT1 [HSA:10585] [KO:K00728]
            (WWS) POMT2 [HSA:29954] [KO:K00728]
            (WWS, FCMD) FKTN [HSA:2218] [KO:K19872]
            (WWS, MDC1C) FKRP [HSA:79147] [KO:K19873]
            (WWS, MDC1D) LARGE [HSA:9215] [KO:K09668]
            (MEB) POMGnT1 [HSA:55624] [KO:K09666]
            (RSS) SEPN1 [HSA:57190] [KO:K19874]
            (LMNA-deficient CMD) LMNA [HSA:4000] [KO:K12641]
COMMENT     About defects in genes encoding for putative or demonstrated glycosyltransferases, see H00120.
DBLINKS     ICD-10: G71.2 G71.8 Q04.3
            MeSH: D058494 D009136 C535683
            OMIM: 236670 253280 253800 254090 602771 607855 613150 613152 613153 613154 613204 613205 613155 613156 613151 613152 608840 606612
REFERENCE   PMID:15351421 (gene, description)
  AUTHORS   Muntoni F, Voit T
  TITLE     The congenital muscular dystrophies in 2004: a century of exciting progress.
  JOURNAL   Neuromuscul Disord 14:635-49 (2004)
REFERENCE   PMID:21496624 (gene, description)
  AUTHORS   Sparks SE, Escolar DM
  TITLE     Congenital muscular dystrophies.
  JOURNAL   Handb Clin Neurol 101:47-79 (2011)
REFERENCE   PMID:16575835
  AUTHORS   van Reeuwijk J, Maugenre S, van den Elzen C, Verrips A, Bertini E, Muntoni F, Merlini L, Scheffer H, Brunner HG, Guicheney P, van Bokhoven H
  TITLE     The expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation.
  JOURNAL   Hum Mutat 27:453-9 (2006)
///
ENTRY       H00591                      Disease
NAME        Facioscapulohumeral muscular dystrophy (FSHD)
DESCRIPTION Facioscapulohumeral muscular dystrophy (FSHD) is a usually autosomal dominant inherited form of muscular dystrophy. At disease onset, typically in the second decade of life, FSHD is characterized by initially restricted weakness of shoulder and facial muscles. With progression, the lower extremities, both distal and proximal, become involved. FSHD is caused by a reduction in the copy number of the D4Z4 macrosatellite repeat. However, the reduction of D4Z4 copy number is not sufficient by itself to cause FSHD. A number of epigenetic events appear to affect the severity of the disease, its rate of progression, and the distribution of muscle weakness.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        DUX4 [HSA:22947]
DBLINKS     ICD-10: G71.0
            MeSH: D020391
            OMIM: 158900
REFERENCE   PMID:21288772 (description, gene)
  AUTHORS   van der Maarel SM, Tawil R, Tapscott SJ
  TITLE     Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence.
  JOURNAL   Trends Mol Med 17:252-8 (2011)
REFERENCE   PMID:21149563 (description, gene)
  AUTHORS   Cabianca DS, Gabellini D
  TITLE     The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy.
  JOURNAL   J Cell Biol 191:1049-60 (2010)
///
ENTRY       H00592                      Disease
NAME        Calpainopathy;
            Limb-girdle muscular dystrophy 2A (LGMD2A)
DESCRIPTION Limb-girdle muscular dystrophy 2A (LGMD2A) is caused by mutations in the CAPN3 gene encoding for calpain-3, a nonlysosomal calcium-dependent protease. This form of disorder is characterized by progressive muscle weakness and atrophy of the shoulder and pelvic girdle musculature, an elevated serum creatine kinase activity and a degeneration/regeneration pattern in muscular biopsy samples.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        CAPN3 [HSA:825] [KO:K08573]
DBLINKS     ICD-10: G71.0
            MeSH: C535895
            OMIM: 253600
REFERENCE   PMID:16884488 (gene, description)
  AUTHORS   Duguez S, Bartoli M, Richard I
  TITLE     Calpain 3: a key regulator of the sarcomere?
  JOURNAL   FEBS J 273:3427-36 (2006)
REFERENCE   PMID:21496626 (gene, description)
  AUTHORS   Gallardo E, Saenz A, Illa I
  TITLE     Limb-girdle muscular dystrophy 2A.
  JOURNAL   Handb Clin Neurol 101:97-110 (2011)
///
ENTRY       H00593                      Disease
NAME        Limb-girdle muscular dystrophy (LGMD)
DESCRIPTION Limb-girdle muscular dystrophy (LGMD) is a heterogeneous group of inherited disorders characterized by progressive muscle weakness that begins from the proximal limb muscles. The disease is not congenital, with the age at onset of symptoms varying from early childhood to late adulthood. The primary distinction is between the autosomal dominant (LGMD1) and the autosomal recessive forms (LGMD2). According to the disease mechanisms, the LGMDs may be grouped as follows: dystrophin-dystroglycan complex defects LGMD2C, D, E, F, I, K, M, N, O, P; membrane defects LGMD1C, LGMD2B, L; enzymatic LGMD2A, H; sarcomeric LGMD1A, LGMD2G, J; and nuclear lamina LGMD1B.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (LGMD1A) TTID [HSA:9499] [KO:K19875]
            (LGMD1B) LMNA [HSA:4000] [KO:K12641]
            (LGMD1C) CAV3 [HSA:859] [KO:K12959]
            (LGMD2A) CAPN3 [HSA:825] [KO:K08573]
            (LGMD2B) DYSF [HSA:8291] [KO:K18261]
            (LGMD2C) SGCG [HSA:6445] [KO:K12564]
            (LGMD2D) SGCA [HSA:6442] [KO:K12565]
            (LGMD2E) SGCB [HSA:6443] [KO:K12566]
            (LGMD2F) SGCD [HSA:6444] [KO:K12563]
            (LGMD2G) TCAP [HSA:8557] [KO:K19879]
            (LGMD2H) TRIM32 [HSA:22954] [KO:K10607]
            (LGMD2I) FKRP [HSA:79147] [KO:K19873]
            (LGMD2K) POMT1 [HSA:10585] [KO:K00728]
            (LGMD2L) ANO5 [HSA:203859] [KO:K19480]
            (LGMD2M) FKTN [HSA:2218] [KO:K19872]
            (LGMD2N) POMT2 [HSA:29954] [KO:K00728]
            (LGMD2O) POMGnT1 [HSA:55624] [KO:K09666]
            (LGMD2P) DAG1 [HSA:1605] [KO:K06265]
            (LGMD2Q) PLEC1 [HSA:5339] [KO:K10388]
DBLINKS     ICD-10: G71.0
            MeSH: D049288
            OMIM: 159000 159001 607801 253600 253601 253700 608099 604286 601287 601954 607155 609308 611307 611588 613158 613157 613818 254110 613723
REFERENCE   PMID:21825984 (gene, description)
  AUTHORS   Nigro V, Aurino S, Piluso G
  TITLE     Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches.
  JOURNAL   Curr Opin Neurol 24:429-36 (2011)
REFERENCE   PMID:11822024 (gene)
  AUTHORS   Frosk P, Weiler T, Nylen E, Sudha T, Greenberg CR, Morgan K, Fujiwara TM, Wrogemann K
  TITLE     Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene.
  JOURNAL   Am J Hum Genet 70:663-72 (2002)
REFERENCE   PMID:21109228 (gene)
  AUTHORS   Gundesli H, Talim B, Korkusuz P, Balci-Hayta B, Cirak S, Akarsu NA, Topaloglu H, Dincer P
  TITLE     Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes  autosomal-recessive limb-girdle muscular dystrophy.
  JOURNAL   Am J Hum Genet 87:834-41 (2010)
///
ENTRY       H00594                      Disease
NAME        Distal myopathy, including:
            Miyoshi myopathy (MM);
            Nonaka distal myopathy with rimmed vacuoles (DMRV);
            Welander distal myopathy (WDM);
            Tibial muscular dystrophy (TMD);
            Distal nebulin myopathy (DNM)
DESCRIPTION Distal myopathies (MPD) are a group of heterogeneous inherited primary muscle disorders classified into one broad category due to the presentation of weakness involving the distal skeletal muscles. Clinical presentation is characterized by progressive muscular weakness and atrophy beginning in the hands, forearm, lower legs or feet. Currently almost 20 different entities of distal muscular dystrophies have been genetically determined. Half of the genes have been associated with distal phenotypes only, whereas the other genes can manifest also with other than distal phenotypes. Most of the genes code for structural and functional components of the sarcomere. The genes responsible for the pathologically defined category of myofibrillar myopathy are frequently display a distal phenotype.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (MM1) DYSF [HSA:8291] [KO:K18261]
            (MM3) ANO5 [HSA:203859] [KO:K19480]
            (DMRV) GNE [HSA:10020] [KO:K12409]
            (WDM) TIA1 [HSA:7072] [KO:K13201]
            (TMD) TTN [HSA:7273] [KO:K12567]
            (DNM) NEB [HSA:4703] [KO:K18267]
            (MPD1) MYH7 [HSA:4625] [KO:K17751]
            (MPD2) MATR3 [HSA:9782] [KO:K13213]
COMMENT     For myofibrillar myopathies, see H00595.
DBLINKS     ICD-10: G71.0 G71.8
            MeSH: D049310
            OMIM: 254130 613319 605820 604454 600334 160500 606070
REFERENCE   PMID:20225017 (description)
  AUTHORS   Udd B
  TITLE     Genetics and pathogenesis of distal muscular dystrophies.
  JOURNAL   Adv Exp Med Biol 652:23-38 (2009)
REFERENCE   PMID:17029922 (gene, description)
  AUTHORS   Udd B
  TITLE     Molecular biology of distal muscular dystrophies--sarcomeric proteins on top.
  JOURNAL   Biochim Biophys Acta 1772:145-58 (2007)
REFERENCE   PMID:18974558 (description)
  AUTHORS   Malicdan MC, Nonaka I
  TITLE     Distal myopathies a review: highlights on distal myopathies with rimmed vacuoles.
  JOURNAL   Neurol India 56:314-24 (2008)
REFERENCE   PMID:17132147 (gene)
  AUTHORS   Jaiswal JK, Marlow G, Summerill G, Mahjneh I, Mueller S, Hill M, Miyake K, Haase H, Anderson LV, Richard I, Kiuru-Enari S, McNeil PL, Simon SM, Bashir R
  TITLE     Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect.
  JOURNAL   Traffic 8:77-88 (2007)
REFERENCE   PMID:23401021 (gene)
  AUTHORS   Hackman P, Sarparanta J, Lehtinen S, Vihola A, Evila A, Jonson PH, Luque H, Kere J, Screen M, Chinnery PF, Ahlberg G, Edstrom L, Udd B
  TITLE     Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1.
  JOURNAL   Ann Neurol 73:500-9 (2013)
///
ENTRY       H00595                      Disease
NAME        Myofibrillar myopathies (MFM), including:
            Desminopathy (MFM1);
            alpha-B Crystallinopathy (MFM2);
            Myotilinopathy (MFM3);
            Zaspopathy (MFM4);
            Filaminopathy (MFM5);
            Bag3opathy
DESCRIPTION Myofibrillar myopathy (MFM) is a group of genetically distinct disorders linked by common morphologic features observed on muscle histology. MFM is characterized by slowly progressive weakness that can involve both proximal and distal muscles. Distal muscle weakness is more pronounced than proximal weakness. All disease proteins identified to date are involved in maintaining the structural integrity of the Z-disk. The pathology includes accumulations of these proteins irrespective of primary gene defect, suggesting that these share molecular pathways involved in actin dynamics organized by the Z-disk. Besides accumulations of these proteins, congophilic amyloid products of myofibrillar degradation and ectopic aggregation of dystrophin and gelsolin appear in abnormal myofibers.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (MFM1) DES [HSA:1674] [KO:K07610]
            (MFM2) CRYAB [HSA:1410] [KO:K09542]
            (MFM3) TTID [HSA:9499] [KO:K19875]
            (MFM4) ZASP [HSA:11155] [KO:K19867]
            (MFM5) FLNC [HSA:2318] [KO:K04437]
            (BAG3-related MFM) BAG3 [HSA:9531] [KO:K09557]
DBLINKS     ICD-10: G71.8
            MeSH: C580316 C563319 C563848 C563775 C563718 C537932 C567843
            OMIM: 601419 608810 609200 609452 609524 612954
REFERENCE   PMID:20301672 (gene, description)
  AUTHORS   Selcen D, Engel AG
  TITLE     Myofibrillar Myopathy
  JOURNAL   (1993)
REFERENCE   PMID:17029922 (gene, description)
  AUTHORS   Udd B
  TITLE     Molecular biology of distal muscular dystrophies--sarcomeric proteins on top.
  JOURNAL   Biochim Biophys Acta 1772:145-58 (2007)
///
ENTRY       H00596                      Disease
NAME        Nonaka distal myopathy (NM);
            Distal myopathy with rimmed vacuoles (DMRV);
            Hereditary inclusion body myopathy (hIBM)
DESCRIPTION Distal myopathy with rimmed vacuoles (DMRV) or hereditary inclusion body myopathy (hIBM) is an adult onset slowly progressive myopathy secondary to mutations in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene that encodes a bifunctional enzyme which catalyzes the rate-limiting step in sialic acid biosynthesis. DMRV is a myopathy involving distal muscles, although other muscles are likewise involved. The pathological characteristics are the presence of rimmed vacuoles in muscle fibers, but are not specific to this myopathy, and the presence of scattered small angular and atrophic fibers.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        GNE [HSA:10020] [KO:K12409]
DBLINKS     ICD-10: G71.8
            MeSH: C536816
            OMIM: 605820 600737
REFERENCE   PMID:18646567 (gene, description)
  AUTHORS   Malicdan MC, Noguchi S, Nishino I
  TITLE     Perspectives on distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy: contributions from an animal model. Lack of sialic acid, a central determinant in sugar chains, causes myopathy?
  JOURNAL   Acta Myol 26:171-5 (2007)
REFERENCE   PMID:17029922 (gene)
  AUTHORS   Udd B
  TITLE     Molecular biology of distal muscular dystrophies--sarcomeric proteins on top.
  JOURNAL   Biochim Biophys Acta 1772:145-58 (2007)
///
ENTRY       H00597                      Disease
NAME        Snyder-Robinson syndrome
DESCRIPTION Snyder-Robinson syndrome (SRS) is an X-linked recessive disease which causes mild-to-moderate mental retardation, osteoporosis, facial asymmetry, thin habitus, hypotonia, and a nonspecific movement disorder. This syndrome is caused by missense mutations in the spermine synthase gene.
CATEGORY    Congenital disorder of development; Mental retardation
GENE        SMS [HSA:6611] [KO:K00802]
DBLINKS     MeSH: C536678
            OMIM: 309583
REFERENCE   PMID:19206178
  AUTHORS   Becerra-Solano LE, Butler J, Castaneda-Cisneros G, McCloskey DE, Wang X, Pegg AE, Schwartz CE, Sanchez-Corona J, Garcia-Ortiz JE
  TITLE     A missense mutation, p.V132G, in the X-linked spermine synthase gene (SMS) causes Snyder-Robinson syndrome.
  JOURNAL   Am J Med Genet A 149A:328-35 (2009)
REFERENCE   PMID:20556796
  AUTHORS   Zhang Z, Teng S, Wang L, Schwartz CE, Alexov E
  TITLE     Computational analysis of missense mutations causing Snyder-Robinson syndrome.
  JOURNAL   Hum Mutat 31:1043-9 (2010)
REFERENCE   PMID:19859664
  AUTHORS   Pegg AE, Michael AJ
  TITLE     Spermine synthase.
  JOURNAL   Cell Mol Life Sci 67:113-21 (2010)
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
///
ENTRY       H00598                      Disease
NAME        46,XX disorders of sex development (Disorders of gonadal development), including:
            Ovotesticular DSD;
            Testicular DSD;
            Ovarian dysgenesis
DESCRIPTION 46,XX disorder of sex development (46,XX DSD) is a condition in which the individual shows ambiguous genitalia with a 46,XX karyotype. One of the categories of 46,XX DSD is disorders of gonadal development, which includes ovotesticular DSD, testicular DSD, and ovarian dysgenesis. Ovotesticular DSD is defined as the simultaneous presence of both testicular and ovarian tissue in the same individual. Approximately 1/3 of the ovotesticular DSD cases have SRY gene, the male-determining factor that is usually located at the Y chromosome. Testicular DSD patients, who have testicular tissue in the absence of an ovarian tissue, are phenotypically normal males. Ovarian dysgenesis is a disorder in which subjects with female phenotype fail to proceed to puberty.
CATEGORY    Reproductive system disease
GENE        (ovotesticular) SRY [HSA:6736] [KO:K09266]
            (testicular) SOX9 (duplication) [HSA:6662] [KO:K18435]
            (testicular) SOX10 (overexpression) [HSA:6663] [KO:K09270]
            (testicular) SOX3 (overexpression) [HSA:6658] [KO:K09267]
            (testicular) WNT4 (overexpression) [HSA:54361] [KO:K00408]
            (testicular) RSPO1 (mutation) [HSA:284654] [KO:K19471]
            (dysgenesis) FSHR [HSA:2492] [KO:K04247]
            (dysgenesis) BMP15 [HSA:9210] [KO:K05498]
DBLINKS     ICD-10: Q56.0 Q99.1
            MeSH: D058489 D058531 D050090
            OMIM: 400045 278850 300833 611812 610644 233300 300510 233400
REFERENCE   PMID:18279784 (descriiption, gene)
  AUTHORS   Hughes IA
  TITLE     Disorders of sex development: a new definition and classification.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 22:119-34 (2008)
REFERENCE   PMID:20688619 (descriiption, gene)
  AUTHORS   Kousta E, Papathanasiou A, Skordis N
  TITLE     Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
  JOURNAL   Hormones (Athens) 9:218-131 (2010)
REFERENCE   PMID:11750731 (gene)
  AUTHORS   Zenteno-Ruiz JC, Kofman-Alfaro S, Mendez JP
  TITLE     46,XX sex reversal.
  JOURNAL   Arch Med Res 32:559-66 (2001)
REFERENCE   PMID:21183788 (gene)
  AUTHORS   Sutton E, Hughes J, White S, Sekido R, Tan J, Arboleda V, Rogers N, Knower K, Rowley L, Eyre H, Rizzoti K, McAninch D, Goncalves J, Slee J, Turbitt E, Bruno D, Bengtsson H, Harley V, Vilain E, Sinclair A, Lovell-Badge R, Thomas P
  TITLE     Identification of SOX3 as an XX male sex reversal gene in mice and humans.
  JOURNAL   J Clin Invest 121:328-41 (2011)
REFERENCE   PMID:9890065 (description)
  AUTHORS   Berkovitz GD, Seeherunvong T
  TITLE     Abnormalities of gonadal differentiation.
  JOURNAL   Baillieres Clin Endocrinol Metab 12:133-42 (1998)
REFERENCE   PMID:16327292 (description)
  AUTHORS   Frimberger D, Gearhart JP
  TITLE     Ambiguous genitalia and intersex.
  JOURNAL   Urol Int 75:291-7 (2005)
///
ENTRY       H00599                      Disease
NAME        46,XX disorders of sex development (Disorders related to androgen excess), including:
            Congenital adrenal hyperplasias;
            Glucocorticoid resistance;
            Aromatase deficiency
DESCRIPTION 46,XX disorder of sex development (46,XX DSD) is a condition in which the individual shows ambiguous genitalia with a 46,XX karyotype. Excess androgen during the critical period of sexual differentiation can lead to 46,XX fetus virilization. Congenital adrenal hyperplasias (CAH) and other genetic disorders in fetuses impair steroidogenesis, resulting in shunting of cortisol precursors to androgen synthesis and accumulation of the product. Masculinization of female fetuses is described in mothers harboring androgen-producing tumors. Luteoma of pregnancy is the most common source of these maternal-derived androgens.
CATEGORY    Reproductive system disease
GENE        (Fetal) CYP21A2 [HSA:1589] [KO:K00513]
            (Fetal) CYP11B1 [HSA:1584] [KO:K00497]
            (Fetal) HSD3B2 [HSA:3284] [KO:K00070]
            (Fetal) GR [HSA:2908] [KO:K05771]
            (Fetal, Fetoplacental) POR [HSA:5447] [KO:K00327] 
            (Fetoplacental) CYP19A1 [HSA:1588] [KO:K07434]
ENV_FACTOR  Maternal luteoma of pregnancy
            Maternal adrenal adenoma
            Maternal Krukenberg tumor
            Maternal adrenal cortical carcinoma
            Danazol [DR:D00289]
            Progestins [DG:DG00458]
DBLINKS     ICD-10: E25.0 E25.8
            MeSH: D058489 D000312 C537436
            OMIM: 201910 202010 201810 613571 613546
REFERENCE   PMID:18279784 (description, gene)
  AUTHORS   Hughes IA
  TITLE     Disorders of sex development: a new definition and classification.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 22:119-34 (2008)
REFERENCE   PMID:20688619 (description, gene, env_factor)
  AUTHORS   Kousta E, Papathanasiou A, Skordis N
  TITLE     Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
  JOURNAL   Hormones (Athens) 9:218-131 (2010)
REFERENCE   PMID:20541149 (description, gene, env_factor)
  AUTHORS   Auchus RJ, Chang AY
  TITLE     46,XX DSD: the masculinised female.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 24:219-42 (2010)
///
ENTRY       H00600                      Disease
NAME        46,XX disorders of sex development (Other), including:
            Mullerian aplasia and hyperandrogenism;
            McKusick-Kaufman syndrome
DESCRIPTION 46,XX disorder of sex development (46,XX DSD) is a condition in which the individual shows ambiguous genitalia with a 46,XX karyotype. Mullerian aplasia and hyperandrogenism is a phenotype characterized by the absence of Mullerian-derived structures and androgen excess. The causative gene is WNT4, whose overexpression leads to testicular DSD. McKusick-Kaufman syndrome is a rare developmental disorder with vaginal atresia.
CATEGORY    Reproductive system disease
GENE        (Mullerian aplasia) WNT4 [HSA:54361] [KO:K00408]
            (McKusick-Kaufman) MKKS [HSA:8195] [KO:K09492]
DBLINKS     MeSH: D058489
            OMIM: 158330 236700
REFERENCE   PMID:18279784 (description, gene)
  AUTHORS   Hughes IA
  TITLE     Disorders of sex development: a new definition and classification.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 22:119-34 (2008)
REFERENCE   PMID:20688619 (description, gene)
  AUTHORS   Kousta E, Papathanasiou A, Skordis N
  TITLE     Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
  JOURNAL   Hormones (Athens) 9:218-131 (2010)
REFERENCE   PMID:15317892 (description, gene)
  AUTHORS   Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ
  TITLE     A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman.
  JOURNAL   N Engl J Med 351:792-8 (2004)
REFERENCE   PMID:7811428
  AUTHORS   Lurie IW, Wulfsberg EA
  TITLE     The McKusick-Kaufman syndrome: phenotypic variation observed in familial cases as a clue for the evaluation of sporadic cases.
  JOURNAL   Genet Couns 5:275-81 (1994)
///
ENTRY       H00601                      Disease
NAME        Hutchinson-Gilford progeria syndrome
DESCRIPTION Hutchinson-Gilford progeria syndrome (HGPS) is a rare hereditary disorder characterized by premature aging. Children born with HGPS begin to develop micrognathia, alopecia, prominent scalp vein, and wrinkled, aged-looking skin within the first year of life. Severe premature atherosclerosis can cause the death at an average age of 13.5 years. Mutations in lamin A/C, an important structural component of the nuclear envelope, have been reported.
CATEGORY    Skin and connective tissue disease; Musculoskeletal disease; Vascular disease
GENE        LMNA [HSA:4000] [KO:K12641]
DBLINKS     ICD-10: E34.8
            MeSH: D011371
            OMIM: 176670
REFERENCE   PMID:21622261 (description, gene)
  AUTHORS   Gonzalez JM, Pla D, Perez-Sala D, Andres V
  TITLE     A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy.
  JOURNAL   Front Biosci (Schol Ed) 3:1133-46 (2011)
REFERENCE   PMID:15479179 (description, gene)
  AUTHORS   Pollex RL, Hegele RA
  TITLE     Hutchinson-Gilford progeria syndrome.
  JOURNAL   Clin Genet 66:375-81 (2004)
///
ENTRY       H00602                      Disease
NAME        Glucocorticoid-remediable aldosteronism (GRA)
DESCRIPTION Glucocorticoid-remediable aldosteronism (GRA), also known as familial hypoaldosteronism type I, is an autosomal dominant disease that causes hypertension, hypokalemia, decreased plasma renin activity and increased aldosterone levels. GRA is caused by a chimeric gene that links the 11 [beta]-hydroxylase promoter sequence to the aldosterone synthase gene's coding region. As a result, aldosterone is ectopically synthesized in the cortisol-secreting zona fasciculata of the adrenal gland under the control of adrenocorticotropin (ACTH). The high levels of mineralocorticoids activate the mineralocorticoid receptor (MR) and upregulate Na reabsorption and K secretion. Most individuals have severe hypertension since infancy but milder phenotypes have been described.
CATEGORY    Endocrine disease
GENE        CYP11B1 [HSA:1584] [KO:K00497]
            CYP11B2 [HSA:1585] [KO:K07433]
DBLINKS     ICD-10: E26.0 I15.2
            MeSH: C563177
            OMIM: 103900
REFERENCE   PMID:21404100 (description, gene)
  AUTHORS   Simonetti GD, Mohaupt MG, Bianchetti MG
  TITLE     Monogenic forms of hypertension.
  JOURNAL   Eur J Pediatr (2011)
REFERENCE   PMID:17496764 (description, gene)
  AUTHORS   Williams SS
  TITLE     Advances in genetic hypertension.
  JOURNAL   Curr Opin Pediatr 19:192-8 (2007)
REFERENCE   PMID:17262198 (gene)
  AUTHORS   Rosskopf D, Schurks M, Rimmbach C, Schafers R
  TITLE     Genetics of arterial hypertension and hypotension.
  JOURNAL   Naunyn Schmiedebergs Arch Pharmacol 374:429-69 (2007)
REFERENCE   PMID:15761539 (description, gene)
  AUTHORS   McMahon GT, Dluhy RG
  TITLE     Glucocorticoid-remediable aldosteronism.
  JOURNAL   Arq Bras Endocrinol Metabol 48:682-6 (2004)
REFERENCE   PMID:11004715 (gene)
  AUTHORS   Torpy DJ, Stratakis CA, Chrousos GP
  TITLE     Familial hyperaldosteronism.
  JOURNAL   Braz J Med Biol Res 33:1149-55 (2000)
///
ENTRY       H00603                      Disease
NAME        Hypertension exacerbated in pregnancy
DESCRIPTION "Hypertension exacerbated by pregnancy" is a syndrome similar to Apparent mineralocorticoid excess (AME) with autosomal dominant early-onset hypertension. The affected individuals have a gain of function mutation in the human mineralocorticoid receptor (MR), resulting in constitutively stimulated Na reabsorption. Hypertension is present in nonpregnant patients and may be severe, but the characteristic feature is marked worsening during pregnancy. The proposed explanation is that the mutation renders the receptor sensitive to nonmineralocorticoid steroids such as progesterone, the level of which rises 100-fold during pregnancy.
CATEGORY    Cardiovascular disease
GENE        NR3C2 [HSA:4306] [KO:K08555]
DBLINKS     ICD-10: I15.8
            OMIM: 605115
REFERENCE   PMID:17647025 (description, gene)
  AUTHORS   Vehaskari VM
  TITLE     Heritable forms of hypertension.
  JOURNAL   Pediatr Nephrol 24:1929-37 (2009)
REFERENCE   PMID:17262198 (description, gene)
  AUTHORS   Rosskopf D, Schurks M, Rimmbach C, Schafers R
  TITLE     Genetics of arterial hypertension and hypotension.
  JOURNAL   Naunyn Schmiedebergs Arch Pharmacol 374:429-69 (2007)
REFERENCE   PMID:12538613 (gene)
  AUTHORS   Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A
  TITLE     The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related.
  JOURNAL   Endocrinology 144:528-33 (2003)
///
ENTRY       H00604                      Disease
NAME        Deafness, autosomal dominant
DESCRIPTION Hereditary deafness is divided into syndromic forms (in which hearing loss is associated with a variety of other anomalies) and non-syndromic forms. Non-syndromic forms are responsible for 70% of the cases of hereditary etiology and syndromic cases represent 30% of them. Among the forms of heritage, autosomal-recessive inheritance is the most frequent one (75%-85%), followed by autosomal-dominant inheritance (12-13%) and X-linked or mitochondrial, with 2-3% of the cases of non-syndromic hearing loss. Autosomal-dominant forms of deafness are usually post-lingual and progressive. Dominant mutations may be consistent with initial function and subsequent hearing loss owing to accumulation of pathology.
CATEGORY    Nervous system disease; Nervous system disease
GENE        DIAPH1 [HSA:1729] [KO:K05740]
            GJB3 [HSA:2707] [KO:K07622]
            MYH14 [HSA:79784] [KO:K10352]
            GJB6 [HSA:10804] [KO:K07625]
            WFS1 [HSA:7466] [KO:K14020]
            KCNQ4 [HSA:9132] [KO:K04929]
            GJB2 [HSA:2706] [KO:K07621]
            DFNA5 [HSA:1687]
            COCH [HSA:1690]
            MYO7A [HSA:4647] [KO:K10359]
            TECTA [HSA:7007] [KO:K18273]
            EYA4 [HSA:2070] [KO:K17622]
            COL11A2 [HSA:1302] [KO:K19721]
            POU4F3 [HSA:5459] [KO:K09366]
            MYH9 [HSA:4627] [KO:K10352]
            ACTG1 [HSA:71] [KO:K05692]
            SIX1 [HSA:6495] [KO:K15614]
            SLC17A8 [HSA:246213] [KO:K12302]
            GRHL2 [HSA:79977] [KO:K09275]
            TMC1 [HSA:117531]
            DSPP [HSA:1834]
            CCDC50 [HSA:152137]
            MYO1A [HSA:4640] [KO:K10356]
            MIR96 [HSA:407053] [KO:K17114]
            MYO6 [HSA:4646] [KO:K10358]
DBLINKS     ICD-10: H91.9
            MeSH: C565121 C567441 C567214 C567277 C567215 C563460 C563410 C563421 C563321 C563335 C563354 C563353 C563295 C566612 C563421 C566545 C565832 C535507 C565267 C565754 C564634 C538197 C565357 C565239 C565319 C563890 C564706 C563888 C564675 C564272 C564246 C564399 C563885 C564322 C564250 C564348 C566495 C567216
            OMIM: 124900 600101 612643 600652 600965 601316 612644 601544 600994 601369 601317 601543 601868 602459 603622 604717 605192 605583 608641 606705 605594 607453 607841 613074 606346
REFERENCE   PMID:12123480 (description, gene)
  AUTHORS   Petersen MB
  TITLE     Non-syndromic autosomal-dominant deafness.
  JOURNAL   Clin Genet 62:1-13 (2002)
REFERENCE   PMID:16446920 (description, gene)
  AUTHORS   Piatto VB, Nascimento EC, Alexandrino F, Oliveira CA, Lopes AC, Sartorato EL, Maniglia JV
  TITLE     Molecular genetics of non-syndromic deafness.
  JOURNAL   Braz J Otorhinolaryngol 71:216-23 (2005)
REFERENCE   PMID:12324385 (gene)
  AUTHORS   Bitner-Glindzicz M
  TITLE     Hereditary deafness and phenotyping in humans.
  JOURNAL   Br Med Bull 63:73-94 (2002)
REFERENCE   PMID:12014894 (gene)
  AUTHORS   Hone SW, Smith RJ
  TITLE     Genetics of hearing impairment.
  JOURNAL   Semin Neonatol 6:531-41 (2001)
REFERENCE   PMID:10471490
  AUTHORS   Grifa A, Wagner CA, D'Ambrosio L, Melchionda S, Bernardi F, Lopez-Bigas N, Rabionet R, Arbones M, Monica MD, Estivill X, Zelante L, Lang F, Gasparini P
  TITLE     Mutations in GJB6 cause nonsyndromic autosomal dominant deafness at DFNA3 locus.
  JOURNAL   Nat Genet 23:16-8 (1999)
REFERENCE   PMID:15015131
  AUTHORS   Donaudy F, Snoeckx R, Pfister M, Zenner HP, Blin N, Di Stazio M, Ferrara A, Lanzara C, Ficarella R, Declau F, Pusch CM, Nurnberg P, Melchionda S, Zelante L, Ballana E, Estivill X, Van Camp G, Gasparini P, Savoia A
  TITLE     Nonmuscle myosin heavy-chain gene MYH14 is expressed in cochlea and mutated in patients affected by autosomal dominant hearing impairment (DFNA4).
  JOURNAL   Am J Hum Genet 74:770-6 (2004)
REFERENCE   PMID:11709538
  AUTHORS   Young TL, Ives E, Lynch E, Person R, Snook S, MacLaren L, Cater T, Griffin A, Fernandez B, Lee MK, King MC
  TITLE     Non-syndromic progressive hearing loss DFNA38 is caused by heterozygous missense  mutation in the Wolfram syndrome gene WFS1.
  JOURNAL   Hum Mol Genet 10:2509-14 (2001)
REFERENCE   PMID:13680526
  AUTHORS   Zhu M, Yang T, Wei S, DeWan AT, Morell RJ, Elfenbein JL, Fisher RA, Leal SM, Smith RJ, Friderici KH
  TITLE     Mutations in the gamma-actin gene (ACTG1) are associated with dominant progressive deafness (DFNA20/26).
  JOURNAL   Am J Hum Genet 73:1082-91 (2003)
REFERENCE   PMID:15141091
  AUTHORS   Ruf RG, Xu PX, Silvius D, Otto EA, Beekmann F, Muerb UT, Kumar S, Neuhaus TJ, Kemper MJ, Raymond RM Jr, Brophy PD, Berkman J, Gattas M, Hyland V, Ruf EM, Schwartz C, Chang EH, Smith RJ, Stratakis CA, Weil D, Petit C, Hildebrandt F
  TITLE     SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes.
  JOURNAL   Proc Natl Acad Sci U S A 101:8090-5 (2004)
REFERENCE   PMID:18674745
  AUTHORS   Ruel J, Emery S, Nouvian R, Bersot T, Amilhon B, Van Rybroek JM, Rebillard G, Lenoir M, Eybalin M, Delprat B, Sivakumaran TA, Giros B, El Mestikawy S, Moser T, Smith RJ, Lesperance MM, Puel JL
  TITLE     Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice.
  JOURNAL   Am J Hum Genet 83:278-92 (2008)
REFERENCE   PMID:21610158
  AUTHORS   Han Y, Mu Y, Li X, Xu P, Tong J, Liu Z, Ma T, Zeng G, Yang S, Du J, Meng A
  TITLE     Grhl2 deficiency impairs otic development and hearing ability in a zebrafish model of the progressive dominant hearing loss DFNA28.
  JOURNAL   Hum Mol Genet 20:3213-26 (2011)
REFERENCE   PMID:18616530
  AUTHORS   Hilgert N, Alasti F, Dieltjens N, Pawlik B, Wollnik B, Uyguner O, Delmaghani S, Weil D, Petit C, Danis E, Yang T, Pandelia E, Petersen MB, Goossens D, Favero JD, Sanati MH, Smith RJ, Van Camp G
  TITLE     Mutation analysis of TMC1 identifies four new mutations and suggests an additional deafness gene at loci DFNA36 and DFNB7/11.
  JOURNAL   Clin Genet 74:223-32 (2008)
REFERENCE   PMID:11175790
  AUTHORS   Xiao S, Yu C, Chou X, Yuan W, Wang Y, Bu L, Fu G, Qian M, Yang J, Shi Y, Hu L, Han B, Wang Z, Huang W, Liu J, Chen Z, Zhao G, Kong X
  TITLE     Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP.
  JOURNAL   Nat Genet 27:201-4 (2001)
REFERENCE   PMID:17503326
  AUTHORS   Modamio-Hoybjor S, Mencia A, Goodyear R, del Castillo I, Richardson G, Moreno F, Moreno-Pelayo MA
  TITLE     A mutation in CCDC50, a gene encoding an effector of epidermal growth factor-mediated cell signaling, causes progressive hearing loss.
  JOURNAL   Am J Hum Genet 80:1076-89 (2007)
REFERENCE   PMID:12736868
  AUTHORS   Donaudy F, Ferrara A, Esposito L, Hertzano R, Ben-David O, Bell RE, Melchionda S, Zelante L, Avraham KB, Gasparini P
  TITLE     Multiple mutations of MYO1A, a cochlear-expressed gene, in sensorineural hearing  loss.
  JOURNAL   Am J Hum Genet 72:1571-7 (2003)
REFERENCE   PMID:22038834
  AUTHORS   Solda G, Robusto M, Primignani P, Castorina P, Benzoni E, Cesarani A, Ambrosetti U, Asselta R, Duga S
  TITLE     A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
  JOURNAL   Hum Mol Genet 21:577-85 (2012)
///
ENTRY       H00605                      Disease
NAME        Deafness, autosomal recessive
DESCRIPTION Hereditary deafness is divided into syndromic forms (in which hearing loss is associated with a variety of other anomalies) and non-syndromic forms. Non-syndromic forms are responsible for 70% of the cases of hereditary etiology and syndromic cases represent 30% of them. Among the forms of heritage, autosomal-recessive inheritance is the most frequent one (75%-85%), followed by autosomal- dominant inheritance (12-13%) and X-linked or mitochondrial, with 2-3% of the cases of non-syndromic hearing loss. The autosomal-recessive forms of deafness are generally the most severe and are almost exclusively caused by cochlear defects (sensorineural deafness), in contrast to the syndromic forms of deafness, where the hearing loss in most cases is conductive (external and/or middle ear developmental defects) or mixed.
CATEGORY    Nervous system disease; Nervous system disease
GENE        GJB2 [HSA:2706] [KO:K07621]
            GJB6 [HSA:10804] [KO:K07625]
            MYO7A [HSA:4647] [KO:K10359]
            MYO15 [HSA:51168] [KO:K10361]
            SLC26A4 [HSA:5172] [KO:K14702]
            TMIE [HSA:259236]
            TMC1 [HSA:117531]
            TMPRSS3 [HSA:64699] [KO:K09634]
            OTOF [HSA:9381] [KO:K19949]
            CDH23 [HSA:64072] [KO:K06813]
            STRC [HSA:161497]
            USH1C [HSA:10083]
            TECTA [HSA:7007] [KO:K18273]
            OTOA [HSA:146183]
            PCDH15 [HSA:65217] [KO:K16500]
            CLDN14 [HSA:23562] [KO:K06087]
            MYO3A [HSA:53904] [KO:K08834]
            WHRN [HSA:25861]
            ESPN [HSA:83715]
            MYO6 [HSA:4646] [KO:K10358]
            COL11A2 [HSA:1302] [KO:K19721]
            GJB3 [HSA:2707] [KO:K07622]
            GJA1 [HSA:2697] [KO:K07372]
            SLC26A5 [HSA:375611] [KO:K14703]
            GRXCR1 [HSA:389207] [KO:K17479]
            TRIOBP [HSA:11078]
            ESRRB [HSA:2103] [KO:K08553]
            HGF [HSA:3082] [KO:K05460]
            MARVELD2 [HSA:153562] [KO:K17291]
            PJVK [HSA:494513]
            LRTOMT [HSA:220074]
            LHFPL5 [HSA:222662]
            MSRB3 [HSA:253827] [KO:K07305]
            LOXHD1 [HSA:125336]
            TPRN [HSA:286262]
            GPSM2 [HSA:29899] [KO:K15837]
            PTPRQ [HSA:374462] [KO:K16910]
            SERPINB6 [HSA:5269] [KO:K13963]
            RDX [HSA:5962] [KO:K05762]
            FGF3 [HSA:2248] [KO:K04358]
DBLINKS     ICD-10: H91.9
            MeSH: C567134 C567213 C564007 C563961 C566366 C563444 C563418 C563417 C563396 C565341 C563417 C563327 C566410 C566344 C566611 C566339 C566418 C566580 C565828 C566353 C564633 C563705 C567027 C565329 C565287
            OMIM: 220290 612645 600060 600316 600791 600971 600974 601072 601071 605316 601386 603720 602092 603629 607039 609533 614035 607101 607084 609006 607821 609706 613285 609823 608565 608265 610153 610220 611451 610265 613718 613079 613307 613557 613391 613453 611022 610706
REFERENCE   PMID:16650073 (gene)
  AUTHORS   Petersen MB, Willems PJ
  TITLE     Non-syndromic, autosomal-recessive deafness.
  JOURNAL   Clin Genet 69:371-92 (2006)
REFERENCE   PMID:16446920 (description, gene)
  AUTHORS   Piatto VB, Nascimento EC, Alexandrino F, Oliveira CA, Lopes AC, Sartorato EL, Maniglia JV
  TITLE     Molecular genetics of non-syndromic deafness.
  JOURNAL   Braz J Otorhinolaryngol 71:216-23 (2005)
REFERENCE   PMID:12324385 (gene)
  AUTHORS   Bitner-Glindzicz M
  TITLE     Hereditary deafness and phenotyping in humans.
  JOURNAL   Br Med Bull 63:73-94 (2002)
REFERENCE   PMID:20137778 (gene)
  AUTHORS   Schraders M, Lee K, Oostrik J, Huygen PL, Ali G, Hoefsloot LH, Veltman JA, Cremers FP, Basit S, Ansar M, Cremers CW, Kunst HP, Ahmad W, Admiraal RJ, Leal SM, Kremer H
  TITLE     Homozygosity mapping reveals mutations of GRXCR1 as a cause of autosomal-recessive nonsyndromic hearing impairment.
  JOURNAL   Am J Hum Genet 86:138-47 (2010)
REFERENCE   PMID:16385457 (gene)
  AUTHORS   Riazuddin S, Khan SN, Ahmed ZM, Ghosh M, Caution K, Nazli S, Kabra M, Zafar AU, Chen K, Naz S, Antonellis A, Pavan WJ, Green ED, Wilcox ER, Friedman PL, Morell RJ, Riazuddin S, Friedman TB
  TITLE     Mutations in TRIOBP, which encodes a putative cytoskeletal-organizing protein, are associated with nonsyndromic recessive deafness.
  JOURNAL   Am J Hum Genet 78:137-43 (2006)
REFERENCE   PMID:18179891 (gene)
  AUTHORS   Collin RW, Kalay E, Tariq M, Peters T, van der Zwaag B, Venselaar H, Oostrik J, Lee K, Ahmed ZM, Caylan R, Li Y, Spierenburg HA, Eyupoglu E, Heister A, Riazuddin S, Bahat E, Ansar M, Arslan S, Wollnik B, Brunner HG, Cremers CW, Karaguzel A, Ahmad W, Cremers FP, Vriend G, Friedman TB, Riazuddin S, Leal SM, Kremer H
  TITLE     Mutations of ESRRB encoding estrogen-related receptor beta cause autosomal-recessive nonsyndromic hearing impairment DFNB35.
  JOURNAL   Am J Hum Genet 82:125-38 (2008)
REFERENCE   PMID:19576567 (gene)
  AUTHORS   Schultz JM, Khan SN, Ahmed ZM, Riazuddin S, Waryah AM, Chhatre D, Starost MF, Ploplis B, Buckley S, Velasquez D, Kabra M, Lee K, Hassan MJ, Ali G, Ansar M, Ghosh M, Wilcox ER, Ahmad W, Merlino G, Leal SM, Riazuddin S, Friedman TB, Morell RJ
  TITLE     Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.
  JOURNAL   Am J Hum Genet 85:25-39 (2009)
REFERENCE   PMID:17186462 (gene)
  AUTHORS   Riazuddin S, Ahmed ZM, Fanning AS, Lagziel A, Kitajiri S, Ramzan K, Khan SN, Chattaraj P, Friedman PL, Anderson JM, Belyantseva IA, Forge A, Riazuddin S, Friedman TB
  TITLE     Tricellulin is a tight-junction protein necessary for hearing.
  JOURNAL   Am J Hum Genet 79:1040-51 (2006)
REFERENCE   PMID:16804542 (gene)
  AUTHORS   Delmaghani S, del Castillo FJ, Michel V, Leibovici M, Aghaie A, Ron U, Van Laer L, Ben-Tal N, Van Camp G, Weil D, Langa F, Lathrop M, Avan P, Petit C
  TITLE     Mutations in the gene encoding pejvakin, a newly identified protein of the afferent auditory pathway, cause DFNB59 auditory neuropathy.
  JOURNAL   Nat Genet 38:770-8 (2006)
REFERENCE   PMID:18953341 (gene)
  AUTHORS   Ahmed ZM, Masmoudi S, Kalay E, Belyantseva IA, Mosrati MA, Collin RW, Riazuddin S, Hmani-Aifa M, Venselaar H, Kawar MN, Tlili A, van der Zwaag B, Khan SY, Ayadi L, Riazuddin SA, Morell RJ, Griffith AJ, Charfedine I, Caylan R, Oostrik J, Karaguzel A, Ghorbel A, Riazuddin S, Friedman TB, Ayadi H, Kremer H
  TITLE     Mutations of LRTOMT, a fusion gene with alternative reading frames, cause nonsyndromic deafness in humans.
  JOURNAL   Nat Genet 40:1335-40 (2008)
REFERENCE   PMID:16752389 (gene)
  AUTHORS   Kalay E, Li Y, Uzumcu A, Uyguner O, Collin RW, Caylan R, Ulubil-Emiroglu M, Kersten FF, Hafiz G, van Wijk E, Kayserili H, Rohmann E, Wagenstaller J, Hoefsloot LH, Strom TM, Nurnberg G, Baserer N, den Hollander AI, Cremers FP, Cremers CW, Becker C, Brunner HG, Nurnberg P, Karaguzel A, Basaran S, Kubisch C, Kremer H, Wollnik B
  TITLE     Mutations in the lipoma HMGIC fusion partner-like 5 (LHFPL5) gene cause autosomal recessive nonsyndromic hearing loss.
  JOURNAL   Hum Mutat 27:633-9 (2006)
REFERENCE   PMID:21185009 (gene)
  AUTHORS   Ahmed ZM, Yousaf R, Lee BC, Khan SN, Lee S, Lee K, Husnain T, Rehman AU, Bonneux S, Ansar M, Ahmad W, Leal SM, Gladyshev VN, Belyantseva IA, Van Camp G, Riazuddin S, Friedman TB, Riazuddin S
  TITLE     Functional null mutations of MSRB3 encoding methionine sulfoxide reductase are associated with human deafness DFNB74.
  JOURNAL   Am J Hum Genet 88:19-29 (2011)
REFERENCE   PMID:19732867 (gene)
  AUTHORS   Grillet N, Schwander M, Hildebrand MS, Sczaniecka A, Kolatkar A, Velasco J, Webster JA, Kahrizi K, Najmabadi H, Kimberling WJ, Stephan D, Bahlo M, Wiltshire T, Tarantino LM, Kuhn P, Smith RJ, Muller U
  TITLE     Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans.
  JOURNAL   Am J Hum Genet 85:328-37 (2009)
REFERENCE   PMID:20170898 (gene)
  AUTHORS   Li Y, Pohl E, Boulouiz R, Schraders M, Nurnberg G, Charif M, Admiraal RJ, von Ameln S, Baessmann I, Kandil M, Veltman JA, Nurnberg P, Kubisch C, Barakat A, Kremer H, Wollnik B
  TITLE     Mutations in TPRN cause a progressive form of autosomal-recessive nonsyndromic hearing loss.
  JOURNAL   Am J Hum Genet 86:479-84 (2010)
REFERENCE   PMID:20602914 (gene)
  AUTHORS   Walsh T, Shahin H, Elkan-Miller T, Lee MK, Thornton AM, Roeb W, Abu Rayyan A, Loulus S, Avraham KB, King MC, Kanaan M
  TITLE     Whole exome sequencing and homozygosity mapping identify mutation in the cell polarity protein GPSM2 as the cause of nonsyndromic hearing loss DFNB82.
  JOURNAL   Am J Hum Genet 87:90-4 (2010)
REFERENCE   PMID:20346435 (gene)
  AUTHORS   Schraders M, Oostrik J, Huygen PL, Strom TM, van Wijk E, Kunst HP, Hoefsloot LH, Cremers CW, Admiraal RJ, Kremer H
  TITLE     Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction.
  JOURNAL   Am J Hum Genet 86:604-10 (2010)
REFERENCE   PMID:20451170 (gene)
  AUTHORS   Sirmaci A, Erbek S, Price J, Huang M, Duman D, Cengiz FB, Bademci G, Tokgoz-Yilmaz S, Hismi B, Ozdag H, Ozturk B, Kulaksizoglu S, Yildirim E, Kokotas H, Grigoriadou M, Petersen MB, Shahin H, Kanaan M, King MC, Chen ZY, Blanton SH, Liu XZ, Zuchner S, Akar N, Tekin M
  TITLE     A truncating mutation in SERPINB6 is associated with autosomal-recessive nonsyndromic sensorineural hearing loss.
  JOURNAL   Am J Hum Genet 86:797-804 (2010)
REFERENCE   PMID:17226784 (gene)
  AUTHORS   Khan SY, Ahmed ZM, Shabbir MI, Kitajiri S, Kalsoom S, Tasneem S, Shayiq S, Ramesh A, Srisailpathy S, Khan SN, Smith RJ, Riazuddin S, Friedman TB, Riazuddin S
  TITLE     Mutations of the RDX gene cause nonsyndromic hearing loss at the DFNB24 locus.
  JOURNAL   Hum Mutat 28:417-23 (2007)
REFERENCE   PMID:17236138 (gene)
  AUTHORS   Tekin M, Hismi BO, Fitoz S, Ozdag H, Cengiz FB, Sirmaci A, Aslan I, Inceoglu B, Yuksel-Konuk EB, Yilmaz ST, Yasun O, Akar N
  TITLE     Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia.
  JOURNAL   Am J Hum Genet 80:338-44 (2007)
REFERENCE   PMID:18435799 (gene)
  AUTHORS   Tekin M, Ozturkmen Akay H, Fitoz S, Birnbaum S, Cengiz FB, Sennaroglu L, Incesulu A, Yuksel Konuk EB, Hasanefendioglu Bayrak A, Senturk S, Cebeci I, Utine GE, Tuncbilek E, Nance WE, Duman D
  TITLE     Homozygous FGF3 mutations result in congenital deafness with inner ear agenesis,  microtia, and microdontia.
  JOURNAL   Clin Genet 73:554-65 (2008)
///
ENTRY       H00606                      Disease
NAME        Early infantile epileptic encephalopathy;
            Ohtahara syndrome
DESCRIPTION Early infantile epileptic encephalopathy (EIEE), also known as Ohtahara syndrome,is characterized by frequent tonic spasms of early onset within a few months of life, and a suppression-burst pattern in electroencephalography (EEG). Many causes have been considered for EIEE. It has been reported that 75% of the cases subsequently evolve to West syndrome, and later a much smaller number progress to Lennox-Gastaut syndrome.
CATEGORY    Congenital disorder; Epilepsy
GENE        (EIEE1) ARX [HSA:170302] [KO:K09452]
            (EIEE2) CDKL5 [HSA:6792] [KO:K08824]
            (EIEE3) SLC25A22 [HSA:79751] [KO:K15107]
            (EIEE4) STXBP1 [HSA:6812] [KO:K15292]
            (EIEE5) SPTAN1 [HSA:6709] [KO:K06114]
            (EIEE7) KCNQ2 [HSA:3785] [KO:K04927]
            (EIEE8) ARHGEF9 [HSA:23229] [KO:K20686]
            (EIEE9) PCDH19 [HSA:57526] [KO:K16499]
            (EIEE10) PNKP [HSA:11284] [KO:K08073]
            (EIEE11) SCN2A1 [HSA:6326] [KO:K04834]
            (EIEE12) PLCB1 [HSA:23236] [KO:K05858]
            (EIEE13) SCN8A [HSA:6334] [KO:K04840]
            (EIEE15) ST3GAL3 [HSA:6487] [KO:K00781]
            (EIEE16) TBC1D24 [HSA:57465]
            (EIEE17) GNAO1 [HSA:2775] [KO:K04534]
            (EIEE18) SZT2 [HSA:23334]
            (EIEE19) GABRA1 [HSA:2554] [KO:K05175]
            (EIEE22) SLC35A2 [HSA:7355] [KO:K15272]
            (EIEE23) DOCK7 [HSA:85440]
            (EIEE24) HCN1 [HSA:348980] [KO:K04954]
            (EIEE25) SLC13A5 [HSA:284111] [KO:K14445]
            (EIEE26) KCNB1 [HSA:3745] [KO:K04885]
            (EIEE27) GRIN2B [HSA:2904] [KO:K05210]
            (EIEE28) WWOX [HSA:51741] [KO:K19329]
            (EIEE29) AARS [HSA:16] [KO:K01872]
            (EIEE30) SIK1 [HSA:150094] [KO:K19008]
            (EIEE31) DNM1 [HSA:1759] [KO:K01528]
            (EIEE32) KCNA2 [HSA:3737] [KO:K04875]
            (EIEE33) EEF1A2 [HSA:1917] [KO:K03231]
            (EIEE35) ITPA [HSA:3704] [KO:K01519]
            (EIEE36) ALG13 [HSA:79868] [KO:K07432]
            (EIEE37) FRRS1L [HSA:23732]
            (EIEE38) ARV1 [HSA:64801]
            (EIEE40) GUF1 [HSA:60558]
            (EIEE41) SLC1A2 [HSA:6506] [KO:K05613]
            (EIEE42) CACNA1A [HSA:773] [KO:K04344]
            (EIEE43) GABRB3 [HSA:2562] [KO:K05181]
            (EIEE44) UBA5 [HSA:79876] [KO:K12164]
            (EIEE45) GABRB1 [HSA:2560] [KO:K05181]
            (EIEE46) GRIN2D [HSA:2906] [KO:K05212]
            (EIEE47) FGF12 [HSA:2257] [KO:K04358]
            (EIEE48) AP3B2 [HSA:8120] [KO:K12397]
            (EIEE49) DENND5A [HSA:23258] [KO:K20164]
            (EIEE51) MDH2 [HSA:4191] [KO:K00026]
            (Lennox-Gastaut type) MAPK10 [HSA:5602] [KO:K04440]
DBLINKS     ICD-10: G40.3
            MeSH: C538670
            OMIM: 308350 300672 609304 612164 613477 613720 300607 300088 613402 613721 613722 614558 615006 615338 615473 615476 615744 300896 615859 615871 615905 616056 616139 616211 616339 616341 616346 616366 616409 616647 300884 616981 617020 617065 617105 617106 617113 617132 617153 617162 617166 617276 617281 617339
REFERENCE   PMID:14734930
  AUTHORS   Ohtahara S, Yamatogi Y
  TITLE     Epileptic encephalopathies in early infancy with suppression-burst.
  JOURNAL   J Clin Neurophysiol 20:398-407 (2003)
REFERENCE   PMID:16829045
  AUTHORS   Ohtahara S, Yamatogi Y
  TITLE     Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy.
  JOURNAL   Epilepsy Res 70 Suppl 1:S58-67 (2006)
REFERENCE   PMID:11751020
  AUTHORS   Yamatogi Y, Ohtahara S
  TITLE     Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases.
  JOURNAL   Brain Dev 24:13-23 (2002)
REFERENCE   PMID:18469812
  AUTHORS   Saitsu H, Kato M, Mizuguchi T, Hamada K, Osaka H, Tohyama J, Uruno K, Kumada S, Nishiyama K, Nishimura A, Okada I, Yoshimura Y, Hirai S, Kumada T, Hayasaka K, Fukuda A, Ogata K, Matsumoto N
  TITLE     De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy.
  JOURNAL   Nat Genet 40:782-8 (2008)
REFERENCE   PMID:22492991
  AUTHORS   Timal S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, Paprocka J, Jamroz E, van Spronsen FJ, Korner C, Gilissen C, Rodenburg RJ, Eidhof I, Van den Heuvel L, Thiel C, Wevers RA, Morava E, Veltman J, Lefeber DJ
  TITLE     Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing.
  JOURNAL   Hum Mol Genet 21:4151-61 (2012)
REFERENCE   PMID:23934111
  AUTHORS   Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, Heinzen EL, Hitomi Y, Howell KB, Johnson MR, Kuzniecky R, Lowenstein DH, Lu YF, Madou MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O'Brien TJ, Ottman R, Petrovski S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil B, Alldredge BK, Bautista JF, Berkovic SF, Boro A, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Friedman D, Geller EB, Glauser T, Glynn S, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, McGuire SM, Motika PV, Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Scheffer IE, Shellhaas RA, Sherr EH, Shih JJ, Singh R, Sirven J, Smith MC, Sullivan J, Lin Thio L, Venkat A, Vining EP, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR
  TITLE     De novo mutations in epileptic encephalopathies.
  JOURNAL   Nature 501:217-21 (2013)
REFERENCE   PMID:23252400
  AUTHORS   Edvardson S, Baumann AM, Muhlenhoff M, Stephan O, Kuss AW, Shaag A, He L, Zenvirt S, Tanzi R, Gerardy-Schahn R, Elpeleg O
  TITLE     West syndrome caused by ST3Gal-III deficiency.
  JOURNAL   Epilepsia 54:e24-7 (2013)
REFERENCE   PMID:24115232
  AUTHORS   Kodera H, Nakamura K, Osaka H, Maegaki Y, Haginoya K, Mizumoto S, Kato M, Okamoto N, Iai M, Kondo Y, Nishiyama K, Tsurusaki Y, Nakashima M, Miyake N, Hayasaka K, Sugahara K, Yuasa I, Wada Y, Matsumoto N, Saitsu H
  TITLE     De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy.
  JOURNAL   Hum Mutat 34:1708-14 (2013)
REFERENCE   PMID:26517219 (gene)
  AUTHORS   Gonsales MC, Montenegro MA, Soler CV, Coan AC, Guerreiro MM, Lopes-Cendes I
  TITLE     Recent developments in the genetics of childhood epileptic encephalopathies: impact in clinical practice.
  JOURNAL   Arq Neuropsiquiatr 73:946-58 (2015)
REFERENCE   PMID:26597089 (gene)
  AUTHORS   McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE
  TITLE     The genetic landscape of the epileptic encephalopathies of infancy and childhood.
  JOURNAL   Lancet Neurol 15:304-16 (2016)
REFERENCE   PMID:27476654 (gene)
  AUTHORS   Myers CT, McMahon JM, Schneider AL, Petrovski S
  TITLE     De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies.
  JOURNAL   Am J Hum Genet 99:287-98 (2016)
REFERENCE   PMID:25164438 (gene)
  AUTHORS   Torkamani A, Bersell K, Jorge BS, Bjork RL Jr, Friedman JR, Bloss CS, Cohen J, Gupta S, Naidu S, Vanoye CG, George AL Jr, Kearney JA
  TITLE     De novo KCNB1 mutations in epileptic encephalopathy.
  JOURNAL   Ann Neurol 76:529-40 (2014)
REFERENCE   PMID:26224535 (gene)
  AUTHORS   Kevelam SH, Bierau J, Salvarinova R, Agrawal S, Honzik T, Visser D, Weiss MM, Salomons GS, Abbink TE, Waisfisz Q, van der Knaap MS
  TITLE     Recessive ITPA mutations cause an early infantile encephalopathy.
  JOURNAL   Ann Neurol 78:649-58 (2015)
REFERENCE   PMID:27239025 (gene)
  AUTHORS   Shaheen R, Al Tala S, Ewida N, Abouelhoda M, Alkuraya FS
  TITLE     Epileptic encephalopathy with continuous spike-and-wave during sleep maps to a homozygous truncating mutation in AMPA receptor component FRRS1L.
  JOURNAL   Clin Genet 90:282-3 (2016)
REFERENCE   PMID:27270415 (gene)
  AUTHORS   Palmer EE, Jarrett KE, Sachdev RK, Al Zahrani F, Hashem MO, Ibrahim N, Sampaio H, Kandula T, Macintosh R, Gupta R, Conlon DM, Billheimer JT, Rader DJ, Funato K, Walkey CJ, Lee CS, Loo C, Brammah S, Elakis G, Zhu Y, Buckley M, Kirk EP, Bye A, Alkuraya FS, Roscioli T, Lagor WR
  TITLE     Neuronal deficiency of ARV1 causes an autosomal recessive epileptic encephalopathy.
  JOURNAL   Hum Mol Genet 25:3042-3054 (2016)
REFERENCE   PMID:26486472 (gene)
  AUTHORS   Alfaiz AA, Muller V, Boutry-Kryza N, Ville D, Guex N, de Bellescize J, Rivier C, Labalme A, des Portes V, Edery P, Till M, Xenarios I, Sanlaville D, Herrmann JM, Lesca G, Reymond A
  TITLE     West syndrome caused by homozygous variant in the evolutionary conserved gene encoding the mitochondrial elongation factor GUF1.
  JOURNAL   Eur J Hum Genet 24:1001-8 (2016)
REFERENCE   PMID:27545681 (gene)
  AUTHORS   Colin E, Daniel J, Ziegler A, Wakim J, Scrivo A, Haack TB, Khiati S, Denomme AS, Amati-Bonneau P, Charif M, Procaccio V, Reynier P, Aleck KA, Botto LD, Herper CL, Kaiser CS, Nabbout R, N'Guyen S, Mora-Lorca JA, Assmann B, Christ S, Meitinger T, Strom TM, Prokisch H, Miranda-Vizuete A, Hoffmann GF, Lenaers G, Bomont P, Liebau E, Bonneau D
  TITLE     Biallelic Variants in UBA5 Reveal that Disruption of the UFM1 Cascade Can Result  in Early-Onset Encephalopathy.
  JOURNAL   Am J Hum Genet 99:695-703 (2016)
REFERENCE   PMID:27616483 (gene)
  AUTHORS   Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, Kosobucki GJ, Chen W, Schulien AJ, Chiavacci R, Tankovic A, Naase C, Brueckner F, von Stulpnagel-Steinbeis C, Hu C, Kusumoto H, Hedrich UB, Elsen G, Hortnagel K, Aizenman E, Lemke JR, Hakonarson H, Traynelis SF, Falk MJ
  TITLE     GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers.
  JOURNAL   Am J Hum Genet 99:802-816 (2016)
REFERENCE   PMID:27164707 (gene)
  AUTHORS   Siekierska A, Isrie M, Liu Y, Scheldeman C, Vanthillo N, Lagae L, de Witte PA, Van Esch H, Goldfarb M, Buyse GM
  TITLE     Gain-of-function FHF1 mutation causes early-onset epileptic encephalopathy with cerebellar atrophy.
  JOURNAL   Neurology 86:2162-70 (2016)
REFERENCE   PMID:27889060 (gene)
  AUTHORS   Assoum M, Philippe C, Isidor B, Perrin L, Makrythanasis P, Sondheimer N, Paris C, Douglas J, Lesca G, Antonarakis S, Hamamy H, Jouan T, Duffourd Y, Auvin S, Saunier A, Begtrup A, Nowak C, Chatron N, Ville D, Mireskandari K, Milani P, Jonveaux P, Lemeur G, Milh M, Amamoto M, Kato M, Nakashima M, Miyake N, Matsumoto N, Masri A, Thauvin-Robinet C, Riviere JB, Faivre L, Thevenon J
  TITLE     Autosomal-Recessive Mutations in AP3B2, Adaptor-Related Protein Complex 3 Beta 2  Subunit, Cause an Early-Onset Epileptic Encephalopathy with Optic Atrophy.
  JOURNAL   Am J Hum Genet 99:1368-1376 (2016)
REFERENCE   PMID:27866705 (gene)
  AUTHORS   Han C, Alkhater R, Froukh T, Minassian AG, Galati M, Liu RH, Fotouhi M, Sommerfeld J, Alfrook AJ, Marshall C, Walker S, Bauer P, Scherer SW, Riess O, Buchert R, Minassian BA, McPherson PS
  TITLE     Epileptic Encephalopathy Caused by Mutations in the Guanine Nucleotide Exchange Factor DENND5A.
  JOURNAL   Am J Hum Genet 99:1359-1367 (2016)
REFERENCE   PMID:27989324 (gene)
  AUTHORS   Ait-El-Mkadem S, Dayem-Quere M, Gusic M, Chaussenot A, Bannwarth S, Francois B, Genin EC, Fragaki K, Volker-Touw CL, Vasnier C, Serre V, van Gassen KL, Lespinasse F, Richter S, Eisenhofer G, Rouzier C, Mochel F, De Saint-Martin A, Abi Warde MT, de Sain-van der Velde MG, Jans JJ, Amiel J, Avsec Z, Mertes C, Haack TB, Strom T, Meitinger T, Bonnen PE, Taylor RW, Gagneur J, van Hasselt PM, Rotig A, Delahodde A, Prokisch H, Fuchs SA, Paquis-Flucklinger V
  TITLE     Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy.
  JOURNAL   Am J Hum Genet 100:151-159 (2017)
///
ENTRY       H00607                      Disease
NAME        46,XY disorders of sex development (Disorders of gonadal development), including:
            Gonadal agenesis;
            Complete and partial gonadal dysgenesis;
            Testis regression;
            Ovotesticular DSD
DESCRIPTION 46,XY disorders of sex development (46,XY DSD) caused by impaired gonadal development includes gonadal agenesis, gonadal dysgenesis, testicular regression, and ovotesticular DSD. Absence of testicular determination results in gonadal agenesis/complete dysgenesis characterized by female external and internal genitalia but fail to develop secondary sexual characteristics, whereas incomplete testicular determination cause partial dysgenesis which show ambiguous genitalia. Testicular regression is part of the clinical spectrum of partial 46,XY gonadal dysgenesis. These forms of 46,XY DSD have been associated with mutations in several genes, and chromosome mosaicism is now recognized as one of the cause.
CATEGORY    Reproductive system disease
GENE        SRY (inactivating mutation) [HSA:6736] [KO:K09266]
            DHH (inactivating mutation) [HSA:50846] [KO:K11990]
            SF1 (inactivating mutation) [HSA:2516] [KO:K08560]
            WT1 [HSA:7490] [KO:K09234]
            WNT4 (duplication) [HSA:54361] [KO:K00408]
            ATRX (inactivating mutation) [HSA:546] [KO:K10779]
            DAX1 (duplication) [HSA:190] [KO:K08562]
            SOX9 (inactivating mutation) [HSA:6662] [KO:K18435] 
            DMRT1 (deletion) [HSA:1761] [KO:K19488]
            CBX2 (inactivating mutation) [HSA:84733] [KO:K11451]
            TSPYL1 (inactivating mutation) [HSA:7258] [KO:K11284]
            AKR1C2 (inactivating mutation) [HSA:1646] [KO:K00089]
            AKR1C4 (inactivating mutation) [HSA:1109] [KO:K00037]
            ZFPM2 (inactivating mutation) [HSA:23414] [KO:K17442]
DBLINKS     ICD-10: Q97.3 Q87.8 D56.0
            MeSH: D006061 D006059
            OMIM: 400044 233420 607080 612965 136680 194080 194072 301040 300018 114290 154230 613080 608800 614279 616067
REFERENCE   PMID:18279784 (description, gene)
  AUTHORS   Hughes IA
  TITLE     Disorders of sex development: a new definition and classification.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 22:119-34 (2008)
REFERENCE   PMID:18811725 (description, gene)
  AUTHORS   Mendonca BB, Domenice S, Arnhold IJ, Costa EM
  TITLE     46,XY disorders of sex development (DSD).
  JOURNAL   Clin Endocrinol (Oxf) 70:173-87 (2009)
REFERENCE   PMID:20301714 (description, gene)
  AUTHORS   Ostrer H
  TITLE     46,XY Disorder of Sex Development and 46,XY Complete Gonadal Dysgenesis
  JOURNAL   (1993)
REFERENCE   PMID:21397195 (description, gene)
  AUTHORS   Rey RA, Grinspon RP
  TITLE     Normal male sexual differentiation and aetiology of disorders of sex development.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 25:221-38 (2011)
REFERENCE   PMID:9890065 (description)
  AUTHORS   Berkovitz GD, Seeherunvong T
  TITLE     Abnormalities of gonadal differentiation.
  JOURNAL   Baillieres Clin Endocrinol Metab 12:133-42 (1998)
REFERENCE   PMID:16327292 (description)
  AUTHORS   Frimberger D, Gearhart JP
  TITLE     Ambiguous genitalia and intersex.
  JOURNAL   Urol Int 75:291-7 (2005)
REFERENCE   PMID:21802064 (gene)
  AUTHORS   Fluck CE, Meyer-Boni M, Pandey AV, Kempna P, Miller WL, Schoenle EJ, Biason-Lauber A
  TITLE     Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation.
  JOURNAL   Am J Hum Genet 89:201-18 (2011)
REFERENCE   PMID:24549039 (gene)
  AUTHORS   Bashamboo A, Brauner R, Bignon-Topalovic J, Lortat-Jacob S, Karageorgou V, Lourenco D, Guffanti A, McElreavey K
  TITLE     Mutations in the FOG2/ZFPM2 gene are associated with anomalies of human testis determination.
  JOURNAL   Hum Mol Genet 23:3657-65 (2014)
///
ENTRY       H00608                      Disease
NAME        46,XY disorders of sex development (Disorders in androgen synthesis or action), including:
            Congenital adrenal hyperplasias;
            Leydig cell hypoplasia;
            Androgen insensitivity syndrome (AIS)
DESCRIPTION 46,XY disorders of sex development (46,XY DSD) can be endocrine-related. Several enzymatic defects that result in insufficient production of testosterone have been reported. These androgen defects and impaired differentiation of Leydig cell, which secretes testosterone, can lead to ambiguous or completely feminized genitalia in 46,XY individuals. Furthermore, defective androgen action due to androgen receptor defects also cause feminization of 46,XY fetuses although they have normal levels of testosterone.
CATEGORY    Reproductive system disease
GENE        (AIS) AR [HSA:367] [KO:K08557]
            (Leydig) LHCGR [HSA:3973] [KO:K04248]
            STAR [HSA:6770] [KO:K16931]
            CYP11A1 [HSA:1583] [KO:K00498]
            CYP17 [HSA:1586] [KO:K00512]
            HSD3B2 [HSA:3284] [KO:K00070]
            HSD17B3 [HSA:3293] [KO:K10207]
            POR [HSA:5447] [KO:K00327]
            SRD5A2 [HSA:6716] [KO:K12344]
            DHCR7 [HSA:1717] [KO:K00213]
DBLINKS     ICD-10: E25.0 E34.5 Q56.1 Q87.1
            MeSH: D058490 D000312 C562567 D013734
            OMIM: 300068 312300 201710 238320 202110 201810 264300 201750 264600 270400 613743
REFERENCE   PMID:18279784 (description, gene)
  AUTHORS   Hughes IA
  TITLE     Disorders of sex development: a new definition and classification.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 22:119-34 (2008)
REFERENCE   PMID:18811725 (description, gene)
  AUTHORS   Mendonca BB, Domenice S, Arnhold IJ, Costa EM
  TITLE     46,XY disorders of sex development (DSD).
  JOURNAL   Clin Endocrinol (Oxf) 70:173-87 (2009)
REFERENCE   PMID:20301714 (description, gene)
  AUTHORS   Ostrer H
  TITLE     46,XY Disorder of Sex Development and 46,XY Complete Gonadal Dysgenesis
  JOURNAL   (1993)
REFERENCE   PMID:21397195 (description, gene)
  AUTHORS   Rey RA, Grinspon RP
  TITLE     Normal male sexual differentiation and aetiology of disorders of sex development.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 25:221-38 (2011)
REFERENCE   PMID:16327292 (description)
  AUTHORS   Frimberger D, Gearhart JP
  TITLE     Ambiguous genitalia and intersex.
  JOURNAL   Urol Int 75:291-7 (2005)
///
ENTRY       H00609                      Disease
NAME        46,XY disorders of sex development (Other), including:
            Persistent Mullerian duct syndrome;
            Hypospadias;
            Cryptorchidism
DESCRIPTION 46,XY disorders of sex development (46,XY DSD) with other various causes includes persistent Mullerian duct syndrome, hypospadias, and cryptorchidism. During embryogenesis, regression of the Mullerian duct is induced by anti-Mullerian hormone (AMH) in normal 46,XY individuals. In perisitent Mullerian duct syndrome, mutations of the AMH and AMH receptor produce persistence of the uterus and Fallopian tubes in males. Hypospadias is a congenital malformation with ectopic opening of the urethral meatus. Compromised androgen effects can cause this malformation. Cryptorchidism, or undescended testes, is a condition controlled by AMH and insulin-like hormone 3.
CATEGORY    Reproductive system disease
GENE        (Mullerian) AMH [HSA:268] [KO:K04665]
            (Mullerian) AMHR2 [HSA:269] [KO:K04672]
            (Hypospadias) AR [HSA:367] [KO:K08557]
            (Hypospadias) MAMLD1 [HSA:10046] [KO:K19512]
            (Cryptorchidism) INSL3 [HSA:3640] [KO:K05255]
            (Cryptorchidism) GREAT [HSA:122042] [KO:K04307]
DBLINKS     ICD-10: Q55.8 Q54.8
            MeSH: D058490 C536665
            OMIM: 261550 300633 300758 219050
REFERENCE   PMID:18279784 (description, gene)
  AUTHORS   Hughes IA
  TITLE     Disorders of sex development: a new definition and classification.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 22:119-34 (2008)
REFERENCE   PMID:18811725 (description, gene)
  AUTHORS   Mendonca BB, Domenice S, Arnhold IJ, Costa EM
  TITLE     46,XY disorders of sex development (DSD).
  JOURNAL   Clin Endocrinol (Oxf) 70:173-87 (2009)
REFERENCE   PMID:15878900 (description, gene)
  AUTHORS   Josso N, Belville C, di Clemente N, Picard JY
  TITLE     AMH and AMH receptor defects in persistent Mullerian duct syndrome.
  JOURNAL   Hum Reprod Update 11:351-6 (2005)
REFERENCE   PMID:21256920 (description, gene)
  AUTHORS   Kalfa N, Philibert P, Baskin LS, Sultan C
  TITLE     Hypospadias: interactions between environment and genetics.
  JOURNAL   Mol Cell Endocrinol 335:89-95 (2011)
REFERENCE   PMID:20920735 (description, gene)
  AUTHORS   Thorup J, McLachlan R, Cortes D, Nation TR, Balic A, Southwell BR, Hutson JM
  TITLE     What is new in cryptorchidism and hypospadias--a critical review on the testicular dysgenesis hypothesis.
  JOURNAL   J Pediatr Surg 45:2074-86 (2010)
///
ENTRY       H00610                      Disease
NAME        Treacher Collins syndrome
DESCRIPTION Treacher Collins syndrome (TCS) is a rare congenital birth disorder characterized by severe craniofacial defects. Autosomal dominant TCS1 and TCS2 are caused by mutations in the TCOF1 and POLR1D genes, respectively. Autosomal recessive TCS3 is caused by mutations in the POLR1C gene. The majority of TCS cases are caused by a mutation in TCOF1 gene which encodes a putative nucleolar phosphoprotein known as treacle. It has suggested that treacle is involved in the production of ribosomal RNA within cells. POLR1C and POLR1D encode subunits present in RNA polymerase I and III. Both of these polymerases are involved in ribosomal RNA transcription.
CATEGORY    Congenital disorder of development; Ribosomopathy
GENE        (TCS1) TCOF1 [HSA:6949] [KO:K14562]
            (TCS2) POLR1D [HSA:9533] [KO:K03027]
            (TCS3) POLR1C [HSA:51082] [KO:K03020]
DBLINKS     ICD-10: Q75.4
            MeSH: D008342
            OMIM: 154500 613717 248390
REFERENCE   PMID:20174677
  AUTHORS   Freed EF, Bleichert F, Dutca LM, Baserga SJ
  TITLE     When ribosomes go bad: diseases of ribosome biogenesis.
  JOURNAL   Mol Biosyst 6:481-93 (2010)
REFERENCE   PMID:19027870
  AUTHORS   Sakai D, Trainor PA
  TITLE     Treacher Collins syndrome: unmasking the role of Tcof1/treacle.
  JOURNAL   Int J Biochem Cell Biol 41:1229-32 (2009)
REFERENCE   PMID:15930015
  AUTHORS   Gonzales B, Henning D, So RB, Dixon J, Dixon MJ, Valdez BC
  TITLE     The Treacher Collins syndrome (TCOF1) gene product is involved in pre-rRNA methylation.
  JOURNAL   Hum Mol Genet 14:2035-43 (2005)
REFERENCE   PMID:21131976
  AUTHORS   Dauwerse JG, Dixon J, Seland S, Ruivenkamp CA, van Haeringen A, Hoefsloot LH, Peters DJ, Boers AC, Daumer-Haas C, Maiwald R, Zweier C, Kerr B, Cobo AM, Toral JF, Hoogeboom AJ, Lohmann DR, Hehr U, Dixon MJ, Breuning MH, Wieczorek D
  TITLE     Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher  Collins syndrome.
  JOURNAL   Nat Genet 43:20-2 (2011)
///
ENTRY       H00611                      Disease
NAME        IRF6-related disorders, including:
            Popliteal pterygium syndrome (PPS);
            Van der Woude syndrome (VWS)
DESCRIPTION Popliteal pterygium syndrome (PPS) and Van der Woude syndrome (VWS) are autosomal dominant orofacial cleft syndromes caused by IRF6 mutations. Clinical manifestations of PPS include cleft lip and/or palate in association with webcausing popliteal connective tissue, syndactyly, and genital abnormalities. VWS shows milder phenotype in which individials with this disorder are born with a cleft lip and cleft palate.
CATEGORY    Developmental disorder
GENE        IRF6 [HSA:3664] [KO:K10154]
COMMENT     Isolated orofacial clefts are described in H00516.
DBLINKS     ICD-10: Q38.0 Q68.2 Q87.2
            MeSH: C562509 C536528
            OMIM: 119500 119300
REFERENCE   PMID:20803643 (description, gene)
  AUTHORS   Matsuzawa N, Kondo S, Shimozato K, Nagao T, Nakano M, Tsuda M, Hirano A, Niikawa N, Yoshiura K
  TITLE     Two missense mutations of the IRF6 gene in two Japanese families with popliteal pterygium syndrome.
  JOURNAL   Am J Med Genet A 152A:2262-7 (2010)
REFERENCE   PMID:20301581 (description, gene)
  AUTHORS   Durda KM, Schutte BC, Murray JC
  TITLE     IRF6-Related Disorders
  JOURNAL   (1993)
///
ENTRY       H00612                      Disease
NAME        Primary open angle glaucoma
DESCRIPTION Primary open angle glaucoma (POAG) is the most prevalent form of glaucoma, and a major cause of irreversible blindness. POAG is often accompanied by ocular hypertension and characterized by progressive loss of retinal ganglion cells, atrophy of the optic nerve, and visual field loss. To date, at least 20 genetic loci for POAG have been reported. And four causative genes (CYP1B1, MYOC, OPTN, and WDR36) are identified from these loci. In addition, recently, heterozygous NTF4 mutation was associated with the phenotype in a small percentage of patients.
CATEGORY    Nervous system disease; Eye disease
GENE        (GLC1A) MYOC [HSA:4653]
            (GLC1A) CYP1B1 [HSA:1545] [KO:K07410]
            (GLC1E) OPTN [HSA:10133] [KO:K19946]
            (GLC1G) WDR36 [HSA:134430] [KO:K14554]
            (GLC1O) NTF4 [HSA:4909] [KO:K12457]
DRUG        Acetazolamide [DG:DG01134]
            Betaxolol [DG:DG00315]
            Brinzolamide [DR:D00652]
            Bunazosin [DG:DG01316]
            Carteolol [DG:DG00308]
            Distigmine [DR:D01228]
            Dorzolamide [DG:DG01135]
            Isopropyl unoprostone [DG:DG01139]
            Isosorbide [DR:D00347]
            Latanoprost [DR:D00356]
            Levobunolol [DG:DG01136]
            Nipradilol [DR:D01691]
            Pilocarpine [DG:DG00992]
            Timolol maleate [DG:DG00306]
            Travoprost [DR:D01964]
COMMENT     GLC1G is a ribosome biogenesis disorder.
DBLINKS     ICD-10: H40.1
            MeSH: C564234 C567753
            OMIM: 137750 137760 609887 613100
REFERENCE   PMID:21655191
  AUTHORS   Carbone MA, Chen Y, Hughes GA, Weinreb RN, Zabriskie NA, Zhang K, Anholt RR
  TITLE     Genes of the unfolded protein response pathway harbor risk alleles for primary open angle glaucoma.
  JOURNAL   PLoS One 6:e20649 (2011)
REFERENCE   PMID:16332362
  AUTHORS   Fan BJ, Wang DY, Lam DS, Pang CP
  TITLE     Gene mapping for primary open angle glaucoma.
  JOURNAL   Clin Biochem 39:249-58 (2006)
REFERENCE   PMID:21730848
  AUTHORS   Khan AO
  TITLE     Genetics of primary glaucoma.
  JOURNAL   Curr Opin Ophthalmol 22:347-55 (2011)
REFERENCE   PMID:20431268
  AUTHORS   Fuse N
  TITLE     Genetic bases for glaucoma.
  JOURNAL   Tohoku J Exp Med 221:1-10 (2010)
REFERENCE   PMID:20174677
  AUTHORS   Freed EF, Bleichert F, Dutca LM, Baserga SJ
  TITLE     When ribosomes go bad: diseases of ribosome biogenesis.
  JOURNAL   Mol Biosyst 6:481-93 (2010)
///
ENTRY       H00613                      Disease
NAME        Infantile cortical hyperostosis;
            Caffey disease
DESCRIPTION Infantile cortical hyperostosis (ICH) is a self-limiting inflammatory disease characterized by swelling of soft tissues and periosteal hyperostosis mainly affecting long bones, mandible, clavicles, and ribs. It usually affects infants less than 6 months of age and spontaneously heals in the first year of life. However severe prenatal form of ICH is lethal in which extensive hyperostosis affects nearly all long bones and the fetus presents with polyhydramnios.
CATEGORY    Skeletal dysplasia
GENE        COL1A1 [HSA:1277] [KO:K06236]
DBLINKS     ICD-10: M89.8
            MeSH: D006958
            OMIM: 114000
REFERENCE   PMID:18848116 (description, gene)
  AUTHORS   Kamoun-Goldrat A, le Merrer M
  TITLE     Infantile cortical hyperostosis (Caffey disease): a review.
  JOURNAL   J Oral Maxillofac Surg 66:2145-50 (2008)
REFERENCE   PMID:18553566 (description, gene)
  AUTHORS   Kamoun-Goldrat A, Martinovic J, Saada J, Sonigo-Cohen P, Razavi F, Munnich A, Le Merrer M
  TITLE     Prenatal cortical hyperostosis with COL1A1 gene mutation.
  JOURNAL   Am J Med Genet A 146A:1820-4 (2008)
REFERENCE   PMID:21567126 (description, gene)
  AUTHORS   Cerruti-Mainardi P, Venturi G, Spunton M, Favaron E, Zignani M, Provera S, Dallapiccola B
  TITLE     Infantile cortical hyperostosis and COL1A1 mutation in four generations.
  JOURNAL   Eur J Pediatr (2011)
///
ENTRY       H00614                      Disease
NAME        Infantile systemic hyalinosis and juvenile hyaline fibromatosis
DESCRIPTION Infantile systemic hyalinosis (ISH) and juvenile hyaline fibromatosis (JHF) are autosomal recessive diseases with considerable overlapping. Abnormal accumulation of an unidentified hyaline material in body tissues can lead to joint contractures, osteopenia, thickened skin with hyperpigmentation, gingival hypertrophy, and diarrhea in ISH. JHF is a milder form with a later onset.
CATEGORY    Skin and connective tissue disease; Skeletal dysplasia
GENE        CMG2 [HSA:118429] [KO:K20909]
DBLINKS     ICD-10: M72.9
            MeSH: D057770
            OMIM: 228600
REFERENCE   PMID:18222328 (gene, description)
  AUTHORS   Lindvall LE, Kormeili T, Chen E, Ramirez MC, Grum-Tokars V, Glucksman MJ, Martignetti JA, Zaragoza MV, Dyson SW
  TITLE     Infantile systemic hyalinosis: Case report and review of the literature.
  JOURNAL   J Am Acad Dermatol 58:303-7 (2008)
REFERENCE   PMID:20301698 (gene, description)
  AUTHORS   Shieh JTC, Hoyme HE, Arbour LT
  TITLE     Hyalinosis, Inherited Systemic
  JOURNAL   (1993)
REFERENCE   PMID:21208784 (description)
  AUTHORS   Tzellos TG, Batzios SP, Dionyssopoulos A, Karakiulakis G, Papakonstantinou E
  TITLE     Differential expression of matrix metalloproteinases and proteoglycans in Juvenile Hyaline Fibromatosis.
  JOURNAL   J Dermatol Sci 61:94-100 (2011)
///
ENTRY       H00615                      Disease
NAME        Amelogenesis imperfecta
DESCRIPTION Amelogenesis imperfecta represents a heterogeneous group of inherited disorders characterized by very thin dental enamel. Defects in mineralization or matrix formation during tooth development lead to enamel hypoplasia and/or hypomineralization. Mutations in several tooth-specific genes are associated with the disease.
CATEGORY    Mouth and dental disease
GENE        (X-linked) AMELX [HSA:265]
            (autosomal dominant, recessive) ENAM [HSA:10117]
            (autosomal recessive) AMBN [HSA:258]
            (autosomal recessive) ACPT [HSA:93650] [KO:K19284]
            (autosomal dominant) FAM83H [HSA:286077]
            (autosomal recessive) KLK4 [HSA:9622] [KO:K08666]
            (autosomal recessive) MMP20 [HSA:9313] [KO:K07999]
            (autosomal recessive) WDR72 [HSA:256764]
            (autosomal recessive) C4orf26 [HSA:152816]
            (autosomal recessive) GPR68 [HSA:8111] [KO:K08408]
            (autosomal recessive) SLC24A4 [HSA:123041] [KO:K13752]
DBLINKS     ICD-10: K00.5
            MeSH: D000567
            OMIM: 301200 104500 616270 617297 130900 204650 204700 612529 613211 614832 617217 615887
REFERENCE   PMID:16304440 (description, gene)
  AUTHORS   Stephanopoulos G, Garefalaki ME, Lyroudia K
  TITLE     Genes and related proteins involved in amelogenesis imperfecta.
  JOURNAL   J Dent Res 84:1117-26 (2005)
REFERENCE   PMID:17408482 (description, gene)
  AUTHORS   Crawford PJ, Aldred M, Bloch-Zupan A
  TITLE     Amelogenesis imperfecta.
  JOURNAL   Orphanet J Rare Dis 2:17 (2007)
REFERENCE   PMID:3150442 (description)
  AUTHORS   Witkop CJ Jr
  TITLE     Amelogenesis imperfecta, dentinogenesis imperfecta and dentin dysplasia revisited: problems in classification.
  JOURNAL   J Oral Pathol 17:547-53 (1988)
REFERENCE   PMID:19853237
  AUTHORS   El-Sayed W, Parry DA, Shore RC, Ahmed M, Jafri H, Rashid Y, Al-Bahlani S, Al Harasi S, Kirkham J, Inglehearn CF, Mighell AJ
  TITLE     Mutations in the beta propeller WDR72 cause autosomal-recessive hypomaturation amelogenesis imperfecta.
  JOURNAL   Am J Hum Genet 85:699-705 (2009)
REFERENCE   PMID:18252228
  AUTHORS   Kim JW, Lee SK, Lee ZH, Park JC, Lee KE, Lee MH, Park JT, Seo BM, Hu JC, Simmer JP
  TITLE     FAM83H mutations in families with autosomal-dominant hypocalcified amelogenesis imperfecta.
  JOURNAL   Am J Hum Genet 82:489-94 (2008)
REFERENCE   PMID:22901946
  AUTHORS   Parry DA, Brookes SJ, Logan CV, Poulter JA, El-Sayed W, Al-Bahlani S, Al Harasi S, Sayed J, Raif el M, Shore RC, Dashash M, Barron M, Morgan JE, Carr IM, Taylor GR, Johnson CA, Aldred MJ, Dixon MJ, Wright JT, Kirkham J, Inglehearn CF, Mighell AJ
  TITLE     Mutations in C4orf26, encoding a peptide with in vitro hydroxyapatite crystal nucleation and growth activity, cause amelogenesis imperfecta.
  JOURNAL   Am J Hum Genet 91:565-71 (2012)
REFERENCE   PMID:24858907 (gene)
  AUTHORS   Poulter JA, Murillo G, Brookes SJ, Smith CE, Parry DA, Silva S, Kirkham J, Inglehearn CF, Mighell AJ
  TITLE     Deletion of ameloblastin exon 6 is associated with amelogenesis imperfecta.
  JOURNAL   Hum Mol Genet 23:5317-24 (2014)
REFERENCE   PMID:27693231 (gene)
  AUTHORS   Parry DA, Smith CE, El-Sayed W, Poulter JA, Shore RC, Logan CV, Mogi C, Sato K, Okajima F, Harada A, Zhang H, Koruyucu M, Seymen F, Hu JC, Simmer JP, Ahmed M, Jafri H, Johnson CA, Inglehearn CF, Mighell AJ
  TITLE     Mutations in the pH-Sensing G-protein-Coupled Receptor GPR68 Cause Amelogenesis Imperfecta.
  JOURNAL   Am J Hum Genet 99:984-990 (2016)
REFERENCE   PMID:27843125 (gene)
  AUTHORS   Seymen F, Kim YJ, Lee YJ, Kang J, Kim TH, Choi H, Koruyucu M, Kasimoglu Y, Tuna EB, Gencay K, Shin TJ, Hyun HK, Kim YJ, Lee SH, Lee ZH, Zhang H, Hu JC, Simmer JP, Cho ES, Kim JW
  TITLE     Recessive Mutations in ACPT, Encoding Testicular Acid Phosphatase, Cause Hypoplastic Amelogenesis Imperfecta.
  JOURNAL   Am J Hum Genet 99:1199-1205 (2016)
REFERENCE   PMID:23375655 (gene)
  AUTHORS   Parry DA, Poulter JA, Logan CV, Brookes SJ, Jafri H, Ferguson CH, Anwari BM, Rashid Y, Zhao H, Johnson CA, Inglehearn CF, Mighell AJ
  TITLE     Identification of mutations in SLC24A4, encoding a potassium-dependent sodium/calcium exchanger, as a cause of amelogenesis imperfecta.
  JOURNAL   Am J Hum Genet 92:307-12 (2013)
///
ENTRY       H00616                      Disease
NAME        Bowen-Conradi syndrome (BCS)
DESCRIPTION Bowen-Conradi syndrome (BCS) is an autosomal-recessive disorder characterized by severely impaired prenatal and postnatal growth, profound psychomotor retardation. Most patients do not survive beyond the first year of life, as a result of complications associated with reduced mobility and failure to thrive. Recently, a missense mutation in EMG1 was reported to be the cause of BCS. EMG1 is a putative methyltransferase that is required for biogenesis of the 40S subunit of the ribosome.
CATEGORY    Congenital disorder of development; Ribosomopathy
GENE        EMG1 [HSA:10436] [KO:K14568]
DBLINKS     ICD-10: Q02
            MeSH: C537081
            OMIM: 211180
REFERENCE   PMID:19463982
  AUTHORS   Armistead J, Khatkar S, Meyer B, Mark BL, Patel N, Coghlan G, Lamont RE, Liu S, Wiechert J, Cattini PA, Koetter P, Wrogemann K, Greenberg CR, Entian KD, Zelinski T, Triggs-Raine B
  TITLE     Mutation of a gene essential for ribosome biogenesis, EMG1, causes Bowen-Conradi  syndrome.
  JOURNAL   Am J Hum Genet 84:728-39 (2009)
REFERENCE   PMID:20174677
  AUTHORS   Freed EF, Bleichert F, Dutca LM, Baserga SJ
  TITLE     When ribosomes go bad: diseases of ribosome biogenesis.
  JOURNAL   Mol Biosyst 6:481-93 (2010)
///
ENTRY       H00617                      Disease
NAME        Desmosterolosis
DESCRIPTION Desmosterolosis is a very rare disorder of cholesterol biosynthesis. Multiple congenital malformations including developmental delay, brain malformations, skeletal anomalies, and facial deformities are caused by impaired cholesterol synthesis due to mutations in the enzyme 24-dehydrocholesterol reductase (DHCR24).
CATEGORY    Developmental disorder
GENE        DHCR24 [HSA:1718] [KO:K09828]
MARKER      elevated levels of the plasma desmosterol [CPD:C01802]
DBLINKS     ICD-10: Q87.8
            MeSH: C566555
            OMIM: 602398
REFERENCE   PMID:21671375 (description, gene)
  AUTHORS   Schaaf CP, Koster J, Katsonis P, Kratz L, Shchelochkov OA, Scaglia F, Kelley RI, Lichtarge O, Waterham HR, Shinawi M
  TITLE     Desmosterolosis-phenotypic and molecular characterization of a third case and review of the literature.
  JOURNAL   Am J Med Genet A 155A:1597-604 (2011)
REFERENCE   PMID:9450875 (description, gene)
  AUTHORS   FitzPatrick DR, Keeling JW, Evans MJ, Kan AE, Bell JE, Porteous ME, Mills K, Winter RM, Clayton PT
  TITLE     Clinical phenotype of desmosterolosis.
  JOURNAL   Am J Med Genet 75:145-52 (1998)
REFERENCE   PMID:12457401 (description, gene)
  AUTHORS   Andersson HC, Kratz L, Kelley R
  TITLE     Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay.
  JOURNAL   Am J Med Genet 113:315-9 (2002)
///
ENTRY       H00618                      Disease
NAME        Amelogenesis imperfecta hypoplastic-hypomaturation with taurodontism (AIHHT)
DESCRIPTION Amelogenesis imperfecta hypoplastic-hypomaturation with taurodontism (AIHHT) is a condition characterized by enamel defects and enlarged pulp chambers. Unlike its allelic disorder trichodentoosseous dysplasia, AIHHT patients do not show hair and bone abnormalities. AIHHT is an autosomal dominant trait.
CATEGORY    Mouth and dental disease
GENE        DLX3 [HSA:1747] [KO:K09315]
COMMENT     Amelogenesis imperfecta and trichodentoosseous dysplasia are described in H00615 and H00487, respectively.
DBLINKS     MeSH: C566293
            OMIM: 104510
REFERENCE   PMID:16304440 (description, gene)
  AUTHORS   Stephanopoulos G, Garefalaki ME, Lyroudia K
  TITLE     Genes and related proteins involved in amelogenesis imperfecta.
  JOURNAL   J Dent Res 84:1117-26 (2005)
REFERENCE   PMID:17408482 (description, gene)
  AUTHORS   Crawford PJ, Aldred M, Bloch-Zupan A
  TITLE     Amelogenesis imperfecta.
  JOURNAL   Orphanet J Rare Dis 2:17 (2007)
REFERENCE   PMID:17552940 (description, gene)
  AUTHORS   Hu JC, Simmer JP
  TITLE     Developmental biology and genetics of dental malformations.
  JOURNAL   Orthod Craniofac Res 10:45-52 (2007)
REFERENCE   PMID:15666299 (gene)
  AUTHORS   Dong J, Amor D, Aldred MJ, Gu T, Escamilla M, MacDougall M
  TITLE     DLX3 mutation associated with autosomal dominant amelogenesis imperfecta with taurodontism.
  JOURNAL   Am J Med Genet A 133A:138-41 (2005)
///
ENTRY       H00619                      Disease
NAME        Kenny-Caffey syndrome
DESCRIPTION Kenny-Caffey syndrome (KCS) is a rare hereditary bone dysplasia characterized by osteosclerosis with medullary stenosis of long bones with hypocalcemia and ocular abnormalities. Recurrent bacterial infections are common in patients with KCS. KCS is mostly inherited as an autosomal dominant trait. Autosomal recessive cases have mutations in TBCE gene that encodes chaperone proteins of tubulins.
CATEGORY    Skeletal dysplasia
GENE        TBCE [HSA:6905]
DBLINKS     MeSH: C537020
            OMIM: 244460
REFERENCE   PMID:9806825 (description)
  AUTHORS   Diaz GA, Khan KT, Gelb BD
  TITLE     The autosomal recessive Kenny-Caffey syndrome locus maps to chromosome 1q42-q43.
  JOURNAL   Genomics 54:13-8 (1998)
REFERENCE   PMID:12389028 (gene)
  AUTHORS   Parvari R, Hershkovitz E, Grossman N, Gorodischer R, Loeys B, Zecic A, Mortier G, Gregory S, Sharony R, Kambouris M, Sakati N, Meyer BF, Al Aqeel AI, Al Humaidan AK, Al Zanhrani F, Al Swaid A, Al Othman J, Diaz GA, Weiner R, Khan KT, Gordon R, Gelb BD
  TITLE     Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal  recessive Kenny-Caffey syndrome.
  JOURNAL   Nat Genet 32:448-52 (2002)
///
ENTRY       H00620                      Disease
NAME        Axenfeld-Rieger syndrome (ARS)
DESCRIPTION Axenfeld-Rieger syndrome (ARS) is a rare autosomal dominant disorder mainly affecting the anterior segment of the eyes congenitally. The ocular features include malformations of aniridia, coloboma of the iris, and ectopic pupils. Open-angle glaucoma can lead to blindness and is the main target of treatment in ARS. Defects in other organ systems, typically the craniofacial, dental, and umbilical abnormalities, are also part of the disorder.
CATEGORY    Developmental disorder; Eye disease
GENE        PITX2 [HSA:5308] [KO:K04686]
            FOXC1 [HSA:2296] [KO:K09396]
COMMENT     For open-angle glaucoma, see H00612.
DBLINKS     ICD-10: Q13.8
            MeSH: C535679
            OMIM: 180500 602482
REFERENCE   PMID:16274491 (description, gene)
  AUTHORS   Hjalt TA, Semina EV
  TITLE     Current molecular understanding of Axenfeld-Rieger syndrome.
  JOURNAL   Expert Rev Mol Med 7:1-17 (2005)
REFERENCE   PMID:19513095 (description, gene)
  AUTHORS   Tumer Z, Bach-Holm D
  TITLE     Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations.
  JOURNAL   Eur J Hum Genet 17:1527-39 (2009)
REFERENCE   PMID:20831741 (description, gene)
  AUTHORS   Waldron JM, McNamara C, Hewson AR, McNamara CM
  TITLE     Axenfeld-Rieger syndrome (ARS): A review and case report.
  JOURNAL   Spec Care Dentist 30:218-22 (2010)
///
ENTRY       H00621                      Disease
NAME        Alopecia neurologic defects and endocrinopathy syndrome (ANE syndrome)
DESCRIPTION Alopecia neurological defects and endocrinopathy syndrome (ANE syndrome) is an autosomal recessive disease that is clinically heterogeneous. ANE syndrome patients display multiple signs including a varied amount of hair loss, mental retardation, progressive loss of motor ability beginning in the second decade of life, hypogonadism, central adrenal insufficiency, short stature, microcephaly, and several other skeletal and skin abnormalities. The syndrome is caused by decreased expression of the nucleolar protein RBM28, known to be required for biogenesis of the 60S subunit of the ribosome.
CATEGORY    Endocrine disease; Ribosomopathy
GENE        RBM28 [HSA:55131] [KO:K14573]
DBLINKS     MeSH: C567425
            OMIM: 612079
REFERENCE   PMID:18439547
  AUTHORS   Nousbeck J, Spiegel R, Ishida-Yamamoto A, Indelman M, Shani-Adir A, Adir N, Lipkin E, Bercovici S, Geiger D, van Steensel MA, Steijlen PM, Bergman R, Bindereif A, Choder M, Shalev S, Sprecher E
  TITLE     Alopecia, neurological defects, and endocrinopathy syndrome caused by decreased expression of RBM28, a nucleolar protein associated with ribosome biogenesis.
  JOURNAL   Am J Hum Genet 82:1114-21 (2008)
REFERENCE   PMID:20231366
  AUTHORS   Spiegel R, Shalev SA, Adawi A, Sprecher E, Tenenbaum-Rakover Y
  TITLE     ANE syndrome caused by mutated RBM28 gene: a novel etiology of combined pituitary hormone deficiency.
  JOURNAL   Eur J Endocrinol 162:1021-5 (2010)
REFERENCE   PMID:20174677
  AUTHORS   Freed EF, Bleichert F, Dutca LM, Baserga SJ
  TITLE     When ribosomes go bad: diseases of ribosome biogenesis.
  JOURNAL   Mol Biosyst 6:481-93 (2010)
///
ENTRY       H00622                      Disease
NAME        Hypoparathyroidism-retardation-dysmorphism syndrome;
            Sanjad-Sakati syndrome
DESCRIPTION Hypoparathyroidism-retardation-dysmorphism (HRD) syndrome is an autosomal recessively inherited condition reported in patients of Middle Eastern origin. It is characterized by permanent congenital hypocalcemia associated with hypoparathyroidism, prenatal and postnatal growth retardation, seizures, and facial anomalies. The dysmorphic features include deep-set eyes, depressed nasal bridge, thin upper lip, and ear anomalies.
CATEGORY    Developmental disorder
GENE        TBCE [HSA:6905]
DBLINKS     ICD-10: Q87.0
            MeSH: C537157
            OMIM: 241410
REFERENCE   PMID:12389028 (gene)
  AUTHORS   Parvari R, Hershkovitz E, Grossman N, Gorodischer R, Loeys B, Zecic A, Mortier G, Gregory S, Sharony R, Kambouris M, Sakati N, Meyer BF, Al Aqeel AI, Al Humaidan AK, Al Zanhrani F, Al Swaid A, Al Othman J, Diaz GA, Weiner R, Khan KT, Gordon R, Gelb BD
  TITLE     Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal  recessive Kenny-Caffey syndrome.
  JOURNAL   Nat Genet 32:448-52 (2002)
REFERENCE   PMID:16470743 (gene, description)
  AUTHORS   Courtens W, Wuyts W, Poot M, Szuhai K, Wauters J, Reyniers E, Eleveld M, Diaz G, Nothen MM, Parvari R
  TITLE     Hypoparathyroidism-retardation-dysmorphism syndrome in a girl: A new variant not  caused by a TBCE mutation--clinical report and review.
  JOURNAL   Am J Med Genet A 140:611-7 (2006)
REFERENCE   PMID:15852474 (gene, description)
  AUTHORS   Al Tawil K, Shataiwi A, Mutair A, Eyaid W, Saif SA
  TITLE     Hypoparathyroidism-retardation-dysmorphism (HRD) syndrome in triplets.
  JOURNAL   Am J Med Genet A 135:200-1 (2005)
///
ENTRY       H00623                      Disease
NAME        Hajdu-Cheney syndrome
DESCRIPTION Hajdu-Cheney Syndrome is a rare connective tissue disorder characterized by acro-osteolysis, osteoporotic changes of the spine/long bones of extremities, and insufficient ossification of the skull. Disturbed notch pathway that plays a role in bone formation leads to these anomalies.
CATEGORY    Skeletal dysplasia
GENE        NOTCH2 [HSA:4853] [KO:K20994]
DBLINKS     ICD-10: M89.5
            MeSH: D031845
            OMIM: 102500
REFERENCE   PMID:21681853 (gene)
  AUTHORS   Majewski J, Schwartzentruber JA, Caqueret A, Patry L, Marcadier J, Fryns JP, Boycott KM, Ste-Marie LG, McKiernan FE, Marik I, Van Esch H, Michaud JL, Samuels ME
  TITLE     Mutations in NOTCH2 in families with Hajdu-Cheney syndrome.
  JOURNAL   Hum Mutat 32:1114-7 (2011)
REFERENCE   PMID:21378989 (gene)
  AUTHORS   Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S, Martin-Coignard D, Thauvin-Robinet C, Le Merrer M, Mandel JL, David A, Faivre L, Cormier-Daire V, Redon R, Le Caignec C
  TITLE     Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis.
  JOURNAL   Nat Genet 43:306-8 (2011)
REFERENCE   PMID:11343321 (description)
  AUTHORS   Brennan AM, Pauli RM
  TITLE     Hajdu--Cheney syndrome: evolution of phenotype and clinical problems.
  JOURNAL   Am J Med Genet 100:292-310 (2001)
///
ENTRY       H00624                      Disease
NAME        Familial cholestasis, including:
            Progressive familial intrahepatic cholestasis (PFIC);
            Benign recurrent intrahepatic cholestasis (BRIC);
            Intrahepatic cholestasis of pregnancy (ICP);
            North American Indian childhood cirrhosis (NAIC)
DESCRIPTION Familial intrahepatic cholestasis is a heterogeneous group of autosomal recessive liver disorders characterized by intrahepatic cholestasis, which can be divided in three main groups based on phenotypical differences: progressive familial intrahepatic cholestasis (PFIC), benign recurrent intrahepatic cholestasis (BRIC) and intrahepatic cholestasis of pregnancy (ICP). PFIC type 1, 2 and 3 are due to mutations in ATP8B1, ABCB11 and ABCB4, respectively. Each of these genes encodes a hepatocanalicular transporter, which is essential for the proper formation of bile. Mutations in ATP8B1 and ABCB11 can also result in the less severe phenotype of BRIC type 1 and 2, respectively, while heterozygous mutations in all three genes are associated with ICP. PFIC type 4 is caused by mutations in HSD3B7,and also known as congenital bile acid synthesis defect type 1. North American Indian childhood cirrhosis (NAIC) is a distinct, rapidly evolving form of familial cholestasis found in aboriginal children from northwestern Quebec. It has reported that a missense mutation in Cirhin causes NAIC. Cirhin/UTP4 is known to be required for ribosome biogenesis.
CATEGORY    Inherited metabolic disease; Liver disease
GENE        (PFIC1/BRIC1/ICP) ATP8B1 [HSA:5205] [KO:K01530]
            (PFIC2/BRIC2/ICP) ABCB11 [HSA:8647] [KO:K05664]
            (PFIC3/ICP) ABCB4 [HSA:5244] [KO:K05659]
            (PFIC4) HSD3B7 [HSA:80270] [KO:K12408]
            (NAIC) CIRH1A [HSA:84916] [KO:K14548]
MARKER      (Common) Elevated serum bile salts
            (ATP8B1 deficiency) Coarse granular bile (electron microscopy)
            (ABCB11 deficiency) Filamentous bile (electron microscopy), Giant cell hepatitis
            (ABCB4 deficiency) Elevated serum gamma-glutamyl transpeptidase, Ductular proliferation
DRUG        Rifampicin [DR:D00211]
            Cholestyramine [DR:D02690]
            Ursodeoxycholic acid [DR:D00734]
DBLINKS     ICD-10: K83.1
            MeSH: D002779
            OMIM: 211600 601847 602347 607765 243300 605479 147480 604901
REFERENCE   PMID:20955958
  AUTHORS   van der Woerd WL, van Mil SW, Stapelbroek JM, Klomp LW, van de Graaf SF, Houwen RH
  TITLE     Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy.
  JOURNAL   Best Pract Res Clin Gastroenterol 24:541-53 (2010)
REFERENCE   PMID:14708891
  AUTHORS   Jansen PL, Sturm E
  TITLE     Genetic cholestasis, causes and consequences for hepatobiliary transport.
  JOURNAL   Liver Int 23:315-22 (2003)
REFERENCE   PMID:11067870 (PFIC4)
  AUTHORS   Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW
  TITLE     The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis.
  JOURNAL   J Clin Invest 106:1175-84 (2000)
REFERENCE   PMID:21854363
  AUTHORS   Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sanchez Pozzi EJ
  TITLE     Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
  JOURNAL   Clin Sci (Lond) 121:523-44 (2011)
REFERENCE   PMID:12377823
  AUTHORS   Hofmann AF
  TITLE     Rifampicin and treatment of cholestatic pruritus.
  JOURNAL   Gut 51:756-7 (2002)
REFERENCE   PMID:12417987
  AUTHORS   Chagnon P, Michaud J, Mitchell G, Mercier J, Marion JF, Drouin E, Rasquin-Weber A, Hudson TJ, Richter A
  TITLE     A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis.
  JOURNAL   Am J Hum Genet 71:1443-9 (2002)
REFERENCE   PMID:11045837
  AUTHORS   Drouin E, Russo P, Tuchweber B, Mitchell G, Rasquin-Weber A
  TITLE     North American Indian cirrhosis in children: a review of 30 cases.
  JOURNAL   J Pediatr Gastroenterol Nutr 31:395-404 (2000)
///
ENTRY       H00625                      Disease
NAME        Tooth agenesis;
            Hypodontia
DESCRIPTION Tooth agenesis, or hypodontia/origodontia, refers to the congenital absence of a few teeth without any systemic disorders. Tooth development is a complex process that involves interactions between the oral epithelium and an underlying mesenchyme. Perturbation of this process results in tooth agenesis. This disease could be inherited as either an autosomal dominant, autosomal recessive, or X-linked trait.
CATEGORY    Mouth and dental disease
GENE        MSX1 [HSA:4487] [KO:K09341]
            PAX9 [HSA:5083] [KO:K09382]
            AXIN2 [HSA:8313] [KO:K04385]
            LTBP3 [HSA:4054] [KO:K08023]
            EDA [HSA:1896] [KO:K05480]
DBLINKS     MeSH: D000848
            OMIM: 106600 604625 613097 313500
REFERENCE   PMID:17552940 (description, gene)
  AUTHORS   Hu JC, Simmer JP
  TITLE     Developmental biology and genetics of dental malformations.
  JOURNAL   Orthod Craniofac Res 10:45-52 (2007)
REFERENCE   PMID:21911943 (description, gene)
  AUTHORS   Pani SC
  TITLE     The genetic basis of tooth agenesis: basic concepts and genes involved.
  JOURNAL   J Indian Soc Pedod Prev Dent 29:84-9 (2011)
REFERENCE   PMID:19344874 (gene)
  AUTHORS   Noor A, Windpassinger C, Vitcu I, Orlic M, Rafiq MA, Khalid M, Malik MN, Ayub M, Alman B, Vincent JB
  TITLE     Oligodontia is caused by mutation in LTBP3, the gene encoding latent TGF-beta binding protein 3.
  JOURNAL   Am J Hum Genet 84:519-23 (2009)
///
ENTRY       H00626                      Disease
NAME        Focal segmental glomerulosclerosis
DESCRIPTION Focal segmental glomerulosclerosis (FSGS) is one of the most common forms of glomerular disorders leading to end stage kidney disease (ESKD). FSGS is defined as a clinicopathologic syndrome manifesting with high-grade proteinuria, associated with lesions of focal and segmental glomerular sclerosis and foot-process effacement. As the disease progresses, a more diffuse and global pattern of sclerosis evolves. FSGS accounts for 7-20 % of idiopathic nephrotic syndrome in children and 40 % in adults. There are two types of FSGS, primary (idiopathic) and secondary forms. The specific cause of primary FSGS has been ill-defined. Secondary FSGS is with recognized etiologic associations, including genetic mutations in podocyte-associated proteins, viruses, and drug toxicities. For the initial treatment of FSGS, corticosteroid and immunosuppressive therapy is recommended.
CATEGORY    Kidney disease
GENE        ACTN4 [HSA:81] [KO:K05699]
            TRPC6 [HSA:7225] [KO:K04969]
            CD2AP [HSA:23607] [KO:K13738]
            APOL1 [HSA:8542] [KO:K14480]
            INF2 [HSA:64423]
            NPHS1 [HSA:4868]
            PDCN [HSA:7827] [KO:K18268]
            WT1 [HSA:7490] [KO:K09234]
ENV_FACTOR  Heroin [DR: D07286 D07810]
            Interferon-alpha
            Lithium [DR:D00801 D04750]
            Pamidronate [DR:D00941]
PATHOGEN    Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Parvovirus B19
DRUG        Prednisolone [DR:D00472]
            Cyclosporine [DR:D00184]
            Cyclophosphamide [DR:D00287]
            Rituximab [DR:D02994]
COMMENT     Congenital nephrotic syndrome (NS) and focal segmental glomerulosclerosis (FSGS) form a spectrum of podocyte diseases. See also H01657 Nephrotic syndrome.
DBLINKS     ICD-10: N05.1
            MeSH: D005923
            OMIM: 603278 603965 607832 612551 613237 256300 600995
REFERENCE   PMID:26156092 (gene, env_factor, pathogen, drug)
  AUTHORS   Chen YM, Liapis H
  TITLE     Focal segmental glomerulosclerosis: molecular genetics and targeted therapies.
  JOURNAL   BMC Nephrol 16:101 (2015)
REFERENCE   PMID:27088082 (gene, env_factor, pathogen)
  AUTHORS   Kim JS, Han BG, Choi SO, Cha SK
  TITLE     Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.
  JOURNAL   Biomed Res Int 2016:1630365 (2016)
REFERENCE   PMID:19562370 (gene, description)
  AUTHORS   Lowik MM, Groenen PJ, Levtchenko EN, Monnens LA, van den Heuvel LP
  TITLE     Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis--a review.
  JOURNAL   Eur J Pediatr 168:1291-304 (2009)
REFERENCE   PMID:14750104 (gene)
  AUTHORS   D'Agati VD, Fogo AB, Bruijn JA, Jennette JC
  TITLE     Pathologic classification of focal segmental glomerulosclerosis: a working proposal.
  JOURNAL   Am J Kidney Dis 43:368-82 (2004)
REFERENCE   PMID:15716334 (drug)
  AUTHORS   Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC
  TITLE     Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.
  JOURNAL   J Am Soc Nephrol 16:1061-8 (2005)
///
ENTRY       H00627                      Disease
NAME        Premature ovarian failure
DESCRIPTION Premature ovarian failure (POF) is characterized by amenorrhea before the age of 40 years with elevated levels of gonadotrophin (LH and FSH) and low levels of gonadal hormones (estrogens and inhibins). The causes of POF can be categorized into genetic and environmental mechanisms. X chromosome defects such as Turner syndrome or trisomy X as well as many genes including BMP15, FMR1, LHR, and FSHR are associated with POF development. For the environmental causes, medical intervention including surgeries and chemotherapies may lead to POF. Autoimmune ovarian failure consists another large category of POF.
CATEGORY    Reproductive system disease
GENE        BMP15 [HSA:9210] [KO:K05498]
            FMR1 [HSA:2332] [KO:K15516]
            FMR2 [HSA:2334] [KO:K15194]
            POF1B [HSA:79983]
            FOXL2 [HSA:668] [KO:K09405]
            LHR [HSA:3973] [KO:K04248]
            FSHR [HSA:2492] [KO:K04247] 
            INHA [HSA:3623] [KO:K05500]
            SF1 [HSA:2516] [KO:K08560]
            DIAPH2 [HSA:1730] [KO:K05741]
            FIGLA [HSA:344018] [KO:K09066]
            NOBOX [HSA:135935]
ENV_FACTOR  Autoimmune diseases
            Radiation
            Chemotherapy (alkylating agents)
            Surgery
            Mumps infection
            Galactosemia
COMMENT     For galactosemia, see H00070.
DBLINKS     ICD-10: E28.3
            MeSH: D016649
            OMIM: 311360 300510 300604 612964 608996 300511 612310 611548
REFERENCE   PMID:16722528 (description, gene)
  AUTHORS   Beck-Peccoz P, Persani L
  TITLE     Premature ovarian failure.
  JOURNAL   Orphanet J Rare Dis 1:9 (2006)
REFERENCE   PMID:21188402 (description, gene)
  AUTHORS   Cordts EB, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP
  TITLE     Genetic aspects of premature ovarian failure: a literature review.
  JOURNAL   Arch Gynecol Obstet 283:635-43 (2011)
REFERENCE   PMID:8591112 (env_factor)
  AUTHORS   Kim JG, Moon SY, Chang YS, Lee JY
  TITLE     Autoimmune premature ovarian failure.
  JOURNAL   J Obstet Gynaecol (Tokyo 1995) 21:59-66 (1995)
REFERENCE   PMID:8243411 (env_factor)
  AUTHORS   Vermeulen A
  TITLE     Environment, human reproduction, menopause, and andropause.
  JOURNAL   Environ Health Perspect 101 Suppl 2:91-100 (1993)
REFERENCE   PMID:11223362 (env_factor)
  AUTHORS   Santoro N
  TITLE     Research on the mechanisms of premature ovarian failure.
  JOURNAL   J Soc Gynecol Investig 8:S10-2 (2001)
REFERENCE   PMID:19465673 (description, gene)
  AUTHORS   Vujovic S
  TITLE     Aetiology of premature ovarian failure.
  JOURNAL   Menopause Int 15:72-5 (2009)
REFERENCE   PMID:9497258
  AUTHORS   Bione S, Sala C, Manzini C, Arrigo G, Zuffardi O, Banfi S, Borsani G, Jonveaux P, Philippe C, Zuccotti M, Ballabio A, Toniolo D
  TITLE     A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in  a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility.
  JOURNAL   Am J Hum Genet 62:533-41 (1998)
REFERENCE   PMID:18499083
  AUTHORS   Zhao H, Chen ZJ, Qin Y, Shi Y, Wang S, Choi Y, Simpson JL, Rajkovic A
  TITLE     Transcription factor FIGLA is mutated in patients with premature ovarian failure.
  JOURNAL   Am J Hum Genet 82:1342-8 (2008)
REFERENCE   PMID:17701902
  AUTHORS   Qin Y, Choi Y, Zhao H, Simpson JL, Chen ZJ, Rajkovic A
  TITLE     NOBOX homeobox mutation causes premature ovarian failure.
  JOURNAL   Am J Hum Genet 81:576-81 (2007)
///
ENTRY       H00628                      Disease
NAME        Congenital bile acid synthesis defect (CBAS), including:
            3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency (CBAS1);
            Delta(4)-3-oxosteroid 5-beta-reductase deficiency (CBAS2);
            Oxysterol 7-alpha-hydroxylase deficiency (CBAS3);
            Alpha-methylacyl-CoA racemase deficiency (CBAS4)
DESCRIPTION Congenital bile acid synthesis defects (CBAS) involve congenital deficiencies in enzymes responsible for catalyzing key reactions in bile acid synthesis. CBAS type 1, 2 ,3  and 4 are due to mutations in HSD3B7, AKR1D1, CYP7B1, and AMACR, respectively. Inherited mutations that impair bile acid synthesis cause a spectrum of human disease ranging from liver failure in early childhood to progressive neuropathy in adults.
CATEGORY    Inherited metabolic disease; Liver disease
GENE        (CBAS1) HSD3B7 [HSA:80270] [KO:K12408]
            (CBAS2) AKR1D1 [HSA:6718] [KO:K00251]
            (CBAS3) CYP7B1 [HSA:9420] [KO:K07430]
            (CBAS4) AMACR [HSA:23600] [KO:K01796]
            (CBAS5) ABCD3 [HSA:5825] [KO:K05677]
MARKER      (Common) Low level or absence of primary bile acids [CPD:C02528] [CPD:C00695]
            (CBAS1) Elevated monohydroxy bile acids
            (CBAS2) Elevated 3-oxo-delta4 bile acids and allo bile acids
            (CBAS3) Elevated dihydroxy and trihydroxy bile acids
            (CBAS4) Elevated C27 trihydroxycholestanoic and pristanic acid
DRUG        Chenodeoxycholic acid [DR:D00163]
COMMENT     Cerebrotendinous xanthomatosis [DS:H00151] and Zellweger syndrome [DS:H00205] are also involved disorders in bile acid synthesis.
DBLINKS     ICD-10: K76.8
            MeSH: C535442 C535443 C566340 C535444 C563673 C567703
            OMIM: 607765 235555 613812 214950 213700 616278
REFERENCE   PMID:18577977
  AUTHORS   Sundaram SS, Bove KE, Lovell MA, Sokol RJ
  TITLE     Mechanisms of disease: Inborn errors of bile acid synthesis.
  JOURNAL   Nat Clin Pract Gastroenterol Hepatol 5:456-68 (2008)
REFERENCE   PMID:15937079
  AUTHORS   van Mil SW, Houwen RH, Klomp LW
  TITLE     Genetics of familial intrahepatic cholestasis syndromes.
  JOURNAL   J Med Genet 42:449-63 (2005)
REFERENCE   PMID:25168382 (gene)
  AUTHORS   Ferdinandusse S, Jimenez-Sanchez G, Koster J, Denis S, Van Roermund CW, Silva-Zolezzi I, Moser AB, Visser WF, Gulluoglu M, Durmaz O, Demirkol M, Waterham HR, Gokcay G, Wanders RJ, Valle D
  TITLE     A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3.
  JOURNAL   Hum Mol Genet 24:361-70 (2015)
///
ENTRY       H00629                      Disease
NAME        Acheiropodia
DESCRIPTION Acheiropodia is an extremely rare, severe congenital malformation caused by LMBR1 deletion. Patients show malformed upper and lower extremities with amputation of distal limbs and aplasia of hands and feet. It is inherited as an autosomal recessive trait.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        LMBR1 (deletion) [HSA:64327]
DBLINKS     ICD-10: Q71.3 Q72.3
            MeSH: C536014
            OMIM: 200500
REFERENCE   PMID:11090342 (gene)
  AUTHORS   Ianakiev P, van Baren MJ, Daly MJ, Toledo SP, Cavalcanti MG, Neto JC, Silveira EL, Freire-Maia A, Heutink P, Kilpatrick MW, Tsipouras P
  TITLE     Acheiropodia is caused by a genomic deletion in C7orf2, the human orthologue of the Lmbr1 gene.
  JOURNAL   Am J Hum Genet 68:38-45 (2001)
REFERENCE   PMID:517582 (description)
  AUTHORS   Marcallo FA, Pilotto RF, Freire-Maia A
  TITLE     Genetics of acheiropodia ("the handless and footless families of Brazil"): XI. Pathologic aspects.
  JOURNAL   Am J Med Genet 4:287-91 (1979)
REFERENCE   PMID:7018242 (description)
  AUTHORS   Freire-Maia A
  TITLE     Historical note: the extraordinary handless and footless families of Brazil - 50  years of acheiropodia.
  JOURNAL   Am J Med Genet 9:31-41 (1981)
///
ENTRY       H00630                      Disease
NAME        Rheumatoid arthritis
DESCRIPTION Rheumatoid arthritis (RA) is a common autoimmune disease that primarily manifests as chronic inflammatory arthropathy. Persistent synovitis leads to cartilage destruction, bone erosions and periarticular decalcification, subsequently resulting in impaired joint function. It is more common between the ages of 35 and 50 years, affecting three times more women than men. Susceptibility to RA is genetically determined with multiple genes contributing. Inheritance of HLA DRB1 alleles encoding a distinctive five-amino-acid sequence known as the "shared epitope" (SE) is the best characterized genetic risk factor. The mechanism by which the SE alleles contribute to the development of RA is not very clear. It has been postulated that the presence of these conserved sequences in the antigen-binding groove alters the way antigenic peptides are bound to and presented to T-cell lymphocytes. This, in turn, may trigger abnormal immune responses and lead to RA.
CATEGORY    Autoimmune disease
DRUG        Prednisone [DR:D00473]
            Methotrexate [DR:D00142]
            Sulfasalazine [DR:D00448]
            Leflunomide [DR:D00749]
            Hydroxychloroquine sulfate [DR:D02114]
            Minocycline [DR:D05045]
            Tofacitinib [DR:D09970]
            Etanercept [DR:D00742]
            Infliximab [DR:D02598]
            Adalimumab [DR:D02597]
            Golimumab [DR:D04358]
            Certolizumab pegol [DR:D03441]
            Abatacept [DR:D03203]
            Rituximab [DR:D02994]
            Tocilizumab [DR:D02596]
DBLINKS     ICD-10: M05
            MeSH: D001172
REFERENCE   PMID:27338350 (gene, drug)
  AUTHORS   Chung IM, Ketharnathan S, Thiruvengadam M, Rajakumar G
  TITLE     Rheumatoid Arthritis: The Stride from Research to Clinical Practice.
  JOURNAL   Int J Mol Sci 17 (2016)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:23998731 (drug)
  AUTHORS   Meier FM, Frerix M, Hermann W, Muller-Ladner U
  TITLE     Current immunotherapy in rheumatoid arthritis.
  JOURNAL   Immunotherapy 5:955-74 (2013)
REFERENCE   PMID:22704962 (gene)
  AUTHORS   Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G
  TITLE     Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction.
  JOURNAL   J Autoimmun 39:222-8 (2012)
///
ENTRY       H00631                      Disease
NAME        Cornelia de Lange syndrome (CdLS)
DESCRIPTION Cornelia de Lange syndrome (CdLS) is a heterogeneous developmental disorder characterized by facial dysmorphia, upper limb defects, hirsutism, and gastrointestinal abnormalities. Mutations in the cohesion proteins NIPBL, SMC1A and SMC3 are present in CdLS patients.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        NIPBL [HSA:25836] [KO:K06672]
            SMC1A [HSA:8243] [KO:K06636]
            SMC3 [HSA:9126] [KO:K06669]
DBLINKS     ICD-10: Q87.1
            MeSH: D003635
            OMIM: 122470 300590 610759
REFERENCE   PMID:19793304 (gene, desription)
  AUTHORS   Liu J, Krantz ID
  TITLE     Cornelia de Lange syndrome, cohesin, and beyond.
  JOURNAL   Clin Genet 76:303-14 (2009)
REFERENCE   PMID:19842212 (gene)
  AUTHORS   Mannini L, Liu J, Krantz ID, Musio A
  TITLE     Spectrum and consequences of SMC1A mutations: the unexpected involvement of a core component of cohesin in human disease.
  JOURNAL   Hum Mutat 31:5-10 (2010)
REFERENCE   PMID:18996922 (gene)
  AUTHORS   Revenkova E, Focarelli ML, Susani L, Paulis M, Bassi MT, Mannini L, Frattini A, Delia D, Krantz I, Vezzoni P, Jessberger R, Musio A
  TITLE     Cornelia de Lange syndrome mutations in SMC1A or SMC3 affect binding to DNA.
  JOURNAL   Hum Mol Genet 18:418-27 (2009)
REFERENCE   PMID:20727427 (gene)
  AUTHORS   Ratajska M, Wierzba J, Pehlivan D, Xia Z, Brundage EK, Cheung SW, Stankiewicz P, Lupski JR, Limon J
  TITLE     Cornelia de Lange syndrome case due to genomic rearrangements including NIPBL.
  JOURNAL   Eur J Med Genet 53:378-82 (2010)
///
ENTRY       H00632                      Disease
NAME        Heterotaxy;
            Situs ambiguus
DESCRIPTION Heterotaxy, or situs ambiguus, is an abnormal arrangement of the thoracic and abdominal viscera. The phenotype with mirror-image reversed left-right axis is called situs inversus, while partial alterations in the left-right organization is referred to as heterotaxy. Heterotaxy is associated with perturbation of nodal signaling during embryogenesis.
CATEGORY    Developmental disorder
GENE        NODAL [HSA:4838] [KO:K04666]
            ZIC3 [HSA:7547] [KO:K18487]
            CFC1 [HSA:55997]
            ACVR2B [HSA:93] [KO:K13596]
            CCDC11 [HSA:220136]
            GDF1 [HSA:2657] [KO:K05495]
DBLINKS     ICD-10: Q89.3
            MeSH: D059446
            OMIM: 270100 306955 605376 613751 614779 208530
REFERENCE   PMID:19876930 (gene)
  AUTHORS   Sutherland MJ, Ware SM
  TITLE     Disorders of left-right asymmetry: heterotaxy and situs inversus.
  JOURNAL   Am J Med Genet C Semin Med Genet 151C:307-17 (2009)
REFERENCE   PMID:9735377 (description)
  AUTHORS   Casey B
  TITLE     Two rights make a wrong: human left-right malformations.
  JOURNAL   Hum Mol Genet 7:1565-71 (1998)
REFERENCE   PMID:9572118 (description)
  AUTHORS   Kosaki K, Casey B
  TITLE     Genetics of human left-right axis malformations.
  JOURNAL   Semin Cell Dev Biol 9:89-99 (1998)
REFERENCE   PMID:11471159 (description)
  AUTHORS   Casey B
  TITLE     Genetics of human situs abnormalities.
  JOURNAL   Am J Med Genet 101:356-8 (2001)
REFERENCE   PMID:22577226
  AUTHORS   Perles Z, Cinnamon Y, Ta-Shma A, Shaag A, Einbinder T, Rein AJ, Elpeleg O
  TITLE     A human laterality disorder associated with recessive CCDC11 mutation.
  JOURNAL   J Med Genet 49:386-90 (2012)
REFERENCE   PMID:20413652
  AUTHORS   Kaasinen E, Aittomaki K, Eronen M, Vahteristo P, Karhu A, Mecklin JP, Kajantie E, Aaltonen LA, Lehtonen R
  TITLE     Recessively inherited right atrial isomerism caused by mutations in growth/differentiation factor 1 (GDF1).
  JOURNAL   Hum Mol Genet 19:2747-53 (2010)
///
ENTRY       H00633                      Disease
NAME        Duane retraction syndrome
DESCRIPTION Duane retraction syndrome (DRS) is a congenital disorder of eye movement that occurs in approximately 1 in 50 patients with strabismus. This condition prevents horizontal eye movement, with absence of outward movement and deficiency of inward movement. Normal ocular motility depends on precise relations between cranial motor neurons and their target, extraocular muscles. In DRS parients, absence of the abducens motor neurons and aberrant innervations of extraocular muscles by third cranial nerve have been reported.
CATEGORY    Developmental disorder; Nervous system disease
GENE        CHN1 (alternative splicing) [HSA:1123] [KO:K20630]
DBLINKS     ICD-10: H50.8
            MeSH: D004370
            OMIM: 604356
REFERENCE   PMID:20801148 (description)
  AUTHORS   Yuksel D, Orban de Xivry JJ, Lefevre P
  TITLE     Review of the major findings about Duane retraction syndrome (DRS) leading to an  updated form of classification.
  JOURNAL   Vision Res 50:2334-47 (2010)
REFERENCE   PMID:18653847 (gene)
  AUTHORS   Miyake N, Chilton J, Psatha M, Cheng L, Andrews C, Chan WM, Law K, Crosier M, Lindsay S, Cheung M, Allen J, Gutowski NJ, Ellard S, Young E, Iannaccone A, Appukuttan B, Stout JT, Christiansen S, Ciccarelli ML, Baldi A, Campioni M, Zenteno JC, Davenport D, Mariani LE, Sahin M, Guthrie S, Engle EC
  TITLE     Human CHN1 mutations hyperactivate alpha2-chimaerin and cause Duane's retraction  syndrome.
  JOURNAL   Science 321:839-43 (2008)
///
ENTRY       H00634                      Disease
NAME        Duane-radial ray syndrome and IVIC syndrome;
            Okihiro syndrome
DESCRIPTION Duane-Radial Ray syndrome alias Okihiro syndrome is an autosomal dominant condition characterized by an association of Duane retraction syndrome (eye retraction) with radial malformations of the upper extremities and deafness. Mutations in the transcription factor SALL4 are the cause of the disorder. IVIC syndrome consists extraocular motor disturbances, radial ray defects, and congenital bilateral non-progressive mixed hearing loss due to a deletion mutation of SALL4.
CATEGORY    Developmental disorder; Skeletal dysplasia; Nervous system disease
GENE        SALL4 [HSA:57167] [KO:K19871]
COMMENT     For Duane retraction syndrome, see H00633.
DBLINKS     MeSH: D004370
            OMIM: 607323 147750
REFERENCE   PMID:20801148 (gene)
  AUTHORS   Yuksel D, Orban de Xivry JJ, Lefevre P
  TITLE     Review of the major findings about Duane retraction syndrome (DRS) leading to an  updated form of classification.
  JOURNAL   Vision Res 50:2334-47 (2010)
REFERENCE   PMID:12395297 (description)
  AUTHORS   Al-Baradie R, Yamada K, St Hilaire C, Chan WM, Andrews C, McIntosh N, Nakano M, Martonyi EJ, Raymond WR, Okumura S, Okihiro MM, Engle EC
  TITLE     Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family.
  JOURNAL   Am J Hum Genet 71:1195-9 (2002)
REFERENCE   PMID:17256792 (description)
  AUTHORS   Paradisi I, Arias S
  TITLE     IVIC syndrome is caused by a c.2607delA mutation in the SALL4 locus.
  JOURNAL   Am J Med Genet A 143:326-32 (2007)
///
ENTRY       H00635                      Disease
NAME        Aniridia
DESCRIPTION Aniridia is a congenital, bilateral ocular malformation defined as iris aplasia or hypoplasia. It can be either isolated or accompanied by other ocular defects. Aniridia is caused by decreased dosage of the PAX6, a master regulatory gene that induces eye formation in a broad range of animals. Recently, it has been reported that aniridia is also caused by heterozygous mutations in the ELP4 gene and TRIM44 gene.
CATEGORY    Developmental disorder; Nervous system disease
GENE        PAX6 [HSA:5080] [KO:K08031]
            ELP4 [HSA:26610] [KO:K11375]
            TRIM44 [HSA:54765] [KO:K12020]
DBLINKS     ICD-10: Q13.1
            MeSH: D015783
            OMIM: 106210 617141 617142
REFERENCE   PMID:20132240 (gene, description)
  AUTHORS   Kokotas H, Petersen MB
  TITLE     Clinical and molecular aspects of aniridia.
  JOURNAL   Clin Genet 77:409-20 (2010)
REFERENCE   PMID:21985185 (gene)
  AUTHORS   Wawrocka A, Budny B, Debicki S, Jamsheer A, Sowinska A, Krawczynski MR
  TITLE     PAX6 3' deletion in a family with aniridia.
  JOURNAL   Ophthalmic Genet 33:44-8 (2012)
REFERENCE   PMID:21850189 (gene)
  AUTHORS   Zhang X, Wang P, Li S, Xiao X, Guo X, Zhang Q
  TITLE     Mutation spectrum of PAX6 in Chinese patients with aniridia.
  JOURNAL   Mol Vis 17:2139-47 (2011)
REFERENCE   PMID:12386836 (gene)
  AUTHORS   Crolla JA, van Heyningen V
  TITLE     Frequent chromosome aberrations revealed by molecular cytogenetic studies in patients with aniridia.
  JOURNAL   Am J Hum Genet 71:1138-49 (2002)
REFERENCE   PMID:26394807 (gene)
  AUTHORS   Zhang X, Qin G, Chen G, Li T, Gao L, Huang L, Zhang Y, Ouyang K, Wang Y, Pang Y, Zeng B, Yu L
  TITLE     Variants in TRIM44 Cause Aniridia by Impairing PAX6 Expression.
  JOURNAL   Hum Mutat 36:1164-7 (2015)
///
ENTRY       H00636                      Disease
NAME        Tetra-amelia
DESCRIPTION Tetra-amelia is an extremely rare condition characterized by the complete absence of all four limbs. Patients commonly have other anomalies involving the face, eyes, heart, nervous system, and urogenital system. Homozygous Wnt3 mutation is responsible for tetra-amelia.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        WNT3 [HSA:7473] [KO:K00312]
DBLINKS     MeSH: C536498
            OMIM: 273395
REFERENCE   PMID:20301453 (description, gene)
  AUTHORS   Niemann S
  TITLE     Tetra-Amelia Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:14872406 (description, gene)
  AUTHORS   Niemann S, Zhao C, Pascu F, Stahl U, Aulepp U, Niswander L, Weber JL, Muller U
  TITLE     Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family.
  JOURNAL   Am J Hum Genet 74:558-63 (2004)
REFERENCE   PMID:20709709 (description, gene)
  AUTHORS   Al-Qattan MM
  TITLE     WNT pathways and upper limb anomalies.
  JOURNAL   J Hand Surg Eur Vol 36:9-22 (2011)
///
ENTRY       H00637                      Disease
NAME        Ulnar-mammary syndrome;
            Schinzel syndrome
DESCRIPTION Ulnar-mammary syndrome (UMS) is an autosomal dominant disorder caused by haploinsufficiency of the TBX3 gene. It is characterized by bilateral hypoplasia or aplasia of upper limbs on the ulnar side, mammary and apocrine gland hypoplasia, and genital abnormalities. Delayed puberty is one of the recognized features in UMS.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        TBX3 [HSA:6926] [KO:K10177]
DBLINKS     ICD-10: Q71.8
            MeSH: C536937
            OMIM: 181450
REFERENCE   PMID:19938096 (description, gene)
  AUTHORS   Linden H, Williams R, King J, Blair E, Kini U
  TITLE     Ulnar Mammary syndrome and TBX3: expanding the phenotype.
  JOURNAL   Am J Med Genet A 149A:2809-12 (2009)
REFERENCE   PMID:21199695 (description)
  AUTHORS   Joss S, Kini U, Fisher R, Mundlos S, Prescott K, Newbury-Ecob R, Tolmie J
  TITLE     The face of Ulnar Mammary syndrome?
  JOURNAL   Eur J Med Genet 54:301-5 (2011)
REFERENCE   PMID:16896345 (gene)
  AUTHORS   Klopocki E, Neumann LM, Tonnies H, Ropers HH, Mundlos S, Ullmann R
  TITLE     Ulnar-mammary syndrome with dysmorphic facies and mental retardation caused by a  novel 1.28 Mb deletion encompassing the TBX3 gene.
  JOURNAL   Eur J Hum Genet 14:1274-9 (2006)
REFERENCE   PMID:9207801 (gene)
  AUTHORS   Bamshad M, Lin RC, Law DJ, Watkins WC, Krakowiak PA, Moore ME, Franceschini P, Lala R, Holmes LB, Gebuhr TC, Bruneau BG, Schinzel A, Seidman JG, Seidman CE, Jorde LB
  TITLE     Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome.
  JOURNAL   Nat Genet 16:311-5 (1997)
///
ENTRY       H00638                      Disease
NAME        Ectrodactyly-ectodermal dysplasia cleft-palate syndrome (EEC syndrome)
DESCRIPTION Ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome is a rare autosomal dominant genetic disorder. This condition is a combination of ectrodactyly, the lobster claw-like deformities of the hands and feet, ectodermal dysplasia affecting skin, hair, and nails, and cleft lip with or without cleft palate. Other symptoms include anomalies of eyes and urinary tract.
CATEGORY    Skeletal dysplasia
GENE        TP63 [HSA:8626] [KO:K10149]
COMMENT     Isolated ectrodactyly is described in split-hand/foot malformation (H00471).
DBLINKS     ICD-10: Q82.4
            MeSH: C565062 C565799
            OMIM: 604292
REFERENCE   PMID:20944926 (description)
  AUTHORS   Trope BM, Salomao JN, Costa VD, Verde RB, Barros DS
  TITLE     Do you know this syndrome? Ectrodactyly - ectodermal dysplasia - cleft lip/palate(EEC) syndrome.
  JOURNAL   An Bras Dermatol 85:573-5 (2010)
REFERENCE   PMID:1261073 (description)
  AUTHORS   Rosenmann A, Shapira T, Cohen MM
  TITLE     Ectrodactyly, ectodermal dysplasia and cleft palate (EEC syndrome). Report of a family and review of the literature.
  JOURNAL   Clin Genet 9:347-53 (1976)
REFERENCE   PMID:10535733 (gene)
  AUTHORS   Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H
  TITLE     Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.
  JOURNAL   Cell 99:143-53 (1999)
///
ENTRY       H00639                      Disease
NAME        Ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM syndrome)
DESCRIPTION Ectodermal dysplasia with ectrodactyly and macular dystrophy (EEM syndrome) is the rare association of several clinical features caused by defects in CDH3. The ectodermal defect is characterized by hypotrichosis with sparse and short scalp hair, eyebrows, and eyelashes. Digit deficiency/syndactyly in hands is often more severe than the feet. Bilateral retinal degeneration appears as prominent pigmentation of the retina.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        CDH3 [HSA:1001] [KO:K06796]
DBLINKS     ICD-10: Q87.8
            MeSH: C536190
            OMIM: 225280
REFERENCE   PMID:11424132 (description)
  AUTHORS   Senecky Y, Halpern GJ, Inbar D, Attias J, Shohat M
  TITLE     Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings.
  JOURNAL   Am J Med Genet 101:195-7 (2001)
REFERENCE   PMID:15805154 (gene)
  AUTHORS   Kjaer KW, Hansen L, Schwabe GC, Marques-de-Faria AP, Eiberg H, Mundlos S, Tommerup N, Rosenberg T
  TITLE     Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).
  JOURNAL   J Med Genet 42:292-8 (2005)
REFERENCE   PMID:19504607 (gene, description)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
///
ENTRY       H00640                      Disease
NAME        Limb-mammary syndrome
DESCRIPTION Limb-mammary syndrome (LMS) is a condition characterized by ectrodactyly, cleft palate, and aplasia or hypoplasia of the mammary gland and nipple. Unlike its allelic disorder EEC syndrome, LMS patients do not have hair and skin defects.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        TP63 [HSA:8626] [KO:K10149]
COMMENT     For EEC syndrome, see H00638.
DBLINKS     ICD-10: Q87.2
            MeSH: C535903
            OMIM: 603543
REFERENCE   PMID:12070241 (gene, description)
  AUTHORS   Brunner HG, Hamel BC, Van Bokhoven H
  TITLE     The p63 gene in EEC and other syndromes.
  JOURNAL   J Med Genet 39:377-81 (2002)
REFERENCE   PMID:12357472 (gene, description)
  AUTHORS   Brunner HG, Hamel BC, Bokhoven Hv H
  TITLE     P63 gene mutations and human developmental syndromes.
  JOURNAL   Am J Med Genet 112:284-90 (2002)
REFERENCE   PMID:19504607 (gene, description)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
///
ENTRY       H00641                      Disease
NAME        ADULT syndrome
DESCRIPTION ADULT syndrome is an acronym for acro-dermato-ungual-lacrimal-tooth syndrome. It is a rare autosomal dominant disorder characterized by ectrodactyly, excessive freckling, nail dysplasia, obstruction of lacrimal ducts, and hypodontia. ADULT syndrome differs from EEC syndrome, an allelic disorder, by the absence of facial clefting.
CATEGORY    Developmental disorder
GENE        TP63 (gain of function) [HSA:8626] [KO:K10149]
COMMENT     For EEC syndrome and EEC-related limb-mammary syndrome, see H00638 and H00640 respectively.
DBLINKS     ICD-10: Q87.2
            MeSH: C538052
            OMIM: 103285
REFERENCE   PMID:12070241 (gene, description)
  AUTHORS   Brunner HG, Hamel BC, Van Bokhoven H
  TITLE     The p63 gene in EEC and other syndromes.
  JOURNAL   J Med Genet 39:377-81 (2002)
REFERENCE   PMID:12357472 (gene, description)
  AUTHORS   Brunner HG, Hamel BC, Bokhoven Hv H
  TITLE     P63 gene mutations and human developmental syndromes.
  JOURNAL   Am J Med Genet 112:284-90 (2002)
REFERENCE   PMID:19504607 (gene, description)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
REFERENCE   PMID:11528512 (gene)
  AUTHORS   Amiel J, Bougeard G, Francannet C, Raclin V, Munnich A, Lyonnet S, Frebourg T
  TITLE     TP63 gene mutation in ADULT syndrome.
  JOURNAL   Eur J Hum Genet 9:642-5 (2001)
///
ENTRY       H00642                      Disease
NAME        Lacrimo-auriculo-dento-digital syndrome (LADD);
            Levy-Hollister syndrome
DESCRIPTION Lacrimo-auriculo-dento-digital (LADD) syndrome is an autosomal dominant disorder characterizd by hypoplasia or aplasia of the lacrimal and salivary glands, cup shaped pinnae with sensorineural deafness, dental abnormalities with small teeth, and radial ray abnormalities in hands.
CATEGORY    Developmental disorder
GENE        FGF10 [HSA:2255] [KO:K04358]
            FGFR2 [HSA:2263] [KO:K05093]
            FGFR3 [HSA:2261] [KO:K05094]
DBLINKS     MeSH: C538132
            OMIM: 149730
REFERENCE   PMID:16501574 (gene)
  AUTHORS   Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nurnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, Lehnerdt K, Cremers CW, Yuksel-Apak M, Nurnberg P, Kubisch C, Schlessinger J, van Bokhoven H, Wollnik B
  TITLE     Mutations in different components of FGF signaling in LADD syndrome.
  JOURNAL   Nat Genet 38:414-7 (2006)
REFERENCE   PMID:17682060 (gene)
  AUTHORS   Shams I, Rohmann E, Eswarakumar VP, Lew ED, Yuzawa S, Wollnik B, Schlessinger J, Lax I
  TITLE     Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway.
  JOURNAL   Mol Cell Biol 27:6903-12 (2007)
REFERENCE   PMID:8411061 (description)
  AUTHORS   Lacombe D, Serville F, Marchand D, Battin J
  TITLE     Split hand/split foot deformity and LADD syndrome in a family: overlap between the EEC and LADD syndromes.
  JOURNAL   J Med Genet 30:700-3 (1993)
REFERENCE   PMID:12070241 (description)
  AUTHORS   Brunner HG, Hamel BC, Van Bokhoven H
  TITLE     The p63 gene in EEC and other syndromes.
  JOURNAL   J Med Genet 39:377-81 (2002)
///
ENTRY       H00643                      Disease
NAME        Tooth and nail syndrome;
            Witkop syndrome
DESCRIPTION Witkop syndrome, also known as tooth and nail syndrome, is a form of ectodermal dysplasia manifested by hypodontia and nail dysplasia. Several teeth are congenitally missing and nails are spoon-shaped and easily broken. Mutations are identified in MSX1 gene.
CATEGORY    Developmental disorder
GENE        MSX1 [HSA:4487] [KO:K09341]
DBLINKS     ICD-10: Q87.8
            MeSH: C536736
            OMIM: 189500
REFERENCE   PMID:11369996 (gene)
  AUTHORS   Jumlongras D, Bei M, Stimson JM, Wang WF, DePalma SR, Seidman CE, Felbor U, Maas R, Seidman JG, Olsen BR
  TITLE     A nonsense mutation in MSX1 causes Witkop syndrome.
  JOURNAL   Am J Hum Genet 69:67-74 (2001)
REFERENCE   PMID:21054511 (description)
  AUTHORS   Memarpour M, Shafiei F
  TITLE     Witkop tooth and nail syndrome: a report of three cases in a family.
  JOURNAL   Pediatr Dermatol 28:281-5 (2011)
REFERENCE   PMID:16129001 (description)
  AUTHORS   Devadas S, Varma B, Mungara J, Joseph T, Saraswathi TR
  TITLE     Witkop tooth and nail syndrome: a case report.
  JOURNAL   Int J Paediatr Dent 15:364-9 (2005)
///
ENTRY       H00644                      Disease
NAME        Ectodermal dysplasia/skin fragility syndrome
DESCRIPTION Ectodermal dysplasia/skin fragility syndrome is a very rare genodermatosis that develops skin fragility with tearing and blisters and congenital ectodermal dysplasia. Progressive keratosis of the palms and soles is always seen in the patients. This conditon is caused by mutations in PKP1, a desmosomal plaque-associated protein.
CATEGORY    Developmental disorder; Skin and connective tissue disease
GENE        PKP1 [HSA:5317] [KO:K10387]
DBLINKS     MeSH: C536183
            OMIM: 604536
REFERENCE   PMID:19504607 (gene, desription)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
REFERENCE   PMID:19945625 (gene, desription)
  AUTHORS   McGrath JA, Mellerio JE
  TITLE     Ectodermal dysplasia-skin fragility syndrome.
  JOURNAL   Dermatol Clin 28:125-9 (2010)
REFERENCE   PMID:9326952 (gene)
  AUTHORS   McGrath JA, McMillan JR, Shemanko CS, Runswick SK, Leigh IM, Lane EB, Garrod DR, Eady RA
  TITLE     Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome.
  JOURNAL   Nat Genet 17:240-4 (1997)
REFERENCE   PMID:16781314 (gene, desription)
  AUTHORS   Ersoy-Evans S, Erkin G, Fassihi H, Chan I, Paller AS, Surucu S, McGrath JA
  TITLE     Ectodermal dysplasia-skin fragility syndrome resulting from a new homozygous mutation, 888delC, in the desmosomal protein plakophilin 1.
  JOURNAL   J Am Acad Dermatol 55:157-61 (2006)
///
ENTRY       H00645                      Disease
NAME        Incontinentia pigmenti
DESCRIPTION Incontinentia pigmenti is an X-linked dominant genodermatosis mostly affecting females. Cutaneous manifestations are present along the lines of Blaschko and are subdivided into four stages: vesicular, verrucous, hyperpigmented, and atrophic. Other tissues of ectodermal origin are also affected, showing hair abnormalities, dental anomalies, and ophthalmologic and neurologic alterations. Familial incontinentia pigmenti is caused by mutations in the NEMO gene.
CATEGORY    Skin and connective tissue disease
GENE        IKBKG [HSA:8517] [KO:K07210]
DBLINKS     ICD-10: Q82.3
            MeSH: D007184
            OMIM: 308300
REFERENCE   PMID:21163160 (description)
  AUTHORS   Jabbari A, Ralston J, Schaffer JV
  TITLE     Incontinentia pigmenti.
  JOURNAL   Dermatol Online J 16:9 (2010)
REFERENCE   PMID:12140463 (description, gene)
  AUTHORS   Berlin AL, Paller AS, Chan LS
  TITLE     Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology.
  JOURNAL   J Am Acad Dermatol 47:169-87; quiz 188-90 (2002)
REFERENCE   PMID:15295921 (description, gene)
  AUTHORS   Bruckner AL
  TITLE     Incontinentia pigmenti: a window to the role of NF-kappaB function.
  JOURNAL   Semin Cutan Med Surg 23:116-24 (2004)
///
ENTRY       H00646                      Disease
NAME        Odontoonychodermal dysplasia
DESCRIPTION Odontoonychodermal dysplasia is a rare autosomal recessive ectodermal dysplasia that presents dry hair, severe hypodontia, smooth tongue, onychodysplasia, and keratoderma of palms and soles.
CATEGORY    Skin and connective tissue disease
GENE        WNT10A (nonsense mutation) [HSA:80326] [KO:K01357]
DBLINKS     MeSH: C537742
            OMIM: 257980
REFERENCE   PMID:6837628 (description)
  AUTHORS   Fadhil M, Ghabra TA, Deeb M, Der Kaloustian VM
  TITLE     Odontoonychodermal dysplasia: a previously apparently undescribed ectodermal dysplasia.
  JOURNAL   Am J Med Genet 14:335-46 (1983)
REFERENCE   PMID:19504607 (gene, description)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
REFERENCE   PMID:17870445 (description)
  AUTHORS   Adams BB
  TITLE     Odonto-onycho-dermal dysplasia syndrome.
  JOURNAL   J Am Acad Dermatol 57:732-3 (2007)
REFERENCE   PMID:17847007 (gene)
  AUTHORS   Adaimy L, Chouery E, Megarbane H, Mroueh S, Delague V, Nicolas E, Belguith H, de Mazancourt P, Megarbane A
  TITLE     Mutation in WNT10A is associated with an autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal dysplasia.
  JOURNAL   Am J Hum Genet 81:821-8 (2007)
///
ENTRY       H00647                      Disease
NAME        Ectodermal dysplasia-syndactyly syndrome (EDSS)
DESCRIPTION Ectodermal dysplasia-syndactyly syndrome (EDSS) is a rare form of ectodermal dysplasia characterized by co-existence of abnormalities in skin/skin-derived structures and bilateral partial cutaneous syndactyly. The causative gene of EDSS is PVRL4, a cell adhesion molecule implicated in cadherin-based adherens junctions.
CATEGORY    Skin and connective tissue disease
GENE        PVRL4 [HSA:81607] [KO:K06593]
DBLINKS     OMIM: 613573
REFERENCE   PMID:21346770 (gene, description)
  AUTHORS   Jelani M, Chishti MS, Ahmad W
  TITLE     Mutation in PVRL4 gene encoding nectin-4 underlies ectodermal-dysplasia-syndactyly syndrome (EDSS1).
  JOURNAL   J Hum Genet 56:352-7 (2011)
REFERENCE   PMID:20691405 (gene, description)
  AUTHORS   Brancati F, Fortugno P, Bottillo I, Lopez M, Josselin E, Boudghene-Stambouli O, Agolini E, Bernardini L, Bellacchio E, Iannicelli M, Rossi A, Dib-Lachachi A, Stuppia L, Palka G, Mundlos S, Stricker S, Kornak U, Zambruno G, Dallapiccola B
  TITLE     Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome.
  JOURNAL   Am J Hum Genet 87:265-73 (2010)
///
ENTRY       H00648                      Disease
NAME        Ectodermal dysplasia, hidrotic;
            Clouston syndrome
DESCRIPTION Hidrotic ectodermal dysplasia, also known as Clouston syndrome, is an autosomal dominant disorder characterized by partial or total alopecia, nail dystrophy, hyperkeratosis of the palms and soles, and hyperpigmentation over the joints. Teeth are normal. Mutated connexin in the disease impairs formation of gap junction channels.
CATEGORY    Skin and connective tissue disease
GENE        GJB6 [HSA:10804] [KO:K07625]
DBLINKS     ICD-10: Q82.8
            MeSH: D004476
            OMIM: 129500
REFERENCE   PMID:19504607 (description, gene)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
REFERENCE   PMID:11546825 (description)
  AUTHORS   Priolo M, Lagana C
  TITLE     Ectodermal dysplasias: a new clinical-genetic classification.
  JOURNAL   J Med Genet 38:579-85 (2001)
REFERENCE   PMID:8741874 (description)
  AUTHORS   Hassed SJ, Kincannon JM, Arnold GL
  TITLE     Clouston syndrome: an ectodermal dysplasia without significant dental findings.
  JOURNAL   Am J Med Genet 61:274-6 (1996)
REFERENCE   PMID:20301379 (description, gene)
  AUTHORS   Der Kaloustian VM
  TITLE     Hidrotic Ectodermal Dysplasia 2
  JOURNAL   (1993)
///
ENTRY       H00649                      Disease
NAME        Ectodermal dysplasia, pure hair-nail type (HNED)
DESCRIPTION Pure hair-nail type ectodermal dysplasia (HNED) is a rare condition involving only tissues of ectodermal origin. Patients show complete alopecia and primitive nails. HNED represents as an autosomal dominant trait.
CATEGORY    Developmental disorder; Skin and connective tissue disease
GENE        KRT85 [HSA:3891] [KO:K07605]
DBLINKS     MeSH: C566592
            OMIM: 602032
REFERENCE   PMID:21890491 (description, gene)
  AUTHORS   McLean WH, Moore CB
  TITLE     Keratin disorders: from gene to therapy.
  JOURNAL   Hum Mol Genet 20:R189-97 (2011)
REFERENCE   PMID:9295083 (description)
  AUTHORS   Barbareschi M, Cambiaghi S, Crupi AC, Tadini G
  TITLE     Family with "pure" hair-nail ectodermal dysplasia.
  JOURNAL   Am J Med Genet 72:91-3 (1997)
REFERENCE   PMID:16525032 (gene)
  AUTHORS   Naeem M, Wajid M, Lee K, Leal SM, Ahmad W
  TITLE     A mutation in the hair matrix and cuticle keratin KRTHB5 gene causes ectodermal dysplasia of hair and nail type.
  JOURNAL   J Med Genet 43:274-9 (2006)
///
ENTRY       H00650                      Disease
NAME        Allan-Herndon-Dudley syndrome;
            Monocarboxylate transporter 8 deficiency
DESCRIPTION Allan-Herndon-Dudley syndrome (AHDS) is an X-linked mental retardation syndrome with neuromuscular involvement characterized by hypotonia, muscular hypoplasia and intellectual deficit. AHDS is caused by mutations in the SLC16A2 gene, encoding MCT8 which is a specific transporter for thyroid hormone T3.
CATEGORY    Endocrine disease; Mental retardation
GENE        SLC16A2 [HSA:6567] [KO:K08231]
MARKER      normal or low serum thyroxine (T4) [CPD:C01829] 
            very elevated triiodothyronine (T3) [CPD:C02465]
DBLINKS     ICD-10: E03.8
            MeSH: C537047
            OMIM: 300523
REFERENCE   PMID:20713192
  AUTHORS   Boccone L, Mariotti S, Dessi V, Pruna D, Meloni A, Loudianos G
  TITLE     Allan-Herndon-Dudley syndrome (AHDS) caused by a novel SLC16A2 gene mutation showing severe neurologic features and unexpectedly low TRH-stimulated serum TSH.
  JOURNAL   Eur J Med Genet 53:392-5 (2010)
REFERENCE   PMID:17574010
  AUTHORS   Schwartz CE, Stevenson RE
  TITLE     The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 21:307-21 (2007)
///
ENTRY       H00651                      Disease
NAME        Ectodermal dysplasia, including:
            Ectodermal dysplasia, anhidrotic;
            Ectodermal dysplasia, hypohidrotic
DESCRIPTION These ectodermal dysplasias are caused by defective epithelial-mesenchymal interaction that involves the Ectodysplasin/Edar/Edaradd signaling pathway. Congenital anhidrotic ectodermal dysplasia is a sex-linked disorder characterized by incomplete development of the dermis, resulting in the absence of hair follicles and sweat glands with anodontia in affected males. Hypohidrotic ectodermal dysplasia is milder with sparse hair and sweat glands and oligodontia.
CATEGORY    Skin and connective tissue disease
GENE        (X-linked) ED1 [HSA:1896] [KO:K05480]
            (autosomal) EDAR [HSA:10913] [KO:K05162]
            (autosomal) EDARADD [HSA:128178]
DBLINKS     ICD-10: Q82.4
            MeSH: D053358 D053359 D053360
            OMIM: 305100 129490 224900
REFERENCE   PMID:19504607 (description, gene)
  AUTHORS   Priolo M
  TITLE     Ectodermal dysplasias: an overview and update of clinical and molecular-functional mechanisms.
  JOURNAL   Am J Med Genet A 149A:2003-13 (2009)
REFERENCE   PMID:12823289 (description, gene)
  AUTHORS   Lamartine J
  TITLE     Towards a new classification of ectodermal dysplasias.
  JOURNAL   Clin Exp Dermatol 28:351-5 (2003)
///
ENTRY       H00652                      Disease
NAME        Solitary median maxillary central incisor syndrome
DESCRIPTION Solitary median maxillary central incisor (SMMCI) syndrome is a rare dental anomaly characterized by the presence of a central incisor with symmetric crown form positioned at the maxillary mid-axis. Missense mutations in the SHH, a key player in ventral axis patterning, is associated with the disorder.
CATEGORY    Mouth and dental disease
GENE        SHH [HSA:6469] [KO:K11988]
DBLINKS     ICD-10: K00.2
            MeSH: C537342
            OMIM: 147250
REFERENCE   PMID:15103725 (description, gene)
  AUTHORS   Garavelli L, Zanacca C, Caselli G, Banchini G, Dubourg C, David V, Odent S, Gurrieri F, Neri G
  TITLE     Solitary median maxillary central incisor syndrome: clinical case with a novel mutation of sonic hedgehog.
  JOURNAL   Am J Med Genet A 127A:93-5 (2004)
REFERENCE   PMID:19341585 (description, gene)
  AUTHORS   Bolan M, Derech CD, Ribeiro GL, Pereira ET, Almeida IC
  TITLE     Solitary median maxillary central incisor.
  JOURNAL   J Dent Child (Chic) 76:82-6 (2009)
///
ENTRY       H00653                      Disease
NAME        Marfan syndrome, including:
            Marfan syndrome (MFS);
            Neonatal MFS;
            Atypically severe MFS;
            New variant of MFS
DESCRIPTION Marfan syndrome (MFS) is a relatively common autosomal dominant disorder of connective tissue. It affects many parts of the body involving the skeletal, ocular, and cardiovascular systems. Cardiac manifestations are significant contributors to morbidity and mortality. MFS is caused by mutations in the gene for fibrillin-1.
CATEGORY    Developmental disorder; Skeletal dysplasia; Eye disease; Cardiovascular disease
GENE        FBN1 [HSA:2200] [KO:K06825]
DBLINKS     ICD-10: Q87.4
            MeSH: D008382
            OMIM: 154700
REFERENCE   PMID:11706995 (description, gene)
  AUTHORS   Robinson PN, Booms P
  TITLE     The molecular pathogenesis of the Marfan syndrome.
  JOURNAL   Cell Mol Life Sci 58:1698-707 (2001)
REFERENCE   PMID:16571647 (description, gene)
  AUTHORS   Robinson PN, Arteaga-Solis E, Baldock C, Collod-Beroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M
  TITLE     The molecular genetics of Marfan syndrome and related disorders.
  JOURNAL   J Med Genet 43:769-87 (2006)
REFERENCE   PMID:12203987 (description, gene)
  AUTHORS   Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, Palz M, Pregla R, Tiecke F, Rosenberg T
  TITLE     Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies.
  JOURNAL   Hum Mutat 20:153-61 (2002)
REFERENCE   PMID:10633129 (description, gene)
  AUTHORS   Robinson PN, Godfrey M
  TITLE     The molecular genetics of Marfan syndrome and related microfibrillopathies.
  JOURNAL   J Med Genet 37:9-25 (2000)
///
ENTRY       H00654                      Disease
NAME        Barth syndrome (BTHS)
DESCRIPTION Barth syndrome is a rare X-linked recessive disorder of infancy characterized by myopathy, cardiomyopathy, cyclic neutropenia, short stature, low cholesterol, and mitochondrial abnormalities. Barth syndrome is due to mutations in the TAZ gene, the exact function of which is unknown but there are indications that it is directly involved in the metabolism of cardiolipin localized in the inner mitochondrial membrane.
CATEGORY    Cardiovascular disease; Inherited metabolic disease
GENE        TAZ [HSA:6901] [KO:K13511]
DBLINKS     ICD-10: E71.1
            OMIM: 302060
REFERENCE   PMID:20812380 (gene)
  AUTHORS   Steward CG, Newbury-Ecob RA, Hastings R, Smithson SF, Tsai-Goodman B, Quarrell OW, Kulik W, Wanders R, Pennock M, Williams M, Cresswell JL, Gonzalez IL, Brennan P
  TITLE     Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth.
  JOURNAL   Prenat Diagn 30:970-6 (2010)
REFERENCE   PMID:18273731 (description, gene)
  AUTHORS   Finsterer J, Stollberger C
  TITLE     Primary myopathies and the heart.
  JOURNAL   Scand Cardiovasc J 42:9-24 (2008)
///
ENTRY       H00655                      Disease
NAME        McLeod syndrome
DESCRIPTION McLeod syndrome is an X-linked multisystem disorder including the CNS (chorea, epilepsy), the PNS (axonal polyneuropathy), and the blood cells (acanthocytosis of the erythrocytes) characterized by late onset abnormalities in the neuromuscular and hematopoietic systems. Mild myopathy is a common manifestation in most cases. Patients often present with mild, asymptomatic hyperCKemia. The absence of the XK membrane transport protein seems to be causative.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        XK [HSA:7504] [KO:K19522]
DBLINKS     MeSH: C564038
            OMIM: 608978
REFERENCE   PMID:18273731 (description, gene)
  AUTHORS   Finsterer J, Stollberger C
  TITLE     Primary myopathies and the heart.
  JOURNAL   Scand Cardiovasc J 42:9-24 (2008)
///
ENTRY       H00656                      Disease
NAME        Scapuloperoneal myopathy (SPM)
DESCRIPTION Scapuloperoneal syndrome encompasses a heterogeneous group of neuromuscular disorders all characterized by slowly progressive weakness in the shoulder-girdle and peroneal muscles. Both neurogenic and myopathic scapuloperoneal syndromes exist, the latter being referred to as scapuloperoneal myopathy (SPM). Distinct subtypes of SPM are caused by mutations in the sarcomeric muscle proteins desmin and myosin heavy chain 7. The X-linked dominant form of SPM (XSPM) is caused by mutations in the FHL1 gene.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        MYH7 [HSA:4625] [KO:K17751]
            DES [HSA:1674] [KO:K07610]
            FHL1 [HSA:2273] [KO:K14365]
DBLINKS     ICD-10: G12.1
            MeSH: C536624
            OMIM: 181430 181400 300695
REFERENCE   PMID:21310615 (description, gene)
  AUTHORS   Cowling BS, Cottle DL, Wilding BR, D'Arcy CE, Mitchell CA, McGrath MJ
  TITLE     Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features.
  JOURNAL   Neuromuscul Disord 21:237-51 (2011)
REFERENCE   PMID:17336526 (gene)
  AUTHORS   Pegoraro E, Gavassini BF, Borsato C, Melacini P, Vianello A, Stramare R, Cenacchi G, Angelini C
  TITLE     MYH7 gene mutation in myosin storage myopathy and scapulo-peroneal myopathy.
  JOURNAL   Neuromuscul Disord 17:321-9 (2007)
REFERENCE   PMID:17439987 (gene)
  AUTHORS   Walter MC, Reilich P, Huebner A, Fischer D, Schroder R, Vorgerd M, Kress W, Born C, Schoser BG, Krause KH, Klutzny U, Bulst S, Frey JR, Lochmuller H
  TITLE     Scapuloperoneal syndrome type Kaeser and a wide phenotypic spectrum of adult-onset, dominant myopathies are associated with the desmin mutation R350P.
  JOURNAL   Brain 130:1485-96 (2007)
///
ENTRY       H00657                      Disease
NAME        Reducing body myopathy (RBM)
DESCRIPTION Reducing body myopathy (RBM) is a rare, sometimes fatal, X-linked disorder characterized by progressive muscle weakness and the presence of intracytoplasmic aggregates in histological muscle sections which exert a reducing activity on nitro-blue tetrazolium (NBT) staining. The causative gene for RBM is FHL1 encoding four and a half LIM domains.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        FHL1 [HSA:2273] [KO:K14365]
DBLINKS     ICD-10: G71.2
            MeSH: C567468 C567469
            OMIM: 300717 300718
REFERENCE   PMID:21310615 (description, gene)
  AUTHORS   Cowling BS, Cottle DL, Wilding BR, D'Arcy CE, Mitchell CA, McGrath MJ
  TITLE     Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features.
  JOURNAL   Neuromuscul Disord 21:237-51 (2011)
REFERENCE   PMID:19171836 (description, gene)
  AUTHORS   Shalaby S, Hayashi YK, Nonaka I, Noguchi S, Nishino I
  TITLE     Novel FHL1 mutations in fatal and benign reducing body myopathy.
  JOURNAL   Neurology 72:375-6 (2009)
///
ENTRY       H00658                      Disease
NAME        Syndromic X-linked mental retardation, including:
            Turner type (MRXST);
            Siderius type (MRXSSD) ;
            Cabezas type (MRXC);
            Raymond type (MRXSR);
            Type10 (MRXS10);
            Type14 (MRXS14);
            Mental retardation with isolated growth hormone deficiency (MRGH)
DESCRIPTION X-linked mental retardation (XMR) is an inherited condition that causes failure to develop cognitive abilities because of mutations in several genes on the X chromosome. XLMR is subdivided into syndromic and non-syndromic forms, depending on whether further abnormalities are found or not. Syndromic XLMR is characterized by recognizable dysmorphic features, neurological complications, and/or metabolic abnormalities.
CATEGORY    Congenital disorder; Mental retardation
GENE        (MRXST) HUWE1 [HSA:10075] [KO:K10592]
            (MRXSSD) PHF8 [HSA:23133] [KO:K19415]
            (MRXC) CUL4B [HSA:8450] [KO:K10609]
            (MRXSR) ZDHHC9 [HSA:51114] [KO:K16675]
            (MRXS10) HSD17B10 [HSA:3028] [KO:K08683]
            (MRXS14) UPF3B [HSA:65109] [KO:K14328]
            (MRGH) SOX3 [HSA:6658] [KO:K09267]
DBLINKS     ICD-10: F78.9
            MeSH: D038901
            OMIM: 300706 300263 300354 300799 300220 300676 300123
REFERENCE   PMID:15630421
  AUTHORS   Ropers HH, Hamel BC
  TITLE     X-linked mental retardation.
  JOURNAL   Nat Rev Genet 6:46-57 (2005)
REFERENCE   PMID:18252223
  AUTHORS   Froyen G, Corbett M, Vandewalle J, Jarvela I, Lawrence O, Meldrum C, Bauters M, Govaerts K, Vandeleur L, Van Esch H, Chelly J, Sanlaville D, van Bokhoven H, Ropers HH, Laumonnier F, Ranieri E, Schwartz CE, Abidi F, Tarpey PS, Futreal PA, Whibley A, Raymond FL, Stratton MR, Fryns JP, Scott R, Peippo M, Sipponen M, Partington M, Mowat D, Field M, Hackett A, Marynen P, Turner G, Gecz J
  TITLE     Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the  E3 ubiquitin ligase HUWE1 are associated with mental retardation.
  JOURNAL   Am J Hum Genet 82:432-43 (2008)
REFERENCE   PMID:20548336
  AUTHORS   Qiu J, Shi G, Jia Y, Li J, Wu M, Li J, Dong S, Wong J
  TITLE     The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation.
  JOURNAL   Cell Res 20:908-18 (2010)
REFERENCE   PMID:21816345
  AUTHORS   Nakagawa T, Xiong Y
  TITLE     X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression.
  JOURNAL   Mol Cell 43:381-91 (2011)
REFERENCE   PMID:17436253
  AUTHORS   Raymond FL, Tarpey PS, Edkins S, Tofts C, O'Meara S, Teague J, Butler A, Stevens C, Barthorpe S, Buck G, Cole J, Dicks E, Gray K, Halliday K, Hills K, Hinton J, Jones D, Menzies A, Perry J, Raine K, Shepherd R, Small A, Varian J, Widaa S, Mallya U, Moon J, Luo Y, Shaw M, Boyle J, Kerr B, Turner G, Quarrell O, Cole T, Easton DF, Wooster R, Bobrow M, Schwartz CE, Gecz J, Stratton MR, Futreal PA
  TITLE     Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus.
  JOURNAL   Am J Hum Genet 80:982-7 (2007)
REFERENCE   PMID:17704778
  AUTHORS   Tarpey PS, Raymond FL, Nguyen LS, Rodriguez J, Hackett A, Vandeleur L, Smith R, Shoubridge C, Edkins S, Stevens C, O'Meara S, Tofts C, Barthorpe S, Buck G, Cole J, Halliday K, Hills K, Jones D, Mironenko T, Perry J, Varian J, West S, Widaa S, Teague J, Dicks E, Butler A, Menzies A, Richardson D, Jenkinson A, Shepherd R, Raine K, Moon J, Luo Y, Parnau J, Bhat SS, Gardner A, Corbett M, Brooks D, Thomas P, Parkinson-Lawrence E, Porteous ME, Warner JP, Sanderson T, Pearson P, Simensen RJ, Skinner C, Hoganson G, Superneau D, Wooster R, Bobrow M, Turner G, Stevenson RE, Schwartz CE, Futreal PA, Srivastava AK, Stratton MR, Gecz J
  TITLE     Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation.
  JOURNAL   Nat Genet 39:1127-33 (2007)
REFERENCE   PMID:12428212
  AUTHORS   Laumonnier F, Ronce N, Hamel BC, Thomas P, Lespinasse J, Raynaud M, Paringaux C, Van Bokhoven H, Kalscheuer V, Fryns JP, Chelly J, Moraine C, Briault S
  TITLE     Transcription factor SOX3 is involved in X-linked mental retardation with growth  hormone deficiency.
  JOURNAL   Am J Hum Genet 71:1450-5 (2002)
///
ENTRY       H00659                      Disease
NAME        Shprintzen-Goldberg syndrome
DESCRIPTION Shprintzen-Goldberg syndrome (SGS) is a group of disorders characterized by craniosynostosis, neurologic abnormalities, and Marfanoid findings. It is a condition that involves skeletal changes and cardiovascular anomalies.
CATEGORY    Developmental disorder; Skeletal dysplasia; Cardiovascular disease; Nervous system disease
GENE        FBN1 [HSA:2200] [KO:K06825]
COMMENT     For closely related Marfan syndrome, see H00653.
DBLINKS     MeSH: C537328
            OMIM: 182212
REFERENCE   PMID:20301454 (description gene)
  AUTHORS   Greally MT
  TITLE     Shprintzen-Goldberg Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:8563763 (description gene)
  AUTHORS   Sood S, Eldadah ZA, Krause WL, McIntosh I, Dietz HC
  TITLE     Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg)  syndrome.
  JOURNAL   Nat Genet 12:209-11 (1996)
REFERENCE   PMID:16333834 (description gene)
  AUTHORS   Kosaki K, Takahashi D, Udaka T, Kosaki R, Matsumoto M, Ibe S, Isobe T, Tanaka Y, Takahashi T
  TITLE     Molecular pathology of Shprintzen-Goldberg syndrome.
  JOURNAL   Am J Med Genet A 140:104-8; author reply 109-10 (2006)
REFERENCE   PMID:9508238 (description)
  AUTHORS   Greally MT, Carey JC, Milewicz DM, Hudgins L, Goldberg RB, Shprintzen RJ, Cousineau AJ, Smith WL Jr, Judisch GF, Hanson JW
  TITLE     Shprintzen-Goldberg syndrome: a clinical analysis.
  JOURNAL   Am J Med Genet 76:202-12 (1998)
///
ENTRY       H00660                      Disease
NAME        Congenital contractural arachnodactyly (CCA);
            Beals syndrome
DESCRIPTION Congenital contractural arachnodactyly (CCA) or Beals syndrome is an autosomal dominant disorder characterized by a Marfan-like appearance and arachnodactyly. Most affected individuals have 'crumpled' ears, contractures of major joints, and camptodactyly. Additional features include muscular hypoplasia and scoliosis. In contrast to Marfan syndrome, CCA does not affect the aorta or the eyes.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FBN2 [HSA:2201]
COMMENT     For Marfan syndrome, see H00653.
DBLINKS     ICD-10: Q87.8
            MeSH: C536211
            OMIM: 121050
REFERENCE   PMID:16571647 (description gene)
  AUTHORS   Robinson PN, Arteaga-Solis E, Baldock C, Collod-Beroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M
  TITLE     The molecular genetics of Marfan syndrome and related disorders.
  JOURNAL   J Med Genet 43:769-87 (2006)
REFERENCE   PMID:10633129 (description gene)
  AUTHORS   Robinson PN, Godfrey M
  TITLE     The molecular genetics of Marfan syndrome and related microfibrillopathies.
  JOURNAL   J Med Genet 37:9-25 (2000)
REFERENCE   PMID:7493032 (gene)
  AUTHORS   Putnam EA, Zhang H, Ramirez F, Milewicz DM
  TITLE     Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly.
  JOURNAL   Nat Genet 11:456-8 (1995)
REFERENCE   PMID:20301560 (description gene)
  AUTHORS   Godfrey M
  TITLE     Congenital Contractural Arachnodactyly
  JOURNAL   (1993)
///
ENTRY       H00661                      Disease
NAME        MASS phenotype
DESCRIPTION MASS Phenotype (Mitral valve prolapse, Aortic dilatation without dissection, Skeletal and Skin abnormalities) is one of the FBN1-related disorders similar to Marfan syndrome. Reduced expression of FBN1 due to a 4 bp deletion in exon 41 is the cause of MASS phenotype.
CATEGORY    Developmental disorder; Cardiovascular disease; Skeletal dysplasia; Skin and connective tissue disease
GENE        FBN1 [HSA:2200] [KO:K06825]
COMMENT     For Marfan syndrome, see H00653.
DBLINKS     MeSH: C536030
            OMIM: 604308
REFERENCE   PMID:16571647 (description, gene)
  AUTHORS   Robinson PN, Arteaga-Solis E, Baldock C, Collod-Beroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M
  TITLE     The molecular genetics of Marfan syndrome and related disorders.
  JOURNAL   J Med Genet 43:769-87 (2006)
REFERENCE   PMID:10633129 (description, gene)
  AUTHORS   Robinson PN, Godfrey M
  TITLE     The molecular genetics of Marfan syndrome and related microfibrillopathies.
  JOURNAL   J Med Genet 37:9-25 (2000)
REFERENCE   PMID:8406497 (description, gene)
  AUTHORS   Dietz HC, McIntosh I, Sakai LY, Corson GM, Chalberg SC, Pyeritz RE, Francomano CA
  TITLE     Four novel FBN1 mutations: significance for mutant transcript level and EGF-like  domain calcium binding in the pathogenesis of Marfan syndrome.
  JOURNAL   Genomics 17:468-75 (1993)
///
ENTRY       H00662                      Disease
NAME        Ectopia lentis
DESCRIPTION Ectopia lentis (EL) is defined as displacement or malposition of the crystalline lens of the eye and is inherited in either autosomal recessive or autosomal dominant manner. Subluxation of the lens is slowly progressive in the first two decades of life. EL may occur as an isolated form or as a part of disorders. Up to about 80% of Marfan syndrome (MFS) patients have bilateral EL.
CATEGORY    Eye disease
GENE        FBN1 [HSA:2200] [KO:K06825]
            ADAMTSL4 [HSA:54507]
COMMENT     For Marfan syndrome, see H00653.
DBLINKS     ICD-10: Q12.1
            MeSH: D004479
            OMIM: 129600 225100
REFERENCE   PMID:7802039 (description, gene)
  AUTHORS   Edwards MJ, Challinor CJ, Colley PW, Roberts J, Partington MW, Hollway GE, Kozman HM, Mulley JC
  TITLE     Clinical and linkage study of a large family with simple ectopia lentis linked to FBN1.
  JOURNAL   Am J Med Genet 53:65-71 (1994)
REFERENCE   PMID:15054843 (description, gene)
  AUTHORS   Ades LC, Holman KJ, Brett MS, Edwards MJ, Bennetts B
  TITLE     Ectopia lentis phenotypes and the FBN1 gene.
  JOURNAL   Am J Med Genet A 126A:284-9 (2004)
REFERENCE   PMID:14502058 (description, gene)
  AUTHORS   Young TL
  TITLE     Ophthalmic genetics/inherited eye disease.
  JOURNAL   Curr Opin Ophthalmol 14:296-303 (2003)
REFERENCE   PMID:19200529 (gene)
  AUTHORS   Ahram D, Sato TS, Kohilan A, Tayeh M, Chen S, Leal S, Al-Salem M, El-Shanti H
  TITLE     A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated ectopia lentis.
  JOURNAL   Am J Hum Genet 84:274-8 (2009)
///
ENTRY       H00663                      Disease
NAME        Restrictive dermopathy
DESCRIPTION Restrictive dermopathy (LD) is a rare, lethal autosomal recessive genodermatosis caused by mutations in either LMNA or ZMPSTE24. Manifestations include a tight, thin, translucent skin, typical face, multiple joint contractures, enlarged fontanelles, and dysplasia of clavicles.
CATEGORY    Developmental disorder; Skeletal dysplasia; Skin and connective tissue disease
GENE        LMNA [HSA:4000] [KO:K12641]
            ZMPSTE24 [HSA:10269] [KO:K06013]
DBLINKS     ICD-10: Q82.8
            MeSH: C536920
            OMIM: 275210
REFERENCE   PMID:19020898 (description, gene)
  AUTHORS   Morais P, Magina S, Ribeiro Mdo C, Rodrigues M, Lopes JM, Thanh Hle T, Wehnert M, Guimaraes H
  TITLE     Restrictive dermopathy--a lethal congenital laminopathy. Case report and review of the literature.
  JOURNAL   Eur J Pediatr 168:1007-12 (2009)
REFERENCE   PMID:9217218 (description)
  AUTHORS   Mau U, Kendziorra H, Kaiser P, Enders H
  TITLE     Restrictive dermopathy: report and review.
  JOURNAL   Am J Med Genet 71:179-85 (1997)
REFERENCE   PMID:1605246 (description)
  AUTHORS   Verloes A, Mulliez N, Gonzales M, Laloux F, Hermanns-Le T, Pierard GE, Koulischer L
  TITLE     Restrictive dermopathy, a lethal form of arthrogryposis multiplex with skin and bone dysplasias: three new cases and review of the literature.
  JOURNAL   Am J Med Genet 43:539-47 (1992)
///
ENTRY       H00664                      Disease
NAME        Anemia due to disorders of glycolytic enzymes, including:
            Hexokinase (HK) deficiency;
            Phosphoglycerate kinase 1 (PGK1) deficiency;
            Triose-phosphate isomerase (TPI) deficiency;
            Glucose phosphate isomerase (GPI) deficiency;
            Bisphosphoglycerate mutase (BPGM) deficiency
DESCRIPTION Anemia due to disorders of glycolytic enzymes is a group of red cell disorders caused by inherited abnormality of glycolytic enzymes. Neurological phenotypes have been found to be associated only with specific mutations affecting TPI, PGK and, in rare cases, GPI. The symptoms of TPI deficiency are generally much more severe than those of any other glycolytic enzyme deficiency.
CATEGORY    Hematologic disease
GENE        HK1 [HSA:3098] [KO:K00844]
            PGK1 [HSA:5230] [KO:K00927]
            TPI1 [HSA:7167] [KO:K01803]
            GPI [HSA:2821] [KO:K01810]
            BPGM [HSA:669] [KO:K01837]
MARKER      (TPI deficiency) Elevation of DHAP [CPD:C00111] level in erythrocytes.
DBLINKS     ICD-10: D55.2
            OMIM: 235700 300653 190450 613470 222800
REFERENCE   PMID:10699493
  AUTHORS   Martinov MV, Plotnikov AG, Vitvitsky VM, Ataullakhanov FI
  TITLE     Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia.
  JOURNAL   Biochim Biophys Acta 1474:75-87 (2000)
REFERENCE   PMID:12393545
  AUTHORS   van Wijk R, Rijksen G, Huizinga EG, Nieuwenhuis HK, van Solinge WW
  TITLE     HK Utrecht: missense mutation in the active site of human hexokinase associated with hexokinase deficiency and severe nonspherocytic hemolytic anemia.
  JOURNAL   Blood 101:345-7 (2003)
REFERENCE   PMID:17222195
  AUTHORS   Beutler E
  TITLE     PGK deficiency.
  JOURNAL   Br J Haematol 136:3-11 (2007)
REFERENCE   PMID:16086671
  AUTHORS   Olah J, Orosz F, Puskas LG, Hackler L Jr, Horanyi M, Polgar L, Hollan S, Ovadi J
  TITLE     Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels.
  JOURNAL   Biochem J 392:675-83 (2005)
REFERENCE   PMID:20516363
  AUTHORS   Rossi F, Ruggiero S, Gallo M, Simeone G, Matarese SM, Nobili B
  TITLE     Amoxicillin-induced hemolytic anemia in a child with glucose 6-phosphate isomerase deficiency.
  JOURNAL   Ann Pharmacother 44:1327-9 (2010)
REFERENCE   PMID:15054810
  AUTHORS   Hoyer JD, Allen SL, Beutler E, Kubik K, West C, Fairbanks VF
  TITLE     Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
  JOURNAL   Am J Hematol 75:205-8 (2004)
///
ENTRY       H00665                      Disease
NAME        Mandibuloacral dysplasia
DESCRIPTION Mandibuloacral dysplasia (MAD) is an autosomal recessive disorder characterized by postnatal growth retardation, hypoplasia of the mandible and clavicles, acro-osteolysis, and partial lipodystrophy. Affected individuals have a normal appearance at birth, then progressively develop dysmorphic skeletal features. Mutations in LMNA or ZMPSTE24 are responsible for the disorder.
CATEGORY    Skeletal dysplasia; Skin and connective tissue disease
GENE        (type A) LMNA [HSA:4000] [KO:K12641]
            (type B) ZMPSTE24 [HSA:10269] [KO:K06013]
DBLINKS     ICD-10: Q87.5
            MeSH: C535705 C535706
            OMIM: 248370 608612
REFERENCE   PMID:20182615 (description, gene)
  AUTHORS   Worman HJ, Ostlund C, Wang Y
  TITLE     Diseases of the nuclear envelope.
  JOURNAL   Cold Spring Harb Perspect Biol 2:a000760 (2010)
REFERENCE   PMID:17467691 (description, gene)
  AUTHORS   Worman HJ, Bonne G
  TITLE     "Laminopathies": a wide spectrum of human diseases.
  JOURNAL   Exp Cell Res 313:2121-33 (2007)
REFERENCE   PMID:14615129 (description)
  AUTHORS   Bonne G, Levy N
  TITLE     LMNA mutations in atypical Werner's syndrome.
  JOURNAL   Lancet 362:1585-6; author reply 1586 (2003)
REFERENCE   PMID:16364671 (description, gene)
  AUTHORS   Jacob KN, Garg A
  TITLE     Laminopathies: multisystem dystrophy syndromes.
  JOURNAL   Mol Genet Metab 87:289-302 (2006)
REFERENCE   PMID:21267004 (gene)
  AUTHORS   Ben Yaou R, Navarro C, Quijano-Roy S, Bertrand AT, Massart C, De Sandre-Giovannoli A, Cadinanos J, Mamchaoui K, Butler-Browne G, Estournet B, Richard P, Barois A, Levy N, Bonne G
  TITLE     Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation.
  JOURNAL   Eur J Hum Genet 19:647-54 (2011)
REFERENCE   PMID:20814950 (gene)
  AUTHORS   Ahmad Z, Zackai E, Medne L, Garg A
  TITLE     Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24.
  JOURNAL   Am J Med Genet A 152A:2703-10 (2010)
///
ENTRY       H00666                      Disease
NAME        Peutz-Jeghers syndrome
DESCRIPTION Peutz-Jeghers syndrome (PJS) is an autosomal dominant condition in which multiple characteristic polyps occur throughout the gastrointestinal tract. Mucocutaneous pigmented lesions, especially of the vermilion border of the lips, are seen in almost all patients. PJS patients have a considerably increased risk of developing intestinal malignancies. The only known cause for PJS is STK11 mutation.
CATEGORY    Gastrointestinal disease
GENE        STK11 [HSA:6794] [KO:K07298]
DBLINKS     ICD-10: Q85.8
            MeSH: D010580
            OMIM: 175200
REFERENCE   PMID:20581245 (description, gene)
  AUTHORS   Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Friedl W, Moller P, Hes FJ, Jarvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV
  TITLE     Peutz-Jeghers syndrome: a systematic review and recommendations for management.
  JOURNAL   Gut 59:975-86 (2010)
REFERENCE   PMID:15121768 (description, gene)
  AUTHORS   Amos CI, Keitheri-Cheteri MB, Sabripour M, Wei C, McGarrity TJ, Seldin MF, Nations L, Lynch PM, Fidder HH, Friedman E, Frazier ML
  TITLE     Genotype-phenotype correlations in Peutz-Jeghers syndrome.
  JOURNAL   J Med Genet 41:327-33 (2004)
REFERENCE   PMID:20051941 (description)
  AUTHORS   van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME
  TITLE     High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance  recommendations.
  JOURNAL   Am J Gastroenterol 105:1258-64; author reply 1265 (2010)
///
ENTRY       H00667                      Disease
NAME        Woolly hair, including:
            Autosomal-dominant woolly hair (ADWH);
            Autosomal-recessive woolly hair (ARWH);
            Autosomal-recessive woolly hair with or without hypotrichosis
DESCRIPTION Woolly hair (WH) is a group of hair shaft dystrophies characterized by fine and tightly curled hair. WH is inherited in either autosomal dominant and autosomal recessive manner. Autosomal recessive woolly hair can also show varying degrees of sparse hair or hypotrichosis.
CATEGORY    Congenital disorder; Skin and connective tissue disease
GENE        (ADWH) KRT74 [HSA:121391] [KO:K07605]
            (ADWH/hypotrichosis) P2RY5 [HSA:10161] [KO:K04273]
            (ADWH/hypotrichosis) LIPH [HSA:200879] [KO:K19404]
DBLINKS     ICD-10: Q84.2
            MeSH: C564735
            OMIM: 194300 278150 604379
REFERENCE   PMID:21890491 (description)
  AUTHORS   McLean WH, Moore CB
  TITLE     Keratin disorders: from gene to therapy.
  JOURNAL   Hum Mol Genet 20:R189-97 (2011)
REFERENCE   PMID:20346438 (gene)
  AUTHORS   Shimomura Y, Wajid M, Petukhova L, Kurban M, Christiano AM
  TITLE     Autosomal-dominant woolly hair resulting from disruption of keratin 74 (KRT74), a potential determinant of human hair texture.
  JOURNAL   Am J Hum Genet 86:632-8 (2010)
REFERENCE   PMID:18830268 (gene)
  AUTHORS   Shimomura Y, Wajid M, Petukhova L, Shapiro L, Christiano AM
  TITLE     Mutations in the lipase H gene underlie autosomal recessive woolly hair/hypotrichosis.
  JOURNAL   J Invest Dermatol 129:622-8 (2009)
REFERENCE   PMID:18297072 (gene)
  AUTHORS   Shimomura Y, Wajid M, Ishii Y, Shapiro L, Petukhova L, Gordon D, Christiano AM
  TITLE     Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair.
  JOURNAL   Nat Genet 40:335-9 (2008)
///
ENTRY       H00668                      Disease
NAME        Anemia due to disorders of glutathione metabolism, including:
            Glucose-6-phosphate dehydrogenase deficiency [DS:H01375];
            Glutathione peroxidase deficiency;
            Gamma-glutamylcysteine synthetase deficiency;
            Glutathione synthetase deficiency
DESCRIPTION Anemia due to disorders of glutathione metabolism is a group of red cell disorders caused by inherited abnormality of enzymes of glutathione metabolism. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells in humans. It is estimated that about 400 million people are affected by this deficiency. A G6PD-deficient patient lacks the ability to protect red blood cells against oxidative stresses from certain drugs, infections, metabolic conditions, and ingestion of fava beans. GCLC catalyzes the initial and the rate-limiting step of glutathione synthesis. Deficiency of GCLC is extremely rare. GSS deficiency is a more frequent cause of glutathione deficiency.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        G6PD [HSA:2539] [KO:K00036]
            GPX1 [HSA:2876] [KO:K00432]
            GCLC [HSA:2729] [KO:K11204]
            GSS [HSA:2937] [KO:K21456]
DBLINKS     ICD-10: D55.0 D55.1
            MeSH: D005955 C564217 C565557 C536835
            OMIM: 300908 614164 230450 231900 266130
REFERENCE   PMID:8634459
  AUTHORS   Hirono A, Iyori H, Sekine I, Ueyama J, Chiba H, Kanno H, Fujii H, Miwa S
  TITLE     Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency.
  JOURNAL   Blood 87:2071-4 (1996)
REFERENCE   PMID:5766310
  AUTHORS   Necheles TF, Maldonado N, Barquet-Chediak A, Allen DM
  TITLE     Homozygous erythrocyte glutathione-peroxidase deficiency: clinical and biochemical studies.
  JOURNAL   Blood 33:164-9 (1969)
REFERENCE   PMID:21852236
  AUTHORS   Lubos E, Kelly NJ, Oldebeken SR, Leopold JA, Zhang YY, Loscalzo J, Handy DE
  TITLE     Glutathione Peroxidase-1 Deficiency Augments Proinflammatory Cytokine-induced Redox Signaling and Human Endothelial Cell Activation.
  JOURNAL   J Biol Chem 286:35407-17 (2011)
REFERENCE   PMID:10515893
  AUTHORS   Beutler E, Gelbart T, Kondo T, Matsunaga AT
  TITLE     The molecular basis of a case of gamma-glutamylcysteine synthetase deficiency.
  JOURNAL   Blood 94:2890-4 (1999)
///
ENTRY       H00669                      Disease
NAME        Naxos disease and Carvajal syndrome
DESCRIPTION Naxos disease and Carvajal syndrome are disorders characterized by cardiomyopathy, palmoplantar keratoderma, and woolly hair. Cardiac manifestation in patients with Naxos disease is arrhythmogenic right ventricular cardiomyopathy that appears by adolescence with 100% penetrance. Carvajal syndrome is a variant of Naxos disease phenotype with left ventricular involvement that manifests in childhood and leads to early morbidity.
CATEGORY    Congenital disorder; Skin and connective tissue disease; Cardiovascular disease
GENE        (Naxos) JUP [HSA:3728] [KO:K10056]
            (Carvajal) DSP [HSA:1832] [KO:K10381]
DBLINKS     ICD-10: Q87.8
            OMIM: 601214 605676
REFERENCE   PMID:15210133 (description, gene)
  AUTHORS   Protonotarios N, Tsatsopoulou A
  TITLE     Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy.
  JOURNAL   Cardiovasc Pathol 13:185-94 (2004)
REFERENCE   PMID:10902626 (gene)
  AUTHORS   McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, Baboonian C, Jeffery S, McKenna WJ
  TITLE     Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).
  JOURNAL   Lancet 355:2119-24 (2000)
REFERENCE   PMID:11063735 (gene)
  AUTHORS   Norgett EE, Hatsell SJ, Carvajal-Huerta L, Cabezas JC, Common J, Purkis PE, Whittock N, Leigh IM, Stevens HP, Kelsell DP
  TITLE     Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma.
  JOURNAL   Hum Mol Genet 9:2761-6 (2000)
REFERENCE   PMID:9738775 (description)
  AUTHORS   Carvajal-Huerta L
  TITLE     Epidermolytic palmoplantar keratoderma with woolly hair and dilated cardiomyopathy.
  JOURNAL   J Am Acad Dermatol 39:418-21 (1998)
///
ENTRY       H00670                      Disease
NAME        Monilethrix
DESCRIPTION Monilethrix is a disease of the hair cortex characterized by an unusually deformed hair shaft and alopecia. It has been named for the beaded appearance of affected hairs. Mutations in type II hair follicle-specific keratins lead to monilethrix.
CATEGORY    Congenital disorder; Skin and connective tissue disease
GENE        KRT81 [HSA:3887] [KO:K07605]
            KRT83 [HSA:3889] [KO:K07605]
            KRT86 [HSA:3892] [KO:K07605]
DRUG        Minoxidil [DR:D00418]
DBLINKS     ICD-10: Q84.1
            MeSH: D056734
            OMIM: 158000
REFERENCE   PMID:17428470 (gene, description)
  AUTHORS   Schweizer J, Langbein L, Rogers MA, Winter H
  TITLE     Hair follicle-specific keratins and their diseases.
  JOURNAL   Exp Cell Res 313:2010-20 (2007)
REFERENCE   PMID:21890491 (gene, description)
  AUTHORS   McLean WH, Moore CB
  TITLE     Keratin disorders: from gene to therapy.
  JOURNAL   Hum Mol Genet 20:R189-97 (2011)
REFERENCE   PMID:21496408 (drug)
  AUTHORS   Rossi A, Iorio A, Scali E, Fortuna MC, Mari E, Palese E, Greco P, Carlesimo M
  TITLE     Monilethrix treated with minoxidil.
  JOURNAL   Int J Immunopathol Pharmacol 24:239-42 (2011)
///
ENTRY       H00671                      Disease
NAME        Netherton syndrome
DESCRIPTION Netherton syndrome is a rare autosomal recessive genodermatosis consisting of erythroderma, ichthyosis linearis circumflexa, and hair shaft abnormalities with a bamboo shoot appearance (trichorrhexis invaginata). Atopic diathesis is commonly associated with the condition.
CATEGORY    Skin and connective tissue disease
GENE        SPINK5 [HSA:11005]
MARKER      elevated serum IgE
DBLINKS     ICD-10: L67.0 Q80.8
            MeSH: D056770
            OMIM: 256500
REFERENCE   PMID:12130905 (description, gene, marker)
  AUTHORS   Siegel DH, Howard R
  TITLE     Molecular advances in genetic skin diseases.
  JOURNAL   Curr Opin Pediatr 14:419-25 (2002)
REFERENCE   PMID:16796630 (description, gene, marker)
  AUTHORS   Sun JD, Linden KG
  TITLE     Netherton syndrome: a case report and review of the literature.
  JOURNAL   Int J Dermatol 45:693-7 (2006)
///
ENTRY       H00672                      Disease
NAME        Pseudofolliculitis barbae
DESCRIPTION Pseudofolliculitis barbae is a common skin disorder occurring predominantly in males of African origin, characterized by acneiform papules and pustules that result in keloidal scarring localized to the facial and submental regions. It is caused when highly curved hair shafts repenetrate the skin. A single nucleotide polymorphism in KRT75, which leads to a disruptive Ala12Thr substitution, has been demonstrated in the disease.
CATEGORY    Skin and connective tissue disease
GENE        KRT75 (polymorphism) [HSA:9119] [KO:K07605]
DBLINKS     MeSH: C563016
            OMIM: 612318
REFERENCE   PMID:15086549 (gene, description)
  AUTHORS   Winter H, Schissel D, Parry DA, Smith TA, Liovic M, Birgitte Lane E, Edler L, Langbein L, Jave-Suarez LF, Rogers MA, Wilde J, Peters G, Schweizer J
  TITLE     An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae.
  JOURNAL   J Invest Dermatol 122:652-7 (2004)
REFERENCE   PMID:17803606 (gene, description)
  AUTHORS   Quarles FN, Brody H, Johnson BA, Badreshia S, Vause SE, Brauner G, Breadon JY, Swinehart J, Callendar V
  TITLE     Pseudofolliculitis barbae.
  JOURNAL   Dermatol Ther 20:133-6 (2007)
REFERENCE   PMID:15113283 (description)
  AUTHORS   Bridgeman-Shah S
  TITLE     The medical and surgical therapy of pseudofolliculitis barbae.
  JOURNAL   Dermatol Ther 17:158-63 (2004)
///
ENTRY       H00673                      Disease
NAME        Weill-Marchesani syndrome, including:
            Weill-Marchesani syndrome;
            Weill-Marchesani-like syndrome
DESCRIPTION Weill-Marchesani syndrome is a rare connective tissue disorder characterized by short stature, brachydactyly, ectopia lentis and spherophakia. Decreased joint flexibility is one of the features of this syndrome.
CATEGORY    Skeletal dysplasia; Skin and connective tissue disease
GENE        (autosomal dominant) FBN1 [HSA:2200] [KO:K06825]
            (autosomal recessive) ADAMTS10 [HSA:81794] [KO:K08625]
            (Weill-Marchesani-like) ADAMTS17 [HSA:170691] [KO:K08631]
DBLINKS     ICD-10: Q87.1
            MeSH: D056846
            OMIM: 608328 277600 613195
REFERENCE   PMID:14598350 (description)
  AUTHORS   Faivre L, Dollfus H, Lyonnet S, Alembik Y, Megarbane A, Samples J, Gorlin RJ, Alswaid A, Feingold J, Le Merrer M, Munnich A, Cormier-Daire V
  TITLE     Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome.
  JOURNAL   Am J Med Genet A 123A:204-7 (2003)
REFERENCE   PMID:20301293 (gene)
  AUTHORS   Tsilou E, MacDonald IM
  TITLE     Weill-Marchesani Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:19836009 (gene)
  AUTHORS   Morales J, Al-Sharif L, Khalil DS, Shinwari JM, Bavi P, Al-Mahrouqi RA, Al-Rajhi A, Alkuraya FS, Meyer BF, Al Tassan N
  TITLE     Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature.
  JOURNAL   Am J Hum Genet 85:558-68 (2009)
///
ENTRY       H00674                      Disease
NAME        Anemia due to disorders of nucleotide metabolism, including:
            Adenylate kinase (AK) deficiency;
            Uridine 5-prime monophosphate hydrolase (UMPH1) deficiency
DESCRIPTION Abnormalities in erythrocyte nucleotide metabolism are associated with hereditary nonspherocytic hemolytic anemia. Deficiency of adenylate kinase and pyrimidine 5'-nucleotidase shorten the red cell lifespan.
CATEGORY    Hematologic disease
GENE        AK1 [HSA:203] [KO:K00939]
            UMPH1 [HSA:51251] [KO:K01081]
DBLINKS     ICD-10: D55.3
            OMIM: 612631 266120
REFERENCE   PMID:8890581
  AUTHORS   Masuda M, Mizoguchi H
  TITLE     [Hemolytic anemia due to abnormalities in erythrocyte nucleotide metabolism].
  JOURNAL   Nihon Rinsho 54:2473-7 (1996)
REFERENCE   PMID:1646049
  AUTHORS   Lachant NA, Zerez CR, Barredo J, Lee DW, Savely SM, Tanaka KR
  TITLE     Hereditary erythrocyte adenylate kinase deficiency: a defect of multiple phosphotransferases?
  JOURNAL   Blood 77:2774-84 (1991)
REFERENCE   PMID:11369620
  AUTHORS   Marinaki AM, Escuredo E, Duley JA, Simmonds HA, Amici A, Naponelli V, Magni G, Seip M, Ben-Bassat I, Harley EH, Thein SL, Rees DC
  TITLE     Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency.
  JOURNAL   Blood 97:3327-32 (2001)
REFERENCE   PMID:16611302
  AUTHORS   Zanella A, Bianchi P, Fermo E, Valentini G
  TITLE     Hereditary pyrimidine 5'-nucleotidase deficiency: from genetics to clinical manifestations.
  JOURNAL   Br J Haematol 133:113-23 (2006)
REFERENCE   PMID:19291420
  AUTHORS   Jurecka A
  TITLE     Inborn errors of purine and pyrimidine metabolism.
  JOURNAL   J Inherit Metab Dis 32:247-63 (2009)
///
ENTRY       H00675                      Disease
NAME        Acrocapitofemoral dysplasia
DESCRIPTION Acrocapitofemoral dysplasia is an autosomal recessive skeletal dysplasia characterized by short stature with brachydactyly, a narrow thorax, and a relatively large head. Radiographically, cone-shaped epiphyses are present in the hands and hips.
CATEGORY    Skeletal dysplasia
GENE        IHH [HSA:3549] [KO:K11989]
DBLINKS     MeSH: C564334
            OMIM: 607778
REFERENCE   PMID:12632327 (gene, description)
  AUTHORS   Hellemans J, Coucke PJ, Giedion A, De Paepe A, Kramer P, Beemer F, Mortier GR
  TITLE     Homozygous mutations in IHH cause acrocapitofemoral dysplasia, an autosomal recessive disorder with cone-shaped epiphyses in hands and hips.
  JOURNAL   Am J Hum Genet 72:1040-6 (2003)
REFERENCE   PMID:12624140 (description)
  AUTHORS   Mortier GR, Kramer PP, Giedion A, Beemer FA
  TITLE     Acrocapitofemoral dysplasia: an autosomal recessive skeletal dysplasia with cone  shaped epiphyses in the hands and hips.
  JOURNAL   J Med Genet 40:201-7 (2003)
///
ENTRY       H00676                      Disease
NAME        Congenital primary aphakia
DESCRIPTION Congenital primary aphakia (CPA) is a rare congenital eye disorder characterized by the absence of lens. Formation of lens and lens-induced anterior structures does not take place in CPA, resulting in complete aplasia of the anterior segment of the eye. CPA is caused by mutations in FOXE3, a lens-specific transcription factor.
CATEGORY    Developmental disorder; Eye disease
GENE        FOXE3 [HSA:2301] [KO:K09398]
DBLINKS     ICD-10: Q12.3
            MeSH: C537786
            OMIM: 610256
REFERENCE   PMID:19708017 (description)
  AUTHORS   Iseri SU, Osborne RJ, Farrall M, Wyatt AW, Mirza G, Nurnberg G, Kluck C, Herbert H, Martin A, Hussain MS, Collin JR, Lathrop M, Nurnberg P, Ragoussis J, Ragge NK
  TITLE     Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies.
  JOURNAL   Hum Mutat 30:1378-86 (2009)
REFERENCE   PMID:17344231 (description)
  AUTHORS   Medina-Martinez O, Jamrich M
  TITLE     Foxe view of lens development and disease.
  JOURNAL   Development 134:1455-63 (2007)
REFERENCE   PMID:16826526 (description, gene)
  AUTHORS   Valleix S, Niel F, Nedelec B, Algros MP, Schwartz C, Delbosc B, Delpech M, Kantelip B
  TITLE     Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans.
  JOURNAL   Am J Hum Genet 79:358-64 (2006)
///
ENTRY       H00677                      Disease
NAME        Aplasia of lacrimal and salivary glands
DESCRIPTION Aplasia of lacrimal and salivary glands (ALSG) is a rare autosomal dominant condition characterized by insufficient development of the lacrimal and salivary systems. Patients with ALSG suffer from irritable eyes and dryness of the mouth. Mutations in FGF10 were recently described in ALSG.
CATEGORY    Developmental disorder
GENE        FGF10 [HSA:2255] [KO:K04358]
COMMENT     Lacrimo-auriculo-dento-digital syndrome (LADD), a closely related disorder, is described in H00642.
DBLINKS     ICD-10: Q10.4 Q38.4
            MeSH: C562407
            OMIM: 180920
REFERENCE   PMID:17213838 (description, gene)
  AUTHORS   Entesarian M, Dahlqvist J, Shashi V, Stanley CS, Falahat B, Reardon W, Dahl N
  TITLE     FGF10 missense mutations in aplasia of lacrimal and salivary glands (ALSG).
  JOURNAL   Eur J Hum Genet 15:379-82 (2007)
REFERENCE   PMID:15654336 (description, gene)
  AUTHORS   Entesarian M, Matsson H, Klar J, Bergendal B, Olson L, Arakaki R, Hayashi Y, Ohuchi H, Falahat B, Bolstad AI, Jonsson R, Wahren-Herlenius M, Dahl N
  TITLE     Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands.
  JOURNAL   Nat Genet 37:125-7 (2005)
REFERENCE   PMID:19102732 (description, gene)
  AUTHORS   Scheckenbach K, Balz V, Wagenmann M, Hoffmann TK
  TITLE     An intronic alteration of the fibroblast growth factor 10 gene causing ALSG-(aplasia of lacrimal and salivary glands) syndrome.
  JOURNAL   BMC Med Genet 9:114 (2008)
///
ENTRY       H00678                      Disease
NAME        Achondrogenesis type IA
DESCRIPTION Achondrogenesis type IA is an extremely rare neonatal lethal chondrodysplasia. The disorder shows poorly ossified vertebral bodies/skull and completely lacked columnar-zone of the growth plate cartilage. Retention of fibrillar material within the rough endoplasmic reticulum is caused by mutated TRIP11 encoding Golgi-associated microtubule-binding protein 210 in the Golgi apparatus.
CATEGORY    Skeletal dysplasia
GENE        TRIP11 [HSA:9321]
DBLINKS     MeSH: C536015
            OMIM: 200600
REFERENCE   PMID:20089978 (gene)
  AUTHORS   Freeze HH
  TITLE     Achondrogenesis type 1A--from mouse to human.
  JOURNAL   N Engl J Med 362:266-7 (2010)
REFERENCE   PMID:20089971 (gene, descrition)
  AUTHORS   Smits P, Bolton AD, Funari V, Hong M, Boyden ED, Lu L, Manning DK, Dwyer ND, Moran JL, Prysak M, Merriman B, Nelson SF, Bonafe L, Superti-Furga A, Ikegawa S, Krakow D, Cohn DH, Kirchhausen T, Warman ML, Beier DR
  TITLE     Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210.
  JOURNAL   N Engl J Med 362:206-16 (2010)
REFERENCE   PMID:17638425 (description)
  AUTHORS   Aigner T, Rau T, Niederhagen M, Zaucke F, Schmitz M, Pohls U, Stoss H, Rauch A, Thiel CT
  TITLE     Achondrogenesis Type IA (Houston-Harris): a still-unresolved molecular phenotype.
  JOURNAL   Pediatr Dev Pathol 10:328-34 (2007)
///
ENTRY       H00679                      Disease
NAME        Hypomyelinating leukodystrophy;
            Pelizaeus-Merzbacher disease (PMD)
DESCRIPTION Hypomyelinating leukodystrophies (HMLs) are disorders involving aberrant myelin formation in the central nervous system. They are clinically characterized by early onset nystagmus, impaired motor development, ataxia, choreoathetoid movements, dysarthria and progressive limb spasticity.  The prototype of primary HMLs is the X-linked Pelizaeus-Merzbacher disease (PMD) caused by mutations in PLP1 encoding proteolipid protein lipophilin. Pelizaeus-Merzbacher-like disease (PMLD) is clinically similar to classical PMD but is not associated with PLP1 mutations. PMLD appears to be inherited in an autosomal recessive manner and mutations have been identified in GJC2, AIMP1, HSPD1 and so on.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        (HLD1/ PMD) PLP1 [HSA:5354] [KO:K17271]
            (HLD2) GJC2 [HSA:57165] [KO:K07619]
            (HLD3) AIMP1 [HSA:9255] [KO:K15437]
            (HLD4) HSPD1 [HSA:3329] [KO:K04077]
            (HLD5) FAM126A [HSA:84668]
            (HLD6) TUBB4A [HSA:10382] [KO:K07375]
            (HLD7) POLR3A [HSA:11128] [KO:K03018]
            (HLD8) POLR3B [HSA:55703] [KO:K03021]
            (HLD9) RARS [HSA:5917] [KO:K01887]
            (HLD10) PYCR2 [HSA:29920] [KO:K00286]
            (HLD11) POLR1C [HSA:9533] [KO:K03027]
            (HLD12) VPS11 [HSA:55823] [KO:K20179]
            (HLD13) HIKESHI [HSA:51501]
DBLINKS     ICD-10: E75.2
            MeSH: D020371
            OMIM: 312080 608804 260600 612233 610532 612438 607694 614381 616140 616420 616494 616683 616881
REFERENCE   PMID:17115121
  AUTHORS   Garbern JY
  TITLE     Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis.
  JOURNAL   Cell Mol Life Sci 64:50-65 (2007)
REFERENCE   PMID:21959080
  AUTHORS   Meyer E, Kurian MA, Morgan NV, McNeill A, Pasha S, Tee L, Younis R, Norman A, van der Knaap MS, Wassmer E, Trembath RC, Brueton L, Maher ER
  TITLE     Promoter mutation is a common variant in GJC2-associated Pelizaeus-Merzbacher-like disease.
  JOURNAL   Mol Genet Metab 104:637-43 (2011)
REFERENCE   PMID:21092922
  AUTHORS   Feinstein M, Markus B, Noyman I, Shalev H, Flusser H, Shelef I, Liani-Leibson K, Shorer Z, Cohen I, Khateeb S, Sivan S, Birk OS
  TITLE     Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation.
  JOURNAL   Am J Hum Genet 87:820-8 (2010)
REFERENCE   PMID:18571143
  AUTHORS   Magen D, Georgopoulos C, Bross P, Ang D, Segev Y, Goldsher D, Nemirovski A, Shahar E, Ravid S, Luder A, Heno B, Gershoni-Baruch R, Skorecki K, Mandel H
  TITLE     Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy.
  JOURNAL   Am J Hum Genet 83:30-42 (2008)
REFERENCE   PMID:16951682 (HLD5)
  AUTHORS   Zara F, Biancheri R, Bruno C, Bordo L, Assereto S, Gazzerro E, Sotgia F, Wang XB, Gianotti S, Stringara S, Pedemonte M, Uziel G, Rossi A, Schenone A, Tortori-Donati P, van der Knaap MS, Lisanti MP, Minetti C
  TITLE     Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract.
  JOURNAL   Nat Genet 38:1111-3 (2006)
REFERENCE   PMID:26643067 (gene)
  AUTHORS   Tonduti D, Aiello C, Renaldo F, Dorboz I, Saaman S, Rodriguez D, Fettah H, Elmaleh M, Biancheri R, Barresi S, Boccone L, Orcesi S, Pichiecchio A, Zangaglia R, Maurey H, Rossi A, Boespflug-Tanguy O, Bertini E
  TITLE     TUBB4A-related hypomyelinating leukodystrophy: New insights from a series of 12 patients.
  JOURNAL   Eur J Paediatr Neurol 20:323-30 (2016)
REFERENCE   PMID:27120463
  AUTHORS   Zhang J, Lachance V, Schaffner A, Li X, Fedick A, Kaye LE, Liao J, Rosenfeld J, Yachelevich N, Chu ML, Mitchell WG, Boles RG, Moran E, Tokita M, Gorman E, Bagley K, Zhang W, Xia F, Leduc M, Yang Y, Eng C, Wong LJ, Schiffmann R, Diaz GA, Kornreich R, Thummel R, Wasserstein M, Yue Z, Edelmann L
  TITLE     A Founder Mutation in VPS11 Causes an Autosomal Recessive Leukoencephalopathy Linked to Autophagic Defects.
  JOURNAL   PLoS Genet 12:e1005848 (2016)
REFERENCE   PMID:26545878
  AUTHORS   Edvardson S, Kose S, Jalas C, Fattal-Valevski A, Watanabe A, Ogawa Y, Mamada H, Fedick AM, Ben-Shachar S, Treff NR, Shaag A, Bale S, Gartner J, Imamoto N, Elpeleg O
  TITLE     Leukoencephalopathy and early death associated with an Ashkenazi-Jewish founder mutation in the Hikeshi gene.
  JOURNAL   J Med Genet 53:132-7 (2016)
///
ENTRY       H00680                      Disease
NAME        Primary failure of tooth eruption
DESCRIPTION Primary failure of tooth eruption (PFE) is a condition in which tooth retention occurs without mechanical interference. Defects in PTHR1 are the cause of PFE.
CATEGORY    Mouth and dental disease
GENE        PTHR1 [HSA:5745] [KO:K04585]
DBLINKS     MeSH: C565114
            OMIM: 125350
REFERENCE   PMID:17041084 (decription)
  AUTHORS   Ahmad S, Bister D, Cobourne MT
  TITLE     The clinical features and aetiological basis of primary eruption failure.
  JOURNAL   Eur J Orthod 28:535-40 (2006)
REFERENCE   PMID:19419448 (decription)
  AUTHORS   Proffit WR, Frazier-Bowers SA
  TITLE     Mechanism and control of tooth eruption: overview and clinical implications.
  JOURNAL   Orthod Craniofac Res 12:59-66 (2009)
REFERENCE   PMID:19061984 (gene)
  AUTHORS   Decker E, Stellzig-Eisenhauer A, Fiebig BS, Rau C, Kress W, Saar K, Ruschendorf F, Hubner N, Grimm T, Weber BH
  TITLE     PTHR1 loss-of-function mutations in familial, nonsyndromic primary failure of tooth eruption.
  JOURNAL   Am J Hum Genet 83:781-6 (2008)
///
ENTRY       H00681                      Disease
NAME        Acne inversa;
            Hidradenitis suppurativa
DESCRIPTION Acne inversa (AI), also known as hidradenitis suppurativa, is a chronic inflammatory disorder of hair follicles involving the apocrine gland-bearing areas of the body. Its characteristic features include recurrent formation of painful skin abscesses, fistulating sinuses, and disfiguring scars.
CATEGORY    Skin and connective tissue disease
GENE        PSENEN [HSA:55851] [KO:K06170]
            PSEN1 [HSA:5663] [KO:K04505] 
            NCSTN [HSA:23385] [KO:K06171]
ENV_FACTOR  Smoking
            Staphylococci infection
            Androgen levels
DBLINKS     ICD-10: L73.2
            MeSH: D017497
            OMIM: 142690 613736 613737
REFERENCE   PMID:21192260 (description, env_factor, drug)
  AUTHORS   Yazdanyar S, Jemec GB
  TITLE     Hidradenitis suppurativa: a review of cause and treatment.
  JOURNAL   Curr Opin Infect Dis 24:118-23 (2011)
REFERENCE   PMID:17958790 (drug)
  AUTHORS   Lam J, Krakowski AC, Friedlander SF
  TITLE     Hidradenitis suppurativa (acne inversa): management of a recalcitrant disease.
  JOURNAL   Pediatr Dermatol 24:465-73 (2007)
REFERENCE   PMID:15264991 (drug)
  AUTHORS   Jemec GB
  TITLE     Medical treatment of hidradenitis suppurativa.
  JOURNAL   Expert Opin Pharmacother 5:1767-70 (2004)
REFERENCE   PMID:21495993 (gene)
  AUTHORS   Li CR, Jiang MJ, Shen DB, Xu HX, Wang HS, Yao X, Zhang Y, Zhou WQ, Wang B
  TITLE     Two novel mutations of the nicastrin gene in Chinese patients with acne inversa.
  JOURNAL   Br J Dermatol 165:415-8 (2011)
REFERENCE   PMID:20929727 (gene)
  AUTHORS   Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T, Chen M, Sun M, Shen Y, Zhang X
  TITLE     Gamma-secretase gene mutations in familial acne inversa.
  JOURNAL   Science 330:1065 (2010)
///
ENTRY       H00682                      Disease
NAME        Woodhouse-Sakati syndrome;
            Hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome
DESCRIPTION Woodhouse-Sakati syndrome (WSS) is a rare autosomal recessive disorder that encompasses alopecia, hypogonadism, diabetes mellitus, mental retardation, and extrapyramidal signs. Additional manifestations include sensorineural hearing loss, seizures, T-wave abnormalities on ECG, and polyneuropathy. The syndrome is caused by mutation of the C2orf37 gene encoding a nucleolar protein.
CATEGORY    Congenital disorder
GENE        C2orf37 [HSA:80067]
DBLINKS     MeSH: C536742
            OMIM: 241080
REFERENCE   PMID:17710875 (description)
  AUTHORS   Medica I, Sepcic J, Peterlin B
  TITLE     Woodhouse-Sakati syndrome: case report and symptoms review.
  JOURNAL   Genet Couns 18:227-31 (2007)
REFERENCE   PMID:19026396 (gene)
  AUTHORS   Alazami AM, Al-Saif A, Al-Semari A, Bohlega S, Zlitni S, Alzahrani F, Bavi P, Kaya N, Colak D, Khalak H, Baltus A, Peterlin B, Danda S, Bhatia KP, Schneider SA, Sakati N, Walsh CA, Al-Mohanna F, Meyer B, Alkuraya FS
  TITLE     Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome.
  JOURNAL   Am J Hum Genet 83:684-91 (2008)
REFERENCE   PMID:20507343 (gene)
  AUTHORS   Alazami AM, Schneider SA, Bonneau D, Pasquier L, Carecchio M, Kojovic M, Steindl K, de Kerdanet M, Nezarati MM, Bhatia KP, Degos B, Goh E, Alkuraya FS
  TITLE     C2orf37 mutational spectrum in Woodhouse-Sakati syndrome patients.
  JOURNAL   Clin Genet 78:585-90 (2010)
REFERENCE   PMID:21964978 (gene)
  AUTHORS   Ben-Omran T, Ali R, Almureikhi M, Alameer S, Al-Saffar M, Walsh CA, Felie JM, Teebi A
  TITLE     Phenotypic heterogeneity in Woodhouse-Sakati syndrome: Two new families with a mutation in the C2orf37 gene.
  JOURNAL   Am J Med Genet A 155:2647-53 (2011)
///
ENTRY       H00683                      Disease
NAME        Anonychia congenita
DESCRIPTION Nonsyndromic anonychia is a condition in which the nails of the fingers and toes are congenitally absent without significant bone anomalies. The teeth and hair are normal. Mutation in RSPO4, a Wnt-signaling component, has been identified.
CATEGORY    Skin and connective tissue disease
GENE        RSPO4 [HSA:343637]
DBLINKS     MeSH: C536377
            OMIM: 206800
REFERENCE   PMID:14126263 (description)
  AUTHORS   LITTMAN A, LEVIN S
  TITLE     ANONYCHIA AS A RECESSIVE AUTOSOMAL TRAIT IN MAN.
  JOURNAL   J Invest Dermatol 42:177-8 (1964)
REFERENCE   PMID:12121551 (description)
  AUTHORS   Al Hawsawi K, Al Aboud K, Alfadley A, Al Aboud D
  TITLE     Anonychia congenita totalis: a case report and review of the literature.
  JOURNAL   Int J Dermatol 41:397-9 (2002)
REFERENCE   PMID:17186469 (gene)
  AUTHORS   Bergmann C, Senderek J, Anhuf D, Thiel CT, Ekici AB, Poblete-Gutierrez P, van Steensel M, Seelow D, Nurnberg G, Schild HH, Nurnberg P, Reis A, Frank J, Zerres K
  TITLE     Mutations in the gene encoding the Wnt-signaling component R-spondin 4 (RSPO4) cause autosomal recessive anonychia.
  JOURNAL   Am J Hum Genet 79:1105-9 (2006)
///
ENTRY       H00684                      Disease
NAME        Pachyonychia congenita, including:
            Jadassohn-Lewandowsky syndrome;
            Jackson-Lawler syndrome ;
            Steatocystoma multiplex
DESCRIPTION Pachyonychia congenita (PC) is a group of autosomal dominant skin disorders characterized by hypertrophic nail dystrophy accompanied by other features of ectodermal dysplasia, prominently painful palmoplantar keratoderma. Additional clinical features include follicular hyperkeratosis, leukokeratosis of the oral mucosa, and various cysts (steatocysts and pilosebaceous cysts). It is caused by a mutation in one of four keratin genes KRT6A, KRT6B, KRT16, or KRT17.
CATEGORY    Skin and connective tissue disease
GENE        KRT6A [HSA:3853] [KO:K07605]
            KRT6B [HSA:3854] [KO:K07605]
            KRT16 [HSA:3868] [KO:K07604]
            KRT17 [HSA:3872] [KO:K07604]
DBLINKS     ICD-10: Q84.5 L72.2
            MeSH: D053549
            OMIM: 167210 167200 184500
REFERENCE   PMID:21890491 (description)
  AUTHORS   McLean WH, Moore CB
  TITLE     Keratin disorders: from gene to therapy.
  JOURNAL   Hum Mol Genet 20:R189-97 (2011)
REFERENCE   PMID:21326300 (gene)
  AUTHORS   Wilson NJ, Leachman SA, Hansen CD, McMullan AC, Milstone LM, Schwartz ME, McLean WH, Hull PR, Smith FJ
  TITLE     A large mutational study in pachyonychia congenita.
  JOURNAL   J Invest Dermatol 131:1018-24 (2011)
REFERENCE   PMID:7545493 (gene)
  AUTHORS   Bowden PE, Haley JL, Kansky A, Rothnagel JA, Jones DO, Turner RJ
  TITLE     Mutation of a type II keratin gene (K6a) in pachyonychia congenita.
  JOURNAL   Nat Genet 10:363-5 (1995)
REFERENCE   PMID:7539673 (gene)
  AUTHORS   McLean WH, Rugg EL, Lunny DP, Morley SM, Lane EB, Swensson O, Dopping-Hepenstal PJ, Griffiths WA, Eady RA, Higgins C, et al.
  TITLE     Keratin 16 and keratin 17 mutations cause pachyonychia congenita.
  JOURNAL   Nat Genet 9:273-8 (1995)
REFERENCE   PMID:9618173 (gene)
  AUTHORS   Smith FJ, Jonkman MF, van Goor H, Coleman CM, Covello SP, Uitto J, McLean WH
  TITLE     A mutation in human keratin K6b produces a phenocopy of the K17 disorder pachyonychia congenita type 2.
  JOURNAL   Hum Mol Genet 7:1143-8 (1998)
///
ENTRY       H00685                      Disease
NAME        Bifid nose with or without anorectal and renal anomalies;
            BNAR syndrome
DESCRIPTION BNAR syndrome is an autosomal recessive condition of nasal anomalies associated with renal and anorectal malformations. Patients have renal agenesis, anorectal malformations ranging from anteriorly placed anus with stenosis to rectal atresia, and overlapping toes. The syndrome is caused by mutations in FREM1 that encodes an extracellular matrix component of basement membranes.
CATEGORY    Developmental disorder
GENE        FREM1 [HSA:158326]
DBLINKS     MeSH: C535441
            OMIM: 608980
REFERENCE   PMID:19732862 (gene)
  AUTHORS   Alazami AM, Shaheen R, Alzahrani F, Snape K, Saggar A, Brinkmann B, Bavi P, Al-Gazali LI, Alkuraya FS
  TITLE     FREM1 mutations cause bifid nose, renal agenesis, and anorectal malformations syndrome.
  JOURNAL   Am J Hum Genet 85:414-8 (2009)
REFERENCE   PMID:11822703 (description)
  AUTHORS   Al-Gazali LI, Bakir M, Hamud OA, Gerami S
  TITLE     An autosomal recessive syndrome of nasal anomalies associated with renal and anorectal malformations.
  JOURNAL   Clin Dysmorphol 11:33-8 (2002)
///
ENTRY       H00686                      Disease
NAME        Manitoba oculotrichoanal syndrome
DESCRIPTION Manitoba oculotrichoanal (MOTA) syndrome is a rare condition characterized by aberrant anterior hairline, upper-eyelid colobomas, hypertelorism, cryptophthalmos, a bifid or notched nose, and anal anomalies. MOTA syndrome is inherited in an autosomal recessive manner.
CATEGORY    Developmental disorder
GENE        FREM1 [HSA:158326]
DBLINKS     MeSH: C536022
            OMIM: 248450
REFERENCE   PMID:17352387 (description)
  AUTHORS   Li C, Marles SL, Greenberg CR, Chodirker BN, van de Kamp J, Slavotinek A, Chudley AE
  TITLE     Manitoba Oculotrichoanal (MOTA) syndrome: report of eight new cases.
  JOURNAL   Am J Med Genet A 143A:853-7 (2007)
REFERENCE   PMID:21507892 (gene)
  AUTHORS   Slavotinek AM, Baranzini SE, Schanze D, Labelle-Dumais C, Short KM, Chao R, Yahyavi M, Bijlsma EK, Chu C, Musone S, Wheatley A, Kwok PY, Marles S, Fryns JP, Maga AM, Hassan MG, Gould DB, Madireddy L, Li C, Cox TC, Smyth I, Chudley AE, Zenker M
  TITLE     Manitoba-oculo-tricho-anal (MOTA) syndrome is caused by mutations in FREM1.
  JOURNAL   J Med Genet 48:375-82 (2011)
REFERENCE   PMID:20301721 (gene)
  AUTHORS   Li C, Slavotinek A, Chudley AE
  TITLE     Manitoba Oculotrichoanal Syndrome
  JOURNAL   (1993)
///
ENTRY       H00687                      Disease
NAME        Fraser syndrome
DESCRIPTION Fraser syndrome or cryptophthalmos is a rare autosomal recessive disorder characterized by major features such as cryptophthalmos with completely fused eyelids, partial syndactyly, renal abnormalities, and genital malformations.
CATEGORY    Developmental disorder
GENE        FRAS1 [HSA:80144]
            GRIP1 [HSA:23426] [KO:K20251]
            FREM2 [HSA:341640]
DBLINKS     ICD-10: Q87.0
            MeSH: D058497
            OMIM: 219000
REFERENCE   PMID:12205104 (description)
  AUTHORS   Slavotinek AM, Tifft CJ
  TITLE     Fraser syndrome and cryptophthalmos: review of the diagnostic criteria and evidence for phenotypic modules in complex malformation syndromes.
  JOURNAL   J Med Genet 39:623-33 (2002)
REFERENCE   PMID:11105430 (description)
  AUTHORS   Kabra M, Gulati S, Ghosh M, Menon PS
  TITLE     Fraser-cryptophthalmos syndrome.
  JOURNAL   Indian J Pediatr 67:775-8 (2000)
REFERENCE   PMID:3099574 (description)
  AUTHORS   Thomas IT, Frias JL, Felix V, Sanchez de Leon L, Hernandez RA, Jones MC
  TITLE     Isolated and syndromic cryptophthalmos.
  JOURNAL   Am J Med Genet 25:85-98 (1986)
REFERENCE   PMID:18661360 (gene)
  AUTHORS   Petrou P, Makrygiannis AK, Chalepakis G
  TITLE     The Fras1/Frem family of extracellular matrix proteins: structure, function, and  association with Fraser syndrome and the mouse bleb phenotype.
  JOURNAL   Connect Tissue Res 49:277-82 (2008)
REFERENCE   PMID:22510445 (gene)
  AUTHORS   Vogel MJ, van Zon P, Brueton L, Gijzen M, van Tuil MC, Cox P, Schanze D, Kariminejad A, Ghaderi-Sohi S, Blair E, Zenker M, Scambler PJ, Ploos van Amstel HK, van Haelst MM
  TITLE     Mutations in GRIP1 cause Fraser syndrome.
  JOURNAL   J Med Genet 49:303-6 (2012)
///
ENTRY       H00688                      Disease
NAME        Familial advanced sleep phase syndrome
DESCRIPTION Familial advanced sleep phase syndrome (FASPS) is characterized by a stable sleep schedule with a 4-hour advance than the conventional or desired time. FASPS is associated with mutations in PER2, whose level oscillates with a nearly 24 hour period. Recently, it has been reported that FASPS is also caused by mutations in CSKD1D gene and PER3 gene.
CATEGORY    Sleep disorder
GENE        PER2 [HSA:8864] [KO:K02633]
            CSNK1D [HSA:1453] [KO:K08959]
            PER3 [HSA:8863] [KO:K02633]
DBLINKS     ICD-10: G47
            MeSH: C565789
            OMIM: 604348 615224 616882
REFERENCE   PMID:21929966 (description)
  AUTHORS   Barion A
  TITLE     Circadian rhythm sleep disorders.
  JOURNAL   Dis Mon 57:423-37 (2011)
REFERENCE   PMID:18845459 (description)
  AUTHORS   Bjorvatn B, Pallesen S
  TITLE     A practical approach to circadian rhythm sleep disorders.
  JOURNAL   Sleep Med Rev 13:47-60 (2009)
REFERENCE   PMID:10470086 (description)
  AUTHORS   Jones CR, Campbell SS, Zone SE, Cooper F, DeSano A, Murphy PJ, Jones B, Czajkowski L, Ptacek LJ
  TITLE     Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans.
  JOURNAL   Nat Med 5:1062-5 (1999)
REFERENCE   PMID:11232563 (gene)
  AUTHORS   Toh KL, Jones CR, He Y, Eide EJ, Hinz WA, Virshup DM, Ptacek LJ, Fu YH
  TITLE     An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome.
  JOURNAL   Science 291:1040-3 (2001)
REFERENCE   PMID:23636092 (gene)
  AUTHORS   Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang Y, Lee HY, Jones CR, Fu YH, Charles AC, Ptacek LJ
  TITLE     Casein kinase idelta mutations in familial migraine and advanced sleep phase.
  JOURNAL   Sci Transl Med 5:183ra56, 1-11 (2013)
REFERENCE   PMID:26903630 (gene)
  AUTHORS   Zhang L, Hirano A, Hsu PK, Jones CR, Sakai N, Okuro M, McMahon T, Yamazaki M, Xu Y, Saigoh N, Saigoh K, Lin ST, Kaasik K, Nishino S, Ptacek LJ, Fu YH
  TITLE     A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal  mood trait.
  JOURNAL   Proc Natl Acad Sci U S A 113:E1536-44 (2016)
///
ENTRY       H00689                      Disease
NAME        Delayed sleep phase syndrome
DESCRIPTION Delayed sleep phase disorder is characterized by a 3 to 6-hour delayed sleep schedule relative to the desired. The single nucleotide polymorphism (Ala129Thr) in Arylalkylamine N-acetyltransferase (AANAT), a rate-limiting enzyme in melatonin synthesis, has been identified in patients with delayed sleep phase disorder.
CATEGORY    Sleep disorder
GENE        AANAT (polymorphism) [HSA:15] [KO:K00669]
DBLINKS     MeSH: D020178
            OMIM: 614163
REFERENCE   PMID:21929966 (descritpion)
  AUTHORS   Barion A
  TITLE     Circadian rhythm sleep disorders.
  JOURNAL   Dis Mon 57:423-37 (2011)
REFERENCE   PMID:18845459 (descritpion)
  AUTHORS   Bjorvatn B, Pallesen S
  TITLE     A practical approach to circadian rhythm sleep disorders.
  JOURNAL   Sleep Med Rev 13:47-60 (2009)
REFERENCE   PMID:12736803 (gene)
  AUTHORS   Hohjoh H, Takasu M, Shishikura K, Takahashi Y, Honda Y, Tokunaga K
  TITLE     Significant association of the arylalkylamine N-acetyltransferase ( AA-NAT) gene  with delayed sleep phase syndrome.
  JOURNAL   Neurogenetics 4:151-3 (2003)
///
ENTRY       H00690                      Disease
NAME        Aland Island eye disease;
            Forsius-Eriksson syndrome
DESCRIPTION Aland Island eye disease (AIED) is an X-linked form of ocular hypopigmentation. Affected males demonstrate nystagmus, decreased visual acuity, myopia, astigmatism, achromatopsia, and fundus hypopigmentation.
CATEGORY    Eye disease
GENE        CACNA1F [HSA:778] [KO:K04853]
DBLINKS     MeSH: C562664
            OMIM: 300600
REFERENCE   PMID:7612552 (descritpion)
  AUTHORS   Hawksworth NR, Headland S, Good P, Thomas NS, Clarke A
  TITLE     Aland island eye disease: clinical and electrophysiological studies of a Welsh family.
  JOURNAL   Br J Ophthalmol 79:424-30 (1995)
REFERENCE   PMID:2220819 (descritpion)
  AUTHORS   Pillers DA, Towbin JA, Chamberlain JS, Wu D, Ranier J, Powell BR, McCabe ER
  TITLE     Deletion mapping of Aland Island eye disease to Xp21 between DXS67 (B24) and Duchenne muscular dystrophy.
  JOURNAL   Am J Hum Genet 47:795-801 (1990)
REFERENCE   PMID:2667510 (descritpion)
  AUTHORS   Weleber RG, Pillers DA, Powell BR, Hanna CE, Magenis RE, Buist NR
  TITLE     Aland Island eye disease (Forsius-Eriksson syndrome) associated with contiguous deletion syndrome at Xp21. Similarity to incomplete congenital stationary night blindness.
  JOURNAL   Arch Ophthalmol 107:1170-9 (1989)
REFERENCE   PMID:17525176 (gene)
  AUTHORS   Jalkanen R, Bech-Hansen NT, Tobias R, Sankila EM, Mantyjarvi M, Forsius H, de la Chapelle A, Alitalo T
  TITLE     A novel CACNA1F gene mutation causes Aland Island eye disease.
  JOURNAL   Invest Ophthalmol Vis Sci 48:2498-502 (2007)
///
ENTRY       H00691                      Disease
NAME        Bullous congenital ichthyosiform erythroderma (BCIE);
            Epidermolytic hyperkeratosis (EHK)
DESCRIPTION Bullous congenital ichthyosiform erythroderma (BCIE), also known as bullous congenital ichthyosiform erythroderma, is characterized by erythema and skin blistering of the newborn. The erythema is replaced with thick scaling later. Neonates with BCIE have higher risk of developing severe infection, such as sepsis.
CATEGORY    Skin and connective tissue disease
GENE        KRT1 [HSA:3848] [KO:K07605]
            KRT10 [HSA:3858] [KO:K07604]
DBLINKS     ICD-10: Q80.3
            MeSH: D017488
            OMIM: 113800
REFERENCE   PMID:18571597 (description, gene)
  AUTHORS   Ross R, DiGiovanna JJ, Capaldi L, Argenyi Z, Fleckman P, Robinson-Bostom L
  TITLE     Histopathologic characterization of epidermolytic hyperkeratosis: a systematic review of histology from the National Registry for Ichthyosis and Related Skin Disorders.
  JOURNAL   J Am Acad Dermatol 59:86-90 (2008)
REFERENCE   PMID:12130905 (description, gene)
  AUTHORS   Siegel DH, Howard R
  TITLE     Molecular advances in genetic skin diseases.
  JOURNAL   Curr Opin Pediatr 14:419-25 (2002)
REFERENCE   PMID:15663649 (description, gene, drug)
  AUTHORS   Lacz NL, Schwartz RA, Kihiczak G
  TITLE     Epidermolytic hyperkeratosis: a keratin 1 or 10 mutational event.
  JOURNAL   Int J Dermatol 44:1-6 (2005)
///
ENTRY       H00692                      Disease
NAME        Lowe syndrome;
            Oculocerebrorenal Dystrophy (OCRL)
DESCRIPTION Lowe Syndrome, or Oculocerebrorenal Dystrophy (OCRL) is a multisystem disorder characterised by anomalies affecting the eye, the nervous system and the kidney. This is a rare X-linked disorder caused by mutations in the OCRL1 gene which encodes the phosphatidylinositol enzyme (4, 5) biphosphate 5-phosphatase present in the Golgi complex. The symptoms of Lowe syndrome include congenital cataracts and glaucoma, delay in neuropsychomotor development, cognitive deficits, and renal tubular abnormalities.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        OCRL1 [HSA:4952] [KO:K01099]
COMMENT     Mutations in OCRL1 gene also cause Dent disease [DS:H00694].
DBLINKS     ICD-10: E72.0
            MeSH: D009800
            OMIM: 309000
REFERENCE   PMID:16722554
  AUTHORS   Loi M
  TITLE     Lowe syndrome.
  JOURNAL   Orphanet J Rare Dis 1:16 (2006)
REFERENCE   PMID:21103682
  AUTHORS   Maia ML, do Val ML, Genzani CP, Fernandes FA, de Andrade MC, Carvalhaes JT
  TITLE     Lowe syndrome: report of five cases.
  JOURNAL   J Bras Nefrol 32:216-22 (2010)
///
ENTRY       H00693                      Disease
NAME        Ichthyosis bullosa of Siemens
DESCRIPTION Ichthyosis Bullosa of Siemens (IBS) is an autosomal dominant disorder characterized by mild hyperkeratosis and blister formation. The blistering is superficial, and areas of peeling of the skin are known as the 'Mauserung phenomenon'. IBS shows similar features to those in epidermolytic hyperkeratosis, but can be distinguished by the absence of erythema.
CATEGORY    Skin and connective tissue disease
GENE        KRT2E [HSA:3849] [KO:K07605]
COMMENT     Ichthyosis bullosa of Siemens is a milder form of Bullous congenital ichthyosiform erythroderma (BCIE) described in H00691.
DBLINKS     ICD-10: Q80.8
            MeSH: D053560
            OMIM: 146800
REFERENCE   PMID:10688369 (description, gene)
  AUTHORS   Suga Y, Arin MJ, Scott G, Goldsmith LA, Magro CM, Baden LA, Baden HP, Roop DR
  TITLE     Hot spot mutations in keratin 2e suggest a correlation between genotype and phenotype in patients with ichthyosis bullosa of Siemens.
  JOURNAL   Exp Dermatol 9:11-5 (2000)
REFERENCE   PMID:15949009 (description, gene)
  AUTHORS   Akiyama M, Tsuji-Abe Y, Yanagihara M, Nakajima K, Kodama H, Yaosaka M, Abe M, Sawamura D, Shimizu H
  TITLE     Ichthyosis bullosa of Siemens: its correct diagnosis facilitated by molecular genetic testing.
  JOURNAL   Br J Dermatol 152:1353-6 (2005)
REFERENCE   PMID:10233323 (description, gene)
  AUTHORS   Basarab T, Smith FJ, Jolliffe VM, McLean WH, Neill S, Rustin MH, Eady RA
  TITLE     Ichthyosis bullosa of Siemens: report of a family with evidence of a keratin 2e mutation, and a review of the literature.
  JOURNAL   Br J Dermatol 140:689-95 (1999)
///
ENTRY       H00694                      Disease
NAME        Dent disease, including:
            Dent disease 1;
            Dent disease 2;
            X-linked recessive nephrolithiasis ;
            Hypophosphatemic rickets;
            Low-molecular-weight proteinuria with hypercalciuria and nephrocalcinosis
DESCRIPTION Dent disease is a renal tubular disorder characterized by manifestations of proximal tubule dysfunction, including low-molecular-weight proteinuria, hypercalciuria, nephrolithiasis, nephrocalcinosis, and progressive renal failure. The disease is caused by mutations in either the CLCN5 or OCRL1 genes. CLCN5 encodes a member of the ClC family of chloride ion channels and ion transporters. OCRL1 encodes a phosphatidylinositol bisphosphate (PIP2) 5-phosphatase and mutations are also associated with Lowe Syndrome.
CATEGORY    Urinary system disease
GENE        CLCN5 [HSA:1184] [KO:K05012]
            OCRL1 [HSA:4952] [KO:K01099]
COMMENT     Mutations in OCRL1 gene also cause Lowe syndrome [DS:H00692].
DBLINKS     ICD-10: N39.8
            MeSH: D057973
            OMIM: 300009 300555 310468 300554 308990 300009
REFERENCE   PMID:20946626
  AUTHORS   Devuyst O, Thakker RV
  TITLE     Dent's disease.
  JOURNAL   Orphanet J Rare Dis 5:28 (2010)
///
ENTRY       H00695                      Disease
NAME        Mal de Meleda;
            Meleda disease
DESCRIPTION Mal de Meleda is an autosomal recessive palmoplantar keratoderma characterized by erythema of the palms and soles, followed by a diffuse yellowish hyperkeratosis. Keratinization extends onto the dorsal surface of the hands and feet as the patient ages. It is associated with brachydactyly and nail abnormalities. Mental retardation may also occur.
CATEGORY    Skin and connective tissue disease
GENE        SLURP1 [HSA:57152]
DBLINKS     ICD-10: Q82.8
            MeSH: D007645
            OMIM: 248300
REFERENCE   PMID:15708285 (description, gene)
  AUTHORS   Itin PH, Fistarol SK
  TITLE     Palmoplantar keratodermas.
  JOURNAL   Clin Dermatol 23:15-22 (2005)
REFERENCE   PMID:12603845 (description, gene)
  AUTHORS   Marrakchi S, Audebert S, Bouadjar B, Has C, Lefevre C, Munro C, Cure S, Jobard F, Morlot S, Hohl D, Prud'homme JF, Zahaf A, Turki H, Fischer J
  TITLE     Novel mutations in the gene encoding secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related protein-1 (SLURP-1) and description of five ancestral haplotypes in patients with Mal de Meleda.
  JOURNAL   J Invest Dermatol 120:351-5 (2003)
REFERENCE   PMID:12483299 (gene)
  AUTHORS   Eckl KM, Stevens HP, Lestringant GG, Westenberger-Treumann M, Traupe H, Hinz B, Frossard PM, Stadler R, Leigh IM, Nurnberg P, Reis A, Hennies HC
  TITLE     Mal de Meleda (MDM) caused by mutations in the gene for SLURP-1 in patients from  Germany, Turkey, Palestine, and the United Arab Emirates.
  JOURNAL   Hum Genet 112:50-6 (2003)
///
ENTRY       H00696                      Disease
NAME        Haim-Munk syndrome;
            Prepubertal periodontitis (PPP)
DESCRIPTION Haim-Munk syndrome is a rare autosomal recessive disorder of keratinization characterized by palmoplantar hyperkeratosis and marked periodontitis. Additional features include onychogryphosis, arachnodactyly, nail dysplasia, pes planus, and acroosteolysis. Prepubertal periodontitis (PPP) is a rare and rapidly progressive disease of young children that results in destruction of the periodontal support of the primary dentition. Both autosomal dominant and recessive forms transmission have been reported for PPP. Mutations in cathepsin C gene cause Papillon-Lefevre syndrome, Haim-Munk syndromes, and PPP.
CATEGORY    Skin and connective tissue disease
GENE        CTSC; cathepsin C [HSA:1075] [KO:K01275]
COMMENT     Papillon-Lefevre syndrome is described in H00274. [DS:H00274]
DBLINKS     MeSH: C537627
            OMIM: 245010 170650
REFERENCE   PMID:15708285 (description, gene)
  AUTHORS   Itin PH, Fistarol SK
  TITLE     Palmoplantar keratodermas.
  JOURNAL   Clin Dermatol 23:15-22 (2005)
REFERENCE   PMID:15727652 (description, gene)
  AUTHORS   Cury VF, Gomez RS, Costa JE, Friedman E, Boson W, De Marco L
  TITLE     A homozygous cathepsin C mutation associated with Haim-Munk syndrome.
  JOURNAL   Br J Dermatol 152:353-6 (2005)
REFERENCE   PMID:10662807 (gene)
  AUTHORS   Hart TC, Hart PS, Michalec MD, Zhang Y, Firatli E, Van Dyke TE, Stabholz A, Zlotogorski A, Shapira L, Soskolne WA
  TITLE     Haim-Munk syndrome and Papillon-Lefevre syndrome are allelic mutations in cathepsin C.
  JOURNAL   J Med Genet 37:88-94 (2000)
REFERENCE   PMID:10662808
  AUTHORS   Hart TC, Hart PS, Michalec MD, Zhang Y, Marazita ML, Cooper M, Yassin OM, Nusier M, Walker S
  TITLE     Localisation of a gene for prepubertal periodontitis to chromosome 11q14 and identification of a cathepsin C gene mutation.
  JOURNAL   J Med Genet 37:95-101 (2000)
///
ENTRY       H00697                      Disease
NAME        X-linked myopathy with postural muscle atrophy (XMPMA)
DESCRIPTION X-linked myopathy with postural muscle atrophy (XMPMA) is characterized by the combined presentation of weakness and atrophy of postural muscles (scapuloperoneal weakness and bent spine) with a pseudoathletic phenotype where alternative muscle groups are hypertrophic. Linkage studies and haplotype analysis followed by direct gene sequencing have identified five mutations in the FHL1 gene in patients with XMPMA.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        FHL1 [HSA:2273] [KO:K14365]
DBLINKS     ICD-10: G71.0
            MeSH: C567480
            OMIM: 300696
REFERENCE   PMID:21310615 (description, gene)
  AUTHORS   Cowling BS, Cottle DL, Wilding BR, D'Arcy CE, Mitchell CA, McGrath MJ
  TITLE     Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features.
  JOURNAL   Neuromuscul Disord 21:237-51 (2011)
REFERENCE   PMID:20874719 (description, gene)
  AUTHORS   Shathasivam T, Kislinger T, Gramolini AO
  TITLE     Genes, proteins and complexes: the multifaceted nature of FHL family proteins in  diverse tissues.
  JOURNAL   J Cell Mol Med 14:2702-20 (2010)
///
ENTRY       H00698                      Disease
NAME        Nemaline myopathy
DESCRIPTION Nemaline myopathy (NM) is the most common congenital myopathy inherited in an autosomal dominant or autosomal recessive manner. It is characterized by the presence of rods or nemaline bodies, which are red-purple inclusions in myofibers detected by modified Gomori trichrome technique. The hallmark symptoms are generalized muscle weakness with facial involvement or predominant involvement of proximal limb and respiratory muscles. Currently, NM is classified into six different forms: severe congenital (neonatal) form; Amish NM, intermediate congenital form; typical congenital form; childhood-onset form; and adult-onset (late-onset) form. Mutations in six genes, encoding components of the sarcomeric thin filaments, have been identified. Mutations in ACTA1 and NEB nebulin are the most common.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        TRM3 [HSA:7170] [KO:K09290]
            NEB [HSA:4703] [KO:K18267]
            ACTA1 [HSA:58] [KO:K10354]
            TRM2 [HSA:7169] [KO:K10374]
            TNNT1 [HSA:7138] [KO:K10372]
            CFL2 [HSA:1073] [KO:K05765]
            KBTBD13 [HSA:390594]
DBLINKS     ICD-10: G71.2
            MeSH: D017696
            OMIM: 609284 256030 161800 609285 605355 610687 609273
REFERENCE   PMID:18367042 (description, gene)
  AUTHORS   D'Amico A, Bertini E
  TITLE     Congenital myopathies.
  JOURNAL   Curr Neurol Neurosci Rep 8:73-9 (2008)
REFERENCE   PMID:20301465 (description)
  AUTHORS   North K, Ryan MM
  TITLE     Nemaline Myopathy
  JOURNAL   (1993)
REFERENCE   PMID:21109227 (gene)
  AUTHORS   Sambuughin N, Yau KS, Olive M, Duff RM, Bayarsaikhan M, Lu S, Gonzalez-Mera L, Sivadorai P, Nowak KJ, Ravenscroft G, Mastaglia FL, North KN, Ilkovski B, Kremer H, Lammens M, van Engelen BG, Fabian V, Lamont P, Davis MR, Laing NG, Goldfarb LG
  TITLE     Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores.
  JOURNAL   Am J Hum Genet 87:842-7 (2010)
///
ENTRY       H00699                      Disease
NAME        Central core disease
DESCRIPTION Central core disease (CCD) is an inherited neuromuscular disorder characterized by central cores on muscle biopsy and clinical features of a congenital myopathy. CCD is usually inherited as an autosomal dominant trait but recessive inheritance has been recently described in few families. The clinical phenotype of dominantly inherited CCD is variable but usually mild and non-progressive; however, more severe forms including the fetal akinesia syndrome have also been reported associated with recessive or de novo dominant mutations. CCD typically presents in infancy with hypotonia and motor developmental delay and is characterized by predominantly proximal weakness pronounced in the hip girdle. CCD is due to mutations in the skeletal muscle ryanodine receptor (RYR1) gene, encoding the principal skeletal muscle sarcoplasmic reticulum calcium release channel (RyR1). Altered excitability and/or changes in calcium homeostasis within muscle cells due to mutation-induced conformational changes of the RyR protein are considered the main pathogenetic mechanisms.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        RYR1 [HSA:6261] [KO:K04961]
DBLINKS     ICD-10: G71.2
            MeSH: D020512
            OMIM: 117000
REFERENCE   PMID:18367042 (description, gene)
  AUTHORS   D'Amico A, Bertini E
  TITLE     Congenital myopathies.
  JOURNAL   Curr Neurol Neurosci Rep 8:73-9 (2008)
REFERENCE   PMID:18313359 (description, gene)
  AUTHORS   Treves S, Jungbluth H, Muntoni F, Zorzato F
  TITLE     Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm.
  JOURNAL   Curr Opin Pharmacol 8:319-26 (2008)
REFERENCE   PMID:17504518 (description, gene)
  AUTHORS   Jungbluth H
  TITLE     Central core disease.
  JOURNAL   Orphanet J Rare Dis 2:25 (2007)
///
ENTRY       H00700                      Disease
NAME        Centronuclear myopathy
DESCRIPTION Centronuclear myopathy (CNM) is an inherited neuromuscular disorder defined by numerous centrally placed nuclei on muscle biopsy and clinical features of a congenital myopathy. CNM exists in the genetic bases of the three main forms: the X-linked recessive form or myotubular myopathy (XLMTM) with severe neonatal phenotype, caused by mutations in the MTM1 gene; the classical autosomal dominant (AD) forms with mild, moderate or severe phenotypes caused by mutations in the DNM2 gene; and an autosomal recessive (AR)  form presenting severe and moderate phenotypes caused by mutations in the BIN1 gene.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        (XLMTM) MTM1 [HSA:4534] [KO:K01108]
            (AD) DNM2 [HSA:1785] [KO:K01528]
            (AR) BIN1 [HSA:274] [KO:K12562]
DBLINKS     ICD-10: G71.2
            MeSH: C538647 C562934 C563544
            OMIM: 310400 160150 255200
REFERENCE   PMID:20181480 (description, gene)
  AUTHORS   Romero NB
  TITLE     Centronuclear myopathies: a widening concept.
  JOURNAL   Neuromuscul Disord 20:223-8 (2010)
REFERENCE   PMID:18817572 (description, gene)
  AUTHORS   Jungbluth H, Wallgren-Pettersson C, Laporte J
  TITLE     Centronuclear (myotubular) myopathy.
  JOURNAL   Orphanet J Rare Dis 3:26 (2008)
///
ENTRY       H00701                      Disease
NAME        Congenital fiber type disproportion (CFTD)
DESCRIPTION Congenital fiber type disproportion (CFTD) is a relatively rare subtype of congenital myopathy characterized by hypotonia and generalized muscle weakness. Pathologic diagnosis of CFTD is based on the presence of type 1 fiber hypotrophy of at least 12% in the absence of other notable pathological findings, in addition to a clinical presentation typical of congenital myopathies. CFTD is a genetically heterogenous condition with X-linked, autosomal dominant, and autosomal recessive inheritance patterns. Mutations of the ACTA1 and SEPN1 genes have been identified in a small percentage of CFTD cases, and recently mutations in the TPM3 gene were also found to cause CFTD.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        ACTA1 [HSA:58] [KO:K10354]
            SEPN1 [HSA:57190] [KO:K19874]
            TRM3 [HSA:7170] [KO:K09290]
DBLINKS     ICD-10: G71.2
            MeSH: C567594
            OMIM: 255310
REFERENCE   PMID:18300303 (description, gene)
  AUTHORS   Clarke NF, Kolski H, Dye DE, Lim E, Smith RL, Patel R, Fahey MC, Bellance R, Romero NB, Johnson ES, Labarre-Vila A, Monnier N, Laing NG, North KN
  TITLE     Mutations in TPM3 are a common cause of congenital fiber type disproportion.
  JOURNAL   Ann Neurol 63:329-37 (2008)
REFERENCE   PMID:19953533 (description, gene)
  AUTHORS   Lawlor MW, Dechene ET, Roumm E, Geggel AS, Moghadaszadeh B, Beggs AH
  TITLE     Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber  hypotrophy in congenital fiber type disproportion.
  JOURNAL   Hum Mutat 31:176-83 (2010)
///
ENTRY       H00702                      Disease
NAME        Cap myopathy
DESCRIPTION Cap myopathy is a rare congenital myopathy morphologically characterized by the presence of cap-like structures which are sharply demarcated structures of disorganized thin filaments in the periphery of muscle fibers. These structures are in fact disarranged myofibrils with enlarged Z discs and no thick filaments. The severity of the disease is related to the number of fibers affected. Therefore, patients may present with a neonatal fatal form or have a more stable course of the disease in the infant non-fatal form. Respiratory problems are common. All the currently recognized genes associated with cap myopathy (TPM2, TPM3 and now ACTA1) encode components of the sarcomeric thin filaments.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        TRM2 [HSA:7169] [KO:K10374]
            TRM3 [HSA:7170] [KO:K09290]
            ACTA1 [HSA:58] [KO:K10354]
DBLINKS     ICD-10: G71.2
            MeSH: C579969
            OMIM: 609285 609284
REFERENCE   PMID:20303757 (description, gene)
  AUTHORS   Hung RM, Yoon G, Hawkins CE, Halliday W, Biggar D, Vajsar J
  TITLE     Cap myopathy caused by a mutation of the skeletal alpha-actin gene ACTA1.
  JOURNAL   Neuromuscul Disord 20:238-40 (2010)
REFERENCE   PMID:19553118 (description, gene)
  AUTHORS   De Paula AM, Franques J, Fernandez C, Monnier N, Lunardi J, Pellissier JF, Figarella-Branger D, Pouget J
  TITLE     A TPM3 mutation causing cap myopathy.
  JOURNAL   Neuromuscul Disord 19:685-8 (2009)
REFERENCE   PMID:19953533 (description)
  AUTHORS   Lawlor MW, Dechene ET, Roumm E, Geggel AS, Moghadaszadeh B, Beggs AH
  TITLE     Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber  hypotrophy in congenital fiber type disproportion.
  JOURNAL   Hum Mutat 31:176-83 (2010)
///
ENTRY       H00703                      Disease
NAME        Myosin storage myopathy (MSM);
            Hyaline body myopathy
DESCRIPTION Myosin storage myopathy (MSM), also called hyaline body myopathy, is a rare congenital myopathy with variable inheritance characterized by the presence of sub-sarcolemmal hyaline bodies in type I muscle fibers and predominantly proximal muscle weakness. Clinically, patients exhibit variable age of onset ranging from birth through childhood, and occasionally middle age. Symptoms also vary, but typically include slowly progressive muscle hypertonia, scapularperoneal weakness, and respiratory insufficiency. MSM has been associated with 4 missense mutations in the MYH7 gene, which encodes slow/beta-cardiac myosin heavy chain (MyHC). The disease causing mutations in MYH7 are located in the alpha-helical coiled-coil tail.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        MYH7 [HSA:4625] [KO:K17751]
DBLINKS     ICD-10: G71.2
            MeSH: C564253
            OMIM: 608358
REFERENCE   PMID:21288719 (description, gene)
  AUTHORS   Ortolano S, Tarrio R, Blanco-Arias P, Teijeira S, Rodriguez-Trelles F, Garcia-Murias M, Delague V, Levy N, Fernandez JM, Quintans B, Millan BS, Carracedo A, Navarro C, Sobrido MJ
  TITLE     A novel MYH7 mutation links congenital fiber type disproportion and myosin storage myopathy.
  JOURNAL   Neuromuscul Disord 21:254-62 (2011)
REFERENCE   PMID:19953533 (description, gene)
  AUTHORS   Lawlor MW, Dechene ET, Roumm E, Geggel AS, Moghadaszadeh B, Beggs AH
  TITLE     Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber  hypotrophy in congenital fiber type disproportion.
  JOURNAL   Hum Mutat 31:176-83 (2010)
///
ENTRY       H00704                      Disease
NAME        Oculopharyngeal muscular dystrophy (OPMD)
DESCRIPTION Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle disease associated with progressive ptosis of the eyelids, dysphagia, and unique tubulofilamentous intranuclear inclusions (INIs) in skeletal muscle. OPMD is caused by expansions of the short (GCG) trinucleotide repeat in the coding sequence of the poly(A) binding protein nuclear 1 (PABPN1) gene. To date OPMD is considered as a primary myopathic disorder and there is little morphologic evidence for neurogenic etiology, though the peripheral nervous system (PNS) seems to be affected in some rare cases.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        PABPN1 [HSA:8106] [KO:K14396]
DBLINKS     ICD-10: G71.0
            MeSH: D039141
            OMIM: 164300
REFERENCE   PMID:17110089 (description, gene)
  AUTHORS   Abu-Baker A, Rouleau GA
  TITLE     Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
  JOURNAL   Biochim Biophys Acta 1772:173-85 (2007)
REFERENCE   PMID:19080757 (description, gene)
  AUTHORS   Brais B
  TITLE     Oculopharyngeal muscular dystrophy: a polyalanine myopathy.
  JOURNAL   Curr Neurol Neurosci Rep 9:76-82 (2009)
REFERENCE   PMID:22001477 (description, gene)
  AUTHORS   Mizoi Y, Yamamoto T, Minami N, Ohkuma A, Nonaka I, Nishino I, Tamura N, Amano T, Araki N
  TITLE     Oculopharyngeal muscular dystrophy associated with dementia.
  JOURNAL   Intern Med 50:2409-12 (2011)
///
ENTRY       H00705                      Disease
NAME        Myotonia congenita, including:
            Autosomal dominant myotonia congenita (Thomsen disease);
            Autosomal recessive myotonia congenita (Becker disease);
            Fluctuating myotonia congenita;
            Myotonia levoir
DESCRIPTION Myotonia congenita is a specific inherited disorder of muscle membrane hyperexcitability caused by reduced sarcolemmal chloride conductance due to mutations in CLCN1, the gene coding for the main skeletal muscle chloride channel ClC-1. Impaired functioning of the ClC-1 leads to an increase in sarcolemmal excitability that clinically presents as delayed muscular relaxation (myotonia). Myotonia congenita may be inherited as either an autosomal dominant (Thomsen disease) or recessive trait (Becker disease). The predominant features of Thomsen disease are a painless, transient, muscle stiffness with a predilection for both the upper extremity and the facial muscles. Compared with Thomsen disease, Becker disease is more common, more insidious, and has initial symptoms that occur later in childhood. Two additional forms of myotonia congenita have been described: myotonia levior and fluctuating myotonia congenita. Like Becker and Thomsen disease, both of these conditions are associated with a defect in the ClC-1. Whether these two entities are truly distinct disorders is under debate, and some propose that they are variants of Thomsen  disease.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        CLCN1 [HSA:1180] [KO:K05010]
DRUG        Mexiletine [DG:DG00197]
            Acetazolamide [DG:DG01134]
            Quinine [DR:D08461]
            Procainamide [DG:DG00193]
DBLINKS     ICD-10: G71.1
            MeSH: D009224
            OMIM: 160800 255700
REFERENCE   PMID:19185184 (description, gene)
  AUTHORS   Lossin C, George AL Jr
  TITLE     Myotonia congenita.
  JOURNAL   Adv Genet 63:25-55 (2008)
REFERENCE   PMID:17395134 (description, gene, drug)
  AUTHORS   Heatwole CR, Moxley RT 3rd
  TITLE     The nondystrophic myotonias.
  JOURNAL   Neurotherapeutics 4:238-51 (2007)
///
ENTRY       H00706                      Disease
NAME        Bart-Pumphrey syndrome
DESCRIPTION Bart-Pumphrey syndrome is an autosomal dominant disorder characterized by congenital deafness and palmoplantar hyperkeratosis. Patients also display knuckle pads and leukonychia. GJB2, the gene encoding connexin-26, is mutated in the disease.
CATEGORY    Nervous system disease; Skin and connective tissue disease
GENE        GJB2 [HSA:2706] [KO:K07621]
DBLINKS     MeSH: C537210
            OMIM: 149200
REFERENCE   PMID:8151643 (descritpion)
  AUTHORS   Ramer JC, Vasily DB, Ladda RL
  TITLE     Familial leuconychia, knuckle pads, hearing loss, and palmoplantar hyperkeratosis: an additional family with Bart-Pumphrey syndrome.
  JOURNAL   J Med Genet 31:68-71 (1994)
REFERENCE   PMID:15952212 (gene)
  AUTHORS   Alexandrino F, Sartorato EL, Marques-de-Faria AP, Steiner CE
  TITLE     G59S mutation in the GJB2 (connexin 26) gene in a patient with Bart-Pumphrey syndrome.
  JOURNAL   Am J Med Genet A 136:282-4 (2005)
REFERENCE   PMID:15482471 (gene)
  AUTHORS   Richard G, Brown N, Ishida-Yamamoto A, Krol A
  TITLE     Expanding the phenotypic spectrum of Cx26 disorders: Bart-Pumphrey syndrome is caused by a novel missense mutation in GJB2.
  JOURNAL   J Invest Dermatol 123:856-63 (2004)
REFERENCE   PMID:19939300 (description, gene)
  AUTHORS   Lee JR, White TW
  TITLE     Connexin-26 mutations in deafness and skin disease.
  JOURNAL   Expert Rev Mol Med 11:e35 (2009)
///
ENTRY       H00707                      Disease
NAME        Ichthyosis hystrix, Curth-Macklin type
DESCRIPTION Ichthyosis hystrix, Curth-Macklin type is a rare autosomal dominant skin disorder characterized by spiky, verrucous hyperkeratosis of palms and soles. Diagnosis is supported by specific ultrastructural abnormalities such as perinuclear tonofibril shells of keratin intermediate filaments in binucleated suprabasal keratinocytes.
CATEGORY    Skin and connective tissue disease
GENE        KRT1 [HSA:3848] [KO:K07605]
DBLINKS     MeSH: C536088
            OMIM: 146590 607602
REFERENCE   PMID:21844476 (description, gene)
  AUTHORS   Kubo Y, Urano Y, Matsuda R, Ishigami T, Murao K, Arase S, Ishida-Yamamoto A
  TITLE     Ichthyosis hystrix, Curth-Macklin type: a new sporadic case with a novel mutation of keratin 1.
  JOURNAL   Arch Dermatol 147:999-1001 (2011)
REFERENCE   PMID:12603866 (gene)
  AUTHORS   Ishida-Yamamoto A, Richard G, Takahashi H, Iizuka H
  TITLE     In vivo studies of mutant keratin 1 in ichthyosis hystrix Curth-Macklin.
  JOURNAL   J Invest Dermatol 120:498-500 (2003)
REFERENCE   PMID:12688839 (description, gene)
  AUTHORS   Smith F
  TITLE     The molecular genetics of keratin disorders.
  JOURNAL   Am J Clin Dermatol 4:347-64 (2003)
REFERENCE   PMID:12196741 (description, gene)
  AUTHORS   Kimyai-Asadi A, Kotcher LB, Jih MH
  TITLE     The molecular basis of hereditary palmoplantar keratodermas.
  JOURNAL   J Am Acad Dermatol 47:327-43; quiz 344-6 (2002)
///
ENTRY       H00708                      Disease
NAME        Naegeli-Franceschetti-Jadassohn syndrome
DESCRIPTION Naegeli-Franceschetti-Jadassohn syndrome is a rare autosomal dominant disorder characterized by complete absence of dermatoglyphics, reticulate hyperpigmentation of the skin, palmoplantar keratoderma, and decreased sweating. Enamel defects and nail dystrophy have been observed in some patients. Decreased expression of keratin 14 in this disorder sensitizes the keratinocytes to TNF-alpha-induced apoptosis.
CATEGORY    Skin and connective tissue disease
GENE        KRT14 [HSA:3861] [KO:K07604]
DBLINKS     MeSH: C538331
            OMIM: 161000
REFERENCE   PMID:18049449 (gene)
  AUTHORS   Lugassy J, McGrath JA, Itin P, Shemer R, Verbov J, Murphy HR, Ishida-Yamamoto A, Digiovanna JJ, Bercovich D, Karin N, Vitenshtein A, Uitto J, Bergman R, Richard G, Sprecher E
  TITLE     KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to  TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome.
  JOURNAL   J Invest Dermatol 128:1517-24 (2008)
REFERENCE   PMID:16960809 (gene)
  AUTHORS   Lugassy J, Itin P, Ishida-Yamamoto A, Holland K, Huson S, Geiger D, Hennies HC, Indelman M, Bercovich D, Uitto J, Bergman R, McGrath JA, Richard G, Sprecher E
  TITLE     Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14.
  JOURNAL   Am J Hum Genet 79:724-30 (2006)
REFERENCE   PMID:7929942 (description)
  AUTHORS   Papini M
  TITLE     Natural history of the Naegeli-Franceschetti-Jadassohn syndrome.
  JOURNAL   J Am Acad Dermatol 31:830 (1994)
///
ENTRY       H00709                      Disease
NAME        Birk Barel mental retardation syndrome (BBMRS);
            Birk-Barel syndrome (BIBAS)
DESCRIPTION Birk Barel mental retardation syndrome (BBMRS) is characterized by mental retardation, hypotonia, hyperactivity, and facial dysmorphism. The potassium channel KCNK9 gene, which is responsible for the disease, was found to be imprinted.
CATEGORY    Developmental disorder; Mental retardation
GENE        KCNK9 [HSA:51305] [KO:K04919]
COMMENT     genomic-imprinting defects
DBLINKS     MeSH: C567357
            OMIM: 612292
REFERENCE   PMID:18678320
  AUTHORS   Barel O, Shalev SA, Ofir R, Cohen A, Zlotogora J, Shorer Z, Mazor G, Finer G, Khateeb S, Zilberberg N, Birk OS
  TITLE     Maternally inherited Birk Barel mental retardation dysmorphism syndrome caused by a mutation in the genomically imprinted potassium channel KCNK9.
  JOURNAL   Am J Hum Genet 83:193-9 (2008)
///
ENTRY       H00710                      Disease
NAME        Erythrokeratodermia variabilis
DESCRIPTION Erythrokeratoderma variabilis is a rare genodermatosis characterized by both transient, demarcated erythema and persistent hyperkeratosis. Lesions usually appear within the first year of life but may arise later in childhood. Diffuse palmoplantar keratoderma is common. This disease is caused by mutations in GJB3 and GJB4, the genes encoding for connexin channels proteins in the epidermis.
CATEGORY    Skin and connective tissue disease
GENE        GJB3 [HSA:2707] [KO:K07622] 
            GJB4 [HSA:127534] [KO:K07623]
DBLINKS     MeSH: D056266
            OMIM: 133200
REFERENCE   PMID:8747585 (description)
  AUTHORS   Hendrix JD Jr, Greer KE
  TITLE     Erythrokeratodermia variabilis present at birth: case report and review of the literature.
  JOURNAL   Pediatr Dermatol 12:351-4 (1995)
REFERENCE   PMID:9784050 (description)
  AUTHORS   Papadavid E, Koumantaki E, Dawber RP
  TITLE     Erythrokeratoderma variabilis: case report and review of the literature.
  JOURNAL   J Eur Acad Dermatol Venereol 11:180-3 (1998)
REFERENCE   PMID:9843209 (gene)
  AUTHORS   Richard G, Smith LE, Bailey RA, Itin P, Hohl D, Epstein EH Jr, DiGiovanna JJ, Compton JG, Bale SJ
  TITLE     Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis.
  JOURNAL   Nat Genet 20:366-9 (1998)
REFERENCE   PMID:12648223 (gene)
  AUTHORS   Richard G, Brown N, Rouan F, Van der Schroeff JG, Bijlsma E, Eichenfield LF, Sybert VP, Greer KE, Hogan P, Campanelli C, Compton JG, Bale SJ, DiGiovanna JJ, Uitto J
  TITLE     Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations.
  JOURNAL   J Invest Dermatol 120:601-9 (2003)
///
ENTRY       H00711                      Disease
NAME        Russell-Silver syndrome;
            Silver-Russell syndrome
DESCRIPTION Russell-Silver syndrome (RSS) is an imprinting disorder characterized by intrauterine and postnatal growth retardation, relative macrocephaly, a typical triangular face, asymmetry and further less characteristic features. SRS is associated with genetic or epigenetic mutations that affect two different chromosomes. In addition to maternal uniparental disomy of chromosome 7, hypomethylation of the imprinting control region 1 (ICR1) in 11p15 and maternal duplication of 11p15 have recently been described as major epigenetic disturbances in SRS. The ICR1 regulates expression of the paternally expressed IGF2 and the maternally expressed H19. The H19 gene encodes a 2.3-kb non-coding mRNA, which is strongly expressed during embryogenesis and possibly functions as a microRNA. It has been proposed that H19 hypomethylation leads to biallelic expression of this gene and downregulation of IGF2 expression resulting in growth retardation.
CATEGORY    Developmental disorder
GENE        H19 [HSA:283120]
            IGF2 [HSA:3481] [KO:K13769]
COMMENT     RSS and the overgrowth disease Beckwith-Wiedemann syndrome [DS:H00713] present two genetically and clinically opposite clinical pictures.
DBLINKS     ICD-10: Q87.1
            MeSH: D056730
            OMIM: 180860
REFERENCE   PMID:19407494
  AUTHORS   Eggermann T
  TITLE     Silver-Russell and Beckwith-Wiedemann syndromes: opposite (epi)mutations in 11p15 result in opposite clinical pictures.
  JOURNAL   Horm Res 71 Suppl 2:30-5 (2009)
REFERENCE   PMID:21282187
  AUTHORS   Nativio R, Sparago A, Ito Y, Weksberg R, Riccio A, Murrell A
  TITLE     Disruption of genomic neighbourhood at the imprinted IGF2-H19 locus in Beckwith-Wiedemann syndrome and Silver-Russell syndrome.
  JOURNAL   Hum Mol Genet 20:1363-74 (2011)
REFERENCE   PMID:20573229
  AUTHORS   Eggermann T, Begemann M, Binder G, Spengler S
  TITLE     Silver-Russell syndrome: genetic basis and molecular genetic testing.
  JOURNAL   Orphanet J Rare Dis 5:19 (2010)
REFERENCE   PMID:20803658
  AUTHORS   Eggermann T
  TITLE     Russell-Silver syndrome.
  JOURNAL   Am J Med Genet C Semin Med Genet 154C:355-64 (2010)
///
ENTRY       H00712                      Disease
NAME        Keratitis-ichthyosis-deafness syndrome;
            KID/HID syndrome
DESCRIPTION Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital ectodermal dysplasia affecting the skin, hearing and vision. Cutaneous findings include red, thickened plaques with scaling that involve palms and soles. Sensorineural deafness or severe hearing impairment is often congenital. Corneal epithelium may be affected, manifesting as keratitis and photophobia. KID syndrome is an autosomal dominant trait but most cases are sporadic.
CATEGORY    Skin and connective tissue disease; Nervous system disease
GENE        GJB2 [HSA:2706] [KO:K07621]
DBLINKS     ICD-10: H90.5 Q80.8
            MeSH: C580224
            OMIM: 148210 602540
REFERENCE   PMID:17381453 (gene)
  AUTHORS   Mazereeuw-Hautier J, Bitoun E, Chevrant-Breton J, Man SY, Bodemer C, Prins C, Antille C, Saurat JH, Atherton D, Harper JI, Kelsell DP, Hovnanian A
  TITLE     Keratitis-ichthyosis-deafness syndrome: disease expression and spectrum of connexin 26 (GJB2) mutations in 14 patients.
  JOURNAL   Br J Dermatol 156:1015-9 (2007)
REFERENCE   PMID:9122065 (description)
  AUTHORS   Caceres-Rios H, Tamayo-Sanchez L, Duran-Mckinster C, de la Luz Orozco M, Ruiz-Maldonado R
  TITLE     Keratitis, ichthyosis, and deafness (KID syndrome): review of the literature and  proposal of a new terminology.
  JOURNAL   Pediatr Dermatol 13:105-13 (1996)
REFERENCE   PMID:2191710 (description)
  AUTHORS   Langer K, Konrad K, Wolff K
  TITLE     Keratitis, ichthyosis and deafness (KID)-syndrome: report of three cases and a review of the literature.
  JOURNAL   Br J Dermatol 122:689-97 (1990)
REFERENCE   PMID:16679758
  AUTHORS   Todt I, Hennies HC, Kuster W, Smolle J, Rademacher G, Mutze S, Basta D, Eisenschenk A, Ernst A
  TITLE     Neurotological and neuroanatomical changes in the connexin-26-related HID/KID syndrome.
  JOURNAL   Audiol Neurootol 11:242-8 (2006)
///
ENTRY       H00713                      Disease
NAME        Beckwith-Wiedemann syndrome
DESCRIPTION Beckwith-Wiedemann syndrome (BWS) is an imprinting disorder characterized by overgrowth, tumor predisposition, and congenital malformations. It is associated with genetic or epigenetic abnormalities in a cluster of imprinted genes found within a genomic region of approximately one megabase on chromosome 11p15. The imprinted region 11p15 is separated into two domains, with each domain regulated by a functionally independent imprinting control regions (ICR). The centromeric ICR2 regulates the expression of CDKN1C, KCNQ1, and further genes. The majority of cases of BWS show hypomethylation in the ICR2 or mutations in the ICR2-regulated CDKN1C gene. In intron 10 of the KCNQ1 locus, the untranslated KCNQ1OT1 RNA is encoded. KCNQ10T1 is expressed by the paternal allele and probably represses realization of the CDKN1C gene. In the telomeric ICR1, hypermethylation of the H19 promoter and loss of imprinting of IGF2 have been reported in a small fraction of patients with BWS. A few BWS cases could be related to NSD1 deletions or mutations.
CATEGORY    Developmental disorder
GENE        CDKN1C [HSA:1028] [KO:K09993]
            KCNQ10T1 [HSA:10984]
            H19 [HSA:283120]
            IGF2 [HSA:3481] [KO:K13769]
            NSD1 [HSA:64324] [KO:K15588]
COMMENT     BWS and the growth retardation disorder Russell-Silver syndrome [DS:H00713] present two genetically and clinically opposite clinical pictures.
DBLINKS     ICD-10: Q87.3
            MeSH: D001506
            OMIM: 130650
REFERENCE   PMID:20803657
  AUTHORS   Choufani S, Shuman C, Weksberg R
  TITLE     Beckwith-Wiedemann syndrome.
  JOURNAL   Am J Med Genet C Semin Med Genet 154C:343-54 (2010)
REFERENCE   PMID:12668598
  AUTHORS   Weksberg R, Smith AC, Squire J, Sadowski P
  TITLE     Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal  development.
  JOURNAL   Hum Mol Genet 12 Spec No 1:R61-8 (2003)
REFERENCE   PMID:19407494
  AUTHORS   Eggermann T
  TITLE     Silver-Russell and Beckwith-Wiedemann syndromes: opposite (epi)mutations in 11p15 result in opposite clinical pictures.
  JOURNAL   Horm Res 71 Suppl 2:30-5 (2009)
REFERENCE   PMID:21282187
  AUTHORS   Nativio R, Sparago A, Ito Y, Weksberg R, Riccio A, Murrell A
  TITLE     Disruption of genomic neighbourhood at the imprinted IGF2-H19 locus in Beckwith-Wiedemann syndrome and Silver-Russell syndrome.
  JOURNAL   Hum Mol Genet 20:1363-74 (2011)
REFERENCE   PMID:14997421
  AUTHORS   Baujat G, Rio M, Rossignol S, Sanlaville D, Lyonnet S, Le Merrer M, Munnich A, Gicquel C, Cormier-Daire V, Colleaux L
  TITLE     Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in  Sotos syndrome.
  JOURNAL   Am J Hum Genet 74:715-20 (2004)
///
ENTRY       H00714                      Disease
NAME        Vohwinkel syndrome, including:
            Vohwinkel syndrome (VS);
            Vohwinkel syndrome with ichthyosis
DESCRIPTION Vohwinkel syndrome is a diffuse palmoplantar keratoderma associated with sensorineural deafness. One of the identifiable characteristics of the disorder is the constriction bands of the digits, leading to autoamputation (pseudoainhum). Vohwinkel syndrome is caused by GJB2 mutations, and its variant that is linked to loricrin also has a feature of ichthyosis.
CATEGORY    Skin and connective tissue disease
GENE        (VS) GJB2 [HSA:2706] [KO:K07621]
            (ichthyosis) LOR [HSA:4014] [KO:K10385]
DBLINKS     ICD-10: Q82.8
            MeSH: C536457
            OMIM: 124500 604117
REFERENCE   PMID:19939300 (description)
  AUTHORS   Lee JR, White TW
  TITLE     Connexin-26 mutations in deafness and skin disease.
  JOURNAL   Expert Rev Mol Med 11:e35 (2009)
REFERENCE   PMID:10369869 (gene)
  AUTHORS   Maestrini E, Korge BP, Ocana-Sierra J, Calzolari E, Cambiaghi S, Scudder PM, Hovnanian A, Monaco AP, Munro CS
  TITLE     A missense mutation in connexin26, D66H, causes mutilating keratoderma with sensorineural deafness (Vohwinkel's syndrome) in three unrelated families.
  JOURNAL   Hum Mol Genet 8:1237-43 (1999)
REFERENCE   PMID:9326398 (gene)
  AUTHORS   Korge BP, Ishida-Yamamoto A, Punter C, Dopping-Hepenstal PJ, Iizuka H, Stephenson A, Eady RA, Munro CS
  TITLE     Loricrin mutation in Vohwinkel's keratoderma is unique to the variant with ichthyosis.
  JOURNAL   J Invest Dermatol 109:604-10 (1997)
REFERENCE   PMID:12615358 (gene, description)
  AUTHORS   Ishida-Yamamoto A
  TITLE     Loricrin keratoderma: a novel disease entity characterized by nuclear accumulation of mutant loricrin.
  JOURNAL   J Dermatol Sci 31:3-8 (2003)
///
ENTRY       H00715                      Disease
NAME        Darier disease;
            Dyskeratosis follicularis
DESCRIPTION Darier disease is an autosomal dominant skin disorder with keratotic papules and plaques in seborrheic areas (central trunk, flexures, scalp, and forehead) and nail abnormalities. The disease usually starts at puberty and characterized by loss of cell-to-cell adhesion and abnormal keratinization. Darier disease is caused by mutations in ATP2A2, the gene encoding a sarco/endoplasmic reticulum Ca2+-ATPase.
CATEGORY    Skin and connective tissue disease
GENE        ATP2A2 [HSA:488] [KO:K05853]
DBLINKS     ICD-10: Q82.8
            MeSH: D007644
            OMIM: 124200
REFERENCE   PMID:21167218 (description, gene)
  AUTHORS   Savignac M, Edir A, Simon M, Hovnanian A
  TITLE     Darier disease : a disease model of impaired calcium homeostasis in the skin.
  JOURNAL   Biochim Biophys Acta 1813:1111-7 (2011)
REFERENCE   PMID:15649206 (description)
  AUTHORS   Zeglaoui F, Zaraa I, Fazaa B, Houimli S, El Fekih N, Ezzine N, Kamoun MR
  TITLE     Dyskeratosis follicularis disease: case reports and review of the literature.
  JOURNAL   J Eur Acad Dermatol Venereol 19:114-7 (2005)
REFERENCE   PMID:15468148 (description)
  AUTHORS   Foggia L, Hovnanian A
  TITLE     Calcium pump disorders of the skin.
  JOURNAL   Am J Med Genet C Semin Med Genet 131C:20-31 (2004)
///
ENTRY       H00716                      Disease
NAME        Palmoplantar keratoderma with deafness
DESCRIPTION Palmoplantar keratoderma with deafness is a Cx26 disorder characterized by sensorineural hearing loss and palmoplantar keratoderma as observed for other Cx26 syndromic deafness disorders such as Vohwinkel syndrome and Bart-Pumphrey syndrome.
CATEGORY    Skin and connective tissue disease; Nervous system disease
GENE        GJB2 [HSA:2706] [KO:K07621]
COMMENT     Vohwinkel syndrome and Bart-Pumphrey syndrome are described in H00714 and H00706, respectively.
DBLINKS     MeSH: C580359
            OMIM: 148350
REFERENCE   PMID:19939300 (description)
  AUTHORS   Lee JR, White TW
  TITLE     Connexin-26 mutations in deafness and skin disease.
  JOURNAL   Expert Rev Mol Med 11:e35 (2009)
REFERENCE   PMID:17428836 (description)
  AUTHORS   Gerido DA, DeRosa AM, Richard G, White TW
  TITLE     Aberrant hemichannel properties of Cx26 mutations causing skin disease and deafness.
  JOURNAL   Am J Physiol Cell Physiol 293:C337-45 (2007)
REFERENCE   PMID:17993581 (gene)
  AUTHORS   de Zwart-Storm EA, Hamm H, Stoevesandt J, Steijlen PM, Martin PE, van Geel M, van Steensel MA
  TITLE     A novel missense mutation in GJB2 disturbs gap junction protein transport and causes focal palmoplantar keratoderma with deafness.
  JOURNAL   J Med Genet 45:161-6 (2008)
REFERENCE   PMID:20583176 (gene)
  AUTHORS   Birkenhager R, Lublinghoff N, Prera E, Schild C, Aschendorff A, Arndt S
  TITLE     Autosomal dominant prelingual hearing loss with palmoplantar keratoderma syndrome: Variability in clinical expression from mutations of R75W and R75Q in the GJB2 gene.
  JOURNAL   Am J Med Genet A 152A:1798-802 (2010)
REFERENCE   PMID:20890442 (gene)
  AUTHORS   Lee JY, In SI, Kim HJ, Jeong SY, Choung YH, Kim YC
  TITLE     Hereditary palmoplantar keratoderma and deafness resulting from genetic mutation  of Connexin 26.
  JOURNAL   J Korean Med Sci 25:1539-42 (2010)
///
ENTRY       H00717                      Disease
NAME        Striate palmoplantar keratoderma
DESCRIPTION Striate palmoplantar keratoderma (SPPK) is an autosomal dominant genodermatosis characterized by linear hyperkeratosis of volar aspects of the fingers and on the palm as well as by focal hyperkeratosis on the soles. SPPK is a heterogenous group of disorders caused by mutations in either desmoglein 1 (DSG1), desmoplakin (DSP), or keratin 1 (KRT1).
CATEGORY    Skin and connective tissue disease
GENE        (type I) DSG1 [HSA:1828] [KO:K07596]
            (type II) DSP [HSA:1832] [KO:K10381]
            (type III) KRT1 [HSA:3848] [KO:K07605]
DBLINKS     MeSH: C536162 C565102 C536163
            OMIM: 148700 612908 607654
REFERENCE   PMID:20883380 (description, gene)
  AUTHORS   Kawai K, Fukushige T, Sakanoue M, Kanekura T
  TITLE     Striate palmoplantar keratoderma.
  JOURNAL   J Dermatol 37:854-6 (2010)
REFERENCE   PMID:18627762 (description)
  AUTHORS   Bragg J, Rizzo C, Mengden S
  TITLE     Striate palmoplantar keratoderma (Brunauer-Fohs-Siemens syndrome).
  JOURNAL   Dermatol Online J 14:26 (2008)
REFERENCE   PMID:19558595 (gene)
  AUTHORS   Zamiri M, Smith FJ, Campbell LE, Tetley L, Eady RA, Hodgins MB, McLean WH, Munro CS
  TITLE     Mutation in DSG1 causing autosomal dominant striate palmoplantar keratoderma.
  JOURNAL   Br J Dermatol 161:692-4 (2009)
REFERENCE   PMID:17194569 (gene)
  AUTHORS   Barber AG, Wajid M, Columbo M, Lubetkin J, Christiano AM
  TITLE     Striate palmoplantar keratoderma resulting from a frameshift mutation in the desmoglein 1 gene.
  JOURNAL   J Dermatol Sci 45:161-6 (2007)
REFERENCE   PMID:11982762 (gene)
  AUTHORS   Whittock NV, Smith FJ, Wan H, Mallipeddi R, Griffiths WA, Dopping-Hepenstal P, Ashton GH, Eady RA, McLean WH, McGrath JA
  TITLE     Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma.
  JOURNAL   J Invest Dermatol 118:838-44 (2002)
///
ENTRY       H00718                      Disease
NAME        Sotos syndrome
DESCRIPTION Overgrowth syndromes are a heterogeneous group of disorders resulting from the dysfunction of various processes involving cell proliferation, cell growth, or apoptosis. Within this group, Sotos syndrome is characterised  by overgrowth, multiple congenital anomalies, and developmental delay.  It has been reported that the majority of patients with typical Sotos and Weaver syndrome have intragenic mutations or deletions of NSD1, and thus, represent allelic disorders.
CATEGORY    Developmental disorder
GENE        NSD1 [HSA:64324] [KO:K15588]
COMMENT     Beckwith-Wiedemann syndrome [DS:H00713] is a distinct overgrowth condition, and a few cases could be related to NSD1 deletions or mutations.
            See also H01751 Weaver syndrome.
DBLINKS     ICD-10: Q87.3
            MeSH: D058495 C536687
            OMIM: 117550 277590
REFERENCE   PMID:12807965
  AUTHORS   Rio M, Clech L, Amiel J, Faivre L, Lyonnet S, Le Merrer M, Odent S, Lacombe D, Edery P, Brauner R, Raoul O, Gosset P, Prieur M, Vekemans M, Munnich A, Colleaux L, Cormier-Daire V
  TITLE     Spectrum of NSD1 mutations in Sotos and Weaver syndromes.
  JOURNAL   J Med Genet 40:436-40 (2003)
REFERENCE   PMID:12464997
  AUTHORS   Douglas J, Hanks S, Temple IK, Davies S, Murray A, Upadhyaya M, Tomkins S, Hughes HE, Cole TR, Rahman N
  TITLE     NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes.
  JOURNAL   Am J Hum Genet 72:132-43 (2003)
REFERENCE   PMID:14997421
  AUTHORS   Baujat G, Rio M, Rossignol S, Sanlaville D, Lyonnet S, Le Merrer M, Munnich A, Gicquel C, Cormier-Daire V, Colleaux L
  TITLE     Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in  Sotos syndrome.
  JOURNAL   Am J Hum Genet 74:715-20 (2004)
///
ENTRY       H00719                      Disease
NAME        Leprechaunism;
            Donohue syndrome
DESCRIPTION Leprechaunism (Donohue syndrome) is an autosomal recessive disorder of insulin-resistance characterized by intrauterine and postnatal growth retardation, acanthosis nigricans, lipoatrophy, and genitomegaly. The disease is known as leprechaunism because infants with the disease show an elf-like face and short stature.
CATEGORY    Developmental disorder; Endocrine disease
GENE        INSR [HSA:3643] [KO:K04527]
DBLINKS     ICD-10: E11 E34.3
            MeSH: D056731
            OMIM: 246200
REFERENCE   PMID:9128805 (description)
  AUTHORS   Kosztolanyi G
  TITLE     Leprechaunism/Donohue syndrome/insulin receptor gene mutations: a syndrome delineation story from clinicopathological description to molecular understanding.
  JOURNAL   Eur J Pediatr 156:253-5 (1997)
REFERENCE   PMID:9703342 (description, gene)
  AUTHORS   Whitehead JP, Soos MA, Jackson R, Tasic V, Kocova M, O'Rahilly S
  TITLE     Multiple molecular mechanisms of insulin receptor dysfunction in a patient with Donohue syndrome.
  JOURNAL   Diabetes 47:1362-4 (1998)
///
ENTRY       H00720                      Disease
NAME        Long QT syndrome, including:
            Romano-Ward syndrome;
            Jervell and Lange-Nielsen syndrome (JLNS)
DESCRIPTION Long QT syndrome (LQTS) is a cardiovascular disorder resulting from mutations in cardiac ion channels. LQTS is characterized by prolongation of the QT interval in the electrocardiogram (ECG) and a propensity to torsades de pointes ventricular tachycardia frequently leading to syncope, cardiac arrest, or sudden death usually in young otherwise healthy individuals. Anesthesia in a patient with LQTS can trigger malignant arrhythmias and is therefore a high-risk procedure. There are two well-known syndromes with a long QT interval. The Romano-Ward syndrome is characterized by an autosomal-dominant inheritance without familial deafness. The Jervell and Lange-Nielsen syndrome (JLNS) has an autosomal-recessive pattern of inheritance and is associated with deafness.
CATEGORY    Cardiovascular disease
GENE        (LQT1) KCNQ1 [HSA:3784] [KO:K04926]
            (LQT2) KCNH2 [HSA:3757] [KO:K04905]
            (LQT3) SCN5A [HSA:6331] [KO:K04838]
            (LQT4) ANK2 [HSA:287] [KO:K10380]
            (LQT5/JLNS2) KCNE1 [HSA:3753] [KO:K04894] 
            (LQT6) KCNE2 [HSA:9992] [KO:K04896]
            (LQT7) KCNJ2 [HSA:3759] [KO:K04996]
            (LQT8) CACNA1C [HSA:775] [KO:K04850]
            (LQT9) CAV3 [HSA:859] [KO:K12959]
            (LQT10) SCN4B [HSA:6330] [KO:K04848]
            (LQT11) AKAP9 [HSA:10142] [KO:K16551]
            (LQT12) SNTA1 [HSA:6640]
            (LQT13) KCNJ5 [HSA:3762] [KO:K04999]
            (JLNS1) KCNQ1 [HSA:3784] [KO:K04926]
ENV_FACTOR  Sevoflurane [DR:D00547]
            Isoflurane [DR:D00545]
            Desflurane [DR:D00546]
DRUG        (Generally) beta-Blockers
            Implantation of a cardioverter defibrillator
            (Torsades de pointes) Magnesium sulphate [DR:D01108]
COMMENT     Please refer to map07214 beta-Adrenergic receptor agonists/antagonists.
DBLINKS     ICD-10: I45.81
            OMIM: 192500 613688 603830 600919 613695 613693 170390 601005 611818 611819 611820 612955 613485 220400 612347
REFERENCE   PMID:21286418
  AUTHORS   Kim HT, Lee JH, Park IB, Heo HE, Kim TY, Lee MJ
  TITLE     Long QT syndrome provoked by induction of general anesthesia -A case report-.
  JOURNAL   Korean J Anesthesiol 59 Suppl:S114-8 (2010)
REFERENCE   PMID:19026859
  AUTHORS   Zareba W, Cygankiewicz I
  TITLE     Long QT syndrome and short QT syndrome.
  JOURNAL   Prog Cardiovasc Dis 51:264-78 (2008)
REFERENCE   PMID:17498019 (environmental factor)
  AUTHORS   Aypar E, Karagoz AH, Ozer S, Celiker A, Ocal T
  TITLE     The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac  rhythm in children.
  JOURNAL   Paediatr Anaesth 17:563-7 (2007)
REFERENCE   PMID:16409532
  AUTHORS   Saussine M, Massad I, Raczka F, Davy JM, Frapier JM
  TITLE     Torsade de pointes during sevoflurane anesthesia in a child with congenital long  QT syndrome.
  JOURNAL   Paediatr Anaesth 16:63-5 (2006)
REFERENCE   PMID:10593671
  AUTHORS   Ilhan A, Tuncer C, Komsuoglu SS, Kali S
  TITLE     Jervell and Lange-Nielsen syndrome: neurologic and cardiologic evaluation.
  JOURNAL   Pediatr Neurol 21:809-13 (1999)
///
ENTRY       H00721                      Disease
NAME        Pyogenic bacterial infections, recurrent, due to MYD88 deficiency
DESCRIPTION Autosomal recessive MyD88 deficiency predisposes affected patients to recurrent pyogenic bacterial infections, including invasive pneumococcal disease. The patients are resistant to other microbes.
CATEGORY    Immune system disease
GENE        MYD88 [HSA:4615] [KO:K04729]
DBLINKS     MeSH: C567379
            OMIM: 612260
REFERENCE   PMID:18669862 (description, gene)
  AUTHORS   von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, Casanova JL
  TITLE     Pyogenic bacterial infections in humans with MyD88 deficiency.
  JOURNAL   Science 321:691-6 (2008)
REFERENCE   PMID:21734245 (description, gene)
  AUTHORS   Picard C, Casanova JL, Puel A
  TITLE     Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency.
  JOURNAL   Clin Microbiol Rev 24:490-7 (2011)
REFERENCE   PMID:20236864 (description, gene)
  AUTHORS   Bousfiha A, Picard C, Boisson-Dupuis S, Zhang SY, Bustamante J, Puel A, Jouanguy E, Ailal F, El-Baghdadi J, Abel L, Casanova JL
  TITLE     Primary immunodeficiencies of protective immunity to primary infections.
  JOURNAL   Clin Immunol 135:204-9 (2010)
///
ENTRY       H00722                      Disease
NAME        Epidermolytic palmoplantar keratoderma (EPPK)
DESCRIPTION Epidermolytic palmoplantar keratoderma (EPPK) is an autosomal dominant dermatosis that present within the first year of life. Patients have diffuse thickening of the skin on the palms and soles with yellow discoloration and erythematous margins. Mutations are identified in KRT9. Mild form of EPPK is linked to KRT1.
CATEGORY    Skin and connective tissue disease
GENE        KRT9 [HSA:3857] [KO:K07604]
            KRT1 [HSA:3848] [KO:K07605]
DBLINKS     ICD-10: Q82.8
            MeSH: D053546
            OMIM: 144200
REFERENCE   PMID:15708285 (description, gene)
  AUTHORS   Itin PH, Fistarol SK
  TITLE     Palmoplantar keratodermas.
  JOURNAL   Clin Dermatol 23:15-22 (2005)
REFERENCE   PMID:19341430 (description, gene)
  AUTHORS   Braun-Falco M
  TITLE     Hereditary palmoplantar keratodermas.
  JOURNAL   J Dtsch Dermatol Ges 7:971-84; quiz 984-5 (2009)
REFERENCE   PMID:15538081 (description, gene)
  AUTHORS   Sehgal VN, Sardana K, Sharma S, Raut D
  TITLE     Hereditary palmoplantar (epidermolytic) keratoderma: illustration through a familial report.
  JOURNAL   Skinmed 3:323-30; quiz 331-2 (2004)
REFERENCE   PMID:12688839 (description, gene)
  AUTHORS   Smith F
  TITLE     The molecular genetics of keratin disorders.
  JOURNAL   Am J Clin Dermatol 4:347-64 (2003)
///
ENTRY       H00723                      Disease
NAME        Non-epidermolytic palmoplantar keratoderma (NEPPK)
DESCRIPTION Nonepidermolytic palmoplantar keratoderma (NEPPK) is an autosomal dominant skin disorder that manifests as keratosis of the palmar and plantar surfaces surrounded by erythema.
CATEGORY    Skin and connective tissue disease
GENE        KRT16 [HSA:3868] [KO:K07604]
DBLINKS     ICD-10: Q82.8
            MeSH: C563422
            OMIM: 600962 613000
REFERENCE   PMID:12688839 (descritpion, gene)
  AUTHORS   Smith F
  TITLE     The molecular genetics of keratin disorders.
  JOURNAL   Am J Clin Dermatol 4:347-64 (2003)
REFERENCE   PMID:8595410 (gene)
  AUTHORS   Shamsher MK, Navsaria HA, Stevens HP, Ratnavel RC, Purkis PE, Kelsell DP, McLean WH, Cook LJ, Griffiths WA, Gschmeissner S, et al.
  TITLE     Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families.
  JOURNAL   Hum Mol Genet 4:1875-81 (1995)
///
ENTRY       H00724                      Disease
NAME        White sponge nevus
DESCRIPTION White sponge nevus is a benign autosomal dominant disorder affecting non-cornifying stratified squamous epithelia with white spongy plaques in the mouth. Mutations in KRT4 and KRT13, which are expressed in the mucosal non-cornifying stratified epithelia, are associated the disease.
CATEGORY    Skin and connective tissue disease; Mouth and dental disease
GENE        KRT4 [HSA:3851] [KO:K07605]
            KRT13 [HSA:3860] [KO:K07604]
DBLINKS     MeSH: D053529
            OMIM: 193900
REFERENCE   PMID:12688839 (description, gene)
  AUTHORS   Smith F
  TITLE     The molecular genetics of keratin disorders.
  JOURNAL   Am J Clin Dermatol 4:347-64 (2003)
REFERENCE   PMID:9028791 (description, gene)
  AUTHORS   Corden LD, McLean WH
  TITLE     Human keratin diseases: hereditary fragility of specific epithelial tissues.
  JOURNAL   Exp Dermatol 5:297-307 (1996)
REFERENCE   PMID:7493030 (gene)
  AUTHORS   Rugg EL, McLean WH, Allison WE, Lunny DP, Macleod RI, Felix DH, Lane EB, Munro CS
  TITLE     A mutation in the mucosal keratin K4 is associated with oral white sponge nevus.
  JOURNAL   Nat Genet 11:450-2 (1995)
REFERENCE   PMID:7493031 (gene)
  AUTHORS   Richard G, De Laurenzi V, Didona B, Bale SJ, Compton JG
  TITLE     Keratin 13 point mutation underlies the hereditary mucosal epithelial disorder white sponge nevus.
  JOURNAL   Nat Genet 11:453-5 (1995)
///
ENTRY       H00725                      Disease
NAME        Short QT syndrome
DESCRIPTION Short QT syndrome (SQTS) is a cardiovascular disorder resulting from mutations in cardiac ion channels. The mutation of genes (KCNH2, KCNQ1, and KCNJ2) encoding for cardiac potassium channels plays a central role in SQTS. SQTS is characterized by constantly short QT interval associated with atrial fibrillation, syncopal episodes, and sudden cardiac death. The implantable cardioverter defibrillator (ICD) therapy in patients with a short QT syndrome has an increased risk due to possible T wave oversensing.
CATEGORY    Cardiovascular disease
GENE        (SQTS1) KCNH2 [HSA:3757] [KO:K04905]
            (SQTS2) KCNQ1 [HSA:3784] [KO:K04926]
            (SQTS3) KCNJ2 [HSA:3759] [KO:K04996]
MARKER      QT interval <300-320 msec
DRUG        Quinidine [DG:DG00192] (still under evaluation)
DBLINKS     OMIM: 609620 609621 609622
REFERENCE   PMID:15890322
  AUTHORS   Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M
  TITLE     Short QT syndrome.
  JOURNAL   Cardiovasc Res 67:357-66 (2005)
REFERENCE   PMID:19026859
  AUTHORS   Zareba W, Cygankiewicz I
  TITLE     Long QT syndrome and short QT syndrome.
  JOURNAL   Prog Cardiovasc Dis 51:264-78 (2008)
REFERENCE   PMID:20126594
  AUTHORS   Crotti L, Taravelli E, Girardengo G, Schwartz PJ
  TITLE     Congenital short QT syndrome.
  JOURNAL   Indian Pacing Electrophysiol J 10:86-95 (2010)
///
ENTRY       H00726                      Disease
NAME        Meesmann corneal dystrophy
DESCRIPTION Meesmann corneal dystrophy is an early-onset disorder of the corneal epithelium caused by heterozygous mutations in KRT3 or KRT12 gene. It presents as ocular irritation but some patients may remain asymptomatic for many years. Characteristic intraepithelial cysts on the anterior cornea are observed. Most cases are inherited as autosomal dominant traits.
CATEGORY    Eye disease
GENE        KRT3 [HSA:3850] [KO:K07605]
            KRT12 [HSA:3859] [KO:K07604]
DBLINKS     ICD-10: H18.5
            MeSH: D053559
            OMIM: 122100
REFERENCE   PMID:12688839 (description, gene)
  AUTHORS   Smith F
  TITLE     The molecular genetics of keratin disorders.
  JOURNAL   Am J Clin Dermatol 4:347-64 (2003)
REFERENCE   PMID:17986293 (description)
  AUTHORS   Ehlers N, Hjortdal J, Nielsen K, Thiel HJ, Orntoft T
  TITLE     Phenotypic variability in Meesmann's dystrophy: clinical review of the literature and presentation of a family genetically identical to the original family.
  JOURNAL   Acta Ophthalmol 86:40-4 (2008)
REFERENCE   PMID:18806880 (gene)
  AUTHORS   Szaflik JP, Oldak M, Maksym RB, Kaminska A, Pollak A, Udziela M, Ploski R, Szaflik J
  TITLE     Genetics of Meesmann corneal dystrophy: a novel mutation in the keratin 3 gene in an asymptomatic family suggests genotype-phenotype correlation.
  JOURNAL   Mol Vis 14:1713-8 (2008)
REFERENCE   PMID:17653038 (gene)
  AUTHORS   Sullivan LS, Baylin EB, Font R, Daiger SP, Pepose JS, Clinch TE, Nakamura H, Zhao XC, Yee RW
  TITLE     A novel mutation of the Keratin 12 gene responsible for a severe phenotype of Meesmann's corneal dystrophy.
  JOURNAL   Mol Vis 13:975-80 (2007)
///
ENTRY       H00727                      Disease
NAME        Bosley-Salih-Alorainy syndrome and Athabascan brainstem dysgenesis syndrome
DESCRIPTION Bosley-Salih-Alorainy syndrome (BSAS) and Athabascan brainstem dysgenesis syndrome (ABDS) are HOXA1-related disorders marked by restricted ocular motility, sensorineural deafness, cerebrovascular malformations, and mental retardation. Cardiac malformations are also present in patients with these disorders.
CATEGORY    Developmental disorder; Nervous system disease
GENE        HOXA1 [HSA:3198] [KO:K09301]
DBLINKS     ICD-10: Q87.8
            MeSH: C535397
            OMIM: 601536
REFERENCE   PMID:18412118 (description, gene)
  AUTHORS   Bosley TM, Alorainy IA, Salih MA, Aldhalaan HM, Abu-Amero KK, Oystreck DT, Tischfield MA, Engle EC, Erickson RP
  TITLE     The clinical spectrum of homozygous HOXA1 mutations.
  JOURNAL   Am J Med Genet A 146A:1235-40 (2008)
REFERENCE   PMID:17875913 (description, gene)
  AUTHORS   Bosley TM, Salih MA, Alorainy IA, Oystreck DT, Nester M, Abu-Amero KK, Tischfield MA, Engle EC
  TITLE     Clinical characterization of the HOXA1 syndrome BSAS variant.
  JOURNAL   Neurology 69:1245-53 (2007)
REFERENCE   PMID:12833395 (description, gene)
  AUTHORS   Holve S, Friedman B, Hoyme HE, Tarby TJ, Johnstone SJ, Erickson RP, Clericuzio CL, Cunniff C
  TITLE     Athabascan brainstem dysgenesis syndrome.
  JOURNAL   Am J Med Genet A 120A:169-73 (2003)
///
ENTRY       H00728                      Disease
NAME        Brugada syndrome (BRS)
DESCRIPTION The Brugada syndrome (BRS) is an autosomal dominant genetic disorder that is characterised by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death. Diagnosis is based on clinical findings. Mutations in eight genes (SCN5A, GPD1L, CACNA1C, CACNB2, SCN1B, KCNE3, SCN3B, and HCN4) are known to cause BRS. In approximately 20% of the cases BRS is caused by mutations in the SCN5A gene, encoding the cardiac sodium channel.
CATEGORY    Cardiovascular disease
GENE        (BRS1) SCN5A [HSA:6331] [KO:K04838]
            (BRS2) GPD1L [HSA:23171] [KO:K00006]
            (BRS3) CACNA1C [HSA:775] [KO:K04850]
            (BRS4) CACNB2 [HSA:783] [KO:K04863]
            (BRS5) SCN1B [HSA:6324] [KO:K04845]
            (BRS6) KCNE3 [HSA:10008] [KO:K04897]
            (BRS7) SCN3B [HSA:55800] [KO:K04847]
            (BRS8) HCN4 [HSA:10021] [KO:K04957]
MARKER      Presenting with a typical ECG pattern of ST segment elevation in leads V1 to V3, and incomplete or complete right bundle branch block.
DRUG        Implantation of a cardioverter defibrillator
            Quinidine [DG:DG00192]
DBLINKS     ICD-10: I49.0
            OMIM: 601144 611777 611875 611876 612838 613119 613120 613123
REFERENCE   PMID:16972995
  AUTHORS   Napolitano C, Priori SG
  TITLE     Brugada syndrome.
  JOURNAL   Orphanet J Rare Dis 1:35 (2006)
REFERENCE   PMID:20301690 (mutations and treatments)
  AUTHORS   Brugada R, Campuzano O, Brugada P, Brugada J, Hong K
  TITLE     Brugada Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:21209740
  AUTHORS   Kalavakunta JK, Bantu V, Tokala H, Kodenchery M
  TITLE     Sudden cause of cardiac death-be aware of me: a case report and short review on brugada syndrome.
  JOURNAL   Case Report Med 2010:823490 (2010)
REFERENCE   PMID:1309182
  AUTHORS   Brugada P, Brugada J
  TITLE     Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report.
  JOURNAL   J Am Coll Cardiol 20:1391-6 (1992)
///
ENTRY       H00729                      Disease
NAME        Sick sinus syndrome (SSS);
            Sinus node dysfunction
DESCRIPTION Sick sinus syndrome (SSS) comprises a variety of conditions involving sinus node dysfunction and commonly affects elderly persons. Patients may experience syncope, pre-syncope, palpitations, or dizziness. SSS has multiple manifestations on electrocardiogram, including sinus bradycardia, sinus arrest, sinoatrial block, and alternating patterns of bradycardia and tachycardia. Autosomal recessive type (SSS1) can be caused by compound heterozygous mutation in the SCN5A gene, and autosomal dominant type (SSS2) can be caused by heterozygous mutation in the HCN4. SCN5A encodes an alpha-subunit of the cardiac sodium channel carrying the current to form a rapid upstroke of action potential, whereas HCN4 codes for an alpha-subunit of hyperpolarization-activated cation channel.
CATEGORY    Cardiovascular disease
GENE        (SSS1) SCN5A [HSA:6331] [KO:K04838]
            (SSS2) HCN4 [HSA:10021] [KO:K04957]
DRUG        Atrial or dual-chamber pacemaker placement
DBLINKS     OMIM: 608567 163800
REFERENCE   PMID:12725451
  AUTHORS   Adan V, Crown LA
  TITLE     Diagnosis and treatment of sick sinus syndrome.
  JOURNAL   Am Fam Physician 67:1725-32 (2003)
REFERENCE   PMID:15123648
  AUTHORS   Ueda K, Nakamura K, Hayashi T, Inagaki N, Takahashi M, Arimura T, Morita H, Higashiuesato Y, Hirano Y, Yasunami M, Takishita S, Yamashina A, Ohe T, Sunamori M, Hiraoka M, Kimura A
  TITLE     Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia.
  JOURNAL   J Biol Chem 279:27194-8 (2004)
///
ENTRY       H00730                      Disease
NAME        Familial idiopathic ventricular fibrillation
DESCRIPTION Idiopathic ventricular fibrillation (IVF) is a syndrome that causes sudden cardiac death in individuals with an apparently normal heart. It has been found a novel SCN5A missense mutation in one symptomatic IVF patient that did not exhibit the typical Brugada electrocardiogram (ECG). Recently, IVF linked to the DPP6 gene has been reported.
CATEGORY    Cardiovascular disease
GENE        (IVF1) SCN5A [HSA:6331] [KO:K04838]
            (IVF2) DPP6 [HSA:1804]
COMMENT     Brugada syndrome [DS:H00728]
DBLINKS     OMIM: 603829 612956
REFERENCE   PMID:10940383
  AUTHORS   Akai J, Makita N, Sakurada H, Shirai N, Ueda K, Kitabatake A, Nakazawa K, Kimura A, Hiraoka M
  TITLE     A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome.
  JOURNAL   FEBS Lett 479:29-34 (2000)
REFERENCE   PMID:21512816
  AUTHORS   Postema PG, Christiaans I, Hofman N, Alders M, Koopmann TT, Bezzina CR, Loh P, Zeppenfeld K, Volders PG, Wilde AA
  TITLE     Founder mutations in the Netherlands: familial idiopathic ventricular fibrillation and DPP6.
  JOURNAL   Neth Heart J 19:290-6 (2011)
///
ENTRY       H00731                      Disease
NAME        Atrial fibrillation
DESCRIPTION Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.
CATEGORY    Cardiovascular disease
GENE        (ATFB3) KCNQ1 [HSA:3784] [KO:K04926]
            (ATFB4) KCNE2 [HSA:9992] [KO:K04896]
            (ATFB6) NPPA [HSA:4878] [KO:K12334]
            (ATFB7) KCNA5 [HSA:3741] [KO:K04878]
            (ATFB9) KCNJ2 [HSA:3759] [KO:K04996]
            (ATFB10) SCN5A [HSA:6331] [KO:K04838]
            (ATFB11) GJA5 [HSA:2702] [KO:K07614]
            (ATFB12) ABCC9 [HSA:10060] [KO:K05033]
            (ATFB13) SCN1B [HSA:6324] [KO:K04845]
            (ATFB14) SCN2B [HSA:6327] [KO:K04846]
            (ATFB15) NUP155 [HSA:9631] [KO:K14312]
            (ATFB16) SCN3B [HSA:55800] [KO:K04847]
            (ATFB17) SCN4B [HSA:6330] [KO:K04848]
            (ATFB18) MYL4 [HSA:4635] [KO:K12750]
DBLINKS     ICD-10: I48
            OMIM: 608583 607554 611493 612201 612240 613980 614022 614049 614050 615377 615378 615770 613120 611819 617280
REFERENCE   PMID:18634977
  AUTHORS   Tsai CT, Lai LP, Hwang JJ, Lin JL, Chiang FT
  TITLE     Molecular genetics of atrial fibrillation.
  JOURNAL   J Am Coll Cardiol 52:241-50 (2008)
REFERENCE   PMID:17768091
  AUTHORS   Otway R, Vandenberg JI, Fatkin D
  TITLE     Atrial fibrillation--a new cardiac channelopathy.
  JOURNAL   Heart Lung Circ 16:356-60 (2007)
REFERENCE   PMID:19808477 (gene)
  AUTHORS   Watanabe H, Darbar D, Kaiser DW, Jiramongkolchai K, Chopra S, Donahue BS, Kannankeril PJ, Roden DM
  TITLE     Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation.
  JOURNAL   Circ Arrhythm Electrophysiol 2:268-75 (2009)
REFERENCE   PMID:19070573 (gene)
  AUTHORS   Zhang X, Chen S, Yoo S, Chakrabarti S, Zhang T, Ke T, Oberti C, Yong SL, Fang F, Li L, de la Fuente R, Wang L, Chen Q, Wang QK
  TITLE     Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early  sudden cardiac death.
  JOURNAL   Cell 135:1017-27 (2008)
REFERENCE   PMID:21051419 (gene)
  AUTHORS   Olesen MS, Jespersen T, Nielsen JB, Liang B, Moller DV, Hedley P, Christiansen M, Varro A, Olesen SP, Haunso S, Schmitt N, Svendsen JH
  TITLE     Mutations in sodium channel beta-subunit SCN3B are associated with early-onset lone atrial fibrillation.
  JOURNAL   Cardiovasc Res 89:786-93 (2011)
REFERENCE   PMID:27066836 (gene)
  AUTHORS   Orr N, Arnaout R, Gula LJ, Spears DA, Leong-Sit P, Li Q, Tarhuni W, Reischauer S, Chauhan VS, Borkovich M, Uppal S, Adler A, Coughlin SR, Stainier DY, Gollob MH
  TITLE     A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial  atrial fibrillation.
  JOURNAL   Nat Commun 7:11303 (2016)
///
ENTRY       H00732                      Disease
NAME        Sorsby fundus dystrophy
DESCRIPTION Sorsby fundus dystrophy is an autosomal dominant disorder characterized by macular degeneration with bilateral central visual loss. The lesions progress into outer retina, resulting in further loss of peripheral vision. The onset is usually in the third to fifth decade of life. The tissue inhibitor of metalloproteinase 3 (TIMP3) is associated with the disease.
CATEGORY    Eye disease
GENE        TIMP3 [HSA:7078] [KO:K16866]
DBLINKS     MeSH: C564992
            OMIM: 136900
REFERENCE   PMID:2695876 (description)
  AUTHORS   Hamilton WK, Ewing CC, Ives EJ, Carruthers JD
  TITLE     Sorsby's fundus dystrophy.
  JOURNAL   Ophthalmology 96:1755-62 (1989)
REFERENCE   PMID:11486938 (description)
  AUTHORS   Weisinger HS, Pesudovs K
  TITLE     Sorsby's fundus dystrophy.
  JOURNAL   Optometry 72:435-40 (2001)
REFERENCE   PMID:1559761 (description)
  AUTHORS   Steinmetz RL, Polkinghorne PC, Fitzke FW, Kemp CM, Bird AC
  TITLE     Abnormal dark adaptation and rhodopsin kinetics in Sorsby's fundus dystrophy.
  JOURNAL   Invest Ophthalmol Vis Sci 33:1633-6 (1992)
REFERENCE   PMID:11556484 (gene, description)
  AUTHORS   Musarella MA
  TITLE     Molecular genetics of macular degeneration.
  JOURNAL   Doc Ophthalmol 102:165-77 (2001)
REFERENCE   PMID:16259644 (gene)
  AUTHORS   Li Z, Clarke MP, Barker MD, McKie N
  TITLE     TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights.
  JOURNAL   Expert Rev Mol Med 7:1-15 (2005)
///
ENTRY       H00733                      Disease
NAME        Harlequin ichthyosis
DESCRIPTION Harlequin ichthyosis (HI) is the most devastating form of congenital ichthyosis. The newborn with this disease show severe hyperkeratosis and scales with fissures over the whole body, pronounced ectropion, and impaired contraction of ears and limbs. HI is associated with truncations/deletions in ABCA12, an ATP-binding cassette (ABC) transporters with lipid transporter activity in keratinocytes.
CATEGORY    Congenital disorder; Skin and connective tissue disease
GENE        ABCA12 [HSA:26154] [KO:K05646]
DBLINKS     ICD-10: Q80.4
            MeSH: C538424
            OMIM: 242500
REFERENCE   PMID:18341575 (gene)
  AUTHORS   Akiyama M, Shimizu H
  TITLE     An update on molecular aspects of the non-syndromic ichthyoses.
  JOURNAL   Exp Dermatol 17:373-82 (2008)
REFERENCE   PMID:16935789 (gene, description)
  AUTHORS   Oji V, Traupe H
  TITLE     Ichthyoses: differential diagnosis and molecular genetics.
  JOURNAL   Eur J Dermatol 16:349-59 (2006)
REFERENCE   PMID:16481150 (gene, description)
  AUTHORS   Akiyama M
  TITLE     Harlequin ichthyosis and other autosomal recessive congenital ichthyoses: the underlying genetic defects and pathomechanisms.
  JOURNAL   J Dermatol Sci 42:83-9 (2006)
///
ENTRY       H00734                      Disease
NAME        Autosomal recessive congenital ichthyosis, including:
            Lamellar ichthyosis (LI);
            Non-bullous congenital ichthyosiform erythroderma (NBCIE)
DESCRIPTION Autosomal recessive congenital ichthyoses comprise a heterogeneous group of skin disorders of hyperkeratosis. Two non-syndromic forms are defined including lamellar ichthyosis (LI) and non-bullous congenital ichthyosiform erythroderma (NBCIE). LI shows more severe phonotype with tight covering of a newborn that is later replaced by large, dark scales. In contrast, NBCIE shows a more pronounced erythroderma with fine, white scaling.
CATEGORY    Skin and connective tissue disease
GENE        (ARCI1/ LI1) TGM1 [HSA:7051] [KO:K05619]
            (ARCI2/ NBCIE) ALOX12B [HSA:242] [KO:K08021]
            (ARCI3/ LI5) ALOXE3 [HSA:59344] [KO:K18684]
            (ARCI4/ LI2) ABCA12 [HSA:26154] [KO:K05646]
            (ARCI5/ LI3) CYP4F22 [HSA:126410] [KO:K17731]
            (ARCI6) NIPAL4 [HSA:348938]
            (ARCI8/ LI4) LIPN [HSA:643418]
            (ARCI9) CERS3 [HSA:204219] [KO:K04710]
            (ARCI10) PNPLA1 [HSA:285848] [KO:K16813]
            (ARCI11) ST14 [HSA:6768] [KO:K08670]
            (ARCI12) CASP14 [HSA:23581] [KO:K04401]
COMMENT     Bullous congenital ichthyosiform erythroderma (BCIE) is described in H00691.
            See also H00733 Harlequin ichthyosis and H00739 Ichthyosis with hypotrichosis.
DBLINKS     ICD-10: Q80.2
            MeSH: D017490
            OMIM: 242300 242100 606545 601277 604777 612281 613943 615023 615024 602400 617320
REFERENCE   PMID:18341575 (description)
  AUTHORS   Akiyama M, Shimizu H
  TITLE     An update on molecular aspects of the non-syndromic ichthyoses.
  JOURNAL   Exp Dermatol 17:373-82 (2008)
REFERENCE   PMID:16935789 (description, gene)
  AUTHORS   Oji V, Traupe H
  TITLE     Ichthyoses: differential diagnosis and molecular genetics.
  JOURNAL   Eur J Dermatol 16:349-59 (2006)
REFERENCE   PMID:16481150 (description, gene)
  AUTHORS   Akiyama M
  TITLE     Harlequin ichthyosis and other autosomal recessive congenital ichthyoses: the underlying genetic defects and pathomechanisms.
  JOURNAL   J Dermatol Sci 42:83-9 (2006)
REFERENCE   PMID:16436457 (gene)
  AUTHORS   Lefevre C, Bouadjar B, Ferrand V, Tadini G, Megarbane A, Lathrop M, Prud'homme JF, Fischer J
  TITLE     Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3.
  JOURNAL   Hum Mol Genet 15:767-76 (2006)
REFERENCE   PMID:15317751 (gene)
  AUTHORS   Lefevre C, Bouadjar B, Karaduman A, Jobard F, Saker S, Ozguc M, Lathrop M, Prud'homme JF, Fischer J
  TITLE     Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis.
  JOURNAL   Hum Mol Genet 13:2473-82 (2004)
REFERENCE   PMID:21439540 (gene)
  AUTHORS   Israeli S, Khamaysi Z, Fuchs-Telem D, Nousbeck J, Bergman R, Sarig O, Sprecher E
  TITLE     A mutation in LIPN, encoding epidermal lipase N, causes a late-onset form of autosomal-recessive congenital ichthyosis.
  JOURNAL   Am J Hum Genet 88:482-7 (2011)
REFERENCE   PMID:23549421 (gene)
  AUTHORS   Eckl KM, Tidhar R, Thiele H, Oji V, Hausser I, Brodesser S, Preil ML, Onal-Akan A, Stock F, Muller D, Becker K, Casper R, Nurnberg G, Altmuller J, Nurnberg P, Traupe H, Futerman AH, Hennies HC
  TITLE     Impaired epidermal ceramide synthesis causes autosomal recessive congenital ichthyosis and reveals the importance of ceramide acyl chain length.
  JOURNAL   J Invest Dermatol 133:2202-11 (2013)
REFERENCE   PMID:22246504 (gene)
  AUTHORS   Grall A, Guaguere E, Planchais S, Grond S, Bourrat E, Hausser I, Hitte C, Le Gallo M, Derbois C, Kim GJ, Lagoutte L, Degorce-Rubiales F, Radner FP, Thomas A, Kury S, Bensignor E, Fontaine J, Pin D, Zimmermann R, Zechner R, Lathrop M, Galibert F, Andre C, Fischer J
  TITLE     PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans.
  JOURNAL   Nat Genet 44:140-7 (2012)
REFERENCE   PMID:27494380 (gene)
  AUTHORS   Kirchmeier P, Zimmer A, Bouadjar B, Rosler B, Fischer J
  TITLE     Whole-Exome-Sequencing Reveals Small Deletions in CASP14 in Patients with Autosomal Recessive Inherited Ichthyosis.
  JOURNAL   Acta Derm Venereol 96:102-104 (2017)
///
ENTRY       H00735                      Disease
NAME        Ichthyosis vulgaris
DESCRIPTION Ichthyosis vulgaris is one of the most common genetic keratinization disorder characterized by follicular keratosis and grey scaling on the flexor limbs. It is caused by defective synthesis of filaggrin that leads to reduction of keratohyalin granules in epidermis. The condition is inherited in an autosomal dominant pattern.
CATEGORY    Congenital disorder; Skin and connective tissue disease
GENE        FLG [HSA:2312]
DRUG        Maxacalcitol [DR:D01098]
DBLINKS     ICD-10: Q80.0
            MeSH: D016112
            OMIM: 146700
REFERENCE   PMID:18341575 (description, gene)
  AUTHORS   Akiyama M, Shimizu H
  TITLE     An update on molecular aspects of the non-syndromic ichthyoses.
  JOURNAL   Exp Dermatol 17:373-82 (2008)
REFERENCE   PMID:16935789 (description, gene)
  AUTHORS   Oji V, Traupe H
  TITLE     Ichthyoses: differential diagnosis and molecular genetics.
  JOURNAL   Eur J Dermatol 16:349-59 (2006)
REFERENCE   PMID:16444271 (gene)
  AUTHORS   Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH
  TITLE     Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris.
  JOURNAL   Nat Genet 38:337-42 (2006)
REFERENCE   PMID:26770148 (drug)
  AUTHORS   Anderson B
  TITLE     The Effect of Dietary Change in a Patient With Ichthyosis Vulgaris: A Case Report.
  JOURNAL   Integr Med (Encinitas) 14:55-8 (2015)
///
ENTRY       H00736                      Disease
NAME        Dorfman-Chanarin syndrome;
            Chanarin-Dorfman syndrome
DESCRIPTION Chanarin-Dorfman syndrome, also referred to as neutral-lipid-storage disease with ichthyosis, is a rare autosomal recessive disease of lipid metabolism. Cutaneous finding is congenital, generalized ichthyosis similar to that of non-bullous congenital ichthyosiform erythroderma. Other characteristics include hepatomegaly, sensorineural deafness, mental retardation, and cataracts. Mutations in the CGI-58 gene encoding a protein of the alpha/beta hydrolase domain subfamily are responsible for this disorder.
CATEGORY    Congenital disorder; Skin and connective tissue disease; Liver disease
GENE        CGI58 [HSA:51099] [KO:K13699]
MARKER      lipid-containing vacuoles in circulating leukocytes
DBLINKS     ICD-10: E75.5
            MeSH: C536560
            OMIM: 275630
REFERENCE   PMID:16935789 (description, gene, marker)
  AUTHORS   Oji V, Traupe H
  TITLE     Ichthyoses: differential diagnosis and molecular genetics.
  JOURNAL   Eur J Dermatol 16:349-59 (2006)
REFERENCE   PMID:15452860 (description, gene)
  AUTHORS   Richard G
  TITLE     Molecular genetics of the ichthyoses.
  JOURNAL   Am J Med Genet C Semin Med Genet 131C:32-44 (2004)
REFERENCE   PMID:19061969 (description, gene, marker)
  AUTHORS   Yamaguchi T, Osumi T
  TITLE     Chanarin-Dorfman syndrome: deficiency in CGI-58, a lipid droplet-bound coactivator of lipase.
  JOURNAL   Biochim Biophys Acta 1791:519-23 (2009)
REFERENCE   PMID:11590543 (gene)
  AUTHORS   Lefevre C, Jobard F, Caux F, Bouadjar B, Karaduman A, Heilig R, Lakhdar H, Wollenberg A, Verret JL, Weissenbach J, Ozguc M, Lathrop M, Prud'homme JF, Fischer J
  TITLE     Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome.
  JOURNAL   Am J Hum Genet 69:1002-12 (2001)
///
ENTRY       H00737                      Disease
NAME        Acral peeling skin syndrome
DESCRIPTION Acral peeling skin syndrome is a rare autosomal recessive disorder characterized by spontaneous, lifelong peeling of the skin at a subcorneal or intracorneal level. Missense mutations in the gene of transglutaminase-5 (TGM5) underlie the disease.
CATEGORY    Skin and connective tissue disease
GENE        TGM5 [HSA:9333] [KO:K05622]
DBLINKS     MeSH: C536316
            OMIM: 609796
REFERENCE   PMID:16935789 (description, gene)
  AUTHORS   Oji V, Traupe H
  TITLE     Ichthyoses: differential diagnosis and molecular genetics.
  JOURNAL   Eur J Dermatol 16:349-59 (2006)
REFERENCE   PMID:22066523 (description, gene)
  AUTHORS   Pavlovic S, Krunic AL, Bulj TK, Medenica MM, Fong K, Arita K, McGrath JA
  TITLE     Acral peeling skin syndrome: a clinically and genetically heterogeneous disorder.
  JOURNAL   Pediatr Dermatol 29:258-63 (2012)
REFERENCE   PMID:11100033 (description)
  AUTHORS   Hashimoto K, Hamzavi I, Tanaka K, Shwayder T
  TITLE     Acral peeling skin syndrome.
  JOURNAL   J Am Acad Dermatol 43:1112-9 (2000)
///
ENTRY       H00738                      Disease
NAME        Ichthyosis with confetti;
            Congenital reticular ichthyosiform erythroderma;
            Ichthyosis variegata
DESCRIPTION Ichthyosis with confetti (IWC) is a rare and severe skin disease characterized by erythroderma, prominent scaling, and palmoplantar keratoderma. Patients develop numerous pale confetti-like white patches on red skin.
CATEGORY    Skin and connective tissue disease
GENE        KRT10 [HSA:3858] [KO:K07604]
DBLINKS     OMIM: 609165
REFERENCE   PMID:20798280 (description, gene)
  AUTHORS   Choate KA, Lu Y, Zhou J, Choi M, Elias PM, Farhi A, Nelson-Williams C, Crumrine D, Williams ML, Nopper AJ, Bree A, Milstone LM, Lifton RP
  TITLE     Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10.
  JOURNAL   Science 330:94-7 (2010)
REFERENCE   PMID:21929535 (description, gene)
  AUTHORS   Burger B, Spoerri I, Schubert M, Has C, Itin PH
  TITLE     Description of the natural course and clinical manifestations of ichthyosis with  confetti caused by a novel KRT10 mutation.
  JOURNAL   Br J Dermatol (2011)
REFERENCE   PMID:9028791 (description)
  AUTHORS   Corden LD, McLean WH
  TITLE     Human keratin diseases: hereditary fragility of specific epithelial tissues.
  JOURNAL   Exp Dermatol 5:297-307 (1996)
///
ENTRY       H00739                      Disease
NAME        Ichthyosis with hypotrichosis
DESCRIPTION Ichthyosis with hypotrichosis is a syndromic form of autosomal recessive congenital ichthyoses associated with abnormal hair. Sparse scalp hair, wrinkled skin, and corneal abnormalities are observed in patients with the disease. It is linked ST14 encoding the matriptase serine protease.
CATEGORY    Skin and connective tissue disease
GENE        ST14 [HSA:6768] [KO:K08670]
DBLINKS     ICD-10: Q80.9
            MeSH: C536273
            OMIM: 610765
REFERENCE   PMID:18445049 (description, gene)
  AUTHORS   Avrahami L, Maas S, Pasmanik-Chor M, Rainshtein L, Magal N, Smitt J, van Marle J, Shohat M, Basel-Vanagaite L
  TITLE     Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype.
  JOURNAL   Clin Genet 74:47-53 (2008)
REFERENCE   PMID:17273967 (description, gene)
  AUTHORS   Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, Rainshtein L, Ben Amitai D, Lurie R, Pasmanik-Chor M, Indelman M, Zvulunov A, Saban S, Magal N, Sprecher E, Shohat M
  TITLE     Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.
  JOURNAL   Am J Hum Genet 80:467-77 (2007)
REFERENCE   PMID:17940283 (gene)
  AUTHORS   List K, Currie B, Scharschmidt TC, Szabo R, Shireman J, Molinolo A, Cravatt BF, Segre J, Bugge TH
  TITLE     Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.
  JOURNAL   J Biol Chem 282:36714-23 (2007)
///
ENTRY       H00740                      Disease
NAME        Ichthyosis follicularis, alopecia, and photophobia syndrome
DESCRIPTION Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome is a rare X-linked genetic disorder characterized by congenital ichthyosis follicularis and noncicatricial universal alopecia. Photophobia is also present in early childhood. Other features include short stature, seizures, and mental retardation. The causative gene is MBTPS2 which encodes a membrane-embedded zinc metalloprotease involved in endoplasmic reticulum stress response.
CATEGORY    Skin and connective tissue disease
GENE        MBTPS2 [HSA:51360] [KO:K07765]
DBLINKS     MeSH: C536085
            OMIM: 308205
REFERENCE   PMID:21600032 (description, gene)
  AUTHORS   Megarbane H, Megarbane A
  TITLE     Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome.
  JOURNAL   Orphanet J Rare Dis 6:29 (2011)
REFERENCE   PMID:14708109 (description)
  AUTHORS   Megarbane H, Zablit C, Waked N, Lefranc G, Tomb R, Megarbane A
  TITLE     Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome: report of a new family with additional features and review.
  JOURNAL   Am J Med Genet A 124A:323-7 (2004)
REFERENCE   PMID:9714442 (description)
  AUTHORS   Keyvani K, Paulus W, Traupe H, Kiesewetter F, Cursiefen C, Huk W, Raab K, Orth U, Rauch A, Pfeiffer RA
  TITLE     Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome: clinical and  neuropathological observations in a 33-year-old man.
  JOURNAL   Am J Med Genet 78:371-7 (1998)
///
ENTRY       H00741                      Disease
NAME        Ichthyosis prematurity syndrome
DESCRIPTION Ichthyosis prematurity syndrome is a form of syndromic congenital ichthyosis characterized by the premature birth, neonatal asphyxia, and epidermal cornification with desquamation. Patients with this disease harbor mutations in the gene encoding the fatty acid transport protein 4 (FATP4).
CATEGORY    Skin and connective tissue disease
GENE        SLC27A4 [HSA:10999] [KO:K08745]
DBLINKS     MeSH: C536271
            OMIM: 608649
REFERENCE   PMID:21856041 (description, gene)
  AUTHORS   Khnykin D, Ronnevig J, Johnsson M, Sitek JC, Blaas HG, Hausser I, Johansen FE, Jahnsen FL
  TITLE     Ichthyosis prematurity syndrome: Clinical evaluation of 17 families with a rare disorder of lipid metabolism.
  JOURNAL   J Am Acad Dermatol (2011)
REFERENCE   PMID:19119129 (description)
  AUTHORS   Bygum A, Westermark P, Brandrup F
  TITLE     Ichthyosis prematurity syndrome: a well-defined congenital ichthyosis subtype.
  JOURNAL   J Am Acad Dermatol 59:S71-4 (2008)
REFERENCE   PMID:19631310 (description)
  AUTHORS   Klar J, Schweiger M, Zimmerman R, Zechner R, Li H, Torma H, Vahlquist A, Bouadjar B, Dahl N, Fischer J
  TITLE     Mutations in the fatty acid transport protein 4 gene cause the ichthyosis prematurity syndrome.
  JOURNAL   Am J Hum Genet 85:248-53 (2009)
///
ENTRY       H00742                      Disease
NAME        Neonatal ichthyosis-sclerosing cholangitis (NISCH) syndrome;
            Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis (ILVASC)
DESCRIPTION Neonatal ichthyosis-sclerosing cholangitis (NISCH) syndrome is an autosomal recessive liver disease caused by mutations of Claudin-1, a tight-junction protein expressed in liver and skin. Patients present epidermal scaling, pruritus, and neonatal cholestatic jaundice. Alopecia is also seen and cholestasis often progresses to sclerosing cholangitis.
CATEGORY    Liver disease; Skin and connective tissue disease
GENE        CLDN1 [HSA:9076] [KO:K06087]
DBLINKS     MeSH: C564365
            OMIM: 607626
REFERENCE   PMID:21865982 (description, gene)
  AUTHORS   Paganelli M, Stephenne X, Gilis A, Jacquemin E, Henrion Caude A, Girard M, Gonzales E, Revencu N, Reding R, Wanty C, Smets F, Sokal EM
  TITLE     Neonatal ichthyosis and sclerosing cholangitis syndrome: extremely variable liver disease severity from claudin-1 deficiency.
  JOURNAL   J Pediatr Gastroenterol Nutr 53:350-4 (2011)
REFERENCE   PMID:22030598 (description, gene)
  AUTHORS   Grosse B, Cassio D, Yousef N, Bernardo C, Jacquemin E, Gonzales E
  TITLE     Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability.
  JOURNAL   Hepatology 55:1249-59 (2012)
REFERENCE   PMID:15768832 (description, gene)
  AUTHORS   Carlton VE, Pawlikowska L, Bull LN
  TITLE     Molecular basis of intrahepatic cholestasis.
  JOURNAL   Ann Med 36:606-17 (2004)
///
ENTRY       H00743                      Disease
NAME        Paramyotonia congenita (PMC)
DESCRIPTION Paramyotonia congenita (PMC), which is also known as Eulenburg's disease, is an autosomal dominant inherited disease whose predominant feature is an episodic cold- or exercise-induced muscle myotonia in exposed areas (mainly the face, neck, and hands) that lasts for minutes to hours. The disease may also progress later in life, with stiffness giving way to flaccid paralysis and weakness in exposed or exercised muscles. It is caused by mutations in the sodium channel gene SCN4A.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        SCN4A [HSA:6329] [KO:K04837]
DRUG        Mexiletine [DG:DG00197]
            Acetazolamide [DG:DG01134]
            Hydrochlorothiazide [DR:D00340]
COMMENT     PMC mutations are concentrated around exons 22 and 24 of SCN4A, the commonest mutations being the Thr1313Met mutation and a variety of substitutions at position 1448.
DBLINKS     ICD-10: G71.1
            MeSH: D020967
            OMIM: 168300
REFERENCE   PMID:20634695 (description, gene)
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
REFERENCE   PMID:19571750 (description, gene)
  AUTHORS   Platt D, Griggs R
  TITLE     Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
  JOURNAL   Curr Opin Neurol 22:524-31 (2009)
REFERENCE   PMID:17395134 (drug)
  AUTHORS   Heatwole CR, Moxley RT 3rd
  TITLE     The nondystrophic myotonias.
  JOURNAL   Neurotherapeutics 4:238-51 (2007)
///
ENTRY       H00744                      Disease
NAME        Potassium-aggravated myotonias (PAMs), including:
            Myotonia fluctuans;
            Myotonia permanens;
            Acetazolamide responsive myotonia
DESCRIPTION The potassium-aggravated myotonias (PAMs), which are also known as sodium channel myotonias (SCMs), are a group of pure myotonic disorders caused by mutations in the SCN4A gene. PAMs include three diseases with very similar phenotypes: myotonia fluctuans, myotonia permanens, and acetazolamide-sensitive myotonia. These disorders differ from the other nondystrophic myotonias in that: (1) the myotonia is exacerbated by potassium ingestion; (2) the myotonia does not worsen with cold exposure; and (3) there is no major weakness.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        SCN4A [HSA:6329] [KO:K04837]
DRUG        Mexiletine [DG:DG00197]
            Acetazolamide [DG:DG01134]
DBLINKS     ICD-10: G71.1
            MeSH: C538353
            OMIM: 608390
REFERENCE   PMID:20634695 (description, gene)
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
REFERENCE   PMID:19571750 (description, gene)
  AUTHORS   Platt D, Griggs R
  TITLE     Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
  JOURNAL   Curr Opin Neurol 22:524-31 (2009)
REFERENCE   PMID:17395134 (drug)
  AUTHORS   Heatwole CR, Moxley RT 3rd
  TITLE     The nondystrophic myotonias.
  JOURNAL   Neurotherapeutics 4:238-51 (2007)
///
ENTRY       H00745                      Disease
NAME        Hyperkalemic periodic paralysis (HyperPP)
DESCRIPTION The periodic paralyses are a group of autosomal-dominant disorders of skeletal muscle sodium, potassium, and calcium channel genes. They are characterized by episodes of muscle weakness associated with variations in serum potassium concentration. Hyperkalemic periodic paralysis (HyperPP) is caused by gain-of-function mutations in the alpha-subunit of the skeletal muscle voltage-gated sodium channel, Nav1.4. However, 20% of cases remain genetically undefined, suggesting genetic heterogeneity. HyperPP is characterized by attacks of flaccid limb paralysis or, rarely, weakness of the eye and throat muscles. Triggers for these attacks include ingestion of potassium-rich food, rest after strenuous exercise, and cold exposure.
CATEGORY    Musculoskeletal disease; Nervous system disease; Inherited metabolic disease
GENE        SCN4A [HSA:6329] [KO:K04837]
DRUG        Hydrochlorothiazide [DR:D00340]
            Mexiletine [DG:DG00197]
            Acetazolamide [DG:DG01134]
            Salbutamol [DR:D02147]
            Dichlorphenamide [DR:D00518]
COMMENT     The T704M and M1592V mutations in the SCN4A gene account for the majority of cases.
DBLINKS     ICD-10: G72.3
            MeSH: D020513
            OMIM: 170500
REFERENCE   PMID:20634695 (description, gene)
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
REFERENCE   PMID:19571750 (description, gene)
  AUTHORS   Platt D, Griggs R
  TITLE     Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
  JOURNAL   Curr Opin Neurol 22:524-31 (2009)
REFERENCE   PMID:17395134 (drug)
  AUTHORS   Heatwole CR, Moxley RT 3rd
  TITLE     The nondystrophic myotonias.
  JOURNAL   Neurotherapeutics 4:238-51 (2007)
///
ENTRY       H00746                      Disease
NAME        Hypokalemic periodic paralysis (HypoPP)
DESCRIPTION The periodic paralyses are a group of autosomal-dominant disorders of skeletal muscle sodium, potassium, and calcium channel genes. They are characterized by episodes of muscle weakness associated with variations in serum potassium concentration. Hypokalemic periodic paralysis (HypoPP) is caused by mutations in both the alpha-subunit of the skeletal muscle voltage-gated sodium channel, Nav1.4, and the homologous alpha1-subunit of the skeletal muscle calcium channel, Cav1.1. HypoPP is associated with point mutations in both CACNA1S (HypoPP1) and SCN4A (HypoPP2); however, approximately 10-20% of cases remain genetically undefined. In general, HypoPP is characterized by reversible attacks of muscle weakness concomitant with decreased blood potassium concentrations. The attacks may be triggered by rest after strenuous exercise, by a meal rich in carbohydrates, or by exposure to cold. Phenotypic differences between HypoPP1 and HypoPP2 include: (1) earlier onset of disease in HypoPP1; (2) myalgias in HypoPP2; (3) on muscle biopsy, predominance of tubular aggregates in HypoPP2 and vacuoles in HypoPP1; and (4) aggravation of HypoPP2 by acetazolamide.
CATEGORY    Musculoskeletal disease; Nervous system disease; Inherited metabolic disease
GENE        (HypoPP1) CACNA1S [HSA:779] [KO:K04857]
            (HypoPP2) SCN4A [HSA:6329] [KO:K04837]
DRUG        Potassium [DR:D02060 D01298]
            Acetazolamide [DG:DG01134]
DBLINKS     ICD-10: G72.3
            MeSH: D020514
            OMIM: 170400 613345
REFERENCE   PMID:20634695 (description, gene, drug)
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
REFERENCE   PMID:19571750 (description, gene)
  AUTHORS   Platt D, Griggs R
  TITLE     Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
  JOURNAL   Curr Opin Neurol 22:524-31 (2009)
///
ENTRY       H00747                      Disease
NAME        Thyrotoxic hypokalemic periodic paralysis (TPP)
DESCRIPTION Thyrotoxic hypokalemic periodic paralysis (TPP) is characterized by thyrotoxicosis in combination with typical episodes of hypokalemic periodic paralysis (HypoPP). People of Asian descent are most often affected, but all ethnicities can present with TPP. Hypokalemia is typical during paralysis, but is not always detected; administration of potassium during the attacks should be offered cautiously, preferably orally, to prevent rebound hyperkalemia. Mutations have been identified in TPP patients in an inwardly rectifying potassium channel, , that is expressed in muscle and transcriptionally regulated by thyroid hormone. Mutations in Kir2.6, which occur in up to 33% of patients, reinforces the hypothesis of genetic heterogeneity in patients with TPP.
CATEGORY    Musculoskeletal disease; Nervous system disease; Inherited metabolic disease
GENE        KCNJ18 [HSA:100134444] [KO:K19468]
DRUG        Methimazole [DR:D00401]
            Propylthiouracil [DR:D00562]
            Propranolol [DG:DG00305]
            Potassium [DR:D02060 D01298]
DBLINKS     ICD-10: G72.3
            OMIM: 613239
REFERENCE   PMID:20634695 (description, gene)
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
REFERENCE   PMID:21556020 (description, gene, drug)
  AUTHORS   Maciel RM, Lindsey SC, Dias da Silva MR
  TITLE     Novel etiopathophysiological aspects of thyrotoxic periodic paralysis.
  JOURNAL   Nat Rev Endocrinol 7:657-67 (2011)
///
ENTRY       H00748                      Disease
NAME        Andersen-Tawil syndrome (ATS)
DESCRIPTION Andersen-Tawil syndrome (ATS) is a distinct type of periodic paralysis characterized in its full form by a triad of cardiac abnormalities, distinctive facial and skeletal features, and periodic paralysis. The distinctive physical features considered characteristic of ATS are: broad forehead, hypoplastic mandible, hypotelorism, low-set ears, digit clinodactyly, and 2-3 syndactyly of the toes. It is obvious that ATS has a high degree of phenotypic heterogeneity. ATS patients have loss-of-function mutations in the KCNJ2 gene, which encodes the voltage-gated inward rectifier potassium channel, Kir2.1. However, described KCNJ2 mutations only account for approximately 60% of diagnoses, suggesting genetic heterogeneity.
CATEGORY    Musculoskeletal disease; Nervous system disease; Inherited metabolic disease
GENE        KCNJ2 [HSA:3759] [KO:K04996]
DRUG        Acetazolamide [DG:DG01134]
DBLINKS     ICD-10: G72.3
            MeSH: D050030
            OMIM: 170390
REFERENCE   PMID:20634695 (description, gene, drug)
  AUTHORS   Raja Rayan DL, Hanna MG
  TITLE     Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.
  JOURNAL   Curr Opin Neurol 23:466-76 (2010)
REFERENCE   PMID:19571750 (description, gene)
  AUTHORS   Platt D, Griggs R
  TITLE     Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
  JOURNAL   Curr Opin Neurol 22:524-31 (2009)
///
ENTRY       H00749                      Disease
NAME        Episodic ataxias
DESCRIPTION Episodic ataxias (EAs) are a group of rare autosomal-dominant diseases characterized by recurrent, discrete episodes of ataxia, giddiness, and vertigo. EA1 and EA2 are the most widely recognized of the autosomal-dominant EAs and are caused by dysfunction of neuronal voltage-gated ion channels. There are central and peripheral nervous system manifestations in both conditions. The current classification is based on genetics and actually includes seven distinct subtypes. But these variants other than EA1 and EA2 are rare, some only occurring in single families, and gene mutations have not been identified in all. It is quite likely, however, that the number of phenotypes and mutated genes will grow further.
CATEGORY    Nervous system disease
GENE        (EA1) KCNA1 [HSA:3736] [KO:K04874]
            (EA2) CACNA1A [HSA:773] [KO:K04344]
            (EA5) CACNB4 [HSA:785] [KO:K04865]
            (EA6) SLC1A3 [HSA:6507] [KO:K05614]
DRUG        Carbamazepine [DR:D00252]
            Phenytoin [DG:DG00846]
            Sulthiame [DR:D01787]
            Acetazolamide [DG:DG01134]
            4-Aminopyridine [DR:D04127]
DBLINKS     ICD-10: G11.8
            OMIM: 160120 108500 613855 612656
REFERENCE   PMID:19650351 (description, gene)
  AUTHORS   Finsterer J
  TITLE     Ataxias with autosomal, X-chromosomal or maternal inheritance.
  JOURNAL   Can J Neurol Sci 36:409-28 (2009)
REFERENCE   PMID:19734086 (description, gene, drug)
  AUTHORS   Tomlinson SE, Hanna MG, Kullmann DM, Tan SV, Burke D
  TITLE     Clinical neurophysiology of the episodic ataxias: insights into ion channel dysfunction in vivo.
  JOURNAL   Clin Neurophysiol 120:1768-76 (2009)
///
ENTRY       H00750                      Disease
NAME        Keratosis follicularis spinulosa decalvans
DESCRIPTION Keratosis follicularis spinulosa decalvans (KFSD) is a rare genodermatosis characterized by hyperkeratotic follicular papules with progressive alopecia of the scalp and photophobia. It is initially described as a sex-linked disorder with typical palmoplantar keratoderma, but autosomal dominant form with marked erythema has been observed as well.
CATEGORY    Skin and connective tissue disease
GENE        (X-linked) MBTPS2 [HSA:51360] [KO:K07765]
            (X-linked) SAT1 [HSA:6303] [KO:K00657]
DBLINKS     ICD-10: Q82.8
            MeSH: C536159
            OMIM: 308800
REFERENCE   PMID:18984066 (descritpion)
  AUTHORS   Castori M, Covaciu C, Paradisi M, Zambruno G
  TITLE     Clinical and genetic heterogeneity in keratosis follicularis spinulosa decalvans.
  JOURNAL   Eur J Med Genet 52:53-8 (2009)
REFERENCE   PMID:18280351 (descritpion)
  AUTHORS   Bellet JS, Kaplan AL, Selim MA, Olsen EA
  TITLE     Keratosis follicularis spinulosa decalvans in a family.
  JOURNAL   J Am Acad Dermatol 58:499-502 (2008)
REFERENCE   PMID:20672378 (gene)
  AUTHORS   Aten E, Brasz LC, Bornholdt D, Hooijkaas IB, Porteous ME, Sybert VP, Vermeer MH, Vossen RH, van der Wielen MJ, Bakker E, Breuning MH, Grzeschik KH, Oosterwijk JC, den Dunnen JT
  TITLE     Keratosis Follicularis Spinulosa Decalvans is caused by mutations in MBTPS2.
  JOURNAL   Hum Mutat 31:1125-33 (2010)
REFERENCE   PMID:12215835 (gene)
  AUTHORS   Gimelli G, Giglio S, Zuffardi O, Alhonen L, Suppola S, Cusano R, Lo Nigro C, Gatti R, Ravazzolo R, Seri M
  TITLE     Gene dosage of the spermidine/spermine N(1)-acetyltransferase ( SSAT) gene with putrescine accumulation in a patient with a Xp21.1p22.12 duplication and keratosis follicularis spinulosa decalvans (KFSD).
  JOURNAL   Hum Genet 111:235-41 (2002)
///
ENTRY       H00751                      Disease
NAME        Asphyxiating thoracic dystrophy;
            Jeune syndrome
DESCRIPTION Asphyxiating thoracic dystrophy (Jeune syndrome) is a rare osteochondrodysplasia with characteristic skeletal abnormalities as well as the involvement of kidneys, liver, pancreas and eyes. Patients have proximal cervical stenosis and severe respiratory insufficiency due to the skeletal abnormalities such as narrow thorax and short ribs.
CATEGORY    Skeletal dysplasia
GENE        IFT80 [HSA:57560] [KO:K19678]
            WDR19 [HSA:57728] [KO:K19671]
            DYNC2H1 [HSA:79659] [KO:K10414]
            TTC21B [HSA:79809] [KO:K19673]
DBLINKS     ICD-10: Q77.2
            MeSH: C537571 C566982 C567761
            OMIM: 611263 613091 613819
REFERENCE   PMID:19644333 (descritpion)
  AUTHORS   Campbell RM Jr
  TITLE     Spine deformities in rare congenital syndromes: clinical issues.
  JOURNAL   Spine (Phila Pa 1976) 34:1815-27 (2009)
REFERENCE   PMID:21465651 (descritpion)
  AUTHORS   Keppler-Noreuil KM, Adam MP, Welch J, Muilenburg A, Willing MC
  TITLE     Clinical insights gained from eight new cases and review of reported cases with Jeune syndrome (asphyxiating thoracic dystrophy).
  JOURNAL   Am J Med Genet A 155A:1021-32 (2011)
REFERENCE   PMID:17468754 (gene)
  AUTHORS   Beales PL, Bland E, Tobin JL, Bacchelli C, Tuysuz B, Hill J, Rix S, Pearson CG, Kai M, Hartley J, Johnson C, Irving M, Elcioglu N, Winey M, Tada M, Scambler PJ
  TITLE     IFT80, which encodes a conserved intraflagellar transport protein, is mutated in  Jeune asphyxiating thoracic dystrophy.
  JOURNAL   Nat Genet 39:727-9 (2007)
REFERENCE   PMID:22019273 (gene)
  AUTHORS   Bredrup C, Saunier S, Oud MM, Fiskerstrand T, Hoischen A, Brackman D, Leh SM, Midtbo M, Filhol E, Bole-Feysot C, Nitschke P, Gilissen C, Haugen OH, Sanders JS, Stolte-Dijkstra I, Mans DA, Steenbergen EJ, Hamel BC, Matignon M, Pfundt R, Jeanpierre C, Boman H, Rodahl E, Veltman JA, Knappskog PM, Knoers NV, Roepman R, Arts HH
  TITLE     Ciliopathies with Skeletal Anomalies and Renal Insufficiency due to Mutations in  the IFT-A Gene WDR19.
  JOURNAL   Am J Hum Genet 89:634-43 (2011)
REFERENCE   PMID:19442771 (gene)
  AUTHORS   Dagoneau N, Goulet M, Genevieve D, Sznajer Y, Martinovic J, Smithson S, Huber C, Baujat G, Flori E, Tecco L, Cavalcanti D, Delezoide AL, Serre V, Le Merrer M, Munnich A, Cormier-Daire V
  TITLE     DYNC2H1 mutations cause asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III.
  JOURNAL   Am J Hum Genet 84:706-11 (2009)
REFERENCE   PMID:21258341 (gene)
  AUTHORS   Davis EE, Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV, Muzny DM, Young AC, Wheeler DA, Cruz P, Morgan M, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG, Gyapay G, Rieger S, Tonshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG, Maher ER, Attie-Bitach T, Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N
  TITLE     TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum.
  JOURNAL   Nat Genet 43:189-96 (2011)
///
ENTRY       H00752                      Disease
NAME        Ankyloblepharon-ctodermal defects-cleft lip/palate (AEC) syndrome and Rapp-Hodgkin syndrome
DESCRIPTION Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome (also known as Hay-Wells syndrome) and Rapp-Hodgkin syndrome are rare ectodermal dysplasias characterized by ankyloblepharon filiforme adnatum and cleft lip/palate. Ectodermal findings include hair, nail, teeth and sweat gland dystrophies.
CATEGORY    Developmental disorder
GENE        TP63 [HSA:8626] [KO:K10149]
DBLINKS     ICD-10: Q87.8
            MeSH: C535847 C535289
            OMIM: 106260 129400
REFERENCE   PMID:20556892 (descritpion, gene)
  AUTHORS   Sutton VR, Bree AF, van Bokhoven H
  TITLE     Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:20491771 (descritpion, gene)
  AUTHORS   Clements SE, Techanukul T, Holden ST, Mellerio JE, Dorkins H, Escande F, McGrath JA
  TITLE     Rapp-Hodgkin and Hay-Wells ectodermal dysplasia syndromes represent a variable spectrum of the same genetic disorder.
  JOURNAL   Br J Dermatol 163:624-9 (2010)
REFERENCE   PMID:19953814 (descritpion)
  AUTHORS   Tosun G, Elbay U
  TITLE     Rapp-Hodgkin syndrome: clinical and dental findings.
  JOURNAL   J Clin Pediatr Dent 34:71-5 (2009)
///
ENTRY       H00753                      Disease
NAME        Urofacial syndrome
DESCRIPTION The urofacial syndrome (UFS) is an autosomal recessive disorder characterized by the combination of urological problems and distorted facial expression. Failure of the urinary bladder to void in patients with UFS leads to recurrent urinary tract infection and subsequent renal failure.
CATEGORY    Kidney disease
GENE        HPSE2 [HSA:60495] [KO:K07965]
DBLINKS     MeSH: C536480
            OMIM: 236730
REFERENCE   PMID:21332471 (description, gene)
  AUTHORS   Mahmood S, Beetz C, Tahir M, Imran M, Mumtaz R, Bassmann I, Jahic A, Malik M, Nurnberg G, Hassan S, Rana S, Nurnberg P, Hubner C
  TITLE     First HPSE2 missense mutation in urofacial syndrome.
  JOURNAL   Clin Genet (2011)
REFERENCE   PMID:20605132 (description, gene)
  AUTHORS   Pang J, Zhang S, Yang P, Hawkins-Lee B, Zhong J, Zhang Y, Ochoa B, Agundez JA, Voelckel MA, Gu W, Xiong WC, Mei L, She JX, Wang CY
  TITLE     Loss-of-Function Mutations in HPSE2 Cause the Autosomal Recessive Urofacial Syndrome.
  JOURNAL   Am J Hum Genet (2010)
REFERENCE   PMID:20605127 (description, gene)
  AUTHORS   Daly SB, Urquhart JE, Hilton E, McKenzie EA, Kammerer RA, Lewis M, Kerr B, Stuart H, Donnai D, Long DA, Burgu B, Aydogdu O, Derbent M, Garcia-Minaur S, Reardon W, Gener B, Shalev S, Smith R, Woolf AS, Black GC, Newman WG
  TITLE     Mutations in HPSE2 Cause Urofacial Syndrome.
  JOURNAL   Am J Hum Genet (2010)
///
ENTRY       H00754                      Disease
NAME        3-Methylglutaconic aciduria (MGCA)
DESCRIPTION 3-Methylglutaconic aciduria (MGCA) is a group of metabolic disorders characterized by increased urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid. Five distinct forms of MGCA have been recognized. MGCA type 1 is caused by primary deficiency of the mitochondrial enzyme 3-methylglutaconyl-CoA hydratase (3-MGCH), resulting in a block of leucine degradation. In all other types, the activities of 3-MGCH and other enzymes of leucine degradation are normal and the MGCA is thought to be secondary to a defect in another pathway. MGCA type 2, also known as Barth syndrome, is an X-linked cardiomyopathy associated with skeletal myopathy, neutropenia, and growth retardation. MGCA type 3, also referred to as Costeff optic atrophy syndrome, is an autosomal recessive disorder caused by mutations in the gene OPA3. It is characterized by early-onset bilateral optic atrophy, later-onset extrapyramidal dysfunction. MGCA type 5 caused by mutation in the DNAJC19 gene, is characterized by early-onset dilated cardiomyopathy with conduction defects, nonprogressive cerebellar ataxia, testicular dysgenesis, and growth failure. MGCA type 6 (MEGDEL) caused by mutation in the SERAC1 gene, is characterized by deafness, encephalopathy, and Leigh-like lesions in the basal ganglia. MGCA type 7 (MEGCANN) caused by mutation in the CLPB gene, is characterized by cataracts, neurologic involvement and neutropenia. MGCA type 8 caused by mutation in the HTRA2 gene, is characterized by hypotonia, abnormal movements, respiratory insufficiency with apneic episodes, lack of developmental progress with seizures, and resulting in death in infancy. MGCA type 4 is the unclassified type, which includes all other patients with MGCA.
CATEGORY    Inherited metabolic disease
GENE        (Type 1) AUH [HSA:549] [KO:K05607]
            (Type 2) TAZ [HSA:6901] [KO:K13511]
            (Type 3) OPA3 [HSA:80207]
            (Type 5) DNAJC19 [HSA:131118] [KO:K09539]
            (Type 6) SERAC1 [HSA:84947]
            (Type 7) CLPB [HSA:81570] [KO:K03695]
            (Type 8) HTRA2 [HSA:27429] [KO:K08669]
MARKER      Elevated urinary levels of 3-methylglutaconic acid and 3-methylglutaric acid
COMMENT     Barth syndrome (MGCA type 2) is described in H00654.
DBLINKS     ICD-10: E71.1
            MeSH: C579867
            OMIM: 250950 302060 258501 610198 614739 616271 617248
REFERENCE   PMID:15719488
  AUTHORS   Gunay-Aygun M
  TITLE     3-Methylglutaconic aciduria: a common biochemical marker in various syndromes with diverse clinical features.
  JOURNAL   Mol Genet Metab 84:1-3 (2005)
REFERENCE   PMID:12434311
  AUTHORS   IJlst L, Loupatty FJ, Ruiter JP, Duran M, Lehnert W, Wanders RJ
  TITLE     3-Methylglutaconic aciduria type I is caused by mutations in AUH.
  JOURNAL   Am J Hum Genet 71:1463-6 (2002)
REFERENCE   PMID:20350831
  AUTHORS   Huizing M, Dorward H, Ly L, Klootwijk E, Kleta R, Skovby F, Pei W, Feldman B, Gahl WA, Anikster Y
  TITLE     OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria.
  JOURNAL   Mol Genet Metab 100:149-54 (2010)
REFERENCE   PMID:16055927
  AUTHORS   Davey KM, Parboosingh JS, McLeod DR, Chan A, Casey R, Ferreira P, Snyder FF, Bridge PJ, Bernier FP
  TITLE     Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition.
  JOURNAL   J Med Genet 43:385-93 (2006)
REFERENCE   PMID:23918762 (gene)
  AUTHORS   Sarig O, Goldsher D, Nousbeck J, Fuchs-Telem D, Cohen-Katsenelson K, Iancu TC, Manov I, Saada A, Sprecher E, Mandel H
  TITLE     Infantile mitochondrial hepatopathy is a cardinal feature of MEGDEL syndrome (3-methylglutaconic aciduria type IV with sensorineural deafness, encephalopathy  and Leigh-like syndrome) caused by novel mutations in SERAC1.
  JOURNAL   Am J Med Genet A 161A:2204-15 (2013)
REFERENCE   PMID:25597510 (gene)
  AUTHORS   Wortmann SB, Zietkiewicz S, Kousi M, Szklarczyk R, Haack TB, Gersting SW, Muntau AC, Rakovic A, Renkema GH, Rodenburg RJ, Strom TM, Meitinger T, Rubio-Gozalbo ME, Chrusciel E, Distelmaier F, Golzio C, Jansen JH, van Karnebeek C, Lillquist Y, Lucke T, Ounap K, Zordania R, Yaplito-Lee J, van Bokhoven H, Spelbrink JN, Vaz FM, Pras-Raves M, Ploski R, Pronicka E, Klein C, Willemsen MA, de Brouwer AP, Prokisch H, Katsanis N, Wevers RA
  TITLE     CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder.
  JOURNAL   Am J Hum Genet 96:245-57 (2015)
REFERENCE   PMID:27208207 (gene)
  AUTHORS   Mandel H, Saita S, Edvardson S, Jalas C, Shaag A, Goldsher D, Vlodavsky E, Langer T, Elpeleg O
  TITLE     Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria.
  JOURNAL   J Med Genet 53:690-6 (2016)
///
ENTRY       H00755                      Disease
NAME        Acrokeratosis verruciformis
DESCRIPTION Acrokeratosis verruciformis is a rare autosomal dominant genodermatosis characterized by multiple planar wart-like lesions on the hands and feet. The lesions are usually present at birth. Mutations in ATP2A2 encoding the calcium pump in sarcoendoplasmic reticulum have been identified.
CATEGORY    Skin and connective tissue disease
GENE        ATP2A2 [HSA:488] [KO:K05853]
DBLINKS     MeSH: D007644
            OMIM: 101900
REFERENCE   PMID:12542527 (description, gene)
  AUTHORS   Dhitavat J, Macfarlane S, Dode L, Leslie N, Sakuntabhai A, MacSween R, Saihan E, Hovnanian A
  TITLE     Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2: evidence that it is allelic to Darier's disease.
  JOURNAL   J Invest Dermatol 120:229-32 (2003)
REFERENCE   PMID:22028575 (description, gene)
  AUTHORS   Bang CH, Kim HS, Park YM, Kim HO, Lee JY
  TITLE     Non-familial Acrokeratosis Verruciformis of Hopf.
  JOURNAL   Ann Dermatol 23 Suppl 1:S61-3 (2011)
REFERENCE   PMID:16150218 (description)
  AUTHORS   Rallis E, Economidi A, Papadakis P, Verros C
  TITLE     Acrokeratosis verruciformis of Hopf (Hopf disease): case report and review of the literature.
  JOURNAL   Dermatol Online J 11:10 (2005)
///
ENTRY       H00756                      Disease
NAME        Pitt-Hopkins syndrome, including:
            Pitt-Hopkins syndrome;
            Pitt-Hopkins-like syndrome
DESCRIPTION Pitt-Hopkins Syndrome (PHS) is a rare disorder of severe mental retardation. Facial dysmorphism include a beaked nose, flared nostrils, and a wide mouth with a 'cupid's-bow' shaped upper lip. A particular breathing pattern is characteristic of PHS. The defective gene is TCF4 in PHS, and in patients who show severe mental retardation and other features resembling PHS have mutations in CNTNAP2 and Neurexin I.
CATEGORY    Mental retardation
GENE        (Pitt-Hopkins) TCF4 [HSA:6925] [KO:K15603]
            (Pitt-Hopkins-like) CNTNAP2 [HSA:26047] [KO:K07380]
            (Pitt-Hopkins-like) NRXN1 [HSA:9378] [KO:K07377]
DBLINKS     ICD-10: Q04.8
            OMIM: 610954 610042 614325
REFERENCE   PMID:20205897 (description, gene)
  AUTHORS   Taddeucci G, Bonuccelli A, Mantellassi I, Orsini A, Tarantino E
  TITLE     Pitt-Hopkins syndrome: report of a case with a TCF4 gene mutation.
  JOURNAL   Ital J Pediatr 36:12 (2010)
REFERENCE   PMID:9475596 (description, gene)
  AUTHORS   Van Balkom ID, Quartel S, Hennekam RC
  TITLE     Mental retardation, "coarse" face, and hyperbreathing: confirmation of the Pitt-Hopkins syndrome.
  JOURNAL   Am J Med Genet 75:273-6 (1998)
///
ENTRY       H00757                      Disease
NAME        Dyggve-Melchior-Clausen disease and Smith-McCort dysplasia
DESCRIPTION Dyggve-Melchior-Clausen (DMC) syndrome is a rare autosomal recessive disorder characterized by the association of spondylo-epi-metaphyseal dysplasia and mental retardation. The patients have a shortened trunk, striking barrel-shaped thorax, rhizomelic limb shortening, and distal deformities. A clinical entity similar to DMC but without mental retardation is called Smith McCort dysplasia.
CATEGORY    Skeletal dysplasia
GENE        DYM [HSA:54808]
DBLINKS     ICD-10: Q87.1
            MeSH: C535726 C564589
            OMIM: 223800 607326
REFERENCE   PMID:15464420 (description, gene)
  AUTHORS   Paupe V, Gilbert T, Le Merrer M, Munnich A, Cormier-Daire V, El Ghouzzi V
  TITLE     Recent advances in Dyggve-Melchior-Clausen syndrome.
  JOURNAL   Mol Genet Metab 83:51-9 (2004)
REFERENCE   PMID:16470731 (description, gene)
  AUTHORS   Neumann LM, El Ghouzzi V, Paupe V, Weber HP, Fastnacht E, Leenen A, Lyding S, Klusmann A, Mayatepek E, Pelz J, Cormier-Daire V
  TITLE     Dyggve-Melchior-Clausen syndrome and Smith-McCort dysplasia: clinical and molecular findings in three families supporting genetic heterogeneity in Smith-McCort dysplasia.
  JOURNAL   Am J Med Genet A 140:421-6 (2006)
REFERENCE   PMID:12499951 (description)
  AUTHORS   Burns C, Powell BR, Hsia YE, Reinker K
  TITLE     Dyggve-Melchior-Clausen syndrome: report of seven patients with the Smith-McCort  variant and review of the literature.
  JOURNAL   J Pediatr Orthop 23:88-93 (2003)
REFERENCE   PMID:16206059 (description)
  AUTHORS   Bayrak IK, Nural MS, Diren HB
  TITLE     Dyggve-Melchior-Clausen syndrome without mental retardation (Smith-McCort dysplasia).
  JOURNAL   Diagn Interv Radiol 11:163-5 (2005)
///
ENTRY       H00758                      Disease
NAME        Progressive pseudorheumatoid dysplasia (PPRD);
            Spondyloepiphyseal dysplasia tarda with progressive arthropathy (SEDT-PA)
DESCRIPTION Progressive pseudorheumatoid dysplasia is an inherited skeletal dysplasia in which the spine is affected as in spondyloepiphyseal dysplasia tarda. There is degeneration of articular cartilage that leads to stiffness and swelling of joints. The disease is caused by mutations of the WISP3 gene.
CATEGORY    Skeletal dysplasia
GENE        WISP3 [HSA:8838]
DBLINKS     MeSH: C535387
            OMIM: 208230
REFERENCE   PMID:9222963 (description)
  AUTHORS   el-Shanti HE, Omari HZ, Qubain HI
  TITLE     Progressive pseudorheumatoid dysplasia: report of a family and review.
  JOURNAL   J Med Genet 34:559-63 (1997)
REFERENCE   PMID:17596985 (description)
  AUTHORS   Bennani L, Amine B, Ichchou L, Lazrak N, Hajjaj-Hassouni N
  TITLE     Progressive pseudorheumatoid dysplasia: three cases in one family.
  JOURNAL   Joint Bone Spine 74:393-5 (2007)
REFERENCE   PMID:17483925 (gene)
  AUTHORS   Zhou HD, Bu YH, Peng YQ, Xie H, Wang M, Yuan LQ, Jiang Y, Li D, Wei QY, He YL, Xiao T, Ni JD, Liao EY
  TITLE     Cellular and molecular responses in progressive pseudorheumatoid dysplasia articular cartilage associated with compound heterozygous WISP3 gene mutation.
  JOURNAL   J Mol Med (Berl) 85:985-96 (2007)
REFERENCE   PMID:16152649 (gene)
  AUTHORS   Delague V, Chouery E, Corbani S, Ghanem I, Aamar S, Fischer J, Levy-Lahad E, Urtizberea JA, Megarbane A
  TITLE     Molecular study of WISP3 in nine families originating from the Middle-East and presenting with progressive pseudorheumatoid dysplasia: identification of two novel mutations, and description of a founder effect.
  JOURNAL   Am J Med Genet A 138A:118-26 (2005)
///
ENTRY       H00759                      Disease
NAME        Waardenburg syndrome (WS)
DESCRIPTION Waardenburg syndrome (WS) is a rare autosomal dominant inherited disorder characterized by sensorineural hearing loss and pigment disturbances of the hair, skin, and iris. Four subtypes of WS have been classified based on the presence or absence of additional symptoms. WS 1 and WS 2 are distinguished by the presence or absence of dystopia canthorum, respectively. WS 3 is similar to WS 1 with additional musculoskeletal abnormalities. WS 4 is characterized by the presence of an aganglionic megacolon. WS is associated with six genes of melanocytic differentiation: PAX3, SOX10, MITF, EDNR, EDN3, and SNAIL2.
CATEGORY    Inherited metabolic disease; Albinism
GENE        (WS 1/3) PAX3 [HSA:5077] [KO:K09381]
            (WS 2A) MITF [HSA:4286] [KO:K09455]
            (WS 2D) SNAI2 [HSA:6591] [KO:K05706]
            (WS 2E/4C) SOX10 [HSA:6663] [KO:K09270]
            (WS 4A) EDNRB [HSA:1910] [KO:K04198]
            (WS 4B) EDN3 [HSA:1908] [KO:K05227]
DBLINKS     ICD-10: E70.3
            MeSH: D014849
            OMIM: 193500 193510 608890 611584 148820 277580 613265 613266 609136
REFERENCE   PMID:20127975
  AUTHORS   Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N
  TITLE     Review and update of mutations causing Waardenburg syndrome.
  JOURNAL   Hum Mutat 31:391-406 (2010)
REFERENCE   PMID:20478267
  AUTHORS   Chen H, Jiang L, Xie Z, Mei L, He C, Hu Z, Xia K, Feng Y
  TITLE     Novel mutations of PAX3, MITF, and SOX10 genes in Chinese patients with type I or type II Waardenburg syndrome.
  JOURNAL   Biochem Biophys Res Commun 397:70-4 (2010)
REFERENCE   PMID:21856949
  AUTHORS   Nissan X, Larribere L, Saidani M, Hurbain I, Delevoye C, Feteira J, Lemaitre G, Peschanski M, Baldeschi C
  TITLE     Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis.
  JOURNAL   Proc Natl Acad Sci U S A 108:14861-6 (2011)
///
ENTRY       H00760                      Disease
NAME        Spondyloepiphyseal dysplasia tarda
DESCRIPTION X-linked spondyloepiphyseal dysplasia tarda is a rare osteochondrodysplasia characterized by disproportionately short stature with short trunk. The symptoms of this condition appear later in childhood between ages 3 and 12.
CATEGORY    Skeletal dysplasia
GENE        TRAPPC2 [HSA:6399] [KO:K20301]
DBLINKS     MeSH: D010009
            OMIM: 313400
REFERENCE   PMID:20301324 (description, gene)
  AUTHORS   Tiller GE, Hannig VL
  TITLE     X-Linked Spondyloepiphyseal Dysplasia Tarda
  JOURNAL   (1993)
REFERENCE   PMID:19417549 (description, gene)
  AUTHORS   Guo H, Xu X, Wang K, Zhang B, Deng G, Wang Y, Bai Y
  TITLE     A novel RNA-splicing mutation in TRAPPC2 gene causing x-linked spondyloepiphyseal dysplasia tarda in a large Chinese family.
  JOURNAL   J Genet 88:87-91 (2009)
REFERENCE   PMID:21858081 (gene)
  AUTHORS   Zong M, Wu XG, Chan CW, Choi MY, Chan HC, Tanner JA, Yu S
  TITLE     The adaptor function of TRAPPC2 in mammalian TRAPPs explains TRAPPC2-associated SEDT and TRAPPC9-associated congenital intellectual disability.
  JOURNAL   PLoS One 6:e23350 (2011)
///
ENTRY       H00761                      Disease
NAME        SEMD, Pakistani type
DESCRIPTION SEMD Pakistani type is a form of spondyloepimetaphyseal dysplasia (SEMD) characterized by short, bowed lower limbs, mild brachydactyly, enlarged knee joints, and early-onset osteoarthropathy. Radiographs show delayed epiphyseal ossification in hips and knees. Nonsense mutation in ATPSK2 has been reported.
CATEGORY    Skeletal dysplasia
GENE        PAPSS2 [HSA:9060] [KO:K13811]
DBLINKS     MeSH: C567551
            OMIM: 612847
REFERENCE   PMID:9714015 (descripion)
  AUTHORS   Ahmad M, Haque MF, Ahmad W, Abbas H, Haque S, Krakow D, Rimoin DL, Lachman RS, Cohn DH
  TITLE     Distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred.
  JOURNAL   Am J Med Genet 78:468-73 (1998)
REFERENCE   PMID:9771708 (gene)
  AUTHORS   Faiyaz ul Haque M, King LM, Krakow D, Cantor RM, Rusiniak ME, Swank RT, Superti-Furga A, Haque S, Abbas H, Ahmad W, Ahmad M, Cohn DH
  TITLE     Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the  brachymorphic mouse.
  JOURNAL   Nat Genet 20:157-62 (1998)
///
ENTRY       H00762                      Disease
NAME        SEMD, Omani type;
            Spondyloepiphyseal dysplasia with congenital joint dislocations
DESCRIPTION SEMD, Omani type is a form of spondyloepi(meta)physeal dysplasia with congenital joint dislocations especially in knees. Hip and elbow dislocations are also common. Thoracic kyphoscoliosis develops in late childhood. Affected individuals are homozygous for a missense mutation of CHST3 encoding the enzyme chondroitin 6-O-sulfotransferase-1 (C6ST-1).
CATEGORY    Skeletal dysplasia
GENE        CHST3 [HSA:9469] [KO:K01020]
DBLINKS     MeSH: C535789
            OMIM: 143095
REFERENCE   PMID:18698629 (description, gene)
  AUTHORS   van Roij MH, Mizumoto S, Yamada S, Morgan T, Tan-Sindhunata MB, Meijers-Heijboer H, Verbeke JI, Markie D, Sugahara K, Robertson SP
  TITLE     Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype.
  JOURNAL   Am J Med Genet A 146A:2376-84 (2008)
REFERENCE   PMID:15602087 (description)
  AUTHORS   Rossi M, De Brasi D, Hall CM, Battagliese A, Melis D, Sebastio G, Andria G
  TITLE     A new familial case of spondylo-epi-metaphyseal dysplasia with multiple dislocations Hall type (leptodactylic form).
  JOURNAL   Clin Dysmorphol 14:13-8 (2005)
REFERENCE   PMID:9678701 (description)
  AUTHORS   Hall CM, Elcioglu NH, Shaw DG
  TITLE     A distinct form of spondyloepimetaphyseal dysplasia with multiple dislocations.
  JOURNAL   J Med Genet 35:566-72 (1998)
///
ENTRY       H00763                      Disease
NAME        Transient bullous dermolysis of the newborn
DESCRIPTION Transient bullous dermolysis of the newborn is a rare disorder in which subepidermal blistering presents at birth. Tissue separation occurs below the lamina densa, due to abnormal intraepidermal accumulation of type VII collagen. The disease usually regresses during early life, as type VII collagen secretion gradually recovers.
CATEGORY    Skin and connective tissue disease
GENE        COL7A1 [HSA:1294] [KO:K16628]
DBLINKS     MeSH: C536979
            OMIM: 131705
REFERENCE   PMID:9856844 (description, gene)
  AUTHORS   Hammami-Hauasli N, Raghunath M, Kuster W, Bruckner-Tuderman L
  TITLE     Transient bullous dermolysis of the newborn associated with compound heterozygosity for recessive and dominant COL7A1 mutations.
  JOURNAL   J Invest Dermatol 111:1214-9 (1998)
REFERENCE   PMID:16225626 (description, gene)
  AUTHORS   Fassihi H, Diba VC, Wessagowit V, Dopping-Hepenstal PJ, Jones CA, Burrows NP, McGrath JA
  TITLE     Transient bullous dermolysis of the newborn in three generations.
  JOURNAL   Br J Dermatol 153:1058-63 (2005)
REFERENCE   PMID:9406826 (description, gene)
  AUTHORS   Christiano AM, Fine JD, Uitto J
  TITLE     Genetic basis of dominantly inherited transient bullous dermolysis of the newborn: a splice site mutation in the type VII collagen gene.
  JOURNAL   J Invest Dermatol 109:811-4 (1997)
///
ENTRY       H00764                      Disease
NAME        Chromosme 5p deletion syndrome;
            Cri du chat syndrome;
            Cat cry syndrome
DESCRIPTION The Cri du Chat syndrome (CdCS) is a genetic disease resulting from a deletion of variable size occurring on the short arm of chromosome 5. The main clinical features are a high-pitched monochromatic cry, microcephaly, broad nasal bridge, epicanthal folds, micrognathia, abnormal dermatoglyphics, and severe psychomotor and mental retardation. SEMAF/ SEMA5A and CTNND2 have been mapped to the critical regions, and their deletion may be associated with mental retardation in CdCS patients. The TERT deletion may contribute to the phenotypic changes in CdCS.
CATEGORY    Chromosomal abnormality
GENE        SEMA5A [HSA:9037] [KO:K06841]
            CTNND2 [HSA:1501]
            TERT [HSA:7015] [KO:K11126]
DBLINKS     ICD-10: Q93.4
            MeSH: D003410
            OMIM: 123450
REFERENCE   PMID:16953888
  AUTHORS   Cerruti Mainardi P
  TITLE     Cri du Chat syndrome.
  JOURNAL   Orphanet J Rare Dis 1:33 (2006)
REFERENCE   PMID:9464278
  AUTHORS   Simmons AD, Puschel AW, McPherson JD, Overhauser J, Lovett M
  TITLE     Molecular cloning and mapping of human semaphorin F from the Cri-du-chat candidate interval.
  JOURNAL   Biochem Biophys Res Commun 242:685-91 (1998)
REFERENCE   PMID:10673328
  AUTHORS   Medina M, Marinescu RC, Overhauser J, Kosik KS
  TITLE     Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome.
  JOURNAL   Genomics 63:157-64 (2000)
///
ENTRY       H00765                      Disease
NAME        Spondyloepiphyseal dysplasia, Kimberley type;
            Spondyloepimetaphyseal dysplasia, aggrecan type
DESCRIPTION Spondyloepiphyseal dysplasia Kimberley type is a mild form of spondyloepiphyseal dysplasia (SED) with early-onset arthropathy. The phenotype of the disease is short stature and stocky build due to flattened vertebral bodies. Aggrecan, the protein of the proteoglycan of cartilage, is linked to the disease.
CATEGORY    Skeletal dysplasia
GENE        ACAN [HSA:176] [KO:K06792]
DBLINKS     MeSH: C564252
            OMIM: 608361 612813
REFERENCE   PMID:16080123 (description, gene)
  AUTHORS   Gleghorn L, Ramesar R, Beighton P, Wallis G
  TITLE     A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis.
  JOURNAL   Am J Hum Genet 77:484-90 (2005)
///
ENTRY       H00766                      Disease
NAME        Wolcott-Rallison syndrome;
            SED, Wolcott-Rallison type
DESCRIPTION Wolcott-Rallison syndrome is a rare autosomal recessive disorder characterized by neonatal insulin-requiring diabetes and spondyloepiphyseal dysplasia. Diabetes appears during the first months of life in most patients and major skeletal manifestations include the long bones, pelvis and vertebrae. Liver is also affected in the disease.
CATEGORY    Skeletal dysplasia
GENE        EIF2AK3 [HSA:9451] [KO:K08860]
DBLINKS     ICD-10: E10 Q77.7
            MeSH: C536739
            OMIM: 226980
REFERENCE   PMID:21050479 (description, gene)
  AUTHORS   Julier C, Nicolino M
  TITLE     Wolcott-Rallison syndrome.
  JOURNAL   Orphanet J Rare Dis 5:29 (2010)
REFERENCE   PMID:15384883 (description, gene)
  AUTHORS   Iyer S, Korada M, Rainbow L, Kirk J, Brown RM, Shaw N, Barrett TG
  TITLE     Wolcott-Rallison syndrome: a clinical and genetic study of three children, novel  mutation in EIF2AK3 and a review of the literature.
  JOURNAL   Acta Paediatr 93:1195-201 (2004)
REFERENCE   PMID:12960215 (description, gene)
  AUTHORS   Brickwood S, Bonthron DT, Al-Gazali LI, Piper K, Hearn T, Wilson DI, Hanley NA
  TITLE     Wolcott-Rallison syndrome: pathogenic insights into neonatal diabetes from new mutation and expression studies of EIF2AK3.
  JOURNAL   J Med Genet 40:685-9 (2003)
///
ENTRY       H00767                      Disease
NAME        SEMD, Matrilin type;
            Spondyloepimetaphyseal dysplasia
DESCRIPTION SEMD, Matrilin type is a form of autosomal recessive spondyloepimetaphyseal dysplasia caused by homozygous mutation in matrilin 3, the extracellular matrix of cartilage. The phenotype is short-limb dwarfism. Several other skeletal changes such as lumbar lordosis and flat vertebral bodies characterize the disease.
CATEGORY    Skeletal dysplasia
GENE        MATN3 [HSA:4148] [KO:K19467]
DBLINKS     ICD-10: Q77.7
            MeSH: C563869
            OMIM: 608728
REFERENCE   PMID:15121775 (description, gene)
  AUTHORS   Borochowitz ZU, Scheffer D, Adir V, Dagoneau N, Munnich A, Cormier-Daire V
  TITLE     Spondylo-epi-metaphyseal dysplasia (SEMD) matrilin 3 type: homozygote matrilin 3  mutation in a novel form of SEMD.
  JOURNAL   J Med Genet 41:366-72 (2004)
REFERENCE   PMID:18328979 (description)
  AUTHORS   Cormier-Daire V
  TITLE     Spondylo-epi-metaphyseal dysplasia.
  JOURNAL   Best Pract Res Clin Rheumatol 22:33-44 (2008)
///
ENTRY       H00768                      Disease
NAME        Nonsyndromic autosomal recessive mental retardation (NS-ARMR)
DESCRIPTION Mental retardation (MR) is a neurodevelopmental disorder characterized by low intelligence quotient (IQ) and deficits in adaptive behaviors. Although X-linked MR has been extensively studied, and over 80 causal genes have been cloned, little is known about the genetic basis of nonsyndromic autosomal-recessive mental retardation (NS-ARMR). To date, only a few genes have been identified for NS-ARMR. These include PRSS12, CRBN, CC2D1A, GRIK2, TUSC3, ST3GAL3, TRAPPC9, MAN1B1, PGAP1 and DNST1. These genes have a variety of functions and participate in multiple biochemical pathways. In addition, there are several known disease loci for NS-ARMR for which genes have not yet been identified.
CATEGORY    Congenital disorder; Mental retardation
GENE        (MRT1) PRSS12 [HSA:8492] [KO:K09624]
            (MRT2) CRBN [HSA:51185] [KO:K11793]
            (MRT3) CC2D1A [HSA:54862] [KO:K18260]
            (MRT6) GRIK2 [HSA:2898] [KO:K05202]
            (MRT7) TUSC3 [HSA:7991] [KO:K12669]
            (MRT12) ST3GAL3 [HSA:6487] [KO:K00781]
            (MRT13) TRAPPC9 [HSA:83696] [KO:K20306]
            (MRT15) MAN1B1 [HSA:11253] [KO:K01230]
            (MRT42) PGAP1 [HSA:80055] [KO:K05294]
            (MRT46) DNST1 [HSA:3340] [KO:K02576]
MARKER      Intelligence quotient (IQ) lower than 70, associated with functional deficit in adaptive behavior, such as daily-living skills, social skills and communication.
DBLINKS     ICD-10: F78.9
            MeSH: C565406 C564404 C563929 C567008 C567018 C567017 C567016 C567015 C567014 C567013 C567019 C567714
            OMIM: 249500 607417 608443 611092 611093 611090 613192 615802 614202 616116
REFERENCE   PMID:21063731
  AUTHORS   Kuss AW, Garshasbi M, Kahrizi K, Tzschach A, Behjati F, Darvish H, Abbasi-Moheb L, Puettmann L, Zecha A, Weissmann R, Hu H, Mohseni M, Abedini SS, Rajab A, Hertzberg C, Wieczorek D, Ullmann R, Ghasemi-Firouzabadi S, Banihashemi S, Arzhangi S, Hadavi V, Bahrami-Monajemi G, Kasiri M, Falah M, Nikuei P, Dehghan A, Sobhani M, Jamali P, Ropers HH, Najmabadi H
  TITLE     Autosomal recessive mental retardation: homozygosity mapping identifies 27 single linkage intervals, at least 14 novel loci and several mutation hotspots.
  JOURNAL   Hum Genet 129:141-8 (2011)
REFERENCE   PMID:20092579
  AUTHORS   Mitsui S, Osako Y, Yokoi F, Dang MT, Yuri K, Li Y, Yamaguchi N
  TITLE     A mental retardation gene, motopsin/neurotrypsin/prss12, modulates hippocampal function and social interaction.
  JOURNAL   Eur J Neurosci 30:2368-78 (2009)
REFERENCE   PMID:17380424
  AUTHORS   Xin W, Xiaohua N, Peilin C, Xin C, Yaqiong S, Qihan W
  TITLE     Primary function analysis of human mental retardation related gene CRBN.
  JOURNAL   Mol Biol Rep 35:251-6 (2008)
REFERENCE   PMID:17714190
  AUTHORS   Rogaeva A, Albert PR
  TITLE     The mental retardation gene CC2D1A/Freud-1 encodes a long isoform that binds conserved DNA elements to repress gene transcription.
  JOURNAL   Eur J Neurosci 26:965-74 (2007)
REFERENCE   PMID:17847003
  AUTHORS   Motazacker MM, Rost BR, Hucho T, Garshasbi M, Kahrizi K, Ullmann R, Abedini SS, Nieh SE, Amini SH, Goswami C, Tzschach A, Jensen LR, Schmitz D, Ropers HH, Najmabadi H, Kuss AW
  TITLE     A defect in the ionotropic glutamate receptor 6 gene (GRIK2) is associated with autosomal recessive mental retardation.
  JOURNAL   Am J Hum Genet 81:792-8 (2007)
REFERENCE   PMID:18452889
  AUTHORS   Garshasbi M, Hadavi V, Habibi H, Kahrizi K, Kariminejad R, Behjati F, Tzschach A, Najmabadi H, Ropers HH, Kuss AW
  TITLE     A defect in the TUSC3 gene is associated with autosomal recessive mental retardation.
  JOURNAL   Am J Hum Genet 82:1158-64 (2008)
REFERENCE   PMID:21907012
  AUTHORS   Hu H, Eggers K, Chen W, Garshasbi M, Motazacker MM, Wrogemann K, Kahrizi K, Tzschach A, Hosseini M, Bahman I, Hucho T, Muhlenhoff M, Gerardy-Schahn R, Najmabadi H, Ropers HH, Kuss AW
  TITLE     ST3GAL3 mutations impair the development of higher cognitive functions.
  JOURNAL   Am J Hum Genet 89:407-14 (2011)
REFERENCE   PMID:20004765
  AUTHORS   Mir A, Kaufman L, Noor A, Motazacker MM, Jamil T, Azam M, Kahrizi K, Rafiq MA, Weksberg R, Nasr T, Naeem F, Tzschach A, Kuss AW, Ishak GE, Doherty D, Ropers HH, Barkovich AJ, Najmabadi H, Ayub M, Vincent JB
  TITLE     Identification of mutations in TRAPPC9, which encodes the NIK- and IKK-beta-binding protein, in nonsyndromic autosomal-recessive mental retardation.
  JOURNAL   Am J Hum Genet 85:909-15 (2009)
REFERENCE   PMID:24784135
  AUTHORS   Murakami Y, Tawamie H, Maeda Y, Buttner C, Buchert R, Radwan F, Schaffer S, Sticht H, Aigner M, Reis A, Kinoshita T, Jamra RA
  TITLE     Null mutation in PGAP1 impairing Gpi-anchor maturation in patients with intellectual disability and encephalopathy.
  JOURNAL   PLoS Genet 10:e1004320 (2014)
REFERENCE   PMID:21763484
  AUTHORS   Rafiq MA, Kuss AW, Puettmann L, Noor A, Ramiah A, Ali G, Hu H, Kerio NA, Xiang Y, Garshasbi M, Khan MA, Ishak GE, Weksberg R, Ullmann R, Tzschach A, Kahrizi K, Mahmood K, Naeem F, Ayub M, Moremen KW, Vincent JB, Ropers HH, Ansar M, Najmabadi H
  TITLE     Mutations in the alpha 1,2-mannosidase gene, MAN1B1, cause autosomal-recessive intellectual disability.
  JOURNAL   Am J Hum Genet 89:176-82 (2011)
REFERENCE   PMID:25125150
  AUTHORS   Reuter MS, Musante L, Hu H, Diederich S, Sticht H, Ekici AB, Uebe S, Wienker TF, Bartsch O, Zechner U, Oppitz C, Keleman K, Jamra RA, Najmabadi H, Schweiger S, Reis A, Kahrizi K
  TITLE     NDST1 missense mutations in autosomal recessive intellectual disability.
  JOURNAL   Am J Med Genet A 164A:2753-63 (2014)
///
ENTRY       H00769                      Disease
NAME        Hyperekplexia
DESCRIPTION Hyperekplexia, also known as startle disease, is a paroxysmal neurological disorder caused by defects in glycinergic neurotransmission. Hyperekplexia is characterized by neonatal hypertonia and an exaggerated startle reflex in response to acoustic or tactile stimuli. Genetic analysis has revealed mutations in genes for several postsynaptic proteins involved in orchestrating glycinergic neurotransmission, including the glycine receptor (GlyR) alpha1 and beta subunits, gephyrin and collybistin.
CATEGORY    Nervous system disease
GENE        GLRA1 [HSA:2741] [KO:K05193]
            GLRB [HSA:2743] [KO:K05196]
            GPHN [HSA:10243] [KO:K15376]
            ARHGEF9 [HSA:23229] [KO:K20686]
            SLC6A5 [HSA:9152] [KO:K05038]
DBLINKS     ICD-10: G25.8
            MeSH: D016750
            OMIM: 149400 300607
REFERENCE   PMID:18707791 (description, gene)
  AUTHORS   Harvey RJ, Topf M, Harvey K, Rees MI
  TITLE     The genetics of hyperekplexia: more than startle!
  JOURNAL   Trends Genet 24:439-47 (2008)
REFERENCE   PMID:20407582 (description, gene)
  AUTHORS   Davies JS, Chung SK, Thomas RH, Robinson A, Hammond CL, Mullins JG, Carta E, Pearce BR, Harvey K, Harvey RJ, Rees MI
  TITLE     The glycinergic system in human startle disease: a genetic screening approach.
  JOURNAL   Front Mol Neurosci 3:8 (2010)
///
ENTRY       H00770                      Disease
NAME        Congenital myasthenic syndrome
DESCRIPTION Congenital myasthenic syndromes (CMSs) are a heterogenous group of genetic disorders caused by mutations in several proteins that compose the neuromuscular junction (NMJ) apparatus on which synaptic formation and function depend. The majority are recessively inherited. The disorders of the NMJ cause weakness and fatigue.
CATEGORY    Nervous system disease
GENE        CHRNE [HSA:1145] [KO:K04817]
            CHRNA1 [HSA:1134] [KO:K04803]
            CHRNB1 [HSA:1140] [KO:K04812]
            CHRND [HSA:1144] [KO:K04816]
            COLQ [HSA:8292]
            CHAT [HSA:1103] [KO:K00623]
            RAPSN [HSA:5913]
            SCN4A [HSA:6329] [KO:K04837]
            MUSK [HSA:4593] [KO:K05129]
            DOK7 [HSA:285489]
            AGRN [HSA:375790] [KO:K06254]
            GFPT1 [HSA:2673] [KO:K00820]
DRUG        Fluoxetine [DG:DG00942]
            Quinidine sulfate [DG:DG00192]
            Ephedrine [DG:DG00227]
            Salbutamol [DR:D02147 D00683]
DBLINKS     ICD-10: G70.2
            MeSH: D020294
            OMIM: 254210 254300 601462 603034 608930 608931 614198 610542
REFERENCE   PMID:19593127 (description)
  AUTHORS   Argov Z
  TITLE     Management of myasthenic conditions: nonimmune issues.
  JOURNAL   Curr Opin Neurol 22:493-7 (2009)
REFERENCE   PMID:20547629 (description, gene, drug)
  AUTHORS   Spillane J, Beeson DJ, Kullmann DM
  TITLE     Myasthenia and related disorders of the neuromuscular junction.
  JOURNAL   J Neurol Neurosurg Psychiatry 81:850-7 (2010)
REFERENCE   PMID:21310273 (gene)
  AUTHORS   Senderek J, Muller JS, Dusl M, Strom TM, Guergueltcheva V, Diepolder I, Laval SH, Maxwell S, Cossins J, Krause S, Muelas N, Vilchez JJ, Colomer J, Mallebrera CJ, Nascimento A, Nafissi S, Kariminejad A, Nilipour Y, Bozorgmehr B, Najmabadi H, Rodolico C, Sieb JP, Steinlein OK, Schlotter B, Schoser B, Kirschner J, Herrmann R, Voit T, Oldfors A, Lindbergh C, Urtizberea A, von der Hagen M, Hubner A, Palace J, Bushby K, Straub V, Beeson D, Abicht A, Lochmuller H
  TITLE     Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.
  JOURNAL   Am J Hum Genet 88:162-72 (2011)
///
ENTRY       H00771                      Disease
NAME        Inherited erythromelalgia (IEM);
            Primary erythromelalgia
DESCRIPTION Inherited erythromelalgia (IEM) is characterized by intense episodic burning pain associated with redness and warmth of the affected extremities and in many instances occurs as an autosomal dominant trait. Symptoms of IEM can start as early as 1 year old (early-onset), or in adults (adult-onset), and both types have been described in families and in sporadic cases. Pharmacotherapy has been largely ineffective, and partial relief of symptoms comes from cooling the affected extremities. Dominantly inherited gain-of-function mutations in SCN9A, the gene encoding Nav1.7, cause IEM.
CATEGORY    Cardiovascular disease; Inherited metabolic disease
GENE        SCN9A [HSA:6335] [KO:K04841]
DBLINKS     ICD-10: I73.8
            OMIM: 133020
REFERENCE   PMID:19005038 (description, gene)
  AUTHORS   Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D
  TITLE     Inherited neuronal ion channelopathies: new windows on complex neurological diseases.
  JOURNAL   J Neurosci 28:11768-77 (2008)
REFERENCE   PMID:19185186 (description, gene)
  AUTHORS   Dib-Hajj SD, Yang Y, Waxman SG
  TITLE     Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes.
  JOURNAL   Adv Genet 63:85-110 (2008)
REFERENCE   PMID:20146699 (description, gene)
  AUTHORS   Fischer TZ, Waxman SG
  TITLE     Familial pain syndromes from mutations of the NaV1.7 sodium channel.
  JOURNAL   Ann N Y Acad Sci 1184:196-207 (2010)
///
ENTRY       H00772                      Disease
NAME        Paroxysmal extreme pain disorder (PEPD)
DESCRIPTION Paroxysmal extreme pain disorder (PEPD) is a autosomal dominant pain disorder resulting from a set of gain-of-function mutations in SCN9A, the gene encoding Nav1.7, that impair inactivation of Nav1.7. Severe pain in PEPD patients along with flushing are induced by bowel movement or probing of the perianal areas, and are sometimes accompanied by tonic nonepileptic seizures and cardiac deficits. The pain attacks are most severe in the lower part of the body and are often triggered by temperature changes (such as cold winds), eating, and/or emotional upsets (such as crying).
CATEGORY    Nervous system disease
GENE        SCN9A [HSA:6335] [KO:K04841]
DRUG        Carbamazepine [DR:D00252]
DBLINKS     MeSH: C563475
            OMIM: 167400
REFERENCE   PMID:19005038 (description, gene, drug)
  AUTHORS   Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D
  TITLE     Inherited neuronal ion channelopathies: new windows on complex neurological diseases.
  JOURNAL   J Neurosci 28:11768-77 (2008)
REFERENCE   PMID:19185186 (description, gene, drug)
  AUTHORS   Dib-Hajj SD, Yang Y, Waxman SG
  TITLE     Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes.
  JOURNAL   Adv Genet 63:85-110 (2008)
REFERENCE   PMID:20146699 (description, gene, drug)
  AUTHORS   Fischer TZ, Waxman SG
  TITLE     Familial pain syndromes from mutations of the NaV1.7 sodium channel.
  JOURNAL   Ann N Y Acad Sci 1184:196-207 (2010)
///
ENTRY       H00773                      Disease
NAME        Autosomal dominant mental retardation
DESCRIPTION Mental retardation (MR) is a neurodevelopmental disorder characterized by low intelligence quotient (IQ) and deficits in adaptive behaviors. Most MR genes identified so far are either located on the X chromosome or are associated with an autosomal recessive mode of inheritance. Only a small number of autosomal dominant MR genes are known, because patients with mental retardation rarely reproduce.
CATEGORY    Congenital disorder; Mental retardation
GENE        (MRD1) MBD5 [HSA:55777]
            (MRD2) DOCK8 [HSA:81704]
            (MRD3) CDH15 [HSA:1013] [KO:K06809]
            (MRD4) KIRREL3 [HSA:84623]
            (MRD5) SYNGAP1 [HSA:8831] [KO:K17631]
            (MRD6) GRIN2B [HSA:2904] [KO:K05210]
            (MRD7) DYRK1A [HSA:1859] [KO:K08825]
            (MRD8) GRIN1 [HSA:2902] [KO:K05208]
            (MRD9) KIF1A [HSA:547] [KO:K10392]
            (MRD10) CACNG2 [HSA:10369] [KO:K04867]
            (MRD11) EPB41L1 [HSA:2036] [KO:K06107]
            (MRD12) ARID1B [HSA:57492] [KO:K11653]
            (MRD13) DYNC1H1 [HSA:1778] [KO:K10413]
            (MRD14) ARID1A [HSA:8289] [KO:K11653]
            (MRD15) SMARCB1 [HSA:6598] [KO:K11648]
            (MRD16) SMARCA4 [HSA:6597] [KO:K11647]
            (MRD17) PACS1 [HSA:55690]
            (MRD18) GATAD2B [HSA:57459]
            (MRD19) CTNNB1 [HSA:1499] [KO:K02105]
            (MRD20) MEF2C [HSA:4208] [KO:K04454]
            (MRD21) CTCF [HSA:10664]
            (MRD22) ZBTB18 [HSA:10472]
            (MRD23) SETD5 [HSA:55209]
            (MRD25) AHDC1 [HSA:27245]
DBLINKS     ICD-10: F78.9
            MeSH: C566947 C567241 C567240 C567234
            OMIM: 156200 614113 612580 612581 612621 613970 614254 614255 614256 614257 614562 614563 614607 614608 614609 615009 615074 615075 613443 615502 612337 615761 615829
REFERENCE   PMID:19904302
  AUTHORS   Williams SR, Mullegama SV, Rosenfeld JA, Dagli AI, Hatchwell E, Allen WP, Williams CA, Elsea SH
  TITLE     Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures.
  JOURNAL   Eur J Hum Genet 18:436-41 (2010)
REFERENCE   PMID:18060736
  AUTHORS   Griggs BL, Ladd S, Saul RA, DuPont BR, Srivastava AK
  TITLE     Dedicator of cytokinesis 8 is disrupted in two patients with mental retardation and developmental disabilities.
  JOURNAL   Genomics 91:195-202 (2008)
REFERENCE   PMID:19012874
  AUTHORS   Bhalla K, Luo Y, Buchan T, Beachem MA, Guzauskas GF, Ladd S, Bratcher SJ, Schroer RJ, Balsamo J, DuPont BR, Lilien J, Srivastava AK
  TITLE     Alterations in CDH15 and KIRREL3 in patients with mild to severe intellectual disability.
  JOURNAL   Am J Hum Genet 83:703-13 (2008)
REFERENCE   PMID:19673947
  AUTHORS   Huang K
  TITLE     SYNGAP: bridging the gap between genetic factors and autosomal non-syndromic mental retardation.
  JOURNAL   Clin Genet 76:149-51 (2009)
REFERENCE   PMID:20890276
  AUTHORS   Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, Milh M, Kortum F, Fritsch A, Pientka FK, Hellenbroich Y, Kalscheuer VM, Kohlhase J, Moog U, Rappold G, Rauch A, Ropers HH, von Spiczak S, Tonnies H, Villeneuve N, Villard L, Zabel B, Zenker M, Laube B, Reis A, Wieczorek D, Van Maldergem L, Kutsche K
  TITLE     Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.
  JOURNAL   Nat Genet 42:1021-6 (2010)
REFERENCE   PMID:21294719
  AUTHORS   van Bon BW, Hoischen A, Hehir-Kwa J, de Brouwer AP, Ruivenkamp C, Gijsbers AC, Marcelis CL, de Leeuw N, Veltman JA, Brunner HG, de Vries BB
  TITLE     Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
  JOURNAL   Clin Genet 79:296-9 (2011)
REFERENCE   PMID:21376300 (MRD8, MRD9, MRD10, MRD11)
  AUTHORS   Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K, Park AR, Spiegelman D, Dobrzeniecka S, Piton A, Tomitori H, Daoud H, Massicotte C, Henrion E, Diallo O, Shekarabi M, Marineau C, Shevell M, Maranda B, Mitchell G, Nadeau A, D'Anjou G, Vanasse M, Srour M, Lafreniere RG, Drapeau P, Lacaille JC, Kim E, Lee JR, Igarashi K, Huganir RL, Rouleau GA, Michaud JL
  TITLE     Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability.
  JOURNAL   Am J Hum Genet 88:306-16 (2011)
REFERENCE   PMID:22368300
  AUTHORS   Willemsen MH, Vissers LE, Willemsen MA, van Bon BW, Kroes T, de Ligt J, de Vries BB, Schoots J, Lugtenberg D, Hamel BC, van Bokhoven H, Brunner HG, Veltman JA, Kleefstra T
  TITLE     Mutations in DYNC1H1 cause severe intellectual disability with neuronal migration defects.
  JOURNAL   J Med Genet 49:179-83 (2012)
REFERENCE   PMID:22426308 (MRD12, MRD14, MRD15, MRD16)
  AUTHORS   Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, Fukushima Y, Homma T, Kato M, Hiraki Y, Yamagata T, Yano S, Mizuno S, Sakazume S, Ishii T, Nagai T, Shiina M, Ogata K, Ohta T, Niikawa N, Miyatake S, Okada I, Mizuguchi T, Doi H, Saitsu H, Miyake N, Matsumoto N
  TITLE     Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.
  JOURNAL   Nat Genet 44:376-8 (2012)
REFERENCE   PMID:23159249
  AUTHORS   Schuurs-Hoeijmakers JH, Oh EC, Vissers LE, Swinkels ME, Gilissen C, Willemsen MA, Holvoet M, Steehouwer M, Veltman JA, de Vries BB, van Bokhoven H, de Brouwer AP, Katsanis N, Devriendt K, Brunner HG
  TITLE     Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome.
  JOURNAL   Am J Hum Genet 91:1122-7 (2012)
REFERENCE   PMID:23644463
  AUTHORS   Willemsen MH, Nijhof B, Fenckova M, Nillesen WM, Bongers EM, Castells-Nobau A, Asztalos L, Viragh E, van Bon BW, Tezel E, Veltman JA, Brunner HG, de Vries BB, de Ligt J, Yntema HG, van Bokhoven H, Isidor B, Le Caignec C, Lorino E, Asztalos Z, Koolen DA, Vissers LE, Schenck A, Kleefstra T
  TITLE     GATAD2B loss-of-function mutations cause a recognisable syndrome with intellectual disability and are associated with learning deficits and synaptic undergrowth in Drosophila.
  JOURNAL   J Med Genet 50:507-14 (2013)
REFERENCE   PMID:23033978 (MRD19)
  AUTHORS   de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, Vulto-van Silfhout AT, Koolen DA, de Vries P, Gilissen C, del Rosario M, Hoischen A, Scheffer H, de Vries BB, Brunner HG, Veltman JA, Vissers LE
  TITLE     Diagnostic exome sequencing in persons with severe intellectual disability.
  JOURNAL   N Engl J Med 367:1921-9 (2012)
REFERENCE   PMID:20513142
  AUTHORS   Zweier M, Gregor A, Zweier C, Engels H, Sticht H, Wohlleber E, Bijlsma EK, Holder SE, Zenker M, Rossier E, Grasshoff U, Johnson DS, Robertson L, Firth HV, Ekici AB, Reis A, Rauch A
  TITLE     Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.
  JOURNAL   Hum Mutat 31:722-33 (2010)
REFERENCE   PMID:23746550
  AUTHORS   Gregor A, Oti M, Kouwenhoven EN, Hoyer J, Sticht H, Ekici AB, Kjaergaard S, Rauch A, Stunnenberg HG, Uebe S, Vasileiou G, Reis A, Zhou H, Zweier C
  TITLE     De novo mutations in the genome organizer CTCF cause intellectual disability.
  JOURNAL   Am J Hum Genet 93:124-31 (2013)
REFERENCE   PMID:21800092 (MRD22)
  AUTHORS   Ballif BC, Rosenfeld JA, Traylor R, Theisen A, Bader PI, Ladda RL, Sell SL, Steinraths M, Surti U, McGuire M, Williams S, Farrell SA, Filiano J, Schnur RE, Coffey LB, Tervo RC, Stroud T, Marble M, Netzloff M, Hanson K, Aylsworth AS, Bamforth JS, Babu D, Niyazov DM, Ravnan JB, Schultz RA, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG
  TITLE     High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44.
  JOURNAL   Hum Genet 131:145-56 (2012)
REFERENCE   PMID:24680889
  AUTHORS   Grozeva D, Carss K, Spasic-Boskovic O, Parker MJ, Archer H, Firth HV, Park SM, Canham N, Holder SE, Wilson M, Hackett A, Field M, Floyd JA, Hurles M, Raymond FL
  TITLE     De novo loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability.
  JOURNAL   Am J Hum Genet 94:618-24 (2014)
REFERENCE   PMID:24791903 (gene)
  AUTHORS   Xia F, Bainbridge MN, Tan TY, Wangler MF, Scheuerle AE, Zackai EH, Harr MH, Sutton VR, Nalam RL, Zhu W, Nash M, Ryan MM, Yaplito-Lee J, Hunter JV, Deardorff MA, Penney SJ, Beaudet AL, Plon SE, Boerwinkle EA, Lupski JR, Eng CM, Muzny DM, Yang Y, Gibbs RA
  TITLE     De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea.
  JOURNAL   Am J Hum Genet 94:784-9 (2014)
///
ENTRY       H00774                      Disease
NAME        Nav1.7-associated congenital insensitivity to pain (CIP)
DESCRIPTION Nav1.7-associated congenital insensitivity to pain (CIP) is a pure form of CIP affecting only pain sensation and olfaction. A loss-of-function of the SCN9A, the gene encoding Nav1.7, can produce CIP. Patients with Nav1.7-related CIP present with a history of not ever experiencing any pain even after burns, bone fractures, lip- and tongue-biting, and they do not experience visceral pain. Additionally, patients with Nav1.7-related CIP do not show apparent sympathetic dysfunction and have a normal axon reflex response to histamine. Homozygous and compound null mutations in SCN9A are predicted to truncate the channel protein, resulting in loss-of-function mutations in Nav1.7 and the complete loss of Nav1.7 current in all of the neurons in which this channel is expressed.
CATEGORY    Nervous system disease
GENE        SCN9A [HSA:6335] [KO:K04841]
DBLINKS     ICD-10: G60.8
            MeSH: D000699
            OMIM: 243000
REFERENCE   PMID:19005038 (description, gene)
  AUTHORS   Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D
  TITLE     Inherited neuronal ion channelopathies: new windows on complex neurological diseases.
  JOURNAL   J Neurosci 28:11768-77 (2008)
REFERENCE   PMID:19185186 (description, gene)
  AUTHORS   Dib-Hajj SD, Yang Y, Waxman SG
  TITLE     Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes.
  JOURNAL   Adv Genet 63:85-110 (2008)
REFERENCE   PMID:20146699 (description, gene)
  AUTHORS   Fischer TZ, Waxman SG
  TITLE     Familial pain syndromes from mutations of the NaV1.7 sodium channel.
  JOURNAL   Ann N Y Acad Sci 1184:196-207 (2010)
///
ENTRY       H00775                      Disease
NAME        Familial or sporadic hemiplegic migraine
DESCRIPTION Sporadic and familial hemiplegic migraines (SHM and FHM) are rare paroxysmal disorders characterized by motor aura and headache. The distinction is based on whether at least one first or second degree relative is also affected, otherwise the diagnostic criteria are similar. The majority of FHM families have a mutation in one of the ion channels CACNA1A, ATP1A2 and SCN1A. SHM is sometimes caused by a de novo mutation in one of the genes. However, at least a quarter of the large families affected and most sporadic cases do not have a mutation in the three genes known to be implicated in this disorder, suggesting that other genes are still to be identified.
CATEGORY    Nervous system disease
GENE        (FHM1, SHM1) CACNA1A [HSA:773] [KO:K04344]
            (FHM2, SHM2) ATP1A2 [HSA:477] [KO:K01539]
            (FHM3) SCN1A [HSA:6323] [KO:K04833]
DRUG        Lamotrigine [DR:D00354]
            Acetazolamide [DG:DG01134]
DBLINKS     ICD-10: G43.1
            MeSH: D020325
            OMIM: 141500 602481 609634
REFERENCE   PMID:21458376 (description, gene, drug)
  AUTHORS   Russell MB, Ducros A
  TITLE     Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management.
  JOURNAL   Lancet Neurol 10:457-70 (2011)
REFERENCE   PMID:20187861 (description, gene)
  AUTHORS   Russell MB
  TITLE     Management of sporadic and familial hemiplegic migraine.
  JOURNAL   Expert Rev Neurother 10:381-7 (2010)
///
ENTRY       H00776                      Disease
NAME        Congenital motor nystagmus (CMN);
            Idiopathic congenital nystagmus (ICN)
DESCRIPTION Nystagmus is an eye movement disorder in which one or both eyes are in constant movement. Nystagmus that occur independent of these known ocular or systemic diseases is referred to as congenital motor nystagmus (CMN) or idiopathic congenital nystagmus (ICN). It can be inherited as an autosomal dominant, an autosomal recessive, or an X-linked trait. At least six genetic loci for CMN have been suggested, including three loci for autosomal dominant CMN, and three loci for X-linked CMN.  A variety of mutations in the FRMD7 gene have been identified in many families with an X-linked recessive pattern. Another mutation associated with X-linked CMN is GPR143.
CATEGORY    Nervous system disease; Eye disease
GENE        (NYS1) FRMD7 [HSA:90167]
            (NYS6) GPR143 [HSA:4935] [KO:K08470]
DBLINKS     ICD-10: H55
            MeSH: C580539
            OMIM: 310700 300814
REFERENCE   PMID:17397053
  AUTHORS   Schorderet DF, Tiab L, Gaillard MC, Lorenz B, Klainguti G, Kerrison JB, Traboulsi EI, Munier FL
  TITLE     Novel mutations in FRMD7 in X-linked congenital nystagmus. Mutation in brief #963. Online.
  JOURNAL   Hum Mutat 28:525 (2007)
REFERENCE   PMID:22065086
  AUTHORS   Xiao X, Li S, Guo X, Zhang Q
  TITLE     A novel locus for autosomal dominant congenital motor nystagmus mapped to 1q31-q32.2 between D1S2816 and D1S2692.
  JOURNAL   Hum Genet 131:697-702 (2012)
REFERENCE   PMID:21423867
  AUTHORS   Hu J, Liang D, Xue J, Liu J, Wu L
  TITLE     A novel GPR143 splicing mutation in a Chinese family with X-linked congenital nystagmus.
  JOURNAL   Mol Vis 17:715-22 (2011)
///
ENTRY       H00777                      Disease
NAME        Spondylometaepiphyseal dysplasia, short limb-hand type;
            Spondylometaepiphyseal dysplasia, short limb-abnormal calcification type
DESCRIPTION Spondylometaepiphyseal dysplasia, short limb-hand type, or spondylometaepiphyseal dysplasia, short limb-abnormal calcification type is a rare skeletal dysplasia. The key clinical features of this condition include short stature with typical short hands and broad, puffy fingers, a narrow chest, and a characteristic craniofacial appearance. Their long bones are short due to premature epiphyses and irregular metaphyses.
CATEGORY    Skeletal dysplasia
GENE        DDR2 [HSA:4921] [KO:K05125]
DBLINKS     MeSH: C564794
            OMIM: 271665
REFERENCE   PMID:19110212 (description, gene)
  AUTHORS   Bargal R, Cormier-Daire V, Ben-Neriah Z, Le Merrer M, Sosna J, Melki J, Zangen DH, Smithson SF, Borochowitz Z, Belostotsky R, Raas-Rothschild A
  TITLE     Mutations in DDR2 gene cause SMED with short limbs and abnormal calcifications.
  JOURNAL   Am J Hum Genet 84:80-4 (2009)
REFERENCE   PMID:19050402 (description)
  AUTHORS   Smithson SF, Grier D, Hall CM
  TITLE     Spondylo-meta-epiphyseal dysplasia, short limb-abnormal calcification type.
  JOURNAL   Clin Dysmorphol 18:31-5 (2009)
REFERENCE   PMID:19002453 (description)
  AUTHORS   Tuysuz B, Gazioglu N, Ungur S, Aji DY, Turkmen S
  TITLE     The time of onset of abnormal calcification in spondylometaepiphyseal dysplasia,  short limb-abnormal calcification type.
  JOURNAL   Pediatr Radiol 39:84-9 (2009)
///
ENTRY       H00778                      Disease
NAME        Tarsal-carpal coalition syndrome
DESCRIPTION Tarsal-carpal coalition syndrome is a condition characterized by fusion of the carpals, tarsals, and phalanges in addition to shortened first metacarpals, brachydactyly, and humeroradial fusion. The fusion of the proximal interphalangeal joints starts at the fifth digit and proceeds to other digits. Humeroradial fusion can also be seen. It is inherited in an autosomal dominant pattern.
CATEGORY    Skeletal dysplasia
GENE        NOG [HSA:9241] [KO:K04658]
DBLINKS     MeSH: C536943
            OMIM: 186570
REFERENCE   PMID:11545688 (description, gene)
  AUTHORS   Dixon ME, Armstrong P, Stevens DB, Bamshad M
  TITLE     Identical mutations in NOG can cause either tarsal/carpal coalition syndrome or proximal symphalangism.
  JOURNAL   Genet Med 3:349-53 (2001)
REFERENCE   PMID:21538686 (description, gene)
  AUTHORS   Potti TA, Petty EM, Lesperance MM
  TITLE     A comprehensive review of reported heritable noggin-associated syndromes and proposed clinical utility of one broadly inclusive diagnostic term: NOG-related-symphalangism spectrum disorder (NOG-SSD).
  JOURNAL   Hum Mutat 32:877-86 (2011)
///
ENTRY       H00779                      Disease
NAME        Usher syndrome (US)
DESCRIPTION Usher syndrome (USH) is a group of autosomal recessively inherited disorders characterized by deafness and vision loss. Three clinical types USH1, USH2, and USH3, are distinguished on the basis of severity of hearing loss and the presence or absence of vestibular dysfunction. USH1 patients are congenitally profoundly deaf, and have vestibular dysfunction as well as prepubertal onset of progressive retinitis pigmentosa (RP). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. USH3 is characterized by a progressive hearing loss, a variable vestibular dysfunction, and RP. USH shows significant genetic heterogeneity, and at least 11 distinct loci have been identified and genes for 9 of them have been cloned.
CATEGORY    Nervous system disease; Eye disease; Ear disease
GENE        (USH1B) MYO7A [HSA:4647] [KO:K10359]
            (USH1C) USH1C [HSA:10083]
            (USH1D/1DF) CDH23, USH1D [HSA:64072] [KO:K06813]
            (USH1F/1DF) PCDH15 [HSA:65217] [KO:K16500]
            (USH1G) USH1G [HSA:124590] [KO:K21414]
            (USH1J) CIB2 [HSA:10518]
            (USH2A) USH2A [HSA:7399] [KO:K19636]
            (USH2A/2C) PDZD7 [HSA:79955]
            (USH2B/2C) GPR98 [HSA:84059] [KO:K18263]
            (USH2D) WHRN [HSA:25861]
            (USH3A) CLRN1 [HSA:7401]
            (USH3B) HARS [HSA:3035] [KO:K01892]
DBLINKS     ICD-10: H35.5
            MeSH: D052245
            OMIM: 276900 276904 601067 602083 606943 614869 276901 605472 611383 276902 614504
REFERENCE   PMID:20379205
  AUTHORS   Yan D, Liu XZ
  TITLE     Genetics and pathological mechanisms of Usher syndrome.
  JOURNAL   J Hum Genet 55:327-35 (2010)
REFERENCE   PMID:16374329
  AUTHORS   Friedman TB, Schultz JM, Ahmed ZM
  TITLE     Usher syndrome type 1: genotype-phenotype relationships.
  JOURNAL   Retina 25:S40-S42 (2005)
REFERENCE   PMID:22009552
  AUTHORS   Vache C, Besnard T, le Berre P, Garcia-Garcia G, Baux D, Larrieu L, Abadie C, Blanchet C, Bolz HJ, Millan J, Hamel C, Malcolm S, Claustres M, Roux AF
  TITLE     Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for diagnosis and therapy.
  JOURNAL   Hum Mutat 33:104-8 (2012)
REFERENCE   PMID:19423712
  AUTHORS   Tian G, Zhou Y, Hajkova D, Miyagi M, Dinculescu A, Hauswirth WW, Palczewski K, Geng R, Alagramam KN, Isosomppi J, Sankila EM, Flannery JG, Imanishi Y
  TITLE     Clarin-1, encoded by the Usher Syndrome III causative gene, forms a membranous microdomain: possible role of clarin-1 in organizing the actin cytoskeleton.
  JOURNAL   J Biol Chem 284:18980-93 (2009)
REFERENCE   PMID:23023331
  AUTHORS   Riazuddin S, Belyantseva IA, Giese AP, Lee K, Indzhykulian AA, Nandamuri SP, Yousaf R, Sinha GP, Lee S, Terrell D, Hegde RS, Ali RA, Anwar S, Andrade-Elizondo PB, Sirmaci A, Parise LV, Basit S, Wali A, Ayub M, Ansar M, Ahmad W, Khan SN, Akram J, Tekin M, Riazuddin S, Cook T, Buschbeck EK, Frolenkov GI, Leal SM, Friedman TB, Ahmed ZM
  TITLE     Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48.
  JOURNAL   Nat Genet 44:1265-71 (2012)
REFERENCE   PMID:22279524 (USH3B)
  AUTHORS   Puffenberger EG, Jinks RN, Sougnez C, Cibulskis K, Willert RA, Achilly NP, Cassidy RP, Fiorentini CJ, Heiken KF, Lawrence JJ, Mahoney MH, Miller CJ, Nair DT, Politi KA, Worcester KN, Setton RA, Dipiazza R, Sherman EA, Eastman JT, Francklyn C, Robey-Bond S, Rider NL, Gabriel S, Morton DH, Strauss KA
  TITLE     Genetic mapping and exome sequencing identify variants associated with five novel diseases.
  JOURNAL   PLoS One 7:e28936 (2012)
///
ENTRY       H00780                      Disease
NAME        Atrichia with papular lesions
DESCRIPTION Atrichia with papular lesions is a rare disease characterized by early onset irreversible alopecia and papular lesions of keratin-filled cysts over the extensor areas of the body. It is caused by mutations in hairless gene, whose defects brings about complete hair loss in mice. It is inherited in autosomal recessive manner.
CATEGORY    Skin and connective tissue disease
GENE        HR [HSA:55806] [KO:K00478]
DBLINKS     ICD-10: L72.8
            MeSH: C565924
            OMIM: 209500
REFERENCE   PMID:18709303 (description, gene)
  AUTHORS   Yip L, Horev L, Sinclair R, Zlotogorski A
  TITLE     Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria.
  JOURNAL   Acta Derm Venereol 88:346-9 (2008)
REFERENCE   PMID:21919222 (description, gene)
  AUTHORS   Azeem Z, Wasif N, Basit S, Razak S, Waheed RA, Islam A, Ayub M, Kafaitullah, Kamran-ul-hassan Naqvi S, Ali G, Ahmad W
  TITLE     Congenital atrichia with papular lesions resulting from novel mutations in human  hairless gene in four consanguineous families.
  JOURNAL   J Dermatol 38:755-60 (2011)
REFERENCE   PMID:21747609 (description, gene)
  AUTHORS   Lee D, Kim SH, Chun JS, Joo MH, Kim JY, Hwang SW, Kang HJ, Park SW, Sung HS
  TITLE     Detection of a novel missense mutations in atrichia with papular lesions.
  JOURNAL   Ann Dermatol 23:132-7 (2011)
REFERENCE   PMID:17609203 (description)
  AUTHORS   Wang J, Malloy PJ, Feldman D
  TITLE     Interactions of the vitamin D receptor with the corepressor hairless: analysis of hairless mutants in atrichia with papular lesions.
  JOURNAL   J Biol Chem 282:25231-9 (2007)
///
ENTRY       H00781                      Disease
NAME        Schopf-Schulz-Passarge syndrome;
            Keratosis palmoplantaris-cystic eyelids-hypodontia-hypotrichosis
DESCRIPTION Schopf-Schulz-Passarge syndrome is a  rare ectodermal dysplasia resulted from mutations in the WNT10A. The combination of multiple eyelid apocrine hidrocystomas, hypodontia, palmoplantar keratoderma, hypotrichosis and nail dystrophy characterize the disease.
CATEGORY    Skin and connective tissue disease
GENE        WNT10A [HSA:80326] [KO:K01357]
COMMENT     WNT10A mutations also underlie odonto-onycho-dermal dysplasia (H00646).
DBLINKS     MeSH: C565607
            OMIM: 224750
REFERENCE   PMID:19002348 (description)
  AUTHORS   Castori M, Ruggieri S, Giannetti L, Annessi G, Zambruno G
  TITLE     Schopf-Schulz-Passarge syndrome: further delineation of the phenotype and genetic considerations.
  JOURNAL   Acta Derm Venereol 88:607-12 (2008)
REFERENCE   PMID:21143469 (description, gene)
  AUTHORS   Castori M, Castiglia D, Brancati F, Foglio M, Heath S, Floriddia G, Madonna S, Fischer J, Zambruno G
  TITLE     Two families confirm Schopf-Schulz-Passarge syndrome as a discrete entity within  the WNT10A phenotypic spectrum.
  JOURNAL   Clin Genet 79:92-5 (2011)
REFERENCE   PMID:21834823 (description, gene)
  AUTHORS   Petrof G, Fong K, Lai-Cheong JE, Cockayne SE, McGrath JA
  TITLE     Schopf-Schulz-Passarge syndrome resulting from a homozygous nonsense mutation, p.Cys107X, in WNT10A.
  JOURNAL   Australas J Dermatol 52:224-6 (2011)
///
ENTRY       H00782                      Disease
NAME        Hypotrichosis and recurrent skin vesicles
DESCRIPTION Hypotrichosis and recurrent skin vesicles is a condition with sparse and fragile hair on scalp and vesicles on the skin over the body. Desmocollin 3, a transmembrane component of desmosomes, is associated with the disease.
CATEGORY    Skin and connective tissue disease
GENE        DSC3 [HSA:1825] [KO:K07602]
DBLINKS     MeSH: C567751
            OMIM: 613102
REFERENCE   PMID:19765682 (description, gene)
  AUTHORS   Ayub M, Basit S, Jelani M, Ur Rehman F, Iqbal M, Yasinzai M, Ahmad W
  TITLE     A homozygous nonsense mutation in the human desmocollin-3 (DSC3) gene underlies hereditary hypotrichosis and recurrent skin vesicles.
  JOURNAL   Am J Hum Genet 85:515-20 (2009)
REFERENCE   PMID:20159115 (description)
  AUTHORS   Payne AS
  TITLE     No evidence of skin blisters with human desmocollin-3 gene mutation.
  JOURNAL   Am J Hum Genet 86:292; author reply 292 (2010)
///
ENTRY       H00783                      Disease
NAME        Febrile seizures, including:
            Febrile convulsions;
            Generalized epilepsy with febrile seizure plus (GEFS+);
            Dravet syndrome/ Severe myoclonic epilepsy in infancy (SMEI)
DESCRIPTION Febrile seizures (FS), or febrile convulsions (FEB), are acute symptomatic seizures that occur in response to fever and represent the most common form of childhood seizures. Generalized epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome with a spectrum of phenotypes including FS. Severe epilepsy phenotypes such as Dravet syndrome (SMEI) have also been described within GEFS+ families. A significant genetic component exists for susceptibility to FS and GEFS+. Extensive genetic studies have shown that at least ten loci are responsible for FS. Furthermore, mutations in the voltage-gated sodium channel subunit genes (SCN1A, SCN2A and SCN1B) and the GABA(A) receptor subunit genes (GABRG2 and GABRD) have been identified in GEFS+.
CATEGORY    Nervous system disease; Epilepsy
GENE        (FEB3A/GEFS+2/SMEI) SCN1A [HSA:6323] [KO:K04833]
            (FEB3B/GEFS+7) SCN9A [HSA:6335] [KO:K04841]
            (FEB4) GPR98 [HSA:84059] [KO:K18263]
            (FEB8/GEFS+3/SMEI) GABRG2 [HSA:2566] [KO:K05186]
            (GEFS+1) SCN1B [HSA:6324] [KO:K04845]
            (GEFS+5) GABRD [HSA:2563] [KO:K05184]
DRUG        Diazepam [DR:D00293]
            Carbamazepine [DR:D00252]
            Phenobarbital [DG:DG00845]
            Phenytoin [DG:DG00846]
            Sodium valproate [DG:DG00849]
DBLINKS     ICD-10: G40.3 G40.4 R56.0
            MeSH: D003294
            OMIM: 121210 604403 613863 604352 611277 604233 613060 607208
REFERENCE   PMID:21858011
  AUTHORS   Piro RM, Molineris I, Ala U, Di Cunto F
  TITLE     Evaluation of candidate genes from orphan FEB and GEFS+ loci by analysis of human brain gene expression atlases.
  JOURNAL   PLoS One 6:e23149 (2011)
REFERENCE   PMID:16887333
  AUTHORS   Nakayama J, Arinami T
  TITLE     Molecular genetics of febrile seizures.
  JOURNAL   Epilepsy Res 70 Suppl 1:S190-8 (2006)
REFERENCE   PMID:19201561
  AUTHORS   Nakayama J
  TITLE     Progress in searching for the febrile seizure susceptibility genes.
  JOURNAL   Brain Dev 31:359-65 (2009)
REFERENCE   PMID:19854599
  AUTHORS   Lux AL
  TITLE     Treatment of febrile seizures: historical perspective, current opinions, and potential future directions.
  JOURNAL   Brain Dev 32:42-50 (2010)
///
ENTRY       H00784                      Disease
NAME        Localized autosomal recessive hypotrichosis
DESCRIPTION Localized autosomal recessive hypotrichosis is a rare non-syndromic human alopecia/hypotrichosis that is inherited as an autosomal recessive trait. Affected individuals display short, sparse hairs on the scalp, trunk, and extremities. Facial hair including the eye-brows, eye-lashes and beard show a broad range of hypotrichosis from almost normal to less dense condition. Patients' skin is normal.
CATEGORY    Skin and connective tissue disease
GENE        HR [HSA:55806] [KO:K00478]
            DSG4 [HSA:147409] [KO:K07599]
            P2Y5 [HSA:10161] [KO:K04273] 
            VDR [HSA:7421] [KO:K08539]
            LIPH [HSA:200879] [KO:K19404]
DBLINKS     MeSH: C564312 C536973 C566950
            OMIM: 607903 611452 604379
REFERENCE   PMID:12705872 (description, gene)
  AUTHORS   Kljuic A, Bazzi H, Sundberg JP, Martinez-Mir A, O'Shaughnessy R, Mahoney MG, Levy M, Montagutelli X, Ahmad W, Aita VM, Gordon D, Uitto J, Whiting D, Ott J, Fischer S, Gilliam TC, Jahoda CA, Morris RJ, Panteleyev AA, Nguyen VT, Christiano AM
  TITLE     Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris.
  JOURNAL   Cell 113:249-60 (2003)
REFERENCE   PMID:17392831 (description, gene)
  AUTHORS   Wajid M, Bazzi H, Rockey J, Lubetkin J, Zlotogorski A, Christiano AM
  TITLE     Localized autosomal recessive hypotrichosis due to a frameshift mutation in the desmoglein 4 gene exhibits extensive phenotypic variability within a Pakistani family.
  JOURNAL   J Invest Dermatol 127:1779-82 (2007)
REFERENCE   PMID:18297070 (description, gene)
  AUTHORS   Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, Betz RC
  TITLE     G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth.
  JOURNAL   Nat Genet 40:329-34 (2008)
REFERENCE   PMID:17095700 (description, gene)
  AUTHORS   Kazantseva A, Goltsov A, Zinchenko R, Grigorenko AP, Abrukova AV, Moliaka YK, Kirillov AG, Guo Z, Lyle S, Ginter EK, Rogaev EI
  TITLE     Human hair growth deficiency is linked to a genetic defect in the phospholipase gene LIPH.
  JOURNAL   Science 314:982-5 (2006)
REFERENCE   PMID:11564167 (description, gene)
  AUTHORS   Miller J, Djabali K, Chen T, Liu Y, Ioffreda M, Lyle S, Christiano AM, Holick M, Cotsarelis G
  TITLE     Atrichia caused by mutations in the vitamin D receptor gene is a phenocopy of generalized atrichia caused by mutations in the hairless gene.
  JOURNAL   J Invest Dermatol 117:612-7 (2001)
REFERENCE   PMID:17609203 (description)
  AUTHORS   Wang J, Malloy PJ, Feldman D
  TITLE     Interactions of the vitamin D receptor with the corepressor hairless: analysis of hairless mutants in atrichia with papular lesions.
  JOURNAL   J Biol Chem 282:25231-9 (2007)
REFERENCE   PMID:21919222 (description)
  AUTHORS   Azeem Z, Wasif N, Basit S, Razak S, Waheed RA, Islam A, Ayub M, Kafaitullah, Kamran-ul-hassan Naqvi S, Ali G, Ahmad W
  TITLE     Congenital atrichia with papular lesions resulting from novel mutations in human  hairless gene in four consanguineous families.
  JOURNAL   J Dermatol 38:755-60 (2011)
///
ENTRY       H00785                      Disease
NAME        Congenital hypotrichosis with juvenile macular dystrophy
DESCRIPTION Hypotrichosis with juvenile macular dystrophy is a rare autosomal recessive disorder characterized by sparse scalp hair from birth and resulting hair loss associated with progressive macular degeneration leading to blindness not later than the third decade of life. The causative gene is CDH3 encoding P-cadherin.
CATEGORY    Skin and connective tissue disease; Eye disease
GENE        CDH3 [HSA:1001] [KO:K06796]
DBLINKS     ICD-10: Q87.8
            MeSH: C537698
            OMIM: 601553
REFERENCE   PMID:7648037 (descriotion)
  AUTHORS   Souied E, Amalric P, Chauvet ML, Chevallier C, Le Hoang P, Munnich A, Kaplan J
  TITLE     Unusual association of juvenile macular dystrophy with congenital hypotrichosis:  occurrence in two siblings suggesting autosomal recessive inheritance.
  JOURNAL   Ophthalmic Genet 16:11-5 (1995)
REFERENCE   PMID:16120155 (description, gene)
  AUTHORS   Indelman M, Leibu R, Jammal A, Bergman R, Sprecher E
  TITLE     Molecular basis of hypotrichosis with juvenile macular dystrophy in two siblings.
  JOURNAL   Br J Dermatol 153:635-8 (2005)
REFERENCE   PMID:12445216 (description, gene)
  AUTHORS   Indelman M, Bergman R, Lurie R, Richard G, Miller B, Petronius D, Ciubutaro D, Leibu R, Sprecher E
  TITLE     A missense mutation in CDH3, encoding P-cadherin, causes hypotrichosis with juvenile macular dystrophy.
  JOURNAL   J Invest Dermatol 119:1210-3 (2002)
///
ENTRY       H00786                      Disease
NAME        Hypotrichosis simplex of scalp
DESCRIPTION Hypotrichosis simplex of the scalp (HSS) is a rare autosomal dominant genotrichosis that affects men and women equally. It is characterized by progressing hair loss from the middle of the first decade, culminating in an almost complete loss of scalp hair by the third decade. CDSN, a keratinocyte adhesion glycoprotein is responsible for the disease.
CATEGORY    Skin and connective tissue disease
GENE        CDSN [HSA:1041]
DBLINKS     MeSH: C564143
            OMIM: 146520
REFERENCE   PMID:16307662 (description, gene)
  AUTHORS   Davalos NO, Garcia-Vargas A, Pforr J, Davalos IP, Picos-Cardenas VJ, Garcia-Cruz D, Kruse R, Figuera LE, Nothen MM, Betz RC
  TITLE     A non-sense mutation in the corneodesmosin gene in a Mexican family with hypotrichosis simplex of the scalp.
  JOURNAL   Br J Dermatol 153:1216-9 (2005)
REFERENCE   PMID:12754508 (description, gene)
  AUTHORS   Levy-Nissenbaum E, Betz RC, Frydman M, Simon M, Lahat H, Bakhan T, Goldman B, Bygum A, Pierick M, Hillmer AM, Jonca N, Toribio J, Kruse R, Dewald G, Cichon S, Kubisch C, Guerrin M, Serre G, Nothen MM, Pras E
  TITLE     Hypotrichosis simplex of the scalp is associated with nonsense mutations in CDSN  encoding corneodesmosin.
  JOURNAL   Nat Genet 34:151-3 (2003)
REFERENCE   PMID:11994181 (description)
  AUTHORS   Vazquez MR, Rodriguez RR, Tapia AG, Diez LI
  TITLE     Hereditary hypotrichosis simplex of the scalp.
  JOURNAL   Pediatr Dermatol 19:148-50 (2002)
///
ENTRY       H00787                      Disease
NAME        Congenital stationary night blindness (CSNB), including:
            CSNB type 1 (CSNB1);
            CSNB type 2 (CSNB2);
            CSNB autosomal dominant (CSNBAD);
            Oguchi disease/ CSNB Oguchi type (CSNBO)
DESCRIPTION Congenital stationary night blindness (CSNB) is a group of nonprogressive retinal disorders characterized by impaired night vision. CSNB is currently associated with X-linked genes (NYX, CACNA1F), autosomal recessive genes (CABP4, GRK1, GRM6, SAG, TRPM1), and autosomal dominant genes (GNAT1, PDE6B, RHO). Two types of CSNB can be distinguished by use of the standard flash electroretinogram (ERG). CSNB type 1 (CSNB1) is characterized by the complete absence of rod pathway function, whereas CSNB type 2 (CSNB2) is caused by impaired rod and cone pathway function. Oguchi disease is a form of CSNB. Patients with the Oguchi disease have a unique yellowish-gold fundus that regains its normal color after prolonged dark adaptation. That is called the Mizuo-Nakamura phenomenon.
CATEGORY    Nervous system disease; Eye disease
GENE        (CSNB1A) NYX [HSA:60506] [KO:K08129]
            (CSNB1B) GRM6 [HSA:2916] [KO:K04608]
            (CSNB1C) TRPM1 [HSA:4308] [KO:K04976]
            (CSNB1D) SLC24A1 [HSA:9187] [KO:K13749]
            (CSNB2A) CACNA1F [HSA:778] [KO:K04853]
            (CSNB2B) CABP4 [HSA:57010]
            (CSNBAD1) RHO [HSA:6010] [KO:K04250]
            (CSNBAD2) PDE6B [HSA:5158] [KO:K13756]
            (CSNBAD3) GNAT1 [HSA:2779] [KO:K04631]
            (CSNBO1) SAG [HSA:6295] [KO:K19627]
            (CSNBO2) GRK1 [HSA:6011] [KO:K00909]
MARKER      Electroretinogram (ERG)
DBLINKS     ICD-10: H53.6
            MeSH: C536122 C537743
            OMIM: 310500 257270 613216 613830 300071 610427 610445 163500 610444 258100 613411
REFERENCE   PMID:20301423
  AUTHORS   Boycott KM, Bech-Hansen NT, Sauve Y, MacDonald IM
  TITLE     X-Linked Congenital Stationary Night Blindness
  JOURNAL   (1993)
REFERENCE   PMID:19896109
  AUTHORS   van Genderen MM, Bijveld MM, Claassen YB, Florijn RJ, Pearring JN, Meire FM, McCall MA, Riemslag FC, Gregg RG, Bergen AA, Kamermans M
  TITLE     Mutations in TRPM1 are a common cause of complete congenital stationary night blindness.
  JOURNAL   Am J Hum Genet 85:730-6 (2009)
REFERENCE   PMID:21920492
  AUTHORS   Chen RW, Greenberg JP, Lazow MA, Ramachandran R, Lima LH, Hwang JC, Schubert C, Braunstein A, Allikmets R, Tsang SH
  TITLE     Autofluorescence Imaging and Spectral-Domain Optical Coherence Tomography in Incomplete Congenital Stationary Night Blindness and Comparison with Retinitis Pigmentosa.
  JOURNAL   Am J Ophthalmol (2011)
REFERENCE   PMID:17765441
  AUTHORS   Oishi A, Akimoto M, Kawagoe N, Mandai M, Takahashi M, Yoshimura N
  TITLE     Novel mutations in the GRK1 gene in Japanese patients With Oguchi disease.
  JOURNAL   Am J Ophthalmol 144:475-7 (2007)
REFERENCE   PMID:20850105
  AUTHORS   Riazuddin SA, Shahzadi A, Zeitz C, Ahmed ZM, Ayyagari R, Chavali VR, Ponferrada VG, Audo I, Michiels C, Lancelot ME, Nasir IA, Zafar AU, Khan SN, Husnain T, Jiao X, MacDonald IM, Riazuddin S, Sieving PA, Katsanis N, Hejtmancik JF
  TITLE     A mutation in SLC24A1 implicated in autosomal-recessive congenital stationary night blindness.
  JOURNAL   Am J Hum Genet 87:523-31 (2010)
///
ENTRY       H00788                      Disease
NAME        Hoyeraal-Hreidarsson syndrome
DESCRIPTION Hoyeraal-Hreidarsson syndrome is a severe variant of the X-linked recessive dyskeratosis congenita. It is a multisystem disorder characterized by intrauterine growth retardation, microcephaly, cerebellar hypoplasia, bone marrow failure associated with immunodeficiency. A missense mutation in the DKC1 gene and  premature short telomeres were found in the disease.
CATEGORY    Developmental disorder
GENE        DKC1 [HSA:1736] [KO:K11131]
COMMENT     Dyskeratosis congenita is described in H00507.
DBLINKS     ICD-10: D61.0
            MeSH: C536068
            OMIM: 300240
REFERENCE   PMID:14648217 (description, gene)
  AUTHORS   Sznajer Y, Baumann C, David A, Journel H, Lacombe D, Perel Y, Blouin P, Segura JF, Cezard JP, Peuchmaur M, Vulliamy T, Dokal I, Verloes A
  TITLE     Further delineation of the congenital form of X-linked dyskeratosis congenita (Hoyeraal-Hreidarsson syndrome).
  JOURNAL   Eur J Pediatr 162:863-7 (2003)
REFERENCE   PMID:20205257 (description, gene)
  AUTHORS   Valera ET, Brassesco MS, Roxo P Jr, Lourenco CM, Scrideli CA, Ferriani VP, Tone LG, Vulliamy T, Sakamoto-Hojo ET
  TITLE     Genomic instability in Hoyeraal-Hreidarsson syndrome.
  JOURNAL   Pediatr Blood Cancer 54:779-80 (2010)
///
ENTRY       H00789                      Disease
NAME        Keratoconus
DESCRIPTION Keratoconus is a frequent corneal ectasia characterized by localized corneal thinning and protrusion. Its exact cause is still unknown and is probably multifactorial.
CATEGORY    Eye disease
GENE        VSX1 [HSA:30813] [KO:K09335]
ENV_FACTOR  eye rubbing
MARKER      Fleischer's ring
            Vogt's striaes
COMMENT     Keratoconus can also be found in sydromic conditions such as Down syndrome, mitral valve prolapse (H00661), Marfan syndrome (H00653), and Ehlers-Danlos syndrome.
DBLINKS     ICD-10: H19.8 Q87.8
            MeSH: D007640
            OMIM: 148300
REFERENCE   PMID:11778802 (description, gene)
  AUTHORS   Edwards M, McGhee CN, Dean S
  TITLE     The genetics of keratoconus.
  JOURNAL   Clin Experiment Ophthalmol 29:345-51 (2001)
REFERENCE   PMID:20537579 (description, gene, marker)
  AUTHORS   Romero-Jimenez M, Santodomingo-Rubido J, Wolffsohn JS
  TITLE     Keratoconus: a review.
  JOURNAL   Cont Lens Anterior Eye 33:157-66; quiz 205 (2010)
REFERENCE   PMID:21976959 (gene)
  AUTHORS   De Bonis P, Laborante A, Pizzicoli C, Stallone R, Barbano R, Longo C, Mazzilli E, Zelante L, Bisceglia L
  TITLE     Mutational screening of VSX1, SPARC, SOD1, LOX, and TIMP3 in keratoconus.
  JOURNAL   Mol Vis 17:2482-94 (2011)
///
ENTRY       H00790                      Disease
NAME        Keratosis linearis with ichthyosis congenita and sclerosing keratoderma;
            KLICK syndrome
DESCRIPTION Keratosis linearis with ichthyosis congenita and sclerosing keratoderma (KLICK) syndrome is a rare combination of congenital ichthyosis, sclerosing palmoplantar keratoderma with pseudoainhum, and bizarre linear hyperkeratotic papules on the flexural side of large joints. There is no associated systemic involvement. The disease is inherited as an autosomal-recessive trait.
CATEGORY    Skin and connective tissue disease
GENE        POMP [HSA:51371] [KO:K11599]
DBLINKS     MeSH: C566600
            OMIM: 601952
REFERENCE   PMID:9188877 (description)
  AUTHORS   Vahlquist A, Ponten F, Pettersson A
  TITLE     Keratosis linearis with ichthyosis congenita and sclerosing keratoderma (KLICK-syndrome): a rare, autosomal recessive disorder of keratohyaline formation?
  JOURNAL   Acta Derm Venereol 77:225-7 (1997)
REFERENCE   PMID:21738991 (description)
  AUTHORS   Baeta IG, Pereira AC, Guedes AC, Pereira LB
  TITLE     Do you know this syndrome?
  JOURNAL   An Bras Dermatol 86:605-7 (2011)
REFERENCE   PMID:20226437 (description, gene)
  AUTHORS   Dahlqvist J, Klar J, Tiwari N, Schuster J, Torma H, Badhai J, Pujol R, van Steensel MA, Brinkhuizen T, Gijezen L, Chaves A, Tadini G, Vahlquist A, Dahl N
  TITLE     A single-nucleotide deletion in the POMP 5' UTR causes a transcriptional switch and altered epidermal proteasome distribution in KLICK genodermatosis.
  JOURNAL   Am J Hum Genet 86:596-603 (2010)
REFERENCE   PMID:21571163 (description, gene)
  AUTHORS   Horev L, Murad S, Maly A, Zlotogorski A
  TITLE     Aggressive cutaneous squamous cell carcinoma in a patient with KLICK.
  JOURNAL   J Am Acad Dermatol 64:e128-30 (2011)
///
ENTRY       H00791                      Disease
NAME        Disseminated superficial actinic porokeratosis (DSAP)
DESCRIPTION Porokeratosis is a disorder of keratinization characterized by atrophic patches surrounded by a ridge of keratin called cornoid lamella. Disseminated superficial actinic porokeratosis (DSAP) is the most common form of porokeratosis. It is induced by exposure to ultraviolet light and usually appears during the third or fourth decade.
CATEGORY    Skin and connective tissue disease
GENE        SART3 [HSA:9733]
ENV_FACTOR  sun exposure
            immunosuppression
            bone marrow transplantation
            ultraviolet A therapy
            Psoralen [DR:D08450]
DBLINKS     MeSH: D017499
            OMIM: 175900
REFERENCE   PMID:21929548 (description)
  AUTHORS   Sertznig P, von Felbert V, Megahed M
  TITLE     Porokeratosis: present concepts.
  JOURNAL   J Eur Acad Dermatol Venereol (2011)
REFERENCE   PMID:2754051 (description)
  AUTHORS   Shumack SP, Commens CA
  TITLE     Disseminated superficial actinic porokeratosis: a clinical study.
  JOURNAL   J Am Acad Dermatol 20:1015-22 (1989)
REFERENCE   PMID:21914157 (description, env_factor)
  AUTHORS   Kawara S, Oiso N, Kawada A
  TITLE     Disseminated superficial actinic porokeratosis in a patient undergoing treatment  with long-term narrowband ultraviolet B for psoriasis.
  JOURNAL   J Dermatol 38:585-7 (2011)
REFERENCE   PMID:20451293 (description)
  AUTHORS   Murase J, Gilliam AC
  TITLE     Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical  expression of porokeratosis.
  JOURNAL   J Am Acad Dermatol 63:886-91 (2010)
REFERENCE   PMID:22121283 (description)
  AUTHORS   Kanak K, Jaiswal AK, Reddy P
  TITLE     Disseminated superficial and warty type of porokeratosis: a rare coexistence.
  JOURNAL   Indian J Dermatol 56:576-7 (2011)
REFERENCE   PMID:15840095 (gene)
  AUTHORS   Zhang ZH, Niu ZM, Yuan WT, Zhao JJ, Jiang FX, Zhang J, Chai B, Cui F, Chen W, Lian CH, Xiang LH, Xu SJ, Liu WD, Zheng ZZ, Huang W
  TITLE     A mutation in SART3 gene in a Chinese pedigree with disseminated superficial actinic porokeratosis.
  JOURNAL   Br J Dermatol 152:658-63 (2005)
///
ENTRY       H00792                      Disease
NAME        Warburg micro syndrome
DESCRIPTION Warburg micro syndrome (WARBM) is a rare, autosomal recessive condition characterized by congenital microcephaly, mental retardation, microcornea, cataracts, hypotonic diplegia and hypothalamic hypogonadism. The neurological manifestations  including corpus callosum hypoplasia, cortical dystrophy, and microphthalmia are severe in Warburg micro syndrome.
CATEGORY    Congenital disorder
GENE        (WARBM1) RAB3GAP1 [HSA:22930] [KO:K18270]
            (WARBM2) RAB3GAP2 [HSA:25782] [KO:K19937]
            (WARBM3) RAB18 [HSA:22931] [KO:K07910]
            (WARBM4) TBC1D20 [HSA:128637] [KO:K20372]
DBLINKS     ICD-10: Q04.3
            MeSH: C536681
            OMIM: 600118 614225 614222 615663
REFERENCE   PMID:20967465 (description, gene)
  AUTHORS   Borck G, Wunram H, Steiert A, Volk AE, Korber F, Roters S, Herkenrath P, Wollnik B, Morris-Rosendahl DJ, Kubisch C
  TITLE     A homozygous RAB3GAP2 mutation causes Warburg Micro syndrome.
  JOURNAL   Hum Genet 129:45-50 (2011)
REFERENCE   PMID:20512159 (description, gene)
  AUTHORS   Morris-Rosendahl DJ, Segel R, Born AP, Conrad C, Loeys B, Brooks SS, Muller L, Zeschnigk C, Botti C, Rabinowitz R, Uyanik G, Crocq MA, Kraus U, Degen I, Faes F
  TITLE     New RAB3GAP1 mutations in patients with Warburg Micro Syndrome from different ethnic backgrounds and a possible founder effect in the Danish.
  JOURNAL   Eur J Hum Genet 18:1100-6 (2010)
REFERENCE   PMID:21473985 (gene)
  AUTHORS   Bem D, Yoshimura S, Nunes-Bastos R, Bond FC, Kurian MA, Rahman F, Handley MT, Hadzhiev Y, Masood I, Straatman-Iwanowska AA, Cullinane AR, McNeill A, Pasha SS, Kirby GA, Foster K, Ahmed Z, Morton JE, Williams D, Graham JM, Dobyns WB, Burglen L, Ainsworth JR, Gissen P, Muller F, Maher ER, Barr FA, Aligianis IA
  TITLE     Loss-of-function mutations in RAB18 cause Warburg micro syndrome.
  JOURNAL   Am J Hum Genet 88:499-507 (2011)
REFERENCE   PMID:15216543 (description)
  AUTHORS   Graham JM Jr, Hennekam R, Dobyns WB, Roeder E, Busch D
  TITLE     MICRO syndrome: an entity distinct from COFS syndrome.
  JOURNAL   Am J Med Genet A 128A:235-45 (2004)
REFERENCE   PMID:24239381
  AUTHORS   Liegel RP, Handley MT, Ronchetti A, Brown S, Langemeyer L, Linford A, Chang B, Morris-Rosendahl DJ, Carpanini S, Posmyk R, Harthill V, Sheridan E, Abdel-Salam GM, Terhal PA, Faravelli F, Accorsi P, Giordano L, Pinelli L, Hartmann B, Ebert AD, Barr FA, Aligianis IA, Sidjanin DJ
  TITLE     Loss-of-function mutations in TBC1D20 cause cataracts and male infertility in blind sterile mice and Warburg micro syndrome in humans.
  JOURNAL   Am J Hum Genet 93:1001-14 (2013)
///
ENTRY       H00793                      Disease
NAME        Poikiloderma with neutropenia
DESCRIPTION Poikiloderma with neutropenia is an inherited genodermatosis found in Navajo people. It is characterized by erythematous rash that appears in the first year of life. The rash starts from the limbs and spreads to the trunk and the face, evolving into poikiloderma. Patients with this disease have recurrent bacterial infections and chronic neutropenia.
CATEGORY    Skin and connective tissue disease
GENE        C16orf57 [HSA:79650]
COMMENT     Dyskeratosis congenita (H00507) and Rothmund-Thomson syndrome (H00296) display clinical overlap with this disease.
DBLINKS     MeSH: C565820
            OMIM: 604173
REFERENCE   PMID:21967010 (description)
  AUTHORS   Chantorn R, Shwayder T
  TITLE     Poikiloderma with neutropenia: report of three cases including one with calcinosis cutis.
  JOURNAL   Pediatr Dermatol 29:463-72 (2012)
REFERENCE   PMID:20618321 (gene, description)
  AUTHORS   Arnold AW, Itin PH, Pigors M, Kohlhase J, Bruckner-Tuderman L, Has C
  TITLE     Poikiloderma with neutropenia: a novel C16orf57 mutation and clinical diagnostic  criteria.
  JOURNAL   Br J Dermatol 163:866-9 (2010)
REFERENCE   PMID:20817924 (gene)
  AUTHORS   Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I
  TITLE     Mutations in C16orf57 and normal-length telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndrome.
  JOURNAL   Hum Mol Genet 19:4453-61 (2010)
REFERENCE   PMID:15558713 (description)
  AUTHORS   Van Hove JL, Jaeken J, Proesmans M, Boeck KD, Minner K, Matthijs G, Verbeken E, Demunter A, Boogaerts M
  TITLE     Clericuzio type poikiloderma with neutropenia is distinct from Rothmund-Thomson syndrome.
  JOURNAL   Am J Med Genet A 132A:152-8 (2005)
///
ENTRY       H00794                      Disease
NAME        Aromatase excess syndrome
DESCRIPTION Aromatase excess syndrome (AEXS) is a rare disorder characterized by gynecomastia. Excessive expression of aromatase, an enzyme that plays a crucial role in the estrogen biosynthesis, causes pre- or peripubertal onset gynecomastia, advanced bone age such as early fusion of epiphyses, and short stature in affected males. Female patients experience premature breast development.
CATEGORY    Endocrine disease
GENE        CYP19A1 (gain of function) [HSA:1588] [KO:K07434]
DBLINKS     ICD-10: E30.1
            MeSH: C537436
            OMIM: 139300
REFERENCE   PMID:21470988 (description, gene)
  AUTHORS   Fukami M, Shozu M, Soneda S, Kato F, Inagaki A, Takagi H, Hanaki K, Kanzaki S, Ohyama K, Sano T, Nishigaki T, Yokoya S, Binder G, Horikawa R, Ogata T
  TITLE     Aromatase excess syndrome: identification of cryptic duplications and deletions leading to gain of function of CYP19A1 and assessment of phenotypic determinants.
  JOURNAL   J Clin Endocrinol Metab 96:E1035-43 (2011)
REFERENCE   PMID:17584767 (description, gene)
  AUTHORS   Demura M, Martin RM, Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Mendonca BB, Hanaki K, Kanzaki S, Rhoads DB, Misra M, Bulun SE
  TITLE     Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters  for the CYP19 (aromatase) gene.
  JOURNAL   Hum Mol Genet 16:2529-41 (2007)
REFERENCE   PMID:12736278 (description, gene)
  AUTHORS   Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Bulun SE
  TITLE     Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
  JOURNAL   N Engl J Med 348:1855-65 (2003)
///
ENTRY       H00795                      Disease
NAME        Seborrhea-like dermatitis with psoriasiform element
DESCRIPTION Seborrhea-like dermatosis with psoriasiform elements is a chronic dermatosis characterized by common dandruffs and eczematous or psoriasiform plaques. Enhanced keratinocyte proliferation and dermal infiltration of inflammatory cells are observed in the disease. Mutations in ZNF750, which encodes a putative C2H2 zinc finger protein, have been reported.
CATEGORY    Skin and connective tissue disease
GENE        ZNF750 [HSA:79755]
DBLINKS     MeSH: C565217
            OMIM: 610227
REFERENCE   PMID:16751772 (description, gene)
  AUTHORS   Birnbaum RY, Zvulunov A, Hallel-Halevy D, Cagnano E, Finer G, Ofir R, Geiger D, Silberstein E, Feferman Y, Birk OS
  TITLE     Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein.
  JOURNAL   Nat Genet 38:749-51 (2006)
///
ENTRY       H00796                      Disease
NAME        Dermatopathia pigmentosa reticularis
DESCRIPTION Dermatopathia pigmentosa reticularis is a rare disorder of pigmentation characterized by a triad of reticulate hyperpigmentation, nonscarring alopecia, and onychodystrophy. Other symptoms observed in the disease are palmoplantar keratoderma and hypohidrosis.
CATEGORY    Skin and connective tissue disease
GENE        KRT14 [HSA:3861] [KO:K07604]
COMMENT     Naegeli-Franceschetti-Jadassohn syndrome (H00708) is an allelic disorder .
DBLINKS     ICD-10: Q82.4
            MeSH: C535374
            OMIM: 125595
REFERENCE   PMID:17958818 (description)
  AUTHORS   Brar BK, Mehta V, Kubba A
  TITLE     Dermatopathia pigmentosa reticularis.
  JOURNAL   Pediatr Dermatol 24:566-70 (2007)
REFERENCE   PMID:20180888 (gene)
  AUTHORS   van Steensel MA, Lemmink HH
  TITLE     A missense mutation in KRT14 causing a dermatopathia pigmentosa reticularis/Naegeli-Franceschetti-Jadassohn phenotype.
  JOURNAL   J Eur Acad Dermatol Venereol 24:1116-7 (2010)
///
ENTRY       H00797                      Disease
NAME        Martsolf syndrome
DESCRIPTION Martsolf syndrome is a rare autosomal recessive condition that shows symptoms similar to Warburg Micro syndrome. It is characterized by severe mental retardation, congenital cataract, microcephaly, bone and joint anomalies, and genital hypoplasia.
CATEGORY    Congenital disorder
GENE        RAB3GAP2 [HSA:25782] [KO:K19937]
DBLINKS     ICD-10: Q87.8
            MeSH: C536028
            OMIM: 212720
REFERENCE   PMID:2738902 (description)
  AUTHORS   Harbord MG, Baraitser M, Wilson J
  TITLE     Microcephaly, mental retardation, cataracts, and hypogonadism in sibs: Martsolf's syndrome.
  JOURNAL   J Med Genet 26:397-400 (1989)
REFERENCE   PMID:16532399 (description, gene)
  AUTHORS   Aligianis IA, Morgan NV, Mione M, Johnson CA, Rosser E, Hennekam RC, Adams G, Trembath RC, Pilz DT, Stoodley N, Moore AT, Wilson S, Maher ER
  TITLE     Mutation in Rab3 GTPase-activating protein (RAB3GAP) noncatalytic subunit in a kindred with Martsolf syndrome.
  JOURNAL   Am J Hum Genet 78:702-7 (2006)
REFERENCE   PMID:17394201 (description)
  AUTHORS   Ehara H, Utsunomiya Y, Ieshima A, Maegaki Y, Nishimura G, Takeshita K, Ohno K
  TITLE     Martsolf syndrome in Japanese siblings.
  JOURNAL   Am J Med Genet A 143A:973-8 (2007)
REFERENCE   PMID:20967465 (description)
  AUTHORS   Borck G, Wunram H, Steiert A, Volk AE, Korber F, Roters S, Herkenrath P, Wollnik B, Morris-Rosendahl DJ, Kubisch C
  TITLE     A homozygous RAB3GAP2 mutation causes Warburg Micro syndrome.
  JOURNAL   Hum Genet 129:45-50 (2011)
///
ENTRY       H00798                      Disease
NAME        Familial carpal tunnel syndrome
DESCRIPTION Carpal tunnel syndrome is an entrapment neuropathy of the median nerve characterized by paresthesias in the district of the median nerve. Familial carpal tunnel syndrome is an extremely rare form with bilateral symptom that is frequently associated with inherited systemic disorders such as mucopolysaccharidosis, mucolipidosis, amyloidosis, collagen vascular disease or hereditary liability to pressure palsies. The cause of the disease is the compression of the median nerve by thickened transverse carpal ligament. Mutations in transthyretin, a gene that plays a role in deposition of amyloid, have been reported.
CATEGORY    Nervous system disease
GENE        TTR; transthyretin [HSA:7276] [KO:K20731]
DBLINKS     ICD-10: G56.0
            MeSH: D002349
            OMIM: 115430
REFERENCE   PMID:9052822 (description)
  AUTHORS   Vadasz AG, Chance PF, Epstein LG, Lou JS
  TITLE     Familial autosomal-dominant carpal tunnel syndrome presenting in a 5-year-old-case report and review of the literature.
  JOURNAL   Muscle Nerve 20:376-8 (1997)
REFERENCE   PMID:9831348 (description)
  AUTHORS   Stoll C, Maitrot D
  TITLE     Autosomal dominant carpal tunnel syndrome.
  JOURNAL   Clin Genet 54:345-8 (1998)
REFERENCE   PMID:19756731 (description)
  AUTHORS   Senel S, Ceylaner G, Yuksel D, Erkek N, Karacan C
  TITLE     Familial primary carpal tunnel syndrome with possible skipped generation.
  JOURNAL   Eur J Pediatr 169:453-5 (2010)
REFERENCE   PMID:8309582 (gene)
  AUTHORS   Murakami T, Tachibana S, Endo Y, Kawai R, Hara M, Tanase S, Ando M
  TITLE     Familial carpal tunnel syndrome due to amyloidogenic transthyretin His 114 variant.
  JOURNAL   Neurology 44:315-8 (1994)
///
ENTRY       H00799                      Disease
NAME        Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome;
            CEDNIK syndrome
DESCRIPTION CEDNIK (Cerebral dysgenesis, neuropathy, ichthyosis and keratoderma) syndrome is a rare condition that shows severe developmental failure of the nervous system and the epidermis. Clinical manifestations include microcephaly, cerebral dysgenesis, facial dysmorphism, palmoplantar keratoderma, and ichthyosis. Decreased expression of SNAP29, a member of the SNARE family of proteins, is linked to abnormal lamellar granule maturation and abnormal epidermal differentiation.
CATEGORY    Nervous system disease; Skin and connective tissue disease
GENE        SNAP29 [HSA:9342] [KO:K08509]
DBLINKS     MeSH: C537943
            OMIM: 609528
REFERENCE   PMID:15968592 (description, gene)
  AUTHORS   Sprecher E, Ishida-Yamamoto A, Mizrahi-Koren M, Rapaport D, Goldsher D, Indelman M, Topaz O, Chefetz I, Keren H, O'brien TJ, Bercovich D, Shalev S, Geiger D, Bergman R, Horowitz M, Mandel H
  TITLE     A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma.
  JOURNAL   Am J Hum Genet 77:242-51 (2005)
REFERENCE   PMID:21073448 (description, gene)
  AUTHORS   Fuchs-Telem D, Stewart H, Rapaport D, Nousbeck J, Gat A, Gini M, Lugassy Y, Emmert S, Eckl K, Hennies HC, Sarig O, Goldsher D, Meilik B, Ishida-Yamamoto A, Horowitz M, Sprecher E
  TITLE     CEDNIK syndrome results from loss-of-function mutations in SNAP29.
  JOURNAL   Br J Dermatol 164:610-6 (2011)
///
ENTRY       H00800                      Disease
NAME        Loeys-Dietz syndrome (LDS)
DESCRIPTION Loeys-Dietz syndrome (LDS) is an autosomal dominant disorder characterized by arterial aneurysms and dissections, pectus excavatum, craniosynostosis, cleft palate, congenital heart disease, and thin, translucent skin. LDS results from mutations in the TGF beta receptor genes.  LDS has been subdivided in LDS1 and LDS2 on the basis of the presence or the absence of craniofacial involvement, respectively. LDS3 is associated with early-onset osteoarthritis and caused by mutation in the SMAD3 gene. LDS4 is caused by mutation in the TGFB2 gene.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        (LDS 1A/2A) TGFBR1 [HSA:7046] [KO:K04674]
            (LDS 1B/2B) TGFBR2 [HSA:7048] [KO:K04388]
            (LDS3) SMAD3 [HSA:4088] [KO:K04500]
            (LDS4) TGFB2 [HSA:7042] [KO:K13376]
COMMENT     LDS and Marfan syndrome [DS:H00653] are both genetic disorders of connective tissue and share many features.
DBLINKS     ICD-10: I71.0
            OMIM: 609192 608967 610168 610380 613795 614816
REFERENCE   PMID:19883511
  AUTHORS   Drera B, Ritelli M, Zoppi N, Wischmeijer A, Gnoli M, Fattori R, Calzavara-Pinton PG, Barlati S, Colombi M
  TITLE     Loeys-Dietz syndrome type I and type II: clinical findings and novel mutations in two Italian patients.
  JOURNAL   Orphanet J Rare Dis 4:24 (2009)
REFERENCE   PMID:21785848
  AUTHORS   Kalra VB, Gilbert JW, Malhotra A
  TITLE     Loeys-Dietz syndrome: cardiovascular, neuroradiological and musculoskeletal imaging findings.
  JOURNAL   Pediatr Radiol 41:1495-504 (2011)
REFERENCE   PMID:18544034
  AUTHORS   Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, Kwartler CS, Pannu H
  TITLE     Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction.
  JOURNAL   Annu Rev Genomics Hum Genet 9:283-302 (2008)
REFERENCE   PMID:21217753
  AUTHORS   van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen LA, Venselaar H, Vriend G, Pattynama PM, Collee M, Majoor-Krakauer D, Poldermans D, Frohn-Mulder IM, Micha D, Timmermans J, Hilhorst-Hofstee Y, Bierma-Zeinstra SM, Willems PJ, Kros JM, Oei EH, Oostra BA, Wessels MW, Bertoli-Avella AM
  TITLE     Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis.
  JOURNAL   Nat Genet 43:121-6 (2011)
REFERENCE   PMID:22772368
  AUTHORS   Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, Kempers MJ, Fishman EK, Chen Y, Myers L, Bjeda D, Oswald G, Elias AF, Levy HP, Anderlid BM, Yang MH, Bongers EM, Timmermans J, Braverman AC, Canham N, Mortier GR, Brunner HG, Byers PH, Van Eyk J, Van Laer L, Dietz HC, Loeys BL
  TITLE     Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm.
  JOURNAL   Nat Genet 44:922-7 (2012)
///
ENTRY       H00801                      Disease
NAME        Familial thoracic aortic aneurysm and dissection (TAAD);
            Aortic aneurysm familial thoracic type (AAT)
DESCRIPTION Thoracic aortic aneurysms leading to acute aortic dissections (TAAD) are the major diseases that affect the thoracic aorta. While majority of the cases are sporadic, more than 20% are inherited as a single gene disorder. Familial TAAD is diagnosed based on the presence of dilatation and/or dissection of the thoracic aorta, absence of clinical features of Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehlers-Danlos syndrome, and presence of a positive family history of TAAD. TGFBR2, TGFBR1, MYH11, ACTA2, and two loci on other chromosomes, AAT1 and AAT2, are associated with familial TAAD.
CATEGORY    Cardiovascular disease
GENE        (AAT3) TGFBR2 [HSA:7048] [KO:K04388]
            (AAT4) MYH11 [HSA:4629] [KO:K10352]
            (AAT5) TGFBR1 [HSA:7046] [KO:K04674]
            (AAT6) ACTA2 [HSA:59] [KO:K12313]
            (AAT7) MYLK [HSA:4638] [KO:K00907]
            (AAT8) PRKG1 [HSA:5592] [KO:K07376]
            (AAT9) MFAP5 [HSA:8076]
            (AAT10) LOX [HSA:4015] [KO:K00277]
            (AAT11) FOXE3 [HSA:2301] [KO:K09398]
MARKER      Echocardiography
            Computed tomography (CT)
            Magnetic resonance imaging (MRI)
            Angiography
COMMENT     Marfan syndrome, Loeys-Dietz syndrome, and Ehlers-Danlos syndrome are described in H00653, H00800, and H00802, respectively. [DS:H00653] [DS:H00800] [DS:H00802]
DBLINKS     ICD-10: I71.2
            OMIM: 607086 607087 610168 132900 608967 611788 613780 615436 616166 617168 617349
REFERENCE   PMID:18544034
  AUTHORS   Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, Kwartler CS, Pannu H
  TITLE     Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction.
  JOURNAL   Annu Rev Genomics Hum Genet 9:283-302 (2008)
REFERENCE   PMID:20301299
  AUTHORS   Milewicz DM, Regalado E
  TITLE     Thoracic Aortic Aneurysms and Aortic Dissections
  JOURNAL   (1993)
REFERENCE   PMID:21163914
  AUTHORS   Guo DC, Regalado ES, Minn C, Tran-Fadulu V, Coney J, Cao J, Wang M, Yu RK, Estrera AL, Safi HJ, Shete SS, Milewicz DM
  TITLE     Familial thoracic aortic aneurysms and dissections: identification of a novel locus for stable aneurysms with a low risk for progression to aortic dissection.
  JOURNAL   Circ Cardiovasc Genet 4:36-42 (2011)
REFERENCE   PMID:11511117
  AUTHORS   Erbel R, Alfonso F, Boileau C, Dirsch O, Eber B, Haverich A, Rakowski H, Struyven J, Radegran K, Sechtem U, Taylor J, Zollikofer C, Klein WW, Mulder B, Providencia LA
  TITLE     Diagnosis and management of aortic dissection.
  JOURNAL   Eur Heart J 22:1642-81 (2001)
REFERENCE   PMID:23910461 (gene)
  AUTHORS   Guo DC, Regalado E, Casteel DE, Santos-Cortez RL, Gong L, Kim JJ, Dyack S, Horne SG, Chang G, Jondeau G, Boileau C, Coselli JS, Li Z, Leal SM, Shendure J, Rieder MJ, Bamshad MJ, Nickerson DA, Kim C, Milewicz DM
  TITLE     Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections.
  JOURNAL   Am J Hum Genet 93:398-404 (2013)
REFERENCE   PMID:25434006 (gene)
  AUTHORS   Barbier M, Gross MS, Aubart M, Hanna N, Kessler K, Guo DC, Tosolini L, Ho-Tin-Noe B, Regalado E, Varret M, Abifadel M, Milleron O, Odent S, Dupuis-Girod S, Faivre L, Edouard T, Dulac Y, Busa T, Gouya L, Milewicz DM, Jondeau G, Boileau C
  TITLE     MFAP5 loss-of-function mutations underscore the involvement of matrix alteration  in the pathogenesis of familial thoracic aortic aneurysms and dissections.
  JOURNAL   Am J Hum Genet 95:736-43 (2014)
REFERENCE   PMID:26838787 (gene)
  AUTHORS   Guo DC, Regalado ES, Gong L, Duan X, Santos-Cortez RL, Arnaud P, Ren Z, Cai B, Hostetler EM, Moran R, Liang D, Estrera A, Safi HJ, Leal SM, Bamshad MJ, Shendure J, Nickerson DA, Jondeau G, Boileau C, Milewicz DM
  TITLE     LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections.
  JOURNAL   Circ Res 118:928-34 (2016)
REFERENCE   PMID:26854927 (gene)
  AUTHORS   Kuang SQ, Medina-Martinez O, Guo DC, Gong L, Regalado ES, Reynolds CL, Boileau C, Jondeau G, Prakash SK, Kwartler CS, Zhu LY, Peters AM, Duan XY, Bamshad MJ, Shendure J, Nickerson DA, Santos-Cortez RL, Dong X, Leal SM, Majesky MW, Swindell EC, Jamrich M, Milewicz DM
  TITLE     FOXE3 mutations predispose to thoracic aortic aneurysms and dissections.
  JOURNAL   J Clin Invest 126:948-61 (2016)
///
ENTRY       H00802                      Disease
NAME        Ehlers-Danlos syndrome (EDS), including:
            EDS classical type (EDS1/2);
            EDS hypermobility type (EDS3);
            EDS vascular type (EDS4);
            EDS kyphoscoliosis type (EDS6);
            EDS arthrochalasia type (EDS7A/7B);
            EDS dermatospraxis type (EDS7C);
            EDS autosomal recessive cardiac valvular form (EDSCV);
            EDS musculocontractural type (EDSMC);
            EDS progeroid form (EDSP);
            Tenascin-X deficiency (TNXD);
            Brittle cornea syndrome (EDS6B);
            EDS-like spondylocheiro dysplasia (SCD-EDS)
DESCRIPTION Ehlers-Danlos syndrome (EDS) is an inherited heterogeneous group of connective tissue disorders, characterized by abnormal collagen synthesis, affecting skin, ligaments, joints, blood vessels and other organs. Most EDS subtypes are caused by mutations in genes encoding the fibrillar collagens type I, III and V, or in genes coding for enzymes involved in the post-translational modification of these collagens. EDS can be classified  into six major types: classical type, hypermobility type, vascular type, kyphoscoliosis type, arthrochalasia type and dermatospraxis type. Additional minor variants of EDS have been identified with molecular and biochemical abnormalities: cardiac valvular form, musculocontractural type, progeroid form, tenascin-X deficiency, Brittle cornea syndrome, and EDS-like spondylocheiro dysplasia.
CATEGORY    Inherited metabolic disease; Connective tissue disease
GENE        (EDS1/7A) COL1A1 [HSA:1277] [KO:K06236]
            (EDS7B/CV) COL1A2 [HSA:1278] [KO:K06236]
            (EDS3/4) COL3A1 [HSA:1281] [KO:K19720] 
            (EDS1/2) COL5A1 [HSA:1289] [KO:K19721]
            (EDS1) COL5A2 [HSA:1290] [KO:K19721]
            (EDS6) PLOD [HSA:5351] [KO:K00473]
            (EDS7C) ADAMTS2 [HSA:9509] [KO:K08618]
            (EDSMC) CHST14 [HSA:113189] [KO:K08105]
            (EDSP1) B4GALT7 [HSA:11285] [KO:K00733]
            (EDSP2) B3GALT6 [HSA:126792] [KO:K00734]
            (TNXD) TNXB [HSA:7148] [KO:K06252]
            (EDS6B) ZNF469 [HSA:84627]
            (SCD-EDS) SLC39A13 [HSA:91252] [KO:K14719]
DBLINKS     ICD-10: Q79.6
            MeSH: D004535
            OMIM: 130000 130010 130020 130050 130060 130070 615349 225400 225410 606408 601776 229200 612350 225320
REFERENCE   PMID:18324963
  AUTHORS   Parapia LA, Jackson C
  TITLE     Ehlers-Danlos syndrome--a historical review.
  JOURNAL   Br J Haematol 141:32-5 (2008)
REFERENCE   PMID:15566352
  AUTHORS   De Paepe A, Malfait F
  TITLE     Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen  vascular disorders.
  JOURNAL   Br J Haematol 127:491-500 (2004)
REFERENCE   PMID:20503305
  AUTHORS   Kosho T, Miyake N, Hatamochi A, Takahashi J, Kato H, Miyahara T, Igawa Y, Yasui H, Ishida T, Ono K, Kosuda T, Inoue A, Kohyama M, Hattori T, Ohashi H, Nishimura G, Kawamura R, Wakui K, Fukushima Y, Matsumoto N
  TITLE     A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations.
  JOURNAL   Am J Med Genet A 152A:1333-46 (2010)
REFERENCE   PMID:23664117
  AUTHORS   Nakajima M, Mizumoto S, Miyake N, Kogawa R, Iida A, Ito H, Kitoh H, Hirayama A, Mitsubuchi H, Miyazaki O, Kosaki R, Horikawa R, Lai A, Mendoza-Londono R, Dupuis L, Chitayat D, Howard A, Leal GF, Cavalcanti D, Tsurusaki Y, Saitsu H, Watanabe S, Lausch E, Unger S, Bonafe L, Ohashi H, Superti-Furga A, Matsumoto N, Sugahara K, Nishimura G, Ikegawa S
  TITLE     Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause a spectrum of skeletal and connective tissue disorders.
  JOURNAL   Am J Hum Genet 92:927-34 (2013)
///
ENTRY       H00803                      Disease
NAME        Seizures-sensorineural deafness-ataxia-mental retardation-electrolyte imbalance (SESAME) ;
            SeSAME/EAST syndrome
DESCRIPTION Seizures-sensorineural deafness-ataxia-mental retardation-electrolyte imbalance (SESAME)  is a channelopathy characterized by seizures, sensorineural deafness, ataxia, intellectual deficit, and electrolyte imbalance. This disease links to autosomal recessive mutations in KCNJ10, which encodes the potassium channel.
CATEGORY    Nervous system disease; Epilepsy; Mental retardation
GENE        KCNJ10 [HSA:3766] [KO:K05003]
DBLINKS     MeSH: C557674
            OMIM: 612780
REFERENCE   PMID:21088294
  AUTHORS   Williams DM, Lopes CM, Rosenhouse-Dantsker A, Connelly HL, Matavel A, O-Uchi J, McBeath E, Gray DA
  TITLE     Molecular basis of decreased Kir4.1 function in SeSAME/EAST syndrome.
  JOURNAL   J Am Soc Nephrol 21:2117-29 (2010)
///
ENTRY       H00804                      Disease
NAME        Multiple cutaneous and uterine leiomyomata
DESCRIPTION Multiple cutaneous and uterine leiomyomatosis (MCUL) is a rare autosomal dominant disorder that affects both sexes. It is characterized by benign skin tumors arising from the arrector pili muscle, and from uterine fibroids in female patients. Some patients with MCUL develop renal cancer and this condition is called hereditary leiomyomatosis and renal cell cancer.
CATEGORY    Cancer
GENE        FH [HSA:2271] [KO:K01679]
DBLINKS     ICD-10: D21.9
            MeSH: C535516
            OMIM: 150800
REFERENCE   PMID:12761039 (description, gene)
  AUTHORS   Alam NA, Rowan AJ, Wortham NC, Pollard PJ, Mitchell M, Tyrer JP, Barclay E, Calonje E, Manek S, Adams SJ, Bowers PW, Burrows NP, Charles-Holmes R, Cook LJ, Daly BM, Ford GP, Fuller LC, Hadfield-Jones SE, Hardwick N, Highet AS, Keefe M, MacDonald-Hull SP, Potts ED, Crone M, Wilkinson S, Camacho-Martinez F, Jablonska S, Ratnavel R, MacDonald A, Mann RJ, Grice K, Guillet G, Lewis-Jones MS, McGrath H, Seukeran DC, Morrison PJ, Fleming S, Rahman S, Kelsell D, Leigh I, Olpin S, Tomlinson IP
  TITLE     Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
  JOURNAL   Hum Mol Genet 12:1241-52 (2003)
REFERENCE   PMID:17768033 (description, gene)
  AUTHORS   Makino T, Nagasaki A, Furuichi M, Matsui K, Watanabe H, Sawamura D, Shimizu H, Shimizu T
  TITLE     Novel mutation in a fumalate hydratase gene of a Japanese patient with multiple cutaneous and uterine leiomyomatosis.
  JOURNAL   J Dermatol Sci 48:151-3 (2007)
REFERENCE   PMID:21051878 (description, gene)
  AUTHORS   Rongioletti F, Fausti V, Ferrando B, Parodi A, Mandich P, Pasini B
  TITLE     A novel missense mutation in fumarate hydratase in an Italian patient with a diffuse variant of cutaneous leiomyomatosis (Reed's syndrome).
  JOURNAL   Dermatology 221:378-80 (2010)
///
ENTRY       H00805                      Disease
NAME        Vitreoretinal degeneration, including:
            Stickler syndrome type I (STL1);
            Stickler syndrome type II (STL2);
            Snowflake vitreoretinal degeneration (SVD);
            Wagner syndrome 1 (WGN1);
            Knobloch syndrome (KNO);
            Enhanced S-cone syndrome (ESCS);
            Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
DESCRIPTION The inherited vitreoretinal degenerations are disorders of the eye characterized by early onset cataract, anomalies of the vitreous manifesting as optically empty vitreous, course fibrils, and membranes, and retinal detachment. These diseases include Stickler syndrome types I (STL1) and II (STL2), caused by mutations in COL2A1 and COL11A1 respectively. Snowflake vitreoretinal degeneration (SVD) is associated with a mutation in a KCNJ13, and Wagner syndrome (WGN1) with mutations in CSPG2. Knobloch syndrome (KNO) may also be caused by mutations in a collagen gene, COL18A1. In addition to Stickler syndrome and other chondrodysplasias, enhanced S-cone syndrome (ESCS) and autosomal dominant vitreoretinochoroidopathy (ADVIRC) are associated with vitreoretinal degeneration.
CATEGORY    Nervous system disease; Eye disease
GENE        (STL1) COL2A1 [HSA:1280] [KO:K19719]
            (STL2) COL11A1 [HSA:1301] [KO:K19721]
            (SVD) KCNJ13 [HSA:3769] [KO:K05006]
            (WGN1) CSPG2 [HSA:1462] [KO:K06793]
            (KNO) COL18A1 [HSA:80781] [KO:K06823]
            (ESCS) NR2E3 [HSA:10002] [KO:K08546]
            (ADVIRC) BEST1 [HSA:7439] [KO:K13878]
COMMENT     STL1 and  STL2 are also included in Type II and XI collagenopathies, respectively. [DS:H00520] [DS:H00519]
DBLINKS     ICD-10: H35.5
            OMIM: 108300 604841 193230 143200 267750 268100 193220
REFERENCE   PMID:18309337
  AUTHORS   Edwards AO
  TITLE     Clinical features of the congenital vitreoretinopathies.
  JOURNAL   Eye (Lond) 22:1233-42 (2008)
REFERENCE   PMID:18179896
  AUTHORS   Hejtmancik JF, Jiao X, Li A, Sergeev YV, Ding X, Sharma AK, Chan CC, Medina I, Edwards AO
  TITLE     Mutations in KCNJ13 cause autosomal-dominant snowflake vitreoretinal degeneration.
  JOURNAL   Am J Hum Genet 82:174-80 (2008)
REFERENCE   PMID:16043844
  AUTHORS   Miyamoto T, Inoue H, Sakamoto Y, Kudo E, Naito T, Mikawa T, Mikawa Y, Isashiki Y, Osabe D, Shinohara S, Shiota H, Itakura M
  TITLE     Identification of a novel splice site mutation of the CSPG2 gene in a Japanese family with Wagner syndrome.
  JOURNAL   Invest Ophthalmol Vis Sci 46:2726-35 (2005)
REFERENCE   PMID:10942434
  AUTHORS   Sertie AL, Sossi V, Camargo AA, Zatz M, Brahe C, Passos-Bueno MR
  TITLE     Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome).
  JOURNAL   Hum Mol Genet 9:2051-8 (2000)
REFERENCE   PMID:12963616
  AUTHORS   Sharon D, Sandberg MA, Caruso RC, Berson EL, Dryja TP
  TITLE     Shared mutations in NR2E3 in enhanced S-cone syndrome, Goldmann-Favre syndrome, and many cases of clumped pigmentary retinal degeneration.
  JOURNAL   Arch Ophthalmol 121:1316-23 (2003)
REFERENCE   PMID:21072067
  AUTHORS   Vincent A, McAlister C, Vandenhoven C, Heon E
  TITLE     BEST1-related autosomal dominant vitreoretinochoroidopathy: a degenerative disease with a range of developmental ocular anomalies.
  JOURNAL   Eye (Lond) 25:113-8 (2011)
///
ENTRY       H00806                      Disease
NAME        Benign familial neonatal and infantile epilepsies, including:
            Benign familial neonatal epilepsy (BFNE);
            Benign familial neonatal infantile epilepsy (BFNIE);
            Benign familial infantile epilepsy (BFIE)
DESCRIPTION Benign familial neonatal epilepsy (BFNE), benign familial neonatal infantile epilepsy (BFNIE), and benign familial infantile epilepsy (BFIE) are three benign epilepsy syndromes with autosomal dominant inheritance distinguished by ascending average ages of seizure onset (mean age at onset of 2-3 days; 11 weeks; and 6 months, respectively). They are a group of genetic (idiopathic) epilepsies which have a primary genetic background, usually no structural brain abnormalities and most of them have a benign course without additional neurological symptoms. For BFNE and BFNIE, genetic defects have already been identified. Whereas BFNE are caused by loss-of-function mutations in the two genes KCNQ2 and KCNQ3 encoding the voltage-gated K+ channels Kv7.2 and Kv7.3, mutations in the gene SCN2A encoding the voltage-gated Na+ channel Nav1.2 have been detected in BFNIE. There are as yet no known genes identified for BFIE.
CATEGORY    Nervous system disease
GENE        (BFNE) KCNQ2 [HSA:3785] [KO:K04927]
            (BFNE) KCNQ3 [HSA:3786] [KO:K04928]
            (BFNIE) SCN2A [HSA:6326] [KO:K04834]
DBLINKS     ICD-10: G40.3
            OMIM: 121200 121201 607745
REFERENCE   PMID:20196795 (name)
  AUTHORS   Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE
  TITLE     Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.
  JOURNAL   Epilepsia 51:676-85 (2010)
REFERENCE   PMID:21395569 (description, gene)
  AUTHORS   Mulley JC, Heron SE, Dibbens LM
  TITLE     Proposed genetic classification of the "benign" familial neonatal and infantile epilepsies.
  JOURNAL   Epilepsia 52:649-50 (2011)
REFERENCE   PMID:20371507 (description, gene)
  AUTHORS   Liao Y, Deprez L, Maljevic S, Pitsch J, Claes L, Hristova D, Jordanova A, Ala-Mello S, Bellan-Koch A, Blazevic D, Schubert S, Thomas EA, Petrou S, Becker AJ, De Jonghe P, Lerche H
  TITLE     Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy.
  JOURNAL   Brain 133:1403-14 (2010)
///
ENTRY       H00807                      Disease
NAME        Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE);
            Nocturnal frontal lobe epilepsy (NFLE)
DESCRIPTION Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is characterized by nocturnal, frequent, brief and stereotypic seizures that include explosive onset, screaming, agitation, stiffening, kicking or bicycling of the legs, and incontinence. Ictal video electroencephalographic (EEG) studies have revealed partial seizures originating from the frontal lobe but also in parts of the insula, suggesting a defect of a broader network. Mutations in CHRNA4, CHRNB2, and CHRNA2, which encodes the alpha4-, beta2-, and alpha2-subunit of neuronal nicotinic acetylcholine receptor, have been reported. These mutations are concentrated in the pore-forming M2 transmembrane segments.
CATEGORY    Nervous system disease
GENE        CHRNA4 [HSA:1137] [KO:K04806]
            CHRNB2 [HSA:1141] [KO:K04813]
            CHRNA2 [HSA:1135] [KO:K04804]
MARKER      long term video EEG monitoring, interictal PET
DBLINKS     MeSH: C579932
            OMIM: 600513 605375 610353
REFERENCE   PMID:15843070 (description, gene, marker)
  AUTHORS   di Corcia G, Blasetti A, De Simone M, Verrotti A, Chiarelli F
  TITLE     Recent advances on autosomal dominant nocturnal frontal lobe epilepsy: "understanding the nicotinic acetylcholine receptor (nAChR)".
  JOURNAL   Eur J Paediatr Neurol 9:59-66 (2005)
REFERENCE   PMID:18754913 (description, gene)
  AUTHORS   Weber YG, Lerche H
  TITLE     Genetic mechanisms in idiopathic epilepsies.
  JOURNAL   Dev Med Child Neurol 50:648-54 (2008)
///
ENTRY       H00808                      Disease
NAME        Idiopathic generalized epilepsies (IGEs), including:
            Childhood absence epilepsy (CAE);
            Juvenile absence epilepsy (JAE);
            Juvenile myoclonic epilepsy (JME);
            Epilepsy with generalized tonic-clonic seizures alone;
            Familial infantile myoclonic epilepsy (FIME)
DESCRIPTION Idiopathic generalized epilepsies (IGEs) are the most common types of epilepsy in childhood and adolescence. Based on the main seizure type and age at onset, four classic subsyndromes exist: childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone. Although autosomal dominant inheritance occurs in rare families, clinical genetic data indicate that complex inheritance involving two or more genes is likely in the majority of families.
CATEGORY    Nervous system disease
GENE        (JAE, ECA3) CLCN2 [HSA:1181] [KO:K05011]
            (ECA2) GABRG2 [HSA:2566] [KO:K05186]
            (ECA4, EJM4) GABRA1 [HSA:2554] [KO:K05175]
            (EJM1) EFHC1 [HSA:114327]
            (EJM5) CACNB4 [HSA:785] [KO:K04865]
            (FIME) TBC1D24 [HSA:57465]
MARKER      EEG monitoring
DBLINKS     ICD-10: G40.3
            OMIM: 607628 607681 611136 254770 607682 605021
REFERENCE   PMID:15101828 (description, marker)
  AUTHORS   Marini C, Scheffer IE, Crossland KM, Grinton BE, Phillips FL, McMahon JM, Turner SJ, Dean JT, Kivity S, Mazarib A, Neufeld MY, Korczyn AD, Harkin LA, Dibbens LM, Wallace RH, Mulley JC, Berkovic SF
  TITLE     Genetic architecture of idiopathic generalized epilepsy: clinical genetic analysis of 55 multiplex families.
  JOURNAL   Epilepsia 45:467-78 (2004)
REFERENCE   PMID:18754913 (description, gene, marker)
  AUTHORS   Weber YG, Lerche H
  TITLE     Genetic mechanisms in idiopathic epilepsies.
  JOURNAL   Dev Med Child Neurol 50:648-54 (2008)
REFERENCE   PMID:20727515 (name, gene)
  AUTHORS   Falace A, Filipello F, La Padula V, Vanni N, Madia F, De Pietri Tonelli D, de Falco FA, Striano P, Dagna Bricarelli F, Minetti C, Benfenati F, Fassio A, Zara F
  TITLE     TBC1D24, an ARF6-interacting protein, is mutated in familial infantile myoclonic  epilepsy.
  JOURNAL   Am J Hum Genet 87:365-70 (2010)
///
ENTRY       H00809                      Disease
NAME        Autosomal dominant temporal lobe epilepsy (ADTLE);
            Autosomal dominant partial epilepsy with auditory features (ADPEAF)
DESCRIPTION Autosomal dominant lateral temporal epilepsy (ADLTE) or autosomal dominant partial epilepsy with auditory features (ADPEAF) is an inherited epilepsy syndrome characterized by onset in adolescence or early adulthood of lateral temporal seizures with predominant auditory symptoms originating from the lateral temporal lobe cortex. Mutations in the leucine-rich glioma-inactivated 1 (LGI1) gene have been reported in up to 50% of ADTLE/ADPEAF pedigrees. In addition, de novo LGI1 mutations are found in about 2% of sporadic cases with idiopathic partial epilepsy with auditory features, who are clinically similar to the majority of patients with ADLTE/ADPEAF but have no family history.
CATEGORY    Nervous system disease
GENE        LGI1 [HSA:9211]
DBLINKS     MeSH: C537297
            OMIM: 600512
REFERENCE   PMID:21444903 (description, gene)
  AUTHORS   Striano P, Busolin G, Santulli L, Leonardi E, Coppola A, Vitiello L, Rigon L, Michelucci R, Tosatto SC, Striano S, Nobile C
  TITLE     Familial temporal lobe epilepsy with psychic auras associated with a novel LGI1 mutation.
  JOURNAL   Neurology 76:1173-6 (2011)
REFERENCE   PMID:19469848 (description, gene)
  AUTHORS   Michelucci R, Pasini E, Nobile C
  TITLE     Lateral temporal lobe epilepsies: clinical and genetic features.
  JOURNAL   Epilepsia 50 Suppl 5:52-4 (2009)
REFERENCE   PMID:19191227 (description, gene)
  AUTHORS   Nobile C, Michelucci R, Andreazza S, Pasini E, Tosatto SC, Striano P
  TITLE     LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy.
  JOURNAL   Hum Mutat 30:530-6 (2009)
///
ENTRY       H00810                      Disease
NAME        Progressive myoclonic epilepsy (PME/ EPM), including:
            Lafora disease (LBD);
            Unverricht-Lundborg disease (ULD);
            Neuronal ceroid lipofuscinoses (NCL);
            Type I sialidosis;
            Action myoclonus-renal failure syndrome (DRPLA);
            Type III Gaucher disease (GD)
DESCRIPTION Progressive myoclonic epilepsy (PME) is a syndrome complex characterized by progressive myoclonus, cognitive impairment, ataxia, and other neurologic deficits. PME is a disease that afflicts previously normal children with ever-worsening and soon-intractable myoclonus and epilepsy, usually associated with neurodegeneration, and eventual dementia and early death. PME include Lafora disease (LBD), Unverricht-Lundborg disease (ULD), the neuronal ceroid lipofuscinoses (NCL), type I sialidosis (cherry-red spot myoclonus), action myoclonus-renal failure syndrome (AMRF/DRPLA), and type III Gaucher disease (GD). Almost all the autosomal recessively inherited PMEs are lysosomal diseases, with the exception of Lafora disease in which neither the accumulating material nor the gene products are in lysosomes. PME also occurs in various forms of mitochondrial encephalomyopathies, especially in myoclonic epilepsy with ragged-red fibers (MERRF).
CATEGORY    Nervous system disease
GENE        (LBD/ EPM2A) EPM2A [HSA:7957] [KO:K14165]
            (LBD/ EPM2B) NHLRC1 [HSA:378884] [KO:K10602]
            (LBD/ EPM1B) PRICKLE1 [HSA:144165] [KO:K04511]
            (ULD/ EPM1) CSTB [HSA:1476] [KO:K13907]
            (CLN1) PPT1 [HSA:5538] [KO:K01074]
            (CLN2) TPP1 [HSA:1200] [KO:K01279]
            (CLN3) CLN3 [HSA:1201] [KO:K12389]
            (CLN5) CLN5 [HSA:1203] [KO:K12390]
            (CLN6) CLN6 [HSA:54982] [KO:K12359]
            (CLN7) MFSD8 [HSA:256471] [KO:K12307]
            (CLN8) CLN8 [HSA:2055] [KO:K12360]
            (CLN10) CTSD [HSA:1509] [KO:K01379]
            (DRPLA/ EPM4) SCARB2 [HSA:950] [KO:K12384]
            (Sialidosis) NEU1 [HSA:4758] [KO:K01186]
            (GD III) NEU1 [HSA:2629] [KO:K01201]
            (MERRF) MTTK [HSA:4566] [KO:K14229]
            (MERRF) MTTL1 [HSA:4567] [KO:K14228]
            (MERRF) MTTH [HSA:4564] [KO:K14226]
            (MERRF) MTTS1 [HSA:4574] [KO:K14233]
            (MERRF) MTTS2 [HSA:4575] [KO:K14233]
            (MERRF) MTTF [HSA:4558] [KO:K14231]
            (EPM3) KCTD7 [HSA:154881]
            (EPM5) PRICKLE2 [HSA:166336] [KO:K04511]
            (EPM6) GOSR2 [HSA:9570] [KO:K08496]
DRUG        Clonazepam [DR:D00280]
            Sodium valproate [DG:DG00849]
            Zonisamide [DR:D00538]
            Piracetam [DR:D01914]
            Levetiracetam [DR:D00709]
COMMENT     See [DS:H00126] for Gaucher disease, [DS:H00142] for sialidosis, and [DS:H00149] for neuronal ceroid lipofuscinoses (NCL).
DBLINKS     ICD-10: G40.3
            MeSH: D020191
            OMIM: 204200 204300 204500 231000 254780 254800 254900 256550 256730 256731 545000 600143 601780 610003 610951 612437 611726 613832 614018
REFERENCE   PMID:20739785 (description, gene)
  AUTHORS   Satishchandra P, Sinha S
  TITLE     Progressive myoclonic epilepsy.
  JOURNAL   Neurol India 58:514-22 (2010)
REFERENCE   PMID:19469843 (description, gene)
  AUTHORS   Ramachandran N, Girard JM, Turnbull J, Minassian BA
  TITLE     The autosomal recessively inherited progressive myoclonus epilepsies and their genes.
  JOURNAL   Epilepsia 50 Suppl 5:29-36 (2009)
REFERENCE   PMID:18976727 (gene)
  AUTHORS   Bassuk AG, Wallace RH, Buhr A, Buller AR, Afawi Z, Shimojo M, Miyata S, Chen S, Gonzalez-Alegre P, Griesbach HL, Wu S, Nashelsky M, Vladar EK, Antic D, Ferguson PJ, Cirak S, Voit T, Scott MP, Axelrod JD, Gurnett C, Daoud AS, Kivity S, Neufeld MY, Mazarib A, Straussberg R, Walid S, Korczyn AD, Slusarski DC, Berkovic SF, El-Shanti HI
  TITLE     A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome.
  JOURNAL   Am J Hum Genet 83:572-81 (2008)
REFERENCE   PMID:21710140
  AUTHORS   Azizieh R, Orduz D, Van Bogaert P, Bouschet T, Rodriguez W, Schiffmann SN, Pirson I, Abramowicz MJ
  TITLE     Progressive myoclonic epilepsy-associated gene KCTD7 is a regulator of potassium  conductance in neurons.
  JOURNAL   Mol Neurobiol 44:111-21 (2011)
REFERENCE   PMID:20301774
  AUTHORS   Fox MH, Bassuk AG
  TITLE     PRICKLE1-Related Progressive Myoclonus Epilepsy with Ataxia
  JOURNAL   (1993)
REFERENCE   PMID:21276947
  AUTHORS   Tao H, Manak JR, Sowers L, Mei X, Kiyonari H, Abe T, Dahdaleh NS, Yang T, Wu S, Chen S, Fox MH, Gurnett C, Montine T, Bird T, Shaffer LG, Rosenfeld JA, McConnell J, Madan-Khetarpal S, Berry-Kravis E, Griesbach H, Saneto RP, Scott MP, Antic D, Reed J, Boland R, Ehaideb SN, El-Shanti H, Mahajan VB, Ferguson PJ, Axelrod JD, Lehesjoki AE, Fritzsch B, Slusarski DC, Wemmie J, Ueno N, Bassuk AG
  TITLE     Mutations in prickle orthologs cause seizures in flies, mice, and humans.
  JOURNAL   Am J Hum Genet 88:138-49 (2011)
REFERENCE   PMID:21549339
  AUTHORS   Corbett MA, Schwake M, Bahlo M, Dibbens LM, Lin M, Gandolfo LC, Vears DF, O'Sullivan JD, Robertson T, Bayly MA, Gardner AE, Vlaar AM, Korenke GC, Bloem BR, de Coo IF, Verhagen JM, Lehesjoki AE, Gecz J, Berkovic SF
  TITLE     A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia.
  JOURNAL   Am J Hum Genet 88:657-63 (2011)
///
ENTRY       H00811                      Disease
NAME        Distal arthrogryposis (DA)
DESCRIPTION Distal arthrogryposis (DA) are a distinct group of syndromes with congenital contractures primarily involving the hands and feet, which often are associated with abnormal facies, and are transmitted by autosomal dominant inheritance. To date, 10 different DA syndromes have been characterized and classified. DA2A and DA2B are also referred to as Freeman-Sheldon syndrome and Sheldon-Hall syndrome, respectively. DA1, DA2A, DA2B, and DA7 are caused by mutations in genes that encode proteins of the contractile apparatus of the fast-twitch myofibers including TNNI2, TNNT3, MYH8, MYH3, and TPM2.
CATEGORY    Musculoskeletal disease
GENE        (DA1, DA2B) TPM2 [HSA:7169] [KO:K10374]
            (DA2B) TNNI2 [HSA:7136] [KO:K12043]
            (DA2B) TNNT3 [HSA:7140] [KO:K12046]
            (DA2A, DA2B) MYH3 [HSA:4621] [KO:K10352]
            (DA7) MYH8 [HSA:4626] [KO:K10352]
DBLINKS     ICD-10: Q87.0 Q74.3
            MeSH: D001176
            OMIM: 108120 193700 601680
REFERENCE   PMID:17103435 (description, gene)
  AUTHORS   Stevenson DA, Swoboda KJ, Sanders RK, Bamshad M
  TITLE     A new distal arthrogryposis syndrome characterized by plantar flexion contractures.
  JOURNAL   Am J Med Genet A 140:2797-801 (2006)
REFERENCE   PMID:15930940 (description)
  AUTHORS   Beals RK
  TITLE     The distal arthrogryposes: a new classification of peripheral contractures.
  JOURNAL   Clin Orthop Relat Res 203-10 (2005)
REFERENCE   PMID:19309503 (description)
  AUTHORS   Toydemir RM, Bamshad MJ
  TITLE     Sheldon-Hall syndrome.
  JOURNAL   Orphanet J Rare Dis 4:11 (2009)
REFERENCE   PMID:19571066 (description)
  AUTHORS   Bamshad M, Van Heest AE, Pleasure D
  TITLE     Arthrogryposis: a review and update.
  JOURNAL   J Bone Joint Surg Am 91 Suppl 4:40-6 (2009)
///
ENTRY       H00812                      Disease
NAME        Trichomoniasis
DESCRIPTION Trichomoniasis is the most common curable sexually transmitted infection caused by a motile flagellate protozoan parasite. An estimated 160 million people are annually infected. Women with trichomoniasis have a wide spectrum of symptoms, ranging from a relatively asymptomatic state in one-third of cases to severe irritation and inflammation. Several complications associated with adverse pregnancy outcome have been reported.
CATEGORY    Infectious disease
PATHOGEN    Trichomonas vaginalis [GN:tva]
            Trichomonas foetus
DRUG        Metronidazole [DG:DG00006]
            Tinidazole [DR:D01426]
            Ornidazole [DR:D05274]
            Secnidazole [DR:D07353]
DBLINKS     ICD-10: A59
            MeSH: D014245
            MedlinePlus: 001331
REFERENCE   PMID:21440359 (description, drug)
  AUTHORS   Harp DF, Chowdhury I
  TITLE     Trichomoniasis: evaluation to execution.
  JOURNAL   Eur J Obstet Gynecol Reprod Biol 157:3-9 (2011)
REFERENCE
  AUTHORS   Papadakis MA, Tierney LM (ed).
  TITLE     [Current Medical Diagnosis & Treatment 2004, Forty-Third Edition] (In Japanese)
  JOURNAL   Nikkei Business Publications, Inc. (2004)
REFERENCE   PMID:18192787 (description)
  AUTHORS   Johnston VJ, Mabey DC
  TITLE     Global epidemiology and control of Trichomonas vaginalis.
  JOURNAL   Curr Opin Infect Dis 21:56-64 (2008)
///
ENTRY       H00813                      Disease
NAME        Laryngo onycho cutaneous syndrome
DESCRIPTION Laryngo onycho cutaneous syndrome is an epithelial disorder characterized by cutaneous erosions at elbows, knees and digits and formation of granulation tissue of the larynx and conjunctiva. The multisystem disorder is caused by deficient laminin synthesis in epithelial basement membrane.
CATEGORY    Skin and connective tissue disease
GENE        LAMA3 [HSA:3909] [KO:K06240]
DBLINKS     MeSH: C537032
            OMIM: 245660
REFERENCE   PMID:20438980 (description, gene)
  AUTHORS   Kadyan A, Aralikatti A, Shah S, Jewell R, Paul L, Darling J, Wood M, Gooi J, Morrell AJ, Newton Bishop JA, Marr JE
  TITLE     Laryngo-onycho-cutaneous syndrome.
  JOURNAL   Ophthalmology 117:1056-1056.e2 (2010)
REFERENCE   PMID:17542886 (description, gene)
  AUTHORS   Kim CC, Liang MG, Pfendner E, Kimonis VE
  TITLE     What syndrome is this? Laryngo-onycho-cutaneous syndrome.
  JOURNAL   Pediatr Dermatol 24:306-8 (2007)
REFERENCE   PMID:8185366 (description)
  AUTHORS   Phillips RJ, Atherton DJ, Gibbs ML, Strobel S, Lake BD
  TITLE     Laryngo-onycho-cutaneous syndrome: an inherited epithelial defect.
  JOURNAL   Arch Dis Child 70:319-26 (1994)
///
ENTRY       H00814                      Disease
NAME        Vitelliform macular dystrophy, including:
            Best disease / Juvenile vitelliform macular dystrophy (VMD2) ;
            Adult-onset vitelliform macular dystrophy (AVMD);
            Autosomal recessive bestrophinopathy (ARB)
DESCRIPTION Vitelliform macular dystrophy is characterized by autosomal dominant inheritance and autofluorescent deposits within and beneath the retinal pigment epithelium. The onset of Juvenile vitelliform macular dystrophy (VMD2) is less than 30 years of age in most cases, whereas the onset of Adult-onset vitelliform macular dystrophy (AVMD) is between 30 and 50 years accompanied by slowly progressive visual loss.
CATEGORY    Nervous system disease; Eye disease
GENE        (VMD2/ AVMD/ ARB) BEST1 [HSA:7439] [KO:K13878]
            (VMD3/ AVMD) PRPH2 [HSA:5961] [KO:K17343]
            (VMD4) IMPG1 [HSA:3617] [KO:K19016]
            (VMD5) IMPG2 [HSA:50939] [KO:K19017]
MARKER      Electro-oculogram (EOG) Arden ratio is generally considered to be decreased in VMD2 and normal or subnormal in AVMD.
DBLINKS     ICD-10: H35.5
            MeSH: D057826
            OMIM: 153840 153700 608161 616151 616152 611809
REFERENCE   PMID:21269699
  AUTHORS   Meunier I, Senechal A, Dhaenens CM, Arndt C, Puech B, Defoort-Dhellemmes S, Manes G, Chazalette D, Mazoir E, Bocquet B, Hamel CP
  TITLE     Systematic screening of BEST1 and PRPH2 in juvenile and adult vitelliform macular dystrophies: a rationale for molecular analysis.
  JOURNAL   Ophthalmology 118:1130-6 (2011)
REFERENCE   PMID:21436265
  AUTHORS   Querques G, Zerbib J, Santacroce R, Margaglione M, Delphin N, Querques L, Rozet JM, Kaplan J, Souied EH
  TITLE     The spectrum of subclinical Best vitelliform macular dystrophy in subjects with mutations in BEST1 gene.
  JOURNAL   Invest Ophthalmol Vis Sci 52:4678-84 (2011)
REFERENCE   PMID:18179881
  AUTHORS   Burgess R, Millar ID, Leroy BP, Urquhart JE, Fearon IM, De Baere E, Brown PD, Robson AG, Wright GA, Kestelyn P, Holder GE, Webster AR, Manson FD, Black GC
  TITLE     Biallelic mutation of BEST1 causes a distinct retinopathy in humans.
  JOURNAL   Am J Hum Genet 82:19-31 (2008)
REFERENCE   PMID:25085631 (gene)
  AUTHORS   Meunier I, Manes G, Bocquet B, Marquette V, Baudoin C, Puech B, Defoort-Dhellemmes S, Audo I, Verdet R, Arndt C, Zanlonghi X, Le Meur G, Dhaenens CM, Hamel CP
  TITLE     Frequency and clinical pattern of vitelliform macular dystrophy caused by mutations of interphotoreceptor matrix IMPG1 and IMPG2 genes.
  JOURNAL   Ophthalmology 121:2406-14 (2014)
///
ENTRY       H00815                      Disease
NAME        Hyperpigmentation, cutaneous, with hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, and hypogonadism;
            H syndrome
DESCRIPTION The H syndrome is an autosomal-recessive condition characterized by the association of cutaneous hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, sensorineural hearing loss, hypogonadism, short stature, and hyperglycemia. Anomalies such as hallux valgus and fixed flexion contractures of the toe and finger joints are additional clinical fiindings.
CATEGORY    Developmental disorder
GENE        SLC29A3 [HSA:55315] [KO:K15014]
DBLINKS     MeSH: C538322
            OMIM: 612391
REFERENCE   PMID:18410979 (description)
  AUTHORS   Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, Zangen DH, Raas-Rothschild A, Ben-Neriah Z, Shweiki S, Elpeleg O, Zlotogorski A
  TITLE     The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and  hypertrichotic skin with systemic manifestations.
  JOURNAL   J Am Acad Dermatol 59:79-85 (2008)
REFERENCE   PMID:18940313 (description, gene)
  AUTHORS   Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Abu Libdeh A, Broshtilova V, Elpeleg O, Zlotogorski A
  TITLE     The H syndrome is caused by mutations in the nucleoside transporter hENT3.
  JOURNAL   Am J Hum Genet 83:529-34 (2008)
REFERENCE   PMID:20199539 (description, gene)
  AUTHORS   Priya TP, Philip N, Molho-Pessach V, Busa T, Dalal A, Zlotogorski A
  TITLE     H syndrome: novel and recurrent mutations in SLC29A3.
  JOURNAL   Br J Dermatol 162:1132-4 (2010)
///
ENTRY       H00816                      Disease
NAME        Agenesis of the corpus callosum with peripheral neuropathy (ACCPN)
DESCRIPTION Agenesis of the corpus callosum with peripheral neuropathy (ACCPN) is a severe neurodegenerative disorder that is transmitted as an autosomal recessive trait. It is associated with mental retardation, progressive peripheral neuropathy caused by axonal degeneration, and complete or partial agenesis of the corpus callosum. ACCPN is found in French Canadian population and could be resulted from a single founder mutation.
CATEGORY    Neurodegenerative disease
GENE        SLC12A6 [HSA:9990] [KO:K14427]
DBLINKS     ICD-10: G60.0
            MeSH: C536446
            OMIM: 218000
REFERENCE   PMID:12368912 (description, gene)
  AUTHORS   Howard HC, Mount DB, Rochefort D, Byun N, Dupre N, Lu J, Fan X, Song L, Riviere JB, Prevost C, Horst J, Simonati A, Lemcke B, Welch R, England R, Zhan FQ, Mercado A, Siesser WB, George AL Jr, McDonald MP, Bouchard JP, Mathieu J, Delpire E, Rouleau GA
  TITLE     The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum.
  JOURNAL   Nat Genet 32:384-92 (2002)
REFERENCE   PMID:8554065 (description)
  AUTHORS   Casaubon LK, Melanson M, Lopes-Cendes I, Marineau C, Andermann E, Andermann F, Weissenbach J, Prevost C, Bouchard JP, Mathieu J, Rouleau GA
  TITLE     The gene responsible for a severe form of peripheral neuropathy and agenesis of the corpus callosum maps to chromosome 15q.
  JOURNAL   Am J Hum Genet 58:28-34 (1996)
///
ENTRY       H00817                      Disease
NAME        Branchiooculofacial syndrome (BOFS)
DESCRIPTION Branchiooculofacial syndrome (BOFS) is an autosomal dominant condition characterized by branchial cleft sinus defects associated with rotated auricles with stenotic auditory canals and conductive hearing loss. Branchial skin lesions covering branchial remnants are noted. Ocular anomalies and characteristic facial appearance including cleft lip/cleft palate together constitute the disease.
CATEGORY    Developmental disorder
GENE        TFAP2A [HSA:7020] [KO:K09176]
DBLINKS     ICD-10: Q18.8
            MeSH: D019280
            OMIM: 113620
REFERENCE   PMID:21634087 (description, gene)
  AUTHORS   Lin AE, Milunsky JM
  TITLE     Branchiooculofacial Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:10906521 (description)
  AUTHORS   Raveh E, Papsin BC, Forte V
  TITLE     Branchio-oculo-facial syndrome.
  JOURNAL   Int J Pediatr Otorhinolaryngol 53:149-56 (2000)
REFERENCE   PMID:3321995 (description)
  AUTHORS   Fujimoto A, Lipson M, Lacro RV, Shinno NW, Boelter WD, Jones KL, Wilson MG
  TITLE     New autosomal dominant branchio-oculo-facial syndrome.
  JOURNAL   Am J Med Genet 27:943-51 (1987)
///
ENTRY       H00818                      Disease
NAME        Birt-Hogg-Dube syndrome
DESCRIPTION Birt-Hogg-Dube syndrome is an autosomal dominant condition characterized by skin fibrofolliculomas, multiple pulmonary cysts, and renal cancer. Skin lesions usually appear after the age of 20 years with multiple white papules in the midface. The disease is caused by mutations in the FLCN gene coding for folliculin, a protein of unknown function.
CATEGORY    Cancer; Skin and connective tissue disease; Kidney disease; Lung disease
GENE        FLCN [HSA:201163] [KO:K09594]
DBLINKS     MeSH: D058249
            OMIM: 135150
REFERENCE   PMID:19959076 (description)
  AUTHORS   Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, Ungari S, Nordenskjold M, Hansen TV, Solly J, Maher ER
  TITLE     Birt-Hogg-Dube syndrome: diagnosis and management.
  JOURNAL   Lancet Oncol 10:1199-206 (2009)
REFERENCE   PMID:21071978 (description, gene)
  AUTHORS   Maher ER
  TITLE     Genetics of familial renal cancers.
  JOURNAL   Nephron Exp Nephrol 118:e21-6 (2011)
REFERENCE   PMID:20484339 (description, gene)
  AUTHORS   Morrison PJ, Donnelly DE, Atkinson AB, Maxwell AP
  TITLE     Advances in the genetics of familial renal cancer.
  JOURNAL   Oncologist 15:532-8 (2010)
///
ENTRY       H00819                      Disease
NAME        Stargardt disease (STGD);
            Fundus flavimaculatus
DESCRIPTION Stargardt disease (STGD) is the most common type of hereditary macular dystrophy. It is characterized by decreased central vision, atrophy of the macula and underlying retinal pigment epithelium (RPE), and frequent presence of prominent flecks in the posterior pole of the retina. Histopathologically, eyes with STGD reveal abnormal accumulations of lipofuscin in the RPE. To date, mutations in four genes have been identified as causing STGD, including ABCA4, ELOVL4, PROM1, and CNGB3.
CATEGORY    Nervous system disease; Eye disease
GENE        (STGD1) ABCA4 [HSA:24] [KO:K05644]
            (STGD1) CNGB3 [HSA:54714] [KO:K04953]
            (STGD3) ELOVL4 [HSA:6785] [KO:K10249]
            (STGD4) PROM1 [HSA:8842] [KO:K06532]
DBLINKS     ICD-10: H35.5
            MeSH: C535804 C535805 C535521
            OMIM: 248200 600110 603786
REFERENCE   PMID:12789571
  AUTHORS   Koenekoop RK
  TITLE     The gene for Stargardt disease, ABCA4, is a major retinal gene: a mini-review.
  JOURNAL   Ophthalmic Genet 24:75-80 (2003)
REFERENCE   PMID:19352439
  AUTHORS   Xi Q, Li L, Traboulsi EI, Wang QK
  TITLE     Novel ABCA4 compound heterozygous mutations cause severe progressive autosomal recessive cone-rod dystrophy presenting as Stargardt disease.
  JOURNAL   Mol Vis 15:638-45 (2009)
REFERENCE   PMID:20393116
  AUTHORS   Michaelides M, Gaillard MC, Escher P, Tiab L, Bedell M, Borruat FX, Barthelmes D, Carmona R, Zhang K, White E, McClements M, Robson AG, Holder GE, Bradshaw K, Hunt DM, Webster AR, Moore AT, Schorderet DF, Munier FL
  TITLE     The PROM1 mutation p.R373C causes an autosomal dominant bull's eye maculopathy associated with rod, rod-cone, and macular dystrophy.
  JOURNAL   Invest Ophthalmol Vis Sci 51:4771-80 (2010)
///
ENTRY       H00820                      Disease
NAME        Bjornstad syndrome
DESCRIPTION Bjornstad syndrome is an autosomal recessive combination of congenital sensorineural hearing loss and pili torti. It is caused by mutations in BCS1L encoding a protein that is necessary for the assembly of complex III in the mitochondria.
CATEGORY    Skin and connective tissue disease; Nervous system disease
GENE        BCS1L [HSA:617] [KO:K08900]
DBLINKS     MeSH: C537633
            OMIM: 262000
REFERENCE   PMID:10694305 (description)
  AUTHORS   Selvaag E
  TITLE     Pili torti and sensorineural hearing loss. A follow-up of Bjornstad's original patients and a review of the literature.
  JOURNAL   Eur J Dermatol 10:91-7 (2000)
REFERENCE   PMID:11807445 (description)
  AUTHORS   Richards KA, Mancini AJ
  TITLE     Three members of a family with pili torti and sensorineural hearing loss: the Bjornstad syndrome.
  JOURNAL   J Am Acad Dermatol 46:301-3 (2002)
REFERENCE   PMID:9545407 (description)
  AUTHORS   Lubianca Neto JF, Lu L, Eavey RD, Flores MA, Caldera RM, Sangwatanaroj S, Schott JJ, McDonough B, Santos JI, Seidman CE, Seidman JG
  TITLE     The Bjornstad syndrome (sensorineural hearing loss and pili torti) disease gene maps to chromosome 2q34-36.
  JOURNAL   Am J Hum Genet 62:1107-12 (1998)
REFERENCE   PMID:17314340 (description, gene)
  AUTHORS   Hinson JT, Fantin VR, Schonberger J, Breivik N, Siem G, McDonough B, Sharma P, Keogh I, Godinho R, Santos F, Esparza A, Nicolau Y, Selvaag E, Cohen BH, Hoppel CL, Tranebjaerg L, Eavey RD, Seidman JG, Seidman CE
  TITLE     Missense mutations in the BCS1L gene as a cause of the Bjornstad syndrome.
  JOURNAL   N Engl J Med 356:809-19 (2007)
///
ENTRY       H00821                      Disease
NAME        Age-related macular degeneration
DESCRIPTION Macular degeneration is the physical breakdown of the central portion of the retina called the macula. Age-related macular degeneration (AMD/ARMD) is the leading cause of blindness. AMD is a complex disease caused by the combination of genetic predisposition and environmental factors. Using genome linkage scan and association studies, multiple potentially causative genes have been identified. In AMD, there are two phenotypes, atrophic/ dry and neovascular/ wet. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is usually characterized by the abnormal growth of new blood vessels under the macula, which causes severe loss of vision. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD.
CATEGORY    Nervous system disease; Eye disease
GENE        (ARMD1) HMCN1 [HSA:83872] [KO:K17341]
            (ARMD2) ABCA4 [HSA:24] [KO:K05644]
            (ARMD3) FBLN5 [HSA:10516] [KO:K17340]
            (ARMD4) HF1 [HSA:3075] [KO:K04004]
            (ARMD5) ERCC6 [HSA:2074] [KO:K10841]
            (ARMD6) RAX2 [HSA:84839] [KO:K09333]
            (ARMD7) HTRA1 [HSA:5654] [KO:K08784]
            (ARMD8) ARMS2 [HSA:387715]
            (ARMD9) C3 [HSA:718] [KO:K03990]
            (ARMD10) TLR4 [HSA:7099] [KO:K10160]
            (ARMD11) CST3 [HSA:1471] [KO:K13899]
            (ARMD12) CX3CR1 [HSA:1524] [KO:K04192]
            (ARMD13) CFI [HSA:3426] [KO:K01333]
            (ARMD14) C2 [HSA:717] [KO:K01332]
            (ARMD14) CFB [HSA:629] [KO:K01335]
            CFHR1 [HSA:3078]
            CFHR3 [HSA:10878]
DRUG        Verteporfin [DR:D01162]
            Bevacizumab [DR:D06409]
            Pegaptanib [DR:D05386]
            Ranibizumab [DR:D05697]
            Anecortave acetate [DR:D01733]
            Laser photocoagulation
COMMENT     A haplotype carrying deletion of the complement factor H-related genes CFHR1 and CFHR3 is also associated with reduced risk of ARMD.
DBLINKS     ICD-10: H35.3
            MeSH: D008268
            OMIM: 603075 153800 608895 610698 613761 613757 610149 613778 611378 611488 611953 613784 615439 615489
REFERENCE   PMID:18097986
  AUTHORS   Montezuma SR, Sobrin L, Seddon JM
  TITLE     Review of genetics in age related macular degeneration.
  JOURNAL   Semin Ophthalmol 22:229-40 (2007)
REFERENCE   PMID:21072178
  AUTHORS   Baas DC, Despriet DD, Gorgels TG, Bergeron-Sawitzke J, Uitterlinden AG, Hofman A, van Duijn CM, Merriam JE, Smith RT, Barile GR, ten Brink JB, Vingerling JR, Klaver CC, Allikmets R, Dean M, Bergen AA
  TITLE     The ERCC6 gene and age-related macular degeneration.
  JOURNAL   PLoS One 5:e13786 (2010)
REFERENCE   PMID:12160730
  AUTHORS   Ayyagari R, Demirci FY, Liu J, Bingham EL, Stringham H, Kakuk LE, Boehnke M, Gorin MB, Richards JE, Sieving PA
  TITLE     X-linked recessive atrophic macular degeneration from RPGR mutation.
  JOURNAL   Genomics 80:166-71 (2002)
REFERENCE   PMID:3718916
  AUTHORS   Giuffre G, Lodato G
  TITLE     Vitelliform dystrophy and pattern dystrophy of the retinal pigment epithelium: concomitant presence in a family.
  JOURNAL   Br J Ophthalmol 70:526-32 (1986)
REFERENCE   PMID:20393116
  AUTHORS   Michaelides M, Gaillard MC, Escher P, Tiab L, Bedell M, Borruat FX, Barthelmes D, Carmona R, Zhang K, White E, McClements M, Robson AG, Holder GE, Bradshaw K, Hunt DM, Webster AR, Moore AT, Schorderet DF, Munier FL
  TITLE     The PROM1 mutation p.R373C causes an autosomal dominant bull's eye maculopathy associated with rod, rod-cone, and macular dystrophy.
  JOURNAL   Invest Ophthalmol Vis Sci 51:4771-80 (2010)
REFERENCE   PMID:18685559 (gene)
  AUTHORS   Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM
  TITLE     Variation near complement factor I is associated with risk of advanced AMD.
  JOURNAL   Eur J Hum Genet 17:100-4 (2009)
REFERENCE   PMID:16518403 (gene)
  AUTHORS   Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Hageman GS, Dean M, Allikmets R
  TITLE     Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
  JOURNAL   Nat Genet 38:458-62 (2006)
REFERENCE   PMID:16998489 (gene)
  AUTHORS   Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U
  TITLE     A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration.
  JOURNAL   Nat Genet 38:1173-7 (2006)
REFERENCE   PMID:21546780 (drug)
  AUTHORS   Koss MJ, Lewicka-Chomont A, Schramm K, Rejdak R, Ohrloff C, Koch FH
  TITLE     Quadruple therapy leads to a sustained improvement of vision in patients with wet age-related macular degeneration.
  JOURNAL   Ophthalmologica 226:45-50 (2011)
REFERENCE   PMID:21623685 (drug)
  AUTHORS   Mitchell P
  TITLE     A systematic review of the efficacy and safety outcomes of anti-VEGF agents used  for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
  JOURNAL   Curr Med Res Opin 27:1465-75 (2011)
REFERENCE   PMID:17636773
  AUTHORS   Virgili G, Bini A
  TITLE     Laser photocoagulation for neovascular age-related macular degeneration.
  JOURNAL   Cochrane Database Syst Rev CD004763 (2007)
REFERENCE   PMID:18462575 (drug)
  AUTHORS   Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A
  TITLE     Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
  JOURNAL   Health Technol Assess 12:iii-iv, ix-201 (2008)
REFERENCE   PMID:23440797 (drug)
  AUTHORS   Geltzer A, Turalba A, Vedula SS
  TITLE     Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.
  JOURNAL   Cochrane Database Syst Rev 1:CD005022 (2013)
///
ENTRY       H00822                      Disease
NAME        Renal agenesis and Renal adysplasia
DESCRIPTION Renal agenesis and renal adysplasia are congenital defects of kidney development. Renal agenesis can be unilateral/bilateral with no kidneys or very little kidney present. Renal adysplasia is a condition in which kidneys begin to form but contain undifferentiated tissues. Sometimes the hypoplastic tissues regress. These diseases can lead to childhood end-stage renal failure.
CATEGORY    Kidney disease
GENE        UPK3A [HSA:7380] [KO:K19520]
            RET [HSA:5979] [KO:K05126]
DBLINKS     ICD-10: Q60.1
            MeSH: C536482 C563261
            OMIM: 191830
REFERENCE   PMID:15888565 (description, gene)
  AUTHORS   Jenkins D, Bitner-Glindzicz M, Malcolm S, Hu CC, Allison J, Winyard PJ, Gullett AM, Thomas DF, Belk RA, Feather SA, Sun TT, Woolf AS
  TITLE     De novo Uroplakin IIIa heterozygous mutations cause human renal adysplasia leading to severe kidney failure.
  JOURNAL   J Am Soc Nephrol 16:2141-9 (2005)
REFERENCE   PMID:16731295 (description, gene)
  AUTHORS   Schonfelder EM, Knuppel T, Tasic V, Miljkovic P, Konrad M, Wuhl E, Antignac C, Bakkaloglu A, Schaefer F, Weber S
  TITLE     Mutations in Uroplakin IIIA are a rare cause of renal hypodysplasia in humans.
  JOURNAL   Am J Kidney Dis 47:1004-12 (2006)
REFERENCE   PMID:20539737 (description, gene)
  AUTHORS   Jain S
  TITLE     The many faces of RET dysfunction in kidney.
  JOURNAL   Organogenesis 5:177-90 (2009)
REFERENCE   PMID:18252215 (description, gene)
  AUTHORS   Skinner MA, Safford SD, Reeves JG, Jackson ME, Freemerman AJ
  TITLE     Renal aplasia in humans is associated with RET mutations.
  JOURNAL   Am J Hum Genet 82:344-51 (2008)
///
ENTRY       H00823                      Disease
NAME        ABCD syndrome
DESCRIPTION ABCD syndrome is defined as albinism, black lock, cell migration disorder of the neurocytes of the gut, and deafness. It is inherited as an autosomal recessive trait.
CATEGORY    Congenital disorder
GENE        EDNRB [HSA:1910] [KO:K04198]
COMMENT     ABCD syndrome is an allelic disorder of Waardenburg syndrome 4A.
DBLINKS     ICD-10: L81.8
            MeSH: C535334
            OMIM: 600501
REFERENCE   PMID:11891690 (gene, description)
  AUTHORS   Verheij JB, Kunze J, Osinga J, van Essen AJ, Hofstra RM
  TITLE     ABCD syndrome is caused by a homozygous mutation in the EDNRB gene.
  JOURNAL   Am J Med Genet 108:223-5 (2002)
REFERENCE   PMID:7778600 (description)
  AUTHORS   Gross A, Kunze J, Maier RF, Stoltenburg-Didinger G, Grimmer I, Obladen M
  TITLE     Autosomal-recessive neural crest syndrome with albinism, black lock, cell migration disorder of the neurocytes of the gut, and deafness: ABCD syndrome.
  JOURNAL   Am J Med Genet 56:322-6 (1995)
///
ENTRY       H00824                      Disease
NAME        Calcification of joints and arteries
DESCRIPTION Calcification of joints and arteries is a condition in which calcifications of the lower-extremity arteries and articular capsules of hand and foot occur. Affected individuals harbor mutations in NT5E encoding CD73 that converts AMP to adenosine.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        NT5E [HSA:4907] [KO:K19970]
DBLINKS     MeSH: C565891
            OMIM: 211800
REFERENCE   PMID:21288095 (description, gene)
  AUTHORS   St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C, Mancini C, Freudenthal B, Stanescu HC, Zdebik AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, Boehm M
  TITLE     NT5E mutations and arterial calcifications.
  JOURNAL   N Engl J Med 364:432-42 (2011)
///
ENTRY       H00825                      Disease
NAME        Familial flecked retina syndrome, including:
            Doyne honeycomb degeneration of retina (DHRD);
            Basal laminar drusen (BLD);
            Fundus albipunctatus (FA);
            Retinitis punctata albescens (RPA);
            Bietti crystalline corneoretinal dystrophy  (BCD)
DESCRIPTION The flecked retina syndrome is characterized by multiple deep, yellow to yellowish white fundus lesions of variable size and shape in eyes without vascular or optic nerve disease. Originally this group consisted of four diseases: fundus albipunctatus, fundus flavimaculatus, familial drusen and fleck retina of Kandori. Doyne honeycomb degeneration of retina (DHRD) and Basal laminar drusen (BLD) are included in familial drusen. However, there are far more diseases with fleck-like deposits in the retina, including primary hereditary ocular diseases such as retinitis punctata albescens (RPA) or Bietti's crystalline dystrophy (BCD), neuro-ophthalmologic syndromes such as Kjellin's syndrome, and secundary retinal flecks due to metabolic disorders.
CATEGORY    Nervous system disease; Eye disease
GENE        (DHRD) EFEMP1 [HSA:2202] [KO:K18262]
            (BLD) CFH [HSA:3075] [KO:K04004]
            (FA) RDH5 [HSA:5959] [KO:K00061]
            (RPA) RLBP1 [HSA:6017] [KO:K19625]
            (RPA) RHO [HSA:6010] [KO:K04250]
            (BCD) CYP4V2 [HSA:285440] [KO:K07427]
COMMENT     Fundus flavimaculatus/ Stargardt disease and Kjellin's syndrome are described in H00819 and H00266, respectively. [DS:H00819] [DS:H00266]
DBLINKS     ICD-10: H35.5
            OMIM: 126600 126700 136880 210370
REFERENCE   PMID:19373677
  AUTHORS   Walia S, Fishman GA, Kapur R
  TITLE     Flecked-retina syndromes.
  JOURNAL   Ophthalmic Genet 30:69-75 (2009)
REFERENCE   PMID:11913893
  AUTHORS   Haimovici R, Wroblewski J, Piguet B, Fitzke FW, Holder GE, Arden GB, Bird AC
  TITLE     Symptomatic abnormalities of dark adaptation in patients with EFEMP1 retinal dystrophy (Malattia Leventinese/Doyne honeycomb retinal dystrophy).
  JOURNAL   Eye (Lond) 16:7-15 (2002)
REFERENCE   PMID:7952338
  AUTHORS   De Laey JJ
  TITLE     Flecked retina disorders.
  JOURNAL   Bull Soc Belge Ophtalmol 249:11-22 (1993)
REFERENCE   PMID:14767656
  AUTHORS   Tsuchiya T, Kato M, Tomita N, Koide K, Hata N, Sato M, Hotta Y, Ueno M, Nakamura M, Miyake Y
  TITLE     A case of sectorial benign flecked retina.
  JOURNAL   Jpn J Ophthalmol 48:72-4 (2004)
///
ENTRY       H00826                      Disease
NAME        Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES)
DESCRIPTION Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a rare autosomal dominant disease. The cardinal feature of this disease is a complex eyelid/ocular malformation such as blepharophimosis, ptosis, epicanthus inversus and telecanthus. The horizontal shortening of the palpebral aperture can lead to amblyopia. It is caused by mutations in FOXL2 gene that is involved in palpebral and ovarian development. Some of the female patients have premature ovarian failure (POF) and this condition is classified as BPES type I. BPES with normal ovarian function is referred to as BPES type II.
CATEGORY    Developmental disorder
GENE        FOXL2 [HSA:668] [KO:K09405]
COMMENT     Premature ovarian failure is described in H00627.
DBLINKS     ICD-10: Q10.3
            MeSH: C562419
            OMIM: 110100
REFERENCE   PMID:21957947 (description)
  AUTHORS   Tyers AG
  TITLE     The blepharophimosis-ptosis-epicanthus inversus syndrome (BPES).
  JOURNAL   Orbit 30:199-201 (2011)
REFERENCE   PMID:21696507 (description, gene)
  AUTHORS   Graziadio C, de Moraes FN, Rosa RF, Zen PR, Travi GM, Waldman C, Medina CT, De Baere E, Paskulin GA
  TITLE     Blepharophimosis-ptosis-epicanthus inversus syndrome.
  JOURNAL   Pediatr Int 53:390-2 (2011)
REFERENCE   PMID:21068205 (description, gene)
  AUTHORS   Fan JY, Han B, Qiao J, Liu BL, Ji YR, Ge SF, Song HD, Fan XQ
  TITLE     Functional study on a novel missense mutation of the transcription factor FOXL2 causes blepharophimosis-ptosis-epicanthus inversus syndrome (BPES).
  JOURNAL   Mutagenesis 26:283-9 (2011)
///
ENTRY       H00827                      Disease
NAME        Brooke-Spiegler syndrome
DESCRIPTION Brooke-Spiegler syndrome is an inherited disease characterized by multiple tumors of tissues derived from folliculo-sebaceous-apocrine unit, including cylindromas, trichoepitheliomas, and/or spiradenomas. It is an autosomal dominant condition.
CATEGORY    Skin and connective tissue disease
GENE        CYLD1 [HSA:1540] [KO:K08601]
DBLINKS     MeSH: C536611
            OMIM: 605041
REFERENCE   PMID:19462465 (description, gene)
  AUTHORS   Blake PW, Toro JR
  TITLE     Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
  JOURNAL   Hum Mutat 30:1025-36 (2009)
REFERENCE   PMID:15854031 (description, gene)
  AUTHORS   Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME, Celebi JT
  TITLE     Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation.
  JOURNAL   J Invest Dermatol 124:919-20 (2005)
REFERENCE   PMID:14632188 (description, gene)
  AUTHORS   Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gurer MA, Celebi JT
  TITLE     A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome.
  JOURNAL   J Invest Dermatol 121:732-4 (2003)
///
ENTRY       H00828                      Disease
NAME        Familial cylindromatosis
DESCRIPTION Familial cylindromatosis is a rare, autosomal dominant disorder characterized by the development of multiple benign tumors originating from the skin appendages. It is linked to CYLD gene, whose loss of function impairs epidermal differentiation.
CATEGORY    Skin and connective tissue disease
GENE        CYLD1 [HSA:1540] [KO:K08601]
DBLINKS     MeSH: C536611
            OMIM: 132700
REFERENCE   PMID:7493027 (description)
  AUTHORS   Biggs PJ, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y, Easton DF, Burn J, Stratton MR
  TITLE     Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene.
  JOURNAL   Nat Genet 11:441-3 (1995)
REFERENCE   PMID:15854031 (description, gene)
  AUTHORS   Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME, Celebi JT
  TITLE     Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation.
  JOURNAL   J Invest Dermatol 124:919-20 (2005)
REFERENCE   PMID:20972631 (gene)
  AUTHORS   van den Ouweland AM, Elfferich P, Lamping R, van de Graaf R, van Veghel-Plandsoen MM, Franken SM, Houweling AC
  TITLE     Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis.
  JOURNAL   Fam Cancer 10:127-32 (2011)
REFERENCE   PMID:21900959 (description)
  AUTHORS   Alameda JP, Fernandez-Acenero MJ, Moreno-Maldonado R, Navarro M, Quintana R, Page A, Ramirez A, Bravo A, Casanova ML
  TITLE     CYLD regulates keratinocyte differentiation and skin cancer progression in humans.
  JOURNAL   Cell Death Dis 2:e208 (2011)
///
ENTRY       H00829                      Disease
NAME        Multiple familial trichoepithelioma
DESCRIPTION Multiple familial trichoepithelioma is a benign epidermal tumor characterized by grouped nodules and papules on the face. The lesions are derived from immature hair follicles. It is inherited in autosomal dominant fashion and is related to Brooke-Spiegler syndrome and Familial cylindromatosis.
CATEGORY    Skin and connective tissue disease
GENE        CYLD1 [HSA:1540] [KO:K08601]
DBLINKS     ICD-10: D23.3
            MeSH: C536552
            OMIM: 601606
REFERENCE   PMID:18355210 (description, gene)
  AUTHORS   Oranje AP, Halley D, den Hollander JC, Teepe RG, van de Graaf R, van den Ouweland A, Wagner A
  TITLE     Multiple familial trichoepithelioma and familial cylindroma: one cause!
  JOURNAL   J Eur Acad Dermatol Venereol 22:1395-6 (2008)
REFERENCE   PMID:22077640 (gene)
  AUTHORS   Ponti G, Nasti S, Losi L, Pastorino L, Pollio A, Benassi L, Giudice S, Bertazzoni G, Veratti E, Azzoni P, Bianchi Scarra G, Seidenari S
  TITLE     Brooke-Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes.
  JOURNAL   J Cutan Pathol 39:366-71 (2012)
REFERENCE   PMID:21389835 (description, gene)
  AUTHORS   Kazakov DV, Vanecek T, Zelger B, Carlson JA, Spagnolo DV, Schaller J, Nemcova J, Kacerovska D, Vazmitel M, Sangueza M, Emberger M, Belousova I, Fernandez-Figueraz MT, Kempf W, Meyer DR, Rutten A, Baltaci M, Michal M
  TITLE     Multiple (familial) trichoepitheliomas: a clinicopathological and molecular biological study, including CYLD and PTCH gene analysis, of a series of 16 patients.
  JOURNAL   Am J Dermatopathol 33:251-65 (2011)
///
ENTRY       H00830                      Disease
NAME        Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV)
DESCRIPTION Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV) is a rare developmental lung disorder of neonates that can cause persistent pulmonary hypertension of the neonate (PPHN). FOXF1 is pathogenic for ACD/MPV and most of the cases have been reported to occur sporadically.
CATEGORY    Developmental disorder; Lung disease
GENE        FOXF1 [HSA:2294] [KO:K09399]
DBLINKS     OMIM: 265380
REFERENCE   PMID:21471096 (description, gene)
  AUTHORS   Bishop NB, Stankiewicz P, Steinhorn RH
  TITLE     Alveolar capillary dysplasia.
  JOURNAL   Am J Respir Crit Care Med 184:172-9 (2011)
REFERENCE   PMID:21835371 (description)
  AUTHORS   Hung SP, Huang SH, Wu CH, Chen WC, Kou KE, Wang NK, Lin LH
  TITLE     Misalignment of lung vessels and alveolar capillary dysplasia: a case report with autopsy.
  JOURNAL   Pediatr Neonatol 52:232-6 (2011)
///
ENTRY       H00831                      Disease
NAME        Primary dystonia
DESCRIPTION Dystonias are a heterogeneous group of hyperkinetic movement disorders characterized by involuntary sustained muscle contractions that lead to abnormal postures and repetitive movements. Presently, 20 distinct monogenic primary dystonias have been recognized. They can be divided into Primary torsin dystonias (PTDs), dystonia-plus syndromes without brain degeneration, dystonia-parkinsonism 
            with brain degeneration (i.e. DYT3), and paroxysmal dyskinesias.
CATEGORY    Nervous system disease
GENE        (DYT1) TOR1A [HSA:1861]
            (DYT2) HPCA [HSA:3208]
            (DYT3) TAF1 [HSA:6872] [KO:K03125]
            (DYT5) GCH1 [HSA:2643] [KO:K01495]
            (DYT6) THAP1 [HSA:55145]
            (DYT8) MR1 [HSA:25953]
            (DYT10) PRRT2 [HSA:112476]
            (DYT11) SGCE [HSA:8910]
            (DYT12) ATP1A3 [HSA:478] [KO:K01539]
            (DYT16) PRKRA [HSA:8575]
            (DYT18) GLUT1 [HSA:6513] [KO:K07299]
            (DYT23) CACNA1B [HSA:774] [KO:K04849]
            (DYT24) ANO3 [HSA:63982] [KO:K19498]
            (DYT25) GNAL [HSA:2774] [KO:K04633]
            (DYT26) KCTD17 [HSA:79734]
            (DYT27) COL6A3 [HSA:1293] [KO:K06238]
            (DRD) SPR [HSA:6697] [KO:K00072]
            (THD) TH [HSA:7054] [KO:K00501]
DBLINKS     ICD-10: G24.1
            MeSH: D020821
            OMIM: 128100 224500 314250 128230 602629 118800 128200 159900 128235 612067 612126 614860 615034 615073 616398 616411 612716 605407
REFERENCE   PMID:22030388 (description, gene)
  AUTHORS   Phukan J, Albanese A, Gasser T, Warner T
  TITLE     Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis.
  JOURNAL   Lancet Neurol 10:1074-85 (2011)
REFERENCE   PMID:20425035 (description, gene)
  AUTHORS   Bruggemann N, Klein C
  TITLE     Genetics of primary torsion dystonia.
  JOURNAL   Curr Neurol Neurosci Rep 10:199-206 (2010)
REFERENCE   PMID:19578124
  AUTHORS   Muller U
  TITLE     The monogenic primary dystonias.
  JOURNAL   Brain 132:2005-25 (2009)
REFERENCE   PMID:21907099 (description, gene)
  AUTHORS   Barrett MJ, Bressman S
  TITLE     Genetics and pharmacological treatment of dystonia.
  JOURNAL   Int Rev Neurobiol 98:525-49 (2011)
REFERENCE   PMID:25799108 (gene)
  AUTHORS   Charlesworth G, Angelova PR, Bartolome-Robledo F, Ryten M, Trabzuni D, Stamelou M, Abramov AY, Bhatia KP, Wood NW
  TITLE     Mutations in HPCA cause autosomal-recessive primary isolated dystonia.
  JOURNAL   Am J Hum Genet 96:657-65 (2015)
REFERENCE   PMID:25296916 (gene)
  AUTHORS   Groen JL, Andrade A, Ritz K, Jalalzadeh H, Haagmans M, Bradley TE, Jongejan A, Verbeek DS, Nurnberg P, Denome S, Hennekam RC, Lipscombe D, Baas F, Tijssen MA
  TITLE     CACNA1B mutation is linked to unique myoclonus-dystonia syndrome.
  JOURNAL   Hum Mol Genet 24:987-93 (2015)
REFERENCE   PMID:23200863 (gene)
  AUTHORS   Charlesworth G, Plagnol V, Holmstrom KM, Bras J, Sheerin UM, Preza E, Rubio-Agusti I, Ryten M, Schneider SA, Stamelou M, Trabzuni D, Abramov AY, Bhatia KP, Wood NW
  TITLE     Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated  in pathogenesis.
  JOURNAL   Am J Hum Genet 91:1041-50 (2012)
REFERENCE   PMID:23222958 (gene)
  AUTHORS   Fuchs T, Saunders-Pullman R, Masuho I, Luciano MS, Raymond D, Factor S, Lang AE, Liang TW, Trosch RM, White S, Ainehsazan E, Herve D, Sharma N, Ehrlich ME, Martemyanov KA, Bressman SB, Ozelius LJ
  TITLE     Mutations in GNAL cause primary torsion dystonia.
  JOURNAL   Nat Genet 45:88-92 (2013)
REFERENCE   PMID:25983243 (gene)
  AUTHORS   Mencacci NE, Rubio-Agusti I, Zdebik A, Asmus F, Ludtmann MH, Ryten M, Plagnol V, Hauser AK, Bandres-Ciga S, Bettencourt C, Forabosco P, Hughes D, Soutar MM, Peall K, Morris HR, Trabzuni D, Tekman M, Stanescu HC, Kleta R, Carecchio M, Zorzi G, Nardocci N, Garavaglia B, Lohmann E, Weissbach A, Klein C, Hardy J, Pittman AM, Foltynie T, Abramov AY, Gasser T, Bhatia KP, Wood NW
  TITLE     A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia.
  JOURNAL   Am J Hum Genet 96:938-47 (2015)
REFERENCE   PMID:26004199 (gene)
  AUTHORS   Zech M, Lam DD, Francescatto L, Schormair B, Salminen AV, Jochim A, Wieland T, Lichtner P, Peters A, Gieger C, Lochmuller H, Strom TM, Haslinger B, Katsanis N, Winkelmann J
  TITLE     Recessive mutations in the alpha3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia.
  JOURNAL   Am J Hum Genet 96:883-93 (2015)
///
ENTRY       H00832                      Disease
NAME        Core neuroacanthocytosis syndromes, including:
            Chorea-acanthocytosis (ChAc);
            McLeod syndrome (MLS);
            Huntington's disease-like 2 (HDL2);
            Pantothenate kinase associated neurodegeneration (PKAN)
DESCRIPTION Neuroacanthocytosis (NA) syndromes are a heterogeneous group of diseases in which nervous system abnormalities coincide with red blood cell acanthocytosis. Core NA syndromes are one of the broad groups of NA disorders characterized by degeneration of the basal ganglia, movement disorders, cognitive impairment, and psychiatric features. NA syndromes are caused by disease-specific genetic mutations. The mechanism by which these mutations cause neurodegeneration is not known.
CATEGORY    Nervous system disease
GENE        (ChAc) VPS13A [HSA:23230] [KO:K19525]
            (MLS) XK [HSA:7504] [KO:K19522]
            (HDL2) JPH3 [HSA:57338] [KO:K19530]
            (PKAN) PANK2 [HSA:80025] [KO:K09680]
COMMENT     McLeod syndrome is described in [HD:H00655].
            Chorea-acanthocytosis is described in [HD:H01432].
            PKAN is allelic with HARP syndrome.
DBLINKS     ICD-10: G23.0
            OMIM: 200150 300842 606438 607236
REFERENCE   PMID:22027213 (description, gene)
  AUTHORS   Jung HH, Danek A, Walker RH
  TITLE     Neuroacanthocytosis syndromes.
  JOURNAL   Orphanet J Rare Dis 6:68 (2011)
REFERENCE   PMID:18567359 (description, gene)
  AUTHORS   Ichiba M, Nakamura M, Sano A
  TITLE     [Neuroacanthocytosis update].
  JOURNAL   Brain Nerve 60:635-41 (2008)
///
ENTRY       H00833                      Disease
NAME        Neurodegeneration with brain iron accumulation (NBIA);
            Hallervorden-Spatz syndrome;
            Pantothenate kinase-associated neurodegeneration (PKAN);
            Neuroferritinopathy;
            Aceruloplasminemia
DESCRIPTION Neurodegeneration with brain iron accumulation (NBIA) is a group of progressive extrapyramidal and cognitive disorders characterized by iron accumulation predominantly in the globus pallidus, as well as extensive axonal spheroids in various regions of the brain. The most frequent genetic form is the pantothenate kinase-2 associated neurodegeneration (PKAN) with a mutation in the pantothenate kinase 2 (PANK2) gene. Other forms are associated with a mutation in phosphoslipase A2 (PLA2G6), FTL (neuroferritinopathy), CP (aceruloplasminemia), FA2H (Fatty acid 2-hydroxylase) and ATP13A2 (ATPase type 13A2) genes. A significant proportion of children with an NBIA phenotype have no genetic diagnosis and there are additional as yet undiscovered genes that account for a number of these cases.
CATEGORY    Nervous system disease
GENE        (NBIA1) PANK2 [HSA:80025] [KO:K09680]
            (NBIA2A, NBIA2B) PLA2G6 [HSA:8398] [KO:K16343]
            (NBIA3) FTL [HSA:2512] [KO:K13625]
            (Aceruloplasminemia) CP [HSA:1356] [KO:K13624]
            (SPG35) FA2H [HSA:79152] [KO:K19703]
            ATP13A2 [HSA:23400] [KO:K13526]
MARKER      The eye-of-the-tiger sign at MR imaging
DBLINKS     ICD-10: G23.0
            MeSH: D006211 D019150 C565699 C548080
            OMIM: 234200 256600 610217 606159 604290 612319
REFERENCE   PMID:21550835 (description, gene)
  AUTHORS   Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J
  TITLE     Ferritin as an important player in neurodegeneration.
  JOURNAL   Parkinsonism Relat Disord 17:423-30 (2011)
REFERENCE   PMID:21480873 (description, gene)
  AUTHORS   Kurian MA, McNeill A, Lin JP, Maher ER
  TITLE     Childhood disorders of neurodegeneration with brain iron accumulation (NBIA).
  JOURNAL   Dev Med Child Neurol 53:394-404 (2011)
REFERENCE   PMID:20882425
  AUTHORS   Kamate M, Mali R, Tonne V, Bubanale S
  TITLE     'Eye-of-the-tiger' sign and classic pantothenate kinase associated neurodegeneration.
  JOURNAL   Indian J Pediatr 78:121-2 (2011)
REFERENCE   PMID:20853438
  AUTHORS   Kruer MC, Paisan-Ruiz C, Boddaert N, Yoon MY, Hama H, Gregory A, Malandrini A, Woltjer RL, Munnich A, Gobin S, Polster BJ, Palmeri S, Edvardson S, Hardy J, Houlden H, Hayflick SJ
  TITLE     Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).
  JOURNAL   Ann Neurol 68:611-8 (2010)
///
ENTRY       H00834                      Disease
NAME        Guanidinoacetate methyltransferase (GAMT) deficiency
DESCRIPTION Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive inborn error of creatine biosynthesis caused by a deficiency of hepatic guanidinoacetate methyltransferase, resulting in a lack of creatine and an accumulation of guanidinoacetic acid, the precursor of creatine. GAMT deficiency is characterized by developmental arrest or delay in the first few months of life with epilepsy and extrapyramidal movements as common features. Neurologic signs and symptoms are variable, and autistic spectrum disorders are sometimes seen in older affected individuals. Pathophysiology of GAMT deficiency is thought that the accumulation of guanidinoacetate can interact with neuronal GABAA receptors and cause the neurological dysfunction which underlies these symptoms.
CATEGORY    Inherited metabolic disease
GENE        GAMT [HSA:2593] [KO:K00542]
MARKER      Decreased creatinine concentrations [CPD:C00791]
            Increased guanidinoacetate concentrations [CPD:C00581]
COMMENT     GAMT deficiency is included in Creatine deficiency syndrome. [DS:H00849]
DBLINKS     ICD-10: E72.8
            MeSH: D050937
            OMIM: 612736
REFERENCE   PMID:18708003 (description, gene, marker)
  AUTHORS   Kayser MA
  TITLE     Inherited metabolic diseases in neurodevelopmental and neurobehavioral disorders.
  JOURNAL   Semin Pediatr Neurol 15:127-31 (2008)
REFERENCE   PMID:19289269 (description, gene)
  AUTHORS   Gordon N
  TITLE     Guanidinoacetate methyltransferase deficiency (GAMT).
  JOURNAL   Brain Dev 32:79-81 (2010)
///
ENTRY       H00835                      Disease
NAME        Succinic semialdehyde dehydrogenase (SSADH) deficiency;
            4-Hydroxybutyric aciduria (4-HBA)
DESCRIPTION Succinic semialdehyde dehydrogenase (SSADH) deficiency, also known as 4-hydroxybutyric aciduria (4-HBA), is an autosomal recessive inborn error of metabolism. Clinical features include intellectual disability with prominent deficits in expressive language, hypotonia, nonprogressive ataxia, and hyporeflexia. The causative gene is aldehyde dehydrogenase 5 family, member A1 (ALDH5A1) encoding SSADH. SSADH is deficient in affected individuals impairing the formation of succinic acid from succinic semialdehyde and leading to the increased production of 4-HBA.
CATEGORY    Inherited metabolic disease
GENE        ALDH5A1 [HSA:7915] [KO:K00139]
MARKER      4-Aminobutanoate [CPD:C00989]
DRUG        Vigabatrin [DR:D00535]
DBLINKS     ICD-10: E72.8
            MeSH: C535803
            OMIM: 271980
REFERENCE   PMID:18708003 (description, gene, drug)
  AUTHORS   Kayser MA
  TITLE     Inherited metabolic diseases in neurodevelopmental and neurobehavioral disorders.
  JOURNAL   Semin Pediatr Neurol 15:127-31 (2008)
REFERENCE   PMID:19172412 (description, gene)
  AUTHORS   Pearl PL, Gibson KM, Cortez MA, Wu Y, Carter Snead O 3rd, Knerr I, Forester K, Pettiford JM, Jakobs C, Theodore WH
  TITLE     Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.
  JOURNAL   J Inherit Metab Dis 32:343-52 (2009)
///
ENTRY       H00836                      Disease
NAME        GLUT1 deficiency syndrome (GLUT1DS);
            Glucose transport defect of the blood-brain barrier
DESCRIPTION GLUT1 deficiency syndrome (GLUT1DS) is an autosomal dominant or recessive inborn error of glucose transport across the blood-brain barrier. The majority of patients carry mutations in the SLC2A1 gene encoding the GLUT1 transporter. Defects in the GLUT1 result in low cerebrospinal fluid (CSF) glucose levels termed hypoglycorrhachia. Affected individuals present with mental retardation and learning disabilities; also common are ataxia, dystonia, seizures, and acquired microcephaly.
CATEGORY    Nervous system disease; Inherited metabolic disease
GENE        GLUT1 [HSA:6513] [KO:K07299]
DBLINKS     ICD-10: G93.4
            MeSH: C536830
            OMIM: 606777 612126
REFERENCE   PMID:18708003 (description, gene)
  AUTHORS   Kayser MA
  TITLE     Inherited metabolic diseases in neurodevelopmental and neurobehavioral disorders.
  JOURNAL   Semin Pediatr Neurol 15:127-31 (2008)
REFERENCE   PMID:21962875 (description, gene)
  AUTHORS   Verrotti A, D'Egidio C, Agostinelli S, Gobbi G
  TITLE     Glut1 deficiency: when to suspect and how to diagnose?
  JOURNAL   Eur J Paediatr Neurol 16:3-9 (2012)
REFERENCE   PMID:21382692 (description, gene)
  AUTHORS   Klepper J
  TITLE     GLUT1 deficiency syndrome in clinical practice.
  JOURNAL   Epilepsy Res (2011)
///
ENTRY       H00837                      Disease
NAME        Leber congenital amaurosis (LCR)
DESCRIPTION Leber congenital amaurosis (LCA) is a heterogeneous group of severe retinal degenerations, which typically becomes evident in the first year of life. Affected infants have little or no retinal photoreceptor function as tested by electroretinography. LCA is generally inherited in an autosomal recessive manner, and caused by mutations in more than a dozen genes. Several have been demonstrated as potentially efficacious gene therapy targets.
CATEGORY    Nervous system disease; Eye disease
GENE        (LCR1) GUCY2D [HSA:3000] [KO:K12321]
            (LCA2) RPE65 [HSA:6121] [KO:K11158]
            (LCA3) SPATA7 [HSA:55812] [KO:K19655]
            (LCA4) AIPL1 [HSA:23746] [KO:K17767]
            (LCA5) LCA5 [HSA:167691]
            (LCA6) RPGRIP1 [HSA:57096] [KO:K16512]
            (LCA7) CRX [HSA:1406] [KO:K09337]
            (LCA8) CRB1 [HSA:23418] [KO:K16681]
            (LCA10) CEP290 [HSA:80184] [KO:K16533]
            (LCA11) IMPDH1 [HSA:3614] [KO:K00088]
            (LCA12) RD3 [HSA:343035]
            (LCA13) RDH12 [HSA:145226] [KO:K11153]
            (LCA14) LRAT [HSA:9227] [KO:K00678]
            (LCA15) TULP1 [HSA:7287] [KO:K19600]
            (LCA16) KCNJ13 [HSA:3769] [KO:K05006]
DRUG        Gene therapy
DBLINKS     ICD-10: H35.5
            MeSH: D057130
            OMIM: 204000 204100 604232 604393 604537 613826 613829 613835 611755 613837 610612 612712 613341 613843 614186
REFERENCE   PMID:20301475
  AUTHORS   Weleber RG, Francis PJ, Trzupek KM
  TITLE     Leber Congenital Amaurosis
  JOURNAL   (1993)
REFERENCE   PMID:21705775
  AUTHORS   Liu MM, Tuo J, Chan CC
  TITLE     Republished review: Gene therapy for ocular diseases.
  JOURNAL   Postgrad Med J 87:487-95 (2011)
REFERENCE   PMID:20399883
  AUTHORS   Cideciyan AV
  TITLE     Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.
  JOURNAL   Prog Retin Eye Res 29:398-427 (2010)
///
ENTRY       H00838                      Disease
NAME        Congenital fibrosis of the extraocular muscles (CFEOM)
DESCRIPTION Congenital fibrosis of the extraocular muscles (CFEOM) describes a group of rare congenital eye movement disorders that result from the dysfunction of all or part of the oculomotor (CN 3) and the trochlear (CN 4) nerves, and/or the muscles these nerves innervate. CFEOM is characterized by non-progressive, restrictive ophthalmoplegia of the extraocular muscles and congenital blepharoptosis. Several clinical phenotypes for familial CFEOM have been delineated.
CATEGORY    Nervous system disease; Eye disease
GENE        (CFEOM1, CFEOM3B) KIF21A [HSA:55605] [KO:K10395]
            (CFEOM2) PHOX2A [HSA:401] [KO:K09330]
            (CFEOM3A) TUBB3 [HSA:10381] [KO:K07375]
            (CFEOM5) COL25A1 [HSA:84570]
DBLINKS     ICD-10: H49.8
            MeSH: C580012
            OMIM: 135700 602078 600638 616219
REFERENCE   PMID:21217899 (description, gene)
  AUTHORS   Cooymans P, Al-Zuhaibi S, Al-Senawi R, Ganesh A
  TITLE     Congenital fibrosis of the extraocular muscles.
  JOURNAL   Oman J Ophthalmol 3:70-4 (2010)
REFERENCE   PMID:18214786 (description)
  AUTHORS   Heidary G, Engle EC, Hunter DG
  TITLE     Congenital fibrosis of the extraocular muscles.
  JOURNAL   Semin Ophthalmol 23:3-8 (2008)
REFERENCE   PMID:20074521 (gene)
  AUTHORS   Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, Chan WM, Andrews C, Demer JL, Robertson RL, Mackey DA, Ruddle JB, Bird TD, Gottlob I, Pieh C, Traboulsi EI, Pomeroy SL, Hunter DG, Soul JS, Newlin A, Sabol LJ, Doherty EJ, de Uzcategui CE, de Uzcategui N, Collins ML, Sener EC, Wabbels B, Hellebrand H, Meitinger T, de Berardinis T, Magli A, Schiavi C, Pastore-Trossello M, Koc F, Wong AM, Levin AV, Geraghty MT, Descartes M, Flaherty M, Jamieson RV, Moller HU, Meuthen I, Callen DF, Kerwin J, Lindsay S, Meindl A, Gupta ML Jr, Pellman D, Engle EC
  TITLE     Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance.
  JOURNAL   Cell 140:74-87 (2010)
REFERENCE   PMID:25500261 (gene)
  AUTHORS   Shinwari JM, Khan A, Awad S, Shinwari Z, Alaiya A, Alanazi M, Tahir A, Poizat C, Al Tassan N
  TITLE     Recessive mutations in COL25A1 are a cause of congenital cranial dysinnervation disorder.
  JOURNAL   Am J Hum Genet 96:147-52 (2015)
///
ENTRY       H00839                      Disease
NAME        Porencephaly
DESCRIPTION Porencephaly is a rare disease of central nervous system characterized by the existence of degenerative cavities filled with cerebrospinal fluid in the brain. It is probably caused by perinatal intracerebral hemorrhages.
CATEGORY    Nervous system disease
GENE        COL4A1 [HSA:1282] [KO:K06237]
DBLINKS     ICD-10: Q04.6 G93.0
            MeSH: C536850
            OMIM: 175780
REFERENCE   PMID:20196853 (description)
  AUTHORS   Douzenis A, Rizos EN, Papadopoulou A, Papathanasiou M, Lykouras L
  TITLE     Porencephaly and psychosis: a case report and review of the literature.
  JOURNAL   BMC Psychiatry 10:19 (2010)
REFERENCE   PMID:21157337 (description, gene)
  AUTHORS   Vahedi K, Alamowitch S
  TITLE     Clinical spectrum of type IV collagen (COL4A1) mutations: a novel genetic multisystem disease.
  JOURNAL   Curr Opin Neurol 24:63-8 (2011)
REFERENCE   PMID:16107487 (description, gene)
  AUTHORS   Breedveld G, de Coo IF, Lequin MH, Arts WF, Heutink P, Gould DB, John SW, Oostra B, Mancini GM
  TITLE     Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly.
  JOURNAL   J Med Genet 43:490-5 (2006)
REFERENCE   PMID:15905400 (description, gene)
  AUTHORS   Gould DB, Phalan FC, Breedveld GJ, van Mil SE, Smith RS, Schimenti JC, Aguglia U, van der Knaap MS, Heutink P, John SW
  TITLE     Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly.
  JOURNAL   Science 308:1167-71 (2005)
///
ENTRY       H00840                      Disease
NAME        Band-like calcification with simplified gyration and polymicrogyria (BLC-PMG);
            Pseudo-TORCH syndrome
DESCRIPTION Band-like calcification with simplified gyration and polymicrogyria (BLC-PMG) is a rare neurological disorder characterized by intracranial calcification and polymicrogyria. This combination is usually seen when congenital infection occurs (TORCH syndrome), but no infectious agents are detected in BLC-PMG (pseudo-TORCH syndrome). Affected individuals show early-onset seizures and severe microcephaly.
CATEGORY    Nervous system disease
GENE        OCLN [HSA:100506658] [KO:K06088]
DBLINKS     OMIM: 251290
REFERENCE   PMID:20727516 (description, gene)
  AUTHORS   O'Driscoll MC, Daly SB, Urquhart JE, Black GC, Pilz DT, Brockmann K, McEntagart M, Abdel-Salam G, Zaki M, Wolf NI, Ladda RL, Sell S, D'Arrigo S, Squier W, Dobyns WB, Livingston JH, Crow YJ
  TITLE     Recessive mutations in the gene encoding the tight junction protein occludin cause band-like calcification with simplified gyration and polymicrogyria.
  JOURNAL   Am J Hum Genet 87:354-64 (2010)
REFERENCE   PMID:19012351 (description, gene)
  AUTHORS   Briggs TA, Wolf NI, D'Arrigo S, Ebinger F, Harting I, Dobyns WB, Livingston JH, Rice GI, Crooks D, Rowland-Hill CA, Squier W, Stoodley N, Pilz DT, Crow YJ
  TITLE     Band-like intracranial calcification with simplified gyration and polymicrogyria: a distinct "pseudo-TORCH" phenotype.
  JOURNAL   Am J Med Genet A 146A:3173-80 (2008)
///
ENTRY       H00841                      Disease
NAME        Infantile progressive bulbar palsy, including:
            Brown-Vialetto-Van Laere syndrome (BVVLS) ;
            Fazio-Londe disease
DESCRIPTION Infantile progressive bulbar palsy is a rare neurological disorder that occurs in children. Infantile progressive bulbar palsy presents as following two forms. The Brown-Vialetto-Van Laere syndrome (BVVLS) is characterized by progressive pontobulbar palsy associated with sensorineural deafness. The same clinical presentation without deafness is also known as Fazio Londe disease. Both are caused by mutation in the RFT2 gene.
CATEGORY    Neurodegenerative disease
GENE        RFT2 [HSA:113278] [KO:K14620]
DBLINKS     ICD-10: G12.1 G12.2
            OMIM: 211500 211530
REFERENCE   PMID:12427524
  AUTHORS   Voudris KA, Skardoutsou A, Vagiakou EA
  TITLE     Infantile progressive bulbar palsy with deafness.
  JOURNAL   Brain Dev 24:732-5 (2002)
REFERENCE   PMID:21110228
  AUTHORS   Bosch AM, Abeling NG, Ijlst L, Knoester H, van der Pol WL, Stroomer AE, Wanders RJ, Visser G, Wijburg FA, Duran M, Waterham HR
  TITLE     Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment.
  JOURNAL   J Inherit Metab Dis 34:159-64 (2011)
REFERENCE   PMID:18416855
  AUTHORS   Sathasivam S
  TITLE     Brown-Vialetto-Van Laere syndrome.
  JOURNAL   Orphanet J Rare Dis 3:9 (2008)
REFERENCE   PMID:16122634
  AUTHORS   Dipti S, Childs AM, Livingston JH, Aggarwal AK, Miller M, Williams C, Crow YJ
  TITLE     Brown-Vialetto-Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease.
  JOURNAL   Brain Dev 27:443-6 (2005)
///
ENTRY       H00842                      Disease
NAME        Epidermodysplasia verruciformis
DESCRIPTION Epidermodysplasia verruciformis is a rare genodermatosis characterized by an increased susceptibility to human papillomavirus infection. It appears during childhood with flat wart-like lesions and pityriasis versicolor-like hypo/hyperpigmented macules that can develop carcinomas.
CATEGORY    Skin and connective tissue disease
GENE        EVER1 [HSA:11322]
            EVER2 [HSA:147138]
DBLINKS     MeSH: D004819
            OMIM: 226400
REFERENCE   PMID:17910717 (description)
  AUTHORS   Gul U, Kilic A, Gonul M, Cakmak SK, Bayis SS
  TITLE     Clinical aspects of epidermodysplasia verruciformis and review of the literature.
  JOURNAL   Int J Dermatol 46:1069-72 (2007)
REFERENCE   PMID:18317036 (description, gene)
  AUTHORS   Gewirtzman A, Bartlett B, Tyring S
  TITLE     Epidermodysplasia verruciformis and human papilloma virus.
  JOURNAL   Curr Opin Infect Dis 21:141-6 (2008)
REFERENCE   PMID:21178278 (description)
  AUTHORS   Patel T, Morrison LK, Rady P, Tyring S
  TITLE     Epidermodysplasia verruciformis and susceptibility to HPV.
  JOURNAL   Dis Markers 29:199-206 (2010)
///
ENTRY       H00843                      Disease
NAME        Hartnup disorder
DESCRIPTION Hartnup disorder is an autosomal recessive defect of neutral amino acid transport in kidney and intestine accompanied by the symptoms including pellagra-like photo-sensitive skin rash, cerebellar ataxia, and renal aminoaciduria. It is caused by hereditary abnormalities in the neutral amino acid transporter B0AT1 (SLC6A19) in apical membrane.
CATEGORY    Inherited metabolic disease
GENE        SLC6A19 [HSA:340024] [KO:K05334]
DBLINKS     ICD-10: E72.0
            MeSH: D006250
            OMIM: 234500
REFERENCE   PMID:15681018 (description, gene)
  AUTHORS   Kraut JA, Sachs G
  TITLE     Hartnup disorder: unraveling the mystery.
  JOURNAL   Trends Pharmacol Sci 26:53-5 (2005)
REFERENCE   PMID:19967017 (description)
  AUTHORS   Patel AB, Prabhu AS
  TITLE     Hartnup disease.
  JOURNAL   Indian J Dermatol 53:31-2 (2008)
REFERENCE   PMID:19472175 (description, gene)
  AUTHORS   Broer S
  TITLE     The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition.
  JOURNAL   IUBMB Life 61:591-9 (2009)
///
ENTRY       H00844                      Disease
NAME        Familial benign chronic pemphigus;
            Benign familial pemphigus;
            Hailey-Hailey disease
DESCRIPTION Familial benign chronic pemphigus, also known as Hailey-Hailey disease, is a rare, autosomal dominant skin disorder. The clinical features are uncomfortable skin blisters and vegetative lesions caused by friction. Lesions generally begin between 20 and 40 years of age. In two third of all cases, positive family history is detected. Mutations in ATP2C1 that encodes a secretory pathway Ca2+/Mn2+-ATPase in the Golgi apparatus impair desmosomal keratinocyte adhesion in Hailey-Hailey disease.
CATEGORY    Developmental disorder; Skin and connective tissue disease
GENE        ATP2C1 [HSA:27032] [KO:K01537]
DBLINKS     ICD-10: Q82.8
            MeSH: D016506
            OMIM: 169600
REFERENCE   PMID:15149492 (description, gene)
  AUTHORS   Dhitavat J, Fairclough RJ, Hovnanian A, Burge SM
  TITLE     Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey-Hailey  disease.
  JOURNAL   Br J Dermatol 150:821-8 (2004)
REFERENCE   PMID:10615129 (description, gene)
  AUTHORS   Hu Z, Bonifas JM, Beech J, Bench G, Shigihara T, Ogawa H, Ikeda S, Mauro T, Epstein EH Jr
  TITLE     Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease.
  JOURNAL   Nat Genet 24:61-5 (2000)
REFERENCE   PMID:26051060
  AUTHORS   Engin B, Kutlubay Z, Celik U, Serdaroglu S, Tuzun Y
  TITLE     Hailey-Hailey disease: A fold (intertriginous) dermatosis.
  JOURNAL   Clin Dermatol 33:452-5 (2015)
///
ENTRY       H00845                      Disease
NAME        Familial amyloidosis
DESCRIPTION The amyloidoses are a group of diseases in which proteins that are normally soluble deposit extracellularly in tissues as insoluble fibrils. The fibrils have a characteristic beta-pleated sheet configuration that renders them avid for Congo red dye. In the familial amyloidoses, a gene mutation inherited in an autosomal-dominant manner results in a single amino acid substitution that renders a plasma protein amyloidogenic. Mutations in the TTR gene are the most common cause of familial amyloidosis. The clinical features of familial amyloidosis vary depending on the underlying amyloidogenic protein and the particular amino acid affected by the mutation, ranging from peripheral and autonomic neuropathy to cardiomyopathy.
CATEGORY    Nervous system disease; Inherited metabolic disease
GENE        TTR [HSA:7276] [KO:K20731]
            APOA1 [HSA:335] [KO:K08757]
            APOA2 [HSA:336] [KO:K08758]
            FGA [HSA:2243] [KO:K03903]
            LYZ [HSA:4069] [KO:K13915]
            GSN [HSA:2934] [KO:K05768]
DBLINKS     ICD-10: E85
            MeSH: D028226
            OMIM: 105210 105200 602078 105200 153450 105120
REFERENCE   PMID:16105087 (description, gene)
  AUTHORS   Dember LM
  TITLE     Emerging treatment approaches for the systemic amyloidoses.
  JOURNAL   Kidney Int 68:1377-90 (2005)
///
ENTRY       H00846                      Disease
NAME        Fuhrmann syndrome;
            Fibular aplasia or hypoplasia, femoral bowing and poly-, syn-, and oligodactyly
DESCRIPTION Fuhrmann syndrome is a non-lethal limb malformation disorder with various degrees of limb aplasia/hypoplasia and joint dysplasia. Major manifestations include hypoplasia of the pelvis, aplasia or hypoplasia of fibulae, severe bowing of femora, absence of nails, and polydactyly.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        WNT7A [HSA:7476] [KO:K00572]
DBLINKS     ICD-10: Q74.8
            MeSH: C538189
            OMIM: 228930
REFERENCE   PMID:1785629 (description)
  AUTHORS   Lipson AH, Kozlowski K, Barylak A, Marsden W
  TITLE     Fuhrmann syndrome of right-angle bowed femora, absence of fibulae and digital anomalies: two further cases.
  JOURNAL   Am J Med Genet 41:176-9 (1991)
REFERENCE   PMID:7363910 (description)
  AUTHORS   Fuhrmann W, Fuhrmann-Rieger A, de Sousa F
  TITLE     Poly-, syn- and oligodactylyl, aplasia or hypoplasia of fibula, hypoplasia of pelvis and bowing of femora in three sibs--a new autosomal recessive syndrome.
  JOURNAL   Eur J Pediatr 133:123-9 (1980)
REFERENCE   PMID:16826533 (description, gene)
  AUTHORS   Woods CG, Stricker S, Seemann P, Stern R, Cox J, Sherridan E, Roberts E, Springell K, Scott S, Karbani G, Sharif SM, Toomes C, Bond J, Kumar D, Al-Gazali L, Mundlos S
  TITLE     Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome.
  JOURNAL   Am J Hum Genet 79:402-8 (2006)
///
ENTRY       H00847                      Disease
NAME        Al-Awadi/Raas-Rothschild syndrome;
            Ulna and fibula, absence of, with sever limb deficiency
DESCRIPTION Al-Awadi/Raas-Rothschild syndrome is a limb malformation disorder that has overlapping phenotype with Fuhrmann syndrome, but more-severe limb truncation is observed. This is due to complete loss of WNT7A function in Al-Awadi/Raas-Rothschild syndrome whereas impairment is partial in Fuhrmann syndrome.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        WNT7A [HSA:7476] [KO:K00572]
DBLINKS     ICD-10: Q87.2
            MeSH: C535612
            OMIM: 276820
REFERENCE   PMID:8423611 (description)
  AUTHORS   Camera G, Ferraiolo G, Leo D, Spaziale A, Pozzolo S
  TITLE     Limb/pelvis-hypoplasia/aplasia syndrome (Al-Awadi/Raas-Rothschild syndrome): report of two Italian sibs and further confirmation of autosomal recessive inheritance.
  JOURNAL   J Med Genet 30:65-9 (1993)
REFERENCE   PMID:16826533 (description, gene)
  AUTHORS   Woods CG, Stricker S, Seemann P, Stern R, Cox J, Sherridan E, Roberts E, Springell K, Scott S, Karbani G, Sharif SM, Toomes C, Bond J, Kumar D, Al-Gazali L, Mundlos S
  TITLE     Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome.
  JOURNAL   Am J Hum Genet 79:402-8 (2006)
REFERENCE   PMID:21271649 (description, gene)
  AUTHORS   Garavelli L, Wischmeijer A, Rosato S, Gelmini C, Reverberi S, Sassi S, Ferrari A, Mari F, Zabel B, Lausch E, Unger S, Superti-Furga A
  TITLE     Al-Awadi-Raas-Rothschild (limb/pelvis/uterus-hypoplasia/aplasia) syndrome and WNT7A mutations: genetic homogeneity and nosological delineation.
  JOURNAL   Am J Med Genet A 155A:332-6 (2011)
///
ENTRY       H00848                      Disease
NAME        Ataxia with ocular apraxia (AOA), including:
            Ataxia telangiectasia (AT);
            Ataxia telangiectasia like disorder (ATLD);
            Ataxia oculomotor apraxia type 1 (AOA1);
            Ataxia oculomotor apraxia type 2 (AOA2)
DESCRIPTION Ataxia with oculomotor apraxia (AOA) is a group of autosomal recessive cerebellar ataxias mainly characterized by ataxia, oculomotor apraxia and choreoathetosis. AOA includes ataxia telangiectasia (AT), ataxia telangiectasia like disorder (ATLD), ataxia oculomotor apraxia type 1 (AOA1) and ataxia oculomotor apraxia type 2 (AOA2). AT, ATLD, and AOA1 are due to homozygous mutations in genes encoding a protein involved in DNA repair. Ophthalmic features of AT include conjunctival telangiectasia, strabismus, saccadic dysfunction with head thrusts, and convergence insufficiency. AOA1 is typically characterized by early-onset cerebellar ataxia, oculomotor apraxia, hypoalbuminemia, hypercholesterolemia and late axonal sensori-motor neuropathy. The gene mutated in AOA2, SETX, encodes senataxin, a putative DNA/RNA helicase which has been shown to play a role in the response to oxidative stress.
CATEGORY    Nervous system disease; Eye disease
GENE        (AT) ATM [HSA:472] [KO:K04728]
            (ATLD) MRE11A [HSA:4361] [KO:K10865]
            (AOA1) APTX [HSA:54840] [KO:K10863] 
            (AOA2) SETX [HSA:23064] [KO:K10706]
COMMENT     AT and ATLD are also described in H00064 and H00094. [DS:H00064] [DS:H00094]
DBLINKS     ICD-10: G11.3 G60.2
            MeSH: C538013
            OMIM: 208900 604391 208920 606002
REFERENCE   PMID:21324166
  AUTHORS   Bohlega SA, Shinwari JM, Al Sharif LJ, Khalil DS, Alkhairallah TS, Al Tassan NA
  TITLE     Clinical and molecular characterization of ataxia with oculomotor apraxia patients in Saudi Arabia.
  JOURNAL   BMC Med Genet 12:27 (2011)
REFERENCE   PMID:17572444
  AUTHORS   Ferrarini M, Squintani G, Cavallaro T, Ferrari S, Rizzuto N, Fabrizi GM
  TITLE     A novel mutation of aprataxin associated with ataxia ocular apraxia type 1: phenotypical and genotypical characterization.
  JOURNAL   J Neurol Sci 260:219-24 (2007)
REFERENCE   PMID:19515850
  AUTHORS   Suraweera A, Lim Y, Woods R, Birrell GW, Nasim T, Becherel OJ, Lavin MF
  TITLE     Functional role for senataxin, defective in ataxia oculomotor apraxia type 2, in  transcriptional regulation.
  JOURNAL   Hum Mol Genet 18:3384-96 (2009)
///
ENTRY       H00849                      Disease
NAME        Creatine deficiency syndrome, including:
            Arginine:glycine amidinotransferase deficiency (AGAT deficiency);
            Guanidinoacetate methyltransferase deficiency (GAMT deficiency);
            X-linked creatine deficiency syndrome (XL-CDS)
DESCRIPTION The creatine deficiency syndrome is a group of inborn errors of creatine metabolism, that includes guanidinoacetate methyltransferase (GAMT) deficiency, arginine:glycine amidinotransferase (AGAT) deficiency, and X-linked creatine deficiency syndrome (XL-CDS). Intellectual disability and seizures are common to all three disorders. GAMT deficiency and AGAT deficiency are creatine biosynthesis disorders and inherited in an autosomal recessive manner. XL-CDS is the creatine transporter (SLC6A8) deficiency.
CATEGORY    Inherited metabolic disease; Mental retardation
GENE        (XL-CDS) SLC6A8 [HSA:6535] [KO:K05039]
            (AGAT deficiency) GATM [HSA:2628] [KO:K00613]
            (GAMT deficiency) GAMT [HSA:2593] [KO:K00542]
DRUG        (GAMT deficiency and AGAT deficiency) Creatine monohydrate
            (GAMT deficiency) Ornithine [DR:D08302] Arginine [DR:D02982]
COMMENT     XL-CDS is also included in syndromic X-linked mental retardation. [DS:H00577]
            GAMT deficiency is also described in H00834. [DS:H00834]
DBLINKS     ICD-10: E72.8
            MeSH: C535598 C567192 C537622
            OMIM: 612718 612736 300352
REFERENCE   PMID:19879361
  AUTHORS   Braissant O, Beard E, Torrent C, Henry H
  TITLE     Dissociation of AGAT, GAMT and SLC6A8 in CNS: relevance to creatine deficiency syndromes.
  JOURNAL   Neurobiol Dis 37:423-33 (2010)
REFERENCE   PMID:20301745
  AUTHORS   Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S, Salomons GS
  TITLE     Creatine Deficiency Syndromes
  JOURNAL   (1993)
///
ENTRY       H00850                      Disease
NAME        Frontorhiny
DESCRIPTION Frontorhiny is a recently characterized autosomal recessive frontonasal malformation with hypertelorism, abnormal nasal configuration, and cleft lip. This disorder is caused by disturbed developmental sequence between 4 and 8 weeks in which formation of the face takes place.
CATEGORY    Developmental disorder
GENE        ALX3 [HSA:257] [KO:K09323]
DBLINKS     ICD-10: Q75.8
            MeSH: C538065
            OMIM: 136760
REFERENCE   PMID:19409524 (description, gene)
  AUTHORS   Twigg SR, Versnel SL, Nurnberg G, Lees MM, Bhat M, Hammond P, Hennekam RC, Hoogeboom AJ, Hurst JA, Johnson D, Robinson AA, Scambler PJ, Gerrelli D, Nurnberg P, Mathijssen IM, Wilkie AO
  TITLE     Frontorhiny, a distinctive presentation of frontonasal dysplasia caused by recessive mutations in the ALX3 homeobox gene.
  JOURNAL   Am J Hum Genet 84:698-705 (2009)
REFERENCE   PMID:22106187 (description)
  AUTHORS   Pham NS, Rafii A, Liu J, Boyadjiev SA, Tollefson TT
  TITLE     Clinical and genetic characterization of frontorhiny: report of 3 novel cases and discussion of the surgical management.
  JOURNAL   Arch Facial Plast Surg 13:415-20 (2011)
///
ENTRY       H00851                      Disease
NAME        Synpolydactyly 2;
            Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses
DESCRIPTION Synpolydactyly 2 (Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses) is a very rare skeletal dysplasia; only one family has been described. Affected individuals show synostosis between 4/5 metacarpals and shortening of third and fourth metatarsals in addition to typical synpolydactyly.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FBLN1 [HSA:2192] [KO:K17307]
DBLINKS     ICD-10: Q70.0 Q70.2
            MeSH: C564278
            OMIM: 608180
REFERENCE   PMID:11836357 (description, gene)
  AUTHORS   Debeer P, Schoenmakers EF, Twal WO, Argraves WS, De Smet L, Fryns JP, Van De Ven WJ
  TITLE     The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly.
  JOURNAL   J Med Genet 39:98-104 (2002)
REFERENCE   PMID:9690000 (description)
  AUTHORS   Debeer P, Schoenmakers EF, De Smet L, Van de Ven WJ, Fryns JP
  TITLE     Co-segregation of an apparently balanced reciprocal t(12;22)(p11.2;q13.3) with a  complex type of 3/3'/4 synpolydactyly associated with metacarpal, metatarsal and  tarsal synostoses in three family members.
  JOURNAL   Clin Dysmorphol 7:225-8 (1998)
REFERENCE   PMID:18177473 (description, gene)
  AUTHORS   Malik S, Grzeschik KH
  TITLE     Synpolydactyly: clinical and molecular advances.
  JOURNAL   Clin Genet 73:113-20 (2008)
///
ENTRY       H00852                      Disease
NAME        Klippel-Feil syndrome(KFS)
DESCRIPTION Klippel-Feil syndrome (KFS) is a rare disorder characterized by congenital fusion of two or more cervical vertebrae. Scoliosis, mirror movements, otolaryngological, kidney, ocular, cranial, limb, and/or digit anomalies are often associated. It has been reported that KFS is caused by mutations in the GDF6 or GDF3 genes in an autosomal dominant manner. Although KFS is also inherited in an autosomal recessive manner, the gene involved is unknown.
CATEGORY    Developmental disorder
GENE        (KFS1) GDF6 [HSA:392255] [KO:K20012]
            (KFS3) GDF3 [HSA:9573] [KO:K05495]
DBLINKS     ICD-10: Q76.1
            MeSH: D007714
            OMIM: 118100 613702
REFERENCE   PMID:1610048
  AUTHORS   Smith BA, Griffin C
  TITLE     Klippel-Feil syndrome.
  JOURNAL   Ann Emerg Med 21:876-9 (1992)
REFERENCE   PMID:12968241
  AUTHORS   Farid IS, Omar OA, Insler SR
  TITLE     Multiple anesthetic challenges in a patient with Klippel-Feil Syndrome undergoing cardiac surgery.
  JOURNAL   J Cardiothorac Vasc Anesth 17:502-5 (2003)
REFERENCE   PMID:18425797
  AUTHORS   Tassabehji M, Fang ZM, Hilton EN, McGaughran J, Zhao Z, de Bock CE, Howard E, Malass M, Donnai D, Diwan A, Manson FD, Murrell D, Clarke RA
  TITLE     Mutations in GDF6 are associated with vertebral segmentation defects in Klippel-Feil syndrome.
  JOURNAL   Hum Mutat 29:1017-27 (2008)
REFERENCE   PMID:19864492
  AUTHORS   Ye M, Berry-Wynne KM, Asai-Coakwell M, Sundaresan P, Footz T, French CR, Abitbol M, Fleisch VC, Corbett N, Allison WT, Drummond G, Walter MA, Underhill TM, Waskiewicz AJ, Lehmann OJ
  TITLE     Mutation of the bone morphogenetic protein GDF3 causes ocular and skeletal anomalies.
  JOURNAL   Hum Mol Genet 19:287-98 (2010)
///
ENTRY       H00853                      Disease
NAME        Cenani-Lenz syndactyly syndrome
DESCRIPTION Cenani-Lenz syndactyly syndrome is an autosomal-recessive congenital malformation syndrome characterized by syndactyly and/or oligodactyly and kidney anomalies. The cause of Cenani-Lenz syndactyly syndrome is LRP4, a low-density lipoprotein receptor that modulates Wnt signaling.
CATEGORY    Developmental disorder; Skeletal dysplasia; Kidney disease
GENE        LRP4 [HSA:4038] [KO:K20051]
DBLINKS     ICD-10: Q78.4
            MeSH: C538150
            OMIM: 212780
REFERENCE   PMID:20381006 (description, gene)
  AUTHORS   Li Y, Pawlik B, Elcioglu N, Aglan M, Kayserili H, Yigit G, Percin F, Goodman F, Nurnberg G, Cenani A, Urquhart J, Chung BD, Ismail S, Amr K, Aslanger AD, Becker C, Netzer C, Scambler P, Eyaid W, Hamamy H, Clayton-Smith J, Hennekam R, Nurnberg P, Herz J, Temtamy SA, Wollnik B
  TITLE     LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome.
  JOURNAL   Am J Hum Genet 86:696-706 (2010)
REFERENCE   PMID:20454682 (description)
  AUTHORS   Karner CM, Dietrich MF, Johnson EB, Kappesser N, Tennert C, Percin F, Wollnik B, Carroll TJ, Herz J
  TITLE     Lrp4 regulates initiation of ureteric budding and is crucial for kidney formation--a mouse model for Cenani-Lenz syndrome.
  JOURNAL   PLoS One 5:e10418 (2010)
///
ENTRY       H00854                      Disease
NAME        Wolfram syndrome (WFS);
            DIDMOAD syndrome
DESCRIPTION Wolfram syndrome (WFS) is a rare hereditary neurodegenerative disorder also known as DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). Two different categories of WFS (WFS1 and 2) are recognized, each with its own subset of variable symptoms, and resulting from mutations in the WFS1 and CISD2 genes, respectively. The WFS1 encodes an endoplasmic reticulum membrane-embedded protein. ERIS, the protein that CISD2 encodes, also localizes to the endoplasmic reticulum.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease
GENE        (WFS1) WFS1 [HSA:7466] [KO:K14020]
            (WFS2) CISD2 [HSA:493856]
DBLINKS     ICD-10: E10.7 H48.0
            MeSH: D014929
            OMIM: 222300 604928
REFERENCE   PMID:15070927
  AUTHORS   Medlej R, Wasson J, Baz P, Azar S, Salti I, Loiselet J, Permutt A, Halaby G
  TITLE     Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese  population.
  JOURNAL   J Clin Endocrinol Metab 89:1656-61 (2004)
REFERENCE   PMID:20649540
  AUTHORS   Chen YF, Wu CY, Kirby R, Kao CH, Tsai TF
  TITLE     A role for the CISD2 gene in lifespan control and human disease.
  JOURNAL   Ann N Y Acad Sci 1201:58-64 (2010)
REFERENCE   PMID:20738327
  AUTHORS   Rigoli L, Lombardo F, Di Bella C
  TITLE     Wolfram syndrome and WFS1 gene.
  JOURNAL   Clin Genet 79:103-17 (2011)
///
ENTRY       H00855                      Disease
NAME        Triphalangeal thumb, including:
            Triphalangeal thumb;
            Triphalangeal thumb-polysyndactyly syndrome
DESCRIPTION Triphalangeal thumb (TPT) is a rare human hand-foot malformation characterized by a long, finger-like thumb with three phalanges. It can occur either in isolated form or in association with other defects such as triphalangeal thumb-polydactyly syndrome (TPT-PS). TPT is caused by defects in a cis-regulatory sequence ZRS, located in intron 5 of LMBR1, which is crucial for expression of sonic hedgehog (SHH) during limb development.
CATEGORY    Skeletal dysplasia
GENE        LMBR1 (mutation in intron 5) [HSA:64327]
DBLINKS     ICD-10: Q74.0
            MeSH: C573898
            OMIM: 174500
REFERENCE   PMID:16424565 (description)
  AUTHORS   Jain V
  TITLE     Bilateral triphalangeal thumbs.
  JOURNAL   Indian Pediatr 42:1246-7 (2005)
REFERENCE   PMID:17300748 (description, gene)
  AUTHORS   Wang ZQ, Tian SH, Shi YZ, Zhou PT, Wang ZY, Shu RZ, Hu L, Kong X
  TITLE     A single C to T transition in intron 5 of LMBR1 gene is associated with triphalangeal thumb-polysyndactyly syndrome in a Chinese family.
  JOURNAL   Biochem Biophys Res Commun 355:312-7 (2007)
REFERENCE   PMID:20068592 (description, gene)
  AUTHORS   Farooq M, Troelsen JT, Boyd M, Eiberg H, Hansen L, Hussain MS, Rehman S, Azhar A, Ali A, Bakhtiar SM, Tommerup N, Baig SM, Kjaer KW
  TITLE     Preaxial polydactyly/triphalangeal thumb is associated with changed transcription factor-binding affinity in a family with a novel point mutation in the long-range cis-regulatory element ZRS.
  JOURNAL   Eur J Hum Genet 18:733-6 (2010)
REFERENCE   PMID:12837695 (description, gene)
  AUTHORS   Lettice LA, Heaney SJ, Purdie LA, Li L, de Beer P, Oostra BA, Goode D, Elgar G, Hill RE, de Graaff E
  TITLE     A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly.
  JOURNAL   Hum Mol Genet 12:1725-35 (2003)
REFERENCE   PMID:21342803 (description)
  AUTHORS   Gosk J, Rutowski R, Urban M, Koszewicz M, Moron K
  TITLE     Rare triphalangeal thumb polydactyly: a case report.
  JOURNAL   J Plast Reconstr Aesthet Surg 64:e165-6 (2011)
REFERENCE   PMID:10869115 (description)
  AUTHORS   Kantaputra PN, Chalidapong P
  TITLE     Are triphalangeal thumb-polysyndactyly syndrome (TPTPS) and tibial hemimelia-polysyndactyly-triphalangeal thumb syndrome (THPTTS) identical? A father with TPTPS and his daughter with THPTTS in a Thai family.
  JOURNAL   Am J Med Genet 93:126-31 (2000)
///
ENTRY       H00856                      Disease
NAME        Distal hereditary motor neuropathies (dHMN)
DESCRIPTION Distal hereditary motor neuropathies (dHMN) comprise a heterogenous group of diseases that share the common feature of a length-dependent predominantly motor neuropathy. Many forms of dHMN have minor sensory abnormalities and/or a significant upper-motor-neuron component, and there is often an overlap with the axonal forms of Charcot-Marie-Tooth disease (CMT2) [DS:H00264] and with juvenile forms of amyotrophic lateral sclerosis [DS:H00058] and hereditary spastic paraplegia [DS:H00266]. The causative genes with autosomal dominant, recessive, and X-linked patterns of inheritance have implicated proteins with diverse functions.
CATEGORY    Nervous system disease
GENE        (dHMN1/2) HSPB1 [HSA:3315] [KO:K04455]
            (dHMN1/2) HSPB8 [HSA:26353] [KO:K08879]
            (dHMN2) HSPB3 [HSA:26353] [KO:K08879]
            (dHMN1/5) GARS [HSA:2617] [KO:K01880]
            (dHMN1) DYNC1H1 [HSA:1778] [KO:K10413]
            (dHMN2/5/dHMN and pyramidal features) BSCL2 [HSA:26580] [KO:K19365]
            (dHMN6) IGHMBP2 [HSA:3508] [KO:K19036]
            (dHMN7) DCTN1 [HSA:1639] [KO:K04648]
            (dHMN7/Congenital distal SMA) TRPV4 [HSA:59341] [KO:K04973]
            (X-linked dHMN) ATP7A [HSA:538] [KO:K17686]
            (dHMN and pyramidal features) SETX [HSA:23064] [KO:K10706]
DBLINKS     ICD-10: G12.1 G12.2
            OMIM: 608634 158590 613376 600794 600794 604320 607641 606071 300489
REFERENCE   PMID:22028385 (description, gene)
  AUTHORS   Rossor AM, Kalmar B, Greensmith L, Reilly MM
  TITLE     The distal hereditary motor neuropathies.
  JOURNAL   J Neurol Neurosurg Psychiatry 83:6-14 (2012)
REFERENCE   PMID:19917815 (description, gene)
  AUTHORS   Reilly MM, Shy ME
  TITLE     Diagnosis and new treatments in genetic neuropathies.
  JOURNAL   J Neurol Neurosurg Psychiatry 80:1304-14 (2009)
///
ENTRY       H00857                      Disease
NAME        Oligodontia-colorectal cancer syndrome
DESCRIPTION Oligodontia-colorectal cancer syndrome is a condition of dominant inheritance in which severe permanent tooth agenesis and a variable colorectal neoplasia occur. Affected individuals lack at least eight permanent teeth. The disease is caused by a nonsense mutation in AXIN2.
CATEGORY    Mouth and dental disease
GENE        AXIN2 [HSA:8313] [KO:K04385]
DBLINKS     MeSH: C563698
            OMIM: 608615
REFERENCE   PMID:15042511 (description, gene)
  AUTHORS   Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P
  TITLE     Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.
  JOURNAL   Am J Hum Genet 74:1043-50 (2004)
REFERENCE   PMID:18499550 (description, gene)
  AUTHORS   Bailleul-Forestier I, Molla M, Verloes A, Berdal A
  TITLE     The genetic basis of inherited anomalies of the teeth. Part 1: clinical and molecular aspects of non-syndromic dental disorders.
  JOURNAL   Eur J Med Genet 51:273-91 (2008)
REFERENCE   PMID:21416598 (description, gene)
  AUTHORS   Marvin ML, Mazzoni SM, Herron CM, Edwards S, Gruber SB, Petty EM
  TITLE     AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.
  JOURNAL   Am J Med Genet A 155A:898-902 (2011)
///
ENTRY       H00858                      Disease
NAME        Marie-Unna hereditary hypotrichosis (MUHH)
DESCRIPTION Marie Unna hereditary hypotrichosis (MUHH) is an autosomal dominant form of hereditary hair loss. It is characterized by sparse or absent scalp hair, eyebrows, and eyelashes at birth. Coarse and wiry hair is progressively lost in this disease. Responsive mutations are found in U2HR, an inhibitory upstream open reading frame in the 5'-untranslated region of the HR gene.
CATEGORY    Skin and connective tissue disease
GENE        HR [HSA:55806] [KO:K00478]
DBLINKS     MeSH: C567718
            OMIM: 146550
REFERENCE   PMID:21504454 (description, gene)
  AUTHORS   Podjasek JO, Hand JL
  TITLE     Marie-Unna hereditary hypotrichosis: case report and review of the literature.
  JOURNAL   Pediatr Dermatol 28:202-4 (2011)
REFERENCE   PMID:19122663 (description, gene)
  AUTHORS   Wen Y, Liu Y, Xu Y, Zhao Y, Hua R, Wang K, Sun M, Li Y, Yang S, Zhang XJ, Kruse R, Cichon S, Betz RC, Nothen MM, van Steensel MA, van Geel M, Steijlen PM, Hohl D, Huber M, Dunnill GS, Kennedy C, Messenger A, Munro CS, Terrinoni A, Hovnanian A, Bodemer C, de Prost Y, Paller AS, Irvine AD, Sinclair R, Green J, Shang D, Liu Q, Luo Y, Jiang L, Chen HD, Lo WH, McLean WH, He CD, Zhang X
  TITLE     Loss-of-function mutations of an inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary hypotrichosis.
  JOURNAL   Nat Genet 41:228-33 (2009)
REFERENCE   PMID:20659777 (description, gene)
  AUTHORS   Redler S, Kruse R, Eigelshoven S, Hanneken S, Refke M, Wen Y, Zhang X, Cichon S, Betz RC, Nothen MM
  TITLE     Marie Unna hereditary hypotrichosis: identification of a U2HR mutation in the family from the original 1925 report.
  JOURNAL   J Am Acad Dermatol 64:e45-50 (2011)
///
ENTRY       H00859                      Disease
NAME        Guttmacher syndrome
DESCRIPTION Guttmacher syndrome is a disorder of distal limb and genital tract that resembles hand-foot-genital syndrome (HFGS). In addition to the typical features of HFGS, namely the combination of hypoplastic thumbs and halluces, 5th finger clinobrachydactyly and hypospadias, Guttmacher syndrome displays postaxial polydactyly of the hands and short or uniphalangeal 2nd toes with absent nails.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        HOXA13 [HSA:3209] [KO:K09298]
COMMENT     Hand-foot-genital syndrome [DS:H00460]
DBLINKS     MeSH: C538278
            OMIM: 176305
REFERENCE   PMID:11968094 (description, gene)
  AUTHORS   Innis JW, Goodman FR, Bacchelli C, Williams TM, Mortlock DP, Sateesh P, Scambler PJ, McKinnon W, Guttmacher AE
  TITLE     A HOXA13 allele with a missense mutation in the homeobox and a dinucleotide deletion in the promoter underlies Guttmacher syndrome.
  JOURNAL   Hum Mutat 19:573-4 (2002)
///
ENTRY       H00860                      Disease
NAME        Benign hereditary chorea
DESCRIPTION Benign hereditary chorea (BHC) is a rare, autosomal dominant, static disorder characterized by onset of chorea in conjunction with hypothyroidism and respiratory problems. Features supporting this diagnosis include normal general examination with no dysmorphic features, broadly normal intellectual development with no regression or loss of cognitive skills, absence of other significant neurologic disturbances, and, with the exception of chorea, normal neurologic examination findings. Mutations in the TTF1 gene  encoding the thyroid transcription factor-1 have been identified in a number of BHC patients, suggesting that aberration of TTF1 transcriptional function or haploinsufficiency is associated with this disorder. TTF1, belonging to the NKX2 homeodomain transcription factor family, has been implicated in several important molecular pathways essential for brain, thyroid and lung morphogenesis.
CATEGORY    Nervous system disease
GENE        TTF1 [HSA:7270] [KO:K15225]
DBLINKS     ICD-10: G25.5
            MeSH: D002819
            OMIM: 118700
REFERENCE   PMID:19501334 (description, gene)
  AUTHORS   Gilbert DL
  TITLE     Acute and chronic chorea in childhood.
  JOURNAL   Semin Pediatr Neurol 16:71-6 (2009)
REFERENCE   PMID:21292530 (description, gene)
  AUTHORS   Inzelberg R, Weinberger M, Gak E
  TITLE     Benign hereditary chorea: an update.
  JOURNAL   Parkinsonism Relat Disord 17:301-7 (2011)
///
ENTRY       H00861                      Disease
NAME        Pancreatic agenesis
DESCRIPTION Pancreatic agenesis is a rare disorder resulted from a failure of the pancreas to develop. It can be associated with the severe form of permanent neonatal diabetes mellitus. Mutations in insulin promoter factor 1 (IPF1), an essential factor for pancreas development, decrease the protein level and lead to the disease.
CATEGORY    Pancreas disease
GENE        IPF1 [HSA:3651] [KO:K07594]
DBLINKS     ICD-10: Q45.0
            OMIM: 260370
REFERENCE   PMID:8988180 (description, gene)
  AUTHORS   Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF
  TITLE     Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence.
  JOURNAL   Nat Genet 15:106-10 (1997)
REFERENCE   PMID:12970316 (description, gene)
  AUTHORS   Schwitzgebel VM, Mamin A, Brun T, Ritz-Laser B, Zaiko M, Maret A, Jornayvaz FR, Theintz GE, Michielin O, Melloul D, Philippe J
  TITLE     Agenesis of human pancreas due to decreased half-life of insulin promoter factor  1.
  JOURNAL   J Clin Endocrinol Metab 88:4398-406 (2003)
///
ENTRY       H00862                      Disease
NAME        Tourette syndrome
DESCRIPTION Tourette's syndrome (TS) is a developmental neuropsychiatric disorder characterized by chronic motor and vocal tics. Rare functional variants in the neuronal transmembrane molecule SLITRK1 have been associated with TS. The SLITRK1 gene is expressed in brain regions and it appears to play a role in dendritic growth. Another possible rare genetic cause of TS is a mutation in the HDC gene. The HDC gene encodes for L-histidine decarboxylase, which is the rate-limiting enzyme that catalyzes the biosynthesis of histamine from histidine.
CATEGORY    Mental, Behavioral and Neurodevelopmental disorders
GENE        SLITRK1 [HSA:114798]
            HDC [HSA:3067] [KO:K01590]
DRUG        Haloperidol [DG:DG00885]
            Pimozide [DR:D00560]
DBLINKS     ICD-10: F95.2
            MeSH: D005879
            OMIM: 137580
REFERENCE   PMID:20445167
  AUTHORS   Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, Tischfield JA, Heiman GA, Singer HS, Gilbert DL, Hoekstra PJ, Morgan TM, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho JH, Mane S, Colangelo CM, Biederer T, Lifton RP, Gunel M, State MW
  TITLE     L-histidine decarboxylase and Tourette's syndrome.
  JOURNAL   N Engl J Med 362:1901-8 (2010)
REFERENCE   PMID:18794888
  AUTHORS   Katayama K, Yamada K, Ornthanalai VG, Inoue T, Ota M, Murphy NP, Aruga J
  TITLE     Slitrk1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities.
  JOURNAL   Mol Psychiatry 15:177-84 (2010)
REFERENCE   PMID:21277193
  AUTHORS   State MW
  TITLE     The genetics of Tourette disorder.
  JOURNAL   Curr Opin Genet Dev 21:302-9 (2011)
REFERENCE   PMID:21386676 (Drug)
  AUTHORS   Bloch M, State M, Pittenger C
  TITLE     Recent advances in Tourette syndrome.
  JOURNAL   Curr Opin Neurol 24:119-25 (2011)
///
ENTRY       H00863                      Disease
NAME        Spondylo-megaepiphyseal-metaphyseal dysplasia
DESCRIPTION Spondylo-megaepiphyseal-metaphyseal dysplasia is a rare skeletal dysplasia. Its features are disproportionate short stature. On radiograph, defective ossification of vertebral bodies, enlarged epiphyses, and metaphyseal dysplasia are noted. It is inherited as an autosomal recessive trait.
CATEGORY    Skeletal dysplasia
GENE        NKX3-2 [HSA:579] [KO:K09995]
COMMENT     The diseases similar to spondylo-megaepiphyseal-metaphyseal dysplasia include spondylometaphyseal dysplasia (H00522), oto-spondylo-megaepiphyseal dysplasia (H00519), and cleidocranial dysplasia (H00521).
DBLINKS     MeSH: C567639
            OMIM: 613330
REFERENCE   PMID:13680008 (description)
  AUTHORS   Agarwal PP, Srinivasan A, Sharma R, Kabra M, Gupta AK
  TITLE     Spondylo-megaepiphyseal-metaphyseal dysplasia: an unusual bone dysplasia.
  JOURNAL   Pediatr Radiol 33:893-6 (2003)
REFERENCE   PMID:20004766 (description, gene)
  AUTHORS   Hellemans J, Simon M, Dheedene A, Alanay Y, Mihci E, Rifai L, Sefiani A, van Bever Y, Meradji M, Superti-Furga A, Mortier G
  TITLE     Homozygous inactivating mutations in the NKX3-2 gene result in spondylo-megaepiphyseal-metaphyseal dysplasia.
  JOURNAL   Am J Hum Genet 85:916-22 (2009)
///
ENTRY       H00864                      Disease
NAME        Trichotillomania
DESCRIPTION Trichotillomania (TTM) is a chronic behavioral disorder characterized by the irresistible urge to pull out one's hair, resulting in noticeable hair loss. Mutations in SLITRK1 are found in patients with TTM.
CATEGORY    Mental, Behavioral and Neurodevelopmental disorders
GENE        SLITRK1 [HSA:114798]
COMMENT     Mutations in SLITRK1 are also found in patients with Tourette syndrome. [DS:H00862]
DBLINKS     ICD-10: F63.3
            MeSH: D014256
            OMIM: 613229
REFERENCE   PMID:17003809
  AUTHORS   Zuchner S, Cuccaro ML, Tran-Viet KN, Cope H, Krishnan RR, Pericak-Vance MA, Wright HH, Ashley-Koch A
  TITLE     SLITRK1 mutations in trichotillomania.
  JOURNAL   Mol Psychiatry 11:887-9 (2006)
REFERENCE   PMID:18794888
  AUTHORS   Katayama K, Yamada K, Ornthanalai VG, Inoue T, Ota M, Murphy NP, Aruga J
  TITLE     Slitrk1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities.
  JOURNAL   Mol Psychiatry 15:177-84 (2010)
///
ENTRY       H00865                      Disease
NAME        Lethal congenital contractural syndrome (LCCS)
DESCRIPTION Lethal congenital contractural syndrome (LCCS) is a heterogeneous group of disorders characterized by congenital nonprogressive joint contractures with a severe form of arthrogryposis. LCCS is inherited in an autosomal recessive manner. It has a worldwide incidence, but it is more common in isolated populations, such as Finland and the Bedouin community in Israel. Mutations in GLE1, ERBB3, and PIP5K1C are associated with LCCS.
CATEGORY    Musculoskeletal disease
GENE        (LCCS1) GLE1 [HSA:2733] [KO:K18723]
            (LCCS2) ERBB3 [HSA:2065] [KO:K05084]
            (LCCS3) PIP5K1C [HSA:23396] [KO:K00889]
DBLINKS     MeSH: C537194 C564369 C566961
            OMIM: 253310 607598 611369
REFERENCE   PMID:18204449 (gene)
  AUTHORS   Nousiainen HO, Kestila M, Pakkasjarvi N, Honkala H, Kuure S, Tallila J, Vuopala K, Ignatius J, Herva R, Peltonen L
  TITLE     Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease.
  JOURNAL   Nat Genet 40:155-7 (2008)
REFERENCE   PMID:17701904 (gene)
  AUTHORS   Narkis G, Ofir R, Manor E, Landau D, Elbedour K, Birk OS
  TITLE     Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway.
  JOURNAL   Am J Hum Genet 81:589-95 (2007)
REFERENCE   PMID:17701898 (description, gene)
  AUTHORS   Narkis G, Ofir R, Landau D, Manor E, Volokita M, Hershkowitz R, Elbedour K, Birk OS
  TITLE     Lethal contractural syndrome type 3 (LCCS3) is caused by a mutation in PIP5K1C, which encodes PIPKI gamma of the phophatidylinsitol pathway.
  JOURNAL   Am J Hum Genet 81:530-9 (2007)
///
ENTRY       H00866                      Disease
NAME        Trichothiodystrophy non-photosensitive type 1 (TTDN1);
            Amish brittle hair syndrome;
            BIDS syndrome;
            Hair-brain syndrome
DESCRIPTION Nonphotosensitive trichothiodystrophy (TTDN1) is an autosomal recessive disorder characterized by short stature, intellectual impairment, sulfur-deficient brittle hair, and decreased male fertility but not cutaneous photosensitivity. TTDN1 may be involved in transcription but not DNA repair.
CATEGORY    Inherited metabolic disease; Developmental disorder
GENE        TTDN1 [HSA:136647]
COMMENT     The photosensitive trichothiodystrophy is included in disorders of nucleotide excision repair [DS:H00403].
DBLINKS     ICD-10: E72.1 Q82.8
            MeSH: D054463
            OMIM: 234050
REFERENCE   PMID:15645389
  AUTHORS   Nakabayashi K, Amann D, Ren Y, Saarialho-Kere U, Avidan N, Gentles S, MacDonald JR, Puffenberger EG, Christiano AM, Martinez-Mir A, Salas-Alanis JC, Rizzo R, Vamos E, Raams A, Les C, Seboun E, Jaspers NG, Beckmann JS, Jackson CE, Scherer SW
  TITLE     Identification of C7orf11 (TTDN1) gene mutations and genetic heterogeneity in nonphotosensitive trichothiodystrophy.
  JOURNAL   Am J Hum Genet 76:510-6 (2005)
///
ENTRY       H00867                      Disease
NAME        Radioulnar synostosis with amegakaryocytic thrombocytopenia
DESCRIPTION This disease is a rare combination of proximal radio-ulnar synostosis and congenital amegakaryocytic thrombocytopenia. Bruising and bleeding problems are observed since birth in affected individuals. The disease is related with HOXA11 mutation.
CATEGORY    Skeletal dysplasia; Hematologic disease
GENE        HOXA11 [HSA:3207] [KO:K09296]
DBLINKS     ICD-10: D69.8
            MeSH: C565328
            OMIM: 605432
REFERENCE   PMID:11101832 (description, gene)
  AUTHORS   Thompson AA, Nguyen LT
  TITLE     Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation.
  JOURNAL   Nat Genet 26:397-8 (2000)
///
ENTRY       H00868                      Disease
NAME        Stapes ankylosis with broad thumb and toes
DESCRIPTION This syndrome is characterized by conductive hearing loss due to congenital fixation of stapes, hyperopia, a hemicylindrical nose, broad thumbs and first toes. Noggin, the causative gene of several symphalangisms, has been implicated in the disease.
CATEGORY    Nervous system disease; Skeletal dysplasia
GENE        NOG [HSA:9241] [KO:K04658]
DBLINKS     ICD-10: Q87.8
            MeSH: C536943
            OMIM: 184460
REFERENCE   PMID:9220188 (description)
  AUTHORS   Hilhorst-Hofstee Y, Watkin PM, Hall CM, Baraitser M
  TITLE     The autosomal dominant syndrome with congenital stapes ankylosis, broad thumbs and hyperopia.
  JOURNAL   Clin Dysmorphol 6:195-203 (1997)
REFERENCE   PMID:12089654 (description, gene)
  AUTHORS   Brown DJ, Kim TB, Petty EM, Downs CA, Martin DM, Strouse PJ, Moroi SE, Milunsky JM, Lesperance MM
  TITLE     Autosomal dominant stapes ankylosis with broad thumbs and toes, hyperopia, and skeletal anomalies is caused by heterozygous nonsense and frameshift mutations in NOG, the gene encoding noggin.
  JOURNAL   Am J Hum Genet 71:618-24 (2002)
///
ENTRY       H00869                      Disease
NAME        Leukoencephalopathy with vanishing white matter;
            Vanishing white matter disease;
            Childhood ataxia with diffuse central nervous system hypomyelination (CACH);
            Cree leukoencephalopathy (CLE)
DESCRIPTION Leukoencephalopathy with vanishing white matter (VWM), also referred to as childhood ataxia with diffuse central nervous system hypomyelination (CACH), is one of the most prevalent inherited childhood disorders of cerebral white matter. This autosomal recessive progressive neurological disorder usually begins in early childhood, but a wide spectrum of clinical severity is now recognized from fatal infantile forms such as Cree leukoencephalopathy to mild later-onset forms associated with ovarian failure. The principal findings are cerebellar ataxia and spasticity with relative preservation of mental abilities. The course is typically relapsing-remitting with progressive neurological deterioration leading to death in the second decade of life. Nearly all patients have mutations in any of the 5 genes encoding the eukaryotic translation initiation factor eIF2B. Mutated eIF2B could impair the ability of cells to regulate protein synthesis, especially under conditions of cell stress. Reduced levels of eIF2 activity as occurs in VWM may lead to activation of the unfolded protein response inducing both prosurvival and proapoptotic signals affecting oligodendrocytes and astrocytes in particular.
CATEGORY    Nervous system disease
GENE        EIF2B1 [HSA:1967] [KO:K03239]
            EIF2B2 [HSA:8892] [KO:K03754]
            EIF2B3 [HSA:8891] [KO:K03241]
            EIF2B4 [HSA:8890] [KO:K03680]
            EIF2B5 [HSA:8893] [KO:K03240]
DBLINKS     ICD-10: E75.2
            MeSH: D056784
            OMIM: 603896
REFERENCE   PMID:17414998 (description, gene)
  AUTHORS   Lyon G, Fattal-Valevski A, Kolodny EH
  TITLE     Leukodystrophies: clinical and genetic aspects.
  JOURNAL   Top Magn Reson Imaging 17:219-42 (2006)
REFERENCE   PMID:16807905 (description, gene)
  AUTHORS   Pronk JC, van Kollenburg B, Scheper GC, van der Knaap MS
  TITLE     Vanishing white matter disease: a review with focus on its genetics.
  JOURNAL   Ment Retard Dev Disabil Res Rev 12:123-8 (2006)
REFERENCE   PMID:20838246 (description, gene)
  AUTHORS   Bugiani M, Boor I, Powers JM, Scheper GC, van der Knaap MS
  TITLE     Leukoencephalopathy with vanishing white matter: a review.
  JOURNAL   J Neuropathol Exp Neurol 69:987-96 (2010)
///
ENTRY       H00870                      Disease
NAME        Brachydactyly-syndactyly syndrome
DESCRIPTION This condition is a rare disease with complex brachydactyly and syndactyly. It is linked to HOXD13, a gene that essential for limb development. Defects in HOXD13 are the cause of brachydactyly (H00483) and synpolydactyly (H00459).
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        HOXD13 [HSA:3239] [KO:K09298]
DBLINKS     ICD-10: Q73.8
            MeSH: C565193
            OMIM: 610713
REFERENCE   PMID:17236141 (description, gene)
  AUTHORS   Zhao X, Sun M, Zhao J, Leyva JA, Zhu H, Yang W, Zeng X, Ao Y, Liu Q, Liu G, Lo WH, Jabs EW, Amzel LM, Shan X, Zhang X
  TITLE     Mutations in HOXD13 underlie syndactyly type V and a novel brachydactyly-syndactyly syndrome.
  JOURNAL   Am J Hum Genet 80:361-71 (2007)
///
ENTRY       H00871                      Disease
NAME        Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation (LBSL)
DESCRIPTION Leukoencephalopathy with brain stem and spinal cord involvement and brain lactate elevation (LBSL) is an autosomal recessive juvenile to adult-onset white matter disorder presenting with slowly progressive pyramidal, cerebellar and dorsal column dysfunction, often leading to wheelchair dependency before age 30 years. LBSL is caused by mutations in the gene DARS2, which codes for mitochondrial aspartyl-tRNA synthetase (mtAspRS).
CATEGORY    Nervous system disease
GENE        DARS2 [HSA:55157] [KO:K01876]
DBLINKS     ICD-10: E75.2
            MeSH: C567009
            OMIM: 611105
REFERENCE   PMID:22023289 (description, gene)
  AUTHORS   van Berge L, Dooves S, van Berkel CG, Polder E, van der Knaap MS, Scheper GC
  TITLE     Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation is associated with cell-type-dependent splicing of mtAspRS mRNA.
  JOURNAL   Biochem J 441:955-62 (2012)
REFERENCE   PMID:21749991 (description, gene)
  AUTHORS   Synofzik M, Schicks J, Lindig T, Biskup S, Schmidt T, Hansel J, Lehmann-Horn F, Schols L
  TITLE     Acetazolamide-responsive exercise-induced episodic ataxia associated with a novel homozygous DARS2 mutation.
  JOURNAL   J Med Genet 48:713-5 (2011)
///
ENTRY       H00872                      Disease
NAME        Trismus-pseudocamptodactyly syndrome;
            Hecht-Beals Syndrome;
            Dutch-Kentucky syndrome
DESCRIPTION Trismus-pseudocamptodactyly syndrome is a rare autosomal dominant distal arthrogryposis characterized by the inability to open the mouth (trismus) causing difficulty with mastication, and an unusual camptodactyly of the fingers that is apparent only while attempting dorsiflexion of the wrist (pseudocamptodactyly).
CATEGORY    Mouth and dental disease
GENE        MYH8 [HSA:4626] [KO:K10352]
DBLINKS     ICD-10: M24.5 Q68.1
            MeSH: C535857
            OMIM: 158300
REFERENCE   PMID:17041932 (description, gene)
  AUTHORS   Toydemir RM, Chen H, Proud VK, Martin R, van Bokhoven H, Hamel BC, Tuerlings JH, Stratakis CA, Jorde LB, Bamshad MJ
  TITLE     Trismus-pseudocamptodactyly syndrome is caused by recurrent mutation of MYH8.
  JOURNAL   Am J Med Genet A 140:2387-93 (2006)
REFERENCE   PMID:15888111 (description)
  AUTHORS   Carlos R, Contreras E, Cabrera J
  TITLE     Trismus-pseudocamptodactyly syndrome (Hecht-Beals' syndrome): case report and literature review.
  JOURNAL   Oral Dis 11:186-9 (2005)
///
ENTRY       H00873                      Disease
NAME        Cousin syndrome
DESCRIPTION Cousin syndrome arises from errors of morphogenesis. It is characterized by scapular and pelvic hypoplasia along with epiphyseal abnormalities, congenital dwarfism, and facial dysmorphy including cranial, cervical, and auricular malformations. Cousin syndrome is linked to TBX15 insufficiency.
CATEGORY    Developmental disorder
GENE        TBX15 [HSA:6913] [KO:K10182]
DBLINKS     MeSH: C535550
            OMIM: 260660
REFERENCE   PMID:19068278 (description, gene)
  AUTHORS   Lausch E, Hermanns P, Farin HF, Alanay Y, Unger S, Nikkel S, Steinwender C, Scherer G, Spranger J, Zabel B, Kispert A, Superti-Furga A
  TITLE     TBX15 mutations cause craniofacial dysmorphism, hypoplasia of scapula and pelvis, and short stature in Cousin syndrome.
  JOURNAL   Am J Hum Genet 83:649-55 (2008)
///
ENTRY       H00874                      Disease
NAME        Leukoencephalopathy with dystonia and motor neuropathy
DESCRIPTION Leukoencephalopathy with dystonia and motor neuropathy is a disorder caused by a deficiency of sterol carrier protein-2 (SCPx), a peroxisomal enzyme with thiolase activity, which is required for the breakdown of branched-chain fatty acids. The patient presents with torticollis and dystonic head tremor as well as slight cerebellar signs with intention tremor, nystagmus, hyposmia, and azoospermia.
CATEGORY    Nervous system disease
GENE        SCP2 [HSA:6342] [KO:K08764]
DBLINKS     ICD-10: E75.2
            MeSH: C566654
            OMIM: 613724
REFERENCE   PMID:16685654 (description, gene)
  AUTHORS   Ferdinandusse S, Kostopoulos P, Denis S, Rusch H, Overmars H, Dillmann U, Reith W, Haas D, Wanders RJ, Duran M, Marziniak M
  TITLE     Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause  leukencephalopathy with dystonia and motor neuropathy.
  JOURNAL   Am J Hum Genet 78:1046-52 (2006)
///
ENTRY       H00875                      Disease
NAME        Megalencephalic leukoencephalopathy with subcortical cysts (MLC)
DESCRIPTION Megalencephaiic leukoencephalopathy with subcortical cysts (MLC) is a rare leukodystrophy characterized by macrocephaly and a slowly progressive clinical course marked by spasticity and cognitive decline. Magnetic resonance imaging (MRI) shows bilateral extensive white-matter changes with cysts in the temporal regions. Based on the clinical and MRI features, MLC can be distinguished from other conditions (ie, Alexander disease [DS:H00065], Canavan disease [DS:H00074], glutaric acidemia type I [DS:H00178]) that present in infancy with megalencephaly. An autosomal recessive mutations in the MLC1 gene have been shown to cause this condition. Recently, mutations in HEPACAM gene are reported to be associated with MLC.
CATEGORY    Nervous system disease
GENE        (MLC1) MLC1 [HSA:23209] [KO:K20070]
            (MLC2A, MLC2B) HEPACAM [HSA:220296]
DBLINKS     ICD-10: E75.2
            MeSH: C536141
            OMIM: 604004 613925 613926
REFERENCE   PMID:14572144 (description, gene)
  AUTHORS   Singhal BS, Gorospe JR, Naidu S
  TITLE     Megalencephalic leukoencephalopathy with subcortical cysts.
  JOURNAL   J Child Neurol 18:646-52 (2003)
REFERENCE   PMID:15832614 (description, gene)
  AUTHORS   Riel-Romero RM, Smith CD, Pettigrew AL
  TITLE     Megalencephalic leukoencephalopathy with subcortical cysts in two siblings owing  to two novel mutations: case reports and review of the literature.
  JOURNAL   J Child Neurol 20:230-4 (2005)
REFERENCE   PMID:21419380 (gene)
  AUTHORS   Lopez-Hernandez T, Ridder MC, Montolio M, Capdevila-Nortes X, Polder E, Sirisi S, Duarri A, Schulte U, Fakler B, Nunes V, Scheper GC, Martinez A, Estevez R, van der Knaap MS
  TITLE     Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation and autism.
  JOURNAL   Am J Hum Genet 88:422-32 (2011)
///
ENTRY       H00876                      Disease
NAME        Mismatch repair deficiency, including:
            Hereditary non-polyposis colorectal cancer (HNPCC);
            Lynch syndrome;
            Muir-Torre syndrome;
            Turcot syndrome
DESCRIPTION Mismatch repair (MMR) deficiency is a condition associated with DNA mismatch repair mutations. MMR deficiency is correlated with hereditary non-polyposis colorectal cancer (HNPCC) and some forms of sporadic tumors. HNPCC also referred to as Lynch syndrome, is an autosomal-dominant-inherited disorder characterized by predisposition to colorectal cancer and extracolonic malignancies, frequent multiple primary tumors in the same patient, and early age of cancer onset. A clinical variant of Lynch syndrome, Muir-Torre syndrome (MTS) is characterized by the association between one or more visceral malignancies, with at least one sebaceous skin tumor or keratoacanthoma. Turcot syndrome is characterized by the concurrence of primary brain tumors and colon cancers and/or multiple colorectal adenomas.
CATEGORY    Congenital disorder of DNA repair systems
GENE        MSH2 [HSA:4436] [KO:K08735]
            MSH6 [HSA:2956] [KO:K08737]
            MLH1 [HSA:4292] [KO:K08734]
            MLH3 [HSA:27030] [KO:K08739]
            PMS2 [HSA:5395] [KO:K10858]
            EPCAM [HSA:4072] [KO:K06737]
DBLINKS     MeSH: D003123 D055847
            OMIM: 276300 120435 609310 614337 614350 614385 613244 158320 608089
REFERENCE   PMID:16826164
  AUTHORS   Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G, Seidenari S
  TITLE     Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
  JOURNAL   J Invest Dermatol 126:2302-7 (2006)
REFERENCE   PMID:11920679
  AUTHORS   Marti TM, Kunz C, Fleck O.
  TITLE     DNA mismatch repair and mutation avoidance pathways.
  JOURNAL   J Cell Physiol 191:28-41 (2002)
REFERENCE   PMID:22175017
  AUTHORS   Masuda K, Banno K, Yanokura M, Kobayashi Y, Kisu I, Ueki A, Ono A, Asahara N, Nomura H, Hirasawa A, Susumu N, Aoki D
  TITLE     Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer.
  JOURNAL   Mol Biol Int 2011:256063 (2011)
REFERENCE   PMID:15256438
  AUTHORS   Nakagawa H, Lockman JC, Frankel WL, Hampel H, Steenblock K, Burgart LJ, Thibodeau SN, de la Chapelle A
  TITLE     Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation.
  JOURNAL   Cancer Res 64:4721-7 (2004)
REFERENCE   PMID:11586295
  AUTHORS   Wu Y, Berends MJ, Sijmons RH, Mensink RG, Verlind E, Kooi KA, van der Sluis T, Kempinga C, van dDer Zee AG, Hollema H, Buys CH, Kleibeuker JH, Hofstra RM
  TITLE     A role for MLH3 in hereditary nonpolyposis colorectal cancer.
  JOURNAL   Nat Genet 29:137-8 (2001)
REFERENCE   PMID:21769135
  AUTHORS   Lynch HT, Riegert-Johnson DL, Snyder C, Lynch JF, Hagenkord J, Boland CR, Rhees J, Thibodeau SN, Boardman LA, Davies J, Kuiper RP, Hoogerbrugge N, Ligtenberg MJ
  TITLE     Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion.
  JOURNAL   Am J Gastroenterol 106:1829-36 (2011)
///
ENTRY       H00877                      Disease
NAME        Brain small vessel disease with Axenfeld-Rieger anomaly
DESCRIPTION Mutations in the COL4A1 gene, encoding the a1 chain of type IV collagen, causes highly variable cerebral haemorrhage disorders with overlapping features. Brain small vessel disease with Axenfeld-Rieger anomaly is a condition associated with diffuse leukoencephalopathy and ocular malformations of the Axenfeld-Rieger type.
CATEGORY    Vascular disease; Nervous system disease
GENE        COL4A1 [HSA:1282] [KO:K06237]
DBLINKS     ICD-10: I67.3
            OMIM: 607595
REFERENCE   PMID:21062344 (description, gene)
  AUTHORS   Yamamoto Y, Craggs L, Baumann M, Kalimo H, Kalaria RN
  TITLE     Review: molecular genetics and pathology of hereditary small vessel diseases of the brain.
  JOURNAL   Neuropathol Appl Neurobiol 37:94-113 (2011)
REFERENCE   PMID:20558831 (description, gene)
  AUTHORS   Lanfranconi S, Markus HS
  TITLE     COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review.
  JOURNAL   Stroke 41:e513-8 (2010)
REFERENCE   PMID:20166936 (description, gene)
  AUTHORS   Volonghi I, Pezzini A, Del Zotto E, Giossi A, Costa P, Ferrari D, Padovani A
  TITLE     Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease.  The COL4A1 stroke syndrome.
  JOURNAL   Curr Med Chem 17:1317-24 (2010)
REFERENCE   PMID:17696175 (description, gene)
  AUTHORS   Sibon I, Coupry I, Menegon P, Bouchet JP, Gorry P, Burgelin I, Calvas P, Orignac I, Dousset V, Lacombe D, Orgogozo JM, Arveiler B, Goizet C
  TITLE     COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke.
  JOURNAL   Ann Neurol 62:177-84 (2007)
///
ENTRY       H00878                      Disease
NAME        Cystic leukoencephalopathy without megalencephaly
DESCRIPTION Cystic leukoencephalopathy without megalencephaly is an autosomal recessive infantile-onset neurological disorder. The affected individuals are asymptomatic at birth and show a static encephalopathy with normo- or microcephaly and psychomotor impairment within the first year of life. Brain magnetic resonance imaging (MRI) shows bilateral anterior temporal lobe cystic lesions and enlarged inferior horns combined with multifocal white matter alterations. Loss-of-function mutations in the gene encoding the RNASET2 glycoprotein lead to this disorder.
CATEGORY    Nervous system disease
GENE        RNASET2 [HSA:8635] [KO:K01166]
DBLINKS     ICD-10: E75.2
            MeSH: C567845
            OMIM: 612951
REFERENCE   PMID:19525954 (description, gene)
  AUTHORS   Henneke M, Diekmann S, Ohlenbusch A, Kaiser J, Engelbrecht V, Kohlschutter A, Kratzner R, Madruga-Garrido M, Mayer M, Opitz L, Rodriguez D, Ruschendorf F, Schumacher J, Thiele H, Thoms S, Steinfeld R, Nurnberg P, Gartner J
  TITLE     RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection.
  JOURNAL   Nat Genet 41:773-5 (2009)
///
ENTRY       H00879                      Disease
NAME        Perry syndrome
DESCRIPTION Perry syndrome is a rapidly progressive, autosomal dominant, neurodegenerative disorder. The cardinal symptoms consist of parkinsonism, depression, severe weight loss and hypoventilation. At a molecular level, Perry syndrome is characterized by TDP-43 inclusions indicating a pathological overlap with amyotrophic lateral sclerosis (ALS) and some forms of frontotemporal lobar degeneration (FTLD). Perry syndrome has recently been identified as being due to mutations in the DCTN1 gene, encoding the component of the dynactin complex.
CATEGORY    Neurodegenerative disease
GENE        DCTN1 [HSA:1639] [KO:K04648]
DBLINKS     MeSH: C566822
            OMIM: 168605
REFERENCE   PMID:19136952
  AUTHORS   Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, Wider C, Vilarino-Guell C, Ross OA, Brown LA, Castanedes-Casey M, Dickson DW, Wszolek ZK
  TITLE     DCTN1 mutations in Perry syndrome.
  JOURNAL   Nat Genet 41:163-5 (2009)
REFERENCE   PMID:20437543
  AUTHORS   Newsway V, Fish M, Rohrer JD, Majounie E, Williams N, Hack M, Warren JD, Morris HR
  TITLE     Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive  disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.
  JOURNAL   Mov Disord 25:767-70 (2010)
///
ENTRY       H00880                      Disease
NAME        Dyschromatosis symmetrica hereditaria
DESCRIPTION Dyschromatosis symmetrica hereditaria (DSH) is a pigmentary genodermatosis of autosomal dominant inheritance. It presents in infancy or early childhood as a mixture of hyperpigmented and hypopigmented macules on dorsa of hands and feet. It is caused by a mutation of adenosine deaminase acting on the RNA 1 gene (ADAR1).
CATEGORY    Skin and connective tissue disease
GENE        ADAR [HSA:103] [KO:K12968]
DBLINKS     MeSH: C535729
            OMIM: 127400
REFERENCE   PMID:16882194 (description, gene)
  AUTHORS   Liu Y, Xiao SX, Peng ZH, Lei XB, Wang JM, Li Y, Li XL
  TITLE     Two frameshift mutations of the double-stranded RNA-specific adenosine deaminase  gene in Chinese pedigrees with dyschromatosis symmetrica hereditaria.
  JOURNAL   Br J Dermatol 155:473-6 (2006)
///
ENTRY       H00881                      Disease
NAME        Li-Fraumeni syndrome, including:
            Classic Li-Fraumeni syndrome (LFS);
            LFS-like syndrome (LFSL)
DESCRIPTION Li-Fraumeni syndrome (LFS) is a familial clustering of early onset tumors including sarcomas, breast cancers, brain tumors and adrenocortical carcinomas (ADR). Initially considered as a rare syndrome, LFS and its variants are increasingly recognized as one of the most frequent and diverse forms of predisposition to cancer. Most cases identified and characterized to date are associated with dominantly inherited germ line mutations in the tumor suppressor gene TP53 (p53). In a subset of non-p53 patients with LFS, CHEK2 has been identified as another predisposing locus. LFS is diagnosed on the basis of the confirmed clinical diagnostic criteria.
CATEGORY    Inherited metabolic disease; Cancer
GENE        TP53 [HSA:7157] [KO:K04451]
            CHEK2 [HSA:11200] [KO:K06641]
DBLINKS     ICD-10: Q93
            MeSH: D016864
            OMIM: 151623 609265
REFERENCE   PMID:19952748 (description)
  AUTHORS   Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P
  TITLE     Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
  JOURNAL   Curr Opin Oncol 22:64-9 (2010)
REFERENCE   PMID:15695383 (description, gene)
  AUTHORS   Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, Lozano G, Amos CI, Strong LC, Krahe R
  TITLE     Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23.
  JOURNAL   Cancer Res 65:427-31 (2005)
REFERENCE   PMID:19652052 (description)
  AUTHORS   Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaiti-Pellie C, Stoppa-Lyonnet D, Frebourg T
  TITLE     2009 version of the Chompret criteria for Li Fraumeni syndrome.
  JOURNAL   J Clin Oncol 27:e108-9; author reply e110 (2009)
///
ENTRY       H00882                      Disease
NAME        Cocoon syndrome
DESCRIPTION Cocoon syndrome is an autosomal recessive lethal syndrome characterized by multiple fetal malformations, the most obvious anomalies being the defective face and seemingly absent limbs, which are bound to the trunk and encased under the skin. It has been reported that defects in CHUK are the cause of cocoon syndrome. CHUK has an essential role in the development of skin epidermis and its derivatives, along with various other morphogenetic events.
CATEGORY    Developmental disorder
GENE        CHUK [HSA:1147] [KO:K04467]
DBLINKS     OMIM: 613630
REFERENCE   PMID:20961246
  AUTHORS   Lahtela J, Nousiainen HO, Stefanovic V, Tallila J, Viskari H, Karikoski R, Gentile M, Saloranta C, Varilo T, Salonen R, Kestila M
  TITLE     Mutant CHUK and severe fetal encasement malformation.
  JOURNAL   N Engl J Med 363:1631-7 (2010)
///
ENTRY       H00883                      Disease
NAME        Lipoid proteinosis;
            Urbach-Wiethe disease
DESCRIPTION Lipoid proteinosis (LP) is a rare autosomal recessive disorder characterized histologically by infiltration of periodic acid Schiff-positive hyaline material into the skin, upper aerodigestive tract, and internal organs. Infantile hoarseness is a common presenting feature of the disease due to infiltration of larynx. In two-thirds of the cases, voice changes are present at birth or in early infancy as the first manifestation. The disorder has been shown to result from loss-of-function mutations in the extracellular matrix protein 1 gene. The function of the protein extracellular matrix protein 1 gene is still unclear.
CATEGORY    Respiratory disease; Skin and connective tissue disease
GENE        ECM1 [HSA:1893]
DBLINKS     ICD-10: E75.5
            MeSH: D008065
            OMIM: 247100
REFERENCE   PMID:17063986 (description, gene)
  AUTHORS   Di Giandomenico S, Masi R, Cassandrini D, El-Hachem M, De Vito R, Bruno C, Santorelli FM
  TITLE     Lipoid proteinosis: case report and review of the literature.
  JOURNAL   Acta Otorhinolaryngol Ital 26:162-7 (2006)
REFERENCE   PMID:15533571 (description)
  AUTHORS   Acar A, Eryilmaz A, Gocer C, Akmansu H, Korkmaz H
  TITLE     Lipoid proteinosis of larynx: review of four cases.
  JOURNAL   Int J Pediatr Otorhinolaryngol 68:1557-61 (2004)
///
ENTRY       H00884                      Disease
NAME        Familial progressive hyperpigmentation
DESCRIPTION Familial progressive hyperpigmentation is a dominantly inherited genodermatosis, in which patches of hyperpigmentation in the skin are present at birth. Increased number and average size of melanin granules in cells of pigmented area are the features of this disease.
CATEGORY    Skin and connective tissue disease
GENE        KITLG [HSA:4254] [KO:K05461]
DBLINKS     MeSH: C564163
            OMIM: 145250
REFERENCE   PMID:21368769 (description, gene)
  AUTHORS   Amyere M, Vogt T, Hoo J, Brandrup F, Bygum A, Boon L, Vikkula M
  TITLE     KITLG mutations cause familial progressive hyper- and hypopigmentation.
  JOURNAL   J Invest Dermatol 131:1234-9 (2011)
REFERENCE   PMID:15708290 (description)
  AUTHORS   Passeron T, Mantoux F, Ortonne JP
  TITLE     Genetic disorders of pigmentation.
  JOURNAL   Clin Dermatol 23:56-67 (2005)
///
ENTRY       H00885                      Disease
NAME        Hypomelanosis of Ito;
            Pigmentary mosaicism
DESCRIPTION Hypomelanosis of Ito is a neurocutaneous syndrome with hypopigmented whorls of skin along the Blaschko lines associated with other congenital defects of central nervous system, the eye, and skeletal system. The hypomelanotic lesions are present at birth and in these lesions decrease in the number of melanocytes is observed. Hypomelanosis of Ito includes many different states of chromosomal mosaicism.
CATEGORY    Skin and connective tissue disease; Nervous system disease; Skeletal dysplasia
GENE        chromosomal mosaicism
DBLINKS     ICD-10: L81.8
            MeSH: D010859
            OMIM: 300337
REFERENCE   PMID:15708290 (description)
  AUTHORS   Passeron T, Mantoux F, Ortonne JP
  TITLE     Genetic disorders of pigmentation.
  JOURNAL   Clin Dermatol 23:56-67 (2005)
REFERENCE   PMID:22150346 (description)
  AUTHORS   Torchia D
  TITLE     Mosaic pigmentation disorders and associated syndromes.
  JOURNAL   J Dermatol 39:414-5 (2012)
///
ENTRY       H00886                      Disease
NAME        Donnai-Barrow syndrome;
            Faciooculoacousticorenal syndrome
DESCRIPTION Donnai-Barrow syndrome is a rare autosomal recessive disorder of multiple anomalies resulting from mutations in the LRP2 gene. It is characterized by agenesis of the corpus callosum, typical craniofacial features (ocular hypertelorism, enlarged fontanelle), ophthalmological abnormalities (high myopia, iris stromal hypoplasia), severe sensorineural deafness, congenital diaphragmatic hernia, and proteinuria. The diagnosis is confirmed by detection of mutations in LRP2.
CATEGORY    Developmental disorder
GENE        LRP2 [HSA:4036] [KO:K06233]
DBLINKS     ICD-10: Q87.8
            MeSH: C536390
            OMIM: 222448
REFERENCE   PMID:20301732 (description, gene)
  AUTHORS   Kantarci S, Donnai D, Noonan KM, Pober BR
  TITLE     Donnai-Barrow Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:19089858 (description, gene)
  AUTHORS   Pober BR, Longoni M, Noonan KM
  TITLE     A review of Donnai-Barrow and facio-oculo-acoustico-renal (DB/FOAR) syndrome: clinical features and differential diagnosis.
  JOURNAL   Birth Defects Res A Clin Mol Teratol 85:76-81 (2009)
REFERENCE   PMID:18553518 (description, gene)
  AUTHORS   Kantarci S, Ragge NK, Thomas NS, Robinson DO, Noonan KM, Russell MK, Donnai D, Raymond FL, Walsh CA, Donahoe PK, Pober BR
  TITLE     Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due  to complete chromosome 2 paternal isodisomy.
  JOURNAL   Am J Med Genet A 146A:1842-7 (2008)
///
ENTRY       H00887                      Disease
NAME        Lipoprotein glomerulopathy
DESCRIPTION Lipoprotein glomerulopathy is a rare hereditary disorder characterized by disturbed remnant lipoprotein catabolism and intravascular glomerular deposition of lipoprotein-containing thrombi. Patients usually present with proteinuria and hypertension, microhematuria is rare, and renal function becomes impaired. Rare mutations in apolipoprotein E (apoE) gene may contribute to the pathogenesis of the disease.
CATEGORY    Inherited metabolic disease; Cardiovascular disease
GENE        APOE [HSA:348] [KO:K04524]
DBLINKS     MeSH: C567089
            OMIM: 611771
REFERENCE   PMID:21464714 (description, gene)
  AUTHORS   Tsimihodimos V, Elisaf M
  TITLE     Lipoprotein glomerulopathy.
  JOURNAL   Curr Opin Lipidol 22:262-9 (2011)
REFERENCE   PMID:16490634 (description, gene)
  AUTHORS   Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK
  TITLE     Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding.
  JOURNAL   Am J Kidney Dis 47:539-48 (2006)
REFERENCE   PMID:16431249 (description, gene)
  AUTHORS   Saito T, Matsunaga A, Oikawa S
  TITLE     Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
  JOURNAL   Am J Kidney Dis 47:199-211 (2006)
///
ENTRY       H00888                      Disease
NAME        Nephrolithiasis/osteoporosis, hypophosphatemic
DESCRIPTION Nephrolithiasis/osteoporosis, hypophosphatemic is a genetically heterologous group of disorders characterized by the formation of renal calcium stones or bone demineralization due to impaired renal phosphate reabsorption. It is caused by either mutations in NPT2A, a sodium-phosphate cotransporter expressed in kidney and polarized osteoclasts, or in sodium-hydrogen exchanger regulatory factor (NHERF)1, that controls renal phosphate transport by trafficking NPT2A.
CATEGORY    Kidney disease; Skeletal dysplasia
GENE        (type 1) NPT2A [HSA:6569] [KO:K14683]
            (type 2) NHERF1 [HSA:9368] [KO:K13365]
DBLINKS     MeSH: C567363 C567362
            OMIM: 612286 612287
REFERENCE   PMID:20924400 (description)
  AUTHORS   Alizadeh Naderi AS, Reilly RF
  TITLE     Hereditary disorders of renal phosphate wasting.
  JOURNAL   Nat Rev Nephrol 6:657-65 (2010)
REFERENCE   PMID:15483460 (description, gene)
  AUTHORS   Prie D, Beck L, Friedlander G, Silve C
  TITLE     Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization.
  JOURNAL   Curr Opin Nephrol Hypertens 13:675-81 (2004)
REFERENCE   PMID:12324554 (gene)
  AUTHORS   Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G
  TITLE     Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.
  JOURNAL   N Engl J Med 347:983-91 (2002)
REFERENCE   PMID:18784102 (gene)
  AUTHORS   Karim Z, Gerard B, Bakouh N, Alili R, Leroy C, Beck L, Silve C, Planelles G, Urena-Torres P, Grandchamp B, Friedlander G, Prie D
  TITLE     NHERF1 mutations and responsiveness of renal parathyroid hormone.
  JOURNAL   N Engl J Med 359:1128-35 (2008)
///
ENTRY       H00889                      Disease
NAME        MED12-related disorders, including:
            Lujan-Fryns syndrome (LFS);
            Lujan syndrome;
            X-linked mental retardation with Marfanoid habitus;
            FG syndrome type 1 (FGS1);
            Opitz-Kaveggia syndrome
DESCRIPTION Lujan-Fryns syndrome (LFS) and FG syndrome type 1 (FGS1) are X-linked mental retardation (XLMR) syndromes. These two syndromes are allelic, with different mutations in the MED12 gene. LFS and FGS1 share certain clinical findings (dysgenesis of the corpus callosum, macrocephaly, a tall forehead, a high palate, hypotonia, mental retardation, and behavioural disturbances). Anal anomalies/constipation are common in FGS1, and tall stature, long hands and fingers, and hypernasal speech are common in families with LFS.
CATEGORY    Skeletal dysplasia; Nervous system disease
GENE        MED12 [HSA:9968] [KO:K15162]
COMMENT     A recurrent mutation (c.2881C->T, p.R961W) in exon 21 of MED12 gene has been found in the family with FGS. A separate sequence alteration (c.3020A->G, p.N1007S) in exon 22 of the MED12 gene has been found in the family with LFS.
DBLINKS     ICD-10: F79 Q87.8
            MeSH: C537724 C537923
            OMIM: 309520 305450
REFERENCE   PMID:17369503 (description, gene, comment)
  AUTHORS   Schwartz CE, Tarpey PS, Lubs HA, Verloes A, May MM, Risheg H, Friez MJ, Futreal PA, Edkins S, Teague J, Briault S, Skinner C, Bauer-Carlin A, Simensen RJ, Joseph SM, Jones JR, Gecz J, Stratton MR, Raymond FL, Stevenson RE
  TITLE     The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene.
  JOURNAL   J Med Genet 44:472-7 (2007)
REFERENCE   PMID:20301719 (description, gene)
  AUTHORS   Lyons MJ
  TITLE     MED12-Related Disorders
  JOURNAL   (1993)
///
ENTRY       H00890                      Disease
NAME        Azoospermia, including:
            Azoospermia;
            Azoospermia due to perturbations of meiosis
DESCRIPTION Azoospermia is a disorder in which there is a complete absence of sperm in the semen. It is classified as obstructive azoospermia caused by problems with sperm transport and nonobstructive azoospermia caused by failure of spermatogenesis. Y-linked gene USP9Y has been implicated in moderate oligoasthenoteratozoospermia and azoospermia. SYCP3 mutations lead to complete infertility due to meiotic arrest.
CATEGORY    Reproductive system disease
GENE        USP9Y [HSA:8287] [KO:K11840]
            (meiosis) SYCP3 [HSA:50511] [KO:K19528]
DBLINKS     ICD-10: N46
            MeSH: D053713 C536875
            OMIM: 415000 270960
REFERENCE   PMID:21195467 (description)
  AUTHORS   Lee JY, Dada R, Sabanegh E, Carpi A, Agarwal A
  TITLE     Role of genetics in azoospermia.
  JOURNAL   Urology 77:598-601 (2011)
REFERENCE   PMID:19246366 (description, gene)
  AUTHORS   Tyler-Smith C, Krausz C
  TITLE     The will-o'-the-wisp of genetics--hunting for the azoospermia factor gene.
  JOURNAL   N Engl J Med 360:925-7 (2009)
REFERENCE   PMID:19246359 (description, gene)
  AUTHORS   Luddi A, Margollicci M, Gambera L, Serafini F, Cioni M, De Leo V, Balestri P, Piomboni P
  TITLE     Spermatogenesis in a man with complete deletion of USP9Y.
  JOURNAL   N Engl J Med 360:881-5 (2009)
REFERENCE   PMID:14643120 (description, gene)
  AUTHORS   Miyamoto T, Hasuike S, Yogev L, Maduro MR, Ishikawa M, Westphal H, Lamb DJ
  TITLE     Azoospermia in patients heterozygous for a mutation in SYCP3.
  JOURNAL   Lancet 362:1714-9 (2003)
REFERENCE   PMID:19110213 (description)
  AUTHORS   Bolor H, Mori T, Nishiyama S, Ito Y, Hosoba E, Inagaki H, Kogo H, Ohye T, Tsutsumi M, Kato T, Tong M, Nishizawa H, Pryor-Koishi K, Kitaoka E, Sawada T, Nishiyama Y, Udagawa Y, Kurahashi H
  TITLE     Mutations of the SYCP3 gene in women with recurrent pregnancy loss.
  JOURNAL   Am J Hum Genet 84:14-20 (2009)
///
ENTRY       H00891                      Disease
NAME        Combined oxidative phosphorylation deficiency (COXPD)
DESCRIPTION Combined oxidative phosphorylation deficiency (COXPD) is a group of multisystem disorders with variable manifestations resulting from a defect in the mitochondrial oxidative phosphorylation system. It has been reported that the mutations in the ribosomal protein gene (MRPS16 and MRPS22) cause severe antenatal-onset infantile disease. The patients with COXPD caused by mutations in mitochondrial translation elongation factor genes (GFM1, TUFM, TSFM and C12orf65) have also been reported.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        (COXPD1) GFM1 [HSA:85476] [KO:K02355]
            (COXPD2) MRPS16 [HSA:51021] [KO:K02959]
            (COXPD3) TSFM [HSA:10102] [KO:K02357]
            (COXPD4) TUFM [HSA:7284] [KO:K02358]
            (COXPD5) MRPS22 [HSA:56945] [KO:K17401]
            (COXPD6) AIFM1 [HSA:9131] [KO:K04727]
            (COXPD7) C12orf65 [HSA:91574]
DBLINKS     MeSH: C563797 C566468 C566467 C565690 C567126
            OMIM: 609060 610498 610505 610678 611719 300816 613559
REFERENCE   PMID:21169334
  AUTHORS   Kemp JP, Smith PM, Pyle A, Neeve VC, Tuppen HA, Schara U, Talim B, Topaloglu H, Holinski-Feder E, Abicht A, Czermin B, Lochmuller H, McFarland R, Chinnery PF, Chrzanowska-Lightowlers ZM, Lightowlers RN, Taylor RW, Horvath R
  TITLE     Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency.
  JOURNAL   Brain 134:183-95 (2011)
REFERENCE   PMID:15505824
  AUTHORS   Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag A, Hershkovitz E, Elpeleg O
  TITLE     Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation.
  JOURNAL   Ann Neurol 56:734-8 (2004)
REFERENCE   PMID:17033963
  AUTHORS   Smeitink JA, Elpeleg O, Antonicka H, Diepstra H, Saada A, Smits P, Sasarman F, Vriend G, Jacob-Hirsch J, Shaag A, Rechavi G, Welling B, Horst J, Rodenburg RJ, van den Heuvel B, Shoubridge EA
  TITLE     Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs.
  JOURNAL   Am J Hum Genet 79:869-77 (2006)
REFERENCE   PMID:17160893
  AUTHORS   Valente L, Tiranti V, Marsano RM, Malfatti E, Fernandez-Vizarra E, Donnini C, Mereghetti P, De Gioia L, Burlina A, Castellan C, Comi GP, Savasta S, Ferrero I, Zeviani M
  TITLE     Infantile encephalopathy and defective mitochondrial DNA translation in patients  with mutations of mitochondrial elongation factors EFG1 and EFTu.
  JOURNAL   Am J Hum Genet 80:44-58 (2007)
REFERENCE   PMID:17873122
  AUTHORS   Saada A, Shaag A, Arnon S, Dolfin T, Miller C, Fuchs-Telem D, Lombes A, Elpeleg O
  TITLE     Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation.
  JOURNAL   J Med Genet 44:784-6 (2007)
REFERENCE   PMID:20362274
  AUTHORS   Ghezzi D, Sevrioukova I, Invernizzi F, Lamperti C, Mora M, D'Adamo P, Novara F, Zuffardi O, Uziel G, Zeviani M
  TITLE     Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor.
  JOURNAL   Am J Hum Genet 86:639-49 (2010)
REFERENCE   PMID:20598281
  AUTHORS   Antonicka H, Ostergaard E, Sasarman F, Weraarpachai W, Wibrand F, Pedersen AM, Rodenburg RJ, van der Knaap MS, Smeitink JA, Chrzanowska-Lightowlers ZM, Shoubridge EA
  TITLE     Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect.
  JOURNAL   Am J Hum Genet 87:115-22 (2010)
///
ENTRY       H00892                      Disease
NAME        Bronchiectasis with or without elevated sweat chloride
DESCRIPTION Bronchiectasis is a condition in which the airways are permanently dilated due to recurrent inflammation or infection. In many cases, the cause is unknown but recently some of the patients have been shown to have mutations in the epithelial sodium channel ENaC. Furthermore, a three-fold significant increase in incidence of several rare ENaC polymorphisms was found in the patients.
CATEGORY    Respiratory disease
GENE        SCNN1B [HSA:6338] [KO:K04825]
            SCNN1A [HSA:6337] [KO:K04824]
            SCNN1G [HSA:6340] [KO:K04827]
DBLINKS     ICD-10: J47
            MeSH: D001987
            OMIM: 211400 613021 613071
REFERENCE   PMID:22211147 (description, gene)
  AUTHORS   Rademacher J, Welte T
  TITLE     Bronchiectasis-diagnosis and treatment.
  JOURNAL   Dtsch Arztebl Int 108:809-15 (2011)
REFERENCE   PMID:18507830 (description, gene)
  AUTHORS   Fajac I, Viel M, Sublemontier S, Hubert D, Bienvenu T
  TITLE     Could a defective epithelial sodium channel lead to bronchiectasis.
  JOURNAL   Respir Res 9:46 (2008)
REFERENCE   PMID:19462466 (description, gene)
  AUTHORS   Azad AK, Rauh R, Vermeulen F, Jaspers M, Korbmacher J, Boissier B, Bassinet L, Fichou Y, des Georges M, Stanke F, De Boeck K, Dupont L, Balascakova M, Hjelte L, Lebecque P, Radojkovic D, Castellani C, Schwartz M, Stuhrmann M, Schwarz M, Skalicka V, de Monestrol I, Girodon E, Ferec C, Claustres M, Tummler B, Cassiman JJ, Korbmacher C, Cuppens H
  TITLE     Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease.
  JOURNAL   Hum Mutat 30:1093-103 (2009)
///
ENTRY       H00893                      Disease
NAME        Skin fragility-woolly hair syndrome
DESCRIPTION Skin fragility-woolly hair syndrome is a rare autosomal recessive genodermatosis caused by defective desmoplakin, an important desmosomal plaque protein. Patients with skin fragility-woolly hair syndrome present with symptoms including focal and diffuse palmoplantar keratoderma, woolly hair, varying degrees of alopecia, and dystrophic nails. Unlike other disorders associated with desmoplakin mutation, no cardiac symptoms are reported in this disease.
CATEGORY    Skin and connective tissue disease
GENE        DSP [HSA:1832] [KO:K10381]
DBLINKS     MeSH: C564359
            OMIM: 607655
REFERENCE   PMID:20738328 (description, gene)
  AUTHORS   Al-Owain M, Wakil S, Shareef F, Al-Fatani A, Hamadah E, Haider M, Al-Hindi H, Awaji A, Khalifa O, Baz B, Ramadhan R, Meyer B
  TITLE     Novel homozygous mutation in DSP causing skin fragility-woolly hair syndrome: report of a large family and review of the desmoplakin-related phenotypes.
  JOURNAL   Clin Genet 80:50-8 (2011)
REFERENCE   PMID:11841538 (description, gene)
  AUTHORS   Whittock NV, Wan H, Morley SM, Garzon MC, Kristal L, Hyde P, McLean WH, Pulkkinen L, Uitto J, Christiano AM, Eady RA, McGrath JA
  TITLE     Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome.
  JOURNAL   J Invest Dermatol 118:232-8 (2002)
///
ENTRY       H00894                      Disease
NAME        FG syndrome (FGS);
            Opitz-Kaveggia syndrome
DESCRIPTION FG syndrome (FGS), also known as Opitz-Kaveggia syndrome, is a rare X-linked multiple congenital anomaly/mental retardation (MCA/MR) disorder characterized by high clinical variability and genetic heterogeneity. The cardinal features of the syndrome are congenital hypotonia, delayed development of speech, relative macrocephaly (as compared to height and weight), anal anomalies or severe constipation, and dysmorphic facial features. Five loci have so far been linked to this phenotype on the X chromosome. A recurrent missense mutation in the MED12 gene has been identified as the cause for the subset of FGS cases. Filamin A gene (FLNA) and CASK gene mutations could be another causes of FG syndrome.
CATEGORY    Skeletal dysplasia; Nervous system disease
GENE        (FGS1) MED12 [HSA:9968] [KO:K15162]
            (FGS2) FLNA [HSA:2316] [KO:K04437]
            (FGS4) CASK [HSA:8573] [KO:K06103]
DBLINKS     ICD-10: Q87.8
            MeSH: C537923
            OMIM: 305450 300321 300422
REFERENCE   PMID:17632775 (description, gene)
  AUTHORS   Unger S, Mainberger A, Spitz C, Bahr A, Zeschnigk C, Zabel B, Superti-Furga A, Morris-Rosendahl DJ
  TITLE     Filamin A mutation is one cause of FG syndrome.
  JOURNAL   Am J Med Genet A 143A:1876-9 (2007)
REFERENCE   PMID:19200522 (description, gene)
  AUTHORS   Piluso G, D'Amico F, Saccone V, Bismuto E, Rotundo IL, Di Domenico M, Aurino S, Schwartz CE, Neri G, Nigro V
  TITLE     A missense mutation in CASK causes FG syndrome in an Italian family.
  JOURNAL   Am J Hum Genet 84:162-77 (2009)
///
ENTRY       H00895                      Disease
NAME        Basal cell nevus syndrome;
            Nevoid basal cell carcinoma syndrome;
            Gorlin syndrome
DESCRIPTION Basal cell nevus syndrome is a rare autosomal dominant disorder that predisposes to tumor formation especially basal cell carcinomas associated with developmental abnormalities such as odontogenic keratocyst of the mandible, calcification of the falx cerebri, multiple nevi, and skeletal anomalies. The genetic basis of the syndrome is defective hedgehog signaling pathway.
CATEGORY    Skin and connective tissue disease
GENE        PTCH1 [HSA:5727] [KO:K06225]
            PTCH2 [HSA:8643] [KO:K11101]
            SUFU [HSA:51684] [KO:K06229]
DBLINKS     ICD-10: D36.9
            MeSH: D001478
            OMIM: 109400
REFERENCE   PMID:21834049 (description, gene)
  AUTHORS   Bree AF, Shah MR
  TITLE     Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS).
  JOURNAL   Am J Med Genet A 155A:2091-7 (2011)
REFERENCE   PMID:19557015 (description, gene)
  AUTHORS   Takahashi C, Kanazawa N, Yoshikawa Y, Yoshikawa R, Saitoh Y, Chiyo H, Tanizawa T, Hashimoto-Tamaoki T, Nakano Y
  TITLE     Germline PTCH1 mutations in Japanese basal cell nevus syndrome patients.
  JOURNAL   J Hum Genet 54:403-8 (2009)
REFERENCE   PMID:18285427 (description, gene)
  AUTHORS   Fan Z, Li J, Du J, Zhang H, Shen Y, Wang CY, Wang S
  TITLE     A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family.
  JOURNAL   J Med Genet 45:303-8 (2008)
REFERENCE   PMID:19533801 (description, gene)
  AUTHORS   Pastorino L, Ghiorzo P, Nasti S, Battistuzzi L, Cusano R, Marzocchi C, Garre ML, Clementi M, Scarra GB
  TITLE     Identification of a SUFU germline mutation in a family with Gorlin syndrome.
  JOURNAL   Am J Med Genet A 149A:1539-43 (2009)
REFERENCE   PMID:20875327 (description)
  AUTHORS   Shivaswamy KN, Sumathy TK, Shyamprasad AL, Ranganathan C
  TITLE     Gorlin syndrome or basal cell nevus syndrome (BCNS): A case report.
  JOURNAL   Dermatol Online J 16:6 (2010)
REFERENCE   PMID:22028568 (description)
  AUTHORS   Go JW, Kim SH, Yi SY, Cho HK
  TITLE     Basal cell nevus syndrome showing several histologic types of Basal cell carcinoma.
  JOURNAL   Ann Dermatol 23 Suppl 1:S36-40 (2011)
///
ENTRY       H00896                      Disease
NAME        Lymphangioleiomyomatosis (LAM)
DESCRIPTION Lymphangioleiomyomatosis (LAM) is a rare lung disease, primarily affecting women. Abnormal proliferation of smooth muscle-like cells (LAM cells) within the lung is responsible for cystic destruction of the lung parenchyma and leads to chronic respiratory failure. Another characteristic feature of the disease is the development of fluid-filled lymphatic cystic structures (lymphangioleiomyomas) in the axial lymphatics and of angiomyolipomas in the kidneys. Its presentation is sporadic or associated with tuberous sclerosis complex, a dominant autosomal neurocutaneous syndrome. Both disorders have their origin in mutations of the tuberous sclerosis genes TSC1 and TSC2, which are involved in the regulation of cell signs critical for energy control and cell nutrition processes.
CATEGORY    Cancer; Cardiovascular disease; Immune system disease
GENE        TSC1 [HSA:7248] [KO:K07206]
            TSC2 [HSA:7249] [KO:K07207]
DRUG        Sirolimus [DR:D00753]
DBLINKS     ICD-10: I89.8
            OMIM: 606690
REFERENCE   PMID:21880281 (description, gene)
  AUTHORS   Taveira-Dasilva AM, Rabel A, Gochuico BR, Avila NA, Moss J
  TITLE     Prevalence of uterine leiomyomas in lymphangioleiomyomatosis.
  JOURNAL   Fertil Steril 96:711-714.e1 (2011)
REFERENCE   PMID:21760507 (description, gene, drug)
  AUTHORS   Taille C, Borie R, Crestani B
  TITLE     Current management of lymphangioleiomyomatosis.
  JOURNAL   Curr Opin Pulm Med 17:374-8 (2011)
REFERENCE   PMID:21255897 (description, gene)
  AUTHORS   Ansotegui Barrera E, Mancheno Franch N, Vera-Sempere F, Padilla Alarcon J
  TITLE     Lymphangioleiomyomatosis.
  JOURNAL   Arch Bronconeumol 47:85-93 (2011)
///
ENTRY       H00897                      Disease
NAME        Pontocerebellar hypoplasia
DESCRIPTION Pontocerebellar hypoplasia (PCH) is a group of inherited progressive neurodegenerative disorders with prenatal onset. Up to now seven different subtypes have been reported. All subtypes share common characteristics, including hypoplasia/atrophy of cerebellum and pons, progressive microcephaly, and variable cerebral involvement. Mutations in three tRNA splicing endonuclease subunit genes were found to be responsible for PCH2, PCH4 and PCH5. Mutations in the nuclear encoded mitochondrial arginyl- tRNA synthetase gene underlie PCH6. PCH1 is caused by homozygous mutation in the VRK1 gene.
CATEGORY    Neurodegenerative disease; Developmental disorder
GENE        (PCH1) VRK1 [HSA:7443] [KO:K08816]
            (PCH2A/4/5) TSEN54 [HSA:283989] [KO:K15326]
            (PCH2B) TSEN2 [HSA:80746] [KO:K15322]
            (PCH2C) TSEN34 [HSA:79042] [KO:K15323]
            (PCH2D) SEPSECS [HSA:51091] [KO:K03341]
            (PCH6) RARS2 [HSA:57038] [KO:K01887]
DBLINKS     ICD-10: Q04.3
            MeSH: C580383
            OMIM: 607596 277470 225753 612389 612390 611523 613811
REFERENCE   PMID:21749694
  AUTHORS   Namavar Y, Barth PG, Poll-The BT, Baas F
  TITLE     Classification, diagnosis and potential mechanisms in pontocerebellar hypoplasia.
  JOURNAL   Orphanet J Rare Dis 6:50 (2011)
REFERENCE   PMID:21368912
  AUTHORS   Namavar Y, Chitayat D, Barth PG, van Ruissen F, de Wissel MB, Poll-The BT, Silver R, Baas F
  TITLE     TSEN54 mutations cause pontocerebellar hypoplasia type 5.
  JOURNAL   Eur J Hum Genet 19:724-6 (2011)
REFERENCE   PMID:20920667
  AUTHORS   Agamy O, Ben Zeev B, Lev D, Marcus B, Fine D, Su D, Narkis G, Ofir R, Hoffmann C, Leshinsky-Silver E, Flusser H, Sivan S, Soll D, Lerman-Sagie T, Birk OS
  TITLE     Mutations disrupting selenocysteine formation cause progressive cerebello-cerebral atrophy.
  JOURNAL   Am J Hum Genet 87:538-44 (2010)
///
ENTRY       H00898                      Disease
NAME        Myopathy with lactic acidosis and sideroblastic anaemia (MLASA);
            Mitochondrial myopathy and sideroblastic anemia;
            Hereditary myopathy with lactic acidosis (HML)
DESCRIPTION Myopathy with lactic acidosis and sideroblastic anaemia (MLASA) is a rare autosomal recessive oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. MLASA has been associated with a missense mutation in pseudouridylate synthase 1 (PUS1), an enzyme located in both nucleus and mitochondria, which converts uridine into pseudouridine in several cytosolic and mitochondrial tRNA positions and increases the efficiency of protein synthesis in both compartments. Recentry, it has been reported that a mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, also causes MLASA. Myopathy with succinate dehydrogenase and aconitase deficiency has been found to be caused by mutations in the gene encoding the iron-sulphur cluster scaffold protein (ISCU). ISCU is essential for the activity mitochondrial iron-sulphur proteins such as succinate dehydrogenase and aconitase.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        (MLASA1) PUS1 [HSA:80324] [KO:K06173]
            (MLASA2) YARS2 [HSA:51067] [KO:K01866]
            (HML) ISCU [HSA:23479]
MARKER      Lactic acidosis
DBLINKS     ICD-10: G71.3
            OMIM: 600462 613561 255125
REFERENCE   PMID:17056637
  AUTHORS   Fernandez-Vizarra E, Berardinelli A, Valente L, Tiranti V, Zeviani M
  TITLE     Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA).
  JOURNAL   J Med Genet 44:173-80 (2007)
REFERENCE   PMID:20598274
  AUTHORS   Riley LG, Cooper S, Hickey P, Rudinger-Thirion J, McKenzie M, Compton A, Lim SC, Thorburn D, Ryan MT, Giege R, Bahlo M, Christodoulou J
  TITLE     Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome.
  JOURNAL   Am J Hum Genet 87:52-9 (2010)
REFERENCE   PMID:18304497
  AUTHORS   Mochel F, Knight MA, Tong WH, Hernandez D, Ayyad K, Taivassalo T, Andersen PM, Singleton A, Rouault TA, Fischbeck KH, Haller RG
  TITLE     Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy  with exercise intolerance.
  JOURNAL   Am J Hum Genet 82:652-60 (2008)
///
ENTRY       H00899                      Disease
NAME        Lysinuric protein intolerance (LPI)
DESCRIPTION Lysinuric protein intolerance (LPI) is an inherited aminoaciduria caused by defective amino acid transport at the basolateral membrane of epithelial cells in intestine and kidney. Patients affected by this disorder, in general, come to medical attention from early on in life with several significant problems including failure to thrive and intellectual impairment. LPI is caused by mutations in the SLC7A7 gene, which encodes the y+LAT-1 protein, the catalytic light chain subunit of a complex belonging to the heterodimeric amino acid transporter family.
CATEGORY    Inherited metabolic disease
GENE        SLC7A7 [HSA:9056] [KO:K13867]
DRUG        Citrulline [DR:D07706]
DBLINKS     ICD-10: E72.0
            MeSH: C562687
            OMIM: 222700
REFERENCE   PMID:18200002 (description, gene, drug)
  AUTHORS   Camargo SM, Bockenhauer D, Kleta R
  TITLE     Aminoacidurias: Clinical and molecular aspects.
  JOURNAL   Kidney Int 73:918-25 (2008)
REFERENCE   PMID:21308987 (description, gene)
  AUTHORS   Sebastio G, Sperandeo MP, Andria G
  TITLE     Lysinuric protein intolerance: reviewing concepts on a multisystem disease.
  JOURNAL   Am J Med Genet C Semin Med Genet 157:54-62 (2011)
REFERENCE   PMID:17764084 (description, gene)
  AUTHORS   Sperandeo MP, Andria G, Sebastio G
  TITLE     Lysinuric protein intolerance: update and extended mutation analysis of the SLC7A7 gene.
  JOURNAL   Hum Mutat 29:14-21 (2008)
///
ENTRY       H00900                      Disease
NAME        Geleophysic dysplasia
DESCRIPTION Geleophysic dysplasia is an autosomal recessive disorder resembling a lysosomal storage disorder. It is characterized by short stature, short hands and feet due to short, plump tubular bones, stiff joints, distinctive facial features, and progressive valvular cardiac disease.
CATEGORY    Developmental disorder
GENE        ADAMTSL2 [HSA:9719]
            FBN1 [HSA:2200] [KO:K06825]
DBLINKS     MeSH: C535662
            OMIM: 231050 614185
REFERENCE   PMID:6507495 (description)
  AUTHORS   Spranger J, Gilbert EF, Arya S, Hoganson GM, Opitz JM
  TITLE     Geleophysic dysplasia.
  JOURNAL   Am J Med Genet 19:487-99 (1984)
REFERENCE   PMID:20301776 (description, gene)
  AUTHORS   Cormier-Daire V, Le Goff C
  TITLE     Geleophysic Dysplasia
  JOURNAL   (1993)
REFERENCE   PMID:21415077 (gene)
  AUTHORS   Allali S, Le Goff C, Pressac-Diebold I, Pfennig G, Mahaut C, Dagoneau N, Alanay Y, Brady AF, Crow YJ, Devriendt K, Drouin-Garraud V, Flori E, Genevieve D, Hennekam RC, Hurst J, Krakow D, Le Merrer M, Lichtenbelt KD, Lynch SA, Lyonnet S, MacDermot K, Mansour S, Megarbane A, Santos HG, Splitt M, Superti-Furga A, Unger S, Williams D, Munnich A, Cormier-Daire V
  TITLE     Molecular screening of ADAMTSL2 gene in 33 patients reveals the genetic heterogeneity of geleophysic dysplasia.
  JOURNAL   J Med Genet 48:417-21 (2011)
REFERENCE   PMID:21683322 (gene)
  AUTHORS   Le Goff C, Mahaut C, Wang LW, Allali S, Abhyankar A, Jensen S, Zylberberg L, Collod-Beroud G, Bonnet D, Alanay Y, Brady AF, Cordier MP, Devriendt K, Genevieve D, Kiper PO, Kitoh H, Krakow D, Lynch SA, Le Merrer M, Megarbane A, Mortier G, Odent S, Polak M, Rohrbach M, Sillence D, Stolte-Dijkstra I, Superti-Furga A, Rimoin DL, Topouchian V, Unger S, Zabel B, Bole-Feysot C, Nitschke P, Handford P, Casanova JL, Boileau C, Apte SS, Munnich A, Cormier-Daire V
  TITLE     Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias.
  JOURNAL   Am J Hum Genet 89:7-14 (2011)
///
ENTRY       H00901                      Disease
NAME        Cystinuria
DESCRIPTION Cystinuria is a inherited disorder of re-absorptive transport of cystine and the dibasic amino acids ornithine, arginine and lysine in the proximal tubule and small intestine. Diagnostically, urinary levels of dibasic amino acids lysine, arginine, and ornithine, and most prominently, of cystine are constantly elevated. Plasma levels of these amino acids in general are at the lower end of the normal range. Patients with cystinuria often present with nephro- or urolithiasis at almost at any age with a clear preference in childhood due to elevated urinary cystine. Early diagnosis is important, as it allows prevention or diminution of kidney stones. Mutations in either interacting subunit SLC3A1 (rBAT) or SLC7A9 (b0,+AT) cause cystinuria. Cystinuria due to mutations in SLC3A1 is an autosomal recessive trait, whereas mutations in SLC7A9 can be seen as an autosomal dominant trait.
CATEGORY    Inherited metabolic disease; Urinary system disease; Kidney disease
GENE        SLC3A1 [HSA:6519] [KO:K14210]
            SLC7A9 [HSA:11136] [KO:K13868]
MARKER      (Urinary elevated) Cystine [CPD:C01420]
            Ornithine [CPD:C00077]
            Arginine [CPD:C00062]
            Lysine [CPD:C00047]
DBLINKS     ICD-10: E72.0
            MeSH: D003555
            OMIM: 220100
REFERENCE   PMID:18781961 (description, gene)
  AUTHORS   Martens K, Jaeken J, Matthijs G, Creemers JW
  TITLE     Multi-system disorder syndromes associated with cystinuria type I.
  JOURNAL   Curr Mol Med 8:544-50 (2008)
REFERENCE   PMID:21308987
  AUTHORS   Sebastio G, Sperandeo MP, Andria G
  TITLE     Lysinuric protein intolerance: reviewing concepts on a multisystem disease.
  JOURNAL   Am J Med Genet C Semin Med Genet 157:54-62 (2011)
REFERENCE   PMID:18200002 (description, gene)
  AUTHORS   Camargo SM, Bockenhauer D, Kleta R
  TITLE     Aminoacidurias: Clinical and molecular aspects.
  JOURNAL   Kidney Int 73:918-25 (2008)
///
ENTRY       H00902                      Disease
NAME        Speech-language disorder 1 (SPCH1)
DESCRIPTION Speech-language disorder-1 is an autosomal dominant disorder caused by mutations of the FOXP2 transcription factor gene. It has been reported that mutations of the FOXP2 cause a monogenic syndrome characterized by impaired speech development and linguistic deficits.
CATEGORY    Congenital disorder
GENE        FOXP2 [HSA:93986] [KO:K09409]
DBLINKS     MeSH: D001072
            OMIM: 602081
REFERENCE   PMID:19304338
  AUTHORS   Fisher SE, Scharff C
  TITLE     FOXP2 as a molecular window into speech and language.
  JOURNAL   Trends Genet 25:166-77 (2009)
REFERENCE   PMID:17196932
  AUTHORS   Mizutani A, Matsuzaki A, Momoi MY, Fujita E, Tanabe Y, Momoi T
  TITLE     Intracellular distribution of a speech/language disorder associated FOXP2 mutant.
  JOURNAL   Biochem Biophys Res Commun 353:869-74 (2007)
///
ENTRY       H00903                      Disease
NAME        Congenital clubfoot;
            Congenital talipes equinovarus
DESCRIPTION Congenital clubfoot is an idiopathic deformity of the lower limb that consists of malalignment of the bones and joints of the foot and ankle. It is defined as a fixation of the foot in a hand-like orientation. The calcaneus, navicular and cuboid bones are medially rotated in relation to talus. PITX1 haploinsufficiency accounts for the disease by causing developmental field defect during embryogenesis.
CATEGORY    Developmental disorder
GENE        PITX1 [HSA:5307] [KO:K09356]
DBLINKS     ICD-10: Q66.0
            MeSH: D003025
            OMIM: 119800
REFERENCE   PMID:21775501 (description, gene)
  AUTHORS   Alvarado DM, McCall K, Aferol H, Silva MJ, Garbow JR, Spees WM, Patel T, Siegel M, Dobbs MB, Gurnett CA
  TITLE     Pitx1 haploinsufficiency causes clubfoot in humans and a clubfoot-like phenotype  in mice.
  JOURNAL   Hum Mol Genet 20:3943-52 (2011)
REFERENCE   PMID:21817922 (description, gene)
  AUTHORS   Dobbs MB, Gurnett CA
  TITLE     Genetics of clubfoot.
  JOURNAL   J Pediatr Orthop B 21:7-9 (2012)
REFERENCE   PMID:12151881 (description)
  AUTHORS   Dietz F
  TITLE     The genetics of idiopathic clubfoot.
  JOURNAL   Clin Orthop Relat Res 39-48 (2002)
REFERENCE   PMID:12587918 (description)
  AUTHORS   Miedzybrodzka Z
  TITLE     Congenital talipes equinovarus (clubfoot): a disorder of the foot but not the hand.
  JOURNAL   J Anat 202:37-42 (2003)
///
ENTRY       H00904                      Disease
NAME        Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities;
            Urban-Rifkin-Davis syndrome
DESCRIPTION Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities or Urban-Rifkin-Davis syndrome is a disorder affecting pulmonary, gastrointestinal, urinary, musculoskeletal, craniofacial, and dermal development. Respiratory distress  with cystic and atelectatic changes in the lungs could be fatal in this disease. Mutations in LTBP4 lead to lack of deposition of LTBP4 into the extracellular matrix and results in increased activity of transforming growth factor-beta.
CATEGORY    Lung disease; Skin and connective tissue disease
GENE        LTBP4 [HSA:8425] [KO:K08023]
DBLINKS     MeSH: C567716
            OMIM: 613177
REFERENCE   PMID:19836010 (description, gene)
  AUTHORS   Urban Z, Hucthagowder V, Schurmann N, Todorovic V, Zilberberg L, Choi J, Sens C, Brown CW, Clark RD, Holland KE, Marble M, Sakai LY, Dabovic B, Rifkin DB, Davis EC
  TITLE     Mutations in LTBP4 cause a syndrome of impaired pulmonary, gastrointestinal, genitourinary, musculoskeletal, and dermal development.
  JOURNAL   Am J Hum Genet 85:593-605 (2009)
REFERENCE   PMID:12208849 (description, gene)
  AUTHORS   Sterner-Kock A, Thorey IS, Koli K, Wempe F, Otte J, Bangsow T, Kuhlmeier K, Kirchner T, Jin S, Keski-Oja J, von Melchner H
  TITLE     Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and  colorectal cancer.
  JOURNAL   Genes Dev 16:2264-73 (2002)
REFERENCE   PMID:21563328 (description, gene)
  AUTHORS   Loeys B, De Paepe A, Urban Z
  TITLE     EFEMP2-Related Cutis Laxa
  JOURNAL   (1993)
///
ENTRY       H00905                      Disease
NAME        Iminoglycinuria
DESCRIPTION Iminoglycinuria is a benign condition characterized by the excretion of proline, hydroxyproline, and glycine in the urine. The disorder is of autosomal recessive inheritance and is genetically complex. Inactivation or reduced function of SLC36A2 (PAT-2) is the predominant determinant of the iminoglycinuria phenotype in humans. Mutations in SLC6A20 (SIT-1) and SLC6A19 (B0AT1) could also be the cause.
CATEGORY    Urinary system disease; Kidney disease; Inherited metabolic disease
GENE        SLC36A2 [HSA:153201] [KO:K14209]
            SLC6A19 [HSA:340024] [KO:K05334]
            SLC6A20 [HSA:54716] [KO:K05048]
DBLINKS     ICD-10: E72.0
            MeSH: C536285
            OMIM: 242600
REFERENCE   PMID:18195088 (description)
  AUTHORS   Broer S
  TITLE     Amino acid transport across mammalian intestinal and renal epithelia.
  JOURNAL   Physiol Rev 88:249-86 (2008)
REFERENCE   PMID:18200002 (description)
  AUTHORS   Camargo SM, Bockenhauer D, Kleta R
  TITLE     Aminoacidurias: Clinical and molecular aspects.
  JOURNAL   Kidney Int 73:918-25 (2008)
REFERENCE   PMID:20377526 (description, gene)
  AUTHORS   Vanslambrouck JM, Broer A, Thavyogarajah T, Holst J, Bailey CG, Broer S, Rasko JE
  TITLE     Renal imino acid and glycine transport system ontogeny and involvement in developmental iminoglycinuria.
  JOURNAL   Biochem J 428:397-407 (2010)
///
ENTRY       H00906                      Disease
NAME        Macrocephaly, alopecia, cutis laxa, and scoliosis;
            MACS syndrome
DESCRIPTION Macrocephaly, alopecia, cutis laxa, and scoliosis is an autosomal-recessive disorder related to the cutis laxa group of inherited disorders associated with macrocephaly, sparse hair, redundant skin, hyperlaxity of joints, gingival hypertrophy, retrognathia with abnormal skull morphology, and severe scoliosis. Homozygous mutations in RIN2, a protein that is involved in the regulation of endocytosis, have been reported.
CATEGORY    Skin and connective tissue disease
GENE        RIN2 [HSA:54453]
DBLINKS     MeSH: C567770
            OMIM: 613075
REFERENCE   PMID:19631308 (description, gene)
  AUTHORS   Basel-Vanagaite L, Sarig O, Hershkovitz D, Fuchs-Telem D, Rapaport D, Gat A, Isman G, Shirazi I, Shohat M, Enk CD, Birk E, Kohlhase J, Matysiak-Scholze U, Maya I, Knopf C, Peffekoven A, Hennies HC, Bergman R, Horowitz M, Ishida-Yamamoto A, Sprecher E
  TITLE     RIN2 deficiency results in macrocephaly, alopecia, cutis laxa, and scoliosis: MACS syndrome.
  JOURNAL   Am J Hum Genet 85:254-63 (2009)
REFERENCE   PMID:20424861 (description, gene)
  AUTHORS   Syx D, Malfait F, Van Laer L, Hellemans J, Hermanns-Le T, Willaert A, Benmansour A, De Paepe A, Verloes A
  TITLE     The RIN2 syndrome: a new autosomal recessive connective tissue disorder caused by deficiency of Ras and Rab interactor 2 (RIN2).
  JOURNAL   Hum Genet 128:79-88 (2010)
///
ENTRY       H00907                      Disease
NAME        Kleefstra syndrome;
            9q Subtelomeric deletion syndrome
DESCRIPTION Kleefstra syndrome, also known as the 9q subtelomeric deletion syndrome is characterized by intellectual disability, childhood hypotonia, and distinctive facial features. About 75% of Kleefstra syndrome is caused by microdeletion of 9q34.3 and 25% by intragenic EHMT1 mutation.
CATEGORY    Developmental disorder; Autism
GENE        EHMT1 [HSA:79813] [KO:K11420]
DBLINKS     MeSH: C563043
            OMIM: 610253
REFERENCE   PMID:21910222
  AUTHORS   Verhoeven WM, Egger JI, Vermeulen K, van de Warrenburg BP, Kleefstra T
  TITLE     Kleefstra syndrome in three adult patients: further delineation of the behavioral and neurological phenotype shows aspects of a neurodegenerative course.
  JOURNAL   Am J Med Genet A 155A:2409-15 (2011)
REFERENCE   PMID:20945554
  AUTHORS   Kleefstra T, Nillesen WM, Yntema HG
  TITLE     Kleefstra Syndrome
  JOURNAL   (1993)
///
ENTRY       H00908                      Disease
NAME        Mowat-Wilson syndrome
DESCRIPTION Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly syndrome characterized by a distinct facial phenotype, intellectual deficiency, epilepsy and variable congenital malformations including Hirschsprung disease, genitourinary anomalies, congenital heart defects, agenesis of the corpus callosum and eye anomalies. MWS is caused by heterozygous mutations or deletions of the ZEB2/ZFHX1B gene.
CATEGORY    Developmental disorder; Mental retardation
GENE        ZEB2 [HSA:9839] [KO:K09299]
DBLINKS     ICD-10: Q43.1
            MeSH: C536990
            OMIM: 235730
REFERENCE   PMID:17958891
  AUTHORS   Garavelli L, Mainardi PC
  TITLE     Mowat-Wilson syndrome.
  JOURNAL   Orphanet J Rare Dis 2:42 (2007)
REFERENCE   PMID:21336163
  AUTHORS   Cui S, Erlichman J, Russo P, Haber BA, Matthews RP
  TITLE     Intrahepatic biliary anomalies in a patient with Mowat-Wilson syndrome uncover a  role for the zinc finger homeobox gene zfhx1b in vertebrate biliary development.
  JOURNAL   J Pediatr Gastroenterol Nutr 52:339-44 (2011)
///
ENTRY       H00909                      Disease
NAME        Cleft palate with ankyloglossia
DESCRIPTION Cleft palate with ankyloglossia is an X-linked semi-dominant craniofacial disorder caused by mutations in the TBX22 transcription factor. It affects male patients and approximately one third of female carriers. It is resulted from failure of the palate to close and affected individuals will have problems with feeding, speech, hearing, and dentition.
CATEGORY    Developmental disorder
GENE        TBX22 [HSA:50945] [KO:K10186]
DBLINKS     ICD-10: Q35
            MeSH: C564442
            OMIM: 303400
REFERENCE   PMID:19648124 (description, gene)
  AUTHORS   Pauws E, Moore GE, Stanier P
  TITLE     A functional haplotype variant in the TBX22 promoter is associated with cleft palate and ankyloglossia.
  JOURNAL   J Med Genet 46:555-61 (2009)
REFERENCE   PMID:11559848 (description, gene)
  AUTHORS   Braybrook C, Doudney K, Marcano AC, Arnason A, Bjornsson A, Patton MA, Goodfellow PJ, Moore GE, Stanier P
  TITLE     The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia.
  JOURNAL   Nat Genet 29:179-83 (2001)
REFERENCE   PMID:21248356 (description, gene)
  AUTHORS   Kantaputra PN, Paramee M, Kaewkhampa A, Hoshino A, Lees M, McEntagart M, Masrour N, Moore GE, Pauws E, Stanier P
  TITLE     Cleft lip with cleft palate, ankyloglossia, and hypodontia are associated with TBX22 mutations.
  JOURNAL   J Dent Res 90:450-5 (2011)
///
ENTRY       H00910                      Disease
NAME        Hirschsprung disease (HD)
DESCRIPTION Hirschsprung disease (HD) is a relatively common cause of intestinal obstruction in the newborn. It is characterized by absence of ganglion cells in the distal bowel and extending proximally for varying distances. Recently, several genes have been identified to be associated with HD. The functions of the gene products include transcription factors regulating gene expression in neural crest cells and in participants in signaling pathways between intestinal mesenchymal cells and neural crest cells.
CATEGORY    Developmental disorder; Digestive disease
GENE        RET [HSA:5979] [KO:K05126]
            EDNRB [HSA:1910] [KO:K04198]
            GDNF [HSA:2668] [KO:K05452]
            EDN3 [HSA:1908] [KO:K05227]
COMMENT     Following syndromes are Hirschsprung-like phenotypes.
            Bardet-Biedl syndrome [DS:H00418]
            Shprintzen-Goldberg syndrome [DS:H00659]
            Waardenburg syndrome [DS:H00759]
            Mowat-Wilson syndrome [DS:H00908]
DBLINKS     ICD-10: Q43.1
            MeSH: D006627
            OMIM: 142623 600155 613711 613712
REFERENCE   PMID:20307847
  AUTHORS   Mundt E, Bates MD
  TITLE     Genetics of Hirschsprung disease and anorectal malformations.
  JOURNAL   Semin Pediatr Surg 19:107-17 (2010)
REFERENCE   PMID:14765367
  AUTHORS   Puri P, Shinkai T
  TITLE     Pathogenesis of Hirschsprung's disease and its variants: recent progress.
  JOURNAL   Semin Pediatr Surg 13:18-24 (2004)
///
ENTRY       H00911                      Disease
NAME        Dicarboxylic aminoaciduria
DESCRIPTION Dicarboxylic aminoaciduria (DA) is an autosomal recessive disorder characterized by a striking excretion of urinary glutamate and aspartate, resulting from the incomplete reabsorption of anionic amino acids from the glomerular filtrate in the kidney. DA is generally considered to be a benign disorder, but cases with mental retardation have been reported as well. Homozygous loss-of-function mutations in SLC1A1 could be associated with DA.
CATEGORY    Urinary system disease; Kidney disease; Inherited metabolic disease
GENE        SLC1A1 [HSA:6505] [KO:K05612]
DBLINKS     MeSH: C536171
            OMIM: 222730
REFERENCE   PMID:21123949 (description, gene)
  AUTHORS   Bailey CG, Ryan RM, Thoeng AD, Ng C, King K, Vanslambrouck JM, Auray-Blais C, Vandenberg RJ, Broer S, Rasko JE
  TITLE     Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria.
  JOURNAL   J Clin Invest 121:446-53 (2011)
REFERENCE   PMID:18195088 (description)
  AUTHORS   Broer S
  TITLE     Amino acid transport across mammalian intestinal and renal epithelia.
  JOURNAL   Physiol Rev 88:249-86 (2008)
///
ENTRY       H00912                      Disease
NAME        Tumor necrosis factor receptor-associated periodic syndrome (TRAPS);
            Familial periodic fever
DESCRIPTION The tumor necrosis factor receptor-associated periodic sydrome (TRAPS) is a multisystem auto-inflammatory disorder that is inherited in an autosomal dominant manner. It is characterized by recurrent febrile attacks and localized inflammation in the absence of autoantibodies. Recurrent fever, abdominal pain, myalgia, and arthralgia are the most common manifestations of TRAPS.
CATEGORY    Autoimmune disease
GENE        TNFRSF1A [HSA:7132] [KO:K03158]
DRUG        Etanercept [DR:D00742]
DBLINKS     ICD-10: R50
            MeSH: C536657
            OMIM: 142680
REFERENCE   PMID:12352631 (description, gene)
  AUTHORS   Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, Dean J, Powell RJ, Kastner DL
  TITLE     The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
  JOURNAL   Medicine (Baltimore) 81:349-68 (2002)
REFERENCE   PMID:16447098 (description, gene)
  AUTHORS   Rezaei N
  TITLE     TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder.
  JOURNAL   Clin Rheumatol 25:773-7 (2006)
REFERENCE   PMID:18408954 (description, gene)
  AUTHORS   Jesus AA, Oliveira JB, Aksentijevich I, Fujihira E, Carneiro-Sampaio MM, Duarte AJ, Silva CA
  TITLE     TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept.
  JOURNAL   Eur J Pediatr 167:1421-5 (2008)
///
ENTRY       H00913                      Disease
NAME        Choreoathetosis, hypothyroidism, and neonatal respiratory distress
DESCRIPTION Choreoathetosis, hypothyroidism, and neonatal respiratory distress is a syndrome of congenital hypothyroidism associated with pulmonary problems, mental retardation, muscular hypotonia and persistent ataxia which could be described as choreoathetosis. This disorder is attributed to mutations of the NKX2.1, a homeodomain transcription factor expressed in the developing thyroid, respiratory epithelium, and specific areas of the forebrain during embrypgenesis.
CATEGORY    Developmental disorder; Endocrine disease; Nervous system disease
GENE        NKX2-1 [HSA:7080] [KO:K09342]
DBLINKS     ICD-10: E03.1 P22.8
            MeSH: C567034
            OMIM: 610978
REFERENCE   PMID:15289765 (description, gene)
  AUTHORS   Doyle DA, Gonzalez I, Thomas B, Scavina M
  TITLE     Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1.
  JOURNAL   J Pediatr 145:190-3 (2004)
REFERENCE   PMID:12566717 (description, gene)
  AUTHORS   Gruters A, Biebermann H, Krude H
  TITLE     Neonatal thyroid disorders.
  JOURNAL   Horm Res 59 Suppl 1:24-9 (2003)
REFERENCE   PMID:18788921 (description, gene)
  AUTHORS   Ferrara AM, De Michele G, Salvatore E, Di Maio L, Zampella E, Capuano S, Del Prete G, Rossi G, Fenzi G, Filla A, Macchia PE
  TITLE     A novel NKX2.1 mutation in a family with hypothyroidism and benign hereditary chorea.
  JOURNAL   Thyroid 18:1005-9 (2008)
///
ENTRY       H00914                      Disease
NAME        Warsaw breakage syndrome
DESCRIPTION Warsaw breakage syndrome is a cohesinopathy characterized by cellular defects in sister chromatid cohesion and hypersensitivity to agents that induce replication stress. It is caused by defective DDX11/ChlR1, a XPD helicase family member. In Warsaw breakage syndrome, features of Fanconi anemia (chromosomal breakage) and Roberts syndrome (sister chromatid cohesion defects) coexist, and individuals with this disorder show severe microcephaly, facial dysmorphy, pre- and post- natal growth retardation, and abnormal skin pigmentation.
CATEGORY    Developmental disorder
GENE        DDX11 [HSA:1663] [KO:K11273]
COMMENT     Fanconi anemia and Roberts syndrome are described in H00238 and H00572, respectively.
DBLINKS     OMIM: 613398
REFERENCE   PMID:20137776 (description, gene)
  AUTHORS   van der Lelij P, Chrzanowska KH, Godthelp BC, Rooimans MA, Oostra AB, Stumm M, Zdzienicka MZ, Joenje H, de Winter JP
  TITLE     Warsaw breakage syndrome, a cohesinopathy associated with mutations in the XPD helicase family member DDX11/ChlR1.
  JOURNAL   Am J Hum Genet 86:262-6 (2010)
REFERENCE   PMID:22102414 (description)
  AUTHORS   Wu Y, Sommers JA, Khan I, de Winter JP, Brosh RM Jr
  TITLE     Biochemical characterization of warsaw breakage syndrome helicase.
  JOURNAL   J Biol Chem 287:1007-21 (2012)
///
ENTRY       H00915                      Disease
NAME        Tuberous sclerosis complex (TSC);
            Bourneville-Pringle disease
DESCRIPTION Tuberous sclerosis complex (TSC), also known as Bourneville-Pringle disease, is a rare, slowly progressive genetic disorder characterized by pervasive benign tumors in most organ systems including the brain, skin, kidney, liver, lung, and heart, which is inherited in an autosomal dominant manner. Patients with TSC are frequently diagnosed with comorbid neurological disorders, including epilepsy, intellectual disability, behavioral dysregulation, sleep disorders, and autism spectrum disorders (ASD). TSC most often results from spontaneous genetic mutations in one or two genes, TSC1 and TSC2, which encode hamartin and tuberin, respectively. These gene products form a physical and functional complex to limit activation of the mammalian target rapamycin (mTOR) complex 1. When these genes are deficient, mTOR complex 1 is constitutively up-regulated, leading to uncontrolled cell growth and protein synthesis.
CATEGORY    Nervous system disease; Skin and connective tissue disease
GENE        TSC1 [HSA:7248] [KO:K07206]
            TSC2 [HSA:7249] [KO:K07207]
DBLINKS     ICD-10: Q85.1
            MeSH: D014402
            OMIM: 191100
REFERENCE   PMID:21692602 (description. gene)
  AUTHORS   Hallett L, Foster T, Liu Z, Blieden M, Valentim J
  TITLE     Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review.
  JOURNAL   Curr Med Res Opin 27:1571-83 (2011)
REFERENCE   PMID:21301339 (description. gene)
  AUTHORS   Tsai P, Sahin M
  TITLE     Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex.
  JOURNAL   Curr Opin Neurol 24:106-13 (2011)
REFERENCE   PMID:21182496 (description. gene)
  AUTHORS   Borkowska J, Schwartz RA, Kotulska K, Jozwiak S
  TITLE     Tuberous sclerosis complex: tumors and tumorigenesis.
  JOURNAL   Int J Dermatol 50:13-20 (2011)
///
ENTRY       H00916                      Disease
NAME        Congenital central hypoventilation syndrome (CCHS)
DESCRIPTION Congenital central hypoventilation syndrome (CCHS) is a disorder characterized by an idiopathic failure of the automatic control of breathing. It is frequently associated with a broad spectrum of dysautonomic symptoms, suggesting the involvement of genes widely expressed in the autonomic nervous system. In particular, the ASCL1-PHOX2A-PHOX2B developmental cascade was proposed as a candidate pathway. Recently, It has been showed that PHOX2B is the major CCHS locus, whose mutation accounts for 60% of cases.
CATEGORY    Nervous system disease
GENE        PHOX2B [HSA:8929] [KO:K09330]
            GDNF [HSA:2668] [KO:K05452]
            RET [HSA:5979] [KO:K05126]
            BDNF [HSA:627] [KO:K04355]
            ASCL1 [HSA:429] [KO:K09067]
            EDN3 [HSA:1908] [KO:K05227]
DBLINKS     ICD-10: G47.3
            MeSH: C536209
            OMIM: 209880
REFERENCE   PMID:14566559
  AUTHORS   Sasaki A, Kanai M, Kijima K, Akaba K, Hashimoto M, Hasegawa H, Otaki S, Koizumi T, Kusuda S, Ogawa Y, Tuchiya K, Yamamoto W, Nakamura T, Hayasaka K
  TITLE     Molecular analysis of congenital central hypoventilation syndrome.
  JOURNAL   Hum Genet 114:22-6 (2003)
REFERENCE   PMID:14532329
  AUTHORS   de Pontual L, Nepote V, Attie-Bitach T, Al Halabiah H, Trang H, Elghouzzi V, Levacher B, Benihoud K, Auge J, Faure C, Laudier B, Vekemans M, Munnich A, Perricaudet M, Guillemot F, Gaultier C, Lyonnet S, Simonneau M, Amiel J
  TITLE     Noradrenergic neuronal development is impaired by mutation of the proneural HASH-1 gene in congenital central hypoventilation syndrome (Ondine's curse).
  JOURNAL   Hum Mol Genet 12:3173-80 (2003)
REFERENCE   PMID:15561428
  AUTHORS   Huang L, Guo H, Hellard DT, Katz DM
  TITLE     Glial cell line-derived neurotrophic factor (GDNF) is required for differentiation of pontine noradrenergic neurons and patterning of central respiratory output.
  JOURNAL   Neuroscience 130:95-105 (2005)
///
ENTRY       H00917                      Disease
NAME        Congenital dyserythropoietic anemias (CDAs)
DESCRIPTION Congenital dyserythropoietic anemias (CDAs) are rare hereditary disorders characterized by ineffective erythropoiesis and by distinct morphological abnormalities of erythroblasts in the bone marrow. Non-erythroid hematopoietic cell lineages are morphologically normal. Three types of the disease are known as type I, II and III, and there is also a huge group of congenital forms that cannot be included with any of the three canonical types. CDA type II is the most widely spread form. CDA type III is the rarest of the three classical types of CDA and both familial and sporadic cases have been reported.
CATEGORY    Hematologic disease
GENE        (CDAN1A) CDAN1 [HSA:146059] [KO:K19531]
            (CDAN1B) C15orf41 [HSA:84529]
            (CDAN2) SEC23B [HSA:10483] [KO:K14006]
            (CDAN4) KLF1 [HSA:10661] [KO:K09204]
COMMENT     (CDAII) SEC23B most frequent mutations: the R14W, E109K, R497C and I318T
DBLINKS     ICD-10: D64.4
            OMIM: 224120 224100 613673 615631
REFERENCE   PMID:21378561 (description, gene)
  AUTHORS   Iolascon A, Russo R, Delaunay J
  TITLE     Congenital dyserythropoietic anemias.
  JOURNAL   Curr Opin Hematol 18:146-51 (2011)
REFERENCE   PMID:21251457 (description, comment)
  AUTHORS   Iolascon A, Russo R, Esposito MR, Piscopo C, Asci R, De Falco L, Di Noce F
  TITLE     Congenital dyserythropoietic anaemias: new acquisitions.
  JOURNAL   Blood Transfus 9:278-80 (2011)
REFERENCE   PMID:20820969 (description)
  AUTHORS   Kamiya T, Manabe A
  TITLE     Congenital dyserythropoietic anemia.
  JOURNAL   Int J Hematol 92:432-8 (2010)
REFERENCE   PMID:21055716 (gene)
  AUTHORS   Arnaud L, Saison C, Helias V, Lucien N, Steschenko D, Giarratana MC, Prehu C, Foliguet B, Montout L, de Brevern AG, Francina A, Ripoche P, Fenneteau O, Da Costa L, Peyrard T, Coghlan G, Illum N, Birgens H, Tamary H, Iolascon A, Delaunay J, Tchernia G, Cartron JP
  TITLE     A dominant mutation in the gene encoding the erythroid transcription factor KLF1  causes a congenital dyserythropoietic anemia.
  JOURNAL   Am J Hum Genet 87:721-7 (2010)
///
ENTRY       H00918                      Disease
NAME        Double-outlet right ventricle
DESCRIPTION Double outlet right ventricle (DORV) is a clinically significant congenital heart defect. DORV is a condition in which the aorta rises from the right ventricle and is associated with ventricular septal defect. Chromosomal abnormalities are present in some cases of DORV. Trisomies 13 and 18, and del 22q11 are the most commonly associated cytogenetic lesions. Mutations in the CFC1 and GDF1 genes were the most commonly reported monogenic loci associated with DORV in humans.
CATEGORY    Cardiovascular disease
GENE        CFC1 [HSA:55997]
            GDF1 [HSA:2657] [KO:K05495]
COMMENT     See also H01525 22q11.2 deletion syndrome.
DBLINKS     ICD-10: Q20.1
            MeSH:D004310
            OMIM: 217095
REFERENCE   PMID:18456715 (description, gene)
  AUTHORS   Obler D, Juraszek AL, Smoot LB, Natowicz MR
  TITLE     Double outlet right ventricle: aetiologies and associations.
  JOURNAL   J Med Genet 45:481-97 (2008)
REFERENCE   PMID:11799476 (description, gene)
  AUTHORS   Goldmuntz E, Bamford R, Karkera JD, dela Cruz J, Roessler E, Muenke M
  TITLE     CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.
  JOURNAL   Am J Hum Genet 70:776-80 (2002)
REFERENCE   PMID:17924340 (description, gene)
  AUTHORS   Karkera JD, Lee JS, Roessler E, Banerjee-Basu S, Ouspenskaia MV, Mez J, Goldmuntz E, Bowers P, Towbin J, Belmont JW, Baxevanis AD, Schier AF, Muenke M
  TITLE     Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans.
  JOURNAL   Am J Hum Genet 81:987-94 (2007)
REFERENCE   PMID:15649947 (description, gene)
  AUTHORS   Heathcote K, Braybrook C, Abushaban L, Guy M, Khetyar ME, Patton MA, Carter ND, Scambler PJ, Syrris P
  TITLE     Common arterial trunk associated with a homeodomain mutation of NKX2.6.
  JOURNAL   Hum Mol Genet 14:585-93 (2005)
REFERENCE   PMID:14585638 (description, gene)
  AUTHORS   Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, Ichida F, Joo K, Kimura M, Imamura S, Kamatani N, Momma K, Takao A, Nakazawa M, Shimizu N, Matsuoka R
  TITLE     Role of TBX1 in human del22q11.2 syndrome.
  JOURNAL   Lancet 362:1366-73 (2003)
///
ENTRY       H00919                      Disease
NAME        Arterial tortuosity syndrome
DESCRIPTION Arterial tortuosity syndrome is an autosomal recessive disorder characterized by tortuosity, elongation, stenosis and aneurysm formation in the large and medium-sized arteries with defective elastic fibers of the arterial wall. Other features of this disease are characteristic face and several connective tissue manifestations. It has been speculated that arterial tortuosity syndrome is caused by the upregulation of TGF-beta signaling that stimulates vessel wall cell proliferation, but other mechanism involving disturbed transport of ascorbate, a cofactor for collagen and elastin hydroxylases, has been proposed recently.
CATEGORY    Vascular disease
GENE        SLC2A10 [HSA:81031] [KO:K08147]
DBLINKS     ICD-10: Q27.8
            OMIM: 208050
REFERENCE   PMID:16550171 (description, gene)
  AUTHORS   Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, Fox JE, Mancini GM, Kambouris M, Gardella R, Facchetti F, Willems PJ, Forsyth R, Dietz HC, Barlati S, Colombi M, Loeys B, De Paepe A
  TITLE     Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome.
  JOURNAL   Nat Genet 38:452-7 (2006)
REFERENCE   PMID:17163528 (description, gene)
  AUTHORS   Drera B, Guala A, Zoppi N, Gardella R, Franceschini P, Barlati S, Colombi M
  TITLE     Two novel SLC2A10/GLUT10 mutations in a patient with arterial tortuosity syndrome.
  JOURNAL   Am J Med Genet A 143:216-8 (2007)
REFERENCE   PMID:20547159 (description, gene)
  AUTHORS   Segade F
  TITLE     Glucose transporter 10 and arterial tortuosity syndrome: the vitamin C connection.
  JOURNAL   FEBS Lett 584:2990-4 (2010)
///
ENTRY       H00920                      Disease
NAME        Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis
DESCRIPTION Patients with this disease suffer from exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis. Mutatioins in COX4I2, an essential component of cytochrome c oxidase complex expressed in acinar cells, leads to failure to absorb fat and deficiency of fat-soluble vitamins.
CATEGORY    Metabolic disease; Pancreas disease; Hematologic disease; Skeletal dysplasia
GENE        COX4I2 [HSA:84701] [KO:K02263]
COMMENT     Shwachman-Bodian-Diamond, Pearson, and Johanson-Blizzard syndromes also show steatorrhea and malabsorption of lipid-soluble vitamin. In addition, Shwachman-Bodian-Diamond and Pearson syndromes are associated with hematologic dysfunction.
DBLINKS     MeSH: C567195
            OMIM: 612714
REFERENCE   PMID:19268275 (description, gene)
  AUTHORS   Shteyer E, Saada A, Shaag A, Al-Hijawi FA, Kidess R, Revel-Vilk S, Elpeleg O
  TITLE     Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene.
  JOURNAL   Am J Hum Genet 84:412-7 (2009)
///
ENTRY       H00921                      Disease
NAME        Revesz syndrome;
            Exudative retinopathy with bone marrow failure
DESCRIPTION Revesz syndrome is a rare congenital disorder characterized by bilateral exudative retinopathy, severe aplastic anaemia, intrauterine growth retardation, fine sparse hair, reticulate skin pigmentation, ataxia because of cerebellar hypoplasia, cerebral calcification, and progressive  psychomotor retardation. Revesz syndrome has many of the features of dyskeratosis congenita. Exudative retinopathy is a diagnostic criterion to establish the diagnosis.
CATEGORY    Congenital disorder; Eye disease; Hematologic disease; Skin and connective tissue disease; Nervous system disease
GENE        TINF2 [HSA:26277] [KO:K11112]
COMMENT     Dyskeratosis congenita is described in H00507.
DBLINKS     MeSH: C538371
            OMIM: 268130
REFERENCE   PMID:17901676 (description)
  AUTHORS   Riyaz A, Riyaz N, Jayakrishnan MP, Mohamed Shiras PT, Ajith Kumar VT, Ajith BS
  TITLE     Revesz syndrome.
  JOURNAL   Indian J Pediatr 74:862-3 (2007)
REFERENCE   PMID:20301779 (description, gene)
  AUTHORS   Savage SA
  TITLE     Dyskeratosis Congenita
  JOURNAL   (1993)
REFERENCE   PMID:18669893 (description, gene)
  AUTHORS   Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I
  TITLE     TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.
  JOURNAL   Blood 112:3594-600 (2008)
REFERENCE   PMID:1404302 (description)
  AUTHORS   Revesz T, Fletcher S, al-Gazali LI, DeBuse P
  TITLE     Bilateral retinopathy, aplastic anaemia, and central nervous system abnormalities: a new syndrome?
  JOURNAL   J Med Genet 29:673-5 (1992)
///
ENTRY       H00922                      Disease
NAME        Schinzel-Giedion midface retraction syndrome
DESCRIPTION Schinzel-Giedion midface retraction syndrome is a rare congenital disorder characterized by severe mental retardation, midface retraction, cardiac and urogenital malformations, skeletal malformations, and neuroepithelial neoplasia. The disorder is lethal and respiratory failure is the major cause of death.
CATEGORY    Developmental disorder
GENE        SETBP1 [HSA:26040]
DBLINKS     ICD-10: Q87.0
            MeSH: C536632
            OMIM: 269150
REFERENCE   PMID:18398855 (description)
  AUTHORS   Lehman AM, McFadden D, Pugash D, Sangha K, Gibson WT, Patel MS
  TITLE     Schinzel-Giedion syndrome: report of splenopancreatic fusion and proposed diagnostic criteria.
  JOURNAL   Am J Med Genet A 146A:1299-306 (2008)
REFERENCE   PMID:20436468 (description, gene)
  AUTHORS   Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M, de Vries P, de Reuver R, Wieskamp N, Mortier G, Devriendt K, Amorim MZ, Revencu N, Kidd A, Barbosa M, Turner A, Smith J, Oley C, Henderson A, Hayes IM, Thompson EM, Brunner HG, de Vries BB, Veltman JA
  TITLE     De novo mutations of SETBP1 cause Schinzel-Giedion syndrome.
  JOURNAL   Nat Genet 42:483-5 (2010)
REFERENCE   PMID:8160760 (description, gene)
  AUTHORS   Labrune P, Lyonnet S, Zupan V, Imbert MC, Goutieres F, Hubert P, Le Merrer M
  TITLE     Three new cases of the Schinzel-Giedion syndrome and review of the literature.
  JOURNAL   Am J Med Genet 50:90-3 (1994)
///
ENTRY       H00923                      Disease
NAME        Congenital systemic glutamine deficiency (CSGD);
            Glutamine synthetase deficiency
DESCRIPTION Congenital systemic glutamine deficiency is a rare developmental disorder with severe brain malformation resulting in multi-organ failure and neonatal death. Glutamine synthetase plays a major role in ammonia detoxification, interorgan nitrogen flux, acid-base homeostasis, and cell signaling. It has been reported that glutamine was largely absent from affected patients serum, urine, and cerebrospinal fluid.
CATEGORY    Inherited metabolic disease
GENE        GLUL [HSA:2752] [KO:K01915]
DBLINKS     ICD-10: E72.8
            MeSH: C536832
            OMIM: 610015
REFERENCE   PMID:16763901
  AUTHORS   Haberle J, Gorg B, Toutain A, Rutsch F, Benoist JF, Gelot A, Suc AL, Koch HG, Schliess F, Haussinger D
  TITLE     Inborn error of amino acid synthesis: human glutamine synthetase deficiency.
  JOURNAL   J Inherit Metab Dis 29:352-8 (2006)
REFERENCE   PMID:16528811
  AUTHORS   Rose C, Jalan R
  TITLE     Congenital glutamine deficiency with glutamine synthetase mutations.
  JOURNAL   N Engl J Med 354:1093-4; author reply 1093-4 (2006)
///
ENTRY       H00924                      Disease
NAME        Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation;
            NHEJ1 syndrome
DESCRIPTION Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation is a syndrome associated with T and B cell-combined lymphocytopenia, growth retardation, microcephaly, and increased cellular radiosensitivity. Mutations in human NHEJ1 can lead to lymphocytopenia due to its role in V(D)J recombination in the immune system. This disease shows features common with the ones observed in LIG4 deficiency or Nijmegen breakage syndrome.
CATEGORY    Primary immunodeficiency
GENE        NHEJ1 [HSA:79840] [KO:K10980]
COMMENT     LIG4 deficiency and Nijmegen breakage syndrome are described in H00094.
DBLINKS     MeSH: C566970
            OMIM: 611291
REFERENCE   PMID:16439204 (description, gene)
  AUTHORS   Buck D, Malivert L, de Chasseval R, Barraud A, Fondaneche MC, Sanal O, Plebani A, Stephan JL, Hufnagel M, le Deist F, Fischer A, Durandy A, de Villartay JP, Revy P
  TITLE     Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly.
  JOURNAL   Cell 124:287-99 (2006)
REFERENCE   PMID:20597108 (description, gene)
  AUTHORS   Dutrannoy V, Demuth I, Baumann U, Schindler D, Konrat K, Neitzel H, Gillessen-Kaesbach G, Radszewski J, Rothe S, Schellenberger MT, Nurnberg G, Nurnberg P, Teik KW, Nallusamy R, Reis A, Sperling K, Digweed M, Varon R
  TITLE     Clinical variability and novel mutations in the NHEJ1 gene in patients with a Nijmegen breakage syndrome-like phenotype.
  JOURNAL   Hum Mutat 31:1059-68 (2010)
REFERENCE   PMID:19223975 (description, gene)
  AUTHORS   Schwartz M, Oren YS, Bester AC, Rahat A, Sfez R, Yitzchaik S, de Villartay JP, Kerem B
  TITLE     Impaired replication stress response in cells from immunodeficiency patients carrying Cernunnos/XLF mutations.
  JOURNAL   PLoS One 4:e4516 (2009)
REFERENCE   PMID:16439205 (description)
  AUTHORS   Ahnesorg P, Smith P, Jackson SP
  TITLE     XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining.
  JOURNAL   Cell 124:301-13 (2006)
///
ENTRY       H00925                      Disease
NAME        2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency;
            HSD10 deficiency
DESCRIPTION 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency is a recently described X-linked inborn error in the metabolism of isoleucine. MHBD is characterized by normal early development followed by progressive loss of mental and motor skills.
CATEGORY    Inherited metabolic disease
GENE        HSD17B10 [HSA:3028] [KO:K08683]
COMMENT     The phenotype of HSD10 deficiency is distinct from that of MRXS10 [DS:H00658], a syndromic form of mental retardation, also caused by mutation in the HSD17B10 gene.
DBLINKS     ICD-10: E71.3
            MeSH: C536080
            OMIM: 300438
REFERENCE   PMID:16148061
  AUTHORS   Perez-Cerda C, Garcia-Villoria J, Ofman R, Sala PR, Merinero B, Ramos J, Garcia-Silva MT, Beseler B, Dalmau J, Wanders RJ, Ugarte M, Ribes A
  TITLE     2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: an X-linked inborn error of isoleucine metabolism that may mimic a mitochondrial disease.
  JOURNAL   Pediatr Res 58:488-91 (2005)
///
ENTRY       H00926                      Disease
NAME        Growth retardation, developmental delay, coarse facies, and early death
DESCRIPTION This disease is characterized by postnatal growth retardation, microcephaly, severe psychomotor delay, functional brain deficits, and characteristic facial dysmorphism. Death within 30 months after birth occurs due to intercurrent infection or unidentified cause in these patients.
CATEGORY    Developmental disorder
GENE        FTO [HSA:79068] [KO:K19469]
DBLINKS     MeSH: C567856
            OMIM: 612938
REFERENCE   PMID:19559399 (description, gene)
  AUTHORS   Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GS, Meyre D, Golzio C, Molinari F, Kadhom N, Etchevers HC, Saudek V, Farooqi IS, Froguel P, Lindahl T, O'Rahilly S, Munnich A, Colleaux L
  TITLE     Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations.
  JOURNAL   Am J Hum Genet 85:106-11 (2009)
///
ENTRY       H00927                      Disease
NAME        Chylomicron retention disease (CRD);
            Anderson disease
DESCRIPTION Chylomicron retention disease (CRD) is a rare autosomal recessive disorder characterized by malabsorption, failure to thrive (FTT), developmental difficulties, mental retardation, abnormal vibration sense, and hyporeflexia. CRD is caused by a mutation in the SAR1B gene, which codes for an essential component of the vesicular coat protein complex II (COPII) necessary for endoplasmic reticulum to Golgi transport.
CATEGORY    Inherited metabolic disease
GENE        SAR1B [HSA:51128] [KO:K07953]
MARKER      Deficiency of fat-soluble vitamins, low blood cholesterol levels, and a selective absence of chylomicrons from blood.
DBLINKS     ICD-10: E78.6
            MeSH: C535460
            OMIM: 246700
REFERENCE   PMID:22104167
  AUTHORS   Okada T, Miyashita M, Fukuhara J, Sugitani M, Ueno T, Samson-Bouma ME, Aggerbeck LP
  TITLE     Anderson's disease/chylomicron retention disease in a Japanese patient with uniparental disomy 7 and a normal SAR1B gene protein coding sequence.
  JOURNAL   Orphanet J Rare Dis 6:78 (2011)
///
ENTRY       H00928                      Disease
NAME        Nephropathy with pretibial epidermolysis bullosa and deafness
DESCRIPTION Nephropathy with pretibial epidermolysis bullosa and deafness is a hereditary nephritis. Patients also have pretibial bullous skin lesions and neurosensory deafness. Nonsense mutations in CD151, an essential protein for the proper assembly of the basement membrane, lead to complete separation of the epidermis from the dermis.
CATEGORY    Kidney disease; Skin and connective tissue disease; Nervous system disease
GENE        CD151 [HSA:977] [KO:K06537]
DBLINKS     MeSH: C563798
            OMIM: 609057
REFERENCE   PMID:15265795 (description, gene)
  AUTHORS   Karamatic Crew V, Burton N, Kagan A, Green CA, Levene C, Flinter F, Brady RL, Daniels G, Anstee DJ
  TITLE     CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin.
  JOURNAL   Blood 104:2217-23 (2004)
REFERENCE   PMID:17015618 (description, gene)
  AUTHORS   Sachs N, Kreft M, van den Bergh Weerman MA, Beynon AJ, Peters TA, Weening JJ, Sonnenberg A
  TITLE     Kidney failure in mice lacking the tetraspanin CD151.
  JOURNAL   J Cell Biol 175:33-9 (2006)
///
ENTRY       H00929                      Disease
NAME        Congenital vertical talus
DESCRIPTION Congenital vertical talus is a primary dislocation of the talonavicular joint of autosomal dominant mode of inheritance. It is associated with rigid dorsal dislocation of the navicular over the neck of the talus, causing a flatfoot deformity known as 'rocker-bottom foot'. It occurs in syndromic deformity but is rarely in isolation.
CATEGORY    Skeletal dysplasia
GENE        HOXD10 [HSA:3236] [KO:K09295]
DBLINKS     MeSH: C536345
            OMIM: 192950
REFERENCE   PMID:20645034 (description, gene)
  AUTHORS   Merrill LJ, Gurnett CA, Connolly AM, Pestronk A, Dobbs MB
  TITLE     Skeletal muscle abnormalities and genetic factors related to vertical talus.
  JOURNAL   Clin Orthop Relat Res 469:1167-74 (2011)
REFERENCE   PMID:15368082 (description, gene)
  AUTHORS   Levinsohn EM, Shrimpton AE, Cady RB, Packard DS, Hootnick DR
  TITLE     Congenital vertical talus in four generations of the same family.
  JOURNAL   Skeletal Radiol 33:649-54 (2004)
REFERENCE   PMID:15146389 (description, gene)
  AUTHORS   Shrimpton AE, Levinsohn EM, Yozawitz JM, Packard DS Jr, Cady RB, Middleton FA, Persico AM, Hootnick DR
  TITLE     A HOX gene mutation in a family with isolated congenital vertical talus and Charcot-Marie-Tooth disease.
  JOURNAL   Am J Hum Genet 75:92-6 (2004)
REFERENCE   PMID:16450407 (description, gene)
  AUTHORS   Dobbs MB, Gurnett CA, Pierce B, Exner GU, Robarge J, Morcuende JA, Cole WG, Templeton PA, Foster B, Bowcock AM
  TITLE     HOXD10 M319K mutation in a family with isolated congenital vertical talus.
  JOURNAL   J Orthop Res 24:448-53 (2006)
///
ENTRY       H00930                      Disease
NAME        Hypoalphalipoproteinemia
DESCRIPTION Hypoalphalipoproteinemia is a common finding in patients with premature coronary artery disease. Familial hypoalphalipoproteinemia syndromes are phenotypically heterogeneous. One form is associated with abnormal cellular cholesterol efflux caused by heterozygous mutations at the ABCA1 gene. Other forms are primary hypoalphalipoproteinemia caused by mutations of APOA1 gene.
CATEGORY    Inherited metabolic disease
GENE        ABCA1 [HSA:19] [KO:K05641]
            APOA1 [HSA:335] [KO:K08757]
COMMENT     Tangier disease [DS:H00159]  is also caused by mutations of ABCA1.
DBLINKS     ICD-10: E78.6
            MeSH: D052456
            OMIM: 604091
REFERENCE   PMID:15841208
  AUTHORS   Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS
  TITLE     Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.
  JOURNAL   J Clin Invest 115:1333-42 (2005)
REFERENCE   PMID:17991432
  AUTHORS   Esperon P, Raggio V, Stoll M, Vital M, Alallon W
  TITLE     A new APOA1 mutation with severe HDL-cholesterol deficiency and premature coronary artery disease.
  JOURNAL   Clin Chim Acta 388:222-4 (2008)
REFERENCE   PMID:10998475
  AUTHORS   Mott S, Yu L, Marcil M, Boucher B, Rondeau C, Genest J Jr
  TITLE     Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations.
  JOURNAL   Atherosclerosis 152:457-68 (2000)
///
ENTRY       H00931                      Disease
NAME        Growth hormone insensitivity with immunodeficiency
DESCRIPTION Growth hormone insensitivity with immunodeficiency is a combined phenotype of growth hormone insensitivity that resembles Laron syndrome and immunodeficiency. Homozygous inactivating mutation in the STAT5b, a component of the GH signaling pathway, leads to a complete absence of protein expression.
CATEGORY    Musculoskeletal disease; Primary immunodeficiency
GENE        STAT5B [HSA:6777] [KO:K11224]
COMMENT     Laron syndrome is described in H00254.
DBLINKS     ICD-10: D82.8 E34.3
            MeSH: C537871
            OMIM: 245590
REFERENCE   PMID:17030597 (description, gene)
  AUTHORS   Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, Ornani A, Paz R, Rivarola MA, Zelazko M, Belgorosky A
  TITLE     Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation.
  JOURNAL   Pediatrics 118:e1584-92 (2006)
REFERENCE   PMID:17287404 (description, gene)
  AUTHORS   Walenkamp MJ, Vidarsdottir S, Pereira AM, Karperien M, van Doorn J, van Duyvenvoorde HA, Breuning MH, Roelfsema F, Kruithof MF, van Dissel J, Janssen R, Wit JM, Romijn JA
  TITLE     Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation.
  JOURNAL   Eur J Endocrinol 156:155-65 (2007)
///
ENTRY       H00932                      Disease
NAME        Tropical calcific pancreatitis
DESCRIPTION Tropical calcific pancreatitis (TCP) is a subtype of chronic pancreatitis unique to developing countries in tropical regions. Patients present with recurrent abdominal pain, nutritional deficiencies, and insulin-requiring diabetes resulting from chronic pancreatitis before age 30. Several environmental and genetic factors are implicated in TCP.
CATEGORY    Pancreas disease
GENE        SPINK1 [HSA:6690]
            CTRC (non-European population) [HSA:11330] [KO:K01311]
            CTSB [HSA:1508] [KO:K01363]
ENV_FACTOR  Protein malnutrition
            Ingestion of cassava roots (cyanogenic glycosides)
DBLINKS     MeSH: C564276
            OMIM: 608189
REFERENCE   PMID:18604651 (description, gene, env_factor)
  AUTHORS   Witt H, Bhatia E
  TITLE     Genetic aspects of tropical calcific pancreatitis.
  JOURNAL   Rev Endocr Metab Disord 9:213-26 (2008)
REFERENCE   PMID:12360463 (description, gene, env_factor)
  AUTHORS   Bhatia E, Choudhuri G, Sikora SS, Landt O, Kage A, Becker M, Witt H
  TITLE     Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor  mutations.
  JOURNAL   Gastroenterology 123:1020-5 (2002)
REFERENCE   PMID:19077465 (description, gene)
  AUTHORS   Sundaresan S, Chacko A, Dutta AK, Bhatia E, Witt H, Te Morsche RH, Jansen JB, Drenth JP
  TITLE     Divergent roles of SPINK1 and PRSS2 variants in tropical calcific pancreatitis.
  JOURNAL   Pancreatology 9:145-9 (2009)
REFERENCE   PMID:21323990 (description, gene)
  AUTHORS   Reddy DN, Prasad SS
  TITLE     Genetic basis of chronic pancreatitis in Asia Pacific region.
  JOURNAL   J Gastroenterol Hepatol 26 Suppl 2:2-5 (2011)
REFERENCE   PMID:18059268 (gene)
  AUTHORS   Rosendahl J, Witt H, Szmola R, Bhatia E, Ozsvari B, Landt O, Schulz HU, Gress TM, Pfutzer R, Lohr M, Kovacs P, Bluher M, Stumvoll M, Choudhuri G, Hegyi P, te Morsche RH, Drenth JP, Truninger K, Macek M Jr, Puhl G, Witt U, Schmidt H, Buning C, Ockenga J, Kage A, Groneberg DA, Nickel R, Berg T, Wiedenmann B, Bodeker H, Keim V, Mossner J, Teich N, Sahin-Toth M
  TITLE     Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis.
  JOURNAL   Nat Genet 40:78-82 (2008)
REFERENCE   PMID:16492714 (gene)
  AUTHORS   Mahurkar S, Idris MM, Reddy DN, Bhaskar S, Rao GV, Thomas V, Singh L, Chandak GR
  TITLE     Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis.
  JOURNAL   Gut 55:1270-5 (2006)
///
ENTRY       H00933                      Disease
NAME        Hereditary pancreatitis;
            Hereditary chronic pancreatitis
DESCRIPTION Hereditary pancreatitis is a very rare form of chronic relapsing pancreatitis.  Its inheritance mode is autosomal dominant with an incomplete penetrance (80%). Patients had recurrent pancreatitis with impairment of endocrine and exocrine pancreatic function, maldigestion, bile duct and duodenal obstruction, and rarely pancreatic cancer. The age of onset is early and differs from the cases of non-hereditary pancreatitis.
CATEGORY    Pancreas disease
GENE        PRSS1 (gain of function) [HSA:5644] [KO:K01312]
            SPINK1 (loss of function) [HSA:6690]
            CFTR (polymorphism) [HSA:1080] [KO:K05031]
            PRSS2 [HSA:5645] [KO:K01312]
            CTRC (polymorphism) [HSA:11330] [KO:K01311]
DBLINKS     ICD-10: K86.1
            MeSH: D010195
            OMIM: 167800
REFERENCE   PMID:21907651 (description, gene)
  AUTHORS   Rebours V, Levy P, Ruszniewski P
  TITLE     An overview of hereditary pancreatitis.
  JOURNAL   Dig Liver Dis 44:8-15 (2012)
REFERENCE   PMID:17204147 (description, gene)
  AUTHORS   Rosendahl J, Bodeker H, Mossner J, Teich N
  TITLE     Hereditary chronic pancreatitis.
  JOURNAL   Orphanet J Rare Dis 2:1 (2007)
REFERENCE   PMID:17238030 (description, gene)
  AUTHORS   Naruse S, Fujiki K, Ishiguro H
  TITLE     Is genetic analysis helpful for diagnosing chronic pancreatitis in its early stage?
  JOURNAL   J Gastroenterol 42 Suppl 17:60-5 (2007)
REFERENCE   PMID:15800694 (gene)
  AUTHORS   Grigorescu M, Grigorescu MD
  TITLE     Genetic factors in pancreatitis.
  JOURNAL   Rom J Gastroenterol 14:53-61 (2005)
REFERENCE   PMID:16699518 (gene)
  AUTHORS   Witt H, Sahin-Toth M, Landt O, Chen JM, Kahne T, Drenth JP, Kukor Z, Szepessy E, Halangk W, Dahm S, Rohde K, Schulz HU, Le Marechal C, Akar N, Ammann RW, Truninger K, Bargetzi M, Bhatia E, Castellani C, Cavestro GM, Cerny M, Destro-Bisol G, Spedini G, Eiberg H, Jansen JB, Koudova M, Rausova E, Macek M Jr, Malats N, Real FX, Menzel HJ, Moral P, Galavotti R, Pignatti PF, Rickards O, Spicak J, Zarnescu NO, Bock W, Gress TM, Friess H, Ockenga J, Schmidt H, Pfutzer R, Lohr M, Simon P, Weiss FU, Lerch MM, Teich N, Keim V, Berg T, Wiedenmann B, Luck W, Groneberg DA, Becker M, Keil T, Kage A, Bernardova J, Braun M, Guldner C, Halangk J, Rosendahl J, Witt U, Treiber M, Nickel R, Ferec C
  TITLE     A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis.
  JOURNAL   Nat Genet 38:668-73 (2006)
REFERENCE   PMID:18172691 (gene)
  AUTHORS   Masson E, Chen JM, Scotet V, Le Marechal C, Ferec C
  TITLE     Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis.
  JOURNAL   Hum Genet 123:83-91 (2008)
///
ENTRY       H00934                      Disease
NAME        Caudal duplication anomaly
DESCRIPTION Caudal duplication anomaly is a rare type of developmental disorder that arises from incomplete separation of mono-ovular twins. It can involve various congenital anomalies, but the hallmark is duplication of organs in the caudal region, and most frequently affected organs are genitourinary and gastrointestinal tracts. Recently AXIN1 promotor has been shown to have methylation in patients with caudal duplication anomaly.
CATEGORY    Developmental disorder
GENE        AXIN1 (methylation at the promoter region) [HSA:8312] [KO:K02157]
DBLINKS     ICD-10: Q87.8
            MeSH: C564315
            OMIM: 607864
REFERENCE   PMID:10955588 (description)
  AUTHORS   Rattan KN, Budhiraja S, Pandit SK, Solanki RS, Sen R, Sen J
  TITLE     Caudal duplication--a case report.
  JOURNAL   Pediatr Surg Int 16:445-6 (2000)
REFERENCE   PMID:9502040 (description)
  AUTHORS   La Torre R, Fusaro P, Anceschi MM, Montanino-Oliva M, Modesto S, Cosmi EV
  TITLE     Unusual case of caudal duplication (dipygus).
  JOURNAL   J Clin Ultrasound 26:163-5 (1998)
REFERENCE   PMID:12376942 (description)
  AUTHORS   Kroes HY, Takahashi M, Zijlstra RJ, Baert JA, Kooi KA, Hofstra RM, van Essen AJ
  TITLE     Two cases of the caudal duplication anomaly including a discordant monozygotic twin.
  JOURNAL   Am J Med Genet 112:390-3 (2002)
REFERENCE   PMID:16773576 (description, gene)
  AUTHORS   Oates NA, van Vliet J, Duffy DL, Kroes HY, Martin NG, Boomsma DI, Campbell M, Coulthard MG, Whitelaw E, Chong S
  TITLE     Increased DNA methylation at the AXIN1 gene in a monozygotic twin from a pair discordant for a caudal duplication anomaly.
  JOURNAL   Am J Hum Genet 79:155-62 (2006)
///
ENTRY       H00935                      Disease
NAME        Cold-induced sweating syndrome (CISS) and Crisponi syndrome (CRISPS)
DESCRIPTION Cold-induced sweating syndrome (CISS) and Crisponi syndrome (CRISPS) are inherited in an autosomal recessive manner. Mutations in CRLF1 account for about 90% and mutations in CLCF1 account for about 10% of CISS and CRISPS. CRISPS is characterized by congenital muscular contractions of facial muscles, with trismus in response to stimuli, dysmorphic features, bilateral camptodactyly, major feeding and respiratory difficulties, and access of hyperthermia leading to death in the first months of life. CISS is characterized by profuse sweating induced by cool surroundings.
CATEGORY    Developmental disorder
GENE        (CISS1/CRISPS) CRLF1 [HSA:9244]
            (CISS2) CLCF1 [HSA:23529] [KO:K05421]
DBLINKS     ICD-10: Q87.0
            MeSH: C536214
            OMIM: 601378 272430 610313
REFERENCE   PMID:17436251
  AUTHORS   Dagoneau N, Bellais S, Blanchet P, Sarda P, Al-Gazali LI, Di Rocco M, Huber C, Djouadi F, Le Goff C, Munnich A, Cormier-Daire V
  TITLE     Mutations in cytokine receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromes.
  JOURNAL   Am J Hum Genet 80:966-70 (2007)
REFERENCE   PMID:21370513
  AUTHORS   Hahn AF, Boman H
  TITLE     Cold-Induced Sweating Syndrome including Crisponi Syndrome
  JOURNAL   (1993)
///
ENTRY       H00936                      Disease
NAME        Goldberg-Shprintzen megacolon syndrome;
            Goldberg-Shprintzen syndrome (GOSHS)
DESCRIPTION Goldberg-Shprintzen megacolon syndrome is a rare disorder caused by inactivating mutations in the kinesin binding protein (KBP) and is characterized by central and enteric nervous system defects. Clinical features of this syndrome include polymicrogyria, mild mental retardation, microcephaly, facial dysmorphisms, and short-segment Hirschsprung disease. The precise function of KBP is largely unclear, but it is required for cell differentiation and neurite development.
CATEGORY    Developmental disorder; Mental retardation
GENE        KBP [HSA:26128]
COMMENT     For Hirschsprung disease, see H00910.
DBLINKS     ICD-10: K59
            MeSH: C537279
            OMIM: 609460
REFERENCE   PMID:15883926 (description, gene)
  AUTHORS   Brooks AS, Bertoli-Avella AM, Burzynski GM, Breedveld GJ, Osinga J, Boven LG, Hurst JA, Mancini GM, Lequin MH, de Coo RF, Matera I, de Graaff E, Meijers C, Willems PJ, Tibboel D, Oostra BA, Hofstra RM
  TITLE     Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems.
  JOURNAL   Am J Hum Genet 77:120-6 (2005)
REFERENCE   PMID:20621975 (description, gene)
  AUTHORS   Alves MM, Burzynski G, Delalande JM, Osinga J, van der Goot A, Dolga AM, de Graaff E, Brooks AS, Metzger M, Eisel UL, Shepherd I, Eggen BJ, Hofstra RM
  TITLE     KBP interacts with SCG10, linking Goldberg-Shprintzen syndrome to microtubule dynamics and neuronal differentiation.
  JOURNAL   Hum Mol Genet 19:3642-51 (2010)
REFERENCE   PMID:18192286 (description, gene)
  AUTHORS   Lyons DA, Naylor SG, Mercurio S, Dominguez C, Talbot WS
  TITLE     KBP is essential for axonal structure, outgrowth and maintenance in zebrafish, providing insight into the cellular basis of Goldberg-Shprintzen syndrome.
  JOURNAL   Development 135:599-608 (2008)
REFERENCE   PMID:9571278 (description)
  AUTHORS   Fryer AE
  TITLE     Goldberg-Shprintzen syndrome: report of a new family and review of the literature.
  JOURNAL   Clin Dysmorphol 7:97-101 (1998)
///
ENTRY       H00937                      Disease
NAME        Precocious puberty, including:
            Central precocious puberty (CEPREPU);
            Familial male precocious puberty (FMPP)
DESCRIPTION Precocious puberty has been classically defined as the onset of secondary sexual characteristics in girls younger than 8 years old and in boys younger than 9 and a half years old. Central precocious puberty (CEPREPU) refers to a gonadotropin-dependent type which results from premature activation of the hypothalamic-pituitary-gonadal axis (HPG). CEPREPU is much more frequent in girls than in boys (up to 20:1 ratio). Recently, kisspeptin receptor (KISS1R) and its ligand, kisspeptin, were revealed as major gatekeepers of puberty onset. Mutations of the KISS1R gene were described in patients with impaired pubertal development. On the other hand, it has been reported that heterozygous mutations of the LHCGR gene cause gonadotropin-independent precocious puberty in males, but have no detectable effects on prepubertal or postpubertal females.
CATEGORY    Endocrine disease
GENE        (CEPREPU) KISS1R [HSA:84634] [KO:K08374]
            (FMPP) LHCGR [HSA:3973] [KO:K04248]
DRUG        Leuprorelin [DR:D00989]
            Nafarelin [DR:D00990]
            Buserelin [DR:D01831]
DBLINKS     ICD-10: E22.8 E30.1
            MeSH: D011629 C562787 C536961
            OMIM: 176400 176410
REFERENCE   PMID:21664234
  AUTHORS   Teles MG, Silveira LF, Tusset C, Latronico AC
  TITLE     New genetic factors implicated in human GnRH-dependent precocious puberty: the role of kisspeptin system.
  JOURNAL   Mol Cell Endocrinol 346:84-90 (2011)
REFERENCE   PMID:20374734
  AUTHORS   Segaloff DL
  TITLE     Diseases associated with mutations of the human lutropin receptor.
  JOURNAL   Prog Mol Biol Transl Sci 89:97-114 (2009)
REFERENCE   PMID:18478155 (drug)
  AUTHORS   Bertelloni S, Mul D
  TITLE     Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
  JOURNAL   Asian J Androl 10:525-34 (2008)
///
ENTRY       H00938                      Disease
NAME        Factor XI deficiency;
            Plasma thromboplastin antecedent deficiency;
            Rosenthal syndrome
DESCRIPTION Factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. FXI deficiency is characterized by infrequent spontaneous bleeding, but increased risk of hemorrhagic complications especially after trauma or surgery. More than 180 mutations in the FXI gene have been reported in patients with FXI deficiency.
CATEGORY    Hematologic disease
GENE        F11 [HSA:2160] [KO:K01323]
DRUG        Replacement therapy with virally inactivated fresh frozen plasma or FXI concentrates.
            Desmopressin [DG:DG00497]
            Tranexamic acid [DR:D01136]
DBLINKS     ICD-10: D68.1
            OMIM: 612416
REFERENCE   PMID:19630775
  AUTHORS   Seligsohn U
  TITLE     Factor XI deficiency in humans.
  JOURNAL   J Thromb Haemost 7 Suppl 1:84-7 (2009)
REFERENCE   PMID:19598070
  AUTHORS   Duga S, Salomon O
  TITLE     Factor XI Deficiency.
  JOURNAL   Semin Thromb Hemost 35:416-25 (2009)
REFERENCE   PMID:19609524
  AUTHORS   Franchini M, Manzato F, Salvagno GL, Montagnana M, Lippi G
  TITLE     The use of desmopressin in congenital factor XI deficiency: a systematic review.
  JOURNAL   Ann Hematol 88:931-5 (2009)
///
ENTRY       H00939                      Disease
NAME        Neutropenia, severe congenital 4, autosomal recessive;
            G6PC3 deficiency;
            Darsun syndrome
DESCRIPTION G6PC3 deficiency is a syndromic variant of severe congenital neutropenia associated by complex organ malformation. Patients often have cardiac defects such as atrial septal defects, an increased superficial venous marking, and urogenital malformations. In the absence of G6PC3, increased ER stress makes neutrophils prone to undergo apoptosis and leads to defective organ development.
CATEGORY    Primary immunodeficiency; Developmental disorder; Cardiovascular disease; Vascular disease
GENE        G6PC3 [HSA:92579] [KO:K01084]
DBLINKS     ICD-10: D70
            MeSH: C567260
            OMIM: 612541
REFERENCE   PMID:19118303 (description, gene)
  AUTHORS   Boztug K, Appaswamy G, Ashikov A, Schaffer AA, Salzer U, Diestelhorst J, Germeshausen M, Brandes G, Lee-Gossler J, Noyan F, Gatzke AK, Minkov M, Greil J, Kratz C, Petropoulou T, Pellier I, Bellanne-Chantelot C, Rezaei N, Monkemoller K, Irani-Hakimeh N, Bakker H, Gerardy-Schahn R, Zeidler C, Grimbacher B, Welte K, Klein C
  TITLE     A syndrome with congenital neutropenia and mutations in G6PC3.
  JOURNAL   N Engl J Med 360:32-43 (2009)
REFERENCE   PMID:21206270 (description, gene)
  AUTHORS   Boztug K, Klein C
  TITLE     Genetic etiologies of severe congenital neutropenia.
  JOURNAL   Curr Opin Pediatr 23:21-6 (2011)
REFERENCE   PMID:19440858 (description, gene)
  AUTHORS   Klein C, Welte K
  TITLE     Genetic insights into congenital neutropenia.
  JOURNAL   Clin Rev Allergy Immunol 38:68-74 (2010)
REFERENCE   PMID:19782549 (description, gene)
  AUTHORS   Boztug K, Klein C
  TITLE     Novel genetic etiologies of severe congenital neutropenia.
  JOURNAL   Curr Opin Immunol 21:472-80 (2009)
REFERENCE   PMID:21219176 (description, gene)
  AUTHORS   Klein C
  TITLE     Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes.
  JOURNAL   Annu Rev Immunol 29:399-413 (2011)
REFERENCE   PMID:20799326 (genev)
  AUTHORS   Banka S, Newman WG, Ozgul RK, Dursun A
  TITLE     Mutations in the G6PC3 gene cause Dursun syndrome.
  JOURNAL   Am J Med Genet A 152A:2609-11 (2010)
///
ENTRY       H00940                      Disease
NAME        Cohen syndrome
DESCRIPTION Cohen syndrome is an autosomal recessive disorder with a broad phenotypic spectrum. Essential symptoms include mental retardation, progressive postnatal microcephaly, typical facial anomalies, ophthalmologic findings such as chorioretinal dystrophy and myopia, and granulocytopenia. Obesity and growth delay could be observed. In most patients, Cohen syndrome is caused by loss-of-function mutations in the COH1 gene.
CATEGORY    Congenital disorder
GENE        COH1 [HSA:157680] [KO:K19526]
DBLINKS     ICD-10: Q87.8
            MeSH: C536438
            OMIM: 216550
REFERENCE   PMID:11477603 (description)
  AUTHORS   Kivitie-Kallio S, Norio R
  TITLE     Cohen syndrome: essential features, natural history, and heterogeneity.
  JOURNAL   Am J Med Genet 102:125-35 (2001)
REFERENCE   PMID:21865173 (description, gene)
  AUTHORS   Seifert W, Kuhnisch J, Maritzen T, Horn D, Haucke V, Hennies HC
  TITLE     Cohen syndrome-associated protein, COH1, is a novel, giant Golgi matrix protein required for Golgi integrity.
  JOURNAL   J Biol Chem 286:37665-75 (2011)
REFERENCE   PMID:18655112 (description, gene)
  AUTHORS   Bugiani M, Gyftodimou Y, Tsimpouka P, Lamantea E, Katzaki E, d'Adamo P, Nakou S, Georgoudi N, Grigoriadou M, Tsina E, Kabolis N, Milani D, Pandelia E, Kokotas H, Gasparini P, Giannoulia-Karantana A, Renieri A, Zeviani M, Petersen MB
  TITLE     Cohen syndrome resulting from a novel large intragenic COH1 deletion segregating  in an isolated Greek island population.
  JOURNAL   Am J Med Genet A 146A:2221-6 (2008)
REFERENCE   PMID:20461111 (description, gene)
  AUTHORS   Parri V, Katzaki E, Uliana V, Scionti F, Tita R, Artuso R, Longo I, Boschloo R, Vijzelaar R, Selicorni A, Brancati F, Dallapiccola B, Zelante L, Hamel CP, Sarda P, Lalani SR, Grasso R, Buoni S, Hayek J, Servais L, de Vries BB, Georgoudi N, Nakou S, Petersen MB, Mari F, Renieri A, Ariani F
  TITLE     High frequency of COH1 intragenic deletions and duplications detected by MLPA in  patients with Cohen syndrome.
  JOURNAL   Eur J Hum Genet 18:1133-40 (2010)
///
ENTRY       H00941                      Disease
NAME        Factor XII deficiency;
            Hageman factor deficiency
DESCRIPTION Factor XII (FXII) deficiency is a rare autosomal recessive disorder. Although FXII deficiency is not associated with a clinical bleeding tendency, FXII is an important protease that plays a major role in the initiation of the intrinsic pathway of blood coagulation. Venous or arterial thrombosis, recurrent miscarriages, and placental abruption were reported in cases with FXII deficiency.
CATEGORY    Hematologic disease
GENE        F12 [HSA:2161] [KO:K01328]
DBLINKS     ICD-10: D68.2
            OMIM: 234000
REFERENCE   PMID:20022081
  AUTHORS   Stavrou E, Schmaier AH
  TITLE     Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis &amp; thrombosis.
  JOURNAL   Thromb Res 125:210-5 (2010)
REFERENCE   PMID:16324213
  AUTHORS   D'Uva M, Strina I, Mollo A, Ranieri A, De Placido G, Di Micco P
  TITLE     Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working  on a differential diagnosis in a single case.
  JOURNAL   J Transl Med 3:43 (2005)
REFERENCE   PMID:18294355
  AUTHORS   Matsubayashi H, Sugi T, Suzuki T, Uchida N, Atsumi H, Izumi S, Mikami M
  TITLE     Decreased factor XII activity is associated with recurrent IVF-ET failure.
  JOURNAL   Am J Reprod Immunol 59:316-22 (2008)
///
ENTRY       H00942                      Disease
NAME        Rabson-Mendenhall syndrome
DESCRIPTION Rabson-Mendenhall syndrome (RMS) is a rare disorder involving severe insulin resistance due to mutations in the insulin receptor (INSR) gene. Obligatory symptoms are extreme hyperinsulinemia and profound insulin-resistance diabetes. Additional characteristics of RMS can include acanthosis nigricans, polycystic ovarian disease, hirsutism, precocity, pineal hyperplasia, and thick nails.
CATEGORY    Endocrine disease
GENE        INSR [HSA:3643] [KO:K04527]
COMMENT     For leprechaunism, a disorder with INSR mutations,  see H00719.
DBLINKS     ICD-10: E13
            MeSH: D056731
            OMIM: 262190
REFERENCE   PMID:21869538 (description, gene)
  AUTHORS   Jiang S, Fang Q, Zhang F, Wan H, Zhang R, Wang C, Bao Y, Zhang L, Ma X, Lu J, Gao F, Xiang K, Jia W
  TITLE     Functional characterization of insulin receptor gene mutations contributing to Rabson-Mendenhall syndrome - phenotypic heterogeneity of insulin receptor gene mutations.
  JOURNAL   Endocr J 58:931-40 (2011)
REFERENCE   PMID:15232309 (description, gene)
  AUTHORS   Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P
  TITLE     Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective.
  JOURNAL   Medicine (Baltimore) 83:209-22 (2004)
REFERENCE   PMID:18717867 (description)
  AUTHORS   Parveen BA, Sindhuja R
  TITLE     Rabson-Mendenhall syndrome.
  JOURNAL   Int J Dermatol 47:839-41 (2008)
///
ENTRY       H00943                      Disease
NAME        TARP syndrome
DESCRIPTION TARP syndrome is a disorder marked by early lethality. It comprises Talipes equinovarus, atrial septal defect, Robin sequence (micrognathia, glossoptosis, and cleft palate), and persistence of the left superior vena cava. It is inherited in an X-linked recessive pattern. Expression analysis of mouse orthologue of the causative gene revealed that the gene is expressed in the parts where malformations in TARP syndrome are observed, such as in the branchial arches and in the limb/tail bud regions.
CATEGORY    Developmental disorder
GENE        RBM10 [HSA:8241] [KO:K13094]
DBLINKS     ICD-10: Q87.8
            MeSH: C536942
            OMIM: 311900
REFERENCE   PMID:20451169 (description, gene)
  AUTHORS   Johnston JJ, Teer JK, Cherukuri PF, Hansen NF, Loftus SK, Chong K, Mullikin JC, Biesecker LG
  TITLE     Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate.
  JOURNAL   Am J Hum Genet 86:743-8 (2010)
REFERENCE   PMID:21910224 (description, gene)
  AUTHORS   Gripp KW, Hopkins E, Johnston JJ, Krause C, Dobyns WB, Biesecker LG
  TITLE     Long-term survival in TARP syndrome and confirmation of RBM10 as the disease-causing gene.
  JOURNAL   Am J Med Genet A 155A:2516-20 (2011)
REFERENCE   PMID:12794682 (description)
  AUTHORS   Kurpinski KT, Magyari PA, Gorlin RJ, Ng D, Biesecker LG
  TITLE     Designation of the TARP syndrome and linkage to Xp11.23-q13.3 without samples from affected patients.
  JOURNAL   Am J Med Genet A 120A:1-4 (2003)
///
ENTRY       H00944                      Disease
NAME        Dowling-Degos disease
DESCRIPTION Dowling-Degos disease is a rare pigmented skin disorder caused by mutations in keratin 5 and protein O-fucosyltransferase 1. Small hyperpigmented macules appear in a clustered or reticulated pattern at flexural sites, such as the neck, axilla, and anticubital fossa. There may be comedo-like papules on the back and pitted scars on perioral or facial regions.
CATEGORY    Skin and connective tissue disease
GENE        KRT5 [HSA:3852] [KO:K07605]
            POFUT1 [HSA:23509] [KO:K03691]
DBLINKS     MeSH: C562924
            OMIM: 179850 615327
REFERENCE   PMID:20332593 (description, gene)
  AUTHORS   Batycka-Baran A, Baran W, Hryncewicz-Gwozdz A, Burgdorf W
  TITLE     Dowling-Degos disease: case report and review of the literature.
  JOURNAL   Dermatology 220:254-8 (2010)
REFERENCE   PMID:22147038 (description, gene)
  AUTHORS   Zimmermann CC, Sforza D, Macedo PM, Azulay-Abulafia L, Alves Mde F, Carneiro SC
  TITLE     Dowling-Degos disease: classic clinical and histopathological presentation.
  JOURNAL   An Bras Dermatol 86:979-82 (2011)
REFERENCE   PMID:21810386 (description)
  AUTHORS   Horner ME, Parkinson KE, Kaye V, Lynch PJ
  TITLE     Dowling-Degos disease involving the vulva and back: case report and review of the literature.
  JOURNAL   Dermatol Online J 17:1 (2011)
REFERENCE   PMID:23684010
  AUTHORS   Li M, Cheng R, Liang J, Yan H, Zhang H, Yang L, Li C, Jiao Q, Lu Z, He J, Ji J, Shen Z, Li C, Hao F, Yu H, Yao Z
  TITLE     Mutations in POFUT1, encoding protein O-fucosyltransferase 1, cause generalized Dowling-Degos disease.
  JOURNAL   Am J Hum Genet 92:895-903 (2013)
///
ENTRY       H00945                      Disease
NAME        Factor XIII deficiency
DESCRIPTION Factor XIII deficiency is a rare autosomal recessive disorder characterized by defective cross-linking of fibrin and poor resistance to fibrinolysis. The severity of the bleeding tendency varies from benign symptoms like excessive bruising to life threatening bleeding emergencies such as intracranial hemorrhages. In plasma, FXIII circulates as a pro-transglutaminase composed of two catalytic A subunits and two non-catalytic B subunits. Symptoms that are almost pathognomonic for A subunit deficiency are umbilical bleeding in the neonatal period and repeated fetal wastage in pregnant females.
CATEGORY    Hematologic disease
GENE        F13A1 [HSA:2162] [KO:K03917]
            F13B [HSA:2165] [KO:K03906]
DRUG        Human blood-coagulation factor XIII fraction, dried [DR:D08802]
DBLINKS     ICD-10: D68.2
            OMIM: 613225 613235
REFERENCE   PMID:19141159
  AUTHORS   Hsieh L, Nugent D
  TITLE     Factor XIII deficiency.
  JOURNAL   Haemophilia 14:1190-200 (2008)
REFERENCE   PMID:9028951
  AUTHORS   Mikkola H, Muszbek L, Laiho E, Syrjala M, Hamalainen E, Haramura G, Salmi T, Peltonen L, Palotie A
  TITLE     Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA.
  JOURNAL   Blood 89:1279-87 (1997)
///
ENTRY       H00946                      Disease
NAME        Arts syndrome
DESCRIPTION Arts syndrome is an X-linked disorder characterized by mental retardation, early-onset hypotonia, delayed motor development, ataxia, congenital sensorineural hearing impairment, and optic atrophy. Patients with Arts syndrome also have an impaired immune system due to impaired hematopoietic differentiation. The causative gene is PRPS1 on the X chromosome that is essential for de novo purine and pyrimidine synthesis.
CATEGORY    Developmental disorder; Nervous system disease
GENE        PRPS1 [HSA:5631] [KO:K00948]
DBLINKS     ICD-10: Q87.8
            MeSH: C535388
            OMIM: 301835
REFERENCE   PMID:20301738 (description, gene)
  AUTHORS   de Brouwer APM, Duley JA, Christodoulou J
  TITLE     Arts Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:17701896
  AUTHORS   de Brouwer AP, Williams KL, Duley JA, van Kuilenburg AB, Nabuurs SB, Egmont-Petersen M, Lugtenberg D, Zoetekouw L, Banning MJ, Roeffen M, Hamel BC, Weaving L, Ouvrier RA, Donald JA, Wevers RA, Christodoulou J, van Bokhoven H
  TITLE     Arts syndrome is caused by loss-of-function mutations in PRPS1.
  JOURNAL   Am J Hum Genet 81:507-18 (2007)
REFERENCE   PMID:20380929
  AUTHORS   de Brouwer AP, van Bokhoven H, Nabuurs SB, Arts WF, Christodoulou J, Duley J
  TITLE     PRPS1 mutations: four distinct syndromes and potential treatment.
  JOURNAL   Am J Hum Genet 86:506-18 (2010)
///
ENTRY       H00947                      Disease
NAME        Pilomatricoma;
            Epithelioma calcificans of Malherbe
DESCRIPTION Pilomatricoma is a benign cutaneous tumor of follicular structures. It occurs either in isolation or in conjunction with other symptoms such as myotonic dystrophy and Rubenstein-Taybi syndrome. The histologic appearance of the tumor is characterized by cells resembling those of the hair follicle matrix and sometimes show differentiation toward the follicular infundibulum and surrounding sheath.
CATEGORY    Skin and connective tissue disease
GENE        CTNNB1 [HSA:1499] [KO:K02105]
DBLINKS     ICD-10: D23
            MeSH: D018296
            OMIM: 132600
REFERENCE   PMID:11708952 (description)
  AUTHORS   Tsao H.
  TITLE     Genetics of nonmelanoma skin cancer.
  JOURNAL   Arch Dermatol 137:1486-92 (2001)
REFERENCE   PMID:10192393 (description, gene)
  AUTHORS   Chan EF, Gat U, McNiff JM, Fuchs E
  TITLE     A common human skin tumour is caused by activating mutations in beta-catenin.
  JOURNAL   Nat Genet 21:410-3 (1999)
REFERENCE   PMID:15606674 (description, gene)
  AUTHORS   Lazar AJ, Calonje E, Grayson W, Dei Tos AP, Mihm MC Jr, Redston M, McKee PH
  TITLE     Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin.
  JOURNAL   J Cutan Pathol 32:148-57 (2005)
///
ENTRY       H00948                      Disease
NAME        Renal hypouricemia (RHUC)
DESCRIPTION Renal hypouricemia (RHUC) is a disorder characterized by impaired uric acid reabsorption at the apical membrane of proximal renal tubule cells, and high urinary urate excretion. Renal urate reabsorption is controlled via two proximal tubular urate transporters: apical URAT1 (SLC22A12) and basolateral GLUT9 (SLC2A9). And it has been suggested that RHUC is caused by mutations in URAT1 or GLUT9. Most of patients were asymptomatic, but some had nephrolithiasis or were predisposed to exercise-induced acute renal failure.
CATEGORY    Urinary system disease
GENE        (RHUC1) SLC22A12 [HSA:116085] [KO:K08208]
            (RHUC2) SLC2A9 [HSA:56606] [KO:K08146]
DBLINKS     MeSH: C537757
            OMIM: 220150 612076
REFERENCE   PMID:19926891
  AUTHORS   Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, Rechavi G, Amariglio N, Ganon L, Sela BA, Bahat H, Goldman M, Weissgarten J, Millar MR, Wright AF, Holtzman EJ
  TITLE     Homozygous SLC2A9 mutations cause severe renal hypouricemia.
  JOURNAL   J Am Soc Nephrol 21:64-72 (2010)
REFERENCE   PMID:21810765
  AUTHORS   Dinour D, Gray NK, Ganon L, Knox AJ, Shalev H, Sela BA, Campbell S, Sawyer L, Shu X, Valsamidou E, Landau D, Wright AF, Holtzman EJ
  TITLE     Two novel homozygous SLC2A9 mutations cause renal hypouricemia type 2.
  JOURNAL   Nephrol Dial Transplant (2011)
REFERENCE   PMID:20810651
  AUTHORS   Jutabha P, Anzai N, Kitamura K, Taniguchi A, Kaneko S, Yan K, Yamada H, Shimada H, Kimura T, Katada T, Fukutomi T, Tomita K, Urano W, Yamanaka H, Seki G, Fujita T, Moriyama Y, Yamada A, Uchida S, Wempe MF, Endou H, Sakurai H
  TITLE     Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory  pathway for drugs and urate.
  JOURNAL   J Biol Chem 285:35123-32 (2010)
///
ENTRY       H00949                      Disease
NAME        Focal dermal hypoplasia;
            Goltz-Gorlin syndrome
DESCRIPTION Focal dermal hypoplasia, also known as Goltz-Gorlin syndrome, is a rare X-linked dominant disorder characterized by patchy dermal hypoplasia and fat herniation through skin in combination with skeletal, ocular and dental abnormalities. Skeletal dysplasia consisting of syndactyly, polydactyly, camptodactyly or ectrodactyly and ocular anomalies such as colobomas, microphthalmia or cataract are frequently reported. Mutations in the PORCN gene has been shown to cause the disease.
CATEGORY    Skin and connective tissue disease; Skeletal dysplasia; Eye disease
GENE        PORCN [HSA:64840] [KO:K00181]
DBLINKS     ICD-10: Q82.8
            MeSH: D005489
            OMIM: 305600
REFERENCE   PMID:22250236 (description)
  AUTHORS   Maalouf D, Megarbane H, Chouery E, Nasr J, Badens C, Lacoste C, Grzeschik KH, Megarbane A
  TITLE     A novel mutation in the PORCN gene underlying a case of almost unilateral focal dermal hypoplasia.
  JOURNAL   Arch Dermatol 148:85-8 (2012)
REFERENCE   PMID:18325042 (description, gene)
  AUTHORS   Leoyklang P, Suphapeetiporn K, Wananukul S, Shotelersuk V
  TITLE     Three novel mutations in the PORCN gene underlying focal dermal hypoplasia.
  JOURNAL   Clin Genet 73:373-9 (2008)
REFERENCE   PMID:21472892 (gene)
  AUTHORS   Lombardi MP, Bulk S, Celli J, Lampe A, Gabbett MT, Ousager LB, van der Smagt JJ, Soller M, Stattin EL, Mannens MA, Smigiel R, Hennekam RC
  TITLE     Mutation update for the PORCN gene.
  JOURNAL   Hum Mutat 32:723-8 (2011)
///
ENTRY       H00950                      Disease
NAME        Arthrogryposis, renal dysfunction, and cholestasis;
            ARC syndrome
DESCRIPTION Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome is a fatal multisystem disorder that causes neonatal intrahepatic cholestasis. It also exhibits notable clinical variability showing anemia, ichthyosis, and diarrhoea. Mutations in VPS33B have been found in 75% cases of ARC syndrome. Individuals without VPS33B defects have mutations in VIPAR that forms a functional complex with VPS33B.
CATEGORY    Musculoskeletal disease; Kidney disease; Liver disease
GENE        VPS33B [HSA:26276]
            VIPAR [HSA:63894]
DBLINKS     ICD-10: Q89.7
            MeSH: C535382
            OMIM: 208085 613404
REFERENCE   PMID:11668108 (description)
  AUTHORS   Eastham KM, McKiernan PJ, Milford DV, Ramani P, Wyllie J, van't Hoff W, Lynch SA, Morris AA
  TITLE     ARC syndrome: an expanding range of phenotypes.
  JOURNAL   Arch Dis Child 85:415-20 (2001)
REFERENCE   PMID:8529684 (description)
  AUTHORS   Di Rocco M, Callea F, Pollice B, Faraci M, Campiani F, Borrone C
  TITLE     Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families.
  JOURNAL   Eur J Pediatr 154:835-9 (1995)
REFERENCE   PMID:20190753 (description, gene)
  AUTHORS   Cullinane AR, Straatman-Iwanowska A, Zaucker A, Wakabayashi Y, Bruce CK, Luo G, Rahman F, Gurakan F, Utine E, Ozkan TB, Denecke J, Vukovic J, Di Rocco M, Mandel H, Cangul H, Matthews RP, Thomas SG, Rappoport JZ, Arias IM, Wolburg H, Knisely AS, Kelly DA, Muller F, Maher ER, Gissen P
  TITLE     Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization.
  JOURNAL   Nat Genet 42:303-12 (2010)
REFERENCE   PMID:19274792 (description, gene)
  AUTHORS   Jang JY, Kim KM, Kim GH, Yu E, Lee JJ, Park YS, Yoo HW
  TITLE     Clinical characteristics and VPS33B mutations in patients with ARC syndrome.
  JOURNAL   J Pediatr Gastroenterol Nutr 48:348-54 (2009)
REFERENCE   PMID:16492441 (description)
  AUTHORS   Bull LN, Mahmoodi V, Baker AJ, Jones R, Strautnieks SS, Thompson RJ, Knisely AS
  TITLE     VPS33B mutation with ichthyosis, cholestasis, and renal dysfunction but without arthrogryposis: incomplete ARC syndrome phenotype.
  JOURNAL   J Pediatr 148:269-71 (2006)
///
ENTRY       H00951                      Disease
NAME        Reis-Bucklers corneal dystrophy (RBCD);
            Corneal dystrophy of Bowman's type I;
            Granular corneal dystrophy type III
DESCRIPTION Reis-Bucklers corneal dystrophy (RBCD) is a progressive autosomal dominant dystrophy and patients are born with normal appearing corneas. In the first or second decade of life, corneal opacification and scarring cause marked visual loss and recurrent corneal erosions lead to significant pain. In RBCD, Bowman's membrane is disrupted or absent and instead is replaced by a fibrocellular tissue with deposition of rodlike bodies best seen with the electron microscope. Thiel-Behnke dystrophies (TBCD) share many similarities as well as some differences with RBCD. Both RBCD and TBCD are linked to mutations in the TGFBI gene.
CATEGORY    Eye disease
GENE        TGFBI [HSA:7045] [KO:K19519]
COMMENT     Thiel-Behnke dystrophies (TBCD) is described in [DS:H00952]
DBLINKS     ICD-10: H18.5
            MeSH: C535476
            OMIM: 608470
REFERENCE   PMID:19236704 (gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
REFERENCE   PMID:16900028 (description, gene)
  AUTHORS   Pieramici SF, Afshari NA
  TITLE     Genetics of corneal dystrophies: the evolving landscape.
  JOURNAL   Curr Opin Ophthalmol 17:361-6 (2006)
///
ENTRY       H00952                      Disease
NAME        Thiel-Behnke dystrophies (TBCD);
            Corneal dystrophy of Bowman layer type II;
            Honeycomb corneal dystrophy;
            Anterior limiting membrane dystrophy type II;
            Curly fibers corneal dystrophy;
            Waardenburg-Jonker corneal dystrophy
DESCRIPTION Thiel-Behnke dystrophy (TBCD) is an autosomal dominant dystrophy with recurrent corneal erosions developing in the first and second decade of life. TBCD shares many similarities with Reis-Bucklers corneal dystrophy (RBCD), but decreasing visual acuity is seen later than with RBCD. Electron microscopy reveals curly fibers deposited in Bowman's layer and this finding differentiates it from RBCD. Both TBCD and RBCD are linked to mutations in the TGFBI gene. TBCD is also linked to a mutation on chromosome 10q23-24, the gene product is currently unknown.
CATEGORY    Eye disease
GENE        TGFBI [HSA:7045] [KO:K19519]
COMMENT     Reis-Bucklers corneal dystrophy (RBCD) is described in [DS:H00951]
DBLINKS     ICD-10: H18.5
            OMIM: 602082
REFERENCE   PMID:19236704 (gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
REFERENCE   PMID:16900028 (description, gene)
  AUTHORS   Pieramici SF, Afshari NA
  TITLE     Genetics of corneal dystrophies: the evolving landscape.
  JOURNAL   Curr Opin Ophthalmol 17:361-6 (2006)
///
ENTRY       H00953                      Disease
NAME        Gelatinous drop-like corneal dystrophy (GDCD);
            Subepithelial amyloidosis;
            Primary familial amyloidosis
DESCRIPTION Gelatinous drop-like corneal dystrophy (GDCD) is a rare autosomal recessive dystrophy characterized by multiple prominent milky-white gelatinous mulberry-shaped nodules formed beneath the corneal epithelium during the first decade of life. Clinical symptoms include photophobia, foreign body sensation, and decreased vision. Fusiform deposits similar to those in lattice corneal dystrophy (LCD) may also form in the deeper stroma. GDCD has been linked to mutations in the TACSTD2 gene. TACSTD2 is a cell surface phosphoglycoprotein as well as a substrate for protein kinase C. Mutations in the gene lead to a truncated protein which is thought to trigger amyloid formation in the cornea.
CATEGORY    Eye disease
GENE        TACSTD2 [HSA:4070] [KO:K17288]
COMMENT     In regard to Lattice corneal dystrophy (LCD), see also [DS:H00956]
DBLINKS     ICD-10: H18.5
            MeSH: C535480
            OMIM: 204870
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
REFERENCE   PMID:16900028 (description, gene)
  AUTHORS   Pieramici SF, Afshari NA
  TITLE     Genetics of corneal dystrophies: the evolving landscape.
  JOURNAL   Curr Opin Ophthalmol 17:361-6 (2006)
///
ENTRY       H00954                      Disease
NAME        Macular corneal dystrophy (MCD);
            Corneal dystrophy Groenouw type II;
            Fehr corneal dystrophy
DESCRIPTION Macular corneal dystrophy (MCD), inherited in an autosomal recessive fashion, is the least common but severe form of stromal dystrophy characterized by superficial gray-white corneal opacities that progressively increase to involve the entire corneal stroma from limbus to limbus. Patients experience progressive decreased vision and irritation as the diseases worsens, and will have vision severely affected by the third to fourth decade of life. It has been shown that a specific sulfation step in the production of keratan sulfate, the major glycosaminoglycan of the corneal stroma, is impaired in MCD. This results in the accumulation of glycosaminoglycans that form the abnormal deposits. Mutations in the CHST6 gene, which encodes an enzyme that catalyzes the sulfation of keratan sulfate, are responsible for most cases of MCD.
CATEGORY    Eye disease
GENE        CHST6 [HSA:4166] [KO:K09671]
DBLINKS     ICD-10: H18.5
            MeSH: D003317
            OMIM: 217800
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
REFERENCE   PMID:16900028 (description, gene)
  AUTHORS   Pieramici SF, Afshari NA
  TITLE     Genetics of corneal dystrophies: the evolving landscape.
  JOURNAL   Curr Opin Ophthalmol 17:361-6 (2006)
///
ENTRY       H00955                      Disease
NAME        Granular corneal dystrophies (GCD), including:
            Corneal dystrophy Groenouw type I;
            Avellino corneal dystrophy;
            Granular-lattice dystrophy
DESCRIPTION Granular dystrophy (GCD), inherited in an autosomal dominant fasion, is one of the most common corneal dystrophies characterized by the deposition of gray-white crumb like opacities in the anterior stroma that slowly increase in number and progress into deeper parts of the cornea. The disease is typically asymptomatic, but can present with pain from recurrent erosions and decreased vision. Opacities in granular dystrophy are composed of eosinophilic hyaline deposits. Differences in the clinical appearance of the discrete corneal opacities permit to divide into types of GCD; Type I classic form of GCD, type II Avellino or granular-lattice type, and type III Reis-Bucklers type. GCD has been linked to several mutations in TGFBI gene.
CATEGORY    Eye disease
GENE        TGFBI [HSA:7045] [KO:K19519]
COMMENT     In regard to Granular corneal dystrophy (GCD) type III, see also [DS:H00951].
DBLINKS     ICD-10: H18.5
            MeSH: C537304 C535474
            OMIM: 121900 607541 608470
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
REFERENCE   PMID:16900028 (description, gene)
  AUTHORS   Pieramici SF, Afshari NA
  TITLE     Genetics of corneal dystrophies: the evolving landscape.
  JOURNAL   Curr Opin Ophthalmol 17:361-6 (2006)
///
ENTRY       H00956                      Disease
NAME        Lattice corneal dystrophies (LCD), including:
            Biber-Haab-Dimmer dystrophy;
            Familial amyloid polyneuropathy type IV;
            Meretoja syndrome
DESCRIPTION Lattice corneal dystrophy (LCD), the most common of the stromal cornea dystrophies, is an autosomal dominant dystrophy with variable expression. Clinical findings include the presence of a linear network of subepithelial opacities (lattice lines). Clinically and histologically there are several types of two genetically distinct inherited LCD so far. One with no systemic manifestations is caused by specific mutations in the TGFBI gene (LCD type I and its variants); the other resulting from a mutation in the GSN gene (LCD type II) has systemic manifestations.
CATEGORY    Eye disease
GENE        (LCDI, LCDIII) TGFBI [HSA:7045] [KO:K19519]
            (LCDII) GSN [HSA:2934] [KO:K05768]
COMMENT     For LCD type II, see also [DS:H00845].
DBLINKS     ICD-10: H18.5
            OMIM: 608471 105120 122200
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
REFERENCE   PMID:16900028 (description, gene)
  AUTHORS   Pieramici SF, Afshari NA
  TITLE     Genetics of corneal dystrophies: the evolving landscape.
  JOURNAL   Curr Opin Ophthalmol 17:361-6 (2006)
///
ENTRY       H00957                      Disease
NAME        Fleck corneal dystrophy (FCD);
            Francois-Neetens speckled corneal dystrophy
DESCRIPTION Fleck corneal dystrophy (FCD) is a rare corneal dystrophy characterized by multiple asymptomatic, non-progressive symmetric minute flecks disseminated throughout the corneal stroma. FCD does not affect vision and does not require treatment, but mild photophobia has been reported. Histopathology of the affected areas showed that the flecks correspond to areas of swollen keratocytes with cytoplasmic vesicles that contain lipids and mucopolysaccharides. FCD has been associated with mutations in the PIP5K3 gene encoding for an enzyme with a dual specificity that has both protein and lipid kinase activity.
CATEGORY    Eye disease
GENE        PIP5K3 [HSA:200576] [KO:K00921]
DBLINKS     ICD-10: H18.5
            MeSH: C563256
            OMIM: 121850
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
///
ENTRY       H00958                      Disease
NAME        Congenital stromal corneal dystrophy (CSCD);
            Congenital hereditary stromal dystrophy;
            Witschel dystrophy
DESCRIPTION Congenital stromal corneal dystrophy (CSCD) is a rare condition characterized by numerous opaque flaky or feathery clouding of the corneal stroma. The flakes and spots become more numerous with age and are slowly progressive to decrease the visual acuity. In CSCD, the morphologic abnormalities include a peculiar arrangement of tightly packed lamellae having highly aligned collagen fibrils of an unusually small diameter. Refractive error, photophobia, strabismus and resulting amblyopia with searching nystagmus are common in affected individuals. CSCD is linked with mutations in the decorin gene, which encodes for a dermatan sulfate proteoglycan.
CATEGORY    Eye disease
GENE        DCN [HSA:1634] [KO:K04660]
DBLINKS     ICD-10: H18.5
            MeSH: C566452
            OMIM: 610048
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
///
ENTRY       H00959                      Disease
NAME        Schnyder corneal dystrophy (SCD);
            Schnyder crystalline corneal dystrophy (SCCD);
            Crystalline stromal dystrophy;
            Schnyder crystalline dystrophy sine crystals
DESCRIPTION Schnyder corneal dystrophy (SCD) is a corneal dystrophy that is characterized by deposition of cholesterol in the corneal stroma. SCD usually becomes apparent early in life with corneal clouding or with crystals within the corneal stroma. Over time, an initially unremarkable corneal stroma acquires small white opacities and a diffuse haze. In approximately 50% of cases, crystals are not evident clinically (Schnyder crystalline dystrophy sine crystals). Most cases of SCD lack an obvious systemic disorder, but hypercholesterolemia is common, and so are associated manifestations, such as arcus lipoides and xanthelasma. An opaque disc of corneal crystals or other lipids may diminish vision sufficiently in both eyes to result in the need for a corneal graft. SCD is caused by one of numerous mutations in the UBIAD1 gene.
CATEGORY    Eye disease
GENE        UBIAD1 [HSA:29914]
DBLINKS     ICD-10: H18.5
            MeSH: C535475
            OMIM: 121800
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:18214787 (description, gene)
  AUTHORS   Poulaki V, Colby K
  TITLE     Genetics of anterior and stromal corneal dystrophies.
  JOURNAL   Semin Ophthalmol 23:9-17 (2008)
///
ENTRY       H00960                      Disease
NAME        Fuchs corneal dystrophy (FECD);
            Fuchs endothelial corneal dystrophy
DESCRIPTION Fuchs endothelial corneal dystrophy (FECD) is characterized by progressive loss of corneal endothelial cells, thickening of Descemet membrane, and deposition of extracellular matrix in the form of guttae. As a result, the endothelial layer is eventually no longer able to support corneal deturgescence, leading to corneal edema and decreased in visual acuity. These findings usually become clinically evident in the fourth and fifth decades of life. Corneal transplantation is currently the only modality used to restore vision. FECD is a genetically complex disorder, but the familial risk is relatively high. Candidate gene studies of COL8A2, solute carrier family 4, sodium borate transporter, member 11 (SLC4A11), and transcription factor 8 (TCF8) have found mixed evidence for potentially causal variants.
CATEGORY    Eye disease
GENE        (FECD1) COL8A2 [HSA:1296]
            (FECD4) SLC4A11 [HSA:83959] [KO:K13862]
            (FECD6) TCF8 [HSA:6935] [KO:K09299]
DBLINKS     ICD-10: H18.5
            MeSH: D005642
            OMIM: 136800 613268 613270
REFERENCE   PMID:19236704 (description, gene)
  AUTHORS   Klintworth GK
  TITLE     Corneal dystrophies.
  JOURNAL   Orphanet J Rare Dis 4:7 (2009)
REFERENCE   PMID:20964980 (description)
  AUTHORS   Elhalis H, Azizi B, Jurkunas UV
  TITLE     Fuchs endothelial corneal dystrophy.
  JOURNAL   Ocul Surf 8:173-84 (2010)
REFERENCE   PMID:22045388 (description, gene)
  AUTHORS   Louttit MD, Kopplin LJ, Igo RP Jr, Fondran JR, Tagliaferri A, Bardenstein D, Aldave AJ, Croasdale CR, Price MO, Rosenwasser GO, Lass JH, Iyengar SK
  TITLE     A multicenter study to map genes for fuchs endothelial corneal dystrophy: baseline characteristics and heritability.
  JOURNAL   Cornea 31:26-35 (2012)
REFERENCE   PMID:20825321 (description)
  AUTHORS   Wright AF, Dhillon B
  TITLE     Major progress in Fuchs's corneal dystrophy.
  JOURNAL   N Engl J Med 363:1072-5 (2010)
///
ENTRY       H00961                      Disease
NAME        Posterior polymorphous corneal dystrophy (PPCD)
DESCRIPTION Posterior polymorphous corneal dystrophy (PPCD) is a very rare, bilateral autosomal dominant disorder affecting primarily the innermost corneal layers, Descemet membrane (DM), and the endothelium, biomicroscopically presenting as geographical lesions, bands, and vesicles. It primarily affects the corneal endothelium to produce epithelial-like transformation and irregular thickening of DM due to the deposition of an abnormal collagenous layer. Most cases are static, but occasionally rapid progression can result in severe visual disability from secondary glaucoma or corneal edema. Three genes have been reported as causing PPCD: VSX1 associated with PPCD1, COL8A2 responsible for PPCD2, and ZEB1 shown to cause PPCD3. The contribution of changes in VSX1 and COL8A2 to the pathogenesis of this dystrophy is considered to be minor compared to ZEB1.
CATEGORY    Eye disease
GENE        (PPCD1) VSX1 [HSA:30813] [KO:K09335]
            (PPCD2) COL8A2 [HSA:1296]
            (PPCD3) ZEB1 [HSA:6935] [KO:K09299]
DBLINKS     ICD-10: H18.5
            MeSH: C562745
            OMIM: 122000 609140 609141
REFERENCE   PMID:18097987 (description, gene)
  AUTHORS   Ciralsky J, Colby K
  TITLE     Congenital corneal opacities: a review with a focus on genetics.
  JOURNAL   Semin Ophthalmol 22:241-6 (2007)
REFERENCE   PMID:21695473 (description)
  AUTHORS   Merjava S, Malinova E, Liskova P, Filipec M, Zemanova Z, Michalova K, Jirsova K
  TITLE     Recurrence of posterior polymorphous corneal dystrophy is caused by the overgrowth of the original diseased host endothelium.
  JOURNAL   Histochem Cell Biol 136:93-101 (2011)
REFERENCE   PMID:21067486 (description, gene)
  AUTHORS   Liskova P, Filipec M, Merjava S, Jirsova K, Tuft SJ
  TITLE     Variable ocular phenotypes of posterior polymorphous corneal dystrophy caused by  mutations in the ZEB1 gene.
  JOURNAL   Ophthalmic Genet 31:230-4 (2010)
///
ENTRY       H00962                      Disease
NAME        RIDDLE syndrome
DESCRIPTION RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties) syndrome is an immunodeficiency disorder that primarily manifests as an immunoglobulin deficiency. The underlying genetic cause of this syndrome is defective RNF168 that functions to recruit DNA double-strand break (DSB) repair proteins, such as 53BP1 and BRCA1, to sites of DNA damage. As with patients with other DSB repair disorders, the RIDDLE patients also present with nonimmunological characteristics including short stature and motor control problems.
CATEGORY    Primary immunodeficiency; Congenital disorder of DNA repair systems
GENE        RNF168 [HSA:165918] [KO:K20779]
DBLINKS     MeSH: C567453
            OMIM: 611943
REFERENCE   PMID:21426255 (description, gene)
  AUTHORS   Blundred RM, Stewart GS
  TITLE     DNA double-strand break repair, immunodeficiency and the RIDDLE syndrome.
  JOURNAL   Expert Rev Clin Immunol 7:169-85 (2011)
REFERENCE   PMID:19372751 (description, gene)
  AUTHORS   Stewart GS
  TITLE     Solving the RIDDLE of 53BP1 recruitment to sites of damage.
  JOURNAL   Cell Cycle 8:1532-8 (2009)
REFERENCE   PMID:19203578 (gene)
  AUTHORS   Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES, Nakada S, Ylanko J, Olivarius S, Mendez M, Oldreive C, Wildenhain J, Tagliaferro A, Pelletier L, Taubenheim N, Durandy A, Byrd PJ, Stankovic T, Taylor AM, Durocher D
  TITLE     The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage.
  JOURNAL   Cell 136:420-34 (2009)
REFERENCE   PMID:17940005 (gene)
  AUTHORS   Stewart GS, Stankovic T, Byrd PJ, Wechsler T, Miller ES, Huissoon A, Drayson MT, West SC, Elledge SJ, Taylor AM
  TITLE     RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling.
  JOURNAL   Proc Natl Acad Sci U S A 104:16910-5 (2007)
///
ENTRY       H00963                      Disease
NAME        Congenital hereditary endothelial dystrophy (CHED);
            Congenital hereditary endothelial dystrophy type 1;
            Congenital hereditary endothelial dystrophy type 2;
            Corneal dystrophy and perceptive deafness (CDPD);
            Harboyan syndrome
DESCRIPTION Congenital hereditary endothelial dystrophy (CHED) is a rare inheritable disorder of the corneal endothelium characterized by bilateral symmetric corneal clouding (edema) with varied severity from mild opacification to milky, ground-glass opacification without other anterior segment abnormalities, usually evident at birth or in the early years of life. Two subtypes of CHED based on differences in the mode of inheritance are known, an autosomal dominant (CHED1) and an autosomal recessive (CHED2) type. Clinically, both forms of the disorder are similar; the distinction between them is made by the age at onset and the presence or absence of associated symptoms. Both CHED1 and CHED2 have been mapped to chromosome 20. The Solute Carrier family 4 (sodium borate cotransporter) member 11 (SLC4A11) has been identified as the candidate gene for CHED2. Mutations in SLC4A11 are described in Harboyan syndrome, which is characterized as CHED2 with hearing loss. Most patients with CHED have severe visual impairment and often require penetrating keratoplasty.
CATEGORY    Eye disease
GENE        (CHED2) SLC4A11 [HSA:83959] [KO:K13862]
DBLINKS     ICD-10: H18.5
            OMIM: 217700 217400
REFERENCE   PMID:18097987 (description, gene)
  AUTHORS   Ciralsky J, Colby K
  TITLE     Congenital corneal opacities: a review with a focus on genetics.
  JOURNAL   Semin Ophthalmol 22:241-6 (2007)
REFERENCE   PMID:21203343 (description, gene)
  AUTHORS   Paliwal P, Sharma A, Tandon R, Sharma N, Titiyal JS, Sen S, Nag TC, Vajpayee RB
  TITLE     Congenital hereditary endothelial dystrophy - mutation analysis of SLC4A11 and genotype-phenotype correlation in a North Indian patient cohort.
  JOURNAL   Mol Vis 16:2955-63 (2010)
REFERENCE   PMID:18474783 (description, gene)
  AUTHORS   Hemadevi B, Veitia RA, Srinivasan M, Arunkumar J, Prajna NV, Lesaffre C, Sundaresan P
  TITLE     Identification of mutations in the SLC4A11 gene in patients with recessive congenital hereditary endothelial dystrophy.
  JOURNAL   Arch Ophthalmol 126:700-8 (2008)
///
ENTRY       H00964                      Disease
NAME        Thiopurine S-methyltransferase deficiency (TPMT deficiency)
DESCRIPTION Thiopurine S-methyltransferase deficiency (TPMT deficiency) is  inherited severe intolerance to thiopurine toxicity, caused by mutation in the TPMT gene. TPMT is part of a cascade of enzymes responsible for the metabolism of thiopurine drugs including azathioprine, mercaptopurine, and thioguanine.
CATEGORY    Inherited metabolic disease
GENE        TPMT [HSA:7172] [KO:K00569]
DRUG        Intolerant to
            Azathioprine [DR:D00238]
            Mercaptopurine [DR:D00161]
            Tioguanine [DR:D08603]
DBLINKS     ICD-10: E79.8
            MeSH: C536512
            OMIM: 610460
REFERENCE   PMID:20354201
  AUTHORS   Ford LT, Berg JD
  TITLE     Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come.
  JOURNAL   J Clin Pathol 63:288-95 (2010)
///
ENTRY       H00965                      Disease
NAME        RAPADILINO syndrome
DESCRIPTION RAPADILINO syndrome is an abbreviation of its hallmark features: radial hypo-/aplasia, patellae hypo-/aplasia and cleft or highly arched palate, diarrhoea and dislocated joints, little size and limb malformation, nose slender and normal intelligence. It is an autosomal recessive disorder caused by mutations in human DNA helicase RECQL4. Unlike its allelic disorders Rothmund-Thomson syndrome and Baller-Gerold syndrome, RAPADILINO syndrome lacks poikiloderma.
CATEGORY    Congenital disorder of DNA repair systems
GENE        RECQL4 [HSA:9401] [KO:K10730]
COMMENT     Rothmund-Thomson syndrome and Baller-Gerold syndrome are described in H00296 and H00458, respectively.
DBLINKS     ICD-10: Q87.1
            MeSH: C535288
            OMIM: 266280
REFERENCE   PMID:18716613 (description, gene)
  AUTHORS   Siitonen HA, Sotkasiira J, Biervliet M, Benmansour A, Capri Y, Cormier-Daire V, Crandall B, Hannula-Jouppi K, Hennekam R, Herzog D, Keymolen K, Lipsanen-Nyman M, Miny P, Plon SE, Riedl S, Sarkar A, Vargas FR, Verloes A, Wang LL, Kaariainen H, Kestila M
  TITLE     The mutation spectrum in RECQL4 diseases.
  JOURNAL   Eur J Hum Genet 17:151-8 (2009)
REFERENCE   PMID:16617241 (description, gene)
  AUTHORS   Kellermayer R
  TITLE     The versatile RECQL4.
  JOURNAL   Genet Med 8:213-6 (2006)
REFERENCE   PMID:17364146 (description, gene)
  AUTHORS   Dietschy T, Shevelev I, Stagljar I
  TITLE     The molecular role of the Rothmund-Thomson-, RAPADILINO- and Baller-Gerold-gene product, RECQL4: recent progress.
  JOURNAL   Cell Mol Life Sci 64:796-802 (2007)
REFERENCE   PMID:12952869 (description, gene)
  AUTHORS   Siitonen HA, Kopra O, Kaariainen H, Haravuori H, Winter RM, Saamanen AM, Peltonen L, Kestila M
  TITLE     Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases.
  JOURNAL   Hum Mol Genet 12:2837-44 (2003)
///
ENTRY       H00966                      Disease
NAME        AICA-ribosiduria;
            ATIC deficiency
DESCRIPTION AICA-ribosiduria is a neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Defects of purine metabolism are characterised by abnormal concentrations of substrates of defective enzymes and/or their metabolites in cells or body fluids.
CATEGORY    Inherited metabolic disease
GENE        ATIC [HSA:471] [KO:K00602]
DBLINKS     ICD-10: E79.8
            MeSH: C563876
            OMIM: 608688
REFERENCE   PMID:15114530
  AUTHORS   Marie S, Heron B, Bitoun P, Timmerman T, Van Den Berghe G, Vincent MF
  TITLE     AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC.
  JOURNAL   Am J Hum Genet 74:1276-81 (2004)
REFERENCE   PMID:16798121
  AUTHORS   Hornik P, Vyskocilova P, Friedecky D, Adam T
  TITLE     Diagnosing AICA-ribosiduria by capillary electrophoresis.
  JOURNAL   J Chromatogr B Analyt Technol Biomed Life Sci 843:15-9 (2006)
///
ENTRY       H00967                      Disease
NAME        Adiponectin deficiency
DESCRIPTION Adiponectin is a major adipocyte-derived protein with insulin-sensitizing, anti-inflammatory and anti-atherogenic properties. Adiponectin deficiency related to several obesity related malignancies including colorectal cancer.
CATEGORY    Metabolic disease
GENE        ADIPOQ [HSA:9370] [KO:K07296]
DBLINKS     MeSH: C567258
            OMIM: 612556
REFERENCE   PMID:22198319
  AUTHORS   Saxena A, Chumanevich A, Fletcher E, Larsen B, Lattwein K, Kaur K, Fayad R
  TITLE     Adiponectin deficiency: Role in chronic inflammation induced colon cancer.
  JOURNAL   Biochim Biophys Acta (2011)
REFERENCE   PMID:12802337
  AUTHORS   Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T
  TITLE     Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.
  JOURNAL   Nature 423:762-9 (2003)
REFERENCE   PMID:12032136
  AUTHORS   Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T
  TITLE     Disruption of adiponectin causes insulin resistance and neointimal formation.
  JOURNAL   J Biol Chem 277:25863-6 (2002)
REFERENCE   PMID:12431986
  AUTHORS   Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T
  TITLE     Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis.
  JOURNAL   J Biol Chem 278:2461-8 (2003)
///
ENTRY       H00968                      Disease
NAME        Raine syndrome;
            Lethal osteosclerotic bone dysplasia
DESCRIPTION Raine syndrome or lethal osteosclerotic bone dysplasia is an autosomal recessive disorder characterized by generalized osteosclerosis and characteristic facial dysmorphism. Death in the neonatal period is due to respiratory failure. Radiographic studies have shown generalized increase in the density of all bones and the basal structures of the skull, which leads to the characteristic facial features including microcephaly, proptosis, hypoplastic nose and midface, small jaw, and cleft palate.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FAM20C [HSA:56975]
DBLINKS     MeSH: C535282
            OMIM: 259775
REFERENCE   PMID:17924334 (description, gene)
  AUTHORS   Simpson MA, Hsu R, Keir LS, Hao J, Sivapalan G, Ernst LM, Zackai EH, Al-Gazali LI, Hulskamp G, Kingston HM, Prescott TE, Ion A, Patton MA, Murday V, George A, Crosby AH
  TITLE     Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development.
  JOURNAL   Am J Hum Genet 81:906-12 (2007)
REFERENCE   PMID:10482879 (description)
  AUTHORS   Shalev SA, Shalev E, Reich D, Borochowitz ZU
  TITLE     Osteosclerosis, hypoplastic nose, and proptosis (Raine syndrome): further delineation.
  JOURNAL   Am J Med Genet 86:274-7 (1999)
REFERENCE   PMID:1642277 (description)
  AUTHORS   Kan AE, Kozlowski K
  TITLE     New distinct lethal osteosclerotic bone dysplasia (Raine syndrome).
  JOURNAL   Am J Med Genet 43:860-4 (1992)
///
ENTRY       H00969                      Disease
NAME        Skeletal defects, genital hypoplasia, and mental retardation
DESCRIPTION This syndrome is associated with mental retardation, craniofacial dysmorphism, disproportionate short stature, and genital hypoplasia. Skeletal dysplasia includes absence of the thumbs, hypoplasia of the radius and ulna, and additional vertebral bodies and ribs. The causative gene is ZBTB16, one of the fusion partners with retinoic acid receptor-alpha in acute promyelocytic leukemia.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        ZBTB16 [HSA:7704] [KO:K10055]
DBLINKS     MeSH: C567306
            OMIM: 612447
REFERENCE   PMID:18611983 (description, gene)
  AUTHORS   Fischer S, Kohlhase J, Bohm D, Schweiger B, Hoffmann D, Heitmann M, Horsthemke B, Wieczorek D
  TITLE     Biallelic loss of function of the promyelocytic leukaemia zinc finger (PLZF) gene causes severe skeletal defects and genital hypoplasia.
  JOURNAL   J Med Genet 45:731-7 (2008)
///
ENTRY       H00970                      Disease
NAME        Juvenile primary lateral sclerosis
DESCRIPTION Juvenile primary lateral sclerosis is a very rare progressive paralytic disorder characterized by increasing weakness and stiffness of muscles in the arms, legs and face. Although primary lateral sclerosis (PLS) is a sporadic disorder of adult middle age, this disease is also observed in children as JSPS. JSPS arises from dysfunction of the upper motoneurons and the causative gene is ALS2.
CATEGORY    Neurodegenerative disease
GENE        ALS2 [HSA:57679] [KO:K04575]
DBLINKS     ICD-10: G12.2
            MeSH: C536416
            OMIM: 606353
REFERENCE   PMID:16670179 (description, gene)
  AUTHORS   Panzeri C, De Palma C, Martinuzzi A, Daga A, De Polo G, Bresolin N, Miller CC, Tudor EL, Clementi E, Bassi MT
  TITLE     The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function.
  JOURNAL   Brain 129:1710-9 (2006)
REFERENCE   PMID:17566607 (description, gene)
  AUTHORS   Hadano S, Kunita R, Otomo A, Suzuki-Utsunomiya K, Ikeda JE
  TITLE     Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration.
  JOURNAL   Neurochem Int 51:74-84 (2007)
REFERENCE   PMID:2812336 (description)
  AUTHORS   Grunnet ML, Leicher C, Zimmerman A, Zalneraitis E, Barwick M
  TITLE     Primary lateral sclerosis in a child.
  JOURNAL   Neurology 39:1530-2 (1989)
REFERENCE   PMID:8719747 (description)
  AUTHORS   Gascon GG, Chavis P, Yaghmour A, Stigsby B, Shums A, Ozand P, Siddique T
  TITLE     Familial childhood primary lateral sclerosis with associated gaze paresis.
  JOURNAL   Neuropediatrics 26:313-9 (1995)
///
ENTRY       H00971                      Disease
NAME        Achromatopsia;
            Rod monochromacy
DESCRIPTION Achromatopsia (Rod monochromacy) is an autosomal recessive retinal dystrophy with a prevalence of 1 in 33,000 individuals. It is characterized by low visual aquity, photophobia, nystagmus, difficulty in color discrimination, and no recordable cone function in electroretinography with normal rod functions. The condition is caused by genetic defects affecting crucial components of the cone photoreceptor signaling.
CATEGORY    Eye disease
GENE        CNGA3 [HSA:1261] [KO:K04950]
            CNGB3 [HSA:54714] [KO:K04953]
            GNAT2 [HSA:2780] [KO:K04631]
            PDE6C [HSA:5146] [KO:K13757]
            PDE6H [HSA:5149] [KO:K13760]
            ATF6 [HSA:22926] [KO:K09054]
DBLINKS     ICD-10: H53.5
            MeSH: D003117
            OMIM: 216900 262300 613856 613093 610024 616517
REFERENCE   PMID:19927164 (description, gene)
  AUTHORS   Simunovic MP
  TITLE     Colour vision deficiency.
  JOURNAL   Eye (Lond) 24:747-55 (2010)
REFERENCE   PMID:21912902 (description, gene)
  AUTHORS   Saqib MA, Awan BM, Sarfraz M, Khan MN, Rashid S, Ansar M
  TITLE     Genetic analysis of four Pakistani families with achromatopsia and a novel S4 motif mutation of CNGA3.
  JOURNAL   Jpn J Ophthalmol 55:676-80 (2011)
REFERENCE   PMID:20454696 (description, gene)
  AUTHORS   Azam M, Collin RW, Shah ST, Shah AA, Khan MI, Hussain A, Sadeque A, Strom TM, Thiadens AA, Roosing S, den Hollander AI, Cremers FP, Qamar R
  TITLE     Novel CNGA3 and CNGB3 mutations in two Pakistani families with achromatopsia.
  JOURNAL   Mol Vis 16:774-81 (2010)
REFERENCE   PMID:9662398 (description, gene)
  AUTHORS   Kohl S, Marx T, Giddings I, Jagle H, Jacobson SG, Apfelstedt-Sylla E, Zrenner E, Sharpe LT, Wissinger B
  TITLE     Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel.
  JOURNAL   Nat Genet 19:257-9 (1998)
REFERENCE   PMID:19887631 (gene)
  AUTHORS   Chang B, Grau T, Dangel S, Hurd R, Jurklies B, Sener EC, Andreasson S, Dollfus H, Baumann B, Bolz S, Artemyev N, Kohl S, Heckenlively J, Wissinger B
  TITLE     A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
  JOURNAL   Proc Natl Acad Sci U S A 106:19581-6 (2009)
REFERENCE   PMID:26063662 (gene)
  AUTHORS   Ansar M, Santos-Cortez RL, Saqib MA, Zulfiqar F, Lee K, Ashraf NM, Ullah E, Wang X, Sajid S, Khan FS, Amin-ud-Din M, Smith JD, Shendure J, Bamshad MJ, Nickerson DA, Hameed A, Riazuddin S, Ahmed ZM, Ahmad W, Leal SM
  TITLE     Mutation of ATF6 causes autosomal recessive achromatopsia.
  JOURNAL   Hum Genet 134:941-50 (2015)
///
ENTRY       H00972                      Disease
NAME        Endocrine-cerebro-osteodysplasia syndrome
DESCRIPTION Endocrine-cerebro-osteodysplasia syndrome is a neonatal lethal recessive disorder found in an Old Order Amish pedigree. This syndrome comprises osteodysplasia, cerebral anomalies, and endocrine gland hypoplasia. A missense mutation in ICK encoding intestinal cell kinase have been reported in the disease.
CATEGORY    Developmental disorder
GENE        ICK [HSA:22858] [KO:K08828]
DBLINKS     ICD-10: Q87.8
            OMIM: 612651
REFERENCE   PMID:19185282 (description, gene)
  AUTHORS   Lahiry P, Wang J, Robinson JF, Turowec JP, Litchfield DW, Lanktree MB, Gloor GB, Puffenberger EG, Strauss KA, Martens MB, Ramsay DA, Rupar CA, Siu V, Hegele RA
  TITLE     A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems.
  JOURNAL   Am J Hum Genet 84:134-47 (2009)
///
ENTRY       H00973                      Disease
NAME        Bradyopsia
DESCRIPTION Bradyopsia is a condition in which patients show a prolonged response suppression on electroretinogram and have delayed adapting to sudden changes in luminance levels, photophobia, and difficulties seeing moving objects. Visual acuity is normal to moderately reduced in the affected individuals. Recessive mutations have been reported in the genes encoding RGS9 and R9AP that have a critical role in the recovery phase of visual transduction.
CATEGORY    Eye disease
GENE        RGS9 [HSA:8787] [KO:K13765]
            RGS9BP [HSA:388531]
DBLINKS     MeSH: C564243
            OMIM: 608415
REFERENCE   PMID:17826834 (description, gene)
  AUTHORS   Hartong DT, Pott JW, Kooijman AC
  TITLE     Six patients with bradyopsia (slow vision): clinical features and course of the disease.
  JOURNAL   Ophthalmology 114:2323-31 (2007)
REFERENCE   PMID:19818506 (description, gene)
  AUTHORS   Michaelides M, Li Z, Rana NA, Richardson EC, Hykin PG, Moore AT, Holder GE, Webster AR
  TITLE     Novel mutations and electrophysiologic findings in RGS9- and R9AP-associated retinal dysfunction (Bradyopsia).
  JOURNAL   Ophthalmology 117:120-127.e1 (2010)
REFERENCE   PMID:14702087 (description, gene)
  AUTHORS   Nishiguchi KM, Sandberg MA, Kooijman AC, Martemyanov KA, Pott JW, Hagstrom SA, Arshavsky VY, Berson EL, Dryja TP
  TITLE     Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation.
  JOURNAL   Nature 427:75-8 (2004)
///
ENTRY       H00974                      Disease
NAME        Blue cone monochromacy
DESCRIPTION Blue cone monochromacy (also known as X-linked recessive incomplete achromatopsia) is a congenital stationary cone dysfunction syndrome characterized by the absence of both red and green cone sensitivities. Vision is derived from the remaining blue cones and rod photoreceptors. Patients present with reduced visual acuity, pendular nystagmus, and photophobia. The prevalence of blue cone monochromacy is estimated to be 1 in 100 000 males.
CATEGORY    Eye disease
GENE        OPN1LW [HSA:5956] [KO:K04251]
            OPN1MW [HSA:2652] [KO:K04251]
DBLINKS     ICD-10: H53.5
            MeSH:D003117
            OMIM: 303700
REFERENCE   PMID:19927164 (description)
  AUTHORS   Simunovic MP
  TITLE     Colour vision deficiency.
  JOURNAL   Eye (Lond) 24:747-55 (2010)
REFERENCE   PMID:19421413 (description, gene)
  AUTHORS   Gardner JC, Michaelides M, Holder GE, Kanuga N, Webb TR, Mollon JD, Moore AT, Hardcastle AJ
  TITLE     Blue cone monochromacy: causative mutations and associated phenotypes.
  JOURNAL   Mol Vis 15:876-84 (2009)
REFERENCE   PMID:2788922 (description, gene)
  AUTHORS   Nathans J, Davenport CM, Maumenee IH, Lewis RA, Hejtmancik JF, Litt M, Lovrien E, Weleber R, Bachynski B, Zwas F, et al.
  TITLE     Molecular genetics of human blue cone monochromacy.
  JOURNAL   Science 245:831-8 (1989)
///
ENTRY       H00975                      Disease
NAME        Rotaviral enteritis;
            Rotaviral gastroenteritis
DESCRIPTION Rotavirus is the most important cause of acute infantile gastroenteritis and causes 611 000 deaths worldwide each year. Infections have been reported to occur repeatedly in humans and most of cases in adults are asymptomatic. Infections in young children lead to acute diarrhea. Symptoms of rotavirus infection are non-specific and include vomiting and diarrhoea, occasionally accompanied by a low grade fever. Dehydration occurs in 40 to 80% of patients and is the most common cause of death. Viral NSP4 enterotoxin is responsible to the diarrhoea by eliciting calcium mobilization in gastrointestinal epithelial cells.
CATEGORY    Infectious disease
PATHOGEN    Rotavirus A [GN:T40092]
            Human rotavirus B [GN:T40123]
            Rotavirus C [GN:T40094]
            Rotavirus H [GN:T40093]
            NSP4 enterotoxin [VG:7011361]
DRUG        Rehydration
DBLINKS     ICD-10: A08.0
            MeSH: D012400
REFERENCE   PMID:9015109 (description, env_factor)
  AUTHORS   Bishop RF
  TITLE     Natural history of human rotavirus infection.
  JOURNAL   Arch Virol Suppl 12:119-28 (1996)
REFERENCE   PMID:2855916 (description)
  AUTHORS   Leung AK, Pai CH
  TITLE     Rotavirus gastroenteritis.
  JOURNAL   J Diarrhoeal Dis Res 6:188-207 (1988)
REFERENCE   PMID:1962726 (description, drug)
  AUTHORS   Maldonado YA, Yolken RH
  TITLE     Rotavirus.
  JOURNAL   Baillieres Clin Gastroenterol 4:609-25 (1990)
REFERENCE   PMID:10659345 (description, drug)
  AUTHORS   Estes MK, Morris AP
  TITLE     A viral enterotoxin. A new mechanism of virus-induced pathogenesis.
  JOURNAL   Adv Exp Med Biol 473:73-82 (1999)
REFERENCE   PMID:11447008 (description, env_factor)
  AUTHORS   Morris AP, Estes MK
  TITLE     Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VIII. Pathological consequences of rotavirus infection and its enterotoxin.
  JOURNAL   Am J Physiol Gastrointest Liver Physiol 281:G303-10 (2001)
REFERENCE   PMID:17376232 (description, env_factor)
  AUTHORS   Lorrot M, Vasseur M
  TITLE     How do the rotavirus NSP4 and bacterial enterotoxins lead differently to diarrhea?
  JOURNAL   Virol J 4:31 (2007)
///
ENTRY       H00976                      Disease
NAME        Colorblindness, including:
            Dichromacy;
            Anomalous trichromacy
DESCRIPTION Colorblindness is the inability or decreased ability to perceive color differences. Dichromacy is a condition characterized by reduced dimension of color vision in which one of the three basic color mechanisms is absent or not functioning. Anomalous trichromacy is the milder form of color vision deficiency, with ability to discriminate between different colors in varying degrees but not normal. Dichromacy and anomalous trichromacy are subdivided into three types: protan, deutan, and tritan depending on the affected cone type. Protan and deuten types consist red-green defects. Inherited red-green color vision defects affect 8% of males. Tritan type defect leads to inherited blue-yellow defect that is fairly rare.
CATEGORY    Eye disease
GENE        (protan) OPN1LW [HSA:5956] [KO:K04251]
            (deutan) OPN1MW [HSA:2652] [KO:K04251]
            (tritan) OPN1SW [HSA:611] [KO:K04252]
DBLINKS     ICD-10: H53.5
            MeSH: D003117
            OMIM: 303800 303900 190900
REFERENCE   PMID:19927164 (description, gene)
  AUTHORS   Simunovic MP
  TITLE     Colour vision deficiency.
  JOURNAL   Eye (Lond) 24:747-55 (2010)
REFERENCE   PMID:7511848 (description)
  AUTHORS   Tovee MJ
  TITLE     The molecular genetics and evolution of primate colour vision.
  JOURNAL   Trends Neurosci 17:30-7 (1994)
REFERENCE   PMID:16377059 (description)
  AUTHORS   Bouman MA
  TITLE     The simple perfection of quantum correlation in human vision.
  JOURNAL   Prog Neurobiol 78:38-60 (2006)
///
ENTRY       H00977                      Disease
NAME        Trichorhinophalangeal dysplasia, including:
            Trichorhinophalangeal syndrome, type I (TRPS1);
            Langer-Giedion Syndrome (TRPS2);
            Sugio-Kajii Syndrome (TRPS3)
DESCRIPTION Trichorhinophalangeal syndromes (TRPS) is a rare peripheral dystosis with mainly autosomal dominant inheritance. Three different forms of TRPS are known: type I (TRPS1), type II (TRPS2) and type III (TRPS3). They are characterized by sparse hair, bulbous pear-shaped nose, long and flat philtrum, thin upper lip, and protruding ears. Skeletal abnormalities that are frequently observed include epiphyses of the middle phalanges with shortened metacarpals, hip malformations, and short stature. The causative gene is TRPS1 that was shown to be a regulator of the Wnt signaling pathway in mouse.
CATEGORY    Skeletal dysplasia; Skin and connective tissue disease
GENE        (TRPS1_2_3) TRPS1 [HSA:7227]
            (TRPS2) EXT1 [HSA:2131] [KO:K02366]
DBLINKS     MeSH: C536820 D015826 C566033
            OMIM: 190350 150230 190351
REFERENCE   PMID:1925732 (description)
  AUTHORS   Burgess RC
  TITLE     Trichorhinophalangeal syndrome.
  JOURNAL   South Med J 84:1268-70 (1991)
REFERENCE   PMID:8034799 (description)
  AUTHORS   Carrington PR, Chen H, Altick JA
  TITLE     Trichorhinophalangeal syndrome, type I.
  JOURNAL   J Am Acad Dermatol 31:331-6 (1994)
REFERENCE   PMID:8993967 (description)
  AUTHORS   Itin PH, Bohn S, Mathys D, Guggenheim R, Richard G
  TITLE     Trichorhinophalangeal syndrome type III.
  JOURNAL   Dermatology 193:349-52 (1996)
REFERENCE   PMID:20394624 (description, gene)
  AUTHORS   Chen LH, Ning CC, Chao SC
  TITLE     Mutations in TRPS1 gene in trichorhinophalangeal syndrome type I in Asian patients.
  JOURNAL   Br J Dermatol 163:416-9 (2010)
REFERENCE   PMID:18544079 (description, gene)
  AUTHORS   Tariq M, Ahmad S, Ahmad W
  TITLE     A novel missense mutation in the TRPS1 gene underlies trichorhinophalangeal syndrome type III.
  JOURNAL   Br J Dermatol 159:476-8 (2008)
REFERENCE   PMID:22115758 (description)
  AUTHORS   Fantauzzo KA, Christiano AM
  TITLE     Trps1 activates a network of secreted Wnt inhibitors and transcription factors crucial to vibrissa follicle morphogenesis.
  JOURNAL   Development 139:203-14 (2012)
REFERENCE   PMID:19012352
  AUTHORS   Shanske AL, Patel A, Saukam S, Levy B, Ludecke HJ
  TITLE     Clinical and molecular characterization of a patient with Langer-Giedion syndrome and mosaic del(8)(q22.3q24.13).
  JOURNAL   Am J Med Genet A 146A:3211-6 (2008)
///
ENTRY       H00978                      Disease
NAME        Thrombocytopenia (THC);
            Familial platelet disorder with associated myeloid malignancy (FPDMM)
DESCRIPTION Thrombocytopenia is defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. Inherited syndromes are relatively rare causes of thrombocytopenia, but some genes underlying these disorders have been elucidated. Some inherited syndromes predispose to the development of bone marrow failure or leukemia. For example, familial platelet disorder with associated myeloid malignancy (FPDMM) is characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
CATEGORY    Hematologic disease
GENE        (THC1) WASP [HSA:7454] [KO:K05747]
            (THC2) ANKRD26 [HSA:22852]
            (THC2) MASTL [HSA:84930] [KO:K16309]
            (THC4) CYCS [HSA:54205] [KO:K08738]
            (THC6) SRC [HSA:6714] [KO:K05704]
            (X-linked) GATA1 [HSA:2623] [KO:K09182]
            (FPDMM) RUNX1 [HSA:861] [KO:K08367]
DBLINKS     ICD-10: D69.4
            OMIM: 313900 188000 612004 314050 601399 616937
REFERENCE   PMID:21680804
  AUTHORS   Geddis AE
  TITLE     A POTEntial new gene for thrombocytopenia.
  JOURNAL   Blood 117:6406-8 (2011)
REFERENCE   PMID:21606161
  AUTHORS   Liew E, Owen C
  TITLE     Familial myelodysplastic syndromes: a review of the literature.
  JOURNAL   Haematologica 96:1536-42 (2011)
REFERENCE   PMID:26936507 (gene)
  AUTHORS   Turro E, Greene D, Wijgaerts A, Thys C, Lentaigne C, Bariana TK, Westbury SK, Kelly AM, Selleslag D, Stephens JC, Papadia S, Simeoni I, Penkett CJ, Ashford S, Attwood A, Austin S, Bakchoul T, Collins P, Deevi SV, Favier R, Kostadima M, Lambert MP, Mathias M, Millar CM, Peerlinck K, Perry DJ, Schulman S, Whitehorn D, Wittevrongel C, De Maeyer M, Rendon A, Gomez K, Erber WN, Mumford AD, Nurden P, Stirrups K, Bradley JR, Raymond FL, Laffan MA, Van Geet C, Richardson S, Freson K, Ouwehand WH
  TITLE     A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
  JOURNAL   Sci Transl Med 8:328ra30 (2016)
///
ENTRY       H00979                      Disease
NAME        Caudal regression syndrome and Sirenomelia
DESCRIPTION Caudal dysgenesis and sirenomelia are rare malformations that represent a spectrum of caudal anomalies. Clinical findings include varying degrees of agenesis of the vertebral column (usually sacral or lumbosacral spine), as well as anorectal and genitourinary anomalies. The most severe end of this spectrum is known as sirenomelia that is characterized by fused lower limbs. These are caused by developmental field defects of blastogenesis involving the caudal mesoderm and usually sporadic.
CATEGORY    Developmental disorder; Nervous system disease
GENE        VANGL1 [HSA:81839] [KO:K04510]
ENV_FACTOR  Maternal diabetes
COMMENT     Spina bifida, a neural tube defect, is described in H00262.
DBLINKS     ICD-10: Q76.0
            MeSH: D004480
            OMIM: 600145
REFERENCE   PMID:19363325 (description, env_factor)
  AUTHORS   Boulas MM
  TITLE     Recognition of caudal regression syndrome.
  JOURNAL   Adv Neonatal Care 9:61-9; quiz 70-1 (2009)
REFERENCE   PMID:15977017 (description)
  AUTHORS   Singh SK, Singh RD, Sharma A
  TITLE     Caudal regression syndrome--case report and review of literature.
  JOURNAL   Pediatr Surg Int 21:578-81 (2005)
REFERENCE   PMID:7936503 (description)
  AUTHORS   Adra A, Cordero D, Mejides A, Yasin S, Salman F, O'Sullivan MJ
  TITLE     Caudal regression syndrome: etiopathogenesis, prenatal diagnosis, and perinatal management.
  JOURNAL   Obstet Gynecol Surv 49:508-16 (1994)
REFERENCE   PMID:17409324 (description, gene)
  AUTHORS   Kibar Z, Torban E, McDearmid JR, Reynolds A, Berghout J, Mathieu M, Kirillova I, De Marco P, Merello E, Hayes JM, Wallingford JB, Drapeau P, Capra V, Gros P
  TITLE     Mutations in VANGL1 associated with neural-tube defects.
  JOURNAL   N Engl J Med 356:1432-7 (2007)
REFERENCE   PMID:20734338 (description, env_factor)
  AUTHORS   Thottungal AD, Charles AK, Dickinson JE, Bower C
  TITLE     Caudal dysgenesis and sirenomelia-single centre experience suggests common pathogenic basis.
  JOURNAL   Am J Med Genet A 152A:2578-87 (2010)
REFERENCE   PMID:18470923 (description, env_factor)
  AUTHORS   Rougemont AL, Bouron-Dal Soglio D, Desilets V, Jovanovic M, Perreault G, Laurier Oligny L, Fournet JC
  TITLE     Caudal dysgenesis, sirenomelia, and situs inversus totalis: a primitive defect in blastogenesis.
  JOURNAL   Am J Med Genet A 146A:1470-6 (2008)
///
ENTRY       H00980                      Disease
NAME        Nevo syndrome
DESCRIPTION Nevo syndrome is a rare autosomal recessive disorder characterized by perinatal overgrowth, joint laxity, kyphosis, muscular hypotonia, wrist drop, spindle shaped fingers, and volar edema. It is an allelic disorder of Ehlers-Danlos syndrome kyphoscoliosis type.
CATEGORY    Connective tissue disease
GENE        PLOD [HSA:5351] [KO:K00473]
COMMENT     Ehlers-Danlos syndrome kyphoscoliosis type is described in H00802.
DBLINKS     MeSH: C536113
            OMIM: 601451
REFERENCE   PMID:15666309 (description, gene)
  AUTHORS   Giunta C, Randolph A, Al-Gazali LI, Brunner HG, Kraenzlin ME, Steinmann B
  TITLE     Nevo syndrome is allelic to the kyphoscoliotic type of the Ehlers-Danlos syndrome (EDS VIA).
  JOURNAL   Am J Med Genet A 133A:158-64 (2005)
REFERENCE   PMID:8574422 (description)
  AUTHORS   Hilderink BG, Brunner HG
  TITLE     Nevo syndrome.
  JOURNAL   Clin Dysmorphol 4:319-23 (1995)
///
ENTRY       H00981                      Disease
NAME        Ataxia with isolated vitamin E deficiency (AVED);
            Friedreich-like ataxia
DESCRIPTION Ataxia with isolated vitamin E deficiency (AVED) is a rare autosomal recessive neurodegenerative disease caused by mutations in the alpha tocopherol transfer protein (TTPA) gene. It causes ataxia and peripheral neuropathy that resembles Friedreich ataxia. AVED patients have markedly reduced plasma levels of vitamin E.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease
GENE        TTPA [HSA:7274]
MARKER      Vitamin E [DR:D02331]
DRUG        Vitamin E [DR:D02331]
COMMENT     Friedreich ataxia is described in H00067. [DS:H00067]
DBLINKS     ICD-10: E56.0 G11.1
            MeSH: C535393
            OMIM: 277460
REFERENCE   PMID:16491382
  AUTHORS   Doria-Lamba L, De Grandis E, Cristiani E, Fiocchi I, Montaldi L, Grosso P, Gellera C
  TITLE     Efficacious vitamin E treatment in a child with ataxia with isolated vitamin E deficiency.
  JOURNAL   Eur J Pediatr 165:494-5 (2006)
///
ENTRY       H00982                      Disease
NAME        Sideroblastic anemia, including:
            Pyridoxine-refractory autosomal recessive sideroblastic anemia (PRARSA);
            X-linked sideroblastic anemia (XLSA);
            X-linked sideroblastic anemia with ataxia (ASAT)
DESCRIPTION Sideroblastic anemias are a group of disorders characterized by anemia with the emergence of ring sideroblasts in the bone marrow. Inherited sideroblastic anemia is a rare and heterogeneous disease caused by mutations of genes involved in heme biosynthesis, iron-sulfur cluster biogenesis or transport, and mitochondrial metabolism.
CATEGORY    Hematologic disease
GENE        (PRARSA) SLC25A38 [HSA:54977] [KO:K15118]
            (PRARSA) GLRX5 [HSA:51218] [KO:K07390]
            (XLSA) ALAS2 [HSA:51218] [KO:K07390]
            (ASAT) ABCB7 [HSA:22] [KO:K05662]
COMMENT     Myopathy with lactic acidosis and sideroblastic anaemia (MLASA) is described in H00898. [DS:H00898]
DBLINKS     ICD-10: D64.0 D64.3
            OMIM: 205950 300751 301310
REFERENCE   PMID:20848343
  AUTHORS   Harigae H, Furuyama K
  TITLE     Hereditary sideroblastic anemia: pathophysiology and gene mutations.
  JOURNAL   Int J Hematol 92:425-31 (2010)
///
ENTRY       H00983                      Disease
NAME        Alpha-2-plasmin inhibitor (a2-PI) deficiency
DESCRIPTION Alpha-2-plasmin inhibitor (a2-PI) deficiency is an autosomal recessive disorder resulting in severe hemorrhagic diathesis. Mutations in SERPINF2 gene cause a2-PI deficiency. A2-PI acts as the primary inhibitor of plasminogen, and its deficiency causes a rare bleeding disorder because of increased fibrinolysis.
CATEGORY    Hematologic disease
GENE        SERPINF2 [HSA:5345] [KO:K03983]
DBLINKS     ICD-10: D68.8
            OMIM: 262850
REFERENCE   PMID:19141165
  AUTHORS   Carpenter SL, Mathew P
  TITLE     Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
  JOURNAL   Haemophilia 14:1250-4 (2008)
///
ENTRY       H00984                      Disease
NAME        Bare lymphocyte syndrome (BLS) type1
DESCRIPTION Bare lymphocyte syndrome (BLS) is a rare recessive genetic immune disorder endorsed by a partial or complete absence of major histocompatibility complex (MHC) or human leukocyte antigen (HLA) expression. BLS could be grouped as Type I, Type II and Type III based on defective surface MHC expression. The mutations in the TAP subunits are one of the most common features of BLS type I. MHC I deficiency due to tapasin (TAPBP) deficiency was also discovered recently.
CATEGORY    Inherited metabolic disease; Immune system disease
GENE        TAP1 [HSA:6890] [KO:K05653]
            TAP2 [HSA:6891] [KO:K05654]
            TAPBP [HSA:6892] [KO:K08058]
COMMENT     H00093 [DS:H00093] is the comprehensive entry of combined immunodeficiencies.
DBLINKS     ICD-10: D81.6
            OMIM: 604571
REFERENCE   PMID:22027563
  AUTHORS   Shrestha D, Szollosi J, Jenei A
  TITLE     Bare lymphocyte syndrome: an opportunity to discover our immune system.
  JOURNAL   Immunol Lett 141:147-57 (2012)
///
ENTRY       H00985                      Disease
NAME        Bare lymphocyte syndrome (BLS) type2
DESCRIPTION Bare lymphocyte syndrome (BLS) is a rare recessive genetic immune disorder endorsed by a partial or complete absence of major histocompatibility complex (MHC) or human leukocyte antigen (HLA) expression. BLS could be grouped as type I, type II, and type III based on defective surface MHC expression. A feature of loss in constitutive and inducible MHC II proteins have been grouped as BLS type II. The abnormality of the transcription factors, which combine to form a singular transcription complex essential for the initiation of the transcription of MHC II, contributes to the development of BLS type II. BLS type III is recognized by the loss of both MHC I and MHC II molecules.
CATEGORY    Inherited metabolic disease; Immune system disease
GENE        CIITA [HSA:4261] [KO:K08060]
            RFXANK [HSA:8625] [KO:K08062]
            RFX5 [HSA:5993] [KO:K08061]
            RFXAP [HSA:5994] [KO:K08063]
COMMENT     H00093 [DS:H00093] is the comprehensive entry of combined immunodeficiencies.
DBLINKS     ICD-10: D81.6
            OMIM: 209920
REFERENCE   PMID:22027563
  AUTHORS   Shrestha D, Szollosi J, Jenei A
  TITLE     Bare lymphocyte syndrome: an opportunity to discover our immune system.
  JOURNAL   Immunol Lett 141:147-57 (2012)
///
ENTRY       H00986                      Disease
NAME        Multiple pterygium syndrome, including:
            Multiple pterygium syndrome, lethal type (LMPS);
            Multiple pterygium syndrome, Escobar variant (EVMPS)
DESCRIPTION The multiple pterygium syndromes (MPS) are a spectrum of phenotypically heterogenous disorders that can be divided into prenatally lethal (LMPS) and nonlethal Escobar (EVMPS) types. The clinical features of MPS are congenital joint contractures (arthrogryposis) and multiple skin webbing (pterygia). Patients may have other developmental defects such as micrognathia, ptosis, and cleft palate. The genes that encode subunits of the embryonal acetylcholine receptor are linked to this disease.
CATEGORY    Developmental disorder
GENE        (LMPS, EVMPS) CHRNG [HSA:1146] [KO:K04818]
            (LMPS) CHRNA1 [HSA:1134] [KO:K04803]
            (LMPS) CHRND [HSA:1144] [KO:K04816]
DBLINKS     ICD-10: Q87.0
            MeSH: C537377
            OMIM: 265000 253290
REFERENCE   PMID:3289375 (description)
  AUTHORS   Ramer JC, Ladda RL, Demuth WW
  TITLE     Multiple pterygium syndrome. An overview.
  JOURNAL   Am J Dis Child 142:794-8 (1988)
REFERENCE   PMID:3430553 (description)
  AUTHORS   Thompson EM, Donnai D, Baraitser M, Hall CM, Pembrey ME, Fixsen J
  TITLE     Multiple pterygium syndrome: evolution of the phenotype.
  JOURNAL   J Med Genet 24:733-49 (1987)
REFERENCE   PMID:22167768 (description, gene)
  AUTHORS   Vogt J, Morgan NV, Rehal P, Faivre L, Brueton LA, Becker K, Fryns JP, Holder S, Islam L, Kivuva E, Lynch SA, Touraine R, Wilson LC, MacDonald F, Maher ER
  TITLE     CHRNG genotype-phenotype correlations in the multiple pterygium syndromes.
  JOURNAL   J Med Genet 49:21-6 (2012)
REFERENCE   PMID:18252226 (description, gene)
  AUTHORS   Michalk A, Stricker S, Becker J, Rupps R, Pantzar T, Miertus J, Botta G, Naretto VG, Janetzki C, Yaqoob N, Ott CE, Seelow D, Wieczorek D, Fiebig B, Wirth B, Hoopmann M, Walther M, Korber F, Blankenburg M, Mundlos S, Heller R, Hoffmann K
  TITLE     Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders.
  JOURNAL   Am J Hum Genet 82:464-76 (2008)
REFERENCE   PMID:19076525 (description)
  AUTHORS   Mayhew JF, Mychaskiw G
  TITLE     Escobar syndrome: is this child prone to malignant hyperthermia?
  JOURNAL   Paediatr Anaesth 19:69-70 (2009)
///
ENTRY       H00987                      Disease
NAME        Fetal akinesia deformation sequence (FADS);
            Pena-Shokeir syndrome, type 1
DESCRIPTION Fetal akinesia deformation sequence (FADS) is a heterogeneous disorder characterized by impaired fetal movement and resulting developmental defects. Fetal movement is essential for normal fetal development and growth. Intrauterine movement restriction causes growth retardation, congenital limb contractures, pterygia, pulmonary hypoplasia, and hydramnios.
CATEGORY    Developmental disorder
GENE        RAPSN [HSA:5913]
            DOK7 [HSA:285489]
DBLINKS     ICD-10: Q87.8
            MeSH: C536647
            OMIM: 208150
REFERENCE   PMID:18252226 (description, gene)
  AUTHORS   Michalk A, Stricker S, Becker J, Rupps R, Pantzar T, Miertus J, Botta G, Naretto VG, Janetzki C, Yaqoob N, Ott CE, Seelow D, Wieczorek D, Fiebig B, Wirth B, Hoopmann M, Walther M, Korber F, Blankenburg M, Mundlos S, Heller R, Hoffmann K
  TITLE     Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders.
  JOURNAL   Am J Hum Genet 82:464-76 (2008)
REFERENCE   PMID:18179903 (description, gene)
  AUTHORS   Vogt J, Harrison BJ, Spearman H, Cossins J, Vermeer S, ten Cate LN, Morgan NV, Beeson D, Maher ER
  TITLE     Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple pterygium syndrome/fetal akinesia patients.
  JOURNAL   Am J Hum Genet 82:222-7 (2008)
REFERENCE   PMID:19261599 (description, gene)
  AUTHORS   Vogt J, Morgan NV, Marton T, Maxwell S, Harrison BJ, Beeson D, Maher ER
  TITLE     Germline mutation in DOK7 associated with fetal akinesia deformation sequence.
  JOURNAL   J Med Genet 46:338-40 (2009)
///
ENTRY       H00988                      Disease
NAME        Enterokinase deficiency
DESCRIPTION Enterokinase deficiency is autosomal recessive defect in the activation of pancreatic proteolytic proenzymes and consequently hypoproteinemia and general weakness results.
CATEGORY    Endocrine disease
GENE        TMPRSS15 [HSA:5651] [KO:K01316]
DBLINKS     MeSH: C562649
            OMIM: 226200
REFERENCE   PMID:11719902
  AUTHORS   Holzinger A, Maier EM, Buck C, Mayerhofer PU, Kappler M, Haworth JC, Moroz SP, Hadorn HB, Sadler JE, Roscher AA
  TITLE     Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency.
  JOURNAL   Am J Hum Genet 70:20-5 (2002)
///
ENTRY       H00989                      Disease
NAME        Mohr-Tranebjaerg syndrome
DESCRIPTION Mohr-Tranebjaerg syndrome is an X-linked recessive condition characterized by progressive postlingual sensorineural hearing impairment that begin in childhood associated by dystonia and optic atrophy. Mohr-Tranebjaerg syndrome is caused by mutations in the TIMM8A, a translocase of the inner mitochrondrial membrane whose dysfunction leads to mitochondrial-based neural degeneration.
CATEGORY    Nervous system disease; Mitochondrial disease
GENE        TIMM8A [HSA:1678] [KO:K17780]
DBLINKS     MeSH: C535808
            OMIM: 304700
REFERENCE   PMID:18952432 (description, gene)
  AUTHORS   Aguirre LA, Perez-Bas M, Villamar M, Lopez-Ariztegui MA, Moreno-Pelayo MA, Moreno F, del Castillo I
  TITLE     A Spanish sporadic case of deafness-dystonia (Mohr-Tranebjaerg) syndrome with a novel mutation in the gene encoding TIMM8a, a component of the mitochondrial protein translocase complexes.
  JOURNAL   Neuromuscul Disord 18:979-81 (2008)
REFERENCE   PMID:11449109 (description, gene)
  AUTHORS   Merchant SN, McKenna MJ, Nadol JB Jr, Kristiansen AG, Tropitzsch A, Lindal S, Tranebjaeizrg L
  TITLE     Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1).
  JOURNAL   Otol Neurotol 22:506-11 (2001)
REFERENCE   PMID:17471106 (description, gene)
  AUTHORS   Bahmad F Jr, Merchant SN, Nadol JB Jr, Tranebjaerg L
  TITLE     Otopathology in Mohr-Tranebjaerg syndrome.
  JOURNAL   Laryngoscope 117:1202-8 (2007)
REFERENCE   PMID:21266802 (description)
  AUTHORS   Cacace AT, Pinheiro JM
  TITLE     The mitochondrial connection in auditory neuropathy.
  JOURNAL   Audiol Neurootol 16:398-413 (2011)
///
ENTRY       H00990                      Disease
NAME        Microcephaly, Amish type
DESCRIPTION Microcephaly, Amish type (MCPHA) is a lethal, autosomal resessive condition characterized by severe congenital microcephaly, elevated levels of alpha-ketoglutarate in the urine, and premature death. This disorder has been observed in Old Order Amish families. Patients have a homozygous point mutation in SLC25A19 that results in loss of transport activity.
CATEGORY    Developmental disorder
GENE        SLC25A19 [HSA:60386] [KO:K15108]
DBLINKS     ICD-10: Q02
            MeSH: C538247
            OMIM: 607196
REFERENCE   PMID:14598172 (description)
  AUTHORS   Palmieri F
  TITLE     The mitochondrial transporter family (SLC25): physiological and pathological implications.
  JOURNAL   Pflugers Arch 447:689-709 (2004)
REFERENCE   PMID:12185364 (description, gene)
  AUTHORS   Rosenberg MJ, Agarwala R, Bouffard G, Davis J, Fiermonte G, Hilliard MS, Koch T, Kalikin LM, Makalowska I, Morton DH, Petty EM, Weber JL, Palmieri F, Kelley RI, Schaffer AA, Biesecker LG
  TITLE     Mutant deoxynucleotide carrier is associated with congenital microcephaly.
  JOURNAL   Nat Genet 32:175-9 (2002)
///
ENTRY       H00991                      Disease
NAME        Microcephalic osteodysplastic primordial dwarfism, type II (MOPD II)
DESCRIPTION Microcephalic osteodysplastic primordial dwarfism, type II (MOPD II) is an autosomal recessive condition characterized by severe intrauterine and postnatal growth failure, microcephaly, and disproportionate short stature due to short limbs. Characteristic skeletal abnormalities are seen.
CATEGORY    Skeletal dysplasia
GENE        PCNT [HSA:5116] [KO:K16481]
COMMENT     MOPD II is distinct from Seckel syndrome by more severe growth retardation, radiological abnormalities, and absent or mild mental retardation.
DBLINKS     ICD-10: Q87.1
            MeSH: C565898
            OMIM: 210720
REFERENCE   PMID:15368497 (description)
  AUTHORS   Hall JG, Flora C, Scott CI Jr, Pauli RM, Tanaka KI
  TITLE     Majewski osteodysplastic primordial dwarfism type II (MOPD II): natural history and clinical findings.
  JOURNAL   Am J Med Genet A 130A:55-72 (2004)
REFERENCE   PMID:9800908 (description)
  AUTHORS   Majewski F, Goecke TO
  TITLE     Microcephalic osteodysplastic primordial dwarfism type II: report of three cases  and review.
  JOURNAL   Am J Med Genet 80:25-31 (1998)
REFERENCE   PMID:19643772 (description, gene)
  AUTHORS   Willems M, Genevieve D, Borck G, Baumann C, Baujat G, Bieth E, Edery P, Farra C, Gerard M, Heron D, Leheup B, Le Merrer M, Lyonnet S, Martin-Coignard D, Mathieu M, Thauvin-Robinet C, Verloes A, Colleaux L, Munnich A, Cormier-Daire V
  TITLE     Molecular analysis of pericentrin gene (PCNT) in a series of 24 Seckel/microcephalic osteodysplastic primordial dwarfism type II (MOPD II) families.
  JOURNAL   J Med Genet 47:797-802 (2010)
REFERENCE   PMID:19839044 (description, gene)
  AUTHORS   Piane M, Della Monica M, Piatelli G, Lulli P, Lonardo F, Chessa L, Scarano G
  TITLE     Majewski osteodysplastic primordial dwarfism type II (MOPD II) syndrome previously diagnosed as Seckel syndrome: report of a novel mutation of the PCNT gene.
  JOURNAL   Am J Med Genet A 149A:2452-6 (2009)
///
ENTRY       H00992                      Disease
NAME        Seckel syndrome
DESCRIPTION Seckel syndrome is a recessively inherited dwarfism characterized by intrauterine growth retardation, proportionate postnatal dwarfism, severe microcephaly, micrognathia, and 'bird-headed' profile. Mental retardation also occurs. Genes that control cellular responses to DNA damage are linked to the syndrome.
CATEGORY    Developmental disorder
GENE        ATR [HSA:545] [KO:K06640]
            CENPJ [HSA:55835] [KO:K11502]
            CTIP [HSA:5932] [KO:K20773]
            PCNT [HSA:5116] [KO:K16481]
            CEP152 [HSA:22995] [KO:K16728]
            CEP63 [HSA:80254] [KO:K16763]
            NIN [HSA:51199] [KO:K16476]
DBLINKS     ICD-10: Q87.1
            MeSH: C537533 C537534
            OMIM: 210600 606744 613676 613823 614728 614851
REFERENCE   PMID:17921644 (description)
  AUTHORS   Harsha Vardhan BG, Muthu MS, Saraswathi K, Koteeswaran D
  TITLE     Bird-headed dwarf of Seckel.
  JOURNAL   J Indian Soc Pedod Prev Dent 25 Suppl:S8-9 (2007)
REFERENCE   PMID:3300331 (description)
  AUTHORS   Majoor-Krakauer DF, Wladimiroff JW, Stewart PA, van de Harten JJ, Niermeijer MF
  TITLE     Microcephaly, micrognathia, and bird-headed dwarfism: prenatal diagnosis of a Seckel-like syndrome.
  JOURNAL   Am J Med Genet 27:183-8 (1987)
REFERENCE   PMID:12640452 (description, gene)
  AUTHORS   O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA
  TITLE     A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome.
  JOURNAL   Nat Genet 33:497-501 (2003)
REFERENCE   PMID:20522431 (description, gene)
  AUTHORS   Al-Dosari MS, Shaheen R, Colak D, Alkuraya FS
  TITLE     Novel CENPJ mutation causes Seckel syndrome.
  JOURNAL   J Med Genet 47:411-4 (2010)
REFERENCE   PMID:21998596 (description, gene)
  AUTHORS   Qvist P, Huertas P, Jimeno S, Nyegaard M, Hassan MJ, Jackson SP, Borglum AD
  TITLE     CtIP Mutations Cause Seckel and Jawad Syndromes.
  JOURNAL   PLoS Genet 7:e1002310 (2011)
REFERENCE   PMID:21131973 (description, gene)
  AUTHORS   Kalay E, Yigit G, Aslan Y, Brown KE, Pohl E, Bicknell LS, Kayserili H, Li Y, Tuysuz B, Nurnberg G, Kiess W, Koegl M, Baessmann I, Buruk K, Toraman B, Kayipmaz S, Kul S, Ikbal M, Turner DJ, Taylor MS, Aerts J, Scott C, Milstein K, Dollfus H, Wieczorek D, Brunner HG, Hurles M, Jackson AP, Rauch A, Nurnberg P, Karaguzel A, Wollnik B
  TITLE     CEP152 is a genome maintenance protein disrupted in Seckel syndrome.
  JOURNAL   Nat Genet 43:23-6 (2011)
REFERENCE   PMID:18157127 (description, gene)
  AUTHORS   Griffith E, Walker S, Martin CA, Vagnarelli P, Stiff T, Vernay B, Al Sanna N, Saggar A, Hamel B, Earnshaw WC, Jeggo PA, Jackson AP, O'Driscoll M
  TITLE     Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling.
  JOURNAL   Nat Genet 40:232-6 (2008)
REFERENCE   PMID:21983783
  AUTHORS   Sir JH, Barr AR, Nicholas AK, Carvalho OP, Khurshid M, Sossick A, Reichelt S, D'Santos C, Woods CG, Gergely F
  TITLE     A primary microcephaly protein complex forms a ring around parental centrioles.
  JOURNAL   Nat Genet 43:1147-53 (2011)
REFERENCE   PMID:22933543
  AUTHORS   Dauber A, Lafranchi SH, Maliga Z, Lui JC, Moon JE, McDeed C, Henke K, Zonana J, Kingman GA, Pers TH, Baron J, Rosenfeld RG, Hirschhorn JN, Harris MP, Hwa V
  TITLE     Novel microcephalic primordial dwarfism disorder associated with variants in the  centrosomal protein ninein.
  JOURNAL   J Clin Endocrinol Metab 97:E2140-51 (2012)
///
ENTRY       H00993                      Disease
NAME        Microcephalic osteodysplastic primordial dwarfism, type I (MOPD I);
            Taybi-Linder syndrome
DESCRIPTION Microcephalic osteodysplastic primordial dwarfism, type I (MOPD I) is a condition comprising sereve intrauterine and postnatal growth retardation, microcephaly, and skeletal anomalies. MOPD I is characterized by short and bowed long bones with enlarged metaphyses. Malformations of the central nervous system have been reported such as partial agenesis of the corpus callosum, hypoplastic frontal lobes, and vermis agenesis.
CATEGORY    Skeletal dysplasia
GENE        RNU4ATAC [HSA:100151683]
DBLINKS     ICD-10: Q87.1
            MeSH: C537577
            OMIM: 210710
REFERENCE   PMID:21474761 (description, gene)
  AUTHORS   Edery P, Marcaillou C, Sahbatou M, Labalme A, Chastang J, Touraine R, Tubacher E, Senni F, Bober MB, Nampoothiri S, Jouk PS, Steichen E, Berland S, Toutain A, Wise CA, Sanlaville D, Rousseau F, Clerget-Darpoux F, Leutenegger AL
  TITLE     Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA.
  JOURNAL   Science 332:240-3 (2011)
REFERENCE   PMID:9800907 (description)
  AUTHORS   Sigaudy S, Toutain A, Moncla A, Fredouille C, Bourliere B, Ayme S, Philip N
  TITLE     Microcephalic osteodysplastic primordial dwarfism Taybi-Linder type: report of four cases and review of the literature.
  JOURNAL   Am J Med Genet 80:16-24 (1998)
REFERENCE   PMID:21990275 (description, gene)
  AUTHORS   Abdel-Salam GM, Miyake N, Eid MM, Abdel-Hamid MS, Hassan NA, Eid OM, Effat LK, El-Badry TH, El-Kamah GY, El-Darouti M, Matsumoto N
  TITLE     A homozygous mutation in RNU4ATAC as a cause of microcephalic osteodysplastic primordial dwarfism type I (MOPD I) with associated pigmentary disorder.
  JOURNAL   Am J Med Genet A 155A:2885-96 (2011)
REFERENCE   PMID:15372530 (description)
  AUTHORS   Kantaputra PN, Tanpaiboon P, Unachak K, Praphanphoj V
  TITLE     Microcephalic osteodysplastic primordial dwarfism with severe microdontia and skin anomalies: confirmation of a new syndrome.
  JOURNAL   Am J Med Genet A 130A:181-90 (2004)
///
ENTRY       H00994                      Disease
NAME        Familial skewed X-chromosome inactivation
DESCRIPTION X chromosome inactivation is the transcriptional silencing of the majority of genes on one of the two X chromosomes in mammalian females that equalizes the effective dosage of X-linked genes between XX females and XY males. Therefore mammalian females are mosaics for two cell populations with different X chromosomes active. Skewed X inactivation is defined as a pattern where the cells show a preferential inactivation of one X chromosome. The incidence of skewing is shown to be age dependent but in general, skewing does not have any biologic consequence. However, in cases of individuals with nonlethal mutated allele, degree of skewing is predisposing to genetic diseases such as hemophilia A. The key player is the X inactivation-specific transcript (XIST), an X-linked untranslated RNA that coats the inactive X-chromosome.
CATEGORY    Other
GENE        XIST [HSA:7503]
COMMENT     Hemophilia A is described in H00219.
DBLINKS     OMIM: 300087
REFERENCE   PMID:19396465 (description)
  AUTHORS   Orstavik KH
  TITLE     X chromosome inactivation in clinical practice.
  JOURNAL   Hum Genet 126:363-73 (2009)
REFERENCE   PMID:16720461 (description)
  AUTHORS   Orstavik KH
  TITLE     Skewed X inactivation in healthy individuals and in different diseases.
  JOURNAL   Acta Paediatr Suppl 95:24-9 (2006)
REFERENCE   PMID:11110715 (description)
  AUTHORS   Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF
  TITLE     Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females.
  JOURNAL   Blood 96:4363-5 (2000)
REFERENCE   PMID:12572852 (description, gene)
  AUTHORS   Lyon MF
  TITLE     X-chromosome inactivation and human genetic disease.
  JOURNAL   Acta Paediatr Suppl 91:107-12 (2002)
REFERENCE   PMID:9585586 (description, gene)
  AUTHORS   Migeon BR, Haisley-Royster C
  TITLE     Familial skewed X inactivation and X-linked mutations: unbalanced X inactivation  is a powerful means to ascertain X-linked genes that affect cell proliferation.
  JOURNAL   Am J Hum Genet 62:1555-7; author reply 1557-8 (1998)
///
ENTRY       H00995                      Disease
NAME        Combined deficiency of vitamin K-dependent clotting factors (VKCFD)
DESCRIPTION Combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder consisting of a deficiency of clotting factors II, VII, IX, and X , as well as the coagulation inhibitors protein C, protein S, and protein Z. VKCFD leads to a bleeding tendency with a variegate clinical picture. Two subtypes have been identified, deriving from mutations of two enzymes of the vitamin K cycle. VKCFD type1 is defined by defective GGCX activity, while VKCFD type 2 derives from functional deficiency of VKORC.
CATEGORY    Inherited metabolic disease
GENE        (VKCFD1) GGCX [HSA:2677] [KO:K10106]
            (VKCFD2) VKORC1 [HSA:79001] [KO:K05357]
DRUG        Vitamin K [DR:D00148]
DBLINKS     ICD-10: D68.4
            OMIM: 277450 607473
REFERENCE   PMID:20630065
  AUTHORS   Napolitano M, Mariani G, Lapecorella M
  TITLE     Hereditary combined deficiency of the vitamin K-dependent clotting factors.
  JOURNAL   Orphanet J Rare Dis 5:21 (2010)
///
ENTRY       H00996                      Disease
NAME        Amish infantile epilepsy syndrome
DESCRIPTION Amish infantile epilepsy syndrome is an autosomal recessive, infantile-onset symptomatic epilepsy associated with developmental stagnation and blindness. A mutation in SIAT9, which is predicted to result in the premature termination of the GM3 synthase enzyme, has been identified.
CATEGORY    Nervous system disease
GENE        ST3GAL5 [HSA:8869] [KO:K03370]
DBLINKS     MeSH: C563799
            OMIM: 609056
REFERENCE   PMID:15502825
  AUTHORS   Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, Wang H, Wiznitzer M, Gurtz K, Verganelaki A, Pryde A, Patton MA, Dwek RA, Butters TD, Platt FM, Crosby AH
  TITLE     Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
  JOURNAL   Nat Genet 36:1225-9 (2004)
///
ENTRY       H00997                      Disease
NAME        CATSHL syndrome
DESCRIPTION CATSHL syndrome is characterised by camptodactyly, tall stature, scoliosis, and hearing loss. The syndrome is caused by a missense mutation in the FGFR3 gene. FGFR3 is a negative regulator of bone growth, and its mutations are well known to cause a variety of short-limbed bone dysplasias and craniosynostosis syndromes. The finding of CATSHL syndrome indicates that abnormal FGFR3 signaling can cause human anomalies by promoting as well as inhibiting endochondral bone growth.
CATEGORY    Developmental disorder; Nervous system disease
GENE        FGFR3 [HSA:2261] [KO:K05094]
COMMENT     Mutations in FGFR3 cause different disorders. 
            FGFR3-related short limb skeletal dysplasias [DS:H00505]
            Muenke craniosynostosis [DS:H00458]
            Lacrimo-auriculo-dento-digital syndrome [DS:H00642]
DBLINKS     ICD-10: Q87.2
            MeSH: C537975
            OMIM: 610474
REFERENCE   PMID:17033969
  AUTHORS   Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC, Bamshad MJ
  TITLE     A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.
  JOURNAL   Am J Hum Genet 79:935-41 (2006)
///
ENTRY       H00998                      Disease
NAME        Alternating hemiplegia of childhood
DESCRIPTION Alternating hemiplegia of childhood (ACH) is a rare disorder with onset before 18 months of age. The earliest manifestations of AHC are recurrent bilateral attacks of hemiplegia lasting minutes to days, abnormal ocular movements, and autonomic disturbances. A characteristic feature of AHC is the disappearance of all abnormalities when the child falls asleep.
CATEGORY    Nervous system disease
GENE        ATP1A2 [HSA:477] [KO:K01539]
ENV_FACTOR  Exposure to cold
            Emotional stress
            Fatigue
            Bathing
            Hyperthermia/hypothermia
            Upper respiratory infection
DRUG        Flunarizine [DG:DG01006]
COMMENT     Hemiplegic migraine (H00775) and alternating hemiplegia of childhood (AHC) share some clinical features.
DBLINKS     ICD-10: G98
            MeSH: C536589
            OMIM: 104290
REFERENCE   PMID:8496742 (description)
  AUTHORS   Bourgeois M, Aicardi J, Goutieres F
  TITLE     Alternating hemiplegia of childhood.
  JOURNAL   J Pediatr 122:673-9 (1993)
REFERENCE   PMID:17880649 (description, drug, env_factor)
  AUTHORS   Neville BG, Ninan M
  TITLE     The treatment and management of alternating hemiplegia of childhood.
  JOURNAL   Dev Med Child Neurol 49:777-80 (2007)
REFERENCE   PMID:15286158 (description, gene)
  AUTHORS   Bassi MT, Bresolin N, Tonelli A, Nazos K, Crippa F, Baschirotto C, Zucca C, Bersano A, Dolcetta D, Boneschi FM, Barone V, Casari G
  TITLE     A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood.
  JOURNAL   J Med Genet 41:621-8 (2004)
REFERENCE   PMID:14667076 (description)
  AUTHORS   Kanavakis E, Xaidara A, Papathanasiou-Klontza D, Papadimitriou A, Velentza S, Youroukos S
  TITLE     Alternating hemiplegia of childhood: a syndrome inherited with an autosomal dominant trait.
  JOURNAL   Dev Med Child Neurol 45:833-6 (2003)
REFERENCE   PMID:18498393 (description)
  AUTHORS   de Vries B, Stam AH, Beker F, van den Maagdenberg AM, Vanmolkot KR, Laan L, Ginjaar IB, Frants RR, Lauffer H, Haan J, Haas JP, Terwindt GM, Ferrari MD
  TITLE     CACNA1A mutation linking hemiplegic migraine and alternating hemiplegia of childhood.
  JOURNAL   Cephalalgia 28:887-91 (2008)
///
ENTRY       H00999                      Disease
NAME        Coenzyme Q10 deficiency
DESCRIPTION Coenzyme Q10 deficiency is an autosomal recessive disorder with variable manifestations, including pure myopathy, myopathy with encephalopathy, cerebellar atrophy with ataxia, and infantile multisystem disease including encephalopathy and nephropathy. It has been shown that mutations in some genes involved in CoQ10 biosynthesis cause primary CoQ10 deficiency.
CATEGORY    Nervous system disease; Hereditary ataxia
GENE        COQ2 [HSA:27235] [KO:K06125]
            COQ4 [HSA:51117] [KO:K18586]
            COQ6 [HSA:51004] [KO:K06126]
            COQ7 [HSA:10229] [KO:K06134]
            COQ8A/ADCK3 [HSA:56997] [KO:K08869]
            COQ9 [HSA:57017] [KO:K18587]
            PDSS1 [HSA:23590] [KO:K12504]
            PDSS2 [HSA:57107] [KO:K12505]
            APTX [HSA:54840] [KO:K10863]
DRUG        CoQ10 [DR:D01065]
DBLINKS     ICD-10: G11.1
            MeSH: C564403
            OMIM: 607426 616276 614650 616733
REFERENCE   PMID:19966907
  AUTHORS   Spindler M, Beal MF, Henchcliffe C
  TITLE     Coenzyme Q10 effects in neurodegenerative disease.
  JOURNAL   Neuropsychiatr Dis Treat 5:597-610 (2009)
REFERENCE   PMID:25658047 (gene)
  AUTHORS   Brea-Calvo G, Haack TB, Karall D, Ohtake A, Invernizzi F, Carrozzo R, Kremer L, Dusi S, Fauth C, Scholl-Burgi S, Graf E, Ahting U, Resta N, Laforgia N, Verrigni D, Okazaki Y, Kohda M, Martinelli D, Freisinger P, Strom TM, Meitinger T, Lamperti C, Lacson A, Navas P, Mayr JA, Bertini E, Murayama K, Zeviani M, Prokisch H, Ghezzi D
  TITLE     COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with  CoQ10 deficiency.
  JOURNAL   Am J Hum Genet 96:309-17 (2015)
REFERENCE   PMID:21540551 (gene)
  AUTHORS   Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, Trevisson E, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, Rotig A, Nurnberg G, Becker C, Wang S, Ozaltin F, Topaloglu R, Bakkaloglu A, Bakkaloglu SA, Muller D, Beissert A, Mir S, Berdeli A, Varpizen S, Zenker M, Matejas V, Santos-Ocana C, Navas P, Kusakabe T, Kispert A, Akman S, Soliman NA, Krick S, Mundel P, Reiser J, Nurnberg P, Clarke CF, Wiggins RC, Faul C, Hildebrandt F
  TITLE     COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness.
  JOURNAL   J Clin Invest 121:2013-24 (2011)
REFERENCE   PMID:26084283 (gene)
  AUTHORS   Freyer C, Stranneheim H, Naess K, Mourier A, Felser A, Maffezzini C, Lesko N, Bruhn H, Engvall M, Wibom R, Barbaro M, Hinze Y, Magnusson M, Andeer R, Zetterstrom RH, von Dobeln U, Wredenberg A, Wedell A
  TITLE     Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybensoic acid.
  JOURNAL   J Med Genet 52:779-83 (2015)
///
ENTRY       H01000                      Disease
NAME        Retinal vasculopathy with cerebral leukodystrophy (RVCL)
DESCRIPTION Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a rare autosomal dominant microvascular endotheliopathy with middle-age onset. At around the age of 45, affected individuals may develop retinal and cerebral dysfunction. Death occurs in most cases within 10 years of the first symptoms appearing. The disease-causing mutations of TREX1 lead to truncation and abnormal localization of the 3'-5' exonuclease.
CATEGORY    Nervous system disease
GENE        TREX1 [HSA:11277] [KO:K10790]
DBLINKS     MeSH: C566007
            OMIM: 192315
REFERENCE   PMID:17660820 (gene, descrition)
  AUTHORS   Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, Liszewski MK, Barilla-Labarca ML, Terwindt GM, Kasai Y, McLellan M, Grand MG, Vanmolkot KR, de Vries B, Wan J, Kane MJ, Mamsa H, Schafer R, Stam AH, Haan J, de Jong PT, Storimans CW, van Schooneveld MJ, Oosterhuis JA, Gschwendter A, Dichgans M, Kotschet KE, Hodgkinson S, Hardy TA, Delatycki MB, Hajj-Ali RA, Kothari PH, Nelson SF, Frants RR, Baloh RW, Ferrari MD, Atkinson JP
  TITLE     C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy.
  JOURNAL   Nat Genet 39:1068-70 (2007)
REFERENCE   PMID:18805785 (gene)
  AUTHORS   Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, Perrino FW
  TITLE     The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.
  JOURNAL   J Biol Chem 283:31649-56 (2008)
REFERENCE   PMID:18724932 (gene)
  AUTHORS   Stetson DB, Ko JS, Heidmann T, Medzhitov R
  TITLE     Trex1 prevents cell-intrinsic initiation of autoimmunity.
  JOURNAL   Cell 134:587-98 (2008)
///
ENTRY       H01001                      Disease
NAME        COACH syndrome
DESCRIPTION COACH syndrome is a rare autosomal recessive disorder with cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis. The vermis hypoplasia comprises a part of a spectrum of mid-hindbrain malformation called the 'molar tooth sign' that is characteristic to Joubert syndrome.
CATEGORY    Developmental disorder
GENE        CC2D2A [HSA:57545] [KO:K19352]
            RPGRIP1L [HSA:23322] [KO:K16550]
            TMEM67 [HSA:91147] [KO:K19348]
DBLINKS     ICD-10: K74.0 Q04.3
            MeSH: C536430
            OMIM: 216360
REFERENCE   PMID:19574260 (description, gene)
  AUTHORS   Doherty D, Parisi MA, Finn LS, Gunay-Aygun M, Al-Mateen M, Bates D, Clericuzio C, Demir H, Dorschner M, van Essen AJ, Gahl WA, Gentile M, Gorden NT, Hikida A, Knutzen D, Ozyurek H, Phelps I, Rosenthal P, Verloes A, Weigand H, Chance PF, Dobyns WB, Glass IA
  TITLE     Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis).
  JOURNAL   J Med Genet 47:8-21 (2010)
REFERENCE   PMID:8862632 (description)
  AUTHORS   Gentile M, Di Carlo A, Susca F, Gambotto A, Caruso ML, Panella C, Vajro P, Guanti G
  TITLE     COACH syndrome: report of two brothers with congenital hepatic fibrosis, cerebellar vermis hypoplasia, oligophrenia, ataxia, and mental retardation.
  JOURNAL   Am J Med Genet 64:514-20 (1996)
REFERENCE   PMID:2929661 (description)
  AUTHORS   Verloes A, Lambotte C
  TITLE     Further delineation of a syndrome of cerebellar vermis hypo/aplasia, oligophrenia, congenital ataxia, coloboma, and hepatic fibrosis.
  JOURNAL   Am J Med Genet 32:227-32 (1989)
///
ENTRY       H01002                      Disease
NAME        Generalized arterial calcification of infancy
DESCRIPTION Generalized arterial calcification of infancy (GACI) is a rare and often fatal genetic disorder, characterized by calcification of the internal elastic lamina, fibrotic myointimal proliferation of muscular arteries, and resultant arterial stenosis. GACI is associated with biallelic inactivating mutations in ENPP1 in about 75% of the cases. ENPP1 generates PPi that inhibits hydroxyapatite crystal growth.
CATEGORY    Cardiovascular Disease
GENE        ENPP1 [HSA:5167] [KO:K01513]
            ABCC6 [HSA:368] [KO:K05669]
DRUG        Pamidronic acid [DR:D00941]
            Risedronic acid [DR:D00942 D03234]
COMMENT     Spontaneous pathologic arterial calcifications in childhood can occur in both GACI and pseudoxanthoma elasticum (H00560).
DBLINKS     ICD-10: Q28.8
            MeSH: C537440
            OMIM: 208000 614473
REFERENCE   PMID:22229486 (gene)
  AUTHORS   Li Q, Schumacher W, Jablonski D, Siegel D, Uitto J
  TITLE     Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene.
  JOURNAL   Br J Dermatol 166:1107-11 (2012)
REFERENCE   PMID:19229237 (description, drug)
  AUTHORS   Ramjan KA, Roscioli T, Rutsch F, Sillence D, Munns CF
  TITLE     Generalized arterial calcification of infancy: treatment with bisphosphonates.
  JOURNAL   Nat Clin Pract Endocrinol Metab 5:167-72 (2009)
REFERENCE   PMID:15940697 (description)
  AUTHORS   Cheng KS, Chen MR, Ruf N, Lin SP, Rutsch F
  TITLE     Generalized arterial calcification of infancy: different clinical courses in two  affected siblings.
  JOURNAL   Am J Med Genet A 136:210-3 (2005)
REFERENCE   PMID:22209248 (gene)
  AUTHORS   Nitschke Y, Baujat G, Botschen U, Wittkampf T, du Moulin M, Stella J, Le Merrer M, Guest G, Lambot K, Tazarourte-Pinturier MF, Chassaing N, Roche O, Feenstra I, Loechner K, Deshpande C, Garber SJ, Chikarmane R, Steinmann B, Shahinyan T, Martorell L, Davies J, Smith WE, Kahler SG, McCulloch M, Wraige E, Loidi L, Hohne W, Martin L, Hadj-Rabia S, Terkeltaub R, Rutsch F
  TITLE     Generalized Arterial Calcification of Infancy and Pseudoxanthoma Elasticum Can Be Caused by Mutations in Either ENPP1 or ABCC6.
  JOURNAL   Am J Hum Genet 90:25-39 (2012)
///
ENTRY       H01003                      Disease
NAME        Dimethylglycine dehydrogenase deficiency (DMGDHD)
DESCRIPTION Dimethylglycine dehydrogenase deficiency is a rare autosomal recessive disorder characterized by fish odor, and unusual muscle fatigue with increased serum creatine kinase. Dimethylglycine dehydrogenase (DMGDH) is a mitochondrial matrix enzyme involved in the metabolism of choline.
CATEGORY    Inherited metabolic disease
GENE        (DMGDHD) DMGDH [HSA:29958] [KO:K00315]
MARKER      Increase of N,N-dimethylglycine [CPD:C01026] in serum and urine.
DBLINKS     ICD-10: E72.5
            MeSH: C565278
            OMIM: 605850 268900
REFERENCE   PMID:11231903
  AUTHORS   Binzak BA, Wevers RA, Moolenaar SH, Lee YM, Hwu WL, Poggi-Bach J, Engelke UF, Hoard HM, Vockley JG, Vockley J
  TITLE     Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency.
  JOURNAL   Am J Hum Genet 68:839-47 (2001)
///
ENTRY       H01004                      Disease
NAME        Velocardiofacial syndrome
DESCRIPTION Velocardiofacial syndrome (VCFS), or 22q11 deletion syndrome, is a condition characterized by multiple congenital abnormalities affecting tissues derived from neural crest cells. Individuals with VCFS are reported to have distinctive dysmorphology, congenital heart disease, learning disabilities, and high rates of psychiatric disorder, especially schizophrenia.
CATEGORY    Developmental disorder
GENE        TBX1 [HSA:6899] [KO:K10175]
COMMENT     Velocardiofacial syndrome is closely related to DiGeorge syndrome (H01524).
DBLINKS     ICD-10: D82.1
            MeSH: D058165
            OMIM: 192430
REFERENCE   PMID:18636637 (description)
  AUTHORS   Gothelf D, Schaer M, Eliez S
  TITLE     Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome.
  JOURNAL   Dev Disabil Res Rev 14:59-68 (2008)
REFERENCE   PMID:15877762 (description)
  AUTHORS   Murphy KC
  TITLE     Annotation: velo-cardio-facial syndrome.
  JOURNAL   J Child Psychol Psychiatry 46:563-71 (2005)
REFERENCE   PMID:11689394 (description)
  AUTHORS   Murphy KC, Owen MJ
  TITLE     Velo-cardio-facial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia.
  JOURNAL   Br J Psychiatry 179:397-402 (2001)
REFERENCE   PMID:11844533 (description)
  AUTHORS   Murphy KC
  TITLE     Schizophrenia and velo-cardio-facial syndrome.
  JOURNAL   Lancet 359:426-30 (2002)
REFERENCE   PMID:14585638 (gene)
  AUTHORS   Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, Ichida F, Joo K, Kimura M, Imamura S, Kamatani N, Momma K, Takao A, Nakazawa M, Shimizu N, Matsuoka R
  TITLE     Role of TBX1 in human del22q11.2 syndrome.
  JOURNAL   Lancet 362:1366-73 (2003)
REFERENCE   PMID:16684884 (gene)
  AUTHORS   Paylor R, Glaser B, Mupo A, Ataliotis P, Spencer C, Sobotka A, Sparks C, Choi CH, Oghalai J, Curran S, Murphy KC, Monks S, Williams N, O'Donovan MC, Owen MJ, Scambler PJ, Lindsay E
  TITLE     Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome.
  JOURNAL   Proc Natl Acad Sci U S A 103:7729-34 (2006)
///
ENTRY       H01005                      Disease
NAME        Dopamine beta-hydroxylase deficiency;
            Norepinephrine deficiency;
            Noradrenaline deficiency
DESCRIPTION Dopamine beta-hydroxylase (DBH) deficiency is a very rare form of primary autonomic failure characterized by cardiovascular disorders and severe orthostatic hypotension. DBH deficiency is caused by a series of mutations in the DBH gene encoding the key enzyme in noradrenaline synthesis.
CATEGORY    Nervous system disease
GENE        DBH [HSA:1621] [KO:K00503]
MARKER      Complete absence of noradrenaline and adrenaline in plasma. 
            Increased dopamine plasma levels.
DRUG        Droxidopa [DR:D01277]
DBLINKS     ICD-10: G90.8
            MeSH: C535600
            OMIM: 223360
REFERENCE   PMID:20301647
  AUTHORS   Robertson D, Garland EM
  TITLE     Dopamine Beta-Hydroxylase Deficiency
  JOURNAL   (1993)
REFERENCE   PMID:16722595
  AUTHORS   Senard JM, Rouet P
  TITLE     Dopamine beta-hydroxylase deficiency.
  JOURNAL   Orphanet J Rare Dis 1:7 (2006)
///
ENTRY       H01006                      Disease
NAME        Hereditary angioedema
DESCRIPTION Hereditary angioedema (HAE) is a rare genetic disorder, manifested by recurrent episodes of angioedema localized to the skin or mucosa of the gastrointestinal tract or larynx. The laryngeal angioedema is potentially lethal. The classic forms, HAE types I and II, result from deficiency of the plasma protease inhibitor, C1 inhibitor (C1INH). Type I HAE is caused by decreased expression of C1INH in the plasma whereas type 2 HAE, consisting approximately 15% of patients with HAE, is due to expression of a dysfunctional C1INH protein. HAE type III has been observed exclusively in women and appears to be correlated with high estrogen levels.
CATEGORY    Vascular disease
GENE        (type I and II) C1NH [HSA:710] [KO:K04001]
            (type III) F12; coagulation factor XII [HSA:2161] [KO:K01328]
DRUG        Ecallantide [DR:D03931]
            Icatibant [DR:D04492] 
            Berinert-P; human plasma-derived C1-INH
            Rhucin; recombinant C1-INH produced in transgenic rabbit
DBLINKS     ICD-10: D84.1
            OMIM: 610618 106100
REFERENCE   PMID:14572810 (description, gene)
  AUTHORS   Davis AE 3rd
  TITLE     The pathogenesis of hereditary angioedema.
  JOURNAL   Transfus Apher Sci 29:195-203 (2003)
REFERENCE   PMID:15596403 (description, gene)
  AUTHORS   Davis AE 3rd
  TITLE     The pathophysiology of hereditary angioedema.
  JOURNAL   Clin Immunol 114:3-9 (2005)
REFERENCE   PMID:21279474 (drug)
  AUTHORS   Antoniu SA
  TITLE     Therapeutic approaches in hereditary angioedema.
  JOURNAL   Clin Rev Allergy Immunol 41:114-22 (2011)
REFERENCE   PMID:19160940 (drug)
  AUTHORS   Reshef A, Leibovich I, Goren A
  TITLE     Hereditary angioedema: new hopes for an orphan disease.
  JOURNAL   Isr Med Assoc J 10:850-5 (2008)
REFERENCE   PMID:17186468 (description, gene)
  AUTHORS   Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renne T, Drouet C, Bork K, Nothen MM
  TITLE     Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.
  JOURNAL   Am J Hum Genet 79:1098-104 (2006)
///
ENTRY       H01007                      Disease
NAME        Choroid plexus papilloma
DESCRIPTION Choroid plexus tumors (CPTs) are rare intraventricular papillary neoplasms of neuroectodermal origin, accounting for less than 1% of all intracranial tumors and 2-4% of pediatric brain tumors. CPTs are categorized by three distinct histologies; choroid plexus papilloma, atypical choroid plexus papilloma, and the malignant choroid plexus carcinoma. Choroid plexus papillomas outnumber choroid plexus carcinomas and are composed of a single layer of cuboidal-to-columnar cells, resting on a basement membrane overlying papillary and vascularized connective tissue.
CATEGORY    Cancer; Nervous system disease
GENE        p53 [HSA:7157] [KO:K04451]
DBLINKS     ICD-10: D33.0
            MeSH: D020288
            OMIM: 260500
REFERENCE   PMID:3217283 (description)
  AUTHORS   Tomita T, McLone DG, Flannery AM
  TITLE     Choroid plexus papillomas of neonates, infants and children.
  JOURNAL   Pediatr Neurosci 14:23-30 (1988)
REFERENCE   PMID:21990040 (description, gene)
  AUTHORS   Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, Krieger MD, Lavey RS, Shlien A, Villablanca JG, Erdreich-Epstein A, Dhall G, Jubran R, Tabori U, Malkin D, Finlay JL
  TITLE     Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni  syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010.
  JOURNAL   Pediatr Blood Cancer 58:905-9 (2012)
REFERENCE   PMID:21970783 (description)
  AUTHORS   Ogiwara H, Dipatri AJ, Alden TD, Bowman RM, Tomita T
  TITLE     Choroid plexus tumors in pediatric patients.
  JOURNAL   Br J Neurosurg 26:32-7 (2012)
REFERENCE   PMID:11135453 (description)
  AUTHORS   Rickert CH, Paulus W
  TITLE     Tumors of the choroid plexus.
  JOURNAL   Microsc Res Tech 52:104-11 (2001)
REFERENCE   PMID:22059144 (description)
  AUTHORS   Imai M, Tominaga J, Matsumae M
  TITLE     Choroid plexus papilloma originating from the cerebrum parenchyma.
  JOURNAL   Surg Neurol Int 2:151 (2011)
///
ENTRY       H01008                      Disease
NAME        C syndrome, including:
            Opitz trigonocephaly syndrome;
            Bohring-Opitz syndrome (BOPS)
DESCRIPTION The C syndrome/ Opitz trigonocephaly syndrome is characterized by trigonocephaly and associated anomalies, such as unusual facies, psychomotor retardation, redundant skin, joint and limb abnormalities, and visceral anomalies. The C syndrome is caused by mutations in CD96, a member of the immunoglobulin superfamily. Because of close similarity between both syndromes, Bohring-Opitz syndrome (BOPS) is considered the more severe form of the C syndrome, therefore known as C-like syndrome. Recently, It has been reported that de novo nonsense mutations in ASXL1 cause BOPS.
CATEGORY    Developmental disorder
GENE        CD96 [HSA:10225] [KO:K06517]
            (BOPS) ASXL1 [HSA:171023] [KO:K11471]
DBLINKS     ICD-10: Q87.8
            MeSH: C537418 C537419
            OMIM: 211750 605039
REFERENCE   PMID:17847009
  AUTHORS   Kaname T, Yanagi K, Chinen Y, Makita Y, Okamoto N, Maehara H, Owan I, Kanaya F, Kubota Y, Oike Y, Yamamoto T, Kurosawa K, Fukushima Y, Bohring A, Opitz JM, Yoshiura K, Niikawa N, Naritomi K
  TITLE     Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome.
  JOURNAL   Am J Hum Genet 81:835-41 (2007)
REFERENCE   PMID:16691589
  AUTHORS   Bohring A, Oudesluijs GG, Grange DK, Zampino G, Thierry P
  TITLE     New cases of Bohring-Opitz syndrome, update, and critical review of the literature.
  JOURNAL   Am J Med Genet A 140:1257-63 (2006)
REFERENCE   PMID:21706002
  AUTHORS   Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BB
  TITLE     De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.
  JOURNAL   Nat Genet 43:729-31 (2011)
///
ENTRY       H01009                      Disease
NAME        Newfoundland rod-cone dystrophy (NFRCD)
DESCRIPTION Newfoundland rod-cone dystrophy (NFRCD) is a disorder characterized by retinal dystrophy reminiscent of retinitis punctata albescens with a substantially lower age at onset and more-rapid and distinctive progression. Mutations in RLBP1 gene, encoding the cellular retinaldehyde-binding protein, are likely to cause NFRCD.
CATEGORY    Eye disease
GENE        RLBP1 [HSA:6017] [KO:K19625]
DBLINKS     MeSH: C564391
            OMIM: 607476
REFERENCE   PMID:11868161 (description, gene)
  AUTHORS   Eichers ER, Green JS, Stockton DW, Jackman CS, Whelan J, McNamara JA, Johnson GJ, Lupski JR, Katsanis N
  TITLE     Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in RLBP1.
  JOURNAL   Am J Hum Genet 70:955-64 (2002)
///
ENTRY       H01010                      Disease
NAME        Occult macular dystrophy (OMD)
DESCRIPTION Occult macular dystrophy (OMD) is an inherited or sporadic macular dystrophy characterized by progressive loss of macular function but normal ophthalmoscopic appearance. Patients with OMD have normal full-field electroretinograms (ERGs), but the focal macular ERGs (FMERGs) and multifocal ERGs are abnormal. OMD is inherited as an autosomal dominant trait. However, patients with sporadic disease have been also reported. Mutations in RP1L1 gene, which plays essential roles in the cone functions, are responsible for OMD.
CATEGORY    Eye disease
GENE        RP1L1 [HSA:94137] [KO:K19538]
DBLINKS     OMIM: 613587
REFERENCE   PMID:20826268 (description, gene)
  AUTHORS   Akahori M, Tsunoda K, Miyake Y, Fukuda Y, Ishiura H, Tsuji S, Usui T, Hatase T, Nakamura M, Ohde H, Itabashi T, Okamoto H, Takada Y, Iwata T
  TITLE     Dominant mutations in RP1L1 are responsible for occult macular dystrophy.
  JOURNAL   Am J Hum Genet 87:424-9 (2010)
REFERENCE   PMID:21555613 (description)
  AUTHORS   Fujinami K, Tsunoda K, Hanazono G, Shinoda K, Ohde H, Miyake Y
  TITLE     Fundus autofluorescence in autosomal dominant occult macular dystrophy.
  JOURNAL   Arch Ophthalmol 129:597-602 (2011)
///
ENTRY       H01011                      Disease
NAME        Adrenocorticotropic hormone deficiency;
            Isolated ACDH deficiency (IAD)
DESCRIPTION Isolated adrenocorticotropic hormone deficiency (IAD) is a rare disease characterized by low plasma ACTH and cortisol levels and preservation of all other pituitary hormones, that may be an underestimated cause of neonatal death. Recently, loss-of-function mutations in the human TPIT (TBX19) gene were detected in IAD. TPIT is a T-box transcription factor with a specific role in differentiation of the corticotroph lineage. It has been reported that TPIT mutations are responsible for two thirds of neonatal-onset complete IAD but can not be detected in partial or late-onset IAD.
CATEGORY    Endocrine disease
GENE        TBX19 [HSA:9095] [KO:K10184]
MARKER      Low plasma ACTH [CPD:C02017] and cortisol [CPD:C00735] levels
DBLINKS     ICD-10: E23.6
            MeSH: C535668
            OMIM: 201400
REFERENCE   PMID:16390921
  AUTHORS   Weintrob N, Drouin J, Vallette-Kasic S, Taub E, Marom D, Lebenthal Y, Klinger G, Bron-Harlev E, Shohat M
  TITLE     Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene.
  JOURNAL   Pediatrics 117:e322-7 (2006)
REFERENCE   PMID:22170728
  AUTHORS   Couture C, Saveanu A, Barlier A, Carel JC, Fassnacht M, Fluck CE, Houang M, Maes M, Phan-Hug F, Enjalbert A, Drouin J, Brue T, Vallette S
  TITLE     Phenotypic homogeneity and genotypic variability in a large series of congenital  isolated ACTH-deficiency patients with TPIT gene mutations.
  JOURNAL   J Clin Endocrinol Metab 97:E486-95 (2012)
REFERENCE   PMID:22028893
  AUTHORS   Pham LL, Garot C, Brue T, Brauner R
  TITLE     Clinical, biological and genetic analysis of 8 cases of congenital isolated adrenocorticotrophic hormone (ACTH) deficiency.
  JOURNAL   PLoS One 6:e26516 (2011)
///
ENTRY       H01012                      Disease
NAME        Oculo-auricular syndrome
DESCRIPTION Oculo-auricular syndrome is a rare developmental recessive condition characterized by ophthalmic anomalies and a particular cleft ear lobule. Previously described ocular abnormalities include bilateral microcornea, posterior synechiae, cataract, chorioretinal colobomas, and rod-cone dystrophy. Mutation in the human Hmx1 ortholog HMX1 (NKX5-3) results in this disease.
CATEGORY    Developmental disorder; Eye disease
GENE        HMX1 [HSA:3166] [KO:K09349]
DBLINKS     ICD-10:Q18
            OMIM: 612109
REFERENCE   PMID:18423520 (description, gene)
  AUTHORS   Schorderet DF, Nichini O, Boisset G, Polok B, Tiab L, Mayeur H, Raji B, de la Houssaye G, Abitbol MM, Munier FL
  TITLE     Mutation in the human homeobox gene NKX5-3 causes an oculo-auricular syndrome.
  JOURNAL   Am J Hum Genet 82:1178-84 (2008)
REFERENCE   PMID:21417677 (description, gene)
  AUTHORS   Vaclavik V, Schorderet DF, Borruat FX, Munier FL
  TITLE     Retinal dystrophy in the oculo-auricular syndrome due to HMX1 mutation.
  JOURNAL   Ophthalmic Genet 32:114-7 (2011)
///
ENTRY       H01013                      Disease
NAME        Adult i phenotype
DESCRIPTION Adult i phenotype is a rare autosomal recessive condition that was found to be highly associated with congenital cataract. The I and i antigens are carbohydrate structures on glycoproteins and glycolipids on the cell surface of a variety of tissues and body fluids. Most adult red blood cells (RBCs) abundantly express I antigen. Conversion of the i antigen into an I structure takes place during the first 18 months after birth as a result of the expression of a specific transferase, I-branching GCNT2. Lack of this enzyme results in the adult i phenotype.
CATEGORY    Hematologic disease
GENE        GCNT2 [HSA:2651] [KO:K00742]
DBLINKS     OMIM: 110800
REFERENCE   PMID:21912254
  AUTHORS   Yu LC, Lin M
  TITLE     Molecular genetics of the blood group I system and the regulation of I antigen expression during erythropoiesis and granulopoiesis.
  JOURNAL   Curr Opin Hematol 18:421-6 (2011)
REFERENCE   PMID:15161861
  AUTHORS   Pras E, Raz J, Yahalom V, Frydman M, Garzozi HJ, Pras E, Hejtmancik JF
  TITLE     A nonsense mutation in the glucosaminyl (N-acetyl) transferase 2 gene (GCNT2): association with autosomal recessive congenital cataracts.
  JOURNAL   Invest Ophthalmol Vis Sci 45:1940-5 (2004)
///
ENTRY       H01014                      Disease
NAME        Sparganosis
DESCRIPTION Human sparganosis is caused by larval form (spargana) of the canine/feline tapeworms belonging to the genus Spirometra. A wide range of amphibians, reptiles, birds, and mammals serve as second intermediate/paratenic hosts. Humans become infected by drinking contaminated water, eating undercooked meat of infected frogs or snakes, or by applying poultices of frog or snake flesh on open wounds in traditional medical treatment in parts of southeast Asia. Spargana invade the brain, eyes, spinal cord, breast, and subcutaneous tissues, resulting in blindness, paralysis, and even death.
CATEGORY    Infectious disease
PATHOGEN    Spirometra mansonoides (United States)
            Spirometra mansoni (Asia)
            Spirometra proliferum
DRUG        Praziquantel [DR:D00471]
DBLINKS     ICD-10: B70.1
            MeSH: D013031
REFERENCE   PMID:9516692 (description, env_factor)
  AUTHORS   Dunn IJ, Palmer PE
  TITLE     Sparganosis.
  JOURNAL   Semin Roentgenol 33:86-8 (1998)
REFERENCE   PMID:21459073 (descritpion, drug)
  AUTHORS   Anantaphruti MT, Nawa Y, Vanvanitchai Y
  TITLE     Human sparganosis in Thailand: an overview.
  JOURNAL   Acta Trop 118:171-6 (2011)
REFERENCE   PMID:21126898 (desription)
  AUTHORS   Li MW, Song HQ, Li C, Lin HY, Xie WT, Lin RQ, Zhu XQ
  TITLE     Sparganosis in mainland China.
  JOURNAL   Int J Infect Dis 15:e154-6 (2011)
///
ENTRY       H01015                      Disease
NAME        Jalili syndrome
DESCRIPTION Jalili syndrome is a combination of recessively inherited cone-rod dystrophy and amelogenesis imperfecta. It is caused mutations in the CNNM4 gene that encodes a putative metal transporter that expressed in the neural retina and in ameloblasts in the developing tooth.
CATEGORY    Developmental disorder
GENE        CNNM4 [HSA:26504] [KO:K16302]
COMMENT     Cone-rod dystrophy and amelogenesis imperfecta are described in H00481 and H00645, respectively.
DBLINKS     ICD-10: H35.5
            MeSH: C536604
            OMIM: 217080
REFERENCE   PMID:19200525 (descritpion, gene)
  AUTHORS   Parry DA, Mighell AJ, El-Sayed W, Shore RC, Jalili IK, Dollfus H, Bloch-Zupan A, Carlos R, Carr IM, Downey LM, Blain KM, Mansfield DC, Shahrabi M, Heidari M, Aref P, Abbasi M, Michaelides M, Moore AT, Kirkham J, Inglehearn CF
  TITLE     Mutations in CNNM4 cause Jalili syndrome, consisting of autosomal-recessive cone-rod dystrophy and amelogenesis imperfecta.
  JOURNAL   Am J Hum Genet 84:266-73 (2009)
REFERENCE   PMID:20706282 (descritpion)
  AUTHORS   Jalili IK
  TITLE     Cone-rod dystrophy and amelogenesis imperfecta (Jalili syndrome): phenotypes and  environs.
  JOURNAL   Eye (Lond) 24:1659-68 (2010)
///
ENTRY       H01016                      Disease
NAME        Primary bile acid malabsorption
DESCRIPTION This disease occurs when there is impaired absorption of bile acids in the terminal ileum. In patients with terminal ileal resection or impaired terminal ileal function, bile acids are not reabsorbed and excess colonic bile acids cause diarrhea. Excess colonic bile acids can be seen in patients with a histological normal terminal ileum and this has been called primary bile acid malabsorption.
CATEGORY    Gastrointestinal disease
GENE        SLC10A2 (polymorphism) [HSA:6555] [KO:K14342]
COMMENT     FGF19, produced in the ileum in response to bile acid absorption, regulates hepatic bile acid synthesis.
DBLINKS     MeSH: C567652
            OMIM: 613291
REFERENCE   PMID:21805078 (description, gene)
  AUTHORS   Johnston I, Nolan J, Pattni SS, Walters JR
  TITLE     New insights into bile acid malabsorption.
  JOURNAL   Curr Gastroenterol Rep 13:418-25 (2011)
REFERENCE   PMID:19426836 (description)
  AUTHORS   Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW
  TITLE     A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.
  JOURNAL   Clin Gastroenterol Hepatol 7:1189-94 (2009)
///
ENTRY       H01017                      Disease
NAME        Choanal atresia and lymphedema
DESCRIPTION Choanal atresia and lymphoedema is a rare congenital malformation caused by loss-of-function mutation in PTPN14 encoding a nonreceptor tyrosine phosphatase. PTPN14 has been shown to interact with the vascular endothelial growth factor receptor 3 (VEGFR3), a receptor tyrosine kinase that is essential for lymphangiogenesis. The mechanism responsible for the development of chanal atresia is not clear but believed to be failure of the breakdown of the bucconasal membrane during embryogenesis.
CATEGORY    Developmental disorder
GENE        PTPN14 [HSA:5784] [KO:K18025]
DBLINKS     MeSH: D002754 D008209
            OMIM: 613611
REFERENCE   PMID:1872518 (description)
  AUTHORS   Har-El G, Borderon ML, Weiss MH
  TITLE     Choanal atresia and lymphedema.
  JOURNAL   Ann Otol Rhinol Laryngol 100:661-4 (1991)
REFERENCE   PMID:20826270 (20826270)
  AUTHORS   Au AC, Hernandez PA, Lieber E, Nadroo AM, Shen YM, Kelley KA, Gelb BD, Diaz GA
  TITLE     Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans.
  JOURNAL   Am J Hum Genet 87:436-44 (2010)
///
ENTRY       H01018                      Disease
NAME        Metachondromatosis
DESCRIPTION Metachondromatosis (MC) is a rare, autosomal dominant condition affecting the growth of bones. It is characterized by exostoses (osteochondromas) and enchondromas. Exostotic lesions occur frequently in the digits and tend to grow toward the joint. MC exostoses may regress or even resolve over time.
CATEGORY    Skeletal dysplasia
GENE        PTPN11 [HSA:5781] [KO:K07293]
DBLINKS     ICD-10: Q78.8
            MeSH: C562938
            OMIM: 156250
REFERENCE   PMID:21533187 (description, gene)
  AUTHORS   Bowen ME, Boyden ED, Holm IA, Campos-Xavier B, Bonafe L, Superti-Furga A, Ikegawa S, Cormier-Daire V, Bovee JV, Pansuriya TC, de Sousa SB, Savarirayan R, Andreucci E, Vikkula M, Garavelli L, Pottinger C, Ogino T, Sakai A, Regazzoni BM, Wuyts W, Sangiorgi L, Pedrini E, Zhu M, Kozakewich HP, Kasser JR, Seidman JG, Kurek KC, Warman ML
  TITLE     Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
  JOURNAL   PLoS Genet 7:e1002050 (2011)
REFERENCE   PMID:6602353 (description)
  AUTHORS   Kennedy LA
  TITLE     Metachondromatosis.
  JOURNAL   Radiology 148:117-8 (1983)
REFERENCE   PMID:20577567 (description)
  AUTHORS   Sobreira NL, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, Ge D, Shianna KV, Smith JP, Maia JM, Gumbs CE, Pevsner J, Thomas G, Valle D, Hoover-Fong JE, Goldstein DB
  TITLE     Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene.
  JOURNAL   PLoS Genet 6:e1000991 (2010)
///
ENTRY       H01019                      Disease
NAME        Catecholaminergic polymorphic ventricular tachycardia
DESCRIPTION Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly lethal form of inherited primary electrical myocardial disease characterized by exercise- and stress-related adrenergic ventricular tachycardia without structural cardiac abnormalities. It manifests as syncope and sudden death and can be caused by mutations in the cardiac ryanodine receptor gene (RYR2) accounting for an autosomal dominant form (CPVT1) or mutations in the cardiac calsequestrin gene CASQ2 accounting for an autosomal recessive form (CPVT2). It was also reported that absence of the inhibitory G-Protein Galphai2 predisposes to ventricular tachycardia.
CATEGORY    Cardiovascular disease
GENE        (CPVT1) RYR2 [HSA:6262] [KO:K04962]
            (CPVT2) CASQ2 [HSA:845]
            GNAI2 [HSA:2771] [KO:K04630]
            (CPVT4) CALM1 [HSA:801] [KO:K02183]
            (CPVT5) TRDN [HSA:10345]
DRUG        Beta-blockers (For primary manifestations)
            Metoprolol (For secondary manifestations) [DG:DG00313]
            Anticoagulant
DBLINKS     ICD-10: I47.2
            OMIM: 604772 611938 192605 614916 615441
REFERENCE   PMID:22119737 (description, gene)
  AUTHORS   Pflaumer A, Davis AM
  TITLE     Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
  JOURNAL   Heart Lung Circ 21:96-100 (2012)
REFERENCE   PMID:20301466 (description, gene, drug)
  AUTHORS   Napolitano C, Priori SG, Bloise R
  TITLE     Catecholaminergic Polymorphic Ventricular Tachycardia
  JOURNAL   (1993)
REFERENCE   PMID:17497254 (description, gene)
  AUTHORS   Liu N, Colombi B, Raytcheva-Buono EV, Bloise R, Priori SG
  TITLE     Catecholaminergic polymorphic ventricular tachycardia.
  JOURNAL   Herz 32:212-7 (2007)
REFERENCE   PMID:19068246 (description, gene)
  AUTHORS   Katz G, Arad M, Eldar M
  TITLE     Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
  JOURNAL   Curr Probl Cardiol 34:9-43 (2009)
REFERENCE   PMID:15176428 (description, gene)
  AUTHORS   Laitinen PJ, Swan H, Piippo K, Viitasalo M, Toivonen L, Kontula K
  TITLE     Genes, exercise and sudden death: molecular basis of familial catecholaminergic polymorphic ventricular tachycardia.
  JOURNAL   Ann Med 36 Suppl 1:81-6 (2004)
REFERENCE   PMID:20495013
  AUTHORS   Zuberi Z, Nobles M, Sebastian S, Dyson A, Lim SY, Breckenridge R, Birnbaumer L, Tinker A
  TITLE     Absence of the inhibitory G-protein Galphai2 predisposes to ventricular cardiac arrhythmia.
  JOURNAL   Circ Arrhythm Electrophysiol 3:391-400 (2010)
REFERENCE   PMID:23040497 (gene)
  AUTHORS   Nyegaard M, Overgaard MT, Sondergaard MT, Vranas M, Behr ER, Hildebrandt LL, Lund J, Hedley PL, Camm AJ, Wettrell G, Fosdal I, Christiansen M, Borglum AD
  TITLE     Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.
  JOURNAL   Am J Hum Genet 91:703-12 (2012)
REFERENCE   PMID:22422768 (gene)
  AUTHORS   Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, Fauconnier J, Brocard J, Denjoy I, Durand P, Guicheney P, Kyndt F, Leenhardt A, Le Marec H, Lucet V, Mabo P, Probst V, Monnier N, Ray PF, Santoni E, Tremeaux P, Lacampagne A, Faure J, Lunardi J, Marty I
  TITLE     Absence of triadin, a protein of the calcium release complex, is responsible for  cardiac arrhythmia with sudden death in human.
  JOURNAL   Hum Mol Genet 21:2759-67 (2012)
///
ENTRY       H01020                      Disease
NAME        Optic atrophy (OPA)
DESCRIPTION Hereditary optic atrophy (OPA) is a group of neurodegenerative disorders characterized by a sudden or gradual loss of retinal ganglion cells function. OPA results from degeneration of the retinal ganglion cells whose axons form the optic nerve. Symptoms include a variable association of decreased visual acuity, visual field defects, and color vision abnormalities. All nonsyndromic OPAs characterized to date result from defects in genes encoding mitochondria-related proteins. The most frequent forms of nonsyndromic OPA are autosomal dominant OPA1-linked OPA (OPA1) and mitochondrial DNA-linked, maternally inherited Leber hereditary optic neuropathy (LHON). By contrast, autosomal recessive forms of optic atrophies (arOAs) are less frequent, and most cases are syndromic (e.g., OPA3 or Type III 3-methylglutaconic aciduria and OPA7). Isolated or nonsyndromic arOAs are believed to be extremely rare.
CATEGORY    Neurodegenerative disease
GENE        (OPA1) OPA1 [HSA:4976] [KO:K17079]
            (OPA3) OPA3 [HSA:80207]
            (OPA7) TMEM126A [HSA:84233] [KO:K18157]
DBLINKS     MeSH: D029241
            OMIM: 165500 125250 165300 612989
REFERENCE   PMID:21112411 (description, gene)
  AUTHORS   Yu-Wai-Man P, Griffiths PG, Chinnery PF
  TITLE     Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.
  JOURNAL   Prog Retin Eye Res 30:81-114 (2011)
REFERENCE   PMID:19268652 (description, gene)
  AUTHORS   Carelli V, La Morgia C, Valentino ML, Barboni P, Ross-Cisneros FN, Sadun AA
  TITLE     Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders.
  JOURNAL   Biochim Biophys Acta 1787:518-28 (2009)
REFERENCE   PMID:21731710 (description)
  AUTHORS   Van Bergen NJ, Crowston JG, Kearns LS, Staffieri SE, Hewitt AW, Cohn AC, Mackey DA, Trounce IA
  TITLE     Mitochondrial oxidative phosphorylation compensation may preserve vision in patients with OPA1-linked autosomal dominant optic atrophy.
  JOURNAL   PLoS One 6:e21347 (2011)
REFERENCE   PMID:22815638 (description, gene)
  AUTHORS   Desir J, Coppieters F, Van Regemorter N, De Baere E, Abramowicz M, Cordonnier M
  TITLE     TMEM126A mutation in a Moroccan family with autosomal recessive optic atrophy.
  JOURNAL   Mol Vis 18:1849-57 (2012)
REFERENCE   PMID:19327736 (description, gene)
  AUTHORS   Hanein S, Perrault I, Roche O, Gerber S, Khadom N, Rio M, Boddaert N, Jean-Pierre M, Brahimi N, Serre V, Chretien D, Delphin N, Fares-Taie L, Lachheb S, Rotig A, Meire F, Munnich A, Dufier JL, Kaplan J, Rozet JM
  TITLE     TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy.
  JOURNAL   Am J Hum Genet 84:493-8 (2009)
REFERENCE   PMID:18222990 (OPA1 plus syndrome)
  AUTHORS   Zeviani M
  TITLE     OPA1 mutations and mitochondrial DNA damage: keeping the magic circle in shape.
  JOURNAL   Brain 131:314-7 (2008)
///
ENTRY       H01021                      Disease
NAME        Rhodococcus equi infection
DESCRIPTION Rhodococcus equi is an aerobic, gram-positive bacillus. Rhodococcus equi infection is rare in humans, but it can cause potentially fatal disease in immunocompromised patients. The clinical spectrum of R. equi infection is broad and pulmonary involvement is a predominant feature in most cases. The characteristic pathological findings, termed malakoplakia that comprises a dense infiltration of foamy histiocytes with intracellular coccobacilli and scattered concentric basophilic inclusions, are observed in biopsy specimens of R. equi infection.
CATEGORY    Infectious disease
PATHOGEN    Rhodococcus equi [GN:req]
DRUG        Penicillin [ATC:J01CE]
            Erythromycin [DG:DG00436]
REFERENCE   PMID:20954468 (description, env_factor)
  AUTHORS   Guyssens V, Vandekerckhove L, Colle I, De Rudder P, Blots S, Vogelaers D
  TITLE     Invasive infection with Rhodococcus equi--two case reports and review of literature.
  JOURNAL   Acta Clin Belg 65:271-5 (2010)
REFERENCE   PMID:20417417 (description, env_factor, drug)
  AUTHORS   Yamshchikov AV, Schuetz A, Lyon GM
  TITLE     Rhodococcus equi infection.
  JOURNAL   Lancet Infect Dis 10:350-9 (2010)
REFERENCE   PMID:1810733 (description, env_factor, drug)
  AUTHORS   Vestbo J, Lundgren JD, Gaub J, Roder B, Gutschik E
  TITLE     Severe Rhodococcus equi pneumonia: case report and literature review.
  JOURNAL   Eur J Clin Microbiol Infect Dis 10:762-8 (1991)
///
ENTRY       H01022                      Disease
NAME        Diseases of the tricarboxylic acid cycle, including:
            Fumarase (FH) deficiency;
            Succinate dehydrogenase (SDH) deficiency;
            Alpha-ketoglutarate dehydrogenase (AKGDH) deficiency
DESCRIPTION Diseases of the tricarboxylic acid cycle (TCA cycle) constitute a group of rare human diseases that affect core mitochondrial metabolism. The Fumarase deficiency is caused by impairment of the fumarate hydratase enzyme. The symptoms of the disorder include developmental delay, severe mental retardation, language impairment, seizures and dysmorphic facial features. The succinate dehydrogenase deficiency affects mitochondrial complex II, which links the TCA cycle with the electron transport chain. The phenotype is highly variable and can include Leigh syndrome, leukodystrophy, cardiomyopathy and mental and motor skill deterioration. The alpha-ketoglutarate dehydrogenase deficiency is extremely rare and characterised by encephalopathy and hyperlactatemia resulting in death in early childhood.
CATEGORY    Metabolic disease
GENE        (FH) FH [HSA:2271] [KO:K01679]
            (SDH) SDHA [HSA:6389] [KO:K00234]
            (AKGDH) OGDH [HSA:4967] [KO:K00164]
MARKER      (FH) Fumarate [CPD:C00122] , 2-Oxoglutarate [CPD:C00026] (urine) Lactate [CPD:C00186] (cerebrospinal fluid)
            (SDH) Lactate (blood plasma) 2-Oxoglutarate and Succinate [CPD:C00042] (urine in some cases) Succinate accumulation (brain)
            (AKGDH) Oxoglutarate [CPD:C00026] Lactate
COMMENT     Succinate dehydrogenase deficiency is also included in mitochondrial respiratory chain deficiencies. [DS:H00473]
DBLINKS     ICD-10: E88.8
            MeSH: C538191 C565375 C536582
            OMIM: 606812 252011 203740
REFERENCE   PMID:21714867
  AUTHORS   Smith AC, Robinson AJ
  TITLE     A metabolic model of the mitochondrion and its use in modelling diseases of the tricarboxylic acid cycle.
  JOURNAL   BMC Syst Biol 5:102 (2011)
REFERENCE   PMID:9300800
  AUTHORS   Rustin P, Bourgeron T, Parfait B, Chretien D, Munnich A, Rotig A
  TITLE     Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human.
  JOURNAL   Biochim Biophys Acta 1361:185-97 (1997)
///
ENTRY       H01023                      Disease
NAME        Juvenile polyposis syndrome
DESCRIPTION Juvenile polyposis syndrome (JPS) is an autosomal dominant condition identified by the presence of multiple benign, non-cancerous polyps called juvenile polyps in the gastrointestinal tract. A germline mutation in the SMAD4 or BMPR1A gene is found in about 50%-60% of patients with JPS. These genes play a role in the BMP/TGF-beta signalling pathway.
CATEGORY    Gastrointestinal disease
GENE        SMAD4 [HSA:4089] [KO:K04501]
            BMPR1A [HSA:657] [KO:K04673]
DBLINKS     ICD-10: D12.6
            MeSH: C537702
            OMIM: 174900
REFERENCE   PMID:22171123 (description, gene)
  AUTHORS   Brosens LA, Langeveld D, van Hattem WA, Giardiello FM, Offerhaus GJ
  TITLE     Juvenile polyposis syndrome.
  JOURNAL   World J Gastroenterol 17:4839-44 (2011)
///
ENTRY       H01024                      Disease
NAME        Hereditary mixed polyposis syndrome
DESCRIPTION Hereditary mixed polyposis syndrome (HMPS) is a rare condition characterized by mixed hyperplastic, adenomatous and juvenile polyps and is associated with an increased risk of colorectal carcinoma. HMPS is linked to mutations in the BMPR1A gene.
CATEGORY    Gastrointestinal disease
GENE        BMPR1A [HSA:657] [KO:K04673]
DBLINKS     MeSH: C563365 C566451
            OMIM: 610069
REFERENCE   PMID:19438883 (description, gene)
  AUTHORS   O'Riordan JM, O'Donoghue D, Green A, Keegan D, Hawkes LA, Payne SJ, Sheahan K, Winter DC
  TITLE     Hereditary mixed polyposis syndrome due to a BMPR1A mutation.
  JOURNAL   Colorectal Dis 12:570-3 (2010)
REFERENCE   PMID:16525031 (description, gene)
  AUTHORS   Cao X, Eu KW, Kumarasinghe MP, Li HH, Loi C, Cheah PY
  TITLE     Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function.
  JOURNAL   J Med Genet 43:e13 (2006)
///
ENTRY       H01025                      Disease
NAME        Familial adenomatous polyposis
DESCRIPTION Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disorder characterized by the early onset of hundreds to thousands of adenomas throughout in the rectum and colon. If left untreated, all patients with FAP develop colon cancer a decade after the appearance of the polyps. The genetic defect in FAP is a germline mutation in the adenomatous polyposis coli (APC) gene. In a subset of individuals, a MUTYH mutation causes a recessively inherited polyposis condition.
CATEGORY    Gastrointestinal disease
GENE        APC [HSA:324] [KO:K02085]
            MUTYH [HSA:4595] [KO:K03575]
DBLINKS     ICD-10: D12.6
            MeSH: D011125
            OMIM: 175100 608456
REFERENCE   PMID:19822006 (description, gene)
  AUTHORS   Half E, Bercovich D, Rozen P
  TITLE     Familial adenomatous polyposis.
  JOURNAL   Orphanet J Rare Dis 4:22 (2009)
REFERENCE   PMID:21884696 (description)
  AUTHORS   Burgess AW, Faux MC, Layton MJ, Ramsay RG
  TITLE     Wnt signaling and colon tumorigenesis--a view from the periphery.
  JOURNAL   Exp Cell Res 317:2748-58 (2011)
///
ENTRY       H01026                      Disease
NAME        Renal coloboma syndrome (RCS);
            Papillorenal syndrome
DESCRIPTION Renal coloboma syndrome (RCS), also called papillorenal syndrome, is an autosomal dominant condition comprising optic nerve dysplasia and oligomeganephronic renal hypodysplasia. Mutations in the paired-box gene, PAX2, have been identified in approximately half of individuals with clinical findings suggestive of RCS.
CATEGORY    Neurodegenerative disease; Eye disease; Urinary system disease
GENE        PAX2 [HSA:5076] [KO:K15608]
DBLINKS     ICD-10: Q14.2 Q60.4
            MeSH: C537168
            OMIM: 120330
REFERENCE   PMID:22213154 (description, gene)
  AUTHORS   Bower M, Salomon R, Allanson J, Antignac C, Benedicenti F, Benetti E, Binenbaum G, Jensen UB, Cochat P, DeCramer S, Dixon J, Drouin R, Falk MJ, Feret H, Gise R, Hunter A, Johnson K, Kumar R, Lavocat MP, Martin L, Moriniere V, Mowat D, Murer L, Nguyen HT, Peretz-Amit G, Pierce E, Place E, Rodig N, Salerno A, Sastry S, Sato T, Sayer JA, Schaafsma GC, Shoemaker L, Stockton DW, Tan WH, Tenconi R, Vanhille P, Vats A, Wang X, Warman B, Weleber RG, White SM, Wilson-Brackett C, Zand DJ, Eccles M, Schimmenti LA, Heidet L
  TITLE     Update of PAX2 mutations in renal coloboma syndrome and establishment of a locus-specific database.
  JOURNAL   Hum Mutat 33:457-66 (2012)
REFERENCE   PMID:21654726 (description, gene)
  AUTHORS   Schimmenti LA
  TITLE     Renal coloboma syndrome.
  JOURNAL   Eur J Hum Genet 19:1207-12 (2011)
///
ENTRY       H01027                      Disease
NAME        Anophthalmia and microphthalmia (A/M)
DESCRIPTION Anophthalmia and/or microphthalmia (A/M) can be defined as an absence or reduced size of the globe in the orbit. Anophthalmia refers to complete absence of the globe in the presence of ocular adnexae. Microphthalmia is defined as a globe with a total axial length that is at least two standard deviations below the mean for age. Coloboma, or a defect in the closure of the choroid fissure, is most common ocular malformation associated with microphthalmia. Coloboma is considered to be part of the A/M spectrum. A/M can be isolated, associated other anomalies or part of a well defined syndrome. A/M have complex aetiology with chromosomal, monogenic and environmental causes identified.
CATEGORY    Eye disease
GENE        (with cataract) SIX6 [HSA:4990] [KO:K19473]
            (with cataract) CRYBA4 [HSA:1413]
            (with coloboma, isolated) VSX2 [HSA:338917] [KO:K09336]
            (with coloboma) SHH [HSA:6469] [KO:K11988]
            (with coloboma, isolated) GDF3 [HSA:9573] [KO:K05495]
            (with coloboma, isolated) GDF6 [HSA:392255] [KO:K20012]
            (isolated) RAX [HSA:30062] [KO:K09332]
            (isolated) MFRP [HSA:83552]
            (isolated) PRSS56 [HSA:646960]
            (isolated) ALDH1A3 [HSA:220] [KO:K00129]
            (syndromic) BCOR [HSA:54880]
            (syndromic) SOX2 [HSA:6657] [KO:K16796]
            (syndromic) OTX2 [HSA:5015] [KO:K18490]
            (syndromic) BMP4 [HSA:652] [KO:K04662]
            (syndromic) HCCS [HSA:3052] [KO:K01764]
            (syndromic) STRA6 [HSA:64220]
ENV_FACTOR  Exposure to drugs [CPD:C00469 C07910 C01541]
            Maternal vitamin A deficiency, fever, hyperthermia, exposure to X-rays, solvent misuse
PATHOGEN    Gestational-acquired infection [RS:NC_001545 NC_006273 NC_000883] [GN:tgo]
DBLINKS     ICD-10: Q11.1 Q11.2
            MeSH: D008850
            OMIM: 206900 212550 300166 309801 601186 607932 610092 610093 610125 610426 611038 611040 611638 613094 613703 613704 613517 615113
REFERENCE   PMID:22005280 (description, gene)
  AUTHORS   Slavotinek AM
  TITLE     Eye development genes and known syndromes.
  JOURNAL   Mol Genet Metab 104:448-56 (2011)
REFERENCE   PMID:21825993 (description, gene)
  AUTHORS   Bardakjian TM, Schneider A
  TITLE     The genetics of anophthalmia and microphthalmia.
  JOURNAL   Curr Opin Ophthalmol 22:309-13 (2011)
REFERENCE   PMID:18039390 (description, gene, environmental factor)
  AUTHORS   Verma AS, Fitzpatrick DR
  TITLE     Anophthalmia and microphthalmia.
  JOURNAL   Orphanet J Rare Dis 2:47 (2007)
REFERENCE   PMID:19864492 (gene)
  AUTHORS   Ye M, Berry-Wynne KM, Asai-Coakwell M, Sundaresan P, Footz T, French CR, Abitbol M, Fleisch VC, Corbett N, Allison WT, Drummond G, Walter MA, Underhill TM, Waskiewicz AJ, Lehmann OJ
  TITLE     Mutation of the bone morphogenetic protein GDF3 causes ocular and skeletal anomalies.
  JOURNAL   Hum Mol Genet 19:287-98 (2010)
REFERENCE   PMID:17167404 (gene)
  AUTHORS   Ayala-Ramirez R, Graue-Wiechers F, Robredo V, Amato-Almanza M, Horta-Diez I, Zenteno JC
  TITLE     A new autosomal recessive syndrome consisting of posterior microphthalmos, retinitis pigmentosa, foveoschisis, and optic disc drusen is caused by a MFRP gene mutation.
  JOURNAL   Mol Vis 12:1483-9 (2006)
REFERENCE   PMID:21397065 (gene)
  AUTHORS   Gal A, Rau I, El Matri L, Kreienkamp HJ, Fehr S, Baklouti K, Chouchane I, Li Y, Rehbein M, Fuchs J, Fledelius HC, Vilhelmsen K, Schorderet DF, Munier FL, Ostergaard E, Thompson DA, Rosenberg T
  TITLE     Autosomal-recessive posterior microphthalmos is caused by mutations in PRSS56, a  gene encoding a trypsin-like serine protease.
  JOURNAL   Am J Hum Genet 88:382-90 (2011)
REFERENCE   PMID:23312594 (gene)
  AUTHORS   Fares-Taie L, Gerber S, Chassaing N, Clayton-Smith J, Hanein S, Silva E, Serey M, Serre V, Gerard X, Baumann C, Plessis G, Demeer B, Bretillon L, Bole C, Nitschke P, Munnich A, Lyonnet S, Calvas P, Kaplan J, Ragge N, Rozet JM
  TITLE     ALDH1A3 mutations cause recessive anophthalmia and microphthalmia.
  JOURNAL   Am J Hum Genet 92:265-70 (2013)
///
ENTRY       H01028                      Disease
NAME        Argininosuccinic aciduria (ARGINSA);
            Argininosuccinate lyase deficiency
DESCRIPTION Arginosuccinicaciduria (ARGINSA) is an autosomal recessive disorder of the urea cycle that is caused by defects in argininosuccinate lyase. ARGINSA is characterized by mental and physical retardation, liver enlargement, skin lesions, dry and brittle hair showing trichorrhexis nodosa microscopically and fluorescing red, convulsions, and episodic unconsciousness.
CATEGORY    Inherited metabolic disease
GENE        ASL [HSA:435] [KO:K01755]
MARKER      Elevated Ammonia [CPD:C00014] (plasma)
            Elevated Citrulline [CPD:C00327] (plasma)
            Elevated Argininosuccinic acid [CPD:C03406] (plasma or urine)
DRUG        Discontinuing oral protein intake
            Supplementing oral intake with intravenous lipids and glucose
            Intravenous arginine and nitrogen scavenging therapy
            NO supplementation
DBLINKS     ICD-10: E72.2
            MeSH: D056807
            OMIM: 207900
REFERENCE   PMID:21290785
  AUTHORS   Nagamani SCS, Erez A, Lee B
  TITLE     Argininosuccinate Lyase Deficiency
  JOURNAL   (1993)
REFERENCE   PMID:20298553
  AUTHORS   Imtiaz F, Al-Sayed M, Trabzuni D, Al-Mubarak BR, Alsmadi O, Rashed MS, Meyer BF
  TITLE     Novel mutations underlying argininosuccinic aciduria in Saudi Arabia.
  JOURNAL   BMC Res Notes 3:79 (2010)
REFERENCE   PMID:11148543 (therapy)
  TITLE     Consensus statement from a conference for the management of patients with urea cycle disorders.
  JOURNAL   J Pediatr 138:S1-5 (2001)
REFERENCE   PMID:22541557 (therapy)
  AUTHORS   Nagamani SC, Campeau PM, Shchelochkov OA, Premkumar MH, Guse K, Brunetti-Pierri N, Chen Y, Sun Q, Tang Y, Palmer D, Reddy AK, Li L, Slesnick TC, Feig DI, Caudle S, Harrison D, Salviati L, Marini JC, Bryan NS, Erez A, Lee B
  TITLE     Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria.
  JOURNAL   Am J Hum Genet 90:836-46 (2012)
///
ENTRY       H01029                      Disease
NAME        Cornea plana congenita
DESCRIPTION Cornea plana congenita is a rare hereditary anomaly in which the normal protrusion of the cornea from the sclera is missing. Clinical features include hyperopia, slight microcornea, an extended limbus zone, and arcus lipoides seen even before the age of 20. Cornea plana congenita occurs in a mild autosomal dominant (CNA1) and a more severe autosomal recessive (CNA2) form. CNA2 has a high prevalence in the Finnish population due to strong founder effect.
CATEGORY    Eye disease
GENE        (CNA2) KERA [HSA:11081] [KO:K08123]
DBLINKS     ICD-10: Q13.4
            OMIM: 217300 121400
REFERENCE   PMID:8929947 (description)
  AUTHORS   Tahvanainen E, Forsius H, Kolehmainen J, Damsten M, Fellman J, de la Chapelle A
  TITLE     The genetics of cornea plana congenita.
  JOURNAL   J Med Genet 33:116-9 (1996)
REFERENCE   PMID:9591953 (description)
  AUTHORS   Forsius H, Damsten M, Eriksson AW, Fellman J, Lindh S, Tahvanainen E
  TITLE     Autosomal recessive cornea plana. A clinical and genetic study of 78 cases in Finland.
  JOURNAL   Acta Ophthalmol Scand 76:196-203 (1998)
REFERENCE   PMID:9228241 (description)
  AUTHORS   Sigler-Villanueva A, Tahvanainen E, Lindh S, Dieguez-Lucena J, Forsius H
  TITLE     Autosomal dominant cornea plana: clinical findings in a Cuban family and a review of the literature.
  JOURNAL   Ophthalmic Genet 18:55-62 (1997)
REFERENCE   PMID:10802664 (gene)
  AUTHORS   Pellegata NS, Dieguez-Lucena JL, Joensuu T, Lau S, Montgomery KT, Krahe R, Kivela T, Kucherlapati R, Forsius H, de la Chapelle A
  TITLE     Mutations in KERA, encoding keratocan, cause cornea plana.
  JOURNAL   Nat Genet 25:91-5 (2000)
///
ENTRY       H01030                      Disease
NAME        Lethal arthrogryposis with anterior horn cell disease
DESCRIPTION Lethal arthrogryposis with anterior horn cell disease (LAAHD) is a condition with fetal akinesia deformation sequence (FADS), multiple contractures and facial anomalies. Motor neuron loss is also present in patients with LAAHD.
CATEGORY    Musculoskeletal disease; Neurodegenerative disease
GENE        GLE1 [HSA:2733] [KO:K18723]
COMMENT     Lethal congenital contracture syndrome 1 (LCCS1, H00865) is an allelic disorder of LAAHD.
DBLINKS     MeSH: C567502
            OMIM: 611890 253310
REFERENCE   PMID:7821908 (description)
  AUTHORS   Vuopala K, Ignatius J, Herva R
  TITLE     Lethal arthrogryposis with anterior horn cell disease.
  JOURNAL   Hum Pathol 26:12-9 (1995)
REFERENCE   PMID:18204449 (gene)
  AUTHORS   Nousiainen HO, Kestila M, Pakkasjarvi N, Honkala H, Kuure S, Tallila J, Vuopala K, Ignatius J, Herva R, Peltonen L
  TITLE     Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease.
  JOURNAL   Nat Genet 40:155-7 (2008)
///
ENTRY       H01031                      Disease
NAME        Orthostatic intolerance (OI);
            Postural tachycardia syndrome (POTS)
DESCRIPTION Orthostatic intolerance (OI) or postural tachycardia syndrome (POTS) is a disorder of the autonomic nervous system primarily affecting young females, and is characterized by lightheadedness, palpitations, fatigue, altered mentation, and syncope primarily occurring with upright posture and being relieved by lying down. Patients often have high plasma norepinephrine (NE) concentrations in relation to sympathetic outflow on standing. Abnormal norepinephrine transporter (NET) function is considered to contribute to the pathophysiology in some patients with OI. The impaired uptake of NE could be caused by a mutation in the SLC6A2 gene that encodes the NET.
CATEGORY    Nervous system disease
GENE        SLC6A2 [HSA:6530] [KO:K05035]
DBLINKS     MeSH: D054971
            OMIM: 604715
REFERENCE   PMID:10684912 (description, gene)
  AUTHORS   Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D
  TITLE     Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.
  JOURNAL   N Engl J Med 342:541-9 (2000)
REFERENCE   PMID:14987367 (description, gene)
  AUTHORS   Tellioglu T, Robertson D
  TITLE     Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications.
  JOURNAL   Expert Rev Mol Med 2001:1-10 (2001)
REFERENCE   PMID:11458707 (description, gene)
  AUTHORS   Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR, Jordan J, Jacob G, Blakely RD, Biaggioni I
  TITLE     Familial orthostatic tachycardia due to norepinephrine transporter deficiency.
  JOURNAL   Ann N Y Acad Sci 940:527-43 (2001)
///
ENTRY       H01032                      Disease
NAME        N-acetylglutamate synthase (NAGS) deficiency
DESCRIPTION N-acetylglutamate synthase (NAGS) deficiency is a rare inborn error of metabolism affecting ammonia detoxification in the urea cycle. The N-acetylglutamate is the absolutely required allosteric activator of the first urea cycle enzyme carbamoylphosphate synthetase 1 (CPS1). In defects of NAGS, the urea cycle function can be severely affected resulting in fatal hyperammonemia in neonatal patients or at any later stage in life. Clinical features of NAGS deficiency include poor feeding, vomiting, altered level of consciousness, seizures, and coma.
CATEGORY    Inherited metabolic disease
GENE        NAGS [HSA:162417] [KO:K11067]
MARKER      Plasma Ammonia [CPD:C00014] and Glutamine [CPD:C00064] are increased.
            Other urea-cycle intermediates are low to normal.
            Urinary Orotic acid [CPD:C00295] is not elevated.
DRUG        Carglumic acid [DR:D07130]
DBLINKS     ICD-10: E72.2
            MeSH: C536109
            OMIM: 237310
REFERENCE   PMID:20303810
  AUTHORS   Caldovic L, Ah Mew N, Shi D, Morizono H, Yudkoff M, Tuchman M
  TITLE     N-acetylglutamate synthase: structure, function and defects.
  JOURNAL   Mol Genet Metab 100 Suppl 1:S13-9 (2010)
REFERENCE   PMID:21941437
  AUTHORS   Haberle J
  TITLE     Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency.
  JOURNAL   Ther Clin Risk Manag 7:327-32 (2011)
///
ENTRY       H01033                      Disease
NAME        Congenital bilateral absence of vas deferens
DESCRIPTION The condition of congenital bilateral absence of the vas deferens (CBAVD) causes obstructive azoospermia frequently seen in cystic fibrosis (CF) that is characterized by progressive lung disease, pancreatic dysfunction, elevated sweat electrolytes, and male infertility. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene are linked to these diseases.
CATEGORY    Reproductive system disease
GENE        CFTR [HSA:1080] [KO:K05031]
COMMENT     Cystic fibrosis is described in H00218.
DBLINKS     ICD-10: Q55.4
            MeSH: C535984
            OMIM: 277180
REFERENCE   PMID:15379964 (description , gene)
  AUTHORS   Cuppens H, Cassiman JJ
  TITLE     CFTR mutations and polymorphisms in male infertility.
  JOURNAL   Int J Androl 27:251-6 (2004)
REFERENCE   PMID:9147111 (description , gene)
  AUTHORS   Lissens W, Mercier B, Tournaye H, Bonduelle M, Ferec C, Seneca S, Devroey P, Silber S, Van Steirteghem A, Liebaers I
  TITLE     Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities.
  JOURNAL   Hum Reprod 11 Suppl 4:55-78; discussion 79-80 (1996)
REFERENCE   PMID:2103471 (description , gene)
  AUTHORS   Linthorst HJ, van Loon LC, Memelink J, Bol JF
  TITLE     Characterization of cDNA clones for a virus-inducible, glycine-rich protein from  petunia.
  JOURNAL   Plant Mol Biol 15:521-3 (1990)
///
ENTRY       H01034                      Disease
NAME        L1 syndrome, including: ;
            X-linked hydrocephalus;
            MASA syndrome;
            X-linked complicated spastic paraplegia type I ;
            X-linked partial agenesis of corpus callosum
DESCRIPTION L1 syndrome comprises a wide variety of X-linked inherited neurodevelopmental disorders caused by mutations in the L1CAM gene, including X-linked hydrocephalus, MASA syndrome (mental retardation, aphasia, spastic paraplegia, adducted thumbs), X-linked complicated hereditary spastic paraplegia type 1, and X-linked partial agenesis of corpus callosum. L1CAM encodes for the L1 cell adhesion molecule (L1-CAM), a member of the immunoglobulin (Ig) superfamily of neural cell adhesion molecules that is expressed in the developing nervous system.
CATEGORY    Nervous system disease
GENE        L1CAM [HSA:3897] [KO:K06550]
DBLINKS     ICD-10: Q03.0 G11.4
            MeSH: C536029
            OMIM: 307000 303350 304100
REFERENCE   PMID:20447653 (description, gene)
  AUTHORS   Bertolin C, Boaretto F, Barbon G, Salviati L, Lapi E, Divizia MT, Garavelli L, Occhi G, Vazza G, Mostacciuolo ML
  TITLE     Novel mutations in the L1CAM gene support the complexity of L1 syndrome.
  JOURNAL   J Neurol Sci 294:124-6 (2010)
REFERENCE   PMID:20301657 (description, gene)
  AUTHORS   Schrander-Stumpel C, Vos YJ
  TITLE     L1 Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:11438988 (description)
  AUTHORS   Weller S, Gartner J
  TITLE     Genetic and clinical aspects of X-linked hydrocephalus (L1 disease): Mutations in the L1CAM gene.
  JOURNAL   Hum Mutat 18:1-12 (2001)
///
ENTRY       H01035                      Disease
NAME        Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia
DESCRIPTION This syndrome is a condition with a unique pattern of malformations that includes coloboma (iris, optic nerve), high forehead, severe retrognathia, mental retardation, and agenesis of the corpus callosum. This syndrome is caused by mutations in 5-prime region of IGBP1 gene, a regulatory subunit of the major cellular phosphatase PP2A.
CATEGORY    Developmental disorder
GENE        IGBP1 (5-prime region) [HSA:3476] [KO:K17606]
DBLINKS     ICD-10: Q87.8
            MeSH: C564509
            OMIM: 300472
REFERENCE   PMID:14556245 (description)
  AUTHORS   Graham JM Jr, Wheeler P, Tackels-Horne D, Lin AE, Hall BD, May M, Short KM, Schwartz CE, Cox TC
  TITLE     A new X-linked syndrome with agenesis of the corpus callosum, mental retardation, coloboma, micrognathia, and a mutation in the Alpha 4 gene at Xq13.
  JOURNAL   Am J Med Genet A 123A:37-44 (2003)
///
ENTRY       H01036                      Disease
NAME        Posterior column ataxia with retinitis pigmentosa (PCARP)
DESCRIPTION Posterior column ataxia with retinitis pigmentosa (PCARP) is an autosomal recessive, childhood onset neurodegenerative disorder characterized by sensory ataxia and retinitis pigmentosa. It has been reported that PCARP is caused by mutations in FLVCR1, a gene encoding a heme-transporter protein.
CATEGORY    Nervous system disease; Eye disease
GENE        FLVCR1 [HSA:28982] [KO:K08220]
DBLINKS     ICD-10: G11.1 H35.5
            MeSH: C536343
            OMIM: 609033
REFERENCE   PMID:21267618
  AUTHORS   Ishiura H, Fukuda Y, Mitsui J, Nakahara Y, Ahsan B, Takahashi Y, Ichikawa Y, Goto J, Sakai T, Tsuji S
  TITLE     Posterior column ataxia with retinitis pigmentosa in a Japanese family with a novel mutation in FLVCR1.
  JOURNAL   Neurogenetics 12:117-21 (2011)
///
ENTRY       H01037                      Disease
NAME        Vesicoureteral reflux
DESCRIPTION Vesicoureteral reflux is the abnormal retrograde urinary flow from the bladder to the kidney that affects approximately 1% of the general population. It is associated with an increased risk of recurrent urinary tract infection, pyelonephritis, and renal scarring.
CATEGORY    Kidney disease
GENE        ROBO2 [HSA:6092] [KO:K06754]
            SOX17 [HSA:64321] [KO:K04495]
DRUG        Continuous antibiotic prophylaxis
DBLINKS     MeSH: D014718
            OMIM: 610878 613674
REFERENCE   PMID:22264440 (description, drug)
  AUTHORS   Routh JC, Bogaert GA, Kaefer M, Manzoni G, Park JM, Retik AB, Rushton HG, Snodgrass WT, Wilcox DT
  TITLE     Vesicoureteral reflux: current trends in diagnosis, screening, and treatment.
  JOURNAL   Eur Urol 61:773-82 (2012)
REFERENCE   PMID:21862976 (description, drug)
  AUTHORS   Puri P, Gosemann JH, Darlow J, Barton DE
  TITLE     Genetics of vesicoureteral reflux.
  JOURNAL   Nat Rev Urol 8:539-52 (2011)
REFERENCE   PMID:21475075 (description, drug)
  AUTHORS   Carvas F, Silva A, Nguyen HT
  TITLE     The genetics of primary, nonsyndromic vesicoureteral reflux.
  JOURNAL   Curr Opin Urol 20:336-42 (2010)
REFERENCE   PMID:20960469 (description, drug)
  AUTHORS   Gimelli S, Caridi G, Beri S, McCracken K, Bocciardi R, Zordan P, Dagnino M, Fiorio P, Murer L, Benetti E, Zuffardi O, Giorda R, Wells JM, Gimelli G, Ghiggeri GM
  TITLE     Mutations in SOX17 are associated with congenital anomalies of the kidney and the urinary tract.
  JOURNAL   Hum Mutat 31:1352-9 (2010)
///
ENTRY       H01038                      Disease
NAME        Cerebellar ataxia cayman type (ATCAY);
            Cayman ataxia
DESCRIPTION Cerebellar ataxia cayman type (ATCAY) is an autosomal recessive disorder characterized by hypotonia, mental retardation, and cerebellar dysfunction with marked cerebellar hypoplasia. It has been reported that mutation of the ATCAY gene encoding Caytaxin causes ATCAY by interfering with normal splicing.
CATEGORY    Nervous system disease
GENE        ATCAY [HSA:85300] [KO:K18450]
DBLINKS     ICD-10: G11.0
            MeSH: C563363
            OMIM: 601238
REFERENCE   PMID:17157273
  AUTHORS   Hayakawa Y, Itoh M, Yamada A, Mitsuda T, Nakagawa T
  TITLE     Expression and localization of Cayman ataxia-related protein, Caytaxin, is regulated in a developmental- and spatial-dependent manner.
  JOURNAL   Brain Res 1129:100-9 (2007)
///
ENTRY       H01039                      Disease
NAME        Ovarian hyperstimulation syndrome (OHSS)
DESCRIPTION Ovarian hyperstimulation syndrome (OHSS) is typically an iatrogenic complication of ovulation induction (OI) occurring during the luteal phase or early pregnancy. OHSS is characterised by a cystic enlargement of the ovaries and an acute fluid shift from the intravascular to the third space, which may result in ascites, pleural infusions, pericardial infusion, and even generalized edema. Majority of OHSS cases have been associated with the use of gonadotrophins for OI in anovulatory women or for ovarian stimulation (OS) in the context of assisted reproductive technology (ART). Recurrent cases and familial occurrence of OHSS have been described, and different mutations in the follicle-stimulating hormone receptor (FSHr) have been reported in these cases. Polycystic ovarian syndrome (PCOS) appears to be the major predisposing factor for OHSS in a large number of studies.
CATEGORY    Endocrine disease; Reproductive system disease
GENE        FSHR [HSA:2492] [KO:K04247]
ENV_FACTOR  Medication for ovulation induction or ovarian stimulation [DG:DG00474 DG00471]
DBLINKS     ICD-10: N98.1
            MeSH: D016471
            OMIM: 608115
REFERENCE   PMID:20977119 (description, gene)
  AUTHORS   Kasum M
  TITLE     New insights in mechanisms for development of ovarian hyperstimulation syndrome.
  JOURNAL   Coll Antropol 34:1139-43 (2010)
REFERENCE   PMID:19632900 (description, gene, environmental factor)
  AUTHORS   Vloeberghs V, Peeraer K, Pexsters A, D'Hooghe T
  TITLE     Ovarian hyperstimulation syndrome and complications of ART.
  JOURNAL   Best Pract Res Clin Obstet Gynaecol 23:691-709 (2009)
REFERENCE   PMID:20416867 (description)
  AUTHORS   Humaidan P, Quartarolo J, Papanikolaou EG
  TITLE     Preventing ovarian hyperstimulation syndrome: guidance for the clinician.
  JOURNAL   Fertil Steril 94:389-400 (2010)
REFERENCE   PMID:17055817 (description)
  TITLE     Ovarian hyperstimulation syndrome.
  JOURNAL   Fertil Steril 86:S178-83 (2006)
///
ENTRY       H01040                      Disease
NAME        Bamforth-Lazarus syndrome
DESCRIPTION Bamforth-Lazarus syndrome is congenital hypothyroidism associated with choanal atresia, bifid epiglottis, and abnormal hair. It has been suggested that mutations in FOXE1 are associated with Bamforth-Lazarus syndrome. FOXE1 is a member of the forkhead/winged-helix family and functions as a thyroid transcription factor which likely plays a crucial role in thyroid morphogenesis.
CATEGORY    Endocrine disease
GENE        FOXE1 [HSA:2304] [KO:K09398]
DBLINKS     ICD-10: E03.1
            MeSH: C537901
            OMIM: 241850
REFERENCE   PMID:20453517
  AUTHORS   Castanet M, Polak M
  TITLE     Spectrum of Human Foxe1/TTF2 Mutations.
  JOURNAL   Horm Res Paediatr 73:423-9 (2010)
REFERENCE   PMID:2918525
  AUTHORS   Bamforth JS, Hughes IA, Lazarus JH, Weaver CM, Harper PS
  TITLE     Congenital hypothyroidism, spiky hair, and cleft palate.
  JOURNAL   J Med Genet 26:49-51 (1989)
///
ENTRY       H01041                      Disease
NAME        Aerococcus urinae infection
DESCRIPTION Aerococcus urinae is a rare pathogen that belongs to gram-positive coccus. Most infections are mild, but fatal infections such as endocarditis with high rates of embolic events and valvular damage and septicemia/urosepsis have also been described.
CATEGORY    Infectious disease
PATHOGEN    Aerococcus urinae [GN:aur]
DRUG        Penicillin [DG:DG00534 DG00535]
            Ampicillin [DG:DG00517]
REFERENCE   PMID:10747177
  AUTHORS   Zhang Q, Kwoh C, Attorri S, Clarridge JE 3rd
  TITLE     Aerococcus urinae in urinary tract infections.
  JOURNAL   J Clin Microbiol 38:1703-5 (2000)
REFERENCE   PMID:20660216
  AUTHORS   de Jong MF, Soetekouw R, ten Kate RW, Veenendaal D
  TITLE     Aerococcus urinae: severe and fatal bloodstream infections and endocarditis.
  JOURNAL   J Clin Microbiol 48:3445-7 (2010)
REFERENCE   PMID:10421047 (description, env_factor, drug)
  AUTHORS   Schuur PM, Sabbe L, van der Wouw AJ, Montagne GJ, Buiting AG
  TITLE     Three cases of serious infection caused by Aerococcus urinae.
  JOURNAL   Eur J Clin Microbiol Infect Dis 18:368-71 (1999)
///
ENTRY       H01042                      Disease
NAME        Buruli ulcer
DESCRIPTION Buruli ulcer (BU) is a neglected emerging disease that has recently been reported in some countries especially in central and western Africa. BU is a serious necrotizing cutaneous infection caused by Mycobacterium ulcerans that is related to the aquatic environment. Lesions heal with scarring, which can result in contractual deformities, amputations, and disabilities.
CATEGORY    Infectious disease
PATHOGEN    Mycobacterium ulcerans [GN:mul]
DBLINKS     ICD-10: A31.1
            MeSH: D054312
REFERENCE   PMID:21179505 (description, env_factor)
  AUTHORS   Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, Benbow ME, Boakye DA
  TITLE     Ecology and transmission of Buruli ulcer disease: a systematic review.
  JOURNAL   PLoS Negl Trop Dis 4:e911 (2010)
REFERENCE   PMID:21095521 (description, env_factor)
  AUTHORS   Walsh DS, Portaels F, Meyers WM
  TITLE     Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.
  JOURNAL   Dermatol Clin 29:1-8 (2011)
REFERENCE   PMID:22004037 (description, env_factor)
  AUTHORS   Converse PJ, Nuermberger EL, Almeida DV, Grosset JH
  TITLE     Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
  JOURNAL   Future Microbiol 6:1185-98 (2011)
///
ENTRY       H01043                      Disease
NAME        Onchocerciasis;
            River blindness;
            Robles' Disease
DESCRIPTION Human onchocerciasis is an infection caused by the filarial nematode Onchocerca volvulus transmitted by Simulium blackflies. Persons with onchocerciasis may have skin disease such as pruritus, lichenification, and depigmentation and blindness due to sclerosing keratitis or iridocyclitis. Onchocerca volvulus have Wolbachia bacteria as mutualistic symbionts and these Wolbachia affects the nematode survival.
CATEGORY    Infectious disease
PATHOGEN    Onchocerca volvulus
DRUG        Ivermectin [DR:D00804]
COMMENT     Vector: Simulium blackflies
DBLINKS     ICD-10: B73
            MeSH: D009855
REFERENCE   PMID:20739055 (description, env_factor)
  AUTHORS   Taylor MJ, Hoerauf A, Bockarie M
  TITLE     Lymphatic filariasis and onchocerciasis.
  JOURNAL   Lancet 376:1175-85 (2010)
REFERENCE   PMID:20801094 (drug)
  AUTHORS   Cupp EW, Sauerbrey M, Richards F
  TITLE     Elimination of human onchocerciasis: history of progress and current feasibility  using ivermectin (Mectizan((R))) monotherapy.
  JOURNAL   Acta Trop 120 Suppl 1:S100-8 (2011)
REFERENCE   PMID:21734243 (env_factor)
  AUTHORS   Tamarozzi F, Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor MJ
  TITLE     Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment.
  JOURNAL   Clin Microbiol Rev 24:459-68 (2011)
REFERENCE   PMID:17264501 (env_factor)
  AUTHORS   Pearlman E, Gillette-Ferguson I
  TITLE     Onchocerca volvulus, Wolbachia and river blindness.
  JOURNAL   Chem Immunol Allergy 92:254-65 (2007)
///
ENTRY       H01044                      Disease
NAME        Dracunculiasis;
            Guinea worm disease
DESCRIPTION Dracunculiasis, or guinea worm disease, is a parasitic disease caused by the nematode Dracunculiasis medinensis. It affects mostly remote rural communities that do not have access to safe drinking water. It is transmitted by contaminated drinking water containing water fleas that are infected with D. medinensis larvae. In infected individuals, the worm emerges as a whitish filament in the center of a painful ulcer of lower extremity, impairing mobility for up to 8 weeks.
CATEGORY    Infectious disease
PATHOGEN    Dracunculus medinensis
DRUG        Prevention is the only effective intervention to reduce the incidence of guinea worm disease.
COMMENT     Intermediate host:Arthropods (Water flea)
DBLINKS     ICD-10: B72
            MeSH: D004320
REFERENCE   PMID:14970098 (description, env_factor)
  AUTHORS   Greenaway C
  TITLE     Dracunculiasis (guinea worm disease).
  JOURNAL   CMAJ 170:495-500 (2004)
REFERENCE   PMID:18074151 (description, env_factor)
  AUTHORS   Iriemenam NC, Oyibo WA, Fagbenro-Beyioku AF
  TITLE     Dracunculiasis--the saddle is virtually ended.
  JOURNAL   Parasitol Res 102:343-7 (2008)
REFERENCE   PMID:10813467 (description)
  AUTHORS   Hopkins DR, Ruiz-Tiben E, Ruebush TK, Diallo N, Agle A, Withers PC Jr
  TITLE     Dracunculiasis eradication: delayed, not denied.
  JOURNAL   Am J Trop Med Hyg 62:163-8 (2000)
REFERENCE   PMID:16735167 (description, env_factor)
  AUTHORS   Ruiz-Tiben E, Hopkins DR
  TITLE     Dracunculiasis (Guinea worm disease) eradication.
  JOURNAL   Adv Parasitol 61:275-309 (2006)
///
ENTRY       H01045                      Disease
NAME        Schistosomiasis
DESCRIPTION Schistosomiasis is a parasitic disease caused by the genus Schistosoma parasites. Schistosomiasis is the third most devastating tropical disease in the world and WHO estimates 600 million people at risk of infection with 200 million infected. Among nonimmune patients, host's immune response to schistosome eggs leads to acute schistosomiasis that is characterized by cercarial dermatitis and 'Katayama fever'. Life-threatening cardiac and neurological complications may occur. Schistosome eggs can also leads to chronic fibrotic response in host tissues, causing gastrointestinal and liver diseases.
CATEGORY    Infectious disease
PATHOGEN    Schistosoma mansoni [GN:smm]
            Schistosoma haematobium
            Schistosoma japonicum
DRUG        Praziquantel [DR:D00471]
            Artemether [DR:D02483]
DBLINKS     ICD-10: B65
            MeSH: D012552
REFERENCE   PMID:19292768 (description, env_factor, drug)
  AUTHORS   Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP
  TITLE     Immunopathogenesis of human schistosomiasis.
  JOURNAL   Parasite Immunol 31:163-76 (2009)
REFERENCE   PMID:17160074 (description, env_factor)
  AUTHORS   Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA
  TITLE     Immunopathology of schistosomiasis.
  JOURNAL   Immunol Cell Biol 85:148-54 (2007)
REFERENCE   PMID:20222897 (description, env_factor, drug)
  AUTHORS   Jaureguiberry S, Paris L, Caumes E
  TITLE     Acute schistosomiasis, a diagnostic and therapeutic challenge.
  JOURNAL   Clin Microbiol Infect 16:225-31 (2010)
///
ENTRY       H01046                      Disease
NAME        Trichuriasis
DESCRIPTION Trichuriasis is a parasitic disease caused by the whipworm Trichuris trichiura. It infects 600-800 million people globally especially in tropical areas, with the highest intensity of infection being in children aged 5-15 years. Adult trichuris whipworms live in the large intestine (caecum and colon) and cause chronic dysentery and/or rectal prolapse.
CATEGORY    Infectious disease
PATHOGEN    Trichuris trichiura
DRUG        Mebendazole [DR:D00368]
            Albendazole [DG:DG01022]
DBLINKS     ICD-10: B79
            MeSH: D014257
REFERENCE   PMID:9754779 (description, env_factor, drug)
  AUTHORS   Chandra B, Long JD
  TITLE     Diagnosis of Trichuris trichiura (whipworm) by colonoscopic extraction.
  JOURNAL   J Clin Gastroenterol 27:152-3 (1998)
REFERENCE   PMID:21295679 (description, env_factor)
  AUTHORS   Jex AR, Lim YA, Bethony JM, Hotez PJ, Young ND, Gasser RB
  TITLE     Soil-transmitted helminths of humans in Southeast Asia--towards integrated control.
  JOURNAL   Adv Parasitol 74:231-65 (2011)
REFERENCE   PMID:16679166 (description, env_factor)
  AUTHORS   Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, Hotez PJ
  TITLE     Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm.
  JOURNAL   Lancet 367:1521-32 (2006)
REFERENCE   PMID:20627144 (drug)
  AUTHORS   Keiser J, Utzinger J
  TITLE     The drugs we have and the drugs we need against major helminth infections.
  JOURNAL   Adv Parasitol 73:197-230 (2010)
REFERENCE   PMID:15662995 (drug)
  AUTHORS   Adams VJ, Lombard CJ, Dhansay MA, Markus MB, Fincham JE
  TITLE     Efficacy of albendazole against the whipworm trichuris trichiura--a randomised, controlled trial.
  JOURNAL   S Afr Med J 94:972-6 (2004)
///
ENTRY       H01047                      Disease
NAME        Cysticercosis
DESCRIPTION Taenia solium, the pork tapeworm, is endemic in many poorer countries of Latin America, Africa, and Asia where pigs are raised. Human infection with T. solium occurs after ingestion of undercooked pork infected with cysticerci. Infection of the human nervous system by T. solium (neurocysticercosis) causes acquired epilepsy and death. Ophthalmic cysticercosis is much less common than neurocysticercosis (occurring in 1-3% of all infections).
CATEGORY    Infectious disease
PATHOGEN    Taenia solium
DRUG        Albendazole [DG:DG01022]
            Praziquantel [DR:D00471]
            Niclosamide [DR:D00436]
COMMENT     Intermediate host: Pig
DBLINKS     ICD-10: B69 B68.0
            MeSH: D003551
REFERENCE   PMID:21788891 (description, env_factor, drug)
  AUTHORS   Garcia HH, Gonzalez AE, Gilman RH
  TITLE     Cysticercosis of the central nervous system: how should it be managed?
  JOURNAL   Curr Opin Infect Dis 24:423-7 (2011)
REFERENCE   PMID:12932389 (description, env_factor, drug)
  AUTHORS   Garcia HH, Gonzalez AE, Evans CA, Gilman RH
  TITLE     Taenia solium cysticercosis.
  JOURNAL   Lancet 362:547-56 (2003)
REFERENCE   PMID:10738675 (description)
  AUTHORS   Garcia HH, Del Brutto OH
  TITLE     Taenia solium cysticercosis.
  JOURNAL   Infect Dis Clin North Am 14:97-119, ix (2000)
REFERENCE   PMID:16735172 (description)
  AUTHORS   Willingham AL 3rd, Engels D
  TITLE     Control of Taenia solium cysticercosis/taeniosis.
  JOURNAL   Adv Parasitol 61:509-66 (2006)
REFERENCE   PMID:16337431 (description)
  AUTHORS   Montresor A, Palmer K
  TITLE     Taeniasis/cysticercosis trend worldwide and rationale for control.
  JOURNAL   Parasitol Int 55 Suppl:S301-3 (2006)
REFERENCE   PMID:22312322 (description)
  AUTHORS   Del Brutto OH
  TITLE     Neurocysticercosis: a review.
  JOURNAL   ScientificWorldJournal 2012:159821 (2012)
REFERENCE   PMID:10774460 (description)
  AUTHORS   White AC Jr
  TITLE     Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management.
  JOURNAL   Annu Rev Med 51:187-206 (2000)
///
ENTRY       H01048                      Disease
NAME        Liver fluke disease;
            Fascioliasis
DESCRIPTION Fascioliasis is a foodborne zoonotic disease caused by the liver flukes Fasciola hepatica and Fasciola gigantica. Whereas in Europe, the Americas and Oceania only F. hepatica is concerned, the distributions of both species overlap in many areas of Africa and Asia. Two hosts are needed for these species to complete their life cycle. The definitive host range is very broad and includes many herbivorous mammals, including humans. Intermediate hosts are freshwater snail species of the family Lymnaeidae. For many years, and still commonly used, bithionol was the first-line agent for the treatment of fascioliasis.
CATEGORY    Infectious disease
PATHOGEN    Fasciola hepatica 
            Fasciola gigantica
DRUG        Bithionol [DR:D00802]
COMMENT     See also H01617 Foodborne trematodiasis.
DBLINKS     ICD-10: B66.3
            MeSH: D005211
REFERENCE   PMID:18725803 (description)
  AUTHORS   Marcos LA, Terashima A, Gotuzzo E
  TITLE     Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis.
  JOURNAL   Curr Opin Infect Dis 21:523-30 (2008)
REFERENCE   PMID:16307491 (drug)
  AUTHORS   Keiser J, Engels D, Buscher G, Utzinger J
  TITLE     Triclabendazole for the treatment of fascioliasis and paragonimiasis.
  JOURNAL   Expert Opin Investig Drugs 14:1513-26 (2005)
REFERENCE   PMID:16150452 (description)
  AUTHORS   Mas-Coma S, Bargues MD, Valero MA
  TITLE     Fascioliasis and other plant-borne trematode zoonoses.
  JOURNAL   Int J Parasitol 35:1255-78 (2005)
///
ENTRY       H01049                      Disease
NAME        Gordonia bronchialis infection
DESCRIPTION Gordonia species are aerobic actinomycetes recently recognized as causing human disease in immunocompromised and immunocompetent patients. Gordonia bronchialis has been isolated from cases of bacteremia, pleural infection, intraventricular shunt, sternal wound, and breast abscess.
CATEGORY    Infectious disease
PATHOGEN    Gordonia bronchialis [GN:gbr]
REFERENCE   PMID:15956447
  AUTHORS   Werno AM, Anderson TP, Chambers ST, Laird HM, Murdoch DR
  TITLE     Recurrent breast abscess caused by Gordonia bronchialis in an immunocompetent patient.
  JOURNAL   J Clin Microbiol 43:3009-10 (2005)
REFERENCE   PMID:15184495
  AUTHORS   Sng LH, Koh TH, Toney SR, Floyd M, Butler WR, Tan BH
  TITLE     Bacteremia caused by Gordonia bronchialis in a patient with sequestrated lung.
  JOURNAL   J Clin Microbiol 42:2870-1 (2004)
REFERENCE   PMID:21270217
  AUTHORS   Johnson JA, Onderdonk AB, Cosimi LA, Yawetz S, Lasker BA, Bolcen SJ, Brown JM, Marty FM
  TITLE     Gordonia bronchialis bacteremia and pleural infection: case report and review of  the literature.
  JOURNAL   J Clin Microbiol 49:1662-6 (2011)
///
ENTRY       H01050                      Disease
NAME        Tsukamurella infections
DESCRIPTION Tsukamurellae species are aerobic gram-positive rods from the order Actinomycetales. They have been uncommonly reported as a cause of different human infections including peritonitis, conjunctivitis, meningitis, tenosynovitis, prosthetic joint infections, cutaneous infections, tuberculosis-like respiratory infection, and catheter-related bloodstream infections.
CATEGORY    Infectious disease
PATHOGEN    Tsukamurella paurometabola [GN:tpr]
            Tsukamurella tyrosinosolvens
            Tsukamurella pulmonis
            Tsukamurella inchonensis
            Tsukamurella strandjordae
DRUG        Amikacin [DG:DG00403]
            Minocycline [DG:DG00009]
            Imipenem [DG:DG01212]
            Ciprofloxacin [DG:DG00617]
            Cefotaxime [DG:DG00570]
COMMENT     Tsukamurella spp. are resistant to cefoxitin, ampicillin, and amoxicillin/clavulanic acid.
REFERENCE   PMID:18810513 (description, env_factor)
  AUTHORS   Bouza E, Perez-Parra A, Rosal M, Martin-Rabadan P, Rodriguez-Creixems M, Marin M
  TITLE     Tsukamurella: a cause of catheter-related bloodstream infections.
  JOURNAL   Eur J Clin Microbiol Infect Dis 28:203-10 (2009)
REFERENCE   PMID:12228839 (description, env_factor, drug)
  AUTHORS   Schwartz MA, Tabet SR, Collier AC, Wallis CK, Carlson LC, Nguyen TT, Kattar MM, Coyle MB
  TITLE     Central venous catheter-related bacteremia due to Tsukamurella species in the immunocompromised host: a case series and review of the literature.
  JOURNAL   Clin Infect Dis 35:e72-7 (2002)
///
ENTRY       H01051                      Disease
NAME        Corynebacterium ulcerans infection
DESCRIPTION Human infections with toxigenic Corynebacterium ulcerans cause respiratory diphtheria-like illness of zoonotic nature that usually occurs in adults. These C. ulcerans strains produce a diphtheria toxin, which is similar to that of Corynebacterium diphtheriae, the causative agent of classical diphtheria.
CATEGORY    Infectious disease
PATHOGEN    Corynebacterium ulcerans [GN:cul cun]
            Diphtheria toxin [KO:K00776]
DBLINKS     MeSH: D003354
REFERENCE   PMID:22124745 (description, env_factor)
  AUTHORS   Dias AA, Santos LS, Sabbadini PS, Santos CS, Silva Junior FC, Napoleao F, Nagao PE, Villas-Boas MH, Hirata Junior R, Guaraldi AL
  TITLE     Corynebacterium ulcerans diphtheria: an emerging zoonosis in Brazil and worldwide.
  JOURNAL   Rev Saude Publica 45:1176-91 (2011)
REFERENCE   PMID:22028605 (description, env_factor)
  AUTHORS   Putong N, Agustin G, Pasubillo M, Miyagi K, Dimaano EM
  TITLE     Diphtheria-like Illness due to Corynebacterium Ulcerans infection.
  JOURNAL   Trop Med Health 39:1-2 (2011)
REFERENCE   PMID:21801446 (description, env_factor)
  AUTHORS   Trost E, Al-Dilaimi A, Papavasiliou P, Schneider J, Viehoever P, Burkovski A, Soares SC, Almeida SS, Dorella FA, Miyoshi A, Azevedo V, Schneider MP, Silva A, Santos CS, Santos LS, Sabbadini P, Dias AA, Hirata R Jr, Mattos-Guaraldi AL, Tauch A
  TITLE     Comparative analysis of two complete Corynebacterium ulcerans genomes and detection of candidate virulence factors.
  JOURNAL   BMC Genomics 12:383 (2011)
///
ENTRY       H01052                      Disease
NAME        Molluscum contagiosum
DESCRIPTION Molluscum contagiosum is a highly contagious poxvirus infection of the mucous membranes and skin that usually affects school-aged children. The infection is transmitted by close physical contact, fomites, and autoinoculation. It is a benign and self-limiting disease, with the majority of lesions spontaneously resolve within 2-4 years without active treatment.
CATEGORY    Infectious disease
PATHOGEN    Molluscum contagiosum virus [GN:T40124]
DBLINKS     ICD-10: B08.1
            MeSH: D008976
REFERENCE   PMID:21214122 (description, env_factor)
  AUTHORS   Lee R, Schwartz RA
  TITLE     Pediatric molluscum contagiosum: reflections on the last challenging poxvirus infection, Part 1.
  JOURNAL   Cutis 86:230-6 (2010)
REFERENCE   PMID:16445494 (description, env_factor)
  AUTHORS   Brown J, Janniger CK, Schwartz RA, Silverberg NB
  TITLE     Childhood molluscum contagiosum.
  JOURNAL   Int J Dermatol 45:93-9 (2006)
REFERENCE   PMID:15792113 (description, env_factor)
  AUTHORS   Smolinski KN, Yan AC
  TITLE     How and when to treat molluscum contagiosum and warts in children.
  JOURNAL   Pediatr Ann 34:211-21 (2005)
///
ENTRY       H01053                      Disease
NAME        Paroxysmal nocturnal hemoglobinuria (PNH)
DESCRIPTION Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon intravascular hemolytic anemia that results from the clonal expansion of hematopoietic stem cells harboring somatic mutations in an X-linked gene, termed PIG-A. PIG-A is required for the biosynthesis of a lipid moiety, glycosylphosphatidylinositol (GPI), that attaches dozens of different proteins to the cell surface. PIG-A mutations block GPI anchor biosynthesis, resulting in a deficiency or absence of all GPI-anchored proteins on the cell surface. This deficiency on erythrocytes leads to intravascular hemolysis since certain GPI anchored proteins normally function as complement regulators.
CATEGORY    Hematologic disease
GENE        PIGA [HSA:5277] [KO:K03857]
DRUG        Eculizumab [DR:D03940]
DBLINKS     ICD-10: D59.5
            OMIM: 300818
REFERENCE   PMID:17852463 (description, gene, drug)
  AUTHORS   Savage WJ, Brodsky RA
  TITLE     New insights into paroxysmal nocturnal hemoglobinuria.
  JOURNAL   Hematology 12:371-6 (2007)
REFERENCE   PMID:18063459 (description, gene, drug)
  AUTHORS   Brodsky RA
  TITLE     Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria.
  JOURNAL   Blood Rev 22:65-74 (2008)
///
ENTRY       H01054                      Disease
NAME        Pediculosis, including:
            Head lice infestation;
            Body lice infestation
DESCRIPTION Pediculosis is the result of infestation by one of two distinctly different families of sucking lice, the Pediculidae and the Pthiridae. Both of them produce equivalent disorders, with itching, bites, and nits on the hairs. Head louse infestation is one of the most frequently occurring parasitic diseases in children, crossing all social and geographic boundaries. Body lice preferentially affect the displaced. They are major vectors of diseases such as typhus, trench fever, and relapsing fever.
CATEGORY    Infectious disease
PATHOGEN    Pediculus humanus capitis (head louse)
            Pthirus pubis (crab louse)
            Pediculus humanus corporis (body louse) [GN:phu]
DRUG        Permethrin [DR:D05443]
            Lindane [DR:D00360]
            Pyrethrins [DR:D08452]
            Malathion [DR:D00534]
COMMENT     Dichlorodiphenyltrichloroethane (DDT) [CPD:C04623] powder was the treatment of choice during World War II, but the lice began to show resistance to this pesticide during the 1950s.
DBLINKS     ICD-10: B85
            MeSH: D010373
REFERENCE   PMID:14699358 (description, env_factor, drug)
  AUTHORS   Ko CJ, Elston DM
  TITLE     Pediculosis.
  JOURNAL   J Am Acad Dermatol 50:1-12; quiz 13-4 (2004)
REFERENCE   PMID:1693887 (description, env_factor, drug)
  AUTHORS   Elgart ML
  TITLE     Pediculosis.
  JOURNAL   Dermatol Clin 8:219-28 (1990)
REFERENCE   PMID:15776778 (drug)
  AUTHORS   Elston DM
  TITLE     Drugs used in the treatment of pediculosis.
  JOURNAL   J Drugs Dermatol 4:207-11 (2005)
REFERENCE   PMID:19104739 (description)
  AUTHORS   Nutanson I, Steen CJ, Schwartz RA, Janniger CK
  TITLE     Pediculus humanus capitis: an update.
  JOURNAL   Acta Dermatovenerol Alp Panonica Adriat 17:147-54, 156-7, 159 (2008)
///
ENTRY       H01055                      Disease
NAME        Giant kidney worm infection;
            Dioctophymosis
DESCRIPTION Dioctophyma renale is a parasite of the Dioctophymidae family that principally occurs in dogs or other carnivores. Humans are accidental definitive hosts. Ingested Dioctophyma larvae migrate directly into the right kidney where they mature. Clinical presentation of D. renale infection is unspecific.
CATEGORY    Infectious disease
PATHOGEN    Dioctophyme renale
DRUG        Ivermectin [DR:D00804]
DBLINKS     ICD-10: B83.8
            MeSH: D017189
REFERENCE   PMID:21158627 (description, env_factor)
  AUTHORS   Li G, Liu C, Li F, Zhou M, Liu X, Niu Y
  TITLE     Fatal bilateral dioctophymatosis.
  JOURNAL   J Parasitol 96:1152-4 (2010)
REFERENCE   PMID:12566820
  AUTHORS   Ignjatovic I, Stojkovic I, Kutlesic C, Tasic S
  TITLE     Infestation of the human kidney with Dioctophyma renale.
  JOURNAL   Urol Int 70:70-3 (2003)
///
ENTRY       H01056                      Disease
NAME        Toxocariasis, including:
            Visceral larva migrans;
            Ocular larva migrans;
            Covert toxocariasis;
            Common toxocariasis
DESCRIPTION Human toxocariasis is the disease caused by infection of zoonotic roundworms Toxocara canis and T. cati, whose definitive hosts are dogs and cats, respectively. Humans become infected by ingesting either embryonated eggs from soil or raw vegetables. Toxocara larval migration in the body can cause four clinical syndromes, namely visceral larva migrans, ocular larva migrans, and covert/common toxocariasis. These are frequently associated with fever, abdominal pain, cough, wheeze, and hepatomegaly. Ocular larva migrans can lead to visual loss.
CATEGORY    Infectious disease
PATHOGEN    Toxocara canis
            Toxocara cati
MARKER      Toxocara excretory-secretory antigens (ELISA and western blot detection)
DRUG        Corticosteroids
            Diethylcarbamazine [DG:DG01024]
DBLINKS     ICD-10: B83.0
            MeSH: D014120 D007816
REFERENCE   PMID:20149289 (description, env_factor)
  AUTHORS   Rubinsky-Elefant G, Hirata CE, Yamamoto JH, Ferreira MU
  TITLE     Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression  of the systemic and ocular forms.
  JOURNAL   Ann Trop Med Parasitol 104:3-23 (2010)
REFERENCE   PMID:11301585 (description, drug, marker)
  AUTHORS   Magnaval JF, Glickman LT, Dorchies P, Morassin B
  TITLE     Highlights of human toxocariasis.
  JOURNAL   Korean J Parasitol 39:1-11 (2001)
REFERENCE   PMID:9347221 (description, env_factor)
  AUTHORS   Overgaauw PA
  TITLE     Aspects of Toxocara epidemiology: human toxocarosis.
  JOURNAL   Crit Rev Microbiol 23:215-31 (1997)
REFERENCE   PMID:9347222 (description)
  AUTHORS   Overgaauw PA
  TITLE     Aspects of Toxocara epidemiology: toxocarosis in dogs and cats.
  JOURNAL   Crit Rev Microbiol 23:233-51 (1997)
///
ENTRY       H01057                      Disease
NAME        Gnathostomiasis
DESCRIPTION Gnathostomiasis is a parasitic infection caused by the helminths Gnathostoma species, which are endemic to tropical and subtropical regions. Humans usually become infected by eating raw freshwater fish. The clinical presentation is characterized by localized, intermittent, migratory swellings of the skin and subcutaneous tissues, often in association with localized pain, pruritus, and erythema.
CATEGORY    Infectious disease
PATHOGEN    Gnathostoma spinigerum
            Gnathostoma hispidum
            Gnathostoma doloresi
MARKER      The triad of eosinophilia, migratory lesions, and obvious exposure risk are highly suggestive of the diagnosis of gnathostomiasis.
COMMENT     For many years, surgical excision of the larvae remained the only effective management.
DBLINKS     ICD-10: B83.1
            MeSH: D058429
REFERENCE   PMID:19597010
  AUTHORS   Herman JS, Chiodini PL
  TITLE     Gnathostomiasis, another emerging imported disease.
  JOURNAL   Clin Microbiol Rev 22:484-92 (2009)
REFERENCE   PMID:15825144
  AUTHORS   Ligon BL
  TITLE     Gnathostomiasis: a review of a previously localized zoonosis now crossing numerous geographical boundaries.
  JOURNAL   Semin Pediatr Infect Dis 16:137-43 (2005)
REFERENCE   PMID:8448317 (description, env_factor)
  AUTHORS   Rusnak JM, Lucey DR
  TITLE     Clinical gnathostomiasis: case report and review of the English-language literature.
  JOURNAL   Clin Infect Dis 16:33-50 (1993)
///
ENTRY       H01058                      Disease
NAME        Anisakiasis
DESCRIPTION Anisakiasis is an acute gastrointestinal disease caused by infection with the larval stages of herring worm (Anisakis spp.) or the cod worm (Pseudoterranova decipiens). Humans can be accidental hosts by consuming raw or undercooked fish. Anisakiasis occurs through the world, with over 90% cases are from Japan. After ingestion, larvae penetrate the gastrointestinal mucosa and there is severe abdominal pain, with nausea and vomiting. Some patients develop syndromes exhibiting clinical manifestations of allergy.
CATEGORY    Infectious disease
PATHOGEN    Anisakis simplex
            Pseudoterranova decipiens
            Anisakis pegreff
DRUG        Albendazole [DG:DG01022]
DBLINKS     ICD-10: B81.0
            MeSH: D017129
REFERENCE   PMID:19559535 (description, env_factor)
  AUTHORS   Dorny P, Praet N, Deckers N, Gabriel S
  TITLE     Emerging food-borne parasites.
  JOURNAL   Vet Parasitol 163:196-206 (2009)
REFERENCE   PMID:16143336 (description, env_factor)
  AUTHORS   Chai JY, Darwin Murrell K, Lymbery AJ
  TITLE     Fish-borne parasitic zoonoses: status and issues.
  JOURNAL   Int J Parasitol 35:1233-54 (2005)
REFERENCE   PMID:16206105 (description, env_factor, drug)
  AUTHORS   Nawa Y, Hatz C, Blum J
  TITLE     Sushi delights and parasites: the risk of fishborne and foodborne parasitic zoonoses in Asia.
  JOURNAL   Clin Infect Dis 41:1297-303 (2005)
///
ENTRY       H01059                      Disease
NAME        Capnocytophaga canimorsus infection
DESCRIPTION Capnocytophaga canimorsus is a fastidious, gram-negative commensal bacterium in the normal oral flora of dogs and cats. The bacterium has been isolated from humans infected by dog or cat bites, scratches or licks. The infection presents as fulminant sepsis, endocarditis, and purulent arthritis associated with a high mortality.
CATEGORY    Infectious disease
PATHOGEN    Capnocytophaga canimorsus [GN:ccm]
DRUG        Penicillin G [DG:DG00534]
COMMENT     Aztronam, polymyxin, fosfomycin, trimethoprim/sulfamethoxazole and aminoglycosides are not effective against C. canimorsus.
REFERENCE   PMID:19268498 (description, env_factor, drug)
  AUTHORS   Gaastra W, Lipman LJ
  TITLE     Capnocytophaga canimorsus.
  JOURNAL   Vet Microbiol 140:339-46 (2010)
REFERENCE   PMID:20407357 (description, env_factor)
  AUTHORS   Stiegler D, Gilbert JD, Warner MS, Byard RW
  TITLE     Fatal dog bite in the absence of significant trauma: Capnocytophaga canimorsus infection and unexpected death.
  JOURNAL   Am J Forensic Med Pathol 31:198-9 (2010)
REFERENCE   PMID:14970251 (description, env_factor)
  AUTHORS   Sandoe JA
  TITLE     Capnocytophaga canimorsus endocarditis.
  JOURNAL   J Med Microbiol 53:245-8 (2004)
REFERENCE   PMID:7588825 (description, env_factor)
  AUTHORS   Valtonen M, Lauhio A, Carlson P, Multanen J, Sivonen A, Vaara M, Lahdevirta J
  TITLE     Capnocytophaga canimorsus septicemia: fifth report of a cat-associated infection  and five other cases.
  JOURNAL   Eur J Clin Microbiol Infect Dis 14:520-3 (1995)
///
ENTRY       H01060                      Disease
NAME        Babesiosis
DESCRIPTION Babesiosis is a malaria-like infection of red blood cells caused by the protozoan parasite Babesia species. It is a well-recognized veterinary disease in cattle, horses and dogs but recently has gained attention as an emerging zoonotic disease problem. Babesia are transmitted by ixodid ticks and infection of the host leads to anemia, hyperbilirubinuria, hemoglobinuria, and possibly organ failure.
CATEGORY    Infectious disease
PATHOGEN    Babesia microti
            Babesia divergens
            Babesia bovis [GN:bbo]
            Babesia canis
            Babesia bigemina
            Babesia duncani
MARKER      Giemsa-stained thin blood smear
            IgG antibody testing
            IgM antibody testing
            18S rDNA (PCR detection) [KO:K01979]
DRUG        Clindamycin [DG:DG00435]
            Quinine [DG:DG01019]
COMMENT     Vector: Ixodes scapularis [GN:isc]
DBLINKS     ICD-10: B60.0
            MeSH: D001404
REFERENCE   PMID:18755385 (description, env_factor, drug)
  AUTHORS   Vannier E, Gewurz BE, Krause PJ
  TITLE     Human babesiosis.
  JOURNAL   Infect Dis Clin North Am 22:469-88, viii-ix (2008)
REFERENCE   PMID:18440005 (description, env_factor, marker)
  AUTHORS   Hunfeld KP, Hildebrandt A, Gray JS
  TITLE     Babesiosis: recent insights into an ancient disease.
  JOURNAL   Int J Parasitol 38:1219-37 (2008)
REFERENCE   PMID:17691604 (description)
  AUTHORS   Genchi C
  TITLE     Human babesiosis, an emerging zoonosis.
  JOURNAL   Parassitologia 49 Suppl 1:29-31 (2007)
///
ENTRY       H01061                      Disease
NAME        Mansonelliasis
DESCRIPTION Mansonelliasis is one of the filarial nematode infections widespread in many parts of Sub-Saharan Africa and in parts of Central and South America. The nematode, Mansonella perstans, is transmitted by tiny blood-sucking flies (biting midges). Infections are usually asymptomatic with no distinct and specific clinical picture, but may cause transient upper abdominal pain, subcutaneous swellings, eosinophilia, and skin rashes.
CATEGORY    Infectious disease
PATHOGEN    Mansonella perstans
DRUG        Diethylcarbamazine [DG:DG01024]
            Ivermectin [DR:D00804]
            Anthelmintic benzimidazoles [ATC:P02CA]
COMMENT     Vector: genus Culicoides (biting midges)
DBLINKS     ICD-10: B74.4
            MeSH: D008368
REFERENCE   PMID:20152790
  AUTHORS   Simonsen PE, Onapa AW, Asio SM
  TITLE     Mansonella perstans filariasis in Africa.
  JOURNAL   Acta Trop 120 Suppl 1:S109-20 (2011)
///
ENTRY       H01062                      Disease
NAME        Histoplasmosis
DESCRIPTION Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum that occurs in temperate and tropical climates. It is the most frequent invasive fungal infection in immunocompromised patients or patients receiving tumor necrosis factor (TNF) blockers, resulting in a mortality rate of 20%. Most affected patients (70-80%) present with pneumonitis, and sometimes the disease may be disseminated from the lungs to other organs.
CATEGORY    Infectious disease
PATHOGEN    Histoplasma capsulatum [GN:aje]
            Tumor necrosis factor (TNF) blockers [DR:D02598 D02597 D00742]
MARKER      Antigen detection (using polyclonal antibodies to Histoplasma capsulatum)
DRUG        Amphotericin B [DR:D00203] [ATC:J02AA01]
            Itraconazole [DR:D00350]
DBLINKS     ICD-10: B39.9
            MeSH: D006660
REFERENCE   PMID:22025021 (description)
  AUTHORS   Gupta AO, Singh N
  TITLE     Immune reconstitution syndrome and fungal infections.
  JOURNAL   Curr Opin Infect Dis 24:527-33 (2011)
REFERENCE   PMID:22196208 (description)
  AUTHORS   Perfect JR
  TITLE     The impact of the host on fungal infections.
  JOURNAL   Am J Med 125:S39-51 (2012)
REFERENCE   PMID:19951231 (env_factor, drug)
  AUTHORS   Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Joseph Wheat L
  TITLE     Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy.
  JOURNAL   Clin Infect Dis 50:85-92 (2010)
REFERENCE   PMID:19843232 (description)
  AUTHORS   Jazwinski A, Naggie S, Perfect J
  TITLE     Immune reconstitution syndrome in a patient with disseminated histoplasmosis and  steroid taper: maintaining the perfect balance.
  JOURNAL   Mycoses 54:270-2 (2011)
REFERENCE   PMID:17409220 (marker)
  AUTHORS   LeMonte A, Egan L, Connolly P, Durkin M, Wheat LJ
  TITLE     Evaluation of the IMMY ALPHA Histoplasma antigen enzyme immunoassay for diagnosis of histoplasmosis marked by antigenuria.
  JOURNAL   Clin Vaccine Immunol 14:802-3 (2007)
///
ENTRY       H01063                      Disease
NAME        Human metapneumovirus infection
DESCRIPTION Human metapneumovirus (hMPV) is an emerging human respiratory pathogen first reported in 2001. hMPV is widely distributed that nearly all individuals have been exposed to the virus by age of 5 years. It causes mild to severe cough, bronchiolitis, and pneumonia and these symptoms cannot be distinguished from those caused by the respiratory syncytial virus, influenza, and parainfluenza viruses.
CATEGORY    Infectious disease
PATHOGEN    Human metapneumovirus [GN:T40095]
REFERENCE   PMID:15575039 (description, env_factor)
  AUTHORS   Alto WA
  TITLE     Human metapneumovirus: a newly described respiratory tract pathogen.
  JOURNAL   J Am Board Fam Pract 17:466-9 (2004)
REFERENCE   PMID:12821817 (description, env_factor)
  AUTHORS   Kahn JS
  TITLE     Human metapneumovirus: a newly emerging respiratory pathogen.
  JOURNAL   Curr Opin Infect Dis 16:255-8 (2003)
///
ENTRY       H01064                      Disease
NAME        Simkania negevensis infection
DESCRIPTION Simkania negevensis is a recently found Chlamydia-like organism. It is associated with respiratory diseases such as pneumonia in adults and bronchiolitis in infants.
CATEGORY    Infectious disease
PATHOGEN    Simkania negevensis [GN:sng]
REFERENCE   PMID:17852931 (description, env_factor)
  AUTHORS   Heiskanen-Kosma T, Paldanius M, Korppi M
  TITLE     Simkania negevensis may be a true cause of community acquired pneumonia in children.
  JOURNAL   Scand J Infect Dis 40:127-30 (2008)
REFERENCE   PMID:12941393 (description, env_factor)
  AUTHORS   Friedman MG, Dvoskin B, Kahane S
  TITLE     Infections with the chlamydia-like microorganism Simkania negevensis, a possible  emerging pathogen.
  JOURNAL   Microbes Infect 5:1013-21 (2003)
///
ENTRY       H01065                      Disease
NAME        Pentosuria
DESCRIPTION Pentosuria is an autosomal recessive inherited condition to be inborn errors of metabolism characterized by high levels of the pentose sugar L-xylulose in blood and urine. The condition is completely clinically benign. Mutations have been identified in the DCXR gene encoding L-xylulose reductase, which are predicted to lead to loss of enzyme activity. In pentosuria, failure to convert L-xylulose to xylitol leads to accumulation of L-xylulose.
CATEGORY    Urinary system disease
GENE        DCXR [HSA:51181] [KO:K03331]
DBLINKS     ICD-10: E74.8
            MeSH: C536652
            OMIM: 260800
REFERENCE   PMID:22042873 (definition, gene)
  AUTHORS   Pierce SB, Spurrell CH, Mandell JB, Lee MK, Zeligson S, Bereman MS, Stray SM, Fokstuen S, MacCoss MJ, Levy-Lahad E, King MC, Motulsky AG
  TITLE     Garrod's fourth inborn error of metabolism solved by the identification of mutations causing pentosuria.
  JOURNAL   Proc Natl Acad Sci U S A 108:18313-7 (2011)
REFERENCE   PMID:4073836 (definition)
  AUTHORS   Lane AB, Jenkins T
  TITLE     Human L-xylulose reductase variation: family and population studies.
  JOURNAL   Ann Hum Genet 49:227-35 (1985)
///
ENTRY       H01066                      Disease
NAME        Bordetella petrii infection
DESCRIPTION Bordetella petrii is one of the members of the genus Bordetella that includes host-restricted and pathogenic species B. pertussis. Unlike other members of Bordetella, B. petrii is an environmental species but sometimes can infect immunocompetent humans.
CATEGORY    Infectious disease
PATHOGEN    Bordetella petrii [GN:bpt]
DBLINKS     MeSH: D001885
REFERENCE   PMID:21470449 (description, env_factor)
  AUTHORS   Le Coustumier A, Njamkepo E, Cattoir V, Guillot S, Guiso N
  TITLE     Bordetella petrii infection with long-lasting persistence in human.
  JOURNAL   Emerg Infect Dis 17:612-8 (2011)
REFERENCE   PMID:17314377
  AUTHORS   Stark D, Riley LA, Harkness J, Marriott D
  TITLE     Bordetella petrii from a clinical sample in Australia: isolation and molecular identification.
  JOURNAL   J Med Microbiol 56:435-7 (2007)
REFERENCE   PMID:18826580 (description)
  AUTHORS   Gross R, Guzman CA, Sebaihia M, dos Santos VA, Pieper DH, Koebnik R, Lechner M, Bartels D, Buhrmester J, Choudhuri JV, Ebensen T, Gaigalat L, Herrmann S, Khachane AN, Larisch C, Link S, Linke B, Meyer F, Mormann S, Nakunst D, Ruckert C, Schneiker-Bekel S, Schulze K, Vorholter FJ, Yevsa T, Engle JT, Goldman WE, Puhler A, Gobel UB, Goesmann A, Blocker H, Kaiser O, Martinez-Arias R
  TITLE     The missing link: Bordetella petrii is endowed with both the metabolic versatility of environmental bacteria and virulence traits of pathogenic Bordetellae.
  JOURNAL   BMC Genomics 9:449 (2008)
REFERENCE   PMID:15831828 (description)
  AUTHORS   Mattoo S, Cherry JD
  TITLE     Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory  infections due to Bordetella pertussis and other Bordetella subspecies.
  JOURNAL   Clin Microbiol Rev 18:326-82 (2005)
///
ENTRY       H01067                      Disease
NAME        Proteus mirabilis infection
DESCRIPTION Proteus mirabilis is a motile gram-negative bacterium within the Enterobacteriaceae that inhabits the environment. It causes a number of infections including those of the skin, respiratory tract, wounds and urinary tract. Pyelonephritis caused by the bacterium primarily affects individuals with indwelling catheters or structural abnormalities of the urinary tract.
CATEGORY    Infectious disease
PATHOGEN    Proteus mirabilis [GN:pmr pmib]
            Urea-inducible urease [pmr:PMI3685 PMI3684 PMI3683] [KO:K01428 K01429 K01430]
            Amino acid deaminase [pmr:PMI2834]
            Hemolysin [pmr:PMI2057] [KO:K11016]
            ZapA metalloprotease (IgA-degrading complex) [pmr:PMI0279] [KO:K01406]
DBLINKS     MeSH: D011512
REFERENCE   PMID:21921687 (description, env_factor)
  AUTHORS   Jacobsen SM, Shirtliff ME
  TITLE     Proteus mirabilis biofilms and catheter-associated urinary tract infections.
  JOURNAL   Virulence 2:460-5 (2011)
REFERENCE   PMID:11099936 (env_factor)
  AUTHORS   Coker C, Poore CA, Li X, Mobley HL
  TITLE     Pathogenesis of Proteus mirabilis urinary tract infection.
  JOURNAL   Microbes Infect 2:1497-505 (2000)
REFERENCE   PMID:18202436
  AUTHORS   Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME
  TITLE     Complicated catheter-associated urinary tract infections due to Escherichia coli  and Proteus mirabilis.
  JOURNAL   Clin Microbiol Rev 21:26-59 (2008)
REFERENCE   PMID:16060714
  AUTHORS   Nicolle LE
  TITLE     Catheter-related urinary tract infection.
  JOURNAL   Drugs Aging 22:627-39 (2005)
REFERENCE   PMID:19926986
  AUTHORS   Trautner BW
  TITLE     Management of catheter-associated urinary tract infection.
  JOURNAL   Curr Opin Infect Dis 23:76-82 (2010)
///
ENTRY       H01068                      Disease
NAME        Aggregatibacter aphrophilus infection
DESCRIPTION Aggregatibacter aphrophilus (formerly Haemophilus aphrophilus) is a capnophilic, fermentative, non-motile, gram-negative coccobacillus that is part of the indiginous microbiota of the human oropharynx. Infections with this bacterium are infrequent. It has mainly been associated with endocarditis, brain abscesses, vertebral osteomyelitis, and bacteremia.
CATEGORY    Infectious disease
PATHOGEN    Aggregatibacter aphrophilus [GN:aap]
DRUG        Ceftriaxone [DG:DG00573]
            Ciprofloxacin [DG:DG00617]
            Fluoroquinolones [ATC:J01MA]
            Penicillin [ATC:J01C]
COMMENT     Resistance to ampicillin, cefuroxime, ceftazidime and cefotaxime has been reported, with clinical failure of treatment with third-generation cephalosporins.
REFERENCE   PMID:6816135 (description, env_factor)
  AUTHORS   Albritton WL
  TITLE     Infections due to Haemophilus species other than H. influenzae.
  JOURNAL   Annu Rev Microbiol 36:199-216 (1982)
REFERENCE   PMID:11318807 (description, env_factor, drug)
  AUTHORS   Colson P, La Scola B, Champsaur P
  TITLE     Vertebral infections caused by Haemophilus aphrophilus: case report and review.
  JOURNAL   Clin Microbiol Infect 7:107-13 (2001)
REFERENCE   PMID:8170429 (description, drug)
  AUTHORS   Wilson CM, Reiss-Levy EA, Sturgess AD, Au TC
  TITLE     Haemophilus paraphrophilus vertebral osteomyelitis.
  JOURNAL   Med J Aust 160:512-4 (1994)
REFERENCE   PMID:3308306 (description, env_factor)
  AUTHORS   Papasian CJ, Reintjes S, Rengachary SS, Neihart RE, Hodges GR
  TITLE     Haemophilus paraphrophilus brain abscess.
  JOURNAL   Diagn Microbiol Infect Dis 7:205-9 (1987)
REFERENCE   PMID:7620027 (description, env_factor, drug)
  AUTHORS   Coll-Vinent B, Suris X, Lopez-Soto A, Miro JM, Coca A
  TITLE     Haemophilus paraphrophilus endocarditis: case report and review.
  JOURNAL   Clin Infect Dis 20:1381-3 (1995)
///
ENTRY       H01069                      Disease
NAME        Stenotrophomonas maltophilia infection
DESCRIPTION Stenotrophomonas maltophilia is a ubiquitous organism found in practically all natural environments with water content. In hospital environments, it is frequently found as a contaminant in many devices, infusion solutions, sterile water and is associated with hospital-acquired infections in patients with compromised immunity. S. maltophilia has been isolated from various clinical settings and the respiratory tract is the most common site of infection.
CATEGORY    Infectious disease
PATHOGEN    Stenotrophomonas maltophilia [GN:sml smt smz]
            StmPr1 [sml:Smlt0861] [KO:K14645]
COMMENT     Stenotrophomonas maltophilia shows high levels of intrinsic or acquired resistance to different antimicrobial agents.
DBLINKS     MeSH: C531821
REFERENCE   PMID:21504403 (description, env_factor, drug)
  AUTHORS   Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ
  TITLE     Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.
  JOURNAL   Expert Rev Anti Infect Ther 9:471-88 (2011)
REFERENCE   PMID:16196464 (description, env_factor)
  AUTHORS   Looney WJ
  TITLE     Role of Stenotrophomonas maltophilia in hospital-acquired infection.
  JOURNAL   Br J Biomed Sci 62:145-54; quiz 1 p following 154 (2005)
REFERENCE   PMID:20526844 (description, env_factor)
  AUTHORS   Nyc O, Matejkova J
  TITLE     Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.
  JOURNAL   Folia Microbiol (Praha) 55:286-94 (2010)
REFERENCE   PMID:17334747 (drug)
  AUTHORS   Nicodemo AC, Paez JI
  TITLE     Antimicrobial therapy for Stenotrophomonas maltophilia infections.
  JOURNAL   Eur J Clin Microbiol Infect Dis 26:229-37 (2007)
///
ENTRY       H01070                      Disease
NAME        Vibrio furnissii infection
DESCRIPTION Vibrio furnissii, first described as a gasproducing biovar of Vibrio fluvialis, is associated with human acute gastroenteritis. The pathology of V. furnissii in gastroenteritis is potentially related to hemolysin production, as it has been shown to have in vitro hemolytic activity.
CATEGORY    Infectious disease
PATHOGEN    Vibrio furnissii [GN:vfu]
            Hly-OppA [vfu:vfu_A01533] [KO:K15580]
DRUG        Fluoroquinolone [ATC:J01MA]
DBLINKS     MeSH: D014735
REFERENCE   PMID:21450956 (description, env_factor)
  AUTHORS   Derber C, Coudron P, Tarr C, Gladney L, Turnsek M, Shankaran S, Wong E
  TITLE     Vibrio furnissii: an unusual cause of bacteremia and skin lesions after ingestion of seafood.
  JOURNAL   J Clin Microbiol 49:2348-9 (2011)
REFERENCE   PMID:17873048 (description)
  AUTHORS   Wu TK, Wang YK, Chen YC, Feng JM, Liu YH, Wang TY
  TITLE     Identification of a Vibrio furnissii oligopeptide permease and characterization of its in vitro hemolytic activity.
  JOURNAL   J Bacteriol 189:8215-23 (2007)
REFERENCE   PMID:8139467 (description)
  AUTHORS   Magalhaes V, Castello Filho A, Magalhaes M, Gomes TT
  TITLE     Laboratory evaluation on pathogenic potentialities of Vibrio furnissii.
  JOURNAL   Mem Inst Oswaldo Cruz 88:593-7 (1993)
///
ENTRY       H01071                      Disease
NAME        Acute alcohol sensitivity
DESCRIPTION Aldehyde dehydrogenases (ALDHs) are important enzymes that eliminate toxic aldehydes by catalysing their oxidation to non-reactive acids. It is reported that a deficiency in the ALDH2 is associated with the alcohol flush reaction. More than 40% of the East Asians population carries a common ALDH2 mutant allele, which results in a dramatic reduction in the enzymatic activity when compared with the wild-type allele.
CATEGORY    Inherited metabolic disease
GENE        ALDH2 [HSA:217] [KO:K00128]
DBLINKS     OMIM: 610251
REFERENCE   PMID:16792555
  AUTHORS   Dickson PA, James MR, Heath AC, Montgomery GW, Martin NG, Whitfield JB, Birley AJ
  TITLE     Effects of variation at the ALDH2 locus on alcohol metabolism, sensitivity, consumption, and dependence in Europeans.
  JOURNAL   Alcohol Clin Exp Res 30:1093-100 (2006)
REFERENCE   PMID:20558439
  AUTHORS   Chen CH, Sun L, Mochly-Rosen D
  TITLE     Mitochondrial aldehyde dehydrogenase and cardiac diseases.
  JOURNAL   Cardiovasc Res 88:51-7 (2010)
///
ENTRY       H01072                      Disease
NAME        Moraxella catarrhalis infection
DESCRIPTION Moraxella catarrhalis is a gram-negative human mucosal pathogen that is morphologically similar to Neisseria spp.. It is found as a common commensal of the nasopharynx and can cause upper respiratory tract infections. The infection presents as otitis media or sinusitis in children and the exacerbation of chronic bronchitis in adults with chronic obstructive pulmonary disease (COPD).
CATEGORY    Infectious disease
PATHOGEN    Moraxella catarrhalis [GN:mct]
DRUG        Macrolides [ATC:J01FA]
            Cephalosporin [ATC:J01DB J01DC J01DD J01DE]
            Tetracycline [DG:DG01197]
            Co-amoxyclav [DR:D06485]
COMMENT     Moraxella catarrhalis is expected to be resistant to beta-lactam antibiotics including penicillin, ampicillin, amoxicillin, and piperacillin [ATC: J01CE01 J01CA04 J01CA01 J01CA12].
REFERENCE   PMID:22234107 (description, env_factor)
  AUTHORS   Gupta N, Arora S, Kundra S
  TITLE     Moraxella catarrhalis as a respiratory pathogen.
  JOURNAL   Indian J Pathol Microbiol 54:769-71 (2011)
REFERENCE   PMID:9152030 (description, env_factor, drug)
  AUTHORS   Enright MC, McKenzie H
  TITLE     Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen.
  JOURNAL   J Med Microbiol 46:360-71 (1997)
REFERENCE   PMID:11781271 (description, env_factor, drug)
  AUTHORS   Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A
  TITLE     Moraxella catarrhalis: from emerging to established pathogen.
  JOURNAL   Clin Microbiol Rev 15:125-44 (2002)
REFERENCE   PMID:10865200 (description, env_factor)
  AUTHORS   Karalus R, Campagnari A
  TITLE     Moraxella catarrhalis: a review of an important human mucosal pathogen.
  JOURNAL   Microbes Infect 2:547-59 (2000)
///
ENTRY       H01073                      Disease
NAME        Shewanella infection
DESCRIPTION Shewanella putrefaciens and Shewanella algae are opportunistically pathogenic for humans. Shewanella infection is associated with a wide clinical spectrum and soft-tissue infection is most frequent. Bacteremia/septicemia can cause death in some cases.
CATEGORY    Infectious disease
PATHOGEN    Shewanella putrefaciens [GN:spc]
            Shewanella algae
DRUG        Cephalosporin [ATC:J01DB J01DC J01DD J01DE]
COMMENT     S. putrefaciens are resistant to cefazolin and cefoxitin.
REFERENCE   PMID:22325004 (description, env_factor, drug)
  AUTHORS   Liu PY, Lin CF, Wu MJ, Kao CC, Shi ZY
  TITLE     Shewanella bloodstream infection.
  JOURNAL   Hemodial Int 16:578-9 (2012)
REFERENCE   PMID:18565779 (description, env_factor)
  AUTHORS   Tsai MS, You HL, Tang YF, Liu JW
  TITLE     Shewanella soft tissue infection: case report and literature review.
  JOURNAL   Int J Infect Dis 12:e119-24 (2008)
REFERENCE   PMID:9332516 (description, env_factor)
  AUTHORS   Chen YS, Liu YC, Yen MY, Wang JH, Wang JH, Wann SR, Cheng DL
  TITLE     Skin and soft-tissue manifestations of Shewanella putrefaciens infection.
  JOURNAL   Clin Infect Dis 25:225-9 (1997)
///
ENTRY       H01074                      Disease
NAME        Aeromonas infection
DESCRIPTION Members of the genus Aeromonas are gram-negatove bacteria that inhabit various aquatic environments. It can cause a wide spectrum of disease in humans as well as other animals, with gastroenteritis being the most common type of infection. Wound infections and septicaemia are the second and third common disease caused by Aeromonas after gastroenteritis.
CATEGORY    Infectious disease
PATHOGEN    Aeromonas hydrophila [GN:aha]
            Aeromonas veronii [GN:avr]
            Aeromonas media
            Aeromonas caviae
            Aeromonas schubertii
            Aeromonas jandaei
            Aeromonas trota
            Aeromonas bestiarum
            Aeromonas popoffii
DRUG        Carbapenems [ATC:J01DH]
            Cephalosporins [DG:DG00586 DG00587 DG00588]
            Macrolides [ATC:J01FA]
            Monobactams [DG:DG00589 DG00590]
            Nitrofurans [ATC:J01XE]
            Penicillins [ATC:J01CA]
            Phenicols [DG:DG00399 DG00516] [ATC:J01BA]
            Quinolones [ATC:J01MA J01MB]
            Tetracyclines [DG:DG01197]
REFERENCE   PMID:21163298 (description, env_factor)
  AUTHORS   Parker JL, Shaw JG
  TITLE     Aeromonas spp. clinical microbiology and disease.
  JOURNAL   J Infect 62:109-18 (2011)
REFERENCE   PMID:20065325 (description, env_factor, drug)
  AUTHORS   Janda JM, Abbott SL
  TITLE     The genus Aeromonas: taxonomy, pathogenicity, and infection.
  JOURNAL   Clin Microbiol Rev 23:35-73 (2010)
REFERENCE   PMID:17401708 (description)
  AUTHORS   von Graevenitz A
  TITLE     The role of Aeromonas in diarrhea: a review.
  JOURNAL   Infection 35:59-64 (2007)
///
ENTRY       H01075                      Disease
NAME        Peters anomaly, including:
            Peters plus syndrome;
            Peters anomaly plus systemic features
DESCRIPTION Peters anomaly is a developmental disorder that presents with central corneal opacity (leukoma), iris and lenticular adhesions to the cornea, and lack of the posterior corneal stroma, and Descemets membrane. Approximately half of patients develop glaucoma. The majority of cases are sporadic; however, autosomal recessive and dominant patterns of inheritance have been found. Specific chromosomal abnormalities have also been found to be responsible for Peters anomaly.
CATEGORY    Eye disease
GENE        PAX6 [HSA:5080] [KO:K08031]
            PITX2 [HSA:5308] [KO:K04686]
            CYP1B1 [HSA:1545] [KO:K07410]
            FOXC1 [HSA:2296] [KO:K09396]
            B3GALTL [HSA:145173] [KO:K13675]
COMMENT     Anterior segment dysgenesis (ASD) have been classified into different subtypes, including aniridia, Axenfeld's anomaly, Rieger's anomaly, iridogoniodysgenesis, Peters anomaly, and posterior embryotoxon.
DBLINKS     ICD-10: Q13.4
            MeSH: C537884
            OMIM: 604229 261540
REFERENCE   PMID:21633242 (description, gene)
  AUTHORS   Girgis N, Chen TC
  TITLE     Genetics of the pediatric glaucomas.
  JOURNAL   Int Ophthalmol Clin 51:107-17 (2011)
REFERENCE   PMID:21738392 (description)
  AUTHORS   Mataftsi A, Islam L, Kelberman D, Sowden JC, Nischal KK
  TITLE     Chromosome abnormalities and the genetics of congenital corneal opacification.
  JOURNAL   Mol Vis 17:1624-40 (2011)
REFERENCE   PMID:21448066 (description, gene)
  AUTHORS   Bhandari R, Ferri S, Whittaker B, Liu M, Lazzaro DR
  TITLE     Peters anomaly: review of the literature.
  JOURNAL   Cornea 30:939-44 (2011)
REFERENCE   PMID:12015278 (comment)
  AUTHORS   Gould DB, John SW
  TITLE     Anterior segment dysgenesis and the developmental glaucomas are complex traits.
  JOURNAL   Hum Mol Genet 11:1185-93 (2002)
///
ENTRY       H01076                      Disease
NAME        Alpha-methylacetoacetic aciduria;
            3-Ketothiolase deficiency
DESCRIPTION Alpha-methylacetoacetic aciduria/3-Ketothiolase deficiency is an autosomal recessive error of isoleucine and ketone body catabolism caused by a deficiency of mitochondrial acetoacetyl-CoA thiolase. The patients present with intermittent ketoacidotic episodes and urinary excretion of 2-methylacetoacetate, 2-methyl-3-hydroxybutyrate, and tiglylglycine.
CATEGORY    Inherited metabolic disease
GENE        ACAT1 [HSA:38] [KO:K00626]
MARKER      Urinary excretion of 2-methylacetoacetate, 2-methyl-3-hydroxybutyrate, and tiglylglycine.
DRUG        protein intake (1.5-2.0 g/kg/day)
            intravenous glucose
            L-carnitine supplementation (50 200 mg/kg/day)
DBLINKS     ICD-10: E72.2
            MeSH: C535434
            OMIM: 203750
REFERENCE   PMID:1346617
  AUTHORS   Fukao T, Yamaguchi S, Orii T, Schutgens RB, Osumi T, Hashimoto T
  TITLE     Identification of three mutant alleles of the gene for mitochondrial acetoacetyl-coenzyme A thiolase. A complete analysis of two generations of a family with 3-ketothiolase deficiency.
  JOURNAL   J Clin Invest 89:474-9 (1992)
REFERENCE   PMID:1715688
  AUTHORS   Fukao T, Yamaguchi S, Tomatsu S, Orii T, Frauendienst-Egger G, Schrod L, Osumi T, Hashimoto T
  TITLE     Evidence for a structural mutation (347Ala to Thr) in a German family with 3-ketothiolase deficiency.
  JOURNAL   Biochem Biophys Res Commun 179:124-9 (1991)
REFERENCE   PMID:7728148
  AUTHORS   Wakazono A, Fukao T, Yamaguchi S, Hori T, Orii T, Lambert M, Mitchell GA, Lee GW, Hashimoto T
  TITLE     Molecular, biochemical, and clinical characterization of mitochondrial acetoacetyl-coenzyme A thiolase deficiency in two further patients.
  JOURNAL   Hum Mutat 5:34-42 (1995)
REFERENCE   PMID:23664791 (therapy)
  AUTHORS   Kayani R, Botros S, Moore P
  TITLE     Beta-ketothiolase deficiency and pregnancy.
  JOURNAL   Int J Obstet Anesth 22:260-1 (2013)
///
ENTRY       H01077                      Disease
NAME        Bordetella hinzii infection
DESCRIPTION Bordetella hinzii is a recently added species to the genus Bordetella that is isolated from poultry with respiratory disease. B. hinzii may cause disease in immunocompromised patients or patients with underlying disease.
CATEGORY    Infectious disease
PATHOGEN    Bordetella hinzii
DRUG        Amoxicillin-clavulanic acid [DR:D00230 D06485]
            Ciprofloxacin [DG:DG00617]
DBLINKS     MeSH: D001885
REFERENCE   PMID:7814500 (description, env_factor)
  AUTHORS   Cookson BT, Vandamme P, Carlson LC, Larson AM, Sheffield JV, Kersters K, Spach DH
  TITLE     Bacteremia caused by a novel Bordetella species, "B. hinzii".
  JOURNAL   J Clin Microbiol 32:2569-71 (1994)
REFERENCE   PMID:8815118 (description, env_factor, drug)
  AUTHORS   Funke G, Hess T, von Graevenitz A, Vandamme P
  TITLE     Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period.
  JOURNAL   J Clin Microbiol 34:966-9 (1996)
REFERENCE   PMID:7857806 (description, env_factor)
  AUTHORS   Vandamme P, Hommez J, Vancanneyt M, Monsieurs M, Hoste B, Cookson B, Wirsing von Konig CH, Kersters K, Blackall PJ
  TITLE     Bordetella hinzii sp. nov., isolated from poultry and humans.
  JOURNAL   Int J Syst Bacteriol 45:37-45 (1995)
///
ENTRY       H01078                      Disease
NAME        Fletcher factor deficiency;
            Prekallikrein deficiency
DESCRIPTION Fletcher factor deficiency, also called Prekallikrein deficiency, is an autosomal recessive heterozygous disorder of coagulation that is caused by defects in KLKB1. Although the patients had no abnormal bleeding tendency, their blood showed much prolonged activated partial thromboplastin time and delayed thromboplastin generation but normal prothrombin time.
CATEGORY    Hematologic disease
GENE        KLKB1 [HSA:3818] [KO:K01324]
DBLINKS     ICD-10: D68.8
            OMIM: 612423
REFERENCE   PMID:21091145
  AUTHORS   Girolami A, Scarparo P, Candeo N, Lombardi AM
  TITLE     Congenital prekallikrein deficiency.
  JOURNAL   Expert Rev Hematol 3:685-95 (2010)
REFERENCE   PMID:6902559
  AUTHORS   Ragni MV, Lewis JH, Hasiba U, Spero JA
  TITLE     Prekallikrein (Fletcher factor) deficiency in clinical disease states.
  JOURNAL   Thromb Res 18:45-54 (1980)
///
ENTRY       H01079                      Disease
NAME        3-Phosphoglycerate dehydrogenase (3-PGDH) deficiency;
            PHGDH Deficiency
DESCRIPTION 3-Phosphoglycerate dehydrogenase (3-PGDH) deficiency is a rare autosomal recessive disorder caused by a defect in the synthesis of the amino acid L-serine characterized clinically by congenital microcephaly, psychomotor retardation, and infantile onset of intractable seizures. The biochemical abnormalities associated with this disorder are low concentrations of L-serine, D-serine, and glycine in cerebrospinal fluid (CSF) and plasma. Mutations have been identified in PHGDH, the gene encoding 3-PGDH.
CATEGORY    Inherited metabolic disease
GENE        PHGDH [HSA:26227] [KO:K00058]
DRUG        L-Serine [DR:D00016]
DBLINKS     ICD-10: E72.8
            MeSH: C566618
            OMIM: 601815
REFERENCE   PMID:21113737 (description, gene, drug)
  AUTHORS   Tabatabaie L, Klomp LW, Rubio-Gozalbo ME, Spaapen LJ, Haagen AA, Dorland L, de Koning TJ
  TITLE     Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency.
  JOURNAL   J Inherit Metab Dis 34:181-4 (2011)
REFERENCE   PMID:19235232 (description, gene, drug)
  AUTHORS   Tabatabaie L, de Koning TJ, Geboers AJ, van den Berg IE, Berger R, Klomp LW
  TITLE     Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics.
  JOURNAL   Hum Mutat 30:749-56 (2009)
REFERENCE   PMID:19963421 (description, gene, drug)
  AUTHORS   Tabatabaie L, Klomp LW, Berger R, de Koning TJ
  TITLE     L-serine synthesis in the central nervous system: a review on serine deficiency disorders.
  JOURNAL   Mol Genet Metab 99:256-62 (2010)
///
ENTRY       H01080                      Disease
NAME        Ralstonia pickettii infection
DESCRIPTION Ralstonia pickettii is a gram-negative aerobic bacillus that can cause infections, mainly of the respiratory tract, in immunocompromised and cystic fibrosis patients.
CATEGORY    Infectious disease
PATHOGEN    Ralstonia pickettii [GN:rpi rpf]
COMMENT     Resistance can occur to ciprofloxacin, trimethoprim-sulphamethoxazole, piperacillin-tazobactam, imipenem-cilastatin and ceftazidime.
REFERENCE   PMID:16441445
  AUTHORS   Stelzmueller I, Biebl M, Wiesmayr S, Eller M, Hoeller E, Fille M, Weiss G, Lass-Floerl C, Bonatti H
  TITLE     Ralstonia pickettii-innocent bystander or a potential threat?
  JOURNAL   Clin Microbiol Infect 12:99-101 (2006)
///
ENTRY       H01081                      Disease
NAME        Achromobacter xylosoxidans keratitis
DESCRIPTION Achromobacter xylosoxidans is a gram-negative bacteria that belongs to the genus Alicaligenes. It can rarely cause keratitis in patients who had worn contact lenses.
CATEGORY    Infectious disease
PATHOGEN    Achromobacter xylosoxidans [GN:axy]
DRUG        Moxifloxacin [DG:DG00626]
            Ceftazidime [DG:DG00571]
            Gatifloxacin [DG:DG00628]
            Tobramycin [DG:DG00608]
COMMENT     Achromobacter xylosoxidans is resistant to aminoglycosides.
REFERENCE   PMID:22323886
  AUTHORS   Park JH, Song NH, Koh JW
  TITLE     Achromobacter xylosoxidans Keratitis after Contact Lens Usage.
  JOURNAL   Korean J Ophthalmol 26:49-53 (2012)
REFERENCE   PMID:21993586
  AUTHORS   Ahmed AA, Pineda R
  TITLE     Alcaligenes xylosoxidans contact lens-related keratitis--a case report and literature review.
  JOURNAL   Eye Contact Lens 37:386-9 (2011)
///
ENTRY       H01082                      Disease
NAME        Phosphoserine aminotransferase (PSAT) deficiency
DESCRIPTION Phosphoserine aminotransferase (PSAT) deficiency is a disorder of serine biosynthesis characterized biochemically by low plasma and CSF concentrations of serine and glycine and clinically by intractable seizures, acquired microcephaly, hypertonia, and psychomotor retardation. The biochemical and clinical features of PSAT deficiency shared some of the features of 3-PGDH deficiency [DS:H01079]. Mutations in the PSAT1 gene have been identified.
CATEGORY    Inherited metabolic disease
GENE        PSAT1 [HSA:29968] [KO:K00831]
DRUG        L-Serine [DR:D00016]
            Glycine [DR:D00011]
DBLINKS     MeSH: C567032
            OMIM: 610992
REFERENCE   PMID:17436247 (description, gene, drug)
  AUTHORS   Hart CE, Race V, Achouri Y, Wiame E, Sharrard M, Olpin SE, Watkinson J, Bonham JR, Jaeken J, Matthijs G, Van Schaftingen E
  TITLE     Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway.
  JOURNAL   Am J Hum Genet 80:931-7 (2007)
REFERENCE   PMID:19963421 (description, gene, drug)
  AUTHORS   Tabatabaie L, Klomp LW, Berger R, de Koning TJ
  TITLE     L-serine synthesis in the central nervous system: a review on serine deficiency disorders.
  JOURNAL   Mol Genet Metab 99:256-62 (2010)
///
ENTRY       H01083                      Disease
NAME        Bordetella bronchiseptica infection
DESCRIPTION Bordetella bronchiseptica is a common pathogen among dogs and pigs, but has rarely been implicated in human infections. Human infections caused by B. bronchiseptica occur mostly in immunocompromised patients and often present as pneumonia.
CATEGORY    Infectious disease
PATHOGEN    Bordetella bronchiseptica [GN:bbr]
DRUG        Meropenem [DG:DG00591]
DBLINKS     MeSH: D001885
REFERENCE   PMID:2373090 (description, env_factor)
  AUTHORS   Meis JF, van Griethuijsen AJ, Muytjens HL
  TITLE     Bordetella bronchiseptica bronchitis in an immunosuppressed patient.
  JOURNAL   Eur J Clin Microbiol Infect Dis 9:366-7 (1990)
REFERENCE   PMID:3571462 (decription, env_factor)
  AUTHORS   Papasian CJ, Downs NJ, Talley RL, Romberger DJ, Hodges GR
  TITLE     Bordetella bronchiseptica bronchitis.
  JOURNAL   J Clin Microbiol 25:575-7 (1987)
REFERENCE   PMID:11168091 (description, env_factor, drug)
  AUTHORS   Petrocheilou-Paschou V, Georgilis K, Kostis E, Prifti H, Zakopoulos N, Stamatelopoulos S
  TITLE     Bronchitis caused by Bordetella bronchiseptica in an elderly woman.
  JOURNAL   Clin Microbiol Infect 6:147-8 (2000)
///
ENTRY       H01084                      Disease
NAME        Bordetella holmesii infection
DESCRIPTION Bordetella holmesii is a fastidious asaccharolytic oxidase-negative gram-negative bacterium closely related to B. pertussis. It has been reported as a rare cause of bacteremia, pertussis-like respiratory tract infection, and endocarditis predominantly in patients with anatomical or functional asplenia.
CATEGORY    Infectious disease
PATHOGEN    Bordetella holmesii
DRUG        Ceftriaxone [DG:DG00573]
            Ciprofloxacin [DG:DG00617]
DBLINKS     MeSH: D001885
REFERENCE   PMID:22098551 (description, env_factor)
  AUTHORS   Mooi FR, Bruisten S, Linde I, Reubsaet F, Heuvelman K, van der Lee S, J King A
  TITLE     Characterization of Bordetella holmesii isolates from patients with pertussis-like illness in the Netherlands.
  JOURNAL   FEMS Immunol Med Microbiol 64:289-91 (2012)
REFERENCE   PMID:21944385 (description)
  AUTHORS   Barrado L, Barrios M, Sanz F, Chaves F
  TITLE     [Bordetella holmesii bacteremia in a child with sickle cell disease].
  JOURNAL   Enferm Infecc Microbiol Clin 29:779-80 (2011)
REFERENCE   PMID:21778268 (description)
  AUTHORS   Moissenet D, Leverger G, Merens A, Bonacorsi S, Guiso N, Vu-Thien H
  TITLE     Septic arthritis caused by Bordetella holmesii in an adolescent with chronic haemolytic anaemia.
  JOURNAL   J Med Microbiol 60:1705-7 (2011)
REFERENCE   PMID:20668129 (description, env_factor, drug)
  AUTHORS   Panagopoulos MI, Saint Jean M, Brun D, Guiso N, Bekal S, Ovetchkine P, Tapiero B
  TITLE     Bordetella holmesii bacteremia in asplenic children: report of four cases initially misidentified as Acinetobacter lwoffii.
  JOURNAL   J Clin Microbiol 48:3762-4 (2010)
REFERENCE   PMID:17174401 (description, env_factor)
  AUTHORS   Dorbecker C, Licht C, Korber F, Plum G, Haefs C, Hoppe B, Seifert H
  TITLE     Community-acquired pneumonia due to Bordetella holmesii in a patient with frequently relapsing nephrotic syndrome.
  JOURNAL   J Infect 54:e203-5 (2007)
///
ENTRY       H01085                      Disease
NAME        Diphyllobothriasis
DESCRIPTION Diphyllobothriasis is a parasitosis caused by the tapeworms of the genus Diphyllobothrium. It has been known as intestinal parasites of humans for a long time and has shown a reemergence in some countries such as Russia and Japan. The worm is acquired by eating raw or poorly cooked fish including salted or marinated fillets. Many infections with this parasite are reported to be asymptomatic.
CATEGORY    Infectious disease
PATHOGEN    Diphyllobothrium latum
            Diphyllobothrium nihonkaiens
            Diphyllobothrium dendriticum
            Diphyllobothrium ditremum
            Diphyllobothrium pacificum
MARKER      COX1 [KO:K02256]
            tRNAPro [KO:K14232]
            tRNAIle [KO:K14227]
            tRNALys [KO:K14229]
            NADH3 [KO:K03880]
            Cytochrome b [KO:K00412]
DRUG        Praziquantel [DR:D00471]
            Niclosamide [DR:D00436]
            Intraduodenal gastrographin
DBLINKS     ICD-10: B70.0
            MeSH: D004169
REFERENCE   PMID:19136438 (env_factor, drug, marker)
  AUTHORS   Scholz T, Garcia HH, Kuchta R, Wicht B
  TITLE     Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance.
  JOURNAL   Clin Microbiol Rev 22:146-60, Table of Contents (2009)
REFERENCE   PMID:12041607 (description)
  AUTHORS   Dick TA, Nelson PA, Choudhury A
  TITLE     Diphyllobothriasis: update on human cases, foci, patterns and sources of human infections and future considerations.
  JOURNAL   Southeast Asian J Trop Med Public Health 32 Suppl 2:59-76 (2001)
REFERENCE   PMID:15208471 (description)
  AUTHORS   Dupouy-Camet J, Peduzzi R
  TITLE     Current situation of human diphyllobothriasis in Europe.
  JOURNAL   Euro Surveill 9:31-5 (2004)
///
ENTRY       H01086                      Disease
NAME        Lymphatic filariasis
DESCRIPTION Lymphatic filariasis is a mosquito-borne parasitic nematode infection that is endemic in 81 countries worldwide with 1.2 billion people at risk and an estimated 120 million infected, especially in tropical regions. Wuchereria bancrofti accounts for 91% of the cases while Brugia malayi and B. timori (which has a distribution restricted to South and Southeast Asia) infections account for the other 9%. Disease pathogenesis is linked to host inflammation invoked by the death of the adult parasite, manifesting as recurrent debilitating fevers, hydrocoeles, lymphangitis and lymphadenitis, and elephantiasis.
CATEGORY    Infectious disease
PATHOGEN    Wuchereria bancrofti
            Brugia malayi [GN:bmy]
            Brugia timori
DRUG        Diethylcarbamazine [DG:DG01024]
            Ivermectin [DR:D00804]
            Albendazole [DG:DG01022]
COMMENT     Vectors: Mosquitos including Anopheles, Aedes, Culex, Mansonia, and Ochlerotatus
DBLINKS     ICD-10: B74.0 B74.1
            MeSH: D004605
REFERENCE   PMID:20739055 (description, env_factor, drug)
  AUTHORS   Taylor MJ, Hoerauf A, Bockarie M
  TITLE     Lymphatic filariasis and onchocerciasis.
  JOURNAL   Lancet 376:1175-85 (2010)
REFERENCE   PMID:21722251 (description, env_factor, drug)
  AUTHORS   Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S
  TITLE     Filariasis in Africa--treatment challenges and prospects.
  JOURNAL   Clin Microbiol Infect 17:977-85 (2011)
REFERENCE   PMID:18978537 (drug)
  AUTHORS   Hoerauf A
  TITLE     Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis.
  JOURNAL   Curr Opin Infect Dis 21:673-81 (2008)
REFERENCE   PMID:20847694 (drug)
  AUTHORS   Bockarie MJ, Deb RM
  TITLE     Elimination of lymphatic filariasis: do we have the drugs to complete the job?
  JOURNAL   Curr Opin Infect Dis 23:617-20 (2010)
REFERENCE   PMID:18798707 (comment)
  AUTHORS   Bockarie MJ, Pedersen EM, White GB, Michael E
  TITLE     Role of vector control in the global program to eliminate lymphatic filariasis.
  JOURNAL   Annu Rev Entomol 54:469-87 (2009)
///
ENTRY       H01087                      Disease
NAME        Balantidiasis;
            Balantidial dysentery
DESCRIPTION Balantidium coli is the only ciliated protozoon known to infect humans. B. coli is acquired by humans via the fecal-oral route from the natural reservoir, pigs. Humans may remain asymptomatic or may develop dysentery due to the ulcerations in the colon which can become secondarily infected by intestinal bacteria. Balantidiosis is mostly restricted to tropical/subtropical regions where people live in close proximity to their livestock.
CATEGORY    Infectious disease
PATHOGEN    Balantidium coli
DRUG        Metronidazole [DG:DG00006]
DBLINKS     ICD-10: A07.0
            MeSH: D001447
REFERENCE   PMID:18854484 (descrription, env_factor)
  AUTHORS   Schuster FL, Ramirez-Avila L
  TITLE     Current world status of Balantidium coli.
  JOURNAL   Clin Microbiol Rev 21:626-38 (2008)
REFERENCE   PMID:15567581 (descrition, env_factor)
  AUTHORS   Schuster FL, Visvesvara GS
  TITLE     Amebae and ciliated protozoa as causal agents of waterborne zoonotic disease.
  JOURNAL   Vet Parasitol 126:91-120 (2004)
REFERENCE   PMID:17402277 (description)
  AUTHORS   Karanis P, Kourenti C, Smith H
  TITLE     Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt.
  JOURNAL   J Water Health 5:1-38 (2007)
///
ENTRY       H01088                      Disease
NAME        Pigmented paravenous chorioretinal atrophy (PPCA)
DESCRIPTION Pigmented paravenous chorioretinal atrophy (PPCRA) is a rare retinal disorder characterized by the presence of bilaterally symmetrical chorioretinal atrophy, with accumulation of bone corpuscle pigmentation along the distribution of the retinal veins. PPCA is bilaterally symmetric, although unilateral cases have been reported. Most cases are sporadic and may represent an acquired response pattern to an infectious or inflammatory disease. There may be an autosomal dominant modes of inheritance caused by a mutation in the CRB1 gene or an X-linked inheritance mode.
CATEGORY    Eye disease
GENE        CRB1 [HSA:23418] [KO:K16681]
DBLINKS     MeSH: C566801
            OMIM: 172870
REFERENCE   PMID:21829406 (description, gene)
  AUTHORS   Hernandez-Da Mota SE, Chacon-Lara A
  TITLE     Bilateral pigmented paravenous chorioretinal atrophy: a case report.
  JOURNAL   Case Report Ophthalmol 2:228-31 (2011)
REFERENCE   PMID:15623792 (description, gene)
  AUTHORS   McKay GJ, Clarke S, Davis JA, Simpson DA, Silvestri G
  TITLE     Pigmented paravenous chorioretinal atrophy is associated with a mutation within the crumbs homolog 1 (CRB1) gene.
  JOURNAL   Invest Ophthalmol Vis Sci 46:322-8 (2005)
REFERENCE   PMID:11116690 (description)
  AUTHORS   Murray AT, Kirkby GR
  TITLE     Pigmented paravenous retinochoroidal atrophy: a literature review supported by a  unique case and insight.
  JOURNAL   Eye (Lond) 14 Pt 5:711-6 (2000)
///
ENTRY       H01089                      Disease
NAME        Dientamoebiasis
DESCRIPTION Dientamoeba fragilis is a trichomonad protozoan that belongs to the Parabasalia group. It is found worldwide in the gastrointestinal tract of humans and implicated as a cause of diarrhoea. The trophozoites of D. fragilis are typically binucleate, with only 30-40% uninucleate.
CATEGORY    Infectious disease
PATHOGEN    Dientamoeba fragilis
DRUG        Iodoquinol [DR:D00581]
            Doxycycline [DG:DG00008]
            Secnidazole [DR:D07353]
            Paramomycin
            Oxytetracycline [DG:DG00397]
            Tinidazole [DR:D01426] [ATC:P01AB02]
            Ornidazole [DR:D05274] [ATC:P01AB03]
            Erythromycin [DG:DG00436]
            Metronidazole [DG:DG00006]
DBLINKS     MeSH: D004030
REFERENCE   PMID:22154849 (description)
  AUTHORS   Banik GR, Birch D, Stark D, Ellis JT
  TITLE     A microscopic description and ultrastructural characterisation of Dientamoeba fragilis: An emerging cause of human enteric disease.
  JOURNAL   Int J Parasitol 42:139-53 (2012)
REFERENCE   PMID:16380293 (description, env_factor, drug)
  AUTHORS   Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J
  TITLE     Dientamoebiasis: clinical importance and recent advances.
  JOURNAL   Trends Parasitol 22:92-6 (2006)
REFERENCE   PMID:21637013 (description, env_factor, drug)
  AUTHORS   Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D
  TITLE     A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness.
  JOURNAL   Gut Microbes 2:3-12 (2011)
REFERENCE   PMID:15258093 (description, env_factor)
  AUTHORS   Johnson EH, Windsor JJ, Clark CG
  TITLE     Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis.
  JOURNAL   Clin Microbiol Rev 17:553-70, table of contents (2004)
///
ENTRY       H01090                      Disease
NAME        Ascariasis
DESCRIPTION Ascariasis is an commonly documented parasitic infection in sub-Saharan Africa, the Americas, China and east Asia, affecting approximately 1.2 billion people. The adult worm are normaly found in the jejunum. Clinical disease increases with worm burden and those who harbour light infections tend to be asymptomatic. Heavy worm load may cause mechanical intestinal obstruction due to entangled adult worms.
CATEGORY    Infectious disease
PATHOGEN    Ascaris lumbricoides
DRUG        Pyrantel [DG:DG01025]
            Mebendazole [DR:D00368]
            Albendazole [DG:DG01022]
            Piperazine [DG:DG01023]
            Levamisole [DG:DG01026]
DBLINKS     ICD-10: B77
            MeSH: D001196
REFERENCE   PMID:20934531 (description, env_factor)
  AUTHORS   Dold C, Holland CV
  TITLE     Ascaris and ascariasis.
  JOURNAL   Microbes Infect 13:632-7 (2011)
REFERENCE   PMID:8863040 (description, drug)
  AUTHORS   Khuroo MS
  TITLE     Ascariasis.
  JOURNAL   Gastroenterol Clin North Am 25:553-77 (1996)
REFERENCE   PMID:6377443 (description)
  AUTHORS   Arfaa F
  TITLE     Selective primary health care: strategies for control of disease in the developing world. XII. Ascariasis and trichuriasis.
  JOURNAL   Rev Infect Dis 6:364-73 (1984)
///
ENTRY       H01091                      Disease
NAME        Enterobiasis;
            Oxyuriasis
DESCRIPTION Enterobiasis is one of the most widedspread parasitic nematode infections caused by Enterobius vermicularis that commonly referred as pinworm. About 209 million persons worldwide are affected. The adult worms live in the large intestine, from which the female migrates at night to lay eggs on the perineum, causing perineal, perianal, and vaginal irritation. Serious disease can rarely result, including urinary tract infection, and acute appendicitis.
CATEGORY    Infectious disease
PATHOGEN    Enterobius vermicularis
MARKER      Cellophane tape test
DRUG        Mebendazole [DR:D00368]
DBLINKS     ICD-10: B80
            MeSH: D017229
REFERENCE   PMID:15023017 (description, env_factor, drug)
  AUTHORS   Kucik CJ, Martin GL, Sortor BV
  TITLE     Common intestinal parasites.
  JOURNAL   Am Fam Physician 69:1161-8 (2004)
REFERENCE   PMID:15301168 (description)
  AUTHORS   Heard S
  TITLE     Pruritus ani.
  JOURNAL   Aust Fam Physician 33:511-3 (2004)
REFERENCE   PMID:11336585 (drug)
  AUTHORS   St Georgiev V
  TITLE     Chemotherapy of enterobiasis (oxyuriasis).
  JOURNAL   Expert Opin Pharmacother 2:267-75 (2001)
REFERENCE   PMID:14618981 (description)
  AUTHORS   Blake J
  TITLE     An action plan to prevent and combat threadworm infection.
  JOURNAL   Nurs Times 99:18-9 (2003)
///
ENTRY       H01092                      Disease
NAME        Human hookworm infections, including:
            Ancylostomiasis;
            Necatoriasis
DESCRIPTION The majority of human hookworm infections are caused by Ancylostoma duodenale or Necator americanus. These worms attach to the intestinal mucosa and live for 1-5 years, sucking host blood. The major clinical features of chronic hookworm infection are iron-deficiency anemia and malnutrition, which are associated with varying degrees of cognitive and growth delay in children.
CATEGORY    Infectious disease
PATHOGEN    Ancylostoma duodenale
            Necator americanus
DRUG        Albendazole [DG:DG01022]
            Mebendazole [DR:D00368]
DBLINKS     ICD-10: B76.0 B76.1
            MeSH: D006725
REFERENCE   PMID:15353961 (description, env_factor, drug)
  AUTHORS   Bungiro R, Cappello M
  TITLE     Hookworm infection: new developments and prospects for control.
  JOURNAL   Curr Opin Infect Dis 17:421-6 (2004)
REFERENCE   PMID:15771680 (description, env_factor)
  AUTHORS   Quinnell RJ, Bethony J, Pritchard DI
  TITLE     The immunoepidemiology of human hookworm infection.
  JOURNAL   Parasite Immunol 26:443-54 (2004)
REFERENCE   PMID:9616967 (description, env_factor)
  AUTHORS   Albonico M, Savioli L
  TITLE     Hookworm infection and disease: advances for control.
  JOURNAL   Ann Ist Super Sanita 33:567-79 (1997)
///
ENTRY       H01093                      Disease
NAME        Paragonimiasis;
            Pulmonary distomatosis;
            Lung fluke disease;
            Benign endemic hemoptysis
DESCRIPTION Paragonimiasis (also known as lung fluke infection) is a food-borne parasitic disease caused by infection with trematodes belonging to the genus Paragonimus. Human infections occur by consuming freshwater crustaceans (second intermediate host) or wild boar meat (paratenic host). Paragonimiasis is generically insidious in its onset and mildly chronic in its course. The symptoms are characteristically referable to the chest, abdomen, lymph nodes or brain. The diagnostic signs include cough, blood-tinged sputum and, less frequently, hemoptysis, distressing chest pain and dyspnea. The drugs of choice for treatment of paragonimiasis are praziquantel and bithionol.
CATEGORY    Infectious disease
PATHOGEN    Paragonimus westermani
            Paragonimus kellicotti
            Paragonimus miyazakii
            Paragonimus skrjabini
            Paragonimus heterotremus
            Paragonimus hueitungensis
            Paragonimus uterobilateralis
            Paragonimus africanus
            Paragonimus mexicanus
MARKER      Antibody detection
            ITS2 (PCR detection)
            Mitochondrial cytochrome c oxidase (PCR detection) [KO:K02256]
DRUG        Praziquantel [DR:D00471]
            Bithionol [DR:D00802]
COMMENT     Intermediate host: Crustacean species
            See also H01617 Foodborne trematodiasis.
DBLINKS     ICD-10: B66.4
            MeSH: D010237
REFERENCE   PMID:19623916 (description, env_factor, drug)
  AUTHORS   Aka NA, Adoubryn K, Rondelaud D, Dreyfuss G
  TITLE     Human paragonimiasis in Africa.
  JOURNAL   Ann Afr Med 7:153-62 (2008)
REFERENCE   PMID:19597007 (description, env_factor, marker)
  AUTHORS   Procop GW
  TITLE     North American paragonimiasis (Caused by Paragonimus kellicotti) in the context of global paragonimiasis.
  JOURNAL   Clin Microbiol Rev 22:415-46 (2009)
REFERENCE   PMID:12590662 (marker)
  AUTHORS   Iwagami M, Monroy C, Rosas MA, Pinto MR, Guevara AG, Vieira JC, Agatsuma Y, Agatsuma T
  TITLE     A molecular phylogeographic study based on DNA sequences from individual metacercariae of Paragonimus mexicanus from Guatemala and Ecuador.
  JOURNAL   J Helminthol 77:33-8 (2003)
REFERENCE   PMID:25743009 (description)
  AUTHORS   Nagayasu E, Yoshida A, Hombu A, Horii Y, Maruyama H
  TITLE     Paragonimiasis in Japan: a twelve-year retrospective case review (2001-2012).
  JOURNAL   Intern Med 54:179-86 (2015)
REFERENCE   PMID:18514575 (description)
  AUTHORS   Liu Q, Wei F, Liu W, Yang S, Zhang X
  TITLE     Paragonimiasis: an important food-borne zoonosis in China.
  JOURNAL   Trends Parasitol 24:318-23 (2008)
REFERENCE   PMID:1822923 (drug)
  AUTHORS   Xu ZB
  TITLE     Studies on clinical manifestations, diagnosis and control of paragonimiasis in China.
  JOURNAL   Southeast Asian J Trop Med Public Health 22 Suppl:345-8 (1991)
///
ENTRY       H01094                      Disease
NAME        Eosinophil peroxidase deficiency
DESCRIPTION Eosinophil peroxidase deficiency is a rare autosomal recessive abnormality of eosinophil granulocytes characterized by decreased or absent peroxidase activity and decreased volume of the granule matrix. Eosinophils are a hallmark of allergic diseases and helminth infection.
CATEGORY    Inherited metabolic disease; Immune system disease
GENE        EPX [HSA:8288] [KO:K10788]
DBLINKS     MeSH: C564893
            OMIM: 261500
REFERENCE   PMID:7809065
  AUTHORS   Romano M, Patriarca P, Melo C, Baralle FE, Dri P
  TITLE     Hereditary eosinophil peroxidase deficiency: immunochemical and spectroscopic studies and evidence for a compound heterozygosity of the defect.
  JOURNAL   Proc Natl Acad Sci U S A 91:12496-500 (1994)
REFERENCE   PMID:16926417
  AUTHORS   Specht S, Saeftel M, Arndt M, Endl E, Dubben B, Lee NA, Lee JJ, Hoerauf A
  TITLE     Lack of eosinophil peroxidase or major basic protein impairs defense against murine filarial infection.
  JOURNAL   Infect Immun 74:5236-43 (2006)
REFERENCE   PMID:15100311
  AUTHORS   Forbes E, Murase T, Yang M, Matthaei KI, Lee JJ, Lee NA, Foster PS, Hogan SP
  TITLE     Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase.
  JOURNAL   J Immunol 172:5664-75 (2004)
///
ENTRY       H01095                      Disease
NAME        Syndactyly
DESCRIPTION Syndactyly is the common hereditary limb malformations depicting the fusion of certain fingers and/or toes. At least nine non-syndromic syndactylies with additional sub-types have been characterized. Most of the syndactyly types are inherited as autosomal dominant but two autosomal recessive and an X-linked recessive entity have also been described.
CATEGORY    Developmental disorder
GENE        GJA1 [HSA:2697] [KO:K07372]
            LMBR1 [HSA:64327]
            HOXD13 [HSA:3239] [KO:K09298]
COMMENT     Cenani-Lenz syndactyly syndrome is described in H00853. [DS:H00853]
DBLINKS     ICD-10: Q70
            MeSH: D013576
            OMIM: 186100 186200 186300
REFERENCE   PMID:22333904
  AUTHORS   Malik S
  TITLE     Syndactyly: phenotypes, genetics and current classification.
  JOURNAL   Eur J Hum Genet 20:817-24 (2012)
REFERENCE   PMID:15039974
  AUTHORS   Malik S, Arshad M, Amin-Ud-Din M, Oeffner F, Dempfle A, Haque S, Koch MC, Ahmad W, Grzeschik KH
  TITLE     A novel type of autosomal recessive syndactyly: clinical and molecular studies in a family of Pakistani origin.
  JOURNAL   Am J Med Genet A 126A:61-7 (2004)
///
ENTRY       H01096                      Disease
NAME        Pyruvate kinase (PK) deficiency, including:
            Red cell pyruvate kinase (PK) deficiency;
            Pyruvate kinase hyperactivity
DESCRIPTION Pyruvate kinase (PK) deficiency is inherited metabolic disorder caused by mutations in PKLR that encodes both L-PK (expressed in liver, renal cortex, and small intestine) and R-PK (restricted to erythrocytes). The symptoms include jaundice, enlargement of the spleen, and hemolysis, leading to anemia. One hundred fifty-eight mutations associated with non-spherocytic haemolytic anaemia and eight polymorphic sites have been so far reported in the PKLR gene. It has also been found that a specific mutation in the PKLR gene causes hereditary increase of red blood cell ATP.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        PKLR [HSA:5313] [KO:K12406]
DBLINKS     ICD-10: D55.2
            OMIM: 266200 102900
REFERENCE   PMID:17550841
  AUTHORS   Zanella A, Bianchi P, Fermo E
  TITLE     Pyruvate kinase deficiency.
  JOURNAL   Haematologica 92:721-3 (2007)
REFERENCE   PMID:15982340
  AUTHORS   Zanella A, Fermo E, Bianchi P, Valentini G
  TITLE     Red cell pyruvate kinase deficiency: molecular and clinical aspects.
  JOURNAL   Br J Haematol 130:11-25 (2005)
REFERENCE   PMID:9090535
  AUTHORS   Beutler E, Westwood B, van Zwieten R, Roos D
  TITLE     G--&gt;T transition at cDNA nt 110 (K37Q) in the PKLR (pyruvate kinase) gene is the  molecular basis of a case of hereditary increase of red blood cell ATP.
  JOURNAL   Hum Mutat 9:282-5 (1997)
///
ENTRY       H01097                      Disease
NAME        Cerebral palsy
DESCRIPTION Cerebral palsy is a heterogeneous group of neurodevelopmental brain disorders resulting in motor and posture impairments often associated with cognitive, sensorial, and behavioural disturbances. It is thought that a half of idiopathic cerebral palsy cases are caused by genetic factors, such as mutations in GAD1, KANK1, and four subunits of the adaptor protein complex-4 (AP-4).
CATEGORY    Nervous system disease
GENE        GAD1 [HSA:2571] [KO:K01580]
            KANK1 [HSA:23189]
            AP4E1 [HSA:9179] [KO:K12402]
            AP4M1 [HSA:23431] [KO:K12400]
            AP4B1 [HSA:10717] [KO:K12401]
            AP4S1 [HSA:11154] [KO:K12403]
DBLINKS     ICD-10: G80.9
            MeSH: D002547
            OMIM: 603513 612900 612936 613744 614066 614067
REFERENCE   PMID:15571623
  AUTHORS   Lynex CN, Carr IM, Leek JP, Achuthan R, Mitchell S, Maher ER, Woods CG, Bonthon DT, Markham AF
  TITLE     Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders.
  JOURNAL   BMC Neurol 4:20 (2004)
REFERENCE   PMID:16301218
  AUTHORS   Lerer I, Sagi M, Meiner V, Cohen T, Zlotogora J, Abeliovich D
  TITLE     Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy.
  JOURNAL   Hum Mol Genet 14:3911-20 (2005)
REFERENCE   PMID:20972249
  AUTHORS   Moreno-De-Luca A, Helmers SL, Mao H, Burns TG, Melton AM, Schmidt KR, Fernhoff PM, Ledbetter DH, Martin CL
  TITLE     Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability.
  JOURNAL   J Med Genet 48:141-4 (2011)
///
ENTRY       H01098                      Disease
NAME        Pentastomiasis
DESCRIPTION Pentastomiasis is an unusual parasitic zoonosis caused by the larval stages of pentastomes (tongue worms). Its definitive hosts are reptiles whilst humans serve as rare intermediate hosts. In humans, the larva penetrates the gut wall and lodges in various internal organs. Infection is usually asymptomatic. In asymptomatic patients, no treatment is necessary.
CATEGORY    Infectious disease
PATHOGEN    Armillifer armillatus
            Armillifer grandis
            Armillifer moniliformis
            Armillifer agkistrodontis
            Porocephalus crotali
            Linguatula serrata
MARKER      Histopathological examinations
DRUG        There is no antiparasitic chemotherapy available for pentastomiasis.
DBLINKS     ICD-10: B88.8
REFERENCE   PMID:22191176 (description, env_factor)
  AUTHORS   Pantchev N, Tappe D
  TITLE     Pentastomiasis and other parasitic zoonoses from reptiles and amphibians.
  JOURNAL   Berl Munch Tierarztl Wochenschr 124:528-35 (2011)
REFERENCE   PMID:3321358 (description, env_factor)
  AUTHORS   Drabick JJ
  TITLE     Pentastomiasis.
  JOURNAL   Rev Infect Dis 9:1087-94 (1987)
REFERENCE   PMID:18576869 (description)
  AUTHORS   Yao MH, Wu F, Tang LF
  TITLE     Human pentastomiasis in China: case report and literature review.
  JOURNAL   J Parasitol 94:1295-8 (2008)
REFERENCE   PMID:19238218 (description, env_factor)
  AUTHORS   Tappe D, Buttner DW
  TITLE     Diagnosis of human visceral pentastomiasis.
  JOURNAL   PLoS Negl Trop Dis 3:e320 (2009)
///
ENTRY       H01099                      Disease
NAME        Trichinosis;
            Trichinellosis
DESCRIPTION Trichinellosis or trichinosis is a widely distributed foodborne disease caused by the parasitic nematode Trichinella. It accounts for up to 10 000 human infections annually in temperate, tropical, and arctic regions, with a mortality rate of 0.2%. Severely affected patients may present with renal, neurological, and cardiovascular complaints.
CATEGORY    Infectious disease
PATHOGEN    Trichinella spiralis  [GN:tsp]
DBLINKS     ICD-10: B75
            MeSH: D014235
REFERENCE   PMID:20491611 (description)
  AUTHORS   Neghina R
  TITLE     Trichinellosis, a Romanian never-ending story. An overview of traditions, culinary customs, and public health conditions.
  JOURNAL   Foodborne Pathog Dis 7:999-1003 (2010)
REFERENCE   PMID:21034231 (description)
  AUTHORS   Neghina R, Neghina AM, Marincu I, Iacobiciu I
  TITLE     Reviews on trichinellosis (I): renal involvement.
  JOURNAL   Foodborne Pathog Dis 8:179-88 (2011)
REFERENCE   PMID:21186993 (description)
  AUTHORS   Neghina R, Neghina AM, Marincu I, Iacobiciu I
  TITLE     Reviews on trichinellosis (II): neurological involvement.
  JOURNAL   Foodborne Pathog Dis 8:579-85 (2011)
REFERENCE   PMID:21438766 (description)
  AUTHORS   Neghina R, Neghina AM, Marincu I
  TITLE     Reviews on trichinellosis (III): cardiovascular involvement.
  JOURNAL   Foodborne Pathog Dis 8:853-60 (2011)
REFERENCE   PMID:21524198 (description)
  AUTHORS   Neghina R, Neghina AM
  TITLE     Reviews on trichinellosis (IV): hepatic involvement.
  JOURNAL   Foodborne Pathog Dis 8:943-8 (2011)
REFERENCE   PMID:22421602 (description)
  AUTHORS   Bruschi F
  TITLE     Trichinellosis in developing countries: is it neglected?
  JOURNAL   J Infect Dev Ctries 6:216-22 (2012)
REFERENCE   PMID:17689195 (description)
  AUTHORS   Pozio E
  TITLE     World distribution of Trichinella spp. infections in animals and humans.
  JOURNAL   Vet Parasitol 149:3-21 (2007)
REFERENCE   PMID:12416233 (description)
  AUTHORS   Geerts S, de Borchgrave J, Dorny P, Brandt J
  TITLE     Trichinellosis: old facts and new developments.
  JOURNAL   Verh K Acad Geneeskd Belg 64:233-48; discussion 249-50 (2002)
REFERENCE   PMID:17432237 (description)
  AUTHORS   Dupouy-Camet J
  TITLE     New challenges in trichinellosis control.
  JOURNAL   Wiad Parazytol 52:155-6 (2006)
///
ENTRY       H01100                      Disease
NAME        Strongyloidiasis
DESCRIPTION Strongyloidiasis is an intestinal parasite infection caused by soil-transmitted helminths of the genus Strongyloides. The disease infects 30 million people in 70 countries especially in tropical and subtropical regions. Strongyloides stercoralis has a complex life cycle. In humans, larvae reach the host's duodenum or jejunum and develop there into adult worms. Only females are found in the host where they are embedded in the duodenum and jejunum mucosa, producing eggs. These hatch, develop into infective larvae and penetrate the intestinal mucosa or perianal skin. Infection usually results in asymptomatic chronic disease of the gut, but in patients receiving long-term corticosteroid therapy, hyperinfection can occur with dissemination of larvae to multiple organs including the brain. The mortality rate of disseminated infections has been estimated to be as high as 87%.
CATEGORY    Infectious disease
PATHOGEN    Strongyloides stercoralis
            Strongyloides fuelleborni
            Human T-lymphotropic virus 1 [GN:T40003]
            Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
MARKER      Strongyloides antibody (ELISA test)
DRUG        Albendazole [DG:DG01022]
            Thiabendazole [DR:D00372]
            Ivermectin [DR:D00804]
DBLINKS     ICD-10: B78
            MeSH: D013322
REFERENCE   PMID:19328508 (description, env_factor, drug)
  AUTHORS   Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, Stothard R, Thybo S, Verweij JJ, Magnussen P
  TITLE     Strongyloidiasis--the most neglected of the neglected tropical diseases?
  JOURNAL   Trans R Soc Trop Med Hyg 103:967-72 (2009)
REFERENCE   PMID:17940124 (description, env_factor)
  AUTHORS   Segarra-Newnham M
  TITLE     Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection.
  JOURNAL   Ann Pharmacother 41:1992-2001 (2007)
REFERENCE   PMID:11528578 (marker)
  AUTHORS   Siddiqui AA, Berk SL
  TITLE     Diagnosis of Strongyloides stercoralis infection.
  JOURNAL   Clin Infect Dis 33:1040-7 (2001)
REFERENCE   PMID:15500376 (decription, env_factor, drug)
  AUTHORS   Satoh M, Kokaze A
  TITLE     Treatment strategies in controlling strongyloidiasis.
  JOURNAL   Expert Opin Pharmacother 5:2293-301 (2004)
///
ENTRY       H01101                      Disease
NAME        Combined lipase deficiency (CLD)
DESCRIPTION Combined lipase deficiency (CLD) is characterized by very severe hypertriglyceridemia, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly. CLD is caused by mutations in lipase maturation factor 1 (LMF1). LMF1 is a chaperone of the endoplasmic reticulum and it is required for the post-translational activation of three vascular lipases, lipoprotein lipase, hepatic lipase and endothelial lipase.
CATEGORY    Inherited metabolic disease
GENE        LMF1 [HSA:64788]
DBLINKS     ICD-10: E78.9
            MeSH: C535904
            OMIM: 246650
REFERENCE   PMID:17994020
  AUTHORS   Peterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P, Doolittle MH
  TITLE     Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia.
  JOURNAL   Nat Genet 39:1483-7 (2007)
REFERENCE   PMID:22063272
  AUTHORS   Peterfy M
  TITLE     Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism.
  JOURNAL   Biochim Biophys Acta 1821:790-4 (2012)
///
ENTRY       H01102                      Disease
NAME        Pituitary adenomas, including:
            Multiple endocrine neoplasia type 1 (MEN1);
            MEN1-like syndrome (MEN4);
            Carney complex (CNC);
            Familial isolated pituitary adenomas (FIPA)
DESCRIPTION Pituitary adenomas are an important and frequently occurring form of intracranial tumour. They are usually benign but can give rise to severe clinical syndromes due to hormonal excess, or to visual/cranial disturbances due to mass effect. The tumour can be clinically nonfunctioning or hormone secreting. Among the latter, prolactin (PRL) and growth hormone (GH)-secreting adenomas are the most common. The majority of pituitary adenomas arise sporadically, although a subset occurs as component tumors of well-characterized familial cancer syndromes, such as multiple endocrine neoplasia type 1 (MEN1), Carney complex, and MEN1-like syndrome (MEN4). It has been described non-MEN/CNC familial pituitary tumours that include all tumour phenotypes as a condition named familial isolated pituitary adenomas (FIPA).
CATEGORY    Nervous system disease; Endocrine disease; Cancer
GENE        (MEN1) MEN1 [HSA:4221] [KO:K14970]
            (MEN4) CDKN1B [HSA:1027] [KO:K06624]
            (CNC) PRKAR1A [HSA:5573] [KO:K04739]
            (FIPA) AIP [HSA:9049] [KO:K17767]
DBLINKS     ICD-10: D44.8
            MeSH: D010911
            OMIM: 172870 610755 160980 219090 102200 600634
REFERENCE   PMID:21454441 (description, gene)
  AUTHORS   Trivellin G, Korbonits M
  TITLE     AIP and its interacting partners.
  JOURNAL   J Endocrinol 210:137-55 (2011)
REFERENCE   PMID:20956458 (description, gene)
  AUTHORS   Heliovaara E, Tuupanen S, Ahlsten M, Hodgson S, de Menis E, Kuismin O, Izatt L, McKinlay Gardner RJ, Gundogdu S, Lucassen A, Arola J, Tuomisto A, Makinen M, Karhu A, Aaltonen LA
  TITLE     No evidence of RET germline mutations in familial pituitary adenoma.
  JOURNAL   J Mol Endocrinol 46:1-8 (2011)
REFERENCE   PMID:19522822 (description, gene)
  AUTHORS   Tichomirowa MA, Daly AF, Beckers A
  TITLE     Familial pituitary adenomas.
  JOURNAL   J Intern Med 266:5-18 (2009)
///
ENTRY       H01103                      Disease
NAME        Alpha-1-antitrypsin (A1AT) deficiency
DESCRIPTION Alpha-1-antitrypsin (A1AT) deficiency is a genetic disorder characterized by low plasma levels of A1AT. The condition is associated with emphysematous lung disease and also with liver disease. A1AT is the archetype of the serine protease inhibitor. Mutations in the A1AT gene lead to misfolding of the protein and accumulation within the endoplasmic reticulum of hepatocytes. The accumulation of mutant A1AT protein has a directly toxic effect on the liver, resulting in hepatitis and cirrhosis. And the decrease in circulating A1AT results in protease-antiprotease imbalance at the lung surface and emphysema ensues.
CATEGORY    Inherited metabolic disease; Lung disease; Liver disease
GENE        SERPINA1 [HSA:5265] [KO:K03984]
ENV_FACTOR  Cigarette smoke
DRUG        Sodium phenylbutyrate [DR:D05868]
DBLINKS     ICD-10: J43.9
            OMIM: 613490
REFERENCE   PMID:18193338
  AUTHORS   Greene CM, Miller SD, Carroll T, McLean C, O'Mahony M, Lawless MW, O'Neill SJ, Taggart CC, McElvaney NG
  TITLE     Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations.
  JOURNAL   J Inherit Metab Dis 31:21-34 (2008)
REFERENCE   PMID:17562108
  AUTHORS   Mulgrew AT, Taggart CC, McElvaney NG
  TITLE     Alpha-1-antitrypsin deficiency: current concepts.
  JOURNAL   Lung 185:191-201 (2007)
REFERENCE   PMID:15187777
  AUTHORS   Teckman JH
  TITLE     Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients  with alpha-1-antitrypsin deficiency: a preliminary study.
  JOURNAL   J Pediatr Gastroenterol Nutr 39:34-7 (2004)
REFERENCE   PMID:22245800
  AUTHORS   Lockett AD, Van Demark M, Gu Y, Schweitzer KS, Sigua N, Kamocki K, Fijalkowska I, Garrison J, Fisher AJ, Serban K, Wise RA, Flotte TR, Mueller C, Presson RG Jr, Petrache HI, Tuder RM, Petrache I
  TITLE     Effect of cigarette smoke exposure and structural modifications on the alpha-1 Antitrypsin interaction with caspases.
  JOURNAL   Mol Med 18:445-54 (2012)
///
ENTRY       H01104                      Disease
NAME        Loiasis
DESCRIPTION Loiasis is an infection with Loa loa, a filarial parasite found in central Africa. The adult worms migrate freely through the subcutaneous tissues and sometimes can be observed moving through the sclera of the eye. Loiasis is often asymptomatic, but when a person has both onchocerciasis and loiasis, administration of ivermectin can cause serious neurological complications.
CATEGORY    Infectious disease
PATHOGEN    Loa loa  [GN:loa]
DRUG        Diethylcarbamazine [DG:DG01024]
            Ivermectin [DR:D00804]
COMMENT     Vector: Mango flies (Chrysops dimidiata, C. silacea, and C. langi)
DBLINKS     ICD-10: B74.3
            MeSH: D008118
REFERENCE   PMID:21722251 (description, env_factor, drug)
  AUTHORS   Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S
  TITLE     Filariasis in Africa--treatment challenges and prospects.
  JOURNAL   Clin Microbiol Infect 17:977-85 (2011)
REFERENCE   PMID:20847694 (description)
  AUTHORS   Bockarie MJ, Deb RM
  TITLE     Elimination of lymphatic filariasis: do we have the drugs to complete the job?
  JOURNAL   Curr Opin Infect Dis 23:617-20 (2010)
REFERENCE   PMID:18466939 (description, drug, comment)
  AUTHORS   Padgett JJ, Jacobsen KH
  TITLE     Loiasis: African eye worm.
  JOURNAL   Trans R Soc Trop Med Hyg 102:983-9 (2008)
REFERENCE   PMID:17227650 (description)
  AUTHORS   Boussinesq M
  TITLE     Loiasis.
  JOURNAL   Ann Trop Med Parasitol 100:715-31 (2006)
///
ENTRY       H01105                      Disease
NAME        Cranio-lenticulo-sutural dysplasia (CLSD);
            Boyadjiev-Jabs syndrome
DESCRIPTION Cranio-lenticulo-sutural dysplasia (CLSD) is a rare autosomal recessive syndrome characterized by late-closing fontanels, sutural cataracts, facial dysmorphisms, and skeletal defects. CLSD is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking.
CATEGORY    Developmental disorder
GENE        SEC23A [HSA:10484] [KO:K14006]
DBLINKS     MeSH: C564332
            OMIM: 607812
REFERENCE   PMID:21039434
  AUTHORS   Boyadjiev SA, Kim SD, Hata A, Haldeman-Englert C, Zackai EH, Naydenov C, Hamamoto S, Schekman RW, Kim J
  TITLE     Cranio-lenticulo-sutural dysplasia associated with defects in collagen secretion.
  JOURNAL   Clin Genet 80:169-76 (2011)
REFERENCE   PMID:16980979
  AUTHORS   Boyadjiev SA, Fromme JC, Ben J, Chong SS, Nauta C, Hur DJ, Zhang G, Hamamoto S, Schekman R, Ravazzola M, Orci L, Eyaid W
  TITLE     Cranio-lenticulo-sutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking.
  JOURNAL   Nat Genet 38:1192-7 (2006)
///
ENTRY       H01106                      Disease
NAME        Plasminogen activator inhibitor type 1 (PAI-1) deficiency
DESCRIPTION Plasminogen activator inhibitor type 1 (PAI-1) deficiency is a disorder resulting in increased fibrinolysis and an associated bleeding diathesis. PAI-1 is an important component of the coagulation system that down-regulates fibrinolysis in the circulation. Affected individuals exhibit mild to moderate bleeding symptoms, including epistaxis, menorrhagia, and delayed bleeding after trauma or surgical procedures. Spontaneous bleeding events are rarely seen in contrast to other procoagulant deficiencies. Generally most of the PAI-1-related diseases are due to elevated antigenic concentrations and their inhibitory activity. However, absence of cellular PAI-1 activity also causes several diseases. Clear documentation of PAI-1 deficiency as a cause of a bleeding disorder has been rare.
CATEGORY    Hematologic disease
GENE        PAI1 [HSA:5054] [KO:K03982]
DRUG        Tranexamic acid [DR:D01136]
            Epsilon-Aminocaproic acid [DR:D00160]
DBLINKS     ICD-10: D68.8
            OMIM: 613329
REFERENCE   PMID:19141166 (description, gene, drug)
  AUTHORS   Mehta R, Shapiro AD
  TITLE     Plasminogen activator inhibitor type 1 deficiency.
  JOURNAL   Haemophilia 14:1255-60 (2008)
REFERENCE   PMID:21465481 (description, gene)
  AUTHORS   Ghosh AK, Vaughan DE
  TITLE     PAI-1 in tissue fibrosis.
  JOURNAL   J Cell Physiol 227:493-507 (2012)
///
ENTRY       H01107                      Disease
NAME        Intestinal fluke infections, including:
            Fasciolopsiasis;
            Echinostomiasis;
            Heterophyiasis;
            Metagonimiasis
DESCRIPTION Intestinal fluke infections are intestinal, food-borne parasitic zoonoses that are endemic to the Far East and Southeast Asia. Morbidity due to these diseases in endemic areas is high. Clinical disease depends on worm burden. Light infections are often characterized by mild symptoms such as diarrhea, constipation, dizziness, and headache. Heavy infections cause severe abdominal pain, diarrhea, vomiting, fever, nausea, and allergic reactions, and even death.
CATEGORY    Infectious disease
PATHOGEN    Fasciolopsis buski
            Echinostoma hortense
            Heterophyidae heterophyes
            Metagonimus yokogawai
DRUG        Niclosamide [DR:D00436]
            Praziquantel [DR:D00471]
COMMENT     Intermediate host of Fasciolopsis buski: Pulmonate planorbid snails
DBLINKS     ICD-10: B66.5
REFERENCE   PMID:11199855 (description, env_factor, drug)
  AUTHORS   Graczyk TK, Gilman RH, Fried B
  TITLE     Fasciolopsiasis: is it a controllable food-borne disease?
  JOURNAL   Parasitol Res 87:80-3 (2001)
REFERENCE   PMID:19885337 (description)
  AUTHORS   Chai JY, Shin EH, Lee SH, Rim HJ
  TITLE     Foodborne intestinal flukes in Southeast Asia.
  JOURNAL   Korean J Parasitol 47 Suppl:S69-102 (2009)
REFERENCE   PMID:19597009 (env_factor)
  AUTHORS   Keiser J, Utzinger J
  TITLE     Food-borne trematodiases.
  JOURNAL   Clin Microbiol Rev 22:466-83 (2009)
///
ENTRY       H01108                      Disease
NAME        CD36 deficiency;
            Platelet glycoprotein IV deficiency
DESCRIPTION Human genetic platelet glycoprotein IV (CD36) deficiency may be related to the phenotypic expression of the metabolic syndrome and is frequently associated with atherosclerotic cardiovascular diseases. CD36 deficiency is relatively frequent in Asian and African populations. It also has been reported that CD36 deficiency might be linked with cardiomyopathy. This deficiency can be classified in two subgroups: the type I phenotype is characterized by platelets and monocytes/macrophages that exhibit CD36 deficiency; whereas in the type II phenotype, the surface expression of CD36 is lacking only in platelets, but expression is near normal in monocytes/macrophages.
CATEGORY    Inherited metabolic disease
GENE        CD36 [HSA:948] [KO:K06259]
DBLINKS     MeSH: C564245
            OMIM: 608404
REFERENCE   PMID:12732446 (description, gene)
  AUTHORS   Hirano K, Kuwasako T, Nakagawa-Toyama Y, Janabi M, Yamashita S, Matsuzawa Y
  TITLE     Pathophysiology of human genetic CD36 deficiency.
  JOURNAL   Trends Cardiovasc Med 13:136-41 (2003)
///
ENTRY       H01109                      Disease
NAME        Chronic mucocutaneous candidiasis (CMC);
            Familial candidiasis (CANDF)
DESCRIPTION Chronic mucocutaneous candidiasis (CMC) is manifested as a primary immunodeficiency characterized by persistent or recurrent infections of the mucosa or the skin with candida species. Most cases are sporadic, but both autosomal dominant inheritance and autosomal recessive inheritance have been described. It has been reported that CMC is caused by mutations in components of a signaling pathway involving the cytokine interleukin-17.
CATEGORY    Immune system disease
GENE        (CANDF2) CARD9 [HSA:64170] [KO:K12794]
            (CANDF4) CLEC7A [HSA:64581] [KO:K10074]
            (CANDF5) IL17RA [HSA:23765] [KO:K05164]
            (CANDF6) IL17F [HSA:112744] [KO:K05494]
            (CANDF7) STAT1 [HSA:6772] [KO:K11220]
DBLINKS     ICD-10: B37.2
            MeSH: D002178
            OMIM: 212050 613108 613953 613956 614162
REFERENCE   PMID:19864672
  AUTHORS   Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, Pfeifer D, Veelken H, Warnatz K, Tahami F, Jamal S, Manguiat A, Rezaei N, Amirzargar AA, Plebani A, Hannesschlager N, Gross O, Ruland J, Grimbacher B
  TITLE     A homozygous CARD9 mutation in a family with susceptibility to fungal infections.
  JOURNAL   N Engl J Med 361:1727-35 (2009)
REFERENCE   PMID:21350122
  AUTHORS   Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL
  TITLE     Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17  immunity.
  JOURNAL   Science 332:65-8 (2011)
REFERENCE   PMID:21727188
  AUTHORS   Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B, Flatot J, Migaud M, Chrabieh M, Kochetkov T, Bolze A, Borghesi A, Toulon A, Hiller J, Eyerich S, Eyerich K, Gulacsy V, Chernyshova L, Chernyshov V, Bondarenko A, Maria Cortes Grimaldo R, Blancas-Galicia L, Madrigal Beas IM, Roesler J, Magdorf K, Engelhard D, Thumerelle C, Burgel PR, Hoernes M, Drexel B, Seger R, Kusuma T, Jansson AF, Sawalle-Belohradsky J, Belohradsky B, Jouanguy E, Bustamante J, Bue M, Karin N, Wildbaum G, Bodemer C, Lortholary O, Fischer A, Blanche S, Al-Muhsen S, Reichenbach J, Kobayashi M, Rosales FE, Lozano CT, Kilic SS, Oleastro M, Etzioni A, Traidl-Hoffmann C, Renner ED, Abel L, Picard C, Marodi L, Boisson-Dupuis S, Puel A, Casanova JL
  TITLE     Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
  JOURNAL   J Exp Med 208:1635-48 (2011)
///
ENTRY       H01110                      Disease
NAME        Pneumothorax
DESCRIPTION Pneumothorax is defined as air or gas accumulated in the pleural space and can be classified as spontaneous or traumatic. Traumatic pneumothorax includes iatrogenic cases caused during procedures such as pacemaker insertion. Spontaneous pneumothorax can be subclassified as primary or secondary. Primary spontaneous pneumothorax (PSP), which is defined as a pneumothorax without underlying lung disease, predominantly occurs in young, thin males. It is usually caused by ruptured pleural blebs or bullae. Approximately 10% of patients with PSP have a positive family history. Gene mutations in folliculin (FLCN) have been found.
CATEGORY    Respiratory disease
GENE        FLCN [HSA:201163] [KO:K09594]
ENV_FACTOR  Smoking
COMMENT     PSP might be associated with some congenital disorders such as Marfan syndrome [DS:H00653].
DBLINKS     ICD-10: J93.1
            OMIM: 173600
REFERENCE   PMID:22343477 (description, environmental factor)
  AUTHORS   Grundy S, Bentley A, Tschopp JM
  TITLE     Primary spontaneous pneumothorax: a diffuse disease of the pleura.
  JOURNAL   Respiration 83:185-9 (2012)
REFERENCE   PMID:20872980 (description, gene, environmental factor)
  AUTHORS   Luh SP
  TITLE     Review: Diagnosis and treatment of primary spontaneous pneumothorax.
  JOURNAL   J Zhejiang Univ Sci B 11:735-44 (2010)
///
ENTRY       H01111                      Disease
NAME        Cortisone reductase deficiency (CRD)
DESCRIPTION Cortisone reductase deficiency (CRD) is a rare abnormality of cortisone metabolism. There are close phenotypic similarities between CRD and polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder characterized by hirsutism, menstrual irregularity, anovulatory infertility, obesity, insulin resistance and hyperandrogenism. 11beta-HSD1 is a dimeric enzyme that catalyzes the reduction of cortisone to cortisol within the endoplasmic reticulum. And loss of its activity results in CRD. Mutations in H6PD, which encodes an enzyme supplying cofactor for the reaction, also have been identified as the cause of CRD.
CATEGORY    Inherited metabolic disease; Endocrine disease
GENE        H6PD [HSA:9563] [KO:K13937]
            HSD11B1 [HSA:3290] [KO:K15680]
MARKER      Extremely low ratio of cortisol to cortisone metabolites in urine.
DRUG        Dexamethasone [DG:DG00011]
DBLINKS     ICD-10: E25.8
            MeSH: C536447
            OMIM: 604931
REFERENCE   PMID:21325058
  AUTHORS   Lawson AJ, Walker EA, Lavery GG, Bujalska IJ, Hughes B, Arlt W, Stewart PM, Ride JP
  TITLE     Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1.
  JOURNAL   Proc Natl Acad Sci U S A 108:4111-6 (2011)
REFERENCE   PMID:12858176
  AUTHORS   Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM
  TITLE     Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.
  JOURNAL   Nat Genet 34:434-9 (2003)
REFERENCE   PMID:16817821
  AUTHORS   Draper N, Powell BL, Franks S, Conway GS, Stewart PM, McCarthy MI
  TITLE     Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome.
  JOURNAL   Clin Endocrinol (Oxf) 65:64-70 (2006)
///
ENTRY       H01112                      Disease
NAME        Polyhydramnios, megalencephaly, and symptomatic epilepsy;
            PMSE syndrome
DESCRIPTION Polyhydramnios, megalencephaly, symptomatic epilepsy (PMSE) is a severe human developmental and epileptic syndrome caused by a homozygous partial deletion in the STRAD-alpha gene (LYK5), truncating 180 C-terminal residues of the protein. Individuals affected by this condition suffer from severe mental retardation, gross movement disorders, and childhood mortality. Severe intractable epilepsy and megalencephaly are characteristic.
CATEGORY    Developmental disorder; Nervous system disease
GENE        STRADA [HSA:92335] [KO:K08271]
DBLINKS     MeSH: C567020
            OMIM: 611087
REFERENCE   PMID:21263450 (description, gene)
  AUTHORS   Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R
  TITLE     Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.
  JOURNAL   Nat Rev Endocrinol 7:219-31 (2011)
REFERENCE   PMID:20424320 (description, gene)
  AUTHORS   Osborne LR
  TITLE     Caveat mTOR: aberrant signaling disrupts corticogenesis.
  JOURNAL   J Clin Invest 120:1392-5 (2010)
REFERENCE   PMID:19513107 (description, gene)
  AUTHORS   Zeqiraj E, Filippi BM, Goldie S, Navratilova I, Boudeau J, Deak M, Alessi DR, van Aalten DM
  TITLE     ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor.
  JOURNAL   PLoS Biol 7:e1000126 (2009)
///
ENTRY       H01113                      Disease
NAME        Acid phosphatase deficiency
DESCRIPTION Acid phosphatase deficiency is caused by defects in ACP2, that encodes the beta subunit of lysosomal acid phosphatase. The clinical features are intermittent vomiting, hypotonia, lethargy, opisthotonos, terminal bleeding, and death in early infancy.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        ACP2 [HSA:53] [KO:K14410]
DBLINKS     ICD-10: E83.3
            MeSH: C562645
            OMIM: 200950
REFERENCE   PMID:5410815
  AUTHORS   Nadler HL, Egan TJ
  TITLE     Deficiency of lysosomal acid phosphatase. A new familial metabolic disorder.
  JOURNAL   N Engl J Med 282:302-7 (1970)
REFERENCE   PMID:4139985
  AUTHORS   Nadler HL
  TITLE     Treatment of acid phosphatase deficiency disorders.
  JOURNAL   Birth Defects Orig Artic Ser 9:195-7 (1973)
///
ENTRY       H01114                      Disease
NAME        Ocular coloboma, including:
            Coloboma of iris choroid and retina (COI);
            Coloboma of optic nerve (COLON);
            Optic nerve hypoplasia
DESCRIPTION Ocular coloboma is a congenital and common malformation which includes a deficiency of the structures of the eye, such as the iris, retina, choroid, or optic disc. It is usually inherited as an autosomal dominant disorder, although autosomal recessive inheritance also occurs. Paired box gene 6 (PAX6), a member of the paired box family of transcription factors, has been identified as a key regulator of eye development. Currently around 500 mutations of PAX6 have been reported. And most PAX6 nonsense mutations lead to aniridia, while missense mutations are related to foveal hypoplasia, congenital cataracts, or anterior segment anomalies.
CATEGORY    Developmental disorder; Eye disease
GENE        PAX6 [HSA:5080] [KO:K08031]
DBLINKS     MeSH: D003103
            OMIM: 120200 120430 165550
REFERENCE   PMID:21655361
  AUTHORS   Kumar K, Tanwar M, Naithani P, Insaan R, Garg S, Venkatesh P, Dada R
  TITLE     PAX6 gene analysis in irido-fundal coloboma.
  JOURNAL   Mol Vis 17:1414-9 (2011)
REFERENCE   PMID:18408502
  AUTHORS   Gopal L
  TITLE     A clinical and optical coherence tomography study of choroidal colobomas.
  JOURNAL   Curr Opin Ophthalmol 19:248-54 (2008)
REFERENCE   PMID:12721955
  AUTHORS   Azuma N, Yamaguchi Y, Handa H, Tadokoro K, Asaka A, Kawase E, Yamada M
  TITLE     Mutations of the PAX6 gene detected in patients with a variety of optic-nerve malformations.
  JOURNAL   Am J Hum Genet 72:1565-70 (2003)
///
ENTRY       H01115                      Disease
NAME        Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC)
DESCRIPTION Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a progressive, autosomal-recessive, neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia. Mutations in the ABHD12 gene cause PHARC disease.
CATEGORY    Neurodegenerative disease
GENE        ABHD12 [HSA:26090] [KO:K13704]
DBLINKS     MeSH: C567203
            OMIM: 612674
REFERENCE   PMID:20797687 (description, gene)
  AUTHORS   Fiskerstrand T, H'mida-Ben Brahim D, Johansson S, M'zahem A, Haukanes BI, Drouot N, Zimmermann J, Cole AJ, Vedeler C, Bredrup C, Assoum M, Tazir M, Klockgether T, Hamri A, Steen VM, Boman H, Bindoff LA, Koenig M, Knappskog PM
  TITLE     Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.
  JOURNAL   Am J Hum Genet 87:410-7 (2010)
///
ENTRY       H01116                      Disease
NAME        Choroideremia (CHM);
            Tapetochoroidal dystrophy
DESCRIPTION Choroideremia (CHM) is an X-linked retinal dystrophy characterized by progressive degeneration of the choriocapillaris, retinal pigment epithelium and photoreceptors. CHM is caused by mutations in the CHM gene, which encodes a protein involved in vesicular trafficking.
CATEGORY    Nervous system disease; Eye disease
GENE        CHM [HSA:1121]
DBLINKS     ICD-10: H31.2
            MeSH: D015794
            OMIM: 303100
REFERENCE   PMID:22017263
  AUTHORS   Coussa RG, Traboulsi EI
  TITLE     Choroideremia: a review of general findings and pathogenesis.
  JOURNAL   Ophthalmic Genet 33:57-65 (2012)
///
ENTRY       H01117                      Disease
NAME        Majeed syndrome;
            Chronic recurrent multifocal osteomyelitis (CRMO)
DESCRIPTION Majeed syndrome is a rare, autosomal recessive autoinflammatory disorder consisting of chronic recurrent multifocal osteomyelitis, congenital dyserythropoietic anemia, and neutrophilic dermatosis. It has been reported that mutations in LPIN2 are responsible for this syndrome.
CATEGORY    Inherited metabolic disease; Immune system disease
GENE        LPIN2 [HSA:9663] [KO:K15728]
DBLINKS     MeSH: C537839
            OMIM: 609628
REFERENCE   PMID:17330256
  AUTHORS   Al-Mosawi ZS, Al-Saad KK, Ijadi-Maghsoodi R, El-Shanti HI, Ferguson PJ
  TITLE     A splice site mutation confirms the role of LPIN2 in Majeed syndrome.
  JOURNAL   Arthritis Rheum 56:960-4 (2007)
REFERENCE   PMID:15994876
  AUTHORS   Ferguson PJ, Chen S, Tayeh MK, Ochoa L, Leal SM, Pelet A, Munnich A, Lyonnet S, Majeed HA, El-Shanti H
  TITLE     Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome).
  JOURNAL   J Med Genet 42:551-7 (2005)
///
ENTRY       H01118                      Disease
NAME        Progressive external ophthalmoplegia (PEO)
DESCRIPTION Progressive external ophthalmoplegia (PEO) is a mitochondrial disorder associated with mtDNA depletion and/or accumulation of mtDNA point mutations and deletions. PEO is characterized by late onset bilateral ptosis and progressive weakening of the external eye muscle, resulting in blepharoptosis and ophthalmoparesis, proximal muscle weakness, and wasting as well as exercise intolerance. Muscle biopsy results typically show ragged red fibers and cytochrome c oxidase-negative fibers. PEO is transmitted as dominant or recessive traits.
CATEGORY    Nervous system disease; Musculoskeletal disease; Eye disease; Inherited metabolic disease
GENE        ANT1 [HSA:291] [KO:K05863]
            TWINKLE [HSA:56652] [KO:K17680]
            POLG [HSA:5428] [KO:K02332]
            POLG2 [HSA:11232] [KO:K02333]
            RRM2B [HSA:50484] [KO:K10808]
DBLINKS     ICD-10: H49.4
            MeSH: D017246
            OMIM: 609283 609286 157640 258450 610131 613077
REFERENCE   PMID:12975295 (description, gene)
  AUTHORS   Filosto M, Mancuso M, Nishigaki Y, Pancrudo J, Harati Y, Gooch C, Mankodi A, Bayne L, Bonilla E, Shanske S, Hirano M, DiMauro S
  TITLE     Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma.
  JOURNAL   Arch Neurol 60:1279-84 (2003)
REFERENCE   PMID:12835509 (description, gene)
  AUTHORS   Van Goethem G, Martin JJ, Van Broeckhoven C
  TITLE     Progressive external ophthalmoplegia characterized by multiple deletions of mitochondrial DNA: unraveling the pathogenesis of human mitochondrial DNA instability and the initiation of a genetic classification.
  JOURNAL   Neuromolecular Med 3:129-46 (2003)
REFERENCE   PMID:22176657 (description, gene)
  AUTHORS   Copeland WC
  TITLE     Defects in mitochondrial DNA replication and human disease.
  JOURNAL   Crit Rev Biochem Mol Biol 47:64-74 (2012)
///
ENTRY       H01119                      Disease
NAME        Prolidase deficiency (PD)
DESCRIPTION Prolidase deficiency (PD) is a severe autosomal recessive disorder due to the lack of prolidase (EC:3.4.13.9), a peptidase with a preference for Xaa-Pro dipeptide substrates that participates in collagen metabolism and in the terminal degradation of endogenous and dietary proteins. It typically begins in childhood and common symptoms include chronic intractable skin ulcerations and mental retardation. Mutations in prolidase gene causing the reduction or the loss of prolidase activity are responsible for PD.
CATEGORY    Inherited metabolic disease
GENE        PEPD [HSA:5184] [KO:K14213]
DBLINKS     ICD-10: E72.8
            MeSH: D056732
            OMIM: 170100
REFERENCE   PMID:18340504 (description, gene)
  AUTHORS   Lupi A, Tenni R, Rossi A, Cetta G, Forlino A
  TITLE     Human prolidase and prolidase deficiency: an overview on the characterization of  the enzyme involved in proline recycling and on the effects of its mutations.
  JOURNAL   Amino Acids 35:739-52 (2008)
REFERENCE   PMID:16434239 (description)
  AUTHORS   Viglio S, Annovazzi L, Conti B, Genta I, Perugini P, Zanone C, Casado B, Cetta G, Iadarola P
  TITLE     The role of emerging techniques in the investigation of prolidase deficiency: from diagnosis to the development of a possible therapeutical approach.
  JOURNAL   J Chromatogr B Analyt Technol Biomed Life Sci 832:1-8 (2006)
///
ENTRY       H01120                      Disease
NAME        Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (PVHH);
            Cerebral proliferative glomeruloid vasculopathy (PGV);
            Fowler syndrome
DESCRIPTION Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (PVHH), also known as Fowler syndrome, is an autosomal-recessively inherited prenatal lethal disorder of brain angiogenesis, resulting in abnormally thickened and aberrant perforating vessels leading to hydranencephaly. Mutations and a large deletion in the FLVCR2 gene have been revealed in the families with Fowler syndrome. FLVCR2 encodes a transmembrane transporter of the major facilitator superfamily (MFS) hypothesized to be involved in regulation of growth, calcium exchange, and homeostasis.
CATEGORY    Developmental disorder; Vascular disease
GENE        FLVCR2 [HSA:55640] [KO:K08220]
DBLINKS     OMIM: 225790
REFERENCE   PMID:20206334 (description, gene)
  AUTHORS   Meyer E, Ricketts C, Morgan NV, Morris MR, Pasha S, Tee LJ, Rahman F, Bazin A, Bessieres B, Dechelotte P, Yacoubi MT, Al-Adnani M, Marton T, Tannahill D, Trembath RC, Fallet-Bianco C, Cox P, Williams D, Maher ER
  TITLE     Mutations in FLVCR2 are associated with proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler syndrome).
  JOURNAL   Am J Hum Genet 86:471-8 (2010)
REFERENCE   PMID:20690116 (description, gene)
  AUTHORS   Thomas S, Encha-Razavi F, Devisme L, Etchevers H, Bessieres-Grattagliano B, Goudefroye G, Elkhartoufi N, Pateau E, Ichkou A, Bonniere M, Marcorelle P, Parent P, Manouvrier S, Holder M, Laquerriere A, Loeuillet L, Roume J, Martinovic J, Mougou-Zerelli S, Gonzales M, Meyer V, Wessner M, Feysot CB, Nitschke P, Leticee N, Munnich A, Lyonnet S, Wookey P, Gyapay G, Foliguet B, Vekemans M, Attie-Bitach T
  TITLE     High-throughput sequencing of a 4.1 Mb linkage interval reveals FLVCR2 deletions  and mutations in lethal cerebral vasculopathy.
  JOURNAL   Hum Mutat 31:1134-41 (2010)
///
ENTRY       H01121                      Disease
NAME        Succinyl CoA:3-oxoacid CoA transferase (SCOT) deficiency
DESCRIPTION Succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency is an inborn error of ketone body metabolism. SCOT/OXCT1 is a key mitochondrial enzyme in the metabolism of ketone bodies in various organs. Deficiency of SCOT activity inhibits peripheral ketone body utilization and causes episodes of severe ketoacidosis.
CATEGORY    Inherited metabolic disease
GENE        OXCT1 [HSA:5019] [KO:K01027]
MARKER      High levels of ketones of blood and urea 
            Normal levels of blood glucose
DRUG        Intravenous fluid therapy including glucose and sodium bicarbonate.
DBLINKS     ICD-10: E71.3
            MeSH: C537527
            OMIM: 245050
REFERENCE   PMID:21296660
  AUTHORS   Fukao T, Sass JO, Kursula P, Thimm E, Wendel U, Ficicioglu C, Monastiri K, Guffon N, Baric I, Zabot MT, Kondo N
  TITLE     Clinical and molecular characterization of five patients with succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency.
  JOURNAL   Biochim Biophys Acta 1812:619-24 (2011)
REFERENCE   PMID:9392403
  AUTHORS   Niezen-Koning KE, Wanders RJ, Ruiter JP, Ijlst L, Visser G, Reitsma-Bierens WC, Heymans HS, Reijngoud DJ, Smit GP
  TITLE     Succinyl-CoA:acetoacetate transferase deficiency: identification of a new patient with a neonatal onset and review of the literature.
  JOURNAL   Eur J Pediatr 156:870-3 (1997)
REFERENCE   PMID:21479626
  AUTHORS   Sass JO
  TITLE     Inborn errors of ketogenesis and ketone body utilization.
  JOURNAL   J Inherit Metab Dis 35:23-8 (2012)
///
ENTRY       H01122                      Disease
NAME        Pulmonary alveolar proteinosis (PAP)
DESCRIPTION Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by alveolar accumulation of surfactant composed of proteins and lipids due to defective surfactant clearance by alveolar macrophages. PAP is caused by a disruption in surfactant catabolism by alveolar macrophages due to loss of functional granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling. Three main categories of PAP have been defined depending on the aetiology: auto-immune, secondary, and genetic. Genetic PAP can result from mutations in CSF2RA, the gene encoding the alpha chain of the GM-CSF receptor and seen especially in children. Adult forms are mostly auto-immune (with GM-CSF antibodies) and/or secondary to toxic inhalation or hematological disorders, without anti-GM-CSF antibodies. Autoimmune PAP is the most common form (90%).
CATEGORY    Respiratory disease
GENE        CSF2RA [HSA:1438] [KO:K05066]
ENV_FACTOR  Inhalation of inorganic dust [CPD:C19572] or toxic fumes, hematologic malignancies, pharmacologic immunosuppression, and certain infections
COMMENT     A similar but histopathologically distinct disorder of surfactant homeostasis can occur with mutations for the genes encoding surfactant proteins B or C [DS:H00217].
DBLINKS     OMIM: 300770
REFERENCE   PMID:21632797 (description, gene)
  AUTHORS   Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M, Epaud R, Crestani B
  TITLE     Pulmonary alveolar proteinosis.
  JOURNAL   Eur Respir Rev 20:98-107 (2011)
REFERENCE   PMID:20623372 (description, gene, environmental factor, comment)
  AUTHORS   Martinez-Moczygemba M, Huston DP
  TITLE     Immune dysregulation in the pathogenesis of pulmonary alveolar proteinosis.
  JOURNAL   Curr Allergy Asthma Rep 10:320-5 (2010)
///
ENTRY       H01123                      Disease
NAME        HMG-CoA synthase (HMGCS) deficiency
DESCRIPTION HMG-CoA synthase (HMGCS) deficiency is a autosomal recessive disorder of ketogenesis. Two isoforms of HMGCS are found in higher eukaryotes: the cytosolic HMGCS1 and mitochondrial HMGCS2. Mitochondrial HMGCS2 is involved in hepatic ketogenesis, and HMGCS2 deficiency causes hypoketotic hypoglycaemia after prolonged fasting. To date, no mutations have been identified in the human cytosolic HMGCS1.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        HMGCS2 [HSA:3158] [KO:K01641]
MARKER      Dicarboxylic aciduria without ketonuria
            Increase in serum free fatty acids
DBLINKS     ICD-10: E71.3
            MeSH: C567784
            OMIM: 605911
REFERENCE   PMID:20346956
  AUTHORS   Shafqat N, Turnbull A, Zschocke J, Oppermann U, Yue WW
  TITLE     Crystal structures of human HMG-CoA synthase isoforms provide insights into inherited ketogenesis disorders and inhibitor design.
  JOURNAL   J Mol Biol 398:497-506 (2010)
REFERENCE   PMID:11479731
  AUTHORS   Aledo R, Zschocke J, Pie J, Mir C, Fiesel S, Mayatepek E, Hoffmann GF, Casals N, Hegardt FG
  TITLE     Genetic basis of mitochondrial HMG-CoA synthase deficiency.
  JOURNAL   Hum Genet 109:19-23 (2001)
REFERENCE   PMID:21479626
  AUTHORS   Sass JO
  TITLE     Inborn errors of ketogenesis and ketone body utilization.
  JOURNAL   J Inherit Metab Dis 35:23-8 (2012)
///
ENTRY       H01124                      Disease
NAME        Pyridox(am)ine-5'-phosphate oxidase (PNPO) deficiency
DESCRIPTION Pyridox(am)ine-5'-phosphate oxidase (PNPO) deficiency is a rare autosomal recessive disorder that causes intractable seizures that are not responsive to anticonvulsant drugs and pyridoxine. Patients with this deficiency have very low concentrations of pyridoxal 5'-phosphate (PLP), leaving exogenous pyridoxal/PLP as the only source of the active cofactor. Clinically, this disease presents with neonatal epileptic encephalopathy with severe seizures which do not respond to anticonvulsant drugs or pyridoxine but shows a dramatic response to PLP. Pathogenic mutations in PNPO gene have been identified.
CATEGORY    Inherited metabolic disease
GENE        PNPO [HSA:55163] [KO:K00275]
DRUG        Pyridoxal phosphate [DG:DG00132]
DBLINKS     ICD-10: G40.8
            MeSH: C566449
            OMIM: 610090
REFERENCE   PMID:18485777 (description, gene)
  AUTHORS   Khayat M, Korman SH, Frankel P, Weintraub Z, Hershckowitz S, Sheffer VF, Ben Elisha M, Wevers RA, Falik-Zaccai TC
  TITLE     PNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism.
  JOURNAL   Mol Genet Metab 94:431-4 (2008)
REFERENCE   PMID:18024216 (description, gene, drug)
  AUTHORS   Ruiz A, Garcia-Villoria J, Ormazabal A, Zschocke J, Fiol M, Navarro-Sastre A, Artuch R, Vilaseca MA, Ribes A
  TITLE     A new fatal case of pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
  JOURNAL   Mol Genet Metab 93:216-8 (2008)
///
ENTRY       H01125                      Disease
NAME        Hereditary pyropoikilocytosis (HPP)
DESCRIPTION Hereditary pyropoikilocytosis (HPP) is a recessively inherited form of hemolytic anemia characterized by peripheral blood morphology presenting with striking anisopoikilocytosis with red cell fragmentation and microspherocytes. Erythrocytes from most HPP patients exhibit qualitative and quantitative abnormalities of the erythrocyte membrane protein spectrin, the principal structural component of the erythrocyte membrane skeleton. Qualitative spectrin defects are typically associated with missense mutations that lead to abnormal spectrin self-association, a process critical for membrane structure and function.
CATEGORY    Hematologic disease
GENE        SPTA1 [HSA:6708] [KO:K06114]
COMMENT     In vitro studies suggest that it may confer some resistance to infection with the malarial parasite Plasmodium falciparum [DS:H00361].
DBLINKS     ICD-10: D58.1
            OMIM: 266140
REFERENCE   PMID:18815189 (description, gene)
  AUTHORS   Tolpinrud W, Maksimova YD, Forget BG, Gallagher PG
  TITLE     Nonsense mutations of the alpha-spectrin gene in hereditary pyropoikilocytosis.
  JOURNAL   Haematologica 93:1752-4 (2008)
REFERENCE   PMID:17279012 (description, gene, comment)
  AUTHORS   Ramos MC, Schafernak KT, Peterson LC
  TITLE     Hereditary pyropoikilocytosis: a rare but potentially severe form of congenital hemolytic anemia.
  JOURNAL   J Pediatr Hematol Oncol 29:128-9 (2007)
///
ENTRY       H01126                      Disease
NAME        Familial renal glucosuria (FRG)
DESCRIPTION Familial renal glucosuria (FRG) is a rare autosomal recessive disorder of the kidney characterized by decreased renal tubular resorption of glucose from the urine in the absence of hyperglycemia and any other signs of tubular dysfunction. The vast majority of affected individuals are asymptomatic, but there is a rare propensity to develop hypoglycemia and hypovolemia. FRG is associated with mutations in the SGLT2 gene.
CATEGORY    Urinary system disease; Inherited metabolic disease
GENE        SLC5A2 [HSA:6524] [KO:K14382]
DBLINKS     ICD-10: E74.8
            MeSH: D006030
            OMIM: 233100
REFERENCE   PMID:20425568 (description, gene)
  AUTHORS   Patel AK, Fonseca V
  TITLE     Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors.
  JOURNAL   Curr Diab Rep 10:101-7 (2010)
REFERENCE   PMID:19965550 (description, gene)
  AUTHORS   Santer R, Calado J
  TITLE     Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
  JOURNAL   Clin J Am Soc Nephrol 5:133-41 (2010)
///
ENTRY       H01127                      Disease
NAME        PIGM-congenital disorder of glycosylation (PIGM-CDG)
DESCRIPTION PIGM-congenital disorder of glycosylation (PIGM-CDG) is an autosomal recessive disorder characterized by portal- and hepatic-vein thrombosis and epilepsy. Hypomorphic promoter mutation in PIGN causes this disorder.
CATEGORY    Inherited metabolic disease
GENE        PIGM [HSA:93183] [KO:K05284]
DBLINKS     ICD-10: E88.8
            MeSH: C537277
            OMIM: 610293
REFERENCE   PMID:16767100
  AUTHORS   Almeida AM, Murakami Y, Layton DM, Hillmen P, Sellick GS, Maeda Y, Richards S, Patterson S, Kotsianidis I, Mollica L, Crawford DH, Baker A, Ferguson M, Roberts I, Houlston R, Kinoshita T, Karadimitris A
  TITLE     Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency.
  JOURNAL   Nat Med 12:846-51 (2006)
REFERENCE   PMID:17442906
  AUTHORS   Almeida AM, Murakami Y, Baker A, Maeda Y, Roberts IA, Kinoshita T, Layton DM, Karadimitris A
  TITLE     Targeted therapy for inherited GPI deficiency.
  JOURNAL   N Engl J Med 356:1641-7 (2007)
///
ENTRY       H01128                      Disease
NAME        Reticular dysgenesis
DESCRIPTION Reticular dysgenesis (RD) is a rare congenital immunodeficiency classified within the severe combined immunodeficiencies (SCIDs). It is inherited in an autosomal recessive manner, and is characterized by absence of granulocytes and almost complete deficiency of lymphocytes in peripheral blood, hypoplasia of the thymus and secondary lymphoid organs, and lack of innate and adaptive humoral and cellular immune functions, leading to fatal septicemia within days after birth. The bone marrow showed a maturation arrest in the myeloid and lymphoid lineage. The underlying genetic defect for most cases of RD have been identified in the gene encoding adenylate kinase 2 (AK2).
CATEGORY    Immune system disease
GENE        AK2 [HSA:204] [KO:K00939]
DBLINKS     MeSH: C538361
            OMIM: 233100
REFERENCE   PMID:20863163 (description, gene)
  AUTHORS   Cosar H, Kahramaner Z, Erdemir A, Kanik A, Turkoglu E, Sutcuoglu S, Ozturk C, Atabay B, Arun Ozer E
  TITLE     Reticular dysgenesis in a preterm infant: a case report.
  JOURNAL   Pediatr Hematol Oncol 27:646-9 (2010)
REFERENCE   PMID:19043417 (description, gene)
  AUTHORS   Pannicke U, Honig M, Hess I, Friesen C, Holzmann K, Rump EM, Barth TF, Rojewski MT, Schulz A, Boehm T, Friedrich W, Schwarz K
  TITLE     Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding  mitochondrial adenylate kinase 2.
  JOURNAL   Nat Genet 41:101-5 (2009)
///
ENTRY       H01129                      Disease
NAME        Brody myopathy
DESCRIPTION Brody myopathy is an autosomal recessive disorder of skeletal muscle function characterized by painless muscle contracture and exercise-induced impairment of muscle relaxation due to a defect of calcium reuptake. Mutations in the human ATP2A1 gene, that encodes one of the SERCA Ca(2+)-ATPases, cause Brody myopathy.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        ATP2A1 [HSA:487] [KO:K05853]
DBLINKS     ICD-10: G71.8
            MeSH: C536607
            OMIM: 601003
REFERENCE   PMID:18786632
  AUTHORS   Drogemuller C, Drogemuller M, Leeb T, Mascarello F, Testoni S, Rossi M, Gentile A, Damiani E, Sacchetto R
  TITLE     Identification of a missense mutation in the bovine ATP2A1 gene in congenital pseudomyotonia of Chianina cattle: an animal model of human Brody disease.
  JOURNAL   Genomics 92:474-7 (2008)
///
ENTRY       H01130                      Disease
NAME        Late-onset retinal degeneration (L-ORD)
DESCRIPTION Late-onset retinal degeneration (L-ORD) is a rare autosomal dominant ocular disease characterized by onset in the fifth to sixth decade with night blindness and punctate yellow-white deposits between the retinal pigment epithelium (RPE) and Bruch's membrane, progressing to severe central and peripheral degeneration, with choroidal neovascularization and chorioretinal atrophy. L-ORD is caused by a mutation in the CTRP5 (C1QTNF5) gene, which encodes a short-chain collagen, changing a highly conserved serine to arginine (Ser163Arg). The mutation results in abnormal high molecular weight aggregate formation which may alter its higher-order structure and interactions.
CATEGORY    Eye disease
GENE        C1QTNF5 [HSA:114902]
DBLINKS     MeSH: C565309
            OMIM: 605670
REFERENCE   PMID:22277927 (gene)
  AUTHORS   Vincent A, Munier FL, Vandenhoven CC, Wright T, Westall CA, Heon E
  TITLE     The characterization of retinal phenotype in a family with C1QTNF5-related late-onset retinal degeneration.
  JOURNAL   Retina 32:1643-51 (2012)
REFERENCE   PMID:12944416 (description, gene)
  AUTHORS   Hayward C, Shu X, Cideciyan AV, Lennon A, Barran P, Zareparsi S, Sawyer L, Hendry G, Dhillon B, Milam AH, Luthert PJ, Swaroop A, Hastie ND, Jacobson SG, Wright AF
  TITLE     Mutation in a short-chain collagen gene, CTRP5, results in extracellular deposit  formation in late-onset retinal degeneration: a genetic model for age-related macular degeneration.
  JOURNAL   Hum Mol Genet 12:2657-67 (2003)
REFERENCE   PMID:11097607 (description)
  AUTHORS   Milam AH, Curcio CA, Cideciyan AV, Saxena S, John SK, Kruth HS, Malek G, Heckenlively JR, Weleber RG, Jacobson SG
  TITLE     Dominant late-onset retinal degeneration with regional variation of sub-retinal pigment epithelium deposits, retinal function, and photoreceptor degeneration.
  JOURNAL   Ophthalmology 107:2256-66 (2000)
///
ENTRY       H01131                      Disease
NAME        Hereditary neuralgic amyotrophy (HNA);
            Hereditary brachial plexus neuropathy
DESCRIPTION Hereditary neuralgic amyotrophy (HNA) is an autosomal dominant peripheral neuropathy characterized by recurrent painful brachial plexus neuropathies with weakness and atrophy of arm muscles and sensory loss. HNA is triggered by environmental factors such as infection or parturition. It has been reported that HNA is caused by mutations in the gene septin 9. Septins are implicated in formation of the cytoskeleton, cell division and tumorigenesis.
CATEGORY    Nervous system disease; Musculoskeletal disease
GENE        SEPT9 [HSA:10801] [KO:K16938]
ENV_FACTOR  Infection or parturition
DBLINKS     ICD-10: G54.5
            MeSH: D020968
            OMIM: 162100
REFERENCE   PMID:16186812
  AUTHORS   Kuhlenbaumer G, Hannibal MC, Nelis E, Schirmacher A, Verpoorten N, Meuleman J, Watts GD, De Vriendt E, Young P, Stogbauer F, Halfter H, Irobi J, Goossens D, Del-Favero J, Betz BG, Hor H, Kurlemann G, Bird TD, Airaksinen E, Mononen T, Serradell AP, Prats JM, Van Broeckhoven C, De Jonghe P, Timmerman V, Ringelstein EB, Chance PF
  TITLE     Mutations in SEPT9 cause hereditary neuralgic amyotrophy.
  JOURNAL   Nat Genet 37:1044-6 (2005)
///
ENTRY       H01132                      Disease
NAME        Aplastic anemia (AA)
DESCRIPTION Aplastic anemia (AA) is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. Most cases of acquired aplastic anemia are the consequence of an immune-mediated destruction of hematopoiesis. Autoreactive cytotoxic T cells play a key role in the pathogenesis of AA by myelosuppressive cytokines including interferon-gamma. It has been reported that polymorphisms in IFNG are related to AA. A minority of patients with AA has heterozygous mutations in genes encoding the telomerase components TERT or TERC. Immunosuppressive therapy (IST) is one of the main treatment modalities for AA, although most patients with telomerase mutations do not respond adequately to IST.
CATEGORY    Hematologic disease
GENE        TERC [HSA:7012]
            TERT [HSA:7015] [KO:K11126]
            IFNG [HSA:3458] [KO:K04687]
DRUG        Immunosuppressive therapy consisting of antithymocyte globulin (ATG) and cyclosporine [DR:D00184]
DBLINKS     ICD-10: D61.0
            OMIM: 609135
REFERENCE   PMID:20008219
  AUTHORS   Calado RT
  TITLE     Telomeres and marrow failure.
  JOURNAL   Hematology Am Soc Hematol Educ Program 338-43 (2009)
REFERENCE   PMID:20953611
  AUTHORS   Lee YG, Kim I, Kim JH, Bae JY, Kwon JH, Shin DY, Lee JE, Song EY, Kim HK, Yoon SS, Park SS, Lee DS, Han KS, Park MH, Hong YC, Park S, Kim BK
  TITLE     Impact of cytokine gene polymorphisms on risk and treatment outcomes of aplastic  anemia.
  JOURNAL   Ann Hematol 90:515-21 (2011)
///
ENTRY       H01133                      Disease
NAME        Reynolds syndrome
DESCRIPTION Reynolds syndrome is a rare disease associating primary biliary cirrhosis (PBC) and systemic scleroderma (SSc). It is typically classified as an autoimmune disorder since there are specific autoantibodies associated with both facets of the disease (antimitochondrial antibodies for PBC and anticentromere/antitopoisomerase for SSc), and suggestive microscopical abnormalities in the skin and liver. A mutation in the Lamin B receptor gene has been discovered in the white blood cells, suggesting that nuclear signalling defects could be a cause in Reynolds syndrome.
CATEGORY    Skin and connective tissue disease; Digestive disease
GENE        LBR [HSA:3930] [KO:K19532]
DBLINKS     ICD-10: K74.5 L94.0
            OMIM: 613471
REFERENCE   PMID:20800400 (description)
  AUTHORS   Cabane J
  TITLE     Is Reynolds syndrome a genetic laminopathy?
  JOURNAL   Gastroenterol Clin Biol 34:509-10 (2010)
REFERENCE   PMID:20522425 (gene)
  AUTHORS   Gaudy-Marqueste C, Roll P, Esteves-Vieira V, Weiller PJ, Grob JJ, Cau P, Levy N, De Sandre-Giovannoli A
  TITLE     LBR mutation and nuclear envelope defects in a patient affected with Reynolds syndrome.
  JOURNAL   J Med Genet 47:361-70 (2010)
///
ENTRY       H01134                      Disease
NAME        Rhabdoid predisposition syndrome (RPS)
DESCRIPTION Rhabdoid predisposition syndrome (RPS) is familial cases of highly malignant, aggressive, embryonal neoplasms manifested in early infancy and childhood that may originate from virtually any tissue, generally resulting in atypical teratoid rhabdoid tumors (AT/RTs) in the central nervous system and malignant rhabdoid tumors in the kidney or retroperitoneum. The vast majority demonstrate biallelic somatic inactivation of the SMARCB1 tumor suppressor within tumor cells. Mutations in SMRCA4 gene have also been identified.
CATEGORY    Cancer
GENE        SMARCB1 [HSA:6598] [KO:K11648]
            SMARCA4 [HSA:6597] [KO:K11647]
MARKER      Fluorescence in-situ hybridization testing of chromosome 22q11.2 locus is a mainstay in the diagnosis of these tumors.
DBLINKS     MeSH: C563738 C567643
            OMIM: 609322 613325
REFERENCE   PMID:21436099 (description, gene, marker)
  AUTHORS   Harris TJ, Donahue JE, Shur N, Tung GA
  TITLE     Case 168: rhabdoid predisposition syndrome--familial cancer syndromes in children.
  JOURNAL   Radiology 259:298-302 (2011)
REFERENCE   PMID:20137775 (description, gene)
  AUTHORS   Schneppenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, Kreuz M, Leuschner I, Martin Subero JI, Obser T, Oyen F, Vater I, Siebert R
  TITLE     Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.
  JOURNAL   Am J Hum Genet 86:279-84 (2010)
REFERENCE   PMID:21208904 (gene)
  AUTHORS   Bourdeaut F, Lequin D, Brugieres L, Reynaud S, Dufour C, Doz F, Andre N, Stephan JL, Perel Y, Oberlin O, Orbach D, Bergeron C, Rialland X, Freneaux P, Ranchere D, Figarella-Branger D, Audry G, Puget S, Evans DG, Pinas JC, Capra V, Mosseri V, Coupier I, Gauthier-Villars M, Pierron G, Delattre O
  TITLE     Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor.
  JOURNAL   Clin Cancer Res 17:31-8 (2011)
///
ENTRY       H01135                      Disease
NAME        Ribose 5-phosphate isomerase (RPI) deficiency
DESCRIPTION Ribose 5-phosphate isomerase (RPI) deficiency is a very rare enzymopathy of the pentose phosphate pathway with one sole diagnosed case. The patient presented with progressive leukoencephalopathy and peripheral neuropathy. Systematic metabolic profiling identified elevated levels of arabitol and ribitol in affected brain regions and body fluids. RPI gene-sequence analysis revealed a frameshift and a missense mutation.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        RPIA [HSA:22934] [KO:K01807]
MARKER      Elevated levels of Arabitol [CPD:C00532] and Ribitol [CPD:C00474]
DBLINKS     MeSH: C563212
            OMIM: 608611
REFERENCE   PMID:20499043 (description)
  AUTHORS   Wamelink MM, Gruning NM, Jansen EE, Bluemlein K, Lehrach H, Jakobs C, Ralser M
  TITLE     The difference between rare and exceptionally rare: molecular characterization of ribose 5-phosphate isomerase deficiency.
  JOURNAL   J Mol Med (Berl) 88:931-9 (2010)
REFERENCE   PMID:14988808 (description, gene)
  AUTHORS   Huck JH, Verhoeven NM, Struys EA, Salomons GS, Jakobs C, van der Knaap MS
  TITLE     Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy.
  JOURNAL   Am J Hum Genet 74:745-51 (2004)
///
ENTRY       H01136                      Disease
NAME        Carboxypeptidase N deficiency
DESCRIPTION Carboxypeptidase N (CPN) is a plasma zinc metalloprotease that inactivates C3a, C4a, C5a, bradykinin, kalladin, and fibrinopeptides. CPN has been implicated as a major regulator of inflammation. Although deficiency of CPN produces a severe allergic syndrome, there are no reported cases of complete deficiency of CPN in humans. There are a few documented cases of partial CPN deficiency. Patients present some combination of angioedema or chronic urticaria, as well as hay fever or asthma. It has been reported that mutations in CPN1, which encodes the catalytic subunit of CPN, cause CPN deficiency.
CATEGORY    Immune system disease
GENE        CPN1 [HSA:1369] [KO:K01292]
DBLINKS     ICD-10: D84.1
            MeSH: C562876
            OMIM: 212070
REFERENCE   PMID:19414808
  AUTHORS   Mueller-Ortiz SL, Wang D, Morales JE, Li L, Chang JY, Wetsel RA
  TITLE     Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock.
  JOURNAL   J Immunol 182:6533-9 (2009)
REFERENCE   PMID:12560874
  AUTHORS   Cao H, Hegele RA
  TITLE     DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency.
  JOURNAL   J Hum Genet 48:20-2 (2003)
///
ENTRY       H01137                      Disease
NAME        Baylisascariasis
DESCRIPTION Baylisascariasis is a parasitic infection caused by Baylisascaris procyonis, a large nematodes of the order Ascaridida. The full clinical spectrum of human baylisascariasis includes visceral larva migrans, neural larva migrans, and ocular larva migrans. Neural larva migrans can lead to severe neurologic disease such as eosinophilic meningoencephalitis in humans.
CATEGORY    Infectious disease
PATHOGEN    Baylisascaris procyonis
MARKER      Larval excretory-secretory antigens (ELISA assay and Western blotting)
DRUG        Empirical anthelmintic treatment with thiabendazole, fenbendazole, tetramisole, or ivermectin has failed to prevent death or unfavorable outcomes.
COMMENT     Definitive host: North American raccoon (Procyon lotor)
REFERENCE   PMID:16223954 (description, env_factor, drug)
  AUTHORS   Gavin PJ, Kazacos KR, Shulman ST
  TITLE     Baylisascariasis.
  JOURNAL   Clin Microbiol Rev 18:703-18 (2005)
REFERENCE   PMID:15715975 (description, drug)
  AUTHORS   Wise ME, Sorvillo FJ, Shafir SC, Ash LR, Berlin OG
  TITLE     Severe and fatal central nervous system disease in humans caused by Baylisascaris procyonis, the common roundworm of raccoons: a review of current literature.
  JOURNAL   Microbes Infect 7:317-23 (2005)
///
ENTRY       H01138                      Disease
NAME        Hymenolepiasis
DESCRIPTION Hymenolepiasis is a very rare infection with rat tapeworms that are common in tropical and subtropical climates. Hymenolepis parasites require beetles and rodents for completion of the life cycle. Humans can be accidental hosts of this parasite and most cases (90%) are asymptomatic.
CATEGORY    Infectious disease
PATHOGEN    Hymenolepsis nana
            Hymenolepis diminuta
DRUG        Niclosamide [DR:D00436]
            Praziquantel [DR:D00471]
DBLINKS     ICD-10: B71.0
            MeSH: D006925
REFERENCE   PMID:15266234 (description, env_factor, drug)
  AUTHORS   Wiwanitkit V
  TITLE     Overview of hymenolepis diminuta infection among Thai patients.
  JOURNAL   MedGenMed 6:7 (2004)
REFERENCE   PMID:9394191 (env_factor)
  AUTHORS   Ito A
  TITLE     Basic and applied immunology in cestode infections: from Hymenolepis to Taenia and Echinococcus.
  JOURNAL   Int J Parasitol 27:1203-11 (1997)
///
ENTRY       H01139                      Disease
NAME        Human granulocytic anaplasmosis
DESCRIPTION Human granulocytic anaplasmosis (HGA), previously known as human granulocytic ehrlichiosis (HGE), is a tick-borne infection caused by Anaplasma phagocytophilum. It results in symptoms ranging mild febrile illness to severe disease characterized by an acute, influenza-like illness in older individuals and immunocompromised patients.
CATEGORY    Infectious disease
PATHOGEN    Anaplasma phagocytophilum [GN:aph]
MARKER      msp2/p44 (PCR detection) [aph:APH_1354]
DRUG        Doxycycline [DG:DG00008]
COMMENT     Vector: Ixodes persulcatus
DBLINKS     MeSH: D000712
REFERENCE   PMID:22321996 (descripion, env_factor, marker)
  AUTHORS   Koebel C, Kern A, Edouard S, Hoang AT, Celestin N, Hansmann Y, Jaulhac B, Brouqui P, De Martino SJ
  TITLE     Human granulocytic anaplasmosis in eastern France: clinical presentation and laboratory diagnosis.
  JOURNAL   Diagn Microbiol Infect Dis 72:214-8 (2012)
REFERENCE   PMID:17114714
  AUTHORS   Bakken JS, Dumler JS
  TITLE     Clinical diagnosis and treatment of human granulocytotropic anaplasmosis.
  JOURNAL   Ann N Y Acad Sci 1078:236-47 (2006)
///
ENTRY       H01140                      Disease
NAME        Sennetsu neorickettsiosis;
            Sennetsu ehrlichiosis
DESCRIPTION Neorickettsia sennetsu, an obligate intracellular bacteria closely related to Ehrlichia and Anaplasma, causes an infectious mononucleosis-like disease. It is very likely linked to consumption of raw fish in tropical Asia. Patients with sennetsu neorickettsiosis experience acute febrile disease, malaise, myalgias, pharyngitis, anorexia, generalized lymphadenopathy, and peripheral blood mononucleosis.
CATEGORY    Infectious disease
PATHOGEN    Neorickettsia sennetsu [GN:nse]
MARKER      Whole cell antigens of N. sennetsu (IFA and Western blot assays)
            16S rRNA (PCR detection) [nse:NSE_0973] [KO:K01977]
            gltA (PCR detection) [nse:NSE_0730] [KO:K01647]
            Omp85 (PCR detection) [nse:NSE_0718] [KO:K07277]
DBLINKS     ICD-10: A79.8
            MeSH: C537582
REFERENCE   PMID:19635866 (description, env_factor)
  AUTHORS   Walker DH
  TITLE     Sennetsu neorickettsiosis: a potentially prevalent, treatable, acutely incapacitating tropical infectious disease.
  JOURNAL   Am J Trop Med Hyg 81:187-8 (2009)
REFERENCE   PMID:19635868 (description, marker)
  AUTHORS   Newton PN, Rolain JM, Rasachak B, Mayxay M, Vathanatham K, Seng P, Phetsouvanh R, Thammavong T, Zahidi J, Suputtamongkol Y, Syhavong B, Raoult D
  TITLE     Sennetsu neorickettsiosis: a probable fish-borne cause of fever rediscovered in Laos.
  JOURNAL   Am J Trop Med Hyg 81:190-4 (2009)
///
ENTRY       H01141                      Disease
NAME        Human monocytic ehrlichiosis
DESCRIPTION Human monocytic ehrlichiosis is a tick-borne infectious disease caused by Ehrlichia chaffeensis that infects mononuclear phagocytic cells. The bacterium is maintained in nature involving many vertebrate species such as deer that serve as competent reservoirs for the bacterium and as sources of blood for tick vectors. Patients experience fever, malaise, low-back pain, or gastrointestinal symptoms.
CATEGORY    Infectious disease
PATHOGEN    Ehrlichia chaffeensis [GN:ech]
MARKER      Antibody titer to E. chaffeensis antigen (IFA)
            Identification of morulae in clinical specimen
            16S rRNA (PCR assay) [ech:ECH_0919] [KO:K01977]
DRUG        Tetracyclines [DG:DG01197]
COMMENT     Vector: Tick (Amblyomma americanum)
DBLINKS     MeSH: D016873
REFERENCE   PMID:19248653 (description, env_factor, marker)
  AUTHORS   Ganguly S, Mukhopadhayay SK
  TITLE     Tick-borne ehrlichiosis infection in human beings.
  JOURNAL   J Vector Borne Dis 45:273-80 (2008)
///
ENTRY       H01142                      Disease
NAME        Ehrlichia ewingii infection
DESCRIPTION Human ehrlichiosis is a recently recognized tick-borne infection. Ehrlichia ewingii has been identified as a cause of human disease in addition to formerly known pathogenic Ehrlichia species.
CATEGORY    Infectious disease
PATHOGEN    Ehrlichia ewingii
MARKER      16S rRNA [KO:K01977]
COMMENT     Other diseases caused by Ehrlichia species include: Human granulocytic anaplasmosis (H01139), Sennetsu neorickettsiosis (H01140), and Human monocytic ehrlichiosis (H01141).
DBLINKS     MeSH: D016873
REFERENCE   PMID:10403852
  AUTHORS   Buller RS, Arens M, Hmiel SP, Paddock CD, Sumner JW, Rikhisa Y, Unver A, Gaudreault-Keener M, Manian FA, Liddell AM, Schmulewitz N, Storch GA
  TITLE     Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis.
  JOURNAL   N Engl J Med 341:148-55 (1999)
///
ENTRY       H01143                      Disease
NAME        Vitamin D-dependent rickets
DESCRIPTION Rickets is the failure of growing bone to mineralize. Many skeletal and radiographic changes can occur because of the lack of calcified osteoid and the buildup of unossified cartilage. Vitamin D-dependent rickets type I results from abnormalities in the gene coding for 25(OH)D3-1-alpha-hydroxylase and vitamin D 25-hydroxylase, and type II results from defective vitamin D receptors. Both diseases are rare autosomal recessive disorders characterized by hypocalcemia, secondary hyperparathyroidism and early onset severe rickets.
CATEGORY    Musculoskeletal disease; Inherited metabolic disease
GENE        (VDDR1A) CYP27B1 [HSA:1594] [KO:K07438]
            (VDDR1B) CYP2R1 [HSA:120227] [KO:K07419]
            (VDDR2A) VDR [HSA:7421] [KO:K08539]
DRUG        Calcitriol [DR:D00129]
            Calcium [ATC:A12A]
DBLINKS     ICD-10: E55.0
            MeSH: C562688 C564005 C562794
            OMIM: 264700 277440 600081
REFERENCE   PMID:16939184 (description, gene, drug)
  AUTHORS   Nield LS, Mahajan P, Joshi A, Kamat D
  TITLE     Rickets: not a disease of the past.
  JOURNAL   Am Fam Physician 74:619-26 (2006)
REFERENCE   PMID:20675935 (description, gene)
  AUTHORS   Kitanaka S
  TITLE     [Genetic basis for skeletal disease. Hereditary rickets].
  JOURNAL   Clin Calcium 20:1238-44 (2010)
REFERENCE   PMID:20511055 (description, gene)
  AUTHORS   Malloy PJ, Feldman D
  TITLE     Genetic disorders and defects in vitamin d action.
  JOURNAL   Endocrinol Metab Clin North Am 39:333-46, table of contents (2010)
REFERENCE   PMID:8201479 (gene)
  AUTHORS   Casella SJ, Reiner BJ, Chen TC, Holick MF, Harrison HE
  TITLE     A possible genetic defect in 25-hydroxylation as a cause of rickets.
  JOURNAL   J Pediatr 124:929-32 (1994)
REFERENCE   PMID:15128933 (gene)
  AUTHORS   Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW
  TITLE     Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase.
  JOURNAL   Proc Natl Acad Sci U S A 101:7711-5 (2004)
///
ENTRY       H01144                      Disease
NAME        Ochrobactrum anthropi infection
DESCRIPTION Ochrobactrum anthropi is an ubiquitous oxidase-producing gram-negative bacillus. The pathogen is recognized increasingly as a causative agent of central catheter-related infections, causing bloodstream infection in patients on hemodialysis. Other manifestations include osteochondritis, necrotizing fasciitis, endophthalmitis, meningitis, and peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.
CATEGORY    Infectious disease
PATHOGEN    Ochrobactrum anthropi [GN:oan]
DRUG        Gentamicin [DG:DG00401]
COMMENT     The pathogen usually displays resistance to commonly used broad-spectrum antimicrobial agents, including penicillins and cephalosporins.
REFERENCE   PMID:12324938 (descirption, env_factor)
  AUTHORS   Daxboeck F, Zitta S, Assadian O, Krause R, Wenisch C, Kovarik J
  TITLE     Ochrobactrum anthropi bloodstream infection complicating hemodialysis.
  JOURNAL   Am J Kidney Dis 40:E17 (2002)
REFERENCE   PMID:22099546
  AUTHORS   Shrishrimal K
  TITLE     Recurrent Ochrobactrum anthropi and Shewanella putrefaciens bloodstream infection complicating hemodialysis.
  JOURNAL   Hemodial Int 16:113-5 (2012)
///
ENTRY       H01145                      Disease
NAME        Atransferrinemia;
            Congenital hypotransferrinemia
DESCRIPTION Atransferrinemia is a rare autosomal recessive disorder characterized by iron overload and hypochromic anemia. A few case of human atransferrinemia with mutations in the transferrin gene has been reported.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        TF [HSA:7018] [KO:K14736]
DRUG        Plasma infusions of transferrin
DBLINKS     ICD-10: D50.8
            OMIM: 209300
REFERENCE   PMID:11110675
  AUTHORS   Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF
  TITLE     Molecular characterization of a case of atransferrinemia.
  JOURNAL   Blood 96:4071-4 (2000)
REFERENCE   PMID:18097132
  AUTHORS   Aslan D, Crain K, Beutler E
  TITLE     A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene.
  JOURNAL   Acta Haematol 118:244-7 (2007)
///
ENTRY       H01146                      Disease
NAME        Aminoacylase 1 deficiency
DESCRIPTION Aminoacylase 1 deficiency is an autosomal recessive disease characterized by accumulation of N-acetyl amino acids in the urine. In affected individuals neurological findings such as febrile seizures, delay of psychomotor development and moderate mental retardation have been reported.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease
GENE        ACY1 [HSA:95] [KO:K14677]
MARKER      Increased urinary levels of N-acetylaspartic acid
COMMENT     Aminoacylase 2, also known as aspartoacylase (ASPA) hydrolyzes specifically N-acetyl-L-aspartate. ASPA deficiency causes spongy degeneration of the brain known as Canavan disease [DS:H00074]
DBLINKS     MeSH: C538246
            OMIM: 609924
REFERENCE   PMID:21414403
  AUTHORS   Sommer A, Christensen E, Schwenger S, Seul R, Haas D, Olbrich H, Omran H, Sass JO
  TITLE     The molecular basis of aminoacylase 1 deficiency.
  JOURNAL   Biochim Biophys Acta 1812:685-90 (2011)
REFERENCE   PMID:16465618
  AUTHORS   Sass JO, Mohr V, Olbrich H, Engelke U, Horvath J, Fliegauf M, Loges NT, Schweitzer-Krantz S, Moebus R, Weiler P, Kispert A, Superti-Furga A, Wevers RA, Omran H
  TITLE     Mutations in ACY1, the gene encoding aminoacylase 1, cause a novel inborn error of metabolism.
  JOURNAL   Am J Hum Genet 78:401-9 (2006)
///
ENTRY       H01147                      Disease
NAME        Methylobacterium infection
DESCRIPTION Methylobacterium species are fastidious, pink-pigmented, gram-negative bacilli that rarely cause human infections. The bacterium can cause catheter-related infection in both immunocompromised and immunocompetent patients.
CATEGORY    Infectious disease
PATHOGEN    Methylobacterium radiotolerans [GN:mrd]
            Methylobacterium thiocyanatum
            Methylobacterium aminovorans
            Methylobacterium lusitanum
MARKER      16S rRNA (PCR detection) [mrd:Mrad2831_R0013] [KO:K01977]
REFERENCE   PMID:21734032 (description, env_factor)
  AUTHORS   Lai CC, Cheng A, Liu WL, Tan CK, Huang YT, Chung KP, Lee MR, Hsueh PR
  TITLE     Infections caused by unusual Methylobacterium species.
  JOURNAL   J Clin Microbiol 49:3329-31 (2011)
REFERENCE   PMID:1600002 (description)
  AUTHORS   Kaye KM, Macone A, Kazanjian PH
  TITLE     Catheter infection caused by Methylobacterium in immunocompromised hosts: report  of three cases and review of the literature.
  JOURNAL   Clin Infect Dis 14:1010-4 (1992)
///
ENTRY       H01148                      Disease
NAME        Caulobacter infection
DESCRIPTION The genus Caulobacter includes gram-negative bacteria characterized by asymmetric cell division and stalk. Although infection with Caulobacter species is rare, it may induce intermittent peritoneal dialysis.
CATEGORY    Infectious disease
PATHOGEN    Caulobacter sp.
MARKER      16S rRNA (PCR detection) [KO:K01977]
COMMENT     The isolate in the first report was found to be sensitive to meropenem, imipenem, erythromycin (disk only), aminoglycosides, tetracycline, chloramphenicol, and sulfadiazine.
REFERENCE   PMID:17267638
  AUTHORS   Justesen US, Holt HM, Thiesson HC, Blom J, Nielsen XC, Dargis R, Kemp M, Christensen JJ
  TITLE     Report of the first human case of Caulobacter sp. infection.
  JOURNAL   J Clin Microbiol 45:1366-9 (2007)
///
ENTRY       H01149                      Disease
NAME        Ring dermoid of cornea
DESCRIPTION The ring dermoid of the cornea (RDC) is an autosomal dominantly inherited syndrome characterised by bilateral annular limbal dermoids with corneal and conjunctival extension. A mutation in PITX2 has been identified in the individuals affected by the RDC. PITX2 encodes a homeodomain transcription factor required for normal development of multiple organs, including eye, heart, and pituitary.
CATEGORY    Eye disease
GENE        PITX2 [HSA:5308] [KO:K04686]
DBLINKS     ICD-10: D31.1
            MeSH: C535684
            OMIM: 180550
REFERENCE   PMID:15591271 (description, gene)
  AUTHORS   Xia K, Wu L, Liu X, Xi X, Liang D, Zheng D, Cai F, Pan Q, Long Z, Dai H, Hu Z, Tang B, Zhang Z, Xia J
  TITLE     Mutation in PITX2 is associated with ring dermoid of the cornea.
  JOURNAL   J Med Genet 41:e129 (2004)
REFERENCE   PMID:22224469 (gene)
  AUTHORS   Doerdelmann T, Kojetin DJ, Baird-Titus JM, Solt LA, Burris TP, Rance M
  TITLE     Structural and biophysical insights into the ligand-free Pitx2 homeodomain and a  ring dermoid of the cornea inducing homeodomain mutant.
  JOURNAL   Biochemistry 51:665-76 (2012)
///
ENTRY       H01150                      Disease
NAME        Phenylobacterium infection
DESCRIPTION Infectious granulomatous lesions may present as skin granulomas. Phenylobacterium, a gram-negative rod bacterium, has been identified in severe cutaneous infectious granuloma.
CATEGORY    Infectious disease
PATHOGEN    Phenylobacterium
MARKER      16S rRNA (PCR detection) [KO:K01977]
DRUG        Erythromycin [DG:DG00436]
            Levofloxacin [DG:DG00624]
REFERENCE   PMID:20394459
  AUTHORS   Zhu XH, Li F, Xu JH, Xiang LH, Kang KF
  TITLE     Cutaneous infectious granuloma caused by Phenylobacterium in an adult with myelodysplastic syndrome: a first case report.
  JOURNAL   Am J Clin Dermatol 11:363-6 (2010)
///
ENTRY       H01151                      Disease
NAME        Brevundimonas infection
DESCRIPTION Brevundimonas species are aerobic non-fermenting gram-negative bacilli. They are infrequently isolated from clinical samples, however it can cause opportunistic infections in patients with underlying diseases.
CATEGORY    Infectious disease
PATHOGEN    Brevundimonas vesicularis
            Brevundimonas diminuta
            Brevundimonas vancanneytii
DRUG        Functional asplenia
            Prolonged steroid use
            End-stage renal disease
            Autoimmune diseases
            Vancomycin [DG:DG00086]
            Ceftazidime [DG:DG00571]
            Levofloxacin [DG:DG00624]
            Tobramycin [DG:DG00608]
            Piperacillin [DG:DG00526]
            Ceftriaxone [DG:DG00573]
            Gentamicin [DG:DG00401]
            Cefotaxime [DR:D07647]
            Amoxicillin [DG:DG00570]
            Tazobactam [DG:DG00546]
            Clavulanic acid [DR:D07711]
REFERENCE   PMID:15000562
  AUTHORS   Chi CY, Fung CP, Wong WW, Liu CY
  TITLE     Brevundimonas bacteremia: two case reports and literature review.
  JOURNAL   Scand J Infect Dis 36:59-61 (2004)
REFERENCE   PMID:19880635 (description, env_factor)
  AUTHORS   Estrela AB, Abraham WR
  TITLE     Brevundimonas vancanneytii sp. nov., isolated from blood of a patient with endocarditis.
  JOURNAL   Int J Syst Evol Microbiol 60:2129-34 (2010)
REFERENCE   PMID:20152619 (description, env_factor, drug)
  AUTHORS   Pelletier JS, Ide T, Yoo SH
  TITLE     Brevundimonas vesicularis keratitis after laser in situ keratomileusis.
  JOURNAL   J Cataract Refract Surg 36:340-3 (2010)
REFERENCE   PMID:21617535 (descritpion)
  AUTHORS   Pandit RT
  TITLE     Brevundimonas diminuta keratitis.
  JOURNAL   Eye Contact Lens 38:63-5 (2012)
///
ENTRY       H01152                      Disease
NAME        Taenia saginata infection
DESCRIPTION Taeniasis is a tapeworm infection of humans that causes chronic abdominal pain or persistent diarrhea. Taenia saginata (beef tapeworm) induces human infections through cattle as intermediate hosts. Patients most commonly become aware of T. saginata infection by noting passage of proglottids in their faeces.
CATEGORY    Infectious disease
PATHOGEN    Taenia saginata
MARKER      T. saginata surface antigens (ELISA)
            HDP2 (PCR and RFLP detection)
            Cathepsin L-like cysteine peptidases (LAMP) [KO:K13537]
            Cytochrome c oxidase subunit 1 (LAMP) [KO:K02256]
DRUG        Nitazoxanide [DR:D02486]
            Meglumine [DR:D01796]
            Diatrizoate sodium [DR:D01013]
DBLINKS     ICD-10: B68.1
            MeSH: D013622
REFERENCE   PMID:20701576 (env_factor, marker, drug)
  AUTHORS   Silva CV, Costa-Cruz JM
  TITLE     A glance at Taenia saginata infection, diagnosis, vaccine, biological control and treatment.
  JOURNAL   Infect Disord Drug Targets 10:313-21 (2010)
REFERENCE   PMID:22246486 (description, drug)
  AUTHORS   Hirasaki S, Murakami K, Mizushima T, Hiramatsu K, Hanayama Y, Kanamori T, Koide N
  TITLE     Long-term Taenia saginata infection successfully treated with meglumine/diatrizoate sodium.
  JOURNAL   Intern Med 51:177-9 (2012)
REFERENCE   PMID:8688859 (marker)
  AUTHORS   Machnicka B, Dziemian E, Zwierz C
  TITLE     Detection of Taenia saginata antigens in faeces by ELISA.
  JOURNAL   Appl Parasitol 37:106-10 (1996)
REFERENCE   PMID:20540755 (marker)
  AUTHORS   Gonzalez LM, Bailo B, Ferrer E, Garcia MD, Harrison LJ, Parkhouse MR, McManus DP, Garate T
  TITLE     Characterization of the Taenia spp HDP2 sequence and development of a novel PCR-based assay for discrimination of Taenia saginata from Taenia asiatica.
  JOURNAL   Parasit Vectors 3:51 (2010)
///
ENTRY       H01153                      Disease
NAME        Human echinococcosis
DESCRIPTION Human echinococcosis is a zoonosis caused by the larval stages of the cestode parasites Echinococcus granulosus and E. multilocularis, affecting an estimated 2-3 million people worldwide. Contamination of humans occurs by the ingestion of the parasite eggs, either after touching carnivore hosts, or after eating food contaminated by carnivore feces. E. granulosus causes benign tumors/cysts (hydatid cyst disease) that is most often curable. Disease due to E. multilocularis (alveolar hydatid disease) is less common but more difficult to treat. In echinococcosis, anaphylactic reactions might occur with fatal outcome.
CATEGORY    Infectious disease
PATHOGEN    Echinococcus granulosus
            Echinococcus multilocularis
DRUG        Antihelmintic drugs
            Surgery
            PAIR (Puncture, Aspirate, Injection of a scolicide, Reaspirate)
            PAIRD (PAIR plus Drainage)
            PPDC (Percutaneous Puncture with Drainage and Curettage)
DBLINKS     ICD-10: B67
            MeSH: D004443
REFERENCE   PMID:22347516 (description, env_factor)
  AUTHORS   Bristow BN, Lee S, Shafir S, Sorvillo F
  TITLE     Human echinococcosis mortality in the United States, 1990-2007.
  JOURNAL   PLoS Negl Trop Dis 6:e1524 (2012)
REFERENCE   PMID:15146106 (descirpion, env_factor)
  AUTHORS   Vuitton DA
  TITLE     Echinococcosis and allergy.
  JOURNAL   Clin Rev Allergy Immunol 26:93-104 (2004)
REFERENCE   PMID:15027603 (drug)
  AUTHORS   Macpherson CN, Bartholomot B, Frider B
  TITLE     Application of ultrasound in diagnosis, treatment, epidemiology, public health and control of Echinococcus granulosus and E. multilocularis.
  JOURNAL   Parasitology 127 Suppl:S21-35 (2003)
///
ENTRY       H01154                      Disease
NAME        Wolff-Parkinson-White (WPW) syndrome;
            Preexcitation syndrome
DESCRIPTION Wolff-Parkinson-White (WPW) syndrome is the most common cause of ventricular pre-excitation, a condition where all or part of the ventricle is excited earlier than would normally be expected, often leading to ventricular fibrillation and sudden cardiac death. It was recently discovered that mutations in PRKAG2, that encodes a subunit of the AMP-activated protein kinase, is responsible for WPW syndrome.
CATEGORY    Cardiovascular disease
GENE        PRKAG2 [HSA:51422] [KO:K07200]
MARKER      (Electrocardiogram) Shortened PQ interval, widened QRS complex, and slowed delta wave.
DRUG        Vagal maneuvers
            Injection of an anti-arrhythmic medication [DR:D00045] [DG:DG00201] [DG:DG00200]
            Radiofrequency catheter ablation
COMMENT     The use of Verapamil [DG:DG00329] or Digoxin [DR:D00298] for long-term therapy appears to be contraindicated for many patients with WPW syndrome.
DBLINKS     ICD-10: I45.6
            OMIM: 194200
REFERENCE   PMID:20888928
  AUTHORS   Sternick EB, Oliva A, Gerken LM, Magalhaes L, Scarpelli R, Correia FS, Rego S, Santana O, Brugada R, Wellens HJ
  TITLE     Clinical, electrocardiographic, and electrophysiologic characteristics of patients with a fasciculoventricular pathway: the role of PRKAG2 mutation.
  JOURNAL   Heart Rhythm 8:58-64 (2011)
REFERENCE   PMID:16686673
  AUTHORS   Light PE
  TITLE     Familial Wolff-Parkinson-White Syndrome: a disease of glycogen storage or ion channel dysfunction?
  JOURNAL   J Cardiovasc Electrophysiol 17 Suppl 1:S158-S161 (2006)
REFERENCE   PMID:15952923
  AUTHORS   Redfearn DP, Krahn AD, Skanes AC, Yee R, Klein GJ
  TITLE     Use of medications in Wolff-Parkinson-White syndrome.
  JOURNAL   Expert Opin Pharmacother 6:955-63 (2005)
REFERENCE   PMID:17547624 (Drug)
  AUTHORS   Fragakis N, Iliadis I, Papanastasiou S, Lambrou A, Katsaris G
  TITLE     Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.
  JOURNAL   Pacing Clin Electrophysiol 30:823-5 (2007)
///
ENTRY       H01155                      Disease
NAME        Roussy-Levy syndrome
DESCRIPTION Roussy-Levy syndrome (RLS) is a dominantly inherited early-onset syndrome consisting of gait ataxia, pes cavus, areflexia, eventually associated with muscle atrophy, postural tremors, limb ataxia, kyphoscoliosis, and sensory loss. The RLS subtype is not genetically homogeneous. RLS has been described as a phenotypic variant of Charcot-Marie-Tooth disease [DS:H00264] type 1A (CMT-1A) associated with duplications of the PMP22 gene. A mutations in the MPZ gene has been revealed indicating that the original RLS may fall under the CMT-1B subgroup of hereditary demyelinating neuropathies.
CATEGORY    Neurodegenerative disease; Eye disease; Urinary system disease
GENE        MPZ [HSA:4359] [KO:K06770]
            PMP22 [HSA:5827] [KO:K13347]
DBLINKS     ICD-10: G60.0
            MeSH: D002607
            OMIM: 180800
REFERENCE   PMID:18592125 (description, gene)
  AUTHORS   Zubair S, Holland NR, Beson B, Parke JT, Prodan CI
  TITLE     A novel point mutation in the PMP22 gene in a family with Roussy-Levy syndrome.
  JOURNAL   J Neurol 255:1417-8 (2008)
REFERENCE   PMID:12428130 (description)
  AUTHORS   Haubrich C, Krings T, Senderek J, Zuchner S, Schroder JM, Noth J, Topper R
  TITLE     Hypertrophic nerve roots in a case of Roussy-Levy syndrome.
  JOURNAL   Neuroradiology 44:933-7 (2002)
REFERENCE   PMID:10553995 (description, gene)
  AUTHORS   Plante-Bordeneuve V, Guiochon-Mantel A, Lacroix C, Lapresle J, Said G
  TITLE     The Roussy-Levy family: from the original description to the gene.
  JOURNAL   Ann Neurol 46:770-3 (1999)
///
ENTRY       H01156                      Disease
NAME        STAR syndrome
DESCRIPTION STAR syndrome is an X-linked dominant disorder caused by mutations in the cyclin family member FAM58A characterized by syndactyly, telecanthus, and anogenital and renal malformations. The cardinal features of this syndrome are a characteristic facial appearance with apparent telecanthus and broad tripartite nasal tip, variable syndactyly of toes 2-5, hypoplastic labia, anal atresia, and urogenital malformations.
CATEGORY    Skeletal dysplasia
GENE        FAM58A [HSA:92002]
DBLINKS     MeSH: C567475
            OMIM: 300707
REFERENCE   PMID:18297069 (description, gene)
  AUTHORS   Unger S, Bohm D, Kaiser FJ, Kaulfuss S, Borozdin W, Buiting K, Burfeind P, Bohm J, Barrionuevo F, Craig A, Borowski K, Keppler-Noreuil K, Schmitt-Mechelke T, Steiner B, Bartholdi D, Lemke J, Mortier G, Sandford R, Zabel B, Superti-Furga A, Kohlhase J
  TITLE     Mutations in the cyclin family member FAM58A cause an X-linked dominant disorder  characterized by syndactyly, telecanthus and anogenital and renal malformations.
  JOURNAL   Nat Genet 40:287-9 (2008)
///
ENTRY       H01157                      Disease
NAME        Agrobacterium radiobacter infection
DESCRIPTION Agrobacteria are small, gram-negative bacilli widely distributed in soil. They are best known for the phytopathogenicity, causing tumorigenic disease in plants. However, Agrobacterium spp. are recognized as rare human pathogens affecting mostly immunocompromised or chronically debilitated hosts and patients with indwelling catheters. Clinical manifestations include bacteremia, peritonitis, and deltoid muscle myositis.
CATEGORY    Infectious disease
PATHOGEN    Agrobacterium radiobacter [GN:ara]
DRUG        Doxycycline [DG:DG00008]
            Imipenem-Cilastatin [DR:D00344]
            Ampicillin [DG:DG00517]
            Ciprofloxacin [DG:DG00617]
            Amikacin [DG:DG00403]
            Ceftazidime [DG:DG00571]
            Ciprofloxacin [DG:DG00617]
            Cotrimoxazole [DR:D00285]
            Vancomycin [DG:DG00086]
            Gentamicin [DG:DG00401]
            Ticarcillin-clavulanate [DR:D02503]
            Cefuroxime [DG:DG00558]
            Mezlocillin [DG:DG00525]
            Oxacillin [DG:DG00542]
            Sulbactam [DG:DG00545]
REFERENCE   PMID:14735386 (description, env_factor, drug)
  AUTHORS   Paphitou NI, Rolston KV
  TITLE     Catheter-related bacteremia caused by Agrobacterium radiobacter in a cancer patient: case report and literature review.
  JOURNAL   Infection 31:421-4 (2003)
REFERENCE   PMID:12586984 (description, env_factor, drug)
  AUTHORS   Amaya RA, Edwards MS
  TITLE     Agrobacterium radiobacter bacteremia in pediatric patients: case report and review.
  JOURNAL   Pediatr Infect Dis J 22:183-6 (2003)
REFERENCE   PMID:18539494 (description, env_factor)
  AUTHORS   Detrait M, D'Hondt L, Andre M, Lonchay C, Holemans X, Maton JP, Canon JL
  TITLE     Agrobacterium radiobacter bacteremia in oncologic and geriatric patients: presentation of two cases and review of the literature.
  JOURNAL   Int J Infect Dis 12:e7-10 (2008)
///
ENTRY       H01158                      Disease
NAME        Alopecia universalis
DESCRIPTION Alopecia universalis is the most severe form of alopecia areata, characterized by generalized scalp and body atrichia with papular lesions. Mutations in the gene HR coding for the Hairless protein are associated with alopecia universalis. It is inherited in autosomal recessive manner.
CATEGORY    Skin and connective tissue disease
GENE        HR [HSA:55806] [KO:K00478]
DBLINKS     ICD-10: L63.1
            MeSH: C537055
            OMIM: 203655
REFERENCE   PMID:21272494
  AUTHORS   Nucara S, Colao E, Mangone G, Baudi F, Fabiani F, Nocera D, Passafaro G, Longo T, Laria AE, Malatesta P, Amato R, Trapasso F, Perrotti N
  TITLE     Identification of a new mutation in the gene coding for hairless protein responsible for alopecia universalis: The importance of direct gene sequencing.
  JOURNAL   Dermatol Online J 17:3 (2011)
REFERENCE   PMID:9445480
  AUTHORS   Ahmad W, Faiyaz ul Haque M, Brancolini V, Tsou HC, ul Haque S, Lam H, Aita VM, Owen J, deBlaquiere M, Frank J, Cserhalmi-Friedman PB, Leask A, McGrath JA, Peacocke M, Ahmad M, Ott J, Christiano AM
  TITLE     Alopecia universalis associated with a mutation in the human hairless gene.
  JOURNAL   Science 279:720-4 (1998)
REFERENCE   PMID:9736769
  AUTHORS   Cichon S, Anker M, Vogt IR, Rohleder H, Putzstuck M, Hillmer A, Farooq SA, Al-Dhafri KS, Ahmad M, Haque S, Rietschel M, Propping P, Kruse R, Nothen MM
  TITLE     Cloning, genomic organization, alternative transcripts and mutational analysis of the gene responsible for autosomal recessive universal congenital alopecia.
  JOURNAL   Hum Mol Genet 7:1671-9 (1998)
///
ENTRY       H01159                      Disease
NAME        Anterior segment dysgenesis (ASD), including:
            Anterior segment mesenchymal dysgenesis;
            Aniridia;
            Axenfeld-Rieger syndrome (ARS);
            Peters anomaly;
            Iridogoniodysgenesis (IRID)
DESCRIPTION Anterior segment dysgenesis (ASD) is a range of developmental defects in structures at the front of the eye. These defects are thought to result from abnormal migration or differentiation of the neural-crest derived mesenchymal cells that give rise to the cornea, iris, and other components of the anterior chamber during eye development. Human ASD phenotypes are genetically heterogeneous resulting from mutations in different transcription factor genes and a cytochrome enzyme gene.
CATEGORY    Developmental disorder; Eye disease
GENE        PAX6 [HSA:5080] [KO:K08031]
            PITX2 [HSA:5308] [KO:K04686]
            PITX3 [HSA:5309] [KO:K09357]
            FOXC1 [HSA:2296] [KO:K09396]
            FOXE3 [HSA:2301] [KO:K09398]
            CYP1B1 [HSA:1545] [KO:K07410]
            B3GALTL [HSA:145173] [KO:K13675]
COMMENT     Aniridia, ARS, and Peters anomaly are also described in H00635, H00620, and H01075, respectively. [DS:H00635] [DS:H00620] [DS:H01075]
DBLINKS     ICD-10: Q13.1 Q13.4 Q13.8
            MeSH: C537775
            OMIM: 107250 106210 180500 602482 604229 601631 137600 261540
REFERENCE   PMID:18989383
  AUTHORS   Summers KM, Withers SJ, Gole GA, Piras S, Taylor PJ
  TITLE     Anterior segment mesenchymal dysgenesis in a large Australian family is associated with the recurrent 17 bp duplication in PITX3.
  JOURNAL   Mol Vis 14:2010-5 (2008)
REFERENCE   PMID:11159941
  AUTHORS   Semina EV, Brownell I, Mintz-Hittner HA, Murray JC, Jamrich M
  TITLE     Mutations in the human forkhead transcription factor FOXE3 associated with anterior segment ocular dysgenesis and cataracts.
  JOURNAL   Hum Mol Genet 10:231-6 (2001)
REFERENCE   PMID:16826526
  AUTHORS   Valleix S, Niel F, Nedelec B, Algros MP, Schwartz C, Delbosc B, Delpech M, Kantelip B
  TITLE     Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans.
  JOURNAL   Am J Hum Genet 79:358-64 (2006)
REFERENCE   PMID:15466012
  AUTHORS   Pal B, Mohamed MD, Keen TJ, Williams GA, Bradbury JA, Sheridan E, Inglehearn CF
  TITLE     A new phenotype of recessively inherited foveal hypoplasia and anterior segment dysgenesis maps to a locus on chromosome 16q23.2-24.2.
  JOURNAL   J Med Genet 41:772-7 (2004)
///
ENTRY       H01160                      Disease
NAME        Schizencephaly
DESCRIPTION Schizencephaly is a clinically and etiologically heterogeneous cerebral malformation presenting as unilateral or bilateral hemispheric cleft with direct connection between the inner and outer liquor spaces. Gray matter-lined clefts in the cerebral cortex and a range of neurological presentations are characteristic. Mutations in SIX3, SHH, and EMX2 have been reported.
CATEGORY    Developmental disorder; Nervous system disease
GENE        SIX3 [HSA:6496] [KO:K19473]
            SHH [HSA:6469] [KO:K11988]
            EMX2 [HSA:2018] [KO:K09317]
COMMENT     Schizencephaly may be considered as part of the wide phenotypic spectrum of the distinct developmental anomaly holoprosencephaly [DS:H00267].
DBLINKS     ICD-10: Q04.6
            MeSH: D054220
            OMIM: 269160
REFERENCE   PMID:20157829 (description, gene, comment)
  AUTHORS   Hehr U, Pineda-Alvarez DE, Uyanik G, Hu P, Zhou N, Hehr A, Schell-Apacik C, Altus C, Daumer-Haas C, Meiner A, Steuernagel P, Roessler E, Winkler J, Muenke M
  TITLE     Heterozygous mutations in SIX3 and SHH are associated with schizencephaly and further expand the clinical spectrum of holoprosencephaly.
  JOURNAL   Hum Genet 127:555-61 (2010)
REFERENCE   PMID:15888615 (description)
  AUTHORS   Oh KY, Kennedy AM, Frias AE Jr, Byrne JL
  TITLE     Fetal schizencephaly: pre- and postnatal imaging with a review of the clinical manifestations.
  JOURNAL   Radiographics 25:647-57 (2005)
REFERENCE   PMID:8528262 (gene)
  AUTHORS   Brunelli S, Faiella A, Capra V, Nigro V, Simeone A, Cama A, Boncinelli E
  TITLE     Germline mutations in the homeobox gene EMX2 in patients with severe schizencephaly.
  JOURNAL   Nat Genet 12:94-6 (1996)
///
ENTRY       H01161                      Disease
NAME        Aromatic L-amino acid decarboxylase (AADC) deficiency
DESCRIPTION Aromatic L-amino acid decarboxylase (AADC) deficiency is an autosomal recessive disorders of monoamine neurotransmitter metabolism, clinically characterized by vegetative symptoms, oculogyric crises, dystonia, and severe neurologic dysfunction in infancy. Mutations in the gene encoding for the enzyme AADC (DDC) lead to a severe combined deficiency of serotonin and the two catecholamines dopamine and norepinephrine.
CATEGORY    Nervous system disease
GENE        DDC [HSA:1644] [KO:K01593]
MARKER      Low homovanillic acidHomovanillic acid [CPD:C05582], 5-hydroxyindoleacetic acid [CPD:C05635], and 3-methoxy-4-hydroxy-phenylglycol [CPD:C05594]
            Elevated 3-O-methyl-L-dopa, L-dopa [CPD:C00355], and 5-hydroxytryptophan [CPD:C01017]
DRUG        Bromocriptine [DG:DG00452] Pergolide [DG:DG00861] (Dopamine agonist)
            Selegiline [DG:DG00864] (MAO inhibitors)
            Pyridoxine [DG:DG00128]
DBLINKS     ICD-10: G24.8
            MeSH: C537437
            OMIM: 608643
REFERENCE   PMID:15079002
  AUTHORS   Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, Sharma R, De Vivo DC
  TITLE     Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.
  JOURNAL   Neurology 62:1058-65 (2004)
REFERENCE   PMID:20505134
  AUTHORS   Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, Lee WT, Willemsen MA, Verbeek MM, Wassenberg T, Regal L, Orcesi S, Tonduti D, Accorsi P, Testard H, Abdenur JE, Tay S, Allen GF, Heales S, Kern I, Kato M, Burlina A, Manegold C, Hoffmann GF, Blau N
  TITLE     Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency.
  JOURNAL   Neurology 75:64-71 (2010)
///
ENTRY       H01162                      Disease
NAME        Scott syndrome
DESCRIPTION Scott syndrome is a rare autosomal recessive congenital bleeding disorder caused by a defect in blood coagulation. When platelets are activated, a calcium-induced rearrangement of the platelet membrane phospholipids takes place, exposing negatively charged phosphatidylserine (PS) at the outer surface of the platelets, where it can anchor coagulation factors. This phenomenon is mediated by lipid scramblase. In patients with Scott syndrome this mechanism is defective, resulting in impaired blood clotting. A mutation in the gene encoding scramblase TMEM16F has been found.
CATEGORY    Hematologic disease
GENE        ANO6 [HSA:196527] [KO:K19500]
DBLINKS     ICD-10: D69.8
            OMIM: 262890
REFERENCE   PMID:18180086 (description)
  AUTHORS   Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H
  TITLE     Inherited traits affecting platelet function.
  JOURNAL   Blood Rev 22:155-72 (2008)
REFERENCE   PMID:21642943 (description)
  AUTHORS   Duran C, Hartzell HC
  TITLE     Physiological roles and diseases of Tmem16/Anoctamin proteins: are they all chloride channels?
  JOURNAL   Acta Pharmacol Sin 32:685-92 (2011)
REFERENCE   PMID:21107324 (description, gene)
  AUTHORS   Suzuki J, Umeda M, Sims PJ, Nagata S
  TITLE     Calcium-dependent phospholipid scrambling by TMEM16F.
  JOURNAL   Nature 468:834-8 (2010)
///
ENTRY       H01163                      Disease
NAME        Corticosteroid-binding globulin (CBG) deficiency
DESCRIPTION Corticosteroid-binding globulin (CBG) deficiency is a rare autosomal recessive disorder associated with hypotension and fatigue. CBG is the main transport protein for glucocorticoids in blood and only a few causative genetic variants in human CBG (SERPINA6) gene have been described.
CATEGORY    Endocrine disease
GENE        SERPINA6 [HSA:866] [KO:K04525]
DBLINKS     ICD-10: E27.8
            MeSH: C565152
            OMIM: 611489
REFERENCE   PMID:20610591
  AUTHORS   Perogamvros I, Underhill C, Henley DE, Hadfield KD, Newman WG, Ray DW, Lightman SL, Hammond GL, Trainer PJ
  TITLE     Novel corticosteroid-binding globulin variant that lacks steroid binding activity.
  JOURNAL   J Clin Endocrinol Metab 95:E142-50 (2010)
///
ENTRY       H01164                      Disease
NAME        Paracoccus yeei infection
DESCRIPTION Paracoccus yeei, a gram-negative bacterium, has been identified as an unusual etiologic opportunistic agent in patients with cardiac transplant, automated peritoneal dialysis, or corneal graft.
CATEGORY    Infectious disease
PATHOGEN    Paracoccus yeei
MARKER      16S rRNA [KO:K01977]
DRUG        Ciprofloxacin [DG:DG00617]
            Cefazolin [DG:DG00550]
            Ofloxacin [DG:DG00616]
            Vancomycin [DG:DG00086]
            Ceftazidime [DG:DG00571]
REFERENCE   PMID:20854281 (description, env_factor, drug)
  AUTHORS   Schweiger M, Stiegler P, Scarpatetti M, Wasler A, Sereinigg M, Prenner G, Tscheliessnigg K
  TITLE     Case of Paracoccus yeei infection documented in a transplanted heart.
  JOURNAL   Transpl Infect Dis 13:200-3 (2011)
REFERENCE   PMID:19556157 (description, env_factor)
  AUTHORS   Wallet F, Blondiaux N, Foy CL, Loiez C, Armand S, Pagniez D, Courcol RJ
  TITLE     Paracoccus yeei: a new unusual opportunistic bacterium in ambulatory peritoneal dialysis.
  JOURNAL   Int J Infect Dis 14:e173-4 (2010)
REFERENCE   PMID:15243119 (description, env_factor, drug)
  AUTHORS   Funke G, Frodl R, Sommer H
  TITLE     First comprehensively documented case of Paracoccus yeei infection in a human.
  JOURNAL   J Clin Microbiol 42:3366-8 (2004)
REFERENCE   PMID:19889897 (description)
  AUTHORS   Kanis MJ, Oosterheert JJ, Lin S, Boel CH, Ekkelenkamp MB
  TITLE     Corneal graft rejection complicated by Paracoccus yeei infection in a patient who had undergone a penetrating keratoplasty.
  JOURNAL   J Clin Microbiol 48:323-5 (2010)
///
ENTRY       H01165                      Disease
NAME        Novosphingobium aromaticivorans infection
DESCRIPTION Novosphingobium aromaticivorans is a gram-negative aerobic bacterium that is well known for its ability to degrade phenolic structures. N. aromaticivorans has been reported to trigger the development of primary biliary cirrhosis because it expresses proteins that have high homology with human pyruvate dehydrogenase component (PDC-E2), which can act as an immunological trigger for T cell-mediated tissue destruction.
CATEGORY    Infectious disease
PATHOGEN    Novosphingobium aromaticivorans [GN:nar]
            PDC-E2 like protein
REFERENCE   PMID:15554995
  AUTHORS   Kaplan MM
  TITLE     Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis.
  JOURNAL   Am J Gastroenterol 99:2147-9 (2004)
///
ENTRY       H01166                      Disease
NAME        Sphingomonas paucimobilis infection
DESCRIPTION Sphingomonas paucimobilis is a yellow-pigmented, non-fermentative, gram-negative bacillus found in water. It rarely causes serious infections but many instances of infections such as bacteraemia can be found in the literature.
CATEGORY    Infectious disease
PATHOGEN    Sphingomonas paucimobilis
DRUG        Cancer
            Chronic renal failure
            Epilepsy
            Aminoglycoside plus a third-generation cephalosporin
            Carbapenem [ATC:J01DH]
            Piperacilin-tazobactam [DR:D02505]
REFERENCE   PMID:20434794 (description, env_factor)
  AUTHORS   Ryan MP, Adley CC
  TITLE     Sphingomonas paucimobilis: a persistent Gram-negative nosocomial infectious organism.
  JOURNAL   J Hosp Infect 75:153-7 (2010)
REFERENCE   PMID:21524965 (env_factor, drug)
  AUTHORS   Toh HS, Tay HT, Kuar WK, Weng TC, Tang HJ, Tan CK
  TITLE     Risk factors associated with Sphingomonas paucimobilis infection.
  JOURNAL   J Microbiol Immunol Infect 44:289-95 (2011)
REFERENCE   PMID:21719938 (description)
  AUTHORS   Mutlu M, Bayramoglu G, Yilmaz G, Saygin B, Aslan Y
  TITLE     Outbreak of Sphingomonas paucimobilis septicemia in a neonatal intensive care unit.
  JOURNAL   Indian Pediatr 48:723-5 (2011)
REFERENCE   PMID:21960744 (description, drug)
  AUTHORS   Ozdemir M, Pekcan S, Demircili ME, Tasbent FE, Feyzioglu B, Pirinc S, Baykan M
  TITLE     A rare cause of bacteremia in a pediatric patient with Down syndrome: Sphingomonas paucimobilis.
  JOURNAL   Int J Med Sci 8:537-9 (2011)
///
ENTRY       H01167                      Disease
NAME        Gluconobacter infection
DESCRIPTION Granulibacter is a gram-negative acetic acid bacterium that is recently reported to be human opportunistic pathogen. Gluconobacter is isolated from patients with chronic granulomatous disease, in which phagocytes are not able to produce bactericidal superoxide anions. Bacteremia has also been observed in a non-immunocompromised patient with a history of intravenous drug abuse.
CATEGORY    Infectious disease
GENE        CYBB (Chronic granulomatous disease) [HSA:1536] [KO:K21421]
            CYBA (Chronic granulomatous disease) [HSA:1535] [KO:K08009]
            NCF1 (Chronic granulomatous disease) [HSA:653361] [KO:K08011]
PATHOGEN    Granulibacter bethesdensis [GN:gbe]
            Gluconobacter spp.
MARKER      16S rRNA [KO:K01977]
            RecA [KO:K03553]
COMMENT     Chronic granulomatous disease is described in H00098.
REFERENCE   PMID:20826638 (description, env_factor)
  AUTHORS   Alauzet C, Teyssier C, Jumas-Bilak E, Gouby A, Chiron R, Rabaud C, Counil F, Lozniewski A, Marchandin H
  TITLE     Gluconobacter as well as Asaia species, newly emerging opportunistic human pathogens among acetic acid bacteria.
  JOURNAL   J Clin Microbiol 48:3935-42 (2010)
REFERENCE   PMID:16617373 (description, env_factor, gene)
  AUTHORS   Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, Miller G, Kleiner DE, Tenorio AR, Brinster L, Dorward DW, Murray PR, Holland SM
  TITLE     A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease.
  JOURNAL   PLoS Pathog 2:e28 (2006)
REFERENCE   PMID:17082400 (description, env_factor, marker)
  AUTHORS   Greenberg DE, Porcella SF, Stock F, Wong A, Conville PS, Murray PR, Holland SM, Zelazny AM
  TITLE     Granulibacter bethesdensis gen. nov., sp. nov., a distinctive pathogenic acetic acid bacterium in the family Acetobacteraceae.
  JOURNAL   Int J Syst Evol Microbiol 56:2609-16 (2006)
REFERENCE   PMID:17827295 (description)
  AUTHORS   Greenberg DE, Porcella SF, Zelazny AM, Virtaneva K, Sturdevant DE, Kupko JJ 3rd, Barbian KD, Babar A, Dorward DW, Holland SM.
  TITLE     Genome sequence analysis of the emerging human pathogenic acetic acid bacterium Granulibacter bethesdensis.
  JOURNAL   J Bacteriol 189:8727-36 (2007)
///
ENTRY       H01168                      Disease
NAME        Sea-blue histiocyte disease
DESCRIPTION Sea-blue histiocyte disease is a clinical entity characterized by splenomegaly, mild purpura secondary to thrombocytopenia, and most often with a relatively prolonged benign course. Numerous sea-blue histiocytes are observed in many organs including the bone marrow, liver, and spleen. This disorder is classified as either primary or secondary; most cases are secondary to lipid metabolic diseases. A mutation in the APOE gene has been reported.
CATEGORY    Inherited metabolic disease
GENE        APOE [HSA:348] [KO:K04524]
ENV_FACTOR  Total parenteral nutrition
COMMENT     Most cases of sea-blue histiocytosis are secondary to lipid metabolic diseases, such as Niemann-Pick disease [DS:H00136], Fabry disease [DS:H00125], or ceroid strage diseases.
DBLINKS     ICD-10: D76.3
            MeSH: D012618
            OMIM: 269600
REFERENCE   PMID:9613982 (description, environmental factor)
  AUTHORS   Bigorgne C, Le Tourneau A, Vahedi K, Rio B, Messing B, Molina T, Audouin J, Diebold J
  TITLE     Sea-blue histiocyte syndrome in bone marrow secondary to total parenteral nutrition.
  JOURNAL   Leuk Lymphoma 28:523-9 (1998)
REFERENCE   PMID:17510534 (description, comment)
  AUTHORS   Suzuki O, Abe M
  TITLE     Secondary sea-blue histiocytosis derived from Niemann-Pick disease.
  JOURNAL   J Clin Exp Hematop 47:19-21 (2007)
REFERENCE   PMID:16094309 (description, gene)
  AUTHORS   Faivre L, Saugier-Veber P, Pais de Barros JP, Verges B, Couret B, Lorcerie B, Thauvin C, Charbonnier F, Huet F, Gambert P, Frebourg T, Duvillard L
  TITLE     Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.
  JOURNAL   Eur J Hum Genet 13:1186-91 (2005)
REFERENCE   PMID:11095479 (gene)
  AUTHORS   Nguyen TT, Kruckeberg KE, O'Brien JF, Ji ZS, Karnes PS, Crotty TB, Hay ID, Mahley RW, O'Brien T
  TITLE     Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)].
  JOURNAL   J Clin Endocrinol Metab 85:4354-8 (2000)
///
ENTRY       H01169                      Disease
NAME        Acetobacter infection
DESCRIPTION Acetobacter belongs to the group of acetic acid bacteria that oxidize alcohols or sugars incompletely. A. cibinongensis is one of the members that is mainly found in tropical fruits and flowers. A case of human infection with A. cibinongensis has been reported.
CATEGORY    Infectious disease
PATHOGEN    Acetobacter cibinongensis
MARKER      16S rDNA [KO:K01977]
DRUG        Pristinamycin [DR:D06311]
            Cefazolin [DG:DG00550]
            Tobramycin [DG:DG00608]
            Amoxicillin [DG:DG00520]
REFERENCE   PMID:18044042
  AUTHORS   Gouby A, Teyssier C, Vecina F, Marchandin H, Granolleras C, Zorgniotti I, Jumas-Bilak E
  TITLE     Acetobacter cibinongensis bacteremia in human.
  JOURNAL   Emerg Infect Dis 13:784-5 (2007)
///
ENTRY       H01170                      Disease
NAME        Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
DESCRIPTION Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a distinct form of hereditary early-onset spastic ataxia related to progressive degeneration of the cerebellum and spinal cord. ARSACS is clinically characterized by spasticity, ataxia, polyneuropathy, retinal changes, and in some cases late cognitive decline. Patients demonstrate an unsteady gait and experience frequent falls as they learn to walk. ARSACS is caused by mutations in the SACS gene, encoding a large protein sacsin. A recent study demonstrated that sacsin may interact with the Hsp70 chaperone machinery, which is an important component of the cellular response towards aggregation prone mutant proteins that are associated with neurodegenerative diseases.
CATEGORY    Nervous system disease
GENE        SACS [HSA:26278] [KO:K17592]
DBLINKS     ICD-10: G11.1
            MeSH: C536787
            OMIM: 270550
REFERENCE   PMID:21450511 (description, gene)
  AUTHORS   Bouhlal Y, Amouri R, El Euch-Fayeche G, Hentati F
  TITLE     Autosomal recessive spastic ataxia of Charlevoix-Saguenay: an overview.
  JOURNAL   Parkinsonism Relat Disord 17:418-22 (2011)
REFERENCE   PMID:21665375 (description, gene)
  AUTHORS   Gazulla J, Vela AC, Marin MA, Pablo L, Santorelli FM, Benavente I, Modrego P, Tintore M, Berciano J
  TITLE     Is the ataxia of Charlevoix-Saguenay a developmental disease?
  JOURNAL   Med Hypotheses 77:347-52 (2011)
REFERENCE   PMID:22307627 (description, gene)
  AUTHORS   Girard M, Lariviere R, Parfitt DA, Deane EC, Gaudet R, Nossova N, Blondeau F, Prenosil G, Vermeulen EG, Duchen MR, Richter A, Shoubridge EA, Gehring K, McKinney RA, Brais B, Chapple JP, McPherson PS
  TITLE     Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).
  JOURNAL   Proc Natl Acad Sci U S A 109:1661-6 (2012)
REFERENCE   PMID:20970105 (SPAX4)
  AUTHORS   Crosby AH, Patel H, Chioza BA, Proukakis C, Gurtz K, Patton MA, Sharifi R, Harlalka G, Simpson MA, Dick K, Reed JA, Al-Memar A, Chrzanowska-Lightowlers ZM, Cross HE, Lightowlers RN
  TITLE     Defective mitochondrial mRNA maturation is associated with spastic ataxia.
  JOURNAL   Am J Hum Genet 87:655-60 (2010)
///
ENTRY       H01171                      Disease
NAME        Poor drug metabolism (PM)
DESCRIPTION Many administered drugs are first activated by phase I drug-metabolizing enzymes, such as cytochrome P450 (CYP). There are some defective activity mutants due to CYP polymorphisms. In these cases, drugs are not metabolized, the high drug levels in blood are maintained, and toxic effects appear in the patients.
CATEGORY    Inherited metabolic disease
GENE        CYP2C19 [HSA:1557] [KO:K17721]
            CYP2D6 [HSA:1565] [KO:K17712]
COMMENT     In Caucasians and Asians, PM and allele frequency levels of CYPs (CYP2A6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) are summarized from previous findings.
DBLINKS     MeSH: C563703 C563835
            OMIM: 609535 608902
REFERENCE   PMID:12959412
  AUTHORS   Mizutani T
  TITLE     PM frequencies of major CYPs in Asians and Caucasians.
  JOURNAL   Drug Metab Rev 35:99-106 (2003)
REFERENCE   PMID:12879168
  AUTHORS   Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I
  TITLE     Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2  and of P-glycoprotein in a Russian population.
  JOURNAL   Eur J Clin Pharmacol 59:303-12 (2003)
REFERENCE   PMID:9093256
  AUTHORS   Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T
  TITLE     High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu.
  JOURNAL   Lancet 349:921-2 (1997)
///
ENTRY       H01172                      Disease
NAME        Infantile ascending hereditary spastic paralysis (IAHSP)
DESCRIPTION Infantile-onset ascending spastic paralysis (IAHSP) is a rare autosomal recessive early onset motor neuron disease caused by mutations in the gene ALS2. IAHSP is allelic to juvenile amyotrophic lateral sclerosis (JALS) [DS:H00058] and juvenile primary lateral sclerosis (JPLS) [DS:H00970]. IAHSP can be distinguished from those two disorders by the association of an infantile onset, at the age of walking achievement, with an ascending progression during childhood but a long survival during adulthood.
CATEGORY    Nervous system disease
GENE        ALS2 [HSA:57679] [KO:K04575]
DBLINKS     MeSH: C537217
            OMIM: 607225
REFERENCE   PMID:12145748 (description, gene)
  AUTHORS   Eymard-Pierre E, Lesca G, Dollet S, Santorelli FM, di Capua M, Bertini E, Boespflug-Tanguy O
  TITLE     Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene.
  JOURNAL   Am J Hum Genet 71:518-27 (2002)
REFERENCE   PMID:18810511 (description, gene)
  AUTHORS   Herzfeld T, Wolf N, Winter P, Hackstein H, Vater D, Muller U
  TITLE     Maternal uniparental heterodisomy with partial isodisomy of a chromosome 2 carrying a splice acceptor site mutation (IVS9-2A&gt;T) in ALS2 causes infantile-onset ascending spastic paralysis (IAHSP).
  JOURNAL   Neurogenetics 10:59-64 (2009)
///
ENTRY       H01173                      Disease
NAME        Stiff skin syndrome (SSS)
DESCRIPTION Stiff skin syndrome (SSS) is an autosomal dominant congenital form of scleroderma characterized by stony-hard skin, limitation of joint mobility, and mild hypertrichosis, remarkable in the areas with abundant fascia on the thighs and buttocks. SSS is caused by mutations in the Arg-Gly-Asp (RGD) sequence-encoding domain of fibrillin-1 that mediates integrin binding.
CATEGORY    Skin and connective tissue disease
GENE        FBN1 [HSA:2200] [KO:K06825]
DBLINKS     MeSH: C566112
            OMIM: 184900
REFERENCE   PMID:18936399 (description)
  AUTHORS   Liu T, McCalmont TH, Frieden IJ, Williams ML, Connolly MK, Gilliam AE
  TITLE     The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature.
  JOURNAL   Arch Dermatol 144:1351-9 (2008)
REFERENCE   PMID:16836505 (description)
  AUTHORS   Geng S, Lei X, Toyohara JP, Zhan P, Wang J, Tan S
  TITLE     Stiff skin syndrome.
  JOURNAL   J Eur Acad Dermatol Venereol 20:729-32 (2006)
REFERENCE   PMID:20375004 (description, gene)
  AUTHORS   Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai LY, Dietz HC
  TITLE     Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.
  JOURNAL   Sci Transl Med 2:23ra20 (2010)
///
ENTRY       H01174                      Disease
NAME        Congenital diarrhea, including:
            Congenital chloride diarrhea (DIAR1);
            Microvillus inclusion disease (DIAR2);
            Congenital sodium diarrhea (DIAR3);
            Congenital malabsorptive diarrhea (DIAR4);
            Congenital tufting enteropathy (DIAR5)
DESCRIPTION Congenital diarrheas are a group of rare chronic enteropathies characterized by a heterogeneous etiology. In the first weeks of life, patients usually present with severe diarrhea that within a few hours leads to a life-threatening condition secondary to massive dehydration and metabolic acidosis.
CATEGORY    Gastrointestinal disease
GENE        (DIAR1) SLC26A3 [HSA:1811] [KO:K14078]
            (DIAR2) MYO5B [HSA:4645] [KO:K10357]
            (DIAR3) SPINT2 [HSA:10653]
            (DIAR4) NEUROG3 [HSA:50674] [KO:K08028]
            (DIAR5) EPCAM [HSA:4072] [KO:K06737]
DBLINKS     MeSH: C536210 C537470 C562576
            OMIM: 214700 251850 270420 610370 613217
REFERENCE   PMID:20216094
  AUTHORS   Berni Canani R, Terrin G, Cardillo G, Tomaiuolo R, Castaldo G
  TITLE     Congenital diarrheal disorders: improved understanding of gene defects is leading to advances in intestinal physiology and clinical management.
  JOURNAL   J Pediatr Gastroenterol Nutr 50:360-6 (2010)
REFERENCE   PMID:21199752
  AUTHORS   Chen CP, Chiang MC, Wang TH, Hsueh C, Chang SD, Tsai FJ, Wang CN, Chern SR, Wang W
  TITLE     Microvillus inclusion disease: prenatal ultrasound findings, molecular diagnosis  and genetic counseling of congenital diarrhea.
  JOURNAL   Taiwan J Obstet Gynecol 49:487-94 (2010)
///
ENTRY       H01175                      Disease
NAME        Staphylococcal infection
DESCRIPTION Staphylococci are widespread as commensals of humans and animals where they colonize the skin or mucous membranes. Firstly, Staphylococcus lugdunensis is a most unusual coagulase-negative staphylococcus found on the human skin. It can cause infections at many sites including superficial skin infections, bacteremia, endocarditis, osteomyelitis, and breast abscess. Endocarditis caused by S. lugdunensis can lead to substantial morbidity and mortality. Secondly, Staphylococcus haemolyticus, found among the normal skin flora, is commonly isolated from the axillae, perineum, and inguinal areas of humans and causes septicemia, peritonitis, otitis, and urinary tract infections. S. haemolyticus is notorious for its multidrug resistance and historically early acquisition of resistance to methicillin and glycopeptide antibiotics. Finally, Staphylococcus pseudintermedius is an important opportunistic pathogen of dogs and cats. S. pseudintermedius colonization is very uncommon in humans. It is rarely isolated from human dog-bite wounds. The infection has been associated with wide range of symptoms such as bacteremia, a brain abscess, and pneumonia.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus lugdunensis [GN:slg sln]
            Staphylococcus haemolyticus [GN:sha]
            Staphylococcus pseudintermedius [GN:ssd]
MARKER      16S rRNA [slg:SLGD_00852] [KO:K01977]
DRUG        Vancomycin [DG:DG00086]
            Penicillin [ATC:J01C]
COMMENT     Treatment was most commonly initiated with vancomycin and narrowed as antibiotic susceptibilities allowed.
            Methicillin resistance has been reported.
DBLINKS     ICD-10: A41.1
            MeSH: D013203
REFERENCE   PMID:21886051 (description, pathogen, drug)
  AUTHORS   Klotchko A, Wallace MR, Licitra C, Sieger B
  TITLE     Staphylococcus lugdunensis: an emerging pathogen.
  JOURNAL   South Med J 104:509-14 (2011)
REFERENCE   PMID:21195974 (description, pathogen, drug)
  AUTHORS   Liu PY, Huang YF, Tang CW, Chen YY, Hsieh KS, Ger LP, Chen YS, Liu YC
  TITLE     Staphylococcus lugdunensis infective endocarditis: a literature review and analysis of risk factors.
  JOURNAL   J Microbiol Immunol Infect 43:478-84 (2010)
REFERENCE   PMID:20434383 (description, pathogen)
  AUTHORS   Chopra A, Gulati D, Woldenberg N, Singh M
  TITLE     Intracardiac lead endocarditis due to Staphylococcus lugdunensis.
  JOURNAL   Int J Infect Dis 14 Suppl 3:e291-3 (2010)
REFERENCE   PMID:19447659 (marker)
  AUTHORS   Pada S, Lye DC, Leo YS, Barkham T
  TITLE     Utility of 16S ribosomal DNA sequencing in the diagnosis of Staphylococcus lugdunensis native valve infective endocarditis: case report and literature review.
  JOURNAL   Int J Infect Dis 13:e511-3 (2009)
REFERENCE   PMID:21930571 (descirption, pathogen)
  AUTHORS   van Duijkeren E, Catry B, Greko C, Moreno MA, Pomba MC, Pyorala S, Ruzauskas M, Sanders P, Threlfall EJ, Torren-Edo J, Torneke K
  TITLE     Review on methicillin-resistant Staphylococcus pseudintermedius.
  JOURNAL   J Antimicrob Chemother 66:2705-14 (2011)
REFERENCE   PMID:20178486 (descirpiton, pathogen)
  AUTHORS   Fitzgerald JR
  TITLE     The Staphylococcus intermedius group of bacterial pathogens: species re-classification, pathogenesis and the emergence of meticillin resistance.
  JOURNAL   Vet Dermatol 20:490-5 (2009)
REFERENCE   PMID:19246166 (description)
  AUTHORS   Weese JS, van Duijkeren E
  TITLE     Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in veterinary medicine.
  JOURNAL   Vet Microbiol 140:418-29 (2010)
REFERENCE   PMID:16237012 (description)
  AUTHORS   Takeuchi F, Watanabe S, Baba T, Yuzawa H, Ito T, Morimoto Y, Kuroda M, Cui L, Takahashi M, Ankai A, Baba S, Fukui S, Lee JC, Hiramatsu K.
  TITLE     Whole-genome sequencing of staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species.
  JOURNAL   J Bacteriol 187:7292-308 (2005)
///
ENTRY       H01176                      Disease
NAME        Uncomplicated urinary tract infection
DESCRIPTION Staphylococci are widespread as commensals of humans and animals where they colonize the skin or mucous membranes. Staphylococcus saprophyticus is a coagulase-negative Staphylococcus, gram-positive uropathogen and frequently isolated from young female outpatients presenting with uncomplicated urinary tract infections. S. saprophyticus causes uncomplicated urinary tract infection (UTI) but no severe bacterial infectious disease as caused by S. aureus. The urease of S. saprophyticus is known to be a virulent factor for the persistent infection in the urinary tract. All of the virulence factors of S. aureus, such as coagulase, hemolysins, enterotoxins, extracellular matrixbinding proteins, and exoenzymes, are absent in the S. saprophyticus genome. Besides S. saprophyticus is a leading gram-positive uropathogen of uncomplicated UTI, a restricted group of gram-negative bacteria, including Escherichia coli, Proteus mirabilis, and Klebsiella spp. is often observed to cause uncomplicated UTI.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus saprophyticus [GN:ssp]
DBLINKS     ICD-10: B95 N39
            MeSH: D013203 D014552
            MedlinePlus: 000521
REFERENCE   PMID:16135568 (description)
  AUTHORS   Kuroda M, Yamashita A, Hirakawa H, Kumano M, Morikawa K, Higashide M, Maruyama A, Inose Y, Matoba K, Toh H, Kuhara S, Hattori M, Ohta T.
  TITLE     Whole genome sequence of Staphylococcus saprophyticus reveals the pathogenesis of uncomplicated urinary tract infection.
  JOURNAL   Proc Natl Acad Sci U S A 102:13272-7 (2005)
///
ENTRY       H01177                      Disease
NAME        Infantile bilateral striatal necrosis (IBSN)
DESCRIPTION Infantile bilateral striatal necrosis (IBSN) is a neurological disorder characterized by symmetrical degeneration of the caudate nucleus, putamen, and occasionally the globus pallidus, with little involvement of the rest of the brain. The clinical features of IBSN include developmental regression, choreoathetosis, dystonia, spasticity, dysphagia, failure to thrive, nystagmus, optic atrophy, and mental retardation. The mechanism of IBSN has not been elucidated, although it has been reported that IBSN usually occurs as a result of metabolic, familial, or toxic diseases. Mutations in the adenosine triphosphatase 6 gene (complex V) have been described in families with mitochondrial inheritance, while there is much evidence that supports the role of the mutation in nup62 as the cause of autosomal recessive IBSN.
CATEGORY    Nervous system disease
GENE        NUP62 [HSA:23636] [KO:K14306]
            MT-ATP6 [HSA:4508] [KO:K02126]
ENV_FACTOR  Human herpes virus-6 (HHV-6) infections in infants
COMMENT     A report says oral biotin may have benefited.
DBLINKS     ICD-10: G23.2
            MeSH: C537500
            OMIM: 271930 500003
REFERENCE   PMID:16786527 (description, gene)
  AUTHORS   Basel-Vanagaite L, Muncher L, Straussberg R, Pasmanik-Chor M, Yahav M, Rainshtein L, Walsh CA, Magal N, Taub E, Drasinover V, Shalev H, Attia R, Rechavi G, Simon AJ, Shohat M
  TITLE     Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis.
  JOURNAL   Ann Neurol 60:214-22 (2006)
REFERENCE   PMID:14718703 (description)
  AUTHORS   Basel-Vanagaite L, Straussberg R, Ovadia H, Kaplan A, Magal N, Shorer Z, Shalev H, Walsh C, Shohat M
  TITLE     Infantile bilateral striatal necrosis maps to chromosome 19q.
  JOURNAL   Neurology 62:87-90 (2004)
REFERENCE   PMID:12374138 (description, comment)
  AUTHORS   Straussberg R, Shorer Z, Weitz R, Basel L, Kornreich L, Corie CI, Harel L, Djaldetti R, Amir J
  TITLE     Familial infantile bilateral striatal necrosis: clinical features and response to biotin treatment.
  JOURNAL   Neurology 59:983-9 (2002)
REFERENCE   PMID:16198210 (description, environmental factor)
  AUTHORS   Murakami A, Morimoto M, Adachi S, Ishimaru Y, Sugimoto T
  TITLE     Infantile bilateral striatal necrosis associated with human herpes virus-6 (HHV-6) infection.
  JOURNAL   Brain Dev 27:527-30 (2005)
REFERENCE   PMID:7668837 (gene)
  AUTHORS   Thyagarajan D, Shanske S, Vazquez-Memije M, De Vivo D, DiMauro S
  TITLE     A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis.
  JOURNAL   Ann Neurol 38:468-72 (1995)
///
ENTRY       H01178                      Disease
NAME        Myiasis
DESCRIPTION Myiasis is a parasitic infection of vital tissue of skin and mucous membranes by dipterous larvae. Human myiasis is a rare clinic condition but more prevalent in humid tropical and subtropical regions. Myiasis may be classified into three types: (i) primary myaisis in which the larva invades healthy tissue of the host, (ii) secondary myaisis where the adult female is attracted to and lays its eggs on wounded skin, and (iii) accidental myaisis caused by ingestion of contaminated food. Among many species of Diptera that cause larval infection in humans, Dermatobia hominis, the human botfly, is responsible for the painful, boil-like lesion of furuncular myiasis.
CATEGORY    Infectious disease
PATHOGEN    Dermatobia hominis (botfly myiasis)
            Callitroga americana
            Cordylobia anthropophaga
            Oestrus ovis
            Wohlfahrtia spp. (secondary/wound myiasis)
            Calliphora spp. (secondary/wound myiasis)
            Lucilia spp. (secondary/wound myiasis)
DRUG        Turpentine oil (Oral myaisis)
            Gatifloxacin (Ophthalmomyiasis) [DG:DG00628]
            Dexamethasone (Ophthalmomyiasis) [DG:DG00011]
DBLINKS     ICD-10: B87
            MeSH: D009198
REFERENCE   PMID:2191797 (description)
  AUTHORS   Elgart ML
  TITLE     Flies and myiasis.
  JOURNAL   Dermatol Clin 8:237-44 (1990)
REFERENCE   PMID:22337450 (description, env_factor)
  AUTHORS   Bayindir T, Cicek MT, Atambay M, Kizilay A
  TITLE     Cutaneous myiasis in a malignant wound of the head and neck region.
  JOURNAL   J Craniofac Surg 23:e19-20 (2012)
REFERENCE   PMID:22114438 (description)
  AUTHORS   Pereira T, Tamgadge AP, Chande MS, Bhalerao S, Tamgadge S
  TITLE     Oral myiasis.
  JOURNAL   Contemp Clin Dent 1:275-6 (2010)
REFERENCE   PMID:22124072 (description)
  AUTHORS   Srivastava R, Devi P, Thimmarasa VB, Jayadev S
  TITLE     Flies blown disease--oral myiasis.
  JOURNAL   Indian J Dent Res 22:615 (2011)
REFERENCE   PMID:21876597
  AUTHORS   Chakraborti C, Mukhopadhya U, Mondal M, Giri D, Khan M
  TITLE     Ophthalmomyiasis in humans.
  JOURNAL   Nepal J Ophthalmol 3:193-5 (2011)
REFERENCE   PMID:11216610 (description)
  AUTHORS   Sampson CE, MaGuire J, Eriksson E
  TITLE     Botfly myiasis: case report and brief review.
  JOURNAL   Ann Plast Surg 46:150-2 (2001)
REFERENCE   PMID:17350494 (description, env_factor)
  AUTHORS   Cestari TF, Pessato S, Ramos-e-Silva M
  TITLE     Tungiasis and myiasis.
  JOURNAL   Clin Dermatol 25:158-64 (2007)
///
ENTRY       H01179                      Disease
NAME        Tungiasis;
            Chigoe flea
DESCRIPTION Tungiasis is a tropical ectoparasitosis caused by the penetration of small hematophagous flea (Tunga penetrans). It is prevalent where people live in extreme poverty, occurring in many Latin American countries. Contamination with adult females occurs when walking barefoot in the sand. After penetration, most commonly on the feet, the flea increases in volume, causing pruritus in hosts. After they eject the eggs, the lesion heals within a few days.
CATEGORY    Infectious disease
PATHOGEN    Tunga penetrans
DRUG        Zanzarin: a repellent based on coconut and jojoba oil [DR:D05326]
DBLINKS     ICD-10: B88.1
            MeSH: D058285
REFERENCE   PMID:21703785 (description, env_factor)
  AUTHORS   Lefebvre M, Capito C, Durant C, Hervier B, Grossi O
  TITLE     Tungiasis: a poorly documented tropical dermatosis.
  JOURNAL   Med Mal Infect 41:465-8 (2011)
REFERENCE   PMID:11348517 (description, env_factor)
  AUTHORS   Heukelbach J, de Oliveira FA, Hesse G, Feldmeier H
  TITLE     Tungiasis: a neglected health problem of poor communities.
  JOURNAL   Trop Med Int Health 6:267-72 (2001)
REFERENCE   PMID:16553319 (description, env_factor)
  AUTHORS   Heukelbach J
  TITLE     Tungiasis.
  JOURNAL   Rev Inst Med Trop Sao Paulo 47:307-13 (2005)
REFERENCE   PMID:17350494 (description, env_factor)
  AUTHORS   Cestari TF, Pessato S, Ramos-e-Silva M
  TITLE     Tungiasis and myiasis.
  JOURNAL   Clin Dermatol 25:158-64 (2007)
///
ENTRY       H01180                      Disease
NAME        Sveinsson chorioretinal atrophy (SCRA);
            Helicoid peripapillary chorioretinal degeneration (HPCD)
DESCRIPTION Sveinsson chorioretinal atrophy (SCRA), also referred to as helicoid peripapillary chorioretinal degeneration (HPCD), is a distinct autosomal dominant disease affecting both eyes characterized clinically by bilateral, well defined, tongue-shaped strips of atrophic retina and choroid that extend from the optic nerve into the peripheral ocular fundus. The lesions may be evident at birth and usually progress throughout life, sometimes leading to central visual loss. Clinical findings suggest that the expansion of the degenerative lesions is caused by dysplastic abnormalities of the peripapillary retinal pigment epithelium (RPE) and the mechanical tearing of the RPE layer owing to the growth of the globe. Patients with SCRA have a mutation in the TEAD1 gene.
CATEGORY    Eye disease
GENE        TEAD1 [HSA:7003] [KO:K09448]
DBLINKS     ICD-10: H35.4
            MeSH: C566236
            OMIM: 108985
REFERENCE   PMID:17339054 (description, gene)
  AUTHORS   Jonasson F, Hardarson S, Olafsson BM, Klintworth GK
  TITLE     Sveinsson chorioretinal atrophy/helicoid peripapillary chorioretinal degeneration: first histopathology report.
  JOURNAL   Ophthalmology 114:1541-6 (2007)
REFERENCE   PMID:17689488 (description, gene)
  AUTHORS   Kitagawa M
  TITLE     A Sveinsson's chorioretinal atrophy-associated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ.
  JOURNAL   Biochem Biophys Res Commun 361:1022-6 (2007)
REFERENCE   PMID:17683515 (description, gene)
  AUTHORS   Jonasson F, Sander B, Eysteinsson T, Jorgensen T, Klintworth GK
  TITLE     Sveinsson chorioretinal atrophy: the mildest changes are located in the photoreceptor outer segment/retinal pigment epithelium junction.
  JOURNAL   Acta Ophthalmol Scand 85:862-7 (2007)
///
ENTRY       H01181                      Disease
NAME        T-cell immunodeficiency congenital alopecia and nail dystrophy (TIDAND)
DESCRIPTION T-cell immunodeficiency congenital alopecia and nail dystrophy (TIDAND) is a severe combined immunodeficiency (SCID) syndrome caused by a mutation in FOXN1 gene encoding the forkhead/winged helix (WHN) FOXN1 transcription factor selectively expressed in thymic epithelia and skin. SCIDs are disorders of both cell-mediated and humoral immunity, characterized by high susceptibility to develop severe and sometimes fatal infections. TIDAND is the only human SCID caused by an intrinsic abnormality of the epithelial component of the thymus. The disease is always associated with a profound T-cell defect.
CATEGORY    Immune system disease
GENE        FOXN1 [HSA:8456] [KO:K09407]
DBLINKS     MeSH: C536781
            OMIM: 601705
REFERENCE   PMID:18339010 (description, gene)
  AUTHORS   Amorosi S, D'Armiento M, Calcagno G, Russo I, Adriani M, Christiano AM, Weiner L, Brissette JL, Pignata C
  TITLE     FOXN1 homozygous mutation associated with anencephaly and severe neural tube defect in human athymic Nude/SCID fetus.
  JOURNAL   Clin Genet 73:380-4 (2008)
REFERENCE   PMID:15180707 (description, gene)
  AUTHORS   Adriani M, Martinez-Mir A, Fusco F, Busiello R, Frank J, Telese S, Matrecano E, Ursini MV, Christiano AM, Pignata C
  TITLE     Ancestral founder mutation of the nude (FOXN1) gene in congenital severe combined immunodeficiency associated with alopecia in southern Italy population.
  JOURNAL   Ann Hum Genet 68:265-8 (2004)
///
ENTRY       H01182                      Disease
NAME        Biotinidase deficiency;
            BTD deficiency;
            Late-onset multiple carboxylase deficiency
DESCRIPTION Biotinidase deficiency is an autosomal recessive metabolic disorder in which the biotinidase is defective and the biotin is not recycled. Patients often exhibit feeding or breathing difficulties, skin rash, alopecia, hypotonia and seizures. Biotin treatment can ameliorate or prevent symptoms.
CATEGORY    Inherited metabolic disease
GENE        BTD [HSA:686] [KO:K01435]
DRUG        Biotin [DR:D00029]
COMMENT     Early-onset multiple carboxylase deficiency is described in H00180. [DS:H00180]
DBLINKS     ICD-10: E53.8
            MeSH: D028921
            OMIM: 253260
REFERENCE   PMID:21696988
  AUTHORS   Wolf B
  TITLE     The neurology of biotinidase deficiency.
  JOURNAL   Mol Genet Metab 104:27-34 (2011)
///
ENTRY       H01183                      Disease
NAME        Thiamine-responsive megaloblastic anemia (TRMA)
DESCRIPTION Thiamine-responsive megaloblastic anemia (TRMA), also known as Rogers syndrome, is a rare autosomal recessive inherited disorder characterized by megaloblastic anemia, diabetes mellitus, and progressive sensorineural deafness, due to mutations in SLC19A2, encoding a high-affinity thiamine transporter protein. In addition to the cardinal components, other findings are also reported in TRMA syndrome including congenital heart disease, arrhythmias, cardiomyopathy, retinal degeneration, optic atrophy, situs inversus, aminoaciduria, and stroke.
CATEGORY    Inherited metabolic disease
GENE        SLC19A2 [HSA:10560] [KO:K14610]
DRUG        Vitamin B1 [DR:D08580]
DBLINKS     ICD-10: D53.1
            OMIM: 249270
REFERENCE   PMID:21285901 (description, gene)
  AUTHORS   Aycan Z, Bas VN, Cetinkaya S, Agladioglu SY, Kendirci HN, Senocak F
  TITLE     Thiamine-responsive megaloblastic anemia syndrome with atrial standstill: a case  report.
  JOURNAL   J Pediatr Hematol Oncol 33:144-7 (2011)
REFERENCE   PMID:11358373 (description, gene, drug)
  AUTHORS   Neufeld EJ, Fleming JC, Tartaglini E, Steinkamp MP
  TITLE     Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport.
  JOURNAL   Blood Cells Mol Dis 27:135-8 (2001)
REFERENCE   PMID:20835854 (description, gene)
  AUTHORS   Bay A, Keskin M, Hizli S, Uygun H, Dai A, Gumruk F
  TITLE     Thiamine-responsive megaloblastic anemia syndrome.
  JOURNAL   Int J Hematol 92:524-6 (2010)
///
ENTRY       H01184                      Disease
NAME        Familial dementia, including:
            Familial British dementia (FBD);
            Familial Danish dementia (FDD)
DESCRIPTION Familial British dementia (FBD) and familial Danish dementia (FDD) are two autosomal dominant neurodegenerative diseases caused by mutations in the BRI/ ITM2B gene. Familial dementia is characterized by widespread cerebral amyloid angiopathy, parenchymal amyloid deposition, and neurofibrillary tangles.
CATEGORY    Neurodegenerative disease
GENE        ITM2B [HSA:9445] [KO:K18264]
DBLINKS     ICD-10: G31.0
            MeSH: D003704
            OMIM: 176500 117300
REFERENCE   PMID:19779737
  AUTHORS   Garringer HJ, Murrell J, D'Adamio L, Ghetti B, Vidal R
  TITLE     Modeling familial British and Danish dementia.
  JOURNAL   Brain Struct Funct 214:235-44 (2010)
///
ENTRY       H01185                      Disease
NAME        Cerebral amyloid angiopathy (CAA);
            Hereditary cerebral hemorrhage with amyloidosis
DESCRIPTION Cerebral amyloid angiopathy (CAA) is characterized by the deposition of congophilic material in the vessels of the cortex and leptomeninges. Although CAA most commonly appears in a sporadic form associated with aging, several familial forms of CAA reported to date. Hereditary cystatin C amyloid angiopathy (HCCAA) is a rare, fatal amyloid disease in young people in Iceland caused by a mutation in cystatin C, which is an inhibitor of several cysteine proteinases. It has also been reported that mutations in APP are linked to CAA.
CATEGORY    Neurodegenerative disease
GENE        CST3 [HSA:1471] [KO:K13899]
            APP [HSA:351] [KO:K04520]
DBLINKS     MeSH: D016657
            OMIM: 105150 605714
REFERENCE   PMID:20697050
  AUTHORS   Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, Mazzoleni G, Cupidi C, Marcon G, Giovagnoli A, Bizzi A, Di Fede G, Puoti G, Carella F, Salmaggi A, Romorini A, Patruno GM, Magoni M, Padovani A, Tagliavini F
  TITLE     Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP.
  JOURNAL   Arch Neurol 67:987-95 (2010)
REFERENCE   PMID:16612982
  AUTHORS   Palsdottir A, Snorradottir AO, Thorsteinsson L
  TITLE     Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects.
  JOURNAL   Brain Pathol 16:55-9 (2006)
///
ENTRY       H01186                      Disease
NAME        Abnormal thyroid hormone metabolism
DESCRIPTION Abnormal thyroid hormone metabolism is a disorder associated with an inherited selenocysteine (Sec) incorporation defect, caused by mutations in SECISBP2 (also called SBP2). Because SBP2 is epistatic to selenoprotein synthesis, these defects have a generalized effect on selenoproteins. Fibroblasts of affected patients show decreased deiodinase type 2 (DIO2) enzymatic activity not linked to the DIO2 locus.
CATEGORY    Inherited metabolic disease
GENE        SECISBP2 [HSA:79048] [KO:K19539]
DBLINKS     ICD-10: E03.8
            MeSH: C566454
            OMIM: 609698
REFERENCE   PMID:16228000 (description, gene)
  AUTHORS   Dumitrescu AM, Liao XH, Abdullah MS, Lado-Abeal J, Majed FA, Moeller LC, Boran G, Schomburg L, Weiss RE, Refetoff S
  TITLE     Mutations in SECISBP2 result in abnormal thyroid hormone metabolism.
  JOURNAL   Nat Genet 37:1247-52 (2005)
REFERENCE   PMID:19769464 (description, gene)
  AUTHORS   Dumitrescu AM, Di Cosmo C, Liao XH, Weiss RE, Refetoff S
  TITLE     The syndrome of inherited partial SBP2 deficiency in humans.
  JOURNAL   Antioxid Redox Signal 12:905-20 (2010)
///
ENTRY       H01187                      Disease
NAME        Tietz syndrome;
            Albinism-deafness syndrome
DESCRIPTION Tietz syndrome is an autosomal dominant syndrome of hypopigmentation and deafness. A missense mutation has been found in the basic region of the MITF (microphthalmia associated transcription factor) gene. Mutations in other regions of this gene have been found to produce Waardenburg syndrome type 2 (WS2) [DS:H00169], which also includes pigmentary changes and hearing loss, but in contrast to Tietz syndrome, depigmentation is patchy and hearing loss is variable in WS2.
CATEGORY    Nervous system disease; Skin and connective tissue disease
GENE        MITF [HSA:4286] [KO:K09455]
DBLINKS     OMIM: 103500
REFERENCE   PMID:16228000
  AUTHORS   Dumitrescu AM, Liao XH, Abdullah MS, Lado-Abeal J, Majed FA, Moeller LC, Boran G, Schomburg L, Weiss RE, Refetoff S
  TITLE     Mutations in SECISBP2 result in abnormal thyroid hormone metabolism.
  JOURNAL   Nat Genet 37:1247-52 (2005)
REFERENCE   PMID:19769464
  AUTHORS   Dumitrescu AM, Di Cosmo C, Liao XH, Weiss RE, Refetoff S
  TITLE     The syndrome of inherited partial SBP2 deficiency in humans.
  JOURNAL   Antioxid Redox Signal 12:905-20 (2010)
REFERENCE   PMID:10851256 (description, gene)
  AUTHORS   Smith SD, Kelley PM, Kenyon JB, Hoover D
  TITLE     Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF.
  JOURNAL   J Med Genet 37:446-8 (2000)
REFERENCE   PMID:9546825 (description, gene)
  AUTHORS   Amiel J, Watkin PM, Tassabehji M, Read AP, Winter RM
  TITLE     Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome).
  JOURNAL   Clin Dysmorphol 7:17-20 (1998)
///
ENTRY       H01188                      Disease
NAME        Tn syndrome
DESCRIPTION Tn syndrome is a rare autoimmune disease characterized by the expression of the Tn antigen, an incompletely glycosylated membrane glycoprotein, on all blood cell lineages. The epitope of the Tn antigen is terminal alpha-N-acetylgalactosamine alpha-linked to either a serine or threonine amino-acid residue. The defect may be due to a malfunction of the glycosylating enzyme T-synthase. Tn syndrome is associated with a somatic mutation in Cosmc gene, encoding a molecular chaperone that is required for the proper folding and hence full activity of T-synthase.
CATEGORY    Hematologic disease
GENE        COSMC [HSA:29071] [KO:K09653]
DBLINKS     MeSH: C562719
            OMIM: 300622
REFERENCE   PMID:16251947 (description, gene)
  AUTHORS   Ju T, Cummings RD
  TITLE     Protein glycosylation: chaperone mutation in Tn syndrome.
  JOURNAL   Nature 437:1252 (2005)
REFERENCE   PMID:21259410 (description, gene)
  AUTHORS   Ju T, Otto VI, Cummings RD
  TITLE     The Tn antigen-structural simplicity and biological complexity.
  JOURNAL   Angew Chem Int Ed Engl 50:1770-91 (2011)
REFERENCE   PMID:10571017 (description)
  AUTHORS   Berger EG
  TITLE     Tn-syndrome.
  JOURNAL   Biochim Biophys Acta 1455:255-68 (1999)
///
ENTRY       H01189                      Disease
NAME        Transaldolase (TALDO) deficiency
DESCRIPTION Transaldolase (TALDO) deficiency is an inborn error of the pentose phosphate pathway (PPP), presenting primarily with liver disease and variable clinical course. TALDO is one of the key enzymes the PPP. The severity of the symptoms can vary, ranging from fetal hydrops to slowly progressive liver cirrhosis, but patients show common symptoms like hydrops fetalis, dysmorphic features, liver dysfunction (cirrhosis), hemolytic anemia with renal involvement, and heart problems. The biochemical profile indicates an elevated level of erythritol, arabitol, ribitol, sedoheptitol, perseitol, sedoheptulose, mannoheptulose, and sedoheptulose-7P. The disorder is caused by mutations in the TALDO gene.
CATEGORY    Inherited metabolic disease
GENE        TALDO1 [HSA:6888] [KO:K00616]
MARKER      Elevated level of Erythritol [CPD:C00503], Arabitol [CPD:C00532], Ribitol [CPD:C00474], Perseitol [CPD:C08255], Sedoheptulose [CPD:C02076], Mannoheptulose [CPD:C08236], and Sedoheptulose-7P [CPD:C05382].
DBLINKS     ICD-10: E74.8
            MeSH: C563207
            OMIM: 606003
REFERENCE   PMID:19401148 (description)
  AUTHORS   Samland AK, Sprenger GA
  TITLE     Transaldolase: from biochemistry to human disease.
  JOURNAL   Int J Biochem Cell Biol 41:1482-94 (2009)
REFERENCE   PMID:17613166 (description)
  AUTHORS   Perl A
  TITLE     The pathogenesis of transaldolase deficiency.
  JOURNAL   IUBMB Life 59:365-73 (2007)
REFERENCE   PMID:21119539 (description, gene)
  AUTHORS   Balasubramaniam S, Wamelink MM, Ngu LH, Talib A, Salomons GS, Jakobs C, Keng WT
  TITLE     Novel heterozygous mutations in TALDO1 gene causing transaldolase deficiency and  early infantile liver failure.
  JOURNAL   J Pediatr Gastroenterol Nutr 52:113-6 (2011)
///
ENTRY       H01190                      Disease
NAME        Transcobalamin II deficiency
DESCRIPTION Transcobalamin (TC) II deficiency is a rare autosomal recessive disorder of vitamin B12 (cobalamin, Cbl) transport that leads to intracellular Cbl depletion with secondary impairment of methionine synthetase and methyl-malonyl CoA mutase activities. This disorder presents with failure to thrive, mucosal ulceration, vomiting, diarrhoea, lethargy, irritability, and occasionally immunological dysfunction. Affected individuals may suffer from long-term neurological sequelae if therapy with intramuscular hydroxocobalamin is not initiated promptly. Mutations in the TCN2 gene are known to cause.
CATEGORY    Inherited metabolic disease
GENE        TCN2 [HSA:6948] [KO:K14619]
DRUG        Hydroxocobalamin [DR:D01027]
DBLINKS     ICD-10: D51.2
            OMIM: 275350
REFERENCE   PMID:20352340 (description, gene)
  AUTHORS   Schiff M, Ogier de Baulny H, Bard G, Barlogis V, Hamel C, Moat SJ, Odent S, Shortland G, Touati G, Giraudier S
  TITLE     Should transcobalamin deficiency be treated aggressively?
  JOURNAL   J Inherit Metab Dis 33:223-9 (2010)
REFERENCE   PMID:19581117 (description, gene, drug)
  AUTHORS   Ratschmann R, Minkov M, Kis A, Hung C, Rupar T, Muhl A, Fowler B, Nexo E, Bodamer OA
  TITLE     Transcobalamin II deficiency at birth.
  JOURNAL   Mol Genet Metab 98:285-8 (2009)
REFERENCE   PMID:18956254 (description, gene)
  AUTHORS   Prasad C, Rosenblatt DS, Corley K, Cairney AE, Rupar CA
  TITLE     Transcobalamin (TC) deficiency--potential cause of bone marrow failure in childhood.
  JOURNAL   J Inherit Metab Dis 31 Suppl 2:S287-92 (2008)
///
ENTRY       H01191                      Disease
NAME        Asthma with nasal polyps and aspirin intolerance
DESCRIPTION Asthma is a phenotypically heterogeneous disorder with many etiologic factors and clinical characteristics. In some patients with asthma, aspirin and all nonsteroidal anti-inflammatory drugs (NSAIDs) trigger asthmatic attacks. This clinical syndrome is characterized by eosinophilic inflammation of nasal and bronchial tissue, often associated with nasal polyps. It has been reported that genetic variations in TBX21 are associated with susceptibility to asthma with nasal polyps and aspirin intolerance.
CATEGORY    Immune system disease
GENE        TBX21 [HSA:30009] [KO:K10166]
ENV_FACTOR  Aspirin [DR:D00109]
DBLINKS     ICD-10: J45
            MeSH: C565935
            OMIM: 208550
REFERENCE   PMID:15806396
  AUTHORS   Akahoshi M, Obara K, Hirota T, Matsuda A, Hasegawa K, Takahashi N, Shimizu M, Nakashima K, Cheng L, Doi S, Fujiwara H, Miyatake A, Fujita K, Higashi N, Taniguchi M, Enomoto T, Mao XQ, Nakashima H, Adra CN, Nakamura Y, Tamari M, Shirakawa T
  TITLE     Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma.
  JOURNAL   Hum Genet 117:16-26 (2005)
REFERENCE   PMID:21370724
  AUTHORS   Schaper C, Noga O, Koch B, Ewert R, Felix SB, Glaser S, Kunkel G, Gustavus B
  TITLE     Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis.
  JOURNAL   J Investig Allergol Clin Immunol 21:51-8 (2011)
///
ENTRY       H01192                      Disease
NAME        Lysyl hydroxylase 3 (LH3) deficiency;
            Bone fragility with contractures arterial rupture and deafness
DESCRIPTION Lysyl hydroxylase 3 (LH3) deficiency is a connective tissue disorder, caused by defects in PLOD3 that encodes LH3. This disease is characterized by congenital malformations severely affecting many tissues and organs and revealing features of several collagen disorders. In addition to lysyl hydroxylase activity, LH3 has also collagen galactosyltransferase and glucosyltransferase activities. It has been reported that one mutation dramatically reduced the sugar-transfer activity of LH3.
CATEGORY    Connective tissue disease
GENE        PLOD3 [HSA:8985] [KO:K13646]
DBLINKS     MeSH: C567320
            OMIM: 612394
REFERENCE   PMID:18834968
  AUTHORS   Salo AM, Cox H, Farndon P, Moss C, Grindulis H, Risteli M, Robins SP, Myllyla R
  TITLE     A connective tissue disorder caused by mutations of the lysyl hydroxylase 3 gene.
  JOURNAL   Am J Hum Genet 83:495-503 (2008)
///
ENTRY       H01193                      Disease
NAME        Familial tumoral calcinosis (FTC)
DESCRIPTION Familial tumoral calcinosis (FTC) refers to a group of disorders inherited in an autosomal recessive fashion, distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). hFTC is characterized by increased re-absorption of phosphate through the renal proximal tubule, resulting in elevated phosphate concentration and deposition of calcified deposits in cutaneous and subcutaneous tissues, occasionally, in visceral organs. hFTC has been shown to result from mutations in three genes: fibroblast growth factor-23 (FGF23), KL encoding Klotho, and GALNT3, which encodes a glycosyltransferase responsible for FGF23 O-glycosylation; defective function of any one of these three proteins results in hyperphosphatemia and ectopic calcification. nFTC is characterized by absence of metabolic abnormalities. nFTC has been found to be associated with absence of functional SAMD9, a putative tumor suppressor and anti-inflammatory protein.
CATEGORY    Inherited metabolic disease
GENE        (hFTC) GALNT3 [HSA:2591] [KO:K00710]
            (hFTC) FGF23 [HSA:8074] [KO:K04358]
            (hFTC) KL [HSA:9365] [KO:K14756]
            (nFTC) SAMD9 [HSA:54809]
DBLINKS     ICD-10: M11.2
            MeSH: C566870 C566473
            OMIM: 211900 610455
REFERENCE   PMID:19865099 (description, gene)
  AUTHORS   Sprecher E
  TITLE     Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.
  JOURNAL   J Invest Dermatol 130:652-60 (2010)
REFERENCE   PMID:22142751 (description, gene)
  AUTHORS   Farrow EG, Imel EA, White KE
  TITLE     Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and alphaKlotho).
  JOURNAL   Best Pract Res Clin Rheumatol 25:735-47 (2011)
REFERENCE   PMID:19013236 (description, gene)
  AUTHORS   Chefetz I, Sprecher E
  TITLE     Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.
  JOURNAL   Biochim Biophys Acta 1792:847-52 (2009)
///
ENTRY       H01194                      Disease
NAME        X-linked chondrodysplasia punctata, including:
            X-linked recessive chondrodysplasia punctata (CDPX1);
            X-linked dominant chondrodysplasia punctata (CDPX2)
DESCRIPTION Chondrodysplasia punctata (CDP) is a congenital disorder characterized by a skeletal abnormality, characterized by punctate calcification of the cartilage of the epiphyses, larynx and trachea. Different forms of CDP exist, the most common of which is inherited as an autosomal recessive trait (Rhizomelic CDP). CDP may also be inherited in a recessive and dominant X-linked fashion. The X-linked recessive CDP (CDPX1) characterized by facial anomalies with severe nasal hypoplasia, short stature, and distal phalangeal hypoplasia. Mutations in ARSE which encodes arylsulfatase E, showing a high sequence homology to steroid sulfatase. In X-linked dominant CDP (CDPX2), aberrant punctate calcification in cartilage is most prominent around the vertebral column, pelvis, and long bones. Additionally, CDPX2 patients may have asymmetric rhizomesomelia, sectorial cataracts, patchy alopecia, ichthyosis, and atrophoderma. It has been found that defects in D8-D7 sterol isomerase (EBP) cause CDPX2 and suggest a role for sterols in bone development.
CATEGORY    Inherited metabolic disease; Musculoskeletal disease
GENE        (CDPX1) ARSE [HSA:415] [KO:K18222] 
            (CDPX2) EBP [HSA:10682] [KO:K01824]
COMMENT     Rhizomelic chondrodysplasia punctata is described in H00207. [DS:H00207]
DBLINKS     ICD-10: Q77.3
            MeSH: C580533 C538416
            OMIM: 302950 302960
REFERENCE   PMID:12567415
  AUTHORS   Brunetti-Pierri N, Andreucci MV, Tuzzi R, Vega GR, Gray G, McKeown C, Ballabio A, Andria G, Meroni G, Parenti G
  TITLE     X-linked recessive chondrodysplasia punctata: spectrum of arylsulfatase E gene mutations and expanded clinical variability.
  JOURNAL   Am J Med Genet A 117A:164-8 (2003)
REFERENCE   PMID:10391219
  AUTHORS   Braverman N, Lin P, Moebius FF, Obie C, Moser A, Glossmann H, Wilcox WR, Rimoin DL, Smith M, Kratz L, Kelley RI, Valle D
  TITLE     Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause X-linked dominant Conradi-Hunermann syndrome.
  JOURNAL   Nat Genet 22:291-4 (1999)
///
ENTRY       H01195                      Disease
NAME        VACTERL/VATER association
DESCRIPTION The acronym VATER/VACTERL association refers to the rare, non-random co-occurrence of vertebral defects (V), anorectal malformations (A), cardiac defects (C), tracheo-esophageal fistula with or without esophageal atresia (TE), renal malformations (R), and limb defects (L). It is typically defined by the presence of at least three of these cardinal features. The aetiology has been identified only in a small fraction of patients to date, likely due to factors such as a high degree of clinical and causal heterogeneity, the largely sporadic nature of the disorder, and the presence of many similar conditions. Chromosomal abnormalities have been described in rare individual cases and proposed as possible causal factors, including: deletions of distal 13q, ring chromosome 12, and 6q; duplication on 9q;  mutations in PTEN, HOXD13, and ZIC3; and a mitochondrial substitution.
CATEGORY    Inherited metabolic disease; Skeletal dysplasia
GENE        PTEN [HSA:5728] [KO:K01110]
            HOXD13 [HSA:3239] [KO:K09298]
            ZIC3 [HSA:7547] [KO:K18487]
ENV_FACTOR  Maternal diabetes, uterine vascular pathology, and infertility treatment
DBLINKS     ICD-10: Q87.2
            MeSH: C564752
            OMIM: 276950 192350 314390
REFERENCE   PMID:20849991 (description, gene)
  AUTHORS   Schramm C, Draaken M, Bartels E, Boemers TM, Aretz S, Brockschmidt FF, Nothen MM, Ludwig M, Reutter H
  TITLE     De novo microduplication at 22q11.21 in a patient with VACTERL association.
  JOURNAL   Eur J Med Genet 54:9-13 (2011)
REFERENCE   PMID:21846383 (description)
  AUTHORS   Solomon BD
  TITLE     VACTERL/VATER Association.
  JOURNAL   Orphanet J Rare Dis 6:56 (2011)
REFERENCE   PMID:22422375 (description, environmental factor)
  AUTHORS   Hilger A, Schramm C, Draaken M, Mughal SS, Dworschak G, Bartels E, Hoffmann P, Nothen MM, Reutter H, Ludwig M
  TITLE     Familial occurrence of the VATER/VACTERL association.
  JOURNAL   Pediatr Surg Int 28:725-9 (2012)
REFERENCE   PMID:11748304 (gene)
  AUTHORS   Reardon W, Zhou XP, Eng C
  TITLE     A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association.
  JOURNAL   J Med Genet 38:820-3 (2001)
REFERENCE   PMID:19006232 (gene)
  AUTHORS   Garcia-Barcelo MM, Wong KK, Lui VC, Yuan ZW, So MT, Ngan ES, Miao XP, Chung PH, Khong PL, Tam PK
  TITLE     Identification of a HOXD13 mutation in a VACTERL patient.
  JOURNAL   Am J Med Genet A 146A:3181-5 (2008)
REFERENCE   PMID:20452998 (gene)
  AUTHORS   Wessels MW, Kuchinka B, Heydanus R, Smit BJ, Dooijes D, de Krijger RR, Lequin MH, de Jong EM, Husen M, Willems PJ, Casey B
  TITLE     Polyalanine expansion in the ZIC3 gene leading to X-linked heterotaxy with VACTERL association: a new polyalanine disorder?
  JOURNAL   J Med Genet 47:351-5 (2010)
///
ENTRY       H01196                      Disease
NAME        Hypochromic microcytic anemia
DESCRIPTION Hypochromic microcytic anemia has been associated with a defect of iron absorption due to reduced iron entry into intestinal cells. Several isoforms of NRAMP2 (SLC11A2) are expressed ubiquitously in recycling endosomes or specifically at the apical membrane of epithelial cells in intestine and kidneys, and can contribute to iron overload, whereas mutations impairing NRAMP2 function cause a form of congenital hypochromic microcytic anemia.
CATEGORY    Hematologic disease
GENE        NRAMP2 [HSA:4891] [KO:K21398]
DBLINKS     ICD-10: D50.8
            OMIM: 206100
REFERENCE   PMID:17215883 (description, gene)
  AUTHORS   Courville P, Chaloupka R, Cellier MF
  TITLE     Recent progress in structure-function analyses of Nramp proton-dependent metal-ion transporters.
  JOURNAL   Biochem Cell Biol 84:960-78 (2006)
REFERENCE   PMID:9808632 (description, gene)
  AUTHORS   Wood RJ, Han O
  TITLE     Recently identified molecular aspects of intestinal iron absorption.
  JOURNAL   J Nutr 128:1841-4 (1998)
///
ENTRY       H01197                      Disease
NAME        Dihydrofolate reductase (DHFR) deficiency
DESCRIPTION Dihydrofolate reductase (DHFR) deficiency is a recessive inborn error of metabolism characterized by megaloblastic anemia and cerebral folate deficiency, with variable neurological findings. It is caused by mutations in the DHFR gene.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        DHFR [HSA:1719] [KO:K00287]
DRUG        Folinic acid [DR:D07986]
DBLINKS     MeSH: C565095
            OMIM: 613839
REFERENCE   PMID:22108709 (description, gene, drug)
  AUTHORS   Watkins D, Rosenblatt DS
  TITLE     Update and new concepts in vitamin responsive disorders of folate transport and metabolism.
  JOURNAL   J Inherit Metab Dis 35:665-70 (2012)
REFERENCE   PMID:21388369 (description, gene, drug)
  AUTHORS   Wijesekara N
  TITLE     Dihydrofolate reductase mutations-associated megaloblastic anemia and cerebral folate deficiency.
  JOURNAL   Clin Genet 79:507-8 (2011)
REFERENCE   PMID:21310276 (description, gene, drug)
  AUTHORS   Banka S, Blom HJ, Walter J, Aziz M, Urquhart J, Clouthier CM, Rice GI, de Brouwer AP, Hilton E, Vassallo G, Will A, Smith DE, Smulders YM, Wevers RA, Steinfeld R, Heales S, Crow YJ, Pelletier JN, Jones S, Newman WG
  TITLE     Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
  JOURNAL   Am J Hum Genet 88:216-25 (2011)
///
ENTRY       H01198                      Disease
NAME        Fanconi renotubular syndrome (FTS)
DESCRIPTION Fanconi renotubular syndrome (FTS) is a disease resulting from a generalized dysfunction of the proximal kidney tubule leading to decreased solute and water reabsorption. Patients had a generalized proximal tubulopathy, renal phosphate wasting, bone mineral deficiency, and decreased glomerular filtration rates. It is reported that mutations in SLC34A1, which encodes the renal sodium-inorganic phosphate cotransporter NaPi-IIa, may cause this disease.
CATEGORY    Inherited metabolic disease; Kidney disease
GENE        SLC34A1 [HSA:6569] [KO:K14683]
DBLINKS     ICD-10: E72.0
            MeSH: D005198
            OMIM: 613388
REFERENCE   PMID:18480181
  AUTHORS   Jaureguiberry G, Carpenter TO, Forman S, Juppner H, Bergwitz C
  TITLE     A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc.
  JOURNAL   Am J Physiol Renal Physiol 295:F371-9 (2008)
REFERENCE   PMID:20335586
  AUTHORS   Magen D, Berger L, Coady MJ, Ilivitzki A, Militianu D, Tieder M, Selig S, Lapointe JY, Zelikovic I, Skorecki K
  TITLE     A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome.
  JOURNAL   N Engl J Med 362:1102-9 (2010)
///
ENTRY       H01199                      Disease
NAME        Hyperalphalipoproteinemia
DESCRIPTION Hyperalphalipoproteinemia (HALP) is a condition of elevated high-density lipoprotein cholesterol (HDL-C) level caused by a variety of genetic and environmental factors. The most important cause of primary HALP is a genetic deficiency of CETP, which has been reported mainly from Japan. A mutation in APOC3 gene is also associated in some families. Familial HALP often coexists with longevity, and that higher HDL-C levels are found among healthy elderly. HALP is also associated with some diseases. Recent studies have shown that hetero and homozygosity for CETP gene mutations is associated with an increased coronary artery disease (CAD) risk.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        CETP [HSA:1071] [KO:K16835]
            APOC3 [HSA:345] [KO:K08759]
DBLINKS     ICD-10: E78.4
            MeSH: C564591
            OMIM: 143470 614028
REFERENCE   PMID:11111094 (description, gene)
  AUTHORS   Yamashita S, Hirano K, Sakai N, Matsuzawa Y
  TITLE     Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.
  JOURNAL   Biochim Biophys Acta 1529:257-75 (2000)
REFERENCE   PMID:19041386 (description, gene)
  AUTHORS   Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F
  TITLE     Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.
  JOURNAL   Exp Gerontol 44:136-60 (2009)
REFERENCE   PMID:15767853 (description, gene)
  AUTHORS   Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ
  TITLE     Inherited disorders of HDL metabolism and atherosclerosis.
  JOURNAL   Curr Opin Lipidol 16:139-45 (2005)
REFERENCE   PMID:19074352 (gene)
  AUTHORS   Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR
  TITLE     A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.
  JOURNAL   Science 322:1702-5 (2008)
REFERENCE   PMID:2022742 (gene)
  AUTHORS   von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G
  TITLE     Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
  JOURNAL   J Clin Invest 87:1724-31 (1991)
///
ENTRY       H01200                      Disease
NAME        Fatal infantile cardioencephalomyopathy
DESCRIPTION Fatal infantile cardioencephalomyopathy (CEMCOX) is a disorder of the mitochondrial respiratory chain characterized by neonatal progressive muscular hypotonia and cardiomyopathy because of severe cytochrome c oxidase deficiency. Mutations in the SCO2 and COX15 gene causing cytochrome c oxidase deficiency have been reported in patients with fatal infantile cardioencephalomyopathy.
CATEGORY    Inherited metabolic disease
GENE        (CEMCOX1) SCO2 [HSA:9997] [KO:K07152]
            (CEMCOX2) COX15 [HSA:1355] [KO:K02259]
DBLINKS     ICD-10: G71.3
            MeSH: C565784
            OMIM: 604377 615119
REFERENCE   PMID:17187620 (description, gene)
  AUTHORS   Knuf M, Faber J, Huth RG, Freisinger P, Zepp F, Kampmann C
  TITLE     Identification of a novel compound heterozygote SCO2 mutation in cytochrome c oxidase deficient fatal infantile cardioencephalomyopathy.
  JOURNAL   Acta Paediatr 96:130-2 (2007)
REFERENCE   PMID:20159436 (description, gene)
  AUTHORS   Joost K, Rodenburg R, Piirsoo A, van den Heuvel B, Zordania R, Ounap K
  TITLE     A novel mutation in the SCO2 gene in a neonate with early-onset cardioencephalomyopathy.
  JOURNAL   Pediatr Neurol 42:227-30 (2010)
REFERENCE   PMID:21412973
  AUTHORS   Alfadhel M, Lillquist YP, Waters PJ, Sinclair G, Struys E, McFadden D, Hendson G, Hyams L, Shoffner J, Vallance HD
  TITLE     Infantile cardioencephalopathy due to a COX15 gene defect: report and review.
  JOURNAL   Am J Med Genet A 155A:840-4 (2011)
///
ENTRY       H01201                      Disease
NAME        Jensen syndrome;
            Opticoacoustic nerve atrophy
DESCRIPTION Jensen syndrome is X-linked deafness syndromes associated with progressive visual deterioration, dystonia, dementia, and psychiatric abnormalities. Causative mutations were identified within the deafness-dystonia peptide (TIMM8a) gene.
CATEGORY    Nervous system disease
GENE        TIMM8A [HSA:1678] [KO:K17780]
COMMENT     Mohr-Tranebjaerg syndrome [DS:H00989] is also caused by defects in TIMM8A.
DBLINKS     ICD-10: H47.2 H90.3
            MeSH: C537568
            OMIM: 311150
REFERENCE   PMID:11803487
  AUTHORS   Tranebjaerg L, Jensen PK, Van Ghelue M, Vnencak-Jones CL, Sund S, Elgjo K, Jakobsen J, Lindal S, Warburg M, Fuglsang-Frederiksen A, Skullerud K
  TITLE     Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome caused by mutations in the TIMM8a gene.
  JOURNAL   Ophthalmic Genet 22:207-23 (2001)
///
ENTRY       H01202                      Disease
NAME        Cataract
DESCRIPTION Cataracts can be defined as any opacity of the crystalline lens, often associated with breakdown of the lens microarchitecture, possibly including vacuole formation and disarray of lens cells, which can cause large fluctuations in density resulting in light scattering. In addition, light scattering and opacity will occur if there is a significant amount of high molecular weight protein aggregates. Cataracts can be classified by the age at onset: a congenital or infantile cataract presents within the first year of life; a juvenile cataract presents within the first decade of life; a presenile cataract presents before the age of about 45 years, and senile or age-related cataract after that. Congenital cataracts are a major cause of induced blindness in children, and inherited cataracts are the major cause of congenital cataracts. Inherited congenital cataracts have been associated with mutations in specific genes, including those of crystallins, gap junction proteins, membrane transport and channel proteins, the cytoskeleton, and growth and transcription factors. Inherited congenital cataracts may be inherited as autosomal dominant (most frequent), autosomal recessive, or X-linked traits.
CATEGORY    Eye disease
GENE        EPHA2 [HSA:1969] [KO:K05103]
            FOXE3 [HSA:2301] [KO:K09398]
            GJA8 [HSA:2703] [KO:K07617]
            CRYGA [HSA:1418]
            CRYGC [HSA:1420]
            CRYGD [HSA:1421]
            BFSP2 [HSA:8419] [KO:K10379]
            CRYGS [HSA:1427]
            SIL1 [HSA:64374] [KO:K14001]
            GCNT2 [HSA:2651] [KO:K00742]
            EYA1 [HSA:2138] [KO:K15616]
            VIM [HSA:7431] [KO:K07606]
            PITX3 [HSA:5309] [KO:K09357]
            CRYAB [HSA:1410] [KO:K09542]
            PAX6 [HSA:5080] [KO:K08031]
            MIP [HSA:4284] [KO:K09863]
            GJA3 [HSA:2700] [KO:K07612]
            MAF [HSA:4094] [KO:K09035]
            HSF4 [HSA:3299] [KO:K09417]
            CRYBA1/3 [HSA:1411]
            LIM2 [HSA:3982]
            FTL [HSA:2512] [KO:K13625]
            CHMP4B [HSA:128866] [KO:K12194]
            CRYAA [HSA:1409] [KO:K09541]
            CRYBA4 [HSA:1413]
            CRYBB1 [HSA:1414]
            CRYBB2 [HSA:1415]
            CRYBB3 [HSA:1417]
            NHS [HSA:4810]
            BFSP1 [HSA:631] [KO:K10378]
            SLC16A12 [HSA:387700] [KO:K11810]
DBLINKS     ICD-10: Q12.0
            MeSH: D002386
            OMIM: 110800 115700 116150 116200 116600 116800 302200 600881 601547 601885 604219 604307 605387 607133 608983 609741 610425 610623 611544 611597 613020 613763 611391 612018 601286 600886
REFERENCE   PMID:17296892 (description, gene)
  AUTHORS   Shiels A, Hejtmancik JF
  TITLE     Genetic origins of cataract.
  JOURNAL   Arch Ophthalmol 125:165-73 (2007)
REFERENCE   PMID:18035564 (description)
  AUTHORS   Hejtmancik JF
  TITLE     Congenital cataracts and their molecular genetics.
  JOURNAL   Semin Cell Dev Biol 19:134-49 (2008)
REFERENCE   PMID:21779674 (description)
  AUTHORS   Santana A, Waiswo M
  TITLE     The genetic and molecular basis of congenital cataract.
  JOURNAL   Arq Bras Oftalmol 74:136-42 (2011)
REFERENCE   PMID:20624502 (description, gene)
  AUTHORS   Huang B, He W
  TITLE     Molecular characteristics of inherited congenital cataracts.
  JOURNAL   Eur J Med Genet 53:347-57 (2010)
REFERENCE   PMID:17225135 (gene)
  AUTHORS   Ramachandran RD, Perumalsamy V, Hejtmancik JF
  TITLE     Autosomal recessive juvenile onset cataract associated with mutation in BFSP1.
  JOURNAL   Hum Genet 121:475-82 (2007)
REFERENCE   PMID:21778275 (gene)
  AUTHORS   Castorino JJ, Gallagher-Colombo SM, Levin AV, Fitzgerald PG, Polishook J, Kloeckener-Gruissem B, Ostertag E, Philp NJ
  TITLE     Juvenile cataract-associated mutation of solute carrier SLC16A12 impairs trafficking of the protein to the plasma membrane.
  JOURNAL   Invest Ophthalmol Vis Sci 52:6774-84 (2011)
REFERENCE   PMID:20159981 (gene)
  AUTHORS   Luscieti S, Santambrogio P, Langlois d'Estaintot B, Granier T, Cozzi A, Poli M, Gallois B, Finazzi D, Cattaneo A, Levi S, Arosio P
  TITLE     Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative  manner to reduce ferritin iron incorporation.
  JOURNAL   J Biol Chem 285:11948-57 (2010)
///
ENTRY       H01203                      Disease
NAME        Primary congenital glaucoma (PCG)
DESCRIPTION Primary congenital glaucoma (PCG) is a severe form of glaucoma that presents early in life. PCG results from developmental abnormalities that affect the aqueous humor outflow pathway. PCG clinical features include elevated IOP, corneal edema, enlargement of the globe (buphthalmos), corneal enlargement, rupture of Descemet's membrane, and optic nerve damage. Two genes have been reported to cause PCG, CYP1B1 and LTBP2. Both genes cause a recessive form of this disease.
CATEGORY    Developmental disorder; Eye disease
GENE        (GLC3A) CYP1B1 [HSA:1545] [KO:K07410]
            (GLC3D) LTBP2 [HSA:4053] [KO:K08023]
DRUG        Surgery for glaucoma: goniotomy, goniopuncture, trabeculotomy, and trabeculectomy.
DBLINKS     ICD-10: Q15.0
            MeSH: C565547 C536824 C567765
            OMIM: 231300 613086
REFERENCE   PMID:22128238
  AUTHORS   Abu-Amero KK, Osman EA, Mousa A, Wheeler J, Whigham B, Allingham RR, Hauser MA, Al-Obeidan SA
  TITLE     Screening of CYP1B1 and LTBP2 genes in Saudi families with primary congenital glaucoma: genotype-phenotype correlation.
  JOURNAL   Mol Vis 17:2911-9 (2011)
REFERENCE   PMID:21081970
  AUTHORS   Azmanov DN, Dimitrova S, Florez L, Cherninkova S, Draganov D, Morar B, Saat R, Juan M, Arostegui JI, Ganguly S, Soodyall H, Chakrabarti S, Padh H, Lopez-Nevot MA, Chernodrinska V, Anguelov B, Majumder P, Angelova L, Kaneva R, Mackey DA, Tournev I, Kalaydjieva L
  TITLE     LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population.
  JOURNAL   Eur J Hum Genet 19:326-33 (2011)
REFERENCE   PMID:21150024
  AUTHORS   Sharaawy T, Bhartiya S
  TITLE     Surgical management of glaucoma: evolving paradigms.
  JOURNAL   Indian J Ophthalmol 59 Suppl:S123-30 (2011)
///
ENTRY       H01204                      Disease
NAME        Cerebellar ataxia, mental retardation (MR), and dysequilibrium syndrome (CAMRQ)
DESCRIPTION Cerebellar ataxia, mental retardation (MR), and dysequilibrium syndrome (CAMRQ) is autosomal recessive, genetically heterogeneous conditions characterized by early onset of cerebellar ataxia and MR. Patients with CAMRQs have a severe disturbance of posture and balance, strabismus, muscular hypotonia during childhood and they have a delayed ability to walk independently. The disease is also characterized by perceptual difficulties and in most cases mild mental retardation. Three subtypes have been mapped so far. CAMRQ1 and CAMRQ3 are caused by mutations in the VLDLR and CA8 genes, respectively, while the gene for CAMRQ2 remains to be cloned.
CATEGORY    Neurodegenerative disease
GENE        (CAMRQ1) VLDLR [HSA:7436] [KO:K20053]
            (CAMRQ3) CA8 [HSA:767] [KO:K01672]
DBLINKS     ICD-10: G11.8
            MeSH: C535731 C567656 C567690
            OMIM: 224050 613227
REFERENCE   PMID:21812104 (description, gene)
  AUTHORS   Kaya N, Aldhalaan H, Al-Younes B, Colak D, Shuaib T, Al-Mohaileb F, Al-Sugair A, Nester M, Al-Yamani S, Al-Bakheet A, Al-Hashmi N, Al-Sayed M, Meyer B, Jungbluth H, Al-Owain M
  TITLE     Phenotypical spectrum of cerebellar ataxia associated with a novel mutation in the CA8 gene, encoding carbonic anhydrase (CA) VIII.
  JOURNAL   Am J Med Genet B Neuropsychiatr Genet 156B:826-34 (2011)
REFERENCE   PMID:20199520 (description, gene)
  AUTHORS   Melberg A, Orlen H, Raininko R, Entesarian M, Dahlqvist J, Gustavson KH, Dahl N
  TITLE     Re-evaluation of the dysequilibrium syndrome.
  JOURNAL   Acta Neurol Scand 123:28-33 (2011)
REFERENCE   PMID:19332571 (description, gene)
  AUTHORS   Boycott KM, Bonnemann C, Herz J, Neuert S, Beaulieu C, Scott JN, Venkatasubramanian A, Parboosingh JS
  TITLE     Mutations in VLDLR as a cause for autosomal recessive cerebellar ataxia with mental retardation (dysequilibrium syndrome).
  JOURNAL   J Child Neurol 24:1310-5 (2009)
///
ENTRY       H01205                      Disease
NAME        Coumarin resistance;
            Warfarin resistance
DESCRIPTION Warfarin is widely prescribed anticoagulant for the prevention of thromboembolic diseases. However, its use is made difficult by the wide interindividual variation in dose required to achieve a therapeutic effect, the narrow therapeutic range, and the risk of serious bleeding. Warfarin dose requirement is influenced by factors such as intake of vitamin K, ethnicity, age, gender, and genetic factors. Warfarin acts through interference with the recycling of vitamin K in the liver. It has been reported that mutations in VKORC1, CYP2C9, and GGCX cause warfarin resistance.
CATEGORY    Inherited metabolic disease
GENE        VKORC1 [HSA:79001] [KO:K05357]
            CYP2A6 [HSA:1548] [KO:K17683]
            CYP2C9 [HSA:1559] [KO:K17719]
            GGCX [HSA:2677] [KO:K10106]
DRUG        Warfarine [DG:DG00149]
DBLINKS     MeSH: C563039
            OMIM: 122700
REFERENCE   PMID:19952297
  AUTHORS   Osinbowale O, Al Malki M, Schade A, Bartholomew JR
  TITLE     An algorithm for managing warfarin resistance.
  JOURNAL   Cleve Clin J Med 76:724-30 (2009)
REFERENCE   PMID:17048007
  AUTHORS   Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P
  TITLE     Association of warfarin dose with genes involved in its action and metabolism.
  JOURNAL   Hum Genet 121:23-34 (2007)
REFERENCE   PMID:10781881
  AUTHORS   Pelkonen O, Rautio A, Raunio H, Pasanen M
  TITLE     CYP2A6: a human coumarin 7-hydroxylase.
  JOURNAL   Toxicology 144:139-47 (2000)
///
ENTRY       H01206                      Disease
NAME        Plasminogen deficiency, including:
            Ligneous conjunctivitis;
            Dysplasminogenemia
DESCRIPTION Plasminogen deficiency is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished. Type 1, also called hypoplasminogenemia, is associated with pseudomembrane disease. Ligneous conjunctivitis is the most common of the clinical syndromes associated with plasminogen deficiency, although numerous other organs have been reported to be affected. Type 2, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations.
CATEGORY    Hematologic disease
GENE        PLG [HSA:5340] [KO:K01315]
DBLINKS     OMIM: 217090
REFERENCE   PMID:19141167
  AUTHORS   Mehta R, Shapiro AD
  TITLE     Plasminogen deficiency.
  JOURNAL   Haemophilia 14:1261-8 (2008)
REFERENCE   PMID:17900274
  AUTHORS   Schuster V, Hugle B, Tefs K
  TITLE     Plasminogen deficiency.
  JOURNAL   J Thromb Haemost 5:2315-22 (2007)
///
ENTRY       H01207                      Disease
NAME        Trigonocephaly
DESCRIPTION Trigonocephaly is a rare form of craniosynostosis characterized by the premature closure of the metopic suture. It has been reported that mutations in FGFR1 and FREM1 can be associated with trigonocephaly.
CATEGORY    Developmental disorder
GENE        FGFR1 [HSA:2260] [KO:K04362]
            FREM1 [HSA:158326]
DBLINKS     ICD-10: Q75.0
            MeSH: D003398
            OMIM: 190440 614485
REFERENCE   PMID:11173846
  AUTHORS   Kress W, Petersen B, Collmann H, Grimm T
  TITLE     An unusual FGFR1 mutation (fibroblast growth factor receptor 1 mutation) in a girl with non-syndromic trigonocephaly.
  JOURNAL   Cytogenet Cell Genet 91:138-40 (2000)
REFERENCE   PMID:21931569
  AUTHORS   Vissers LE, Cox TC, Maga AM, Short KM, Wiradjaja F, Janssen IM, Jehee F, Bertola D, Liu J, Yagnik G, Sekiguchi K, Kiyozumi D, van Bokhoven H, Marcelis C, Cunningham ML, Anderson PJ, Boyadjiev SA, Passos-Bueno MR, Veltman JA, Smyth I, Buckley MF, Roscioli T
  TITLE     Heterozygous mutations of FREM1 are associated with an increased risk of isolated metopic craniosynostosis in humans and mice.
  JOURNAL   PLoS Genet 7:e1002278 (2011)
REFERENCE   PMID:15185114
  AUTHORS   Shimoji T, Tomiyama N
  TITLE     Mild trigonocephaly and intracranial pressure: report of 56 patients.
  JOURNAL   Childs Nerv Syst 20:749-56 (2004)
///
ENTRY       H01208                      Disease
NAME        Globozoospermia;
            Round-headed spermatozoa
DESCRIPTION Globozoospermia is a rare form of teratozoospermia, mainly characterized by round-headed spermatozoa that lack an acrosome. Acrosome plays an important role at the site of sperm-zonapellucida binding during the fertilization process. It was suggested that a homozygous mutation in SPATA16 was associated with male infertility in human globozoospermia. It has also been reported that a recurrent deletion of DPY19L2 causes infertility in man by blocking sperm head elongation and acrosome formation.
CATEGORY    Developmental disorder
GENE        SPATA16 [HSA:83893]
            DPY19L2 [HSA:283417]
COMMENT     Disruption of several mouse genes, including GOPC, HRB, and CSNK2A2, results in a phenotype similar to globozoospermia in humans. However, no causative gene mutations have been identified in these orthologues. Recently, a newly discovered mutation in PICK1 in a human with globozoospermia was reported.
DBLINKS     OMIM: 102530 613958
REFERENCE   PMID:17847006
  AUTHORS   Dam AH, Koscinski I, Kremer JA, Moutou C, Jaeger AS, Oudakker AR, Tournaye H, Charlet N, Lagier-Tourenne C, van Bokhoven H, Viville S
  TITLE     Homozygous mutation in SPATA16 is associated with male infertility in human globozoospermia.
  JOURNAL   Am J Hum Genet 81:813-20 (2007)
REFERENCE   PMID:21397064
  AUTHORS   Harbuz R, Zouari R, Pierre V, Ben Khelifa M, Kharouf M, Coutton C, Merdassi G, Abada F, Escoffier J, Nikas Y, Vialard F, Koscinski I, Triki C, Sermondade N, Schweitzer T, Zhioua A, Zhioua F, Latrous H, Halouani L, Ouafi M, Makni M, Jouk PS, Sele B, Hennebicq S, Satre V, Viville S, Arnoult C, Lunardi J, Ray PF
  TITLE     A recurrent deletion of DPY19L2 causes infertility in man by blocking sperm head  elongation and acrosome formation.
  JOURNAL   Am J Hum Genet 88:351-61 (2011)
REFERENCE   PMID:20562896
  AUTHORS   Liu G, Shi QW, Lu GX
  TITLE     A newly discovered mutation in PICK1 in a human with globozoospermia.
  JOURNAL   Asian J Androl 12:556-60 (2010)
///
ENTRY       H01209                      Disease
NAME        Deafness, X-linked
DESCRIPTION Hereditary deafness is divided into syndromic forms (in which hearing loss is associated with a variety of other anomalies) and non-syndromic forms. Non-syndromic forms are responsible for 70% of the cases of hereditary etiology and syndromic cases represent 30% of them. Among the forms of heritage, autosomal-recessive inheritance is the most frequent one (75%-85%), followed by autosomal-dominant inheritance (12-13%) and X-linked or mitochondrial, with 2-3% of the cases of non-syndromic hearing loss. X-linked deafness is clinically and genetically heterogeneous disorder. PRPS1 and POU3F4 have been identified as the genes to be implicated in X-linked non-syndromic hearing loss.
CATEGORY    Nervous system disease; Nervous system disease
GENE        PRPS1 [HSA:5631] [KO:K00948]
            POU3F4 [HSA:5456] [KO:K09365]
DBLINKS     ICD-10: H91.9
            MeSH: C564433 C536424 C564727 C564723 C564472
            OMIM: 304500 304400
REFERENCE   PMID:16446920 (description, gene)
  AUTHORS   Piatto VB, Nascimento EC, Alexandrino F, Oliveira CA, Lopes AC, Sartorato EL, Maniglia JV
  TITLE     Molecular genetics of non-syndromic deafness.
  JOURNAL   Braz J Otorhinolaryngol 71:216-23 (2005)
REFERENCE   PMID:20021999 (description, gene)
  AUTHORS   Liu X, Han D, Li J, Han B, Ouyang X, Cheng J, Li X, Jin Z, Wang Y, Bitner-Glindzicz M, Kong X, Xu H, Kantardzhieva A, Eavey RD, Seidman CE, Seidman JG, Du LL, Chen ZY, Dai P, Teng M, Yan D, Yuan H
  TITLE     Loss-of-function mutations in the PRPS1 gene cause a type of nonsyndromic X-linked sensorineural deafness, DFN2.
  JOURNAL   Am J Hum Genet 86:65-71 (2010)
REFERENCE   PMID:19671658 (gene)
  AUTHORS   Lee HK, Song MH, Kang M, Lee JT, Kong KA, Choi SJ, Lee KY, Venselaar H, Vriend G, Lee WS, Park HJ, Kwon TK, Bok J, Kim UK
  TITLE     Clinical and molecular characterizations of novel POU3F4 mutations reveal that DFN3 is due to null function of POU3F4 protein.
  JOURNAL   Physiol Genomics 39:195-201 (2009)
///
ENTRY       H01210                      Disease
NAME        Hypomagnesemia
DESCRIPTION Hypomagnesemia is defined as a serum magnesium level less than 1.8 mg/dl. Hypomagnesemia may result from inadequate magnesium intake, increased gastrointestinal or renal losses, or redistribution from extracellular to intracellular space.
CATEGORY    Inherited metabolic disease
GENE        TRPM6 [HSA:140803] [KO:K04981]
            FXYD2 [HSA:486] [KO:K01538]
            CLDN16 [HSA:10686] [KO:K06087]
            EGF [HSA:1950] [KO:K04357]
            CLDN19 [HSA:149461] [KO:K06087]
ENV_FACTOR  Furosemide [DR:D00331]
DRUG        Magnesium oxide [DR:D01167]
            Magnesium sulfate heptahydrate [DR:D01108]
COMMENT     Gitelman syndrome is described in H00240. [DS:H00240]
DBLINKS     ICD-10: E83.4
            MeSH: C566593 C537152 C537153 C564024 C567127
            OMIM: 602014 154020 248250 248190 611718
REFERENCE   PMID:20081299
  AUTHORS   Assadi F
  TITLE     Hypomagnesemia: an evidence-based approach to clinical cases.
  JOURNAL   Iran J Kidney Dis 4:13-9 (2010)
///
ENTRY       H01211                      Disease
NAME        MECP2-related severe neonatal encephalopathy
DESCRIPTION MECP2-related severe neonatal encephalopathy is a rare disorder of males characterized by a static encephalopathy, severe developmental delays, hypotonia, seizures, and respiratory abnormalities that often leads to death at an early age. Mutations in the MECP2 gene cause this disease, and females with these same mutations typically have a disorder called Rett syndrome. Most boys with this disorder have been identified because they have female siblings with Rett syndrome.
CATEGORY    Developmental disorder
GENE        MECP2 [HSA:4204] [KO:K11588]
COMMENT     Rett syndrome is described in H00440. [DS:H00440]
DBLINKS     MeSH: C580273
            OMIM: 300673
REFERENCE   PMID:11930274
  AUTHORS   Geerdink N, Rotteveel JJ, Lammens M, Sistermans EA, Heikens GT, Gabreels FJ, Mullaart RA, Hamel BC
  TITLE     MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings.
  JOURNAL   Neuropediatrics 33:33-6 (2002)
REFERENCE   PMID:11071498
  AUTHORS   Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, Fontes M
  TITLE     Two affected boys in a Rett syndrome family: clinical and molecular findings.
  JOURNAL   Neurology 55:1188-93 (2000)
REFERENCE   PMID:20425298
  AUTHORS   Gonzales ML, LaSalle JM
  TITLE     The role of MeCP2 in brain development and neurodevelopmental disorders.
  JOURNAL   Curr Psychiatry Rep 12:127-34 (2010)
///
ENTRY       H01212                      Disease
NAME        Familial encephalopathy with neuroserpin inclusion bodies (FENIB)
DESCRIPTION Familial encephalopathy with neuroserpin inclusion bodies (FEBIB) is an autosomal dominant dementia that is characterized by the accumulation of mutant neuroserpin as periodic acid Schiff (PAS) positive diastase-resistant inclusions. Kindreds with FENIB present with presenile dementia and cognitive deficits.
CATEGORY    Neurodegenerative disease
GENE        SERPINI1 [HSA:5274]
DBLINKS     MeSH: C536841
            OMIM: 604218
REFERENCE   PMID:10517635
  AUTHORS   Davis RL, Shrimpton AE, Holohan PD, Bradshaw C, Feiglin D, Collins GH, Sonderegger P, Kinter J, Becker LM, Lacbawan F, Krasnewich D, Muenke M, Lawrence DA, Yerby MS, Shaw CM, Gooptu B, Elliott PR, Finch JT, Carrell RW, Lomas DA
  TITLE     Familial dementia caused by polymerization of mutant neuroserpin.
  JOURNAL   Nature 401:376-9 (1999)
REFERENCE   PMID:11880376
  AUTHORS   Belorgey D, Crowther DC, Mahadeva R, Lomas DA
  TITLE     Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro.
  JOURNAL   J Biol Chem 277:17367-73 (2002)
REFERENCE   PMID:19164889
  AUTHORS   Belorgey D, Hagglof P, Karlsson-Li S, Lomas DA
  TITLE     Protein misfolding and the serpinopathies.
  JOURNAL   Prion 1:15-20 (2007)
///
ENTRY       H01213                      Disease
NAME        Gallbladder disease;
            Cholecystitis;
            Cholelithiasis
DESCRIPTION Gallbladder disease is one of the most common digestive disorders. Cholecystitis is an inflammation of the gallbladder wall, that is almost always associated with cholelithiasis, or gallstones. Cholecystitis and cholelithiasis appear to be caused by the actions of several genes and environment working together. It has been reported that an ABCB4 mutation which causes a deficiency in biliary phosphatidylcholine secretion is associated with gallstones. Recently, several common DNA polymorphisms in the ABCG8 gene were discovered that are associated with gallstone disease.
CATEGORY    Digestive disease
GENE        ABCB4 [HSA:5244] [KO:K05659]
            ABCG8 [HSA:64241] [KO:K05684]
DRUG        Cholecystectomy
            Ursodeoxycholic acid [DR:D00734]
            Chenodeoxycholic acid [DR:D00163]
DBLINKS     ICD-10: K80 K81.9
            MeSH: D005705
            OMIM: 600803 611465
REFERENCE   PMID:15696852
  AUTHORS   vanBerge-Henegouwen GP, Venneman NG, Portincasa P, Kosters A, van Erpecum KJ, Groen AK
  TITLE     Relevance of hereditary defects in lipid transport proteins for the pathogenesis  of cholesterol gallstone disease.
  JOURNAL   Scand J Gastroenterol Suppl 60-9 (2004)
REFERENCE   PMID:20594224
  AUTHORS   Siddapuram SP, Mahurkar S, Duvvuru NR, Mitnala S, Guduru VR, Rebala P, Mansard MJ
  TITLE     Hepatic cholesterol transporter ABCG8 polymorphisms in gallstone disease in an Indian population.
  JOURNAL   J Gastroenterol Hepatol 25:1093-8 (2010)
REFERENCE   PMID:17562004
  AUTHORS   Rosmorduc O, Poupon R
  TITLE     Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.
  JOURNAL   Orphanet J Rare Dis 2:29 (2007)
REFERENCE   PMID:19803550
  AUTHORS   Gaby AR
  TITLE     Nutritional approaches to prevention and treatment of gallstones.
  JOURNAL   Altern Med Rev 14:258-67 (2009)
///
ENTRY       H01214                      Disease
NAME        Rh-null hemolytic anemia (RHN);
            Rh-deficiency syndrome
DESCRIPTION Rh (Rhesus) null hemolytic anemia (RHN) is a rare autosomal recessive disorder characterized by an absence of Rh antigens and a varying degree of hemolytic anemia and spherostomatocytosis. The Rh protein family comprises Rh50 glycoprotein and Rh30 polypeptides, which form a complex essential for Rh antigen expression and erythrocyte membrane integrity. It is reported that RHN is caused by mutations of RHAG that encodes Rh50 glycoprotein.
CATEGORY    Hematologic disease
GENE        RHAG [HSA:6005] [KO:K06580]
DBLINKS     ICD-10: D58.8
            OMIM: 268150
REFERENCE   PMID:10467273
  AUTHORS   Huang CH, Cheng G, Liu Z, Chen Y, Reid ME, Halverson G, Okubo Y
  TITLE     Molecular basis for Rh(null) syndrome: identification of three new missense mutations in the Rh50 glycoprotein gene.
  JOURNAL   Am J Hematol 62:25-32 (1999)
REFERENCE   PMID:9442063
  AUTHORS   Huang CH
  TITLE     The human Rh50 glycoprotein gene. Structural organization and associated splicing defect resulting in Rh(null) disease.
  JOURNAL   J Biol Chem 273:2207-13 (1998)
///
ENTRY       H01215                      Disease
NAME        Simpson-Golabi-Behmel syndrome (SGBS)
DESCRIPTION Simpson Golabi Behmel syndrome (SGBS) is a complex congenital overgrowth syndrome with features that include macroglossia, macrosomia, and renal and skeletal abnormalities as well as an increased risk of embryonal cancers. Most cases of SGBS is type 1, that appear to arise as a result of either deletions or point mutations within the glypican-3 (GPC3) gene. SGBS type 2 is a severe variant, that is associated with defects in OFD1.
CATEGORY    Skeletal dysplasia
GENE        (Type 1) GPC3 [HSA:2719] [KO:K08109]
            (Type 2) OFD1 [HSA:8481] [KO:K16480]
COMMENT     Simpson-Golabi-Behmel syndrome, type 1 is also described in Heparan sulfate proteoglycan gene defects. [DS:H00493]
DBLINKS     MeSH: C537340
            OMIM: 312870 300209
REFERENCE   PMID:11286501
  AUTHORS   DeBaun MR, Ess J, Saunders S
  TITLE     Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition.
  JOURNAL   Mol Genet Metab 72:279-86 (2001)
REFERENCE   PMID:10441586
  AUTHORS   Brzustowicz LM, Farrell S, Khan MB, Weksberg R
  TITLE     Mapping of a new SGBS locus to chromosome Xp22 in a family with a severe form of  Simpson-Golabi-Behmel syndrome.
  JOURNAL   Am J Hum Genet 65:779-83 (1999)
REFERENCE   PMID:22548404
  AUTHORS   Tsurusaki Y, Kosho T, Hatasaki K, Narumi Y, Wakui K, Fukushima Y, Doi H, Saitsu H, Miyake N, Matsumoto N
  TITLE     Exome sequencing in a family with an X-linked lethal malformation syndrome: clinical consequences of hemizygous truncating OFD1 mutations in male patients.
  JOURNAL   Clin Genet 83:135-44 (2013)
///
ENTRY       H01216                      Disease
NAME        Left ventricular noncompaction (LVNC)
DESCRIPTION Left ventricular noncompaction (LVNC) is a rare and potentially progressive cardiomyopathy, characterized by the presence of prominent trabeculations of the left ventricle, associated with progressive systolic failure, stroke and arrhythmia. It has been linked to mutations in several genes, including LIM domain binding protein 3 (ZASP), alpha-dystrobrevin (DTNA), tafazzin (TAZ/G4.5), lamin A/C (LMNA), and genes encoding the sarcomeric proteins, beta-myosin heavy chain (MYH7), alpha-cardiac actin (ACTC), and cardiac troponin T (TNNT2).
CATEGORY    Cardiovascular disease
GENE        ZASP (mutation) [HSA:11155] [KO:K19867]
            DTNA (mutation) [HSA:1837]
            TAZ (mutation) [HSA:6901] [KO:K13511]
            LMNA (mutation) [HSA:4000] [KO:K12641]
            MYH7 (mutation) [HSA:4625] [KO:K17751]
            ACTC (mutation) [HSA:70] [KO:K12314]
            TNNT2 (mutation) [HSA:7139] [KO:K12045]
DBLINKS     ICD-10: I42.8
            OMIM: 604169 601493 300183
REFERENCE   PMID:19057090 (gene, description)
  AUTHORS   Ichida F
  TITLE     Left ventricular noncompaction.
  JOURNAL   Circ J 73:19-26 (2009)
REFERENCE   PMID:19318934 (gene, description)
  AUTHORS   Pantazis AA, Elliott PM
  TITLE     Left ventricular noncompaction.
  JOURNAL   Curr Opin Cardiol 24:209-13 (2009)
REFERENCE   PMID:21638988 (gene, description)
  AUTHORS   Antonio M, Costa C, Venancio M, Martins P, Dionisio T, Pires A, Sousa G, Santos I, Mota A, Duarte R, Costa H, Ribeiro L, Saraiva J, Castela E
  TITLE     Left ventricular noncompaction: analysis of a pediatric population.
  JOURNAL   Rev Port Cardiol 30:295-311 (2011)
REFERENCE   PMID:21285074 (gene, description)
  AUTHORS   Oechslin E, Jenni R
  TITLE     Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity?
  JOURNAL   Eur Heart J 32:1446-56 (2011)
///
ENTRY       H01217                      Disease
NAME        Primary localized cutaneous amyloidosis (PLCA)
DESCRIPTION Primary localized cutaneous amyloidosis (PLCA) is a chronic itchy skin disorder associated with amyloid deposits in the superficial dermis. It is a purely cutaneous disease with no association with systemic forms of amyloidosis. Clinically, skin lesions comprise small, flat-top papules (lichen amyloidosis) or brown-gray macules (macular amyloidosis). PLCA is relatively common in South America and Asia, and some cases have an autosomal dominant family history (familial PLCA, FPLCA). The genetic basis of FPLCA involves mutations in the OSMR and IL31RA genes. Both belong to the family of interleukin (IL)-6 family cytokine receptors.
CATEGORY    Skin and connective tissue disease
GENE        (PLCA1) OSMR [HSA:9180] [KO:K05057]
            (PLCA2) IL31RA [HSA:133396]
DBLINKS     MeSH: C562642
            OMIM: 105250 613955
REFERENCE   PMID:20507362 (description, gene)
  AUTHORS   Tanaka A, Lai-Cheong JE, van den Akker PC, Nagy N, Millington G, Diercks GF, van Voorst Vader PC, Clements SE, Almaani N, Techanukul T, Hide M, South AP, McGrath JA
  TITLE     The molecular skin pathology of familial primary localized cutaneous amyloidosis.
  JOURNAL   Exp Dermatol 19:416-23 (2010)
REFERENCE   PMID:19375894 (description, gene)
  AUTHORS   Arita K, Abe R, Baba K, McGrath JA, Akiyama M, Shimizu H
  TITLE     A novel OSMR mutation in familial primary localized cutaneous amyloidosis in a Japanese family.
  JOURNAL   J Dermatol Sci 55:64-5 (2009)
///
ENTRY       H01218                      Disease
NAME        P14 deficiency
DESCRIPTION The deficiency of the late endosomal-lysosomal MEK binding partner 1 (MP1)-interacting protein (also known as p14 and MAPBPIP) causes a primary immunodeficiency syndrome comprising congenital neutropenia, partial albinism, short stature and B-cell and cytotoxic T-cell deficiency. This protein is an adaptor molecule orchestrating the subcellular anatomy of MAP kinase signaling, and is crucial for the function of neutrophils, B cells, cytotoxic T cells and melanocytes.
CATEGORY    Primary immunodeficiency
GENE        MAPBPIP [HSA:28956] [KO:K20398]
DBLINKS     ICD-10: D70
            OMIM: 610798
REFERENCE   PMID:20004777 (gene)
  AUTHORS   Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Hammartrom L, Nonoyama S, Ochs HD, Puck J, Roifman C, Seger R, Wedgwood J
  TITLE     Primary immunodeficiencies: 2009 update.
  JOURNAL   J Allergy Clin Immunol 124:1161-78 (2009)
REFERENCE   PMID:19811314 (gene)
  AUTHORS   Rezaei N, Moazzami K, Aghamohammadi A, Klein C
  TITLE     Neutropenia and primary immunodeficiency diseases.
  JOURNAL   Int Rev Immunol 28:335-66 (2009)
REFERENCE   PMID:17195838 (gene, description)
  AUTHORS   Bohn G, Allroth A, Brandes G, Thiel J, Glocker E, Schaffer AA, Rathinam C, Taub N, Teis D, Zeidler C, Dewey RA, Geffers R, Buer J, Huber LA, Welte K, Grimbacher B, Klein C
  TITLE     A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14.
  JOURNAL   Nat Med 13:38-45 (2007)
///
ENTRY       H01219                      Disease
NAME        Restrictive cardiomyopathy (RCM)
DESCRIPTION Restrictive cardiomyopathy (RCM) is an uncommon heart muscle disorder characterized by impaired ventricular filling and increased stiffness of the myocardium with diastolic dysfunction, resulting in atrial enlargement and elevated systemic and pulmonary venous pressure. To date, mutations have been identified in the cardiac genes for desmin, alpha-actin, troponin I and troponin T.
CATEGORY    Cardiovascular disease
GENE        DES (mutation) [HSA:1674] [KO:K07610]
            ACTC (mutation) [HSA:70] [KO:K12314]
            TNNI3 (mutation) [HSA:7137] [KO:K12044]
            TNNT2 (mutation) [HSA:7139] [KO:K12045]
DBLINKS     ICD-10: I42
            OMIM: 115210 612422
REFERENCE   PMID:20617149 (gene, description)
  AUTHORS   Parvatiyar MS, Pinto JR, Dweck D, Potter JD
  TITLE     Cardiac troponin mutations and restrictive cardiomyopathy.
  JOURNAL   J Biomed Biotechnol 2010:350706 (2010)
REFERENCE   PMID:18646564 (gene, description)
  AUTHORS   Arimura T, Hayashi T, Kimura A
  TITLE     Molecular etiology of idiopathic cardiomyopathy.
  JOURNAL   Acta Myol 26:153-8 (2007)
REFERENCE   PMID:15201162 (gene, description)
  AUTHORS   Gomes AV, Potter JD
  TITLE     Molecular and cellular aspects of troponin cardiomyopathies.
  JOURNAL   Ann N Y Acad Sci 1015:214-24 (2004)
///
ENTRY       H01220                      Disease
NAME        Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN)
DESCRIPTION Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) syndrome is a rare autosomal recessive, complex developmental disorder exclusively manifested in the Roma population. CCFDN is a genetically homogeneous condition in which all patients are homozygous for the same ancestral mutation in the CTDP1 gene. Affected patients display congenital cataracts, microcornea, peripheral neuropathy, mild facial dysmorphism, hypogonadism, and psychomotor delay.
CATEGORY    Developmental disorder; Nervous system disease
GENE        CTDP1 [HSA:9150] [KO:K15732]
DBLINKS     ICD-10: G60.8 Q13.8
            MeSH: C565822
            OMIM: 604168
REFERENCE   PMID:21824574 (description, gene)
  AUTHORS   Tzifi F, Pons R, Athanassaki C, Poulou M, Kanavakis E
  TITLE     Congenital cataracts, facial dysmorphism, and neuropathy syndrome.
  JOURNAL   Pediatr Neurol 45:206-8 (2011)
REFERENCE   PMID:16939648 (description, gene)
  AUTHORS   Kalaydjieva L
  TITLE     Congenital cataracts-facial dysmorphism-neuropathy.
  JOURNAL   Orphanet J Rare Dis 1:32 (2006)
REFERENCE   PMID:16194727 (description, gene)
  AUTHORS   Shabo G, Scheffer H, Cruysberg JR, Lammens M, Pasman JW, Spruit M, Willemsen MA
  TITLE     Congenital cataract facial dysmorphism neuropathy syndrome: a clinically recognizable entity.
  JOURNAL   Pediatr Neurol 33:277-9 (2005)
///
ENTRY       H01221                      Disease
NAME        Epithelial basement membrane corneal dystrophy (EBMD);
            Cogan microcystic epithelial dystrophy;
            Map-dot-fingerprint dystrophy
DESCRIPTION Epithelial basement membrane corneal dystrophy (EBMD) is a common bilateral epithelial dystrophy. There is usually no hereditary pattern, but some cases presented with an autosomal dominant inheritance. Mutations in the TGFBI/BIGH3 genes, which are known to cause various forms of corneal dystrophies, have been identified. Sheet-like areas of basement membrane originating from the basal epithelial cells of the corneal epithelium and extending superficially into the epithelium are the hallmarks of EBMD. Most patients are asymptomatic before the age of 30 years, but 10% of them may have recurrent idiopathic erosions and a loss of vision due to surface irregularity.
CATEGORY    Eye disease
GENE        TGFBI [HSA:7045] [KO:K19519]
DBLINKS     ICD-10: H18.5
            MeSH: C535477
            OMIM: 121820
REFERENCE   PMID:16652336 (description, gene)
  AUTHORS   Boutboul S, Black GC, Moore JE, Sinton J, Menasche M, Munier FL, Laroche L, Abitbol M, Schorderet DF
  TITLE     A subset of patients with epithelial basement membrane corneal dystrophy have mutations in TGFBI/BIGH3.
  JOURNAL   Hum Mutat 27:553-7 (2006)
///
ENTRY       H01222                      Disease
NAME        Cowden-like syndrome
DESCRIPTION Cowden syndrome (CS) is a autosomal dominant inherited cancer syndrome characterized by benign and malignant breast, thyroid, and endometrial neoplasias in addition to cutaneous findings and macrocephaly. Germ line PTEN mutations have been found in 85% of those with CS. A large heterogeneous group of individuals with Cowden-like syndrome, who have various combinations of Cowden syndrome features but who do not meet Cowden syndrome diagnostic criteria, have PTEN mutations less than 10% of the time. In the absence of germline PTEN mutations, approximately 10% of individuals with Cowden syndrome or Cowden-like syndrome harbor germline succinate dehydrogenase variants SDHB and SDHD.
CATEGORY    Developmental disorder
GENE        SDHB [HSA:6390] [KO:K00235]
            SDHD [HSA:6392] [KO:K00237]
COMMENT     Cowden syndrome is described in PTEN hamartoma tumor syndrome. [DS:H00539]
DBLINKS     ICD-10: Q85.9
            MeSH: C567337
            OMIM: 612359
REFERENCE   PMID:18678321
  AUTHORS   Ni Y, Zbuk KM, Sadler T, Patocs A, Lobo G, Edelman E, Platzer P, Orloff MS, Waite KA, Eng C
  TITLE     Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.
  JOURNAL   Am J Hum Genet 83:261-8 (2008)
REFERENCE   PMID:21177507
  AUTHORS   Bennett KL, Mester J, Eng C
  TITLE     Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
  JOURNAL   JAMA 304:2724-31 (2010)
///
ENTRY       H01223                      Disease
NAME        Mental retardation-stereotypic movements-epilepsy and/or cerebral malformations (MRSME);
            Chromosome 5q14.3 deletion syndrome
DESCRIPTION Mental retardation-stereotypic movements-epilepsy and/or cerebral malformations (MRSME) is a disorder characterized by severe mental retardation, absent speech, hypotonia, poor eye contact and stereotypic movements. Most of the patients presented also with facial dysmorphic features, epilepsy and cerebral malformations. It has been suggested that haploinsufficiency of MEF2C is responsible for MRSME.
CATEGORY    Developmental disorder
GENE        MEF2C [HSA:4208] [KO:K04454]
DBLINKS     ICD-10: Q93.5 F98.4
            OMIM: 613443
REFERENCE   PMID:19592390
  AUTHORS   Le Meur N, Holder-Espinasse M, Jaillard S, Goldenberg A, Joriot S, Amati-Bonneau P, Guichet A, Barth M, Charollais A, Journel H, Auvin S, Boucher C, Kerckaert JP, David V, Manouvrier-Hanu S, Saugier-Veber P, Frebourg T, Dubourg C, Andrieux J, Bonneau D
  TITLE     MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations.
  JOURNAL   J Med Genet 47:22-9 (2010)
///
ENTRY       H01224                      Disease
NAME        Ketosis-prone diabetes mellitus (KPD)
DESCRIPTION Ketosis-prone diabetes (KPD) is a widespread, emerging, heterogeneous syndrome, mostly observed in subjects of west African origin (west Africans and African-Americans), characterized by patients who present with diabetic ketoacidosis or unprovoked ketosis but do not necessarily have the typical phenotype of autoimmune type 1 diabetes. Multiple, severe forms of beta-cell dysfunction appear to underlie the pathophysiology of KPD. KPD can be classified into four A beta groups, based on the presence of glutamic acid decarboxylase (GAD)65, GAD67, or IA-2 autoantibodies (A+ or A-) and beta-cell functional reserve (beta+ or beta-). Homozygous carriers of the PAX4 R133W variant have an increased risk of KPD.
CATEGORY    Metabolic disease; Endocrine disease
GENE        PAX4 [HSA:5078] [KO:K08032]
DBLINKS     OMIM: 612227
            MeSH: D003922
REFERENCE   PMID:16652336 (description)
  AUTHORS   Boutboul S, Black GC, Moore JE, Sinton J, Menasche M, Munier FL, Laroche L, Abitbol M, Schorderet DF
  TITLE     A subset of patients with epithelial basement membrane corneal dystrophy have mutations in TGFBI/BIGH3.
  JOURNAL   Hum Mutat 27:553-7 (2006)
REFERENCE   PMID:14602731 (description)
  AUTHORS   Maldonado M, Hampe CS, Gaur LK, D'Amico S, Iyer D, Hammerle LP, Bolgiano D, Rodriguez L, Rajan A, Lernmark A, Balasubramanyam A
  TITLE     Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and  clinical outcomes.
  JOURNAL   J Clin Endocrinol Metab 88:5090-8 (2003)
REFERENCE   PMID:15509590 (description, gene)
  AUTHORS   Mauvais-Jarvis F, Smith SB, Le May C, Leal SM, Gautier JF, Molokhia M, Riveline JP, Rajan AS, Kevorkian JP, Zhang S, Vexiau P, German MS, Vaisse C
  TITLE     PAX4 gene variations predispose to ketosis-prone diabetes.
  JOURNAL   Hum Mol Genet 13:3151-9 (2004)
///
ENTRY       H01225                      Disease
NAME        D-2-hydroxyglutaric aciduria (D-2-HGA)
DESCRIPTION D-2-hydroxyglutaric aciduria (D-2-HGA) is an autosomal recessive neurometabolic disorder. Clinical symptoms of D-2-HGA are developmental delay, epilepsy, hypotonia, and dysmorphic features. It has been suggested that mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Recently, IDH2 mutations in patients with D-2-HGA were reported.
CATEGORY    Inherited metabolic disease
GENE        D2HGDH [HSA:728294]
            IDH2 [HSA:3418] [KO:K00031]
MARKER      Increased levels of D-2-hydroxyglutarate in body fluids.
DBLINKS     MeSH: C535306
            OMIM: 613657 600721
REFERENCE   PMID:15609246
  AUTHORS   Struys EA, Salomons GS, Achouri Y, Van Schaftingen E, Grosso S, Craigen WJ, Verhoeven NM, Jakobs C
  TITLE     Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria.
  JOURNAL   Am J Hum Genet 76:358-60 (2005)
REFERENCE   PMID:16601864
  AUTHORS   Struys EA
  TITLE     D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect.
  JOURNAL   J Inherit Metab Dis 29:21-9 (2006)
REFERENCE   PMID:20847235
  AUTHORS   Kranendijk M, Struys EA, van Schaftingen E, Gibson KM, Kanhai WA, van der Knaap MS, Amiel J, Buist NR, Das AM, de Klerk JB, Feigenbaum AS, Grange DK, Hofstede FC, Holme E, Kirk EP, Korman SH, Morava E, Morris A, Smeitink J, Sukhai RN, Vallance H, Jakobs C, Salomons GS
  TITLE     IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.
  JOURNAL   Science 330:336 (2010)
///
ENTRY       H01226                      Disease
NAME        GLI3 morphopathies, including:
            Greig cephalopolysyndactyly syndrome;
            Pallister-Hall syndrome;
            Preaxial polydactyly type-IV;
            Postaxial polydactyly types A1 and B
DESCRIPTION GLI3 morphopathies are autosomal dominant developmental defect syndromes, including Greig cephalopolysyndactyly syndrome, Pallister-Hall syndrome, preaxial polydactyly type-IV, and postaxial polydactyly. All GLI3 morphopathies show malformations of the autopod, such as polydactylies or syndactylies. Heterozygous mutations in human GLI3, a zinc-finger transcription factor, are associated with these syndromes. GLI3 is regarded as a mediator of sonic hedgehog signaling regulating development at multiple sites such as the limbs, the lungs, and the brain.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        GLI3 [HSA:2737] [KO:K06230]
COMMENT     Greig cephalopolysyndactyly syndrome and Pallister-Hall syndrome are described in H00263 and H00502, respectively. [DS:H00263] [DS:H00502]
DBLINKS     ICD-10: Q69.1
            MeSH: D054975 C537300
            OMIM: 175700 146510 174700 174200
REFERENCE   PMID:15811011
  AUTHORS   Fujioka H, Ariga T, Horiuchi K, Otsu M, Igawa H, Kawashima K, Yamamoto Y, Sugihara T, Sakiyama Y
  TITLE     Molecular analysis of non-syndromic preaxial polydactyly: preaxial polydactyly type-IV and preaxial polydactyly type-I.
  JOURNAL   Clin Genet 67:429-33 (2005)
REFERENCE   PMID:10441570
  AUTHORS   Radhakrishna U, Bornholdt D, Scott HS, Patel UC, Rossier C, Engel H, Bottani A, Chandal D, Blouin JL, Solanki JV, Grzeschik KH, Antonarakis SE
  TITLE     The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations.
  JOURNAL   Am J Hum Genet 65:645-55 (1999)
REFERENCE   PMID:17661744
  AUTHORS   Paparidis Z, Abbasi AA, Malik S, Goode DK, Callaway H, Elgar G, deGraaff E, Lopez-Rios J, Zeller R, Grzeschik KH
  TITLE     Ultraconserved non-coding sequence element controls a subset of spatiotemporal GLI3 expression.
  JOURNAL   Dev Growth Differ 49:543-53 (2007)
///
ENTRY       H01227                      Disease
NAME        Inflammatory bowel disease (IBD)
DESCRIPTION Inflammatory bowel disease is a heterogeneous group of chronic disorders, which includes Crohn's disease and ulcerative colitis. Patients suffer chronically from abdominal pain, diarrhea, bleeding, and malabsorption. In most patients, these disorders are manifested in adolescence or adulthood, however, they may present in infancy and may be inherited as an autosomal recessive trait. It has been reported that mutations in genes encoding the IL10R subunit proteins were found in patients with early-onset enterocolitis, involving hyperinflammatory immune responses in the intestine. Additional genes associated with the disease have been identified.
CATEGORY    Immune system disease
GENE        NOD2 (polymorphism) [HSA:64127] [KO:K10165]
            ATG16L1 (polymorphism) [HSA:55054] [KO:K17890]
            IL23R (polymorphism) [HSA:149233] [KO:K05065]
            IL10RB [HSA:3588] [KO:K05135]
            IL10RA [HSA:3587] [KO:K05134]
            IL10 (polymorphism) [HSA:3586] [KO:K05443]
            MST1 (polymorphism) [HSA:4485]
            IRGM (polymorphism) [HSA:345611] [KO:K14139]
MARKER      Ulcerative colitisis: Superficial inflammation of the colonic mucosa, beginning in the rectum and extending proximally
DRUG        Infliximab [DR:D02598] Golimumab [DR:D04358] Adalimuab [DR:D02597] Certolizumab pegol [DR:D03441] (anti-TNF-alpha agents)
            Vedolizumab [DR:D08083] Natalizumab [DR:D06886] (anti-integrin agents)
            Mesalzine [DR:D00377] Salazosulfapyridine [DR:D00448] Balsalazide disodium [DR:D02715] Olsalazine sodium [DR:D00727] (Aminosalicylates)
            Budesonide [DR:D00246] Prednisolone [DG:DG00093] (Corticosteroids)
COMMENT     Crohn's disease is described in H00286. [DS:H00286]
            Ulcerative colitis is described in H01466. [DS:H01466]
DBLINKS     MeSH: D015212
            OMIM: 266600 611081 612261 612567 613148 612241 612278
REFERENCE   PMID:11385576
  AUTHORS   Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G
  TITLE     Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.
  JOURNAL   Nature 411:599-603 (2001)
REFERENCE   PMID:19890111
  AUTHORS   Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hatscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C
  TITLE     Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.
  JOURNAL   N Engl J Med 361:2033-45 (2009)
REFERENCE   PMID:22236434
  AUTHORS   Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B
  TITLE     IL-10 and IL-10 receptor defects in humans.
  JOURNAL   Ann N Y Acad Sci 1246:102-7 (2011)
REFERENCE   PMID:19923578 (gene)
  AUTHORS   Abraham C, Cho JH
  TITLE     Inflammatory bowel disease.
  JOURNAL   N Engl J Med 361:2066-78 (2009)
REFERENCE   PMID:26339135 (drug)
  AUTHORS   de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU
  TITLE     Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
  JOURNAL   Mediators Inflamm 2015:493012 (2015)
REFERENCE   PMID:26600980 (drug)
  AUTHORS   Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H
  TITLE     Promising biological therapies for ulcerative colitis: A review of the literature.
  JOURNAL   World J Gastrointest Pathophysiol 6:219-27 (2015)
REFERENCE   PMID:26284562 (drug)
  AUTHORS   Danese S, Vuitton L, Peyrin-Biroulet L
  TITLE     Biologic agents for IBD: practical insights.
  JOURNAL   Nat Rev Gastroenterol Hepatol 12:537-45 (2015)
///
ENTRY       H01228                      Disease
NAME        Insulin-resistant diabetes mellitus with acanthosis nigricans (IRAN);
            Type A insulin resistance
DESCRIPTION Insulin-resistant diabetes mellitus with acanthosis nigricans (IRAN) is an unusual cause of diabetes that result from metabolic abnormalities associated with mutations of the insulin receptor (INSR) gene, characterized by phenotypic description of extreme insulin resistance, acanthosis nigricans, and hyperandrogenism. Other phenotype of IRAN form includes hirsutism and polycystic ovarian disease in a patient who is usually not obese. There is no distinctive serum marker. Leprechaunism [DS:H00719] and the Rabson-Mendenhall syndrome [DS:H00942] also have mutations in INSR with subsequent alterations in insulin receptor function and extreme insulin resistance.
CATEGORY    Metabolic disease; Endocrine disease
GENE        INSR [HSA:3643] [KO:K04527]
DBLINKS     ICD-10: E11
            MeSH: C562710
            OMIM: 610549
REFERENCE   PMID:22187472 (description, gene)
  TITLE     Diagnosis and classification of diabetes mellitus.
  JOURNAL   Diabetes Care 35 Suppl 1:S64-71 (2012)
REFERENCE   PMID:15232309 (description, gene)
  AUTHORS   Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P
  TITLE     Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective.
  JOURNAL   Medicine (Baltimore) 83:209-22 (2004)
///
ENTRY       H01229                      Disease
NAME        Inclusion body myopathy 3 (IBM3)
DESCRIPTION Inclusion body myopathy 3 (IBM3) is an autosomal dominant myopathy associated with a heterozygous missense mutation in the myosin heavy chain (MyHC) IIa gene (MYH2), changing the highly conserved and negatively charged glutamate at position 706 to the positively charged lysine (E706K). This region is important for myosin functioning during muscle contraction, because it undergoes conformational changes during adenosine triphosphate (ATP) hydrolysis. Clinical characteristics include congenital joint contractures, a progressive course in adulthood, and external ophthalmoplegia.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        MHY2 [HSA:4620] [KO:K10352]
DBLINKS     ICD-10: G71.8
            MeSH: C538330
            OMIM: 605637
REFERENCE   PMID:11889243 (description, gene)
  AUTHORS   Tajsharghi H, Thornell LE, Darin N, Martinsson T, Kyllerman M, Wahlstrom J, Oldfors A
  TITLE     Myosin heavy chain IIa gene mutation E706K is pathogenic and its expression increases with age.
  JOURNAL   Neurology 58:780-6 (2002)
REFERENCE   PMID:17434305 (description, gene)
  AUTHORS   Oldfors A
  TITLE     Hereditary myosin myopathies.
  JOURNAL   Neuromuscul Disord 17:355-67 (2007)
///
ENTRY       H01230                      Disease
NAME        Adult-onset autosomal dominant leukodystrophy (ADLD)
DESCRIPTION Adult-onset autosomal dominant leukodystrophy (ADLD) is a slowly progressive neurological disorder characterized by symmetrical widespread myelin loss in the central nervous system. Although a phenotype is similar to that of multiple sclerosis, ADLD neuropathology shows preservation of oligodendroglia in the presence of subtotal demyelination and lack of astrogliosis.  It has been reported that ADLD can be caused by a tandem genomic duplication resulting in an extra copy of the lamin B1 gene.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        LMNB1 [HSA:4001] [KO:K07611]
DBLINKS     ICD-10: E75.2 G35
            MeSH: C566813
            OMIM: 169500
REFERENCE   PMID:16951681
  AUTHORS   Padiath QS, Saigoh K, Schiffmann R, Asahara H, Yamada T, Koeppen A, Hogan K, Ptacek LJ, Fu YH
  TITLE     Lamin B1 duplications cause autosomal dominant leukodystrophy.
  JOURNAL   Nat Genet 38:1114-23 (2006)
///
ENTRY       H01231                      Disease
NAME        Biotin-responsive basal ganglia disease (BBGD)
DESCRIPTION Biotin-responsive basal ganglia disease (BBGD) is a rare autosomal recessive disorder. The disease has its onset in childhood, and is characterized by episodic encephalopathy presenting as confusion, seizures, external ophthalmoplegia, dysphagia, and sometimes coma and death. BBGD symptoms disappear within a few days with the administration of high doses of biotin (5-10 mg/kg/d). It has been reported that BBGD is due to mutations in the transporter gene SLC19A3.
CATEGORY    Inherited metabolic disease
GENE        SLC19A3 [HSA:80704] [KO:K14610]
DRUG        Biotin [DR:D00029]
DBLINKS     MeSH: C537658
            OMIM: 607483
REFERENCE   PMID:15871139
  AUTHORS   Zeng WQ, Al-Yamani E, Acierno JS Jr, Slaugenhaupt S, Gillis T, MacDonald ME, Ozand PT, Gusella JF
  TITLE     Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.
  JOURNAL   Am J Hum Genet 77:16-26 (2005)
///
ENTRY       H01232                      Disease
NAME        Syndromic multisystem autoimmune disease
DESCRIPTION Syndromic multisystem autoimmune disease is characterized by organomegaly, failure to thrive, developmental delay, dysmorphic features and autoimmune inflammatory cell infiltration of the lungs, liver and gut. It has been reported that human ITCH E3 ubiquitin ligase deficiency causes this disease.
CATEGORY    Immune system disease
GENE        ITCH [HSA:83737] [KO:K05632]
DBLINKS     OMIM: 613385
REFERENCE   PMID:20170897
  AUTHORS   Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, Rider NL, Chikwava KR, Cummings OW, Morton DH, Puffenberger EG
  TITLE     Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease.
  JOURNAL   Am J Hum Genet 86:447-53 (2010)
///
ENTRY       H01233                      Disease
NAME        Urocanase deficiency;
            Urocanic aciduria
DESCRIPTION Urocanase deficiency is an autosomal recessive disoder of histidine metabolism caused by mutations in the UROC1 gene. It is characterized by mental retardation, urocanic aciduria, and a defective activity of urocanase of the liver. Patients sometimes display ataxia.
CATEGORY    Inherited metabolic disease
GENE        UROC1 [HSA:131669] [KO:K01712]
DBLINKS     ICD-10: E70.8
            MeSH: C536479
            OMIM: 276880
REFERENCE   PMID:19304569 (description, gene)
  AUTHORS   Espinos C, Pineda M, Martinez-Rubio D, Lupo V, Ormazabal A, Vilaseca MA, Spaapen LJ, Palau F, Artuch R
  TITLE     Mutations in the urocanase gene UROC1 are associated with urocanic aciduria.
  JOURNAL   J Med Genet 46:407-11 (2009)
REFERENCE   PMID:5124677 (description)
  AUTHORS   Yoshida T, Tada K, Honda Y, Arakawa T
  TITLE     Urocanic aciduria: a defect in the urocanase activity in the liver of a mentally  retarded.
  JOURNAL   Tohoku J Exp Med 104:305-12 (1971)
///
ENTRY       H01234                      Disease
NAME        Trimethylaminuria (TMAU);
            Fish-odor syndrome
DESCRIPTION Trimethylaminuria (TMAU), also known as fish odour syndrome, is a metabolic disorder. TMAU usually presents with a body odour resembling that of rotten or decaying fish, the result of excess excretion of trimethylamine (TMA) in the breath, sweat, urine, and reproductive fluids. Primary TMAU is most often caused by a functional defect of flavin mono-oxygenase 3 (FMO3), and the genetic disorder is inherited in an autosomal recessive manner as a consequence of mutations in the FMO3 gene. Secondary TMAU has been described in patients with severe liver disease (which is the major site of activity of the FMO3 enzyme) and chronic renal disease (as a consequence of bacterial overgrowth in the gut), and in patients treated with large doses of betaine or possibly L-carnitine. In addition, transient TMAU has been reported in a preterm infant who was fed with choline-rich food supplements and has been reported in some women just at the onset of menstruation.
CATEGORY    Inherited metabolic disease
GENE        FMO3 [HSA:2328] [KO:K00485]
MARKER      (urine) Trimethylamine [CPD:C00565]
            Trimethylamine N-oxide [CPD:C01104]
DBLINKS     ICD-10: E88.8
            MeSH: C536561
            OMIM: 602079
REFERENCE   PMID:21276117 (description, gene)
  AUTHORS   Christodoulou J
  TITLE     Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder.
  JOURNAL   J Paediatr Child Health 48:E153-5 (2012)
REFERENCE   PMID:22126753 (description, gene)
  AUTHORS   Shephard EA, Treacy EP, Phillips IR
  TITLE     Clinical utility gene card for: trimethylaminuria.
  JOURNAL   Eur J Hum Genet 20 (2012)
REFERENCE   PMID:12653714
  AUTHORS   Fraser-Andrews EA, Manning NJ, Ashton GH, Eldridge P, McGrath J, Menage Hdu P
  TITLE     Fish odour syndrome with features of both primary and secondary trimethylaminuria.
  JOURNAL   Clin Exp Dermatol 28:203-5 (2003)
///
ENTRY       H01235                      Disease
NAME        Bleeding disorder platelet-type
DESCRIPTION Bleeding disorder platelet-type is a condition characterized by mild to moderate mucocutaneous bleeding. Patients are with platelet dysfunction but normal platelet number. It has been reported that these disorders are associated with mutations in key platelet activation receptors, namely those for ADP, collagen and thromboxane A2.
CATEGORY    Hematologic disease
GENE        P2RY12 [HSA:64805] [KO:K04298]
            GP6 [HSA:51206] [KO:K06264]
            TBXA2R [HSA:6915] [KO:K04264]
DBLINKS     ICD-10: D69.8
            OMIM: 609821 614201 614009
REFERENCE   PMID:12578987
  AUTHORS   Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM
  TITLE     Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.
  JOURNAL   Proc Natl Acad Sci U S A 100:1978-83 (2003)
REFERENCE   PMID:19552682
  AUTHORS   Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K
  TITLE     A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding  disorder.
  JOURNAL   J Thromb Haemost 7:1356-63 (2009)
REFERENCE   PMID:20162250
  AUTHORS   Watson S, Daly M, Dawood B, Gissen P, Makris M, Mundell S, Wilde J, Mumford A
  TITLE     Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors.
  JOURNAL   Hamostaseologie 30:29-38 (2010)
///
ENTRY       H01236                      Disease
NAME        Familial articular chondrocalcinosis
DESCRIPTION Chondrocalcinosis is a common cause of joint pain and arthritis caused by calcium deposition in articular cartilage and the presence of calcium hypophosphate crystals in synovial fluid, cartilage and periarticular soft tissue. Although most cases are sporadic, rare familial forms have been linked to human chromosomes 8 (CCAL1) or 5p (CCAL2). It has been suggested that mutations in the ANKH gene, which is located on the chromosome 5p, are one cause of chondrocalcinosis.
CATEGORY    Musculoskeletal disease
GENE        ANKH [HSA:56172]
DBLINKS     ICD-10: M11.1
            MeSH: C563162
            OMIM: 118600
REFERENCE   PMID:12297987
  AUTHORS   Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley DM
  TITLE     Mutations in ANKH cause chondrocalcinosis.
  JOURNAL   Am J Hum Genet 71:933-40 (2002)
///
ENTRY       H01237                      Disease
NAME        Sulfite oxidase deficiency
DESCRIPTION Sulfite oxidase deficiency is a rare inherited disease with severe neurological symptoms such as intractable neonatal or infantile seizures, hypotonia or hypertonia, feeding difficulties, profound developmental delay, and dislocated lens. Isolated sulfite oxidase deficiency results from defects in the enzyme sulfite oxidase, which is responsible for the oxidation of sulfite to sulfate. Several mutations have been identified from patients suffering from isolated sulfite oxidase deficiency. The more common molybdenum cofactor deficiency [DS:H00192] leads to combined defects in xanthine dehydrogenase and sulfite oxidase, as sulfite oxidase is 1 of 3 enzymes in humans that requires molybdenum as a cofactor, the other 2 being xanthine oxidase and aldehyde oxidase. The seizures in isolated sulfite oxidase deficiency may even begin prenatally, and are much more severe compared with those in molybdenum cofactor deficiency.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        SUOX [HSA:6821] [KO:K00387]
COMMENT     Molybdenum cofactor deficiency is described in [DS:H00192].
DBLINKS     ICD-10: E72.1
            MeSH: C538141
            OMIM: 272300
REFERENCE   PMID:16140720 (description, gene)
  AUTHORS   Tan WH, Eichler FS, Hoda S, Lee MS, Baris H, Hanley CA, Grant PE, Krishnamoorthy KS, Shih VE
  TITLE     Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature.
  JOURNAL   Pediatrics 116:757-66 (2005)
REFERENCE   PMID:16234925 (description, gene)
  AUTHORS   Karakas E, Kisker C
  TITLE     Structural analysis of missense mutations causing isolated sulfite oxidase deficiency.
  JOURNAL   Dalton Trans 3459-63 (2005)
REFERENCE   PMID:21803516 (description, gene)
  AUTHORS   Lee WT
  TITLE     Disorders of amino acid metabolism associated with epilepsy.
  JOURNAL   Brain Dev 33:745-52 (2011)
///
ENTRY       H01238                      Disease
NAME        Phelan-McDermid syndrome;
            Chromosome 22q13.3 deletion syndrome
DESCRIPTION Phelan-McDermid syndrome is a genetic disorder caused by a microdeletion on chromosome 22. It is characterized by severe expressive-language delay, mild mental retardation, hypotonia, joint laxity, dolichocephaly, and minor facial dysmorphisms. It has been indicated  that this syndrome may also be caused by mutations in the SHANK3/PROSAP2 gene.
CATEGORY    Developmental disorder
GENE        SHANK3 [HSA:85358] [KO:K15009]
DBLINKS     ICD-10: Q93.5
            MeSH: C536801
            OMIM: 606232
REFERENCE   PMID:11431708
  AUTHORS   Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, Selicorni A, Zuffardi O
  TITLE     Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the  22q13.3 deletion syndrome.
  JOURNAL   Am J Hum Genet 69:261-8 (2001)
///
ENTRY       H01239                      Disease
NAME        Combined SAP deficiency;
            Prosaposin deficiency
DESCRIPTION Combined SAP deficiency is a fatal infantile lysosomal storage disorder with hepatosplenomegaly and severe neurological disease. It is caused by mutations in the PSAP gene leading to absence or non-functionality of the prosaposin protein. Mammalian prosaposin encodes in tandem four small acidic activator proteins (saposins) with specificities for glycosphingolipids hydrolases.
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
GENE        PSAP [HSA:5660] [KO:K12382]
COMMENT     Defects in PSAP saposin-B region are the cause of metachromatic leukodystrophy [DS:H00127]. Defects in PSAP saposin-C region are the cause of atypical Gaucher disease [DS:H00126]. Defects in PSAP saposin-A region are the cause of atypical Krabbe disease [DS:H00135].
DBLINKS     ICD-10: E75.2
            MeSH: C567125
            OMIM: 611721
REFERENCE   PMID:1371116
  AUTHORS   Schnabel D, Schroder M, Furst W, Klein A, Hurwitz R, Zenk T, Weber J, Harzer K, Paton BC, Poulos A, et al.
  TITLE     Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene.
  JOURNAL   J Biol Chem 267:3312-5 (1992)
REFERENCE   PMID:11309366
  AUTHORS   Hulkova H, Cervenkova M, Ledvinova J, Tochackova M, Hrebicek M, Poupetova H, Befekadu A, Berna L, Paton BC, Harzer K, Boor A, Smid F, Elleder M
  TITLE     A novel mutation in the coding region of the prosaposin gene leads to a complete  deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation.
  JOURNAL   Hum Mol Genet 10:927-40 (2001)
REFERENCE   PMID:17353235
  AUTHORS   Sun Y, Witte DP, Zamzow M, Ran H, Quinn B, Matsuda J, Grabowski GA
  TITLE     Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype,  glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin  trafficking.
  JOURNAL   Hum Mol Genet 16:957-71 (2007)
///
ENTRY       H01240                      Disease
NAME        Immune thrombocytopenia (ITP);
            Autoimmune thrombocytopenic purpura
DESCRIPTION Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder, and the most common cause of isolated thrombocytopenia in children. Destruction of autoantibody-sensitized platelets by Fc[gamma]R-bearing phagocytic cells in the reticuloendothelial system plays an important role. ITP is diagnosed clinically, based upon onset of thrombocytopenia in the absence of other hematologic abnormalities, or other causes of low platelets, and with a characteristic blood smear. While around 50% of typical childhood acute ITP is preceded by a viral or bacterial infection and commonly resolves within weeks to months without treatment, fewer adult cases are acute and self-resolving. Typical adult primary ITP is very similar clinically to chronic pediatric ITP. Intravenous immunoglobulin (IVIg) treatment and splenectomy (removal of the platelet-destructing organ) are effective treatment options. It has been reported that the activating FCGR2C-ORF genotype predisposes to ITP by altering the balance of activating and inhibitory Fc[gamma]R on immune cells.
CATEGORY    Primary immunodeficiency; Hematologic disease
GENE        FCGR2C [HSA:9103] [KO:K16824]
ENV_FACTOR  Quinine [DR:D08460]
            Trimethoprim-sulfamethoxazole [DR:D00285]
PATHOGEN    Hepatitis C virus [GN:T40066]
            Human immunodeficiency virus 1 [GN:T40001]
            Helicobacter pylori [GN:hpy hpj hpa]
DRUG        Prednisone [DG:DG00094]
            Dexamethasone [DG:DG00011]
            Intravenous immunoglobulin (IVIG)
            Intravenous anti-Rho(D) [DR:D08789 D05723]
            Rituximab [DR:D02994]
            Romiplostim (Nplate) [DR:D08990]
            Eltrombopag (Promacta) [DR:D03978]
DBLINKS     ICD-10: D69.3
            MeSH: D016553
            OMIM: 188030
REFERENCE   PMID:21632906 (description, environmental factor, drug)
  AUTHORS   McCrae K
  TITLE     Immune thrombocytopenia: no longer 'idiopathic'.
  JOURNAL   Cleve Clin J Med 78:358-73 (2011)
REFERENCE   PMID:17934360 (description)
  AUTHORS   Cines DB, McMillan R
  TITLE     Pathogenesis of chronic immune thrombocytopenic purpura.
  JOURNAL   Curr Opin Hematol 14:511-4 (2007)
REFERENCE   PMID:20309691 (description)
  AUTHORS   Bergmann AK, Grace RF, Neufeld EJ
  TITLE     Genetic studies in pediatric ITP: outlook, feasibility, and requirements.
  JOURNAL   Ann Hematol 89:S95-103 (2010)
REFERENCE   PMID:17827395 (description, gene)
  AUTHORS   Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, Roos D, de Haas M, Koene HR, Kuijpers TW
  TITLE     Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura.
  JOURNAL   Blood 111:1029-38 (2008)
///
ENTRY       H01241                      Disease
NAME        Congenital diaphragmatic hernia (CDH)
DESCRIPTION Congenital diaphragmatic hernia (CDH) is defined as a protrusion of abdominal viscera into the thorax through an abnormal opening or defect that is present at birth. CDH is often associated with potentially lethal lung hypoplasia and pulmonary hypertension. Despite advances in therapy, mortality remains high. Although the etiology of most cases of CDH remains unknown, there is increasing evidence that specific pathways and genes play a role in the development of CDH. It has been reported that a patient who has nonsense mutation in FOG2/ ZFPM2, died at birth with a diaphragmatic defect and severe pulmonary hypoplasia.
CATEGORY    Developmental disorder
GENE        ZFPM2 [HSA:23414] [KO:K17442]
DBLINKS     ICD-10: Q79.0
            MeSH: C538080
            OMIM: 610187
REFERENCE   PMID:17436238
  AUTHORS   Holder AM, Klaassens M, Tibboel D, de Klein A, Lee B, Scott DA
  TITLE     Genetic factors in congenital diaphragmatic hernia.
  JOURNAL   Am J Hum Genet 80:825-45 (2007)
REFERENCE   PMID:16103912
  AUTHORS   Ackerman KG, Herron BJ, Vargas SO, Huang H, Tevosian SG, Kochilas L, Rao C, Pober BR, Babiuk RP, Epstein JA, Greer JJ, Beier DR
  TITLE     Fog2 is required for normal diaphragm and lung development in mice and humans.
  JOURNAL   PLoS Genet 1:58-65 (2005)
///
ENTRY       H01242                      Disease
NAME        Saccharopinuria
DESCRIPTION Saccharopinuria is a metabolic disorder caused by a defect in a bifunctional protein with lysine-ketoglutarate reductase (LKR) activity and saccharopine dehydrogenase (SDH) activity, aminoadipic semialdehyde synthase (AASS), which catalyzes the first two steps in the lysine-degradation pathway. Patients with this disorder have both hyperlysinemia and saccharopinuria, although the saccharopinuria is much more severe. It seems likely that this disorder results from specific mutations in the portion of AASS encoding SDH, which could explain the high levels of saccharopine, compared with that in patients with hyperlysinemia [DS:H00188].
CATEGORY    Inherited metabolic disease
GENE        AASS [HSA:10157] [KO:K14157]
DBLINKS     ICD-10: E72.3
            MeSH: C537218
            OMIM: 268700
REFERENCE   PMID:10775527 (description, gene)
  AUTHORS   Sacksteder KA, Biery BJ, Morrell JC, Goodman BK, Geisbrecht BV, Cox RP, Gould SJ, Geraghty MT
  TITLE     Identification of the alpha-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia.
  JOURNAL   Am J Hum Genet 66:1736-43 (2000)
REFERENCE   PMID:463877 (description)
  AUTHORS   Dancis J, Hutzler J, Cox RP
  TITLE     Familial hyperlysinemia: enzyme studies, diagnostic methods, comments on terminology.
  JOURNAL   Am J Hum Genet 31:290-9 (1979)
///
ENTRY       H01243                      Disease
NAME        Huntington's disease-like syndrome
DESCRIPTION Huntington's disease (HD), which is caused by a triplet-repeat expansion in the IT15 gene (also known as huntingtin or HD), accounts for about 90% of cases of chorea of genetic etiology. In recent years, several other distinct genetic disorders have been identified that can present with a clinical picture indistinguishable from HD, termed HD-like (HDL) syndromes. So far, four genes associated with HDL syndromes have been identified, including the prion protein gene (HDL1), the junctophilin 3 gene (HDL2) and, the gene encoding the TATA box-binding protein (HDL4).
CATEGORY    Neurodegenerative disease
GENE        PRNP [HSA:5621] [KO:K05634]
            HDL2 [HSA:57338] [KO:K19530]
            HDL4 [HSA:6908] [KO:K03120]
DBLINKS     MeSH: C580174
            OMIM: 603218 606438 607136
REFERENCE   PMID:17805246 (description, gene)
  AUTHORS   Schneider SA, Walker RH, Bhatia KP
  TITLE     The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test.
  JOURNAL   Nat Clin Pract Neurol 3:517-25 (2007)
REFERENCE   PMID:18181206 (gene)
  AUTHORS   Wild EJ, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, Rossor MN, Davis MB, Tabrizi SJ
  TITLE     Huntington's disease phenocopies are clinically and genetically heterogeneous.
  JOURNAL   Mov Disord 23:716-20 (2008)
///
ENTRY       H01244                      Disease
NAME        T+B+Severe combined immunodeficiencies (SCIDs)
DESCRIPTION Recently, several groups reported a novel clinical and immunological phenotype of T+B+NK+SCID (severe combined immunodeficiencies) associated with recessive RAG1 hypomorphic mutations. The immunological phenotype consists of the oligoclonal expansion of TCR-gamma/delta T cells combined with TCR-alpha/beta T cell lymphopenia. The clinical phenotype consists of severe, disseminated cytomegalovirus (CMV) infection and autoimmune blood cell manifestations.
CATEGORY    Primary immunodeficiency
GENE        RAG-1 [HSA:5896] [KO:K10628]
DBLINKS     ICD-10: D81
            MeSH: C563311
            OMIM: 609889
REFERENCE   PMID:16276422 (description, gene)
  AUTHORS   de Villartay JP, Lim A, Al-Mousa H, Dupont S, Dechanet-Merville J, Coumau-Gatbois E, Gougeon ML, Lemainque A, Eidenschenk C, Jouanguy E, Abel L, Casanova JL, Fischer A, Le Deist F
  TITLE     A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection.
  JOURNAL   J Clin Invest 115:3291-9 (2005)
REFERENCE   PMID:19243569 (description, gene)
  AUTHORS   Pasic S, Djuricic S, Ristic G, Slavkovic B
  TITLE     Recombinase-activating gene 1 immunodeficiency: different immunological phenotypes in three siblings.
  JOURNAL   Acta Paediatr 98:1062-4 (2009)
REFERENCE   PMID:16211094 (gene)
  AUTHORS   Ehl S, Schwarz K, Enders A, Duffner U, Pannicke U, Kuhr J, Mascart F, Schmitt-Graeff A, Niemeyer C, Fisch P
  TITLE     A variant of SCID with specific immune responses and predominance of gamma delta  T cells.
  JOURNAL   J Clin Invest 115:3140-8 (2005)
///
ENTRY       H01245                      Disease
NAME        Immunodeficiency without anhidrotic ectodermal  dysplasia
DESCRIPTION A NEMO mutant causing immunodeficiency without any sign of anhidrotic ectodermal dysplasia (EDA) has  been identified. The mutation, which altered the exon 9 splice site, was present in cells of ectodermal and hematopoietic origin and resulted in a heterogeneous mixture of mutant and wild-type cDNA species.
CATEGORY    Primary immunodeficiency
GENE        IKBKG [HSA:8517] [KO:K07210]
DBLINKS     MeSH: C536289
            OMIM: 300584
REFERENCE   PMID:16397577 (gene)
  AUTHORS   Courtois G, Smahi A
  TITLE     NF-kappaB-related genetic diseases.
  JOURNAL   Cell Death Differ 13:843-51 (2006)
REFERENCE   PMID:15577852 (gene)
  AUTHORS   Niehues T, Reichenbach J, Neubert J, Gudowius S, Puel A, Horneff G, Lainka E, Dirksen U, Schroten H, Doffinger R, Casanova JL, Wahn V
  TITLE     Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia.
  JOURNAL   J Allergy Clin Immunol 114:1456-62 (2004)
REFERENCE   PMID:15356572 (description, gene)
  AUTHORS   Orange JS, Levy O, Brodeur SR, Krzewski K, Roy RM, Niemela JE, Fleisher TA, Bonilla FA, Geha RS
  TITLE     Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia.
  JOURNAL   J Allergy Clin Immunol 114:650-6 (2004)
///
ENTRY       H01246                      Disease
NAME        Isolated congenital nail clubbing (ICNC);
            Isolated congenital digital clubbing
DESCRIPTION Isolated congenital nail clubbing (ICNC) is a rare autosomal recessive disorder characterised by enlargement of the terminal segments of fingers and toes with thickened nails due to proliferation of the connective tissues and abnormal function of the nail matrix. It has been reported that mutation in the HPGD gene underlies ICNC.
CATEGORY    Developmental disorder
GENE        HPGD [HSA:3248] [KO:K00069]
DBLINKS     ICD-10: Q68.1
            MeSH: D010004
            OMIM: 119900
REFERENCE   PMID:18805827
  AUTHORS   Tariq M, Azeem Z, Ali G, Chishti MS, Ahmad W
  TITLE     Mutation in the HPGD gene encoding NAD+ dependent 15-hydroxyprostaglandin dehydrogenase underlies isolated congenital nail clubbing (ICNC).
  JOURNAL   J Med Genet 46:14-20 (2009)
///
ENTRY       H01247                      Disease
NAME        Pyridoxine-dependent epilepsy (PDE)
DESCRIPTION Pyridoxine-dependent epilepsy (PDE) is an autosomal recessive epileptic encephalopathy characterized by a therapeutic response to pharmacological dosages of pyridoxine hydrochloride (vitamin B6) and resistance to conventional antiepileptic treatment. Antiquitin (ATQ) deficiency is the main cause of PDE. Antiquitin is encoded by ALDH7A1 gene, and functions in the lysine degradation pathway. Its deficiency results in accumulation of alpha-aminoadipic semialdehyde (AASA), piperideine-6-carboxylate (P6C) and pipecolic acid, which serve as diagnostic markers in urine, plasma, and CSF.
CATEGORY    Nervous system disease; Epilepsy
GENE        ALDH7A1 [HSA:501] [KO:K14085]
MARKER      Alpha-aminoadipic semialdehyde [CPD:C04076]
            Piperideine-6-carboxylate [CPD:C00450]
            Pipecolic acid [CPD:C00408]
DRUG        Pyridoxine [DG:DG00128]
DBLINKS     ICD-10: G40.8
            MeSH: C536254
            OMIM: 266100
REFERENCE   PMID:16491085
  AUTHORS   Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, Willemsen MA, Omran H, Tacke U, Uhlenberg B, Weschke B, Clayton PT
  TITLE     Mutations in antiquitin in individuals with pyridoxine-dependent seizures.
  JOURNAL   Nat Med 12:307-9 (2006)
REFERENCE   PMID:21704546
  AUTHORS   Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, Mercimek-Mahmutoglu S, Hartmann H, Scharer G, Struijs E, Tein I, Jakobs C, Clayton P, Van Hove JL
  TITLE     Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.
  JOURNAL   Mol Genet Metab 104:48-60 (2011)
///
ENTRY       H01248                      Disease
NAME        Erythrocyte lactate transporter defect
DESCRIPTION Erythrocyte lactate transporter defect is a rare condition characterized by severe chest pain and muscle cramping on vigorous exercise. The patient was found to have a missense mutation in monocarboxylate transporter 1 (MCT1), the gene for the red cell lactate transporter.
CATEGORY    Musculoskeletal disease
GENE        SLC16A1 [HSA:6566] [KO:K08179]
DBLINKS     MeSH: C565449
            OMIM: 245340
REFERENCE   PMID:10590411
  AUTHORS   Merezhinskaya N, Fishbein WN, Davis JI, Foellmer JW
  TITLE     Mutations in MCT1 cDNA in patients with symptomatic deficiency in lactate transport.
  JOURNAL   Muscle Nerve 23:90-7 (2000)
REFERENCE   PMID:12739169
  AUTHORS   Halestrap AP, Meredith D
  TITLE     The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino  acid transporters and beyond.
  JOURNAL   Pflugers Arch 447:619-28 (2004)
///
ENTRY       H01249                      Disease
NAME        Ethylmalonic encephalopathy (EE)
DESCRIPTION Ethylmalonic encephalopathy (EE) is an autosomal recessive metabolic disease caused by mutations in the ETHE1 gene. EE is is characterized by early onset of neurological degeneration, chronic diarrhea, recurrent petechiae, orthostatic acrocyanosis, and death in the first years of life.
CATEGORY    Inherited metabolic disease
GENE        ETHE1 [HSA:23474] [KO:K17725]
MARKER      High levels of ethylmalonic acid in urine
            High levels of C4-C5 acylglycines and acylcarnitines in blood
DRUG        Riboflavin [DR:D00050]
DBLINKS     MeSH: C535737
            OMIM: 602473
REFERENCE   PMID:14732903
  AUTHORS   Tiranti V, D'Adamo P, Briem E, Ferrari G, Mineri R, Lamantea E, Mandel H, Balestri P, Garcia-Silva MT, Vollmer B, Rinaldo P, Hahn SH, Leonard J, Rahman S, Dionisi-Vici C, Garavaglia B, Gasparini P, Zeviani M
  TITLE     Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein.
  JOURNAL   Am J Hum Genet 74:239-52 (2004)
REFERENCE   PMID:16828325
  AUTHORS   Di Rocco M, Caruso U, Briem E, Rossi A, Allegri AE, Buzzi D, Tiranti V
  TITLE     A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation.
  JOURNAL   Mol Genet Metab 89:395-7 (2006)
REFERENCE   PMID:11916321
  AUTHORS   Yoon HR, Hahn SH, Ahn YM, Jang SH, Shin YJ, Lee EH, Ryu KH, Eun BL, Rinaldo P, Yamaguchi S
  TITLE     Therapeutic trial in the first three Asian cases of ethylmalonic encephalopathy:  response to riboflavin.
  JOURNAL   J Inherit Metab Dis 24:870-3 (2001)
///
ENTRY       H01250                      Disease
NAME        Hereditary gingival fibromatosis (HGF)
DESCRIPTION Hereditary gingival fibromatosis (HGF) is a rare autosomal dominant overgrowth condition characterized by a benign, slowly progressive, nonhemorrhagic, fibrous enlargement of maxillary and mandibular keratinized gingiva. Four gene loci have been mapped for autosomal dominant HGF. Although the molecular basis of HGF remains largely unknown, only a SOS1 gene mutation is identified.
CATEGORY    Developmental disorder
GENE        SOS1 [HSA:6654] [KO:K03099]
DBLINKS     ICD-10: K06.1
            MeSH: D005351
            OMIM: 135300
REFERENCE   PMID:11868160
  AUTHORS   Hart TC, Zhang Y, Gorry MC, Hart PS, Cooper M, Marazita ML, Marks JM, Cortelli JR, Pallos D
  TITLE     A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1.
  JOURNAL   Am J Hum Genet 70:943-54 (2002)
REFERENCE   PMID:19633868
  AUTHORS   Pampel M, Maier S, Kreczy A, Weirich-Schwaiger H, Utermann G, Janecke AR
  TITLE     Refinement of the GINGF3 locus for hereditary gingival fibromatosis.
  JOURNAL   Eur J Pediatr 169:327-32 (2010)
///
ENTRY       H01251                      Disease
NAME        Focal cortical dysplasia of Taylor;
            Focal cortical dysplasia  type II
DESCRIPTION Focal cortical dysplasia of Taylor (FCDT) is a subtype of cortical displasias. FCDT is characterized by epilepsy associated malformations that are often composed of balloon cells and dysplastic neurons. It has been found that inherited mutations in the TSC1 gene can cause this disorder.
CATEGORY    Developmental disorder
GENE        TSC1 [HSA:7248] [KO:K07206]
DBLINKS     ICD-10: Q04.8
            MeSH: C537067
            OMIM: 607341
REFERENCE   PMID:12112044
  AUTHORS   Becker AJ, Urbach H, Scheffler B, Baden T, Normann S, Lahl R, Pannek HW, Tuxhorn I, Elger CE, Schramm J, Wiestler OD, Blumcke I
  TITLE     Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis.
  JOURNAL   Ann Neurol 52:29-37 (2002)
REFERENCE   PMID:12135964
  AUTHORS   Tassi L, Colombo N, Garbelli R, Francione S, Lo Russo G, Mai R, Cardinale F, Cossu M, Ferrario A, Galli C, Bramerio M, Citterio A, Spreafico R
  TITLE     Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome.
  JOURNAL   Brain 125:1719-32 (2002)
REFERENCE   PMID:15642904
  AUTHORS   Lawson JA, Birchansky S, Pacheco E, Jayakar P, Resnick TJ, Dean P, Duchowny MS
  TITLE     Distinct clinicopathologic subtypes of cortical dysplasia of Taylor.
  JOURNAL   Neurology 64:55-61 (2005)
REFERENCE   PMID:19918125
  AUTHORS   Lugnier C, Majores M, Fassunke J, Pernhorst K, Niehusmann P, Simon M, Nellist M, Schoch S, Becker A
  TITLE     Hamartin variants that are frequent in focal dysplasias and cortical tubers have  reduced tuberin binding and aberrant subcellular distribution in vitro.
  JOURNAL   J Neuropathol Exp Neurol 68:1136-46 (2009)
///
ENTRY       H01252                      Disease
NAME        Hereditary folate malabsorption (HFM)
DESCRIPTION Hereditary folate malabsorption (HFM) is a rare autosomal recessive disorder caused by impaired intestinal folate absorption. HFM is characterized by anemia, hypoimmunoglobulinemia, and recurrent infections. When diagnosed early, the signs and symptoms can be obviated by high oral doses of folates. Recently, several mutations were identified in the proton-coupled folate transporter (PCFT/SLC46A1) gene from patients with HFM.
CATEGORY    Hematologic disease
GENE        SLC46A1 [HSA:113235] [KO:K14613]
MARKER      Low folate levels in the blood and cerebrospinal fluid
DRUG        Folate [DR:D07985]
DBLINKS     ICD-10: D52.8
            OMIM: 229050
REFERENCE   PMID:17129779
  AUTHORS   Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID
  TITLE     Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
  JOURNAL   Cell 127:917-28 (2006)
REFERENCE   PMID:18559978
  AUTHORS   Lasry I, Berman B, Straussberg R, Sofer Y, Bessler H, Sharkia M, Glaser F, Jansen G, Drori S, Assaraf YG
  TITLE     A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for  function.
  JOURNAL   Blood 112:2055-61 (2008)
REFERENCE   PMID:19508863
  AUTHORS   Lasry I, Berman B, Glaser F, Jansen G, Assaraf YG
  TITLE     Hereditary folate malabsorption: a positively charged amino acid at position 113  of the proton-coupled folate transporter (PCFT/SLC46A1) is required for folic acid binding.
  JOURNAL   Biochem Biophys Res Commun 386:426-31 (2009)
///
ENTRY       H01253                      Disease
NAME        Isolated follicle-stimulating hormone deficiency (IFSHD)
DESCRIPTION Isolated follicle-stimulating hormone deficiency (IFSHD) can be caused by mutations in the gene encoding the beta chain of follicle-stimulating hormone (FSH).  FSH is essential for normal puberty and fertility in females, particularly ovarian follicular development beyond the antral stage. In males, FSH is necessary for normal spermatogenesis and when FSH function is completely absent, infertility occurs. With partial FSH deficiency in males, spermatogenesis is affected, but fertility may still be possible.
CATEGORY    Endocrine disease
GENE        FSHB [HSA:2488] [KO:K05250]
DRUG        Recombinant human FSH (rhFSH)
            Chorionic gonadotrophin [DG:DG00471]
DBLINKS     ICD-10: E23.6
            MeSH: C537070
            OMIM: 229070
REFERENCE   PMID:10773385
  AUTHORS   Layman LC, McDonough PG
  TITLE     Mutations of follicle stimulating hormone-beta and its receptor in human and mouse: genotype/phenotype.
  JOURNAL   Mol Cell Endocrinol 161:9-17 (2000)
REFERENCE   PMID:9280841
  AUTHORS   Matthews C, Chatterjee VK
  TITLE     Isolated deficiency of follicle-stimulating hormone re-revisited.
  JOURNAL   N Engl J Med 337:642 (1997)
REFERENCE   PMID:17854805
  AUTHORS   Calongos G, Hasegawa A, Komori S, Koyama K
  TITLE     Comparison of urinary and recombinant follicle-stimulating hormone in in vitro growth, maturation, and fertilization of mouse preantral follicles.
  JOURNAL   Fertil Steril 89:1482-9 (2008)
///
ENTRY       H01254                      Disease
NAME        Congenital prothrombin deficiency
DESCRIPTION Prothrombin (factor II) deficiency is an autosomal recessive disorder associated with moderate or severe bleeding tendency. It occurs in approximately 1 in 1-2 million people. Prothrombin is activated to thrombin, which in turn proteolytically cleaves fibrinogen to fibrin and contributes to forming a stable fibrin clot.
CATEGORY    Hematologic disease
GENE        F2 [HSA:2147] [KO:K01313]
DBLINKS     ICD-10: D68
            OMIM: 613679
REFERENCE   PMID:19141155
  AUTHORS   Meeks SL, Abshire TC
  TITLE     Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment.
  JOURNAL   Haemophilia 14:1159-63 (2008)
REFERENCE   PMID:21692854
  AUTHORS   Pasmant E, Dumont B, Lacapere JJ, Dautzenberg MD, Bezeaud A
  TITLE     A severe neonatal presentation of factor II deficiency.
  JOURNAL   Eur J Haematol 87:464-6 (2011)
///
ENTRY       H01255                      Disease
NAME        Juvenile-onset dystonia
DESCRIPTION Juvenile-onset dystonia is a rare progressive neurodegenerative disorder with a primarily dystonic phenotype of juvenile onset, caused by a mutation in one of the major forms of nonmuscle actin gene, ACTB, which is associated with a broad spectrum of developmental malformations and/or neurological abnormalities such as dystonia.
CATEGORY    Nervous system disease
GENE        ACTB [HSA:60] [KO:K05692]
DBLINKS     MeSH: C537704
            OMIM: 607371
REFERENCE   PMID:16685646 (description, gene)
  AUTHORS   Procaccio V, Salazar G, Ono S, Styers ML, Gearing M, Davila A, Jimenez R, Juncos J, Gutekunst CA, Meroni G, Fontanella B, Sontag E, Sontag JM, Faundez V, Wainer BH
  TITLE     A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia.
  JOURNAL   Am J Hum Genet 78:947-60 (2006)
REFERENCE   PMID:12325076 (description, gene)
  AUTHORS   Gearing M, Juncos JL, Procaccio V, Gutekunst CA, Marino-Rodriguez EM, Gyure KA, Ono S, Santoianni R, Krawiecki NS, Wallace DC, Wainer BH
  TITLE     Aggregation of actin and cofilin in identical twins with juvenile-onset dystonia.
  JOURNAL   Ann Neurol 52:465-76 (2002)
///
ENTRY       H01256                      Disease
NAME        Foveal hypoplasia
DESCRIPTION Foveal hypoplasia is characterized by absence or abnormal foveomacular reflex, unclear definition of the foveomacular area, and presence of capillaries running abnormally close to the macula. It can be isolated or associated with presenile cataract. The mutations in the PAX6 gene have been described in foveal hypoplasia.
CATEGORY    Eye disease
GENE        PAX6 [HSA:5080] [KO:K08031]
DBLINKS     ICD-10: H26.0
            MeSH: C565005
            OMIM: 136520
REFERENCE   PMID:8640214
  AUTHORS   Azuma N, Nishina S, Yanagisawa H, Okuyama T, Yamada M
  TITLE     PAX6 missense mutation in isolated foveal hypoplasia.
  JOURNAL   Nat Genet 13:141-2 (1996)
REFERENCE   PMID:9931324
  AUTHORS   Hanson I, Churchill A, Love J, Axton R, Moore T, Clarke M, Meire F, van Heyningen V
  TITLE     Missense mutations in the most ancient residues of the PAX6 paired domain underlie a spectrum of human congenital eye malformations.
  JOURNAL   Hum Mol Genet 8:165-72 (1999)
REFERENCE   PMID:19590516
  AUTHORS   Vincent A, Kemmanu V, Shetty R, Anandula V, Madhavarao B, Shetty B
  TITLE     Variable expressivity of ocular associations of foveal hypoplasia in a family.
  JOURNAL   Eye (Lond) 23:1735-9 (2009)
///
ENTRY       H01257                      Disease
NAME        GABA-transaminase deficiency;
            4-Aminobutyrate aminotransferase deficiency
DESCRIPTION GABA-transaminase deficiency is a very rare inborn error of GABA degradation. The phenotype of this deficiency includes psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and electroencephalographic abnormalities.
CATEGORY    Inherited metabolic disease
GENE        ABAT [HSA:18] [KO:K13524]
DBLINKS     ICD-10: E72.8
            MeSH: C535407
            OMIM: 613163
REFERENCE   PMID:10407778
  AUTHORS   Medina-Kauwe LK, Tobin AJ, De Meirleir L, Jaeken J, Jakobs C, Nyhan WL, Gibson KM
  TITLE     4-Aminobutyrate aminotransferase (GABA-transaminase) deficiency.
  JOURNAL   J Inherit Metab Dis 22:414-27 (1999)
///
ENTRY       H01258                      Disease
NAME        Generalized epilepsy and paroxysmal dyskinesia (GEPD)
DESCRIPTION Epilepsy is one of the most common and debilitating neurological disorders, and Paroxysmal dyskinesias are another heterogeneous group of neurological disorders characterized by sudden, unpredictable, disabling attacks of involuntary movement often requiring life-long treatment. GEPD is a syndrome of coexistent generalized epilepsy and paroxysmal dyskinesia. It has been reported that a mutation of the alpha subunit of the BK channel causes this syndrome.
CATEGORY    Nervous system disease; Epilepsy
GENE        KCNMA1 [HSA:3778] [KO:K04936]
DBLINKS     ICD-10: G40.4
            MeSH: C563719
            OMIM: 609446
REFERENCE   PMID:15937479
  AUTHORS   Du W, Bautista JF, Yang H, Diez-Sampedro A, You SA, Wang L, Kotagal P, Luders HO, Shi J, Cui J, Richerson GB, Wang QK
  TITLE     Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder.
  JOURNAL   Nat Genet 37:733-8 (2005)
///
ENTRY       H01259                      Disease
NAME        Giant axonal neuropathy
DESCRIPTION Giant axonal neuropathy is an autosomal recessive disorder characterized by an early onset severe peripheral neuropathy, varying central nervous system involvement and strikingly frizzly hair. Peripheral nerve biopsies show giant axons, caused by accumulation of neurofilaments. Several disease causative mutations were identified in the gigaxonin (GAN) gene. These result in loss of function of gigaxonin, that plays an important role in the cytoskeleton.
CATEGORY    Neurodegenerative disease
GENE        GAN [HSA:8139] [KO:K10453]
DBLINKS     ICD-10: G60.8
            MeSH: D056768
            OMIM: 256850
REFERENCE   PMID:17587580
  AUTHORS   Koop O, Schirmacher A, Nelis E, Timmerman V, De Jonghe P, Ringelstein B, Rasic VM, Evrard P, Gartner J, Claeys KG, Appenzeller S, Rautenstrauss B, Huhne K, Ramos-Arroyo MA, Worle H, Moilanen JS, Hammans S, Kuhlenbaumer G
  TITLE     Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN).
  JOURNAL   Neuromuscul Disord 17:624-30 (2007)
///
ENTRY       H01260                      Disease
NAME        Glomerulopathy with fibronectin deposits (GFND)
DESCRIPTION Glomerulopathy with fibronectin deposits (GFND) is a hereditary kidney disease with proteinuria, microscopic hematuria, and hypertension that lead to end-stage renal failure in the second to sixth decade of life. It has been reported that mutations in FN1, which encodes fibronectin, are the cause of GFND.
CATEGORY    Kidney disease
GENE        FN1 [HSA:2335] [KO:K05717]
DBLINKS     ICD-10: N07.6
            MeSH: C536826
            OMIM: 601894
REFERENCE   PMID:18268355
  AUTHORS   Castelletti F, Donadelli R, Banterla F, Hildebrandt F, Zipfel PF, Bresin E, Otto E, Skerka C, Renieri A, Todeschini M, Caprioli J, Caruso RM, Artuso R, Remuzzi G, Noris M
  TITLE     Mutations in FN1 cause glomerulopathy with fibronectin deposits.
  JOURNAL   Proc Natl Acad Sci U S A 105:2538-43 (2008)
///
ENTRY       H01261                      Disease
NAME        Congenital glucose-galactose malabsorption (GGM)
DESCRIPTION Glucose-galactose malabsorption (GGM) is an autosomal recessive disorder that is due to mutations in the gene coding for the sodium-glucose cotransporter (SGLT1/SLC5A1). GGM is characterized by neonatal onset of watery and acidic diarrhea, which becomes fatal within a few weeks unless glucose and galactose containing nutrients are removed from the diet.
CATEGORY    Inherited metabolic disease
GENE        SLC5A1 [HSA:6523] [KO:K14158]
DBLINKS     ICD-10: E74.3
            MeSH: C562602
            OMIM: 606824
REFERENCE   PMID:10036327
  AUTHORS   Lam JT, Martin MG, Turk E, Hirayama BA, Bosshard NU, Steinmann B, Wright EM
  TITLE     Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking  defects.
  JOURNAL   Biochim Biophys Acta 1453:297-303 (1999)
REFERENCE   PMID:11406349
  AUTHORS   Kasahara M, Maeda M, Hayashi S, Mori Y, Abe T
  TITLE     A missense mutation in the Na(+)/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein.
  JOURNAL   Biochim Biophys Acta 1536:141-7 (2001)
///
ENTRY       H01262                      Disease
NAME        Formiminotransferase deficiency
DESCRIPTION Formiminotransferase deficiency is an autosomal recessive disorder of folate metabolism. It is due to defects in the bifunctional enzyme glutamate formiminotransferase-cyclodeaminase (FTCD). Features of a severe phenotype include megaloblastic anemia and mental retardation. Features of a mild phenotype include mild developmental delay and no hematological abnormalities.
CATEGORY    Inherited metabolic disease
GENE        FTCD [HSA:10841] [KO:K13990]
MARKER      Elevated levels of formiminoglutamate [CPD:C00439] in urine
DBLINKS     ICD-10: E70.8
            MeSH: C537425
            OMIM: 229100
REFERENCE   PMID:12815595
  AUTHORS   Hilton JF, Christensen KE, Watkins D, Raby BA, Renaud Y, de la Luna S, Estivill X, MacKenzie RE, Hudson TJ, Rosenblatt DS
  TITLE     The molecular basis of glutamate formiminotransferase deficiency.
  JOURNAL   Hum Mutat 22:67-73 (2003)
///
ENTRY       H01263                      Disease
NAME        Progressive cardiac conduction defect (PCCD);
            Progressive familial heart block (PFHB);
            Lenegre-Lev disease
DESCRIPTION Progressive cardiac conduction defect (PCCD) is a cardiac bundle branch disorder characterized by progressive alteration of cardiac conduction through the His-Purkinje system. It leads to complete atrioventricular block causing syncope and sudden death. Mutations in the SCN5A gene encoding the cardiac sodium channel are responsible for Brugada syndrome (BS) and also for PCCD. Furthermore, another PCCD is caused by mutations in TRPM4.
CATEGORY    Cardiovascular disease
GENE        (type IA) SCN5A [HSA:6331] [KO:K04838]
            (type IB) TRPM4 [HSA:54795] [KO:K04979]
COMMENT     Brugada syndrome is described in H00728. [DS:H00728]
DBLINKS     ICD-10: Q20.9
            OMIM: 113900 604559
REFERENCE   PMID:16643399
  AUTHORS   Probst V, Allouis M, Sacher F, Pattier S, Babuty D, Mabo P, Mansourati J, Victor J, Nguyen JM, Schott JJ, Boisseau P, Escande D, Le Marec H
  TITLE     Progressive cardiac conduction defect is the prevailing phenotype in carriers of  a Brugada syndrome SCN5A mutation.
  JOURNAL   J Cardiovasc Electrophysiol 17:270-5 (2006)
REFERENCE   PMID:19726882
  AUTHORS   Kruse M, Schulze-Bahr E, Corfield V, Beckmann A, Stallmeyer B, Kurtbay G, Ohmert I, Schulze-Bahr E, Brink P, Pongs O
  TITLE     Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I.
  JOURNAL   J Clin Invest 119:2737-44 (2009)
///
ENTRY       H01264                      Disease
NAME        Hepatic venoocclusive disease with immunodeficiency (VODI)
DESCRIPTION Hepatic venoocclusive disease with immunodeficiency (VODI) is an autosomal recessive primary immunodeficiency associated with hepatic vascular occlusion and fibrosis. Mutations in the gene coding PML nuclear body protein Sp110 were found to be associated with VODI.
CATEGORY    Immune system disease; Liver disease
GENE        SP110 [HSA:3431]
MARKER      Low serum concentrations of IgA, IgM, and IgG for age
            Normal lymphocyte numbers
            Normal CD4 and CD8 percentages
DBLINKS     ICD-10: K76.5
            MeSH: C537257
            OMIM: 235550
REFERENCE   PMID:16648851
  AUTHORS   Roscioli T, Cliffe ST, Bloch DB, Bell CG, Mullan G, Taylor PJ, Sarris M, Wang J, Donald JA, Kirk EP, Ziegler JB, Salzer U, McDonald GB, Wong M, Lindeman R, Buckley MF
  TITLE     Mutations in the gene encoding the PML nuclear body protein Sp110 are associated  with immunodeficiency and hepatic veno-occlusive disease.
  JOURNAL   Nat Genet 38:620-2 (2006)
///
ENTRY       H01265                      Disease
NAME        Hydrolethalus syndrome
DESCRIPTION Hydrolethalus syndrome (HLS) is an autosomal recessive lethal malformation syndrome leading to stillbirth or death shortly after birth. HLS is characterized by hydrocephaly with absent upper midline structures of the brain, micrognathia and polydactyly. HLS is caused by mutations in HYLS1 and KIF7. Both genes code for ciliary or centriolar proteins that seem to be involved in early embryonic development of the midline.
CATEGORY    Developmental disorder
GENE        HYLS1 [HSA:219844] [KO:K16472]
            KIF7 [HSA:374654] [KO:K18806]
DBLINKS     ICD-10: Q87.8
            MeSH: C536079
            OMIM: 236680 614120
REFERENCE   PMID:15843405
  AUTHORS   Mee L, Honkala H, Kopra O, Vesa J, Finnila S, Visapaa I, Sang TK, Jackson GR, Salonen R, Kestila M, Peltonen L
  TITLE     Hydrolethalus syndrome is caused by a missense mutation in a novel gene HYLS1.
  JOURNAL   Hum Mol Genet 14:1475-88 (2005)
REFERENCE   PMID:21552264
  AUTHORS   Putoux A, Thomas S, Coene KL, Davis EE, Alanay Y, Ogur G, Uz E, Buzas D, Gomes C, Patrier S, Bennett CL, Elkhartoufi N, Frison MH, Rigonnot L, Joye N, Pruvost S, Utine GE, Boduroglu K, Nitschke P, Fertitta L, Thauvin-Robinet C, Munnich A, Cormier-Daire V, Hennekam R, Colin E, Akarsu NA, Bole-Feysot C, Cagnard N, Schmitt A, Goudin N, Lyonnet S, Encha-Razavi F, Siffroi JP, Winey M, Katsanis N, Gonzales M, Vekemans M, Beales PL, Attie-Bitach T
  TITLE     KIF7 mutations cause fetal hydrolethalus and acrocallosal syndromes.
  JOURNAL   Nat Genet 43:601-6 (2011)
///
ENTRY       H01266                      Disease
NAME        Hypercarotenemia and vitamin A deficiency
DESCRIPTION Hypercarotenemia and vitamin A deficiency is caused by mutation in the CMO1(BCMO1) gene, that catalyzes the first step in the conversion of dietary provitamin A carotenoids to vitamin A. Vitamin A is essential for normal embryonic development as well as normal physiological functions.
CATEGORY    Inherited metabolic disease
GENE        BCMO1 [HSA:53630] [KO:K00515]
DBLINKS     ICD-10: E50 E67.1
            MeSH: C567296
            OMIM: 115300
REFERENCE   PMID:17951468
  AUTHORS   Lindqvist A, Sharvill J, Sharvill DE, Andersson S
  TITLE     Loss-of-function mutation in carotenoid 15,15'-monooxygenase identified in a patient with hypercarotenemia and hypovitaminosis A.
  JOURNAL   J Nutr 137:2346-50 (2007)
///
ENTRY       H01267                      Disease
NAME        Familial hyperinsulinemic hypoglycemia (HHF)
DESCRIPTION Familial hyperinsulinemic hypoglycemia is the most common cause of persistent hypoglycemia in infancy. Recent studies on the molecular basis of the disease have disclosed specific genetic defects in the regulation of insulin secretion. Seven different loci have been associated with hyperinsulinism: ABCC8, KCNJ11, HADHSC, GCK, GLUD1, SLC16A1, and INSR. Mutations of these loci have significant differences in phenotype and inheritance pattern. The most common genes associated with hyperinsulinism, involve the ABCC8 and KCNJ11 genes that encode the two subunits of the beta-cell ATP-dependent potassium channel. Recessive mutations of these genes cause a severe form of neonatal hypoglycemia that frequently requires near-total pancreatectomy. Diazoxide, a drug that acts as an agonist of the ATP-dependent potassium channel to suppress insulin secretion, is effective in defects associated with mutations of GLUD1 and HADHSC. Diazoxide is often ineffective in mutations of the ATP- dependent potassium channel and may not adequately control hypoglycemia in GCK or SLC16A1 mutations.
CATEGORY    Inherited metabolic disease
GENE        (HHF1/ LIH) ABCC8 [HSA:6833] [KO:K05032]
            (HHF2) KCNJ11 [HSA:3767] [KO:K05004]
            (HHF3) GCK [HSA:2645] [KO:K12407]
            (HHF4) HADHSC [HSA:3033] [KO:K00022]
            (HHF5) INSR [HSA:3643] [KO:K04527]
            (HHF6) GLUD1 [HSA:2746] [KO:K00261]
            (HHF7) SLC16A1 [HSA:6566] [KO:K08179]
DRUG        Diazoxide [DR:D00294]
COMMENT     Leucine-induced hypoglycemia (LIH)
DBLINKS     ICD-10: E16.1
            MeSH: D006946
            OMIM: 256450 601820 602485 609975 609968 606762 610021 240800
REFERENCE   PMID:16357843 (HHF1/2)
  AUTHORS   Suchi M, MacMullen CM, Thornton PS, Adzick NS, Ganguly A, Ruchelli ED, Stanley CA
  TITLE     Molecular and immunohistochemical analyses of the focal form of congenital hyperinsulinism.
  JOURNAL   Mod Pathol 19:122-9 (2006)
REFERENCE   PMID:9435328 (HHF3)
  AUTHORS   Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC
  TITLE     Familial hyperinsulinism caused by an activating glucokinase mutation.
  JOURNAL   N Engl J Med 338:226-30 (1998)
REFERENCE   PMID:11489939 (HHF4)
  AUTHORS   Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, van den Berg IE
  TITLE     Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion.
  JOURNAL   J Clin Invest 108:457-65 (2001)
REFERENCE   PMID:15161766 (HHF5)
  AUTHORS   Hojlund K, Hansen T, Lajer M, Henriksen JE, Levin K, Lindholm J, Pedersen O, Beck-Nielsen H
  TITLE     A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a  mutation in the human insulin receptor gene.
  JOURNAL   Diabetes 53:1592-8 (2004)
REFERENCE   PMID:9571255 (HHF6)
  AUTHORS   Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M
  TITLE     Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene.
  JOURNAL   N Engl J Med 338:1352-7 (1998)
REFERENCE   PMID:17701893 (HHF7)
  AUTHORS   Otonkoski T, Jiao H, Kaminen-Ahola N, Tapia-Paez I, Ullah MS, Parton LE, Schuit F, Quintens R, Sipila I, Mayatepek E, Meissner T, Halestrap AP, Rutter GA, Kere J
  TITLE     Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells.
  JOURNAL   Am J Hum Genet 81:467-74 (2007)
REFERENCE   PMID:16356235 (Drug)
  AUTHORS   Lheureux PE, Zahir S, Penaloza A, Gris M
  TITLE     Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.
  JOURNAL   Crit Care 9:543-9 (2005)
REFERENCE   PMID:21378225 (Description)
  AUTHORS   Palladino AA, Stanley CA
  TITLE     Nesidioblastosis no longer! It's all about genetics.
  JOURNAL   J Clin Endocrinol Metab 96:617-9 (2011)
REFERENCE   PMID:15356046 (LIH)
  AUTHORS   Magge SN, Shyng SL, MacMullen C, Steinkrauss L, Ganguly A, Katz LE, Stanley CA
  TITLE     Familial leucine-sensitive hypoglycemia of infancy due to a dominant mutation of  the beta-cell sulfonylurea receptor.
  JOURNAL   J Clin Endocrinol Metab 89:4450-6 (2004)
///
ENTRY       H01268                      Disease
NAME        Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;
            HHH syndrome
DESCRIPTION Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive disorder, characterized by mental retardation, progressive spastic paraparesis, seizures, and myoclonus epilepsy. This disease varies widely in its severity and age of onset. The HHH syndrome is thought to be caused by the defective activities of the mitochondrial carrier responsible for transporting ornithine from the cytoplasm into the inner mitochondrial membrane. Mutations in the SLC25A15 gene, that encodes the mitochondrial ornithine transporter have been shown to be correlated with the HHH syndrome.
CATEGORY    Inherited metabolic disease
GENE        SLC25A15 [HSA:10166] [KO:K15101]
MARKER      Increased plasma concentration of ornithine [CPD:C00077]
            Urinary excretion of homocitrulline [CPD:C02427]
DBLINKS     ICD-10: E72.4
            MeSH: C538380
            OMIM: 238970
REFERENCE   PMID:22292090
  AUTHORS   Wang JF, Chou KC
  TITLE     Insights into the mutation-induced HHH syndrome from modeling human mitochondrial ornithine transporter-1.
  JOURNAL   PLoS One 7:e31048 (2012)
REFERENCE   PMID:22649802
  AUTHORS   Camacho J, Rioseco-Camacho N
  TITLE     Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome
  JOURNAL   (1993)
///
ENTRY       H01269                      Disease
NAME        Congenital hyperthyroidism, including:
            Familial gestational hyperthyroidism (HTFG);
            Hyperthyroidism non-autoimmune (HTNA)
DESCRIPTION Congenital hyperthyroidism is a rare clinical condition, and in most cases, it is a transient disorder caused by maternal Graves disease associated with the transplacental passage of maternal thyroid-stimulating antibodies. Germline mutations of thyrotropin receptor (TSHR) gene determining a constitutive activation of the receptor were identified as a molecular cause of congenital nonautoimmune hyperthyroidism. TSHR gene mutations also causes the familial gestational hyperthyroidism, that is characterized by thyrotoxicosis and hyperemesis gravidarum.
CATEGORY    Endocrine disease
GENE        TSHR [HSA:7253] [KO:K04249]
DRUG        Propylthiouracil [DR:D00562]
            Sodium iodide [DR:D02259]
DBLINKS     ICD-10: E05.8
            MeSH: C563786 C566384
            OMIM: 603373 609152
REFERENCE   PMID:22371259
  AUTHORS   Agretti P, De Marco G, Biagioni M, Iannilli A, Marigliano M, Pinchera A, Vitti P, Cherubini V, Tonacchera M
  TITLE     Sporadic congenital nonautoimmune hyperthyroidism caused by P639S mutation in thyrotropin receptor gene.
  JOURNAL   Eur J Pediatr 171:1133-7 (2012)
REFERENCE   PMID:10427147
  AUTHORS   Asteria C
  TITLE     TSH receptor gene mutations and familial gestational hyperthyroidism.
  JOURNAL   Eur J Endocrinol 141:93-4 (1999)
REFERENCE   PMID:20172477 (drug)
  AUTHORS   Leung AM, Pearce EN, Braverman LE
  TITLE     Perchlorate, iodine and the thyroid.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 24:133-41 (2010)
///
ENTRY       H01270                      Disease
NAME        Familial hypobetalipoproteinemia (FHBL)
DESCRIPTION Familial hypobetalipoproteinemia (FHBL) is an inherited disorder of lipid metabolism defined by very low levels of plasma apolipoprotein B and LDL cholesterol. Mutations in the gene encoding apolipoprotein B (APOB) have been found in FHBL. It has been identified that mutations in ANGPTL3 also cause this disease.
CATEGORY    Inherited metabolic disease
GENE        APOB [HSA:338] [KO:K14462]
            ANGPTL3 [HSA:27329]
DBLINKS     ICD-10: E78.6
            MeSH: D006995
            OMIM: 107730 605019
REFERENCE   PMID:12551903
  AUTHORS   Burnett JR, Shan J, Miskie BA, Whitfield AJ, Yuan J, Tran K, McKnight CJ, Hegele RA, Yao Z
  TITLE     A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia.
  JOURNAL   J Biol Chem 278:13442-52 (2003)
REFERENCE   PMID:20942659
  AUTHORS   Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S
  TITLE     Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.
  JOURNAL   N Engl J Med 363:2220-7 (2010)
///
ENTRY       H01271                      Disease
NAME        Hypoparathyroidism with sensorineural deafness and renal dysplasia;
            HDR syndrome;
            Barakat syndrome
DESCRIPTION Hypoparathyroidism with sensorineural deafness and renal dysplasia (HDR syndrome) is a DiGeorge-like phenotype that includes hypoparathyroidism, heart defects, immune deficiency, deafness and renal malformations. It has been reported that mutations in GATA3 cause HDR syndrome.
CATEGORY    Developmental disorder
GENE        GATA3 [HSA:2625] [KO:K17895]
COMMENT     DiGeorge syndrome is described in H00107. [DS:H00107]
DBLINKS     ICD-10: Q87.8
            MeSH: C537907
            OMIM: 146255
REFERENCE   PMID:11389161
  AUTHORS   Muroya K, Hasegawa T, Ito Y, Nagai T, Isotani H, Iwata Y, Yamamoto K, Fujimoto S, Seishu S, Fukushima Y, Hasegawa Y, Ogata T
  TITLE     GATA3 abnormalities and the phenotypic spectrum of HDR syndrome.
  JOURNAL   J Med Genet 38:374-80 (2001)
REFERENCE   PMID:10935639
  AUTHORS   Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, Vanderlinden G, Harding B, Beetz R, Bilous RW, Holdaway I, Shaw NJ, Fryns JP, Van de Ven W, Thakker RV, Devriendt K
  TITLE     GATA3 haplo-insufficiency causes human HDR syndrome.
  JOURNAL   Nature 406:419-22 (2000)
///
ENTRY       H01272                      Disease
NAME        Hypoplastic left heart syndrome (HLHS)
DESCRIPTION Hypoplastic left heart syndrome (HLHS) is a severe, uniformly fatal congenital heart defect typically characterized by hypoplasia of the left ventricular chamber and aorta in association with stenosis and/or atresia of the mitral and aortic valves. There is now strong evidence implicating multiple genetic loci for HLHS. Potential mutations in at least 4 genes, GJA1, NKX2-5, NOTCH1, and HAND1, have been associated with HLHS.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        GJA1 [HSA:2697] [KO:K07372]
            NKX2-5 [HSA:1482] [KO:K09345]
            HAND1 [HSA:9421] [KO:K09071]
COMMENT     Defects in NOTCH1 are a cause of bicuspid aortic valve. [DS:H00554]
DBLINKS     ICD-10: Q23.4
            MeSH: D018636
            OMIM: 241550 614435
REFERENCE   PMID:19298922
  AUTHORS   Grossfeld P, Ye M, Harvey R
  TITLE     Hypoplastic left heart syndrome: new genetic insights.
  JOURNAL   J Am Coll Cardiol 53:1072-4 (2009)
REFERENCE   PMID:11470490
  AUTHORS   Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH
  TITLE     Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE).
  JOURNAL   Mutat Res 479:173-86 (2001)
REFERENCE   PMID:12798584
  AUTHORS   Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, Grossfeld P, Fatkin D, Jones O, Hayes P, Feneley M, Harvey RP
  TITLE     Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome.
  JOURNAL   J Am Coll Cardiol 41:2072-6 (2003)
REFERENCE   PMID:18276607
  AUTHORS   Reamon-Buettner SM, Ciribilli Y, Inga A, Borlak J
  TITLE     A loss-of-function mutation in the binding domain of HAND1 predicts hypoplasia of the human hearts.
  JOURNAL   Hum Mol Genet 17:1397-405 (2008)
///
ENTRY       H01273                      Disease
NAME        Autosomal dominant keratitis (ADK);
            Hereditary keratitis
DESCRIPTION Autosomal dominant keratitis (ADK) is a very rare ocular disorder characterised by corneal opacification and vascularization and by foveal hypoplasia. ADK is associated with mutations in the PAX6 gene, that is essential for ocular morphogenesis.
CATEGORY    Eye disease
GENE        PAX6 [HSA:5080] [KO:K08031]
COMMENT     Mutations in the PAX6 gene produce various phenotypes, including aniridia [DS:H00635], Peters anomaly [DS:H01075], foveal hypoplasia [DS:H01256], and congenital cataracts [DS:H01202].
DBLINKS     ICD-10: H16.8
            OMIM: 148190
REFERENCE   PMID:7668281
  AUTHORS   Mirzayans F, Pearce WG, MacDonald IM, Walter MA
  TITLE     Mutation of the PAX6 gene in patients with autosomal dominant keratitis.
  JOURNAL   Am J Hum Genet 57:539-48 (1995)
REFERENCE   PMID:9482572
  AUTHORS   Prosser J, van Heyningen V
  TITLE     PAX6 mutations reviewed.
  JOURNAL   Hum Mutat 11:93-108 (1998)
REFERENCE   PMID:11309364
  AUTHORS   Singh S, Chao LY, Mishra R, Davies J, Saunders GF
  TITLE     Missense mutation at the C-terminus of PAX6 negatively modulates homeodomain function.
  JOURNAL   Hum Mol Genet 10:911-8 (2001)
///
ENTRY       H01274                      Disease
NAME        Growth delay due to insulin-like growth factor I resistance;
            IGF-I resistance
DESCRIPTION Growth delay due to IGF-I resistance is characterised by variable prenatal and postnatal growth retardation and elevated serum IGF-I levels. It has been described that the defects in the IGF-IR gene cause postnatal growth failure.
CATEGORY    Endocrine disease
GENE        IGF1R [HSA:3480] [KO:K05087]
DBLINKS     ICD-10: E34.3
            MeSH: C564816
            OMIM: 270450
REFERENCE   PMID:14657428
  AUTHORS   Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfaffle R, Raile K, Seidel B, Smith RJ, Chernausek SD
  TITLE     IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation.
  JOURNAL   N Engl J Med 349:2211-22 (2003)
REFERENCE   PMID:15928254
  AUTHORS   Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi J, Ohtsuka Y, Hisatome I, Ninomoya H, Nanba E, Fukushima T, Takahashi S
  TITLE     Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation.
  JOURNAL   J Clin Endocrinol Metab 90:4679-87 (2005)
///
ENTRY       H01275                      Disease
NAME        Interleukin 1 receptor antagonist deficiency (DIRA);
            Multifocal osteomyelitis with periostitis and pustulosis (OMPP)
DESCRIPTION Interleukin 1 receptor antagonist deficiency (DIRA) is a rare autosomal recessive autoinflammatory disease caused by mutations in IL1RN. The absence of interleukin 1 receptor (IL-1R) antagonist allows unopposed action of IL-1, resulting in life threatening systemic inflammation with skin and bone involvement.
CATEGORY    Immune system disease
GENE        IL1RN [HSA:3557] [KO:K05481]
DRUG        Anakinra [DR:D02934]
DBLINKS     MeSH: C557815
            OMIM: 612852
REFERENCE   PMID:19494218
  AUTHORS   Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R
  TITLE     An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
  JOURNAL   N Engl J Med 360:2426-37 (2009)
///
ENTRY       H01276                      Disease
NAME        X-linked chronic idiopathic intestinal pseudo-obstruction;
            CIIPX
DESCRIPTION Chronic idiopathic intestinal pseudo-obstruction is a rare, often fatal syndrome in infancy, caused by a heterogeneous group of enteric neuromuscular diseases that result in a severe abnormality of gastrointestinal motility. It has been reported that flamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction.
CATEGORY    Gastrointestinal disease
GENE        FLNA [HSA:2316] [KO:K04437]
DBLINKS     MeSH: D007418
            OMIM: 300048
REFERENCE   PMID:17357080
  AUTHORS   Gargiulo A, Auricchio R, Barone MV, Cotugno G, Reardon W, Milla PJ, Ballabio A, Ciccodicola A, Auricchio A
  TITLE     Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement.
  JOURNAL   Am J Hum Genet 80:751-8 (2007)
///
ENTRY       H01277                      Disease
NAME        Vitamin B12 deficiency anaemia, including:
            Hereditary intrinsic factor deficiency (IFD);
            Imerslund-Grasbeck syndrome (IGS)/ Megaloblastic anemia 1
DESCRIPTION Vitamin B12 deficiency anaemia is caused by intestinal malabsorption of cobalamin. Imerslund-Grasbeck syndrome (IGS) is an autosomal recessive disorder characterized by juvenile megaloblastic anaemia and neurological symptoms such as peripheral neuropathy, cognitive problems, and dementia. If untreated, the disease is fatal. Biallelic mutations either in the cubilin (CUBN) or amnionless (AMN) gene cause IGS. Both proteins are involved in intestinal absorption and renal tubular reabsorption. Hereditary intrinsic factor deficiency (IFD) is a phenotype that is caused by mutations in GIF, the gene encoding intrinsic factor.
CATEGORY    Hematologic disease
GENE        (IFD) GIF [HSA:2694] [KO:K14615]
            (IGS) CUBN [HSA:8029] [KO:K14616]
            (IGS) AMN [HSA:81693] [KO:K18259]
MARKER      Low serum Vitamin B12 [CPD:C05776]
            Low urinary radioactive vit B12 excretion (Schilling test)
DRUG        Vitamin B12 [DR:D00191]
DBLINKS     ICD-10: D51.0 D51.1
            OMIM: 261000 261100
REFERENCE   PMID:15738392
  AUTHORS   Tanner SM, Li Z, Perko JD, Oner C, Cetin M, Altay C, Yurtsever Z, David KL, Faivre L, Ismail EA, Grasbeck R, de la Chapelle A
  TITLE     Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene.
  JOURNAL   Proc Natl Acad Sci U S A 102:4130-3 (2005)
REFERENCE   PMID:10080186
  AUTHORS   Aminoff M, Carter JE, Chadwick RB, Johnson C, Grasbeck R, Abdelaal MA, Broch H, Jenner LB, Verroust PJ, Moestrup SK, de la Chapelle A, Krahe R
  TITLE     Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1.
  JOURNAL   Nat Genet 21:309-13 (1999)
REFERENCE   PMID:12590260
  AUTHORS   Tanner SM, Aminoff M, Wright FA, Liyanarachchi S, Kuronen M, Saarinen A, Massika O, Mandel H, Broch H, de la Chapelle A
  TITLE     Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary  megaloblastic anemia.
  JOURNAL   Nat Genet 33:426-9 (2003)
REFERENCE   PMID:16722557
  AUTHORS   Grasbeck R
  TITLE     Imerslund-Grasbeck syndrome (selective vitamin B(12) malabsorption with proteinuria).
  JOURNAL   Orphanet J Rare Dis 1:17 (2006)
///
ENTRY       H01278                      Disease
NAME        Iron-refractory iron deficiency anemia (IRIDA)
DESCRIPTION Iron-refractory iron deficiency anemia (IRIDA) is a rare autosomal recessive disorder characterized by hypochromic microcytic anaemia, low transferrin saturation and high levels of the iron-regulated hormone hepcidin. The disease is caused by mutations in TMPRSS6, which encodes a type II transmembrane serine protease that regulates the expression of the hepcidin.
CATEGORY    Hematologic disease
GENE        TMPRSS6 [HSA:164656] [KO:K09637]
DBLINKS     ICD-10: D50.8
            OMIM: 206200
REFERENCE   PMID:18408718
  AUTHORS   Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD
  TITLE     Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).
  JOURNAL   Nat Genet 40:569-71 (2008)
REFERENCE   PMID:20704562
  AUTHORS   Altamura S, D'Alessio F, Selle B, Muckenthaler MU
  TITLE     A novel TMPRSS6 mutation that prevents protease auto-activation causes IRIDA.
  JOURNAL   Biochem J 431:363-71 (2010)
///
ENTRY       H01279                      Disease
NAME        Isobutyryl-CoA dehydrogenase (IBD) deficiency
DESCRIPTION Isobutyryl-CoA dehydrogenase (IBD) deficiency is a rare inborn error of valine metabolism. The patients present dilated cardiomyopathy, anemia, and carnitine deficiency. Mutations in the ACAD8 gene cause IBD deficiency.
CATEGORY    Inherited metabolic disease
GENE        ACAD8 [HSA:27034] [KO:K11538]
MARKER      Elevated C4-acylcarnitine in a plasma acylcarnitine profile
DRUG        L-carnitine [DR:D02176]
DBLINKS     ICD-10: E71.1
            MeSH: C535541
            OMIM: 611283
REFERENCE   PMID:12359132
  AUTHORS   Nguyen TV, Andresen BS, Corydon TJ, Ghisla S, Abd-El Razik N, Mohsen AW, Cederbaum SD, Roe DS, Roe CR, Lench NJ, Vockley J
  TITLE     Identification of isobutyryl-CoA dehydrogenase and its deficiency in humans.
  JOURNAL   Mol Genet Metab 77:68-79 (2002)
REFERENCE   PMID:16857760
  AUTHORS   Pedersen CB, Bischoff C, Christensen E, Simonsen H, Lund AM, Young SP, Koeberl DD, Millington DS, Roe CR, Roe DS, Wanders RJ, Ruiter JP, Keppen LD, Stein Q, Knudsen I, Gregersen N, Andresen BS
  TITLE     Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening.
  JOURNAL   Pediatr Res 60:315-20 (2006)
///
ENTRY       H01280                      Disease
NAME        L-2-hydroxyglutaric aciduria (L2HGA)
DESCRIPTION L-2-hydroxyglutaric aciduria (L2HGA) is a rare autosomal recessive neurometabolic disorder characterized by progressive ataxia, mental deficiency with subcortical leukoencephalopathy, and cerebellar atrophy.
CATEGORY    Inherited metabolic disease
GENE        L2HGDH [HSA:79944] [KO:K00109]
MARKER      L-2-hydroxyglutaric acid in urine, blood and cerebrospinal fluid
COMMENT     D-2-hydroxyglutaric aciduria is described in H01225. [DS:H01225]
DBLINKS     MeSH: C535306
            OMIM: 236792
REFERENCE   PMID:15548604
  AUTHORS   Rzem R, Veiga-da-Cunha M, Noel G, Goffette S, Nassogne MC, Tabarki B, Scholler C, Marquardt T, Vikkula M, Van Schaftingen E
  TITLE     A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria.
  JOURNAL   Proc Natl Acad Sci U S A 101:16849-54 (2004)
REFERENCE   PMID:15385440
  AUTHORS   Topcu M, Jobard F, Halliez S, Coskun T, Yalcinkayal C, Gerceker FO, Wanders RJ, Prud'homme JF, Lathrop M, Ozguc M, Fischer J
  TITLE     L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1.
  JOURNAL   Hum Mol Genet 13:2803-11 (2004)
REFERENCE   PMID:16134148
  AUTHORS   Vilarinho L, Cardoso ML, Gaspar P, Barbot C, Azevedo L, Diogo L, Santos M, Carrilho I, Fineza I, Kok F, Chorao R, Alegria P, Martins E, Teixeira J, Cabral Fernandes H, Verhoeven NM, Salomons GS, Santorelli FM, Cabral P, Amorim A, Jakobs C
  TITLE     Novel L2HGDH mutations in 21 patients with L-2-hydroxyglutaric aciduria of Portuguese origin.
  JOURNAL   Hum Mutat 26:395-6 (2005)
///
ENTRY       H01281                      Disease
NAME        Lathosterolosis
DESCRIPTION Lathosterolosis is an inborn error of cholesterol biosynthesis caused by mutations in SC5D gene encoding lathosterol 5-desaturase. It is characterized by a complex phenotype, including multiple congenital anomalies, mental retardation, and liver disease.
CATEGORY    Developmental disorder
GENE        SC5DL [HSA:6309] [KO:K00227]
DBLINKS     ICD-10: Q87.8
            MeSH: C537880
            OMIM: 607330
REFERENCE   PMID:12189593
  AUTHORS   Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, Rivasi F, Annunziata I, Ballabio A, Russo AD, Andria G, Parenti G
  TITLE     Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase.
  JOURNAL   Am J Hum Genet 71:952-8 (2002)
REFERENCE   PMID:12812989
  AUTHORS   Krakowiak PA, Wassif CA, Kratz L, Cozma D, Kovarova M, Harris G, Grinberg A, Yang Y, Hunter AG, Tsokos M, Kelley RI, Porter FD
  TITLE     Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency.
  JOURNAL   Hum Mol Genet 12:1631-41 (2003)
///
ENTRY       H01282                      Disease
NAME        Spermatogenic failure
DESCRIPTION Spermatogenic failure is reflected in a lower or absent production of spermatozoa and is described by routine semen analysis using terms such as azoospermia, oligozoospermia, teratozoospermia or asthenozoospermia. The genetic causes of spermatogenetic failure still remain largely unknown. It has been estimated that more than 2300 genes play a role in spermatogenesis. But only a few of these genes have been investigated in humans.
CATEGORY    Developmental disorder
GENE        AURKC [HSA:6795] [KO:K11480]
            CATSPER1 [HSA:117144] [KO:K16889]
            NR5A1 [HSA:2516] [KO:K08560]
            KLHL10 [HSA:317719] [KO:K10448]
COMMENT     Globozoospermia and Azoospermia is described in H01208 and H00890, respectively. [DS:H01208] [DS:H00890]
DBLINKS     ICD-10: N46
            MeSH: C567832 C564030
            OMIM: 243060 612997 613957
REFERENCE   PMID:22138898
  AUTHORS   Massart A, Lissens W, Tournaye H, Stouffs K
  TITLE     Genetic causes of spermatogenic failure.
  JOURNAL   Asian J Androl 14:40-8 (2012)
REFERENCE   PMID:21733974
  AUTHORS   Ben Khelifa M, Zouari R, Harbuz R, Halouani L, Arnoult C, Lunardi J, Ray PF
  TITLE     A new AURKC mutation causing macrozoospermia: implications for human spermatogenesis and clinical diagnosis.
  JOURNAL   Mol Hum Reprod 17:762-8 (2011)
REFERENCE   PMID:19344877
  AUTHORS   Avenarius MR, Hildebrand MS, Zhang Y, Meyer NC, Smith LL, Kahrizi K, Najmabadi H, Smith RJ
  TITLE     Human male infertility caused by mutations in the CATSPER1 channel protein.
  JOURNAL   Am J Hum Genet 84:505-10 (2009)
REFERENCE   PMID:20887963
  AUTHORS   Bashamboo A, Ferraz-de-Souza B, Lourenco D, Lin L, Sebire NJ, Montjean D, Bignon-Topalovic J, Mandelbaum J, Siffroi JP, Christin-Maitre S, Radhakrishna U, Rouba H, Ravel C, Seeler J, Achermann JC, McElreavey K
  TITLE     Human male infertility associated with mutations in NR5A1 encoding steroidogenic  factor 1.
  JOURNAL   Am J Hum Genet 87:505-12 (2010)
REFERENCE   PMID:17047026
  AUTHORS   Yatsenko AN, Roy A, Chen R, Ma L, Murthy LJ, Yan W, Lamb DJ, Matzuk MM
  TITLE     Non-invasive genetic diagnosis of male infertility using spermatozoal RNA: KLHL10 mutations in oligozoospermic patients impair homodimerization.
  JOURNAL   Hum Mol Genet 15:3411-9 (2006)
///
ENTRY       H01283                      Disease
NAME        Malonyl-CoA decarboxylase deficiency
DESCRIPTION Malonyl-CoA decarboxylase deficiency is a rare autosomal recessive disease characterized by developmental delay, seizure, hypoglycemia, cardiomyopathy and malonic aciduria. Malonyl-CoA decarboxylase (MCD) is an enzyme involved in the metabolism of fatty acids synthesis and is important in muscle and brain metabolism. Mutations in MLYCD gene that encodes MCD, result in a deficiency of MCD activity.
CATEGORY    Inherited metabolic disease
GENE        MLYCD [HSA:23417] [KO:K01578]
MARKER      Malonic aciduria [CPD:C00383]
DBLINKS     ICD-10: E72.8
            MeSH: C535702
            OMIM: 248360
REFERENCE   PMID:10417274
  AUTHORS   FitzPatrick DR, Hill A, Tolmie JL, Thorburn DR, Christodoulou J
  TITLE     The molecular basis of malonyl-CoA decarboxylase deficiency.
  JOURNAL   Am J Hum Genet 65:318-26 (1999)
REFERENCE   PMID:11550227
  AUTHORS   Surendran S, Sacksteder KA, Gould SJ, Coldwell JG, Rady PL, Tyring SK, Matalon R
  TITLE     Malonyl CoA decarboxylase deficiency: C to T transition in intron 2 of the MCD gene.
  JOURNAL   J Neurosci Res 65:591-4 (2001)
///
ENTRY       H01284                      Disease
NAME        Marinesco-Sjogren syndrome
DESCRIPTION Marinesco-Sjogren syndrome is an autosomal recessive multisystem disorder which is characterized by cerebellar ataxia, progressive myopathy and cataracts. Mutations in the endoplasmic reticulum associated co-chaperone SIL1/BAP were identified to be the major cause of this syndrome.
CATEGORY    Nervous system disease
GENE        SIL1 [HSA:64374] [KO:K14001]
DBLINKS     ICD-10: G11.1
            MeSH: D013132
            OMIM: 248800
REFERENCE   PMID:22219183
  AUTHORS   Howes J, Shimizu Y, Feige MJ, Hendershot LM
  TITLE     C-terminal mutations destabilize SIL1/BAP and can cause Marinesco-Sjogren syndrome.
  JOURNAL   J Biol Chem 287:8552-60 (2012)
REFERENCE   PMID:16282978
  AUTHORS   Anttonen AK, Mahjneh I, Hamalainen RH, Lagier-Tourenne C, Kopra O, Waris L, Anttonen M, Joensuu T, Kalimo H, Paetau A, Tranebjaerg L, Chaigne D, Koenig M, Eeg-Olofsson O, Udd B, Somer M, Somer H, Lehesjoki AE
  TITLE     The gene disrupted in Marinesco-Sjogren syndrome encodes SIL1, an HSPA5 cochaperone.
  JOURNAL   Nat Genet 37:1309-11 (2005)
REFERENCE   PMID:16282977
  AUTHORS   Senderek J, Krieger M, Stendel C, Bergmann C, Moser M, Breitbach-Faller N, Rudnik-Schoneborn S, Blaschek A, Wolf NI, Harting I, North K, Smith J, Muntoni F, Brockington M, Quijano-Roy S, Renault F, Herrmann R, Hendershot LM, Schroder JM, Lochmuller H, Topaloglu H, Voit T, Weis J, Ebinger F, Zerres K
  TITLE     Mutations in SIL1 cause Marinesco-Sjogren syndrome, a cerebellar ataxia with cataract and myopathy.
  JOURNAL   Nat Genet 37:1312-4 (2005)
///
ENTRY       H01285                      Disease
NAME        Methylcobalamin deficiency type G (cblG)
DESCRIPTION Methylcobalamin deficiency type G (cblG) is an autosomal recessive disease characterized by homocystinuria, hyperhomocysteinemia, and hypomethioninemia. Mutations in the MTR gene, which encodes methionine synthase result in this disease.
CATEGORY    Inherited metabolic disease
GENE        MTR [HSA:4548] [KO:K00548]
DBLINKS     ICD-10: E72.1
            MeSH: C565394
            OMIM: 250940
REFERENCE   PMID:12068375
  AUTHORS   Watkins D, Ru M, Hwang HY, Kim CD, Murray A, Philip NS, Kim W, Legakis H, Wai T, Hilton JF, Ge B, Dore C, Hosack A, Wilson A, Gravel RA, Shane B, Hudson TJ, Rosenblatt DS
  TITLE     Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L.
  JOURNAL   Am J Hum Genet 71:143-53 (2002)
///
ENTRY       H01286                      Disease
NAME        Microtia hearing impairment and cleft palate (MHICP)
DESCRIPTION Microtia is a congenital anomaly of the ear characterized by a small abnormally shaped outer ear. It is often associated with hearing loss. Syndromic form of microtia occur in conjunction with other abnormalities. The most common associated malformation is the cleft palate. It has been reported that a mutation in the HOXA2 homeobox gene causes microtia, severe hearing impairment, and partial cleft palate.
CATEGORY    Developmental disorder
GENE        HOXA2 [HSA:3199] [KO:K09302]
DRUG        Surgical ear reconstruction
DBLINKS     MeSH: C567359
            OMIM: 612290
REFERENCE   PMID:18394579
  AUTHORS   Alasti F, Sadeghi A, Sanati MH, Farhadi M, Stollar E, Somers T, Van Camp G
  TITLE     A mutation in HOXA2 is responsible for autosomal-recessive microtia in an Iranian family.
  JOURNAL   Am J Hum Genet 82:982-91 (2008)
REFERENCE   PMID:22106030
  AUTHORS   Luquetti DV, Heike CL, Hing AV, Cunningham ML, Cox TC
  TITLE     Microtia: Epidemiology and genetics.
  JOURNAL   Am J Med Genet A (2011)
///
ENTRY       H01287                      Disease
NAME        Congenital mirror movements (CMM)
DESCRIPTION Mirror movements are involuntary movements of one side of the body that mirror intentional movements on the opposite side. While mirror movements are occasionally found in young children, persistence beyond the age of 10 is abnormal. Congenital mirror movements (CMM) is a rare disorder that is mainly inherited in an autosomal-dominant fashion. Mutations in DCC, the gene encoding receptor for netrin 1 have been identified in CMM patients. It has also been reported that RAD51 haploinsufficiency causes the heterogeneous CMM.
CATEGORY    Nervous system disease
GENE        DCC [HSA:1630] [KO:K06765]
            RAD51A [HSA:5888] [KO:K04482]
DBLINKS     OMIM: 157600 614508
REFERENCE   PMID:20431009
  AUTHORS   Srour M, Riviere JB, Pham JM, Dube MP, Girard S, Morin S, Dion PA, Asselin G, Rochefort D, Hince P, Diab S, Sharafaddinzadeh N, Chouinard S, Theoret H, Charron F, Rouleau GA
  TITLE     Mutations in DCC cause congenital mirror movements.
  JOURNAL   Science 328:592 (2010)
REFERENCE   PMID:22305526
  AUTHORS   Depienne C, Bouteiller D, Meneret A, Billot S, Groppa S, Klebe S, Charbonnier-Beaupel F, Corvol JC, Saraiva JP, Brueggemann N, Bhatia K, Cincotta M, Brochard V, Flamand-Roze C, Carpentier W, Meunier S, Marie Y, Gaussen M, Stevanin G, Wehrle R, Vidailhet M, Klein C, Dusart I, Brice A, Roze E
  TITLE     RAD51 haploinsufficiency causes congenital mirror movements in humans.
  JOURNAL   Am J Hum Genet 90:301-7 (2012)
///
ENTRY       H01288                      Disease
NAME        Mosaic variegated aneuploidy (MVA) syndrome
DESCRIPTION Mosaic variegated aneuploidy syndrome (MVA) is a rare autosomal recessive disorder characterized by mosaic aneuploidies, diverse phenotypic abnormalities and predisposition to cancer. MVA is due to defective cell division, leading to aberrant disjunction of chromosomes during mitosis. It has been reported that mutations of the BUB1B and CEP57 genes cause MVA.
CATEGORY    Developmental disorder
GENE        BUB1B [HSA:701] [KO:K06637]
            CEP57 [HSA:9702] [KO:K16762]
DBLINKS     ICD-10: Q99.8
            MeSH: C536987
            OMIM: 257300 614114
REFERENCE   PMID:15475955
  AUTHORS   Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D, Kidd A, Mehes K, Nash R, Robin N, Shannon N, Tolmie J, Swansbury J, Irrthum A, Douglas J, Rahman N
  TITLE     Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B.
  JOURNAL   Nat Genet 36:1159-61 (2004)
REFERENCE   PMID:21552266
  AUTHORS   Snape K, Hanks S, Ruark E, Barros-Nunez P, Elliott A, Murray A, Lane AH, Shannon N, Callier P, Chitayat D, Clayton-Smith J, Fitzpatrick DR, Gisselsson D, Jacquemont S, Asakura-Hay K, Micale MA, Tolmie J, Turnpenny PD, Wright M, Douglas J, Rahman N
  TITLE     Mutations in CEP57 cause mosaic variegated aneuploidy syndrome.
  JOURNAL   Nat Genet 43:527-9 (2011)
///
ENTRY       H01289                      Disease
NAME        Mulibrey nanism
DESCRIPTION Mulibrey nanism is an autosomal recessive growth disorder characterized by prenatal-onset growth failure and heart disease involving constrictive pericarditis and restrictive cardiomyopathy. Mutations in the TRIM37 gene have been reported in Mulibrey nanism patients.
CATEGORY    Developmental disorder
GENE        TRIM37 [HSA:4591] [KO:K10608]
DBLINKS     ICD-10: Q87.1
            MeSH: D050336
            OMIM: 253250
REFERENCE   PMID:15108285
  AUTHORS   Hamalainen RH, Avela K, Lambert JA, Kallijarvi J, Eyaid W, Gronau J, Ignaszewski AP, McFadden D, Sorge G, Lipsanen-Nyman M, Lehesjoki AE
  TITLE     Novel mutations in the TRIM37 gene in Mulibrey Nanism.
  JOURNAL   Hum Mutat 23:522 (2004)
///
ENTRY       H01290                      Disease
NAME        Acute recurrent myoglobinuria
DESCRIPTION Acute recurrent myoglobinuria is caused by inborn errors of glycogenolysis, mitochondrial fatty acid beta-oxidation, and oxidative phosphorylation. It has been reported that mutations in LPIN1 cause recurrent acute myoglobinuria in childhood.
CATEGORY    Inherited metabolic disease
GENE        LPIN1 [HSA:23175] [KO:K15728]
MARKER      Increased myoglobin [CPD:C05782] in urine
DBLINKS     ICD-10: R82.1
            MeSH: C564832
            OMIM: 268200
REFERENCE   PMID:18817903
  AUTHORS   Zeharia A, Shaag A, Houtkooper RH, Hindi T, de Lonlay P, Erez G, Hubert L, Saada A, de Keyzer Y, Eshel G, Vaz FM, Pines O, Elpeleg O
  TITLE     Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood.
  JOURNAL   Am J Hum Genet 83:489-94 (2008)
///
ENTRY       H01291                      Disease
NAME        Spheroid body myopathy (SBM)
DESCRIPTION Spheroid body myopathy (SBM) is a rare autosomal dominant neuromuscular disorder characterized by slowly progressing proximal muscle weakness and dysarthric nasal speech. The unique feature noted pathologically was the spheroid bodies found within the type I muscle fibers. SBM is caused by mutations in TTID/ MYOT. Myotilin induces actin filament bundling and stabilizes the assembled bundles.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        MYOT [HSA:9499] [KO:K19875]
DBLINKS     ICD-10: G71.8
            MeSH: C535466
            OMIM: 182920
REFERENCE   PMID:16380616
  AUTHORS   Foroud T, Pankratz N, Batchman AP, Pauciulo MW, Vidal R, Miravalle L, Goebel HH, Cushman LJ, Azzarelli B, Horak H, Farlow M, Nichols WC
  TITLE     A mutation in myotilin causes spheroid body myopathy.
  JOURNAL   Neurology 65:1936-40 (2005)
///
ENTRY       H01292                      Disease
NAME        Nance-Horan syndrome
DESCRIPTION Nance-Horan syndrome (NHS) is an X-linked developmental disorder characterized by congenital cataract, dental anomalies, facial dysmorphism and, in some cases, mental retardation. Mutations in NHS gene have been identified in patients with this syndrome.
CATEGORY    Developmental disorder; Mouth and dental disease; Eye disease
GENE        NHS [HSA:4810]
DBLINKS     ICD-10: K00.1 K00.2 Q12.0
            MeSH: C538336
            OMIM: 302350
REFERENCE   PMID:19414485
  AUTHORS   Coccia M, Brooks SP, Webb TR, Christodoulou K, Wozniak IO, Murday V, Balicki M, Yee HA, Wangensteen T, Riise R, Saggar AK, Park SM, Kanuga N, Francis PJ, Maher ER, Moore AT, Russell-Eggitt IM, Hardcastle AJ
  TITLE     X-linked cataract and Nance-Horan syndrome are allelic disorders.
  JOURNAL   Hum Mol Genet 18:2643-55 (2009)
///
ENTRY       H01293                      Disease
NAME        Narcolepsy
DESCRIPTION Narcolepsy is a disabling sleep disorder characterized by irresistible excessive daytime sleepiness and cataplexy, a condition triggered by strong emotions leading to a sudden loss of muscle tone. Narcolepsy is a rare and mainly sporadic disorder. Familial narcolepsy accounts for less than 10% of all narcolepsy cases, and causative mutations have not been identified to date. The discovery of hypocretin-1 (HCRT) deficiency shed light on the underlying pathophysiology of the disease. The hypocretin neurotransmission system was shown to play a major role in controlling vigilance states. Because of the strong HLA association, hypocretin deficiency is believed to be caused by an autoimmune attack. It has also been reported that a missense mutation in myelin oligodendrocyte glycoprotein (MOG) is the cause of narcolepsy.
CATEGORY    Nervous system disease
GENE        HCRT [HSA:3060] [KO:K05246]
            MOG [HSA:4340] [KO:K17270]
DRUG        Modafinil [DR:D01832]
            Sodium oxybate [DR:D05866]
            Methylphenidate [DG:DG00969]
            Methamphetamine hydrochloride [DR:D02242]
            Amphetamine sulfate [DR:D02074]
            Mazindol [DR:D00367]
            Armodafinil [DR:D03215]
DBLINKS     ICD-10: G47.4
            MeSH: D009290
            OMIM: 161400 614250
REFERENCE   PMID:10973318
  AUTHORS   Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E
  TITLE     A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
  JOURNAL   Nat Med 6:991-7 (2000)
REFERENCE   PMID:21907016
  AUTHORS   Hor H, Bartesaghi L, Kutalik Z, Vicario JL, de Andres C, Pfister C, Lammers GJ, Guex N, Chrast R, Tafti M, Peraita-Adrados R
  TITLE     A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy.
  JOURNAL   Am J Hum Genet 89:474-9 (2011)
REFERENCE   PMID:21963829
  AUTHORS   Kornum BR, Faraco J, Mignot E
  TITLE     Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the  brain.
  JOURNAL   Curr Opin Neurobiol 21:897-903 (2011)
REFERENCE   PMID:21748548
  AUTHORS   Hirai N, Nishino S
  TITLE     Recent advances in the treatment of narcolepsy.
  JOURNAL   Curr Treat Options Neurol 13:437-57 (2011)
///
ENTRY       H01294                      Disease
NAME        Nephrogenic syndrome of inappropriate antidiuresis (NSIAD)
DESCRIPTION Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a disorder of water balance caused by gain of function mutation of arginine vasopressin receptor type 2 (AVPR2) resulting in free water reabsorption and episodes of hyponatremia.
CATEGORY    Endocrine disease; Urinary system disease
GENE        AVPR2 [HSA:554] [KO:K04228]
DRUG        Fruid restriction (FR)
            Urea [DR:D00023]
DBLINKS     ICD-10: E22.2
            MeSH: C564491
            OMIM: 300539
REFERENCE   PMID:22722264
  AUTHORS   Vandergheynst F, Brachet C, Heinrichs C, Decaux G
  TITLE     Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports.
  JOURNAL   Nephron Clin Pract 120:c168-72 (2012)
REFERENCE   PMID:15872203
  AUTHORS   Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE
  TITLE     Nephrogenic syndrome of inappropriate antidiuresis.
  JOURNAL   N Engl J Med 352:1884-90 (2005)
///
ENTRY       H01295                      Disease
NAME        Neurodegeneration due to cerebral folate transport deficiency
DESCRIPTION Neurodegeneration due to cerebral folate transport deficiency is an autosomal recessive disorder of brain specific folate deficiency, characterized by severe developmental regression, movement disturbances, epilepsy, and leukodystrophy. Folate-receptor alpha (FOLR1) is of central importance for folate transport across the blood brain barrier via the choroid plexus. It has been reported that mutations in FOLR1 cause this disease. Folinic acid therapy can reverse the clinical symptoms and improve brain abnormalities and function.
CATEGORY    Neurodegenerative disease
GENE        FOLR1 [HSA:2348] [KO:K13649]
DRUG        Folinic acid [DR:D07986]
DBLINKS     ICD-10: G31.8
            MeSH: C567791
            OMIM: 613068
REFERENCE   PMID:19732866
  AUTHORS   Steinfeld R, Grapp M, Kraetzner R, Dreha-Kulaczewski S, Helms G, Dechent P, Wevers R, Grosso S, Gartner J
  TITLE     Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism.
  JOURNAL   Am J Hum Genet 85:354-63 (2009)
REFERENCE   PMID:20018644
  AUTHORS   Cario H, Bode H, Debatin KM, Opladen T, Schwarz K
  TITLE     Congenital null mutations of the FOLR1 gene: a progressive neurologic disease and its treatment.
  JOURNAL   Neurology 73:2127-9 (2009)
///
ENTRY       H01296                      Disease
NAME        Hereditary neuropathy with liability to pressure palsies (HNPP)
DESCRIPTION Hereditary neuropathy with liability to pressure palsy (HNPP) is a rare autosomal dominant peripheral neuropathy characterized by compressive focal neuropathies and an underlying sensorimotor demyelinative polyneuropathy. HNPP is caused by a peripheral myelin protein (PMP22) gene deletion. PMP22 is duplicated in Charcot-Marie-Tooth disease type 1A (CMT1A). The other identified underlying genetic defects in HNPP are point mutations in PMP22 that lead to premature or delayed translation.
CATEGORY    Nervous system disease
GENE        PMP22 [HSA:5376] [KO:K19289]
COMMENT     Charcot-Marie-Tooth disease is described in H00264. [DS:H00264]
DBLINKS     ICD-10: G60.0
            MeSH: C536965
            OMIM: 162500
REFERENCE   PMID:12796555
  AUTHORS   Nodera H, Nishimura M, Logigian EL, Herrmann DN, Kaji R
  TITLE     HNPP due to a novel missense mutation of the PMP22 gene.
  JOURNAL   Neurology 60:1863-4 (2003)
REFERENCE   PMID:19078663
  AUTHORS   Kumar N, Muley S, Pakiam A, Parry GJ
  TITLE     Phenotypic Variability Leads to Under-recognition of HNPP.
  JOURNAL   J Clin Neuromuscul Dis 3:106-12 (2002)
///
ENTRY       H01297                      Disease
NAME        Neutral lipid storage disease with myopathy
DESCRIPTION Neutral lipid storage disease (NLSD) comprises a heterogeneous group of autosomal recessive disorders characterized by systemic accumulation of triglycerides in cytoplasmic droplets. Neutral lipid storage disease with myopathy is the subgroup of NLSD, characterized by mild myopathy, absence of ichthyosis and mutations in adipose triglyceride lipase (PNPLA2).
CATEGORY    Inherited metabolic disease
GENE        PNPLA2 [HSA:57104] [KO:K16816]
COMMENT     Dorfman-Chanarin syndrome [DS:H00736] is defined as an NLSD with ichthyosis.
DBLINKS     ICD-10: E75.5
            MeSH: C565192
            OMIM: 610717
REFERENCE   PMID:17187067
  AUTHORS   Fischer J, Lefevre C, Morava E, Mussini JM, Laforet P, Negre-Salvayre A, Lathrop M, Salvayre R
  TITLE     The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy.
  JOURNAL   Nat Genet 39:28-30 (2007)
///
ENTRY       H01298                      Disease
NAME        Pulmonary alveolar microlithiasis (PALM)
DESCRIPTION Pulmonary alveolar microlithiasis is a rare disease characterized by the deposition of calcium phosphate microliths throughout the lungs. Most patients are asymptomatic for several years, and cases with early onset or rapid progression are rare. One-third of the reported cases are familial. It has been suggested that mutations in SLC34A2 cause this disease.
CATEGORY    Lung disease
GENE        SLC34A2 [HSA:10568] [KO:K14683]
DBLINKS     OMIM: 265100
REFERENCE   PMID:16960801
  AUTHORS   Corut A, Senyigit A, Ugur SA, Altin S, Ozcelik U, Calisir H, Yildirim Z, Gocmen A, Tolun A
  TITLE     Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis.
  JOURNAL   Am J Hum Genet 79:650-6 (2006)
///
ENTRY       H01299                      Disease
NAME        Idiopathic pulmonary fibrosis
DESCRIPTION Idiopathic pulmonary fibrosis is a scarring lung disease that presents in older adults with shortness of breath and cough. Mutations in surfactant protein C (SFTPC), surfactant protein A (SFTPA), telomerase reverse transcriptase (TERT), and telomerase RNA component (TERC) have been identified in familial cases of pulmonary fibrosis. Recently, promoter variant of MUC5B was confirmed as an idiopathic pulmonary fibrosis risk variant.
CATEGORY    Lung disease
GENE        TERC [HSA:7012]
            TERT [HSA:7015] [KO:K11126]
            SFTPA1 [HSA:653509] [KO:K10067]
            SFTPA2 [HSA:729238] [KO:K10067]
            SFTPC [HSA:6440]
            MUC5B [HSA:727897] [KO:K13908]
MARKER      SP-A, SP-D, KL-6, CCL18, and MMP-7 (high serum level)
DRUG        Nintedanib [DR:D10396]
            Pirfenidone [DR:D01583]
DBLINKS     ICD-10: J84.1
            OMIM: 178500
REFERENCE   PMID:19100526
  AUTHORS   Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, DiMaio JM, Kinch LN, Grishin NV, Garcia CK
  TITLE     Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.
  JOURNAL   Am J Hum Genet 84:52-9 (2009)
REFERENCE   PMID:21613931
  AUTHORS   Lawson WE, Loyd JE, Degryse AL
  TITLE     Genetics in pulmonary fibrosis--familial cases provide clues to the pathogenesis  of idiopathic pulmonary fibrosis.
  JOURNAL   Am J Med Sci 341:439-43 (2011)
REFERENCE   PMID:17168848
  AUTHORS   Heinrich S, Hartl D, Griese M
  TITLE     Surfactant protein A--from genes to human lung diseases.
  JOURNAL   Curr Med Chem 13:3239-52 (2006)
REFERENCE   PMID:21506748
  AUTHORS   Zhang Y, Noth I, Garcia JG, Kaminski N
  TITLE     A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis.
  JOURNAL   N Engl J Med 364:1576-7 (2011)
REFERENCE   PMID:26846335 (drug)
  AUTHORS   Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, Zagai U, Skold MC, Kaarteenaho R
  TITLE     Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts  in idiopathic pulmonary fibrosis.
  JOURNAL   Respir Res 17:14 (2016)
REFERENCE   PMID:24032382 (marker)
  AUTHORS   Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D
  TITLE     An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
  JOURNAL   Am J Respir Crit Care Med 188:733-48 (2013)
///
ENTRY       H01301                      Disease
NAME        Hemorrhagic destruction of the brain, subependymal calcification, and cataracts
DESCRIPTION Hemorrhagic destruction of the brain, subependymal calcification, and cataracts is an autosomal-recessive syndrome with severe hemorrhagic destruction of the brain as a cardinal feature. A mutation in JAM3 that encodes tight-junction protein causes this syndrome.
CATEGORY    Nervous system disease
GENE        JAM3 [HSA:83700] [KO:K06785]
DBLINKS     OMIM: 613730
REFERENCE   PMID:21109224
  AUTHORS   Mochida GH, Ganesh VS, Felie JM, Gleason D, Hill RS, Clapham KR, Rakiec D, Tan WH, Akawi N, Al-Saffar M, Partlow JN, Tinschert S, Barkovich AJ, Ali B, Al-Gazali L, Walsh CA
  TITLE     A homozygous mutation in the tight-junction protein JAM3 causes hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts.
  JOURNAL   Am J Hum Genet 87:882-9 (2010)
///
ENTRY       H01302                      Disease
NAME        Hyperchlorhidrosis isolated (HCHLH)
DESCRIPTION Hyperchlorhidrosis is excessive chloride secretion in sweat. Abnormal sweat chloride levels is found also in conjunction with various metabolic, endocrine, and dermatological disorders. Hyperchlorhidrosis isolated (HCHLH) is autosomal recessive nonsyndromic disorder characterized by excessive sweating and increased sweat chloride levels. HCHLH is caused by homozygous mutation in CA12, encoding carbonic anhydrase.
CATEGORY    Inherited metabolic disease
GENE        CA12 [HSA:771] [KO:K01672]
DBLINKS     OMIM: 143860
REFERENCE   PMID:21035102
  AUTHORS   Feldshtein M, Elkrinawi S, Yerushalmi B, Marcus B, Vullo D, Romi H, Ofir R, Landau D, Sivan S, Supuran CT, Birk OS
  TITLE     Hyperchlorhidrosis caused by homozygous mutation in CA12, encoding carbonic anhydrase XII.
  JOURNAL   Am J Hum Genet 87:713-20 (2010)
///
ENTRY       H01303                      Disease
NAME        Hypercatabolic hypoproteinemia
DESCRIPTION Hypercatabolic hypoproteinemia is a disorder of endogenous catabolism of albumin and immunoglobulin. FcRn is a heterodimeric receptor composed of a nonclassical MHC class I alpha-chain and beta-2-microglobulin (B2M) that binds two ligands, IgG and albumin. It has been suggested that a mutation in B2M gene causes this disease.
CATEGORY    Hematologic disease
GENE        B2M [HSA:567] [KO:K08055]
DBLINKS     OMIM: 241600
REFERENCE   PMID:16549777
  AUTHORS   Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, Waldmann TA, Robinson JM, Anderson CL
  TITLE     Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene.
  JOURNAL   Proc Natl Acad Sci U S A 103:5084-9 (2006)
REFERENCE   PMID:2254461
  AUTHORS   Waldmann TA, Terry WD
  TITLE     Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin.
  JOURNAL   J Clin Invest 86:2093-8 (1990)
///
ENTRY       H01304                      Disease
NAME        Hyperglycinuria
DESCRIPTION Hyperglycinuria (HG) is an autosomal recessive abnormality of renal transport of glycine, resulting from mutations in genes encoding proline and glycine transporters.
CATEGORY    Kidney disease
GENE        SLC6A20 [HSA:54716] [KO:K05048]
            SLC6A19 [HSA:340024] [KO:K05334]
            SLC36A2 [HSA:153201] [KO:K14209]
COMMENT     Iminoglycinuria [DS:H00905] is related disorder.
DBLINKS     OMIM: 138500
REFERENCE   PMID:19033659
  AUTHORS   Broer S, Bailey CG, Kowalczuk S, Ng C, Vanslambrouck JM, Rodgers H, Auray-Blais C, Cavanaugh JA, Broer A, Rasko JE
  TITLE     Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from  complex mutations in proline and glycine transporters.
  JOURNAL   J Clin Invest 118:3881-92 (2008)
///
ENTRY       H01305                      Disease
NAME        Global cerebral hypomyelination
DESCRIPTION Global cerebral hypomyelination is a syndrome characterized by arrested psychomotor development, hypotonia, and seizures. A missense mutation in the SLC25A12, which encodes the AGC1 protein, causes this syndrome. AGC1 is thought to be important in providing energy for neurons in the central nervous system.
CATEGORY    Developmental disorder; Nervous system disease
GENE        SLC25A12 [HSA:8604] [KO:K15105]
DBLINKS     ICD-10: G31.8
            MeSH: C567847
            OMIM: 612949
REFERENCE   PMID:19641205
  AUTHORS   Wibom R, Lasorsa FM, Tohonen V, Barbaro M, Sterky FH, Kucinski T, Naess K, Jonsson M, Pierri CL, Palmieri F, Wedell A
  TITLE     AGC1 deficiency associated with global cerebral hypomyelination.
  JOURNAL   N Engl J Med 361:489-95 (2009)
///
ENTRY       H01306                      Disease
NAME        FRA12A mental retardation
DESCRIPTION FRA12A mental retardation is a rare form of mental retardation caused by expansion of CGG repeat. This repeat is in the 5' untranslated region of the gene DIP2B. It has been suggested that deficiency of DIP2B, a brain-expressed gene, may mediate the neurocognitive problems associated with FRA12A.
CATEGORY    Congenital disorder; Mental retardation
GENE        DIP2B [HSA:57609]
DBLINKS     MeSH: C566980
            OMIM: 136630
REFERENCE   PMID:17236128
  AUTHORS   Winnepenninckx B, Debacker K, Ramsay J, Smeets D, Smits A, FitzPatrick DR, Kooy RF
  TITLE     CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1.
  JOURNAL   Am J Hum Genet 80:221-31 (2007)
REFERENCE   PMID:18957431
  AUTHORS   Kumari D, Usdin K
  TITLE     Chromatin remodeling in the noncoding repeat expansion diseases.
  JOURNAL   J Biol Chem 284:7413-7 (2009)
///
ENTRY       H01307                      Disease
NAME        Nonsyndromic congenital nail disorder (NDNC)
DESCRIPTION Nonsyndromic congenital nail disorder is rare and has been reported in only a small number of families. There is variable expression of nail phenotypes among individuals. It have identified that mutations in the RSPO4 and FZD6, components of the Wnt pathway, cause the hypoplastic nail disorders. Hereditary leukonychia is caused by mutations in PLCD1. Defects in COL7A1 can cause heterogeneous clinical phenotypes extending from simple toe nail dystrophy without skin fragility to typical dominant dystrophic epidermolysis bullosa.
CATEGORY    Developmental disorder
GENE        PLCD1 [HSA:5333] [KO:K05857]
            RSPO4 [HSA:343637]
            COL7A1 [HSA:1294] [KO:K16628]
            FZD6 [HSA:8323] [KO:K02376]
COMMENT     Defects in RSPO4 are the cause of Anonychia congenita. [DS:H00683]
            Dominant dystrophic epidermolysis bullosa is described in H00587. [DS:H00587]
DBLINKS     ICD-10: L60.3
            OMIM: 161050 151600 206800 607523 614157 161200
REFERENCE   PMID:22211385
  AUTHORS   Naz G, Pasternack SM, Perrin C, Mattheisen M, Refke M, Khan S, Gul A, Simons M, Ahmad W, Betz RC
  TITLE     FZD6 encoding the Wnt receptor frizzled 6 is mutated in autosomal-recessive nail  dysplasia.
  JOURNAL   Br J Dermatol 166:1088-94 (2012)
REFERENCE   PMID:21665001
  AUTHORS   Kiuru M, Kurban M, Itoh M, Petukhova L, Shimomura Y, Wajid M, Christiano AM
  TITLE     Hereditary leukonychia, or porcelain nails, resulting from mutations in PLCD1.
  JOURNAL   Am J Hum Genet 88:839-44 (2011)
REFERENCE   PMID:17041604
  AUTHORS   Blaydon DC, Ishii Y, O'Toole EA, Unsworth HC, Teh MT, Ruschendorf F, Sinclair C, Hopsu-Havu VK, Tidman N, Moss C, Watson R, de Berker D, Wajid M, Christiano AM, Kelsell DP
  TITLE     The gene encoding R-spondin 4 (RSPO4), a secreted protein implicated in Wnt signaling, is mutated in inherited anonychia.
  JOURNAL   Nat Genet 38:1245-7 (2006)
REFERENCE   PMID:15113589
  AUTHORS   Nakamura H, Sawamura D, Goto M, Sato-Matsumura KC, LaDuca J, Lee JY, Masunaga T, Shimizu H
  TITLE     The G2028R glycine substitution mutation in COL7A1 leads to marked inter-familiar clinical heterogeneity in dominant dystrophic epidermolysis bullosa.
  JOURNAL   J Dermatol Sci 34:195-200 (2004)
///
ENTRY       H01308                      Disease
NAME        Macrocephaly macrosomia facial dysmorphism syndrome
DESCRIPTION Macrocephaly macrosomia facial dysmorphism syndrome is characterized by overgrowth, learning disability, and dysmorphic features. Mutations in RNF135 cause this syndrome.
CATEGORY    Developmental disorder
GENE        RNF135 [HSA:84282] [KO:K16272]
DBLINKS     OMIM: 614192
REFERENCE   PMID:17632510
  AUTHORS   Douglas J, Cilliers D, Coleman K, Tatton-Brown K, Barker K, Bernhard B, Burn J, Huson S, Josifova D, Lacombe D, Malik M, Mansour S, Reid E, Cormier-Daire V, Cole T, Rahman N
  TITLE     Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth.
  JOURNAL   Nat Genet 39:963-5 (2007)
///
ENTRY       H01309                      Disease
NAME        Sarcoidosis, early-onset
DESCRIPTION Early-onset sarcoidosis (EOS) is a special subtype of sarcoidosis, a systematic inflammatory disease with unknown etiology. It occurs in children younger than 4 years of age and is characterized by a distinct triad of skin, joint, and eye disorders without apparent pulmonary involvement. Mutations in the gene encoding NOD2 in humans have been associated with EOS. NOD2 is an intracellular microbial sensor of the innate immune system that can act as a potent activator and regulator of inflammation.
CATEGORY    Immune system disease
GENE        NOD2 [HSA:64127] [KO:K10165]
DBLINKS     ICD-10: D86
            MeSH: D012507
            OMIM: 609464
REFERENCE   PMID:19467619
  AUTHORS   Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F
  TITLE     NOD2-associated diseases: Bridging innate immunity and autoinflammation.
  JOURNAL   Clin Immunol 134:251-61 (2010)
REFERENCE   PMID:19116920
  AUTHORS   Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S, Saito M, Yoshioka T, Kawai T, Sakai H, Tanizaki H, Heike T, Miyachi Y, Nakahata T
  TITLE     Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis.
  JOURNAL   Arthritis Rheum 60:242-50 (2009)
///
ENTRY       H01310                      Disease
NAME        Multi-minicore disease (MmD);
            Multicore myopathy with external ophthalmoplegia
DESCRIPTION Multi-minicore Disease (MmD) is a recessively inherited neuromuscular disorder characterized by multiple cores on muscle biopsy and clinical features of a congenital myopathy. It is morphologically defined by localized multiple areas of mitochondrial depletion and sarcomere disorganization, running to a limited extent along the longitudinal axis of muscle fiber ("minicores"). Marked clinical variability corresponds to genetic heterogeneity. Mutations in the SEPN1 gene have been identified in patients with the classic axial phenotype characterized by spinal rigidity, early scoliosis, and respiratory impairment, whereas mutations in the RYR1 gene have been associated with a wider range of clinical features comprising external ophthalmoplegia, distal weakness and wasting or predominant hip girdle involvement.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        SEPN1 [HSA:57190] [KO:K19874]
            RYR1 [HSA:6261] [KO:K04961]
DBLINKS     ICD-10: G71.2
            MeSH: C564969
            OMIM: 602771 255320
REFERENCE   PMID:18367042
  AUTHORS   D'Amico A, Bertini E
  TITLE     Congenital myopathies.
  JOURNAL   Curr Neurol Neurosci Rep 8:73-9 (2008)
REFERENCE   PMID:17631035
  AUTHORS   Jungbluth H
  TITLE     Multi-minicore Disease.
  JOURNAL   Orphanet J Rare Dis 2:31 (2007)
///
ENTRY       H01311                      Disease
NAME        Enteroinvasive Escherichia coli (EIEC) infection
DESCRIPTION Enteroinvasive Escherichia coli (EIEC) infection is common in developing countries and comparatively rare in developed countries. EIEC invades intestinal epithelial cells, causing necrosis, ulceration of the mucous membrane, resulting in a dysentery-like syndrome with fever and mucous-bloody stools. EIEC strains contain a large invasion-associated plasmid, which are nearly identical to those of Shigella species.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli (EIEC)
DBLINKS     ICD-10: A04.2
REFERENCE   PMID:16182469
  AUTHORS   Parsot C
  TITLE     Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors.
  JOURNAL   FEMS Microbiol Lett 252:11-8 (2005)
REFERENCE   PMID:21901636
  AUTHORS   van den Beld MJ, Reubsaet FA
  TITLE     Differentiation between Shigella, enteroinvasive Escherichia coli (EIEC) and noninvasive Escherichia coli.
  JOURNAL   Eur J Clin Microbiol Infect Dis 31:899-904 (2012)
///
ENTRY       H01312                      Disease
NAME        Enteroaggregative Escherichia coli (EAEC) infection;
            Enteroaggregative Escherichia coli (EAggEC) infection
DESCRIPTION Enteroaggregative Escherichia coli (EAEC, also known as EAggEC) infection is a cause of traveler's diarrhea and persistent watery diarrhea in young children and patients infected with HIV. EAEC adheres to the small intestine via aggregative adherence fimbriae. The adherent rods resemble stacked bricks and result in shortening of microvilli. Approximately 40% of EAEC strains produce a heat-stable toxin, EAST1.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli (EAEC) [GN:eck elo]
DBLINKS     ICD-10: A04.4
            MeSH: D004927
REFERENCE   PMID:11871803
  AUTHORS   Okeke IN, Nataro JP
  TITLE     Enteroaggregative Escherichia coli.
  JOURNAL   Lancet Infect Dis 1:304-13 (2001)
REFERENCE   PMID:17005776
  AUTHORS   Huang DB, Mohanty A, DuPont HL, Okhuysen PC, Chiang T
  TITLE     A review of an emerging enteric pathogen: enteroaggregative Escherichia coli.
  JOURNAL   J Med Microbiol 55:1303-11 (2006)
///
ENTRY       H01313                      Disease
NAME        Escherichia coli meningitis;
            Neonatal meningitis-associated Escherichia coli (NMEC) infection
DESCRIPTION Escherichia coli meningitis is a bacterial meningitis caused by Escherichia coli, and is common in the newborn within the first month of life (neonatal meningitis). Neonatal meningitis-associated Escherichia coli (NMEC) strains possessing the K1 capsular polysaccharide is a major cause of neonatal meningitis.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli (NMEC) [GN:eoc ecz eih]
DBLINKS     ICD-10: G00.8
            MeSH: D020814
REFERENCE   PMID:22123760
  AUTHORS   Lu S, Zhang X, Zhu Y, Kim KS, Yang J, Jin Q
  TITLE     Complete genome sequence of the neonatal-meningitis-associated Escherichia coli strain CE10.
  JOURNAL   J Bacteriol 193:7005 (2011)
///
ENTRY       H01314                      Disease
NAME        Rat-bite fever;
            Haverhill fever
CATEGORY    Infectious disease
PATHOGEN    Streptobacillus moniliformis [GN:smf]
            Spirillum minus
DBLINKS     ICD-10: A25 A25.0 A25.1
            MeSH: D011906
///
ENTRY       H01315                      Disease
NAME        Erysipeloid;
            Swine erysipelas
CATEGORY    Infectious disease
PATHOGEN    Erysipelothrix rhusiopathiae [GN:erh]
DBLINKS     ICD-10: A26
            MeSH: D004887 D013554
///
ENTRY       H01316                      Disease
NAME        Dermatophytosis
CATEGORY    Infectious disease
PATHOGEN    Trichophyton verrucosum [GN:tve]
            Trichophyton rubrum
            Trichophyton mentagrophytes
            Trichophyton tonsurans
            Trichophyton interdigitale
DRUG        Fluconazole [DG:DG00371]
            Itraconazole [DR:D00350]
            Ketoconazole [DR:D00351]
            Voriconazole [DR:D00578]
            Fosfluconazole [DG:DG00371]
DBLINKS     ICD-10: B35
            MeSH: D014005
REFERENCE   PMID:17667895
  AUTHORS   Hiruma S
  TITLE     [Clinical aspect of dermatophytosis (ringworm)].
  JOURNAL   Nihon Ishinkin Gakkai Zasshi 48:116-9 (2007)
REFERENCE   PMID:17853533
  AUTHORS   Nishimoto K
  TITLE     [Clinical aspect and mycology of dermatophytosis--the first step in identifying dermatophytes].
  JOURNAL   Nihon Ishinkin Gakkai Zasshi 48:120-2 (2007)
///
ENTRY       H01317                      Disease
NAME        Periodontosis
CATEGORY    Infectious disease
PATHOGEN    Aggregatibacter actinomycetemcomitans [GN:aat aan]
DRUG        Epidihydrocholesterin [DR:D01527]
DBLINKS     ICD-10: K05
            MeSH: D010518
///
ENTRY       H01318                      Disease
NAME        Yaws
DESCRIPTION Treponemal infections occurring in humans comprise venereal syphilis and the non-venereal endemic treponematoses. The non-venereal endemic treponematoses are yaws, pinta, and endemic syphilis. Yaws is a chronic, relapsing disease predominantly affecting children living in certain tropical regions. Clinical manifestations of yaws are divided into various stages. Early stage skin lesions are infectious and can persist for weeks or months. Involvement of the bones of the upper and lower limbs and the fingers and toes can cause pain and digital swelling. After the early stage lesions subside due to the host immune response, the patient enters a latent stage that can be lifelong.
CATEGORY    Infectious disease
PATHOGEN    Treponema pallidum subsp. pertenue [GN:tpc tpm tpg]
COMMENT     See also H01530 Pinta and H01531 Bejel.
DBLINKS     ICD-10: A66
            MeSH: D015001
            MedlinePlus: 001341
REFERENCE   PMID:10330597 (description)
  AUTHORS   Engelkens HJ, Vuzevski VD, Stolz E
  TITLE     Nonvenereal treponematoses in tropical countries.
  JOURNAL   Clin Dermatol 17:143-52; discussion 105-6 (1999)
REFERENCE   PMID:25870417 (description)
  AUTHORS   Stamm LV
  TITLE     Yaws: 110 years after Castellani's discovery of Treponema pallidum subspecies pertenue.
  JOURNAL   Am J Trop Med Hyg 93:4-6 (2015)
REFERENCE   PMID:11825779 (pathogen)
  AUTHORS   Antal GM, Lukehart SA, Meheus AZ
  TITLE     The endemic treponematoses.
  JOURNAL   Microbes Infect 4:83-94 (2002)
///
ENTRY       H01319                      Disease
NAME        Coccidioidomycosis;
            Valley fever
CATEGORY    Infectious disease
PATHOGEN    Coccidioides immitis [GN:cim]
            Coccidioides posadasii [GN:cpw]
DBLINKS     ICD-10: B38
            MeSH: D003047
            MedlinePlus: 001322
///
ENTRY       H01320                      Disease
NAME        Epidemic keratoconjunctivitis (EKC)
DESCRIPTION Epidemic keratoconjunctivitis (EKC) is a highly contagious and severe form of eye disease caused by human adenoviruses (HAdVs). There are two well-defined adenoviral keratoconjunctivitis clinical syndromes: EKC and pharyngoconjunctival fever (PCF) [DS:H01420], which are caused by different HAdV serotypes. HAdV-8, HAdV-19, and HAdV-37 are common causative agents of EKC. In addition to these above-mentioned types, HAdV-3, HAdV-4, HAdV-7, HAdV-9, HAdV-15, HAdV-53, and HAdV-54 have also been identified as causative agents of EKC. However, HAV-8 is responsible for the highest number of EKC cases worldwide and is associated with severe clinical manifestations. EKC patients may complain about influenza-like symptoms, including fever, malaise, respiratory symptoms, nausea, vomiting, diarrhea, and myalgia. The incubation period is 2-14 days, and the person may remain infectious for 10-14 days after the onset of the symptoms. Symptoms tend to last for 7-21 days.
CATEGORY    Infectious disease
PATHOGEN    Human mastadenovirus B [GN:T40100]
            Human mastadenovirus D [GN:T40102]
            Human mastadenovirus E [GN:T40101]
            Human adenovirus 8, 19, 37
DBLINKS     ICD-10: B30.0
            MeSH: D007639
REFERENCE   PMID:25464969
  AUTHORS   Adhikary AK, Banik U
  TITLE     Human adenovirus type 8: the major agent of epidemic keratoconjunctivitis (EKC).
  JOURNAL   J Clin Virol 61:477-86 (2014)
REFERENCE   PMID:24678403
  AUTHORS   Ghebremedhin B
  TITLE     Human adenovirus: Viral pathogen with increasing importance.
  JOURNAL   Eur J Microbiol Immunol (Bp) 4:26-33 (2014)
///
ENTRY       H01321                      Disease
NAME        Pneumococcal disease, including:
            Invasive pneumoniae disease;
            Non-invasive pneumoniae disease;
            Pneumonia due to Streptococcus pneumoniae
DESCRIPTION Pneumococcal disease (PD) is infectious disease caused by Streptococcus pneumoniae (pneumococcus). PD is particularly common in younger children and in older adults and is roughly divided into invasive and non-invasive disease; the former refers to infections in which the microorganism is isolated from normal sterile body sites, such as the blood or the cerebrospinal fluid. Non-invasive PD can principally be divided into sinusitis, acute otitis media, and community-acquired pneumonia. S. pneumoniae remains the most common bacterial cause of community-acquired pneumonia. The invasive PD burden is mainly determined by pneumococcal meningitis, bacteremic pneumococcal pneumonia, and pneumococcal bacteremia without a primary focus. Incidence and mortality rates of both non-invasive and invasive disease have changed as a result of pneumococcal vaccination in children. However, especially elderly patients with comorbidities remain vulnerable to morbidity and mortality caused by PD.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pneumoniae [GN:spn spd spw spx sne]
DRUG        Beta-lactams [DG:DG01710]
            Macrolides [DG:DG01551]
            Fluoroquinolones [DG:DG01549]
DBLINKS     ICD-10: A40.3 A49.1
            MeSH: D011008
REFERENCE   PMID:24313448 (description)
  AUTHORS   Drijkoningen JJ, Rohde GG
  TITLE     Pneumococcal infection in adults: burden of disease.
  JOURNAL   Clin Microbiol Infect 20 Suppl 5:45-51 (2014)
REFERENCE   PMID:25343039 (description, drug)
  AUTHORS   Feldman C, Anderson R
  TITLE     Recent advances in our understanding of Streptococcus pneumoniae infection.
  JOURNAL   F1000Prime Rep 6:82 (2014)
///
ENTRY       H01322                      Disease
NAME        Kyasanur Forest disease
CATEGORY    Infectious disease
PATHOGEN    Kyasanur forest disease virus (KFDV)
DBLINKS     ICD-10: A98.2
            MeSH: D007733
///
ENTRY       H01323                      Disease
NAME        Acute gastroenteropathy due to Norwalk agent
CATEGORY    Infectious disease
PATHOGEN    Norwalk virus [GN:T40107]
DBLINKS     ICD-10: A08.1
            MedlinePlus: 000252
///
ENTRY       H01324                      Disease
NAME        Lymphocytic choriomeningitis
CATEGORY    Infectious disease
PATHOGEN    Lymphocytic choriomeningitis mammarenavirus [GN:T40091]
DBLINKS     ICD-10: A87.2
            MeSH: D008216
///
ENTRY       H01325                      Disease
NAME        Actinomycosis
DESCRIPTION Actinomycosis is an uncommon chronic granulomatous infection caused by several members of the order Actinomycetales, most notably, Actinomyces israelii. Additional species that are established but less common causes of actinomycosis include A. naeslundii/viscosus complex, A. odontolyticus, A. meyeri and A. gerencseriae.
CATEGORY    Infectious disease
PATHOGEN    Actinomyces israelii
            Actinomyces naeslundii
            Actinomyces viscosus
            Actinomyces odontolyticus
            Actinomyces meyeri
            Actinomyces gerencseriae
COMMENT     See also H01451 Actinomycetoma and H00345 Nocardiosis.
DBLINKS     ICD-10: A42
            MeSH: D000196
            MedlinePlus: 000599
REFERENCE   PMID:16582679 (description)
  AUTHORS   Yildiz O, Doganay M
  TITLE     Actinomycoses and Nocardia pulmonary infections.
  JOURNAL   Curr Opin Pulm Med 12:228-34 (2006)
REFERENCE   PMID:25233694 (description)
  AUTHORS   Vidakovic B, Macan D, Peric B, Spomenka M
  TITLE     Actinomycosis of the cheek.
  JOURNAL   Srp Arh Celok Lek 142:472-5 (2014)
///
ENTRY       H01326                      Disease
NAME        Hand, foot and mouth disease
DESCRIPTION HFMD is generally a benign febrile exanthematous childhood disease but the brain stem can also be affected, causing meningitis and encephalitis. The disease may be complicated by myocarditis.
CATEGORY    Infectious disease
PATHOGEN    Human enterovirus 71
            Enterovirus A [GN:T40103]
MARKER      5' untranslated or VP1 region of the viral genome (PCR detection)
            IgM antibodies (ELISA test)
DRUG        Intravenous immunoglobulin
DBLINKS     ICD-10: B08.4
            MeSH: D006232
            MedlinePlus: 000965
REFERENCE   PMID:17671037 (description)
  AUTHORS   Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY
  TITLE     Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005.
  JOURNAL   Pediatrics 120:e244-52 (2007)
REFERENCE   PMID:20961813 (description)
  AUTHORS   Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH
  TITLE     Virology, epidemiology, pathogenesis, and control of enterovirus 71.
  JOURNAL   Lancet Infect Dis 10:778-90 (2010)
REFERENCE   PMID:20056019 (marker, drug)
  AUTHORS   Wong SS, Yip CC, Lau SK, Yuen KY
  TITLE     Human enterovirus 71 and hand, foot and mouth disease.
  JOURNAL   Epidemiol Infect 138:1071-89 (2010)
REFERENCE   PMID:20965438 (drug)
  AUTHORS   Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T
  TITLE     Clinical features, diagnosis, and management of enterovirus 71.
  JOURNAL   Lancet Neurol 9:1097-105 (2010)
///
ENTRY       H01327                      Disease
NAME        Herpangina
DESCRIPTION Herpangina is a vesicular exanthem of the fauces and soft palate, often accompanied by fever, sore throat, and pain on swallowing.
CATEGORY    Infectious disease
PATHOGEN    Enterovirus A [GN:T40103]
DBLINKS     ICD-10: B08.5
            MeSH: D006557
            MedlinePlus: 000969
REFERENCE   PMID:17671037 (description)
  AUTHORS   Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY
  TITLE     Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005.
  JOURNAL   Pediatrics 120:e244-52 (2007)
///
ENTRY       H01328                      Disease
NAME        Aspergillosis
DESCRIPTION Pulmonary aspergillus infections can be classified based on clinical syndromes into saprophytic infections, allergic disease and invasive disease. Invasive pulmonary aspergillosis, occurring in immunocompromised patients, reflects the most serious disease with a high case-fatality rate. Of the 185 recognized species of Aspergillus, 20 are known to cause infections in humans. Aspergillus fumigatus accounts for about 65 percent of all invasive infections in humans and is the mostly encountered species in pulmonary infections. Aspergillus flavus, Aspergillus niger, Aspergillus terreus and Aspergillus nidulans are less frequently causes of invasive and pulmonary infections.
CATEGORY    Infectious disease
PATHOGEN    Aspergillus fumigatus [GN:afm]
            Aspergillus flavus [GN:afv]
DBLINKS     ICD-10: B44
            MeSH: D001228
            MedlinePlus: 001326
REFERENCE   PMID:25135079
  AUTHORS   Warris A
  TITLE     The biology of pulmonary aspergillus infections.
  JOURNAL   J Infect 69 Suppl 1:S36-41 (2014)
///
ENTRY       H01329                      Disease
NAME        Paracoccidioidomycosis
CATEGORY    Infectious disease
PATHOGEN    Paracoccidioides brasiliensis [GN:pbn]
            Paracoccidioides lutzii [GN:pbl]
DBLINKS     ICD-10: B41
            MeSH: D010229
///
ENTRY       H01330                      Disease
NAME        Brazilian purpuric fever (BPF)
DESCRIPTION Brazilian purpuric fever (BPF), which is caused by Haemophilus influenzae biogroup aegyptius (H. aegyptius), is a recently described pediatric disease that is often fatal. The vascular destruction is a distinctive trait, and little is known about the mechanism(s) of the overwhelming purpura fulminans that causes the high mortality. This disease is preceded by purulent conjunctivitis which resolves but is followed 10-14 days later by acute onset of fever associated with systemic toxicity, petechiae, purpura, and vascular collapse.
CATEGORY    Infectious disease
PATHOGEN    Haemophilus influenzae biogroup aegyptius [GN:hif]
DBLINKS     ICD-10: A48.4
            MeSH: D006192
REFERENCE   PMID:3262623
  AUTHORS   Brenner DJ, Mayer LW, Carlone GM, Harrison LH, Bibb WF, Brandileone MC, Sottnek FO, Irino K, Reeves MW, Swenson JM, et al.
  TITLE     Biochemical, genetic, and epidemiologic characterization of Haemophilus influenzae biogroup aegyptius (Haemophilus aegyptius) strains associated with Brazilian purpuric fever.
  JOURNAL   J Clin Microbiol 26:1524-34 (1988)
REFERENCE   PMID:9727086 (description)
  AUTHORS   Smoot LM, Bell EC, Paz RL, Corbin KA, Hall DD, Steenbergen JN, Harner AC, Actis LA.
  TITLE     Molecular and genetic analysis of iron uptake proteins in the brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius.
  JOURNAL   Front Biosci 3:D989-96 (1998)
REFERENCE   PMID:21413340 (description)
  AUTHORS   Musher DM
  TITLE     Haemophilus Species
  JOURNAL   (1996)
///
ENTRY       H01331                      Disease
NAME        Dental caries
DESCRIPTION Dental caries occurs due to demineralization of enamel and dentine (the hard tissues of the teeth) by organic acids formed by bacteria in dental plaque through the anaerobic metabolism of sugars derived from the diet. The 2 primary bacteria involved in caries formation are mutans streptococci and lactobacilli. When sugars or other fermentable carbohydrates are ingested, the resulting fall in dental plaque pH caused by organic acids increases the solubility of calcium hydroxyapatite in the dental hard tissues and demineralization occurs as calcium is lost from the tooth surface. The pH at which demineralization occurs is often referred to as the critical pH and is approximately 5.5.
CATEGORY    Infectious disease
ENV_FACTOR  Dietary sugar [CPD:C00089 C00095 C00031]
PATHOGEN    Streptococcus mutans [GN:smu smc smj smut]
            Cryptobacterium curtum [GN:ccu]
            Lactobacilli
DBLINKS     ICD-10: K02
            MedlinePlus: 001055
            MeSH: D003731
REFERENCE   PMID:14972061 (description, env_factor, pathogen)
  AUTHORS   Moynihan P, Petersen PE
  TITLE     Diet, nutrition and the prevention of dental diseases.
  JOURNAL   Public Health Nutr 7:201-26 (2004)
REFERENCE   PMID:14522753 (description, env_factor, pathogen)
  AUTHORS   Touger-Decker R, van Loveren C
  TITLE     Sugars and dental caries.
  JOURNAL   Am J Clin Nutr 78:881S-892S (2003)
REFERENCE   PMID:20331803 (pathogen)
  AUTHORS   Piwat S, Teanpaisan R, Thitasomakul S, Thearmontree A, Dahlen G
  TITLE     Lactobacillus species and genotypes associated with dental caries in Thai preschool children.
  JOURNAL   Mol Oral Microbiol 25:157-64 (2010)
///
ENTRY       H01332                      Disease
NAME        Helicobacter heilmannii infection
DESCRIPTION Helicobacter heilmannii (H. heilmannii) infection is a relatively rare causative agent of gastroduodenal diseases in children. H. heilmannii frequently colonizes gastric mucosa of animals, mainly cats and dogs, from where it can be transmitted to humans. Generally, H. heilmannii infection is associated with mild gastritis. However, association with duodenal ulcer, acute gastric mucosal lesion, and gastric carcinoma have been observed. In addition, a close association with low-grade primary gastric mucosa-associated lymphoid tissue (MALT) lymphoma has been described both in humans and in experimental animals.
CATEGORY    Infectious disease
PATHOGEN    Helicobacter heilmannii [GN:hhm]
DBLINKS     MeSH: D016481
REFERENCE   PMID:15982214 (description)
  AUTHORS   Okiyama Y, Matsuzawa K, Hidaka E, Sano K, Akamatsu T, Ota H
  TITLE     Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.
  JOURNAL   Pathol Int 55:398-404 (2005)
REFERENCE   PMID:22653899 (description)
  AUTHORS   Iwanczak B, Biernat M, Iwanczak F, Grabinska J, Matusiewicz K, Gosciniak G
  TITLE     The clinical aspects of Helicobacter heilmannii infection in children with dyspeptic symptoms.
  JOURNAL   J Physiol Pharmacol 63:133-6 (2012)
///
ENTRY       H01333                      Disease
NAME        Nonalcoholic fatty liver disease (NAFLD)
DESCRIPTION It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.
CATEGORY    Metabolic disease; Endocrine disease
GENE        PNPLA3(polymorphism) [HSA:80339] [KO:K13534]
DRUG        Clofibrate [DG:DG00358] (fibrates)
            Metformin [DG:DG00113] (biguanides)
            L-Carnitine [DR:D02176] (affecting metabolism)
            beta-Aminoisobutyrid acid [DR:D05014] (leptin receptor)
            Vitamin E [DR:D02331] 
            Ursodeoxycholic acid [DR:D00734] 
            Somatostatin [DR:D07431] (Statins) 
            Ursodeoxycholic acid [DR:D00743]
DBLINKS     ICD-10: K75.8 K76.0
REFERENCE   PMID:20373368
  AUTHORS   Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP
  TITLE     Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism  influences liver fibrosis in patients with nonalcoholic fatty liver disease.
  JOURNAL   Hepatology 51:1209-17 (2010)
REFERENCE   PMID:20684021
  AUTHORS   Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ
  TITLE     The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.
  JOURNAL   Hepatology 52:894-903 (2010)
REFERENCE   PMID:20648472
  AUTHORS   Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN
  TITLE     PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.
  JOURNAL   Hepatology 52:904-12 (2010)
///
ENTRY       H01334                      Disease
NAME        Tinea versicolor;
            Pityriasis versicolor
DESCRIPTION Tinea versicolor, also known as pityriasis versicolor, dermatomycosis furfuracea and tinea flava, is caused by Malassezia species which are naturally found on the skin surfaces of many animals, including humans.
            Patients with tinea versicolor most commonly have multiple macules or patches on the trunk, with skip regions of normal skin in between.
            In addition, it is estimated that these species cause most skin disease in humans, including the most common cause of atopic dermatitis and seborrhoeic dermatitis.
CATEGORY    Infectious disease
PATHOGEN    Malassezia globosa [GN:mgl]
DRUG        Itraconazole [DR:D00350] sterol 14alpha-demethylase ihibitor
DBLINKS     ICD-10: B36.0
            MeSH: D014010
            MedlinePlus: 001465
REFERENCE   PMID:16463088 (description
            pathogen)
  AUTHORS   Morishita N, Sei Y, Sugita T
  TITLE     Molecular analysis of malassezia microflora from patients with pityriasis versicolor.
  JOURNAL   Mycopathologia 161:61-5 (2006)
REFERENCE   PMID:9762812 (description)
  AUTHORS   Sunenshine PJ, Schwartz RA, Janniger CK
  TITLE     Tinea versicolor.
  JOURNAL   Int J Dermatol 37:648-55 (1998)
REFERENCE   PMID:21114623 (drug)
  AUTHORS   Kim D, Lim YR, Ohk SO, Kim BJ, Chun YJ
  TITLE     Functional expression and characterization of CYP51 from dandruff-causing Malassezia globosa.
  JOURNAL   FEMS Yeast Res 11:80-7 (2011)
///
ENTRY       H01335                      Disease
NAME        Photorhabdus asymbiotica infection
DESCRIPTION Photorhabdus asymbiotica, a gram-negative bacterium is an opportunistic human pathogen that causes locally invasive soft tissue and disseminated bacteremic infections in the United States and Australia. Australian isolates of P. asymbiotica formed mutualistic association with Heterorhabditis indica, a nematode species but although unproven for P. asymbiotica in North America. Whether this nematode is able to penetrate intact human skin is unclear, although direct skin penetration by nematodes is well recognized (e.g. hookworm, Strongyloides stercoralis).
CATEGORY    Infectious disease
PATHOGEN    Photorhabdus asymbiotica [GN:pay]
REFERENCE   PMID:19583835 (description)
  AUTHORS   Wilkinson P, Waterfield NR, Crossman L, Corton C, Sanchez-Contreras M, Vlisidou I, Barron A, Bignell A, Clark L, Ormond D, Mayho M, Bason N, Smith F, Simmonds M, Churcher C, Harris D, Thompson NR, Quail M, Parkhill J, Ffrench-Constant RH
  TITLE     Comparative genomics of the emerging human pathogen Photorhabdus asymbiotica with the insect pathogen Photorhabdus luminescens.
  JOURNAL   BMC Genomics 10:302 (2009)
REFERENCE   PMID:17176572 (description)
  AUTHORS   Gerrard JG, Joyce SA, Clarke DJ, ffrench-Constant RH, Nimmo GR, Looke DF, Feil EJ, Pearce L, Waterfield NR
  TITLE     Nematode symbiont for Photorhabdus asymbiotica.
  JOURNAL   Emerg Infect Dis 12:1562-4 (2006)
REFERENCE   PMID:18538616 (description)
  AUTHORS   Kuwata R, Yoshiga T, Yoshida M, Kondo E
  TITLE     Mutualistic association of Photorhabdus asymbiotica with Japanese heterorhabditid entomopathogenic nematodes.
  JOURNAL   Microbes Infect 10:734-41 (2008)
///
ENTRY       H01336                      Disease
NAME        Encephalitozoon infection
DESCRIPTION The genus Encephalitozoon are spore-forming obligate intracellular microsporidian parasites that infect a wide range of organisms, including protists, invertebrates, humans, and many other vertebrates and known as opportunistic pathogen associated with immunocompromised individuals. Major symptoms include a life-threatening chronic diarrhea and systemic disease. The transmission routes may involve person-to-person as well as waterborne or foodborne, especially in developing countries with poor sanitation. E. intestinalis is recognized as one of the most frequently identified microsporidia in humans, and is associated with diarrhea, malabsorption, cholangitis, cholecystitis, sinusitis, bronchitis, conjunctivitis, nephritis and intestinal perforation.
CATEGORY    Infectious disease
PATHOGEN    Encephalitozoon cuniculi [GN:ecu]
            Encephalitozoon intestinalis [GN:ein]
DBLINKS     ICD-10: B60.8
REFERENCE   PMID:11719806 (description)
  AUTHORS   Katinka MD, Duprat S, Cornillot E, Metenier G, Thomarat F, Prensier G, Barbe V, Peyretaillade E, Brottier P, Wincker P, Delbac F, El Alaoui H, Peyret P, Saurin W, Gouy M, Weissenbach J, Vivares CP.
  TITLE     Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi.
  JOURNAL   Nature 414:450-3 (2001)
REFERENCE   PMID:22496910 (description)
  AUTHORS   Ojuromi OT, Izquierdo F, Fenoy S, Fagbenro-Beyioku A, Oyibo W, Akanmu A, Odunukwe N, Henriques-Gil N, del Aguila C
  TITLE     Identification and characterization of microsporidia from fecal samples of HIV-positive patients from Lagos, Nigeria.
  JOURNAL   PLoS One 7:e35239 (2012)
REFERENCE   PMID:22824062 (description)
  AUTHORS   Velasquez JN, Chertcoff AV, Etchart C, di Risio C, Sodre FC, Cucher MA, Carnevale S
  TITLE     First case report of infection caused by Encephalitozoon intestinalis in a domestic cat and a patient with AIDS.
  JOURNAL   Vet Parasitol 190:583-6 (2012)
REFERENCE   PMID:20865802 (description)
  AUTHORS   Corradi N, Pombert JF, Farinelli L, Didier ES, Keeling PJ
  TITLE     The complete sequence of the smallest known nuclear genome from the microsporidian Encephalitozoon intestinalis.
  JOURNAL   Nat Commun 1:77 (2010)
///
ENTRY       H01337                      Disease
NAME        Laribacter hongkongensis infection
DESCRIPTION Laribacter hongkongensis is a facultatively anaerobic, nonsporulating, gram-negative, spiral rod-shaped bacterium belongs to the Neisseriaceae family of the subclass of Proteobacteria. L. hongkongensis was isolated from the blood and empyema of a cirrhotic patient and associated with freshwater fish-borne gastroenteritis and traveler's diarrhea.
CATEGORY    Infectious disease
PATHOGEN    Laribacter hongkongensis HLHK9 [GN:lhk]
REFERENCE   PMID:11724825 (description)
  AUTHORS   Yuen KY, Woo PC, Teng JL, Leung KW, Wong MK, Lau SK
  TITLE     Laribacter hongkongensis gen. nov., sp. nov., a novel gram-negative bacterium isolated from a cirrhotic patient with bacteremia and empyema.
  JOURNAL   J Clin Microbiol 39:4227-32 (2001)
REFERENCE   PMID:19283063 (description)
  AUTHORS   Woo PC, Lau SK, Tse H, Teng JL, Curreem SO, Tsang AK, Fan RY, Wong GK, Huang Y, Loman NJ, Snyder LA, Cai JJ, Huang JD, Mak W, Pallen MJ, Lok S, Yuen KY
  TITLE     The complete genome and proteome of Laribacter hongkongensis reveal potential mechanisms for adaptations to different temperatures and habitats.
  JOURNAL   PLoS Genet 5:e1000416 (2009)
///
ENTRY       H01338                      Disease
NAME        Myosclerosis
DESCRIPTION Myosclerosis is an autosomal recessive disorder caused by nonsense mutation of COL6A2. This disease is one of the collagen VI myopathies, characterized by difficulty in walking in early childhood, toe walking, and progressive contractures of calf muscles. In the early 30s the muscles are slender with a firm woody consistency and associated with contractures that restrict range of motion of many joints.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        COL6A2 [HSA:1292] [KO:K06238]
DBLINKS     ICD-10: G71.8
            MeSH: C564968
            OMIM: 255600
REFERENCE   PMID:18852439
  AUTHORS   Merlini L, Martoni E, Grumati P, Sabatelli P, Squarzoni S, Urciuolo A, Ferlini A, Gualandi F, Bonaldo P
  TITLE     Autosomal recessive myosclerosis myopathy is a collagen VI disorder.
  JOURNAL   Neurology 71:1245-53 (2008)
///
ENTRY       H01339                      Disease
NAME        Asymptomatic bacteriuria
DESCRIPTION The term asymptomatic bacteriuria is generally used to distinguish colonization from infection and to emphasize that the presence of bacteria at mucosal surfaces does not always cause symptoms and tissue damage. Asymptomatic bacteriuria has been attracting attention as a model to study mechanisms underlying the development of commensalism. Escherichia coli strain 83972 was isolated from the urine of a Swedish patient who was colonized for at least 3 years without displaying clinical signs of a urinary tract infection.
CATEGORY    Infectious disease
PATHOGEN    Escherichia coli ABU 83972 [GN:eab]
DBLINKS     ICD-10: R82.9
            MeSH: D001437
            MedlinePlus: 000520
REFERENCE   PMID:20865122 (description)
  AUTHORS   Zdziarski J, Brzuszkiewicz E, Wullt B, Liesegang H, Biran D, Voigt B, Gronberg-Hernandez J, Ragnarsdottir B, Hecker M, Ron EZ, Daniel R, Gottschalk G, Hacker J, Svanborg C, Dobrindt U
  TITLE     Host imprints on bacterial genomes--rapid, divergent evolution in individual patients.
  JOURNAL   PLoS Pathog 6:e1001078 (2010)
REFERENCE   PMID:20638202 (description)
  AUTHORS   Thompson MF, Totsika M, Schembri MA, Mills PC, Seton EJ, Trott DJ
  TITLE     Experimental colonization of the canine urinary tract with the asymptomatic bacteriuria Escherichia coli strain 83972.
  JOURNAL   Vet Microbiol 147:205-8 (2011)
///
ENTRY       H01340                      Disease
NAME        Bethlem myopathy
DESCRIPTION Bethlem myopathy is one of the collagen VI myopathies, caused by mutation of COL6A. Bethlem myopathy is usually inherited in an autosomal dominant manner, but a rare autosomal recessive inheritance has recently been reported. This disease is characterized by a combination of proximal muscle weakness and contractures of finger, elbow, and ankle joints.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        COL6A1 [HSA:1291] [KO:K06238]
            COL6A2 [HSA:1292] [KO:K06238]
            COL6A3 [HSA:1293] [KO:K06238]
            COL12A1 [HSA:1303] [KO:K08132]
DBLINKS     ICD-10: G71.8
            MeSH: C535436
            OMIM: 158810 616471
REFERENCE   PMID:20301676
  AUTHORS   Lampe AK, Flanigan KM, Bushby KM, Hicks D
  TITLE     Collagen Type VI-Related Disorders
  JOURNAL   (1993)
REFERENCE   PMID:19949035
  AUTHORS   Gualandi F, Urciuolo A, Martoni E, Sabatelli P, Squarzoni S, Bovolenta M, Messina S, Mercuri E, Franchella A, Ferlini A, Bonaldo P, Merlini L
  TITLE     Autosomal recessive Bethlem myopathy.
  JOURNAL   Neurology 73:1883-91 (2009)
REFERENCE   PMID:24334769 (gene)
  AUTHORS   Hicks D, Farsani GT, Laval S, Collins J, Sarkozy A, Martoni E, Shah A, Zou Y, Koch M, Bonnemann CG, Roberts M, Lochmuller H, Bushby K, Straub V
  TITLE     Mutations in the collagen XII gene define a new form of extracellular matrix-related myopathy.
  JOURNAL   Hum Mol Genet 23:2353-63 (2014)
///
ENTRY       H01341                      Disease
NAME        Collagen VI myopathy, including:
            Ullrich congenital muscular dystrophy (UCMD) [DS:H00590];
            Bethlem myopathy [DS:H01340];
            Myosclerosis [DS:H01338]
DESCRIPTION Collagen VI-related myopathy include severe Ullrich congenital muscular dystrophy (UCMD) and milder Bethlem myopathy. Mutations in each of the three collagen VI genes COL6A1, COL6A2, and COL6A3 cause these diseases. Recently, an additional phenotypes, autosomal recessive myosclerosis with mutations in COL6A2 have been reported. Collagen VI is an important component of the extracellular matrix which forms a microfibrillar network that is found in close association with the cell and surrounding basement membrane. Thus, collagen VI mutations result in disorders with combined muscle and connective tissue involvement, including weakness, joint and contractures, and abnormal skin findings.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        COL6A1 [HSA:1291] [KO:K06238]
            COL6A2 [HSA:1292] [KO:K06238]
            COL6A3 [HSA:1293] [KO:K06238]
DBLINKS     ICD-10: G71.8
            MeSH: C537521 C535436 C564968
            OMIM: 254090 158810 255600
REFERENCE   PMID:18852439
  AUTHORS   Merlini L, Martoni E, Grumati P, Sabatelli P, Squarzoni S, Urciuolo A, Ferlini A, Gualandi F, Bonaldo P
  TITLE     Autosomal recessive myosclerosis myopathy is a collagen VI disorder.
  JOURNAL   Neurology 71:1245-53 (2008)
REFERENCE   PMID:20301676
  AUTHORS   Lampe AK, Flanigan KM, Bushby KM, Hicks D
  TITLE     Collagen Type VI-Related Disorders
  JOURNAL   (1993)
///
ENTRY       H01342                      Disease
NAME        Zellweger syndrome (ZS)
DESCRIPTION Zellweger syndrome is the most severe form seen in the peroxisome biogenesis disorder, characterized by neurological dysfunction, craniofacial abnormalities, eye abnormalities, hepatomegaly, and chondrodysplasia punctata. This disease is caused by mutation of peroxisomal biogenesis factor (PEX) genes.
CATEGORY    Inherited metabolic disease; Nervous system disease; Liver disease; Peroxisomal disease
GENE        PEX1 [HSA:5189] [KO:K13338]
            PEX2 [HSA:5828] [KO:K06664]
            PEX3 [HSA:8504] [KO:K13336]
            PEX5 [HSA:5830] [KO:K13342]
            PEX6 [HSA:5190] [KO:K13339]
            PEX10 [HSA:5192] [KO:K13346]
            PEX12 [HSA:5193] [KO:K13345]
            PEX13 [HSA:5194] [KO:K13344]
            PEX14 [HSA:5195] [KO:K13343]
            PEX16 [HSA:9409] [KO:K13335]
            PEX19 [HSA:5824] [KO:K13337]
            PEX26 [HSA:55670] [KO:K13340]
DBLINKS     ICD-10: Q87.8
            MeSH: D015211
            OMIM: 214100 214110 614859 614862 614866 614870 614872 614876 614882 614883 614886 614887
REFERENCE   PMID:15098234
  AUTHORS   Wanders RJ
  TITLE     Metabolic and molecular basis of peroxisomal disorders: a review.
  JOURNAL   Am J Med Genet A 126A:355-75 (2004)
REFERENCE   PMID:12169017
  AUTHORS   Brosius U, Gartner J
  TITLE     Cellular and molecular aspects of Zellweger syndrome and other peroxisome biogenesis disorders.
  JOURNAL   Cell Mol Life Sci 59:1058-69 (2002)
///
ENTRY       H01343                      Disease
NAME        Pantoea ananatis infection
DESCRIPTION Pantoea ananatis, a gram-negative, motile rod belonging to the family Enterobacteriaceae, is known as an emerging phytopathogen infecting a wide range of important crop and forest plants, and has been reported as an occasional clinical isolate. It has been considered a presumptive and opportunistic human pathogen that associated with septicemia following penetrating trauma with plant material, nosocomial infections due to exposure to contaminated hospital materials, and secondary complications of preexisting illnesses.
CATEGORY    Infectious disease
PATHOGEN    Pantoea ananatis [GN:plf pam]
REFERENCE   PMID:22374951 (description)
  AUTHORS   De Maayer P, Chan WY, Rezzonico F, Buhlmann A, Venter SN, Blom J, Goesmann A, Frey JE, Smits TH, Duffy B, Coutinho TA
  TITLE     Complete genome sequence of clinical isolate Pantoea ananatis LMG 5342.
  JOURNAL   J Bacteriol 194:1615-6 (2012)
REFERENCE   PMID:20348253 (description)
  AUTHORS   De Maayer P, Chan WY, Venter SN, Toth IK, Birch PR, Joubert F, Coutinho TA
  TITLE     Genome sequence of Pantoea ananatis LMG20103, the causative agent of Eucalyptus blight and dieback.
  JOURNAL   J Bacteriol 192:2936-7 (2010)
REFERENCE   PMID:15365053 (description)
  AUTHORS   De Baere T, Verhelst R, Labit C, Verschraegen G, Wauters G, Claeys G, Vaneechoutte M
  TITLE     Bacteremic infection with Pantoea ananatis.
  JOURNAL   J Clin Microbiol 42:4393-5 (2004)
///
ENTRY       H01344                      Disease
NAME        Nijmegen Breakage Syndrome, including:
            Nijmegen Breakage Syndrome (NBS);
            Nijmegen Breakage Syndrome-Like Disorder (NBSLD)
DESCRIPTION Nijmegen Breakage Syndrome (NBS) is a rare autosomal recessive disorder characterized by microcephaly, growth retardation, immunodeficiency, radiosensitivity, and cancer predisposition. Due to a founder mutation in the NBN gene, the disease is encountered most frequently among Slavic populations. Recently, a disease due to RAD50 deficiency has been reported. The patient displayed symptoms similar to NBS, microcephaly, mental retardation, bird-like face, and short stature. The MRE11/RAD50/NBN (MRN) complex plays a key role in recognizing and signaling DNA double-strand breaks.
CATEGORY    Congenital disorder of DNA repair systems
GENE        (NBS) NBN (Nibrin) [HSA:4683] [KO:K10867]
            (NBSLD) RAD50 [HSA:10111] [KO:K10866]
DBLINKS     MeSH: D049932 C567767
            OMIM: 251260 613078
REFERENCE   PMID:22373003
  AUTHORS   Chrzanowska KH, Gregorek H, Dembowska-Baginska B, Kalina MA, Digweed M
  TITLE     Nijmegen breakage syndrome (NBS).
  JOURNAL   Orphanet J Rare Dis 7:13 (2012)
REFERENCE   PMID:19409520
  AUTHORS   Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon R, Lerenthal Y, Lavin MF, Schindler D, Dork T
  TITLE     Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder.
  JOURNAL   Am J Hum Genet 84:605-16 (2009)
///
ENTRY       H01345                      Disease
NAME        Providencia stuartii infection
DESCRIPTION Providencia is a gram-negative urea-metabolizing bacilli that readily incorporates DNA from other bacteria, enabling it to acquire resistance to a broad spectrum of antibiotics. Providencia stuartii is a bacterium normally found in patients with indwelling urinary catheters, where it causes urinary tract infections. These infections may progress to bacteremia. Diarrhea, peritonitis, meningitis, and infections of burn wounds, the endocarditis and the brain abscess attributed to P. stuartii have also been reported.
CATEGORY    Infectious disease
PATHOGEN    Providencia stuartii  [GN:psi psx]
DBLINKS     ICD-10: B96.4
            MeSH: D011512
REFERENCE   PMID:22740665 (description)
  AUTHORS   Clifford RJ, Hang J, Riley MC, Onmus-Leone F, Kuschner RA, Lesho EP, Waterman PE
  TITLE     Complete genome sequence of Providencia stuartii clinical isolate MRSN 2154.
  JOURNAL   J Bacteriol 194:3736-7 (2012)
///
ENTRY       H01346                      Disease
NAME        Bloom syndrome
DESCRIPTION Bloom syndrome is a rare autosomal recessive genetic disorder due to mutation in BLM (RecQ protein-like 3). This disease is characterized by dwarfism, photosensitivity, immunodeficiency and a high predisposition to various types of cancer. The function of BLM as a helicase and its role during the regulation of homologous recombination (HR) is well characterized. Recently, the role of BLM as a DNA damage sensor has been revealed.
CATEGORY    Congenital disorder of DNA repair systems
GENE        BLM [HSA:641] [KO:K10901]
DBLINKS     ICD-10: Q82.8
            MeSH: D001816
            OMIM: 210900
REFERENCE   PMID:23543275
  AUTHORS   Manthei KA, Keck JL
  TITLE     The BLM dissolvasome in DNA replication and repair.
  JOURNAL   Cell Mol Life Sci 70:4067-84 (2013)
REFERENCE   PMID:21050475
  AUTHORS   Tikoo S, Sengupta S
  TITLE     Time to bloom.
  JOURNAL   Genome Integr 1:14 (2010)
REFERENCE   PMID:19661064
  AUTHORS   Kikuchi K, Abdel-Aziz HI, Taniguchi Y, Yamazoe M, Takeda S, Hirota K
  TITLE     Bloom DNA helicase facilitates homologous recombination between diverged homologous sequences.
  JOURNAL   J Biol Chem 284:26360-7 (2009)
///
ENTRY       H01347                      Disease
NAME        MELAS Syndrome;
            Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, Stroke-like episodes
DESCRIPTION MELAS Syndrome (Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) is a maternally inherited multisystem mitochondrial disorder. This disease is associated with mutations in mitochondrial DNA and a biochemical deficiency of respiratory chain complex I. About 80% of MELAS patients have an A3243G mutation in the MTTL1 gene. Other mutations in MTTL1, other mitochondrial tRNA genes, and the mitochondrial MTND subunit genes of complex I have also been reported to cause MELAS.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        MTTL1 [HSA:4567] [KO:K14228]
            MTTQ [HSA:4572] [KO:K14223]
            MTTH [HSA:4564] [KO:K14226]
            MTTK [HSA:4566] [KO:K14229]
            MTTC [HSA:4511] [KO:K14222]
            MTTS1 [HSA:4574] [KO:K14233]
            MTTS2 [HSA:4575] [KO:K14233]
            MTND1 [HSA:4535] [KO:K03878]
            MTND5 [HSA:4540] [KO:K03883]
            MTND6 [HSA:4541] [KO:K03884]
DRUG        L-arginin [DR:D02982]
            Coenzyme Q10 [DR:D01065]
DBLINKS     ICD-10: G71.3
            MeSH: D017241
            OMIM: 540000
REFERENCE   PMID:15466014
  AUTHORS   Kirby DM, McFarland R, Ohtake A, Dunning C, Ryan MT, Wilson C, Ketteridge D, Turnbull DM, Thorburn DR, Taylor RW
  TITLE     Mutations of the mitochondrial ND1 gene as a cause of MELAS.
  JOURNAL   J Med Genet 41:784-9 (2004)
REFERENCE   PMID:20649546
  AUTHORS   Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T
  TITLE     MELAS and L-arginine therapy: pathophysiology of stroke-like episodes.
  JOURNAL   Ann N Y Acad Sci 1201:104-10 (2010)
REFERENCE   PMID:21944974
  AUTHORS   Koga Y, Povalko N, Nishioka J, Katayama K, Yatsuga S, Matsuishi T
  TITLE     Molecular pathology of MELAS and L-arginine effects.
  JOURNAL   Biochim Biophys Acta 1820:608-14 (2012)
///
ENTRY       H01348                      Disease
NAME        Mitochondrial phosphate carrier deficiency (MPCD)
DESCRIPTION Mitochondrial phosphate carrier deficiency (MPCD) is a novel disorder of oxidative phosphorylation caused by mutation in the SLC25A3 gene. The mitochondrial phosphate carrier SLC25A3 transports inorganic phosphate into the mitochondrial matrix, which is essential for the aerobic synthesis of adenosine triphosphate (ATP). The patients present with severe neonatal lactic acidosis, hypertrophic cardiomyopathy and generalised muscular hypotonia.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        SLC25A3 [HSA:5250] [KO:K15102]
DBLINKS     ICD-10: G71.3
            MeSH: C563665
            OMIM: 610773
REFERENCE   PMID:17273968
  AUTHORS   Mayr JA, Merkel O, Kohlwein SD, Gebhardt BR, Bohles H, Fotschl U, Koch J, Jaksch M, Lochmuller H, Horvath R, Freisinger P, Sperl W
  TITLE     Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.
  JOURNAL   Am J Hum Genet 80:478-84 (2007)
REFERENCE   PMID:21763135
  AUTHORS   Mayr JA, Zimmermann FA, Horvath R, Schneider HC, Schoser B, Holinski-Feder E, Czermin B, Freisinger P, Sperl W
  TITLE     Deficiency of the mitochondrial phosphate carrier presenting as myopathy and cardiomyopathy in a family with three affected children.
  JOURNAL   Neuromuscul Disord 21:803-8 (2011)
///
ENTRY       H01349                      Disease
NAME        Methacrylic aciduria;
            3-Hydroxy-isobutyryl-CoA hydrolase (HIBCH) deficiency
DESCRIPTION Methacrylic aciduria is a very rare cerebral organic aciduria caused by HIBCH mutations. 3-Hydroxy-isobutyryl-CoA hydrolase (HIBCH) is a mitochondrial enzyme of valine catabolism. Patients demonstrated delayed development of motor skills, hypotonia, initial poor feeding, and a deterioration in neurological function during the first stages of life.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        HIBCH [HSA:26275] [KO:K05605]
DBLINKS     ICD-10: E71.1
            MeSH: C562803
            OMIM: 250620
REFERENCE   PMID:17160907
  AUTHORS   Loupatty FJ, Clayton PT, Ruiter JP, Ofman R, Ijlst L, Brown GK, Thorburn DR, Harris RA, Duran M, Desousa C, Krywawych S, Heales SJ, Wanders RJ
  TITLE     Mutations in the gene encoding 3-hydroxyisobutyryl-CoA hydrolase results in progressive infantile neurodegeneration.
  JOURNAL   Am J Hum Genet 80:195-9 (2007)
REFERENCE   PMID:24299452
  AUTHORS   Ferdinandusse S, Waterham HR, Heales SJ, Brown GK, Hargreaves IP, Taanman JW, Gunny R, Abulhoul L, Wanders RJ, Clayton PT, Leonard JV, Rahman S
  TITLE     HIBCH mutations can cause Leigh-like disease with combined deficiency of multiple mitochondrial respiratory chain enzymes and pyruvate dehydrogenase.
  JOURNAL   Orphanet J Rare Dis 8:188 (2013)
///
ENTRY       H01350                      Disease
NAME        Morganella morganii infection
DESCRIPTION The genera Morganella are gram-negative anaerobic rods and important opportunistic pathogens, which cause a wide variety of nosocomial infections following surgery. Morganella morganii can cause bacteremia and lead to major clinical problems, which are usually associated with common causes of catheter-associated bacteriuria, infections of the urinary and hepatobiliary tracts, wound infection, and septicemia.
CATEGORY    Infectious disease
PATHOGEN    Morganella morganii subsp. morganii KT  [GN:mmk]
DBLINKS     ICD-10: B96.4
            MeSH: D011512
REFERENCE   PMID:23282187 (description)
  AUTHORS   Chen YT, Peng HL, Shia WC, Hsu FR, Ken CF, Tsao YM, Chen CH, Liu CE, Hsieh MF, Chen HC, Tang CY, Ku TH
  TITLE     Whole-genome sequencing and identification of Morganella morganii KT pathogenicity-related genes.
  JOURNAL   BMC Genomics 13 Suppl 7:S4 (2012)
///
ENTRY       H01351                      Disease
NAME        Spastic ataxia (SPAX)
DESCRIPTION Spastic ataxia is a heterogeneous group of progressive neurodegenerative disorders, characterized by lower-limb spasticity and generalized ataxia with dysarthria, impaired ocular movements, and gait disturbance. Mostly, mutations in the mitochondrial factors cause this disease.
CATEGORY    Neurodegenerative disease
GENE        (SPAX2) KIF1C [HSA:10749] [KO:K10392]
            (SPAX3/ARSAL) MARS2 [HSA:92935] [KO:K01874] 
            (SPAX4) MTPAP [HSA:55149] [KO:K18060]
            (SPAX5) AFG3L2 [HSA:10939] [KO:K08956]
            (SPAX6/ARSACS) SACS [HSA:26278] [KO:K17592]
COMMENT     About Spastic ataxia of Charlevoix-Saguenay (SPAX6/ARSACS), please refer to H01170.
DBLINKS     ICD-10: G11.4
            MeSH: C564815
            OMIM: 108600 611302 611390 613672 614487 270550
REFERENCE   PMID:11774073
  AUTHORS   Meijer IA, Hand CK, Grewal KK, Stefanelli MG, Ives EJ, Rouleau GA
  TITLE     A locus for autosomal dominant hereditary spastic ataxia, SAX1, maps to chromosome 12p13.
  JOURNAL   Am J Hum Genet 70:763-9 (2002)
REFERENCE   PMID:24319291 (SPAX2)
  AUTHORS   Dor T, Cinnamon Y, Raymond L, Shaag A, Bouslam N, Bouhouche A, Gaussen M, Meyer V, Durr A, Brice A, Benomar A, Stevanin G, Schuelke M, Edvardson S
  TITLE     KIF1C mutations in two families with hereditary spastic paraparesis and cerebellar dysfunction.
  JOURNAL   J Med Genet 51:137-42 (2014)
REFERENCE   PMID:16672289 (SPAX3, SPAX6)
  AUTHORS   Thiffault I, Rioux MF, Tetreault M, Jarry J, Loiselle L, Poirier J, Gros-Louis F, Mathieu J, Vanasse M, Rouleau GA, Bouchard JP, Lesage J, Brais B
  TITLE     A new autosomal recessive spastic ataxia associated with frequent white matter changes maps to 2q33-34.
  JOURNAL   Brain 129:2332-40 (2006)
REFERENCE   PMID:22448145 (SPAX3)
  AUTHORS   Bayat V, Thiffault I, Jaiswal M, Tetreault M, Donti T, Sasarman F, Bernard G, Demers-Lamarche J, Dicaire MJ, Mathieu J, Vanasse M, Bouchard JP, Rioux MF, Lourenco CM, Li Z, Haueter C, Shoubridge EA, Graham BH, Brais B, Bellen HJ
  TITLE     Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans.
  JOURNAL   PLoS Biol 10:e1001288 (2012)
REFERENCE   PMID:20970105 (SPAX4)
  AUTHORS   Crosby AH, Patel H, Chioza BA, Proukakis C, Gurtz K, Patton MA, Sharifi R, Harlalka G, Simpson MA, Dick K, Reed JA, Al-Memar A, Chrzanowska-Lightowlers ZM, Cross HE, Lightowlers RN
  TITLE     Defective mitochondrial mRNA maturation is associated with spastic ataxia.
  JOURNAL   Am J Hum Genet 87:655-60 (2010)
REFERENCE   PMID:22022284 (SPAX5)
  AUTHORS   Pierson TM, Adams D, Bonn F, Martinelli P, Cherukuri PF, Teer JK, Hansen NF, Cruz P, Mullikin For The Nisc Comparative Sequencing Program JC, Blakesley RW, Golas G, Kwan J, Sandler A, Fuentes Fajardo K, Markello T, Tifft C, Blackstone C, Rugarli EI, Langer T, Gahl WA, Toro C
  TITLE     Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases.
  JOURNAL   PLoS Genet 7:e1002325 (2011)
///
ENTRY       H01352                      Disease
NAME        Mitochondrial trifunctional protein (TFP) deficiency, including:
            Long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency
DESCRIPTION Mitochondrial trifunctional protein (TFP) deficiency is a rare autosomal recessive disorder that is caused by mutations in HADHA and HADHB. TFP is a multienzyme complex of the fatty acid beta-oxidation cycle. Human TFP is an octamer composed of four alpha-subunits harboring long-chain enoyl-CoA hydratase and long-chain L-3-hydroxyacyl-CoA dehydrogenase and four beta-subunits encoding long-chain 3-ketoacyl-CoA thiolase. This disease includes a lethal neonatal phenotype with cardiomyopathy and Reye-like syndrome, an infantile hepatic phenotype with recurrent hypoketotic hypoglycemia, and a childhood or adolescent-onset neuromyopathic phenotype with peripheral neuropathy and recurrent rhabdomyolysis.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        HADHA [HSA:3030] [KO:K07515]
            HADHB [HSA:3032] [KO:K07509]
DRUG        medium-chain triglyceride
DBLINKS     ICD-10: E71.3
            MeSH: C566945
            OMIM: 609015 609016
REFERENCE   PMID:14630990
  AUTHORS   Spiekerkoetter U, Khuchua Z, Yue Z, Bennett MJ, Strauss AW
  TITLE     General mitochondrial trifunctional protein (TFP) deficiency as a result of either alpha- or beta-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover.
  JOURNAL   Pediatr Res 55:190-6 (2004)
REFERENCE   PMID:12621125
  AUTHORS   Jones PM, Butt Y, Bennett MJ
  TITLE     Accumulation of 3-hydroxy-fatty acids in the culture medium of long-chain L-3-hydroxyacyl CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein-deficient skin fibroblasts: implications for medium chain triglyceride dietary treatment of LCHAD deficiency.
  JOURNAL   Pediatr Res 53:783-7 (2003)
REFERENCE   PMID:23868323
  AUTHORS   Liewluck T, Mundi MS, Mauermann ML
  TITLE     Mitochondrial trifunctional protein deficiency: a rare cause of adult-onset rhabdomyolysis.
  JOURNAL   Muscle Nerve 48:989-91 (2013)
REFERENCE   PMID:9739053
  AUTHORS   Ibdah JA, Tein I, Dionisi-Vici C, Bennett MJ, IJlst L, Gibson B, Wanders RJ, Strauss AW
  TITLE     Mild trifunctional protein deficiency is associated with progressive neuropathy and myopathy and suggests a novel genotype-phenotype correlation.
  JOURNAL   J Clin Invest 102:1193-9 (1998)
///
ENTRY       H01353                      Disease
NAME        Chromobacterium violaceum infection
DESCRIPTION Chromobacterium violaceum is a gram-negative, facultative anaerobic, opportunistic pathogenic bacterium that infects both humans and animals. The major symptoms in most of the cases with fatal results seem to be sepsis, multiple liver abscesses, and diffuse pustular dermatitis. Some studies have reported instances of untreated C. violaceum causing brain abscess and diarrhea. Recent findings indicate that the type III secretion system (T3SS) encoded by Chromobacterium pathogenicity islands 1 and 1a (Cpi-1/-1a) is critical for C. violaceum pathogenesis.
CATEGORY    Infectious disease
PATHOGEN    Chromobacterium violaceum ATCC 12472 [GN:cvi]
DBLINKS     ICD-10: A41.5
            MeSH: D016870
REFERENCE   PMID:21435035 (description)
  AUTHORS   Miki T, Akiba K, Iguchi M, Danbara H, Okada N
  TITLE     The Chromobacterium violaceum type III effector CopE, a guanine nucleotide exchange factor for Rac1 and Cdc42, is involved in bacterial invasion of epithelial cells and pathogenesis.
  JOURNAL   Mol Microbiol 80:1186-203 (2011)
REFERENCE   PMID:14500782 (description)
  AUTHORS   Brazilian National Genome Project Consortium.
  TITLE     The complete genome sequence of Chromobacterium violaceum reveals remarkable and exploitable bacterial adaptability.
  JOURNAL   Proc Natl Acad Sci U S A 100:11660-5 (2003)
REFERENCE   PMID:23776815 (description)
  AUTHORS   Kumar MR
  TITLE     Chromobacterium violaceum: A rare bacterium isolated from a wound over the scalp.
  JOURNAL   Int J Appl Basic Med Res 2:70-2 (2012)
///
ENTRY       H01354                      Disease
NAME        Leigh syndrome, including:
            Leigh syndrome, French-Canadian type (LSFC);
            X-linked Leigh syndrome
DESCRIPTION Leigh syndrome is a severe neurological disorder, characterized by bilaterally symmetrical necrotic lesions in the basal ganglia and brainstem. Most frequently the central nervous system is affected, with psychomotor retardation, seizures, nystagmus, optic atrophy, ataxia, or respiratory failure. Some patients also present with peripheral nervous system involvement or non-neurologic abnormalities. In the majority of cases, dysfunction of the mitochondrial respiratory chain complex or of the pyruvate dehydrogenase complex are responsible for the disease. Patterns of inheritance include X-linked recessive, autosomal recessive, and mitochondrial.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease; Mitochondrial disease
GENE        NDUFS3 [HSA:4722] [KO:K03936]
            NDUFS4 [HSA:4724] [KO:K03937]
            NDUFS7 [HSA:374291] [KO:K03940]
            NDUFS8 [HSA:4728] [KO:K03941]
            NDUFA2 [HSA:4695] [KO:K03946]
            NDUFA9 [HSA:4704] [KO:K03953]
            NDUFA10 [HSA:4705] [KO:K03954]
            NDUFA12 [HSA:55967] [KO:K11352]
            NDUFAF2 [HSA:91942] [KO:K18160]
            NDUFAF6 [HSA:137682] [KO:K18163]
            FOXRED1 [HSA:55572] [KO:K18166]
            SDHA [HSA:6389] [KO:K00234]
            COX10 [HSA:1352] [KO:K02257]
            COX15 [HSA:1355] [KO:K02259]
            SURF1 [HSA:6834] [KO:K14998]
            BCS1L [HSA:617] [KO:K08900]
            TACO1 [HSA:51204] [KO:K18189]
            (LSFC) LRPPRC [HSA:10128] [KO:K17964]
            (X-linked) PDHA1 [HSA:5160] [KO:K00161]
MARKER      (Cerebrospinal Fluid)
            Lactate [CPD:C00186] 
            Pyruvate [CPD:C00022]
DRUG        Thiamine [DR:D08580]
            Co-enzyme Q [DR:D01065]
            Vitamin E [DR:D02331]
            Vitamin C [DR:D00018]
            Carnitine [DR:D02176]
DBLINKS     ICD-10: G31.8
            MeSH: D007888
            OMIM: 256000 220111 308930
REFERENCE   PMID:18805359
  AUTHORS   Finsterer J
  TITLE     Leigh and Leigh-like syndrome in children and adults.
  JOURNAL   Pediatr Neurol 39:223-35 (2008)
REFERENCE   PMID:21150889
  AUTHORS   Hoefs SJ, van Spronsen FJ, Lenssen EW, Nijtmans LG, Rodenburg RJ, Smeitink JA, van den Heuvel LP
  TITLE     NDUFA10 mutations cause complex I deficiency in a patient with Leigh disease.
  JOURNAL   Eur J Hum Genet 19:270-4 (2011)
REFERENCE   PMID:23389837
  AUTHORS   Mermigkis C, Bouloukaki I, Mastorodemos V, Plaitakis A, Alogdianakis V, Siafakas N, Schiza S
  TITLE     Medical treatment with thiamine, coenzyme Q, vitamins E and C, and carnitine improved obstructive sleep apnea in an adult case of Leigh disease.
  JOURNAL   Sleep Breath 17:1129-35 (2013)
REFERENCE   PMID:19503089
  AUTHORS   Weraarpachai W, Antonicka H, Sasarman F, Seeger J, Schrank B, Kolesar JE, Lochmuller H, Chevrette M, Kaufman BA, Horvath R, Shoubridge EA
  TITLE     Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome.
  JOURNAL   Nat Genet 41:833-7 (2009)
///
ENTRY       H01355                      Disease
NAME        Kearns-Sayre Syndrome
DESCRIPTION Kearns-Sayre Syndrome is a multisystem disorder characterized by ophthalmoplegia, pigmentary retinopathy, heart block, and cerebellar ataxia. This disease is caused by various large-scale deletions of mitochondrial DNA.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        MT-ATP6 [HSA:4508] [KO:K02126]
            MT-ATP8 [HSA:4509] [KO:K02125]
            MT-CO3 [HSA:4514] [KO:K02262]
            MT-CYB [HSA:4519] [KO:K00412]
            MT-ND3 [HSA:4537] [KO:K03880]
            MT-ND4 [HSA:4538] [KO:K03881]
            MT-ND4L [HSA:4539] [KO:K03882]
            MT-ND5 [HSA:4540] [KO:K03883]
            MT-ND6 [HSA:4541] [KO:K03884]
DBLINKS     ICD-10: H49.8
            MeSH: D007625
            OMIM: 530000
REFERENCE   PMID:23421922
  AUTHORS   Obara-Moszynska M, Maceluch J, Bobkowski W, Baszko A, Jaremba O, Krawczynski MR, Niedziela M
  TITLE     A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment.
  JOURNAL   BMC Pediatr 13:27 (2013)
REFERENCE   PMID:9727847
  AUTHORS   Boles RG, Roe T, Senadheera D, Mahnovski V, Wong LJ
  TITLE     Mitochondrial DNA deletion with Kearns Sayre syndrome in a child with Addison disease.
  JOURNAL   Eur J Pediatr 157:643-7 (1998)
///
ENTRY       H01356                      Disease
NAME        Myoclonic Epilepsy and Ragged-Red Fiber Disease;
            MERRF syndrome;
            Fukuhara syndrome
DESCRIPTION Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF) is a mitochondrial encephalomyopathy characterized by myoclonic seizures, cerebellar ataxia, myopathy, and ragged-red fibers (RRFs) on muscle biopsy. RRFs are muscle fibers with subsarcolemmal mitochondria that stained red with Gomori trichrome stain. The MERRF syndrome is most commonly caused by the A8344G mutation in the mitochondrial tRNA Lys gene.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        MTTK [HSA:4566] [KO:K14229]
            MTTL1 [HSA:4567] [KO:K14228]
            MTTH [HSA:4564] [KO:K14226]
            MTTS1 [HSA:4574] [KO:K14233]
            MTTS2 [HSA:4575] [KO:K14233]
            MTTF [HSA:4558] [KO:K14231]
            MTND5 [HSA:4540] [KO:K03883]
DBLINKS     ICD-10: G71.3
            MeSH: D017243
            OMIM: 545000
REFERENCE   PMID:1910259
  AUTHORS   Noer AS, Sudoyo H, Lertrit P, Thyagarajan D, Utthanaphol P, Kapsa R, Byrne E, Marzuki S
  TITLE     A tRNA(Lys) mutation in the mtDNA is the causal genetic lesion underlying myoclonic epilepsy and ragged-red fiber (MERRF) syndrome.
  JOURNAL   Am J Hum Genet 49:715-22 (1991)
REFERENCE   PMID:24338029
  AUTHORS   Liu K, Zhao H, Ji K, Yan C
  TITLE     MERRF/MELAS overlap syndrome due to the m.3291T&gt;C mutation.
  JOURNAL   Metab Brain Dis 29:139-44 (2014)
///
ENTRY       H01357                      Disease
NAME        Allergic contact dermatitis
DESCRIPTION Allergic contact dermatitis (ACD) is a T-cell mediated skin inflammation caused by repeated skin exposure to contact allergens. Although regarded as a dermatosis that is typically triggered by environmental factors, ACD may affect certain individuals more easily than others. A higher risk for polysensitization has been found for polymorphism in the TNFA (TNFA-308) and IL-16 (IL-16-295 C/C) genes.
CATEGORY    Immune system disease
GENE        TNFA (polymorphism) [HSA:712] [KO:K03986]
            IL-16 (polymorphism) [HSA:3603]
ENV_FACTOR  Nickel [CPD:C00291]
            Fragrances
            Cobalt [CPD:C00175]
            Chrominium [CPD:C06268]
            Peru balsam
            Neomycin [CPD:C00384]
            Rubber [CPD:C02321]
DRUG        Fluocinonide [DR:D00325]
            Clobetasol [DG:DG00422]
            Halobetasol [DR:D08660]
            Triamcinolone [DG:DG00010]
            Amcinonide [DR:D01387]
            Desoximetasone [DR:D03697]
            Desonide ointment [DR:D03696]
DBLINKS     ICD-10: L23
            MeSH: D017449
REFERENCE   PMID:19834255 (gene, description)
  AUTHORS   Kezic S, Visser MJ, Verberk MM
  TITLE     Individual susceptibility to occupational contact dermatitis.
  JOURNAL   Ind Health 47:469-78 (2009)
REFERENCE   PMID:21166814 (gene)
  AUTHORS   Schnuch A, Westphal G, Mossner R, Uter W, Reich K
  TITLE     Genetic factors in contact allergy--review and future goals.
  JOURNAL   Contact Dermatitis 64:2-23 (2011)
REFERENCE   PMID:12694213 (gene, description)
  AUTHORS   Westphal GA, Schnuch A, Moessner R, Konig IR, Kranke B, Hallier E, Ziegler A, Reich K
  TITLE     Cytokine gene polymorphisms in allergic contact dermatitis.
  JOURNAL   Contact Dermatitis 48:93-8 (2003)
REFERENCE   PMID:21489368 (description)
  AUTHORS   Toncic RJ, Lipozencic J, Martinac I, Greguric S
  TITLE     Immunology of allergic contact dermatitis.
  JOURNAL   Acta Dermatovenerol Croat 19:51-68 (2011)
REFERENCE   PMID:19447733 (description)
  AUTHORS   Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF
  TITLE     Allergic and irritant contact dermatitis.
  JOURNAL   Eur J Dermatol 19:325-32 (2009)
REFERENCE   PMID:11173201 (description, env_factor)
  AUTHORS   Wolf R, Wolf D
  TITLE     Contact dermatitis.
  JOURNAL   Clin Dermatol 18:661-6 (2000)
REFERENCE   PMID:15243515 (env_factor)
  AUTHORS   Cohen DE
  TITLE     Contact dermatitis: a quarter century perspective.
  JOURNAL   J Am Acad Dermatol 51:S60-3 (2004)
REFERENCE   PMID:24193097 (env_factor)
  AUTHORS   Macan J, Rimac D, Kezic S, Varnai VM
  TITLE     Occupational and non-occupational allergic contact dermatitis: a follow-up study.
  JOURNAL   Dermatology 227:321-9 (2013)
REFERENCE   PMID:20672788 (drug)
  AUTHORS   Usatine RP, Riojas M
  TITLE     Diagnosis and management of contact dermatitis.
  JOURNAL   Am Fam Physician 82:249-55 (2010)
REFERENCE   (drug)
  AUTHORS   Papadakis MA, McPhee SJ, Rabow MW (ed).
  TITLE     Current Medical Diagnosis & Treatment 2013, Fifty-Second Edition
  JOURNAL   The McGraw-Hill Companies, Inc. (2013)
///
ENTRY       H01358                      Disease
NAME        Atopic dermatitis
DESCRIPTION Atopic dermatitis (AD) is a relapsing chronic inflammatory skin disease characterized by eczematous skin lesions and intense pruritus. A genetic defect in the filaggrin (FLG) protein and/or environmental factors are thought to cause AD by disrupting the epidermis. This disruption, in turn, results in contact between immune cells in the dermis and antigens from the external environment leading to intense itching, scratching, and inflammation. Apart from FLG, recent genome-wide association studies (GWASs)  have identified many susceptibility loci of atopic dermatitis with genome-wide significance.
CATEGORY    Immune system disease
GENE        FLG (mutation) [HSA:2312]
            IL4 (polymorphism) [HSA:3656] [KO:K04731]
            IL4RA (polymorphism) [HSA:3566] [KO:K05071]
            SPINK5 (polymorphism) [HSA:11005]
            IL13 (polymorphism) [HSA:3596] [KO:K05435]
            RANTES (polymorphism) [HSA:6352] [KO:K12499]
            NOD1 (polymorphism) [HSA:10392] [KO:K08727]
            CARD15 (polymorphism) [HSA:64127] [KO:K10165]
            TLR-2 (polymorphism) [HSA:7097] [KO:K10159]
            TLR-9 (polymorphism) [HSA:54106] [KO:K10161]
            COL29A1 (polymorphism) [HSA:256076] [KO:K06238]
ENV_FACTOR  Soap
            Detergent
            Proteases from house dust mites
            Topical corticosteroids
PATHOGEN    Staphylococcus aureus
DRUG        Clobetasol [DG:DG00422]
            Halobetasol propionate [DR:D04409]
            Betamethasone [DG:DG00095]
            Desoximetasone [DR:D03697]
            Fluocinonide [DR:D00325]
            Betamethasone [DG:DG00095]
            Fluticasone [DG:DG00420]
            Triamcinolone [DG:DG00010]
            Hydrocortisone [DG:DG00012]
            Mometasone [DG:DG00419]
            Cyclosporin [DR:D00184]
            Azathioprine [DG:DG00743]
            Methotrexate [DG:DG00681]
            Mycophenolate mofeti [DR:D00752]
            Alitretinoin [DR:D02815]
            Prednisolone [DG:DG00093]
DBLINKS     ICD-10: L20
            MeSH: D003876
            OMIM: 605803
REFERENCE   PMID:23473856 (gene, description)
  AUTHORS   Kabashima K
  TITLE     New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity.
  JOURNAL   J Dermatol Sci 70:3-11 (2013)
REFERENCE   PMID:23439055 (gene, description)
  AUTHORS   Tamari M, Tanaka S, Hirota T
  TITLE     Genome-wide association studies of allergic diseases.
  JOURNAL   Allergol Int 62:21-8 (2013)
REFERENCE   PMID:21518425 (gene)
  AUTHORS   Bussmann C, Weidinger S, Novak N
  TITLE     Genetics of atopic dermatitis.
  JOURNAL   J Dtsch Dermatol Ges 9:670-6 (2011)
REFERENCE   PMID:20109730 (gene)
  AUTHORS   Barnes KC
  TITLE     An update on the genetics of atopic dermatitis: scratching the surface in 2009.
  JOURNAL   J Allergy Clin Immunol 125:16-29.e1-11; quiz 30-1 (2010)
REFERENCE   PMID:22962911 (description)
  AUTHORS   Berke R, Singh A, Guralnick M
  TITLE     Atopic dermatitis: an overview.
  JOURNAL   Am Fam Physician 86:35-42 (2012)
REFERENCE   PMID:16815133 (env_factor)
  AUTHORS   Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R
  TITLE     New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions.
  JOURNAL   J Allergy Clin Immunol 118:3-21; quiz 22-3 (2006)
REFERENCE   PMID:22586797 (drug)
  AUTHORS   Cookson H, Smith C
  TITLE     Systemic treatment of adult atopic dermatitis.
  JOURNAL   Clin Med 12:172-6 (2012)
REFERENCE   PMID:20070141 (drug)
  AUTHORS   Simpson EL
  TITLE     Atopic dermatitis: a review of topical treatment options.
  JOURNAL   Curr Med Res Opin 26:633-40 (2010)
REFERENCE   PMID:24354911 (drug)
  AUTHORS   Simon D, Bieber T
  TITLE     Systemic therapy for atopic dermatitis.
  JOURNAL   Allergy 69:46-55 (2014)
///
ENTRY       H01359                      Disease
NAME        Anaphylaxis
DESCRIPTION Anaphylaxis is a severe, life-threatening, systemic allergic reaction that is almost always unanticipated and may lead to death by airway obstruction or vascular collapse. Anaphylaxis can be triggered by a broad range of triggers. Food is the commonest trigger in children and drugs the commonest in adults. In addition to the environmental influences, studies suggest that a complex of genes affects the anaphylactic response. Anaphylaxis occurs as the result of an allergen response, usually immunoglobulin E-mediated, which leads to mast cell and basophil activation and a combination of dermatologic, respiratory, cardiovascular, gastrointestinal, and neurologic symptoms.
CATEGORY    Immune system disease
GENE        c-KIT (mutation) [HSA:3815] [KO:K05091]
            NLRP3 (polymorphism) [HSA:114548] [KO:K12800]
            IL-10 (polymorphism) [HSA:3586] [KO:K05443]
ENV_FACTOR  Milk
            Egg
            Fish
            Peanut
            Tree nut
            Sesame
            Shellfish
            Food additives
            Penicillin [DR:D05411]
            Cephalosporin [CPD:C00875]
            Vanomycin
            Bee
            Wasp
            Fire ants
            Aspirin [DR:D00109]
            Latex
DRUG        Epinephrine [DG:DG00013]
            Albuterol [DR:D02147]
            Diphenhydramine [DG:DG00390]
            Ranitidine [DG:DG00018]
            Prednisone [DG:DG00094]
            Methylprednisolone [DG:DG00410]
DBLINKS     MeSH: D000707
REFERENCE   PMID:20560905 (gene, description, env_factor)
  AUTHORS   Ben-Shoshan M, Clarke AE
  TITLE     Anaphylaxis: past, present and future.
  JOURNAL   Allergy 66:1-14 (2011)
REFERENCE   PMID:22085665 (description, env_factor, drug)
  AUTHORS   Arnold JJ, Williams PM
  TITLE     Anaphylaxis: recognition and management.
  JOURNAL   Am Fam Physician 84:1111-8 (2011)
REFERENCE   PMID:20236436 (description, env_factor)
  AUTHORS   Younker J, Soar J
  TITLE     Recognition and treatment of anaphylaxis.
  JOURNAL   Nurs Crit Care 15:94-8 (2010)
REFERENCE   PMID:20176258 (env_factor)
  AUTHORS   Simons FE
  TITLE     Anaphylaxis.
  JOURNAL   J Allergy Clin Immunol 125:S161-81 (2010)
REFERENCE   PMID:21682750 (drug)
  AUTHORS   Boden SR, Wesley Burks A
  TITLE     Anaphylaxis: a history with emphasis on food allergy.
  JOURNAL   Immunol Rev 242:247-57 (2011)
///
ENTRY       H01360                      Disease
NAME        Allergic rhinitis
DESCRIPTION Allergic rhinitis (AR) is an inflammation of nasal mucosa mediated by IgE-associated processes, which is characterised by pruritus, sneezing, rhinorrhoea, and nasal congestion. The development of AR entails a complex interaction between genetic predisposition and environmental exposure to different factors, of which the most important is the implicated allergen. Single-nucleotide polymorphism studies involving genes encoding for molecules implicated in the pathogenesis of AR have also been made. Such molecules comprise chemokines and their receptors, interleukins and their receptors, eosinophil peroxidase and leukotrienes, among others.
CATEGORY    Immune system disease
GENE        GATA3 (polymorphism) [HSA:2625] [KO:K17895]
            IL-13 (polymorphism) [HSA:3596] [KO:K05435]
            IL-18 (polymorphism) [HSA:3606] [KO:K05482]
            IL-28RA (polymorphism) [HSA:163702] [KO:K05140]
            EPO (polymorphism) [HSA:2056] [KO:K05437]
            CCXCR1 (polymorphism) [HSA:2829] [KO:K04193]
            CCR1 (polymorphism) [HSA:1230] [KO:K04176]
            CCR2 (polymorphism) [HSA:729230] [KO:K04177]
            CCR3 (polymorphism) [HSA:1232] [KO:K04178]
            CCR5 (polymorphism) [HSA:1234] [KO:K04180]
            SDAD1 (polymorphism) [HSA:55153] [KO:K14856]
            CXCL9 (polymorphism) [HSA:4283] [KO:K05416]
            CXCL10 (polymorphism) [HSA:3627] [KO:K12671]
            CXCL11 (polymorphism) [HSA:6373] [KO:K12672]
            RANTES (polymorphism) [HSA:6352] [KO:K12499]
            Eotaxin-3 (polymorphism) [HSA:10344] [KO:K21096]
            CD14 (polymorphism) [HSA:929] [KO:K04391]
            FOXJ1 (polymorphism) [HSA:2302] [KO:K09402]
            FCGR2A (polymorphism) [HSA:2212] [KO:K06472]
ENV_FACTOR  Dust mite
            Mold
            Animal dander
            Cockroach
            Tree, Grass, and weed pollens
DRUG        Azelastine [DG:DG01036]
            Olopatadine [DG:DG01039]
            Diphenhydramine [DG:DG00390]
            Chlorpheniramine maleate [DR:D00665]
            Hydroxyzine [DG:DG00912]
            Loratadine [DR:D00364]
            Desloratidine [DR:D03693]
            Cetirizine [DG:DG01107]
            Fexofenadine [DG:DG01117]
            Beclomethasone dipropionate [DR:D00689]
            Triamcinolone [DG:DG00010]
            Flunisolide [DG:DG01040]
            Mometasone [DG:DG00419]
            Budesonide [DR:D00246]
            Fluticasone [DG:DG00420]
            Prednisolone [DG:DG00093]
            Prednisone [DG:DG00094]
            Dexamethasone [DG:DG00011]
            Hydrocortisone [DG:DG00012]
            Betamethasone [DG:DG00095]
            Montelukast [DG:DG01066]
            Oxymetazoline [DG:DG01029]
            Xylometazoline [DG:DG01031]
            Pseudoephedrine [DG:DG01042]
            Phenylephrine [DG:DG00215]
            Cromolyn sodium [DR:D00526]
            Ipratropium bromide [DR:D02212]
DBLINKS     ICD-10: J30
            MeSH: C567078
            OMIM: 607154
REFERENCE   PMID:19476051 (gene, description)
  AUTHORS   Davila I, Mullol J, Ferrer M, Bartra J, del Cuvillo A, Montoro J, Jauregui I, Sastre J, Valero A
  TITLE     Genetic aspects of allergic rhinitis.
  JOURNAL   J Investig Allergol Clin Immunol 19 Suppl 1:25-31 (2009)
REFERENCE   PMID:22053313 (gene)
  AUTHORS   Pawankar R, Mori S, Ozu C, Kimura S
  TITLE     Overview on the pathomechanisms of allergic rhinitis.
  JOURNAL   Asia Pac Allergy 1:157-67 (2011)
REFERENCE   PMID:21913195 (env_factor)
  AUTHORS   Mucci T, Govindaraj S, Tversky J
  TITLE     Allergic rhinitis.
  JOURNAL   Mt Sinai J Med 78:634-44 (2011)
REFERENCE   PMID:21783242 (description, env_factor, drug)
  AUTHORS   Greiner AN, Hellings PW, Rotiroti G, Scadding GK
  TITLE     Allergic rhinitis.
  JOURNAL   Lancet 378:2112-22 (2011)
REFERENCE   PMID:21784174 (description, env_factor, drug)
  AUTHORS   Mandhane SN, Shah JH, Thennati R
  TITLE     Allergic rhinitis: an update on disease, present treatments and future prospects.
  JOURNAL   Int Immunopharmacol 11:1646-62 (2011)
REFERENCE   PMID:18360551 (env_factor)
  AUTHORS   Wang DY
  TITLE     Risk factors of allergic rhinitis: genetic or environmental?
  JOURNAL   Ther Clin Risk Manag 1:115-23 (2005)
REFERENCE   PMID:24535140 (drug)
  AUTHORS   Braido F, Arcadipane F, Marugo F, Hayashi M, Pawankar R
  TITLE     Allergic rhinitis: current options and future perspectives.
  JOURNAL   Curr Opin Allergy Clin Immunol 14:168-76 (2014)
///
ENTRY       H01361                      Disease
NAME        Eosinophilic esophagitis
DESCRIPTION Eosinophilic esophagitis (EoE) is a chronic immune and antigen-mediated clinicopathologic disease that is characterized by eosinophil infiltration into the esophageal epithelium and results in esophageal fibrosis and dysfunction. Several factors contribute to the development of EoE, including genetic predisposition, history of allergies, and presence of environmental and food allergens. Recently, an association between a single nuclear polymorphism (SNP) in the gene encoding thymic stromal lymphopoietin (TSLP) or eotaxin-3 (CCL-26) and risk for EoE was found.
CATEGORY    Immune system disease
GENE        TSLP (polymorphism) [HSA:85480] [KO:K05436] 
            CCL-26 (polymorphism) [HSA:10344] [KO:K21096]
ENV_FACTOR  Milk
            Wheat
            Egg
            Soy
            Fish
            Peanut
            Dust mites
            Aspergillus fumigatus [GN:afm]
            Alternaria alternata
            Ragweed pollen
DRUG        Omeprazole [DG:DG00020]
            Lansoprazole [DR:D00355]
            Pantoprazole [DG:DG00021]
            Esomeprazole [DG:DG00023]
            Rabeprazole [DG:DG00022]
            Fluticasone [DG:DG00420]
            Budesonide [DR:D00246]
DBLINKS     MeSH: D057765
REFERENCE   PMID:22313241 (gene, env_factor)
  AUTHORS   Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I, Schoepfer AM, Simon D, Simon HU
  TITLE     Pediatric and adult eosinophilic esophagitis: similarities and differences.
  JOURNAL   Allergy 67:477-90 (2012)
REFERENCE   PMID:21228772 (gene)
  AUTHORS   Mulder DJ, Justinich CJ
  TITLE     Understanding eosinophilic esophagitis: the cellular and molecular mechanisms of  an emerging disease.
  JOURNAL   Mucosal Immunol 4:139-47 (2011)
REFERENCE   PMID:17088129 (gene)
  AUTHORS   Blanchard C, Wang N, Rothenberg ME
  TITLE     Eosinophilic esophagitis: pathogenesis, genetics, and therapy.
  JOURNAL   J Allergy Clin Immunol 118:1054-9 (2006)
REFERENCE   PMID:24566295 (gene, description)
  AUTHORS   Merves J, Muir A, Modayur Chandramouleeswaran P, Cianferoni A, Wang ML, Spergel JM
  TITLE     Eosinophilic esophagitis.
  JOURNAL   Ann Allergy Asthma Immunol (2014)
REFERENCE   PMID:23130328 (env_factor)
  AUTHORS   Ridolo E, Montagni M, Olivieri E, Rogkakou A, De' Angelis GL, Canonica GW
  TITLE     Eosinophilic esophagitis: which role for food and inhalant allergens?
  JOURNAL   Asia Pac Allergy 2:237-41 (2012)
REFERENCE   PMID:21991511 (env_factor)
  AUTHORS   Shahzad G, Mustacchia P, Frieri M
  TITLE     Role of mucosal inflammation in eosinophilic esophagitis: review of the literature.
  JOURNAL   ISRN Gastroenterol 2011:468073 (2011)
REFERENCE   PMID:23001405 (drug, description)
  AUTHORS   Redd M, Schey R
  TITLE     Eosinophilic esophagitis: current treatment.
  JOURNAL   Dig Dis Sci 58:613-20 (2013)
REFERENCE   PMID:22034864 (drug)
  AUTHORS   Abonia JP, Rothenberg ME
  TITLE     Eosinophilic esophagitis: rapidly advancing insights.
  JOURNAL   Annu Rev Med 63:421-34 (2012)
REFERENCE   (drug)
  AUTHORS   Papadakis MA, McPhee SJ, Rabow MW (ed).
  TITLE     Current Medical Diagnosis & Treatment 2013, Fifty-Second Edition
  JOURNAL   The McGraw-Hill Companies, Inc. (2013)
///
ENTRY       H01362                      Disease
NAME        Dermatitis herpetiformis
DESCRIPTION Dermatitis herpetiformis (DH) is a chronic, polymorphic, pruritic skin disease that develops mostly in patients with latent gluten-sensitive enteropathy. There is an association with the genotypes HLA DR3, HLA DQw2, found in 80-90% of cases. Owing to the granular immunoglobulin (Ig) A deposition at the tips of the papillary dermis and to the subepidermal blister formation associated with neutrophilic accumulations underlying the basement membrane, DH is considered to be an autoimmune blistering disease.
CATEGORY    Immune system disease
GENE        HLA-DQA1 [HSA:3117] [KO:K06752]
            HLA-DQB1 [HSA:3119] [KO:K06752]
            HLA-DR3
            HLA-B8
ENV_FACTOR  Gluten
DRUG        Dapsone [DR:D00592]
            Sulfapyridine [DR:D02434]
            Sulfapyridine [DR:D02434]
            Sulfamethoxypyridine
            Colobetasol propionate
            Antihistamines
DBLINKS     ICD-10: L13.0
REFERENCE   PMID:22811741 (gene, env_factor)
  AUTHORS   Nakajima K
  TITLE     Recent advances in dermatitis herpetiformis.
  JOURNAL   Clin Dev Immunol 2012:914162 (2012)
REFERENCE   PMID:24068131 (gene, description, env_factor)
  AUTHORS   Mendes FB, Hissa-Elian A, de Abreu MA, Goncalves VS
  TITLE     Review: dermatitis herpetiformis.
  JOURNAL   An Bras Dermatol 88:594-9 (2013)
REFERENCE   PMID:22137227 (gene, description, env_factor)
  AUTHORS   Karpati S
  TITLE     Dermatitis herpetiformis.
  JOURNAL   Clin Dermatol 30:56-9 (2012)
REFERENCE   PMID:21571168 (gene, drug)
  AUTHORS   Bolotin D, Petronic-Rosic V
  TITLE     Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis.
  JOURNAL   J Am Acad Dermatol 64:1027-33; quiz 1033-4 (2011)
REFERENCE   PMID:23674144 (drug)
  AUTHORS   Plotnikova N, Miller JL
  TITLE     Dermatitis herpetiformis.
  JOURNAL   Skin Therapy Lett 18:1-3 (2013)
REFERENCE   PMID:19470076 (drug)
  AUTHORS   Caproni M, Antiga E, Melani L, Fabbri P
  TITLE     Guidelines for the diagnosis and treatment of dermatitis herpetiformis.
  JOURNAL   J Eur Acad Dermatol Venereol 23:633-8 (2009)
///
ENTRY       H01363                      Disease
NAME        NARP syndrome;
            Neuropathy ataxia and retinis pigmentosa
DESCRIPTION Neuropathy ataxia and retinis pigmentosa (NARP syndrome) is a mitochondrial disorder characterized by retinal, central and peripheral neurodegeneration. Point mutations of the mitochondrial DNA ATPase 6 gene cause this disease.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease; Mitochondrial disease
GENE        MT-ATP6 [HSA:4508] [KO:K02126]
DBLINKS     ICD-10: G31.8
            MeSH: C537396
            OMIM: 551500
REFERENCE   PMID:20953793
  AUTHORS   Gelfand JM, Duncan JL, Racine CA, Gillum LA, Chin CT, Zhang Y, Zhang Q, Wong LJ, Roorda A, Green AJ
  TITLE     Heterogeneous patterns of tissue injury in NARP syndrome.
  JOURNAL   J Neurol 258:440-8 (2011)
///
ENTRY       H01364                      Disease
NAME        3-Hydroxyacyl-CoA dehydrogenase deficiency;
            HADH deficiency;
            SCHAD deficiency
DESCRIPTION 3-Hydroxyacyl-CoA dehydrogenase (HADH, SCHAD) deficiency is an autosomal recessive metabolic disorder, resulting from mutations in the HADH gene. HADH deficiency is one of the mitochondrial fatty acid oxidation disorder that has been the most recently described only in a few patients. The clinical phenotype of most patients that have been described is recurrent hypoglycemia associated with hyperinsulinism.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        HADH [HSA:3033] [KO:K00022]
MARKER      Elevated C4-OH acylcarnitine
DBLINKS     ICD-10: E71.3
            MeSH: C535310
            OMIM: 231530
REFERENCE   PMID:16176262
  AUTHORS   Yang SY, He XY, Schulz H
  TITLE     3-Hydroxyacyl-CoA dehydrogenase and short chain 3-hydroxyacyl-CoA dehydrogenase in human health and disease.
  JOURNAL   FEBS J 272:4874-83 (2005)
REFERENCE   PMID:21347589
  AUTHORS   Martins E, Cardoso ML, Rodrigues E, Barbot C, Ramos A, Bennett MJ, Teles EL, Vilarinho L
  TITLE     Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: the clinical relevance of an early diagnosis and report of four new cases.
  JOURNAL   J Inherit Metab Dis 34:835-42 (2011)
REFERENCE   PMID:22579592
  AUTHORS   Vilarinho L, Marques JS, Rocha H, Ramos A, Lopes L, Narayan SB, Bennett MJ
  TITLE     Diagnosis of a patient with a kinetic variant of medium and short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency by newborn screening.
  JOURNAL   Mol Genet Metab 106:277-80 (2012)
///
ENTRY       H01365                      Disease
NAME        Leber hereditary optic neuropathy and dystonia (LDYT)
DESCRIPTION Leber hereditary optic neuropathy and dystonia (LDYT) is a maternally-inherited mitochondrial disorder characterized by variable combinations of visual loss and progressive generalized dystonia. LDYT is a unique oxidative phosphorylation disorder caused by mutations in mitochondrial DNA.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease; Mitochondrial disease
GENE        MT-ND6 [HSA:4541] [KO:K03884]
            MT-ND4 [HSA:4538] [KO:K03881]
            MT-ND1 [HSA:4535] [KO:K03878]
            MT-ND3 [HSA:4537] [KO:K03880]
DBLINKS     ICD-10: H47.2
            MeSH: D029242
            OMIM: 500001
REFERENCE   PMID:8016139
  AUTHORS   Jun AS, Brown MD, Wallace DC
  TITLE     A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia.
  JOURNAL   Proc Natl Acad Sci U S A 91:6206-10 (1994)
REFERENCE   PMID:19458970
  AUTHORS   Wang K, Takahashi Y, Gao ZL, Wang GX, Chen XW, Goto J, Lou JN, Tsuji S
  TITLE     Mitochondrial ND3 as the novel causative gene for Leber hereditary optic neuropathy and dystonia.
  JOURNAL   Neurogenetics 10:337-45 (2009)
REFERENCE   PMID:17562939
  AUTHORS   Spruijt L, Smeets HJ, Hendrickx A, Bettink-Remeijer MW, Maat-Kievit A, Schoonderwoerd KC, Sluiter W, de Coo IF, Hintzen RQ
  TITLE     A MELAS-associated ND1 mutation causing leber hereditary optic neuropathy and spastic dystonia.
  JOURNAL   Arch Neurol 64:890-3 (2007)
///
ENTRY       H01366                      Disease
NAME        Bacterial conjunctivitis
DESCRIPTION Bacterial conjunctivitis is an infection caused by bacterial pathogens, such as Haemophilus influenza, Streptococcus pneumoniae and Moraxella catarrhalis. Most cases of conjunctivitis in adults are likely to be caused by viral infection, but children are more likely to develop bacterial conjunctivitis than viral infection. The contact lens wearers are associated with an increased risk of conjunctivitis or keratitis.
CATEGORY    Infectious disease
PATHOGEN    Haemophilus influenzae (nontypeable) [GN:hil]
            Streptococcus pneumoniae
            Moraxella catarrhalis
DBLINKS     ICD-10: H10.9
            MeSH: D003234
REFERENCE   PMID:22348418 (description)
  AUTHORS   Epling J
  TITLE     Bacterial conjunctivitis.
  JOURNAL   Clin Evid (Online) 2012 (2012)
REFERENCE   PMID:22377449 (pathogen)
  AUTHORS   Strouts FR, Power P, Croucher NJ, Corton N, van Tonder A, Quail MA, Langford PR, Hudson MJ, Parkhill J, Kroll JS, Bentley SD
  TITLE     Lineage-specific virulence determinants of Haemophilus influenzae biogroup aegyptius.
  JOURNAL   Emerg Infect Dis 18:449-57 (2012)
///
ENTRY       H01367                      Disease
NAME        Infantile liver failure, including:
            Infantile liver failure syndrome (IFLS);
            Transient infantile liver failure (LFIT)
DESCRIPTION Infantile liver failure is a life-threatening condition characterized by poor feeding, vomiting, jaundice, distended abdomen, hemorrhagic diathesis, and hypoactivity. Clinically, patients manifest with elevated liver transaminases, hypoglycemia, cholestasis, coagulopathy and hyperbilirubinemia. It has been reported that infantile liver failure syndrome is caused by mutations in aminoacyl-tRNA synthetase genes. A transient form of infantile liver failure is caused by mutation in the TRMU gene, which encodes a mitochondria specific tRNA-modifying enzyme.
CATEGORY    Inherited metabolic disease; Liver disease; Mitochondrial disease
GENE        (IFLS1) LARS [HSA:51520] [KO:K01869]
            (IFLS2) MARS [HSA:4141] [KO:K01874]
            (LFIT) TRMU [HSA:55687] [KO:K21027]
MARKER      Elevated liver transaminases
            Hyperbilirubinemia
DBLINKS     ICD-10: K72.0
            MeSH: D017093
            OMIM: 615438 615486 613070
REFERENCE   PMID:19732863
  AUTHORS   Zeharia A, Shaag A, Pappo O, Mager-Heckel AM, Saada A, Beinat M, Karicheva O, Mandel H, Ofek N, Segel R, Marom D, Rotig A, Tarassov I, Elpeleg O
  TITLE     Acute infantile liver failure due to mutations in the TRMU gene.
  JOURNAL   Am J Hum Genet 85:401-7 (2009)
REFERENCE   PMID:22607940
  AUTHORS   Casey JP, McGettigan P, Lynam-Lennon N, McDermott M, Regan R, Conroy J, Bourke B, O'Sullivan J, Crushell E, Lynch S, Ennis S
  TITLE     Identification of a mutation in LARS as a novel cause of infantile hepatopathy.
  JOURNAL   Mol Genet Metab 106:351-8 (2012)
///
ENTRY       H01368                      Disease
NAME        Cytochrome c oxidase (COX) deficiency, including:
            Mitochondrial complex IV deficiency (MT-C4D);
            Fatal infantile cardioencephalomyopathy (CEMCOX) [DS:H01200];
            Leigh syndrome (LS) [DS:H01354];
            Kearns-Sayre Syndrome (KSS) [DS:H01355];
            Leber Hereditary Optic Neuropathy (LHON) [DS:H00068]
DESCRIPTION Cytochrome c oxidase (COX) deficiency is a mitochondrial disease that is caused by the lack of the COX. Cytochrome c oxidase (COX) is the terminal enzyme of the mitochondrial respiratory chain (complex IV). Since COX is encoded by nuclear and mitochondrial genes, COX deficiency can be inherited in either an autosomal recessive or a maternal pattern. Patients can present with a number of different clinical phenotypes, including Leigh syndrome, Fatal infantile cardioencephalomyopathy, and Leber hereditary optic neuropathy.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        (MT-C4D) COX6B1 [HSA:1340] [KO:K02267]
            (MT-C4D) COX14 [HSA:84987] [KO:K18181]
            (LS/CEMCOX2) COX15 [HSA:1355] [KO:K02259]
            (MT-C4D) COX10 [HSA:1352] [KO:K02257]
            (MT-C4D) COX20 [HSA:116228] [KO:K18184]
            (MT-C4D) COA5 [HSA:493753] [KO:K18178]
            (MT-C4D) SCO1 [HSA:6341] [KO:K07152]
            (CEMCOX2) SCO2 [HSA:9997] [KO:K07152]
            (LS) TACO1 [HSA:51204] [KO:K18189]
            (MT-C4D) FASTKD2 [HSA:22868] [KO:K18190]
            (LS) LRPPRC [HSA:10128] [KO:K17964]
            (LS) SURF1 [HSA:6834] [KO:K14998]
            (MT-C4D/LHON) MT-CO1 [HSA:4512] [KO:K02256]
            (MT-C4D) MT-CO2 [HSA:4513] [KO:K02261]
            (MT-C4D/LHON/KSS) MT-CO3 [HSA:4514] [KO:K02262]
            (MT-C4D) APOPT1 [HSA:84334]
            (MT-C4D) PET100 [HSA:100131801] [KO:K18186]
COMMENT     (Nuclear genes) COX6B1, COX10, COX15, SCO1, SCO2, SURF1, LRPPRC, TACO1, FASTKD2
            (mitochondrial genes) MT-CO1, MT-CO2, MT-CO3
DBLINKS     ICD-10: G71.3
            MeSH: D030401
            OMIM: 220110 220111 604377 615119 603358 535000
REFERENCE   PMID:11579424
  AUTHORS   Shoubridge EA
  TITLE     Cytochrome c oxidase deficiency.
  JOURNAL   Am J Med Genet 106:46-52 (2001)
REFERENCE   PMID:21412973
  AUTHORS   Alfadhel M, Lillquist YP, Waters PJ, Sinclair G, Struys E, McFadden D, Hendson G, Hyams L, Shoffner J, Vallance HD
  TITLE     Infantile cardioencephalopathy due to a COX15 gene defect: report and review.
  JOURNAL   Am J Med Genet A 155A:840-4 (2011)
REFERENCE   PMID:25175347 (gene)
  AUTHORS   Melchionda L, Haack TB, Hardy S, Abbink TE, Fernandez-Vizarra E, Lamantea E, Marchet S, Morandi L, Moggio M, Carrozzo R, Torraco A, Diodato D, Strom TM, Meitinger T, Tekturk P, Yapici Z, Al-Murshedi F, Stevens R, Rodenburg RJ, Lamperti C, Ardissone A, Moroni I, Uziel G, Prokisch H, Taylor RW, Bertini E, van der Knaap MS, Ghezzi D, Zeviani M
  TITLE     Mutations in APOPT1, encoding a mitochondrial protein, cause cavitating leukoencephalopathy with cytochrome c oxidase deficiency.
  JOURNAL   Am J Hum Genet 95:315-25 (2014)
REFERENCE   PMID:24462369 (gene)
  AUTHORS   Lim SC, Smith KR, Stroud DA, Compton AG, Tucker EJ, Dasvarma A, Gandolfo LC, Marum JE, McKenzie M, Peters HL, Mowat D, Procopis PG, Wilcken B, Christodoulou J, Brown GK, Ryan MT, Bahlo M, Thorburn DR
  TITLE     A founder mutation in PET100 causes isolated complex IV deficiency in Lebanese individuals with Leigh syndrome.
  JOURNAL   Am J Hum Genet 94:209-22 (2014)
///
ENTRY       H01369                      Disease
NAME        ATP synthase deficiency, including:
            Mitochondrial respiratory chain complex V deficiency nuclear type (MC5DN);
            Mitochondrial respiratory chain complex V deficiency mitochondrial type (MC5DM);
            Mitochondrial encephalo-cardio-myopathy due to mitochondrial respiratory chain complex V deficiency;
            NARP syndrome [DS:H01363];
            Mitochondrial infantile bilateral striatal necrosis (MIBSN)
DESCRIPTION ATP synthase deficiency is mitochondrial disease caused by inborn defects in the mitochondrial F1Fo-ATP synthase (respiratory chain complex V). Many patients die within a few months or years. It have been shown to result from mutations in mtDNA genes for the subunits ATP6 and ATP8 or in nuclear genes encoding the biogenesis factors ATPAF2 and TMEM70. Recently, mutations has been found in a nuclear encoded structural complex V subunit, ATP5E and ATP5A1.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        (MC5DN1) ATPAF2 [HSA:91647] [KO:K07556]
            (MC5DN2) TMEM70 [HSA:54968] [KO:K17966]
            (MC5DN3) ATP5E [HSA:514] [KO:K02135]
            (MC5DN4) ATP5A1 [HSA:498] [KO:K02132]
            (MC5DM1/NARP/MIBSN) MT-ATP6 [HSA:4508] [KO:K02126]
            (MC5DM2) MT-ATP8 [HSA:4509] [KO:K02125]
DBLINKS     ICD-10: G71.3
            MeSH: C567528
            OMIM: 604273 614052 514053 615228 551500 500003 516060 516070
REFERENCE   PMID:20566710
  AUTHORS   Mayr JA, Havlickova V, Zimmermann F, Magler I, Kaplanova V, Jesina P, Pecinova A, Nuskova H, Koch J, Sperl W, Houstek J
  TITLE     Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 epsilon subunit.
  JOURNAL   Hum Mol Genet 19:3430-9 (2010)
REFERENCE   PMID:19188198
  AUTHORS   Ware SM, El-Hassan N, Kahler SG, Zhang Q, Ma YW, Miller E, Wong B, Spicer RL, Craigen WJ, Kozel BA, Grange DK, Wong LJ
  TITLE     Infantile cardiomyopathy caused by a mutation in the overlapping region of mitochondrial ATPase 6 and 8 genes.
  JOURNAL   J Med Genet 46:308-14 (2009)
REFERENCE   PMID:23599390
  AUTHORS   Jonckheere AI, Renkema GH, Bras M, van den Heuvel LP, Hoischen A, Gilissen C, Nabuurs SB, Huynen MA, de Vries MC, Smeitink JA, Rodenburg RJ
  TITLE     A complex V ATP5A1 defect causes fatal neonatal mitochondrial encephalopathy.
  JOURNAL   Brain 136:1544-54 (2013)
REFERENCE   PMID:7668837
  AUTHORS   Thyagarajan D, Shanske S, Vazquez-Memije M, De Vivo D, DiMauro S
  TITLE     A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis.
  JOURNAL   Ann Neurol 38:468-72 (1995)
REFERENCE   PMID:18953340
  AUTHORS   Cizkova A, Stranecky V, Mayr JA, Tesarova M, Havlickova V, Paul J, Ivanek R, Kuss AW, Hansikova H, Kaplanova V, Vrbacky M, Hartmannova H, Noskova L, Honzik T, Drahota Z, Magner M, Hejzlarova K, Sperl W, Zeman J, Houstek J, Kmoch S
  TITLE     TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy.
  JOURNAL   Nat Genet 40:1288-90 (2008)
///
ENTRY       H01370                      Disease
NAME        SHORT syndrome
DESCRIPTION SHORT syndrome is a rare autosomal-dominant disorder characterized by short stature, hyperextensibility of joints, hernias, ocular depression, ophthalmic anomalies, teething delay, partial lipodystrophy, insulin resistance, and facial dysmorphic signs. Mutations in PIK3R1 cause this syndrome.
CATEGORY    Developmental disorder
GENE        PIK3R1 [HSA:5295] [KO:K02649]
DBLINKS     ICD-10: Q87.1
            MeSH: C537327
            OMIM: 269880
REFERENCE   PMID:23810379
  AUTHORS   Chudasama KK, Winnay J, Johansson S, Claudi T, Konig R, Haldorsen I, Johansson B, Woo JR, Aarskog D, Sagen JV, Kahn CR, Molven A, Njolstad PR
  TITLE     SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3  kinase signaling.
  JOURNAL   Am J Hum Genet 93:150-7 (2013)
REFERENCE   PMID:23810382
  AUTHORS   Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, Majewski J, Bulman DE, O'Driscoll M, Boycott KM, Innes AM
  TITLE     Mutations in PIK3R1 cause SHORT syndrome.
  JOURNAL   Am J Hum Genet 93:158-66 (2013)
///
ENTRY       H01371                      Disease
NAME        Hypercalcemia infantile;
            Idiopathic infantile hypercalcemia
DESCRIPTION Idiopathic infantile hypercalcemia is autosomal recessive disorder that is characterized by severe hypercalcemia, failure to thrive, vomiting, dehydration, and nephrocalcinosis. It has been reported that mutations in the vitamin D-metabolizing enzyme CYP24A1 cause this disease. The presence of CYP24A1 mutations explains the increased sensitivity to vitamin D in patients with idiopathic infantile hypercalcemia.
CATEGORY    Inherited metabolic disease
GENE        CYP24A1 [HSA:1591] [KO:K07436]
ENV_FACTOR  VitaminD [DR:D00188]
DBLINKS     ICD-10: E83.5
            MeSH: C562581
            OMIM: 143880
REFERENCE   PMID:21675912
  AUTHORS   Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H, Wingen AM, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M
  TITLE     Mutations in CYP24A1 and idiopathic infantile hypercalcemia.
  JOURNAL   N Engl J Med 365:410-21 (2011)
///
ENTRY       H01372                      Disease
NAME        Vitiligo
DESCRIPTION Vitiligo is a common, multifactorial, polygenic disease in which autoimmune loss of melanocytes results in depigmented spots of skin, overlying hair, and mucous membranes. Some familial forms of vitiligo have recently been linked to polymorphisms in the innate immunity gene, NLRP1.
CATEGORY    Skin and connective tissue disease
GENE        NLRP1 [HSA:22861] [KO:K12798]
DRUG        Vitamin D [DR:D00188]
            Calcineurin inhibitor
            Topical corticosteroid
            Betamethasone [DG:DG00095]
            Dexamethasone [DG:DG00011]
            Phototherapy
DBLINKS     ICD-10: L80
            MeSH: D014820
            OMIM: 606579
REFERENCE   PMID:17637824
  AUTHORS   Jin Y, Birlea SA, Fain PR, Spritz RA
  TITLE     Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population.
  JOURNAL   J Invest Dermatol 127:2558-62 (2007)
REFERENCE   PMID:22117610
  AUTHORS   D'Osualdo A, Reed JC
  TITLE     NLRP1, a regulator of innate immunity associated with vitiligo.
  JOURNAL   Pigment Cell Melanoma Res 25:5-8 (2012)
REFERENCE   PMID:22835073
  AUTHORS   Colucci R, Lotti T, Moretti S
  TITLE     Vitiligo: an update on current pharmacotherapy and future directions.
  JOURNAL   Expert Opin Pharmacother 13:1885-99 (2012)
///
ENTRY       H01373                      Disease
NAME        Achromobacter xylosoxidans infection, including:
            Achromobacter xylosoxidans keratitis
DESCRIPTION Achromobacter xylosoxidans, also known as Alcaligenes xylosoxidans, is an environmental opportunistic pathogen that causes nosocomial infections targeting immunocompromised patients suffering from cancer, advanced HIV, diabetes mellitus or chronic renal failure. A. xylosoxidans is highly resistant to a broad range of antibiotics including resistance to narrow-spectrum penicillins, aminoglycosides and several cephalosporins. This bacterium can rarely cause keratitis in patients who had worn contact lenses.
CATEGORY    Infectious disease
PATHOGEN    Achromobacter xylosoxidans [GN:axo axy]
COMMENT     Please see H01081.
REFERENCE   PMID:23894309
  AUTHORS   Jakobsen TH, Hansen MA, Jensen PO, Hansen L, Riber L, Cockburn A, Kolpen M, Ronne Hansen C, Ridderberg W, Eickhardt S, Hansen M, Kerpedjiev P, Alhede M, Qvortrup K, Burmolle M, Moser C, Kuhl M, Ciofu O, Givskov M, Sorensen SJ, Hoiby N, Bjarnsholt T
  TITLE     Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes.
  JOURNAL   PLoS One 8:e68484 (2013)
///
ENTRY       H01374                      Disease
NAME        Helicobacter cinaedi infection
DESCRIPTION Helicobacter cinaedi (previously called Campylobacter cinaedi) causes cellulitis, bacteremia and diarrhea frequently in immunocompromised patients and occasionally in immunocompetent individuals. In addition to these things, Nosocomial H. cinaedi infections have recently been reported.
CATEGORY    Infectious disease
PATHOGEN    Helicobacter cinaedi [GN:hcp hcb]
DBLINKS     MeSH: D016481
REFERENCE   PMID:22740670
  AUTHORS   Goto T, Ogura Y, Hirakawa H, Tomida J, Morita Y, Akaike T, Hayashi T, Kawamura Y
  TITLE     Complete genome sequence of Helicobacter cinaedi strain PAGU611, isolated in a case of human bacteremia.
  JOURNAL   J Bacteriol 194:3744-5 (2012)
REFERENCE   PMID:23012276
  AUTHORS   Miyoshi-Akiyama T, Takeshita N, Ohmagari N, Kirikae T
  TITLE     Complete genome sequence of Helicobacter cinaedi type strain ATCC BAA-847.
  JOURNAL   J Bacteriol 194:5692 (2012)
///
ENTRY       H01375                      Disease
NAME        Glucose 6-phosphate dehydrogenase deficiency
DESCRIPTION Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked, hereditary disorder due to mutations in the G6PD gene, resulting in protein variants with different levels of enzyme activity, that are associated with a wide range of biochemical and clinical phenotypes. G6PD deficiency is the most common enzymatic disorder in humans. It is estimated that about 400 million people are affected by this deficiency. More than 400 biochemical variants of G6PD deficiency have since been defined, and grouped into five classes based on enzyme activity and clinical manifestations. The most common clinical manifestations are neonatal jaundice and acute haemolytic anaemia, which in most patients is triggered by an exogenous agent. A G6PD-deficient patient lacks the ability to protect red blood cells against oxidative stresses from certain drugs, infections, metabolic conditions, and ingestion of fava beans.
CATEGORY    Inherited metabolic disease; Hematologic disease
GENE        G6PD [HSA:2539] [KO:K00036]
DBLINKS     ICD-10: D55.0
            MeSH: D005955
            OMIM: 300908
REFERENCE   PMID:18177777 (Common mutations,
            Drugs and Chemicals Associated With Hemolysis in G6PD Deficiency)
  AUTHORS   Cappellini MD, Fiorelli G
  TITLE     Glucose-6-phosphate dehydrogenase deficiency.
  JOURNAL   Lancet 371:64-74 (2008)
REFERENCE   PMID:17365988
  AUTHORS   Ronquist G, Theodorsson E
  TITLE     Inherited, non-spherocytic haemolysis due to deficiency of glucose-6-phosphate dehydrogenase.
  JOURNAL   Scand J Clin Lab Invest 67:105-11 (2007)
REFERENCE   PMID:19769422 (Drugs and Chemicals Associated With Hemolysis in G6PD Deficiency)
  AUTHORS   Elyassi AR, Rowshan HH
  TITLE     Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature.
  JOURNAL   Anesth Prog 56:86-91 (2009)
///
ENTRY       H01376                      Disease
NAME        Acrofacial dysostosis, including:
            Nager syndrome;
            Genee-Wiedemann syndrome;
            Miller syndrome
DESCRIPTION Acrofacial dysostosis (AFD) is a heterogeneous group of disorders combining mandibulofacial dysostosis (micrognathia and ear anomalies) with limb defects. The predominantly preaxial form is called Nager AFD, the predominantly postaxial form of AFD (POADS) is also known as the Genee-Wiedemann or Miller syndrome. Among several AFDs, causative mutations have recently been identified in an enzyme involved in pyrimidine biosynthesis in association with Miller syndrome, and in a component of the pre-mRNA spliceosomal complex with respect to Nager syndrome.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        DHODH [hsa:1723] [KO:K00254]
            SF3B4 [hsa:10262] [KO:K12831]
DBLINKS     ICD-10: Q75.4
            MeSH: C537680 C538182 C538183 C538184 C538185
            OMIM: 154400 263750
REFERENCE   PMID:8266994
  AUTHORS   Opitz JM, Mollica F, Sorge G, Milana G, Cimino G, Caltabiano M
  TITLE     Acrofacial dysostoses: review and report of a previously undescribed condition: the autosomal or X-linked dominant Catania form of acrofacial dysostosis.
  JOURNAL   Am J Med Genet 47:660-78 (1993)
REFERENCE   PMID:24123981
  AUTHORS   Trainor PA, Andrews BT
  TITLE     Facial dysostoses: Etiology, pathogenesis and management.
  JOURNAL   Am J Med Genet C Semin Med Genet 163:283-94 (2013)
REFERENCE   PMID:17674260
  AUTHORS   Verrotti C, Benassi G, Piantelli G, Magnani C, Giordano G, Gramellini D
  TITLE     Acrofacial dysostosis syndromes: a relevant prenatal dilemma. A case report and brief literature review.
  JOURNAL   J Matern Fetal Neonatal Med 20:487-90 (2007)
///
ENTRY       H01377                      Disease
NAME        Mitchell-Riley syndrome
DESCRIPTION Mitchell-Riley syndrome is a neonatal diabetes syndrome that involves abnormalities of the anterior gut as well as diabetes. Patients with this syndrome are typically diagnosed within the first week of life and generally die within their first year of life. Mutations in rfx6 have been associated with Mitchell-Riley syndrome.
CATEGORY    Inherited metabolic disease
GENE        RFX6 [hsa:222546]
DBLINKS     MeSH: C567570
            OMIM: 615710
REFERENCE   PMID:23914949
  AUTHORS   Concepcion JP, Reh CS, Daniels M, Liu X, Paz VP, Ye H, Highland HM, Hanis CL, Greeley SA
  TITLE     Neonatal diabetes, gallbladder agenesis, duodenal atresia, and intestinal malrotation caused by a novel homozygous mutation in RFX6.
  JOURNAL   Pediatr Diabetes 15:67-72 (2014)
REFERENCE   PMID:21215266
  AUTHORS   Pearl EJ, Jarikji Z, Horb ME
  TITLE     Functional analysis of Rfx6 and mutant variants associated with neonatal diabetes.
  JOURNAL   Dev Biol 351:135-45 (2011)
///
ENTRY       H01378                      Disease
NAME        Bosch-Boonstra optic atrophy syndrome
DESCRIPTION Bosch-Boonstra optic atrophy syndrome is an autosomal dominant disorder characterized by mild to moderate intellectual impairment and optic atrophy. Heterozygous mutations in the NR2F1 gene have been associated with this disease.
CATEGORY    Eye disease
GENE        NR2F1 [hsa:7025] [KO:K08547]
DBLINKS     OMIM: 615722
REFERENCE   PMID:24462372
  AUTHORS   Bosch DG, Boonstra FN, Gonzaga-Jauregui C, Xu M, de Ligt J, Jhangiani S, Wiszniewski W, Muzny DM, Yntema HG, Pfundt R, Vissers LE, Spruijt L, Blokland EA, Chen CA, Lewis RA, Tsai SY, Gibbs RA, Tsai MJ, Lupski JR, Zoghbi HY, Cremers FP, de Vries BB, Schaaf CP
  TITLE     NR2F1 mutations cause optic atrophy with intellectual disability.
  JOURNAL   Am J Hum Genet 94:303-9 (2014)
///
ENTRY       H01379                      Disease
NAME        Arcobacter butzleri infection
DESCRIPTION Arcobacter butzleri is the best characterized of all Arcobacters and an emerging pathogen causes diarrhea, recurrent abdominal cramps and bacteremia. A. butzleri is isolated often from aqueous environments, multiple animals and food sources. In recent years, there is an increase in isolation from human diarrheal stool samples.
CATEGORY    Infectious disease
PATHOGEN    Arcobacter butzleri [GN:abu]
REFERENCE   PMID:18159241
  AUTHORS   Miller WG, Parker CT, Rubenfield M, Mendz GL, Wosten MM, Ussery DW, Stolz JF, Binnewies TT, Hallin PF, Wang G, Malek JA, Rogosin A, Stanker LH, Mandrell RE.
  TITLE     The complete genome sequence and analysis of the epsilonproteobacterium Arcobacter butzleri.
  JOURNAL   PLoS ONE 2:e1358 (2007)
///
ENTRY       H01380                      Disease
NAME        Bacterial vaginosis
DESCRIPTION Bacterial vaginosis (BV) flora is dominated by Gardnerella vaginalis and includes many anaerobic organisms as contrasted with normal lactobacillus-dominated vaginal flora. BV flora is thought to be related to vaginal discharge, poor pregnancy outcomes, pelvic inflammatory disease, postoperative wound infections, endometritis following elective abortions. Additionally, BV flora predisposes women to infection by HIV as well as other Sexually Transmitted Diseases (STDs).
CATEGORY    Infectious disease
PATHOGEN    Gardnerella vaginalis [GN:gvg]
DBLINKS     ICD-10: N76 
            MeSH: D016585
REFERENCE   PMID:20865041
  AUTHORS   Yeoman CJ, Yildirim S, Thomas SM, Durkin AS, Torralba M, Sutton G, Buhay CJ, Ding Y, Dugan-Rocha SP, Muzny DM, Qin X, Gibbs RA, Leigh SR, Stumpf R, White BA, Highlander SK, Nelson KE, Wilson BA
  TITLE     Comparative genomics of Gardnerella vaginalis strains reveals substantial differences in metabolic and virulence potential.
  JOURNAL   PLoS One 5:e12411 (2010)
REFERENCE   PMID:22143133
  AUTHORS   Martin DH
  TITLE     The microbiota of the vagina and its influence on women's health and disease.
  JOURNAL   Am J Med Sci 343:2-9 (2012)
///
ENTRY       H01381                      Disease
NAME        Antithrombin III deficiency;
            Inherited Antithrombin deficiency
DESCRIPTION Inherited Antithrombin (AT) deficiency is an autosomal dominant disorder, that is associated with an increased risk for venous thromboembolism (VTE) and pregnancy loss. AT is a potent inactivator of thrombin and factor Xa and the major inhibitor of blood coagulation. This disease is divided into type I deficiency, in which both the functional activity and antigenic levels AT are proportionately reduced, and type II deficiency, in which normal antigen levels are found in association with low AT activity due to a dysfunctional protein. Type II deficiencies can be further subclassified into three types, depending on the location of the mutations. Type IIa is caused by mutations that affect AT's reactive site. Type IIb is characterized by an abnormality of the heparin-binding domain. Type IIc variants are a pleiotropic group of mutations near the reactive loop site.
CATEGORY    Hematologic disease
GENE        SERPINC1 [HSA:462] [KO:K03911]
DRUG        (The initial management of VTE)
            Heparin [DR:D02112 D04427 D03337 D03353 D03674 D04977]
            Human anti-thrombin III, Neuart [DR:D08795]
            (Long-term anticoagulation)
            Warfarin [DR:D00564]
DBLINKS     ICD-10: D68.5
            MeSH: D020152
            OMIM: 613118
REFERENCE   PMID:19141163
  AUTHORS   Patnaik MM, Moll S
  TITLE     Inherited antithrombin deficiency: a review.
  JOURNAL   Haemophilia 14:1229-39 (2008)
REFERENCE   PMID:21401902
  AUTHORS   Cooper PC, Coath F, Daly ME, Makris M
  TITLE     The phenotypic and genetic assessment of antithrombin deficiency.
  JOURNAL   Int J Lab Hematol 33:227-37 (2011)
///
ENTRY       H01382                      Disease
NAME        Polyarteritis nodosa;
            ADA2 deficiency
DESCRIPTION Polyarteritis nodosa is a systemic necrotizing vasculitis that affects medium and small muscular arteries. The ensuing tissue ischemia can affect any organ, including the skin, musculoskeletal system, kidneys, gastrointestinal tract, and the cardiovascular and nervous systems. In most cases, onset of the disease occurred during childhood. Polyarteritis nodosa is most often primary. Recessive mutations in the adenosine deaminase 2 (ADA2)-encoding gene CECR1 have been found from patients of this disease.
CATEGORY    Cardiovascular disease; Skin and connective tissue disease
GENE        CECR1 [hsa:51816]
ENV_FACTOR  Hepatitis B virus (HBV)
DBLINKS     ICD-10: M30.0
            MeSH: D010488
            OMIM: 615688
REFERENCE   PMID:24552285 (description, gene)
  AUTHORS   Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E
  TITLE     Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy.
  JOURNAL   N Engl J Med 370:921-31 (2014)
REFERENCE   PMID:16148731 (env_factor)
  AUTHORS   Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P
  TITLE     Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.
  JOURNAL   Medicine (Baltimore) 84:313-22 (2005)
///
ENTRY       H01383                      Disease
NAME        Hyperlipoproteinemia type IIa;
            LDL receptor disorder
DESCRIPTION Familial hypercholesterolemia is characterized by severely elevated low-density lipoprotein (LDL) cholesterol, xanthomas, and the development of premature cardiovascular disease. Hyperlipoproteinemia type IIa is an autosomal dominant disorder caused by mutations in the LDL receptor. The LDL receptor gene consists of a number of distinct functional domains such as signal sequence, ligand binding, and so on. There are more than 1600 mutations in the LDLR gene that can cause familial hypercholesterolemia, accounting for up to 95% of all cases.
CATEGORY    Inherited metabolic disease
GENE        LDLR [HSA:3949] [KO:K12473]
MARKER      Elevated plasma LDL cholesterol
DRUG        Pravastatin [DG:DG00353]
            Atorvastatin [DG:DG00355]
            Rosuvastatin [DG:DG00357]
COMMENT     Familial hypercholesterolemia is also due to mutations in APOB, and PCSK9 genes.
            Please see H00155.
DBLINKS     ICD-10: E78.0
            MeSH: D006938
            OMIM: 143890
REFERENCE   PMID:21945105
  AUTHORS   Chan DC, Watts GF
  TITLE     Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box.
  JOURNAL   Metabolism 61:3-11 (2012)
REFERENCE   PMID:24253857
  AUTHORS   Kassner U, Wuhle-Demuth M, Missala I, Humphries SE, Steinhagen-Thiessen E, Demuth I
  TITLE     Clinical utility gene card for: hyperlipoproteinemia, TYPE II.
  JOURNAL   Eur J Hum Genet 22 (2014)
REFERENCE   PMID:17664376 (Drug)
  AUTHORS   Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA
  TITLE     Statin treatment in children with familial hypercholesterolemia: the younger, the better.
  JOURNAL   Circulation 116:664-8 (2007)
REFERENCE   PMID:24529145 (Drug)
  AUTHORS   Santos PC, Morgan AC, Jannes CE, Turolla L, Krieger JE, Santos RD, Pereira AC
  TITLE     Presence and type of low density lipoprotein receptor (LDLR) mutation influences  the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
  JOURNAL   Atherosclerosis 233:206-10 (2014)
REFERENCE   PMID:24079281 (Drug)
  AUTHORS   Kusters DM, Hutten BA, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Langslet G, Kastelein JJ, Wiegman A
  TITLE     Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia.
  JOURNAL   J Clin Lipidol 7:408-13 (2013)
///
ENTRY       H01384                      Disease
NAME        The ataxia neuropathy spectrum (ANS), including:
            Mitochondrial recessive ataxia syndrome (MIRAS);
            Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO)
DESCRIPTION The ataxia neuropathy spectrum (ANS) is the mitochondrial disease, that is caused by mutations of the POLG1 gene encoding the mitochondrial DNA polymerase gamma enzyme. ANS includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). MIRAS is a common cause of autosomal recessive juvenile- or adult-onset ataxia, at least in Scandinavia. Most cases of SANDO present with an initial stage of sensory neuropathy, a second stage of progressive external ophahlmoplegia and dysarthria, which is then followed by other symptoms, often with epilepsia or myoclonus.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        POLG [HSA:5428] [KO:K02332]
COMMENT     (MIRAS)
            W748S, E1143G
            (early onset SANDO)
            A467T, W748S
            (late onset SANDO)
            T251I, P587L, G848S
DBLINKS     ICD-10: G71.3
            MeSH: C579922 C537583
            OMIM: 607459
REFERENCE   PMID:12210792
  AUTHORS   Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, Papadimitriou A, Spelbrink H, Silvestri L, Casari G, Comi GP, Zeviani M
  TITLE     Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia.
  JOURNAL   Ann Neurol 52:211-9 (2002)
REFERENCE   PMID:20513108
  AUTHORS   Weiss MD, Saneto RP
  TITLE     Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) in late life due to compound heterozygous POLG mutations.
  JOURNAL   Muscle Nerve 41:882-5 (2010)
REFERENCE   PMID:22616202
  AUTHORS   Gati I, Danielsson O, Jonasson J, Landtblom AM
  TITLE     Sensory ataxic neuropathy with dysarthria/dysphagia and ophthalmoplegia (SANDO).  Two case reports.
  JOURNAL   Acta Myol 30:188-90 (2011)
REFERENCE   PMID:16080118
  AUTHORS   Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M, Goethem GV, Lofgren A, Hackman P, Paetau A, Kaakkola S, Majamaa K, Varilo T, Udd B, Kaariainen H, Bindoff LA, Suomalainen A
  TITLE     Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin.
  JOURNAL   Am J Hum Genet 77:430-41 (2005)
///
ENTRY       H01385                      Disease
NAME        Rienhoff syndrome
DESCRIPTION Rienhoff syndrome is a congenital syndrome presenting at birth with distal arthrogryposis, hypotonia, bifid uvula, and a failure of normal post-natal muscle development but no evidence of vascular disease. A mutation in TGFB3 was identified suggesting that decreased TGF-beta signaling from a loss of TGFB3 activity is likely responsible for the clinical phenotype.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        TGFB3 [hsa:7043] [KO:K13377]
DBLINKS     OMIM: 615582
REFERENCE   PMID:23824657 (description, gene)
  AUTHORS   Rienhoff HY Jr, Yeo CY, Morissette R, Khrebtukova I, Melnick J, Luo S, Leng N, Kim YJ, Schroth G, Westwick J, Vogel H, McDonnell N, Hall JG, Whitman M
  TITLE     A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan  and Loeys-Dietz syndrome.
  JOURNAL   Am J Med Genet A 161A:2040-6 (2013)
///
ENTRY       H01386                      Disease
NAME        Asparagine synthetase deficiency
DESCRIPTION Asparagine synthetase deficiency is an autosomal recessive disorder characterized by congenital microcephaly, intellectual disability, progressive cerebral atrophy, and intractable seizures. Recessive mutations in the ASNS gene, encoding asparagine synthetase which catalyzes the synthesis of asparagine from glutamine and aspartate, are responsible for this syndrome.
CATEGORY    Inherited metabolic disease; Nervous system disease
GENE        ASNS [hsa:440] [KO:K01953]
DBLINKS     OMIM: 615574
REFERENCE   PMID:24139043 (description, gene)
  AUTHORS   Ruzzo EK, Capo-Chichi JM, Ben-Zeev B, Chitayat D, Mao H, Pappas AL, Hitomi Y, Lu YF, Yao X, Hamdan FF, Pelak K, Reznik-Wolf H, Bar-Joseph I, Oz-Levi D, Lev D, Lerman-Sagie T, Leshinsky-Silver E, Anikster Y, Ben-Asher E, Olender T, Colleaux L, Decarie JC, Blaser S, Banwell B, Joshi RB, He XP, Patry L, Silver RJ, Dobrzeniecka S, Islam MS, Hasnat A, Samuels ME, Aryal DK, Rodriguiz RM, Jiang YH, Wetsel WC, McNamara JO, Rouleau GA, Silver DL, Lancet D, Pras E, Mitchell GA, Michaud JL, Goldstein DB
  TITLE     Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy.
  JOURNAL   Neuron 80:429-41 (2013)
///
ENTRY       H01387                      Disease
NAME        Activated PI3K-delta syndrome (APDS)
DESCRIPTION Activated PI3K-delta syndrome (APDS) is a primary immunodeficiency characterized by recurrent respiratory infections, progressive airway damage, lymphopenia, increased circulating transitional B cells, increased immunoglobulin M, and reduced immunoglobulin G2 levels in serum and impaired vaccine responses. A dominant gain-of-function mutation has been found in the p110-delta protein, the catalytic subunit of phosphoinositide 3-kinase delta (PI3K-delta), encoded by the PIK3CD gene.
CATEGORY    Primary immunodeficiency
GENE        PIK3CD [hsa:5293] [KO:K00922]
DBLINKS     OMIM: 615513
REFERENCE   PMID:24136356 (description, gene)
  AUTHORS   Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O, Smyth D, Maes M, Fiddler C, Juss J, Cilliers D, Markelj G, Chandra A, Farmer G, Kielkowska A, Clark J, Kracker S, Debre M, Picard C, Pellier I, Jabado N, Morris JA, Barcenas-Morales G, Fischer A, Stephens L, Hawkins P, Barrett JC, Abinun M, Clatworthy M, Durandy A, Doffinger R, Chilvers ER, Cant AJ, Kumararatne D, Okkenhaug K, Williams RL, Condliffe A, Nejentsev S
  TITLE     Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage.
  JOURNAL   Science 342:866-71 (2013)
///
ENTRY       H01388                      Disease
NAME        Hyperprolactinemia
DESCRIPTION Hyperprolactinemia unrelated to pregnancy is a disorder characterized by excess production of prolactin and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiological hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, which are usually identifiable by means of magnetic resonance imaging (MRI). Some cases are due to prolactinomas and lesions in the pituitary stalk. A human germline PRLR mutation has been found in familial isolated hyperprolactinemia.
CATEGORY    Endocrine disease
GENE        PRLR [hsa:5618] [KO:K05081]
COMMENT     See also H01607.
DBLINKS     ICD-10: E22.1
            MeSH: D006966
            OMIM: 615555
REFERENCE   PMID:24195502 (description, gene)
  AUTHORS   Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV
  TITLE     Mutant prolactin receptor and familial hyperprolactinemia.
  JOURNAL   N Engl J Med 369:2012-20 (2013)
///
ENTRY       H01389                      Disease
NAME        Alpers syndrome;
            Alpers-Huttenlocher syndrome;
            Diffuse cerebral sclerosis of Schilder;
            Hepatocerebral degeneration of childhood;
            Mitochondrial DNA depletion syndrome 4A
DESCRIPTION Alpers syndrome is a rare mitochondrial disease associated with mutations in the POLG1 gene encoding the mitochondrial DNA polymerase gamma. Alpers syndrome affects children and young adults and is characterized by the clinical triad of refractory seizures, psychomotor regression, and characteristic liver disease. The tempo of disease progression and onset varies among patients. The majority of patients are healthy before disease onset, and seizures herald the disorder in most patients.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        POLG [HSA:5428] [KO:K02332]
COMMENT     (The most common mutation) A467T
            (Juvenile-onset) W748S G848S E1143G E873X
DBLINKS     ICD-10: G31.8
            MeSH: D002549
            OMIM: 203700
REFERENCE   PMID:23419467
  AUTHORS   Saneto RP, Cohen BH, Copeland WC, Naviaux RK
  TITLE     Alpers-Huttenlocher syndrome.
  JOURNAL   Pediatr Neurol 48:167-78 (2013)
REFERENCE   PMID:18294203
  AUTHORS   Uusimaa J, Hinttala R, Rantala H, Paivarinta M, Herva R, Roytta M, Soini H, Moilanen JS, Remes AM, Hassinen IE, Majamaa K
  TITLE     Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus.
  JOURNAL   Epilepsia 49:1038-45 (2008)
REFERENCE   PMID:16177225
  AUTHORS   Nguyen KV, Ostergaard E, Ravn SH, Balslev T, Danielsen ER, Vardag A, McKiernan PJ, Gray G, Naviaux RK
  TITLE     POLG mutations in Alpers syndrome.
  JOURNAL   Neurology 65:1493-5 (2005)
///
ENTRY       H01390                      Disease
NAME        Mitochondrial neurogastrointestinal encephalomyopathy;
            MNGIE Syndrome
DESCRIPTION Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is an autosomal recessive neurodegenerative disorder associated with thymidine phosphorylase deficiency resulting in high levels of plasma thymidine and a characteristic clinical phenotype. The disease is characterized clinically by ptosis, progressive external ophthalmoparesis, gastrointestinal dysmotility, cachexia, peripheral neuropathy, and leukoencephalopathy. MNGIE is caused by TYMP mutations. Rare cases of MNGIE-like phenotype have been linked to RRM2B and POLG mutations.
CATEGORY    Inherited metabolic disease; Neurodegenerative disease; Mitochondrial disease
GENE        TYMP [HSA:1890] [KO:K00758]
            RRM2B [HSA:50484] [KO:K10808]
            POLG [HSA:5428] [KO:K02332]
MARKER      Elevated plasma Thymidine [CPD:C00214]
COMMENT     (TYMP mutation)
            G1419A, G1443A, A3371C
            (RRM2B mutation)
            G329A, G362A
            (POLG mutation)
            C752T, C1760T, A2591T
DBLINKS     ICD-10: G71.3
            MeSH: C537477
            OMIM: 613662 603041 612075
REFERENCE   PMID:11166160
  AUTHORS   Nishino I, Spinazzola A, Hirano M
  TITLE     MNGIE: from nuclear DNA to mitochondrial DNA.
  JOURNAL   Neuromuscul Disord 11:7-10 (2001)
REFERENCE   PMID:21993618
  AUTHORS   Tang S, Dimberg EL, Milone M, Wong LJ
  TITLE     Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an  expanded clinical spectrum of POLG1 mutations.
  JOURNAL   J Neurol 259:862-8 (2012)
REFERENCE   PMID:19667227
  AUTHORS   Shaibani A, Shchelochkov OA, Zhang S, Katsonis P, Lichtarge O, Wong LJ, Shinawi M
  TITLE     Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
  JOURNAL   Arch Neurol 66:1028-32 (2009)
REFERENCE   PMID:9924029
  AUTHORS   Nishino I, Spinazzola A, Hirano M
  TITLE     Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.
  JOURNAL   Science 283:689-92 (1999)
REFERENCE   PMID:12825077
  AUTHORS   Van Goethem G, Schwartz M, Lofgren A, Dermaut B, Van Broeckhoven C, Vissing J
  TITLE     Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy.
  JOURNAL   Eur J Hum Genet 11:547-9 (2003)
///
ENTRY       H01391                      Disease
NAME        Familial episodic pain syndrome (FEPS)
DESCRIPTION Familial episodic pain syndrome (FEPS) is an autosomal dominant neurological disorder characterized by episodes of debilitating pain in the upper body and the distal lower extremities, triggered by conditions of fatigue, fasting, and cold. Gain-of-function mutations in TRPA1, SCN10A, and SCN11A can be causative of FEPS.
CATEGORY    Nervous system disease
GENE        (FEPS1) TRPA1 [hsa:8989] [KO:K04984]
            (FEPS2) SCN10A [hsa:6336] [KO:K04842]
            (FEPS3) SCN11A [hsa:11280] [KO:K04843]
DBLINKS     MeSH: C538101
            OMIM: 615040 615551 615552
REFERENCE   PMID:20547126 (description, gene)
  AUTHORS   Kremeyer B, Lopera F, Cox JJ, Momin A, Rugiero F, Marsh S, Woods CG, Jones NG, Paterson KJ, Fricker FR, Villegas A, Acosta N, Pineda-Trujillo NG, Ramirez JD, Zea J, Burley MW, Bedoya G, Bennett DL, Wood JN, Ruiz-Linares A
  TITLE     A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome.
  JOURNAL   Neuron 66:671-80 (2010)
REFERENCE   PMID:23115331 (description, gene)
  AUTHORS   Faber CG, Lauria G, Merkies IS, Cheng X, Han C, Ahn HS, Persson AK, Hoeijmakers JG, Gerrits MM, Pierro T, Lombardi R, Kapetis D, Dib-Hajj SD, Waxman SG
  TITLE     Gain-of-function Nav1.8 mutations in painful neuropathy.
  JOURNAL   Proc Natl Acad Sci U S A 109:19444-9 (2012)
REFERENCE   PMID:24207120 (description, gene)
  AUTHORS   Zhang XY, Wen J, Yang W, Wang C, Gao L, Zheng LH, Wang T, Ran K, Li Y, Li X, Xu M, Luo J, Feng S, Ma X, Ma H, Chai Z, Zhou Z, Yao J, Zhang X, Liu JY
  TITLE     Gain-of-function mutations in SCN11A cause familial episodic pain.
  JOURNAL   Am J Hum Genet 93:957-66 (2013)
///
ENTRY       H01392                      Disease
NAME        Arthrogryposis, mental retardation, and seizures (AMRS)
DESCRIPTION Arthrogryposis, mental retardation, and seizures (AMRS) is a neuroskeletal disorder comprising autism spectrum disorder (ASD), epilepsy, and arthrogryposis. Mutations in the SLC35A3 gene are associated with AMRS. The gene encodes a UDP-GlcNAc transporter, and the mutations abolish its activity.
CATEGORY    Skeletal dysplasia; Epilepsy
GENE        SLC35A3 [hsa:23443] [KO:K15272]
DBLINKS     OMIM: 615553
REFERENCE   PMID:24031089 (description, gene)
  AUTHORS   Edvardson S, Ashikov A, Jalas C, Sturiale L, Shaag A, Fedick A, Treff NR, Garozzo D, Gerardy-Schahn R, Elpeleg O
  TITLE     Mutations in SLC35A3 cause autism spectrum disorder, epilepsy and arthrogryposis.
  JOURNAL   J Med Genet 50:733-9 (2013)
///
ENTRY       H01393                      Disease
NAME        Van Maldergem syndrome (VMLDS/VMS);
            Cerebro-facio-articular syndrome
DESCRIPTION Van Maldergem syndrome (VMS) is an autosomal-recessive disorder characterized by intellectual disability, hypotonia, distinctive combination of minor facial anomalies, finger camptodactyly, and joint hyperlaxity. Biallelic mutations in genes encoding the receptor-ligand cadherin pair DCHS1 and FAT4 result in VMS.
CATEGORY    Skeletal dysplasia; Musculoskeletal disease
GENE        (VMLDS1) DCHS1 [hsa:8642] [KO:K16507]
            (VMLDS2) FAT4 [hsa:79633] [KO:K16669]
DBLINKS     MeSH: C536530
            OMIM: 601390 615546
REFERENCE   PMID:24056717 (description, gene)
  AUTHORS   Cappello S, Gray MJ, Badouel C, Lange S, Einsiedler M, Srour M, Chitayat D, Hamdan FF, Jenkins ZA, Morgan T, Preitner N, Uster T, Thomas J, Shannon P, Morrison V, Di Donato N, Van Maldergem L, Neuhann T, Newbury-Ecob R, Swinkells M, Terhal P, Wilson LC, Zwijnenburg PJ, Sutherland-Smith AJ, Black MA, Markie D, Michaud JL, Simpson MA, Mansour S, McNeill H, Gotz M, Robertson SP
  TITLE     Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
  JOURNAL   Nat Genet 45:1300-8 (2013)
REFERENCE   PMID:22469822 (description)
  AUTHORS   Neuhann TM, Muller D, Hackmann K, Holzinger S, Schrock E, Di Donato N
  TITLE     A further patient with van Maldergem syndrome.
  JOURNAL   Eur J Med Genet 55:423-8 (2012)
///
ENTRY       H01394                      Disease
NAME        Cole disease
DESCRIPTION Cole disease is a rare autosomal-dominant disorder characterized by congenital or early-onset punctate keratoderma associated with irregularly shaped hypopigmented macules, which are typically found over the arms and legs, but not the trunk or acral regions. Mutations in ENPP1, encoding ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), are associated with Cole disease. ENPP1 catalyzes the hydrolysis of ATP to AMP and generates extracellular inorganic pyrophosphate.
CATEGORY    Skin and connective tissue disease
GENE        ENPP1 [HSA:5167] [KO:K01513]
DBLINKS     OMIM: 615522
REFERENCE   PMID:24075184 (description, gene)
  AUTHORS   Eytan O, Morice-Picard F, Sarig O, Ezzedine K, Isakov O, Li Q, Ishida-Yamamoto A, Shomron N, Goldsmith T, Fuchs-Telem D, Adir N, Uitto J, Orlow SJ, Taieb A, Sprecher E
  TITLE     Cole Disease Results from Mutations in ENPP1.
  JOURNAL   Am J Hum Genet 93:752-7 (2013)
REFERENCE   PMID:19380683 (description)
  AUTHORS   Moore MM, Orlow SJ, Kamino H, Wang N, Schaffer JV
  TITLE     Cole disease: guttate hypopigmentation and punctate palmoplantar keratoderma.
  JOURNAL   Arch Dermatol 145:495-7 (2009)
///
ENTRY       H01395                      Disease
NAME        POLG related disorders, including:
            Alpers syndrome [DS:H01389];
            Childhood myocerebrohepatopathy spectrum (MCHS);
            The ataxia neuropathy spectrum (ANS)  [DS:H01384];
            Myoclonic epilepsy myopathy sensory ataxia (MEMSA);
            Progressive external ophthalmoplegia [DS:H01118]
DESCRIPTION Except for autosomal dominant progressive external ophthalmoplegia, all of other POLG-related disorders are inherited in an autosomal recessive manner. The POLG-related disorders comprise a continuous spectrum of overlapping symptoms and signs; and range from a rapidly fatal infantile cerebrohepatic disease to a progressive external ophthalmoplegia (PEO) that may not present until the sixth decade of life. The POLG gene is comprised of a polymerase domain, linker region domain and exonuclease domain. Mutations in the polymerase domain tend to result in reduced synthesis of mtDNA. Exonuclease domain mutations result in a high frequency of randomly distributed rare mtDNA point mutations. Mutations within the Linker region can influence the association of POLG with the accessory subunit POLG2.
CATEGORY    Inherited metabolic disease; Mitochondrial disease
GENE        POLG [HSA:5428] [KO:K02332]
DBLINKS     ICD-10: E88.8
            MeSH: D002549 C579990 C564395 D017246 C564926
            OMIM: 203700 607459 157640 258450
REFERENCE   PMID:20558295 (mutations)
  AUTHORS   Cohen BH, Naviaux RK
  TITLE     The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders.
  JOURNAL   Methods 51:364-73 (2010)
REFERENCE   PMID:20301791
  AUTHORS   Cohen BH, Chinnery PF, Copeland WC
  TITLE     POLG-Related Disorders
  JOURNAL   (1993)
///
ENTRY       H01396                      Disease
NAME        Moyamoya Disease
DESCRIPTION Moyamoya disease is a rare cerebrovascular disease characterized by a progressive stenosis or occlusion of the terminal portion of the internal carotid artery. This disease is associated with the compensatory development of abnormally thin and fragile collateral vessels at the base of the brain.
CATEGORY    Cerebrovascular disease
GENE        RNF213 [HSA:57674]
            ACTA2 [HSA:59] [KO:K12313]
            GUCY1A3 [HSA:2982] [KO:K12318]
COMMENT     The homozygous c.14576G>A variant in RNF213 could be a good DNA biomarker for predicting the severe type of Moyamoya Disease.
DBLINKS     ICD-10: I67.5
            MeSH: D009072
            OMIM: 252350 607151 614042 615750
REFERENCE   PMID:20591301
  AUTHORS   Komiyama M
  TITLE     Moyamoya Disease is a Progressive Occlusive Arteriopathy of the Primitive Internal Carotid Artery.
  JOURNAL   Interv Neuroradiol 9:39-45 (2003)
REFERENCE   PMID:21048783
  AUTHORS   Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J, Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S
  TITLE     A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.
  JOURNAL   J Hum Genet 56:34-40 (2011)
REFERENCE   PMID:22377813
  AUTHORS   Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, Tsurusaki Y, Doi H, Sakai H, Saitsu H, Shimojima K, Yamamoto T, Higurashi M, Kawahara N, Kawauchi H, Nagasaka K, Okamoto N, Mori T, Koyano S, Kuroiwa Y, Taguri M, Morita S, Matsubara Y, Kure S, Matsumoto N
  TITLE     Homozygous c.14576G&gt;A variant of RNF213 predicts early-onset and severe form of moyamoya disease.
  JOURNAL   Neurology 78:803-10 (2012)
REFERENCE   PMID:19409525
  AUTHORS   Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, Kim DH, Pannu H, Willing MC, Sparks E, Pyeritz RE, Singh MN, Dalman RL, Grotta JC, Marian AJ, Boerwinkle EA, Frazier LQ, LeMaire SA, Coselli JS, Estrera AL, Safi HJ, Veeraraghavan S, Muzny DM, Wheeler DA, Willerson JT, Yu RK, Shete SS, Scherer SE, Raman CS, Buja LM, Milewicz DM
  TITLE     Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease.
  JOURNAL   Am J Hum Genet 84:617-27 (2009)
REFERENCE   PMID:24581742
  AUTHORS   Herve D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, Bergametti F, Essongue A, Berrou E, Krivosic V, Sainte-Rose C, Houdart E, Adam F, Billiemaz K, Lebret M, Roman S, Passemard S, Boulday G, Delaforge A, Guey S, Dray X, Chabriat H, Brouckaert P, Bryckaert M, Tournier-Lasserve E
  TITLE     Loss of alpha1beta1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia.
  JOURNAL   Am J Hum Genet 94:385-94 (2014)
///
ENTRY       H01397                      Disease
NAME        Tick-borne lymphadenopathy;
            Tick-borne lymphadenitis
DESCRIPTION Rickettsia species are arthropod-associated intracellular bacteria and cause diseases in human such as Tick-borne lymphadenopathy, Typhus fever and Spotted fever. Dermacentor marginatus and Dermacentor reticulatus are known vector of Rickettsia slovaca that is the main agent of tick-borne lymphadenopathy (TIBOLA), which is found only in Europe. Its symptoms are generally mild and can be characterized by inoculation eschar on the scalp and cervical lymphadenopathies after a tick bite. Moreover, most of the cases occur during European cool months related to the activity of Dermacentor ticks.
CATEGORY    Infectious disease
PATHOGEN    Rickettsia slovaca [GN:rsv]
DBLINKS     ICD-10: R59 L04 I88
            MeSH: D008199 D008206
REFERENCE   PMID:22374949 (description)
  AUTHORS   Fournier PE, El Karkouri K, Robert C, Medigue C, Raoult D
  TITLE     Complete genome sequence of Rickettsia slovaca, the agent of tick-borne lymphadenitis.
  JOURNAL   J Bacteriol 194:1612 (2012)
REFERENCE   PMID:19547738 (description)
  AUTHORS   Dobler G, Wolfel R
  TITLE     Typhus and other rickettsioses: emerging infections in Germany.
  JOURNAL   Dtsch Arztebl Int 106:348-54 (2009)
///
ENTRY       H01398                      Disease
NAME        Primary hyperammonemic disorders (Urea cycle disorders), including:
            N-acetylglutamate synthase (NAGS) deficiency [DS:H01032];
            Carbamoylphosphate synthetase 1 (CPS1) deficiency [DS:H00164];
            Ornithine carbamoyltransferase (OTC) deficiency [DS:H00187];
            Argininosuccinate synthetase (ASS) deficiency [DS:H00185];
            Argininosuccinate lyase (ASL) deficiency [DS:H01028];
            Arginase 1 (AR1) deficiency [DS:H00186];
            Hyperammonemia-Hyperornithinemia-Homocitrullinuria syndrome [DS:H01268];
            Citrullinemia type II  [DS:H00185]
DESCRIPTION Hyperammonemia is a metabolic condition characterized by elevated levels of ammonia in the blood, and may result in irreversible brain damage if not treated early and thoroughly. Hyperammonemia can be classified into primary or secondary hyperammonemias depending on the underlying pathophysiology. Detoxification of ammonia is mainly accomplished by the urea cycle in periportal hepatocytes. If the urea cycle is directly affected by a defect of any of the involved enzymes or transporters, this results in primary hyperammonemia.
CATEGORY    Inherited metabolic disease
GENE        NAGS [HSA:162417] [KO:K11067]
            CPS1 [HSA:1373] [KO:K01948]
            OTC [HSA:5009] [KO:K00611]
            ASS1 [HSA:445] [KO:K01940]
            ASL [HSA:435] [KO:K01755]
            ARG1 [HSA:383] [KO:K01476]
            SLC25A15 [HSA:10166] [KO:K15101]
            SLC25A13 [HSA:10165] [KO:K15105]
MARKER      Plasma ammonia level >50 micromol/L (>100 micromol/L in newborns)
DRUG        Sodium phenylbutyrate [DR:D05868]
            Sodium phenylacetate and sodium benzoate [DR:D10205]
            Arginine glutamate [DR:D02397]
            Arginine [DR:D01126]
DBLINKS     ICD-10: E72.2
            MeSH: D022124 D056806
            OMIM: 237310 237300 311250 215700 207900 207800 238970 603471 605814
REFERENCE   PMID:23628343
  AUTHORS   Haberle J
  TITLE     Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.
  JOURNAL   Arch Biochem Biophys 536:101-8 (2013)
REFERENCE   PMID:20138956
  AUTHORS   Wilkinson DJ, Smeeton NJ, Watt PW
  TITLE     Ammonia metabolism, the brain and fatigue; revisiting the link.
  JOURNAL   Prog Neurobiol 91:200-19 (2010)
REFERENCE   PMID:25042691 (drug)
  AUTHORS   Burrage LC, Jain M, Gandolfo L, Lee BH, Nagamani SC
  TITLE     Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders.
  JOURNAL   Mol Genet Metab 113:131-5 (2014)
REFERENCE   PMID:25908985 (drug)
  AUTHORS   Machado MC, Pinheiro da Silva F
  TITLE     Hyperammonemia due to urea cycle disorders: a potentially fatal condition in the  intensive care setting.
  JOURNAL   J Intensive Care 2:22 (2014)
REFERENCE   PMID:25895618 (drug)
  AUTHORS   Matoori S, Leroux JC
  TITLE     Recent advances in the treatment of hyperammonemia.
  JOURNAL   Adv Drug Deliv Rev 90:55-68 (2015)
///
ENTRY       H01399                      Disease
NAME        Bacillus thuringiensis infection
DESCRIPTION Bacillus thuringiensis is a close taxonomic relative of Bacillus cereus and an insect pathogen that is widely used as a biopesticide. Additionally, this bacterium is known to induce myonecrosis in immunosuppressed mice after cutaneous infection. Human infection is unusual, and apart from gastrointestinal tract infections or those following laboratory contamination, there are only two clinical reports of B. thuringiensis infection. Both the cases were isolated from severe human tissue necrosis by burn wounds or severe war wounds.
CATEGORY    Infectious disease
PATHOGEN    Bacillus thuringiensis [GN:btk]
REFERENCE   PMID:9215586 (description)
  AUTHORS   Damgaard PH, Granum PE, Bresciani J, Torregrossa MV, Eilenberg J, Valentino L
  TITLE     Characterization of Bacillus thuringiensis isolated from infections in burn wounds.
  JOURNAL   FEMS Immunol Med Microbiol 18:47-53 (1997)
REFERENCE   PMID:10340711 (description)
  AUTHORS   Hernandez E, Ramisse F, Cruel T, le Vagueresse R, Cavallo JD
  TITLE     Bacillus thuringiensis serotype H34 isolated from human and insecticidal strains  serotypes 3a3b and H14 can lead to death of immunocompetent mice after pulmonary  infection.
  JOURNAL   FEMS Immunol Med Microbiol 24:43-7 (1999)
REFERENCE   PMID:9650985 (description)
  AUTHORS   Hernandez E, Ramisse F, Ducoureau JP, Cruel T, Cavallo JD
  TITLE     Bacillus thuringiensis subsp. konkukian (serotype H34) superinfection: case report and experimental evidence of pathogenicity in immunosuppressed mice.
  JOURNAL   J Clin Microbiol 36:2138-9 (1998)
///
ENTRY       H01400                      Disease
NAME        Secondary hyperammonemia, including:
            Methylmalonic aciduria [DS:H00174];
            Propionic aciduria [DS:H00175];
            Isovaleric aciduria [DS:H00173];
            Fatty acid oxidation and carnitine cycle defects [DS:H00525];
            Glutaric acidemia [DS:H00178];
            Lysinuric protein intolerance [DS:H00899];
            Pyruvate carboxylase deficiency [DS:H00073];
            Ornithinaemia [DS:H00189];
            Hyperinsulinism-hyperammonemia syndrome;
            Glutamine synthetase deficiency [DS:H00923]
DESCRIPTION Hyperammonemia is a metabolic condition characterized by elevated levels of ammonia in the blood, and may result in irreversible brain damage if not treated early and thoroughly. Hyperammonemia can be classified into primary or secondary hyperammonemias depending on the underlying pathophysiology. Detoxification of ammonia is mainly accomplished by the urea cycle in periportal hepatocytes. The function of the urea cycle may be affected in a secondary way in a number of different situations. For example, intermediary metabolites that accumulate due to enzymatic defects in other pathways, may inhibit the urea cycle. The most relevant group of disorders in this respect is that of organic acidemias. The urea cycle function may be impaired by substrate deficiencies assumed cause in various disorders including lysinuric protein intolerance, pyrroline-5-carboxylate synthetase deficiency, and fatty acid oxidation defects. In addition to the urea cycle, mammals require the function of glutamine synthetase to completely detoxify ammonia.
CATEGORY    Inherited metabolic disease
GENE        MUT [HSA:4594] [KO:K01847]
            PCCA [HSA:5095] [KO:K01965]
            PCCB [HSA:5096] [KO:K01966]
            IVD [HSA:3712] [KO:K00253]
            ACADM [HSA:34] [KO:K00249]
            ETFDH [HSA:2110] [KO:K00311]
            ETFA [HSA:2108] [KO:K03522]
            ETFB [HSA:2109] [KO:K03521]
            CPT2 [HSA:1376] [KO:K08766]
            SLC25A20 [HSA:788] [KO:K15109]
            SLC7A7 [HSA:9056] [KO:K13867]
            ALDH18A1 [HSA:5832] [KO:K12657]
            PC [HSA:5091] [KO:K01958]
            OAT [HSA:4942] [KO:K00819]
            CA5A [HSA:763] [KO:K01672]
            GLUD1 [HSA:2746] [KO:K00261]
            TMEM70 [HSA:54968] [KO:K17966]
            GLUL [HSA:2752] [KO:K01915]
MARKER      Plasma ammonia level >50 micromol/L (>100 micromol/L in newborns)
DRUG        Lactitol [DR:D02039] (hepatic encephalopathy)
            Lactulose [DR:D00352]
            Arginine glutamate [DR:D02397]
DBLINKS     ICD-10: E72.2
            MeSH: D022124
            OMIM: 251000 606054 243500 201450 231680 608836 212138 222700 219150 266150 258870 615751 606762 614052 610015
REFERENCE   PMID:23628343
  AUTHORS   Haberle J
  TITLE     Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.
  JOURNAL   Arch Biochem Biophys 536:101-8 (2013)
REFERENCE   PMID:19707277 (drug)
  AUTHORS   Al Sibae MR, McGuire BM
  TITLE     Current trends in the treatment of hepatic encephalopathy.
  JOURNAL   Ther Clin Risk Manag 5:617-26 (2009)
REFERENCE   PMID:25895618 (drug)
  AUTHORS   Matoori S, Leroux JC
  TITLE     Recent advances in the treatment of hyperammonemia.
  JOURNAL   Adv Drug Deliv Rev 90:55-68 (2015)
REFERENCE   PMID:14085036 (drug)
  AUTHORS   SCHROEDER HA
  TITLE     AN AMMONIA DETOXICANT, ARGININE GLUTAMATE.
  JOURNAL   JAMA 187:359-60 (1964)
///
ENTRY       H01401                      Disease
NAME        Methicillin-resistant Staphylococcus epidermidis (MRSE) infection
DESCRIPTION The genus Staphylococcus known as pathogen of human and other mammals causes various diseases ranging from minor skin infections to life-threatening bacteremia. The two major opportunistic pathogens in the Staphylococcus genus, Staphylococcus aureus and Staphylococcus epidermis, colonize a sizable portion of the human population. S. epidermidis as the predominant species is quite widespread throughout the cutaneous ecosystem, whereas S. aureus colonizes primarily on mucosal surfaces. Staphylococcal infections are commonly caused by S. aureus. However, the infections due to S. epidermidis and other coagulase-negative staphylococci have been also increasing. S. epidermidis is primarily associated with infections of implanted medical devices, such as prosthetic heart valves and joint prostheses. The treatments of staphylococcal infections are complicated by the development of antibiotic resistance, and the remaining effective treatment against most strains of multidrug-resistant staphylococci, including MRSA and MRSE, is the glycopeptide antibiotic vancomycin.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus epidermidis [GN:ser]
DBLINKS     ICD-10: B95
REFERENCE   PMID:15774886 (description)
  AUTHORS   Gill SR, Fouts DE, Archer GL, Mongodin EF, Deboy RT, Ravel J, Paulsen IT, Kolonay JF, Brinkac L, Beanan M, Dodson RJ, Daugherty SC, Madupu R, Angiuoli SV, Durkin AS, Haft DH, Vamathevan J, Khouri H, Utterback T, Lee C, Dimitrov G, Jiang L, Qin H, Weidman J, Tran K, Kang K, Hance IR, Nelson KE, Fraser CM.
  TITLE     Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain.
  JOURNAL   J Bacteriol 187:2426-38 (2005)
REFERENCE   PMID:20419353 (description)
  AUTHORS   Nomura K, Mizumachi E, Yamashita M, Ohshiro M, Komori T, Sugai M, Taniwaki M, Ishida Y
  TITLE     Drug susceptibility and clonality of methicillin-resistant Staphylococcus epidermidis in hospitalized patients with hematological malignancies.
  JOURNAL   Ir J Med Sci 179:351-6 (2010)
///
ENTRY       H01402                      Disease
NAME        Nicolaides-Baraitser syndrome
DESCRIPTION Nicolaides-Baraitser syndrome (NBS) is characterized by sparse hair, distinctive facial morphology, distal-limb anomalies, and intellectual disability. Heterozygous missense mutations in SMARCA2 cause this disease.
CATEGORY    Developmental disorder
GENE        SMARCA2 [HSA:6595] [KO:K11647]
DBLINKS     MeSH: C536116
            OMIM: 601358
REFERENCE   PMID:22366787
  AUTHORS   Van Houdt JK, Nowakowska BA, Sousa SB, van Schaik BD, Seuntjens E, Avonce N, Sifrim A, Abdul-Rahman OA, van den Boogaard MJ, Bottani A, Castori M, Cormier-Daire V, Deardorff MA, Filges I, Fryer A, Fryns JP, Gana S, Garavelli L, Gillessen-Kaesbach G, Hall BD, Horn D, Huylebroeck D, Klapecki J, Krajewska-Walasek M, Kuechler A, Lines MA, Maas S, Macdermot KD, McKee S, Magee A, de Man SA, Moreau Y, Morice-Picard F, Obersztyn E, Pilch J, Rosser E, Shannon N, Stolte-Dijkstra I, Van Dijck P, Vilain C, Vogels A, Wakeling E, Wieczorek D, Wilson L, Zuffardi O, van Kampen AH, Devriendt K, Hennekam R, Vermeesch JR
  TITLE     Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome.
  JOURNAL   Nat Genet 44:445-9, S1 (2012)
REFERENCE   PMID:23010866
  AUTHORS   Santen GW, Kriek M, van Attikum H
  TITLE     SWI/SNF complex in disorder: SWItching from malignancies to intellectual disability.
  JOURNAL   Epigenetics 7:1219-24 (2012)
///
ENTRY       H01403                      Disease
NAME        Coffin-Siris syndrome
DESCRIPTION Coffin-Siris syndrome is a rare congenital anomaly syndrome characterized by growth deficiency, severe intellectual disability, microcephaly, coarse facial features and hypoplastic nail of the fifth finger and/or toe. Recently, it has been reported that mutations in genes encoding subunits of the SWI/SNF complex cause this disease.
CATEGORY    Developmental disorder
GENE        SMARCB1 [HSA:6598] [KO:K11648]
            SMARCA4 [HSA:6597] [KO:K11647]
            SMARCA2 [HSA:6595] [KO:K11647]
            SMARCE1 [HSA:6605] [KO:K11651]
            ARID1A [HSA:8289] [KO:K11653]
            ARID1B [HSA:57492] [KO:K11653]
DBLINKS     ICD-10: Q87.1
            MeSH: C536436
            OMIM: 135900
REFERENCE   PMID:22426308
  AUTHORS   Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, Fukushima Y, Homma T, Kato M, Hiraki Y, Yamagata T, Yano S, Mizuno S, Sakazume S, Ishii T, Nagai T, Shiina M, Ogata K, Ohta T, Niikawa N, Miyatake S, Okada I, Mizuguchi T, Doi H, Saitsu H, Miyake N, Matsumoto N
  TITLE     Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.
  JOURNAL   Nat Genet 44:376-8 (2012)
REFERENCE   PMID:22426309
  AUTHORS   Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilhorst-Hofstee Y, Wessels MW, den Hollander NS, Ruivenkamp CA, van Ommen GJ, Breuning MH, den Dunnen JT, van Haeringen A, Kriek M
  TITLE     Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris  syndrome.
  JOURNAL   Nat Genet 44:379-80 (2012)
REFERENCE   PMID:23815551
  AUTHORS   Tsurusaki Y, Okamoto N, Ohashi H, Mizuno S, Matsumoto N, Makita Y, Fukuda M, Isidor B, Perrier J, Aggarwal S, Dalal AB, Al-Kindy A, Liebelt J, Mowat D, Nakashima M, Saitsu H, Miyake N, Matsumoto N
  TITLE     Coffin-Siris syndrome is a SWI/SNF complex disorder.
  JOURNAL   Clin Genet 85:548-54 (2014)
///
ENTRY       H01404                      Disease
NAME        Punctate palmoplantar keratoderma (PPKP), including:
            Brauer-Buschke-Fischer disease;
            Porokeratosis punctata palmaris et plantaris;
            Acrokeratoelastoidosis
DESCRIPTION Punctate palmoplantar keratodermas (PPKPs) are rare autosomal-dominant inherited skin diseases that are characterized by multiple hyperkeratotic plaques distributed on the palms and soles. PPKPs are classified into 3 types; PPKP1 (Brauer-Buschke-Fischer disease), PPKP2 (porokeratosis punctata palmaris et plantaris), and PPKP3 (Acrokeratoelastoidosis lichenoides). PPKP has previously been mapped to chromosomal region 15q22-15q24 and region 8q24.13-8q24.21, but the molecular basis has not been identified yet. Recently, it has been reported that nonsense mutations in AAGAB gene cause PPKP1.
CATEGORY    Skin and connective tissue disease
GENE        (PPKP1A) AAGAB [HSA:79719]
            (PPKP1B) COL14A1 [HSA:7373] [KO:K08133]
DBLINKS     ICD-10: Q82.8
            MeSH: C536161 C535653
            OMIM: 148600 614936 175860 101850
REFERENCE   PMID:23000146
  AUTHORS   Giehl KA, Eckstein GN, Pasternack SM, Praetzel-Wunder S, Ruzicka T, Lichtner P, Seidl K, Rogers M, Graf E, Langbein L, Braun-Falco M, Betz RC, Strom TM
  TITLE     Nonsense mutations in AAGAB cause punctate palmoplantar keratoderma type Buschke-Fischer-Brauer.
  JOURNAL   Am J Hum Genet 91:754-9 (2012)
REFERENCE   PMID:23064416
  AUTHORS   Pohler E, Mamai O, Hirst J, Zamiri M, Horn H, Nomura T, Irvine AD, Moran B, Wilson NJ, Smith FJ, Goh CS, Sandilands A, Cole C, Barton GJ, Evans AT, Shimizu H, Akiyama M, Suehiro M, Konohana I, Shboul M, Teissier S, Boussofara L, Denguezli M, Saad A, Gribaa M, Dopping-Hepenstal PJ, McGrath JA, Brown SJ, Goudie DR, Reversade B, Munro CS, McLean WH
  TITLE     Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma.
  JOURNAL   Nat Genet 44:1272-6 (2012)
REFERENCE   PMID:22972947
  AUTHORS   Guo BR, Zhang X, Chen G, Zhang JG, Sun LD, Du WD, Zhang Q, Cui Y, Zhu J, Tang XF, Xiao R, Liu Y, Li M, Tang HY, Yang X, Cheng H, Li M, Gao M, Li P, Wang JB, Xu FP, Zuo XB, Zheng XD, Zhang XG, Yang L, Liu JJ, Wang J, Yang S, Zhang XJ
  TITLE     Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma.
  JOURNAL   J Med Genet 49:563-8 (2012)
///
ENTRY       H01405                      Disease
NAME        Lactococcus garvieae infection
DESCRIPTION Lactococcus garvieae, catalase-negative, facultative anaerobic cocci, is a major pathogen of fish and causes fatal hemorrhagic septicemia in fish such as yellowtail and trout, and it has also been isolated from buffaloes with mastitis, and clinical specimens of human blood, urine, and skin. However, it is an unusual human pathogen. Only a few infections have been described so far, including several cases of infective endocarditis on native or prosthetic valve, one case of osteomyelitis, and septicaemia with liver abscess.
CATEGORY    Infectious disease
PATHOGEN    Lactococcus garvieae [GN:lgv]
REFERENCE   PMID:21935642 (description)
  AUTHORS   Nadrah K, Cerar T, Papst L, Volkar-Meglic J, Maticic M, Karner P, Vidmar L, Premru MM, Beovic B
  TITLE     Lactococcus garvieae septicaemia in a patient with artificial heart valves.
  JOURNAL   Wien Klin Wochenschr 123:677-9 (2011)
REFERENCE   PMID:21829716 (description)
  AUTHORS   Morita H, Toh H, Oshima K, Yoshizaki M, Kawanishi M, Nakaya K, Suzuki T, Miyauchi E, Ishii Y, Tanabe S, Murakami M, Hattori M
  TITLE     Complete genome sequence and comparative analysis of the fish pathogen Lactococcus garvieae.
  JOURNAL   PLoS One 6:e23184 (2011)
///
ENTRY       H01406                      Disease
NAME        Streptococcus suis infection
DESCRIPTION Streptococcus suis, a Gram positive coccus, is a zoonotic pathogen that infects pigs and can occasionally cause serious infections in humans. Although it is generally carried asymptomatically in adult pigs, it can cause severe systemic disease in piglets, manifested as a rapidly fatal sepsis associated with meningitis, polyarthritis and pneumonia. The first case in humans was reported in Denmark in 1968. Human infection with S. suis occurs sporadically in Europe and North-America and case reports suggest that it is almost exclusively related to occupational exposure to pigs or pork products. Incidences of human infection with S. suis are greater in S.E. Asia and China. Meningitis is the most common presentation in humans, but septicaemia and endocarditis are also seen.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus suis [GN:ssb ssi sss ssk ssq ssw sui suo ssuy ssus]
DBLINKS     ICD-10: G00.2
            MeSH: D008581
REFERENCE   PMID:19603075 (description)
  AUTHORS   Holden MT, Hauser H, Sanders M, Ngo TH, Cherevach I, Cronin A, Goodhead I, Mungall K, Quail MA, Price C, Rabbinowitsch E, Sharp S, Croucher NJ, Chieu TB, Mai NT, Diep TS, Chinh NT, Kehoe M, Leigh JA, Ward PN, Dowson CG, Whatmore AM, Chanter N, Iversen P, Gottschalk M, Slater JD, Smith HE, Spratt BG, Xu J, Ye C, Bentley S, Barrell BG, Schultsz C, Maskell DJ, Parkhill J
  TITLE     Rapid evolution of virulence and drug resistance in the emerging zoonotic pathogen Streptococcus suis.
  JOURNAL   PLoS One 4:e6072 (2009)
///
ENTRY       H01407                      Disease
NAME        Capnocytophaga ochracea infection
DESCRIPTION Capnocytophaga ochracea is a Gram-negative bacterium, capnophilic (CO2-requiring) organism, originally isolated from a human oral cavity. C. ochracea is a normal inhabitant of the human mouth and other non-oral sites and associated with juvenile and adult periodontitis and may cause severe infections in immunocompromised as well as in immunocompetent patients. Among these are endocarditis, endometritis, osteomyelitis, abscesses, peritonitis, and keratitis.
CATEGORY    Infectious disease
PATHOGEN    Capnocytophaga ochracea [GN:coc]
DBLINKS     ICD-10: K05 
            MeSH: D010518
REFERENCE   PMID:21304645 (description)
  AUTHORS   Mavrommatis K, Gronow S, Saunders E, Land M, Lapidus A, Copeland A, Glavina Del Rio T, Nolan M, Lucas S, Chen F, Tice H, Cheng JF, Bruce D, Goodwin L, Pitluck S, Pati A, Ivanova N, Chen A, Palaniappan K, Chain P, Hauser L, Chang YJ, Jeffries CD, Brettin T, Detter JC, Han C, Bristow J, Goker M, Rohde M, Eisen JA, Markowitz V, Kyrpides NC, Klenk HP, Hugenholtz P
  TITLE     Complete genome sequence of Capnocytophaga ochracea type strain (VPI 2845).
  JOURNAL   Stand Genomic Sci 1:101-9 (2009)
///
ENTRY       H01408                      Disease
NAME        Periodontal diseases
DESCRIPTION During the early stages of the periodontal disease, saccharolytic, aerobic Streptococcus spp. and other bacteria adhere to and colonize the tooth enamel and root surface. This sets the stage for Fusobacterium nucleatum to coaggregate with these early colonizers and to permit late colonizers, including dental pathogens, to eventually form a biofilm. These complex interactions result in the release of factors that lead to tooth decay. Physical interaction is very specific among various genera in this complex microbial community. Due to the unusual length, adhesive nature, and other cell surface properties of F. nucleatum, periodontal disease-causing bacteria such as Porphyromonas gingivalis, Bacteroides forsythus, Aggregatibacter actinomycetemcomitans, Treponema denticola, and Streptococcus spp. aggregate and thrive; hence, F. nucleatum is thought of as a 'bridge bacterium'.
CATEGORY    Infectious disease
PATHOGEN    Fusobacterium nucleatum [GN:fnu]
            Porphyromonas gingivalis [GN:pgi pgn pgt]
            Treponema denticola [GN:tde]
            Aggregatibacter actinomycetemcomitans [GN:aat aan]
            Olsenella uli [GN:ols]
            Cryptobacterium curtum [GN:ccu]
DBLINKS     ICD-10: K05 
            MeSH: D010510
REFERENCE   PMID:11889109 (description)
  AUTHORS   Kapatral V, Anderson I, Ivanova N, Reznik G, Los T, Lykidis A, Bhattacharyya A, Bartman A, Gardner W, Grechkin G, Zhu L, Vasieva O, Chu L, Kogan Y, Chaga O, Goltsman E, Bernal A, Larsen N, D'Souza M, Walunas T, Pusch G, Haselkorn R, Fonstein M, Kyrpides N, Overbeek R.
  TITLE     Genome sequence and analysis of the oral bacterium Fusobacterium nucleatum strain ATCC 25586.
  JOURNAL   J Bacteriol 184:2005-18 (2002)
REFERENCE   PMID:12949112 (pathogen)
  AUTHORS   Nelson KE, Fleischmann RD, DeBoy RT, Paulsen IT, Fouts DE, Eisen JA, Daugherty SC, Dodson RJ, Durkin AS, Gwinn M, Haft DH, Kolonay JF, Nelson WC, Mason T, Tallon L, Gray J, Granger D, Tettelin H, Dong H, Galvin JL, Duncan MJ, Dewhirst FE, Fraser CM.
  TITLE     Complete genome sequence of the oral pathogenic Bacterium porphyromonas gingivalis strain W83.
  JOURNAL   J Bacteriol 185:5591-601 (2003)
REFERENCE   PMID:18524787 (pathogen)
  AUTHORS   Naito M, Hirakawa H, Yamashita A, Ohara N, Shoji M, Yukitake H, Nakayama K, Toh H, Yoshimura F, Kuhara S, Hattori M, Hayashi T, Nakayama K.
  TITLE     Determination of the genome sequence of Porphyromonas gingivalis strain ATCC 33277 and genomic comparison with strain W83 revealed extensive genome rearrangements in P. gingivalis.
  JOURNAL   DNA Res 15:215-25 (2008)
REFERENCE   PMID:21705612 (pathogen)
  AUTHORS   Watanabe T, Maruyama F, Nozawa T, Aoki A, Okano S, Shibata Y, Oshima K, Kurokawa K, Hattori M, Nakagawa I, Abiko Y
  TITLE     Complete genome sequence of the bacterium Porphyromonas gingivalis TDC60, which causes periodontal disease.
  JOURNAL   J Bacteriol 193:4259-60 (2011)
REFERENCE   PMID:15064399 (pathogen)
  AUTHORS   Seshadri R, Myers GS, Tettelin H, Eisen JA, Heidelberg JF, Dodson RJ, Davidsen TM, DeBoy RT, Fouts DE, Haft DH, Selengut J, Ren Q, Brinkac LM, Madupu R, Kolonay J, Durkin SA, Daugherty SC, Shetty J, Shvartsbeyn A, Gebregeorgis E, Geer K, Tsegaye G, Malek J, Ayodeji B, Shatsman S, McLeod MP, Smajs D, Howell JK, Pal S, Amin A, Vashisth P, McNeill TZ, Xiang Q, Sodergren E, Baca E, Weinstock GM, Norris SJ, Fraser CM, Paulsen IT.
  TITLE     Comparison of the genome of the oral pathogen Treponema denticola with other spirochete genomes.
  JOURNAL   Proc Natl Acad Sci U S A 101:5646-51 (2004)
REFERENCE   PMID:17488447 (description)
  AUTHORS   Thiha K, Takeuchi Y, Umeda M, Huang Y, Ohnishi M, Ishikawa I
  TITLE     Identification of periodontopathic bacteria in gingival tissue of Japanese periodontitis patients.
  JOURNAL   Oral Microbiol Immunol 22:201-7 (2007)
///
ENTRY       H01409                      Disease
NAME        Methicillin-sensitive Staphylococcus aureus (MSSA) infection
DESCRIPTION Staphylococcus aureus is a Gram-positive human commensal bacterium persistently colonizing the anterior nares of about 30% of the human population. Methicillin-resistant S. aureus (MRSA) is known to have evolved from methicillin-susceptible S. aureus (MSSA) after acquiring the staphylococcal cassette chromosome mec (SCCmec) element which includes the mecA gene coding for resistance to the antibiotic methicillin. A highly cytotoxic and clinically virulent methicillin-sensitive strain, S. aureus strain 6850 is a well-characterized prototype strain isolated from a patient with a skin abscess which had progressed to S. aureus bacteremia, osteomyelitis, septic arthritis, and multiple systemic abscesses.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus aureus [GN:saue]
DBLINKS     ICD-10: B95 
            MeSH: D013203
REFERENCE   PMID:24072870 (description)
  AUTHORS   Fraunholz M, Bernhardt J, Schuldes J, Daniel R, Hecker M, Sinha B
  TITLE     Complete Genome Sequence of Staphylococcus aureus 6850, a Highly Cytotoxic and Clinically Virulent Methicillin-Sensitive Strain with Distant Relatedness to Prototype Strains.
  JOURNAL   Genome Announc 1 (2013)
REFERENCE   PMID:23183202 (description)
  AUTHORS   Lim KT, Yeo CC, Suhaili Z, Thong KL
  TITLE     Comparison of methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains isolated from a tertiary hospital in Terengganu, Malaysia.
  JOURNAL   Jpn J Infect Dis 65:502-9 (2012)
///
ENTRY       H01410                      Disease
NAME        Anaerobic infection
DESCRIPTION Anaerobic infections are common and some are serious with a high mortality rate. The clinically important anaerobes are several genera of Gram-negative rods (Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Bilophila). Among the Gram-positive anaerobes, there are cocci (primarily Peptostreptococcus) and sporeforming (Clostridium) and non-sporeforming bacilli (especially Actinomyces and Propionibacterium). In terms of frequency, there are four major sites of anaerobic infection - pleuropulmonary, intra-abdominal, female genital tract, and skin and soft tissue infections (with or without involvement of underlying bone). Infectious diseases caused by these anaerobes include following symptoms, bacteremia, brain abscess, neck space infections and infections following head and neck surgery, chronic sinusitis and otitis media, dental and oral infections, pleuropulmonary infections, intra-abdominal infections, female genital tract infections, non-puerperal breast abscesses and diabetic foot ulcers.
CATEGORY    Infectious disease
PATHOGEN    Clostridium perfringens [GN:cpe cpf cpr]
            Clostridium botulinum [GN:cbo cba cbh cby cbl cbk cbb cbi cbt cbf cbj ctc]
            Peptoclostridium difficile [GN:cdf pdc cdc cdl cdg] 
            Finegoldia magna [GN:fma]
            Propionibacterium acnes [GN:pac paw pad]
            Fusobacterium nucleatum [GN:fnu]
            Bacteroides fragilis  [GN:bfr bfs]
            Porphyromonas gingivalis [GN:pgi pgn pgt]
            Parabacteroides distasonis [GN:pdi]
            Eggerthella lenta [GN:ele]
COMMENT     Infectious disease caused by Bacteroides spp., Prevotella spp., Porphyromonas spp., Porphyromonas spp., Fusobacterium spp., Peptostreptococcus spp., Clostridium spp., Bilophila spp. and Actinomyces spp..
DBLINKS     ICD-10: A49 B96
REFERENCE   PMID:16887500 (description)
  AUTHORS   Finegold SM
  TITLE     Anaerobic infections in humans: an overview.
  JOURNAL   Anaerobe 1:3-9 (1995)
REFERENCE   PMID:18263572 (description)
  AUTHORS   Goto T, Yamashita A, Hirakawa H, Matsutani M, Todo K, Ohshima K, Toh H, Miyamoto K, Kuhara S, Hattori M, Shimizu T, Akimoto S.
  TITLE     Complete genome sequence of Finegoldia magna, an anaerobic opportunistic pathogen.
  JOURNAL   DNA Res 15:39-47 (2008)
///
ENTRY       H01411                      Disease
NAME        Saccharomonospora viridis infection
DESCRIPTION Saccharomonospora viridis is the type species of the genus Saccharomonospora which belongs to the family Pseudonocardiaceae. Members of the species are frequently found in hot compost and hay, and its spores can cause farmer's lung disease, bagassosis, and humidifier fever. Spores of S. viridis are readily dispersed in air, and the prolonged exposure to spores can apparently result in acute respiratory distress which may lead to irreversible lung damage.
CATEGORY    Infectious disease
PATHOGEN    Saccharomonospora viridis [GN:svi]
DBLINKS     ICD-10: J67
REFERENCE   PMID:21304650 (description)
  AUTHORS   Pati A, Sikorski J, Nolan M, Lapidus A, Copeland A, Glavina Del Rio T, Lucas S, Chen F, Tice H, Pitluck S, Cheng JF, Chertkov O, Brettin T, Han C, Detter JC, Kuske C, Bruce D, Goodwin L, Chain P, D'haeseleer P, Chen A, Palaniappan K, Ivanova N, Mavromatis K, Mikhailova N, Rohde M, Tindall BJ, Goker M, Bristow J, Eisen JA, Markowitz V, Hugenholtz P, Kyrpides NC, Klenk HP
  TITLE     Complete genome sequence of Saccharomonospora viridis type strain (P101).
  JOURNAL   Stand Genomic Sci 1:141-9 (2009)
///
ENTRY       H01412                      Disease
NAME        Perlman syndrome
DESCRIPTION Perlman syndrome is a rare  autosomal recessive overgrowth disorder characterized by polyhydramnios with neonatal macrosomia, visceromegaly, distinctive facial appearance, renal dysplasia, nephroblastomatosis, and predisposition to Wilms tumor. It has been reported that germline mutations in DIS3L2 cause this disease.
CATEGORY    Developmental disorder
GENE        DIS3L2 [HSA:129563] [KO:K18758]
COMMENT     Perlman syndrome is with phenotypic similarities to Beckwith-Wiedemann syndrome. [DS:H00713]
DBLINKS     ICD-10: Q87.3
            MeSH: C536399
            OMIM: 267000
REFERENCE   PMID:22306653
  AUTHORS   Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA, Gill H, Gentle D, Shuib S, Ricketts CJ, Cole T, van Essen AJ, van Lingen RA, Neri G, Opitz JM, Rump P, Stolte-Dijkstra I, Muller F, Pruijn GJ, Latif F, Maher ER
  TITLE     Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.
  JOURNAL   Nat Genet 44:277-84 (2012)
REFERENCE   PMID:18780370
  AUTHORS   Alessandri JL, Cuillier F, Ramful D, Ernould S, Robin S, de Napoli-Cocci S, Riviere JP, Rossignol S
  TITLE     Perlman syndrome: report, prenatal findings and review.
  JOURNAL   Am J Med Genet A 146A:2532-7 (2008)
///
ENTRY       H01413                      Disease
NAME        Adams-Oliver syndrome (AOS)
DESCRIPTION Adams-Oliver syndrome (AOS) is a rare condition defined by the combination of aplasia cutis congenita (ACC), characterized by scalp and skull lesions, and transverse limb abnormalities. Mutations in ARHGAP31 (AOS1), RBPJ (AOS3) and NOTCH1 (AOS5) cause autosomal dominant AOS.  Mutations in DOCK6 (AOS2) and EOGT (AOS4) result in autosomal recessive AOS.
CATEGORY    Developmental disorder
GENE        (AOS1) ARHGAP31 [HSA:57514] [KO:K20646]
            (AOS2) DOCK6 [HSA:57572]
            (AOS3) RBPJ [HSA:3516] [KO:K06053]
            (AOS4) EOGT [HSA:285203] [KO:K18134]
            (AOS5) NOTCH1 [HSA:4851] [KO:K02599]
DBLINKS     ICD-10: Q87.2
            MeSH: C538225
            OMIM: 100300 614219 614814 615297 616028
REFERENCE   PMID:22307742
  AUTHORS   Silva G, Braga A, Leitao B, Mesquita A, Reis A, Duarte C, Barbot J, Silva ES
  TITLE     Adams-Oliver syndrome and portal hypertension: fortuitous association or common mechanism?
  JOURNAL   Am J Med Genet A 158A:648-51 (2012)
REFERENCE   PMID:21565291
  AUTHORS   Southgate L, Machado RD, Snape KM, Primeau M, Dafou D, Ruddy DM, Branney PA, Fisher M, Lee GJ, Simpson MA, He Y, Bradshaw TY, Blaumeiser B, Winship WS, Reardon W, Maher ER, FitzPatrick DR, Wuyts W, Zenker M, Lamarche-Vane N, Trembath RC
  TITLE     Gain-of-function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies.
  JOURNAL   Am J Hum Genet 88:574-85 (2011)
REFERENCE   PMID:21820096
  AUTHORS   Shaheen R, Faqeih E, Sunker A, Morsy H, Al-Sheddi T, Shamseldin HE, Adly N, Hashem M, Alkuraya FS
  TITLE     Recessive mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal actin cytoskeleton organization and Adams-Oliver syndrome.
  JOURNAL   Am J Hum Genet 89:328-33 (2011)
REFERENCE   PMID:22883147
  AUTHORS   Hassed SJ, Wiley GB, Wang S, Lee JY, Li S, Xu W, Zhao ZJ, Mulvihill JJ, Robertson J, Warner J, Gaffney PM
  TITLE     RBPJ mutations identified in two families affected by Adams-Oliver syndrome.
  JOURNAL   Am J Hum Genet 91:391-5 (2012)
REFERENCE   PMID:23522784
  AUTHORS   Shaheen R, Aglan M, Keppler-Noreuil K, Faqeih E, Ansari S, Horton K, Ashour A, Zaki MS, Al-Zahrani F, Cueto-Gonzalez AM, Abdel-Salam G, Temtamy S, Alkuraya FS
  TITLE     Mutations in EOGT confirm the genetic heterogeneity of autosomal-recessive Adams-Oliver syndrome.
  JOURNAL   Am J Hum Genet 92:598-604 (2013)
REFERENCE   PMID:25132448
  AUTHORS   Stittrich AB, Lehman A, Bodian DL, Ashworth J, Zong Z, Li H, Lam P, Khromykh A, Iyer RK, Vockley JG, Baveja R, Silva ES, Dixon J, Leon EL, Solomon BD, Glusman G, Niederhuber JE, Roach JC, Patel MS
  TITLE     Mutations in NOTCH1 cause Adams-Oliver syndrome.
  JOURNAL   Am J Hum Genet 95:275-84 (2014)
///
ENTRY       H01414                      Disease
NAME        Hafnia alvei infection
DESCRIPTION The genus Hafnia, a member of the family Enterobacteriaceae, is occasionally implicated in both intestinal and extraintestinal infections in humans. Hafnia alvei is a facultative anaerobic opportunistic pathogen that is also known to play a role in microbial food spoilage. This species has been isolated from a wide range of nosocomial infections, including septicaemia, as well as respiratory, enteric, and urinary tract infections.
CATEGORY    Infectious disease
PATHOGEN    Hafnia alvei [GN:hav]
DBLINKS     ICD-10: A41
            MeSH: D018805 D004756
REFERENCE   PMID:25075225 (description)
  AUTHORS   Tan JY, Yin WF, Chan KG
  TITLE     Gene clusters of Hafnia alvei strain FB1 important in survival and pathogenesis:  a draft genome perspective.
  JOURNAL   Gut Pathog 6:29 (2014)
REFERENCE   PMID:16418520 (description)
  AUTHORS   Janda JM, Abbott SL
  TITLE     The genus Hafnia: from soup to nuts.
  JOURNAL   Clin Microbiol Rev 19:12-8 (2006)
///
ENTRY       H01415                      Disease
NAME        Donovanosis;
            Granuloma inguinale
DESCRIPTION Donovanosis (granuloma inguinale) is an acquired chronic, slowly progressive, mildly contagious disease caused by Klebsiella granulomatis that was called Calymmatobacterium granulomatis. This sexually transmitted disease is characterized by granulomatous ulceration of the genitalia and neighboring sites, with little or no tendency to spontaneous healing.
CATEGORY    Infectious disease
PATHOGEN    Klebsiella granulomatis
DBLINKS     ICD-10: A58
            MeSH: D006100
            MedlinePlus: 000636
REFERENCE   PMID:12473810 (description)
  AUTHORS   O'Farrell N
  TITLE     Donovanosis.
  JOURNAL   Sex Transm Infect 78:452-7 (2002)
REFERENCE   PMID:24958990 (description)
  AUTHORS   Pilani A, Vora R, Anjaneyan G
  TITLE     Granuloma inguinale mimicking as squamous cell carcinoma of penis.
  JOURNAL   Indian J Sex Transm Dis 35:56-8 (2014)
///
ENTRY       H01416                      Disease
NAME        Severe fever with thrombocytopenia syndrome
DESCRIPTION Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne systemic emerging haemorrhagic fever. The causative agent, SFTS virus (SFTSV), is a novel phlebovirus in the Bunyaviridae family. SFTS presents with fever, thrombocytopenia, leukocytopenia, and considerable changes in several serum biomarkers. The disease has 10-15% mortality rate, commonly because of multiorgan dysfunction. No specific treatment of SFTS is available, and avoiding tick bites is an important measure to prevent the infection and transmission of SFTSV.
CATEGORY    Infectious disease
PATHOGEN    SFTS virus HB29 [GN:T40096]
DBLINKS     ICD-10: A93.8
REFERENCE   PMID:24837566
  AUTHORS   Liu Q, He B, Huang SY, Wei F, Zhu XQ
  TITLE     Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis.
  JOURNAL   Lancet Infect Dis 14:763-72 (2014)
REFERENCE   PMID:24310908
  AUTHORS   Liu S, Chai C, Wang C, Amer S, Lv H, He H, Sun J, Lin J
  TITLE     Systematic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics.
  JOURNAL   Rev Med Virol 24:90-102 (2014)
///
ENTRY       H01417                      Disease
NAME        Acute encephalitis
DESCRIPTION Acute encephalitis is a serious form of neurological disease caused by inflammation of the brain parenchyma. It is generally characterized by the acute onset of fever, altered mental status, new onset of focal neurological symptoms, and generalized or focal seizures. It can be produced by various etiologies, but viral infection and autoimmune disorders are the most common. Causes of acute viral encephalitis are herpes simplex virus, other herpes viruses, adenoviruses, influenza A, and so on. Mortality rates range between 7 % and 18 %, and severe disability has been reported in up to 56 % of survivors.
CATEGORY    Infectious disease; Immune system disease
PATHOGEN    Herpesvirus
            Mastadenovirus
            Influenza A virus
            Arboviruse
DRUG        Acyclovir [DG:DG00406]
            Ganciclovir [DG:DG00646]
DBLINKS     ICD-10: G04.9
REFERENCE   PMID:14978145 (description, pathogen)
  AUTHORS   Kennedy PG
  TITLE     Viral encephalitis: causes, differential diagnosis, and management.
  JOURNAL   J Neurol Neurosurg Psychiatry 75 Suppl 1:i10-5 (2004)
REFERENCE   PMID:25540320 (description)
  AUTHORS   Singh TD, Fugate JE, Rabinstein AA
  TITLE     The spectrum of acute encephalitis: Causes, management, and predictors of outcome.
  JOURNAL   Neurology 84:359-66 (2015)
REFERENCE   PMID:15804262 (drug)
  AUTHORS   Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, Kennedy PG
  TITLE     Viral encephalitis: a review of diagnostic methods and guidelines for management.
  JOURNAL   Eur J Neurol 12:331-43 (2005)
///
ENTRY       H01418                      Disease
NAME        Condyloma acuminatum;
            Condylomata acuminata;
            Genital warts
DESCRIPTION Condyloma acuminatum is a sexually transmitted infection (STI) caused by the human papillomavirus (HPV). HPV-6, HPV-10, and HPV-11 are predominately found in the anogenital region and causing approximately 90% of this disease. They appear as fleshy papules on the mucosa and skin of the anorectum and genitalia, with genital disease being more prevalent than anorectal disease. The warts tend to be painless, but may be associated with some discomfort or itching.
CATEGORY    Infectious disease
PATHOGEN    Human papillomavirus type 6b [GN:T40097]
            Human papillomavirus type 10 [GN:T40098]
            human papillomavirus type 11
DBLINKS     ICD-10: A63.0
            MeSH: D003218
REFERENCE   PMID:24517695
  AUTHORS   Richards S
  TITLE     An overview of genital warts.
  JOURNAL   Nurs Stand 28:46-50 (2014)
REFERENCE   PMID:19820442
  AUTHORS   McCutcheon T
  TITLE     Anal condyloma acuminatum.
  JOURNAL   Gastroenterol Nurs 32:342-9 (2009)
///
ENTRY       H01419                      Disease
NAME        Middle East respiratory syndrome (MERS)
DESCRIPTION Middle East respiratory syndrome (MERS) is a severe viral illness caused by Middle East respiratory syndrome coronavirus (MERS-CoV), a novel coronavirus that emerged in the Middle East in 2012. Since then, MERS-CoV has caused an ongoing epidemic in the Arabian Peninsula with sporadic cases imported in Europe, North Africa, Southeast Asia, and the United States of America. MERS is often a lower respiratory tract disease associated with fever, cough, breathing difficulties, pneumonia that can progress to acute respiratory distress syndrome, multiorgan failure, and death among more than a third of those infected. Severe disease is usually found in older males and comorbidities are frequently present in cases of MERS.
CATEGORY    Infectious disease
PATHOGEN    Middle East respiratory syndrome coronavirus [GN:T40090]
DBLINKS     ICD-10: J20.8
            MeSH: D018352
REFERENCE   PMID:25457301
  AUTHORS   Pavli A, Tsiodras S, Maltezou HC
  TITLE     Middle East respiratory syndrome coronavirus (MERS-CoV): prevention in travelers.
  JOURNAL   Travel Med Infect Dis 12:602-8 (2014)
REFERENCE   PMID:25656066
  AUTHORS   Mackay IM, Arden KE
  TITLE     Middle East respiratory syndrome: An emerging coronavirus infection tracked by the crowd.
  JOURNAL   Virus Res (2015)
///
ENTRY       H01420                      Disease
NAME        Pharyngoconjunctival fever (PCF)
DESCRIPTION Pharyngoconjunctival fever (PCF) is a syndrome attributed to human adenovirus B, particularly serotype 3, which causes small outbreaks, mainly among children. The syndrome may occur sporadically and can cause outbreaks in families and other closed populations. The main sources of infection are contaminated waters of swimming pools and water reservoirs. Acute onset of PCF comprises fever, pharyngitis, rhinitis, cervical adenopathies and bulbar and palpebral conjunctivitis with moderate follicular reaction which can last for 3-5 days. PCF associated ocular inflammation begins unilateral and generally becomes bilateral in the course of the disease.
CATEGORY    Infectious disease
PATHOGEN    Human mastadenovirus B [GN:T40100]
DBLINKS     ICD-10: B30.2
REFERENCE   PMID:24678403
  AUTHORS   Ghebremedhin B
  TITLE     Human adenovirus: Viral pathogen with increasing importance.
  JOURNAL   Eur J Microbiol Immunol (Bp) 4:26-33 (2014)
REFERENCE   PMID:11280197
  AUTHORS   Harley D, Harrower B, Lyon M, Dick A
  TITLE     A primary school outbreak of pharyngoconjunctival fever caused by adenovirus type 3.
  JOURNAL   Commun Dis Intell 25:9-12 (2001)
///
ENTRY       H01421                      Disease
NAME        Acute hemorrhagic conjunctivitis
DESCRIPTION Acute hemorrhagic conjunctivitis (AHC) is a rapidly progressive and highly contagious viral disease characterized by sudden onset of painful, swollen, red eyes with subconjunctival hemorrhages, excessive tearing, and photophobia. A palpebral conjunctival follicular reaction, subconjunctival hemorrhage, and congestion are common. Symptoms start after an incubation period of 12 to 48 hours, and the clinical signs usually disappear in 1 to 2 weeks. Enterovirus 70 (EV70) and coxsackievirus A24 variant (CA24v) have caused large outbreaks of AHC. The AHC epidemic had begun in 1969 in Ghana and spread across Africa to India and the Far East, with small outbreaks in Europe.
CATEGORY    Infectious disease
PATHOGEN    Human enterovirus 70
            Human coxsackievirus A24
DBLINKS     ICD-10: B30.3
            MeSH: D003232
REFERENCE   PMID:16287683 (description, pathogen)
  AUTHORS   Palacios G, Oberste MS
  TITLE     Enteroviruses as agents of emerging infectious diseases.
  JOURNAL   J Neurovirol 11:424-33 (2005)
REFERENCE   PMID:16704792 (description, pathogen)
  AUTHORS   Tavares FN, Costa EV, Oliveira SS, Nicolai CC, Baran M, da Silva EE
  TITLE     Acute hemorrhagic conjunctivitis and coxsackievirus A24v, Rio de Janeiro, Brazil, 2004.
  JOURNAL   Emerg Infect Dis 12:495-7 (2006)
REFERENCE   PMID:12967504 (description, pathogen)
  AUTHORS   Oh MD, Park S, Choi Y, Kim H, Lee K, Park W, Yoo Y, Kim EC, Choe K
  TITLE     Acute hemorrhagic conjunctivitis caused by coxsackievirus A24 variant, South Korea, 2002.
  JOURNAL   Emerg Infect Dis 9:1010-2 (2003)
///
ENTRY       H01422                      Disease
NAME        Carbapenem-resistant Enterobacteriaceae (CRE) infection
DESCRIPTION Enterobacteriaceae are among the most common human pathogens, causing community-acquired as well as hospital-acquired infections. Carbapenem-resistant Enterobacteriaceae (CRE) have been increasingly reported worldwide. Bacterial acquisition of carbapenemases, enzymes that inactivate carbapenems, is crucial to the emergence of CRE. In 2001, the first report of carbapenem-resistant Klebsiella pneumoniae carrying a new carbapenemase, KPC, was published.
CATEGORY    Infectious disease
PATHOGEN    Klebsiella pneumoniae [GN:kpa kps kpb kpc]
            Pseudomonas aeruginosa
            Escherichia coli
            Serratia marcescens
DRUG        Colistin [DG:DG00087]
            Tigecycline [DR:D01079]
            Aminoglycosides [DG:DG01447]
            Carbapenems [DG:DG01458]
            Fosfomycin [DG:DG00633]
DBLINKS     ICD-10: A49.8 B96.1 J15.0 J15.1
            MeSH: D007710 D011552 D016868
REFERENCE   PMID:24360201 (pathogen)
  AUTHORS   Nordmann P
  TITLE     Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge.
  JOURNAL   Med Mal Infect 44:51-6 (2014)
REFERENCE   PMID:24639510 (pathogen)
  AUTHORS   Deleo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, Porter AR, Chavda KD, Jacobs MR, Mathema B, Olsen RJ, Bonomo RA, Musser JM, Kreiswirth BN
  TITLE     Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae.
  JOURNAL   Proc Natl Acad Sci U S A 111:4988-93 (2014)
REFERENCE   PMID:24798270 (pathogen)
  AUTHORS   van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, Webber R, Fox J, Mason P, Richter SS, Cline M, Hall GS, Kaye KS, Jacobs MR, Kalayjian RC, Salata RA, Segre JA, Conlan S, Evans S, Fowler VG Jr, Bonomo RA
  TITLE     Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.
  JOURNAL   Antimicrob Agents Chemother 58:4035-41 (2014)
REFERENCE   PMID:25758700 (pathogen)
  AUTHORS   Tai AY, Stuart RL, Sidjabat HE, Lemoh CN, Rogers BA, Graham M, Paterson DL, Korman TM
  TITLE     Local acquisition and nosocomial transmission of Klebsiella pneumoniae harbouring the blaNDM-1 gene in Australia.
  JOURNAL   Med J Aust 202:270-1 (2015)
REFERENCE   PMID:23547093 (pathogen, drug)
  AUTHORS   Perez F, Van Duin D
  TITLE     Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients.
  JOURNAL   Cleve Clin J Med 80:225-33 (2013)
REFERENCE   PMID:25195939 (drug)
  AUTHORS   Temkin E, Adler A, Lerner A, Carmeli Y
  TITLE     Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.
  JOURNAL   Ann N Y Acad Sci 1323:22-42 (2014)
REFERENCE   PMID:25556628 (drug)
  AUTHORS   Tangden T, Giske CG
  TITLE     Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.
  JOURNAL   J Intern Med 277:501-12 (2015)
///
ENTRY       H01423                      Disease
NAME        Penicillin-resistant Streptococcus pneumoniae infection
DESCRIPTION Streptococcus pneumoniae is a common causative pathogen in community-acquired respiratory tract infections (RTIs), including acute otitis media, acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community-acquired pneumonia. It is also a major cause of bacteremia. Pneumococcal antibiotic resistance towards different families of antibiotics, in particular, penicillin and the macrocodes, continues to be a much-debated issue. The main mechanism of resistance in clinical isolates of S. pneumoniae involves the alteration of penicillin target proteins, the so-called penicillin binding protein (PBPs), which cause reduced affinities and/or binding capacities for the antibiotic molecule.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pneumoniae [GN:spw sne]
DRUG        Linezolid [DR:D00947]
            Telavancin [DR:D06057]
            Vancomycin [DG:DG00086]
            Third-generation cephalosporin [DG:DG01776]
            Ceftaroline [DR:D08884]
COMMENT     S. pneumoniae genes containing mutations:
            pbp1A [SPW:SPCG_0365] [KO:K05366]
            pbp2X [SPW:SPCG_0339] [KO:K12556]
            pbp2B [SPW:SPCG_1645] [KO:K00687]
DBLINKS     ICD-10: J13
            MeSH: D013290
REFERENCE   PMID:18201146 (description, comment)
  AUTHORS   Aspa J, Rajas O, de Castro FR
  TITLE     Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.
  JOURNAL   Expert Opin Pharmacother 9:229-41 (2008)
REFERENCE   PMID:18190701 (description)
  AUTHORS   Jenkins SG, Brown SD, Farrell DJ
  TITLE     Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
  JOURNAL   Ann Clin Microbiol Antimicrob 7:1 (2008)
REFERENCE   PMID:19366363 (pathogen, comment)
  AUTHORS   Reinert RR
  TITLE     The antimicrobial resistance profile of Streptococcus pneumoniae.
  JOURNAL   Clin Microbiol Infect 15 Suppl 3:7-11 (2009)
REFERENCE   PMID:19114491 (pathogen)
  AUTHORS   Croucher NJ, Walker D, Romero P, Lennard N, Paterson GK, Bason NC, Mitchell AM, Quail MA, Andrew PW, Parkhill J, Bentley SD, Mitchell TJ
  TITLE     Role of conjugative elements in the evolution of the multidrug-resistant pandemic clone Streptococcus pneumoniaeSpain23F ST81.
  JOURNAL   J Bacteriol 191:1480-9 (2009)
REFERENCE   PMID:22134942 (drug)
  AUTHORS   Rivera AM, Boucher HW
  TITLE     Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.
  JOURNAL   Mayo Clin Proc 86:1230-43 (2011)
REFERENCE   PMID:21308542 (drug)
  AUTHORS   Hameed N, Tunkel AR
  TITLE     Treatment of Drug-resistant Pneumococcal Meningitis.
  JOURNAL   Curr Infect Dis Rep 12:274-81 (2010)
REFERENCE   PMID:16524418 (drug)
  AUTHORS   Faella F, Pagliano P, Fusco U, Attanasio V, Conte M
  TITLE     Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains.
  JOURNAL   Clin Microbiol Infect 12:391-4 (2006)
REFERENCE   PMID:19233207 (comment)
  AUTHORS   Contreras-Martel C, Dahout-Gonzalez C, Martins Ados S, Kotnik M, Dessen A
  TITLE     PBP active site flexibility as the key mechanism for beta-lactam resistance in pneumococci.
  JOURNAL   J Mol Biol 387:899-909 (2009)
///
ENTRY       H01424                      Disease
NAME        Group A streptococcal pharyngitis;
            Group A streptococcal tonsillitis;
            Group A streptococcal pharyngotonsillitis
DESCRIPTION Group A streptococcal pharyngitis is an acute infection of the oropharynx and/or nasopharynx that is caused by group A streptococcus (Streptococcus pyogenes). Group A streptococcus is responsible for 5-15% of cases of pharyngitis in adults and 20-30% of cases in children, and is the most common cause of bacterial pharyngitis. The disorder is primarily a disease of children between 5 and 15 years of age, and, in temperate climates, it usually occurs in the winter and early spring. The onset of symptoms in patients is often abrupt. In addition to throat pain, symptoms may include fever, chills, malaise, headache, and particularly in younger children abdominal pain, nausea, and vomiting. Cough, coryza, and conjunctivitis are not typical symptoms of streptococcal pharyngitis, and, if present, they suggest an alternative cause such as a viral infection. In most persons, fever resolves within 3-5 days, and throat pain resolves within 1 week, even without specific treatment. Antibiotic treatment reduces the risk of subsequent development of acute rheumatic fever and suppurative complications.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spa spb stg soz spyo]
DRUG        Penicillin V [DG:DG00535]
            Benzathine penicillin G [DG:DG00534]
            Amoxicillin [DG:DG00520]
            Cephalexin [DG:DG00548]
            Cefadroxil [DG:DG00551]
            Azithromycin [DG:DG00606]
            Clindamycin [DG:DG00435]
COMMENT     For Streptococcal infection, see H00333.
DBLINKS     ICD-10: J02.0
REFERENCE   PMID:12087516 (description)
  AUTHORS   Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH
  TITLE     Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America.
  JOURNAL   Clin Infect Dis 35:113-25 (2002)
REFERENCE   PMID:21323542 (description, drug)
  AUTHORS   Wessels MR
  TITLE     Clinical practice. Streptococcal pharyngitis.
  JOURNAL   N Engl J Med 364:648-55 (2011)
///
ENTRY       H01425                      Disease
NAME        Lysosomal storage diseases
DESCRIPTION Lysosomal storage diseases (LSDs) are a group of inherited diseases that are characterised by the intracellular accumulation of incompletely degraded macromolecules. They result from a genetic defect in cellular transport or metabolism of molecules within the lysosome. Most of the patients with a LSD are born apparently healthy and the symptoms develop progressively. Treatment is directed toward symptomatic care of secondary complications for most of these diseases. For some individuals, hematopoietic stem cell transplantation or enzyme-replacement therapy can be effective.
            LSDs are divided into the following 5 groups. For details, please refer to the each entry.
            1. Defects in glycan degradation: H00125 Fabry disease, H00421 Mucopolysaccharidosis, H00422 Glycoproteinoses, H00423 Defects in the degradation of sulfatide, H00426 Defects in the degradation of ganglioside, H00069 Pompe disease, H01239 Prosaposin deficiency
            2. Defects in lipid degradation: H00424 Defects in the degradation of sphingomyelin, H00148 Lysosomal acid lipase deficiency
            3. Defects in protein degradation: H00149 Neuronal ceroid lipofuscinosis, H00425  Lysosomal cysteine protease deficiencies, H01113  Acid phosphatase deficiency
            4. Defects in lysosomal transporters: H00275 Cystinosis, H00147 Sialuria
            5. Defects in lysosomal trafficking: H00136 Niemann-Pick disease type C, H00143 Mucolipidosis II and III, H00144 Mucolipidosis IV, H00149 Neuronal ceroid lipofuscinosis, H00150 Danon disease, H00166 Hermansky-Pudlak syndrome, H00101 Chediak-Higashi syndrome, Griscelli syndrome
CATEGORY    Inherited metabolic disease; Lysosomal storage disease
DRUG        (Gaucher disease) Alglucerase [DR:D02810], Imiglucerase [DR:D03020], Miglustat [DR:D05032], Velaglucerase alfa [DR:D09029]
            (Fabry disease) Carbamazepine [DR:D00252], Agalsidase alfa [DR:D02784], Agalsidase beta [DR:D03228]
            (Pompe disease) Myozyme [DR:D03207]
            (MPS1) Aldurazyme [DR:D04670]
            (MPS2) Elaprase [DR:D04499]
            (MPS6) Aryplase [DR:D06565]
DBLINKS     ICD-10: E70 E72 E74 E75 E76 E77 E83 Q82
            MeSH: D016464
REFERENCE   PMID:18708002
  AUTHORS   Heese BA
  TITLE     Current strategies in the management of lysosomal storage diseases.
  JOURNAL   Semin Pediatr Neurol 15:119-26 (2008)
REFERENCE
  AUTHORS   Greiner-Tollersrud OK. and Berg T.
  TITLE     Lysosomal Storage Disorders
  JOURNAL   Lysosomes, edited by Paul Saftig: 60-73
///
ENTRY       H01426                      Disease
NAME        Invasive streptococcal disease
DESCRIPTION Invasive streptococcal disease is defined as an infection associated with group A Streptococcus pyogenes. Since the mid-1980s, there have been reports from around the world of an increase in the incidence, and associated morbidity and mortality. One of clinical presentations is group A streptococcal toxic shock syndrome, which is differentiated from other types of this disease by the occurrence of shock and multi-organ system failure early in the course of the infection. Another is necrotising fasciitis, characterized by extensive local necrosis of subcutaneous soft tissues and skin and the isolation of S. pyogenes from a normally sterile body site. The other is a group of infections characterized by the isolation of S. pyogenes from a normally sterile site in patients not meeting the criteria for streptococcal toxic shock syndrome or necrotising fasciitis. Recently, cases associated with group B, C and G Streptococcus have been reported but less frequent.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spa spb stg soz spyo] 
            Streptococcus agalactiae [GN:sag san sak sagn]
            Streptococcus equi [GN:sez] 
            Streptococcus dysgalactiae [GN:sdg sdq]
DRUG        Penicillin G [DG:DG00534]
            Clindamycin [DG:DG00435]
            Ampicillin [DG:DG00517]
            Cefazolin [DG:DG00550]
            Vancomycin [DG:DG00086]
COMMENT     Streptococcal infection is described in H00333.
DBLINKS     ICD-10: A40 A49.1
            MeSH: D013290
REFERENCE   PMID:16048718 (description)
  AUTHORS   Smith A, Lamagni TL, Oliver I, Efstratiou A, George RC, Stuart JM
  TITLE     Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis?
  JOURNAL   Lancet Infect Dis 5:494-500 (2005)
REFERENCE   PMID:20212993 (description)
  TITLE     Invasive group A streptococcal infections.
  JOURNAL   Paediatr Child Health 4:73-82 (1999)
REFERENCE   PMID:20456456 (description)
  AUTHORS   Kittang BR, Bruun T, Langeland N, Mylvaganam H, Glambek M, Skrede S
  TITLE     Invasive group A, C and G streptococcal disease in western Norway: virulence gene profiles, clinical features and outcomes.
  JOURNAL   Clin Microbiol Infect 17:358-64 (2011)
REFERENCE   PMID:11345977 (drug)
  TITLE     American Academy of Pediatrics. Committee on Infectious Diseases. Severe invasive group A streptococcal infections: a subject review.
  JOURNAL   Pediatrics 101:136-40 (1998)
REFERENCE   PMID:21422882 (drug)
  TITLE     ACOG Committee Opinion No. 485: Prevention of early-onset group B streptococcal disease in newborns.
  JOURNAL   Obstet Gynecol 117:1019-27 (2011)
///
ENTRY       H01427                      Disease
NAME        Mitochondrial diseases
DESCRIPTION Mitochondrial diseases are clinically heterogeneous group of disorders that arise as a result of dysfunction of the mitochondria. They can be caused by mutation of genes encoded by either nuclear DNA or mitochondrial DNA. While some mitochondrial disorders only affect a single organ (e.g.H00068 Leber hereditary optic atrophy), most of them involve multiple organ systems and often present with prominent neurologic and myopathic features. Many individuals display a cluster of clinical features that fall into a discrete clinical syndrome, such as H01347 MELAS syndrome, H01354 Leigh syndrome, H01355 Kearns-Sayre syndrome, H01356 Myoclonic Epilepsy and Ragged-Red Fiber Disease, H01363 NARP syndrome. However, there are many cases do not fit neatly into one particular category. For example, mutations in POLG are associated with a variety of phenotypes. (see H01395 POLG related disorders)
CATEGORY    Inherited metabolic disease; Mitochondrial disease
COMMENT     For details, please refer to each entry. See also H00473 Mitochondrial respiratory chain deficiencies.
DBLINKS     ICD-10: E88
            MeSH: D028361
REFERENCE   PMID:20301403
  AUTHORS   Chinnery PF
  TITLE     Mitochondrial Disorders Overview
  JOURNAL   (1993)
///
ENTRY       H01428                      Disease
NAME        Xeroderma pigmentosum (XP)
DESCRIPTION Xeroderma pigmentosum (XP) is a rare autosomal-inherited, skin and neurodegenerative disease in which exposure to sunlight can result in a high incidence of skin and mucous membrane cancer. XP is classified into eight genetic complementation groups by the present. In this inside, 7 groups from the XP-A group to the G group show the abnormality in nucleotide excision repair (NER). The symptoms of XP begin in early life. Severe sunburn and blistering occurs in a half of patients, and all show early extensive freckling. Cancer incidence for individuals with XP under 20 years of age is 2,000 times as high as incidence in the general population. Neurodegeneration can be correlated with mutations in specific XP genes (XPA, ERCC3, ERCC2 and ERCC5).
CATEGORY    Congenital disorder of DNA repair systems
GENE        (XPA) XPA [HSA:7507] [KO:K10847]
            (XPB) ERCC3 [HSA:2071] [KO:K10843]
            (XPC) XPC [HSA:7508] [KO:K10838]
            (XPD) ERCC2 [HSA:2068] [KO:K10844]
            (XPE) DDB2 [HSA:1643] [KO:K10140]
            (XPE) DDB1 [HSA:1642] [KO:K10610] 
            (XPF) ERCC4 [HSA:2072] [KO:K10848]
            (XPG) ERCC5 [HSA:2073] [KO:K10846]
            (XPV) POLH [HSA:5429] [KO:K03509]
COMMENT     See also H00403 Disorders of nucleotide excision repair.
DBLINKS     ICD-10: Q82.1 Q87.1 
            MeSH: D014983
            OMIM: 278700 61065 278720 278730 278740 278760 278780 278750
REFERENCE   PMID:19809470
  AUTHORS   Cleaver JE, Lam ET, Revet I
  TITLE     Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity.
  JOURNAL   Nat Rev Genet 10:756-68 (2009)
REFERENCE   PMID:11710928
  AUTHORS   Queille S, Drougard C, Sarasin A, Daya-Grosjean L
  TITLE     Effects of XPD mutations on ultraviolet-induced apoptosis in relation to skin cancer-proneness in repair-deficient syndromes.
  JOURNAL   J Invest Dermatol 117:1162-70 (2001)
///
ENTRY       H01429                      Disease
NAME        Aseptic meningitis
DESCRIPTION The term aseptic meningitis can be used broadly to include all types of meningitis with negative bacterial cultures from cerebrospinal fluid. Etiology of aseptic meningitis is very wide and includes both viral and non-viral infections, drugs, malignancy, and systemic illness. Viral meningitis constitutes the most common cause of aseptic meningitis and enteroviruses, including Coxsackie and ECHO viruses, account for more than half of all cases. Clinical manifestations include headache, fever, malaise, photophobia, and meningeal signs. Treatment is mostly supportive and includes analgesics, antipyretics, antiemetics, maintenance of fluid balance, and prevention and treatment of complications.
CATEGORY    Nervous system disease; Infectious disease
ENV_FACTOR  Nonsteroidal anti-inflammatory drugs (NSAIDs)
            Trimethoprim-sulfamethoxazole, amoxicillin [DG:DG00520]
            Muromonab-CD3 (OKT3) [DR:D05092]
            Azathioprine [DG:DG00743]
            Intravenous immunoglobulin
            Isoniazid [DG:DG00642]
            Intrathecal methotrexate [DG:DG00681]
            Intrathecal cytosine arabinoside [DR:D00168]
            Allopurinol [DG:DG00779]
            Carbamazepine [DR:D00252]
            Sulfasalazine [DR:D00448]
PATHOGEN    Enteroviruses (polio, coxsackie, ECHO virus)
            Herpes group of viruses
            Respiratory viruses
            Arboviruses
            Mumps virus [GN:T40034]
            Lymphocytic choreomeningitis
            HIV
            Parameningeal infection
            Endocarditis
            Mycoplasma pneumoniae
            Mycobacterium tuberculosis
            Ehrlichiosis
            Borrelia burgdorferi
            Treponema pallidum
            Brucella
            Leptospirosis
            Cryptococcus neoformans
            Histoplasma capsulatum
            Coccidiodes immitis
            Blastomyces dermatitides
            Candida
            Toxoplasma gondii
            Neurocysticercosis
            Trichinosis
            Naeglaria
            Hartmannella
            Bartonella henselae
            Rocky Mountain spotted fever
            Typhus
DBLINKS     ICD-10: G03
            MeSH: D008582
REFERENCE   PMID:15684450 (description, env_factor, pathogen)
  AUTHORS   Kumar R
  TITLE     Aseptic meningitis: diagnosis and management.
  JOURNAL   Indian J Pediatr 72:57-63 (2005)
REFERENCE   PMID:17471037 (description)
  AUTHORS   Lee BE, Davies HD
  TITLE     Aseptic meningitis.
  JOURNAL   Curr Opin Infect Dis 20:272-7 (2007)
///
ENTRY       H01430                      Disease
NAME        Viral gastroenteritis, including:
            Rotaviral enteritis [DS:H00975];
            Acute gastroenteropathy due to Norwalk agent [DS:H01323]
DESCRIPTION Viral gastroenteritis is an infection of the stomach and intestines caused by a variety of viruses. Rotavirus, enteric adenovirus, calicivirus, and astrovirus typically cause diarrhea in infants and young children, whereas the Norwalk group of viruses (and occasionally calicivirus and astrovirus) produces explosive epidemics of gastroenteritis associated with contaminated water and foods, in adults as well as school-age children. No effective treatments have been developed for viral gastroenteritis. Current efforts are targeted at the development of suitable vaccines and the implementation of infection control measures.
CATEGORY    Infectious disease
PATHOGEN    Rotavirus A [GN:T40092]
            Human rotavirus B [GN:T40123]
            Rotavirus C [GN:T40094]
            Rotavirus H [GN:T40093]
            Enteric adenovirus
            Norwalk virus [GN:T40107]
            Norwalk-like virus
            Calicivirus
            Astrovirus
DBLINKS     ICD-10: A08
            MeSH: D005759
REFERENCE   PMID:15353966 (description)
  AUTHORS   Clark B, McKendrick M
  TITLE     A review of viral gastroenteritis.
  JOURNAL   Curr Opin Infect Dis 17:461-9 (2004)
REFERENCE   PMID:1647494 (description, pathogen)
  AUTHORS   Blacklow NR, Greenberg HB
  TITLE     Viral gastroenteritis.
  JOURNAL   N Engl J Med 325:252-64 (1991)
///
ENTRY       H01431                      Disease
NAME        Cushing's syndrome
DESCRIPTION Cushing's syndrome is the manifestations induced by chronic exposure to glucocorticoid excess. It most commonly arises from iatrogenic causes, when glucocorticoids are given to treat inflammatory diseases. In contrast, spontaneous Cushing's syndrome is rare. It results from various causes that all have in common a chronic over-secretion of cortisol by the adrenals. Cases due to a pituitary adenoma are known as Cushing's disease. It is the most common cause of spontaneous Cushing's syndrome. Symptoms associated with this disease include weight gain, lethargy, menstrual irregularities, hirsutism, acne, purplish skin striae, and hyperpigmentation. Problems such as diabetes mellitus or hypertension may be associated. Central obesity is the most common manifestation. Fat accumulates in the face and the supraclavicular and dorsocervical fat pads, resulting in a typical moon face and buffalo hump, which is most often accompanied by facial plethora.
CATEGORY    Endocrine disease
GENE        GNAS [HSA:2778] [KO:K04632]
            AIP [HSA:9049] [KO:K17767]
MARKER      See also H00260 Pigmented micronodular adrenocortical disease (PPNAD), and H01102 Pituitary adenomas.
DRUG        Trans-sphenoidal pituitary surgery
            Pituitary irradiation (gamma Knife surgery)
            Medical treatments towards the pituitary: Cabergoline [DR:D00987] Temozolomide [DR:D06067]
            Medical treatments for the adrenals: Mitotane [DR:D00420] Metyrapone [DR:D00410] Ketoconazole [DR:D00351] Mifepristone [DR:D00585]
DBLINKS     ICD-10: E24
            MeSH: D003480
            OMIM: 219080 219090
REFERENCE   PMID:22385888
  AUTHORS   Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO
  TITLE     Mortality in Cushing's syndrome: a systematic review and meta-analysis.
  JOURNAL   Eur J Intern Med 23:278-82 (2012)
REFERENCE   PMID:19945026
  AUTHORS   Bertagna X, Guignat L, Groussin L, Bertherat J
  TITLE     Cushing's disease.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 23:607-23 (2009)
REFERENCE   PMID:9793762
  AUTHORS   Newell-Price J, Trainer P, Besser M, Grossman A
  TITLE     The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.
  JOURNAL   Endocr Rev 19:647-72 (1998)
REFERENCE   PMID:17564168
  AUTHORS   Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML
  TITLE     Gamma Knife surgery for Cushing's disease.
  JOURNAL   J Neurosurg 106:980-7 (2007)
///
ENTRY       H01432                      Disease
NAME        Choreoacanthocytosis;
            Chorea-acanthocytosis
DESCRIPTION Choreoacanthocytosis (CHAC) is a type of neuroacanthocytosis, a heterogeneous group of hereditary syndromes characterized by the association of neurologic abnormalities with acanthocytic red blood cells. This disease caused by a variety of mutations in the VPS13A gene. The inheritance is mainly autosomal recessive, although apparent sporadic and autosomal dominant instances are also known. VPS13A gene encodes the chorein protein, which is thought to have a role in the change of cellular structures. CHAC is characterized by involuntary movements, cognitive decline, behavioral changes, seizures, and polyneuropathy. Oral-lingual dystonia is a noticeable feature, often resulting in mouth or tongue lacerations. Symptoms typically begin between 20 and 40 years of age, but earlier and later onset occurs as well.
CATEGORY    Nervous system disease
GENE        VPS13A [HSA:23230] [KO:K19525]
MARKER      Bilateral caudate atrophy on MRI brain scan
            Acanthocytes in the peripheral blood film
            Increased serum creatine kinase
            Low serum chorein level
COMMENT     See also H00832 Core neuroacanthocytosis syndromes.
DBLINKS     ICD-10: G25
            MeSH: D054546
            OMIM: 200150
REFERENCE   PMID:15824261
  AUTHORS   Lossos A, Dobson-Stone C, Monaco AP, Soffer D, Rahamim E, Newman JP, Mohiddin S, Fananapazir L, Lerer I, Linetsky E, Reches A, Argov Z, Abramsky O, Gadoth N, Sadeh M, Gomori JM, Boher M, Meiner V
  TITLE     Early clinical heterogeneity in choreoacanthocytosis.
  JOURNAL   Arch Neurol 62:611-4 (2005)
REFERENCE   PMID:17998451
  AUTHORS   Ruiz-Sandoval JL, Garcia-Navarro V, Chiquete E, Dobson-Stone C, Monaco AP, Alvarez-Palazuelos LE, Padilla-Martinez JJ, Barrera-Chairez E, Rodriguez-Figueroa EI, Perez-Garcia G
  TITLE     Choreoacanthocytosis in a Mexican family.
  JOURNAL   Arch Neurol 64:1661-4 (2007)
REFERENCE   PMID:22258171
  AUTHORS   Sokolov E, Schneider SA, Bain PG
  TITLE     Chorea-acanthocytosis.
  JOURNAL   Pract Neurol 12:40-3 (2012)
///
ENTRY       H01433                      Disease
NAME        Budd-Chiari syndrome
DESCRIPTION Budd-Chiari syndrome is a heterogeneous group of disorders characterized by hepatic venous outflow obstruction at the hepatic veins or inferior vena cava.  Clinically, the disease is characterized by hepatomegaly, manifestations of portal hypertension, and sometimes rapidly deteriorating liver function. Factors that confer a predisposition to the development of the Budd-Chiari syndrome, including hypercoagulable states, both hereditary and acquired, and a variety of other causes, can be identified in about 75 percent of patients. The factor V Leiden mutation and V617F mutation in the JAK2 gene have been noted in patients with the Budd-Chiari syndrome.
CATEGORY    Cardiovascular disease
GENE        F5 [HSA:2153] [KO:K03902]
            JAK2 [HSA:3717] [KO:K04447]
DRUG        Anticoagulation and medical therapy
            Revascularization
            Transjugular intrahepatic portasystemic shunt (TIPS)
            Orthotopic liver transplantation (OLT)
DBLINKS     ICD-10: I82.0
            MeSH: D006502
            OMIM: 600880
REFERENCE   PMID:14762185
  AUTHORS   Menon KV, Shah V, Kamath PS
  TITLE     The Budd-Chiari syndrome.
  JOURNAL   N Engl J Med 350:578-85 (2004)
REFERENCE   PMID:16762626
  AUTHORS   Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gaken J, Wendon J, Heaton ND, Mufti GJ
  TITLE     Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
  JOURNAL   Gastroenterology 130:2031-8 (2006)
REFERENCE   PMID:11001884
  AUTHORS   Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR
  TITLE     Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.
  JOURNAL   Blood 96:2364-8 (2000)
REFERENCE   PMID:22059108
  AUTHORS   Mancuso A
  TITLE     Budd-Chiari syndrome management: Lights and shadows.
  JOURNAL   World J Hepatol 3:262-4 (2011)
///
ENTRY       H01434                      Disease
NAME        Atypical hemolytic uremic syndrome (aHUS)
DESCRIPTION The haemolytic uraemic syndrome (HUS) is characterized by the triad of thrombocytopenia, microangiopathic haemolytic anaemia and acute renal failure. HUS may be classified as either diarrhoeal-associated (D+HUS) or non-diarrhoeal/atypical (aHUS). Approximately half of the patients with aHUS have mutations in genes that regulate the complement system. Several other conditions and factors, such as infection, drugs, pregnancy, and malignancy, have been reported to cause aHUS.
CATEGORY    Hematologic disease
GENE        (AHUS1) CFH [HSA:3075] [KO:K04004]
            (AHUS1) CFHR3 [HSA:10878]
            (AHUS1) CFHR1 [HSA:3078]
            (AHUS2) CD46, MCP [HSA:4179] [KO:K04007]
            (AHUS3) CFI, IF [HSA:3426] [KO:K01333]
            (AHUS4) CFB [HSA:629] [KO:K01335]
            (AHUS5) C3 [HSA:718] [KO:K03990]
            (AHUS6) THBD [HSA:7056] [KO:K03907]
            (AHUS7) DGKE [HSA:8526] [KO:K00901]
ENV_FACTOR  Bacterial: Streptococcus pneumoniae
            Viruses: HIV
            Drugs (Chemotherapy): Mitomycin C [DR:D00208], Gemcitabine [DG:DG00688], Cisplatin [DG:DG01679], Bleomycin [DG:DG00705],
            Quinine [DR:D08460]
            (Immunosuppressive agents): Cyclosporin [DR:D00184], Tacrolimus [DG:DG00439]
            Oral contraceptive pill
DBLINKS     ICD-10: D58.8
            MeSH: D065766
            OMIM: 235400 612922 612923 612924 612925 612926 615008
REFERENCE   PMID:16968692
  AUTHORS   Kavanagh D, Goodship TH, Richards A
  TITLE     Atypical haemolytic uraemic syndrome.
  JOURNAL   Br Med Bull 77-78:5-22 (2006)
REFERENCE   PMID:17182750
  AUTHORS   Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S
  TITLE     Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.
  JOURNAL   Proc Natl Acad Sci U S A 104:240-5 (2007)
REFERENCE   PMID:18796626
  AUTHORS   Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP
  TITLE     Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.
  JOURNAL   Blood 112:4948-52 (2008)
REFERENCE   PMID:19625716
  AUTHORS   Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM
  TITLE     Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
  JOURNAL   N Engl J Med 361:345-57 (2009)
REFERENCE   PMID:23542698
  AUTHORS   Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP
  TITLE     Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.
  JOURNAL   Nat Genet 45:531-6 (2013)
///
ENTRY       H01435                      Disease
NAME        Congenital asplenia, including:
            Isolated congenital asplenia;
            Asplenia syndrome;
            Ivemark syndrome
DESCRIPTION Congenital asplenia is a rare developmental disorder that is characterized by the absence of a spleen at birth. The patients are prone to life-threatening bacterial infections. Isolated congenital asplenia has no other developmental defects. Mutations in the gene RPSA, which encodes ribosomal protein, cause more than half of the cases of isolated congenital asplenia. The mode of inheritance is usually autosomal dominant, though sporadic cases are also reported. Congenital asplenia often occurs in the context of a recognised malformation syndrome, called the Ivemark syndrome.
CATEGORY    Developmental disorder
GENE        RPSA [HSA:3921] [KO:K02998]
            GDF1 [HSA:2657] [KO:K05495]
COMMENT     Please see also H00632 Heterotaxy.
DBLINKS     ICD-10: Q89.0
            MeSH: C563028 D059446
            OMIM: 271400 208530
REFERENCE   PMID:23579497
  AUTHORS   Bolze A, Mahlaoui N, Byun M, Turner B, Trede N, Ellis SR, Abhyankar A, Itan Y, Patin E, Brebner S, Sackstein P, Puel A, Picard C, Abel L, Quintana-Murci L, Faust SN, Williams AP, Baretto R, Duddridge M, Kini U, Pollard AJ, Gaud C, Frange P, Orbach D, Emile JF, Stephan JL, Sorensen R, Plebani A, Hammarstrom L, Conley ME, Selleri L, Casanova JL
  TITLE     Ribosomal protein SA haploinsufficiency in humans with isolated congenital asplenia.
  JOURNAL   Science 340:976-8 (2013)
REFERENCE   PMID:19618213
  AUTHORS   Ahmed SA, Zengeya S, Kini U, Pollard AJ
  TITLE     Familial isolated congenital asplenia: case report and literature review.
  JOURNAL   Eur J Pediatr 169:315-8 (2010)
REFERENCE   PMID:20413652 (gene)
  AUTHORS   Kaasinen E, Aittomaki K, Eronen M, Vahteristo P, Karhu A, Mecklin JP, Kajantie E, Aaltonen LA, Lehtonen R
  TITLE     Recessively inherited right atrial isomerism caused by mutations in growth/differentiation factor 1 (GDF1).
  JOURNAL   Hum Mol Genet 19:2747-53 (2010)
///
ENTRY       H01436                      Disease
NAME        Guillain-Barre syndrome
DESCRIPTION Guillain-Barre syndrome (GBS) is an acute polyneuropathy characterized by progressive motor weakness of limbs with areflexia. This disease is usually triggered by an infection, which provokes immune-mediated nerve dysfunction. GBS can be subdivided into the classic acute demyelinating type, acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN). Classic acute demyelinating type is designated acute inflammatory demyelinating polyneuropathy (AIDP), representing the great majority of cases in Europe and North America. A mutation in the PMP22 gene was identified in a family with AIDP. AMAN is the most prevalent form in China. The incidence of AMSAN is very low. The axonal forms of GBS are caused by certain autoimmune mechanisms, due to a molecular mimicry between antecedent bacterial infection (particularly Campylobacter jejuni) and human peripheral nerve gangliosides.
CATEGORY    Nervous system disease
GENE        PMP22 [HSA:5376] [KO:K19289]
DRUG        Plasma exchange
            Intravenous immunoglobulin
            Prednison [DG:DG00094]
DBLINKS     ICD-10: G61.0
            MeSH: D020275
            OMIM: 139393
REFERENCE   PMID:12439896 (gene)
  AUTHORS   Korn-Lubetzki I, Argov Z, Raas-Rothschild A, Wirguin I, Steiner I
  TITLE     Family with inflammatory demyelinating polyneuropathy and the HNPP 17p12 deletion.
  JOURNAL   Am J Med Genet 113:275-8 (2002)
REFERENCE   PMID:15958124 (drug)
  AUTHORS   van Doorn PA
  TITLE     Treatment of Guillain-Barre syndrome and CIDP.
  JOURNAL   J Peripher Nerv Syst 10:113-27 (2005)
REFERENCE   PMID:25738052
  AUTHORS   Kumar M, Aroor S, Mundkur S, Kumar S
  TITLE     Guillain-barre syndrome: a clinical study of twenty children.
  JOURNAL   J Clin Diagn Res 9:SC09-12 (2015)
REFERENCE   PMID:16271648
  AUTHORS   Hughes RA, Cornblath DR
  TITLE     Guillain-Barre syndrome.
  JOURNAL   Lancet 366:1653-66 (2005)
REFERENCE   PMID:22850724
  AUTHORS   Yuki N
  TITLE     Guillain-Barre syndrome and anti-ganglioside antibodies: a clinician-scientist's  journey.
  JOURNAL   Proc Jpn Acad Ser B Phys Biol Sci 88:299-326 (2012)
///
ENTRY       H01437                      Disease
NAME        Neurofibromatosis type 1;
            Von Recklinghausen disease
DESCRIPTION Neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is an autosomal dominant disease caused by mutations of NF1 gene on chromosome 17. The NF1 gene encodes a RAS GTPase-activating protein called neurofibromin. It is one of the most frequent human genetic diseases, with a prevalence of one case in 3000 births and there is no sex or racial predilection. NF1 is characterized by multiple cafe-au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules. Learning disabilities are present in at least 50% of individuals with NF1. Less common but potentially more serious manifestations include plexiform neurofibromas, optic nerve and other central nervous system gliomas, malignant peripheral nerve sheath tumors, scoliosis, tibial dysplasia, and vasculopathy.
CATEGORY    Developmental disorder; Skin and connective tissue disease
GENE        NF1 [HSA:4763] [KO:K08052]
COMMENT     See also H00523 Noonan syndrome and related disorders.
DBLINKS     ICD-10: Q85.0
            MeSH: D009456
            OMIM: 162200
REFERENCE   PMID:19117870
  AUTHORS   Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL
  TITLE     Neurofibromatosis type 1 revisited.
  JOURNAL   Pediatrics 123:124-33 (2009)
REFERENCE   PMID:23162593
  AUTHORS   Ghalayani P, Saberi Z, Sardari F
  TITLE     Neurofibromatosis type I (von Recklinghausen's disease): A family case report and literature review.
  JOURNAL   Dent Res J (Isfahan) 9:483-8 (2012)
REFERENCE   PMID:20301288
  AUTHORS   Friedman JM
  TITLE     Neurofibromatosis 1
  JOURNAL   (1993)
///
ENTRY       H01438                      Disease
NAME        Neurofibromatosis type 2
DESCRIPTION Neurofibromatosis 2 (NF2) is a rare autosomal dominant multiple neoplasia syndrome that is caused by inactivating mutations of the NF2 tumour suppressor gene. The course of the disease is usually progressive, though variable, causing significant morbidity associated with deafness, blindness, brain stem compression, gait instability, and paralysis. Onset typically occurs while a patient is in their 20s. Vestibular schwannomas, usually bilateral, occur in more than 90% of adult patients and intracranial meningiomas occur in about 50% of patients.
CATEGORY    Developmental disorder; Nervous system disease
GENE        NF2 [HSA:4771] [KO:K16684]
DRUG        Bevacizumab [DR:D06409]
            Lapatinib [DG:DG00715]
DBLINKS     ICD-10: Q85.0
            MeSH: D016518
            OMIM: 101000
REFERENCE   PMID:19545378
  AUTHORS   Evans DG
  TITLE     Neurofibromatosis type 2 (NF2): a clinical and molecular review.
  JOURNAL   Orphanet J Rare Dis 4:16 (2009)
REFERENCE   PMID:15994874 (gene)
  AUTHORS   Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lazaro C, Joncourt F, Parry DM, Rouleau GA, Evans DG
  TITLE     The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
  JOURNAL   J Med Genet 42:540-6 (2005)
REFERENCE   PMID:24877986 (drug)
  AUTHORS   Lim SH, Ardern-Holmes S, McCowage G, de Souza P
  TITLE     Systemic therapy in neurofibromatosis type 2.
  JOURNAL   Cancer Treat Rev 40:857-61 (2014)
///
ENTRY       H01439                      Disease
NAME        Williams-Beuren syndrome
DESCRIPTION Williams-Beuren syndrome (WBS) is a rare autosomal dominant multisystem disorder associated with the hemizygous deletion of a number of genes on chromosome 7q11.23. The range of phenotypes may include congenital vascular and heart disease, characteristic facial features, premature aging, generally mild mental retardation, short stature, myopathy, hypercalcemia, and a unique cognitive profile. To date at least 28 genes have been identified within the deleted region.
CATEGORY    Developmental disorder
GENE        ELN [HSA:2006] [KO:K14211]
            LIMK1 [HSA:3984] [KO:K05743]
            CLIP2 [HSA:7461] [KO:K10422]
            RFC2 [HSA:5982] [KO:K10755]
            BCL7B [HSA:9275]
            GTF2I [HSA:2969] [KO:K03121]
            GTF2IRD [HSA:9569] [KO:K03121]
            EIF4H [HSA:7458]
            TBL2 [HSA:26608]
            MLXIPL [HSA:51085] [KO:K09113]
            FKBP6 [HSA:8468] [KO:K09572]
            BAZ1B [HSA:9031] [KO:K11658]
            CLDN3 [HSA:1365] [KO:K06087]
            CLDN4 [HSA:1364] [KO:K06087]
            DNAJC30 [HSA:84277] [KO:K19374]
            LAT2 [HSA:7462]
            FZD9 [HSA:8326] [KO:K02842]
            STX1A [HSA:6804] [KO:K04560]
            SPDYE1 [HSA:285955] [KO:K08694]
            NSUN5 [HSA:55695] [KO:K15264]
            ABHD11 [HSA:83451] [KO:K13703]
            TRIM50 [HSA:135892] [KO:K12024]
            VPS37D [HSA:155382] [KO:K12185]
            WBSCR22 [HSA:114049] [KO:K19306]
            WBSCR16 [HSA:64409] [KO:K00710]
            WBSCR17 [HSA:81554]
            WBSCR27 [HSA:155368]
            WBSCR28 [HSA:135886]
DBLINKS     ICD-10: Q93.8
            MeSH: D018980
            OMIM: 194050
REFERENCE   PMID:20089974
  AUTHORS   Pober BR
  TITLE     Williams-Beuren syndrome.
  JOURNAL   N Engl J Med 362:239-52 (2010)
REFERENCE   PMID:23401415
  AUTHORS   Delio M, Pope K, Wang T, Samanich J, Haldeman-Englert CR, Kaplan P, Shaikh TH, Cai J, Marion RW, Morrow BE, Babcock M
  TITLE     Spectrum of elastin sequence variants and cardiovascular phenotypes in 49 patients with Williams-Beuren syndrome.
  JOURNAL   Am J Med Genet A 161A:527-33 (2013)
REFERENCE   PMID:21655442
  AUTHORS   Matsumoto N, Kitani R, Kalinec F
  TITLE     Linking LIMK1 deficiency to hyperacusis and progressive hearing loss in individuals with Williams syndrome.
  JOURNAL   Commun Integr Biol 4:208-10 (2011)
REFERENCE   PMID:22608712
  AUTHORS   Vandeweyer G, Van der Aa N, Reyniers E, Kooy RF
  TITLE     The contribution of CLIP2 haploinsufficiency to the clinical manifestations of the Williams-Beuren syndrome.
  JOURNAL   Am J Hum Genet 90:1071-8 (2012)
REFERENCE   PMID:23018576
  AUTHORS   Zhukova N, Naqvi A
  TITLE     Williams-Beuren Syndrome and Burkitt Leukemia.
  JOURNAL   J Pediatr Hematol Oncol 35:e30-2 (2013)
REFERENCE   PMID:12073013
  AUTHORS   Merla G, Ucla C, Guipponi M, Reymond A
  TITLE     Identification of additional transcripts in the Williams-Beuren syndrome critical region.
  JOURNAL   Hum Genet 110:429-38 (2002)
REFERENCE   PMID:11124535
  AUTHORS   Doyle JL, DeSilva U, Miller W, Green ED
  TITLE     Divergent human and mouse orthologs of a novel gene (WBSCR15/Wbscr15) reside within the genomic interval commonly deleted in Williams syndrome.
  JOURNAL   Cytogenet Cell Genet 90:285-90 (2000)
REFERENCE   PMID:11978965
  AUTHORS   Doll A, Grzeschik KH
  TITLE     Characterization of two novel genes, WBSCR20 and WBSCR22, deleted in Williams-Beuren syndrome.
  JOURNAL   Cytogenet Cell Genet 95:20-7 (2001)
REFERENCE   PMID:18398435
  AUTHORS   Micale L, Fusco C, Augello B, Napolitano LM, Dermitzakis ET, Meroni G, Merla G, Reymond A
  TITLE     Williams-Beuren syndrome TRIM50 encodes an E3 ubiquitin ligase.
  JOURNAL   Eur J Hum Genet 16:1038-49 (2008)
///
ENTRY       H01440                      Disease
NAME        Acute necrotizing ulcerative gingivitis;
            Vincent's gingivitis;
            Vincent angina;
            Trench mouth
DESCRIPTION Acute necrotizing ulcerative gingivitis, also known as Trench mouth, Vincent angina and Vincent's gingivitis is an acute bacterial infection of the gingiva caused by spirochetes, fusiform bacteria, or an overgrowth of normal oral flora. Predisposing factors include poor oral hygiene, advancing age, impaired nutritional status, smoking or chewing tobacco, immunosuppression, preexisting gingivitis, extreme stress, or lack of sleep. If the symptom progresses, the periodontium may be destroyed. Possible systemic manifestations include fever, anorexia, weakness, and fatigue.
CATEGORY    Infectious disease
PATHOGEN    Fusobacterium nucleatum
            Fusobacterium fusiforme
            Fusobacterium periodonticurm
            Fusobacterium naviforme
            Fusobacterium alocis
            Fusobacterium sulci
            Leptotrichia buccalis
            Borrelia vincentii
DBLINKS     ICD-10: A69.1 K05
            MeSH: D005892
            MedlinePlus: 001044
REFERENCE   PMID:2196849 (description, pathogen)
  AUTHORS   Holbrook WP, Cawson RA
  TITLE     The problem of the taxonomy of the fusiform bacillus of acute necrotizing ulcerative gingivitis (Vincent's gingivitis).
  JOURNAL   Antonie Van Leeuwenhoek 57:55-8 (1990)
REFERENCE   PMID:21248581 (description, pathogen)
  AUTHORS   Carlson DS, Pfadt E
  TITLE     Vincent and Ludwig angina: two damaging oral infections.
  JOURNAL   Nursing 41:55-8 (2011)
///
ENTRY       H01441                      Disease
NAME        Pseudomonas aeruginosa infection
DESCRIPTION Pseudomonas aeruginosa is a leading cause of nosocomial bloodstream infections, ranking third among gram-negative bacteria, after Escherichia coli and Klebsiella species. Intrinsic resistance has been traditionally attributed to the low permeability of cellular envelopes together with the presence of chromosomally-encoded detoxification systems such as multidrug efflux pumps or antibiotic inactivating enzymes. Some strains acquire increased resistance via the horizontal transfer of resistance determinants and mutations in chromosomal genes.
CATEGORY    Infectious disease
PATHOGEN    Pseudomonas aeruginosa [GN:pae]
DBLINKS     ICD-10: A49.8 J15.1
            MeSH: D011552
REFERENCE   PMID:17876002 (description)
  AUTHORS   Henrichfreise B, Wiegand I, Pfister W, Wiedemann B
  TITLE     Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.
  JOURNAL   Antimicrob Agents Chemother 51:4062-70 (2007)
REFERENCE   PMID:21304266 (description)
  AUTHORS   Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL
  TITLE     The intrinsic resistome of Pseudomonas aeruginosa to beta-lactams.
  JOURNAL   Virulence 2:144-6 (2011)
REFERENCE   PMID:11692297 (description)
  AUTHORS   El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C
  TITLE     Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.
  JOURNAL   Clin Infect Dis 33:1859-64 (2001)
///
ENTRY       H01442                      Disease
NAME        Septic arthritis;
            Pyogenic arthritis
DESCRIPTION Septic arthritis is defined as a purulent infection in a joint cavity. The infection commonly reaches the joint in children by hematogenous spread or by direct extension of pathogenic bacteria. Staphylococcus aureus, Haemophilus influenzae type-b, and Group A Streptococcus, Streptococcus pneumoniae, Kingela kingae, Neisseria meningiditis and Salmonella spp. are the predominant anaerobic bacteria that cause arthritis in children. One of the most predominant aetiologic agent of septic arthritis in all age groups is Staphylococcus aureus. Also, Gonococcal arthritis can occur in sexually active adolescents.
CATEGORY    Infectious disease
PATHOGEN    Staphylococcus aureus
            Streptococcus pneumoniae
            Haemophilus influenza
            Kingela kingae
            Neisseria meningiditis 
            Salmonella spp.
            Escherichia coli 
            Pseudomonas aeruginosa
            Neisseria gonorrhea
DBLINKS     ICD-10: M00.9
            MeSH: D001170
            MedlinePlus: 000430
REFERENCE   PMID:12528083 (pathogen)
  AUTHORS   Bar-Natan M, Salai M, Sidi Y, Gur H
  TITLE     Sternoclavicular infectious arthritis in previously healthy adults.
  JOURNAL   Semin Arthritis Rheum 32:189-95 (2002)
REFERENCE   PMID:12396847 (description)
  AUTHORS   Brook I
  TITLE     Joint and bone infections due to anaerobic bacteria in children.
  JOURNAL   Pediatr Rehabil 5:11-9 (2002)
///
ENTRY       H01443                      Disease
NAME        Viridans group streptococcal infection
DESCRIPTION The viridans group streptococci (VGS), a heterogenous group of streptococcal species, are the predominant species of the human oral flora and commonly inhabit other areas of the upper respiratory, gastrointestinal, and female genital tracts. VGS are usually organisms of low virulence. However, VGS are a major cause of sepsis and pneumonia in neutropenic individuals, and an important cause of sepsis and meningitis in neonates. These organisms are also occasional pathogens in healthy children and adults, causing infections such as subacute endocarditis. Although VGS resistance to penicillin and the macrolide-lincosamide-streptogramin B (MLS) drugs is an evolving problem, several drugs remain uniformly active against the VGS. Thus far, VGS resistance to vancomycin, linezolid, and daptomycin remains extremely rare.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus mitis [GN:smb]
            Streptococcus pseudopneumoniae [GN:std]
            Streptococcus sanguinis [GN:ssa]
            Streptococcus parasanguinis [GN:scp scf]
            Streptococcus gordonii [GN:sgo]
            Streptococcus constellatus [GN:scg scon scos]
            Streptococcus intermedius [GN:sie sib siu]
            Streptococcus anginosus [GN:sang sanc sans]
            Streptococcus mutans [GN:smu smc smj smut smua]
            Streptococcus sobrinus
            Streptococcus salivarius [GN:ssr stf stj strs]
            Streptococcus vestibularis
            Streptococcus thermophilus [GN:stc stl ste stn stu stw sthe]
            Streptococcus equinus
            Streptococcus gallolyticus [GN:sga sgg sgt]
            Streptococcus infantarius [GN:sif]
DBLINKS     ICD-10: A49.1 B95.4
            MeSH: D013290
REFERENCE   PMID:20810781 (description, pathogen)
  AUTHORS   Doern CD, Burnham CA
  TITLE     It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations.
  JOURNAL   J Clin Microbiol 48:3829-35 (2010)
REFERENCE   PMID:10720803 (description, pathogen)
  AUTHORS   Shenep JL
  TITLE     Viridans-group streptococcal infections in immunocompromised hosts.
  JOURNAL   Int J Antimicrob Agents 14:129-35 (2000)
REFERENCE   PMID:17588233 (pathogen)
  AUTHORS   Reilly AF, Lange BJ
  TITLE     Infections with viridans group streptococci in children with cancer.
  JOURNAL   Pediatr Blood Cancer 49:774-80 (2007)
///
ENTRY       H01444                      Disease
NAME        Enterococcal infection
DESCRIPTION Enterococci are Gram-positive, catalase-negative, non-spore-forming, facultative anaerobic bacteria, which usually inhabit the alimentary tract of humans in addition to being isolated from environmental and animal sources. The species of the greatest clinical importance are Enterococcus faecalis and Enterococcus faecium. Enterococcal infections include urinary tract infections, hepatobiliary sepsis, endocarditis, surgical wound infection, bacteraemia and neonatal sepsis.
CATEGORY    Infectious disease
PATHOGEN    Enterococcus faecalis 
            Enterococcus faecium
DBLINKS     ICD-10: A41 I39 N39
REFERENCE   PMID:24585051 (description)
  AUTHORS   Yuen GJ, Ausubel FM
  TITLE     Enterococcus infection biology: lessons from invertebrate host models.
  JOURNAL   J Microbiol 52:200-10 (2014)
REFERENCE   PMID:19383684 (description)
  AUTHORS   Fisher K, Phillips C
  TITLE     The ecology, epidemiology and virulence of Enterococcus.
  JOURNAL   Microbiology 155:1749-57 (2009)
///
ENTRY       H01445                      Disease
NAME        Acne vulgaris
DESCRIPTION Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production, altered keratinization, inflammation, and bacterial colonization of hair follicles on the face, neck, chest, and back by Propionibacterium acnes. P. acnes is a Gram-positive bacterium that forms part of the normal flora of the skin, oral cavity, large intestine, the conjunctiva and the external ear canal. Although P. acnes is primarily recognized for its role in acne, it's also famous as an opportunistic pathogen causing a range of postoperative and device-related infections.
CATEGORY    Infectious disease
PATHOGEN    Propionibacterium acnes [GN:pac pach]
DBLINKS     ICD-10: L70.0
            MeSH: D000152
            MedlinePlus: 000873
REFERENCE   PMID:21880356 (description)
  AUTHORS   Williams HC, Dellavalle RP, Garner S
  TITLE     Acne vulgaris.
  JOURNAL   Lancet 379:361-72 (2012)
REFERENCE   PMID:22114965 (description)
  AUTHORS   Perry A, Lambert P
  TITLE     Propionibacterium acnes: infection beyond the skin.
  JOURNAL   Expert Rev Anti Infect Ther 9:1149-56 (2011)
///
ENTRY       H01446                      Disease
NAME        Propionibacterium acnes infection
DESCRIPTION The anaerobic Gram-positive bacterium Propionibacterium acnes which forms part of the normal resident human microbiota of the skin, oral cavity, and gastrointestinal and genitourinary tracts. The organism is an opportunistic pathogen most widely known for its association with acne vulgaris but it also causes bacterial keratitis and endophthalmitis after ophthalmic surgery, and is increasingly recognized as a significant cause of medical device-related infections. It has also been linked to synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, sarcoidosis, primary biliary cirrhosis, sciatica, spondylodiscitis, corneal ulcers, cholesterol gallstones, allergic alveolitis, pulmonary angiitis, synovitis, pustulosis, hyperostosis and, more recently, prostate cancer.
CATEGORY    Infectious disease
PATHOGEN    Propionibacterium acnes [GN:pav pax paz paw pad]
COMMENT     See also H01445 Acne vulgaris.
REFERENCE   PMID:15286373 (description)
  AUTHORS   Bruggemann H, Henne A, Hoster F, Liesegang H, Wiezer A, Strittmatter A, Hujer S, Durre P, Gottschalk G.
  TITLE     The complete genome sequence of Propionibacterium acnes, a commensal of human skin.
  JOURNAL   Science 305:671-3 (2004)
REFERENCE   PMID:21511767 (description)
  AUTHORS   McDowell A, Gao A, Barnard E, Fink C, Murray PI, Dowson CG, Nagy I, Lambert PA, Patrick S
  TITLE     A novel multilocus sequence typing scheme for the opportunistic pathogen Propionibacterium acnes and characterization of type I cell surface-associated antigens.
  JOURNAL   Microbiology 157:1990-2003 (2011)
REFERENCE   PMID:22374954 (description)
  AUTHORS   Voros A, Horvath B, Hunyadkurti J, McDowell A, Barnard E, Patrick S, Nagy I
  TITLE     Complete genome sequences of three Propionibacterium acnes isolates from the type IA(2) cluster.
  JOURNAL   J Bacteriol 194:1621-2 (2012)
///
ENTRY       H01447                      Disease
NAME        Body Dysmorphic Disorder
DESCRIPTION Body dysmorphic disorder (BDD) is a psychiatric disorder in which individuals are preoccupied with imagined defects in their appearance, which are not noticeable or appear slight to others. It is characterized by time-consuming behaviors such as mirror gazing, comparing one's appearance with the appearance of others, excessive camouflaging to hide the defect, and seeking reassurance. Patients experience significant distress, disability, and functional impairment, often accompanied by depression and suicidality. There is some clinical and pathologic overlap between obsessive-compulsive disorder (OCD) and BDD such as obsessive thoughts and the performance of ritual behavior. Patients with BDD respond to treatment with serotonergic agents such as clomipramine or selective serotonin reuptake inhibitors (SSRIs), which suggests a dysfunction of central serotonergic neurotransmission as a possible etiological factor. A recent study suggests that cognitive-behavior therapy (CBT) was more effective than treatment with medications.
CATEGORY    Mental and behavioural disorders
DRUG        Fluoxetine [DG:DG00942]
COMMENT     In the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5), body dysmorphic disorder (BDD) has been subsumed into the obsessive-compulsive disorders and related disorders (OCDRD) category.
DBLINKS     ICD-10: F45.2
            MeSH: D057215
REFERENCE   PMID:26345330
  AUTHORS   Frias A, Palma C, Farriols N, Gonzalez L
  TITLE     Comorbidity between obsessive-compulsive disorder and body dysmorphic disorder: prevalence, explanatory theories, and clinical characterization.
  JOURNAL   Neuropsychiatr Dis Treat 11:2233-44 (2015)
REFERENCE   PMID:18224271
  AUTHORS   Pavan C, Simonato P, Marini M, Mazzoleni F, Pavan L, Vindigni V
  TITLE     Psychopathologic aspects of body dysmorphic disorder: a literature review.
  JOURNAL   Aesthetic Plast Surg 32:473-84 (2008)
REFERENCE   PMID:25419211
  AUTHORS   Li W, Arienzo D, Feusner JD
  TITLE     Body Dysmorphic Disorder: Neurobiological Features and an Updated Model.
  JOURNAL   Z Klin Psychol Psychother (Gott) 42:184-191 (2013)
REFERENCE   PMID:11926939 (Drug)
  AUTHORS   Phillips KA, Albertini RS, Rasmussen SA
  TITLE     A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
  JOURNAL   Arch Gen Psychiatry 59:381-8 (2002)
REFERENCE   PMID:23459093
  AUTHORS   Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A
  TITLE     The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses.
  JOURNAL   Cognit Ther Res 36:427-440 (2012)
///
ENTRY       H01448                      Disease
NAME        Hoarding disorder
DESCRIPTION Hoarding disorder is characterized by persistent difficulty discarding possessions, regardless of the value others may attribute to these possessions. They accumulate a large number of possessions that often fill up or clutter active living areas of the home or workplace to the extent that their intended use is no longer possible. Previously, hoarding has been treated as a typical obsessive-compulsive disorder (OCD) symptom, using first-line pharmacological and psychological treatments for OCD, however, the results have not been robust. Clinical trial evidence suggests that OCD patients with hoarding symptoms are less responsive to selective serotonin reuptake inhibitors (SSRIs) than those without hoarding symptoms. On the other hand, hoarding and non-hoarding OCD patients fared equally well in one open trial of paroxetine.
CATEGORY    Mental and behavioural disorders
DRUG        Paroxetine [DG:DG00944]
COMMENT     In the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5), hoarding disorder has been subsumed into the obsessive-compulsive disorders and related disorders (OCDRD) category.
DBLINKS     ICD-10: F42.8
            MeSH: D060845
REFERENCE   PMID:8512538
  AUTHORS   Frost RO, Gross RC
  TITLE     The hoarding of possessions.
  JOURNAL   Behav Res Ther 31:367-81 (1993)
REFERENCE   PMID:20336805
  AUTHORS   Mataix-Cols D, Frost RO, Pertusa A, Clark LA, Saxena S, Leckman JF, Stein DJ, Matsunaga H, Wilhelm S
  TITLE     Hoarding disorder: a new diagnosis for DSM-V?
  JOURNAL   Depress Anxiety 27:556-72 (2010)
REFERENCE   PMID:24467873
  AUTHORS   Morein-Zamir S, Papmeyer M, Pertusa A, Chamberlain SR, Fineberg NA, Sahakian BJ, Mataix-Cols D, Robbins TW
  TITLE     The profile of executive function in OCD hoarders and hoarding disorder.
  JOURNAL   Psychiatry Res 215:659-67 (2014)
REFERENCE   PMID:16824483
  AUTHORS   Samuels JF, Bienvenu OJ 3rd, Pinto A, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Greenberg BD, Knowles JA, Piacentini J, Cannistraro PA, Cullen B, Riddle MA, Rasmussen SA, Pauls DL, Willour VL, Shugart YY, Liang KY, Hoehn-Saric R, Nestadt G
  TITLE     Hoarding in obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study.
  JOURNAL   Behav Res Ther 45:673-86 (2007)
REFERENCE   PMID:16790250 (Drug)
  AUTHORS   Saxena S, Brody AL, Maidment KM, Baxter LR Jr
  TITLE     Paroxetine treatment of compulsive hoarding.
  JOURNAL   J Psychiatr Res 41:481-7 (2007)
///
ENTRY       H01449                      Disease
NAME        Excoriation disorder;
            Skin picking disorder
DESCRIPTION Excoriation Disorder, also known as Skin Picking Disorder, is characterized by the repetitive and compulsive scratching or picking of skin, which causes tissue damage. Patients spend a significant amount of time each day picking their skin, that causes psychosocial impairment. Triggers to pick vary greatly. For example, stress, anxiety, boredom, and feeling tired or angry have all been reported as triggers. Co-occurring psychiatric conditions are common in this disease. The most commonly reported comorbid conditions are trichotillomania, substance dependence, major depressive disorder, anxiety disorders, obsessive compulsive disorder (OCD), and body dysmorphic disorder (BDD). So far, there is no clear neurobiological explanation for the etiology of this disease. Recent research showed bilateral abnormalities in the anterior cingulate cortex and abnormalities on the left temporoparietal junction. Another study has shown deficits in motor inhibition, which appears to be correlated with frontal cortex abnormalities. Furthermore, severity of excoriation disorder may be associated with higher levels of impulsivity. Treatment for this disease has largely focused on cognitive behavioral therapy and pharmacology. Early psychosocial treatment studies provided evidence for skin picking reduction with habit reversal or acceptance-enhanced behavior therapy (AEBT). The data for selective serotonin reuptake inhibitors (SSRIs) efficacy in this disease are not convincing, although some studies suggested that fluoxetine is effective. Tricyclic antidepressants, neuroleptics, and the dopamine-blocking opioid antagonist have also been found to be effective for skin-picking.
CATEGORY    Mental and behavioural disorders; Skin and connective tissue disease
DRUG        Fluoxetine [DG:DG00942]
            Naltrexone [DG:DG00997]
            Doxepin [DG:DG00937]
            Clomipramine [DG:DG00929]
            Olanzapine [DG:DG00898]
COMMENT     In the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5), excoriation disorder has been subsumed into the obsessive-compulsive disorders and related disorders (OCDRD) category.
DBLINKS     ICD-10: F48.9 L98.1
REFERENCE   PMID:25591046
  AUTHORS   Oliveira EC, Leppink EW, Derbyshire KL, Grant JE
  TITLE     Excoriation disorder: impulsivity and its clinical associations.
  JOURNAL   J Anxiety Disord 30:19-22 (2015)
REFERENCE   PMID:23128921
  AUTHORS   Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ
  TITLE     Skin picking disorder.
  JOURNAL   Am J Psychiatry 169:1143-9 (2012)
REFERENCE   PMID:20575652
  AUTHORS   Odlaug BL, Grant JE
  TITLE     Pathologic skin picking.
  JOURNAL   Am J Drug Alcohol Abuse 36:296-303 (2010)
REFERENCE   PMID:18334614 (treatment)
  AUTHORS   Flessner CA, Busch AM, Heideman PW, Woods DW
  TITLE     Acceptance-enhanced behavior therapy (AEBT) for trichotillomania and chronic skin picking: exploring the effects of component sequencing.
  JOURNAL   Behav Modif 32:579-94 (2008)
REFERENCE   PMID:20694122 (Drug)
  AUTHORS   Jafferany M, Shireen F, Ibrahim A
  TITLE     An open-label trial of topiramate in the treatment of skin picking in pervasive developmental disorder not otherwise specified.
  JOURNAL   Prim Care Companion J Clin Psychiatry 12 (2010)
///
ENTRY       H01450                      Disease
NAME        Obsessive-compulsive disorder (OCD)
DESCRIPTION Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent, intrusive and disturbing thoughts as well as by repetitive stereotypic behaviors. OCD is a complex disorder and its pathogenesis is most likely influenced by both genetic and environmental factors. Although more than 140 candidate gene studies have been conducted, the findings have been inconclusive due to small sample size and few study replications. Many studies suggest that abnormal serotonergic neurotransmission is one of the most consistent biological findings in OCD. Studies have also reported dopaminergic abnormalities in the basal ganglia and nucleus accumbens, as well as altered glutamate transmission. First line treatments for this disorder are cognitive behavioral therapy (exposure and response prevention) and selective serotonin reuptake inhibitors (SSRIs). In recent years, one of the promising novel treatment strategies developed to improve the efficacy of treatment for patients with OCD is acceptance and commitment therapy (ACT). Recent studies have suggested that age of onset is an important factor in subtyping OCD. Early-onset OCD has been proposed to be associated with greater symptom severity, a higher prevalence of tic-related disorders, a more familial form of the condition, and a greater prevalence of psychiatry disorders in first-degree relatives as compared to late-onset OCD.
CATEGORY    Mental and behavioural disorders
GENE        BDNF (polymorphism) [HSA:627] [KO:K04355]
            HTR2A (promoter polymorphism) [HSA:3356] [KO:K04157]
            SLC6A4 (polymorphism) [HSA:6532] [KO:K05037]
            COMT (polymorphism) [HSA:1312] [KO:K00545]
            MAOA (polymorphism) [HSA:4128] [KO:K00274]
            SLC1A1 (polymorphism) [HSA:6505] [KO:K05612]
            DRD4 (polymorphism) [HSA:1815] [KO:K04147]
DRUG        Paroxetine [DG:DG00944]
            Fluoxetine [DG:DG00942]
            Clomipramine [DG:DG00929]
            Haloperidol [DG:DG00885]
            Risperidone [DR:D00426]
COMMENT     For Tourette syndrome, see H00862.
DBLINKS     ICD-10: F42
            MeSH: D009771
            OMIM: 164230
REFERENCE   PMID:21820387
  AUTHORS   Taylor S
  TITLE     Early versus late onset obsessive-compulsive disorder: evidence for distinct subtypes.
  JOURNAL   Clin Psychol Rev 31:1083-100 (2011)
REFERENCE   PMID:19432385
  AUTHORS   Leckman JF, Bloch MH, King RA
  TITLE     Symptom dimensions and subtypes of obsessive-compulsive disorder: a developmental perspective.
  JOURNAL   Dialogues Clin Neurosci 11:21-33 (2009)
REFERENCE   PMID:22911909 (gene)
  AUTHORS   Tukel R, Gurvit H, Ozata B, Ozturk N, Ertekin BA, Ertekin E, Baran B, Kalem SA, Buyukgok D, Direskeneli GS
  TITLE     Brain-derived neurotrophic factor gene Val66Met polymorphism and cognitive function in obsessive-compulsive disorder.
  JOURNAL   Am J Med Genet B Neuropsychiatr Genet 159B:850-8 (2012)
REFERENCE   PMID:12476319 (gene)
  AUTHORS   Walitza S, Wewetzer C, Warnke A, Gerlach M, Geller F, Gerber G, Gorg T, Herpertz-Dahlmann B, Schulz E, Remschmidt H, Hebebrand J, Hinney A
  TITLE     5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders.
  JOURNAL   Mol Psychiatry 7:1054-7 (2002)
REFERENCE   PMID:16642437 (gene)
  AUTHORS   Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D
  TITLE     Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.
  JOURNAL   Am J Hum Genet 78:815-26 (2006)
REFERENCE   PMID:25793616 (gene)
  AUTHORS   Sampaio AS, Hounie AG, Petribu K, Cappi C, Morais I, Vallada H, do Rosario MC, Stewart SE, Fargeness J, Mathews C, Arnold P, Hanna GL, Richter M, Kennedy J, Fontenelle L, de Braganca Pereira CA, Pauls DL, Miguel EC
  TITLE     COMT and MAO-A polymorphisms and obsessive-compulsive disorder: a family-based association study.
  JOURNAL   PLoS One 10:e0119592 (2015)
REFERENCE   PMID:16818867 (gene)
  AUTHORS   Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL
  TITLE     Association testing of the positional and functional candidate gene SLC1A1/EAAC1  in early-onset obsessive-compulsive disorder.
  JOURNAL   Arch Gen Psychiatry 63:778-85 (2006)
REFERENCE   PMID:12497615 (gene)
  AUTHORS   Millet B, Chabane N, Delorme R, Leboyer M, Leroy S, Poirier MF, Bourdel MC, Mouren-Simeoni MC, Rouillon F, Loo H, Krebs MO
  TITLE     Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder.
  JOURNAL   Am J Med Genet B Neuropsychiatr Genet 116B:55-9 (2003)
REFERENCE   PMID:26288647 (treatment)
  AUTHORS   Vakili Y, Gharaee B, Habibi M
  TITLE     Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder.
  JOURNAL   Iran J Psychiatry Behav Sci 9:e845 (2015)
REFERENCE   PMID:16585942 (treatment)
  AUTHORS   Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF
  TITLE     A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
  JOURNAL   Mol Psychiatry 11:622-32 (2006)
///
ENTRY       H01451                      Disease
NAME        Actinomycetoma
DESCRIPTION Nocardia brasiliensis is a nonmotile, Gram-positive bacterium that lives as a saprophyte in soil and is classified as an aerobic actinomycete. In Latin-American countries, this organism causes actinomycetoma which is a chronic disease usually located on the extremities and is characterized by slow progressing tumefaction with nodules, abscess and draining sinuses.
CATEGORY    Infectious disease
PATHOGEN    Nocardia brasiliensis [GN:nbr]
COMMENT     See also H01325 Actinomycosis and H00345 Nocardiosis.
DBLINKS     ICD-10: B47.1
            MeSH: D008271
REFERENCE   PMID:11018454 (description)
  AUTHORS   Salinas-Carmona MC
  TITLE     Nocardia brasiliensis: from microbe to human and experimental infections.
  JOURNAL   Microbes Infect 2:1373-81 (2000)
REFERENCE   PMID:22535940 (pathogen)
  AUTHORS   Vera-Cabrera L, Ortiz-Lopez R, Elizondo-Gonzalez R, Perez-Maya AA, Ocampo-Candiani J
  TITLE     Complete genome sequence of Nocardia brasiliensis HUJEG-1.
  JOURNAL   J Bacteriol 194:2761-2 (2012)
REFERENCE   PMID:8819830 (description)
  AUTHORS   Hernandez-Hernandez F, Lopez-Martinez R, Mendez-Tovar LJ, Manzano-Gayosso P
  TITLE     Nocardia brasiliensis: in vitro and in vivo growth response to steroid sex hormones.
  JOURNAL   Mycopathologia 132:79-85 (1995)
///
ENTRY       H01452                      Disease
NAME        Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS)
DESCRIPTION Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) is an autoimmune disorder presenting with obsessive compulsive disorder and/or tics. PANDAS is believed to be caused by antibodies generated in response to a group A beta-hemolytic streptococcal (GAS) infection in genetically susceptible individuals. PANDAS is defined by five diagnostic criteria: (1) the presence of OCD and/or a tic disorder, (2) prepubertal symptom onset, (3) an abrupt onset of symptoms that are episodic in severity, (4) a temporal association between symptom exacerbations and GAS infections, and (5) the presence of neurological abnormalities (e.g., choreiform movements) during exacerbations. It has been reported that antibiotics and immunomodulatory therapies (plasma exchange and IVIG) were effective in lessening of symptom severity.
CATEGORY    Immune system disease; Mental and behavioural disorders
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spa spb stg soz spyo]
DRUG        Azithromycin [DG:DG00606]
            Penicillin V [DG:DG00535]
            Gammagard [DR:D08785]
DBLINKS     ICD-10: B95.0
            MeSH: C537163
REFERENCE   PMID:26196024
  AUTHORS   Helm CE, Blackwood RA
  TITLE     Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS): Experience at a Tertiary Referral Center.
  JOURNAL   Tremor Other Hyperkinet Mov (N Y) 5:270 (2015)
REFERENCE   PMID:15241433
  AUTHORS   Snider LA, Swedo SE
  TITLE     PANDAS: current status and directions for research.
  JOURNAL   Mol Psychiatry 9:900-7 (2004)
REFERENCE   PMID:18495013
  AUTHORS   Moretti G, Pasquini M, Mandarelli G, Tarsitani L, Biondi M
  TITLE     What every psychiatrist should know about PANDAS: a review.
  JOURNAL   Clin Pract Epidemiol Ment Health 4:13 (2008)
REFERENCE   PMID:10513708 (Treatment)
  AUTHORS   Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE
  TITLE     Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood.
  JOURNAL   Lancet 354:1153-8 (1999)
REFERENCE   PMID:15820236 (Drug)
  AUTHORS   Snider LA, Lougee L, Slattery M, Grant P, Swedo SE
  TITLE     Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders.
  JOURNAL   Biol Psychiatry 57:788-92 (2005)
///
ENTRY       H01453                      Disease
NAME        Obsessive-Compulsive and Related Disorder (OCRD)
DESCRIPTION Obsessive-Compulsive and Related Disorder (OCRD) is a group of disorders that is characterized by having preoccupations (obsessions) and/or repetitive behaviors (compulsions). Previously, Obsessive-compulsive disorder (OCD) was grouped with the anxiety disorders. However, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) moved OCD into a new category, because much of the evidence suggests OCD and OC-spectrum disorders are distinct from other anxiety disorders. Although OCD and anxiety disorders often share core clinical feature, significant differences also exist in effective first-line pharmacological interventions. Patients with anxiety disorders respond to a wide range of pharmacological interventions. In contrast, patients with OCD do not respond to nonserotonergic agents. OCRD includes OCD, Trichotillomania, Hoarding disorder, Excoriation disorder, and Body dysmorphic disorder.
            The usual treatments of OCRD are cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI).
CATEGORY    Mental and behavioural disorders
DRUG        Paroxetine [DG:DG00944]
            Fluoxetine [DG:DG00942]
            Clomipramine [DG:DG00929]
COMMENT     See also H01450 Obsessive-compulsive disorder (OCD), H00864 Trichotillomania, H01448 Hoarding disorder, H01449 Excoriation disorder, and H01447 Body Dysmorphic Disorder.
DBLINKS     ICD-10: F42
REFERENCE   PMID:24616177
  AUTHORS   Van Ameringen M, Patterson B, Simpson W
  TITLE     DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria.
  JOURNAL   Depress Anxiety 31:487-93 (2014)
REFERENCE   PMID:20623919
  AUTHORS   Murphy DL, Timpano KR, Wheaton MG, Greenberg BD, Miguel EC
  TITLE     Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts.
  JOURNAL   Dialogues Clin Neurosci 12:131-48 (2010)
REFERENCE   PMID:19819022
  AUTHORS   Nicolini H, Arnold P, Nestadt G, Lanzagorta N, Kennedy JL
  TITLE     Overview of genetics and obsessive-compulsive disorder.
  JOURNAL   Psychiatry Res 170:7-14 (2009)
///
ENTRY       H01454                      Disease
NAME        Colonic spirochetosis
DESCRIPTION Colonic spirochetosis (CS) is a disease caused by the Brachyspira genus, Brachyspira aalborgi and Brachyspira pilosicoli. B. pilosicoli induces disease in both humans and animals, whereas B. aalborgi affects only humans and higher primates. CS is a polymicrobial disease characterized by persistent intimate mucosal epithelial cell attachment of spirochetes alone or together with certain enterohepatic Helicobacter species. Symptoms in humans include diarrhea, rectal bleeding, and abdominal cramps.
CATEGORY    Infectious disease
PATHOGEN    Brachyspira pilosicoli [GN:bpip]
DBLINKS     ICD-10: A04.9 A69.9
REFERENCE   PMID:16013401 (description)
  AUTHORS   Smith JL
  TITLE     Colonic spirochetosis in animals and humans.
  JOURNAL   J Food Prot 68:1525-34 (2005)
REFERENCE   PMID:23469345 (pathogen)
  AUTHORS   Lin C, den Bakker HC, Suzuki H, Lefebure T, Ponnala L, Sun Q, Stanhope MJ, Wiedmann M, Duhamel GE
  TITLE     Complete Genome Sequence of the Porcine Strain Brachyspira pilosicoli P43/6/78(T.).
  JOURNAL   Genome Announc 1 (2013)
///
ENTRY       H01455                      Disease
NAME        Necrotizing fasciitis
DESCRIPTION Necrotizing fasciitis (NF) is a severe life-threatening soft tissue infection characterized by rapidly spreading necrosis of the fascia and the subcutaneous tissue. Although more common in adults, NF also affects the pediatric population. Many bacterial organisms can cause NF, but group A Streptococcus is the most common monomicrobial cause of disease. Other bacterial pathogens that have been implicated in NF include Staphylococcus aureus, Clostridium species, and mixed Gram-negative and anaerobic organisms.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spb stg soz spyo]
            Ochrobactrum anthropi [GN:oan]
            Myroides sp. [GN:myr]
DBLINKS     ICD-10: M72.6
            MeSH: D019115
            MedlinePlus: 001443
REFERENCE   PMID:26548496 (description)
  AUTHORS   Arif N, Yousfi S, Vinnard C
  TITLE     Deaths from necrotizing fasciitis in the United States, 2003-2013.
  JOURNAL   Epidemiol Infect 1-7 (2015)
REFERENCE   PMID:22158285 (description)
  AUTHORS   Jamal N, Teach SJ
  TITLE     Necrotizing fasciitis.
  JOURNAL   Pediatr Emerg Care 27:1195-9; quiz 1200-2 (2011)
REFERENCE   PMID:25745004 (pathogen)
  AUTHORS   Burghartz M, Bunk B, Sproer C, Voget S, Daniel R, Overmann J, Jahn M
  TITLE     Complete Genome Sequence of the Urethral Catheter Isolate Myroides sp. A21.
  JOURNAL   Genome Announc 3 (2015)
///
ENTRY       H01456                      Disease
NAME        Diabetic nephropathy
DESCRIPTION Diabetic nephropathy (DN), also called diabetic kidney disease, is a microvascular complication of diabetes which induces dysfunction in various cell types of the kidney, ultimately leading to the renal failure. A clinical syndrome of DN is characterized by decreased Glomerular Filteration Rate (GFR), excessive deposition of extracellular matrix proteins, thickening of the peripheral glomerular basement membrane, glomerular hypertrophy, tubulointerstitial fibrosis, increased excretion of albumin and decreased creatinine clearance. Generally, DN is divided into five stages: (i) hyperfunction with raised GFR and increased kidney volume; (ii) normalbuminuria with the thickening of the glomerular basement membrane (GBM) and the expansion of the mesangial matrix; (iii) incipient DN with MAU (30-299 mg per day); (iv) overt DN with macroalbuminuria (>300 mg per day); (v) uremia with end-stage renal disease. It has been reported that angiotension-vonverting enzyme, vascular endothelial growth factor A and superoxide dismutase 2 are associated with DN.
CATEGORY    Metabolic disease; Endocrine disease; Urinary system disease
GENE        (Type 1 DN) Vascular endothelial growth factor A (polymorphism) [hsa:7422] [KO:K05448]
            (Type 1,2 DN) Angiotensin-converting enzyme (polymorphism) [HSA:1636] [KO:K01283]
            (Type 1,2 DN) Superoxide dismutase 2 (polymorphism) [HSA:6648] [KO:K04564]
DRUG        Imidapril [DG:DG00347] (ACE inhibitor)
            Irbesartan [DR:D00523] Losartan [DG:DG00348] (Angiotensin receptor blocker)
DBLINKS     ICD-10: E14.2
            MeSH: D003928
            OMIM: 603933 612624 612634
REFERENCE   PMID:25169573 (gene)
  AUTHORS   Alkayyali S, Lyssenko V
  TITLE     Genetics of diabetes complications.
  JOURNAL   Mamm Genome 25:384-400 (2014)
REFERENCE   PMID:21127830 (gene)
  AUTHORS   Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, Dekkers OM, Baelde HJ
  TITLE     Genetic associations in diabetic nephropathy: a meta-analysis.
  JOURNAL   Diabetologia 54:544-53 (2011)
REFERENCE   PMID:17192491 (gene)
  AUTHORS   Mollsten A, Marklund SL, Wessman M, Svensson M, Forsblom C, Parkkonen M, Brismar K, Groop PH, Dahlquist G
  TITLE     A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy.
  JOURNAL   Diabetes 56:265-9 (2007)
REFERENCE   PMID:25512783 (gene)
  AUTHORS   Rizvi S, Raza ST, Mahdi F
  TITLE     Association of genetic variants with diabetic nephropathy.
  JOURNAL   World J Diabetes 5:809-16 (2014)
REFERENCE   PMID:25342915 (description, gene, drug)
  AUTHORS   Lim AKh
  TITLE     Diabetic nephropathy - complications and treatment.
  JOURNAL   Int J Nephrol Renovasc Dis 7:361-81 (2014)
REFERENCE   PMID:26438328 (drug)
  AUTHORS   Montero RM, Covic A, Gnudi L, Goldsmith D
  TITLE     Diabetic nephropathy: What does the future hold?
  JOURNAL   Int Urol Nephrol (2015)
///
ENTRY       H01457                      Disease
NAME        Diabetic retinopathy
DESCRIPTION Diabetic retinopathy (DR), one of the most common vascular complication of diabetes, is the leading cause of visual deficits and blindness around the world.  The development of DR is divided into two stages: in the early stages, also called as nonproliferative stage, it is asymptomatic because the signs are not visible to the eye. however, some defects including microaneurysms, intraretinal hemorrhaging, narrowing or blocked retinal blood vessels can be seen by detection; in the second stage, known as proliferative diabetic retinopathy, where neovascularization appears at the back of the eye and extend into the vitreous of the eye, and these new blood vessels are fragile. If they leak blood, the bleeding causes shrinkage of the retina, leading to retinal detachment, and ultimately to blindness. It has been reported that vascular endothelial growth factor A, angiotensin-converting enzyme, paraoxonase, erythropoietin are associated with DR development and progression.
CATEGORY    Metabolic disease; Endocrine disease; Eye disease
GENE        Vascular endothelial growth factor A (polymorphism) [hsa:7422] [KO:K05448]
            Erythropoietin (polymophism) [HSA:2056] [KO:K05437]
            Angiotensin-converting enzyme (polymorphism) [HSA:1636] [KO:K01283]
            Paraoxonase (polymorphism) [HSA:5444] [KO:K01045]
DRUG        Ranibizumab [DR:D05697] Aflibercept [DR:D09574] (VEGF inhibitor)
DBLINKS     ICD-10: E14.3
            MeSH: D003930
            OMIM: 603933 612623 612624 612633
REFERENCE   PMID:26648684 (gene)
  AUTHORS   Hampton BM, Schwartz SG, Brantley MA Jr, Flynn HW Jr
  TITLE     Update on genetics and diabetic retinopathy.
  JOURNAL   Clin Ophthalmol 9:2175-93 (2015)
REFERENCE   PMID:16120858 (gene)
  AUTHORS   Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H
  TITLE     Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
  JOURNAL   N Engl J Med 353:782-92 (2005)
REFERENCE   PMID:9661650 (gene)
  AUTHORS   Kao YL, Donaghue K, Chan A, Knight J, Silink M
  TITLE     A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM.
  JOURNAL   J Clin Endocrinol Metab 83:2589-92 (1998)
REFERENCE   PMID:25949073 (description, drug)
  AUTHORS   Dedania VS, Bakri SJ
  TITLE     Novel pharmacotherapies in diabetic retinopathy.
  JOURNAL   Middle East Afr J Ophthalmol 22:164-73 (2015)
REFERENCE   PMID:25419235 (description)
  AUTHORS   Marozas LM, Fort PE
  TITLE     Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New  Leads.
  JOURNAL   US Ophthalmic Rev 7:54-58 (2014)
///
ENTRY       H01458                      Disease
NAME        Nontuberculous mycobacterial infection
DESCRIPTION Mycobacteria species other than the obligate pathogens Mycobacterium tuberculosis complex and Mycobacterium leprae are known as nontuberculous mycobacteria (NTM) or atypical mycobacteria. NTM are normal inhabitants of soil and treated water. Although generally of low pathogenicity to humans, NTM can cause a wide range of clinical diseases, for instance, pulmonary disease is most frequent, followed by lymphadenitis in children, skin disease and other extrapulmonary or disseminated infections in the severely immunocompromised.
CATEGORY    Infectious disease
PATHOGEN    Mycobacterium intracellulare [GN:mit mir mia]
            Mycobacterium sp. JDM601 [GN:mjd]
            Mycobacterium abscessus [GN:mab mabb mmv mabl]
DBLINKS     ICD-10: A31.9
            MeSH: D009165
REFERENCE   PMID:23460010 (description)
  AUTHORS   van Ingen J
  TITLE     Diagnosis of nontuberculous mycobacterial infections.
  JOURNAL   Semin Respir Crit Care Med 34:103-9 (2013)
REFERENCE   PMID:26143432 (description)
  AUTHORS   Gonzalez-Santiago TM, Drage LA
  TITLE     Nontuberculous Mycobacteria: Skin and Soft Tissue Infections.
  JOURNAL   Dermatol Clin 33:563-77 (2015)
///
ENTRY       H01459                      Disease
NAME        Diabetic neuropathy
DESCRIPTION Diabetic neuropathies (DNs) are nerve damaging disorders caused by diabetes. Diabetic neuropathy broadly comprise generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic) and asymmetric (focal and multifocal) neuropathies (cranial, truncal, focal-limb, proximal-motor, coexisting chronic inflammatory demyelinating), which affect all organs and system. Of all types, diabetic sensorimotor polyneuropathy (DSPN), also called distal symmetric neuropathy, is the most typical form. Typical Symptoms vary from person to person, but may include numbness, tingling, pain, or weakness that typically starts in the feet and progresses up the legs. This pattern of neuropathy shows a progressive distal axonopathy. It has been reported that vascular endothelial growth factor A is associated with DNs development and progression.
CATEGORY    Metabolic disease; Endocrine disease; Nervous system disease
GENE        Vascular endothelial growth factor A (polymorphism) [hsa:7422] [KO:K05448]
DRUG        Mexiletine [DG:DG00197] (Sodium channel blocking type (class I) antiarrhythmics) 
            Duloxetine [DG:DG00962] (Antidepressants) 
            Pregabalin [DR:D02716] (Calcium channel alpha-2 delat blocker) 
            Tapentadol [DG:DG00826] (Opioid analgesics)
COMMENT     Pregabalin [DR:D02716] (US and EU approved)
DBLINKS     ICD-10: E14.4
            MeSH: D003929
            OMIM: 603933
REFERENCE   PMID:16932298 (description)
  AUTHORS   Vinik A, Ullal J, Parson HK, Casellini CM
  TITLE     Diabetic neuropathies: clinical manifestations and current treatment options.
  JOURNAL   Nat Clin Pract Endocrinol Metab 2:269-81 (2006)
REFERENCE   PMID:25252500 (description)
  AUTHORS   Gupta A, Gupta Y
  TITLE     Diabetic neuropathy: Part 1.
  JOURNAL   J Pak Med Assoc 64:714-8 (2014)
REFERENCE   PMID:16461471 (description)
  AUTHORS   Bansal V, Kalita J, Misra UK
  TITLE     Diabetic neuropathy.
  JOURNAL   Postgrad Med J 82:95-100 (2006)
REFERENCE   PMID:26074879 (gene)
  AUTHORS   Witzel II, Jelinek HF, Khalaf K, Lee S, Khandoker AH, Alsafar H
  TITLE     Identifying Common Genetic Risk Factors of Diabetic Neuropathies.
  JOURNAL   Front Endocrinol (Lausanne) 6:88 (2015)
REFERENCE   PMID:25171371 (drug)
  AUTHORS   Adeghate E, Feher E, Kalasz H
  TITLE     Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.
  JOURNAL   Expert Opin Investig Drugs 24:1-15 (2015)
REFERENCE   PMID:25905398 (drug)
  AUTHORS   Vinik A, Casellini C, Nevoret ML
  TITLE     Diabetic Neuropathies
  JOURNAL   (2000)
///
ENTRY       H01460                      Disease
NAME        West syndrome;
            Infantile spasms (IS)
DESCRIPTION West syndrome, or infantile spasms (IS), is an infantile epileptic encephalopathy characterized by at least two of the following features: (a) clusters of flexion or extension epileptic spasms, (b) interictal electroencephalographic pattern (hypsarrhythmia), and (c) intellectual or neurodevelopmental disabilities. Most cases present at peak age of onset between 3 and 7 months, with 90% of patients presenting in the first year. The etiology of West syndrome is varied, ranging from structural, metabolic, unknown etiologies or genetic causes. Approximately 50% of cases have a prenatal cause, which includes central nervous system malformations, intrauterine insults, neurocutaneous syndromes such as tuberous sclerosis complex (TSC), metabolic disorders, and genetic syndromes such as Down's syndrome. The treatment options are hormonal therapy (adrenocorticotropic hormone ACTH, glucocorticosteroids) or the GABA aminotransferase inhibitor vigabatrin.
CATEGORY    Nervous system disease; Epilepsy
GENE        ARX [hsa:170302] [KO:K09452]
            CDKL5 [hsa:6792] [KO:K08824]
            ST3GAL3 [HSA:6487] [KO:K00781]
DRUG        Vigabatrin [DR:D00535]
DBLINKS     ICD-10: G40.4
            MeSH: D013036
            OMIM: 308350 300672 615006
REFERENCE   PMID:25968935 (description)
  AUTHORS   Galanopoulou AS, Moshe SL
  TITLE     Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies.
  JOURNAL   Neurobiol Dis 79:135-49 (2015)
REFERENCE   PMID:23312951 (description)
  AUTHORS   Galanopoulou AS
  TITLE     Basic mechanisms of catastrophic epilepsy -- overview from animal models.
  JOURNAL   Brain Dev 35:748-56 (2013)
REFERENCE   PMID:20618396 (description)
  AUTHORS   Chudomelova L, Scantlebury MH, Raffo E, Coppola A, Betancourth D, Galanopoulou AS
  TITLE     Modeling new therapies for infantile spasms.
  JOURNAL   Epilepsia 51 Suppl 3:27-33 (2010)
REFERENCE   PMID:20608959 (description)
  AUTHORS   Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, Gaillard WD, Gibson PA, Holmes GL, Nordl DR, O'Dell C, Shields WD, Trevathan E, Wheless JW
  TITLE     Infantile spasms: a U.S. consensus report.
  JOURNAL   Epilepsia 51:2175-89 (2010)
REFERENCE   PMID:17668384 (gene)
  AUTHORS   Kato M, Saitoh S, Kamei A, Shiraishi H, Ueda Y, Akasaka M, Tohyama J, Akasaka N, Hayasaka K
  TITLE     A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome).
  JOURNAL   Am J Hum Genet 81:361-6 (2007)
REFERENCE   PMID:18564362 (gene)
  AUTHORS   Nishimura A, Takano T, Mizuguchi T, Saitsu H, Takeuchi Y, Matsumoto N
  TITLE     CDKL5 disruption by t(X;18) in a girl with West syndrome.
  JOURNAL   Clin Genet 74:288-90 (2008)
REFERENCE   PMID:23252400
  AUTHORS   Edvardson S, Baumann AM, Muhlenhoff M, Stephan O, Kuss AW, Shaag A, He L, Zenvirt S, Tanzi R, Gerardy-Schahn R, Elpeleg O
  TITLE     West syndrome caused by ST3Gal-III deficiency.
  JOURNAL   Epilepsia 54:e24-7 (2013)
///
ENTRY       H01461                      Disease
NAME        POEMS syndrome;
            Crow-Fukase syndrome
DESCRIPTION POEMS syndrome, also called Crow-Fukase syndrome, is a rare paraneoplastic syndrome due to an underlying plasma cell neoplasm, characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes as its salient features. Major diagnostic criteria include sclerotic bone lesions, elevated serum or plasma levels of vascular endothelial growth factor (VEGF), and Castleman disease. The misdiagnosis is very common due to its rarity and complicated clinical manifestations. Recognition of the complex of clinical complications is the first step in effectively managing the disease. The pathogenesis  is not well understood. VEGF appears to play an important role in the disease and is especially useful for monitoring therapy, but it is not likely the sole factor driving the disease. The most commonly used therapies include alkylators and steroids, high-dose chemotherapy with peripheral blood stem cell transplantation, lenalidomide, and bortezomib.
CATEGORY    Nervous system disease; Hematologic disease; Immune system disease
DRUG        Thalidomide [DR:D00754]
DBLINKS     ICD-10: D47.7
            MeSH: D016878
REFERENCE   PMID:24624542 (description)
  AUTHORS   Dispenzieri A, Buadi FK
  TITLE     A review of POEMS syndrome.
  JOURNAL   Oncology (Williston Park) 27:1242-50 (2013)
REFERENCE   PMID:24519469 (description)
  AUTHORS   Cui RT, Yu SY, Huang XS, Zhang JT, Tian CL, Dou LP, Pu CQ
  TITLE     Incidence and risk factors of pleural effusions in patients with POEMS syndrome.
  JOURNAL   Hematol Oncol 33:80-4 (2015)
REFERENCE   PMID:25288371 (description)
  AUTHORS   Raheja D, Specht C, Simmons Z
  TITLE     Paraproteinemic neuropathies.
  JOURNAL   Muscle Nerve 51:1-13 (2015)
///
ENTRY       H01462                      Disease
NAME        Rapidly growing mycobacteria infection
DESCRIPTION Nontuberculous mycobacteria (NTM) are classified into 2 categories: slow-growing mycobacteria (SGM) and rapidly-growing mycobacteria (RGM), based on interval to colony formation by subculture on solid media. More than 50 species of RGM have been identified, more than a third of which are opportunistic human pathogens. The most frequently encountered RGM that cause human infections are Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum (complex), Mycobacterium mucogenicum, and Mycobacterium neoaurum. RGM, generally of low virulence, are capable of causing a wide spectrum of infections. Many RGM species, well-known and recently described species, caused significant infections in patients with cancer, including catheter-related bacteremia, disseminated infection, bronchopulmonary infections, dermatitis, cellulitis, and others.
CATEGORY    Infectious disease
PATHOGEN    Mycobacterium abscessus [GN:mab mabb mmv mabl]
COMMENT     See also H01458 Nontuberculous mycobacterial infection.
DBLINKS     ICD-10: A31.9
            MeSH: D009165
REFERENCE   PMID:23114094 (description)
  AUTHORS   Kim CJ, Kim NH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Kim EC, Park WB, Oh MD
  TITLE     Differentiating rapid- and slow-growing mycobacteria by difference in time to growth detection in liquid media.
  JOURNAL   Diagn Microbiol Infect Dis 75:73-6 (2013)
REFERENCE   PMID:25503461 (description)
  AUTHORS   Sekizuka T, Kai M, Nakanaga K, Nakata N, Kazumi Y, Maeda S, Makino M, Hoshino Y, Kuroda M
  TITLE     Complete genome sequence and comparative genomic analysis of Mycobacterium massiliense JCM 15300 in the Mycobacterium abscessus group reveal a conserved genomic island MmGI-1 related to putative lipid metabolism.
  JOURNAL   PLoS One 9:e114848 (2014)
REFERENCE   PMID:23347634 (description)
  AUTHORS   El Helou G, Viola GM, Hachem R, Han XY, Raad II
  TITLE     Rapidly growing mycobacterial bloodstream infections.
  JOURNAL   Lancet Infect Dis 13:166-74 (2013)
REFERENCE   PMID:17875513 (description)
  AUTHORS   Han XY, De I, Jacobson KL
  TITLE     Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases.
  JOURNAL   Am J Clin Pathol 128:612-21 (2007)
REFERENCE   PMID:16705584 (description)
  AUTHORS   De Groote MA, Huitt G
  TITLE     Infections due to rapidly growing mycobacteria.
  JOURNAL   Clin Infect Dis 42:1756-63 (2006)
///
ENTRY       H01463                      Disease
NAME        Mycosis fungoides
DESCRIPTION Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphomas (CTCL), which are a heterogeneous group of malignancies derived from skin-homing T cells. MF presents in the skin with erythematous patches, plaques, and less frequently, tumours. Although the aetiologies of MF are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases.  Mutations in the p53, p15, p16, JunB, and PTEN genes generally occur in later-stage disease. Loss of normal apoptotic T-cell pathways has also been reported. Apoptosis is partly mediated by death receptors, notably Fas, which is part of the tumor necrosis factor family of receptors. Decreased and/or defective Fas expression by neoplastic T cells has been associated with advanced/aggressive disease and impaired Fas-mediated apoptosis.
CATEGORY    Cancer
GENE        p16/INK4a, ARF (mutation,deletion) [HSA:1029] [KO:K06621]
            p15/INK4b (mutation, deletion) [HSA:1030] [KO:K04685]
            PTEN (mutation) [HSA:5728] [KO:K01110]
            p53 (mutation) [HSA:7157] [KO:K04451]
            JUNB (mutation) [HSA:3726] [KO:K09028]
            Fas (loss of expression) [HSA:355] [KO:K04390]
            Nav3 (deletion) [HSA:89795]
            c-MYC (amplification) [HSA:4609] [KO:K04377]
DRUG        Cyclophosphamide [DG:DG00675]
            Doxorubicin [DG:DG00696]
            Vincristine [DG:DG00690]
            Prednisolone [DG:DG00094]
            Rituximab [DR:D02994]
            Bexarotene [DR:D03106]
            Vorinostat [DR:D06320]
COMMENT     ICD-O-3.1: 9700/3 Mycosis fungoides
DBLINKS     ICD-10: C84
            MeSH: D009182
REFERENCE   PMID:18342689 (description, gene)
  AUTHORS   Hwang ST, Janik JE, Jaffe ES, Wilson WH
  TITLE     Mycosis fungoides and Sezary syndrome.
  JOURNAL   Lancet 371:945-57 (2008)
REFERENCE   PMID:21371258 (description)
  AUTHORS   Beyer M, Mobs M, Humme D, Sterry W
  TITLE     Pathogenesis of Mycosis fungoides.
  JOURNAL   J Dtsch Dermatol Ges 9:594-8 (2011)
REFERENCE   PMID:24438969 (description)
  AUTHORS   Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C
  TITLE     Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
  JOURNAL   J Am Acad Dermatol 70:205.e1-16; quiz 221-2 (2014)
REFERENCE   PMID:20118908 (gene)
  AUTHORS   Laharanne E, Chevret E, Idrissi Y, Gentil C, Longy M, Ferrer J, Dubus P, Jouary T, Vergier B, Beylot-Barry M, Merlio JP
  TITLE     CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.
  JOURNAL   Mod Pathol 23:547-58 (2010)
REFERENCE   PMID:18976417 (gene)
  AUTHORS   Smoller BR
  TITLE     Mycosis fungoides: what do/do not we know?
  JOURNAL   J Cutan Pathol 35 Suppl 2:35-9 (2008)
REFERENCE   PMID:16166283 (gene)
  AUTHORS   Karenko L, Hahtola S, Paivinen S, Karhu R, Syrja S, Kahkonen M, Nedoszytko B, Kytola S, Zhou Y, Blazevic V, Pesonen M, Nevala H, Nupponen N, Sihto H, Krebs I, Poustka A, Roszkiewicz J, Saksela K, Peterson P, Visakorpi T, Ranki A
  TITLE     Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.
  JOURNAL   Cancer Res 65:8101-10 (2005)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:24841586 (drug)
  AUTHORS   Wu PA, Huang V, Bigby ME
  TITLE     Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.
  JOURNAL   Br J Dermatol 170:1015-20 (2014)
REFERENCE   PMID:20568590 (drug)
  AUTHORS   Galper SL, Smith BD, Wilson LD
  TITLE     Diagnosis and management of mycosis fungoides.
  JOURNAL   Oncology (Williston Park) 24:491-501 (2010)
///
ENTRY       H01464                      Disease
NAME        Mantle cell lymphoma
DESCRIPTION Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (NHL) and it accounts for about 6% of all NHL cases. Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. The molecular hallmark and putative initiating oncogenic event in MCL is the t(11;14)(q13;q32) translocation resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course.
CATEGORY    Cancer
GENE        Cyclin D1 (overexpression) [HSA:595] [KO:K04503]
            p16/INK4a (deletion) [HSA:1029] [KO:K06621]
            p53 (mutation) [HSA:7157] [KO:K04451]
MARKER      CD20 [HSA:931] [KO:K06466]
DRUG        Cyclophosphamide [DG:DG00675]
            Doxorubicin [DG:DG00696]
            Vincristine [DG:DG00690]
            Prednisolone [DG:DG00094]
            Rituximab [DR:D02994]
            Ibrutinib [DR:D10223]
            Bortezomib [DR:D03150]
            Bendamustine hydrochloride [DR:D07085]
COMMENT     ICD-O-3.1: 9673/3 Mantle cell lymphoma
DBLINKS     ICD-10: C83
            MeSH: D020522
REFERENCE   PMID:26103436 (description, gene, drug)
  AUTHORS   Vose JM
  TITLE     Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
  JOURNAL   Am J Hematol 90:739-45 (2015)
REFERENCE   PMID:24559208 (description, gene)
  AUTHORS   Wang Y, Ma S
  TITLE     Risk factors for etiology and prognosis of mantle cell lymphoma.
  JOURNAL   Expert Rev Hematol 7:233-43 (2014)
REFERENCE   PMID:26755518 (description, gene, drug)
  AUTHORS   Cheah CY, Seymour JF, Wang ML
  TITLE     Mantle Cell Lymphoma.
  JOURNAL   J Clin Oncol (2016)
REFERENCE   PMID:24857076 (description, gene, drug)
  AUTHORS   Dreyling M
  TITLE     Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches.
  JOURNAL   Am Soc Clin Oncol Educ Book 191-8 (2014)
REFERENCE   PMID:24974852 (drug)
  AUTHORS   Chen Y, Wang M, Romaguera J
  TITLE     Current regimens and novel agents for mantle cell lymphoma.
  JOURNAL   Br J Haematol 167:3-18 (2014)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H01465                      Disease
NAME        Large-vessel vasculitis (LVV), including:
            Giant cell arteritis (GCA);
            Takayasu arteritis (TAK)
DESCRIPTION Large vessel vasculitis (LVV) covers a spectrum of primary vasculitides predominantly affecting the aorta and its major branches. Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main subtypes. GCA is the most common vasculitis affecting adults aged 50 years or more, while TAK is a rare vasculitis that affects younger individuals mainly under 40 years. Clinical presentations vary from asymptomatic to significant systemic symptoms such as fever, weight loss, and symptoms that result from aortitis and high inflammatory markers; C-reactive protein (CRP); and erythrocyte sedimentation rate (ESR) levels. Glucocorticoids are the mainstay of therapy of LVV. Patients may develop predictable adverse effects from long-term glucocorticoid use.
CATEGORY    Nervous system disease; Cardiovascular disease
DRUG        Tocilizumab [DR:D02596]
DBLINKS     ICD-10: M31.4 M31.6
            MeSH: D013700 D013625
REFERENCE   PMID:24893935 (description)
  AUTHORS   Chatterjee S, Flamm SD, Tan CD, Rodriguez ER
  TITLE     Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.
  JOURNAL   Curr Cardiol Rep 16:498 (2014)
REFERENCE   PMID:23949338 (description, drug)
  AUTHORS   Al-Homood IA
  TITLE     Tocilizumab: a new therapy for large vessel vasculitis.
  JOURNAL   Clin Exp Med 14:355-60 (2014)
///
ENTRY       H01466                      Disease
NAME        Ulcerative colitis (UC)
DESCRIPTION Ulcerative colitis (UC) is one subtype of inflammatory bowel disease (IBD) whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. In UC the inflammatory is limited to the musoca of the colon and rectum. Clinically, the most common manifestation of UC may include bloody diarrhea, abdominal pain. In most severe cases, patients may experience fever, weight loss, anemia, and the intestine can get distended, presenting deep ulceration and possibly intestinal perforation.The long-time duration of the disease increases a colorectal caner risk. UC is associated with a Th2 immune response. Recent genetic analyses have linked genes including interleukin 23 receptor, interleukin 10 and macrophage stimulating 1.
CATEGORY    Immune system disease
GENE        IL23R (polymorphism) [HSA:149233] [KO:K05065]
            IL10 (polymorphism) [HSA:3586] [KO:K05443]
            MST1 (polymorphism) [HSA:4485]
DRUG        Infliximab [DR:D02598] Golimumab [DR:D04358] Adalimuab [DR:D02597] (anti-TNF-alpha agents)
            Vedolizumab [DR:D08083] (anti-integrin agent)
            Mesalzine [DR:D00377] Salazosulfapyridine [DR:D00448] Balsalazide disodium [DR:D02715] Olsalazine sodium [DR:D00727] (Aminosalicylates)
            Budesonide [DR:D00246] Prednisolone [DG:DG00093] (Corticosteroids)
DBLINKS     ICD-10: K51
            MeSH: D003093
            OMIM: 612261 612241 612381
REFERENCE   PMID:26339135 (description and drug)
  AUTHORS   de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU
  TITLE     Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
  JOURNAL   Mediators Inflamm 2015:493012 (2015)
REFERENCE   PMID:19923578 (description and gene)
  AUTHORS   Abraham C, Cho JH
  TITLE     Inflammatory bowel disease.
  JOURNAL   N Engl J Med 361:2066-78 (2009)
REFERENCE   PMID:18048021 (description)
  AUTHORS   Pang YH, Zheng CQ, Yang XZ, Zhang WJ
  TITLE     Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients.
  JOURNAL   Cell Immunol 248:115-20 (2007)
REFERENCE   PMID:18836448 (gene)
  AUTHORS   Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S
  TITLE     Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.
  JOURNAL   Nat Genet 40:1319-23 (2008)
REFERENCE   PMID:26600980 (drug)
  AUTHORS   Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H
  TITLE     Promising biological therapies for ulcerative colitis: A review of the literature.
  JOURNAL   World J Gastrointest Pathophysiol 6:219-27 (2015)
REFERENCE   PMID:26284562 (drug)
  AUTHORS   Danese S, Vuitton L, Peyrin-Biroulet L
  TITLE     Biologic agents for IBD: practical insights.
  JOURNAL   Nat Rev Gastroenterol Hepatol 12:537-45 (2015)
///
ENTRY       H01467                      Disease
NAME        Primary biliary cirrhosis (PBC)
DESCRIPTION Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease characterised by destruction of small intrahepatic bile ducts, eventually leading to fibrosis and potential cirrhosis. Patients are usually middle-aged women and presents in the fifth or sixth decade of life. The most common symptoms are pruritus. It is not clear what causes PBC. It may be relate to problems in the autoimmune mechanism. The increased risk of genetic predisposition and environmental factors (infectious or toxic agents) trigger the disease. Ursodeoxycholic acid is currently the only medicine approved for the treatment of the disease.
CATEGORY    Autoimmune disease; Liver disease
ENV_FACTOR  Chemical toxins
            Xenobiotics
            Smoking
MARKER      Antimitochondrial antibody (AMA)
DRUG        Ursodeoxycholic acid [DR:D00734]
DBLINKS     ICD-10: K74.3
            MeSH: D008105
REFERENCE   PMID:26250073 (description)
  AUTHORS   Webb GJ, Siminovitch KA, Hirschfield GM
  TITLE     The immunogenetics of primary biliary cirrhosis: A comprehensive review.
  JOURNAL   J Autoimmun 64:42-52 (2015)
REFERENCE   PMID:19458352 (description)
  AUTHORS   Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, Mason AL, Myers RP, Peltekian KM, Ghent CN, Coltescu C, Atkinson EJ, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA
  TITLE     Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.
  JOURNAL   N Engl J Med 360:2544-55 (2009)
REFERENCE   PMID:26364546 (description and drug)
  AUTHORS   Carey EJ, Ali AH, Lindor KD
  TITLE     Primary biliary cirrhosis.
  JOURNAL   Lancet 386:1565-75 (2015)
REFERENCE   PMID:25057950 (environmental factor)
  AUTHORS   Juran BD, Lazaridis KN
  TITLE     Environmental factors in primary biliary cirrhosis.
  JOURNAL   Semin Liver Dis 34:265-72 (2014)
REFERENCE   PMID:21297251 (pathogen and environmental factor)
  AUTHORS   Dronamraju D, Odin J, Bach N
  TITLE     Primary biliary cirrhosis: environmental risk factors.
  JOURNAL   Dis Markers 29:323-8 (2010)
///
ENTRY       H01468                      Disease
NAME        Eosinophilic granulomatosis with polyangiitis;
            Churg-Strauss syndrome
DESCRIPTION Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitic disorder of unknown etiology that affects small-to-medium-size blood vessels. This disease has been called Churg-Strauss syndrome (CSS) for many years, and renamed eosinophilic granulomatosis with polyangiitis (EGPA) in 2012. EGPA is characterized by asthma, hypereosinophilia, and extravascular eosinophilic granulomas. Clinically, three phases may be distinguished. The prodromal phase may persist for many years, consisting of asthma possibly associated with allergic rhinitis and often complicated by recurrent rhinosinusitis and nasal polyps. The second phase is characterized by peripheral blood eosinophilia or eosinophilic tissue infiltrates. The third phase is dominated by manifestations resulting from systemic vasculitis. Vasculitis commonly affects the skin, nerves, gastrointestinal tract, and heart. It can be serious and life-threatening. EGPA pathogenesis is not well known. The disease is probably the result of a complex interaction in which genetically and environmental factors lead to an inflammatory response whose principal players are eosinophils, T, and B lymphocytes. HLA-DRB1 and DRB4 alleles and IL10.2 haplotype of the IL-10 promoter gene are the most studied genetic determinants. A combination of high-dose corticosteroids and cyclophosphamide is still the gold standard for the treatment of severe cases, but the use of biological agents such as rituximab or mepolizumab seems to be a promising therapeutic alternative.
CATEGORY    Cardiovascular disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DRB4 (polymorphism) [HSA:3126] [KO:K06752]
            IL10 (polymorphism) [HSA:3586] [KO:K05443]
MARKER      Eosinophilia (>10% of total WBC)
            PR3-ANCA (+)
DRUG        Prednisolone [DG:DG00093]
            Cyclophosphamide [DG:DG00675]
            Rituximab [DR:D02994]
            Mepolizumab [DR:D04923]
DBLINKS     ICD-10: M30.1
            MeSH: D015267
REFERENCE   PMID:25404930 (gene, marker)
  AUTHORS   Gioffredi A, Maritati F, Oliva E, Buzio C
  TITLE     Eosinophilic granulomatosis with polyangiitis: an overview.
  JOURNAL   Front Immunol 5:549 (2014)
REFERENCE   PMID:25500434
  AUTHORS   Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Altissimi G, De Vincentiis M
  TITLE     Churg-Strauss syndrome.
  JOURNAL   Autoimmun Rev 14:341-8 (2015)
REFERENCE   PMID:24072416
  AUTHORS   Jennette JC
  TITLE     Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides.
  JOURNAL   Clin Exp Nephrol 17:603-6 (2013)
REFERENCE   PMID:17989571
  AUTHORS   Bacciu A, Buzio C, Giordano D, Pasanisi E, Vincenti V, Mercante G, Grasselli C, Bacciu S
  TITLE     Nasal polyposis in Churg-Strauss syndrome.
  JOURNAL   Laryngoscope 118:325-9 (2008)
REFERENCE   PMID:18512809 (gene)
  AUTHORS   Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT
  TITLE     Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis.
  JOURNAL   Arthritis Rheum 58:1839-48 (2008)
REFERENCE   PMID:25709744 (drug)
  AUTHORS   Mukherjee M, Sehmi R, Nair P
  TITLE     Anti-IL5 therapy for asthma and beyond.
  JOURNAL   World Allergy Organ J 7:32 (2014)
REFERENCE   PMID:25467294 (drug)
  AUTHORS   Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, Smith R, Sivasothy P, Guillevin L, Merkel PA, Jayne DR
  TITLE     Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
  JOURNAL   Ann Rheum Dis (2014)
///
ENTRY       H01469                      Disease
NAME        Short bowel syndrome (SBS)
DESCRIPTION Short bowel syndrome (SBS), also called short gut syndrome or simply short gut, is a malabsorption disorder. It typically occurs in people who lost at least half of their small intestine due to surgical resection for various disorders, including crohn's disease, volvulus, cancer, or significant damage (injury, trauma). In infants, necrotizing enterocolitis is the most common cause for surgical resection of the small intestines. Patients usually experience symptoms that include abdominal pain, diarrhea. The main treatment is nutritional support such as oral rehydration, parenteral nutrition, enteral nutrition, vitamin and mineral supplements, and special diet. Currently, a recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide associated with the treatment for SBS has been reported to improve intestinal absorption.
CATEGORY    Gastrointestinal disease
DRUG        Teduglutide [DR:D06053]
COMMENT     Congenital small bowel syndrome is described in H01477. [DS:H01477]
DBLINKS     ICD-10: K91.8
            MeSH: D012778
REFERENCE   PMID:24486858 (description)
  AUTHORS   Jeppesen PB
  TITLE     Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure.
  JOURNAL   JPEN J Parenter Enteral Nutr 38:8S-13S (2014)
REFERENCE   PMID:22244264 (description and drug)
  AUTHORS   Thompson JS, Rochling FA, Weseman RA, Mercer DF
  TITLE     Current management of short bowel syndrome.
  JOURNAL   Curr Probl Surg 49:52-115 (2012)
REFERENCE   PMID:23830324 (description)
  AUTHORS   Wall EA
  TITLE     An overview of short bowel syndrome management: adherence, adaptation, and practical recommendations.
  JOURNAL   J Acad Nutr Diet 113:1200-8 (2013)
REFERENCE   PMID:22224470 (drug)
  AUTHORS   Norholk LM, Holst JJ, Jeppesen PB
  TITLE     Treatment of adult short bowel syndrome patients with teduglutide.
  JOURNAL   Expert Opin Pharmacother 13:235-43 (2012)
///
ENTRY       H01470                      Disease
NAME        Giant cell tumor of bone
DESCRIPTION Giant-cell tumor of bone (GCTB) is a rare osteolytic tumor of the bone. Although classified as a benign tumor, GCTB is characterized by local aggressiveness and risk of local recurrence. Its name is derived from the numerous multinucleated giant cells found within the tumor, which are principally responsible for the extensive bone resorption that is characteristic of GCTB. However, the neoplastic components of GCTB are the spindle-like stromal cells, which produce RANKL that recruits monocytic osteoclast precursors from blood to the tumor, and stimulates differentiation into multinucleated giant cells. Recently, denosumab (RANKL inhibitor) has become a new treatment option for locally advanced GCTB.
CATEGORY    Skeletal diseases
GENE        RANKL (overexpression) [HSA:8600] [KO:K05473]
            H3F3A (mutation) [HSA:3020] [KO:K11253]
            TP53 (mutation) [HSA:7157] [KO:K04451]
            HRAS (mutation) [HSA:3265] [KO:K02833]
DRUG        Phenol [DG:DG00070]
            Liquid nitrogen [DR:D00083]
            Polymethylmethacrylate (PMMA) [CPD:C19504]
            Denosumab [DR:D03684]
            Bisphosphonate [DG:DG01600]
            IFN-alpha [DG:DG01750]
COMMENT     ICD-O-3.1: 9250/1 Giant cell tumor of bone, NOS
            ICD-O-3.1: 9250/3 Giant cell tumor of bone, malignant
DBLINKS     ICD-10: D48.0
            MeSH: D018212
REFERENCE   PMID:24718514 (description, gene, drug)
  AUTHORS   van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovee JV, Hogendoorn PC, Gelderblom H
  TITLE     The clinical approach toward giant cell tumor of bone.
  JOURNAL   Oncologist 19:550-61 (2014)
REFERENCE   PMID:24363925 (description, gene, drug)
  AUTHORS   Dufresne A, Derbel O, Cassier P, Vaz G, Decouvelaere AV, Blay JY
  TITLE     Giant-cell tumor of bone, anti-RANKL therapy.
  JOURNAL   Bonekey Rep 1:149 (2012)
REFERENCE   PMID:23063845 (description, gene, drug)
  AUTHORS   Cowan RW, Singh G
  TITLE     Giant cell tumor of bone: a basic science perspective.
  JOURNAL   Bone 52:238-46 (2013)
REFERENCE   PMID:24788576 (description, gene, drug)
  AUTHORS   Skubitz KM
  TITLE     Giant cell tumor of bone: current treatment options.
  JOURNAL   Curr Treat Options Oncol 15:507-18 (2014)
///
ENTRY       H01471                      Disease
NAME        Lymphangioma
DESCRIPTION Lymphangiomas are congenital malformations of the lymphatic system. The lesions consist of dilated endothelium-lined spaces that vary in size from microscopic channels (cavernous lymphangioma) to large cysts (cystic hygroma). Although histologically benign, these lesions may expand into surrounding tissues and/or infiltrate vital structures similar to malignancies, sometimes causing life-threatening complications. The etiology of lymphangioma is not certain. The presence of lymphatic endothelial cell (LEC)-specific markers on the endothelial lining of lymphangiomas (e.g. the transcription factor Prox1) indicates that the neoplasm may result from transformed LECs and/or stromal cells. This transformation is modulated by VEGF-C, a specific lymphatic endothelial growth factor, and its receptor VEGFR-3.
CATEGORY    Vascular diseases
GENE        VEGFR-3 (overexpression) [HSA:2324] [KO:K05097]
DRUG        Picibanil (OK-432) [DR:D08756]
COMMENT     ICD-O-3.1: 9170/0 Lymphangioma, NOS
DBLINKS     ICD-10: D18.1
            MeSH: D008202
REFERENCE   PMID:8801295 (description)
  AUTHORS   Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N
  TITLE     OK-432 therapy for lymphangioma in children: why and how does it work?
  JOURNAL   J Pediatr Surg 31:477-80 (1996)
REFERENCE   PMID:8078021 (description)
  AUTHORS   Ogita S, Tsuto T, Nakamura K, Deguchi E, Iwai N
  TITLE     OK-432 therapy in 64 patients with lymphangioma.
  JOURNAL   J Pediatr Surg 29:784-5 (1994)
REFERENCE   PMID:20382171 (description)
  AUTHORS   Ji RC, Eshita Y, Xing L, Miura M
  TITLE     Multiple expressions of lymphatic markers and morphological evolution of newly formed lymphatics in lymphangioma and lymph node lymphangiogenesis.
  JOURNAL   Microvasc Res 80:195-201 (2010)
REFERENCE   PMID:17584927 (description, gene)
  AUTHORS   Norgall S, Papoutsi M, Rossler J, Schweigerer L, Wilting J, Weich HA
  TITLE     Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas.
  JOURNAL   BMC Cancer 7:105 (2007)
REFERENCE   PMID:12107533 (drug)
  AUTHORS   Laranne J, Keski-Nisula L, Rautio R, Rautiainen M, Airaksinen M
  TITLE     OK-432 (Picibanil) therapy for lymphangiomas in children.
  JOURNAL   Eur Arch Otorhinolaryngol 259:274-8 (2002)
REFERENCE   PMID:20170968 (drug)
  AUTHORS   Oosthuizen JC, Burns P, Russell JD
  TITLE     Lymphatic malformations: a proposed management algorithm.
  JOURNAL   Int J Pediatr Otorhinolaryngol 74:398-403 (2010)
///
ENTRY       H01472                      Disease
NAME        Multi-drug-resistant tuberculosis
DESCRIPTION Multi-drug-resistant tuberculosis is generally defined as infection with M. tuberculosis strains that are resistant to isoniazid and rifampin, the first-line antibiotics for treating tuberculosis. Drug-resistant tuberculosis has reached new levels of concern because of the recent identification of strains that are resistant not only to rifampin and isoniazid but also to any fluoroquinolone and at least 1 of the second-line injectable agents (amikacin, kanamycin, and capreomycin); this type of drug-resistant tuberculosis has been designated extensively drug-resistant tuberculosis.
CATEGORY    Infectious disease
PATHOGEN    Mycobacterium tuberculosis
DRUG        Delamanid [DR:D09785]
COMMENT     See also H00342 Tuberculosis.
DBLINKS     ICD-10: U84.3 U84.7
            MeSH: D018088
REFERENCE   PMID:25721508 (description)
  AUTHORS   Millard J, Ugarte-Gil C, Moore DA
  TITLE     Multidrug resistant tuberculosis.
  JOURNAL   BMJ 350:h882 (2015)
REFERENCE   PMID:19191632 (description)
  AUTHORS   Chan ED, Strand MJ, Iseman MD
  TITLE     Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.
  JOURNAL   Clin Infect Dis 48:e50-2 (2009)
///
ENTRY       H01473                      Disease
NAME        Erythema nodosum leprosum (ENL)
DESCRIPTION Reactional states of leprosy are expressions of immunological disturbance and are generally divided into two variants: type 1 (Jopling's type I or reversal reaction) and type 2 (Jopling's type II reaction). Erythema Nodosum Leprosum (ENL), the main symptom of a type-2 reaction in leprosy, is caused by a humoral immune response to Mycobacterium leprae. Patients with ENL become acutely sick with fever, malaise, and crops of painful erythematous nodules. Inflammation often affects other systems causing iritis, neuritis, myositis, lymphadenitis, arthritis, dactylitis, and orchitis.
CATEGORY    Skin and soft tissue diseases
PATHOGEN    Mycobacterium leprae [GN:mle mlb]
DRUG        Thalidomide [DR:D00754]
COMMENT     See also H00344 Leprosy.
DBLINKS     ICD-10: A30.8 L52
            MeSH: D004893
REFERENCE   PMID:16687695 (description)
  AUTHORS   Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, Lockwood DN
  TITLE     Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
  JOURNAL   Am J Trop Med Hyg 74:868-79 (2006)
REFERENCE   PMID:24098819 (description)
  AUTHORS   Voorend CG, Post EB
  TITLE     A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.
  JOURNAL   PLoS Negl Trop Dis 7:e2440 (2013)
REFERENCE   PMID:23000940 (description)
  AUTHORS   Travassos AR, Antunes J, Pacheco D, Almeida LS, Filipe P, Marques MS
  TITLE     Erythema nodosum leprosum associated with minocycline.
  JOURNAL   Acta Dermatovenerol Alp Pannonica Adriat 21:39-41 (2012)
///
ENTRY       H01474                      Disease
NAME        Acquired generalized lipodystrophy (AGL) ;
            Lawrence syndrome
DESCRIPTION Acquired generalized lipodystrophy, also called the Lawrence syndrome, is one subtype of acquired lipodystrophy caused by autoimmune disease, panniculitis or idiopathic. The disorder appears during the childhood and adolescence. Clinically, loss of subcutaneous fat occurs highly variable, exclusively at the face and extremities including legs, palms and some soles. In rare cases, intraabdomianl fat and bone marrow fat may also be spared. Similarly to congential generalized lipodystrophy, people with the disorder usually appear severe hepatic steatosis and fibrosis, diabetes, and hypertriglyceridemia. Metreleptin, as a recombinant analog of human leptin, has been approved for the treatment for the disorder as well as diet.
CATEGORY    Metabolic disease; Skin and connective tissue disease
DRUG        Metreleptin [DR:D05014]
DBLINKS     ICD-10: E88.1
            MeSH: D008060
REFERENCE   PMID:21865368 (description)
  AUTHORS   Garg A
  TITLE     Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.
  JOURNAL   J Clin Endocrinol Metab 96:3313-25 (2011)
REFERENCE   PMID:26063386 (drug)
  AUTHORS   Tchang BG, Shukla AP, Aronne LJ
  TITLE     Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
  JOURNAL   Expert Opin Biol Ther 15:1061-75 (2015)
///
ENTRY       H01475                      Disease
NAME        Lipodystrophy ;
            Lipoatrophy
DESCRIPTION Lipodystrophies are a group of rare disorders characterized by selectively loss of fat tissue, which can be congential or acquired, and generalized or partial. People with the diseases more frequently appear severe metabolic abnormality including insulin resistance and its associated complications such as diabetes mellitus, hypertriglyceridemia, hepatic steatosis, polycystic ovaries, and acanthosis nigricans. Genetic predisposition to inherited lipodystrophies has been discovered. Compared with them, the causes of the acquired lipodystrophies are still unknown, but mainly related to autoimmune mechanism, medications or other unknown mechanisms.
            Lipodystrophy can be classified to the following subtypes.
            Genetic forms: H00419 Congential generalized lipodystrophy (CGL), H00420 Familial partial lipodystrophy (FPL), H00665 Mandibuloacral dysplasia-associated lipodystrophy (MDAL)
            Acquired forms: H01474 Acquired generalized lipodystrophy (AGL), Acquired partial, HIV-associated lipodystrophy
CATEGORY    Metabolic disease; Skin and connective tissue disease
DRUG        Metreleptin [DR:D05014] (currently approved for the treatment of congenital or acquired generalized lipodystrophy)
DBLINKS     ICD-10: E88.1
            MeSH: D008060
REFERENCE   PMID:21865368 (description)
  AUTHORS   Garg A
  TITLE     Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.
  JOURNAL   J Clin Endocrinol Metab 96:3313-25 (2011)
REFERENCE   PMID:25690482 (description)
  AUTHORS   Bindlish S, Presswala LS, Schwartz F
  TITLE     Lipodystrophy: Syndrome of severe insulin resistance.
  JOURNAL   Postgrad Med 127:511-6 (2015)
REFERENCE   PMID:26063386 (drug)
  AUTHORS   Tchang BG, Shukla AP, Aronne LJ
  TITLE     Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
  JOURNAL   Expert Opin Biol Ther 15:1061-75 (2015)
///
ENTRY       H01476                      Disease
NAME        Behcet Disease;
            Behcet Syndrome
DESCRIPTION Behcet disease is a multisystemic inflammatory disease characterized by relapsing episodes of oral aphthous ulcers, genital ulcers, other skin lesions, and uveitis. It can also involve visceral organs such as the gastrointestinal tract, pulmonary, musculoskeletal, cardiovascular and neurological systems. This disease is more common in countries along the ancient Silk Road, including Asia, Middle East, and Mediterranean. Although the etiology is still unknown, this disease is believed to be triggered by environmental factors such as microbial agents in individuals with a particular genetic background. The positive association of HLA-B51 was identified more than four decades ago, and has been confirmed in multiple populations. Recent genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet disease.
CATEGORY    Immune system disease; Skin and connective tissue disease
GENE        HLA-B (polymorphism) [HSA:3106] [KO:K06751]
            IL10 (polymorphism) [HSA:3586] [KO:K05443]
            IL23R (polymorphism) [HSA:149233] [KO:K05065]
            IL12RB2 (polymorphism) [HSA:3595] [KO:K05064]
DRUG        Infliximab [DR:D02598]
            Tacrolimus [DG:DG00439] (uveitis)
DBLINKS     ICD-10: M35.2
            MeSH: D001528
            OMIM: 109650
REFERENCE   PMID:16282155
  AUTHORS   Bonfioli AA, Orefice F
  TITLE     Behcet's disease.
  JOURNAL   Semin Ophthalmol 20:199-206 (2005)
REFERENCE   PMID:25062414 (gene)
  AUTHORS   Demirseren DD, Ceylan GG, Akoglu G, Emre S, Erten S, Arman A, Metin A
  TITLE     HLA-B51 subtypes in Turkish patients with Behcet's disease and their correlation  with clinical manifestations.
  JOURNAL   Genet Mol Res 13:4788-96 (2014)
REFERENCE   PMID:26347074 (gene)
  AUTHORS   Takeuchi M, Kastner DL, Remmers EF
  TITLE     The immunogenetics of Behcet's disease: A comprehensive review.
  JOURNAL   J Autoimmun 64:137-48 (2015)
REFERENCE   PMID:26318435 (drug)
  AUTHORS   Kuroyanagi K, Sakai T, Kohno H, Okano K, Akiyama G, Aoyagi R, Inaba M, Tsuneoka H
  TITLE     Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behcet uveitis.
  JOURNAL   Jpn J Ophthalmol 59:401-8 (2015)
REFERENCE   PMID:19504615 (drug)
  AUTHORS   Matsumura K, Nakase H, Chiba T
  TITLE     Efficacy of oral tacrolimus on intestinal Behcet's disease.
  JOURNAL   Inflamm Bowel Dis 16:188-9 (2010)
///
ENTRY       H01477                      Disease
NAME        Congenital short bowel syndrome (CSBS)
DESCRIPTION Congenital short bowel syndrome (CSBS) is an inherited intestinal disorder occurring in newborns and infants. Affected babies typically present a shortened bowel (approximately 50 cm) compared with normal lenth rages from 190 to 280 cm. CSBS causes malabsorption and the most common symptoms including chronic diarrhea, vomiting and weight loss, thus leading to failure to thrive. Gene mutation in coxsakie and adenovirus receptor-like membrane protein (CLMP) has been reported to be associated with this disease.
CATEGORY    Developmental disorder; Gastrointestinal disease
GENE        CLMP [HSA:79827] [KO:K06789]
COMMENT     Acquired small bowel syndrome is described in H01469.
DBLINKS     ICD-10: Q43.8
            OMIM: 615237
REFERENCE   PMID:26282049 (description)
  AUTHORS   van der Werf CS, Halim D, Verheij JB, Alves MM, Hofstra RM
  TITLE     Congenital Short Bowel Syndrome: from clinical and genetic diagnosis to the molecular mechanisms involved in intestinal elongation.
  JOURNAL   Biochim Biophys Acta 1852:2352-61 (2015)
REFERENCE   PMID:20123268 (description)
  AUTHORS   Wales PW, Christison-Lagay ER
  TITLE     Short bowel syndrome: epidemiology and etiology.
  JOURNAL   Semin Pediatr Surg 19:3-9 (2010)
REFERENCE   PMID:22155368 (gene)
  AUTHORS   Van Der Werf CS, Wabbersen TD, Hsiao NH, Paredes J, Etchevers HC, Kroisel PM, Tibboel D, Babarit C, Schreiber RA, Hoffenberg EJ, Vekemans M, Zeder SL, Ceccherini I, Lyonnet S, Ribeiro AS, Seruca R, Te Meerman GJ, van Ijzendoorn SC, Shepherd IT, Verheij JB, Hofstra RM
  TITLE     CLMP is required for intestinal development, and loss-of-function mutations cause congenital short-bowel syndrome.
  JOURNAL   Gastroenterology 142:453-462.e3 (2012)
///
ENTRY       H01478                      Disease
NAME        Machado-Joseph disease;
            Spinocerebellar ataxia 3
DESCRIPTION Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is one of the most common hereditary ataxias and is distributed worldwide. MJD is an autosomal dominant neurodegenerative disorder, involving predominantly the cerebellar, pyramidal, extrapyramidal, motor neuron and oculomotor systems. Minor, but more specific, features such as external progressive ophthalmoplegia (EPO), dystonia, intention fasciculation-like movements of facial and lingual muscles, as well as bulging eyes, may also be of major importance for the clinical diagnosis of MJD. The mean age at onset is around 40 years. MJD is associated with CAG repeat expansions in the ATXN3 gene. CAG repeat varies in size among affected persons. There is no effective treatment of ataxia. Case series and small controlled trials of several medications including antianxiolytics, antidepressants, and antiepileptics have shown limited efficacy.
CATEGORY    Neurodegenerative disease
GENE        ATXN3 (CAG repeat expansion) [HSA:4287] [KO:K11863]
DRUG        Sapropterin [DG:DG00147]
            Lamictal [DR:D00354]
            Chantix [DG:DG00995]
COMMENT     See also H00063 Spinocerebellar ataxia (SCA)
DBLINKS     ICD-10: G11.8
            MeSH: D017827
            OMIM: 109150
REFERENCE   PMID:21635785
  AUTHORS   Bettencourt C, Lima M
  TITLE     Machado-Joseph Disease: from first descriptions to new perspectives.
  JOURNAL   Orphanet J Rare Dis 6:35 (2011)
REFERENCE   PMID:21827905
  AUTHORS   Paulson H
  TITLE     Machado-Joseph disease/spinocerebellar ataxia type 3.
  JOURNAL   Handb Clin Neurol 103:437-49 (2012)
REFERENCE   PMID:11461169 (drug)
  AUTHORS   Sakai T
  TITLE     Effects of tetrahydrobiopterin on ataxia in Machado-Joseph disease may be based upon the theory of 'cerebellar long-term depression'.
  JOURNAL   Med Hypotheses 57:180-2 (2001)
REFERENCE   PMID:15876340 (drug)
  AUTHORS   Liu CS, Hsu HM, Cheng WL, Hsieh M
  TITLE     Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy.
  JOURNAL   Acta Neurol Scand 111:385-90 (2005)
REFERENCE   PMID:19050414 (drug)
  AUTHORS   Zesiewicz TA, Sullivan KL
  TITLE     Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14).
  JOURNAL   Clin Neuropharmacol 31:363-5 (2008)
///
ENTRY       H01479                      Disease
NAME        Castleman disease
DESCRIPTION Castleman disease is a rare lymphoproliferative disorder with two primary subtypes that vary in presentation and course. Unicentric Castleman disease is localized and carries an excellent prognosis. Multicentric Castleman disease can be associated with HIV and human herpesvirus-8 and is characterized by generalized lymphadenopathy and systemic symptoms, such as fever, fatigue, anorexia, anemia, and cachexia. Castleman disease is unique in that dysregulated secretion of interleukin-6 (IL-6) plays a central pathogenetic role, although the exact events precipitating the oversecretion of IL-6 are unknown. Recently, two antibody-based therapeutics targeting components of the IL-6/IL-6R complex have been approved for the treatment of Castleman disease. Tocilizumab is a monoclonal antibody directed against the IL-6 receptor, and siltuximab is a monoclonal antibody specific for IL-6.
CATEGORY    Immune system disease
GENE        IL6 [HSA:3569] [KO:K05405]
MARKER      Increased serum amyloid A (SAA) and C-reactive protein (CRP)
DRUG        Tocilizumab [DR:D02596]
            Siltuximab [DR:D09669]
DBLINKS     ICD-10: D36.0
            MeSH: D005871
            OMIM: 148000
REFERENCE   PMID:25310208
  AUTHORS   Soumerai JD, Sohani AR, Abramson JS
  TITLE     Diagnosis and management of Castleman disease.
  JOURNAL   Cancer Control 21:266-78 (2014)
REFERENCE   PMID:23375540
  AUTHORS   Puram SV, Hasserjian RP, Faquin WC, Lin HW, Rocco JW
  TITLE     Castleman disease presenting in the neck: report of a case and review of the literature.
  JOURNAL   Am J Otolaryngol 34:239-44 (2013)
REFERENCE   PMID:26555695
  AUTHORS   Ranganath S, Bhandari A, Avitahl-Curtis N, McMahon J, Wachtel D, Zhang J, Leitheiser C, Bernier SG, Liu G, Tran TT, Celino H, Tobin J, Jung J, Zhao H, Glen KE, Graul C, Griffin A, Schairer WC, Higgins C, Reza TL, Mowe E, Rivers S, Scott S, Monreal A, Shea C, Bourne G, Coons C, Smith A, Tang K, Mandyam RA, Masferrer J, Liu D, Patel DV, Fretzen A, Murphy CA, Milne GT, Smythe ML, Carlson KE
  TITLE     Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.
  JOURNAL   PLoS One 10:e0141330 (2015)
REFERENCE   PMID:26749192 (drug)
  AUTHORS   Gonzalez Garcia A, Moreno Cobo MA, Patier de la Pena JL
  TITLE     Current diagnosis and treatment of Castleman's disease.
  JOURNAL   Rev Clin Esp (2015)
REFERENCE   PMID:20625121 (drug)
  AUTHORS   van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R
  TITLE     Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
  JOURNAL   J Clin Oncol 28:3701-8 (2010)
///
ENTRY       H01480                      Disease
NAME        Idiopathic macular hole;
            Retinal Perforations
DESCRIPTION Idiopathic macular hole is a common cause of visual impairment in people in their sixth decade or older, with a higher prevalence in females. Although existing theories of macular hole pathogenesis are constantly being changed and refined, nearly all confirm the predominant role of the vitreous in their formation. Until 1991, it was considered an untreatable condition, but now interventions are carried out to close the hole and thereby improve the central visual defect. Initially, vitrectomy surgery with long-acting gas (SF6, C3F8) and postoperative face-down positioning for at least 1 week was the only option. However, nowadays, there are a number of possible treatment choices including ocriplasmin treatment.
CATEGORY    Nervous system disease; Eye disease
DRUG        Ocriplasmin [DR:D09646]
            Perflutren (C3F8) [DR:D01738]
            Sulfur hexafluoride (SF6) [DR:D05962]
DBLINKS     ICD-10: H35.3
            MeSH: D012167
REFERENCE   PMID:26834454
  AUTHORS   Madi HA, Masri I, Steel DH
  TITLE     Optimal management of idiopathic macular holes.
  JOURNAL   Clin Ophthalmol 10:97-116 (2016)
REFERENCE   PMID:21677885 (drug)
  AUTHORS   Xirou T, Xirou V, Mangouritsas G, Feretis E, Kabanarou SA
  TITLE     Full Thickness Macular Hole Closure after Exchanging Silicone-Oil Tamponade with  C(3)F(8) without Posturing.
  JOURNAL   Case Rep Ophthalmol 2:166-9 (2011)
REFERENCE   PMID:22894573 (drug)
  AUTHORS   Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA
  TITLE     Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
  JOURNAL   N Engl J Med 367:606-15 (2012)
///
ENTRY       H01481                      Disease
NAME        Myelodysplastic syndrome
DESCRIPTION Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic stem cell disorders characterized by ineffective hematopoiesis resulting in low blood counts, and a risk of progression to acute myeloid leukemia. Currently, there are a few FDA-approved drugs for treatment of MDS none of which are curative. Allogeneic stem cell transplantation (ASCT) is the only curative therapy. But many MDS patients have been ineligible for transplants, since the median age at diagnosis for MDS is 75 years. Sequencing of MDS genomes has identified mutations in genes implicated in RNA splicing, DNA modification, chromatin regulation, and cell signaling.
CATEGORY    Hematologic disease
GENE        TET2 [HSA:54790]
            ASXL1 [HSA:171023] [KO:K11471]
            DNMT3A [HSA:1788] [KO:K17398]
            IDH1 [HSA:3417] [KO:K00031]
            IDH2 [HSA:3418] [KO:K00031]
            GATA2 [HSA:2624] [KO:K17894]
            SF3B1 [HSA:23451] [KO:K12828]
            SRSF2 [HSA:6427] [KO:K12891]
            U2AF1 [HSA:7307] [KO:K12836]
            ZRSR2 [HSA:8233]
            RUNX1 [HSA:861] [KO:K08367]
            TP53 [HSA:7157] [KO:K04451]
            NRAS [HSA:4893] [KO:K07828]
            JAK2 [HSA:3717] [KO:K04447]
DRUG        Azacitidine [DR:D03021]
            Darbepoetin alfa [DR:D03651]
            Decitabine [DR:D03665]
COMMENT     See also H01484 5q- syndrome.
DBLINKS     ICD-10: D46
            MeSH: D009190
            OMIM: 614286
REFERENCE   PMID:26769228 (gene, drug)
  AUTHORS   Gangat N, Patnaik MM, Tefferi A
  TITLE     Myelodysplastic syndromes: Contemporary review and how we treat.
  JOURNAL   Am J Hematol 91:76-89 (2016)
REFERENCE   PMID:26323997 (drug)
  AUTHORS   Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K
  TITLE     A randomized controlled trial comparing darbepoetin alfa doses in red blood cell  transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.
  JOURNAL   Int J Hematol 102:401-12 (2015)
REFERENCE   PMID:22389253 (gene)
  AUTHORS   Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking B, Wichmann M, Gorlich K, Gohring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M
  TITLE     Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
  JOURNAL   Blood 119:3578-84 (2012)
REFERENCE   PMID:24136165 (gene)
  AUTHORS   Cazzola M, Della Porta MG, Malcovati L
  TITLE     The genetic basis of myelodysplasia and its clinical relevance.
  JOURNAL   Blood 122:4021-34 (2013)
///
ENTRY       H01482                      Disease
NAME        Infantile hemangioma
DESCRIPTION Infantile hemangiomas (IH) are neoplastic proliferations of vascular endothelial cells (ECs), characterized by a period of growth after birth, and eventual spontaneous involution. Forty percent of the lesions are associated with complications such as ulceration, bleeding, infection, pain, cardiac failure, airway compromise or eye impairment. Pathogenesis of IH is still shrouded in mystery even though various theories have been postulated to explain its origin. Recent studies provide strong evidence for the conclusion that the VEGF receptor 2 (VEGFR2) and Tumor Endothelial Marker 8  (TEM8) mutations represent risk factor mutations for hemangioma formation. In the proliferating phase, constitutive VEGFR2 signaling in ECs from hemangioma lesions affects downstream processes, including EC proliferation and migration, providing a mechanistic explanation for the rapid endothelial proliferation seen in hemangioma.
CATEGORY    Vascular disease
GENE        TEM8 [HSA:84168] [KO:K20909]
            VEGFR2 [HSA:3791] [KO:K05098]
MARKER      GLUT1 [HSA:6513] [KO:K07299]
DRUG        Systemic corticosteroids
            Vincristine [DG:DG00690]
            Interferon-alpha [DG:DG01750]
            Bleomycin [DG:DG00705]
            Cyclophosphamide [DG:DG00675]
            Propranolol [DG:DG00305]
COMMENT     ICD-O-3.1: 9131/0 Infantile hemangioma
DBLINKS     ICD-10: D18.00
            MeSH: D018324
            OMIM: 602089
REFERENCE   PMID:19190505 (description, gene)
  AUTHORS   Boye E, Jinnin M, Olsen BR
  TITLE     Infantile hemangioma: challenges, new insights, and therapeutic promise.
  JOURNAL   J Craniofac Surg 20 Suppl 1:678-84 (2009)
REFERENCE   PMID:19367160 (description, gene)
  AUTHORS   Boye E, Olsen BR
  TITLE     Signaling mechanisms in infantile hemangioma.
  JOURNAL   Curr Opin Hematol 16:202-8 (2009)
REFERENCE   PMID:23668474 (gene)
  AUTHORS   Greenberger S, Bischoff J
  TITLE     Pathogenesis of infantile haemangioma.
  JOURNAL   Br J Dermatol 169:12-9 (2013)
REFERENCE   PMID:18931684 (gene)
  AUTHORS   Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR
  TITLE     Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in  infantile hemangioma.
  JOURNAL   Nat Med 14:1236-46 (2008)
REFERENCE   PMID:17478771 (marker)
  AUTHORS   Drut R, Altamirano E
  TITLE     Endothelial cells of intramuscular (infantile) hemangioma express glut1.
  JOURNAL   Int J Surg Pathol 15:166-8 (2007)
REFERENCE   PMID:21039783 (description, marker, drug)
  AUTHORS   Jinnin M, Ishihara T, Boye E, Olsen BR
  TITLE     Recent progress in studies of infantile hemangioma.
  JOURNAL   J Dermatol 37:939-55 (2010)
REFERENCE   PMID:20826985 (description, marker, drug)
  AUTHORS   Mendiratta V, Jabeen M
  TITLE     Infantile hemangioma: an update.
  JOURNAL   Indian J Dermatol Venereol Leprol 76:469-75 (2010)
REFERENCE   PMID:23266916 (drug)
  AUTHORS   Chen TS, Eichenfield LF, Friedlander SF
  TITLE     Infantile hemangiomas: an update on pathogenesis and therapy.
  JOURNAL   Pediatrics 131:99-108 (2013)
REFERENCE   PMID:24906291 (drug)
  AUTHORS   Laranjo S, Costa G, Parames F, Freitas I, Martins JD, Trigo C, Pinto FF
  TITLE     The role of propranolol in the treatment of infantile hemangioma.
  JOURNAL   Rev Port Cardiol 33:289-95 (2014)
///
ENTRY       H01483                      Disease
NAME        Acromegaly
DESCRIPTION Acromegaly (ACM) is a disorder characterized by increased circulating GH and IGF-I (a GH-induced liver protein) levels that is associated with significant morbidity and excess mortality. Patients with persistently elevated GH and IGF-I levels have an increased risk of multiple comorbidities, including left ventricular dysfunction, obstructive sleep apnea, arthritis, impaired glucose tolerance, and colonic polyps. Most cases of ACM occur as a result of a sporadic GH-secreting pituitary adenoma (PA). However, ACM can occur in a familial setting, either associated with other endocrine abnormalities or as an isolated disorder. Somatic activating mutations in the GNAS gene, which encodes for the Gs-alpha subunit of G-proteins, are found in up to 40% of sporadic GH-secreting PA. Familial ACM can occur in the context of rare inherited syndromes such as familial isolated pituitary adenoma (FIPA), which is caused in 15-20% of cases by aryl hydrocarbon receptor interacting protein (AIP) gene germline mutations. Moreover, a recurrent mutation was found in GPR101 in some patients with non-familial ACM.
CATEGORY    Endocrine disease
GENE        AIP [HSA:9049] [KO:K17767]
            GNAS [HSA:2778] [KO:K04632]
            GPR101 [HSA:83550] [KO:K08423]
MARKER      IGF1 [HSA:3479] [KO:K05459]
DRUG        Octreotide [DG:DG00501]
            Lanreotide [DR:D04666]
            Cabergoline [DR:D00987]
            Pegvisomant [DR:D05394]
            Tamoxifen [DR:D08559]
DBLINKS     ICD-10: E22.0
            MeSH: D000172
            OMIM: 300943 102200
REFERENCE   PMID:26136383 (description, gene, drug)
  AUTHORS   Capatina C, Wass JA
  TITLE     60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly.
  JOURNAL   J Endocrinol 226:T141-60 (2015)
REFERENCE   PMID:26815903 (descroiption, gene)
  AUTHORS   Ferrau F, Romeo PD, Puglisi S, Ragonese M, Torre ML, Scaroni C, Occhi G, De Menis E, Arnaldi G, Trimarchi F, Cannavo S
  TITLE     Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study.
  JOURNAL   Endocrine (2016)
REFERENCE   PMID:16118335 (description)
  AUTHORS   Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S
  TITLE     The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
  JOURNAL   J Clin Endocrinol Metab 90:6290-5 (2005)
REFERENCE   PMID:25470569 (gene)
  AUTHORS   Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E, Leal LF, Caberg JH, Castermans E, Villa C, Dimopoulos A, Chittiboina P, Xekouki P, Shah N, Metzger D, Lysy PA, Ferrante E, Strebkova N, Mazerkina N, Zatelli MC, Lodish M, Horvath A, de Alexandre RB, Manning AD, Levy I, Keil MF, Sierra Mde L, Palmeira L, Coppieters W, Georges M, Naves LA, Jamar M, Bours V, Wu TJ, Choong CS, Bertherat J, Chanson P, Kamenicky P, Farrell WE, Barlier A, Quezado M, Bjelobaba I, Stojilkovic SS, Wess J, Costanzi S, Liu P, Lupski JR, Beckers A, Stratakis CA
  TITLE     Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.
  JOURNAL   N Engl J Med 371:2363-74 (2014)
REFERENCE   PMID:20720589 (marker)
  AUTHORS   Biermasz N
  TITLE     Pituitary gland: New consensus in acromegaly: criteria for cure and control.
  JOURNAL   Nat Rev Endocrinol 6:480-1 (2010)
REFERENCE   PMID:12670296 (marker)
  AUTHORS   Brabant G
  TITLE     Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
  JOURNAL   Eur J Endocrinol 148 Suppl 2:S15-20 (2003)
REFERENCE   PMID:17077948 (drug)
  AUTHORS   Scacchi M, Cavagnini F
  TITLE     Acromegaly.
  JOURNAL   Pituitary 9:297-303 (2006)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H01484                      Disease
NAME        5q- syndrome
DESCRIPTION 5q- syndrome is a subtype of myelodysplastic syndrome (MDS) characterized by bone marrow erythroid hyperplasia, atypical megakaryocytes, thrombocythemia, refractory anemia, and low risk of progression to acute myeloid leukemia (AML) compared with other types of MDS. The WHO has proposed diagnostic criteria for the 5q- syndrome, defining the syndrome as representing de novo MDS, with a 5q interstitial deletion between bands 31 and 33 as the sole cytogenetic abnormality, macrocytic anemia, less than 5% blasts in the peripheral blood, and a normal or increased platelet count. The 5q- syndrome is also unique because it shows a remarkable response to treatment with the lenalidomide. It has been suggested that the 5q- syndrome is caused by haploinsufficiency of the ribosomal protein S14 (RPS14) gene which maps to the commonly deleted region.
CATEGORY    Hematologic disease
GENE        RPS14 [HSA:6208] [KO:K02955]
DRUG        Lenalidomide [DG:DG00744]
COMMENT     See also H01481 Myelodysplastic syndrome.
DBLINKS     ICD-10: D46.7
            MeSH: C535323
            OMIM: 153550
REFERENCE   PMID:24627193 (description, drug)
  AUTHORS   Gaballa MR, Besa EC
  TITLE     Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
  JOURNAL   Ann Hematol 93:723-33 (2014)
REFERENCE   PMID:18202658 (gene)
  AUTHORS   Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR
  TITLE     Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
  JOURNAL   Nature 451:335-9 (2008)
REFERENCE   PMID:16735711
  AUTHORS   Nimer SD
  TITLE     Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
  JOURNAL   J Clin Oncol 24:2576-82 (2006)
REFERENCE   PMID:26131937 (drug)
  AUTHORS   Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Jaras M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL
  TITLE     Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS.
  JOURNAL   Nature 523:183-8 (2015)
///
ENTRY       H01485                      Disease
NAME        Autosomal recessive mental retardation-42 (MRT42)
DESCRIPTION Autosomal recessive mental retardation-42 (MRT42) is a neurodevelopmental disorder. Clinic features are variable and include neonatal hypotonia, severe intellectual disability, and major and absence epilepsy. Homozygous mutation in PGAP1 has been identified.
CATEGORY    Inherited metabolic disease
GENE        PGAP1 [HSA:80055] [KO:K05294]
DBLINKS     OMIM: 615802
REFERENCE   PMID:24784135 (description and gene)
  AUTHORS   Murakami Y, Tawamie H, Maeda Y, Buttner C, Buchert R, Radwan F, Schaffer S, Sticht H, Aigner M, Reis A, Kinoshita T, Jamra RA
  TITLE     Null mutation in PGAP1 impairing Gpi-anchor maturation in patients with intellectual disability and encephalopathy.
  JOURNAL   PLoS Genet 10:e1004320 (2014)
///
ENTRY       H01486                      Disease
NAME        Multiple congenital anomalies-hypotonia-seizures syndrome (MCAHS)
DESCRIPTION The Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome (MCAHS) comprises three phenotypes caused by mutations in PIGN, PIGA and PIGT respectively. PIGN and PIGT mutations lead to autosomal recessive disorders whereas PIGA deficiency causes an X-linked lethal disorder. Clinical features are variable dependent on genotypes, often include (neonatal) hypotonia, seizures, various anomalies involving nervous system structural malformations, delayed or lack of psychomotor development, and various congenial organ anomalies.
CATEGORY    Inherited metabolic disease
GENE        (MCAHS 1) PIGN [HSA:23556] [KO:K05285]
            (MCAHS 2) PIGA [HSA:5277] [KO:K03857]
            (MCAHS 3) PIGT [HSA:51604] [KO:K05292]
DBLINKS     ICD-10: Q87.8
            OMIM: 614080 300868 615398
REFERENCE   PMID:26879448 (description and gene)
  AUTHORS   Jezela-Stanek A, Ciara E, Piekutowska-Abramczuk D, Trubicka J, Jurkiewicz E, Rokicki D, Mierzewska H, Spychalska J, Uhrynowska M, Szwarc-Bronikowska M, Buda P, Said AR, Jamroz E, Rydzanicz M, Ploski R, Krajewska-Walasek M, Pronicka E
  TITLE     Congenital disorder of glycosylphosphatidylinositol (GPI)-anchor biosynthesis-The phenotype of two patients with novel mutations in the PIGN and PGAP2 genes.
  JOURNAL   Eur J Paediatr Neurol (2016)
REFERENCE   PMID:24259184 (description and gene)
  AUTHORS   van der Crabben SN, Harakalova M, Brilstra EH, van Berkestijn FM, Hofstede FC, van Vught AJ, Cuppen E, Kloosterman W, Ploos van Amstel HK, van Haaften G, van Haelst MM
  TITLE     Expanding the spectrum of phenotypes associated with germline PIGA mutations: a child with developmental delay, accelerated linear growth, facial dysmorphisms, elevated alkaline phosphatase, and progressive CNS abnormalities.
  JOURNAL   Am J Med Genet A 164A:29-35 (2014)
REFERENCE   PMID:23636107 (description and gene)
  AUTHORS   Kvarnung M, Nilsson D, Lindstrand A, Korenke GC, Chiang SC, Blennow E, Bergmann M, Stodberg T, Makitie O, Anderlid BM, Bryceson YT, Nordenskjold M, Nordgren A
  TITLE     A novel intellectual disability syndrome caused by GPI anchor deficiency due to homozygous mutations in PIGT.
  JOURNAL   J Med Genet 50:521-8 (2013)
///
ENTRY       H01487                      Disease
NAME        CHIME syndrome;
            Coloboma, congenital heart disease, ichthyosiform dermatosis, mental retardation, and ear anomalies syndrome;
            Zunich neuroectodermal syndrome
DESCRIPTION CHIME syndrome (coloboma, congenital heart disease, ichthyosiform dermatosis, mental retardation, and ear anomalies syndrome), also known as Zunich neuroectodermal syndrome, is an autosomal recessive disorder characterized by colobomas of the eye, heart defects, ichthyosiform dermatosis, mental retardation, and ear defects, including conductive hearing loss. Homozygous and compound heterozygous mutations in PIGL lead to this disorder.
CATEGORY    Inherited metabolic disease
GENE        PIGL [HSA:9487] [KO:K03434]
DBLINKS     ICD-10: Q87.8
            OMIM: 280000
REFERENCE   PMID:22444671 (description and gene)
  AUTHORS   Ng BG, Hackmann K, Jones MA, Eroshkin AM, He P, Wiliams R, Bhide S, Cantagrel V, Gleeson JG, Paller AS, Schnur RE, Tinschert S, Zunich J, Hegde MR, Freeze HH
  TITLE     Mutations in the glycosylphosphatidylinositol gene PIGL cause CHIME syndrome.
  JOURNAL   Am J Hum Genet 90:685-8 (2012)
REFERENCE   PMID:8893234 (description and gene)
  AUTHORS   Tinschert S, Anton-Lamprecht I, Albrecht-Nebe H, Audring H
  TITLE     Zunich neuroectodermal syndrome: migratory ichthyosiform dermatosis, colobomas, and other abnormalities.
  JOURNAL   Pediatr Dermatol 13:363-71 (1996)
///
ENTRY       H01488                      Disease
NAME        Hyperphosphatasia with mental retardation syndrome (HPMPS);
            Mabry syndrome
DESCRIPTION Hyperphosphatasia with mental retardation syndrome (HPMRS), also known as Mabry syndrome, is an autosomal recessive disorder comprising intellectual disability and elevated levels of serum alkaline phosphatase, often accompanied by seizures, facial dysmorphism, and various anomalies such as brachytelephalangy. Mutation in different genes result in phenotypic variation.
CATEGORY    Inherited metabolic disease
GENE        (HPMRS1) PIGV [HSA:55650] [KO:K07542]
            (HPMRS2) PIGO [HSA:84720] [KO:K05288]
            (HPMRS3) PGAP2 [HSA:27315]
            (HPMRS4) PGAP3 [HSA:93210]
            (HPMRS5) PIGW [HSA:284098] [KO:K05283]
            (HPMRS6) PIGY [HSA:84992] [KO:K11001]
DBLINKS     OMIM: 239300 614749 614207 615716 616025 616809
REFERENCE   PMID:26879448 (description and gene)
  AUTHORS   Jezela-Stanek A, Ciara E, Piekutowska-Abramczuk D, Trubicka J, Jurkiewicz E, Rokicki D, Mierzewska H, Spychalska J, Uhrynowska M, Szwarc-Bronikowska M, Buda P, Said AR, Jamroz E, Rydzanicz M, Ploski R, Krajewska-Walasek M, Pronicka E
  TITLE     Congenital disorder of glycosylphosphatidylinositol (GPI)-anchor biosynthesis-The phenotype of two patients with novel mutations in the PIGN and PGAP2 genes.
  JOURNAL   Eur J Paediatr Neurol (2016)
REFERENCE   PMID:21739589 (gene)
  AUTHORS   Horn D, Krawitz P, Mannhardt A, Korenke GC, Meinecke P
  TITLE     Hyperphosphatasia-mental retardation syndrome due to PIGV mutations: expanded clinical spectrum.
  JOURNAL   Am J Med Genet A 155A:1917-22 (2011)
REFERENCE   PMID:22683086 (gene)
  AUTHORS   Krawitz PM, Murakami Y, Hecht J, Kruger U, Holder SE, Mortier GR, Delle Chiaie B, De Baere E, Thompson MD, Roscioli T, Kielbasa S, Kinoshita T, Mundlos S, Robinson PN, Horn D
  TITLE     Mutations in PIGO, a member of the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation.
  JOURNAL   Am J Hum Genet 91:146-51 (2012)
REFERENCE   PMID:23561847 (gene)
  AUTHORS   Krawitz PM, Murakami Y, Riess A, Hietala M, Kruger U, Zhu N, Kinoshita T, Mundlos S, Hecht J, Robinson PN, Horn D
  TITLE     PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation syndrome.
  JOURNAL   Am J Hum Genet 92:584-9 (2013)
REFERENCE   PMID:24439110 (gene)
  AUTHORS   Howard MF, Murakami Y, Pagnamenta AT, Daumer-Haas C, Fischer B, Hecht J, Keays DA, Knight SJ, Kolsch U, Kruger U, Leiz S, Maeda Y, Mitchell D, Mundlos S, Phillips JA 3rd, Robinson PN, Kini U, Taylor JC, Horn D, Kinoshita T, Krawitz PM
  TITLE     Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardation.
  JOURNAL   Am J Hum Genet 94:278-87 (2014)
REFERENCE   PMID:24367057 (gene)
  AUTHORS   Chiyonobu T, Inoue N, Morimoto M, Kinoshita T, Murakami Y
  TITLE     Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW  is associated with West syndrome and hyperphosphatasia with mental retardation syndrome.
  JOURNAL   J Med Genet 51:203-7 (2014)
REFERENCE   PMID:26293662 (gene)
  AUTHORS   Ilkovski B, Pagnamenta AT, O'Grady GL, Kinoshita T, Howard MF, Lek M, Thomas B, Turner A, Christodoulou J, Sillence D, Knight SJ, Popitsch N, Keays DA, Anzilotti C, Goriely A, Waddell LB, Brilot F, North KN, Kanzawa N, Macarthur DG, Taylor JC, Kini U, Murakami Y, Clarke NF
  TITLE     Mutations in PIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficiencies.
  JOURNAL   Hum Mol Genet 24:6146-59 (2015)
///
ENTRY       H01489                      Disease
NAME        Inherited glycosylphosphatidylinositol (GPI) deficiencies, including:
            PIGM-congenital disorder of glycosylation (PIGM-CDG) [DS:H01127] ;
            Autosomal recessive mental retardation-42 (MRT42) [DS:H01485];
            Multiple congential anomalies-hypotonia-seizures (MCAHS) syndrom [DS:H01486];
            CHIME syndrome [DS:H01487];
            Hyperphosphatasia with mental retardation syndrome (HPMRS) [DS:H01488]
DESCRIPTION Inherited glycosylphosphatidylinositol (GPI) deficiencies (IGD) are a group of glycosylation disorders, which result from mutation in genes involved in the biosynthesis of GPI anchors. Mutation in at least twelve have been identified, mostly related to autosomal recessive. Clinical phenotypes are variable, often include developmental delay, hyperphosphatasia, (neonatal) seizures, hypotonia, and neurological symptoms, growth abnormalities, and congenital abnormalities.
CATEGORY    Inherited metabolic disease
GENE        (PIGM-CDG) PIGM [HSA:93183] [KO:K05284]
            (MRT42) PGAP1 [HSA:80055] [KO:K05294]
            (MCAHS 1) PIGN [HSA:23556] [KO:K05285]
            (MCAHS 2) PIGA [HSA:5277] [KO:K03857]
            (MCAHS 3) PIGT [HSA:51604] [KO:K05292]
            (CHIME) PIGL [HSA:9487] [KO:K03434]
            (HPMRS1) PIGV [HSA:55650] [KO:K07542]
            (HPMRS2) PIGO [HSA:84720] [KO:K05288]
            (HPMRS3) PGAP2 [HSA:27315]
            (HPMRS4) PGAP3 [HSA:93210]
            (HPMRS5) PIGW [HSA:284098] [KO:K05283]
            (HPMRS6) PIGY [HSA:84992] [KO:K11001]
DBLINKS     OMIM: 610293 615802 614080 300868 615398 280000 239300 614749 614207 615716 616025 616809
REFERENCE   PMID:26879448 (description and gene)
  AUTHORS   Jezela-Stanek A, Ciara E, Piekutowska-Abramczuk D, Trubicka J, Jurkiewicz E, Rokicki D, Mierzewska H, Spychalska J, Uhrynowska M, Szwarc-Bronikowska M, Buda P, Said AR, Jamroz E, Rydzanicz M, Ploski R, Krajewska-Walasek M, Pronicka E
  TITLE     Congenital disorder of glycosylphosphatidylinositol (GPI)-anchor biosynthesis-The phenotype of two patients with novel mutations in the PIGN and PGAP2 genes.
  JOURNAL   Eur J Paediatr Neurol (2016)
REFERENCE   PMID:24727937 (description and gene)
  AUTHORS   Kinoshita T
  TITLE     Biosynthesis and deficiencies of glycosylphosphatidylinositol.
  JOURNAL   Proc Jpn Acad Ser B Phys Biol Sci 90:130-43 (2014)
REFERENCE   PMID:24784135 (description and gene)
  AUTHORS   Murakami Y, Tawamie H, Maeda Y, Buttner C, Buchert R, Radwan F, Schaffer S, Sticht H, Aigner M, Reis A, Kinoshita T, Jamra RA
  TITLE     Null mutation in PGAP1 impairing Gpi-anchor maturation in patients with intellectual disability and encephalopathy.
  JOURNAL   PLoS Genet 10:e1004320 (2014)
///
ENTRY       H01490                      Disease
NAME        Multiple sclerosis
DESCRIPTION Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by inflammation, demyelination and axonal loss. This disease typically strikes young adults, especially women. There are four types of MS according to their relapsing or progressive pattern that include relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). In most patients, the disease has a relapsing-remitting course during the first years. Within 10 years, approximately 50% of patients progress to SPMS. The aetiology of MS is not well understood, but it is likely multifactorial, combining both genetic and environmental factors. Recently, the literature on the risk factors for MS has grown substantially. They indicate that a combination of a genetic predisposition, exposure to Epstein-Barr virus, cigarette smoking, and reduced sunlight exposure/vitamin D levels is involved. Authorized first-line treatments are considered equally effective, and include interferon beta and glatiramer acetate. They are primarily directed against inflammation, and might fail to adequately control disease activity in some patients. In that case, it has been recommended to switch these patients early to a therapy of higher efficacy. Currently, 13 different drugs with ten different active components are licensed in the European Union (EU) and the United States (US) for the treatment of MS.
CATEGORY    Nervous system disease
GENE        PDCD1 [HSA:5133] [KO:K06744]
            HLA-DRB1 [HSA:3123] [KO:K06752]
            HLA-DQB1 [HSA:3119] [KO:K06752]
            TNFRSF1A [HSA:7132] [KO:K03158]
ENV_FACTOR  Epstein-Barr virus, cigarette smoking, and reduced sunlight exposure/vitamin D levels
MARKER      Cerebrospinal fluid (CSF) Oligoclonal IgG bands (OB) positive
DRUG        Interferon beta-1a [DR:D04554]
            Interferon beta-1b [DR:D00746]
            Glatiramer acetate [DR:D04318]
            Dimethyl fumarate [DR:D03846]
            Teriflunomide [DR:D10172]
            Fingolimod [DG:DG00741]
            Natalizumab [DR:D06886]
            Alemtuzumab  [DR:D02802]
            Mitoxantrone [DG:DG00701]
            Azathioprin [DG:DG00743]
DBLINKS     ICD-10: G35
            MeSH: D009103
            OMIM: 126200 614810
REFERENCE   PMID:24424194
  AUTHORS   Milo R, Miller A
  TITLE     Revised diagnostic criteria of multiple sclerosis.
  JOURNAL   Autoimmun Rev 13:518-24 (2014)
REFERENCE   PMID:25802867
  AUTHORS   McKay KA, Kwan V, Duggan T, Tremlett H
  TITLE     Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review.
  JOURNAL   Biomed Res Int 2015:817238 (2015)
REFERENCE   PMID:23730204 (gene)
  AUTHORS   Goris A, Pauwels I, Dubois B
  TITLE     Progress in multiple sclerosis genetics.
  JOURNAL   Curr Genomics 13:646-63 (2012)
REFERENCE   PMID:16945427 (marker)
  AUTHORS   Link H, Huang YM
  TITLE     Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.
  JOURNAL   J Neuroimmunol 180:17-28 (2006)
REFERENCE   PMID:26810535 (drug)
  AUTHORS   Rio J, Ruiz-Pena JL
  TITLE     Short-term suboptimal response criteria for predicting long-term non-response to  first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
  JOURNAL   J Neurol Sci 361:158-67 (2016)
REFERENCE   PMID:25912246 (drug)
  AUTHORS   Dorr J, Paul F
  TITLE     The transition from first-line to second-line therapy in multiple sclerosis.
  JOURNAL   Curr Treat Options Neurol 17:354 (2015)
///
ENTRY       H01491                      Disease
NAME        Neuromyelitis optica;
            Devic disease
DESCRIPTION Neuromyelitis optica (NMO), also known as Devic's disease is an inflammatory demyelinating disease that selectively affects optic nerves and spinal cord. The etiology of NMO is unknown but it is believed to be an autoimmune disorder triggered by an environmental factor, possibly an infection, in genetically susceptible individuals. The principal effector in NMO is the self-reactive, complement-activating anti-AQP4 antibody. AQP4 water channel is a component of the dystroglycan protein complex located in astrocytic foot processes at the blood-brain barrier. Anti-AQP4 antibody is sensitive and highly specific serum markers of autoimmune NMO. For many decades, NMO was considered to be a subtype of multiple sclerosis (MS), but prognosis and optimal treatments differ. Corticosteroids and plasma exchange (PLEX) are the most commonly used therapeutic modalities in acute settings. Corticosteroids exert global immunosuppressive and anti-inflammatory effects, whereas PLEX removes antibodies, complement, and cytokines from the blood. Besides, immunosuppressant agents interfering with the function of T and B cells have been shown to prevent disease relapses and reduce neurological disability in NMO.
CATEGORY    Nervous system disease; Immune system disease
GENE        AQP4 [HSA:361] [KO:K09866]
DRUG        Methylprednisolone [DR:D00407 D00751 D00979]
            Prednisolone [DR:D00472 D00980 D00981]
            Azathioprine [DR:D00238]
            Mycophenolate mofetil [DR:D00752]
            Rituximab [DR:D02994]
            Eculizumab [DR:D03940]
COMMENT     See also H01490 Multiple sclerosis.
DBLINKS     ICD-10: G36.0
            MeSH: D009471
REFERENCE   PMID:26950113
  AUTHORS   Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W
  TITLE     The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications,  Controversies and Future Perspectives.
  JOURNAL   Int J Mol Sci 17 (2016)
REFERENCE   PMID:20639914 (marker)
  AUTHORS   Jarius S, Wildemann B
  TITLE     AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.
  JOURNAL   Nat Rev Neurol 6:383-92 (2010)
REFERENCE   PMID:16087714 (marker)
  AUTHORS   Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR
  TITLE     IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.
  JOURNAL   J Exp Med 202:473-7 (2005)
REFERENCE   PMID:24455211 (drug)
  AUTHORS   Bienia B, Balabanov R
  TITLE     Immunotherapy of neuromyelitis optica.
  JOURNAL   Autoimmune Dis 2013:741490 (2013)
REFERENCE   PMID:23623397 (drug)
  AUTHORS   Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM
  TITLE     Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
  JOURNAL   Lancet Neurol 12:554-62 (2013)
///
ENTRY       H01492                      Disease
NAME        Systemic sclerosis;
            Systemic scleroderma
DESCRIPTION Systemic sclerosis (scleroderma) is an autoimmune disease that is characterized by fibrosis of the skin and major internal organs. The core symptoms of this disease are Raynaud's phenomenon, skin thickening, Nail-fold capillary, and serum autoantibody production. Systemic sclerosis can manifest as either the diffuse or the limited variant, distinguished by the degree and the extent of cutaneous sclerosis. A highly variable clinical course exists that spans from mild and subtle findings to aggressive life-threatening multisystem disease. Anti-nuclear antibodies (ANA) are present in more than 90% of patients, and these ANA react against various intracellular components. However, one patient rarely has two or more types of ANA. The particular ANA types are often indicative of clinical features, disease course and overall severity. At present, there is no treatment that has been proven to modify the overall disease course, but therapy that targets specific organ involvement early before irreversible damage occurs does improve both quality of life and survival. Although the precise pathogenesis of this disease remains unknown, the consensus is that it is triggered in genetically-susceptible individuals by exposure to specific environmental agents.
CATEGORY    Immune system disease; Skin and connective tissue disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            HLA-DPA1 (polymorphism) [HSA:3113] [KO:K06752]
            HLA-DPB1 (polymorphism) [HSA:3115] [KO:K06752]
            HLA-DQA1 (polymorphism) [HSA:3117] [KO:K06752]
            HLA-DQB1 (polymorphism) [HSA:3119] [KO:K06752]
            STAT4 (polymorphism) [HSA:6775] [KO:K11222]
            IRF5 (polymorphism) [HSA:3663] [KO:K09446]
            CD247 (polymorphism) [HSA:919] [KO:K06453]
            PTPN22 (polymorphism) [HSA:26191] [KO:K18024]
            BANK1 (polymorphism)  [HSA:55024]
            TNFAIP3 (polymorphism) [HSA:7128] [KO:K11859]
            TNIP1 (polymorphism) [HSA:10318]
            TNFSF4 (polymorphism) [HSA:7292] [KO:K05469]
            IL-1A (polymorphism) [HSA:3552] [KO:K04383]
            IL-1B (polymorphism) [HSA:3553] [KO:K04519]
            IL-1R1 (polymorphism) [HSA:3554] [KO:K04386]
            CCR6 (polymorphism) [HSA:1235] [KO:K04181]
ENV_FACTOR  Cytomegalovirus, Epstein-Barr virus, and Toxoplasma gondii
MARKER      Anti-centromere (Limited, Digital ulcers and gangrene, Calcinosis, Pulmonary arterial hypertension)
            Anti-topoisomerase I (anti-Scl-70) (Diffuse, Digital ulcers and gangrene, Pulmonary fibrosis, Severe heart disease, Renal crisis)
            Anti-RNAP (Diffuse, Renal crisis)
            Anti-Th/To (Limited, Pulmonary arterial hypertension, Pulmonary fibrosis)
            Anti-U3RNP (Diffuse, Pulmonary arterial hypertension, Pulmonary fibrosis)
DRUG        Cyclophosphamide [DG:DG00675] (Pulmonary fibrosis)
            Proton pump inhibitor [DG:DG01646] (Gastroesophageal reflux disease)
            Epoprostenol [DG:DG00157] (Pulmonary arterial hypertension)
            ACE inhibitors [DG:DG01501] (Renal crisis)
            Endothelin receptor antagonists [DG:DG01502] (Pulmonary hypertension)
COMMENT     CREST syndrome is the limited cutaneous form of systemic sclerosis.
DBLINKS     ICD-10: M34
            MeSH: D012595
            OMIM: 181750
REFERENCE   PMID:23541012
  AUTHORS   Shah AA, Wigley FM
  TITLE     My approach to the treatment of scleroderma.
  JOURNAL   Mayo Clin Proc 88:377-93 (2013)
REFERENCE   PMID:20175839 (marker)
  AUTHORS   Hamaguchi Y
  TITLE     Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
  JOURNAL   J Dermatol 37:42-53 (2010)
REFERENCE   PMID:25777745 (gene)
  AUTHORS   Korman BD, Criswell LA
  TITLE     Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance.
  JOURNAL   Curr Rheumatol Rep 17:21 (2015)
REFERENCE   PMID:26826434 (gene)
  AUTHORS   Murdaca G, Contatore M, Gulli R, Mandich P, Puppo F
  TITLE     Genetic factors and systemic sclerosis.
  JOURNAL   Autoimmun Rev 15:427-32 (2016)
REFERENCE   PMID:19758208 (env_factor)
  AUTHORS   Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, Maya R, Shoenfeld Y
  TITLE     The role of infections in the immunopathogensis of systemic sclerosis--evidence from serological studies.
  JOURNAL   Ann N Y Acad Sci 1173:627-32 (2009)
REFERENCE   PMID:21691743 (drug)
  AUTHORS   Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N
  TITLE     Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis.
  JOURNAL   Rheumatol Int 32:2431-44 (2012)
REFERENCE   PMID:25475597 (drug)
  AUTHORS   Carlson DA, Hinchcliff M, Pandolfino JE
  TITLE     Advances in the evaluation and management of esophageal disease of systemic sclerosis.
  JOURNAL   Curr Rheumatol Rep 17:475 (2015)
REFERENCE   PMID:24387049 (drug)
  AUTHORS   Murdaca G, Spano F, Puppo F
  TITLE     Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.
  JOURNAL   Expert Opin Drug Saf 13:295-305 (2014)
REFERENCE   PMID:21061100 (drug)
  AUTHORS   Bussone G, Berezne A, Pestre V, Guillevin L, Mouthon L
  TITLE     The scleroderma kidney: progress in risk factors, therapy, and prevention.
  JOURNAL   Curr Rheumatol Rep 13:37-43 (2011)
REFERENCE   PMID:21184655 (drug)
  AUTHORS   Shetty N, Derk CT
  TITLE     Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
  JOURNAL   Inflamm Allergy Drug Targets 10:19-26 (2011)
///
ENTRY       H01493                      Disease
NAME        Localized Scleroderma;
            Morphea
DESCRIPTION Localized scleroderma, also known as morphea, is a rare fibrosing disorder of the skin and underlying tissues. Sclerosis is mainly limited to the skin, but subcutaneous tissue, fascia, and underlying muscles and bone may also be involved. It is generally differentiated from systemic scleroderma by the lack of Raynaud's phenomenon and visceral involvements. Localized scleroderma is classified into plaque morphea, generalized morphea, and linear scleroderma subtypes according to the clinical presentation and depth of tissue involvement. Localized scleroderma generally appears at any age, and onset at 20-50 years old is common, with the exception of the linear type, which often develops in childhood. Extracutaneous manifestations in morphea are not rare. The most common extracutaneous manifestations are arthralgia and myalgia. Neurologic manifestations and ocular complications are the most common in those children with head and neck involvement.
CATEGORY    Skin and connective tissue disease
ENV_FACTOR  Borrelia burgdorferi infection
DRUG        Prednisolone [DG:DG00093]
            Prednisone [DG:DG00094]
            Methylprednisolone [DG:DG00410]
            Methotrexate [DG:DG00681]
COMMENT     See also H01492 Systemic sclerosis
DBLINKS     ICD-10: L94.0
            MeSH: D012594
REFERENCE   PMID:26321403
  AUTHORS   Gorkiewicz-Petkow A, Kalinska-Bienias A
  TITLE     Systemic involvement in localized scleroderma/morphea.
  JOURNAL   Clin Dermatol 33:556-62 (2015)
REFERENCE   PMID:25582037
  AUTHORS   Toki S, Motegi S, Yamada K, Uchiyama A, Kanai S, Yamanaka M, Ishikawa O
  TITLE     Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.
  JOURNAL   J Dermatol 42:283-7 (2015)
REFERENCE   PMID:25672301 (description and drug)
  AUTHORS   Careta MF, Romiti R
  TITLE     Localized scleroderma: clinical spectrum and therapeutic update.
  JOURNAL   An Bras Dermatol 90:62-73 (2015)
REFERENCE   PMID:19022534 (env_factor)
  AUTHORS   Prinz JC, Kutasi Z, Weisenseel P, Poto L, Battyani Z, Ruzicka T
  TITLE     "Borrelia-associated early-onset morphea": a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases.
  JOURNAL   J Am Acad Dermatol 60:248-55 (2009)
REFERENCE   PMID:26892661 (drug)
  AUTHORS   Mazori DR, Wright NA, Patel M, Liu SW, Ramachandran SM, Franks AG Jr, Vleugels RA, Femia AN
  TITLE     Characteristics and treatment of adult-onset linear morphea: A retrospective cohort study of 61 patients at 3 tertiary care centers.
  JOURNAL   J Am Acad Dermatol 74:577-9 (2016)
///
ENTRY       H01494                      Disease
NAME        Spondyloepimetaphyseal dysplasia with joint laxity type (SEMD-JL) ;
            SEMDJL-Beighton type ;
            SEMDJL-Leptodactylic or Hall type
DESCRIPTION Spondyloepimetaphyseal dysplasia with joint laxity type is an autosomal recessive skeletal dysplasia that consists of type 1 (SEMDJL1, SEMD-JL Beighton type) and type 2 (SEMDJL2, SEMD-leptodactylic or Hall type). SEMDJL1 is caused by mutation in the B3GALT6 gene. The individuals with SEMDJL1 show the characteristic vertebral abnormalities, ligamentous laxity that result in spinal misalignment and progressive severe kyphoscoliosis, thoracic asymmetry, and respiratory compromise resulting in early death. The individuals with SEMDJL2 was identified mutations in KIF22 as the cause of this diesease. Its characteristic manisfestation includes short stature, midface hypoplasia, generalized ligamentous laxity causing mild kyphoscoliosis and progressive genuvalgum.
CATEGORY    Skeletal dysplasia
GENE        (SEMDJL1) B3GALT6 [HSA:126792] [KO:K00734]
            (SEMDJL2) KIF22 [HSA:3835] [KO:K10403]
DBLINKS     ICD-10: Q77.7
            MeSH: C562968
            OMIM: 271640 603546
REFERENCE   PMID:23664117 (description and gene)
  AUTHORS   Nakajima M, Mizumoto S, Miyake N, Kogawa R, Iida A, Ito H, Kitoh H, Hirayama A, Mitsubuchi H, Miyazaki O, Kosaki R, Horikawa R, Lai A, Mendoza-Londono R, Dupuis L, Chitayat D, Howard A, Leal GF, Cavalcanti D, Tsurusaki Y, Saitsu H, Watanabe S, Lausch E, Unger S, Bonafe L, Ohashi H, Superti-Furga A, Matsumoto N, Sugahara K, Nishimura G, Ikegawa S
  TITLE     Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause a spectrum of skeletal and connective tissue disorders.
  JOURNAL   Am J Hum Genet 92:927-34 (2013)
REFERENCE   PMID:12567412 (description and gene)
  AUTHORS   Nishimura G, Honma T, Shiihara T, Manabe N, Nakajima E, Adachi M, Mikawa M, Fukushima Y, Ikegawa S
  TITLE     Spondyloepimetaphyseal dysplasia with joint laxity leptodactylic form: clinical course and phenotypic variations in four patients.
  JOURNAL   Am J Med Genet A 117A:147-53 (2003)
REFERENCE   PMID:22152677 (gene)
  AUTHORS   Min BJ, Kim N, Chung T, Kim OH, Nishimura G, Chung CY, Song HR, Kim HW, Lee HR, Kim J, Kang TH, Seo ME, Yang SD, Kim DH, Lee SB, Kim JI, Seo JS, Choi JY, Kang D, Kim D, Park WY, Cho TJ
  TITLE     Whole-exome sequencing identifies mutations of KIF22 in spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type.
  JOURNAL   Am J Hum Genet 89:760-6 (2011)
///
ENTRY       H01495                      Disease
NAME        Meniere disease
DESCRIPTION Meniere disease is an inner ear disorder characterized by episodic vertigo attacks, sensorineural hearing loss, tinnitus, and aural fullness. Prevailing theories on its pathogenesis point to endolymphatic hydrops as one derangement responsible for producing dysfunction within the cochlea and peripheral vestibular apparatus. Although the familial clustering and the geographical and racial differences in incidence suggest a certain role for genetic factors in the development of Meniere disease, no convincing evidence for an association with any gene exists, at present.
CATEGORY    Nervous system disease
MARKER      Furosemide test
            Glycerol test
DRUG        Isosorbide [DR:D00347]
            Betahistine [DG:DG01004]
            Gentamicin [DG:DG00401] (intratympanic)
DBLINKS     ICD-10: H81.0
            MeSH: D008575
            OMIM: 156000
REFERENCE   PMID:25609993
  AUTHORS   Chiarella G, Petrolo C, Cassandro E
  TITLE     The genetics of Meniere's disease.
  JOURNAL   Appl Clin Genet 8:9-17 (2015)
REFERENCE   PMID:26932948 (drug)
  AUTHORS   Crowson MG, Patki A, Tucci DL
  TITLE     A Systematic Review of Diuretics in the Medical Management of Meniere's Disease.
  JOURNAL   Otolaryngol Head Neck Surg (2016)
REFERENCE   PMID:26810620 (drug)
  AUTHORS   Seyed Tootoonchi SJ, Ghiasi S, Shadara P, Samani SM, Fouladi DF
  TITLE     Hearing function after betahistine therapy in patients with Meniere's disease.
  JOURNAL   Braz J Otorhinolaryngol (2015)
REFERENCE   PMID:15564826 (drug)
  AUTHORS   Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA
  TITLE     Intratympanic gentamicin for Meniere's disease: a meta-analysis.
  JOURNAL   Laryngoscope 114:2085-91 (2004)
REFERENCE   PMID:16699291 (marker)
  AUTHORS   Kakigi A, Takeda T, Sawada S, Taguchi D
  TITLE     Antidiuretic hormone and osmolality in isosorbide therapy and glycerol test.
  JOURNAL   ORL J Otorhinolaryngol Relat Spec 68:279-82 (2006)
REFERENCE   PMID:2635549 (marker)
  AUTHORS   Kobayashi H, Ito M, Mizukoshi K, Watanabe Y, Ohashi N, Shojaku H
  TITLE     The furosemide VOR test for Meniere's disease. A preliminary report.
  JOURNAL   Acta Otolaryngol Suppl 468:81-5 (1989)
///
ENTRY       H01496                      Disease
NAME        Spondyloocular syndrome (SOS)
DESCRIPTION Spondyloocular syndrome is a rare autosomal recessive disorder due to mutations in the XYLT2 gene. XYLT2 encodes xylosyltransferases involved in proteoglycan biosynthesis. The affected individuals were found to produce lower amount of chondroitin and heparan sulfate. Clinically, the major features include crystalline lens malformation, cataract, retinal detachment that result in loss of vision, facial dysmorphism, generalized osteoporosis, and immobile spine and platyspondly.
CATEGORY    Eye diseases; Skeletal dysplasia
GENE        XYLT2 [HSA:64132] [KO:K00771]
DBLINKS     ICD-10: Q87.5
            MeSH: C565285
            OMIM: 605822
REFERENCE   PMID:12719077 (description)
  AUTHORS   Rudolph G, Kalpadakis P, Bettecken T, Lichtner P, Haritoglou C, Hergersberg M, Meitinger T, Schmidt H
  TITLE     Spondylo-ocular syndrome: a new entity with crystalline lens malformation, cataract, retinal detachment, osteoporosis, and platyspondyly.
  JOURNAL   Am J Ophthalmol 135:681-7 (2003)
REFERENCE   PMID:26987875 (description and gene)
  AUTHORS   Taylan F, Costantini A, Coles N, Pekkinen M, Heon E, Siklar Z, Berberoglu M, Kampe A, Kiykim E, Grigelioniene G, Tuysuz B, Makitie O
  TITLE     Spondyloocular Syndrome - Novel Mutations in XYLT2 Gene and Expansion of the Phenotypic Spectrum.
  JOURNAL   J Bone Miner Res (2016)
REFERENCE   PMID:26027496 (description and gene)
  AUTHORS   Munns CF, Fahiminiya S, Poudel N, Munteanu MC, Majewski J, Sillence DO, Metcalf JP, Biggin A, Glorieux F, Fassier F, Rauch F, Hinsdale ME
  TITLE     Homozygosity for frameshift mutations in XYLT2 result in a spondylo-ocular syndrome with bone fragility, cataracts, and hearing defects.
  JOURNAL   Am J Hum Genet 96:971-8 (2015)
///
ENTRY       H01497                      Disease
NAME        Temtamy preaxial brachydactyly syndrome (TPBS)
DESCRIPTION Temtamy preaxial brachydactyly syndrome (TPBS) is an autosomal recessive rare disorder that is caused by the mutations in the CHSY1 gene. CHSY1 encodes chondroitin synthase 1 involving in the biosynthesis of chondroitin sulfate and perhaps affecting bone morphogenetic protein (BMP) signaling. The loss-of-function mutations in the protein cause defects in multiple development processes. The major features include limb malformations, short stature, hearing loss, delayed motor and mental development,  facial dysmorphism and dental anomalies.
CATEGORY    Skeletal dysplasia; developmental disorder
GENE        CHSY1 [HSA:22856] [KO:K13499]
DBLINKS     ICD-10: Q87.2
            MeSH: C536958
            OMIM: 605282
REFERENCE   PMID:21129728 (description and gene)
  AUTHORS   Li Y, Laue K, Temtamy S, Aglan M, Kotan LD, Yigit G, Canan H, Pawlik B, Nurnberg G, Wakeling EL, Quarrell OW, Baessmann I, Lanktree MB, Yilmaz M, Hegele RA, Amr K, May KW, Nurnberg P, Topaloglu AK, Hammerschmidt M, Wollnik B
  TITLE     Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling.
  JOURNAL   Am J Hum Genet 87:757-67 (2010)
REFERENCE   PMID:24269551 (description and gene)
  AUTHORS   Sher G, Naeem M
  TITLE     A novel CHSY1 gene mutation underlies Temtamy preaxial brachydactyly syndrome in  a Pakistani family.
  JOURNAL   Eur J Med Genet 57:21-4 (2014)
///
ENTRY       H01498                      Disease
NAME        Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects (JDSSDHD);
            Larsen-like syndrome
DESCRIPTION Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects, also termed Larsen-like syndrome, is an autosomal recessive disease that is caused by the mutations in the B3GAT3. B3GAT3 encodes key enzyme involving in glycosaminoglycan biosynthses. The mutation results in decreased levels of dermatan sulfate, chondroitin sulfate, and heparan sulfate proteoglycans. The affected individuals showed dysmorphic faces, bilateral dislocations of the elbows, hips, and knees, and short stature, as well as cardiovascular defects.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        B3GAT3 [HSA:26229] [KO:K10158]
DBLINKS     ICD-10: Q74.8
            MeSH: C563914
            OMIM: 245600
REFERENCE   PMID:21763480 (description and gene)
  AUTHORS   Baasanjav S, Al-Gazali L, Hashiguchi T, Mizumoto S, Fischer B, Horn D, Seelow D, Ali BR, Aziz SA, Langer R, Saleh AA, Becker C, Nurnberg G, Cantagrel V, Gleeson JG, Gomez D, Michel JB, Stricker S, Lindner TH, Nurnberg P, Sugahara K, Mundlos S, Hoffmann K
  TITLE     Faulty initiation of proteoglycan synthesis causes cardiac and joint defects.
  JOURNAL   Am J Hum Genet 89:15-27 (2011)
REFERENCE   PMID:24668659 (description and gene)
  AUTHORS   von Oettingen JE, Tan WH, Dauber A
  TITLE     Skeletal dysplasia, global developmental delay, and multiple congenital anomalies in a 5-year-old boy-report of the second family with B3GAT3 mutation and expansion of the phenotype.
  JOURNAL   Am J Med Genet A 164A:1580-6 (2014)
///
ENTRY       H01499                      Disease
NAME        Sporotrichosis
DESCRIPTION Sporotrichosis is an endemic mycosis in tropical and subtropical areas caused by Sporothrix schenckii which is a common saprophyte of soil, decaying wood, hay and sphagnum moss. S. schenckii usually causes a mixed suppurative and granulomatous inflammatory reaction in the dermis and subcutaneous tissue, frequently accompanied by microabscess and fibrosis. The most common symptom is cutaneous disease, which is classified into fixed and lymphocutaneous forms. Osteoarticular, pulmonary, mucosal, disseminated and systemic infections are less common and usually occur in immunosuppressed individuals.
CATEGORY    Infectious disease
PATHOGEN    Sporothrix schenckii
DBLINKS     ICD-10: B42
            MeSH: D013174
            MedlinePlus: 001338
REFERENCE   PMID:25526781 (description)
  AUTHORS   Chakrabarti A, Bonifaz A, Gutierrez-Galhardo MC, Mochizuki T, Li S
  TITLE     Global epidemiology of sporotrichosis.
  JOURNAL   Med Mycol 53:3-14 (2015)
REFERENCE   PMID:25614735 (description)
  AUTHORS   Mahajan VK
  TITLE     Sporotrichosis: an overview and therapeutic options.
  JOURNAL   Dermatol Res Pract 2014:272376 (2014)
REFERENCE   PMID:22682194 (description)
  AUTHORS   Vasquez-del-Mercado E, Arenas R, Padilla-Desgarenes C
  TITLE     Sporotrichosis.
  JOURNAL   Clin Dermatol 30:437-43 (2012)
///
ENTRY       H01500                      Disease
NAME        Lupus nephritis
DESCRIPTION Lupus nephritis is a severe organ manifestation of systemic lupus erythematosus (SLE) that can affect up to 70% of the SLE population. In childhood SLE, nephritis is present in up to 90% of the cases. This disease is one of the most serious complications of SLE, with a high morbidity and mortality. Clinical manifestations of active lupus nephritis include proteinuria, active urinary sediments, and progressive renal dysfunction. It is initiated by the deposition of immunoglobulins and formation of immune complexes in the glomerular and tubulo-interstitial compartments of the kidney. There is emerging evidence that the interaction between anti-dsDNA antibodies and kidney cells, notably mesangial cells, proximal renal tubular epithelial cells, and glomerular endothelial cells plays a significant role in disease pathogenesis.
CATEGORY    Immune system disease; Kidney disease
MARKER      Proteinuria
            Hematuria
            Active urinary sediment
            Urinary gamma globulin
            Antibodies (anti-nuclear, anti-dsDNA, anti-C1q)
DRUG        Cyclophosphamide [DG:DG00675]
            Prednisone [DG:DG00094]
            Tacrolimus [DG:DG00439]
            Hydroxychloroquine [DG:DG01015]
COMMENT     See also H00080 Systemic lupus erythematosus.
            Lupus nephritis is staged according to the classification revised by the International Society of Nephrology (ISN) and the Renal Pathology Society (RPS) in 2003.
DBLINKS     ICD-10: M32.1 N08.5 N16.4
            MeSH: D008181
            OMIM: 607965 607966 607967
REFERENCE   PMID:14747370
  AUTHORS   Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M
  TITLE     The classification of glomerulonephritis in systemic lupus erythematosus revisited.
  JOURNAL   J Am Soc Nephrol 15:241-50 (2004)
REFERENCE   PMID:22761629 (marker)
  AUTHORS   Yung S, Chan TM
  TITLE     Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown.
  JOURNAL   Clin Dev Immunol 2012:139365 (2012)
REFERENCE   PMID:12215904
  AUTHORS   Quintero-Del-Rio AI, Kelly JA, Kilpatrick J, James JA, Harley JB
  TITLE     The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3).
  JOURNAL   Genes Immun 3 Suppl 1:S57-62 (2002)
REFERENCE   PMID:22570338 (drug)
  AUTHORS   Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, He X, Zhang X, Wang H, Wu J, Xu Y, Chen J
  TITLE     Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
  JOURNAL   Lupus 21:1025-35 (2012)
REFERENCE   PMID:19479701 (drug)
  AUTHORS   Pons-Estel GJ, Alarcon GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vila LM
  TITLE     Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.
  JOURNAL   Arthritis Rheum 61:830-9 (2009)
///
ENTRY       H01501                      Disease
NAME        Blastomycosis
DESCRIPTION Blastomycosis is a fungal infection caused by the organism Blastomyces dermatitidis, is a dimorphic fungus that grows as a filamentous mold in the environment and as budding yeast in human tissue. Blastomycosis is primarily a pulmonary infection, but dissemination occurs frequently and leads to involvement of skin, bones and joints, the genitourinary tract, and other areas.
CATEGORY    Infectious disease
PATHOGEN    Blastomyces dermatitidis
DBLINKS     ICD-10: B40
            MeSH: D001759
            MedlinePlus: 000102
REFERENCE   PMID:26398538 (description)
  AUTHORS   Smith JA, Gauthier G
  TITLE     New Developments in Blastomycosis.
  JOURNAL   Semin Respir Crit Care Med 36:715-28 (2015)
REFERENCE   PMID:15636375 (description)
  AUTHORS   Baumgardner DJ, Halsmer SE, Egan G
  TITLE     Symptoms of pulmonary blastomycosis: northern Wisconsin, United States.
  JOURNAL   Wilderness Environ Med 15:250-6 (2004)
REFERENCE   PMID:20463245 (description)
  AUTHORS   Smith JA, Kauffman CA
  TITLE     Blastomycosis.
  JOURNAL   Proc Am Thorac Soc 7:173-80 (2010)
///
ENTRY       H01502                      Disease
NAME        Sjogren's Syndrome
DESCRIPTION Sjogren's Syndrome (SS) is a chronic inflammatory systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands leading to sicca symptoms of the eyes and mouth. Several systemic and extraglandular manifestations can develop, including fatigue, arthritis, and involvement of organs such as the skin, lungs, and kidneys. SS may occur as a primary disorder or in association with other systemic autoimmune diseases, traditionally defined as secondary SS, such as rheumatoid arthritis, and systemic lupus erythematosus. Salivary secretions from these patients exhibit elevated levels of antibodies and cytokines. This is accompanied by a reduction in oral phosphate levels and xerostomia due to reduced salivary flow, which can lead to infections, progressive caries, dysphagia and oral pain. Current tests for SS include sialometry, salivary scintigraphy, sialography, serological tests or minor salivary gland biopsies. Recently, salivary biomarkers of SS has been investigated. The etiology of SS is still unclear. Since there is a familial aggregation of primary SS, however, genetic factors have been suspected for a long time. Initially, HLA haplotypes were shown to be associated with primary SS. Recently, polymorphisms in the genes IRF5 and STAT4 have been convincingly identified and replicated in several studies as susceptibility factors.
CATEGORY    Immune system disease; Skin and connective tissue disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            IRF5 (polymorphism) [HSA:3663] [KO:K09446]
            STAT4 (polymorphism) [HSA:6775] [KO:K11222]
MARKER      Salivary secretions exhibit elevated levels of antibodies (IgA, IgG) and cytokines (prostaglandin-E2, and interleukin-6).
DRUG        Hyaluronic acid [DG:DG00380]
            Pilocarpine [DG:DG00992]
            Saliva substitutes [DR:D04424]
            Cevimeline [DG:DG00993]
            Cyclosporin [DR:D00184]
DBLINKS     ICD-10: M35.0
            MeSH: D012859
            OMIM: 270150
REFERENCE   PMID:11000325
  AUTHORS   Stiller M, Golder W, Doring E, Biedermann T
  TITLE     Primary and secondary Sjogren's syndrome in children--a comparative study.
  JOURNAL   Clin Oral Investig 4:176-82 (2000)
REFERENCE   PMID:26809028
  AUTHORS   van Nimwegen JF, Moerman RV, Sillevis Smitt N, Brouwer E, Bootsma H, Vissink A
  TITLE     Safety of treatments for primary Sjogren's syndrome.
  JOURNAL   Expert Opin Drug Saf 15:513-24 (2016)
REFERENCE   PMID:21635716 (gene)
  AUTHORS   Low HZ, Witte T
  TITLE     Aspects of innate immunity in Sjogren's syndrome.
  JOURNAL   Arthritis Res Ther 13:218 (2011)
REFERENCE   PMID:26937373 (marker)
  AUTHORS   Javaid MA, Ahmed AS, Durand R, Tran SD
  TITLE     Saliva as a diagnostic tool for oral and systemic diseases.
  JOURNAL   J Oral Biol Craniofac Res 6:66-75 (2016)
REFERENCE   PMID:22117835 (marker)
  AUTHORS   Baldini C, Giusti L, Ciregia F, Da Valle Y, Giacomelli C, Donadio E, Sernissi F, Bazzichi L, Giannaccini G, Bombardieri S, Lucacchini A
  TITLE     Proteomic analysis of saliva: a unique tool to distinguish primary Sjogren's syndrome from secondary Sjogren's syndrome and other sicca syndromes.
  JOURNAL   Arthritis Res Ther 13:R194 (2011)
REFERENCE   PMID:12038948 (drug)
  AUTHORS   Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, Suen JY
  TITLE     Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial.
  JOURNAL   Arch Intern Med 162:1293-300 (2002)
REFERENCE   PMID:22870445 (drug)
  AUTHORS   Vitali C, Palombi G, Cataleta P
  TITLE     Treating Sjogren's Syndrome: Insights for the Clinician.
  JOURNAL   Ther Adv Musculoskelet Dis 2:155-66 (2010)
///
ENTRY       H01503                      Disease
NAME        Zygomycosis, including:
            Mucormycosis;
            Entomophthoramycosis
DESCRIPTION The class Zygomycetes is divided into two orders, Mucorales and Entomophthorales. These two orders produce different infections. Genera from the order Mucorales cause an angioinvasive infection called mucormycosis. Mucormycosis can present as rhinocerebral, pulmonary, disseminated, cutaneous and gastrointestinal involvement. Genera from the order Entomophthorales cause a chronic subcutaneous infection called entomophthoramycosis in immunocompetent patients.
CATEGORY    Infectious disease
PATHOGEN    Mucor racemosus
            Mucor circinelloides
            Mucor ramosissimus
            Mucor indicus
            Mucor hiemalis
            Rhizopus arrhizus
            Rhizopus rhizopodiformis
            Rhizopus azygosporus
            Rhizopus stolonifer
            Rhizopus schipperae
            Rhizopus microsporus 
            Rhizomucor pusillus
            Absidia corymbifera
            Apophysomyces elegans
            Cunninghamella bertholletiae
            Saksenaea vasiformis
            Cokeromyces recurvatus
            Basidiobolus ranarum
            Conidiobolus coronatus
            Conidiobolus incongruus
DBLINKS     ICD-10: B46
            MeSH: D020096
            MedlinePlus: 000649
REFERENCE   PMID:14748801 (description, pathogen)
  AUTHORS   Prabhu RM, Patel R
  TITLE     Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment.
  JOURNAL   Clin Microbiol Infect 10 Suppl 1:31-47 (2004)
REFERENCE   PMID:19466966 (description)
  AUTHORS   Pagano L, Valentini CG, Caira M, Fianchi L
  TITLE     ZYGOMYCOSIS: current approaches to management of patients with haematological malignancies.
  JOURNAL   Br J Haematol 146:597-606 (2009)
///
ENTRY       H01504                      Disease
NAME        Vogt-Koyanagi-Harada syndrome;
            Vogt-Koyanagi-Harada disease;
            Uveomeningoencephalitic syndrome
DESCRIPTION Vogt-Koyanagi-Harada syndrome (VKHS), initially described as an uveomeningoencephalitic syndrome, is a rare systemic autoimmune disease that targets melanocyte-rich tissues, such as the eye, inner ear, meninges, skin and hair. This disease is characterized by panuveitis, often associated with neurologic and cutaneous manifestations, including headache, hearing loss, vitiligo, and poliosis. VKHS is more common in individuals of pigmented skin, such as Asians, Middle Easterners, Hispanics and Native Americans. Although the exact etiology of VKHS remains unclear, it has also been postulated that such an autoimmune response might be triggered by an infectious agent in a genetically susceptible individual. Several studies have demonstrated that HLA-DR4 is strongly associated with VKHD.
CATEGORY    Immune system disease; Nervous system disease
GENE        HLA-DRB1 [HSA:3123] [KO:K06752]
            HLA-DRB4 [HSA:3126] [KO:K06752]
ENV_FACTOR  Epstein-Barr virus, Cytomegalovirus
MARKER      Optical coherence tomography (OCT)
            Autofluorescence imaging
DRUG        Methylprednisolone [DG:DG00410]
            Prednisone [DG:DG00094]
            Prednisolone [DG:DG00093]
            Betamethasone [DG:DG00095]
            Cyclosporine [DR:D00184]
            Chlorambucil [DR:D00266]
            Azathioprine [DG:DG00743]
DBLINKS     ICD-10: H20.8 H30.8
            MeSH: D014607
REFERENCE   PMID:27008848
  AUTHORS   Lavezzo MM, Sakata VM, Morita C, Rodriguez EE, Abdallah SF, da Silva FT, Hirata CE, Yamamoto JH
  TITLE     Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.
  JOURNAL   Orphanet J Rare Dis 11:29 (2016)
REFERENCE   PMID:23567866 (env_factor, marker, drug)
  AUTHORS   Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, De Virgilio A, de Vincentiis M
  TITLE     Vogt-Koyanagi-Harada syndrome.
  JOURNAL   Autoimmun Rev 12:1033-8 (2013)
///
ENTRY       H01505                      Disease
NAME        Inclusion body myositis
DESCRIPTION Inclusion body myositis (IBM) is the most frequent acquired myopathy after age 45. It is distinguished from other inflammatory myopathies by its selective pattern of muscle involvement and slowly progressive course, and by the combination of inflammatory and degenerative muscle pathology and multi-protein deposits in muscle tissue. It typically presents with chronic insidious proximal leg and/or distal arm asymmetric muscle weakness leading to recurrent falls and loss of dexterity. Creatine kinase (CK) is elevated in IBM and needle electromyography (EMG) mostly shows a chronic irritative myopathy. Muscle histopathology demonstrates endomysial inflammatory exudates surrounding and invading non-necrotic muscle fibers often times accompanied by rimmed vacuoles and protein deposits. IBM is refractory to all known immunosuppressive therapies. It has been shown in small short-term trials that individualised exercise programs can lead to improvement or maintenance of muscle strength and aerobic capacity.
CATEGORY    Musculoskeletal disease; Nervous system disease
DRUG        Bimagrumab [DR:D10620]
DBLINKS     ICD-10: G72.4
            MeSH: D018979
REFERENCE   PMID:25037082 (definition)
  AUTHORS   Dimachkie MM, Barohn RJ
  TITLE     Inclusion body myositis.
  JOURNAL   Neurol Clin 32:629-46, vii (2014)
REFERENCE   PMID:26778717 (definition)
  AUTHORS   Needham M, Mastaglia FL
  TITLE     Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment.
  JOURNAL   Clin Neurophysiol 127:1764-73 (2016)
REFERENCE   PMID:26335925 (definition)
  AUTHORS   Gang Q, Bettencourt C, Houlden H, Hanna MG, Machado PM
  TITLE     Genetic advances in sporadic inclusion body myositis.
  JOURNAL   Curr Opin Rheumatol 27:586-94 (2015)
///
ENTRY       H01506                      Disease
NAME        Hepatic encephalopathy;
            Hepatic coma
DESCRIPTION Hepatic encephalopathy (HE) is a brain dysfunction caused by liver insufficiency or portal systemic shunting. HE most commonly occurs in decompensated liver cirrhosis and incorporates a spectrum of manifestations that ranges from mild cognitive impairment to coma. Although its pathogenesis is not entirely understood, one of the main factors is thought to be ammonia. Apart from hyperammonemia, various other pathogenic mechanisms, such as the gamma-aminobutyric acid (GABA) theory, the benzodiazepine theory, the manganese theory, and the theory of oxidative/nitrosative stress, have been implicated in the development of HE. The pharmacological treatments that are currently used in clinical practice are directed toward reducing the production and absorption of gut-derived ammonia.
CATEGORY    Liver disease; Nervous system disease; Metabolic disease
DRUG        Rifaximin [DR:D02554]
COMMENT     Lactulose, probiotics, and extracorporeal albumin dialysis, especially MARS, have been demonstrated to be beneficial in cirrhotic patients.
DBLINKS     ICD-10: K72
            MeSH: D006501
REFERENCE   PMID:26557005 (definition, drug)
  AUTHORS   Luo M, Guo JY, Cao WK
  TITLE     Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.
  JOURNAL   World J Gastroenterol 21:11815-24 (2015)
REFERENCE   PMID:26719720 (definition)
  AUTHORS   Grover VP, Tognarelli JM, Massie N, Crossey MM, Cook NA, Taylor-Robinson SD
  TITLE     The why and wherefore of hepatic encephalopathy.
  JOURNAL   Int J Gen Med 8:381-90 (2015)
REFERENCE   PMID:21885692 (definition)
  AUTHORS   Wakim-Fleming J
  TITLE     Hepatic encephalopathy: suspect it early in patients with cirrhosis.
  JOURNAL   Cleve Clin J Med 78:597-605 (2011)
///
ENTRY       H01507                      Disease
NAME        Seronegative arthritis (SpA), including:
            Ankylosing spondylosis;
            Undifferentiated spondylarthritis;
            Reactive arthritis;
            Psoriatic arthritis;
            Enteropathic arthritis
DESCRIPTION Seronegative spondyloarthropathies (SpA) represent a group of chronic articular inflammatory diseases which differ from rheumatoid arthritis for the typical absence of rheumatoid factor in serum, and have in common several epidemiological, pathological, clinical, and radiological features. SpA include ankylosing spondylitis (AS), reactive arthritis (ReA), enteropathic (IBD) associated arthritis, psoriatic arthritis (PsA), as well as undifferentiated, and juvenile SpA. The main clinical manifestations include inflammatory back pain, peripheral arthritis, enthesitis, and extra-skeletal manifestations, such as uveitis. Although the cause of SpA is unknown, it is generally accepted that SpA is a multifactorial disease. Genetics (such as HLA-B27), inflammatory cytokines (such as TNF), and more recently the IL-23/IL-17 cytokine pathway have links to pathogenesis. Biologic agents, particularly TNF blockers, are primary treatment options and have been shown to reduce symptomatic inflammation.
CATEGORY    Musculoskeletal disease
GENE        HLA-B [HSA:3106] [KO:K06751]
DRUG        Infliximab [DR:D02598]
DBLINKS     MeSH: D025241
            OMIM: 106300
REFERENCE   PMID:24272481 (definition, gene)
  AUTHORS   Paparo F, Revelli M, Semprini A, Camellino D, Garlaschi A, Cimmino MA, Rollandi GA, Leone A
  TITLE     Seronegative spondyloarthropathies: what radiologists should know.
  JOURNAL   Radiol Med 119:156-63 (2014)
REFERENCE   PMID:22428451 (definition, gene)
  AUTHORS   Wilson G, Folzenlogen DD
  TITLE     Spondyloarthropathies: new directions in etiopathogenesis, diagnosis and treatment.
  JOURNAL   Mo Med 109:69-74 (2012)
REFERENCE   PMID:19591637 (definition, gene)
  AUTHORS   Melis L, Elewaut D
  TITLE     Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?
  JOURNAL   Arthritis Res Ther 11:233 (2009)
///
ENTRY       H01508                      Disease
NAME        Salivary gland cancer
DESCRIPTION Salivary gland carcinomas are rare tumours representing about 0.5% of all malignancies and less than 5 % of all head and neck cancers. These are a heterogeneous group of tumors that include 24 histologically distinct tumor types. Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. The most common genetic alteration in MECs is a unique translocation t(11;19)(q21;p13) producing the MECT1-MAML2 fusion protein. This fusion transcript can activate transcription of targets in the Notch pathway. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) overexpression is present in a minority of MECs and is associated with higher rate of metastasis and worse overall survival. Recent studies have evaluated the epidermal growth factor receptor family including EGFR and HER2 as potential therapeutic targets.
CATEGORY    Cancer
GENE        CRTC1-MAML2 (translocation) [HSA:23373 84441] [KO:K15309 K06061]
            MYB-NF1B (translocation) [HSA:4602 6928] [KO:K09420 K08034]
            ETV6-NTRK3 (translocation) [HSA:2120 4916] [KO:K03211 K05101]
            EGFR (overexpression) [HSA:1956] [KO:K04361]
            HER2 (overexpression) [HSA:2064] [KO:K05083]
            CDKN2A (deletion) [HSA:1029] [KO:K06621]
MARKER      KIT [HSA:3815] [KO:05091]
            EGFR [HSA:1956] [KO:04361]
            HER2 [HSA:2064] [KO:05083]
            AR [HSA:367] [KO:08557]
DRUG        Cisplatin [DR:D00275]
            Paclitaxel [DG:DG01430]
            Gemcitabine [DG:DG00688]
            Mitoxantrone [DG:DG00701]
            Vinorelbine [DG:DG00692]
            Anthracycline [DG:DG01682]
            Imatinib [DG:DG00710]
            Trastuzumab [DG:DG01358]
            Cetuximab [DR:D03455]
            Gefitinib [DR:D01977]
            Lapatinib [DG:DG00715]
COMMENT     ICD-O-3: 8430/3 mucoepidermoid carcinoma (MEC) 
            ICD-O-3: 8550/3 acinic cell carcinoma
            ICD-O-3: 8200/3 adenoid cystic carcinoma 
            ICD-O-3: 8140/3 adenocarcinoma not otherwise specified (NOS) 
            ICD-O-3: 8525/3 polynorphous low grade adenocarcinoma
            ICD-O-3: 8940/0 pleomorphic adenoma
            ICD-O-3: 8500/3 salivary duct carcinoma
            ICD-O-3: 8070/3 squamous cell carcinoma
DBLINKS     ICD-10: C08.9
            MeSH: D012468
REFERENCE   PMID:22842859 (description, gene, marker, drug, tumor type)
  AUTHORS   Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE
  TITLE     Salivary gland carcinomas.
  JOURNAL   Oral Maxillofac Surg 16:267-83 (2012)
REFERENCE   PMID:26928905 (description, gene, tumor type)
  AUTHORS   Yin LX, Ha PK
  TITLE     Genetic alterations in salivary gland cancers.
  JOURNAL   Cancer (2016)
REFERENCE   PMID:23821214 (gene)
  AUTHORS   Stenman G
  TITLE     Fusion oncogenes in salivary gland tumors: molecular and clinical consequences.
  JOURNAL   Head Neck Pathol 7 Suppl 1:S12-9 (2013)
REFERENCE   PMID:26470903 (gene, marker, tumor type)
  AUTHORS   Goyal G, Mehdi SA, Ganti AK
  TITLE     Salivary Gland Cancers: Biology and Systemic Therapy.
  JOURNAL   Oncology (Williston Park) 29:773-80 (2015)
REFERENCE   PMID:22687949 (description, marker, drug, tumor type)
  AUTHORS   Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY
  TITLE     Biology and management of salivary gland cancers.
  JOURNAL   Semin Radiat Oncol 22:245-53 (2012)
REFERENCE   PMID:19939701 (marker, drug, tumor type)
  AUTHORS   Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L
  TITLE     Major and minor salivary gland tumors.
  JOURNAL   Crit Rev Oncol Hematol 74:134-48 (2010)
///
ENTRY       H01509                      Disease
NAME        Tonsillar cancer
DESCRIPTION Tonsillar cancer (TC) is the most common oropharyngeal cancer and tumours are mainly squamous cell carcinomas. Traditionally, risk factors for the development of TC include the use of alcohol and/or tobacco, however a significant proportion of new cases develop in young patients without these risk factors. Recent investigation suggests that human papilloma virus (HPV) may serve as an etiology in such cases and represent a unique risk factor in a sub-set of patients. Compared with HPV-negative TC, HPV-positive TC showed a strong association with p16 overexpression, and an inverse association with EGFR amplification. HPV-16 integration status was strongly associated with c-myc amplification and HIF-1a overexpression. HPV-16 integration could be directly related to tonsillar carcinogenesis initially in tonsillar crypts, followed by cell cycle aberration such as p16 overexpression related to the G1-S phase.
CATEGORY    Cancer
GENE        CDKN2A (overexpression) [HSA:1029] [KO:K06621]
            MYC (amplification) [HSA:4609] [KO:K04377]
            HIF1A (overexpression) [HSA:3091] [KO:K08268]
CARCINOGEN  Alcohol
            Tobacco
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
MARKER      human papilloma virus types 16 [RS:NC_001526]
            CDKN2A (overexpression) [HSA:1029] [KO:K06621]
DRUG        Cisplatin [DR:D00275]
            Fluorouracil [DG:DG00687]
            Paclitaxel [DG:DG01430]
            Carboplatin [DR:D01363]
            Docetaxel[DG:DG00694]
            Cetuximab [DR:D03455]
COMMENT     ICD-O-3: 8070/3 Squamous cell carcinoma, NOS
            ICD-O-3: 8082/3 Lymphoepithelioma
            ICD-O-3: 9591/3 Malignant lymphoma, non-Hodgkin, NOS
DBLINKS     ICD-10: C09.9
            MeSH: D014067
REFERENCE   PMID:12676252 (description, carcinogen, tumor type)
  AUTHORS   Genden EM, Ferlito A, Scully C, Shaha AR, Higgins K, Rinaldo A
  TITLE     Current management of tonsillar cancer.
  JOURNAL   Oral Oncol 39:337-42 (2003)
REFERENCE   PMID:25803099 (carcinogen, marker)
  AUTHORS   Ramqvist T, Grun N, Dalianis T
  TITLE     Human papillomavirus and tonsillar and base of tongue cancer.
  JOURNAL   Viruses 7:1332-43 (2015)
REFERENCE   PMID:18505048 (carcinogen, tumor type)
  AUTHORS   Dahlstrand H, Nasman A, Romanitan M, Lindquist D, Ramqvist T, Dalianis T
  TITLE     Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer.
  JOURNAL   Anticancer Res 28:1133-8 (2008)
REFERENCE   PMID:17205528 (description, gene, carcinogen)
  AUTHORS   Kim SH, Koo BS, Kang S, Park K, Kim H, Lee KR, Lee MJ, Kim JM, Choi EC, Cho NH
  TITLE     HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation.
  JOURNAL   Int J Cancer 120:1418-25 (2007)
REFERENCE   PMID:15113849 (carcinogen, tumor type)
  AUTHORS   Syrjanen S
  TITLE     HPV infections and tonsillar carcinoma.
  JOURNAL   J Clin Pathol 57:449-55 (2004)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H01510                      Disease
NAME        Malignant paraganglioma
DESCRIPTION Paragangliomas (PGLs) are rare neuroendocrine tumors that arise in sympathetic and parasympathetic paraganglia and derive from neural crest cells. Malignancy is defined by presence of metastases, tumor spread in sites where chromaffin tissue is normally absent such as lymph nodes, liver, lungs, and bones. Malignant PGLs are extremely rare. The pathogenesis and progression of PGLs are very strongly influenced by genetics. A germline mutation in one of the susceptibility genes identified so far explains ~40% of all cases; the remaining 60% are thought to be sporadic cases. Sporadic as well as hereditary PGLs have been divided in two main clusters linked to two different signalling pathways: the first cluster contains all VHL-, SDHx-, and FH- mutated tumors and is associated to the activation of hypoxic pathway, while the second cluster contains all RET- , NF1-, MAX and TMEM127- mutated tumors and is associated to the activation of MAPK and mTOR (mammalian target of rapamycin) signaling pathways.
CATEGORY    Cancer
GENE        SDHD (mutation) [HSA:6392] [KO:K00237]
            SDHB (mutation) [HSA:6390] [KO:K00235]
            SDHC (mutation) [HSA:6391] [KO:K00236]
            NF1 (mutation) [HSA:4763] [KO:K08052]
            RET (mutation) [HSA:5979] [KO:K05126]
            VHL (mutation) [HSA:7428] [KO:K03871]
            TMEM127 (mutation) [HSA:55654]
            MAX (mutation) [HSA:4149] [KO:K04453]
            EPAS1 (mutation) [HSA:2034] [KO:K09095]
            FH (mutation) [HSA:2271] [KO:K01679]
MARKER      MK167 [HSA:4288] [KO:K17582]
            hTERT [HSA:7015] [KO:K11126]
            HSP90 [HSA:3320 3326] [KO:K04079]
            COX2 [HSA:5743] [KO:K11987]
            NCAD [HSA:1000] [KO:K06736]
            VEGF [HSA:7422 7423 7424 2277] [KO:K05448 K16858 K05449]
            ETA [HSA:1909] [KO:K04197]
            ETB [HSA:1910] [KO:K04198]
DRUG        Cyclophosphamide [DG:DG00675]
            Vincristine [DG:DG00690]
            Dacarbazine [DG:DG00680]
COMMENT     ICD-O-3: 8700/3 Pheochromocytoma, malignant
            ICD-O-3: 8680/3 Paraganglioma, malignant
            ICD-O-3: 8693/3 Extra-adrenal paraganglioma, malignant
DBLINKS     ICD-10: C75.5
            MeSH: D010235
REFERENCE   PMID:25385035 (description, gene)
  AUTHORS   Favier J, Amar L, Gimenez-Roqueplo AP
  TITLE     Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.
  JOURNAL   Nat Rev Endocrinol 11:101-11 (2015)
REFERENCE   PMID:18978332 (gene)
  AUTHORS   Baysal BE
  TITLE     Clinical and molecular progress in hereditary paraganglioma.
  JOURNAL   J Med Genet 45:689-94 (2008)
REFERENCE   PMID:17298303 (gene)
  AUTHORS   Martin TP, Irving RM, Maher ER
  TITLE     The genetics of paragangliomas: a review.
  JOURNAL   Clin Otolaryngol 32:7-11 (2007)
REFERENCE   PMID:24891137 (drug)
  AUTHORS   Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C
  TITLE     Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma.
  JOURNAL   Eur J Endocrinol 171:R111-22 (2014)
REFERENCE   PMID:22851969 (description, gene, marker, drug, tumor type)
  AUTHORS   Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giache V, Mannelli M
  TITLE     Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.
  JOURNAL   J Oncol 2012:872713 (2012)
REFERENCE   PMID:17914089 (gene, marker, drug)
  AUTHORS   Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB
  TITLE     The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
  JOURNAL   Endocr Relat Cancer 14:569-85 (2007)
REFERENCE   PMID:26839173 (description, gene)
  AUTHORS   Pillai S, Gopalan V, Smith RA, Lam AK
  TITLE     Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
  JOURNAL   Crit Rev Oncol Hematol 100:190-208 (2016)
///
ENTRY       H01511                      Disease
NAME        Mast-cell leukemia
DESCRIPTION Mast cell leukemia (MCL), the leukemic manifestation of systemic mastocytosis (SM), is characterized by leukemic expansion of immature mast cells (MCs) in the bone marrow (BM) and other internal organs; and a poor prognosis. Gain-of-function mutations in the proto-oncogene c-kit that induce constitutive kinase activity of its product, KIT protein, are characteristic of various neoplastic diseases including MCL. Downstream signaling pathways, including PI3 kinase (PI3K)/AKT, are inappropriately activated, and this is believed to contribute to the abnormal proliferation and survival of these neoplastic cells. The reason why the prognosis of patients with MCL is mostly that MCs in these patients are largely resistant against conventional drugs and targeted drugs, including tyrosine kinase inhibitors (TKI) directed against KIT D816V such as PKC412 (midostaurin).
CATEGORY    Cancer
GENE        KIT (mutation) [HSA:3815] [KO:K05091]
MARKER      CD117/KIT [HSA:3815] [KO:K05091]
            Tryptase [HSA:7177 23430 64499] [KO:K01340]
            CD33/Siglec-3 [HSA:945] [KO:K06473]
            CD123/IL-3RA [HSA:3563] [KO:K04737]
            CD2/LFA-2 [HSA:914] [KO:K06449]
            CD25/IL-2RA [HSA:3559] [KO:K05068]
            CD30/Ki-1 [HSA:943] [KO:K05145]
            FCERI [HSA:2205 2207] [KO:K08089 K07983]
DRUG        Midostaurin [DR:D05029]
            Cladribine [DR:D01370]
            Corticosteroid
            Imatinib [DG:DG00710]
COMMENT     ICD-O-3: 9742/3 Mast cell leukaemia
DBLINKS     ICD-10: C94.3
            MeSH: D007946
REFERENCE   PMID:23243287 (gene, drug)
  AUTHORS   Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G
  TITLE     Mast cell leukemia.
  JOURNAL   Blood 121:1285-95 (2013)
REFERENCE   PMID:24675021 (description, gene, marker)
  AUTHORS   Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hagglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP
  TITLE     Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.
  JOURNAL   Ann Oncol 25:1691-700 (2014)
REFERENCE   PMID:22997594 (gene, marker)
  AUTHORS   Joris M, Georgin-Lavialle S, Chandesris MO, Lhermitte L, Claisse JF, Canioni D, Hanssens K, Damaj G, Hermine O, Hamidou M
  TITLE     Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.
  JOURNAL   Case Rep Hematol 2012:517546 (2012)
REFERENCE   PMID:25443885 (description, gene, marke)
  AUTHORS   Valent P, Sotlar K, Sperr WR, Reiter A, Arock M, Horny HP
  TITLE     Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological  and clinical features.
  JOURNAL   Leuk Res 39:1-5 (2015)
REFERENCE   PMID:17949810 (description, pathway, drug)
  AUTHORS   Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L
  TITLE     KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.
  JOURNAL   Leuk Res 32:761-70 (2008)
///
ENTRY       H01512                      Disease
NAME        Langerhans cell histiocytosis
DESCRIPTION Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder characterized by a clonal proliferation of specialized cells with characteristics resembling antigen-presenting cells that reside in the skin and mucosa. Its clinical presentation is variable and ranges from isolated skin or bone disease to a life-threatening multisystem condition. Historically, it has been hypothesized that the disease originated from epidermal Langerhans cells. However, new evidence supports a model in which LCH occurs as a consequence of a misguided differentiation programme of myeloid dendritic cell precursors. In LCH, there is a very high frequency of activating mutations in MAPK signaling pathway genes, most notably BRAF-V600E, as well as MAP2K1. Genetic, molecular and functional data implicate activation of the MAPK (ERK) signalling pathway at critical stages in myeloid differentiation as an essential and universal driver of LCH pathology.
CATEGORY    Cancer
GENE        BRAF (mutation) [HSA:673] [KO:K04365]
            MAP2K1 (mutation) [HSA:5604] [KO:K04368]
MARKER      CD1a [HSA:909] [KO:K06448]
            CD207 [HSA:50489] [KO:K06561]
DRUG        Vinblastine [DG:DG00689]
            Prednisone [DG:DG00094]
            Mercaptopurine [DG:DG00683]
COMMENT     ICD-O-3: 9752/1 Langerhans cell histiocytosis, unifocal
            ICD-O-3: 9753/1 Langerhans cell histiocytosis, multifocal
            ICD-O-3: 9754/3 Langerhans cell histiocytosis, disseminated
DBLINKS     ICD-10: C96.0 C96.5 C96.6
            MeSH: D006646
REFERENCE   PMID:26414464 (description, gene,marker, tumor type)
  AUTHORS   Harmon CM, Brown N
  TITLE     Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update.
  JOURNAL   Arch Pathol Lab Med 139:1211-4 (2015)
REFERENCE   PMID:25430560 (description, pathway, gene, marker, drug)
  AUTHORS   Berres ML, Merad M, Allen CE
  TITLE     Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?
  JOURNAL   Br J Haematol 169:3-13 (2015)
REFERENCE   PMID:26888790 (pathway, gene, marker)
  AUTHORS   Zinn DJ, Chakraborty R, Allen CE
  TITLE     Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.
  JOURNAL   Oncology (Williston Park) 30:122-32, 139 (2016)
REFERENCE   PMID:25310214 (description, gene, marker, drug)
  AUTHORS   Grana N
  TITLE     Langerhans cell histiocytosis.
  JOURNAL   Cancer Control 21:328-34 (2014)
REFERENCE   PMID:25827831 (pathway, gene, drug)
  AUTHORS   Allen CE, Ladisch S, McClain KL
  TITLE     How I treat Langerhans cell histiocytosis.
  JOURNAL   Blood 126:26-35 (2015)
REFERENCE   PMID:22906202 (marker)
  AUTHORS   Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ
  TITLE     Pathogenesis of Langerhans cell histiocytosis.
  JOURNAL   Annu Rev Pathol 8:1-20 (2013)
///
ENTRY       H01513                      Disease
NAME        Retinoblastoma
DESCRIPTION The retinoblastoma is an eye tumor of childhood that arises in the retina and represents the most common intraocular malignancy of infancy and childhood. Tumor formation usually begins with mutation in both alleles of the retinoblastoma tumor suppressor gene RB1, followed by a series of other genetic alterations that correlate with the clinical stage and pathologic findings of the tumor. In retinoblastoma, mutation of RB1 leads to dysfunction or absence of the Rb protein. These mutations promote tumour development by deregulating the E2F family of transcription factors leading to uncontrolled cell cycle progression.
CATEGORY    Cancer
GENE        RB1 (mutation) [HSA:5925] [KO:K06618]
            MDM4 (amplification) [HSA:4194] [KO:K10127]
            MDM2 (amplification) [HSA:4193] [KO:K06643]
            KIF14 (amplification) [HSA:9928] [KO:K17915]
            CDH11 (loss) [HSA:1009] [KO:K06803]
            p16/INK (loss) [HSA:1029] [KO:K06621]
MARKER      RB1 [HSA:5925] [KO:K06618]
DRUG        Vincristine [DG:DG00690]
            Carboplatin [DR:D01363]
            Etoposide [DG:DG00693]
COMMENT     ICD-O-3: 9510/3 Retinoblastoma, NOS
            ICD-O-3: 9511/3 Retinoblastoma, differentiated
            ICD-O-3: 9512/3 Retinoblastoma, undifferentiated
            ICD-O-3: 9513/3 Retinoblastoma, diffuse
            ICD-O-3: 9514/1 Retinoblastoma, spontaneously regressed
DBLINKS     ICD-10: C69.2
            MeSH: D012175
REFERENCE   PMID:26310174 (description, pathway, gene, drug)
  AUTHORS   Mendoza PR, Grossniklaus HE
  TITLE     The Biology of Retinoblastoma.
  JOURNAL   Prog Mol Biol Transl Sci 134:503-16 (2015)
REFERENCE   PMID:25940424 (description, drug)
  AUTHORS   Jenkinson H
  TITLE     Retinoblastoma: diagnosis and management--the UK perspective.
  JOURNAL   Arch Dis Child 100:1070-5 (2015)
REFERENCE   PMID:22414599 (pathway, gene, marker, drug)
  AUTHORS   Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, Gallie BL
  TITLE     Retinoblastoma.
  JOURNAL   Lancet 379:1436-46 (2012)
REFERENCE   PMID:23154492 (gene)
  AUTHORS   Eagle RC Jr
  TITLE     The pathology of ocular cancer.
  JOURNAL   Eye (Lond) 27:128-36 (2013)
REFERENCE   PMID:25621664 (gene)
  AUTHORS   Benavente CA, Dyer MA
  TITLE     Genetics and epigenetics of human retinoblastoma.
  JOURNAL   Annu Rev Pathol 10:547-62 (2015)
REFERENCE   PMID:15306814 (description)
  AUTHORS   Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C
  TITLE     Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.
  JOURNAL   Nature 430:797-802 (2004)
///
ENTRY       H01514                      Disease
NAME        Landau-Kleffner syndrome;
            Acquired epileptic aphasia
DESCRIPTION Landau-Kleffner syndrome (LKS) is an epileptic encephalopathy that usually manifests itself in children aged 3-8 years with previously normal development. All LKS patients have abnormal EEG that is compatible with the diagnosis of epilepsy, however, only 70% have clinical seizures. The main symptoms are acute or subacute aphasia with inability to recognise, process or interpret verbal and/or non-verbal sounds. Although the exact etiology of LKS remains unclear, families with mutations in the GRIN2A gene have been described, in which some members have LKS. Recent reports have implicated susceptibility genes (SRPX2, ELP4) to idiopathic focal epilepsies.
CATEGORY    Nervous system disease; Epilepsy
GENE        GRIN2A [HSA:2903] [KO:K05209]
            SRPX2 [HSA:27286] [KO:K19408]
            ELP4 [HSA:26610] [KO:K11375]
DRUG        Valproic acid [DG:DG00849]
            Clobazam [DR:D01253]
            Clonazepam [DR:D00280]
            Carbamazepine [DR:D00252]
            Prednisone [DG:DG00094]
            Gamma globulin [DR:D06458]
DBLINKS     ICD-10: F80.3
            MeSH: D018887
            OMIM: 245570
REFERENCE   PMID:26627294
  AUTHORS   Tuft M, Arva M, Bjornvold M, Wilson JA, Nakken KO
  TITLE     Landau-Kleffner syndrome.
  JOURNAL   Tidsskr Nor Laegeforen 135:2061-4 (2015)
REFERENCE   PMID:20637551
  AUTHORS   Deonna T, Roulet-Perez E
  TITLE     Early-onset acquired epileptic aphasia (Landau-Kleffner syndrome, LKS) and regressive autistic disorders with epileptic EEG abnormalities: the continuing debate.
  JOURNAL   Brain Dev 32:746-52 (2010)
REFERENCE   PMID:24828792 (gene)
  AUTHORS   Conroy J, McGettigan PA, McCreary D, Shah N, Collins K, Parry-Fielder B, Moran M, Hanrahan D, Deonna TW, Korff CM, Webb D, Ennis S, Lynch SA, King MD
  TITLE     Towards the identification of a genetic basis for Landau-Kleffner syndrome.
  JOURNAL   Epilepsia 55:858-65 (2014)
REFERENCE   PMID:19682046 (gene)
  AUTHORS   Rudolf G, Valenti MP, Hirsch E, Szepetowski P
  TITLE     From rolandic epilepsy to continuous spike-and-waves during sleep and Landau-Kleffner syndromes: insights into possible genetic factors.
  JOURNAL   Epilepsia 50 Suppl 7:25-8 (2009)
REFERENCE   PMID:21887181 (drug)
  AUTHORS   Bhardwaj P, Sharma VK, Sharma R, Gautam P
  TITLE     Acquired epileptic aphasia: Landau-Kleffner syndrome.
  JOURNAL   J Pediatr Neurosci 4:52-3 (2009)
REFERENCE   PMID:9118856 (drug)
  AUTHORS   Fayad MN, Choueiri R, Mikati M
  TITLE     Landau-Kleffner syndrome: consistent response to repeated intravenous gamma-globulin doses: a case report.
  JOURNAL   Epilepsia 38:489-94 (1997)
///
ENTRY       H01515                      Disease
NAME        Scarlet fever;
            Scarlatina
DESCRIPTION Scarlet fever, also called scarlatina, is caused by Streptococcus pyogenes (GroupA Streptococcus, GAS). The important diagnostic signs of scarlet fever include fever, sore throat, rash and bright red tongue with a "strawberry" appearance. Scarlet fever can affect people of all ages, but it is usually attacking children under 10.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spb stg soz spyo]
DBLINKS     ICD-10: A38
            MeSH: D012541
            MedlinePlus: 000974
REFERENCE   PMID:24331532 (description)
  AUTHORS   You YH, Song YY, Yan XM, Wang HB, Zhang MH, Tao XX, Li LL, Zhang YX, Jiang XH, Zhang BH, Zhou H, Xiao D, Jin LM, Feng ZJ, Luo FJ, Zhang JZ
  TITLE     Molecular epidemiological characteristics of Streptococcus pyogenes strains involved in an outbreak of scarlet fever in China, 2011.
  JOURNAL   Biomed Environ Sci 26:877-85 (2013)
///
ENTRY       H01516                      Disease
NAME        Adult onset Still's disease;
            Adult Still's disease
DESCRIPTION Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder. The disease manifestations are protean ranging from high fever, arthralgia, skin rash, sore throat, lymphadenopathy, and hepatosplenomegaly accompanied by systemic manifestations. Complications of AOSD include transient pulmonary hypertension, macrophage activation syndrome, diffuse alveolar hemorrhage, thrombotic thrombocytopenic purpura and amyloidosis. Common laboratory abnormalities include neutrophilic leukocytosis, abnormal liver function tests, and elevated acute-phase reactants (ESR, CRP, ferritin). The exact pathogenesis of AOSD is unknown. Several factors such as genetics, infectious (bacterial and viral) agents, and environmental factors have been thought to play a causative role. Although no familial trend has been reported in AOSD, some studies have reported an association between AOSD and gene polymorphism of HLA, IL-18, and MEFV. Recent advances have revealed a pivotal role of proinflammatory cytokines such as TNF-alpha, IL-1, IL-6, IL-8, and IL-18 in disease pathogenesis. Treatment consists of anti-inflammatory medications. Non-steroidal anti-inflammatory drugs have limited efficacy, and corticosteroid therapy and disease-modifying anti-rheumatic drugs are usually required.
CATEGORY    Immune system disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            IL-18 (polymorphism) [HSA:3606] [KO:K05482]
            MEFV (polymorphism) [HSA:4210] [KO:K12803]
ENV_FACTOR  Viruses (Rubella, measles, Echovirus 7, Coxsackievirus B4, Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, Parainfluenza, Influenza A, Adenovirus, hepatitis B and C, and Parvovirus B19)
            Bacteria (Mycoplasma pneumonia, Chlamydia pneumonia, Yersinia enterocolitica, Brucella abortus, and Borrelia burgdorferi)
MARKER      Elevated erythrocyte sedimentation rate (ESR)
            Leukocytosis (in most cases within 15,000-30,000, mainly neutrophils)
            Thrombocytopenia > 400,000
            Elevated ferritin levels
            Negative antinuclear antibody (ANA) and Rheumatoid factor (RF)
DRUG        Prednisolone [DG:DG00093]
            Tocilizumab [DR:D02596]
            Anakinra [DR:D02934]
            Cyclosporine [DR:D00184]
            Methotrexate [DG:DG00681]
            Tacrolimus [DG:DG00439]
DBLINKS     ICD-10: M06.1
            MeSH: D016706
REFERENCE   PMID:25613167
  AUTHORS   Kadavath S, Efthimiou P
  TITLE     Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options.
  JOURNAL   Ann Med 47:6-14 (2015)
REFERENCE   PMID:24657513 (gene, env-factor)
  AUTHORS   Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P
  TITLE     Adult-onset Still's disease.
  JOURNAL   Autoimmun Rev 13:708-22 (2014)
REFERENCE   PMID:27042373 (marker)
  AUTHORS   Gopalarathinam R, Orlowsky E, Kesavalu R, Yelaminchili S
  TITLE     Adult Onset Still's Disease: A Review on Diagnostic Workup and Treatment Options.
  JOURNAL   Case Rep Rheumatol 2016:6502373 (2016)
REFERENCE   PMID:17611971 (gene)
  AUTHORS   Woo JH, Seong SS, Yoo DH
  TITLE     Association of interleukin 18 polymorphisms with adult onset Still's disease in Korea.
  JOURNAL   J Rheumatol 34:1637-9 (2007)
REFERENCE   PMID:25286988 (gene)
  AUTHORS   Nonaka F, Migita K, Jiuchi Y, Shimizu T, Umeda M, Iwamoto N, Fujikawa K, Izumi Y, Mizokami A, Nakashima M, Ueki Y, Yasunami M, Kawakami A, Eguchi K
  TITLE     Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still's disease.
  JOURNAL   Clin Exp Immunol 179:392-7 (2015)
REFERENCE   PMID:26981304 (drug)
  AUTHORS   Nataraja C, Griffiths H
  TITLE     Atypical Cutaneous Manifestations in Adult Onset Still's Disease.
  JOURNAL   Case Rep Rheumatol 2016:4835147 (2016)
REFERENCE   PMID:24648814 (drug)
  AUTHORS   Ohe M, Oku K, Kono M, Bohgaki T
  TITLE     Successful treatment with tacrolimus of refractory adult-onset Still's disease.
  JOURNAL   Korean J Intern Med 29:259-61 (2014)
///
ENTRY       H01517                      Disease
NAME        Erysipelas
DESCRIPTION Streptococcus pyogenes (group A Streptococcus) is the usual etiologic agent of erysipelas. Symptoms and signs of erysipelas are chills, fever, a well-demarcated, erythematous, indurated, rapidly spreading patch with a palpable advancing border on the face or extremities. This disease most frequently affects infants, small children and the elderly.
CATEGORY    Infectious disease
PATHOGEN    Streptococcus pyogenes [GN:spy spz spym spm spg sps sph spi spj spk spf spb stg soz spyo]
DBLINKS     ICD-10: A46
            MeSH: D004886
            MedlinePlus: 000618
REFERENCE   PMID:17994173 (description)
  AUTHORS   Celestin R, Brown J, Kihiczak G, Schwartz RA
  TITLE     Erysipelas: a common potentially dangerous infection.
  JOURNAL   Acta Dermatovenerol Alp Pannonica Adriat 16:123-7 (2007)
REFERENCE   PMID:26866211 (description)
  AUTHORS   Stevens DL, Bryant AE
  TITLE     Impetigo, Erysipelas and Cellulitis
  JOURNAL   (2016)
///
ENTRY       H01518                      Disease
NAME        Lobomycosis;
            Lobo's disease;
            Lacaziosis
DESCRIPTION Lobomycosis, also known as Lobo's disease or lacaziosis, is a chronic, granulomatous and cutaneous-subcutaneous infection that primarily occurs in tropical climates of Latin America. It is a zoonotic disease in humans and some species of dolphins. Main etiological agent is Lacazia loboi, a uncultivable dimorphic onygenale fungi.
CATEGORY    Infectious disease
PATHOGEN    Lacazia loboi
DBLINKS     ICD-10: B48
            MeSH: D060368
REFERENCE   PMID:22429689 (description)
  AUTHORS   Paniz-Mondolfi A, Talhari C, Sander Hoffmann L, Connor DL, Talhari S, Bermudez-Villapol L, Hernandez-Perez M, Van Bressem MF
  TITLE     Lobomycosis: an emerging disease in humans and delphinidae.
  JOURNAL   Mycoses 55:298-309 (2012)
REFERENCE   PMID:23919604 (description)
  AUTHORS   Reif JS, Schaefer AM, Bossart GD
  TITLE     Lobomycosis: risk of zoonotic transmission from dolphins to humans.
  JOURNAL   Vector Borne Zoonotic Dis 13:689-93 (2013)
///
ENTRY       H01519                      Disease
NAME        Scabies
DESCRIPTION Scabies is a disease caused by the ectoparasitic mite Sarcoptes scabiei. Scabies is a contagious cutaneous inflammation and common among many different species of animals. S. scabiei burrows into the skin of their host, reproducing and laying eggs in the burrows. Transmission of the mite commonly occurs by skin-to-skin contact, but with crusted scabies it may also occur through fomites, such as infected clothing or bedding.
CATEGORY    Infectious disease
PATHOGEN    Sarcoptes scabiei
DBLINKS     ICD-10: B86
            MeSH: D012532
            MedlinePlus: 000830
REFERENCE   PMID:22726646 (description)
  AUTHORS   Fischer K, Holt D, Currie B, Kemp D
  TITLE     Scabies: important clinical consequences explained by new molecular studies.
  JOURNAL   Adv Parasitol 79:339-73 (2012)
///
ENTRY       H01520                      Disease
NAME        Chromomycosis;
            Chromoblastomycosis
DESCRIPTION Chromomycosis, also known as Chromoblastomycosis, is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi usually found in tropical and subtropical areas. Main etiological agents belong to Fonsecaea and Cladophialophora genus and, while scattered cases have been reported in Phialophora, Rhinocladiella and Exophiala genus.
CATEGORY    Infectious disease
PATHOGEN    Fonsecaea pedrosoi
            Fonsecaea compactum
            Cladosporium carrionii
            Phialophora verrucosa
            Rhinocladiella aquaspersa
DBLINKS     ICD-10: B43
            MeSH: D002862
REFERENCE   PMID:26465369 (description)
  AUTHORS   Queiroz-Telles F
  TITLE     CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE.
  JOURNAL   Rev Inst Med Trop Sao Paulo 57 Suppl 19:46-50 (2015)
///
ENTRY       H01521                      Disease
NAME        Pneumocystis pneumonia
DESCRIPTION Members of the genus Pneumocystis are unicellular, eukaryotic organisms that reside in the lungs of many mammals. The 5 main species are have been identified: Pneumocystis carinii and Pneumocystis wakefieldiae in rats, Pneumocystis murina in mice, Pneumocystis oryctolagi in rabbits, and Pneumocystis jirovecii in humans. P. jirovecii infection causes Pneumocystis pneumonia (PCP), a potentially life-threatening disease that occurs in immunocompromised patients.
CATEGORY    Infectious disease
PATHOGEN    Pneumocystis jirovecii
DBLINKS     ICD-10: B59
            MeSH: D011020
            MedlinePlus: 000671
REFERENCE   PMID:26281787 (description)
  AUTHORS   Sokulska M, Kicia M, Wesolowska M, Hendrich AB
  TITLE     Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review.
  JOURNAL   Parasitol Res 114:3577-85 (2015)
///
ENTRY       H01522                      Disease
NAME        Zollinger-Ellison Syndrome (ZES)
DESCRIPTION Zollinger-Ellison Syndrome (ZES) is a rare endocrinopathy caused by tumors of the pancreas and duodenum. These tumors, called gastrinomas, release gastrin to produce large amounts of acid that result in severe gastroesophageal peptic ulcer disease and diarrhea. Most ZES cases are sporadic, but about over 20 percent are caused by an inherited genetic disorder called multiple endocrine neoplasia type 1 (see H00247). The clinical presentation is not specific for this disease and there is overlap of symptoms similar to those of a peptic ulcer. The most common symptoms include abdominal pain and diarrhea, sometimes accompanied by heartburn, nausea, and weight loss.  Peptic ulceration complicated by bleeding is present in 25% of patients, and is more frequently in patients with sporadic ZES than in those with MEN1. In addition, the gastrinomas may be cancerous. The cancer can be spread to other parts of the body, most commonly to regional lymph nodes and the liver. The treatment of the ZES includes surgical removal and medical management of gastric acid hypersecretion for the prevention of malignant transformation and  the genesis of complications.
CATEGORY    Endocrine disease; Cancer
GENE        MEN1 [HSA:4221] [KO:K14970]
MARKER      Serum gastrin [HSA:2520]
DRUG        Omeprazole [DG:DG00020] Rabeprazole [DG:DG00022] Pantoprazole [DG:DG00021] Lansoprazole [DR:D00355] Esomeprazole [DG:DG00023] (Proton pump inhibitors) 
            Cimetidine [DG:DG00295] Ranitidine [DG:DG00018] Famotidine [DR:D00318] (H2-receptor antagonist)
DBLINKS     ICD-10: E16.4
            MeSH: D015043
            OMIM: 131100
REFERENCE   PMID:23363383 (description)
  AUTHORS   Ito T, Igarashi H, Uehara H, Jensen RT
  TITLE     Pharmacotherapy of Zollinger-Ellison syndrome.
  JOURNAL   Expert Opin Pharmacother 14:307-21 (2013)
REFERENCE   PMID:14747767 (description)
  AUTHORS   Gibril F, Schumann M, Pace A, Jensen RT
  TITLE     Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature.
  JOURNAL   Medicine (Baltimore) 83:43-83 (2004)
REFERENCE   PMID:24319020 (description and diagnosis)
  AUTHORS   Epelboym I, Mazeh H
  TITLE     Zollinger-Ellison syndrome: classical considerations and current controversies.
  JOURNAL   Oncologist 19:44-50 (2014)
REFERENCE   PMID:19351273 (drug)
  AUTHORS   Wilcox CM, Hirschowitz BI
  TITLE     Treatment strategies for Zollinger-Ellison syndrome.
  JOURNAL   Expert Opin Pharmacother 10:1145-57 (2009)
REFERENCE   PMID:16433582 (drug)
  AUTHORS   Nieto JM, Pisegna JR
  TITLE     The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome.
  JOURNAL   Expert Opin Pharmacother 7:169-75 (2006)
///
ENTRY       H01523                      Disease
NAME        Wiskott-Aldrich syndrome
DESCRIPTION The Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive immunodeficiency disorder, caused by mutations in the Wiskott-Aldrich syndrome protein (WASP) gene, and characterised by thrombocytopenia, small platelets, eczema, and recurrent infections associated with increased risk of autoimmunity and malignancy disorders. Recent research suggested that the WIPF1-encoded protein WIP binds to the region of WASP which is frequently mutated in patients with this disease, and WIP mutations themselves lead to an immunological disorder resembling Wiskott-Aldrich syndrome.
CATEGORY    Primary immunodeficiency
GENE        WAS [HSA:7454] [KO:K05747]
            WIPF1 [HSA:7456] [KO:K19475]
DRUG        Bone marrow transplantation
            Hematopoietic stem cell gene therapy
COMMENT     X-linked thrombocytopenia (H00978) is an allelic variant of WAS which presents with a milder phenotype, generally limited to thrombocytopenia.
            See also H00107 Other well-defined immunodeficiency syndromes.
DBLINKS     ICD-10: D82.0
            MeSH: D014923
            OMIM: 301000 614493
REFERENCE   PMID:15284122 (description, gene)
  AUTHORS   Jin Y, Mazza C, Christie JR, Giliani S, Fiorini M, Mella P, Gandellini F, Stewart DM, Zhu Q, Nelson DL, Notarangelo LD, Ochs HD
  TITLE     Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation.
  JOURNAL   Blood 104:4010-9 (2004)
REFERENCE   PMID:22231303 (gene)
  AUTHORS   Lanzi G, Moratto D, Vairo D, Masneri S, Delmonte O, Paganini T, Parolini S, Tabellini G, Mazza C, Savoldi G, Montin D, Martino S, Tovo P, Pessach IM, Massaad MJ, Ramesh N, Porta F, Plebani A, Notarangelo LD, Geha RS, Giliani S
  TITLE     A novel primary human immunodeficiency due to deficiency in the WASP-interacting  protein WIP.
  JOURNAL   J Exp Med 209:29-34 (2012)
REFERENCE   PMID:19399471 (description)
  AUTHORS   Staub E, Groene J, Heinze M, Mennerich D, Roepcke S, Klaman I, Hinzmann B, Castanos-Velez E, Pilarsky C, Mann B, Brummendorf T, Weber B, Buhr HJ, Rosenthal A
  TITLE     An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.
  JOURNAL   J Mol Med (Berl) 87:633-44 (2009)
REFERENCE   PMID:18194074 (treatment)
  AUTHORS   Galy A, Roncarolo MG, Thrasher AJ
  TITLE     Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
  JOURNAL   Expert Opin Biol Ther 8:181-90 (2008)
///
ENTRY       H01524                      Disease
NAME        DiGeorge syndrome
DESCRIPTION DiGeorge syndrome (DGS) is a primary immunodeficiency disease characterized by dysgenesis of the thymus and parathyroid glands, conotruncal cardiac anomalies, and other dysmorphic features. This syndrome is usually associated with hypocalcemia resulting from hypoparathyroidism. In most cases the initial symptom is tetany caused by hypocalcemia within 24-48 hours after birth, with symptoms by immune abnormality appearing later. Most patients with this syndrome have a genomic deletion of chromosome 22q11, including the DiGeorge critical region (DGCR). A small number of cases of DGS have defects in other chromosomes, notably 10p13. Approximately 17% of patients with the phenotypic features of this syndrome have no detectable genomic deletion. Several mutations in TBX1 have been identified recently in non-deleted patients, including missense and frameshift mutations.
CATEGORY    Primary immunodeficiency; Developmental disorder
GENE        TBX1 [HSA:6899] [KO:K10175]
DRUG        Calcium chloride [DG:DG00137]
            Vitamin D [DG:DG01606]
COMMENT     DiGeorge syndrome is closely related to H01004 Velocardiofacial syndrome.  
            See also H00107 Other well-defined immunodeficiency syndromes, and H01525 22q11.2 deletion syndrome.
DBLINKS     ICD-10: D82.1
            MeSH: D004062
            OMIM: 188400
REFERENCE   PMID:24198816
  AUTHORS   Davies EG
  TITLE     Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia.
  JOURNAL   Front Immunol 4:322 (2013)
REFERENCE   PMID:9781025 (gene)
  AUTHORS   Schuffenhauer S, Lichtner P, Peykar-Derakhshandeh P, Murken J, Haas OA, Back E, Wolff G, Zabel B, Barisic I, Rauch A, Borochowitz Z, Dallapiccola B, Ross M, Meitinger T
  TITLE     Deletion mapping on chromosome 10p and definition of a critical region for the second DiGeorge syndrome locus (DGS2).
  JOURNAL   Eur J Hum Genet 6:213-25 (1998)
REFERENCE   PMID:15703190 (gene)
  AUTHORS   Stoller JZ, Epstein JA
  TITLE     Identification of a novel nuclear localization signal in Tbx1 that is deleted in  DiGeorge syndrome patients harboring the 1223delC mutation.
  JOURNAL   Hum Mol Genet 14:885-92 (2005)
REFERENCE   PMID:11339371 (drug)
  AUTHORS   Weinzimer SA
  TITLE     Endocrine aspects of the 22q11.2 deletion syndrome.
  JOURNAL   Genet Med 3:19-22 (2001)
///
ENTRY       H01525                      Disease
NAME        22q11.2 deletion syndrome;
            DiGeorge/ Velo-Cardio-Facial syndrome;
            CATCH22
DESCRIPTION The 22q11.2 deletion syndrome is the most common microdeletion disorder with an estimated prevalence of 1 in 3000-6000 live births. Most of the patients show the common 3 Mb deletion, but proximal 1.5 Mb deletion and unusual deletions located outside the common deleted region, have been detected. Various syndromes have been associated with 22q11.2 deletion including DiGeorge syndrome (DGS), velocardiofacial syndrome (VCFS), conotruncal anomaly face syndrome (CTAF), and isolated and familial forms of cardiovascular malformation. Microdeletions of 22q11.2 have been found in more than 90% of patients with DGS and over 85% of VCFS/ CTAF patients. In addition, several patients with Opitz-GBBB syndrome have been reported with microdeletions of 22q11. The variability in the clinical expression of this disease is extremely wide. Classical features include congenital heart disease, velopharyngeal insufficiency or cleft palate, facial anomalies, speech and learning disabilities, neonatal hypocalcemia, and T-cell immune deficit. Nevertheless, the spectrum of anomalies associated with 22q11.2 deletion is becoming wider and wider. Some cardiovascular abnormalities are relatively specific for the syndrome. An interruption of the aortic arch, type-B (IAA-B) is associated with deletion 22q11 in approximately 50% of cases. Other defects including tetralogy of Fallot, double outflow right ventricle, ventricular septal defect and an aberrant origin of the right subclavian artery are frequently found.
CATEGORY    Developmental disorder
GENE        TBX1 [HSA:6899] [KO:K10175]
COMMENT     See also H01524 DiGeorge syndrome, H01004 Velocardiofacial syndrome, H00583 Opitz-GBBB syndrome, H00549 Tetralogy of Fallot, and H00918 Conotruncal heart malformations.
DBLINKS     ICD-10: Q93.8
            MeSH: D058165
            OMIM: 188400 611867
REFERENCE   PMID:25123577
  AUTHORS   Leoni C, Stevenson DA, Geiersbach KB, Paxton CN, Krock BL, Mao R, Rope AF
  TITLE     Neural tube defects and atypical deletion on 22q11.2.
  JOURNAL   Am J Med Genet A 164A:2701-6 (2014)
REFERENCE   PMID:22368650
  AUTHORS   Digilio M, Marino B, Capolino R, Dallapiccola B
  TITLE     Clinical manifestations of Deletion 22q11.2 syndrome (DiGeorge/Velo-Cardio-Facial syndrome).
  JOURNAL   Images Paediatr Cardiol 7:23-34 (2005)
REFERENCE   PMID:9268629 (gene)
  AUTHORS   Chieffo C, Garvey N, Gong W, Roe B, Zhang G, Silver L, Emanuel BS, Budarf ML
  TITLE     Isolation and characterization of a gene from the DiGeorge chromosomal region homologous to the mouse Tbx1 gene.
  JOURNAL   Genomics 43:267-77 (1997)
REFERENCE   PMID:20054531 (gene)
  AUTHORS   Scambler PJ
  TITLE     22q11 deletion syndrome: a role for TBX1 in pharyngeal and cardiovascular development.
  JOURNAL   Pediatr Cardiol 31:378-90 (2010)
REFERENCE   PMID:12644781 (gene)
  AUTHORS   Kato T, Kosaka K, Kimura M, Imamura S, Yamada O, Iwai K, Ando M, Joh-o K, Kuroe K, Ohtake A, Takao A, Momma K, Matsuoka R
  TITLE     Thrombocytopenia in patients with 22q11.2 deletion syndrome and its association with glycoprotein Ib-beta.
  JOURNAL   Genet Med 5:113-9 (2003)
///
ENTRY       H01526                      Disease
NAME        Legg-Calve-Perthes Disease
DESCRIPTION Legg-Calve-Perthes disease (LCPD) is a particular type of femoral head necrosis occurring in children. It is more common among boys, and bilateral involvement occurs in 8-24% of cases. The disease is usually diagnosed among children under age 14 years, with a peak onset between 5 and 8 years of age. There is delayed skeletal maturation and impaired growth. In addition to congenital abnormalities, LCPD is associated with greater risk of cardiovascular diseases and diseases of the blood. Most cases are sporadic, but familial cases have been described. It has been reported that COL2A1 mutations are associated with this disease.
CATEGORY    Skeletal dysplasia
DRUG        Bisphosphonate [DG:DG01600]
DBLINKS     ICD-10: M91.1
            MeSH: D007873
            OMIM: 150600
REFERENCE   PMID:26962263
  AUTHORS   Bansal T, Jaiswal R
  TITLE     Legg-Calve-Perthes disease: A must know entity for anaesthesiologists.
  JOURNAL   Indian J Anaesth 60:68-9 (2016)
REFERENCE   PMID:22270467 (drug)
  AUTHORS   Young ML, Little DG, Kim HK
  TITLE     Evidence for using bisphosphonate to treat Legg-Calve-Perthes disease.
  JOURNAL   Clin Orthop Relat Res 470:2462-75 (2012)
REFERENCE   PMID:17394019 (gene)
  AUTHORS   Miyamoto Y, Matsuda T, Kitoh H, Haga N, Ohashi H, Nishimura G, Ikegawa S
  TITLE     A recurrent mutation in type II collagen gene causes Legg-Calve-Perthes disease in a Japanese family.
  JOURNAL   Hum Genet 121:625-9 (2007)
///
ENTRY       H01527                      Disease
NAME        Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
DESCRIPTION Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a polyneuropathy that is often disabling, with more than 50% of patients reported as having temporary disability, and about 10% eventually becoming persistently disabled. The core clinical features are a chronic progressive or relapsing and remitting, symmetrical, and sensory and motor polyradiculoneuropathy causing weakness of proximal and distal muscles. The etiology is suspected to be of autoimmune origin, and the diagnosis is typically based on clinical history, neurologic examination, electrophysiologic studies, cerebrospinal fluid (CSF) studies, and pathologic examination. CIDP often responds to immune therapies including corticosteroids, plasma exchange, and high-dose intravenous immunoglobulin (IVIg).
CATEGORY    Nervous system disease; Immune system disease
DRUG        Intravenous immunoglobulin (IVIg) [DR:D08788]
            Corticosteroids
            Plasma exchange
DBLINKS     ICD-10: G61.8
            MeSH: D020277
REFERENCE   PMID:26437234 (description, drug)
  AUTHORS   Press R, Hiew FL, Rajabally YA
  TITLE     Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence  base and clinical practice.
  JOURNAL   Acta Neurol Scand 133:228-38 (2016)
REFERENCE   PMID:26203970 (description)
  AUTHORS   Nobile-Orazio E, Gallia F
  TITLE     Update on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
  JOURNAL   Curr Opin Neurol 28:480-5 (2015)
REFERENCE   PMID:26008811 (description)
  AUTHORS   Kleyman I, Brannagan TH 3rd
  TITLE     Treatment of chronic inflammatory demyelinating polyneuropathy.
  JOURNAL   Curr Neurol Neurosci Rep 15:47 (2015)
REFERENCE   PMID:16519780 (description)
  AUTHORS   Hughes RA, Allen D, Makowska A, Gregson NA
  TITLE     Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy.
  JOURNAL   J Peripher Nerv Syst 11:30-46 (2006)
///
ENTRY       H01529                      Disease
NAME        Avascular necrosis of femoral head;
            Osteonecrosis of the femoral head
DESCRIPTION Avascular necrosis of the femoral head (ANFH) is one of the most common diseases of osteonecrosis that leads to destruction of the hip joint. Osteonecrosis is a pathological process in which cellular death in the bone constituents occurs because of decreased blood flow or an interruption in the blood supply. ANFH occurs mainly in young individuals between 30 and 50 years old. The clinical manifestations of ANFH, including pain on exertion, limping gait, and discrepancy in leg length, cause considerable disability. The etiology of ANFH is unknown, but previous studies have indicated that heritable thrombophilia and hypofibrinolysis, alcohol intake, and steroid use are risk factors for ANFH. Most cases are sporadic, but familial cases have been described. It has been reported Legg-Calve-Perthes disease (LCPD) is a particular type of femoral head necrosis occurring in children. It is more common among boys, and bilateral involvement occurs in 8-24% of cases. The disease is usually diagnosed among children under age 14 years, with a peak onset between 5 and 8 years of age. There is delayed skeletal maturation and impaired growth. In addition to congenital abnormalities, LCPD is associated with greater risk of cardiovascular diseases and diseases of the blood. Most cases are sporadic, but familial cases have been described. It has been reported that COL2A1 mutations are associated with this disease. Recent studies have suggested that an association exists between ANFH and genetic polymorphisms in the plasminogen activator inhibitor (SERPINE1), vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (NOS3), and P-glycoprotein (ABCB1) genes.
CATEGORY    Skeletal dysplasia
GENE        COL2A1 (mutation) [HSA:1280] [KO:K19719]
            SERPINE1 (polymorphism) [HSA:5054] [KO:K03982]
            VEGF (polymorphism) [HSA:7422] [KO:K05448]
            NOS3 (polymorphism) [HSA:4846] [KO:K13242]
            ABCB1 (polymorphism) [HSA:5243] [KO:K05658]
DRUG        Osteotomy
            Pulsed electromagnetic field stimulation
            HMG-CoA reductase inhibitor [DG:DG01660]
            Alendronic acid [DG:DG00783]
            Enoxaparin [DG:DG00151]
COMMENT     Legg-Calve-Perthes Disease (H01526) is a particular type of ANFH occurring in children.
DBLINKS     ICD-10: M87.8
            MeSH: D005271
            OMIM: 608805
REFERENCE   PMID:15179599
  AUTHORS   Chen WM, Liu YF, Lin MW, Chen IC, Lin PY, Lin GL, Jou YS, Lin YT, Fann CS, Wu JY, Hsiao KJ, Tsai SF
  TITLE     Autosomal dominant avascular necrosis of femoral head in two Taiwanese pedigrees  and linkage to chromosome 12q13.
  JOURNAL   Am J Hum Genet 75:310-7 (2004)
REFERENCE   PMID:21671384 (gene)
  AUTHORS   Kannu P, O'Rielly DD, Hyland JC, Kokko LA
  TITLE     Avascular necrosis of the femoral head due to a novel C propeptide mutation in COL2A1.
  JOURNAL   Am J Med Genet A 155A:1759-62 (2011)
REFERENCE   PMID:26535684 (gene)
  AUTHORS   Zhou ZC, Gu SZ, Wu J, Liang QW
  TITLE     VEGF, eNOS, and ABCB1 genetic polymorphisms may increase the risk of osteonecrosis of the femoral head.
  JOURNAL   Genet Mol Res 14:13688-98 (2015)
REFERENCE   PMID:23856555 (gene)
  AUTHORS   Liang XN, Xie L, Cheng JW, Tan Z, Yao J, Liu Q, Su W, Qin X, Zhao JM
  TITLE     Association between PAI-1 4G/5G Polymorphisms and osteonecrosis of femoral head:  a meta-analysis.
  JOURNAL   Thromb Res 132:158-63 (2013)
REFERENCE   PMID:19753173 (drug)
  AUTHORS   Sen RK
  TITLE     Management of avascular necrosis of femoral head at pre-collapse stage.
  JOURNAL   Indian J Orthop 43:6-16 (2009)
REFERENCE   PMID:15657765 (treatment)
  AUTHORS   Matsusaki H, Noguchi M, Kawakami T, Tani T
  TITLE     Use of vascularized pedicle iliac bone graft combined with transtrochanteric rotational osteotomy in the treatment of avascular necrosis of the femoral head.
  JOURNAL   Arch Orthop Trauma Surg 125:95-101 (2005)
///
ENTRY       H01530                      Disease
NAME        Pinta;
            Mal del pinto;
            Carate
DESCRIPTION Treponemal infections occurring in humans comprise venereal syphilis and the non-venereal endemic treponematoses. The non-venereal endemic treponematoses are yaws, pinta, and endemic syphilis. Pinta, also known as mal del pinto or carate, is the most benign of the endemic treponematoses since it affects only the skin. This mild disease is characterized solely by alterations in skin color. Pinta is still prevalent in remote rural regions in tropical Central and South America.
CATEGORY    Infectious disease
PATHOGEN    Treponema carateum
COMMENT     See also H01318 Yaws and H01531 Bejel.
DBLINKS     ICD-10: A67
            MeSH: D010874
REFERENCE   PMID:10330597 (description)
  AUTHORS   Engelkens HJ, Vuzevski VD, Stolz E
  TITLE     Nonvenereal treponematoses in tropical countries.
  JOURNAL   Clin Dermatol 17:143-52; discussion 105-6 (1999)
REFERENCE   PMID:26304920 (description)
  AUTHORS   Stamm LV
  TITLE     Pinta: Latin America's Forgotten Disease?
  JOURNAL   Am J Trop Med Hyg 93:901-3 (2015)
REFERENCE   PMID:11825779 (pathogen)
  AUTHORS   Antal GM, Lukehart SA, Meheus AZ
  TITLE     The endemic treponematoses.
  JOURNAL   Microbes Infect 4:83-94 (2002)
///
ENTRY       H01531                      Disease
NAME        Bejel;
            Endemic syphilis
DESCRIPTION Treponemal infections occurring in humans comprise venereal syphilis and the non-venereal endemic treponematoses. The non-venereal endemic treponematoses are yaws, pinta, and bejel. Bejel, also known as endemic syphilis, is endemic in many parts of the world including Saudi Arabia. The disease usually occurs in patients living in primitive environments with low standard of hygiene. Clinical manifestations of bejel are divided into various stages. Patches on the mucous membranes, angular stomatitis, nonitchy skin eruptions, and generalized lymphadenopathy are the most important early manifestations. In the late stage, affection of skin, bones, and cartilage may lead to severe destruction, especially of the nose and palate.
CATEGORY    Infectious disease
PATHOGEN    Treponema pallidum subsp. endemicum
COMMENT     See also H01318 Yaws and H01530 Pinta.
DBLINKS     ICD-10: A65
            MeSH: D014211
REFERENCE   PMID:10330597 (description)
  AUTHORS   Engelkens HJ, Vuzevski VD, Stolz E
  TITLE     Nonvenereal treponematoses in tropical countries.
  JOURNAL   Clin Dermatol 17:143-52; discussion 105-6 (1999)
REFERENCE   PMID:2249914 (description)
  AUTHORS   Tabbara KF
  TITLE     Endemic syphilis (Bejel).
  JOURNAL   Int Ophthalmol 14:379-81 (1990)
REFERENCE   PMID:11825779 (pathogen)
  AUTHORS   Antal GM, Lukehart SA, Meheus AZ
  TITLE     The endemic treponematoses.
  JOURNAL   Microbes Infect 4:83-94 (2002)
///
ENTRY       H01532                      Disease
NAME        Gout
DESCRIPTION Gout is a kind of arthritis associated with hyperuricemia. It is triggered due to precipitation and deposition of inflammatory monosodium urate crystals in synovial and other tissues, accompanied by severe pain. The most common symptom include swelling, tenderness, warmth and redness.  Mostly, the joint at the base of the big toe is affected, gout progresses with more frequent attacks that involve multiple joints. Joint pain that used to resolve in a week to 10 days could become a milder, but constant pain. Eventually, untreated gout can cause other comorbidities such as high blood pressure, diabetes, chronic kidney disease and cardiovascular disease. The incidence of the disease is more common in 40s men than women, but gout in women after menopause appears increased risk. Recently, the onset in 20s increases. The development of gout is not only associated with sex, age, race and genetics, but also diet and lifestyle are contributed to increasing prevalence of the disease. Epidemiology studies reported that the excessive intake of alcohol and purine rich food, which excessively produce uric acid, leads to accumulation of uric acid.
CATEGORY    Metabolic disease; Skeletal dysplasia
ENV_FACTOR  Alcohol, Purine rich food, Fructose/Sugar-sweetened beverages
DRUG        Indomethacin [DG:DG00241] Celecoxib [DR:D00567] (NSAIDs)
            Colchicine [DR:D00570]
            Allopurinol [DG:DG00779] Febuxostat [DR:D01206] (Xanthine oxidase inhibitor)
            Benzbromarone [DR:D01056] Probenecid [DR:D00475] (Uricosuric drugs) 
            Pegloticase [DR:D09316] (Uricase)
            Prednisone [DG:DG00094] (Glucocorticoid)
            Sulindac [DR:D00120] Naproxen [DG:DG00455]
DBLINKS     ICD-10: M10
            MeSH: D006073
REFERENCE   PMID:25151572 (description and drug)
  AUTHORS   Dalbeth N, Lauterio TJ, Wolfe HR
  TITLE     Mechanism of action of colchicine in the treatment of gout.
  JOURNAL   Clin Ther 36:1465-79 (2014)
REFERENCE   PMID:21894471 (description and drug)
  AUTHORS   Sunkureddi P
  TITLE     Gouty arthritis: understanding the disease state and management options in primary care.
  JOURNAL   Adv Ther 28:748-60 (2011)
REFERENCE   PMID:26977282 (drug)
  AUTHORS   Bernal JA, Quilis N, Andres M, Sivera F, Pascual E
  TITLE     Gout: optimizing treatment to achieve a disease cure.
  JOURNAL   Ther Adv Chronic Dis 7:135-44 (2016)
REFERENCE   PMID:25437279 (description)
  AUTHORS   MacFarlane LA, Kim SC
  TITLE     Gout: a review of nonmodifiable and modifiable risk factors.
  JOURNAL   Rheum Dis Clin North Am 40:581-604 (2014)
///
ENTRY       H01533                      Disease
NAME        Japanese encephalitis
DESCRIPTION Japanese encephalitis (JE) is a mosquito borne zoonotic disease caused by JE virus (JEV) in eastern and southern Asia. Culex tritaeniorhynchus is the primary vector of the JE virus, although species such as Cx. gelidus, Cx. fuscocephala, and Cx. annulirostris are important secondary or regional vectors. JEV predominately affects the thalamus, anterior horns of the spinal cord, cerebral cortex, and cerebellum. It mainly affects children under 15 and is mostly asymptomatic. JEV is maintained in an enzootic cycle involving mosquitoes and amplifying vertebrate hosts, mainly pigs and wading birds.
CATEGORY    Infectious disease
PATHOGEN    Japanese encephalitis virus [GN:T40052]
COMMENT     See also H00379  Mosquito-borne viral encephalitis.
DBLINKS     ICD-10: A83.0
            MeSH: D004672
REFERENCE   PMID:19067628 (description)
  AUTHORS   van den Hurk AF, Ritchie SA, Mackenzie JS
  TITLE     Ecology and geographical expansion of Japanese encephalitis virus.
  JOURNAL   Annu Rev Entomol 54:17-35 (2009)
REFERENCE   PMID:11930023 (description)
  AUTHORS   Tiroumourougane SV, Raghava P, Srinivasan S
  TITLE     Japanese viral encephalitis.
  JOURNAL   Postgrad Med J 78:205-15 (2002)
///
ENTRY       H01534                      Disease
NAME        Western equine encephalitis
DESCRIPTION Western equine encephalitis virus (WEEV) is an enveloped RNA virus that is an arbovirus from the genus Alphavirus, family Togaviridae. WEEV circulates in North America between birds and mosquitoes, occasionally causing disease in humans and equids, and infection results in a range of disease, from mild flu-like illnesses to encephalitis, coma, and death.
CATEGORY    Infectious disease
PATHOGEN    Western equine encephalitis virus [GN:T40053]
COMMENT     See also H00379  Mosquito-borne viral encephalitis.
DBLINKS     ICD-10: A83.1
            MeSH: D020241
REFERENCE   PMID:20631130 (description)
  AUTHORS   Sherman MB, Weaver SC
  TITLE     Structure of the recombinant alphavirus Western equine encephalitis virus revealed by cryoelectron microscopy.
  JOURNAL   J Virol 84:9775-82 (2010)
REFERENCE   PMID:24899192 (description)
  AUTHORS   Bergren NA, Auguste AJ, Forrester NL, Negi SS, Braun WA, Weaver SC
  TITLE     Western equine encephalitis virus: evolutionary analysis of a declining alphavirus based on complete genome sequences.
  JOURNAL   J Virol 88:9260-7 (2014)
///
ENTRY       H01535                      Disease
NAME        Eastern equine encephalitis
DESCRIPTION Eastern equine encephalitis virus (EEEV) is important zoonotic pathogen that is an arbovirus from the genus Alphavirus, family Togaviridae. EEEV has been shown to infect horses, humans, birds, and other animals. The primary vector of EEEV is ornithophagic mosquito, Culiseta melanura. Eastern equine encephalitis is the most severe neuroinvasive arboviral infection in the United States, frequently progressing to coma and death.
CATEGORY    Infectious disease
PATHOGEN    Eastern equine encephalitis virus [GN:T40054]
COMMENT     See also H00379 Mosquito-borne viral encephalitis.
DBLINKS     ICD-10: A83.2
            MeSH: D020242
REFERENCE   PMID:19889755 (description)
  AUTHORS   Arrigo NC, Adams AP, Weaver SC
  TITLE     Evolutionary patterns of eastern equine encephalitis virus in North versus South  America suggest ecological differences and taxonomic revision.
  JOURNAL   J Virol 84:1014-25 (2010)
REFERENCE   PMID:26740855 (description)
  AUTHORS   Mukerji SS, Lam AD, Wilson MR
  TITLE     Eastern Equine Encephalitis Treated With Intravenous Immunoglobulins.
  JOURNAL   Neurohospitalist 6:29-31 (2016)
REFERENCE   PMID:25070997 (description)
  AUTHORS   Bingham AM, Burkett-Cadena ND, Hassan HK, McClure CJ, Unnasch TR
  TITLE     Field investigations of winter transmission of eastern equine encephalitis virus  in Florida.
  JOURNAL   Am J Trop Med Hyg 91:685-93 (2014)
///
ENTRY       H01536                      Disease
NAME        Murray Valley encephalitis;
            Australian encephalitis
DESCRIPTION Murray Valley encephalitis virus (MVEV) is considered the pathogenic agent of Murray Valley encephalitis (previously known as Australian encephalitis) and a significant arboviral pathogen capable of causing severe neurological infections in humans and horses. Murray Valley encephalitis is endemic in Northern West Australia and Papua New Guinea. MVEV is a mosquito-borne pathogen and primarily exists in a transmission cycle between Culex annulirostris and birds.
CATEGORY    Infectious disease
PATHOGEN    Murray Valley encephalitis virus [GN:T40055]
COMMENT     See also H00379  Mosquito-borne viral encephalitis.
DBLINKS     ICD-10: A83.4
REFERENCE   PMID:27086158 (description)
  AUTHORS   Cella E, Gabrielli I, Zehender G, Giovanetti M, Lo Presti A, Lai A, Dicuonzo G, Angeletti S, Salemi M, Ciccozzi M
  TITLE     Phylogeny of Murray Valley encephalitis virus in Australia and Papua New Guinea.
  JOURNAL   Asian Pac J Trop Med 9:385-9 (2016)
///
ENTRY       H01537                      Disease
NAME        California encephalitis;
            La Crosse encephalitis
DESCRIPTION California encephalitis is caused primarily by La Crosse virus, the most pathogenic agent of the California encephalitis serogroup, family Bunyaviridae. Its vector and primary host, Ochlerotatus triseriatus (also known by the synonym Aedes triseriatus), the Eastern Treehole Mosquito, transmits the virus to humans. Arbovirus infections in humans are primarily central nervous system infections, but other clinical manifestations include febrile illness and fever with hemorrhagic diathesis.
CATEGORY    Infectious disease
PATHOGEN    La Crosse virus [GN:T40056]
COMMENT     See also H00379  Mosquito-borne viral encephalitis.
DBLINKS     ICD-10: A83.5
            MeSH: D004670
REFERENCE   PMID:11384526 (description)
  AUTHORS   Eldridge BF, Glaser C, Pedrin RE, Chiles RE
  TITLE     The first reported case of California encephalitis in more than 50 years.
  JOURNAL   Emerg Infect Dis 7:451-2 (2001)
REFERENCE   PMID:3613 (description)
  AUTHORS   Balfour HH Jr, Edelman CK, Bauer H, Siem RA
  TITLE     California arbovirus (La Crosse) infections. III. Epidemiology of California encephalitis in Minnesota.
  JOURNAL   J Infect Dis 133:293-301 (1976)
REFERENCE   PMID:27086496 (description)
  AUTHORS   Teleron AL, Rose BK, Williams DM, Kemper SE, McJunkin JE
  TITLE     La Crosse Encephalitis: An Adult Case Series.
  JOURNAL   Am J Med (2016)
///
ENTRY       H01538                      Disease
NAME        Hendra virus infection
DESCRIPTION Hendra virus (HeV) is an enveloped, single-stranded negative sense RNA virus that is a prototype member of the genus Henipavirus in the family Paramyxoviridae. HeV is a zoonotic virus that emerged in 1994 in the Brisbane suburb of Hendra, Queensland, Australia. HeV causes severe respiratory and neurological disease. The known natural reservoir hosts of HeV are several species of pteropid fruit bats.
CATEGORY    Infectious disease
PATHOGEN    Hendra virus [GN:T40046]
COMMENT     See also H00391  Henipavirus infection.
DBLINKS     ICD-10: B33.8
REFERENCE   PMID:27154393 (description)
  AUTHORS   Broder CC, Weir DL, Reid PA
  TITLE     Hendra virus and Nipah virus animal vaccines.
  JOURNAL   Vaccine (2016)
REFERENCE   PMID:25281398 (description)
  AUTHORS   Middleton D
  TITLE     Hendra virus.
  JOURNAL   Vet Clin North Am Equine Pract 30:579-89 (2014)
///
ENTRY       H01539                      Disease
NAME        Nipah virus infection
DESCRIPTION Nipah virus (NiV) is an enveloped, single-stranded negative sense RNA virus that is a prototype member of the genus Henipavirus in the family Paramyxoviridae. NiV is a zoonotic virus that emerged in Malaysia and Singapore in 1998-1999 causing a large outbreak of encephalitis with high mortality in people and also respiratory disease in pigs which served as amplifying hosts. The known natural reservoir hosts of NiV are several species of pteropid fruit bats.
CATEGORY    Infectious disease
PATHOGEN    Nipah virus [GN:T40047]
COMMENT     See also H00391  Henipavirus infection.
DBLINKS     ICD-10: B33.8
REFERENCE   PMID:27154393 (description)
  AUTHORS   Broder CC, Weir DL, Reid PA
  TITLE     Hendra virus and Nipah virus animal vaccines.
  JOURNAL   Vaccine (2016)
///
ENTRY       H01540                      Disease
NAME        Chikungunya fever
DESCRIPTION Chikungunya fever is an acute febrile illness associated with severe, often debilitating polyarthralgias. The disease is caused by Chikungunya virus (CHIKV), an arthropod-borne virus that is transmitted by Aedes mosquitoes. CHIKV was first recognized as a human pathogen during the 1950s in Africa, and since then, cases have been identified in many countries in Africa and Asia. Since a re-emergence of CHIKV in 2004, the virus has spread into novel locations, such as Europe, and has led to millions of cases of disease throughout countries in and around the Indian Ocean. Symptomatic patients generally report an abrupt onset of disease characterised by high fever, polyarthralgia, backache, headache, and fatigue. Fever and characteristic clinical symptoms appear within 4-7 days. Polyarthralgia is reported in 87-98% of cases and represents the most characteristic symptom. In children, clinical manifestations of chikungunya fever appear to be quite specific. The main clinical characteristics in infants are the high prevalence of dermatological manifestations (hyperpigmentation, generalised erythema, maculopapular rash and vesicuobullous lesions) and neurological complications (encephalitis, seizures, meningeal syndrome or acute encephalopathy). Treatment for chikungunya fever is limited to supportive care, such as rest, fluids, antipyretics, and analgesics. Several drugs are known to be effective against CHIKV when tested in vitro, but no recognised antiviral treatment is currently available.
CATEGORY    Infectious disease
PATHOGEN    Chikungunya virus [GN:T40026]
MARKER      Viral RNA in serum (RT-PCR)
            Anti-CHIKV IgM and IgG antibodies (ELISAs)
            Lymphopenia
            Elevated liver enzymes
            Anemia
            Elevated creatinine
DRUG        Acetaminophen [DR:D00217]
            Chloroquine [DG:DG01014], Acyclovir [DG:DG00406], Ribavirin [DR:D00423], Interferon alpha [DG:DG01750] (still under evaluation)
COMMENT     See also H00382 Mosquito-borne viral fevers.
DBLINKS     ICD-10: A92.0
            MeSH: D065632
REFERENCE   PMID:19663604 (description, drug)
  AUTHORS   Staples JE, Breiman RF, Powers AM
  TITLE     Chikungunya fever: an epidemiological review of a re-emerging infectious disease.
  JOURNAL   Clin Infect Dis 49:942-8 (2009)
REFERENCE   PMID:23811281 (description, marker)
  AUTHORS   Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X
  TITLE     Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy.
  JOURNAL   Antiviral Res 99:345-70 (2013)
///
ENTRY       H01541                      Disease
NAME        Argentine hemorrhagic fever
DESCRIPTION Argentine hemorrhagic fever (AHF) is a rodent-borne illness caused by Junin virus (JUNV, Arenaviridae). AHF is endemic to the humid pampas of Argentina. The known principal reservoir host of JUNV is Calomys musculinus. AHF can be divided into three distinct phases: prodromal, neurological-hemorrhagic, and convalescent. The prodromal phase includes non-specific symptoms such as fever (38-39 deg C), malaise and myalgia as well as petechiae on the soft palate and cutaneous petechiae. Around 20-30 percent of AHF cases progress to the neurologic-hemorrhagic phase of disease characterized by severe hemorrhagic or neurological manifestations and shock.
CATEGORY    Infectious disease
PATHOGEN    Junin mammarenavirus [GN:T40005]
COMMENT     See also H00385  South American (new world arenaviral) hemorrhagic fevers.
DBLINKS     ICD-10: A96.0
            MeSH: D006478
REFERENCE   PMID:18054395 (description)
  AUTHORS   Enria DA, Briggiler AM, Sanchez Z
  TITLE     Treatment of Argentine hemorrhagic fever.
  JOURNAL   Antiviral Res 78:132-9 (2008)
REFERENCE   PMID:21572983 (description)
  AUTHORS   Groseth A, Hoenen T, Weber M, Wolff S, Herwig A, Kaufmann A, Becker S
  TITLE     Tacaribe virus but not junin virus infection induces cytokine release from primary human monocytes and macrophages.
  JOURNAL   PLoS Negl Trop Dis 5:e1137 (2011)
///
ENTRY       H01542                      Disease
NAME        Bolivian hemorrhagic fever
DESCRIPTION Bolivian hemorrhagic fever (BHF) is highly lethal viral hemorrhagic fever caused by Machupo virus (MACV) that is a member of the family Arenaviridae. Natural vector and reservoir for MACV is the large vesper mouse, Calomys callosus. BHF was first described in 1959 during outbreaks affecting isolated human communities in eastern Bolivia. Initial symptoms include headache, fever, arthralgia, and myalgia. In the later stages of this illness, patients may develop hemorrhagic manifestations including subconjunctival hemorrhage, epistaxis, hematemesis, melena, and hematuria, as well as neurological signs including tremor, seizures, and coma.
CATEGORY    Infectious disease
PATHOGEN    Machupo mammarenavirus [GN:T40006]
COMMENT     See also H00385 South American (new world arenaviral) hemorrhagic fevers.
DBLINKS     ICD-10: A96.1
            MeSH: D006478
REFERENCE   PMID:24636947 (description)
  AUTHORS   Patterson M, Grant A, Paessler S
  TITLE     Epidemiology and pathogenesis of Bolivian hemorrhagic fever.
  JOURNAL   Curr Opin Virol 5:82-90 (2014)
REFERENCE   PMID:19788833 (description)
  AUTHORS   Aguilar PV, Camargo W, Vargas J, Guevara C, Roca Y, Felices V, Laguna-Torres VA, Tesh R, Ksiazek TG, Kochel TJ
  TITLE     Reemergence of Bolivian hemorrhagic fever, 2007-2008.
  JOURNAL   Emerg Infect Dis 15:1526-8 (2009)
REFERENCE   PMID:9145749 (description)
  AUTHORS   Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, Montenegro MJ, Costales MA, Paredes LC, Peters CJ
  TITLE     Treatment of Bolivian hemorrhagic fever with intravenous ribavirin.
  JOURNAL   Clin Infect Dis 24:718-22 (1997)
///
ENTRY       H01543                      Disease
NAME        Venezuelan hemorrhagic fever
DESCRIPTION Venezuelan hemorrhagic fever (VHF) is a severe hemorrhagic illness caused by Guanarito virus which is a newly recognized member of the Tacaribe complex of the family Arenaviridae. VHF is endemic in the municipality of Guanarito and other localities in the plains of central Venezuela. VHF is characterized by the gradual onset of chills, fever, headache, myalgia, sore throat, weakness, anorexia, nausea, and vomiting. Zygodontomys brevicauda is a natural host of Guanarito virus.
CATEGORY    Infectious disease
PATHOGEN    Guanarito mammarenavirus [GN:T40007]
COMMENT     See also H00385 South American (new world arenaviral) hemorrhagic fevers.
DBLINKS     ICD-10: A96.8
REFERENCE   PMID:7840443 (description)
  AUTHORS   Tesh RB
  TITLE     The emerging epidemiology of Venezuelan hemorrhagic fever and Oropouche fever in  tropical South America.
  JOURNAL   Ann N Y Acad Sci 740:129-37 (1994)
REFERENCE   PMID:10479119 (description)
  AUTHORS   Fulhorst CF, Ksiazek TG, Peters CJ, Tesh RB
  TITLE     Experimental infection of the cane mouse Zygodontomys brevicauda (family Muridae) with guanarito virus (Arenaviridae), the etiologic agent of Venezuelan hemorrhagic fever.
  JOURNAL   J Infect Dis 180:966-9 (1999)
///
ENTRY       H01544                      Disease
NAME        Brazilian hemorrhagic fever
DESCRIPTION Brazilian hemorrhagic fever is caused by the Sabia virus that is a new member of the Tacaribe complex of the family Arenaviridae. Sabia virus was first isolated in Sao Paulo, Brazil, in 1990 from an agricultural engineer who presented with a hemorrhagic fever syndrome and ultimately died. Necrosis of the liver was found at autopsy. Other symptoms may include fever, malaise, backache, stiff neck, myalgia.
CATEGORY    Infectious disease
PATHOGEN    Sabia mammarenavirus [GN:T40008]
COMMENT     See also H00385 South American (new world arenaviral) hemorrhagic fevers.
DBLINKS     ICD-10: A96.8
REFERENCE   PMID:7596373 (description)
  AUTHORS   Barry M, Russi M, Armstrong L, Geller D, Tesh R, Dembry L, Gonzalez JP, Khan AS, Peters CJ
  TITLE     Brief report: treatment of a laboratory-acquired Sabia virus infection.
  JOURNAL   N Engl J Med 333:294-6 (1995)
REFERENCE   PMID:9018837 (description)
  AUTHORS   Gandsman EJ, Aaslestad HG, Ouimet TC, Rupp WD
  TITLE     Sabia virus incident at Yale University.
  JOURNAL   Am Ind Hyg Assoc J 58:51-3 (1997)
///
ENTRY       H01545                      Disease
NAME        O'nyong-nyong fever
DESCRIPTION O'nyong-nyong fever is one of the mosquito-borne viral fevers. The disease is caused by o'nyong-nyong virus (ONNV), an alphavirus that is transmitted by anopheline mosquitoes. ONNV has been involved in large scale epidemics in Africa. Although no fatalities occurred, the 1959-1962 epidemic involved more than two million cases. In 1996, ONNV was the cause of another epidemic in Uganda after an absence of 35 years. ONNV produces symptoms such as fever, althralgia, and rash that generally last for less than one week. Analgesics and/or NSAIDs remain the main treatment options for the symptoms of arthritogenic alphaviral disease.
CATEGORY    Infectious disease
PATHOGEN    O'nyong-nyong virus [GN:T40027]
MARKER      Serodiagnosis by IgM and IgG ELISA tests
            PCR-based diagnosis
DRUG        Acetaminophen [DR:D00217]
COMMENT     See also H00382 Mosquito-borne viral fevers.
DBLINKS     ICD-10: A92.1
            MeSH: D018354
REFERENCE   PMID:16607002
  AUTHORS   Vanlandingham DL, Tsetsarkin K, Klingler KA, Hong C, McElroy KL, Lehane MJ, Higgs S
  TITLE     Determinants of vector specificity of o'nyong nyong and chikungunya viruses in Anopheles and Aedes mosquitoes.
  JOURNAL   Am J Trop Med Hyg 74:663-9 (2006)
REFERENCE   PMID:22565316 (marker, drug)
  AUTHORS   Suhrbier A, Jaffar-Bandjee MC, Gasque P
  TITLE     Arthritogenic alphaviruses--an overview.
  JOURNAL   Nat Rev Rheumatol 8:420-9 (2012)
///
ENTRY       H01546                      Disease
NAME        Mayaro fever
DESCRIPTION Mayaro fever is one of the mosquito-borne viral fevers. The disease is caused by Mayaro virus (MAYV), an alphavirus that is transmitted by Haemagogus mosquitoes. MAYV was first isolated in 1954 and is enzootic in northern South America. The virus causes sporadic human cases and recurrent small outbreaks, usually associated with residence in, or travel to, humid tropical forests. MAYV produces symptoms such as fever, althralgia, and rash that generally last for less than one week. Analgesics and/or NSAIDs remain the main treatment options for the symptoms of arthritogenic alphaviral disease.
CATEGORY    Infectious disease
PATHOGEN    Mayaro virus [GN:T40032]
MARKER      Serodiagnosis by IgM ELISA tests
            PCR-based diagnosis
DRUG        Acetaminophen [DR:D00217]
            Ibuprofen [DG:DG00245]
            Naproxen [DG:DG00455]
COMMENT     See also H00382 Mosquito-borne viral fevers.
DBLINKS     ICD-10: A92.8
            MeSH: D018354
REFERENCE   PMID:19891877
  AUTHORS   Azevedo RS, Silva EV, Carvalho VL, Rodrigues SG, Nunes-Neto JP, Monteiro H, Peixoto VS, Chiang JO, Nunes MR, Vasconcelos PF
  TITLE     Mayaro fever virus, Brazilian Amazon.
  JOURNAL   Emerg Infect Dis 15:1830-2 (2009)
REFERENCE   PMID:22565316
  AUTHORS   Suhrbier A, Jaffar-Bandjee MC, Gasque P
  TITLE     Arthritogenic alphaviruses--an overview.
  JOURNAL   Nat Rev Rheumatol 8:420-9 (2012)
REFERENCE   PMID:25626645 (drug, marker)
  AUTHORS   Figueiredo ML, Figueiredo LT
  TITLE     Emerging alphaviruses in the Americas: Chikungunya and Mayaro.
  JOURNAL   Rev Soc Bras Med Trop 47:677-83 (2014)
///
ENTRY       H01547                      Disease
NAME        Venezuelan equine fever
DESCRIPTION Venezuelan equine fever is one of the mosquito-borne viral fevers. The disease is caused by Venezuelan equine encephalitis virus (VEEV), an alphavirus that is transmitted by Ochlerotatus mosquitoes. VEEV is the most important human and equine pathogen. VEEV has caused periodic outbreaks of febrile and neurological disease, primarily in Latin America. VEEV is also a highly developed biological weapon amenable to use in warfare or terrorism. In human VEEV infection the incubation period is usually 2-5 days. Symptoms appear abruptly, including malaise, fever, chills, and severe retro-orbital or occipital headache. Myalgia typically centers in the thighs and lumbar region of the back. Signs usually include leukopenia and tachycardia, and are frequently accompanied by nausea, vomiting, and diarrhea. Symptoms of central nervous system involvement include convulsions, somnolence, confusion, and photo-phobia. Acute disease usually subsides 4-6 days after onset, followed by asthenia of several weeks duration. Occasionally, illness is biphasic with recurrence 4-8 days after onset. A small proportion of human cases proceed to stupor and coma and are sometimes followed by death.
CATEGORY    Infectious disease
PATHOGEN    Venezuelan equine encephalitis virus [GN:T40028]
MARKER      Serodiagnosis by IgM ELISA tests
            PCR-based diagnosis
COMMENT     See also H00382 Mosquito-borne viral fevers.
DBLINKS     ICD-10: A92.2
            MeSH: D004685
REFERENCE   PMID:23968890
  AUTHORS   Taylor KG, Paessler S
  TITLE     Pathogenesis of Venezuelan equine encephalitis.
  JOURNAL   Vet Microbiol 167:145-50 (2013)
REFERENCE   PMID:14651460
  AUTHORS   Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC
  TITLE     Venezuelan equine encephalitis.
  JOURNAL   Annu Rev Entomol 49:141-74 (2004)
///
ENTRY       H01548                      Disease
NAME        West Nile fever;
            West Nile virus infection
DESCRIPTION West Nile fever is one of the mosquito-borne viral fevers caused by West Nile virus (WNV). WNV is a neurotropic, flavivirus that is maintained in an enzootic cycle between mosquitoes and birds, but can also infect and cause disease in horses and humans. However, approximately 80% of people who are infected will not show any symptoms. WNV is endemic in parts of Africa, Europe, the Middle East, and Asia, and since 1999 has spread to North America, Mexico, South America, and the Caribbean. Symptoms are of sudden onset and may include malaise, eye pain, headache, myalgia, gastro-intestinal discomfort and rash. A small percentage of cases may develop encephalitis, meningitis, or acute flaccid paralysis, and long-term neurological sequelae are common in more than 50% of these cases. Currently, no specific therapy or vaccine has been approved for use against WNV infection in humans.
CATEGORY    Infectious disease
PATHOGEN    West Nile virus [GN:T40029]
COMMENT     See also H00382 Mosquito-borne viral fevers.
DBLINKS     ICD-10: A92.3
            MeSH: D014901
REFERENCE   PMID:21994755
  AUTHORS   Lim SM, Koraka P, Osterhaus AD, Martina BE
  TITLE     West Nile virus: immunity and pathogenesis.
  JOURNAL   Viruses 3:811-28 (2011)
REFERENCE   PMID:11352595 (marker)
  AUTHORS   Hadfield TL, Turell M, Dempsey MP, David J, Park EJ
  TITLE     Detection of West Nile virus in mosquitoes by RT-PCR.
  JOURNAL   Mol Cell Probes 15:147-50 (2001)
///
ENTRY       H01549                      Disease
NAME        Rift Valley fever
DESCRIPTION Rift Valley fever is one of the mosquito-borne viral fevers caused by Rift Valley fever virus (RVFV), genus Phlebovirus, family Bunyaviridae. RVFV is a zoonotic pathogen that primarily affects ruminants but can also be lethal in humans. In humans, the disease is generally of short duration and presents clinically as a mild self-limiting illness. The incubation period is generally 3-6 days, after which a sometimes biphasic febrile period follows that may last for several days. Patients may suffer from general malaise including a feeling of nausea, profuse sweating, sensation of fullness over the liver, vertigo, constipation, severe headache and pain in the back, shoulders and legs and may experience photophobia. In a few cases (1-2%), the disease can be more serious with complications which may include acute hepatitis, encephalitis, retinitis, and hemorrhagic syndrome with high mortality. While outbreaks have traditionally occurred in sub-Saharan Africa, recent outbreaks in the Middle East have raised awareness of the potential of this virus to spread to Europe, Asia, and the Americas.
CATEGORY    Infectious disease
PATHOGEN    Rift Valley fever virus [GN:T40030]
MARKER      Serodiagnosis by IgM and IgG  ELISA tests
            PCR-based diagnosis
DRUG        Ribavirin [DR:D00423]
COMMENT     See also H00382 Mosquito-borne viral fevers.
DBLINKS     ICD-10: A92.4
            MeSH: D012295
REFERENCE   PMID:21450816
  AUTHORS   Boshra H, Lorenzo G, Busquets N, Brun A
  TITLE     Rift valley fever: recent insights into pathogenesis and prevention.
  JOURNAL   J Virol 85:6098-105 (2011)
REFERENCE   PMID:22841800 (marker)
  AUTHORS   Mwaengo D, Lorenzo G, Iglesias J, Warigia M, Sang R, Bishop RP, Brun A
  TITLE     Detection and identification of Rift Valley fever virus in mosquito vectors by quantitative real-time PCR.
  JOURNAL   Virus Res 169:137-43 (2012)
REFERENCE   PMID:24486952 (drug)
  AUTHORS   Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB
  TITLE     Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.
  JOURNAL   Antiviral Res 104:84-92 (2014)
///
ENTRY       H01550                      Disease
NAME        Bunyamwera fever
DESCRIPTION Bunyamwera fever is a febrile illness of humans in Africa caused by the Bunyamwera virus. Symptoms include febrile illness, headache, arthralgia, rash and infrequent central nervous system involvement. Bunyamwera virus is the prototype virus of the Orthobunyavirus genus as well as the Bunyaviridae family of arboviruses. Orthobunyavirus, is composed of over 150 viruses that infect humans and are transmitted by mosquitoes, midges and ticks from reservoir animals like rodents and livestock. Orthobunyaviruses were generally not associated with haemorrhagic symptoms until Ngari virus was implicated in haemorrhagic fever outbreaks in East Africa. Their potential to reassort and cause severe human disease has been suggested.
CATEGORY    Infectious disease
PATHOGEN    Bunyamwera virus [GN:T40031]
DBLINKS     ICD-10: A92.8
            MeSH: D002042
REFERENCE   PMID:26118981
  AUTHORS   Odhiambo C, Venter M, Lwande O, Swanepoel R, Sang R
  TITLE     Phylogenetic analysis of Bunyamwera and Ngari viruses (family Bunyaviridae, genus Orthobunyavirus) isolated in Kenya.
  JOURNAL   Epidemiol Infect 144:389-95 (2016)
///
ENTRY       H01551                      Disease
NAME        Interstitial cystitis (IC);
            Bladder pain syndrome (BPS)
DESCRIPTION Interstitial cystitis (IC), also referred to as bladder pain syndrome (BPS), is a chronic non-infectious inflammatory condition characterized by recurring discomfort, pain or pressure in the bladder and the surrounding pelvic region. IC/BPS most often affect females compared with males. The affected individuals experience urinary frequency and urgency. The duration of irritative symptoms associated with unpleasant sensation are longer than six weeks duration. At present, there are two major subtypes of IC/BPS: those with or without Hunner lesion, which are also known as ulcerative or non-ulcerative IC/BPS, respectively.
CATEGORY    Urinary system disease
DRUG        Pentosan polysulfate [DR:D05428]
            Oxybutynin [DG:DG00478] Tolterodine [DG:DG00480] (Anticholinergic drugs)
DBLINKS     ICD-10: N30.1
            MeSH: D018856
REFERENCE   PMID:26535808 (description and drug)
  AUTHORS   Ogawa T, Ishizuka O, Ueda T, Tyagi P, Chancellor MB, Yoshimura N
  TITLE     Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS).
  JOURNAL   Expert Opin Emerg Drugs 20:555-70 (2015)
REFERENCE   PMID:10799190 (drug)
  AUTHORS   Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G
  TITLE     Interstitial cystitis: bladder training with intravesical oxybutynin.
  JOURNAL   J Urol 163:1818-22 (2000)
REFERENCE   PMID:17853025 (description and drug)
  AUTHORS   Taneja R, Jawade KK
  TITLE     A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis.
  JOURNAL   Scand J Urol Nephrol 41:511-5 (2007)
///
ENTRY       H01552                      Disease
NAME        Down syndrome;
            Trisomy 21
DESCRIPTION Down syndrome (DS), a genetic condition characterized by mental retardation and distinctive facial appearance, is caused by trisomy of chromosome 21 (HSA21). Down syndrome (DS) is the most common chromosomal malformation in newborns. Throughout the world, the overall prevalence of DS is 1 per 1,000 live births, although in recent years this figure has been increasing. Roughly 95% of cases of DS are due to the presence of an extra (third) copy of HSA21.  Most often, the non-disjunction event leading to DS occurs in maternal meiosis I. In about 5% of patients, 1 copy is translocated to another acrocentric chromosome, most often chromosome 14 or 21. In 2 to 4% of cases with free trisomy 21 there is recognizable mosaicism for a trisomic and a normal cell line. DS occurs at a much higher incidence in older mothers. Nonetheless, the vast majority of DS births are to younger mothers. Clinical and experimental studies have shown that age independent DNA hypo-methylation is associated with chromosomal instability and abnormal segregation. Recent studies have linked the increased frequency of polymorphism of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase gene (MTRR) in mothers with DS child. The phenotypic features of DS are quite variable from person to person and include learning disability, heart defects, early-onset Alzheimer's disease and childhood leukaemia. This phenotypic variation is likely to be caused by a combination of environmental and genetic causes. Genetic polymorphisms in both Hsa21 and non-Hsa21 genes may account for much of this variation. Trisomy of Hsa21 has a significant impact on the development of many tissues, most notably the heart and the brain. A recent paper has suggested that RCAN1 and DYRK1A, localized in the Down syndrome critical region (DSCR) of HSA21, may have an impact on the development of multiple tissues.
CATEGORY    Chromosomal abnormality
GENE        RCAN1 [HSA:1827] [KO:K17901]
            DYRK1A [HSA:1859] [KO:K08825]
            MTHFR (maternal polymorphism) [HSA:4524] [KO:K00297]
            MTRR (maternal polymorphism) [HSA:4552] [KO:K00597]
MARKER      Alphafetoprotein (AFP), Human chorionic gonadotrophin (hCG), Unconjungated estriol (uE3), Inhibin-A (serum screening)
            Amniotic diagnosis
            Chorionic villus sampling (CVS)
            Noninvasive prenatal testing (NIPT)
DBLINKS     ICD-10: Q90
            MeSH: D004314
            OMIM: 190685
REFERENCE   PMID:19297404
  AUTHORS   Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM
  TITLE     Down syndrome--recent progress and future prospects.
  JOURNAL   Hum Mol Genet 18:R75-83 (2009)
REFERENCE   PMID:18660978
  AUTHORS   Sommer C, Henrique-Silva F
  TITLE     Trisomy 21 and Down syndrome: a short review.
  JOURNAL   Braz J Biol 68:447-52 (2008)
REFERENCE   PMID:26062604 (gene, marker)
  AUTHORS   Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S
  TITLE     "Down syndrome: an insight of the disease".
  JOURNAL   J Biomed Sci 22:41 (2015)
REFERENCE   PMID:22354166 (gene)
  AUTHORS   Birger Y, Izraeli S
  TITLE     DYRK1A in Down syndrome: an oncogene or tumor suppressor?
  JOURNAL   J Clin Invest 122:807-10 (2012)
REFERENCE   PMID:12626825 (maternal polymorphism)
  AUTHORS   Sheth JJ, Sheth FJ
  TITLE     Gene polymorphism and folate metabolism: a maternal risk factor for Down syndrome.
  JOURNAL   Indian Pediatr 40:115-23 (2003)
REFERENCE   PMID:16390612 (marker)
  AUTHORS   Harrison G, Goldie D
  TITLE     Second-trimester Down's syndrome serum screening: double, triple or quadruple marker testing?
  JOURNAL   Ann Clin Biochem 43:67-72 (2006)
REFERENCE   PMID:25598039 (marker)
  AUTHORS   Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, Zhu Z, Lin M, Liu Q, Tian Z, Zhang H, Chen F, Lau TK, Zhao L, Yi X, Yin Y, Wang W
  TITLE     Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies.
  JOURNAL   Ultrasound Obstet Gynecol 45:530-8 (2015)
///
ENTRY       H01553                      Disease
NAME        Zika fever;
            Zika virus disease
DESCRIPTION Zika fever is one of the mosquito-borne viral fevers caused by Zika virus (ZIKV), genus Flavivirus, family Flaviviridae. ZIKV is transmissible from human to human through bites of Aedes species. ZIKV was initially distinguished in rhesus monkeys in the Zika forest of Uganda throughout the period of a yellow fever study. No outbreak had been reported until 2007, when ZIKV spread further to the Pacific Island of Yap. In 2013, the second and largest outbreak occurred in French Polynesia. In 2015, ZIKV infection has been confirmed in 18 states of Brazil, and the geographical distribution of ZIKV has steadily broadened given the wide distribution of the mosquito vector. Clinical manifestations of infection include fever, headache, retro-orbital pain, arthralgia, malaise, myalgia, anorexia, rash, oedema, lymphadenopathy and diarrhoea. In most cases, the infection appeared mild and self-limiting, with a mean symptom duration of 3-6 days. Shock complications and haemorrhagic signs have not been reported. However, Guillain-Barre syndrome, a neurologic complication, was reported. Clinical and epidemiological study showed that there is a link between microcephaly and of Zika virus. It has been reported that ZIKV-infected children, who were born to ZIKV-infected mothers during pregnancy, were found to have neonatal head circumferences below the 10th percentile.
CATEGORY    Infectious disease
PATHOGEN    Zika virus [GN:T40049]
MARKER      Serodiagnosis by IgM ELISA tests
            PCR-based diagnosis
COMMENT     See also H01436 Guillain-Barre syndrome.
DBLINKS     ICD-10: U06
            MeSH: D000071243
REFERENCE   PMID:27236440
  AUTHORS   Maharajan MK, Ranjan A, Chu JF, Foo WL, Chai ZX, Lau EY, Ye HM, Theam XJ, Lok YL
  TITLE     Zika Virus Infection: Current Concerns and Perspectives.
  JOURNAL   Clin Rev Allergy Immunol (2016)
///
ENTRY       H01554                      Disease
NAME        Fallopian tube cancer
DESCRIPTION Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis.
CATEGORY    Cancer
GENE        BRCA1 (mutation) [HSA:672] [KO:K10605]
            BRCA2 (mutation) [HSA:675] [KO:K08775]
            TP53 (overexpression) [HSA:7157] [KO:K04451]
            ERBB2 (overexpression) [HSA:2064] [KO:K05083]
            c-myc (overexpression) [HSA:4609] [KO:K04377]
MARKER      CA125 [HSA:94025] [KO:K16145]
DRUG        Carboplatin (AUC 6) [DR:D01363]
            Paclitaxel [DG:DG01430]
            Bevacizumab [DR:D06409]
DBLINKS     ICD-10: C57.0
            MeSH: D005185
REFERENCE   PMID:25286779 (marker)
  AUTHORS   Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, Tsui KH, Wen KC, Chen YJ, Chuang CM, Chao HT, Chang WH
  TITLE     Primary fallopian tube cancer: domestic data and up-to-date review.
  JOURNAL   Taiwan J Obstet Gynecol 53:287-92 (2014)
REFERENCE   PMID:23622731 (description, gene, marker, drug)
  AUTHORS   Kalampokas E, Kalampokas T, Tourountous I
  TITLE     Primary fallopian tube carcinoma.
  JOURNAL   Eur J Obstet Gynecol Reprod Biol 169:155-61 (2013)
REFERENCE   PMID:23937438 (gene)
  AUTHORS   Nik NN, Vang R, Shih IeM, Kurman RJ
  TITLE     Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.
  JOURNAL   Annu Rev Pathol 9:27-45 (2014)
REFERENCE   PMID:21922146 (description)
  AUTHORS   Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H
  TITLE     Molecular genetics and epidemiology of epithelial ovarian cancer (Review).
  JOURNAL   Oncol Rep 26:1347-56 (2011)
REFERENCE   PMID:24511245 (gene, drug)
  AUTHORS   Sama AR, Schilder RJ
  TITLE     Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.
  JOURNAL   Int J Womens Health 6:149-57 (2014)
REFERENCE   PMID:7773939 (description, gene)
  AUTHORS   Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC
  TITLE     c-erbB-2 and p53 expression in fallopian tube carcinoma.
  JOURNAL   Cancer 75:2891-6 (1995)
REFERENCE   PMID:23240669 (description, gene)
  AUTHORS   Vang R, Shih IeM, Kurman RJ
  TITLE     Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
  JOURNAL   Histopathology 62:44-58 (2013)
REFERENCE   PMID:25315029 (drug)
  AUTHORS   Keating GM
  TITLE     Bevacizumab: a review of its use in advanced cancer.
  JOURNAL   Drugs 74:1891-925 (2014)
///
ENTRY       H01555                      Disease
NAME        Merkel cell carcinoma
DESCRIPTION Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine malignancy that exhibits clinically aggressive features and is associated with a poor prognosis. Ultraviolet (UV) radiation may be a cause, and corresponds with the sites of these tumours, often on sun-exposed skin, mostly (94%) in the White population. UV light may exert local immunomodulating action as it decreases amount of epidermal T cells and Langerhans cells, inducing hapten tolerance. Additionally, UV- specific mutations in TP53 and Harvey (Ha)-RAS genes are present in some MCC cell lines. Recently, the polyomavirus group has been linked with MCC. The MCC polyomavirus (MCPyV) has been isolated from MCC tissue and thought to be present in up to 80% of MCC. Tumorigenesis likely is caused by a number of sequential steps from viral integration into host DNA, mutagenic events, and specific immune responses.
CATEGORY    Cancer
GENE        TP53 (mutation) [HSA:7157] [KO:K04451]
            Ha-RAS (mutation) [HSA:3265] [KO:K02833]
PATHOGEN    Merkel cell polyomavirus (MCPyV) [GN:T40051]
MARKER      Cytokeratins (AE1/3, CAM5.2)
            Cytokeratin 20 (CK20) [HSA:54474] [KO:07604]
            Synaptophysin [HSA:6855]
            Neuron-specific enolase [HSA:2026] [KO:01689]
            Chromogranin A [HSA:1113] [KO:19990]
            TTF-1 [HSA:7270] [KO:15225]
DRUG        Carboplatin [DR:D01363]
            Cisplatin [DR:D00275]
            Etoposide [DG:DG00693]
            Anthracycline [DG:DG01682]
            Bleomycin [DG:DG00705]
            Cyclophosphamide [DG:DG00675]
DBLINKS     ICD-10: C44.3
            MeSH: D015266
REFERENCE   PMID:24811434 (description, gene, pathogen, marker)
  AUTHORS   Czapiewski P, Biernat W
  TITLE     Merkel cell carcinoma - recent advances in the biology, diagnostics and treatment.
  JOURNAL   Int J Biochem Cell Biol 53:536-46 (2014)
REFERENCE   PMID:26009549 (description, pathogen)
  AUTHORS   Prewett SL, Ajithkumar T
  TITLE     Merkel Cell Carcinoma: Current Management and Controversies.
  JOURNAL   Clin Oncol (R Coll Radiol) 27:436-44 (2015)
REFERENCE   PMID:26716756 (description, pathogen, marker, drug)
  AUTHORS   Miles BA, Goldenberg D
  TITLE     Merkel cell carcinoma: Do you know your guidelines?
  JOURNAL   Head Neck 38:647-52 (2016)
REFERENCE   PMID:22234254 (drug)
  AUTHORS   Schrama D, Ugurel S, Becker JC
  TITLE     Merkel cell carcinoma: recent insights and new treatment options.
  JOURNAL   Curr Opin Oncol 24:141-9 (2012)
REFERENCE   PMID:23476782 (pathogen, drug)
  AUTHORS   Desch L, Kunstfeld R
  TITLE     Merkel cell carcinoma: chemotherapy and emerging new therapeutic options.
  JOURNAL   J Skin Cancer 2013:327150 (2013)
REFERENCE   PMID:27163912 (description, pathogen, marker)
  AUTHORS   Oram CW, Bartus CL, Purcell SM
  TITLE     Merkel cell carcinoma: a review.
  JOURNAL   Cutis 97:290-5 (2016)
///
ENTRY       H01556                      Disease
NAME        Meningioma
DESCRIPTION Meningiomas are the second-most common central nervous system tumor in adults. These tumors arise from arachnoid cells of the meninges, the covering layer of the brain. The majority of meningiomas tend to be benign, localized, and non-invasive. However, some meningiomas tend to be more aggressive with tendencies toward invasion of the surrounding brain, high propensity for recurrence, and in rare cases extracranial metastasis. Hereditary factors and ionizing radiation play an important role in the initiation of at least some meningiomas. Inactivation of the NF2 tumor suppressor gene is likely responsible for the initiation of more than half of all meningiomas and may cause a mesenchymal-like cytomorphology. Recently, novel mutations have been discovered in non-NF2 meningiomas. The somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas.
CATEGORY    Cancer
GENE        NF2 (mutation) [HSA:4771] [KO:K16684]
            SMARCB1 (mutation) [HSA:6598] [KO:K11648]
            SMARCE1 (mutation) [HSA:6605] [KO:K11651]
            SUFU (mutation) [HSA:51684] [KO:K06229]
            PTEN (mutation) [HSA:5728] [KO:K01110]
            CDKN2A (mutation) [HSA:1029] [KO:K06621]
            CDKN2B (mutation) [HSA:1030] [KO:K04685]
            TRAF7 (mutation) [HSA:84231] [KO:K10646]
            AKT1 (mutation) [HSA:207] [KO:K04456]
            KLF4 (mutation) [HSA:9314] [KO:K17846]
            SMO (mutation) [HSA:6608] [KO:K06226]
CARCINOGEN  Ionising radiation
DRUG        Imatinib [DG:DG00710]
            Hydroxyurea [DR:D00341]
            Interferon-alpha 2B [DG:DG01750]
            Octreotide [DG:DG00501]
COMMENT     ICD-O-3: 9530/0 Meningioma, NOS
            ICD-O-3: 9530/1 Meningiomatosis, NOS
            ICD-O-3: 9230/3 Meningioma, malignant
            ICD-O-3: 9531/0 Meningothelial meningioma
            ICD-O-3: 9532/0 Fibrous meningioma
            ICD-O-3: 9533/0 Psammomatous meningioma
            ICD-O-3: 9534/0 Angiomatous meningioma
            ICD-O-3: 9535/0 Hemangioblastic meningioma
            ICD-O-3: 9537/0 Transitional meningioma
            ICD-O-3: 9538/1 Clear cell meningioma
            ICD-O-3: 9538/3 Papillary meningioma
            ICD-O-3: 9539/1 Atypical meningioma
DBLINKS     ICD-10: D32.9
            MeSH: D008579
REFERENCE   PMID:25857641 (description, gene)
  AUTHORS   Smith MJ
  TITLE     Germline and somatic mutations in meningiomas.
  JOURNAL   Cancer Genet 208:107-14 (2015)
REFERENCE   PMID:25485306 (description, gene)
  AUTHORS   Miller R Jr, DeCandio ML, Dixon-Mah Y, Giglio P, Vandergrift WA 3rd, Banik NL, Patel SJ, Varma AK, Das A
  TITLE     Molecular Targets and Treatment of Meningioma.
  JOURNAL   J Neurol Neurosurg 1 (2014)
REFERENCE   PMID:21529177 (gene, drug)
  AUTHORS   Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I
  TITLE     The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
  JOURNAL   Neurosurg Focus 30:E6 (2011)
REFERENCE   PMID:24289126 (drug)
  AUTHORS   Moazzam AA, Wagle N, Zada G
  TITLE     Recent developments in chemotherapy for meningiomas: a review.
  JOURNAL   Neurosurg Focus 35:E18 (2013)
REFERENCE   PMID:23463172 (drug, ICD-O-3)
  AUTHORS   Fathi AR, Roelcke U
  TITLE     Meningioma.
  JOURNAL   Curr Neurol Neurosci Rep 13:337 (2013)
REFERENCE   PMID:25744347 (description, gene)
  AUTHORS   Shibuya M
  TITLE     Pathology and molecular genetics of meningioma: recent advances.
  JOURNAL   Neurol Med Chir (Tokyo) 55:14-27 (2015)
REFERENCE   PMID:19194129 (carcinogen)
  AUTHORS   Campbell BA, Jhamb A, Maguire JA, Toyota B, Ma R
  TITLE     Meningiomas in 2009: controversies and future challenges.
  JOURNAL   Am J Clin Oncol 32:73-85 (2009)
REFERENCE   PMID:17110285 (ICD-O-3)
  AUTHORS   Riemenschneider MJ, Perry A, Reifenberger G
  TITLE     Histological classification and molecular genetics of meningiomas.
  JOURNAL   Lancet Neurol 5:1045-54 (2006)
REFERENCE   PMID:17460514 (description, gene)
  AUTHORS   Simon M, Bostrom JP, Hartmann C
  TITLE     Molecular genetics of meningiomas: from basic research to potential clinical applications.
  JOURNAL   Neurosurgery 60:787-98; discussion 787-98 (2007)
///
ENTRY       H01557                      Disease
NAME        Hepatic angiosarcoma
DESCRIPTION Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. Primary hepatic angiosarcomas (HAS) are much rare tumors, with worse prognosis compared with other angiosarcomas. HAS has been found to be caused by occupational exposure to vinyl chloride (VC) monomer since 1970, and the number of VC-associated HAS cases reported up to the end of 1998 was 197 worldwide. Exposure of VC connects with a series of mechanistic events leading to carcinogenic outcome; mutations of K-ras and p53 are also detected.
CATEGORY    Cancer
GENE        TP53 (mutation) [HSA:7157] [KO:K04451]
            KRAS-2 (mutation) [HSA:3845] [KO:K07827]
CARCINOGEN  Vinyl chloride [CPD:C06793]
MARKER      CD31 [HSA:5175] [KO:K06471]
            CD34 [HSA:947] [KO:K06474]
            Ulex europaeus agglutinin I
            Factor VIII-related antigen (FVIIIRAg)
            ERG [HSA:2078] [KO:K09435]
DRUG        Doxorubicin [DG:DG00696]
            5-Fluorouracil [DG:DG00687]
            Carboplatin [DR:D01363]
            Ifosfamide [DR:D00343]
            Cisplatin [DR:D00275]
            Paclitaxel [DG:DG01430]
COMMENT     ICD-O-3: 9120/3 Angiosarcoma
DBLINKS     ICD-10: C22.3
            MeSH: D006394
REFERENCE   PMID:26008857 (description, gene, carcinogen, marker, drug)
  AUTHORS   Chaudhary P, Bhadana U, Singh RA, Ahuja A
  TITLE     Primary hepatic angiosarcoma.
  JOURNAL   Eur J Surg Oncol 41:1137-43 (2015)
REFERENCE   PMID:24372769 (description, gene, carcinogen, marker, drug)
  AUTHORS   Zheng YW, Zhang XW, Zhang JL, Hui ZZ, Du WJ, Li RM, Ren XB
  TITLE     Primary hepatic angiosarcoma and potential treatment options.
  JOURNAL   J Gastroenterol Hepatol 29:906-11 (2014)
REFERENCE   PMID:20537949 (description, gene, carcinogen, marker, drug)
  AUTHORS   Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ
  TITLE     Angiosarcoma.
  JOURNAL   Lancet Oncol 11:983-91 (2010)
REFERENCE   PMID:19031953 (marker, drug)
  AUTHORS   Asmane I, Litique V, Heymann S, Marcellin L, Metivier AC, Duclos B, Bergerat JP, Kurtz JE
  TITLE     Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three  case reports and review of the literature.
  JOURNAL   Anticancer Res 28:3041-5 (2008)
REFERENCE   PMID:24707153 (marker)
  AUTHORS   Wang ZB, Yuan J, Chen W, Wei LX
  TITLE     Transcription factor ERG is a specific and sensitive diagnostic marker for hepatic angiosarcoma.
  JOURNAL   World J Gastroenterol 20:3672-9 (2014)
///
ENTRY       H01558                      Disease
NAME        Parathyroid carcinoma
DESCRIPTION Parathyroid carcinoma (PC) is a highly aggressive endocrine tumor, with an annual incidence of less than 1 per million. Over 90% of patients present with excess parathyroid hormone (PTH), representing <1-5% of all patients with primary hyperparathyroidism. PC is associated with mutations in the HRPT2/CDC73 gene and with decreased parafibromin and calcium-sensing receptor (CASR) expression. Negative parafibromin staining together with a CDC73 gene mutation increases the likelihood of malignancy and also predicts the clinical outcome, namely local invasion and/or metastases and mortality. An increased mortality is predicted by either of these abnormality combined with down regulation of the calcium-sensing receptor (CaSR) expression.
CATEGORY    Cancer
GENE        CDC73/HRPT2 (mutation) [HSA:79577] [KO:K15175]
            CASR [HSA:846] [KO:K04612]
MARKER      CDC73/HRPT2 (Loss of nuclear and/or nucleolar expression) [HSA:79577] [KO:K15175]
            PGP9.5 [HSA:7345] [KO:K05611]
            Galectin-3 [HSA:3958] [KO:K06831]
            Ki67 [HSA:4288] [KO:K17582]
DRUG        Dacarbazine [DG:DG00680]
            Fluorouracil [DG:DG00687]
            Cyclophosphamide [DG:DG00675]
DBLINKS     ICD-10: D09.3
            MeSH: D010282
REFERENCE   PMID:26177319 (description, gene, marker)
  AUTHORS   Duan K, Mete O
  TITLE     Parathyroid Carcinoma: Diagnosis and Clinical Implications.
  JOURNAL   Turk Patoloji Derg 31 Suppl 1:80-97 (2015)
REFERENCE   PMID:26312219 (drug)
  AUTHORS   McClenaghan F, Qureshi YA
  TITLE     Parathyroid cancer.
  JOURNAL   Gland Surg 4:329-38 (2015)
REFERENCE   PMID:24035866 (gene)
  AUTHORS   Costa-Guda J, Arnold A
  TITLE     Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors.
  JOURNAL   Mol Cell Endocrinol 386:46-54 (2014)
REFERENCE   PMID:20510594 (gene)
  AUTHORS   Givi B, Shah JP
  TITLE     Parathyroid carcinoma.
  JOURNAL   Clin Oncol (R Coll Radiol) 22:498-507 (2010)
REFERENCE   PMID:25002250 (marker)
  AUTHORS   Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR
  TITLE     Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
  JOURNAL   World J Surg 38:2845-54 (2014)
REFERENCE   PMID:26675091 (marker)
  AUTHORS   Karaarslan S, Yurum FN, Kumbaraci BS, Pala EE, Sivrikoz ON, Akyildiz M, Bugdayci MH
  TITLE     The Role of Parafibromin, Galectin-3, HBME-1, and Ki-67 in the Differential Diagnosis of Parathyroid Tumors.
  JOURNAL   Oman Med J 30:421-7 (2015)
REFERENCE   PMID:27001435 (description, gene)
  AUTHORS   Cetani F, Pardi E, Marcocci C
  TITLE     Update on parathyroid carcinoma.
  JOURNAL   J Endocrinol Invest 39:595-606 (2016)
REFERENCE   PMID:21240254 (description, gene)
  AUTHORS   Witteveen JE, Hamdy NA, Dekkers OM, Kievit J, van Wezel T, Teh BT, Romijn JA, Morreau H
  TITLE     Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
  JOURNAL   Mod Pathol 24:688-97 (2011)
///
ENTRY       H01559                      Disease
NAME        Oropharyngeal cancer
DESCRIPTION Oropharyngeal cancer is a generic term that includes tumors arising within the anatomic confines of the posterior pharyngeal wall, soft palate, tonsillar region and posterior one-third (base) of the tongue. The vast majority of these tumors (>95%) includes squamous cell carcinomas of mucosal origin. Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally categorized as head and neck squamous cell carcinoma (HNSCC). High-risk human papillomavirus (HR-HPV) is now recognised as a causative agent in a subset of OPSCCs. HPV-driven OPSCC and tobacco- and alcohol-related OPSCC are biologically distinct entities. In the former, p53 and pRb are both inactivated at the protein level by, respectively, E6 and E7 viral oncoproteins. The majority of HPV-negative tumors, instead, harbor mutations in the TP53 gene, an increased epidermal growth factor receptor (EGFR) gene copy number and higher EGFR expression by immunohistochemistry (IHC).
CATEGORY    Cancer
GENE        TP53 (mutation) [HSA:7157] [KO:K04451]
            EGFR (amplification, overexpression) [HSA:1956] [KO:K04361]
CARCINOGEN  Tobacco
            Alcohol
            Areca nut
PATHOGEN    Human papillomavirus type 16 [GN:T40087]
MARKER      HPV E6 and E7 mRNA [VG:1489368 1489369]
DRUG        Cisplatin [DR:D00275]
            Carboplatin [DR:D01363]
            5-fluorouracil [DG:DG00687]
            Cetuximab [DR:D03455]
COMMENT     ICD-O-3:8071/3 Squamous cell carcinoma, keratinizing, NOS
            ICD-O-3:8072/3 Squamous cell carcinoma, nonkeratinizing, NOS
            ICD-O-3:8083/3 Basaloid squamous cell carcinoma
            ICD-O-3:8051/3 Verrucous carcinoma, NOS
            ICD-O-3:8032/3 Spindle cell carcinoma, NOS
            ICD-O-3:8082/3 Lymphoepithelial carcinoma
DBLINKS     ICD-10: C10
            MeSH: D009959
REFERENCE   PMID:26152442 (pathogen)
  AUTHORS   Moore KA 2nd, Mehta V
  TITLE     The Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers.
  JOURNAL   J Am Board Fam Med 28:498-503 (2015)
REFERENCE   PMID:24578320 (description, gene, pathogen, drug)
  AUTHORS   Urban D, Corry J, Rischin D
  TITLE     What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?
  JOURNAL   Cancer 120:1462-70 (2014)
REFERENCE   PMID:26547133 (description, marker, gene, carcinogen, pathogen)
  AUTHORS   Boscolo-Rizzo P, Pawlita M, Holzinger D
  TITLE     From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas.
  JOURNAL   Cancer Treat Rev 42:24-9 (2016)
REFERENCE   PMID:24424107 (description, gene, pathogen)
  AUTHORS   Mirghani H, Amen F, Moreau F, Guigay J, Hartl DM, Lacau St Guily J
  TITLE     Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status.
  JOURNAL   Eur J Cancer 50:1100-11 (2014)
REFERENCE   PMID:11796235 (carcinogen, pathogen)
  AUTHORS   Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL
  TITLE     Cancer of the oropharynx.
  JOURNAL   Crit Rev Oncol Hematol 41:107-22 (2002)
REFERENCE   PMID:19111679 (carcinogen, pathogen, drug, ICD-O-3)
  AUTHORS   Duvvuri U, Myers JN
  TITLE     Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx.
  JOURNAL   Curr Probl Surg 46:119-84 (2009)
REFERENCE   PMID:20920878 (description)
  AUTHORS   van Monsjou HS, Balm AJ, van den Brekel MM, Wreesmann VB
  TITLE     Oropharyngeal squamous cell carcinoma: a unique disease on the rise?
  JOURNAL   Oral Oncol 46:780-5 (2010)
///
ENTRY       H01560                      Disease
NAME        Alkhumra hemorrhagic fever (AHF)
DESCRIPTION Alkhumra hemorrhagic fever is severe, often fatal disease in humans caused by Alkhumra hemorrhagic fever virus (AHFV). AHFV is a newly described flavivirus first isolated in 1994-1995 from the Alkhumra district south of Jeddah, Saudi Arabia. Full genome sequencing has indicated that ALKV is a distinct variant of Kyasanur Forest disease virus. Alkhumra hemorrhagic fever is thought to be a zoonotic disease, and reservoir hosts may include camels and sheep. Suggested routes of transmission are contamination of a skin wound with blood of an infected vertebrate, bite of an infected tick, or drinking of unpasteurized, contaminated milk. Clinical features include fever, headache, malaise, arthralgia, anorexia, myalgia, backache, nausea and vomiting, chills, retro-orbital pain, diarrhea, abdominal pain, hemorrhagic manifestations, and central nervous system manifestations.
CATEGORY    Infectious disease
PATHOGEN    Alkhumra hemorrhagic fever virus [GN:T40050]
MARKER      Leucopenia, elevated liver enzymes, prolonged partial thromboplastin time, thrombocytopenia, elevated creatine kinase level, and elevated lactate dehydrogenase.
            Serodiagnosis by IgM and IgG ELISA tests
            PCR-based diagnosis
DBLINKS     ICD-10: A98.8
            MeSH: D004669
REFERENCE   PMID:25096447
  AUTHORS   Madani TA, Azhar EI, Abuelzein el-TM, Kao M, Al-Bar HM, Farraj SA, Masri BE, Al-Kaiedi NA, Shakil S, Sohrab SS, SantaLucia J Jr, Ksiazek TG
  TITLE     Complete genome sequencing and genetic characterization of Alkhumra hemorrhagic fever virus isolated from Najran, Saudi Arabia.
  JOURNAL   Intervirology 57:300-10 (2014)
REFERENCE   PMID:20920527 (marker)
  AUTHORS   Madani TA, Azhar EI, Abuelzein el-TM, Kao M, Al-Bar HM, Abu-Araki H, Niedrig M, Ksiazek TG
  TITLE     Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: epidemiological, clinical, and laboratory characteristics.
  JOURNAL   J Infect 62:67-76 (2011)
REFERENCE   PMID:21122217
  AUTHORS   Alzahrani AG, Al Shaiban HM, Al Mazroa MA, Al-Hayani O, Macneil A, Rollin PE, Memish ZA
  TITLE     Alkhurma hemorrhagic fever in humans, Najran, Saudi Arabia.
  JOURNAL   Emerg Infect Dis 16:1882-8 (2010)
///
ENTRY       H01561                      Disease
NAME        Chiari malformation;
            Arnold-Chiari syndrome
DESCRIPTION Chiari malformations, also known as Arnold-Chiari syndrome,  is a group of syndromes consisting of different kinds of pathologic conditions of the posterior fossa development. They are congenital in most cases, caused by structural defects in the brain spinal cord which may involve genetic mutations or lack of proper vitamins or nutrients in the maternal diet. Less frequently, Chiari malformations are acquired after birth. Causes of acquired Chiari malformations involve injuries, exposure to harmful substances, infections. More rarely, chronic subdural hematoma can be the cause of progressive caudal descent of the cerebellar tonsils. Chiari malformations were classified by Hans Chiari in 1891, into four groups. Chiari malformation type I (CM I), the most frequent of Chiari malformations, is characterized by the inferior displacement of cerebellar tonsillas through the foramen magnum. This leads to different symptoms and clinical features, such as headaches, syringomyelia, and hydrocephalus. CM II is characterized by displacement of the parts of the inferior vermis, pons, and medulla oblongata together with elongation of the fourth ventricle. Most cases are associated with myelomeningocele. CM III is characterized by an occipital or cervical encephalocele along with the intracranial abnormalities seen with CM II malformation and a wide foramen magnum. It causes severe neurological defects. CM IV is characterized by marked cerebellar hypoplasia or aplasia.
CATEGORY    Developmental disorder; Nervous system disease
DRUG        Folic acid [DR:D00070]
DBLINKS     ICD-10: Q07.0
            MeSH: D001139
            OMIM: 118420 207950
REFERENCE   PMID:22576785
  AUTHORS   Grazzi L, Andrasik F
  TITLE     Headaches and Arnold-Chiari syndrome: when to suspect and how to investigate.
  JOURNAL   Curr Pain Headache Rep 16:350-3 (2012)
REFERENCE   PMID:20228456
  AUTHORS   Vannemreddy P, Nourbakhsh A, Willis B, Guthikonda B
  TITLE     Congenital Chiari malformations.
  JOURNAL   Neurol India 58:6-14 (2010)
REFERENCE   PMID:25653995 (gene, drug)
  AUTHORS   Ganesh D, Sagayaraj BM, Barua RK, Sharma N, Ranga U
  TITLE     Arnold Chiari malformation with spina bifida: a lost opportunity of folic Acid supplementation.
  JOURNAL   J Clin Diagn Res 8:OD01-3 (2014)
REFERENCE   PMID:23468202
  AUTHORS   Welsch M, Antes S, Kiefer M, Meyer S, Eymann R
  TITLE     Association of Chiari malformation and vitamin B12 deficit in a family.
  JOURNAL   Childs Nerv Syst 29:1193-8 (2013)
///
ENTRY       H01562                      Disease
NAME        Patau syndrome;
            Trisomy 13
DESCRIPTION Patau syndrome, also known as trisomy 13, is a chromosomal disorder characterized by the severe clinical picture of multiple congenital anomalies. It is one of the least common autosomal trisomies among live births with an estimated prevalence of 1:12000 - 1:29000 in newborns. The major clinical findings include cryptorchidism, abnormal auricles, congenital heart defects, polydactyly, microphthalmia, and micrognathia. Median survival time for patients with trisomy 13 is between 7 and 10 days and it is reported that between 86% and 91% of live-born patients with Patau syndrome do not survive beyond 1 year of life. Survival beyond the first year has been associated with mosaicism.
CATEGORY    Chromosomal abnormality
DBLINKS     ICD-10: Q91
            MeSH: C536305
REFERENCE   PMID:23220825
  AUTHORS   Peroos S, Forsythe E, Pugh JH, Arthur-Farraj P, Hodes D
  TITLE     Longevity and Patau syndrome: what determines survival?
  JOURNAL   BMJ Case Rep 2012 (2012)
REFERENCE   PMID:23613355
  AUTHORS   Petry P, Polli JB, Mattos VF, Rosa RC, Zen PR, Graziadio C, Paskulin GA, Rosa RF
  TITLE     Clinical features and prognosis of a sample of patients with trisomy 13 (Patau syndrome) from Brazil.
  JOURNAL   Am J Med Genet A 161A:1278-83 (2013)
///
ENTRY       H01563                      Disease
NAME        HIV infection
DESCRIPTION The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). Two types of HIV has been characterized. HIV-1 is the most virulent and pathogenic strain. Worldwide, the predominant virus is HIV-1. The relatively uncommon HIV-2 type is concentrated in West Africa and is rarely found elsewhere. Infection with HIV occurs by transfer of blood, semen, and breast milk. The identification of HIV as the causative agent of AIDS catalyzed efforts to develop antiviral agents. The licenced anti-HIV drugs fall into some categories: reverse transcriptase inhibitors (NRTIs and NNRTs), integrase inhibitors, protease inhibitors (PIs), fusion inhibitors (FIs), and coreceptor inhibitors. The advent of highly active antiretroviral therapy (HAART) as the standard of care for the treatment of HIV infection was seminal in reducing the morbidity and mortality associated with HIV infection and progression to AIDS. Combination antiretroviral therapy dramatically suppresses HIV replication and reduces the plasma HIV-1 viral load, resulting in significant reconstitution of the immune system.
CATEGORY    Infectious disease
PATHOGEN    Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
DRUG        Zidovudine [DR:D00413] Didanosine [DR:D00296] Zalcitabine [DR:D00412] Sanilvudine [DR:D00445] Lamivudine [DR:D00353] Abacavir [DR:D00891] Emtricitabine [DR:D01199] Tenofovir disoproxil fumarate [DR:D01982] (NRTIs)
            Nevirapine [DR:D00435] Efavirenz [DR:D00896] Delavirdine [DR:D00895] Etravirine [DR:D04112] Rilpivirine [DR:D09958] (NNRTIs)
            Ritonavir [DR:D00427] Nelfinavir [DR:D00899] Saquinavir [DR:D01160] Fosamprenavir [DR:D02867] (PIs)
            Raltegravir [DR:D07133] Dolutegravir [DR:D10113] (Integrase inhibitors)
            Maraviroc [DR:D06670] (FIs)
            Truvada [DR:D02297] Complera [DR:D10571] Stribild [DR:D10756] Kaletra [DR:D02498] Combivir [DR:D07507] Epzicom [DR:D08775] Triumeq [DR:D10600] (Mixture)
COMMENT     See also H00406 Acquired immunodeficiency syndrome (AIDS).
DBLINKS     ICD-10: B24
            MeSH: D015658
REFERENCE   PMID:21838892
  AUTHORS   Yousaf MZ, Zia S, Babar ME, Ashfaq UA
  TITLE     The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan.
  JOURNAL   Virol J 8:401 (2011)
REFERENCE   PMID:18928385 (drug)
  AUTHORS   Hazuda D, Iwamoto M, Wenning L
  TITLE     Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
  JOURNAL   Annu Rev Pharmacol Toxicol 49:377-94 (2009)
REFERENCE   PMID:15934866 (drug)
  AUTHORS   De Clercq E
  TITLE     Emerging anti-HIV drugs.
  JOURNAL   Expert Opin Emerg Drugs 10:241-73 (2005)
///
ENTRY       H01564                      Disease
NAME        Edwards syndrome;
            Trisomy 18
DESCRIPTION Edwards syndrome, also known as trisomy 18, is a chromosomal disorder due to the presence of an extra chromosome 18, either full, mosaic trisomy, or partial trisomy 18q. This disease is the second-most common autosomal trisomy, after Down syndrome. The live born prevalence is estimated as 1/6,000-1/8,000, but the overall prevalence is higher (1/2500-1/2600) due to the high frequency of fetal loss and pregnancy termination after prenatal diagnosis. The main clinical features include prenatal growth deficiency, characteristic craniofacial features, distinctive hand posture, nail hypoplasia, short hallux, short sternum, and major malformations (particularly involving the heart). Approximately 50% of newborns survive beyond 1 week while more than 90% do not survive beyond 1 years of age.
CATEGORY    Chromosomal abnormality
DBLINKS     ICD-10: Q91
            MeSH: C580500
REFERENCE   PMID:26820816
  AUTHORS   Imataka G, Suzumura H, Arisaka O
  TITLE     Clinical features and survival in individuals with trisomy 18: A retrospective one-center study of 44 patients who received intensive care treatments.
  JOURNAL   Mol Med Rep 13:2457-66 (2016)
REFERENCE   PMID:23088440
  AUTHORS   Cereda A, Carey JC
  TITLE     The trisomy 18 syndrome.
  JOURNAL   Orphanet J Rare Dis 7:81 (2012)
REFERENCE   PMID:25598039
  AUTHORS   Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, Zhu Z, Lin M, Liu Q, Tian Z, Zhang H, Chen F, Lau TK, Zhao L, Yi X, Yin Y, Wang W
  TITLE     Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies.
  JOURNAL   Ultrasound Obstet Gynecol 45:530-8 (2015)
///
ENTRY       H01565                      Disease
NAME        Wernicke encephalopathy;
            Wernicke-Korsakoff syndrome
DESCRIPTION Wernicke encephalopathy is a rare but serious neurological pathology due to a vitamin B1 deficiency. It is commonly associated with heavy alcohol consumption. Other clinical associations are with hyperemesis gravidarum, starvation, and prolonged intravenous feeding. Most patients present with the triad of ophthalmoplegia, ataxia, and confusion. It can be associated with life-threatening complication like central pontine myelinolysis. When Wernicke encephalopathy is suspected, treatment with high-dose parenteral thiamine (vitamin B1) should be given. If it is not treated promptly or if treatment is inadequate it can lead to death or to the chronic memory disorder, Korsakoff syndrome. Recent studies have suggested that an association exists between Wernicke encephalopathy and genetic polymorphisms in the thiamine transporter (SLC19A2).
CATEGORY    Metabolic disorders; Nervous system disease
GENE        SLC19A2 [HSA:10560] [KO:K14610]
DRUG        Thiamine (vitamin B1) [DR:D01225 D02094]
DBLINKS     ICD-10: E51.2
            MeSH: D014899
            OMIM: 277730
REFERENCE   PMID:26004883
  AUTHORS   Yahia M, Najeh H, Zied H, Khalaf M, Salah AM, Sofienne BM, Laidi B, Hamed J, Hayenne M
  TITLE     Wernicke's encephalopathy: A rare complication of hyperemesis gravidarum.
  JOURNAL   Anaesth Crit Care Pain Med 34:173-7 (2015)
REFERENCE   PMID:24701066
  AUTHORS   Kantor S, Prakash S, Chandwani J, Gokhale A, Sarma K, Albahrani MJ
  TITLE     Wernicke's encephalopathy following hyperemesis gravidarum.
  JOURNAL   Indian J Crit Care Med 18:164-6 (2014)
REFERENCE   PMID:16015585 (gene)
  AUTHORS   Guerrini I, Thomson AD, Cook CC, McQuillin A, Sharma V, Kopelman M, Reynolds G, Jauhar P, Harper C, Gurling HM
  TITLE     Direct genomic PCR sequencing of the high affinity thiamine transporter (SLC19A2) gene identifies three genetic variants in Wernicke Korsakoff syndrome (WKS).
  JOURNAL   Am J Med Genet B Neuropsychiatr Genet 137B:17-9 (2005)
REFERENCE   PMID:19151162 (drug)
  AUTHORS   Kopelman MD, Thomson AD, Guerrini I, Marshall EJ
  TITLE     The Korsakoff syndrome: clinical aspects, psychology and treatment.
  JOURNAL   Alcohol Alcohol 44:148-54 (2009)
///
ENTRY       H01566                      Disease
NAME        Beriberi
DESCRIPTION Beriberi is the classical syndrome caused by thiamine (vitamin B1) deficiency. Beriberi has two major clinical manifestations, dry beriberi characterized by neurologic manifestations that include peripheral neuropathy and acute encephalopathy, and wet beriberi with cardiovascular involvement including high cardiac output heart failure. Rarely, a fulminant or pernicious variant, termed Shoshin beriberi may occur, and is characterized by cardiovascular collapse. Appropriate management of this form is mandatory since thiamine supplementation leads to rapid recovery while untreated forms are fatal.
CATEGORY    Metabolic disorders; Nervous system disease; Cardiovascular disease
MARKER      Decrease in serum and urinary thiamine level.
            Decrease in erythrocyte transketolase activity.
            Increase in thiamine pyrophosphate (TPP) effect.
DRUG        Thiamine (vitamin B1) [DR:D01225 D02094]
DBLINKS     ICD-10: E51.1
            MeSH: D001602
REFERENCE   PMID:25982313
  AUTHORS   Dabar G, Harmouche C, Habr B, Riachi M, Jaber B
  TITLE     Shoshin Beriberi in Critically-Ill patients: case series.
  JOURNAL   Nutr J 14:51 (2015)
REFERENCE   PMID:18660937
  AUTHORS   Coelho LS, Hueb JC, Minicucci MF, Azevedo PS, Paiva SA, Zornoff LA
  TITLE     Thiamin deficiency as a cause of reversible cor pulmonale.
  JOURNAL   Arq Bras Cardiol 91:e7-9 (2008)
REFERENCE   PMID:23910704 (marker, drug)
  AUTHORS   DiNicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH, Ventura HO
  TITLE     Thiamine supplementation for the treatment of heart failure: a review of the literature.
  JOURNAL   Congest Heart Fail 19:214-22 (2013)
///
ENTRY       H01567                      Disease
NAME        Thiamine pyrophosphokinase deficiency;
            Thiamine metabolism dysfunction syndrome 5
DESCRIPTION Thiamine pyrophosphokinase (TPK) deficiency is a recently described rare disorder that present as episodic encephalopathy or Leigh syndrome like early-onset global developmental delay. TPK deficiency is one of thiamine metabolism dysfunction syndrome caused by mutations TPK1. TPK produces thiamine pyrophosphate (TPP). TPP is a cofactor for enzymes important in a range of fundamental processes such as cellular respiration. It has been reported that early thiamine supplementation prevented encephalopathic episodes and improved developmental progression.
CATEGORY    Inherited metabolic disease
GENE        TPK1 [HSA:27010] [KO:K00949]
MARKER      2-ketoglutaric acid (urea) [CPD:C00026]
DRUG        Thiamine (vitamin B1) [DR:D01225 D02094]
COMMENT     See also H01354 Leigh syndrome, H00990 Microcephaly, Amish type, H01231 Biotin-responsive basal ganglia disease, and H01183 Thiamine-responsive megaloblastic anemia.
DBLINKS     ICD-10: E51.8
            OMIM: 614458
REFERENCE   PMID:25458521
  AUTHORS   Banka S, de Goede C, Yue WW, Morris AA, von Bremen B, Chandler KE, Feichtinger RG, Hart C, Khan N, Lunzer V, Matakovic L, Marquardt T, Makowski C, Prokisch H, Debus O, Nosaka K, Sonwalkar H, Zimmermann FA, Sperl W, Mayr JA
  TITLE     Expanding the clinical and molecular spectrum of thiamine pyrophosphokinase deficiency: a treatable neurological disorder caused by TPK1 mutations.
  JOURNAL   Mol Genet Metab 113:301-6 (2014)
///
ENTRY       H01568                      Disease
NAME        3C syndrome;
            Ritscher-Schinzel syndrome;
            Craniocerebellocardiac dysplasia
DESCRIPTION The 3C syndrome, also known as Ritscher-Schinzel syndrome, is a rare, presumably autosomal recessive syndrome characterized by craniofacial, cerebellar, and cardiac anomalies. Cardiac manifestations include ventricular septal defect, atrial septal defect, tetralogy of Fallot, double outlet right ventricle, hypoplastic left heart, aortic stenosis, pulmonic stenosis, and other valvular anomalies. Central nervous system anomalies include Dandy-Walker malformation, cerebellar vermis hypoplasia, and enlargement of the cisterna magna. Craniofacial abnormalities seen are cleft palate, ocular coloboma, prominent occiput, low-set ears, hypertelorism, down-slanting palpebral fissures, depressed nasal bridge, and micrognathia. The phenotypic manifestations can vary and cardiac and cerebellar manifestations are not always present. A recent study identified homozygous sequence variants affecting the KIAA0196 gene, which encodes the WASH (Wiskott-Aldrich Syndrome Protein and SCAR Homolog) complex protein strumpellin as causal to a form of 3C syndrome. Another study showed that a missense variant in CCDC22 is associated with a form of X-linked intellectual disability with features of 3C syndrome.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        KIAA0196 [HSA:9897] [KO:K18464]
            CCDC22 [HSA:28952]
DBLINKS     ICD-10: Q87.8
            MeSH: C535313
            OMIM: 220210 300963
REFERENCE   PMID:11484200 (description)
  AUTHORS   Leonardi ML, Pai GS, Wilkes B, Lebel RR
  TITLE     Ritscher-Schinzel cranio-cerebello-cardiac (3C) syndrome: report of four new cases and review.
  JOURNAL   Am J Med Genet 102:237-42 (2001)
REFERENCE   PMID:24916641 (description, gene)
  AUTHORS   Kolanczyk M, Krawitz P, Hecht J, Hupalowska A, Miaczynska M, Marschner K, Schlack C, Emmerich D, Kobus K, Kornak U, Robinson PN, Plecko B, Grangl G, Uhrig S, Mundlos S, Horn D
  TITLE     Missense variant in CCDC22 causes X-linked recessive intellectual disability with features of Ritscher-Schinzel/3C syndrome.
  JOURNAL   Eur J Hum Genet 23:633-8 (2015)
REFERENCE   PMID:24065355 (gene)
  AUTHORS   Elliott AM, Simard LR, Coghlan G, Chudley AE, Chodirker BN, Greenberg CR, Burch T, Ly V, Hatch GM, Zelinski T
  TITLE     A novel mutation in KIAA0196: identification of a gene involved in Ritscher-Schinzel/3C syndrome in a First Nations cohort.
  JOURNAL   J Med Genet 50:819-22 (2013)
///
ENTRY       H01569                      Disease
NAME        CHOPS syndrome
DESCRIPTION CHOPS syndrome is a congenital disorder involving multiple abnormalities. The symptoms include cognitive impairment, coarse facies, heart defects, obesity, pulmonary involvement, short stature, and skeletal dysplasia. The gain-of-function mutations in the AFF4 gene, encoding a critical component of the super elongation complex (SEC), cause CHOPS syndrome. While CHOPS syndrome and Cornelia de Lange syndrome are clinically recognizable distinct entities there is some phenotypic overlap between these two diagnoses.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        AFF4 [HSA:27125] [KO:K15185]
COMMENT     See also H00631.
DBLINKS     ICD-10: Q87.8
            OMIM: 616368
REFERENCE   PMID:25730767 (description, gene)
  AUTHORS   Izumi K, Nakato R, Zhang Z, Edmondson AC, Noon S, Dulik MC, Rajagopalan R, Venditti CP, Gripp K, Samanich J, Zackai EH, Deardorff MA, Clark D, Allen JL, Dorsett D, Misulovin Z, Komata M, Bando M, Kaur M, Katou Y, Shirahige K, Krantz ID
  TITLE     Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin.
  JOURNAL   Nat Genet 47:338-44 (2015)
///
ENTRY       H01570                      Disease
NAME        Autosomal dominant striatal degeneration (ADSD)
DESCRIPTION Autosomal-dominant striatal degeneration (ADSD) is a rare autosomal-dominant movement disorder affecting the striatal part of the basal ganglia, with onset in the fourth to fifth decade. The main clinical features are mild, slowly progressive dysarthria and hypokinesia without any apparent reduction in life expectancy. Brain MRI shows distinctive lesions of the putamen and caudate nucleus appearing earlier than the onset of symptoms. Causal gene mutations are discovered in the cyclic nucleotide phosphodiesterase (PDE) genes.
CATEGORY    Nervous system disease
GENE        PDE8B [HSA:8622] [KO:K18437]
            PDE10A [HSA:10846] [KO:K18438]
DBLINKS     MeSH: C563783
            OMIM: 609161 616922
REFERENCE   PMID:20085714 (description, gene)
  AUTHORS   Appenzeller S, Schirmacher A, Halfter H, Baumer S, Pendziwiat M, Timmerman V, De Jonghe P, Fekete K, Stogbauer F, Ludemann P, Hund M, Quabius ES, Ringelstein EB, Kuhlenbaumer G
  TITLE     Autosomal-dominant striatal degeneration is caused by a mutation in the phosphodiesterase 8B gene.
  JOURNAL   Am J Hum Genet 86:83-7 (2010)
REFERENCE   PMID:15210883 (description)
  AUTHORS   Kuhlenbaumer G, Ludemann P, Schirmacher A, De Vriendt E, Hunermund G, Young P, Hund-Georgiadis M, Schuierer G, Moller H, Ringelstein EB, Van Broeckhoven C, Timmerman V, Stogbauer F
  TITLE     Autosomal dominant striatal degeneration (ADSD): clinical description and mapping to 5q13-5q14.
  JOURNAL   Neurology 62:2203-8 (2004)
REFERENCE   PMID:26475694 (description)
  AUTHORS   Barsottini OG, Martins Pde M, Chien HF, Raskin S, Nunes RH, da Rocha AJ, Pedroso JL
  TITLE     Familial striatal degeneration: New mutation and neuroimaging clues.
  JOURNAL   Neurology 85:1816-8 (2015)
REFERENCE   PMID:26769607 (description)
  AUTHORS   Azuma R, Ishikawa K, Hirata K, Hashimoto Y, Takahashi M, Ishii K, Inaba A, Yokota T, Orimo S
  TITLE     A novel mutation of PDE8B Gene in a Japanese family with autosomal-dominant striatal degeneration.
  JOURNAL   Mov Disord 30:1964-7 (2015)
REFERENCE   PMID:27058447 (gene)
  AUTHORS   Mencacci NE, Kamsteeg EJ, Nakashima K, R'Bibo L, Lynch DS, Balint B, Willemsen MA, Adams ME, Wiethoff S, Suzuki K, Davies CH, Ng J, Meyer E, Veneziano L, Giunti P, Hughes D, Raymond FL, Carecchio M, Zorzi G, Nardocci N, Barzaghi C, Garavaglia B, Salpietro V, Hardy J, Pittman AM, Houlden H, Kurian MA, Kimura H, Vissers LE, Wood NW, Bhatia KP
  TITLE     De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal  Lesions.
  JOURNAL   Am J Hum Genet 98:763-71 (2016)
///
ENTRY       H01571                      Disease
NAME        Singleton-Merten syndrome (SMS)
DESCRIPTION Singleton-Merten syndrome (SMS) is a rare autosomal-dominant multisystem disorder characterized by early and extreme aortic and valvular calcification, dental anomalies (early-onset periodontitis and root resorption), osteopenia, and acro-osteolysis. A gain-of-function mutation in interferon induced with helicase C domain 1 (IFIH1), encoding melanoma differentiation-associated protein 5 (MDA5), causes  SMS through dysregulation of the human innate immune response. DDX58 mutations cause atypical SMS manifesting with variable expression of glaucoma, aortic calcification, and skeletal abnormalities without dental anomalies.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        IFIH1 [HSA:64135] [KO:K12647]
            DDX58 [HSA:23586] [KO:K12646]
DBLINKS     ICD-10: Q78.8
            MeSH: C537343
            OMIM: 182250 616298
REFERENCE   PMID:23322711 (description)
  AUTHORS   Feigenbaum A, Muller C, Yale C, Kleinheinz J, Jezewski P, Kehl HG, MacDougall M, Rutsch F, Hennekam RC
  TITLE     Singleton-Merten syndrome: an autosomal dominant disorder with variable expression.
  JOURNAL   Am J Med Genet A 161A:360-70 (2013)
REFERENCE   PMID:25620204 (description, gene)
  AUTHORS   Rutsch F, MacDougall M, Lu C, Buers I, Mamaeva O, Nitschke Y, Rice GI, Erlandsen H, Kehl HG, Thiele H, Nurnberg P, Hohne W, Crow YJ, Feigenbaum A, Hennekam RC
  TITLE     A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome.
  JOURNAL   Am J Hum Genet 96:275-82 (2015)
REFERENCE   PMID:25620203 (description, gene)
  AUTHORS   Jang MA, Kim EK, Now H, Nguyen NT, Kim WJ, Yoo JY, Lee J, Jeong YM, Kim CH, Kim OH, Sohn S, Nam SH, Hong Y, Lee YS, Chang SA, Jang SY, Kim JW, Lee MS, Lim SY, Sung KS, Park KT, Kim BJ, Lee JH, Kim DK, Kee C, Ki CS
  TITLE     Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome.
  JOURNAL   Am J Hum Genet 96:266-74 (2015)
///
ENTRY       H01572                      Disease
NAME        Cole-Carpenter syndrome
DESCRIPTION Cole-Carpenter syndrome (CCS) is a severe bone fragility disorder that is characterized by frequent fractures, craniosynostosis, ocular proptosis, hydrocephalus, and distinctive facial features. CCS was first described in 1987 as a newly recognized type of osteogenesis imperfecta (OI). Despite its apparent extreme rarity, CCS is commonly classified as a separate OI-like disorder. CCS is caused by a specific de novo mutation in P4HB, the gene that encodes protein disulfide isomerase (PDI), that impairs the disulfide isomerase activity. Mutations in SEC24D, a gene encoding a component of the COPII complex machinery, have been reported to cause CCS as well.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        P4HB [HSA:5034] [KO:K09580]
            SEC24D [HSA:9871] [KO:K14007]
DBLINKS     ICD-10: Q78.0
            MeSH: C535963
            OMIM: 112240 616294
REFERENCE   PMID:25683117 (description, gene)
  AUTHORS   Rauch F, Fahiminiya S, Majewski J, Carrot-Zhang J, Boudko S, Glorieux F, Mort JS, Bachinger HP, Moffatt P
  TITLE     Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB.
  JOURNAL   Am J Hum Genet 96:425-31 (2015)
REFERENCE   PMID:25683121 (gene)
  AUTHORS   Garbes L, Kim K, Riess A, Hoyer-Kuhn H, Beleggia F, Bevot A, Kim MJ, Huh YH, Kweon HS, Savarirayan R, Amor D, Kakadia PM, Lindig T, Kagan KO, Becker J, Boyadjiev SA, Wollnik B, Semler O, Bohlander SK, Kim J, Netzer C
  TITLE     Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta.
  JOURNAL   Am J Hum Genet 96:432-9 (2015)
///
ENTRY       H01573                      Disease
NAME        Zimmermann-Laband syndrome (ZLS)
DESCRIPTION Zimmermann-Laband syndrome (ZLS) is a rare craniofacial malformation syndrome with predominant intraoral involvement consisting in diffuse gingival fibromatosis of early onset. Most cases are sporadic, suggesting autosomal dominant inheritance with de novo mutations. The main clinical characteristics of ZLS are gingival enlargement, prominent nose and thick ears with soft cartilages, nail aplasia or hypoplasia, hypertrichosis, joint hyperextensibility, hepato(spleno)megaly, and intellectual disability with or without epilepsy. Mutations in KCNH1 and ATP6V1B2 account for a proportion of ZLS.
CATEGORY    Skeletal dysplasia; Developmental disorder
GENE        KCNH1 [HSA:3756] [KO:K04904]
            ATP6B1B2 [HSA:526] [KO:K02147]
DBLINKS     ICD-10: Q87.8
            MeSH: C536725
            OMIM: 135500 616455
REFERENCE   PMID:25915598 (description, gene)
  AUTHORS   Kortum F, Caputo V, Bauer CK, Stella L, Ciolfi A, Alawi M, Bocchinfuso G, Flex E, Paolacci S, Dentici ML, Grammatico P, Korenke GC, Leuzzi V, Mowat D, Nair LD, Nguyen TT, Thierry P, White SM, Dallapiccola B, Pizzuti A, Campeau PM, Tartaglia M, Kutsche K
  TITLE     Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome.
  JOURNAL   Nat Genet 47:661-7 (2015)
REFERENCE   PMID:23994350 (description)
  AUTHORS   Castori M, Valiante M, Pascolini G, Leuzzi V, Pizzuti A, Grammatico P
  TITLE     Clinical and genetic study of two patients with Zimmermann-Laband syndrome and literature review.
  JOURNAL   Eur J Med Genet 56:570-6 (2013)
///
ENTRY       H01574                      Disease
NAME        Familial idiopathic basal ganglia calcification;
            Bilateral striopallidodentate calcinosis (BSPDC);
            Fahr's disease
DESCRIPTION Familial idiopathic basal ganglia calcification (IBGC), also known as Fahr disease, is an inherited neurological disorder characterized by symmetric calcification in the basal ganglia and other brain regions, a wide spectrum of neuropsychiatric symptoms, including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, seizures and chronic headache, and normal serum levels of calcium, phosphate, alkaline phosphatase and parathyroid hormone. The typical age at clinical onset is between 30 and 50 years, and most individuals affected with IBGC are asymptomatic during childhood and young adulthood. The diagnosis of IBGC generally relies on the visualization of bilateral calcification mainly in the basal ganglia by neuroimaging and the absence of metabolic, infectious, toxic, or traumatic causes. Familial IBGC is genetically heterogeneous and typically transmitted in an autosomal dominant fashion. The mutations in SLC20A2 encoding type III sodium-dependent phosphate transporter 2 (PiT-2) are a major cause of familial IBGC. Recently the mutations of PDGFRB encoding platelet-derived growth factor (PDGF) receptor-beta, PDGFB encoding the PDGFR receptor-beta main ligand and XRP1 encoding a retroviral receptor have been reported to cause calcification in the brain.
CATEGORY    Nervous system disease
GENE        SLC20A2 [HSA:6575] [KO:K14640]
            PDGFRB [HSA:5159] [KO:K05089]
            PDGFB [HSA:5155] [KO:K17386]
            XPR1 [HSA:9213]
DBLINKS     ICD-10: G23.8
            MeSH: C536275 C537657 C536276
            OMIM: 213600 615007 615483 616413
REFERENCE   PMID:22327515 (description, gene)
  AUTHORS   Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, de Oliveira JR, Sobrido MJ, Quintans B, Baquero M, Cui X, Zhang XY, Wang L, Xu H, Wang J, Yao J, Dai X, Liu J, Zhang L, Ma H, Gao Y, Ma X, Feng S, Liu M, Wang QK, Forster IC, Zhang X, Liu JY
  TITLE     Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis.
  JOURNAL   Nat Genet 44:254-6 (2012)
REFERENCE   PMID:23334463 (description)
  AUTHORS   Hsu SC, Sears RL, Lemos RR, Quintans B, Huang A, Spiteri E, Nevarez L, Mamah C, Zatz M, Pierce KD, Fullerton JM, Adair JC, Berner JE, Bower M, Brodaty H, Carmona O, Dobricic V, Fogel BL, Garcia-Estevez D, Goldman J, Goudreau JL, Hopfer S, Jankovic M, Jauma S, Jen JC, Kirdlarp S, Klepper J, Kostic V, Lang AE, Linglart A, Maisenbacher MK, Manyam BV, Mazzoni P, Miedzybrodzka Z, Mitarnun W, Mitchell PB, Mueller J, Novakovic I, Paucar M, Paulson H, Simpson SA, Svenningsson P, Tuite P, Vitek J, Wetchaphanphesat S, Williams C, Yang M, Schofield PR, de Oliveira JR, Sobrido MJ, Geschwind DH, Coppola G
  TITLE     Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification.
  JOURNAL   Neurogenetics 14:11-22 (2013)
REFERENCE   PMID:24463626 (description)
  AUTHORS   Yamada M, Tanaka M, Takagi M, Kobayashi S, Taguchi Y, Takashima S, Tanaka K, Touge T, Hatsuta H, Murayama S, Hayashi Y, Kaneko M, Ishiura H, Mitsui J, Atsuta N, Sobue G, Shimozawa N, Inuzuka T, Tsuji S, Hozumi I
  TITLE     Evaluation of SLC20A2 mutations that cause idiopathic basal ganglia calcification in Japan.
  JOURNAL   Neurology 82:705-12 (2014)
REFERENCE   PMID:23255827 (gene)
  AUTHORS   Nicolas G, Pottier C, Maltete D, Coutant S, Rovelet-Lecrux A, Legallic S, Rousseau S, Vaschalde Y, Guyant-Marechal L, Augustin J, Martinaud O, Defebvre L, Krystkowiak P, Pariente J, Clanet M, Labauge P, Ayrignac X, Lefaucheur R, Le Ber I, Frebourg T, Hannequin D, Campion D
  TITLE     Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification.
  JOURNAL   Neurology 80:181-7 (2013)
REFERENCE   PMID:23913003 (gene)
  AUTHORS   Keller A, Westenberger A, Sobrido MJ, Garcia-Murias M, Domingo A, Sears RL, Lemos RR, Ordonez-Ugalde A, Nicolas G, da Cunha JE, Rushing EJ, Hugelshofer M, Wurnig MC, Kaech A, Reimann R, Lohmann K, Dobricic V, Carracedo A, Petrovic I, Miyasaki JM, Abakumova I, Mae MA, Raschperger E, Zatz M, Zschiedrich K, Klepper J, Spiteri E, Prieto JM, Navas I, Preuss M, Dering C, Jankovic M, Paucar M, Svenningsson P, Saliminejad K, Khorshid HR, Novakovic I, Aguzzi A, Boss A, Le Ber I, Defer G, Hannequin D, Kostic VS, Campion D, Geschwind DH, Coppola G, Betsholtz C, Klein C, Oliveira JR
  TITLE     Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice.
  JOURNAL   Nat Genet 45:1077-82 (2013)
REFERENCE   PMID:25938945 (gene)
  AUTHORS   Legati A, Giovannini D, Nicolas G, Lopez-Sanchez U, Quintans B, Oliveira JR, Sears RL, Ramos EM, Spiteri E, Sobrido MJ, Carracedo A, Castro-Fernandez C, Cubizolle S, Fogel BL, Goizet C, Jen JC, Kirdlarp S, Lang AE, Miedzybrodzka Z, Mitarnun W, Paucar M, Paulson H, Pariente J, Richard AC, Salins NS, Simpson SA, Striano P, Svenningsson P, Tison F, Unni VK, Vanakker O, Wessels MW, Wetchaphanphesat S, Yang M, Boller F, Campion D, Hannequin D, Sitbon M, Geschwind DH, Battini JL, Coppola G
  TITLE     Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export.
  JOURNAL   Nat Genet 47:579-81 (2015)
///
ENTRY       H01575                      Disease
NAME        Roifman syndrome;
            Spondyloepiphseal dysplasia, retinal dystrophy, and antibody deficiency
DESCRIPTION Roifman syndrome is a multi-system disorder with a physical phenotype that includes B-cell immunodeficiency, intra-uterine and postnatal growth retardation, spondyloepiphyseal dysplasia, retinal dystrophy, and characteristic facial dysmorphism. Recently, whole-genome sequencing of Roifman syndrome patients have demonstrated that Roifman syndrome is caused by compound heterozygous single-nucleotide variants (SNVs) in the minor spliceosomal small nuclear RNA (snRNA) gene RNU4ATAC, which was already implicated in a severe congenital disorder, microcephalic osteodysplastic primordial dwarfism, type I (MOPD1) [DS:H00993]. Roifman syndrome is phenotypically distinct from MOPD1.
CATEGORY    Skeletal dysplasia; Immune system disease
GENE        RNU4ATAC [HSA:5190] [KO:K13339]
DBLINKS     ICD-10: Q77.7
            MeSH: C535866
            OMIM: 616651
REFERENCE   PMID:16901296 (description)
  AUTHORS   de Vries PJ, McCartney DL, McCartney E, Woolf D, Wozencroft D
  TITLE     The cognitive and behavioural phenotype of Roifman syndrome.
  JOURNAL   J Intellect Disabil Res 50:690-6 (2006)
REFERENCE   PMID:26522830 (description, gene)
  AUTHORS   Merico D, Roifman M, Braunschweig U, Yuen RK, Alexandrova R, Bates A, Reid B, Nalpathamkalam T, Wang Z, Thiruvahindrapuram B, Gray P, Kakakios A, Peake J, Hogarth S, Manson D, Buncic R, Pereira SL, Herbrick JA, Blencowe BJ, Roifman CM, Scherer SW
  TITLE     Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome  by disrupting minor intron splicing.
  JOURNAL   Nat Commun 6:8718 (2015)
///
ENTRY       H01576                      Disease
NAME        Spondyloenchondrodysplasia with immune dysregulation (SPENCDI);
            Spondyloenchondrodysplasia (SPENCD)
DESCRIPTION Spondyloenchondrodysplasia with immune dysregulation (SPENCDI) is an autosomal recessive skeletal dysplasia, characterised by radiolucent metaphyseal and vertebral lesions. Patients may exhibit varying degrees of neurological impairment including spasticity, developmental delay, and basal ganglia calcification. In addition, signs of autoimmune disease resembling systemic lupus erythematosus (SLE) are commonly observed. Furthermore, patients may also suffer from recurrent infections. SPENCD is caused by biallelic mutations in ACP5, encoding tartrate-resistant acid phosphatase (TRAP). Affected individuals displayed an absence of TRAP serum expression and, in keeping with autoimmune manifestations, increased levels of serum interferon-alpha (IFNalpha) and an upregulation of interferon-stimulated genes (ISGs).
CATEGORY    Skeletal dysplasia; Immune system disease
GENE        ACP5 [HSA:54] [KO:K14379]
DBLINKS     MeSH: C564307
            OMIM: 607944
REFERENCE   PMID:26951490 (description)
  AUTHORS   Briggs TA, Rice GI, Adib N, Ades L, Barete S, Baskar K, Baudouin V, Cebeci AN, Clapuyt P, Coman D, De Somer L, Finezilber Y, Frydman M, Guven A, Heritier S, Karall D, Kulkarni ML, Lebon P, Levitt D, Le Merrer M, Linglart A, Livingston JH, Navarro V, Okenfuss E, Puel A, Revencu N, Scholl-Burgi S, Vivarelli M, Wouters C, Bader-Meunier B, Crow YJ
  TITLE     Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey.
  JOURNAL   J Clin Immunol 36:220-34 (2016)
REFERENCE   PMID:21217752 (description, gene)
  AUTHORS   Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, De Laet C, Hubner CA, Meinecke P, Nishimura G, Matsuo M, Hirano Y, Tenoutasse S, Kiss A, Rosa RF, Unger SL, Renella R, Bonafe L, Spranger J, Unger S, Zabel B, Superti-Furga A
  TITLE     Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity.
  JOURNAL   Nat Genet 43:132-7 (2011)
REFERENCE   PMID:26346816 (description)
  AUTHORS   Girschick H, Wolf C, Morbach H, Hertzberg C, Lee-Kirsch MA
  TITLE     Severe immune dysregulation with neurological impairment and minor bone changes in a child with spondyloenchondrodysplasia due to two novel mutations in the ACP5 gene.
  JOURNAL   Pediatr Rheumatol Online J 13:37 (2015)
///
ENTRY       H01577                      Disease
NAME        Essential tremor
DESCRIPTION Essential tremor (ET) is a neurological disorder that is considered to be one of the most common adult-onset movement disorders. ET is typically characterized by rhythmic, involuntary shaking of one or more parts of the body, and occurs exclusively during voluntary movements (action tremor) or in positions against gravity (postural tremor). The phenotypic severity of ET is variable, as evidenced by the existence of both highly disabling and milder forms of the disease. There are three subtypes of ET, namely hereditary, sporadic, and senile, and most studies indicate that ET is a hereditary disorder in more than half of affected individuals (and presumably has autosomal-dominant inheritance). The diagnostic approach includes obtaining a history, physical examination, and laboratory tests. At present, there are no validated serologic, radiologic, or pathological markers.
CATEGORY    Nervous system disease
GENE        FUS [HSA:2521] [KO:K13098]
            TENM4 [HSA:26011]
DBLINKS     ICD-10: G25.0
            MeSH: D020329
            OMIM: 614782 616736
REFERENCE   PMID:11565522 (description)
  AUTHORS   Louis ED
  TITLE     Clinical practice. Essential tremor.
  JOURNAL   N Engl J Med 345:887-91 (2001)
REFERENCE   PMID:17353225 (description)
  AUTHORS   Deng H, Le W, Jankovic J
  TITLE     Genetics of essential tremor.
  JOURNAL   Brain 130:1456-64 (2007)
REFERENCE   PMID:22863194 (description, gene)
  AUTHORS   Merner ND, Girard SL, Catoire H, Bourassa CV, Belzil VV, Riviere JB, Hince P, Levert A, Dionne-Laporte A, Spiegelman D, Noreau A, Diab S, Szuto A, Fournier H, Raelson J, Belouchi M, Panisset M, Cossette P, Dupre N, Bernard G, Chouinard S, Dion PA, Rouleau GA
  TITLE     Exome sequencing identifies FUS mutations as a cause of essential tremor.
  JOURNAL   Am J Hum Genet 91:313-9 (2012)
REFERENCE   PMID:26188006 (description, gene)
  AUTHORS   Hor H, Francescatto L, Bartesaghi L, Ortega-Cubero S, Kousi M, Lorenzo-Betancor O, Jimenez-Jimenez FJ, Gironell A, Clarimon J, Drechsel O, Agundez JA, Kenzelmann Broz D, Chiquet-Ehrismann R, Lleo A, Coria F, Garcia-Martin E, Alonso-Navarro H, Marti MJ, Kulisevsky J, Hor CN, Ossowski S, Chrast R, Katsanis N, Pastor P, Estivill X
  TITLE     Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor.
  JOURNAL   Hum Mol Genet 24:5677-86 (2015)
///
ENTRY       H01578                      Disease
NAME        Subacute myelo-optico-neuropathy (SMON)
DESCRIPTION Subacute myelo-optico-neuropathy (SMON) is a severe neurodegenerative disorder caused by poisoning due to over-dose and prolonged oral administration of clioquinol. SMON is characterized by subacute onset of sensory and motor disorders in the lower half of the body and visual impairment preceded by abdominal symptoms, such as abdominal pain and diarrhea. Despite clinical features mimicking infection or multiple sclerosis, the discovery of the green hairy tongue and the green urine in SMON patients aroused researchers' interest and thereby began solving the cause of SMON. The green color was derived from a chelate compound of clioquinol with ferric iron. A large number of SMON were observed throughout Japan, and the total number of cases reached nearly 10,000 by 1970. After the governmental ban on the use of clioquinol in September 1970, there was a dramatic disappearance of new case of SMON. However, in Japan, there are still more than 2500 SMON patients suffering from severe dysesthesia/paresthesia and ataxic paraplegia.
CATEGORY    Neurodegenerative disease
ENV_FACTOR  Clioquinol [DR:D03538]
DRUG        Neurotropin [DR:D07630]
DBLINKS     ICD-10: G62.0
            MeSH: D011115
REFERENCE   PMID:20548321
  AUTHORS   Kimura E, Hirano T, Yamashita S, Hirai T, Uchida Y, Maeda Y, Uchino M
  TITLE     Cervical MRI of subacute myelo-optico-neuropathy.
  JOURNAL   Spinal Cord 49:182-5 (2011)
REFERENCE   PMID:23222550
  AUTHORS   Igata A
  TITLE     Subacute myelooptic neuropathy, beriberi, and HTLVIassociated myelopathy: elucidation of some neurological diseases in Japan.
  JOURNAL   Pol Arch Med Wewn 122 Suppl 1:32-41 (2012)
REFERENCE   PMID:3210443
  AUTHORS   Hata T, Kita T, Itoh E, Oyama R, Kawabata A
  TITLE     Mechanism of the analgesic effect of neurotropin.
  JOURNAL   Jpn J Pharmacol 48:165-73 (1988)
///
ENTRY       H01579                      Disease
NAME        Congenital symmetric circumferential skin creases;
            Kunze-Riehm syndrome;
            Michelin tire baby syndrome
DESCRIPTION Congenital symmetric circumferential skin creases, also known as Michelin tire baby syndrome, is a rare genetic disorder characterized by generalized folding of excess skin. This feature was first described in 1969, then subsequent reports described variable additional features, such as intellectual disability (ID), facial dysmorphism, and cardiac and genital anomalies. It has been reported that mutations in either MAPRE2 or TUBB underlie the genetic origin of this syndrome. MAPRE2 encodes a member of the microtubule end-binding family of proteins that bind to the guanosine triphosphate cap at growing microtubule plus ends, and TUBB encodes a beta-tubulin isotype that is expressed abundantly in the developing brain.
CATEGORY    Skin and connective tissue disease
GENE        TUBB [HSA:203068] [KO:K07375]
            MAPRE2 [HSA:10982] [KO:K10436]
DBLINKS     ICD-10: Q82.8
            MeSH: C537575
            OMIM: 156610 616734
REFERENCE   PMID:26637975 (description, gene)
  AUTHORS   Isrie M, Breuss M, Tian G, Hansen AH, Cristofoli F, Morandell J, Kupchinsky ZA, Sifrim A, Rodriguez-Rodriguez CM, Dapena EP, Doonanco K, Leonard N, Tinsa F, Moortgat S, Ulucan H, Koparir E, Karaca E, Katsanis N, Marton V, Vermeesch JR, Davis EE, Cowan NJ, Keays DA, Van Esch H
  TITLE     Mutations in Either TUBB or MAPRE2 Cause Circumferential Skin Creases Kunze Type.
  JOURNAL   Am J Hum Genet 97:790-800 (2015)
REFERENCE   PMID:21381593 (description)
  AUTHORS   Farooqi GA, Mulla SA, Ahmad M
  TITLE     Michelin tire baby syndrome--a case report and literature review.
  JOURNAL   J Pak Med Assoc 60:777-9 (2010)
///
ENTRY       H01580                      Disease
NAME        Vitamin C deficiency;
            Scurvy
DESCRIPTION Scurvy occurs because of reduced intake or absorption of vitamin C, which is characterized by bleeding gums, impaired wound healing, petechiae, perifollicular hemorrhage, anemia, arthralgia and joint effusions, fatigue, depression, and sudden death. It appears to result primarily from the decreased synthesis of collagen, a major protein in the body dependent on vitamin C for its biosynthesis. However, this role of vitamin C does not explain all of the manifestations associated with scurvy. At-risk groups include the poor (because of reduced access to groceries), food faddists, and individuals with purported allergies to multiple fruit and vegetable products. Other at-risk groups include persons with gastrointestinal disease (e.g. colitis), anatomical abnormalities, poor dentition, cancer patients on chemotherapy, patients on hemodialysis, and psychiatric disorders (e.g. depression, schizophrenia, or anorexia). Alcoholic persons represent one of the largest groups at risk for scurvy because they may have poorly balanced diets and because alcohol decreases the absorption of vitamin C. The diagnosis of scurvy is generally based on clinical features and dietary history, and there is rapid resolution of signs and symptoms after vitamin C supplementation.
CATEGORY    Hematologic disease; Cardiovascular disease; Metabolic disease
DRUG        Ascorbic acid [DR:D00018]
DBLINKS     ICD-10: E54
            MeSH: D012614
REFERENCE   PMID:7946525 (description)
  AUTHORS   Sauberlich HE
  TITLE     Pharmacology of vitamin C.
  JOURNAL   Annu Rev Nutr 14:371-91 (1994)
REFERENCE   PMID:16911372 (description, drug)
  AUTHORS   Olmedo JM, Yiannias JA, Windgassen EB, Gornet MK
  TITLE     Scurvy: a disease almost forgotten.
  JOURNAL   Int J Dermatol 45:909-13 (2006)
///
ENTRY       H01581                      Disease
NAME        IgA nephropathy;
            Berger disease
DESCRIPTION Primary IgA nephropathy is an immune-complex-mediated glomerulonephritis defined immunohistologically by the presence of glomerular IgA deposits accompanied by a variety of histopathologic lesions. It is known to be the most prevalent primary chronic glomerular disease worldwide. Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. Since the features of IgA nephropathy identified by light microscopy are nonspecific, immunofluorescence or immunoperoxidase studies demonstrating a predominant deposition of IgA are essential to establish a definitive diagnosis of IgA nephropathy. Genetic factors undoubtedly influence the pathogenesis of IgA nephropathy. Genomewide association studies have identified common susceptibility loci in the absence of a priori mechanistic hypotheses.
CATEGORY    Inherited metabolic disease; Urologic disease; Immune system disease
DRUG        Dilazep [DR:D02631]
DBLINKS     ICD-10: N02.8
            MeSH: D005922
REFERENCE   PMID:12213946 (description)
  AUTHORS   Donadio JV, Grande JP
  TITLE     IgA nephropathy.
  JOURNAL   N Engl J Med 347:738-48 (2002)
REFERENCE   PMID:23782179 (descrition)
  AUTHORS   Wyatt RJ, Julian BA
  TITLE     IgA nephropathy.
  JOURNAL   N Engl J Med 368:2402-14 (2013)
///
ENTRY       H01582                      Disease
NAME        Pellagra
DESCRIPTION Pellagra is a remarkable chronic wasting disorder, the late stage of a severe cellular deficiency of niacin (vitamin B3). The classical triad of pellagra is dermatitis, diarrhea and dementia. Early symptoms include lassitude, weakness, loss of appetite, mild digestive disturbances and psychiatric distress. The dermatitis caused by pellagra is a bilaterally symmetrical eruption at cutaneous sites of solar exposure. It tends to be painful to touch during the acute phase and can eventually become so clinically striking that the patient may become ostracized.  Untreated pellagra results in death from multiorgan failure. Pellagra used to be a disease of epidemic proportions in the developed world. In the 18th century, it was linked with poverty and subsistence on nutritionally marginal corn-based diets. In the 1940s and 1950s, with expanded biochemical knowledge, pellagra was reformulated as a deficiency disease due to inadequate niacin and its amino acid precursor tryptophan.  It is currently seen in association with other conditions of chronic nutritional deficiencies, like alcoholism.
CATEGORY    Metabolic disorders; Nervous system disease; Skin disease
DRUG        Nicotinamide [DR:D00036]
            Nicotinic acid [DR:D00049]
            Flavin [DR:D02011]
            Riboflavin [DR:D00050 D01622]
DBLINKS     ICD-10: E52
            MeSH: D010383
REFERENCE   PMID:14693013
  AUTHORS   Hegyi J, Schwartz RA, Hegyi V
  TITLE     Pellagra: dermatitis, dementia, and diarrhea.
  JOURNAL   Int J Dermatol 43:1-5 (2004)
REFERENCE   PMID:24627570
  AUTHORS   Badawy AA
  TITLE     Pellagra and alcoholism: a biochemical perspective.
  JOURNAL   Alcohol Alcohol 49:238-50 (2014)
REFERENCE   PMID:19892133 (drug)
  AUTHORS   Lanska DJ
  TITLE     Chapter 30: historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins.
  JOURNAL   Handb Clin Neurol 95:445-76 (2010)
REFERENCE   PMID:16745723 (drug)
  AUTHORS   Harris LJ
  TITLE     Flavin and the pellagra-preventing factor as separate constituents of a complex vitamin B(2).
  JOURNAL   Biochem J 29:776-81 (1935)
///
ENTRY       H01583                      Disease
NAME        Hydroxykynureninuria;
            Xanthurenic aciduria;
            Kynureninase deficiency
DESCRIPTION Hydroxykynureninuria, also known as xanthurenic aciduria is autosomal recessive disorder of tryptophan metabolism. It is characterized by excessive output of xanthutrenic acid, 3-hydroxykynurenine, and kynurenine in urine. This disease is caused by homozygous mutation in the KYNU gene, which encodes kynureninase. Kynureninase is an enzyme in the catabolic pathway of tryptophan metabolism. Some of these deficiencies lead to pellagra or mild pellagra-like symptoms, while it was reported in some patients no symptom of niacin deficiency was observed. The different clinical outcomes could be explained by differences in the intake of niacin. The sufficient intake of niacin could prevent depletion in some patients despite their impaired niacin synthesis.
CATEGORY    Inherited metabolic disease
GENE        KYNU [HSA:8942] [KO:K01556]
MARKER      Kynurenine [CPD:C00328]
            3-hydroxykynurenine [CPD:C03227]
            Xanthurenic acid [CPD:C02470]
DRUG        Nicotinamide [DR:D00036]
            Nicotinic acid [DR:D00049]
COMMENT     See also H01582 Pellagra.
DBLINKS     ICD-10: E70.8
            MeSH: C536081
            OMIM: 236800
REFERENCE   PMID:17334708
  AUTHORS   Christensen M, Duno M, Lund AM, Skovby F, Christensen E
  TITLE     Xanthurenic aciduria due to a mutation in KYNU encoding kynureninase.
  JOURNAL   J Inherit Metab Dis 30:248-55 (2007)
///
ENTRY       H01584                      Disease
NAME        IgA vasculitis;
            Henoch-Schonlein purpura
DESCRIPTION Henoch-Schonlein purpura (HSP) is the most common systemic small vessel vasculitis in childhood with clinical characteristics of non-thrombocytopenic palpable purpura, arthritis, and involvement of internal organs such as gastrointestine (GI) and kidney. HSP has been associated with a history of preceding infections, especially upper respiratory tract infection. In addition, other characteristics of HSP include the deposition of IgA and C3 in small vessel walls, polymorphonuclear neutrophil infiltration around the vessel and in vessel walls, and increased serum levels of IgA and proinflammatory cytokines at the acute stage. Combined, HSP is regarded as a specific immune-mediated entity induced by environmental factors, particularly infections. Clinically, since there are no disease-specific laboratory abnormalities, HSP is currently diagnosed based on symptoms and signs and histopathological findings. Treatment is supportive because HSP is usually self-limiting except for serious GI or renal involvement.
CATEGORY    Cardiovascular disease; Hematologic disease; Immune system disease
DRUG        Betamethasone [DR:D00244]
DBLINKS     ICD-10: D69.0
            MeSH: D011695
REFERENCE   PMID:24424188 (description)
  AUTHORS   Yang YH, Yu HH, Chiang BL
  TITLE     The diagnosis and classification of Henoch-Schonlein purpura: an updated review.
  JOURNAL   Autoimmun Rev 13:355-8 (2014)
REFERENCE   PMID:23325094 (description)
  AUTHORS   He X, Yu C, Zhao P, Ding Y, Liang X, Zhao Y, Yue X, Wu Y, Yin W
  TITLE     The genetics of Henoch-Schonlein purpura: a systematic review and meta-analysis.
  JOURNAL   Rheumatol Int 33:1387-95 (2013)
///
ENTRY       H01585                      Disease
NAME        Autoimmune hemolytic anemia (AIHA)
DESCRIPTION Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by the increased destruction of red blood cells (RBCs) by anti-RBC autoantibodies with or without complement activation. AIHAs can be distinguished on the basis of the autoantibody Ig class and thermal characteristics, i.e. the optimal temperature of reaction with autologous erythrocytes, in warm (wAIHA), cold (cold agglutinin disease; CAD), and mixed forms, although atypical cases of difficult diagnostic classification are reported with increasing frequency. Moreover, AIHAs are classified in primary (idiopathic), in which hemolysis dominates the clinical picture in the absence of any other coexisting disorder, and in secondary forms, accompanying and complicating an underlying disease. AIHA may develop gradually, or have a fulminant onset with life-threatening anemia. The diagnosis is usually simple, based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test (DAT).
CATEGORY    Hematologic disease; Immune system disease
DRUG        Eculizumab [DR:D03940]
DBLINKS     ICD-10: D59.0 D59.1
            MeSH: D000744
REFERENCE   PMID:26696796 (description)
  AUTHORS   Barcellini W
  TITLE     New Insights in the Pathogenesis of Autoimmune Hemolytic Anemia.
  JOURNAL   Transfus Med Hemother 42:287-93 (2015)
REFERENCE   PMID:25271314 (description)
  AUTHORS   Zanella A, Barcellini W
  TITLE     Treatment of autoimmune hemolytic anemias.
  JOURNAL   Haematologica 99:1547-54 (2014)
///
ENTRY       H01586                      Disease
NAME        Acquired pure red cell aplasia
DESCRIPTION Pure red cell aplasia (PRCA) is a rare condition characterised by selective inhibition and the absence of red cell precursors in the bone marrow with consequent anaemia and reticulocytopenia in the presence of normal granulocytic and megakaryocytic lineages. RPCA can be classified into congenital and acquired. Congenital PRCA is also known as Diamond-Blackfan anemia [DS:H00237] and is a disease of infancy and early childhood. The aetiology of acquired PRCA can be subclassified into primary and secondary. Primary PRCA is defined when no aetiology can be identified using available investigations. The causes of secondary PRCA are again diverse and can be due to infections (viral, bacterial, etc.), drugs (erythropoietin, carbamazepine, etc.), collagen vascular disorders (rheumatoid arthritis, systemic lupus erythematosus, etc.), malignancies (e.g. thymoma), ABO-incompatible haematopoietic stem cell transplantation, and pregnancy. Depending on the cause, the course can be acute and self-limiting or chronic with rare spontaneous remissions. PRCA can be easily diagnosed when isolated anaemia, in the presence of normal white cell and platelet counts, is associated with a marrow of normal cellularity in which there is an almost complete absence of erythroblasts but normal myeloid cells and megakaryocytes. Primary, or secondary PRCA not responding to treatment of the underlying diseases, is treated as an immunologically-mediated disease. The therapeutic plan usually focuses on the sequential use of various immunosuppressive therapies until a remission is obtained.
CATEGORY    Hematologic disease; Immune system disease
DRUG        Ciclosporin [DR:D00184]
COMMENT     See also H00237.
DBLINKS     ICD-10: D60
            MeSH: D012010
REFERENCE   PMID:18616874 (description)
  AUTHORS   Malhotra P, Muralikrishna GK, Varma N, Kumari S, Das R, Ahluwalia J, Jain S, Varma S
  TITLE     Spectrum of pure red cell aplasia in adult population of north-west India.
  JOURNAL   Hematology 13:88-91 (2008)
REFERENCE   PMID:18510682 (description)
  AUTHORS   Sawada K, Fujishima N, Hirokawa M
  TITLE     Acquired pure red cell aplasia: updated review of treatment.
  JOURNAL   Br J Haematol 142:505-14 (2008)
///
ENTRY       H01587                      Disease
NAME        Disseminated intravascular coagulation (DIC)
DESCRIPTION Disseminated intravascular coagulation (DIC) is an acquired syndrome characterised by the intravascular activation of coagulation with loss of localisation arising from different causes. It can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction. DIC is not a disease entity on itself but is always associated to an underlying disease. The clinical conditions that may be associated with DIC include sepsis, trauma, malignancy, liver disease, obstetric disorders, envenomation, vascular anomalies, and major transfusion reactions. A diagnosis of DIC should be made only in the presence of a clinical condition (causative factor) supported by repeated laboratory tests for coagulation profile and clotting factors. Treatment of DIC is aimed at combating the underlying disorder followed by supportive management.
CATEGORY    Hematologic disease
DRUG        Antithrombin [DR:D08795 D10684]
            Thrombomodulin alfa [DR:D06410]
            Heparin derivatives [DR:D03353 D03644]
DBLINKS     ICD-10: D65
            MeSH: D004211
REFERENCE   PMID:12350365 (description)
  AUTHORS   Levi M, de Jonge E, Meijers J
  TITLE     The diagnosis of disseminated intravascular coagulation.
  JOURNAL   Blood Rev 16:217-23 (2002)
REFERENCE   PMID:23015284 (description)
  AUTHORS   Levi M, van der Poll T
  TITLE     Disseminated intravascular coagulation: a review for the internist.
  JOURNAL   Intern Emerg Med 8:23-32 (2013)
REFERENCE   PMID:25535423 (description)
  AUTHORS   Venugopal A
  TITLE     Disseminated intravascular coagulation.
  JOURNAL   Indian J Anaesth 58:603-8 (2014)
///
ENTRY       H01588                      Disease
NAME        Cluster headache
DESCRIPTION Cluster headache (CH) is the commonest of the trigeminal autonomic cephalalgias (TAC) characterized by attacks of severe, strictly unilateral pain, which is orbital, supraorbital, temporal, or in any combination of these sites, with duration of pain attacks of 15 to 180 min. The pain of CH is associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or restlessness or agitation. Headaches often recur at the same time each day during the cluster period, which can last for weeks to months. CH occurs more commonly in male patients (2.5:1 to 4.3:1 male to female) with an average age of onset in the third or fourth decade. The pathophysiology of CH is not fully understood, but may include a genetic component. Treatment focuses on avoiding triggers and includes abortive therapies, prophylaxis during the cluster period, and long-term treatment in patients with chronic CH. Evidence supports the use of supplemental oxygen, sumatriptan, and zolmitriptan for acute treatment of episodic CH. Verapamil is used to treat chronic CH. More invasive treatments, including nerve stimulation and surgery, may be helpful in refractory cases.
CATEGORY    Nervous system disease
DRUG        Sumatriptan [DR:D00676]
DBLINKS     ICD-10: G44.0
            MeSH: D003027
REFERENCE   PMID:26711274 (description, drug)
  AUTHORS   VanderPluym J
  TITLE     Cluster Headache: Special Considerations for Treatment of Female Patients of Reproductive Age and Pediatric Patients.
  JOURNAL   Curr Neurol Neurosci Rep 16:5 (2016)
REFERENCE   PMID:26635477 (description)
  AUTHORS   Gooriah R, Buture A, Ahmed F
  TITLE     Evidence-based treatments for cluster headache.
  JOURNAL   Ther Clin Risk Manag 11:1687-96 (2015)
REFERENCE   PMID:23939643 (description)
  AUTHORS   Weaver-Agostoni J
  TITLE     Cluster headache.
  JOURNAL   Am Fam Physician 88:122-8 (2013)
///
ENTRY       H01589                      Disease
NAME        Systemic primary carnitine deficiency
DESCRIPTION Systemic primary carnitine deficiency is a rare autosomal recessive disorder characterized by cardiomyopathy, muscle weakness, hypoglycemic hypoketotic coma, and hyperammonemia. Carnitine plays essential roles in the transportation of long-chain fatty acids into the mitochondria for beta-oxidation. This disease is caused by mutations in SLC22A5 that encodes the high-affinity sodium-dependent carnitine transporter, organic cation transporter 2 (OCTN2). The hallmark of systemic primary carnitine deficiency is low concentrations of carnitine in plasma, with accumulation of lipid deposits and renal leakage of carnitine. The clinical symptoms are alleviated dramatically by oral administration of L-carnitine. However, if untreated, patients are precipitated into a crisis with cardiac arrest or Reye-like syndrome that includes acute encephalopathy and fatty degenerative liver failure.
CATEGORY    Inherited metabolic disease
GENE        SLC22A5 [HSA:6584] [KO:K08202]
MARKER      Low serum free-carnitine [CPD:C00318] and acylcarnitine [CPD:C02301] levels.
DRUG        Levocarnitine [DR:D02030 D02176]
COMMENT     See also H00525  Disorders of fatty-acid oxidation.
DBLINKS     ICD-10: E71.3
            MeSH: C536778
            OMIM: 212140
REFERENCE   PMID:23379544 (gene, drug)
  AUTHORS   Shibbani K, Fahed AC, Al-Shaar L, Arabi M, Nemer G, Bitar F, Majdalani M
  TITLE     Primary carnitine deficiency: novel mutations and insights into the cardiac phenotype.
  JOURNAL   Clin Genet 85:127-37 (2014)
REFERENCE   PMID:9634512 (gene, marker)
  AUTHORS   Shoji Y, Koizumi A, Kayo T, Ohata T, Takahashi T, Harada K, Takada G
  TITLE     Evidence for linkage of human primary systemic carnitine deficiency with D5S436:  a novel gene locus on chromosome 5q.
  JOURNAL   Am J Hum Genet 63:101-8 (1998)
REFERENCE   PMID:16865412 (marker)
  AUTHORS   Vijay S, Patterson A, Olpin S, Henderson MJ, Clark S, Day C, Savill G, Walter JH
  TITLE     Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants.
  JOURNAL   J Inherit Metab Dis 29:627-30 (2006)
///
ENTRY       H01590                      Disease
NAME        Chronic eosinophilic leukemia
DESCRIPTION Chronic eosinophilic leukemia (CEL) is a chronic myeloproliferative disease of unknown etiology in which a clonal proliferation of eosinophilic precursors results in a persistently elevated number of eosinophils in blood, bone marrow or peripheral tissues. In most patients with CEL (about 60%), eosinophils display PDGFRA-fusion genes and related cytogenetic defects. The most commonly detected oncoprotein is FIP1L1/PDGFRA. FIP1L1-PDGFRA is a constitutively activated tyrosine kinase, which is suggested to induce the proliferation of EoL-1 (The eosinophilic leukemia cell line) cells by inducing c-Myc expression at the mRNA level via ERK and JNK signaling pathways.
CATEGORY    Cancer
GENE        FIP1L1-PDGFRA (deletion) [HSA:81608 5156] [KO:K14405 K04363]
            BCR-PDGFRA (translocation) [HSA:613 5156] [KO:K08878 K04363]
MARKER      FIP1L1-PDGFRA [HSA:81608 5156] [KO:K14405 K04363]
            BCR-PDGFRA [HSA:613 5156] [KO:K08878 K04363]
            KIF5B-PDGFRA [HSA:3799 5156] [KO:K10396 K04363]
            CDK5RAP2-PDGFRA [HSA:55755 5156] [KO:K16542 K04363]
DRUG        Imatinib [DR:D08066]
            Prednisone [DR:D00473]
            Hydroxyurea [DR:D00341]
            Interferon-alpha [DR:D03305]
COMMENT     ICD-O-3:9964/3 Chronic eosinophilic leukemia, NOS
DBLINKS     ICD-10: D47.5
            MeSH: C580364
REFERENCE   PMID:15070659 (gene)
  AUTHORS   Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE
  TITLE     The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
  JOURNAL   Blood 103:2879-91 (2004)
REFERENCE   PMID:23100928 (description)
  AUTHORS   Kumar A, Sinha S, Tripathi AK
  TITLE     Chronic eosinophilic leukemia: a case report and review of literature.
  JOURNAL   Indian J Hematol Blood Transfus 23:112-5 (2007)
REFERENCE   PMID:23662039 (gene)
  AUTHORS   Yamada Y, Rothenberg ME, Cancelas JA
  TITLE     Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.
  JOURNAL   Transl Oncogenomics 1:53-63 (2006)
REFERENCE   PMID:16781488 (gene, drug)
  AUTHORS   Gotlib J, Cross NC, Gilliland DG
  TITLE     Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
  JOURNAL   Best Pract Res Clin Haematol 19:535-69 (2006)
REFERENCE   PMID:19246139 (description, marker)
  AUTHORS   Valent P
  TITLE     Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
  JOURNAL   Blood Rev 23:157-65 (2009)
REFERENCE   PMID:18086564 (description, gene)
  AUTHORS   Ishihara K, Kitamura H, Hiraizumi K, Kaneko M, Takahashi A, Zee O, Seyama T, Hong J, Ohuchi K, Hirasawa N
  TITLE     Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
  JOURNAL   Biochem Biophys Res Commun 366:1007-11 (2008)
REFERENCE   PMID:16341034 (gene)
  AUTHORS   De Keersmaecker K, Cools J
  TITLE     Chronic myeloproliferative disorders: a tyrosine kinase tale.
  JOURNAL   Leukemia 20:200-5 (2006)
///
ENTRY       H01591                      Disease
NAME        Gastrotintestinal stromal tumor
DESCRIPTION Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract, arising from the interstitial cells of Cajal, or their precursor stem cells. GISTs account for about 80% of gastrointestinal sarcomas, with a mean annual incidence of 10-15 per million. Nearly 50-70% of the clinically apparent tumors arise in the stomach, 20-30% arise in the small intestine, 5-15% in the large intestine, and less than 5% in other locations. The genetic basis of GIST growth is a mutation of the KIT or PDGFRA gene leading to constitutional activation of receptor tyrosine kinases, which is the driving force behind tumor development.
CATEGORY    Cancer
GENE        KIT (mutation) [HSA:3815] [KO:K05091]
            PDGFRA (mutation) [HSA:5156] [KO:K04363]
MARKER      KIT [HSA:3815] [KO:K05091]
            PDGFRA [HSA:5156] [KO:K04363]
DRUG        Imatinib mesylate [DR:D08066]
            Sunitinib malate [DR:D06402]
COMMENT     ICD-O-3:8936/1 Gastrointestinal stromal tumor, NOS
            ICD-O-3:8936/3 Gastrointestinal stromal sarcoma
DBLINKS     ICD-10: C26
            MeSH: D046152
REFERENCE   PMID:25414046 (gene, drug)
  AUTHORS   Yamamoto H, Oda Y
  TITLE     Gastrointestinal stromal tumor: recent advances in pathology and genetics.
  JOURNAL   Pathol Int 65:9-18 (2015)
REFERENCE   PMID:26098203 (description, gene, drug)
  AUTHORS   Alturkmani HJ, Pessetto ZY, Godwin AK
  TITLE     Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.
  JOURNAL   Expert Opin Investig Drugs 24:1045-58 (2015)
REFERENCE   PMID:26276366 (gene, drug)
  AUTHORS   Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK
  TITLE     The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
  JOURNAL   Gastric Cancer 19:3-14 (2016)
REFERENCE   PMID:24384849 (description, gene, drug)
  AUTHORS   Corless CL
  TITLE     Gastrointestinal stromal tumors: what do we know now?
  JOURNAL   Mod Pathol 27 Suppl 1:S1-16 (2014)
REFERENCE   PMID:22124674 (description, gene, drug)
  AUTHORS   Beham AW, Schaefer IM, Schuler P, Cameron S, Ghadimi BM
  TITLE     Gastrointestinal stromal tumors.
  JOURNAL   Int J Colorectal Dis 27:689-700 (2012)
REFERENCE   PMID:26243346 (gene, marker, drug)
  AUTHORS   Valsangkar N, Sehdev A, Misra S, Zimmers TA, O'Neil BH, Koniaris LG
  TITLE     Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy.
  JOURNAL   Surgery 158:1149-64 (2015)
///
ENTRY       H01592                      Disease
NAME        Medullary thyroid cancer
DESCRIPTION Medullary thyroid carcinoma (MTC) is a malignant tumor originating from thyroid parafollicular C cells and accounts for only <5% of thyroid cancers, but it causes a disproportionate number of thyroid cancer deaths due to its more aggressive clinical behavior compared with well-differentiated papillary and follicular thyroid carcinomas. A subset of MTC cases is hereditary and due to germline mutations in the RET tyrosine kinase receptor gene. Somatic mutations in either RET or RAS are also present in most sporadic tumors. In MTC, RET mutations lead to substrate-independent dimerization of the receptor causing constitutive activation, unrestricted signaling, and ultimately, cancer.
CATEGORY    Cancer
GENE        RET [HSA:5979] [KO:K05126]
            HRAS [HSA:3265] [KO:K02833]
            KRAS [HSA:3845] [KO:K07827]
MARKER      Calcitonin [CPD:C06865]
DRUG        Vandetanib [DR:D06407]
            Cabozantinib [DR:D10062]
COMMENT     ICD-O-3:8345/3 Medullary carcinoma with amyloid stroma
DBLINKS     ICD-10: C73
            MeSH: C536914
REFERENCE   PMID:25972318 (gene, drug)
  AUTHORS   Chernock RD, Hagemann IS
  TITLE     Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.
  JOURNAL   Am J Clin Pathol 143:768-77 (2015)
REFERENCE   PMID:24316908 (gene)
  AUTHORS   Pusztaszeri MP, Bongiovanni M, Faquin WC
  TITLE     Update on the cytologic and molecular features of medullary thyroid carcinoma.
  JOURNAL   Adv Anat Pathol 21:26-35 (2014)
REFERENCE   PMID:23955938
  AUTHORS   Trimboli P, Giovanella L, Crescenzi A, Romanelli F, Valabrega S, Spriano G, Cremonini N, Guglielmi R, Papini E
  TITLE     Medullary thyroid cancer diagnosis: an appraisal.
  JOURNAL   Head Neck 36:1216-23 (2014)
REFERENCE   PMID:26494384
  AUTHORS   Raue F, Frank-Raue K
  TITLE     Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
  JOURNAL   Recent Results Cancer Res 204:61-90 (2015)
REFERENCE   PMID:24942936 (gene, drug)
  AUTHORS   Maxwell JE, Sherman SK, O'Dorisio TM, Howe JR
  TITLE     Medical management of metastatic medullary thyroid cancer.
  JOURNAL   Cancer 120:3287-301 (2014)
///
ENTRY       H01593                      Disease
NAME        Osteoporosis
DESCRIPTION Osteoporosis is a common disease characterised by a generalised reduction in bone mineral density (BMD), microarchitectural deterioration of bone tissue and an increased risk of fracture. Since BMD values fall progressively with age, the prevalence of osteoporosis increases with age. It has been estimated that approximately 50% of all women will have osteoporosis by the age of 80. Studies in twins and families indicate that genetic factors play an important role in the regulation of BMD and other determinants of osteoporotic fracture risk. Osteoporosis is a polygenic disorder, determined by the effects of several genes, each with relatively modest effects. Population-based studies and case-control studies have similarly identified polymorphisms in several candidate genes that have been associated with bone mass or osteoporotic fracture, including the vitamin D receptor, oestrogen receptor and collagen gene. Bisphosphonates, and in some patients denosumab, are first-line drugs for osteoporosis.
CATEGORY    Skeletal dysplasia
GENE        PDLIM4 (polymorphism) [HSA:8572]
            CALCR (polymorphism) [HSA:799] [KO:K04576]
            COL1A1 (polymorphism) [HSA:1277] [KO:K06236]
            COL1A2 (polymorphism) [HSA:1278] [KO:K06236]
            LRP5 (polymorphism) [HSA:4041] [KO:K03068]
            VDR (polymorphism) [HSA:7421] [KO:K08539]
            TGFB1 (polymorphism) [HSA:7040] [KO:K13375]
            PTH (polymorphism) [HSA:5741] [KO:K05261]
            UGT2B17 (polymorphism) [HSA:7367] [KO:K00699]
            MIR2861 (polymorphism) [HSA:100422910]
            WNT1 (polymorphism) [HSA:7471] [KO:K03209]
            LGR4 (polymorphism) [HSA:55366] [KO:K04309]
            PLS3 (polymorphism) [HSA:5358] [KO:K17336]
DRUG        Risedronate [DR:D03234] Ibandronate [DR:D04486] Alendronate [DR:D00939] Zoledronate [DR:D01968] (Bisphosphonate)
            Denosumab [DR:D03684] (anti-RANKL antibody)
            Teriparatide [DR:D06078] (Parathyroid hormone)
            Strontium ranelate [DR:D08468]
            Raloxifene [DR:D02217] (Selective estrogen receptor modulator)
DBLINKS     ICD-10: M80 M81 M82
            MeSH: D010024
            OMIM: 166710 603506 612560 613418 615220 615311 300910
REFERENCE   PMID:10927613 (gene)
  AUTHORS   Stewart TL, Ralston SH
  TITLE     Role of genetic factors in the pathogenesis of osteoporosis.
  JOURNAL   J Endocrinol 166:235-45 (2000)
REFERENCE   PMID:12908099 (gene)
  AUTHORS   Omasu F, Ezura Y, Kajita M, Ishida R, Kodaira M, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Orimo H, Emi M
  TITLE     Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese  women.
  JOURNAL   J Hum Genet 48:342-5 (2003)
REFERENCE   PMID:9675109 (gene)
  AUTHORS   Masi L, Becherini L, Colli E, Gennari L, Mansani R, Falchetti A, Becorpi AM, Cepollaro C, Gonnelli S, Tanini A, Brandi ML
  TITLE     Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women.
  JOURNAL   Biochem Biophys Res Commun 248:190-5 (1998)
REFERENCE   PMID:14727154 (gene)
  AUTHORS   Mizuguchi T, Furuta I, Watanabe Y, Tsukamoto K, Tomita H, Tsujihata M, Ohta T, Kishino T, Matsumoto N, Minakami H, Niikawa N, Yoshiura K
  TITLE     LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density.
  JOURNAL   J Hum Genet 49:80-6 (2004)
REFERENCE   PMID:14999526 (gene)
  AUTHORS   Lau EM, Wong SY, Li M, Ma CH, Lim PL, Woo J
  TITLE     Osteoporosis and transforming growth factor-beta-1 gene polymorphism in Chinese men and women.
  JOURNAL   J Bone Miner Metab 22:148-52 (2004)
REFERENCE   PMID:26194148 (gene)
  AUTHORS   Noordin S, Glowacki J
  TITLE     Parathyroid hormone and its receptor gene polymorphisms: implications in osteoporosis and in fracture healing.
  JOURNAL   Rheumatol Int 36:1-6 (2016)
REFERENCE   PMID:19760059
  AUTHORS   Saito M, Marumo K
  TITLE     Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.
  JOURNAL   Osteoporos Int 21:195-214 (2010)
REFERENCE   PMID:26010450 (drug)
  AUTHORS   Chen LX, Zhou ZR, Li YL, Ning GZ, Zhang TS, Zhang D, Feng SQ
  TITLE     Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight  Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
  JOURNAL   PLoS One 10:e0128032 (2015)
REFERENCE   PMID:27340321 (drug)
  AUTHORS   Gupta A, March L
  TITLE     Treating osteoporosis.
  JOURNAL   Aust Prescr 39:40-6 (2016)
REFERENCE   PMID:18992858 (gene)
  AUTHORS   Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, Pan F, Chen Y, Zhang ZX, Dong SS, Xu XH, Yan H, Liu X, Qiu C, Zhu XZ, Chen T, Li M, Zhang H, Zhang L, Drees BM, Hamilton JJ, Papasian CJ, Recker RR, Song XP, Cheng J, Deng HW
  TITLE     Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis.
  JOURNAL   Am J Hum Genet 83:663-74 (2008)
REFERENCE   PMID:19920351 (gene)
  AUTHORS   Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH
  TITLE     A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans.
  JOURNAL   J Clin Invest 119:3666-77 (2009)
REFERENCE   PMID:23499310 (gene)
  AUTHORS   Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH
  TITLE     WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta.
  JOURNAL   Am J Hum Genet 92:590-7 (2013)
REFERENCE   PMID:23644456 (gene)
  AUTHORS   Styrkarsdottir U, Thorleifsson G, Sulem P, Gudbjartsson DF, Sigurdsson A, Jonasdottir A, Jonasdottir A, Oddsson A, Helgason A, Magnusson OT, Walters GB, Frigge ML, Helgadottir HT, Johannsdottir H, Bergsteinsdottir K, Ogmundsdottir MH, Center JR, Nguyen TV, Eisman JA, Christiansen C, Steingrimsson E, Jonasson JG, Tryggvadottir L, Eyjolfsson GI, Theodors A, Jonsson T, Ingvarsson T, Olafsson I, Rafnar T, Kong A, Sigurdsson G, Masson G, Thorsteinsdottir U, Stefansson K
  TITLE     Nonsense mutation in the LGR4 gene is associated with several human diseases and  other traits.
  JOURNAL   Nature 497:517-20 (2013)
REFERENCE   PMID:24088043 (gene)
  AUTHORS   van Dijk FS, Zillikens MC, Micha D, Riessland M, Marcelis CL, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, Pruijs HE, Rubio-Gozalbo ME, Zwertbroek R, Moutaouakil Y, Egthuijsen J, Hammerschmidt M, Bijman R, Semeins CM, Bakker AD, Everts V, Klein-Nulend J, Campos-Obando N, Hofman A, te Meerman GJ, Verkerk AJ, Uitterlinden AG, Maugeri A, Sistermans EA, Waisfisz Q, Meijers-Heijboer H, Wirth B, Simon ME, Pals G
  TITLE     PLS3 mutations in X-linked osteoporosis with fractures.
  JOURNAL   N Engl J Med 369:1529-36 (2013)
///
ENTRY       H01594                      Disease
NAME        Myasthenia gravis
DESCRIPTION Myasthenia gravis (MG) is an autoimmune disorder characterized by a defective transmission of nerve impulses to muscles leading to muscle weakness and fatigability. Some, but not all, muscles are affected and not necessarily symmetrically. Increased weakness with continued muscle activity represents a diagnostic clue for MG, but these clinical features can vary. MG is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor (AChR), muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. Patients should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroups based on serum antibodies and clinical features include early-onset, late-onset, thymoma, MUSK, LRP4, antibody-negative, and ocular forms of myasthenia gravis. Agrin-associated MG might emerge as a new entity. The prognosis is good with optimum symptomatic, immunosuppressive, and supportive treatment. The evolution of MG is unpredictable, but it is generally characterized by the occurrence of relapses, sometimes subsequent to remissions and a worsening trend. For 85% of MG patients, the maximum severity is reached within less than 3 years.
CATEGORY    Nervous system disease; Immune system disease
DRUG        Pyridostigmine bromide [DR:D00487]
            Distigmine [DR:D01228]
            Ambenonium [DR:D01001]
            Edrophonium [DR:D00994]
            Neostigmine [DR:D00995 D00998]
            Betamethasone [DR:D00244]
            Tacrolimus [DR:D00107]
            Cyclosporine [DR:D00184]
            Eculizumab [DR:D03940]
COMMENT     Autoantigen:
            CHRNA1 [HSA:1134] [KO:K04803]
            MUSK [HSA:4593] [KO:K05129]
            LRP4 [HSA:4038] [KO:K20051]
DBLINKS     ICD-10: G70.0
            MeSH: D009157
REFERENCE   PMID:24530233 (description)
  AUTHORS   Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B
  TITLE     Diagnostic and clinical classification of autoimmune myasthenia gravis.
  JOURNAL   J Autoimmun 48-49:143-8 (2014)
REFERENCE   PMID:26376969 (description)
  AUTHORS   Gilhus NE, Verschuuren JJ
  TITLE     Myasthenia gravis: subgroup classification and therapeutic strategies.
  JOURNAL   Lancet Neurol 14:1023-36 (2015)
REFERENCE   PMID:26600875 (description)
  AUTHORS   Dalakas MC
  TITLE     Future perspectives in target-specific immunotherapies of myasthenia gravis.
  JOURNAL   Ther Adv Neurol Disord 8:316-27 (2015)
REFERENCE   PMID:27103470 (description)
  AUTHORS   Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S
  TITLE     Myasthenia gravis - autoantibody characteristics and their implications for therapy.
  JOURNAL   Nat Rev Neurol 12:259-68 (2016)
REFERENCE   PMID:21180568 (drug)
  AUTHORS   Gold R, Hohlfeld R, Toyka KV
  TITLE     Progress in the treatment of myasthenia gravis.
  JOURNAL   Ther Adv Neurol Disord 1:36-51 (2008)
REFERENCE   PMID:23252892 (autoantigen)
  AUTHORS   Lindstrom J, Luo J
  TITLE     Myasthenogenicity of the main immunogenic region.
  JOURNAL   Ann N Y Acad Sci 1274:9-13 (2012)
REFERENCE   PMID:11231638 (autoantigen)
  AUTHORS   Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A
  TITLE     Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia  gravis without acetylcholine receptor antibodies.
  JOURNAL   Nat Med 7:365-8 (2001)
REFERENCE   PMID:21387385 (autoantigen)
  AUTHORS   Higuchi O, Hamuro J, Motomura M, Yamanashi Y
  TITLE     Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
  JOURNAL   Ann Neurol 69:418-22 (2011)
///
ENTRY       H01595                      Disease
NAME        Cutaneous lupus erythematosus
DESCRIPTION Cutaneous lupus erythematosus (CLE) is the skin-related form of lupus erythematosus (LE), with a broad spectrum of clinical manifestations and a variable course. CLE is a frequent finding in patients with systemic lupus erythematosus (SLE) and can also exist as a single entity without associated systemic autoimmunity (LE-specific skin disease). Despite ongoing research into the cause of CLE, it remains unclear how CLE relates to SLE pathogenesis. LE-specific skin disease includes the subtypes of CLE such as acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE), and intermittent CLE (ICLE). ACLE is characterized by malar rash or maculopapular eruption on sun exposed areas. SCLE characteristically presents as annular or psoriasiform plaques in a photo distribution. CCLE can be further divided into discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain LE (CLE), and LE tumidus (LET). The pathogenesis of CLE is multifactorial and involves genetic predisposition, environmental triggers, and abnormalities in the immune response. It has been reported that many genetic risk factors for CLE involve HLA or interferon-related pathways. Corticosteroids and antimalarials were considered as the most suitable and effective systemic drugs for CLE patients.
CATEGORY    Immune system disease; Skin disease
DRUG        Hydroxychloroquine [DR:D02114]
COMMENT     See also H00080 Systemic lupus erythematosus, and H00291 Familial chilblain lupus (FCL).
DBLINKS     ICD-10: L93
            MeSH: D008178
REFERENCE   PMID:27270345
  AUTHORS   Stannard JN, Kahlenberg JM
  TITLE     Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
  JOURNAL   Curr Opin Rheumatol (2016)
REFERENCE   PMID:18042093
  AUTHORS   Kuhn A, Sticherling M, Bonsmann G
  TITLE     Clinical manifestations of cutaneous lupus erythematosus.
  JOURNAL   J Dtsch Dermatol Ges 5:1124-37 (2007)
REFERENCE   PMID:26850655 (drug)
  AUTHORS   Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Frances C
  TITLE     The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
  JOURNAL   J Am Acad Dermatol 74:693-699.e3 (2016)
///
ENTRY       H01596                      Disease
NAME        Lambert-Eaton myasthenic syndrome (LEMS)
DESCRIPTION The Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease of neuromuscular transmission in which autoantibodies against the P/Q-type voltage-gated calcium channel (VGCC) at the presynaptic nerve terminal play a major role in decreasing quantal release of acetylcholine (ACh). Clinically, LEMS patients suffer from characteristic muscle weakness and autonomic symptoms. The underlying cause of LEMS in slightly more than half of all patients is small cell lung carcinoma (SCLC) [DS:H00013]. The nerve terminal and carcinoma cells apparently share a common antigen (VGCC), suggesting an immunological cross-reactivity that may lead to the neurological abnormality. Cancer therapy is the priority for these patients. As for the remaining cases, no antibodies to P/Q-type VGCCs have been found in 10-15% of patients with LEMS. The fact that these seronegative patients positively respond to immunotherapy leads to the presumption that antibodies to other proteins might play a role in LEMS. Diagnosis of LEMS is ascertained on the basis of clinical symptoms and is further supported by electrophysiological and serological tests. The clinical triad in LEMS consists of weakness predominantly affecting proximal muscle groups, autonomic dysfunctions, and areflexia. Besides oncological treatment in case of case of SCLC-LEMS, treatment is based on symptomatic and semi-specific immunosuppressive therapy.
CATEGORY    Nervous system disease; Immune system disease
DRUG        Amifampridine [DR:D10228 D10689]
COMMENT     Autoantigen:
            CACNB2 [HSA:783] [KO:K04863]
DBLINKS     ICD-10: G73.1
            MeSH: D015624
REFERENCE   PMID:25195700 (description, drug)
  AUTHORS   Tarr TB, Wipf P, Meriney SD
  TITLE     Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
  JOURNAL   Mol Neurobiol 52:456-63 (2015)
REFERENCE   PMID:25065299 (description)
  AUTHORS   Hulsbrink R, Hashemolhosseini S
  TITLE     Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
  JOURNAL   Clin Neurophysiol 125:2328-36 (2014)
REFERENCE   PMID:18653248 (description, autoantigen)
  AUTHORS   Takamori M
  TITLE     Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and  possible compensatory mechanisms based on presynaptic calcium homeostasis.
  JOURNAL   J Neuroimmunol 201-202:145-52 (2008)
///
ENTRY       H01597                      Disease
NAME        Restless legs syndrome;
            Willis Ekbom disease
DESCRIPTION The restless legs syndrome (RLS), also known as Willis Ekbom disease is a neurologic disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them (akathisia). These symptoms occur predominantly at rest and worsen at night, resulting in nocturnal insomnia and chronic sleep deprivation. The prevalence of RLS increases with age and appears to be higher among women than among men. RLS has a high familial aggregation. To date, several loci and genetic risk factors have been identified, but no causative gene mutation has been found. Standard medications for RLS are dopamine agonists and CACN alpha-2 delta blocker. A high prevalence of iron deficiency has been found among patients with RLS. It has been reported that treatment with oral iron supplements resulted in improvements in the severity of the symptoms in patients with a low serum ferritin level.
CATEGORY    Nervous system disease
DRUG        Pramipexole [DR:D00559] Rotigotine [DR:D05768] (Dopamine agonist)
            Gabapentin [DR:D00332] Gabapentin enacarbil [DR:D09539] (CACN alpha-2 delta blocker)
DBLINKS     ICD-10: G25.8
            MeSH: D012148
            OMIM: 102300
REFERENCE   PMID:12761367
  AUTHORS   Earley CJ
  TITLE     Clinical practice. Restless legs syndrome.
  JOURNAL   N Engl J Med 348:2103-9 (2003)
REFERENCE   PMID:23192925 (gene)
  AUTHORS   Weissbach A, Siegesmund K, Bruggemann N, Schmidt A, Kasten M, Pichler I, Muhle H, Lohmann E, Lohnau T, Schwinger E, Hagenah J, Stephani U, Pramstaller PP, Klein C, Lohmann K
  TITLE     Exome sequencing in a family with restless legs syndrome.
  JOURNAL   Mov Disord 27:1686-9 (2012)
REFERENCE   PMID:27224246 (drug)
  AUTHORS   Ferini-Strambi L, Marelli S, Galbiati A
  TITLE     Clinical pharmacology and efficacy of rotigotine (Neupro(R) patch) in the treatment of restless leg syndrome.
  JOURNAL   Expert Opin Drug Metab Toxicol 1-9 (2016)
///
ENTRY       H01598                      Disease
NAME        Addison's disease;
            Primary adrenal insufficiency;
            Hypoadrenocorticism
DESCRIPTION Primary adrenocortical insufficiency, also known as Addison's disease, is a rare but fatal endocrine disorder characterized by the progressive destruction of the adorenal cortex, resulting in insufficient production of glucocorticoids, mineralocorticoids, and adrenal androgens. Although tuberculosis remains a significant cause in developing countries, autoimmune adrenalitis is the most common cause of Addison's disease in developed nations. The clinical manifestations before a life-threatening adrenal crisis (shock, hypotension, and volume depletion) are subtle and can include hyperpigmentation, fatigue, anorexia, orthostasis, nausea, muscle and joint pain, and salt craving. Symptoms are gradual and worsen over a period of years, making early diagnosis difficult. Treatment for Addison's disease consists of lifelong hormone therapy with glucocorticoids and mineralocorticoids.
CATEGORY    Endocrine System Disease
MARKER      Low cortisol level
            Normal to high potassium level
            Low to normal sodium level
DRUG        Prednisone [DR:D00473]
            Hydrocortisone [DR:D00088 D00165 D00978 D01619]
            Dexamethasone [DR:D00292 D00975]
            Fludrocortisone [DR:D00986]
            Dehydroepiandrosterone [DR:D01616]
DBLINKS     ICD-10: E27.1
            MeSH: D000224
            OMIM: 240200
REFERENCE   PMID:24755997
  AUTHORS   Napier C, Pearce SH
  TITLE     Current and emerging therapies for Addison's disease.
  JOURNAL   Curr Opin Endocrinol Diabetes Obes 21:147-53 (2014)
REFERENCE   PMID:24695602 (drug, marker)
  AUTHORS   Michels A, Michels N
  TITLE     Addison disease: early detection and treatment principles.
  JOURNAL   Am Fam Physician 89:563-8 (2014)
///
ENTRY       H01599                      Disease
NAME        Hypereosinophilic syndrome
DESCRIPTION Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders characterized by marked blood or tissue eosinophilia resulting in a wide variety of clinical manifestations. A number of HES subtypes, or variants, have recently been identified. The best characterized of the clonal molecular defects implicated in myeloproliferative variant HES is the 800-kb interstitial deletion on chromosome 4q12 resulting in the fusion of 2 distinct genes, Fip1-like 1 (FIP1L1) and platelet-derived growth factor receptor-a (PDGFRA), leading to the FIP1L1-PDGFRA fusion kinase. PDGFR is a membrane-bound tyrosine kinase receptor and the fusion PDGFRA kinase has constitutive/unregulated tyrosine kinase activity. The lymphocytic HES variant is associated with T-cell clones producing interleukin-5 (IL-5) and can evolve into lymphoma. While myeloproliferative and lymphocytic HES are well established and permit elimination of the term, idiopathic, to these varieties, most HES patients do not fall into these categories and are classified as complex.
CATEGORY    Cancer
GENE        FIP1L1-PDGFRA (deletion) [HSA:81608 5156] [KO:K14405 K04363]
CARCINOGEN  Penicillins [DG:DG01480]
            Cephalosporins [DG:DG01488]
            Quinolones [DG:DG01550]
            Sulfonamides [DG:DG01690]
            NSAIDs 
            Phenytoin [DR:D00512]
            Valproate [DR:D00710]
            Fluoxetine [DR:D00326]
            Amitriptyline [DR:D07448]
            Anti-hypertensives (ACE inhibitors, beta blockers)
PATHOGEN    Parasitic (helminths, ectoparasites, Isospora, Sarcocystis) 
            Fungal (coccidiomycosis) 
            Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human T-lymphotropic virus 1 [GN:T40003]
            Mycobacterium tuberculosis [GN:mtu mtc mra mtf mtb mtg mti mte mtl mtj mtuh mtuc mtue]
MARKER      FIP1L1-PDGFRA [HSA:81608 5156] [KO:K14405 K04363]
DRUG        Prednisone [DR:D00473]
            Hydroxyurea [DR:D00341]
            Interferon-alpha [DR:D03305]
            Imatinib mesylate [DR:D01441]
            Mepolizumab [DR:D04923]
            Alemtuzumab [DR:D02802]
COMMENT     ICD-O-3: 9964/3 Chronic eosinophilic leukemia, NOS
DBLINKS     ICD-10: D47.5
            MeSH: D017681
            OMIM: 607685
REFERENCE   PMID:26475367 (gene, env_factor, drug)
  AUTHORS   Curtis C, Ogbogu P
  TITLE     Hypereosinophilic Syndrome.
  JOURNAL   Clin Rev Allergy Immunol 50:240-51 (2016)
REFERENCE   PMID:24726650 (description, gene, drug)
  AUTHORS   Hsieh FH
  TITLE     Hypereosinophilic syndrome.
  JOURNAL   Ann Allergy Asthma Immunol 112:484-8 (2014)
REFERENCE   PMID:19630574 (description, drug)
  AUTHORS   Klion A
  TITLE     Hypereosinophilic syndrome: current approach to diagnosis and treatment.
  JOURNAL   Annu Rev Med 60:293-306 (2009)
REFERENCE   PMID:16184589 (drug)
  AUTHORS   Wilkins HJ, Crane MM, Copeland K, Williams WV
  TITLE     Hypereosinophilic syndrome: an update.
  JOURNAL   Am J Hematol 80:148-57 (2005)
REFERENCE   PMID:19243381 (description, gene, drug)
  AUTHORS   Gleich GJ, Leiferman KM
  TITLE     The hypereosinophilic syndromes: current concepts and treatments.
  JOURNAL   Br J Haematol 145:271-85 (2009)
REFERENCE   PMID:20071982 (gene, marker, drug)
  AUTHORS   Gotlib J
  TITLE     Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
  JOURNAL   Curr Opin Hematol 17:117-24 (2010)
///
ENTRY       H01600                      Disease
NAME        Parkinsonian syndrome
DESCRIPTION Parkinsonian syndromes (PS) are multisystemic diseases that produce not only motor and cognitive function impairment, but also other disorders that require the intervention of specialists other than the neurologist. PS include idiopathic Parkinson disease (PD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP), among other rarer causes of parkinsonism. Point mutations, duplications and triplications in the alpha-synuclein gene cause a rare dominant form of PS in families. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as a much more common cause for dominant PS, especially in certain ethnic groups, while mutations in the parkin gene, in DJ-1, PINK1 and ATP13A2 cause autosomal recessive parkinsonism of early onset.
CATEGORY    Neurodegenerative disease
GENE        SNCA [HSA:6622] [KO:K04528]
            LRRK2 [HSA:120892] [KO:K08844]
            Parkin [HSA:5071] [KO:K04556]
            PINK1 [HSA:65018] [KO:K05688]
            DJ-1 [HSA:11315] [KO:K05687]
            ATP13A2 [HSA:23400] [KO:K13526]
            SYNJ1 [HSA:8867] [KO:K20279]
            DNAJC13 [HSA:23317] [KO:K09533]
            VPS13C [HSA:54832] [KO:K19525]
ENV_FACTOR  MPTP [CPD:C04599]
            Rotenone [CPD:C07593]
            Maneb [CPD:C15231]
            Paraquat [CPD:C14701]
DRUG        Carbidopa [DR:D00558]
            Levodopa [DR:D00059]
            Benserazide [DR:D03082]
            entacapone [DR:D00781]
            Tolcapone [DR:D00786]
            Pramipexole [DR:D05575]
            Ropinirole [DR:D08489]
            Rotigotine [DR:D05768]
            Cabergoline [DR:D00987]
            Apomorphine [DR:D07460]
            Rasagiline [DR:D08469]
            Selegiline [DR:D03731]
            Amantadine [DR:D07441]
DBLINKS     ICD-10: G20 G21
            MeSH: D020734
REFERENCE   PMID:24092286 (description, drug)
  AUTHORS   Williams DR, Litvan I
  TITLE     Parkinsonian syndromes.
  JOURNAL   Continuum (Minneap Minn) 19:1189-212 (2013)
REFERENCE   PMID:18267242 (gene)
  AUTHORS   Bonifati V
  TITLE     Genetics of parkinsonism.
  JOURNAL   Parkinsonism Relat Disord 13 Suppl 3:S233-41 (2007)
REFERENCE   PMID:15033141 (description)
  AUTHORS   Pezzoli G, Canesi M, Galli C
  TITLE     An overview of parkinsonian syndromes: data from the literature and from an Italian data-base.
  JOURNAL   Sleep Med 5:181-7 (2004)
REFERENCE   PMID:18787878 (description, gene)
  AUTHORS   Biskup S, Gerlach M, Kupsch A, Reichmann H, Riederer P, Vieregge P, Wullner U, Gasser T
  TITLE     Genes associated with Parkinson syndrome.
  JOURNAL   J Neurol 255 Suppl 5:8-17 (2008)
REFERENCE   PMID:19729209 (env_factor)
  AUTHORS   Cicchetti F, Drouin-Ouellet J, Gross RE
  TITLE     Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?
  JOURNAL   Trends Pharmacol Sci 30:475-83 (2009)
REFERENCE   PMID:23804577 (gene)
  AUTHORS   Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, Wu B, Xu F, Erro R, Amboni M, Pappata S, Quarantelli M, Annesi G, Quattrone A, Chien HF, Barbosa ER, Oostra BA, Barone P, Wang J, Bonifati V
  TITLE     Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism.
  JOURNAL   Hum Mutat 34:1208-15 (2013)
REFERENCE   PMID:25186792 (gene)
  AUTHORS   Appel-Cresswell S, Rajput AH, Sossi V, Thompson C, Silva V, McKenzie J, Dinelle K, McCormick SE, Vilarino-Guell C, Stoessl AJ, Dickson DW, Robinson CA, Farrer MJ, Rajput A
  TITLE     Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.
  JOURNAL   Mov Disord 29:1684-7 (2014)
REFERENCE   PMID:26942284 (gene)
  AUTHORS   Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, Usenko T, Maurage CA, Sahbatou M, Liebau S, Ding J, Bilgic B, Emre M, Erginel-Unaltuna N, Guven G, Tison F, Tranchant C, Vidailhet M, Corvol JC, Krack P, Leutenegger AL, Nalls MA, Hernandez DG, Heutink P, Gibbs JR, Hardy J, Wood NW, Gasser T, Durr A, Deleuze JF, Tazir M, Destee A, Lohmann E, Kabashi E, Singleton A, Corti O, Brice A
  TITLE     Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial  Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.
  JOURNAL   Am J Hum Genet 98:500-13 (2016)
///
ENTRY       H01601                      Disease
NAME        Anaplastic large-cell lymphoma
DESCRIPTION Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by a proliferation of large lymphoid cells, referred to as hallmark cells, with strong expression of CD30. The World Health Organization recognizes 3 entities: primary cutaneous ALCL (pcALCL), anaplastic lymphoma kinase (ALK)-positive ALCL, and, provisionally, ALK-negative ALCL.  pcALCL presents in the skin and, while it may involve locoregional lymph nodes, rarely disseminates. ALK-positive ALCL, by definition overexpresses an ALK-fusion gene, typically via t(2;5)(p23;35) which fuses the ALK gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5,  resulting in a NPM-ALK chimeric protein with constitutive tyrosine kinase activity. ALK-negative ALCLs lack ALK rearrangements and their genetic and clinical features are more variable. A subset of ALK-negative ALCLs has rearrangements at 6p25.3 involving DUSP22, a gene encoding a dual-specificity phosphatase that inhibits T-cell receptor signaling. DUSP22 rearrangements also are seen in a subset of pcALCLs.
CATEGORY    Cancer
GENE        NPM-ALK (translocation) [HSA:4869 10361 10360 238] [KO:K11276 K11277 K11278 K05119]
            DUSP22-IRF4 (translocation) [HSA:56940 3662] [KO:K14165 K09445]
MARKER      NPM-ALK (translocation) [HSA:4869 10361 10360 238] [KO:K11276 K11277 K11278 K05119]
DRUG        Cyclophosphamide [DR:D00287 D07760]
            Doxorubicin [DR:D03899]
            Vincristine [DR:D08679]
            Prednisone [DR:D00473]
            Brentuximab vedotin [DR:D09587]
COMMENT     ICD-O-3: 9718/3 Primary cutaneous CD30+ T-cell lymphoproliferative disorder (C44._)
            ICD-O-3: 9702/3 Mature T-cell lymphoma, NOS
            ICD-O-3: 9714/3 Anaplastic large cell lymphoma, T cell and Null cell type
DBLINKS     ICD-10: C84.6 C84.7
            MeSH: D017728
REFERENCE   PMID:25869285 (gene, drug)
  AUTHORS   Hapgood G, Savage KJ
  TITLE     The biology and management of systemic anaplastic large cell lymphoma.
  JOURNAL   Blood 126:17-25 (2015)
REFERENCE   PMID:23065407 (drug)
  AUTHORS   Vadakara J, Pro B
  TITLE     Targeting CD30 in anaplastic large cell lymphoma.
  JOURNAL   Curr Hematol Malig Rep 7:285-91 (2012)
REFERENCE   PMID:25461779 (description, gene, ICD-O-3)
  AUTHORS   Xing X, Feldman AL
  TITLE     Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.
  JOURNAL   Adv Anat Pathol 22:29-49 (2015)
REFERENCE   PMID:24766435 (description, gene, ICD-O-3, drug)
  AUTHORS   Eyre TA, Khan D, Hall GW, Collins GP
  TITLE     Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
  JOURNAL   Eur J Haematol 93:455-68 (2014)
REFERENCE   PMID:26769771 (description, gene)
  AUTHORS   Gaulard P, de Leval L
  TITLE     ALK-negative anaplastic large-cell lymphoma.
  JOURNAL   Blood 127:175-7 (2016)
///
ENTRY       H01602                      Disease
NAME        Gastroesophageal reflux disease (GERD), including:
            Non-erosive reflux disease (NERD);
            Erosive reflux disease (ERD)
DESCRIPTION Gastro-oesophageal reflux disease (GERD) is a condition in which reflux of the stomach contents into the oesophagus results in symptoms or, occasionally, complications. GERD can be classified as non-erosive reflux disease (NERD) or erosive reflux disease (ERD) based on the presence or absence of esophageal mucosal damage seen on endoscopy. ERD can manifest in a wide range of symptoms which can be subdivided into typical, atypical, and extraesophageal symptoms. Typical symptoms include heartburn and acid regurgitation which have high specificity but low sensitivity for GERD. Atypical symptoms such as epigastric pain, dyspepsia, nausea, bloating, and belching may be suggestive of GERD but may overlap with other conditions in the differential diagnosis. Lastly, there are various extraesophageal symptoms including chronic cough, asthma, laryngitis, and dental erosions. In a small but important minority, complications of peptic oesophagitis may occur including oesophageal strictures, Barrett's oesophagus, and rarely oesophageal adenocarcinoma. Hiatus hernia is statistically associated with GERD, the presence of which is relevant to surgical treatment. The diagnosis is typically made by a combination of clinical symptoms, response to acid suppression, as well as objective testing with upper endoscopy and esophageal pH monitoring. GERD is a chronic disease that typically requires long term management in the form of lifestyle modification, medical therapy and, for a subset of patients, surgical therapy. The mainstay of treatment is acid suppression which can be achieved with several classes of medications including antacids, histamine-receptor antagonists (H2RAs), or proton-pump inhibitors (PPIs).
CATEGORY    Digestive system disease
DRUG        Lansoprazole [DR:D00355] Rabeprazole [DR:D00724] Esomeprazole [DR:D01984] Omeprazole [DR:D00455] (Proton pump inhibitor)
            Cimetidine [DR:D00295] Ranitidine [DR:D00673] Famotidine [DR:D00318] Nizatidine [DR:D00440] Roxatidine [DR:D01467] Lafutidine [DR:D01131] (H2 receptor antagonist)
            Vonoprazan [DR:D10466] (Acid pump inhibitor)
            Sodium alginate [DR:D03336] (Gastric mucosal repair promotor)
            Camostat mesilate [DR:D01766]
DBLINKS     ICD-10: K21
            MeSH: D005764
REFERENCE   PMID:21649454 (description)
  AUTHORS   Patrick L
  TITLE     Gastroesophageal reflux disease (GERD): a review of conventional and alternative  treatments.
  JOURNAL   Altern Med Rev 16:116-33 (2011)
REFERENCE   PMID:25133039 (description, drug)
  AUTHORS   Badillo R, Francis D
  TITLE     Diagnosis and treatment of gastroesophageal reflux disease.
  JOURNAL   World J Gastrointest Pharmacol Ther 5:105-12 (2014)
REFERENCE   PMID:27041798 (description)
  AUTHORS   Keung C, Hebbard G
  TITLE     The management of gastro-oesophageal reflux disease.
  JOURNAL   Aust Prescr 39:6-10 (2016)
///
ENTRY       H01603                      Disease
NAME        Primary aldosteronism
DESCRIPTION Primary aldosteronism is a clinical syndrome characterized by excess secretion of aldosterone from the adrenal gland. It is manifested by hypertension and hyporeninemia. In the past, hypokalemia was thought to be a mandatory finding in primary aldosteronism. However, later studies confirmed that most patients with primary aldosteronism are normokalemic. The prevalence of primary aldosteronism among nonselected hypertensive persons is between 5% and 13%, and it is now recognized to be the most common form of secondary hypertension. There are the seven subtypes of primary aldosteronism. Aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA) are the most common subtypes of primary aldosteronism. Unilateral adrenal hyperplasia, aldosterone-producing adrenocortical carcinoma, ectopic aldosterone-producing adenoma, and familial hyperaldosteronism (type I and typeII) are unusual subtypes. Somatic mutations in KCNJ5, ATP1A1, ATP2B3, and CACNA1D have been described in APAs. Usually, adenomas are managed surgically and bilateral hyperplasia, medically.
CATEGORY    Endocrine disease
GENE        KCNJ5 [HSA:3762] [KO:K04999]
            CACNA1D [HSA:776] [KO:K04851]
            ATP1A1 [HSA:476] [KO:K01539]
            ATP2B3 [HSA:492] [KO:K05850]
MARKER      PAC (plasma aldosterone concentration) : PRA (plasma renin activity) > 20
            PAC > 15 (ng/dL)
DRUG        Spironolactone [DR:D00443]
            Eplerenone [DR:D01115]
COMMENT     See also H00602 Glucocorticoid-remediable aldosteronism (Familial hyperaldosteronism type I)
DBLINKS     ICD-10: E26.0
            MeSH: D006929
            OMIM: 615474 613677
REFERENCE   PMID:16932426
  AUTHORS   Mattsson C, Young WF Jr
  TITLE     Primary aldosteronism: diagnostic and treatment strategies.
  JOURNAL   Nat Clin Pract Nephrol 2:198-208; quiz, 1 p following 230 (2006)
REFERENCE   PMID:23913001 (gene)
  AUTHORS   Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerstrom G, Bjorklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP
  TITLE     Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism.
  JOURNAL   Nat Genet 45:1050-4 (2013)
REFERENCE   PMID:24866132 (gene)
  AUTHORS   Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T, Mantero F, Cicala MV, Quinkler M, Fallo F, Allolio B, Bernini G, Maccario M, Giacchetti G, Jeunemaitre X, Mulatero P, Reincke M, Zennaro MC
  TITLE     Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma.
  JOURNAL   Hypertension 64:354-61 (2014)
REFERENCE   PMID:23229280 (gene)
  AUTHORS   Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA
  TITLE     Role of KCNJ5 in familial and sporadic primary aldosteronism.
  JOURNAL   Nat Rev Endocrinol 9:104-12 (2013)
REFERENCE   PMID:25538205 (marker)
  AUTHORS   Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G
  TITLE     Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension.
  JOURNAL   Eur J Endocrinol 172:R191-203 (2015)
REFERENCE   PMID:17018542 (drug)
  AUTHORS   Karagiannis A, Tziomalos K, Kakafika A, Florentin M, Athyros VG
  TITLE     Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.
  JOURNAL   Nephrol Dial Transplant 22:293 (2007)
///
ENTRY       H01604                      Disease
NAME        Polymyositis and dermatomyositis (PM/DM)
DESCRIPTION Polymyositis (PM) and dermatomyositis (DM) are the two major forms of inflammatory muscle diseases. PM and DM, along with sporadic inclusion-body myositis (sIBM), belong to the heterogeneous group of the idiopathic inflammatory myopathies (IIMs), which are characterized by weakness and chronic inflammation of skeletal muscle. PM and DM differ in their clinical features, histopathology, response to treatment, and prognosis. Although their clinical pictures differ, they both present with symmetrical, proximal muscle weakness. PM is a term that was used traditionally to denote all IIMs that were not DM or sIBM, but it is now a controversial entity with questionable specificity. Traditionally, PM is described as presenting with weakness of the proximal muscles that evolves over weeks to months and affects adults, but rarely children. DM typically includes subacute progressive proximal muscle weakness and a skin rash. The disease mechanisms of PM and DM that cause muscle damage and dysfunction are not fully understood. However, because of the association with other autoimmune diseases, the presence of autoantibodies, and response to immunosuppressive medication, they are believed to be autoimmune in origin. Recent studies have highlighted the importance of the innate immune system and non-immune mechanisms and described novel adaptive immune-based pathways in the pathogenesis of PM and DM. Treatment of inflammatory myopathies is generally empirical. Corticosteroids still remain the agents of choice for the initial treatment, but their use is limited by the high frequency of side effects. In addition, as a substantial number of patients do not respond to glucocorticoids alone, additional agents such as immunosuppressants, immunomodulators, and more recently, biologics are commonly used in clinical practice.
CATEGORY    Musculoskeletal disease; Nervous system disease; Skin and connective tissue disease
DRUG        Hydrocortisone [DR:D00088]
            Betamethasone [DR:D00244]
            Human normal immunoglobulin [DR:D08783]
            Eculizumab [DR:D03940]
COMMENT     Autoantigen:
            HARS [HSA:3035] [KO:K01892]
            TARS [HSA:6897] [KO:K01868]
            AARS [HSA:16] [KO:K01872]
            GARS [HSA:2617] [KO:K01880]
            IARS [HSA:3376] [KO:K01870]
            NARS [HSA:4677] [KO:K01893]
            FARSA [HSA:2193] [KO:K01889]
            FARSB [HSA:10056] [KO:K01890]
            IFIH1 [HSA:64135] [KO:K12647]
            TRIM33 [HSA:51592] [KO:K08883]
            MORC3 [HSA:23515]
            SAE1 [HSA:10055] [KO:K10684]
            SAE2 [HSA:10054] [KO:K10685]
DBLINKS     ICD-10: M33
            MeSH: D017285 D003882
REFERENCE   PMID:26299472 (description)
  AUTHORS   Vermaak E, Tansley SL, McHugh NJ
  TITLE     The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic  review.
  JOURNAL   Clin Rheumatol 34:2089-95 (2015)
REFERENCE   PMID:26175404 (description)
  AUTHORS   Lahouti AH, Christopher-Stine L
  TITLE     Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets.
  JOURNAL   Discov Med 19:463-70 (2015)
REFERENCE   PMID:23758833 (autoantigen, description)
  AUTHORS   Rayavarapu S, Coley W, Kinder TB, Nagaraju K
  TITLE     Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness.
  JOURNAL   Skelet Muscle 3:13 (2013)
REFERENCE   PMID:25641317 (description)
  AUTHORS   Findlay AR, Goyal NA, Mozaffar T
  TITLE     An overview of polymyositis and dermatomyositis.
  JOURNAL   Muscle Nerve 51:638-56 (2015)
///
ENTRY       H01605                      Disease
NAME        Myelofibrosis
DESCRIPTION Myelofibrosis (MF), one of the three classic Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs), is characterized by symptoms mainly derived from anemia and splenomegaly and constitutional symptoms and associated with a median survival around 6 years. Most MPN patients harbor an acquired mutation in the hemopoietic cells, the V617F mutation, located in the pseudokinase domain of the JAK2 gene. This mutation results in a gain of function, i.e., in the constitutive activation of the JAK-STAT pathway, which plays an important role in the proliferation, differentiation, and survival of the hemopoietic cells, as well as in the immune function. Besides, a minority of patients with MF (most of them negative for the JAK2 mutation) harbor other JAK-STAT-activating mutation, the MPL mutation, in the gene of the receptor of the thrombopoietin. Recently, mutations in the CALR gene have been described in 86% of cases with primary MF that are negative for JAK2 or MPL mutations. CALR mutation also showed cytokine independent growth of cells due to activation of STAT5 involved with the JAK-STAT pathway but its exact role in MPN remains to be clarified.
CATEGORY    Cancer; Hematologic disease
GENE        MPL [HSA:4352] [KO:K05082]
            JAK2 [HSA:3717] [KO:K04447]
            CALR [HSA:811] [KO:K08057]
DRUG        Ruxolitinib [DR:D09960]
            Fedratinib [DR:D10630]
COMMENT     ICD-0-3: 9961/3 Primary myelofibrosis
DBLINKS     ICD-10: C94.4 D47.4 D75.8
            MeSH: D055728
REFERENCE   PMID:25635755 (description, gene)
  AUTHORS   Hobbs GS, Rampal RK
  TITLE     Clinical and molecular genetic characterization of myelofibrosis.
  JOURNAL   Curr Opin Hematol 22:177-83 (2015)
REFERENCE   PMID:23514013 (description, gene)
  AUTHORS   Cervantes F, Martinez-Trillos A
  TITLE     Myelofibrosis: an update on current pharmacotherapy and future directions.
  JOURNAL   Expert Opin Pharmacother 14:873-84 (2013)
REFERENCE   PMID:26835366 (description, gene, drug)
  AUTHORS   Singh NR
  TITLE     Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.
  JOURNAL   Transl Pediatr 4:107-15 (2015)
REFERENCE   PMID:25124313 (marker, drug)
  AUTHORS   Tefferi A
  TITLE     Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
  JOURNAL   Am J Hematol 89:915-25 (2014)
REFERENCE   PMID:17107350 (gene)
  AUTHORS   Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A
  TITLE     Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal  emergence and changes in mutant allele burden over time.
  JOURNAL   Br J Haematol 135:683-7 (2006)
///
ENTRY       H01606                      Disease
NAME        Polymyalgia rheumatica
DESCRIPTION Polymyalgia rheumatica (PMR) is a relatively common inflammatory rheumatic disease in people older than 50 years of age. PMR is a clinical condition defined as the presence of inflammatory pain in the limb girdles. Range of motion is decreased at the shoulder and pelvic girdles, and the neck and hip girdle may also be involved. These symptoms often persist for at least 1 month and are combined with incapacitating morning stiffness, a decline in general health, and an elevated acute-phase response. Onset of PMR symptoms may be acute or gradual. It is known that PMR patients share many pathogenetic features with giant cell arteritis (GCA). Despite the similarities in age of onset and some of the clinical manifestations, the relationship between GCA and PMR is not yet clearly established. One-third of PMR patients have systemic manifestations such as low-grade fever, malaise, and anorexia, but these are often milder than systemic symptoms in GCA patients. PMR is a benign and highly steroid-sensitive disease that should resolve fully with low-dose glucocorticoid therapy for 12-24 months, although one or two relapses may occur. The diagnosis of PMR is made primarily on clinical grounds and is bolstered by laboratory evidence of an acute-phase reaction. There is no single diagnostic test for PMR, but sets of diagnostic and classification criteria have been suggested by several groups of investigators.
CATEGORY    Musculoskeletal disease; Skin and connective tissue disease
DRUG        Betamethasone [DR:D00244]
DBLINKS     ICD-10: M35.3
            MeSH: D011111
REFERENCE   PMID:24897986 (description)
  AUTHORS   Ameer F, McNeil J
  TITLE     Polymyalgia rheumatica: clinical update.
  JOURNAL   Aust Fam Physician 43:373-6 (2014)
REFERENCE   PMID:24462129 (description)
  AUTHORS   De Bandt M
  TITLE     Current diagnosis and treatment of polymyalgia rheumatica.
  JOURNAL   Joint Bone Spine 81:203-8 (2014)
REFERENCE   PMID:24461540 (description)
  AUTHORS   Nesher G
  TITLE     Polymyalgia rheumatica--diagnosis and classification.
  JOURNAL   J Autoimmun 48-49:76-8 (2014)
///
ENTRY       H01607                      Disease
NAME        Galactorrhea;
            Lactation suppression
DESCRIPTION Galactorrhea is a discharge of milk or a milk-like secretion from the breast in the absence of parturition or beyond six months' post-partum in a nonbreastfeeding woman. The condition is more common in women who are 20 to 35 years of age and in previously parous women. It is less common in children and nulligravid women. Galactorrhea also can occur in men. After infancy, galactorrhea usually is medication-induced. The most common pathologic cause of galactorrhea is a pituitary tumor. Other causes include hypothalamic and pituitary stalk lesions, neurogenic stimulation, thyroid disorders, and chronic renal failure. Tests for pregnancy, serum prolactin level and serum thyroid-stimulating hormone level, and magnetic resonance imaging are important diagnostic tools that should be employed when clinically indicated. The decision to treat patients with galactorrhea is based on the serum prolactin level, the severity of galactorrhea, and the patient's fertility desires. Dopamine agonists are the treatment of choice in most patients with hyperprolactinemic disorders. Medications causing hyperprolactinemia should be discontinued or replaced with a medication from a similar class with lower potential for causing hyperprolactinemia. For women who cannot breastfeed after childbirth for some reasons, various pharmacologic and nonpharmacologic interventions have been used to suppress lactation and relieve associated symptoms. Pharmacological options mainly involve dopamine agonist medications.
CATEGORY    Reproductive system disease; Skin and connective tissue disease
DRUG        Bromocriptine [DR:D00780]
            Cabergoline [DR:D00987]
COMMENT     See also H01388.
DBLINKS     ICD-10: O92.5 O92.6 N64.3
            MeSH: D005687
REFERENCE   PMID:22962879 (description, drug)
  AUTHORS   Huang W, Molitch ME
  TITLE     Evaluation and management of galactorrhea.
  JOURNAL   Am Fam Physician 85:1073-80 (2012)
REFERENCE   PMID:15317441 (description)
  AUTHORS   Leung AK, Pacaud D
  TITLE     Diagnosis and management of galactorrhea.
  JOURNAL   Am Fam Physician 70:543-50 (2004)
REFERENCE   PMID:11352287 (description)
  AUTHORS   Pena KS, Rosenfeld JA
  TITLE     Evaluation and treatment of galactorrhea.
  JOURNAL   Am Fam Physician 63:1763-70 (2001)
REFERENCE   PMID:27297803 (drug)
  AUTHORS   Snellen M, Power J, Blankley G, Galbally M
  TITLE     Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: A systematic review.
  JOURNAL   Aust N Z J Obstet Gynaecol (2016)
///
ENTRY       H01608                      Disease
NAME        Cervical dystonia;
            Spasmodic torticollis
DESCRIPTION Cervical dystonia (CD), formerly referred to as spasmodic torticollis, is a condition characterized by simultaneous and sustained contractions of both agonist and antagonist muscles of the neck, which frequently result in abnormal movements or postures. CD is considered a form of primary adult-onset focal dystonia. The majority of patients complain of pain, which is not a common feature of other focal dystonias. Head rotation is common, but head tilt, neck extension, and flexionmay also occur, often in combination. The pathogenesis of primary CD is unclear. Patients with secondary CD may have an abnormal birth or developmental history, exposure to drugs known to cause dystonia (tardive dystonia), or neurological illness. Intramuscular injections of botulinum toxin (BoNT), have been shown to be efficacious and well tolerated when used to treat CD, and are therefore recommended as first-line therapy by current treatment guidelines.
CATEGORY    Nervous system disease
DRUG        Rimabotulinumtoxin B [DR:D02735]
DBLINKS     ICD-10: G24.3
            MeSH: D014103
REFERENCE   PMID:26914922 (description, drug)
  AUTHORS   Han Y, Stevens AL, Dashtipour K, Hauser RA, Mari Z
  TITLE     A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
  JOURNAL   J Neurol 263:772-80 (2016)
REFERENCE   PMID:24413637 (description, drug)
  AUTHORS   De Pauw J, Van der Velden K, Meirte J, Van Daele U, Truijen S, Cras P, Mercelis R, De Hertogh W
  TITLE     The effectiveness of physiotherapy for cervical dystonia: a systematic literature review.
  JOURNAL   J Neurol 261:1857-65 (2014)
REFERENCE   PMID:17878433 (description, drug)
  AUTHORS   Crowner BE
  TITLE     Cervical dystonia: disease profile and clinical management.
  JOURNAL   Phys Ther 87:1511-26 (2007)
///
ENTRY       H01609                      Disease
NAME        Insomnia
DESCRIPTION Insomnia is a common disorder with a prevalence of about 10% in the general population. The most common complaints related to insomnia are difficulty initiating sleep (sleep-onset insomnia), difficulty maintaining sleep due to prolonged nocturnal awakenings (sleep-maintenance insomnia), early morning awakenings, and excessive daytime sleepiness resulting from lack of sleep. Furthermore, insomnia is associated with an increased risk of anxiety and depression, suicidality, and cardiovascular diseases. Currently, cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line therapy. While behavioral therapies are effective for chronic insomnia in some patients, pharmacotherapy is frequently used when immediate short-term symptom relief is needed. The most effective pharmacologic therapies for insomnia are benzodiazepines, benzodiazepine-receptor agonists, melatonin-receptor agonists, and antidepressants.
CATEGORY    Nervous system disease
DRUG        Rilmazafone [DR:D01564] Zolpidem [DR:D00706] Zopiclone [DR:D01372] Eszopiclone [DR:D02624] (Benzodiazepine-receptor agonists)
            Ramelteon [DR:D02689] (Melatonin-receptor agonists)
            Suvorexant [DR:D10082] (Orexin receptor antagonists)
            Trazodone [DR:D00820] (Antidepressants)
DBLINKS     ICD-10: F51.0 G47.0
            MeSH: D007319
REFERENCE   PMID:26414893
  AUTHORS   Lancee J, van Straten A, Morina N, Kaldo V, Kamphuis JH
  TITLE     Guided Online or Face-to-Face Cognitive Behavioral Treatment for Insomnia: A Randomized Wait-List Controlled Trial.
  JOURNAL   Sleep 39:183-91 (2016)
REFERENCE   PMID:27198954
  AUTHORS   Palagini L, Faraguna U, Mauri M, Gronchi A, Morin CM, Riemann D
  TITLE     Association between stress-related sleep reactivity and cognitive processes in insomnia disorder and insomnia subgroups: preliminary results.
  JOURNAL   Sleep Med 19:101-7 (2016)
REFERENCE   PMID:16750462 (drug)
  AUTHORS   Najib J
  TITLE     Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
  JOURNAL   Clin Ther 28:491-516 (2006)
REFERENCE   PMID:27253658 (drug)
  AUTHORS   Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA
  TITLE     Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant,  Compared With Zolpidem in a Randomized Crossover Study.
  JOURNAL   J Clin Psychopharmacol 36:314-23 (2016)
REFERENCE   PMID:26438969 (drug)
  AUTHORS   Cardinali DP, Golombek DA, Rosenstein RE, Brusco LI, Vigo DE
  TITLE     Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse.
  JOURNAL   Pharmacol Res 109:12-23 (2016)
REFERENCE   PMID:18463341 (drug)
  AUTHORS   Passarella S, Duong MT
  TITLE     Diagnosis and treatment of insomnia.
  JOURNAL   Am J Health Syst Pharm 65:927-34 (2008)
REFERENCE   PMID:26940892 (drug)
  AUTHORS   Morin CM, Edinger JD, Krystal AD, Buysse DJ, Beaulieu-Bonneau S, Ivers H
  TITLE     Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.
  JOURNAL   Trials 17:118 (2016)
///
ENTRY       H01610                      Disease
NAME        Clonorchiasis
DESCRIPTION Clonorchis sinensis, the most common human liver fluke, is endemic in East Asia, particularly in China, Japan, Taiwan, Vietnam, and Korea. There are three hosts in the life cycle of C. sinensis including freshwater snails (the first intermediate hosts), Numerous species of freshwater fish (the second intermediate hosts), and human or carnivorous mammals (dog, pig, cat, wild cat, marten, badger, mink, weasel and rat). The human and animal reservoir hosts acquire the infection from the ingestion of raw fish containing infectious metacercariae. Clinical symptoms of this disease range from asymptomatic in light infections to serious symptoms, including marked gastrointestinal disturbances with a syndrome associated with biliary obstruction. Generally, chronic heavy infections cause damage to the bile duct epithelium, eliciting gastrointestinal symptoms, jaundice, cholangitis, biliary stones and possibly cholangiocarcinoma. Praziquantel is the drug of choice for clonorchiasis.
CATEGORY    Infectious disease
PATHOGEN    Clonorchis sinensis
DRUG        Praziquantel [DR:D00471]
COMMENT     See also H01617 Foodborne trematodiasis.
DBLINKS     ICD-10: B66.1
            MeSH: D003003
REFERENCE   PMID:16153321 (description)
  AUTHORS   Rim HJ
  TITLE     Clonorchiasis: an update.
  JOURNAL   J Helminthol 79:269-81 (2005)
///
ENTRY       H01611                      Disease
NAME        Alcohol dependence
DESCRIPTION Alcohol dependence (AD) is a chronic but often disease that includes problems in controlling one's drinking, being preoccupied with alcohol, continuing to use alcohol even when it causes problems, having to drink more to get the same effect (physical dependence), or having withdrawal symptoms when one rapidly decreases or stops drinking. The contribution of genetic factors to the development of AD is high. The best classical candidate genes for AD are alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Both genes are involved in enzymatic degradation of alcohol. Recent genome-wide association studies (GWAS) have reported that the most robust associations for AD have been with such enzyme genes, especially ALDH2 in East Asian populations and ADH1B in European American and African American populations.
CATEGORY    Nervous system diseases; Other nervous system diseases
GENE        ALDH2 (polymorphism) [HSA:217] [KO:K00128]
            ADH1B (polymorphism) [HSA:125] [KO:K13951]
            OPRM1 (polymorphism) [HSA:4988] [KO:K04215]
            DRD2 (polymorphism) [HSA:1813] [KO:K04145]
DRUG        Naltrexone [DR:D05113]
            Acamprosate [DR:D07058]
            Disulfiram [DR:D00131]
            Nalmefene [DR:D05111]
            Baclofen [DR:D00241]
            Ondansetron [DR:D00456]
            Sertraline [DR:D02360]
            Topiramate [DR:D00537]
DBLINKS     ICD-10: F10.2 F10.5
            MeSH: D000437
REFERENCE   PMID:25985735 (gene, drug)
  AUTHORS   Thompson A, Owens L, Pushpakom SP, Faizal M, Pirmohamed M
  TITLE     Pharmacotherapy for alcohol dependence: A stratified approach.
  JOURNAL   Pharmacol Ther 153:10-24 (2015)
REFERENCE   PMID:23810221 (drug)
  AUTHORS   Franck J, Jayaram-Lindstrom N
  TITLE     Pharmacotherapy for alcohol dependence: status of current treatments.
  JOURNAL   Curr Opin Neurobiol 23:692-9 (2013)
REFERENCE   PMID:25359488 (gene)
  AUTHORS   Samochowiec J, Samochowiec A, Puls I, Bienkowski P, Schott BH
  TITLE     Genetics of alcohol dependence: a review of clinical studies.
  JOURNAL   Neuropsychobiology 70:77-94 (2014)
REFERENCE   PMID:26110981 (description, gene)
  AUTHORS   Hart AB, Kranzler HR
  TITLE     Alcohol Dependence Genetics: Lessons Learned From Genome-Wide Association Studies (GWAS) and Post-GWAS Analyses.
  JOURNAL   Alcohol Clin Exp Res 39:1312-27 (2015)
REFERENCE   PMID:25278008 (description,gene)
  AUTHORS   Zuo L, Lu L, Tan Y, Pan X, Cai Y, Wang X, Hong J, Zhong C, Wang F, Zhang XY, Vanderlinden LA, Tabakoff B, Luo X
  TITLE     Genome-wide association discoveries of alcohol dependence.
  JOURNAL   Am J Addict 23:526-39 (2014)
REFERENCE   PMID:24456374 (drug)
  AUTHORS   Muller CA, Geisel O, Banas R, Heinz A
  TITLE     Current pharmacological treatment approaches for alcohol dependence.
  JOURNAL   Expert Opin Pharmacother 15:471-81 (2014)
REFERENCE   PMID:23170934 (gene)
  AUTHORS   Rietschel M, Treutlein J
  TITLE     The genetics of alcohol dependence.
  JOURNAL   Ann N Y Acad Sci 1282:39-70 (2013)
REFERENCE   PMID:25408904 (description, gene)
  AUTHORS   Nieratschker V, Batra A, Fallgatter AJ
  TITLE     Genetics and epigenetics of alcohol dependence.
  JOURNAL   J Mol Psychiatry 1:11 (2013)
///
ENTRY       H01612                      Disease
NAME        Essential thrombocytosis
DESCRIPTION Essential thrombocythemia (ET) is one of the myeloproliferative neoplasms (MPNs), a group of clonal stem cell disorders with similarities at the phenotypic and molecular level. ET is characterized by an isolated thrombocytosis and overlaps clinically with polycythemia vera and primary myelofibrosis (PMF). The V617F mutation in the tyrosine pseudokinase region of the JAK2 gene is found in 50 - 60% of ET patients. This mutation produces an increased tyrosine kinase activity of JAK2, resulting in uncontrolled cellular growth in the hematopoietic compartment. Calreticulin (CALR) or myeloproliferative leukemia virus oncogene (MPL) mutations occur in approximately 25%, and 3% of ET patients, respectively.
CATEGORY    Cancer
GENE        JAK2 (mutation) [HSA:3717] [KO:K04447]
            CALR (mutation) [HSA:811] [KO:K08057]
            MPL (mutation) [HSA:4352] [KO:K05082]
MARKER      JAK2 [HSA:3717] [KO:K04447]
            MPL [HSA:4352] [KO:K05082]
DRUG        Aspirin [DR:D00109]
            Hydroxicarbamide [DR:D00341]
            Anagrelide [DR:D07455]
            Interferon alpha [DR:D03305]
DBLINKS     ICD-10: D47.3
            MeSH: D013920
REFERENCE   PMID:25611051 (description, gene, marker)
  AUTHORS   Tefferi A, Barbui T
  TITLE     Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
  JOURNAL   Am J Hematol 90:162-73 (2015)
REFERENCE   PMID:26137205 (drug, marker)
  AUTHORS   Birgegard G
  TITLE     Advances and challenges in the management of essential thrombocythemia.
  JOURNAL   Ther Adv Hematol 6:142-56 (2015)
REFERENCE   PMID:23668666 (description, gene, drug)
  AUTHORS   Birgegard G
  TITLE     Pharmacological management of essential thrombocythemia.
  JOURNAL   Expert Opin Pharmacother 14:1295-306 (2013)
REFERENCE   PMID:21825979 (description, gene)
  AUTHORS   Beer PA
  TITLE     The pathogenesis of essential thrombocythemia.
  JOURNAL   Curr Opin Hematol 18:323-9 (2011)
REFERENCE   PMID:22160037 (gene, drug)
  AUTHORS   Cervantes F
  TITLE     Management of essential thrombocythemia.
  JOURNAL   Hematology Am Soc Hematol Educ Program 2011:215-21 (2011)
///
ENTRY       H01613                      Disease
NAME        Follicular lymphoma
DESCRIPTION Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by diffuse lymphoadenopathy, bone marrow involvement, splenomegaly, and less commonly other extranodal sites of involvement. The genetic hallmark of FL, the translocation t(14;18)(q32;q21), results in the constitutive overexpression of the bcl 2 protein, which impairs the normal germinal centre apoptotic programme. Inactivating mutations of MLL2 are found in >80% of FL and interfere with the ability of MLL2 to activate gene transcription through H3K4 methylation. Mutations of other histone modifiers (CREBBP, EZH2, MEF2B, and EP300) are found in ;33%, 27%, 15%, and 9% of FL, respectively.
CATEGORY    Cancer
GENE        IgH-BCL2 (translocation) [HSA:596] [KO:K06856 K02161]
            EZH2 (mutation) [HSA:2146] [KO:K11430]
            MLL2 (mutation) [HSA:9757 8085] [KO:K14959 K09187]
            CREBBP (mutation) [HSA:1387] [KO:K04498]
            MEF2B (mutation) [HSA:4207] [KO:K09261]
            EP300 (mutation) [HSA:2033] [KO:K04498]
MARKER      CD20 [HSA:931] [KO:K06466]
DRUG        Rituximab [DR:D02994]
            Interferon alpha-2a [DR:D00745]
COMMENT     ICD-O-3: 9690/3 Follicular lymphoma, NOS
            ICD-O-3: 9691/3 Follicular lymphoma, grade 2
            ICD-O-3: 9695/3 Follicular lymphoma, grade 1
            ICD-O-3: 9698/3 Follicular lymphoma, grade 3
DBLINKS     ICD-10: C82
            MeSH: D008224
REFERENCE   PMID:24687887 (gene, drug)
  AUTHORS   Freedman A
  TITLE     Follicular lymphoma: 2014 update on diagnosis and management.
  JOURNAL   Am J Hematol 89:429-36 (2014)
REFERENCE   PMID:24942941 (gene, ICD-O-3)
  AUTHORS   Takata K, Miyata-Takata T, Sato Y, Yoshino T
  TITLE     Pathology of follicular lymphoma.
  JOURNAL   J Clin Exp Hematop 54:3-9 (2014)
REFERENCE   PMID:26989204 (gene, drug)
  AUTHORS   Kahl BS, Yang DT
  TITLE     Follicular lymphoma: evolving therapeutic strategies.
  JOURNAL   Blood 127:2055-63 (2016)
REFERENCE   PMID:24577532 (gene)
  AUTHORS   Hiddemann W, Cheson BD
  TITLE     How we manage follicular lymphoma.
  JOURNAL   Leukemia 28:1388-95 (2014)
REFERENCE   PMID:23023713 (gene, drug)
  AUTHORS   Kridel R, Sehn LH, Gascoyne RD
  TITLE     Pathogenesis of follicular lymphoma.
  JOURNAL   J Clin Invest 122:3424-31 (2012)
REFERENCE   PMID:25804839 (drug)
  AUTHORS   Herold M, Scholz CW, Rothmann F, Hirt C, Lakner V, Naumann R
  TITLE     Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.
  JOURNAL   J Cancer Res Clin Oncol 141:1689-95 (2015)
REFERENCE   PMID:20943608 (drug)
  AUTHORS   Ghielmini M
  TITLE     Follicular lymphoma.
  JOURNAL   Ann Oncol 21 Suppl 7:vii151-3 (2010)
REFERENCE   PMID:15684317 (drug)
  AUTHORS   Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA
  TITLE     Meta-analysis to evaluate the role of interferon in follicular lymphoma.
  JOURNAL   J Clin Oncol 23:2215-23 (2005)
///
ENTRY       H01614                      Disease
NAME        Multiple system atrophy, including:
            Striatonigral degeneration;
            Olivopontocerebellar atrophy;
            Shy-Drager syndrome
DESCRIPTION Multiple system atrophy (MSA) is an intractable neurodegenerative disease characterized by autonomic failure in addition to various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction. MSA encompasses striatonigral degeneration, olivopontocerebellar atrophy, and Shy-Drager syndrome, which were originally described as independent clinicopathological entities. The coexistence was detected later, and these conditions were regarded as nosologically allied. The disease is characterized by the accumulation of alpha-synuclein fibrils in oligodendrocytes that form glial cytoplasmic inclusions (GCI), a neuropathological hallmark and central player in the pathogenesis of MSA.  Although MSA is widely considered to be a nongenetic disorder, genetic mutations of the COQ2 gene have been linked to MSA as identified in Japanese families.
CATEGORY    Neurodegenerative disease
GENE        COQ2 [HSA:27235] [KO:K06125]
DRUG        Droxidopa [DR:D01277]
COMMENT     See also H01600 Parkinsonian syndrome.
DBLINKS     ICD-10: G23
            MeSH: D019578 D020955 D009849 D012791
            OMIM: 146500
REFERENCE   PMID:26785838
  AUTHORS   Stefanova N, Wenning GK
  TITLE     Review: Multiple system atrophy: emerging targets for interventional therapies.
  JOURNAL   Neuropathol Appl Neurobiol 42:20-32 (2016)
REFERENCE   PMID:18018485
  AUTHORS   Yoshida M
  TITLE     Multiple system atrophy: alpha-synuclein and neuronal degeneration.
  JOURNAL   Neuropathology 27:484-93 (2007)
REFERENCE   PMID:27123473 (gene)
  AUTHORS   Sun Z, Ohta Y, Yamashita T, Sato K, Takemoto M, Hishikawa N, Abe K
  TITLE     New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple  system atrophy.
  JOURNAL   Neurol Genet 2:e54 (2016)
REFERENCE   PMID:26092297 (drug)
  AUTHORS   Kaufmann H, Norcliffe-Kaufmann L, Palma JA
  TITLE     Droxidopa in neurogenic orthostatic hypotension.
  JOURNAL   Expert Rev Cardiovasc Ther 13:875-91 (2015)
///
ENTRY       H01615                      Disease
NAME        Irritable bowel syndrome
DESCRIPTION Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.
CATEGORY    Digestive system disease
GENE        GUCY2C [HSA:2984] [KO:K12320]
DRUG        Ramosetron [DR:D02016] (5-HT3 receptor antagonist)
            Polycarbophil calcium [DR:D03306]
            Tiquizium bromide [DR:D01875] Mepenzolate bromide [DR:D00720 D04059] (Anticholinergic)
DBLINKS     ICD-10: K58
            MeSH: D043183
            OMIM: 614616
REFERENCE   PMID:21333900
  AUTHORS   Saito YA
  TITLE     The role of genetics in IBS.
  JOURNAL   Gastroenterol Clin North Am 40:45-67 (2011)
REFERENCE   PMID:27372289
  AUTHORS   Shah SL, Lacy BE
  TITLE     Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence.
  JOURNAL   Curr Gastroenterol Rep 18:41 (2016)
REFERENCE   PMID:27338166 (gene)
  AUTHORS   von Volkmann HL, Nylund K, Tronstad RR, Hovdenak N, Hausken T, Fiskerstrand T, Gilja OH
  TITLE     An activating gucy2c mutation causes impaired contractility and fluid stagnation  in the small bowel.
  JOURNAL   Scand J Gastroenterol 1-8 (2016)
REFERENCE   PMID:11488427 (drug)
  AUTHORS   Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K
  TITLE     Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
  JOURNAL   Jpn J Pharmacol 86:281-8 (2001)
REFERENCE   PMID:22837880 (drug)
  AUTHORS   Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T
  TITLE     Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.
  JOURNAL   J Neurogastroenterol Motil 18:317-23 (2012)
///
ENTRY       H01616                      Disease
NAME        Spinocerebellar degeneration, including:
            Spinocerebellar ataxia (SCA) [DS:H00063];
            Dentatorubropallidoluysian atrophy (DRPLA) [DS:H00060];
            Friedreich ataxia [DS:H00067];
            Multiple system atrophy [DS:H01614]
DESCRIPTION Spinocerebellar degenerations are neurodegenerative diseases that involve the cerebellum, brain stem, spinal cord, and basal ganglia to various degrees. Patients display limb and truncal ataxia, dysarthria, dysphagia, extrapyramidal sign, pyramidal sign, and autonomic disorder. Spinocerebellar degeneration includes both sporadic and hereditary forms. Most cases of sporadic spinocerebellar degeneration are now considered to be multiple system atrophy (MSA). Hereditary spinocerebellar degeneration includes spinocerebellar ataxia (SCA), dentatorubral-pallidoluysian atrophy (DRPLA), and Friedreich ataxia (FA).
CATEGORY    Neurodegenerative disease
DRUG        Taltirelin [DR:D01925]
COMMENT     See also H00063 Spinocerebellar ataxia (SCA), H00060 Dentatorubropallidoluysian atrophy (DRPLA), H00067 Friedreich ataxia, and H01614 Multiple system atrophy.
DBLINKS     ICD-10: G31.9
            MeSH: D013132
REFERENCE   PMID:19295212
  AUTHORS   Kawai Y, Suenaga M, Watanabe H, Sobue G
  TITLE     Cognitive impairment in spinocerebellar degeneration.
  JOURNAL   Eur Neurol 61:257-68 (2009)
REFERENCE   PMID:22017410 (drug)
  AUTHORS   Khomane KS, Meena CL, Jain R, Bansal AK
  TITLE     Novel thyrotropin-releasing hormone analogs: a patent review.
  JOURNAL   Expert Opin Ther Pat 21:1673-91 (2011)
///
ENTRY       H01617                      Disease
NAME        Foodborne trematodiasis;
            Food-borne trematode infections
DESCRIPTION Foodborne trematode infections, which are caused by four main genera: Clonorchis spp. that cause clonorchiasis, Opisthorchis spp. that cause opisthorchiasis, Fasciola spp. that cause fascioliasis and Paragonimus spp. that cause paragonimiasis. Foodborne trematode infections are accomplished through ingestion of metacercariae by eating raw or insufficiently cooked freshwater fish (C. sinensis, Opisthorchis spp., Echinostoma spp., heterophyids, Metagonimus spp.), freshwater crab or crayfish (Paragonimus spp.), aquatic plants (Fasciola spp., Fasciolopis buski), snails or tadpoles (Echinostoma spp.), or by drinking contaminated water (Fasciola spp.). The drugs of choice for treatment of Foodborne trematode infections are praziquantel and triclabendazole.
CATEGORY    Infectious disease
PATHOGEN    Haplorchis spp.
            Heterophyes heterophyes
            Metagonimus yokogawai
            Metagonimus takahashii
            Clonorchis sinensis
            Opisthorchis felineus
            Opisthorchis viverrini
            Paragonimus westermani complex
            Paragonimus skrjabini complex
            Paragonimus miyazakii
            Paragonimus africanus
            Paragonimus heterotremus
            Paragonimus kellicotti
            Paragonimus mexicanus
            Paragonimus uterbilateralis
            Fasciolopsis buski
            Fasciolopsis hepatica
            Fasciolopsis gigantica
            Echinostoma hortense
            Echinostoma angustitestis
            Echinostoma cinetorchis
            Echinostoma echinatum
            Echinostoma ilocanum
            Echinostoma macrorchis
            Echinostoma malayanum
            Echinostoma revolutum
DRUG        Praziquantel [DR:D00471]
            Triclabendazole [DR:D07364]
DBLINKS     ICD-10: B66
            MeSH: D014201
REFERENCE   PMID:16318688 (description)
  AUTHORS   Keiser J, Utzinger J
  TITLE     Emerging foodborne trematodiasis.
  JOURNAL   Emerg Infect Dis 11:1507-14 (2005)
REFERENCE   PMID:20352454 (description)
  AUTHORS   Fried B, Abruzzi A
  TITLE     Food-borne trematode infections of humans in the United States of America.
  JOURNAL   Parasitol Res 106:1263-80 (2010)
REFERENCE   PMID:19597009 (pathogen)
  AUTHORS   Keiser J, Utzinger J
  TITLE     Food-borne trematodiases.
  JOURNAL   Clin Microbiol Rev 22:466-83 (2009)
///
ENTRY       H01618                      Disease
NAME        Pituitary gigantism
DESCRIPTION Pituitary gigantism is very rare conditions resulting from excessive secretion of growth hormone (GH). Most cases are due to benign pituitary adenomas. Nonadenomatous GH excess is exceptional but occasionally occurs in patients with multiple endocrine neoplasia syndrome type 1 (MEN1), Carney complex, or McCune-Albright syndrome. The clinical manifestations may include increased growth velocity with tall stature, enlargement of the hands and feet, excessive perspiration, coarsening of facial features, and headaches. It has been reported that duplication of GPR101 probably causes gigantism and acromegaly. Therapeutic modalities for the treatment of pituitary gigantism include surgery, medication and radiation.
CATEGORY    Endocrine disease
GENE        GPR101 (duplication) [HSA:83550] [KO:K08423]
MARKER      Increased circulating GH and IGF-I levels
            GH suppression test (OGTT)
DRUG        Octreotide [DR:D02250 D06495] (Somatostatin analogues)
            Bromocriptine [DR:D00780] Cabergoline [DR:D00987] (Dopamine agonists)
            Pegvisomant [DR:D05394] (GH receptor antagonists)
COMMENT     See also H00247  Multiple endocrine neoplasia syndrome (MEN), H01102  Pituitary adenomas, and H01483  Acromegaly.
DBLINKS     ICD-10: E22.0
            MeSH: D005877
            OMIM:300943
REFERENCE   PMID:21976722
  AUTHORS   Glasker S, Vortmeyer AO, Lafferty AR, Hofman PL, Li J, Weil RJ, Zhuang Z, Oldfield EH
  TITLE     Hereditary pituitary hyperplasia with infantile gigantism.
  JOURNAL   J Clin Endocrinol Metab 96:E2078-87 (2011)
REFERENCE   PMID:26845047 (marker)
  AUTHORS   Hannema SE, Savendahl L
  TITLE     The Evaluation and Management of Tall Stature.
  JOURNAL   Horm Res Paediatr 85:347-52 (2016)
REFERENCE   PMID:25470569 (gene)
  AUTHORS   Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E, Leal LF, Caberg JH, Castermans E, Villa C, Dimopoulos A, Chittiboina P, Xekouki P, Shah N, Metzger D, Lysy PA, Ferrante E, Strebkova N, Mazerkina N, Zatelli MC, Lodish M, Horvath A, de Alexandre RB, Manning AD, Levy I, Keil MF, Sierra Mde L, Palmeira L, Coppieters W, Georges M, Naves LA, Jamar M, Bours V, Wu TJ, Choong CS, Bertherat J, Chanson P, Kamenicky P, Farrell WE, Barlier A, Quezado M, Bjelobaba I, Stojilkovic SS, Wess J, Costanzi S, Liu P, Lupski JR, Beckers A, Stratakis CA
  TITLE     Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.
  JOURNAL   N Engl J Med 371:2363-74 (2014)
REFERENCE   PMID:25905378 (drug)
  AUTHORS   Eugster E
  TITLE     Gigantism
  JOURNAL   (2000)
///
ENTRY       H01619                      Disease
NAME        Primary pulmonary hypertension (PPH)
DESCRIPTION Primary pulmonary hypertension (PPH) is a progressive disease characterised by raised pulmonary vascular resistance, which results in diminished right-heart function due to increased right ventricular afterload. PPH occurs most commonly in young and middle-aged women; mean survival from onset of symptoms is 2-3 years. Mutations in the type II bone morphogenetic protein (BMP) receptor (BMPR)-II are now considered to be the genetic basis for familial PPH and ~30% of cases of sporadic PPH. BMPs are members of the transforming growth factor beta superfamily and affect intracellular signalling via Smads and mitogen-activated protein kinases.  It has been shown that missense mutations of cysteine residues in the extracellular or kinase domain of BMPR2 result in intracellular localisation of the mutated receptor and negligible Smad signalling.
CATEGORY    Cardiovascular disease
GENE        BMPR2 [HSA:659] [KO:K04671]
PATHOGEN    Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human herpesvirus 8 [GN:T40081]
DRUG        Beraprost [DR:D02720 D01551]
            Iloprost [DR:D02721]
            Treprostinil [DR:D06213]
DBLINKS     ICD-10: I27.0
            MeSH: D065627
            OMIM:178600
REFERENCE   PMID:9729004 (description, pathogen)
  AUTHORS   Gaine SP, Rubin LJ
  TITLE     Primary pulmonary hypertension.
  JOURNAL   Lancet 352:719-25 (1998)
REFERENCE   PMID:12737878 (description, gene, drug)
  AUTHORS   Runo JR, Loyd JE
  TITLE     Primary pulmonary hypertension.
  JOURNAL   Lancet 361:1533-44 (2003)
REFERENCE   PMID:15005857 (description, gene, pathogen)
  AUTHORS   Rudarakanchana N, Morrell NW
  TITLE     Primary pulmonary hypertension: molecular basis and potential for therapy.
  JOURNAL   Expert Rev Mol Med 6:1-15 (2004)
REFERENCE   PMID:12503718 (description, gene)
  AUTHORS   Eddahibi S, Morrell N, d'Ortho MP, Naeije R, Adnot S
  TITLE     Pathobiology of pulmonary arterial hypertension.
  JOURNAL   Eur Respir J 20:1559-72 (2002)
REFERENCE   PMID:15049720 (drug)
  AUTHORS   Nagaya N
  TITLE     Drug therapy of primary pulmonary hypertension.
  JOURNAL   Am J Cardiovasc Drugs 4:75-85 (2004)
///
ENTRY       H01620                      Disease
NAME        Raynaud syndrome, including:
            Raynaud disease;
            Raynaud phenomenon
DESCRIPTION Raynaud syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. Although the underlying pathophysiological mechanism is unclear, alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors. RS can occur as an isolated entity, historically referred to as Raynaud disease or now primary RS, or in association with other conditions, most frequently the connective tissue diseases (eg, scleroderma [DS:H01492], systemic lupus erythematosus [DS:H00080], rheumatoid arthritis [DS:H00630], and Sjogren's syndrome [DS:H01502]), often referred to as Raynaud phenomenon or secondary RS. The diagnosis is mainly clinical, based on patient descriptions of skin changes. Therapy has been focused on the use of general vasodilation strategies.
CATEGORY    Cardiovascular disease
DRUG        Niacinamide [DR:D00036]
            Niacin [DR:D00049]
            Betamethasone  [DR:D00244]
            Nicomol [DR:D01291]
            Niceritrol  [DR:D01754]
            Isoxsuprine hydrochloride [DR:D01748]
            Hepronicate [DR:D01882]
            Ergoloid mesylates [DR:D02268]
DBLINKS     ICD-10: I73.0
            MeSH: D011928
REFERENCE   PMID:23618525 (description)
  AUTHORS   Landry GJ
  TITLE     Current medical and surgical management of Raynaud's syndrome.
  JOURNAL   J Vasc Surg 57:1710-6 (2013)
REFERENCE   PMID:25770637 (description)
  AUTHORS   Valdovinos ST, Landry GJ
  TITLE     Raynaud syndrome.
  JOURNAL   Tech Vasc Interv Radiol 17:241-6 (2014)
///
ENTRY       H01621                      Disease
NAME        Pulmonary arterial hypertension (PAH)
DESCRIPTION Pulmonary arterial hypertension (PAH) is a progressive disorder in which endothelial dysfunction and vascular remodeling obstruct small pulmonary arteries, resulting in increased pulmonary vascular resistance and pulmonary pressures. This leads to reduced cardiac output, right heart failure, and ultimately death. PAH is divided into disease subgroups that include heritable (HPAH, formerly familial PAH), idiopathic (IPAH), and PAH associated with a variety of other systemic diseases or drug/toxin exposures. It has been discovered that altered BMPR2 signaling is the major heritable risk factor for development of PAH, via rare variants (mutations) in the BMPR2 gene (coding for a type II receptor member of the transforming growth factor [TGF]-beta family). Pathogenic mutations in the type I receptor ACVRL1 and, at a significantly lower frequency, the type III receptor endoglin in multiple kindreds cause PAH associated with hereditary hemorrhagic telangiectasia (HHT). Together, these observations support a prominent role for TGF-beta family members in the development of PAH.
CATEGORY    Cardiovascular disease
GENE        BMPR2 [HSA:659] [KO:K04671]
            ACVRL1 [HSA:94] [KO:K13594]
            ENG [HSA:2022] [KO:K06526]
            CAV1 [HSA:857] [KO:K06278]
            KCNK3 [HSA:3777] [KO:K04914]
            SMAD9 [HSA:4093] [KO:K16791]
            EIF2AK4 [HSA:440275] [KO:K16196]
DRUG        Bosentan [DR:D01227 D07538]
            Ambrisentan [DR:D07077]
            Sildenafil [DR:D08514]
            Tadalafil [DR:D02008]
            Riociguat [DR:D09572]
            Treprostinil [DR:D06213]
            Epoprostenol [DR:D00106]
            Iloprost [DR:D02721]
            Macitentan [DR:D10135]
DBLINKS     ICD-10: I27
            MeSH: D065627
REFERENCE   PMID:25082294 (drug)
  AUTHORS   Matsubara H, Ogawa A
  TITLE     Treatment of idiopathic/hereditary pulmonary arterial hypertension.
  JOURNAL   J Cardiol 64:243-9 (2014)
REFERENCE   PMID:24951762 (description, gene)
  AUTHORS   Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT
  TITLE     Pulmonary arterial hypertension: the clinical syndrome.
  JOURNAL   Circ Res 115:115-30 (2014)
REFERENCE   PMID:24355637 (description, gene)
  AUTHORS   Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, Loyd JE, Elliott CG, Trembath RC, Newman JH, Humbert M
  TITLE     Genetics and genomics of pulmonary arterial hypertension.
  JOURNAL   J Am Coll Cardiol 62:D13-21 (2013)
REFERENCE   PMID:24951767 (gene)
  AUTHORS   Austin ED, Loyd JE
  TITLE     The genetics of pulmonary arterial hypertension.
  JOURNAL   Circ Res 115:189-202 (2014)
REFERENCE   PMID:24912571 (drug)
  AUTHORS   Kylhammar D, Persson L, Hesselstrand R, Radegran G
  TITLE     Prognosis and response to first-line single and combination therapy in pulmonary  arterial hypertension.
  JOURNAL   Scand Cardiovasc J 48:223-33 (2014)
///
ENTRY       H01622                      Disease
NAME        Chronic thromboembolic pulmonary hypertension
DESCRIPTION Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group 4 pulmonary hypertension (PH) by the World Health Organization. It is a rare, but underdiagnosed, complication of acute pulmonary embolism (PE) resulting from occlusion of large pulmonary arteries with a fibrothrombotic material and in many cases, the development of a distal vessel arteriopathy that closely mimics pulmonary arterial hypertension.  While the pathogenesis of CTEPH is not entirely understood, the primary pathophysiology appears to be related to an initial thrombotic event followed by both inadequate thrombus resolution and secondary arteriopathy. Several risk factors for development of CTEPH have been found, including the size of the initial PE, splenectomy, chronic inflammatory conditions, and indwelling catheters and cardiac pacemaker leads. There is however an increased incidence of elevated factor VIII levels in CTEPH, and this finding persists after treatment. However, none of these findings explain the development of CTEPH in the majority of patients affected by this disease.
CATEGORY    Cardiovascular diseases
DRUG        Riociguat [DR:D09572]
DBLINKS     ICD-10: I27.2
REFERENCE   PMID:26739298 (drug)
  AUTHORS   Poch DS, Auger WR
  TITLE     Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.
  JOURNAL   Heart Fail Rev 21:309-22 (2016)
REFERENCE   PMID:26585271 (description, drug)
  AUTHORS   O'Connell C, Montani D, Savale L, Sitbon O, Parent F, Seferian A, Bulifon S, Fadel E, Mercier O, Mussot S, Fabre D, Dartevelle P, Humbert M, Simonneau G, Jais X
  TITLE     Chronic thromboembolic pulmonary hypertension.
  JOURNAL   Presse Med 44:e409-16 (2015)
REFERENCE   PMID:27345156 (description, drug)
  AUTHORS   Robbins IM, Pugh ME, Hemnes AR
  TITLE     Update on chronic thromboembolic pulmonary hypertension.
  JOURNAL   Trends Cardiovasc Med (2016)
REFERENCE   PMID:26099554 (description, drug)
  AUTHORS   Witkin AS, Channick RN
  TITLE     Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism.
  JOURNAL   Curr Cardiol Rep 17:63 (2015)
///
ENTRY       H01624                      Disease
NAME        Postherpetic neuralgia
DESCRIPTION Herpes zoster (HZ) presents as a rash of 2-3 weeks duration in immunocompetent patients that is accompanied by moderate or severe pain. In some patients, pain does not resolve when the rash heals but continues for weeks and, sometimes, for months or years; this phenomenon is known as postherpetic neuralgia (PHN). PHN is the most troublesome side effect associated with HZ. Both gabapentin and pregabalin can reduce pain and improve sleep patterns in patients with PHN.
CATEGORY    Neurodegenerative disease
DRUG        Pregabalin [DR:D02716]
            Gabapentin enacarbil [DR:D09539]
COMMENT     See also H00366 Herpes zoster.
DBLINKS     ICD-10: B02.2 G53.0
            MeSH: D051474
REFERENCE   PMID:26175877 (description)
  AUTHORS   Jeon YH
  TITLE     Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention  and Treatment.
  JOURNAL   Korean J Pain 28:177-84 (2015)
REFERENCE   PMID:12652389 (description)
  AUTHORS   Dworkin RH, Schmader KE
  TITLE     Treatment and prevention of postherpetic neuralgia.
  JOURNAL   Clin Infect Dis 36:877-82 (2003)
///
ENTRY       H01625                      Disease
NAME        Buerger's disease;
            Thromboangiitis obliterans
DESCRIPTION Buerger's disease, also known as thromboangiitis obliterans, is a nonatherosclerotic, inflammatory disease that most commonly affects the small and medium-sized arteries and veins in the upper and lower extremities. Cigarette smoking has been implicated as the main etiology of the disease. Although Buerger's disease has a worldwide distribution, it is more prevalent in the Middle East and Far East and classically develops in male smokers younger than 45 years. There may be a predisposition to development of Buerger's disease, although no gene has been identified to date. The most common symptom is pain at rest and claudication in the affected hands or feet. Other symptoms include cold insensitivity, diminished peripheral pulses, cyanosis, skin atrophy, and reduced hair growth. As the disease progresses, patients will develop ischemic ulcerations and eventually gangrene. Abstinence from smoking is the definitive treatment to prevent disease progression. Medical line of treatment with vasodilators, pentoxyfylline, and cilostazol may help improve pain-free walking distance but cannot prevent disease progression. Surgical treatment in form of revascularization and sympathectomy increases peripheral blood flow and decreases the rate of amputations. Newer therapy with prostaglandins, bosentan, and stem cell therapy has shown promising results.
CATEGORY    Vascular disease
ENV_FACTOR  Cigarette smoking
DRUG        Hepronicate [DR:D01882]
            Pentoxifylline [DR:D00501]
            Cilostazol [DR:D01896]
            Alprostadil [DR:D00180] (Prostaglandin)
DBLINKS     ICD-10: I73.1
            MeSH: D013919
            OMIM: 211480
REFERENCE   PMID:27144003
  AUTHORS   Rivera-Chavarria IJ, Brenes-Gutierrez JD
  TITLE     Thromboangiitis obliterans (Buerger's disease).
  JOURNAL   Ann Med Surg (Lond) 7:79-82 (2016)
REFERENCE   PMID:25987945
  AUTHORS   Sinclair NR, Laub DR
  TITLE     Thromboangiitis Obliterans (Buerger's Disease).
  JOURNAL   Eplasty 15:ic22 (2015)
REFERENCE   PMID:24102033 (drug)
  AUTHORS   Vijayakumar A, Tiwari R, Kumar Prabhuswamy V
  TITLE     Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.
  JOURNAL   Int J Inflam 2013:156905 (2013)
///
ENTRY       H01626                      Disease
NAME        Arteriosclerosis obliterans
DESCRIPTION Arteriosclerosis obliterans (ASO) is one of the most common peripheral vascular diseases that causes ischemic symptoms of the lower limbs. Symptoms include discomfort, numbness, intermittent claudication, or even gangrene and ulceration. The risk factors of ASO include age, male gender, smoking, hypertension, hyperlipidemia, diabetes mellitus, chronic renal failure, and hyperhomocysteinemia. There are no definitive treatments for ASO. The efficacy of surgical treatment is not satisfactory, and medication is required to maintain the postoperative vascular patency. In order to relieve symptoms such as cold sensation and intermittent claudication, drug therapy such as antiplatelet therapy and vasodilatory drugs are useful in the treatment of some patients with ASO. Adsorption of low-density lipoprotein (LDL) has also been applied for the treatment of ASO. At present, the diagnosis of ASO depends on several clinical tests, such as angiography, estimations of ankle/brachial index (ABI), and pulse-wave velocity (PWV), as well as the measurement of circulating hs-CRP levels. However, these examinations can only be detectable when ASO already developed, and there was no predictable markers for ASO in its earlier stages. Recent studies have reported that some micro RNAs could be serum markers for early-stage ASO.
CATEGORY    Vascular disease
ENV_FACTOR  Cigarette smoking
DRUG        Tocopherol nicotinate [DR:D01530]
            Hepronicate [DR:D01882]
            Beraprost [DR:D01551]
            Cilostazol [DR:D01896]
DBLINKS     ICD-10: I70
            MeSH: D001162
REFERENCE   PMID:26632166
  AUTHORS   Horie T, Kimura T, Ono K
  TITLE     Emerging Novel Biomarkers for Arteriosclerosis Obliterans.
  JOURNAL   J Atheroscler Thromb 23:171-2 (2016)
REFERENCE   PMID:23364237
  AUTHORS   Ren S, Qian S, Wang W, Liu J, Liu P
  TITLE     Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans.
  JOURNAL   Ann Thorac Cardiovasc Surg 19:30-4 (2013)
REFERENCE   PMID:26370316
  AUTHORS   He XM, Zheng YQ, Liu SZ, Liu Y, He YZ, Zhou XY
  TITLE     Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans.
  JOURNAL   J Atheroscler Thromb 23:196-206 (2016)
REFERENCE   PMID:26272221 (drug)
  AUTHORS   Mathur P, Ding Z, Saldeen T, Mehta JL
  TITLE     Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease.
  JOURNAL   Clin Cardiol 38:570-6 (2015)
REFERENCE   PMID:23749750 (drug)
  AUTHORS   Arai T
  TITLE     Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients.
  JOURNAL   Adv Ther 30:528-40 (2013)
REFERENCE   PMID:22142554 (drug)
  AUTHORS   Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G
  TITLE     A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
  JOURNAL   Health Technol Assess 15:1-210 (2011)
REFERENCE   PMID:12886046
  AUTHORS   Nakamura T, Kawagoe Y, Matsuda T, Takahashi Y, Sekizuka K, Ebihara I, Koide H
  TITLE     Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans.
  JOURNAL   Kidney Blood Press Res 26:185-91 (2003)
///
ENTRY       H01628                      Disease
NAME        Opisthorchiasis
DESCRIPTION Opisthorchiasis comprises diverse clinical symptoms caused by infections with Opisthorchis felineus or Opisthorchis viverrini liver flukes, which are transmitted by eating infected raw or undercooked fish and other aquatic products. Opisthorchiasis is characterized by hepatosplenomegaly, abdominal tenderness, eosinophilia, chills, and fever. Left untreated, it can lead to obstructive jaundice, cholangitis, cholecystitis, and intra-abdominal masses. Praziquantel is the drug of choice for the treatment of opisthorchiasis.
CATEGORY    Infectious disease
PATHOGEN    Opisthorchis viverrini
            Opisthorchis felineus
DRUG        Praziquantel [DR:D00471]
COMMENT     See also H01617 Foodborne trematodiasis.
DBLINKS     ICD-10: B66.0
            MeSH: D009889
REFERENCE   PMID:24520562 (description)
  AUTHORS   Wunderink HF, Rozemeijer W, Wever PC, Verweij JJ, van Lieshout L
  TITLE     Foodborne trematodiasis and Opisthorchis felineus acquired in Italy.
  JOURNAL   Emerg Infect Dis 20:154-5 (2014)
///
ENTRY       H01629                      Disease
NAME        Chronic arterial occlusive disease
DESCRIPTION Chronic arterial occlusive disease is a highly prevalent peripheral vascular disorder. This disease is caused by arteriosclerosis obliterans (ASO), thromboangiitis obliterans (Buerger's disease), primary arterial thrombosis, embolism and so on. Of these, ASO is the most frequently encountered. Although differing clinically and pathologically, these diseases are similar in that they cause ischemia of tissues. The symptoms of chronic occlusive arterial disease result from impairment of blood flow to the extremities. Intermittent claudication is the commonest and usually the earliest symptom.
CATEGORY    Vascular disease
DRUG        Beraprost [DR:D01551]
COMMENT     See also H01625 Buerger's disease and H01626 Arteriosclerosis obliterans.
DBLINKS     ICD-10: I74
            MeSH: D001157
REFERENCE   PMID:14042045
  AUTHORS   JUERGENS JL
  TITLE     Chronic occlusive arterial disease of the extremities.
  JOURNAL   Circulation 27:964-9 (1963)
REFERENCE   PMID:21115876
  AUTHORS   Idei N, Nishioka K, Soga J, Hidaka T, Hata T, Fujii Y, Fujimura N, Maruhashi T, Mikami S, Teragawa H, Kihara Y, Noma K, Chayama K, Higashi Y
  TITLE     Vascular function and circulating progenitor cells in thromboangitis obliterans (Buerger's disease) and atherosclerosis obliterans.
  JOURNAL   Hypertension 57:70-8 (2011)
REFERENCE   PMID:10908215 (drug)
  AUTHORS   Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP
  TITLE     Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
  JOURNAL   Circulation 102:426-31 (2000)
///
ENTRY       H01630                      Disease
NAME        Patent ductus arteriosus
DESCRIPTION Patent ductus arteriosus (PDA) is a common congenital heart defect with both inherited and acquired causes. The ductus arteriosus (DA) is a fetal specific vascular connection between the main pulmonary artery and the aorta. After birth, the DA normally closes within the first several days of life. If present after the age of 3 month, this condition is known as PDA. PDA can cause significant problems, especially in premature infants. It can be associated with an increased incidence of chronic lung disease, intraventricular hemorrhage, and necrotizing enterocolitis. Clinicians may choose to treat the PDA in an attempt to minimize the risk of these complications. Prostaglandin inhibition using indomethacin or ibuprofen is the standard strategy to close the DA. Surgical closure of the DA is an alternative option. Autosomal dominant forms of PDA caused by mutation in the TFAP2B and PRDM6 gene has been reported. PDA has been reported in a few subjects with thoracic aortic aneurysm and rare genetic variants in MYH11 and ACTA2.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        TFAP2B [HSA:7021] [KO:K09176]
            PRDM6 [HSA:93166] [KO:K20795]
            MYH11 [HSA:4629] [KO:K10352]
            ACTA2 [HSA:59] [KO:K12313]
DRUG        Indomethacin [DR:D02110]
            Ibuprofen [DR:D00126]
DBLINKS     ICD-10: Q25.0
            MeSH: D004374
            OMIM: 607411 617035 617039 132900 611788
REFERENCE   PMID:23316351
  AUTHORS   Olsson KW, Jonzon A, Sindelar R
  TITLE     A high ductal flow velocity is associated with successful pharmacological closure of patent ductus arteriosus in infants 22-27 weeks gestational age.
  JOURNAL   Crit Care Res Pract 2012:715265 (2012)
REFERENCE   PMID:27181681 (gene)
  AUTHORS   Li N, Subrahmanyan L, Smith E, Yu X, Zaidi S, Choi M, Mane S, Nelson-Williams C, Bahjati M, Kazemi M, Hashemi M, Fathzadeh M, Narayanan A, Tian L, Montazeri F, Mani M, Begleiter ML, Coon BG, Lynch HT, Olson EN, Zhao H, Ruland J, Lifton RP, Mani A
  TITLE     Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus.
  JOURNAL   Am J Hum Genet 98:1082-91 (2016)
REFERENCE   PMID:24507797 (gene)
  AUTHORS   Ji W, Benson MA, Bhattacharya S, Chen Y, Hu J, Li F
  TITLE     Characterization of transcription factor AP-2 beta mutations involved in familial isolated patent ductus arteriosus suggests haploinsufficiency.
  JOURNAL   J Surg Res 188:466-72 (2014)
REFERENCE   PMID:22368623 (drug)
  AUTHORS   Mehta S, Younoszai A, Pietz J, Achanti B
  TITLE     Pharmacological closure of the patent ductus arteriosus.
  JOURNAL   Images Paediatr Cardiol 5:1-15 (2003)
REFERENCE   PMID:21532789 (drug)
  AUTHORS   Thebaud B, Lacaze-Mazmonteil T
  TITLE     Patent ductus arteriosus in premature infants: A never-closing act.
  JOURNAL   Paediatr Child Health 15:267-70 (2010)
///
ENTRY       H01631                      Disease
NAME        Acute heart failure
DESCRIPTION Acute heart failure (AHF) can be defined as a heterogeneous syndrome of signs and symptoms of new-onset or gradual/rapidly worsening heart failure (HF), requiring urgent therapy. Intrinsic cardiac abnormalities and comorbid conditions, including lung and renal disease, and sleep-disordered breathing, can contribute to the development of AHF. Factors triggering AHF may include ischemia, hypertension, arrhythmias, noncardiac comorbidities, and administered drugs, etc. Because of the poor clinical outcome and the relevant associated morbidity and mortality, it remains a major public health issue with a substantial socioeconomic burden.
CATEGORY    Cardiovascular diseases
MARKER      B-type natriuretic peptide (BNP) [HSA:4879] [KO:K12335]
            N-terminal pro B-type natriuretic peptide (NT-proBNP)
            Soluble ST2 (sST2)
            Troponin I [HSA:7137] [KO:K12044]
            Troponin T [HSA:7139] [KO:K12045]
            Galectin 3 [HSA:3958] [KO:K06831]
            Mid-regional proadrenomedullin (MR-proADM)
            Copeptin [HSA:551] [KO:K05242]
DRUG        Hydrochlorothiazide [DR:D00340]
            Metolazone [DR:D00431]
            Chlorthalidone [DR:D00272]
            Nitroglycerin [DR:D00515]
DBLINKS     ICD-10: I11 I13 I43 I50 I51 P29
            MeSH: D006333
REFERENCE   PMID:26370473
  AUTHORS   Mentz RJ, O'Connor CM
  TITLE     Pathophysiology and clinical evaluation of acute heart failure.
  JOURNAL   Nat Rev Cardiol 13:28-35 (2016)
REFERENCE   PMID:25743769
  AUTHORS   Ponikowski P, Jankowska EA
  TITLE     Pathogenesis and clinical presentation of acute heart failure.
  JOURNAL   Rev Esp Cardiol (Engl Ed) 68:331-7 (2015)
REFERENCE   PMID:23644993 (marker)
  AUTHORS   Chowdhury P, Kehl D, Choudhary R, Maisel A
  TITLE     The use of biomarkers in the patient with heart failure.
  JOURNAL   Curr Cardiol Rep 15:372 (2013)
REFERENCE   PMID:26088867 (drug)
  AUTHORS   Di Somma S, Magrini L
  TITLE     Drug Therapy for Acute Heart Failure.
  JOURNAL   Rev Esp Cardiol (Engl Ed) 68:706-13 (2015)
REFERENCE   PMID:23863875 (drug)
  AUTHORS   Poss J, Link A, Bohm M
  TITLE     Pharmacological treatment of acute heart failure: current treatment and new targets.
  JOURNAL   Clin Pharmacol Ther 94:499-508 (2013)
///
ENTRY       H01632                      Disease
NAME        Angina pectoris
DESCRIPTION Angina pectoris is defined as cardiac-induced pain arising from a lack of myocardial oxygen. "Angina" is used to describe clinical symptoms such as discomfort in the chest, jaw, shoulder, back, or arms that are induced by physical exertion or emotional stress and subside with rest or treatment with nitroglycerin. Angina is clinically classified into stable angina (SA) and unstable angina (UA). SA is a chronic medical condition while UA is an acute coronary syndrome. Among the causes of angina pectoris, the most common is coronary artery disease (CAD). At the cellular level, angina pectoris is a result of increased myocardial oxygen demand or decreased myocardial oxygen supply.
CATEGORY    Cardiovascular diseases
MARKER      Creatine kinase (CK) [HSA:1158 1152] [KO:K00933]
            Troponin I [HSA:7137] [KO:K12044]
            Troponin T [HSA:7139] [KO:K12045]
DRUG        Metoprolol [DR:D02358]
            Atenolol [DR:D00235]
            Bisoprolol [DR:D02342]
            Nebivolol [DR:D05127]
            Diltiazem [DR:D07845]
            Verapamil [DR:D02356]
            Nitrate [DR:D02313]
            Ranolazine [DR:D05700]
DBLINKS     ICD-10: I20
            MeSH: D000787
REFERENCE   PMID:20693568
  AUTHORS   Tobin KJ
  TITLE     Stable angina pectoris: what does the current clinical evidence tell us?
  JOURNAL   J Am Osteopath Assoc 110:364-70 (2010)
REFERENCE
  AUTHORS   Albrecht S.
  TITLE     The pathophysiology and treatment of stable angina pectoris.
  JOURNAL   US Pharm 38(2):43-60 (2013)
REFERENCE   PMID:10631280 (drug, marker)
  AUTHORS   Yeghiazarians Y, Braunstein JB, Askari A, Stone PH
  TITLE     Unstable angina pectoris.
  JOURNAL   N Engl J Med 342:101-14 (2000)
REFERENCE   PMID:20384546 (drug)
  AUTHORS   Fernandez SF, Tandar A, Boden WE
  TITLE     Emerging medical treatment for angina pectoris.
  JOURNAL   Expert Opin Emerg Drugs 15:283-98 (2010)
REFERENCE   PMID:14570861 (drug)
  AUTHORS   Aronow WS
  TITLE     Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
  JOURNAL   J Gerontol A Biol Sci Med Sci 58:M927-33 (2003)
REFERENCE   PMID:24416066
  AUTHORS   Mao C, Chung VC, Yuan JQ, Yu YY, Yang ZY, Wu XY, Tang JL
  TITLE     Evaluation of the add-on effect of chinese patent medicine for patients with stable or unstable angina: a systematic review and meta-analysis.
  JOURNAL   Evid Based Complement Alternat Med 2013:673193 (2013)
REFERENCE   PMID:25039022
  AUTHORS   Andrikopoulos G, Parissis J, Filippatos G, Nikolaou M, Pantos K, Voudris V, Karvounis H, Alexopoulos D, Goudevenos J
  TITLE     Medical management of stable angina.
  JOURNAL   Hellenic J Cardiol 55:272-80 (2014)
REFERENCE   PMID:15771924 (marker)
  AUTHORS   Jordanova N, Gyongyosi M, Khorsand A, Falkensammer C, Zorn G, Wojta J, Anvari A, Huber K
  TITLE     New cut-off values of cardiac markers for risk stratification of angina pectoris.
  JOURNAL   Int J Cardiol 99:429-35 (2005)
///
ENTRY       H01633                      Disease
NAME        High blood pressure;
            Hypertension
DESCRIPTION High blood pressure (hypertension) is the most frequent classic cardiovascular risk factor and accounts for a large proportion of cardiovascular mortality, the main cause of death worldwide. Hypertension is generally classified as primary (essential) or secondary. Essential hypertension (EH) is the most common diagnosis in this disease, suggesting that a monocausal etiology has not been identified. However, a number of risk factors associated with EH have also been identified such as age, sex, demographic, environmental, genetic, and vascular factors. Secondary hypertension generally has an earlier age at onset, no family history, and a clear cause such as a renal or endocrine disorder, or an iatrogenic trigger, such as use of oral contraceptives. Blood pressure is a heritable trait; an estimated 30% of variance in blood pressure relates to genetic factors. Understanding of the genetic architecture of traits has progressed in rare mendelian hypertensive phenotypes, such as Gordon's syndrome.
CATEGORY    Cardiovascular diseases
GENE        CYP11B2 [HSA:1585] [KO:K07433]
            CYP11B1 [HSA:1584] [KO:K00497]
            HSD11B2 [HSA:3291] [KO:K00071]
            NR3C2 [HSA:4306] [KO:K08555]
            SCNN1B [HSA:6338] [KO:K04825]
            SCNN1G [HSA:6340] [KO:K04827]
ENV_FACTOR  Excess consumption of sodium [CPD:C01330]
            Excess consumption of coffee
            Excess consumption of alcohol
DRUG        Hydrochlorothiazide [DR:D00340]
            Chlorthalidone [DR:D00272]
            Metolazone [DR:D00431]
            Indapamide [DR:D00345]
            Furosemide [DR:D00331]
            Ethacrynic acid [DR:D00313]
            Bumetanide [DR:D00247]
            Torsemide [DR:D00382]
            Spironolactone [DR:D00443]
            Amiloride [DR:D07447]
            Eplerenone [DR:D01115]
            Acebutolol [DR:D02338]
            Atenolol [DR:D00235]
            Betaxolol [DR:D07526]
            Bisoprolol [DR:D02342]
            Carvedilol [DR:D00255]
            Labetalol [DR:D08106]
            Metoprolol [DR:D02358]
            Nadolol [DR:D00432]
            Nebivolol [DR:D05127]
            Penbutolol [DR:D08074]
            Pindolol [DR:D00513]
            Propranolol [DR:D08443]
            Timolol [DR:D00378]
            Aliskiren [DR:D03208]
            Benazepril [DR:D07499]
            Captopril [DR:D00251]
            Enalapril [DR:D07892]
            Fosinopril [DR:D07992]
            Lisinopril [DR:D08131]
            Moexipril [DR:D08225]
            Perindopril [DR:D03753]
            Quinapril [DR:D03752]
            Ramipril [DR:D00421]
            Trandolapril [DR:D00383]
            Verapamil [DR:D02356]
            Candesartan cilexetil [DR:D00626]
            Eprosartan [DR:D04040]
            Irbesartan [DR:D00523]
            Losartan [DR:D08146]
DBLINKS     ICD-10: I10
            MeSH: D006973
REFERENCE   (drug)
  AUTHORS   Foex P, Sear JW.
  TITLE     Hypertension: pathophysiology and treatment.
  JOURNAL   Critical Care & Pain 4(3):71-75 (2004)
REFERENCE   PMID:25832858
  AUTHORS   Poulter NR, Prabhakaran D, Caulfield M
  TITLE     Hypertension.
  JOURNAL   Lancet 386:801-12 (2015)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:27028574 (gene, env_factor)
  AUTHORS   Singh M, Singh AK, Pandey P, Chandra S, Singh KA, Gambhir IS
  TITLE     Molecular genetics of essential hypertension.
  JOURNAL   Clin Exp Hypertens 38:268-77 (2016)
REFERENCE   PMID:23303660 (gene)
  AUTHORS   Ehret GB, Caulfield MJ
  TITLE     Genes for blood pressure: an opportunity to understand hypertension.
  JOURNAL   Eur Heart J 34:951-61 (2013)
///
ENTRY       H01634                      Disease
NAME        Peptic ulcer
DESCRIPTION Peptic ulcer is a common disorder of gastrointestinal system characterized by mucosal damage secondary to pepsin and gastric acid secretion. It usually occurs in the stomach and proximal duodenum. Typical symptoms include episodic burning epigastric pain, loss of appetite, and weight loss. Pain usually occurs two to five hours after meals or on an empty stomach. The most common causes of peptic ulcer are Helicobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Smoking increases the risk of ulcer recurrence and slows healing. Most patients are treated successfully with eradication of H. pylori and/or avoidance of NSAIDs, along with the appropriate use of antisecretory therapy. About 25 percent of patients with peptic ulcer have a serious complication such as hemorrhage, perforation, or gastric outlet obstruction. Administration of proton pump inhibitors (PPIs) and endoscopic therapy control most bleeds.
CATEGORY    Digestive system disease
ENV_FACTOR  Helicobacter pylori infection
            Nonsteroidal anti-inflammatory drugs (NSAIDs)
            Smoking
            Age (older than 55 years)
DRUG        Cimetidine [DR:D00295]
            Pirenzepine [DR:D05276]
            Mepenzolate bromide [DR:D00720]
            Omeprazole [DR:D00455]
COMMENT     See also H00320 Helicobacter pylori infection.
DBLINKS     ICD-10: K25 K26 K27
            MeSH: D010437
REFERENCE   PMID:17956071
  AUTHORS   Ramakrishnan K, Salinas RC
  TITLE     Peptic ulcer disease.
  JOURNAL   Am Fam Physician 76:1005-12 (2007)
REFERENCE   PMID:25955624
  AUTHORS   Fashner J, Gitu AC
  TITLE     Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection.
  JOURNAL   Am Fam Physician 91:236-42 (2015)
REFERENCE   PMID:2892567 (drug)
  AUTHORS   Weir DG
  TITLE     Peptic ulceration.
  JOURNAL   Br Med J (Clin Res Ed) 296:195-200 (1988)
///
ENTRY       H01635                      Disease
NAME        Hyperlipidemia, including:
            Hyperlipoproteinemia;
            Hypercholesterolemia;
            Hypertriglyceridemia;
            Mixed dyslipidemia
DESCRIPTION Dyslipidemia is a condition characterized by either an increase or decrease in concentration of lipids in the blood. Hyperlipidemia, which refers to an increase in cholesterol, triglyceride (TG), or both, is the most common form of dyslipidemia. Hyperlipidemias can be classified as familial (also called primary) caused by an inherited gene mutation, or acquired (also called secondary) when resulting from underlying disorders that lead to alterations in plasma lipid and lipoprotein metabolism. The causes of acquired hyperlipidemia include dietary, alcohol intake, oral contraceptives, diabetes mellitus, and pharmacological agents (e.g., retinoic acid derivatives, steroids, and beta-blockers). Familial hyperlipidemias are classified according to the Fredrickson classification (hyperlipoproteinemia types I to V) which is based on lipoprotein analyses by electrophoresis or ultracentrifugation. It was later adopted by the World Health Organization (WHO). Hyperlipidemias are also classified according to which types of lipids are elevated. Hypercholesterolemia, hypertriglyceridemia, and combined hyperlipidemia refer to elevations involving the major cholesterol-rich lipoproteins (LDL), triglyceride-rich lipoproteins (VLDL), and both, respectively.
CATEGORY    Metabolic disease
GENE        (Hyperlipoproteinemia type 1) APOC2 [HSA:344]
            (Hyperlipoproteinemia type 1,2) LPL [HSA:4023] [KO:K01059]
            (Hyperlipoproteinemia type 2) LDLR [HSA:3949] [KO:K12473]
            (Hyperlipoproteinemia type 5) APOA5 [HSA:116519] [KO:K09025]
DRUG        Pravastatin [DR:D00893]
            Simvastatin  [DR:D00434]
            Fluvastatin [DR:D00892]
            Atorvastatin [DR:D02258]
            Pitavastatin [DR:D10568 D01862]
            Rosuvastatin [DR:D01915]
            Colestyramine [DR:D02690]
            Colestimide [DR:D01934]
            Ezetimibe [DR:D01966]
            Bezafibrate [DR:D01366]
            Fenofibrate [DR:D00565]
            Clofibrate [DR:D00279]
            Clinofibrate [DR:D01300]
            Probucol [DR:D00476]
            Icosapent ethyl [DR:D01892]
            Omega-3-acid ethyl esters [DR:D05255]
DBLINKS     ICD-10: E78
            MeSH: D006949
            OMIM: 238600 207750 143890 144250 144650
REFERENCE   PMID:19306526 (description)
  AUTHORS   Alwaili K, Alrasadi K, Awan Z, Genest J
  TITLE     Approach to the diagnosis and management of lipoprotein disorders.
  JOURNAL   Curr Opin Endocrinol Diabetes Obes 16:132-40 (2009)
REFERENCE   PMID:2192873 (description)
  AUTHORS   Chait A, Brunzell JD
  TITLE     Acquired hyperlipidemia (secondary dyslipoproteinemias).
  JOURNAL   Endocrinol Metab Clin North Am 19:259-78 (1990)
REFERENCE   PMID:4930042 (description)
  AUTHORS   Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T
  TITLE     Classification of hyperlipidaemias and hyperlipoproteinaemias.
  JOURNAL   Bull World Health Organ 43:891-915 (1970)
REFERENCE   PMID:193431 (description)
  AUTHORS   Havel RJ
  TITLE     Classifications of the hyperlipidemias.
  JOURNAL   Annu Rev Med 28:195-209 (1977)
///
ENTRY       H01636                      Disease
NAME        Fibromyalgia;
            Fibromyalgia syndrome
DESCRIPTION Fibromyalgia is a common and chronic pain disorder that predominantly affects women. It belongs to the group of rheumatic disorders of the soft tissues, and is characterised by widespread chronic pain, cognitive and affective disturbances and fatigue. The etiology and pathogenesis of fibromyalgia is uncertain. Genetic studies suggest an association with polymorphisms in serotonergic, dopaminergic, and catecholaminergic pathways involved in pain transmission and modulation. The disease is likely expressed in the presence of environmental trigger, which lead to expression of multiple genes that amplify pain perception in the pain processing pathway. Although there is no ultimate cure for fibromyalgia, some medications can alleviate symptoms of the disease.
CATEGORY    Skin and connective tissue disease
DRUG        Pregabalin [DR:D02716]
DBLINKS     ICD-10: M79.7
            MeSH: D005356
REFERENCE   PMID:26488355
  AUTHORS   Binkiewicz-Glinska A, Bakula S, Tomczak H, Landowski J, Ruckemann-Dziurdzinska K, Zaborowska-Sapeta K, Kowalski I, Kiebzak W
  TITLE     Fibromyalgia Syndrome - a multidisciplinary approach.
  JOURNAL   Psychiatr Pol 49:801-10 (2015)
REFERENCE   PMID:26937205 (drug)
  AUTHORS   Bhusal S, Diomampo S, Magrey MN
  TITLE     Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia.
  JOURNAL   Drug Healthc Patient Saf 8:13-23 (2016)
///
ENTRY       H01637                      Disease
NAME        Hypertriglyceridemia
DESCRIPTION Hypertriglyceridemia (HTG) is a condition with fasting triglyceride (TG) levels in blood continuing to rise. HTG generally refers to an increase of plasma triglyceride (TG) concentrations above the 95th percentile for age and gender of a reference population. HTG has generally been classified as primary when a definite familial or inherited basis is suspected, whereas secondary HTG refers to cases where there coexist one or more identifiable secondary conditions such as metabolic syndrome, type 2 diabetes (T2D), alcohol consumption, various medications, renal insufficiency, pregnancy, etc. Genetic conditions with HTG include familial HTG (FHTG), familial combined hyperlipidemia (FCHL) [DS:H00153], and familial dysbetalipoproteinemia (Type III hyperlipidemia) [DS:H00156]. Three drug classes are clinically available for treatment of HTG, fibrates, niacin and n-3 fatty acids. Each of these classes has limitations. There is inconsistency in the evidence base for cardiovascular risk reduction using fibrates, the use of niacin is associated with significant side effects, and there are limited data on the use of n-3 fatty acids to reduce cardiovascular risk.
CATEGORY    Metabolic disease
GENE        USF1 [HSA:7391] [KO:K09106]
            APOE [HSA:348] [KO:K04524]
            LPL [HSA:4023] [KO:K01059]
DRUG        Gemfibrozil [DR:D00334] Bezafibrate [DR:D01366] Fenofibrate [DR:D00565] (Fibrates)
            Icosapent ethyl [DR:D08061] (n-3 fatty acids)
            Niacin [DR:D00049] Nicomol [DR:D01291] Niceritrol [DR:D01754] (Niacins)
DBLINKS     ICD-10: E78.1 E78.2 E78.4
            MeSH: D015228
            OMIM: 144250
REFERENCE   PMID:25554923 (description)
  AUTHORS   Lewis GF, Xiao C, Hegele RA
  TITLE     Hypertriglyceridemia in the genomic era: a new paradigm.
  JOURNAL   Endocr Rev 36:131-47 (2015)
REFERENCE   PMID:26044648 (description)
  AUTHORS   Sahebkar A, Watts GF
  TITLE     Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?
  JOURNAL   Expert Rev Clin Pharmacol 8:363-6 (2015)
REFERENCE   PMID:24840268 (description)
  AUTHORS   Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A
  TITLE     Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 28:423-37 (2014)
REFERENCE   PMID:23009777 (drug)
  AUTHORS   Maki KC, Bays HE, Dicklin MR
  TITLE     Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence.
  JOURNAL   J Clin Lipidol 6:413-26 (2012)
///
ENTRY       H01638                      Disease
NAME        Neuropathic pain;
            Neuralgia
DESCRIPTION Neuropathic pain is defined as pain caused by a lesion or disease affecting the somatosensory nervous system, and may be generated by either the peripheral or central nervous system, or both. It is especially problematic because of its severity, chronicity and resistance to simple analgesics. It may result from various causes including cervical or lumbar radiculopathy, diabetic neuropathy, cancer-related neuropathic pain, postherpetic neuralgia, HIV-related neuropathy, spinal cord injury, trigeminal neuralgia and complex regional pain syndrome type II, among others. Treatments are generally palliative and include conservative nonpharmacologic therapies, drugs and interventional therapies such as spinal cord stimulation. Analgesic agents recommended for first-line treatments are gabapentinoids, tricyclic antidepressants (TCAs) and serotonin noradrenaline reuptake inhibitors (SNRIs).
CATEGORY    Nervous system disease
DRUG        Pregabalin [DR:D02716] Gabapentin [DR:D00332 D09539] (Gabapentinoid)
            Amitriptyline [DR:D00809] (TCAs)
            Duloxetine [DR:D01179] (SNRIs)
COMMENT     See also H01459 Diabetic neuropathy and H01624 Postherpetic neuralgia.
DBLINKS     ICD-10: M79.2
            MeSH: D009437
REFERENCE   PMID:16880448
  AUTHORS   Gilron I, Watson CP, Cahill CM, Moulin DE
  TITLE     Neuropathic pain: a practical guide for the clinician.
  JOURNAL   CMAJ 175:265-75 (2006)
REFERENCE   PMID:25479151 (drug)
  AUTHORS   Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD
  TITLE     Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.
  JOURNAL   Pain Res Manag 19:328-35 (2014)
///
ENTRY       H01639                      Disease
NAME        Endometriosis
DESCRIPTION Endometriosis is defined as the growth of the endometrial glands and stroma at extra-uterine sites, which are most commonly implanted over and under visceral and peritoneal surfaces within the female pelvis but which can also be found in the connective tissue in the pelvis areas and, more rarely, in any anatomic district. It is a major cause of infertility, dysmenorrhea, dyspareunia, and chronic pelvic pain, mediated by marked pelvic inflammation. While retrograde menstruation is the most widely accepted cause, its pathogenesis and natural course are not fully understood. Endometriosis is known to be a estrogen-dependent disease, manifests during reproductive years.
CATEGORY    Reproductive system diseases
ENV_FACTOR  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) [CPD:C07557]
            Polyhalogenated aromatic hydrocarbon chemicals (PHAHs)
            Polychlorinated biphenyls (PCBs)
MARKER      CA125 [HSA:94025] [KO:K16145]
            Annexin V [HSA:308] [KO:K16646]
            VEGF [HSA:7422] [KO:K05448]
DRUG        Danazol [DR:D00289]
            Anastrozole [DR:D00960]
            Letrozole [DR:D00964]
            Goserelin [DR:D04405]
            Nafarelin [DR:D08241]
            Progestin
DBLINKS     ICD-10: N80
            MeSH: D004715
REFERENCE   PMID:24927773 (env_factor, marker)
  AUTHORS   Aznaurova YB, Zhumataev MB, Roberts TK, Aliper AM, Zhavoronkov AA
  TITLE     Molecular aspects of development and regulation of endometriosis.
  JOURNAL   Reprod Biol Endocrinol 12:50 (2014)
REFERENCE   PMID:25578564 (marker)
  AUTHORS   Signorile PG, Baldi A
  TITLE     New evidence in endometriosis.
  JOURNAL   Int J Biochem Cell Biol 60:19-22 (2015)
REFERENCE   PMID:24366116
  AUTHORS   Vercellini P, Vigano P, Somigliana E, Fedele L
  TITLE     Endometriosis: pathogenesis and treatment.
  JOURNAL   Nat Rev Endocrinol 10:261-75 (2014)
REFERENCE   PMID:26125255 (env_factor)
  AUTHORS   Soave I, Caserta D, Wenger JM, Dessole S, Perino A, Marci R
  TITLE     Environment and Endometriosis: a toxic relationship.
  JOURNAL   Eur Rev Med Pharmacol Sci 19:1964-72 (2015)
REFERENCE   PMID:26050551 (drug)
  AUTHORS   Lindsay SF, Luciano DE, Luciano AA
  TITLE     Emerging therapy for endometriosis.
  JOURNAL   Expert Opin Emerg Drugs 20:449-61 (2015)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
///
ENTRY       H01640                      Disease
NAME        Uterine leiomyoma;
            Fibroid
DESCRIPTION Uterine leiomyoma, also known as fibroid, is the most common benign neoplasm of the female genital tract. It is a discrete, round, firm, often multiple uterine tumor composed of smooth muscle and connective tissue. The findings derived from high-throughput sequencing combined with previous knowledge have led to an emerging molecular classification of leiomyomas, suggesting that there are several distinct pathogenic pathways involved in leiomyoma formation. The evidence points to at least 4 molecular subclasses: leiomyomas with MED12 mutation, FH inactivation, HMGA2 overexpression, and COL4A6-COL4A5 deletion. While it is thought that the initial events that trigger leiomyoma tumorigenesis involves somatic mutations, it is evident that the development and growth of leiomyoma are highly dependent on ovarian steroid hormones, in particular, progesterone.
CATEGORY    Reproductive system diseases
GENE        HMGA2 (rearrangement) [HSA:8091] [KO:K09283]
            MED12 (mutation) [HSA:9968] [KO:K15162]
            COL4A6-COL4A5 (deletion) [HSA:1288 1287] [KO:K06237]
            Fumarate hydratase (FH) (inactivation) [HSA:2271] [KO:K01679]
DRUG        DMPA
            Leuprolide acetate [DR:D00989]
            Nafarelin [DR:D08241]
            Triptorelin [DR:D06247]
COMMENT     ICD-O-3: 8890/0 Leiomyoma, NOS
DBLINKS     ICD-10: D25
            MeSH: D007889
            OMIM: 150699
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:21672608
  AUTHORS   Kim JJ, Sefton EC
  TITLE     The role of progesterone signaling in the pathogenesis of uterine leiomyoma.
  JOURNAL   Mol Cell Endocrinol 358:223-31 (2012)
REFERENCE   PMID:25106763 (gene)
  AUTHORS   Mehine M, Makinen N, Heinonen HR, Aaltonen LA, Vahteristo P
  TITLE     Genomics of uterine leiomyomas: insights from high-throughput sequencing.
  JOURNAL   Fertil Steril 102:621-9 (2014)
REFERENCE   PMID:17613550 (gene)
  AUTHORS   Hodge JC, Morton CC
  TITLE     Genetic heterogeneity among uterine leiomyomata: insights into malignant progression.
  JOURNAL   Hum Mol Genet 16 Spec No 1:R7-13 (2007)
REFERENCE   PMID:25205766 (drug)
  AUTHORS   Moravek MB, Yin P, Ono M, Coon JS 5th, Dyson MT, Navarro A, Marsh EE, Chakravarti D, Kim JJ, Wei JJ, Bulun SE
  TITLE     Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.
  JOURNAL   Hum Reprod Update 21:1-12 (2015)
REFERENCE   PMID:26236472 (gene)
  AUTHORS   Taylor DK, Holthouser K, Segars JH, Leppert PC
  TITLE     Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management.
  JOURNAL   F1000Res 4:183 (2015)
REFERENCE   PMID:24819877
  AUTHORS   Doherty L, Mutlu L, Sinclair D, Taylor H
  TITLE     Uterine fibroids: clinical manifestations and contemporary management.
  JOURNAL   Reprod Sci 21:1067-92 (2014)
///
ENTRY       H01641                      Disease
NAME        Dry eye desease;
            Keratoconjunctivitis sicca
DESCRIPTION Dry eye disease (also called keratoconjunctivitis sicca) is multifactorial disease of the tears, lids, and ocular surface which can result in symptoms of discomfort and/or visual disturbance and/or tear film instability with the potential for damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eye disease is subdivided into two forms, aqueous insufficiency (tear deficiency) and hyperevaporative (increased evaporation). However, mixed forms are common. Aqueous insufficiency is divided into two main groups: Sjogren's syndrome-related dry eye and non-Sjogren's syndrome-related dry eye (which includes the use of systemic medication). Dry eye in Sjogren's syndrome (an autoimmune disease) is often severe and requires more aggressive treatment. Evapourative dry eye is most commonly a result of meibomian gland dysfunction. Tests used to diagnose dry eye disease and to assess efficacy of treatments in clinical trials include the following: measurement of tear film break-up time (the interval between the individual's last complete blink and the break up of the tear film) using fluorescein (shortened in dry eye disease), evaluation of tear quantity with Schirmer's test (using a strip of filter paper placed under the lower eyelid), assessment of corneal and conjunctival epithelium integrity using stains and dyes, and evaluation of meibomian glands. Artificial tears of various kinds are recommended if the symptoms are mild. Lid hygiene is helpful in the treatment of hyperevaporative dry eye, while collagen or silicon plugs can be used for partial occlusion of the efferent lacrimal ducts to treat severe hyposecretory dry eye. The benefit of long-term topical anti-inflammatory treatment of moderate or severe dry eye disease with corticosteroids or cyclosporine A eye drops has been documented in clinical trials on a high evidence level. Orally administered tetraycycline derivatives and omega-3 or omega-6 fatty acids are also used.
CATEGORY    Eye disease
DRUG        Cyclosporine [DR:D00184]
COMMENT     See also H01502.
DBLINKS     ICD-10: H04.1
            MeSH: D015352
REFERENCE   PMID:25686388 (description, drug)
  AUTHORS   Messmer EM
  TITLE     The pathophysiology, diagnosis, and treatment of dry eye disease.
  JOURNAL   Dtsch Arztebl Int 112:71-81; quiz 82 (2015)
REFERENCE   PMID:27146709 (description)
  TITLE     The management of dry eye.
  JOURNAL   BMJ 353:i2333 (2016)
///
ENTRY       H01642                      Disease
NAME        Renal anemia
DESCRIPTION Renal anemia is one of the most frequent complications of chronic kidney disease. Anemia leads to a decrease in oxygen delivery to vital organs, which is initially compensated for by tachycardia and cardiac hypertrophy, but eventually leads to the development of cardiovascular disease. Renal anemia is caused by the deficiency of endogenous erythropoietin (EPO) due to renal dysfunction. EPO is a glycoprotein hormone that has the role of the primary regulator of erythropoiesis. Formerly, treatment options were essentially limited to blood transfusions and androgen therapy, with its risks. However, since the late 1980s, the availability of recombinant human erythropoietin has revolutionized the management of renal anemia, and erythropoiesis-stimulating agents (ESAs) are now the mostly widely used drugs.
CATEGORY    Kidney disease
DRUG        Epoetin alfa [DR:D3231]
            Epoetin beta [DR:D3232]
            Darbepoetin alfa [DR:D03651]
            Continuous erythropoietin receptor activator [DR:D09998]
            Mepitiostane [DR:D01602]
DBLINKS     ICD-10: N19
            MeSH: D007676
REFERENCE   PMID:26381503
  AUTHORS   Mimura I, Tanaka T, Nangaku M
  TITLE     How the Target Hemoglobin of Renal Anemia Should Be.
  JOURNAL   Nephron 131:202-9 (2015)
REFERENCE   PMID:16281953
  AUTHORS   Eckardt KU, Kurtz A
  TITLE     Regulation of erythropoietin production.
  JOURNAL   Eur J Clin Invest 35 Suppl 3:13-9 (2005)
REFERENCE   PMID:26456375 (drug)
  AUTHORS   Kawahara K, Minakuchi J, Yokota N, Suekane H, Tsuchida K, Kawashima S
  TITLE     Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis  chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
  JOURNAL   Nephrology (Carlton) 20 Suppl 4:29-32 (2015)
REFERENCE   PMID:21930831 (drug)
  AUTHORS   Locatelli F, Del Vecchio L
  TITLE     Erythropoiesis-stimulating agents in renal medicine.
  JOURNAL   Oncologist 16 Suppl 3:19-24 (2011)
///
ENTRY       H01643                      Disease
NAME        Chilblains;
            Pernio
DESCRIPTION Chilblains, or pernio, is a localized inflammatory lesion of the skin resulting from an abnormal response to cold. It is characterized by persistent purple or purple-red nodules on acral skin, most commonly the feet. Chilblains occurs most commonly among young women between the ages of 15 and 30 years but may occur among older individuals or children. Treatment of chilblains is focused on keeping the affected area warm, and occasionally using vasodilator agents.
CATEGORY    Skin and connective tissue disease
DRUG        Hirudoid [DR:D04799]
            Tocopherol [DR:D01735]
            Nicomol [DR:D01291]
DBLINKS     ICD-10: T69.1
            MeSH: D002647
REFERENCE   PMID:16140694
  AUTHORS   Simon TD, Soep JB, Hollister JR
  TITLE     Pernio in pediatrics.
  JOURNAL   Pediatrics 116:e472-5 (2005)
REFERENCE   PMID:26991468
  AUTHORS   Al-Sudany NK
  TITLE     Treatment of primary perniosis with oral pentoxifylline (a double-blind placebo-controlled randomized therapeutic trial).
  JOURNAL   Dermatol Ther 29:263-8 (2016)
///
ENTRY       H01644                      Disease
NAME        Blepharitis
DESCRIPTION Blepharitis is a chronic inflammatory condition of the eyelids associated with itchiness, redness, flaking, and crusting. It is among the most common ocular conditions affecting both children and adults. The etiology is complex and not fully understood, but the general consensus is that bacteria and inflammation contribute to the pathology. Blepharitis can be classified into anterior blepharitis and posterior blepharitis. Anterior blepharitis describes inflammation of the eyelid skin and eyelash follicles and may be accompanied by squamous debris or collarettes. Anterior blepharitis has classically been associated with Staphylococcus infection and seborrheic dermatitis. Posterior blepharitis describes inflammation of the meibomian glands and their orifices and may be a result of or cause of meibomian gland dysfunction (MGD). MGD is one cause of posterior blepharitis but others include infectious or allergic conjunctivitis, and rosacea. The diagnosis of blepharitis is almost always based on the history and clinical examination. Long-term management of symptoms may include daily eyelid cleansing routines and the use of therapeutic agents that reduce infection and inflammation. Recent clinical trials have shown that antibiotics and topical corticosteroids can produce significant improvement in signs and symptoms of blepharitis.
CATEGORY    Eye disease
DRUG        Levofloxacin [DR:D00588] Besifloxacin [DR:D08872] (Fluoroqunolones)
            Azithromycin [DR:D02134 D07486 D06390]
            Tobramycin [DR:D00063 D02542]
            Dexamethasone [DR:D00292 D00975 D01510] Loteprednol [DR:D01689] (Corticosteroids)
DBLINKS     ICD-10: H01.0 H01.1
            MeSH: D001762
REFERENCE   PMID:26058027 (description)
  AUTHORS   Duncan K, Jeng BH
  TITLE     Medical management of blepharitis.
  JOURNAL   Curr Opin Ophthalmol 26:289-94 (2015)
REFERENCE   PMID:25284773 (description, drug)
  AUTHORS   Pflugfelder SC, Karpecki PM, Perez VL
  TITLE     Treatment of blepharitis: recent clinical trials.
  JOURNAL   Ocul Surf 12:273-84 (2014)
///
ENTRY       H01645                      Disease
NAME        Hyperthyroidism;
            Thyrotoxicosis
DESCRIPTION Hyperthyroidism is a pathological disorder characterised by increased thyroid hormone synthesis and secretion from the thyroid gland. The term thyrotoxicosis is not synonymous with hyperthyroidism. Thyrotoxicosis is defined as the clinical syndrome of hypermetabolism resulting from increased thyroid hormone levels, irrespective of the source. The causes of hyperthyroidism include Graves' disease, toxic multinodular goiter, and solitary toxic adenoma. Less common causes of hyperthyroidism include thyrotropin-induced thyrotoxicosis and trophoblastic tumours. The causes of thyrotoxicosis without hyperthyroidism are less common and generally transient. In patients with silent thyroiditis, post-partum thyroiditis, or subacute painful thyroiditis, the destruction of thyrocytes leads to release of preformed hormones into the circulation. Drug-induced thyrotoxicosis has the same pathogenic mechanism as thyroiditis. Exogenous thyrotoxicosis develops after ingestion of excessive amounts of thyroid hormone, and is associated with low serum thyroglobulin concentrations. Patients of hyperthyroidism/thyrotoxicosis usually have fatigue, nervousness or anxiety, weight loss, palpitations, and heat sensitivity. Clinical findings almost always include tachycardia, warm moist skin, the presence of an enlarged thyroid, and a slight tremor. The three options for treating patients with hyperthyroidism are antithyroid drugs (ATDs), radioactive iodine ablation, and surgery. All three therapeutic options would be effective in the treatment of patients with Graves' disease, whereas patients with toxic adenoma or toxic multinodular goiter should have either radioactive iodine therapy or surgery, since these patients rarely go into remission. In patients with toxic nodular goiter, ATDs are generally used to restore euthyroidism before definitive treatment with surgery or radioactive iodine, and infrequently used as long-term treatment when the other two therapies are contraindicated or the patient has a short life expectancy.
CATEGORY    Endocrine disease
ENV_FACTOR  Lithium [DR:D00801 D04750]
            Interferon alfa [DR:D02745 D03305]
            Amiodarone [DR:D00636]
DRUG        Methimazole [DR:D00401]
            Sodium iodide [DR:D05328 D02259]
COMMENT     See also H00082 and H01269.
DBLINKS     ICD-10: E05
            MeSH: D006980 D013971
REFERENCE   PMID:27038492 (description, env_factor, drug)
  AUTHORS   De Leo S, Lee SY, Braverman LE
  TITLE     Hyperthyroidism.
  JOURNAL   Lancet (2016)
REFERENCE   PMID:12927435 (description)
  AUTHORS   Cooper DS
  TITLE     Hyperthyroidism.
  JOURNAL   Lancet 362:459-68 (2003)
///
ENTRY       H01646                      Disease
NAME        Major depressive disorder
DESCRIPTION Major depressive disorder (MDD) is the most common psychiatric disorder mainly characterized by depressed mood, loss of interest, feelings of worthlessness, and a high risk of suicide. Accumulated evidence suggests that both environmental and genetic factors are involved in the etiology of MDD although the pathogenesis of MDD remains unknown. Mutations in genes involved in brain serotonin synthesis, have been identified in patients. Brain serotonin deficiency has been hypothesized to play a role in a wide range of psychiatric diseases, including MDD. Several efficacious treatments for MDD are available, including different forms of psychotherapy and antidepressant medication. Recently, selective reuptake inhibitors (SSRIs, SNRIs,) have become the first-line antidepressant drug treatment of depression and replaced tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) due to fewer side-effects and ease of use.
CATEGORY    Mental disorders
GENE        TPH2 [HSA:121278] [KO:K00502]
            HTR2A [HSA:3356] [KO:K04157]
            FKBP5 [HSA:2289] [KO:K09571]
DRUG        Fluoxetine [DR:D00823]
            Paroxetine [DR:D02260 D05374]
            Sertraline [DR:D00825]
            Duloxetine [DR:D01179]
            Levomilnacipran [DR:D10133]
DBLINKS     ICD-10: F32 F33
            MeSH: D003863
            OMIM: 608516
REFERENCE   PMID:27497214
  AUTHORS   Hou Z, Song X, Jiang W, Yue Y, Yin Y, Zhang Y, Liu Y, Yuan Y
  TITLE     Prognostic value of imbalanced interhemispheric functional coordination in early  therapeutic efficacy in major depressive disorder.
  JOURNAL   Psychiatry Res 255:1-8 (2016)
REFERENCE   PMID:25602134 (gene)
  AUTHORS   Sachs BD, Rodriguiz RM, Tran HL, Iyer A, Wetsel WC, Caron MG
  TITLE     Serotonin deficiency alters susceptibility to the long-term consequences of adverse early life experience.
  JOURNAL   Psychoneuroendocrinology 53:69-81 (2015)
REFERENCE   PMID:26885016 (gene)
  AUTHORS   Lin CX, Hu Z, Yan ZM, Li W, Chen YS, Zhao JH, Zhang LQ, Zhao B, Zhong WT, Feng D
  TITLE     Association between HTR2A T102C polymorphism and major depressive disorder: a meta-analysis in the Chinese population.
  JOURNAL   Int J Clin Exp Med 8:20897-903 (2015)
REFERENCE   PMID:24856550 (gene)
  AUTHORS   Szczepankiewicz A, Leszczynska-Rodziewicz A, Pawlak J, Narozna B, Rajewska-Rager A, Wilkosc M, Zaremba D, Maciukiewicz M, Twarowska-Hauser J
  TITLE     FKBP5 polymorphism is associated with major depression but not with bipolar disorder.
  JOURNAL   J Affect Disord 164:33-7 (2014)
REFERENCE   PMID:25159460 (drug)
  AUTHORS   Zhang Y, Becker T, Ma Y, Koesters M
  TITLE     A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
  JOURNAL   BMC Psychiatry 14:245 (2014)
REFERENCE   PMID:23737423 (drug)
  AUTHORS   Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd
  TITLE     The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons.
  JOURNAL   World Psychiatry 12:137-48 (2013)
REFERENCE   PMID:26572745 (drug)
  AUTHORS   Bruno A, Morabito P, Spina E, Muscatello MR
  TITLE     The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
  JOURNAL   Curr Neuropharmacol 14:191-9 (2016)
///
ENTRY       H01647                      Disease
NAME        Subacute thyroiditis;
            Subacute granulomatous thyroiditis;
            De Quervain thyroiditis
DESCRIPTION Subacute thyroiditis (SAT), also called subacute granulomatous or de Quervain thyroiditis, is a spontaneously remitting, painful, inflammatory disease of the thyroid gland, which is considered the most common cause of painful thyroiditis. It is an uncommon but important cause of fever of unknown origin (FUO). SAT is often preceded by an upper respiratory tract infection and occurs concurrently with outbreaks of viral diseases (mumps, measles, influenza). However, the exact etiology is unknown. Clinically, it presents with acute onset of pain in the thyroid region. The pain may be exacerbated by turning the head or swallowing, and may radiate to the jaw, ear or chest. Common initial clinical features include low-grade fever, fatigue, and mild thyrotoxic manifestations. The physical examination, an elevated erythrocyte sedimentation rate, an elevated thyroglobulin level, and a depressed radioactive iodine uptake confirm the diagnosis. Therapy with antithyroid drugs is not indicated in patients with SAT because this disorder is caused by the release of preformed thyroid hormone rather than synthesis of new T3 and T4. Therapy with beta blockers may be indicated for the symptomatic treatment of thyrotoxicosis. Nonsteroidal anti-inflammatory drugs are generally effective in reducing thyroid pain in patients with mild cases. Patients with more severe disease require a tapering dosage of prednisone given over two to four weeks.
CATEGORY    Endocrine disease
ENV_FACTOR  Viral infection (mumps virus, hepatitis B and C viruses, cytomegalovirus, enterovirus, and coxsackieviruses A and B)
DRUG        Prednisone [DR:D00473]
COMMENT     See also H01645.
DBLINKS     ICD-10: E06.1
            MeSH: D013968
REFERENCE   PMID:10706157 (description, drug)
  AUTHORS   Slatosky J, Shipton B, Wahba H
  TITLE     Thyroiditis: differential diagnosis and management.
  JOURNAL   Am Fam Physician 61:1047-52, 1054 (2000)
REFERENCE   PMID:24803929 (description, env_factor)
  AUTHORS   Alfadda AA, Sallam RM, Elawad GE, Aldhukair H, Alyahya MM
  TITLE     Subacute thyroiditis: clinical presentation and long term outcome.
  JOURNAL   Int J Endocrinol 2014:794943 (2014)
REFERENCE   PMID:17956558 (description)
  AUTHORS   Karachalios GN, Amantos K, Kanakis KV, Deliousis A, Karachaliou IG, Zacharof AK
  TITLE     Subacute thyroiditis presenting as fever of unknown origin.
  JOURNAL   Int J Clin Pract 64:97-8 (2010)
///
ENTRY       H01648                      Disease
NAME        Pemphigus
DESCRIPTION Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by circulating autoantibodies that target desmosomal components as well as other epithelial antigens and impair keratinocytes adhesion with subsequent acantholysis. Although the precise pathomechanisms of pemphigus have not yet been fully elucidated, recent studies have shown that desmosome disassembling involves not only the direct inhibition of desmosome formation caused by IgGs, but also desmosome remodeling. Pemphigus can be divided into non-inflammatory types, which are the major and common types, and inflammatory types, which are much less common and include necrolytic (apoptotic) type. Non-inflammatory pemphigus includes two types: pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The former is caused by autoantibodies to desmoglein (Dsg) 3 only or to both Dsg1 and Dsg3 and generates clinically multiple flaccid blisters and erosions due to acantholysis at the lower, typically along the suprabasal, layers in the epidermis and mucous membranes. The latter is caused by autoantibodies to Dsg1 and clinically characterized by very fragile superficial blisters and large leafy scales due to acantholysis at the granular cell layer in the epidermis, but not observed in the mucous membranes. Inflammatory types of pemphigus include pemphigus herpetiformis (PH), pemphigus vegetans (PVeg) and the so-called paraneoplastic pemphigus (PP). Because pemphigus is an autoimmune disease, the most common treatment is the administration of oral steroids to inhibit antibody production, combined with the use of topical agents to prevent infection, protect the eroded areas and promote epithelialization. Other concomitant therapy can include the use of immunosuppressants, plasma exchange, and the administration of high-dose intravenous immunoglobulin (IVIG).
CATEGORY    Skin and connective tissue disease; Immune system disease
DRUG        Clobetasol [DR:D01272]
COMMENT     Autoantigen:
            DSG1 [HSA:1828] [KO:K07596]
            DSG3 [HSA:1830] [KO:K07598]
DBLINKS     ICD-10: L10
            MeSH: D010392
REFERENCE   PMID:25078507 (description)
  AUTHORS   Kitajima Y
  TITLE     150(th) anniversary series: Desmosomes and autoimmune disease, perspective of dynamic desmosome remodeling and its impairments in pemphigus.
  JOURNAL   Cell Commun Adhes 21:269-80 (2014)
REFERENCE   PMID:24909210 (description)
  AUTHORS   Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, Kurosawa M, Niizeki H, Aoyama Y, Iwatsuki K, Kitajima Y
  TITLE     Japanese guidelines for the management of pemphigus.
  JOURNAL   J Dermatol 41:471-86 (2014)
REFERENCE   PMID:27329525 (description)
  AUTHORS   Celentano A, Cirillo N
  TITLE     Desmosomes in disease: a guide for clinicians.
  JOURNAL   Oral Dis (2016)
REFERENCE   PMID:25405675 (drug)
  AUTHORS   Hooten J, Hall R 3rd, Cardones A
  TITLE     Updates on the management of autoimmune blistering diseases.
  JOURNAL   Skin Therapy Lett 19:1-6 (2014)
///
ENTRY       H01649                      Disease
NAME        Schizophrenia
DESCRIPTION Schizophrenia is a common serious psychotic illness that typically emerges in late adolescence and early adulthood. It is characterized by hallucinations and delusions (commonly known as positive symptoms), social withdrawal, alogia, and flat affect (negative symptoms), and cognitive disabilities. While treatments exist for the psychotic symptoms of schizophrenia, there is no effective therapy to prevent the cognitive impairments. The disorder is substantially heritable, but expression of the clinical phenotype is likely to involve the interplay of multiple susceptibility variants, epigenetic factors, and environmental influences. Although it has been suggested that many of the promising candidate genes are involved in the development and maintenance of synaptic function, the most of them remains to be identified. The pathogenic mechanisms underlying schizophrenia are unknown, but observers have repeatedly noted pathological features involving excessive loss of gray matter and reduced numbers of synaptic structures on neurons. Recently, it has been found that alleles of the C4 genes are associated with schizophrenia in proportion to their tendency to promote greater expression of C4A in the brain.
CATEGORY    Mental disorder
GENE        MTHFR [HSA:4524] [KO:K00297]
            CHI3L1 [HSA:1116] [KO:K17523]
            DISC1 [HSA:27185] [KO:K16534]
            SYN2 [HSA:6854] [KO:K19941]
            DRD3 [HSA:1814] [KO:K04146]
            DAOA [HSA:267012]
            HTR2A [HSA:3356] [KO:K04157]
            AKT1 [HSA:207] [KO:K04456]
            C4A [HSA:720] [KO:K03989]
DRUG        Prochlorperazine [DR:D00479]
            Perphenazine [DR:D00503 D02037 D04038 D04965]
            Chlorpromazine [DR:D00789 D04034]
            Fluphenazine [DR:D00793 D02163]
            Propericiazine [DR:D01485]
DBLINKS     ICD-10: F20
            MeSH: D012559
            OMIM: 181500
REFERENCE   PMID:16195940
  AUTHORS   Austin J
  TITLE     Schizophrenia: an update and review.
  JOURNAL   J Genet Couns 14:329-40 (2005)
REFERENCE   PMID:20718829 (gene, drug)
  AUTHORS   Cacabelos R, Martinez-Bouza R
  TITLE     Genomics and pharmacogenomics of schizophrenia.
  JOURNAL   CNS Neurosci Ther 17:541-65 (2011)
REFERENCE   PMID:26814963 (gene)
  AUTHORS   Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE, Daly MJ, Carroll MC, Stevens B, McCarroll SA
  TITLE     Schizophrenia risk from complex variation of complement component 4.
  JOURNAL   Nature 530:177-83 (2016)
///
ENTRY       H01650                      Disease
NAME        Pemphigoid
DESCRIPTION Pemphigoid diseases are group of autoimmune blistering disorders of the skin and mucous membranes characterized by autoantibodies directed against structural proteins of the dermal-epidermal junction that clinically can manifest with urticarial lesions, tense blisters, and erosions which may involve the mucous membranes. Diseases in this group include bullous pemphigoid (BP), dermatitis herpetiformis, mucous membrane pemphigois, linear IgA bullous dermatosis, herpes gestationis, and epidermolysis bullosa acquisita. BP is the most common acquired bullous autoimmune dermatosis disease. It is primarily a disease of the elderly with an equal incidence in men and women. The clinical characteristics are the formation of tense blisters and pruritic urticarial erythema. Histopathologically, subepidermal blister formation associated with eosinophil infiltration is commonly observed in BP. The main autoantigens targeted by BP autoantibodies are hemidesmosomal transmembrane collagen XVII (COL17, also known as BP180/BPAG2) and the intracytoplasmic plakin family protein BP230. Most of these antibodies belong to the immunoglobulin G class. Diagnosis of BP relies on the clinical and histological aspects, but the most reliable clues are given by direct and indirect immunofluorescence. Three types of drugs, with distinct mechanisms of action, are used to treat BP: anti-inflammatory drugs, drugs designed to reduce the production of pathogenic antibodies, and treatments that increase the elimination of pathogenic antibodies from the serum of patients, such as high-dose intravenous immunoglobulin (IVIG) therapy and therapeutic plasma exchange.
CATEGORY    Skin and connective tissue disease; Immune system disease
COMMENT     Autoantigen:
            BP180 [HSA:1308] [KO:K07603]
            BP230 [HSA:667] [KO:K10382]
            LAMA3 [HSA:3909] [KO:K06240]
            LAMB3 [HSA:3914] [KO:K06244]
            ITGA6 [HSA:3655] [KO:K06485]
            ITGB4 [HSA:3691] [KO:K06525]
            COL7A1 [HSA:1294] [KO:K16628]
            TGM3 [HSA:7053] [KO:K05620]
DBLINKS     ICD-10: L12
            MeSH: D010391
REFERENCE   PMID:25797172 (description)
  AUTHORS   Ujiie H
  TITLE     IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
  JOURNAL   J Dermatol Sci 78:5-10 (2015)
REFERENCE   PMID:23540594 (description)
  AUTHORS   Fuertes de Vega I, Iranzo-Fernandez P, Mascaro-Galy JM
  TITLE     Bullous pemphigoid: clinical practice guidelines.
  JOURNAL   Actas Dermosifiliogr 105:328-46 (2014)
REFERENCE   PMID:26173987 (description)
  AUTHORS   Danescu S, Chiorean R, Macovei V, Sitaru C, Baican A
  TITLE     Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work.
  JOURNAL   J Dermatol 43:134-40 (2016)
REFERENCE   PMID:24434358 (description, autoantigen)
  AUTHORS   Baum S, Sakka N, Artsi O, Trau H, Barzilai A
  TITLE     Diagnosis and classification of autoimmune blistering diseases.
  JOURNAL   Autoimmun Rev 13:482-9 (2014)
///
ENTRY       H01651                      Disease
NAME        Macular edema
DESCRIPTION Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents.
CATEGORY    Nervous system disease; Eye disease
DRUG        Ranibizumab [DR:D05697]
            Bevacizumab [DR:D06409]
            Pegaptanib [DR:D05386]
DBLINKS     ICD-10: H35.8
            MeSH: D008269
            OMIM: 153880
REFERENCE   PMID:19668445
  AUTHORS   Rotsos TG, Moschos MM
  TITLE     Cystoid macular edema.
  JOURNAL   Clin Ophthalmol 2:919-30 (2008)
REFERENCE   PMID:21860693
  AUTHORS   Romero-Aroca P
  TITLE     Managing diabetic macular edema: The leading cause of diabetes blindness.
  JOURNAL   World J Diabetes 2:98-104 (2011)
REFERENCE   PMID:27256304
  AUTHORS   Fardeau C, Champion E, Massamba N, LeHoang P
  TITLE     Uveitic macular edema.
  JOURNAL   Eye (Lond) (2016)
REFERENCE   PMID:27330464 (drug)
  AUTHORS   Andreoli MT, Pinnolis M, Kieser T, Sun J, Andreoli CM
  TITLE     Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration.
  JOURNAL   Digit J Ophthalmol 21:1-17 (2015)
///
ENTRY       H01652                      Disease
NAME        Seborrheic dermatitis
DESCRIPTION Seborrheic Dermatitis (SD) is a common inflammatory dermatological disorder. The characteristic symptoms include scaling, erythema, and itching, which occur most often on the scalp, face, chest, back, axilla, and groin. Its incidence peaks during three age periods: in the first three months of life, during puberty, and in adulthood with an apex at 40 to 60 years of age. The cause of SD is unknown and the disease seems to be multifactorial. Malassezia yeasts are considered to play an important role. They cause an inflammatory reaction that seems to be mediated by free fatty acids, released from sebaceous triglycerides by fungal enzymes such as lipases. The lipid layer of Malassezia can also modulate pro-inflammatory cytokine production by keratinocytes. Although it can be associated with human immunodeficiency virus infection and neurologic disease (e.g., cerebrovascular event, Parkinson disease), SD typically occurs in healthy persons. Its prevalence is 1% to 3% in the general population and 34% to 83% in immunocompromised persons. Topical antifungal agents are the first-line therapy for acute and long-term treatment of SD of the face and body. Treatment includes over-the-counter shampoos and topical antifungals, calcineurin inhibitors, and corticosteroids.
CATEGORY    Skin and connective tissue disease
PATHOGEN    Malassezia globosa [GN:mgl]
            Malassezia restricta
DRUG        Ciclopirox [DR:D03488 D01364]
            Ketoconazole [DR:D00351]
            Betamethasone valerate [DR:D01357]
            Clobetasol propionate [DR:D01272]
            Fluocinolone [DR:D01825]
DBLINKS     ICD-10: L21
            MeSH: D012628
REFERENCE   PMID:27148560 (description, pathogen)
  AUTHORS   Borda LJ, Wikramanayake TC
  TITLE     Seborrheic Dermatitis and Dandruff: A Comprehensive Review.
  JOURNAL   J Clin Investig Dermatol 3 (2015)
REFERENCE   PMID:26016669 (description)
  AUTHORS   Naldi L, Diphoorn J
  TITLE     Seborrhoeic dermatitis of the scalp.
  JOURNAL   BMJ Clin Evid 2015 (2015)
REFERENCE   PMID:25822272 (description, drug)
  AUTHORS   Clark GW, Pope SM, Jaboori KA
  TITLE     Diagnosis and treatment of seborrheic dermatitis.
  JOURNAL   Am Fam Physician 91:185-90 (2015)
///
ENTRY       H01653                      Disease
NAME        Bipolar disorder;
            Manic depressive illness
DESCRIPTION Bipolar disorder, previously known as manic depressive illness, is a severe chronic mood disorder, characterized by the recurrence of mania (hypomania), depression, or mixed episodes. It is one of the main causes of disability among young people, leading to cognitive and functional impairment and raised mortality, particularly death by suicide. Mania is the most characteristic phase of bipolar disorder. While mood elevation and euphoria are commonly described phenotypic descriptors of mania, irritability and anger may dominate. At the present time, there is solid evidence supporting the use of lithium, the anticonvulsants valproate and carbamazepine, and some antipsychotics in mania. Manic or hypomanic episodes differ in severity and length. In a hypomanic episode, a disturbance in functioning can be seen by others but does not typically cause severe impairment or require admission to hospital. At onset, most patients with bipolar disorder present with a depressive episode that differs subtly from unipolar depression. The first step in the management of bipolar disorder is to confirm the diagnosis of mania or hypomania and define the patient's mood state, because the therapeutic approach differs considerably for hypomania, mania, depression, and euthymia. While effective pharmacological treatments exist for bipolar disorder, the pathophysiology of the condition essentially remains unknown. Although bipolar disorder is one of the most heritable psychiatric disorders, a multifactorial model in which gene and environment interact is currently thought to best fit this disorder. Many risk alleles of small effect which are described in genome-wide association studies, contribute to the polygenic risk of bipolar disorder. It is suggested that the dopaminergic system may play a central role in bipolar disorder, although no singular dysfunction of neurotransmitter systems has been identified.
CATEGORY    Mental disorder
DRUG        Lithium [DR:D00801 D04750]
            Valproate [DR:D00304 D00710]
            Carbamazepine [DR:D00252]
            Olanzapine [DR:D00454]
            Chlorpromazine [DR:D00789 D04034]
            Levomepromazine [DR:D01520 D02248]
            Haloperidol [DR:D00136]
COMMENT     Bipolar I disorder: At least one manic episode must be presented, although major depressive episodes are typical but not needed for diagnosis.
            Bipolar II disorder: At least one hypomanic episode and one major depressive episode are needed for diagnosis.
            See also H01646 Major depressive disorder.
DBLINKS     ICD-10: F31
            MeSH: D001714
            OMIM: 125480 309200
REFERENCE   PMID:26388529
  AUTHORS   Grande I, Berk M, Birmaher B, Vieta E
  TITLE     Bipolar disorder.
  JOURNAL   Lancet 387:1561-72 (2016)
REFERENCE   PMID:25497471
  AUTHORS   Graham RK, Parker GB, Breakspear M, Mitchell PB
  TITLE     Clinical characteristics and temperament influences on 'happy' euphoric and 'snappy' irritable bipolar hypo/manic mood states.
  JOURNAL   J Affect Disord 174:144-9 (2015)
REFERENCE   PMID:19922550
  AUTHORS   Cousins DA, Butts K, Young AH
  TITLE     The role of dopamine in bipolar disorder.
  JOURNAL   Bipolar Disord 11:787-806 (2009)
REFERENCE   PMID:23361832 (drug)
  AUTHORS   Citrome L
  TITLE     Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
  JOURNAL   Adv Ther 30:102-13 (2013)
REFERENCE   PMID:18689287 (drug)
  AUTHORS   Vieta E, Sanchez-Moreno J
  TITLE     Acute and long-term treatment of mania.
  JOURNAL   Dialogues Clin Neurosci 10:165-79 (2008)
///
ENTRY       H01654                      Disease
NAME        Lichen planus
DESCRIPTION Lichen planus (LP) is a chronic inflammatory and immune mediated skin disease with characteristic clinical and histopathologic features. The skin and oral mucosa are the most frequently involved areas. Other mucous membranes (including the genitalia, esophagus, and conjunctiva) and skin appendages (e.g., scalp hair and nails) can also be affected. The etiology and pathogenesis of LP remain unclear. An autoimmune reaction in which CD8+-T lymphocytes attack basal keratinocytes leading to apoptosis of the cells has been favored. Various potential triggers, e.g. viral or bacterial antigens, metal ions, drugs or physical factors, could initiate the autoimmune process. Nonetheless, the role of the individual trigger factors is controversial. There is a significant association between lichen planus and infection with hepatitis C virus (HCV). The diagnosis of LP is based on the clinical presentation and should be confirmed by biopsy, if suspected. Histopathology is often conclusive, but in vesiculobullous cutaneous LP or erosive oral LP, direct immunofluorescence (DIF) studies can be an integral step in differentiating between LP and other diseases. With few exceptions, all forms of LP are treated with the same measures. Depending on the severity of the findings, topical and systemic treatment options are available.
CATEGORY    Skin and connective tissue disease; Immune system disease
PATHOGEN    Hepatitis C virus (HCV) [GN:T40066]
DRUG        Clobetasol [DR:D01272]
            Prednisolone [DR:D00472]
            Tacrolimus [DR:D00107]
            Pimecrolimus [DR:D05480]
            Cyclosporine [DR:D00184]
            Isotretinoin [DR:D00348]
            Acitretin [DR:D02754]
DBLINKS     ICD-10: L43
            MeSH: D008010
REFERENCE   PMID:22356325 (description, drug)
  AUTHORS   Le Cleach L, Chosidow O
  TITLE     Clinical practice. Lichen planus.
  JOURNAL   N Engl J Med 366:723-32 (2012)
REFERENCE   PMID:24672362 (description)
  AUTHORS   Gorouhi F, Davari P, Fazel N
  TITLE     Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis.
  JOURNAL   ScientificWorldJournal 2014:742826 (2014)
REFERENCE   PMID:23320493 (description, drug)
  AUTHORS   Wagner G, Rose C, Sachse MM
  TITLE     Clinical variants of lichen planus.
  JOURNAL   J Dtsch Dermatol Ges 11:309-19 (2013)
REFERENCE   PMID:20412447 (pathogen)
  AUTHORS   Lodi G, Pellicano R, Carrozzo M
  TITLE     Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis.
  JOURNAL   Oral Dis 16:601-12 (2010)
///
ENTRY       H01655                      Disease
NAME        Granulomatosis with polyangiitis (GPA);
            Wegener's granulomatosis
DESCRIPTION Granulomatosis with polyangitis (GPA) is an idiopathic, systemic inflammatory disease characterized by necrotizing granulomatous inflammation and pauci-immune small- vessel vasculitis of upper and lower respiratory tract and kidneys. The discovery of anti-neutrophil cytoplasmic antibodies (ANCAs) as a marker associated with GPA focused attention on the potential pathogenic role of these antibodies. Although ANCAs have been described that recognise a variety of myeloid antigens, only antibodies that react with proteinase 3 (Pr3) and myeloperoxidase (MPO) have consistently been linked to vasculitis syndromes. Pr3-ANCA is the predominant autoantibody found in patients with GPA. The discovery of ANCA has made the diagnosis of this disease even more possible but there is almost always a need to confirm the diagnosis via histological examination of the lesional tissue.
CATEGORY    Skin and connective tissue disease
MARKER      Anti- neutrophil cytoplasmic antibodies (ANCAs)
DRUG        Rituximab [DR:D02994]
            Cyclophosphamide [DR:D00287]
            Prednisone [DR:D00473]
            Azathioprine [DR:D00238]
DBLINKS     ICD-10: M31.3
            MeSH: D014890
REFERENCE   PMID:25149391 (drug)
  AUTHORS   Comarmond C, Cacoub P
  TITLE     Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment.
  JOURNAL   Autoimmun Rev 13:1121-5 (2014)
REFERENCE   (drug)
  AUTHORS   Papadakis MA and McPhee SJ |(ed)
  TITLE     Current Medical Diagnosis & Treatment 2015, Fifty-Fourth Edition
  JOURNAL   McGraw Hill Education
REFERENCE   PMID:23301777 (marker, drug)
  AUTHORS   Almouhawis HA, Leao JC, Fedele S, Porter SR
  TITLE     Wegener's granulomatosis: a review of clinical features and an update in diagnosis and treatment.
  JOURNAL   J Oral Pathol Med 42:507-16 (2013)
REFERENCE   PMID:15890083 (marker)
  AUTHORS   Sarraf P, Sneller MC
  TITLE     Pathogenesis of Wegener's granulomatosis: current concepts.
  JOURNAL   Expert Rev Mol Med 7:1-19 (2005)
///
ENTRY       H01656                      Disease
NAME        Psoriasis
DESCRIPTION Psoriasis is a chronic, immune-mediated inflammatory skin disease, characterized by increased propagation of the epidermis with dilation of dermal capillaries. The major symptoms of psoriasis are itchy, scaly, and flaky skin, swelling, pain, and disfiguring skin lesions. Plaque psoriasis is the most common form. Other forms include flexural, guttate, nail, inverse psoriasis, erythroderma, and psoriatic arthritis. It can occur in any age group, but psoriatic arthritis usually develops between the ages of 30-50 years. Various factors such as bacterial infection, genetic and environmental factors, and immune disorders play an important role in causing psoriasis. Psoriasis is associated with several comorbidities, including cardiovascular disease, lymphoma, and depression. Psoriasis is an immune-mediated disease with genetic predisposition, but no distinct immunogen has been identified. The presence of cytokines, dendritic cells, and T lymphocytes in psoriatic lesions has prompted the development of biologic therapies. The diagnosis is usually clinical, based on the presence of typical erythematous scaly patches, papules, and plaques that are often pruritic and sometimes painful. Biopsy is rarely needed to confirm the diagnosis. First-line therapies for most patients are topical treatments such as topical corticosteroids and vitamin D analogues. For those with more severe or treatment-resistant disease, second- or third-line therapies include phototherapy, systemic therapies such as methotrexate, and more recently biologic therapies such as tumour necrosis factor (TNF) inhibitors.
CATEGORY    Skin and connective tissue disease; Immune system disease
DRUG        Clobetasol [DR:D01272]
            Betamethasone [DR:D01637]
            Halobetasol [DR:D04409]
            Diflorasone [DR:D01327]
            Calcipotriol [DR:D01125]
            Salicylic acid [DR:D00097]
            Dithranol [DR:D00233]
            Coal tar [DR:D03573]
            Tazarotene [DR:D01132]
            Tacrolimus [DR:D00107 D08556]
DBLINKS     ICD-10: L40
            MeSH: D011565
REFERENCE   PMID:25919064 (description)
  AUTHORS   Garg T, Rath G, Goyal AK
  TITLE     Nanotechnological approaches for the effective management of psoriasis.
  JOURNAL   Artif Cells Nanomed Biotechnol 44:1374-82 (2016)
REFERENCE   PMID:23668525 (description)
  AUTHORS   Weigle N, McBane S
  TITLE     Psoriasis.
  JOURNAL   Am Fam Physician 87:626-33 (2013)
REFERENCE   PMID:24350319 (description, drug)
  AUTHORS   Burfield L, Burden AD
  TITLE     Psoriasis.
  JOURNAL   J R Coll Physicians Edinb 43:334-8; quiz 339 (2013)
REFERENCE   PMID:15708945 (drug)
  AUTHORS   Lebwohl M, Ting PT, Koo JY
  TITLE     Psoriasis treatment: traditional therapy.
  JOURNAL   Ann Rheum Dis 64 Suppl 2:ii83-6 (2005)
///
ENTRY       H01657                      Disease
NAME        Nephrotic syndrome
DESCRIPTION Nephrotic syndrome is a heterogeneous group of disorders characterized by heavy proteinuria (more than 3.5 grams per day), hypoalbuminemia, hyperlipidemia, and edema. Congenital nephrotic syndrome is most frequently related to mutations in genes specific for structural integrity of the glomerular basement membrane and associated filtration structures within the kidney, resulting in massive leakage of plasma proteins into the urine. First line treatment is with oral corticosteroids, but some patients do not respond to this treatment. Steroid-resistant nephrotic syndrome (SRNS) typically manifests histologically as focal segmental glomerulosclerosis. Calcineurin inhibitors with/without intravenous methylprednisolone pulse therapy (MPT) constitute the standard treatment for SRNS. It has been reported that additional rituximab treatment combined with conventional MPT and immunosuppressive agents is a promising option.
CATEGORY    Kidney disease
GENE        NPHS1 [HSA:4868]
            PDCN [HSA:7827] [KO:K18268]
            WT1 [HSA:7490] [KO:K09234]
            PLCE1 [HSA:51196] [KO:K05860]
MARKER      Proteinuria (more than 3.5 g per day)
            Serum albumin (less than 2.5 g/dL)
DRUG        Prednisolone [DR:D00472] Methylprednisolone [DR:D00407] Cortisone [DR:D00973] Hydrocortisone [DR:D00088] (Corticosteroid)
            Ciclosporin [DR:D00184] (Calcineurin inhibitor)
            Cyclophosphamide [DR:D00287]
            Mizoribine [DR:D01392]
            Rituximab [DR:D02994]
COMMENT     See also H00626 Focal segmental glomerulosclerosis.
            Congenital nephrotic syndrome and focal segmental glomerulosclerosis form a spectrum of podocyte diseases.
DBLINKS     ICD-10: N04
            MeSH: D009404
            OMIM: 256300 600995 610725 256370
REFERENCE   PMID:21691316 (gene, description)
  AUTHORS   Gubler MC
  TITLE     Nephrotic syndrome: Genetic testing in steroid-resistant nephrotic syndrome.
  JOURNAL   Nat Rev Nephrol 7:430-1 (2011)
REFERENCE   PMID:20969579 (gene)
  AUTHORS   Benoit G, Machuca E, Heidet L, Antignac C
  TITLE     Hereditary kidney diseases: highlighting the importance of classical Mendelian phenotypes.
  JOURNAL   Ann N Y Acad Sci 1214:83-98 (2010)
REFERENCE   PMID:17537341 (drug)
  AUTHORS   Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS
  TITLE     The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review.
  JOURNAL   Health Technol Assess 11:iii-iv, ix-xi, 1-93 (2007)
REFERENCE   PMID:24500706 (drug)
  AUTHORS   Kamei K, Okada M, Sato M, Fujimaru T, Ogura M, Nakayama M, Kaito H, Iijima K, Ito S
  TITLE     Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome.
  JOURNAL   Pediatr Nephrol 29:1181-7 (2014)
///
ENTRY       H01658                      Disease
NAME        Microscopic polyangiitis
DESCRIPTION Microscopic polyangiitis (MPA) is an idiopathic autoimmune disease characterized by systemic vasculitis. MPA predominantly affects small-calibre blood vessels and is associated with the presence of antineutrophil cytoplasmic autoantibodies (ANCA). The association with ANCAs originally defined the group of ANCA-associated vasculitides, comprising granulomatosis with polyangitis (GPA, formerly known as Wegener granulomatosis) [DS:H01655], microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome) [DS:H01468], which have different frequencies of ANCA-positivity. ANCA in MPA are predominantly directed against myeloperoxidase (MPO-ANCA) but may, in a minority of patients, be directed against proteinase 3 (PR3-ANCA). Not all patients, however, have ANCA. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and the lungs but other organs may be involved as well. Renal involvement, which can be the only manifestation, is clinically apparent as rapidly progressive glomerulonephritis and histopathologically as pauci-immune necrotizing and crescentic glomerulonephritis. Diagnosis is mainly established by clinical manifestations, computed tomography (TC), ANCA antibody detection, and renal and pulmonary biopsy. The introduction of aggressive immunosuppressive treatment has substantially improved the prognosis. The standardized therapeutic regimen is based on cyclophosphamide and corticosteroids. Using this regimen, remission can be achieved in most of the patients. Rituximab may represent an important alternative to cyclophosphamide for patients who may not respond adequately to antimetabolite therapies.
CATEGORY    Nervous system disease; Cardiovascular disease; Immune system disease
MARKER      Anti-neutrophil cytoplasmic antibodies (ANCAs)
DRUG        Methotrexate [DR:D00142]
            Cyclophosphamide [DR:D00287]
            Rituximab [DR:D02994]
            Mycophenolate mofetil [DR:D00752]
            Azathioprine [DR:D01327]
            Leflunomide [DR:D00749]
            Prednisone [DR:D00473]
DBLINKS     ICD-10: M31.7
            MeSH: D055953
REFERENCE   PMID:25992801 (description, drug)
  AUTHORS   Greco A, De Virgilio A, Rizzo MI, Gallo A, Magliulo G, Fusconi M, Ruoppolo G, Tombolini M, Turchetta R, de Vincentiis M
  TITLE     Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches.
  JOURNAL   Autoimmun Rev 14:837-44 (2015)
REFERENCE   PMID:24461388 (description)
  AUTHORS   Kallenberg CG
  TITLE     The diagnosis and classification of microscopic polyangiitis.
  JOURNAL   J Autoimmun 48-49:90-3 (2014)
///
ENTRY       H01659                      Disease
NAME        Pityriasis rubra pilaris
DESCRIPTION Pityriasis rubra pilaris (PRP) is a spectrum of rare chronic inflammatory disorders with papulosquamous eruptions of unknown cause.  The prototypical clinical characteristics of PRP are follicular hyperkeratotic papules on an erythematous base that can eventually coalesce to large red plaques. Its classification into five subgroups is based on age at onset, clinical course, morphologic features, and prognosis. More than 50% of patients are best classified as type I with adult-onset PRP. It is comprised of widespread, follicular papules and plaques and tends to clear spontaneously in 80% of patients in one to three years. Type II, which is the atypical adult subtype, tends to be more chronic and presents with areas of alopecia, eczematous patches, and a palmoplantar keratoderma. The classic juvenile type III is observed in only 10% of patients. It is similar clinically to type I but occurs in children and tends to remit in one year. Type IV, which is the circumscribed, juvenile subtype, presents with sharply-demarcated areas of follicular hyperkeratosis and erythema of the elbows and knees. An estimated 5% of children with PRP develop an atypical form classified as juvenile type V. Most familial cases that are published belong to this group. Recently, the designation of a new category of PRP (type VI) has been proposed that is characterized by the presence of HIV infection with different clinical features and a poorer prognosis. Treatment of PRP can be difficult, and no standardized approach has been established, although systemic retinoids are considered first-line therapy. Cyclosporin, methotrexate, and azathioprine are alternatives.
CATEGORY    Skin and connective tissue disease
GENE        CARD14 [HSA:79092] [KO:K20913]
PATHOGEN    Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
            Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
DRUG        Salicylic acid [DR:D00097]
            Isotretinoin [DR:D00348]
            Acitretin [DR:D02754]
            Calcipotriene [DR:D01125]
            Methotrexate [DR:D00142]
            Cyclosporine [DR:D00184]
            Azathioprine [DR:D00238]
DBLINKS     ICD-10: L44.0
            MeSH: D010916
            OMIM: 173200
REFERENCE   PMID:23286804 (description)
  AUTHORS   Leger M, Newlove T, Robinson M, Patel R, Meehan S, Ramachandran S
  TITLE     Pityriasis rubra pilaris.
  JOURNAL   Dermatol Online J 18:14 (2012)
REFERENCE   PMID:22508269 (description)
  AUTHORS   Ivanova K, Itin P, Haeusermann P
  TITLE     Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?
  JOURNAL   Dermatology 224:120-5 (2012)
REFERENCE   PMID:20184391 (description, drug)
  AUTHORS   Klein A, Landthaler M, Karrer S
  TITLE     Pityriasis rubra pilaris: a review of diagnosis and treatment.
  JOURNAL   Am J Clin Dermatol 11:157-70 (2010)
REFERENCE   PMID:22703878 (gene)
  AUTHORS   Fuchs-Telem D, Sarig O, van Steensel MA, Isakov O, Israeli S, Nousbeck J, Richard K, Winnepenninckx V, Vernooij M, Shomron N, Uitto J, Fleckman P, Richard G, Sprecher E
  TITLE     Familial pityriasis rubra pilaris is caused by mutations in CARD14.
  JOURNAL   Am J Hum Genet 91:163-70 (2012)
REFERENCE   PMID:8547057 (pathogen)
  AUTHORS   Miralles ES, Nunez M, De Las Heras ME, Perez B, Moreno R, Ledo A
  TITLE     Pityriasis rubra pilaris and human immunodeficiency virus infection.
  JOURNAL   Br J Dermatol 133:990-3 (1995)
///
ENTRY       H01660                      Disease
NAME        Pityriasis rosea
DESCRIPTION Pityriasis rosea (PR) is an acute exanthem, which prevalently affects children and young adults. The cause of PR is uncertain but epidemiological (seasonal variation and clustering in communities) and clinical features suggest an infective agent. Light and electron microscopy findings suggest infection with human herpesviruses 6 and 7 (HHV-6/7). HHV-6 and HHV-7 may also interact with each other, explaining recurrences and atypical presentations. PR is self limiting and resolves within one to three months. It typically starts with the development of a large erythematous scaly plaque also called the herald patch or mother patch on trunk or neck, which is followed by an eruption of multiple secondary small erythematous scaly lesions located predominantly on the trunk and following the lines of cleavage on the back (Christmas tree or inverted fir tree appearance). Collarette scaling is seen typically. The eruption is usually preceded by a prodrome of sore throat, gastrointestinal disturbance, fever, and arthralgia. A case of PR is diagnosed mainly on clinical grounds. A biopsy is needed in atypical cases, and it mainly helps in excluding other differentials rather than diagnosing PR as the histopathological examination in a case of PR is relatively nonspecific and resembles a subacute or chronic dermatitis. As PR is a self-limiting disorder, most patients just need to be counseled regarding the natural course of the disease instead of putting them on an aggressive treatment protocol. Most patients would just need emollients, antihistaminics, and sometimes topical steroids to control pruritus.
CATEGORY    Skin and connective tissue disease
PATHOGEN    Human herpesvirus 6B [GN:T40075]
            Human herpesvirus 7 [GN:T40076]
DBLINKS     ICD-10: L42
            MeSH: D017515
REFERENCE   PMID:25200809 (description)
  AUTHORS   Guarneri F, Cannavo SP, Minciullo PL, Gangemi S
  TITLE     Pityriasis rosea of Gibert: immunological aspects.
  JOURNAL   J Eur Acad Dermatol Venereol 29:21-5 (2015)
REFERENCE   PMID:27512182 (description)
  AUTHORS   Mahajan K, Relhan V, Relhan AK, Garg VK
  TITLE     Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects.
  JOURNAL   Indian J Dermatol 61:375-84 (2016)
REFERENCE   PMID:26514823 (description)
  AUTHORS   Eisman S, Sinclair R
  TITLE     Pityriasis rosea.
  JOURNAL   BMJ 351:h5233 (2015)
REFERENCE   PMID:11720179 (pathogen)
  AUTHORS   Chuh AA, Chiu SS, Peiris JS
  TITLE     Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: a prospective case control study.
  JOURNAL   Acta Derm Venereol 81:289-90 (2001)
///
ENTRY       H01661                      Disease
NAME        Xanthoma;
            Xanthomatosis
DESCRIPTION Xanthomas are benign and usually yellow plaques, papules, or nodules that develop in the cutis and subcutaneous tissue. They evolve as clusters of foam cells and favor the neck, upper trunk, flexural folds and periorbital region. The foam cells are formed from macrophages as a consequence of gradual intracellular accumulation of lipids taken up by specific receptors or by the mechanism of phagocytosis. They are seen in several lipidoses and are usually indicative of a derangement in lipoprotein metabolism, in particular familial hypercholesterolemia. Prevention of xanthomas goes hand in hand with the management of the underlying disorders of lipid metabolism. Normolipemic xanthomatosis may be seen in several rare conditions.
CATEGORY    Inherited metabolic disease; Skin and connective tissue disease
DRUG        Statins
            Probucol [DR:D00476]
COMMENT     See also H00151 Cerebrotendinous xanthomatosis, and H00155 Hypercholesterolemia.
DBLINKS     ICD-10: E75.5 E78 H02.6
            MeSH: D014973
            OMIM: 602247
REFERENCE   PMID:24781043
  AUTHORS   Zak A, Zeman M, Slaby A, Vecka M
  TITLE     Xanthomas: clinical and pathophysiological relations.
  JOURNAL   Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:181-8 (2014)
REFERENCE   PMID:23112520
  AUTHORS   Babu R, Venkataram A, Santhosh S, Shivaswamy S
  TITLE     Giant Tuberous Xanthomas in a Case of Type IIA Hypercholesterolemia.
  JOURNAL   J Cutan Aesthet Surg 5:204-6 (2012)
REFERENCE   PMID:23741215 (drug)
  AUTHORS   Miyagawa F, Fukumoto T, Kobayashi N, Asada H
  TITLE     Successful treatment of diffuse normolipemic plane xanthoma with probucol.
  JOURNAL   Case Rep Dermatol 5:148-51 (2013)
REFERENCE   PMID:20043058
  AUTHORS   Pietroleonardo L, Ruzicka T
  TITLE     Skin manifestations in familial heterozygous hypercholesterolemia.
  JOURNAL   Acta Dermatovenerol Alp Pannonica Adriat 18:183-7 (2009)
///
ENTRY       H01662                      Disease
NAME        Generalized anxiety disorder;
            Anxiety neurosis
DESCRIPTION Generalized anxiety disorder is a persistent and common mental disorder. This disorder is twice as common in women than it is in men. The symptoms include generalised and persistent excessive anxiety and a combination of various psychological and somatic complaints, such as  threat, restlessness, irritability, sleep disturbance, tension, palpitations, dry mouth, and sweating. The symptoms overlap greatly with those of other mental disorders and we could regard the disorder as part of a spectrum of mood and related disorders rather than an independent disorder. Generalized anxiety disorder has a relapsing course, and intervention rarely results in complete resolution of symptoms. But in the short term and medium term, effective treatments include psychological therapies, such as cognitive behavioural therapy, and pharmacological treatments, mainly selective serotonin reuptake inhibitors (SSRIs).
CATEGORY    Mental disorder
DRUG        Paroxetine [DR:D02260]
            Escitalopram [DR:D02567]
            Diazepam [DR:D00293]
DBLINKS     ICD-10: F41.1
            MeSH: D001008
REFERENCE   PMID:17174708
  AUTHORS   Tyrer P, Baldwin D
  TITLE     Generalised anxiety disorder.
  JOURNAL   Lancet 368:2156-66 (2006)
REFERENCE   PMID:24326166 (drug)
  AUTHORS   Chollet J, Saragoussi D, Clay E, Francois C
  TITLE     A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.
  JOURNAL   Value Health 16:1133-9 (2013)
///
ENTRY       H01663                      Disease
NAME        Pustular psoriasis, including:
            Generalized pustular psoriasis;
            Acrodermatitis continua of Hallopeau;
            Pustulosis palmoplantaris
DESCRIPTION Pustular psoriasis is a form of psoriasis [DS:H01656] characterized by multiple tender sterile pustules with an underlying, blotchy, erythematous base. It has been classified into localized and generalized forms. Generalized pustular psoriasis (GPP) is the development of extensive sterile pustules with widespread erythema. The von Zumbusch type often starts abruptly and can be associated with painful skin, fever, and chills. The disease course varies from a benign, chronic process to an acute life-threatening episode, and as such optimal treatment depends on severity. Diseases considered within the spectrum of GPP include: impetigo herpetiformis and childhood GPP. Acrodermatitis continua of Hallopeau and palmoplantar pustulosis are two distinct forms of localized pustular psoriasis. Treatment should be governed by the extent of involvement and severity of disease. Acitretin, cyclosporine, methotrexate, and infliximab are considered to be first-line therapies for those with GPP. Adalimumab, etanercept, and psoralen plus ultraviolet A are second-line modalities in this setting. Pustular psoriasis in children, in pregnant women, and in localized forms alter which agents are first-line modalities as concerns such as teratogenicity need to be factored into the decisionmaking for the individual patient.
CATEGORY    Skin and connective tissue disease
DRUG        Acitretin [DR:D02754]
            Cyclosporine [DR:D00184]
            Methotrexate [DR:D00142]
            Infliximab [DR:D02598]
            Adalimumab [DR:D02597]
            Etanercept [DR:D00742]
            Psoralen [DR:D08450]
DBLINKS     ICD-10: L40.1 L40.3
            MeSH: D011565
REFERENCE   PMID:22609220 (description, drug)
  AUTHORS   Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Kalb RE
  TITLE     Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.
  JOURNAL   J Am Acad Dermatol 67:279-88 (2012)
REFERENCE   PMID:24434359 (description)
  AUTHORS   Raychaudhuri SK, Maverakis E, Raychaudhuri SP
  TITLE     Diagnosis and classification of psoriasis.
  JOURNAL   Autoimmun Rev 13:490-5 (2014)
///
ENTRY       H01664                      Disease
NAME        Panic disorder
DESCRIPTION Panic disorder (PD) is a common type of anxiety disorder, characterized by unexpected and repeated panic attacks or fear of future panic attacks. It has a rapid onset and includes symptoms such as palpitations, chest pain, sweating and shaking. Some physical illnesses (e.g. asthma) commonly occur with panic disorder, and certain lifestyle factors (e.g. smoking) increase the risk for the disorder, but causal pathways are still unclear. In recent years, an association was found between panic symptoms and increased activity in the right frontal region of the brain. Genetic susceptibility factors also exist, but their exact nature and pathophysiological mechanisms remain unknown. Cognitive behavioural therapy (CBT) and several medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and benzodiazepines are effective for PD. Among these, SSRIs and SNRIs are considered to be first-line treatment agents because of their efficacy and favorable side effect profile.
CATEGORY    Mental disorder
ENV_FACTOR  Nicotine [CPD:C00745]
            Caffeine [CPD:C07481]
DRUG        Paroxetine [DR:D02260]
            Sertraline [DR:D00825]
            Venlafaxine [DR:D00821]
            Imipramine [DR:D00815]
DBLINKS     ICD-10: F41.0
            MeSH: D016584
            OMIM: 167870
REFERENCE   PMID:16980119
  AUTHORS   Roy-Byrne PP, Craske MG, Stein MB
  TITLE     Panic disorder.
  JOURNAL   Lancet 368:1023-32 (2006)
REFERENCE   PMID:25230088
  AUTHORS   Li H, Wang J, Li C, Xiao Z
  TITLE     Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults.
  JOURNAL   Cochrane Database Syst Rev CD009083 (2014)
REFERENCE   PMID:27089322 (drug)
  AUTHORS   Giampaolo P, Alessandra A, Raffaele B, Elisa M, Giuseppina D, Paolo C, Maria N, Daniela C
  TITLE     Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines.
  JOURNAL   Int J Mol Sci 17:551 (2016)
///
ENTRY       H01665                      Disease
NAME        Primary peritoneal carcinoma
DESCRIPTION Female primary peritoneal carcinoma (PPC) has the characteristic of diffuse involvement of the peritoneum by papillary carcinoma in the absence of an obvious primary site and grossly normal ovaries, or minimal involvement. It is histologically indistinguishable from primary epithelial ovarian carcinoma (EOC) and is diagnosed in the absence of another identifiable primary. Most reported PPC cases are primary peritoneal serous papillary carcinoma (PPSPC), while peritoneal mixed epithelial carcinoma (MEC) and malignant mixed Mullerian tumor (MMMT) are rarely reported. Germline BRCA1 mutations in 26% of PPSPC patients was detected. BRCA1 mutation carriers had a higher overall incidence of p53 mutations than wildtype BRCA1 case subjects. It is suggested that p53 has a unique role in the development and progression of BRCA1-related PPSPC.
CATEGORY    Cancer
GENE        BRCA1 (mutation) [HSA:672] [KO:K10605]
DRUG        Bevacizumab [DR:D06409]
            Paclitaxel [DR:D00491]
            Carboplatin [DR:D01363]
            Cisplatin [DR:D00275]
COMMENT     ICD-O-3: 8461/3  Serous surface papillary carcinoma (C56.9)
DBLINKS     ICD-10: C48.1
            MeSH: D010534
REFERENCE   PMID:11014956
  AUTHORS   Cormio G, Di Vagno G, Di Gesu G, Mastroianni M, Melilli GA, Vimercati A, Putignano G, Loverro G, Selvaggi L
  TITLE     Primary peritoneal carcinoma: a report of twelve cases and a review of the literature.
  JOURNAL   Gynecol Obstet Invest 50:203-6 (2000)
REFERENCE   PMID:19897383 (gene)
  AUTHORS   Pentheroudakis G, Pavlidis N
  TITLE     Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review.
  JOURNAL   Crit Rev Oncol Hematol 75:27-42 (2010)
REFERENCE   PMID:10728699 (gene)
  AUTHORS   Schorge JO, Muto MG, Lee SJ, Huang LW, Welch WR, Bell DA, Keung EZ, Berkowitz RS, Mok SC
  TITLE     BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis.
  JOURNAL   Cancer Res 60:1361-4 (2000)
REFERENCE   PMID:21352070 (drug)
  AUTHORS   Slomovitz BM, Worley MJ, Markman M, Coleman RL
  TITLE     Emerging therapeutics for primary peritoneal cancer.
  JOURNAL   Expert Opin Emerg Drugs 16:71-84 (2011)
REFERENCE   PMID:18543395 (drug, ICD-O-3)
  AUTHORS   Zhang C, Li XP, Cui H, Shen DH, Wei LH
  TITLE     Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor  analyses.
  JOURNAL   J Zhejiang Univ Sci B 9:435-40 (2008)
REFERENCE   PMID:25315029 (drug)
  AUTHORS   Keating GM
  TITLE     Bevacizumab: a review of its use in advanced cancer.
  JOURNAL   Drugs 74:1891-925 (2014)
///
ENTRY       H01666                      Disease
NAME        Angiosarcoma
DESCRIPTION Angiosarcomas are rare, generally aggressive, malignant mesenchymal tumours of vascular origin and constitute less than 1% of all sarcomas. Their most frequent site of origin is the head and neck, especially the scalp, of elderly men. Angiosarcomas are likely derived from vascular endothelial cells, possibly resulting from aberrant angiogenesis. Studies have shown relatively increased expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFr1-3) in human angiosarcoma. The most common gene mutation in angiosarcomas is KRAS as well as other RAS mutations. Activation of the RAS pathway is often tumorigenic. Although immortalised murine endothelial cells form benign haemangiomas in vivo, the addition of activated HRAS produces rapidly growing, poorly differentiated angiosarcomas.
CATEGORY    Cancer
GENE        KRAS (mutation) [HSA:3845] [KO:K07827]
            HRAS (mutation) [HSA:3265] [KO:K02833]
            NRAS (mutation) [HSA:4893] [KO:K07828]
CARCINOGEN  Vinyl chloride [CPD:C06793]
            Thorium dioxide
            Arsenic [CPD:C06269]
            Anabolic steroids
MARKER      ERG [HSA:2078] [KO:K09435]
            CD34 [HSA:947] [KO:K06474]
            CD31 [HSA:5175] [KO:K06471]
DRUG        Paclitaxel [DG:DG01430]
            Doxorubicin [DG:DG00696]
            Ifosfamide [DR:D00343]
            Miltefosine [DR:D02494]
            Cediranib [DR:D08881]
            Anthracycline [DG:DG01682]
            Teceleukin [DR:D02749]
COMMENT     ICD-O-3: 9120/3 Angiosarcoma
DBLINKS     ICD-10: C44.9 C22.3
            MeSH: D006394
REFERENCE   PMID:11251578 (drug)
  AUTHORS   Tanioka M, Ikoma A, Morita K, Fujii H, Toda KI, Takahashi K, Tanaka T, Nishigori C, Jin G, Higashi S, Toyokuni S, Miyachi Y
  TITLE     Angiosarcoma of the scalp: absence of vascular endothelial cadherin in primary and metastatic lesions.
  JOURNAL   Br J Dermatol 144:380-3 (2001)
REFERENCE   PMID:24685486 (drug)
  AUTHORS   Letsa I, Benson C, Al-Muderis O, Judson I
  TITLE     Angiosarcoma of the face and scalp: effective systemic treatment in the older patient.
  JOURNAL   J Geriatr Oncol 5:276-80 (2014)
REFERENCE   PMID:25634014 (carcinogen)
  AUTHORS   Patel SH, Hayden RE, Hinni ML, Wong WW, Foote RL, Milani S, Wu Q, Ko SJ, Halyard MY
  TITLE     Angiosarcoma of the scalp and face: the Mayo Clinic experience.
  JOURNAL   JAMA Otolaryngol Head Neck Surg 141:335-40 (2015)
REFERENCE   PMID:20537949 (gene, marker, carcinogen)
  AUTHORS   Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ
  TITLE     Angiosarcoma.
  JOURNAL   Lancet Oncol 11:983-91 (2010)
REFERENCE   PMID:26031299 (gene)
  AUTHORS   Huntington JT, Jones C, Liebner DA, Chen JL, Pollock RE
  TITLE     Angiosarcoma: A rare malignancy with protean clinical presentations.
  JOURNAL   J Surg Oncol 111:941-50 (2015)
REFERENCE   PMID:24384851 (marker)
  AUTHORS   Antonescu C
  TITLE     Malignant vascular tumors--an update.
  JOURNAL   Mod Pathol 27 Suppl 1:S30-8 (2014)
REFERENCE   PMID:25352641 (marker)
  AUTHORS   Sullivan HC, Edgar MA, Cohen C, Kovach CK, HooKim K, Reid MD
  TITLE     The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases.
  JOURNAL   J Clin Pathol 68:44-50 (2015)
REFERENCE   PMID:15817349 (drug)
  AUTHORS   Ohguri T, Imada H, Nomoto S, Yahara K, Hisaoka M, Hashimoto H, Tokura Y, Nakamura K, Shioyama Y, Honda H, Terashima H, Moroi Y, Furue M, Korogi Y
  TITLE     Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy.
  JOURNAL   Int J Radiat Oncol Biol Phys 61:1446-53 (2005)
///
ENTRY       H01667                      Disease
NAME        Medulloblastoma
DESCRIPTION Medulloblastoma is the most common embryonal CNS tumor of childhood and is likely composed of biologically different subsets of tumors arising from stem and/or progenitor cells of the cerebellum. Recently, four distinct molecular subgroups of medulloblastoma have been identified [WNT (wingless), SHH (sonic hedgehog), Group 3, and Group 4]. Nearly all (90 %) of WNT patients have somatic missense mutations in CTNNB1 which promote protein stabilization. Alterations in SHH subgroup most often fall within the Shh signalling pathway. The most common are somatic or germline inactivating alterations or loss of PTCH1 and SUFU, or somatic missense mutations activating SMO. Group 3 tumors are characterized by MYC amplification resulting in high MYC mRNA expression levels compared with SHH and Group 4 tumors.The most frequently mutated somatic gene in Group 4 medulloblastoma is KDM6A, a histone H3 Lys27 (H3K27) demethylase.
CATEGORY    Cancer
GENE        PTCH1 (mutation) [HSA:5727] [KO:K06225]
            SUFU (mutation) [HSA:51684] [KO:K06229]
            SMO (mutation) [HSA:6608] [KO:K06226]
            Axin1 (mutation) [HSA:8312] [KO:K02157]
            Axin2 (mutation) [HSA:8313] [KO:K04385]
            APC (mutation) [HSA:324 10297] [KO:K02085]
            CTNNB1 (mutation) [HSA:1499] [KO:K02105]
            MYC (amplification) [HSA:4609] [KO:K04377]
            OTX2 (amplification) [HSA:5015] [KO:K18490]
            TP53 (mutation) [HSA:7157] [KO:K04451]
            NF2 (mutation) [HSA:4771] [KO:K16684]
            MEN1 (mutation) [HSA:4221] [KO:K14970]
            hTERT (amplification) [HSA:7015] [KO:K11126]
            MDM2 (amplification) [HSA:4193] [KO:K06643]
            KDM6A (mutation) [HSA:7403] [KO:K11447]
MARKER      MYC [HSA:4609] [KO:04377]
            CTNNB1 [HSA:1499] [KO:02105]
            FSTL5 [HSA:56884]
DRUG        Cisplatin [DR:D00275]
            Carboplatin [DR:D01363]
            Cyclophosphamide [DR:D00287 D07760]
            Vincristine [DR:D08679]
            Topotecan [DR:D02168]
COMMENT     ICD-O-3: 9471/3 Desmoplastic nodular medulloblastoma
DBLINKS     ICD-10: C71.6
            MeSH: D008527
REFERENCE   PMID:18676356 (gene)
  AUTHORS   de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R
  TITLE     Biological background of pediatric medulloblastoma and ependymoma: a review from  a translational research perspective.
  JOURNAL   Neuro Oncol 10:1040-60 (2008)
REFERENCE   PMID:26350064 (gene)
  AUTHORS   Skowron P, Ramaswamy V, Taylor MD
  TITLE     Genetic and molecular alterations across medulloblastoma subgroups.
  JOURNAL   J Mol Med (Berl) 93:1075-84 (2015)
REFERENCE   PMID:25768332
  AUTHORS   Gopalakrishnan V, Tao RH, Dobson T, Brugmann W, Khatua S
  TITLE     Medulloblastoma development: tumor biology informs treatment decisions.
  JOURNAL   CNS Oncol 4:79-89 (2015)
REFERENCE   PMID:24076581 (gene)
  AUTHORS   Remke M, Ramaswamy V, Taylor MD
  TITLE     Medulloblastoma molecular dissection: the way toward targeted therapy.
  JOURNAL   Curr Opin Oncol 25:674-81 (2013)
REFERENCE   PMID:25348790 (ICD-O-3)
  AUTHORS   Gajjar AJ, Robinson GW
  TITLE     Medulloblastoma-translating discoveries from the bench to the bedside.
  JOURNAL   Nat Rev Clin Oncol 11:714-22 (2014)
REFERENCE   PMID:24389035 (gene, marker)
  AUTHORS   Gerber NU, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S
  TITLE     Recent developments and current concepts in medulloblastoma.
  JOURNAL   Cancer Treat Rev 40:356-65 (2014)
REFERENCE   PMID:23245832 (drug)
  AUTHORS   Bartlett F, Kortmann R, Saran F
  TITLE     Medulloblastoma.
  JOURNAL   Clin Oncol (R Coll Radiol) 25:36-45 (2013)
REFERENCE   PMID:25174961 (drug)
  AUTHORS   Yamada A, Moritake H, Kamimura S, Yamashita S, Takeshima H, Nunoi H
  TITLE     Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma.
  JOURNAL   Pediatr Blood Cancer 61:2316-8 (2014)
///
ENTRY       H01668                      Disease
NAME        Neoplastic meningitis
DESCRIPTION Neoplastic meningitis (NM) is a diffuse dissemination of tumor cells into the cerebrospinal fluid (CSF) and/or leptomeninges. NM is reported in patients with solid tumours (carcinomatous meningitis), haematological malignancies (leukaemic or lymphomatous meningitis), or primary brain tumours. Malignant cells reach the CSF and meninges by direct invasion from tumors located near or within the central nervous system (CNS), or via the bloodstream or other pathways that contact the CNS. The molecular changes responsible for the development of NM are not well delineated, but it is likely that they involve changes in molecules responsible for tumor cell adhesion, migration, and proliferation.
CATEGORY    Nervous system disease
MARKER      Carcinoembryonic antigen (CEA)
            alpha-Fetoprotein [HSA:174] [KO:K16144]
            beta-Human chorionic gonadotropin [HSA:114335 114336 1082 93659 94027 94115] [KO:K10045]
            Creatine-kinase BB isoenzyme [HSA:1152] [KO:K00933]
            Tissue polypeptide antigen
            beta2-Microglobulin [HSA:567] [KO:K08055]
            beta-Glucuronidase [HSA:2990] [KO:K01195]
            Lactate dehydrogenase isoenzyme-5
            Vascular endothelial growth factor [HSA:7422] [KO:K05448]
DRUG        Methotrexate [DR:D00142]
            Cytarabine [DR:D00168]
            Thiotepa [DR:D00583]
            alpha-Interferon [DR:D03305]
            Etoposide [DR:D00125]
            Topotecan [DR:D02168]
            Rituximab [DR:D02994]
DBLINKS     ICD-10: G03
            MeSH: D008581
REFERENCE   PMID:18776058 (marker, drug)
  AUTHORS   Chamberlain MC
  TITLE     Neoplastic meningitis.
  JOURNAL   Oncologist 13:967-77 (2008)
REFERENCE   PMID:25031995 (drug)
  AUTHORS   Fields MM
  TITLE     How to recognize and treat neoplastic meningitis.
  JOURNAL   J Adv Pract Oncol 4:155-60 (2013)
REFERENCE   PMID:20645702
  AUTHORS   Strik H, Prommel P
  TITLE     Diagnosis and individualized therapy of neoplastic meningitis.
  JOURNAL   Expert Rev Anticancer Ther 10:1137-48 (2010)
REFERENCE   PMID:16632315 (marker, drug)
  AUTHORS   Gleissner B, Chamberlain MC
  TITLE     Neoplastic meningitis.
  JOURNAL   Lancet Neurol 5:443-52 (2006)
REFERENCE   PMID:20425607
  AUTHORS   Mammoser AG, Groves MD
  TITLE     Biology and therapy of neoplastic meningitis.
  JOURNAL   Curr Oncol Rep 12:41-9 (2010)
REFERENCE   PMID:12493146
  AUTHORS   Groves MD
  TITLE     The pathogenesis of neoplastic meningitis.
  JOURNAL   Curr Oncol Rep 5:15-23 (2003)
///
ENTRY       H01669                      Disease
NAME        Secondary hyperparathyroidism
DESCRIPTION Secondary hyperparathyroidism (SHPT) is a chronic and progressive disorder characterized by elevated serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and disturbances in mineral metabolism, mainly calcium and phosphorus. SHPT is generally caused by diffuse parathyroid hyperplasia in response to prolonged reduced levels of extracellular calcium from various secondary aetiologies. Although it is initially and adaptive response to a variety of stimuli resulting mainly in extracellular hypocalcaemia (vitamin D deficiency, chronic kidney disease, idiopathic hypercalciuria, calcium malabsorption), long-standing SHPT may eventually develop into autonomous HPT (ie, tertiary HPT). Because SHPT is a compensatory mechanism of the parathyroid glands, it commonly resolves with normalization of calcium and phosphorus homeostasis. After excluding reversible secondary aetiologies, first-line treatment of irreversible SHPT (often related to chronic kidney disease) mainly involves medical therapies.
CATEGORY    Endocrine system disease
DRUG        Calcium acetate [DR:D00931] Sevelamer hydrochloride [DR:D01983] Sevelamer carbonate [DR:D06642] Lanthanum carbonate [DR:D04667] (Phosphate binders)
            Calcitriol [DR:D00129] Maxacalcitol [DR:D01098] (Vitamin D analogs)
            Cinacalcet [DR:D03505] (Calcimimetics)
DBLINKS     ICD-10: E21.1
            MeSH: D006962
REFERENCE   PMID:25702624 (description)
  AUTHORS   Cozzolino M, Tomlinson J, Walsh L, Bellasi A
  TITLE     Emerging drugs for secondary hyperparathyroidism.
  JOURNAL   Expert Opin Emerg Drugs 20:197-208 (2015)
REFERENCE   PMID:26163537 (description)
  AUTHORS   Duan K, Gomez Hernandez K, Mete O
  TITLE     Clinicopathological correlates of hyperparathyroidism.
  JOURNAL   J Clin Pathol 68:771-87 (2015)
REFERENCE   PMID:27479950 (description, drug)
  AUTHORS   Yuen NK, Ananthakrishnan S, Campbell MJ
  TITLE     Hyperparathyroidism of Renal Disease.
  JOURNAL   Perm J 20:78-83 (2016)
///
ENTRY       H01670                      Disease
NAME        Social anxiety disorder;
            Social phobia
DESCRIPTION Social anxiety disorder (SAD) is the most common anxiety disorder. SAD is generally considered a chronic disorder and has its onset during early adolescence. It is a risk factor for subsequent depressive illness and substance abuse. Patients with SAD have an extreme fear of being negatively evaluated in social situations and, as a result, avoid social events or endure them with excessive fear or anxiety. Although the etiology of SAD is not yet fully established, twin and family studies suggest that SAD is heritable. Functional neuroimaging studies point to increased activity in amygdala and insula in patients with social anxiety disorder. In addition, there is evidence from various studies, that the serotonin, and dopamine neurotransmitter systems mediate the symptoms of SAD. A range of effective cognitive behavioural and pharmacological treatments now exists. However, they don't work for the 30-40% of patients.
CATEGORY    Mental disorder
DRUG        Paroxetine [DR:D02260]
            Fluvoxamine [DR:D00824]
DBLINKS     ICD-10: F40.1 F93.2
            MeSH: D010698
REFERENCE   PMID:18374843 (description, drug)
  AUTHORS   Stein MB, Stein DJ
  TITLE     Social anxiety disorder.
  JOURNAL   Lancet 371:1115-25 (2008)
REFERENCE   PMID:27593443
  AUTHORS   Bas-Hoogendam JM, Blackford JU, Bruhl AB, Blair KS, van der Wee NJ, Westenberg PM
  TITLE     Neurobiological Candidate Endophenotypes of Social Anxiety Disorder.
  JOURNAL   Neurosci Biobehav Rev (2016)
REFERENCE   PMID:16899354
  AUTHORS   Lochner C, Hemmings S, Seedat S, Kinnear C, Schoeman R, Annerbrink K, Olsson M, Eriksson E, Moolman-Smook J, Allgulander C, Stein DJ
  TITLE     Genetics and personality traits in patients with social anxiety disorder: a case-control study in South Africa.
  JOURNAL   Eur Neuropsychopharmacol 17:321-7 (2007)
///
ENTRY       H01671                      Disease
NAME        Neurosis;
            Neurotic disorder
DESCRIPTION Neurosis is a class of functional mental disorders involving distress but neither delusions nor hallucinations, whereby behavior is not outside socially acceptable norms. The state of research on neurosis has moved towards looking at biological and genetic substrates or mechanisms underlying neurosis. The recent literature shows acceptance of common mental disorders such as Generalized anxiety disorder (GAD), Panic disorder (PD), and Obsessive-compulsive disorder (OCD), across cultures replacing neurotic disorder. Usage of the diagnosis of neurosis has been decreased, and replaced by newer categories in the current popular classificatory systems. In the International Classification of Diseases (ICD-10), all disorders regarded as neurosis remained together but under the division of rubric 'neurotic, stress-related and somatoform disorders'. In the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), neurosis has been eliminated as a category.
CATEGORY    Mental disorder
GENE        DRD4 (polymorphism) [HSA:1815] [KO:K04147]
COMMENT     See also H01662 Generalized anxiety disorder, H01664 Panic disorder, H01670 Social anxiety disorder, and H01453 Obsessive-Compulsive and Related Disorder (OCRD).
DBLINKS     ICD-10: F48
            MeSH: D009497
REFERENCE   PMID:17143082
  AUTHORS   Chaturvedi SK, Bhugra D
  TITLE     The concept of neurosis in a cross-cultural perspective.
  JOURNAL   Curr Opin Psychiatry 20:47-51 (2007)
REFERENCE   PMID:16472910 (gene)
  AUTHORS   Tochigi M, Hibino H, Otowa T, Kato C, Marui T, Ohtani T, Umekage T, Kato N, Sasaki T
  TITLE     Association between dopamine D4 receptor (DRD4) exon III polymorphism and Neuroticism in the Japanese population.
  JOURNAL   Neurosci Lett 398:333-6 (2006)
///
ENTRY       H01672                      Disease
NAME        Juvenile idiopathic arthritis (JIA), including:
            Juvenile rheumatoid arthritis;
            Still's disease
DESCRIPTION Juvenile idiopathic arthritis (JIA) is one of the most common childhood rheumatic diseases. Clinically, it is defined as arthritis of unknown origin that starts before the age of 16, and persists for at least 6 weeks. Next to a certain genetic predisposition, environmental factors play a role leading to a chronic inflammatory response. JIA is not a single disorder but consists of a heterogeneous group of auto-immune inflammatory diseases. It has variable rates in course and activity of disease. Based on 6 months of clinical symptoms and global prognostic factors, the following clinical subtypes of JIA are recognized: systemic JIA, oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic JIA, enthesitis- related arthritis, and undifferentiated arthritis. Systemic JIA, also known as Still's disease, is a subtype with strong systemic clinical symptoms. Patients with systemic JIA have, in addition to arthritis, prominent symptoms of systemic inflammation such as spiking fever, rash, pericarditis, peritonitis, lymphadenopathy and organomegaly. A severe and often life-threatening complication occurring in 10-30% of patients with systemic JIA  is macrophage activation syndrome. Polymorphisms in the IL6 and in the MIF gene have been found to be associated with susceptibility to the disorder. Based on the known relevance of IL6 in JIA pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA.
CATEGORY    Immune system disease
GENE        IL6 (polymorphism) [HSA:3569] [KO:K05405]
            MIF (polymorphism) [HSA:4282] [KO:K07253]
MARKER      CRP, ESR, MRP8, MRP14 (Common)
            S100A12, IL-18 (Systemic JIA)
            Rheumatoid factor (RF)
            HLA-B27 (Enthesitis related arthritis)
DRUG        Methotrexate [DR:D00142]
            Sulfasalazine [DR:D00448]
            Leflunomide [DR:D00749]
            Etanercept [DR:D00742]
            Adalimumab [DR:D02597]
            Tocilizumab [DR:D02596]
COMMENT     See also H01516 Adult onset Still's disease.
DBLINKS     ICD-10: M08
            MeSH: D001171
            OMIM: 604302
REFERENCE   PMID:27461267 (description, marker)
  AUTHORS   Swart JF, de Roock S, Prakken BJ
  TITLE     Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype.
  JOURNAL   Eur J Immunol 46:2068-77 (2016)
REFERENCE   PMID:18078632 (gene)
  AUTHORS   Vivarelli M, D'Urbano LE, Insalaco A, Lunt M, Jury F, Tozzi AE, Ravelli A, Martini A, Donn R, De Benedetti F
  TITLE     Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids.
  JOURNAL   Clin Exp Rheumatol 25:775-81 (2007)
REFERENCE   PMID:23543063 (gene)
  AUTHORS   Woo P, Humphries SE
  TITLE     IL-6 polymorphisms: a useful genetic tool for inflammation research?
  JOURNAL   J Clin Invest 123:1413-4 (2013)
REFERENCE   PMID:26848760 (drug)
  AUTHORS   Turnier JL, Brunner HI
  TITLE     Tocilizumab for treating juvenile idiopathic arthritis.
  JOURNAL   Expert Opin Biol Ther 16:559-66 (2016)
REFERENCE   PMID:26678914 (drug)
  AUTHORS   Hugle B, Horneff G
  TITLE     The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
  JOURNAL   Expert Opin Pharmacother 17:703-14 (2016)
///
ENTRY       H01673                      Disease
NAME        Palmoplantar keratoderma
DESCRIPTION Palmoplantar keratodermas (PPK) comprise a heterogeneous group of keratinization disorders with hyperkeratotic thickening of palms and soles. Sporadic or acquired forms of PPKs and hereditary forms exist. The causes of acquired PPK vary, and include exposure to certain chemicals, side effects of certain drugs, and metabolic disorders. There is as yet no cure for hereditary PPK. In patients with acquired PPK, the cause should be treated or eliminated, if possible. In both instances, optimized treatment can lead to a significant improvement in symptoms. Topical therapy with urea-based ointments improves the skin's absorption of moisture and has keratolytic effects. Topical vitamin D therapy is another option.
CATEGORY    Skin and connective tissue disease
GENE        KRT1 [HSA:3848] [KO:K07605]
            KRT9 [HSA:3857] [KO:K07604]
            AQP5 [HSA:362] [KO:K09867]
            SERPINB7 [HSA:8710] [KO:K13964]
            GJB2 [HSA:2706] [KO:K07621]
ENV_FACTOR  Arsenic, Chlorinated hydrocarbon fluids, Beta-glucan, Lithium, Chemotherapy agents
DRUG        Urea [DR:D00023]
            Lactic acid [DR:D02920]
            Vitamin A [DR:D00069]
            Maxacalcitol [DR:D01098]
COMMENT     See also H00716 Palmoplantar keratoderma with deafness, H00717 Striate palmoplantar keratoderma, and H00722 Epidermolytic palmoplantar keratoderma (EPPK).
DBLINKS     ICD-10: L85.1
            MeSH: D007645
            OMIM: 144200 148350 600962 600231 615598
REFERENCE   PMID:25176457
  AUTHORS   Schiller S, Seebode C, Hennies HC, Giehl K, Emmert S
  TITLE     Palmoplantar keratoderma (PPK): acquired and genetic causes of a not so rare disease.
  JOURNAL   J Dtsch Dermatol Ges 12:781-8 (2014)
///
ENTRY       H01674                      Disease
NAME        Ankylosing spondylitis;
            Bechterew's disease
DESCRIPTION Ankylosing spondylitis (AS), formerly also known as Bechterew's disease, is a rheumatic disease of the axial skeleton that mainly affects the spine and the sacroiliac joint in the pelvis. AS is one of a group of inflammatory diseases, called spondyloarthritides, which share features. This disease is characterized by erosion, sclerosis, and ossification, which may result in complete fusion and rigidity of the spine. Regarding extra-articular manifestations, the most frequent is anterior uveitis. The major functional losses occur during the first 10 years of disease. It usually begins in the second or third decade of life, preferentially in HLA-B27-positive Caucasian males. Its etiology and pathogenesis are not completely understood, but the most prevalent hypothesis involves immune mediation as its major mechanism, including several cytokines. To date, more than 40 genetic variants have been identified that influence the risk of developing AS, including HLA alleles such as HLA-B27. Non-steroid anti-inflammatory drugs (NSAIDs) are used to reduce pain and inflammation. Additional disease-modifying anti-rheumatic drugs (DMARDs) are prescribed to slowdown disease progression. The most frequently applied biological agents approved for AS are TNF alpha inhibitors. The IL-17 inhibitor secukinumab has been recently approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and AS.
CATEGORY    Musculoskeletal diseases; Immune system diseases
GENE        HLA-B [HSA:3106] [KO:K06751]
DRUG        Sulfasalazine [DR:D00448]
            Infliximab [DR:D02598]
            Adalimumab [DR:D02597]
            Secukinumab [DR:D09967]
COMMENT     See also H00630 Rheumatoid arthritis and H01656 Psoriasis.
DBLINKS     ICD-10: M45
            MeSH: D013167
            OMIM: 106300
REFERENCE   PMID:23090374
  AUTHORS   Gouveia EB, Elmann D, Morales MS
  TITLE     Ankylosing spondylitis and uveitis: overview.
  JOURNAL   Rev Bras Reumatol 52:742-56 (2012)
REFERENCE   PMID:27445458 (drug)
  AUTHORS   Koenders MI, van den Berg WB
  TITLE     Secukinumab for rheumatology: development and its potential place in therapy.
  JOURNAL   Drug Des Devel Ther 10:2069-80 (2016)
REFERENCE   PMID:26439405 (gene)
  AUTHORS   Brown MA, Kenna T, Wordsworth BP
  TITLE     Genetics of ankylosing spondylitis--insights into pathogenesis.
  JOURNAL   Nat Rev Rheumatol 12:81-91 (2016)
///
ENTRY       H01675                      Disease
NAME        Syringomyelia
DESCRIPTION Syringomyelia is a spinal disorder characterized by the presence of abnormal fluid-filled cavities within the spinal cord. Early symptoms include headache, altered pain and temperature sensation, and paresthesia. If fluid continues to enlarge the cyst, the syrinx has the potential to compress or destroy the affected portions of the spinal cord. Surgical intervention is typically recommended to treat this condition, although a successful procedure often is limited to providing minimal neurological improvement or simply halting the deterioration. The term syringomyelia describes many pathogenetically different disorders. A popular broad grouping is a classification based on the assumed pathogenesis and association with other disorders. It has been proposed to divide the disorder into three subgroups. (1) Syringomyelia as a result of changed cerebrospinal fluid (CSF) flow dynamics related to hindbrain disorders, e.g. Chiari malformation, Dandy-Walker syndrome, arachnoiditis or osseous abnormalities. (2) Syringomyelia as a result of intramedullary tissue damage caused by haemorrhage or infarction. (3) Syringomyelia as a result of intramedullary tumour with secretory capabilities. Other proposed classifications are based on syrinx fluid composition, central canal communication between syrinx and the fourth ventricle, or the microanatomical localisation of the syrinx.
CATEGORY    Nervous system disease; Developmental disorder
COMMENT     See also H01561 Chiari malformation, and H01675 Dandy-Walker syndrome.
DBLINKS     ICD-10: G95.0 Q06.4
            MeSH: D013595
            OMIM: 186700
REFERENCE   PMID:25236931
  AUTHORS   Blegvad C, Grotenhuis JA, Juhler M
  TITLE     Syringomyelia: a practical, clinical concept for classification.
  JOURNAL   Acta Neurochir (Wien) 156:2127-38 (2014)
REFERENCE   PMID:19119392
  AUTHORS   Rene Hudson B, Cook C, Goode A
  TITLE     Identifying myelopathy caused by thoracic syringomyelia: a case report.
  JOURNAL   J Man Manip Ther 16:82-8 (2008)
///
ENTRY       H01676                      Disease
NAME        Normal pressure hydrocephalus
DESCRIPTION Normal pressure hydrocephalus (NPH) is a progressive brain disease characterized by gait impairment, urinary incontinence, and dementia, and by ventricular enlargement in the absence of elevated intracranial pressure. NPH can be secondary to disease processes that cause inflammation of the arachnoid, such as subarachnoid hemorrhage, traumatic brain injury, or meningitis. As many as half of patients with NPH have no identifiable risk factor, and it is called idiopathic normal pressure hydrocephalus (INPH). Although INPH is usually considered an acquired form of hydrocephalus because the onset of symptoms is not until late in life, it has been reported that a subset of patients with INPH may actually have congenital hydrocephalus. Symptoms can be alleviated with a cerebrospinal fluid (CSF) shunt.
CATEGORY    Nervous system disease
DBLINKS     ICD-10: G91.2
            MeSH: D006850
            OMIM: 236690 611808
REFERENCE   PMID:25061869
  AUTHORS   Golz L, Ruppert FH, Meier U, Lemcke J
  TITLE     Outcome of modern shunt therapy in patients with idiopathic normal pressure hydrocephalus 6 years postoperatively.
  JOURNAL   J Neurosurg 121:771-5 (2014)
REFERENCE   PMID:17202229
  AUTHORS   Wilson RK, Williams MA
  TITLE     Evidence that congenital hydrocephalus is a precursor to idiopathic normal pressure hydrocephalus in only a subset of patients.
  JOURNAL   J Neurol Neurosurg Psychiatry 78:508-11 (2007)
REFERENCE   PMID:16239882 (treatment)
  AUTHORS   McGirt MJ, Woodworth G, Coon AL, Thomas G, Williams MA, Rigamonti D
  TITLE     Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus.
  JOURNAL   Neurosurgery 57:699-705; discussion 699-705 (2005)
REFERENCE   PMID:18203159 (gene)
  AUTHORS   Zhang J, Williams MA, Rigamonti D
  TITLE     Heritable essential tremor-idiopathic normal pressure hydrocephalus (ETINPH).
  JOURNAL   Am J Med Genet A 146A:433-9 (2008)
///
ENTRY       H01677                      Disease
NAME        Congenital hydrocephalus
DESCRIPTION Congenital hydrocephalus is a common birth defect in the circulation of the cerebrospinal fluid (CSF). It is characterized by ventricular dilatation. Although commonly considered a single disorder, hydrocephalus is a collection of a heterogeneous complex and multifactorial disorders. It may occur alone (non-syndromic) or as part of a syndrome with other anomalies. Almost 50% of all cases of hydrocephalus are congenital and these are usually associated with adverse neurological outcome. It is probably the consequence of abnormal brain development. Genetic factors are involved in the pathogenesis of this disease. Molecular genetic studies have revealed that the responsible gene for X-linked human congenital hydrocephalus is encoding for L1CAM. Although the recurrence risk for congenital hydrocephalus excluding X-linked hydrocephalus is low, recently, a few genes for autosomal recessive congenital hydrocephalus have been identified. Besides genetic factors, many other factors influence the development of congenital hydrocephalus, such as congenital malformations, intracerebral hemorrhage, maternal alcohol use, infection, and X-ray radiation during pregnancy.
CATEGORY    Nervous system disease; Developmental disorder
GENE        L1CAM [HSA:3897] [KO:K06550]
            CCDC88C [HSA:440193]
            MPDZ [HSA:8777] [KO:K06095]
COMMENT     See also H01034 L1 syndrome
DBLINKS     ICD-10: Q03
            MeSH: D006849
            OMIM: 307000 236600 615219
REFERENCE   PMID:16773266 (description, gene)
  AUTHORS   Zhang J, Williams MA, Rigamonti D
  TITLE     Genetics of human hydrocephalus.
  JOURNAL   J Neurol 253:1255-66 (2006)
REFERENCE   PMID:23240096 (gene)
  AUTHORS   Al-Dosari MS, Al-Owain M, Tulbah M, Kurdi W, Adly N, Al-Hemidan A, Masoodi TA, Albash B, Alkuraya FS
  TITLE     Mutation in MPDZ causes severe congenital hydrocephalus.
  JOURNAL   J Med Genet 50:54-8 (2013)
REFERENCE   PMID:23042809 (gene)
  AUTHORS   Drielsma A, Jalas C, Simonis N, Desir J, Simanovsky N, Pirson I, Elpeleg O, Abramowicz M, Edvardson S
  TITLE     Two novel CCDC88C mutations confirm the role of DAPLE in autosomal recessive congenital hydrocephalus.
  JOURNAL   J Med Genet 49:708-12 (2012)
///
ENTRY       H01678                      Disease
NAME        Dandy-Walker syndrome
DESCRIPTION Dandy-Walker syndrome (DWS) is a congenital brain malformation, characterized by posterior fossa cyst, cystic dilatation of the fourth ventricle, cerebellar vermis dysgenesis, and an upwardly displaced tentorium. Patients often have motor deficits such as delayed motor development, hypotonia and ataxia. About half have mental retardation, and some have hydrocephalus. It has been suggested that heterozygous loss of ZIC1 and ZIC4 is the cause of this disease. Various managements of DWS have been reported from open excision of the cysts to CSF diversion. Ventriculoperitoneal (VP) and cystoperitoneal (CP) shunt insertion are the most common choices in the treatment of DWS.
CATEGORY    Developmental disorder; Nervous system disease
GENE        ZIC1 [HSA:7545] [KO:K09224]
            ZIC4 [HSA:84107] [KO:K09225]
DBLINKS     ICD-10: Q03.1
            MeSH: D003616
            OMIM: 220200
REFERENCE   PMID:15338008 (gene)
  AUTHORS   Grinberg I, Northrup H, Ardinger H, Prasad C, Dobyns WB, Millen KJ
  TITLE     Heterozygous deletion of the linked genes ZIC1 and ZIC4 is involved in Dandy-Walker malformation.
  JOURNAL   Nat Genet 36:1053-5 (2004)
REFERENCE   PMID:26770421 (treatment)
  AUTHORS   Lin J, Liang G, Liang Y, Kou Y
  TITLE     Long-term follow-up of successful treatment for dandy-walker syndrome (DWS).
  JOURNAL   Int J Clin Exp Med 8:18203-7 (2015)
///
ENTRY       H01679                      Disease
NAME        Intrahepatic lithiasis;
            Intrahepatic calculosis;
            Hepatolithiasis
DESCRIPTION Intrahepatic lithiasis is very common disease in East Asia, characterized by the recurrent pyogenic cholangitis. The main clinical symptoms are abdominal pain, fever and jaundice. Pathologically, the intrahepatic ducts are dilated and contain soft, pigmented stones, mainly calcium bilirubinate stones. It is likely to lead to biliary cirrhosis and increase the risk of cholangiocarcinoma. Hence, the treatment of this disease is difficult but vital. Currently, various treatment options have been available, including liver resection, percutaneous approach, endoscopic approach and laser lithotripsy.
CATEGORY    Liver diseases
DBLINKS     ICD-10: K80
            MeSH: D020347
REFERENCE   PMID:23558070
  AUTHORS   Jiang ZJ, Chen Y, Wang WL, Shen Y, Zhang M, Xie HY, Zhou L, Zheng SS
  TITLE     Management hepatolithiasis with operative choledochoscopic FREDDY laser lithotripsy combined with or without hepatectomy.
  JOURNAL   Hepatobiliary Pancreat Dis Int 12:160-4 (2013)
REFERENCE   PMID:2048504
  AUTHORS   Lim JH
  TITLE     Oriental cholangiohepatitis: pathologic, clinical, and radiologic features.
  JOURNAL   AJR Am J Roentgenol 157:1-8 (1991)
///
ENTRY       H01680                      Disease
NAME        Chronic pancreatitis
DESCRIPTION Chronic pancreatitis is a progressive inflammatory disease of the pancreas that will finally result in both exocrine and endocrine insufficiency. Chronic pancreatitis develops gradually and worsens over time, resulting in permanent organ damage. It is usually caused by recurrent episodes of pancreatic necro-inflammation, leading to pancreatic atrophy and dysfunction. It manifests clinically as maldigestion, weight loss, abdominal pain and eventually diabetes. Six major etiologies for chronic pancreatitis have been identified, namely toxic-metabolic (to include alcohol), idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, and obstruction. Oral protease inhibitors are currently used as a medical treatment for chronic pancreatitis.
CATEGORY    Pancreas disease
ENV_FACTOR  Alcohol and smoking.
MARKER      BT-PABA test
DRUG        Camostat mesilate [DR:D01766]
            Nafamostat mesylate [DR:D01670]
COMMENT     See also H00933  Hereditary pancreatitis.
DBLINKS     ICD-10: K86.1
            MeSH: D050500
            OMIM: 167800
REFERENCE   PMID:20567557
  AUTHORS   Banks PA, Conwell DL, Toskes PP
  TITLE     The management of acute and chronic pancreatitis.
  JOURNAL   Gastroenterol Hepatol (N Y) 6:1-16 (2010)
REFERENCE   PMID:18442214 (gene)
  AUTHORS   Frossard JL, Dumonceau JM, Pastor C, Spahr L, Hadengue A
  TITLE     Concomitant autoimmune and genetic pancreatitis leads to severe inflammatory conditions.
  JOURNAL   World J Gastroenterol 14:2596-8 (2008)
REFERENCE   PMID:25228979 (marker)
  AUTHORS   Hirano K, Saito T, Mizuno S, Tada M, Sasahira N, Isayama H, Matsukawa M, Umefune G, Akiyama D, Saito K, Kawahata S, Takahara N, Uchino R, Hamada T, Miyabayashi K, Mohri D, Sasaki T, Kogure H, Yamamoto N, Nakai Y, Koike K
  TITLE     Total cholesterol level for assessing pancreatic insufficiency due to chronic pancreatitis.
  JOURNAL   Gut Liver 8:563-8 (2014)
REFERENCE   PMID:17625311 (drug)
  AUTHORS   Motoo Y
  TITLE     Antiproteases in the treatment of chronic pancreatitis.
  JOURNAL   JOP 8:533-7 (2007)
REFERENCE   PMID:17625312 (drug)
  AUTHORS   Kitagawa M, Hayakawa T
  TITLE     Antiproteases and the pancreas: basic and clinical update. Conclusion remarks.
  JOURNAL   JOP 8:538-44 (2007)
///
ENTRY       H01681                      Disease
NAME        Acute pancreatitis
DESCRIPTION Acute pancreatitis ranges from a mild, self- limiting disease to a life-threatening condition with multiple organ failure. Abdominal pain is the predominant symptom. Nausea and vomiting may accompany the pain. Patients frequently have a low-grade fever, tachycardia, and hypotension. The most common causes of acute pancreatitis are alcohol abuse and gallstones. The currently accepted pathogenic mechanism includes autodigestion and acute inflammation of the pancreas by the activation of proteases of the pancreas and acute inflammatory cells. Severe acute pancreatitis is defined by the presence of organ failure persisting beyond 48 hour. Organ failure that develops during the early phase is set in motion by the activation of cytokine cascades resulting in systemic inflammatory response syndrome (SIRS). Although effective therapies for acute pancreatitis are still limited, protease inhibitors have been considered to be a potential treatment to inhibit the pancreatic inflammation.
CATEGORY    Pancreas disease
MARKER      Incleased serum amylase 
            Increased plasma pro-inflammatory cytokine concentrations
            Leukocytosis
DRUG        Nafamostat mesilate [DR:D01670]
            Gabexate mesilate [DR:D01672]
            Ulinastatin [DR:D05183]
            Aprotinin [DR:D02971]
DBLINKS     ICD-10: K85
            MeSH: D019283
REFERENCE   PMID:23100216
  AUTHORS   Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS
  TITLE     Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus.
  JOURNAL   Gut 62:102-11 (2013)
REFERENCE   PMID:16374372
  AUTHORS   Granger J, Remick D
  TITLE     Acute pancreatitis: models, markers, and mediators.
  JOURNAL   Shock 24 Suppl 1:45-51 (2005)
REFERENCE   PMID:17625305
  AUTHORS   Chen CC, Wang SS, Lee FY
  TITLE     Action of antiproteases on the inflammatory response in acute pancreatitis.
  JOURNAL   JOP 8:488-94 (2007)
///
ENTRY       H01682                      Disease
NAME        Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
DESCRIPTION The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an endocrine disease, characterized by inappropriately concentrated urine, dilutional hyponatremia, and subsequent manifestations of various central nervous system (CNS) symptoms. Though usually transient, SIADH may be chronic. It is often associated with drug use or a lesion in the central nervous system or lung. SIADH is divided into two categories. One is the ectopic ADH syndrome induced by abnormally secreted arginine vasopressin (ADH/AVP) from cancer cells. Another is the morbidity caused by inappropriately secreted ADH from the pituitary gland. In both situations of SIADH, ADH binds to vasopressin V2 receptors (V2Rs) in renal tubules and thereby increasing water reabsorption. SIADH is difficult to distinguish from cerebral salt wasting syndrome (CSWS), another cause of hyponatremia characterized by renal loss of sodium and decreases in extracellular fluid volume during intracranial disorders. SIADH occurs in the setting of euvolemia, without evidence of renal disease or thyroxine or cortisol deficiency. Treatment options for SIADH include fluid restriction, demeclocycline, urea, frusemide and saline infusion, all of which have their limitations. The introduction of the vasopressin-2 receptor antagonists has allowed clinicians to specifically target the underlying pathophysiology of SIADH.
CATEGORY    Endocrine disease
MARKER      Plasma osmolality (<270 mosmol/kg H2O)
            Inappropriate urinary concentration
            Elevated urinary sodium, with normal salt and water intake
            Abnormal water load test
            Plasma AVP levels inappropriately elevated
DRUG        Tolvaptan [DR:D01213]
            Mozavaptane [DR:D01855]
            Demeclocycline [DR:D00290]
            Frusemide [DR:D00331]
COMMENT     Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is characterized by a clinical picture similar to SIADH, but is associated with undetectable levels of AVP.
            See also H01294 Nephrogenic syndrome of inappropriate antidiuresis (NSIAD).
DBLINKS     ICD-10: E22.2
            MeSH: D007177
            OMIM: 300539
REFERENCE   PMID:20164215 (marker, drug)
  AUTHORS   Sherlock M, Thompson CJ
  TITLE     The syndrome of inappropriate antidiuretic hormone: current and future management options.
  JOURNAL   Eur J Endocrinol 162 Suppl 1:S13-8 (2010)
REFERENCE   PMID:21087977 (drug)
  AUTHORS   Yamaguchi K, Shijubo N, Kodama T, Mori K, Sugiura T, Kuriyama T, Kawahara M, Shinkai T, Iguchi H, Sakurai M
  TITLE     Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.
  JOURNAL   Jpn J Clin Oncol 41:148-52 (2011)
REFERENCE   PMID:15872203
  AUTHORS   Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE
  TITLE     Nephrogenic syndrome of inappropriate antidiuresis.
  JOURNAL   N Engl J Med 352:1884-90 (2005)
///
ENTRY       H01683                      Disease
NAME        Disorders of antidiuretic hormone (ADH) secretion
DESCRIPTION Water imbalance is common among the critically ill. The excessive increases or decreases in body water can be lethal. There are numerous pathologic and iatrogenic causes for water imbalance, the most troublesome being disorders of antidiuretic hormone (ADH) secretion. ADH is also known as arginine vasopressin (AVP). The prime determinant of free water excretion is the regulation of urinary flow by circulating levels of arginine vasopressin (AVP) in plasma. Disorders of water metabolism can be divided into hyperosmolar disorders, in which there is a deficiency of body water relative to body solute, and hypo-osmolar disorders, in which there is an excess of body water relative to body solute. The classical hyperosmolar disorder is diabetes insipidus (DI), and the classical hypo-osmolar disorder is the syndrome of inappropriate antidiuretic hormone secretion (SIADH). DI can result from either inadequate AVP secretion (central or neurogenic DI) or inadequate renal response to AVP (nephrogenic DI). On the other hand, the dilutional hyponatraemia of SIADH develops due to persistent detectable or elevated plasma AVP concentrations.
CATEGORY    Endocrine disease
COMMENT     See also H00253 Neurohypophyseal diabetes insipidus (NPDI), and H01682 Syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
DBLINKS     ICD-10: E22 E23
            MeSH: D003919 D007177
REFERENCE   PMID:14687585
  AUTHORS   Verbalis JG
  TITLE     Disorders of body water homeostasis.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 17:471-503 (2003)
REFERENCE   PMID:1576035
  AUTHORS   Batcheller J
  TITLE     Disorders of antidiuretic hormone secretion.
  JOURNAL   AACN Clin Issues Crit Care Nurs 3:370-8 (1992)
///
ENTRY       H01684                      Disease
NAME        Primary sclerosing cholangitis (PSC)
DESCRIPTION Primary sclerosing cholangitis (PSC) is a rare progressive disease of the liver characterized by cholestasis and bile duct fibrosis, leading to decreased quality of life, cirrhosis, and the need for liver transplantation within an average of 12 years. The disease occurs in children and adults, and is closely linked with inflammatory bowel disease (IBD), most often ulcerative colitis (UC). The clinical presentation is variable. Typical symptoms include right upper quadrant abdominal discomfort, fatigue, pruritus, and weight loss. The most frequent abnormal physical exam findings are jaundice, hepatomegaly, and splenomegaly. The pathogenesis of PSC remains unclear but hypotheses include genetic factors lymphocyte recruitment and activation, portal bacteraemia, and bile salt toxicity. Ursodeoxycholic acid (UDCA) is widely used for PSC patients and UDCA can lead to improvements in serum hepatobiliary enzymes. UDCA has been tested alone and in combination with corticosteroids or other immunosuppressant agents. However, there is no medical treatment for PSC with enough evidence to show a delay in disease progression, and new therapy is needed.
CATEGORY    Liver diseases
MARKER      Elevation of serum alkaline phosphatase and aminotransferase
DRUG        Ursodeoxycholic acid [DR:D00734]
            Bezafibrate [DR:D01366]
COMMENT     See also H01227 Inflammatory bowel disease (IBD) and H01466 ulcerative colitis (UC).
DBLINKS     ICD-10: K83.0
            MeSH: D015209
            OMIM: 613806
REFERENCE   PMID:26357617 (marker)
  AUTHORS   Saadi M, Yu C, Othman MO
  TITLE     A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis.
  JOURNAL   J Clin Transl Hepatol 2:45-52 (2014)
REFERENCE   PMID:26925200 (drug)
  AUTHORS   Nayagam JS, Pereira SP, Devlin J, Harrison PM, Joshi D
  TITLE     Controversies in the management of primary sclerosing cholangitis.
  JOURNAL   World J Hepatol 8:265-72 (2016)
REFERENCE   PMID:20127368 (drug)
  AUTHORS   Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K
  TITLE     Bezafibrate for the treatment of primary sclerosing cholangitis.
  JOURNAL   J Gastroenterol 45:758-62 (2010)
///
ENTRY       H01685                      Disease
NAME        Autoimmune hepatitis (AIH)
DESCRIPTION Autoimmune hepatitis (AIH) is a chronic inflammatory liver disorder with an etiology that remains unclear. The pathogenesis may be a result of alterations in immune tolerance, a genetic predisposition and environmental conditions, which in collaboration induce a T-cell-mediated attack on liver antigens, leading to necro-inflammation and liver damage. AIH has marked female predilection. AIH can present at all ages, but the two peak ages of incidence are in childhood or adolescence and at around 40 years of age. Trademark biochemical/serological characteristics of AIH are elevated aminotransferase levels, positivity for autoantibodies and increased IgG. A histological picture of interface hepatitis is typical of AIH. The value of immunosuppressive therapy with glucocorticoids, alone or in combination with azathioprine, was well documented in numerous studies of AIH.
CATEGORY    Immune system disease; Liver diseases
MARKER      Elevated aminotransferase levels
            Increased IgG level
            Positivity for autoantibodies (ANA, SMA, LKM, SLA, LC-1)
DRUG        Prednisolone [DR:D00472]
            Azathioprine [DR:D00238]
COMMENT     Patients seropositive for ANA and/or anti-smooth muscle autoantibodies (SMA) have AIH type-1 whereas those presenting with positivity for anti-liver kidney type-1 autoantibody (anti-LKM-1) or anti-liver cytosol type-1 (anti-LC-1) have AIH type-2.
DBLINKS     ICD-10: K75.4
            MeSH: D019693
REFERENCE   PMID:27729952 (marker)
  AUTHORS   Liberal R, Grant CR
  TITLE     Cirrhosis and autoimmune liver disease: Current understanding.
  JOURNAL   World J Hepatol 8:1157-1168 (2016)
REFERENCE   PMID:15954109 (drug)
  AUTHORS   Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ
  TITLE     Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.
  JOURNAL   Hepatology 42:53-62 (2005)
///
ENTRY       H01686                      Disease
NAME        Idiopathic portal hypertension;
            Non-cirrhotic portal fibrosis;
            Banti's syndrome
DESCRIPTION Idiopathic portal hypertension (IPH) is a disorder generally classified as a noncirrhotic portal hypertension of unknown etiology, and is clinically characterized by portal hypertension, splenomegaly, and pancytopenia. The principal pathologic changes of IPH are devastation of the intrahepatic terminal portal radicles with considerable portal fibrosis and secondary atrophy of the liver parenchyma that follows portal thrombosis. The incidence varies considerably with the country. In contrast to its high prevalence in India, IPH is comparatively a rare disorder in Western countries. Middle-aged women are more prone to IPH in Japan. IPH usually suggests a benign prognosis, but sometimes is complicated with severe hemorrhage due to ruptured esophageal varices, or massive splenomegaly. It is mainly managed by supportive treatment such as endoscopic, radiological and/or surgical management for esophageal varices and/or splenomegaly. The definite etiology of IPH is still uncertain, but there are several theories on the potential pathogenesis of IPH. These theories include immunological disorders, infections, and genetic variants.
CATEGORY    Liver diseases
MARKER      The presense of a porto-caval venous pressure gradient > 5 mmHg
            Pancytopenia
COMMENT     Japanese study groups usually use the term of "IPH", whereas Indian researchers prefer to use the term non-cirrhotic portal fibrosis for the name of this disorder. Groups in Western countries have proposed terms such as nodular regenerative hyperplasia (NRH), hepatoportal sclerosis, or Idiopathic noncirrhotic portal hypertension.
DBLINKS     ICD-10: K76.6
            MeSH: C537903
REFERENCE   PMID:25343110 (marker)
  AUTHORS   Tanaka T, Sugawara Y, Kokudo N
  TITLE     The current clinical aspects of idiopathic portal hypertension.
  JOURNAL   Intractable Rare Dis Res 2:94-7 (2013)
REFERENCE   PMID:11928079
  AUTHORS   Okudaira M, Ohbu M, Okuda K
  TITLE     Idiopathic portal hypertension and its pathology.
  JOURNAL   Semin Liver Dis 22:59-72 (2002)
///
ENTRY       H01687                      Disease
NAME        Extrahepatic portal vein obstruction (EHPVO);
            Extrahepatic portal venous obstruction
DESCRIPTION Extrahepatic portal vein obstruction is a vascular disorder of liver characterized by obstruction and cavernomatous transformation of portal vein with or without the involvement of intrahepatic portal vein, splenic vein, or superior mesenteric vein. The most characteristic imaging manifestation is the formation of porto-portal collaterals that allow hepatopetal flow. Gradually there is organization and temporal evolution of thrombus with formation of portal collaterals termed "cavernoma" aiming to bypass the obstructed portal vein. Patients generally present in childhood with multiple episodes of variceal bleed and EHPVO is the predominant cause of paediatric portal hypertension (PHT) in developing countries.
CATEGORY    Liver diseases; Cardiovascular disease
COMMENT     See also H01686 Idiopathic portal hypertension
DBLINKS     ICD-10: I81
REFERENCE   PMID:27358683
  AUTHORS   Pargewar SS, Desai SN, Rajesh S, Singh VP, Arora A, Mukund A
  TITLE     Imaging and radiological interventions in extra-hepatic portal vein obstruction.
  JOURNAL   World J Radiol 8:556-70 (2016)
REFERENCE   PMID:26111208
  AUTHORS   Arora A, Sarin SK
  TITLE     Multimodality imaging of primary extrahepatic portal vein obstruction (EHPVO): what every radiologist should know.
  JOURNAL   Br J Radiol 88:20150008 (2015)
REFERENCE   PMID:26021771
  AUTHORS   Wani ZA, Bhat RA, Bhadoria AS, Maiwall R
  TITLE     Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification.
  JOURNAL   Saudi J Gastroenterol 21:129-38 (2015)
///
ENTRY       H01688                      Disease
NAME        Rapidly progressive glomerulonephritis (RPGN)
DESCRIPTION Rapidly progressive glomerulonephritis (RPGN) or crescentic glomerulonephritis is a life-threatening disease that destroys kidneys over a period of days to weeks. Proliferation of epithelial cells and infiltration of inflammatory cells lead to glomerular crescent formation and disruption of the specialized microvascular network in the glomerulus. This causes hematuria, albuminuria and loss of renal function. From an immunopathologic standpoint, primary RPGN is divided into pauci-immune GN (PIGN), anti-glomerular basement membrane antibody (anti-GBM) GN, and immune complex GN. PIGN, the most common etiology of primary RPGN, refers to a necrotizing glomerulonephritis with few or no immune deposits by immunofluorescence or electron microscopy. Approximately 90% of patients with PICG have circulating ANCA antibodies, leading to the systemic small vessel vasculitis such as granulomatosis with polyangiitis (GPA). Corticosteroids and cyclophosphamide are the first-line treatment, but infection is the most common cause of death of RPGN patients. Several new treatment strategies, such as leukocytaphereis (LCAP) and intravenous immunoglobulin (IVIg), have become available and these treatments have made it possible to treat high-risk RPGN patients without inducing serious immunosuppressive states.
CATEGORY    Kidney disease
MARKER      Proteinuria
            Hematuria
            Increased serum creatinine and CRP level
            Anti-GBM
            ANCAs
DRUG        Corticosteroids
            Cyclophosphamide [DR:D00287]
COMMENT     See also H01655 Wegener's granulomatosis
DBLINKS     ICD-10: N01.9
            MeSH: C538458
REFERENCE   PMID:26798468
  AUTHORS   Cheungpasitporn W, Zacharek CC, Fervenza FC, Cornell LD, Sethi S, Herrera Hernandez LP, Nasr SH, Alexander MP
  TITLE     Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis.
  JOURNAL   Clin Kidney J 9:97-101 (2016)
REFERENCE   PMID:21946538
  AUTHORS   Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL
  TITLE     Epidermal growth factor receptor promotes glomerular injury and renal failure in  rapidly progressive crescentic glomerulonephritis.
  JOURNAL   Nat Med 17:1242-50 (2011)
REFERENCE   PMID:26023554 (marker)
  AUTHORS   Mannan R, Singh PA, Misra V, Singh M, Mehrotra R, Tewarson SL, Gupta A, Manjari M
  TITLE     Comparative Changes Noted in Renal Biopsies on Light Microscopy of ANCA Positive  Vs ANCA Negative Serology.
  JOURNAL   J Clin Diagn Res 9:EC01-6 (2015)
REFERENCE   PMID:17096692 (drug)
  AUTHORS   Hotta O, Ishida A, Kimura T, Taguma Y
  TITLE     Improvements in treatment strategies for patients with antineutrophil cytoplasmic antibody-associated rapidly progressive glomerulonephritis.
  JOURNAL   Ther Apher Dial 10:390-5 (2006)
///
ENTRY       H01689                      Disease
NAME        Fisher syndrome;
            Miller Fisher syndrome
DESCRIPTION Fisher syndrome is a variant of the Guillain- Barre syndrome (GBS) and its classical clinical triad consists of ophthalmoplegia, ataxia, and areflexia. It is a relatively rare neurological disorder, accounting for approximately 5% of acute inflammatory polyneuropathies. This disease is an immune-mediated condition and specific anti-ganglioside antibodies, especially IgG anti-GQ1b antibodies, are found in over 80% of the patients. Campylobacter and Haemophilus influenzae have been reported as infectious agents prior to the onset of Fisher syndrome. It has been reported that the median period required for the disappearance of ataxia was about 1 month, without therapy.
CATEGORY    Nervous system disease
ENV_FACTOR  Influenza bacilli
            Campylobacter jejuni
MARKER      Anti-GQ1b antibody
COMMENT     See also H01436 Guillain-Barre syndrome
DBLINKS     ICD-10: G61.0
            MeSH: D019846
REFERENCE   PMID:27239355
  AUTHORS   Dagklis IE, Papagiannopoulos S, Theodoridou V, Kazis D, Argyropoulou O, Bostantjopoulou S
  TITLE     Miller-Fisher Syndrome: Are Anti-GAD Antibodies Implicated in Its Pathophysiology?
  JOURNAL   Case Rep Neurol Med 2016:3431849 (2016)
REFERENCE   PMID:21104459 (env_factor)
  AUTHORS   Mori M, Kuwabara S
  TITLE     Fisher syndrome.
  JOURNAL   Curr Treat Options Neurol 13:71-8 (2011)
///
ENTRY       H01690                      Disease
NAME        Lichen sclerosus et atrophphicus (LSA)
DESCRIPTION Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory dermatitis affecting primarily vulvar, perianal and perineal skin. Extragenital lichen sclerosus is most common on the neck, shoulders, and upper portion of the trunk. It is generally asymptomatic or is occasionally pruritic and presents as flat, white, polygonal papules and atrophic white plaques. It is primarily seen in postmenopausal women, but also men and children can be affected. The aetiology is not clearly established, although there is a strong association with autoimmune diseases. Morphoea may coexist with LSA. Standard treatment includes topical corticosteroid and calcineurin inhibitors, such as tacrolimus. The association between LSA and squamous cell carcinoma (SCC) is confirmed and has been described chiefly in females. The risk of SCC of the vulva has been estimated to about 5% in women with LSA.
CATEGORY    Skin and connective tissue disease
DRUG        Corticosteroids
            Tacrolimus [DR:D00107]
COMMENT     See also H01493 Localized Scleroderma.
DBLINKS     ICD-10: L90.0
            MeSH: D008011
            OMIM: 151590
REFERENCE   PMID:26500867
  AUTHORS   Diwan NG, Nair PA
  TITLE     Extragenital lichen sclerosus et atrophicus along the lines of Blaschko.
  JOURNAL   Indian Dermatol Online J 6:342-4 (2015)
REFERENCE   PMID:24470666
  AUTHORS   Kar BR, Dash K
  TITLE     Co-existence of Lichen Sclerosus et Atrophicus and Morphoea Along Lines of Blaschko.
  JOURNAL   Indian J Dermatol 59:77-9 (2014)
REFERENCE   PMID:24549239
  AUTHORS   Kantere D, Lowhagen GB, Alvengren G, Maneskold A, Gillstedt M, Tunback P
  TITLE     The clinical spectrum of lichen sclerosus in male patients - a retrospective study.
  JOURNAL   Acta Derm Venereol 94:542-6 (2014)
///
ENTRY       H01691                      Disease
NAME        Renal angiomyolipoma
DESCRIPTION Renal angiomyolipoma (AML) is one of the most common solid benign renal tumours,  composed of fat, smooth muscle, and blood vessels. About 80% of AMLs are sporadic and not associated with any genetic syndrome. Remaining cases are associated with tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis (LAM). The pathogenesis of TSC is thought to result from mutations in either the TSC1 or TSC2 genes that encode the proteins tuberin and hamartin, respectively. These proteins interact with each other to form heterodimers, whose most important role is inhibition of the mTOR pathway. Loss of inhibition of mTORC1 leads to increased activation of this pathway and the formation of the lesions characteristic of TSC. Sporadic renal AML usually have mutations in TSC2, but not TSC1.
CATEGORY    Kidney diseases
GENE        TSC1 (mutation) [HSA:7248] [KO:K07206]
            TSC2 (mutation) [HSA:7249] [KO:K07207]
DRUG        Everolimus [DR:D02714]
            Sirolimus [DR:D00753]
COMMENT     See also H00915 Tuberous sclerosis complex (TSC)
DBLINKS     ICD-10: D30.0
            MeSH: D018207
REFERENCE   PMID:26612197 (gene, drug)
  AUTHORS   Flum AS, Hamoui N, Said MA, Yang XJ, Casalino DD, McGuire BB, Perry KT, Nadler RB
  TITLE     Update on the Diagnosis and Management of Renal Angiomyolipoma.
  JOURNAL   J Urol 195:834-46 (2016)
REFERENCE   PMID:23194120
  AUTHORS   Lienert AR, Nicol D
  TITLE     Renal angiomyolipoma.
  JOURNAL   BJU Int 110 Suppl 4:25-7 (2012)
REFERENCE   PMID:26873836 (gene)
  AUTHORS   Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, Evans A, Pei Y, Sykes J, Jhaveri K, Jewett MA
  TITLE     Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs &gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy.
  JOURNAL   Eur Urol 70:85-90 (2016)
REFERENCE   PMID:24170533 (drug)
  AUTHORS   Coombs EJ
  TITLE     Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
  JOURNAL   J Am Assoc Nurse Pract 25:588-96 (2013)
REFERENCE   PMID:21949787 (gene)
  AUTHORS   Qin W, Bajaj V, Malinowska I, Lu X, MacConaill L, Wu CL, Kwiatkowski DJ
  TITLE     Angiomyolipoma have common mutations in TSC2 but no other common genetic events.
  JOURNAL   PLoS One 6:e24919 (2011)
///
ENTRY       H01692                      Disease
NAME        Subependymal giant cell astrocytoma (SEGA)
DESCRIPTION Subependymal giant cell astrocytoma (SEGA) is the most common central nervous system tumor in patients with tuberous sclerosis complex (TSC). Although these lesions are generally benign and non-infiltrative, they commonly arise in the region of the foramen of Monro, where they can cause obstructive hydrocephalus and sudden death. TSC is an autosomal dominant genetic disorder caused by inactivating mutations in either the TSC1 or TSC2 genes. These mutations lead to constitutive upregulation of the mammalian target of rapamycin (mTOR) pathway, which affects many cellular processes involved in tumor growth. Clinical studies have demonstrated that mTOR inhibitors can induce regression of SEGA in patients with TSC, providing a viable alternative to surgical removal.
CATEGORY    Nervous system diseases
GENE        TSC1 (mutation) [HSA:7248] [KO:K07206]
            TSC2 (mutation) [HSA:7249] [KO:K07207]
DRUG        Everolimus [DR:D02714]
            Sirolimus [DR:D00753]
COMMENT     See also H00915 Tuberous sclerosis complex (TSC)
DBLINKS     ICD-10: D43.2
            MeSH: D001254
REFERENCE   PMID:22562196 (gene, drug)
  AUTHORS   Beaumont TL, Limbrick DD, Smyth MD
  TITLE     Advances in the management of subependymal giant cell astrocytoma.
  JOURNAL   Childs Nerv Syst 28:963-8 (2012)
REFERENCE   PMID:21047224 (gene, drug)
  AUTHORS   Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN
  TITLE     Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
  JOURNAL   N Engl J Med 363:1801-11 (2010)
REFERENCE   PMID:24143074 (gene, drug)
  AUTHORS   Franz DN
  TITLE     Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.
  JOURNAL   Biologics 7:211-21 (2013)
REFERENCE   PMID:23391693 (gene, drug)
  AUTHORS   Jozwiak S, Nabbout R, Curatolo P
  TITLE     Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
  JOURNAL   Eur J Paediatr Neurol 17:348-52 (2013)
REFERENCE   PMID:25557360 (gene, drug)
  AUTHORS   Trelinska J, Dachowska I, Kotulska K, Baranska D, Fendler W, Jozwiak S, Mlynarski W
  TITLE     Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
  JOURNAL   Pediatr Blood Cancer 62:616-21 (2015)
///
ENTRY       H01693                      Disease
NAME        Eosinophilic fasciitis;
            Diffuse fasciitis
DESCRIPTION Eosinophilic fasciitis (EF) is a systemic inflammatory disease characterized by symmetrical swelling and skin induration of the arms and/or legs, evolving into a scleroderma-like appearance, accompanied by peripheral blood eosinophilia. The disease is present almost equally in both sexes. The etiology of EF remains uncertain. Hematological, infectious, and autoimmune diseases, as well as intense physical exertion, chemical compounds, drugs, solid neoplasms, and physical factors have been proposed as possible triggers and associated factors. Some researchers have proposed an aberrant immune response as the main pathogenetic mechanism. Some EF patients improve spontaneously without treatment, but in those who do not, glucocorticoids are the mainstay therapy. Methotrexate at low doses is probably the most favored second-line treatment, especially in patients with morphea-like skin lesions.
CATEGORY    Musculoskeletal disease; Skin and connective tissue disease
PATHOGEN    Borrelia burgdorferi [GN:bbu bbz bbn bbj bbur]
            Borrelia afzelii [GN:baf bafz bafh baft bafe]
            Mycoplasma arginini [GN:marg]
MARKER      Peripheral eosinophilia
            Hypergammaglobulinemia
            Elevated erythrocyte sedimentation rate (ESR)
DRUG        Glucocorticoids
            Methotrexate [DR:D00142]
COMMENT     See also H01493 Localized Scleroderma.
DBLINKS     ICD-10: M35.4
            MeSH: C562487
            OMIM: 226350
REFERENCE   PMID:24424187 (marker, drug)
  AUTHORS   Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM
  TITLE     Diagnosis and classification of eosinophilic fasciitis.
  JOURNAL   Autoimmun Rev 13:379-82 (2014)
REFERENCE   PMID:27407276
  AUTHORS   Oliveira M, Patinha F, Marinho A
  TITLE     Eosinophilic fasciitis after parasite infection.
  JOURNAL   Reumatologia 54:38-41 (2016)
///
ENTRY       H01694                      Disease
NAME        Stevens-Johnson syndrome and toxic epidermal necrolysis;
            Lyell's syndrome
DESCRIPTION Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe acute mucocutaneous diseases. The early stage of the disease is characterized by red-purple maculopapular eruptions. Then epidermal separation occurs and vesicles and bullae are formed. Inflammatory changes including purulent conjunctivitis, erosion, ulcer and crusts may be observed in the eye, mouth, nose, pharynx, esophagus, trachea, gastrointestinal tract, urinary tract and genital mucosae. Life-threatening bleeding and infections may be observed as a result of these changes. The rates of severe complications or sequelae secondary to SJS and TEN are higher in patients with mucosal and ophthalmic involvement. The SJS and TEN are considered the same disease process, and the distinction is made based on body surface area involvement. The SJS is characterized by less than 10% of the body surface area of epidermal detachment, and TEN by more than 30%. Various etiologic factors have been implicated as causes of SJS-TEN. These include infection, vaccination, drugs, systemic diseases, physical agents, and food. Drugs are the most commonly blamed. It has been reported that SJS-TEN is strongly associated with the specific variants of the human leukocyte antigen HLA-A and HLA-B genes. There is still no consensus on a definite treatment method for SJS-TEN. Systemic steroids and IVIG are used most frequently in medical treatment and treatment options including cyclosporine, plasmapheresis and hemodialysis are required more rarely.
CATEGORY    Skin and connective tissue disease
GENE        HLA-A (polymorphism) [HSA:3105] [KO:K06751]
            HLA-B (polymorphism) [HSA:3106] [KO:K06751]
ENV_FACTOR  Carbamazepine, Aminopenicillins, Cephalosporins, Macrolides, Tetracyclines, Quinolones
PATHOGEN    Mycoplasma spp.
            Herpes simplex virus
            Hepatitis C and B viruses
DRUG        Glucocorticoids
            Immunoglobulin [DR:D06458]
            Cyclosporine [DR:D00184]
COMMENT     Two genetic risk variants, HLA-B1502 and HLA-A3101, for Carbamazepine-induced hypersensitivity reactions have been identified.
DBLINKS     ICD-10: L51.1 L51.2
            MeSH: D013262
            OMIM: 608579
REFERENCE   PMID:15875523 (drug)
  AUTHORS   Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS
  TITLE     Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
  JOURNAL   Ann Allergy Asthma Immunol 94:419-36; quiz 436-8, 456 (2005)
REFERENCE   PMID:27738400
  AUTHORS   Cekic S, Canitez Y, Sapan N
  TITLE     Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience.
  JOURNAL   Turk Pediatri Ars 51:152-158 (2016)
REFERENCE   PMID:25097494 (env_factor, pathogen)
  AUTHORS   Maciejewska J, Jankowski M, Zegarska B, Czajkowski R
  TITLE     Stevens-Johnson syndrome/toxic epidermal necrolysis presumably induced by norfloxacin.
  JOURNAL   Postepy Dermatol Alergol 31:194-6 (2014)
REFERENCE   PMID:24597466 (gene)
  AUTHORS   Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC
  TITLE     Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
  JOURNAL   Epilepsia 55:496-506 (2014)
///
ENTRY       H01695                      Disease
NAME        Erythema multiforme
DESCRIPTION Erythema multiforme (EM) is an immune-mediated, mucocutaneous condition characterized by "target" lesions. Classically, EM has been separated into 2 subgroups, EM minor and EM major. In EM minor, lesions often present as papules, which might enlarge and eventually form the typical target lesion with erythema surrounding an area of central clearing. The rash in EM minor preferentially affects the limbs, specifically the extensor surfaces, however, it can also be seen throughout the body, excluding mucous membranes. EM major has mucous membrane involvement. The oral mucosa is most commonly affected, initially with edema that progresses to superficial erosions. Other surfaces that might be involved include the anogenital, ocular, and nasal mucosa. Although previously thought to be on a similar continuum of EM, and histologically appearing the same, Stevens-Johnson syndrome (SJS) is increasingly being considered a separate disease process. It is currently believed that EM is a result of an immune reaction to an inciting infectious or pharmacologic antigen. The most common infectious organisms in EM are herpes simplex virus types 1 and 2, as well as Mycoplasma pneumonia. The first line of treatment for EM is removal of the inciting factor when possible. Systemic steroids have been suggested as adjuvant therapy based on their immunosuppressant effects. To date, their use has been limited to EM major, as EM minor is self-limited.
CATEGORY    Skin and connective tissue disease
PATHOGEN    Herpes simplex virus types 1 and 2 [GN:T40073 T40074]
            Mycoplasma pneumoniae [GN:mpn mpm mpj]
DRUG        Glucocorticoids
COMMENT     See also H01694 Stevens-Johnson syndrome and Toxic epidermal necrolysis, H00365 Herpes simplex infection, and H00341 Mycoplasma pneumonia.
DBLINKS     ICD-10: L51.9
            MeSH: D004892
REFERENCE   PMID:23766045
  AUTHORS   Chan M, Goldman RD
  TITLE     Erythema multiforme in children: the steroid debate.
  JOURNAL   Can Fam Physician 59:635-6 (2013)
REFERENCE   PMID:26627523 (drug)
  AUTHORS   AlFar MY, AlRousan M, Almajali Z, Batarseh E, Alsaddi R
  TITLE     The use of corticosteroids in management of Herpes associated Erythema Multiforme.
  JOURNAL   J Pak Med Assoc 65:1351-3 (2015)
///
ENTRY       H01696                      Disease
NAME        Subacute sclerosing panencephalitis (SSPE)
DESCRIPTION Subacute sclerosing panencephalitis is a progressive, fatal neurologic disorder of childhood and early adolescence. It is caused by a persistent infection of the brain by an aberrant measles virus. Signs attributable to subacute sclerosing panencephalitis usually develop 4-8 years after the onset of measles infection. It is not precisely known how the measles virus remains dormant for so many years and why it becomes active again. More recent data indicate that it can follow acute measles infection in 1:10,000 cases. The incidence of SSPE is inversely related to measles vaccination coverage. In the developed world, the prevalence of SSPE has steadily declined since the introduction of the measles virus vaccine. The characteristic clinical manifestations of SSPE include behavioral abnormalities, cognitive decline, myoclonic jerks, seizures and abnormalities in vision. Clinical manifestations of SSPE usually start with subtle intellectual deterioration of the affected child causing deterioration in school performance. One of the most characteristic manifestations of SSPE is periodic myoclonic jerks that often leads to difficulty in walking and repeated falls. In the terminal stages of the disease, decerebrate and decorticate rigidity appear. Ultimately the patient becomes vegetative. Management of the disease includes seizure control and avoidance of secondary complications associated with the progressive disability. Treatment with interferon, ribavirin, and isoprinosine have reported beneficial results. However, there is no definitively effective treatment for SSPE.
CATEGORY    Infectious disease; Neurodegenerative disease
PATHOGEN    Measles virus [GN:T40033]
MARKER      Elevated cerebrospinal fluid measles antibody titres 
            Increased cerebrospinal fluid IgG
DRUG        Isoprinosine [DR:D01995]
            Interferon alfa [DR:D03305]
            Ribavirin [DR:D00423]
COMMENT     See also H00394 Measles.
DBLINKS     ICD-10: A81.1
            MeSH: D013344
            OMIM: 260470
REFERENCE   PMID:18846316
  AUTHORS   Garg RK
  TITLE     Subacute sclerosing panencephalitis.
  JOURNAL   J Neurol 255:1861-71 (2008)
REFERENCE   PMID:18279759
  AUTHORS   Sharma V, Gupta VB, Eisenhut M
  TITLE     Familial subacute sclerosing panencephalitis associated with short latency.
  JOURNAL   Pediatr Neurol 38:215-7 (2008)
REFERENCE   PMID:20561004 (drug, marker)
  AUTHORS   Gutierrez J, Issacson RS, Koppel BS
  TITLE     Subacute sclerosing panencephalitis: an update.
  JOURNAL   Dev Med Child Neurol 52:901-7 (2010)
REFERENCE   PMID:16752349
  AUTHORS   Teksam M, Cakir B, Agildere AM
  TITLE     Proton MR spectroscopy in the diagnosis of early-stage subacute sclerosing panencephalitis.
  JOURNAL   Diagn Interv Radiol 12:61-3 (2006)
///
ENTRY       H01697                      Disease
NAME        Antiphospholipid syndrome (APS)
DESCRIPTION Antiphospholipid syndrome (APS) is characterized by a variety of clinical and immunological manifestations. The clinical hallmarks of this syndrome are thrombosisand poor obstetric outcomes in the presence of antiphospholipid antibodies. APS can occur within the context of several diseases, mainly autoimmune disorders, and is then called secondary APS. About 40% of patients with systemic lupus erythematosus (SLE) have antiphospholipid antibodies, but less than 40% of them will eventually have thrombotic events. On the other hand, it may be also be present without any recognizable disease, or so-called primary APS. Pregnancy complications in APS, such as recurrent unexplained abortions, fetal loss, preeclampsia, and premature birth, have been attributed to placental thrombosis and infarcts, and management of these patients is based on attenuating the procoagulant state. Treatment with low-dose aspirin (LDA) and heparinoids has become a conventional option for pregnant women with APS. Possible future therapies for non-pregnant patients with antiphospholipid syndrome are statins, rituximab, and new anticoagulant drugs.
CATEGORY    Hematologic disease
MARKER      Lupus anticoagulant (LAC)
            Anticardiolipin antibodies (aCL)
            Anti-beta2 glycoprotein I antibodies (aB2GPI)
DRUG        Aspirin [DR:D00109]
            Heparin [DR:D04427]
COMMENT     See also H00080 Systemic lupus erythematosus
DBLINKS     ICD-10: D68.8
            MeSH: D016736
            OMIM: 107320
REFERENCE   PMID:20822807
  AUTHORS   Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA
  TITLE     Antiphospholipid syndrome.
  JOURNAL   Lancet 376:1498-509 (2010)
REFERENCE   PMID:26835148 (marker)
  AUTHORS   Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, Lockshin MD, Petri M, Merrill JT, Sammaritano LR, Kim MY, Salmon JE
  TITLE     Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.
  JOURNAL   Lupus Sci Med 3:e000131 (2016)
REFERENCE   PMID:27454295 (drug)
  AUTHORS   Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G
  TITLE     Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.
  JOURNAL   J Clin Invest 126:2933-40 (2016)
REFERENCE   PMID:14679358
  AUTHORS   Gezer S
  TITLE     Antiphospholipid syndrome.
  JOURNAL   Dis Mon 49:696-741 (2003)
///
ENTRY       H01698                      Disease
NAME        Giant cell arteritis;
            Temporal arteritis
DESCRIPTION Giant cell arteritis (GCA), also known as temporal arteritis, is a chronic and polygenic immune-mediated disease of unknown etiology. It is the most common form of vasculitis in individuals over the age of 50 in Western countries. It is characterized by inflammatory damage of the aorta and/or aortic branches, particularly the temporal artery, which can lead to severe complications such as blindness or cerebrovascular disorders. GCA is twice as common in women. It is frequently associated with polymyalgia rheumatica. Laboratory tests usually reveal high erythrocyte sedimentation rate (ESR), elevated levels of C-reactive protein (CRP) and other acute phase proteins, anemia of chronic disease, and thrombocytosis. Genetic association studies have described several genes that are associated with predisposition to GCA, including genes of immune-inflammatory pathways and genes of the HLA class I and II regions. The HLA-DRB1*04 alleles seem to be the most consistently associated genetic risk factors for GCA. Outside the HLA region, the most significant loci included PTPN22. Glucocorticoids are currently the mainstay of treatment for GCA but are associated with frequent adverse events. Tocilizumab, a humanised antihuman IL-6 receptor antibody, has been used successfully in several reports as a treatment of GCA.
CATEGORY    Immune system disease; Cardiovascular disease; Nervous system disease
GENE        HLA-DRB1 (polymorphism) [HSA:3123] [KO:K06752]
            PTPN22 (polymorphism) [HSA:26191] [KO:K18024]
MARKER      High erythrocyte sedimentation rate (ESR)
            Elevated levels of C-reactive protein (CRP)
DRUG        Glucocorticoids
            Tocilizumab [DR:D02596]
COMMENT     See also H01465 Large-vessel vasculitis (LVV).
DBLINKS     ICD-10: M31.6
            MeSH: D013700
            OMIM: 187360
REFERENCE   PMID:27708947 (marker)
  AUTHORS   Gracanin AG, Curic J, Loncarevic J, Morovic-Vergles J
  TITLE     Magnetic resonance imaging in the diagnosis and follow-up of giant cell arteritis: case report and review of literature.
  JOURNAL   Eur J Rheumatol 2:125-128 (2015)
REFERENCE   PMID:25817017 (gene)
  AUTHORS   Carmona FD, Mackie SL, Martin JE, Taylor JC, Vaglio A, Eyre S, Bossini-Castillo L, Castaneda S, Cid MC, Hernandez-Rodriguez J, Prieto-Gonzalez S, Solans R, Ramentol-Sintas M, Gonzalez-Escribano MF, Ortiz-Fernandez L, Morado IC, Narvaez J, Miranda-Filloy JA, Beretta L, Lunardi C, Cimmino MA, Gianfreda D, Santilli D, Ramirez GA, Soriano A, Muratore F, Pazzola G, Addimanda O, Wijmenga C, Witte T, Schirmer JH, Moosig F, Schonau V, Franke A, Palm O, Molberg O, Diamantopoulos AP, Carette S, Cuthbertson D, Forbess LJ, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland L, Monach PA, Pagnoux C, Seo P, Spiera R, Sreih AG, Warrington KJ, Ytterberg SR, Gregersen PK, Pease CT, Gough A, Green M, Hordon L, Jarrett S, Watts R, Levy S, Patel Y, Kamath S, Dasgupta B, Worthington J, Koeleman BP, de Bakker PI, Barrett JH, Salvarani C, Merkel PA, Gonzalez-Gay MA, Morgan AW, Martin J
  TITLE     A large-scale genetic analysis reveals a strong contribution of the HLA class II  region to giant cell arteritis susceptibility.
  JOURNAL   Am J Hum Genet 96:565-80 (2015)
REFERENCE   PMID:26819753 (drug)
  AUTHORS   Evans J, Steel L, Borg F, Dasgupta B
  TITLE     Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.
  JOURNAL   RMD Open 2:e000137 (2016)
///
ENTRY       H01699                      Disease
NAME        Isolated TSH deficiency
DESCRIPTION Isolated TSH deficiency is a rare autosomal recessive disease, that cause congenital hypothyroidism. Patients were found to have homozygous splice site mutation in the TSH beta subunit gene. They show symptoms of severe mental and growth retardation that can be prevented by early administration of exogenous thyroid hormone. Levothyroxine replacement therapy is the treatment of choice. Concomitant corticotropin deficiency should be excluded prior to starting therapy in order to avoid an adrenal crisis.
CATEGORY    Endocrine disease
GENE        TSHB [HSA:7252] [KO:K05251]
MARKER      Low basal serum free/total thyroxine (T4) with inappropriately normal or low TSH levels.
DRUG        Levothyroxine [DR:D01010]
COMMENT     See also H00250 Congenital nongoitrous hypothyroidism (CHNG).
DBLINKS     ICD-10: E23.0
            MeSH: C536917
            OMIM: 275100
REFERENCE   PMID:15292359 (gene)
  AUTHORS   Borck G, Topaloglu AK, Korsch E, Martine U, Wildhardt G, Onenli-Mungan N, Yuksel B, Aumann U, Koch G, Ozer G, Pfaffle R, Scherberg NH, Refetoff S, Pohlenz J
  TITLE     Four new cases of congenital secondary hypothyroidism due to a splice site mutation in the thyrotropin-beta gene: phenotypic variability and founder effect.
  JOURNAL   J Clin Endocrinol Metab 89:4136-41 (2004)
REFERENCE   PMID:1971148 (gene)
  AUTHORS   Dacou-Voutetakis C, Feltquate DM, Drakopoulou M, Kourides IA, Dracopoli NC
  TITLE     Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating  hormone beta-subunit gene.
  JOURNAL   Am J Hum Genet 46:988-93 (1990)
REFERENCE   PMID:17077946 (drug, marker)
  AUTHORS   Ascoli P, Cavagnini F
  TITLE     Hypopituitarism.
  JOURNAL   Pituitary 9:335-42 (2006)
///
ENTRY       H01700                      Disease
NAME        Hypopituitarism
DESCRIPTION Hypopituitarism is a chronic endocrine illness, and is the partial or complete insufficiency of anterior pituitary hormone secretion. Anterior pituitary is composed of five cell types that secrete growth hormone (GH), prolactin (PRL), follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thyroid stimulating hormone (TSH) and corticotropin hormone (ACTH). Clinical manifestations of hypopituitarism are variable, often insidious in onset and dependent on the degree and severity of hormone deficiency. However, it is associated with increased mortality and morbidity. A variety of diseases may cause hypopituitarism and, accordingly, this disorder can be divided into two types depending on its cause. Primary hypopituitarism is caused by disorders of the pituitary gland itself and may be due to the loss, damage, or dysfunction of pituitary hormone-secreting cells. On the other hand, secondary hypopituitarism is the result of diseases of the hypothalamus or pituitary stalk interrupting the nerve or vascular connections to the pituitary gland, thereby reducing the secretion of the pituitary hormones. Hypopituitarism can be easily diagnosed by measuring basal pituitary and target hormone levels. MR imaging of the hypothalamo-pituitary region may provide essential information. The most common causes of primary hypopituitarism are pituitary adenoma and complications from surgery or radiation therapy for the treatment of pituitary adenoma. In rare cases, hypopituitarism has been observed when the infection occurs. Sheehan's syndrome is hypopituitarism caused by the postpartum hemorrhage of the pituitary gland. In still rarer cases, solitary or complicated pituitary hormone deficiency syndromes may occur due to genetic causes and typically affect children. The treatment of hypopituitarism typically involves a replacement of the deficient hormone but care must be taken because several studies have reported an increased incidence of cardiovascular disorders and number of deaths among these patients.
CATEGORY    Endocrine disease
GENE        POU1F1 [HSA:5449] [KO:K09363]
            PROP1 [HSA:5626] [KO:K09327]
            HESX1 [HSA:8820] [KO:K09354]
            LHX3 [HSA:8022] [KO:K09374]
            LHX4 [HSA:89884] [KO:K09374]
            PITX2 [HSA:5308] [KO:K04686]
            GH1 [HSA:2688] [KO:K05438]
            GHRH [HSA:2691] [KO:K05260]
            KAL [HSA:3730]
            GnRH receptor [HSA:2798] [KO:K04280]
            DAX1/AHC [HSA:190] [KO:K08562]
            TBX19 [HSA:9095] [KO:K10184]
            LH-beta [HSA:3972] [KO:K08521]
            TSH-beta [HSA:7252] [KO:K05251]
            TRH receptor [HSA:7201] [KO:K04282]
PATHOGEN    Human cytomegalovirus [GN:T40080]
DRUG        Hydrocortisone [DR:D00088] (ACTH deficiency)
            Somatropin [DR:D02691] (GH deficiency)
            Testosterone enanthate [DR:D04454] Estrogens [DR:D04070] Progesterone [DR:D00066] (LH/FSH deficiency)
COMMENT     See also H00254 Pituitary Dwarfism (PD), H00255 Hypogonadotropic hypogonadism, H01011 Adrenocorticotropic hormone deficiency, H01253 Isolated follicle-stimulating hormone deficiency (IFSHD), and H01699 Isolated TSH deficiency.
DBLINKS     ICD-10: E23.0
            MeSH: D007018
            OMIM: 613038
REFERENCE   PMID:17077946
  AUTHORS   Ascoli P, Cavagnini F
  TITLE     Hypopituitarism.
  JOURNAL   Pituitary 9:335-42 (2006)
REFERENCE   PMID:15519252 (gene)
  AUTHORS   Reynaud R, Saveanu A, Barlier A, Enjalbert A, Brue T
  TITLE     Pituitary hormone deficiencies due to transcription factor gene alterations.
  JOURNAL   Growth Horm IGF Res 14:442-8 (2004)
REFERENCE   PMID:18174732 (gene)
  AUTHORS   Kelberman D, Dattani MT
  TITLE     Hypopituitarism oddities: congenital causes.
  JOURNAL   Horm Res 68 Suppl 5:138-44 (2007)
REFERENCE   PMID:26790380 (drug)
  AUTHORS   Kim SY
  TITLE     Diagnosis and Treatment of Hypopituitarism.
  JOURNAL   Endocrinol Metab (Seoul) 30:443-55 (2015)
REFERENCE   PMID:21897892 (drug)
  AUTHORS   Brar KS, Garg MK, Suryanarayana KM
  TITLE     Adult hypopituitarism: Are we missing or is it clinical lethargy?
  JOURNAL   Indian J Endocrinol Metab 15:170-4 (2011)
///
ENTRY       H01701                      Disease
NAME        Pituitary TSH hypersecretion;
            Syndrome of inappropriate secretion of TSH (SITSH)
DESCRIPTION Pituitary TSH hypersecretion is disease of the anterior portion of the pituitary resulting in hypersecretion of thyroid stimulating hormone (TSH). It includes two forms of central hyperthyroidism, i.e. TSH-secreting pituitary adenoma (TSHoma) and resistance to thyroid hormone action (RTH). The incidence of hyperthyroidism due to a TSHoma is extremely low, 1-2% of all cases of hyperthyroidism. Most of the tumors are macroadenomas usually presenting with symptoms such as headache and/or visual field impairment while the symptoms of hyperthyroidism seem to be milder compared with those caused by primary hyperthyroidism. First-line treatment of TSHoma is pituitary adenomectomy followed by irradiation in the case of surgical failure. However, medical treatment with somatostatin analogs, such as octreotide and lanreotide, are effective in reducing TSH secretion.
CATEGORY    Endocrine disease
MARKER      High levels of circulating free thyroid hormones (FT4 and FT3)
            Normal or elevated TSH levels
DRUG        Octreotide [DR:D02250]
            Lanreotide [DR:D04666]
COMMENT     See also H00249 Thyroid hormone resistance syndrome, H01102 Pituitary adenomas, and H01645 Hyperthyroidism.
DBLINKS     ICD-10: E22.9
            MeSH: D006964
REFERENCE   PMID:25905212
  AUTHORS   Beck-Peccoz P, Persani L, Lania A
  TITLE     Thyrotropin-Secreting Pituitary Adenomas
  JOURNAL   (2000)
REFERENCE   PMID:23402621
  AUTHORS   Tong A, Xia W, Qi F, Jin Z, Yang D, Zhang Z, Li F, Xing X, Lian X
  TITLE     Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature.
  JOURNAL   Thyroid 23:1172-7 (2013)
REFERENCE   PMID:26765410 (drug)
  AUTHORS   Mousiolis AC, Rapti E, Grammatiki M, Yavropoulou M, Efstathiou M, Foroglou N, Daniilidis M, Kotsa K
  TITLE     Somatostatin Analogue Treatment of a TSH-Secreting Adenoma Presenting With Accelerated Bone Metabolism and a Pericardial Effusion: A Case Report.
  JOURNAL   Medicine (Baltimore) 95:e2358 (2016)
REFERENCE   PMID:24783044 (drug, marker)
  AUTHORS   Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL
  TITLE     2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.
  JOURNAL   Eur Thyroid J 2:76-82 (2013)
///
ENTRY       H01702                      Disease
NAME        Glucocorticoid resistance
DESCRIPTION Glucocorticoid resistance is a rare syndrome characterized by decreased sensitivity to cortisol, increased secretion of cortisol, resistance to adrenal suppression by dexamethasone and the absence of the clinical stigmata of Cushing's syndrome. The clinical symptom of glucocorticoid resistance is variable. Phenotypes commonly include hypoglycemia, hypertension, and metabolic alkalosis. Mutations in the the glucocorticoid receptor (GR) gene NR3C1 have been reported.
CATEGORY    Endocrine disease
GENE        NR3C1 [HSA:2908] [KO:K05771]
COMMENT     See also H01431 Cushing's syndrome.
DBLINKS     ICD-10:E25.8
            MeSH: C564221
            OMIM: 615962
REFERENCE   PMID:15265781
  AUTHORS   Charmandari E, Kino T, Chrousos GP
  TITLE     Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms.
  JOURNAL   Ann N Y Acad Sci 1024:168-81 (2004)
REFERENCE   PMID:12754700 (gene)
  AUTHORS   Bray PJ, Cotton RG
  TITLE     Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms.
  JOURNAL   Hum Mutat 21:557-68 (2003)
REFERENCE   PMID:23076843 (gene)
  AUTHORS   Donner KM, Hiltunen TP, Janne OA, Sane T, Kontula K
  TITLE     Generalized glucocorticoid resistance caused by a novel two-nucleotide deletion in the hormone-binding domain of the glucocorticoid receptor gene NR3C1.
  JOURNAL   Eur J Endocrinol 168:K9-K18 (2013)
///
ENTRY       H01703                      Disease
NAME        Eating Disorders, including:
            Anorexia nervosa;
            Bulimia nervosa;
            Binge eating disorder
DESCRIPTION Eating disorders, which include anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), are disorders defined by disturbances in eating behavior. Anorexia nervosa (AN) is the oldest recognized eating disorder. The salient features of this eating disorder are a relentless pursuit of thinness, accompanied by a fear of becoming fat despite being markedly underweight. In women, anorexia nervosa is associated with global endocrine dysregulation, including hypothalamic-pituitary axis dysfunction and alterations in adipokine and appetite regulating hormone levels. Bulimia nervosa (BN) is defined by eating behaviors that include episodes of binge eating which are followed by recurrent self-induced vomiting performed in an attempt to avoid weight gain from the caloric overload. Binge eating disorder (BED) is currently characterized by recurrent episodes of binge eating occurring at least twice a week for 6 months or longer. In contrast to bulimia nervosa, there are no inappropriate compensatory behaviors such as vomiting. Eating disorders frequently develop during adolescence or early adulthood, but some studies have reported their onset during childhood or later in adulthood. There is growing evidence supporting a multifactorial etiology that includes genetic, neurochemical, and physiological components for eating disorders above and beyond the more conventional theories based on psychological and sociocultural factors. Brain-derived neurotrophic factor (BDNF) plays a critical role in regulating nerves in the brain. Recent studies have provided evidence that BDNF also plays a role in regulating eating behaviors. In addition, an association between the BDNF gene polymorphism and eating disorders has been demonstrated. Other genetic risk factors for eating disorders has also been reported.
CATEGORY    Mental and behavioural disorders; Endocrine disease
GENE        BDNF (polymorphism) [HSA:627] [KO:K04355]
            AGRP (polymorphism) [HSA:181] [KO:K05231]
            GHRL (polymorphism) [HSA:51738] [KO:K05254]
            OPRD1 (polymorphism) [HSA:4985] [KO:K04213]
            HTR1D (polymorphism) [HSA:3352] [KO:K04153]
MARKER      Suppressed serum levels of sodium, oxytocin, oestrogen, androgen, and leptin.
            Elevated serum levels of cortisol, ghrelin, and peptide YY.
DBLINKS     ICD-10: F50
            MeSH: D001068
            OMIM: 606788 610269
REFERENCE   PMID:23348361
  AUTHORS   Heaner MK, Walsh BT
  TITLE     A history of the identification of the characteristic eating disturbances of Bulimia Nervosa, Binge Eating Disorder and Anorexia Nervosa.
  JOURNAL   Appetite 65:185-8 (2013)
REFERENCE   PMID:27811940 (marker)
  AUTHORS   Schorr M, Miller KK
  TITLE     The endocrine manifestations of anorexia nervosa: mechanisms and management.
  JOURNAL   Nat Rev Endocrinol (2016)
REFERENCE   PMID:12888803 (gene)
  AUTHORS   Ribases M, Gratacos M, Armengol L, de Cid R, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez F, Estivill X
  TITLE     Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type.
  JOURNAL   Mol Psychiatry 8:745-51 (2003)
REFERENCE   PMID:22960103 (gene)
  AUTHORS   Atalayer D, Gibson C, Konopacka A, Geliebter A
  TITLE     Ghrelin and eating disorders.
  JOURNAL   Prog Neuropsychopharmacol Biol Psychiatry 40:70-82 (2013)
REFERENCE   PMID:24831852 (gene)
  AUTHORS   Yilmaz Z, Kaplan AS, Tiwari AK, Levitan RD, Piran S, Bergen AW, Kaye WH, Hakonarson H, Wang K, Berrettini WH, Brandt HA, Bulik CM, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson CL, Keel PK, Klump KL, Magistretti P, Mitchell JE, Strober M, Thornton LM, Treasure J, Woodside DB, Knight J, Kennedy JL
  TITLE     The role of leptin, melanocortin, and neurotrophin system genes on body weight in anorexia nervosa and bulimia nervosa.
  JOURNAL   J Psychiatr Res 55:77-86 (2014)
REFERENCE   PMID:15389773 (gene)
  AUTHORS   Koronyo-Hamaoui M, Gak E, Stein D, Frisch A, Danziger Y, Leor S, Michaelovsky E, Laufer N, Carel C, Fennig S, Mimouni M, Apter A, Goldman B, Barkai G, Weizman A
  TITLE     CAG repeat polymorphism within the KCNN3 gene is a significant contributor to susceptibility to anorexia nervosa: a case-control study of female patients and several ethnic groups in the Israeli Jewish population.
  JOURNAL   Am J Med Genet B Neuropsychiatr Genet 131B:76-80 (2004)
REFERENCE   PMID:12740597 (gene)
  AUTHORS   Bergen AW, van den Bree MB, Yeager M, Welch R, Ganjei JK, Haque K, Bacanu S, Berrettini WH, Grice DE, Goldman D, Bulik CM, Klump K, Fichter M, Halmi K, Kaplan A, Strober M, Treasure J, Woodside B, Kaye WH
  TITLE     Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D  and delta opioid receptor loci exhibit significant association to anorexia nervosa.
  JOURNAL   Mol Psychiatry 8:397-406 (2003)
///
ENTRY       H01704                      Disease
NAME        Sudden sensorineural hearing loss
DESCRIPTION Sudden sensorineural hearing loss (SNHL) is commonly defined as hearing loss of more than 30 dB, affecting three or more frequencies, arising over less than 3 days. The predominant form of sudden SNHL is unilateral in location, and the main aetiology is idiopathic. As the majority of patients (30-65 %) with unilateral sudden SNHL report spontaneous recovery within 2 weeks, unilateral disease is mostly regarded as a benign condition. Prognosis for recovery is dependent on a number of factors, including patient age, presence of vertigo at onset, degree of hearing loss, and time between onset of hearing loss and treatment. The pathology of sudden SNHL remains unclear. However, a series of factors, including viral infections, microcirculatory disorders, autoimmune disorders, and labyrinthine hemorrhage, have been proposed as causative factors. Different treatment regimens like antioxidants, corticosteroids, vasodilatators, hyperbaric oxygen (HBO), or carbogen therapy have been described. Among these approaches, steroid treatment is the most common.
CATEGORY    Nervous system disease
DRUG        Corticosteroid
DBLINKS     ICD-10: H91.2
            MeSH: D003639
REFERENCE   PMID:27460341
  AUTHORS   Ergun Tasdoven G, Derin AT, Yaprak N, Ozcaglar HU
  TITLE     The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss.
  JOURNAL   Braz J Otorhinolaryngol (2016)
REFERENCE   PMID:27014454 (drug)
  AUTHORS   Lamm H, Muller-Kortkamp C, Warnecke A, Pohl F, Paasche G, Lenarz T, Stolle SR
  TITLE     Concurrent hyperbaric oxygen therapy and intratympanic steroid application as salvage therapy after severe sudden sensorineural hearing loss.
  JOURNAL   Clin Case Rep 4:287-93 (2016)
REFERENCE   PMID:26568939
  AUTHORS   Arjun D, Neha G, Surinder K S, Ravi K
  TITLE     Sudden Sensorineural Hearing Loss; Prognostic Factors.
  JOURNAL   Iran J Otorhinolaryngol 27:355-9 (2015)
REFERENCE   PMID:27064040
  AUTHORS   Li FJ, Wang DY, Wang HY, Wang L, Yang FB, Lan L, Guan J, Yin ZF, Rosenhall U, Yu L, Hellstrom S, Xue XJ, Duan ML, Wang QJ
  TITLE     Clinical Study on 136 Children with Sudden Sensorineural Hearing Loss.
  JOURNAL   Chin Med J (Engl) 129:946-52 (2016)
///
ENTRY       H01705                      Disease
NAME        Bilateral sudden sensorineural hearing loss
DESCRIPTION Bilateral sudden sensorineural hearing loss (SNHL) represents a rare disease entity, constituting less than 5 % of all sudden SNHL cases. Unlike unilateral disease, bilateral sudden SNHL appears to be mostly related to serious systemic pathology, and is associated with a more severe degree of hearing loss, poorer prognosis following treatment, and more significant impairment in morbidity and overall quality of life.
CATEGORY    Nervous system disease
GENE        ACTG1 [HSA:71] [KO:K05692]
            CDH23 [HSA:64072] [KO:K06813]
            COCH [HSA:1690]
            KCNQ4 [HSA:9132] [KO:K04929]
            TECTA [HSA:7007] [KO:K18273]
            TMPRSS3 [HSA:64699] [KO:K09634]
            WFS1 [HSA:7466] [KO:K14020]
COMMENT     See also H01704 Sudden sensorineural hearing loss, H00604 Deafness, autosomal dominant, and H00605  Deafness, autosomal recessive.
DBLINKS     ICD-10: H90.3 H91.2
            MeSH: D006312
            OMIM: 604717 601386 601369 600101 601543 603629 601072 600965
REFERENCE   PMID:24331736
  AUTHORS   Sara SA, Teh BM, Friedland P
  TITLE     Bilateral sudden sensorineural hearing loss: review.
  JOURNAL   J Laryngol Otol 128 Suppl 1:S8-15 (2014)
REFERENCE   PMID:26944135
  AUTHORS   Chen YH, Young YH
  TITLE     Bilateral simultaneous sudden sensorineural hearing loss.
  JOURNAL   J Neurol Sci 362:139-43 (2016)
REFERENCE   PMID:20301607 (gene)
  AUTHORS   Smith RJH, Shearer AE, Hildebrand MS, Van Camp G
  TITLE     Deafness and Hereditary Hearing Loss Overview
  JOURNAL   (1993)
///
ENTRY       H01706                      Disease
NAME        Delayed endolymphatic hydrops
DESCRIPTION Delayed endolymphatic hydrops (DEH) is a disorder, characterized by episodic vertigo that develops some time after the onset of a profound, typically unilateral sensorineural hearing loss. DEH can be differentiated from Meniere's disease. The age of onset of symptoms is typically in later childhood and adolescence or between 40 and 60 years of age. DEH probably is caused by atrophy or fibrous obliteration of the endolymphatic resorptive system of the membranous labyrinth. It has been reported that genetic factors may sometimes be the cause of this disease. Two types of DEH exist: the ipsilateral type, in which the ear with profound hearing loss suffers progressive endolymphatic hydrops, and the contralateral type, in which the formation of progressive endolymphatic hydrops takes place in the ear opposite to the previously deafened ear. DEH requires conservative treatment, such as that typically used for Meniere's disease, including the appropriate concomitant use of diuretics, such as isosorbide or steroids for at least 3-6 months. When recurrent episodic vertigo cannot be remedied through conservative treatment, labyrinthectomy and vestibular neurectomy on the deaf ear are curative for ipsilateral DEH. However, no such surgical treatment is available for the contralateral type.
CATEGORY    Nervous system disease
DRUG        Corticosteroid
            Isosorbide [DR:D00347]
COMMENT     See also H01495 Meniere disease.
DBLINKS     ICD-10: H81.0
            MeSH: D018159
            OMIM: 612097
REFERENCE   PMID:17497713
  AUTHORS   Dodson KM, Kamei T, Sismanis A, Nance WE
  TITLE     Familial unilateral deafness and delayed endolymphatic hydrops.
  JOURNAL   Am J Med Genet A 143A:1661-5 (2007)
REFERENCE   PMID:15732511 (drug)
  AUTHORS   Kamei T
  TITLE     Delayed endolymphatic hydrops as a clinical entity.
  JOURNAL   Int Tinnitus J 10:137-43 (2004)
///
ENTRY       H01707                      Disease
NAME        Ossified ligamentum flavum;
            Ossification of the yellow ligament
DESCRIPTION Ossified ligamentum flavum (OLF) is a condition of heterotopic lamellar bone formation within the yellow ligament. OLF is a widely described pathology in eastern Asia and rare in other parts of the world. The disease process first causes hypertrophy of the ligamentum flavum and subsequent ossification, which narrows the spinal canal and leads to myeloradiculopathy. The lower thoracic spine is most commonly affected. Previous hyperkyphosis and mechanical stress are thought to be predisposing conditions. It is tempting to think that OLF is genetically or pathologically inherited based on abnormalities of calcium or phosphate metabolism, on endocrinologic abnormalities, or on the presence of autoimmune disease. Such relationships, however, have not been documented. Treatment of cervical stenosis related to OLF is based on the standard principle of managing neural spinal abnormalities. Acute episodes of pain and onset of or increase in neurological deficits are treated with rest, external spinal immobilization with a collar or brace, and analgesics, anti-inflammatory, and/or antispasmodic medicines. Surgery is indicated for patients with acute or chronic progression of neurological deficits or persistent neurological deficits.
CATEGORY    Skeletal dysplasia
COMMENT     See also H00431 Ossification of the posterior longitudinal ligament of spine.
DBLINKS     ICD-10: M48.8
            MeSH: D017887
REFERENCE   PMID:21600492
  AUTHORS   Sonntag VK
  TITLE     Ossification of the ligamentum flavum (OLF): an increasing cause of cervical myelopathy.
  JOURNAL   World Neurosurg 75:445-6 (2011)
REFERENCE   PMID:26885431
  AUTHORS   Burke SM, Hwang SW, Safain MG, Riesenburger RI
  TITLE     Iatrogenic Spinal Cord Injury during Removal of the Inferior Articular Process in the Presence of Ossification of the Ligamentum Flavum.
  JOURNAL   Case Rep Surg 2016:2318759 (2016)
REFERENCE   PMID:24083054
  AUTHORS   Toledo JA, Isseldyk FV, Re M, Garrote M
  TITLE     Ossification of the ligamentum flavum as cause of thoracic cord compression: Case report of a Latin American man and review of the literature.
  JOURNAL   Surg Neurol Int 4:119 (2013)
///
ENTRY       H01708                      Disease
NAME        Diffuse idiopathic skeletal hyperostosis;
            Forestier disease;
            Ankylosing hyperostosis;
            Ossification of the anterior longitudinal ligament
DESCRIPTION Diffuse idiopathic skeletal hyperostosis (DISH), also known as Forestier disease, is a systemic noninflammatory disease characterized by ossification of the entheses. It affects mainly elderly men, and involves the ossification of the anterior longitudinal ligament (OALL). Although it is asymptomatic in some occasions, the disease may produce dysphagia, dysphonia, and exceptionally breathing difficulties due to airway compromise. In these cases, early surgery is recommended to alleviate airway obstruction. Although the hallmark of the DISH is considered to be the anterolateral aspect of the thoracic spine, various signs and symptoms is not limited to the spine and has often been reported to involve multiple peripheral locations as well. While the cause of DISH remains unclear, mechanical factors, genetic factors, environmental factors, drugs, and metabolic conditions have been hypothesized to be relevant. Most of the current theories focus on the pathologic OALL. There's no cure for DISH. Therapy for DISH is based on symptomatic and empiric treatment. In general, physical therapy, analgesics, antiinflammatory drugs, and muscle relaxants have been successful in managing the majority of patients with DISH.
CATEGORY    Skeletal dysplasia
ENV_FACTOR  Vitamin A derivatives
COMMENT     OPLL, OALL, and DISH may coexist.
            See also H00431 Ossification of the posterior longitudinal ligament of spine (OPLL).
DBLINKS     ICD-10: M48.1
            MeSH: D004057
            OMIM: 106400
REFERENCE   PMID:24843807
  AUTHORS   Nascimento FA, Gatto LA, Lages RO, Neto HM, Demartini Z, Koppe GL
  TITLE     Diffuse idiopathic skeletal hyperostosis: A review.
  JOURNAL   Surg Neurol Int 5:S122-5 (2014)
REFERENCE   PMID:19091295
  AUTHORS   Caminos CB, Cenoz IZ, Louis CJ, Otano TB, Esain BF, Perez de Ciriza MT
  TITLE     Forestier disease: an unusual cause of upper airway obstruction.
  JOURNAL   Am J Emerg Med 26:1072.e1-3 (2008)
///
ENTRY       H01709                      Disease
NAME        Glucocorticoid-induced osteonecrosis
DESCRIPTION Glucocorticoid-induced osteonecrosis is a common and severe adverse event. Glucocorticoid use is one of the most important causes of osteonecrosis. In patients receiving long-term therapy, glucocorticoids induce fractures in 30 to 50% and osteonecrosis in 9 to 40%. The pathogenesis of glucocorticoid-induced osteonecrosis is not fully understood but postulated mechanisms include hyperlipidemia, fat emboli and intravascular coagulation that reduce the supply of blood to the bones. Since not all patients who are treated with steroids develop osteonecrosis, the presence of additional risk factors or individual variation of glucocorticoids sensitivity has been suggested. The risks of this disease include advancing age, prolonged duration of treatment, increased daily dosage and cumulative dose, low body mass index, underlying disease, and polymorphisms in the glucocorticoid receptor. Bisphosphonates are first-line options for glucocorticoid-induced osteoporosis and may also be useful in glucocorticoid-induced osteonecrosis. It has been indicated that bisphosphonates may rapidly reduce pain, and delay joint collapse in patients with osteonecrosis.
CATEGORY    Skeletal dysplasia
GENE        HSD11B2 (polymorphism) [HSA:3291] [KO:K00071]
            VEGF (polymorphism) [HSA:7422] [KO:K05448]
            COL2A1 (polymorphism) [HSA:1280] [KO:K19719]
            NR3C1 (polymorphism) [HSA:2908] [KO:K05771]
            SERPINE1 (polymorphism) [HSA:5054] [KO:K03982]
            ABCB1 (polymorphism) [HSA:5243] [KO:K05658]
ENV_FACTOR  Glucocorticoid
DRUG        Alendronate [DR:D00939]
            Zoledronic acid [DR:D01968]
            Teriparatide [DR:D06078]
            Denosumab [DR:D03684]
COMMENT     See also H01529 Avascular necrosis of femoral head.
DBLINKS     ICD-10: M87.1
            MeSH: D005271
REFERENCE   PMID:21732837
  AUTHORS   Weinstein RS
  TITLE     Clinical practice. Glucocorticoid-induced bone disease.
  JOURNAL   N Engl J Med 365:62-70 (2011)
REFERENCE   PMID:22169965 (gene)
  AUTHORS   Weinstein RS
  TITLE     Glucocorticoid-induced osteonecrosis.
  JOURNAL   Endocrine 41:183-90 (2012)
REFERENCE   PMID:23357434 (gene)
  AUTHORS   Gong LL, Fang LH, Wang HY, Peng JH, Si K, Zhu J, Han FF, Wang YH, Du GH, Pei LX, Liu LH
  TITLE     Genetic risk factors for glucocorticoid-induced osteonecrosis: a meta-analysis.
  JOURNAL   Steroids 78:401-8 (2013)
REFERENCE   PMID:22877431 (drug)
  AUTHORS   Weinstein RS
  TITLE     Glucocorticoid-induced osteoporosis and osteonecrosis.
  JOURNAL   Endocrinol Metab Clin North Am 41:595-611 (2012)
///
ENTRY       H01710                      Disease
NAME        Mixed connective tissue disease
DESCRIPTION Mixed connective tissue disease (MCTD) is a rare autoimmune disease characterized by a combination of clinical features of systemic lupus erythematosus, systemic sclerosis, and polymyositis with elevated antibodies to U1 small nuclear ribonucleoprotein (U1-RNP). The most common clinical manifestations of this disease are Raynaud's phenomenon, arthralgias, swollen joints, esophageal dysfunction, muscle weakness and fingers sausage-like appearance. The disease can be serious with development of pulmonary, kidney, cardiovascular, gastrointestinal, and central nervous system manifestations. The worst prognosis and high mortality are associated with the presence of pulmonary disease. Therapy should be individualised for each patient to address the specific organs involved and the severity of underlying disease activity. Inflammatory manifestations usually respond to steroid treatment, whereas clinical sclerodermatous manifestations such as sclerodactyly, and pulmonary interstitial disease more often require cytotoxic immunosuppressive treatment.
CATEGORY    Immune system disease
MARKER      Elevated antibodies to U1-RNP
DRUG        Corticosteroids
            Cyclophosphamide [DR:D00287]
COMMENT     See also H00080 Systemic lupus erythematosus, H01492 Systemic sclerosis, and H01604 Polymyositis and dermatomyositis.
DBLINKS     ICD-10: M35.1
            MeSH: D008947
REFERENCE   PMID:27421219
  AUTHORS   Gunnarsson R, Hetlevik SO, Lilleby V, Molberg O
  TITLE     Mixed connective tissue disease.
  JOURNAL   Best Pract Res Clin Rheumatol 30:95-111 (2016)
REFERENCE   PMID:27238624 (drug)
  AUTHORS   Sato S, Yashiro M, Matsuoka N, Uematsu M, Asano T, Kobayashi H, Watanabe H, Ohira H
  TITLE     Successful Immunosuppressive Treatment of Mixed Connective Tissue Disease Complicated by Microscopic Polyangiitis.
  JOURNAL   Tohoku J Exp Med 239:111-6 (2016)
REFERENCE   PMID:22424193 (drug)
  AUTHORS   Ortega-Hernandez OD, Shoenfeld Y
  TITLE     Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment.
  JOURNAL   Best Pract Res Clin Rheumatol 26:61-72 (2012)
///
ENTRY       H01711                      Disease
NAME        Spinal stenosis
DESCRIPTION Spinal stenosis is an abnormal narrowing of the spinal canal that mainly occurs in the cervical and lumbar regions. Cervical stenosis presents with axial neck pain, radiculopathy, myelopathy, or a combination of these presentations. Axial pain refers to pain that occurs along the spinal column, while radiculopathy refers to complaints in a dermatomal or myotomal distribution often occurring in the arms. Patients may complain of numbness, pain or loss of function. Myelopathy refers to a cluster of complaints and findings due to intrinsic damage to the spinal cord itself. Patients might report numbness, coordination and gait issues, grip weakness and bowel and bladder complaint. Lumbar spinal stenosis is a major cause of pain and functional disability for the elderly. Neurogenic claudication symptoms are a hallmark of lumbar spinal stenosis, where patients develop low back or leg pain when walking or standing that is relieved by sitting or lumbar flexion. The treatment of lumbar spinal stenosis generally begins with conservative management such as physical therapy, home exercise programs, and oral analgesics. Once these therapies fail, patients commonly move forward with interventional pain treatment options such as epidural steroid injections (ESIs), nerve block, or surgery as the next step. Coexisting lumbar and cervical stenosis (tandem spinal stenosis) is an infrequent presentation with mixed presentation of upper motor neuron and lower motor neuron signs. But very few reports of tandem spinal stenosis are available.
CATEGORY    Skeletal dysplasia
DRUG        Limaprost [DR:D02860]
            Mecobalamin [DR:D03246]
            Cyanocobalamin [DR:D00166]
            Gabapentin [DR:D00332]
            Pregabalin [DR:D02716]
DBLINKS     ICD-10: M48.0
            MeSH: D013130
            OMIM: 152550
REFERENCE   PMID:22021015
  AUTHORS   Todd AG
  TITLE     Cervical spine: degenerative conditions.
  JOURNAL   Curr Rev Musculoskelet Med 4:168-74 (2011)
REFERENCE   PMID:27228511
  AUTHORS   Benyamin RM, Staats PS, MiDAS Encore I
  TITLE     MILD(R) Is an Effective Treatment for Lumbar Spinal Stenosis with Neurogenic Claudication: MiDAS ENCORE Randomized Controlled Trial.
  JOURNAL   Pain Physician 19:229-42 (2016)
REFERENCE   PMID:23793607
  AUTHORS   Krishnan A, Dave BR, Kambar AK, Ram H
  TITLE     Coexisting lumbar and cervical stenosis (tandem spinal stenosis): an infrequent presentation. Retrospective analysis of single-stage surgery (53 cases).
  JOURNAL   Eur Spine J 23:64-73 (2014)
REFERENCE   PMID:20428988 (drug)
  AUTHORS   Tran DQ, Duong S, Finlayson RJ
  TITLE     Lumbar spinal stenosis: a brief review of the nonsurgical management.
  JOURNAL   Can J Anaesth 57:694-703 (2010)
///
ENTRY       H01712                      Disease
NAME        Fulminant hepatic failure;
            Fulminant hepatitis
DESCRIPTION Fulminant hepatic failure (FHF) is a life-threatening condition characterized by the rapid deterioration of liver functions and hepatic encephalopathy. FHF is with the basic definition of the onset of hepatic encephalopathy within 8 weeks of the appearance of the first symptoms like jaundice, fever, nausea, and vomiting. The prothrombin time is prolonged by 4-6 seconds or more. While the etiologies of FHF are multiple and varied, viral hepatitis is the most frequent cause. Around 40-60% of patients with FHF are thought to be due to some viral infection. The prognosis is dependent on several factors, including the underlying cause of liver failure. For instance, it is well known that the spontaneous recovery rates from FHF from such etiologies as hepatitis A and acetaminophen toxicity are high, whereas those same rates for other types of viral hepatitis and idiosyncratic drug reactions are quite low. Identification of the cause of FHF is important because some causes have specific treatment interventions or antidotes. Specific therapies include N-acetylcysteine for acetaminophen overdose, and acyclovir for herpesvirus infection. Different therapeutic options such as complete exchange blood transfusion, corticosteroids, and plasma pheresis, have been tried. However, the overall prognosis for patients with FHF is quite poor, with survival rates usually reported between 10% and 30% without liver transplantation.
CATEGORY    Liver disease
ENV_FACTOR  Acetaminophen [DR:D00217]
PATHOGEN    Hepatitis A virus (HAV) [GN:T40068], HBV [GN:T40004], HCV [GN:T40066], HDV [GN:T40085], HEV [GN:T40067]
MARKER      Hyperbilirubinaemia
            High activities of aminotransferases
            Low values of coagulation factors
DRUG        Corticosteroids
            Acetylcysteine [DR:D00221] (for acetaminophen induced FHF)
COMMENT     See also H01506 Hepatic encephalopathy, H00411 Hepatitis A, H00412 Hepatitis B, H00413 Hepatitis C, H00414 Hepatitis D, and H00415 Hepatitis E.
DBLINKS     ICD-10: K72
            MeSH: D017114
REFERENCE   PMID:26430449
  AUTHORS   Younis BB, Arshad R, Khurhsid S, Masood J, Nazir F, Tahira M
  TITLE     Fulminant hepatic failure (FHF) due to acute hepatitis C.
  JOURNAL   Pak J Med Sci 31:1009-11 (2015)
REFERENCE   PMID:12724633
  AUTHORS   Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M, Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein L, Holt C, Busuttil RW
  TITLE     Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period.
  JOURNAL   Ann Surg 237:666-75; discussion 675-6 (2003)
REFERENCE   PMID:9107258 (marker, drug)
  AUTHORS   Mas A, Rodes J
  TITLE     Fulminant hepatic failure.
  JOURNAL   Lancet 349:1081-5 (1997)
///
ENTRY       H01713                      Disease
NAME        Diffuse panbronchiolitis
DESCRIPTION Diffuse panbronchiolitis (DPB) is a chronic inflammatory lung disease, which predominantly affects East Asians. Clinically, DPB is characterized by chronic inflammation of the respiratory bronchioles and sinobronchial infection. While DPB is frequently compared with cystic fibrosis, a common genetic disease encountered in Caucasians, neither pancreatic insufficiency nor any obvious abnormalities of the sweat electrolytes are seen in DPB, and the two are considered to be entirely different diseases. Immunogenetic studies revealed a strong association with human HLA-B54 in Japanese, whereas an association with HLA-A11 was reported in Koreans. These findings imply that a major susceptibility gene may be located between the HLA-A and HLA-B loci on the short arm of human chromosome 6. Recently, novel mucin-like genes has been cloned in this candidate region. And it was found that their polymorphisms were associated with DPB. Over the past two decades, DPB has shifted from being a near-fatal to a treatable disease. A significant improvement in the prognosis of this disease has been attributed to the long-term use of macrolides. The five-year survival rate increased to about 90% after treatment with erythromycin became widely used.
CATEGORY    Respiratory disease
GENE        HLA-A(polymorphism) [HSA:3105] [KO:K06751]
            HLA-B(polymorphism) [HSA:3106] [KO:K06751]
            MUC22(polymorphism) [HSA:100507679]
            HCG22(polymorphism) [HSA:285834]
DRUG        Erythromycin [DR:D00140]
COMMENT     See also H00218 Cystic fibrosis.
DBLINKS     ICD-10: J44.8
            MeSH: C536174
            OMIM: 604809
REFERENCE   PMID:26888742
  AUTHORS   Sugimoto S, Miyoshi K, Yamane M, Oto T
  TITLE     Lung transplantation for diffuse panbronchiolitis: 5 cases from a single centre.
  JOURNAL   Interact Cardiovasc Thorac Surg 22:679-81 (2016)
REFERENCE   PMID:21303426 (gene)
  AUTHORS   Keicho N, Hijikata M
  TITLE     Genetic predisposition to diffuse panbronchiolitis.
  JOURNAL   Respirology 16:581-8 (2011)
REFERENCE   PMID:20981447 (gene)
  AUTHORS   Hijikata M, Matsushita I, Tanaka G, Tsuchiya T, Ito H, Tokunaga K, Ohashi J, Homma S, Kobashi Y, Taguchi Y, Azuma A, Kudoh S, Keicho N
  TITLE     Molecular cloning of two novel mucin-like genes in the disease-susceptibility locus for diffuse panbronchiolitis.
  JOURNAL   Hum Genet 129:117-28 (2011)
REFERENCE   PMID:25618845 (drug)
  AUTHORS   Lin X, Lu J, Yang M, Dong BR, Wu HM
  TITLE     Macrolides for diffuse panbronchiolitis.
  JOURNAL   Cochrane Database Syst Rev 1:CD007716 (2015)
///
ENTRY       H01714                      Disease
NAME        Chronic obstructive pulmonary disease (COPD);
            Emphysema
DESCRIPTION Chronic obstructive pulmonary disease (COPD) is a representative chronic inflammatory disorder of the lungs that includes chronic bronchitis and emphysema. COPD is characterized by airway inflammation and progressive airflow obstruction, most commonly caused by cigarette smoking. The major symptoms of which patients complain are cough, breathlessness, and sputum production. COPD is associated with underlying inflammation in response to chronic exposure to noxious particulates and gases and with a number of comorbid conditions. The onset of COPD generally occurs in the 6th to 8th decades of life. Early onset COPD is defined as disease onset before the age of 50 years, irrespective of smoking history. The presence of persons with early onset, severely reduced pulmonary function suggests that individuals may vary in their genetic susceptibility to the effects of smoking. Alpha-1-antitrypsin deficiency is the only proven genetic risk factor for COPD. Bronchodilators are the mainstay of treatment since they improve lung function and reduce acute exacerbations. Long-acting inhaled bronchodilators are recommended as first line treatment for patients with persistent symptoms.
CATEGORY    Lung disease
GENE        SERPINA1 [HSA:5265] [KO:K03984]
ENV_FACTOR  Cigarette smoking
DRUG        Formoterol [DR:D05277]
            Salmeterol [DR:D00687]
            Tiotropium [DR:D01929]
            Indacaterol maleate [DR:D09319]
COMMENT     See also H01103 Alpha-1-antitrypsin (A1AT) deficiency
DBLINKS     ICD-10: J43 J44
            MeSH: D029424
            OMIM: 606963
REFERENCE   PMID:18046867
  AUTHORS   Smith J, Woodcock A
  TITLE     Cough and its importance in COPD.
  JOURNAL   Int J Chron Obstruct Pulmon Dis 1:305-14 (2006)
REFERENCE   PMID:23257530
  AUTHORS   Tsuchida T, Matsuse H, Nishino T, Kawano T, Fukushima C, Hayashi T, Kohno S
  TITLE     Pathologically confirmed, early-onset, severe chronic obstructive pulmonary disease.
  JOURNAL   Intern Med 51:3411-4 (2012)
REFERENCE   PMID:9620904 (gene)
  AUTHORS   Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, O'DONNELL WJ, Reilly JJ, Ginns L, Mentzer S, Wain J, Speizer FE
  TITLE     Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.
  JOURNAL   Am J Respir Crit Care Med 157:1770-8 (1998)
REFERENCE   PMID:20642373 (drug)
  AUTHORS   Tashkin DP
  TITLE     Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
  JOURNAL   Expert Opin Pharmacother 11:2077-85 (2010)
///
ENTRY       H01715                      Disease
NAME        Obesity hypoventilation syndrome;
            Pickwickian Syndrome
DESCRIPTION Obesity hypoventilation syndrome (OHS) is defined as the triad of obesity (BMI of 30 or higher), daytime hypoventilation, and sleep-disordered breathing in the absence of any other cause of hypoventilation. The features include marked obesity, somnolence, twitching, cyanosis, periodic respiration, polycythemia, and right ventricular hypertrophy and failure. Patients with untreated OHS have a significant risk of death. While continuous positive airway pressure (CPAP) treatments may temporize cardiopulmonary disease progression, simultaneous pursuit of weight reduction is central to long-term management of this condition.
CATEGORY    Respiratory disease
MARKER      Hypercapnia (awake PCO2 > 45mmHg)
            Hypoxia (PO2 < 70 mmHg)
DBLINKS     ICD-10: E66.2
            MeSH: D010845
            OMIM: 257500
REFERENCE   PMID:20875161
  AUTHORS   Mokhlesi B
  TITLE     Obesity hypoventilation syndrome: a state-of-the-art review.
  JOURNAL   Respir Care 55:1347-62; discussion 1363-5 (2010)
REFERENCE   PMID:23094151 (marker)
  AUTHORS   Chanda A, Kwon JS, Wolff AJ, Manthous CA
  TITLE     Positive pressure for obesity hypoventilation syndrome.
  JOURNAL   Pulm Med 2012:568690 (2012)
///
ENTRY       H01716                      Disease
NAME        Idiopathic interstitial pneumonias
DESCRIPTION Idiopathic interstitial pneumonias (IIP) are a heterogeneous subset of interstitial lung diseases, characterized by unknown aetiology. Despite the varied nature of IIPs, the common histological feature is distortion of lung interstitium by highly variable combinations of inflammation and fibrosis. Patients experience common symptoms related to their chronic lung disease. Dyspnoea, cough, fatigue and depression contribute substantially to morbidity and are often difficult to manage. It has been reported that pulmonary rehabilitation plays a central role in symptom management and has beneficial effects. According to the current American thoracic society/European respiratory society (ATS/ERS), IIPs are categorised as major IIPs, rare IIPs and unclassifiable IIPs. There are six major IIPs, namely, idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-interstitial lung disease (RB-ILD), desquamative interstitial pneumonia (DIP), cryptogenic organizing pneumonia (COP), and acute interstitial pneumonia (AIP). And they are divided into three major groups;  chronic fibrosing IIP (IPF, NSIP), smoking-related IIP (RB-ILD, DIP), and acute/ subacute IIP (COP, AIP). The rare IIPs include idiopathic lymphoid interstitial pneumonia (LIP) and idiopathic pleuroparenchymal fibroelastosis. IPF accounts for the majority of IIP. It is considered to be lethal because prognosis is very poor and far worse than other types of IIP. An early and accurate diagnosis of IPF is critical.
CATEGORY    Lung disease
DRUG        Corticosteroids
COMMENT     See also H01299  Idiopathic pulmonary fibrosis.
DBLINKS     ICD-10: J84
            MeSH: D054988
REFERENCE   PMID:24032382
  AUTHORS   Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D
  TITLE     An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
  JOURNAL   Am J Respir Crit Care Med 188:733-48 (2013)
REFERENCE   PMID:24591661
  AUTHORS   Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V
  TITLE     Interstitial lung disease.
  JOURNAL   Eur Respir Rev 23:40-54 (2014)
REFERENCE   PMID:26011188
  AUTHORS   Neurohr C, Behr J
  TITLE     Changes in the current classification of IIP: A critical review.
  JOURNAL   Respirology 20:699-704 (2015)
REFERENCE   PMID:26949346
  AUTHORS   Hashisako M, Fukuoka J
  TITLE     Pathology of Idiopathic Interstitial Pneumonias.
  JOURNAL   Clin Med Insights Circ Respir Pulm Med 9:123-33 (2015)
REFERENCE   PMID:26450007 (drug)
  AUTHORS   Garibaldi BT, Danoff SK
  TITLE     Symptom-based management of the idiopathic interstitial pneumonia.
  JOURNAL   Respirology 21:1357-1365 (2016)
///
ENTRY       H01717                      Disease
NAME        Optic neuritis
DESCRIPTION Optic neuritis is a demyelinating inflammatory disease of the optic nerve that presents with an abrupt loss of vision. The majority of patients are between the ages of 20 and 50 years, with a mean age ranging from 30 to 35 years. It occurs more commonly in women than in men. The onset is usually with pain on eye movement in one eye and subacute visual loss. One-third of patients have a mildly edematous optic disc. The visual disturbance resolves in 95% of cases. Many cases of optic neuritis are associated with multiple sclerosis or neuromyelitis optica or can occur in isolation. Occasionally, optic neuritis can result from infectious processes involving the paranasal sinuses or occur in the course of a systemic viral infection. High-dosed intravenous methylprednisolone therapy speeds recovery but does not improve the final outcome. For patients judged to be at high risk of developing multiple sclerosis, immune prophylaxis with beta-interferon or glatiramer acetate is recommended.
CATEGORY    Nervous system disease
DRUG        Methylprednisolone [DR:D00751]
            Interferon beta [DR:D04554 D00746]
            Glatiramer acetate [DR:D04318]
COMMENT     See also H01490 Multiple sclerosis and H01491 Neuromyelitis optica.
DBLINKS     ICD-10: H46
            MeSH: D009902
REFERENCE   PMID:22960967
  AUTHORS   Pedro-Egbe CN, Fiebai B, Ejimadu CS
  TITLE     Visual outcome following optic neuritis: a 5-year review.
  JOURNAL   Niger J Clin Pract 15:311-4 (2012)
REFERENCE   PMID:26273799
  AUTHORS   Gal RL, Vedula SS, Beck R
  TITLE     Corticosteroids for treating optic neuritis.
  JOURNAL   Cochrane Database Syst Rev CD001430 (2015)
REFERENCE   PMID:26396053 (drug)
  AUTHORS   Wilhelm H, Schabet M
  TITLE     The Diagnosis and Treatment of Optic Neuritis.
  JOURNAL   Dtsch Arztebl Int 112:616-25; quiz 626 (2015)
///
ENTRY       H01718                      Disease
NAME        Kawasaki disease;
            Mucocutaneous lymph node syndrome
DESCRIPTION Kawasaki disease (KD) is an acute systemic vasculitis of childhood that does not have a known cause or aetiology. KD is a self-limited illness that is not associated with the production of autoantibodies or the deposition of immune complexes, and it rarely recurs. The disease is believed to result from an aberrant inflammatory response to an infectious trigger in a genetically predisposed individual. Classic (typical) Kawasaki disease is diagnosed based on the presence of a fever lasting five or more days, accompanied by four out of five findings: bilateral conjunctival injection, oral changes such as cracked and erythematous lips and strawberry tongue, cervical lymphadenopathy, extremity changes such as erythema or palm and sole desquamation, and polymorphous rash. Incomplete (atypical) Kawasaki disease occurs in persons with fever lasting five or more days and with two or three of these findings. The standard treatment of acute KD is intravenous immunoglobulin (IVIG) infusion and aspirin. However, 10-20% of patients show resistance to IVIG therapy and present higher risk of coronary vasculitis. If there is no response to treatment, patients are given a second dose of IVIG with or without corticosteroids or other adjunctive treatment.
CATEGORY    Cardiovascular disease; Hematologic disease; Skin and connective tissue disease
DRUG        Infliximab [DR:D02598]
            Human normal immunoglobulin [DR:D08779 D08783 D08786 D08788]
            Aspirin [DR:D00109]
DBLINKS     ICD-10: M30.3
            MeSH: D009080
REFERENCE   PMID:27342882 (description)
  AUTHORS   Hara T, Nakashima Y, Sakai Y, Nishio H, Motomura Y, Yamasaki S
  TITLE     Kawasaki disease: a matter of innate immunity.
  JOURNAL   Clin Exp Immunol 186:134-143 (2016)
REFERENCE   PMID:27506874 (description)
  AUTHORS   Galeotti C, Kaveri SV, Cimaz R, Kone-Paut I, Bayry J
  TITLE     Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease.
  JOURNAL   Drug Discov Today 21:1850-1857 (2016)
REFERENCE   PMID:25822554 (description, drug)
  AUTHORS   Saguil A, Fargo M, Grogan S
  TITLE     Diagnosis and management of kawasaki disease.
  JOURNAL   Am Fam Physician 91:365-71 (2015)
REFERENCE   PMID:24701096 (drug)
  AUTHORS   Rodriguez-Gonzalez M, Matamala-Morillo MA, Segado-Arenas A
  TITLE     Infliximab as rescue therapy in refractory Kawasaki disease.
  JOURNAL   Ann Pediatr Cardiol 7:74-5 (2014)
///
ENTRY       H01719                      Disease
NAME        Optic neuropathy
DESCRIPTION Optic neuropathy is damage to the optic nerve that causes vision loss frequently. The optic nerve is susceptible to a number of pathologic processes. Causes of the disease include demyelinating, inflammatory, toxic, nutritional, compressive, infiltrative, hereditary, traumatic, and neoplastic. The classic clinical signs of optic neuropathy are visual field defect, dyschromatopsia, and abnormal papillary response. A rapid onset is typical of demyelinating, inflammatory, ischemic, and traumatic causes.
CATEGORY    Nervous system disease
ENV_FACTOR  Ethambutol [DR:D00878]
            Methanol [DR:D02309]
            Linezolid [DR:D00947]
            Amiodarone [DR:D00636]
DRUG        Corticosteroids
            Mecobalamin [DR:D03246] (for nutritional optic neuropathy)
COMMENT     See also H00068 Leber optic atrophy, H01490 Multiple sclerosis, H01491 Neuromyelitis optica, and H01717 Optic neuritis.
DBLINKS     ICD-10: H46
            MeSH: D009901 D018917
REFERENCE   PMID:19668477 (drug)
  AUTHORS   Behbehani R
  TITLE     Clinical approach to optic neuropathies.
  JOURNAL   Clin Ophthalmol 1:233-46 (2007)
REFERENCE   PMID:25099099 (drug, env_factor)
  AUTHORS   Van Stavern GP
  TITLE     Metabolic, hereditary, traumatic, and neoplastic optic neuropathies.
  JOURNAL   Continuum (Minneap Minn) 20:877-906 (2014)
///
ENTRY       H01720                      Disease
NAME        Southeast Asian ovalocytosis (SAO)
DESCRIPTION Southeast Asian ovalocytosis (SAO) is a very common condition in the aboriginal peoples from Papua New Guinea, Indonesia, Malaysia, the Philippines, and southern Thailand, in areas where malaria is endemic, with prevalence varying between 5% and 25%. SAO is now known to be caused by a 27 base-pair deletion in SLC4A1, which codes for band 3, a 911 amino acid protein that is both a structural component of the red cell membrane cytoskeleton and the chloride-bicarbonate anion-exchanger in this membrane. SAO is believed to have evolved because these parts of Southeast Asia historically have had a high incidence of Plasmodium falciparum malaria, against which SAO offers clinical protection. Individuals with SAO are characterized as having oval-shaped red blood cells with increased membrane rigidity and decreased anion transport, but no clinical symptoms beyond sporadic associations with anemia in both adults and neonates. The diagnosis is made accidentally as a result of a peripheral blood smear examination, showing the characteristic rounded elliptocytes (ovalocytes).
CATEGORY    Hematologic disease
GENE        SLC4A1 [HSA:6521] [KO:K06573]
COMMENT     See also H00361 Malaria.
DBLINKS     ICD-10: D58.1
            OMIM: 166900
REFERENCE   PMID:27756835 (description)
  AUTHORS   Andolfo I, Russo R, Gambale A, Iolascon A
  TITLE     New insights on hereditary erythrocyte membrane defects.
  JOURNAL   Haematologica 101:1284-1294 (2016)
REFERENCE   PMID:12081559 (description)
  AUTHORS   Wrong O, Bruce LJ, Unwin RJ, Toye AM, Tanner MJ
  TITLE     Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis.
  JOURNAL   Kidney Int 62:10-9 (2002)
REFERENCE   PMID:26047685 (description)
  AUTHORS   Paquette AM, Harahap A, Laosombat V, Patnode JM, Satyagraha A, Sudoyo H, Thompson MK, Yusoff NM, Wilder JA
  TITLE     The evolutionary origins of Southeast Asian Ovalocytosis.
  JOURNAL   Infect Genet Evol 34:153-9 (2015)
REFERENCE   PMID:1722314 (gene)
  AUTHORS   Jarolim P, Palek J, Amato D, Hassan K, Sapak P, Nurse GT, Rubin HL, Zhai S, Sahr KE, Liu SC
  TITLE     Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis.
  JOURNAL   Proc Natl Acad Sci U S A 88:11022-6 (1991)
///
ENTRY       H01721                      Disease
NAME        Anti-glomerular basement membrane (GBM) disease;
            Goodpasture syndrome
DESCRIPTION Goodpasture syndrome (GS), or anti-glomerular basement membrane (anti-GBM) disease, is a rare and organ-specific autoimmune disease defined by anti-GBM antibody-mediated damage (mainly immunoglobulin G-1) resulting in progressive crescentic glomerulonephritis and, frequently, diffuse pulmonary alveolar hemorrhage. Clinically, GS is characterized by pulmonary hemorrhage and renal failure, although the clinical spectrum may range from only mild symptoms to a relentless and finally lethal outcome. This disease accounts for 10-20% of the patients with acute renal failure following a rapidly progressive glomerulonephritis. The disease is caused by an autoimmune response against the non-collagenase domain of the alpha 3 chain of type IV collagen [alpha3(IV)NC1], found in the glomerular and alveolar basement membranes. Without prompt diagnosis and treatment, the disease can lead to bleeding in the lungs, kidney failure, and even death. Early and intensive treatment with plasmapheresis and immunosuppression with systemic corticosteroids pending results of diagnostic testing, and later cyclophosphamide, is often beneficial, with 90% of patients surviving the acute presentation of GS.
CATEGORY    Immune system disease; Kidney disease
MARKER      Anti-GBM
DRUG        Cyclophosphamide [DR:D00287]
            Corticosteroids
COMMENT     Autoantigen:
            COL4A3 [HSA:1285] [KO:K06237]
            See also H01688 Rapidly progressive glomerulonephritis (RPGN).
DBLINKS     ICD-10: M31.0 N08.5
            MeSH: D019867
REFERENCE   PMID:18502098 (description, autoantigen)
  AUTHORS   Ooi JD, Holdsworth SR, Kitching AR
  TITLE     Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells.
  JOURNAL   J Autoimmun 31:295-300 (2008)
REFERENCE   PMID:21207195 (description)
  AUTHORS   Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE
  TITLE     Cutting edge issues in Goodpasture's disease.
  JOURNAL   Clin Rev Allergy Immunol 41:151-62 (2011)
REFERENCE   PMID:23806563 (description)
  AUTHORS   Dammacco F, Battaglia S, Gesualdo L, Racanelli V
  TITLE     Goodpasture's disease: a report of ten cases and a review of the literature.
  JOURNAL   Autoimmun Rev 12:1101-8 (2013)
REFERENCE   PMID:25462583 (description, drug)
  AUTHORS   Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G, Martellucci S, Turchetta R, Longo L, De Vincentiis M
  TITLE     Goodpasture's syndrome: a clinical update.
  JOURNAL   Autoimmun Rev 14:246-53 (2015)
///
ENTRY       H01722                      Disease
NAME        Galloway-Mowat syndrome
DESCRIPTION Galloway-Mowat Syndrome (GMS) is an autosomal recessively inherited condition characterized by the association of nephrotic syndrome and central nervous system involvement. Several case reports and studies on small series describing the clinical and histopathological features of GMS have revealed the clinical heterogeneity of this condition. The consistent morphological hallmark is microcephaly, which is often present at birth (primary microcephaly) but might also develop postnatally (secondary microcephaly). Major brain abnormalities include cerebral atrophy and neural-migration defects, such as agyria, microgyria, or polymicrogyria. These structural brain abnormalities are associated with severe psychomotor impairment, hypotonia, and seizures in half of all cases. The nephrotic syndrome occurs in the first four months of life with an average of three months, and a congenital nephrotic syndrome has rarely been described. This nephrotic syndrome is steroid-resistant and associated with a constant and rapid deterioration of renal function. Death usually occurs within few years from the onset. Very recently, WDR73 deficiency was identified as the cause of GMS.
CATEGORY    Nervous system disease
GENE        WDR73 [HSA:84942]
DBLINKS     ICD-10: Q04.3
            MeSH: C537548
            OMIM: 251300
REFERENCE   PMID:20083416 (description)
  AUTHORS   Pezzella M, Yeghiazaryan NS, Veggiotti P, Bettinelli A, Giudizioso G, Zara F, Striano P, Minetti C
  TITLE     Galloway-Mowat syndrome: an early-onset progressive encephalopathy with intractable epilepsy associated to renal impairment. Two novel cases and review of literature.
  JOURNAL   Seizure 19:132-5 (2010)
REFERENCE   PMID:18276083 (description)
  AUTHORS   Sartelet H, Pietrement C, Noel LH, Sabouraud P, Birembaut P, Oligny LL, Roussel B, Doco-Fenzy M
  TITLE     Collapsing glomerulopathy in Galloway-Mowat syndrome: a case report and review of the literature.
  JOURNAL   Pathol Res Pract 204:401-6 (2008)
REFERENCE   PMID:25466283 (description, gene)
  AUTHORS   Colin E, Huynh Cong E, Mollet G, Guichet A, Gribouval O, Arrondel C, Boyer O, Daniel L, Gubler MC, Ekinci Z, Tsimaratos M, Chabrol B, Boddaert N, Verloes A, Chevrollier A, Gueguen N, Desquiret-Dumas V, Ferre M, Procaccio V, Richard L, Funalot B, Moncla A, Bonneau D, Antignac C
  TITLE     Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome: Galloway-Mowat syndrome.
  JOURNAL   Am J Hum Genet 95:637-48 (2014)
///
ENTRY       H01723                      Disease
NAME        Deep vein thrombosis (DVT)
DESCRIPTION Deep vein thrombosis (DVT) is the formation of blood clots (thrombi) in the deep veins. It can lead to complications such as postphlebitic syndrome, pulmonary embolism and death. DVT has genetic and acquired risk factors. The genetic risk factors can be subdivided into those that are strong, moderate and weak. Strong risk factors are deficiencies of antithrombin, protein C and protein S. Moderately strong are factor V Leiden, prothrombin 20210A, non-O blood group and fibrinogen 10034T. There are many weak genetic risk factors, including fibrinogen, factor XIII and factor XI variants. Acquired risk factors include surgery, oral contraceptives, trauma, obesity, cancer, and so on. In some patients, venous thrombosis occurs in the presence of such risk factors for DVT. These patients are classified as having secondary DVT. In the other patients, no predisposing factors are found, and thus, are considered as having an idiopathic DVT.
CATEGORY    Hematologic diseases
GENE        Antithrombin (deficiency) [HSA:462] [KO:K03911]
            Protein C (deficiency) [HSA:5624] [KO:K01344]
            Protein S (deficiency) [HSA:5627] [KO:K03908]
DRUG        Heparin [DR:D07510]
DBLINKS     ICD-10: I80.2
            MeSH: D020246
REFERENCE   PMID:8568483
  AUTHORS   Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL
  TITLE     The incidence of occult cancer in patients with deep venous thrombosis: a prospective study.
  JOURNAL   J Intern Med 239:153-6 (1996)
REFERENCE   PMID:17060659
  AUTHORS   Scarvelis D, Wells PS
  TITLE     Diagnosis and treatment of deep-vein thrombosis.
  JOURNAL   CMAJ 175:1087-92 (2006)
REFERENCE   PMID:19630821 (gene)
  AUTHORS   Rosendaal FR, Reitsma PH
  TITLE     Genetics of venous thrombosis.
  JOURNAL   J Thromb Haemost 7 Suppl 1:301-4 (2009)
REFERENCE   PMID:19784750 (drug)
  AUTHORS   Spiezia L, Simioni P
  TITLE     Upper extremity deep vein thrombosis.
  JOURNAL   Intern Emerg Med 5:103-9 (2010)
REFERENCE   PMID:22287864
  AUTHORS   Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A
  TITLE     Deep vein thrombosis: a clinical review.
  JOURNAL   J Blood Med 2:59-69 (2011)
REFERENCE   PMID:27766050 (gene)
  AUTHORS   Rosendaal FR
  TITLE     Causes of venous thrombosis.
  JOURNAL   Thromb J 14:24 (2016)
REFERENCE   PMID:27572888 (drug)
  AUTHORS   Cote LP, Greenberg S, Caprini JA, Tafur A, Choi C, Munoz FJ, Skride A, Valero B, Porras JA, Ciammaichella M, Hernandez-Blasco LM, Monreal M
  TITLE     Comparisons Between Upper and Lower Extremity Deep Vein Thrombosis: A Review of the RIETE Registry.
  JOURNAL   Clin Appl Thromb Hemost (2016)
///
ENTRY       H01724                      Disease
NAME        HTLV1-Associated Myelopathy (HAM);
            Tropical spastic paraparesis (TSP)
DESCRIPTION Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic progressive myelopathy characterized by bilateral pyramidal tract involvement with sphincteric disturbances. HTLV-1 is the etiologic agent of HAM/TSP. Although the majority of HTLV-1-infected individuals remain asymptomatic during their lifetime, approximately one percent of this population develops a myelopathy consisting of a chronic inflammation of the white and gray matter of the spinal cord. Early in the disease process the leptomeninges, blood vessels and parenchyma are infiltrated with CD4+, CD8+, B lymphocytes and foamy macrophages, whereas later in the disease CD8+ lymphocytes predominate with subsequent progression to a relatively acellular, atrophic pattern with axonal and myelin degeneration.
CATEGORY    Nervous system disease
PATHOGEN    human T-lymphotropic virus type 1 [GN:T40003]
DRUG        Glucocorticoids
            Histone Deacetylase Inhibitor
            Interferon-alpha [DR:D00745 D02745]
            Vitamin C [DR:D00018]
DBLINKS     ICD-10: G04.1
            MeSH: D015493
REFERENCE   PMID:23217623 (pathogen)
  AUTHORS   Cook LB, Elemans M, Rowan AG, Asquith B
  TITLE     HTLV-1: persistence and pathogenesis.
  JOURNAL   Virology 435:131-40 (2013)
REFERENCE   PMID:22300227 (drug)
  AUTHORS   Pillat MM, Bauer ME, de Oliveira AC, Ulrich H, Casseb J
  TITLE     HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP): still an obscure disease.
  JOURNAL   Cent Nerv Syst Agents Med Chem 11:239-45 (2011)
REFERENCE   PMID:21994794
  AUTHORS   Araya N, Sato T, Yagishita N, Ando H, Utsunomiya A, Jacobson S, Yamano Y
  TITLE     Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease.
  JOURNAL   Viruses 3:1532-48 (2011)
REFERENCE   PMID:19618340
  AUTHORS   Nakamura T
  TITLE     HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of  HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy.
  JOURNAL   Folia Neuropathol 47:182-94 (2009)
REFERENCE   PMID:18691139 (pathogen)
  AUTHORS   Goncalves DU, Proietti FA, Barbosa-Stancioli EF, Martins ML, Ribas JG, Martins-Filho OA, Teixeira-Carvalho A, Peruhype-Magalhaes V, Carneiro-Proietti AB
  TITLE     HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory  network.
  JOURNAL   Inflamm Allergy Drug Targets 7:98-107 (2008)
///
ENTRY       H01725                      Disease
NAME        Primary immunodeficiency diseases
DESCRIPTION Primary immunodeficiency diseases (PIDs) are genetically determined disorders of the immune system resulting in greatly enhanced susceptibility to infectious disease, autoimmunity and malignancy. Many are associated with single gene defects, whereas others may be polygenic or may represent interactions of genetically determined characteristics with environmental or infectious stresses. There are more than 150 different disorders which have been described till date. PIDs are broadly classified as disorders of adaptive immunity (i.e., T-cell, B-cell or combined immunodeficiencies) or of innate immunity (e.g., phagocyte and complement disorders).  Early diagnosis and treatment are imperative for preventing significant disease-associated morbidity.
CATEGORY    Immune system disease
COMMENT     See [DS:H00085], [DS:H00086], [DS:H00087], [DS:H00088], [DS:H00089], [DS:H00090], [DS:H00091], [DS:H00092], [DS:H00093], [DS:H00094], [DS:H00095], [DS:H00096], [DS:H00097], [DS:H00098], [DS:H00099], [DS:H00100], [DS:H00101], [DS:H00102], [DS:H00103], [DS:H00104], [DS:H00105], [DS:H00106], [DS:H00107], [DS:H00108], [DS:H00109], [DS:H00939], [DS:H01218], [DS:H01240], [DS:H01244], [DS:H01245], [DS:H01387], [DS:H01523] and [DS:H01524].
DBLINKS     ICD-10: D69 D70 D71 D76 D80 D81 D82 D84
            MeSH: D000361 D053306 D017074 D053632 D001260 D049932 D564694 D0001816 D006105 D056735 D016553 D014923 D004062
REFERENCE   PMID:22165913
  AUTHORS   McCusker C, Warrington R
  TITLE     Primary immunodeficiency.
  JOURNAL   Allergy Asthma Clin Immunol 7 Suppl 1:S11 (2011)
REFERENCE   PMID:23942400
  AUTHORS   Madkaikar M, Mishra A, Ghosh K
  TITLE     Diagnostic approach to primary immunodeficiency disorders.
  JOURNAL   Indian Pediatr 50:579-86 (2013)
REFERENCE   PMID:20075404
  AUTHORS   Turvey SE, Bonilla FA, Junker AK
  TITLE     Primary immunodeficiency diseases: a practical guide for clinicians.
  JOURNAL   Postgrad Med J 85:660-6 (2009)
REFERENCE   PMID:26482257
  AUTHORS   Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Puck JM, Sullivan KE, Tang ML, Franco JL, Gaspar HB
  TITLE     Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015.
  JOURNAL   J Clin Immunol 35:696-726 (2015)
REFERENCE   PMID:18093537
  AUTHORS   Fischer A.
  TITLE     Human primary immunodeficiency diseases.
  JOURNAL   Immunity 27:835-45 (2007)
REFERENCE   PMID:12592303
  AUTHORS   Bonilla FA, Geha RS
  TITLE     12. Primary immunodeficiency diseases.
  JOURNAL   J Allergy Clin Immunol 111:S571-81 (2003)
///
ENTRY       H01726                      Disease
NAME        Membranoproliferative glomerulonephritis, including:
            Dense deposit disease (DDD);
            C3 glomerulonephritis (C3GN);
            Immunoglobulin-mediated membranoproliferative glomerulonephritis
DESCRIPTION Membranoproliferative glomerulonephritis (MPGN) represents a pattern of glomerular injury, characterized by mesangial proliferation and expansion, lobularization of the glomerular tufts and double contours. Classification of MPGN has been updated in the 2010s, and is now categorized according to the immunofluorescence microscopy findings. Until recently, the MPGNs have been distinguished according to the histological and ultra structural findings and were classified as MPGN type I, type II and type III. A new terminology that distinguishes immunoglobulin-mediated MPGN (ie, the former type I) from complement-mediated MPGN has been proposed. Immune-complexes mediated MPGN is caused by the deposition of immunocomplexes in the glomeruli. The immunocomplexes activate the classical pathway (CP) of complement and cause the deposition of complement factors or of the membrane attack complex (MAC) in the mesangium and capillary loops. The most frequent underlying disorders associated with immune complex MPGN include chronic infections, autoimmune diseases, and monoclonal gammopathies. The complement-mediated MPGN, termed C3 glomerulopathy, is characterised by defects in the alternative pathway of complement, in particular of factor H, or autoantibodies to complement-regulatory proteins (so-called C3 nephritic factors) leading to increased complement activation. The group includes dense deposit disease (DDD) and C3 glomerulonephritis. The two entities are distinguished on the basis of the immunohistological pattern of C3 and the electron microscopy detection of ribbon-like electron-dense deposits in the glomerular basement membrane in DDD, versus deposits of usual density in C3 glomerulonephritis.
CATEGORY    Immune system disease; Kidney disease
GENE        CFH [HSA:3075] [KO:K04004]
            CFHR5 [HSA:81494]
            DGKE [HSA:8526] [KO:K00901]
DBLINKS     ICD-10: N00.5
            MeSH: D015432
            OMIM: 609814 614809 615008
REFERENCE   PMID:27356907 (description)
  AUTHORS   Lionaki S, Gakiopoulou H, Boletis JN
  TITLE     Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.
  JOURNAL   APMIS 124:725-35 (2016)
REFERENCE   PMID:27458560 (description, gene)
  AUTHORS   Salvadori M, Rosso G
  TITLE     Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.
  JOURNAL   World J Nephrol 5:308-20 (2016)
REFERENCE   PMID:26921911 (description)
  AUTHORS   Floege J, Amann K
  TITLE     Primary glomerulonephritides.
  JOURNAL   Lancet 387:2036-48 (2016)
///
ENTRY       H01727                      Disease
NAME        Primary alveolar hypoventilation syndrome
DESCRIPTION Primary alveolar hypoventilation syndrome (PAHS) is a rare disorder which shows hypoxemia and hypercapnia without apparent associated pulmonary, neuromuscular, and central nervous diseases. PAHS is characterized by exacerbation of hypoxemia during sleep. Disorders of both automatic and chemical control of ventilation are considered as a cause of this syndrome. PAHS occuring during infancy is called congenital cenral alveolar hypoventilation syndrome (CCHS). Although the relationship between CCHS and adult onset PAHS is unclear, the familial occurrence of PAHS may suggest an underlying genetic mechanism. It has been represented that some adult onset PAHS may be a mild type of CCHS. Recently, noninvasive positive pressure ventilation (NIPPV) has become available for PAHS.
CATEGORY    Respiratory disease
COMMENT     See also H00916  Congenital central hypoventilation syndrome (CCHS).
DBLINKS     ICD-10: R06.8
            MeSH: D020182
REFERENCE   PMID:11446680
  AUTHORS   Funada Y, Nishimura Y, Kamemura K, Nakajima T, Tsuchiya T, Nishiuma T, Kotani Y, Yamanaka Y, Ohnishi Y, Yokoyama M
  TITLE     Familial adult onset primary alveolar hypoventilation syndrome.
  JOURNAL   Intern Med 40:526-31 (2001)
REFERENCE   PMID:16258218
  AUTHORS   Hara J, Fujimura M, Myou S, Oribe Y, Furusho S, Yamazaki M, Nakao S
  TITLE     Primary alveolar hypoventilation syndrome complicated with antiphospholipid syndrome.
  JOURNAL   Intern Med 44:987-9 (2005)
///
ENTRY       H01728                      Disease
NAME        Potter syndrome;
            Potter sequence
DESCRIPTION Potter syndrome is a rare fatal disorder that occurs in sporadic and hereditary forms. It affects predominantly male babies and is accompanied by severe oligohydramnios, polycystic kidney, bilateral renal agenesis, and obstructive uropathy during middle gestational weeks. Renal failure is the main defect in Potter syndrome. Other characteristic features include premature birth, breech presentation, atypical facial appearance, and limb malformations. Severe respiratory insufficiency leads to a fatal outcome in most infants. Potter syndrome has been divided into 4 distinct subgroups. Potter syndrome type I is referred to as autosomal recessive polycystic kidney disease (ARPKD), type II as renal dysplasia, type III as autosomal dominant polycystic kidney disease (ADPKD), and type IV occurs when a longstanding obstruction in either the kidney or ureter leads to cystic kidneys or hydronephrosis. Particularly types II-IV can be part of many syndromes.
CATEGORY    Developmental disorder; Kidney disease
GENE        (ARPKD) PKHD1 [HSA:5314] [KO:K19865]
            (ADPKD) PKD1 [HSA:5310] [KO:K04985]
            (ADPKD) PKD2 [HSA:5311] [KO:K04986]
            (ADPKD) GANAB [HSA:23193] [KO:K05546]
            (RA) ITGA8 [HSA:8516] [KO:K06584]
            (RA) FGF20 [HSA:26281] [KO:K04358]
COMMENT     See also H00542 Polycystic kidney disease.
DBLINKS     ICD-10: Q60.6
            MeSH: C536482
            OMIM: 606702 173900 613095 600666 191830 615721
REFERENCE   PMID:14120686 (description)
  AUTHORS   OSATHANONDH V, POTTER EL
  TITLE     PATHOGENESIS OF POLYCYSTIC KIDNEYS. SURVEY OF RESULTS OF MICRODISSECTION.
  JOURNAL   Arch Pathol 77:510-2 (1964)
REFERENCE   PMID:25673607 (description)
  AUTHORS   Sarkar S, DasGupta S, Barua M, Ghosh R, Mondal K, Chatterjee U, Datta C
  TITLE     Potter's sequence: a story of the rare, rarer and the rarest.
  JOURNAL   Indian J Pathol Microbiol 58:102-4 (2015)
REFERENCE   PMID:24584572 (description)
  AUTHORS   Bergmann C
  TITLE     ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies.
  JOURNAL   Pediatr Nephrol 30:15-30 (2015)
REFERENCE   PMID:24027716 (description)
  AUTHORS   Shastry SM, Kolte SS, Sanagapati PR
  TITLE     Potter's Sequence.
  JOURNAL   J Clin Neonatol 1:157-9 (2012)
REFERENCE   PMID:18947299 (gene)
  AUTHORS   Harris PC, Torres VE
  TITLE     Polycystic kidney disease.
  JOURNAL   Annu Rev Med 60:321-37 (2009)
REFERENCE   PMID:27259053 (gene)
  AUTHORS   Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Banales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrezet MP, Ferec C, Le Meur Y, Torres VE, Harris PC
  TITLE     Mutations in GANAB, Encoding the Glucosidase IIalpha Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
  JOURNAL   Am J Hum Genet 98:1193-207 (2016)
REFERENCE   PMID:24439109 (gene)
  AUTHORS   Humbert C, Silbermann F, Morar B, Parisot M, Zarhrate M, Masson C, Tores F, Blanchet P, Perez MJ, Petrov Y, Khau Van Kien P, Roume J, Leroy B, Gribouval O, Kalaydjieva L, Heidet L, Salomon R, Antignac C, Benmerah A, Saunier S, Jeanpierre C
  TITLE     Integrin alpha 8 recessive mutations are responsible for bilateral renal agenesis in humans.
  JOURNAL   Am J Hum Genet 94:288-94 (2014)
REFERENCE   PMID:22698282 (gene)
  AUTHORS   Barak H, Huh SH, Chen S, Jeanpierre C, Martinovic J, Parisot M, Bole-Feysot C, Nitschke P, Salomon R, Antignac C, Ornitz DM, Kopan R
  TITLE     FGF9 and FGF20 maintain the stemness of nephron progenitors in mice and man.
  JOURNAL   Dev Cell 22:1191-207 (2012)
///
ENTRY       H01729                      Disease
NAME        Premature ventricular complexes (PVCs);
            Premature ventricular contractions
DESCRIPTION Premature ventricular complex (PVC) is characterized by the premature occurrence of a QRS complex that is bizarre in shape and lasts longer than 120 msec. The T wave is large and usually of opposite polarity to the QRS complex. A PVC is usually followed by a full compensatory pause. PVCs are commonly encountered in apparently healthy individuals with a reported incidence of approximately 1% on standard 12-lead electrocardiograms (ECG) and 40% to 75% on routine 24 hour to 48 hour Holter monitoring. The clinical presentation may range from asymptomatic to left ventricular (LV) dysfunction with congestive heart failure. In many patients, ectopic ventricular events manifest as asymptomatic, isolated PVCs that have a benign prognosis in those without structural heart disease. In others, PVCs may be frequent and highly symptomatic, presenting as palpitations, chest discomfort, or presyncope. Clinical evidence suggests that frequent PVCs (variably defined in the literature) are more strongly associated with concomitant cardiac disease. The decision to suppress PVCs is largely based on the presence of symptoms, interference with other therapy (e.g., cardiac resynchronization therapy), or suspicion of PVC-mediated cardiomyopathy. When necessary, treatment for PVCs involves beta-blockers, calcium channel blockers, or other antiarrhythmic drugs and catheter ablation in selected cases. Catheter ablation of frequent PVCs has been demonstrated to be effective at PVC suppression and is associated with improvement or normalization of ventricular function.
CATEGORY    Cardiovascular disease
ENV_FACTOR  Stimulants: caffeine, cocaine, alcohol
            Metabolic abnormalities: acidosis, hypoxemia, hyperkalemia, hypokalemia, hypomagnesemia
            Drugs: Digoxin [DR:D00298], Theophylline [DR:D00371], Antipsychotics, Tricyclic antidepressants
DRUG        Propranolol [DR:D00483] Atenolol [DR:D00235] (Beta-blockers)
            Diltiazem [DR:D00616] Verapamil [DR:D00619] (Calcium channel blockers)
            Adenosine [DR:D00045] Sotalol [DR:D01026] Amiodarone [DR:D00636] (Other antiarrhythmic drugs)
DBLINKS     ICD-10: I49.1 I49.2 I49.3 I49.4
            MeSH: D018879
REFERENCE   PMID:25741605 (description)
  AUTHORS   Eugenio PL
  TITLE     Frequent Premature Ventricular Contractions: An Electrical Link to Cardiomyopathy.
  JOURNAL   Cardiol Rev 23:168-72 (2015)
REFERENCE   PMID:25678299 (description)
  AUTHORS   Saurav A, Smer A, Abuzaid A, Bansal O, Abuissa H
  TITLE     Premature ventricular contraction-induced cardiomyopathy.
  JOURNAL   Clin Cardiol 38:251-8 (2015)
REFERENCE   PMID:23733905 (description, drug)
  AUTHORS   Cantillon DJ
  TITLE     Evaluation and management of premature ventricular complexes.
  JOURNAL   Cleve Clin J Med 80:377-87 (2013)
REFERENCE   PMID:22875587 (description)
  AUTHORS   Adams JC, Srivathsan K, Shen WK
  TITLE     Advances in management of premature ventricular contractions.
  JOURNAL   J Interv Card Electrophysiol 35:137-49 (2012)
REFERENCE   PMID:12086238 (description, env_factor, drug)
  AUTHORS   Hebbar AK, Hueston WJ
  TITLE     Management of common arrhythmias: Part II. Ventricular arrhythmias and arrhythmias in special populations.
  JOURNAL   Am Fam Physician 65:2491-6 (2002)
///
ENTRY       H01730                      Disease
NAME        Myocardial infarction
DESCRIPTION Myocardial infarction (MI) or acute myocardial infarction (AMI) is a term for an event of heart attack. It is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply. The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, nausea, epigastric discomfort, syncope, diaphoresis, and other factors. The diagnosis of MI is dependent on the sensitivity and specificity of the clinical criteria, electrocardiographic (ECG) findings, imaging studies and biomarkers used to detect death of cardiomyocytes. The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack. Nitroglycerin and antihypertensive drugs such as beta-blockers and ACE inhibitors may also be used to lower blood pressure and to improve the oxygen demand of heart.
CATEGORY    Cardiovascular disease
ENV_FACTOR  Old age
            Tobacco smoking
            High blood pressure
            High levels of LDL
            High cholesterol and fat
            Diabetes
            Obesity
            Chronic kidney disease
            Alcohol
            Cocaine
            Amphetamines
MARKER      Cardiac troponin I
            Cardiac troponin T
DRUG        Aspirin [DR:D00109]
            Propranolol [DR:D00483] Timolol [DR:D00603] Metoprolol [DR:D00601 D00635] (Beta-blockers)
            Enalapril [DR:D00621] (ACE inhibitors)
            Simvastatin [DR:D00434] (Statins)
            Nitroglycerin [DR:D00515]
DBLINKS     ICD-10: I21
            MeSH: D009203
REFERENCE   PMID:25638347 (definition, env_factor, drug)
  AUTHORS   Lu L, Liu M, Sun R, Zheng Y, Zhang P
  TITLE     Myocardial Infarction: Symptoms and Treatments.
  JOURNAL   Cell Biochem Biophys 72:865-7 (2015)
REFERENCE   PMID:22922597 (description, marker)
  AUTHORS   Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD
  TITLE     Third universal definition of myocardial infarction.
  JOURNAL   Nat Rev Cardiol 9:620-33 (2012)
REFERENCE   PMID:26426469 (description, drug)
  AUTHORS   Frangogiannis NG
  TITLE     Pathophysiology of Myocardial Infarction.
  JOURNAL   Compr Physiol 5:1841-75 (2015)
///
ENTRY       H01731                      Disease
NAME        Fragile X tremor/ataxia syndrome (FXTAS)
DESCRIPTION Fragile X tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder affecting carriers of premutation CGG repeat expansions (range: 55-200) in the fragile X mental retardation 1 (FMR1) gene. Common manifestations of FXTAS are progressive intention tremor, cerebellar gait ataxia, parkinsonism, working memory impairment, and frontal executive dysfunction. FXTAS occurs predominantly in men over age 50 years.
CATEGORY    Chromosomal abnormality; Neurodegenerative disorder
GENE        FMR1 [HSA:2332] [KO:K15516]
COMMENT     See also H00465 Fragile X syndrome (FXS).
            (FXR) Full mutation expansions (>200 CGG repeats)
            (FXTAS) Smaller expansions in the premutation range (55-200 CGG repeats)
DBLINKS     ICD-10: Q99.2
            MeSH: C564105
            OMIM: 300623
REFERENCE   PMID:18057320
  AUTHORS   Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ
  TITLE     FMR1 CGG repeat length predicts motor dysfunction in premutation carriers.
  JOURNAL   Neurology 70:1397-402 (2008)
REFERENCE   PMID:24491663
  AUTHORS   Niu YQ, Yang JC, Hall DA, Leehey MA, Tassone F, Olichney JM, Hagerman RJ, Zhang L
  TITLE     Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited.
  JOURNAL   Parkinsonism Relat Disord 20:456-9 (2014)
///
ENTRY       H01732                      Disease
NAME        Angelman syndrome (AS)
DESCRIPTION Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are the most studied genomic-imprinting disorders mapped to chromosome 15q11-q13. Lack of a functional maternal copy of UBE3A, a gene within 15q11-q13, causes AS.  PWS and AS have characteristic neurologic, developmental, and behavioral phenotypes plus other structural and functional abnormalities. However, the cognitive and neurologic impairment is more severe in AS, including seizures and ataxia.
CATEGORY    Developmental disorder
GENE        UBE3A [HSA:7337] [KO:K10587]
            MECP2 [HSA:4204] [KO:K11588]
            CDKL5 [HSA:6792] [KO:K08824]
COMMENT     See also H00478 Prader-Willi syndrome (PWS).
DBLINKS     ICD-10: Q93.5
            MeSH: D017204
            OMIM: 105830
REFERENCE   PMID:11180221
  AUTHORS   Cassidy SB, Dykens E, Williams CA
  TITLE     Prader-Willi and Angelman syndromes: sister imprinted disorders.
  JOURNAL   Am J Med Genet 97:136-46 (2000)
REFERENCE   PMID:21592595
  AUTHORS   Mabb AM, Judson MC, Zylka MJ, Philpot BD
  TITLE     Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes.
  JOURNAL   Trends Neurosci 34:293-303 (2011)
REFERENCE   PMID:18627066
  AUTHORS   Horsthemke B, Wagstaff J
  TITLE     Mechanisms of imprinting of the Prader-Willi/Angelman region.
  JOURNAL   Am J Med Genet A 146A:2041-52 (2008)
REFERENCE   PMID:15757975
  AUTHORS   Makedonski K, Abuhatzira L, Kaufman Y, Razin A, Shemer R
  TITLE     MeCP2 deficiency in Rett syndrome causes epigenetic aberrations at the PWS/AS imprinting center that affects UBE3A expression.
  JOURNAL   Hum Mol Genet 14:1049-58 (2005)
REFERENCE   PMID:19241098
  AUTHORS   Russo S, Marchi M, Cogliati F, Bonati MT, Pintaudi M, Veneselli E, Saletti V, Balestrini M, Ben-Zeev B, Larizza L
  TITLE     Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.
  JOURNAL   Neurogenetics 10:241-50 (2009)
REFERENCE   PMID:20211139
  AUTHORS   Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Griffith EC, Waldon Z, Maehr R, Ploegh HL, Chowdhury S, Worley PF, Steen J, Greenberg ME
  TITLE     The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
  JOURNAL   Cell 140:704-16 (2010)
///
ENTRY       H01733                      Disease
NAME        Werner syndrome
DESCRIPTION Werner syndrome (WS) is a premature aging disorder with a complex phenotype, which includes many age-related disorders that develop from puberty, including greying and thinning of the hair, bilateral cataract formation, type II diabetes mellitus, osteoporosis and atherosclerosis. WS patients also experience an increased risk of rare non-epithelial cancers, especially sarcomas. Death usually occurs in the fourth decade from cardiovascular compromise or cancer. WS is caused by mutation of WRN gene, that play a major role in genome stability, particularly during DNA replication and telomere metabolism.
CATEGORY    Congenital disorder of DNA repair systems
GENE        WRN [HSA:7486] [KO:K10900]
COMMENT     See also H00296 Defects in RecQ helicases.
DBLINKS     ICD-10: E34.8
            MeSH: D014898
            OMIM: 277700
REFERENCE   PMID:12200042
  AUTHORS   Mohaghegh P, Hickson ID
  TITLE     Premature aging in RecQ helicase-deficient human syndromes.
  JOURNAL   Int J Biochem Cell Biol 34:1496-501 (2002)
REFERENCE   PMID:17314245
  AUTHORS   Multani AS, Chang S
  TITLE     WRN at telomeres: implications for aging and cancer.
  JOURNAL   J Cell Sci 120:713-21 (2007)
///
ENTRY       H01734                      Disease
NAME        Rothmund-Thomson syndrome
DESCRIPTION Rothmund-Thomson syndrome (RTS) is a rare autosomal recessive disorder that presents with growth deficiency, photosensitivity with poikilodermatous skin changes, cataracts, early greying and loss of hair, and an increased incidence of cancer, including osteosarcoma and hematological malignancy. RTS is caused by mutations in RECQL4 helicase. RECQL4 is shown to be important protein for DNA replication, repair, and telomere maintenance.
CATEGORY    Congenital disorder of DNA repair systems
GENE        RECQL4 [HSA:9401] [KO:K10730]
COMMENT     See also H00296 Defects in RecQ helicases.
DBLINKS     ICD-10: Q82.8
            MeSH: D011038
            OMIM: 268400
REFERENCE   PMID:12200042
  AUTHORS   Mohaghegh P, Hickson ID
  TITLE     Premature aging in RecQ helicase-deficient human syndromes.
  JOURNAL   Int J Biochem Cell Biol 34:1496-501 (2002)
REFERENCE   PMID:24960165
  AUTHORS   Smeets MF, DeLuca E, Wall M, Quach JM, Chalk AM, Deans AJ, Heierhorst J, Purton LE, Izon DJ, Walkley CR
  TITLE     The Rothmund-Thomson syndrome helicase RECQL4 is essential for hematopoiesis.
  JOURNAL   J Clin Invest 124:3551-65 (2014)
REFERENCE   PMID:23683351
  AUTHORS   Ferrarelli LK, Popuri V, Ghosh AK, Tadokoro T, Canugovi C, Hsu JK, Croteau DL, Bohr VA
  TITLE     The RECQL4 protein, deficient in Rothmund-Thomson syndrome is active on telomeric D-loops containing DNA metabolism blocking lesions.
  JOURNAL   DNA Repair (Amst) 12:518-28 (2013)
///
ENTRY       H01735                      Disease
NAME        Lymphangiomatosis
DESCRIPTION Lymphangiomatosis is a well-recognized congenital benign tumour, frequently seen in infancy and childhood, characterized by the presence of multiple lymphangiomas. The lymphangiomatosis spectrum encompasses a remarkable heterogeneity in its potential presentation, including micro- and macrocystic isolated lymphatic malformations, thoracic and intraabdominal diffuse lymphangiomatosis, and osseous and soft-tissue presentations known as Gorham disease. The disease can be considered a failure of normal lymphatic development, but the etiology remains poorly understood. Treatment has been limited to surgical resection or drainage procedures because there is no accepted effective systemic therapy.
CATEGORY    Vascular diseases
COMMENT     See also H01471 Lymphangioma.
DBLINKS     ICD-10: M89.5
            MeSH: D010015
REFERENCE   PMID:18667106
  AUTHORS   Naguib MB, Al-Jazan N, Hashem T
  TITLE     Lymphangiomatosis: a differential diagnosis of lytic lesions of the temporal bone.
  JOURNAL   J Laryngol Otol 122:e23 (2008)
REFERENCE   PMID:25173588
  AUTHORS   Rockson SG
  TITLE     Laboratory models for the investigation of lymphangiomatosis.
  JOURNAL   Microvasc Res 96:64-7 (2014)
REFERENCE   PMID:22196284
  AUTHORS   Satria MN, Pacheco-Rodriguez G, Moss J
  TITLE     Pulmonary lymphangiomatosis.
  JOURNAL   Lymphat Res Biol 9:191-3 (2011)
REFERENCE   PMID:21518582
  AUTHORS   DU MH, Ye RJ, Sun KK, Li JF, Shen DH, Wang J, Gao ZC
  TITLE     Diffuse pulmonary lymphangiomatosis: a case report with literature review.
  JOURNAL   Chin Med J (Engl) 124:797-800 (2011)
REFERENCE   PMID:27059187
  AUTHORS   Libby LJ, Narula N, Fernandes H, Gruden JF, Wolf DJ, Libby DM
  TITLE     Imatinib Treatment of Lymphangiomatosis (Generalized Lymphatic Anomaly).
  JOURNAL   J Natl Compr Canc Netw 14:383-6 (2016)
REFERENCE   PMID:19322127
  AUTHORS   Barbagallo M, Incorpora G, Magro G, D'Amico S, Pavone V
  TITLE     Splenic lymphangiomatosis associated with skeletal involvement (Gorham's disease): a new case and review of literature.
  JOURNAL   Minerva Pediatr 61:231-6 (2009)
///
ENTRY       H01736                      Disease
NAME        Persistent truncus arteriosus
DESCRIPTION Persistent truncus arteriosus (PTA) is a rare congenital condition in which a solitary arterial trunk arises from the base of the heart and supplies the coronary, pulmonary and systemic arteries. It is recognized as the most severe phenotype of outflow tract defect, and survival into adulthood is dismal without surgery. It is often associated with an unfavorable prognosis because complete surgical repair is not always possible. Mutations in the NKX2-6 gene and GATA6 gene have been found in patients with PTA. The association between truncus arteriosus and chromosome 22q11 deletion is well recognized.
CATEGORY    Cardiovascular disease
GENE        NKX2-6 [HSA:137814] [KO:K09346]
            GATA6 [HSA:2627] [KO:K17897]
COMMENT     See also H01525 22q11.2 deletion syndrome.
DBLINKS     ICD-10: Q20.0
            MeSH: D014339
            OMIM: 217095
REFERENCE   PMID:15649947 (gene)
  AUTHORS   Heathcote K, Braybrook C, Abushaban L, Guy M, Khetyar ME, Patton MA, Carter ND, Scambler PJ, Syrris P
  TITLE     Common arterial trunk associated with a homeodomain mutation of NKX2.6.
  JOURNAL   Hum Mol Genet 14:585-93 (2005)
REFERENCE   PMID:19666519 (gene)
  AUTHORS   Kodo K, Nishizawa T, Furutani M, Arai S, Yamamura E, Joo K, Takahashi T, Matsuoka R, Yamagishi H
  TITLE     GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling.
  JOURNAL   Proc Natl Acad Sci U S A 106:13933-8 (2009)
REFERENCE   PMID:12947506
  AUTHORS   McElhinney DB, Driscoll DA, Emanuel BS, Goldmuntz E
  TITLE     Chromosome 22q11 deletion in patients with truncus arteriosus.
  JOURNAL   Pediatr Cardiol 24:569-73 (2003)
REFERENCE   PMID:27025216
  AUTHORS   Ruan W, Loh YJ, Guo KW, Tan JL
  TITLE     Surgical correction of persistent truncus arteriosus on a 33-year-old male with unilateral pulmonary hypertension from migration of pulmonary artery band.
  JOURNAL   J Cardiothorac Surg 11:39 (2016)
///
ENTRY       H01737                      Disease
NAME        Epidermolysis bullosa
DESCRIPTION Inherited epidermolysis bullosa (EB) is a diverse group of disorders that encompass dozens of clinically and genotypically distinct diseases. It is characterized by mechanically fragile skin that readily blister. Most of the more severe subtypes are associated with clinically significant extracutaneous complications. Some subtypes may lead to death, even in early infancy. There are four major types of EB: EB simplex (H00584, H00585), junctional EB (H00586), dystrophic EB (H00587), and Kindler syndrome (H00588).
CATEGORY    Skin and connective tissue disease
COMMENT     See also H00584  Epidermolysis bullosa, simplex, H00585  Epidermolysis bullosa, hemidesmosomal, H00586  Epidermolysis bullosa, junctional, H00587  Epidermolysis bullosa, dysprophic, and H00588  Kindler syndrome.
DBLINKS     ICD-10: Q81
            MeSH: D004820
REFERENCE   PMID:20536471
  AUTHORS   Fine JD
  TITLE     Inherited epidermolysis bullosa: past, present, and future.
  JOURNAL   Ann N Y Acad Sci 1194:213-22 (2010)
REFERENCE   PMID:24007552
  AUTHORS   Tampoia M, Bonamonte D, Filoni A, Garofalo L, Morgese MG, Brunetti L, Di Giorgio C, Annicchiarico G
  TITLE     Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa.
  JOURNAL   Orphanet J Rare Dis 8:132 (2013)
///
ENTRY       H01738                      Disease
NAME        Noonan syndrome
DESCRIPTION Noonan syndrome (NS) is an autosomal dominant disorder characterised by short stature, craniofacial dysmorphism, congenital cardiac defects, cryptorchidism in men, coagulation defects, and neurocognitive delay. In addition, individuals with NS have an increased risk of developing cancer. NS is caused by germline mutations in genes that encode components or regulators of the Ras/MAPK pathway. Heterozygous, pathogenic variants in 11 known genes account for approximately 80% of cases. The most common gene associated with NS is PTPN11, which accounts for approximately 50% of all cases.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        PTPN11 [HSA:5781] [KO:K07293]
            KRAS [HSA:3845] [KO:K07827]
            SOS1 [HSA:6654] [KO:K03099]
            RAF1 [HSA:369] [KO:K08845]
            NRAS [HSA:4893] [KO:K07828]
            BRAF [HSA:673] [KO:K04365]
            RIT1 [HSA:6016] [KO:K07832]
            SOS2 [HSA:6655] [KO:K03099]
            LZTR1 [HSA:8216]
            CBL [HSA:867] [KO:K04707]
            SHOC2 [HSA:8036] [KO:K19613]
COMMENT     See also H00523 Noonan syndrome and related disorders.
DBLINKS     ICD-10: Q87.1
            MeSH:D009634
            OMIM: 163950 609942 610733 611553 613224 613706 615355 616559 616564 613563
REFERENCE   PMID:21396583
  AUTHORS   Tartaglia M, Gelb BD, Zenker M
  TITLE     Noonan syndrome and clinically related disorders.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 25:161-79 (2011)
REFERENCE   PMID:25795793 (gene)
  AUTHORS   Yamamoto GL, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S, Abramowicz A, Cristian I, Buscarilli M, Naslavsky MS, Malaquias AC, Zatz M, Bodamer O, Majewski J, Jorge AA, Pereira AC, Kim CA, Passos-Bueno MR, Bertola DR
  TITLE     Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome.
  JOURNAL   J Med Genet 52:413-21 (2015)
///
ENTRY       H01739                      Disease
NAME        Polycystic ovary syndrome
DESCRIPTION Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. Clinical manifestations include oligomenorrhea or amenorrhea, hirsutism, and frequently infertility. Clinical signs of PCOS include elevated luteinizing hormone (LH) and gonadotropin-releasing hormone (GnRH) levels, whereas follicle-stimulating hormone (FSH) levels are muted or unchanged. As a result of the increase in GnRH, stimulation of the ovarian theca cells, in turn, produces more androgens. Risk factors for PCOS in adults includes insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease. PCOS can be described as an oligogenic disorder in which the interaction of a number of genetic and environmental factors determine the heterogeneous, clinical, and biochemical phenotype. Management of clinical manifestations of PCOS includes oral contraceptives for menstrual irregularities and hirsutism. Treatment options for infertility include clomiphene, laparoscopic ovarian drilling, gonadotropins, and assisted reproductive technology.
CATEGORY    Endocrine system disease; Reproductive system disease
DRUG        Clomiphene citrate [DR:D00962]
            Metformin hydrochloride [DR:D00944]
            Human menopausal gonadotrophin (FSH) [DR:D04429 D06459]
DBLINKS     ICD-10: E28.2
            MeSH: D011085
REFERENCE   PMID:24379699 (description)
  AUTHORS   Sirmans SM, Pate KA
  TITLE     Epidemiology, diagnosis, and management of polycystic ovary syndrome.
  JOURNAL   Clin Epidemiol 6:1-13 (2013)
REFERENCE   PMID:23946629 (description, drug)
  AUTHORS   Ndefo UA, Eaton A, Green MR
  TITLE     Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches.
  JOURNAL   P T 38:336-55 (2013)
REFERENCE   PMID:24389146 (description)
  AUTHORS   Barthelmess EK, Naz RK
  TITLE     Polycystic ovary syndrome: current status and future perspective.
  JOURNAL   Front Biosci (Elite Ed) 6:104-19 (2014)
///
ENTRY       H01740                      Disease
NAME        Macrothrombocytopenia
DESCRIPTION Macrothrombocytopenia (MTP) is a heterogeneous group of disorders characterized by enlarged and reduced numbers of circulating platelets, sometimes resulting in abnormal bleeding. The clinical presentations of MTP-affected individuals vary considerably and range from no symptoms to a severe bleeding tendency. MTP-causing mutations have been reported in several genes, involved in various functions such as cell signaling, cytoskeleton organization, and gene expression. Among these, the most common is MYH9, which is responsible for MYH9-related disease. The second most common are GP1BA, GP1BB, and GP, which are responsible for Bernard-Soulier syndrome.
CATEGORY    Hematologic disease
GENE        MYH9 [HSA:4627] [KO:K10352]
            GP1BA [HSA:2811] [KO:K06261]
            GP1BB [HSA:2812] [KO:K06262]
            GP9 [HSA:2815] [KO:K06263]
            ITGA2B [HSA:3674] [KO:K06476]
            ITGB3 [HSA:3690] [KO:K06493]
            FLNA [HSA:2316] [KO:K04437]
            GATA1 [HSA:2623] [KO:K09182]
            TUBB1 [HSA:81027] [KO:K07375]
            NBEAL2 [HSA:23218]
            VWF [HSA:7450] [KO:K03900]
            GFI1B [HSA:8328] [KO:K09223]
            ACTN1[HSA:87] [KO:K05699]
            ABCG5 [HSA:64240] [KO:K05683]
            ABCG8 [HSA:64241] [KO:K05684]
            PRKACG [HSA:5568] [KO:K04345]
            DIAPH1 [HSA:1729] [KO:K05740]
COMMENT     See also H00233 MYH9-related disease, and H00224 Bernard-Soulier syndrome.
DBLINKS     ICD-10: D69.6
            MeSH: D013921
            OMIM: 155100 605249 153640 600208 153670 231200 187800 300049 300367 613112 139090 613554 187900 615193 210250 616176
REFERENCE   PMID:25944497 (gene)
  AUTHORS   Favier R, Raslova H
  TITLE     Progress in understanding the diagnosis and molecular genetics of macrothrombocytopenias.
  JOURNAL   Br J Haematol 170:626-39 (2015)
REFERENCE   PMID:23434115 (gene)
  AUTHORS   Kunishima S, Okuno Y, Yoshida K, Shiraishi Y, Sanada M, Muramatsu H, Chiba K, Tanaka H, Miyazaki K, Sakai M, Ohtake M, Kobayashi R, Iguchi A, Niimi G, Otsu M, Takahashi Y, Miyano S, Saito H, Kojima S, Ogawa S
  TITLE     ACTN1 mutations cause congenital macrothrombocytopenia.
  JOURNAL   Am J Hum Genet 92:431-8 (2013)
REFERENCE   PMID:26912466 (gene)
  AUTHORS   Stritt S, Nurden P, Turro E, Greene D, Jansen SB, Westbury SK, Petersen R, Astle WJ, Marlin S, Bariana TK, Kostadima M, Lentaigne C, Maiwald S, Papadia S, Kelly AM, Stephens JC, Penkett CJ, Ashford S, Tuna S, Austin S, Bakchoul T, Collins P, Favier R, Lambert MP, Mathias M, Millar CM, Mapeta R, Perry DJ, Schulman S, Simeoni I, Thys C, Gomez K, Erber WN, Stirrups K, Rendon A, Bradley JR, van Geet C, Raymond FL, Laffan MA, Nurden AT, Nieswandt B, Richardson S, Freson K, Ouwehand WH, Mumford AD
  TITLE     A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss.
  JOURNAL   Blood 127:2903-14 (2016)
///
ENTRY       H01741                      Disease
NAME        Autoinflammation lipodystrophy and dermatosis syndrome (ALDD) ;
            Proteasome associated autoinflammatory syndromes (PRAAS);
            Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome;
            Joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy (JMP);
            Japanese autoinflammatory syndrome with lipodystrophy (JASL)
DESCRIPTION Autoinflammation lipodystrophy and dermatosis syndrome (ALDD) is a systemic inflammatory condition characterized by recurrent episodes of fever, cutaneous lesions, lipodystrophy, and visceral inflammatory manifestations. In 2011, several studies showed that a number of disorders referred to as joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy (JMP) syndrome, Nakajo-Nishimura syndrome, Japanese autoinflammatory syndrome with lipodystrophy (JASL), and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome are caused by mutations in proteasome subunit beta type 8 (PSMB8) gene, indicating that these disorders are disease phenotypes along the same disease spectrum. Key symptoms include a persistent fever (higher than 38.5 degrees Celsius), steroid-sensitive erythema nodosum-like (edematous and purpuric) plaques, long clubbed fingers, hyperhidrosis, myositis, hepatosplenomegaly, macroglossia, facial and limbs lipoatrophy, and developmental (height, weight, and IQ) retardation. Skin biopsies show immature myeloid-lineage cells with mitoses. Some patients may have joint contracture, auricular and nasal chondritis, and calcification of the basal ganglia. Acute cardiovascular event is the leading cause of death in these patients for whom life expectancy is notably reduced. Management of these patients is by palliative care. The need for steroids is very high even in combination with anti IL-1, anti IL-6 or anti-TNF treatments.
CATEGORY    Immune system disease
GENE        PSMB8 [HSA:5696] [KO:K02740]
DRUG        Steroids
DBLINKS     ICD-10: D89.8
            OMIM: 256040
REFERENCE   PMID:23711932 (description, gene)
  AUTHORS   Almeida de Jesus A, Goldbach-Mansky R
  TITLE     Monogenic autoinflammatory diseases: concept and clinical manifestations.
  JOURNAL   Clin Immunol 147:155-74 (2013)
REFERENCE   PMID:24131530 (description, gene)
  AUTHORS   Touitou I, Galeotti C, Rossi-Semerano L, Hentgen V, Piram M, Kone-Paut I
  TITLE     The expanding spectrum of rare monogenic autoinflammatory diseases.
  JOURNAL   Orphanet J Rare Dis 8:162 (2013)
REFERENCE   PMID:25017460 (description)
  AUTHORS   Davila-Seijo P, Hernandez-Martin A, Torrelo A
  TITLE     Autoinflammatory syndromes for the dermatologist.
  JOURNAL   Clin Dermatol 32:488-501 (2014)
///
ENTRY       H01742                      Disease
NAME        Coronary artery disease
DESCRIPTION Coronary artery disease (CAD) is one of the leading causes of death globally. CAD is coupled to a pathogenic process in which lipids and lipoproteins accumulate in the subendothelial intimal layer of the vessel wall. A variety of environmental and genetic risk factors are associated with CAD, including hypercholesterolemia, hypertension, obesity, diabetes, and a family history of early CAD. It has been reported that an autosomal dominant form of CAD is caused by the mutation in transcription factor MEF2A. A missense mutation in LRP6, which encodes a co-receptor in the Wnt signaling pathway, has also been identified.
CATEGORY    Vascular disease
GENE        MEF2A [HSA:4205] [KO:K09260]
            LRP6 [HSA:4040] [KO:K03068]
DBLINKS     ICD-10: I25.1
            MeSH: D003324
            OMIM: 608320 610947
REFERENCE   PMID:14657507 (gene)
  AUTHORS   Olson EN
  TITLE     Coronary artery disease and the MEF2A transcription factor.
  JOURNAL   Sci Aging Knowledge Environ 2003:pe33 (2003)
REFERENCE   PMID:14645853 (gene)
  AUTHORS   Wang L, Fan C, Topol SE, Topol EJ, Wang Q
  TITLE     Mutation of MEF2A in an inherited disorder with features of coronary artery disease.
  JOURNAL   Science 302:1578-81 (2003)
REFERENCE   PMID:17332414 (gene)
  AUTHORS   Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP
  TITLE     LRP6 mutation in a family with early coronary disease and metabolic risk factors.
  JOURNAL   Science 315:1278-82 (2007)
REFERENCE   PMID:26044129
  AUTHORS   Grover MP, Ballouz S, Mohanasundaram KA, George RA, Goscinski A, Crowley TM, Sherman CD, Wouters MA
  TITLE     Novel therapeutics for coronary artery disease from genome-wide association study data.
  JOURNAL   BMC Med Genomics 8 Suppl 2:S1 (2015)
///
ENTRY       H01743                      Disease
NAME        Autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID)
DESCRIPTION Autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) is a rare autosomal dominant autoinflammatory disease caracterized by early-onset recurrent erythematous plaques and vesiculopustular skin lesions associated with arthralgia, corneal erosions, and interstitial pneumonia. APLAID is an allelic disorder of PLCG2-associated antibody deficiency and immune dysregulation (PLAID) with some overlapping features. A recent study demonstrated that a family with an autoinflammatory disease was found to have point mutations in the same CSH2 domain of PLCG2. The patients identified with APLAID developed recurrent sinopulmonary infections presumably due to a lack of class-switched memory B cells on lymphocyte immunophenotyping. The patients were partially responsive to anakinra and to high-dose corticosteroids.
CATEGORY    Immune system disease
GENE        PLCG2 [HSA:5336] [KO:K05859]
COMMENT     See also H00282.
DBLINKS     ICD-10: D89.8
            OMIM: 614878
REFERENCE   PMID:23711932 (description)
  AUTHORS   Almeida de Jesus A, Goldbach-Mansky R
  TITLE     Monogenic autoinflammatory diseases: concept and clinical manifestations.
  JOURNAL   Clin Immunol 147:155-74 (2013)
REFERENCE   PMID:26206677 (description)
  AUTHORS   Milner JD
  TITLE     PLAID: a Syndrome of Complex Patterns of Disease and Unique Phenotypes.
  JOURNAL   J Clin Immunol 35:527-30 (2015)
REFERENCE   PMID:23887241 (description)
  AUTHORS   Milner JD, Holland SM
  TITLE     The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases.
  JOURNAL   Nat Rev Immunol 13:635-48 (2013)
REFERENCE   PMID:23000145 (gene)
  AUTHORS   Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, Martins MS, Bunney TD, Santich BH, Moir S, Kuhns DB, Long Priel DA, Ombrello A, Stone D, Ombrello MJ, Khan J, Milner JD, Kastner DL, Aksentijevich I
  TITLE     A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.
  JOURNAL   Am J Hum Genet 91:713-20 (2012)
///
ENTRY       H01744                      Disease
NAME        Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis;
            HOIL-1 deficiency
DESCRIPTION Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis is a rare autosomal recessive disorder characterized by chronic autoinflammation, invasive bacterial infections, and muscular amylopectinosis. Patients carried biallelic loss-of-expression and loss-of-function mutations in HOIL1 (RBCK1) gene coding for a component of the linear ubiquitination chain assembly complex (LUBAC). The patients developed recurrent episodes of fever and systemic inflammation with higher concentrations of acute-phase markers, hepatosplenomegaly and lymphadenopathy very early in life. These features are commonly seen in the primary autoinflammatory diseases, although these HOIL-1-deficient patients failed to develop other cardinal features of the primary autoinflammatory diseases, such as pleuritis, pericarditis, peritonitis, or neutrophilic dermatoses.
CATEGORY    Immune system disease
GENE        RBCK1 [HSA:10616] [KO:K10630]
DBLINKS     ICD-10: D89.8
            OMIM: 615895
REFERENCE   PMID:23104095 (description, gene)
  AUTHORS   Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, Abhyankar A, Israel L, Trevejo-Nunez G, Bogunovic D, Cepika AM, MacDuff D, Chrabieh M, Hubeau M, Bajolle F, Debre M, Mazzolari E, Vairo D, Agou F, Virgin HW, Bossuyt X, Rambaud C, Facchetti F, Bonnet D, Quartier P, Fournet JC, Pascual V, Chaussabel D, Notarangelo LD, Puel A, Israel A, Casanova JL, Picard C
  TITLE     Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency.
  JOURNAL   Nat Immunol 13:1178-86 (2012)
REFERENCE   PMID:23798481 (description, gene)
  AUTHORS   Nilsson J, Schoser B, Laforet P, Kalev O, Lindberg C, Romero NB, Davila Lopez M, Akman HO, Wahbi K, Iglseder S, Eggers C, Engel AG, Dimauro S, Oldfors A
  TITLE     Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
  JOURNAL   Ann Neurol 74:914-9 (2013)
REFERENCE   PMID:23160206 (description)
  AUTHORS   Ombrello MJ, Kastner DL, Milner JD
  TITLE     HOIL and water: the two faces of HOIL-1 deficiency.
  JOURNAL   Nat Immunol 13:1133-5 (2012)
///
ENTRY       H01745                      Disease
NAME        Cardiofaciocutaneous syndrome
DESCRIPTION Cardio-facio-cutaneous (CFC) syndrome is a congenital disorder characterized by short stature, a characteristic face, cardiac defects, developmental delay and mental retardation. Affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial characteristics include high forehead, down-slanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears. CFC can be caused by mutations in BRAF, KRAS, MEK1, and MEK2, encoding components of the RAS-MAPK pathway.
CATEGORY    Developmental disorder; Cardiovascular disease
COMMENT     See also H00523 Noonan syndrome and related disorders.
DBLINKS     ICD-10: Q87.8
            MeSH: C535579
            OMIM: 115150 615278 615279 615280
REFERENCE   PMID:16474404 (gene)
  AUTHORS   Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y
  TITLE     Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
  JOURNAL   Nat Genet 38:294-6 (2006)
REFERENCE   PMID:18042262 (gene)
  AUTHORS   Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, Hubner CA, Korenke GC, Konig R, Kress W, Kruger G, Meinecke P, Mucke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M
  TITLE     Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
  JOURNAL   Clin Genet 73:62-70 (2008)
///
ENTRY       H01746                      Disease
NAME        STING-associated basculopathy with onset in infancy (SAVI)
DESCRIPTION STING (stimulator of interferon genes)-associated basculopathy with onset in infancy (SAVI) is a rare hereditary autoinflammatory disorder caused by gain-of-function mutations in TMEM173, the gene encoding the STING protein. It is considered that the mutations in the TMEM173 gene confer constitutive activation of STING and hypersensitivity to ligand stimulation, resulting in chronic activation of the STING-interferon pathway. Patients with SAVI have severe neonatal-onset small vessel vasculitis, which is expressed by telangiectatic ulcerative rashes in the limbs, earlobes, or nose, leading to microangiopathic thrombosis, vessel occlusion, and even risk of gangrene. Some SAVI patients may present chronic interstitial lung disease, which can be severe and lethal.
CATEGORY    Immune system disease
GENE        TMEM173 [HSA:340061] [KO:K12654]
DBLINKS     ICD-10: D89.8
            OMIM: 615934
REFERENCE   PMID:27983684 (description)
  AUTHORS   Tarantino G, Esposito S, Andreozzi L, Bracci B, D'Errico F, Rigante D
  TITLE     Lung Involvement in Children with Hereditary Autoinflammatory Disorders.
  JOURNAL   Int J Mol Sci 17 (2016)
REFERENCE   PMID:25029335 (description, gene)
  AUTHORS   Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, Lee CC, DiMattia MA, Cowen EW, Gonzalez B, Palmer I, DiGiovanna JJ, Biancotto A, Kim H, Tsai WL, Trier AM, Huang Y, Stone DL, Hill S, Kim HJ, St Hilaire C, Gurprasad S, Plass N, Chapelle D, Horkayne-Szakaly I, Foell D, Barysenka A, Candotti F, Holland SM, Hughes JD, Mehmet H, Issekutz AC, Raffeld M, McElwee J, Fontana JR, Minniti CP, Moir S, Kastner DL, Gadina M, Steven AC, Wingfield PT, Brooks SR, Rosenzweig SD, Fleisher TA, Deng Z, Boehm M, Paller AS, Goldbach-Mansky R
  TITLE     Activated STING in a vascular and pulmonary syndrome.
  JOURNAL   N Engl J Med 371:507-18 (2014)
REFERENCE   PMID:25401470 (gene)
  AUTHORS   Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, Goudin N, Fremond ML, Nitschke P, Molina TJ, Blanche S, Picard C, Rice GI, Crow YJ, Manel N, Fischer A, Bader-Meunier B, Rieux-Laucat F
  TITLE     Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations.
  JOURNAL   J Clin Invest 124:5516-20 (2014)
///
ENTRY       H01747                      Disease
NAME        Costello syndrome
DESCRIPTION Costello syndrome (CS) is a rare multiple congenital abnormality syndrome. Patients present with the typical coarse face, deep palmar and plantar creases, redundant and loose skin, severe failure to thrive, congenital heart defect, and mild to severe mental retardation. Hyperpigmentation and papillomas can also be present. They have an increased risk of malignancy. The majority of patients show a mutation in HRAS.
CATEGORY    Developmental disorder; Cardiovascular disease
GENE        HRAS [HSA:3265] [KO:K02833]
COMMENT     See also H00523 Noonan syndrome and related disorders.
DBLINKS     ICD-10: Q87.1
            MeSH: D056685
            OMIM: 218040
REFERENCE   PMID:18042262
  AUTHORS   Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, Hubner CA, Korenke GC, Konig R, Kress W, Kruger G, Meinecke P, Mucke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M
  TITLE     Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
  JOURNAL   Clin Genet 73:62-70 (2008)
REFERENCE   PMID:16443854 (gene)
  AUTHORS   Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cave H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G
  TITLE     Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.
  JOURNAL   J Med Genet 43:401-5 (2006)
///
ENTRY       H01748                      Disease
NAME        Autoinflammation with infantile enterocolitis (AIFEC)
DESCRIPTION Autoinflammation with infantile enterocolitis (AIFEC) is a rare autosomal dominant disease characterized by neonatal-onset enterocolitis, periodic fever, and fatal/near-fatal episodes of autoinflammation. It was shown that the disease is caused by gain-of-function mutations in NLRC4. NLRC4 protein is known to directly assemble inflammasomes that activate IL-1beta and IL-18.
CATEGORY    Immune system disease
GENE        NLRC4 [HSA:58484] [KO:K12805]
DBLINKS     ICD-10: D89.8
            OMIM: 616050
REFERENCE   PMID:25217959 (description, gene)
  AUTHORS   Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, DiMattia MA, Zaal KJ, Sanchez GA, Kim H, Chapelle D, Plass N, Huang Y, Villarino AV, Biancotto A, Fleisher TA, Duncan JA, O'Shea JJ, Benseler S, Grom A, Deng Z, Laxer RM, Goldbach-Mansky R
  TITLE     An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent  macrophage activation syndrome.
  JOURNAL   Nat Genet 46:1140-6 (2014)
REFERENCE   PMID:25217960 (description, gene)
  AUTHORS   Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, Overton J, Meffre E, Khokha MK, Huttner AJ, West B, Podoltsev NA, Boggon TJ, Kazmierczak BI, Lifton RP
  TITLE     Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation.
  JOURNAL   Nat Genet 46:1135-9 (2014)
///
ENTRY       H01749                      Disease
NAME        Achondroplasia
DESCRIPTION Achondroplasia is the most common skeletal dysplasia and the most frequent cause of short-limbed dwarfism. It is usually recognised at birth because of its distinctive clinical and radiographic features. Newborn infants with achondroplasia typically present with disproportionate shortening of the limbs, a long and narrow trunk, a large head with frontal bossing and midface retrusion. This disease is caused by mutations of the transmembrane receptor FGFR3, an important regulator of bone growth. It is inherited in an autosomal dominant manner, but in the majority of cases it results from de novo mutations. The most common complications of achondroplasia are medullary and radicular compressions due to spinal stenosis and deformities of the lower limbs. Most individuals with achondroplasia have normal intelligence.
CATEGORY    Skeletal dysplasia
GENE        FGFR3 [HSA:2261] [KO:K05094]
COMMENT     See also H00505 FGFR3-related short limb skeletal dysplasias.
DBLINKS     ICD-10: Q78.9
            MeSH: D000130
            OMIM: 100800
REFERENCE   PMID:22559284 (gene, description)
  AUTHORS   Laederich MB, Horton WA
  TITLE     FGFR3 targeting strategies for achondroplasia.
  JOURNAL   Expert Rev Mol Med 14:e11 (2012)
REFERENCE   PMID:17950653 (gene, description)
  AUTHORS   Richette P, Bardin T, Stheneur C
  TITLE     Achondroplasia: from genotype to phenotype.
  JOURNAL   Joint Bone Spine 75:125-30 (2008)
REFERENCE   PMID:23200862
  AUTHORS   Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O'Neill CA, Di Rocco F, Munnich A, Legeai-Mallet L
  TITLE     Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
  JOURNAL   Am J Hum Genet 91:1108-14 (2012)
REFERENCE   PMID:25231866
  AUTHORS   Yamashita A, Morioka M, Kishi H, Kimura T, Yahara Y, Okada M, Fujita K, Sawai H, Ikegawa S, Tsumaki N
  TITLE     Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
  JOURNAL   Nature 513:507-11 (2014)
///
ENTRY       H01750                      Disease
NAME        Thanatophoric dysplasia
DESCRIPTION Thanatophoric dysplasia (TD) is a congenital skeletal dysplasia characterized by marked underdevelopment of the skeletal system and short-limb dwarfism. It is the most common form of lethal skeletal dysplasia syndromes. Two types of TD have been described. Type I TD (TDI) is associated with curved and short femurs. The shortness of the bones in type II TD (TDII) is not as significant as in TDI. TDII is characterized by straight femurs and cloverleaf skull deformity. Other features common to type I and type II include short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Both TDI and TDII are caused by heterozygous fibroblast growth factor receptor 3 (FGFR3) missense mutations. Its incidence is 1 in 20 000 to 50 000 births and it is an autosomal dominant condition. The mutation in most TD cases is de novo.
CATEGORY    Skeletal dysplasia
GENE        FGFR3 [HSA:2261] [KO:K05094]
COMMENT     TDI is known to arise because of five different mutations, all involving the substitution of an amino acid with a cysteine in FGFR3: Arg248Cys, Ser249Cys, Gly370Cys, Ser371Cys, and Tyr373Cys.
            See also H00505 FGFR3-related short limb skeletal dysplasias.
DBLINKS     ICD-10: Q77.1
            MeSH: D013796
            OMIM: 187600 187601
REFERENCE   PMID:20301540
  AUTHORS   Karczeski B, Cutting GR
  TITLE     Thanatophoric Dysplasia
  JOURNAL   (1993)
REFERENCE   PMID:19449430 (gene)
  AUTHORS   Pannier S, Martinovic J, Heuertz S, Delezoide AL, Munnich A, Schibler L, Serre V, Legeai-Mallet L
  TITLE     Thanatophoric dysplasia caused by double missense FGFR3 mutations.
  JOURNAL   Am J Med Genet A 149A:1296-301 (2009)
REFERENCE   PMID:25606676 (gene)
  AUTHORS   Del Piccolo N, Placone J, Hristova K
  TITLE     Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
  JOURNAL   Biophys J 108:272-8 (2015)
REFERENCE   PMID:25800480 (gene)
  AUTHORS   Gulasi S, Atici A, Celik Y
  TITLE     A case of thanatophoric dysplasia type 2: a novel mutation.
  JOURNAL   J Clin Res Pediatr Endocrinol 7:73-6 (2015)
///
ENTRY       H01751                      Disease
NAME        Weaver syndrome
DESCRIPTION Weaver syndrome (WS) is an overgrowth syndrome, characterized by tall stature, a typical facial appearance, and variable intellectual disability. Although there is phenotypic overlap between Weaver syndrome and Sotos syndrome, WS patients have additional clinical features including camptodactyly, doughy skin, umbilical hernia, and a low hoarse cry. Recently, mutations in the histone methyltransferase, EZH2, were shown to cause WS.
CATEGORY    Developmental disorder
GENE        EZH2 [HSA:2146] [KO:K11430]
COMMENT     See also H00718 Sotos syndrome.
DBLINKS     ICD-10: Q87.3
            MeSH: C536687
            OMIM:277590
REFERENCE   PMID:24214728 (gene)
  AUTHORS   Tatton-Brown K, Murray A, Hanks S, Douglas J, Armstrong R, Banka S, Bird LM, Clericuzio CL, Cormier-Daire V, Cushing T, Flinter F, Jacquemont ML, Joss S, Kinning E, Lynch SA, Magee A, McConnell V, Medeira A, Ozono K, Patton M, Rankin J, Shears D, Simon M, Splitt M, Strenger V, Stuurman K, Taylor C, Titheradge H, Van Maldergem L, Temple IK, Cole T, Seal S, Rahman N
  TITLE     Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.
  JOURNAL   Am J Med Genet A 161A:2972-80 (2013)
REFERENCE   PMID:23865096 (gene)
  AUTHORS   Tatton-Brown K, Rahman N
  TITLE     EZH2-Related Overgrowth
  JOURNAL   (1993)
///
ENTRY       H01752                      Disease
NAME        ATR-X syndrome;
            X-linked alpha-thalassemia/mental retardation syndrome
DESCRIPTION X-linked alpha-thalassemia/mental retardation syndrome (ATR-X syndrome) is a rare syndromic form of X-linked mental retardation. It is characterized by severe mental retardation in males, characteristic facial appearance, alpha thalassaemia, genital anomalies, skeletal abnormalities, and characteristic posture and/or behavior. ATR-X syndrome is caused by a mutation in the ATRX gene, a critical factor involved in heterochromatin formation at mammalian centromeres and telomeres.
CATEGORY    Developmental disorder; Hematologic disease; Mental retardation
GENE        ATRX [HSA:546] [KO:K10779]
COMMENT     See also H00228 Thalassemia and H00577 Syndromic X-linked mental retardation with epilepsy or seizures.
DBLINKS     ICD-10: Q87.0
            MeSH: C538258
            OMIM: 301040
REFERENCE   PMID:16100724
  AUTHORS   Wada T, Sugie H, Fukushima Y, Saitoh S
  TITLE     Non-skewed X-inactivation may cause mental retardation in a female carrier of X-linked alpha-thalassemia/mental retardation syndrome (ATR-X): X-inactivation study of nine female carriers of ATR-X.
  JOURNAL   Am J Med Genet A 138:18-20 (2005)
REFERENCE   PMID:17579672 (gene)
  AUTHORS   Thienpont B, de Ravel T, Van Esch H, Van Schoubroeck D, Moerman P, Vermeesch JR, Fryns JP, Froyen G, Lacoste C, Badens C, Devriendt K
  TITLE     Partial duplications of the ATRX gene cause the ATR-X syndrome.
  JOURNAL   Eur J Hum Genet 15:1094-7 (2007)
REFERENCE   PMID:21653732 (gene)
  AUTHORS   De La Fuente R, Baumann C, Viveiros MM
  TITLE     Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease.
  JOURNAL   Reproduction 142:221-34 (2011)
///
ENTRY       H01753                      Disease
NAME        Antley-Bixler syndrome
DESCRIPTION Antley-Bixler syndrome (ABS) is a rare craniosynostosis syndrome characterized by radiohumeral synostosis. There is a wide spectrum of anomalies seen in ABS. Other features include midface hypoplasia, choanal stenosis or atresia, and multiple joint contractures. Two genetically distinctive forms have been observed. Type 1 ABS involves mutations in the FGFR2 gene without impairment of steroidogenesis. Type 1 ABS patients are with the most severe skeletal abnormalities but normal genitalia. Type 2 ABS involves mutations in the gene encoding cytochrome P450 oxidoreductase (POR), an enzyme which plays a direct role in steroidogenesis. Type 2 ABS is an autosomal recessive disorder, and it is associated with abnormal genitalia in both sexes due to impaired steroidogenesis. Mortality has been reported to be as high as 80% in the neonatal period, primarily due to airway compromise, and prognosis improves with increasing age.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FGFR2 [HSA:2263] [KO:K05093]
            POR [HSA:5447] [KO:K00327]
ENV_FACTOR  Fluconazole [DR:D00322]
COMMENT     High doses of fluconazole taken during the first trimester of pregnancy may be associated with Antley-Bixler syndrome.
            See also H00458 Craniosynostosis.
DBLINKS     ICD-10: Q87.0
            MeSH: D054882
            OMIM:201750 207410
REFERENCE   PMID:24027687
  AUTHORS   Lahiri S, Ghoshal B, Nandi D
  TITLE     A case of antley-bixler syndrome.
  JOURNAL   J Clin Neonatol 1:46-8 (2012)
REFERENCE   PMID:24334858
  AUTHORS   Boia ES, Popoiu MC, Puiu M, Stanciulescu CM, David VL
  TITLE     Antley-Bixler syndrome: surgical management of ambiguous genitalia - a case report.
  JOURNAL   Med Princ Pract 23:384-6 (2014)
REFERENCE   PMID:18455494 (gene)
  AUTHORS   Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, Rueff J
  TITLE     Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.
  JOURNAL   Arch Biochem Biophys 475:93-9 (2008)
REFERENCE   PMID:10633130 (Env_factor)
  AUTHORS   Reardon W, Smith A, Honour JW, Hindmarsh P, Das D, Rumsby G, Nelson I, Malcolm S, Ades L, Sillence D, Kumar D, DeLozier-Blanchet C, McKee S, Kelly T, McKeehan WL, Baraitser M, Winter RM
  TITLE     Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?
  JOURNAL   J Med Genet 37:26-32 (2000)
///
ENTRY       H01754                      Disease
NAME        Crouzon syndrome
DESCRIPTION Crouzon syndrome (CS) is an autosomal dominant disorder characterized by generalized craniosynostoses, maxillary hypoplasia, widely spaced but shallow orbits with prominent globes. Heterozygous mutations of FGFR2 cause three classical craniosynostosis syndromes, Apert, Crouzon and Pfeiffer. Crouzon syndrome is usually the mildest of the FGFR2-associated disorders and the clinical diagnosis is suggested by the combination of characteristic facies and absence of major abnormalities of the hands and feet. It has also been reported that a mutation of FGFR3 gene causes Crouzon syndrome with acanthosis nigricans.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FGFR2 [HSA:2263] [KO:K05093]
            FGFR3 [HSA:2261] [KO:K05094]
COMMENT     See also H00458 Craniosynostosis.
DBLINKS     ICD-10: Q75.1
            MeSH: D003394
            OMIM:123500 612247
REFERENCE   PMID:21248745
  AUTHORS   Johnson D, Wilkie AO
  TITLE     Craniosynostosis.
  JOURNAL   Eur J Hum Genet 19:369-76 (2011)
REFERENCE   PMID:24346169
  AUTHORS   Weiss AH, Phillips J, Kelly JP
  TITLE     Crouzon syndrome: relationship of rectus muscle pulley location to pattern strabismus.
  JOURNAL   Invest Ophthalmol Vis Sci 55:310-7 (2014)
REFERENCE   PMID:26362256 (gene)
  AUTHORS   Bagheri-Fam S, Ono M, Li L, Zhao L, Ryan J, Lai R, Katsura Y, Rossello FJ, Koopman P, Scherer G, Bartsch O, Eswarakumar JV, Harley VR
  TITLE     FGFR2 mutation in 46,XY sex reversal with craniosynostosis.
  JOURNAL   Hum Mol Genet 24:6699-710 (2015)
REFERENCE   PMID:17935505 (gene)
  AUTHORS   Arnaud-Lopez L, Fragoso R, Mantilla-Capacho J, Barros-Nunez P
  TITLE     Crouzon with acanthosis nigricans. Further delineation of the syndrome.
  JOURNAL   Clin Genet 72:405-10 (2007)
///
ENTRY       H01755                      Disease
NAME        Apert syndrome
DESCRIPTION Apert syndrome is a rare autosomal dominant disorder characterized by craniosynostosis, severe syndactyly of hands and feet, and dysmorphic facial features. Other frequent complications include cleft palate and learning disability. Over 98% of cases are caused by specific missense mutations of FGFR2, either Ser252Trp or Pro253Arg.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FGFR2 [HSA:2263] [KO:K05093]
COMMENT     See also H00458 Craniosynostosis.
DBLINKS     ICD-10: Q87.0
            MeSH: D000168
            OMIM:101200
REFERENCE   PMID:21248745
  AUTHORS   Johnson D, Wilkie AO
  TITLE     Craniosynostosis.
  JOURNAL   Eur J Hum Genet 19:369-76 (2011)
REFERENCE   PMID:28058401
  AUTHORS   Koca TT
  TITLE     Apert syndrome: A case report and review of the literature.
  JOURNAL   North Clin Istanb 3:135-139 (2016)
REFERENCE   PMID:23546041 (gene)
  AUTHORS   Mundhofir FE, Sistermans EA, Faradz SM, Hamel BC
  TITLE     p.Ser252Trp and p.Pro253Arg mutations in FGFR2 gene causing Apert syndrome: the first clinical and molecular report of Indonesian patients.
  JOURNAL   Singapore Med J 54:e72-5 (2013)
///
ENTRY       H01756                      Disease
NAME        Pfeiffer syndrome
DESCRIPTION Pfeiffer syndrome is a rare autosomal dominant disorder characterized by craniosynostosis, brachycephaly, midface hypoplasia, and broad and deviated thumbs and great toes. Based on the severity of the phenotype, Pfeiffer syndrome is divided into three subtypes. Type 1 involves individuals with mild manifestations including brachycephaly, midface hypoplasia and finger and toe abnormalities. It is associated with normal intelligence and generally good outcome. Type 2 consists of cloverleaf skull, extreme proptosis, finger and toe abnormalities, elbow ankylosis or synostosis, developmental delay and neurological complications. Type 3 is similar to type 2 but without a cloverleaf skull. Mutations of the FGFR1 gene or FGFR2 gene can cause Pfeiffer syndrome.
CATEGORY    Developmental disorder; Skeletal dysplasia
GENE        FGFR1 [HSA:2260] [KO:K04362]
            FGFR2 [HSA:2263] [KO:K05093]
COMMENT     See also H00458 Craniosynostosis.
DBLINKS     ICD-10: Q87.0
            MeSH: D000168
            OMIM:101600
REFERENCE   PMID:21248745
  AUTHORS   Johnson D, Wilkie AO
  TITLE     Craniosynostosis.
  JOURNAL   Eur J Hum Genet 19:369-76 (2011)
REFERENCE   PMID:16740155
  AUTHORS   Vogels A, Fryns JP
  TITLE     Pfeiffer syndrome.
  JOURNAL   Orphanet J Rare Dis 1:19 (2006)
REFERENCE   PMID:21189955 (gene)
  AUTHORS   Lee MY, Jeon GW, Jung JM, Sin JB
  TITLE     A case of Pfeiffer syndrome with c833_834GC&gt;TG (Cys278Leu) mutation in the FGFR2  gene.
  JOURNAL   Korean J Pediatr 53:774-7 (2010)
///
ENTRY       H01757                      Disease
NAME        Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy;
            CARASIL
DESCRIPTION Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a very rare autosomal recessive vascular disorder characterized by nonhypertensive cerebral small-vessel disease with early adulthood onset subcortical infarcts, progressive motor and cognitive impairment, alopecia, and spondylosis. Until recently, this disorder was almost exclusively reported in the Asian population. It has been found that CARASIL is associated with mutations in the HTRA1 gene encoding HtrA serine protease 1.
CATEGORY    Developmental disorder; Vascular disease
GENE        HTRA1 [HSA:5654] [KO:K08784]
DBLINKS     ICD-10: F01.1
            MeSH: C563990
            OMIM:600142
REFERENCE   PMID:25712943
  AUTHORS   Menezes Cordeiro I, Nzwalo H, Sa F, Ferreira RB, Alonso I, Afonso L, Basilio C
  TITLE     Shifting the CARASIL paradigm: report of a non-Asian family and literature review.
  JOURNAL   Stroke 46:1110-2 (2015)
REFERENCE   PMID:22900900 (gene)
  AUTHORS   Wang XL, Li CF, Guo HW, Cao BZ
  TITLE     A novel mutation in the HTRA1 gene identified in Chinese CARASIL pedigree.
  JOURNAL   CNS Neurosci Ther 18:867-9 (2012)
///
ENTRY       H01758                      Disease
NAME        Relapsing polychondritis
DESCRIPTION Relapsing polychondritis (RP) is a rare multisystemic disease widely accepted as a complex autoimmune disorder affecting proteoglycan-rich structures and cartilaginous tissues, including the ear, nose, larynx, trachea, bronchi, peripheral joints, eye, heart, and skin, with high risk of misdiagnosis. The clinical spectrum may vary from intermittent inflammatory episodes leading to unesthetic structural deformities to life-threatening cardiopulmonary manifestations, such as airway collapse and valvular regurgitation. The diagnosis of RP is largely based on the clinical features and the role of laboratory investigations is purely supportive and to rule out other related or associated systemic diseases. Treatment in RP is largely symptomatic and a standard management protocol is yet to be established due to its rarity.
CATEGORY    Musculoskeletal disease; Skin and connective tissue disease
DBLINKS     ICD-10: M94.1
            MeSH: D011081
REFERENCE   PMID:23887438 (description)
  AUTHORS   Sharma A, Gnanapandithan K, Sharma K, Sharma S
  TITLE     Relapsing polychondritis: a review.
  JOURNAL   Clin Rheumatol 32:1575-83 (2013)
REFERENCE   PMID:24461536 (description)
  AUTHORS   Cantarini L, Vitale A, Brizi MG, Caso F, Frediani B, Punzi L, Galeazzi M, Rigante D
  TITLE     Diagnosis and classification of relapsing polychondritis.
  JOURNAL   J Autoimmun 48-49:53-9 (2014)
REFERENCE   PMID:26711694 (description)
  AUTHORS   Vitale A, Sota J, Rigante D, Lopalco G, Molinaro F, Messina M, Iannone F, Cantarini L
  TITLE     Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives.
  JOURNAL   Curr Rheumatol Rep 18:3 (2016)
///
ENTRY       H01759                      Disease
NAME        Autoimmune hemorrhaphilia XIII/13;
            Autoimmune acquired factor XIII (F13) deficiency
DESCRIPTION Autoimmune acquired factor XIII (F13) deficiency or autoimmune hemorrhaphilia resulted from the generation of anti-F13 antibodies (AHFXIII) is a rare but severe life-threatening bleeding disorder. In contrast, non-autoimmune hemorrhagic acquired F13 deficiency (HAF13D) is a less severe bleeding disease secondary to various disease conditions. AHFXIII must be distinguished from HAF13D since AHFXIII requires immunosuppressive therapy to eradicate autoantibodies in addition to F13 replacement therapy to arrest bleeding. Patients with acquired F13 deficiency, in particular those with AHFXIII, are on the increase, at least in Japan.
CATEGORY    Hematologic disease
DRUG        Human blood-coagulation factor XIII fraction, dried [DR:08802]
DBLINKS     ICD-10: D68.4
REFERENCE   PMID:27542511 (description)
  AUTHORS   Ichinose A
  TITLE     Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients.
  JOURNAL   Blood Rev 31:37-45 (2017)
REFERENCE   PMID:24476525 (description)
  AUTHORS   Tahlan A, Ahluwalia J
  TITLE     Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII  A-subunit, and factor XIII B-subunit.
  JOURNAL   Arch Pathol Lab Med 138:278-81 (2014)
REFERENCE   PMID:22477542 (description)
  AUTHORS   Ichinose A
  TITLE     Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.
  JOURNAL   Int J Hematol 95:362-70 (2012)
///
ENTRY       H01760                      Disease
NAME        Hepatic glycogen storage disease
DESCRIPTION Glycogen storage diseases (GSD) are inherited metabolic disorders of glycogen metabolism. They are divided into types 0 to XV, according to enzyme or transporter deficiency and organ distribution. The hepatic GSDs lead to hepatomegaly and hypoglycemia due to the lack of distribution of glucose to the organism. 80% of hepatic GSD is formed by types I, III, and IX. GSD I involves the liver, kidney and intestine, and the clinical manifestations are hepatomegaly, failure to thrive, hypoglycemia, hyperlactatemia, hyperuricemia and hyperlipidemia. GSD IIIa patients display symptoms and signs due to the enzyme deficiency in liver, skeletal muscle and heart, whereas the remaining patients with GSD IIIb have only liver-related phenotypes. GSD IV usually presents in the first year of life, with hepatomegaly and growth retardation. GSD VI and IX are caused by a deficiency of the liver phosphorylase and phosphorylase kinase system, and with usually moderate symptoms which manifest mainly in childhood.
CATEGORY    Inherited metabolic disease; Liver disease
GENE        (GSB Ia) G6PC [HSA:2538] [KO:K01084]
            (GSB Ib) SLC37A4 [HSA:2542] [KO:K08171]
            (GSB IIIa/b) AGL [HSA:178] [KO:K01196]
            (GSB IV) GBE1 [HSA:2632] [KO:K00700]
            (GSB VI) PYGL [HSA:5836] [KO:K00688]
            (GSB IX) PHKA2 [HSA:5256] [KO:K07190]
            (GSB IXb) PHKB [HSA:5257] [KO:K07190]
            (GSB IXc) PHKG2 [HSA:5261] [KO:K00871]
            (GSB 0a) GYS2 [HSA:2998] [KO:K00693]
MARKER      Hyperlactacidaemia
            Hyperuricaemia
            Hyperlipidaemia
COMMENT     See also H00069 Glycogen storage diseases (GSD).
DBLINKS     ICD-10: E74.0
            MeSH: D006008
            OMIM: 232200 232220 232240 232400 232500 232700 306000 261750 613027 240600
REFERENCE   PMID:17552001
  AUTHORS   Ozen H
  TITLE     Glycogen storage diseases: new perspectives.
  JOURNAL   World J Gastroenterol 13:2541-53 (2007)
REFERENCE   PMID:21646031 (gene)
  AUTHORS   Davit-Spraul A, Piraud M, Dobbelaere D, Valayannopoulos V, Labrune P, Habes D, Bernard O, Jacquemin E, Baussan C
  TITLE     Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies.
  JOURNAL   Mol Genet Metab 104:137-43 (2011)
REFERENCE   PMID:25633903 (gene)
  AUTHORS   Derks TG, van Rijn M
  TITLE     Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.
  JOURNAL   J Inherit Metab Dis 38:537-43 (2015)
///
ENTRY       H01761                      Disease
NAME        Immunoglobulin G4-related disease;
            Immunoglobulin G4-positive multi-organ lymphoproliferative syndrome
DESCRIPTION Immunoglobulin G4-related disease is a distinct clinical entity characterised by hyper-IgG4 gammaglobulinemia and IgG4 positive plasma cell infiltration in the tissue. Other characteristic features of this syndrome include mass-forming lesion with fibrosis and prompt and good response to corticosteroids. This disease includes Mikulicz's disease (MD), autoimmune pancreatitis, sclerosing cholangitis, Kuttner's tumour, inflammatory pseudotumor of the lung, liver, and breast, retroperitoneal and mediastinal fibrosis, interstitial nephritis, autoimmune hypophysitis, and many other inflammatory conditions in multiple organs. Glucocorticoids are the mainstay of treatment; recently, rituximab, a select B-cell depleting agent, has been shown to provide an excellent clinical response in select patients.
CATEGORY    Immune system disease
DRUG        Rituximab [DR:D02994]
DBLINKS     ICD-10: M35.9 K11.8
REFERENCE   PMID:20457280 (description)
  AUTHORS   Takahashi H, Yamamoto M, Suzuki C, Naishiro Y, Shinomura Y, Imai K
  TITLE     The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity.
  JOURNAL   Autoimmun Rev 9:591-4 (2010)
REFERENCE   PMID:18701557 (description)
  AUTHORS   Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, Takahashi H, Shinomura Y, Imai K, Saeki T, Azumi A, Nakada S, Sugiyama E, Matsui S, Origuchi T, Nishiyama S, Nishimori I, Nojima T, Yamada K, Kawano M, Zen Y, Kaneko M, Miyazaki K, Tsubota K, Eguchi K, Tomoda K, Sawaki T, Kawanami T, Tanaka M, Fukushima T, Sugai S, Umehara H
  TITLE     Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative  syndrome: analysis of 64 cases of IgG4-related disorders.
  JOURNAL   Ann Rheum Dis 68:1310-5 (2009)
REFERENCE   PMID:27153787 (description, drug)
  AUTHORS   Katabathina VS, Khalil S, Shin S, Lath N, Menias CO, Prasad SR
  TITLE     Immunoglobulin G4-Related Disease: Recent Advances in Pathogenesis and Imaging Findings.
  JOURNAL   Radiol Clin North Am 54:535-51 (2016)
///
ENTRY       H01762                      Disease
NAME        Muscle glycogen storage disease
DESCRIPTION Glycogen storage diseases (GSD) are inherited metabolic disorders of glycogen metabolism. They are divided into types 0 to XV, according to enzyme or transporter deficiency and organ distribution. Disorders of glycogen degradation may affect primarily the liver, the muscle, or both. GSD has been known to mainly be a liver disease with the exception of Pompe (GSD II), McArdle (GSD V), or Tarui (GSD VII) diseases. Recently, however, various muscular disorders involving different types of muscles have been described to be caused by defective glycogen metabolism. In the Muscle GSDs, the consequence of a block in skeletal muscle glycogenolysis, or in the glycolysis, is an impairment of muscular performance, owing to an increase in glycogen storage that disrupts contractile function and/or a reduced substrate turnover, which inhibits skeletal muscle ATP production.
CATEGORY    Inherited metabolic disease; Musculoskeletal disease
GENE        (GSD II) GAA [HSA:2548] [KO:K12316]
            (GSDIII) AGL [HSA:178] [KO:K01196]
            (GSDIV) GBE1 [HSA:2632] [KO:K00700]
            (GSDV) PYGM [HSA:5837] [KO:K00688]
            (GSDVII) PFKM [HSA:5213] [KO:K00850]
            (GSDIXd) PHKA1 [HSA:5255] [KO:K07190]
            (GSD X) PGAM2 [HSA:5224] [KO:K01834]
            (GSD XI) LDHA [HSA:3939] [KO:K00016]
            (GSD XII) ALDOA [HSA:226] [KO:K01623]
            (GSD XIII) ENO3 [HSA:2027] [KO:K01689]
            (GSD XIV) PGM1 [HSA:5236] [KO:K01835]
            (GSD V) GYG1 [HSA:2992] [KO:K00750]
            (GSB 0) GYS1 [HSA:2997] [KO:K00693]
COMMENT     See also H00069 Glycogen storage diseases (GSD).
DBLINKS     ICD-10: E74.0
            MeSH: D006008
            OMIM: 232300 232400 232500 232600 232800 300559 261670 612933 611881 612932 614921 613507 611556
REFERENCE   PMID:17552001
  AUTHORS   Ozen H
  TITLE     Glycogen storage diseases: new perspectives.
  JOURNAL   World J Gastroenterol 13:2541-53 (2007)
REFERENCE   PMID:17027861 (gene)
  AUTHORS   Shin YS
  TITLE     Glycogen storage disease: clinical, biochemical, and molecular heterogeneity.
  JOURNAL   Semin Pediatr Neurol 13:115-20 (2006)
REFERENCE   PMID:25326273
  AUTHORS   Preisler N, Haller RG, Vissing J
  TITLE     Exercise in muscle glycogen storage diseases.
  JOURNAL   J Inherit Metab Dis 38:551-63 (2015)
///
ENTRY       H01763                      Disease
NAME        Porphyria
DESCRIPTION Porphyria is an inborn error of heme biosynthesis porphyrin metabolism caused by deficiency of enzymes of porphyrin metabolism. The intermediates of this pathway (porphyrinogens, porphyrins and their precursors) are produced in excess and accumulate in tissues, resulting in neurological and/or photocutaneous symptoms, and hematological disturbances. Porphyrias are divided into erythropoietic and hepatic according to the predominant porphyrin-accumulating tissue. Erythropoietic porphyrias include erythropoietic protoporphyria (EPP), congenital erythropoietic porphyria (CEP), and the very rare hepatoerythropoietic porphyria (HEP). Hepatic porphyrias include ALA-dehydratase deficiency porphyria (ADP), acute intermittent porphyria (AIP), porphyria cutanea tarda (PCT), hereditary coproporphyria (HCP), and variegate porphyria (VP). Recently, a new type of erythroid porphyria, X-linked dominant protoporphyria (XLDPP) has been reported.
CATEGORY    Inherited metabolic disease
GENE        (EPP) FECH [HSA:2235] [KO:K01772]
            (CEP) UROS [HSA:7390] [KO:K01719]
            (HEP) UROD [HSA:7389] [KO:K01599]
            (ADP) ALAD [HSA:210] [KO:K01698]
            (AIP) HMBS [HSA:3145] [KO:K01749]
            (PCT) UROD [HSA:7389] [KO:K01599]
            (HCP) CPOX [HSA:1371] [KO:K00228]
            (VP) PPOX [HSA:5498] [KO:K00231]
            (XLDPP) ALAS2 [HSA:212] [KO:K00643]
DRUG        Hemin [DR:D10003] (Hepatic)
COMMENT     See also H00201 Erythropoietic porphyria, and H00202 Hepatic porphyria.
DBLINKS     ICD-10: E80
            MeSH: D017092 D017094
            OMIM: 177000 263700 176000 176100 176200 121300 125270 300752
REFERENCE   PMID:18537592 (gene)
  AUTHORS   Richard E, Robert-Richard E, Ged C, Moreau-Gaudry F, de Verneuil H
  TITLE     Erythropoietic porphyrias: animal models and update in gene-based therapies.
  JOURNAL   Curr Gene Ther 8:176-86 (2008)
REFERENCE   PMID:12367763 (gene, drug)
  AUTHORS   Nordmann Y, Puy H
  TITLE     Human hereditary hepatic porphyrias.
  JOURNAL   Clin Chim Acta 325:17-37 (2002)
REFERENCE   PMID:21653323 (gene)
  AUTHORS   To-Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, Lyoumi S, Gouya L, de Verneuil H, Beaumont C, Ferreira GC, Deybach JC, Herrero C, Puy H
  TITLE     ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
  JOURNAL   Blood 118:1443-51 (2011)
///
ENTRY       H01764                      Disease
NAME        Polysplenia syndrome
DESCRIPTION Polysplenia syndrome (PSS) is a rare subtype of heterotaxy syndrome with multiple spleens. It has been reported that most patients die before 5 years of age because the disease is often associated with congenital anomalies, such as cardiovascular anomalies. Some patients have a normal heart or only minor cardiac defects, are often diagnosed incidentally in patients being treated for other disease. The patient has bilateral bilobed lungs with hyparterial bronchi, abnormal location of abdominal solid organs and malrotation of bowels with multiple spleens. The etiology of PSS is not known yet. The causative factors of PSS are thought to be association of embryonic, genetic and teratogenic components.
CATEGORY    Developmental disorder
COMMENT     See also H00632 Heterotaxy and H01435 Congenital asplenia.
DBLINKS     ICD-10: Q89.0
            MeSH: D059446
            OMIM: 208530
REFERENCE   PMID:19009663
  AUTHORS   Seo HI, Jeon TY, Sim MS, Kim S
  TITLE     Polysplenia syndrome with preduodenal portal vein detected in adults.
  JOURNAL   World J Gastroenterol 14:6418-20 (2008)
REFERENCE   PMID:25237401
  AUTHORS   Yilmaz G, Akpinar SH, Alicioglu B
  TITLE     Polysplenia syndrome detected after chest symptoms in two adult patients: case report and review of literature.
  JOURNAL   Pol J Radiol 79:311-4 (2014)
///
ENTRY       H01765                      Disease
NAME        Eosinophilic sinusitis;
            Eosinophilic chronic rhinosinusitis
DESCRIPTION Eosinophilic chronic rhinosinusitis (ECRS) is an inflammatory pathological condition of the nose and paranasal sinuses. Chronic rhinosinusitis (CRS) is a common disease worldwide, and CRS may be divided into ECRS and non-ECRS subtypes based on the presence of tissue eosinophilic infiltration or not. There are significant geographic and ethnic differences in the tissue eosinophilic infiltration, which is predominant in Western white patients and less common in East Asians, despite an increasing tendency for its prevalence in East Asia countries. ECRS commonly demonstrates more severe symptoms, polyp diseases with a higher incidence of bilateral polyps and sinonasal diseases on computed tomography, and the increase in blood eosinophils. Patients with ECRS exhibit clinical characteristics that include long term nasal congestion, mucus production, olfactory disturbances, bilateral nasal polyposis, and intermittent acute exacerbation of secondary bacterial infections. Since there is no approved medication to treat patients with ECRS with nasal polyps completely, surgery is often needed to clear the sinonasal passage, and repeated endoscopic sinus surgery (ESS) is often required. The effectiveness of low-dose, long-term erythromycin treatment (macrolide therapy) was reported for the treatment of CRS in Japan.
CATEGORY    Immune system disease; Respiratory disease; Skin and connective tissue disease
DRUG        Erythromycin [DR:D00140]
DBLINKS     ICD-10: J32.8
REFERENCE   PMID:25516863 (description)
  AUTHORS   Wang ET, Zheng Y, Liu PF, Guo LJ
  TITLE     Eosinophilic chronic rhinosinusitis in East Asians.
  JOURNAL   World J Clin Cases 2:873-82 (2014)
REFERENCE   PMID:27053925 (description, drug)
  AUTHORS   Shah SA, Ishinaga H, Takeuchi K
  TITLE     Pathogenesis of eosinophilic chronic rhinosinusitis.
  JOURNAL   J Inflamm (Lond) 13:11 (2016)
///
ENTRY       H01766                      Disease
NAME        Juvenile retinoschisis
DESCRIPTION Juvenile retinoschisis is an early-onset X-linked retinal disease caused by mutations in retinoschisin (RS1), extracellular protein implicated in retinal cell adhesion. This disease is the leading cause of macular degeneration in males and leads to splitting within the inner retinal layers leading to visual deterioration. Affected persons typically display cystic streaks projecting from the parafoveal region of the retina, and a reduction in the b-wave amplitude of the full-field electroretinogram (ERG). Optical coherence tomography (OCT) further reveals a splitting of the outer plexiform and adjacent retinal layers.
CATEGORY    Nervous system disease; Eye disease
DBLINKS     ICD-10: Q14.1
            MeSH: D041441
            OMIM: 312700
REFERENCE   PMID:17172462
  AUTHORS   Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D
  TITLE     X-linked retinoschisis: an update.
  JOURNAL   J Med Genet 44:225-32 (2007)
REFERENCE   PMID:17525175 (gene)
  AUTHORS   Dyka FM, Molday RS
  TITLE     Coexpression and interaction of wild-type and missense RS1 mutants associated with X-linked retinoschisis: its relevance to gene therapy.
  JOURNAL   Invest Ophthalmol Vis Sci 48:2491-7 (2007)
///
ENTRY       H01767                      Disease
NAME        Henoch-Schonlein purpura nephritis
DESCRIPTION Henoch-Schonlein purpura nephritis (HSPN) is a rare kidney disease leading to chronic kidney disease in a non-negligible percentage of patients. Generally, the prognosis of Henoch-Schonlein purpura [DS:H01584] in children is favorable, but there are severe complications, one of which is renal involvement. HSPN is mainly characterized by acute episodes of glomerular inflammation with endocapillary and mesangial proliferation, fibrin deposits, and epithelial crescents that can heal spontaneously or lead to chronic lesions. HSPN and IgA nephropathy [DR:H01581] are currently considered related diseases resulting from glomerular deposition of aberrantly glycosylated IgA1. Although both nephritides present with similar histological findings and IgA abnormalities, they display pathophysiological differences with important therapeutic implications. Although there have been few evidence-based treatment strategies for HSPN, several studies have suggested that immunosuppressive drugs and multiple drug combination therapy were effective in ameliorating proteinuria and histological severity.
CATEGORY    Kidney disease; Hematologic disease; Immune system disease
DBLINKS     ICD-10: D69.0
REFERENCE   PMID:21393485 (description)
  AUTHORS   Davin JC
  TITLE     Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy.
  JOURNAL   Clin J Am Soc Nephrol 6:679-89 (2011)
REFERENCE   PMID:25557596 (description)
  AUTHORS   Chen JY, Mao JH
  TITLE     Henoch-Schonlein purpura nephritis in children: incidence, pathogenesis and management.
  JOURNAL   World J Pediatr 11:29-34 (2015)
REFERENCE   PMID:25072122 (description)
  AUTHORS   Davin JC, Coppo R
  TITLE     Henoch-Schonlein purpura nephritis in children.
  JOURNAL   Nat Rev Nephrol 10:563-73 (2014)
///
ENTRY       H01768                      Disease
NAME        Central areolar choroidal dystrophy
DESCRIPTION Central areolar choroidal dystrophy (CACD) is a hereditary retinal disorder that principally affects the macula, often resulting in atrophy of the retinal pigment epithelium and choriocapillaris in the center of the macula. Dysfunction of macular photoreceptors usually leads to a decrease in visual acuity, generally occurring between the ages of 30 and 60 years. In most cases, CACD is inherited as an autosomal-dominant trait, although autosomal-recessive cases have been reported. Autosomal-dominant CACD is genetically heterogeneous but mutations in the peripherin/RDS gene (PRPH2) seem to be the most common cause. The PRPH2 encodes a photoreceptor-specific glycoprotein. It is believed to play an important role in the assembly, orientation, and physical stability of photoreceptor outer segment disks.
CATEGORY    Nervous system disease; Eye disease
GENE        PRPH2 [HSA:5961] [KO:K17343]
DBLINKS     ICD-10: H31.2
            MeSH: C535358 C567750
            OMIM: 215500 613105
REFERENCE   PMID:19243827
  AUTHORS   Boon CJ, Klevering BJ, Cremers FP, Zonneveld-Vrieling MN, Theelen T, Den Hollander AI, Hoyng CB
  TITLE     Central areolar choroidal dystrophy.
  JOURNAL   Ophthalmology 116:771-82, 782.e1 (2009)
REFERENCE   PMID:19262438 (gene)
  AUTHORS   Anand S, Sheridan E, Cassidy F, Inglehearn C, Williams G, Springell K, Allgar V, Kelly TL, McKibbin M
  TITLE     Macular dystrophy associated with the Arg172Trp substitution in peripherin/RDS: genotype-phenotype correlation.
  JOURNAL   Retina 29:682-8 (2009)
///
ENTRY       H01769                      Disease
NAME        ZTTK syndrome
DESCRIPTION ZTTK syndrome is an intellectual disability syndrome characterized by intellectual disability and/or developmental delay, malformations of the cerebral cortex, epilepsy, vision problems, musculoskeletal abnormalities, and congenital malformations. Several studies have reported that deleterious variants in SON gene are associated with this disease.
CATEGORY    Developmental disorder
GENE        SON [HSA:6651]
DBLINKS     OMIM: 617140
REFERENCE   PMID:27545680 (description, gene)
  AUTHORS   Kim JH, Shinde DN, Reijnders MR, Hauser NS, Belmonte RL, Wilson GR, Bosch DG, Bubulya PA, Shashi V, Petrovski S, Stone JK, Park EY, Veltman JA, Sinnema M, Stumpel CT, Draaisma JM, Nicolai J, Yntema HG, Lindstrom K, de Vries BB, Jewett T, Santoro SL, Vogt J, Bachman KK, Seeley AH, Krokosky A, Turner C, Rohena L, Hempel M, Kortum F, Lessel D, Neu A, Strom TM, Wieczorek D, Bramswig N, Laccone FA, Behunova J, Rehder H, Gordon CT, Rio M, Romana S, Tang S, El-Khechen D, Cho MT, McWalter K, Douglas G, Baskin B, Begtrup A, Funari T, Schoch K, Stegmann AP, Stevens SJ, Zhang DE, Traver D, Yao X, MacArthur DG, Brunner HG, Mancini GM, Myers RM, Owen LB, Lim ST, Stachura DL, Vissers LE, Ahn EY
  TITLE     De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
  JOURNAL   Am J Hum Genet 99:711-9 (2016)
REFERENCE   PMID:27545676 (description, gene)
  AUTHORS   Tokita MJ, Braxton AA, Shao Y, Lewis AM, Vincent M, Kury S, Besnard T, Isidor B, Latypova X, Bezieau S, Liu P, Motter CS, Melver CW, Robin NH, Infante EM, McGuire M, El-Gharbawy A, Littlejohn RO, McLean SD, Bi W, Bacino CA, Lalani SR, Scott DA, Eng CM, Yang Y, Schaaf CP, Walkiewicz MA
  TITLE     De Novo Truncating Variants in SON Cause Intellectual Disability, Congenital Malformations, and Failure to Thrive.
  JOURNAL   Am J Hum Genet 99:720-7 (2016)
REFERENCE   PMID:27256762 (description, gene)
  AUTHORS   Takenouchi T, Miura K, Uehara T, Mizuno S, Kosaki K
  TITLE     Establishing SON in 21q22.11 as a cause a new syndromic form of intellectual disability: Possible contribution to Braddock-Carey syndrome phenotype.
  JOURNAL   Am J Med Genet A 170:2587-90 (2016)
///
ENTRY       H01770                      Disease
NAME        Macular dystrophy
DESCRIPTION The inherited macular dystrophies are characterized by bilateral visual loss and the finding of generally symmetrical macular abnormalities visible either on ophthalmoscopy or on retinal angiographs. They include Stargardt disease (H00819), Cone-rod dystrophy (H00481), Vitelliform macular dystrophy (H00814), X-linked juvenile retinoschisis (H01766), Occult macular dystrophy (H01010), and Central areolar choroidal dystrophy (H01768).
CATEGORY    Nervous system disease; Eye disease
COMMENT     See also H00819 Stargardt disease, H00481 Cone-rod dystrophy and cone dystrophy, H00814 Vitelliform macular dystrophy, H01010  Occult macular dystrophy, H01766 Juvenile retinoschisis, H01768 Central areolar choroidal dystrophy, and H00821 Age-related macular degeneration.
DBLINKS     ICD-10: H35.5
            MeSH: D057826 D008268
            OMIM: 248200 120970 153840 613587 312700 215500
REFERENCE   PMID:21834622
  AUTHORS   Bitoun P, Pipiras E, Rigaudiere F
  TITLE     Congenital macular dystrophy, corpus callosum agenesis, hippocampi hypoplasia--a  novel neuro-ophthalmic syndrome: case report.
  JOURNAL   Ophthalmic Genet 33:39-43 (2012)
REFERENCE   PMID:23168924
  AUTHORS   Liutkeviciene R, Lesauskaite V, Asmoniene V, Gelzinis A, Zaliuniene D, Jasinskas V
  TITLE     Inherited macular dystrophies and differential diagnostics.
  JOURNAL   Medicina (Kaunas) 48:485-95 (2012)
REFERENCE   PMID:12960208
  AUTHORS   Michaelides M, Hunt DM, Moore AT
  TITLE     The genetics of inherited macular dystrophies.
  JOURNAL   J Med Genet 40:641-50 (2003)
///
ENTRY       H01771                      Disease
NAME        Congenital ichthyosis
DESCRIPTION The ichthyoses represent a large group of cutaneous disorders linked by the common finding of abnormal epidermal differentiation. These disorders are characterized by the cutaneous scaling, which is said to resemble the scales of a fish. Scaling can be localized or generalized and can be associated with a variety of additional cutaneous and/or systemic manifestations. In patients with ichthyosis, the barrier function of the skin is compromised and has a decreased ability to protect against bacterial or chemical assault and to prevent transepidermal water loss.  Ichthyosis vulgaris (H00735) is the most frequent type. X-linked ichthyosis (H00134) occurs almost exclusively in boys. Autosomal recessive congenital ichthyosis (H00734) is genetically very heterogeneous and several different genes have been identified. Mutations in keratin genes are the cause of the keratinopathic ichthyoses (H00691), such as epidermolytic ichthyosis.
CATEGORY    Skin and connective tissue disease
COMMENT     See also H00735 Ichthyosis vulgaris, H00134 X-linked ichthyosis, H00734 Autosomal recessive congenital ichthyosis, and H00691 Bullous congenital ichthyosiform erythroderma (BCIE).
DBLINKS     ICD-10: Q80
            MeSH: D007057
            OMIM: 146700 308100 242300 113800
REFERENCE   PMID:23419760
  AUTHORS   Craiglow BG
  TITLE     Ichthyosis in the newborn.
  JOURNAL   Semin Perinatol 37:26-31 (2013)
REFERENCE   PMID:24119255
  AUTHORS   Traupe H, Fischer J, Oji V
  TITLE     Nonsyndromic types of ichthyoses - an update.
  JOURNAL   J Dtsch Dermatol Ges 12:109-21 (2014)
///
ENTRY       H01772                      Disease
NAME        Adrenal hypoplasia congenita, ingluding:;
            X-linked adrenal hypoplasia congenita;
            Autosomal recessive adrenal hypoplasia congenita;
            IMAGe syndrome
DESCRIPTION Adrenal hypoplasia congenita (AHC) is an inherited disorder of the adrenal cortex commonly manifested as an early onset adrenal insufficiency syndrome. AHC includes X-linked form, a rare autosomal recessive form, and IMAGe syndrome. If untreated with glucocorticoids and mineralocorticoids, adrenal insufficiency is rapidly lethal as a result of hyperkalemia, acidosis, hypoglycemia, and shock. A constant feature of the X-linked AHC is the association with hypogonadotropic hypogonadism (HHG). Affected males typically have delayed puberty or arrested puberty caused by HHG. Mutations in the DAX-1 (NR0B1) gene are responsible for X-linked AHC. Autosomal recessive AHC is caused by mutations in SF-1 (NR5A1) gene. However, disruption of SF-1 only rarely causes adrenal insufficiency, usually in combination with testicular dysgenesis. IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital anomalies) is an autosomal dominant undergrowth developmental disorder with life-threatening consequences and caused by mutations in CDKN1C.
CATEGORY    Endocrine System Disease
GENE        DAX1 [HSA:190] [KO:K08562]
            NR5A1 [HSA:2516] [KO:K08560]
            CDKN1C [HSA:1028] [KO:K09993]
DRUG        Saline, glucose, and hydrocortisone (acute adrenal insufficiency)
            Glucocorticoids and mineralocorticoids (lifelong follow-up)
COMMENT     See also H01598 Addison's disease.
DBLINKS     ICD-10: E27.4
            MeSH: C536757 C564543
            OMIM:300200 614732
REFERENCE   PMID:12034880
  AUTHORS   Lehmann SG, Lalli E, Sassone-Corsi P
  TITLE     X-linked adrenal hypoplasia congenita is caused by abnormal nuclear localization  of the DAX-1 protein.
  JOURNAL   Proc Natl Acad Sci U S A 99:8225-30 (2002)
REFERENCE   PMID:26303087 (gene)
  AUTHORS   Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC
  TITLE     DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease.
  JOURNAL   Best Pract Res Clin Endocrinol Metab 29:607-19 (2015)
REFERENCE   PMID:22634751 (gene)
  AUTHORS   Arboleda VA, Lee H, Parnaik R, Fleming A, Banerjee A, Ferraz-de-Souza B, Delot EC, Rodriguez-Fernandez IA, Braslavsky D, Bergada I, Dell'Angelica EC, Nelson SF, Martinez-Agosto JA, Achermann JC, Vilain E
  TITLE     Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome.
  JOURNAL   Nat Genet 44:788-92 (2012)
REFERENCE   PMID:20301604 (drug)
  AUTHORS   Achermann JC, Vilain EJ
  TITLE     X-Linked Adrenal Hypoplasia Congenita
  JOURNAL   (1993)
///
ENTRY       H01773                      Disease
NAME        4p deletion syndrome;
            Wolf-Hirschhorn syndrome
DESCRIPTION 4p deletion syndrome, also known as Wolf-Hirschhorn syndrome (WHS), is a congenital disorder associated with various deformities. WHS is caused by deletion of the WHS critical resion (WHSCR) of chromosome 4p16.3. Because WHS is a contiguous gene deletion syndrome, loss of one copy of a single gene or the synergistic effects of loss of two or more genes could give rise to the features of WHS. The "Greek warrior helmet appearance" is the most characteristic feature and refers to the facial view with prominent glabella, high arched eyebrow, broad nasal bridge and hypertelorism. Developmental delay and intellectual disability of variable degree is present in all. Seizures occur in 90% to 100% of children. Other findings include skeletal anomalies, congenital heart defects, hearing loss, urinary tract malformations, and structural brain abnormalities. Incidence is estimated to be about 1:50.000 births with a 2:1 female: male ratio.
CATEGORY    Developmental disorder
GENE        CPLX1 [HSA:10815] [KO:K15294]
            CTBP1 [HSA:1487] [KO:K04496]
            FGFRL1 [HSA:53834]
            LETM1 [HSA:3954] [KO:K17800]
            NSD2 [HSA:7468] [KO:K11424]
DBLINKS     ICD-10: Q93.3
            MeSH: D054877
            OMIM:194190
REFERENCE   PMID:26747863
  AUTHORS   Ho KS, South ST, Lortz A, Hensel CH, Sdano MR, Vanzo RJ, Martin MM, Peiffer A, Lambert CG, Calhoun A, Carey JC, Battaglia A
  TITLE     Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome.
  JOURNAL   J Med Genet 53:256-63 (2016)
REFERENCE   PMID:20301362
  AUTHORS   Battaglia A, Carey JC, South ST
  TITLE     Wolf-Hirschhorn Syndrome
  JOURNAL   (1993)
///
ENTRY       H01774                      Disease
NAME        Hyperostosis corticalis generalisata;
            Van Buchem disease
DESCRIPTION Hyperostosis corticalis generalisata, also known as Van Buchem disease (VBD), is autosomal recessive disease. This disease is characterized by progressive bone overgrowth, with narrowing of the neuroforamina in the skull causing cranial neuropathies. VBD is due to a homozygous deletion of a 52-kb regulatory element 35 kb downstream of the SOST gene, which leads to impaired production of sclerostin. Sclerostin, the gene product of SOST, is an inhibitor of the canonical Wnt signaling pathway.
CATEGORY    Skeletal dysplasia
GENE        SOST [HSA:50964] [KO:K16834]
COMMENT     VBD phenotype can be caused by mutation in the LRP5 gene. See also H00450 Sclerosing bone dysplasias.
            VBD is sclerosteosis related disease. See also H00486 Sclerosteosis.
DBLINKS     ICD-10: M85.2
            MeSH: D010009
            OMIM: 239100
REFERENCE   PMID:22445802
  AUTHORS   van Egmond ME, Dikkers FG, Boot AM, van Lierop AH, Papapoulos SE, Brouwer OF
  TITLE     A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review.
  JOURNAL   Eur J Paediatr Neurol 16:740-3 (2012)
REFERENCE   PMID:23074140
  AUTHORS   van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE
  TITLE     Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
  JOURNAL   J Bone Miner Res 28:848-54 (2013)
REFERENCE   PMID:26751728 (gene)
  AUTHORS   Fijalkowski I, Geets E, Steenackers E, Van Hoof V, Ramos FJ, Mortier G, Fortuna AM, Van Hul W, Boudin E
  TITLE     A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
  JOURNAL   J Bone Miner Res 31:874-81 (2016)
///
ENTRY       H01775                      Disease
NAME        PCDH19-related epilepsy syndrome;
            Early infantile epileptic encephalopathy 9;
            Epilepsy with mental retardation limited to females
DESCRIPTION PCDH19-related epilepsy syndrome is a disorder characterized by the recurrence of seizures during infancy, which is often combined with intellectual disability or autistic features manifested exclusively in females. This disorder, first reported as epilepsy and mental retardation limited to females (EMFR) and recently renamed early infantile epileptic encephalopathy 9 (EIEE9). It was transmitted via asymptomatic males, suggesting an unusual X-linked inheritance with selective involvement of females. Mutations in the X-chromosome-encoded protocadherin 19 (PCDH19) cause this disorder, and are confirmatory for the diagnosis.
CATEGORY    Congenital disorder; Epilepsy
GENE        PCDH19 [HSA:57526] [KO:K16499]
COMMENT     See also H00606 Ohtahara syndrome.
DBLINKS     ICD-10: G40.3
            MeSH: C564715
            OMIM: 300088
REFERENCE   PMID:22949144
  AUTHORS   Terracciano A, Specchio N, Darra F, Sferra A, Bernardina BD, Vigevano F, Bertini E
  TITLE     Somatic mosaicism of PCDH19 mutation in a family with low-penetrance EFMR.
  JOURNAL   Neurogenetics 13:341-5 (2012)
REFERENCE   PMID:22267240 (gene)
  AUTHORS   Depienne C, LeGuern E
  TITLE     PCDH19-related infantile epileptic encephalopathy: an unusual X-linked inheritance disorder.
  JOURNAL   Hum Mutat 33:627-34 (2012)
///
ENTRY       H01776                      Disease
NAME        Aicardi syndrome
DESCRIPTION Aicardi syndrome is a rare neurodevelopmental disorder. The main diagnostic features are agenesis of corpus callosum, chorioretinal lacunae, and infantile spasms. Along with agenesis of corpus callosum, typical brain abnormalities include polymicrogyria, periventricular and subcortical heterotopia, intracranial cysts, cerebellar abnormalities, and enlarged cisterna magna. Neurological abnormalities include microcephaly, optic nerve coloboma, developmental delay, mental retardation, intractable epilepsy, hypotonia and limb hypertonia with spasticity. The etiology of Aicardi syndrome is still unknown. However, as the disorder is only observed in females and in males with chromosome 47, XXY, it is assumed to be caused by a de novo mutation on the X chromosome and inherited in a dominant manner with lethality in males.
CATEGORY    Developmental disorder
DBLINKS     ICD-10: Q87.8
            MeSH: D058540
            OMIM: 304050
REFERENCE   PMID:22815034
  AUTHORS   Singh P, Goraya JS, Saggar K, Ahluwalia A
  TITLE     Aicardi syndrome.
  JOURNAL   Singapore Med J 53:e153-5 (2012)
REFERENCE   PMID:25443581
  AUTHORS   Lund C, Bjornvold M, Tuft M, Kostov H, Rosby O, Selmer KK
  TITLE     Aicardi syndrome: an epidemiologic and clinical study in Norway.
  JOURNAL   Pediatr Neurol 52:182-6.e3 (2015)
///
ENTRY       H01777                      Disease
NAME        Schwartz-Jampel syndrome
DESCRIPTION Schwartz-Jampel syndrome (SJS) is a rare hereditary disorder with joint contractures, generalized myotonia, skeletal anomalies, and facial dysmorphism. Schwartz-Jampel syndrome (SJS) is a term now applied to 2 different autosomal recessive disorder, sometimes termed SJS type 1 and SJS type 2. SJS type 1 results from mutations in the HSPG2 gene, which encodes perlecan, a major component of basement membranes. It exhibits muscle stiffness, mild muscle weakness, and a number of minor morphological abnormalities. In affected patients, problems with motor development frequently become evident during the first year of life. SJS type 2, also known as Stuve-Wiedemann syndrome (H00462), is a genetically distinct disorder with a more severe phenotype.
CATEGORY    Skeletal dysplasia
GENE        HSPG2 [HSA:3339] [KO:K06255]
COMMENT     Silverman-Handmaker type of dyssegmental dysplasia is an allelic disorder with a more severe phenotype.
            See also H00462 Stuve-Wiedemann syndrome and H00493 Heparan sulfate proteoglycan gene defects.
DBLINKS     ICD-10: G71.1
            MeSH: D010009
            OMIM: 255800
REFERENCE   PMID:27857801
  AUTHORS   Polat I, Karaoglu P, Yis U, Kurul SH
  TITLE     Schwartz-Jampel syndrome with gastroduodenal bleeding.
  JOURNAL   J Pediatr Neurosci 11:255-257 (2016)
REFERENCE   PMID:16927315 (gene)
  AUTHORS   Stum M, Davoine CS, Vicart S, Guillot-Noel L, Topaloglu H, Carod-Artal FJ, Kayserili H, Hentati F, Merlini L, Urtizberea JA, Hammouda el-H, Quan PC, Fontaine B, Nicole S
  TITLE     Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome.
  JOURNAL   Hum Mutat 27:1082-91 (2006)
///
ENTRY       H01778                      Disease
NAME        Ullrich disease;
            Ullrich congenital muscular dystrophy
DESCRIPTION Ullrich disease or Ullrich congenital muscular dystrophy (UCMD) is a severe congenital disorder characterized clinically by generalized muscle weakness, contractures of the proximal joints and hyperextensibility of the distal joints and begins from birth or early infancy. Mutations in the three collagen VI genes COL6A1, COL6A2 and COL6A3 cause Ullrich disease.
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        COL6A1 [HSA:1291] [KO:K06238]
            COL6A2 [HSA:1292] [KO:K06238]
            COL6A3 [HSA:1293] [KO:K06238]
            COL12A1 [HSA:1303] [KO:K08132]
COMMENT     See also H01341 Collagen VI myopathy.
DBLINKS     ICD-10: G71.0
            MeSH: C537521
            OMIM: 254090 616470
REFERENCE   PMID:19305075
  AUTHORS   Nalini A, Gayathri N, Santosh V
  TITLE     Ullrich congenital muscular dystrophy: report of nine cases from India.
  JOURNAL   Neurol India 57:41-5 (2009)
REFERENCE   PMID:15563506 (gene)
  AUTHORS   Baker NL, Morgelin M, Peat R, Goemans N, North KN, Bateman JF, Lamande SR
  TITLE     Dominant collagen VI mutations are a common cause of Ullrich congenital muscular  dystrophy.
  JOURNAL   Hum Mol Genet 14:279-93 (2005)
REFERENCE   PMID:24334604 (gene)
  AUTHORS   Zou Y, Zwolanek D, Izu Y, Gandhy S, Schreiber G, Brockmann K, Devoto M, Tian Z, Hu Y, Veit G, Meier M, Stetefeld J, Hicks D, Straub V, Voermans NC, Birk DE, Barton ER, Koch M, Bonnemann CG
  TITLE     Recessive and dominant mutations in COL12A1 cause a novel EDS/myopathy overlap syndrome in humans and mice.
  JOURNAL   Hum Mol Genet 23:2339-52 (2014)
///
ENTRY       H01779                      Disease
NAME        Neuroferritinopathy
DESCRIPTION Neuroferritinopathy is a rare autosomal dominant disease caused by mutations in the ferritin light chain (FTL) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia. Clinically, the disease presents as a chorea and dystonia. Clinical presentation may also include extrapyramidal and pyramidal tract signs as well as cerebellar ataxia, dysautonomia, cognitive decline, and psychiatric symptoms.
CATEGORY    Neurodegenerative disease
GENE        FTL [HSA:2512] [KO:K13625]
COMMENT     Neuroferritinopathy belongs to the group of disorders collectively known as neurodegeneration with brain iron accumulation (NBIA).
            See also H00833 Neurodegeneration with brain iron accumulation (NBIA).
DBLINKS     ICD-10: G23.8
            MeSH: C548080
            OMIM: 606159
REFERENCE   PMID:27022507
  AUTHORS   Kumar N, Rizek P, Jog M
  TITLE     Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management.
  JOURNAL   Tremor Other Hyperkinet Mov (N Y) 6:355 (2016)
REFERENCE   PMID:24825732 (gene)
  AUTHORS   Nishida K, Garringer HJ, Futamura N, Funakawa I, Jinnai K, Vidal R, Takao M
  TITLE     A novel ferritin light chain mutation in neuroferritinopathy with an atypical presentation.
  JOURNAL   J Neurol Sci 342:173-7 (2014)
///
ENTRY       H01780                      Disease
NAME        Non-dystrophic myotonia
DESCRIPTION Non-dystrophic myotonias are rare diseases caused by mutations in key skeletal muscle ion channels. The major clinical manifestation is muscle stiffness as a consequence of the myotonia. Additional common symptoms include pain, weakness and fatigue. They are considered to be distinct from myotonic dystrophy because of the absence of progressive weakness and systemic features. Non-dystrophic myotonias include myotonia congenita (H00705), paramyotonia congenita (H00743), and the sodium channel myotonias (H00744).
CATEGORY    Musculoskeletal disease; Nervous system disease
GENE        CLCN1 [HSA:1180] [KO:K05010]
            SCN4A [HSA:6329] [KO:K04837]
COMMENT     See also H00705 Myotonia congenita, H00743 Paramyotonia congenita (PMC), and H00744 Potassium-aggravated myotonias (PAMs).
DBLINKS     ICD-10: G71.1
            MeSH: D020967 D009224 
            OMIIM: 160800 255700 168300 608390
REFERENCE   PMID:19917643 (gene)
  AUTHORS   Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, Fontaine B, Amato AA, Barohn RJ, Griggs RC, Hanna MG
  TITLE     The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.
  JOURNAL   Brain 133:9-22 (2010)
REFERENCE   PMID:23771340
  AUTHORS   Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, Wang Y, Fialho D, Matthews E, Cleland J, Gorham N, Herbelin L, Cannon S, Amato A, Griggs RC, Hanna MG, Barohn RJ
  TITLE     Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.
  JOURNAL   Brain 136:2189-200 (2013)
///
ENTRY       H01781                      Disease
NAME        Autophagic vacuolar myopathy
DESCRIPTION Autophagic vacuolar myopathies (AVM) are a group of disorders united by shared histopathological features on muscle biopsy that include the aberrant accumulation of autophagic vacuoles. They are characterized by autophagic vacuoles in which the vacuolar membranes have sarcolemmal features, and include four entities: Danon disease, X-linked myopathy with excessive autophagy (XMEA), infantile AVM, and adult onset AVM with multiorgan involvement. Danon disease has been shown to be associated with mutations in the LAMP2 gene located on the X chromosome. XMEA is characterized by weakness and wasting primarily of the proximal muscles of the lower extremities. Mutations in the VMA21 gene at Xq28 cause XMEA by reducing the activity of lysosomal hydrolases.
CATEGORY    Musculoskeletal disease
GENE        LAMP2 [HSA:3920] [KO:K06528]
            VMA21 [HSA:203547]
COMMENT     See also H00150 Danon disease.
DBLINKS     ICD-10: G71.8
            MeSH: D052120 C564093 C536522
            OMIM: 300257 310440 609500
REFERENCE   PMID:16640643
  AUTHORS   Holton JL, Beesley C, Jackson M, Venner K, Bhardwaj N, Winchester B, Al-Memar A
  TITLE     Autophagic vacuolar myopathy in twin girls.
  JOURNAL   Neuropathol Appl Neurobiol 32:253-9 (2006)
REFERENCE   PMID:25644398
  AUTHORS   Dowling JJ, Moore SA, Kalimo H, Minassian BA
  TITLE     X-linked myopathy with excessive autophagy: a failure of self-eating.
  JOURNAL   Acta Neuropathol 129:383-90 (2015)
REFERENCE   PMID:25817839 (gene)
  AUTHORS   Munteanu I, Ramachandran N, Ruggieri A, Awaya T, Nishino I, Minassian BA
  TITLE     Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy.
  JOURNAL   Neurology 84:1714-6 (2015)
///
ENTRY       H01782                      Disease
NAME        Eosinophilic gastrointestinal disorder
DESCRIPTION Eosinophilic gastrointestinal disorder (EGID) is a disorder characterised by eosinophilic infiltration of the gastrointestinal tract. The most common form of EGID is Eosinophilic Esophagitis (EoE). Other forms of EGID include eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis and eosinophilic gastroenteritis (EGE). While these disorders are less frequent than EoE, their pathogenesis and treatment are probably similar. Clinically, patients with EGID often present with dysphagia, vomiting or abdominal pain. While the etiology remains unclear, there is a well documented association of atopy with EGID. Clinical studies in children and adults have demonstrated an association with food allergy.
CATEGORY    Immune system disease; Digestive system disease
DRUG        Glucocorticoid
COMMENT     See also H01361 Eosinophilic esophagitis.
DBLINKS     ICD-10: K20 K52.8
            MeSH: D057765 C535952
            OMIM: 610247 613412
REFERENCE   PMID:24813518
  AUTHORS   Prussin C
  TITLE     Eosinophilic gastroenteritis and related eosinophilic disorders.
  JOURNAL   Gastroenterol Clin North Am 43:317-27 (2014)
REFERENCE   PMID:22792476
  AUTHORS   Jawairia M, Shahzad G, Mustacchia P
  TITLE     Eosinophilic gastrointestinal diseases: review and update.
  JOURNAL   ISRN Gastroenterol 2012:463689 (2012)
REFERENCE   PMID:23346427
  AUTHORS   Lim DN, Wilkins A, Horton LE, Ahmad I, Lo Polito C, Phillips C
  TITLE     Eosinophilic gastrointestinal disorder in coeliac disease: a case report and review.
  JOURNAL   Case Rep Gastrointest Med 2012:124275 (2012)
///
ENTRY       H01783                      Disease
NAME        Ebstein anomaly
DESCRIPTION Ebstein anomaly is a rare congenital heart abnormality, characterized by downward displacement of the tricuspid valve into the right ventricle. Displacement and malformation of the tricuspid valve is accompanied by an enlarged right atrium and a dilated, thinned right ventricle. Ebstein anomaly can occur as a sporadic or a familial defect. It has been reported that deletion 1p36 and deletion 8p23.1 are the most frequent chromosomal structural changes associated with Ebstein anomaly.
CATEGORY    Developmental disorder; Cardiovascular disease
ENV_FACTOR  Lithium carbonate [DR:D00801]  (during early pregnancy)
DBLINKS     ICD-10: Q22.5
            MeSH: D004437
            OMIM: 224700
REFERENCE   PMID:26395651 (env_factor)
  AUTHORS   Johnstad CM, Hecker-Fernandes JR, Fernandes R
  TITLE     Ebstein Anomaly: An Overview for Nursing.
  JOURNAL   J Pediatr Nurs 30:927-30 (2015)
REFERENCE   PMID:21815254
  AUTHORS   Digilio MC, Bernardini L, Lepri F, Giuffrida MG, Guida V, Baban A, Versacci P, Capolino R, Torres B, De Luca A, Novelli A, Marino B, Dallapiccola B
  TITLE     Ebstein anomaly: Genetic heterogeneity and association with microdeletions 1p36 and 8p23.1.
  JOURNAL   Am J Med Genet A 155A:2196-202 (2011)
///
ENTRY       H01784                      Disease
NAME        Primary hyperchylomicronemia, including:
            Hyperlipoproteinemia, type I [DS:H00154];
            Hyperlipoproteinemia, type V [DS:H00157]
DESCRIPTION Primary hyperchylomicronemia is characterized by a marked hypertriglyceridemia due to the accumulation of chylomicron occurs in the circulation. The main clinical symptoms of this disorder are the huge increase in plasma trigriceride and cholesterol, and the presence of xanthomatous eruption, lipemia retinalis, hepatosplenomegaly, and the complication of acute pancreatitis. The genetic basis for primary hyperchylomicronemia is heterogeneous. The familial chylomicronemia (known as Fredrickson's classification of type 1 hyperlipoproteinemia) [DS:H00154] is a clinical condition showing the severest hypertriglyceridemia and is classically represented by two rare genetic disorders, i.e., familial lipoprotein lipase (LPL) deficiency and familial apolipoprotein C-II deficiency. Even rarer conditions such as circulating inhibitor of lipoprotein lipase and the presence of autoantibodies also cause type 1 hyperlipoproteinemia. More recently, patients with primary hyperchylomicronemia caused by mutations in the gene for glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) or lipase maturation factor 1 (LMF1). By contrast, the more commonly encountered polygenic chylomicronemia of adulthood, referred to as mixed dyslipidemia (known as type 5 hyperlipoproteinemia) [DS:H00157], can present later in life and is characterized by increased levels of hepatically derived triglyceride-rich lipoproteins and triglyceride-rich remnant particles together with reduced levels of HDL cholesterol.
CATEGORY    Inherited metabolic disease; Cardiovascular disease
GENE        LPL [HSA:4023] [KO:K01059]
            APOC2 [HSA:344]
            GPIHBP1 [HSA:338328] [KO:K20001]
            LMF1 [HSA:64788]
            APOA5 [HSA:116519] [KO:K09025]
DBLINKS     ICD-10: E78.3
            MeSH: D006954 D008072
            OMIM: 238600 207750 615947 246650 144650
REFERENCE   PMID:22129523 (description)
  AUTHORS   Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N
  TITLE     Diagnosis and management of type I and type V hyperlipoproteinemia.
  JOURNAL   J Atheroscler Thromb 19:1-12 (2012)
REFERENCE   PMID:25732519 (description)
  AUTHORS   Brahm AJ, Hegele RA
  TITLE     Chylomicronaemia--current diagnosis and future therapies.
  JOURNAL   Nat Rev Endocrinol 11:352-62 (2015)
REFERENCE   PMID:24205717 (description)
  AUTHORS   Yamashita S
  TITLE     [Primary hyperchylomicronemia].
  JOURNAL   Nihon Rinsho 71:1578-83 (2013)
REFERENCE   PMID:10638209 (description)
  AUTHORS   Iwasaki M, Tada N
  TITLE     [Primary hyperchylomicronemia and gene defects].
  JOURNAL   Nihon Rinsho 57:2759-64 (1999)
///
ENTRY       H01785                      Disease
NAME        Tricuspid atresia
DESCRIPTION Tricuspid atresia is the third most common cyanotic congenital heart defect. It consists of complete lack of tricuspid valve formation, with no connection between the right atrium and the right ventricle. Severe cyanosis associated with diminished pulmonary blood flow is a prominent feature in tricuspid atresia. The malformation brings about high morbidity and mortality, thus requiring the utilization of an adequate surgical technique for its correction. The genetic mechanism responsible of tricuspid atresia is still obscure. However, animal models have suggested a role of cardiogenic Zfpm2/Fog2 and Hey2 genes in the pathogenesis.
CATEGORY    Developmental disorder; Cardiovascular disease
DRUG        Prostaglandin E1 [DR:D00180]
DBLINKS     ICD-10: Q22.4
            MeSH: D018785
            OMIM: 605067
REFERENCE   PMID:12163945
  AUTHORS   Mastalir ET, Kalil RA, Horowitz ES, Wender O, Sant'Anna JR, Prates PR, Nesralla IA
  TITLE     Late clinical outcomes of the fontan operation in patients with tricuspid atresia.
  JOURNAL   Arq Bras Cardiol 79:56-60 (2002)
REFERENCE   PMID:19727322
  AUTHORS   Steinhorn RH
  TITLE     Evaluation and management of the cyanotic neonate.
  JOURNAL   Clin Pediatr Emerg Med 9:169-175 (2008)
REFERENCE   PMID:15643620
  AUTHORS   Sarkozy A, Conti E, D'Agostino R, Digilio MC, Formigari R, Picchio F, Marino B, Pizzuti A, Dallapiccola B
  TITLE     ZFPM2/FOG2 and HEY2 genes analysis in nonsyndromic tricuspid atresia.
  JOURNAL   Am J Med Genet A 133A:68-70 (2005)
REFERENCE   PMID:23244255 (drug)
  AUTHORS   Guleserian KJ, Barker GM, Sharma MS, Macaluso J, Huang R, Nugent AW, Forbess JM
  TITLE     Bilateral pulmonary artery banding for resuscitation in high-risk, single-ventricle neonates and infants: a single-center experience.
  JOURNAL   J Thorac Cardiovasc Surg 145:206-13; discussion 213-4 (2013)
///
ENTRY       H01786                      Disease
NAME        Congenitally corrected transposition of the great arteries
DESCRIPTION Congenitally corrected transposition of the great arteries is a rare cardiac defect characterized by characterised by the combination of atrioventricular (AV) discordance and ventriculo-arterial (VA) discordance. The morphologic left ventricle and mitral valve supply the pulmonary circulation and the morphologic right ventricle and tricuspid valve supply the systemic circulation. The anatomy is described as congenitally 'corrected' because the flow of blood is normal with the deoxygenated systemic venous blood being pumped to the lungs and the well oxygenated pulmonary venous blood being pumped to the body. More than 90% of patients have additional anatomical abnormalities. The most frequent are ventricular septal defects, left ventricular outflow tract obstruction, and abnormalities of the tricuspid valve.
CATEGORY    Developmental disorder; Cardiovascular disease
DBLINKS     ICD-10: Q20.5
            MeSH: C535426
REFERENCE   PMID:20610462
  AUTHORS   Hornung TS, Calder L
  TITLE     Congenitally corrected transposition of the great arteries.
  JOURNAL   Heart 96:1154-61 (2010)
REFERENCE   PMID:14971003
  AUTHORS   McEwing RL, Chaoui R
  TITLE     Congenitally corrected transposition of the great arteries: clues for prenatal diagnosis.
  JOURNAL   Ultrasound Obstet Gynecol 23:68-72 (2004)
///
ENTRY       H01787                      Disease
NAME        Univentricular Heart
DESCRIPTION Univentricular heart is a term used to describe a wide variety of structural cardiac abnormalities associated with a functional single ventricular chamber. Truly solitary ventricles are exceedingly rare. It is generally agreed that the atrioventricular connection is central in defining the univentricular heart. More specifically, the well-developed ventricle may be designated left, right, or indeterminate. Clinical manifestations hinge on the presence or absence of pulmonary outflow obstruction. Without pulmonary stenosis, infants with low pulmonary resistance present with signs and symptoms typical of large left-to-right shunting, ie, congestive heart failure and failure-to-thrive. A certain degree of pulmonary stenosis is physiologically desirable to prevent pulmonary overcirculation. However, severe pulmonary stenosis or atresia may result in profound hypoxemia and cyanosis.
CATEGORY    Developmental disorder; Cardiovascular disease
DBLINKS     ICD-10: Q20.4
REFERENCE   PMID:17296869
  AUTHORS   Khairy P, Poirier N, Mercier LA
  TITLE     Univentricular heart.
  JOURNAL   Circulation 115:800-12 (2007)
REFERENCE   PMID:15985742
  AUTHORS   Krishnan U
  TITLE     Univentricular heart: management options.
  JOURNAL   Indian J Pediatr 72:519-24 (2005)
///
ENTRY       H01788                      Disease
NAME        Klippel-Trenaunay-Weber syndrome
DESCRIPTION Klippel-Trenaunay-Weber syndrome is a rare congenital syndrome, consisting of vascular malformation of blood and lymph vessels. This disease is characterized by a classic triad of cutaneous hemangiomas, varicose veins, and bone or soft tissue hypertrophy causing limb asymmetry. Clinical presentation may vary from being asymptomatic to developing potentially life-threatening complications, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and recurrent bleeding. Most cases arise from sporadic mutations in one or more genes involved in early embryonic angiogenesis.
CATEGORY    Developmental disorder; Cardiovascular disease
DBLINKS     ICD-10: Q87.2
            MeSH: D007715
            OMIM: 149000
REFERENCE   PMID:26615353
  AUTHORS   Bhat L, Bisht S, Khanijo K
  TITLE     Klippel-Trenaunay-Weber Syndrome with Kasabach-Merritt Coagulopathy and Hydronephrosis.
  JOURNAL   Indian Pediatr 52:987-8 (2015)
REFERENCE   PMID:25293688
  AUTHORS   Ricks CB, Grandhi R, Ducruet AF
  TITLE     Klippel-Trenaunay syndrome and cavernous malformations.
  JOURNAL   BMJ Case Rep 2014 (2014)
REFERENCE   PMID:23799311
  AUTHORS   Oduber CE, van Beers EJ, Bresser P, van der Horst CM, Meijers JC, Gerdes VE
  TITLE     Venous thromboembolism and prothrombotic parameters in Klippel-Trenaunay syndrome.
  JOURNAL   Neth J Med 71:246-52 (2013)
///
ENTRY       H01789                      Disease
NAME        You-Hoover-Fong syndrome
DESCRIPTION You-Hoover-Fong syndrome is an autosomal-recessive syndromic form of intellectual disability. It has been reported that compound heterozygous variants in TELO2 were found from six affected individuals from four families with intellectual disability and neurological and other congenital abnormalities, suggesting that these TELO2 variants result in loss of function and cause this disease.
CATEGORY    Developmental disorder; Nervous system disease
GENE        TELO2 [HSA:9894] [KO:K11137]
DBLINKS     OMIM: 616954
REFERENCE   PMID:27132593 (description, gene)
  AUTHORS   You J, Sobreira NL, Gable DL, Jurgens J, Grange DK, Belnap N, Siniard A, Szelinger S, Schrauwen I, Richholt RF, Vallee SE, Dinulos MB, Valle D, Armanios M, Hoover-Fong J
  TITLE     A Syndromic Intellectual Disability Disorder Caused by Variants in TELO2, a Gene  Encoding a Component of the TTT Complex.
  JOURNAL   Am J Hum Genet 98:909-18 (2016)
///
ENTRY       H01790                      Disease
NAME        Emanuel syndrome;
            Supernumerary derivative 22 syndrome
DESCRIPTION Emanuel syndrome (ES) is a rare anomaly characterized by a distinctive phenotype, consisting of characteristic facial dysmorphism, microcephaly, severe mental retardation, developmental delay, renal anomalies, congenital cardiac defects, and genital anomalies in boys. Patients have a supernumerary derivative chromosome caused by a parental balanced translocation between chromosomes 11 and 22.
CATEGORY    Chromosomal abnormality; Developmental disorder
COMMENT     In more than 99% of cases, one of the parents of a proband with Emanuel syndrome is a balanced carrier of a t(11;22)(q23;q11.2) and is phenotypically normal.
DBLINKS     ICD-10: Q92.8
            MeSH: C535733
            OMIM: 609029
REFERENCE   PMID:20301440
  AUTHORS   Emanuel BS, Zackai EH, Medne L
  TITLE     Emanuel Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:23691404
  AUTHORS   Choudhary MG, Babaji P, Sharma N, Dhamankar D, Naregal G, Reddy VS
  TITLE     Derivative 11;22 (emanuel) syndrome: a case report and a review.
  JOURNAL   Case Rep Pediatr 2013:237935 (2013)
REFERENCE   PMID:19606488
  AUTHORS   Carter MT, St Pierre SA, Zackai EH, Emanuel BS, Boycott KM
  TITLE     Phenotypic delineation of Emanuel syndrome (supernumerary derivative 22 syndrome): Clinical features of 63 individuals.
  JOURNAL   Am J Med Genet A 149A:1712-21 (2009)
///
ENTRY       H01791                      Disease
NAME        Smith-Magenis syndrome
DESCRIPTION Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder caused by haploinsufficiency of the retinoic acid-induced 1 (RAI1) gene on chromosome 17p11.2. SMS is characterised by intellectual disability, self-injurious behaviours, sleep disturbance, obesity, and craniofacial and skeletal anomalies. Most SMS features are due to RAI1 haploinsufficiency, while the variability and severity of the disorder are modified by other genes in the 17p11.2 region.
CATEGORY    Chromosomal abnormality; Developmental disorder
GENE        RAI1 (haploinsufficiency) [HSA:10743] [KO:K19749]
DBLINKS     ICD-10: Q93.8
            MeSH: D058496
            OMIM: 182290
REFERENCE   PMID:18231123
  AUTHORS   Elsea SH, Girirajan S
  TITLE     Smith-Magenis syndrome.
  JOURNAL   Eur J Hum Genet 16:412-21 (2008)
REFERENCE   PMID:21545756 (gene)
  AUTHORS   Elsea SH, Williams SR
  TITLE     Smith-Magenis syndrome: haploinsufficiency of RAI1 results in altered gene regulation in neurological and metabolic pathways.
  JOURNAL   Expert Rev Mol Med 13:e14 (2011)
///
ENTRY       H01792                      Disease
NAME        1p36 deletion syndrome
DESCRIPTION 1p36 deletion syndrome is is a recently delineated disorder, considered to be the most common subtelomeric microdeletion syndrome. 1p36 deletion syndrome is characterized by typical craniofacial features consisting of straight eyebrows, deep-set eyes, midface hypoplasia, wide and depressed nasal bridge, long philtrum, and pointed chin. Developmental delay/intellectual disability of variable degree and hypotonia are present in almost all patients. Seizures occur in around half of affected individuals. Other findings include structural brain abnormalities, congenital heart defects, eye/vision problems, hearing loss, skeletal anomalies, abnormalities of the external genitalia, and renal abnormalities. There is significant phenotypic variation among affected individuals. This variation is due, at least in part, to the genetic heterogeneity seen in 1p36 deletions which include terminal and interstitial deletions of varying lengths.
CATEGORY    Chromosomal abnormality; Developmental disorder
DBLINKS     ICD-10: Q93.5
            MeSH: C535362
            OMIM: 607872
REFERENCE   PMID:26345236
  AUTHORS   Jordan VK, Zaveri HP, Scott DA
  TITLE     1p36 deletion syndrome: an update.
  JOURNAL   Appl Clin Genet 8:189-200 (2015)
REFERENCE   PMID:20301370
  AUTHORS   Battaglia A
  TITLE     1p36 Deletion Syndrome
  JOURNAL   (1993)
REFERENCE   PMID:18245432
  AUTHORS   Battaglia A, Hoyme HE, Dallapiccola B, Zackai E, Hudgins L, McDonald-McGinn D, Bahi-Buisson N, Romano C, Williams CA, Brailey LL, Zuberi SM, Carey JC
  TITLE     Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation.
  JOURNAL   Pediatrics 121:404-10 (2008)
///
ENTRY       H01793                      Disease
NAME        Young-Simpson syndrome;
            Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS);
            Say-Barber-Biesecker variant of Ohdo syndrome
DESCRIPTION Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS), also referred to as the Say-Barber-Biesecker variant of Ohdo syndrome, is a rare multiple anomaly syndrome characterized by severe intellectual disability, blepharophimosis, and a mask-like facial appearance. A number of individuals with SBBYSS also have thyroid abnormalities and cleft palate. In 1986, Ohdo described two siblings and their cousin with blepharophimosis, ptosis, congenital heart defects, intellectual disability, and hypoplastic teeth. Subsequently, the Young-Simpson syndrome was described. Later the Young-Simpson syndrome was renamed the Say-Barber-Biesecker-Young-Simpson (SBBYS) variant of Ohdo syndrome. SBBYSS and genitopatellar syndrome (GPS) [DS:H01794] are clinically similar disorders with some overlapping features. They were found to be caused by de novo truncating sequence variants in the KAT6B (histone acetyltransferase) gene, strongly suggesting that they are allelic disorders.
CATEGORY    Developmental disorder; Nervous system disease
GENE        KAT6B [HSA:23522] [KO:K11306]
COMMENT     See also H01795.
DBLINKS     ICD-10: Q87.8
            OMIM: 603736
REFERENCE   PMID:23236640 (description)
  AUTHORS   Campeau PM, Lee BH
  TITLE     KAT6B-Related Disorders
  JOURNAL   (1993)
REFERENCE   PMID:22715153 (description)
  AUTHORS   Campeau PM, Lu JT, Dawson BC, Fokkema IF, Robertson SP, Gibbs RA, Lee BH
  TITLE     The KAT6B-related disorders genitopatellar syndrome and Ohdo/SBBYS syndrome have  distinct clinical features reflecting distinct molecular mechanisms.
  JOURNAL   Hum Mutat 33:1520-5 (2012)
REFERENCE   PMID:27452416 (description, gene)
  AUTHORS   Radvanszky J, Hyblova M, Durovcikova D, Hikkelova M, Fiedler E, Kadasi L, Turna J, Minarik G, Szemes T
  TITLE     Complex phenotypes blur conventional borders between Say-Barber-Biesecker-Young-Simpson syndrome and genitopatellar syndrome.
  JOURNAL   Clin Genet 91:339-343 (2017)
REFERENCE   PMID:25424711 (description, gene)
  AUTHORS   Gannon T, Perveen R, Schlecht H, Ramsden S, Anderson B, Kerr B, Day R, Banka S, Suri M, Berland S, Gabbett M, Ma A, Lyonnet S, Cormier-Daire V, Yilmaz R, Borck G, Wieczorek D, Anderlid BM, Smithson S, Vogt J, Moore-Barton H, Simsek-Kiper PO, Maystadt I, Destree A, Bucher J, Angle B, Mohammed S, Wakeling E, Price S, Singer A, Sznajer Y, Toutain A, Haye D, Newbury-Ecob R, Fradin M, McGaughran J, Tuysuz B, Tein M, Bouman K, Dabir T, Van den Ende J, Luk HM, Pilz DT, Eason J, Davies S, Reardon W, Garavelli L, Zuffardi O, Devriendt K, Armstrong R, Johnson D, Doco-Fenzy M, Bijlsma E, Unger S, Veenstra-Knol HE, Kohlhase J, Lo IF, Smith J, Clayton-Smith J
  TITLE     Further delineation of the KAT6B molecular and phenotypic spectrum.
  JOURNAL   Eur J Hum Genet 23:1165-70 (2015)
///
ENTRY       H01794                      Disease
NAME        Genitopatellar syndrome (GPS)
DESCRIPTION Genitopatellar syndrome (GPS) is a rare disorder in which patellar aplasia or hypoplasia is associated with external genital and renal anomalies, congenital flexion deformities of the limbs, distinctive facial features, corpus callosum agenesis, and severe intellectual disability. GPS and Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS) [DS:H01793] are clinically similar disorders with some overlapping features. They were found to be caused by de novo truncating sequence variants in the KAT6B (histone acetyltransferase) gene, strongly suggesting that they are allelic disorders. In GPS, the overall clinical picture tends to be more severe than in SBBYSS. Features present only in GPS are contractures, anomalies of the spine, ribs and pelvis, renal cysts, hydronephrosis, and agenesis of the corpus callosum. Thyroid abnormalities have been reported in rare cases.
CATEGORY    Developmental disorder; Nervous system disease
GENE        KAT6B [HSA:23522] [KO:K11306]
DBLINKS     ICD-10: Q87.8
            OMIM: 606170
REFERENCE   PMID:22265017 (description, gene)
  AUTHORS   Simpson MA, Deshpande C, Dafou D, Vissers LE, Woollard WJ, Holder SE, Gillessen-Kaesbach G, Derks R, White SM, Cohen-Snuijf R, Kant SG, Hoefsloot LH, Reardon W, Brunner HG, Bongers EM, Trembath RC
  TITLE     De novo mutations of the gene encoding the histone acetyltransferase KAT6B cause  Genitopatellar syndrome.
  JOURNAL   Am J Hum Genet 90:290-4 (2012)
REFERENCE   PMID:27452416 (description, gene)
  AUTHORS   Radvanszky J, Hyblova M, Durovcikova D, Hikkelova M, Fiedler E, Kadasi L, Turna J, Minarik G, Szemes T
  TITLE     Complex phenotypes blur conventional borders between Say-Barber-Biesecker-Young-Simpson syndrome and genitopatellar syndrome.
  JOURNAL   Clin Genet 91:339-343 (2017)
REFERENCE   PMID:25424711 (description, gene)
  AUTHORS   Gannon T, Perveen R, Schlecht H, Ramsden S, Anderson B, Kerr B, Day R, Banka S, Suri M, Berland S, Gabbett M, Ma A, Lyonnet S, Cormier-Daire V, Yilmaz R, Borck G, Wieczorek D, Anderlid BM, Smithson S, Vogt J, Moore-Barton H, Simsek-Kiper PO, Maystadt I, Destree A, Bucher J, Angle B, Mohammed S, Wakeling E, Price S, Singer A, Sznajer Y, Toutain A, Haye D, Newbury-Ecob R, Fradin M, McGaughran J, Tuysuz B, Tein M, Bouman K, Dabir T, Van den Ende J, Luk HM, Pilz DT, Eason J, Davies S, Reardon W, Garavelli L, Zuffardi O, Devriendt K, Armstrong R, Johnson D, Doco-Fenzy M, Bijlsma E, Unger S, Veenstra-Knol HE, Kohlhase J, Lo IF, Smith J, Clayton-Smith J
  TITLE     Further delineation of the KAT6B molecular and phenotypic spectrum.
  JOURNAL   Eur J Hum Genet 23:1165-70 (2015)
REFERENCE   PMID:22715153 (description, gene)
  AUTHORS   Campeau PM, Lu JT, Dawson BC, Fokkema IF, Robertson SP, Gibbs RA, Lee BH
  TITLE     The KAT6B-related disorders genitopatellar syndrome and Ohdo/SBBYS syndrome have  distinct clinical features reflecting distinct molecular mechanisms.
  JOURNAL   Hum Mutat 33:1520-5 (2012)
///
ENTRY       H01795                      Disease
NAME        Blepharophimosis-mental retardation syndrome (BMRS);
            Ohdo syndrome
DESCRIPTION Blepharophimosis-mental retardation syndromes (BMRS) include a group of clinically and etiologically heterogeneous conditions, which can occur as isolated features or as part of distinct disorders displaying multiple congenital anomalies. The majority of syndromic patients with blepharophimosis show a variable degree of mental retardation. In 1986, Ohdo et al. delineated a syndrome of blepharophimosis, ptosis, hypoplastic teeth, heart defect, and mental handicap, to which his name was attached. Subsequently, several cases have been reported as Ohdo/Ohdo-like syndrome, widening the spectrum of clinical findings of BMRS, which lately were classified into five subtypes by Verloes et al: (1) del(3p) syndrome; (2) BMRS, Ohdo type; (3) BMRS, SBBYS (Say-Barber/Biesecker/Young-Simpson) type [DS:H01793]; (4) BMRS, MKB (Maat-Kievit-Brunner) type; (5) BMRS, Verloes type. BMR may also be found in relatively nonspecific developmental anomalies and in unclassified individuals, further widening the etiology of BMR disorders.
CATEGORY    Developmental disorder; Nervous system disease
GENE        (SBBYS type) KAT6B [HSA:23522] [KO:K11306]
            (MKB type) MED12 [HSA:9968] [KO:K15162]
DBLINKS     ICD-10: Q87.8
            OMIM: 613792 603736 300895
REFERENCE   PMID:16700052 (description)
  AUTHORS   Verloes A, Bremond-Gignac D, Isidor B, David A, Baumann C, Leroy MA, Stevens R, Gillerot Y, Heron D, Heron B, Benzacken B, Lacombe D, Brunner H, Bitoun P
  TITLE     Blepharophimosis-mental retardation (BMR) syndromes: A proposed clinical classification of the so-called Ohdo syndrome, and delineation of two new BMR syndromes, one X-linked and one autosomal recessive.
  JOURNAL   Am J Med Genet A 140:1285-96 (2006)
REFERENCE   PMID:21567902 (description)
  AUTHORS   Dentici ML, Mingarelli R, Dallapiccola B
  TITLE     The difficult nosology of blepharophimosis-mental retardation syndromes: report on two siblings.
  JOURNAL   Am J Med Genet A 155A:459-65 (2011)
REFERENCE   PMID:22077973 (gene)
  AUTHORS   Clayton-Smith J, O'Sullivan J, Daly S, Bhaskar S, Day R, Anderson B, Voss AK, Thomas T, Biesecker LG, Smith P, Fryer A, Chandler KE, Kerr B, Tassabehji M, Lynch SA, Krajewska-Walasek M, McKee S, Smith J, Sweeney E, Mansour S, Mohammed S, Donnai D, Black G
  TITLE     Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome.
  JOURNAL   Am J Hum Genet 89:675-81 (2011)
REFERENCE   PMID:23395478 (gene)
  AUTHORS   Vulto-van Silfhout AT, de Vries BB, van Bon BW, Hoischen A, Ruiterkamp-Versteeg M, Gilissen C, Gao F, van Zwam M, Harteveld CL, van Essen AJ, Hamel BC, Kleefstra T, Willemsen MA, Yntema HG, van Bokhoven H, Brunner HG, Boyer TG, de Brouwer AP
  TITLE     Mutations in MED12 cause X-linked Ohdo syndrome.
  JOURNAL   Am J Hum Genet 92:401-6 (2013)
///
ENTRY       H01796                      Disease
NAME        Uncombable hair syndrome;
            Spun glass hair syndrome;
            Pili trianguli et canaliculi
DESCRIPTION Uncombable hair syndrome (UHS) is a rare anomaly of the hair shaft characterized by dry, frizzy, spangly, and often fair hair that is resistant to being combed flat. Both simplex and familial UHS-affected cases with autosomal dominant as well as recessive inheritance have been described. Recently, the identification of causative mutations were reported. No proven therapy exists. In the typical case, improvement may occur over time and spontaneous regression has been reported. Scanning electron microscopy of hair samples provides definitive evidence for diagnosis of clinically suspected UHS and eliminates other hair abnormalities from the differential diagnosis.
CATEGORY    Skin and connective tissue disease
GENE        PADI3 [HSA:51702] [KO:K01481]
            TGM3 [HSA:7053] [KO:K05620]
            TCHH [HSA:7062] [KO:K18626]
DBLINKS     ICD-10: Q87.8
            MeSH: C536939
            OMIM: 191480 617251 617252
REFERENCE   PMID:11407534 (description)
  AUTHORS   Hicks J, Metry DW, Barrish J, Levy M
  TITLE     Uncombable hair (cheveux incoiffables, pili trianguli et canaliculi) syndrome: brief review and role of scanning electron microscopy in diagnosis.
  JOURNAL   Ultrastruct Pathol 25:99-103 (2001)
REFERENCE   PMID:27866708 (description, gene)
  AUTHORS   U Basmanav FB, Cau L, Tafazzoli A, Mechin MC, Wolf S, Romano MT, Valentin F, Wiegmann H, Huchenq A, Kandil R, Garcia Bartels N, Kilic A, George S, Ralser DJ, Bergner S, Ferguson DJ, Oprisoreanu AM, Wehner M, Thiele H, Altmuller J, Nurnberg P, Swan D, Houniet D, Buchner A, Weibel L, Wagner N, Grimalt R, Bygum A, Serre G, Blume-Peytavi U, Sprecher E, Schoch S, Oji V, Hamm H, Farrant P, Simon M, Betz RC
  TITLE     Mutations in Three Genes Encoding Proteins Involved in Hair Shaft Formation Cause Uncombable Hair Syndrome.
  JOURNAL   Am J Hum Genet 99:1292-1304 (2016)
///
ENTRY       H01797                      Disease
NAME        Webb-Dattani syndrome;
            Hypothalamic insufficiency-secondary microcephaly-visual impairment-urinary anomalies syndrome
DESCRIPTION Webb-Dattani syndrome is an autosomal recessive disorder characterized by secondary (post-natal) microcephaly with fronto-temporal lobe hypoplasia, multiple pituitary hormone deficiency, seizures, severe visual impairment, and abnormalities of the kidneys and urinary tract. A homozygous frameshift mutation in the basic HLH transcription factor ARNT2 has been revealed in affected individuals.
CATEGORY    Developmental disorder
GENE        ARNT2 [HSA:9915] [KO:K15589]
DBLINKS     ICD-10: Q87.8
            OMIM: 615926
REFERENCE   PMID:24022475 (description, gene)
  AUTHORS   Webb EA, AlMutair A, Kelberman D, Bacchelli C, Chanudet E, Lescai F, Andoniadou CL, Banyan A, Alsawaid A, Alrifai MT, Alahmesh MA, Balwi M, Mousavy-Gharavy SN, Lukovic B, Burke D, McCabe MJ, Kasia T, Kleta R, Stupka E, Beales PL, Thompson DA, Chong WK, Alkuraya FS, Martinez-Barbera JP, Sowden JC, Dattani MT
  TITLE     ARNT2 mutation causes hypopituitarism, post-natal microcephaly, visual and renal  anomalies.
  JOURNAL   Brain 136:3096-105 (2013)
///
ENTRY       H01798                      Disease
NAME        Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV)
DESCRIPTION Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an inherited autoimmune uveitis and vitreoretinal degeneration characterized by inflammatory cells in the vitreous and anterior chamber, photoreceptor degeneration, vitreous hemorrhages, epiretinal membranes (ERMs), and proliferative iris and retinal neovascularization. It is caused by mutations in CAPN5 gene, encoding an intracellular protease expressed in the retina. In most patients the diagnosis is difficult to make before age 40. Electroretinography can help make the diagnosis in younger individuals in whom the only other sign is the presence of vitreous cells.
CATEGORY    Eye disease
GENE        CAPN5 [HSA:726] [KO:K08574]
DRUG        Steroids
DBLINKS     ICD-10: H35.2
            MeSH: D018630
            OMIM: 193235
REFERENCE   PMID:27390515 (description)
  AUTHORS   Cham A, Bansal M, Banda HK, Kwon Y, Tlucek PS, Bassuk AG, Tsang SH, Sobol WM, Folk JC, Yeh S, Mahajan VB
  TITLE     Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy.
  JOURNAL   Clin Ophthalmol 10:1187-97 (2016)
REFERENCE   PMID:1284594 (description)
  AUTHORS   Stone EM, Kimura AE, Folk JC, Bennett SR, Nichols BE, Streb LM, Sheffield VC
  TITLE     Genetic linkage of autosomal dominant neovascular inflammatory vitreoretinopathy  to chromosome 11q13.
  JOURNAL   Hum Mol Genet 1:685-9 (1992)
REFERENCE   PMID:23055945 (gene)
  AUTHORS   Mahajan VB, Skeie JM, Bassuk AG, Fingert JH, Braun TA, Daggett HT, Folk JC, Sheffield VC, Stone EM
  TITLE     Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration.
  JOURNAL   PLoS Genet 8:e1003001 (2012)
///
ENTRY       H01799                      Disease
NAME        Vibratory urticaria;
            Vibratory angioedema
DESCRIPTION Vibratory urticaria is a rare type of physical skin reactivity characterized by the occurrence of local erythematous, edematous, cutaneous and subcutaneous lesions that result from stimuli of a vibratory nature. A local stimulus of sufficient intensity will also result in generalized or facial erythema accompanied by a transient headache. The histamine release that is associated with urticarias has implicated aberrant degranulation of mast cells in their pathogenesis. A missense variant in ADGRE2 gene has been found in families with vibratory urticaria, implicating the encoded adhesion G-protein-coupled receptor (GPCR) as a mechanosensor in mast cells.
CATEGORY    Skin and connective tissue disease
GENE        ADGRE2 [HSA:30817] [KO:K08443]
DBLINKS     ICD-10: L50.4
            MeSH: C536347
            OMIM: 125630
REFERENCE   PMID:5050327 (description)
  AUTHORS   Patterson R, Mellies CJ, Blankenship ML, Pruzansky JJ
  TITLE     Vibratory angioedema: a hereditary type of physical hypersensitivity.
  JOURNAL   J Allergy Clin Immunol 50:174-82 (1972)
REFERENCE   PMID:26841242 (description, gene)
  AUTHORS   Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM, Eisch AR, Long RD, Lee CC, Satorius CL, Pakstis AJ, Olivera A, Mullikin JC, Chouery E, Megarbane A, Medlej-Hashim M, Kidd KK, Kastner DL, Metcalfe DD, Komarow HD
  TITLE     Vibratory Urticaria Associated with a Missense Variant in ADGRE2.
  JOURNAL   N Engl J Med 374:656-63 (2016)
///
ENTRY       H01800                      Disease
NAME        Verheij syndrome;
            Chromosome 8q24.3 deletion syndrome
DESCRIPTION Verheij syndrome is rare condition characterized by ante- and postnatal growth retardation, microcephaly, vertebral anomalies, joint laxity/dislocation, developmental delay, cardiac and renal defects, and dysmorphic features. Overlapping interstitial microdeletions of chromosome 8q24 have been reported from patients of this disease. Recently, PUF60, which encodes a component of the spliceosome, has been discussed as the best candidate gene for the Verheij syndrome phenotype, regarding the cardiac and short stature phenotype.
CATEGORY    Developmental disorder
GENE        PUF60 [HSA:22827] [KO:K12838]
DBLINKS     ICD-10: Q87.8
            OMIM: 615583
REFERENCE   PMID:19464398 (description)
  AUTHORS   Verheij JB, de Munnik SA, Dijkhuizen T, de Leeuw N, Olde Weghuis D, van den Hoek GJ, Rijlaarsdam RS, Thomasse YE, Dikkers FG, Marcelis CL, van Ravenswaaij-Arts CM
  TITLE     An 8.35 Mb overlapping interstitial deletion of 8q24 in two patients with coloboma, congenital heart defect, limb abnormalities, psychomotor retardation and convulsions.
  JOURNAL   Eur J Med Genet 52:353-7 (2009)
REFERENCE   PMID:27804958 (description, gene)
  AUTHORS   El Chehadeh S, Kerstjens-Frederikse WS, Thevenon J, Kuentz P, Bruel AL, Thauvin-Robinet C, Bensignor C, Dollfus H, Laugel V, Riviere JB, Duffourd Y, Bonnet C, Robert MP, Isaiko R, Straub M, Creuzot-Garcher C, Calvas P, Chassaing N, Loeys B, Reyniers E, Vandeweyer G, Kooy F, Hancarova M, Havlovicova M, Prchalova D, Sedlacek Z, Gilissen C, Pfundt R, Wassink-Ruiter JS, Faivre L
  TITLE     Dominant variants in the splicing factor PUF60 cause a recognizable syndrome with intellectual disability, heart defects and short stature.
  JOURNAL   Eur J Hum Genet 25:43-51 (2016)
REFERENCE   PMID:28327570 (description, gene)
  AUTHORS   Low KJ, Ansari M, Abou Jamra R, Clarke A, El Chehadeh S, FitzPatrick DR, Greenslade M, Henderson A, Hurst J, Keller K, Kuentz P, Prescott T, Roessler F, Selmer KK, Schneider MC, Stewart F, Tatton-Brown K, Thevenon J, Vigeland MD, Vogt J, Willems M, Zonana J, Study DD, Smithson SF
  TITLE     PUF60 variants cause a syndrome of ID, short stature, microcephaly, coloboma, craniofacial, cardiac, renal and spinal features.
  JOURNAL   Eur J Hum Genet (2017)
///
ENTRY       H01801                      Disease
NAME        Kagami-Ogata syndrome;
            Paternal uniparental disomy 14
DESCRIPTION Paternal uniparental disomy 14 syndrome is characterized by characteristic face, a small bell-shaped thorax with coat-hanger appearance of the ribs, abdominal wall defects, placentomegaly and polyhydramnios. Human chromosome 14q32.2 carries a cluster of imprinted genes including paternally expressed genes (PEGs) such as DLK1 and RTL1 and maternally expressed genes (MEGs) such as MEG3, RTL1as (RTL1 antisense) and MEG8, together with the intergenic differentially methylated region (IG-DMR) and the MEG3-DMR. It has been reported that epimutations (hypermethylations) and microdeletions affecting the IG-DMR and/or the MEG3-DMR, result in paternal uniparental disomy 14 like phenotype. Recently, the name 'Kagami-Ogata syndrome' has been approved for this clinically recognizable disorder.
CATEGORY    Chromosomal abnormality; Developmental disorder
DBLINKS     ICD-10: Q99.8
            MeSH: C536471
            OMIM: 608149
REFERENCE   PMID:18176563
  AUTHORS   Kagami M, Sekita Y, Nishimura G, Irie M, Kato F, Okada M, Yamamori S, Kishimoto H, Nakayama M, Tanaka Y, Matsuoka K, Takahashi T, Noguchi M, Tanaka Y, Masumoto K, Utsunomiya T, Kouzan H, Komatsu Y, Ohashi H, Kurosawa K, Kosaki K, Ferguson-Smith AC, Ishino F, Ogata T
  TITLE     Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes.
  JOURNAL   Nat Genet 40:237-42 (2008)
REFERENCE   PMID:26377239
  AUTHORS   Ogata T, Kagami M
  TITLE     Kagami-Ogata syndrome: a clinically recognizable upd(14)pat and related disorder  affecting the chromosome 14q32.2 imprinted region.
  JOURNAL   J Hum Genet 61:87-94 (2016)
REFERENCE   PMID:26333487
  AUTHORS   Corsello G, Salzano E, Vecchio D, Antona V, Grasso M, Malacarne M, Carella M, Palumbo P, Piro E, Giuffre M
  TITLE     Paternal uniparental disomy chromosome 14-like syndrome due a maternal de novo 160 kb deletion at the 14q32.2 region not encompassing the IG- and the MEG3-DMRs: Patient report and genotype-phenotype correlation.
  JOURNAL   Am J Med Genet A 167A:3130-8 (2015)
///
ENTRY       H01802                      Disease
NAME        Pulmonary atresia with intact ventricular septum
DESCRIPTION Pulmonary atresia with intact ventricular septum (PAIVS) is a severe cardiac malformation characterized by variable right ventricular development and imperforate pulmonary valve. PAIVS has a wide spectrum of clinical presentation ranging from cyanosis to shock due to closure of ductus arteriosus. The treatment follows initial stabilization with prostaglandin and establishment of antegrade flow. Because of the morphologic heterogeneity, repair or palliation strategies vary widely, ranging from single ventricle palliation to complete biventricular repair. Overall, regardless of anatomical subtype, survival is poor, reported to be as low as 50% at 5 years.
CATEGORY    Developmental disorder; Cardiovascular disease
DRUG        Prostaglandin [DR:D00180]
DBLINKS     ICD-10: Q25.5
            MeSH: C562832
            OMIM: 265150
REFERENCE   PMID:18570204
  AUTHORS   Iacobelli R, Pasquini L, Toscano A, Raimondi F, Michielon G, Tozzi AE, Sanders SP
  TITLE     Role of tricuspid regurgitation in fetal echocardiographic diagnosis of pulmonary atresia with intact ventricular septum.
  JOURNAL   Ultrasound Obstet Gynecol 32:31-5 (2008)
REFERENCE   PMID:28163422 (drug)
  AUTHORS   Bakhru S, Marathe S, Saxena M, Verma S, Saileela R, Dash TK, Koneti NR
  TITLE     Transcatheter pulmonary valve perforation using chronic total occlusion wire in pulmonary atresia with intact ventricular septum.
  JOURNAL   Ann Pediatr Cardiol 10:5-10 (2017)
REFERENCE   PMID:22640635
  AUTHORS   Alwi M, Budi RR, Mood MC, Leong MC, Samion H
  TITLE     Pulmonary atresia with intact septum: the use of Conquest Pro coronary guidewire  for perforation of atretic valve and subsequent interventions.
  JOURNAL   Cardiol Young 23:197-202 (2013)
///
ENTRY       H01803                      Disease
NAME        Pulmonary atresia with ventricular septal defect
DESCRIPTION Pulmonary atresia with ventricular septal defect (PA-VSD) is a rare and complex cyanotic congenital heart malformation that has a high incidence of early mortality. PA-VSD presents with complete absence of any communication between the right ventricle and the pulmonary arteries. The blood supply to the pulmonary arteries is provided by a patent arterial duct or by major aorto pulmonary collateral arteries (MAPCAs). Two-thirds of the cases with pulmonary atresia are associated with MAPCAs, which can vary greatly in number and site of origin. PA-VSD shares similarities with tetralogy of Fallot (TOF) and has been considered a severe end of the spectrum of TOF. Although surgical interventions have been employed successfully for a number of years, the long-term prognosis has remained poor with an increased incidence of sudden death. An association between conotruncal cardiac abnormalities and 22q11.2 deletion during fetal life has been investigated and reported to occur in 20% of cases of PA-VSD.
CATEGORY    Developmental disorder; Cardiovascular disease
COMMENT     See also H01525 22q11.2 deletion syndrome, and H00549 Tetralogy of Fallot.
DBLINKS     ICD-10: Q21.3
            MeSH: D018633
            OMIM: 178370
REFERENCE   PMID:28231853
  AUTHORS   Fan C, Yang Y, Xiong L, Yin N, Wu Q, Tang M, Yang J
  TITLE     Reconstruction of the pulmonary posterior wall using in situ autologous tissue for the treatment of pulmonary atresia with ventricular septal defect.
  JOURNAL   J Cardiothorac Surg 12:12 (2017)
REFERENCE   PMID:23199622
  AUTHORS   Fouilloux V, Bonello B, Kammache I, Fraisse A, Mace L, Kreitmann B
  TITLE     Management of patients with pulmonary atresia, ventricular septal defect, hypoplastic pulmonary arteries and major aorto-pulmonary collaterals: Focus on the strategy of rehabilitation of the native pulmonary arteries.
  JOURNAL   Arch Cardiovasc Dis 105:666-75 (2012)
REFERENCE   PMID:16547205
  AUTHORS   Vesel S, Rollings S, Jones A, Callaghan N, Simpson J, Sharland GK
  TITLE     Prenatally diagnosed pulmonary atresia with ventricular septal defect: echocardiography, genetics, associated anomalies and outcome.
  JOURNAL   Heart 92:1501-5 (2006)
REFERENCE   PMID:21234191
  AUTHORS   Murthy K, Reddy KP, Nagarajan R, Goutami V, Cherian K
  TITLE     Management of ventricular septal defect with pulmonary atresia and major aorto pulmonary collateral arteries: Challenges and controversies.
  JOURNAL   Ann Pediatr Cardiol 3:127-35 (2010)
REFERENCE   PMID:25580345
  AUTHORS   Kulkarni DV, Hegde RG, Balani A, Joshi AR
  TITLE     A Rare Case of Pulmonary Atresia with Ventricular Septal Defect with a Right Sided Aortic Arch and a Calcified Pulmonary AVM Presenting in an Adult without Cyanosis.
  JOURNAL   Case Rep Radiol 2014:614647 (2014)
///
ENTRY       H01804                      Disease
NAME        Isaacs syndrome
DESCRIPTION Isaacs syndrome is a rare neuromuscular disorder of continuous muscle fibre activity resulting from peripheral nerve hyper excitability. Symptoms commonly include myokymia, pseudomyotonia, muscle cramps and stiffness. It is caused by voltage-gated potassium channel dysfunction and may be inherited or acquired. Recent evidences suggest that autoantibodies against voltage-gated potassium channels (VGKC-Abs) are associated with this disease. Treatment commonly includes anticonvulsants, immunosuppressive therapy and plasma exchange.
CATEGORY    Nervous system disease; Musculoskeletal disease
DRUG        Phenytoin [DR:D00512]
            Carbamazepine [DR:D00252]
            Azathioprine [DR:D00238]
DBLINKS     ICD-10: G71.1
            MeSH: D020386
REFERENCE   PMID:25301428
  AUTHORS   Lide B, Singh J, Haeri S
  TITLE     Isaacs' syndrome in pregnancy.
  JOURNAL   BMJ Case Rep 2014 (2014)
REFERENCE   PMID:18801496
  AUTHORS   Takahashi H, Mori M, Sekiguchi Y, Misawa S, Sawai S, Hattori T, Kuwabara S
  TITLE     Development of Isaacs' syndrome following complete recovery of voltage-gated potassium channel antibody-associated limbic encephalitis.
  JOURNAL   J Neurol Sci 275:185-7 (2008)
REFERENCE   PMID:21144646 (drug)
  AUTHORS   Meyniel C, Ollivier Y, Hamidou M, Pereon Y, Derkinderen P
  TITLE     Dramatic improvement of refractory Isaacs' syndrome after treatment with dronabinol.
  JOURNAL   Clin Neurol Neurosurg 113:323-4 (2011)
REFERENCE   PMID:21577108 (drug)
  AUTHORS   Panzer J, Dalmau J
  TITLE     Movement disorders in paraneoplastic and autoimmune disease.
  JOURNAL   Curr Opin Neurol 24:346-53 (2011)
///
ENTRY       H01805                      Disease
NAME        Tricho-hepato-enteric syndrome;
            Syndromic diarrhea
DESCRIPTION Tricho-hepato-enteric syndrome (THE), also known as syndromic diarrhea (SD), is a congenital enteropathy presenting with early-onset severe intractable diarrhea and associated with non-specific villous atrophy with low or no mononuclear cell infiltration of the lamina propria nor specific histological abnormalities involving the epithelium. Infants are born small for gestational age. Patients present with facial dysmorphism, immune disorders and, in some patients, early onset of severe liver cirrhosis. It has been linked to abnormalities in two components of the putative human ski complex: SKIV2L and TTC37. During their clinical course, most of the patients require parenteral nutrition and often immunoglobulin supplementation.
CATEGORY    Developmental disorder; Gastrointestinal disease
GENE        (THES1) TTC37 [HSA:9652] [KO:K12600]
            (THES2) SKIV2L [HSA:6499] [KO:K12599]
DBLINKS     MeSH: C565627
            OMIM: 222470 614602
REFERENCE   PMID:23302111 (description)
  AUTHORS   Fabre A, Martinez-Vinson C, Goulet O, Badens C
  TITLE     Syndromic diarrhea/Tricho-hepato-enteric syndrome.
  JOURNAL   Orphanet J Rare Dis 8:5 (2013)
REFERENCE   PMID:24108068 (description)
  AUTHORS   Fabre A, Breton A, Coste ME, Colomb V, Dubern B, Lachaux A, Lemale J, Mancini J, Marinier E, Martinez-Vinson C, Peretti N, Perry A, Roquelaure B, Venaille A, Sarles J, Goulet O, Badens C
  TITLE     Syndromic (phenotypic) diarrhoea of infancy/tricho-hepato-enteric syndrome.
  JOURNAL   Arch Dis Child 99:35-8 (2014)
REFERENCE   PMID:18304370 (description)
  AUTHORS   Goulet O, Vinson C, Roquelaure B, Brousse N, Bodemer C, Cezard JP
  TITLE     Syndromic (phenotypic) diarrhea in early infancy.
  JOURNAL   Orphanet J Rare Dis 3:6 (2008)
REFERENCE   PMID:25976726 (gene)
  AUTHORS   Chong JH, Jamuar SS, Ong C, Thoon KC, Tan ES, Lai A, Aan MK, Tan WL, Foo R, Tan EC, Lau YL, Liew WK
  TITLE     Tricho-hepato-enteric syndrome (THE-S): two cases and review of the literature.
  JOURNAL   Eur J Pediatr 174:1405-11 (2015)
REFERENCE   PMID:22444670 (gene)
  AUTHORS   Fabre A, Charroux B, Martinez-Vinson C, Roquelaure B, Odul E, Sayar E, Smith H, Colomb V, Andre N, Hugot JP, Goulet O, Lacoste C, Sarles J, Royet J, Levy N, Badens C
  TITLE     SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome.
  JOURNAL   Am J Hum Genet 90:689-92 (2012)
///
ENTRY       H01806                      Disease
NAME        Tenorio syndrome
DESCRIPTION Tenorio syndrome is a overgrowth syndrome characterized by overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycemia, and inflammatory diseases resembling Sjogren's syndrome. Mutations in RNF125, encoding an E3 ubiquitin ligase, have been found from patients. It have been demonstrated that mutations in RNF125 result in a loss of function of RNF125 and dysregulation of the RIG-I-IPS1, PI3K-AKT, and interferon pathways.
CATEGORY    Developmental disorder
GENE        RNF125 [HSA:54941] [KO:K12170]
COMMENT     See also H01502.
DBLINKS     OMIM: 616260
REFERENCE   PMID:25196541 (description, gene)
  AUTHORS   Tenorio J, Mansilla A, Valencia M, Martinez-Glez V, Romanelli V, Arias P, Castrejon N, Poletta F, Guillen-Navarro E, Gordo G, Mansilla E, Garcia-Santiago F, Gonzalez-Casado I, Vallespin E, Palomares M, Mori MA, Santos-Simarro F, Garcia-Minaur S, Fernandez L, Mena R, Benito-Sanz S, del Pozo A, Silla JC, Ibanez K, Lopez-Granados E, Martin-Trujillo A, Montaner D, Heath KE, Campos-Barros A, Dopazo J, Nevado J, Monk D, Ruiz-Perez VL, Lapunzina P
  TITLE     A new overgrowth syndrome is due to mutations in RNF125.
  JOURNAL   Hum Mutat 35:1436-41 (2014)
///
ENTRY       H01807                      Disease
NAME        Hereditary diffuse leukoencephalopathy with spheroids
DESCRIPTION Hereditary diffuse leukoencephalopathy with spheroids (HDLS) is an autosomal dominant central nervous system disease with variable clinical presentations, including personality and behavioral changes, dementia, depression, parkinsonism, seizures and other phenotypes. HDLS is a rare progressive neurodegenerative disease with symptomatic onset in midlife and death within a few years after symptom onset. White matter lesions with accumulation of axonal spheroids are the pathological hallmark of HDLS. It has been reported that mutations in the colony-stimulating factor 1 receptor (CSF1R) gene cause this disease. CSF1R is a crucial mediator of microglial proliferation and differentiation in the brain.
CATEGORY    Neurodegenerative disease
GENE        CSF1R [HSA:1436] [KO:K05090]
DBLINKS     ICD-10: G93.4
            MeSH: C580150
            OMIM: 221820
REFERENCE   PMID:23787135
  AUTHORS   Sundal C, Fujioka S, Van Gerpen JA, Wider C, Nicholson AM, Baker M, Shuster EA, Aasly J, Spina S, Ghetti B, Roeber S, Garbern J, Tselis A, Swerdlow RH, Miller BB, Borjesson-Hanson A, Uitti RJ, Ross OA, Stoessl AJ, Rademakers R, Josephs KA, Dickson DW, Broderick D, Wszolek ZK
  TITLE     Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations.
  JOURNAL   Parkinsonism Relat Disord 19:869-77 (2013)
REFERENCE   PMID:22197934 (gene)
  AUTHORS   Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, Lash J, Wider C, Wojtas A, DeJesus-Hernandez M, Adamson J, Kouri N, Sundal C, Shuster EA, Aasly J, MacKenzie J, Roeber S, Kretzschmar HA, Boeve BF, Knopman DS, Petersen RC, Cairns NJ, Ghetti B, Spina S, Garbern J, Tselis AC, Uitti R, Das P, Van Gerpen JA, Meschia JF, Levy S, Broderick DF, Graff-Radford N, Ross OA, Miller BB, Swerdlow RH, Dickson DW, Wszolek ZK
  TITLE     Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids.
  JOURNAL   Nat Genet 44:200-5 (2011)
///
ENTRY       H01809                      Disease
NAME        Sturge-Weber syndrome
DESCRIPTION Sturge-Weber syndrome (SWS) is a rare sporadic neurocutaneous syndrome the hallmark of which is a facial port-wine stain (PWS) involving the first division of the trigeminal nerve, ipsilateral leptomeningeal angiomata, and angioma of the eye (leading to glaucoma). The clinical course is highly variable but usually progressive course in early childhood characterised by seizures, stroke-like episodes, headaches, neurological and cognitive deterioration, hemiparesis, glaucoma and visual field defects. Although patients with a PWS plus leptomeningeal involvement alone are generally diagnosed as having SWS, those with a facial PWS and glaucoma alone are usually classified separately or considered as having partial SWS. Leptomeningeal and choroidal vascular anomalies have also been described in the absence of a PWS and may represent another partial variant of SWS. A somatic activating missense mutation in the GNAQ gene was recently identified in affected tissues (both skin and brain). This gene encodes the Q-class G protein alpha-subunit, activation of which increases MAPK signaling. Standard treatment includes laser therapy for the birthmark, control of glaucoma through eyedrops or surgery, and the use of anticonvulsants. Treatment with an anticonvulsant or low-dose aspirin or both before the onset of seizures is an option.
CATEGORY    Nervous system disease; Cardiovascular disease
GENE        GNAQ [HSA:2776] [KO:K04634]
DRUG        Antiglaucoma [DR:D00603 D00356]
            Anticonvulsant [DR:D00533 D00709 D00506 D00537 D00535]
            Aspirin [DR:D00109]
DBLINKS     ICD-10: Q85.8
            MeSH: D013341
            OMIM: 185300
REFERENCE   PMID:26706016 (description, drug)
  AUTHORS   Comi A
  TITLE     Current Therapeutic Options in Sturge-Weber Syndrome.
  JOURNAL   Semin Pediatr Neurol 22:295-301 (2015)
REFERENCE   PMID:24275166 (description)
  AUTHORS   Sudarsanam A, Ardern-Holmes SL
  TITLE     Sturge-Weber syndrome: from the past to the present.
  JOURNAL   Eur J Paediatr Neurol 18:257-66 (2014)
REFERENCE   PMID:26903185 (description)
  AUTHORS   Chernoff KA, Schaffer JV
  TITLE     Cutaneous and ocular manifestations of neurocutaneous syndromes.
  JOURNAL   Clin Dermatol 34:183-204 (2016)
REFERENCE   PMID:23656586 (gene)
  AUTHORS   Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM, Pevsner J
  TITLE     Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.
  JOURNAL   N Engl J Med 368:1971-9 (2013)
///
